drug,adverse_event,comp_term,is_overlapping
XEOMIN,Hypersensitivity,Precautions Dysphagia and,0
XEOMIN,Hypersensitivity,reactions to XEOMIN are discussed in greater detail in other sections of,0
XEOMIN,Dysphagia,Dysphagia and Breathing Difficulties in Treatment,1
XEOMIN,Dysphagia,Dysphagia and,1
XEOMIN,Dysphagia,Dysphagia and,1
XEOMIN,Dysphagia,Dysphagia and Breathing,1
XEOMIN,Dysphagia,Dysphagia and,1
XEOMIN,Dysphagia,cervical dystonia,0
XEOMIN,Dysphagia,and Dysphagia,1
XEOMIN,Dysphagia,cervical dystonia,0
XEOMIN,Breathing Difficulties,and Warnings,0
XEOMIN,Breathing Difficulties,Dysphagia Breathing Difficulties in Treatment of,1
XEOMIN,Breathing Difficulties,and Warnings,0
XEOMIN,Breathing Difficulties,and Warnings and Precautions Dysphagia and,0
XEOMIN,Breathing Difficulties,Spread of,0
XEOMIN,Breathing Difficulties,and Precautions Spread of,0
XEOMIN,Breathing Difficulties,Breathing Difficulties in Treatment,1
XEOMIN,Breathing Difficulties,and Precautions Spread of,0
XEOMIN,Breathing Difficulties,Precautions Spread of Effects,0
XEOMIN,Breathing Difficulties,and Precautions,0
XEOMIN,Breathing Difficulties,Precautions Dysphagia Breathing Difficulties in Treatment of cervical dystonia,1
XEOMIN,Breathing Difficulties,and Precautions,0
XEOMIN,Spread of Effects from Toxin,dystonia see Warnings and Spread of Effects from Toxin see,1
XEOMIN,Spread of Effects from Toxin,and Precautions,0
XEOMIN,dysphagia,site pain and musculoskeletal,0
XEOMIN,dysphagia,dysphagia neck pain muscle,1
XEOMIN,dysphagia,site pain and musculoskeletal,0
XEOMIN,dysphagia,dysphagia,1
XEOMIN,dysphagia,pain muscle weakness injection site pain and,0
XEOMIN,neck pain,neck pain muscle weakness injection site pain,1
XEOMIN,neck pain,injection,0
XEOMIN,neck pain,most commonly,0
XEOMIN,neck pain,are neck pain muscle,1
XEOMIN,neck pain,most commonly,0
XEOMIN,neck pain,neck pain muscle weakness,1
XEOMIN,neck pain,most commonly,0
XEOMIN,neck pain,and placebo are neck pain,1
XEOMIN,neck pain,most commonly,0
XEOMIN,neck pain,and musculoskeletal pain Blepharospasm,0
XEOMIN,neck pain,musculoskeletal pain,0
XEOMIN,neck pain,neck pain,1
XEOMIN,neck pain,commonly observed adverse reactions,0
XEOMIN,injection site pain,injection site,1
XEOMIN,injection site pain,injection site pain and musculoskeletal pain Blepharospasm,1
XEOMIN,injection site pain,injection site,1
XEOMIN,injection site pain,muscle injection,1
XEOMIN,injection site pain,muscle injection site pain and musculoskeletal,1
XEOMIN,injection site pain,muscle injection,1
XEOMIN,injection site pain,injection site pain and musculoskeletal pain Blepharospasm,1
XEOMIN,injection site pain,muscle injection,1
XEOMIN,injection site pain,pain muscle injection site,1
XEOMIN,eyelid ptosis,eyelid ptosis dry eye dry mouth diarrhea,1
XEOMIN,eyelid ptosis,pain muscle injection site,1
XEOMIN,eyelid ptosis,most,0
XEOMIN,dry eye,are eyelid dry eye dry mouth diarrhea headache,1
XEOMIN,dry eye,most,0
XEOMIN,dry eye,nasopharyngitis and,0
XEOMIN,dry eye,dry eye dry mouth diarrhea headache,1
XEOMIN,dry eye,placebo are eyelid dry eye dry mouth diarrhea headache visual,1
XEOMIN,dry eye,dry eye dry mouth diarrhea headache,1
XEOMIN,dry eye,dry eye dry mouth diarrhea headache,1
XEOMIN,dry eye,eyelid dry,1
XEOMIN,dry eye,placebo are eyelid dry eye dry mouth diarrhea,1
XEOMIN,dry eye,eyelid dry,1
XEOMIN,dry eye,The most commonly observed adverse reactions of patients,0
XEOMIN,dry eye,patients,0
XEOMIN,dry eye,are eyelid dry eye dry mouth diarrhea headache visual,1
XEOMIN,dry eye,patients,0
XEOMIN,dry mouth,are eyelid ptosis dry dry mouth diarrhea headache visual impairment,1
XEOMIN,dry mouth,patients,0
XEOMIN,dry mouth,dry mouth diarrhea headache visual impairment,1
XEOMIN,dry mouth,dry mouth diarrhea headache visual impairment dyspnea,1
XEOMIN,dry mouth,eyelid ptosis dry dry mouth diarrhea headache,1
XEOMIN,dry mouth,dry mouth diarrhea headache visual impairment dyspnea,1
XEOMIN,dry mouth,eyelid ptosis dry dry mouth diarrhea headache,1
XEOMIN,dry mouth,dry mouth diarrhea headache visual impairment dyspnea,1
XEOMIN,dry mouth,dry mouth diarrhea,1
XEOMIN,dry mouth,dry dry mouth diarrhea headache visual impairment,1
XEOMIN,dry mouth,dry mouth diarrhea,1
XEOMIN,dry mouth,are eyelid ptosis dry dry mouth,1
XEOMIN,dry mouth,dry mouth diarrhea,1
XEOMIN,dry mouth,dry mouth diarrhea headache visual impairment dyspnea,1
XEOMIN,dry mouth,impairment dyspnea nasopharyngitis and,0
XEOMIN,headache,dry eye dry mouth diarrhea,0
XEOMIN,headache,adverse reactions of patients and placebo are eyelid ptosis dry,0
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis and,1
XEOMIN,headache,headache visual,1
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis and,1
XEOMIN,headache,headache,1
XEOMIN,headache,headache visual impairment,1
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis,1
XEOMIN,headache,headache,1
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis,1
XEOMIN,headache,visual impairment,0
XEOMIN,visual impairment,and respiratory,0
XEOMIN,visual impairment,ptosis dry eye dry mouth diarrhea,0
XEOMIN,visual impairment,infection,0
XEOMIN,visual impairment,dry mouth diarrhea visual impairment,1
XEOMIN,visual impairment,infection,0
XEOMIN,visual impairment,eyelid ptosis dry,0
XEOMIN,dyspnea,dyspnea nasopharyngitis,1
XEOMIN,dyspnea,dyspnea nasopharyngitis and respiratory,1
XEOMIN,dyspnea,dyspnea,1
XEOMIN,nasopharyngitis,nasopharyngitis and,1
XEOMIN,nasopharyngitis,headache visual impairment nasopharyngitis,1
XEOMIN,nasopharyngitis,nasopharyngitis and,1
XEOMIN,nasopharyngitis,nasopharyngitis and,1
XEOMIN,nasopharyngitis,impairment,0
XEOMIN,respiratory tract infection,impairment dyspnea nasopharyngitis respiratory tract infection Glabellar Lines,1
XEOMIN,respiratory tract infection,impairment,0
XEOMIN,respiratory tract infection,dyspnea nasopharyngitis respiratory tract infection Glabellar Lines The,1
XEOMIN,respiratory tract infection,impairment,0
XEOMIN,respiratory tract infection,Glabellar Lines The most commonly observed adverse reaction of patients and,0
XEOMIN,respiratory tract infection,visual impairment dyspnea nasopharyngitis respiratory tract infection,1
XEOMIN,respiratory tract infection,observed adverse reaction,0
XEOMIN,respiratory tract infection,respiratory tract infection Glabellar Lines The most commonly,1
XEOMIN,headache,ADVERSE REACTIONS contact Merz Pharmaceuticals LLC at,0
XEOMIN,headache,The most,0
XEOMIN,headache,headache,1
XEOMIN,headache,observed adverse reaction of patients and placebo,0
XEOMIN,headache,of patients and placebo headache To report,1
XEOMIN,headache,observed adverse reaction of patients and placebo,0
XEOMIN,dysphagia,dysphagia neck pain muscle weakness injection,1
XEOMIN,dysphagia,XEOMIN Units or Units dysphagia neck pain,1
XEOMIN,dysphagia,dysphagia neck pain muscle weakness injection,1
XEOMIN,dysphagia,weakness injection site pain and musculoskeletal pain,0
XEOMIN,dysphagia,pain muscle weakness injection site pain and musculoskeletal pain,0
XEOMIN,dysphagia,or Units dysphagia neck pain muscle weakness injection,1
XEOMIN,dysphagia,pain muscle weakness injection site pain and musculoskeletal pain,0
XEOMIN,dysphagia,Table Most Commo,0
XEOMIN,dysphagia,Units or Units dysphagia neck pain muscle weakness injection,1
XEOMIN,dysphagia,Table Most Commo,0
XEOMIN,neck pain,included neck,1
XEOMIN,neck pain,Units,0
XEOMIN,neck pain,Units or Units included neck,1
XEOMIN,neck pain,and musculoskeletal pain Table,0
XEOMIN,neck pain,neck pain muscle weakness injection,1
XEOMIN,neck pain,muscle weakness injection site pain,0
XEOMIN,neck pain,site pain and musculoskeletal pain Table Most Common,0
XEOMIN,neck pain,injection site pain and,0
XEOMIN,neck pain,or Units included neck,1
XEOMIN,neck pain,observed in patients who,0
XEOMIN,muscle weakness,muscle weakness injection site,1
XEOMIN,muscle weakness,TEAEs and Greater t,0
XEOMIN,muscle weakness,Units included dysphagia neck muscle weakness injection site pain and,1
XEOMIN,muscle weakness,TEAEs and Greater t,0
XEOMIN,muscle weakness,muscle weakness injection site pain and,1
XEOMIN,muscle weakness,Units included dysphagia neck muscle weakness injection site pain,1
XEOMIN,muscle weakness,muscle weakness injection site pain and,1
XEOMIN,muscle weakness,observed in,0
XEOMIN,muscle weakness,muscle weakness injection site,1
XEOMIN,injection site pain,site pain and musculoskeletal pain,1
XEOMIN,injection site pain,pain muscle injection site,1
XEOMIN,injection site pain,neck pain muscle injection site pain and,1
XEOMIN,injection site pain,pain muscle injection site,1
XEOMIN,injection site pain,pain muscle,0
XEOMIN,injection site pain,pain Table Most Common TEAEs and Greater than,0
XEOMIN,injection site pain,and musculoskeletal,0
XEOMIN,injection site pain,Table Most Common,0
XEOMIN,injection site pain,injection site pain,1
XEOMIN,musculoskeletal pain,and,0
XEOMIN,blepharospasm,blepharospasm previously treated,1
XEOMIN,blepharospasm,the placebocontrolled Phase trial in patients,0
XEOMIN,blepharospasm,blepharospasm previously treated with,1
XEOMIN,blepharospasm,the placebocontrolled Phase trial in patients,0
XEOMIN,blepharospasm,blepharospasm previously,1
XEOMIN,blepharospasm,Phase trial in patients blepharospasm previously treated with onabotulinumtoxinA Botox,1
XEOMIN,blepharospasm,blepharospasm previously,1
XEOMIN,blepharospasm,previously treated with onabotulinumtoxinA Botox see Clinical,0
XEOMIN,blepharospasm,in patients blepharospasm previously treated with,1
XEOMIN,blepharospasm,previously treated with onabotulinumtoxinA Botox see Clinical,0
XEOMIN,blepharospasm,Botox see Clinical Studies patients,0
XEOMIN,blepharospasm,Phase trial in patients blepharospasm previously treated with onabotulinumtoxinA Botox,1
XEOMIN,blepharospasm,Botox see Clinical Studies patients,0
XEOMIN,eyelid ptosis,eyelid ptosis dry eye dry mouth diarrhea,1
XEOMIN,eyelid ptosis,Botox see Clinical Studies patients,0
XEOMIN,eyelid ptosis,dry eye dry mouth diarrhea headache visual impairment dyspnea nasopharyngitis,0
XEOMIN,dry mouth,Phase study were eyelid ptosis dry eye,0
XEOMIN,dry mouth,dry mouth diarrhea headache,1
XEOMIN,dry mouth,Phase study were eyelid ptosis dry eye,0
XEOMIN,dry mouth,diarrhea headache visual impairment dyspnea nasopharyngitis and respiratory tract infection,0
XEOMIN,dry mouth,dry,1
XEOMIN,dry mouth,eyelid ptosis dry dry mouth,1
XEOMIN,dry mouth,dry,1
XEOMIN,dry mouth,respiratory,0
XEOMIN,dry mouth,eyelid ptosis dry dry mouth diarrhea headache visual,1
XEOMIN,dry mouth,respiratory,0
XEOMIN,dry mouth,in,0
XEOMIN,dry mouth,patients and greater than placebo,0
XEOMIN,dry mouth,dry mouth,1
XEOMIN,diarrhea,diarrhea headache,1
XEOMIN,diarrhea,diarrhea,1
XEOMIN,diarrhea,diarrhea,1
XEOMIN,diarrhea,dyspnea nasopharyngitis,0
XEOMIN,diarrhea,eyelid ptosis dry eye,0
XEOMIN,diarrhea,ptosis dry eye dry diarrhea headache visual impairment dyspnea,1
XEOMIN,diarrhea,eyelid ptosis dry eye,0
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis and,1
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis,1
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis,1
XEOMIN,headache,and greater than placebo in the Phase study were eyelid ptosis,0
XEOMIN,headache,dry,0
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis,1
XEOMIN,headache,dry mouth headache visual impairment dyspnea nasopharyngitis,1
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis,1
XEOMIN,headache,dry mouth headache visual impairment dyspnea nasopharyngitis,1
XEOMIN,headache,headache visual impairment dyspnea nasopharyngitis,1
XEOMIN,headache,ptosis dry,0
XEOMIN,headache,headache,1
XEOMIN,visual impairment,mouth diarrhea,0
XEOMIN,dyspnea,in patients,0
XEOMIN,dyspnea,headache visual dyspnea nasopharyngitis and,1
XEOMIN,dyspnea,in patients,0
XEOMIN,dyspnea,the Phase study were eyelid ptosis dry eye dry mouth diarrhea,0
XEOMIN,dyspnea,in the Phase study were eyelid ptosis dry eye dry,0
XEOMIN,dyspnea,were eyelid ptosis dry eye dry,0
XEOMIN,dyspnea,in the Phase study were eyelid,0
XEOMIN,dyspnea,dyspnea,1
XEOMIN,nasopharyngitis,and respiratory tract infection No serious adverse events occurred in patients,0
XEOMIN,nasopharyngitis,headache visual impairment,0
XEOMIN,nasopharyngitis,nasopharyngitis,1
XEOMIN,nasopharyngitis,ase study were eyelid ptosis dry eye dry mouth,0
XEOMIN,nasopharyngitis,diarrhea headache visual impairment nasopharyngitis and respiratory,1
XEOMIN,nasopharyngitis,ase study were eyelid ptosis dry eye dry mouth,0
XEOMIN,nasopharyngitis,headache visual impairment,0
XEOMIN,nasopharyngitis,nasopharyngitis,1
XEOMIN,nasopharyngitis,nasopharyngitis and respiratory,1
XEOMIN,nasopharyngitis,impairment nasopharyngitis and respiratory,1
XEOMIN,nasopharyngitis,nasopharyngitis and respiratory,1
XEOMIN,respiratory tract infection,visual impairment dyspnea nasopharyngitis respiratory tract,1
XEOMIN,respiratory tract infection,eye dry mouth diarrhea headache visual,0
XEOMIN,respiratory tract infection,id ptosis dry,0
XEOMIN,respiratory tract infection,respiratory tract infection No,1
XEOMIN,respiratory tract infection,nasopharyngitis respiratory tract infection,1
XEOMIN,respiratory tract infection,respiratory tract infection No,1
XEOMIN,dyspnea,of Clinical Tr,0
XEOMIN,dyspnea,than Placebo DoubleBlind Phase of,0
XEOMIN,dyspnea,dyspnea Table,1
XEOMIN,dyspnea,than Placebo DoubleBlind Phase of,0
XEOMIN,dyspnea,dyspnea Table,1
XEOMIN,dyspnea,serious adverse dyspnea Table Most Common,1
XEOMIN,dyspnea,dyspnea Table,1
XEOMIN,dyspnea,dyspnea Table Most Common TEAEs and,1
XEOMIN,dyspnea,dyspnea Table Most Common TEAEs,1
XEOMIN,dyspnea,dyspnea Table Most Common TEAEs and,1
XEOMIN,dyspnea,dyspnea Table Most,1
XEOMIN,facial paresis,subjects were headache,0
XEOMIN,facial paresis,adverse events,0
XEOMIN,injection site hematoma,occurred in two placebotreated sub,0
XEOMIN,eyelid edema,were,0
XEOMIN,eyelid edema,hematoma eyelid,1
XEOMIN,eyelid edema,site hematoma eyelid edema Four,1
XEOMIN,eyelid edema,hematoma eyelid,1
XEOMIN,eyelid edema,eyelid edema,1
XEOMIN,eyelid edema,eyelid edema Four serious adverse,1
XEOMIN,eyelid edema,hematoma eyelid,1
XEOMIN,eyelid edema,hematoma eyelid edema Four serious adverse events occurred,1
XEOMIN,eyelid edema,hematoma eyelid,1
XEOMIN,eyelid edema,eyelid edema Four,1
XEOMIN,eyelid edema,subjects were headache facial,0
XEOMIN,eyelid edema,subjects Six,0
XEOMIN,brow ptosis,brow ptosis General disorders,1
XEOMIN,brow ptosis,subjects Six,0
XEOMIN,brow ptosis,Facial paresis,0
XEOMIN,Injection site hematoma,Injection site,1
XEOMIN,Injection site hematoma,conditions,0
XEOMIN,Injection site hematoma,Injection site hematoma,1
XEOMIN,Injection site hematoma,conditions,0
XEOMIN,Injection site hematoma,tion,0
XEOMIN,Injection site hematoma,tion site,0
XEOMIN,Injection site hematoma,site hematoma Injection si,1
XEOMIN,Injection site hematoma,tion site Injection site hematoma Injection si,1
XEOMIN,Injection site hematoma,site hematoma Injection si,1
XEOMIN,Injection site hematoma,site Injection,1
XEOMIN,Injection site swelling,pain,0
XEOMIN,Sensation of pressure,Sensation of pressure Eye,1
XEOMIN,Sensation of pressure,pain,0
XEOMIN,Sensation of pressure,Sensation of pressure Eye,1
XEOMIN,Sensation of pressure,pain,0
XEOMIN,injection site hematoma,followed injection site,1
XEOMIN,injection site hematoma,injection site hematoma in subjects Adverse reactions,1
XEOMIN,injection site hematoma,reported for subjects followed injection site hematoma in,1
XEOMIN,injection site hematoma,injection site hematoma in subjects Adverse reactions,1
XEOMIN,injection site hematoma,reported for subjects followed injection site,1
XEOMIN,injection site hematoma,than of subjects were facial paresis,0
XEOMIN,injection site hematoma,subjects followed injection,1
XEOMIN,injection site hematoma,injection site hematoma in subjects Adverse,1
XEOMIN,injection site hematoma,subjects followed injection,1
XEOMIN,injection site hematoma,followed injection site hematoma,1
XEOMIN,injection site hematoma,site hematoma in,1
XEOMIN,facial paresis,subjects Adverse reactions reported in less than,0
XEOMIN,facial paresis,subjects were,0
XEOMIN,facial paresis,subjects facial,1
XEOMIN,facial paresis,facial paresis brow ptosis muscle disorder elevation,1
XEOMIN,brow ptosis,facial,0
XEOMIN,brow ptosis,brow ptosis muscle disorder,1
XEOMIN,brow ptosis,of eyebrow injection site pain,0
XEOMIN,brow ptosis,facial brow ptosis,1
XEOMIN,brow ptosis,subjects were facial brow ptosis muscle disorder elevation of eyebrow,1
XEOMIN,brow ptosis,facial brow ptosis,1
XEOMIN,brow ptosis,injection site pain and eyelid edema,0
XEOMIN,brow ptosis,eyelid edema Immunoge,0
XEOMIN,brow ptosis,brow ptosis muscle disorder elevation,1
XEOMIN,brow ptosis,brow,1
XEOMIN,muscle disorder,muscle disorder elevation of eyebrow injection site,1
XEOMIN,muscle disorder,muscle disorder elevation of eyebrow injection site,1
XEOMIN,muscle disorder,muscle disorder elevation of eyebrow injection site,1
XEOMIN,muscle disorder,were,0
XEOMIN,muscle disorder,muscle disorder elevation of eyebrow injection site,1
XEOMIN,elevation of eyebrow,pain and eyelid edema Immunogenicity As with all,0
XEOMIN,elevation of eyebrow,of eyebrow injection site pain and eyelid,1
XEOMIN,injection site pain,elevation of injection site,1
XEOMIN,injection site pain,site pain and eyelid edema Immunogenicity,1
XEOMIN,injection site pain,muscle disorder elevation of injection site pain and,1
XEOMIN,injection site pain,site pain and eyelid edema Immunogenicity,1
XEOMIN,injection site pain,disorder elevation of injection,1
XEOMIN,eyelid edema,eyelid edema Immunogenicity As with,1
XEOMIN,eyelid edema,site pain eyelid edema,1
XEOMIN,eyelid edema,eyelid edema Immunogenicity As with,1
XEOMIN,eyelid edema,eyelid edema Immunogenicity As with all,1
XEOMIN,eyelid edema,site pain eyelid edema Immunogenicity As with,1
XEOMIN,eyelid edema,eyelid edema Immunogenicity As with all,1
XEOMIN,eye swelling,drug eye,1
XEOMIN,eye swelling,eye swelling eyelid,1
XEOMIN,eye swelling,drug eye,1
XEOMIN,eyelid edema,eyelid edema dysphagia,1
XEOMIN,eyelid edema,drug eye,1
XEOMIN,eyelid edema,eyelid edema,1
XEOMIN,eyelid edema,drug exposure,0
XEOMIN,dysphagia,dysphagia nausea flulike symptoms injection site,1
XEOMIN,dysphagia,dysphagia nausea flulike symptoms,1
XEOMIN,dysphagia,dysphagia nausea flulike symptoms injection site,1
XEOMIN,dysphagia,dysphagia nausea flulike,1
XEOMIN,dysphagia,causal relationship to drug exposure eye swelling,0
XEOMIN,nausea,nausea flulike symptoms,1
XEOMIN,nausea,causal relationship to drug exposure eye swelling,0
XEOMIN,nausea,edema nausea flulike symptoms injection site,1
XEOMIN,nausea,causal relationship to drug exposure eye swelling,0
XEOMIN,nausea,eye swelling eyelid edema nausea flulike,1
XEOMIN,nausea,causal relationship to drug exposure eye swelling,0
XEOMIN,nausea,nausea flulike symptoms injection,1
XEOMIN,flu-like symptoms,eyelid edema dysphagia flu-like,1
XEOMIN,flu-like symptoms,swelling eyelid edema dysphagia flu-like symptoms injection site,1
XEOMIN,flu-like symptoms,eyelid edema dysphagia flu-like,1
XEOMIN,flu-like symptoms,allergic,0
XEOMIN,injection site pain,injection site pain injection site,1
XEOMIN,injection site pain,eye swelling eyelid edema dysphagia nausea,0
XEOMIN,injection site pain,dysphagia nausea flulike injection site pain injection site reaction,1
XEOMIN,injection site pain,eye swelling eyelid edema dysphagia nausea,0
XEOMIN,injection site pain,dysphagia,0
XEOMIN,injection site pain,site pain injection site,1
XEOMIN,injection site pain,injection,1
XEOMIN,injection site pain,exposure eye swelling eyelid,0
XEOMIN,injection site pain,nausea flulike injection site pain injection site reaction allergic,1
XEOMIN,injection site pain,exposure eye swelling eyelid,0
XEOMIN,injection site pain,drug exposure eye swelling eyelid edema dysphagia nausea flulike,0
XEOMIN,injection site pain,edema dysphagia nausea flulike injection site,1
XEOMIN,injection site reaction,injection,1
XEOMIN,injection site reaction,symptoms,0
XEOMIN,injection site reaction,site injection site reaction,1
XEOMIN,injection site reaction,site injection site reaction allergic dermatitis localized allergic reactions,1
XEOMIN,injection site reaction,site injection site reaction,1
XEOMIN,injection site reaction,site reaction allergic dermatitis localized allergic,1
XEOMIN,injection site reaction,swelling,0
XEOMIN,injection site reaction,like swelling edema,0
XEOMIN,injection site reaction,eyelid edema dysphagia nausea flulike,0
XEOMIN,allergic dermatitis,pain injection,0
XEOMIN,allergic dermatitis,reaction,0
XEOMIN,allergic dermatitis,dysphagia nausea flulike symptoms injection site pain injection site,0
XEOMIN,localized allergic reactions,reaction allergic localized,1
XEOMIN,herpes zoster,dermatitis,0
XEOMIN,muscular weakness,edema erythema pruritus or rash,0
XEOMIN,muscular weakness,muscular,1
XEOMIN,muscular weakness,muscular weakness muscle spasm dysarthria myalgia and,1
XEOMIN,muscular weakness,localized allergic reactions like swelling edema erythema,0
XEOMIN,muscular weakness,muscle spasm dysarthria myalgia and,0
XEOMIN,muscular weakness,spasm dysarthria myalgia and hypersensitivity,0
XEOMIN,muscular weakness,pruritus or rash herpes muscular weakness,1
XEOMIN,muscular weakness,muscle spasm dysarthria,0
XEOMIN,muscular weakness,muscular,1
XEOMIN,muscular weakness,rash herpes muscular weakness muscle,1
XEOMIN,muscular weakness,muscular,1
XEOMIN,muscle spasm,pruritus or rash herpes zoster muscular weakness,0
XEOMIN,muscle spasm,muscular weakness,0
XEOMIN,muscle spasm,herpes zoster muscular muscle,1
XEOMIN,muscle spasm,muscle,1
XEOMIN,muscle spasm,zoster muscular muscle spasm dysarthria myalgia and hypersensitivity,1
XEOMIN,muscle spasm,muscle,1
XEOMIN,muscle spasm,muscle spasm dysarthria myalgia and hypersensitivity,1
XEOMIN,muscle spasm,muscle spasm dysarthria,1
XEOMIN,muscle spasm,ergic reactions like swelling edema erythema,0
XEOMIN,muscle spasm,muscle spasm,1
XEOMIN,muscle spasm,herpes,0
XEOMIN,dysarthria,muscle dysarthria myalgia,1
XEOMIN,dysarthria,herpes,0
XEOMIN,myalgia,myalgia,1
XEOMIN,myalgia,spasm myalgia and,1
XEOMIN,myalgia,myalgia,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,REACTIONS following adverse reactions,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,scussed in greater detail in o,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,to XEOMIN are di,0
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,the labeling Hypersensitivity see Contraindications,0
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,scussed in greater detail in o ther sections,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,the labeling Hypersensitivity see Contraindications,0
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,detail in o ther sections,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,XEOMIN are scussed in greater detail in o ther sections,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,detail in o ther sections,1
XEOMIN,spread from the area of injection,"Precautions (5.3)  ]  
 *  Dyspha gia",1
XEOMIN,spread from the area of injection,detail in o ther sections,1
XEOMIN,spread from the area of injection,and Warnings Precautions (5.3) ] *,1
XEOMIN,spread from the area of injection,and,0
XEOMIN,spread from the area of injection,Precautions (5.3) ] * Dyspha gia,1
XEOMIN,spread from the area of injection,gia and Breathing,0
XEOMIN,spread from the area of injection,* Dyspha gia and Breathing Difficulties,1
XEOMIN,spread from the area of injection,"Contraindications and Warnings Precautions (5.3)  ]  
 *  Dyspha gia and Breathing Difficulties in",1
XEOMIN,spread from the area of injection,* Dyspha gia and Breathing Difficulties,1
XEOMIN,toxin effects,cervical dyst,1
XEOMIN,toxin effects,of,0
XEOMIN,toxin effects,cervical dyst onia see,1
XEOMIN,toxin effects,of,0
XEOMIN,toxin effects,Difficulties in Treatment cervical,1
XEOMIN,toxin effects,Breathing Difficulties in Treatment cervical dyst onia see Warnings and,1
XEOMIN,toxin effects,Difficulties in Treatment cervical,1
XEOMIN,toxin effects,cervical dyst onia see Warnings and,1
XEOMIN,toxin effects,of Effects from Toxin see Warnings,0
XEOMIN,toxin effects,Difficulties in Treatment cervical,1
XEOMIN,toxin effects,cervical dyst,1
XEOMIN,toxin effects,and,0
XEOMIN,asthenia,Difficulties in,0
XEOMIN,asthenia,and Pre cautions Spread of Effects from,1
XEOMIN,asthenia,Difficulties in Treatment,0
XEOMIN,asthenia, and Pre cautions Spread of Effects,1
XEOMIN,asthenia,Difficulties in Treatment,0
XEOMIN,asthenia,cervical dystonia see  and Pre cautions Spread of Effects,1
XEOMIN,asthenia,Difficulties in Treatment,0
XEOMIN,asthenia,see and Pre,1
XEOMIN,asthenia,Toxin see Warnings and Precautions,0
XEOMIN,generalized muscle weakness,(5.4) ] * Sprea,1
XEOMIN,generalized muscle weakness,d of Effects from Toxin see Warnings and Precautions EXCERPT Cervical,0
XEOMIN,generalized muscle weakness,dystonia see Warnings and utions (5.4) ] *,1
XEOMIN,generalized muscle weakness,Warnings and utions (5.4) ] *,1
XEOMIN,generalized muscle weakness,Preca,0
XEOMIN,generalized muscle weakness,utions (5.4) ] *,1
XEOMIN,generalized muscle weakness,and utions (5.4) ] *,1
XEOMIN,generalized muscle weakness,"utions (5.4)   ] 
 *  Sprea d of",1
XEOMIN,generalized muscle weakness,and utions (5.4) ] *,1
XEOMIN,generalized muscle weakness,"Warnings and utions (5.4)   ] 
 *  Sprea d of Effects from Toxin",1
XEOMIN,generalized muscle weakness,and utions (5.4) ] *,1
XEOMIN,diplopia,see Warnings and Precautions Spread,0
XEOMIN,blurred vision,Toxin [s ee Warnings and,1
XEOMIN,blurred vision,Effects,0
XEOMIN,blurred vision,Precautions Spread of from Toxin [s,1
XEOMIN,ptosis,Effects from Toxin   Warn,1
XEOMIN,ptosis,Precautions Spread of from Toxin [s,1
XEOMIN,ptosis,  Warn ings and Precautions EXCERPT,1
XEOMIN,dysphagia,from Toxin see gs and Pr,1
XEOMIN,dysphagia,  Warn ings and Precautions EXCERPT,1
XEOMIN,dysphagia,The most commonly observed,0
XEOMIN,dysphagia,gs and Pr ecautions EXCERPT Cervical Dystonia,1
XEOMIN,dysphagia,The most commonly observed,0
XEOMIN,dysphagia,gs and Pr ecautions EXCERPT Cervical Dystonia The,1
XEOMIN,dysphagia,ecautions EXCERPT Cervical,0
XEOMIN,dysphagia,Warnings and Precautions Spread,0
XEOMIN,dysphagia,Effects from Toxin see gs and Pr ecautions EXCERPT Cervical Dystonia The,1
XEOMIN,dysphagia,Warnings and Precautions Spread,0
XEOMIN,dysphagia,Toxin see,0
XEOMIN,dysphagia,Effects from Toxin see gs and Pr ecautions EXCERPT Cervical,1
XEOMIN,dysphagia,Toxin see,0
XEOMIN,dysphonia,autions ( EXCERPT Cervical,1
XEOMIN,dysphonia,Warnings and Precautions Spread of Effects from Toxin see Warnings and Prec,0
XEOMIN,dysphonia,Dystonia The,0
XEOMIN,dysphonia,autions ( EXCERPT Cervical Dystonia The most,1
XEOMIN,dysphonia,autions ( EXCERPT Cervical Dystonia,1
XEOMIN,dysphonia,and autions ( EXCERPT Cervical Dystonia The,1
XEOMIN,dysphonia,autions ( EXCERPT Cervical Dystonia,1
XEOMIN,dysphonia,and autions ( EXCERPT Cervical,1
XEOMIN,dysphonia,autions ( EXCERPT Cervical Dystonia,1
XEOMIN,dysphonia,see Warnings and autions,1
XEOMIN,dysphonia,most commonly observed,0
XEOMIN,dysphonia,Warnings and autions (,1
XEOMIN,dysarthria,"Warnings and 1)  ]  
   EXCERPT Cervical",1
XEOMIN,dysarthria,Warnings and autions (,1
XEOMIN,dysarthria,1) ] EXCERPT,1
XEOMIN,urinary incontinence,EXCERPT:,1
XEOMIN,urinary incontinence,ecautions Spread of,0
XEOMIN,urinary incontinence,EXCERPT: Cervi cal,1
XEOMIN,urinary incontinence,commonly observed adverse reactions of patients and,0
XEOMIN,urinary incontinence,EXCERPT: Cervi cal Dystonia The most,1
XEOMIN,urinary incontinence,EXCERPT: Cervi cal Dystonia The most,1
XEOMIN,urinary incontinence,commonly observed adverse reactions of patients and placebo are dys,0
XEOMIN,urinary incontinence,see Warnings and   EXCERPT:     Cervi cal Dystonia,1
XEOMIN,urinary incontinence,commonly observed adverse reactions of patients and placebo are dys,0
XEOMIN,urinary incontinence,patients,0
XEOMIN,breathing difficulties,Toxin see Warnings and Precautions,0
XEOMIN,breathing difficulties,Precautions EXCERPT Cervical ystonia:  The most com monly,1
XEOMIN,breathing difficulties,Toxin see Warnings and Precautions,0
XEOMIN,breathing difficulties,EXCERPT Cervical ystonia: The most,1
XEOMIN,breathing difficulties,EXCERPT Cervical ystonia: The most,1
XEOMIN,breathing difficulties,injection site pain and musculoskeletal pain Blepharospasm The most,0
XEOMIN,breathing difficulties,"ck pain, muscle weakne ss injection site pain and",1
XEOMIN,breathing difficulties,injection site pain and musculoskeletal pain Blepharospasm The most,0
XEOMIN,breathing difficulties,"dysphagia ck pain,",1
XEOMIN,breathing difficulties,muscle weakne ss,1
XEOMIN,breathing difficulties,"placebo are dysphagia ck pain, muscle weakne ss",1
XEOMIN,breathing difficulties,muscle weakne ss,1
XEOMIN,breathing difficulties,"ck pain, muscle weakne ss",1
XEOMIN,breathing difficulties,pain,0
XEOMIN,breathing difficulties,"pain, muscle weakne ss injection site",1
XEOMIN,breathing difficulties,dysphagia ne,0
XEOMIN,breathing difficulties,"are dysphagia ck pain, muscle weakne",1
XEOMIN,breathing difficulties,"pain, muscle weakne ss injection site",1
XEOMIN,breathing difficulties,muscle weakne ss injection site pain and,1
XEOMIN,breathing difficulties,musculoskeletal pain,0
XEOMIN,breathing difficulties,"pain, muscle weakne ss injection site pain",1
XEOMIN,death,"  ).
",1
XEOMIN,death,"  ).
 Blepharospasm The",1
XEOMIN,death,ebo are dysphagia neck pain muscle,0
XEOMIN,death,are dysphagia neck pain muscle weakness injection site pain,0
XEOMIN,death,"  ).
 Blepharospasm The",1
XEOMIN,death,"  ).
 Blepharospasm The most commonly",1
XEOMIN,death,"musculoskeletal   ).
 Blepharospasm The most commonly",1
XEOMIN,death,"  ).
 Blepharospasm The most commonly",1
XEOMIN,spread of effect,report SUS PECTED ADVERSE REACTIONS contact Merz,1
XEOMIN,spread of effect,PECTED ADVERSE REACTIONS contact Merz Pharmaceuticals LLC at or FDA,0
XEOMIN,spread of effect,PECTED ADVERSE REACTIONS contact Merz Pharmaceuticals LLC at,0
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,wwwfdagovmedwatch Clinical,0
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,trials are conducted under,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,are conducted,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,wwwfdagovmedwatch Clinical Trials Experience clinical trials are conducted,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,Clinical Trials Experience,0
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,are conducted under widely,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,Trials Experience  clinical trials are conducted under widely varying conditions adverse,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,are conducted under widely,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,Experience  clinical trials are conducted under,1
XEOMIN,DISTANT SPREAD OF TOXIN EFFECT,are conducted under widely,1
XEOMIN,spread from the area of injection,directly compared to  in the clinical trials of anothe r drug and,1
XEOMIN,spread from the area of injection,are conducted under widely,1
XEOMIN,spread from the area of injection,trials of anothe r drug,1
XEOMIN,spread from the area of injection,directly compared to in the clinical trials,1
XEOMIN,toxin effects,in,1
XEOMIN,toxin effects,"rates in practice.
 Cervical Dystonia",1
XEOMIN,toxin effects,in,1
XEOMIN,toxin effects,not reflect the rates in,1
XEOMIN,toxin effects,"in practice.
 Cervical",1
XEOMIN,toxin effects,not reflect the rates in,1
XEOMIN,toxin effects,"not reflect the rates in practice.
 Cervical Dystonia The data",1
XEOMIN,toxin effects,not reflect the rates in,1
XEOMIN,toxin effects,rates in the,0
XEOMIN,toxin effects,rates in practice.,1
XEOMIN,toxin effects,"reflect the rates in practice.
 Cervical Dystonia",1
XEOMIN,toxin effects,rates in practice.,1
XEOMIN,death,ents  with cervical dystonia see,1
XEOMIN,death,trial in ents  with cervical,1
XEOMIN,death,ents  with cervical dystonia see,1
XEOMIN,death,ents  with cervical dystonia see Clinical,1
XEOMIN,death,ents  with cervical dystonia see Clinical,1
XEOMIN,death,cervical dystonia see Clinical Studies In this study patients received XE,0
XEOMIN,dysphagia,"visual impairment dyspnea ngitis,",1
XEOMIN,dysphagia,commonly observed adverse,0
XEOMIN,dysphagia,diarrhea headache visual impairment dyspnea,0
XEOMIN,dysphagia,ptosis dry eye dry,0
XEOMIN,dysphagia,"visual impairment dyspnea ngitis, a nd respiratory tract",1
XEOMIN,dysphagia,ptosis dry eye dry,0
XEOMIN,dysphagia,"headache visual impairment dyspnea ngitis, a nd respiratory tract",1
XEOMIN,dysphagia,ptosis dry eye dry,0
XEOMIN,dysphagia,ptosis dry eye dry,0
XEOMIN,dysphagia,"ngitis, a",1
XEOMIN,dysphagia,"ngitis, a nd respiratory",1
XEOMIN,dysphagia,"impairment dyspnea ngitis, a nd respiratory tract",1
XEOMIN,dysphagia,"ngitis, a nd respiratory",1
XEOMIN,Corneal exposure,( 6.1 ).,1
XEOMIN,Corneal exposure,"is e (  6.1  ).



",1
XEOMIN,Corneal exposure,( 6.1 ).,1
XEOMIN,Corneal exposure,ellar Lines The most commonly observed adverse,0
XEOMIN,Corneal exposure,6.1 ). To report SUSPECTED ADVERSE REACTIONS,1
XEOMIN,Corneal exposure,report,0
XEOMIN,Corneal exposure,6.1 ). To report SUSPECTED,1
XEOMIN,Corneal exposure,most commonly observed adverse reaction of patients and placebo,0
XEOMIN,reduced blinking,report SUSPECTED,0
XEOMIN,reduced blinking,contact Merz Pharmaceuticals LLC 6646 or FDA at 1 FDA or wwwfdagovmedwatch Clinical,1
XEOMIN,reduced blinking,report SUSPECTED,0
XEOMIN,reduced blinking,wwwfdagovmedwatch Clinical,0
XEOMIN,reduced blinking,at,0
XEOMIN,reduced blinking,at 1 FDA or,1
XEOMIN,reduced blinking,Merz Pharmaceuticals LLC,0
XEOMIN,reduced blinking,Experience Because clinic,0
XEOMIN,corneal exposure,clinical trials,0
XEOMIN,asthenia,cervical dystonia see Clinical tudies ( In this,1
XEOMIN,asthenia,clinical trials,0
XEOMIN,asthenia,tudies,1
XEOMIN,generalized muscle weakness,"In this study, 15 patients received XEOMIN were randomized",1
XEOMIN,generalized muscle weakness,Clinical .1) ]. In,1
XEOMIN,diplopia,patients received XEOMIN were randomized to,1
XEOMIN,blurred vision,study patients eceived,1
XEOMIN,blurred vision,Clinical Studies In this,0
XEOMIN,blurred vision,randomized to receive a total dose of Units and were randomized to,0
XEOMIN,blurred vision,total dose of Units and were randomized,0
XEOMIN,blurred vision,eceived XEOMIN were,1
XEOMIN,blurred vision,Clinical Studies In this study patients r,0
XEOMIN,ptosis,this study patients received 78 wer,1
XEOMIN,dysphagia,receive a total dose,0
XEOMIN,dysphagia,Units and were randomized to receive a total dose of,0
XEOMIN,dysphagia,study patients,0
XEOMIN,dysphagia,randomize d to,1
XEOMIN,dysphagia,randomize d to receive a,1
XEOMIN,dysphagia,Studies In this,0
XEOMIN,dysphagia,patients received XEOMIN randomize d to receive,1
XEOMIN,dysphagia,Studies In this,0
XEOMIN,dysphagia,total dose of,0
XEOMIN,dysphagia,randomize,1
XEOMIN,dysphagia,randomize d to,1
XEOMIN,dysphonia,patients received XEOMIN were,0
XEOMIN,dysphonia,to,1
XEOMIN,dysphonia,this study patients received XEOMIN,0
XEOMIN,dysphonia,patients received XEOMIN were to receiv e a total dose,1
XEOMIN,dysphonia,this study patients received XEOMIN,0
XEOMIN,dysphonia,Studies In this,0
XEOMIN,dysarthria,total do se of,1
XEOMIN,dysarthria,were randomized to a total do se of,1
XEOMIN,dysarthria,total do se of,1
XEOMIN,dysarthria,were randomized to a,1
XEOMIN,dysarthria,a total do se of,1
XEOMIN,dysarthria,a total do se of Units and were,1
XEOMIN,dysarthria,a total do se of,1
XEOMIN,dysarthria,total do se of Units and were,1
XEOMIN,dysarthria,total do se of,1
XEOMIN,dysarthria,receive a total dose of Units,0
XEOMIN,dysarthria,XEOMIN were randomized to a total do se of Units and,1
XEOMIN,dysarthria,receive a total dose of Units,0
XEOMIN,dysarthria,XEOMIN were randomized to a total,1
XEOMIN,urinary incontinence,were,0
XEOMIN,breathing difficulties,and randomized,1
XEOMIN,breathing difficulties,patients were to years,0
XEOMIN,breathing difficulties,"years old 53 years), and",1
XEOMIN,breathing difficulties,years old 53,1
XEOMIN,breathing difficulties,"53 years), and",1
XEOMIN,breathing difficulties,were pr,1
XEOMIN,breathing difficulties,and were pr edominantly female,1
XEOMIN,breathing difficulties,At study baseline approximately had,0
XEOMIN,breathing difficulties,of Units XEOMINtreated patients were to,0
XEOMIN,breathing difficulties,female and Caucasian At,0
XEOMIN,breathing difficulties,to years old 53,1
XEOMIN,breathing difficulties,"to years old 53 years), and were pr edominantly female",1
XEOMIN,breathing difficulties,to years old 53,1
XEOMIN,death,female and Caucasian At study,0
XEOMIN,death,had severe cervical dystonia Approximatel,0
XEOMIN,death,aseli ne approximately,1
XEOMIN,death,had severe cervical dystonia Approximatel,0
XEOMIN,death,had moderate and,0
XEOMIN,death,aseli,1
XEOMIN,spread of toxin effects,Approximately of XEOMINtreated patients,0
XEOMIN,spread of toxin effects,"study baseline y 25% had mild, 50% had",1
XEOMIN,spread of toxin effects,At study baseline y 25%,1
XEOMIN,spread of toxin effects,"baseline y 25% had mild, 50% had moderate and had",1
XEOMIN,spread of toxin effects,At study baseline y 25%,1
XEOMIN,spread of toxin effects,"study baseline y 25% had mild, 50% had moderate",1
XEOMIN,spread of toxin effects,At study baseline y 25%,1
XEOMIN,spread of toxin effect,musculoskeletal pain 2: Most Common TEAEs ( and Greater than,1
XEOMIN,spread of toxin effect,At study baseline y 25%,1
XEOMIN,spread of toxin effect,pain 2: Most Common TEAEs,1
XEOMIN,spread of toxin effect,and musculoskeletal pain 2: Most Common TEAEs ( and Greater than Placebo DoubleBlind,1
XEOMIN,spread of toxin effect,pain 2: Most Common TEAEs,1
XEOMIN,spread of toxin effect,muscle weakness injection site pain,0
XEOMIN,spread of toxin effect,ded dysphagia neck pain muscle weakness injection site,0
XEOMIN,spread of toxin effect,2: Most Common TEAEs ( and Greater than,1
XEOMIN,spread of toxin effect,musculoskeletal pain 2: Most Common TEAEs ( and,1
XEOMIN,spread of toxin effect,2: Most Common TEAEs ( and Greater than,1
XEOMIN,spread of toxin effect,2: Most,1
XEOMIN,spread of toxin effect,2: Most Common TEAEs ( and,1
XEOMIN,Hypersensitivity reactions,         7%                Gastrointestinal,1
XEOMIN,Hypersensitivity reactions,Musculoskeletal          7%                Gastrointestinal disorders,1
XEOMIN,Hypersensitivity reactions,         7%                Gastrointestinal,1
XEOMIN,Hypersensitivity reactions,pain,0
XEOMIN,Hypersensitivity reactions,         7%                Gastrointestinal,1
XEOMIN,anaphylaxis,"     
 Gast rointestinal disorders",1
XEOMIN,anaphylaxis,"     
 Gast",1
XEOMIN,anaphylaxis,"     
 Gast rointestinal",1
XEOMIN,anaphylaxis,"     
 Gast rointestinal disorders",1
XEOMIN,anaphylaxis,"     
 Gast rointestinal",1
XEOMIN,anaphylaxis,pain,0
XEOMIN,anaphylaxis,"     
 Gast rointestinal disorders",1
XEOMIN,anaphylaxis,pain,0
XEOMIN,anaphylaxis,"     
 Gast rointestinal",1
XEOMIN,anaphylaxis,"sculoskeletal      
 Gast rointestinal",1
XEOMIN,anaphylaxis,"     
 Gast rointestinal",1
XEOMIN,serum sickness,pain intestinal dis,1
XEOMIN,serum sickness,"     
 Gast rointestinal",1
XEOMIN,serum sickness,intestinal dis,1
XEOMIN,serum sickness,pain intestinal dis,1
XEOMIN,serum sickness,intestinal dis,1
XEOMIN,serum sickness,intestinal dis,1
XEOMIN,serum sickness,intestinal dis,1
XEOMIN,serum sickness,pain intestinal,1
XEOMIN,Dysphagia,blepharos pasm previously treated with onabotulinumtoxinA,1
XEOMIN,Dysphagia,blepharos pasm previously treated with,1
XEOMIN,Dysphagia,blepharos pasm previously treated,1
XEOMIN,Dysphagia,blepharos pasm previously treated,1
XEOMIN,Dysphagia,Phase trial in patients blepharos pasm previously treated,1
XEOMIN,Dysphagia,blepharos pasm previously treated,1
XEOMIN,Dysphagia,patients blepharos,1
XEOMIN,Dysphagia,blepharos pasm previously treated,1
XEOMIN,Aspiration,XEOMIN at,1
XEOMIN,Aspiration,Studies patients  XEOMIN at a mean dose,1
XEOMIN,Aspiration,XEOMIN at,1
XEOMIN,Aspiration,minimum Units maximum,0
XEOMIN,Aspiration,patients  XEOMIN at,1
XEOMIN,Aspiration,minimum Units maximum,0
XEOMIN,Aspiration,XEOMIN at,1
XEOMIN,dysphagia,ately 33 Units per eye minimum Units,1
XEOMIN,dysphagia,ately 33 Units,1
XEOMIN,dysphagia,Clinical Studies patients received XEOMIN at a mean dose of approxim,0
XEOMIN,dysphagia,XEOMINtreated patients were to,0
XEOMIN,dysphagia,of ately 33  Units per eye minimum,1
XEOMIN,dysphagia,XEOMINtreated patients were to,0
XEOMIN,weaken neck muscles,age mean years predominantly,0
XEOMIN,weaken neck muscles,mean years predominantly,0
XEOMIN,weaken neck muscles,since diagn osis of,1
XEOMIN,weaken neck muscles,an time since diagn osis of,1
XEOMIN,weaken neck muscles,since diagn osis of,1
XEOMIN,weaken neck muscles,age mean years predominantly female Caucasian and had,0
XEOMIN,weaken neck muscles,an time,1
XEOMIN,weaken neck muscles,and had a an time since diagn osis,1
XEOMIN,weaken neck muscles,an time,1
XEOMIN,weaken neck muscles,and had a an time since diagn,1
XEOMIN,weaken neck muscles,an time,1
XEOMIN,weaken neck muscles,an time since,1
XEOMIN,loss of breathing capacity,occurring in of,0
XEOMIN,loss of breathing capacity,diagnosis of approximately years The adverse events occurring,0
XEOMIN,loss of breathing capacity,patients and greater,1
XEOMIN,loss of breathing capacity,OMIN-treated patients,1
XEOMIN,loss of breathing capacity,occurring in of OMIN-treated patients and,1
XEOMIN,breathing difficulties,headache visual impairment dyspnea,0
XEOMIN,breathing difficulties,dry eye dry mouth diarrhea headache visual,0
XEOMIN,breathing difficulties,one placebotreated,0
XEOMIN,breathing difficulties,impairment dyspnea nasopharyngitis  respiratory tract inf ection No,1
XEOMIN,breathing difficulties,one placebotreated,0
XEOMIN,breathing difficulties,visual impairment dyspnea nasopharyngitis  respiratory tract inf ection No serious adverse,1
XEOMIN,breathing difficulties,one placebotreated,0
XEOMIN,breathing difficulties,nasopharyngitis,0
XEOMIN,breathing difficulties,diarrhea headache,0
XEOMIN,breathing difficulties,respiratory tract inf ection No,1
XEOMIN,respiratory failure,adverse even ts occurred in patients,1
XEOMIN,respiratory failure,erious adverse even ts occurred,1
XEOMIN,respiratory failure,in patients,0
XEOMIN,respiratory failure,erious adverse even ts occurred,1
XEOMIN,respiratory failure,No erious adverse even,1
XEOMIN,respiratory failure,infection No erious adverse,1
XEOMIN,respiratory failure,infection No erious adverse even,1
XEOMIN,respiratory failure,visual impairment dyspnea nasopharyngitis and,0
XEOMIN,respiratory failure,received XEOMIN one placebotreated patient,0
XEOMIN,respiratory failure,erious adverse even ts occurred in patients who,1
XEOMIN,dysphagia,System Organ,0
XEOMIN,dysphagia,          DoubleBlind Phase,1
XEOMIN,dysphagia,Trial,0
XEOMIN,transmission of viral diseases,N with glabellar lines,0
XEOMIN,transmission of viral diseases,adverse events in there is some basis to,1
XEOMIN,transmission of viral diseases,is some basis to believe,1
XEOMIN,transmission of viral diseases,there is some basis to believe there is a causal,1
XEOMIN,transmission of viral diseases,is some basis to believe,1
XEOMIN,Creutzfeldt-Jakob disease,drug and the occurrenc e of the adverse,1
XEOMIN,Creutzfeldt-Jakob disease,causal relationship between he drug and the occurrenc e of the adverse event,1
XEOMIN,Creutzfeldt-Jakob disease,drug and the occurrenc e of the adverse,1
XEOMIN,Creutzfeldt-Jakob disease,is a causal,0
XEOMIN,Creutzfeldt-Jakob disease,a causal relationship between he drug and,1
XEOMIN,Creutzfeldt-Jakob disease,between he drug and the occurrenc,1
XEOMIN,Creutzfeldt-Jakob disease,between he drug and the occurrenc e,1
XEOMIN,Creutzfeldt-Jakob disease,between he drug and the occurrenc,1
XEOMIN,Creutzfeldt-Jakob disease,a causal relationship between he drug and the,1
XEOMIN,Creutzfeldt-Jakob disease,there is some,0
XEOMIN,Creutzfeldt-Jakob disease,there is,0
XEOMIN,CJD,of  the adverse,1
XEOMIN,CJD,of  the adverse event Because clinical,1
XEOMIN,CJD,under widely varying,0
XEOMIN,CJD,is a causal relationship between the drug,0
XEOMIN,CJD,clinical trials are conducted under,0
XEOMIN,CJD,basis to believe there is a causal relationship between the drug and the,0
XEOMIN,CJD,of  the adverse event Because,1
XEOMIN,CJD,basis to believe there is a causal relationship between the drug and the,0
XEOMIN,CJD,of  the,1
QUTENZA,Application-Associated Pain,in the Application-Associated Pain see Warnings and Precautions Increase,1
QUTENZA,Application-Associated Pain,of  the,1
QUTENZA,Application-Associated Pain,Application-Associated Pain see Warnings,1
QUTENZA,Application-Associated Pain,Application-Associated Pain,1
QUTENZA,Application-Associated Pain,Application-Associated Pain see,1
QUTENZA,Application-Associated Pain,Application-Associated Pain,1
QUTENZA,Application-Associated Pain,in the Application-Associated,1
QUTENZA,Application-Associated Pain,Warnings,0
QUTENZA,Application-Associated Pain,Increase in Blood Pressure see Warnings and,0
QUTENZA,Increase in Blood Pressure,and Increase in,1
QUTENZA,Increase in Blood Pressure,in Blood Pressure see Warnings and,1
QUTENZA,Increase in Blood Pressure,Increase in,1
QUTENZA,Increase in Blood Pressure,Pain see Warnings and Increase in Blood Pressure,1
QUTENZA,Increase in Blood Pressure,Warnings and Increase in Blood Pressure see Warnings and Precautions EXCERPT,1
QUTENZA,Increase in Blood Pressure,Pain see Warnings and Increase in Blood Pressure,1
QUTENZA,Increase in Blood Pressure,and Increase in,1
QUTENZA,Increase in Blood Pressure,Increase in Blood Pressure,1
QUTENZA,Increase in Blood Pressure,Increase in Blood Pressure see Warnings and Precautions,1
QUTENZA,Increase in Blood Pressure,Pain see Warnings and Precautions,0
QUTENZA,application site erythema,control application site erythema application,1
QUTENZA,application site erythema,Pain see Warnings and Precautions,0
QUTENZA,application site erythema,are,0
QUTENZA,application site erythema,control application site erythema,1
QUTENZA,application site erythema,are,0
QUTENZA,application site erythema,are,0
QUTENZA,application site erythema,site papules,0
QUTENZA,application site erythema,pruritus and application site,0
QUTENZA,application site erythema,pain application site pruritus and application site papules To,0
QUTENZA,application site pain,and application site papules To report SUSPECTED,0
QUTENZA,application site pain,application site pain application site pruritus,1
QUTENZA,application site pain,and application site papules To report SUSPECTED,0
QUTENZA,application site pain,application site pain application site pruritus,1
QUTENZA,application site pruritus,application site,1
QUTENZA,application site papules,site papules,1
QUTENZA,application site papules,ADVERSE REACTIONS,0
QUTENZA,application site papules,contact,0
QUTENZA,application site papules,To report SUSPECTED ADVERSE REACTIONS contact,0
QUTENZA,application site papules,site pruritus and,0
QUTENZA,application site papules,pruritus application site papules,1
QUTENZA,application site papules,application site papules To report SUSPECTED ADVERSE REACTIONS,1
QUTENZA,application site erythema,pruritus and application site papules Table,0
QUTENZA,application site erythema,site papules Table,0
QUTENZA,application site erythema,group application site,1
QUTENZA,application site erythema,application site,0
QUTENZA,application site erythema,application site erythema,1
QUTENZA,application site erythema,in the control,0
QUTENZA,application site erythema,application,0
QUTENZA,application site erythema,control group application site erythema application site pain application site,1
QUTENZA,application site erythema,application,0
QUTENZA,application site erythema,control group application site erythema application,1
QUTENZA,application site erythema,application,0
QUTENZA,application site pain,an incidence,0
QUTENZA,application site pain,site pain application,1
QUTENZA,application site pain,application site pruritus and application site papules Table summarizes all adverse,0
QUTENZA,application site pain,application site application site,1
QUTENZA,application site pain,application site pain,1
QUTENZA,application site pain,application site application site,1
QUTENZA,application site pain,application site pruritus and application site papules Table,0
QUTENZA,application site pain,application site application site pain,1
QUTENZA,application site pain,Table summarizes all,0
QUTENZA,application site pain,group were application site application,1
QUTENZA,application site pain,site papules Table,0
QUTENZA,application site pruritus,application site application site pruritus,1
QUTENZA,application site pruritus,site erythema application site application site pruritus and,1
QUTENZA,application site pruritus,application site application site pruritus,1
QUTENZA,application site pruritus,application site pruritus and application site papules Table,1
QUTENZA,application site pruritus,control group were application site erythema application site pain,0
QUTENZA,application site pruritus,application site pruritus and,1
QUTENZA,application site pruritus,site pruritus and application site papules,1
QUTENZA,application site pruritus,application site pruritus,1
QUTENZA,application site pruritus,site,0
QUTENZA,application site pruritus,reactions,0
QUTENZA,application site pruritus,application site pruritus and application site,1
QUTENZA,application site papules,application site papules Table summarizes all,1
QUTENZA,application site papules,application site pruritus and application site,1
QUTENZA,application site papules,were application site erythema application site pain application site,0
QUTENZA,application site papules,site,0
QUTENZA,application site papules,pain application site pruritus application site papules Table summarizes,1
QUTENZA,application site papules,site,0
QUTENZA,application site reactions,majority,0
QUTENZA,application site reactions,majority,0
QUTENZA,application site reactions,observed on the day of,0
QUTENZA,application site reactions,The,0
QUTENZA,application site reactions,group for which the incidence was greater,0
QUTENZA,application site reactions,application site,1
QUTENZA,application site reactions,site reactions were,1
QUTENZA,application site reactions,application site reactions were transient and,1
QUTENZA,application site reactions,site reactions were,1
QUTENZA,application site reactions,transient and,0
QUTENZA,application site reactions,in,0
QUTENZA,application site reactions,group The majority application,1
QUTENZA,increases in pain,increases in pain were commonly observed on the,1
QUTENZA,increases in pain,group The majority application,1
QUTENZA,increases in pain,and selflimited increases in pain,1
QUTENZA,increases in pain,increases,1
QUTENZA,Pain increases,Pain increases occurring during patch application usually,1
QUTENZA,Pain increases,patients treated with Pain increases,1
QUTENZA,Pain increases,Pain increases occurring during patch application usually,1
QUTENZA,Pain increases,Qutenza,0
QUTENZA,Pain increases,Pain,1
QUTENZA,Pain increases,treated with Pain increases,1
QUTENZA,Pain increases,Pain increases occurring during patch application usually,1
QUTENZA,Application Site Erythema,Site Conditions,0
QUTENZA,Application Site Erythema,Administration Site Application Site Erythema Application,1
QUTENZA,Application Site Erythema,Site Conditions,0
QUTENZA,Application Site Erythema,Application Site Erythema Application Site,1
QUTENZA,Application Site Erythema,ders and Administration Site Application Site,1
QUTENZA,Application Site Erythema,Application Site Erythema Application Site,1
QUTENZA,Application Site Erythema,Site Erythema Application,1
QUTENZA,Application Site Erythema,Application Site Erythema,1
QUTENZA,Application Site Papules,Site,0
QUTENZA,Application Site Papules,Application Site Papules,1
QUTENZA,Application Site Papules,Site,0
QUTENZA,Application Site Papules,on Site Pruritus,0
QUTENZA,Application Site Papules,on Site Application Site Papules Application,1
QUTENZA,Application Site Papules,on Site Pruritus,0
QUTENZA,Application Site Papules,Application Site Papules,1
QUTENZA,Application Site Papules,on Site Pruritus,0
QUTENZA,Application Site Papules,Site Application Site Papules Application Sit,1
QUTENZA,Application Site Papules,on Site Pruritus,0
QUTENZA,Application Site Edema,Application Site Edema Application S,1
QUTENZA,Application Site Edema,on Site Application Site Edema,1
QUTENZA,Application Site Edema,on Site Application Site Edema Application,1
QUTENZA,Application Site Edema,on Site Application Site Edema,1
QUTENZA,Application Site Edema,Application Site Edema Application,1
QUTENZA,Application Site Edema,Site Edema,1
QUTENZA,Application Site Edema,Site Application Site,1
QUTENZA,Application Site Swelling,Application Site,1
QUTENZA,Application Site Dryness,Site Application Site Dryness Infections,1
QUTENZA,Application Site Dryness,Application Site,1
QUTENZA,Application site urticaria,Disorders and Administration Site Application site,1
QUTENZA,Application site urticaria,Application site urticaria,1
QUTENZA,Application site urticaria,and Administration Site Application site urticaria Application,1
QUTENZA,Application site urticaria,Application site urticaria,1
QUTENZA,Application site paresthesia,Conditions Application,0
QUTENZA,Application site paresthesia,Site Conditions Application site Application site paresthesia Application site dermatitis,1
QUTENZA,Application site paresthesia,Conditions Application,0
QUTENZA,Application site paresthesia,site paresthesia,1
QUTENZA,Application site paresthesia,site Application,1
QUTENZA,Application site paresthesia,Application site dermatitis Application site hyperesthesia Application site excoriation Applica,0
QUTENZA,Application site paresthesia,Conditions Application site Application site paresthesia Application site dermatitis Application,1
QUTENZA,Application site paresthesia,Application site dermatitis Application site hyperesthesia Application site excoriation Applica,0
QUTENZA,Application site paresthesia,Application site Application site paresthesia,1
QUTENZA,Application site paresthesia,Application site dermatitis Application site hyperesthesia Application site excoriation Applica,0
QUTENZA,Application site paresthesia,Application site paresthesia Application site dermatitis Application,1
QUTENZA,Application site paresthesia,Site Conditions Application site Application,1
QUTENZA,Application site paresthesia,Application site paresthesia Application site dermatitis,1
QUTENZA,Application site dermatitis,Administration Site Conditions Application site urticaria Application site paresthesia,0
QUTENZA,Application site dermatitis,Application site hyperesthesia Application site excoriation Application,0
QUTENZA,Application site dermatitis,site dermatitis Application site hyperesthesia Application,1
QUTENZA,Application site dermatitis,site dermatitis,1
QUTENZA,Application site dermatitis,Application site paresthesia,0
QUTENZA,Application site dermatitis,site dermatitis Application site hyperesthesia Application site,1
QUTENZA,Application site dermatitis,Administration Site Conditions Application site urticaria Application site paresthesia,0
QUTENZA,Application site dermatitis,site dermatitis Application site hyperesthesia Application,1
QUTENZA,Application site dermatitis,site dermatitis Application site,1
QUTENZA,Application site dermatitis,urticaria Application site Application site,1
QUTENZA,Application site excoriation,Application site warmth Application site anesthesia Application site,0
QUTENZA,Application site excoriation,bruising Application site,0
QUTENZA,Application site warmth,hyperesthesia Application,0
QUTENZA,Application site warmth,hyperesthesia Application,0
QUTENZA,Application site warmth,hyperesthesia Application site excoriation,0
QUTENZA,Application site warmth,Application site warmth Application site anesthesia,1
QUTENZA,Application site warmth,hyperesthesia Application site excoriation,0
QUTENZA,Application site warmth,site hyperesthesia Application site Application site warmth Application,1
QUTENZA,Application site warmth,hyperesthesia Application site excoriation,0
QUTENZA,Application site warmth,site anesthesia Application site bruising,0
QUTENZA,Application site warmth,site Application site warmth,1
QUTENZA,Application site warmth,site anesthesia Application site bruising,0
QUTENZA,Application site anesthesia,Application site anesthesia,1
QUTENZA,Application site anesthesia,Application site,0
QUTENZA,Application site bruising,inflammation Application site exfoliation Peripheral edema,0
QUTENZA,Application site bruising,Application site Application,1
QUTENZA,Application site bruising,edema Nervous,0
QUTENZA,Application site bruising,site inflammation Application site exfoliation,0
QUTENZA,Application site inflammation,Application site inflammation Application,1
QUTENZA,Application site inflammation,site inflammation Application site exfoliation,0
QUTENZA,Application site exfoliation,Application site exfoliation,1
QUTENZA,Application site exfoliation,site inflammation Application site exfoliation,0
QUTENZA,Application site exfoliation,site Application site exfoliation Peripheral edema Nervous System Disorders,1
QUTENZA,Application site exfoliation,site inflammation Application site exfoliation,0
QUTENZA,Application site exfoliation,site Application site exfoliation Peripheral edema Nervous System Disorders,1
QUTENZA,Application site exfoliation,site inflammation Application site exfoliation,0
QUTENZA,Application site exfoliation,sensation Peripheral sensory neu,0
QUTENZA,Application site exfoliation,site exfoliation Peripheral edema,1
QUTENZA,Application site exfoliation,bruising Application site Application,1
QUTENZA,Application site exfoliation,Application site,1
QUTENZA,Application site exfoliation,Application site,0
QUTENZA,Application site exfoliation,Application site bruising,0
QUTENZA,Peripheral edema,Application site inflammation Application site exfoliation,0
QUTENZA,Peripheral edema,Peripheral edema Nervous System,1
QUTENZA,Peripheral edema,Peripheral edema Nervous System Disorders,1
QUTENZA,Peripheral edema,Peripheral edema Nervous System,1
QUTENZA,Peripheral edema,site inflammation Application site Peripheral edema,1
QUTENZA,Peripheral edema,inflammation Application site exfoliation,0
QUTENZA,Headache,exfoliation Peripheral edema Nervous System Disorders,0
QUTENZA,Headache,Headache Burning,1
QUTENZA,Headache,ion site inflammation Application site exfoliation Peripheral edema Nervous System,0
QUTENZA,Headache,inflammation,0
QUTENZA,Headache,Headache Burning sensation,1
QUTENZA,Headache,sensory,0
QUTENZA,Burning sensation,System Disorders,0
QUTENZA,Burning sensation,edema Nervous System Disorders Burning sensation Peripheral sensory neuropathy,1
QUTENZA,Burning sensation,System Disorders,0
QUTENZA,Burning sensation,nflammation Application site,0
QUTENZA,Burning sensation,Dizziness Dysgeusia Hyperesthesia Hypoesthesia,0
QUTENZA,Burning sensation,Nervous System Disorders Headache,0
QUTENZA,Burning sensation,Disorders Burning sensation,1
QUTENZA,Burning sensation,Nervous System,0
QUTENZA,Burning sensation,Peripheral edema,0
QUTENZA,Peripheral sensory neuropathy,sensory neuropathy Dizziness Dysgeusia Hyperesthesia Hypoesthesia,1
QUTENZA,Peripheral sensory neuropathy,sensation,0
QUTENZA,Peripheral sensory neuropathy,exfoliation Peripheral edema Nervous System Disorders Headache Burning sensation,0
QUTENZA,Peripheral sensory neuropathy,Burning Peripheral,1
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia Hypoesthesia Respiratory Thoracic,1
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia Hypoesthesia Respiratory,1
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia Hypoesthesia Respiratory Thoracic,1
QUTENZA,Dizziness,System Disorders Headache,0
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia Hypoesthesia Respiratory Thoracic,1
QUTENZA,Dizziness,Hyperesthesia Hypoesthesia Respiratory,0
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia Hypoesthesia,1
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia,1
QUTENZA,Dizziness,Peripheral sensory Dizziness Dysgeusia Hyperesthesia Hypoesthesia Respiratory,1
QUTENZA,Dizziness,Dizziness Dysgeusia Hyperesthesia,1
QUTENZA,Hypoesthesia,Hypoesthesia Respiratory Thoracic and Mediastinal,1
QUTENZA,Hypoesthesia,Peripheral,0
QUTENZA,Hypoesthesia,Hypoesthesia Respiratory Thoracic and Mediastinal Disorders,1
QUTENZA,Hypoesthesia,Peripheral sensory neuropathy Dizziness Dysgeusia,0
QUTENZA,Hypoesthesia,Headache Burning sensation Peripheral sensory neuropathy Dizziness Dysgeusia,0
QUTENZA,Hypoesthesia,Dizziness,0
QUTENZA,Hypoesthesia,neuropathy Dizziness Dysgeusia,0
QUTENZA,Hypoesthesia,Dysgeusia Hyperesthesia,0
QUTENZA,Hypoesthesia,Hypoesthesia Respiratory Thoracic and Mediastinal Disorders,1
QUTENZA,Hypoesthesia,Hypoesthesia Respiratory Thoracic and Mediastinal,1
QUTENZA,Hypoesthesia,Hypoesthesia Respiratory Thoracic and Mediastinal Disorders,1
QUTENZA,Cough,Cough Throat,1
QUTENZA,Cough,Cough Throat irritation Skin and Subcutaneous,1
QUTENZA,Cough,Mediastinal Cough Throat irritation,1
QUTENZA,Cough,Cough Throat irritation Skin and Subcutaneous,1
QUTENZA,Throat irritation,Hypoesthesia Respiratory Thoracic,0
QUTENZA,Throat irritation,Hyperesthesia Hypoesthesia Respiratory Thoracic and Mediastinal,0
QUTENZA,Throat irritation,Cough,0
QUTENZA,Throat irritation,Tissue Disorders,0
QUTENZA,Throat irritation,Throat irritation,1
QUTENZA,sneezing,and ions (5. Increase in Blood Pressure see,1
QUTENZA,sneezing,Throat irritation,1
QUTENZA,sneezing,and ions (5. Increase in Blood,1
QUTENZA,sneezing,Throat irritation,1
QUTENZA,sneezing,in Blood Pressure see Warnings,0
QUTENZA,sneezing,ions (5. Increase in,1
QUTENZA,increases in blood pressure,"ACTIONS, contact Acorda The rapeutics at",1
QUTENZA,increases in blood pressure,ions (5. Increase in,1
QUTENZA,increases in blood pressure,or,0
QUTENZA,increases in blood pressure,"ACTIONS,",1
QUTENZA,increases in blood pressure,To report SUSPECTED ADVERSE,0
QUTENZA,increases in blood pressure,or,0
QUTENZA,coughing,in the Qutenza,0
QUTENZA,coughing,in,0
QUTENZA,coughing,an e greate r than in,1
QUTENZA,coughing,in,0
QUTENZA,coughing,e greate r than in,1
QUTENZA,coughing,at an e,1
QUTENZA,coughing,and at an e greate,1
QUTENZA,coughing,application site erythema application site pain application,0
QUTENZA,coughing,than in the control,0
QUTENZA,coughing,at an e greate r,1
QUTENZA,coughing,than in the control,0
QUTENZA,sneezing,incidence greater an in th,1
QUTENZA,sneezing,in th e,1
QUTENZA,sneezing,and at an,0
QUTENZA,sneezing,in th e,1
QUTENZA,procedural pain,day of treatme nt in patients treated,1
QUTENZA,procedural pain,day,1
QUTENZA,procedural pain,of treatme nt,1
QUTENZA,procedural pain,observed on day of treatme,1
QUTENZA,procedural pain,day of,1
QUTENZA,procedural pain,observed on  day of treatme nt in,1
QUTENZA,procedural pain,day of,1
QUTENZA,increases in blood pressure,"reactions with a maximum ntensity of ""mild"" or ""mode rate",1
QUTENZA,increases in blood pressure,day of,1
QUTENZA,Increases in blood pressure,in,0
QUTENZA,Increases in blood pressure,"Qutenza group than the Control group) 
 Body S ystemPreferred Term",1
QUTENZA,Increases in blood pressure,in,0
QUTENZA,increases in pain,Disorders and Administration Site Conditions,0
QUTENZA,increases in pain,"Control tes(N = 495)%   
 General Disorders and",1
QUTENZA,increases in pain,Disorders and Administration Site Conditions,0
QUTENZA,increases in pain,Body,0
QUTENZA,increases in pain,tes(N = 495)% General Disorders and Administration,1
QUTENZA,increases in pain,"minutesN Control tes(N = 495)%   
 General Disorders",1
QUTENZA,increases in pain,tes(N = 495)% General Disorders and Administration,1
QUTENZA,increases in pain,Qutenza minutesN,0
QUTENZA,increases in pain,General Disorders and Administration,0
QUTENZA,increases in pain,tes(N = 495)% General Disorders and,1
QUTENZA,increases in pain,"Term Qutenza minutesN Control tes(N = 495)%   
",1
QUTENZA,increases in pain,tes(N = 495)% General Disorders and,1
QUTENZA,adverse cardiovascular effects,                     42        Application,1
ZYTIGA,Hypertension,of the Hypertension Hypokalemia and Fluid Retention,1
ZYTIGA,Hypertension,                     42        Application,1
ZYTIGA,Hypertension,Hypertension Hypokalemia and Fluid Retention due,1
ZYTIGA,Hypertension,sections of the Hypertension Hypokalemia and Fluid,1
ZYTIGA,Hypertension,Hypertension Hypokalemia and Fluid Retention due,1
ZYTIGA,Hypertension,Hypertension Hypokalemia,1
ZYTIGA,Hypertension,more detail in other sections of,0
ZYTIGA,Hypertension,Mineralocorticoid Excess seeWarnings,0
ZYTIGA,Hypertension,Hypertension Hypokalemia and Fluid,1
ZYTIGA,Hypertension,Hypertension Hypokalemia and Fluid Retention,1
ZYTIGA,Hypertension,more detail in other sections of the,0
ZYTIGA,Hypertension,of the Hypertension Hypokalemia and,1
ZYTIGA,Hypertension,more detail in other sections of the,0
ZYTIGA,Hypokalemia,Fluid Retention due to Mineralocorticoid Excess seeWarnings and Precautions Adr,0
ZYTIGA,Hypokalemia,Hypokalemia and Fluid Retention due to,1
ZYTIGA,Hypokalemia,Hypokalemia and Fluid Retention,1
ZYTIGA,Hypokalemia,following are discussed in,0
ZYTIGA,Hypokalemia,due to Mineralocorticoid,0
ZYTIGA,Hypokalemia,labeling,0
ZYTIGA,Hypokalemia,Hypokalemia and,1
ZYTIGA,Fluid Retention,due to Mineralocorticoid Excess seeWarnings and Precautions,0
ZYTIGA,Adrenocortical Insufficiency,seeWarnings,0
ZYTIGA,Adrenocortical Insufficiency,Precautions Hepatotoxicity seeWarnings and,0
ZYTIGA,Adrenocortical Insufficiency,Precautions Hepatotoxicity seeWarnings,0
ZYTIGA,Hepatotoxicity,Hepatotoxicity,1
ZYTIGA,Hepatotoxicity,Hepatotoxicity seeWarnings,1
ZYTIGA,Hepatotoxicity,seeWarnings and Hepatotoxicity seeWarnings and Precautions,1
ZYTIGA,Hepatotoxicity,Hepatotoxicity seeWarnings,1
ZYTIGA,Hepatotoxicity,d Precautions Adrenocortical Insufficiency seeWarnings,0
ZYTIGA,Hepatotoxicity,Precautions Adrenocortical Insufficiency seeWarnings and,0
ZYTIGA,Hepatotoxicity,Insufficiency seeWarnings and Hepatotoxicity,1
ZYTIGA,Hepatotoxicity,Precautions Adrenocortical Insufficiency seeWarnings and,0
ZYTIGA,Hepatotoxicity,Hepatotoxicity seeWarnings and,1
ZYTIGA,Hepatotoxicity,most common adverse reactions,0
ZYTIGA,fatigue,fatigue joint swelling or,1
ZYTIGA,fatigue,fatigue joint swelling or,1
ZYTIGA,fatigue,fatigue joint swelling or discomfort edema,1
ZYTIGA,fatigue,joint swelling or discomfort,0
ZYTIGA,joint swelling,hypertension dyspnea,0
ZYTIGA,joint swelling,urinary,0
ZYTIGA,joint swelling,joint swelling,1
ZYTIGA,joint swelling,joint swelling or discomfort,1
ZYTIGA,joint swelling,joint swelling,1
ZYTIGA,joint swelling,Precautions,0
ZYTIGA,edema,edema hot flush diarrhea vomiting cough,1
ZYTIGA,edema,flush diarrhea vomiting cough hypertension dyspnea,0
ZYTIGA,edema,joint swelling or edema hot flush,1
ZYTIGA,edema,flush diarrhea vomiting cough hypertension dyspnea,0
ZYTIGA,edema,edema hot flush diarrhea vomiting,1
ZYTIGA,edema,or edema hot flush diarrhea vomiting cough,1
ZYTIGA,edema,edema hot flush diarrhea vomiting,1
ZYTIGA,hot flush,or discomfort hot flush,1
ZYTIGA,hot flush,edema hot flush diarrhea vomiting,1
ZYTIGA,diarrhea,diarrhea vomiting cough hypertension dyspnea urinary,1
ZYTIGA,diarrhea,edema hot flush diarrhea vomiting,1
ZYTIGA,diarrhea,reactions are fatigue joint swelling or discomfort,0
ZYTIGA,diarrhea,urinary tract infection and contusion The,0
ZYTIGA,cough,reactions are fatigue joint,0
ZYTIGA,hypertension,diarrhea vomiting hypertension dyspnea urinary tract infection,1
ZYTIGA,hypertension,reactions are fatigue joint,0
ZYTIGA,hypertension,vomiting hypertension dyspnea,1
ZYTIGA,hypertension,reactions are fatigue joint,0
ZYTIGA,dyspnea,vomiting cough dyspnea urinary tract infection and contusion,1
ZYTIGA,dyspnea,reactions are fatigue joint,0
ZYTIGA,dyspnea,dyspnea urinary,1
ZYTIGA,urinary tract infection,hypertension urinary tract infection,1
ZYTIGA,urinary tract infection,vomiting cough hypertension urinary tract infection,1
ZYTIGA,contusion,flush diarrhea vomiting cough hypertension dyspnea urinary tract infection,0
ZYTIGA,contusion,contusion The,1
ZYTIGA,contusion,The most common laboratory abnormalities are,0
ZYTIGA,contusion,contusion The most common,1
ZYTIGA,anemia,common laboratory abnormalities anemia elevated alkaline,1
ZYTIGA,anemia,contusion The most common,1
ZYTIGA,anemia,and contusion The most,0
ZYTIGA,anemia,anemia elevated alkaline phosphatase hypertriglyceridemia,1
ZYTIGA,anemia,alkaline phosphatase,0
ZYTIGA,elevated alkaline phosphatase,hypercholesterolemia hyperglycemia elevated AST,0
ZYTIGA,elevated alkaline phosphatase,elevated alkaline phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia,1
ZYTIGA,elevated alkaline phosphatase,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia elevated,0
ZYTIGA,elevated alkaline phosphatase,laboratory,0
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia elevated AST,1
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia,1
ZYTIGA,hypertriglyceridemia,lymphopenia hypercholesterolemia hyperglycemia elevated AST,0
ZYTIGA,hypertriglyceridemia,hypercholesterolemia hyperglycemia elevated AST hypophosphatemia elevated,0
ZYTIGA,lymphopenia,elevated ALT,0
ZYTIGA,lymphopenia,abnormalities are anemia elevated alkaline phosphatase hypertriglyceridemia,0
ZYTIGA,lymphopenia,lymphopenia hypercholesterolemia,1
ZYTIGA,lymphopenia,lymphopenia hypercholesterolemia hyperglycemia elevated AST,1
ZYTIGA,hyperglycemia,anemia elevated,0
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,hypophosphatemia,hypophosphatemia elevated ALT,1
ZYTIGA,elevated ALT,elevated ALT and,1
ZYTIGA,elevated ALT,elevated AST elevated ALT and hypokalemia To report SUSPECTED,1
ZYTIGA,elevated ALT,elevated ALT and,1
ZYTIGA,elevated ALT,elevated ALT and hypokalemia To report,1
ZYTIGA,elevated ALT,report,0
ZYTIGA,elevated ALT,AST elevated,1
ZYTIGA,elevated ALT,ADVERSE REACTIONS contact Janssen Biotech Inc at,0
ZYTIGA,elevated ALT,To report SUSPECTED ADVERSE REACTIONS contact Janssen Biotech,0
ZYTIGA,elevated ALT,elevated ALT,1
ZYTIGA,elevated ALT,elevated ALT and hypokalemia To report SUSPECTED,1
ZYTIGA,elevated ALT,elevated AST elevated ALT,1
ZYTIGA,elevated ALT,elevated ALT and hypokalemia To report SUSPECTED,1
ZYTIGA,hypokalemia,hypokalemia To,1
ZYTIGA,joint swelling,acetate arm were joint,1
ZYTIGA,joint swelling,joint swelling or,1
ZYTIGA,joint swelling,acetate arm were joint,1
ZYTIGA,joint swelling,flush diarrhea vomiting cough hypertension dyspnea urinary,0
ZYTIGA,joint swelling,joint swelling,1
ZYTIGA,joint swelling,were,0
ZYTIGA,joint swelling,clinical trials that occurred more commonly in the abiraterone acetate arm,0
ZYTIGA,joint swelling,edema hot flush diarrhea vomiting cough hypertension dyspnea urinary tract in,0
ZYTIGA,joint swelling,abiraterone acetate arm were,0
ZYTIGA,joint swelling,were joint swelling or,1
ZYTIGA,joint swelling,abiraterone acetate arm were,0
ZYTIGA,edema,edema hot flush diarrhea vomiting,1
ZYTIGA,edema,vomiting,0
ZYTIGA,edema,edema hot flush,1
ZYTIGA,edema,edema hot flush,1
ZYTIGA,hot flush,infection,0
ZYTIGA,hot flush,cough,0
ZYTIGA,hot flush,vomiting cough hypertension dyspnea urinary tract infection,0
ZYTIGA,diarrhea,hot diarrhea vomiting cough hypertension dyspnea,1
ZYTIGA,diarrhea,vomiting cough hypertension dyspnea urinary tract infection,0
ZYTIGA,diarrhea,abiraterone acetate,0
ZYTIGA,diarrhea,or discomfort edema,0
ZYTIGA,diarrhea,or discomfort edema hot diarrhea vomiting cough hypertension,1
ZYTIGA,diarrhea,or discomfort edema,0
ZYTIGA,diarrhea,or discomfort,0
ZYTIGA,diarrhea,or discomfort edema,0
ZYTIGA,vomiting,vomiting cough hypertension dyspnea,1
ZYTIGA,vomiting,vomiting cough hypertension dyspnea urinary,1
ZYTIGA,vomiting,vomiting cough hypertension dyspnea,1
ZYTIGA,vomiting,most common,0
ZYTIGA,vomiting,vomiting cough hypertension dyspnea urinary,1
ZYTIGA,vomiting,dyspnea urinary tract infection and contusion The most common laborator,0
ZYTIGA,vomiting,vomiting cough hypertension dyspnea,1
ZYTIGA,vomiting,discomfort edema,0
ZYTIGA,cough,and contusion The,0
ZYTIGA,cough,most common,0
ZYTIGA,cough,cough hypertension dyspnea,1
ZYTIGA,cough,and contusion The most common,0
ZYTIGA,cough,dyspnea,0
ZYTIGA,cough,cough hypertension dyspnea urinary tract,1
ZYTIGA,cough,cough hypertension,1
ZYTIGA,cough,vomiting,0
ZYTIGA,hypertension,vomiting,0
ZYTIGA,hypertension,hypertension dyspnea urinary,1
ZYTIGA,hypertension,vomiting,0
ZYTIGA,hypertension,hypertension dyspnea urinary tract infection,1
ZYTIGA,hypertension,hypertension dyspnea,1
ZYTIGA,hypertension,hypertension dyspnea,1
ZYTIGA,dyspnea,dyspnea urinary tract,1
ZYTIGA,dyspnea,dyspnea urinary tract infection and contusion,1
ZYTIGA,dyspnea,fatigue joint swelling or discomfort edema,0
ZYTIGA,dyspnea,diarrhea vomiting cough dyspnea,1
ZYTIGA,dyspnea,fatigue joint swelling or discomfort edema,0
ZYTIGA,dyspnea,common laboratory abnormalities,0
ZYTIGA,dyspnea,dyspnea urinary tract,1
ZYTIGA,urinary tract infection,tract infection and contusion,1
ZYTIGA,urinary tract infection,urinary tract infection,1
ZYTIGA,urinary tract infection,urinary tract infection and,1
ZYTIGA,urinary tract infection,most common laboratory abnormalities reported in the two randomized,0
ZYTIGA,contusion,dyspnea urinary tract infection contusion The most common laboratory,1
ZYTIGA,contusion,most common laboratory abnormalities reported in the two randomized,0
ZYTIGA,contusion,rt edema hot flush diarrhea,0
ZYTIGA,contusion,randomized,0
ZYTIGA,contusion,contusion The most,1
ZYTIGA,contusion,urinary tract infection contusion The,1
ZYTIGA,contusion,contusion The most,1
ZYTIGA,contusion,infection and,0
ZYTIGA,contusion,contusion The most common laboratory,1
ZYTIGA,anemia,elevated,0
ZYTIGA,anemia,anemia elevated alkaline phosphatase hypertriglyceridemia,1
ZYTIGA,anemia,elevated alkaline phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia,0
ZYTIGA,anemia,acetate arm,0
ZYTIGA,anemia,anemia,1
ZYTIGA,anemia,the abiraterone acetate arm anemia elevated alkaline,1
ZYTIGA,anemia,anemia,1
ZYTIGA,anemia,anemia,1
ZYTIGA,anemia,commonly,0
ZYTIGA,anemia,anemia elevated,1
ZYTIGA,elevated alkaline phosphatase,hypercholesterolemia hyperglycemia elevated,0
ZYTIGA,elevated alkaline phosphatase,abiraterone acetate arm were elevated alkaline phosphatase hypertriglyceridemia lymphopenia,1
ZYTIGA,elevated alkaline phosphatase,hypercholesterolemia hyperglycemia elevated,0
ZYTIGA,elevated alkaline phosphatase,more,0
ZYTIGA,elevated alkaline phosphatase,trials that occurred more commonly in the,0
ZYTIGA,elevated alkaline phosphatase,that occurred more commonly in the abiraterone acetate arm,0
ZYTIGA,elevated alkaline phosphatase,were elevated alkaline phosphatase hypertriglyceridemia lymphopenia,1
ZYTIGA,elevated alkaline phosphatase,that occurred more commonly in the abiraterone acetate arm,0
ZYTIGA,elevated alkaline phosphatase,alkaline phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia,1
ZYTIGA,elevated alkaline phosphatase,occurred more commonly in the abiraterone,0
ZYTIGA,elevated alkaline phosphatase,alkaline phosphatase hypertriglyceridemia lymphopenia,1
ZYTIGA,elevated alkaline phosphatase,arm were elevated alkaline phosphatase hypertriglyceridemia,1
ZYTIGA,elevated alkaline phosphatase,alkaline phosphatase hypertriglyceridemia lymphopenia,1
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia,1
ZYTIGA,hypertriglyceridemia,phosphatase,0
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia elevated AST,1
ZYTIGA,hypertriglyceridemia,AST hypophosphatemia,0
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia,1
ZYTIGA,hypertriglyceridemia,AST hypophosphatemia,0
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia,1
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia,1
ZYTIGA,hypertriglyceridemia,hypertriglyceridemia lymphopenia hypercholesterolemia hyperglycemia elevated,1
ZYTIGA,hypertriglyceridemia,elevated AST hypophosphatemia elevated ALT,0
ZYTIGA,lymphopenia,lymphopenia hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1
ZYTIGA,lymphopenia,lymphopenia hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1
ZYTIGA,lymphopenia,lymphopenia hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1
ZYTIGA,lymphopenia,alkaline phosphatase lymphopenia hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1
ZYTIGA,lymphopenia,lymphopenia hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1
ZYTIGA,hypercholesterolemia,hypercholesterolemia hyperglycemia,1
ZYTIGA,hypercholesterolemia,hypercholesterolemia hyperglycemia elevated AST hypophosphatemia elevated,1
ZYTIGA,hypercholesterolemia,hypercholesterolemia hyperglycemia elevated AST,1
ZYTIGA,hypercholesterolemia,alkaline phosphatase hypertriglyceridemia,0
ZYTIGA,hypercholesterolemia,alkaline phosphatase hypertriglyceridemia hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1
ZYTIGA,hypercholesterolemia,alkaline phosphatase hypertriglyceridemia,0
ZYTIGA,hypercholesterolemia,hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1
ZYTIGA,hyperglycemia,hyperglycemia,1
ZYTIGA,hyperglycemia,hypercholesterolemia hyperglycemia elevated AST hypophosphatemia,1
ZYTIGA,hyperglycemia,lymphopenia hypercholesterolemia,0
ZYTIGA,hyperglycemia,hyperglycemia elevated AST hypophosphatemia elevated ALT,1
ZYTIGA,hyperglycemia,elevated,0
ZYTIGA,hyperglycemia,hyperglycemia elevated AST,1
ZYTIGA,elevated AST,elevated AST,1
ZYTIGA,elevated AST,Study Metastatic,0
ZYTIGA,elevated AST,elevated AST hypophosphatemia elevated ALT and hypokalemia,1
ZYTIGA,elevated AST,lymphopenia,0
ZYTIGA,elevated AST,elevated AST hypophosphatemia elevated ALT and hypokalemia,1
ZYTIGA,elevated AST,phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia elevated,1
ZYTIGA,elevated AST,lymphopenia hypercholesterolemia elevated AST hypophosphatemia,1
ZYTIGA,elevated AST,phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia elevated,1
ZYTIGA,elevated AST,lymphopenia hypercholesterolemia elevated AST,1
ZYTIGA,elevated AST,phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia elevated,1
ZYTIGA,elevated AST,lymphopenia hypercholesterolemia elevated AST hypophosphatemia,1
ZYTIGA,elevated AST,phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia elevated,1
ZYTIGA,hypophosphatemia,hypercholesterolemia hyperglycemia elevated hypophosphatemia elevated ALT and hypokalemia,1
ZYTIGA,hypophosphatemia,phosphatase hypertriglyceridemia lymphopenia hypercholesterolemia elevated,1
ZYTIGA,hypophosphatemia,AST,0
ZYTIGA,hypophosphatemia,hypophosphatemia elevated ALT and,1
ZYTIGA,hypophosphatemia,ALT and hypokalemia Study Metastatic CRPC Following Chemotherapy,0
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,hypophosphatemia,hypophosphatemia elevated,1
ZYTIGA,hypophosphatemia,hypophosphatemia elevated ALT,1
ZYTIGA,hypophosphatemia,hypophosphatemia,1
ZYTIGA,elevated ALT,hypercholesterolemia hyperglycemia elevated AST elevated ALT,1
ZYTIGA,elevated ALT,elevated ALT and hypokalemia Study Metastatic CRPC,1
ZYTIGA,elevated ALT,Study Metastatic,0
ZYTIGA,Joint swelling,tissue disorders,0
ZYTIGA,Joint swelling,Joint swelling discomfort M,1
ZYTIGA,Joint swelling,ective tissue disorders,0
ZYTIGA,Urinary tract infection,d Urinary tract infection Upper resp,1
ZYTIGA,Urinary tract infection,ective tissue disorders,0
ZYTIGA,Urinary tract infection,d,0
ZYTIGA,chest discomfort,pain,0
ZYTIGA,chest discomfort,chest discomfort,1
ZYTIGA,chest discomfort,or,0
ZYTIGA,low serum phosphorus,serum phosphorus and,1
ZYTIGA,low serum phosphorus,Study low serum phosphorus,1
ZYTIGA,low serum phosphorus,equal to rate in the ZYTIGA arm,0
ZYTIGA,low serum phosphorus,serum phosphorus and low potassium occurred at,1
ZYTIGA,low potassium,occurred at a greater than or equal to rate,0
ZYTIGA,low potassium,interest,0
ZYTIGA,low potassium,low serum phosphorus low,1
ZYTIGA,low potassium,of interest,0
ZYTIGA,low potassium,ZYTIGA,0
ZYTIGA,low potassium,shows laboratory abnormalities of interest from Study Grade low serum,0
ZYTIGA,low potassium,low potassium occurred at a greater,1
ZYTIGA,low potassium,at a greater than or equal to rate in the ZYTIGA arm,0
ZYTIGA,low potassium,low potassium occurred at a greater than,1
ZYTIGA,Hypertriglyceridemia,Hypertriglyceridemia High,1
ZYTIGA,Hypertriglyceridemia,All Grades Grade,0
ZYTIGA,lymphopenia,placebo in Study lymphopenia hyperglycemia and high alanine aminotransferase,1
ZYTIGA,lymphopenia,All Grades Grade,0
ZYTIGA,lymphopenia,lymphopenia hyperglycemia and high,1
ZYTIGA,lymphopenia,lymphopenia hyperglycemia and high alanine,1
ZYTIGA,lymphopenia,lymphopenia hyperglycemia and high alanine,1
ZYTIGA,hyperglycemia,hyperglycemia,1
ZYTIGA,hyperglycemia,hyperglycemia and high alanine,1
ZYTIGA,hyperglycemia,Study Grade hyperglycemia and high alanine,1
ZYTIGA,hyperglycemia,hyperglycemia and high alanine,1
ZYTIGA,hyperglycemia,placebo in Study Grade hyperglycemia and high,1
ZYTIGA,hyperglycemia,hyperglycemia and high alanine,1
ZYTIGA,hyperglycemia,hyperglycemia and high alanine aminotransferase occurred,1
ZYTIGA,hyperglycemia,hyperglycemia and high,1
ZYTIGA,hyperglycemia,hyperglycemia and high alanine aminotransferase occurred,1
ZYTIGA,hyperglycemia,hyperglycemia and high,1
ZYTIGA,hyperglycemia,and high alanine aminotransferase occurred at a greater than rate in the,0
ZYTIGA,hyperglycemia,aminotransferase occurred at a greater than,0
ZYTIGA,high alanine aminotransferase,ZYTIGA arm compared,0
ZYTIGA,high alanine aminotransferase,greater than rate in the ZYTIGA arm,0
ZYTIGA,high alanine aminotransferase,arm,0
ZYTIGA,high alanine aminotransferase,to placebo in Study Grade,0
ZYTIGA,high alanine aminotransferase,high alanine aminotransferase occurred at a greater than,1
ZYTIGA,high alanine aminotransferase,to placebo in Study Grade,0
ZYTIGA,high alanine aminotransferase,lymphopenia hyperglycemia high,1
ZYTIGA,high alanine aminotransferase,at,0
ZYTIGA,cardiac failure,data for studies cardiac failure occurred more commonly in patients,1
ZYTIGA,cardiac failure,at,0
ZYTIGA,cardiac failure,data for studies and,0
ZYTIGA,cardiac failure,cardiac failure occurred more,1
ZYTIGA,cardiac failure,data for studies and,0
ZYTIGA,cardiac failure,cardiac failure occurred more commonly in,1
ZYTIGA,cardiac failure,data for studies and,0
ZYTIGA,cardiac failure,combined data for studies cardiac,1
ZYTIGA,cardiac failure,cardiac failure occurred more commonly,1
ZYTIGA,cardiac failure,cardiac,1
ZYTIGA,cardiac failure,versus cardiac failure occurred,1
ZYTIGA,cardiac failure,cardiac,1
ZYTIGA,cardiac failure,placebo,0
ZYTIGA,cardiac failure,cardiac failure occurred,1
ZYTIGA,cardiac failure,patients taking ZYTIGA and led to treatment discontinuations and,0
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,to treatment discontinuations deaths Grade cardiac failure occurred in,1
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,led to treatment discontinuations deaths Grade cardiac failure occurred,1
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,patients,0
ZYTIGA,deaths,deaths Grade cardiac,1
ZYTIGA,deaths,patients,0
ZYTIGA,deaths,taking placebo There were no treatment dis,0
ZYTIGA,cardiac failure,occurred in of patients taking placebo There were no treatment discontinuations and one death,0
ZYTIGA,cardiac failure,and deaths cardiac failure occurred in of patients taking,1
ZYTIGA,cardiac failure,occurred in of patients taking placebo There were no treatment discontinuations and one death,0
ZYTIGA,cardiac failure,and deaths cardiac,1
ZYTIGA,cardiac failure,treatment discontinuations and deaths cardiac failure occurred in of,1
ZYTIGA,cardiac failure,and deaths cardiac,1
ZYTIGA,cardiac failure,cardiac failure occurred in of patients taking,1
ZYTIGA,cardiac failure,and,0
ZYTIGA,cardiac failure,cardiac failure,1
ZYTIGA,cardiac failure,cardiac failure occurred in of patients,1
ZYTIGA,death,death due to cardiac,1
ZYTIGA,death,treatment discontinuations and death due to cardiac failure in,1
ZYTIGA,death,death due to cardiac,1
ZYTIGA,death,discontinuations and death due to cardiac failure in,1
ZYTIGA,death,death due to cardiac,1
ZYTIGA,death,death due to cardiac,1
ZYTIGA,death,death due to cardiac,1
ZYTIGA,death,majority,0
ZYTIGA,death,and death due,1
ZYTIGA,death,majority,0
ZYTIGA,death,discontinuations and death due to cardiac failure,1
ZYTIGA,death,majority,0
ZYTIGA,death,discontinuations and death due to cardiac failure,1
ZYTIGA,death,majority,0
ZYTIGA,cardiac failure,of patients taking placebo There were no treatment discontinuations,0
ZYTIGA,cardiac failure,in the placebo group In Study and the majority of arrhythmias were grade or,0
ZYTIGA,cardiac failure,and one death due cardiac,1
ZYTIGA,cardiac failure,to,0
ZYTIGA,cardiac failure,There were no treatment discontinuations and one death due to,0
ZYTIGA,cardiac failure,due cardiac failure in the placebo group In,1
ZYTIGA,cardiac failure,There were no treatment discontinuations and one death due to,0
ZYTIGA,cardiac failure,cardiac,1
ZYTIGA,cardiac failure,cardiac failure in the placebo group,1
ZYTIGA,cardiac failure,group In Study and the majority of,0
ZYTIGA,arrhythmias,arrhythmias were grade,1
ZYTIGA,arrhythmias,Study and the majority arrhythmias were grade or There was,1
ZYTIGA,arrhythmias,arrhythmias were grade,1
ZYTIGA,arrhythmias,Study and the majority arrhythmias,1
ZYTIGA,arrhythmias,arrhythmias were grade,1
ZYTIGA,arrhythmias,arrhythmias were,1
ZYTIGA,arrhythmias,patient with sudden,0
ZYTIGA,arrhythmias,the placebo group In Study,0
ZYTIGA,death,in the ZYTIGA arms and no deaths in,0
ZYTIGA,death,no,0
ZYTIGA,death,death,1
ZYTIGA,death,death associated with arrhythmia and one,1
ZYTIGA,death,In Study and,0
ZYTIGA,death,e placebo group In Study and the majority,0
ZYTIGA,death,death associated with arrhythmia and,1
ZYTIGA,death,death associated with arrhythmia and,1
ZYTIGA,death,death associated with,1
ZYTIGA,death,in the ZYTIGA arms and,0
ZYTIGA,arrhythmia,and no deaths in the placebo arms,0
ZYTIGA,arrhythmia,arrhythmia and one,1
ZYTIGA,arrhythmia,was one death associated,0
ZYTIGA,arrhythmia,arrhythmia and one patient with sudden,1
ZYTIGA,arrhythmia,arrhythmia,1
ZYTIGA,arrhythmia,arrhythmia and,1
ZYTIGA,sudden death,patient sudden,1
ZYTIGA,sudden death,arrhythmias were grade or There was one death associated with arrhythmia and one patient,0
ZYTIGA,sudden death,sudden,1
ZYTIGA,sudden death,with arrhythmia and,0
ZYTIGA,sudden death,patient sudden death,1
ZYTIGA,sudden death,and one patient sudden death,1
ZYTIGA,sudden death,and one patient sudden,1
ZYTIGA,sudden death,one patient sudden,1
ZYTIGA,sudden death,patient sudden death in the ZYTIGA arms,1
ZYTIGA,sudden death,one patient sudden,1
ZYTIGA,deaths,deaths in the placebo arms,1
ZYTIGA,deaths,due to cardiorespiratory arrest in,0
ZYTIGA,deaths,arms and deaths in the placebo arms There,1
ZYTIGA,deaths,due to cardiorespiratory arrest in,0
ZYTIGA,deaths,deaths in the,1
ZYTIGA,deaths,arrest,0
ZYTIGA,deaths,deaths in the placebo arms,1
ZYTIGA,deaths,arrest,0
ZYTIGA,deaths,deaths in the,1
ZYTIGA,deaths,and deaths in the,0
ZYTIGA,deaths,deaths,1
ZYTIGA,deaths,and deaths in the placebo arms,0
ZYTIGA,deaths,in the ZYTIGA arms and no deaths in the,0
ZYTIGA,deaths,deaths due to,1
ZYTIGA,deaths,placebo arms There deaths due,1
ZYTIGA,deaths,deaths due to,1
ZYTIGA,deaths,There deaths due to cardiorespiratory arrest in,1
ZYTIGA,deaths,deaths due to,1
ZYTIGA,deaths,the placebo arms There deaths due,1
ZYTIGA,deaths,deaths due to,1
ZYTIGA,deaths,deaths due to cardiorespiratory arrest in,1
ZYTIGA,deaths,There deaths due to,1
ZYTIGA,deaths,deaths due to cardiorespiratory arrest in,1
ZYTIGA,cardiorespiratory arrest,arms and no,0
ZYTIGA,cardiorespiratory arrest,arms and,0
ZYTIGA,cardiorespiratory arrest,due cardiorespiratory arrest in the ZYTIGA arms and,1
ZYTIGA,cardiorespiratory arrest,arms and,0
ZYTIGA,deaths,deaths in,1
ZYTIGA,deaths,bo arms There were deaths,0
ZYTIGA,deaths,bo arms There were deaths due to cardiorespiratory arrest in,0
ZYTIGA,deaths,deaths in the,1
ZYTIGA,Myocardial ischemia,arms,0
ZYTIGA,Myocardial ischemia,deaths in,0
ZYTIGA,Myocardial ischemia,in the placebo Myocardial,1
ZYTIGA,Myocardial ischemia,Myocardial,1
ZYTIGA,Myocardial ischemia,Myocardial ischemia or,1
ZYTIGA,Myocardial ischemia,Myocardial ischemia or myocardial infarction,1
ZYTIGA,Myocardial ischemia,the placebo Myocardial ischemia or myocardial,1
ZYTIGA,Myocardial ischemia,Myocardial ischemia or myocardial infarction,1
ZYTIGA,Myocardial ischemia,infarction led to death in,0
ZYTIGA,Myocardial ischemia,in the placebo Myocardial ischemia or myocardial infarction,1
ZYTIGA,Myocardial ischemia,infarction led to death in,0
ZYTIGA,Myocardial ischemia,Myocardial ischemia or,1
ZYTIGA,myocardial infarction,placebo arms Myocardial ischemia myocardial infarction led to,1
ZYTIGA,myocardial infarction,Myocardial ischemia or,1
ZYTIGA,myocardial infarction,deaths in the ZYTIGA arms,0
ZYTIGA,death,Myocardial ischemia,0
ZYTIGA,death,death in,1
ZYTIGA,death,myocardial infarction led death in patients,1
ZYTIGA,death,death in,1
ZYTIGA,death,Post Marketing,0
ZYTIGA,deaths,Experience The following additional adverse,0
ZYTIGA,deaths,the placebo arms deaths in the ZYTIGA,1
ZYTIGA,deaths,Experience The following additional adverse,0
ZYTIGA,non-infectious pneumonitis,Disorders,0
ZYTIGA,myopathy,myopathy,1
ZYTIGA,myopathy,myopathy,1
ZYTIGA,myopathy,myopathy including rhabdomyolysis,1
ZYTIGA,myopathy,myopathy,1
ZYTIGA,Mineralocorticoid excess,discu,0
ZYTIGA,Mineralocorticoid excess,are ssed in more detail in o ther sections of,1
ZYTIGA,Mineralocorticoid excess,discu,0
ZYTIGA,Mineralocorticoid excess,REACTIONS The following are discu,0
ZYTIGA,Hepatotoxicity,cholesterolemi a hyperglycemia,1
ZYTIGA,Hepatotoxicity,cholesterolemi a hyperglycemia elevated,1
ZYTIGA,Hepatotoxicity,cholesterolemi a hyperglycemia elevated,1
ZYTIGA,Hepatotoxicity,hypertriglyceridemia lymphopenia cholesterolemi a hyperglycemia,1
ZYTIGA,Hepatotoxicity,cholesterolemi a hyperglycemia elevated,1
ZYTIGA,Hepatotoxicity,phosphatase hypertriglyceridemia lymphopenia cholesterolemi a hyperglycemia,1
ZYTIGA,Hepatotoxicity,cholesterolemi a hyperglycemia elevated,1
ZYTIGA,Hepatotoxicity,cholesterolemi a hyperglycemia,1
ZYTIGA,Increases in liver enzymes,hypophosphatemia elevated ALT and,0
ZYTIGA,hypertension,Experience Because clinical trials e conducted,1
ZYTIGA,hypertension,e conducted under widely,1
ZYTIGA,hypertension,rates observed in the,0
ZYTIGA,hypertension,e conducted,1
ZYTIGA,hypertension,a drug ca,0
ZYTIGA,hypertension,ar,0
ZYTIGA,hypokalemia,der widely,1
ZYTIGA,hypokalemia,der widely varying conditions adverse reaction,1
ZYTIGA,hypokalemia,the clinical trials,0
ZYTIGA,hypokalemia,Experience Because clinical trials are,0
ZYTIGA,hypokalemia,varying conditions adverse reaction rates,0
ZYTIGA,hypokalemia,the clinical,0
ZYTIGA,hypokalemia,der widely varying conditions adverse reaction,1
ZYTIGA,fluid retention,directly compared to rates,0
ZYTIGA,fluid retention,"g conditions, a dverse",1
ZYTIGA,fluid retention,"widely g conditions, a dverse reaction rates",1
ZYTIGA,fluid retention,"g conditions, a dverse",1
ZYTIGA,fluid retention,compared to,0
ZYTIGA,fluid retention,"conditions, a dverse",1
ZYTIGA,increased mineralocorticoid levels,reaction rates,0
ZYTIGA,increased mineralocorticoid levels,adverse reaction  observed in the clinical trials o f a drug,1
ZYTIGA,increased mineralocorticoid levels,reaction rates,0
ZYTIGA,hypertension,randomized placebocontrolled multicenter clinical trials enrolled patients,0
ZYTIGA,hypertension,placebocontrolled multicenter clinical trials enrolled patients who,0
ZYTIGA,hypertension,in clinical practice Two,1
ZYTIGA,hypertension,in the clinical trials of another drug,0
ZYTIGA,hypertension,reflect the rates  in clinical practice Two randomized placebocontrolled multicenter,1
ZYTIGA,hypertension,in the clinical trials of another drug,0
ZYTIGA,hypertension,reflect,0
ZYTIGA,hypertension,reflect the rates in,1
ZYTIGA,hypokalemia,drug,0
ZYTIGA,hypokalemia,not reflect the rates observed in,0
ZYTIGA,hypokalemia,metastatic,0
ZYTIGA,hypokalemia,"rolled, mul ticenter clinical trials",1
ZYTIGA,hypokalemia,placebocont,0
ZYTIGA,hypokalemia,"randomized rolled, mul",1
ZYTIGA,hypokalemia,clinical trials enrolled patients who had,0
ZYTIGA,hypokalemia,patients who had metastatic castrationresistant prostate,0
ZYTIGA,Adrenal insufficiency,Following Chemotherapy Study nrolled 1195 patients,1
ZYTIGA,Adrenal insufficiency,who had received prior docetaxel chemotherapy Patients were not,0
ZYTIGA,Adrenal insufficiency,Metastatic CRPC,0
ZYTIGA,Adrenal insufficiency,eligible,0
ZYTIGA,Adrenal insufficiency,nrolled 1195 patients,1
ZYTIGA,Adrenal insufficiency,Metastatic CRPC,0
ZYTIGA,Adrenal insufficiency,with metastatic CRPC who had received prior docetaxel chemotherapy Patients were not eligible if A,0
ZYTIGA,Adrenal insufficiency,Study Metastatic CRPC Following Chemotherapy Study e,0
ZYTIGA,Adrenal insufficiency,docetaxel chemotherapy Patients,0
ZYTIGA,Adrenocortical insufficiency,were,0
ZYTIGA,Adrenocortical insufficiency,ho had received prior docetaxel chemotherapy Patients were,0
ZYTIGA,Adrenocortical insufficiency,ULN Table,0
ZYTIGA,Adrenocortical insufficiency,prior docetaxel chemotherapy Patients were not,0
ZYTIGA,Adrenocortical insufficiency,ALT N,1
ZYTIGA,Adrenocortical insufficiency,N in the absence of liver me tastases Patients with,1
ZYTIGA,Adrenocortical insufficiency,ALT N,1
ZYTIGA,Adrenocortical insufficiency,andor ALT N,1
ZYTIGA,Adrenocortical insufficiency,received prior docetaxel chemotherapy Patients were not eligible if,0
ZYTIGA,Adrenocortical insufficiency,ALT N in,1
ZYTIGA,Adrenocortical insufficiency,Patients were not eligible if AST,0
ZYTIGA,adrenocortical insufficiency,to ZYTIGA in Study,0
ZYTIGA,adrenocortical insufficiency,PrednisoneN SystemOrgan Class Adve,0
ZYTIGA,deaths,Vascular       ,1
ZYTIGA,deaths,PrednisoneN SystemOrgan Class Adve,0
TOVIAZ,dry mouth,dry mouth placebo Toviaz,1
TOVIAZ,dry mouth,Toviaz dry,1
TOVIAZ,dry mouth,Toviaz dry mouth,1
TOVIAZ,dry mouth,Toviaz dry,1
TOVIAZ,constipation,constipation placebo Toviaz mg Toviaz mg,1
TOVIAZ,constipation,constipation,1
TOVIAZ,constipation,constipation placebo Toviaz mg,1
TOVIAZ,constipation,constipation placebo Toviaz mg,1
TOVIAZ,constipation,constipation placebo Toviaz mg Toviaz mg,1
TOVIAZ,constipation,constipation placebo Toviaz mg,1
TOVIAZ,angina,angina chest pain gastroenteritis and,1
TOVIAZ,angina,except for four patients receiving Toviaz who reported,0
TOVIAZ,angina,gastroenteritis and QT prolongation on ECG The most commonly reported,0
TOVIAZ,angina,angina chest pain,1
TOVIAZ,angina,gastroenteritis and QT prolongation on ECG,0
TOVIAZ,angina,Toviaz who,0
TOVIAZ,chest pain,each chest pain gastroenteritis and QT prolongation,1
TOVIAZ,chest pain,Toviaz who,0
TOVIAZ,chest pain,chest pain gastroenteritis and QT,1
TOVIAZ,chest pain,chest pain gastroenteritis and,1
TOVIAZ,chest pain,chest pain gastroenteritis and QT,1
TOVIAZ,chest pain,adverse event each chest pain gastroenteritis and QT,1
TOVIAZ,chest pain,chest pain gastroenteritis and QT,1
TOVIAZ,chest pain,chest pain,1
TOVIAZ,gastroenteritis,chest gastroenteritis and QT,1
TOVIAZ,gastroenteritis,chest pain,1
TOVIAZ,gastroenteritis,gastroenteritis and QT prolongation on ECG,1
TOVIAZ,gastroenteritis,gastroenteritis and QT prolongation,1
TOVIAZ,gastroenteritis,adverse event in patients treated,0
TOVIAZ,gastroenteritis,gastroenteritis and QT prolongation,1
TOVIAZ,gastroenteritis,in patients,0
TOVIAZ,gastroenteritis,gastroenteritis and QT prolongation on ECG,1
TOVIAZ,gastroenteritis,chest gastroenteritis and QT prolongation on,1
TOVIAZ,gastroenteritis,gastroenteritis and QT prolongation on ECG,1
TOVIAZ,gastroenteritis,four patients receiving Toviaz who reported one serious adverse,0
TOVIAZ,gastroenteritis,gastroenteritis and QT prolongation on,1
TOVIAZ,QT prolongation,angina chest pain gastroenteritis QT prolongation,1
TOVIAZ,QT prolongation,serious adverse event,0
TOVIAZ,QT prolongation,serious adverse,0
TOVIAZ,QT prolongation,adverse event in patients treated with,0
TOVIAZ,QT prolongation,chest pain gastroenteritis QT prolongation on ECG The most,1
TOVIAZ,QT prolongation,adverse event in patients treated with,0
TOVIAZ,dry mouth,Toviaz dry mouth,1
TOVIAZ,dry mouth,olongation on ECG The most commonly reported adverse event in patients treated with,0
TOVIAZ,dry mouth,adverse event in patients,0
TOVIAZ,dry mouth,treated with Toviaz dry mouth The incidence of dry,1
TOVIAZ,dry mouth,adverse event in patients,0
TOVIAZ,dry mouth,dry mouth The,1
TOVIAZ,dry mouth,Toviaz was,0
TOVIAZ,dry mouth,dry mouth,1
TOVIAZ,Dry mouth,compared to placebo,0
TOVIAZ,Dry mouth,as compared,0
TOVIAZ,Dry mouth,Dry mouth led to discontinuation,1
TOVIAZ,Dry mouth,receiving,0
TOVIAZ,Dry mouth,led to discontinuation in and of patients receiving placebo Toviaz mg and,0
TOVIAZ,dry mouth,receiving placebo Toviaz mg and Toviaz mg respectively For those,0
TOVIAZ,dry mouth,those patients who dry,1
TOVIAZ,dry mouth,dry mouth most had,1
TOVIAZ,constipation,was in those taking placebo in those taking,0
TOVIAZ,constipation,in those taking,0
TOVIAZ,constipation,reported adverse event constipation The incidence of constipation,1
TOVIAZ,constipation,in those taking,0
TOVIAZ,constipation,constipation The incidence of,1
TOVIAZ,constipation,constipation,1
TOVIAZ,constipation,constipation The incidence of constipation,1
TOVIAZ,constipation,placebo,0
TOVIAZ,constipation,constipation was in those taking placebo,1
TOVIAZ,constipation,constipation was in those taking placebo,1
TOVIAZ,constipation,those taking mgday and in those taking,0
TOVIAZ,Upper respiratory tract infection,ract Upper respiratory tract infection Eye,1
TOVIAZ,Upper respiratory tract infection,those taking mgday and in those taking,0
TOVIAZ,Upper respiratory tract infection,tract infection Eye disorders,1
TOVIAZ,Upper respiratory tract infection,ract Upper respiratory tract,1
TOVIAZ,Upper respiratory tract infection,respiratory tract infection,1
TOVIAZ,Upper respiratory tract infection,ract Upper respiratory tract infection,1
TOVIAZ,dry mouth,were similar to those observed in the week placebocontrolled,0
TOVIAZ,dry mouth,week placebocontrolled studies and dry,1
TOVIAZ,constipation,dry constipation dry,1
TOVIAZ,constipation,week placebocontrolled studies and dry,1
TOVIAZ,constipation,constipation dry,1
TOVIAZ,constipation,to those observed in the week placebocontrolled studies and included dry mouth,0
TOVIAZ,constipation,most adverse events of,0
TOVIAZ,constipation,constipation dry eyes dyspepsia and abdominal,1
TOVIAZ,constipation,and,0
TOVIAZ,constipation,week placebocontrolled studies and included dry,0
TOVIAZ,constipation,constipation dry eyes dyspepsia and,1
TOVIAZ,constipation,the,0
TOVIAZ,constipation,week placebocontrolled studies and included dry,0
TOVIAZ,dry eyes,dry eyes dyspepsia and abdominal pain Similar,1
TOVIAZ,dry eyes,dry mouth dry eyes dyspepsia and,1
TOVIAZ,dry eyes,dry eyes dyspepsia and abdominal pain Similar,1
TOVIAZ,dry eyes,and included dry mouth dry eyes,1
TOVIAZ,dry eyes,to the controlled studies most,0
TOVIAZ,dry eyes,dry eyes,1
TOVIAZ,dry eyes,dry eyes dyspepsia and abdominal,1
TOVIAZ,dry eyes,Similar to the controlled studies most adverse events,0
TOVIAZ,dry eyes,dry eyes dyspepsia and,1
TOVIAZ,dyspepsia,mouth constipation dry dyspepsia and abdominal,1
TOVIAZ,dyspepsia,dry eyes dyspepsia and,1
TOVIAZ,dyspepsia,dyspepsia and abdominal,1
TOVIAZ,dyspepsia,mouth constipation dry dyspepsia,1
TOVIAZ,dyspepsia,dyspepsia and abdominal,1
TOVIAZ,dyspepsia,included dry mouth,0
TOVIAZ,dyspepsia,dyspepsia and abdominal pain Similar to,1
TOVIAZ,abdominal pain,abdominal pain Similar to,1
TOVIAZ,abdominal pain,abdominal pain Similar to the controlled studies,1
TOVIAZ,abdominal pain,included dry mouth constipation dry,0
TOVIAZ,abdominal pain,constipation dry eyes dyspepsia abdominal pain,1
TOVIAZ,abdominal pain,included dry mouth constipation dry,0
TOVIAZ,abdominal pain,abdominal,1
TOVIAZ,abdominal pain,and included,0
TOVIAZ,constipation,mild to,0
TOVIAZ,constipation,Similar to the controlled studies most,0
TOVIAZ,urinary retention,of up to years urinary,1
TOVIAZ,urinary retention,years,0
TOVIAZ,urinary retention,cases constipation cases irritable bowel,0
TOVIAZ,urinary retention,constipation cases,0
TOVIAZ,urinary retention,the openlabel treatment period of up to,0
TOVIAZ,urinary retention,to years urinary retention cases,1
TOVIAZ,urinary retention,the openlabel treatment period of up to,0
TOVIAZ,diverticulitis,retention,0
TOVIAZ,diverticulitis,diverticulitis,1
TOVIAZ,diverticulitis,cases constipation cases irritable bowel syndrome cases and electrocardiogram QT,0
TOVIAZ,diverticulitis,diverticulitis cases,1
TOVIAZ,diverticulitis,diverticulitis cases,1
TOVIAZ,diverticulitis,urinary retention diverticulitis cases constipation,1
TOVIAZ,diverticulitis,diverticulitis cases,1
TOVIAZ,diverticulitis,cases,0
TOVIAZ,diverticulitis,the openlabel treatment period of,0
TOVIAZ,diverticulitis,diverticulitis cases constipation cases irritable bowel,1
TOVIAZ,constipation,up to years included,0
TOVIAZ,constipation,cases,0
TOVIAZ,constipation,urinary retention cases diverticulitis constipation cases irritable,1
TOVIAZ,constipation,cases,0
TOVIAZ,constipation,cases diverticulitis cases,0
TOVIAZ,constipation,diverticulitis constipation cases,1
TOVIAZ,constipation,cases diverticulitis cases,0
TOVIAZ,constipation,constipation cases irritable,1
TOVIAZ,constipation,constipation cases,1
TOVIAZ,constipation,constipation cases irritable bowel syndrome,1
TOVIAZ,constipation,irritable bowel syndrome cases,0
TOVIAZ,constipation,constipation,1
TOVIAZ,QT corrected interval prolongation,QT corrected interval prolongation cases Postmarketing Experience The,1
TOVIAZ,QT corrected interval prolongation,following events have been reported in associ,0
TOVIAZ,QT corrected interval prolongation,bowel syndrome cases and QT corrected interval,1
TOVIAZ,QT corrected interval prolongation,interval prolongation cases Postmarketing Experience,1
TOVIAZ,QT corrected interval prolongation,bowel syndrome cases and QT corrected interval prolongation,1
TOVIAZ,QT corrected interval prolongation,cases,0
TOVIAZ,Blurred vision,use in worldwide postmarketing,0
TOVIAZ,Blurred vision,Blurred vision Cardiac,1
TOVIAZ,Blurred vision,use in worldwide postmarketing,0
TOVIAZ,Blurred vision,postmarketing,0
TOVIAZ,Blurred vision,association,0
TOVIAZ,Blurred vision,Cardiac disorders Palpitations General disorders,0
TOVIAZ,Blurred vision,Blurred,1
TOVIAZ,Palpitations,Palpitations,1
TOVIAZ,Palpitations,Blurred vision Cardiac Palpitations General disorders and,1
TOVIAZ,Palpitations,Palpitations,1
TOVIAZ,Palpitations,disorders and administrative,0
TOVIAZ,Hypersensitivity reactions,disorders and administrative site Hypersensitivity reactions including,1
TOVIAZ,Hypersensitivity reactions,disorders and administrative,0
TOVIAZ,angioedema,angioedema with airway obstruction face edema,1
TOVIAZ,angioedema,Dizziness headache s,0
TOVIAZ,angioedema,reactions angioedema with airway obstruction,1
TOVIAZ,angioedema,Dizziness headache s,0
TOVIAZ,angioedema,administrative site conditions Hypersensitivity reactions,0
TOVIAZ,angioedema,angioedema with airway,1
TOVIAZ,angioedema,site conditions,0
TOVIAZ,angioedema,Dizziness headache,0
TOVIAZ,angioedema,angioedema with airway obstruction face edema,1
TOVIAZ,angioedema,face edema,0
TOVIAZ,face edema,reactions including angioedema with,0
TOVIAZ,Dizziness,subcutaneous tissue,0
TOVIAZ,Dizziness,Skin,0
TOVIAZ,Dizziness,Dizziness headache,1
TOVIAZ,Dizziness,Dizziness headache somnolence Skin,1
TOVIAZ,Dizziness,Dizziness headache,1
TOVIAZ,Dizziness,Dizziness headache somnolence Skin and,1
TOVIAZ,Dizziness,Dizziness headache,1
TOVIAZ,Dizziness,with airway obstruction face edema Central nervous system,0
TOVIAZ,headache,headache somnolence,1
TOVIAZ,headache,headache,1
TOVIAZ,headache,system disorders,0
TOVIAZ,headache,headache somnolence Skin and,1
TOVIAZ,headache,somnolence Skin and subcutaneous tissue disorders Urticaria pruritus Because these sp,0
TOVIAZ,headache,headache somnolence Skin and subcutaneous,1
TOVIAZ,headache,nervous system disorders headache somnolence Skin and subcutaneous tissue,1
TOVIAZ,headache,headache somnolence Skin and subcutaneous,1
TOVIAZ,headache,headache somnolence Skin and subcutaneous tissue,1
TOVIAZ,somnolence,Dizziness somnolence Skin and subcutaneous tissue,1
TOVIAZ,somnolence,headache somnolence Skin and subcutaneous tissue,1
TOVIAZ,somnolence,somnolence Skin and subcutaneous,1
TOVIAZ,somnolence,headache somnolence Skin and subcutaneous tissue,1
TOVIAZ,somnolence,nervous system disorders,0
TOVIAZ,somnolence,somnolence Skin and,1
TOVIAZ,somnolence,disorders Dizziness,0
TOVIAZ,somnolence,disorders Dizziness somnolence,1
TOVIAZ,somnolence,disorders Dizziness,0
TOVIAZ,pruritus,pruritus Because these spontaneously reported,1
TOVIAZ,pruritus,these spontaneously reported events are from the worldwide postmarketing experience t,0
TOVIAZ,pruritus,rders Dizziness headache somnolence Skin and subcutaneous tissue disorders Urticaria,0
TOVIAZ,pruritus,pruritus Because these spontaneously reported,1
TOVIAZ,pruritus,postmarketing experience t,0
TOVIAZ,pruritus,pruritus Because these spontaneously reported,1
TOVIAZ,Angioedema of the face,EXCERPT The most,0
TOVIAZ,Angioedema of the face,most tly reported adverse e vents for,1
TOVIAZ,Angioedema of the face,EXCERPT The most,0
TOVIAZ,Central Nervous System Effects,Toviaz mgday in 2 or 3 studies with treatment  periods,1
TOVIAZ,Central Nervous System Effects,EXCERPT The most,0
TOVIAZ,Central Nervous System Effects,mgday in Phase,0
TOVIAZ,Central Nervous System Effects,2 or,1
TOVIAZ,Central Nervous System Effects,of or weeks Approximately,0
TOVIAZ,Central Nervous System Effects,mgday in 2 or 3 studies,1
TOVIAZ,Central Nervous System Effects,studies with treatment periods of or weeks Approximately,1
TOVIAZ,Central Nervous System Effects,received Toviaz mgday in 2 or 3 studies,1
TOVIAZ,Central Nervous System Effects,3 studies with treatment periods of or weeks Approximately,1
TOVIAZ,Somnolence,or studies with treatment riods of 8,1
TOVIAZ,Somnolence,3 studies with treatment periods of or weeks Approximately,1
TOVIAZ,Somnolence,or studies with treatment riods of 8,1
TOVIAZ,Somnolence,exposure to Toviaz in,0
TOVIAZ,Somnolence,and received Toviaz mgday in Phase or studies,0
TOVIAZ,Somnolence,riods of 8 or weeks Approximately of,1
TOVIAZ,Somnolence,or,0
TOVIAZ,Somnolence,to Toviaz,0
TOVIAZ,Angioedema of the face,received Toviaz ay.,1
TOVIAZ,Angioedema of the face,ay. In Phase 2 and placebocontrolled trials combined the,1
TOVIAZ,Angioedema of the face,received Toviaz ay.,1
TOVIAZ,Angioedema,and respectively All serious adverse events were judged,0
TOVIAZ,Angioedema,Toviaz and,1
TOVIAZ,Angioedema,receiving,0
TOVIAZ,Angioedema,Toviaz and Tovia,1
TOVIAZ,Angioedema,adverse events,0
TOVIAZ,Angioedema,and Tovia,1
TOVIAZ,Angioedema,Toviaz  and Tovia z mg were and,1
TOVIAZ,Angioedema,and Tovia,1
TOVIAZ,Angioedema,patients receiving placebo Toviaz  and Tovia,1
TOVIAZ,Angioedema,and Tovia,1
TOVIAZ,upper airway swelling,in patients,0
TOVIAZ,upper airway swelling,placebo Toviaz mg and Toviaz mg were,0
TOVIAZ,CNS anticholinergic effects,that were reported in the combined,0
TOVIAZ,headache,an place bo and,1
TOVIAZ,headache,greater an place bo,1
TOVIAZ,headache,an place bo and,1
TOVIAZ,headache,an place bo and in,1
TOVIAZ,headache,of patients treated with Toviaz or mg once daily for up to weeks,0
TOVIAZ,headache,combined,0
TOVIAZ,headache,incidence greater an place bo,1
TOVIAZ,headache,combined,0
TOVIAZ,headache,an incidence greater an place bo and,1
TOVIAZ,headache,combined,0
TOVIAZ,headache,an place bo and in,1
TOVIAZ,headache,for up,0
TOVIAZ,somnolence,ore of,1
TOVIAZ,somnolence,or ore,1
TOVIAZ,somnolence,in or ore of pat ients treated with Toviaz or,1
TOVIAZ,somnolence,or ore,1
TOVIAZ,somnolence,of pat ients,1
STRIBILD,Lactic Acidosis,the Lactic Acidosis Severe Hepatomegaly with Steatosis see,1
STRIBILD,Lactic Acidosis,of pat ients,1
STRIBILD,Lactic Acidosis,ONS The following adverse,0
STRIBILD,Lactic Acidosis,Steatosis see Boxed,0
STRIBILD,Lactic Acidosis,Hepatomegaly with Steatosis see,0
STRIBILD,Lactic Acidosis,of the Lactic Acidosis,1
STRIBILD,Lactic Acidosis,reactions are discussed in other sections of the labeling,0
STRIBILD,Lactic Acidosis,other sections of the Lactic,1
STRIBILD,Lactic Acidosis,Hepatomegaly with Steatosis see,0
STRIBILD,Lactic Acidosis,other sections of the Lactic Acidosis,1
STRIBILD,Hepatomegaly,Hepatomegaly with Steatosis,1
STRIBILD,Hepatomegaly,Warnings,0
STRIBILD,Hepatomegaly,Lactic Hepatomegaly,1
STRIBILD,Hepatomegaly,Warnings,0
STRIBILD,Hepatomegaly,are discussed in,0
STRIBILD,Hepatomegaly,Hepatomegaly with Steatosis see,1
STRIBILD,Hepatomegaly,Lactic Hepatomegaly with Steatosis see Boxed,1
STRIBILD,Hepatomegaly,Hepatomegaly with Steatosis see,1
STRIBILD,Hepatomegaly,in other sections of the labeling Lactic AcidosisSevere,0
STRIBILD,Steatosis,Steatosis see Boxed Warning Warnings and,1
STRIBILD,Steatosis,Hepatomegaly Steatosis see Boxed,1
STRIBILD,Steatosis,Steatosis see Boxed Warning Warnings and,1
STRIBILD,Steatosis,Steatosis see,1
STRIBILD,Steatosis,Steatosis,1
STRIBILD,Steatosis,Steatosis see,1
STRIBILD,Steatosis,labeling Lactic AcidosisSevere Hepatomegaly Steatosis see Boxed,1
STRIBILD,Steatosis,Steatosis see,1
STRIBILD,Steatosis,are discussed in other sections of the labeling Lactic AcidosisSevere Hepatomegaly with,0
STRIBILD,Acute Exacerbations of Hepatitis B,and Precautions Severe,0
STRIBILD,Acute Exacerbations of Hepatitis B,Hepatomegaly with Steatosis see Boxed Warning Warnings and Precautions,0
STRIBILD,Acute Exacerbations of Hepatitis B,Precautions Acute Exacerbations of Hepatitis B,1
STRIBILD,Acute Exacerbations of Hepatitis B,Hepatomegaly with Steatosis see Boxed Warning Warnings and Precautions,0
STRIBILD,Acute Exacerbations of Hepatitis B,Precautions,0
STRIBILD,Acute Exacerbations of Hepatitis B,and Precautions Acute Exacerbations of Hepatitis B,1
STRIBILD,Acute Exacerbations of Hepatitis B,Precautions,0
STRIBILD,Acute Exacerbations of Hepatitis B,Precautions Acute Exacerbations of Hepatitis B see Boxed,1
STRIBILD,Acute Exacerbations of Hepatitis B,Precautions,0
STRIBILD,Acute Exacerbations of Hepatitis B,Boxed Warning Warnings and Precautions New Onset or Worsening Renal,0
STRIBILD,Acute Exacerbations of Hepatitis B,and Precautions Acute Exacerbations of Hepatitis B,1
STRIBILD,Acute Exacerbations of Hepatitis B,Boxed Warning Warnings and Precautions New Onset or Worsening Renal,0
STRIBILD,Worsening Renal Impairment,Renal Impairment see Warnings and,1
STRIBILD,Worsening Renal Impairment,and Precautions New Onset Worsening,1
STRIBILD,Worsening Renal Impairment,Precautions New Onset Worsening Renal,1
STRIBILD,Bone Effects,Warnings and Precautions Immune Reconstitution Syndrome see,0
STRIBILD,Immune Reconstitution Syndrome,and Precautions,0
STRIBILD,nausea,diarrhea To report,0
STRIBILD,nausea,nausea and diarrhea,1
STRIBILD,nausea,nausea and,1
STRIBILD,nausea,nausea,1
STRIBILD,nausea,nausea and diarrhea To,1
STRIBILD,nausea,equal to all grades nausea and diarrhea,1
STRIBILD,nausea,nausea and diarrhea To,1
STRIBILD,nausea,STRIBILD incidence greater than or equal to all,0
STRIBILD,nausea,nausea and diarrhea To,1
STRIBILD,diarrhea,drug reactions to STRIBILD incidence,0
STRIBILD,diarrhea,grades are nausea diarrhea To,1
STRIBILD,diarrhea,drug reactions to STRIBILD incidence,0
STRIBILD,diarrhea,ADVERSE,0
STRIBILD,diarrhea,are nausea diarrhea,1
STRIBILD,diarrhea,ADVERSE,0
STRIBILD,diarrhea,and,0
STRIBILD,diarrhea,diarrhea To report SUSPECTED ADVERSE,1
STRIBILD,diarrhea,STRIBILD incidence greater than or equal to all grades are nausea,0
STRIBILD,diarrhea,Inc,0
STRIBILD,diarrhea,incidence greater than or equal,0
STRIBILD,renal adverse reactions,renal adverse,1
STRIBILD,suicidal ideation,preexisting history,0
STRIBILD,suicidal ideation,observed with STRIBILD suicidal ideation and,1
STRIBILD,suicidal ideation,preexisting history,0
STRIBILD,suicidal ideation,reactions observed with STRIBILD suicidal,1
STRIBILD,suicidal ideation,suicide attempt all in subjects with,0
STRIBILD,suicidal ideation,STRIBILD suicidal ideation and suicide attempt,1
STRIBILD,suicidal ideation,suicide attempt all in subjects with,0
STRIBILD,suicidal ideation,suicide attempt all,0
STRIBILD,suicidal ideation,with STRIBILD suicidal ideation and suicide,1
STRIBILD,suicidal ideation,suicide attempt all,0
STRIBILD,suicidal ideation,with STRIBILD Additional,0
STRIBILD,suicidal ideation,suicidal ideation and suicide,1
STRIBILD,suicidal ideation,suicidal ideation and,1
STRIBILD,suicide attempt,suicide attempt,1
STRIBILD,suicide attempt,included suicidal ideation suicide attempt all in,1
STRIBILD,suicide attempt,suicide attempt,1
STRIBILD,suicide attempt,ideation,0
STRIBILD,suicide attempt,and,0
STRIBILD,suicide attempt,adverse drug reactions observed with STRIBILD included suicidal ideation and,0
STRIBILD,suicide attempt,ideation suicide attempt all in subjects,1
STRIBILD,suicide attempt,adverse drug reactions observed with STRIBILD included suicidal ideation and,0
STRIBILD,suicide attempt,included suicidal ideation suicide attempt,1
STRIBILD,suicide attempt,suicide attempt,1
STRIBILD,suicide attempt,included suicidal ideation,0
STRIBILD,nausea,nausea flatulence and headache,1
STRIBILD,nausea,nausea,1
STRIBILD,nausea,nausea flatulence and headache The,1
STRIBILD,nausea,nausea,1
STRIBILD,nausea,headache The proportion of subjects who discontinued treatment wit,0
STRIBILD,nausea,nausea flatulence,1
STRIBILD,flatulence,flatulence and headache The proportion of,1
STRIBILD,flatulence,flatulence and headache The proportion of,1
STRIBILD,flatulence,flatulence and headache The,1
STRIBILD,flatulence,subjects switching,0
STRIBILD,flatulence,equal to of subjects switching to STRIBILD were,0
STRIBILD,flatulence,flatulence and,1
STRIBILD,headache,headache The,1
STRIBILD,headache,headache The proportion of subjects who,1
STRIBILD,headache,headache The proportion,1
STRIBILD,headache,headache The proportion of,1
STRIBILD,headache,to STRIBILD were nausea flatulence,0
STRIBILD,headache,headache The proportion of subjects who,1
STRIBILD,headache,of subjects who discontinued treatment with STRIBILD the RTVboosted,0
STRIBILD,depression,depression abdominal pain,1
STRIBILD,depression,clinical,0
STRIBILD,depression,depression abdominal pain,1
STRIBILD,depression,abdominal,0
STRIBILD,depression,other clinical depression abdominal pain,1
STRIBILD,depression,abdominal,0
STRIBILD,abdominal pain,other clinical trials abdominal pain,1
STRIBILD,abdominal pain,abdominal,0
STRIBILD,dyspepsia,fever pain nasopharyngitis pneumonia sinusitis upper respiratory tract infection a,0
STRIBILD,dyspepsia,dyspepsia,1
STRIBILD,dyspepsia,dyspepsia vomiting fever,1
STRIBILD,dyspepsia,dyspepsia vomiting fever,1
STRIBILD,dyspepsia,other,0
STRIBILD,dyspepsia,other antiretroviral agents in,0
STRIBILD,vomiting,trials depression abdominal pain vomiting fever pain nasopharyngitis,1
STRIBILD,vomiting,other antiretroviral agents in,0
STRIBILD,vomiting,vomiting fever pain nasopharyngitis,1
STRIBILD,vomiting,pneumonia sinusitis upper respiratory tract infection arthralgia,0
STRIBILD,vomiting,vomiting fever pain nasopharyngitis pneumonia sinusitis,1
STRIBILD,vomiting,trials depression abdominal pain dyspepsia,0
STRIBILD,fever,nasopharyngitis,0
STRIBILD,fever,fever pain nasopharyngitis pneumonia,1
STRIBILD,fever,fever pain,1
STRIBILD,fever,fever pain nasopharyngitis pneumonia,1
STRIBILD,fever,fever pain,1
STRIBILD,fever,upper respiratory tract infection arthralgia back,0
STRIBILD,fever,fever pain nasopharyngitis pneumonia sinusitis upper,1
STRIBILD,fever,fever pain nasopharyngitis pneumonia,1
STRIBILD,fever,fever pain,1
STRIBILD,fever,abdominal pain dyspepsia fever pain nasopharyngitis pneumonia,1
STRIBILD,fever,fever pain,1
STRIBILD,pain,pain,1
STRIBILD,pain,pain,1
STRIBILD,pain,respiratory tract infection arthralgia back pain m,0
STRIBILD,pain,pain,1
STRIBILD,pain,respiratory tract infection arthralgia back pain m,0
STRIBILD,pneumonia,pneumonia sinusitis upper respiratory tract,1
STRIBILD,pneumonia,dyspepsia vomiting fever pain pneumonia sinusitis upper respiratory tract,1
STRIBILD,pneumonia,pneumonia sinusitis upper respiratory tract,1
STRIBILD,pneumonia,vomiting fever pain pneumonia sinusitis,1
STRIBILD,pneumonia,pneumonia sinusitis upper respiratory tract,1
STRIBILD,pneumonia,fever pain pneumonia,1
STRIBILD,pneumonia,pneumonia sinusitis upper respiratory tract,1
STRIBILD,pneumonia,back pain myalgia paresthesia,0
STRIBILD,pneumonia,pneumonia sinusitis upper respiratory,1
STRIBILD,pneumonia,vomiting fever pain pneumonia sinusitis,1
STRIBILD,pneumonia,pneumonia sinusitis upper respiratory,1
STRIBILD,pneumonia,pneumonia sinusitis upper respiratory,1
STRIBILD,pneumonia,trials,0
STRIBILD,sinusitis,sinusitis upper respiratory tract infection arthralgia,1
STRIBILD,sinusitis,arthralgia back pain myalgia paresthesia,0
STRIBILD,sinusitis,paresthesia,0
STRIBILD,sinusitis,pain nasopharyngitis sinusitis upper,1
STRIBILD,sinusitis,paresthesia,0
STRIBILD,sinusitis,pneumonia,0
STRIBILD,sinusitis,depression abdominal pain dyspepsia,0
STRIBILD,sinusitis,pneumonia,0
STRIBILD,sinusitis,fever pain nasopharyngitis sinusitis upper respiratory tract infection arthralgia,1
STRIBILD,sinusitis,pneumonia,0
STRIBILD,sinusitis,sinusitis upper respiratory tract,1
STRIBILD,sinusitis,sinusitis upper respiratory tract infection arthralgia,1
STRIBILD,sinusitis,sinusitis upper respiratory tract,1
STRIBILD,upper respiratory tract infection,nasopharyngitis,0
STRIBILD,upper respiratory tract infection,upper respiratory tract infection arthralgia back pain,1
STRIBILD,arthralgia,neuropathy,0
STRIBILD,arthralgia,including peripheral,0
STRIBILD,arthralgia,arthralgia,1
STRIBILD,arthralgia,arthralgia back,1
STRIBILD,arthralgia,arthralgia back pain myalgia paresthesia peripheral,1
STRIBILD,back pain,back pain myalgia paresthesia,1
STRIBILD,back pain,pain nasopharyngitis pneumonia sinusitis upper respiratory tract,0
STRIBILD,back pain,back pain myalgia paresthesia peripheral neuropathy including,1
STRIBILD,back pain,infection arthralgia,0
STRIBILD,myalgia,myalgia paresthesia peripheral neuropathy,1
STRIBILD,myalgia,myalgia,1
STRIBILD,myalgia,myalgia paresthesia,1
STRIBILD,myalgia,myalgia paresthesia peripheral neuropathy,1
STRIBILD,paresthesia,pain paresthesia peripheral,1
STRIBILD,paresthesia,myalgia paresthesia peripheral neuropathy,1
STRIBILD,paresthesia,peripheral neuropathy including peripheral,0
STRIBILD,peripheral neuropathy,neuropathy anxiety,0
STRIBILD,peripheral neuropathy,anxiety increased cough and rhinitis Skin,0
STRIBILD,peripheral neuropathy,pain myalgia peripheral neuropathy,1
STRIBILD,peripheral neuropathy,myalgia peripheral neuropathy including peripheral neuritis and,1
STRIBILD,peripheral neuropathy,pain myalgia peripheral neuropathy,1
STRIBILD,peripheral neuritis,paresthesia peripheral neuropathy peripheral neuritis,1
STRIBILD,peripheral neuritis,peripheral,0
STRIBILD,peripheral neuritis,neuropathy peripheral,1
STRIBILD,peripheral neuritis,discoloration has,0
STRIBILD,peripheral neuritis,myalgia paresthesia peripheral neuropathy peripheral neuritis,1
STRIBILD,anxiety,neuropathy including peripheral neuritis,0
STRIBILD,anxiety,higher frequency amon,0
STRIBILD,anxiety,anxiety increased cough and rhinitis Skin,1
STRIBILD,increased cough,increased cough,1
STRIBILD,increased cough,with,0
STRIBILD,increased cough,and,0
STRIBILD,increased cough,increased cough and rhinitis,1
STRIBILD,increased cough,neuropathy including peripheral,0
STRIBILD,rhinitis,Skin discoloration has been reported with higher,0
STRIBILD,rhinitis,has been reported with,0
STRIBILD,rhinitis,increased cough rhinitis Skin discoloration,1
STRIBILD,rhinitis,has been reported with,0
STRIBILD,rhinitis,rhinitis,1
STRIBILD,rhinitis,rhinitis Skin,1
STRIBILD,rhinitis,rhinitis,1
STRIBILD,rhinitis,rhinitis Skin,1
STRIBILD,Skin discoloration,including peripheral neuritis and neuropathy anxiety increased cough,0
STRIBILD,Skin discoloration,cough and Skin discoloration has been,1
STRIBILD,Skin discoloration,including peripheral neuritis and neuropathy anxiety increased cough,0
STRIBILD,Skin discoloration,among emtricitabinetreated subjects it,0
STRIBILD,hyperpigmentation on the palms,was manifested hyperpigmentation on the palms andor,1
STRIBILD,hyperpigmentation on the palms,among emtricitabinetreated subjects it,0
STRIBILD,hyperpigmentation on the palms,hyperpigmentation on the palms andor,1
STRIBILD,hyperpigmentation on the palms,manifested hyperpigmentation on the palms andor soles,1
STRIBILD,hyperpigmentation on the palms,hyperpigmentation on the palms andor,1
STRIBILD,hyperpigmentation on the palms,it was manifested by,0
STRIBILD,hyperpigmentation on the palms,hyperpigmentation on the palms andor soles and was,1
STRIBILD,hyperpigmentation on the palms,it was manifested by,0
STRIBILD,hyperpigmentation on the palms,higher frequency among,0
STRIBILD,hyperpigmentation on the palms,subjects it was manifested hyperpigmentation on the palms andor,1
STRIBILD,hyperpigmentation on the palms,higher frequency among,0
STRIBILD,hyperpigmentation on the palms,it was manifested hyperpigmentation on the palms andor,1
STRIBILD,hyperpigmentation on the palms,higher frequency among,0
STRIBILD,hyperpigmentation on the palms,subjects it was manifested hyperpigmentation on the palms andor soles and,1
STRIBILD,hyperpigmentation on the palms,higher frequency among,0
STRIBILD,Urine RBC,Urine,1
STRIBILD,Urine RBC,Urine,1
STRIBILD,Urine RBC,Urine RBC Hematuria RBCHPF,1
STRIBILD,Urine RBC,Urine,1
STRIBILD,Urine RBC,nase,0
STRIBILD,Urine RBC,Urine RBC Hematuria RBCHPF,1
STRIBILD,Urine RBC,nase Urine RBC,1
STRIBILD,Urine RBC,ULN,0
STRIBILD,Urine RBC,ULN,0
STRIBILD,decreases in BMD,TRUVADA group N Mean,0
STRIBILD,decreases in BMD,STRIBILD group were comparable to the ATV RTV TRUVADA,0
STRIBILD,decreases in BMD,Mean decreases,1
STRIBILD,decreases in BMD,decreases in BMD from,1
STRIBILD,decreases in BMD,in BMD,1
STRIBILD,decreases in BMD,Mean decreases in BMD from baseline to Week in,1
STRIBILD,decreases in BMD,in BMD,1
STRIBILD,decreases in BMD,Mean decreases,1
STRIBILD,decreases in BMD,Mean decreases in BMD,1
STRIBILD,decreases in BMD,subset of subjects STRIBILD group N ATV RTV TRUVADA group N Mean,0
STRIBILD,decreases in BMD,RTV TRUVADA group N Mean,0
STRIBILD,bone fractures,respectively In Studies bone fractures occurred,1
STRIBILD,bone fractures,RTV TRUVADA group N Mean,0
STRIBILD,bone fractures,in the,0
STRIBILD,bone fractures,STRIBILD group subjects,0
STRIBILD,Proteinuria,treatmentnaive subjects receiving tenofovir,0
STRIBILD,Proteinuria,Proteinuria all,1
STRIBILD,Proteinuria,week trial of treatmentnaive subjects receiving tenofovir DF lamivudine,0
STRIBILD,Proteinuria,Proteinuria all grades occurred in,1
STRIBILD,Proteinuria,receiving,0
STRIBILD,Proteinuria,Proteinuria all grades occurred,1
STRIBILD,Proteinuria,Proteinuria all grades,1
STRIBILD,Proteinuria,Proteinuria all grades occurred,1
STRIBILD,Proteinuria,Proteinuria all grades occurred in,1
STRIBILD,Proteinuria,Proteinuria all grades occurred in of,1
STRIBILD,increase serum creatinine,has been shown increase serum,1
STRIBILD,increase serum creatinine,decrease estimated creatinine clearance due to inhibition of tubular secretion of,0
STRIBILD,increase serum creatinine,cobicistat component of STRIBILD has,0
STRIBILD,increase serum creatinine,has been shown increase serum creatinine,1
STRIBILD,increase serum creatinine,increase serum creatinine and decrease estimated,1
STRIBILD,increase serum creatinine,to,0
STRIBILD,increase serum creatinine,shown,0
STRIBILD,increase serum creatinine,component of STRIBILD has been,0
STRIBILD,increase serum creatinine,serum creatinine and decrease estimated creatinine clearance,1
STRIBILD,increase serum creatinine,been shown,0
STRIBILD,decrease estimated creatinine clearance,tubular,0
STRIBILD,decrease estimated creatinine clearance,to increase serum creatinine and,0
STRIBILD,decrease estimated creatinine clearance,creatinine clearance due to inhibition,1
STRIBILD,decrease estimated creatinine clearance,inhibition of,0
STRIBILD,decrease estimated creatinine clearance,serum creatinine decrease estimated creatinine clearance due to inhibition of,1
STRIBILD,decrease estimated creatinine clearance,inhibition of,0
STRIBILD,decrease estimated creatinine clearance,of tubular secretion of creatinine without affecting renal glomerular function I,0
STRIBILD,decrease estimated creatinine clearance,increase serum creatinine decrease estimated creatinine,1
STRIBILD,affecting renal glomerular function,affecting renal glomerular,1
STRIBILD,affecting renal glomerular function,In Studies and increases in serum creatinine and,0
STRIBILD,affecting renal glomerular function,in serum,0
STRIBILD,affecting renal glomerular function,affecting,1
STRIBILD,affecting renal glomerular function,affecting renal,1
STRIBILD,affecting renal glomerular function,creatinine affecting renal glomerular function In Studies and,1
STRIBILD,affecting renal glomerular function,affecting renal,1
STRIBILD,affecting renal glomerular function,tubular secretion of creatinine affecting,1
STRIBILD,affecting renal glomerular function,clearance due to,0
STRIBILD,increases in serum creatinine,increases in serum creatinine and decreases,1
STRIBILD,increases in serum creatinine,function In Studies increases in,1
STRIBILD,increases in serum creatinine,serum creatinine and,1
STRIBILD,increases in serum creatinine,STRIBILD,0
STRIBILD,increases in serum creatinine,without,0
STRIBILD,increases in serum creatinine,increases in serum creatinine and decreases,1
STRIBILD,decreases in estimated creatinine clearance,in serum creatinine decreases in estimated creatinine,1
STRIBILD,decreases in estimated creatinine clearance,creatinine and,0
STRIBILD,decreases in estimated creatinine clearance,in estimated creatinine clearance occurred early,1
STRIBILD,elevations in serum creatinine,Table Change from,0
STRIBILD,elevations in serum creatinine,changes in serum creatinine and eGFR levels at Week,0
STRIBILD,Elevated Serum Creatinine,Studies and at Week,0
STRIBILD,Elevated Serum Creatinine,Serum Creatinine and,0
STRIBILD,Elevated Serum Creatinine,and at Week STR,0
STRIBILD,Elevated Serum Creatinine,Serum Creatinine All Grades in,1
STRIBILD,Elevated Serum Creatinine,Elevated Serum Creatinine,1
STRIBILD,Elevated Serum Creatinine,Serum Creatinine All Grades,1
STRIBILD,Elevations in Serum Creatinine,All Grades,0
STRIBILD,Elevations in Serum Creatinine,Subjects Elevations in Serum Creatinine All Grades Emt,1
STRIBILD,Elevations in Serum Creatinine,All Grades,0
STRIBILD,Elevations in Serum Creatinine,in Serum Creatinine All Grades Emt,1
STRIBILD,Elevations in Serum Creatinine,Subjects with,0
STRIBILD,Elevations in Serum Creatinine,mLminute Subjects Elevations in,1
STRIBILD,Elevations in Serum Creatinine,All Grades Emt,0
STRIBILD,Elevations in Serum Creatinine,Subjects,0
STRIBILD,abnormalities of ALT,abnormalities of ALT M,1
STRIBILD,abnormalities of ALT,Subjects,0
STRIBILD,abnormalities of ALT,of ALT M,1
STRIBILD,abnormalities of ALT,with other antiretroviral agents in other,0
STRIBILD,abnormalities of ALT,abnormalities of ALT M greater than U per,1
STRIBILD,abnormalities of ALT,or abnormalities of ALT M greater than U per,1
STRIBILD,abnormalities of ALT,abnormalities of ALT M greater than U per,1
STRIBILD,abnormalities of ALT,trials Grade or abnormalities of ALT M greater than U,1
STRIBILD,abnormalities of ALT,abnormalities of ALT M greater than U per,1
STRIBILD,abnormalities of ALT,or abnormalities of,1
STRIBILD,abnormalities of ALT,abnormalities of ALT,1
STRIBILD,abnormalities of ALT,clinical trials Grade or abnormalities of ALT,1
STRIBILD,abnormalities of ALT,abnormalities of ALT,1
STRIBILD,allergic reaction,Immune System Disorders,0
STRIBILD,allergic reaction,Immune System allergic reaction,1
STRIBILD,allergic reaction,Immune System Disorders,0
STRIBILD,allergic reaction,and,0
STRIBILD,allergic reaction,allergic reaction including angioedema Metabolism and,1
STRIBILD,allergic reaction,Immune System allergic reaction including,1
STRIBILD,allergic reaction,allergic reaction including angioedema Metabolism and,1
STRIBILD,allergic reaction,specific for emtricitabine,0
STRIBILD,allergic reaction,been identified Immune System allergic reaction including angioedema Metabolism and Nutrition,1
STRIBILD,allergic reaction,specific for emtricitabine,0
STRIBILD,allergic reaction,emtricitabine have been,0
STRIBILD,angioedema,angioedema Metabolism,1
STRIBILD,angioedema,emtricitabine have been,0
STRIBILD,angioedema,Disorders,0
STRIBILD,angioedema,Nutrition Disorders,0
STRIBILD,angioedema,lactic acidosis hypokalemia,0
STRIBILD,angioedema,identified,0
STRIBILD,angioedema,angioedema Metabolism and Nutrition Disorders lactic,1
STRIBILD,angioedema,and Nutrition Disorders lactic,0
STRIBILD,angioedema,angioedema Metabolism,1
STRIBILD,lactic acidosis,Nutrition lactic acidosis hypokalemia,1
STRIBILD,lactic acidosis,angioedema Metabolism,1
STRIBILD,lactic acidosis,Thoracic,0
STRIBILD,lactic acidosis,angioedema Metabolism and Nutrition lactic acidosis hypokalemia hypophosphatemia,1
STRIBILD,lactic acidosis,Thoracic,0
STRIBILD,lactic acidosis,lactic acidosis hypokalemia hypophosphatemia Respiratory,1
STRIBILD,lactic acidosis,Thoracic,0
STRIBILD,lactic acidosis,Thoracic and Mediastinal Disorders dyspnea,0
STRIBILD,lactic acidosis,angioedema Metabolism and Nutrition lactic acidosis hypokalemia hypophosphatemia Respiratory Thoracic and,1
STRIBILD,lactic acidosis,Thoracic and Mediastinal Disorders dyspnea,0
STRIBILD,hypokalemia,hypokalemia hypophosphatemia Respiratory Thoracic,1
STRIBILD,hypokalemia,hypokalemia,1
STRIBILD,hypokalemia,and Mediastinal,0
STRIBILD,hypokalemia,hypokalemia hypophosphatemia Respiratory Thoracic and,1
STRIBILD,hypokalemia,hypokalemia hypophosphatemia Respiratory Thoracic and Mediastinal,1
STRIBILD,hypokalemia,Disorders lactic hypokalemia hypophosphatemia Respiratory Thoracic and Mediastinal,1
STRIBILD,hypokalemia,hypokalemia hypophosphatemia Respiratory Thoracic and Mediastinal,1
STRIBILD,hypokalemia,hypokalemia,1
STRIBILD,hypophosphatemia,lactic acidosis hypophosphatemia Respiratory,1
STRIBILD,hypophosphatemia,hypokalemia,1
STRIBILD,hypophosphatemia,hypophosphatemia Respiratory Thoracic and Mediastinal Disorders,1
STRIBILD,hypophosphatemia,hypophosphatemia Respiratory Thoracic,1
STRIBILD,hypophosphatemia,hypophosphatemia Respiratory Thoracic and Mediastinal Disorders,1
STRIBILD,dyspnea,hypophosphatemia Respiratory Thoracic and Mediastinal Disorders,0
STRIBILD,dyspnea,dyspnea Gastrointestinal Disorders pancreatitis,1
STRIBILD,dyspnea,dyspnea Gastrointestinal Disorders pancreatitis increased amylase,1
STRIBILD,dyspnea,dyspnea,1
STRIBILD,dyspnea,Gastrointestinal Disorders pancreatitis,0
STRIBILD,dyspnea,dyspnea Gastrointestinal Disorders pancreatitis,1
STRIBILD,dyspnea,dyspnea Gastrointestinal Disorders,1
STRIBILD,dyspnea,Mediastinal Disorders,0
STRIBILD,dyspnea,cidosis hypokalemia,0
STRIBILD,pancreatitis,pancreatitis increased amylase abdominal pain Hepatobiliary,1
STRIBILD,increased amylase,hepatitis increased liver e,0
STRIBILD,abdominal pain,increased abdominal pain Hepatobiliary Disorders hepatic,1
STRIBILD,abdominal pain,hepatitis increased liver e,0
STRIBILD,abdominal pain,Hepatobiliary Disorders hepatic steatosis hepatitis increased liver enzymes most com,0
STRIBILD,abdominal pain,Disorders pancreatitis increased abdominal pain,1
STRIBILD,abdominal pain,abdominal pain Hepatobiliary Disorders hepatic,1
STRIBILD,abdominal pain,Disorders pancreatitis increased abdominal pain,1
STRIBILD,abdominal pain,hepatitis increased liver enzymes most com,0
STRIBILD,abdominal pain,abdominal pain Hepatobiliary Disorders hepatic steatosis hepatitis,1
STRIBILD,abdominal pain,Disorders pancreatitis increased abdominal pain Hepatobiliary Disorders,1
STRIBILD,abdominal pain,abdominal pain Hepatobiliary Disorders hepatic steatosis hepatitis,1
STRIBILD,abdominal pain,dyspnea Gastrointestinal Disorders pancreatitis,0
STRIBILD,abdominal pain,Disorders pancreatitis increased abdominal pain,1
STRIBILD,abdominal pain,dyspnea Gastrointestinal Disorders pancreatitis,0
STRIBILD,abdominal pain,abdominal pain,1
STRIBILD,hepatic steatosis,hepatic steatosis hepatitis,1
STRIBILD,hepatic steatosis,pain Hepatobiliary hepatic steatosis hepatitis increased liver enzymes,1
STRIBILD,hepatic steatosis,hepatic steatosis hepatitis,1
STRIBILD,hepatic steatosis,Hepatobiliary hepatic steatosis,1
STRIBILD,hepatic steatosis,hepatic steatosis hepatitis,1
STRIBILD,hepatic steatosis,increased liver enzymes,0
STRIBILD,hepatic steatosis,pain Hepatobiliary hepatic steatosis hepatitis,1
STRIBILD,hepatic steatosis,increased liver enzymes,0
STRIBILD,hepatic steatosis,Hepatobiliary,0
STRIBILD,hepatitis,commonly AST ALT gamma GT Skin,0
STRIBILD,hepatitis,hepatic steatosis,0
STRIBILD,rash,rash Musculoskeletal and Connective Tissue,1
STRIBILD,rash,Skin and Subcutaneous Tissue rash Musculoskeletal,1
STRIBILD,rash,rash Musculoskeletal and Connective Tissue,1
STRIBILD,rash,rash Musculoskeletal and,1
STRIBILD,rhabdomyolysis,rhabdomyolysis,1
STRIBILD,rhabdomyolysis,Disorders rash Musculoskeletal and Connective,0
STRIBILD,rhabdomyolysis,muscular,0
STRIBILD,rhabdomyolysis,as bone pain and which may contribute to,0
STRIBILD,rhabdomyolysis,rhabdomyolysis osteomalacia manifested as bone pain,1
STRIBILD,rhabdomyolysis,Tissue rhabdomyolysis,1
STRIBILD,rhabdomyolysis,rhabdomyolysis osteomalacia manifested as bone pain,1
STRIBILD,rhabdomyolysis,Disorders rash Musculoskeletal and Connective,0
STRIBILD,rhabdomyolysis,bone pain and,0
STRIBILD,rhabdomyolysis,Musculoskeletal and Connective Tissue Disorders,0
STRIBILD,rhabdomyolysis,rhabdomyolysis osteomalacia manifested as,1
STRIBILD,bone pain,osteomalacia manifested bone pain and which,1
STRIBILD,bone pain,rhabdomyolysis osteomalacia manifested as,1
STRIBILD,bone pain,manifested bone pain,1
STRIBILD,bone pain,myopathy Renal and Urinary,0
STRIBILD,bone pain,bone pain and which may contribute,1
STRIBILD,bone pain,osteomalacia manifested bone pain and which may contribute,1
STRIBILD,bone pain,bone pain and which may contribute,1
STRIBILD,bone pain,manifested bone pain and,1
STRIBILD,bone pain,bone pain and which may contribute,1
STRIBILD,bone pain,manifested bone pain,1
STRIBILD,bone pain,manifested bone pain,1
STRIBILD,bone pain,bone pain and,1
STRIBILD,fractures,Renal and Urinary,0
STRIBILD,fractures,fractures muscular weakness,1
STRIBILD,fractures,osteomalacia manifested as bone pain and which,0
STRIBILD,fractures,which may contribute fractures muscular weakness myopathy Renal,1
STRIBILD,fractures,osteomalacia manifested as bone pain and which,0
STRIBILD,fractures,e Disorders rhabdomyolysis,0
STRIBILD,acute renal failure,renal failure renal failure acute,1
STRIBILD,acute renal failure,and Urinary acute renal failure renal failure acute tubular necrosis,1
STRIBILD,acute renal failure,renal failure renal failure acute,1
STRIBILD,acute renal failure,proximal renal tubulopathy interstitial,0
STRIBILD,acute renal failure,renal failure acute,0
STRIBILD,acute renal failure,and Urinary acute renal failure renal,1
STRIBILD,acute renal failure,renal failure acute,0
STRIBILD,acute renal failure,Fanconi syndrome proximal renal tubulopathy,0
STRIBILD,acute renal failure,syndrome proximal renal,0
STRIBILD,acute renal failure,and Urinary acute renal failure,1
STRIBILD,acute renal failure,Urinary acute renal failure renal failure acute tubular necrosis,1
STRIBILD,acute renal failure,and Urinary acute renal failure,1
STRIBILD,renal failure,renal failure acute tubular necrosis Fanconi syndrome,1
STRIBILD,renal failure,myopathy Renal and Urinary Disorders,0
STRIBILD,renal failure,myopathy,0
STRIBILD,renal failure,Urinary Disorders acute renal renal failure acute tubular necrosis,1
STRIBILD,renal failure,myopathy,0
STRIBILD,acute tubular necrosis,acute tubular necrosis,1
STRIBILD,acute tubular necrosis,acute tubular necrosis,1
STRIBILD,acute tubular necrosis,renal failure renal acute tubular necrosis,1
STRIBILD,acute tubular necrosis,renal acute tubular necrosis,1
STRIBILD,Fanconi syndrome,renal tubulopathy,0
STRIBILD,Fanconi syndrome,acute tubular,0
STRIBILD,Fanconi syndrome,Urinary Disorders acute renal failure renal failure,0
STRIBILD,proximal renal tubulopathy,diabetes,0
STRIBILD,proximal renal tubulopathy,tubular necrosis Fanconi proximal renal tubulopathy interstitial nephritis including acute cases,1
STRIBILD,proximal renal tubulopathy,diabetes,0
STRIBILD,proximal renal tubulopathy,Fanconi proximal renal,1
STRIBILD,proximal renal tubulopathy,renal,0
STRIBILD,proximal renal tubulopathy,proximal renal tubulopathy interstitial nephritis including acute cases,1
STRIBILD,proximal renal tubulopathy,renal,0
STRIBILD,proximal renal tubulopathy,proximal renal tubulopathy,1
STRIBILD,proximal renal tubulopathy,renal tubulopathy interstitial nephritis including,1
STRIBILD,proximal renal tubulopathy,insipidus,0
STRIBILD,proximal renal tubulopathy,nephritis including acute cases nephrogenic,0
STRIBILD,proximal renal tubulopathy,proximal renal tubulopathy interstitial nephritis including,1
STRIBILD,interstitial nephritis,insufficiency increased creatinine,0
STRIBILD,interstitial nephritis,interstitial nephritis including,1
STRIBILD,interstitial nephritis,renal interstitial nephritis including acute cases nephrogenic diabetes,1
STRIBILD,interstitial nephritis,interstitial nephritis including,1
STRIBILD,interstitial nephritis,renal interstitial nephritis,1
STRIBILD,interstitial nephritis,renal interstitial nephritis,1
STRIBILD,renal insufficiency,General Disorders,0
STRIBILD,renal insufficiency,renal insufficiency increased creatinine proteinuria,1
STRIBILD,renal insufficiency,acute cases nephrogenic diabetes renal insufficiency increased,1
STRIBILD,renal insufficiency,renal insufficiency increased creatinine proteinuria,1
STRIBILD,renal insufficiency,renal insufficiency increased creatinine proteinuria polyuria General,1
STRIBILD,renal insufficiency,polyuria General Disorders and,0
STRIBILD,renal insufficiency,acute cases nephrogenic diabetes renal insufficiency,1
STRIBILD,renal insufficiency,polyuria General Disorders and,0
STRIBILD,renal insufficiency,cases nephrogenic diabetes renal insufficiency,1
STRIBILD,renal insufficiency,polyuria General Disorders and,0
STRIBILD,renal insufficiency,cases nephrogenic diabetes renal insufficiency,1
STRIBILD,proteinuria,Disorders and Administration Site,0
STRIBILD,proteinuria,proteinuria polyuria General Disorders and,1
STRIBILD,asthenia,Disorders and Administration Site asthenia The following adverse reactions listed,1
STRIBILD,asthenia,proteinuria polyuria General Disorders and,1
STRIBILD,asthenia,Administration Site asthenia The following,1
STRIBILD,asthenia,proteinuria polyuria General Disorders and,1
STRIBILD,asthenia,asthenia The following adverse,1
STRIBILD,proximal renal tubulopathy,proximal renal tubulopathy,1
STRIBILD,proximal renal tubulopathy,occur,0
STRIBILD,proximal renal tubulopathy,renal tubulopathy rhabdomyolysis osteomalacia hypokalemia muscular weakness,1
STRIBILD,proximal renal tubulopathy,rhabdomyolysis osteomalacia hypokalemia muscular weakness myopathy hypophosphatemia,0
STRIBILD,proximal renal tubulopathy,reactions listed under the,0
STRIBILD,osteomalacia,osteomalacia hypokalemia muscular,1
STRIBILD,osteomalacia,reactions listed under the,0
STRIBILD,osteomalacia,system headings,0
STRIBILD,osteomalacia,muscular weakness myopathy,0
STRIBILD,osteomalacia,hypokalemia,0
STRIBILD,osteomalacia,hypokalemia muscular,0
STRIBILD,osteomalacia,osteomalacia hypokalemia,1
STRIBILD,osteomalacia,osteomalacia hypokalemia muscular weakness myopathy,1
STRIBILD,osteomalacia,osteomalacia,1
STRIBILD,osteomalacia,proximal renal tubulopathy osteomalacia hypokalemia muscular weakness myopathy hypophosphatemia,1
STRIBILD,osteomalacia,osteomalacia,1
STRIBILD,osteomalacia,osteomalacia hypokalemia muscular weakness myopathy hypophosphatemia,1
STRIBILD,hypokalemia,hypokalemia muscular,1
STRIBILD,hypokalemia,hypokalemia muscular weakness myopathy hypophosphatemia,1
STRIBILD,hypokalemia,consequence of,0
STRIBILD,hypokalemia,osteomalacia,0
STRIBILD,hypokalemia,hypokalemia muscular weakness,1
STRIBILD,hypokalemia,proximal renal tubulopathy rhabdomyolysis hypokalemia muscular weakness myopathy hypophosphatemia,1
STRIBILD,hypokalemia,hypokalemia muscular weakness,1
STRIBILD,hypokalemia,hypokalemia muscular weakness myopathy hypophosphatemia,1
STRIBILD,hypokalemia,hypokalemia muscular weakness,1
STRIBILD,hypokalemia,renal tubulopathy rhabdomyolysis hypokalemia muscular,1
STRIBILD,hypokalemia,hypokalemia muscular weakness,1
STRIBILD,hypokalemia,renal tubulopathy rhabdomyolysis hypokalemia muscular,1
STRIBILD,hypokalemia,hypokalemia muscular weakness,1
STRIBILD,hypokalemia,a consequence of proximal,0
STRIBILD,muscular weakness,a consequence,0
STRIBILD,muscular weakness,a consequence of proximal,0
STRIBILD,muscular weakness,tubulopathy rhabdomyolysis osteomalacia muscular,1
STRIBILD,muscular weakness,rhabdomyolysis osteomalacia muscular weakness myopathy,1
STRIBILD,muscular weakness,tubulopathy rhabdomyolysis osteomalacia muscular,1
STRIBILD,HEPATOMEGALY,labeling Lactic AcidosisSevere Hepatomegaly with Stea,0
STRIBILD,STEATOSIS,drug reactions are cussed,1
STRIBILD,STEATOSIS,REACTIONS,0
STRIBILD,STEATOSIS,The following,0
STRIBILD,STEATOSIS,are cussed,1
STRIBILD,STEATOSIS,cussed in other sections of the,1
STRIBILD,STEATOSIS,adverse drug reactions are cussed in other,1
STRIBILD,STEATOSIS,cussed in other sections of the,1
STRIBILD,STEATOSIS,Steatosis,0
STRIBILD,LACTIC ACIDOSIS,AcidosisSevere omegaly with St,1
STRIBILD,HEPATOMEGALY,[see  Boxed  Warning Warnings,1
STRIBILD,HEPATOMEGALY,AcidosisSevere omegaly with St,1
STRIBILD,STEATOSIS,"Steatosis see Boxed g ,",1
STRIBILD,STEATOSIS,see Boxed Warnin,0
STRIBILD,STEATOSIS,"g , War nings",1
STRIBILD,STEATOSIS,see,0
STRIBILD,STEATOSIS,Severe Acute Exacerbations,0
STRIBILD,STEATOSIS,"Boxed g , War",1
STRIBILD,STEATOSIS,"see Boxed g  ,  War nings",1
STRIBILD,STEATOSIS,"Boxed g , War",1
STRIBILD,STEATOSIS,Warnin,0
STRIBILD,STEATOSIS,"Steatosis see Boxed g  ,  War nings and Precautions Severe Acute",1
STRIBILD,STEATOSIS,Warnin,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"s (5.1)  ] . 
 *  Severe Acute Ex acerbations of",1
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,Warnin,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,Acute Ex acerbations of Hepatitis,1
STRIBILD,Lactic acidosis,Precautions Severe Acute ons,1
STRIBILD,Lactic acidosis,Precautions,0
STRIBILD,Lactic acidosis,Acute ons of Hepatiti s,1
STRIBILD,Lactic acidosis,Precautions,0
STRIBILD,Lactic acidosis,and,0
STRIBILD,Lactic acidosis,of Hepatiti,1
STRIBILD,Lactic acidosis,Exacerbati,0
STRIBILD,Lactic acidosis,ons of Hepatiti,1
STRIBILD,hepatomegaly,of Hepatitis B see xed Warning ,1
STRIBILD,hepatomegaly,ons of Hepatiti,1
STRIBILD,hepatomegaly,B see xed,1
STRIBILD,hepatomegaly,of Hepatitis B see xed Warning  Warnings,1
STRIBILD,hepatomegaly,B see xed,1
STRIBILD,hepatomegaly,Onset or Worsening Renal,0
STRIBILD,steatosis,rnings an d Precautions New Onset,1
STRIBILD,steatosis,Onset or Worsening Renal,0
STRIBILD,steatosis,see,0
STRIBILD,steatosis,rnings an d Precautions,1
STRIBILD,steatosis,see,0
STRIBILD,steatosis,rnings an d Precautions New Onset or,1
STRIBILD,steatosis,see,0
STRIBILD,steatosis,B see Boxed Warning rnings an d,1
STRIBILD,steatosis,see,0
STRIBILD,steatosis,Precautions Severe,0
STRIBILD,acute exacerbations of hepatitis B,SUSPECTED A,0
STRIBILD,acute exacerbations of hepatitis B,Gilead S ciences Inc at GILEAD or,1
STRIBILD,acute exacerbations of hepatitis B,"report SUSPECTED DVERSE REACTIONS, contact Gilead S",1
STRIBILD,acute exacerbations of hepatitis B,"DVERSE REACTIONS, contact Gilead S ciences",1
STRIBILD,acute exacerbations of hepatitis B,"report SUSPECTED DVERSE REACTIONS, contact Gilead S",1
STRIBILD,LACTIC ACIDOSIS,of STRIBILD is based,1
STRIBILD,LACTIC ACIDOSIS,History The safety of STRIBILD,1
STRIBILD,LACTIC ACIDOSIS,History The safety of STRIBILD is  based on,1
STRIBILD,LACTIC ACIDOSIS,History The safety of STRIBILD,1
STRIBILD,LACTIC ACIDOSIS,The safety assessment,0
STRIBILD,HEPATOMEGALY,based  the Week 14 pooled data from,1
STRIBILD,HEPATOMEGALY,The safety assessment,0
STRIBILD,HEPATOMEGALY,the Week,1
STRIBILD,HEPATOMEGALY,of STRIBILD is based the,1
STRIBILD,HEPATOMEGALY,Antiretroviral Treatment History The safety assessment of STRIBILD is,0
STRIBILD,HEPATOMEGALY,STRIBILD is based the,1
STRIBILD,HEPATOMEGALY,is based  the Week 14 pooled data from,1
STRIBILD,HEPATOMEGALY,STRIBILD is based the,1
STRIBILD,HEPATOMEGALY,subjects in two randomized,0
STRIBILD,HEPATOMEGALY,is based the Week 14,1
STRIBILD,HEPATOMEGALY,STRIBILD is based the,1
STRIBILD,STEATOSIS,the Week ed data f rom subjects in two randomized,1
STRIBILD,STEATOSIS,STRIBILD is based the,1
STRIBILD,STEATOSIS,the Week ed,1
STRIBILD,STEATOSIS,the Week ed data,1
STRIBILD,STEATOSIS,doubleblind activecontrolled clinical trials,0
STRIBILD,STEATOSIS,on the Week ed data f,1
STRIBILD,STEATOSIS,doubleblind activecontrolled clinical trials,0
STRIBILD,STEATOSIS,based on the Week ed data f,1
STRIBILD,STEATOSIS,on the,0
STRIBILD,STEATOSIS,based on the Week ed,1
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,is based on the Week pooled data from subjects in,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"randomized, double-blind, ac tivecontrolled clinical trials Study and",1
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,safety assessment of STRIBILD is,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,The,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,clinical trials Study and Study in antiretroviral treatmentnaive,0
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"from subjects two randomized,",1
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"two randomized, double-blind, ac tivecontrolled",1
STRIBILD,ACUTE EXACERBATION OF HEPATITIS B,"from subjects two randomized, double-blind, ac",1
STRIBILD,Lactic acidosis,HIV infected adult subjects see Clinical Studies A total of subjects received STR,0
STRIBILD,Lactic acidosis,Study in antiretroviral reatment-naive  HIV infected adult,1
STRIBILD,Lactic acidosis,HIV infected adult subjects see Clinical Studies A total of subjects received STR,0
STRIBILD,Lactic acidosis,reatment-naive  HIV infected,1
STRIBILD,Lactic acidosis,A total of subjects received,0
STRIBILD,Lactic acidosis,in antiretroviral reatment-naive  HIV infected adult,1
STRIBILD,Lactic acidosis,A total of subjects received,0
STRIBILD,Lactic acidosis,in antiretroviral reatment-naive  HIV infected adult subjects,1
STRIBILD,Lactic acidosis,A total of subjects received,0
STRIBILD,Lactic acidosis,Clinical Studies A total of subjects,0
STRIBILD,Lactic acidosis,Clinical Studies A total,0
STRIBILD,Lactic acidosis,Study in antiretroviral reatment-naive  HIV infected adult subjects see,1
STRIBILD,Lactic acidosis,Clinical Studies A total,0
STRIBILD,Lactic acidosis,antiretroviral reatment-naive  HIV infected adult subjects,1
STRIBILD,Lactic acidosis,Clinical Studies A total,0
STRIBILD,hepatomegaly,and Study in,0
STRIBILD,hepatomegaly,in antiretroviral treatmentnaive HIV ed adult sub jects see Clinical,1
STRIBILD,hepatomegaly,and Study in,0
STRIBILD,steatosis,daily in,0
STRIBILD,steatosis,treatmentnaive HIV infected adult subjects,0
STRIBILD,steatosis,HIV infected adult [see,1
STRIBILD,steatosis,Study,0
STRIBILD,fatal,subjects see,0
STRIBILD,fatal,es (1,1
STRIBILD,fatal,antiretroviral treatmentnaive HIV infected adult subjects,0
STRIBILD,fatal,treatmentnaive HIV,0
STRIBILD,acute exacerbations of hepatitis B,mg PLA (efavirenz 600 mg/emtricitabin,1
STRIBILD,acute exacerbations of hepatitis B,treatmentnaive HIV,0
STRIBILD,acute exacerbations of hepatitis B,RTV TRUVADA,0
STRIBILD,acute exacerbations of hepatitis B,mgtenofovir DF mg PLA (efavirenz 600 mg/emtricitabin,1
STRIBILD,acute exacerbations of hepatitis B,mgcobicistat mgemtricitabine mgtenofovir DF,0
STRIBILD,acute exacerbations of hepatitis B,ATV ritonavir RTV TRUVADA emtricitabine mg,0
STRIBILD,acute exacerbations of hepatitis B,(efavirenz 600 mg/emtricitabin e mgtenofovir,1
STRIBILD,acute exacerbations of hepatitis B,(efavirenz 600 mg/emtricitabin e mgtenofovir DF mg or,1
STRIBILD,acute exacerbations of hepatitis B,RTV TRUVADA emtricitabine mg,0
STRIBILD,worsening renal impairment,see Boxed,0
STRIBILD,worsening renal impairment,adverse drug reactions re,1
STRIBILD,Fanconi syndrome,idosis/Severe He,1
STRIBILD,Fanconi syndrome,discussed in other,0
STRIBILD,Fanconi syndrome,Lactic idosis/Severe He patomegaly with Steatosis see,1
STRIBILD,Fanconi syndrome,discussed in other,0
STRIBILD,Fanconi syndrome,Precautions Severe,0
STRIBILD,Fanconi syndrome,labeling Lactic idosis/Severe He,1
STRIBILD,Fanconi syndrome,idosis/Severe He,1
STRIBILD,Fanconi syndrome,the,0
STRIBILD,Fanconi syndrome,patomegaly with Steatosis,0
STRIBILD,Decreases in bone mineral density,is,0
STRIBILD,Decreases in bone mineral density,sed on the Week 144 pooled data f rom subjects in,1
STRIBILD,Decreases in bone mineral density,is,0
STRIBILD,Decreases in bone mineral density,The,0
STRIBILD,Decreases in bone mineral density,rom subjects in two randomized doubleblind activecontrolled clinical trials Study and,0
STRIBILD,Decreases in bone mineral density,Week 144 pooled data f rom subjects in two,1
STRIBILD,Decreases in bone mineral density,of STRIBILD is,0
STRIBILD,Decreases in bone mineral density,the Week 144 pooled data f rom subjects in two,1
STRIBILD,Decreases in bone mineral density,History,0
STRIBILD,Immune reconstitution syndrome,adult subjects see Clinical Studies A total of subjects received,0
STRIBILD,Immune reconstitution syndrome,total of subjects received STRIBILD once dail,0
STRIBILD,Immune reconstitution syndrome,"subjects received STRIBILD once y in these two studies.



 Th e proportion of",1
STRIBILD,Immune reconstitution syndrome,total of subjects received STRIBILD once dail,0
STRIBILD,Lactic acidosis,mgemtricitabine r DF 300 mg); A TRIPLA efavirenz mgemtricitabine,1
STRIBILD,Lactic acidosis,total of subjects received STRIBILD once dail,0
STRIBILD,Lactic acidosis,with STRIBILD elvitegravir mgcobicistat mgemtricitabine,0
STRIBILD,Lactic acidosis,ntinued treatment with STRIBILD elvitegravir,0
STRIBILD,Lactic acidosis,efavirenz mgemtricitabine mgtenofovir DF mg or atazanavir ATV ritonavir,0
STRIBILD,Lactic acidosis,r DF 300 mg); A TRIPLA efavirenz mgemtricitabine mgtenofovir,1
STRIBILD,Lactic acidosis,mgemtricitabine r DF,1
STRIBILD,Lactic acidosis,r DF 300 mg); A TRIPLA,1
STRIBILD,Lactic acidosis,mgemtricitabine r DF,1
STRIBILD,hepatomegaly,ATRIPLA efav,0
STRIBILD,hepatomegaly,mg ATRIPLA irenz 600 mg,1
STRIBILD,hepatomegaly,mgcobicistat mgemtricitabine mgtenofovir,0
STRIBILD,hepatomegaly,mgtenofovir DF mg ATRIPLA irenz,1
STRIBILD,hepatomegaly,mgtenofovir DF mg ATRIPLA irenz 600 mg emtricitabine mgtenofovir DF,1
STRIBILD,hepatomegaly,mgtenofovir DF mg ATRIPLA irenz,1
STRIBILD,hepatomegaly,ATRIPLA irenz,1
STRIBILD,fatal,ovir  DF mg or atazanavir ATV,1
STRIBILD,fatal,ovir  DF mg or,1
STRIBILD,fatal,mgtenof,0
STRIBILD,fatal,mgtenofovir DF mg ATRIPLA,0
STRIBILD,fatal,ovir  DF,1
STRIBILD,fatal,ovir  DF,1
STRIBILD,proximal renal tubular dysfunction,dreams,0
STRIBILD,proximal renal tubular dysfunction,SUBCUTANEOUS TISSUE DISORDERS,0
STRIBILD,proximal renal tubular dysfunction,4% SKIN AND,1
STRIBILD,proximal renal tubular dysfunction,dreams,0
STRIBILD,proximal renal tubular dysfunction,SUBCUTANEOUS,0
STRIBILD,proximal renal tubular dysfunction,Abnormal dreams,0
STRIBILD,proximal renal tubular dysfunction,with a -existing history of depression or psychiatric illness,1
STRIBILD,proximal renal tubular dysfunction,Abnormal dreams,0
STRIBILD,proximal renal tubular dysfunction,VirologicallySuppressed HIVInfected Subjects,0
STRIBILD,proximal renal tubular dysfunction,depression or psychiatric illness In,1
STRIBILD,proximal renal tubular dysfunction,in subjects with a -existing history of depression or,1
STRIBILD,proximal renal tubular dysfunction,depression or psychiatric illness In,1
STRIBILD,increases in serum creatinine,agents in other clinical trials depression abdominal,0
STRIBILD,increases in serum creatinine,"pneumonia, si",1
STRIBILD,increases in serum creatinine,"fever pain asopharyngitis, pneumonia, si",1
STRIBILD,increases in serum creatinine,"pneumonia, si",1
STRIBILD,increases in serum creatinine,"asopharyngitis, pneumonia, si nusitis",1
STRIBILD,declines in estimated creatinine clearance,"tract infection, arthralgia back pain myalgia paresthesia",1
STRIBILD,declines in estimated creatinine clearance,myalgia,0
STRIBILD,decreases in bone mineral density,"occurred in subjects receiving STRIBILD, 41%",1
STRIBILD,decreases in bone mineral density,occurred in subjects receiving,1
STRIBILD,decreases in bone mineral density,of subjects receiving ATRIPLA,0
STRIBILD,decreases in bone mineral density,"all grades occurred in subjects receiving STRIBILD,",1
STRIBILD,increases in biochemical markers of bone metabolism,receiving,0
STRIBILD,increases in biochemical markers of bone metabolism,TRUVADA The cobicistat component of STRIBILD has been shown,0
STRIBILD,increases in biochemical markers of bone metabolism,"receiving STRIBILD of  receiving ATRIPLA, and 42% of subjects receiving A",1
STRIBILD,increases in biochemical markers of bone metabolism,TRUVADA The cobicistat component of STRIBILD has been shown,0
STRIBILD,increases in biochemical markers of bone metabolism,"STRIBILD of  receiving ATRIPLA, and 42% of subjects receiving A TV RTV",1
STRIBILD,increases in biochemical markers of bone metabolism,TRUVADA The cobicistat component of STRIBILD has been shown,0
STRIBILD,increases in biochemical markers of bone metabolism,"of  receiving ATRIPLA, and 42% of subjects receiving A TV RTV TRUVADA The cobicistat",1
STRIBILD,increases in biochemical markers of bone metabolism,TRUVADA The cobicistat component of STRIBILD has been shown,0
STRIBILD,increases in biochemical markers of bone metabolism,42% of subjects receiving A TV RTV TRUVADA The,1
STRIBILD,increases in biochemical markers of bone metabolism,"receiving STRIBILD of receiving ATRIPLA, and 42% of subjects receiving",1
STRIBILD,increased bone turnover,serum creatinine and,0
STRIBILD,increased bone turnover,subjects receiving ATV RTV UVADA. The cobicist,1
STRIBILD,increased bone turnover,"UVADA.



 The cobicist at component",1
STRIBILD,increased bone turnover,subjects receiving ATV RTV UVADA. The cobicist,1
STRIBILD,increased bone turnover,The cobicist at component,1
STRIBILD,increased bone turnover,ATV RTV UVADA. The cobicist,1
STRIBILD,increased bone turnover,RTV TR,0
STRIBILD,increased bone turnover,receiving ATRIPLA and of subjects receiving,0
STRIBILD,osteomalacia,ATRIPLAN ATV RTV TRUVADAN Seru,0
STRIBILD,osteomalacia,RTV TRUVADAN m Creatinine,1
STRIBILD,osteomalacia,Seru,0
STRIBILD,osteomalacia,ATV RTV TRUVADAN m Creatinine,1
STRIBILD,osteomalacia,m Creatinine mgdL,1
STRIBILD,osteomalacia,RTV TRUVADAN m Creatinine,1
STRIBILD,osteomalacia,m Creatinine mgdL,1
STRIBILD,osteomalacia,STRIBILDN ATRIPLAN ATV RTV,0
STRIBILD,proximal renal tubulopathy,LDN ATRIPLAN ATV RTV TRUVADAN Serum Creatinine,0
STRIBILD,proximal renal tubulopathy,Serum Creatinine 0.14,1
STRIBILD,proximal renal tubulopathy,RTV TRUVADAN Serum Creatinine               0.14 (+/-0.1,1
STRIBILD,proximal renal tubulopathy,Serum Creatinine 0.14,1
STRIBILD,proximal renal tubulopathy,eGFR by CockcroftGault,0
STRIBILD,proximal renal tubulopathy,eGFR by CockcroftGault mLminute,0
STRIBILD,proximal renal tubulopathy,Creatinine mgdL,0
STRIBILD,proximal renal tubulopathy,Serum Creatinine               0.14 (+/-0.1 eGFR by CockcroftGault,1
STRIBILD,proximal renal tubulopathy,Creatinine mgdL,0
STRIBILD,proximal renal tubulopathy,TRUVADAN,0
STRIBILD,proximal renal tubulopathy,Serum Creatinine               0.14 (+/-0.1 eGFR by CockcroftGault mLminute,1
STRIBILD,proximal renal tubulopathy,TRUVADAN,0
STRIBILD,bone pain,-0.12)   ,1
STRIBILD,bone pain,Creatinine -0.12)    eGFR,1
STRIBILD,bone pain,-0.12)   ,1
STRIBILD,bone pain,-0.12)    eGFR,1
STRIBILD,bone pain,Serum,0
STRIBILD,bone pain,-0.12)   ,1
STRIBILD,bone pain,-0.12)    eGFR by CockcroftGault,1
STRIBILD,bone pain,-0.12)   ,1
STRIBILD,pain in extremities,mgdL,0
STRIBILD,pain in extremities,Creatinine 0.09 (+/-0.15)      eGFR by CockcroftGault mLminute,1
STRIBILD,pain in extremities,mgdL,0
STRIBILD,fractures,CockcroftGault,0
STRIBILD,fractures,mL/minute Subjects with,1
STRIBILD,fractures,eGFR by mL/minute Subjects with Elevation,1
STRIBILD,fractures,mL/minute Subjects with,1
STRIBILD,fractures,mL/minute,1
STRIBILD,fractures,mL/minute Subjects with,1
STRIBILD,fractures,mL/minute Subjects,1
STRIBILD,fractures,Subjects with Elevation,0
STRIBILD,Arthralgias,with  in Serum C reatinine All,1
STRIBILD,Arthralgias,Subjects with Elevation,0
STRIBILD,Arthralgias,reatinine,0
STRIBILD,Arthralgias,Serum C,1
STRIBILD,Arthralgias,Subjects,0
STRIBILD,Arthralgias,with in,1
STRIBILD,Arthralgias,in Serum C reatinine All,1
STRIBILD,Arthralgias,Subjects with,0
STRIBILD,Arthralgias,reatinine All Grades,0
STRIBILD,muscle pain,(All G rades,1
STRIBILD,muscle pain,nine (All G,1
STRIBILD,muscle pain,(All G rades,1
STRIBILD,muscle pain,with Elevations,0
STRIBILD,muscle pain,Elevations in,0
STRIBILD,muscle pain,in Serum nine (All G rades,1
STRIBILD,muscle pain,Elevations in,0
STRIBILD,proximal renal tubulopathy,in Serum Creatinine All             6              Emtricitabine or Tenofovir DF,1
STRIBILD,proximal renal tubulopathy,Elevations in,0
STRIBILD,proximal renal tubulopathy,Elevations in Serum,0
STRIBILD,proximal renal tubulopathy,Emtricitabine or Tenofovir DF In addition to the laboratory,0
STRIBILD,proximal renal tubulopathy,in Serum,0
STRIBILD,proximal renal tubulopathy,            6              Emtricitabine or Tenofovir DF,1
STRIBILD,proximal renal tubulopathy,Creatinine,0
STRIBILD,proximal renal tubulopathy,            6              Emtricitabine or,1
STRIBILD,proximal renal tubulopathy,or Tenofovir DF In addition to the laboratory,0
STRIBILD,proximal renal tubulopathy,Tenofovir DF In addition to the laboratory abnormalities,0
STRIBILD,proximal renal tubulopathy,Elevations in Serum Creatinine All Grades,0
STRIBILD,central obesity,than U,0
STRIBILD,central obesity,F ter than 170 U  per,1
STRIBILD,central obesity,than U,0
STRIBILD,central obesity,than 170 U per,1
STRIBILD,central obesity,alkaline phosphatase,0
STRIBILD,central obesity,170 U per,1
STRIBILD,central obesity,U per L F ter than,1
STRIBILD,dorsocervical fat enlargement,"r L), alkaline phosphatase (g reater than U per L",1
STRIBILD,dorsocervical fat enlargement,U per L F ter than,1
STRIBILD,dorsocervical fat enlargement,Grade or laboratory abnormalities of ALT M greater than U per L F greater than U pe,0
STRIBILD,dorsocervical fat enlargement,ULN serum glucose less than,0
STRIBILD,buffalo hump,per L alkaline phosphatase ater than 55 U per L bilirubin greater,1
STRIBILD,buffalo hump,ULN serum glucose less than,0
STRIBILD,buffalo hump,alkaline phosphatase ater than 55 U per L bilirubin greater,1
STRIBILD,buffalo hump,ULN serum glucose less than,0
STRIBILD,buffalo hump,U,0
STRIBILD,buffalo hump,U per L bilirubin greater than ULN serum glucose less than or greater than mg p,0
STRIBILD,buffalo hump,phosphatase ater,1
STRIBILD,facial wasting,or greater than mg,0
STRIBILD,facial wasting,than U per L alkaline phosphatase greater than U per L,0
STRIBILD,facial wasting,per L greater than 2 ULN serum glucose,1
STRIBILD,facial wasting,than U per L alkaline phosphatase greater than U per L,0
STRIBILD,facial wasting,phosphatase greater than U per L bilirubin,0
STRIBILD,facial wasting,per L greater than 2 ULN serum glucose less than,1
STRIBILD,facial wasting,phosphatase greater than U per L bilirubin,0
STRIBILD,facial wasting,than,0
STRIBILD,facial wasting,greater,1
STRIBILD,breast enlargement,"per L bilirubin greater * ULN),",1
STRIBILD,breast enlargement,L bilirubin,0
STRIBILD,breast enlargement,U per,0
STRIBILD,breast enlargement,"greater * ULN), serum glu",1
STRIBILD,breast enlargement," * ULN), serum glu cose less",1
STRIBILD,breast enlargement,"greater * ULN), serum glu",1
STRIBILD,breast enlargement,"per L bilirubin greater * ULN),",1
STRIBILD,breast enlargement,"per L bilirubin greater * ULN),",1
STRIBILD,breast enlargement," * ULN), serum glu cose less",1
STRIBILD,breast enlargement,"per L bilirubin greater * ULN),",1
STRIBILD,cushingoid appearance,ess than 40 or greate r than mg,1
STRIBILD,cushingoid appearance,"per L bilirubin greater * ULN),",1
STRIBILD,cushingoid appearance,or greate r than mg per dL,1
STRIBILD,cushingoid appearance,ess than 40 or greate,1
STRIBILD,cushingoid appearance,or greate r than mg per dL,1
STRIBILD,cushingoid appearance,glycosuria greater than or equal to neutrophils,0
STRIBILD,cushingoid appearance,than ULN serum glucose ess than 40 or greate r than mg per dL,1
STRIBILD,cushingoid appearance,glycosuria greater than or equal to neutrophils,0
STRIBILD,cushingoid appearance,40 or greate r than mg per,1
STRIBILD,cushingoid appearance,40 or greate r than,1
STRIBILD,cushingoid appearance,greater than or equal to neutrophils less than per,0
STRIBILD,Immune reconstitution syndrome,similar percentage of subjects receiving STRIBILD ATRIPLA and,0
STRIBILD,Immune reconstitution syndrome,greater than mg per dL,0
STRIBILD,Immune reconstitution syndrome,triglycerides,0
STRIBILD,Immune reconstitution syndrome,percentage of subjects receiving STRIBILD ATRIPLA and,0
STRIBILD,Immune reconstitution syndrome,TRUVADA were,0
STRIBILD,Immune reconstitution syndrome,"clinical trials of STRIBILD, a similar",1
STRIBILD,Immune reconstitution syndrome,"STRIBILD, a similar",1
STRIBILD,Immune reconstitution syndrome,Lipids In clinical,1
STRIBILD,Mycobacterium avium infection,Changes from baseline in total cholesterol HDLcholesterol,0
STRIBILD,Mycobacterium avium infection,and 12% of ATV + RTV TRUVADA subjects,1
STRIBILD,Mycobacterium avium infection,additional of STRIBILD subjects were,0
STRIBILD,Mycobacterium avium infection,% of,1
STRIBILD,Mycobacterium avium infection,RTV TRUVADA subjects Changes from baseline in total,0
STRIBILD,Mycobacterium avium infection,agents compared % of ATRIPLA and 12% of ATV +  RTV,1
STRIBILD,Mycobacterium avium infection,RTV TRUVADA subjects Changes from baseline in total,0
STRIBILD,Mycobacterium avium infection,% of ATRIPLA and 12% of ATV +  RTV TRUVADA subjects Changes from,1
STRIBILD,Mycobacterium avium infection,RTV TRUVADA subjects Changes from baseline in total,0
STRIBILD,cytomegalovirus,ATV V,1
STRIBILD,cytomegalovirus,ATRIPLA and of ATV V + TRUVADA,1
STRIBILD,cytomegalovirus,and of ATV V + TRUVADA sub jects Changes from baseline in,1
STRIBILD,cytomegalovirus,ATRIPLA and of ATV V + TRUVADA,1
STRIBILD,PCP,triglycerides,0
STRIBILD,PCP,subjects Changes from baseline in,0
STRIBILD,PCP,ota,1
STRIBILD,Autoimmune disorders,5. Tabl e Lipid Values Mean Change,1
STRIBILD,Autoimmune disorders,are in Table,1
STRIBILD,Graves' disease,Mean Ch ange from Baseline at Week,1
STRIBILD,Graves' disease,STRIBILD or Comparator in Studies and,0
STRIBILD,Graves' disease,"presented in Table Table Values, Mean Ch ange from Baseline at Week",1
STRIBILD,Graves' disease,STRIBILD or Comparator in Studies and,0
STRIBILD,Graves' disease,Table,0
STRIBILD,Graves' disease,Mean Ch,1
STRIBILD,Graves' disease,"Table Values, Mean",1
STRIBILD,Graves' disease,Table,0
STRIBILD,Graves' disease,and triglycerides,0
STRIBILD,Guillain-Barre syndrome,Change from Baseline t Week 144 in Subjects  Receiving,1
STRIBILD,Guillain-Barre syndrome,and triglycerides,0
STRIBILD,Guillain-Barre syndrome,t Week 144 in Subjects Receiving,1
STRIBILD,Guillain-Barre syndrome,t Week 144 in Subjects  Receiving STRIBILD,1
STRIBILD,Guillain-Barre syndrome,t Week 144 in Subjects Receiving,1
STRIBILD,Guillain-Barre syndrome,from Baseline t Week 144 in,1
STRIBILD,Guillain-Barre syndrome,STRIBILD or Comparator in,0
STRIBILD,Guillain-Barre syndrome,Mean Change from Baseline t Week 144 in Subjects,1
STRIBILD,Guillain-Barre syndrome,Change from Baseline t Week 144,1
STRIBILD,Guillain-Barre syndrome,t Week 144 in Subjects,1
STRIBILD,Guillain-Barre syndrome,Table Lipid Values Mean Change,0
STRIBILD,Guillain-Barre syndrome,in Subjects Receiving STRIBILD or Comparator in,1
FARXIGA,Hypotension,Hypotension see Warnings,1
FARXIGA,Hypotension,Hypotension see Warnings,1
FARXIGA,Hypotension,Hypotension see Warnings and Precautions Impairment,1
FARXIGA,Impairment in Renal Function,and Precautions Hypoglycemia with Concomitant Use with Insulin and,0
FARXIGA,Impairment in Renal Function,see Warnings and Impairment in Renal Function,1
FARXIGA,Hypoglycemia,Insulin Secretagogues see Warnings and Precautions,0
FARXIGA,Hypoglycemia,Hypoglycemia,1
FARXIGA,Hypoglycemia,Insulin Secretagogues see,0
FARXIGA,Hypoglycemia,Hypoglycemia with Concomitant Use,1
FARXIGA,Hypoglycemia,Hypoglycemia with,1
FARXIGA,Hypoglycemia,Hypoglycemia with,1
FARXIGA,Hypoglycemia,Hypoglycemia with Concomitant Use,1
FARXIGA,Genital Mycotic Infections,Mycotic Infections see Warnings and Precautions,1
FARXIGA,Genital Mycotic Infections,Secretagogues see Warnings and Genital Mycotic Infections,1
FARXIGA,Genital Mycotic Infections,Mycotic Infections see Warnings and Precautions,1
FARXIGA,Genital Mycotic Infections,Warnings and Genital,1
FARXIGA,Genital Mycotic Infections,and,0
FARXIGA,Genital Mycotic Infections,Genital Mycotic,1
FARXIGA,Genital Mycotic Infections,in LowDensity Lipoprotein Cholesterol,0
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Precautions Bladder Cancer see Warnings and Precautio,0
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,and Increases in Low-Density Lipoprotein Cholesterol,1
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Precautions Bladder Cancer see Warnings and Precautio,0
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,in Low-Density Lipoprotein Cholesterol LDLC see Warnings,1
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Genital Mycotic Infections see,0
FARXIGA,Increases in Low-Density Lipoprotein Cholesterol,Infections see Warnings and Increases in Low-Density Lipoprotein,1
FARXIGA,Bladder Cancer,Bladder,1
FARXIGA,Bladder Cancer,in LowDensity Lipoprotein,0
FARXIGA,Bladder Cancer,Warnings and Bladder Cancer,1
FARXIGA,Bladder Cancer,see Warnings and Bladder,1
FARXIGA,Bladder Cancer,Warnings and Bladder Cancer,1
FARXIGA,Bladder Cancer,see Warnings and Bladder,1
FARXIGA,Bladder Cancer,Bladder Cancer see Warnings and Precautions The,1
FARXIGA,Bladder Cancer,common adverse reactions associated with,0
FARXIGA,Bladder Cancer,Warnings and Precautions The most common,0
FARXIGA,Bladder Cancer,LowDensity Lipoprotein,0
FARXIGA,female genital mycotic infections,greater incidence female genital mycotic infections nasopharyngitis and,1
FARXIGA,female genital mycotic infections,LowDensity Lipoprotein,0
FARXIGA,female genital mycotic infections,FARXIGA or greater incidence female genital,1
FARXIGA,female genital mycotic infections,or greater incidence female,1
FARXIGA,female genital mycotic infections,female genital mycotic infections nasopharyngitis and urinary tract,1
FARXIGA,female genital mycotic infections,mycotic infections nasopharyngitis,1
FARXIGA,female genital mycotic infections,mycotic infections nasopharyngitis and,1
FARXIGA,female genital mycotic infections,female genital mycotic infections,1
FARXIGA,female genital mycotic infections,mycotic infections nasopharyngitis and urinary tract infections,1
FARXIGA,female genital mycotic infections,incidence female,1
FARXIGA,female genital mycotic infections,genital mycotic infections nasopharyngitis and urinary tract infections,1
FARXIGA,nasopharyngitis,nasopharyngitis and urinary tract,1
FARXIGA,nasopharyngitis,nasopharyngitis and urinary tract infections EXCERPT,1
FARXIGA,nasopharyngitis,nasopharyngitis and urinary tract infections EXCERPT,1
FARXIGA,nasopharyngitis,nasopharyngitis,1
FARXIGA,nasopharyngitis,nasopharyngitis,1
FARXIGA,nasopharyngitis,nasopharyngitis,1
FARXIGA,nasopharyngitis,incidence were female genital,0
FARXIGA,nasopharyngitis,nasopharyngitis and urinary tract,1
FARXIGA,nasopharyngitis,nasopharyngitis and urinary tract,1
FARXIGA,nasopharyngitis,nasopharyngitis and,1
FARXIGA,urinary tract infections,FARXIGA or greater incidence,0
FARXIGA,urinary tract infections,urinary tract,1
FARXIGA,urinary tract infections,tract infections EXCERPT,1
FARXIGA,urinary tract infections,urinary tract infections EXCERPT To report SUSPECTED,1
FARXIGA,urinary tract infections,tract infections EXCERPT,1
FARXIGA,vulvovaginal mycotic infection,reactions listed in order of,0
FARXIGA,vulvovaginal mycotic infection,following adverse reactions,0
FARXIGA,vulvovaginal mycotic infection,ections include the following adverse reactions listed,0
FARXIGA,vulvovaginal mycotic infection,vaginal infection vulvovaginal candidiasis,0
FARXIGA,vulvovaginal mycotic infection,frequency reported for vulvovaginal mycotic infection vaginal infection,1
FARXIGA,vulvovaginal mycotic infection,vaginal infection vulvovaginal candidiasis,0
FARXIGA,vulvovaginal mycotic infection,of frequency reported for vulvovaginal mycotic infection vaginal infection vulvovaginal candidiasis vulvovaginitis,1
FARXIGA,vulvovaginal mycotic infection,vaginal infection vulvovaginal candidiasis,0
FARXIGA,vulvovaginal mycotic infection,reported for vulvovaginal mycotic infection,1
FARXIGA,vulvovaginal mycotic infection,vulvovaginal mycotic infection vaginal,1
FARXIGA,vulvovaginal mycotic infection,reported for vulvovaginal mycotic infection,1
FARXIGA,vaginal infection,order of,0
FARXIGA,vaginal infection,in order of,0
FARXIGA,vaginal infection,vaginal infection vulvovaginal,1
FARXIGA,vaginal infection,for females vulvovaginal mycotic vaginal infection,1
FARXIGA,vaginal infection,for females vulvovaginal mycotic vaginal,1
FARXIGA,vaginal infection,for females vulvovaginal mycotic,0
FARXIGA,vaginal infection,vaginal infection vulvovaginal,1
FARXIGA,vaginal infection,for females vulvovaginal mycotic vaginal infection,1
FARXIGA,vaginal infection,females vulvovaginal mycotic vaginal,1
FARXIGA,vulvovaginal candidiasis,genital candidiasis,0
FARXIGA,vulvovaginal candidiasis,vulvovaginal candidiasis vulvovaginitis genital infection genital,1
FARXIGA,vulvovaginal candidiasis,vaginal vulvovaginal candidiasis vulvovaginitis genital infection,1
FARXIGA,vulvovaginal candidiasis,vulvovaginal candidiasis vulvovaginitis genital infection genital,1
FARXIGA,vulvovaginal candidiasis,vulvovaginal candidiasis vulvovaginitis genital,1
FARXIGA,vulvovaginal candidiasis,reported for females vulvovaginal mycotic infection,0
FARXIGA,vulvovaginal candidiasis,vulvovaginal candidiasis vulvovaginitis genital infection,1
FARXIGA,vulvovaginal candidiasis,reported for females vulvovaginal mycotic infection,0
FARXIGA,vulvovaginal candidiasis,vulvovaginal candidiasis,1
FARXIGA,vulvovaginitis,vaginal,0
FARXIGA,vulvovaginitis,vulvovaginitis genital,1
FARXIGA,vulvovaginitis,vaginal,0
FARXIGA,vulvovaginitis,vulvovaginitis genital infection,1
FARXIGA,vulvovaginitis,vulvovaginitis,1
FARXIGA,vulvovaginitis,females,0
FARXIGA,vulvovaginitis,mycotic infection vaginal infection vulvovaginal candidiasis,0
FARXIGA,genital infection,genital infection genital candidiasis,1
FARXIGA,genital infection,mycotic infection vaginal infection vulvovaginal candidiasis,0
FARXIGA,genital infection,genital infection genital,1
FARXIGA,genital infection,vulvovaginal candidiasis,0
FARXIGA,genital candidiasis,candidiasis vulvovaginitis genital genital candidiasis,1
FARXIGA,genital candidiasis,vulvovaginal candidiasis,0
FARXIGA,genital candidiasis,genital,1
FARXIGA,genital candidiasis,genital candidiasis,1
FARXIGA,genital candidiasis,vulvovaginitis,0
FARXIGA,genital candidiasis,genital candidiasis fungal genital,1
FARXIGA,genital candidiasis,vulvovaginal candidiasis vulvovaginitis genital genital candidiasis,1
FARXIGA,genital candidiasis,candidiasis vulvovaginitis genital genital candidiasis,1
FARXIGA,genital candidiasis,genital candidiasis fungal genital infection,1
FARXIGA,fungal genital infection,candidiasis,0
FARXIGA,fungal genital infection,candidiasis vulvovaginitis genital,0
FARXIGA,fungal genital infection,genital,0
FARXIGA,fungal genital infection,aginal infection vulvovaginal candidiasis vulvovaginitis genital infection genital candidiasis,0
FARXIGA,fungal genital infection,genital infection,0
FARXIGA,fungal genital infection,genital fungal genital,1
FARXIGA,fungal genital infection,vulvovaginitis genital infection genital fungal genital,1
FARXIGA,fungal genital infection,infection genital,0
FARXIGA,fungal genital infection,genital infection,0
FARXIGA,fungal genital infection,infection genital fungal genital,1
FARXIGA,vulvitis,infection genital candidiasis fungal genital infection,0
FARXIGA,vulvitis,vulvitis genitourinary tract infection vulval,1
FARXIGA,vulvitis,vulvitis genitourinary,1
FARXIGA,vulvitis,vulvovaginitis genital infection genital candidiasis,0
FARXIGA,vulvitis,vulvitis genitourinary tract infection vulval abscess,1
FARXIGA,genitourinary tract infection,genitourinary tract infection vulval abscess and,1
FARXIGA,genitourinary tract infection,vulvitis genitourinary tract infection vulval abscess,1
FARXIGA,genitourinary tract infection,fungal,0
FARXIGA,genitourinary tract infection,females Placebo,0
FARXIGA,vulval abscess,vulval abscess,1
FARXIGA,vulval abscess,females Placebo,0
FARXIGA,vulval abscess,females,0
FARXIGA,vulval abscess,vulval abscess and vaginitis,1
FARXIGA,vulval abscess,vulval abscess and vaginitis bacterial,1
FARXIGA,vulval abscess,tract infection,0
FARXIGA,vulval abscess,genital,0
FARXIGA,vulval abscess,genital infection vulvitis genitourinary tract,0
FARXIGA,vulval abscess,tract vulval abscess,1
FARXIGA,vulval abscess,tract infection,0
FARXIGA,vulval abscess,bacterial N for females,0
FARXIGA,vaginitis bacterial,abscess vaginitis bacterial,1
FARXIGA,vaginitis bacterial,for females Placebo,0
FARXIGA,vaginitis bacterial,infection vulvitis genitourinary tract infection vulval abscess,0
FARXIGA,vaginitis bacterial,N for females Placebo FARXIGA,0
FARXIGA,vaginitis bacterial,vaginitis bacterial,1
FARXIGA,urinary tract infection,urinary tract infection cystitis Escherichia urinary,1
FARXIGA,urinary tract infection,tract infection cystitis Escherichia urinary tract,1
FARXIGA,urinary tract infection,infection,0
FARXIGA,urinary tract infection,tract infection genitourinary,0
FARXIGA,urinary tract infection,order of frequency urinary tract,1
FARXIGA,urinary tract infection,order of frequency urinary tract infection,1
FARXIGA,urinary tract infection,order of frequency urinary tract,1
FARXIGA,urinary tract infection,urinary tract infection cystitis Escherichia,1
FARXIGA,urinary tract infection,order of frequency urinary tract,1
FARXIGA,urinary tract infection,tract infection genitourinary tract infection pyelonephritis trig,0
FARXIGA,cystitis,tract infection,0
FARXIGA,cystitis,cystitis,1
FARXIGA,cystitis,cystitis Escherichia urinary tract infection,1
FARXIGA,cystitis,cystitis,1
FARXIGA,cystitis,cystitis Escherichia,1
FARXIGA,cystitis,cystitis Escherichia urinary tract infection genitourinary,1
FARXIGA,cystitis,the following adverse reactions,0
FARXIGA,cystitis,cystitis Escherichia urinary,1
FARXIGA,cystitis,cystitis Escherichia urinary tract,1
FARXIGA,Escherichia urinary tract infection,reported urinary tract infection Escherichia,1
FARXIGA,Escherichia urinary tract infection,tract infection Escherichia urinary tract infection,1
FARXIGA,Escherichia urinary tract infection,urinary tract infection genitourinary tract infection,1
FARXIGA,Escherichia urinary tract infection,Escherichia urinary tract infection genitourinary tract,1
FARXIGA,Escherichia urinary tract infection,Escherichia urinary tract infection genitourinary tract infection pyelonephritis trigonitis,1
FARXIGA,Escherichia urinary tract infection,Escherichia urinary tract infection genitourinary tract,1
FARXIGA,Escherichia urinary tract infection,tract infection genitourinary tract,1
FARXIGA,Escherichia urinary tract infection,kidney,0
FARXIGA,Escherichia urinary tract infection,Escherichia urinary tract infection,1
FARXIGA,Escherichia urinary tract infection,tract infection genitourinary tract infection,1
FARXIGA,Escherichia urinary tract infection,infection Escherichia urinary,1
FARXIGA,genitourinary tract infection,infection and prostatitis,0
FARXIGA,pyelonephritis,trigonitis urethritis kidney infection and,0
FARXIGA,pyelonephritis,infection,0
FARXIGA,pyelonephritis,infection and prostatitis,0
FARXIGA,pyelonephritis,pyelonephritis trigonitis urethritis kidney,1
FARXIGA,trigonitis,trigonitis urethritis kidney infection,1
FARXIGA,trigonitis,infection genitourinary tract infection trigonitis urethritis kidney infection,1
FARXIGA,trigonitis,trigonitis urethritis kidney infection,1
FARXIGA,trigonitis,trigonitis urethritis kidney infection,1
FARXIGA,trigonitis,kidney infection and,0
FARXIGA,trigonitis,trigonitis urethritis kidney infection and prostatitis,1
FARXIGA,kidney infection,kidney infection,1
FARXIGA,kidney infection,pyelonephritis trigonitis kidney infection and prostatitis Back,1
FARXIGA,kidney infection,kidney infection,1
FARXIGA,kidney infection,tract infection pyelonephritis trigonitis urethritis,0
FARXIGA,kidney infection,and prostatitis,0
FARXIGA,kidney infection,trigonitis kidney,1
FARXIGA,kidney infection,infection pyelonephritis trigonitis kidney infection,1
FARXIGA,kidney infection,trigonitis kidney infection and prostatitis,1
FARXIGA,kidney infection,infection pyelonephritis trigonitis kidney infection,1
FARXIGA,kidney infection,infection genitourinary tract infection pyelonephritis,0
FARXIGA,kidney infection,urethritis,0
FARXIGA,kidney infection,prostatitis,0
FARXIGA,prostatitis,infection prostatitis,1
FARXIGA,prostatitis,prostatitis,0
FARXIGA,prostatitis,prostatitis Back,1
FARXIGA,prostatitis,kidney,0
FARXIGA,prostatitis,prostatitis Back,1
FARXIGA,prostatitis,ction genitourinary tract infection pyelonephritis trigonitis,0
FARXIGA,prostatitis,urethritis kidney infection prostatitis Back,1
FARXIGA,prostatitis,ction genitourinary tract infection pyelonephritis trigonitis,0
FARXIGA,Increased urination,Increased Increased urination includes the following,1
FARXIGA,Increased urination,ction genitourinary tract infection pyelonephritis trigonitis,0
FARXIGA,Increased urination,Increased,0
FARXIGA,Increased urination,Increased Increased urination,1
FARXIGA,Increased urination,Increased,0
FARXIGA,pollakiuria,reported,0
FARXIGA,pollakiuria,polyuria and,0
FARXIGA,pollakiuria,the,0
FARXIGA,polyuria,urine,0
FARXIGA,polyuria,frequency reported,0
FARXIGA,polyuria,ation,0
FARXIGA,balanitis,infection male penile i,0
FARXIGA,balanitis,balanitis fungal genital infection balanitis,1
FARXIGA,balanitis,of frequency reported for balanitis fungal genital infection,1
FARXIGA,balanitis,balanitis fungal genital infection balanitis,1
FARXIGA,balanitis,balanitis,1
FARXIGA,balanitis,genital infection,0
FARXIGA,balanitis,frequency reported for balanitis fungal genital,1
FARXIGA,balanitis,genital infection,0
FARXIGA,balanitis,of frequency reported for balanitis fungal genital infection balanitis,1
FARXIGA,balanitis,genital infection,0
FARXIGA,balanitis,balanitis fungal genital infection balanitis candida,1
FARXIGA,balanitis,males,0
FARXIGA,balanitis,balanitis,1
FARXIGA,fungal genital infection,fungal genital infection,1
FARXIGA,fungal genital infection,balanitis,1
FARXIGA,fungal genital infection,reported for males fungal,1
FARXIGA,fungal genital infection,balanitis,0
FARXIGA,fungal genital infection,adverse reactions listed in order of frequency reported,0
FARXIGA,fungal genital infection,penile,0
FARXIGA,fungal genital infection,for males fungal,1
FARXIGA,fungal genital infection,frequency reported for males,0
FARXIGA,fungal genital infection,genital infection balanitis candida genital candidiasis,1
FARXIGA,fungal genital infection,the following adverse reactions listed in order of frequency reported for,0
FARXIGA,fungal genital infection,frequency reported for males balanitis,0
FARXIGA,balanitis candida,balanitis candida genital,1
FARXIGA,balanitis candida,balanitis fungal genital balanitis candida genital candidiasis,1
FARXIGA,balanitis candida,balanitis candida genital,1
FARXIGA,balanitis candida,balanitis candida,1
FARXIGA,balanitis candida,balanitis candida genital,1
FARXIGA,balanitis candida,balanitis candida,1
FARXIGA,balanitis candida,balanitis candida genital candidiasis genital,1
FARXIGA,balanitis candida,candidiasis genital infection male penile,0
FARXIGA,balanitis candida,balanitis,1
FARXIGA,balanitis candida,reactions listed in order of frequency reported for males balanitis fungal,0
FARXIGA,balanitis candida,balanitis fungal genital,0
FARXIGA,balanitis candida,balanitis candida genital,1
FARXIGA,genital candidiasis,genital infection male penile infection balanoposthitis balanoposthitis,0
FARXIGA,genital infection male,balanitis candida genital genital infection male,1
FARXIGA,genital infection male,genital infection male penile infection balanoposthitis balanoposthitis,0
FARXIGA,penile infection,penile infection balanoposthitis balanoposthitis,1
FARXIGA,penile infection,genital infection male penile infection balanoposthitis balanoposthitis,0
FARXIGA,penile infection,genital infection,0
FARXIGA,penile infection,penile infection balanoposthitis,1
FARXIGA,penile infection,genital candidiasis genital infection penile,1
FARXIGA,penile infection,genital candidiasis genital infection penile infection,1
FARXIGA,penile infection,infection,0
FARXIGA,penile infection,infection posthitis N for males,0
FARXIGA,penile infection,genital infection balanitis candida genital,0
FARXIGA,penile infection,candidiasis genital infection penile,1
FARXIGA,penile infection,infection penile infection balanoposthitis balanoposthitis infective genital,1
FARXIGA,penile infection,candidiasis genital infection penile,1
FARXIGA,balanoposthitis,genital candidiasis genital infection male penile,0
FARXIGA,balanoposthitis,balanoposthitis balanoposthitis infective genital infection posthitis,1
FARXIGA,balanoposthitis,male penile balanoposthitis balanoposthitis infective genital infection,1
FARXIGA,balanoposthitis,balanoposthitis balanoposthitis infective genital infection posthitis,1
FARXIGA,balanoposthitis,genital candidiasis genital infection male penile infection,0
FARXIGA,balanoposthitis,infection male penile balanoposthitis balanoposthitis infective genital infection,1
FARXIGA,balanoposthitis,genital candidiasis genital infection male penile infection,0
FARXIGA,balanoposthitis infective,FARXIGA mg FARXIGA mg,0
FARXIGA,balanoposthitis infective,balanoposthitis,0
FARXIGA,balanoposthitis infective,infection male penile infection balanoposthitis infective,1
FARXIGA,balanoposthitis infective,balanoposthitis,0
FARXIGA,balanoposthitis infective,FARXIGA mg FARXIGA mg,0
FARXIGA,balanoposthitis infective,male penile infection balanoposthitis infective genital infection,1
FARXIGA,balanoposthitis infective,FARXIGA mg FARXIGA mg,0
FARXIGA,balanoposthitis infective,balanoposthitis infective genital infection posthitis,1
FARXIGA,genital infection,penile infection balanoposthitis balanoposthitis genital infection posthitis N for males,1
FARXIGA,genital infection,balanoposthitis infective genital infection posthitis,1
FARXIGA,genital infection,balanoposthitis balanoposthitis genital infection posthitis N for males,1
FARXIGA,genital infection,balanoposthitis infective genital infection posthitis,1
FARXIGA,genital infection,males Placebo FARXIGA,0
FARXIGA,genital infection,infection balanoposthitis balanoposthitis genital infection posthitis N for,1
FARXIGA,genital infection,males Placebo FARXIGA,0
FARXIGA,genital infection,genital infection,1
FARXIGA,genital infection,penile infection balanoposthitis balanoposthitis genital,1
FARXIGA,genital infection,balanoposthitis genital infection posthitis N for males,1
FARXIGA,genital infection,penile infection balanoposthitis balanoposthitis genital,1
FARXIGA,genital infection,infection,0
FARXIGA,genital infection,FARXIGA mg FARXIGA,0
FARXIGA,genital infection,balanoposthitis balanoposthitis genital infection,1
FARXIGA,posthitis,male penile infection balanoposthitis balanoposthitis infective,0
FARXIGA,posthitis,posthitis N for males Placebo,1
FARXIGA,osmotic diuresis,patients mean eGFR mLmin m Volume Depletion FARXIGA causes an,0
FARXIGA,osmotic diuresis,osmotic diuresis,1
FARXIGA,osmotic diuresis,Volume Depletion FARXIGA causes osmotic,1
FARXIGA,osmotic diuresis,mLmin m Volume Depletion,0
FARXIGA,osmotic diuresis,volume,0
FARXIGA,osmotic diuresis,Volume Depletion FARXIGA causes osmotic diuresis,1
FARXIGA,osmotic diuresis,an,0
FARXIGA,osmotic diuresis,in intravascular volume Adverse reactions related,0
FARXIGA,volume depletion,volume depletion including reports of dehydration hypovolemia,1
FARXIGA,dehydration,related to,0
FARXIGA,dehydration,reports dehydration hypovolemia orthostatic hypotension or,1
FARXIGA,dehydration,related to,0
FARXIGA,dehydration,reports dehydration hypovolemia orthostatic hypotension or,1
FARXIGA,dehydration,related to,0
FARXIGA,dehydration,reports dehydration hypovolemia,1
FARXIGA,dehydration,related to,0
FARXIGA,dehydration,reports of,0
FARXIGA,dehydration,hypotension or hypotension are shown in Table for the,0
FARXIGA,hypovolemia,hypovolemia orthostatic,1
FARXIGA,hypovolemia,hypotension or hypotension are shown in Table for the,0
FARXIGA,hypovolemia,to,0
FARXIGA,hypovolemia,reactions related,0
FARXIGA,hypovolemia,the study and,0
FARXIGA,hypovolemia,ravascular volume Adverse reactions related to volume depletion,0
FARXIGA,hypovolemia,in Table for the study and study,0
FARXIGA,hypovolemia,hypovolemia orthostatic hypotension or hypotension,1
FARXIGA,hypovolemia,ravascular,0
FARXIGA,orthostatic hypotension,orthostatic,1
FARXIGA,orthostatic hypotension,for,0
FARXIGA,orthostatic hypotension,reports of dehydration orthostatic hypotension or hypotension are shown,1
FARXIGA,orthostatic hypotension,for,0
FARXIGA,orthostatic hypotension,orthostatic hypotension or hypotension,1
FARXIGA,orthostatic hypotension,and,0
FARXIGA,orthostatic hypotension,Table for the study,0
FARXIGA,orthostatic hypotension,in Table for the,0
FARXIGA,orthostatic hypotension,dehydration orthostatic hypotension or hypotension are shown,1
FARXIGA,orthostatic hypotension,in Table for the,0
FARXIGA,orthostatic hypotension,of dehydration orthostatic hypotension or hypotension are shown in,1
FARXIGA,orthostatic hypotension,in Table for the,0
FARXIGA,orthostatic hypotension,reports of dehydration hypovolemia,0
FARXIGA,Volume Depletion,Volume Depletion,1
FARXIGA,Volume Depletion,Precautions,0
FARXIGA,Volume depletion,Volume depletion includes reports of dehydration,1
FARXIGA,Volume depletion,Precautions,0
FARXIGA,dehydration,DepletionVolume depletion includes reports dehydration hypovolemia orthostatic hypotension or hypotension,1
FARXIGA,dehydration,Precautions,0
FARXIGA,dehydration,dehydration hypovolemia orthostatic hypotension or,1
FARXIGA,dehydration,or hypotension in Clinical Studies with,0
FARXIGA,dehydration,of,0
FARXIGA,dehydration,dehydration hypovolemia orthostatic hypotension or,1
FARXIGA,dehydration,dehydration hypovolemia,1
FARXIGA,dehydration,dehydration hypovolemia orthostatic,1
FARXIGA,dehydration,dehydration,1
FARXIGA,hypovolemia,hypovolemia orthostatic hypotension,1
FARXIGA,hypovolemia,dehydration,1
FARXIGA,hypovolemia,hypovolemia orthostatic hypotension or hypotension in,1
FARXIGA,orthostatic hypotension,DepletionVolume depletion,0
FARXIGA,orthostatic hypotension,dehydration orthostatic,1
FARXIGA,orthostatic hypotension,or hypotension in Clinical Studies with FARXIGA,0
FARXIGA,orthostatic hypotension,includes reports of dehydration orthostatic hypotension or hypotension,1
FARXIGA,orthostatic hypotension,or hypotension in Clinical Studies with FARXIGA,0
FARXIGA,hypotension,Studies,0
FARXIGA,increases in serum creatinine,Renal Function,0
FARXIGA,increases in serum creatinine,increases,1
FARXIGA,increases in serum creatinine,serum creatinine and decreases in eGFR,1
FARXIGA,increases in serum creatinine,with,0
FARXIGA,increases in serum creatinine,in serum creatinine,1
FARXIGA,increases in serum creatinine,serum creatinine and,1
FARXIGA,increases in serum creatinine,serum creatinine and decreases in eGFR,1
FARXIGA,increases in serum creatinine,of,0
FARXIGA,increases in serum creatinine,In patients with normal,0
FARXIGA,decreases in eGFR,in serum,0
FARXIGA,decreases in eGFR,increases in serum creatinine decreases,1
FARXIGA,decreases in eGFR,Table In,0
FARXIGA,Renal-related adverse reactions,Renal-related adverse reactions including renal failure and,1
FARXIGA,Renal-related adverse reactions,Week,0
FARXIGA,Renal-related adverse reactions,baseline values at Renal-related adverse reactions including renal failure and blood,1
FARXIGA,Renal-related adverse reactions,Week,0
FARXIGA,Renal-related adverse reactions,values at Renal-related adverse reactions,1
FARXIGA,renal failure,adverse reactions renal,1
FARXIGA,renal failure,renal failure and blood,1
FARXIGA,renal failure,reactions renal failure,1
FARXIGA,renal failure,baseline values at Week,0
FARXIGA,renal failure,and eGFR returned to baseline values at,0
FARXIGA,blood creatinine increase,including renal failure,0
FARXIGA,blood creatinine increase,Elderly patients and,0
FARXIGA,blood creatinine increase,values at Week Renalrelated adverse reactions including renal failure and,0
FARXIGA,blood creatinine increase,failure blood creatinine increase,1
FARXIGA,blood creatinine increase,baseline values at Week Renalrelated adverse reactions including,0
FARXIGA,blood creatinine increase,including renal failure blood creatinine,1
FARXIGA,blood creatinine increase,including renal failure blood creatinine increase were more frequent in,1
FARXIGA,blood creatinine increase,including renal failure blood creatinine,1
FARXIGA,blood creatinine increase,failure blood creatinine increase were more,1
FARXIGA,blood creatinine increase,including renal failure blood creatinine,1
FARXIGA,Renal Impairment-Related Adverse Reaction,Least,0
FARXIGA,Renal Impairment-Related Adverse Reaction,with at Least Renal Impairment-Related Adverse Reaction,1
FARXIGA,Renal Impairment-Related Adverse Reaction,Least,0
FARXIGA,Renal Impairment-Related Adverse Reaction,Pool of PlaceboControlled,0
FARXIGA,Renal Impairment-Related Adverse Reaction,Table Proportion of Patients with at Least One,0
FARXIGA,Renal Impairment-Related Adverse Reaction,with at Least Renal Impairment-Related,1
FARXIGA,bone fractures,Studies In this study patients experienced,0
FARXIGA,bone fractures,this study patients,0
FARXIGA,bone fractures,No fractures occurred in the placebo group,0
FARXIGA,bone fractures,bone fractures for treatment durations up to,1
FARXIGA,bone fractures,In this study patients bone fractures for,1
FARXIGA,bone fractures,bone fractures for treatment durations up to,1
FARXIGA,bone fractures,this study patients bone fractures,1
FARXIGA,bone fractures,Studies In,0
FARXIGA,bone fractures,In this study patients,0
FARXIGA,fractures,fractures occurred in the,1
FARXIGA,fractures,fractures occurred in the,1
FARXIGA,fractures,fractures occurred in the placebo,1
FARXIGA,fractures,fractures occurred in the,1
FARXIGA,fractures,up to,0
FARXIGA,fractures,to weeks No,0
FARXIGA,fractures,fractures occurred in,1
FARXIGA,fractures,bone fractures,0
FARXIGA,fractures,in the FARXIGA mg group,0
FARXIGA,fractures,fractures were in patients who,1
FARXIGA,fractures,was no apparent pattern,0
FARXIGA,fractures,in patients who had a,0
FARXIGA,fractures,weeks There was no apparent pattern with,0
FARXIGA,fractures,fractures were in patients who had a,0
FARXIGA,fractures,in patients who had a baseline eGFR of,0
FARXIGA,fractures,first weeks,0
FARXIGA,fracture,fracture Hypoglycemia,1
FARXIGA,fracture,first weeks,0
FARXIGA,fracture,site of,0
FARXIGA,fracture,There was no apparent pattern with respect,0
FARXIGA,fracture,hypoglycemia by study see Clinical Studies,0
FARXIGA,fracture,fracture,1
FARXIGA,fracture,hypoglycemia by study see Clinical Studies,0
FARXIGA,hypoglycemia,to the,0
FARXIGA,hypoglycemia,The frequency hypoglycemia by study,1
FARXIGA,hypoglycemia,to the,0
FARXIGA,hypoglycemia,The frequency hypoglycemia by study see Clinical,1
FARXIGA,hypoglycemia,to the,0
FARXIGA,hypoglycemia,hypoglycemia by,1
FARXIGA,hypoglycemia,study see Clinical Studies is shown in Table,0
FARXIGA,hypoglycemia,Table Hypoglycemia,0
FARXIGA,hypoglycemia,hypoglycemia by study see Clinical,1
FARXIGA,Hypoglycemia,of hypoglycemia by study see Clinical Studies is shown in,0
FARXIGA,Hypoglycemia,Hypoglycemia was more frequent when FARXIGA,1
FARXIGA,hypoglycemia,requiring,0
FARXIGA,hypoglycemia,hypoglycemia were defined as symptomatic,1
FARXIGA,hypoglycemia,assistance due to severe,0
FARXIGA,hypoglycemia,hypoglycemia,1
FARXIGA,hypoglycemia,nsulin see Warnings and Precautions Table Incidence,0
FARXIGA,hypoglycemia,hypoglycemia,1
FARXIGA,hypoglycemia,defined as symptomatic episodes requiring external third party assistance,0
FARXIGA,impairment in consciousness,severe,0
FARXIGA,impairment in consciousness,in consciousness or behavior with a capillary,1
FARXIGA,impairment in consciousness,assistance due to impairment in consciousness or behavior with a capillary,1
FARXIGA,impairment in consciousness,in consciousness or behavior with a capillary,1
FARXIGA,impairment in consciousness,impairment in consciousness,1
FARXIGA,impairment in consciousness,in consciousness or behavior with a capillary,1
FARXIGA,impairment in consciousness,impairment in consciousness or behavior,1
FARXIGA,impairment in consciousness,requiring external third party,0
FARXIGA,impairment in consciousness,requiring external third party assistance due to severe,0
FARXIGA,impairment in consciousness,assistance due to impairment in consciousness,1
FARXIGA,impairment in consciousness,impairment in consciousness,1
FARXIGA,impairment in consciousness,capillary or plasma glucose value mgdL and prompt,0
FARXIGA,plasma glucose value <54 mg/dL,a,0
FARXIGA,plasma glucose value <54 mg/dL,capillary plasma glucose value <54 mg/dL and prompt,1
FARXIGA,plasma glucose value <54 mg/dL,a,0
FARXIGA,plasma glucose value <54 mg/dL,with a capillary plasma,1
FARXIGA,plasma glucose value <54 mg/dL,and MinorMinor,0
FARXIGA,plasma glucose value <54 mg/dL,with a capillary plasma glucose value <54,1
FARXIGA,hypoglycemia,were defined as either a symptomatic,0
FARXIGA,hypoglycemia,hypoglycemia were defined as either,1
FARXIGA,hypoglycemia,were defined as either a symptomatic,0
FARXIGA,plasma glucose measurement <63 mg/dL,with a capillary plasma glucose measurement,1
FARXIGA,plasma glucose measurement <63 mg/dL,measurement <63 mg/dL,1
FARXIGA,plasma glucose measurement <63 mg/dL,episode with a capillary plasma glucose measurement <63 mg/dL,1
FARXIGA,plasma glucose measurement <63 mg/dL,measurement <63 mg/dL,1
FARXIGA,plasma glucose measurement <63 mg/dL,<63 mg/dL regardless of,1
FARXIGA,plasma glucose measurement <63 mg/dL,plasma glucose measurement <63 mg/dL regardless of need,1
FARXIGA,plasma glucose measurement <63 mg/dL,<63 mg/dL regardless of,1
FARXIGA,plasma glucose measurement <63 mg/dL,a capillary plasma glucose measurement <63 mg/dL,1
FARXIGA,plasma glucose measurement <63 mg/dL,of need for external,0
FARXIGA,plasma glucose measurement <63 mg/dL,with a capillary or,0
FARXIGA,plasma glucose measurement <63 mg/dL,capillary plasma,1
FARXIGA,plasma glucose measurement <63 mg/dL,an asymptomatic capillary plasma glucose measurement <63 mg/dL that does not qualify,1
FARXIGA,plasma glucose measurement <63 mg/dL,capillary plasma,1
FARXIGA,plasma glucose measurement <63 mg/dL,external assistance,0
FARXIGA,plasma glucose measurement <63 mg/dL,an asymptomatic capillary plasma glucose measurement <63,1
FARXIGA,plasma glucose measurement <63 mg/dL,<63 mg/dL that does not qualify,1
FARXIGA,plasma glucose measurement <63 mg/dL,mgdL regardless of,0
FARXIGA,plasma glucose measurement <63 mg/dL,Hypoglycemia in Controlled Clinical,0
FARXIGA,plasma glucose measurement <63 mg/dL,asymptomatic capillary plasma glucose measurement <63 mg/dL,1
FARXIGA,Hypoglycemia,Controlled Clinical,0
FARXIGA,Hypoglycemia,mgdL that does not,0
FARXIGA,Hypoglycemia,qualify as a major Hypoglycemia in Controlled Clinical,1
FARXIGA,Hypoglycemia,mgdL that does not,0
FARXIGA,Hypoglycemia,qualify as a major Hypoglycemia in Controlled Clinical Studies,1
FARXIGA,Hypoglycemia,mgdL that does not,0
FARXIGA,Hypoglycemia,as a major Hypoglycemia in Controlled,1
FARXIGA,Hypoglycemia,mgdL that does not,0
FARXIGA,Hypoglycemia,Controlled,0
FARXIGA,Genital mycotic infections,mycotic infections were more frequent,1
FARXIGA,Genital mycotic infections,Genital mycotic infections were more frequent with FARXIGA,1
FARXIGA,Genital mycotic infections,Genital Mycotic,0
FARXIGA,Genital mycotic infections,frequent with FARXIGA Genital,1
FARXIGA,Genital mycotic infections,more frequent with FARXIGA Genital mycotic infections were reported in of,1
FARXIGA,Genital mycotic infections,frequent with FARXIGA Genital,1
FARXIGA,Genital mycotic infections,were more frequent with FARXIGA treatment,0
FARXIGA,Genital mycotic infections,of patients on placebo,0
FARXIGA,Genital mycotic infections,mycotic infections were reported,1
FARXIGA,Genital mycotic infections,of,0
FARXIGA,Genital mycotic infections,more frequent with FARXIGA Genital,1
FARXIGA,Genital mycotic infections,on FARXIGA,0
FARXIGA,Genital mycotic infections,with FARXIGA Genital mycotic infections,1
FARXIGA,Genital mycotic infections,on FARXIGA,0
FARXIGA,genital infection,study due genital infection,1
FARXIGA,genital infection,on FARXIGA,0
FARXIGA,genital infection,study due genital,1
FARXIGA,genital infection,due to,0
FARXIGA,genital infection,d on,0
FARXIGA,genital infection,patients and of patients,0
FARXIGA,Infections,Infections were more frequently reported in,1
FARXIGA,Infections,patients and of patients,0
FARXIGA,Infections,Infections,1
FARXIGA,Infections,patients,0
FARXIGA,Infections,patients and of patients treated with,0
FARXIGA,Infections,Infections were more,1
FARXIGA,Infections,Infections were more frequently reported,1
FARXIGA,Infections,Infections were more frequently reported,1
FARXIGA,Infections,Infections were more,1
FARXIGA,genital mycotic infections,reported,0
FARXIGA,genital mycotic infections,mycotic infections were vulvovaginal mycotic infections in,1
FARXIGA,genital mycotic infections,with,0
FARXIGA,genital mycotic infections,frequently reported,0
FARXIGA,genital mycotic infections,vulvovaginal mycotic infections in females and balanitis in males,0
FARXIGA,genital mycotic infections,genital mycotic infections were,1
FARXIGA,genital mycotic infections,mycotic infections were,1
FARXIGA,genital mycotic infections,infections,0
FARXIGA,vulvovaginal mycotic infections,infections vulvovaginal,1
FARXIGA,vulvovaginal mycotic infections,mycotic infections,1
FARXIGA,genital mycotic infection,than those with,0
FARXIGA,genital mycotic infection,to have genital mycotic infection,1
FARXIGA,Hypersensitivity reactions,respectively Hypersensitivity Hypersensitivity reactions,1
FARXIGA,Hypersensitivity reactions,respectively Hypersensitivity Hypersensitivity,1
FARXIGA,Hypersensitivity reactions,were reported,0
FARXIGA,angioedema,angioedema urticaria,1
FARXIGA,angioedema,the clinical,0
FARXIGA,angioedema,angioedema urticaria hypersensitivity were,1
FARXIGA,angioedema,angioedema urticaria hypersensitivity were,1
FARXIGA,angioedema,urticaria hypersensitivity were reported with FARXIGA,0
FARXIGA,angioedema,angioedema urticaria hypersensitivity were,1
FARXIGA,angioedema,the clinical program se,0
FARXIGA,angioedema,angioedema urticaria hypersensitivity were reported,1
FARXIGA,angioedema,angioedema urticaria hypersensitivity were reported with,1
FARXIGA,angioedema,angioedema urticaria hypersensitivity,1
FARXIGA,urticaria,urticaria hypersensitivity were reported,1
FARXIGA,urticaria,Across the clinical program serious anaph,0
FARXIGA,urticaria,urticaria hypersensitivity were reported with FARXIGA,1
FARXIGA,urticaria,clinical program serious,0
FARXIGA,urticaria,urticaria hypersensitivity were,1
FARXIGA,hypersensitivity,reactions eg angioedema hypersensitivity were reported with FARXIGA,1
FARXIGA,hypersensitivity,urticaria hypersensitivity were,1
FARXIGA,hypersensitivity,were,0
FARXIGA,hypersensitivity,eg angioedema urticaria,0
FARXIGA,anaphylactic reactions,cutaneous adverse reactions and angioedema were reported in of,0
FARXIGA,anaphylactic reactions,Across the clinical program anaphylactic reactions and severe cutaneous adverse reactions,1
FARXIGA,anaphylactic reactions,cutaneous adverse reactions and angioedema were reported in of,0
FARXIGA,anaphylactic reactions,anaphylactic reactions and severe cutaneous adverse reactions,1
FARXIGA,anaphylactic reactions,anaphylactic reactions and severe cutaneous adverse reactions,1
FARXIGA,anaphylactic reactions,anaphylactic reactions and severe cutaneous adverse reactions,1
FARXIGA,anaphylactic reactions,treatment Across the clinical program,0
FARXIGA,anaphylactic reactions,anaphylactic reactions and severe cutaneous,1
FARXIGA,anaphylactic reactions,anaphylactic reactions and severe cutaneous adverse reactions,1
FARXIGA,anaphylactic reactions,clinical program anaphylactic,1
FARXIGA,anaphylactic reactions,and angioedema were reported in,0
FARXIGA,anaphylactic reactions,anaphylactic reactions and,1
FARXIGA,cutaneous adverse reactions,serious anaphylactic reactions and,0
FARXIGA,cutaneous adverse reactions,reactions and,0
FARXIGA,cutaneous adverse reactions,anaphylactic reactions and cutaneous adverse reactions and angioedema were,1
FARXIGA,cutaneous adverse reactions,reactions and,0
FARXIGA,angioedema,comparatortreated patients and of FARXIGAtreated,0
FARXIGA,angioedema,the clinical program serious anaphylactic reactions and severe,0
FARXIGA,angioedema,severe cutaneous adverse reactions angioedema were reported,1
FARXIGA,angioedema,the clinical program serious anaphylactic reactions and severe,0
FARXIGA,angioedema,the clinical program serious anaphylactic,0
FARXIGA,hematocrit values >55%,By hematocrit values >55% were reported in of,1
FARXIGA,hematocrit values >55%,the clinical program serious anaphylactic,0
FARXIGA,hematocrit values >55%,hematocrit values >55% were reported in,1
FARXIGA,hyperphosphatemia,hyperphosphatemia mgdL for,1
FARXIGA,hyperphosphatemia,hematocrit values >55% were reported in,1
FARXIGA,hyperphosphatemia,laboratory abnormalities of,0
FARXIGA,hyperphosphatemia,marked,0
FARXIGA,hyperphosphatemia,hyperphosphatemia,1
FARXIGA,hyperphosphatemia,marked,0
FARXIGA,hyperphosphatemia,of,0
FARXIGA,hyperphosphatemia,with marked,0
FARXIGA,hyperphosphatemia,hyperphosphatemia mgdL for age years,1
FARXIGA,hyperphosphatemia,with marked,0
FARXIGA,hyperphosphatemia,hyperphosphatemia mgdL for age years,1
FARXIGA,hyperphosphatemia,proportions of,0
FARXIGA,Hypotension,are described below and elsewhere in the labeling Hypotension see Warnings and,0
FARXIGA,Impairment in renal function,[see Warning s and Precautions Genital Mycotic,1
FARXIGA,Impairment in renal function,Insulin and Secretagogues,1
FARXIGA,Impairment in renal function,Concomitant,0
FARXIGA,Hypoglycemia,and Precautions Genital Mycotic ons,1
FARXIGA,Hypoglycemia,Mycotic ons [see Wa,1
FARXIGA,Increased LDL-C,(5% or g reater incidence were,1
FARXIGA,Increased LDL-C,ARXIGA (5% or g reater,1
FARXIGA,Increased LDL-C,see Warnings and Precautions The most common adverse,0
FARXIGA,Increased LDL-C,nasopharyngitis and urinary tract,0
FARXIGA,Increased LDL-C,adverse reactions associated with ARXIGA (5% or g reater incidence were female genital,1
FARXIGA,Increased LDL-C,nasopharyngitis and urinary tract,0
FARXIGA,Increased LDL-C,urinary,0
FARXIGA,Increased LDL-C,ARXIGA,1
FARXIGA,Increased LDL-C,incidence were female genital mycotic infections nasopharyngitis,0
FARXIGA,Increased LDL-C,ARXIGA (5% or g reater,1
FARXIGA,Increased LDL-C,incidence were female genital mycotic infections nasopharyngitis,0
FARXIGA,Bladder Cancer,asopharyngitis,1
FARXIGA,bladder cancers,infections nasopharyngitis and urinary t infections.   EXCERPT,1
FARXIGA,bladder cancers,asopharyngitis,1
FARXIGA,intravascular volume contraction,and may not eflect the rates observed in cli,1
FARXIGA,intravascular volume contraction,eflect the rates observed in cli nical practice Pool,1
FARXIGA,intravascular volume contraction,directly compared to rates in the clinical trials of another drug and may not r,0
FARXIGA,intravascular volume contraction,may not eflect the rates observed,1
FARXIGA,intravascular volume contraction,rates in the clinical trials of another drug and,0
FARXIGA,intravascular volume contraction,drug and may not eflect the rates observed in cli,1
FARXIGA,intravascular volume contraction,rates in the clinical trials of another drug and,0
FARXIGA,intravascular volume contraction,drug and may not eflect the rates observed in,1
FARXIGA,Symptomatic hypotension,in the clinical trials of another drug and,0
FARXIGA,Symptomatic hypotension,"cal practice.



     P ool of PlaceboControlled Studies",1
FARXIGA,Symptomatic hypotension,in the clinical trials of another drug and,0
FARXIGA,Symptomatic hypotension,"cal practice.



     P ool of PlaceboControlled Studies",1
FARXIGA,Symptomatic hypotension,in the clinical trials of another drug and,0
FARXIGA,Symptomatic hypotension,observed in cal,1
FARXIGA,Symptomatic hypotension,cal practice. P ool,1
FARXIGA,Symptomatic hypotension,reflect the rates observed in clini,0
FARXIGA,Symptomatic hypotension,cal practice. P ool of PlaceboControlled Studies for,1
FARXIGA,Symptomatic hypotension,practice. P ool of PlaceboControlled Studies,1
FARXIGA,Symptomatic hypotension,the rates observed in cal,1
FARXIGA,increases serum creatinine,placebo (N FARXIGA,1
FARXIGA,increases serum creatinine,Pa,0
FARXIGA,increases serum creatinine,duration of weeks tients received,1
FARXIGA,increases serum creatinine,mg,0
FARXIGA,increases serum creatinine,Pa,0
FARXIGA,increases serum creatinine,FARXIGA mg,0
FARXIGA,increases serum creatinine,placebo (N FARXIGA mg N or,1
FARXIGA,increases serum creatinine,of the population,0
FARXIGA,decreases eGFR,5 m g N or FARXIGA,1
FARXIGA,decreases eGFR,Patients,0
FARXIGA,decreases eGFR,N once daily The mean age of the population was years and,0
FARXIGA,decreases eGFR,to,0
FARXIGA,decreases eGFR,the,0
FARXIGA,decreases eGFR,FARXIGA 5 m g N or FARXIGA,1
FARXIGA,decreases eGFR,patients to FARXIGA with a,0
FARXIGA,decreases eGFR,FARXIGA 5 m g,1
FARXIGA,decreases eGFR,N or FARXIGA mg N once daily The mean,0
FARXIGA,decreases eGFR,FARXIGA 5 m g N or,1
FARXIGA,hypoglycemia,and ately,1
FARXIGA,hypoglycemia,ed in,0
FARXIGA,hypoglycemia,ately impair ed in of,1
FARXIGA,hypoglycemia,ately impair,1
FARXIGA,genital mycotic infections,FARXIGA Adverse Reac,0
FARXIGA,genital mycotic infections,in PlaceboControlled Studies Reported in of Patients Treated with FARXIGA Adverse Reac,0
FARXIGA,genital mycotic infections,"FARXIGA 

 Table 1: Adverse Reacti ons in PlaceboControlled",1
FARXIGA,genital mycotic infections,in PlaceboControlled Studies Reported in of Patients Treated with FARXIGA Adverse Reac,0
FARXIGA,genital mycotic infections,"FARXIGA 

 Table 1: Adverse Reacti ons in PlaceboControlled Studies",1
FARXIGA,genital mycotic infections,in PlaceboControlled Studies Reported in of Patients Treated with FARXIGA Adverse Reac,0
FARXIGA,genital mycotic infections,Studies Reported,0
FARXIGA,genital mycotic infections,PlaceboControlled Studies Reported in of Patients Treated with FARXIGA Adverse,0
FARXIGA,genital mycotic infections,Studies Reported in of Patients Treated with FARXIGA,0
FARXIGA,genital mycotic infections,of patients,0
FARXIGA,genital mycotic infections,"mg or FARXIGA 

 Table 1: Adverse Reacti ons in PlaceboControlled Studies",1
FARXIGA,genital mycotic infections,of patients,0
FARXIGA,genital mycotic infections,mg or FARXIGA,0
FARXIGA,Increases in LDL-C,                   Placebo N FARXIGA,1
FARXIGA,Increases in LDL-C,                   Placebo N,1
FARXIGA,Increases in LDL-C,                   Placebo N FARXIGA mg,1
FARXIGA,Increases in LDL-C,Studies,0
FARXIGA,Increases in LDL-C,FARXIGA,0
FARXIGA,Increases in LDL-C,                   Placebo,1
FARXIGA,bladder cancer,for females vulvovaginal,0
FARXIGA,bladder cancer,n order of fre quency reported for females vulvovaginal,1
FARXIGA,bladder cancer,for females vulvovaginal,0
FARXIGA,bladder cancer,reactions,0
FARXIGA,bladder cancer,infection vulvovaginal candidi,0
FARXIGA,bladder cancer,order of fre quency,1
FARXIGA,bladder cancer,adverse reactions listed n,1
FARXIGA,bladder cancer,"genitourinary tract infection lval abscess,  and vaginitis",1
FARXIGA,bladder cancer,adverse reactions listed n,1
FARXIGA,bladder cancer,infection,0
FARXIGA,bladder cancer,fungal genital,0
FARXIGA,bladder cancer,and vaginitis,0
FARXIGA,bladder cancer,"infection lval abscess,  and vaginitis bacterial N for",1
FARXIGA,bladder cancer,and vaginitis,0
FARXIGA,bladder cancer,N for,0
VICTRELIS,fatigue,nausea headache and dysgeusia To report SUSPECTED ADVERSE,0
VICTRELIS,fatigue,with PegIntron and REBETOL fatigue anemia nausea headache and dysgeusia,1
VICTRELIS,fatigue,nausea headache and dysgeusia To report SUSPECTED ADVERSE,0
VICTRELIS,fatigue,nausea headache and dysgeusia,0
VICTRELIS,fatigue,fatigue anemia nausea headache,1
VICTRELIS,fatigue,with PegIntron and REBETOL fatigue anemia nausea headache and dysgeusia,1
VICTRELIS,fatigue,fatigue anemia nausea headache,1
VICTRELIS,fatigue,fatigue anemia nausea,1
VICTRELIS,anemia,anemia nausea headache and dysgeusia,1
VICTRELIS,anemia,anemia,1
VICTRELIS,nausea,nausea headache and,1
VICTRELIS,nausea,were fatigue nausea headache,1
VICTRELIS,nausea,nausea headache and,1
VICTRELIS,headache,report SUSPECTED ADVERSE REACTIONS contact Merck Sharp Dohme,0
VICTRELIS,headache,headache and,1
VICTRELIS,dysgeusia,headache dysgeusia To report SUSPECTED,1
VICTRELIS,dysgeusia,headache and,1
VICTRELIS,dysgeusia,SUSPECTED ADVERSE REACTIONS contact Merck Sharp Dohme Corp a,0
VICTRELIS,dysgeusia,fatigue anemia nausea headache dysgeusia To report SUSPECTED,1
VICTRELIS,dysgeusia,SUSPECTED ADVERSE REACTIONS contact Merck Sharp Dohme Corp a,0
VICTRELIS,dysgeusia,dysgeusia To report,1
VICTRELIS,dysgeusia,Dohme Corp a,0
VICTRELIS,dysgeusia,To report SUSPECTED ADVERSE REACTIONS contact Merck Sharp,0
VICTRELIS,dysgeusia,dysgeusia To,1
VICTRELIS,Anemia,Anemia see Warnings and Precautions Neutropenia,1
VICTRELIS,Anemia,section of the Anemia see Warnings and Precautions Neutropenia,1
VICTRELIS,Anemia,Anemia see Warnings and Precautions Neutropenia,1
VICTRELIS,Anemia,section of the Anemia,1
VICTRELIS,Anemia,Anemia see Warnings and Precautions Neutropenia,1
VICTRELIS,Anemia,are discussed in detail,0
VICTRELIS,Anemia,Anemia see,1
VICTRELIS,Anemia,Anemia see Warnings,1
VICTRELIS,Anemia,Anemia,1
VICTRELIS,Anemia,discussed,0
VICTRELIS,Anemia,adverse drug reactions ADRs are discussed in detail in another section of,0
VICTRELIS,Anemia,another section of the Anemia see,1
VICTRELIS,Anemia,adverse drug reactions ADRs are discussed in detail in another section of,0
VICTRELIS,Neutropenia,of the labeling,0
VICTRELIS,Pancytopenia,see Warnings and Precautions,0
VICTRELIS,Pancytopenia,see Contraindications and,0
VICTRELIS,Pancytopenia,Pancytopenia see Warnings and,1
VICTRELIS,Hypersensitivity,see Warnings and Hypersensitivity,1
VICTRELIS,Hypersensitivity,Pancytopenia see Warnings and,1
VICTRELIS,Hypersensitivity,Hypersensitivity,1
VICTRELIS,Hypersensitivity,Pancytopenia see Warnings and Hypersensitivity see,1
VICTRELIS,Hypersensitivity,Hypersensitivity,1
VICTRELIS,Hypersensitivity,Hypersensitivity see Contraindications,1
VICTRELIS,Hypersensitivity,Hypersensitivity see Contraindications and Warnings,1
VICTRELIS,Hypersensitivity,and Warnings and,0
VICTRELIS,Hypersensitivity,Warnings and Precautions Pancytopenia,0
VICTRELIS,Hypersensitivity,see Warnings and Hypersensitivity,1
VICTRELIS,Hypersensitivity,Warnings and Precautions Pancytopenia,0
VICTRELIS,Hypersensitivity,see Warnings and Hypersensitivity see,1
VICTRELIS,Hypersensitivity,Warnings and Precautions Pancytopenia,0
VICTRELIS,fatigue,fatigue anemia,1
VICTRELIS,fatigue,fatigue anemia nausea,1
VICTRELIS,fatigue,fatigue,1
VICTRELIS,fatigue,was used in combination with,0
VICTRELIS,fatigue,dysgeusia when VICTRELIS,0
VICTRELIS,fatigue,fatigue anemia nausea headache and,1
VICTRELIS,anemia,in,0
VICTRELIS,anemia,in combination,0
VICTRELIS,anemia,assessment in adult,0
VICTRELIS,anemia,headache and dysgeusia when VICTRELIS,0
VICTRELIS,anemia,were anemia nausea headache and,1
VICTRELIS,anemia,headache and dysgeusia when VICTRELIS,0
VICTRELIS,anemia,in combination with PegIntron and,0
VICTRELIS,anemia,of investigators causality assessment in adult subjects were fatigue,0
VICTRELIS,nausea,nausea headache and,1
VICTRELIS,nausea,fatigue nausea headache and dysgeusia,1
VICTRELIS,nausea,nausea headache and,1
VICTRELIS,nausea,used in combination with PegIntron and REBETOL,0
VICTRELIS,nausea,subjects regardless,0
VICTRELIS,nausea,was used in combination with PegIntron and,0
VICTRELIS,headache,were fatigue anemia,0
VICTRELIS,headache,regardless of investigators causality assessment in adult subjects were,0
VICTRELIS,headache,subjects were fatigue anemia nausea,0
VICTRELIS,headache,headache and dysgeusia when VICTRELIS,1
VICTRELIS,dysgeusia,fatigue anemia nausea headache dysgeusia when VICTRELIS was used in,1
VICTRELIS,dysgeusia,headache and dysgeusia when VICTRELIS,1
VICTRELIS,dysgeusia,were fatigue anemia,0
VICTRELIS,dysgeusia,dysgeusia when VICTRELIS was,1
VICTRELIS,dysgeusia,were fatigue anemia,0
VICTRELIS,dysgeusia,investigators causality assessment in adult,0
VICTRELIS,dysgeusia,combination,0
VICTRELIS,anemia,anemia and,1
VICTRELIS,anemia,anemia and fatigue were reported as,1
VICTRELIS,anemia,anemia,1
VICTRELIS,anemia,anemia and fatigue,1
VICTRELIS,anemia,with PegIntronREBETOL anemia and fatigue were reported,1
VICTRELIS,anemia,anemia and fatigue,1
VICTRELIS,fatigue,PegIntronREBETOL Only anemia fatigue were,1
VICTRELIS,fatigue,anemia and fatigue,1
VICTRELIS,fatigue,fatigue were reported as events,1
VICTRELIS,fatigue,fatigue were reported as events that,1
VICTRELIS,fatigue,similar to those seen in,0
VICTRELIS,fatigue,fatigue were reported as,1
VICTRELIS,fatigue,to discontinuation in more than,0
VICTRELIS,anemia,anemia which,1
VICTRELIS,anemia,frequently in subjects receiving the,0
VICTRELIS,anemia,anemia which occurred more,1
VICTRELIS,anemia,anemia,1
VICTRELIS,anemia,anemia,1
VICTRELIS,anemia,VICTRELIS with PegIntronR,0
VICTRELIS,anemia,anemia which occurred more frequently,1
VICTRELIS,anemia,anemia which occurred more frequently in,1
VICTRELIS,anemia,anemia which occurred more frequently in,1
VICTRELIS,anemia,occurred more frequently in subjects,0
VICTRELIS,alteration of taste,of taste was,1
VICTRELIS,alteration of taste,and ribavirin Gastrointestinal Disorders alteration of taste was an adverse,1
VICTRELIS,alteration of taste,of taste was,1
VICTRELIS,alteration of taste,and ribavirin Gastrointestinal Disorders alteration of taste was an,1
VICTRELIS,alteration of taste,of taste was,1
VICTRELIS,alteration of taste,Gastrointestinal Disorders alteration of taste was an adverse event,1
VICTRELIS,alteration of taste,of taste was,1
VICTRELIS,alteration of taste,of taste was an,1
VICTRELIS,alteration of taste,and ribavirin Gastrointestinal Disorders Dysgeusia,0
VICTRELIS,alteration of taste,alteration of taste was an adverse,1
VICTRELIS,dry mouth,dry mouth nausea vomiting and diarrhea,1
VICTRELIS,vomiting,increased frequency in subjects receiving VICTRELIS in,0
VICTRELIS,vomiting,were also reported at an increased frequency,0
VICTRELIS,vomiting,vomiting and diarrhea were also reported,1
VICTRELIS,vomiting,and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in,0
VICTRELIS,vomiting,vomiting and diarrhea,1
VICTRELIS,vomiting,such as dry mouth vomiting and diarrhea,1
VICTRELIS,vomiting,vomiting and diarrhea,1
VICTRELIS,vomiting,subjects receiving VICTRELIS,0
VICTRELIS,vomiting,vomiting and,1
VICTRELIS,vomiting,dry mouth vomiting and diarrhea,1
VICTRELIS,vomiting,vomiting and,1
VICTRELIS,vomiting,VICTRELIS in,0
VICTRELIS,platelet counts of less than 50 * 10 9 per L,with PegIntronREBETOL had,0
VICTRELIS,platelet counts of less than 50 * 10 9 per L,9 per L compared to of,1
VICTRELIS,platelet counts of less than 50 * 10 9 per L,counts of less than 50 * 10 9 per L compared to of subjects,1
VICTRELIS,platelet counts of less than 50 * 10 9 per L,to,0
VICTRELIS,platelet counts of less than 50 * 10 9 per L,platelet counts of less than 50 * 10  9  per L compared,1
VICTRELIS,platelet counts of less than 50 * 10 9 per L,to,0
VICTRELIS,platelet counts of less than 50 * 10 9 per L,PegIntronREBETOL platelet counts of less than 50 * 10  9  per L compared to of subjects receiving,1
VICTRELIS,platelet counts of less than 50 * 10 9 per L,to,0
VICTRELIS,agranulocytosis,pancytopenia thrombocytopenia see,0
VICTRELIS,pancytopenia,Blood and Lymphatic System,0
VICTRELIS,pancytopenia,and Precautions Gastrointestinal,0
VICTRELIS,pancytopenia,pancytopenia thrombocytopenia see Warnings and Precautions,1
VICTRELIS,pancytopenia,Lymphatic System Disorders pancytopenia,1
VICTRELIS,pancytopenia,pancytopenia thrombocytopenia see Warnings and Precautions,1
VICTRELIS,pancytopenia,Warnings and Precautions,0
VICTRELIS,pancytopenia,Disorders pancytopenia,1
VICTRELIS,pancytopenia,Warnings and Precautions,0
VICTRELIS,thrombocytopenia,Blood and Lymphatic System,0
VICTRELIS,thrombocytopenia,thrombocytopenia see Warnings and,1
VICTRELIS,thrombocytopenia,System Disorders agranulocytosis thrombocytopenia see Warnings and Precautions,1
VICTRELIS,thrombocytopenia,thrombocytopenia see Warnings and,1
VICTRELIS,thrombocytopenia,and Precautions Gastrointestinal Disorders mouth ulceration,0
VICTRELIS,thrombocytopenia,thrombocytopenia see Warnings and Precautions Gastrointestinal,1
VICTRELIS,thrombocytopenia,thrombocytopenia see Warnings and,1
VICTRELIS,thrombocytopenia,thrombocytopenia see Warnings and Precautions Gastrointestinal,1
VICTRELIS,thrombocytopenia,agranulocytosis thrombocytopenia see Warnings,1
VICTRELIS,thrombocytopenia,thrombocytopenia see Warnings and Precautions Gastrointestinal,1
VICTRELIS,mouth ulceration,Skin and,0
VICTRELIS,mouth ulceration,mouth ulceration stomatitis Infections and,1
VICTRELIS,mouth ulceration,mouth ulceration stomatitis Infections and Infestations pneumonia,1
VICTRELIS,mouth ulceration,Disorders,0
VICTRELIS,mouth ulceration,mouth ulceration stomatitis Infections and,1
VICTRELIS,mouth ulceration,mouth ulceration stomatitis Infections and Infestations,1
VICTRELIS,mouth ulceration,Infestations pneumonia sepsis Skin,0
VICTRELIS,mouth ulceration,Warnings and Precautions Gastrointestinal mouth ulceration stomatitis Infections and,1
VICTRELIS,mouth ulceration,Infestations pneumonia sepsis Skin,0
VICTRELIS,mouth ulceration,Precautions Gastrointestinal mouth ulceration stomatitis Infections and,1
VICTRELIS,mouth ulceration,Infestations pneumonia sepsis Skin,0
VICTRELIS,mouth ulceration,Gastrointestinal,0
VICTRELIS,stomatitis,stomatitis,1
VICTRELIS,stomatitis,stomatitis Infections and Infestations pneumonia,1
VICTRELIS,stomatitis,and Subcutaneous,0
VICTRELIS,pneumonia,pneumonia sepsis Skin and Subcutaneous Tissue,1
VICTRELIS,pneumonia,pneumonia sepsis Skin and,1
VICTRELIS,pneumonia,pneumonia,1
VICTRELIS,pneumonia,pneumonia sepsis Skin and Subcutaneous,1
VICTRELIS,pneumonia,pneumonia,1
VICTRELIS,pneumonia,see Warnings and,0
VICTRELIS,pneumonia,Infections and pneumonia sepsis Skin and Subcutaneous,1
VICTRELIS,pneumonia,see Warnings and,0
VICTRELIS,pneumonia,ulceration stomatitis Infections,0
VICTRELIS,pneumonia,Infections and,0
VICTRELIS,sepsis,sepsis Skin and Subcutaneous,1
VICTRELIS,sepsis,Infections and,0
VICTRELIS,sepsis,sepsis Skin and,1
VICTRELIS,sepsis,Infestations sepsis Skin and Subcutaneous Tissue,1
VICTRELIS,sepsis,sepsis Skin and,1
VICTRELIS,sepsis,stomatitis Infections and Infestations sepsis Skin,1
VICTRELIS,sepsis,sepsis Skin and,1
VICTRELIS,sepsis,stomatitis,0
VICTRELIS,sepsis,mouth ulceration,0
VICTRELIS,sepsis,sepsis Skin and Subcutaneous,1
VICTRELIS,sepsis,mouth ulceration,0
VICTRELIS,angioedema,pneumonia sepsis Skin and Subcutaneous Tissue,0
VICTRELIS,urticaria,urticaria see Warnings and Precautions drug,1
VICTRELIS,urticaria,ons and,0
VICTRELIS,urticaria,Infestations pneumonia,0
VICTRELIS,urticaria,urticaria see Warnings and Precautions drug,1
VICTRELIS,urticaria,urticaria see,1
VICTRELIS,exfoliative rash,symptoms DRESS exfoliative rash,1
VICTRELIS,exfoliative rash,systemic symptoms DRESS syndrome,0
VICTRELIS,exfoliative rash,symptoms DRESS exfoliative rash exfoliative dermatitis StevensJohnson syndrome,1
VICTRELIS,exfoliative rash,systemic symptoms DRESS syndrome,0
VICTRELIS,exfoliative rash,exfoliative rash exfoliative dermatitis,1
VICTRELIS,exfoliative rash,syndrome,0
VICTRELIS,exfoliative rash,DRESS,0
VICTRELIS,exfoliative rash,dermatitis StevensJohnson syndrome toxic skin eruption,0
VICTRELIS,exfoliative rash,DRESS,0
VICTRELIS,exfoliative rash,eosinophilia,0
VICTRELIS,exfoliative rash,exfoliative rash exfoliative dermatitis StevensJohnson syndrome,1
VICTRELIS,exfoliative dermatitis,syndrome exfoliative exfoliative dermatitis StevensJohnson syndrome toxic skin eruption,1
VICTRELIS,exfoliative dermatitis,exfoliative rash exfoliative dermatitis StevensJohnson syndrome,1
VICTRELIS,exfoliative dermatitis,drug rash with eosinophilia and,0
VICTRELIS,exfoliative dermatitis,syndrome exfoliative exfoliative dermatitis StevensJohnson syndrome toxic,1
VICTRELIS,exfoliative dermatitis,drug rash with eosinophilia and,0
VICTRELIS,exfoliative dermatitis,StevensJohnson,0
VICTRELIS,exfoliative dermatitis,syndrome exfoliative exfoliative,1
VICTRELIS,exfoliative dermatitis,syndrome exfoliative exfoliative dermatitis StevensJohnson syndrome toxic,1
VICTRELIS,exfoliative dermatitis,syndrome exfoliative exfoliative,1
VICTRELIS,exfoliative dermatitis,exfoliative exfoliative dermatitis,1
VICTRELIS,exfoliative dermatitis,syndrome exfoliative exfoliative,1
VICTRELIS,exfoliative dermatitis,exfoliative dermatitis StevensJohnson,1
VICTRELIS,exfoliative dermatitis,and systemic,0
VICTRELIS,Stevens-Johnson syndrome,Stevens-Johnson syndrome toxic skin eruption,1
VICTRELIS,Stevens-Johnson syndrome,exfoliative Stevens-Johnson syndrome toxic skin eruption,1
VICTRELIS,Stevens-Johnson syndrome,Stevens-Johnson syndrome toxic skin eruption,1
VICTRELIS,Stevens-Johnson syndrome,toxic skin eruption toxicoderma,0
VICTRELIS,Stevens-Johnson syndrome,Stevens-Johnson syndrome toxic skin,1
VICTRELIS,Stevens-Johnson syndrome,rash exfoliative Stevens-Johnson syndrome,1
VICTRELIS,Embryofetal Toxicity,peginterferon alfa and ribavirin prescribing information for,0
VICTRELIS,fetal death,(greater th an of subjects in,1
VICTRELIS,fetal death,peginterferon alfa and ribavirin prescribing information for,0
VICTRELIS,fetal death,reactions,0
VICTRELIS,fetal death,adverse (greater th,1
VICTRELIS,fetal death,reactions,0
VICTRELIS,fetal death,(greater th an of,1
VICTRELIS,Anemia,"ONS, c ontact Merck",1
VICTRELIS,decrease in hemoglobin concentrations,or www.fda.gov/med watch Clinical Trials Experience,1
VICTRELIS,decrease in hemoglobin concentrations,Sharp Dohme Corp a subsidiary of Merck Co Inc at,0
VICTRELIS,decrease in hemoglobin concentrations,Inc at or FDA -800-FDA-1088 or      www.fda.gov/med watch Clinical Trials Experience,1
VICTRELIS,decrease in hemoglobin concentrations,Sharp Dohme Corp a subsidiary of Merck Co Inc at,0
VICTRELIS,decrease in hemoglobin concentrations,FDA -800-FDA-1088,1
VICTRELIS,decrease in hemoglobin concentrations,-800-FDA-1088 or www.fda.gov/med,1
VICTRELIS,decrease in hemoglobin concentrations,at or FDA -800-FDA-1088 or      www.fda.gov/med watch Clinical,1
VICTRELIS,decrease in hemoglobin concentrations,-800-FDA-1088 or www.fda.gov/med,1
VICTRELIS,decrease in hemoglobin concentrations,Merck Sharp Dohme Corp a subsidiary of Merck,0
VICTRELIS,decrease in hemoglobin concentrations,at or FDA -800-FDA-1088 or      www.fda.gov/med watch,1
VICTRELIS,decrease in hemoglobin concentrations,Merck Sharp Dohme Corp a subsidiary of Merck,0
VICTRELIS,decrease in hemoglobin concentrations,Because clinical trials are,0
VICTRELIS,Neutropenia,Because trials are,1
VICTRELIS,worsening of neutropenia,in c,0
VICTRELIS,worsening of neutropenia,rates in the clinical trials of another drug and,0
VICTRELIS,worsening of neutropenia,observed,0
VICTRELIS,worsening of neutropenia,are conducted under widely varying,0
VICTRELIS,worsening of neutropenia,are conducted under widely,0
VICTRELIS,acute hypersensitivity reactions,to rates in the clinical trials of another drug and may not,0
VICTRELIS,acute hypersensitivity reactions,of another drug and may not reflect the rat,0
VICTRELIS,urticaria,practice The ng seriou,1
VICTRELIS,urticaria,of another drug and may not reflect the rat,0
VICTRELIS,urticaria,practice The ng seriou s and otherwise important adverse,1
VICTRELIS,urticaria,of another drug and may not reflect the rat,0
VICTRELIS,urticaria,ng seriou s,1
VICTRELIS,urticaria,in practice The ng seriou,1
VICTRELIS,urticaria,ng seriou s,1
VICTRELIS,urticaria,The followi,0
VICTRELIS,urticaria,trials of another drug and may,0
VICTRELIS,urticaria,observed in practice The ng seriou,1
VICTRELIS,urticaria,in practice The ng seriou,1
VICTRELIS,urticaria,in another section,0
VICTRELIS,urticaria,drug and may not reflect the rates observed in practice The,0
VICTRELIS,angioedema,in practice The following and otherw ise important,1
VICTRELIS,angioedema,drug and may not reflect the rates observed in practice The,0
VICTRELIS,angioedema,reactions ADRs are,0
VICTRELIS,angioedema,not reflect the rates observed in practice The following serious,0
VICTRELIS,birth defects,"Warnings and ]  
 *  Pancy",1
VICTRELIS,birth defects,not reflect the rates observed in practice The following serious,0
VICTRELIS,birth defects,"and ]  
 *  Pancy topenia",1
VICTRELIS,birth defects,not reflect the rates observed in practice The following serious,0
VICTRELIS,birth defects,Precautions Hypersensitivity see Contraindications,0
VICTRELIS,birth defects,* Pancy topenia see,1
VICTRELIS,birth defects,Neutropenia see Warnings and,0
VICTRELIS,birth defects,see Warnings and ] *,1
VICTRELIS,birth defects,Precautions Hypersensitivity,0
VICTRELIS,birth defects,see Warnings and,0
VICTRELIS,birth defects,and ] * Pancy,1
VICTRELIS,death of the exposed fetus,[see Warnings and,1
VICTRELIS,death of the exposed fetus,and Precautions [see Warnings and,1
VICTRELIS,death of the exposed fetus,Precautions [see,1
VICTRELIS,death of the exposed fetus,see Warnings and Precautions [see Warnings and Precaut,1
VICTRELIS,death of the exposed fetus,Hypersensitivity see Contraindications,0
VICTRELIS,death of the exposed fetus,see,0
VICTRELIS,Anemia,combination with PegIntronREBETOL with a fourweek leadi,0
VICTRELIS,Anemia,mg three times daily in combination with PegIntronREBETOL with a,0
VICTRELIS,Anemia,he,1
VICTRELIS,additional decrease in hemoglobin concentrations,PegIntronREBETOL compared to PegInt,0
VICTRELIS,hemoglobin values less than 10 g per dL,"more than of jects in any arm.



 Adverse reactions that led",1
VICTRELIS,hemoglobin values less than 10 g per dL,PegIntronREBETOL compared to PegInt,0
VICTRELIS,hemoglobin values less than 10 g per dL,of jects in,1
VICTRELIS,hemoglobin less than 10 g per dL,than in bjects receiving PegIntron/REBET OL,1
VICTRELIS,hemoglobin less than 10 g per dL,of jects in,1
VICTRELIS,hemoglobin less than 10 g per dL,bjects receiving PegIntron/REBET OL alone,1
VICTRELIS,hemoglobin less than 10 g per dL,receiving the combination of,0
VICTRELIS,hemoglobin less than 10 g per dL,bjects receiving PegIntron/REBET,1
VICTRELIS,hemoglobin less than 10 g per dL,bjects receiving PegIntron/REBET OL alone Serious adverse events,1
VICTRELIS,hemoglobin less than 10 g per dL,bjects receiving PegIntron/REBET,1
VICTRELIS,hemoglobin less than 10 g per dL,reported in of,0
VICTRELIS,hemoglobin less than 10 g per dL,were,0
VICTRELIS,hemoglobin less than 10 g per dL,in bjects receiving,1
VICTRELIS,hemoglobin less than 10 g per dL,receiving the combination of VICTRELIS with PegIntronREBETOL than in su,0
VICTRELIS,hemoglobin less than 10 g per dL,than in bjects receiving PegIntron/REBET OL alone Serious,1
VICTRELIS,hemoglobin less than 10 g per dL,receiving the combination of VICTRELIS with PegIntronREBETOL than in su,0
VICTRELIS,anemia,of cts re,1
VICTRELIS,anemia,of investigators causality assessment reported in greater than,0
VICTRELIS,anemia,assessment reported in greater than or equal,0
VICTRELIS,anemia,assessment reported in greater than or equal to,0
VICTRELIS,dyspnea,to of subjects receiving e,1
VICTRELIS,dyspnea,e combi nation of VICTRELIS with PegIntronREBETOL,1
VICTRELIS,dyspnea,e,1
VICTRELIS,dyspnea,receiving e combi nation of,1
VICTRELIS,dyspnea,e,1
VICTRELIS,dyspnea,with PegIntronREBETOL and reported at a rate of greater than or,0
VICTRELIS,dyspnea,and reported at a rate of greater than or,0
VICTRELIS,exertional dyspnea,tion,1
VICTRELIS,exertional dyspnea,rate of greater than or equal to than PegIntronREBETOL,0
VICTRELIS,exertional dyspnea,of VICTRELIS with,1
VICTRELIS,dizziness,of VICTRELIS th,1
VICTRELIS,dizziness,th PegInt ronREBETOL,1
VICTRELIS,dizziness,of VICTRELIS th PegInt,1
VICTRELIS,dizziness,th PegInt ronREBETOL,1
VICTRELIS,dizziness,of VICTRELIS th PegInt ronREBETOL,1
VICTRELIS,dizziness,th PegInt ronREBETOL,1
VICTRELIS,dizziness,th PegInt ronREBETOL and,1
VICTRELIS,dizziness,th PegInt ronREBETOL and,1
VICTRELIS,syncope,EBETOL ,1
VICTRELIS,syncope,combination of VICTRELIS with EBETOL  and reported,1
VICTRELIS,syncope,EBETOL ,1
VICTRELIS,syncope,EBETOL ,1
VICTRELIS,syncope,EBETOL ,1
VICTRELIS,syncope,than or equal to of subjects receiving the combination of VICTRELIS,0
VICTRELIS,syncope,EBETOL  and reported at,1
VICTRELIS,syncope,EBETOL ,1
VICTRELIS,syncope,EBETOL  and reported at a,1
VICTRELIS,syncope,EBETOL ,1
VICTRELIS,anemia, >=5%  than,1
VICTRELIS,anemia,Combination of,0
VICTRELIS,anemia,UntreatedSPRINT and SPRINT,0
VICTRELIS,anemia,Events Previously,0
VICTRELIS,anemia,Events Previously,0
VICTRELIS,anemia,PegIntronREBETOL alone Adverse Events Previously UntreatedSPRINT,0
VICTRELIS,anemia,with PegIntronREBETOL,0
VICTRELIS,anemia, >=5%  than PegIntronREBETOL,1
VICTRELIS,anemia,Rate  >=5%  than PegIntronREBETOL,1
VICTRELIS,anemia, >=5%  than PegIntronREBETOL,1
VICTRELIS,anemia,Subjects Reporting Adv,0
VICTRELIS,anemia,of Subjects Reporting erse E vents Percentage,1
VICTRELIS,anemia,Subjects Reporting Adv,0
VICTRELIS,anemia,of Subjects Reporting erse E vents Percentage of,1
VICTRELIS,anemia,Subjects Reporting Adv,0
VICTRELIS,anemia,erse,1
VICTRELIS,anemia,Adv,0
VICTRELIS,anemia,Adv,0
VICTRELIS,anemia,Reporting erse E,1
VICTRELIS,anemia,erse E vents Percentage of Subjects,1
VICTRELIS,pancytopenia,3 ). Adverse,1
VICTRELIS,pancytopenia,and ribavirin,0
VICTRELIS,pancytopenia,Table 3 ). Adverse events such as,1
VICTRELIS,acute hypersensitivity reactions,and Clinical Studies (14),1
VICTRELIS,urticaria, prescrib ing information,1
VICTRELIS,urticaria,for ribavirin If,0
VICTRELIS,urticaria,Precautions and Clinical Studies  prescrib ing information,1
VICTRELIS,urticaria,for ribavirin If,0
VICTRELIS,urticaria, prescrib ing information,1
VICTRELIS,urticaria,ribavirin is permanently,0
VICTRELIS,urticaria,and Clinical Studies  prescrib ing information for,1
VICTRELIS,urticaria,ribavirin is permanently,0
VICTRELIS,urticaria,permanently discontinued then peginterferon,0
VICTRELIS,urticaria,and Precautions and Clinical,0
VICTRELIS,urticaria,and Clinical Studies  prescrib ing information for ribavirin,1
VICTRELIS,urticaria,and Precautions and Clinical,0
VICTRELIS,urticaria,Clinical Studies  prescrib ing,1
VICTRELIS,urticaria,and Precautions and Clinical,0
VICTRELIS,angioedema,alfa,0
VICTRELIS,angioedema,and Clinical Studies see g informat ion for,1
VICTRELIS,angioedema,alfa,0
VICTRELIS,angioedema,g informat ion for ribavirin If ribavirin,1
VICTRELIS,angioedema,see g informat ion for ribavirin If,1
VICTRELIS,angioedema,g informat ion for ribavirin If ribavirin,1
VICTRELIS,angioedema,and Clinical Studies see g,1
VICTRELIS,angioedema,see prescribin,0
VIMIZIM,Anaphylaxis,Anaphylaxis and hypersensitivity,1
VIMIZIM,Anaphylaxis,see prescribin,0
VIMIZIM,Anaphylaxis,the Anaphylaxis and hypersensitivity,1
VIMIZIM,Anaphylaxis,see prescribin,0
VIMIZIM,hypersensitivity reactions,common adverse,0
VIMIZIM,pyrexia,a higher incidence than placebotreated patients,0
VIMIZIM,pyrexia,incidence than placebotreated patients pyrexia vomiting headache nausea,1
VIMIZIM,pyrexia,a higher incidence than placebotreated patients,0
VIMIZIM,pyrexia,pyrexia vomiting headache nausea abdominal,1
VIMIZIM,pyrexia,pyrexia,1
VIMIZIM,vomiting,nausea abdominal pain chills and fatigue To report,0
VIMIZIM,vomiting,occurring at a higher incidence than placebotreated,0
VIMIZIM,headache,placebotreated patients were,0
VIMIZIM,headache,and fatigue To report SUSPECTED,0
VIMIZIM,headache,patients were pyrexia headache nausea abdominal pain chills and,1
VIMIZIM,headache,and fatigue To report SUSPECTED,0
VIMIZIM,headache,abdominal pain chills and fatigue,0
VIMIZIM,headache,and fatigue To report SUSPECTED,0
VIMIZIM,headache,incidence than placebotreated,0
VIMIZIM,headache,were pyrexia headache nausea,1
VIMIZIM,headache,incidence than placebotreated,0
VIMIZIM,headache,headache nausea abdominal pain chills,1
VIMIZIM,nausea,a higher incidence than placebotreated patients were pyrexia,0
VIMIZIM,nausea,nausea,1
VIMIZIM,chills,vomiting headache nausea abdominal pain,0
VIMIZIM,chills,chills and,1
VIMIZIM,chills,chills and,1
VIMIZIM,chills,headache nausea abdominal chills and fatigue To report,1
VIMIZIM,chills,chills and,1
VIMIZIM,chills,chills,1
VIMIZIM,chills,chills and fatigue,1
VIMIZIM,chills,chills,1
VIMIZIM,chills,chills,1
VIMIZIM,fatigue,han,0
VIMIZIM,Fatigue,pain,0
VIMIZIM,Fatigue,Fatigue,1
VIMIZIM,Fatigue,Fatigue Extension Trial An,1
VIMIZIM,Fatigue,An,0
VIMIZIM,Fatigue,Fatigue Extension Trial An openlabel,1
VIMIZIM,Fatigue,Fatigue,1
VIMIZIM,Fatigue,Extension,0
VIMIZIM,Fatigue,An openlabel,0
VIMIZIM,Fatigue,Trial An openlabel extensio,0
VIMIZIM,ANAPHYLAXIS,are conducted under widely varying conditions adverse reaction rates,0
VIMIZIM,ANAPHYLAXIS,ADVERSE REACTIONS Because nical trial,1
VIMIZIM,ANAPHYLAXIS,nical trial s are conducted under widely,1
VIMIZIM,ANAPHYLAXIS,trials are conducted under idely varyi,1
VIMIZIM,ANAPHYLAXIS,under idely varyi ng conditions adverse,1
VIMIZIM,ANAPHYLAXIS,trials are conducted under idely varyi,1
VIMIZIM,ANAPHYLAXIS,trials are conducted under,0
VIMIZIM,ANAPHYLAXIS,conducted under idely varyi ng conditions adverse reaction rates,1
VIMIZIM,ANAPHYLAXIS,trials are conducted under,0
VIMIZIM,anaphylactic reactions,varying conditions adverse action rates observed ,1
VIMIZIM,anaphylactic reactions,trials are conducted under,0
VIMIZIM,anaphylactic reactions,conditions adverse action rates,1
VIMIZIM,anaphylactic reactions,conditions adverse action rates observed  in the clinical,1
VIMIZIM,anaphylactic reactions,conditions adverse action rates,1
VIMIZIM,anaphylactic reactions,of a drug cannot be directly compared,0
VIMIZIM,anaphylactic reactions,in the,0
VIMIZIM,anaphylactic reactions,clinical trials,0
VIMIZIM,anaphylactic reactions,varying conditions adverse action rates observed  in the,1
VIMIZIM,anaphylactic reactions,clinical trials,0
VIMIZIM,anaphylactic reactions,adverse action,1
VIMIZIM,anaphylactic reactions,a drug cannot be directly compared to rates in the clinical trials,0
VIMIZIM,anaphylactic reactions,adverse action rates observed  in the,1
VIMIZIM,anaphylactic reactions,a drug cannot be directly compared to rates in the clinical trials,0
VIMIZIM,Anaphylaxis,a drug cannot,0
VIMIZIM,Anaphylaxis,cannot be directly ed to rates,1
VIMIZIM,Anaphylaxis,cannot be directly ed,1
VIMIZIM,Anaphylaxis,drug cannot be directly ed to rates,1
VIMIZIM,Anaphylaxis,cannot be directly ed,1
VIMIZIM,Anaphylaxis,to rates,1
VIMIZIM,Anaphylaxis,cannot be directly ed,1
VIMIZIM,Anaphylaxis,drug cannot be directly ed to rates in,1
VIMIZIM,Anaphylaxis,cannot be directly ed,1
VIMIZIM,Anaphylaxis,another drug and may not reflect the rates observed in practice The,0
VIMIZIM,Anaphylaxis,the rates observed in,0
VIMIZIM,cough,cannot,0
VIMIZIM,erythema,observed in practice The following serious adverse,0
VIMIZIM,erythema,be,0
VIMIZIM,erythema,of,1
VIMIZIM,erythema,compared to rates,0
VIMIZIM,erythema,of anot her drug and may,1
VIMIZIM,erythema,clinical  of anot her,1
VIMIZIM,erythema,of anot her drug and may,1
VIMIZIM,erythema,in the clinical  of anot her drug and may,1
VIMIZIM,erythema,of anot her drug and may,1
VIMIZIM,erythema,in the clinical  of anot her drug and may not,1
VIMIZIM,erythema,of anot her drug and may,1
VIMIZIM,erythema,of anot,1
VIMIZIM,erythema,cannot be directly compared to,0
VIMIZIM,throat tightness,clinical trials of r drug and may,1
VIMIZIM,throat tightness,r,1
VIMIZIM,urticaria,a drug cannot be directly compared to rates in,0
VIMIZIM,urticaria, reflect  the rates observed,1
VIMIZIM,urticaria, reflect  the,1
VIMIZIM,urticaria,drug and may  reflect  the,1
VIMIZIM,urticaria, reflect  the,1
VIMIZIM,urticaria,to rates,0
VIMIZIM,urticaria, reflect  the,1
VIMIZIM,urticaria,following serious adverse reactions are described below,0
VIMIZIM,flushing,reflect e,1
VIMIZIM,flushing,and may not reflect e rates  observed,1
VIMIZIM,flushing,reflect e,1
VIMIZIM,flushing,observed in practice The following serious adverse reactions are described below and,0
VIMIZIM,flushing,serious adverse,0
VIMIZIM,flushing,e rates,1
VIMIZIM,flushing,The following serious adverse reactions,0
VIMIZIM,flushing,rates in the clinical trials of another drug and,0
VIMIZIM,cyanosis,in the lab,0
VIMIZIM,hypotension,following serious adverse reactions,0
VIMIZIM,rash,and elsewhere in the labeling,0
VIMIZIM,rash,the rates observed in  The following serious adverse,1
VIMIZIM,rash,and elsewhere in the labeling,0
VIMIZIM,rash,the rates observed in  The following serious adverse,1
VIMIZIM,rash,and elsewhere in the labeling,0
VIMIZIM,rash,adverse reactions are described below,0
VIMIZIM,rash,elsewhere in,0
VIMIZIM,rash, The following serious adverse,1
VIMIZIM,rash,clinical trials of another drug and may not reflect,0
VIMIZIM,rash,clinical trials of another drug,0
VIMIZIM,rash, The following serious adverse reactions are,1
VIMIZIM,rash,serious adverse reactions are described,0
VIMIZIM,dyspnea,observed in practice The ollowin g serious adverse reactions are,1
VIMIZIM,dyspnea,serious adverse reactions are described,0
VIMIZIM,dyspnea,observed in practice,0
VIMIZIM,dyspnea,the labeling,0
VIMIZIM,dyspnea,another drug and may not reflect the rates observed in practice,0
VIMIZIM,dyspnea,elsewhere,0
VIMIZIM,dyspnea,ollowin g serious adverse reactions,1
VIMIZIM,dyspnea,ollowin,1
VIMIZIM,chest discomfort,following,0
VIMIZIM,chest discomfort,and may not reflect the rates,0
VIMIZIM,gastrointestinal symptoms,are described below a nd elsewhere in the,1
VIMIZIM,gastrointestinal symptoms,following serious adverse ons are,1
VIMIZIM,gastrointestinal symptoms,adverse ons are,1
VIMIZIM,gastrointestinal symptoms,ons are,1
VIMIZIM,gastrointestinal symptoms,below a nd,1
VIMIZIM,gastrointestinal symptoms,described below a nd,1
VIMIZIM,gastrointestinal symptoms,the rates observed in practice The following serious,0
VIMIZIM,gastrointestinal symptoms,adverse ons are described below a nd elsewhere,1
VIMIZIM,gastrointestinal symptoms,the rates observed in practice The following serious,0
VIMIZIM,gastrointestinal symptoms,observed in practice The following,0
VIMIZIM,nausea,below and here,1
VIMIZIM,nausea,Anaphylaxis and hypersensitivity reactions,0
VIMIZIM,nausea,described,0
VIMIZIM,nausea,Anaphylaxis and hypersensitivity reactions see Warnings,0
VIMIZIM,nausea,here i,1
VIMIZIM,nausea,here i n,1
VIMIZIM,nausea,here i,1
VIMIZIM,abdominal pain,"elsewhere the labeling:
 Anaphylaxis and hypersensitivity",1
VIMIZIM,abdominal pain,here i,1
VIMIZIM,abdominal pain,below and elsewhere the labeling:,1
VIMIZIM,abdominal pain,erved in practice The following serious adverse reactions are described,0
VIMIZIM,abdominal pain,the labeling: Anaphylaxis and hypersensitivity,1
VIMIZIM,abdominal pain,"below and elsewhere the labeling:
 Anaphylaxis and hypersensitivity reactions see",1
VIMIZIM,abdominal pain,the labeling: Anaphylaxis and hypersensitivity,1
VIMIZIM,abdominal pain,the labeling:,1
VIMIZIM,abdominal pain,below,0
VIMIZIM,retching,. Anap hylaxis and hypersensitivity reactions,1
VIMIZIM,retching,"elsewhere in the 
 . Anap hylaxis and hypersensitivity",1
VIMIZIM,retching,. Anap hylaxis and hypersensitivity reactions,1
VIMIZIM,retching,. Anap hylaxis and,1
VIMIZIM,retching,and Precautions The most,0
VIMIZIM,retching,elsewhere in the .,1
VIMIZIM,retching,and hypersensitivity reactions see,0
VIMIZIM,vomiting,labeling s and hy,1
VIMIZIM,vomiting,and hypersensitivity reactions see,0
VIMIZIM,vomiting,s and hy persensitivity reactions see,1
VIMIZIM,vomiting,persensitivity reactions see Warnings and Precautions The most,0
VIMIZIM,urticaria,ns [ see Warnings and,1
VIMIZIM,urticaria,ns are described below and elsewhere in the,0
VIMIZIM,urticaria,and Precautions The most common adverse reactions observed ac,0
VIMIZIM,urticaria,and,0
VIMIZIM,urticaria,ns [ see Warnings and Precautions The,1
VIMIZIM,urticaria,described below and elsewhere in the labeling,0
VIMIZIM,ANAPHYLAXIS,d fatigue ( To report SUSPECTED ADVERSE,1
VIMIZIM,ANAPHYLAXIS,described below and elsewhere in the labeling,0
VIMIZIM,ANAPHYLAXIS,pain chills d fatigue ( To,1
VIMIZIM,ANAPHYLAXIS,described below and elsewhere in the labeling,0
VIMIZIM,ANAPHYLAXIS,contact BioMarin at or FDA at,0
VIMIZIM,ANAPHYLAXIS,ADVERSE,0
VIMIZIM,ANAPHYLAXIS,vomiting headache,0
VIMIZIM,ANAPHYLAXIS,nausea abdominal pain chills d fatigue ( To report,1
VIMIZIM,ANAPHYLAXIS,vomiting headache,0
VIMIZIM,anaphylactic reactions,or www fdagovmedwatch,1
VIMIZIM,anaphylactic reactions,BioMarin at or FDA  1-800-FDA-1088 or www fdagovmedwatch,1
VIMIZIM,anaphylactic reactions,or www fdagovmedwatch,1
VIMIZIM,Anaphylaxis,trial of Vimizim was,0
VIMIZIM,Anaphylaxis,"Clinical Trials e

  A 24-w eek randomized doubleblind placebocontrolled",1
VIMIZIM,Anaphylaxis,trial of Vimizim was,0
VIMIZIM,Anaphylaxis,"wwwfdagovmedwatch Clinical Trials e

  A 24-w eek randomized",1
VIMIZIM,Anaphylaxis,trial of Vimizim was,0
VIMIZIM,Anaphylaxis,"Clinical Trials e

  A 24-w eek randomized doubleblind placebocontrolled clinical",1
VIMIZIM,Anaphylaxis,trial of Vimizim was,0
VIMIZIM,Anaphylaxis,e,1
VIMIZIM,Anaphylaxis,"wwwfdagovmedwatch Clinical Trials e

  A 24-w eek randomized doubleblind placebocontrolled",1
VIMIZIM,Anaphylaxis,e,1
VIMIZIM,Anaphylaxis,wwwfdagovmedwatch Clinical,0
VIMIZIM,Anaphylaxis,wwwfdagovmedwatch Clinical,0
VIMIZIM,Anaphylaxis,A 24-w eek randomized,1
VIMIZIM,Anaphylaxis,e A 24-w eek,1
VIMIZIM,cough,MPS IVA,0
VIMIZIM,cough, doub leblind placebocontrolled clinical,1
VIMIZIM,cough,with MPS IVA,0
VIMIZIM,cough, doub,1
VIMIZIM,cough, doub,1
VIMIZIM,cough,Vimizim was,0
VIMIZIM,cough, doub leblind placebocontrolled,1
VIMIZIM,cough,Vimizim was,0
VIMIZIM,cough,Trials Experience A week  doub leblind placebocontrolled clinical trial of,1
VIMIZIM,cough,Vimizim was,0
VIMIZIM,cough,MPS IVA a,0
VIMIZIM,erythema,"-blind, ",1
VIMIZIM,erythema,of Vimizim was conducted in patients with MPS IVA ages,0
VIMIZIM,erythema,"-blind,  placebocontrolled clinical trial of Vimizim",1
VIMIZIM,erythema,"-blind,  placebocontrolled clinical trial of Vimizim",1
VIMIZIM,erythema,randomized,0
VIMIZIM,erythema,"-blind,  placebocontrolled",1
VIMIZIM,erythema,"A week randomized -blind,  placebocontrolled clinical trial of",1
VIMIZIM,erythema,"-blind,  placebocontrolled",1
VIMIZIM,erythema,Trials Experience A week,0
VIMIZIM,throat tightness,A week randomized doubleblind acebo-controlled clinical trial of,1
VIMIZIM,throat tightness,Trials Experience A week,0
VIMIZIM,throat tightness,A week randomized doubleblind,0
VIMIZIM,throat tightness,A week randomized doubleblind pl,0
VIMIZIM,throat tightness,week randomized doubleblind acebo-controlled clinical trial of Vimizim,1
VIMIZIM,throat tightness,A week randomized doubleblind pl,0
VIMIZIM,throat tightness,acebo-controlled,1
VIMIZIM,throat tightness,Experience A,0
VIMIZIM,throat tightness,Experience A week randomized doubleblind pl,0
VIMIZIM,throat tightness,week randomized doubleblind acebo-controlled clinical trial of Vimizim,1
VIMIZIM,throat tightness,Experience A week randomized doubleblind pl,0
VIMIZIM,urticaria,years old Approximately h,0
VIMIZIM,urticaria,c,0
VIMIZIM,urticaria,randomized doubleblind placebocontrolled linical t rial of Vimizim was,1
VIMIZIM,urticaria,c,0
VIMIZIM,flushing,al of Vi mizim was conducted in patients,1
VIMIZIM,flushing,c,0
VIMIZIM,flushing,MPS,0
VIMIZIM,flushing,randomized doubleblind placebocontrolled clinical al,1
VIMIZIM,flushing,doubleblind,0
VIMIZIM,flushing,tri,0
VIMIZIM,flushing,randomized doubleblind placebocontrolled clinical al of Vi mizim,1
VIMIZIM,flushing,tri,0
VIMIZIM,hypotension,nducted in  patients with MPS IVA,1
VIMIZIM,hypotension,tri,0
VIMIZIM,hypotension,half of the patients,0
VIMIZIM,hypotension,of Vimizim,0
VIMIZIM,hypotension,trial of Vimizim was nducted in  patients with MPS,1
VIMIZIM,hypotension,of Vimizim,0
VIMIZIM,hypotension,nducted in,1
VIMIZIM,rash,Vimizim was conducted 6 pa tients with MPS IVA,1
VIMIZIM,rash,nducted in,1
VIMIZIM,dyspnea,was conducted in ents,1
VIMIZIM,dyspnea,ents wi th MPS IVA ages,1
VIMIZIM,dyspnea,Vimizim was conducted in ents wi th MPS IVA,1
VIMIZIM,dyspnea,ents wi th MPS IVA ages,1
VIMIZIM,dyspnea,ents wi th MPS,1
VIMIZIM,chest discomfort,"IVA, ages 5 to years old",1
VIMIZIM,chest discomfort,male Of the patients wer,0
VIMIZIM,chest discomfort,doubleblind,0
VIMIZIM,chest discomfort,"in patients MPS IVA, ages",1
VIMIZIM,gastrointestinal symptoms,MPS IVA ages years,1
VIMIZIM,gastrointestinal symptoms,ages to,0
VIMIZIM,gastrointestinal symptoms,years old. Approximatel y half of,1
VIMIZIM,gastrointestinal symptoms,Asian,0
VIMIZIM,gastrointestinal symptoms,patients were White Asian Black,0
VIMIZIM,gastrointestinal symptoms,years old. Approximatel,1
VIMIZIM,gastrointestinal symptoms,of the patients were,0
VIMIZIM,urticaria,of the s (49%) w,1
VIMIZIM,urticaria,male Of the patients were White Asian Black and Other,0
VIMIZIM,urticaria,were White Asian Black and,0
VIMIZIM,urticaria,Black and Other race The majori,0
VIMIZIM,urticaria,the s (49%) w ere male Of the,1
VIMIZIM,urticaria,Black and Other race The majori,0
VIMIZIM,urticaria,of the s,1
VIMIZIM,urticaria,half of the s (49%) w ere male,1
VIMIZIM,urticaria,of the s,1
VIMIZIM,urticaria,with MPS IVA ages to years old Approximately,0
VIMIZIM,urticaria,(49%) w ere,1
VIMIZIM,urticaria,(49%) w ere male,1
VIMIZIM,Hypersensitivity Reactions,the clinical trials,0
VIMIZIM,Hypersensitivity Reactions,clinical trials are under widely varying,1
VIMIZIM,Hypersensitivity Reactions,observed in the clinical trials of a drug cannot be directly compared,0
VIMIZIM,Hypersensitivity Reactions,clinical trials are conducted,0
VIMIZIM,Hypersensitivity Reactions,under widely varying condi tions,1
VIMIZIM,anaphylaxis,the,0
VIMIZIM,anaphylaxis,conditions adverse tion rates  observed in the,1
VIMIZIM,anaphylaxis,the,0
VIMIZIM,anaphylaxis,tion rates observed in the clinical trials,1
VIMIZIM,anaphylaxis,tion rates observed,1
VIMIZIM,anaphylaxis,compared to rates in the,0
VIMIZIM,anaphylaxis,are,0
VIMIZIM,anaphylaxis,a,0
VIMIZIM,anaphylaxis,widely varying conditions adverse tion rates,1
VIMIZIM,anaphylaxis,conditions adverse tion,1
VIMIZIM,Acute Respiratory Complications,observed across premarketing clinical trials were,0
VIMIZIM,Acute Respiratory Complications,common adverse reactio ns,1
VIMIZIM,Acute Respiratory Complications,clinical trials were similar in type and frequency as,0
VIMIZIM,Acute Respiratory Complications,and Precautions,0
VIMIZIM,Acute Respiratory Complications,and The most common adverse reactio ns observed across premarketing clinical,1
VIMIZIM,Acute Respiratory Complications,and Precautions,0
VIMIZIM,Acute Respiratory Complications,see Warnings and The most common adverse reactio ns observed across,1
VIMIZIM,Acute Respiratory Complications,and Precautions,0
VIMIZIM,Acute Respiratory Complications,reactions see Warnings and The most,1
VIMIZIM,Acute Respiratory Complications,reactions see Warnings and The,1
VIMIZIM,hypersensitivity reactions,he placebo-controlled tria l,1
VIMIZIM,hypersensitivity reactions,t,0
VIMIZIM,hypersensitivity reactions,he placebo-controlled,1
VIMIZIM,hypersensitivity reactions,he,1
VIMIZIM,hypersensitivity reactions,as those observed in he placebo-controlled tria l see Table The,1
VIMIZIM,hypersensitivity reactions,he,1
VIMIZIM,Anaphylaxis,corticosteroids :   The mos t common adverse,1
VIMIZIM,Anaphylaxis,he,1
VIMIZIM,Anaphylaxis,antipyretics or corticosteroids :   The mos t,1
VIMIZIM,Anaphylaxis,he,1
VIMIZIM,Anaphylaxis,The mos t,1
VIMIZIM,Anaphylaxis,additional antihistamine antipyretics or,0
VIMIZIM,Anaphylaxis,: The mos t common adverse,1
VIMIZIM,Anaphylaxis,reactions in Vimizim patients and occurring at,0
VIMIZIM,hypersensitivity,occurring at a higher incidence than,0
VIMIZIM,hypersensitivity,corticosteroids,0
VIMIZIM,hypersensitivity,The most mon adverse reac,1
VIMIZIM,hypersensitivity,corticosteroids,0
VIMIZIM,hypersensitivity,in Vimizim patients and occurring at a higher incidence than placebotreated patients,0
VIMIZIM,hypersensitivity,mon adverse reac,1
VIMIZIM,hypersensitivity,occurring at,0
VIMIZIM,hypersensitivity,com,0
VIMIZIM,anaphylaxis,chills and To repo,1
VIMIZIM,anaphylaxis,To repo,1
VIMIZIM,anaphylaxis,"abdominal pain chills and 
   To repo rt",1
VIMIZIM,anaphylaxis,To repo,1
VIMIZIM,anaphylactic reactions,REACTIONS tact BioMarin at 1-866,1
VIMIZIM,anaphylactic reactions,To repo,1
VIMIZIM,anaphylactic reactions,REACTIONS tact BioMarin at,1
VIMIZIM,anaphylactic reactions,tact BioMarin at 1-866 or FDA at,1
VIMIZIM,anaphylactic reactions,FDA or wwwfdagovmedwatch Clinical,0
VIMIZIM,anaphylactic reactions,tact BioMarin at 1-866 or FDA at,1
VIMIZIM,anaphylactic reactions,SUSPECTED ADVERSE REACTIONS tact BioMarin at 1-866 or FDA at FDA or,1
VIMIZIM,anaphylactic reactions,tact BioMarin at 1-866 or FDA at,1
VIMIZIM,anaphylactic reactions,SUSPECTED ADVERSE REACTIONS tact BioMarin at 1-866,1
VIMIZIM,anaphylactic reactions,tact BioMarin at 1-866,1
VIMIZIM,erythema,VERSE REACTIONS contact BioMarin at or,0
VIMIZIM,erythema,"or .  



  Clinical Trials Experience",1
VIMIZIM,erythema,VERSE REACTIONS contact BioMarin at or,0
VIMIZIM,erythema,".  



  Clinical",1
VIMIZIM,erythema,randomized doubleblind placebocontrolled,0
VIMIZIM,erythema,"FDA or .  



  Clinical",1
VIMIZIM,erythema,randomized doubleblind placebocontrolled,0
VIMIZIM,throat tightness,or wwwfdagovmedwatch,0
VIMIZIM,throat tightness,Clinical T rials Experience A,1
VIMIZIM,throat tightness,or   6.1 Clinical T rials Experience A week randomized,1
VIMIZIM,throat tightness,Clinical T rials Experience A,1
VIMIZIM,urticaria,Vimizim was,0
VIMIZIM,urticaria,FDA at FDA or wwwfdagovmedwatch Clinical Tri,0
VIMIZIM,urticaria,als,1
VIMIZIM,urticaria,week randomized doubleblind placebocontrolled clinical trial of,0
VIMIZIM,urticaria,wwwfdagovmedwatch Clinical als Exper ience,1
VIMIZIM,urticaria,week randomized doubleblind placebocontrolled clinical trial of,0
VIMIZIM,urticaria,or FDA at FDA or,0
VIMIZIM,flushing,"or wwwfdagovmedwatch Clinical Trials nce

  A week randomized",1
VIMIZIM,flushing,or FDA at FDA or,0
VIMIZIM,flushing,Experie,0
VIMIZIM,flushing,nce A week,1
VIMIZIM,flushing,was conducted,0
VIMIZIM,hypotension,week ra,0
VIMIZIM,hypotension,FDA or wwwfdagovmedwatch Clinical Trials Experience A week,0
VIMIZIM,hypotension,"A week ndomized, d oubleblind placebocontrolled clinical trial",1
VIMIZIM,hypotension,FDA or wwwfdagovmedwatch Clinical Trials Experience A week,0
VIMIZIM,hypotension,"ndomized, d",1
VIMIZIM,hypotension,conducted,0
VIMIZIM,hypotension,"Experience A week ndomized, d oubleblind placebocontrolled clinical trial of",1
VIMIZIM,hypotension,conducted,0
VIMIZIM,hypotension,"A week ndomized, d",1
VIMIZIM,hypotension,"ndomized, d oubleblind placebocontrolled clinical trial of",1
VIMIZIM,hypotension,"A week ndomized, d",1
VIMIZIM,hypotension,"ndomized, d oubleblind placebocontrolled",1
VIMIZIM,rash,ble- blind placebocontrolled clinical trial,1
VIMIZIM,dyspnea,was conducted in patients with MPS IVA,0
VIMIZIM,chest discomfort,A week randomized,0
VIMIZIM,gastrointestinal symptoms,of Vimizim was co nducted,1
VIMIZIM,gastrointestinal symptoms,Approximately half of the patients,0
VIMIZIM,gastrointestinal symptoms,l trial of Vimizim was co nducted in patients with MPS,1
VIMIZIM,abdominal pain,conducted in atients with M PS,1
VIMIZIM,abdominal pain,l trial of Vimizim was co nducted in patients with MPS,1
VIMIZIM,retching,"conducted in patients with  IVA, ag es to years",1
VIMIZIM,retching,l trial of Vimizim was co nducted in patients with MPS,1
VIMIZIM,retching,"IVA, ag es to",1
VIMIZIM,retching,years old Approximately half of the,0
VIMIZIM,retching,conducted,0
VIMIZIM,retching,"with IVA,",1
VIMIZIM,retching,of Vimizim was conducted in patients with MPS,0
VIMIZIM,retching,Approximately half of the patients were male Of the patients,0
VIMIZIM,retching,"conducted in patients with IVA, ag",1
VIMIZIM,vomiting,was conducted in,0
VIMIZIM,urticaria,ages to years old half,1
VIMIZIM,urticaria,conducted,0
VIMIZIM,urticaria,ages to years old half of,1
VIMIZIM,urticaria,patients were male Of the,0
VIMIZIM,urticaria,MPS,0
VIMIZIM,urticaria,years old half,1
VIMIZIM,anaphylaxis,majority,0
VIMIZIM,anaphylaxis,to years old Approximately,0
VIMIZIM,anaphylaxis,Black,0
VIMIZIM,anaphylaxis,with MPS IVA ages,0
VIMIZIM,anaphylaxis,Black and Other race The majority of pa,0
VIMIZIM,anaphylaxis,),1
VIMIZIM,hypersensitivity,n All patients were treated with antihistamines prior,0
VIMIZIM,hypersensitivity,groups,0
VIMIZIM,hypersensitivity,Vimizim mgkg every other week,1
VIMIZIM,hypersensitivity,n Vimizim mgkg every other week n or placebo n,1
VIMIZIM,hypersensitivity,Vimizim mgkg every other week,1
VIMIZIM,hypersensitivity,n Vimizim mgkg every other week n,1
VIMIZIM,hypersensitivity,Vimizim mgkg every other week,1
VIMIZIM,hypersensitivity,Vimizim mgkg every other week,1
VIMIZIM,anaphylaxis,=59). All patients were treated with antihistamines,1
VIMIZIM,anaphylaxis,or,0
VIMIZIM,anaphylaxis,placebo,0
VIMIZIM,anaphylaxis,placebo =59).  All  patients were,1
VIMIZIM,anaphylaxis,placebo,0
VIMIZIM,anaphylaxis,=59). All patients were,1
VIMIZIM,anaphylaxis,week n or placebo =59).,1
VIMIZIM,anaphylaxis,placebo =59).,1
VIMIZIM,anaphylaxis,=59). All,1
VIMIZIM,anaphylaxis,Table,0
VIMIZIM,Hypersensitivity,or placebo n All tients were trea ted with antihistamines prior to,1
VIMIZIM,Hypersensitivity,Table,0
VIMIZIM,Hypersensitivity,tients were trea ted,1
VIMIZIM,Hypersensitivity,were trea ted with antihistamines prior,1
VIMIZIM,Hypersensitivity,week n or placebo,0
VIMIZIM,Hypersensitivity,antihistamines prior to each infusion Table summarizes,0
VIMIZIM,Hypersensitivity,week n Vimizim mgkg once every other week n or placebo n,0
VIMIZIM,Hypersensitivity,once,0
VIMIZIM,hypersensitivity,the ntrolled trial,1
VIMIZIM,hypersensitivity,that occurred in,0
VIMIZIM,anaphylactic reactions,2 mg/kg once per w,1
VIMIZIM,anaphylactic reactions,with an incidence of in,0
VIMIZIM,anaphylactic reactions,a higher,0
VIMIZIM,anaphylactic reactions,treated with zim 2 mg/kg once per w,1
VIMIZIM,anaphylactic reactions,a higher,0
VIMIZIM,anaphylactic reactions,once per w eek and with a,1
VIMIZIM,anaphylactic reactions,zim 2 mg/kg once per w,1
VIMIZIM,anaphylactic reactions,zim 2 mg/kg once per w,1
VIMIZIM,anaphylactic reactions,in patients treated with,0
VIMIZIM,anaphylactic reactions,in patients treated with zim,1
VIMIZIM,urticaria,and wit h a higher incidence,1
VIMIZIM,peripheral edema,a higher inciden ce than in the placebotreated,1
VIMIZIM,peripheral edema,a higher,1
VIMIZIM,peripheral edema,a higher inciden ce than in the placebotreated,1
VIMIZIM,peripheral edema,a higher,1
VIMIZIM,peripheral edema,Table Adverse Reactions That Occurred,0
VIMIZIM,peripheral edema,incidence of in patients treated with Vimizim mgkg once per week and with,0
VIMIZIM,peripheral edema,once per week and a higher,1
VIMIZIM,peripheral edema,in the Plac,0
VIMIZIM,cough, than in,1
VIMIZIM,cough, than,1
VIMIZIM,cough, than in the,1
VIMIZIM,cough,placebotreated patients Table Adverse Reactions That Occurred in the PlaceboCon,0
VIMIZIM,dyspnea,Occurred,0
VIMIZIM,dyspnea,a higher incidence than n,1
VIMIZIM,dyspnea,incidence than n,1
VIMIZIM,dyspnea,Occurred in the,0
VIMIZIM,dyspnea,the p lacebotreated patients Table Adverse,1
VIMIZIM,dyspnea,Table Adverse Reactions That Occurred in the PlaceboControlled T,0
VIMIZIM,dyspnea,Adverse,0
VIMIZIM,dyspnea,patients,0
VIMIZIM,dyspnea,higher incidence than n the,1
VIMIZIM,dyspnea,patients Table Adverse Reactions That Occurred in,0
VIMIZIM,hypersensitivity reactions,antibody titers were sustained or,0
VIMIZIM,hypersensitivity reactions,or,0
VIMIZIM,hypersensitivity reactions,developed ant idrug antibodies associations between,1
VIMIZIM,hypersensitivity reactions,antibodies associations between antibody titers and reductions in treatment effect,0
VIMIZIM,hypersensitivity reactions,reductions in treatment effect or the oc,0
BEPREVE,taste following instillation,irritation headache,0
BEPREVE,taste following instillation,taste following instillation Other,1
BEPREVE,taste following instillation,irritation headache,0
BEPREVE,taste following instillation,of patients was a taste following instillation Other adverse reactions which,1
BEPREVE,taste following instillation,irritation headache,0
BEPREVE,taste following instillation,taste following instillation Other adverse reactions,1
BEPREVE,taste following instillation,irritation headache,0
BEPREVE,taste following instillation,a taste following instillation,1
BEPREVE,eye irritation,SUSPECTED ADVERSE REACTIONS contact,0
BEPREVE,eye irritation,eye irritation headache and nasopharyngitis To report,1
BEPREVE,eye irritation,eye irritation,1
BEPREVE,eye irritation,eye irritation headache and nasopharyngitis To report,1
BEPREVE,eye irritation,eye irritation headache and,1
BEPREVE,eye irritation,in of subjects eye irritation,1
BEPREVE,eye irritation,SUSPECTED ADVERSE REACTIONS contact,0
BEPREVE,eye irritation,reactions which occurred in of subjects,0
BEPREVE,eye irritation,REACTIONS contact,0
BEPREVE,headache,headache and nasopharyngitis To,1
BEPREVE,headache,REACTIONS contact,0
BEPREVE,headache,headache and nasopharyngitis,1
BEPREVE,headache,headache and nasopharyngitis To report,1
BEPREVE,headache,and nasopharyngitis To report,0
BEPREVE,headache,of subjects were eye headache and nasopharyngitis To report,1
BEPREVE,headache,and nasopharyngitis To report,0
BEPREVE,headache,headache and nasopharyngitis,1
BEPREVE,headache,nasopharyngitis To report SUSPECTED ADVERSE REACTIONS contact Bausch Lomb In,0
BEPREVE,headache,adverse reactions which occurred,0
BEPREVE,nasopharyngitis,which occurred in of subjects were eye irritation,0
BEPREVE,nasopharyngitis,irritation headache,0
BEPREVE,nasopharyngitis,Bausch Lomb,0
BEPREVE,nasopharyngitis,contact Bausch Lomb Incorporated,0
BEPREVE,taste following instillation,taste,1
BEPREVE,taste following instillation,following instillation Other adverse,1
BEPREVE,taste following instillation,was a mild,0
BEPREVE,eye irritation,occurring in of subjects,0
BEPREVE,headache,Hypersensitivity reactions,0
BEPREVE,headache,and nasopharyngitis Post,0
BEPREVE,headache,subjects were eye headache and nasopharyngitis,1
BEPREVE,headache,and nasopharyngitis Post,0
BEPREVE,nasopharyngitis,reported rarely during,0
BEPREVE,nasopharyngitis,in of subjects were,0
BEPREVE,nasopharyngitis,irritation headache,0
BEPREVE,nasopharyngitis,adverse,0
BEPREVE,Hypersensitivity reactions,Because these,0
BEPREVE,Hypersensitivity reactions,Post Marketing Hypersensitivity reactions have been,1
BEPREVE,Hypersensitivity reactions,Because these,0
BEPREVE,Hypersensitivity reactions,Marketing Hypersensitivity reactions,1
BEPREVE,Hypersensitivity reactions,and nasopharyngitis Post Marketing Hypersensitivity reactions,1
BEPREVE,hypersensitivity reactions,body rash and swelling of,0
BEPREVE,hypersensitivity reactions,hypersensitivity reactions include itching body,1
BEPREVE,hypersensitivity reactions,estimate their frequency or establish a casual relationship to drug,0
BEPREVE,hypersensitivity reactions,hypersensitivity reactions,1
BEPREVE,hypersensitivity reactions,drug exposure hypersensitivity,1
BEPREVE,hypersensitivity reactions,hypersensitivity reactions include itching body rash,1
BEPREVE,itching,reactions itching body rash,1
BEPREVE,itching,hypersensitivity reactions include itching body rash,1
BEPREVE,itching,drug exposure The hypersensitivity reactions,0
BEPREVE,itching,lips tongue,0
BEPREVE,itching,itching body rash and swelling of,1
BEPREVE,itching,itching body rash and swelling,1
BEPREVE,itching,itching body rash and,1
BEPREVE,body rash,body rash and swelling of lips tongue,1
BEPREVE,body rash,The hypersensitivity reactions include body rash and swelling,1
BEPREVE,body rash,body rash and swelling of lips tongue,1
BEPREVE,body rash,The hypersensitivity reactions include body rash,1
BEPREVE,body rash,body rash and swelling of lips tongue,1
BEPREVE,swelling of lips,itching body rash swelling of lips,1
BEPREVE,swelling of lips,itching body rash swelling of lips tongue andor throat,1
BEPREVE,swelling of lips,itching body rash swelling of lips,1
BEPREVE,swelling of lips,rash swelling of,1
BEPREVE,swelling of lips,itching body rash swelling of,1
BEPREVE,swelling of lips,exposure,0
PRISTIQ,Hypersensitivity,in Adolescents and Young,0
PRISTIQ,Hypersensitivity,other sections of the Hypersensitivity see Contraindications,1
PRISTIQ,Hypersensitivity,in Adolescents and Young,0
PRISTIQ,Hypersensitivity,Hypersensitivity,1
PRISTIQ,Hypersensitivity,in other sections of the label,0
PRISTIQ,Hypersensitivity,sections,0
PRISTIQ,Hypersensitivity,and Behaviors in,0
PRISTIQ,Hypersensitivity,of the Hypersensitivity see Contraindications Suicidal Thoughts,1
PRISTIQ,Hypersensitivity,and Behaviors in,0
PRISTIQ,Hypersensitivity,Suicidal Thoughts and Behaviors in Adolescents and,0
PRISTIQ,Suicidal Thoughts,Hypersensitivity,0
PRISTIQ,Suicidal Thoughts,Suicidal Thoughts and Behaviors,1
PRISTIQ,Suicidal Thoughts,Suicidal Thoughts,1
PRISTIQ,Serotonin Syndrome,ughts and Behaviors in Adolescents and Young Adults see,0
PRISTIQ,Serotonin Syndrome,Adolescents and Young Adults,0
PRISTIQ,Serotonin Syndrome,and Serotonin Syndrome,1
PRISTIQ,Serotonin Syndrome,ughts and Behaviors in Adolescents and Young Adults see Warnings,0
PRISTIQ,Serotonin Syndrome,Adults see Warnings and Serotonin Syndrome see,1
PRISTIQ,Serotonin Syndrome,ughts and Behaviors in Adolescents and Young Adults see Warnings,0
PRISTIQ,Elevated Blood Pressure,Blood Pressure see Warnings and,1
PRISTIQ,Elevated Blood Pressure,Syndrome see,0
PRISTIQ,Elevated Blood Pressure,Elevated Blood Pressure see Warnings and Precautions,1
PRISTIQ,Elevated Blood Pressure,Syndrome see,0
PRISTIQ,Elevated Blood Pressure,Serotonin Syndrome see Warnings,0
PRISTIQ,Abnormal Bleeding,Closure Glaucoma see Warnings and Precauti,0
PRISTIQ,Abnormal Bleeding,Abnormal Bleeding see Warnings,1
PRISTIQ,Abnormal Bleeding,Pressure see Warnings,0
PRISTIQ,Abnormal Bleeding,Elevated Blood Pressure see Warnings and Precautions,0
PRISTIQ,Abnormal Bleeding,and Precautions Angle Closure Glaucoma see Warnings,0
PRISTIQ,Angle Closure Glaucoma,Warnings and Angle,1
PRISTIQ,Angle Closure Glaucoma,Angle Closure Glaucoma see Warnings and Precautions Activation,1
PRISTIQ,Angle Closure Glaucoma,Precautions,0
PRISTIQ,Mania,Precautions Discontinuation Syndrome,0
PRISTIQ,Mania,Precautions Activation Mania,1
PRISTIQ,Mania,Precautions Discontinuation Syndrome,0
PRISTIQ,Mania,Mania Hypomania see Warnings and,1
PRISTIQ,Mania,Mania Hypomania see Warnings,1
PRISTIQ,Mania,and Precautions Activation Mania Hypomania,1
PRISTIQ,Mania,Mania Hypomania see Warnings,1
PRISTIQ,Mania,Mania Hypomania see Warnings,1
PRISTIQ,Discontinuation Syndrome,Precautions,0
PRISTIQ,Discontinuation Syndrome,Discontinuation Syndrome see Warnings and Precautions Seizure,1
PRISTIQ,Discontinuation Syndrome,and Discontinuation Syndrome see Warnings and Precautions Seizure,1
PRISTIQ,Discontinuation Syndrome,Discontinuation Syndrome see Warnings and Precautions Seizure,1
PRISTIQ,Seizure,and Seizure see Warnings and,1
PRISTIQ,Seizure,Discontinuation Syndrome see Warnings and Precautions Seizure,1
PRISTIQ,Seizure,Seizure see,1
PRISTIQ,Seizure,Warnings and Precautions Hyponatremia see Warnings,0
PRISTIQ,Seizure,Warnings and Seizure see Warnings and Precautions,1
PRISTIQ,Seizure,Warnings and Precautions Hyponatremia see Warnings,0
PRISTIQ,Interstitial Lung Disease,and Precautions,0
PRISTIQ,Interstitial Lung Disease,nings,0
PRISTIQ,Interstitial Lung Disease,see Warnings and Interstitial Lung,1
PRISTIQ,Interstitial Lung Disease,Hyponatremia see Warnings and Interstitial,1
PRISTIQ,Interstitial Lung Disease,Hyponatremia see Warnings and Interstitial Lung Disease and Eosinophilic Pneumonia see Warnings,1
PRISTIQ,Interstitial Lung Disease,Hyponatremia see Warnings and Interstitial,1
PRISTIQ,Interstitial Lung Disease,Hyponatremia see Warnings and Interstitial Lung Disease and,1
PRISTIQ,Interstitial Lung Disease,Hyponatremia see Warnings and Interstitial,1
PRISTIQ,Interstitial Lung Disease,Warnings and Precautions,0
PRISTIQ,Eosinophilic Pneumonia,Disease Eosinophilic,1
PRISTIQ,Eosinophilic Pneumonia,Lung Disease,0
PRISTIQ,Eosinophilic Pneumonia,Lung Disease,0
PRISTIQ,Eosinophilic Pneumonia,and,0
PRISTIQ,Eosinophilic Pneumonia,Interstitial Lung Disease and,0
PRISTIQ,Eosinophilic Pneumonia,Disease Eosinophilic,1
PRISTIQ,Eosinophilic Pneumonia,Interstitial Lung Disease and,0
PRISTIQ,Eosinophilic Pneumonia,Lung Disease Eosinophilic,1
PRISTIQ,Eosinophilic Pneumonia,common adverse,0
PRISTIQ,nausea,nausea dizziness insomnia hyperhidrosis constipation somnolence,1
PRISTIQ,nausea,mg dose groups,0
PRISTIQ,nausea,reactions incidence and twice,0
PRISTIQ,dizziness,were dizziness insomnia hyperhidrosis constipation,1
PRISTIQ,dizziness,reactions incidence and twice,0
PRISTIQ,dizziness,groups were dizziness insomnia hyperhidrosis constipation somnolence,1
PRISTIQ,dizziness,reactions incidence and twice,0
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis,1
PRISTIQ,dizziness,dizziness,1
PRISTIQ,dizziness,decreased appetite anxiety and specific male,0
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis constipation,1
PRISTIQ,dizziness,dizziness insomnia hyperhidrosis constipation,1
PRISTIQ,dizziness,dizziness insomnia,1
PRISTIQ,insomnia,were nausea insomnia hyperhidrosis,1
PRISTIQ,insomnia,dizziness insomnia,1
PRISTIQ,insomnia,and twice the rate of placebo in the or mg dose groups,0
PRISTIQ,insomnia,insomnia,1
PRISTIQ,hyperhidrosis,hyperhidrosis constipation somnolence decreased,1
PRISTIQ,hyperhidrosis,dizziness hyperhidrosis constipation somnolence,1
PRISTIQ,hyperhidrosis,hyperhidrosis constipation somnolence decreased,1
PRISTIQ,hyperhidrosis,hyperhidrosis constipation somnolence decreased appetite,1
PRISTIQ,hyperhidrosis,hyperhidrosis,1
PRISTIQ,hyperhidrosis,were nausea dizziness hyperhidrosis,1
PRISTIQ,hyperhidrosis,hyperhidrosis,1
PRISTIQ,hyperhidrosis,hyperhidrosis constipation somnolence decreased appetite anxiety,1
PRISTIQ,somnolence,nausea dizziness insomnia hyperhidrosis somnolence decreased appetite anxiety and specific,1
PRISTIQ,somnolence,hyperhidrosis constipation somnolence decreased appetite anxiety,1
PRISTIQ,decreased appetite,insomnia hyperhidrosis constipation decreased,1
PRISTIQ,decreased appetite,mg dose groups were nausea dizziness insomnia hyperhidrosis constipation somnolence,0
PRISTIQ,decreased appetite,constipation decreased appetite anxiety,1
PRISTIQ,decreased appetite,mg dose groups were nausea dizziness insomnia hyperhidrosis constipation somnolence,0
PRISTIQ,decreased appetite,disorders,0
PRISTIQ,decreased appetite,dose groups were nausea dizziness insomnia hyperhidrosis constipation,0
PRISTIQ,decreased appetite,male sexual function disorders To,0
PRISTIQ,decreased appetite,decreased appetite anxiety and specific male,1
PRISTIQ,anxiety,somnolence,0
PRISTIQ,anxiety,anxiety and specific male,1
PRISTIQ,anxiety,anxiety,1
PRISTIQ,nausea,In a,0
PRISTIQ,nausea,headache and vomiting each In a longerterm,0
PRISTIQ,nausea,longerterm,0
PRISTIQ,nausea,nausea dizziness headache and vomiting each,1
PRISTIQ,nausea,than placebo of the PRISTIQ treated patients in the shortterm studies up to weeks were,0
PRISTIQ,nausea,in the,0
PRISTIQ,dizziness,months the most common was,0
PRISTIQ,dizziness,to months,0
PRISTIQ,dizziness,PRISTIQ treated patients in the,0
PRISTIQ,dizziness,were nausea,0
PRISTIQ,headache,headache and vomiting each,1
PRISTIQ,headache,headache and,1
PRISTIQ,headache,in,0
PRISTIQ,headache,weeks were nausea,0
PRISTIQ,vomiting,to weeks were nausea,0
PRISTIQ,vomiting,months the most,0
PRISTIQ,vomiting,vomiting each In,1
PRISTIQ,vomiting,headache vomiting,1
PRISTIQ,vomiting,vomiting each In,1
PRISTIQ,vomiting,vomiting each In a longerterm,1
PRISTIQ,vomiting,eated patients in the shortterm studies up to weeks were nausea dizziness,0
PRISTIQ,vomiting,vomiting,1
PRISTIQ,vomiting,vomiting Common adverse reactions in placebocontrolled,1
PRISTIQ,vomiting,MDD studies The most commonly ob,0
PRISTIQ,vomiting,common vomiting Common adverse reactions in,1
PRISTIQ,vomiting,MDD studies The most commonly ob,0
PRISTIQ,vomiting,the most common vomiting,1
PRISTIQ,vomiting,MDD studies The most commonly ob,0
PRISTIQ,vomiting,vomiting Common adverse reactions,1
PRISTIQ,vomiting,vomiting Common adverse,1
PRISTIQ,vomiting,vomiting Common adverse reactions,1
PRISTIQ,vomiting,common was,0
PRISTIQ,nausea,mg dose groups nausea dizziness insomnia hyperhidrosis,1
PRISTIQ,nausea,common was,0
PRISTIQ,nausea,nausea dizziness insomnia hyperhidrosis constipation somnolence,1
PRISTIQ,nausea,mg dose,0
PRISTIQ,nausea,nausea dizziness,1
PRISTIQ,nausea,nausea dizziness insomnia hyperhidrosis constipation somnolence,1
PRISTIQ,nausea,nausea dizziness insomnia hyperhidrosis constipation somnolence,1
PRISTIQ,dizziness,mg dose groups were dizziness insomnia hyperhidrosis constipation,1
PRISTIQ,dizziness,nausea dizziness insomnia hyperhidrosis constipation somnolence,1
PRISTIQ,dizziness,decreased appetite anxiety and,0
PRISTIQ,hyperhidrosis,hyperhidrosis constipation,1
PRISTIQ,hyperhidrosis,groups were nausea dizziness hyperhidrosis,1
PRISTIQ,hyperhidrosis,hyperhidrosis constipation,1
PRISTIQ,hyperhidrosis,dizziness hyperhidrosis,1
PRISTIQ,hyperhidrosis,hyperhidrosis constipation,1
PRISTIQ,constipation,constipation somnolence,1
PRISTIQ,constipation,in the or mg dose groups were nausea dizziness insomnia hyperhidrosis,0
PRISTIQ,constipation,nausea dizziness insomnia constipation somnolence decreased,1
PRISTIQ,constipation,in the or mg dose groups were nausea dizziness insomnia hyperhidrosis,0
PRISTIQ,constipation,constipation somnolence decreased,1
PRISTIQ,constipation,constipation somnolence decreased appetite anxiety and,1
PRISTIQ,constipation,dizziness insomnia constipation somnolence decreased appetite,1
PRISTIQ,constipation,constipation somnolence decreased appetite anxiety and,1
PRISTIQ,decreased appetite,the incidence of common ad,0
PRISTIQ,decreased appetite,constipation decreased appetite anxiety and specific male,1
PRISTIQ,decreased appetite,the incidence of common ad,0
PRISTIQ,decreased appetite,decreased,1
PRISTIQ,decreased appetite,and,0
PRISTIQ,decreased appetite,nausea dizziness insomnia hyperhidrosis,0
PRISTIQ,anxiety,sexual function disorders Table shows the incidence of common adverse,0
PRISTIQ,anxiety,of common adverse rea,0
PRISTIQ,male sexual function disorders,reactions that occurred in of PRISTIQ,0
PRISTIQ,male sexual function disorders,sexual function disorders Table,1
PRISTIQ,male sexual function disorders,decreased appetite anxiety and male sexual function disorders Table shows the incidence,1
PRISTIQ,male sexual function disorders,sexual function disorders Table,1
PRISTIQ,male sexual function disorders,sexual function disorders Table,1
PRISTIQ,male sexual function disorders,sexual function disorders Table shows,1
PRISTIQ,male sexual function disorders,function disorders Table shows the,1
PRISTIQ,male sexual function disorders,that,0
PRISTIQ,sexual function adverse reactions,the incidence sexual function adverse reactions,1
PRISTIQ,sexual function adverse reactions,occurred in of PRISTIQ treated MDD patients in any fixeddose,0
PRISTIQ,sexual function adverse reactions,MDD,0
PRISTIQ,sexual function adverse reactions,adverse reactions,1
PRISTIQ,sexual function adverse reactions,the incidence sexual function adverse reactions,1
PRISTIQ,sexual function adverse reactions,adverse reactions,1
PRISTIQ,sexual function adverse reactions,sexual function adverse reactions that occurred in of PRISTIQ,1
PRISTIQ,sexual function adverse reactions,adverse reactions,1
PRISTIQ,Sexual Function Adverse Reactions,Sexual Function Adverse Reactions,1
PRISTIQ,Sexual Function Adverse Reactions,pooled week,0
PRISTIQ,Sexual Function Adverse Reactions,clinical studies Sexual Function Adverse Reactions,1
PRISTIQ,Sexual Function Adverse Reactions,Function Adverse Reactions in,1
PRISTIQ,Tachycardia,were,0
PRISTIQ,Tachycardia,at an,0
PRISTIQ,Tachycardia,were Cardiac Tachycardia General disorders and administration site,1
PRISTIQ,Tachycardia,at an,0
PRISTIQ,Tachycardia,Tachycardia General,1
PRISTIQ,Tachycardia,with PRISTIQ were Cardiac Tachycardia General disorders,1
PRISTIQ,Tachycardia,Tachycardia General,1
PRISTIQ,Tachycardia,Tachycardia General,1
PRISTIQ,Asthenia,Asthenia Investigations Weight,1
PRISTIQ,Asthenia,Weight increased liver function test abnormal blood prolactin,0
PRISTIQ,Asthenia,administration site Asthenia Investigations,1
PRISTIQ,Asthenia,Weight increased liver function test abnormal blood prolactin,0
PRISTIQ,Asthenia,Asthenia Investigations Weight,1
PRISTIQ,Weight increased,Weight increased liver,1
PRISTIQ,Weight increased,abnormal blood,0
PRISTIQ,Weight increased,Weight,1
PRISTIQ,liver function test abnormal,ers and administration site,0
PRISTIQ,blood prolactin increased,nditions Asthenia Investigations Weight increased liver function,0
PRISTIQ,blood prolactin increased,blood prolactin increased Musculoskeletal,1
PRISTIQ,blood prolactin increased,nditions Asthenia Investigations Weight increased liver function,0
PRISTIQ,blood prolactin increased,function,0
PRISTIQ,blood prolactin increased,test blood prolactin increased,1
PRISTIQ,blood prolactin increased,Investigations Weight increased,0
PRISTIQ,blood prolactin increased,test blood prolactin increased Musculoskeletal and connective tissue disorders,1
PRISTIQ,blood prolactin increased,Investigations Weight increased,0
PRISTIQ,blood prolactin increased,function test blood prolactin,1
PRISTIQ,blood prolactin increased,prolactin increased Musculoskeletal and connective tissue,1
PRISTIQ,blood prolactin increased,liver function test blood prolactin,1
PRISTIQ,Musculoskeletal stiffness,Musculoskeletal,1
PRISTIQ,Syncope,Psychiatric disorders,0
PRISTIQ,Syncope,Syncope convulsion dystonia Psychiatric disorders Depersonalization,1
PRISTIQ,Syncope,Syncope,1
PRISTIQ,Syncope,Musculoskeletal stiffness Nervous system Syncope convulsion dystonia Psychiatric disorders Depersonalization,1
PRISTIQ,Syncope,Syncope,1
PRISTIQ,Syncope,dystonia,0
PRISTIQ,Syncope,Syncope,1
PRISTIQ,Syncope,Syncope,1
PRISTIQ,Syncope,Syncope,1
PRISTIQ,convulsion,convulsion,1
PRISTIQ,dystonia,disorders Syncope dystonia Psychiatric disorders Depersonalization bruxism,1
PRISTIQ,dystonia,convulsion,1
PRISTIQ,dystonia,disorders Depersonalization bruxism Renal and urinary,0
PRISTIQ,Depersonalization,Depersonalization bruxism Renal,1
PRISTIQ,Depersonalization,Depersonalization bruxism Renal,1
PRISTIQ,Depersonalization,Depersonalization bruxism Renal,1
PRISTIQ,Depersonalization,Syncope convulsion,0
PRISTIQ,Depersonalization,Depersonalization,1
PRISTIQ,Depersonalization,Depersonalization,1
PRISTIQ,Depersonalization,Depersonalization,1
PRISTIQ,Depersonalization,Nervous system disorders Syncope convulsion dystonia Psychiatric disorders,0
PRISTIQ,Depersonalization,Depersonalization bruxism,1
PRISTIQ,bruxism,bruxism Renal,1
PRISTIQ,bruxism,bruxism Renal and urinary,1
PRISTIQ,Urinary retention,and subcutaneous tissue disorders Rash alopecia photosensitivity reaction angi,0
PRISTIQ,Urinary retention,Renal and urinary Urinary retention Skin,1
PRISTIQ,Urinary retention,and subcutaneous tissue disorders Rash alopecia photosensitivity reaction angi,0
PRISTIQ,Urinary retention,Urinary retention,1
PRISTIQ,Urinary retention,and urinary Urinary retention Skin,1
PRISTIQ,Urinary retention,Urinary retention,1
PRISTIQ,Urinary retention,alopecia photosensitivity,0
PRISTIQ,Urinary retention,urinary Urinary,1
PRISTIQ,Urinary retention,urinary Urinary,1
PRISTIQ,Urinary retention,Urinary retention Skin and subcutaneous tissue,1
PRISTIQ,Urinary retention,bruxism Renal and urinary Urinary retention,1
PRISTIQ,Urinary retention,Urinary retention Skin and subcutaneous tissue,1
PRISTIQ,Urinary retention,tissue disorders Rash alopecia,0
PRISTIQ,Rash,clinical studies there,0
PRISTIQ,Rash,and urinary disorders Urinary retention Skin and,0
PRISTIQ,alopecia,alopecia,1
PRISTIQ,alopecia,subcutaneous tissue disorders alopecia,1
PRISTIQ,alopecia,alopecia,1
PRISTIQ,alopecia,alopecia,1
PRISTIQ,alopecia,alopecia photosensitivity,1
PRISTIQ,alopecia,alopecia photosensitivity reaction angioedema In clinical,1
PRISTIQ,photosensitivity,photosensitivity reaction angioedema In,1
PRISTIQ,photosensitivity,alopecia photosensitivity reaction angioedema In clinical,1
PRISTIQ,photosensitivity,studies there were uncommon reports of ischemic cardiac adve,0
PRISTIQ,photosensitivity,photosensitivity,1
PRISTIQ,angioedema,In clinical studies there were uncommon reports of ischemic cardiac adverse,0
PRISTIQ,angioedema,Rash alopecia photosensitivity angioedema In,1
PRISTIQ,angioedema,In clinical studies there were uncommon reports of ischemic cardiac adverse,0
PRISTIQ,angioedema,tissue disorders,0
PRISTIQ,angioedema,of ischemic,0
PRISTIQ,angioedema,angioedema In clinical,1
PRISTIQ,angioedema,angioedema In clinical studies there were,1
PRISTIQ,angioedema,studies there were uncommon,0
PRISTIQ,ischemic cardiac adverse reactions,there were uncommon reports ischemic cardiac adverse reactions,1
PRISTIQ,ischemic cardiac adverse reactions,studies there were uncommon,0
PRISTIQ,ischemic cardiac adverse reactions,studies there,0
PRISTIQ,ischemic cardiac adverse reactions,cardiac adverse reactions including myocardial ischemia,1
PRISTIQ,ischemic cardiac adverse reactions,coronary,0
PRISTIQ,ischemic cardiac adverse reactions,were uncommon reports ischemic cardiac adverse,1
PRISTIQ,ischemic cardiac adverse reactions,ischemic cardiac adverse reactions including myocardial ischemia,1
PRISTIQ,ischemic cardiac adverse reactions,myocardial ischemia myocardial infarction and coronary occlusion requiring revasculari,0
PRISTIQ,myocardial ischemia,myocardial ischemia myocardial infarction and coronary,1
PRISTIQ,myocardial ischemia,myocardial ischemia myocardial infarction and,1
PRISTIQ,myocardial infarction,adverse reactions including myocardial myocardial,1
PRISTIQ,myocardial infarction,including myocardial myocardial infarction,1
PRISTIQ,myocardial infarction,myocardial myocardial infarction,1
PRISTIQ,myocardial infarction,and coronary occlusion,0
PRISTIQ,myocardial infarction,revascularization these,0
PRISTIQ,myocardial infarction,including myocardial myocardial,1
PRISTIQ,myocardial infarction,occlusion requiring revascularization these patients had multiple underlying cardiac,0
PRISTIQ,myocardial infarction,requiring revascularization these,0
PRISTIQ,myocardial infarction,myocardial infarction and coronary occlusion requiring,1
PRISTIQ,myocardial infarction,requiring revascularization these,0
PRISTIQ,myocardial infarction,of ischemic cardiac adverse reactions,0
PRISTIQ,coronary occlusion,including,0
PRISTIQ,coronary occlusion,myocardial infarction and,0
PRISTIQ,coronary occlusion,factors,0
PRISTIQ,coronary occlusion,infarction coronary occlusion,1
PRISTIQ,coronary occlusion,of ischemic cardiac adverse reactions including myocardial ischemia myocardial infarction,0
PRISTIQ,Elevations in fasting serum total cholesterol,with PRISTIQ,0
PRISTIQ,Lipid Abnormalities,of Patients Lipid Abnormalities,1
PRISTIQ,Lipid Abnormalities,Incidence of Patients Lipid Abnormalities,1
PRISTIQ,Lipid Abnormalities,Incidence of Patients Lipid Abnormalities of Potential Clinical Significance PRISTIQ,1
PRISTIQ,Lipid Abnormalities,Incidence of Patients Lipid Abnormalities,1
PRISTIQ,Lipid Abnormalities,Lipid,1
PRISTIQ,Lipid Abnormalities,Lipid Abnormalities of Potential Clinical,1
PRISTIQ,Lipid Abnormalities,Lipid,1
PRISTIQ,Lipid Abnormalities,Clinical,0
PRISTIQ,Lipid Abnormalities,Lipid Abnormalities of Potential Clinical Significance PRISTIQ,1
PRISTIQ,Lipid Abnormalities,of Patients Lipid Abnormalities,1
PRISTIQ,proteinuria,proteinuria was not associated with,1
PRISTIQ,increases in BUN,creatinine and was generally transient Table Incidence,0
PRISTIQ,increases in BUN,in BUN or,1
PRISTIQ,increases in BUN,Table Incidence of Patients with Proteinuria,0
PRISTIQ,increases in BUN,and was generally transient Table Incidence of,0
PRISTIQ,increases in BUN,and was generally,0
PRISTIQ,increases in BUN,proteinuria was not associated increases in BUN or creatinine,1
PRISTIQ,increases in BUN,and was generally,0
PRISTIQ,Proteinuria,Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,Incidence of Patients Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,of Patients Proteinuria,1
PRISTIQ,Proteinuria,Proteinuria in the Fixeddose Clinical Studies,1
PRISTIQ,Proteinuria,Fixeddose Clinical,0
PRISTIQ,Proteinuria,Clinical Studies PRISTIQ,0
PRISTIQ,Proteinuria,in the Fixeddose Clinical Studies PRISTIQ,0
PRISTIQ,hypertension,studies was associated with hypertension defined as,1
PRISTIQ,hypertension,in the Fixeddose Clinical Studies PRISTIQ,0
PRISTIQ,hypertension,SDBP,0
PRISTIQ,hypertension,hypertension defined as treatmentemergent supine diastolic,1
PRISTIQ,hypertension,hypertension defined as,1
PRISTIQ,hypertension,studies was associated with hypertension,1
PRISTIQ,hypertension,hypertension defined as,1
PRISTIQ,hypertension,hypertension revealed a,1
PRISTIQ,hypertension,hypertension revealed a consistent increase in,1
PRISTIQ,hypertension,hypertension,1
PRISTIQ,hypertension,hypertension revealed a consistent increase,1
PRISTIQ,hypertension,for sustained,0
PRISTIQ,hypertension,hypertension revealed a consistent increase in,1
PRISTIQ,hypertension,who developed sustained,0
PRISTIQ,hypertension,hypertension This was,1
PRISTIQ,hypertension,a higher rate at,0
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,Patients with Sustained,0
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,Group Proportion,0
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,Elevation of Supine,1
PRISTIQ,Elevation of Supine Diastolic Blood Pressure,of Patients with Elevation of Supine Diastolic Blood Pressure,1
PRISTIQ,systolic orthostatic hypotension,with doses of to systolic orthostatic,1
PRISTIQ,systolic orthostatic hypotension,orthostatic hypotension decrease mm Hg,1
PRISTIQ,systolic orthostatic hypotension,standing position occurred,0
PRISTIQ,systolic orthostatic hypotension,to systolic orthostatic hypotension decrease mm Hg from supine,1
PRISTIQ,systolic orthostatic hypotension,standing position occurred,0
PRISTIQ,SUICIDAL THOUGHTS,following advers,1
PRISTIQ,SUICIDAL THOUGHTS,following advers e reactions are,1
PRISTIQ,SUICIDAL THOUGHTS,sections of the label,0
PRISTIQ,SUICIDAL THOUGHTS,of the,0
PRISTIQ,SUICIDAL THOUGHTS,discussed in,0
PRISTIQ,SUICIDAL THOUGHTS,greater detail in,1
PRISTIQ,SUICIDAL THOUGHTS,discussed in,0
PRISTIQ,SUICIDAL THOUGHTS,discussed greater detail in other sections of the,1
PRISTIQ,SUICIDAL THOUGHTS,discussed in,0
PRISTIQ,SUICIDAL THOUGHTS,detail in,1
PRISTIQ,SUICIDAL THOUGHTS,REACTIONS The following adverse,0
PRISTIQ,suicidal thoughts,  Contraindicatio ns,1
PRISTIQ,suicidal thoughts,  Contraindicatio ns Suicidal Thoughts and Behaviors,1
PRISTIQ,suicidal thoughts,  Contraindicatio ns,1
PRISTIQ,suicidal thoughts,Precautions tonin Syndrome [s,1
PRISTIQ,suicidal thoughts,and Young Adults see Warnings and Precautions,0
PRISTIQ,suicidal thoughts,tonin,1
PRISTIQ,suicidal thoughts,tonin Syndrome [s ee Warnings and Precautions,1
PRISTIQ,suicidal thoughts,Behaviors in Adolescents and Young Adults see Warnings,0
PRISTIQ,suicidal thoughts,see Warnings and Precautions tonin Syndrome [s,1
PRISTIQ,suicidal thoughts,Warnings and Precautions tonin Syndrome [s ee,1
PRISTIQ,suicidal thoughts,see Warnings and Precautions tonin Syndrome [s,1
PRISTIQ,suicidal thoughts,Young Adults see,0
PRISTIQ,suicidal thoughts,Sero,0
PRISTIQ,SUICIDAL THOUGHTS,incidence and twice the rate of,0
PRISTIQ,SUICIDAL THOUGHTS,Most ommon adverse rea ctions incidence and,1
PRISTIQ,SUICIDAL THOUGHTS,incidence and twice the rate of,0
PRISTIQ,SUICIDAL THOUGHTS,see Warnings and Precautions EXCERPT,0
PRISTIQ,SUICIDAL THOUGHTS,ommon,1
PRISTIQ,SUICIDAL THOUGHTS,mg,0
PRISTIQ,SUICIDAL THOUGHTS,and Precautions EXCERPT Most ommon adverse rea ctions incidence and twice,1
PRISTIQ,SUICIDAL THOUGHTS,mg,0
PRISTIQ,SUICIDAL THOUGHTS,Precautions EXCERPT Most ommon,1
PRISTIQ,suicidal thinking,"dizziness somnia, hyperhidr",1
PRISTIQ,suicidal thinking,male,0
PRISTIQ,suicidal thinking,ence,0
PRISTIQ,suicidal thinking,or mg dose groups were nausea dizziness,0
PRISTIQ,Clinical Worsening,following adverse ons are discussed  in greater detail in,1
PRISTIQ,Clinical Worsening,or mg dose groups were nausea dizziness,0
PRISTIQ,Clinical Worsening,of the label Hypersensitivity see,0
PRISTIQ,Suicide Risk,sections of the,0
PRISTIQ,Suicide Risk,n greater de tail in,1
PRISTIQ,Suicide Risk,adverse reactions are discussed n greater de,1
PRISTIQ,Suicide Risk,n greater de tail in,1
PRISTIQ,Serotonin Syndrome,Contraindications  Suicidal,1
PRISTIQ,Serotonin Syndrome,ons are discussed in,0
PRISTIQ,Serotonin Syndrome,Hypersensitivity Contraindications  Suicidal Thoughts and Behaviors,1
PRISTIQ,Serotonin Syndrome,ons are discussed in,0
PRISTIQ,Serotonin syndrome,and Behaviors in,0
PRISTIQ,Serotonin syndrome,"Hypersensitivity see )  ]  
 *    Suici dal Thoughts and Behaviors",1
PRISTIQ,Serotonin syndrome,and Behaviors in,0
PRISTIQ,Serotonin syndrome,"see )  ]  
 *    Suici",1
PRISTIQ,Serotonin syndrome,and Behaviors in,0
PRISTIQ,Elevated Blood Pressure,Warnings and Precautions [see Warnings,1
PRISTIQ,Elevated Blood Pressure,Warnings and Precautions [see Warnings,1
PRISTIQ,Abnormal Bleeding,Disease and Eosinophilic Pneumonia see Warnings and,0
PRISTIQ,Abnormal Bleeding,the rate of placebo in the or,0
PRISTIQ,Abnormal Bleeding,and       EXCERPT:    Most,1
PRISTIQ,Abnormal Bleeding,the rate of placebo in the or,0
PRISTIQ,Abnormal Bleeding,Pneumonia see Warnings and       EXCERPT:    Most common adverse,1
PRISTIQ,Abnormal Bleeding,the rate of placebo in the or,0
PRISTIQ,Abnormal Bleeding,      EXCERPT:   ,1
PRISTIQ,Abnormal Bleeding,and Precautions,0
PRISTIQ,Abnormal Bleeding,placebo in the,0
PRISTIQ,Abnormal Bleeding,      EXCERPT:    Most common,1
PRISTIQ,Abnormal Bleeding,      EXCERPT:    Most common adverse reactions,1
PRISTIQ,bleeding,placebo in the or mg dose groups were nausea,0
PRISTIQ,bleeding,incidenc e and twice the,1
PRISTIQ,bleeding,adverse,0
PRISTIQ,Angle Closure Glaucoma,ADVERSE REACTIONS contact Wyeth,0
PRISTIQ,Angle Closure Glaucoma,appetite anxie,0
PRISTIQ,Angle Closure Glaucoma,SUSPECTED ADVERSE,0
PRISTIQ,Angle Closure Glaucoma,anxie,0
PRISTIQ,Angle Closure Glaucoma,"somnolence decreased appetite ty, and",1
PRISTIQ,Angle closure glaucoma,ADVERSE REACTIONS contact Wyeth,0
PRISTIQ,Angle closure glaucoma,male xual function disorder,1
PRISTIQ,Activation of Mania,wwwfdagovmedwatch Clinical Studies Experience,0
PRISTIQ,Discontinuation Syndrome,r widely varying conditi,1
PRISTIQ,Discontinuation Syndrome,r widely varying conditi,1
PRISTIQ,Discontinuation Syndrome,varying conditi ons,1
PRISTIQ,Discontinuation Syndrome,drug cannot,0
PRISTIQ,Discontinuation Syndrome,widely varying conditi ons adverse reaction rates,1
PRISTIQ,Hyponatremia,reflect the s observed i,1
PRISTIQ,Hyponatremia,widely varying conditi ons adverse reaction rates,1
PRISTIQ,Interstitial Lung Disease,exposure PRIST,0
PRISTIQ,Interstitial Lung Disease,patients,0
PRISTIQ,Interstitial Lung Disease,in patients diagnosed with major depressive disorder who participated in multipledose pre,0
PRISTIQ,Interstitial Lung Disease,practice Patient exposure IQ was evaluated for safe ty in,1
PRISTIQ,Interstitial Lung Disease,in patients diagnosed with major depressive disorder who participated in multipledose pre,0
PRISTIQ,Interstitial Lung Disease,practice,0
PRISTIQ,Interstitial Lung Disease,the rates observed in clinical practice Patient exposure PRIST,0
PRISTIQ,Interstitial Lung Disease,evaluated for safe ty in,1
PRISTIQ,Interstitial Lung Disease,exposure IQ was,1
PRISTIQ,Interstitial Lung Disease,clinical practice Patient exposure IQ was evaluated for safe,1
PRISTIQ,Interstitial Lung Disease,exposure IQ was,1
PRISTIQ,Interstitial Lung Disease,practice Patient exposure IQ was,1
PRISTIQ,Eosinophilic Pneumonia,disorder who,0
PRISTIQ,Eosinophilic Pneumonia,"was evaluated for safety 8,394",1
PRISTIQ,Eosinophilic Pneumonia,for safety in,0
PRISTIQ,Eosinophilic Pneumonia,"8,394 patients diagno sed with major",1
PRISTIQ,Eosinophilic Pneumonia,"8,394 patients diagno sed with major depressive disorder",1
PRISTIQ,worsening of depression,with of,0
PRISTIQ,suicidality,At the dose of 50,1
PRISTIQ,suicidality,discontinuation rate due to an adverse reaction for PRISTIQ was similar to the rate f,0
PRISTIQ,suicidality,the rate,0
PRISTIQ,suicidality,mg the discontinuation rate due to an adverse reaction for PRISTIQ,0
PRISTIQ,suicidality,placebotreated patients At the dose of 50  mg the discontinuation,1
PRISTIQ,suicidality,mg the discontinuation rate due to an adverse reaction for PRISTIQ,0
PRISTIQ,suicidality,the dose of 50  mg the discontinuation,1
PRISTIQ,suicidality,mg the discontinuation rate due to an adverse reaction for PRISTIQ,0
PRISTIQ,suicidality,of 50 mg the discontinuation rate due,1
PRISTIQ,suicidal thinking,adverse reaction s 8.7%. The m,1
PRISTIQ,suicidal thinking,to an adverse reaction s,1
PRISTIQ,suicidal thinking,adverse reaction s 8.7%.,1
PRISTIQ,suicidal thinking,common adverse reactions leading to discontinuation in at least and at a,0
PRISTIQ,suicidal thinking,to,0
PRISTIQ,suicidal thinking,mg dose of PRISTIQ the discontinuation rate due to an,0
PRISTIQ,suicidal thinking,an adverse reaction s 8.7%.,1
PRISTIQ,suicidal thinking,at a,0
PRISTIQ,suicidal thinking,8.7%. The m ost,1
PRISTIQ,suicidal thinking,reaction s 8.7%. The,1
PRISTIQ,suicidality,least and at a rate greater,0
PRISTIQ,suicidality,was The most common rse reactio ns leading to,1
PRISTIQ,suicidality,least and at a rate greater,0
PRISTIQ,suicidality,ns leading to discontinuation in at,0
PRISTIQ,suicidality,rse reactio,1
PRISTIQ,suicidality,studies up,0
PRISTIQ,suicidality,weeks were nausea dizziness he and,1
PRISTIQ,suicidality,he and vomi ting each In,1
PRISTIQ,suicidality,he and vomi,1
PRISTIQ,suicidality,he and vomi ting each In a longerterm,1
PRISTIQ,suicidality,and vomi ting each In a,1
PRISTIQ,suicidality,and twice rate of pla cebo at any,1
PRISTIQ,suicidality,and vomi ting each In a,1
PRISTIQ,suicidality,Adverse,0
PRISTIQ,suicidality,Adverse  in any Fix edDose Group,1
PRISTIQ,suicidality,Adverse,0
PRISTIQ,suicidality,Adverse in,1
PRISTIQ,suicidality,Common Adverse in any Fix,1
PRISTIQ,suicidality,Reporting Reaction PRISTIQ Organ Class Preferred Term Placebo n mg,1
PRISTIQ,suicidality,Common Adverse in any Fix,1
PRISTIQ,suicidality,PRISTIQ Organ Class Preferred Term,1
PRISTIQ,suicidality,Common Adverse in any Fix,1
PRISTIQ,suicidality,Reporting Reaction PRISTIQ Organ Class,1
PRISTIQ,suicidality,Organ Class Preferred Term Placebo n mg,1
PRISTIQ,suicidality,Reporting Reaction PRISTIQ Organ Class,1
PRISTIQ,Suicidality,"   
  
  Ca",1
PRISTIQ,suicides,disorders and on site  conditions,1
PRISTIQ,suicides,"   
  
  Ca",1
PRISTIQ,suicides,and on,1
PRISTIQ,suicides,on site conditions,1
PRISTIQ,suicides,on site conditions Fatigue,1
PRISTIQ,serotonin syndrome,delayed,0
PRISTIQ,serotonin syndrome,                7  Erectile dysfunction,1
PRISTIQ,serotonin syndrome,delayed,0
PRISTIQ,tachycardia,ebo(n=397)  mgn,1
PRISTIQ,tachycardia,PRISTIQ ebo(n=397)  mgn mgn mgn,1
PRISTIQ,tachycardia,ebo(n=397)  mgn,1
PRISTIQ,tachycardia,ebo(n=397)  mgn mgn,1
PRISTIQ,tachycardia,PRISTIQ,0
PRISTIQ,tachycardia,Plac,0
PRISTIQ,tachycardia,mgn mgn mgn mgn Women,0
PRISTIQ,tachycardia,ebo(n=397)  mgn mgn mgn mgn,1
PRISTIQ,tachycardia,ebo(n=397)  mgn mgn mgn mgn Women,1
PRISTIQ,labile blood pressure,Placebon,0
PRISTIQ,labile blood pressure,PRISTIQ 50 mg(n=209) 10,1
PRISTIQ,labile blood pressure, 50 mg(n=209)      10,1
PRISTIQ,labile blood pressure,PRISTIQ 50 mg(n=209) 10,1
PRISTIQ,labile blood pressure,PRISTIQ  50 mg(n=209)      10 mgn mgn,1
PRISTIQ,labile blood pressure,PRISTIQ 50 mg(n=209) 10,1
PRISTIQ,labile blood pressure,mgn Women,0
PRISTIQ,labile blood pressure,PRISTIQ  50 mg(n=209)      10 mgn mgn mgn Women only,1
PRISTIQ,labile blood pressure,mgn Women,0
PRISTIQ,labile blood pressure,PRISTIQ  50 mg(n=209)      10 mgn mgn mgn,1
PRISTIQ,labile blood pressure,mgn Women,0
PRISTIQ,labile blood pressure,50 mg(n=209) 10 mgn mgn mgn Women only,1
PRISTIQ,labile blood pressure, 50 mg(n=209)      10,1
PRISTIQ,labile blood pressure,50 mg(n=209) 10 mgn mgn mgn Women only,1
PRISTIQ,dizziness,mg(n=267) mgn,1
PRISTIQ,dizziness,mgn,0
PRISTIQ,dizziness,mg(n=267),1
PRISTIQ,dizziness,mgn Women only Anorgasmia,0
PRISTIQ,dizziness,mgn mgn Women only Anorgasmia,0
PRISTIQ,diaphoresis,Placebon mgn,0
PRISTIQ,diaphoresis,PRISTIQ Placebon mgn    200 mg(n mgn Women only,1
PRISTIQ,diaphoresis,Placebon mgn,0
PRISTIQ,diaphoresis,200 mg(n mgn Women only,1
PRISTIQ,diaphoresis,200 mg(n mgn Women only Anorgasmia,1
PRISTIQ,diaphoresis,mgn 200 mg(n,1
PRISTIQ,diaphoresis,Placebon mgn    200 mg(n mgn,1
PRISTIQ,diaphoresis,mgn 200 mg(n,1
PRISTIQ,diaphoresis,Placebon mgn    200 mg(n mgn Women only Anorgasmia,1
PRISTIQ,diaphoresis,mgn 200 mg(n,1
PRISTIQ,diaphoresis,Placebon,0
PRISTIQ,diaphoresis,200,1
PRISTIQ,diaphoresis,mgn    200 mg(n mgn Women only,1
PRISTIQ,diaphoresis,200,1
PRISTIQ,flushing,mgn,0
PRISTIQ,flushing,76)      mgn Women only Anorgasmia,1
PRISTIQ,flushing,76)      mgn Women only Anorgasmia,1
PRISTIQ,hyperthermia,mgn mgn,0
PRISTIQ,hyperthermia,0 mg(n=163),1
PRISTIQ,hyperthermia,mgn mgn 0,1
PRISTIQ,hyperthermia,0 mg(n=163),1
PRISTIQ,hyperthermia,0,1
PRISTIQ,hyperreflexia,Women only           1  ,1
PRISTIQ,hyperreflexia,0,1
PRISTIQ,hyperreflexia,          1  ,1
PRISTIQ,hyperreflexia,0,1
PRISTIQ,hyperreflexia,          1  ,1
PRISTIQ,hyperreflexia,          1  ,1
PRISTIQ,hyperreflexia,          1  ,1
PRISTIQ,hyperreflexia,          1   Other,1
PRISTIQ,hyperreflexia,Women only           1   Other,1
PRISTIQ,hyperreflexia,          1   Other,1
PRISTIQ,hyperreflexia,Anorgasmia,0
PRISTIQ,incoordination,Women only              1 Other adverse reactions observ,1
PRISTIQ,incoordination,Anorgasmia,0
PRISTIQ,incoordination,             1 Other adverse reactions observ,1
PRISTIQ,incoordination,Other adverse reactions observ,0
PRISTIQ,incoordination,Women only,0
PRISTIQ,seizures,         Other adverse reactions observed in,1
PRISTIQ,gastrointestinal symptoms,               3         ,1
PRISTIQ,gastrointestinal symptoms,         Other adverse reactions observed in,1
PRISTIQ,gastrointestinal symptoms,reactions observed,0
PRISTIQ,gastrointestinal symptoms,only,0
PRISTIQ,gastrointestinal symptoms,premarketing and postmarketing clinical,0
PRISTIQ,gastrointestinal symptoms,men only,0
PRISTIQ,gastrointestinal symptoms,only                3         ,1
PRISTIQ,gastrointestinal symptoms,men only,0
PRISTIQ,gastrointestinal symptoms,               3          Other adverse,1
PRISTIQ,increases in blood pressure,of,0
PRISTIQ,increases in blood pressure,es were considered potentia lly clinically significant,1
PRISTIQ,increases in blood pressure,clinically significant The,0
PRISTIQ,increases in blood pressure,es were,1
PRISTIQ,increases in blood pressure,were considered potentia,1
PRISTIQ,increases in blood pressure,studies Some of these es were considered potentia,1
PRISTIQ,increases in blood pressure,were considered potentia,1
PRISTIQ,increases in blood pressure,considered potentia lly clinically,1
PRISTIQ,increases in blood pressure,controlled studies Some of these abnormaliti,0
PRISTIQ,increases in blood pressure,the controlled studies Some of,0
PRISTIQ,elevated blood pressure,100 mg 200 m,1
PRISTIQ,elevated blood pressure,Placebo     100 mg        200 m,1
PRISTIQ,elevated blood pressure,100 mg 200 m,1
PRISTIQ,elevated blood pressure,Placebo     100 mg        200 m g,1
PRISTIQ,elevated blood pressure,100 mg 200 m,1
PRISTIQ,elevated blood pressure,mg 200 m g mg,1
PRISTIQ,elevated blood pressure,100 mg 200 m,1
PRISTIQ,elevated blood pressure,CholesterolIncrease of mgdl and an absolute value,0
PRISTIQ,elevated blood pressure,PRISTIQ Placebo     100 mg        200 m g mg Total,1
PRISTIQ,elevated blood pressure,CholesterolIncrease of mgdl and an absolute value,0
PRISTIQ,elevated blood pressure,Placebo 100 mg 200 m,1
PRISTIQ,elevated blood pressure,an,0
PRISTIQ,blood pressure increases,>= 261 mgdl LDL,1
PRISTIQ,blood pressure increases,CholesterolIncrease of mgdl and absolute value of >= 261 mgdl LDL Cholesterol,1
PRISTIQ,blood pressure increases,>= 261 mgdl LDL,1
PRISTIQ,blood pressure increases,mgdl LDL Cholesterol,0
PRISTIQ,blood pressure increases,mgdl,0
PRISTIQ,blood pressure increases,mg Total CholesterolIncrease of mgdl and,0
PRISTIQ,bleeding,Proteinuria,0
PRISTIQ,bleeding,greater than,0
PRISTIQ,bleeding,Proteinuria,0
PRISTIQ,bleeding,         Proteinuria Proteinuria greater,1
PRISTIQ,bleeding,         Proteinuria Proteinuria,1
PRISTIQ,bleeding,        ,1
PRISTIQ,bleeding,         Proteinuria,1
PRISTIQ,bleeding,        ,1
PRISTIQ,gastrointestinal bleeding,ot associated with increases in BUN or creatinine and was generally transient,0
PRISTIQ,gastrointestinal bleeding,e (%) of Patients with Pr oteinuria in the,1
PRISTIQ,gastrointestinal bleeding,ot associated with increases in BUN or creatinine and was generally transient,0
PRISTIQ,gastrointestinal bleeding,in BUN or creatinine and was,0
PRISTIQ,gastrointestinal bleeding,Table e (%) of Patients with Pr oteinuria in the,1
PRISTIQ,gastrointestinal bleeding,in BUN or creatinine and was,0
PRISTIQ,gastrointestinal bleeding,in the Fixeddose Clinical,0
PRISTIQ,gastrointestinal bleeding,creatinine and was generally,0
PRISTIQ,gastrointestinal bleeding,generally transient Table e (%) of Patients with Pr oteinuria in,1
PRISTIQ,gastrointestinal bleeding,creatinine and was generally,0
PRISTIQ,gastrointestinal bleeding,(%) of Patients with Pr oteinuria in,1
PRISTIQ,gastrointestinal bleeding,of Patients with Pr oteinuria,1
PRISTIQ,gastrointestinal bleeding,e (%) of Patients with Pr oteinuria in the Fixeddose,1
PRISTIQ,gastrointestinal bleeding,of Patients with Pr oteinuria,1
PRISTIQ,Bleeding,einuria  in the,1
PRISTIQ,Bleeding,of Patients with Pr oteinuria,1
PRISTIQ,Bleeding,with einuria  in the,1
PRISTIQ,Bleeding,of Patients with Pr oteinuria,1
PRISTIQ,ecchymosis,          ,1
PRISTIQ,hematoma,Proteinuria in the Fixeddose,0
PRISTIQ,hematoma,        ,1
PRISTIQ,hematoma,         PRISTIQ Placebo mg mg,1
PRISTIQ,hematoma,         PRISTIQ Placebo mg mg,1
PRISTIQ,hematoma,        ,1
PRISTIQ,epistaxis,Clinical Studies,0
PRISTIQ,epistaxis,mg mg mg,0
PRISTIQ,epistaxis,Proteinuria in the Fixeddose Clinical,0
PRISTIQ,epistaxis,Placebo,0
PRISTIQ,epistaxis,in the Fixeddose,0
PRISTIQ,epistaxis,with Proteinuria in the Fixeddose Clinical Studies,0
PRISTIQ,epistaxis,   PRISTI Q Placebo,1
PRISTIQ,epistaxis,Fixeddose Clinical    PRISTI Q Placebo mg mg mg,1
PRISTIQ,epistaxis,   PRISTI Q Placebo,1
PRISTIQ,petechiae,"    
     Placebo mg mg",1
PRISTIQ,petechiae,   PRISTI Q Placebo,1
PRISTIQ,petechiae,mg,0
PRISTIQ,petechiae,"    
     Placebo mg mg mg",1
PRISTIQ,petechiae,mg,0
PRISTIQ,petechiae,Placebo mg mg,0
PRISTIQ,petechiae,mg,0
PRISTIQ,petechiae,"    
     Placebo",1
PRISTIQ,petechiae,the Fixeddose Clinical Studies PRISTIQ,0
PRISTIQ,hemorrhages,Studies PRISTIQ lacebo      mg mg,1
PRISTIQ,hemorrhages,the Fixeddose Clinical Studies PRISTIQ,0
PRISTIQ,hemorrhages,lacebo      mg mg,1
PRISTIQ,hemorrhages,the Fixeddose Clinical Studies PRISTIQ,0
PRISTIQ,hemorrhages,lacebo     ,1
PRISTIQ,hemorrhages,the Fixeddose Clinical Studies PRISTIQ,0
PRISTIQ,hemorrhages,linical Studies,0
PRISTIQ,hemorrhages,linical Studies PRISTIQ lacebo      mg mg mg,1
PRISTIQ,hemorrhages,linical Studies,0
PRISTIQ,hemorrhages,lacebo      mg mg,1
PRISTIQ,hemorrhages,lacebo      mg,1
PRISTIQ,hemorrhages,lacebo     ,1
PRISTIQ,hemorrhages,lacebo      mg mg mg,1
PRISTIQ,hemorrhages,lacebo      mg,1
PRISTIQ,Angle-Closure Glaucoma,Vital sign chan,0
PRISTIQ,angle closure attack,PRISTIQ patients,1
PRISTIQ,angle closure attack,in,0
PRISTIQ,angle closure attack,observed in placebocontrolled shortterm premarketing studies with,0
PRISTIQ,angle closure attack,shortterm premarketing studies with PRISTIQ in,0
PRISTIQ,angle closure attack,Signs,0
PRISTIQ,angle closure attack,patients with MDD (d oses to mg,1
PRISTIQ,angle closure attack,patients with MDD (d,1
PRISTIQ,mania,for,0
PRISTIQ,Activation of mania,PRISTIQ Placebo mg            200 mg   mg,1
PRISTIQ,Activation of mania,for,0
PRISTIQ,Activation of mania,PRISTIQ Placebo mg            200 mg   mg Blood pressure,1
PRISTIQ,Activation of mania,for,0
PRISTIQ,Activation of mania,bp,0
PRISTIQ,Activation of mania,200 mg mg Blood pressure Supine,1
PRISTIQ,Activation of mania,200 mg mg Blood pressure,1
PRISTIQ,Activation of mania,200 mg mg Blood pressure Supine systolic,1
PRISTIQ,Activation of mania,Blood pressure Supine systolic bp mm Hg,0
PRISTIQ,Activation of mania,PRISTIQ Placebo mg 200 mg,1
PRISTIQ,dizziness,to 400,1
PRISTIQ,dizziness,to 400 m g,1
PRISTIQ,dizziness,defined as,0
PRISTIQ,dizziness,PRISTIQ at all,0
PRISTIQ,dizziness, to 400 m g per day in controlled,1
PRISTIQ,dizziness,PRISTIQ at all,0
PRISTIQ,dizziness,per  to 400 m g per day,1
PRISTIQ,dizziness,PRISTIQ at all,0
PRISTIQ,dizziness,controlled studies was associated with sustained hypertension defined as treatmenteme,0
PRISTIQ,nausea,per da y in controlled,1
PRISTIQ,nausea,controlled studies was associated with sustained hypertension defined as treatmenteme,0
PRISTIQ,nausea,mg,0
PRISTIQ,nausea,mg,0
PRISTIQ,nausea,mg per day to per,1
PRISTIQ,headache,in,1
PRISTIQ,headache,doses from mg,0
PRISTIQ,headache,treatmentemergent supine diast,0
PRISTIQ,headache,as,0
PRISTIQ,headache,treatmentemergent supine,0
PRISTIQ,headache,treatmentemergent supine,0
PRISTIQ,irritability,day in led studies  was associated with,1
PRISTIQ,irritability,treatmentemergent supine,0
PRISTIQ,insomnia,to mg per day in controlled studies,0
PRISTIQ,insomnia,s associ ated with sustained hypertension defined,1
PRISTIQ,insomnia,s associ ated with,1
PRISTIQ,insomnia,s associ ated with sustained hypertension defined,1
PRISTIQ,insomnia,in controlled studies s associ ated with sustained hypertension,1
PRISTIQ,insomnia,s associ ated with sustained hypertension defined,1
PRISTIQ,insomnia,blood,0
PRISTIQ,insomnia,day in controlled studies s,1
PRISTIQ,insomnia,studies s associ ated with sustained hypertension defined,1
PRISTIQ,insomnia,day in controlled studies s,1
PRISTIQ,insomnia,supine diastolic blood pressure,0
PRISTIQ,insomnia,from mg per day to mg per day in controlled studies wa,0
PRISTIQ,insomnia,s associ ated with sustained hypertension,1
PRISTIQ,diarrhea,pressure,0
PRISTIQ,diarrhea,supine diastolic blood pressure SDBP,0
PRISTIQ,diarrhea,sustained hypertension defined as treatmentemergent supine,0
PRISTIQ,diarrhea,studies was ed with  sustained hypertension,1
PRISTIQ,diarrhea,sustained hypertension defined as treatmentemergent supine,0
PRISTIQ,anxiety,studies was associated with stained hypertension,1
PRISTIQ,anxiety,sustained hypertension defined as treatmentemergent supine,0
PRISTIQ,anxiety,studies was associated with stained,1
PRISTIQ,anxiety,sustained hypertension defined as treatmentemergent supine,0
PRISTIQ,anxiety,with stained hypertension defined as treatmentemergent,1
PRISTIQ,anxiety,sustained hypertension defined as treatmentemergent supine,0
PRISTIQ,anxiety,from mg per day to mg per,0
PRISTIQ,anxiety,as treatmentemergent supine diastolic blood pressure SDBP mm Hg,0
PRISTIQ,anxiety,stained hypertension defined as,1
PRISTIQ,hyperhidrosis,mm Hg and mm Hg above baseline,0
PRISTIQ,hyperhidrosis,ent-emergent  supine diastolic blood,1
PRISTIQ,hyperhidrosis,with sustained hypertension defined as treatm,0
PRISTIQ,hyperhidrosis,treatm,0
PRISTIQ,hyperhidrosis,SDBP mm Hg and mm Hg above baseline for consecutive on,0
PRISTIQ,hyperhidrosis,ent-emergent ,1
PRISTIQ,hyperhidrosis,defined as ent-emergent  supine diastolic blood pressure SDBP,1
PRISTIQ,hyperhidrosis,ent-emergent ,1
PRISTIQ,hyperhidrosis,ent-emergent  supine,1
PRISTIQ,hyperhidrosis,ent-emergent ,1
PRISTIQ,hyperhidrosis,ent-emergent  supine diastolic blood,1
PRISTIQ,seizure,doses of to mg lic ort hostatic hypotension decrease mm,1
PRISTIQ,seizure,ent-emergent  supine diastolic blood,1
PRISTIQ,seizure,lic ort hostatic hypotension decrease mm Hg,1
PRISTIQ,Hyponatremia,adverse reac,1
PRISTIQ,Hyponatremia,adverse reac tion has been identified,1
PRISTIQ,Hyponatremia,postapproval use of PRISTIQ Because these reactions are,0
PRISTIQ,Hyponatremia,Postmarketing Experience The adverse reac,1
PRISTIQ,hyponatremia,reactions are d voluntaril,1
PRISTIQ,hyponatremia,d voluntaril y from a population of,1
PRISTIQ,hyponatremia,are d,1
PRISTIQ,hyponatremia,are d voluntaril,1
PRISTIQ,hyponatremia,d voluntaril y,1
PRISTIQ,hyponatremia,reactions are d,1
PRISTIQ,hyponatremia,these reactions are d,1
PRISTIQ,hyponatremia,are d,1
PRISTIQ,SIADH,oluntarily from a,0
PRISTIQ,SIADH, freq uency or establish,1
PRISTIQ,SIADH, freq uency,1
PRISTIQ,SIADH,to reliably estimate  freq uency or establish a causal,1
PRISTIQ,SIADH, freq uency,1
PRISTIQ,SIADH,oluntarily from a population of uncertain size it is not always possible to reliably,0
PRISTIQ,SIADH, freq uency or establish a,1
PRISTIQ,SIADH,establish,0
PRISTIQ,SIADH, freq,1
PRISTIQ,SIADH,reliably estimate  freq uency or establish a causal,1
PRISTIQ,SIADH, freq,1
PRISTIQ,serum sodium lower than 110 mmol/L,frequency or lish a causal relationship to drug exposure,1
PRISTIQ,serum sodium lower than 110 mmol/L, freq,1
PRISTIQ,serum sodium lower than 110 mmol/L,their frequency or lish a causal relationship to drug exposure Skin and subcutaneous,1
PRISTIQ,serum sodium lower than 110 mmol/L, freq,1
PRISTIQ,serum sodium lower than 110 mmol/L,lish a causal relationship,1
PRISTIQ,serum sodium lower than 110 mmol/L,their frequency or lish a causal relationship to drug exposure Skin and subcutaneous,1
PRISTIQ,serum sodium lower than 110 mmol/L,lish a causal relationship,1
PRISTIQ,serum sodium lower than 110 mmol/L,relationship to drug exposure Skin and subcutaneous,1
PRISTIQ,serum sodium lower than 110 mmol/L,of uncertain size it is not,0
PRISTIQ,serum sodium lower than 110 mmol/L,lish a causal,1
PRISTIQ,serum sodium lower than 110 mmol/L,disorders StevensJohnson syndrome,0
PRISTIQ,serum sodium lower than 110 mmol/L,subcutaneous tissue disorders StevensJohnson syndrome,0
PRISTIQ,serum sodium lower than 110 mmol/L,lish a causal relationship to drug exposure Skin and subcutaneous,1
PRISTIQ,serum sodium lower than 110 mmol/L,subcutaneous tissue disorders StevensJohnson syndrome,0
TAFINLAR,Primary Malignancies,in another section of the label,0
TAFINLAR,Primary Malignancies,Primary Malignancies see Warnings and Precautions Tumor,1
TAFINLAR,Primary Malignancies,WildType,0
TAFINLAR,Primary Malignancies,in,0
TAFINLAR,Primary Malignancies,Primary Malignancies,1
TAFINLAR,Primary Malignancies,Primary Malignancies see Warnings and Precautions Tumor,1
TAFINLAR,Primary Malignancies,Primary Malignancies see Warnings and Precautions,1
TAFINLAR,Primary Malignancies,Primary Malignancies see Warnings and Precautions Tumor,1
TAFINLAR,Primary Malignancies,Primary Malignancies see Warnings and Precautions Tumor,1
TAFINLAR,Primary Malignancies,Precautions Tumor Promotion in BRAF WildType,0
TAFINLAR,Primary Malignancies,label Primary Malignancies see Warnings and,1
TAFINLAR,Primary Malignancies,Precautions Tumor Promotion in BRAF WildType,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,and Tumor Promotion in BRAF Wild-Type Melanoma see Warnings and Precautions Hemorrhage,1
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,Precautions Tumor Promotion in BRAF WildType,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,and Tumor,1
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,New,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,and Tumor Promotion,1
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,of the label,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,see Warnings and Precautions,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,Primary Malignancies see Warnings,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,see Warnings and Precautions,0
TAFINLAR,Hemorrhage,and,0
TAFINLAR,Hemorrhage,see Warnings and Precautions Venous Thromboembolism see Warnings and,0
TAFINLAR,Hemorrhage,Precautions Venous Thromboembolism see,0
TAFINLAR,Venous Thromboembolism,see Warnings,0
TAFINLAR,Venous Thromboembolism,and Precautions,0
TAFINLAR,Venous Thromboembolism,Venous Thromboembolism,1
TAFINLAR,Venous Thromboembolism,Venous Thromboembolism,1
TAFINLAR,Venous Thromboembolism,Hemorrhage see Warnings and Venous,1
TAFINLAR,Venous Thromboembolism,see Warnings and Venous Thromboembolism see Warnings and,1
TAFINLAR,Venous Thromboembolism,Hemorrhage see Warnings and Venous,1
TAFINLAR,Venous Thromboembolism,see Warnings and Precautions Cardiomyopathy see,0
TAFINLAR,Cardiomyopathy,and Precautions,0
TAFINLAR,Ocular Toxicities,Cardiomyopathy,0
TAFINLAR,Ocular Toxicities,Warnings and Ocular Toxicities,1
TAFINLAR,Febrile Reactions,see Warnings and Precautions Febrile Reactions,1
TAFINLAR,Febrile Reactions,and Precautions Serious Skin Toxicity,0
TAFINLAR,Febrile Reactions,Warnings and,0
TAFINLAR,Febrile Reactions,and Precautions Serious,0
TAFINLAR,Febrile Reactions,and Precautions Febrile Reactions see Warnings and,1
TAFINLAR,Febrile Reactions,and Precautions Serious,0
TAFINLAR,Febrile Reactions,and Precautions Febrile Reactions,1
TAFINLAR,Skin Toxicity,Precautions Skin Toxicity see Warnings and Precautions,1
TAFINLAR,Skin Toxicity,and Precautions Febrile Reactions,1
TAFINLAR,Skin Toxicity,Hyperglycemia,0
TAFINLAR,Skin Toxicity,and Precautions,0
TAFINLAR,Skin Toxicity,see Warnings and Precautions Hyperglycemia,0
TAFINLAR,Skin Toxicity,Hyperglycemia see Warnings and Precautions,0
TAFINLAR,Skin Toxicity,Precautions Skin Toxicity,1
TAFINLAR,Skin Toxicity,Skin Toxicity see Warnings,1
TAFINLAR,Hyperglycemia,Hyperglycemia see,1
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,see Warnings and Glucose-6-Phosphate,1
TAFINLAR,hyperkeratosis,as a single agent hyperkeratosis,1
TAFINLAR,hyperkeratosis,see Warnings and Glucose-6-Phosphate,1
TAFINLAR,hyperkeratosis,headache pyrexia arthralgia papilloma alopecia and,0
TAFINLAR,hyperkeratosis,hyperkeratosis headache pyrexia,1
TAFINLAR,hyperkeratosis,single agent hyperkeratosis headache pyrexia,1
TAFINLAR,hyperkeratosis,hyperkeratosis headache pyrexia,1
TAFINLAR,hyperkeratosis,common adverse reactions for TAFINLAR as a single agent,0
TAFINLAR,hyperkeratosis,palmarplantar erythrodysesthesia,0
TAFINLAR,hyperkeratosis,arthralgia papilloma alopecia and,0
TAFINLAR,hyperkeratosis,alopecia and palmarplantar,0
TAFINLAR,headache,headache pyrexia arthralgia,1
TAFINLAR,headache,arthralgia papilloma alopecia,0
TAFINLAR,headache,TAFINLAR as a single agent are,0
TAFINLAR,headache,agent are headache pyrexia arthralgia papilloma alopecia and,1
TAFINLAR,headache,TAFINLAR as a single agent are,0
TAFINLAR,headache,are headache pyrexia arthralgia papilloma,1
TAFINLAR,headache,TAFINLAR as a single agent are,0
TAFINLAR,headache,pyrexia arthralgia papilloma,0
TAFINLAR,headache,headache pyrexia arthralgia papilloma alopecia and,1
TAFINLAR,headache,headache,1
TAFINLAR,headache,headache pyrexia arthralgia papilloma alopecia and,1
TAFINLAR,pyrexia,pyrexia arthralgia papilloma alopecia,1
TAFINLAR,pyrexia,TAFINLAR as a single agent are hyperkeratosis headache,0
TAFINLAR,pyrexia,pyrexia arthralgia papilloma alopecia and palmarplantar,1
TAFINLAR,pyrexia,alopecia,0
TAFINLAR,pyrexia,pyrexia arthralgia papilloma,1
TAFINLAR,pyrexia,pyrexia arthralgia papilloma alopecia,1
TAFINLAR,pyrexia,and palmarplantar,0
TAFINLAR,pyrexia,pyrexia arthralgia papilloma alopecia,1
TAFINLAR,alopecia,palmarplantar erythrodysesthesia syndrome Most,0
TAFINLAR,alopecia,erythrodysesthesia syndrome Most common,0
TAFINLAR,alopecia,hyperkeratosis headache pyrexia arthralgia alopecia and,1
TAFINLAR,alopecia,erythrodysesthesia syndrome Most common,0
TAFINLAR,alopecia,arthralgia alopecia and palmarplantar erythrodysesthesia syndrome,1
TAFINLAR,alopecia,erythrodysesthesia syndrome Most common,0
TAFINLAR,alopecia,headache,0
TAFINLAR,alopecia,single agent are hyperkeratosis headache pyrexia arthralgia,0
TAFINLAR,alopecia,palmarplantar erythrodysesthesia syndrome Most common,0
TAFINLAR,alopecia,agent are hyperkeratosis headache pyrexia,0
TAFINLAR,alopecia,alopecia and palmarplantar,1
TAFINLAR,alopecia,alopecia and palmarplantar erythrodysesthesia syndrome Most,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,common adverse reactions for TAFINLAR in combination with trametinib,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome Most common,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,TAFINLAR,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome Most common,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,papilloma alopecia and,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,alopecia palmar-plantar erythrodysesthesia syndrome,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome Most common adverse,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,papilloma alopecia palmar-plantar,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome,1
TAFINLAR,pyrexia,pyrexia chills fatigue rash nausea,1
TAFINLAR,pyrexia,in combination with trametinib pyrexia,1
TAFINLAR,pyrexia,pyrexia chills fatigue rash nausea,1
TAFINLAR,pyrexia,pyrexia chills fatigue,1
TAFINLAR,pyrexia,pyrexia chills fatigue rash nausea,1
TAFINLAR,pyrexia,Most common adverse reactions for TAFINLAR in,0
TAFINLAR,pyrexia,diarrhea abdominal pain peripheral edema cough headac,0
TAFINLAR,chills,adverse,0
TAFINLAR,chills,edema cough headache arth,0
TAFINLAR,chills,cough,0
TAFINLAR,chills,fatigue,0
TAFINLAR,chills,chills fatigue rash nausea,1
TAFINLAR,chills,fatigue rash nausea vomiting diarrhea abdominal pain,0
TAFINLAR,chills,in combination,0
TAFINLAR,chills,Most common adverse reactions for TAFINLAR in combination with,0
TAFINLAR,chills,are chills fatigue rash,1
TAFINLAR,chills,Most common adverse reactions for TAFINLAR in combination with,0
TAFINLAR,chills,chills fatigue rash nausea vomiting diarrhea,1
TAFINLAR,fatigue,fatigue rash nausea vomiting diarrhea,1
TAFINLAR,fatigue,fatigue rash nausea,1
TAFINLAR,rash,TAFINLAR in combination with trametinib are pyrexia chills fatigue,0
TAFINLAR,nausea,nausea vomiting diarrhea,1
TAFINLAR,nausea,nausea vomiting diarrhea abdominal pain,1
TAFINLAR,nausea,TAFINLAR,0
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,pyrexia chills fatigue nausea vomiting,1
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,e,0
TAFINLAR,nausea,pyrexia chills fatigue nausea vomiting diarrhea abdominal pain,1
TAFINLAR,nausea,e,0
TAFINLAR,nausea,nausea vomiting diarrhea abdominal,1
TAFINLAR,nausea,e,0
TAFINLAR,nausea,nausea vomiting diarrhea abdominal pain peripheral,1
TAFINLAR,vomiting,fatigue rash vomiting,1
TAFINLAR,vomiting,nausea vomiting diarrhea abdominal pain peripheral,1
TAFINLAR,vomiting,vomiting diarrhea abdominal pain peripheral,1
TAFINLAR,vomiting,vomiting diarrhea abdominal pain,1
TAFINLAR,vomiting,combination with trametinib are pyrexia chills fatigue rash,0
TAFINLAR,vomiting,vomiting,1
TAFINLAR,vomiting,night,0
TAFINLAR,vomiting,trametinib are pyrexia chills,0
TAFINLAR,vomiting,rash,0
TAFINLAR,vomiting,vomiting diarrhea abdominal pain peripheral edema,1
TAFINLAR,vomiting,vomiting diarrhea abdominal pain peripheral edema,1
TAFINLAR,diarrhea,rash nausea diarrhea abdominal pain peripheral,1
TAFINLAR,diarrhea,vomiting diarrhea abdominal pain peripheral edema,1
TAFINLAR,diarrhea,fatigue rash nausea diarrhea abdominal,1
TAFINLAR,diarrhea,vomiting diarrhea abdominal pain peripheral edema,1
TAFINLAR,diarrhea,diarrhea abdominal,1
TAFINLAR,diarrhea,night,0
TAFINLAR,diarrhea,in combination with trametinib are pyrexia chills,0
TAFINLAR,diarrhea,diarrhea abdominal pain,1
TAFINLAR,diarrhea,diarrhea abdominal pain peripheral edema,1
TAFINLAR,abdominal pain,are pyrexia chills fatigue rash nausea vomiting,0
TAFINLAR,abdominal pain,abdominal pain peripheral edema cough headache arthralgia,1
TAFINLAR,abdominal pain,abdominal pain peripheral edema cough headache arthralgia,1
TAFINLAR,abdominal pain,abdominal pain peripheral edema cough headache,1
TAFINLAR,abdominal pain,abdominal pain peripheral,1
TAFINLAR,abdominal pain,abdominal pain peripheral edema cough headache,1
TAFINLAR,abdominal pain,vomiting abdominal pain,1
TAFINLAR,abdominal pain,abdominal pain peripheral edema cough headache,1
TAFINLAR,abdominal pain,in combination with trametinib are,0
TAFINLAR,abdominal pain,fatigue rash nausea vomiting abdominal pain peripheral edema cough headache arthralgia,1
TAFINLAR,abdominal pain,in combination with trametinib are,0
TAFINLAR,peripheral edema,nausea vomiting diarrhea abdominal peripheral,1
TAFINLAR,peripheral edema,headache arthralgia,0
TAFINLAR,cough,edema,0
TAFINLAR,cough,peripheral,0
TAFINLAR,arthralgia,sweats decreased appetite constipation and,0
TAFINLAR,arthralgia,arthralgia night sweats decreased,1
TAFINLAR,night sweats,arthralgia,0
TAFINLAR,night sweats,headache night sweats decreased appetite constipation,1
TAFINLAR,night sweats,arthralgia,0
TAFINLAR,night sweats,diarrhea abdominal pain peripheral edema cough,0
TAFINLAR,night sweats,To report,0
TAFINLAR,night sweats,constipation and myalgia EXCERPT To report SUSPECTED A,0
TAFINLAR,night sweats,headache night sweats decreased appetite,1
TAFINLAR,night sweats,constipation and myalgia EXCERPT To report SUSPECTED A,0
TAFINLAR,night sweats,report SUSPECTED A,0
TAFINLAR,decreased appetite,report SUSPECTED ADVERSE,0
TAFINLAR,decreased appetite,night decreased appetite,1
TAFINLAR,decreased appetite,decreased appetite constipation,1
TAFINLAR,decreased appetite,peripheral,0
TAFINLAR,decreased appetite,headache arthralgia,0
TAFINLAR,decreased appetite,sweats,0
TAFINLAR,decreased appetite,headache arthralgia night decreased appetite,1
TAFINLAR,decreased appetite,decreased,1
TAFINLAR,decreased appetite,vomiting diarrhea abdominal pain peripheral edema cough headache arthralgia night,0
TAFINLAR,constipation,constipation and myalgia EXCERPT,1
TAFINLAR,constipation,a abdominal,0
TAFINLAR,constipation,REACTIONS contact,0
TAFINLAR,constipation,sweats decreased constipation,1
TAFINLAR,constipation,REACTIONS contact,0
TAFINLAR,constipation,constipation and myalgia,1
TAFINLAR,constipation,SUSPECTED ADVERSE,0
TAFINLAR,constipation,constipation and myalgia,1
TAFINLAR,constipation,constipation,1
TAFINLAR,myalgia,myalgia EXCERPT To,1
TAFINLAR,myalgia,myalgia,1
TAFINLAR,myalgia,myalgia EXCERPT To,1
TAFINLAR,myalgia,myalgia EXCERPT To,1
TAFINLAR,myalgia,myalgia EXCERPT,1
TAFINLAR,myalgia,myalgia EXCERPT To,1
TAFINLAR,myalgia,myalgia EXCERPT To report SUSPECTED,1
TAFINLAR,myalgia,contact,0
TAFINLAR,hyperkeratosis,papilloma alopecia and palmarplantar erythrodysesthesia syndrome,0
TAFINLAR,hyperkeratosis,in order of decreasing hyperkeratosis headache pyrexia arthralgia,1
TAFINLAR,hyperkeratosis,papilloma alopecia and palmarplantar erythrodysesthesia syndrome,0
TAFINLAR,hyperkeratosis,hyperkeratosis headache pyrexia,1
TAFINLAR,hyperkeratosis,adverse reactions in patients treated with TAFINLAR were in order of decreasing frequency,0
TAFINLAR,hyperkeratosis,hyperkeratosis headache pyrexia arthralgia papilloma alopecia,1
TAFINLAR,hyperkeratosis,hyperkeratosis,1
TAFINLAR,hyperkeratosis,hyperkeratosis headache pyrexia arthralgia papilloma alopecia,1
TAFINLAR,hyperkeratosis,decreasing frequency,0
TAFINLAR,headache,in,0
TAFINLAR,headache,of decreasing,0
TAFINLAR,headache,headache,1
TAFINLAR,headache,headache pyrexia arthralgia papilloma alopecia,1
TAFINLAR,headache,headache pyrexia arthralgia papilloma alopecia and,1
TAFINLAR,headache,headache pyrexia arthralgia,1
TAFINLAR,pyrexia,pyrexia arthralgia papilloma alopecia,1
TAFINLAR,pyrexia,pyrexia arthralgia papilloma alopecia and palmarplantar,1
TAFINLAR,pyrexia,pyrexia arthralgia papilloma,1
TAFINLAR,pyrexia,with TAFINLAR were,0
TAFINLAR,pyrexia,pyrexia arthralgia,1
TAFINLAR,pyrexia,PPES The in,0
TAFINLAR,alopecia,alopecia and palmarplantar erythrodysesthesia syndrome PPES,1
TAFINLAR,alopecia,headache pyrexia arthralgia alopecia and,1
TAFINLAR,alopecia,alopecia and palmarplantar erythrodysesthesia syndrome PPES,1
TAFINLAR,alopecia,alopecia and,1
TAFINLAR,alopecia,hyperkeratosis headache pyrexia arthralgia alopecia and palmarplantar,1
TAFINLAR,alopecia,alopecia and,1
TAFINLAR,alopecia,alopecia,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,papilloma alopecia palmar-plantar,1
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,of decreasing frequency hyperkeratosis headache pyrexia arthralgia papilloma,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,The incidence of adverse events resulting in,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,pyrexia arthralgia,0
TAFINLAR,palmar-plantar erythrodysesthesia syndrome,The incidence of adverse events resulting in permanent discontinuation of study,0
TAFINLAR,PPES,PPES The incidence of adverse events,1
TAFINLAR,PPES,PPES,1
TAFINLAR,PPES,PPES,1
TAFINLAR,PPES,PPES,1
TAFINLAR,PPES,PPES The incidence of adverse,1
TAFINLAR,PPES,PPES The incidence of adverse events,1
TAFINLAR,PPES,papilloma alopecia and,0
TAFINLAR,PPES,and palmarplantar erythrodysesthesia,0
TAFINLAR,PPES,PPES The,1
TAFINLAR,PPES,PPES The incidence of adverse,1
TAFINLAR,pyrexia,pyrexia PPES chills fatigue and,1
TAFINLAR,pyrexia,PPES The incidence of adverse,1
TAFINLAR,pyrexia,pyrexia PPES,1
TAFINLAR,pyrexia,reduction of TAFINLAR pyrexia PPES chills fatigue and,1
TAFINLAR,pyrexia,pyrexia PPES,1
TAFINLAR,pyrexia,most frequent adverse reactions leading to dose reduction of TAFINLAR,0
TAFINLAR,pyrexia,reduction of TAFINLAR pyrexia,1
TAFINLAR,pyrexia,most frequent adverse reactions leading to dose reduction of TAFINLAR,0
TAFINLAR,pyrexia,chills fatigue and headache Table,0
TAFINLAR,PPES,leading to dose reduction,0
TAFINLAR,chills,chills fatigue and headache Table,1
TAFINLAR,chills,chills fatigue and,1
TAFINLAR,fatigue,fatigue and headache Table Selected,1
TAFINLAR,fatigue,fatigue and,1
TAFINLAR,fatigue,Adverse Reactions Occurring,0
TAFINLAR,fatigue,Occurring in All Gra,0
TAFINLAR,fatigue,fatigue and headache,1
TAFINLAR,fatigue,PPES fatigue and headache Table Selected Common,1
TAFINLAR,fatigue,fatigue and headache,1
TAFINLAR,fatigue,pyrexia PPES chills,0
TAFINLAR,fatigue,chills,0
TAFINLAR,headache,fatigue and,0
TAFINLAR,headache,chills fatigue headache,1
TAFINLAR,headache,fatigue and,0
TAFINLAR,headache,Reactions Occurring in All Grades,0
TAFINLAR,headache,to dose reduction of TAFINLAR were pyrexia PPES chills fatigue,0
TAFINLAR,headache,headache Table Selected,1
TAFINLAR,headache,dose reduction of TAFINLAR were pyrexia PPES,0
TAFINLAR,hyperkeratosis,hyperkeratosis n and constipation n,1
TAFINLAR,hyperkeratosis,skin papilloma and papilloma d,0
TAFINLAR,hyperkeratosis,hyperkeratosis n and,1
TAFINLAR,hyperkeratosis,constipation n c Includes skin papilloma and,0
TAFINLAR,hyperkeratosis,n c,0
TAFINLAR,constipation,n,0
TAFINLAR,papilloma,papilloma d Includes,1
TAFINLAR,papilloma,papilloma d Includes squamous cell carcinoma,1
TAFINLAR,papilloma,skin papilloma papilloma d Includes squamous cell,1
TAFINLAR,papilloma,papilloma d Includes squamous cell carcinoma,1
TAFINLAR,papilloma,papilloma,1
TAFINLAR,papilloma,to hyperkeratosis n and constipation n c,0
TAFINLAR,squamous cell carcinoma of the skin,Includes skin papilloma,0
TAFINLAR,squamous cell carcinoma of the skin,cutaneous squamous cell carcinoma were required to,0
TAFINLAR,squamous cell carcinoma of the skin,papilloma d squamous cell carcinoma of the skin and keratoacanthoma,1
TAFINLAR,squamous cell carcinoma of the skin,cutaneous squamous cell carcinoma were required to,0
TAFINLAR,squamous cell carcinoma of the skin,skin papilloma and papilloma d,0
TAFINLAR,squamous cell carcinoma of the skin,carcinoma were,0
TAFINLAR,squamous cell carcinoma of the skin,papilloma d squamous cell carcinoma of the,1
TAFINLAR,squamous cell carcinoma of the skin,the skin and,1
TAFINLAR,squamous cell carcinoma of the skin,cutaneous squamous cell carcinoma were,0
TAFINLAR,squamous cell carcinoma of the skin,d squamous cell,1
TAFINLAR,keratoacanthoma,be reported as Grade per pr,0
TAFINLAR,keratoacanthoma,skin keratoacanthoma e Cases of,1
TAFINLAR,keratoacanthoma,be reported as Grade per pr,0
TAFINLAR,keratoacanthoma,keratoacanthoma e Cases,1
TAFINLAR,keratoacanthoma,keratoacanthoma e Cases of cutaneous,1
TAFINLAR,keratoacanthoma,skin papilloma and papilloma d Includes squamous cell carcinoma of the,0
TAFINLAR,keratoacanthoma,keratoacanthoma e Cases of,1
TAFINLAR,keratoacanthoma,keratoacanthoma e Cases of,1
TAFINLAR,cutaneous squamous cell carcinoma,not applicable,0
TAFINLAR,cutaneous squamous cell carcinoma,Includes squamous cell carcinoma of the,0
TAFINLAR,hypophosphatemia,hypophosphatemia n Other clinically important adverse,1
TAFINLAR,hypophosphatemia,laboratory abnormality limited hypophosphatemia n Other clinically,1
TAFINLAR,hypophosphatemia,hypophosphatemia n Other clinically important adverse,1
TAFINLAR,hypophosphatemia,abnormality limited hypophosphatemia n Other clinically important adverse,1
TAFINLAR,hypophosphatemia,hypophosphatemia n Other clinically important adverse,1
TAFINLAR,hypophosphatemia,Grade laboratory abnormality limited hypophosphatemia,1
TAFINLAR,hypophosphatemia,hypophosphatemia n Other clinically important adverse,1
TAFINLAR,hypophosphatemia,hypophosphatemia n Other clinically,1
TAFINLAR,hypophosphatemia,hypophosphatemia,1
TAFINLAR,hypophosphatemia,limited to,0
TAFINLAR,bullous rash,bullous rash Renal,1
TAFINLAR,bullous rash,limited to,0
TAFINLAR,bullous rash,Hypersensitivity manifesting bullous rash,1
TAFINLAR,bullous rash,ntestinal Disorders Pancreatitis,0
TAFINLAR,bullous rash,Disorders Hypersensitivity manifesting bullous rash Renal and Urinary Disorders Interstitial,1
TAFINLAR,bullous rash,ntestinal Disorders Pancreatitis,0
TAFINLAR,bullous rash,Disorders Hypersensitivity manifesting bullous rash Renal,1
TAFINLAR,bullous rash,ntestinal Disorders Pancreatitis,0
TAFINLAR,bullous rash,System Disorders,0
TAFINLAR,bullous rash,Hypersensitivity manifesting bullous,1
TAFINLAR,bullous rash,and,0
TAFINLAR,bullous rash,Urinary Disorders Interstitial nephritis BRAF VE or,0
TAFINLAR,bullous rash,manifesting bullous,1
TAFINLAR,Interstitial nephritis,Disorders Hypersensitivity manifesting as bullous rash,0
TAFINLAR,Interstitial nephritis,Interstitial nephritis,1
TAFINLAR,Interstitial nephritis,Interstitial nephritis BRAF VE,1
TAFINLAR,Interstitial nephritis,Interstitial nephritis BRAF VE or VK Unresectable,1
TAFINLAR,Interstitial nephritis,Interstitial nephritis BRAF VE or,1
TAFINLAR,Interstitial nephritis,bullous rash,0
TAFINLAR,Interstitial nephritis,Urinary Interstitial,1
TAFINLAR,Interstitial nephritis,Interstitial nephritis BRAF VE or VK,1
TAFINLAR,Interstitial nephritis,VE or VK Unresectable or Metastatic Melanoma The,0
TAFINLAR,Interstitial nephritis,Renal and Urinary Interstitial nephritis BRAF VE,1
TAFINLAR,Interstitial nephritis,VE or VK Unresectable or Metastatic Melanoma The,0
TAFINLAR,pyrexia,led to dose reductions in and dose,0
TAFINLAR,pyrexia,Adverse reactions led to,0
TAFINLAR,pyrexia,discontinuation pyrexia Adverse,1
TAFINLAR,pyrexia,Adverse reactions led to,0
TAFINLAR,pyrexia,interruptions,0
TAFINLAR,Pyrexia,Pyrexia,1
TAFINLAR,Pyrexia,in combination with Pyrexia chills,1
TAFINLAR,Pyrexia,Pyrexia,1
TAFINLAR,Pyrexia,Pyrexia,1
TAFINLAR,chills,chills and decreas,0
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,and pyrexia,0
TAFINLAR,nausea,in combination,0
TAFINLAR,nausea,nausea were the most,1
TAFINLAR,nausea,nausea,1
TAFINLAR,nausea,reductions,0
TAFINLAR,pyrexia,dose reductions pyrexia chills and decreased ejection,1
TAFINLAR,pyrexia,reductions,0
TAFINLAR,pyrexia,pyrexia chills,1
TAFINLAR,pyrexia,cited for,0
TAFINLAR,pyrexia,dose reductions pyrexia,1
TAFINLAR,pyrexia,cited for,0
TAFINLAR,pyrexia,for dose reductions pyrexia chills and decreased ejection fraction,1
TAFINLAR,pyrexia,cited for,0
TAFINLAR,peripheral edema,the,0
TAFINLAR,peripheral edema,terms rash rash generalized rash,0
TAFINLAR,peripheral edema,the following peripheral edema edema and lymphedema,1
TAFINLAR,peripheral edema,terms rash rash generalized rash,0
TAFINLAR,peripheral edema,peripheral edema edema and,1
TAFINLAR,peripheral edema,rash,0
TAFINLAR,peripheral edema,Events version,0
TAFINLAR,lymphedema,lymphedema c Includes the following,1
TAFINLAR,lymphedema,lymphedema c Includes,1
TAFINLAR,lymphedema,lymphedema c Includes the following terms,1
TAFINLAR,lymphedema,lymphedema,1
TAFINLAR,lymphedema,peripheral edema edema lymphedema,1
TAFINLAR,lymphedema,lymphedema,1
TAFINLAR,rash,erythematous rash papular rash vesicular rash,0
TAFINLAR,rash,rash rash generalized rash pruritic,1
TAFINLAR,rash,rash rash generalized rash pruritic rash,1
TAFINLAR,rash,rash rash generalized rash pruritic rash,1
TAFINLAR,rash,rash rash generalized rash,1
TAFINLAR,rash,rash vesicular,0
TAFINLAR,rash generalized,rash generalized,1
TAFINLAR,rash pruritic,rash pruritic,1
TAFINLAR,rash pruritic,rash papular rash vesicular rash macular,0
TAFINLAR,rash pruritic,rash,0
TAFINLAR,rash erythematous,dema and lymphedema c Includes the following,0
TAFINLAR,rash erythematous,rash rash generalized rash rash erythematous rash papular rash,1
TAFINLAR,rash erythematous,dema and lymphedema c Includes the following,0
TAFINLAR,rash erythematous,rash rash erythematous rash,1
TAFINLAR,rash erythematous,dema and lymphedema c Includes the following,0
TAFINLAR,rash erythematous,papular rash,0
TAFINLAR,rash erythematous,terms rash rash generalized rash pruritic,0
TAFINLAR,rash erythematous,macular and rash maculopapular d Includes,0
TAFINLAR,rash erythematous,papular rash vesicular,0
TAFINLAR,rash papular,following terms rash rash,0
TAFINLAR,rash papular,the following terms,0
TAFINLAR,rash vesicular,pruritic rash erythematous rash rash vesicular rash macular and rash maculopapular,1
TAFINLAR,rash vesicular,the following terms,0
TAFINLAR,rash vesicular,rash erythematous rash rash vesicular,1
TAFINLAR,rash vesicular,the following terms,0
TAFINLAR,rash vesicular,erythematous rash rash vesicular,1
TAFINLAR,rash vesicular,erythematous rash rash vesicular,1
TAFINLAR,rash vesicular,rash vesicular,1
TAFINLAR,rash vesicular,rash rash,0
TAFINLAR,rash vesicular,rash rash generalized rash pruritic rash erythematous rash papular,0
TAFINLAR,rash vesicular,maculopapular d Includes the following terms abdominal pain,0
TAFINLAR,rash vesicular,rash vesicular rash,1
TAFINLAR,rash macular,pruritic rash erythematous rash papular rash vesicular,0
TAFINLAR,rash macular,papular rash rash,1
TAFINLAR,rash macular,abdominal pain,0
TAFINLAR,rash macular,rash macular and rash,1
TAFINLAR,rash macular,abdominal pain,0
TAFINLAR,rash macular,rash pruritic rash,0
TAFINLAR,rash macular,rash macular and rash maculopapular,1
TAFINLAR,rash macular,abdominal pain,0
TAFINLAR,rash macular,pain,0
TAFINLAR,rash maculo-papular,Includes the following terms abdominal pain abdominal pain upper abdominal pain,0
TAFINLAR,rash maculo-papular,rash maculo-papular d,1
TAFINLAR,rash maculo-papular,pain,0
TAFINLAR,rash maculo-papular,rash vesicular rash,0
TAFINLAR,rash maculo-papular,rash maculo-papular d Includes the following,1
TAFINLAR,abdominal pain upper,pain,0
TAFINLAR,abdominal pain upper,abdominal pain lower and abdominal discomfort e Includes the following terms brain,0
TAFINLAR,abdominal pain upper,following terms brain stem,0
TAFINLAR,abdominal pain lower,abdominal pain abdominal pain abdominal pain lower,1
TAFINLAR,abdominal pain lower,pain abdominal pain lower,1
TAFINLAR,abdominal pain lower,maculopapular d Includes the following terms abdominal pain,0
TAFINLAR,abdominal pain lower,abdominal pain lower,1
TAFINLAR,abdominal pain lower,maculopapular d Includes the following terms abdominal pain,0
TAFINLAR,abdominal discomfort,terms brain,0
TAFINLAR,abdominal discomfort,abdominal discomfort e,1
TAFINLAR,abdominal discomfort,e Includes the following,0
TAFINLAR,abdominal discomfort,pain lower abdominal discomfort,1
TAFINLAR,abdominal discomfort,e Includes the following,0
TAFINLAR,abdominal discomfort,abdominal,0
TAFINLAR,brain stem hemorrhage,brain stem hemorrhage cerebral hemorrhage gastric,1
TAFINLAR,brain stem hemorrhage,brain,1
TAFINLAR,brain stem hemorrhage,brain stem hemorrhage cerebral,1
TAFINLAR,brain stem hemorrhage,brain,1
TAFINLAR,brain stem hemorrhage,e Includes the following brain,1
TAFINLAR,brain stem hemorrhage,hematuria,0
TAFINLAR,brain stem hemorrhage,gingival hemorrhage hematuria vaginal hemorr,0
TAFINLAR,brain stem hemorrhage,brain,1
TAFINLAR,cerebral hemorrhage,hemorrhage hematuria vaginal hemorrhage hemorrhage intr,0
TAFINLAR,cerebral hemorrhage,gastric hemorrhage epistaxis,0
TAFINLAR,cerebral hemorrhage,cerebral hemorrhage gastric hemorrhage epistaxis gingival hemorrhage,1
TAFINLAR,cerebral hemorrhage,gastric hemorrhage epistaxis,0
TAFINLAR,cerebral hemorrhage,stem cerebral,1
TAFINLAR,gastric hemorrhage,gastric hemorrhage epistaxis gingival,1
TAFINLAR,gastric hemorrhage,hemorrhage cerebral gastric hemorrhage epistaxis gingival hemorrhage hematuria vaginal,1
TAFINLAR,gastric hemorrhage,gastric hemorrhage epistaxis gingival,1
TAFINLAR,gastric hemorrhage,brain stem hemorrhage cerebral gastric hemorrhage epistaxis,1
TAFINLAR,gastric hemorrhage,gastric hemorrhage epistaxis gingival,1
TAFINLAR,gastric hemorrhage,brain stem hemorrhage cerebral gastric hemorrhage,1
TAFINLAR,gastric hemorrhage,stem hemorrhage cerebral gastric hemorrhage epistaxis gingival,1
TAFINLAR,gastric hemorrhage,brain stem hemorrhage cerebral gastric hemorrhage,1
TAFINLAR,gastric hemorrhage,cerebral,0
TAFINLAR,gastric hemorrhage,brain stem hemorrhage cerebral gastric hemorrhage epistaxis,1
TAFINLAR,gastric hemorrhage,cerebral,0
TAFINLAR,gastric hemorrhage,hemorrhage cerebral hemorrhage,0
TAFINLAR,gastric hemorrhage,brain stem hemorrhage cerebral gastric hemorrhage epistaxis gingival hemorrhage hematuria vaginal,1
TAFINLAR,gastric hemorrhage,hemorrhage cerebral hemorrhage,0
TAFINLAR,gastric hemorrhage,hemorrhage,0
TAFINLAR,epistaxis,hemorrhage gastric epistaxis gingival hemorrhage hematuria,1
TAFINLAR,epistaxis,hemorrhage,0
TAFINLAR,epistaxis,epistaxis gingival hemorrhage hematuria vaginal hemorrhage,1
TAFINLAR,epistaxis,epistaxis gingival hemorrhage,1
TAFINLAR,epistaxis,epistaxis,1
TAFINLAR,gingival hemorrhage,hemorrhage gingival hemorrhage,1
TAFINLAR,gingival hemorrhage,hemorrhage gingival hemorrhage hematuria vaginal hemorrhage hemorrhage,1
TAFINLAR,gingival hemorrhage,hemorrhage gingival hemorrhage,1
TAFINLAR,gingival hemorrhage,eye hemorrhage and,0
TAFINLAR,hematuria,hemorrhage epistaxis gingival hematuria vaginal hemorrhage hemorrhage intracranial,1
TAFINLAR,hematuria,eye hemorrhage and,0
TAFINLAR,hematuria,hematuria vaginal hemorrhage hemorrhage intracranial,1
TAFINLAR,hematuria,hematuria vaginal hemorrhage hemorrhage intracranial eye,1
TAFINLAR,hematuria,vaginal hemorrhage hemorrhage intracranial,0
TAFINLAR,hematuria,cerebral hemorrhage,0
TAFINLAR,hematuria,epistaxis gingival hematuria,1
TAFINLAR,hematuria,cerebral hemorrhage,0
TAFINLAR,hematuria,hematuria vaginal,1
TAFINLAR,hematuria,intracranial eye hemorrhage and,0
TAFINLAR,hematuria,hematuria vaginal,1
TAFINLAR,hematuria,eye,0
TAFINLAR,vaginal hemorrhage,gastric hemorrhage epistaxis gingival,0
TAFINLAR,hemorrhage intracranial,hemorrhage intracranial,1
TAFINLAR,hemorrhage intracranial,vaginal hemorrhage intracranial,1
TAFINLAR,hemorrhage intracranial,gingival hemorrhage hematuria vaginal hemorrhage intracranial,1
TAFINLAR,hemorrhage intracranial,vaginal hemorrhage intracranial,1
TAFINLAR,eye hemorrhage,hemorrhage hemorrhage eye hemorrhage,1
TAFINLAR,eye hemorrhage,vaginal hemorrhage intracranial,1
TAFINLAR,eye hemorrhage,hematuria vaginal hemorrhage hemorrhage eye hemorrhage and vitreous,1
TAFINLAR,eye hemorrhage,vaginal hemorrhage intracranial,1
TAFINLAR,eye hemorrhage,hemorrhage hematuria vaginal hemorrhage,0
TAFINLAR,eye hemorrhage,eye hemorrhage and vitreous hemorrhage,1
TAFINLAR,eye hemorrhage,following terms renal failure and,0
TAFINLAR,eye hemorrhage,hematuria vaginal hemorrhage hemorrhage eye hemorrhage,1
TAFINLAR,eye hemorrhage,following terms renal failure and,0
TAFINLAR,vitreous hemorrhage,hemorrhage vitreous hemorrhage,1
TAFINLAR,vitreous hemorrhage,following terms renal failure and,0
TAFINLAR,vitreous hemorrhage,vitreous hemorrhage f Includes,1
TAFINLAR,vitreous hemorrhage,hemorrhage intracranial eye hemorrhage vitreous hemorrhage,1
TAFINLAR,vitreous hemorrhage,intracranial eye hemorrhage vitreous hemorrhage f Includes,1
TAFINLAR,vitreous hemorrhage,hemorrhage intracranial eye hemorrhage vitreous hemorrhage,1
TAFINLAR,vitreous hemorrhage,vaginal hemorrhage hemorrhage intracranial,0
TAFINLAR,vitreous hemorrhage,hemorrhage intracranial eye hemorrhage vitreous hemorrhage,1
TAFINLAR,renal failure,renal failure and renal failure acute Other,1
TAFINLAR,renal failure,vitreous hemorrhage f,0
TAFINLAR,renal failure,eye hemorrhage and vitreous,0
TAFINLAR,renal failure,hemorrhage and vitreous hemorrhage,0
TAFINLAR,renal failure,the following renal failure,1
TAFINLAR,renal failure,renal failure and,1
TAFINLAR,renal failure,terms,0
TAFINLAR,renal failure,Includes the following renal failure,1
TAFINLAR,renal failure,following renal,1
TAFINLAR,renal failure acute,renal failure acute Other clinically,1
TAFINLAR,renal failure acute,renal failure acute Other clinically important adverse reactions,1
TAFINLAR,renal failure acute,renal failure acute Other clinically,1
TAFINLAR,renal failure acute,failure acute,1
TAFINLAR,renal failure acute,following terms renal failure,0
TAFINLAR,renal failure acute,failure acute Other,1
TAFINLAR,renal failure acute,failure renal failure acute,1
TAFINLAR,renal failure acute,and vitreous hemorrhage f Includes the,0
TAFINLAR,renal failure acute,renal failure renal failure acute Other clinically important adverse reactions,1
TAFINLAR,renal failure acute,and vitreous hemorrhage f Includes the,0
TAFINLAR,renal failure acute,renal failure renal,1
TAFINLAR,Vision blurred,Gastrointestinal,0
TAFINLAR,Vision blurred,blindness,0
TAFINLAR,Vision blurred,were,0
TAFINLAR,Vision blurred,trametinib were Eye Vision blurred,1
TAFINLAR,Vision blurred,in combination,0
TAFINLAR,Vision blurred,patients treated with TAFINLAR in combination with trametinib,0
TAFINLAR,transient blindness,Gastrointestinal Disorders Stomatitis pancreatitis General Disorders and,0
TAFINLAR,transient blindness,Eye Disorders Vision transient blindness,1
TAFINLAR,transient blindness,Disorders and Administr,0
TAFINLAR,transient blindness,Disorders,0
TAFINLAR,transient blindness,were Eye Disorders Vision transient,1
TAFINLAR,transient blindness,Disorders,0
TAFINLAR,transient blindness,combination with trametinib were Eye Disorders,0
TAFINLAR,transient blindness,Vision transient,1
TAFINLAR,transient blindness,Vision transient blindness Gastrointestinal Disorders Stomatitis pancreatitis,1
TAFINLAR,transient blindness,Vision transient,1
TAFINLAR,Stomatitis,transient blindness Gastrointestinal Stomatitis pancreatitis General Disorders and Administration,1
TAFINLAR,Stomatitis,Vision transient,1
TAFINLAR,Stomatitis,Vision blurred,0
TAFINLAR,Stomatitis,Stomatitis pancreatitis,1
TAFINLAR,Stomatitis,Stomatitis,1
TAFINLAR,Stomatitis,Stomatitis pancreatitis General Disorders and Administration,1
TAFINLAR,Stomatitis,blurred transient blindness Gastrointestinal Stomatitis pancreatitis General,1
TAFINLAR,Stomatitis,Stomatitis pancreatitis General Disorders and Administration,1
TAFINLAR,Stomatitis,Stomatitis pancreatitis General Disorders and,1
TAFINLAR,Stomatitis,Disorders Vision blurred,0
TAFINLAR,pancreatitis,pancreatitis,1
TAFINLAR,pancreatitis,pancreatitis,1
TAFINLAR,pancreatitis,Eye Disorders Vision,0
TAFINLAR,pancreatitis,Stomatitis,0
TAFINLAR,pancreatitis,pancreatitis General Disorders and Administration Site,1
TAFINLAR,pancreatitis,pancreatitis General,1
TAFINLAR,pancreatitis,Site Conditions,0
TAFINLAR,pancreatitis,pancreatitis General Disorders and Administration,1
TAFINLAR,pancreatitis,Eye Disorders Vision blurred,0
TAFINLAR,pancreatitis,Eye Disorders Vision,0
TAFINLAR,Asthenia,Asthenia,1
TAFINLAR,Asthenia,Administration Site Asthenia Infections and Infestations Cellulitis,1
TAFINLAR,Asthenia,Asthenia,1
TAFINLAR,Asthenia,and Administration Site Asthenia,1
TAFINLAR,Asthenia,Asthenia,1
TAFINLAR,Asthenia,Asthenia Infections and Infestations Cellulitis folliculitis,1
TAFINLAR,Asthenia,Infections and Infestations Cellulitis folliculitis paronychia rash,0
TAFINLAR,Asthenia,Administration Site Asthenia Infections,1
TAFINLAR,Asthenia,Infections and Infestations Cellulitis folliculitis paronychia rash,0
TAFINLAR,Asthenia,Asthenia Infections and,1
TAFINLAR,Asthenia,and Administration Site Conditions,0
TAFINLAR,Asthenia,Asthenia Infections and Infestations Cellulitis,1
TAFINLAR,Asthenia,and Administration Site Conditions,0
TAFINLAR,Asthenia,Disorders and Administration,0
TAFINLAR,Cellulitis,and Cellulitis folliculitis paronychia rash,1
TAFINLAR,Cellulitis,Disorders and Administration,0
TAFINLAR,Cellulitis,Conditions,0
TAFINLAR,Cellulitis,Cellulitis folliculitis paronychia rash,1
TAFINLAR,Cellulitis,and Cellulitis,1
TAFINLAR,Cellulitis,Cellulitis folliculitis paronychia rash,1
TAFINLAR,Cellulitis,Cellulitis folliculitis paronychia rash,1
TAFINLAR,Cellulitis,paronychia rash pustular Neoplasms Benign Malignant and Unspecified,0
TAFINLAR,Cellulitis,and,0
TAFINLAR,Cellulitis,Cellulitis folliculitis paronychia rash pustular,1
TAFINLAR,Cellulitis,and,0
TAFINLAR,Cellulitis,and Infestations,0
TAFINLAR,folliculitis,Conditions Asthenia Infections and Infestations Cellulitis,0
TAFINLAR,folliculitis,folliculitis paronychia rash pustular Neoplasms,1
TAFINLAR,folliculitis,folliculitis paronychia rash pustular Neoplasms,1
TAFINLAR,paronychia,Malignant and Unspecified including cysts and polyps S,0
TAFINLAR,paronychia,Infections and Infestations Cellulitis folliculitis,0
TAFINLAR,rash pustular,folliculitis rash pustular Neoplasms Benign Malignant and,1
TAFINLAR,rash pustular,Infections and Infestations Cellulitis folliculitis,0
TAFINLAR,rash pustular,rash pustular,1
TAFINLAR,rash pustular,Malignant and Unspecified including cysts and polyps Skin,0
TAFINLAR,rash pustular,Cellulitis folliculitis rash pustular,1
TAFINLAR,Skin papilloma,polyps,0
TAFINLAR,Skin papilloma,Skin and Subcutaneous Tissue Disorders Palmarplantar erythrodysesthesia,0
TAFINLAR,Skin papilloma,Tissue Disorders Palmarplantar erythrodysesthesia,0
TAFINLAR,Skin papilloma,Unspecified including cysts and Skin papilloma,1
TAFINLAR,Skin papilloma,including cysts and Skin papilloma Skin and Subcutaneous Tissue Disorders,1
TAFINLAR,Skin papilloma,Unspecified including cysts and Skin papilloma,1
TAFINLAR,Skin papilloma,pustular Neoplasms Benign Malignant and,0
TAFINLAR,Skin papilloma,Skin papilloma Skin and Subcutaneous Tissue Disorders,1
TAFINLAR,Skin papilloma,erythrodysesthesia,0
TAFINLAR,Skin papilloma,and Skin papilloma,1
TAFINLAR,Skin papilloma,cysts and Skin papilloma Skin and Subcutaneous Tissue,1
TAFINLAR,Skin papilloma,and Skin papilloma,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome hyperkeratosis hyperhidrosis Vascular Disorders Hypertension,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,and Skin papilloma,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome hyperkeratosis hyperhidrosis Vascular,1
TAFINLAR,Palmar-plantar erythrodysesthesia syndrome,Disorders Hypertension,0
TAFINLAR,hyperkeratosis,Table,0
TAFINLAR,hyperkeratosis,erythrodysesthesia hyperkeratosis hyperhidrosis Vascular Disorders,1
TAFINLAR,hyperkeratosis,Table,0
TAFINLAR,hyperkeratosis,Table TreatmentEmergent,0
TAFINLAR,hyperkeratosis,erythrodysesthesia syndrome,0
TAFINLAR,hyperkeratosis,hyperkeratosis hyperhidrosis Vascular,1
TAFINLAR,hyperhidrosis,Palmarplantar erythrodysesthesia syndrome hyperhidrosis Vascular Disorders Hypertension Table,1
TAFINLAR,hyperhidrosis,hyperkeratosis hyperhidrosis Vascular,1
TAFINLAR,hyperhidrosis,hyperhidrosis Vascular Disorders,1
TAFINLAR,hyperhidrosis,Subcutaneous Tissue Disorders,0
TAFINLAR,hyperhidrosis,Tissue Disorders Palmarplantar,0
TAFINLAR,hyperhidrosis,syndrome hyperhidrosis,1
TAFINLAR,hyperhidrosis,Tissue Disorders Palmarplantar,0
TAFINLAR,hyperhidrosis,Tissue Disorders Palmarplantar erythrodysesthesia syndrome,0
TAFINLAR,hyperhidrosis,hyperhidrosis Vascular Disorders Hypertension Table,1
TAFINLAR,hyperhidrosis,Tissue Disorders Palmarplantar erythrodysesthesia syndrome,0
TAFINLAR,Hypertension,hyperkeratosis hyperhidrosis Vascular Hypertension Table TreatmentEmergent Laboratory,1
TAFINLAR,Hypertension,Tissue Disorders Palmarplantar erythrodysesthesia syndrome,0
TAFINLAR,Hypertension,Abnormalities Occurring at All,0
TAFINLAR,QTcF prolongation,QT Prolongation In QTcF prolongation to,1
TAFINLAR,QTcF prolongation,Abnormalities Occurring at All,0
TAFINLAR,QTcF prolongation,In QTcF prolongation,1
TAFINLAR,QTcF prolongation,in of patients treated with TAFINLAR,0
TAFINLAR,QTcF prolongation,to msec occurred in of patients treated with TAFINLAR in combination,0
TAFINLAR,QTcF prolongation,TAFINLAR,0
TAFINLAR,QTcF prolongation,Prolongation In,0
TAFINLAR,QTcF prolongation,QTcF prolongation to msec,1
TAFINLAR,QTcF was increased,in of,0
TAFINLAR,QTcF was increased,and in,0
TAFINLAR,QTcF was increased,TAFINLAR as a single agent,0
TAFINLAR,QTcF was increased,agent QTcF was increased more than,1
TAFINLAR,QTcF was increased,TAFINLAR as a single agent,0
TAFINLAR,QTcF was increased,a single agent QTcF was increased more than msec from baseline,1
TAFINLAR,QTcF was increased,TAFINLAR as a single agent,0
TAFINLAR,QTcF was increased,QTcF was,1
TAFINLAR,QTcF was increased,QTcF was increased more than msec,1
TAFINLAR,QTcF was increased,The,0
TAFINLAR,Retinal vein occlusion,and Precautions ( Cardiomyopathy see Warnings and Precautions,1
TAFINLAR,Retinal vein occlusion,Precautions,0
TAFINLAR,Retinal vein occlusion,Precautions Venous Thromboembolism see ings,1
TAFINLAR,Retinal vein occlusion,Precautions Venous Thromboembolism,0
TAFINLAR,Retinal vein occlusion,see ings and Precautions (,1
TAFINLAR,Retinal vein occlusion,Ocular Toxicities see War,0
TAFINLAR,Interstitial lung disease,[see W arnings and Precautions Ocular Toxicities,1
TAFINLAR,Interstitial lung disease,Thromboembolism see Warnings and Cardiomyopathy,1
TAFINLAR,Interstitial lung disease,Warnings and Cardiomyopathy [see W,1
TAFINLAR,Interstitial lung disease,Precautions Ocular Toxicities see,0
TAFINLAR,Interstitial lung disease,ings and Precautions,0
TAFINLAR,Interstitial lung disease,Warnings,0
TAFINLAR,"primary malignancies, cutaneous",see Warnings and,0
TAFINLAR,"primary malignancies, cutaneous",cautions (5.5)] * Ocular Toxicities see Warnings and,1
TAFINLAR,"primary malignancies, cutaneous","Cardiomyopathy see Warnings and cautions (5.5)]  
 *    Ocular  Toxicities",1
TAFINLAR,"primary malignancies, cutaneous",cautions (5.5)] * Ocular Toxicities see Warnings and,1
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,agent are hyperkeratosis hea,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,GlucosePhosphate,0
TAFINLAR,Tumor Promotion in BRAF Wild-Type Melanoma,common adverse reactions for TAFINLAR,0
TAFINLAR,Increased cell proliferation,Warnings and * Most common,1
TAFINLAR,Increased cell proliferation,Precautions,0
TAFINLAR,Hemorrhage,agent,0
TAFINLAR,Hemorrhage,as a single agent  hyperkera tosis headache pyrexia,1
TAFINLAR,Hemorrhage,agent,0
TAFINLAR,Hemorrhage, hyperkera tosis headache pyrexia,1
TAFINLAR,Hemorrhage,and,0
TAFINLAR,Hemorrhage, hyperkera tosis headache pyrexia arthralgia,1
TAFINLAR,Hemorrhage, hyperkera tosis headache pyrexia,1
TAFINLAR,hemorrhagic events,"eadache, pyrexia, arthralgia papilloma",1
TAFINLAR,hemorrhagic events,"single agent are hyperkeratosis eadache, pyrexia,  arthralgia papilloma alopecia and palmarplantar",1
TAFINLAR,hemorrhagic events,"eadache, pyrexia, arthralgia papilloma",1
TAFINLAR,hemorrhagic events,"are hyperkeratosis eadache, pyrexia,  arthralgia papilloma alopecia and",1
TAFINLAR,hemorrhagic events,"eadache, pyrexia, arthralgia papilloma",1
TAFINLAR,hemorrhagic events,palmarplantar,0
TAFINLAR,Venous Thromboembolism,Most common adverse for TAFINLAR in,1
TAFINLAR,Venous Thromboembolism,trametinib are pyrexia chills fatigue rash nausea vomiting diarrhea abdominal pai,0
TAFINLAR,Venous Thromboembolism,vomiting diarrhea abdominal,0
TAFINLAR,Venous Thromboembolism,palmarplantar erythrodysesthesia syndrome Most common adverse,0
TAFINLAR,Venous Thromboembolism,are pyrexia chills fatigue rash nausea,0
TAFINLAR,Venous Thromboembolism,in combi,1
TAFINLAR,Venous Thromboembolism,fatigue rash nausea vomiting diarrhea abdominal pai,0
TAFINLAR,Deep vein thrombosis,TAFINLAR in tion,1
TAFINLAR,Deep vein thrombosis,nausea vomiting diarrhea abdominal pain peripheral,0
TAFINLAR,Deep vein thrombosis,tion with trametinib are,1
TAFINLAR,Deep vein thrombosis,nausea vomiting diarrhea abdominal pain peripheral,0
TAFINLAR,Deep vein thrombosis,peripheral edema,0
TAFINLAR,pulmonary embolism,"trametinib pyrexia, chills,",1
TAFINLAR,pulmonary embolism,nausea vomiting,0
TAFINLAR,Cardiomyopathy,"lgia, night sw",1
TAFINLAR,Cardiomyopathy,"edema cough headache lgia,",1
TAFINLAR,Cardiomyopathy,"cough headache lgia, night sw eats decreased",1
TAFINLAR,Cardiomyopathy,"edema cough headache lgia,",1
TAFINLAR,Cardiomyopathy,"lgia, night sw eats decreased appetite constipation",1
TAFINLAR,Cardiomyopathy,"edema cough headache lgia,",1
TAFINLAR,Cardiomyopathy,"cough headache lgia, night sw eats decreased appetite constipation",1
TAFINLAR,Cardiomyopathy,"edema cough headache lgia,",1
TAFINLAR,Cardiomyopathy,"peripheral edema cough headache lgia, night sw",1
TAFINLAR,Cardiomyopathy,"edema cough headache lgia,",1
TAFINLAR,Cardiomyopathy,headache arthra,0
TAFINLAR,Ocular Toxicities,at 1-800-FDA-10,1
TAFINLAR,Ocular Toxicities,at 1-800-FDA-10 or wwwfdagovmedwatch Clinical Trials Experience,1
TAFINLAR,Ocular Toxicities,at or,0
TAFINLAR,Ocular Toxicities,EXCERPT To report SUSPECTED,0
TAFINLAR,Ocular Toxicities,A at 1-800-FDA-10 or,1
TAFINLAR,Ocular Toxicities,EXCERPT To report SUSPECTED,0
TAFINLAR,Ocular Toxicities,or wwwfdagovmedwatch Clinical Trials Experience Because clinical trials a,0
TAFINLAR,Ocular Toxicities,Trials Experience Because clinical trials,0
TAFINLAR,Ocular Toxicities,A at 1-800-FDA-10 or,1
TAFINLAR,Ocular Toxicities,Trials Experience Because clinical trials,0
TAFINLAR,Febrile Reactions,of a drug cann,0
TAFINLAR,pyrexia,"widely varying s, adve rse reaction",1
TAFINLAR,pyrexia,of a drug cann,0
TAFINLAR,pyrexia,"s, adve rse reaction rates",1
TAFINLAR,pyrexia,"s, adve rse reaction rates",1
TAFINLAR,pyrexia,"s, adve rse reaction rates observed",1
TAFINLAR,Skin Toxicity,in the cl inical trials of another drug,1
TAFINLAR,Hyperglycemia,with trametinib BRAF,0
TAFINLAR,Hyperglycemia,as a single agent in combinatio,1
TAFINLAR,Hyperglycemia,with trametinib BRAF,0
TAFINLAR,Hyperglycemia,agent and,0
TAFINLAR,Hyperglycemia,Precautions section and,0
TAFINLAR,Hyperglycemia,BRAF VE Unresectable or Metastatic Melanoma The,0
TAFINLAR,Hyperglycemia,or Metastatic,0
TAFINLAR,Hyperglycemia,as a single,0
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,Unresectable or Metastatic Melanoma The,0
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,agent was evaluated in 586 patients with BRAF V mutationpositive unresectable,1
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,Unresectable or Metastatic Melanoma The safety,0
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,The safety of TAFINLAR a single agent,1
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,treated or untreat,0
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,Metastatic Melanoma The,0
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,of TAFINLAR a,1
TAFINLAR,Glucose-6-Phosphate Dehydrogenase Deficiency,melanoma,0
TAFINLAR,Embryofetal Toxicity,"unresectable or ic melanoma, previou sly treated or untreated who",1
TAFINLAR,Embryofetal Toxicity,melanoma,0
TAFINLAR,Embryofetal Toxicity,single agent was evaluated in,0
TAFINLAR,Embryofetal Toxicity,"ic melanoma, previou sly treated or",1
TAFINLAR,Embryofetal Toxicity,single agent was evaluated in,0
TAFINLAR,Embryofetal Toxicity,"ic melanoma, previou",1
TAFINLAR,Embryofetal Toxicity,evaluated in patients with BRAF,0
TAFINLAR,fetal harm,metastatic melanoma previously or untreat ed who received TAFINLAR mg,1
TAFINLAR,fetal harm,evaluated in patients with BRAF,0
TAFINLAR,fetal harm,melanoma previously or untreat ed who received TAFINLAR,1
TAFINLAR,fetal harm,evaluated in patients with BRAF,0
TAFINLAR,fetal harm,or untreat ed who,1
TAFINLAR,fetal harm,or untreat,1
TAFINLAR,fetal harm,metastatic melanoma previously,0
TAFINLAR,fetal harm,until disease progression,0
TAFINLAR,fetal harm,or untreat ed,1
TAFINLAR,"primary malignancies, cutaneous",The median daily dose,0
TAFINLAR,"primary malignancies, cutaneous",TAFINLAR was studied,0
TAFINLAR,"primary malignancies, cutaneous","d in an open-label, randomized,",1
TAFINLAR,"primary malignancies, cutaneous",TAFINLAR was studied,0
TAFINLAR,"primary malignancies, cutaneous","in an open-label, randomized, activecontrolled",1
TAFINLAR,"primary malignancies, cutaneous",patients treated,0
TAFINLAR,"primary malignancies, cutaneous","singlearm trials d in an open-label,",1
TAFINLAR,"primary malignancies, cutaneous",was mg range to mg,0
TAFINLAR,"primary malignancies, cutaneous",openlabel singlearm trials d,1
TAFINLAR,"primary malignancies, cutaneous",trial The median daily,0
TAFINLAR,cutaneous squamous cell carcinoma,from of Trial,1
TAFINLAR,cutaneous squamous cell carcinoma,and,0
TAFINLAR,cutaneous squamous cell carcinoma,randomized controlled trial all,0
TAFINLAR,cutaneous squamous cell carcinoma,abnormalities identified from of Trial 1 [see,1
TAFINLAR,cutaneous squamous cell carcinoma,randomized controlled trial all,0
TAFINLAR,cutaneous squamous cell carcinoma,of Trial 1,1
TAFINLAR,cutaneous squamous cell carcinoma,laboratory abnormalities identified from of Trial 1,1
TAFINLAR,cutaneous squamous cell carcinoma,from of Trial 1  [see Clinical Studies Trial a multicenter international openlabel,1
TAFINLAR,cutaneous squamous cell carcinoma,laboratory abnormalities identified from of Trial 1,1
TAFINLAR,cutaneous squamous cell carcinoma,laboratory abnormalities identified from analyses,0
TAFINLAR,keratoacanthoma,international openlabel randomized controlled trial,0
TAFINLAR,keratoacanthoma,14.1)]. Trial a,1
TAFINLAR,keratoacanthoma,14.1)]. Trial a multicenter,1
TAFINLAR,keratoacanthoma,international openlabel randomized controlled trial,0
TAFINLAR,keratoacanthoma,of Trial see Clinical 14.1)].  Trial  a multicenter,1
TAFINLAR,keratoacanthoma,international openlabel randomized controlled trial,0
TAFINLAR,keratoacanthoma,a multicenter international openlabel randomized controlled trial allocated,0
TAFINLAR,keratoacanthoma,Clinical 14.1)]. Trial,1
TAFINLAR,keratoacanthoma,international,0
TAFINLAR,keratoacanthoma,Clinical 14.1)]. Trial,1
TAFINLAR,keratoacanthoma,Clinical Studies,0
TAFINLAR,melanoma,ulticent er,1
TAFINLAR,melanoma,Clinical Studies,0
TAFINLAR,basal cell carcinoma,mg,0
TAFINLAR,basal cell carcinoma,allocated with unresectable or metastatic BRAF VE,1
TAFINLAR,basal cell carcinoma,mg,0
TAFINLAR,basal cell carcinoma,with unresectable or metastatic,1
TAFINLAR,basal cell carcinoma,controlled trial allocated with unresectable,1
TAFINLAR,basal cell carcinoma,with unresectable or,1
TAFINLAR,basal cell carcinoma,with unresectable,1
TAFINLAR,basal cell carcinoma,TAFINLAR mg,0
TAFINLAR,basal cell carcinoma,with unresectable or metastatic BRAF VE mutationpositive,1
TAFINLAR,basal cell carcinoma,TAFINLAR mg,0
TAFINLAR,basal cell carcinoma,randomized controlled trial allocated patients,0
TAFINLAR,cutaneous squamous cell carcinomas,metastatic,0
TAFINLAR,cutaneous squamous cell carcinomas,unresectable or metastatic BRAF 0E mutation-positive,1
TAFINLAR,cutaneous squamous cell carcinomas,or dacarbazine mgm intravenously,0
TAFINLAR,cutaneous squamous cell carcinomas,to r eceive,1
TAFINLAR,keratoacanthomas,n or dacarbazine mgm intravenously every weeks,0
TAFINLAR,keratoacanthomas,metastatic BRAF VE mutationpositive melanoma to,0
TAFINLAR,keratoacanthomas,to e TAFINLAR 150,1
TAFINLAR,keratoacanthomas,mutationpositive melanoma to e TAFINLAR 150,1
TAFINLAR,keratoacanthomas,mutationpositive melanoma to e TAFINLAR 150 m g orally twice,1
TAFINLAR,keratoacanthomas,mutationpositive melanoma to e TAFINLAR 150,1
TAFINLAR,cuSCC,orall y twice daily n or,1
TAFINLAR,cuSCC,orall y twice,1
TAFINLAR,cuSCC,n or dacarbazine mgm intravenously,0
TAFINLAR,cuSCC,orall,1
TAFINLAR,cuSCC,orall y twice daily,1
TAFINLAR,cuSCC,orall y,1
TAFINLAR,cuSCC,abnormal left ventricular ejection fraction or cardiac,0
TAFINLAR,cuSCC,fraction or cardiac v,0
TAFINLAR,cuSCC,alve  morphology Grade corrected,1
TAFINLAR,cuSCC,fraction or cardiac v,0
TAFINLAR,cuSCC,cardiac v,0
TAFINLAR,cuSCC,alve  morphology Grade corrected QT interval,1
TAFINLAR,cuSCC,corrected QT,0
TAFINLAR,cuSCC,n The,0
TAFINLAR,cuSCC,alve  morphology Grade corrected QT,1
TAFINLAR,cuSCC,alve  morphology Grade corrected,1
TAFINLAR,cuSCC,morphology Grade,0
TAFINLAR,cuSCC,T int erval milliseconds on,1
TAFINLAR,cuSCC,T int erval,1
TAFINLAR,cuSCC,corrected T int,1
TAFINLAR,cuSCC,or,0
TAFINLAR,cuSCC,history of ose-6 phosphate dehydrogenase,1
TAFINLAR,cuSCC,or,0
TAFINLAR,cuSCC,known history of,0
TAFINLAR,cuSCC,ose-6 phosphate dehydrogenase deficiency The,1
TAFINLAR,cuSCC,ose-6 phosphate dehydrogenase,1
TAFINLAR,cuSCC,ose-6 phosphate dehydrogenase deficiency The median,1
TAFINLAR,cuSCC,months for,0
TAFINLAR,cuSCC,on treatment was,0
TAFINLAR,cuSCC,edian duration on treatment was months,1
TAFINLAR,cuSCC,edian,1
TAFINLAR,cuSCC,dehydrogenase deficiency The edian duration,1
TAFINLAR,cuSCC,edian,1
TAFINLAR,cuSCC,months for patients treated with,0
TAFINLAR,cuSCC,edian duration on treatment,1
TAFINLAR,cuSCC,edian duration on,1
TAFINLAR,cuSCC,edian duration,1
TAFINLAR,cuSCC,on treatment was months for patients treated with TAFINLAR and months for dacarbaz,0
TAFINLAR,cuSCC,months for patients treated with TAFINLAR and months for,0
TAFINLAR,cuSCC,edian duration on treatment was months,1
TAFINLAR,cuSCC,treatment was months for patients treated with TAFINLAR and months,0
TAFINLAR,cuSCC,with TAFINLAR and,0
TAFINLAR,cuSCC,with TAFINLAR and months  daca rbazinetreated,1
TAFINLAR,cuSCC,with TAFINLAR and,0
TAFINLAR,cuSCC,male white and had a medi,0
TAFINLAR,cuSCC,TAFINLAR and months  daca rbazinetreated patients The population,1
TAFINLAR,cuSCC,male white and had a medi,0
TAFINLAR,cuSCC,had a medi,0
TAFINLAR,cuSCC,patie nts,1
TAFINLAR,cuSCC,patie nts The population,1
TAFINLAR,cuSCC,months for patients treated with TAFINLAR and,0
TAFINLAR,cuSCC,exposed,0
TAFINLAR,cuSCC,patie nts The population exposed to,1
TAFINLAR,cuSCC,TAFINLAR and months for patie nts The population exposed,1
TAFINLAR,cuSCC,patie nts The population exposed to,1
TAFINLAR,primary malignant melanomas,"exposed to TAFINLAR was e, 99% white, and had a",1
TAFINLAR,primary malignant melanomas,The most commonly occurring adverse,0
TAFINLAR,primary malignant melanomas,a med ian,1
TAFINLAR,primary malignant melanomas,reactions in patients treated,0
TAFINLAR,primary malignant melanomas,reactions in patients treated w,0
TAFINLAR,primary malignant melanomas,population exposed to TAFINLAR was mal,0
TAFINLAR,primary malignant melanomas,and had a med ian age of years,1
TAFINLAR,basal cell carcinoma,"pyrexia, ar",1
TAFINLAR,basal cell carcinoma,"of decreasing frequency hyperkeratosis eadache, pyrexia, ar",1
TAFINLAR,basal cell carcinoma,PPES The incide,0
TAFINLAR,basal cell carcinoma,syndrome PPES,0
TAFINLAR,basal cell carcinoma,palmarplantar erythrodysesthesia syndrome PPES The,0
TAFINLAR,basal cell carcinoma,ted with dacarbazine,1
TAFINLAR,basal cell carcinoma,palmarplantar erythrodysesthesia syndrome PPES The,0
TAFINLAR,basal cell carcinoma,ted,1
TAFINLAR,basal cell carcinoma,was for patients treated with TAFINLAR and for patients trea,0
TAFINLAR,basal cell carcinoma,TAFINLAR and for patients ted with,1
TAFINLAR,basal cell carcinoma,ted with dacarbazine,1
TAFINLAR,basal cell carcinoma,for patients trea,0
TAFINLAR,basal cell carcinoma,was for patients treated with TAFINLAR,0
TAFINLAR,basal cell carcinoma,reduction of,0
TAFINLAR,SCC,of Patients Treated,0
TAFINLAR,SCC,Patients,0
TAFINLAR,SCC,Selected Common Adverse,0
TAFINLAR,SCC, Re actions Occurring,1
TAFINLAR,SCC, Re actions,1
TAFINLAR,SCC, Re actions,1
TAFINLAR,SCC, Re actions,1
TAFINLAR,SCC,Treated,0
TAFINLAR,SCC,fatigue and headache Table Selected Common,0
TAFINLAR,SCC, Re,1
TAFINLAR,SCC,headache Table,0
TAFINLAR,keratoacanthoma,>=10% ( All Grades,1
TAFINLAR,keratoacanthoma,Table Selected Common Adverse,0
TAFINLAR,keratoacanthoma,Treated With,0
TAFINLAR,keratoacanthoma,Selected Common Adverse Reactions,0
TAFINLAR,keratoacanthoma,Adverse Reactions ring in >=10% (,1
TAFINLAR,primary melanoma,All Grades,1
TAFINLAR,primary melanoma,d Skin and subcutaneous tissue disorders,0
TAFINLAR,primary melanoma,All Grades 3 an,1
TAFINLAR,primary melanoma,and b All Grades,1
TAFINLAR,primary melanoma,b All     Grades  3 an d Skin and subcutaneous tissue,1
TAFINLAR,primary melanoma,and b All Grades,1
TAFINLAR,deep venous thrombosis,                      ,1
TAFINLAR,deep venous thrombosis,polyps,0
TAFINLAR,DVT,polyps,0
TAFINLAR,DVT,including,0
TAFINLAR,pulmonary embolism,and                   ,1
TAFINLAR,pulmonary embolism,including,0
TAFINLAR,pulmonary embolism,including cysts and                    Papilloma,1
TAFINLAR,pulmonary embolism,including,0
TAFINLAR,pulmonary embolism,                  ,1
TAFINLAR,pulmonary embolism,                   Papilloma c,1
TAFINLAR,pulmonary embolism,                  ,1
TAFINLAR,pulmonary embolism,                  ,1
TAFINLAR,pulmonary embolism,                  ,1
TAFINLAR,PE,and    Papilloma,1
TAFINLAR,PE,                  ,1
TAFINLAR,PE,   Papilloma,1
TAFINLAR,PE,   Papilloma c,1
TAFINLAR,PE,   Papilloma c,1
TAFINLAR,Retinal detachments,"           
  Incre ased alkaline",1
TAFINLAR,Retinal detachments,   Papilloma c,1
TAFINLAR,Retinal detachments,a,0
TAFINLAR,Retinal detachments,"           
  Incre ased",1
TAFINLAR,Retinal detachments,ased,0
TAFINLAR,Retinal detachments,"           
  Incre ased",1
TAFINLAR,Retinal detachments,a,0
TAFINLAR,RPED,bnor mality limited,1
TAFINLAR,RPED,a,0
TAFINLAR,RPED,  Pa ncreatitis Immune System,1
TAFINLAR,RPED,TAFINLAR were Gastrointestinal   Pa ncreatitis Immune,1
TAFINLAR,RPED,  Pa ncreatitis Immune System,1
TAFINLAR,RPED,Disorders Hypersensitivity,0
TAFINLAR,RPED,  Pa ncreatitis Immune System,1
TAFINLAR,RPED,  Pa,1
TAFINLAR,RPED,  Pa,1
TAFINLAR,RPED,manifesting as bullous rash,0
TAFINLAR,Uveitis,toxicity Among these patients were,0
TAFINLAR,Uveitis, or una cceptable toxicity Among these patients,1
TAFINLAR,Uveitis,toxicity Among these patients were,0
TAFINLAR,Uveitis,or una,1
TAFINLAR,Uveitis,or una cceptable,1
TAFINLAR,Uveitis,until disease,0
TAFINLAR,Uveitis,to,0
TAFINLAR,Uveitis,daily until disease,0
TAFINLAR,Uveitis,orally once daily until disease progression,0
TAFINLAR,iritis,able t oxicity Among these patients,1
TAFINLAR,iritis,orally once daily until disease progression,0
TAFINLAR,iritis,able t,1
TAFINLAR,iritis,orally once daily,0
TAFINLAR,iritis,able t,1
TAFINLAR,iritis,were,0
TAFINLAR,Uveitis,r great er than,1
TAFINLAR,Uveitis,exposed to trametinib r great er than to months while,1
TAFINLAR,Uveitis,r great er than,1
TAFINLAR,Uveitis,exposed to trametinib r great er than to months while,1
TAFINLAR,Uveitis,r great er than,1
TAFINLAR,Uveitis,to trametinib r great,1
TAFINLAR,Uveitis,trametinib fo,0
TAFINLAR,Uveitis,fo,0
TAFINLAR,Uveitis,trametinib r great er than to,1
TAFINLAR,Uveitis,fo,0
TAFINLAR,iritis,while were exposed to TAFINLAR and were exposed to trametinib for,0
TAFINLAR,iritis,to TAFINLAR and,0
TAFINLAR,iritis,greater than 12,1
TAFINLAR,iritis,trametinib for greater than  12 mo nths while were exposed to,1
TAFINLAR,iritis,greater than 12,1
TAFINLAR,iritis,to,0
TAFINLAR,iritis,greater than  12 mo nths while were,1
TAFINLAR,iritis,to,0
TAFINLAR,iritis,12 mo nths while,1
TAFINLAR,iritis,for greater,0
TAFINLAR,iritis,12 mo nths while were exposed,1
TAFINLAR,iritis,and were exposed to trametinib for,0
TAFINLAR,uveitis,while were exposed,0
TAFINLAR,uveitis,exposed to nib for greater than one year,1
TAFINLAR,uveitis,while were exposed,0
TAFINLAR,uveitis,greater than one year The median,0
TAFINLAR,uveitis,male,0
TAFINLAR,uveitis,nib,1
TAFINLAR,uveitis,nib for greater than one year,1
TAFINLAR,uveitis,and were exposed to nib for greater than one year,1
TAFINLAR,uveitis,nib for greater than one year,1
TAFINLAR,uveitis,and were exposed to nib for,1
TAFINLAR,febrile reactions,coronary syndrome,0
TAFINLAR,febrile reactions,(14.2)] . Pa tients with,1
TAFINLAR,febrile reactions,of acute coronary syndrome within months current evidence of,0
TAFINLAR,febrile reactions,evidence of,0
TAFINLAR,febrile reactions,as a single agent mg orally,0
TAFINLAR,febrile reactions,daily n see Clinical ies (14.2)] .,1
TAFINLAR,febrile reactions,with abnormal LVEF history of acute coronary syndrome within months current evidence of C,0
TAFINLAR,fever,see Clinical Studies s,1
TAFINLAR,fever,s wit h abnormal LVEF history of,1
TAFINLAR,fever,s wit h abnormal LVEF history,1
TAFINLAR,fever,Clinical Studies s,1
TAFINLAR,fever,Studies s wit,1
TAFINLAR,fever,Clinical Studies s wit h abnormal LVEF history of,1
TAFINLAR,fever,Studies s wit,1
TAFINLAR,fever,see Clinical Studies s wit h abnormal LVEF history,1
TAFINLAR,fever,Studies s wit,1
TAFINLAR,fever,Studies s wit h abnormal LVEF,1
TAFINLAR,fever,Studies s wit,1
TAFINLAR,fever,s wit h abnormal,1
TAFINLAR,fever,Studies s wit,1
TAFINLAR,hypotension,Studies Patients,0
TAFINLAR,hypotension,abnormal LVEF history of e coronary  syndrome within months current,1
TAFINLAR,hypotension,Studies Patients,0
TAFINLAR,hypotension,e coronary,1
TAFINLAR,hypotension,Clinical Studies Patients,0
TAFINLAR,hypotension,greater congestive heart,0
TAFINLAR,rigors,Class II or greater congestive heart,0
TAFINLAR,rigors,Studies Patients with abnormal,0
TAFINLAR,rigors,n see Clinical Studies Patients with abnormal LVEF history of acute coronary,0
TAFINLAR,chills,evidence of Class II,0
TAFINLAR,chills,syndrome hin 6  months current,1
TAFINLAR,chills,evidence of Class II,0
TAFINLAR,chills,York,0
TAFINLAR,chills,LVEF history of acute coronary,0
TAFINLAR,chills,hin 6 months current,1
TAFINLAR,chills,syndrome hin 6,1
TAFINLAR,chills,hin 6 months current evidence of Class,1
TAFINLAR,chills,of acute coronary syndrome hin,1
TAFINLAR,chills,hin 6 months current evidence of Class,1
TAFINLAR,dehydration,greater congestive heart failure New York Heart,0
TAFINLAR,dehydration,"syndrome within nths,",1
TAFINLAR,dehydration,LVEF history,0
TAFINLAR,dehydration,"coronary syndrome within nths, curre",1
TAFINLAR,dehydration,York Heart Association history RV,0
TAFINLAR,renal failure,idence of Cla ss II or greater,1
TAFINLAR,renal failure,months current idence of Cla ss II or,1
TAFINLAR,renal failure,idence of Cla ss II or greater,1
TAFINLAR,renal failure,RVO or RPED QTc,0
TAFINLAR,renal failure,ss II or greater congestive heart failure New,0
TAFINLAR,renal failure,greater congestive heart,0
TAFINLAR,pyrexia,treatment ory hyp ertension uncontrolled arrhythmias history,1
TAFINLAR,pyrexia,greater congestive heart,0
TAFINLAR,pyrexia,ory hyp ertension uncontrolled arrhythmias,1
TAFINLAR,pyrexia,ory,1
TAFINLAR,pyrexia,pneumonitis or interstitial lung disease or a,0
TAFINLAR,pyrexia,ory hyp ertension uncontrolled arrhythmias history,1
TAFINLAR,pyrexia,ory hyp ertension uncontrolled arrhythmias history of,1
TAFINLAR,pyrexia,msec treatment refract,0
TAFINLAR,pyrexia,QTc interval msec treatment ory hyp,1
TAFINLAR,pyrexia,msec treatment refract,0
TAFINLAR,pyrexia,pneumonitis or interstitial lung disease or,0
TAFINLAR,pyrexia,msec,0
TAFINLAR,fever,as 10 months for,1
TAFINLAR,fever,as 10,1
TAFINLAR,fever,nt gr oup when used,1
TAFINLAR,fever,orally oncedaily nt gr,1
TAFINLAR,fever,nt gr oup when used,1
TAFINLAR,fever,nt gr,1
TAFINLAR,fever,for,0
TAFINLAR,fever,of patients receiving,0
TAFINLAR,fever,"


 I n Trial of patients receiving",1
TAFINLAR,fever,"TAFINLAR as a single 


 I n Trial of patients",1
TAFINLAR,fever,"


 I n Trial of patients receiving",1
TAFINLAR,fever,"


 I",1
TAFINLAR,febrile reactions,R in combination with trametinib experienced adverse,1
TAFINLAR,febrile reactions,receiving R in combination,1
TAFINLAR,febrile reactions,resulting in permanent discontinuation,0
TAFINLAR,febrile reactions,Trial of patients receiving R in combination  with trametinib experienced,1
TAFINLAR,febrile reactions,resulting in permanent discontinuation,0
TAFINLAR,fever,resulting in,0
TAFINLAR,fever,Trial of patients receiving TAFINLAR,0
TAFINLAR,fever,receiving TAFINLAR in combination trame tinib,1
TAFINLAR,fever,Trial of patients receiving TAFINLAR,0
TAFINLAR,fever,trame tinib,1
TAFINLAR,fever,trame tinib experienced adverse reactions,1
TAFINLAR,fever,resulting in permanent,0
TAFINLAR,fever,trame,1
TAFINLAR,fever,resulting in permanent,0
TAFINLAR,fever,trame tinib experienced adverse,1
TAFINLAR,fever,trame tinib experienced adverse,1
TAFINLAR,chills,resulting,0
TAFINLAR,chills,TAFINLAR in combination with trametinib experienced adverse reactions resulting in,0
TAFINLAR,chills,ent di scontinuation of trial medications,1
TAFINLAR,fever,reactions led dose  reductions in,1
TAFINLAR,fever,ent di scontinuation of trial medications,1
TAFINLAR,fever,of patients treated with,0
TAFINLAR,fever,reactions led dose ,1
TAFINLAR,fever,of patients treated with,0
TAFINLAR,fever,reactions led dose  reductions in,1
TAFINLAR,fever,of patients treated with,0
TAFINLAR,fever,led dose  reductions in and,1
TAFINLAR,fever,of patients treated with,0
TAFINLAR,fever,dose  reductions in and dose,1
TAFINLAR,fever,Adverse reactions led dose  reductions in and dose interruptions,1
TAFINLAR,fever,dose  reductions in and dose,1
TAFINLAR,fever,dose  reductions in and dose,1
TAFINLAR,fever,dose ,1
TAFINLAR,fever,dose  reductions in and dose,1
TAFINLAR,fever,dose  reductions in,1
TAFINLAR,fever,reactions led to,0
TAFINLAR,fever,decreased ejection fraction were the most common reasons cited for dose interruptions,0
TAFINLAR,hypotension,ction were the,1
TAFINLAR,hypotension,ction were,1
TAFINLAR,rigors,TAFINLAR and trametinib when used,0
TAFINLAR,chills,ejection fraction were the most,0
TAFINLAR,chills,were the,0
TAFINLAR,chills,most mon re asons cited for dose,1
TAFINLAR,chills,were the,0
TAFINLAR,chills,mon re asons cited for dose,1
TAFINLAR,chills,cited for dose interruptions of TAFINLAR and trametinib when used in combination,0
TAFINLAR,chills,mon re,1
TAFINLAR,chills,and pyrexia chills and decreased ejection,0
TAFINLAR,chills,mon re,1
TAFINLAR,Fever,r >=5 Grades or of,1
TAFINLAR,Fever,With TAFINLAR in Combination With Trametinib in,0
TAFINLAR,Fever,Grades or of,0
TAFINLAR,Fever,at All Grades r >=5 Grades or of,1
TAFINLAR,Fever,Grades or of,0
TAFINLAR,chills,atient s Treated With TAFINLAR,1
TAFINLAR,chills,TAFINLAR in Combination With Trametinib in Trial Adverse Reactions,0
TAFINLAR,chills,Grades or of atient s Treated With TAFINLAR,1
TAFINLAR,chills,TAFINLAR in Combination With Trametinib in Trial Adverse Reactions,0
TAFINLAR,chills,atient,1
TAFINLAR,chills,of atient,1
TAFINLAR,chills,atient,1
TAFINLAR,rigors,Grades or,0
TAFINLAR,dehydration,in Combinat ion With Trametinib in,1
TAFINLAR,dehydration,in Combinat ion,1
TAFINLAR,dehydration,of Patients Treated With in Combinat,1
TAFINLAR,dehydration,in Combinat ion,1
TAFINLAR,syncope,ions    TAFINLAR plus Trametinib,1
TAFINLAR,fever,TAFINLAR N All Gradesa 3 and,1
TAFINLAR,fever,General disorders and ive s ite conditions Pyrexia,1
TAFINLAR,fever,TAFINLAR N All Gradesa 3 and,1
TAFINLAR,fever,All,0
TAFINLAR,fever,and ive,1
TAFINLAR,fever,ive s ite conditions,1
TAFINLAR,fever,disorders and ive s ite conditions,1
TAFINLAR,fever,ive s ite conditions,1
TAFINLAR,fever,and General disorders and ive s,1
TAFINLAR,fever,ite conditions Pyrexia,0
TAFINLAR,fever,ite,0
TAFINLAR,fever,and ive s ite,1
TAFINLAR,fever,ite,0
MULTAQ,worsening heart failure,worsening heart failure,1
MULTAQ,worsening heart failure,safety concerns are described elsewhere in the label,0
MULTAQ,Liver Injury,Liver Injury,1
MULTAQ,Liver Injury,Warnings,0
MULTAQ,Liver Injury,label New or worsening heart failure see,0
MULTAQ,Pulmonary toxicity,Pulmonary toxicity,1
MULTAQ,Pulmonary toxicity,hypomagnesemia,0
MULTAQ,Pulmonary toxicity,Pulmonary toxicity see,1
MULTAQ,Pulmonary toxicity,see Warnings and Precautions Hypokalemia and hypomagnesemia with potassiumdeple,0
MULTAQ,Pulmonary toxicity,Injury see Warnings and Pulmonary toxicity,1
MULTAQ,Pulmonary toxicity,see Warnings and Precautions Hypokalemia and hypomagnesemia with potassiumdeple,0
MULTAQ,Pulmonary toxicity,Liver Injury see Warnings and,0
MULTAQ,Hypokalemia,Hypokalemia and hypomagnesemia,1
MULTAQ,Hypokalemia,toxicity see Warnings and Hypokalemia and hypomagnesemia with,1
MULTAQ,Hypokalemia,Hypokalemia and hypomagnesemia,1
MULTAQ,Hypokalemia,toxicity see Warnings and Hypokalemia,1
MULTAQ,Hypokalemia,Hypokalemia and hypomagnesemia,1
MULTAQ,Hypokalemia,Warnings and Hypokalemia and hypomagnesemia,1
MULTAQ,Hypokalemia,Hypokalemia and hypomagnesemia,1
MULTAQ,Hypokalemia,toxicity see Warnings and Hypokalemia and hypomagnesemia with potassiumdepleting diuretics,1
MULTAQ,Hypokalemia,Hypokalemia and hypomagnesemia,1
MULTAQ,Hypokalemia,and Hypokalemia and hypomagnesemia,1
MULTAQ,Hypokalemia,Hypokalemia and hypomagnesemia,1
MULTAQ,Hypokalemia,Precautions,0
MULTAQ,hypomagnesemia,hypomagnesemia with potassiumdepleting diuretics,1
MULTAQ,hypomagnesemia,Precautions,0
MULTAQ,hypomagnesemia,hypomagnesemia with potassiumdepleting diuretics,1
MULTAQ,hypomagnesemia,Precautions,0
MULTAQ,QT prolongation,QT prolongation see Warnings and,1
MULTAQ,QT prolongation,Warnings and Precautions EXCERPT Most common,0
MULTAQ,QT prolongation,and,0
MULTAQ,QT prolongation,adverse reactions,0
MULTAQ,QT prolongation,EXCERPT Most common adverse reactions,0
MULTAQ,diarrhea,diarrhea,1
MULTAQ,diarrhea,diarrhea nausea abdominal pain vomiting and,1
MULTAQ,diarrhea,are,0
MULTAQ,diarrhea,Most common adverse reactions diarrhea nausea abdominal,1
MULTAQ,diarrhea,are,0
MULTAQ,diarrhea,adverse reactions diarrhea nausea abdominal,1
MULTAQ,diarrhea,are,0
MULTAQ,diarrhea,pain vomiting and asthenia To report,0
MULTAQ,diarrhea,diarrhea nausea abdominal,1
MULTAQ,diarrhea,pain vomiting and asthenia To report,0
MULTAQ,diarrhea,reactions,0
MULTAQ,diarrhea,diarrhea nausea abdominal pain vomiting,1
MULTAQ,nausea,Most common adverse reactions are,0
MULTAQ,nausea,reactions are nausea abdominal pain vomiting and,1
MULTAQ,nausea,Most common adverse reactions are,0
MULTAQ,nausea,report SUSPECTED ADVERSE REACTIONS,0
MULTAQ,nausea,diarrhea,0
MULTAQ,nausea,common,0
MULTAQ,nausea,nausea abdominal pain,1
MULTAQ,nausea,pain vomiting and asthenia To report,0
MULTAQ,nausea,report SUSPECTED ADVERSE REACTIONS,0
MULTAQ,nausea,asthenia To report SUSPECTED,0
MULTAQ,abdominal pain,Most common adverse reactions are,0
MULTAQ,abdominal pain,abdominal pain vomiting,1
MULTAQ,abdominal pain,Most common adverse reactions are,0
MULTAQ,abdominal pain,vomiting and asthenia To report SUSPECTED ADVERSE,0
MULTAQ,abdominal pain,abdominal pain vomiting and asthenia,1
MULTAQ,abdominal pain,abdominal pain vomiting and asthenia To,1
MULTAQ,abdominal pain,EXCERPT Most,0
MULTAQ,vomiting,nausea abdominal pain,0
MULTAQ,vomiting,vomiting and asthenia,1
MULTAQ,vomiting,vomiting and asthenia To,1
MULTAQ,vomiting,vomiting and,1
MULTAQ,vomiting,and,0
MULTAQ,vomiting,report,0
MULTAQ,vomiting,vomiting and asthenia,1
MULTAQ,vomiting,diarrhea nausea abdominal vomiting and,1
MULTAQ,vomiting,vomiting and asthenia,1
MULTAQ,vomiting,asthenia To report,0
MULTAQ,asthenia,and,0
MULTAQ,asthenia,contact sanofiaventis US LLC,0
MULTAQ,gastrointestinal disorders,therapy with MULTAQ gastrointestinal disorders versus in the placebo,1
MULTAQ,gastrointestinal disorders,contact sanofiaventis US LLC,0
MULTAQ,gastrointestinal disorders,gastrointestinal disorders versus,1
MULTAQ,gastrointestinal disorders,gastrointestinal disorders,1
MULTAQ,gastrointestinal disorders,group and QT prolongation versus,0
MULTAQ,gastrointestinal disorders,gastrointestinal disorders,1
MULTAQ,gastrointestinal disorders,gastrointestinal disorders versus in,1
MULTAQ,gastrointestinal disorders,gastrointestinal disorders,1
MULTAQ,gastrointestinal disorders,gastrointestinal disorders versus in the,1
MULTAQ,gastrointestinal disorders,gastrointestinal disorders,1
MULTAQ,gastrointestinal disorders,gastrointestinal disorders versus in the,1
MULTAQ,QT prolongation,QT prolongation,1
MULTAQ,QT prolongation,QT prolongation,1
MULTAQ,QT prolongation,QT prolongation versus in the placebo group,1
MULTAQ,QT prolongation,reactions,0
MULTAQ,QT prolongation,placebo group The most,0
MULTAQ,QT prolongation,placebo group,0
MULTAQ,QT prolongation,QT prolongation versus,1
MULTAQ,QT prolongation,group QT prolongation versus in the placebo group,1
MULTAQ,QT prolongation,QT prolongation versus,1
MULTAQ,QT prolongation,and,0
MULTAQ,QT prolongation,QT,1
MULTAQ,diarrhea,reactions more common,0
MULTAQ,diarrhea,diarrhea nausea abdominal pain,1
MULTAQ,diarrhea,diarrhea nausea abdominal pain vomiting and,1
MULTAQ,diarrhea,daily in the studies diarrhea nausea abdominal,1
MULTAQ,diarrhea,diarrhea nausea abdominal pain vomiting and,1
MULTAQ,diarrhea,diarrhea nausea,1
MULTAQ,nausea,nausea,1
MULTAQ,abdominal pain,abdominal pain vomiting,1
MULTAQ,abdominal pain,abdominal pain vomiting and asthenia Table,1
MULTAQ,abdominal pain,abdominal pain vomiting and asthenia Table displays,1
MULTAQ,abdominal pain,were diarrhea abdominal pain vomiting and asthenia,1
MULTAQ,abdominal pain,abdominal pain vomiting and asthenia Table displays,1
MULTAQ,abdominal pain,studies were diarrhea abdominal,1
MULTAQ,abdominal pain,abdominal pain,1
MULTAQ,abdominal pain,abdominal pain vomiting,1
MULTAQ,abdominal pain,abdominal pain,1
MULTAQ,abdominal pain,the studies were diarrhea abdominal pain vomiting and,1
MULTAQ,abdominal pain,abdominal pain,1
MULTAQ,abdominal pain,diarrhea abdominal pain vomiting,1
MULTAQ,abdominal pain,abdominal pain,1
MULTAQ,abdominal pain,abdominal pain,1
MULTAQ,vomiting,vomiting and asthenia Table,1
MULTAQ,vomiting,vomiting and asthenia Table,1
MULTAQ,vomiting,vomiting and asthenia Table,1
MULTAQ,asthenia,were,0
MULTAQ,asthenia,asthenia Table displays adverse reactions,1
MULTAQ,asthenia,daily in the studies were diarrhea nausea abdominal,0
MULTAQ,asthenia,than with p,0
MULTAQ,asthenia,asthenia,1
MULTAQ,asthenia,vomiting asthenia,1
MULTAQ,asthenia,asthenia,1
MULTAQ,asthenia,pain vomiting asthenia Table displays adverse reactions,1
MULTAQ,asthenia,asthenia,1
MULTAQ,asthenia,asthenia Table displays adverse reactions more,1
MULTAQ,asthenia,daily than with p,0
MULTAQ,asthenia,asthenia,1
MULTAQ,asthenia,daily than with p,0
MULTAQ,rashes,rashes generalized,1
MULTAQ,rashes,daily than with p,0
MULTAQ,rashes,rashes generalized macular maculopapular erythematous pruritus,1
MULTAQ,rashes,Including,0
MULTAQ,rashes,tissue rashes,1
MULTAQ,rashes,Including,0
MULTAQ,rashes,rashes generalized macular maculopapular erythematous,1
MULTAQ,rashes,rashes generalized,1
MULTAQ,rashes,rashes generalized,1
MULTAQ,rashes,rashes generalized macular maculopapular erythematous,1
MULTAQ,rashes,rashes generalized macular,1
MULTAQ,rashes,rashes generalized macular maculopapular erythematous,1
MULTAQ,rashes,tissue rashes generalized macular maculopapular,1
MULTAQ,rashes,rashes generalized macular maculopapular erythematous,1
MULTAQ,pruritus,pruritus eczema dermatitis dermatitis,1
MULTAQ,eczema,pruritus,0
MULTAQ,eczema,dermatitis dermatitis allergic,0
MULTAQ,eczema,macular maculopapular erythematous eczema dermatitis dermatitis allergic,1
MULTAQ,eczema,dermatitis dermatitis allergic,0
MULTAQ,dermatitis,erythematous pruritus,0
MULTAQ,dermatitis,pruritus dermatitis,1
MULTAQ,dermatitis,erythematous pruritus,0
MULTAQ,dermatitis,dermatitis,0
MULTAQ,dermatitis,pruritus,0
MULTAQ,dermatitis,dermatitis dermatitis allergic P,1
MULTAQ,dermatitis,maculopapular erythematous pruritus dermatitis dermatitis allergic,1
MULTAQ,dermatitis,dermatitis dermatitis allergic P,1
MULTAQ,dermatitis,erythematous,0
MULTAQ,dermatitis allergic,dermatitis,1
MULTAQ,dermatitis allergic,dermatitis allergic Photosensitivity react,1
MULTAQ,dermatitis allergic,dermatitis allergic Photosensitivity react,1
MULTAQ,dermatitis allergic,dermatitis,0
MULTAQ,dermatitis allergic,rashes generalized macular maculopapular erythematous pruritus eczema,0
MULTAQ,dermatitis allergic,pruritus eczema dermatitis allergic,1
MULTAQ,dermatitis allergic,rashes generalized macular maculopapular erythematous pruritus eczema,0
MULTAQ,Photosensitivity reaction,s dermatitis Photosensitivity reaction and dysgeusia have also been,1
MULTAQ,Photosensitivity reaction,rashes generalized macular maculopapular erythematous pruritus eczema,0
MULTAQ,Photosensitivity reaction,dysgeusia have also been,0
MULTAQ,Photosensitivity reaction,dermatitis,0
MULTAQ,dysgeusia,reaction dysgeusia have also been reported,1
MULTAQ,dysgeusia,dermatitis,0
MULTAQ,heart failure,New,0
MULTAQ,heart failure,or heart failure see Warnings and Precautions Atrial,1
MULTAQ,heart failure,New,0
MULTAQ,Atrial flutter,failure see Warnings and Atrial flutter,1
MULTAQ,Atrial flutter,Atrial flutter with atrioventricular conduction,1
MULTAQ,Atrial flutter,see,0
MULTAQ,Atrial flutter,Hepatic Liver,0
MULTAQ,Atrial flutter,failure see Warnings and Atrial flutter with atrioventricular,1
MULTAQ,Atrial flutter,Hepatic Liver,0
MULTAQ,Liver Injury,been reported very rarely Liver,1
MULTAQ,Liver Injury,very rarely Hepatic,0
MULTAQ,Liver Injury,very rarely Liver Injury see Warnings and,1
MULTAQ,Liver Injury,very rarely Hepatic,0
MULTAQ,Liver Injury,Liver Injury see Warnings,1
MULTAQ,Liver Injury,very rarely Liver Injury see,1
MULTAQ,Liver Injury,Liver Injury see Warnings,1
MULTAQ,Interstitial lung disease,Interstitial lung disease including pneumonitis,1
MULTAQ,Interstitial lung disease,lung disease,1
MULTAQ,Interstitial lung disease,Precautions Interstitial,1
MULTAQ,pneumonitis,see Warnings and Precautions Immune Anaphylactic,0
MULTAQ,pulmonary fibrosis,pneumonitis pulmonary fibrosis see Warnings and,1
MULTAQ,pulmonary fibrosis,see Warnings and Precautions Immune Anaphylactic,0
MULTAQ,pulmonary fibrosis,including,0
MULTAQ,pulmonary fibrosis,pulmonary fibrosis see Warnings and,1
MULTAQ,pulmonary fibrosis,pneumonitis pulmonary,1
MULTAQ,pulmonary fibrosis,Precautions Immune Anaphylactic reactions including,0
MULTAQ,Anaphylactic reactions,including leukocytoclastic vasculitis,0
MULTAQ,Anaphylactic reactions,ding pneumonitis and pulmonary fibrosis see Warnings,0
MULTAQ,Anaphylactic reactions,including,0
MULTAQ,Anaphylactic reactions,and pulmonary fibrosis see Warnings and Precautions,0
MULTAQ,Anaphylactic reactions,including angioedema Vascular Vasculitis,0
MULTAQ,Anaphylactic reactions,Anaphylactic reactions,1
MULTAQ,Anaphylactic reactions,Vasculitis,0
MULTAQ,Anaphylactic reactions,see Warnings and Precautions Anaphylactic reactions including angioedema Vascular Vasculitis,1
MULTAQ,Anaphylactic reactions,Vasculitis,0
MULTAQ,angioedema,angioedema Vascular Vasculitis,1
MULTAQ,angioedema,angioedema Vascular Vasculitis including leukocytoclastic,1
MULTAQ,angioedema,Warnings and,0
MULTAQ,angioedema,and,0
MULTAQ,Vasculitis,Anaphylactic reactions including angioedema Vasculitis including leukocytoclastic vasculitis,1
MULTAQ,Vasculitis,and,0
MULTAQ,Vasculitis,including leukocytoclastic vasculitis,0
MULTAQ,Vasculitis,including leukocytoclastic vasculitis,0
MULTAQ,Vasculitis,Vasculitis including,1
MULTAQ,Vasculitis,Vasculitis,1
MULTAQ,Vasculitis,including angioedema Vasculitis including leukocytoclastic,1
MULTAQ,Vasculitis,Vasculitis,1
MULTAQ,Vasculitis,Vasculitis including leukocytoclastic,1
MULTAQ,DEATH,REACTIONS The following,0
MULTAQ,DEATH,elsewhere in the label New or worsening,0
MULTAQ,DEATH,ADVERSE REACTIONS The following,0
MULTAQ,DEATH,conce rns are,1
MULTAQ,DEATH,REACTIONS The following conce rns are described elsewhere,1
MULTAQ,DEATH,conce rns are,1
MULTAQ,DEATH,ADVERSE REACTIONS The following conce rns,1
MULTAQ,DEATH,conce rns are,1
MULTAQ,DEATH,following conce rns are described elsewhere in,1
MULTAQ,DEATH,conce rns are,1
MULTAQ,DEATH,described elsewhere in the label New,0
MULTAQ,STROKE,safety s are  described elsewhere in the,1
MULTAQ,STROKE,described elsewhere in the label New,0
MULTAQ,STROKE,failure see Warnings and Precaut,0
MULTAQ,STROKE,s are described elsewhere in,1
MULTAQ,DEATH,njury see Warnings,1
MULTAQ,DEATH,toxicity,0
MULTAQ,DEATH,heart failure see Warnings,0
MULTAQ,DEATH,see Warnings and Precautions Pulmonary toxicity see Warnings and Precautions,0
MULTAQ,DEATH,and Precautions Liver njury see Warnings and Precautions,1
MULTAQ,DEATH,see Warnings and Precautions Pulmonary toxicity see Warnings and Precautions,0
MULTAQ,DEATH,njury see Warnings and Precautions Pulmonary,1
MULTAQ,STROKE,see W arnings and Precautions Pulmonary,1
MULTAQ,STROKE,New or worsening heart,0
MULTAQ,HEART FAILURE,or worsening heart failure see Warnings and Precautions Liver Injury see,0
MULTAQ,HEART FAILURE,gs and Precau tions Pulmonary toxicity see Warnings,1
MULTAQ,HEART FAILURE,gs and Precau tions,1
MULTAQ,HEART FAILURE,gs and Precau tions Pulmonary toxicity see Warnings,1
MULTAQ,death,ADVERSE REACTIONS contact sanofiaventis US LLC at or FDA at FDA,0
MULTAQ,death,r www fdagovmedwatch Clinical Trials Experience,1
MULTAQ,death,FDA r www,1
MULTAQ,death,r www,1
MULTAQ,death,at or FDA at FDA,0
MULTAQ,death,r www fdagovmedwatch Clinical Trials,1
MULTAQ,death,safety,0
MULTAQ,death,evaluation,0
MULTAQ,stroke,da.gov medwatch Clinical Trials,1
MULTAQ,stroke,evaluation of dronedarone mg tw,0
MULTAQ,stroke,da.gov medwatch Clinical Trials Experience The,1
MULTAQ,stroke,da.gov medwatch Clinical Trials Experience The,1
MULTAQ,stroke,FDA or da.gov medwatch Clinical Trials Experience The,1
MULTAQ,stroke,da.gov medwatch Clinical Trials Experience The,1
MULTAQ,stroke,FDA or da.gov medwatch,1
MULTAQ,stroke,da.gov medwatch Clinical Trials Experience The,1
MULTAQ,stroke,evaluation of dronedarone,0
MULTAQ,heart failure,in patients with AF or AFL,0
MULTAQ,heart failure,linical Trial s Experience,1
MULTAQ,heart failure,in patients with AF or AFL,0
MULTAQ,heart failure,or wwwfdagovmedwatch linical Trial,1
MULTAQ,heart failure,The safety evaluation of dronedarone,0
MULTAQ,heart failure,or wwwfdagovmedwatch linical Trial s,1
MULTAQ,heart failure,The safety evaluation of dronedarone,0
MULTAQ,heart failure,The safety evaluation of dronedarone mg twice,0
MULTAQ,DEATH,these studies a of 62,1
MULTAQ,DEATH,studies a of 62,1
MULTAQ,DEATH,daily,0
MULTAQ,DEATH,In these studies a of 62,1
MULTAQ,DEATH,of 62 patients were,1
MULTAQ,DEATH,In these studies a of 62,1
MULTAQ,DEATH,of 62 patients were randomized and treated,1
MULTAQ,DEATH,of 62 patients were randomized,1
MULTAQ,DEATH,patients with,0
MULTAQ,DEATH,and treated patients with MULTAQ mg twice,0
MULTAQ,STROKE, patie nts,1
MULTAQ,HEART FAILURE,ADONIS ERATO and DAFNE In these studies a total of,0
MULTAQ,HEART FAILURE,of patients ere randomize,1
MULTAQ,death,occurred,0
MULTAQ,death,versu s in the placebo group,1
MULTAQ,death,versu s in the placebo,1
MULTAQ,death,versu s in the placebo group,1
MULTAQ,death,the placebo group The most frequent adverse,0
MULTAQ,death,versu s in the placebo,1
MULTAQ,stroke,prolongation 0.5% i,1
MULTAQ,heart failure,prolongation versus in,0
MULTAQ,heart failure,studies,0
MULTAQ,heart failure,The most freq uent adverse,1
MULTAQ,heart failure,placebo The most freq,1
MULTAQ,heart failure,placebo The,1
MULTAQ,heart failure,adverse reactions observed with MULTAQ mg twice daily in the studies were,0
MULTAQ,Liver injury,rnings and P recautions,1
MULTAQ,Liver injury,adverse reactions observed with MULTAQ mg twice daily in the studies were,0
MULTAQ,Liver injury,rnings and P,1
MULTAQ,Liver injury,Wa,0
MULTAQ,Liver injury,Precautions Pulmonary toxicity see rnings,1
MULTAQ,Liver injury,with potassiumdepleting diuretics see,0
MULTAQ,Liver injury,hypomagnesemia with potassiumdepleting diuretics,0
MULTAQ,Liver injury,and hypomagnesemia with potassiumdepleting diuretics see,0
MULTAQ,Liver injury,and hypomagnesemia with,0
MULTAQ,Hypokalemia,prolongatio,1
MULTAQ,Hypokalemia,Warnings and,0
MULTAQ,Hypokalemia,prolongatio n see Warnings and,1
MULTAQ,Hypokalemia,QT,0
MULTAQ,Hypokalemia,and Precautions prolongatio,1
MULTAQ,Hypokalemia,QT,0
MULTAQ,Hypokalemia,prolongatio n see Warnings and Precautions,1
MULTAQ,Hypokalemia,prolongatio n,1
MULTAQ,Hypokalemia,common adverse reactions ar,0
MULTAQ,Hypokalemia,and Precautions prolongatio n see Warnings and,1
MULTAQ,Hypokalemia,common adverse reactions ar,0
MULTAQ,Hypokalemia,Most,0
MULTAQ,hypomagnesemia,prolongation e,1
MULTAQ,hypomagnesemia,QT prolongation e,1
MULTAQ,hypomagnesemia,Warnings an d,1
MULTAQ,Teratogen,"


   To  report SUSPECTED ADVERSE REACTIONS contact",1
MULTAQ,Teratogen,Warnings an d,1
MULTAQ,Teratogen,"


   To  report SUSPECTED ADVERSE REACTIONS contact",1
MULTAQ,Teratogen,diarrhea nausea abdominal pain,0
MULTAQ,Teratogen,"


   To  report",1
MULTAQ,Teratogen,"


   To  report SUSPECTED ADVERSE REACTIONS",1
MULTAQ,Teratogen,US LLC at or FDA,0
MULTAQ,death,studies a total f 628 patients were randomized and treated,1
MULTAQ,death,US LLC at or FDA,0
MULTAQ,death,these studies a total f 628 patients,1
MULTAQ,death,US LLC at or FDA,0
MULTAQ,death,these studies a total f 628,1
MULTAQ,death,these studies a total f 628,1
MULTAQ,death,these studies a total f 628,1
MULTAQ,death,patients were randomized,0
MULTAQ,death,total f 628,1
MULTAQ,death,patients were randomized,0
MULTAQ,death,twice daily and with,0
MULTAQ,death,these studies a total f,1
MULTAQ,death,studies a total f 628 patients were randomized and,1
MULTAQ,death,these studies a total f,1
MULTAQ,cardiovascular death,and placebo. The mean ex posure across studies,1
MULTAQ,cardiovascular death,these studies a total f,1
MULTAQ,cardiovascular death,twice daily and placebo. The mean ex posure across studies,1
MULTAQ,cardiovascular death,these studies a total f,1
MULTAQ,cardiovascular death,twice daily and placebo. The mean ex,1
MULTAQ,cardiovascular death,these studies a total f,1
MULTAQ,cardiovascular death,daily and placebo. The mean ex posure across,1
MULTAQ,cardiovascular death,these studies a total f,1
MULTAQ,cardiovascular death,and with,0
MULTAQ,cardiovascular death,and placebo. The mean ex,1
MULTAQ,cardiovascular death,randomized and treated patients with,0
MULTAQ,heart failure events,In clinical trials,0
MULTAQ,heart failure events,mean exposure across studies 12,1
MULTAQ,heart failure events,12 months. In ATHENA the maximum,1
MULTAQ,heart failure events,months. In ATHENA,1
MULTAQ,heart failure events,months. In ATHENA the,1
MULTAQ,heart failure events,studies 12 months.,1
MULTAQ,heart failure events,mean exposure across studies 12 months. In ATHENA,1
MULTAQ,heart failure events,months. In ATHENA the maximum followup was,1
MULTAQ,worsening of heart failure,laboratory ECG,1
MULTAQ,heart failure,              Placebo Dronedarone mg twice,1
MULTAQ,heart failure,mg twice,0
MULTAQ,heart failure,              Placebo Dronedarone mg twice daily,1
MULTAQ,heart failure,              Placebo Dronedarone mg twice,1
MULTAQ,heart failure,             ,1
MULTAQ,heart failure,Frequent than               Placebo,1
MULTAQ,heart failure,             ,1
MULTAQ,heart failure,at Least of Patients,0
MULTAQ,interstitial lung disease,allergic,0
MULTAQ,interstitial lung disease,also been reported at an incidence less than in patients treated,0
MULTAQ,interstitial lung disease,dermatitis,0
MULTAQ,interstitial lung disease,"
         Photosensitivit y reaction and dysgeusia have",1
MULTAQ,interstitial lung disease,have also been reported,0
MULTAQ,interstitial lung disease,"
         Photosensitivit y reaction and dysgeusia",1
MULTAQ,pneumonitis,treated with MULTAQ,0
MULTAQ,pulmonary fibrosis,been repor ted at an,1
MULTAQ,Hypokalemia,Placebo MULTAQ,0
MULTAQ,Hypokalemia,twice,0
MULTAQ,Hypokalemia,            N N Early increases in,1
MULTAQ,Hypokalemia,Placebo MULTAQ mg twice             N N Early increases in,1
MULTAQ,Hypokalemia,            N N Early increases in,1
MULTAQ,Hypokalemia,            N N Early,1
MULTAQ,Hypokalemia,N,0
MULTAQ,Hypokalemia,MULTAQ mg twice             N N,1
MULTAQ,Hypokalemia,N,0
MULTAQ,Hypokalemia,twice,0
MULTAQ,hypomagnesemia,N Early increases in creatinine,0
MULTAQ,hypomagnesemia,       (N=2875 N Early,1
MULTAQ,hypomagnesemia,       (N=2875 N Early increases,1
MULTAQ,hypomagnesemia,twice daily,0
MULTAQ,hypomagnesemia,       (N=2875 N Early increases in creatinine,1
MULTAQ,increase in serum creatinine,Postmarketing Experience The wing adverse reactions have  been identified during,1
MULTAQ,increase in serum creatinine,       (N=2875 N Early increases in creatinine,1
MULTAQ,increase in serum creatinine,events in any particular,0
MULTAQ,increase in serum creatinine,use of,0
MULTAQ,increase in serum creatinine,subgroup Postmarketing Experience The wing adverse reactions have  been identified during postapproval use,1
MULTAQ,increase in serum creatinine,use of,0
MULTAQ,increase in serum creatinine,The wing,1
MULTAQ,increase in serum creatinine,subgroup Postmarketing Experience The wing adverse reactions have  been,1
MULTAQ,increase in serum creatinine,The wing,1
MULTAQ,increase in serum creatinine,of MULTAQ Because these reactions are reported voluntarily,0
MULTAQ,increase in serum creatinine,are reported,0
MULTAQ,increase in serum creatinine,adverse reactions have been identified during postapproval use,1
MULTAQ,pre-renal azotemia,particular subgroup Postmarketing Experience The following adverse,0
MULTAQ,acute renal failure,The,0
MULTAQ,heart failure,have been identified during postapproval use of MULTAQ,0
MULTAQ,heart failure,of MULTAQ Because these tions,1
MULTAQ,heart failure,postapproval use of MULTAQ Because these reac,0
MULTAQ,heart failure,is not always possible to,0
MULTAQ,heart failure,MULTAQ Because these tions are rep orted voluntarily from,1
MULTAQ,heart failure,is not always possible to,0
MULTAQ,heart failure,tions are rep orted voluntarily from a,1
MULTAQ,heart failure,is not always possible to,0
MULTAQ,hypovolemia,use of MULTAQ Because these reactions,0
MULTAQ,hypovolemia,it is no t always possible to reliably,1
MULTAQ,hypovolemia,"e, it is no t always possible to reliably",1
MULTAQ,hypovolemia,it is no t always possible to reliably,1
MULTAQ,hypovolemia,is no t,1
MULTAQ,hypovolemia,"population of an unknown e, it is no",1
MULTAQ,hypovolemia,is no t,1
MULTAQ,hypovolemia,"e, it is no t always possible to",1
MULTAQ,hypovolemia,is no t,1
MULTAQ,hypovolemia,is no,1
MULTAQ,hypovolemia,frequency or establish a,0
MULTAQ,increases in creatinine levels,with 1:1 atrioventricular c onduction has been reported very,1
MULTAQ,increases in creatinine levels,1:1 atrioventricular c onduction has been,1
MULTAQ,increases in creatinine levels,Warnings and Precautions Atrial er with 1:1 atrioventricular c onduction has been reported very,1
MULTAQ,increases in creatinine levels,1:1 atrioventricular c onduction has been,1
MULTAQ,increases in creatinine levels,Atrial er with,1
TANZEUM,Thyroid C-cell Tumors,the prescribing information Risk of,0
TANZEUM,Thyroid C-cell Tumors,information Risk,0
TANZEUM,Thyroid C-cell Tumors,Precautions Acute Pancreatitis,0
TANZEUM,Thyroid C-cell Tumors,serious reactions are described below or elsewhere in the prescribing information Risk of,0
TANZEUM,Thyroid C-cell Tumors,see Warnings and Precautions,0
TANZEUM,Acute Pancreatitis,ng information Risk of Thyroid Ccell,0
TANZEUM,Acute Pancreatitis,Acute Pancreatitis see Warnings and Precautions Hypoglycemia,1
TANZEUM,Acute Pancreatitis,Tumors see Warnings and Precautions,0
TANZEUM,Acute Pancreatitis,Hypoglycemia with Concomitant Use,0
TANZEUM,Acute Pancreatitis,Warnings and Acute Pancreatitis,1
TANZEUM,Acute Pancreatitis,Hypoglycemia with Concomitant Use,0
TANZEUM,Acute Pancreatitis,Tumors see Warnings and Acute Pancreatitis see Warnings and Precautions Hypoglycemia,1
TANZEUM,Acute Pancreatitis,Hypoglycemia with Concomitant Use,0
TANZEUM,Hypoglycemia,Hypoglycemia with Concomitant Use of,1
TANZEUM,Hypersensitivity Reactions,Hypersensitivity Reactions,1
TANZEUM,Hypersensitivity Reactions,Impairment see,0
TANZEUM,Hypersensitivity Reactions,Hypersensitivity Reactions see Warnings and Precautions,1
TANZEUM,Hypersensitivity Reactions,Hypersensitivity Reactions see,1
TANZEUM,Hypersensitivity Reactions,th Concomitant Use of Insulin Secretagogues or Insulin see Warnings,0
TANZEUM,Renal Impairment,Hypersensitivity Reactions see Warnings and,0
TANZEUM,Renal Impairment,Warnings and Renal Impairment,1
TANZEUM,Renal Impairment,Hypersensitivity Reactions see Warnings and,0
TANZEUM,Renal Impairment,Warnings and Precautions EXCERPT,0
TANZEUM,Renal Impairment,and Renal Impairment,1
TANZEUM,upper respiratory tract infection,placebo upper respiratory tract infection,1
TANZEUM,upper respiratory tract infection,and Renal Impairment,1
TANZEUM,upper respiratory tract infection,tract infection diarrhea,1
TANZEUM,upper respiratory tract infection,placebo upper,1
TANZEUM,upper respiratory tract infection,in patients on placebo upper respiratory tract infection diarrhea nausea injection site reaction,1
TANZEUM,upper respiratory tract infection,placebo upper,1
TANZEUM,upper respiratory tract infection,in patients on placebo upper respiratory tract infection diarrhea nausea,1
TANZEUM,upper respiratory tract infection,placebo upper,1
TANZEUM,upper respiratory tract infection,tract infection diarrhea nausea injection,1
TANZEUM,upper respiratory tract infection,upper respiratory tract infection diarrhea nausea injection,1
TANZEUM,upper respiratory tract infection,in patients on placebo upper respiratory tract infection,1
TANZEUM,upper respiratory tract infection,upper respiratory tract infection diarrhea nausea injection,1
TANZEUM,upper respiratory tract infection,placebo upper respiratory tract infection,1
TANZEUM,upper respiratory tract infection,upper respiratory tract infection diarrhea nausea injection,1
TANZEUM,diarrhea,respiratory tract diarrhea nausea injection site reaction cough,1
TANZEUM,diarrhea,upper respiratory tract infection diarrhea nausea injection,1
TANZEUM,diarrhea,in,0
TANZEUM,diarrhea,diarrhea nausea injection site reaction cough,1
TANZEUM,diarrhea,placebo were upper respiratory tract,0
TANZEUM,diarrhea,upper respiratory tract infection,0
TANZEUM,diarrhea,diarrhea,1
TANZEUM,diarrhea,upper respiratory tract infection,0
TANZEUM,nausea,more,0
TANZEUM,nausea,nausea,1
TANZEUM,nausea,tract infection nausea injection site,1
TANZEUM,nausea,nausea,1
TANZEUM,nausea,nausea injection site reaction cough,1
TANZEUM,nausea,respiratory,0
TANZEUM,nausea,site reaction cough back,0
TANZEUM,nausea,reaction cough back pain arthralgia sinusitis and,0
TANZEUM,nausea,tract infection nausea injection site reaction,1
TANZEUM,nausea,reaction cough back pain arthralgia sinusitis and,0
TANZEUM,nausea,patients on placebo,0
TANZEUM,nausea,nausea injection site reaction,1
TANZEUM,cough,site cough back pain arthralgia,1
TANZEUM,cough,nausea injection site reaction,1
TANZEUM,cough,To report,0
TANZEUM,back pain,were upper respiratory,0
TANZEUM,arthralgia,reaction cough back arthralgia sinusitis,1
TANZEUM,arthralgia,were upper respiratory,0
TANZEUM,arthralgia,To report SUSPECTED ADVERSE REACTIONS contact,0
TANZEUM,sinusitis,sinusitis and influenza To report,1
TANZEUM,sinusitis,reaction cough back pain sinusitis and influenza,1
TANZEUM,sinusitis,sinusitis and influenza To report,1
TANZEUM,sinusitis,pain sinusitis and,1
TANZEUM,sinusitis,sinusitis and influenza To report,1
TANZEUM,sinusitis,cough back pain sinusitis and influenza To,1
TANZEUM,sinusitis,sinusitis and influenza To report,1
TANZEUM,influenza,influenza To report SUSPECTED ADVERSE REACTIONS,1
TANZEUM,influenza,back,0
TANZEUM,influenza,injection site reaction cough back pain arthralgia,0
TANZEUM,influenza,sinusitis influenza,1
TANZEUM,influenza,injection site reaction cough back pain arthralgia,0
TANZEUM,influenza,SUSPECTED ADVERSE REACTIONS contact,0
TANZEUM,influenza,influenza To,1
TANZEUM,influenza,pain arthralgia sinusitis influenza To,1
TANZEUM,influenza,influenza To,1
TANZEUM,influenza,back pain arthralgia sinusitis influenza To report SUSPECTED ADVERSE REACTIONS,1
TANZEUM,influenza,influenza To,1
TANZEUM,influenza,influenza,1
TANZEUM,influenza,influenza To,1
TANZEUM,hypoglycemia,hypoglycemia associated,1
TANZEUM,hypoglycemia,hypoglycemia associated with the,1
TANZEUM,hypoglycemia,hypoglycemia associated with the use of,1
TANZEUM,hypoglycemia,hypoglycemia associated with the use,1
TANZEUM,hypoglycemia,pool of placebocontrolled,0
TANZEUM,hypoglycemia,hypoglycemia associated,1
TANZEUM,injection site reactions,for other events injection site reactions,1
TANZEUM,injection site reactions,hypoglycemia associated,1
TANZEUM,injection site reactions,for other events injection site reactions,1
TANZEUM,injection site reactions,injection site reactions reported Gastrointestinal Adverse,1
TANZEUM,injection site reactions,placebo and for TANZEUM b See below,0
TANZEUM,gastrointestinal complaints,of placebocontrolled gastrointestinal complaints occurred more,1
TANZEUM,gastrointestinal complaints,placebo and for TANZEUM b See below,0
TANZEUM,gastrointestinal complaints,gastrointestinal complaints occurred,1
TANZEUM,gastrointestinal complaints,occurred,0
TANZEUM,diarrhea,diarrhea and nausea see,1
TANZEUM,diarrhea,diarrhea and nausea see Table,1
TANZEUM,diarrhea,receiving placebo In addition diarrhea and,1
TANZEUM,diarrhea,diarrhea and nausea see Table,1
TANZEUM,diarrhea,diarrhea and nausea,1
TANZEUM,diarrhea,Table the,0
TANZEUM,diarrhea,diarrhea and nausea,1
TANZEUM,nausea,nausea see,1
TANZEUM,nausea,more,0
TANZEUM,nausea,addition to diarrhea,0
TANZEUM,nausea,nausea see Table the,1
TANZEUM,nausea,to diarrhea and,0
TANZEUM,nausea,gastrointestinal adverse reactions also,0
TANZEUM,nausea,nausea see,1
TANZEUM,nausea,and,0
TANZEUM,gastrointestinal adverse reactions,patients receiving,0
TANZEUM,gastrointestinal adverse reactions,adverse reactions also occurred more frequently,1
TANZEUM,gastrointestinal adverse reactions,receiving,0
TANZEUM,gastrointestinal adverse reactions,adverse reactions,1
TANZEUM,gastrointestinal adverse reactions,the gastrointestinal adverse,1
TANZEUM,gastrointestinal adverse reactions,and nausea,0
TANZEUM,gastrointestinal adverse reactions,gastrointestinal adverse reactions,1
TANZEUM,gastrointestinal adverse reactions,TANZEUM vomiting versus for placebo,0
TANZEUM,vomiting,disease,0
TANZEUM,vomiting,patients receiving,0
TANZEUM,vomiting,reactions also occurred more,0
TANZEUM,vomiting,in patients receiving vomiting,1
TANZEUM,vomiting,reactions also occurred more,0
TANZEUM,vomiting,vomiting versus for placebo versus TANZEUM,1
TANZEUM,vomiting,reactions also occurred more,0
TANZEUM,vomiting,patients receiving vomiting versus for placebo versus TANZEUM,1
TANZEUM,vomiting,reactions also occurred more,0
TANZEUM,vomiting,patients,0
TANZEUM,vomiting,frequently in patients receiving vomiting versus for,1
TANZEUM,vomiting,patients,0
TANZEUM,gastroesophageal reflux disease,vomiting versus for placebo versus TANZEUM,0
TANZEUM,gastroesophageal reflux disease,gastroesophageal reflux disease versus for placebo versus,1
TANZEUM,gastroesophageal reflux disease,for placebo versus gastroesophageal reflux disease versus,1
TANZEUM,gastroesophageal reflux disease,gastroesophageal reflux disease versus for placebo versus,1
TANZEUM,dyspepsia,dyspepsia,1
TANZEUM,dyspepsia,dyspepsia versus for placebo versus,1
TANZEUM,dyspepsia,dyspepsia,1
TANZEUM,dyspepsia,dyspepsia,1
TANZEUM,dyspepsia,for placebo versus TANZEUM dyspepsia versus,1
TANZEUM,dyspepsia,dyspepsia,1
TANZEUM,dyspepsia,TANZEUM dyspepsia versus for placebo versus,1
TANZEUM,dyspepsia,dyspepsia,1
TANZEUM,dyspepsia,placebo versus TANZEUM dyspepsia versus,1
TANZEUM,dyspepsia,dyspepsia,1
TANZEUM,Constipation,Constipation also contributed to,1
TANZEUM,Constipation,Constipation also contributed to,1
TANZEUM,GI reactions,GI reactions as mild in of cases,1
TANZEUM,GI reactions,and severe in,0
TANZEUM,GI reactions,GI reactions,1
TANZEUM,GI reactions,severity GI,1
TANZEUM,GI reactions,graded the severity of,0
TANZEUM,GI reactions,GI reactions as mild in,1
TANZEUM,GI reactions,In the group treated with,0
TANZEUM,injection site reactions,Reactions In,0
TANZEUM,injection site reactions,the pool of placebocontrolled injection,1
TANZEUM,injection site reactions,addition to the term injection s,0
TANZEUM,injection site reactions,occurred more frequently,0
TANZEUM,injection site reactions,placebo Injection Site Reactions In,0
TANZEUM,injection site reactions,pool of placebocontrolled injection site reactions,1
TANZEUM,injection site reactions,placebo Injection Site Reactions In,0
TANZEUM,injection site reactions,pool of placebocontrolled injection site reactions occurred more,1
TANZEUM,injection site reactions,placebo Injection Site Reactions In,0
TANZEUM,injection site reactions,term injection s,0
TANZEUM,injection site reactions,Site,0
TANZEUM,injection site reactions,to the term,0
TANZEUM,injection site reaction,injection site reaction see Table,1
TANZEUM,injection site reaction,more frequently on TANZEUM than on placebo In addition to,0
TANZEUM,injection site reaction,site reactions also,0
TANZEUM,injection site reaction,site reaction,1
TANZEUM,injection site reaction,types of injection site reactions also,0
TANZEUM,injection site reaction,injection site reaction,1
TANZEUM,injection site reaction,types of injection site reactions also,0
TANZEUM,injection site reaction,In addition to the injection,1
TANZEUM,injection site reaction,occurred,0
TANZEUM,injection site reaction,also occurred,0
TANZEUM,injection site reaction,addition,0
TANZEUM,injection site reactions,types injection site reactions,1
TANZEUM,injection site reactions,following other types injection site reactions also occurred,1
TANZEUM,injection site reactions,types injection site reactions,1
TANZEUM,injection site reactions,occurred more frequently on TANZEUM injection site hematoma versus for placebo ver,0
TANZEUM,injection site reactions,the following other types injection site reactions,1
TANZEUM,injection site reactions,site reaction see Table the following,0
TANZEUM,injection site reactions,following other types injection site reactions also occurred,1
TANZEUM,injection site reactions,site reaction see Table the following,0
TANZEUM,injection site reactions,versus for,0
TANZEUM,injection site reactions,more frequently on TANZEUM injection site hematoma,0
TANZEUM,injection site hematoma,occurred more frequently on injection site hematoma versus for placebo versus TANZEUM,1
TANZEUM,injection site hematoma,more frequently on TANZEUM injection site hematoma,0
TANZEUM,injection site hematoma,erythema versus for,0
TANZEUM,injection site hematoma,occurred more frequently on injection site hematoma versus for placebo versus,1
TANZEUM,injection site hematoma,erythema versus for,0
TANZEUM,injection site hematoma,the following other types of injection site reactions,0
TANZEUM,injection site erythema,hematoma versus for placebo versus TANZEUM,0
TANZEUM,injection site rash,site rash versus for placebo versus TANZEUM,1
TANZEUM,injection site rash,injection site rash,1
TANZEUM,injection site rash,TANZEUM injection site hypersensitivity versus,0
TANZEUM,injection site rash,placebo versus injection,1
TANZEUM,injection site rash,placebo versus TANZEUM,0
TANZEUM,injection site rash,versus,0
TANZEUM,injection site rash,for placebo versus injection site rash versus,1
TANZEUM,injection site rash,versus,0
TANZEUM,injection site rash,versus TANZEUM injection site erythema,0
TANZEUM,injection site rash,versus for placebo versus,0
TANZEUM,injection site rash,versus,0
TANZEUM,injection site hypersensitivity,versus injection site hypersensitivity versus,1
TANZEUM,injection site hypersensitivity,versus,0
TANZEUM,injection site hypersensitivity,versus TANZEUM and injection site hemorrhage versus for,0
TANZEUM,injection site hypersensitivity,placebo versus TANZEUM injection site rash versus for,0
TANZEUM,injection site hypersensitivity,versus injection site hypersensitivity versus for,1
TANZEUM,injection site hypersensitivity,placebo versus TANZEUM injection site rash versus for,0
TANZEUM,injection site hypersensitivity,versus for,0
TANZEUM,injection site hypersensitivity,versus injection site hypersensitivity versus,1
TANZEUM,injection site hypersensitivity,versus for,0
TANZEUM,injection site hemorrhage,placebo versus TANZEUM injection site hemorrhage,1
TANZEUM,injection site hemorrhage,placebo versus TANZEUM and,0
TANZEUM,injection site hemorrhage,versus TANZEUM injection site hemorrhage,1
TANZEUM,injection site hemorrhage,placebo versus TANZEUM injection,1
TANZEUM,injection site hemorrhage,versus TANZEUM and,0
TANZEUM,injection site hemorrhage,TANZEUM injection site,1
TANZEUM,Injection site pruritus,versus Injection,1
TANZEUM,Injection site pruritus,injection site reactions wer,0
TANZEUM,Injection site pruritus,site pruritus also contributed to,1
TANZEUM,Injection site pruritus,Injection site pruritus also contributed to,1
TANZEUM,Injection site pruritus,for placebo versus Injection site pruritus also contributed,1
TANZEUM,Injection site pruritus,Injection site pruritus also contributed to,1
TANZEUM,Injection site pruritus,placebo versus Injection site pruritus also contributed to,1
TANZEUM,Injection site pruritus,Injection site pruritus also contributed to,1
TANZEUM,Injection site pruritus,site pruritus also contributed to,1
TANZEUM,Injection site pruritus,versus Injection site pruritus,1
TANZEUM,injection site reactions,injection site reactions were judged as,1
TANZEUM,injection site reactions,judged as mild by investigators in both groups for TANZEUM versus for placebo,0
TANZEUM,injection site reactions,were judged as mild by investigators in both groups for TANZEUM,0
TANZEUM,injection site reactions,site reactions,1
TANZEUM,injection site reactions,majority injection,1
TANZEUM,injection site reactions,The majority injection,1
TANZEUM,injection site reactions,reported reactions The majority injection site,1
TANZEUM,injection site reactions,site reactions were,1
TANZEUM,injection site reactions,frequently reported reactions,0
TANZEUM,injection site reactions,reactions The majority of,0
TANZEUM,injection site reactions,The,0
TANZEUM,injection site reaction,injection site,1
TANZEUM,injection site reaction,for placebo More patients on TANZEUM than on placebo,0
TANZEUM,injection site reaction,than reactions versus had a reaction judged by inve,0
TANZEUM,injection site reaction,injection site reaction versus experienced more than reactions,1
TANZEUM,injection site reaction,versus for,0
TANZEUM,injection site reaction,a reaction judged,0
TANZEUM,injection site reaction,injection site reaction versus experienced,1
TANZEUM,hypoglycemia,hypoglycemia were similar to those listed,1
TANZEUM,hypoglycemic episode,at least one documented hypoglycemic,1
TANZEUM,hypoglycemic episode,hypoglycemic episode on,1
TANZEUM,hypoglycemic episode,hypoglycemic episode on TANZEUM and the,1
TANZEUM,hypoglycemic episode,at least one documented hypoglycemic,1
TANZEUM,hypoglycemic episode,one documented hypoglycemic episode,1
TANZEUM,hypoglycemic episode,hypoglycemic episode on TANZEUM and,1
TANZEUM,hypoglycemic episode,one hypoglycemic episode,1
TANZEUM,hypoglycemic episode,least one hypoglycemic episode,1
TANZEUM,Hypoglycemia,TANZEUM was added,0
TANZEUM,Hypoglycemia,Hypoglycemia was more,1
TANZEUM,hypoglycemia,no documented symptomatic or hypoglycemia,1
TANZEUM,hypoglycemia,Hypoglycemia was more,1
TANZEUM,hypoglycemia,and these data are omitted from the table,0
TANZEUM,hypoglycemia,from the table c Plasma gluc,0
TANZEUM,hypoglycemia,hypoglycemia were,1
TANZEUM,hypoglycemia,In this trial no documented symptomatic or,0
TANZEUM,Plasma glucose concentration <=70 mg/dL,the table Plasma glucose concentration <=70 mg/dL and,1
TANZEUM,Plasma glucose concentration <=70 mg/dL,In this trial no documented symptomatic or,0
TANZEUM,Plasma glucose concentration <=70 mg/dL,the table Plasma glucose concentration,1
TANZEUM,Plasma glucose concentration <=70 mg/dL,of hypoglycemic symptoms,0
TANZEUM,Plasma glucose concentration <=70 mg/dL,table Plasma glucose concentration <=70 mg/dL,1
TANZEUM,Plasma glucose concentration <=70 mg/dL,concentration <=70 mg/dL and presence of hypoglycemic,1
TANZEUM,Plasma glucose concentration <=70 mg/dL,the table Plasma glucose concentration <=70 mg/dL,1
TANZEUM,Plasma glucose concentration <=70 mg/dL,concentration <=70 mg/dL and presence of hypoglycemic,1
TANZEUM,Plasma glucose concentration <=70 mg/dL,are omitted from the table,0
TANZEUM,hypoglycemic symptoms,to administer a resuscitative action e,0
TANZEUM,hypoglycemic symptoms,and presence hypoglycemic symptoms d,1
TANZEUM,hypoglycemic symptoms,to administer a resuscitative action e,0
TANZEUM,hypoglycemia,another person to administer a,0
TANZEUM,pneumonia,adverse reaction pneumonia was reported more,1
TANZEUM,pneumonia,another person to administer a,0
TANZEUM,pneumonia,cases pneumonia in the group,1
TANZEUM,pneumonia,another person to administer a,0
TANZEUM,pneumonia,pneumonia in the group receiving,1
TANZEUM,pneumonia,TANZEUM versus,0
TANZEUM,pneumonia,group More,0
TANZEUM,pneumonia,cases pneumonia in the group receiving TANZEUM,1
TANZEUM,pneumonia,group More,0
TANZEUM,pneumonia,group receiving TANZEUM were serious for,0
TANZEUM,pneumonia,pneumonia in the group receiving TANZEUM,1
TANZEUM,pneumonia,than in patients in the allcomparators group More cases,0
TANZEUM,atrial fibrillation,atrial fibrillation,1
TANZEUM,atrial fibrillation,illationFlutte r In the pool of placebo and activecontrolled,0
TANZEUM,atrial fibrillation,atrial fibrillation and atrial,1
TANZEUM,atrial flutter,fibrillation atrial flutter,1
TANZEUM,atrial flutter,atrial fibrillation atrial flutter,1
TANZEUM,atrial flutter,fibrillation atrial flutter,1
TANZEUM,atrial flutter,comparators and respectivel,0
TANZEUM,atrial flutter,atrial flutter were reported,1
TANZEUM,atrial flutter,fibrillation atrial flutter were reported more frequently,1
TANZEUM,atrial flutter,atrial flutter were reported,1
TANZEUM,atrial flutter,fibrillation atrial flutter were reported more frequently,1
TANZEUM,atrial flutter,atrial flutter were reported,1
TANZEUM,atrial flutter,atrial flutter were,1
TANZEUM,atrial flutter,atrial flutter,1
TANZEUM,appendicitis,trials serious events appendicitis occurred,1
TANZEUM,appendicitis,atrial flutter,1
TANZEUM,appendicitis,appendicitis occurred in of patients treated,1
TANZEUM,appendicitis,TANZEUM compared with among all,0
TANZEUM,appendicitis,serious events appendicitis occurred in,1
TANZEUM,appendicitis,TANZEUM compared with among all,0
TANZEUM,appendicitis,appendicitis,1
TANZEUM,appendicitis,events of,0
TANZEUM,appendicitis,In the pool of,0
TANZEUM,ALT increase,least one event ALT increase of fold or greater above,1
TANZEUM,ALT increase,In the pool of,0
TANZEUM,ALT increase,ALT increase of fold or,1
TANZEUM,ALT increase,greater above the upper limit of normal In one of the cases an,0
TANZEUM,ALT increase,subject in the allcomparator group experienced at least one,0
TANZEUM,ALT increase,fold or greater above the upper limit of normal,0
TANZEUM,elevation in ALT,total bilirubin times the,0
TANZEUM,elevation in ALT,third,0
TANZEUM,elevation in ALT,the third case,0
TANZEUM,elevation in ALT,refute,0
TANZEUM,elevation in ALT,elevation in ALT times the,1
TANZEUM,elevation in ALT,in ALT,1
TANZEUM,elevation in ALT,elevation in ALT times,1
TANZEUM,elevation in ALT,a drugrelated causality,0
TANZEUM,increase in total bilirubin,by increase,1
TANZEUM,increase in total bilirubin,total bilirubin,1
TANZEUM,increase in total bilirubin,normal and,0
TANZEUM,increase in total bilirubin,normal was accompanied by increase in total bilirubin,1
TANZEUM,increase in total bilirubin,of TANZEUM The etiolo,0
TANZEUM,increase in total bilirubin,normal and occurred days,0
TANZEUM,increase in total bilirubin,in total bilirubin times the upper limit,1
TANZEUM,increase in total bilirubin,case elevation in ALT times the upper limit of,0
TANZEUM,increase in total bilirubin,total bilirubin times,1
TANZEUM,hepatocellular injury,of TANZEUM The etiology of,0
TANZEUM,hepatocellular injury,etiology hepatocellular injury,1
TANZEUM,hepatocellular injury,of TANZEUM The etiology of,0
TANZEUM,hepatocellular injury,TANZEUM The etiology hepatocellular injury,1
TANZEUM,increased GGT,more frequently in the group treated with TANZEUM and for placebo,0
TANZEUM,increased GGT,event of,0
TANZEUM,increased GGT,increased GGT occurred more frequently,1
TANZEUM,increased GGT,trials the adverse event increased GGT,1
TANZEUM,increased GGT,increased GGT occurred,1
TANZEUM,increased GGT,trials the adverse event increased GGT,1
TANZEUM,increased GGT,and,0
TANZEUM,increase in heart rate,established,0
TANZEUM,increase in heart rate,been established,0
TANZEUM,THYROID C-CELL TUMORS,ng serious reactions,1
TANZEUM,THYROID C-CELL TUMORS,ng serious reactions are described below or elsewhere,1
TANZEUM,THYROID C-CELL TUMORS,ng serious,1
TANZEUM,THYROID C-CELL TUMORS,ng serious reactions ,1
TANZEUM,THYROID C-CELL TUMORS,ng serious,1
TANZEUM,THYROID C-CELL TUMORS,ng serious,1
TANZEUM,THYROID C-CELL TUMORS,The ng serious reactions  are described below or,1
TANZEUM,THYROID C-CELL TUMORS,ng serious,1
TANZEUM,THYROID C-CELL TUMORS,o,0
TANZEUM,THYROID C-CELL TUMORS,described below r elsewhere in the pr,1
TANZEUM,THYROID C-CELL TUMORS,below,0
TANZEUM,THYROID C-CELL TUMORS,described,0
TANZEUM,THYROID C-CELL TUMORS,elsewhere in the pr escribing information Risk of Thyroid,1
TANZEUM,THYROID C-CELL TUMORS,elsewhere in the pr escribing information Risk of Thyroid,1
TANZEUM,thyroid C-cell tumors,(5.2)] *,1
TANZEUM,thyroid C-cell tumors,"see Warnings and ecautions (5.2)]  
 * Hypoglycemia with Concomitant Use of",1
TANZEUM,thyroid C-cell tumors,(5.2)] *,1
TANZEUM,thyroid C-cell tumors,Precautions,0
TANZEUM,thyroid C-cell tumors,ecautions (5.2)] *,1
TANZEUM,C-cell tumors,Precautions Renal,0
TANZEUM,C-cell tumors,Insulin Secretagogues or Insulin see Warnings and,0
TANZEUM,C-cell tumors,autions (5.3) Hypersensitivity Reactions see Warnings,1
TANZEUM,C-cell tumors,Insulin see Warnings and autions (5.3),1
TANZEUM,C-cell tumors,Hypersensitivity Reactions see Warnings and Precautions Renal,0
TANZEUM,C-cell tumors,Precautions Renal,0
TANZEUM,C-cell tumors,and Precautions Renal Impairment,0
TANZEUM,thyroid C-cell tumors,Renal Impairment see,1
TANZEUM,thyroid C-cell tumors,and *    Renal Impairment see Warnings and Precautions EXCERPT,1
TANZEUM,thyroid C-cell tumors,Renal Impairment see,1
TANZEUM,thyroid C-cell tumors,and *    Renal Impairment see Warnings,1
TANZEUM,thyroid C-cell tumors,Renal Impairment see,1
TANZEUM,thyroid C-cell tumors,and *    Renal Impairment see Warnings and,1
TANZEUM,thyroid C-cell tumors,Renal Impairment see,1
TANZEUM,thyroid C-cell tumors,Reactions see Warnings and * Renal Impairment,1
TANZEUM,thyroid C-cell tumors,Reactions see Warnings and *    Renal Impairment see Warnings and Precautions EXCERPT,1
TANZEUM,thyroid C-cell tumors,Reactions see Warnings and * Renal Impairment,1
TANZEUM,thyroid C-cell tumors,Warnings,0
TANZEUM,thyroid C-cell tumors,Warnings and * Renal Impairment,1
TANZEUM,thyroid C-cell tumors,reported in,0
TANZEUM,medullary thyroid carcinoma,Renal,0
TANZEUM,medullary thyroid carcinoma,and Precautions,0
TANZEUM,medullary thyroid carcinoma,patients treated with,0
TANZEUM,medullary thyroid carcinoma,see gs and Precautions (5.5)],1
TANZEUM,medullary thyroid carcinoma,Renal Impairment see gs and Precautions,1
TANZEUM,medullary thyroid carcinoma,Warnin,0
TANZEUM,medullary thyroid carcinoma,Impairment see Warnin,0
TANZEUM,medullary thyroid carcinoma,with TANZEUM and more freq,0
TANZEUM,MTC,and more,0
TANZEUM,MTC,Impairment see Warnings and     EXCERPT,1
TANZEUM,MTC,and more,0
TANZEUM,MTC,    EXCERPT Adverse,1
TANZEUM,MTC,and more,0
TANZEUM,MTC,and more,0
TANZEUM,thyroid C-cell tumors,see Cli,0
TANZEUM,thyroid C-cell tumors,olled trials TANZEUM was used as monotherapy in trial and as addon therapy in trials see Cli,0
TANZEUM,thyroid C-cell tumors,trials see nical Studies (14)]   These data reflect,1
TANZEUM,thyroid C-cell tumors,olled trials TANZEUM was used as monotherapy in trial and as addon therapy in trials see Cli,0
TANZEUM,thyroid C-cell tumors,therapy in trials see nical Studies (14)]   These data reflect exposure of,1
TANZEUM,thyroid C-cell tumors,olled trials TANZEUM was used as monotherapy in trial and as addon therapy in trials see Cli,0
TANZEUM,thyroid C-cell tumors,in trials see nical Studies (14)],1
TANZEUM,thyroid C-cell tumors,mean duration of,0
TANZEUM,thyroid C-cell tumors,nical Studies (14)]   These data reflect,1
TANZEUM,thyroid C-cell tumors,mean duration of,0
TANZEUM,thyroid C-cell tumors,nical Studies (14)] These data reflect,1
TANZEUM,thyroid C-cell tumors,Studies (14)] These,1
TANZEUM,C-cell tumors,TANZEUM and a mean,0
TANZEUM,C-cell tumors,years or older and,0
TANZEUM,C-cell tumors,of exposure to EUM of 93 wee,1
TANZEUM,C-cell tumors,years or older and,0
TANZEUM,C-cell tumors,exposure to EUM of 93,1
TANZEUM,C-cell tumors,reflect exposure of patients to TANZEUM and a,0
TANZEUM,thyroid C-cell tumors,years or older and 53,1
TANZEUM,thyroid C-cell tumors,years or older and 53 of participants were male,1
TANZEUM,thyroid C-cell tumors,years or older and 53,1
TANZEUM,medullary thyroid carcinoma,or older and of pants were male. The popula tion in,1
TANZEUM,medullary thyroid carcinoma,years or older and 53,1
TANZEUM,medullary thyroid carcinoma,of,0
TANZEUM,medullary thyroid carcinoma,of partici,0
TANZEUM,medullary thyroid carcinoma,and of pants were male. The popula tion in,1
TANZEUM,medullary thyroid carcinoma,of partici,0
TANZEUM,medullary thyroid carcinoma,were male. The popula tion,1
TANZEUM,medullary thyroid carcinoma,were male. The popula tion in these studies was,1
TANZEUM,medullary thyroid carcinoma,The popula,1
TANZEUM,medullary thyroid carcinoma,studies was white AfricanAfrican American Asian,0
TANZEUM,MTC,white AfricanAfrican American Asian and HispanicLatino At,0
TANZEUM,MTC,white AfricanAfrican American Asian,0
TANZEUM,MTC,or older and of participants were,0
TANZEUM,MTC,on  in,1
TANZEUM,MTC,and HispanicLatino,0
TANZEUM,MTC,The on  in these studies,1
TANZEUM,MTC,and HispanicLatino,0
TANZEUM,MTC,American Asian and HispanicLatino,0
TANZEUM,Thyroid C-cell Tumors,described b elow,1
TANZEUM,Thyroid C-cell Tumors,elsewhere in the prescribing information Risk of Thyroid Ccell Tumors see Warnin,0
TANZEUM,Thyroid C-cell Tumors,are described b elow or elsewhere in,1
TANZEUM,Thyroid C-cell Tumors,Tumors see Warnin,0
TANZEUM,Thyroid C-cell Tumors,tions are described b elow or elsewhere,1
TANZEUM,Thyroid C-cell Tumors,The following serious,0
TANZEUM,Thyroid C-cell Tumors,tions are described b elow or elsewhere,1
TANZEUM,Thyroid C-cell Tumors,reac,0
TANZEUM,Pancreatitis,prescribin,0
TANZEUM,Pancreatitis,Ccell Tumors see,0
TANZEUM,Hypoglycemia,Hypoglycemi,0
TANZEUM,Hypoglycemia,and Precautions a with Conco mitant Use of Insulin,1
TANZEUM,Hypoglycemia,Hypoglycemi,0
TANZEUM,Hypersensitivity Reactions,with,0
TANZEUM,Hypersensitivity Reactions,treated,0
TANZEUM,Hypersensitivity Reactions,treated with TANZEUM and,0
TANZEUM,Renal Impairment,"placebo, wer e",1
TANZEUM,Renal Impairment,"on placebo, wer e upper respiratory",1
TANZEUM,Renal Impairment,"on placebo, wer e upper respiratory tract infection",1
TANZEUM,thyroid C-cell tumors,Controlled,1
TANZEUM,thyroid C-cell tumors,Controlled Trials The,1
TANZEUM,thyroid C-cell tumors,"in practice Pool of Controlled Trials  

 The",1
TANZEUM,thyroid C-cell tumors,Controlled Trials The,1
TANZEUM,C-cell tumors, monotherapy  in,1
TANZEUM,C-cell tumors, monotherapy  in,1
TANZEUM,C-cell tumors, monotherapy  in trial,1
TANZEUM,C-cell tumors,data reflect,0
TANZEUM,C-cell tumors,are,0
TANZEUM,C-cell tumors, monotherapy  in trial and,1
TANZEUM,C-cell tumors,in Table are derived from placebocontrolled trials,0
TANZEUM,thyroid C-cell tumors,and a,0
TANZEUM,MTC,TANZEUM and a mean duration of exposure to TANZEUM of weeks The,0
TANZEUM,MTC, 92 patients to TANZEUM,1
TANZEUM,MTC,reflect exposure  92 patients to TANZEUM and,1
TANZEUM,MTC, 92 patients to TANZEUM,1
TANZEUM,MTC,in trials see,0
TANZEUM,MTC,exposure,0
TANZEUM,MTC,patients to,0
TANZEUM,MTC,mean,0
TANZEUM,MTC,nts were years or older,1
TANZEUM,MTC,nts,1
TANZEUM,MTC,in these studies was,0
TANZEUM,MTC,was years of nts were years or,1
TANZEUM,MTC,in these studies was,0
TANZEUM,MTC,nts,1
TANZEUM,MTC,participants was years,0
TANZEUM,MTC,of nts were years,1
TANZEUM,MTC,participants was years,0
TANZEUM,MTC,diabetes for an average,0
TANZEUM,MTC,pat hy Baseline estimated renal,1
TANZEUM,hypoglycemia,Adverse Reactions In the pool of placebocontroll,0
TANZEUM,hypoglycemia,pool of,0
TANZEUM,hypoglycemia,"of ed trials, g astrointestinal complaints occurred more",1
TANZEUM,hypoglycemia,pool of,0
TANZEUM,hypoglycemia,of ed,1
TANZEUM,hypoglycemia,"trials, g astrointestinal complaints occurred more frequently",1
TANZEUM,hypoglycemia,"ed trials, g astrointestinal",1
TANZEUM,hypoglycemia,"ed trials,",1
TANZEUM,hypoglycemia,the following tinal advers e,1
TANZEUM,hypoglycemia,"ed trials,",1
TANZEUM,hypoglycemia,addition to diarrhea,0
TANZEUM,hypersensitivity reaction,versus TANZEUM gastroesophageal reflux disease versus for placebo versus TAN,0
TANZEUM,hypersensitivity reaction,"versus ZEUM), and",1
TANZEUM,hypersensitivity reaction,and dyspepsia (2.8 versus for,1
TANZEUM,hypersensitivity reaction,to the,0
TANZEUM,pruritus,reflux disease,0
TANZEUM,pruritus,us 3.4% for,1
TANZEUM,pruritus,contributed to the frequently,0
TANZEUM,pruritus,versus TANZEUM and dyspepsia us 3.4%  for placebo,1
TANZEUM,pruritus,contributed to the frequently,0
TANZEUM,pruritus,us 3.4% for placebo versus TANZEUM,1
TANZEUM,pruritus,dyspepsia us,1
TANZEUM,pruritus,TANZEUM and dyspepsia us 3.4%  for placebo,1
TANZEUM,pruritus,dyspepsia us,1
TANZEUM,pruritus,reported,0
TANZEUM,pruritus,vers,0
TANZEUM,rash,r pl,1
TANZEUM,rash,versus TANZEUM Constipation also contributed to the frequently,0
TANZEUM,rash,r pl acebo,1
TANZEUM,rash,versus TANZEUM Constipation also contributed to the frequently,0
TANZEUM,rash,r pl acebo versus TANZEUM,1
TANZEUM,dyspnea,versus  TANZEUM Constipation also contributed to,1
TANZEUM,dyspnea,dyspepsia versus for versus  TANZEUM Constipation,1
TANZEUM,dyspnea,versus  TANZEUM Constipation also contributed to,1
TANZEUM,dyspnea,dyspepsia versus for versus ,1
TANZEUM,dyspnea,versus  TANZEUM Constipation also contributed to,1
TANZEUM,dyspnea,the group treated w,0
TANZEUM,dyspnea,versus  TANZEUM Constipation also contributed,1
TANZEUM,dyspnea,versus  TANZEUM Constipation,1
TANZEUM,dyspnea,versus ,1
TANZEUM,dyspnea,disease versus for placebo,0
TANZEUM,dyspnea,placebo,0
TANZEUM,dyspnea,for versus  TANZEUM Constipation also,1
TANZEUM,dyspnea,placebo,0
TANZEUM,worsening of chronic renal failure,"Site ions  



 In the pool of placebo- controlled trials injection site",1
TANZEUM,worsening of chronic renal failure,placebo,0
TANZEUM,worsening of chronic renal failure,Injection Site ions In the,1
TANZEUM,worsening of chronic renal failure,of placebo- controlled trials injection site reactions,1
TANZEUM,worsening of chronic renal failure,adverse reactions occurred in of individuals on TANZEUM,0
TANZEUM,worsening of chronic renal failure,Site,0
TANZEUM,worsening of chronic renal failure,In the pool of placebo- controlled trials injection site,1
TANZEUM,vomiting,types of site rea ctions,1
TANZEUM,vomiting,In the pool of placebo- controlled trials injection site,1
TANZEUM,vomiting,types of injection,0
TANZEUM,vomiting,the following other types of injection,0
TANZEUM,vomiting,types of,0
TANZEUM,diarrhea,ions als o occurred,1
TANZEUM,diarrhea,on TANZEUM injection site hematoma,0
TANZEUM,diarrhea,injection site ions als o occurred more frequently on,1
TANZEUM,diarrhea,on TANZEUM injection site hematoma,0
TANZEUM,diarrhea,to the term injection site reaction see Table the following other types,0
TANZEUM,diarrhea,see Table the following other types of injection site react,0
TANZEUM,diarrhea,types of injection site ions,1
TANZEUM,diarrhea,frequently on TANZEUM injection site hematoma versus for placebo,0
TANZEUM,dehydration,injection site reactions also urred,1
TANZEUM,dehydration,injection site hematoma versus for placebo versus TANZEUM injec,0
TANZEUM,dehydration,urred more frequently on TANZEUM injection site,1
TANZEUM,dehydration,njection site reaction,0
TANZEUM,dehydration,occ,0
TANZEUM,dehydration,urred more,1
TANZEUM,dehydration,urred more,1
TANZEUM,dehydration,reactions also occ,0
TANZEUM,dehydration,versus for placebo versus TANZEUM,0
TANZEUM,renal function declined,"for placebo s TANZEUM), injection",1
TANZEUM,renal function declined,injection s ite rash,1
TANZEUM,renal function declined,for,0
TANZEUM,renal function declined,site,0
TANZEUM,renal function declined,for,0
TANZEUM,renal function declined,ersus for placebo versus TANZEUM injection site erythema,0
TANZEUM,renal function declined,"for placebo s TANZEUM),",1
TANZEUM,renal function declined,for placebo,0
BELEODAQ,Infection,Infection see Warnings and Precautions Hepatotoxicity,1
BELEODAQ,Infection,Infection see Warnings and Precautions Hepatotoxicity,1
BELEODAQ,Infection,Infection see,1
BELEODAQ,Infection,Infection see Warnings,1
BELEODAQ,Hepatotoxicity,Infection see Warnings and Hepatotoxicity see Warnings,1
BELEODAQ,Hepatotoxicity,Infection see Warnings,1
BELEODAQ,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions,1
BELEODAQ,Hepatotoxicity,Infection see Warnings and Hepatotoxicity see Warnings,1
BELEODAQ,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions,1
BELEODAQ,Hepatotoxicity,Hepatotoxicity see Warnings,1
BELEODAQ,Hepatotoxicity,see Warnings and,0
BELEODAQ,Hepatotoxicity,see Warnings and Precautions,0
BELEODAQ,Gastrointestinal Toxicity,and Gastrointestinal Toxicity see,1
BELEODAQ,Gastrointestinal Toxicity,see Warnings and Precautions,0
BELEODAQ,Gastrointestinal Toxicity,see Warnings and Gastrointestinal Toxicity see,1
BELEODAQ,Gastrointestinal Toxicity,see Warnings and Precautions,0
BELEODAQ,Gastrointestinal Toxicity,Syndrome see Warnings and Gastrointestinal Toxicity see Warnings and Precautions,1
BELEODAQ,Gastrointestinal Toxicity,see Warnings and Precautions,0
BELEODAQ,Gastrointestinal Toxicity,adverse reactions observed in the tr,0
BELEODAQ,Gastrointestinal Toxicity,see Warnings and Gastrointestinal Toxicity see Warnings and Precautions The,1
BELEODAQ,Gastrointestinal Toxicity,adverse reactions observed in the tr,0
BELEODAQ,Gastrointestinal Toxicity,and Precautions The most common adverse reactions observed,0
BELEODAQ,nausea,refractory PTCL treated with Beleodaq,0
BELEODAQ,nausea,tions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq,0
BELEODAQ,nausea,with Beleodaq nausea fatigue pyrexia anemia and,1
BELEODAQ,nausea,tions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq,0
BELEODAQ,nausea,see,0
BELEODAQ,nausea,nausea,1
BELEODAQ,fatigue,with,0
BELEODAQ,pyrexia,were nausea pyrexia anemia and vomiting see,1
BELEODAQ,pyrexia,with,0
BELEODAQ,anemia,Beleodaq were nausea fatigue anemia and,1
BELEODAQ,anemia,with,0
BELEODAQ,nausea,nausea fatigue pyrexia,1
BELEODAQ,nausea,nausea fatigue pyrexia anemia,1
BELEODAQ,nausea,nausea fatigue pyrexia,1
BELEODAQ,nausea,reactions nausea fatigue pyrexia anemia and vomiting,1
BELEODAQ,nausea,nausea fatigue pyrexia,1
BELEODAQ,nausea,nausea,1
BELEODAQ,nausea,nausea fatigue pyrexia,1
BELEODAQ,nausea,nausea fatigue pyrexia anemia and vomiting,1
BELEODAQ,nausea,report SUSPECTED ADVERSE,0
BELEODAQ,fatigue,reactions are fatigue pyrexia anemia and vomiting,1
BELEODAQ,fatigue,report SUSPECTED ADVERSE,0
BELEODAQ,fatigue,pyrexia anemia and vomiting To report SUSPECTED,0
BELEODAQ,fatigue,common adverse reactions are fatigue pyrexia anemia and vomiting To,1
BELEODAQ,fatigue,pyrexia anemia and vomiting To report SUSPECTED,0
BELEODAQ,fatigue,fatigue pyrexia anemia and,1
BELEODAQ,fatigue,fatigue pyrexia,1
BELEODAQ,fatigue,fatigue pyrexia,1
BELEODAQ,fatigue,fatigue pyrexia anemia and vomiting,1
BELEODAQ,fatigue,fatigue pyrexia anemia and vomiting,1
BELEODAQ,fatigue,are fatigue pyrexia anemia and,1
BELEODAQ,fatigue,fatigue pyrexia anemia and vomiting,1
BELEODAQ,fatigue,most common adverse reactions are nausea,0
BELEODAQ,pyrexia,pyrexia anemia and vomiting To,1
BELEODAQ,pyrexia,EXCERPT,0
BELEODAQ,anemia,anemia and vomiting To report SUSPECTED,1
BELEODAQ,anemia,EXCERPT The most common adverse reactions are nausea fatigue,0
BELEODAQ,anemia,anemia,1
BELEODAQ,anemia,pyrexia,0
BELEODAQ,vomiting,anemia vomiting,1
BELEODAQ,vomiting,pyrexia,0
BELEODAQ,vomiting,fatigue pyrexia anemia vomiting To report SUSPECTED,1
BELEODAQ,vomiting,pyrexia,0
BELEODAQ,vomiting,vomiting To,1
BELEODAQ,vomiting,vomiting To report SUSPECTED ADVERSE REACTIONS,1
BELEODAQ,vomiting,are nausea fatigue pyrexia anemia and,0
BELEODAQ,vomiting,ADVERSE REACTIONS contact Spectrum Pharmaceuticals Inc at,0
BELEODAQ,pneumonia,pneumonia pyrexia infection,1
BELEODAQ,pneumonia,and multiorgan,0
BELEODAQ,pneumonia,after their last dose of Beleodaq,0
BELEODAQ,pneumonia,pneumonia pyrexia infection anemia increased,1
BELEODAQ,pneumonia,pneumonia pyrexia infection anemia,1
BELEODAQ,pneumonia,multiorgan,0
BELEODAQ,pneumonia,multiorgan failure One t,0
BELEODAQ,pyrexia,their last dose of Beleodaq The most common,0
BELEODAQ,pyrexia,creatinine thrombocytopenia and multiorgan failure,0
BELEODAQ,pyrexia,pyrexia infection anemia,1
BELEODAQ,infection,pneumonia infection anemia increased creatinine thrombocytopenia and,1
BELEODAQ,infection,pyrexia infection anemia,1
BELEODAQ,infection,increased creatinine thrombocytopenia and,0
BELEODAQ,infection,common serious,0
BELEODAQ,infection,were pneumonia pyrexia,0
BELEODAQ,infection,infection anemia increased creatinine thrombocytopenia and,1
BELEODAQ,anemia,failure,0
BELEODAQ,anemia,pneumonia pyrexia anemia,1
BELEODAQ,anemia,failure,0
BELEODAQ,anemia,anemia increased creatinine,1
BELEODAQ,anemia,were pneumonia pyrexia anemia increased,1
BELEODAQ,anemia,anemia increased creatinine,1
BELEODAQ,increased creatinine,infection increased,1
BELEODAQ,increased creatinine,increased creatinine,1
BELEODAQ,increased creatinine,increased creatinine thrombocytopenia,1
BELEODAQ,increased creatinine,death associated with hepatic,0
BELEODAQ,increased creatinine,pneumonia pyrexia infection increased creatinine,1
BELEODAQ,increased creatinine,death associated with hepatic,0
BELEODAQ,increased creatinine,increased creatinine thrombocytopenia and multiorgan failure One,1
BELEODAQ,thrombocytopenia,infection anemia increased,0
BELEODAQ,thrombocytopenia,serious adverse,0
BELEODAQ,thrombocytopenia,associated with hepatic failure was reported,0
BELEODAQ,multi-organ failure,creatinine thrombocytopenia multi-organ failure One treatmentrelated,1
BELEODAQ,multi-organ failure,associated with hepatic failure was reported,0
BELEODAQ,multi-organ failure,multi-organ failure One treatmentrelated,1
BELEODAQ,hepatic failure,death associated hepatic,1
BELEODAQ,hepatic failure,One treatmentrelated death associated hepatic,1
BELEODAQ,hepatic failure,the trial One patient with baseline,0
BELEODAQ,hepatic failure,hyperuricemia and bulky disease experience,0
BELEODAQ,hepatic failure,One patient with,0
BELEODAQ,hepatic failure,hepatic failure was reported,1
BELEODAQ,hepatic failure,One patient with,0
BELEODAQ,hepatic failure,One treatmentrelated death associated hepatic,1
BELEODAQ,tumor lysis syndrome,tumor lysis,1
BELEODAQ,tumor lysis syndrome,experienced,0
BELEODAQ,tumor lysis syndrome,Grade,0
BELEODAQ,tumor lysis syndrome,the first cycle of treatment and died,0
BELEODAQ,tumor lysis syndrome,lysis syndrome during the first,1
BELEODAQ,died,ventricular fibrillation was reported in,0
BELEODAQ,multi-organ failure,lysis syndrome,0
BELEODAQ,multi-organ failure,multi-organ failure A treatmentrelated death,1
BELEODAQ,multi-organ failure,treatment and died due multi-organ failure,1
BELEODAQ,multi-organ failure,multi-organ failure A treatmentrelated death,1
BELEODAQ,multi-organ failure,died due multi-organ failure,1
BELEODAQ,multi-organ failure,multi-organ failure A treatmentrelated death,1
BELEODAQ,multi-organ failure,multi-organ failure A treatmentrelated death from,1
BELEODAQ,multi-organ failure,due multi-organ failure A treatmentrelated death from,1
BELEODAQ,multi-organ failure,multi-organ failure A treatmentrelated death from,1
BELEODAQ,death,death from ventricular,1
BELEODAQ,death,to multiorgan failure A death from ventricular fibrillation was reported,1
BELEODAQ,death,death from ventricular,1
BELEODAQ,QTc prolongation,Twentyfive patients discontinued tr,0
BELEODAQ,QTc prolongation,Adverse,0
BELEODAQ,QTc prolongation,clinical trial with Beleodaq ECG analysis did,0
BELEODAQ,QTc prolongation,QTc prolongation,1
BELEODAQ,QTc prolongation,Twentyfive patients,0
BELEODAQ,QTc prolongation,analysis did not QTc prolongation Discontinuations due to Adverse Reactions,1
BELEODAQ,QTc prolongation,Twentyfive patients,0
BELEODAQ,QTc prolongation,Discontinuations due to Adverse,0
BELEODAQ,QTc prolongation,not QTc prolongation,1
BELEODAQ,QTc prolongation,not QTc prolongation,1
BELEODAQ,QTc prolongation,not QTc prolongation,1
BELEODAQ,febrile neutropenia,treatment,0
BELEODAQ,febrile neutropenia,discontinuation of treatment included febrile neutropenia,1
BELEODAQ,febrile neutropenia,febrile neutropenia,1
BELEODAQ,febrile neutropenia,included febrile neutropenia,1
BELEODAQ,febrile neutropenia,febrile neutropenia,1
BELEODAQ,febrile neutropenia,Modifications due to Adverse Reactions,0
BELEODAQ,febrile neutropenia,febrile neutropenia fatigue and,1
BELEODAQ,febrile neutropenia,Modifications due to Adverse Reactions,0
BELEODAQ,febrile neutropenia,febrile neutropenia,1
BELEODAQ,febrile neutropenia,Modifications due to Adverse Reactions,0
BELEODAQ,febrile neutropenia,febrile neutropenia fatigue and multiorgan failure Dosage,1
BELEODAQ,febrile neutropenia,treatment included febrile,1
BELEODAQ,febrile neutropenia,febrile neutropenia,1
BELEODAQ,febrile neutropenia,treatment included febrile,1
BELEODAQ,fatigue,fatigue and,1
BELEODAQ,fatigue,fatigue and,1
BELEODAQ,fatigue,fatigue and multiorgan failure Dosage,1
BELEODAQ,leukopenia,are escribed i n more detail in other,1
BELEODAQ,leukopenia,fatigue and multiorgan failure Dosage,1
BELEODAQ,leukopenia,escribed i,1
BELEODAQ,leukopenia,fatigue and multiorgan failure Dosage,1
BELEODAQ,leukopenia,adverse reactions are escribed i n more,1
BELEODAQ,leukopenia,fatigue and multiorgan failure Dosage,1
BELEODAQ,leukopenia,the prescribing information Hematologic Toxicity,0
BELEODAQ,leukopenia,escribed i n more,1
BELEODAQ,leukopenia,are,0
BELEODAQ,leukopenia,the prescribing information Hematologic Toxicity,0
BELEODAQ,leukopenia,prescribing information Hematologic,0
BELEODAQ,leukopenia,escribed i n more detail in,1
BELEODAQ,neutropenia,more detail in other sections,1
BELEODAQ,neutropenia,escribed i n more detail in,1
BELEODAQ,lymphopenia,in ther sectio,1
BELEODAQ,lymphopenia,information Hematologic Toxicity see,0
BELEODAQ,lymphopenia,ther sectio ns of the prescribing information,1
BELEODAQ,lymphopenia,information Hematologic Toxicity see,0
BELEODAQ,lymphopenia,in ther sectio ns of the prescribing information,1
BELEODAQ,lymphopenia,information Hematologic Toxicity see,0
BELEODAQ,anemia,he pre,1
BELEODAQ,Infection,Toxicity see Warnings and * In,1
BELEODAQ,Infection,*,1
BELEODAQ,Infection,"see Warnings and 
 *    In fection",1
BELEODAQ,Infection,*,1
BELEODAQ,Infection,and Precautions Hepatotoxicity,0
BELEODAQ,Infection,Warnings and *,1
BELEODAQ,fatal,arnin gs and Precautions,1
BELEODAQ,fatal,arnin gs,1
BELEODAQ,fatal,arnin gs and Precautions,1
BELEODAQ,fatal,arnin gs and Precautions Hepatotoxicity,1
BELEODAQ,fatal,arnin gs,1
BELEODAQ,fatal,see Warnings and Precautions Infection,0
BELEODAQ,fatal,and,0
BELEODAQ,fatal,Infection see,0
BELEODAQ,infections,Infection see s and Prec autions,1
BELEODAQ,infections,Infection see,0
BELEODAQ,infections,see Warnings and Precautions Tumor Lys,0
BELEODAQ,infections,s,1
BELEODAQ,infections,autions Hepatotoxicity see Warnings and,0
BELEODAQ,infections,Toxicity see Warnings and,0
BELEODAQ,infections,Infection see s,1
BELEODAQ,pneumonia,5.2 ) Hepatotoxicity see,1
BELEODAQ,pneumonia,( 5.2 ) Hepatotoxicity see Warnings and Precautions,1
BELEODAQ,pneumonia,Infection see,0
BELEODAQ,pneumonia,Precautions Infection see Warnings and Precautions,0
BELEODAQ,pneumonia,see Warnings and Precautions Tumor Lysis Syndrome see,0
BELEODAQ,pneumonia,see Warnings and ( 5.2,1
BELEODAQ,pneumonia,Toxicity see Warnings and Precautions Infection see Warnings,0
BELEODAQ,pneumonia,Lysis,0
BELEODAQ,pneumonia,see Warnings and ( 5.2,1
BELEODAQ,pneumonia,Hepatotoxicity see Warnings and,0
BELEODAQ,sepsis,* H epatotoxicity see Warnings and Precautions,1
BELEODAQ,sepsis,Warnings and *    H epatotoxicity see Warnings,1
BELEODAQ,sepsis,* H epatotoxicity see Warnings and Precautions,1
BELEODAQ,sepsis,see Warnings,0
BELEODAQ,sepsis,and Precautions Infection see Warnings and,0
BELEODAQ,sepsis,and *    H epatotoxicity see,1
BELEODAQ,sepsis,and Precautions Infection see Warnings and,0
BELEODAQ,sepsis,Precautions Infection,0
BELEODAQ,sepsis,* H epatotoxicity see Warnings and Precautions,1
BELEODAQ,Hepatotoxicity,and Prec autions Tumor Lysis Syndrome see,1
BELEODAQ,Hepatotoxicity,Infection see,0
BELEODAQ,Hepatotoxicity,see nings and Prec autions Tumor Lysis Syndrome see,1
BELEODAQ,Hepatotoxicity,Infection see,0
BELEODAQ,Hepatotoxicity,and Prec,1
BELEODAQ,Hepatotoxicity,see nings and Prec,1
BELEODAQ,Hepatotoxicity,Hepatotoxicity see nings,1
BELEODAQ,Tumor lysis syndrome,on adverse reactions observed in the trial of,1
BELEODAQ,Tumor lysis syndrome,on,1
BELEODAQ,Tumor lysis syndrome,refractory PTCL treated with Beleodaq were nause,0
BELEODAQ,Tumor lysis syndrome,relapsed or refractory PTCL,0
BELEODAQ,Tumor lysis syndrome,on adverse reactions observed in the,1
BELEODAQ,Tumor lysis syndrome,relapsed or refractory PTCL,0
BELEODAQ,thrombocytopenia,d vomiting To report SUSPECTED ADVERSE REACTIONS contact Spectrum Pharmaceutical,0
BELEODAQ,thrombocytopenia,"s, Inc. at 1-888 or FDA",1
BELEODAQ,thrombocytopenia,"s, Inc. at 1-888 or FDA at FDA",1
BELEODAQ,thrombocytopenia,"s, Inc. at 1-888 or FDA",1
BELEODAQ,thrombocytopenia,"REACTIONS contact Spectrum s, Inc. at 1-888 or FDA at FDA",1
BELEODAQ,thrombocytopenia,"s, Inc. at 1-888 or FDA",1
BELEODAQ,thrombocytopenia,"REACTIONS contact Spectrum s, Inc. at",1
BELEODAQ,thrombocytopenia,report SUSPECTED,0
BELEODAQ,thrombocytopenia,at 1-888 or FDA,1
BELEODAQ,leukopenia,92-9617 or FDA at,1
BELEODAQ,leukopenia,92-9617 or,1
BELEODAQ,leukopenia,Inc 92-9617 or,1
BELEODAQ,leukopenia,wwwfdagovmedwatch Clinical,0
BELEODAQ,leukopenia,92-9617 or FDA at,1
BELEODAQ,leukopenia,contact Spectrum Pharmaceuticals,0
BELEODAQ,leukopenia,92-9617 or,1
BELEODAQ,leukopenia,REACTIONS,0
BELEODAQ,leukopenia,FDA or wwwfdagovmedwatch,0
BELEODAQ,leukopenia,contact Spectrum Pharmaceuticals Inc 92-9617 or,1
BELEODAQ,neutropenia,Pharmaceuticals Inc at or DA at 1-800,1
BELEODAQ,neutropenia,Inc at or DA,1
BELEODAQ,neutropenia,Inc at or DA,1
BELEODAQ,neutropenia,DA at 1-800,1
BELEODAQ,neutropenia,at 1-800 FDA,1
BELEODAQ,neutropenia,at or DA,1
BELEODAQ,neutropenia,F,0
BELEODAQ,neutropenia,at or DA at 1-800,1
BELEODAQ,neutropenia,F,0
BELEODAQ,lymphopenia,clinical trials,0
BELEODAQ,lymphopenia,clinical trials ar,0
BELEODAQ,lymphopenia,FDA at 1088     or wwwfdagovmedwatch,1
BELEODAQ,lymphopenia,clinical trials ar,0
BELEODAQ,lymphopenia,at 1088     or,1
BELEODAQ,lymphopenia,clinical trials ar,0
BELEODAQ,lymphopenia,1088 or wwwfdagovmedwatch,1
BELEODAQ,lymphopenia,Trials Experience,0
BELEODAQ,lymphopenia,1088 or wwwfdagovmedwatch Clinical,1
BELEODAQ,lymphopenia,Clinical Trials Experience Because clinical trials ar,0
BELEODAQ,lymphopenia,FDA,0
BELEODAQ,anemia,.fda.g ovmedwatch,1
BELEODAQ,fatal,in practice Adverse Reactions in Patients with Peripheral,0
BELEODAQ,fatal,t the rates,1
BELEODAQ,fatal,t the rates,1
BELEODAQ,fatal,t the rates observed in practice,1
BELEODAQ,fatal,t the,1
BELEODAQ,infections,rates obse rved in practice,1
BELEODAQ,infections,reflect rates,1
BELEODAQ,infections,not reflect rates obse,1
BELEODAQ,infections,reflect rates,1
BELEODAQ,infections,TCell Lymphoma The safe,0
BELEODAQ,infections,may not reflect rates obse rved,1
BELEODAQ,infections,TCell Lymphoma The safe,0
BELEODAQ,infections,rates obse,1
BELEODAQ,infections,Reactions in Patients with Peripheral TCell Lymphoma The safe,0
BELEODAQ,infections,reflect rates obse rved in practice Adverse Reactions,1
BELEODAQ,infections,Reactions in Patients with Peripheral TCell Lymphoma The safe,0
BELEODAQ,infections,in Patients with Peripheral TCell Lymphoma The,0
BELEODAQ,pneumonia,"tice.



 Adverse Reactions in",1
BELEODAQ,pneumonia,"in tice.



 Adverse Reactions in Patients",1
BELEODAQ,pneumonia,"tice.



 Adverse Reactions in",1
BELEODAQ,pneumonia,Adverse Reactions in Patients with Peripheral TCell Lymphoma The safety of,0
BELEODAQ,pneumonia,"tice.



 Adverse Reactions",1
BELEODAQ,pneumonia,"rates observed in tice.



 Adverse",1
BELEODAQ,pneumonia,"tice.



 Adverse Reactions",1
BELEODAQ,pneumonia,"tice.



 Adverse",1
BELEODAQ,pneumonia,"tice.



 Adverse",1
BELEODAQ,pneumonia,Lymphoma The safety of,0
BELEODAQ,pneumonia,"observed in tice.



 Adverse Reactions in Patients",1
BELEODAQ,pneumonia,Lymphoma The safety of,0
BELEODAQ,pneumonia,in,0
BELEODAQ,sepsis,observed in,0
BELEODAQ,sepsis,practice verse  Reactions in Patients with,1
BELEODAQ,sepsis,observed in,0
BELEODAQ,sepsis,observed in the clinical trials of Beleodaq,0
BELEODAQ,fatal, dail y on Days of,1
BELEODAQ,fatal,minutes by IV infusion  dail y on Days of,1
BELEODAQ,fatal, dail y on Days of,1
BELEODAQ,fatal, dail y on Days of,1
BELEODAQ,fatal,IV infusion  dail,1
BELEODAQ,fatal, dail y on Days of,1
BELEODAQ,fatal,minutes by IV infusion  dail y on Days of,1
BELEODAQ,fatal, dail y on Days of,1
BELEODAQ,liver function test abnormalities,of 1-day cycle [see Clinical,1
BELEODAQ,liver function test abnormalities,1-day cycle  [see Clinical Studie s The median,1
BELEODAQ,liver function test abnormalities,of 1-day cycle [see Clinical,1
BELEODAQ,liver function test abnormalities,daily on Days of 1-day cycle [see Clinical Studie,1
BELEODAQ,liver function test abnormalities,Clinical Studie s The median duration,1
BELEODAQ,liver function test abnormalities,on Days of 1-day cycle [see Clinical Studie,1
BELEODAQ,liver function test abnormalities,on Days of 1-day cycle  [see Clinical Studie,1
BELEODAQ,liver function test abnormalities,on Days of 1-day cycle [see Clinical Studie,1
BELEODAQ,liver function test abnormalities,Clinical Studie s,1
BELEODAQ,liver function test abnormalities,Days of 1-day cycle,1
BELEODAQ,liver function test abnormalities,Days of 1-day cycle [see,1
BELEODAQ,liver function test abnormalities,range cycles,0
BELEODAQ,Tumor lysis syndrome,Preferred,0
BELEODAQ,Tumor lysis syndrome,with psed or Refractory P TCL NCICTC,1
BELEODAQ,Tumor lysis syndrome,Preferred,0
BELEODAQ,Tumor lysis syndrome,psed,1
BELEODAQ,Tumor lysis syndrome,Preferred Term Percentage,0
BELEODAQ,Tumor lysis syndrome,with psed or Refractory P TCL NCICTC Grade MedDRA Preferred,1
BELEODAQ,Tumor lysis syndrome,Preferred Term Percentage,0
BELEODAQ,Tumor lysis syndrome,of Patients by Preferred Term and Severity in,0
BELEODAQ,Tumor lysis syndrome,MedDRA Preferred Term Percentage of Patie,0
BELEODAQ,Tumor lysis syndrome,NCICTC Grade MedDRA,0
BELEODAQ,Tumor lysis syndrome,or Refractory P,1
BELEODAQ,Tumor lysis syndrome,with psed or Refractory,1
HALAVEN,neutropenia,reactions incidence neutropenia anemia astheniafatigue alopecia peripheral neuropathy,1
HALAVEN,neutropenia,with psed or Refractory,1
HALAVEN,neutropenia,common adverse reactions incidence neutropenia anemia astheniafatigue alopecia peripheral neuropathy,1
HALAVEN,neutropenia,with psed or Refractory,1
HALAVEN,neutropenia,common adverse reactions incidence neutropenia,1
HALAVEN,neutropenia,with psed or Refractory,1
HALAVEN,neutropenia,reactions incidence neutropenia anemia,1
HALAVEN,neutropenia,with psed or Refractory,1
HALAVEN,neutropenia,reactions incidence neutropenia anemia astheniafatigue,1
HALAVEN,neutropenia,with psed or Refractory,1
HALAVEN,neutropenia,adverse reactions incidence neutropenia anemia astheniafatigue alopecia,1
HALAVEN,neutropenia,with psed or Refractory,1
HALAVEN,neutropenia,neutropenia anemia astheniafatigue alopecia,1
HALAVEN,neutropenia,alopecia,0
HALAVEN,neutropenia,reactions incidence neutropenia anemia astheniafatigue alopecia peripheral neuropathy,1
HALAVEN,neutropenia,alopecia,0
HALAVEN,neutropenia,neutropenia anemia astheniafatigue,1
HALAVEN,anemia,anemia astheniafatigue,1
HALAVEN,anemia,neutropenia anemia astheniafatigue,1
HALAVEN,anemia,RSE REACTIONS EXCERPT The most common adverse reactions incidence were neutropenia,0
HALAVEN,anemia,anemia,1
HALAVEN,anemia,anemia astheniafatigue alopecia peripheral neuropathy,1
HALAVEN,anemia,anemia astheniafatigue alopecia,1
HALAVEN,anemia,anemia astheniafatigue alopecia peripheral,1
HALAVEN,anemia,incidence were anemia astheniafatigue alopecia peripheral,1
HALAVEN,anemia,anemia astheniafatigue alopecia peripheral,1
HALAVEN,anemia,constipation,0
HALAVEN,asthenia,asthenia fatigue alopecia peripheral neuropathy,1
HALAVEN,asthenia,asthenia fatigue alopecia peripheral neuropathy nausea,1
HALAVEN,asthenia,asthenia,1
HALAVEN,fatigue,were neutropenia anemia asthenia,0
HALAVEN,fatigue,anemia fatigue,1
HALAVEN,fatigue,were neutropenia anemia asthenia,0
HALAVEN,alopecia,alopecia peripheral neuropathy nausea,1
HALAVEN,alopecia,alopecia peripheral,1
HALAVEN,alopecia,incidence were neutropenia anemia,0
HALAVEN,alopecia,adverse reactions incidence were,0
HALAVEN,peripheral neuropathy,peripheral neuropathy nausea and,1
HALAVEN,peripheral neuropathy,neutropenia anemia astheniafatigue peripheral,1
HALAVEN,peripheral neuropathy,peripheral neuropathy nausea and constipation To report,1
HALAVEN,peripheral neuropathy,astheniafatigue,0
HALAVEN,peripheral neuropathy,REACTIONS contact Eisai Inc a,0
HALAVEN,peripheral neuropathy,anemia astheniafatigue peripheral,1
HALAVEN,nausea,were neutropenia anemia astheniafatigue alopecia peripheral neuropathy,0
HALAVEN,nausea,nausea and,1
HALAVEN,nausea,constipation To report SUSPECTED ADVERSE,0
HALAVEN,nausea,anemia astheniafatigue alopecia peripheral nausea and constipation To report SUSPECTED,1
HALAVEN,nausea,constipation To report SUSPECTED ADVERSE,0
HALAVEN,constipation,nausea constipation To,1
HALAVEN,constipation,constipation To report SUSPECTED ADVERSE,0
HALAVEN,constipation,constipation To report,1
HALAVEN,constipation,constipation To report SUSPECTED ADVERSE,0
HALAVEN,constipation,alopecia peripheral neuropathy nausea and,0
HALAVEN,constipation,constipation To,1
HALAVEN,constipation,alopecia peripheral neuropathy nausea and,0
HALAVEN,Neutropenia,other sections of the Neutropenia,1
HALAVEN,Neutropenia,alopecia peripheral neuropathy nausea and,0
HALAVEN,Neutropenia,Warnings,0
HALAVEN,Neutropenia,sections of the Neutropenia see,1
HALAVEN,Neutropenia,Warnings,0
HALAVEN,Neutropenia,Warnings and Precautions Peripheral neuropathy see,0
HALAVEN,Peripheral neuropathy,see Warnings and Peripheral neuropathy see Warnings and Precautions QT,1
HALAVEN,Peripheral neuropathy,Warnings and Precautions Peripheral neuropathy see,0
HALAVEN,Peripheral neuropathy,and Peripheral neuropathy see Warnings and,1
HALAVEN,Peripheral neuropathy,Warnings and Precautions Peripheral neuropathy see,0
HALAVEN,Peripheral neuropathy,Peripheral neuropathy see Warnings,1
HALAVEN,Peripheral neuropathy,see Warnings and Pr,0
HALAVEN,Peripheral neuropathy,and,0
HALAVEN,Peripheral neuropathy,Peripheral neuropathy see Warnings,1
HALAVEN,QT interval prolongation,QT interval prolongation see,1
HALAVEN,QT interval prolongation,Peripheral neuropathy see Warnings,1
HALAVEN,QT interval prolongation,and QT interval prolongation see Warnings and Precautions,1
HALAVEN,QT interval prolongation,Peripheral neuropathy see Warnings,1
HALAVEN,QT interval prolongation,ns Peripheral neuropathy see,0
HALAVEN,QT interval prolongation,Warnings and QT interval prolongation see Warnings and Precautions The,1
HALAVEN,QT interval prolongation,ns Peripheral neuropathy see,0
HALAVEN,QT interval prolongation,neuropathy see Warnings and QT interval prolongation,1
HALAVEN,QT interval prolongation,Peripheral neuropathy see Warnings and Precautions,0
HALAVEN,neutropenia,in patients receiving HALAVEN were,0
HALAVEN,neutropenia,nausea and constipation The,0
HALAVEN,neutropenia,The most comm,0
HALAVEN,anemia,anemia astheniafatigue,1
HALAVEN,anemia,HALAVEN were anemia astheniafatigue alopecia peripheral neuropathy,1
HALAVEN,anemia,anemia astheniafatigue,1
HALAVEN,anemia,and constipation The most,0
HALAVEN,anemia,anemia astheniafatigue alopecia,1
HALAVEN,anemia,The most,0
HALAVEN,anemia,anemia astheniafatigue,1
HALAVEN,anemia,The most,0
HALAVEN,asthenia,were neutropenia asthenia,1
HALAVEN,asthenia,The most,0
HALAVEN,asthenia,asthenia,1
HALAVEN,fatigue,HALAVEN were neutropenia anemia fatigue alopecia peripheral neuropathy nausea and,1
HALAVEN,fatigue,asthenia,1
HALAVEN,fatigue,fatigue alopecia peripheral neuropathy nausea,1
HALAVEN,fatigue,fatigue alopecia peripheral,1
HALAVEN,alopecia,and constipation The most common serious adverse reactions,0
HALAVEN,alopecia,alopecia peripheral neuropathy nausea and,1
HALAVEN,alopecia,reported in patients,0
HALAVEN,alopecia,astheniafatigue,0
HALAVEN,alopecia,alopecia peripheral neuropathy nausea and constipation,1
HALAVEN,alopecia,most common,0
HALAVEN,peripheral neuropathy,were,0
HALAVEN,peripheral neuropathy,neutropenia anemia astheniafatigue peripheral neuropathy nausea and constipation,1
HALAVEN,peripheral neuropathy,were,0
HALAVEN,peripheral neuropathy,astheniafatigue,0
HALAVEN,peripheral neuropathy,anemia astheniafatigue peripheral,1
HALAVEN,peripheral neuropathy,astheniafatigue alopecia,0
HALAVEN,peripheral neuropathy,were neutropenia anemia astheniafatigue peripheral,1
HALAVEN,peripheral neuropathy,neutropenia anemia astheniafatigue peripheral,1
HALAVEN,nausea,nausea and,1
HALAVEN,nausea,peripheral,0
HALAVEN,constipation,constipation The most,1
HALAVEN,constipation,astheniafatigue alopecia,0
HALAVEN,constipation,constipation The most common serious adverse,1
HALAVEN,constipation,constipation,1
HALAVEN,constipation,constipation The most common serious,1
HALAVEN,constipation,constipation The most common serious adverse,1
HALAVEN,febrile neutropenia,patients receiving HALAVEN febrile neutropenia and neutropenia The most,1
HALAVEN,febrile neutropenia,constipation The most common serious adverse,1
HALAVEN,febrile neutropenia,in patients receiving HALAVEN febrile neutropenia and neutropenia,1
HALAVEN,febrile neutropenia,constipation The most common serious adverse,1
HALAVEN,febrile neutropenia,febrile neutropenia and neutropenia The most,1
HALAVEN,febrile neutropenia,most common,0
HALAVEN,febrile neutropenia,in patients receiving HALAVEN febrile neutropenia and neutropenia,1
HALAVEN,febrile neutropenia,most common,0
HALAVEN,febrile neutropenia,receiving HALAVEN febrile neutropenia and,1
HALAVEN,febrile neutropenia,most common,0
HALAVEN,febrile neutropenia,adverse reaction resulting in discontinuation of,0
HALAVEN,febrile neutropenia,The most common serious,0
HALAVEN,neutropenia,HALAVEN were febrile neutropenia neutropenia The,1
HALAVEN,neutropenia,The most common serious,0
HALAVEN,neutropenia,was peripheral,0
HALAVEN,neutropenia,discontinuation of HALAVEN was peripheral neuro,0
HALAVEN,neutropenia,neutropenia The most,1
HALAVEN,neutropenia,neutropenia The most common adverse reaction,1
HALAVEN,neutropenia,neutropenia The most common,1
HALAVEN,neutropenia,were febrile neutropenia neutropenia The most common adverse reaction,1
HALAVEN,neutropenia,neutropenia The most common,1
HALAVEN,neutropenia,neutropenia,1
HALAVEN,peripheral neuropathy,adverse,0
HALAVEN,peripheral neuropathy,administered to patients with multiple,0
HALAVEN,peripheral neuropathy,of HALAVEN peripheral,1
HALAVEN,peripheral neuropathy,and neutropenia The most common adverse reaction,0
HALAVEN,peripheral neuropathy,peripheral neuropathy In clinical trials HALAVEN has,1
HALAVEN,peripheral neuropathy,and neutropenia The most common adverse reaction,0
HALAVEN,peripheral neuropathy,of HALAVEN peripheral neuropathy,1
HALAVEN,peripheral neuropathy,of HALAVEN peripheral,1
HALAVEN,peripheral neuropathy,of HALAVEN peripheral neuropathy,1
HALAVEN,peripheral neuropathy,in discontinuation of HALAVEN peripheral neuropathy In,1
HALAVEN,peripheral neuropathy,of HALAVEN peripheral neuropathy,1
HALAVEN,peripheral neuropathy,peripheral neuropathy In clinical trials HALAVEN has,1
HALAVEN,peripheral neuropathy,of HALAVEN peripheral neuropathy,1
HALAVEN,Peripheral neuropathy,system Peripheral neuropathy,1
HALAVEN,Peripheral neuropathy,disorders,0
HALAVEN,Peripheral neuropathy,system disorders,0
HALAVEN,Peripheral neuropathy,disorders,0
HALAVEN,Peripheral neuropathy,system,0
HALAVEN,Peripheral neuropathy,Peripheral,1
HALAVEN,Peripheral neuropathy,rvous system Peripheral neuropathy,1
HALAVEN,Peripheral neuropathy,Peripheral neuropathy,1
HALAVEN,Headache,General,0
HALAVEN,Headache,ripheral neuropathy Headache,1
HALAVEN,Headache,General,0
HALAVEN,Headache,Headache General disorders,1
HALAVEN,Headache,ripheral neuropathy b,0
HALAVEN,Headache,Headache General,1
HALAVEN,Headache,b,0
HALAVEN,Headache,General disorders,0
HALAVEN,Headache,Headache,1
HALAVEN,Headache,Headache,1
HALAVEN,Asthenia,Fatigue Mucosal inflamma,0
HALAVEN,Asthenia,Fatigue,0
HALAVEN,Asthenia,Asthenia Fatigue Mucosal inflamma,1
HALAVEN,Asthenia,Fatigue,0
HALAVEN,Arthralgia,Arthralgia Myalgia Back,1
HALAVEN,Arthralgia,Arthralgia Myalgia,1
HALAVEN,Arthralgia,Arthralgia Myalgia Back,1
HALAVEN,Arthralgia,Arthralgia,1
HALAVEN,Arthralgia,Myalgia,0
HALAVEN,Arthralgia,Arthralgia,1
HALAVEN,Arthralgia,Myalgia,0
HALAVEN,Arthralgia,Arthralgia,1
HALAVEN,Arthralgia,Arthralgia Myalgia Back pain,1
HALAVEN,Myalgia,Myalgia Back pain,1
HALAVEN,Myalgia,disorders,0
HALAVEN,Bone pain,Back Bone pain,1
HALAVEN,Bone pain,Bone pain Pain in,1
HALAVEN,Bone pain,Bone pain Pain,1
HALAVEN,Bone pain,Pain in,0
HALAVEN,Bone pain,Pain,0
HALAVEN,Bone pain,Back Bone pain Pain in extremity,1
HALAVEN,Bone pain,Pain,0
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,nutrition Anorexia Respiratory thoracic,1
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,Anorexia Respiratory,1
HALAVEN,Anorexia,Anorexia,1
HALAVEN,Urinary Tract Infection,a based upon,0
HALAVEN,Urinary Tract Infection,and,0
HALAVEN,Urinary Tract Infection,a based,0
HALAVEN,Urinary Tract Infection,and Urinary Tract Infection a,1
HALAVEN,Urinary Tract Infection,a based,0
HALAVEN,Urinary Tract Infection,a,0
HALAVEN,neuropathy peripheral,neuropathy peripheral neuropathy peripheral,1
HALAVEN,neuropathy peripheral,neuropathy polyneuropathy peripheral,0
HALAVEN,neuropathy peripheral,b neuropathy peripheral neuropathy,1
HALAVEN,neuropathy peripheral,neuropathy polyneuropathy peripheral,0
HALAVEN,neuropathy peripheral,b neuropathy,1
HALAVEN,neuropathy peripheral,neuropathy peripheral,1
HALAVEN,neuropathy,neuropathy peripheral motor neuropathy,1
HALAVEN,neuropathy,data b includes neuropathy,0
HALAVEN,neuropathy,neuropathy peripheral motor neuropathy,1
HALAVEN,neuropathy,upon laboratory data b includes neuropathy peripheral,0
HALAVEN,neuropathy,data b includes neuropathy neuropathy peripheral,1
HALAVEN,neuropathy,upon laboratory data b includes neuropathy peripheral,0
HALAVEN,neuropathy,neuropathy,1
HALAVEN,neuropathy,neuropathy peripheral motor neuropathy polyneuropathy,1
HALAVEN,neuropathy,neuropathy peripheral motor neuropathy,1
HALAVEN,neuropathy,neuropathy peripheral,1
HALAVEN,neuropathy,neuropathy peripheral motor neuropathy,1
HALAVEN,peripheral motor neuropathy,peripheral motor neuropathy,1
HALAVEN,peripheral motor neuropathy,neuropathy peripheral,0
HALAVEN,peripheral motor neuropathy,b includes neuropathy peripheral peripheral motor neuropathy,1
HALAVEN,peripheral motor neuropathy,motor neuropathy polyneuropathy peripheral sensoryneuropathy and paraesthesia,1
HALAVEN,polyneuropathy,polyneuropathy peripheral sensoryneuropathy and paraesthesia,1
HALAVEN,polyneuropathy,polyneuropathy peripheral sensoryneuropathy and paraesthesia c,1
HALAVEN,polyneuropathy,polyneuropathy peripheral sensoryneuropathy and,1
HALAVEN,polyneuropathy,includes neuropathy peripheral,0
HALAVEN,polyneuropathy,polyneuropathy peripheral sensoryneuropathy and paraesthesia c,1
HALAVEN,peripheral sensoryneuropathy,peripheral sensoryneuropathy and paraesthesia c not,1
HALAVEN,peripheral sensoryneuropathy,peripheral sensoryneuropathy and paraesthesia c not applicable,1
HALAVEN,peripheral sensoryneuropathy,includes neuropathy peripheral neuropathy peripheral motor,0
HALAVEN,peripheral sensoryneuropathy,peripheral sensoryneuropathy and paraesthesia c,1
HALAVEN,peripheral sensoryneuropathy,neuropathy peripheral motor neuropathy peripheral sensoryneuropathy and paraesthesia c not applicable,1
HALAVEN,peripheral sensoryneuropathy,peripheral sensoryneuropathy and paraesthesia c,1
HALAVEN,paraesthesia,Grade,0
HALAVEN,paraesthesia,specify Grade,0
HALAVEN,paraesthesia,paraesthesia c not applicable grading,1
HALAVEN,paraesthesia,paraesthesia c,1
HALAVEN,paraesthesia,paraesthesia c not applicable grading,1
HALAVEN,paraesthesia,paraesthesia c not applicable,1
HALAVEN,paraesthesia,sensoryneuropathy paraesthesia c not applicable grading,1
HALAVEN,paraesthesia,paraesthesia c not applicable,1
HALAVEN,paraesthesia,paraesthesia,1
HALAVEN,paraesthesia,polyneuropathy,0
HALAVEN,paraesthesia,and,0
HALAVEN,paraesthesia,polyneuropathy peripheral sensoryneuropathy,0
HALAVEN,alopecia,Cytopenias Grade neutropenia,0
HALAVEN,alopecia,alopecia Cytopenias Grade neutropenia occurred,1
HALAVEN,alopecia,specify Grade alopecia Cytopenias Grade neutropenia occurred,1
HALAVEN,alopecia,alopecia Cytopenias Grade neutropenia occurred,1
HALAVEN,alopecia,neutropenia occurred,0
HALAVEN,alopecia,does not specify Grade alopecia Cytopenias Grade neutropenia,1
HALAVEN,alopecia,neutropenia occurred,0
HALAVEN,alopecia,alopecia Cytopenias Grade,1
HALAVEN,alopecia,alopecia Cytopenias,1
HALAVEN,alopecia,alopecia Cytopenias Grade neutropenia occurred in,1
HALAVEN,alopecia,alopecia,1
HALAVEN,alopecia,specify Grade alopecia Cytopenias Grade,1
HALAVEN,alopecia,alopecia,1
HALAVEN,neutropenia,two patients,0
HALAVEN,neutropenia,of patients two,0
HALAVEN,neutropenia,in of,0
HALAVEN,neutropenia,neutropenia Febrile,1
HALAVEN,Febrile neutropenia,of patients two patients died from complications,0
HALAVEN,Febrile neutropenia,patients experienced Grade neutropenia,0
HALAVEN,Febrile neutropenia,experienced Grade Febrile neutropenia occurred in of,1
HALAVEN,Febrile neutropenia,patients experienced Grade neutropenia,0
HALAVEN,Febrile neutropenia,Febrile neutropenia occurred,1
HALAVEN,Febrile neutropenia,Febrile neutropenia,1
HALAVEN,Febrile neutropenia,Febrile neutropenia occurred,1
HALAVEN,Febrile neutropenia,who received HALAVEN in Study,0
HALAVEN,febrile neutropenia,febrile neutropenia Dose,1
HALAVEN,febrile neutropenia,neutropenia occurred in of patients two patients died from complications of,0
HALAVEN,febrile neutropenia,patients died from complications,0
HALAVEN,febrile neutropenia,from complications febrile neutropenia,1
HALAVEN,febrile neutropenia,patients died from complications,0
HALAVEN,febrile neutropenia,died from complications febrile neutropenia Dose reduction,1
HALAVEN,febrile neutropenia,patients died from complications,0
HALAVEN,febrile neutropenia,in of patients,0
HALAVEN,febrile neutropenia,febrile,1
HALAVEN,febrile neutropenia,complications febrile neutropenia Dose,1
HALAVEN,febrile neutropenia,febrile,1
HALAVEN,febrile neutropenia,complications febrile neutropenia,1
HALAVEN,neutropenia,neutropenia was required in,1
HALAVEN,neutropenia,complications febrile neutropenia,1
HALAVEN,neutropenia,neutropenia mm was,1
HALAVEN,neutropenia,complications febrile neutropenia,1
HALAVEN,neutropenia,to recovery from neutropenia mm was days,1
HALAVEN,neutropenia,complications febrile neutropenia,1
HALAVEN,neutropenia,neutropenia mm was,1
HALAVEN,neutropenia,thrombocytopenia occurred in of patients,0
HALAVEN,neutropenia,neutropenia mm was days Grade,1
HALAVEN,neutropenia,neutropenia mm,1
HALAVEN,neutropenia,to recovery from neutropenia mm was days Grade,1
HALAVEN,neutropenia,neutropenia mm,1
HALAVEN,neutropenia,or greater thrombocytopenia occurred in of patients,0
HALAVEN,neutropenia,neutropenia mm,1
HALAVEN,neutropenia,time to recovery from neutropenia mm was days Grade or,1
HALAVEN,neutropenia,neutropenia mm,1
HALAVEN,thrombocytopenia,days Grade or thrombocytopenia occurred in,1
HALAVEN,thrombocytopenia,neutropenia mm,1
HALAVEN,thrombocytopenia,thrombocytopenia occurred,1
HALAVEN,thrombocytopenia,mm was days Grade or greater,0
HALAVEN,thrombocytopenia,thrombocytopenia,1
HALAVEN,thrombocytopenia,thrombocytopenia occurred,1
HALAVEN,thrombocytopenia,thrombocytopenia,1
HALAVEN,thrombocytopenia,thrombocytopenia occurred in of patients,1
HALAVEN,thrombocytopenia,thrombocytopenia,1
HALAVEN,thrombocytopenia,Grade or thrombocytopenia occurred in,1
HALAVEN,thrombocytopenia,thrombocytopenia,1
HALAVEN,peripheral neuropathy,peripheral neuropathy and,1
HALAVEN,peripheral neuropathy,thrombocytopenia,1
HALAVEN,peripheral neuropathy,peripheral neuropathy and of patients,1
HALAVEN,peripheral neuropathy,enrolled patients had,0
HALAVEN,peripheral neuropathy,Dose reduction due,0
HALAVEN,peripheral neuropathy,patients had peripheral,1
HALAVEN,peripheral neuropathy,peripheral neuropathy and of patients,1
HALAVEN,peripheral neuropathy,of enrolled patients had peripheral neuropathy and of patients had,1
HALAVEN,peripheral neuropathy,peripheral neuropathy and of patients,1
HALAVEN,peripheral neuropathy,due to peripheral,0
HALAVEN,peripheral neuropathy,peripheral neuropathy,1
HALAVEN,peripheral neuropathy,peripheral neuropathy,1
HALAVEN,peripheral neuropathy,Dose reduction due peripheral neuropathy was required by of,1
HALAVEN,peripheral neuropathy,peripheral neuropathy,1
HALAVEN,peripheral neuropathy,Dose reduction due peripheral neuropathy was required by of patients,1
HALAVEN,peripheral neuropathy,peripheral neuropathy,1
HALAVEN,peripheral neuropathy,peripheral neuropathy was,1
HALAVEN,peripheral neuropathy,reduction due peripheral neuropathy,1
HALAVEN,peripheral neuropathy,neuropathy at baseline Dose reduction due,0
HALAVEN,peripheral neuropathy,due to,0
HALAVEN,peripheral neuropathy,who received HALAVEN Four,0
HALAVEN,peripheral motor neuropathy,motor neuropathy of,1
HALAVEN,peripheral motor neuropathy,of any grade and of patients developed Grade peripheral motor neuropathy Liver,0
HALAVEN,peripheral motor neuropathy,Grade peripheral motor,0
HALAVEN,peripheral motor neuropathy,peripheral motor,1
HALAVEN,peripheral motor neuropathy,patients with Grade or ALT levels at,0
HALAVEN,peripheral motor neuropathy,Function Test Abnormalities Among patients with Grade or,0
HALAVEN,peripheral motor neuropathy,peripheral motor neuropathy,1
HALAVEN,peripheral motor neuropathy,of patients developed peripheral motor neuropathy Liver Function Test Abnormalities,1
HALAVEN,peripheral motor neuropathy,peripheral motor neuropathy,1
HALAVEN,peripheral motor neuropathy,peripheral motor neuropathy Liver,1
HALAVEN,peripheral motor neuropathy,developed peripheral,1
HALAVEN,peripheral motor neuropathy,of patients developed peripheral motor neuropathy,1
HALAVEN,peripheral motor neuropathy,developed peripheral,1
HALAVEN,ALT elevation,or ALT elevation One HALAVENtreated,1
HALAVEN,ALT elevation,developed peripheral,1
HALAVEN,ALT elevation,ALT elevation,1
HALAVEN,ALT elevation,ALT elevation,1
HALAVEN,ALT elevation,ALT elevation One HALAVENtreated,1
HALAVEN,ALT elevation,ALT elevation One HALAVENtreated patient without,1
HALAVEN,ALT elevation,Grade or ALT elevation,1
HALAVEN,ALT elevation,ALT elevation One HALAVENtreated patient without,1
HALAVEN,elevations in bilirubin,had concomitant elevations,1
HALAVEN,elevations in bilirubin,elevations in bilirubin and ALT these abnormalities resolved,1
HALAVEN,elevations in bilirubin,patient,0
HALAVEN,elevations in bilirubin,and did not recur,0
HALAVEN,elevations in bilirubin,had concomitant elevations in bilirubin,1
HALAVEN,increased lacrimation,Eye increased lacrimation Gastrointestinal Disorders dyspepsia abdominal,1
HALAVEN,increased lacrimation,had concomitant elevations in bilirubin,1
HALAVEN,increased lacrimation,increased lacrimation Gastrointestinal Disorders,1
HALAVEN,increased lacrimation,had concomitant elevations in bilirubin,1
HALAVEN,abdominal pain,Disorders and Administration Site Conditions,0
HALAVEN,stomatitis,stomatitis,1
HALAVEN,stomatitis,stomatitis dry mouth General Disorders and,1
HALAVEN,stomatitis,stomatitis,1
HALAVEN,stomatitis,abdominal stomatitis,1
HALAVEN,stomatitis,stomatitis,1
HALAVEN,stomatitis,stomatitis dry mouth General Disorders and,1
HALAVEN,stomatitis,Disorders and Administration Site Conditions,0
HALAVEN,stomatitis,stomatitis dry mouth General Disorders and,1
HALAVEN,stomatitis,stomatitis dry,1
HALAVEN,stomatitis,stomatitis dry mouth General Disorders and,1
HALAVEN,dry mouth,increased lacrimation Gastrointestinal Disorders dyspepsia abdominal pain,0
HALAVEN,dry mouth,dry mouth General Disorders and Administration Site,1
HALAVEN,dry mouth,dry,1
HALAVEN,dry mouth,edema Infections,0
HALAVEN,dry mouth,dry mouth General Disorders and Administration,1
HALAVEN,dry mouth,edema Infections,0
HALAVEN,peripheral edema,Site Conditions,0
HALAVEN,peripheral edema,peripheral edema Infections and Infestations upper,1
HALAVEN,peripheral edema,upper respiratory tract,0
HALAVEN,peripheral edema,and Administration,0
HALAVEN,peripheral edema,Disorders and Administration Site peripheral edema Infections and Infestations upper,1
HALAVEN,peripheral edema,and Administration,0
HALAVEN,upper respiratory tract infection,and upper respiratory tract infection Metabolism and Nutrition,1
HALAVEN,upper respiratory tract infection,and Administration,0
HALAVEN,upper respiratory tract infection,Infections and upper,1
HALAVEN,hypokalemia,hypokalemia Musculoskeletal,1
HALAVEN,hypokalemia,hypokalemia Musculoskeletal and Connective Tissue,1
HALAVEN,hypokalemia,hypokalemia Musculoskeletal and,1
HALAVEN,hypokalemia,hypokalemia Musculoskeletal,1
HALAVEN,muscle spasms,Musculoskeletal and Connective,0
HALAVEN,muscular weakness,Connective Tissue Disorders muscle muscular weakness,1
HALAVEN,muscular weakness,muscular weakness Nervous System Disorders dysgeusia dizziness,1
HALAVEN,muscular weakness,hypokalemia Musculoskeletal and Connective Tissue Disorders muscle,0
HALAVEN,muscular weakness,dysgeusia,0
HALAVEN,muscular weakness,muscular weakness Nervous System Disorders dysgeusia dizziness,1
HALAVEN,muscular weakness,System Disorders dysgeusia,0
HALAVEN,dysgeusia,insomnia depression Skin,0
HALAVEN,dysgeusia,dysgeusia dizziness,1
HALAVEN,dysgeusia,dysgeusia dizziness Psychiatric Disorders insomnia,1
HALAVEN,dysgeusia,dysgeusia dizziness,1
HALAVEN,dysgeusia,dysgeusia dizziness Psychiatric Disorders,1
HALAVEN,dysgeusia,dysgeusia dizziness Psychiatric Disorders insomnia depression,1
HALAVEN,dysgeusia,dysgeusia,1
HALAVEN,dysgeusia,Psychiatric Disorders,0
HALAVEN,dysgeusia,Disorders insomnia depression,0
HALAVEN,dysgeusia,Nervous System dysgeusia dizziness Psychiatric Disorders insomnia depression,1
HALAVEN,dysgeusia,Disorders insomnia depression,0
HALAVEN,dizziness,muscle spasms muscular weakness Nervous System Disorders,0
HALAVEN,dizziness,dizziness,1
HALAVEN,dizziness,dizziness Psychiatric Disorders insomnia depression,1
HALAVEN,dizziness,dizziness Psychiatric Disorders,1
HALAVEN,dizziness,weakness Nervous System Disorders dizziness Psychiatric Disorders,1
HALAVEN,dizziness,dizziness Psychiatric Disorders,1
HALAVEN,dizziness,Nervous System Disorders dizziness Psychiatric Disorders insomnia,1
HALAVEN,dizziness,dizziness Psychiatric Disorders,1
HALAVEN,insomnia,Disorders,0
HALAVEN,insomnia,insomnia depression Skin,1
HALAVEN,insomnia,insomnia depression Skin,1
HALAVEN,insomnia,insomnia depression Skin and,1
HALAVEN,insomnia,and Subcutaneous Tissue Disorders rash Postmarketing,0
HALAVEN,insomnia,Disorders,0
HALAVEN,depression,Disorders rash Postmarketing,0
HALAVEN,depression,rash Postmarketing,0
HALAVEN,depression,Tissue Disorders rash Postmarketing Experience,0
HALAVEN,depression,depression Skin and Subcutaneous,1
HALAVEN,depression,Disorders dysgeusia,0
HALAVEN,rash,following adverse drug reactions,0
HALAVEN,rash,rash Postmarketing,1
HALAVEN,rash,The following adverse drug reactions have,0
HALAVEN,lymphopenia,Hepatobiliary Disorders,0
HALAVEN,lymphopenia,lymphopenia Gastrointestinal,1
HALAVEN,lymphopenia,Hepatobiliary Disorders,0
HALAVEN,lymphopenia,System lymphopenia Gastrointestinal Disorders pancreatitis Hepatobiliary,1
HALAVEN,lymphopenia,Hepatobiliary Disorders,0
HALAVEN,lymphopenia,Lymphatic System lymphopenia,1
HALAVEN,lymphopenia,Hepatobiliary Disorders,0
HALAVEN,lymphopenia,or establish a,0
HALAVEN,lymphopenia,Blood and Lymphatic System lymphopenia Gastrointestinal Disorders,1
HALAVEN,lymphopenia,or establish a,0
HALAVEN,lymphopenia,lymphopenia Gastrointestinal Disorders pancreatitis,1
HALAVEN,lymphopenia,or establish a causal relationship to drug exposure Blood and Lymphatic System Disorders,0
HALAVEN,pancreatitis,Disorders hepatotoxicity Immune,0
HALAVEN,pancreatitis,pancreatitis Hepatobiliary,1
HALAVEN,pancreatitis,lymphopenia Gastrointestinal pancreatitis Hepatobiliary Disorders,1
HALAVEN,pancreatitis,pancreatitis Hepatobiliary,1
HALAVEN,pancreatitis,hepatotoxicity Immune System,0
HALAVEN,pancreatitis,pancreatitis Hepatobiliary,1
HALAVEN,hepatotoxicity,hepatotoxicity Immune System Disorders,1
HALAVEN,hepatotoxicity,hepatotoxicity Immune System Disorders drug hypersensitivity,1
HALAVEN,hepatotoxicity,isorders lymphopenia Gastrointestinal Disorders pancreatitis,0
HALAVEN,hepatotoxicity,Gastrointestinal Disorders pancreatitis Hepatobiliary hepatotoxicity Immune System Disorders,1
HALAVEN,hepatotoxicity,isorders lymphopenia Gastrointestinal Disorders pancreatitis,0
HALAVEN,hepatotoxicity,pancreatitis Hepatobiliary,0
HALAVEN,hepatotoxicity,hypersensitivity Infections and Infestations pneumonia,0
HALAVEN,hepatotoxicity,hepatotoxicity Immune System Disorders,1
HALAVEN,hepatotoxicity,hypersensitivity Infections and Infestations pneumonia,0
HALAVEN,hypersensitivity,Immune System Disorders hypersensitivity Infections and Infestations,1
HALAVEN,hypersensitivity,hypersensitivity Infections and Infestations pneumonia,0
HALAVEN,pneumonia,Infections and Infestations,0
HALAVEN,pneumonia,hypersensitivity Infections and pneumonia sepsisneutropenic,1
HALAVEN,pneumonia,Infections and Infestations,0
HALAVEN,pneumonia,pneumonia sepsisneutropenic,1
HALAVEN,pneumonia,hypersensitivity Infections,0
HALAVEN,pneumonia,pneumonia sepsisneutropenic,1
HALAVEN,pneumonia,drug hypersensitivity Infections and Infestations,0
HALAVEN,sepsis,Infections and Infestations sepsis neutropenic sepsis Metabolism,1
HALAVEN,sepsis,drug hypersensitivity Infections and Infestations,0
HALAVEN,sepsis,hypersensitivity Infections and Infestations,0
HALAVEN,sepsis,sepsis neutropenic,1
HALAVEN,neutropenic sepsis,and Nutrition Disorders hypomagnesemia dehydration,0
HALAVEN,neutropenic sepsis,hypomagnesemia dehydration Respiratory thoracic,0
HALAVEN,neutropenic sepsis,Infestations,0
HALAVEN,neutropenic sepsis,sepsis,0
HALAVEN,neutropenic sepsis,pneumonia neutropenic sepsis Metabolism and,1
HALAVEN,neutropenic sepsis,sepsis,0
HALAVEN,neutropenic sepsis,and Infestations pneumonia neutropenic,1
HALAVEN,neutropenic sepsis,pneumonia neutropenic sepsis,1
HALAVEN,neutropenic sepsis,dehydration,0
HALAVEN,neutropenic sepsis,Immune System Disorders drug hypersensitivity Infections and Infestations pneumonia sepsis,0
HALAVEN,neutropenic sepsis,neutropenic sepsis Metabolism and Nutrition Disorders hypomagnesemia,1
HALAVEN,hypomagnesemia,hypomagnesemia dehydration,1
HALAVEN,hypomagnesemia,disorders,0
HALAVEN,hypomagnesemia,hypomagnesemia dehydration,1
HALAVEN,hypomagnesemia,sepsis Metabolism and Nutrition hypomagnesemia dehydration Respiratory,1
HALAVEN,hypomagnesemia,hypomagnesemia dehydration,1
HALAVEN,hypomagnesemia,and Infestations,0
HALAVEN,hypomagnesemia,hypomagnesemia dehydration,1
HALAVEN,hypomagnesemia,Respiratory,0
HALAVEN,hypomagnesemia,hypomagnesemia dehydration Respiratory thoracic and mediastinal,1
HALAVEN,hypomagnesemia,Nutrition Disorders,0
HALAVEN,hypomagnesemia,dehydration Respiratory thoracic and mediastinal disorders interstitial lung,0
HALAVEN,dehydration,Respiratory thoracic and mediastinal disorders interstitial,0
HALAVEN,dehydration,dehydration Respiratory thoracic and,1
HALAVEN,dehydration,Nutrition Disorders dehydration Respiratory thoracic and,1
HALAVEN,dehydration,dehydration Respiratory thoracic and,1
HALAVEN,dehydration,Disorders dehydration Respiratory thoracic and mediastinal disorders,1
HALAVEN,dehydration,dehydration Respiratory thoracic and,1
HALAVEN,dehydration,Nutrition Disorders dehydration Respiratory thoracic and mediastinal disorders,1
HALAVEN,dehydration,dehydration Respiratory thoracic and,1
HALAVEN,dehydration,and Nutrition Disorders dehydration Respiratory,1
HALAVEN,dehydration,dehydration Respiratory thoracic and,1
HALAVEN,interstitial lung disease,Skin and Subcutaneous Tissue Disorders,0
HALAVEN,interstitial lung disease,thoracic and mediastinal interstitial lung disease Skin and Subcutaneous Tissue,1
HALAVEN,interstitial lung disease,Skin and Subcutaneous Tissue Disorders,0
HALAVEN,interstitial lung disease,and Subcutaneous,0
HALAVEN,interstitial lung disease,thoracic and mediastinal interstitial lung disease Skin and Subcutaneous Tissue Disorders,1
HALAVEN,interstitial lung disease,and Subcutaneous,0
HALAVEN,interstitial lung disease,thoracic and mediastinal interstitial lung disease Skin and Subcutaneous Tissue,1
HALAVEN,interstitial lung disease,and Subcutaneous,0
HALAVEN,interstitial lung disease,lung disease Skin and Subcutaneous,1
HALAVEN,interstitial lung disease,interstitial lung disease Skin and Subcutaneous Tissue,1
HALAVEN,interstitial lung disease,lung disease Skin and,1
HALAVEN,interstitial lung disease,and mediastinal interstitial lung disease Skin and Subcutaneous,1
HALAVEN,interstitial lung disease,lung disease Skin and,1
HALAVEN,Neutropenia,were neutropenia anemia astheniafatigue alopecia peripheral,0
HALAVEN,Neutropenia,REACTIONS EXCERPT The most on adverse,1
HALAVEN,Neutropenia,reactions incidence were neutropenia anemia,0
HALAVEN,Neutropenia,most on adverse  reactions incidence,1
HALAVEN,Neutropenia,reactions incidence were neutropenia anemia,0
HALAVEN,Neutropenia,ADVERSE REACTIONS EXCERPT The most comm,0
HALAVEN,Neutropenia,on adverse reactions,1
HALAVEN,Peripheral Neuropathy,REACTIONS contact Eisai,0
HALAVEN,Peripheral Neuropathy,"alopecia peripheral hy, nausea, and const ipation To report",1
HALAVEN,Peripheral Neuropathy,REACTIONS contact Eisai,0
HALAVEN,Peripheral Neuropathy,neutropenia anemia astheniafatigue,0
HALAVEN,Peripheral Neuropathy,astheniafatigue alopecia,0
HALAVEN,Peripheral Neuropathy,"hy, nausea, and const ipation To report SUSPECTED",1
HALAVEN,Peripheral Neuropathy,astheniafatigue alopecia,0
HALAVEN,Peripheral Neuropathy,"hy,",1
HALAVEN,Peripheral Neuropathy,"hy,",1
HALAVEN,Peripheral Neuropathy,report,0
HALAVEN,Peripheral Neuropathy,"hy, nausea, and const ipation To",1
HALAVEN,Embryo-Fetal Toxicity,Inc at or ontact,1
HALAVEN,Embryo-Fetal Toxicity,FDA at 1-800-F DA or wwwfdagovmedwatch Clinical Trials,1
HALAVEN,Embryo-Fetal Toxicity,FDA at 1-800-F DA or wwwfdagovmedwatch Clinical,1
HALAVEN,Embryo-Fetal Toxicity,ontact FDA at 1-800-F DA or wwwfdagovmedwatch Clinical,1
HALAVEN,Embryo-Fetal Toxicity,at or ontact FDA at 1-800-F,1
HALAVEN,Embryo-Fetal Toxicity,Clinical Trials Experience Because,0
HALAVEN,Embryo-Fetal Toxicity,FDA at 1-800-F DA,1
HALAVEN,Embryo-Fetal Toxicity,ontact FDA at 1-800-F,1
HALAVEN,Fetal harm,contact FDA,0
HALAVEN,Fetal harm,ADVERSE REACTIONS contact Eisai Inc at or contact FDA at FDA,0
HALAVEN,QT Prolongation,clinical tri als are conducted under,1
HALAVEN,QT Prolongation,Clinical Trials Experience se clinical tri als,1
HALAVEN,QT Prolongation,clinical tri als are conducted under,1
HALAVEN,QT Prolongation,wwwfdagovmedwatch Clinical Trials Experience se clinical tri als,1
HALAVEN,QT Prolongation,clinical tri als are conducted under,1
HALAVEN,neutropenia,practice The following adverse ns are,1
HALAVEN,neutropenia,reactions reported,0
HALAVEN,neutropenia,reported patients re,1
HALAVEN,neutropenia,reactions reported,0
HALAVEN,neutropenia,and Precautions The most common adverse,0
HALAVEN,febrile neutropenia,patients ng HALAVEN,1
HALAVEN,febrile neutropenia,HALAVEN were neu tropenia anemia astheniafatigue alopecia,1
HALAVEN,febrile neutropenia,and constipation The m,0
HALAVEN,febrile neutropenia,patients ng HALAVEN were neu tropenia anemia astheniafatigue alopecia peripheral,1
HALAVEN,febrile neutropenia,and constipation The m,0
HALAVEN,febrile neutropenia,patients ng HALAVEN were neu,1
HALAVEN,neutropenia,reactions,1
HALAVEN,neutropenia,common serious reactions,1
HALAVEN,neutropenia,reactions r eported in patients receiving,1
HALAVEN,neutropenia,The most common serious reactions r eported in patients,1
HALAVEN,neutropenia,reactions r eported in patients receiving,1
HALAVEN,neutropenia,serious,0
HALAVEN,peripheral neuropathy,Caucasian,0
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot her The adverse reactions described",1
HALAVEN,peripheral neuropathy,"was Caucasian ), Asian (2%), and ot her The adverse reactions described",1
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot her The adverse reactions described",1
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot",1
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot her The adverse reactions described",1
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot her The adverse reactions",1
HALAVEN,peripheral neuropathy,"Caucasian ), Asian (2%), and ot",1
HALAVEN,peripheral neuropathy,"(2%), and ot her The adverse reactions described",1
HALAVEN,peripheral neuropathy,The adverse,0
HALAVEN,peripheral neuropathy,in,0
HALAVEN,peripheral neuropathy,racial and ethnic distribution,0
HALAVEN,peripheral neuropathy,"), Asian (2%), and ot her The",1
HALAVEN,peripheral neuropathy,"Caucasian ),",1
HALAVEN,Peripheral neuropathy,1 [,1
HALAVEN,Peripheral neuropathy,Study 1 [ see Clinical Studies,1
HALAVEN,Peripheral neuropathy,Study 1 [ see Clinical Studies In Study,1
HALAVEN,Peripheral neuropathy,patients reated in Study 1 [,1
HALAVEN,Peripheral neuropathy,were identified in patients reated in Study 1,1
HALAVEN,Peripheral neuropathy,patients,0
HALAVEN,Peripheral neuropathy,1 [,1
HALAVEN,Peripheral neuropathy,were identified in patients reated in Study 1 [   see,1
HALAVEN,Peripheral neuropathy,1 [,1
HALAVEN,Peripheral neuropathy,1 [ see Clinical,1
HALAVEN,Peripheral neuropathy,patients reated in,1
HALAVEN,Neuropathy,e either H ALAVEN,1
HALAVEN,Neuropathy,either H ALAVEN mgm,1
HALAVEN,Neuropathy,were randomized to e either H ALAVEN mgm on Days and,1
HALAVEN,Neuropathy,either H ALAVEN mgm,1
HALAVEN,Neuropathy,e either H ALAVEN mgm on Days and,1
HALAVEN,Neuropathy,receiv,0
HALAVEN,neuropathy,A total 503,1
HALAVEN,neuropathy,503 patie nts received,1
HALAVEN,neuropathy,patients in the control group received therapy consisting,0
HALAVEN,neuropathy,total 503 patie,1
HALAVEN,fetal harm,with a atient,1
HALAVEN,fetal harm,Reactions with a atient Inc idence of at Least in,1
HALAVEN,fetal harm,with a atient,1
HALAVEN,fetal harm,a atient Inc idence,1
HALAVEN,fetal harm,with a atient,1
HALAVEN,fetal harm,Reactions with a atient Inc,1
HALAVEN,fetal harm,in Study MedDRA ver HALAVEN,0
HALAVEN,fetal harm,atient Inc idence of at Least in,1
HALAVEN,fetal harm,patients in either group Table Adverse Reactions with a PerP,0
HALAVEN,Embryo-fetal toxicity,a PerPatient Incidence of at,0
HALAVEN,Embryo-fetal toxicity,10.0 HA LAVEN n Control Group,1
HALAVEN,Embryo-fetal toxicity,Table Adverse Reactions with a PerPatient Incidence of at Least in,0
HALAVEN,Embryo-fetal toxicity,at,0
HALAVEN,Embryo-fetal toxicity,in Study,0
HALAVEN,Embryo-fetal toxicity,Least in Study dDRA,1
HALAVEN,Embryo-fetal toxicity,dDRA ver 10.0      HA LAVEN,1
HALAVEN,Embryo-fetal toxicity,Least in Study dDRA,1
HALAVEN,teratogenicity,Control Group n All Grades Grade All Grades,0
HALAVEN,teratogenicity,    n=503      Control Group n All,1
HALAVEN,teratogenicity,Control,0
HALAVEN,teratogenicity,    n=503      Control,1
HALAVEN,teratogenicity,    n=503      Control Group n All Grades,1
HALAVEN,QT prolongation,orders          Peripheral neuropathy b,1
HALAVEN,QT prolongation,Peripheral neuropathy,0
HALAVEN,QT prolongation,orders          Peripheral neuropathy b,1
HALAVEN,QT prolongation,disorders ripheral neurop athy b,1
HALAVEN,QT prolongation,orders          Peripheral neuropathy b,1
HALAVEN,QT prolongation,athy b Headache,0
HALAVEN,QT prolongation,disorders ripheral neurop athy,1
HALAVEN,QT prolongation,athy b Headache,0
HALAVEN,QT prolongation,athy b Headache,0
HALAVEN,QT prolongation,athy b,0
HALAVEN,QT prolongation,disorders ripheral,1
HALAVEN,QT prolongation,disorders,0
HALAVEN,QT prolongation,athy b,0
HALAVEN,QT prolongation,ripheral,1
HALAVEN,QT prolongation,ripheral neurop,1
XIAFLEX,Tendon ruptures,the Tendon ruptures or other serious injury to,1
XIAFLEX,Tendon ruptures,ripheral neurop,1
XIAFLEX,Tendon ruptures,Tendon ruptures or other serious injury to,1
XIAFLEX,Tendon ruptures,ripheral neurop,1
XIAFLEX,Tendon ruptures,elsewhere in,0
XIAFLEX,Tendon ruptures,see Warnings,0
XIAFLEX,Tendon ruptures,detail elsewhere in,0
XIAFLEX,Tendon ruptures,Tendon ruptures or other serious injury,1
XIAFLEX,Tendon ruptures,or other serious injury to the injected extremity see Warnings and Precautions Th,0
XIAFLEX,Tendon ruptures,Tendon ruptures or,1
XIAFLEX,Tendon ruptures,Warnings and Precautions,0
XIAFLEX,injury to the injected extremity,or other injury to the injected extremity see Warnings and Precautions,1
XIAFLEX,injury to the injected extremity,Warnings and Precautions,0
XIAFLEX,injury to the injected extremity,the injected extremity see,1
XIAFLEX,injury to the injected extremity,other injury,1
XIAFLEX,injury to the injected extremity,reactions in,0
XIAFLEX,injury to the injected extremity,to the injected extremity see Warnings and Precautions The,1
XIAFLEX,Corporal rupture,Corporal rupture,1
XIAFLEX,Corporal rupture,to the injected extremity see Warnings and Precautions The,1
XIAFLEX,Corporal rupture,Corporal rupture penile fracture and severe penile,1
XIAFLEX,Corporal rupture,Warnings and Precautions In,0
XIAFLEX,Corporal rupture,Corporal rupture penile fracture and severe penile,1
XIAFLEX,Corporal rupture,detail elsewhere in the Corporal,1
XIAFLEX,Corporal rupture,and Precautions In othe,0
XIAFLEX,Corporal rupture,the Corporal rupture,1
XIAFLEX,penile fracture,Precautions,0
XIAFLEX,penile fracture,rupture,0
XIAFLEX,penile hematoma,rupture penile fracture and penile,1
XIAFLEX,penile hematoma,and penile hematoma,1
XIAFLEX,penile hematoma,and Precautions In other XIAFLEXtreated patients a,0
XIAFLEX,penile hematoma,rupture penile fracture and penile hematoma,1
XIAFLEX,penile hematoma,penile hematoma see Warnings and,1
XIAFLEX,penile ecchymoses,penile ecchymoses or hematoma sudden penile detumescence,1
XIAFLEX,penile ecchymoses,penile ecchymoses or hematoma,1
XIAFLEX,penile ecchymoses,Warnings and Precautions,0
XIAFLEX,penile ecchymoses,combination,0
XIAFLEX,penile ecchymoses,penile ecchymoses or hematoma,1
XIAFLEX,penile ecchymoses,penile ecchymoses or,1
XIAFLEX,penile ecchymoses,see Warnings,0
XIAFLEX,penile ecchymoses,penile ecchymoses,1
XIAFLEX,penile ecchymoses,penile ecchymoses,1
XIAFLEX,penile ecchymoses,penile ecchymoses,1
XIAFLEX,penile detumescence,combination of penile ecchymoses or hematoma,0
XIAFLEX,penile detumescence,a penile popping sound or sensation was,0
XIAFLEX,penile detumescence,or hematoma penile detumescence andor a,1
XIAFLEX,penile detumescence,a penile popping sound or sensation was,0
XIAFLEX,penile detumescence,or hematoma penile,1
XIAFLEX,penile detumescence,penile popping sound,0
XIAFLEX,penile detumescence,penile detumescence andor a penile popping sound,1
XIAFLEX,penile detumescence,penile popping sound,0
XIAFLEX,penile detumescence,penile detumescence andor a penile popping,1
XIAFLEX,"penile ""popping"" sound","sudden penile detumescence andor penile ""popping""",1
XIAFLEX,"penile ""popping"" sound",penile,0
XIAFLEX,"penile ""popping"" sound",was reported,0
XIAFLEX,"penile ""popping"" sound","detumescence andor penile ""popping"" sound or sensation",1
XIAFLEX,"penile ""popping"" sound",was reported,0
XIAFLEX,corporal rupture,cannot be excluded see Warnings and Precautions EXCERPT,0
XIAFLEX,edema peripheral,placebo,0
XIAFLEX,edema peripheral,placebo edema,1
XIAFLEX,edema peripheral,edema peripheral,1
XIAFLEX,edema peripheral,placebo edema peripheral,1
XIAFLEX,edema peripheral,patients treated with XIAFLEX and at,0
XIAFLEX,swelling of the injected hand,and at an incidence greater than placebo,0
XIAFLEX,swelling of the injected hand,swelling of the injected hand contusion,1
XIAFLEX,swelling of the injected hand,of the injected hand contusion injection,1
XIAFLEX,contusion,contusion injection site hemorrhage injection site,1
XIAFLEX,contusion,injection site hemorrhage injection site,0
XIAFLEX,contusion,contusion,1
XIAFLEX,contusion,injection site hemorrhage injection site,0
XIAFLEX,contusion,contusion injection site hemorrhage injection,1
XIAFLEX,contusion,contusion,1
XIAFLEX,contusion,of the injected contusion injection site hemorrhage injection,1
XIAFLEX,contusion,contusion,1
XIAFLEX,contusion,placebo were edema peripheral eg,0
XIAFLEX,contusion,injected contusion injection site hemorrhage injection,1
XIAFLEX,contusion,placebo were edema peripheral eg,0
XIAFLEX,injection site reaction,injection site injection site reaction and pain in the,1
XIAFLEX,injection site reaction,placebo were edema peripheral eg,0
XIAFLEX,injection site reaction,site reaction and pain,1
XIAFLEX,injection site reaction,extremity,0
XIAFLEX,injection site reaction,edema peripheral eg swelling of the injected hand,0
XIAFLEX,injection site reaction,site injection site reaction and pain in the injected,1
XIAFLEX,injection site reaction,edema peripheral eg swelling of the injected hand,0
XIAFLEX,injection site reaction,Peyronies Disease The,0
XIAFLEX,pain in the injected extremity,reaction pain in the injected extremity,1
XIAFLEX,pain in the injected extremity,Peyronies Disease The,0
XIAFLEX,pain in the injected extremity,injection site reaction pain,1
XIAFLEX,penile hematoma,incidence greater,0
XIAFLEX,penile hematoma,greater than placebo penile hematoma penile swelling and,1
XIAFLEX,penile hematoma,incidence greater,0
XIAFLEX,penile swelling,penile swelling and penile pain,1
XIAFLEX,penile swelling,treated with XIAFLEX and at an incidence greater than placebo were,0
XIAFLEX,penile swelling,than placebo were penile penile swelling,1
XIAFLEX,penile swelling,treated with XIAFLEX and at an incidence greater than placebo were,0
XIAFLEX,penile pain,and at,0
XIAFLEX,penile pain,penile,1
XIAFLEX,penile pain,penile swelling penile,1
XIAFLEX,penile pain,penile pain,1
XIAFLEX,penile pain,swelling penile pain,1
XIAFLEX,penile pain,penile pain,1
XIAFLEX,penile pain,penile pain To report SUSPECTED,1
XIAFLEX,penile pain,report SUSPECTED ADVERSE REACTIONS contact,0
XIAFLEX,penile pain,swelling penile pain,1
XIAFLEX,penile pain,penile hematoma penile swelling and,0
XIAFLEX,adverse reaction of the injected extremity,XIAFLEXtreated patients had adverse reaction of the injected extremity,1
XIAFLEX,adverse reaction of the injected extremity,of the injected extremity,1
XIAFLEX,adverse reaction of the injected extremity,patients had adverse reaction of the injected extremity after,1
XIAFLEX,adverse reaction of the injected extremity,of the injected extremity,1
XIAFLEX,adverse reaction of the injected extremity,these local reactions resolved without,0
XIAFLEX,adverse reaction of the injected extremity,patients had,0
XIAFLEX,adverse reaction of the injected extremity,injected extremity after up to,1
XIAFLEX,edema peripheral,edema peripheral mostly swelling,1
XIAFLEX,edema peripheral,clinical trials in patients with Dupuytrens contracture included,0
XIAFLEX,edema peripheral,Dupuytrens contracture edema peripheral mostly swelling of the injected,1
XIAFLEX,edema peripheral,clinical trials in patients with Dupuytrens contracture included,0
XIAFLEX,edema peripheral,reactions in the,0
XIAFLEX,edema peripheral,patients with Dupuytrens contracture edema peripheral,1
XIAFLEX,edema peripheral,Dupuytrens contracture edema peripheral mostly swelling of,1
XIAFLEX,edema peripheral,patients with Dupuytrens contracture edema peripheral,1
XIAFLEX,edema peripheral,edema,1
XIAFLEX,edema peripheral,with Dupuytrens contracture edema peripheral mostly swelling,1
XIAFLEX,edema peripheral,edema,1
XIAFLEX,swelling of the injected hand,edema peripheral mostly,0
XIAFLEX,swelling of the injected hand,peripheral swelling of,1
XIAFLEX,contusion,reaction and pain in the,0
XIAFLEX,contusion,contusion injection,1
XIAFLEX,contusion,hand,0
XIAFLEX,contusion,injected contusion injection,1
XIAFLEX,contusion,hand,0
XIAFLEX,contusion,contusion injection site hemorrhage injection site,1
XIAFLEX,contusion,contusion injection site hemorrhage,1
XIAFLEX,contusion,reaction and pain in the,0
XIAFLEX,contusion,contracture included edema peripheral mostly swelling of,0
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection site reaction and,1
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection site reaction and,1
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection site reaction and,1
XIAFLEX,injection site hemorrhage,injected hand injection site hemorrhage injection,1
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection site reaction and,1
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection,1
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection site reaction and,1
XIAFLEX,injection site hemorrhage,of the injected hand injection site hemorrhage injection site reaction,1
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection site reaction and,1
XIAFLEX,injection site hemorrhage,injection site hemorrhage injection site reaction and,1
XIAFLEX,injection site hemorrhage,injected hand injection,1
XIAFLEX,injection site hemorrhage,the injected hand injection,1
XIAFLEX,injection site reaction,injection site reaction,1
XIAFLEX,injection site reaction,contusion injection site injection,1
XIAFLEX,injection site reaction,adverse reactions that were repo,0
XIAFLEX,injection site reaction,hand contusion injection site injection site reaction,1
XIAFLEX,injection site reaction,hand contusion injection site injection site reaction,1
XIAFLEX,injection site reaction,hand contusion injection site injection site reaction,1
XIAFLEX,injection site reaction,injection site reaction and pain in the treated,1
XIAFLEX,injection site reaction,contusion injection site injection site,1
XIAFLEX,injection site reaction,shows the incidence,0
XIAFLEX,pain in the treated extremity,greater than or equal to,0
XIAFLEX,pain in the treated extremity,reaction pain in the treated extremity Table shows the incidence of,1
XIAFLEX,pain in the treated extremity,greater than or equal to,0
XIAFLEX,swelling of the injected hand,of these events swelling of the injected hand b Includes the,1
XIAFLEX,swelling of the injected hand,greater than or equal to,0
XIAFLEX,swelling of the injected hand,body system and ecchymosis,0
XIAFLEX,swelling of the injected hand,of the injected hand b Includes the,1
XIAFLEX,swelling of the injected hand,injected hand b Includes the terms,1
XIAFLEX,swelling of the injected hand,of the injected hand b Includes the terms,1
XIAFLEX,swelling of the injected hand,swelling of the injected hand b Includes the terms contusion,1
XIAFLEX,swelling of the injected hand,of the injected hand b Includes the terms,1
XIAFLEX,swelling of the injected hand,the injected hand b,1
XIAFLEX,contusion,contusion any body,1
XIAFLEX,contusion,terms injection site reaction,0
XIAFLEX,contusion,contusion any body system and,1
XIAFLEX,contusion,system and ecchymosis c Includes the terms injection site reaction injection,0
XIAFLEX,contusion,the terms injection site reaction injection s,0
XIAFLEX,contusion,any body system and ecchymosis c,0
XIAFLEX,contusion,contusion any body system and ecchymosis,1
XIAFLEX,contusion,any body system and ecchymosis c,0
XIAFLEX,contusion,contusion any body,1
XIAFLEX,ecchymosis,body system and,0
XIAFLEX,ecchymosis,contusion any body system ecchymosis c Includes the terms,1
XIAFLEX,ecchymosis,body system and,0
XIAFLEX,ecchymosis,of,0
XIAFLEX,ecchymosis,ecchymosis c Includes,1
XIAFLEX,ecchymosis,terms,0
XIAFLEX,ecchymosis,site reaction injection,0
XIAFLEX,ecchymosis,ecchymosis c Includes the terms,1
XIAFLEX,ecchymosis,any body system ecchymosis c Includes,1
XIAFLEX,ecchymosis,ecchymosis c Includes the terms,1
XIAFLEX,injection site reaction,injection site reaction injection site,1
XIAFLEX,injection site reaction,injection site reaction injection,1
XIAFLEX,injection site reaction,injection,1
XIAFLEX,injection site reaction,Includes the injection site reaction,1
XIAFLEX,injection site reaction,the injection site,1
XIAFLEX,injection site reaction,injection site inflammation injection site irritation injection,0
XIAFLEX,injection site reaction,and ecchymosis c Includes the terms,0
XIAFLEX,injection site reaction,the injection site reaction injection site,1
XIAFLEX,injection site reaction,and ecchymosis c Includes the terms,0
XIAFLEX,injection site erythema,injection site injection site,1
XIAFLEX,injection site irritation,site injection site irritation injection site pain and injection,1
XIAFLEX,injection site irritation,injection site injection site,1
XIAFLEX,injection site irritation,injection site injection site,1
XIAFLEX,injection site irritation,injection,1
XIAFLEX,injection site irritation,injection site warmth d Includes the terms injection site,0
XIAFLEX,injection site irritation,injection site pain and injection site warmth,0
XIAFLEX,injection site irritation,site irritation injection site pain,1
XIAFLEX,injection site irritation,injection site injection site irritation injection site pain and,1
XIAFLEX,injection site irritation,site irritation injection site pain,1
XIAFLEX,injection site irritation,site pain and injection site warmth d Includes the terms,0
XIAFLEX,injection site irritation,injection site pain and injection site warmth d Includes the terms injection,0
XIAFLEX,injection site pain,site injection site pain,1
XIAFLEX,injection site pain,injection site pain and injection site warmth d Includes the terms injection,0
XIAFLEX,injection site pain,inflammation injection site injection site pain and injection site warmth,1
XIAFLEX,injection site pain,injection site pain and injection site warmth d Includes the terms injection,0
XIAFLEX,injection site pain,site injection site pain and injection site,1
XIAFLEX,injection site pain,injection site pain and injection site warmth d Includes the terms injection,0
XIAFLEX,injection site pain,reaction injection site erythema injection site inflammation injection,0
XIAFLEX,injection site pain,inflammation injection site injection site pain,1
XIAFLEX,injection site pain,Includes the terms injection site swelling and injection site,0
XIAFLEX,injection site pain,injection site pain and injection site warmth,1
XIAFLEX,injection site pain,site inflammation injection site injection site pain,1
XIAFLEX,injection site warmth,pain injection site,1
XIAFLEX,injection site warmth,site pain injection site warmth,1
XIAFLEX,injection site warmth,pain injection site,1
XIAFLEX,injection site warmth,injection site pain injection site warmth d Includes the terms,1
XIAFLEX,injection site warmth,pain injection site,1
XIAFLEX,injection site warmth,site,0
XIAFLEX,injection site warmth,swelling,0
XIAFLEX,injection site warmth,terms injection site swelling and injection site edema e Includes,0
XIAFLEX,injection site warmth,injection site inflammation,0
XIAFLEX,injection site warmth,pain injection site,1
XIAFLEX,injection site warmth,injection site warmth d,1
XIAFLEX,injection site swelling,d Includes the injection site swelling,1
XIAFLEX,injection site swelling,and injection site edema e Includes the terms pruritus and injection,0
XIAFLEX,injection site swelling,d Includes the injection site swelling,1
XIAFLEX,injection site swelling,and injection site edema e Includes the terms pruritus and injection,0
XIAFLEX,injection site swelling,site edema e,0
XIAFLEX,injection site swelling,Includes the injection site swelling and injection site edema,1
XIAFLEX,injection site swelling,site edema e,0
XIAFLEX,injection site swelling,injection,1
XIAFLEX,injection site swelling,injection,1
XIAFLEX,injection site swelling,site swelling and,1
XIAFLEX,pruritus,pruritus and,1
XIAFLEX,pruritus,site swelling and,1
XIAFLEX,pruritus,and axillary mass,0
XIAFLEX,pruritus,pruritus and injection site,1
XIAFLEX,pruritus,Includes,0
XIAFLEX,injection site pruritus,Adverse Reaction,0
XIAFLEX,injection site pruritus,site pruritus,1
XIAFLEX,injection site pruritus,injection site pruritus f Includes,1
XIAFLEX,injection site pruritus,site pruritus,1
XIAFLEX,injection site pruritus,injection site pruritus f Includes the terms lymphadenopathy,1
XIAFLEX,injection site pruritus,site pruritus f Includes the terms,1
XIAFLEX,lymphadenopathy,mass Adverse Reaction,0
XIAFLEX,lymphadenopathy,Adverse Reaction,0
XIAFLEX,lymphadenopathy,and axillary mass Adverse Reaction XIAFLEXN PlaceboN,0
XIAFLEX,lymphadenopathy,lymphadenopathy and axillary mass Adverse Reaction,1
XIAFLEX,axillary mass,All,0
XIAFLEX,axillary mass,axillary mass Adverse Reaction XIAFLEXN PlaceboN All,1
XIAFLEX,axillary mass,PlaceboN All Adverse Reactions,0
XIAFLEX,axillary mass,lymphadenopathy axillary mass,1
XIAFLEX,axillary mass,terms lymphadenopathy axillary,1
XIAFLEX,axillary mass,axillary mass Adverse Reaction,1
XIAFLEX,axillary mass,XIAFLEXN,0
XIAFLEX,axillary mass,lymphadenopathy axillary,1
XIAFLEX,axillary mass,terms lymphadenopathy axillary mass Adverse Reaction XIAFLEXN PlaceboN,1
XIAFLEX,axillary mass,lymphadenopathy axillary,1
XIAFLEX,axillary mass,the terms pruritus and,0
XIAFLEX,Contusion,Contusion b Injection Site Hemorrhage Injection,1
XIAFLEX,Contusion,Adverse Reactions Edema Peripheral Contusion b Injection Site,1
XIAFLEX,Contusion,Contusion b Injection Site Hemorrhage Injection,1
XIAFLEX,Injection Site Hemorrhage,Peripheral a Contusion Injection,1
XIAFLEX,Injection Site Reaction,Hemorrhage,0
XIAFLEX,Pain in Extremity,c,0
XIAFLEX,Pain in Extremity,Pain in Extremity Tenderness Injection Site Swelling d,1
XIAFLEX,Pain in Extremity,c,0
XIAFLEX,Tenderness,Tenderness Injection Site Swelling d,1
XIAFLEX,Tenderness,Pain in Extremity,0
XIAFLEX,Tenderness,Tenderness Injection Site Swelling d,1
XIAFLEX,Tenderness,in Tenderness Injection Site Swelling d,1
XIAFLEX,Tenderness,Tenderness Injection Site Swelling d,1
XIAFLEX,Tenderness,Tenderness Injection Site Swelling d,1
XIAFLEX,Tenderness,in Extremity,0
XIAFLEX,Tenderness,Injection,0
XIAFLEX,Tenderness,Injection Site Swelling d Pruritus e,0
XIAFLEX,Tenderness,hage,0
XIAFLEX,Tenderness,Tenderness Injection Site,1
XIAFLEX,Injection Site Swelling,in Extremity Injection Site Swelling d Pruritus e Lymphadenopathy,1
XIAFLEX,Injection Site Swelling,Tenderness Injection Site,1
XIAFLEX,Injection Site Swelling,f Skin Lacera,0
XIAFLEX,Injection Site Swelling,e Lymphadenopathy f,0
XIAFLEX,Injection Site Swelling,e Lymphadenopathy,0
XIAFLEX,Injection Site Swelling,Injection Site Swelling d Pruritus e Lymphadenopathy,1
XIAFLEX,Injection Site Swelling,Extremity Injection Site Swelling d,1
XIAFLEX,Injection Site Swelling,Injection Site Swelling d Pruritus e Lymphadenopathy,1
XIAFLEX,Injection Site Swelling,Lymphadenopathy,0
XIAFLEX,Injection Site Swelling,Lymphadenopathy f Skin,0
XIAFLEX,Injection Site Swelling,Pain in Extremity Injection Site Swelling,1
XIAFLEX,Injection Site Swelling,Injection,1
XIAFLEX,Pruritus,e Lymphadenopathy f Skin Laceration Lymph,0
XIAFLEX,Pruritus,Pruritus,1
XIAFLEX,Pruritus,Pruritus e,1
XIAFLEX,Pruritus,Extremity Tenderness Injection Site Swelling d,0
XIAFLEX,Lymphadenopathy,Swelling d,0
XIAFLEX,Lymphadenopathy,Lymph Node,0
XIAFLEX,Lymphadenopathy,Lymphadenopathy,1
XIAFLEX,Lymphadenopathy,Lymphadenopathy f,1
XIAFLEX,Lymphadenopathy,Pruritus Lymphadenopathy f Skin Laceration Lymph,1
XIAFLEX,Lymphadenopathy,Lymphadenopathy f,1
XIAFLEX,Lymphadenopathy,nderness Injection Site Swelling d Pruritus,0
XIAFLEX,Lymphadenopathy,Lymphadenopathy f Skin Laceration,1
XIAFLEX,Skin Laceration,Pruritus e Lymphadenopathy Skin Laceration,1
XIAFLEX,Lymph Node Pain,Lymph Node,1
XIAFLEX,Lymph Node Pain,f Skin Lymph Node Pain Erythema,1
XIAFLEX,Lymph Node Pain,Lymph Node,1
XIAFLEX,Lymph Node Pain,Lymphadenopathy f Skin,0
XIAFLEX,Lymph Node Pain,e Lymphadenopathy f,0
XIAFLEX,Lymph Node Pain,Skin,0
XIAFLEX,Lymph Node Pain,Lymph Node Pain Erythema Axillary,1
XIAFLEX,Lymph Node Pain,Skin,0
XIAFLEX,Lymph Node Pain,Lymph Node Pain Erythema Axillary Pain Some,1
XIAFLEX,Erythema,Node Erythema Axillary Pain Some patients,1
XIAFLEX,Erythema,Lymph Node Pain Erythema Axillary Pain Some,1
XIAFLEX,Erythema,Erythema Axillary Pain Some,1
XIAFLEX,Axillary Pain,Some patients developed vasovagal syncope after finger,0
XIAFLEX,Axillary Pain,Skin,0
XIAFLEX,vasovagal syncope,patients vasovagal syncope after,1
XIAFLEX,vasovagal syncope,Skin,0
XIAFLEX,vasovagal syncope,Erythema Axillary Pain Some patients developed,0
XIAFLEX,vasovagal syncope,vasovagal syncope,1
XIAFLEX,vasovagal syncope,Pain,0
XIAFLEX,vasovagal syncope,vasovagal syncope after,1
XIAFLEX,vasovagal syncope,Pain Some patients,0
XIAFLEX,vasovagal syncope,extension procedures The safety of,0
XIAFLEX,Lymphadenopathy,site,0
XIAFLEX,Lymphadenopathy,Lymphadenopathy Blood,1
XIAFLEX,Lymphadenopathy,site,0
XIAFLEX,Lymphadenopathy,Lymphadenopathy Blood bl,1
XIAFLEX,Lymphadenopathy,pain,0
XIAFLEX,Lymphadenopathy,Lymphadenopathy,1
XIAFLEX,Lymphadenopathy,Lymphadenopathy,1
XIAFLEX,Lymphadenopathy,Lymphadenopathy,1
XIAFLEX,Injection site hemorrhage,pain,0
XIAFLEX,Injection site hemorrhage,y Injection site hemorrhage,1
XIAFLEX,Injection site hemorrhage,pain,0
XIAFLEX,Injection site hemorrhage,site hemorrhage Injection site,1
XIAFLEX,Injection site hemorrhage,Injection site,1
XIAFLEX,Injection site hemorrhage,Injection site hemorrhage Injection,1
XIAFLEX,Injection site hemorrhage,Injection site,0
XIAFLEX,Injection site hemorrhage,y,0
XIAFLEX,Corporal rupture,Corporal rupture was reported,1
XIAFLEX,Corporal rupture,y,0
XIAFLEX,Corporal rupture,Serious Penile Corporal rupture was reported as an adverse,1
XIAFLEX,Corporal rupture,y,0
XIAFLEX,Corporal rupture,adverse reaction after XIAFLEX injections,0
XIAFLEX,Corporal rupture,total of XIAFLEX,0
XIAFLEX,Corporal rupture,XIAFLEX injections in of XIAFLEX treated,0
XIAFLEX,Corporal rupture,Penile Corporal rupture,1
XIAFLEX,Corporal rupture,was reported as an adverse reaction after XIAFLEX injections in of XIAFLEX,0
XIAFLEX,Corporal rupture,Other Serious Penile Corporal,1
XIAFLEX,Corporal rupture,Corporal rupture was reported as an,1
XIAFLEX,Corporal rupture,Other Serious Penile Corporal,1
XIAFLEX,penile ecchymoses,a combination penile ecchymoses or,1
XIAFLEX,penile ecchymoses,Other Serious Penile Corporal,1
XIAFLEX,penile ecchymoses,penile ecchymoses or,1
XIAFLEX,penile ecchymoses,penile,1
XIAFLEX,penile ecchymoses,penile ecchymoses,1
XIAFLEX,penile ecchymoses,penile ecchymoses,1
XIAFLEX,penile ecchymoses,penile ecchymoses,1
XIAFLEX,penile ecchymoses,penile ecchymoses,1
XIAFLEX,penile ecchymoses,of a combination penile ecchymoses,1
XIAFLEX,penile detumescence,or hematoma penile detumescence,1
XIAFLEX,penile detumescence,was reported and in these cases,0
XIAFLEX,penile detumescence,patients,0
XIAFLEX,penile detumescence,ecchymoses or hematoma penile detumescence,1
XIAFLEX,penile detumescence,penile ecchymoses,0
XIAFLEX,penile detumescence,or hematoma penile detumescence,1
XIAFLEX,"penile ""popping"" sound",andor penile,1
XIAFLEX,"penile ""popping"" sound",or sensation was reported and in these cases a diagnosis of corporal rupture,0
XIAFLEX,"penile ""popping"" sound","detumescence andor penile ""popping"" sound",1
XIAFLEX,corporal rupture,managed without surgical intervention but,0
XIAFLEX,corporal rupture,corporal rupture,1
XIAFLEX,corporal rupture,managed without surgical intervention but,0
XIAFLEX,corporal rupture,corporal rupture cannot,1
XIAFLEX,corporal rupture,These patients were managed without surgical intervention but the longterm co,0
XIAFLEX,corporal rupture,managed without surgical intervention but the longterm,0
XIAFLEX,corporal rupture,cannot be excluded These patients were managed without,0
XIAFLEX,corporal rupture,patients were managed without,0
XIAFLEX,corporal rupture,diagnosis of,0
XIAFLEX,corporal rupture,these cases a,0
XIAFLEX,penile hematoma,unknown penile hematoma,1
XIAFLEX,penile hematoma,these cases a,0
XIAFLEX,penile hematoma,unknown penile hematoma was also reported,1
XIAFLEX,penile hematoma,these cases a,0
XIAFLEX,penile hematoma,Severe,0
XIAFLEX,penile hematoma,as an adverse reaction in of patients,0
XIAFLEX,penile hematoma,longterm consequences are unknown penile hematoma,1
XIAFLEX,penile hematoma,as an adverse reaction in of patients,0
XIAFLEX,penile hematoma,consequences are unknown penile,1
XIAFLEX,penile hematoma,longterm consequences are unknown penile hematoma,1
XIAFLEX,penile hematoma,consequences are unknown penile,1
XIAFLEX,penile hematoma,Peyronies disease penile hematoma penile swelling,1
XIAFLEX,penile hematoma,consequences are unknown penile,1
XIAFLEX,penile hematoma,of adverse reactions,0
XIAFLEX,penile hematoma,Peyronies disease penile hematoma,1
XIAFLEX,penile hematoma,penile hematoma penile swelling and penile,1
XIAFLEX,penile hematoma,Peyronies disease penile hematoma,1
XIAFLEX,penile swelling,penile penile swelling and,1
XIAFLEX,penile swelling,Peyronies disease penile hematoma,1
XIAFLEX,penile swelling,incidence of adverse reactions that were reported in,0
XIAFLEX,penile swelling,penile penile swelling and penile pain Table,1
XIAFLEX,penile swelling,incidence of adverse reactions that were reported in,0
XIAFLEX,penile swelling,the incidence of adverse reactions that,0
XIAFLEX,penile swelling,penile swelling and penile pain Table,1
XIAFLEX,penile swelling,with,0
XIAFLEX,penile swelling,penile swelling and penile,1
XIAFLEX,penile swelling,with,0
XIAFLEX,penile swelling,of adverse reactions that were reported,0
XIAFLEX,penile pain,penile pain Table shows,1
XIAFLEX,penile pain,penile hematoma penile swelling penile,1
XIAFLEX,penile pain,incidence of adverse reactions that were reported in greater than or equal,0
XIAFLEX,penile pain,Peyronies disease were,0
XIAFLEX,penile pain,penile,0
XIAFLEX,penile pain,penile pain Table,1
XIAFLEX,penile pain,penile pain,1
XIAFLEX,penile pain,Peyronies disease were penile hematoma penile swelling,0
XIAFLEX,penile pain,hematoma penile swelling penile pain,1
XIAFLEX,penile pain,penile pain Table shows,1
XIAFLEX,injection site hematoma,Placebo After Up to Four Treatment Cycles in Studies and Combined a Includes,0
XIAFLEX,injection site hematoma,Studies and,0
XIAFLEX,injection site hematoma,and Combined a injection,1
XIAFLEX,injection site hematoma,Studies and Combined a injection site hematoma and,1
XIAFLEX,injection site hematoma,and Combined a injection,1
XIAFLEX,injection site hematoma,penile hematoma were reported with,0
XIAFLEX,injection site hematoma,verbatim term of penile bruising,0
XIAFLEX,injection site hematoma,Combined,0
XIAFLEX,penile hematoma,Combined a Includes,0
XIAFLEX,penile hematoma,site hematoma penile hematoma were reported with,1
XIAFLEX,penile hematoma,Combined a Includes,0
XIAFLEX,penile hematoma,penile hematoma,1
XIAFLEX,penile hematoma,site hematoma penile hematoma,1
XIAFLEX,penile hematoma,to Four Treatment Cycles in Studies and Combined a Includes injection,0
XIAFLEX,penile hematoma,to Four Treatment Cycles in Studies and Combined a Includes injection,0
XIAFLEX,penile hematoma,penile hematoma,1
XIAFLEX,penile bruising,penile bruising or injection site,1
XIAFLEX,penile bruising,in of subjects b Includes injection site swelling,0
XIAFLEX,injection site bruising,the,0
XIAFLEX,injection site bruising,penile bruising injection site bruising in of subjects b,1
XIAFLEX,injection site bruising,the,0
XIAFLEX,injection site bruising,and penile hematoma,0
XIAFLEX,injection site bruising,of penile bruising injection site,1
XIAFLEX,injection site bruising,injection site bruising in of subjects,1
XIAFLEX,injection site bruising,injection site bruising in,1
XIAFLEX,injection site bruising,edema penile swelling,0
XIAFLEX,injection site bruising,penile bruising injection site bruising in of subjects b,1
XIAFLEX,injection site bruising,edema penile swelling,0
XIAFLEX,injection site bruising,penile bruising injection,1
XIAFLEX,penile edema,penile edema penile,1
XIAFLEX,penile edema,penile edema penile swelling local,1
XIAFLEX,penile edema,b Includes injection site swelling,0
XIAFLEX,penile edema,swelling scrotal swelling and,0
XIAFLEX,penile edema,b Includes,0
XIAFLEX,penile edema,site penile edema,1
XIAFLEX,penile swelling,injection site edema c Includes,0
XIAFLEX,penile swelling,penile swelling,1
XIAFLEX,penile swelling,and injection site edema,0
XIAFLEX,penile swelling,bruising in of subjects b Includes injection site,0
XIAFLEX,penile swelling,injection site swelling penile penile swelling,1
XIAFLEX,penile swelling,swelling scrotal,0
XIAFLEX,penile swelling,swelling penile penile swelling,1
XIAFLEX,penile swelling,swelling penile penile,1
XIAFLEX,local swelling,swelling and injection site edema,0
XIAFLEX,local swelling,local swelling scrotal,1
XIAFLEX,local swelling,local swelling scrotal swelling and injection site,1
XIAFLEX,local swelling,penile,0
XIAFLEX,local swelling,Includes injection site pain,0
XIAFLEX,local swelling,pain penile pain,0
XIAFLEX,local swelling,penile edema penile local swelling,1
XIAFLEX,local swelling,b Includes injection site,0
XIAFLEX,local swelling,local swelling scrotal swelling and injection,1
XIAFLEX,scrotal swelling,swelling local scrotal,1
XIAFLEX,scrotal swelling,scrotal swelling and injection site,1
XIAFLEX,scrotal swelling,site edema c,0
XIAFLEX,scrotal swelling,site swelling penile edema penile swelling,0
XIAFLEX,scrotal swelling,injection site swelling,0
XIAFLEX,injection site edema,local swelling scrotal swelling injection site edema c,1
XIAFLEX,injection site edema,injection site swelling,0
XIAFLEX,injection site edema,injection site pain penile pain and injection site,0
XIAFLEX,injection site edema,injection site,0
XIAFLEX,injection site edema,site edema c Includes injection,1
XIAFLEX,injection site edema,scrotal swelling injection site edema,1
XIAFLEX,injection site edema,site edema c Includes injection,1
XIAFLEX,injection site edema,swelling scrotal swelling injection site edema c Includes,1
XIAFLEX,injection site edema,site edema c Includes injection,1
XIAFLEX,injection site edema,injection site,1
XIAFLEX,injection site edema,Includes injection site pain,0
XIAFLEX,injection site edema,scrotal swelling injection site edema c,1
XIAFLEX,injection site edema,Includes injection site pain,0
XIAFLEX,injection site pain,and injection site edema c Includes,0
XIAFLEX,injection site pain,c injection site pain,1
XIAFLEX,injection site pain,injection site pain penile pain,1
XIAFLEX,injection site pain,c injection site pain,1
XIAFLEX,injection site pain,c injection site pain penile pain,1
XIAFLEX,injection site pain,c injection site pain,1
XIAFLEX,injection site pain,site pain,1
XIAFLEX,injection site pain,a penile swelling local swelling scrotal swelling,0
XIAFLEX,injection site pain,site pain penile pain and injection site,1
XIAFLEX,penile pain,penile pain,1
XIAFLEX,penile pain,Includes injection site penile pain,1
XIAFLEX,penile pain,c,0
XIAFLEX,penile pain,scrotal swelling and injection site edema c Includes injection site pain,0
XIAFLEX,penile pain,c Includes injection site penile pain and injection,1
XIAFLEX,penile pain,scrotal swelling and injection site edema c Includes injection site pain,0
XIAFLEX,contusion,injection site discomfort d contusion ecchymoses,1
XIAFLEX,contusion,scrotal swelling and injection site edema c Includes injection site pain,0
XIAFLEX,contusion,d Includes,0
XIAFLEX,contusion,discomfort d contusion ecchymoses penile hemorrhage,1
XIAFLEX,contusion,d Includes,0
XIAFLEX,contusion,contusion ecchymoses,1
XIAFLEX,contusion,d Includes,0
XIAFLEX,contusion,and injection site hemorrhage Adverse,0
XIAFLEX,ecchymoses,ecchymoses penile hemorrhage and,1
XIAFLEX,ecchymoses,ecchymoses penile hemorrhage and injection,1
XIAFLEX,ecchymoses,ecchymoses penile,1
XIAFLEX,ecchymoses,Includes ecchymoses penile hemorrhage and injection site,1
XIAFLEX,ecchymoses,ecchymoses penile,1
XIAFLEX,ecchymoses,es injection,0
XIAFLEX,ecchymoses,ecchymoses,1
XIAFLEX,ecchymoses,ecchymoses penile hemorrhage and,1
XIAFLEX,ecchymoses,ecchymoses penile,1
XIAFLEX,ecchymoses,injection site pain,0
XIAFLEX,penile hemorrhage,Includes contusion penile,1
XIAFLEX,penile hemorrhage,Includes contusion penile hemorrhage and injection site hemorrhage Adverse,1
XIAFLEX,penile hemorrhage,Includes contusion penile,1
XIAFLEX,penile hemorrhage,hemorrhage Adverse,0
XIAFLEX,penile hemorrhage,penile hemorrhage and injection,1
XIAFLEX,penile hemorrhage,hemorrhage Adverse,0
XIAFLEX,penile hemorrhage,Includes contusion penile hemorrhage and injection,1
XIAFLEX,penile hemorrhage,hemorrhage Adverse,0
XIAFLEX,penile hemorrhage,ecchymoses,0
XIAFLEX,injection site hemorrhage,hemorrhage and,0
XIAFLEX,injection site hemorrhage,Reaction,0
XIAFLEX,injection site hemorrhage,hemorrhage injection site hemorrhage Adverse Reaction,1
XIAFLEX,injection site hemorrhage,Reaction,0
XIAFLEX,injection site hemorrhage,injection,1
XIAFLEX,injection site hemorrhage,site hemorrhage Adverse Reaction,1
XIAFLEX,injection site hemorrhage,site hemorrhage Adverse Reaction XIAFLEXN PlaceboN,1
XIAFLEX,injection site hemorrhage,Adverse,0
XIAFLEX,injection site hemorrhage,discomfort,0
XIAFLEX,Penile hematoma,se Penile hematoma a Penile,1
XIAFLEX,Penile hematoma,discomfort,0
XIAFLEX,Penile hematoma,se Reactions,0
XIAFLEX,Penile swelling,a,0
XIAFLEX,Penile swelling,Penile swelling,1
XIAFLEX,Penile swelling,a,0
XIAFLEX,Penile swelling,Penile swelling,1
XIAFLEX,Penile swelling,a,0
XIAFLEX,Penile swelling,Penile swelling b,1
XIAFLEX,Penile pain,elling Penile pain c,1
XIAFLEX,Penile pain,Penile swelling b,1
XIAFLEX,Penile pain,b,0
XIAFLEX,Penile pain,Penile pain,1
XIAFLEX,Penile pain,Penile,1
XIAFLEX,Penile ecchymoses,d,0
XIAFLEX,Penile ecchymoses,Penile ecchymoses d,1
XIAFLEX,Penile ecchymoses,d,0
XIAFLEX,Penile ecchymoses,in Penile,1
XIAFLEX,Penile ecchymoses,Penile ecchymoses d Blood bl,1
XIAFLEX,Penile ecchymoses,Penile ecchymoses,1
XIAFLEX,Penile ecchymoses,d Blood bl,0
XIAFLEX,Injection site vesicles,l Injection site vesicles Localized,1
XIAFLEX,Injection site vesicles,d Blood bl,0
XIAFLEX,Injection site vesicles,Injection site vesicles Localized,1
XIAFLEX,Injection site vesicles,Injection site vesicles Localized,1
XIAFLEX,Injection site vesicles,l,0
XIAFLEX,Injection site vesicles,site vesicles,1
XIAFLEX,injection site hematoma,severe,0
XIAFLEX,injection site hematoma,hematoma,0
XIAFLEX,injection site hematoma,site hematoma were,1
XIAFLEX,injection site hematoma,Severe penile hematoma or injection site,1
XIAFLEX,injection site hematoma,of,0
XIAFLEX,injection site hematoma,of XIAFLEXtreated patients and,0
XIAFLEX,injection site hematoma,hematoma or injection site,1
XIAFLEX,injection site hematoma,hematoma,0
XIAFLEX,injection site hematoma,Severe,0
XIAFLEX,popping sensation in the penis,penile popping,0
XIAFLEX,popping sensation in the penis,sometimes accompanied,0
XIAFLEX,popping sensation in the penis,in the penis sometimes,1
XIAFLEX,popping sensation in the penis,popping noise,0
XIAFLEX,popping sensation in the penis,and sometimes accompanied,0
XIAFLEX,popping sensation in the penis,sensations A popping noise popping sensation in the,1
XIAFLEX,popping sensation in the penis,noise popping,1
XIAFLEX,detumescence,accompanied detumescence hematoma andor pain were reported,1
XIAFLEX,detumescence,noise popping,1
XIAFLEX,detumescence,detumescence,1
XIAFLEX,detumescence,detumescence hematoma andor pain were,1
XIAFLEX,detumescence,as snapping or,0
XIAFLEX,detumescence,detumescence hematoma andor pain,1
XIAFLEX,detumescence,snapping or cracking and sometimes accompanied by,0
XIAFLEX,detumescence,cracking and sometimes accompanied detumescence hematoma andor pain,1
XIAFLEX,detumescence,snapping or cracking and sometimes accompanied by,0
XIAFLEX,detumescence,detumescence,1
XIAFLEX,detumescence,detumescence hematoma andor pain were,1
XIAFLEX,detumescence,the penis sometimes described as snapping or cracking and,0
XIAFLEX,hematoma,andor pain were reported in XIAFLEXtreated patients and placebotrea,0
XIAFLEX,hematoma,hematoma,1
XIAFLEX,pain,accompanied by detumescence hematoma pain were reported,1
XIAFLEX,pain,hematoma,1
XIAFLEX,pain,andor,0
XIAFLEX,pain,described as snapping or cracking and,0
XIAFLEX,pain,were reported,0
XIAFLEX,pain,reported in XIAFLEXtreated patients and placebotreated patients,0
XIAFLEX,CORPORAL RUPTURE,ADVERSE REACTIONS The lowing serious a dverse reactions,1
XIAFLEX,CORPORAL RUPTURE,reported in XIAFLEXtreated patients and placebotreated patients,0
XIAFLEX,CORPORAL RUPTURE,ADVERSE REACTIONS The,0
XIAFLEX,CORPORAL RUPTURE,REACTIONS The lowing serious a,1
XIAFLEX,CORPORAL RUPTURE,The lowing serious a dverse reactions in patients,1
XIAFLEX,CORPORAL RUPTURE,REACTIONS The lowing serious a,1
XIAFLEX,CORPORAL RUPTURE,Dupuytrens contracture are discussed in greater,0
XIAFLEX,CORPORAL RUPTURE,The lowing serious a dverse reactions in,1
XIAFLEX,CORPORAL RUPTURE,Dupuytrens contracture are discussed in greater,0
XIAFLEX,CORPORAL RUPTURE,serious a,1
XIAFLEX,CORPORAL RUPTURE,ADVERSE REACTIONS The,0
XIAFLEX,CORPORAL RUPTURE,serious a dverse reactions,1
XIAFLEX,PENILE FRACTURE,following serious erse reactions ,1
XIAFLEX,PENILE FRACTURE,serious a dverse reactions,1
XIAFLEX,PENILE FRACTURE,The following serious erse reactions,1
XIAFLEX,PENILE FRACTURE,erse reactions in patients,1
XIAFLEX,PENILE FRACTURE,erse reactions in patients with Dupuytrens,1
XIAFLEX,PENILE FRACTURE,serious erse reactions  in patients with Dupuytrens,1
XIAFLEX,PENILE FRACTURE,erse reactions in patients with Dupuytrens,1
XIAFLEX,PENILE FRACTURE,erse reactions in patients,1
XIAFLEX,PENILE FRACTURE,REACTIONS The following serious erse reactions,1
XIAFLEX,PENILE INJURY,adverse reactions in patients with,0
XIAFLEX,PENILE INJURY,reactions in patients with,0
XIAFLEX,CORPORAL RUPTURE,in,0
XIAFLEX,PENILE FRACTURE,detail elsewhere in the Tendon ruptures,1
XIAFLEX,PENILE FRACTURE,in,0
XIAFLEX,PENILE FRACTURE,ents with Dupuytrens contracture are discussed in greater detail,0
XIAFLEX,PENILE FRACTURE,detail elsewhere in the Tendon ruptures,1
XIAFLEX,PENILE FRACTURE,ents with Dupuytrens contracture are discussed in greater detail,0
XIAFLEX,PENILE FRACTURE,Tendon ruptures or other serious,1
XIAFLEX,PENILE FRACTURE,Tendon ruptures,1
XIAFLEX,PENILE FRACTURE,Tendon ruptures,1
XIAFLEX,PENILE FRACTURE,elsewhere in the Tendon ruptures or other serious,1
XIAFLEX,PENILE FRACTURE,Tendon ruptures,1
XIAFLEX,PENILE FRACTURE,Tendon ruptures or other serious,1
XIAFLEX,PENILE FRACTURE,in the Tendon ruptures or other serious injury,1
XIAFLEX,PENILE FRACTURE,Tendon ruptures or other serious,1
XIAFLEX,PENILE FRACTURE,discussed in greater detail elsewhere in the labeling,0
XIAFLEX,Corporal rupture,and utions,1
XIAFLEX,Corporal rupture,extremity see Warnings and utions,1
XIAFLEX,Corporal rupture,utions (5.1)] The following serious,1
XIAFLEX,penile fracture,extremity see Warnings and     The followi ng,1
XIAFLEX,penile fracture,utions (5.1)] The following serious,1
XIAFLEX,penile fracture,see Warnings and     The followi ng serious,1
XIAFLEX,penile fracture,utions (5.1)] The following serious,1
XIAFLEX,penile ecchymoses,re penile hematom a,1
XIAFLEX,penile ecchymoses,Corporal rupture,0
XIAFLEX,penile ecchymoses,labeling Corporal rupture penile fracture and seve,0
XIAFLEX,penile ecchymoses,re,1
XIAFLEX,penile ecchymoses,XIAFLEXtreated patients,0
XIAFLEX,penile ecchymoses,penile hematom a see,1
XIAFLEX,penile ecchymoses,re penile hematom a see Warnings and,1
XIAFLEX,penile ecchymoses,ssed in greater detail elsewhere in the labeling Corporal rupture penile,0
XIAFLEX,"penile ""popping"" sound",and Precautions other,1
XIAFLEX,corporal rupture,patients a combination of,0
XIAFLEX,corporal rupture,or hematoma en,1
XIAFLEX,penile hematoma,penile detumescence andor a penile,0
XIAFLEX,penile hematoma,of,0
XIAFLEX,penile hematoma,"andor a penile ping"" sound or  sensation",1
XIAFLEX,penile hematoma,of,0
XIAFLEX,penile hematoma,"a penile ping"" sound or  sensation was reported and",1
XIAFLEX,penile hematoma,of,0
XIAFLEX,penile hematoma,a,0
XIAFLEX,penile hematoma,combination of penile ecchymoses or hematoma sudden penile detumescence,0
XIAFLEX,penile hematoma,sound or,1
XIAFLEX,penile hematoma,"penile ping"" sound or  sensation was reported and",1
XIAFLEX,penile hematoma,sound or,1
XIAFLEX,penile hematoma,hematoma,0
XIAFLEX,penile hematoma,"a penile ping"" sound",1
XIAFLEX,penile injury,injection s ite reaction and pain,1
XIAFLEX,penile injury,", injection s ite reaction and pain",1
XIAFLEX,penile injury,injection s ite reaction and pain,1
XIAFLEX,penile injury,", injection s ite",1
XIAFLEX,penile injury,the injected,0
XIAFLEX,penile injury,"site , injection s ite reaction and",1
XIAFLEX,penile injury,the injected,0
XIAFLEX,penile injury,"injection site , injection s ite",1
XIAFLEX,penile injury,the injected,0
XIAFLEX,penile injury,the injected extremity Peyronies,0
XIAFLEX,penile injury,"hand contusion injection site , injection",1
XIAFLEX,CORPORAL RUPTURE,penile s welling,1
XIAFLEX,CORPORAL RUPTURE,"were penile matoma, penile",1
XIAFLEX,CORPORAL RUPTURE,"were penile matoma, penile s welling and",1
XIAFLEX,CORPORAL RUPTURE,"were penile matoma, penile",1
XIAFLEX,CORPORAL RUPTURE,"were penile matoma, penile s",1
XIAFLEX,CORPORAL RUPTURE,"were penile matoma, penile",1
XIAFLEX,CORPORAL RUPTURE,To report SUSPECTED ADVERSE,0
XIAFLEX,CORPORAL RUPTURE,ADVERSE REACTIONS contact,0
XIAFLEX,CORPORAL RUPTURE,report SUSPECTED ADVERSE REACTIONS contact Auxilium Pharmaceutica,0
XIAFLEX,CORPORAL RUPTURE,and at an incidence,0
XIAFLEX,CORPORAL RUPTURE,"placebo were penile matoma, penile s",1
XIAFLEX,CORPORAL RUPTURE,penile pain To report SUSPECTED ADVERSE REACTIONS contact Auxilium,0
XIAFLEX,PENILE FRACTURE,penile lling and penil e pain To report,1
XIAFLEX,PENILE FRACTURE,penile pain To report SUSPECTED ADVERSE REACTIONS contact Auxilium,0
XIAFLEX,PENILE INJURY,at or,0
XIAFLEX,PENILE INJURY,penile pain To port,1
XIAFLEX,PENILE INJURY,penile pain To port SUSPECTE,1
XIAFLEX,PENILE INJURY,penile pain To port,1
XIAFLEX,PENILE INJURY,port SUSPECTE D ADVERSE REACTIONS contact Auxilium,1
XIAFLEX,PENILE INJURY,or FDA at FDA,0
XIAFLEX,PENILE INJURY,To,0
XIAFLEX,PENILE INJURY,pain To port SUSPECTE,1
XIAFLEX,Corporal rupture,"at FDA or medwatch.    


 Clinical",1
XIAFLEX,Corporal rupture,pain To port SUSPECTE,1
XIAFLEX,Corporal rupture,contact Auxilium Pharmaceuticals Inc,0
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies Experience",1
XIAFLEX,Corporal rupture,contact Auxilium Pharmaceuticals Inc,0
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical",1
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies Experience in",1
XIAFLEX,Corporal rupture,"at FDA or medwatch.    


 Clinical Studies",1
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies Experience in",1
XIAFLEX,Corporal rupture,"or medwatch.    


",1
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies Experience in",1
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies Experience in",1
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical",1
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies Experience in",1
XIAFLEX,Corporal rupture,"medwatch.    


 Clinical Studies Experience in",1
XIAFLEX,penile fracture,studies are conduc,0
XIAFLEX,penile fracture,Patients with Dupuytrens Contracture Because clinical studies,0
XIAFLEX,penile fracture,"FDA or 

  6.1 Clinica l Studies Experience in",1
XIAFLEX,penile fracture,Patients with Dupuytrens Contracture Because clinical studies,0
XIAFLEX,penile fracture,clinical,0
XIAFLEX,penile fracture,Patients with Dupuytrens,0
XIAFLEX,penile fracture,FDA or 6.1 Clinica,1
XIAFLEX,corporal rupture,reaction rates observed the clinical stu,1
XIAFLEX,penile hematoma,and may,0
XIAFLEX,penile hematoma,ectly compared,1
XIAFLEX,penile hematoma,ectly compared  to,1
XIAFLEX,penile hematoma,ectly compared,1
XIAFLEX,penile hematoma,ectly compared to rates,1
XIAFLEX,penile hematoma,observed,0
XIAFLEX,penile hematoma,ectly compared to rates,1
XIAFLEX,penile hematoma,drug cannot be ectly compared  to rates,1
XIAFLEX,penile hematoma,ectly compared to rates,1
XIAFLEX,penile hematoma,ectly compared to rates in the clinical,1
XIAFLEX,penile hematoma,cannot be ectly,1
XIAFLEX,penile hematoma,rates observed in,0
XIAFLEX,Tendon rupture,erse reactions in patients with,1
XIAFLEX,Tendon rupture,with,0
XIAFLEX,Tendon rupture,erse reactions in patients with Dupuytrens,1
XIAFLEX,Tendon rupture,with,0
XIAFLEX,injury to the injected finger,serious adverse reactions in with Dupuytren's contracture,1
XIAFLEX,injury to the injected finger,discussed in greater detail,0
XIAFLEX,injury to the injected finger,in the,0
XIAFLEX,injury to the injected finger,in with Dupuytren's contracture,1
XIAFLEX,injury to the injected finger,patients,0
XIAFLEX,injury to the injected finger,ADVERSE REACTIONS The following serious adverse reactions in,0
XIAFLEX,Corporal rupture,i,0
XIAFLEX,Corporal rupture,n greater detail elsewhere in the labeling Corporal,1
XIAFLEX,Corporal rupture,Corporal rupture penile fracture and,0
XIAFLEX,Corporal rupture,discussed i,0
XIAFLEX,Corporal rupture,are discussed n,1
XIAFLEX,penile fracture,hematoma,0
XIAFLEX,penile fracture,adverse reactions in patients with Peyronies,0
XIAFLEX,penile fracture,lsewhere,1
XIAFLEX,penile fracture,reactions in patients,0
XIAFLEX,penile fracture,discussed in greater detail lsewhere in the labeling,1
XIAFLEX,penile fracture,reactions in patients,0
XIAFLEX,penile fracture,in greater detail lsewhere in,1
XIAFLEX,penile fracture,in greater detail lsewhere in,1
XIAFLEX,injury to the penis,elsewhere in the labeling orporal rupture,1
XIAFLEX,injury to the penis,the labeling orporal rupture (pe nile fracture and severe penile,1
XIAFLEX,injury to the penis,elsewhere in the labeling orporal rupture,1
XIAFLEX,injury to the penis,orporal rupture (pe,1
XIAFLEX,injury to the penis,elsewhere in the labeling orporal rupture,1
XIAFLEX,injury to the penis,orporal rupture (pe nile fracture and severe,1
XIAFLEX,injury to the penis,elsewhere in the labeling orporal rupture,1
XIAFLEX,injury to the penis,greater detail elsewhere in the labeling C,0
XIAFLEX,permanent injury,"ecchymoses or hematoma sudden detumescence,",1
XIAFLEX,permanent injury,patients a combination of penile ecchymoses,0
XIAFLEX,permanent injury,"detumescence, an dor a penile popping",1
XIAFLEX,corporal rupture,and in these cases a diagnosis of corporal,0
XIAFLEX,penile fracture,andor a penile popping nd or sensation,1
XIAFLEX,penile fracture,and in these cases a diagnosis of corporal,0
XIAFLEX,penile fracture,andor,0
XIAFLEX,penile fracture,a penile popping nd,1
XIAFLEX,penile fracture,or sensation,1
XIAFLEX,penile fracture,or sensation was reported and in,1
XIAFLEX,penile fracture,penile popping nd or sensation,1
XIAFLEX,penile fracture,or sensation was reported and in,1
XIAFLEX,penile fracture,popping nd or sensation,1
XIAFLEX,penile fracture,or sensation was reported and in,1
XIAFLEX,penile fracture,bination of penile ecchymoses or hematoma sudden penile detumescence,0
XIAFLEX,penile fracture,or hematoma sudden penile detumescence andor a penile popping sou,0
XIAFLEX,penile fracture,detumescence andor a penile popping,0
XIAFLEX,anaphylaxis,EXCERPT,0
XIAFLEX,anaphylaxis,and in these cases a,0
XIAFLEX,anaphylaxis,cases a diagnosis of al rupture  cannot,1
XIAFLEX,anaphylaxis,and in these cases a,0
XIAFLEX,anaphylaxis,EXCERPT Dupuytrens Contrac,0
XIAFLEX,anaphylaxis,al rupture,1
XIAFLEX,anaphylaxis,cases a diagnosis of al rupture  cannot be excluded see,1
XIAFLEX,anaphylaxis,al rupture,1
XIAFLEX,anaphylaxis,of al,1
XIAFLEX,anaphylaxis,al rupture,1
XIAFLEX,permanent injury,Patients with Dupuytrens Contracture Because clinical studies are,0
XIAFLEX,permanent injury,Dupuytrens Contracture Because clinical,0
XIAFLEX,permanent injury,Because clinical,0
XIAFLEX,permanent injury,"FDA at FDA or 



 

  6.1 Cli",1
XIAFLEX,permanent injury,Because clinical,0
XIAFLEX,permanent injury,FDA or 6.1 Cli,1
XIAFLEX,permanent injury,6.1 Cli nical,1
XIAFLEX,permanent injury,ilium Pharmaceuticals Inc at or FDA at FDA or,0
XIAFLEX,tendon rupture,FDA or wwwfdagovmedwatch Clinical dies Experienc,1
XIAFLEX,tendon rupture,or,0
XIAFLEX,tendon rupture,dies Experienc e in Patients with Dupuytrens,1
XIAFLEX,tendon rupture,Clinical dies Experienc e in Patients with,1
XIAFLEX,tendon rupture,dies Experienc e in Patients with Dupuytrens,1
XIAFLEX,tendon rupture,dies,1
XIAFLEX,ligament damage,or FDA at FDA or wwwfdagovmedwatch Clinical,0
XIAFLEX,ligament damage,wwwfdagovmedwatch Clinical Studies Experience Patients,1
XIAFLEX,ligament damage,FDA at FDA,0
XIAFLEX,ligament damage,Studies Experience  Patients with  Dupuytrens Contracture Because clinical,1
XIAFLEX,ligament damage,FDA at FDA,0
XIAFLEX,ligament damage,Dupuytrens Contracture Because clinical studies are conducted under widely varying,0
XIAFLEX,ligament damage,Patients with Dupuytrens Contracture,1
XIAFLEX,ligament damage,or wwwfdagovmedwatch,0
XIAFLEX,ligament damage,clinical studies are conducted under widely varying conditions a,0
XIAFLEX,ligament damage,Patients with Dupuytrens Contracture Because clinical studies,1
XIAFLEX,pulley rupture,ata described,1
XIAFLEX,pulley rupture,ata described below are,1
XIAFLEX,ligament injury,be,0
XIAFLEX,ligament injury,through Day in patients with,0
XIAFLEX,complex regional pain syndrome,"based two pooled randomized, double-",1
XIAFLEX,complex regional pain syndrome,through Day in patients with,0
XIAFLEX,complex regional pain syndrome,"are based two pooled randomized, double-",1
XIAFLEX,complex regional pain syndrome,"based two pooled randomized, double- blind placebocontrolled",1
XIAFLEX,complex regional pain syndrome,"are based two pooled randomized, double-",1
XIAFLEX,complex regional pain syndrome,"pooled randomized, double- blind placebocontrolled trials through",1
XIAFLEX,complex regional pain syndrome,"based two pooled randomized, double- blind placebocontrolled trials",1
XIAFLEX,complex regional pain syndrome,"pooled randomized, double- blind placebocontrolled trials through",1
XIAFLEX,complex regional pain syndrome,"pooled randomized, double- blind placebocontrolled trials through Day",1
XIAFLEX,complex regional pain syndrome,"randomized, double- blind placebocontrolled trials through Day",1
XIAFLEX,complex regional pain syndrome,in patients with Dupuytrens contracture,0
XIAFLEX,complex regional pain syndrome,"below are based two pooled randomized, double- blind placebocontrolled trials",1
XIAFLEX,complex regional pain syndrome,in patients with Dupuytrens contracture,0
XIAFLEX,complex regional pain syndrome,blind placebocontrolled trials through,0
XIAFLEX,CRPS,"ind, placebocontrolled trials",1
XIAFLEX,CRPS,"ind, placebocontrolled trials through",1
XIAFLEX,CRPS,"two pooled randomized ind, placebocontrolled trials through",1
XIAFLEX,CRPS,"ind, placebocontrolled trials through",1
XIAFLEX,CRPS,"ind, placebocontrolled",1
XIAFLEX,CRPS,"ind, placebocontrolled trials through",1
XIAFLEX,sensory abnormality of the hand,and In these trials patients were,0
XIAFLEX,sensory abnormality of the hand,trials through,1
XIAFLEX,sensory abnormality of the hand,pooled randomized doubleblind acebo-controlled trials through Day in patients with Dupuytrens,1
XIAFLEX,sensory abnormality of the hand,trials through,1
XIAFLEX,sensory abnormality of the hand,based on two,0
XIAFLEX,sensory abnormality of the hand,based,0
XIAFLEX,sensory abnormality of the hand,in patients with Dupuytrens contracture Studies and In these trials patients were,0
XIAFLEX,skin laceration,pooled randomized doubleblind,0
XIAFLEX,skin laceration,doubleblind placebocontrolled trials through 0 in patients,1
XIAFLEX,skin laceration,doubleblind placebocontrolled trials through 0 in patients w ith Dupuytrens,1
XIAFLEX,skin laceration,doubleblind placebocontrolled trials through 0 in patients,1
XIAFLEX,skin laceration,in patients w ith Dupuytrens contracture Studies and,1
XIAFLEX,skin laceration,were treated with up to,0
XIAFLEX,skin laceration,0,1
XIAFLEX,skin laceration,treated with up to,0
XIAFLEX,skin laceration,0 in patients w ith Dupuytrens,1
XIAFLEX,skin laceration,treated with up to,0
XIAFLEX,skin laceration,placebocontrolled trials through 0 in,1
XIAFLEX,skin laceration,of,0
XIAFLEX,skin laceration,with u p to injections,1
XIAFLEX,skin laceration,see Clinical Studies,0
XIAFLEX,skin laceration,Studies These trials,0
XIAFLEX,skin laceration,to facilitate ruption of the  cord,1
XIAFLEX,skin laceration,Studies These trials,0
XIAFLEX,skin laceration,to facilitate ruption,1
XIAFLEX,skin laceration,of patients,0
XIAFLEX,skin laceration,ruption of the cord,1
XIAFLEX,skin laceration,cord see Clinical Studies These trials were comprised of patients of,0
XIAFLEX,Corporal rupture,XIAFLEXtreated and placebotreated ts had an advers,1
XIAFLEX,penile ecchymoses,within weeks XIAFLEX injection s The adverse reaction,1
XIAFLEX,penile ecchymoses,XIAFLEXtreated and placebotreated ts had an advers,1
XIAFLEX,penile ecchymoses,injection,0
XIAFLEX,penile detumescence,profile was simi lar,1
XIAFLEX,penile detumescence,for each,0
XIAFLEX,penile detumescence,on profile was simi lar,1
XIAFLEX,penile detumescence,The adverse on profile,1
XIAFLEX,"penile ""popping"" sound",of,0
XIAFLEX,"penile ""popping"" sound","h injection, regardles s of the number",1
XIAFLEX,"penile ""popping"" sound","injection, regardles",1
XIAFLEX,corporal rupture,of pruritus increased with more,1
XIAFLEX,corporal rupture,the nce,1
XIAFLEX,corporal rupture,injection regardless of the,0
XIAFLEX,corporal rupture,nce of pruritus  increased,1
XIAFLEX,corporal rupture,injection regardless of the,0
XIAFLEX,corporal rupture,administered However the nce of pruritus  increased with more injections see,1
XIAFLEX,corporal rupture,injection regardless of the,0
XIAFLEX,corporal rupture,the nce of,1
XIAFLEX,corporal rupture,nce of pruritus,1
XIAFLEX,corporal rupture,Adverse Reactions Occurring  of XIAFLEX-Trea ted Patients with Dupuytrens,1
XIAFLEX,corporal rupture,nce of pruritus,1
XIAFLEX,corporal rupture,ted Patients with Dupuytrens Contracture and at a Greater,0
XIAFLEX,corporal rupture,Reactions Occurring of XIAFLEX-Trea,1
XIAFLEX,corporal rupture,in,0
XIAFLEX,corporal rupture,and Table Adverse,0
XIAFLEX,penile fracture,of d Patients with Dupuytrens Contracture and at,1
XIAFLEX,penile fracture,and Table Adverse,0
XIAFLEX,penile fracture,and at a Greater Incidence than Placebo in the PlaceboControlled,0
XIAFLEX,penile fracture,Contracture and at a Greater Incidence than,0
XIAFLEX,penile fracture,d Patients with Dupuytrens Contracture,1
XIAFLEX,penile fracture,d Patients with Dupuytrens Contracture and at,1
XIAFLEX,penile fracture,d,1
XIAFLEX,penile fracture,of d Patients with Dupuytrens Contracture and at,1
XIAFLEX,penile fracture,d,1
XIAFLEX,allergic reactions,"   
         Some  patients developed vasovagal",1
XIAFLEX,allergic reactions,finger extension procedures The safety,0
XIAFLEX,allergic reactions,procedures The safety,0
XIAFLEX,allergic reactions,"Pain Erythema Axillary    
         Some  patients developed",1
XIAFLEX,allergic reactions,procedures The safety,0
XIAFLEX,allergic reactions,"   
         Some  patients developed vasovagal syncope",1
XIAFLEX,pruritus,two concurrent,0
XIAFLEX,pruritus,after finger extension procedures The safety of two concurrent injec,0
XIAFLEX,pruritus,tients d eveloped vasovagal syncope after,1
XIAFLEX,pruritus,Erythema Axillary Pain Some tients d,1
XIAFLEX,pruritus,vasovagal,0
XIAFLEX,pruritus,pa,0
XIAFLEX,pruritus,tients d eveloped vasovagal syncope after,1
XIAFLEX,pruritus,tients,1
XIAFLEX,pruritus,The sa fety of,1
XIAFLEX,pruritus,syncope after,0
XIAFLEX,pruritus,The sa fety of two,1
XIAFLEX,pruritus,"finger extension 
 The sa fety",1
XIAFLEX,pruritus,The sa fety of two,1
XIAFLEX,pruritus,hand was eva,0
XIAFLEX,pruritus,finger extension The,1
XIAFLEX,pruritus,"syncope after finger extension 
 The sa fety of",1
XIAFLEX,pruritus,finger extension The,1
XIAFLEX,pruritus,"finger extension 
 The sa",1
XIAFLEX,pruritus,finger extension The,1
XIAFLEX,pruritus,"finger extension 
 The sa",1
XIAFLEX,pruritus,finger extension The,1
XIAFLEX,pruritus,The sa,1
XIAFLEX,localized pruritus,72 hours after injection,1
XIAFLEX,localized pruritus,procedures were performed to 72,1
XIAFLEX,localized pruritus,to 72 hours after injection The patient demographics were,1
XIAFLEX,localized pruritus,were performed to 72 hours after ,1
XIAFLEX,localized pruritus,to 72 hours after injection The patient demographics were,1
XIAFLEX,localized pruritus,Study In Study finger,0
XIAFLEX,localized pruritus,were performed to 72 hours after ,1
XIAFLEX,localized pruritus,Study In Study finger,0
XIAFLEX,localized pruritus,to 72 hours after  injection The,1
XIAFLEX,localized pruritus,Study In Study finger,0
XIAFLEX,localized pruritus,to Studies and Out of,0
XIAFLEX,localized pruritus,hours after,1
XIAFLEX,localized pruritus,were performed to 72,1
XIAFLEX,pruritus,nt injec tions of,1
XIAFLEX,pruritus,same hand XIAFLEX injections in Study one patient,0
XIAFLEX,pruritus,patients who received two nt injec,1
XIAFLEX,pruritus,nt injec tions of,1
XIAFLEX,pruritus,received two nt,1
XIAFLEX,pruritus,nt injec tions of,1
XIAFLEX,pruritus,received two nt injec tions of XIAFLEX,1
XIAFLEX,pruritus,nt injec tions of,1
XIAFLEX,pruritus,of XIAFLEX mg in the same hand XIAFLEX injections in Study,0
XIAFLEX,pruritus,who received two nt injec tions of XIAFLEX,1
XIAFLEX,pruritus,of XIAFLEX mg in the same hand XIAFLEX injections in Study,0
XIAFLEX,pruritus,nt injec tions of XIAFLEX mg in,1
XIAFLEX,allergic reactions,tendon,0
XIAFLEX,allergic reactions,within 3 day s of,1
XIAFLEX,allergic reactions,of the treated inger within,1
XIAFLEX,allergic reactions,Table shows the incidence of adverse reactions that were,0
XIAFLEX,allergic reactions,rupture of the treated inger within 3 day s of the injection Table,1
XIAFLEX,allergic reactions,Table shows the incidence of adverse reactions that were,0
XIAFLEX,allergic reactions,treated inger within 3 day s,1
XIAFLEX,allergic reactions,Table shows the incidence of adverse reactions that were,0
XIAFLEX,injection site hemorrhage,"Edema          
 Contusion      Pain",1
XIAFLEX,injection site hemorrhage,Table shows the incidence of adverse reactions that were,0
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain in",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain in",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain in",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain",1
XIAFLEX,injection site hemorrhage,"         
 Contusion      Pain",1
CIMZIA,upper respiratory tract infection,respiratory tract infection,1
CIMZIA,upper respiratory tract infection,common adverse reactions incidence and higher,0
CIMZIA,upper respiratory tract infection,tract infection To report SUSPECTED ADVERSE REACTIONS,0
CIMZIA,upper respiratory tract infection,upper respiratory tract infection rash and urinary,1
CIMZIA,upper respiratory tract infection,tract infection To report SUSPECTED ADVERSE REACTIONS,0
CIMZIA,upper respiratory tract infection,and higher than upper respiratory tract infection rash,1
CIMZIA,upper respiratory tract infection,tract infection To report SUSPECTED ADVERSE REACTIONS,0
CIMZIA,upper respiratory tract infection,urinary tract infection To report SUSPECTED ADVERSE REACTIONS,0
CIMZIA,upper respiratory tract infection,respiratory tract infection rash and urinary,1
CIMZIA,rash,rash and urinary,1
CIMZIA,urinary tract infection,contact UCB Inc at or FDA at,0
CIMZIA,urinary tract infection,and,0
CIMZIA,urinary tract infection,infection rash urinary,1
CIMZIA,urinary tract infection,To report SUSPECTED ADVERSE,0
CIMZIA,urinary tract infection,rash urinary,1
CIMZIA,urinary tract infection,urinary tract infection To report,1
CIMZIA,urinary tract infection,rash urinary,1
CIMZIA,Infections,Experience The most serious,0
CIMZIA,Infections,Malignancies see Warnings and,0
CIMZIA,Infections,see Warnings and Precautions,0
CIMZIA,Infections,Infections,1
CIMZIA,Infections,see Warnings and Precautions,0
CIMZIA,Malignancies,Malignancies see Warnings and,1
CIMZIA,Malignancies,see Warnings and Precautions,0
CIMZIA,Malignancies,Malignancies see Warnings,1
CIMZIA,Malignancies,Malignancies see Warnings and Precautions Heart,1
CIMZIA,Malignancies,Malignancies,1
CIMZIA,Malignancies,Malignancies see,1
CIMZIA,Malignancies,Warnings and,0
CIMZIA,Malignancies,Serious Infections,0
CIMZIA,Heart Failure,see Warnings and Heart Failure,1
CIMZIA,Heart Failure,and Precautions,0
CIMZIA,Heart Failure,see Warnings and Heart,1
CIMZIA,Heart Failure,see Warnings and Heart Failure see Warnings,1
CIMZIA,Heart Failure,see Warnings and Heart,1
CIMZIA,Heart Failure,Heart Failure see Warnings and Precautions,1
CIMZIA,Heart Failure,Malignancies see Warnings and Heart Failure,1
CIMZIA,Heart Failure,Heart Failure see Warnings and Precautions,1
CIMZIA,Heart Failure,Malignancies see Warnings and Heart Failure see Warnings and,1
CIMZIA,Heart Failure,Heart Failure see Warnings and Precautions,1
CIMZIA,Heart Failure,Warnings,0
CIMZIA,Heart Failure,Malignancies see Warnings and Heart,1
CIMZIA,Heart Failure,and Heart Failure see Warnings and Precautions,1
CIMZIA,Heart Failure,Malignancies see Warnings and Heart,1
CIMZIA,upper respiratory infections,infections Adverse Reactions Most Commonly,0
CIMZIA,upper respiratory infections,respiratory infections rash and urinary tract,1
CIMZIA,upper respiratory infections,ontrolled trials of all patient populations combined the most common adverse reactions were,0
CIMZIA,upper respiratory infections,and urinary tract infections,0
CIMZIA,upper respiratory infections,upper,1
CIMZIA,upper respiratory infections,trials of all patient populations,0
CIMZIA,upper respiratory infections,common adverse reactions upper respiratory infections,1
CIMZIA,rash,Adverse Reactions Most,0
CIMZIA,rash,respiratory rash and urinary tract,1
CIMZIA,rash,Adverse Reactions Most,0
CIMZIA,rash,infections Adverse,0
CIMZIA,rash,infections Adverse Reactions Most Commonly Leading to,0
CIMZIA,rash,rash and urinary,1
CIMZIA,rash,rash and,1
CIMZIA,rash,rash and urinary tract infections,1
CIMZIA,rash,rash and,1
CIMZIA,rash,rash,1
CIMZIA,urinary tract infections,reactions,0
CIMZIA,urinary tract infections,rash and,0
CIMZIA,urinary tract infections,respiratory infections rash,0
CIMZIA,urinary tract infections,most common adverse reactions were,0
CIMZIA,urinary tract infections,respiratory infections rash,0
CIMZIA,abdominal pain,abdominal pain,1
CIMZIA,abdominal pain,abdominal pain CIMZIA placebo diarrhea,1
CIMZIA,abdominal pain,higher incidence than placebo abdominal,1
CIMZIA,abdominal pain,than placebo abdominal,1
CIMZIA,abdominal pain,CIMZIA,0
CIMZIA,abdominal pain,than placebo abdominal pain,1
CIMZIA,abdominal pain,abdominal pain CIMZIA placebo diarrhea CIMZIA,1
CIMZIA,abdominal pain,and intestinal obstruction C,0
CIMZIA,diarrhea,CIMZIA placebo,0
CIMZIA,diarrhea,diarrhea CIMZIA placebo and intestinal obstruction,1
CIMZIA,diarrhea,diarrhea CIMZIA placebo and,1
CIMZIA,diarrhea,abdominal pain CIMZIA diarrhea CIMZIA placebo and intestinal obstruction,1
CIMZIA,diarrhea,diarrhea CIMZIA placebo and,1
CIMZIA,diarrhea,were abdominal,0
CIMZIA,diarrhea,diarrhea CIMZIA placebo and intestinal,1
CIMZIA,diarrhea,placebo The proportion,0
CIMZIA,intestinal obstruction,CIMZIA placebo intestinal obstruction,1
CIMZIA,tuberculosis infections,and pyrexia urticaria pneumonia and,0
CIMZIA,tuberculosis infections,tuberculosis infections and pyrexia urticaria,1
CIMZIA,tuberculosis infections,were,0
CIMZIA,tuberculosis infections,to discontinuation of CIMZIA tuberculosis,1
CIMZIA,tuberculosis infections,discontinuation of CIMZIA tuberculosis infections,1
CIMZIA,tuberculosis infections,placebo The most common adverse reactions leading to discontinuation of CIMZIA,0
CIMZIA,urticaria,urticaria pneumonia and rash Controlled Studies,1
CIMZIA,urticaria,urticaria pneumonia and,1
CIMZIA,urticaria,urticaria pneumonia,1
CIMZIA,urticaria,Crohns,0
CIMZIA,urticaria,urticaria pneumonia and rash Controlled Studies,1
CIMZIA,urticaria,urticaria pneumonia and rash Controlled,1
CIMZIA,urticaria,and urticaria,1
CIMZIA,urticaria,urticaria pneumonia and rash Controlled,1
CIMZIA,urticaria,urticaria pneumonia and rash Controlled,1
CIMZIA,urticaria,se reactions leading to discontinuation of CIMZIA,0
CIMZIA,urticaria,and urticaria,1
CIMZIA,urticaria,se reactions leading to discontinuation of CIMZIA,0
CIMZIA,pneumonia,pneumonia and rash,1
CIMZIA,pneumonia,tuberculosis infections and pyrexia pneumonia,1
CIMZIA,pneumonia,pneumonia and rash,1
CIMZIA,pneumonia,pneumonia and rash,1
CIMZIA,pneumonia,Controlled Studies with,0
CIMZIA,pneumonia,pneumonia and rash Controlled Studies with,1
CIMZIA,rash,CIMZIA were tuberculosis infections and pyrexia urticaria,0
CIMZIA,rash,scontinuation of CIMZIA were tuberculosis infections and,0
CIMZIA,upper respiratory infections,upper respiratory infections eg,1
CIMZIA,upper respiratory infections,with CIMZIA upper respiratory infections eg nasopharyngitis,1
CIMZIA,upper respiratory infections,upper respiratory infections eg,1
CIMZIA,upper respiratory infections,to placebo in controlled clinical studies with,0
CIMZIA,upper respiratory infections,upper respiratory infections,1
CIMZIA,upper respiratory infections,clinical studies,0
CIMZIA,upper respiratory infections,studies with CIMZIA upper respiratory infections,1
CIMZIA,upper respiratory infections,upper respiratory,1
CIMZIA,nasopharyngitis,nasopharyngitis laryngitis viral infection in of,1
CIMZIA,nasopharyngitis,nasopharyngitis laryngitis viral infection in,1
CIMZIA,nasopharyngitis,clinical,0
CIMZIA,nasopharyngitis,nasopharyngitis laryngitis viral infection in of,1
CIMZIA,nasopharyngitis,nasopharyngitis laryngitis viral infection in of,1
CIMZIA,laryngitis,laryngitis viral,1
CIMZIA,laryngitis,laryngitis viral infection in of CIMZIAtreated,1
CIMZIA,viral infection,eg nasopharyngitis viral,1
CIMZIA,urinary tract infections,patients and of placebotreated urinary tract,1
CIMZIA,urinary tract infections,urinary tract infections eg bladder infection bacteriuria,1
CIMZIA,urinary tract infections,patients and of placebotreated urinary tract,1
CIMZIA,bladder infection,urinary tract infections bladder infection,1
CIMZIA,bladder infection,of CIMZIAtreated patients,0
CIMZIA,bladder infection,of placebotreated patients,0
CIMZIA,bladder infection,and in of placebotreated,0
CIMZIA,bladder infection,patients urinary tract infections bladder infection bacteriuria cystitis in of,1
CIMZIA,bladder infection,and in of placebotreated,0
CIMZIA,bacteriuria,bacteriuria cystitis in of CIMZIAtreated,1
CIMZIA,bacteriuria,bacteriuria cystitis in,1
CIMZIA,bacteriuria,infection,0
CIMZIA,bacteriuria,infections eg bladder bacteriuria cystitis in of CIMZIAtreated patients,1
CIMZIA,bacteriuria,infection,0
CIMZIA,bacteriuria,eg bladder bacteriuria,1
CIMZIA,bacteriuria,infection,0
CIMZIA,bacteriuria,eg,0
CIMZIA,bacteriuria,in of placebotreated patients,0
CIMZIA,bacteriuria,patients and in of placebotreated patients and,0
CIMZIA,cystitis,bladder infection cystitis in of CIMZIAtreated,1
CIMZIA,cystitis,patients and in of placebotreated patients and,0
CIMZIA,cystitis,bladder infection cystitis,1
CIMZIA,cystitis,patients and in of placebotreated patients and,0
CIMZIA,cystitis,cystitis in of CIMZIAtreated patients and,1
CIMZIA,cystitis,bladder infection cystitis in of,1
CIMZIA,cystitis,cystitis in of CIMZIAtreated patients and,1
CIMZIA,cystitis,tract infections eg bladder infection,0
CIMZIA,cystitis,placebotreated patients urinary tract infections eg bladder,0
CIMZIA,cystitis,placebotreated patients and,0
CIMZIA,cystitis,cystitis in of CIMZIAtreated patients,1
CIMZIA,cystitis,cystitis in of,1
CIMZIA,arthralgia,patients arthralgia,1
CIMZIA,arthralgia,cystitis in of,1
CIMZIA,arthralgia,Reactions The most commonly occurring,0
CIMZIA,arthralgia,patients and in of placebotreated patients,0
CIMZIA,arthralgia,and in of placebotreated,0
CIMZIA,arthralgia,placebotreated patients arthralgia CIMZIA placebo Other,1
CIMZIA,arthralgia,and in of placebotreated,0
CIMZIA,arthralgia,arthralgia CIMZIA placebo Other,1
CIMZIA,arthralgia,arthralgia,1
CIMZIA,Anemia,Anemia,1
CIMZIA,Anemia,or other doses include Blood and lymphatic system,0
CIMZIA,Anemia,other doses include Blood and lymphatic system,0
CIMZIA,leukopenia,Cardiac disorders,0
CIMZIA,leukopenia,doses,0
CIMZIA,leukopenia,leukopenia lymphadenopathy pancytopenia and thrombophilia,1
CIMZIA,leukopenia,disorders Anemia,0
CIMZIA,leukopenia,lymphatic system disorders leukopenia lymphadenopathy pancytopenia and thrombophilia,1
CIMZIA,leukopenia,disorders Anemia,0
CIMZIA,leukopenia,Angina pectoris,0
CIMZIA,leukopenia,disorders Angina pectoris,0
CIMZIA,leukopenia,system disorders leukopenia lymphadenopathy pancytopenia,1
CIMZIA,leukopenia,disorders Angina pectoris,0
CIMZIA,lymphadenopathy,lymphadenopathy pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,lymphadenopathy,disorders Anemia lymphadenopathy pancytopenia and,1
CIMZIA,lymphadenopathy,lymphadenopathy pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,pancytopenia,pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,pancytopenia,disorders Angina,0
CIMZIA,pancytopenia,pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,pancytopenia,pancytopenia,1
CIMZIA,pancytopenia,er doses include Blood and lymphatic system disorders,0
CIMZIA,pancytopenia,pectoris arrhythmias,0
CIMZIA,pancytopenia,atrial fibrillation,0
CIMZIA,pancytopenia,Blood and,0
CIMZIA,pancytopenia,lymphatic system disorders Anemia leukopenia,0
CIMZIA,pancytopenia,system disorders Anemia leukopenia pancytopenia and thrombophilia Cardiac disorders,1
CIMZIA,pancytopenia,lymphatic system disorders Anemia leukopenia,0
CIMZIA,thrombophilia,Angina pectoris arrhythmias atrial fibrillation,0
CIMZIA,thrombophilia,pectoris arrhythmias atrial fibrillation cardiac failure,0
CIMZIA,thrombophilia,thrombophilia Cardiac disorders Angina pectoris arrhythmias,1
CIMZIA,Angina pectoris,atrial fibrillation cardiac failure hypertensive heart,0
CIMZIA,Angina pectoris,lymphadenopathy pancytopenia,0
CIMZIA,Angina pectoris,s Anemia,0
CIMZIA,Angina pectoris,arrhythmias atrial fibrillation cardiac failure hypertensive heart disease,0
CIMZIA,Angina pectoris,arrhythmias atrial,0
CIMZIA,arrhythmias,myocardial,0
CIMZIA,arrhythmias,hypertensive heart,0
CIMZIA,arrhythmias,arrhythmias,1
CIMZIA,arrhythmias,hypertensive heart,0
CIMZIA,arrhythmias,arrhythmias atrial fibrillation cardiac failure hypertensive,1
CIMZIA,arrhythmias,hypertensive heart,0
CIMZIA,arrhythmias,lymphadenopathy,0
CIMZIA,atrial fibrillation,atrial fibrillation cardiac failure hypertensive heart disease,1
CIMZIA,atrial fibrillation,atrial fibrillation,1
CIMZIA,atrial fibrillation,arrhythmias,0
CIMZIA,atrial fibrillation,disorders Angina pectoris atrial,1
CIMZIA,atrial fibrillation,atrial fibrillation cardiac failure hypertensive heart,1
CIMZIA,atrial fibrillation,disorders Angina pectoris atrial,1
CIMZIA,atrial fibrillation,myocardial ischemia,0
CIMZIA,cardiac failure,myocardial infarction myocardial ischemia pericardial,0
CIMZIA,cardiac failure,pectoris arrhythmias atrial cardiac failure,1
CIMZIA,cardiac failure,atrial fibrillation,0
CIMZIA,cardiac failure,pectoris arrhythmias atrial cardiac failure,1
CIMZIA,cardiac failure,pectoris arrhythmias atrial cardiac,1
CIMZIA,hypertensive heart disease,atrial fibrillation cardiac hypertensive,1
CIMZIA,hypertensive heart disease,pericarditis stroke and transie,0
CIMZIA,hypertensive heart disease,heart disease myocardial infarction,1
CIMZIA,hypertensive heart disease,pectoris arrhythmias atrial fibrillation cardiac failure,0
CIMZIA,hypertensive heart disease,pericarditis stroke and transie,0
CIMZIA,hypertensive heart disease,arrhythmias atrial fibrillation cardiac hypertensive heart disease myocardial infarction,1
CIMZIA,hypertensive heart disease,pericarditis stroke and transie,0
CIMZIA,hypertensive heart disease,hypertensive heart disease,1
CIMZIA,hypertensive heart disease,pericarditis stroke and transie,0
CIMZIA,hypertensive heart disease,fibrillation cardiac hypertensive heart disease myocardial infarction myocardial ischemia,1
CIMZIA,hypertensive heart disease,pericarditis stroke and transie,0
CIMZIA,hypertensive heart disease,heart disease myocardial infarction myocardial ischemia pericardial,1
CIMZIA,myocardial infarction,myocardial ischemia pericardial,0
CIMZIA,myocardial ischemia,hypertensive heart disease myocardial myocardial,1
CIMZIA,myocardial ischemia,myocardial myocardial ischemia pericardial effusion pericarditis stroke and,1
CIMZIA,myocardial ischemia,hypertensive heart disease myocardial myocardial,1
CIMZIA,myocardial ischemia,pericarditis stroke and transient ischemic attack,0
CIMZIA,myocardial ischemia,myocardial,1
CIMZIA,myocardial ischemia,pericarditis stroke and,0
CIMZIA,myocardial ischemia,heart disease myocardial myocardial ischemia,1
CIMZIA,myocardial ischemia,pericarditis stroke and,0
CIMZIA,myocardial ischemia,myocardial ischemia pericardial effusion pericarditis stroke and,1
CIMZIA,myocardial ischemia,myocardial myocardial ischemia,1
CIMZIA,myocardial ischemia,disease myocardial myocardial ischemia,1
CIMZIA,myocardial ischemia,transient ischemic attack Eye disorders,0
CIMZIA,pericardial effusion,pericardial effusion pericarditis,1
CIMZIA,pericardial effusion,transient ischemic attack Eye disorders,0
CIMZIA,pericardial effusion,pericardial effusion pericarditis stroke,1
CIMZIA,pericarditis,lure hypertensive heart disease myocardial infarction myocardial,0
CIMZIA,pericarditis,pericarditis stroke,1
CIMZIA,pericarditis,attack,0
CIMZIA,pericarditis,pericardial,0
CIMZIA,pericarditis,transient ischemic attack Eye disorders,0
CIMZIA,stroke,transient ischemic attack Eye disorders Optic neuritis retinal hemorrhage and,0
CIMZIA,stroke,stroke and transient ischemic,1
CIMZIA,transient ischemic attack,stroke transient ischemic attack Eye,1
CIMZIA,transient ischemic attack,stroke and transient ischemic,1
CIMZIA,transient ischemic attack,and,0
CIMZIA,transient ischemic attack,effusion pericarditis stroke transient,1
CIMZIA,transient ischemic attack,Optic neuritis retinal hemorrhage,0
CIMZIA,transient ischemic attack,pericarditis stroke transient ischemic attack,1
CIMZIA,transient ischemic attack,General disorders and,0
CIMZIA,transient ischemic attack,transient ischemic attack Eye disorders Optic neuritis retinal,1
CIMZIA,transient ischemic attack,transient ischemic attack Eye disorders Optic neuritis,1
CIMZIA,transient ischemic attack,transient ischemic attack Eye disorders Optic neuritis retinal,1
CIMZIA,Optic neuritis,ischemic attack Eye Optic neuritis retinal hemorrhage and uveitis,1
CIMZIA,Optic neuritis,transient ischemic attack Eye disorders Optic neuritis retinal,1
CIMZIA,Optic neuritis,transient ischemic attack Eye Optic neuritis,1
CIMZIA,Optic neuritis,transient ischemic attack Eye Optic neuritis retinal hemorrhage and uveitis General,1
CIMZIA,Optic neuritis,transient ischemic attack Eye Optic neuritis,1
CIMZIA,retinal hemorrhage,Bleeding and injection s,0
CIMZIA,retinal hemorrhage,retinal hemorrhage,1
CIMZIA,retinal hemorrhage,ischemic attack Eye disorders,0
CIMZIA,retinal hemorrhage,and uveitis General disorders and administration,0
CIMZIA,retinal hemorrhage,ischemic attack Eye disorders,0
CIMZIA,retinal hemorrhage,retinal hemorrhage and uveitis General disorders and,1
CIMZIA,retinal hemorrhage,ischemic attack Eye disorders,0
CIMZIA,retinal hemorrhage,retinal hemorrhage and,1
CIMZIA,retinal hemorrhage,and,0
CIMZIA,retinal hemorrhage,and transient ischemic,0
CIMZIA,retinal hemorrhage,retinal hemorrhage,1
CIMZIA,uveitis,uveitis General disorders,1
CIMZIA,uveitis,uveitis General disorders and administration site,1
CIMZIA,uveitis,uveitis General disorders and,1
CIMZIA,uveitis,Bleeding and,0
CIMZIA,uveitis,and,0
CIMZIA,uveitis,uveitis General disorders,1
CIMZIA,uveitis,and injection site reactions,0
CIMZIA,uveitis,uveitis General disorders and administration,1
CIMZIA,Bleeding,Bleeding and injection site reactions,1
CIMZIA,Bleeding,uveitis General disorders and administration,1
CIMZIA,Bleeding,Bleeding and,1
CIMZIA,Bleeding,uveitis General disorders and administration,1
CIMZIA,Bleeding,Bleeding,1
CIMZIA,injection site reactions,hemorrhage and uveitis General,0
CIMZIA,injection site reactions,liver enzymes and hepatitis Immune system,0
CIMZIA,injection site reactions,uveitis General disorders and,0
CIMZIA,injection site reactions,Elevated liver enzymes and hepatitis Immune system,0
CIMZIA,injection site reactions,conditions Bleeding injection site reactions,1
CIMZIA,injection site reactions,Elevated liver enzymes and hepatitis Immune system,0
CIMZIA,injection site reactions,Elevated liver enzymes,0
CIMZIA,injection site reactions,enzymes and hepatitis Immune system disorde,0
CIMZIA,injection site reactions,Hepatobiliary disorders Elevated liver,0
CIMZIA,injection site reactions,Bleeding injection site reactions,1
CIMZIA,injection site reactions,uveitis General disorders and administration site conditions,0
CIMZIA,hepatitis,disorders Alopecia totalis Psychiatric disorders,0
CIMZIA,hepatitis,hepatitis Immune,1
CIMZIA,hepatitis,hepatitis Immune system disorders Alopecia totalis,1
CIMZIA,hepatitis,and,0
CIMZIA,Alopecia totalis,and suicide attempt,0
CIMZIA,Alopecia totalis,Alopecia totalis Psychiatric disorders Anxiety,1
CIMZIA,Anxiety,disorders,0
CIMZIA,Anxiety,and hepatitis Immune,0
CIMZIA,Anxiety,Anxiety,1
CIMZIA,bipolar disorder,bipolar disorder,1
CIMZIA,bipolar disorder,totalis Psychiatric disorders bipolar,1
CIMZIA,bipolar disorder,Psychiatric disorders bipolar disorder and suicide attempt Renal,1
CIMZIA,bipolar disorder,totalis Psychiatric disorders bipolar,1
CIMZIA,bipolar disorder,Immune system disorders Alopecia totalis Psychiatric disorders,0
CIMZIA,bipolar disorder,Psychiatric disorders bipolar disorder and suicide,1
CIMZIA,bipolar disorder,Immune system disorders Alopecia totalis Psychiatric disorders,0
CIMZIA,bipolar disorder,bipolar disorder and suicide,1
CIMZIA,bipolar disorder,bipolar disorder and suicide attempt,1
CIMZIA,bipolar disorder,bipolar disorder and suicide,1
CIMZIA,bipolar disorder,Psychiatric,0
CIMZIA,bipolar disorder,epatitis Immune system,0
CIMZIA,bipolar disorder,Anxiety,0
CIMZIA,suicide attempt,suicide attempt Renal,1
CIMZIA,suicide attempt,and urinary disorders Nephrotic syndrome and renal,0
CIMZIA,suicide attempt,disorder and,0
CIMZIA,suicide attempt,disorders Alopecia totalis Psychiatric,0
CIMZIA,suicide attempt,suicide attempt Renal and,1
CIMZIA,suicide attempt,suicide attempt,1
CIMZIA,suicide attempt,syndrome and renal failure Reproductive,0
CIMZIA,suicide attempt,bipolar disorder and,0
CIMZIA,suicide attempt,disorder suicide,1
CIMZIA,Nephrotic syndrome,attempt Renal and urinary Nephrotic,1
CIMZIA,Nephrotic syndrome,and breast disorders,0
CIMZIA,Nephrotic syndrome,urinary Nephrotic syndrome,1
CIMZIA,renal failure,Nephrotic syndrome renal,1
CIMZIA,renal failure,urinary disorders Nephrotic syndrome renal failure Reproductive system and,1
CIMZIA,renal failure,Nephrotic syndrome renal,1
CIMZIA,renal failure,disorders Nephrotic syndrome,0
CIMZIA,renal failure,urinary disorders Nephrotic syndrome renal failure Reproductive,1
CIMZIA,renal failure,disorders Nephrotic syndrome,0
CIMZIA,Menstrual disorder,Menstrual,1
CIMZIA,Menstrual disorder,Menstrual disorder Skin and subcutaneous tissue disorders,1
CIMZIA,Menstrual disorder,Skin and subcutaneous,0
CIMZIA,Menstrual disorder,system and breast Menstrual disorder Skin and,1
CIMZIA,Menstrual disorder,Skin and subcutaneous,0
CIMZIA,Menstrual disorder,Reproductive system and breast Menstrual,1
CIMZIA,erythema nodosum,tissue disorders erythema,1
CIMZIA,erythema nodosum,Dermatitis,0
CIMZIA,erythema nodosum,erythema nodosum and,1
CIMZIA,erythema nodosum,Dermatitis,0
CIMZIA,urticaria,Controlled Studies with,0
CIMZIA,urticaria,urticaria Vascular disorders Thrombophlebitis,1
CIMZIA,urticaria,Thrombophlebitis vasculitis,0
CIMZIA,vasculitis,with Rheumatoid Arthritis CIMZIA was studied primarily in placebo,0
CIMZIA,vasculitis,urticaria Vascular disorders vasculitis Controlled Studies with Rheumatoid,1
CIMZIA,vasculitis,with Rheumatoid Arthritis CIMZIA was studied primarily in placebo,0
CIMZIA,vasculitis,vasculitis Controlled,1
CIMZIA,infections,infections,1
CIMZIA,infections,disease was,0
CIMZIA,infections,infections in,1
CIMZIA,infections,disease was,0
CIMZIA,infections,in Crohns disease was for CIMZIAtreated patients and,0
CIMZIA,infections,Infections The incidence infections in controlled,1
CIMZIA,infections,in Crohns disease was for CIMZIAtreated patients and,0
CIMZIA,infections,placebotreated patients infections consisted,1
CIMZIA,infections,in Crohns disease was for CIMZIAtreated patients and,0
CIMZIA,infections,and for placebotreated patients infections consisted,1
CIMZIA,infections,in Crohns disease was for CIMZIAtreated patients and,0
CIMZIA,infections,infections for CIMZIA for,0
CIMZIA,infections,infections consisted primarily of upper,1
CIMZIA,infections,placebo,0
CIMZIA,infections,consisted primarily of upper respiratory,0
CIMZIA,infections,infections consisted,1
CIMZIA,infections,infections consisted primarily of,1
CIMZIA,infections,infections consisted,1
CIMZIA,infections,infections consisted primarily,1
CIMZIA,upper respiratory infections,during,0
CIMZIA,upper respiratory infections,upper respiratory infections,1
CIMZIA,upper respiratory infections,infections consisted primarily upper respiratory infections for,1
CIMZIA,upper respiratory infections,upper respiratory infections,1
CIMZIA,upper respiratory infections,serious infections during the controlled,0
CIMZIA,upper respiratory infections,for placebotreated patients The,0
CIMZIA,upper respiratory infections,infections consisted primarily upper respiratory infections for CIMZIA,1
CIMZIA,upper respiratory infections,for placebotreated patients The,0
CIMZIA,upper respiratory infections,upper respiratory infections for,1
CIMZIA,upper respiratory infections,infections consisted primarily upper respiratory infections for CIMZIA for placebo,1
CIMZIA,upper respiratory infections,upper respiratory infections for,1
CIMZIA,infections,infections,1
CIMZIA,infections,infections,1
CIMZIA,infections,infections,1
CIMZIA,infections,infections during the,1
CIMZIA,infections,the controlled clinical studies was per patientyear for,0
CIMZIA,infections,controlled clinical studies was per,0
CIMZIA,infections,upper respiratory infections for CIMZIA for placebo The incidence,0
CIMZIA,infections,for CIMZIA for placebo The incidence,0
CIMZIA,infections,infections for CIMZIA for placebo The incidence of,0
CIMZIA,infections,infections during the,1
CIMZIA,infections,infections,1
CIMZIA,infections,infections,1
CIMZIA,infections,patients infections,1
CIMZIA,infections,infections,1
CIMZIA,infections,infections observed,1
CIMZIA,infections,infections,1
CIMZIA,infections,pneumonia and pyelonephritis The incidence,0
CIMZIA,infections,for placebotreated patients,0
CIMZIA,infections,infections observed,1
CIMZIA,infections,was,0
CIMZIA,viral infections,included,0
CIMZIA,viral infections,viral infections pneumonia and pyelonephritis The incidence,1
CIMZIA,viral infections,included,0
CIMZIA,viral infections,and pyelonephritis The incidence of new cases of infections in controlled,0
CIMZIA,viral infections,viral infections pneumonia and pyelonephritis The incidence,1
CIMZIA,viral infections,viral,1
CIMZIA,viral infections,included bacterial viral infections,1
CIMZIA,viral infections,viral,1
CIMZIA,viral infections,and for placebotreated patients Serious,0
CIMZIA,viral infections,patients Serious infections observed included,0
CIMZIA,viral infections,infections observed included bacterial and,0
CIMZIA,pneumonia,in controlled clinical studies,0
CIMZIA,pneumonia,bacterial and viral infections,0
CIMZIA,pneumonia,patients Serious infections observed included bacterial and viral,0
CIMZIA,pneumonia,pneumonia and pyelonephritis,1
CIMZIA,pneumonia,pneumonia and pyelonephritis The incidence of,1
CIMZIA,pneumonia,pneumonia and,1
CIMZIA,pyelonephritis,of new cases of,0
CIMZIA,pyelonephritis,pyelonephritis The incidence,1
CIMZIA,pyelonephritis,pneumonia pyelonephritis,1
CIMZIA,pyelonephritis,pyelonephritis The incidence,1
CIMZIA,pyelonephritis,and,0
CIMZIA,pyelonephritis,pyelonephritis,1
CIMZIA,pyelonephritis,pyelonephritis The incidence,1
CIMZIA,infections,new cases infections in controlled clinical,1
CIMZIA,infections,pyelonephritis The incidence,1
CIMZIA,infections,clinical studies in rheumatoid arthritis,0
CIMZIA,infections,bacterial and viral infections pneumonia and pyelonephritis The incidence of,0
CIMZIA,infections,and pyelonephritis The incidence of new cases of,0
CIMZIA,infections,pneumonia and pyelonephritis The incidence of new,0
CIMZIA,infections,studies in rheumatoid arthritis was per,0
CIMZIA,infections,pyelonephritis The incidence of new cases of,0
CIMZIA,infections,infections in controlled,1
CIMZIA,infections,pyelonephritis The incidence of new cases of,0
CIMZIA,infections,for,0
CIMZIA,infections,infections consisted primarily of upper respiratory,1
CIMZIA,infections,upper respiratory tract infections herpes infections urinary tract,0
CIMZIA,infections,infections consisted primarily of,1
CIMZIA,infections,infections consisted primarily of upper,1
CIMZIA,infections,The,0
CIMZIA,infections,ntyear for all,0
CIMZIA,infections,infections,1
CIMZIA,infections,patientyear for placebotreated patients infections consisted primarily of upper respiratory,1
CIMZIA,infections,infections,1
CIMZIA,infections,for placebotreated patients infections,1
CIMZIA,infections,infections,1
CIMZIA,upper respiratory tract infections,primarily upper respiratory tract infections herpes infections urinary tract,1
CIMZIA,upper respiratory tract infections,infections,1
CIMZIA,herpes infections,tract infections,0
CIMZIA,herpes infections,lower,0
CIMZIA,urinary tract infections,respiratory tract infections herpes urinary tract,1
CIMZIA,urinary tract infections,infections herpes urinary tract,1
CIMZIA,lower respiratory tract infections,arthritis studies there,0
CIMZIA,lower respiratory tract infections,infections urinary tract infections and,0
CIMZIA,lower respiratory tract infections,tract infections lower respiratory,1
CIMZIA,lower respiratory tract infections,infections lower respiratory tract infections,1
CIMZIA,lower respiratory tract infections,tract infections lower respiratory,1
CIMZIA,lower respiratory tract infections,tract infections lower,1
CIMZIA,infection,groups per,0
CIMZIA,infection,reactions in the CIMZIA treatment groups compared to,0
CIMZIA,infection,infection adverse reactions,1
CIMZIA,infection,controlled rheumatoid arthritis studies there,0
CIMZIA,infection,to the placebo groups,0
CIMZIA,infection,treatment groups compared to,0
CIMZIA,infection,the controlled rheumatoid arthritis studies there were more new cases of serious,0
CIMZIA,infection,cases of infection adverse,1
CIMZIA,infection,the controlled rheumatoid arthritis studies there were more new cases of serious,0
CIMZIA,infections,mg,0
CIMZIA,infections,of infections in the mg,1
CIMZIA,infections,mg,0
CIMZIA,infections,patientyear for placebo,0
CIMZIA,infections,per,0
CIMZIA,infections,other week dose,0
CIMZIA,infections,infections in,1
CIMZIA,infections,infections in the mg every other,1
CIMZIA,infections,per patientyear for all CIMZIA doses vs per patientyear for placebo Rates of,0
CIMZIA,infections,infections,1
CIMZIA,infections,of,0
CIMZIA,infections,infections included tuberculosis,1
CIMZIA,infections,infections included tuberculosis,1
CIMZIA,infections,tuberculosis,0
CIMZIA,infections,infections included,1
CIMZIA,infections,patientyear,0
CIMZIA,infections,infections included,1
CIMZIA,infections,infections included tuberculosis pneumonia cellulitis and,1
CIMZIA,tuberculosis,per patientyear Serious infections tuberculosis pneumonia cellulitis and pyelonephritis In,1
CIMZIA,tuberculosis,infections included tuberculosis pneumonia cellulitis and,1
CIMZIA,tuberculosis,tuberculosis pneumonia cellulitis,1
CIMZIA,tuberculosis,infections included tuberculosis pneumonia cellulitis and,1
CIMZIA,pneumonia,pneumonia,1
CIMZIA,pneumonia,occurred in more,0
CIMZIA,pneumonia,weeks,0
CIMZIA,pneumonia,included,0
CIMZIA,pneumonia,In the placebo group no serious infection occurred,0
CIMZIA,pneumonia,Serious infections included pneumonia cellulitis and pyelonephritis In the,1
CIMZIA,pneumonia,In the placebo group no serious infection occurred,0
CIMZIA,pneumonia,patientyear Serious,0
CIMZIA,cellulitis,cellulitis,1
CIMZIA,cellulitis,patientyear Serious infections included tuberculosis,0
CIMZIA,pyelonephritis,pyelonephritis In the,1
CIMZIA,pyelonephritis,were per patientyear Serious infections included tuberculosis pneumonia cellulitis and,0
CIMZIA,pyelonephritis,pyelonephritis In,1
CIMZIA,pyelonephritis,per patientyear Serious infections included tuberculosis pneumonia,0
CIMZIA,pyelonephritis,pyelonephritis,1
CIMZIA,pyelonephritis,infection occurred in more than one subject There,0
CIMZIA,infection,no infection occurred in,1
CIMZIA,infection,infection occurred in more than one subject There,0
CIMZIA,infection,the placebo group no infection occurred in more than one,1
CIMZIA,infection,infection occurred in more than one subject There,0
CIMZIA,infection,group no infection occurred in more than one,1
CIMZIA,infection,infection occurred in more than one subject There,0
CIMZIA,infection,infection,1
CIMZIA,infection,placebo group,0
CIMZIA,infection,infection occurred,1
CIMZIA,infection,placebo group,0
CIMZIA,infection,the placebo group no serious,0
CIMZIA,infection,infection,1
CIMZIA,infection,no infection,1
CIMZIA,infection,infection,1
CIMZIA,tuberculosis,tuberculosis is approximately per,1
CIMZIA,tuberculosis,rate tuberculosis is,1
CIMZIA,tuberculosis,tuberculosis is approximately per,1
CIMZIA,tuberculosis,tuberculosis is,1
CIMZIA,tuberculosis,overall rate tuberculosis is,1
CIMZIA,tuberculosis,tuberculosis is,1
CIMZIA,tuberculosis,all,0
CIMZIA,tuberculosis,tuberculosis is approximately per patientyears across,1
CIMZIA,tuberculosis,all,0
CIMZIA,tuberculosis,tuberculosis is,1
CIMZIA,tuberculosis,patientyears across all indications The majority of cases,0
CIMZIA,tuberculosis,tuberculosis is,1
CIMZIA,tuberculosis,all indications The,0
CIMZIA,TB,rates TB Reports include cases,1
CIMZIA,TB,all indications The,0
CIMZIA,TB,across all,0
CIMZIA,TB,TB,1
CIMZIA,pulmonary TB,lymphatic peritoneal as well pulmonary TB The median time to onset,1
CIMZIA,pulmonary TB,TB,1
CIMZIA,pulmonary TB,pulmonary TB The median time to onset,1
CIMZIA,TB,all indications was days In the studies with CIMZIA,0
CIMZIA,TB,TB among exposed,1
CIMZIA,TB,there were,0
CIMZIA,TB,cases Rare cases of opportunistic infections ha,0
CIMZIA,fatal,fatal cases Rare cases,1
CIMZIA,fatal,fatal cases Rare cases,1
CIMZIA,fatal,patients including fatal,1
CIMZIA,fatal,fatal cases Rare cases,1
CIMZIA,fatal,fatal cases,1
CIMZIA,fatal,studies with CIMZIA in RA there were cases of TB among exposed,0
CIMZIA,opportunistic infections,cases Rare cases opportunistic infections,1
CIMZIA,opportunistic infections,studies with CIMZIA in RA there were cases of TB among exposed,0
CIMZIA,malignancies,malignancies was,1
CIMZIA,malignancies,studies with CIMZIA in RA there were cases of TB among exposed,0
CIMZIA,malignancies,For some,0
CIMZIA,malignancies,In clinical studies of,0
CIMZIA,malignancies,malignancies was similar for CIMZIAtreated,1
CIMZIA,malignancies,malignancies was similar for CIMZIAtreated and,1
CIMZIA,malignancies,malignancies have been,1
CIMZIA,malignancies,malignancies have been observed among patients,1
CIMZIA,malignancies,ignancies,0
CIMZIA,worsening heart failure,new worsening heart failure,1
CIMZIA,worsening heart failure,were,0
CIMZIA,worsening heart failure,majority of these cases were,0
CIMZIA,worsening heart failure,worsening heart failure,1
CIMZIA,worsening heart failure,majority of these cases were,0
CIMZIA,worsening heart failure,worsening,1
CIMZIA,lupus-like syndrome,One of the Crohns disease patients treated with CIMZIA developed symptoms of,0
CIMZIA,lupus-like syndrome,clinical,0
CIMZIA,lupus-like syndrome,In clinical trials of TNF blockers including CIMZIA,0
CIMZIA,lupus-like syndrome,lupus-like syndrome In clinical,1
CIMZIA,lupus-like syndrome,lupus-like syndrome In,1
CIMZIA,lupus-like syndrome,lupus-like syndrome In clinical,1
CIMZIA,lupus-like syndrome,of TNF blockers including,0
CIMZIA,lupus-like syndrome,CIMZIA developed symptoms of lupus-like syndrome In,1
CIMZIA,lupus-like syndrome,of TNF blockers including,0
CIMZIA,lupus-like syndrome,lupus-like syndrome,1
CIMZIA,lupus-like syndrome,some patients,0
CIMZIA,ANA,treated with CIMZIA in,0
CIMZIA,ANA,ANA,1
CIMZIA,ANA,patients have ANA Four patients out of,1
CIMZIA,ANA,ANA,1
CIMZIA,ANA,patients have ANA Four patients out,1
CIMZIA,ANA,ANA,1
CIMZIA,ANA,RA some patients have ANA Four patients,1
CIMZIA,ANA,ANA,1
CIMZIA,ANA,ANA Four patients out of patients,1
CIMZIA,ANA,ANA,1
CIMZIA,ANA,in RA clinical studies,0
CIMZIA,ANA,patients have ANA Four patients out,1
CIMZIA,ANA,in RA clinical studies,0
CIMZIA,ANA,ANA,1
CIMZIA,lupus-like syndrome,with CIMZIA in RA clinical studies developed clinical signs suggestive of,0
CIMZIA,lupus-like syndrome,the development of autoimmune diseases is unknown,0
CIMZIA,lupus-like syndrome,treatment with CIMZIA on the development of autoimmune diseases is unknown,0
CIMZIA,lupus-like syndrome,clinical signs suggestive of lupus-like,1
CIMZIA,lupus-like syndrome,lupus-like syndrome The impact of,1
CIMZIA,lupus-like syndrome,CIMZIA in RA clinical,0
CIMZIA,lupus-like syndrome,with CIMZIA on the development of autoimmune diseases is,0
CIMZIA,lupus-like syndrome,lupus-like syndrome The impact of,1
CIMZIA,lupus-like syndrome,suggestive of lupus-like syndrome The impact of,1
CIMZIA,lupus-like syndrome,lupus-like syndrome The impact of,1
CIMZIA,abdominal pain,abdominal pain,1
CIMZIA,abdominal pain,arthralgia,0
CIMZIA,abdominal pain,abdominal pain arthralgia,1
CIMZIA,abdominal pain,arthralgia,0
CIMZIA,arthralgia,arthralgia edema peripheral erythema,1
CIMZIA,arthralgia,to antibodynegative patients N,0
CIMZIA,arthralgia,compared to antibodynegative patients N,0
CIMZIA,arthralgia,injection site pain pain,0
CIMZIA,arthralgia,pain in,0
CIMZIA,arthralgia,compared to antibodynegative patients N abdominal,0
CIMZIA,arthralgia,patients N abdominal arthralgia edema peripheral erythema,1
CIMZIA,arthralgia,compared to antibodynegative patients N abdominal,0
CIMZIA,arthralgia,arthralgia,1
CIMZIA,arthralgia,peripheral erythema nodosum injection site erythema injection site pain pain in extremit,0
CIMZIA,arthralgia,pain,0
CIMZIA,edema peripheral,N abdominal pain edema,1
CIMZIA,edema peripheral,pain edema peripheral,1
CIMZIA,injection site erythema,erythema,0
CIMZIA,injection site erythema,erythema injection,1
CIMZIA,injection site erythema,respiratory,0
CIMZIA,injection site erythema,injection site erythema injection site pain,1
CIMZIA,injection site erythema,bodynegative patients N abdominal pain arthralgia,0
CIMZIA,injection site erythema,pain,0
CIMZIA,injection site erythema,injection site erythema injection site pain pain in,1
CIMZIA,injection site erythema,arthralgia edema peripheral erythema injection site erythema injection site pain pain,1
CIMZIA,injection site erythema,injection site erythema injection site pain pain in,1
CIMZIA,injection site erythema,peripheral erythema injection site erythema injection,1
CIMZIA,injection site erythema,injection site erythema injection site pain pain in,1
CIMZIA,injection site pain,site injection site pain,1
CIMZIA,pain in extremity,erythema injection site pain,0
CIMZIA,pain in extremity,injection site pain in extremity,1
CIMZIA,pain in extremity,pain in extremity,1
CIMZIA,pain in extremity,pain in extremity and,1
CIMZIA,pain in extremity,erythema injection site pain in extremity and upper,1
CIMZIA,pain in extremity,pain in extremity and,1
CIMZIA,pain in extremity,injection site pain,0
CIMZIA,pain in extremity,in extremity and upper respiratory tract infection,1
CIMZIA,upper respiratory tract infection,in extremity upper respiratory tract infection The overall percentage,1
CIMZIA,upper respiratory tract infection,in extremity and upper respiratory tract infection,1
CIMZIA,upper respiratory tract infection,tract infection The overall percentage,1
CIMZIA,upper respiratory tract infection,extremity upper respiratory tract infection,1
CIMZIA,upper respiratory tract infection,extremity upper respiratory tract infection The,1
CIMZIA,upper respiratory tract infection,extremity upper respiratory tract infection,1
CIMZIA,upper respiratory tract infection,tract infection The,1
CIMZIA,upper respiratory tract infection,pain in extremity upper respiratory tract,1
CIMZIA,hypersensitivity reactions,hypersensitivity reactions,1
CIMZIA,hypersensitivity reactions,hypersensitivity reactions have,1
CIMZIA,hypersensitivity reactions,Hypersensitivity Reactions The,0
CIMZIA,hypersensitivity reactions,hypersensitivity reactions have been reported rarely,1
CIMZIA,hypersensitivity reactions,that could be compatible hypersensitivity reactions have been reported rarely following,1
CIMZIA,hypersensitivity reactions,hypersensitivity reactions have been reported rarely,1
CIMZIA,angioedema,angioedema dermatitis allergic dizziness postural dyspnea,1
CIMZIA,dermatitis allergic,to patients dermatitis allergic dizziness postural dyspnea,1
CIMZIA,dermatitis allergic,angioedema dermatitis allergic dizziness postural dyspnea,1
CIMZIA,dermatitis allergic,to patients dermatitis allergic,1
CIMZIA,dermatitis allergic,reactions have been reported rarely following,0
CIMZIA,dermatitis allergic,administration to,0
CIMZIA,dermatitis allergic,dermatitis allergic,1
CIMZIA,dyspnea,CIMZIA administration to patients angioedema dermatitis allergic,0
CIMZIA,dyspnea,following CIMZIA,0
CIMZIA,dyspnea,dyspnea hot,1
CIMZIA,dyspnea,flush hypotension injection site reactions malaise pyrexia rash serum sickness and vas,0
CIMZIA,dyspnea,to patients angioedema dermatitis allergic,0
CIMZIA,dyspnea,dyspnea,1
CIMZIA,dyspnea,dyspnea hot flush hypotension injection,1
CIMZIA,dyspnea,allergic dizziness dyspnea hot flush hypotension,1
CIMZIA,dyspnea,dyspnea hot flush hypotension injection,1
CIMZIA,hot flush,dermatitis,0
CIMZIA,hot flush,allergic dizziness postural dyspnea,0
CIMZIA,hot flush,dizziness postural hot flush hypotension,1
CIMZIA,hot flush,allergic dizziness postural dyspnea,0
CIMZIA,hot flush,postural hot flush hypotension injection,1
CIMZIA,hot flush,allergic dizziness postural dyspnea,0
CIMZIA,hot flush,CIMZIA administration to patients,0
CIMZIA,hot flush,hot flush hypotension injection site,1
CIMZIA,hot flush,CIMZIA administration to patients angioedema dermatitis allergic dizziness,0
CIMZIA,hot flush,hot flush hypotension injection site,1
CIMZIA,hot flush,CIMZIA administration to patients angioedema dermatitis allergic dizziness,0
CIMZIA,hot flush,dizziness postural hot flush,1
CIMZIA,hot flush,CIMZIA administration to patients angioedema dermatitis allergic dizziness,0
CIMZIA,hypotension,reactions malaise pyrexia,0
CIMZIA,hypotension,hypotension injection site reactions malaise,1
CIMZIA,hypotension,pyrexia rash,0
CIMZIA,hypotension,hypotension,1
CIMZIA,hypotension,hypotension injection site reactions malaise pyrexia,1
CIMZIA,hypotension,hypotension,1
CIMZIA,hypotension,injection site reactions malaise pyrexia rash serum sickness and vasovagal syncope,0
CIMZIA,injection site reactions,injection site reactions malaise pyrexia rash serum,1
CIMZIA,injection site reactions,injection site reactions malaise pyrexia rash serum sickness and vasovagal syncope,0
CIMZIA,injection site reactions,hot flush injection site reactions malaise pyrexia rash serum sickness,1
CIMZIA,injection site reactions,injection site reactions malaise pyrexia rash serum sickness and vasovagal syncope,0
CIMZIA,injection site reactions,sickness and vasovagal syncope see Warnings,0
CIMZIA,injection site reactions,injection site reactions malaise pyrexia rash serum sickness,1
CIMZIA,injection site reactions,postural dyspnea hot flush injection site,1
CIMZIA,malaise,malaise,1
CIMZIA,malaise,site malaise pyrexia rash serum sickness and,1
CIMZIA,malaise,malaise,1
CIMZIA,malaise,flush hypotension injection site malaise pyrexia rash serum,1
CIMZIA,malaise,malaise,1
CIMZIA,malaise,hypotension injection site malaise pyrexia rash serum sickness,1
CIMZIA,malaise,malaise,1
CIMZIA,malaise,malaise pyrexia rash serum,1
CIMZIA,malaise,sickness and,0
CIMZIA,malaise,syncope see Warnings,0
CIMZIA,malaise,Warnings and,0
CIMZIA,malaise,site malaise pyrexia rash serum,1
CIMZIA,malaise,Warnings and,0
CIMZIA,malaise,injection,0
CIMZIA,pyrexia,injection site reactions pyrexia rash serum sickness,1
CIMZIA,pyrexia,injection,0
CIMZIA,pyrexia,injection site reactions pyrexia rash serum sickness and,1
CIMZIA,pyrexia,injection,0
CIMZIA,pyrexia,allergic dizziness postural dyspnea hot flush,0
CIMZIA,pyrexia,pyrexia,1
CIMZIA,rash,and Precautions Post,0
CIMZIA,rash,hypotension injection site,0
CIMZIA,rash,dyspnea hot flush hypotension injection site reactions malaise pyrexia,0
CIMZIA,rash,rash serum,1
CIMZIA,systemic vasculitis,systemic vasculitis has been identified,1
CIMZIA,systemic vasculitis,been identified during postapproval use of TNF,0
CIMZIA,systemic vasculitis,systemic vasculitis has been,1
CIMZIA,systemic vasculitis,been identified during postapproval use of TNF,0
CIMZIA,systemic vasculitis,Vascular systemic vasculitis,1
CIMZIA,systemic vasculitis,been identified during postapproval use of TNF,0
CIMZIA,systemic vasculitis,systemic vasculitis has been identified,1
CIMZIA,systemic vasculitis,to drug exposure Vascular systemic,1
CIMZIA,systemic vasculitis,drug exposure Vascular disorder,0
CIMZIA,systemic vasculitis,has been,0
CIMZIA,skin reactions,skin reactions including StevensJohnson syndrome toxic epidermal,1
CIMZIA,skin reactions,of TNF blockers,0
CIMZIA,skin reactions,erythema multiforme,0
CIMZIA,skin reactions,Skin case of skin reactions,1
CIMZIA,skin reactions,erythema multiforme,0
CIMZIA,skin reactions,erythema multiforme and,0
CIMZIA,skin reactions,skin reactions including,1
CIMZIA,skin reactions,Skin case of skin reactions including StevensJohnson,1
CIMZIA,skin reactions,skin reactions including,1
CIMZIA,Stevens-Johnson syndrome,skin reactions Stevens-Johnson syndrome,1
CIMZIA,Stevens-Johnson syndrome,use of TNF blockers Skin case of severe,0
CIMZIA,Stevens-Johnson syndrome,severe skin reactions Stevens-Johnson syndrome,1
CIMZIA,Stevens-Johnson syndrome,blockers Skin case of severe skin reactions,0
CIMZIA,Stevens-Johnson syndrome,case,0
CIMZIA,Stevens-Johnson syndrome,skin reactions Stevens-Johnson syndrome,1
CIMZIA,Stevens-Johnson syndrome,case,0
CIMZIA,Stevens-Johnson syndrome,toxic epidermal necrolysis erythema multiforme and,0
CIMZIA,Stevens-Johnson syndrome,Stevens-Johnson syndrome toxic epidermal necrolysis erythema,1
CIMZIA,Stevens-Johnson syndrome,severe skin reactions Stevens-Johnson,1
CIMZIA,Stevens-Johnson syndrome,Skin case of severe,0
CIMZIA,toxic epidermal necrolysis,all subtypes including pustular,0
CIMZIA,toxic epidermal necrolysis,including StevensJohnson toxic epidermal necrolysis erythema multiforme,1
CIMZIA,toxic epidermal necrolysis,all subtypes including pustular,0
CIMZIA,toxic epidermal necrolysis,worsening psoriasis all subtypes,0
CIMZIA,toxic epidermal necrolysis,toxic epidermal necrolysis erythema multiforme and new,1
CIMZIA,toxic epidermal necrolysis,toxic epidermal necrolysis erythema multiforme and,1
CIMZIA,toxic epidermal necrolysis,epidermal necrolysis erythema multiforme and new,1
CIMZIA,erythema multiforme,erythema multiforme and new or worsening,1
CIMZIA,erythema multiforme,including StevensJohnson syndrome toxic,0
CIMZIA,erythema multiforme,severe skin,0
CIMZIA,erythema multiforme,erythema multiforme and new or worsening psoriasis,1
CIMZIA,erythema multiforme,severe skin,0
CIMZIA,erythema multiforme,toxic,0
CIMZIA,erythema multiforme,and new or worsening psoriasis all subtypes including pustular and,0
CIMZIA,erythema multiforme,toxic epidermal necrolysis,0
CIMZIA,erythema multiforme,epidermal erythema multiforme and new or,1
CIMZIA,erythema multiforme,toxic epidermal necrolysis,0
CIMZIA,erythema multiforme,erythema multiforme,1
CIMZIA,psoriasis,psoriasis all subtypes including,1
CIMZIA,psoriasis,erythema multiforme,1
CIMZIA,psoriasis,been,0
CIMZIA,INFECTIONS,ADVERSE REACTIONS The most,1
CIMZIA,INFECTIONS,incidence and higher than placebo upper respiratory,0
CIMZIA,INFECTIONS,REACTIONS,0
CIMZIA,INFECTIONS,EXCERPT,0
CIMZIA,INFECTIONS,most c,1
CIMZIA,INFECTIONS,The most c ommon,1
CIMZIA,INFECTIONS,most c,1
CIMZIA,INFECTIONS,EXCERPT,0
CIMZIA,INFECTIONS,The most c ommon adverse reactions,1
CIMZIA,INFECTIONS,EXCERPT,0
CIMZIA,INFECTIONS,ADVERSE REACTIONS EXCERPT,0
CIMZIA,INFECTIONS,The most c ommon adverse,1
CIMZIA,INFECTIONS,ADVERSE REACTIONS EXCERPT,0
CIMZIA,MALIGNANCY,adverse r eactions incidence and higher,1
CIMZIA,MALIGNANCY,adverse r,1
CIMZIA,MALIGNANCY,EXCERPT The most adverse r,1
CIMZIA,MALIGNANCY, adverse r eactions incidence,1
CIMZIA,MALIGNANCY,EXCERPT The most adverse r,1
CIMZIA,MALIGNANCY,The most  adverse r eactions incidence,1
CIMZIA,MALIGNANCY,EXCERPT The most adverse r,1
CIMZIA,MALIGNANCY,most  adverse r eactions incidence and higher than,1
CIMZIA,MALIGNANCY,EXCERPT The most adverse r,1
CIMZIA,MALIGNANCY,REACTIONS EXCERPT The most  adverse r eactions,1
CIMZIA,MALIGNANCY,EXCERPT The most adverse r,1
CIMZIA,INFECTIONS,common adverse reactions %,1
CIMZIA,INFECTIONS,most common adverse,0
CIMZIA,INFECTIONS,EXCERPT The most common adverse reactions,0
CIMZIA,INFECTIONS,adverse reactions % and high er,1
CIMZIA,INFECTIONS,EXCERPT The most common adverse reactions,0
CIMZIA,INFECTIONS,and high er than,1
CIMZIA,MALIGNANCY,reactions incidence and higher an placebo,1
CIMZIA,MALIGNANCY,ADVERSE REACTIONS,0
CIMZIA,MALIGNANCY,an,1
CIMZIA,MALIGNANCY,an placebo,1
CIMZIA,MALIGNANCY,and higher an placebo,1
CIMZIA,MALIGNANCY,incidence and higher an placebo,1
CIMZIA,MALIGNANCY,an placebo upper respiratory tract infection rash,1
CIMZIA,MALIGNANCY,and higher an placebo upper respiratory,1
CIMZIA,MALIGNANCY,an placebo upper respiratory tract infection rash,1
CIMZIA,Active tuberculosis,conducted un der widely,1
CIMZIA,Active tuberculosis,der widely varying and controlled conditions adverse reaction rates observed in,0
CIMZIA,Active tuberculosis,der widely varying and controlled conditions,0
CIMZIA,reactivation of latent tuberculosis,"controlled conditions, a dverse",1
CIMZIA,reactivation of latent tuberculosis,"widely arying and controlled conditions, a dverse reaction",1
CIMZIA,reactivation of latent tuberculosis,"controlled conditions, a dverse",1
CIMZIA,reactivation of latent tuberculosis,"are conducted under widely arying and controlled conditions, a dverse",1
CIMZIA,reactivation of latent tuberculosis,"controlled conditions, a dverse",1
CIMZIA,reactivation of latent tuberculosis,"controlled conditions, a",1
CIMZIA,reactivation of latent tuberculosis,"and controlled conditions, a dverse reaction rates observed",1
CIMZIA,reactivation of latent tuberculosis,"controlled conditions, a dverse reaction rates observed",1
CIMZIA,reactivation of latent tuberculosis,"conducted under widely arying and controlled conditions, a",1
CIMZIA,reactivation of latent tuberculosis,"under widely arying and controlled conditions, a",1
CIMZIA,reactivation of latent tuberculosis,Precautions Because clinical studies,0
CIMZIA,histoplasmosis,mmon adverse reactions were upper respiratory infections rash and,0
CIMZIA,histoplasmosis,in clinical practice In premarketing controlled trials of,0
CIMZIA,histoplasmosis,the most co mmon adverse reactions were upper,1
CIMZIA,histoplasmosis,mmon adverse reactions were upper respiratory infections rash and,0
CIMZIA,histoplasmosis,all patient populations ed the most co mmon adverse reactions were,1
CIMZIA,histoplasmosis,mmon adverse reactions were upper respiratory infections rash and,0
CIMZIA,coccidioidomycosis,adverse reactio ns,1
CIMZIA,coccidioidomycosis,adverse reactio ns,1
CIMZIA,coccidioidomycosis,the most on adverse reactio ns,1
CIMZIA,coccidioidomycosis,adverse reactio ns,1
CIMZIA,coccidioidomycosis,on adverse reactio ns were upper respiratory infections,1
CIMZIA,coccidioidomycosis,combined the most on,1
CIMZIA,coccidioidomycosis,on adverse reactio ns were upper respiratory,1
CIMZIA,coccidioidomycosis,combined the most on,1
CIMZIA,coccidioidomycosis,populations combined the most on adverse,1
CIMZIA,coccidioidomycosis,urinary,0
CIMZIA,coccidioidomycosis,controlled trials of all,0
CIMZIA,coccidioidomycosis,combined the most on adverse,1
CIMZIA,candidiasis,combined the most,0
CIMZIA,candidiasis,(>= 8%) we re upper,1
CIMZIA,candidiasis,premarketing controlled trials of all patient populations combined the most,0
CIMZIA,candidiasis,8%) we re upper respiratory,1
CIMZIA,candidiasis,most common adverse (>=,1
CIMZIA,candidiasis,adverse (>=,1
CIMZIA,candidiasis,adverse  (>= 8%) we re,1
CIMZIA,candidiasis,adverse (>=,1
CIMZIA,aspergillosis,upper respir atory infections,1
CIMZIA,aspergillosis,reactions  upper respir atory,1
CIMZIA,aspergillosis,upper respir atory infections,1
CIMZIA,aspergillosis,Adverse Reactions Most,0
CIMZIA,blastomycosis,patient populations combined,0
CIMZIA,blastomycosis,upper ory,1
CIMZIA,blastomycosis,and urinary,0
CIMZIA,blastomycosis,ory infection s rash,1
CIMZIA,pneumocystosis,"reactions were upper respiratory ),",1
CIMZIA,histoplasmosis,infections (8 Adverse,1
CIMZIA,histoplasmosis, infections (8 Adverse Reactions Most Commonly,1
CIMZIA,histoplasmosis,infections (8 Adverse,1
CIMZIA,histoplasmosis,urinary tract,0
CIMZIA,histoplasmosis,infections (8 Adverse Reactions,1
CIMZIA,invasive fungal infections,and urinary tract   Adverse Reactions Most C ommonly Leading to Discontinuation of,1
CIMZIA,invasive fungal infections,infections (8 Adverse Reactions,1
CIMZIA,invasive fungal infections,tract   Adverse Reactions Most C ommonly Leading to,1
CIMZIA,invasive fungal infections,infections (8 Adverse Reactions,1
CIMZIA,invasive fungal infections,Controlled Trials,0
CIMZIA,invasive fungal infections,rash and urinary,0
CIMZIA,invasive fungal infections,and urinary tract Adverse,1
CIMZIA,invasive fungal infections,urinary tract Adverse Reactions Most C,1
CIMZIA,invasive fungal infections,and urinary tract Adverse Reactions,1
CIMZIA,Lymphoma,The data described,0
CIMZIA,Lymphoma,lect exp osure to,1
CIMZIA,Lymphoma,The data described,0
CIMZIA,Lymphoma,with Crohns Disease,0
CIMZIA,Lymphoma,below lect,1
CIMZIA,malignancies,studies of patients with Crohns disease In the safety,0
CIMZIA,malignancies,at 400 mg,1
CIMZIA,malignancies,Studies with Crohns Disease The data described below reflect exposure to CI,0
CIMZIA,malignancies,population,0
CIMZIA,malignancies,reflect exposure to MZIA at 400,1
CIMZIA,malignancies,reflect exposure to MZIA at 400  mg subcutaneous dosing in,1
CIMZIA,malignancies,reflect exposure to MZIA at 400,1
CIMZIA,malignancies,below reflect exposure to CI,0
CIMZIA,fatal,studies of patients with Crohns,0
CIMZIA,fatal,utane ous,1
CIMZIA,fatal,utane ous dosing in,1
CIMZIA,fatal,utane ous,1
CIMZIA,fatal,reflect,0
CIMZIA,fatal,utane ous dosing in,1
CIMZIA,fatal,utane ous dosing in studies,1
CIMZIA,fatal,utane ous dosing in,1
CIMZIA,fatal,utane,1
CIMZIA,INFECTIONS,to placebo,1
CIMZIA,INFECTIONS,placebo including,0
CIMZIA,INFECTIONS,mg and subjects received placebo including subjects randomized,0
CIMZIA,INFECTIONS,to placebo in Study CD following open,1
CIMZIA,MALIGNANCY,at Weeks In controlled and uncontrolled,0
CIMZIA,infections,controlled and uncontrolled studies ients rece,1
CIMZIA,infections,at some dose level of whom patients received mg CIMZIA,0
CIMZIA,infections,dose level of whom patients received mg CIMZIA Approximately,0
CIMZIA,infections,and uncontrolled studies,0
CIMZIA,infections,ients rece ived CIMZIA at,1
CIMZIA,infections,open label dosing of CIMZIA,0
CIMZIA,infections,CIMZIA at,0
CIMZIA,infections,In controlled and uncontrolled studies,0
CIMZIA,death,Approximately of,0
CIMZIA,death,dose  of w hom,1
CIMZIA,death,Approximately of,0
CIMZIA,death,at some dose  of w,1
CIMZIA,death,Approximately of,0
CIMZIA,death,and uncontrolled studies patients received CIMZIA at some dose,0
CIMZIA,tuberculosis,atients rece ived mg,1
CIMZIA,TB,ed mg CIMZIA Approximately of subjects,1
CIMZIA,TB,atients rece ived mg,1
CIMZIA,TB,male,0
CIMZIA,TB,ed mg CIMZIA Approximately of subjects,1
CIMZIA,TB,studies patients received CIMZIA at some dose level of whom,0
CIMZIA,TB,ed mg CIMZIA Approximately of,1
CIMZIA,TB,and,0
CIMZIA,TB,male and were,0
CIMZIA,TB,ed,1
CIMZIA,TB,patients ed mg CIMZIA Approximately,1
CIMZIA,TB,ed,1
CIMZIA,TB,ed mg CIMZIA Approximately,1
CIMZIA,TB,ed,1
CIMZIA,bacterial sepsis,CIMZIA. App,1
CIMZIA,invasive fungal infections,received mg CIMZIA ximately 55% of subjects,1
CIMZIA,invasive fungal infections,of subjects w ere,1
CIMZIA,invasive fungal infections,patients received mg CIMZIA ximately 55% of subjects w ere female,1
CIMZIA,invasive fungal infections,of subjects w ere,1
CIMZIA,invasive fungal infections,of,0
CIMZIA,invasive fungal infections,patients received mg CIMZIA ximately 55% of subjects w ere female were,1
CIMZIA,invasive fungal infections,of,0
CIMZIA,histoplasmosis,were between the,0
CIMZIA,histoplasmosis,"Approximately of subjects were , 45% were",1
CIMZIA,histoplasmosis,received mg CIMZIA Approximately of,0
CIMZIA,histoplasmosis,"were , 45% were mal",1
CIMZIA,histoplasmosis,received mg CIMZIA Approximately of,0
CIMZIA,histoplasmosis,mg CIMZIA Approximately of subjects,0
CIMZIA,infections due to other opportunistic pathogens,female were male and,0
CIMZIA,infections due to other opportunistic pathogens,were male 94% were Caucasian. The majority of patients in the,1
CIMZIA,infections due to other opportunistic pathogens,female were male and,0
CIMZIA,Lymphoma,acebo) i n controlled clinical,1
CIMZIA,malignancies,in d clinical s,1
CIMZIA,malignancies,acebo) i n controlled clinical,1
CIMZIA,malignancies,placebo in d,1
CIMZIA,malignancies,to placebo in d,1
CIMZIA,malignancies,placebo in d clinical s,1
CIMZIA,malignancies,a higher incidence,0
CIMZIA,malignancies,clinical s tudies,1
CIMZIA,malignancies,in d clinical,1
CIMZIA,malignancies,in,0
CIMZIA,malignancies,placebo in d clinical,1
CIMZIA,Invasive fungal infections,ADVERSE,0
CIMZIA,Invasive fungal infections,"TIONS,",1
CIMZIA,Invasive fungal infections,FDA at FDA,0
CIMZIA,Invasive fungal infections,"TIONS, contact UCB, Inc. a",1
CIMZIA,lymphoma,Infections see Wa,0
CIMZIA,lymphoma,rnings a nd Precautions Malignancies see Warnings,1
CIMZIA,lymphoma,Infections see Wa,0
CIMZIA,lymphoma,nd Precautions,0
CIMZIA,lymphoma,rnings a nd Precautions Malignancies see Warnings,1
CIMZIA,lymphoma,were Serious Infections see rnings a,1
CIMZIA,malignancies,Warnings and ons (5.1)  ] Malignancies see Warnings and,1
CIMZIA,malignancies,were Serious Infections see rnings a,1
CIMZIA,malignancies,The,0
CIMZIA,"Heart failure, worsening",varying and,0
CIMZIA,"Heart failure, worsening",Precautions Heart ailure [see Warnings,1
CIMZIA,"Heart failure, worsening",[see Warnings an,1
CIMZIA,"Heart failure, worsening",and,0
CIMZIA,"Heart failure, worsening",and Precautions Heart ailure [see  Warnings an,1
CIMZIA,"Heart failure, worsening",and,0
CIMZIA,"Heart failure, worsening",Heart ailure [see,1
CIMZIA,"Heart failure, worsening",clinical studies are conducted under widely varying,0
CIMZIA,"Heart failure, worsening",Heart,0
CIMZIA,"Heart failure, worsening",ailure [see  Warnings an d Precautions,1
CIMZIA,"Heart failure, worsening",Heart,0
CIMZIA,Anaphylaxis,widely varying and controlled conditions adverse reaction rates observed in,0
CIMZIA,Anaphylaxis,Failure see Warnings and,0
CIMZIA,Anaphylaxis,Precautions Heart Failure see Warnings and Precautions,0
CIMZIA,Anaphylaxis,conducted under widely varying and controlled,0
CIMZIA,Anaphylaxis,reaction,0
CIMZIA,Anaphylaxis,Precautions,0
CIMZIA,Anaphylaxis,Because cl,0
CIMZIA,Anaphylaxis,under widely varying and controlled conditions,0
CIMZIA,allergic reactions,are ucted,1
CIMZIA,allergic reactions,in,0
CIMZIA,allergic reactions,Because clinical studies are ucted under widely varying and,1
CIMZIA,allergic reactions,in,0
CIMZIA,allergic reactions,Because clinical,0
CIMZIA,allergic reactions,clinical studies are ucted under widely varying and,1
CIMZIA,allergic reactions,Because clinical,0
CIMZIA,allergic reactions,studies are ucted under widely varying and,1
CIMZIA,allergic reactions,Because clinical,0
CIMZIA,Hepatitis B virus reactivation,rates in the clinical studi,0
CIMZIA,Hepatitis B virus reactivation,Because clinical studies are conducted under widely varying and controlled,0
CIMZIA,Hepatitis B virus reactivation,"widely varying and controlled nditions,",1
CIMZIA,Hepatitis B virus reactivation,"widely varying and controlled nditions, adverse reaction",1
CIMZIA,Hepatitis B virus reactivation,"nditions, adverse reaction rat es observed in clinical",1
CIMZIA,Hepatitis B virus reactivation,"widely varying and controlled nditions, adverse reaction",1
CIMZIA,Hepatitis B virus reactivation,to rates in,0
CIMZIA,Hepatitis B virus reactivation,Because clinical studies,0
CIMZIA,Hepatitis B virus reactivation,widely varying,0
CIMZIA,Hepatitis B virus reactivation,to rates in the,0
CIMZIA,Demyelinating disease,"a broader patient population n clinical practice.
 In premarketing controlled",1
CIMZIA,Demyelinating disease,to rates in the,0
CIMZIA,Cytopenias,clinical practice In premarketing,0
CIMZIA,Cytopenias,opulations combined the,1
CIMZIA,Cytopenias,patient opulations combined the most common,1
CIMZIA,Cytopenias,opulations combined the,1
CIMZIA,Cytopenias,In,0
CIMZIA,pancytopenia,adverse reactions were upper respiratory infections rash and,0
CIMZIA,pancytopenia,ombined,1
CIMZIA,pancytopenia,all patient populations ombined,1
CIMZIA,Lupus-like syndrome,rash and urinary tract %). Adverse,1
CIMZIA,Lupus-like syndrome,"and urinary tract %).



     Adverse",1
CIMZIA,Lupus-like syndrome,rash and urinary tract %). Adverse,1
CIMZIA,Lupus-like syndrome,%). Adverse Reactions Most Commonly,1
CIMZIA,Lupus-like syndrome,"tract %).



     Adverse Reactions",1
CIMZIA,Lupus-like syndrome,%). Adverse Reactions Most Commonly,1
CIMZIA,Lupus-like syndrome,%). Adverse Reactions,1
CIMZIA,Lupus-like syndrome,"and urinary tract %).



     Adverse Reactions",1
CIMZIA,Lupus-like syndrome,%). Adverse Reactions,1
CIMZIA,Lupus-like syndrome,%). Adverse Reactions Most Commonly,1
CIMZIA,infections,who,0
CIMZIA,infections,ons in the controlled clinical studies,1
CIMZIA,infections,to,0
CIMZIA,death,for CIMZIA and for,0
CIMZIA,death,was for CIMZIA and for placebo The,0
CIMZIA,death,for placebo The most mon,1
CIMZIA,death,CIMZIA and,0
CIMZIA,death,The most mon a,1
CIMZIA,death,CIMZIA and,0
CIMZIA,death,CIMZIA and for placebo The most com,0
CIMZIA,death,mon a dverse reactions,1
CIMZIA,Opportunistic infections,for,0
CIMZIA,Opportunistic infections,a higher incidence than,0
CIMZIA,Opportunistic infections,common  reactions leading to th e,1
CIMZIA,Opportunistic infections,a higher incidence than,0
CIMZIA,Opportunistic infections,placebo The most common,0
CIMZIA,Opportunistic infections,reactions leading to th e discontinuation of CIMZIA,1
CIMZIA,Opportunistic infections,reactions leading to th,1
CIMZIA,Opportunistic infections,reactions leading to th,1
CIMZIA,Opportunistic infections, reactions leading to th e,1
CIMZIA,Opportunistic infections,reactions leading to th,1
CIMZIA,aspergillosis,in (0.4% CIMZ IA,1
CIMZIA,aspergillosis,reactions leading to th,1
CIMZIA,aspergillosis,patients and with a,0
CIMZIA,aspergillosis,were abdominal in (0.4% CIMZ,1
CIMZIA,aspergillosis,(0.4% CIMZ IA placebo,1
CIMZIA,aspergillosis,were abdominal in (0.4% CIMZ IA placebo diarrhea CIMZIA placebo,1
CIMZIA,aspergillosis,(0.4% CIMZ IA placebo,1
CIMZIA,blastomycosis,", 0.2%",1
CIMZIA,blastomycosis,"abdominal pain , 0.2% placeb o diarrhea CIMZIA placebo and",1
CIMZIA,blastomycosis,", 0.2%",1
CIMZIA,blastomycosis,placebo and intestinal,0
CIMZIA,blastomycosis,", 0.2%",1
CIMZIA,blastomycosis,", 0.2% placeb",1
CIMZIA,blastomycosis,"placebo were abdominal pain , 0.2% placeb o diarrhea CIMZIA",1
CIMZIA,blastomycosis,", 0.2% placeb",1
CIMZIA,blastomycosis,", 0.2% placeb o diarrhea CIMZIA",1
CIMZIA,blastomycosis,obstruction,0
CIMZIA,candidiasis,", diarrhea CIMZIA placebo",1
CIMZIA,candidiasis,CIMZIA,0
CIMZIA,candidiasis,", diarrhea",1
CIMZIA,candidiasis,"were abdominal pain CIMZIA ,",1
CIMZIA,candidiasis,", diarrhea",1
CIMZIA,candidiasis,patients and with a higher incidence than placebo were abdominal,0
CIMZIA,coccidioidomycosis,".4% CIMZIA, 0%",1
CIMZIA,coccidioidomycosis,pain CIMZIA placebo .4%,1
CIMZIA,coccidioidomycosis,0% pla cebo,1
CIMZIA,coccidioidomycosis,and intestinal,0
CIMZIA,histoplasmosis,proportion,0
CIMZIA,histoplasmosis,"placebo diarrhea CIMZIA bo), and intes",1
CIMZIA,histoplasmosis,"CIMZIA bo), and",1
CIMZIA,histoplasmosis,"diarrhea CIMZIA bo), and intes tinal obstruction CIMZIA",1
CIMZIA,histoplasmosis,"CIMZIA bo), and",1
CIMZIA,histoplasmosis,"diarrhea CIMZIA bo), and intes tinal obstruction",1
CIMZIA,histoplasmosis,"CIMZIA bo), and",1
CIMZIA,histoplasmosis,"placebo diarrhea CIMZIA bo), and intes",1
CIMZIA,histoplasmosis,placebo The proportion of patients with,0
CIMZIA,legionellosis,arthritis who,0
CIMZIA,legionellosis,and nal obstructi,1
CIMZIA,legionellosis,arthritis who,0
CIMZIA,tuberculosis,on of patients with rheumatoid arthritis who discontinued treatment due,0
CIMZIA,tuberculosis,The proporti on,1
CIMZIA,tuberculosis,CIMZIA The,1
CIMZIA,infection,CIMZIA at mg subcutaneous ing in,1
CIMZIA,infection,ing in st udies of patients with,1
CIMZIA,infection,CIMZIA at mg subcutaneous ing in,1
CIMZIA,reactivation of tuberculosis,"emale, 45% were male, and 94 were Caucasian",1
CIMZIA,reactivation of tuberculosis,CIMZIA at mg subcutaneous ing in,1
CIMZIA,reactivation of tuberculosis,"of subjects were emale, 45% were male, and 94",1
CIMZIA,reactivation of tuberculosis,CIMZIA at mg subcutaneous ing in,1
CIMZIA,reactivation of tuberculosis,whom patients received mg CIMZIA Approximately of subjects,0
CIMZIA,tuberculosis infections,and were aucasian. The majority  of patients in the,1
CIMZIA,tuberculosis infections,whom patients received mg CIMZIA Approximately of subjects,0
CIMZIA,tuberculosis infections,subjects were female were male and,0
CIMZIA,tuberculosis infections,aucasian. The majority  of patients in the active,1
CIMZIA,tuberculosis infections,subjects were female were male and,0
CIMZIA,malignancies,Period of Rheumatoid Arthritis Studies with Concomitant Methotrexate Adverse ReactionPre,0
CIMZIA,malignancies,Dosed Every Other Week Placebo-Cont rolled,1
CIMZIA,malignancies,Period of Rheumatoid Arthritis Studies with Concomitant Methotrexate Adverse ReactionPre,0
CIMZIA,malignancies,Every Other,0
CIMZIA,malignancies,Arthritis Studies,0
CIMZIA,malignancies,during,0
CIMZIA,malignancies,rolled Period,0
CIMZIA,malignancies,Studies with Concomitant Methotrexate Adverse,0
CIMZIA,malignancies,Week Placebo-Cont rolled Period,1
CIMZIA,malignancies,Studies with Concomitant Methotrexate Adverse,0
CIMZIA,malignancies,piratory tract infection,0
CIMZIA,malignancies,Upper res,1
CIMZIA,malignancies,CIMZIA mg EOW,0
CIMZIA,malignancies,Upper res piratory,1
CIMZIA,malignancies,MTXN CIMZIA mg EOW,0
CIMZIA,malignancies,EOW Upper res,1
CIMZIA,malignancies,CIMZIA mg EOW MTXN,0
CIMZIA,malignancies,Upper res piratory tract infection,1
CIMZIA,malignancies,"CIMZIA mg EOW  
 Upper res piratory tract",1
CIMZIA,malignancies,Upper res piratory tract infection,1
CIMZIA,malignancies,"MTXN CIMZIA mg EOW  
 Upper res piratory tract",1
CIMZIA,malignancies,Upper res piratory tract infection,1
CIMZIA,lymphoma,teroidal antiinflammatory,1
CIMZIA,lymphoma,patients rec,0
CIMZIA,lymphoma,controlled clinical trials had similar adverse reactions,0
CIMZIA,lymphoma,patients eiving C,1
CIMZIA,lymphoma,those patients eiving C IMZIA,1
CIMZIA,lymphoma,patients eiving C,1
CIMZIA,Hodgkin's lymphoma,e Reactions Other infrequent adverse,1
CIMZIA,Hodgkin's lymphoma,every other week Other e Reactions,1
CIMZIA,Hodgkin's lymphoma,Other e Reactions,1
CIMZIA,Hodgkin's lymphoma,e Reactions Other infrequent adverse,1
CIMZIA,Hodgkin's lymphoma,Other,0
CIMZIA,Hodgkin's lymphoma,those patients,0
CIMZIA,Hodgkin's lymphoma,receiving CIMZIA mg every other,0
CIMZIA,Hodgkin's lymphoma,Other Advers,0
CIMZIA,Hodgkin's lymphoma,week Other e,1
CIMZIA,lymphoma,"
     Ps oriatic Arthritis Clinical",1
CIMZIA,lymphoma,CIMZIA has been studied in patients with psoriatic arthri,0
CIMZIA,lymphoma,CIMZIA was,0
CIMZIA,lymphoma,was similar to the ty profi le,1
CIMZIA,lymphoma,CIMZIA was,0
CIMZIA,lymphoma,similar to the ty,1
CIMZIA,lymphoma,with RA Infections,0
CIMZIA,lymphoma,AS The safety profile for patients in study AS treated with CIMZIA was similar to the safe,0
CIMZIA,lymphoma,RA,0
CIMZIA,lymphoma,safety profile for patients in study AS treated with CIMZIA was,0
CIMZIA,lymphoma,to the ty,1
CIMZIA,lymphoma,to the ty profi,1
CIMZIA,lymphoma,to the ty,1
CIMZIA,lymphoma,was similar to,0
CIMZIA,hepatosplenic T-cell lymphoma,tions consisted primarily of upper respiratory infections for,1
CIMZIA,hepatosplenic T-cell lymphoma,tions consisted primarily of upper respiratory infections for CIMZIA,1
CIMZIA,hepatosplenic T-cell lymphoma,for placebotreated patients The tions consisted primarily of  upper respiratory infections,1
CIMZIA,hepatosplenic T-cell lymphoma,tions consisted primarily of upper respiratory infections for CIMZIA,1
CIMZIA,hepatosplenic T-cell lymphoma,patients The tions,1
CIMZIA,hepatosplenic T-cell lymphoma,patients The tions consisted primarily of  upper,1
CIMZIA,hepatosplenic T-cell lymphoma,patients The tions,1
CIMZIA,hepatosplenic T-cell lymphoma,The tions consisted primarily of  upper respiratory infections for CIMZIA,1
CIMZIA,hepatosplenic T-cell lymphoma,patients The tions,1
CIMZIA,hepatosplenic T-cell lymphoma,patients The tions consisted primarily of,1
CIMZIA,hepatosplenic T-cell lymphoma,placebotreated patients The tions consisted primarily of,1
CIMZIA,hepatosplenic T-cell lymphoma,tions consisted primarily of,1
CIMZIA,hepatosplenic T-cell lymphoma,The tions,1
CIMZIA,HSTCL,of per r espiratory infections,1
CIMZIA,HSTCL,The tions,1
CIMZIA,HSTCL,of per,1
CIMZIA,HSTCL,infections consisted primarily,0
CIMZIA,HSTCL,of serious,0
CIMZIA,HSTCL,infections consisted primarily of per r,1
CIMZIA,HSTCL,of serious,0
CIMZIA,fatal,incidence of serious s dur ing the controlled clinical,1
CIMZIA,fatal,of serious,0
CIMZIA,fatal,CIMZIA for placebo The incidence of serious,0
CIMZIA,chronic leukemia,groups,0
CIMZIA,chronic leukemia,serious fection,1
CIMZIA,chronic leukemia,fection adverse  reactions,1
CIMZIA,chronic leukemia,serious fection,1
CIMZIA,chronic leukemia,fection adverse reactions,1
CIMZIA,chronic leukemia,of serious fection,1
CIMZIA,chronic leukemia,fection adverse reactions in,1
CIMZIA,chronic leukemia,serious fection adverse,1
CIMZIA,chronic leukemia,fection adverse reactions in the CIMZIA treatment,1
CIMZIA,chronic leukemia,CIMZIA treatment groups compared to the placebo groups per patientyear for,0
CIMZIA,chronic leukemia,reactions in the CIMZIA treatment groups compared to the placebo groups per patientyear,0
CIMZIA,worsening congestive heart failure,no serious infection occurred in more than one subject There,1
CIMZIA,worsening congestive heart failure,placebo,0
CIMZIA,worsening congestive heart failure,"placebo , no serious infection occurred in",1
CIMZIA,worsening congestive heart failure,placebo,0
CIMZIA,worsening congestive heart failure,pyelonephritis,0
CIMZIA,new onset CHF,one subject.,1
CIMZIA,new onset CHF,one subject.  There,1
CIMZIA,new onset CHF,one subject.,1
CIMZIA,worsening congestive heart failure,Infections I,0
CIMZIA,worsening congestive heart failure,Infections I,0
CIMZIA,worsening congestive heart failure,Opportunistic Infections n completed and,1
CIMZIA,worsening congestive heart failure,the overall rate of tuberc,0
CIMZIA,worsening congestive heart failure,Opportunistic Infections n completed and,1
CIMZIA,worsening congestive heart failure,completed and ongoing global cli nical studies in all,1
CIMZIA,worsening congestive heart failure,all indications including CIMZIAtreated,0
CIMZIA,worsening congestive heart failure,Opportunistic,0
CIMZIA,worsening congestive heart failure,Tuberculosis and Opportunistic Infections,0
CIMZIA,worsening congestive heart failure,n completed and ongoing global,1
CIMZIA,CHF,din g CIMZIAtreated,1
CIMZIA,CHF,din g CIMZIAtreated patients,1
CIMZIA,CHF,all indications din g CIMZIAtreated patients,1
CIMZIA,CHF,din g CIMZIAtreated patients,1
CIMZIA,CHF,completed and ongoing global,0
CIMZIA,CHF,din g CIMZIAtreated patients,1
CIMZIA,CHF,g CIMZIAtreated patients the overall rate of tuberculosis is approximately,0
CIMZIA,hypersensitivity reactions,ude,1
CIMZIA,hypersensitivity reactions,"ude cases of miliary, lymp hatic peritoneal as well as",1
CIMZIA,hypersensitivity reactions,median time to onset of TB for all patients exposed,0
CIMZIA,angioedema,indications was days In the studies with CIMZIA,0
CIMZIA,angioedema,for all patients,1
CIMZIA,angioedema,to onset TB,1
CIMZIA,angioedema,to onset TB for all patients exposed to CIMZIA,1
CIMZIA,angioedema,to onset TB,1
CIMZIA,angioedema,pulmonary TB The,0
CIMZIA,hypotension,as pulmonary TB The median time to onset of TB for all,0
CIMZIA,hypotension,IMZIA across all indications was days In the studies,0
CIMZIA,hypotension,days In the studies with CIMZIA in RA there were,0
CIMZIA,hypotension,xposed to C IMZIA,1
CIMZIA,hypotension,days In the studies with CIMZIA in RA there were,0
CIMZIA,hypotension,to C IMZIA across,1
CIMZIA,hypotension,for all patients xposed to,1
CIMZIA,hypotension,to C,1
CIMZIA,rash,exposed to ZIA  across all indications was days,1
CIMZIA,rash,to C,1
CIMZIA,rash,ZIA  across,1
CIMZIA,serum sickness,all indic ations was days,1
CIMZIA,serum sickness,CIMZIA ross all indic ations was days In the,1
CIMZIA,serum sickness,all indic ations was days,1
CIMZIA,serum sickness,RA,0
CIMZIA,serum sickness,CIMZIA in,0
CIMZIA,serum sickness,CIMZIA ross all,1
CIMZIA,serum sickness,ross all indic ations was days,1
CIMZIA,reactivation of hepatitis B virus,rol patients see Warnings and Precautions Heart,0
CIMZIA,reactivation of hepatitis B virus,receiving,0
CIMZIA,reactivation of hepatitis B virus,ose TNF blockers compared to cont rol patients see,1
CIMZIA,reactivation of hepatitis B virus,For some TNF blockers more cases,0
CIMZIA,reactivation of hepatitis B virus,malignancies have been,0
CIMZIA,reactivation of hepatitis B virus,compared to cont rol,1
CIMZIA,reactivation of hepatitis B virus,Failure,0
CIMZIA,HBV reactivation,patients see Warnings and,0
CIMZIA,HBV reactivation,of new or worsening,0
CIMZIA,HBV reactivation,"and Precautions Heart ailure    



 I n placebocontrolled and",1
CIMZIA,HBV reactivation,of new or worsening,0
CIMZIA,HBV reactivation,"and Precautions Heart ailure    



 I n placebocontrolled and",1
CIMZIA,HBV reactivation,of new or worsening,0
CIMZIA,HBV reactivation,ckers compared to control patients see Warnings,0
CIMZIA,HBV reactivation,ailure I n placebocontrolled,1
CIMZIA,HBV reactivation,ailure I n placebocontrolled and openlabel rheumatoid,1
CIMZIA,HBV reactivation,ailure I,1
CIMZIA,fatal,"dies, cases of new or",1
CIMZIA,fatal,"dies, cases of new or worsening",1
CIMZIA,fatal,"openlabel rheumatoid arthritis dies, cases",1
CIMZIA,fatal,"dies, cases of new or worsening",1
CIMZIA,fatal,placebocontrolled,0
CIMZIA,fatal,arthritis stu,0
CIMZIA,fatal,"dies, cases",1
CIMZIA,HBV reactivation,moderate and occurred ng the,1
CIMZIA,HBV reactivation,Autoantibodies In clini,0
CIMZIA,HBV reactivation,to moderate and occurred ng the,1
CIMZIA,HBV reactivation,see,0
CIMZIA,HBV reactivation,occurred ng the,1
CIMZIA,HBV reactivation,and Precautions,0
CIMZIA,HBV reactivation,first yea r of exposure see,1
CIMZIA,HBV reactivation,moderate and occurred ng the first yea,1
CIMZIA,HBV reactivation,Precautions Autoantibodies,0
CIMZIA,HBV reactivation,ng the first yea r,1
CIMZIA,central nervous system demyelinating disease,treated with t immunosuppressants had a lower rate of ant,1
CIMZIA,central nervous system demyelinating disease,with t immunosuppressants had a lower rate of ant,1
CIMZIA,central nervous system demyelinating disease,treated with t immunosuppressants had a lower rate of ant,1
CIMZIA,peripheral demyelinating disease,immunosuppressants had a lower rate,0
CIMZIA,peripheral demyelinating disease,than patients not g immunosuppressants at baseline and respectively The following adverse,1
CIMZIA,peripheral demyelinating disease,immunosuppressants had a lower rate,0
CIMZIA,peripheral demyelinating disease,than,0
CIMZIA,peripheral demyelinating disease,patients not g immunosuppressants at baseline,1
CIMZIA,peripheral demyelinating disease,than,0
CIMZIA,peripheral demyelinating disease,not g immunosuppressants at baseline and respectively The following,1
CIMZIA,peripheral demyelinating disease,than,0
CIMZIA,peripheral demyelinating disease,g,1
CIMZIA,peripheral demyelinating disease,patients not g immunosuppressants at baseline and respectively,1
CIMZIA,peripheral demyelinating disease,g,1
CIMZIA,Guillain-Barre syndrome,patients who were antibodypositive N,0
CIMZIA,Guillain-Barre syndrome,"immunosuppressants at baseline , respectively). The fo",1
CIMZIA,Guillain-Barre syndrome,patients who were antibodypositive N,0
CIMZIA,Guillain-Barre syndrome,were antibodypositive,0
CIMZIA,Guillain-Barre syndrome,at,0
CIMZIA,Guillain-Barre syndrome,at,0
CIMZIA,Guillain-Barre syndrome,"taking immunosuppressants at baseline , respectively).",1
CIMZIA,Guillain-Barre syndrome,than patients not taking immunosuppressants at baseline and,0
CIMZIA,Guillain-Barre syndrome,"taking immunosuppressants at baseline , respectively). The fo llowing",1
CIMZIA,Guillain-Barre syndrome,than patients not taking immunosuppressants at baseline and,0
CIMZIA,Guillain-Barre syndrome,who were antibodypositive,0
CIMZIA,Guillain-Barre syndrome,"baseline ,",1
CIMZIA,neurological disorders,"(N = 1,242): abdomina l pain arthralgia edema peripheral",1
CIMZIA,seizure disorder,"pain ralgia, edema pe ripheral erythema",1
CIMZIA,seizure disorder,"(N = 1,242): abdomina l pain arthralgia edema peripheral",1
CIMZIA,seizure disorder,abdominal,0
CIMZIA,seizure disorder,"N abdominal pain ralgia, edema pe ripheral erythema nodosum injection",1
CIMZIA,seizure disorder,abdominal,0
CIMZIA,seizure disorder,"pain ralgia, edema",1
CIMZIA,seizure disorder,"ralgia, edema pe ripheral erythema nodosum injection site",1
CIMZIA,seizure disorder,edema pe ripheral,1
CIMZIA,seizure disorder,"N abdominal pain ralgia, edema pe ripheral erythema nodosum injection site",1
CIMZIA,seizure disorder,edema pe ripheral,1
CIMZIA,seizure disorder,in,0
CIMZIA,seizure disorder,N,0
CIMZIA,optic neuritis,injection,0
CIMZIA,optic neuritis,"pheral, erythe ma nodosum",1
CIMZIA,optic neuritis,"pheral, erythe ma nodosum injection",1
CIMZIA,optic neuritis,"pheral, erythe ma nodosum",1
CIMZIA,optic neuritis,upper,0
CIMZIA,optic neuritis,peri,0
CIMZIA,optic neuritis,"pheral, erythe ma",1
CIMZIA,optic neuritis,arthralgia,0
CIMZIA,peripheral neuropathy,edema peripheral erythema nod,0
CIMZIA,peripheral neuropathy,pain pain in extremity and upper respiratory,0
CIMZIA,peripheral neuropathy,"osum, injection site",1
CIMZIA,peripheral neuropathy,pain in extremity and upper respiratory,0
CIMZIA,peripheral neuropathy,infection The,0
CIMZIA,peripheral neuropathy,"peripheral erythema osum, injection site  erythema injection site",1
CIMZIA,peripheral neuropathy,infection The,0
CIMZIA,peripheral neuropathy,site,0
CIMZIA,peripheral neuropathy,pain pain in extremity,0
CIMZIA,peripheral neuropathy,"osum, injection site  erythema injection site",1
CIMZIA,peripheral neuropathy,pain pain in extremity,0
CIMZIA,peripheral neuropathy,"peripheral erythema osum, injection site  erythema injection site pain pain",1
CIMZIA,peripheral neuropathy,pain pain in extremity,0
CIMZIA,pancytopenia,percentage of patients with to certolizu mab pegol detectable on at,1
CIMZIA,pancytopenia,pain pain in extremity,0
CIMZIA,pancytopenia,to certolizu mab pegol,1
CIMZIA,pancytopenia,with to certolizu mab pegol detectable,1
CIMZIA,pancytopenia,to certolizu mab pegol,1
CIMZIA,pancytopenia,with to certolizu,1
CIMZIA,pancytopenia,to certolizu mab pegol,1
CIMZIA,aplastic anemia,tectable on at least one occasion was,1
CIMZIA,aplastic anemia,overall percentage of patients with,0
CIMZIA,aplastic anemia,of patients with antibodies to,0
CIMZIA,aplastic anemia,percentage of patients,0
CIMZIA,aplastic anemia,certolizumab pegol tectable on at  least one,1
CIMZIA,aplastic anemia,percentage of patients,0
CIMZIA,aplastic anemia,certolizumab pegol tectable on at  least one occasion,1
CIMZIA,aplastic anemia,percentage of patients,0
CIMZIA,aplastic anemia,certolizumab pegol tectable,1
CIMZIA,aplastic anemia,on at least one occasion,1
CIMZIA,Adverse reactions of the hematologic system,antibodies with,0
CIMZIA,Adverse reactions of the hematologic system,of,0
CIMZIA,Adverse reactions of the hematologic system,was  in the rheumatoid arthritis placebo-contro lled trials Approximately one,1
CIMZIA,Adverse reactions of the hematologic system,of,0
CIMZIA,Adverse reactions of the hematologic system,in the rheumatoid arthritis placebo-contro lled trials Approximately one,1
CIMZIA,Adverse reactions of the hematologic system,in the rheumatoid arthritis placebo-contro,1
CIMZIA,Adverse reactions of the hematologic system,occasion,0
CIMZIA,Adverse reactions of the hematologic system,arthritis placebo-contro lled trials,1
CIMZIA,Adverse reactions of the hematologic system,arthritis placebo-contro lled,1
CIMZIA,Adverse reactions of the hematologic system,ents with antibodies to certolizumab pegol,0
CIMZIA,Adverse reactions of the hematologic system,on at least one occasion was,0
CIMZIA,cytopenia,of in the rheumatoid arthritis,0
CIMZIA,cytopenia,arthritis placebocontrolled trials Approximately,0
CIMZIA,cytopenia,"Approximately one rd (3%, 3 of",1
CIMZIA,cytopenia,arthritis placebocontrolled trials Approximately,0
CIMZIA,cytopenia,one,0
CIMZIA,cytopenia,"rd (3%, 3 of of these",1
CIMZIA,cytopenia,of in the rheumatoid,0
CIMZIA,cytopenia,arthritis placebocontrolled trials Approximately one,0
CIMZIA,cytopenia,rheumatoid arthritis placebocontrolled,0
CIMZIA,cytopenia,"trials Approximately one rd (3%, 3 of of",1
CIMZIA,cytopenia,rheumatoid arthritis placebocontrolled,0
CIMZIA,cytopenia,"one rd (3%, 3 of of these patients had",1
CIMZIA,cytopenia,rheumatoid arthritis placebocontrolled,0
CIMZIA,leukopenia,09) of the se patients,1
CIMZIA,leukopenia,patients had antibodies with neutralizing activity in vitro Patients,0
CIMZIA,leukopenia,trials Approximately one third 09) of,1
CIMZIA,leukopenia,antibodies with neutralizing activity in vitro,0
CIMZIA,leukopenia,09) of,1
CIMZIA,leukopenia,third of,0
CIMZIA,leukopenia,trials Approximately one third,0
CIMZIA,leukopenia,Approximately one third 09) of the,1
CIMZIA,leukopenia,trials Approximately one third,0
CIMZIA,pancytopenia,placebocontrolled trials Approximately,0
CIMZIA,pancytopenia,Approximately one,0
CIMZIA,pancytopenia,patients ha d,1
CIMZIA,pancytopenia,placebocontrolled trials,0
CIMZIA,pancytopenia,trials Approximately one third of of,0
CIMZIA,pancytopenia,of patients ha,1
CIMZIA,thrombocytopenia,vitro Patients treated with,0
CIMZIA,infections,"X, the ACR response was",1
CIMZIA,infections,"with concomitant X, the",1
CIMZIA,infections,the ACR response was lower among,1
CIMZIA,infections,"X, the ACR response was lower",1
CIMZIA,infections,recommended CIMZIA dosage of mg,0
CIMZIA,infections,"concomitant X, the ACR",1
CIMZIA,infections,"concomitant X, the ACR",1
CIMZIA,infections,"concomitant X, the ACR",1
CIMZIA,infections,"X, the ACR response was lower among",1
CIMZIA,infections,d antibodi es,1
CIMZIA,infections,patients d antibodi es to allow for meaningful,1
CIMZIA,infections,d antibodi es,1
CIMZIA,infections,RAIII too few patients d antibodi,1
CIMZIA,infections,RAIII too few patients d antibodi,1
CIMZIA,infections,ACR,0
CIMZIA,infections,RAII versus respectively In Study RAIII too few patients,0
CIMZIA,infections,d antibodi,1
CIMZIA,infections,RAIII too few patients d antibodi,1
CIMZIA,infections,d antibodi,1
CIMZIA,infections,es to allow for meaningful analysis of ACR,0
CIMZIA,lupus-like syndrome,including,0
CIMZIA,lupus-like syndrome,ELISA and are highly ent on the,1
CIMZIA,lupus-like syndrome,the sensitiv ity and,1
GRANIX,Splenic Rupture,of the Splenic,1
GRANIX,Splenic Rupture,other sections of the Splenic Rupture,1
GRANIX,Splenic Rupture,the Splenic Rupture,1
GRANIX,Splenic Rupture,Syndrome,0
GRANIX,Splenic Rupture,other sections of the Splenic,1
GRANIX,Splenic Rupture,sections of the Splenic Rupture see Warnings,1
GRANIX,Splenic Rupture,other sections of the Splenic,1
GRANIX,Splenic Rupture,serious adverse reactions are discussed in greater detail in,0
GRANIX,Splenic Rupture,Splenic Rupture see Warnings and,1
GRANIX,Acute Respiratory Distress Syndrome,of the labeling Splenic Rupture see,0
GRANIX,Allergic Reactions,see Warnings and Precautions Allergic,1
GRANIX,Capillary Leak Syndrome,Cell Disease see Warnings and Precautions,0
GRANIX,Capillary Leak Syndrome,Warnings and Capillary Leak Syndrome see Warnings and Precautions Potential,1
GRANIX,Capillary Leak Syndrome,Cell Disease see Warnings and Precautions,0
GRANIX,Capillary Leak Syndrome,Warnings and Precautions Potential for Tumor Growth Stimulatory,0
GRANIX,Capillary Leak Syndrome,Precautions,0
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,and,0
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Warnings and,0
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Potential Tumor Growth Stimulatory Effects,1
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Potential Tumor Growth Stimulatory Effects on Malignant,1
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Precautions Potential Tumor Growth Stimulatory Effects on Malignant Cells see Warnings and Precautions The,1
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Potential Tumor Growth Stimulatory Effects on Malignant,1
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,and,0
GRANIX,Tumor Growth Stimulatory Effects on Malignant Cells,Growth Stimulatory Effects on Malignant Cells see Warnings and Precautions,1
GRANIX,bone pain,bone pain EXCERPT,1
GRANIX,bone pain,placebo group bone pain EXCERPT,1
GRANIX,bone pain,bone pain EXCERPT,1
GRANIX,bone pain,bone pain EXCERPT Most,1
GRANIX,bone pain,bone pain EXCERPT,1
GRANIX,bone pain,placebo group bone pain,1
GRANIX,bone pain,at the recommended dose and was numerically two times more frequent than,0
GRANIX,bone pain,the placebo group bone,1
GRANIX,bone pain,the placebo group bone pain,1
GRANIX,bone pain,EXCERPT Most,0
GRANIX,bone pain,two times more,0
GRANIX,bone pain,at or FDA,0
GRANIX,bone pain,placebo group was bone pain EXCERPT Most common adverse reaction,0
GRANIX,bone pain,pain,0
GRANIX,bone pain,reaction to GRANIX bone pain To report SUSPECTED ADVERSE,1
GRANIX,bone pain,pain,0
GRANIX,bone pain,REACTIONS contact TEVA at or FDA,0
GRANIX,bone pain,reaction to GRANIX bone pain To report SUSPECTED ADVERSE REACTIONS,1
GRANIX,bone pain,REACTIONS contact TEVA at or FDA,0
GRANIX,bone pain,bone pain To report SUSPECTED,1
GRANIX,bone pain,REACTIONS contact TEVA at or FDA at,0
GRANIX,bone pain,bone pain To report SUSPECTED ADVERSE,1
GRANIX,Bone pain,Bone pain was the most frequent,1
GRANIX,Bone pain,reaction that occurred in,0
GRANIX,Bone pain,L after nadir was Bone pain was the most frequent,1
GRANIX,Bone pain,reaction that occurred in,0
GRANIX,Bone pain,Bone pain,1
GRANIX,Bone pain,Bone pain was,1
GRANIX,Bone pain,Bone pain,1
GRANIX,Bone pain,Bone pain was the most,1
GRANIX,Bone pain,tinued to a maximum of days or until an ANC of x L after nadir,0
GRANIX,Bone pain,to a maximum of days or until an ANC of x L after nadir,0
GRANIX,Bone pain,Bone pain was the most frequent treatmentemergent,1
GRANIX,Bone pain,to a maximum of days or until an ANC of x L after nadir,0
GRANIX,bone pain,placebo,0
GRANIX,bone pain,overall incidence,0
GRANIX,bone pain,incidence bone pain in Cycle of treatment was,1
GRANIX,bone pain,overall incidence,0
GRANIX,bone pain,bone pain in Cycle of treatment was,1
GRANIX,bone pain,The overall incidence bone pain,1
GRANIX,bone pain,numerically two times more frequent than in the placebo,0
GRANIX,bone pain,of,0
GRANIX,bone pain,bone pain,1
GRANIX,bone pain,overall incidence of,0
GRANIX,bone pain,incidence bone,1
GRANIX,leukocytosis,Reactions Other adverse,0
GRANIX,leukocytosis,leukocytosis were reported,1
GRANIX,leukocytosis,Other,0
GRANIX,leukocytosis,complications attributable leukocytosis,1
GRANIX,leukocytosis,Other,0
GRANIX,leukocytosis,leukocytosis,1
GRANIX,leukocytosis,GRANIX No complications attributable leukocytosis were,1
GRANIX,leukocytosis,leukocytosis,1
GRANIX,leukocytosis,were reported in clinical studies Additional Adverse Reactions Other adverse reactions kno,0
GRANIX,leukocytosis,No complications attributable leukocytosis were reported,1
GRANIX,leukocytosis,were reported in clinical studies Additional Adverse Reactions Other adverse reactions kno,0
GRANIX,leukocytosis,s than,0
GRANIX,leukocytosis,leukocytosis,1
GRANIX,myalgia,myalgia headache vomiting,1
GRANIX,myalgia,factors myalgia,1
GRANIX,myalgia,myalgia headache vomiting,1
GRANIX,myalgia,acute febrile neutrophilic dermatosis,0
GRANIX,myalgia,colonystimulating factors myalgia,1
GRANIX,myalgia,acute febrile neutrophilic dermatosis,0
GRANIX,myalgia,myalgia headache vomiting,1
GRANIX,myalgia,myalgia headache vomiting Sweets syndrome acute,1
GRANIX,headache,headache vomiting Sweets,1
GRANIX,headache,myalgia headache vomiting Sweets syndrome acute,1
GRANIX,headache,include headache vomiting Sweets syndrome acute febrile,1
GRANIX,headache,myalgia headache vomiting Sweets syndrome acute,1
GRANIX,vomiting,vomiting Sweets syndrome,1
GRANIX,vomiting,myalgia,0
GRANIX,Sweet's syndrome,include myalgia headache Sweet's syndrome acute febrile neutrophilic dermatosis,1
GRANIX,Sweet's syndrome,myalgia,0
GRANIX,Sweet's syndrome,acute,0
GRANIX,acute febrile neutrophilic dermatosis,myalgia headache vomiting Sweets acute febrile neutrophilic dermatosis cutaneous vasculitis and thrombocytopenia,1
GRANIX,acute febrile neutrophilic dermatosis,acute,0
GRANIX,acute febrile neutrophilic dermatosis,with all therapeutic pr,0
GRANIX,acute febrile neutrophilic dermatosis,include myalgia headache vomiting Sweets syndrome,0
GRANIX,acute febrile neutrophilic dermatosis,febrile neutrophilic dermatosis cutaneous vasculitis and thrombocytopenia Immunogenicity,1
GRANIX,acute febrile neutrophilic dermatosis,neutrophilic dermatosis cutaneous vasculitis and thrombocytopenia,1
GRANIX,acute febrile neutrophilic dermatosis,vomiting Sweets acute febrile,1
GRANIX,acute febrile neutrophilic dermatosis,vomiting Sweets,0
GRANIX,acute febrile neutrophilic dermatosis,vasculitis and thrombocytopenia Immunogenicity As,0
GRANIX,acute febrile neutrophilic dermatosis,Immunogenicity As with,0
GRANIX,acute febrile neutrophilic dermatosis,vomiting Sweets acute febrile neutrophilic,1
GRANIX,cutaneous vasculitis,neutrophilic cutaneous vasculitis and thrombocytopenia Immunogenicity As with,1
GRANIX,cutaneous vasculitis,vomiting Sweets acute febrile neutrophilic,1
GRANIX,cutaneous vasculitis,neutrophilic cutaneous vasculitis,1
GRANIX,cutaneous vasculitis,neutrophilic cutaneous vasculitis and thrombocytopenia Immunogenicity,1
GRANIX,cutaneous vasculitis,neutrophilic cutaneous vasculitis,1
GRANIX,cutaneous vasculitis,acute febrile neutrophilic cutaneous vasculitis and thrombocytopenia Immunogenicity,1
GRANIX,cutaneous vasculitis,neutrophilic cutaneous vasculitis,1
GRANIX,thrombocytopenia,vasculitis thrombocytopenia Immunogenicity As with all,1
GRANIX,thrombocytopenia,neutrophilic cutaneous vasculitis,1
GRANIX,Splenic Rupture,potential ser,0
GRANIX,Splenic Rupture,ious adverse re actions,1
GRANIX,Splenic Rupture,following potential ious adverse,1
GRANIX,Splenic Rupture,The following potential ser,0
GRANIX,Splenic Rupture,discussed in greater detail in other sections of the,0
GRANIX,Splenic Rupture,ious adverse re actions,1
GRANIX,Splenic Rupture,discussed in greater detail in other sections of the,0
GRANIX,Splenic Rupture,following potential ious adverse re,1
GRANIX,Splenic Rupture,actions are discussed in greater detail in other sections of the labeling Splenic,0
GRANIX,Acute Respiratory Distress Syndrome,Rupture see Warnings and Precautions Acute,0
GRANIX,Acute Respiratory Distress Syndrome,Precautions Acute,0
GRANIX,Acute Respiratory Distress Syndrome,potential serious adverse reactions are discussed in greater,0
GRANIX,Acute Respiratory Distress Syndrome,in other se,0
GRANIX,Acute Respiratory Distress Syndrome,labeling: Spleni c,1
GRANIX,Acute Respiratory Distress Syndrome,ctions of the labeling: Spleni c Rupture see Warnings and,1
GRANIX,ARDS,reactions are discussed,0
GRANIX,ARDS,Rupt,1
GRANIX,ARDS,the labeling Rupt ure see Warnings and Precautions,1
GRANIX,ARDS,Rupt,1
GRANIX,ARDS,Rupt ure see Warnings,1
GRANIX,ARDS,Rupt ure see Warnings and Precautions,1
GRANIX,ARDS,Rupt ure see Warnings and Precautions,1
GRANIX,ARDS,labeling Rupt ure see Warnings and Precautions,1
GRANIX,ARDS,Rupt ure see Warnings and Precautions,1
GRANIX,ARDS,Rupt ure see Warnings and,1
GRANIX,ARDS,Rupt ure see Warnings and,1
GRANIX,ARDS,Rupt ure see Warnings and,1
GRANIX,Allergic reactions,Acute,0
GRANIX,Allergic reactions,see Warnings and,0
GRANIX,Allergic reactions,Precautions Acute Respiratory Distress [,1
GRANIX,Allergic reactions,Acute,0
GRANIX,Allergic reactions,Precautions Acute Respiratory Distress [ see Warnings,1
GRANIX,Allergic reactions,Warnings and Precautions Acute Respiratory Distress Syndrome,0
GRANIX,Allergic reactions, [  see  Warnings  and Precautions Serious Allergic Reactions,1
GRANIX,Allergic reactions,Warnings and Precautions Acute Respiratory Distress Syndrome,0
GRANIX,Allergic reactions,see Warnings,0
GRANIX,angioneurotic edema,d Precautions (5.2),1
GRANIX,dermatitis allergic,Serious Al lergic Reactions,1
GRANIX,dermatitis allergic,Sickle Cell,0
GRANIX,dermatitis allergic,Warnings and ] Serious Al,1
GRANIX,dermatitis allergic,with Sickle Cell,0
GRANIX,dermatitis allergic,"Warnings and   ]



  Serious Al lergic Reactions see",1
GRANIX,dermatitis allergic,with Sickle Cell,0
GRANIX,dermatitis allergic,Warnings and ] Serious Al,1
GRANIX,dermatitis allergic,],1
GRANIX,hypersensitivity,Cell Disease see Warnings,0
GRANIX,hypersensitivity,stress Syndrome see Warnings and Precautions Serious Allergic Reactions,0
GRANIX,hypersensitivity,stress Syndrome,0
GRANIX,hypersensitivity,Allergic Reactions Warnings and Pre,1
GRANIX,hypersensitivity,stress Syndrome,0
GRANIX,hypersensitivity,Syndrome,0
GRANIX,hypersensitivity,Allergic Reactions Warnings,1
GRANIX,rash,Warnings and utio,1
GRANIX,rash,Allergic Reactions Warnings,1
GRANIX,rash,Disease see Warnings and Precautions,0
GRANIX,rash,and Precautions Serious Allergic Reactions,0
GRANIX,rash,utio ns,1
GRANIX,rash,utio ns Use in,1
GRANIX,rash,utio ns,1
GRANIX,rash,utio ns Use,1
GRANIX,rash,utio ns Use in Patients,1
GRANIX,rash,Reactions see Warnings and utio ns Use in Patients with,1
GRANIX,rash,utio ns Use in Patients,1
GRANIX,pruritic rash,Warnings,0
GRANIX,pruritic rash,Cell Disease see Warnings and,0
GRANIX,pruritic rash,Precautions,0
GRANIX,pruritic rash,Warnings and,0
GRANIX,pruritic rash,(5.3) ] Use in Patients,1
GRANIX,pruritic rash,and Precautions,0
GRANIX,urticaria,se in Pat,1
GRANIX,urticaria,se in Pat ients with,1
GRANIX,urticaria,se in Pat,1
GRANIX,urticaria,utions Serious Allergic Reactions see Warnings and Precautions,0
GRANIX,urticaria,Warnings and Precautions se,1
GRANIX,urticaria,and Precautions se in Pat ients with Sickle Cell,1
GRANIX,urticaria,Warnings and Precautions se,1
GRANIX,urticaria,Cell Disease see,0
GRANIX,urticaria,Capillary Leak Syndr,0
GRANIX,urticaria,Reactions see Warnings and Precautions,0
GRANIX,urticaria,se in Pat ients with Sickle Cell,1
GRANIX,Sickle cell crisis,Leak Syndrome see Warnings,0
GRANIX,Sickle cell crisis,Capillary Leak Syndrome see Warnings and,0
GRANIX,Sickle cell crisis,Sickle ell Disease [,1
GRANIX,Sickle cell crisis,Sickle ell Disease [,1
GRANIX,Sickle cell crisis,Precautions Capillary Leak Syndrome see Warnings,0
GRANIX,Sickle cell crisis,ell Disease [  see Warnings and Precautions,1
GRANIX,Sickle cell crisis,Precautions Capillary Leak Syndrome see Warnings,0
GRANIX,fatal,ons ( Capillary Leak Syndrome,1
GRANIX,fatal,Leak Syndrome see,0
GRANIX,fatal,ons ( Capillary Leak Syndrome see Warnings,1
GRANIX,fatal,ons ( Capillary Leak Syndrome,1
GRANIX,fatal,ons ( Capillary Leak Syndrome see Warnings,1
GRANIX,fatal,and ons (,1
GRANIX,Capillary Leak Syndrome,"autions (5.5)    ]



  Potential for Tumor",1
GRANIX,Capillary Leak Syndrome,and ons (,1
GRANIX,Capillary Leak Syndrome,"see Warnings and autions (5.5)    ]



  Potential for Tumor Growth Stimulatory",1
GRANIX,Capillary Leak Syndrome,and ons (,1
GRANIX,Capillary Leak Syndrome,Growth Stimulatory Effects on Malignant Cells see Warnings and,0
GRANIX,Capillary Leak Syndrome,Cells see Warnings,0
GRANIX,Splenic rupture,most common tre atmentemergent adverse,1
GRANIX,Splenic rupture,common tre,1
GRANIX,Splenic rupture,on Malignant Cells see Warnings,0
GRANIX,Splenic rupture,and Precautions most common tre atmentemergent adverse reaction,1
GRANIX,Splenic rupture,on Malignant Cells see Warnings,0
GRANIX,Splenic rupture,and Precautions most common tre atmentemergent adverse reaction,1
GRANIX,Splenic rupture,on Malignant Cells see Warnings,0
GRANIX,Splenic rupture,Cells see Warnings and Precautions The,0
GRANIX,fatal,Precautions The most common ent a dverse reaction that,1
GRANIX,fatal,Cells see Warnings and Precautions The,0
GRANIX,fatal,in patients treated,0
GRANIX,fatal,Precautions,0
GRANIX,fatal,ent a dverse reaction that occurred,1
GRANIX,fatal,ent,1
GRANIX,fatal,ent a dverse reaction,1
GRANIX,fatal,common treatmentemerg,0
GRANIX,fatal,ent,1
GRANIX,Acute respiratory distress syndrome,TEVA at or FDA at FDA or wwwfdagovmedwatch Clin,0
GRANIX,Acute respiratory distress syndrome,EXCERPT Most,0
GRANIX,Acute respiratory distress syndrome,To eport,1
GRANIX,Acute respiratory distress syndrome,GRANIX is bone,0
GRANIX,Acute respiratory distress syndrome,"ADVERSE REACTIONS,",1
GRANIX,Acute respiratory distress syndrome,at or FDA at FDA or wwwfdagovmedwatch Clin,0
GRANIX,Acute respiratory distress syndrome,"ADVERSE REACTIONS, contact",1
GRANIX,Acute respiratory distress syndrome,eport SUSPECTED,1
GRANIX,ARDS,ntac t TEVA at or FDA,1
GRANIX,ARDS,ADVERSE REACTIONS ntac t TEVA at or FDA,1
GRANIX,ARDS,ntac t TEVA at or FDA,1
GRANIX,ARDS,at or FDA at FDA,0
GRANIX,allergic reactions,red to rates in th e clinical trials of,1
GRANIX,allergic reactions,drug cannot be,0
GRANIX,allergic reactions,rates in th e clinical trials of,1
GRANIX,anaphylaxis,trials of a nother drug and may not,1
GRANIX,anaphylaxis,to rates in the trials of,1
GRANIX,fatal,age was years 95% o,1
GRANIX,fatal,to rates in the trials of,1
GRANIX,fatal,95% o,1
GRANIX,fatal,95% o f patients were Caucasian,1
GRANIX,sickle cell crises,patients were Cau casian In the nonHodgkins lymphoma,1
GRANIX,sickle cell crises,patients were Cau casian In,1
GRANIX,sickle cell crises,patients were Cau casian,1
GRANIX,Capillary leak syndrome,daily beg inning one,1
GRANIX,Capillary leak syndrome,of days or,0
GRANIX,Capillary leak syndrome,after chemotherapy for at least five days and continued to a maximum of days or,0
GRANIX,Capillary leak syndrome,aneously once daily beg inning one day after chemotherapy,1
GRANIX,CLS,nin g one,1
GRANIX,CLS,nin g one,1
GRANIX,CLS,subcutaneously once daily nin g one,1
GRANIX,CLS,nin g one,1
GRANIX,CLS,subcutaneously once daily nin,1
GRANIX,CLS,nin g one,1
GRANIX,CLS,subcutaneously once daily nin,1
GRANIX,CLS,nin g one,1
GRANIX,CLS,one day after chemotherapy for at least five days and continued to,0
GRANIX,hypotension,"or until an NC of >=10,",1
GRANIX,hypotension,"NC of >=10, x L after nadir was",1
GRANIX,hypotension,"NC of >=10, x L after",1
GRANIX,hypotension,"of >=10, x",1
GRANIX,hypotension,pain,0
GRANIX,hypotension,days or,0
GRANIX,hypoalbuminemia,to a maximum of days or until,0
GRANIX,hypoalbuminemia,maximum of,0
GRANIX,hypoalbuminemia,ANC 0 x 10  6  /L a fter,1
GRANIX,hypoalbuminemia,maximum of,0
GRANIX,hypoalbuminemia,0 x 10  6  /L a fter nadir was reached,1
GRANIX,hypoalbuminemia,maximum of,0
GRANIX,hypoalbuminemia,frequent treatmentemergent adverse reaction,0
GRANIX,hypoalbuminemia,ANC 0 x 10,1
GRANIX,hypoalbuminemia,or until an ANC 0,1
GRANIX,edema,of x L er na,1
GRANIX,edema,and continued to a maximum of days or until an ANC of x L,0
GRANIX,edema,er na dir was reached Bone pain,1
GRANIX,edema,er na dir was reached,1
GRANIX,edema,adverse,0
GRANIX,edema,Bone pain was the most frequent treatmentemergent adverse reaction that,0
GRANIX,edema,was,0
GRANIX,hemoconcentration,of days or until an ANC of x L after nadir,0
GRANIX,hemoconcentration,reached. B one pain was the,1
GRANIX,hemoconcentration,at,0
GRANIX,hemoconcentration,of days or,0
GRANIX,myeloid malignancies,less than patients with nonmyeloid malignancies,0
GRANIX,myeloid malignancies,No complications attributable to leukocytosis were reported,1
GRANIX,myeloid malignancies,less than patients with nonmyeloid,0
GRANIX,myeloid malignancies,attributable to leukocytosis were reported in clinical,0
GRANIX,myelodysplasia,less than patients with,0
GRANIX,myelodysplasia,reported in clinical studies,0
GRANIX,myelodysplasia,complications ibutable to le ukocytosis were reported in,1
GRANIX,myelodysplasia,reported in clinical studies,0
GRANIX,myelodysplasia,receiving GRANIX No complications ibutable to le,1
GRANIX,myelodysplasia,reported in clinical studies,0
GRANIX,myelodysplasia,in clinical studies,0
GRANIX,myelodysplasia,ibutable to le ukocytosis were reported,1
GRANIX,myelodysplasia,less than,0
GRANIX,myelodysplasia,erved in less than patients with nonmyeloid malignancies receiving GRANIX,0
GRANIX,myelodysplasia,complications ibutable to le ukocytosis were,1
GRANIX,myelodysplasia,erved in less than patients with nonmyeloid malignancies receiving GRANIX,0
TUDORZA,Paradoxical bronchospasm,see Warnings and Precautions,0
TUDORZA,Paradoxical bronchospasm,glaucoma see Warnings,0
TUDORZA,Paradoxical bronchospasm,Paradoxical bronchospasm see Warnings and Precautions Worsening,1
TUDORZA,Paradoxical bronchospasm,in other Paradoxical bronchospasm,1
TUDORZA,Paradoxical bronchospasm,Paradoxical bronchospasm see Warnings and Precautions Worsening,1
TUDORZA,Paradoxical bronchospasm,other Paradoxical bronchospasm see Warnings and Precautions,1
TUDORZA,Paradoxical bronchospasm,Paradoxical bronchospasm see Warnings and Precautions Worsening,1
TUDORZA,Paradoxical bronchospasm,Paradoxical bronchospasm,1
TUDORZA,Paradoxical bronchospasm,Paradoxical bronchospasm see Warnings and Precautions Worsening,1
TUDORZA,Paradoxical bronchospasm,detail in other Paradoxical bronchospasm see Warnings and Precautions,1
TUDORZA,Paradoxical bronchospasm,Paradoxical bronchospasm see Warnings and Precautions Worsening,1
TUDORZA,Worsening of narrow-angle glaucoma,and Worsening of narrow-angle glaucoma see Warnings and Precautions,1
TUDORZA,Worsening of narrow-angle glaucoma,Paradoxical bronchospasm see Warnings and Precautions Worsening,1
TUDORZA,Worsening of narrow-angle glaucoma,other sections Paradoxical bronchospasm see Warnings and,0
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of narrow-angle glaucoma see Warnings and,1
TUDORZA,Worsening of narrow-angle glaucoma,Warnings and Precautions Worsening of urinary retention see Warnings and,0
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of narrow-angle glaucoma see Warnings and Precautions Worsening,1
TUDORZA,Worsening of narrow-angle glaucoma,Warnings and Precautions Worsening of urinary retention see Warnings and,0
TUDORZA,Worsening of narrow-angle glaucoma,and Worsening,1
TUDORZA,Worsening of narrow-angle glaucoma,bronchospasm see Warnings and Worsening of narrow-angle glaucoma,1
TUDORZA,Worsening of narrow-angle glaucoma,Precautions Worsening of urinary retention,0
TUDORZA,Worsening of narrow-angle glaucoma,narrow-angle glaucoma see Warnings,1
TUDORZA,Worsening of narrow-angle glaucoma,of narrow-angle glaucoma see Warnings and Precautions Worsening,1
TUDORZA,Worsening of urinary retention,Precautions,0
TUDORZA,Worsening of urinary retention,Reactions see,0
TUDORZA,Worsening of urinary retention,Warnings and Worsening of urinary retention,1
TUDORZA,Worsening of urinary retention,narrowangle,0
TUDORZA,Worsening of urinary retention,and Worsening of urinary retention,1
TUDORZA,Worsening of urinary retention,urinary retention,1
TUDORZA,Worsening of urinary retention,narrowangle glaucoma see Warnings,0
TUDORZA,Worsening of urinary retention,urinary retention see Warnings and Precautions Immediate,1
TUDORZA,Worsening of urinary retention,Warnings and,0
TUDORZA,Worsening of urinary retention,and,0
TUDORZA,Immediate Hypersensitivity Reactions,retention see Warnings,0
TUDORZA,headache,REACTIONS Contact,0
TUDORZA,headache,and greater than placebo headache,1
TUDORZA,headache,REACTIONS Contact,0
TUDORZA,nasopharyngitis,greater,0
TUDORZA,nasopharyngitis,nasopharyngitis and,1
TUDORZA,nasopharyngitis,than placebo are nasopharyngitis and cough To,1
TUDORZA,nasopharyngitis,nasopharyngitis and,1
TUDORZA,nasopharyngitis,reactions incidence and greater than placebo are,0
TUDORZA,cough,are headache nasopharyngitis cough To report SUSPECTED,1
TUDORZA,cough,reactions incidence and greater than placebo are,0
TUDORZA,cough,placebo are headache nasopharyngitis,0
TUDORZA,cough,reactions incidence and greater than placebo are headache,0
TUDORZA,cough,ommon adverse reactions incidence and greater than placebo,0
TUDORZA,cough,report SUSPECTED ADVERSE REACTIONS,0
TUDORZA,cough,cough To report SUSPECTED,1
TUDORZA,cough,report SUSPECTED ADVERSE REACTIONS,0
TUDORZA,cough,To report SUSPECTED ADVERSE REACTIONS Contact AstraZeneca at,0
TUDORZA,dry mouth,diabetes dry mouth st degree,1
TUDORZA,dry mouth,To report SUSPECTED ADVERSE REACTIONS Contact AstraZeneca at,0
TUDORZA,dry mouth,mellitus,0
TUDORZA,dry mouth,failure and cardiorespiratory,0
TUDORZA,dry mouth,mellitus,0
TUDORZA,dry mouth,dry mouth st,1
TUDORZA,dry mouth,degree AV block osteoarthritis cardiac,0
TUDORZA,dry mouth,than were diabetes dry mouth,1
TUDORZA,dry mouth,degree AV block osteoarthritis cardiac,0
TUDORZA,dry mouth,dry mouth st degree,1
TUDORZA,AV block,Longterm,0
TUDORZA,AV block,cardiorespiratory arrest,0
TUDORZA,AV block,mellitus dry mouth st AV block osteoarthritis cardiac failure and cardiorespiratory,1
TUDORZA,AV block,cardiorespiratory arrest,0
TUDORZA,AV block,Longterm Safety Trials,0
TUDORZA,AV block,AV block,1
TUDORZA,AV block,mellitus dry,0
TUDORZA,AV block,AV block osteoarthritis cardiac failure,1
TUDORZA,AV block,mellitus,0
TUDORZA,AV block,AV block osteoarthritis cardiac failure and,1
TUDORZA,osteoarthritis,cardiorespiratory arrest Longterm Safety Trials TUDORZA,0
TUDORZA,osteoarthritis,AV osteoarthritis cardiac,1
TUDORZA,osteoarthritis,cardiorespiratory arrest Longterm Safety Trials TUDORZA,0
TUDORZA,osteoarthritis,osteoarthritis cardiac failure and cardiorespiratory arrest,1
TUDORZA,osteoarthritis,Longterm Safety,0
TUDORZA,osteoarthritis,AV osteoarthritis cardiac failure and cardiorespiratory,1
TUDORZA,osteoarthritis,Longterm Safety,0
TUDORZA,osteoarthritis,Safety Trials,0
TUDORZA,osteoarthritis,osteoarthritis cardiac failure and cardiorespiratory arrest,1
TUDORZA,osteoarthritis,mouth st degree AV osteoarthritis cardiac failure and,1
TUDORZA,osteoarthritis,osteoarthritis cardiac failure and cardiorespiratory arrest,1
TUDORZA,osteoarthritis,arrest Longterm Safety Trials,0
TUDORZA,osteoarthritis,incidence of less than were diabetes mellitus dry mouth,0
TUDORZA,cardiac failure,block,0
TUDORZA,cardiac failure,less than were diabetes mellitus dry mouth st degree,0
TUDORZA,cardiac failure,arrest Longterm Safety Trials TUDORZA PRESSAIR was stud,0
TUDORZA,cardiac failure,osteoarthritis,0
TUDORZA,cardio-respiratory arrest,st degree AV block osteoarthritis cardiac failure,0
TUDORZA,cardio-respiratory arrest,cardiac failure cardio-respiratory arrest Longterm Safety Trials TUDORZA,1
TUDORZA,cardio-respiratory arrest,st degree AV block osteoarthritis cardiac failure,0
TUDORZA,cardio-respiratory arrest,cardio-respiratory arrest Longterm Safety,1
TUDORZA,cardio-respiratory arrest,block osteoarthritis cardiac failure cardio-respiratory arrest Longterm Safety Trials TUDORZA PRESSAIR,1
TUDORZA,cardio-respiratory arrest,cardio-respiratory arrest Longterm Safety,1
TUDORZA,cardio-respiratory arrest,mouth st degree AV block osteoarthritis,0
TUDORZA,cardio-respiratory arrest,osteoarthritis cardiac failure,0
TUDORZA,cardio-respiratory arrest,mellitus,0
TUDORZA,immediate hypersensitivity reactions,immediate hypersensitivity reactions including anaphylaxis angioedema including swelling,1
TUDORZA,immediate hypersensitivity reactions,postmarketing experience with TUDORZA immediate hypersensitivity reactions including anaphylaxis,1
TUDORZA,immediate hypersensitivity reactions,immediate hypersensitivity reactions including anaphylaxis angioedema including swelling,1
TUDORZA,immediate hypersensitivity reactions,the,0
TUDORZA,immediate hypersensitivity reactions,with TUDORZA immediate hypersensitivity reactions including anaphylaxis,1
TUDORZA,immediate hypersensitivity reactions,the,0
TUDORZA,anaphylaxis,lips tongue or throat,0
TUDORZA,anaphylaxis,reactions anaphylaxis angioedema including swelling of the,1
TUDORZA,anaphylaxis,lips tongue or throat,0
TUDORZA,anaphylaxis,angioedema including swelling of the lips,0
TUDORZA,anaphylaxis,In postmarketing experience with TUDORZA,0
TUDORZA,anaphylaxis,urticaria rash bronchospasm,0
TUDORZA,angioedema,reactions including angioedema including swelling,1
TUDORZA,angioedema,urticaria rash bronchospasm,0
TUDORZA,angioedema,immediate hypersensitivity reactions including angioedema including swelling of,1
TUDORZA,angioedema,urticaria rash bronchospasm,0
TUDORZA,angioedema,or itching have,0
TUDORZA,angioedema,PRESSAIR,0
TUDORZA,angioedema,including,0
TUDORZA,angioedema,angioedema including swelling of,1
TUDORZA,angioedema,immediate hypersensitivity reactions including angioedema including swelling of the,1
TUDORZA,angioedema,angioedema including swelling of,1
TUDORZA,angioedema,experience,0
TUDORZA,angioedema,angioedema including swelling of the lips,1
TUDORZA,angioedema,including angioedema including swelling of,1
TUDORZA,angioedema,angioedema including swelling of the lips,1
TUDORZA,urticaria,or urticaria,1
TUDORZA,urticaria,angioedema including swelling of the lips,1
TUDORZA,urticaria,the lips tongue or urticaria rash bronchospasm or,1
TUDORZA,urticaria,angioedema including swelling of the lips,1
TUDORZA,urticaria,urticaria rash bronchospasm or,1
TUDORZA,urticaria,including swelling of the lips tongue,0
TUDORZA,urticaria,the lips tongue or urticaria rash bronchospasm or itching have,1
TUDORZA,urticaria,including swelling of the lips tongue,0
TUDORZA,rash,tongue or throat rash bronchospasm,1
TUDORZA,rash,including swelling of the lips tongue,0
TUDORZA,rash,rash bronchospasm or itching have,1
TUDORZA,rash,or throat rash bronchospasm or itching have,1
TUDORZA,rash,rash bronchospasm or itching have,1
TUDORZA,rash,throat rash bronchospasm or itching have,1
TUDORZA,rash,rash bronchospasm or itching have,1
TUDORZA,rash,have been,0
TUDORZA,bronchospasm,rash,0
TUDORZA,bronchospasm,itching have been,0
TUDORZA,bronchospasm,of,0
TUDORZA,itching,have been reported,0
TUDORZA,itching,itching have been reported,1
TUDORZA,itching,swelling of the lips tongue or,0
TUDORZA,itching,have been reported,0
TUDORZA,Paradoxical bronchospasm,other sections aradoxical bronchospasm,1
TUDORZA,Paradoxical bronchospasm,aradoxical bronchospasm,1
TUDORZA,Paradoxical bronchospasm,Worsening of narrowangle glaucoma see Warnings and Pr,0
TUDORZA,Paradoxical bronchospasm,detail in other sections aradoxical bronchospasm  see Warnings and,1
TUDORZA,Paradoxical bronchospasm,Worsening of narrowangle glaucoma see Warnings and Pr,0
TUDORZA,Paradoxical bronchospasm,detail in other sections,0
TUDORZA,Paradoxical bronchospasm,greater detail,0
TUDORZA,Paradoxical bronchospasm,glaucoma see,0
TUDORZA,Paradoxical bronchospasm,in other sections aradoxical bronchospasm ,1
TUDORZA,Paradoxical bronchospasm,glaucoma see,0
TUDORZA,Paradoxical bronchospasm,aradoxical bronchospasm,1
TUDORZA,Worsening of narrow-angle glaucoma,see Warnings and Precautions Immediate Hypersensitivity Reactions,0
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of narrowangle,0
TUDORZA,Worsening of narrow-angle glaucoma,Worsening of urinar y retention see Warnings and,1
TUDORZA,Worsening of narrow-angle glaucoma,and Precautions Immediate Hypersensitivity,0
TUDORZA,Worsening of urinary retention,Warnings and Precautions EXCERPT t common adverse reactions (>=,1
TUDORZA,Worsening of urinary retention,and Precautions Immediate Hypersensitivity,0
TUDORZA,Worsening of urinary retention,EXCERPT t,1
TUDORZA,Worsening of urinary retention,t common adverse reactions (>= incidence and greater,1
TUDORZA,Worsening of urinary retention,EXCERPT t,1
TUDORZA,Worsening of urinary retention,adverse reactions (>= incidence and greater than placebo,1
TUDORZA,Worsening of urinary retention,Immediate Hypersensitivity Reactions,0
TUDORZA,Worsening of urinary retention,and Precautions EXCERPT t common adverse reactions (>= incidence and greater than placebo,1
TUDORZA,Worsening of urinary retention,Immediate Hypersensitivity Reactions,0
TUDORZA,hypersensitivity reactions,8 or www.fda.gov/medwatch. Clinical Trials,1
TUDORZA,paradoxical bronchospasm,PRESSAIR at recommended dose,1
TUDORZA,paradoxical bronchospasm,of,0
TUDORZA,paradoxical bronchospasm,the,0
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n n",1
TUDORZA,Immediate hypersensitivity reactions,the,0
TUDORZA,Immediate hypersensitivity reactions,"Term N=640)             
                ",1
TUDORZA,Immediate hypersensitivity reactions,the,0
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n n",1
TUDORZA,Immediate hypersensitivity reactions,"Term N=640)             
                 n",1
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n n",1
TUDORZA,Immediate hypersensitivity reactions,"Term N=640)             
                 n n",1
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n n",1
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n n Heada",1
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n n",1
TUDORZA,Immediate hypersensitivity reactions,"N=640)             
                 n",1
TUDORZA,anaphylaxis,            n,1
TUDORZA,anaphylaxis,            n,1
TUDORZA,anaphylaxis,N,0
TUDORZA,anaphylaxis,N,0
TUDORZA,swelling of the lips,                    ,1
TUDORZA,swelling of the lips,N,0
TUDORZA,swelling of the lips,n,0
TUDORZA,swelling of the lips,                     n Headache,1
TUDORZA,swelling of the lips,                    ,1
TUDORZA,swelling of the lips,                     n Headache,1
JEVTANA,Bone Marrow Suppression,of the Bone,1
JEVTANA,Bone Marrow Suppression,Bone Marrow Suppression see,1
JEVTANA,Bone Marrow Suppression,in,0
JEVTANA,Bone Marrow Suppression,of the Bone Marrow Suppression see Warnings and Precautions Hypersensitivity,1
JEVTANA,Bone Marrow Suppression,in,0
JEVTANA,Bone Marrow Suppression,Warnings,0
JEVTANA,Bone Marrow Suppression,Bone Marrow Suppression see Warnings and Precautions,1
JEVTANA,Bone Marrow Suppression,are discussed in greater detail in another section of,0
JEVTANA,Bone Marrow Suppression,Hypersensitivity Reactions see Warnings and,0
JEVTANA,Bone Marrow Suppression,Reactions,0
JEVTANA,Bone Marrow Suppression,adverse reactions are discussed in greater detail in another section,0
JEVTANA,Hypersensitivity Reactions,Precautions Gastrointestinal,0
JEVTANA,Hypersensitivity Reactions,see Warnings and Hypersensitivity Reactions,1
JEVTANA,Hypersensitivity Reactions,Hypersensitivity Reactions,1
JEVTANA,Hypersensitivity Reactions,Warnings and Hypersensitivity Reactions,1
JEVTANA,Hypersensitivity Reactions,see Warnings and Hypersensitivity,1
JEVTANA,Hypersensitivity Reactions,Gastrointestinal Adverse Reactions see Warnings,0
JEVTANA,Gastrointestinal Adverse Reactions,Gastrointestinal Adverse Reactions see,1
JEVTANA,Gastrointestinal Adverse Reactions,see Warnings,0
JEVTANA,Gastrointestinal Adverse Reactions,ecautions Hypersensitivity Reactions see Warnings and Precautions,0
JEVTANA,Gastrointestinal Adverse Reactions,Precautions,0
JEVTANA,Gastrointestinal Adverse Reactions,and,0
JEVTANA,Embryo-Fetal Toxicity,in Patients,0
JEVTANA,Embryo-Fetal Toxicity,Impairment see Warnings and Embryo-Fetal,1
JEVTANA,Embryo-Fetal Toxicity,Patients with Hepatic Impairment see Warnings and,0
JEVTANA,Embryo-Fetal Toxicity,Most common all grades,0
JEVTANA,Embryo-Fetal Toxicity,Impairment see Warnings and Embryo-Fetal Toxicity see Warnings,1
JEVTANA,Embryo-Fetal Toxicity,Most common all grades,0
JEVTANA,Embryo-Fetal Toxicity,Impairment see,0
JEVTANA,Embryo-Fetal Toxicity,Precautions EXCERPT Most common,0
JEVTANA,neutropenia,reactions are,0
JEVTANA,anemia,grades adverse reactions are anemia leukopenia thrombocytopenia diarrhea,1
JEVTANA,anemia,reactions are,0
JEVTANA,anemia,adverse reactions are anemia leukopenia thrombocytopenia,1
JEVTANA,anemia,reactions are,0
JEVTANA,anemia,anemia leukopenia,1
JEVTANA,anemia,reactions are anemia leukopenia,1
JEVTANA,anemia,anemia leukopenia,1
JEVTANA,anemia,reactions are anemia leukopenia thrombocytopenia diarrhea,1
JEVTANA,anemia,anemia leukopenia,1
JEVTANA,anemia,reactions are anemia leukopenia thrombocytopenia diarrhea fatigue,1
JEVTANA,anemia,anemia leukopenia,1
JEVTANA,anemia,anemia leukopenia thrombocytopenia diarrhea fatigue nausea,1
JEVTANA,leukopenia,leukopenia thrombocytopenia,1
JEVTANA,thrombocytopenia,neutropenia,0
JEVTANA,thrombocytopenia,vomiting constipation,0
JEVTANA,thrombocytopenia,thrombocytopenia diarrhea fatigue nausea,1
JEVTANA,thrombocytopenia,are neutropenia anemia thrombocytopenia,1
JEVTANA,thrombocytopenia,thrombocytopenia diarrhea fatigue nausea,1
JEVTANA,thrombocytopenia,neutropenia anemia thrombocytopenia diarrhea fatigue nausea,1
JEVTANA,thrombocytopenia,thrombocytopenia diarrhea fatigue nausea,1
JEVTANA,thrombocytopenia,grades adverse reactions are neutropenia,0
JEVTANA,thrombocytopenia,are neutropenia,0
JEVTANA,thrombocytopenia,fatigue nausea vomiting constipation asthenia abdominal pain,0
JEVTANA,thrombocytopenia,thrombocytopenia diarrhea fatigue nausea vomiting,1
JEVTANA,thrombocytopenia,Most common all grades adverse reactions,0
JEVTANA,fatigue,anemia leukopenia thrombocytopenia diarrhea,0
JEVTANA,fatigue,fatigue nausea vomiting constipation,1
JEVTANA,fatigue,leukopenia thrombocytopenia fatigue nausea vomiting constipation,1
JEVTANA,fatigue,fatigue nausea vomiting constipation,1
JEVTANA,fatigue,fatigue,1
JEVTANA,fatigue,fatigue nausea vomiting constipation asthenia abdominal,1
JEVTANA,fatigue,fatigue,1
JEVTANA,fatigue,fatigue nausea vomiting constipation,1
JEVTANA,fatigue,neutropenia anemia leukopenia thrombocytopenia fatigue nausea vomiting constipation,1
JEVTANA,fatigue,fatigue nausea vomiting constipation,1
JEVTANA,fatigue,constipation asthenia,0
JEVTANA,nausea,constipation asthenia abdominal pain hematuria back pain anorexia,0
JEVTANA,nausea,nausea vomiting constipation asthenia abdominal pain,1
JEVTANA,nausea,nausea vomiting constipation asthenia abdominal pain,1
JEVTANA,nausea,nausea vomiting constipation asthenia abdominal pain,1
JEVTANA,nausea,anemia leukopenia thrombocytopenia diarrhea nausea vomiting,1
JEVTANA,nausea,nausea vomiting constipation asthenia abdominal pain,1
JEVTANA,vomiting,vomiting constipation asthenia,1
JEVTANA,vomiting,vomiting constipation asthenia abdominal pain,1
JEVTANA,vomiting,neutropenia anemia leukopenia thrombocytopenia diarrhea fatigue nausea,0
JEVTANA,vomiting,anemia leukopenia thrombocytopenia,0
JEVTANA,vomiting,vomiting constipation asthenia abdominal,1
JEVTANA,vomiting,vomiting constipation,1
JEVTANA,vomiting,vomiting constipation asthenia abdominal,1
JEVTANA,vomiting,vomiting constipation asthenia abdominal pain hematuria,1
JEVTANA,vomiting,vomiting constipation asthenia abdominal pain,1
JEVTANA,constipation,constipation asthenia abdominal,1
JEVTANA,constipation,constipation asthenia,1
JEVTANA,constipation,nausea constipation asthenia abdominal pain hematuria,1
JEVTANA,constipation,constipation asthenia,1
JEVTANA,constipation,constipation asthenia abdominal pain hematuria,1
JEVTANA,constipation,nausea constipation,1
JEVTANA,constipation,constipation asthenia abdominal pain hematuria,1
JEVTANA,constipation,asthenia abdominal pain hematuria back pain anorexia peripheral,0
JEVTANA,constipation,back pain anorexia peripheral neuropathy pyrexia,0
JEVTANA,constipation,constipation,1
JEVTANA,constipation,constipation,1
JEVTANA,constipation,constipation asthenia abdominal pain,1
JEVTANA,asthenia,nausea vomiting asthenia abdominal pain hematuria back pain,1
JEVTANA,asthenia,constipation asthenia abdominal pain,1
JEVTANA,asthenia,asthenia abdominal pain hematuria back,1
JEVTANA,asthenia,vomiting,0
JEVTANA,asthenia,asthenia abdominal pain,1
JEVTANA,asthenia,asthenia abdominal,1
JEVTANA,asthenia,asthenia abdominal pain hematuria back pain,1
JEVTANA,abdominal pain,thrombocytopenia diarrhea fatigue nausea vomiting constipation asthenia,0
JEVTANA,hematuria,hematuria back pain anorexia peripheral,1
JEVTANA,hematuria,diarrhea fatigue nausea vomiting constipation asthenia abdominal,0
JEVTANA,hematuria,hematuria back pain anorexia peripheral,1
JEVTANA,hematuria,anorexia peripheral neuropathy pyrexia dyspnea dysgeusia cough arthralgia,0
JEVTANA,hematuria,hematuria back pain anorexia peripheral,1
JEVTANA,back pain,asthenia abdominal pain back,1
JEVTANA,back pain,constipation asthenia abdominal pain back pain anorexia peripheral neuropathy pyrexia dyspnea,1
JEVTANA,back pain,asthenia abdominal pain back,1
JEVTANA,back pain,pyrexia dyspnea dysgeusia cough arthralgia and,0
JEVTANA,back pain,neuropathy pyrexia dyspnea dysgeusia,0
JEVTANA,back pain,abdominal pain back pain anorexia peripheral,1
JEVTANA,back pain,neuropathy pyrexia dyspnea dysgeusia,0
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,fatigue nausea,0
JEVTANA,anorexia,fatigue nausea vomiting constipation asthenia,0
JEVTANA,anorexia,anorexia peripheral,1
JEVTANA,anorexia,pyrexia,0
JEVTANA,peripheral neuropathy,back pain anorexia,0
JEVTANA,peripheral neuropathy,cough arthralgia and alopecia,0
JEVTANA,peripheral neuropathy,hematuria back pain peripheral neuropathy,1
JEVTANA,peripheral neuropathy,hematuria back pain peripheral neuropathy,1
JEVTANA,peripheral neuropathy,pain peripheral neuropathy pyrexia dyspnea,1
JEVTANA,peripheral neuropathy,hematuria back pain peripheral neuropathy,1
JEVTANA,peripheral neuropathy,abdominal pain hematuria back pain,0
JEVTANA,peripheral neuropathy,peripheral neuropathy pyrexia dyspnea dysgeusia cough arthralgia,1
JEVTANA,peripheral neuropathy,back pain peripheral neuropathy pyrexia dyspnea,1
JEVTANA,peripheral neuropathy,peripheral neuropathy pyrexia dyspnea dysgeusia cough arthralgia,1
JEVTANA,peripheral neuropathy,dysgeusia cough arthralgia and alopecia To report,0
JEVTANA,pyrexia,and alopecia,0
JEVTANA,pyrexia,pain hematuria,0
JEVTANA,pyrexia,To report,0
JEVTANA,pyrexia,peripheral,0
JEVTANA,pyrexia,pyrexia dyspnea dysgeusia cough arthralgia and,1
JEVTANA,pyrexia,peripheral pyrexia,1
JEVTANA,pyrexia,pyrexia dyspnea dysgeusia cough arthralgia and,1
JEVTANA,pyrexia,arthralgia and alopecia To,0
JEVTANA,pyrexia,pyrexia dyspnea,1
JEVTANA,pyrexia,SUSPECTED,0
JEVTANA,pyrexia,alopecia To,0
JEVTANA,dyspnea,arthralgia and alopecia,0
JEVTANA,dyspnea,pain,0
JEVTANA,dyspnea,asthenia abdominal pain hematuria back pain anorexia,0
JEVTANA,dyspnea,dyspnea dysgeusia cough arthralgia and,1
JEVTANA,dyspnea,dyspnea dysgeusia cough arthralgia and alopecia,1
JEVTANA,dyspnea,dyspnea dysgeusia,1
JEVTANA,dysgeusia,pain hematuria back pain anorexia peripheral,0
JEVTANA,dysgeusia,REACTIONS,0
JEVTANA,dysgeusia,neuropathy pyrexia dyspnea,0
JEVTANA,dysgeusia,dysgeusia cough arthralgia and,1
JEVTANA,dysgeusia,dysgeusia,1
JEVTANA,dysgeusia,pyrexia dyspnea,0
JEVTANA,dysgeusia,peripheral neuropathy pyrexia dyspnea,0
JEVTANA,dysgeusia,report SUSPECTED ADVERSE,0
JEVTANA,cough,REACTIONS contact,0
JEVTANA,cough,cough arthralgia and,1
JEVTANA,cough,pyrexia dyspnea cough arthralgia,1
JEVTANA,cough,cough arthralgia and,1
JEVTANA,cough,cough arthralgia and alopecia,1
JEVTANA,cough,cough arthralgia and alopecia To report,1
JEVTANA,cough,cough arthralgia and alopecia,1
JEVTANA,cough,and alopecia To,0
JEVTANA,cough,cough arthralgia and alopecia To,1
JEVTANA,cough,pyrexia dyspnea,0
JEVTANA,cough,peripheral neuropathy pyrexia dyspnea cough,1
JEVTANA,cough,pyrexia dyspnea,0
JEVTANA,arthralgia,arthralgia and alopecia To report SUSPECTED,1
JEVTANA,alopecia,alopecia To report SUSPECTED ADVERSE,1
JEVTANA,alopecia,arthralgia and alopecia To report SUSPECTED,1
JEVTANA,alopecia,peripheral neuropathy pyrexia,0
JEVTANA,alopecia,To report SUSPECTED ADVERSE REACTIONS contact sanofiaventis,0
JEVTANA,alopecia,US,0
JEVTANA,alopecia,alopecia To report SUSPECTED,1
JEVTANA,Deaths,plus prednisone,0
JEVTANA,Deaths,treated in a single randomized trial compared to,0
JEVTANA,Deaths,disease progression within days of last study drug,0
JEVTANA,Deaths,to mitoxantrone plus Deaths due to causes other,1
JEVTANA,Deaths,disease progression within days of last study drug,0
JEVTANA,fatal,n,0
JEVTANA,fatal,most fatal adverse reactions in JEVTANAtreated,1
JEVTANA,fatal,n,0
JEVTANA,fatal,fatal adverse reactions in,1
JEVTANA,fatal,common,0
JEVTANA,fatal,failure n The ma,0
JEVTANA,fatal,fatal adverse reactions in JEVTANAtreated,1
JEVTANA,infections,infections n and renal,1
JEVTANA,renal failure,patients were infections n and,0
JEVTANA,renal failure,n,0
JEVTANA,renal failure,JEVTANAtreated,0
JEVTANA,renal failure,patients were infections n renal failure n The,1
JEVTANA,renal failure,JEVTANAtreated,0
JEVTANA,fatal,infections n and renal failure n The majority,0
JEVTANA,fatal,patients fatal infectionrelated adverse reactions occurred,1
JEVTANA,fatal,infections n and renal failure n The majority,0
JEVTANA,fatal,fatal infectionrelated,1
JEVTANA,fatal,renal failure n The majority of,0
JEVTANA,fatal,fatal infectionrelated adverse,1
JEVTANA,fatal,patients fatal infectionrelated,1
JEVTANA,fatal,fatal infectionrelated adverse,1
JEVTANA,fatal,fatal infectionrelated adverse reactions,1
JEVTANA,fatal,of patients fatal infectionrelated adverse,1
JEVTANA,fatal,fatal infectionrelated adverse reactions,1
JEVTANA,fatal,fatal,1
JEVTANA,fatal,dose of JEVTANA Other fatal adverse re,0
JEVTANA,fatal,fatal,1
JEVTANA,fatal,fatal adverse,1
JEVTANA,fatal,after a,0
JEVTANA,fatal,included ventricular fibrillation cerebral hemorrhag,0
JEVTANA,fatal,fatal adverse,1
JEVTANA,ventricular fibrillation,reactions in JEVTANAtreated patients ventricular fibrillation cerebral hemorrhage and dyspnea,1
JEVTANA,ventricular fibrillation,fatal adverse,1
JEVTANA,ventricular fibrillation,in JEVTANAtreated patients included,0
JEVTANA,ventricular fibrillation,adverse reactions,0
JEVTANA,ventricular fibrillation,cerebral hemorrhage and dyspnea,0
JEVTANA,ventricular fibrillation,dyspnea,0
JEVTANA,ventricular fibrillation,in JEVTANAtreated patients included,0
JEVTANA,cerebral hemorrhage,cerebral hemorrhage,1
JEVTANA,cerebral hemorrhage,cerebral hemorrhage and dyspnea The,1
JEVTANA,cerebral hemorrhage,included ventricular cerebral hemorrhage and,1
JEVTANA,cerebral hemorrhage,cerebral hemorrhage and dyspnea The,1
JEVTANA,cerebral hemorrhage,cerebral,1
JEVTANA,cerebral hemorrhage,cerebral hemorrhage and dyspnea The most common,1
JEVTANA,dyspnea,e,0
JEVTANA,dyspnea,cerebral hemorrhage and,0
JEVTANA,dyspnea,ventricular fibrillation cerebral,0
JEVTANA,dyspnea,hemorrhage dyspnea The most common grade adverse,1
JEVTANA,dyspnea,ventricular fibrillation cerebral,0
JEVTANA,dyspnea,fibrillation cerebral hemorrhage dyspnea The,1
JEVTANA,dyspnea,ventricular fibrillation cerebral,0
JEVTANA,dyspnea,hemorrhage dyspnea The,1
JEVTANA,dyspnea,ventricular fibrillation cerebral,0
JEVTANA,dyspnea,dyspnea The most common grade,1
JEVTANA,dyspnea,hemorrhage dyspnea,1
JEVTANA,dyspnea,dyspnea The most common grade,1
JEVTANA,dyspnea,fibrillation cerebral hemorrhage dyspnea The,1
JEVTANA,dyspnea,dyspnea The most common grade,1
JEVTANA,anemia,anemia leukopenia,1
JEVTANA,anemia,anemia leukopenia,1
JEVTANA,anemia,neutropenia thrombocytopenia diarrhea fatigue,0
JEVTANA,anemia,neutropenia thrombocytopenia diarrhea fatigue,0
JEVTANA,anemia,adverse,0
JEVTANA,anemia,anemia leukopenia neutropenia thrombocytopenia diarrhea,1
JEVTANA,anemia,anemia leukopenia neutropenia,1
JEVTANA,leukopenia,grade adverse reactions were leukopenia neutropenia thrombocytopenia diarrhea fatigue,1
JEVTANA,leukopenia,anemia leukopenia neutropenia,1
JEVTANA,leukopenia,leukopenia neutropenia thrombocytopenia diarrhea,1
JEVTANA,leukopenia,most common grade adverse reactions were anemia,0
JEVTANA,leukopenia,leukopenia neutropenia thrombocytopenia diarrhea fatigue nausea,1
JEVTANA,leukopenia,grade adverse reactions were anemia,0
JEVTANA,leukopenia,leukopenia neutropenia thrombocytopenia diarrhea fatigue,1
JEVTANA,leukopenia,leukopenia neutropenia,1
JEVTANA,leukopenia,leukopenia neutropenia thrombocytopenia diarrhea fatigue,1
JEVTANA,neutropenia,neutropenia thrombocytopenia,1
JEVTANA,thrombocytopenia,leukopenia thrombocytopenia diarrhea fatigue,1
JEVTANA,thrombocytopenia,neutropenia thrombocytopenia,1
JEVTANA,thrombocytopenia,leukopenia neutropenia,0
JEVTANA,thrombocytopenia,abdominal pain hematuria,0
JEVTANA,diarrhea,diarrhea fatigue nausea vomiting constipation,1
JEVTANA,diarrhea,grade adverse reactions,0
JEVTANA,diarrhea,reactions were,0
JEVTANA,diarrhea,diarrhea,1
JEVTANA,fatigue,anemia leukopenia,0
JEVTANA,fatigue,neutropenia thrombocytopenia diarrhea,0
JEVTANA,fatigue,fatigue nausea vomiting constipation,1
JEVTANA,nausea,nausea,1
JEVTANA,nausea,leukopenia neutropenia thrombocytopenia diarrhea nausea vomiting constipation,1
JEVTANA,nausea,nausea,1
JEVTANA,nausea,neutropenia thrombocytopenia diarrhea nausea vomiting,1
JEVTANA,nausea,nausea,1
JEVTANA,nausea,back pain anorexia peripheral,0
JEVTANA,nausea,were anemia leukopenia neutropenia thrombocytopenia,0
JEVTANA,nausea,nausea vomiting constipation,1
JEVTANA,nausea,nausea vomiting constipation asthenia abdominal,1
JEVTANA,nausea,thrombocytopenia diarrhea fatigue,0
JEVTANA,nausea,nausea,1
JEVTANA,nausea,nausea vomiting,1
JEVTANA,nausea,nausea,1
JEVTANA,vomiting,vomiting constipation asthenia,1
JEVTANA,vomiting,vomiting constipation asthenia,1
JEVTANA,vomiting,vomiting constipation asthenia abdominal pain,1
JEVTANA,vomiting,vomiting constipation asthenia abdominal pain hematuria,1
JEVTANA,vomiting,diarrhea fatigue vomiting constipation asthenia abdominal pain,1
JEVTANA,vomiting,vomiting constipation asthenia abdominal pain hematuria,1
JEVTANA,vomiting,vomiting constipation asthenia,1
JEVTANA,vomiting,vomiting constipation,1
JEVTANA,vomiting,neutropenia thrombocytopenia,0
JEVTANA,vomiting,diarrhea fatigue,0
JEVTANA,vomiting,anorexia peripheral neuropathy pyr,0
JEVTANA,constipation,constipation asthenia abdominal,1
JEVTANA,constipation,diarrhea fatigue nausea constipation asthenia abdominal pain,1
JEVTANA,constipation,constipation asthenia abdominal,1
JEVTANA,constipation,diarrhea fatigue nausea constipation asthenia abdominal pain hematuria back,1
JEVTANA,constipation,constipation asthenia abdominal,1
JEVTANA,constipation,back pain anorexia peripheral neuropathy,0
JEVTANA,constipation,constipation asthenia abdominal,1
JEVTANA,constipation,anemia leukopenia,0
JEVTANA,constipation,constipation asthenia,1
JEVTANA,constipation,were anemia leukopenia neutropenia thrombocytopenia,0
JEVTANA,asthenia,asthenia,1
JEVTANA,asthenia,pain anorexia peripheral neuropathy pyrexia dyspnea,0
JEVTANA,asthenia,nausea vomiting asthenia abdominal pain hematuria back,1
JEVTANA,asthenia,pain anorexia peripheral neuropathy pyrexia dyspnea,0
JEVTANA,asthenia,thrombocytopenia diarrhea fatigue nausea vomiting constipation,0
JEVTANA,asthenia,peripheral neuropathy,0
JEVTANA,asthenia,asthenia abdominal pain,1
JEVTANA,asthenia,asthenia abdominal,1
JEVTANA,asthenia,asthenia,1
JEVTANA,asthenia,diarrhea fatigue nausea vomiting asthenia abdominal pain hematuria,1
JEVTANA,asthenia,asthenia,1
JEVTANA,asthenia,diarrhea fatigue nausea vomiting,0
JEVTANA,hematuria,hematuria back pain,1
JEVTANA,hematuria,hematuria back,1
JEVTANA,hematuria,pain,0
JEVTANA,hematuria,neuropathy pyrexia dyspnea dysguesia cough arthralgia,0
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,hematuria back pain,1
JEVTANA,hematuria,asthenia abdominal hematuria back pain anorexia,1
JEVTANA,hematuria,hematuria back pain,1
JEVTANA,back pain,ocytopenia diarrhea fatigue nausea vomiting constipation,0
JEVTANA,back pain,constipation asthenia abdominal pain back pain,1
JEVTANA,back pain,ocytopenia diarrhea fatigue nausea,0
JEVTANA,back pain,pain back pain,1
JEVTANA,back pain,ocytopenia diarrhea fatigue nausea,0
JEVTANA,back pain,abdominal,0
JEVTANA,back pain,back pain anorexia peripheral neuropathy pyrexia dyspnea,1
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,pain,0
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,back anorexia,1
JEVTANA,anorexia,anorexia,1
JEVTANA,anorexia,constipation asthenia abdominal pain,0
JEVTANA,anorexia,neuropathy pyrexia dyspnea dysguesia cough arthralgia and,0
JEVTANA,anorexia,anorexia peripheral,1
JEVTANA,peripheral neuropathy,asthenia abdominal pain hematuria back pain,0
JEVTANA,peripheral neuropathy,back pain peripheral neuropathy pyrexia dyspnea,1
JEVTANA,peripheral neuropathy,asthenia abdominal pain hematuria back pain,0
JEVTANA,peripheral neuropathy,peripheral neuropathy pyrexia dyspnea,1
JEVTANA,peripheral neuropathy,asthenia abdominal pain hematuria back pain,0
JEVTANA,peripheral neuropathy,peripheral neuropathy pyrexia dyspnea dysguesia cough,1
JEVTANA,pyrexia,anorexia peripheral pyrexia dyspnea dysguesia cough,1
JEVTANA,pyrexia,peripheral neuropathy pyrexia dyspnea dysguesia cough,1
JEVTANA,pyrexia,pyrexia dyspnea dysguesia,1
JEVTANA,pyrexia,peripheral pyrexia dyspnea dysguesia cough,1
JEVTANA,pyrexia,pyrexia dyspnea dysguesia,1
JEVTANA,pyrexia,hematuria back pain anorexia peripheral,0
JEVTANA,pyrexia,pyrexia dyspnea dysguesia cough,1
JEVTANA,pyrexia,pyrexia dyspnea,1
JEVTANA,pyrexia,pyrexia dyspnea dysguesia cough,1
JEVTANA,pyrexia,neuropathy,0
JEVTANA,pyrexia,pyrexia dyspnea,1
JEVTANA,pyrexia,ing constipation asthenia abdominal pain,0
JEVTANA,dyspnea,dyspnea dysguesia cough,1
JEVTANA,dyspnea,neuropathy dyspnea dysguesia cough arthralgia and alopecia,1
JEVTANA,dyspnea,dyspnea dysguesia cough,1
JEVTANA,dyspnea,and alopecia The most common grade adverse,0
JEVTANA,dyspnea,dyspnea dysguesia cough arthralgia,1
JEVTANA,dyspnea,dyspnea dysguesia,1
JEVTANA,dyspnea,grade adverse reaction,0
JEVTANA,dyspnea,abdominal,0
JEVTANA,dyspnea,asthenia abdominal,0
JEVTANA,dyspnea,pain hematuria back,0
JEVTANA,dyspnea,dyspnea dysguesia cough arthralgia,1
JEVTANA,dysguesia,dysguesia cough arthralgia and alopecia The,1
JEVTANA,dysguesia,abdominal pain hematuria back pain anorexia peripheral neuropathy pyrexia dyspnea,0
JEVTANA,dysguesia,dysguesia cough arthralgia and alopecia The,1
JEVTANA,dysguesia,grade adverse reactions in patien,0
JEVTANA,dysguesia,back pain,0
JEVTANA,cough,hematuria back,0
JEVTANA,cough,abdominal pain hematuria back pain anorexia peripheral,0
JEVTANA,cough,cough arthralgia and,1
JEVTANA,cough,pyrexia dyspnea cough arthralgia and,1
JEVTANA,cough,cough arthralgia and,1
JEVTANA,cough,pyrexia,0
JEVTANA,cough,pain hematuria back pain anorexia peripheral neuropathy pyrexia dyspnea dysguesia,0
JEVTANA,cough,cough arthralgia,1
JEVTANA,cough,most common grade adverse reactions,0
JEVTANA,cough,cough arthralgia,1
JEVTANA,arthralgia,arthralgia,1
JEVTANA,arthralgia,most common,0
JEVTANA,arthralgia,dysguesia arthralgia and alopecia The,1
JEVTANA,arthralgia,most common,0
JEVTANA,arthralgia,peripheral neuropathy,0
JEVTANA,arthralgia,arthralgia and alopecia The most common,1
JEVTANA,arthralgia,neuropathy pyrexia dyspnea dysguesia arthralgia and alopecia The most,1
JEVTANA,arthralgia,arthralgia and alopecia The most common,1
JEVTANA,arthralgia,arthralgia and alopecia The most,1
JEVTANA,arthralgia,arthralgia and alopecia The most common,1
JEVTANA,arthralgia,neuropathy pyrexia dyspnea dysguesia arthralgia and alopecia The most,1
JEVTANA,arthralgia,arthralgia and alopecia The most common,1
JEVTANA,neutropenia,JEVTANA neutropenia leukopenia anemia febrile neutropenia diarrhea,1
JEVTANA,neutropenia,arthralgia and alopecia The most common,1
JEVTANA,neutropenia,asthenia,0
JEVTANA,neutropenia,anemia febrile neutropenia,0
JEVTANA,neutropenia,neutropenia leukopenia anemia febrile neutropenia,1
JEVTANA,neutropenia,received JEVTANA neutropenia leukopenia anemia,1
JEVTANA,neutropenia,neutropenia leukopenia anemia febrile neutropenia,1
JEVTANA,neutropenia,anemia febrile neutropenia diarrhea fatigue and,0
JEVTANA,neutropenia,ecia The most common grade,0
JEVTANA,neutropenia,patients who received JEVTANA neutropenia leukopenia,1
JEVTANA,neutropenia,ecia The most common grade,0
JEVTANA,leukopenia,diarrhea fatigue and asthenia,0
JEVTANA,leukopenia,leukopenia anemia febrile neutropenia diarrhea,1
JEVTANA,leukopenia,leukopenia anemia,1
JEVTANA,leukopenia,diarrhea fatigue and,0
JEVTANA,leukopenia,leukopenia anemia febrile neutropenia,1
JEVTANA,anemia,discontinuations due to,0
JEVTANA,anemia,were neutropenia anemia febrile neutropenia,1
JEVTANA,anemia,discontinuations due to,0
JEVTANA,anemia,JEVTANA were neutropenia leukopenia,0
JEVTANA,anemia,febrile neutropenia diarrhea fatigue and asthenia Treatment discontinuations,0
JEVTANA,anemia,asthenia Treatment discontinuations due to,0
JEVTANA,febrile neutropenia,who received JEVTANA were neutropenia leukopenia anemia,0
JEVTANA,febrile neutropenia,febrile neutropenia,1
JEVTANA,febrile neutropenia,febrile neutropenia,1
JEVTANA,febrile neutropenia,febrile neutropenia diarrhea fatigue and,1
JEVTANA,diarrhea,due to adverse,0
JEVTANA,diarrhea,diarrhea,1
JEVTANA,diarrhea,discontinuations due,0
JEVTANA,diarrhea,anemia,0
JEVTANA,diarrhea,diarrhea,1
JEVTANA,diarrhea,anemia febrile diarrhea fatigue and,1
JEVTANA,diarrhea,diarrhea,1
JEVTANA,diarrhea,diarrhea fatigue and asthenia Treatment,1
JEVTANA,diarrhea,diarrhea fatigue,1
JEVTANA,diarrhea,diarrhea fatigue and asthenia Treatment,1
JEVTANA,diarrhea,were neutropenia leukopenia anemia febrile,0
JEVTANA,fatigue,JEVTANA were neutropenia leukopenia,0
JEVTANA,fatigue,fatigue and asthenia,1
JEVTANA,fatigue,JEVTANA were neutropenia leukopenia anemia febrile neutropenia diarrhea,0
JEVTANA,fatigue,neutropenia fatigue and asthenia,1
JEVTANA,fatigue,JEVTANA were neutropenia leukopenia anemia febrile neutropenia diarrhea,0
JEVTANA,fatigue,discontinuations due to adverse,0
JEVTANA,fatigue,patients who,0
JEVTANA,fatigue,fatigue and asthenia Treatment discontinuations due,1
JEVTANA,fatigue,febrile neutropenia fatigue,1
JEVTANA,fatigue,fatigue and asthenia Treatment discontinuations due,1
JEVTANA,asthenia,asthenia Treatment discontinuations,1
JEVTANA,asthenia,neutropenia diarrhea fatigue asthenia Treatment discontinuations due to adverse,1
JEVTANA,asthenia,asthenia Treatment discontinuations,1
JEVTANA,asthenia,and,0
JEVTANA,asthenia,asthenia Treatment discontinuations due to adverse,1
JEVTANA,asthenia,neutropenia,0
JEVTANA,asthenia,asthenia Treatment discontinuations due to,1
JEVTANA,renal failure,JEVTANAtreated patients,0
JEVTANA,renal failure,JEVTANA group were neutropenia renal,1
JEVTANA,renal failure,were reported in of JEVTANAtreated patients and of mitoxantronetreated pa,0
JEVTANA,renal failure,patients and,0
JEVTANA,Hematologic Abnormalities,Hematologic,1
JEVTANA,Hematologic Abnormalities,or Mitoxantrone,0
JEVTANA,Hematologic Abnormalities,Hematologic Abnormalities in of Patients Receiving,1
JEVTANA,Hematologic Abnormalities,Combination with,0
JEVTANA,Hematologic Abnormalities,patients,0
JEVTANA,Hematologic Abnormalities,Hematologic,1
JEVTANA,Hematologic Abnormalities,JEVTANA in Combination with Prednisone or Mitoxantrone in Combinatio,0
JEVTANA,Hematologic Abnormalities,using NCI CTCAE version and,0
JEVTANA,infectious adverse events,infectious adverse events,1
JEVTANA,infectious adverse events,using NCI CTCAE version and,0
JEVTANA,infectious adverse events,or septic shock All had grade,0
JEVTANA,infectious adverse events,Five patients experienced infectious,1
JEVTANA,sepsis,One,0
JEVTANA,sepsis,Associated Clinical Events Five patients experienced fatal infectious adverse events,0
JEVTANA,sepsis,sepsis or septic shock All had,1
JEVTANA,sepsis,sepsis or septic shock All had,1
JEVTANA,neutropenia,neutropenia and,1
JEVTANA,neutropenia,death,0
JEVTANA,neutropenia,adverse events sepsis or septic shock,0
JEVTANA,febrile neutropenia,neutropenia and one febrile,1
JEVTANA,febrile neutropenia,One additional patients,0
JEVTANA,death,neutropenia One additional death was attributed,1
JEVTANA,death,One additional patients,0
JEVTANA,death,infection Twentytwo,0
JEVTANA,death,One additional,0
JEVTANA,death,neutropenia One additional,0
JEVTANA,death,neutropenia,0
JEVTANA,death,death was attributed,1
JEVTANA,death,death was attributed to neutropenia without,1
JEVTANA,death,death was,1
JEVTANA,death,infection Twentytwo patients discontinued,0
JEVTANA,death,death was attributed to,1
JEVTANA,infection,infection Twentytwo patients,1
JEVTANA,infection,neutropenia febrile neutropenia i,0
JEVTANA,infection,neutropenia without a infection Twentytwo patients discontinued,1
JEVTANA,infection,neutropenia febrile neutropenia i,0
JEVTANA,infection,infection Twentytwo patients discontinued JEVTANA,1
JEVTANA,infection,neutropenia without a infection Twentytwo patients discontinued,1
JEVTANA,infection,infection Twentytwo patients discontinued JEVTANA,1
JEVTANA,infection,attributed to neutropenia without a documented,0
JEVTANA,infection,infection Twentytwo patients discontinued,1
JEVTANA,infection,neutropenia One additional patients death was attributed to neutropenia without a documented,0
JEVTANA,infection,One additional patients death was attributed,0
JEVTANA,infection,infection Twentytwo patients discontinued,1
JEVTANA,neutropenia,neutropenia febrile neutropenia infection or,1
JEVTANA,neutropenia,neutropenia febrile,1
JEVTANA,neutropenia,neutropenia infection or sepsis The most common adverse reaction leading to treatment d,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,reaction leading,0
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,neutropenia febrile neutropenia infection or,1
JEVTANA,neutropenia,neutropenia febrile neutropenia infection,1
JEVTANA,neutropenia,neutropenia febrile neutropenia infection or,1
JEVTANA,neutropenia,neutropenia infection or sepsis The most common adverse reaction leading to,0
JEVTANA,neutropenia,patients discontinued,0
JEVTANA,febrile neutropenia,febrile neutropenia infection or,1
JEVTANA,febrile neutropenia,treatment due to febrile neutropenia,1
JEVTANA,febrile neutropenia,leading,0
JEVTANA,febrile neutropenia,treatment due to febrile neutropenia infection,1
JEVTANA,febrile neutropenia,leading,0
JEVTANA,febrile neutropenia,JEVTANA,0
JEVTANA,febrile neutropenia,to neutropenia,0
JEVTANA,infection,infection or,1
JEVTANA,infection,neutropenia febrile infection or,1
JEVTANA,infection,infection or,1
JEVTANA,infection,febrile infection,1
JEVTANA,infection,infection or,1
JEVTANA,infection,leading to treatment discontinuation in the,0
JEVTANA,infection,febrile neutropenia,0
JEVTANA,infection,The most common adverse reaction leading,0
JEVTANA,sepsis,neutropenia febrile neutropenia infection sepsis,1
JEVTANA,sepsis,The most common adverse reaction leading,0
JEVTANA,sepsis,neutropenia infection sepsis The,1
JEVTANA,sepsis,The most common adverse reaction leading,0
JEVTANA,hematuria,including those requiring medical intervention were more common,0
JEVTANA,hematuria,hematuria including those requiring,1
JEVTANA,hematuria,neutropenia Hematuria Adverse events hematuria,1
JEVTANA,hematuria,hematuria including those requiring,1
JEVTANA,hematuria,neutropenia Hematuria Adverse events hematuria including,1
JEVTANA,hematuria,hematuria including those requiring,1
JEVTANA,hematuria,hematuria including those requiring,1
JEVTANA,hematuria,hematuria including those requiring medical intervention,1
JEVTANA,hematuria,the JEVTANA group was neutropenia Hematuria Adverse,0
JEVTANA,hematuria,events hematuria including those,1
JEVTANA,hematuria,the JEVTANA group was neutropenia Hematuria Adverse,0
JEVTANA,hematuria,Hematuria Adverse events hematuria including those requiring medical,1
JEVTANA,hematuria,the JEVTANA group was neutropenia Hematuria Adverse,0
JEVTANA,hematuria,hematuria was in JEVTANAtreated patients and,1
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,medical intervention,0
JEVTANA,hematuria,hematuria was in JEVTANAtreated patients,1
JEVTANA,hematuria,hematuria were wellbalanced between arms and,1
JEVTANA,hematuria,and do not account for the increased,0
JEVTANA,hematuria,hematuria,1
JEVTANA,hematuria,JEVTANAtreated patients and in mitoxantronetreated patients Other factors associated with,0
JEVTANA,hematuria,hematuria were wellbalanced between,1
JEVTANA,hematuria,hematuria on the,1
JEVTANA,hematuria,Laboratory Abnormalities The incidences of grade,0
JEVTANA,hematuria,rate,0
JEVTANA,increased AST,increased AST increased ALT and increased,1
JEVTANA,increased AST,rate,0
JEVTANA,increased ALT,AST,0
JEVTANA,increased ALT,incidences of grade increased increased,1
JEVTANA,increased ALT,increased ALT and increased bilirubin were,1
JEVTANA,increased ALT,increased increased ALT,1
JEVTANA,increased ALT,increased ALT and increased bilirubin were,1
JEVTANA,increased ALT,grade increased increased ALT,1
JEVTANA,increased ALT,increased ALT,1
JEVTANA,increased ALT,incidences of,0
JEVTANA,increased ALT,Elderly Population The following,0
JEVTANA,increased bilirubin,ALT,0
JEVTANA,increased bilirubin,following grade adverse reactions were,0
JEVTANA,increased bilirubin,Hepatic Laboratory Abnormalities The incidences of,0
JEVTANA,asthenia,asthenia vs pyrexia vs dizziness,1
JEVTANA,pyrexia,tract infection vs,0
JEVTANA,pyrexia,neutropenia vs asthenia pyrexia vs dizziness vs,1
JEVTANA,pyrexia,tract infection vs,0
JEVTANA,pyrexia,vs neutropenia vs asthenia pyrexia vs dizziness vs,1
JEVTANA,pyrexia,tract infection vs,0
JEVTANA,dizziness,infection vs and dehydration,0
JEVTANA,dizziness,urinary tract infection vs,0
JEVTANA,dizziness,dizziness vs urinary tract infection,1
JEVTANA,urinary tract infection,urinary tract infection vs and dehydration,1
JEVTANA,urinary tract infection,dizziness urinary,1
JEVTANA,urinary tract infection,and,0
JEVTANA,urinary tract infection,vs,0
JEVTANA,urinary tract infection,and dehydration vs respectively The incidence of,0
JEVTANA,urinary tract infection,vs pyrexia vs dizziness urinary,1
JEVTANA,urinary tract infection,respectively The incidence of,0
JEVTANA,urinary tract infection,tract infection vs and,1
JEVTANA,urinary tract infection,urinary tract infection,1
JEVTANA,urinary tract infection,urinary tract infection vs and dehydration,1
JEVTANA,dehydration,dehydration vs respectively The incidence of,1
JEVTANA,dehydration,dehydration vs respectively The,1
JEVTANA,dehydration,adverse reactions were high,0
JEVTANA,dehydration,dehydration vs respectively The,1
JEVTANA,dehydration,the following grade adverse reactions,0
JEVTANA,dehydration,dehydration vs respectively The,1
JEVTANA,dehydration,dehydration vs respectively The incidence,1
JEVTANA,dehydration,vs respectively The incidence,0
JEVTANA,dehydration,following grade adverse,0
JEVTANA,dehydration,tract infection vs,0
JEVTANA,neutropenia,neutropenia vs,1
JEVTANA,neutropenia,Use in,0
JEVTANA,neutropenia,vs see,0
JEVTANA,neutropenia,compared to younger neutropenia vs and febrile neutropenia,1
JEVTANA,neutropenia,vs see,0
JEVTANA,neutropenia,neutropenia vs and,1
JEVTANA,neutropenia,neutropenia,1
JEVTANA,neutropenia,higher in patients years of age compared,0
JEVTANA,neutropenia,neutropenia vs and,1
JEVTANA,febrile neutropenia,patients neutropenia vs febrile,1
JEVTANA,febrile neutropenia,Use,0
JEVTANA,febrile neutropenia,neutropenia vs febrile,1
JEVTANA,febrile neutropenia,febrile neutropenia vs see Use,1
JEVTANA,febrile neutropenia,vs febrile neutropenia,1
JEVTANA,febrile neutropenia,febrile neutropenia vs see Use,1
JEVTANA,febrile neutropenia,Postmarketing Experience Th,0
JEVTANA,febrile neutropenia,Specific Populations,0
JEVTANA,febrile neutropenia,younger patients neutropenia vs febrile neutropenia,1
JEVTANA,febrile neutropenia,patients neutropenia vs febrile,1
JEVTANA,Gastritis,Gastritis,1
JEVTANA,NEUTROPENIA, following ,1
JEVTANA,NEUTROPENIA, following  serious adverse reactions are,1
JEVTANA,NEUTROPENIA,REACTIONS  following  serious adverse,1
JEVTANA,NEUTROPENIA, following  serious adverse reactions are,1
JEVTANA,NEUTROPENIA,in greater detail in another,0
JEVTANA,NEUTROPENIA, following  serious,1
JEVTANA,NEUTROPENIA,ADVERSE,0
JEVTANA,NEUTROPENIA, following  serious,1
JEVTANA,HYPERSENSITIVITY,us adverse react,1
JEVTANA,HYPERSENSITIVITY,REACTIONS The following us adverse react ions are discussed in,1
JEVTANA,HYPERSENSITIVITY,us adverse react,1
JEVTANA,NEUTROPENIA,are,0
JEVTANA,NEUTROPENIA,reactions,0
JEVTANA,NEUTROPENIA,serious adverse reactions are sed in grea,1
JEVTANA,NEUTROPENIA,reactions,0
JEVTANA,NEUTROPENIA,discus,0
JEVTANA,NEUTROPENIA,serious adverse reactions are sed,1
JEVTANA,NEUTROPENIA,sed in,1
JEVTANA,NEUTROPENIA,sed in grea ter,1
JEVTANA,NEUTROPENIA,serious adverse reactions are sed in,1
JEVTANA,NEUTROPENIA,adverse reactions are sed in grea,1
JEVTANA,HYPERSENSITIVITY,etail in another,1
JEVTANA,NEUTROPENIA,of the Bone Marr,1
JEVTANA,NEUTROPENIA,section of the Bone,1
JEVTANA,NEUTROPENIA,Suppression see Warnings and Precautions Hypersensitivity Reactions,0
JEVTANA,HYPERSENSITIVITY,see Warnings and,0
JEVTANA,HYPERSENSITIVITY,Precautions Hypersensitivity Reactions see Warnings and,0
JEVTANA,HYPERSENSITIVITY,Warnings and Precautions Hypersensitivity Reactions,0
JEVTANA,HYPERSENSITIVITY,ppression [see Warnings and Precautions Hypersensitivity,1
JEVTANA,HYPERSENSITIVITY,Bone Marrow ppression [see,1
JEVTANA,HYPERSENSITIVITY,ppression [see Warnings and Precautions Hypersensitivity Reactions,1
JEVTANA,HYPERSENSITIVITY,ppression [see Warnings,1
JEVTANA,HYPERSENSITIVITY,label Bone Marrow ppression [see   Warnings and Precautions Hypersensitivity Reactions,1
JEVTANA,HYPERSENSITIVITY,ppression [see Warnings,1
JEVTANA,HYPERSENSITIVITY,ppression [see Warnings and Precautions,1
JEVTANA,HYPERSENSITIVITY,see,0
JEVTANA,Neutropenic,Warnings,0
JEVTANA,Neutropenic,Precautions Hypersensitivity Reactions see and Precaut ions,1
JEVTANA,Neutropenic,Warnings,0
JEVTANA,Neutropenic,and Precaut ions Gastrointestinal Adverse Reactions see,1
JEVTANA,Neutropenic,Reactions see and Precaut ions Gastrointestinal Adverse,1
JEVTANA,Neutropenic,and Precaut ions Gastrointestinal Adverse Reactions see,1
JEVTANA,Neutropenic,Reactions see and,1
JEVTANA,Neutropenic,see and,1
JEVTANA,Neutropenic,Precautions Hypersensitivity Reactions see and Precaut ions Gastrointestinal Adverse,1
JEVTANA,Neutropenic,see and,1
JEVTANA,Neutropenic,Reactions see and,1
JEVTANA,deaths,Precautions Hypersensitivity Reactions see Warnings and Precauti,0
JEVTANA,deaths,ons (5 Gastrointestinal Adverse Reactions see,1
JEVTANA,deaths,Precauti,0
JEVTANA,deaths,ons (5,1
JEVTANA,deaths,Precauti,0
JEVTANA,deaths,Warnings,0
JEVTANA,hypersensitivity, Elderly Patient s,1
JEVTANA,hypersensitivity,Warnings,0
JEVTANA,hypersensitivity,Use Elderly,1
JEVTANA,hypersensitivity,Use in Patients,0
JEVTANA,hypersensitivity,Use Elderly,1
JEVTANA,hypersensitivity,Impairment see Warni,0
JEVTANA,hypersensitivity,Elderly Patient s,1
JEVTANA,hypersensitivity,see Warnings and Precautions Use,0
JEVTANA,hypersensitivity,in,0
JEVTANA,hypersensitivity,see Warnings,0
JEVTANA,hypersensitivity,Hepatic Impairment,0
JEVTANA,generalized rash,Warnings and tions (5.5)  ] .,1
JEVTANA,generalized rash,Hepatic Impairment,0
JEVTANA,erythema,Patients see,0
JEVTANA,erythema,Impairment see Warnings and Precautions EmbryoFetal,0
JEVTANA,hypotension,n Patients with Hepatic Impairment,1
JEVTANA,hypotension,Impairment see Warnings and Precautions EmbryoFetal Toxicity,0
JEVTANA,hypotension,n Patients with Hepatic Impairment see Warnings,1
JEVTANA,hypotension,n Patients,1
JEVTANA,hypotension,Precautions Use n Patients  with Hepatic Impairment,1
JEVTANA,hypotension,n Patients,1
JEVTANA,hypotension,n Patients with Hepatic,1
JEVTANA,hypotension,Warnings and Precautions Use i,0
JEVTANA,hypotension,n Patients with,1
JEVTANA,hypotension,Warnings and Precautions Use n Patients,1
JEVTANA,bronchospasm,Hepatic,1
JEVTANA,bronchospasm,irment see,0
JEVTANA,bronchospasm,Hepatic Impa,1
JEVTANA,bronchospasm,Precautions EmbryoFetal Toxicity see Warnings and,0
JEVTANA,Neutropenic,pain hematuria,0
JEVTANA,deaths,consti pation asthenia abdominal pain hematuria,1
JEVTANA,deaths,consti pation asthenia abdominal,1
JEVTANA,deaths,consti pation asthenia abdominal pain,1
JEVTANA,deaths,pain hematuria back pain anorexia peripheral,0
JEVTANA,deaths,consti pation asthenia,1
JEVTANA,deaths,anemia,0
JEVTANA,deaths,thrombocytopenia diarrhea fatigue nausea consti pation asthenia,1
JEVTANA,deaths,anemia,0
JEVTANA,deaths,neuropathy pyrexia,0
JEVTANA,hypersensitivity reactions,trials are conducted under widely varying,1
JEVTANA,hypersensitivity reactions,neuropathy pyrexia,0
JEVTANA,hypersensitivity reactions,conditions,0
JEVTANA,hypersensitivity reactions,trials are,1
JEVTANA,hypersensitivity reactions,trials are conducted under widely varying,1
JEVTANA,hypersensitivity reactions,or wwwfdagovmedwatch Clinical,0
JEVTANA,hypersensitivity reactions,trials are conducted under widely,1
JEVTANA,hypersensitivity reactions,or wwwfdagovmedwatch Clinical,0
JEVTANA,hypersensitivity reactions,trials are conducted under widely varying conditions,1
JEVTANA,generalized rash,be directly compared to rates in other trials and may not,0
JEVTANA,hypotension,reaction rates,0
JEVTANA,bronchospasm,be directly compared to rates in,1
JEVTANA,bronchospasm,trials are conducted under widely varying conditions the adverse,0
JEVTANA,hypersensitivity reactions,rates in other trials and may not reflect the,1
JEVTANA,hypersensitivity reactions,be directly to rates in other,1
JEVTANA,hypersensitivity reactions,be directly  to rates in other trials  and may not reflect the,1
JEVTANA,hypersensitivity reactions,be directly to rates in other,1
JEVTANA,hypersensitivity reactions,directly to rates in other,1
JEVTANA,hypersensitivity reactions,cannot be directly to rates in,1
JEVTANA,hypersensitivity reactions,cannot be,0
JEVTANA,hypersensitivity reactions,cannot be directly  to rates in other trials  and may not,1
JEVTANA,hypersensitivity reactions,cannot be,0
JEVTANA,hypersensitivity reactions,rates in other trials and may not,1
JEVTANA,hypersensitivity reactions,directly  to rates in other trials  and,1
JEVTANA,hypersensitivity reactions,rates in other trials and may not,1
JEVTANA,Bone marrow suppression,serious erse reactions are disc ussed in greater detail,1
JEVTANA,Bone marrow suppression,rates in other trials and may not,1
JEVTANA,Bone marrow suppression,erse reactions are disc,1
JEVTANA,Bone marrow suppression,REACTIONS The,0
JEVTANA,Bone marrow suppression,are disc ussed in,1
JEVTANA,Bone marrow suppression,The following serious erse reactions are disc ussed in greater detail in,1
JEVTANA,Bone marrow suppression,are disc ussed in,1
JEVTANA,Bone marrow suppression,serious erse reactions are disc ussed in greater,1
JEVTANA,Bone marrow suppression,are disc ussed in,1
JEVTANA,neutropenia,r detail in another section of the,1
JEVTANA,febrile neutropenia,serious adverse reactions are discussed,0
JEVTANA,febrile neutropenia,of the * Bone Marrow,1
JEVTANA,febrile neutropenia,and,0
JEVTANA,febrile neutropenia,"section of the 
 *  Bone Marrow Su ppression see Warnings and Precautions",1
JEVTANA,febrile neutropenia,and,0
JEVTANA,febrile neutropenia,Hypersensitivity,0
JEVTANA,neutropenic infections,the label Bone Marrow ression [see  Warnings and Precautions Hypersensitivity Reactions see,1
JEVTANA,neutropenic infections,Hypersensitivity,0
JEVTANA,neutropenic infections,and Precautions Hypersensitivity,0
JEVTANA,neutropenic infections,Marrow ression [see  Warnings,1
JEVTANA,neutropenic infections,and Precautions Hypersensitivity,0
JEVTANA,neutropenic infections,Bone Marrow ression [see,1
JEVTANA,neutropenic infections,Precautions Hypersensitivity Reactions see,0
JEVTANA,Hypersensitivity,ngs and Precauti ons Use in Patients,1
JEVTANA,Hypersensitivity,ngs,1
JEVTANA,Hypersensitivity,ngs and Precauti ons Use,1
JEVTANA,Hypersensitivity,in Elderly Patients see ngs and Precauti ons,1
JEVTANA,Hypersensitivity,ngs and Precauti ons Use,1
JEVTANA,Gastrointestinal disorders,see Warnings and Precautions EXCERPT Most common all,0
JEVTANA,Gastrointestinal disorders,adverse reactions (>=10%) are neutropenia anemia leukopenia,1
JEVTANA,Gastrointestinal disorders,are neutropenia anemia leukopenia thrombocytopenia,0
JEVTANA,Gastrointestinal disorders,diarrhea fatigue nausea vomiting constip,0
JEVTANA,Gastrointestinal disorders,see Warnings and Precautions EXCERPT Most,0
JEVTANA,Gastrointestinal disorders,EXCERPT Most common all adverse,1
JEVTANA,Gastrointestinal disorders,diarrhea fatigue nausea vomiting constip,0
JEVTANA,Gastrointestinal disorders,common all adverse reactions,1
JEVTANA,Nausea,re neu tropenia anemia,1
JEVTANA,Nausea,grades adverse reactions re neu tropenia anemia leukopenia thrombocytopenia diarrhea,1
JEVTANA,Nausea,re neu tropenia anemia,1
JEVTANA,Nausea,a,0
JEVTANA,Nausea,vomiting constipation a,0
JEVTANA,vomiting,vomiting constipation asthenia,0
JEVTANA,vomiting,"openia,  anemia",1
JEVTANA,vomiting,common all grades adverse reactions are,0
JEVTANA,vomiting,"openia,  anemia leukopenia thrombocytopenia",1
JEVTANA,diarrhea,", leukop enia thrombocytopenia diarrhea fatigue",1
JEVTANA,diarrhea,"openia,  anemia leukopenia thrombocytopenia",1
JEVTANA,Mortality,diarrhea fatigue nausea vomiting constipation asthenia abdominal pain hematuria back pain,0
JEVTANA,Mortality,ocytopeni,1
JEVTANA,Mortality,pain hematuria,0
JEVTANA,Mortality,ocytopeni a diarrhea fatigue,1
JEVTANA,diarrhea,adverse reactions are,0
JEVTANA,Deaths,and al opecia To report,1
JEVTANA,Deaths,To,0
JEVTANA,gastrointestinal hemorrhage,SUSPECTED ADVERSE REACTIONS,1
JEVTANA,gastrointestinal hemorrhage,arthralgia and To report SUSPECTED ADVERSE,1
JEVTANA,gastrointestinal hemorrhage,cough arthralgia and To report SUSPECTED ADVERSE REACTIONS,1
JEVTANA,gastrointestinal hemorrhage,arthralgia and To report SUSPECTED ADVERSE,1
JEVTANA,gastrointestinal hemorrhage,dysgeusia cough arthralgia and To report,1
JEVTANA,neutropenic enterocolitis,contac,0
JEVTANA,neutropenic enterocolitis,sanofi-aventis U.S. LLC at or,1
JEVTANA,neutropenic enterocolitis,SUSPECTED ADVERSE REACTIONS t sanofi-aventis,1
JEVTANA,neutropenic enterocolitis,geusia cough arthralgia and alopecia To report SUSPECTED ADVERSE REACTIONS,0
JEVTANA,Renal failure, www.fda.gov/ medwatch,1
JEVTANA,Renal failure, www.fda.gov/ medwatch Clinical,1
JEVTANA,Renal failure, www.fda.gov/ medwatch,1
JEVTANA,Renal failure,at FDA  www.fda.gov/ medwatch Clinical Trial,1
JEVTANA,Renal failure, www.fda.gov/ medwatch,1
JEVTANA,Renal failure, www.fda.gov/ medwatch Clinical Trial,1
JEVTANA,Renal failure, www.fda.gov/ medwatch Clinical,1
JEVTANA,Renal failure,Clinical Trial Experience Because clinical trials,0
JEVTANA,fatal,.1 Cl inical,1
JEVTANA,fatal,Trial Experience Because clinical trials are conducted under,0
JEVTANA,fatal,be directly to ra,1
JEVTANA,fatal,observed,0
JEVTANA,fatal,to ra tes in,1
JEVTANA,fatal,to ra tes in other trials,1
JEVTANA,fatal,and may not reflect the rates observed in clinical,0
JEVTANA,fatal,cannot be directly to ra tes in,1
JEVTANA,fatal,and may not reflect the rates observed in clinical,0
JEVTANA,neutropenia,rates observed in clinical practice T,0
JEVTANA,neutropenia,clinical practice he,1
JEVTANA,neutropenia,safety o f JEVTANA in,1
JEVTANA,neutropenia,practice,0
JEVTANA,neutropenia,in clinical practice he safety o f,1
JEVTANA,neutropenia,practice,0
JEVTANA,febrile neutropenia,The safety of TANA,1
JEVTANA,febrile neutropenia,may not reflect the rates observed in,0
JEVTANA,febrile neutropenia,safety of TANA in combination with prednisone,1
JEVTANA,febrile neutropenia,may not reflect the rates observed in,0
JEVTANA,febrile neutropenia,of JEV,0
JEVTANA,febrile neutropenia,rates observed in clinical practice The safety of JEV,0
JEVTANA,febrile neutropenia,practice The,0
JEVTANA,febrile neutropenia,in combination,1
JEVTANA,febrile neutropenia,rates,0
JEVTANA,febrile neutropenia,evaluated in patients with hormonerefractory metastatic,0
JEVTANA,Hepatic impairment,patients wit,0
JEVTANA,Hepatic impairment,h hormone-refracto,1
JEVTANA,fetal harm,progression within of,1
JEVTANA,fetal harm,of last s tudy,1
JEVTANA,fetal harm,progression within  of last s,1
JEVTANA,fetal harm,of last s tudy,1
JEVTANA,fetal harm,Deaths due to causes other than disease progression within days,0
JEVTANA,neutropenia,patients were infections n and,0
JEVTANA,neutropenia,tions in JE VTANAtreated patients were,1
JEVTANA,neutropenia,patients were infections n and,0
JEVTANA,neutropenia,common fatal adverse tions in,1
JEVTANA,neutropenia,patients and mitoxantronetreated patients The most common,0
JEVTANA,neutropenia,n The majority,0
JEVTANA,neutropenia,majority of,0
JEVTANA,neutropenia,common fatal adverse reac,0
JEVTANA,neutropenia,fatal adverse tions in JE VTANAtreated patients were infections,1
JEVTANA,neutropenia,common fatal adverse reac,0
JEVTANA,anemia,infections n and renal failure n The majority,0
JEVTANA,anemia,of patients,0
JEVTANA,anemia,patients,0
JEVTANA,anemia,ANA-tr,1
JEVTANA,anemia,ANA-tr eated,1
JEVTANA,anemia,ANA-tr,1
JEVTANA,anemia,in ANA-tr eated patients were infections n,1
JEVTANA,anemia,ANA-tr,1
JEVTANA,anemia,ANA-tr eated patients were infections,1
JEVTANA,anemia,ANA-tr eated patients were,1
JEVTANA,anemia,fatal adverse,0
JEVTANA,thrombocytopenia,most,0
JEVTANA,pancytopenia,were ions (n=5) a nd,1
JEVTANA,pancytopenia,most,0
JEVTANA,pancytopenia,JEVTANAtreated patients were,0
JEVTANA,pancytopenia,ions (n=5) a nd renal failure,1
JEVTANA,pancytopenia,of,0
JEVTANA,pancytopenia,were ions,1
JEVTANA,pancytopenia,failure n The majority of patients of,0
JEVTANA,Neutropenic,adverse reactions in JEVTANAtreated patients were,0
JEVTANA,Neutropenic,JEVTANAtreated patients were infections n and renal fai,0
JEVTANA,deaths,jority of patients of fatal,0
JEVTANA,deaths,reactions in JEVTANAtreated patients were infections n,0
JEVTANA,deaths,of fatal infectionrelated adverse reactions occurred after,0
JEVTANA,deaths,n and renal failure The ma,1
JEVTANA,deaths,The ma jority of,1
JEVTANA,deaths,failure The ma jority of patients of fatal,1
JEVTANA,deaths,The ma jority of,1
JEVTANA,deaths,The ma,1
JEVTANA,deaths,The,1
JEVTANA,deaths,failure The ma,1
JEVTANA,fatal,of fatal infectionrelated adverse reactions,0
JEVTANA,fatal,after,1
JEVTANA,fatal,of fatal infectionrelated adverse reactions,0
JEVTANA,fatal,reactions after a single,1
JEVTANA,fatal,of fatal infectionrelated adverse reactions,0
JEVTANA,fatal,infectionrelated adverse reactions after a single dose of JEVTANA,1
JEVTANA,fatal,of fatal infectionrelated adverse reactions,0
JEVTANA,fatal,adverse reactions after a single dose,1
JEVTANA,fatal,of fatal infectionrelated adverse reactions,0
JEVTANA,fatal,patients of,0
JEVTANA,fatal,after a single dose,1
JEVTANA,fatal,after a,1
JEVTANA,fatal,after a,1
JEVTANA,fatal,fatal infectionrelated adverse reactions after,1
JEVTANA,fatal,after a,1
JEVTANA,infectious adverse events,e n The majority of patients,0
JEVTANA,infectious adverse events,a,1
JEVTANA,infectious adverse events,of JEVTANA. Other fatal adverse,1
JEVTANA,infectious adverse events,ventricular fibrillation cerebr,0
JEVTANA,sepsis,ther f,1
JEVTANA,sepsis,in JEVTANAtreated,0
JEVTANA,sepsis,adverse reactions occurred,0
JEVTANA,sepsis,ventricular fibrillation,0
JEVTANA,sepsis,ther f atal adverse reactions in,1
JEVTANA,sepsis,JEVTANAtreated patients included ventricular,0
JEVTANA,sepsis,ther f atal adverse,1
JEVTANA,neutropenia,reated pati ents included ventricular fibrillation cerebral,1
JEVTANA,neutropenia,ents,0
JEVTANA,neutropenia,ventricular fibrillation cerebral,0
JEVTANA,neutropenia,reated pati ents included ventricular,1
JEVTANA,febrile neutropenia,reactions,0
JEVTANA,febrile neutropenia, ventricular fibril,1
JEVTANA,febrile neutropenia,reactions,0
JEVTANA,febrile neutropenia,The most common grade,0
JEVTANA,febrile neutropenia,ventricular fibril lation cerebral hemorrhage and dyspnea,1
JEVTANA,febrile neutropenia,dose of JEVTANA Other fatal adverse,0
JEVTANA,febrile neutropenia,grade adverse,0
JEVTANA,febrile neutropenia,most,0
JEVTANA,febrile neutropenia,ventricular,1
JEVTANA,febrile neutropenia,in,0
JEVTANA,death,", and dyspnea The most common grade",1
JEVTANA,death,", and",1
JEVTANA,death,were anemia leukopenia neutrope,0
JEVTANA,neutropenia,leukopenia neutropenia thrombocytopenia diarrhe,0
JEVTANA,neutropenia,hemorrhage and dyspnea The ost common  grade adverse reactions were anemia,1
JEVTANA,neutropenia,leukopenia neutropenia thrombocytopenia diarrhe,0
JEVTANA,infection,common grade erse reac tions were,1
JEVTANA,infection,leukopenia neutropenia thrombocytopenia diarrhe,0
JEVTANA,infection,common grade erse,1
JEVTANA,neutropenia,nausea,0
JEVTANA,neutropenia,"nemia, leuk openia neutropenia thrombocytopenia diarrhea fatigue",1
JEVTANA,neutropenia,vomiting constipation,0
JEVTANA,neutropenia,"grade adverse reactions were nemia,",1
JEVTANA,neutropenia,"nemia, leuk openia neutropenia thrombocytopenia diarrhea",1
JEVTANA,neutropenia,vomiting constipation,0
JEVTANA,Hypersensitivity reactions,mg dailyn,0
JEVTANA,Hypersensitivity reactions,"sone 
                     JEVTANA mgm every weeks",1
JEVTANA,Hypersensitivity reactions,"with sone 
                    ",1
JEVTANA,Hypersensitivity reactions,"sone 
                     JEVTANA mgm every weeks",1
JEVTANA,Hypersensitivity reactions,"sone 
                    ",1
JEVTANA,Hypersensitivity reactions,"sone 
                     JEVTANA mgm",1
JEVTANA,hypersensitivity reactions,n Any Adverse,0
JEVTANA,generalized rash,Grade n Grade n de 1-4n (%)   Gr ade,1
JEVTANA,generalized rash,n Any Adverse,0
JEVTANA,generalized rash,Grade n Grade n de 1-4n (%) Gr,1
JEVTANA,generalized rash,Grade n de,1
JEVTANA,generalized rash,Grade n Grade n de,1
JEVTANA,generalized rash,ade n,0
JEVTANA,erythema,Any Adverse,0
JEVTANA,erythema,de 3-4n Any Adverse Reaction,1
JEVTANA,erythema,n Gra,0
JEVTANA,erythema,n de,1
JEVTANA,erythema,Grade,0
JEVTANA,erythema,Grade n de,1
JEVTANA,erythema,de 3-4n Any Adverse,1
JEVTANA,erythema,Grade,0
JEVTANA,erythema,de,1
JEVTANA,erythema,de 3-4n Any Adverse,1
JEVTANA,hypotension,")    
  
   Any Adverse Reaction",1
JEVTANA,hypotension,Grade n Grade n Grade,0
JEVTANA,hypotension,")    
  
  ",1
JEVTANA,hypotension,Grade n Grade n Grade,0
JEVTANA,hypotension,")    
  
  ",1
JEVTANA,hypotension,Grade n,0
JEVTANA,hypotension,Any Adverse Reaction,0
JEVTANA,bronchospasm,Grade n Adverse,1
JEVTANA,bronchospasm,Grade n,0
JEVTANA,bronchospasm,Grade n Grade n Adverse,1
JEVTANA,bronchospasm,Adverse Reac tion Blo,1
JEVTANA,neutropenia,ons and,0
JEVTANA,neutropenia,ry Tract Infection,0
JEVTANA,neutropenia,"and   
   Urina ry Tract",1
JEVTANA,neutropenia,ry Tract Infection,0
JEVTANA,fetal harm, (7%)      Nervous System,1
JEVTANA,fetal harm,ry Tract Infection,0
JEVTANA,fetal harm, (7%)      Nervous System Disorders,1
JEVTANA,fetal harm,Nervous System Disorders,0
JEVTANA,fetal harm,Muscle  (7%)     ,1
JEVTANA,fetal harm,Nervous System Disorders,0
JEVTANA,fetotoxic,         ,1
JEVTANA,fetotoxic,         ,1
JEVTANA,fetotoxic,         ,1
JEVTANA,fetotoxic,Disorders,0
JEVTANA,abortifacient,             ,1
JEVTANA,abortifacient,Nervous,0
JEVTANA,abortifacient,              Peripheral,1
JEVTANA,abortifacient,              Peripheral,1
ILARIS,infections,infections,1
ILARIS,infections,infections,1
ILARIS,infections,were observed The type and frequency of adverse,0
ILARIS,infections,infections,1
ILARIS,infections,to moderate although infections,1
ILARIS,infections,infections,1
ILARIS,infections,infections were observed,1
ILARIS,infections,infections were observed The type,1
ILARIS,infections,infections were,1
ILARIS,Opportunistic infections,patients treated with ILARIS,0
ILARIS,nasopharyngitis,nasopharyngitis diarrhea influenza headache and,1
ILARIS,nasopharyngitis,CAPS treated with ILARIS nasopharyngitis diarrhea influenza,1
ILARIS,nasopharyngitis,nasopharyngitis diarrhea influenza headache and,1
ILARIS,nasopharyngitis,nasopharyngitis,1
ILARIS,nasopharyngitis,The most common adverse drug,0
ILARIS,nasopharyngitis,CAPS treated with ILARIS nasopharyngitis diarrhea influenza headache,1
ILARIS,nasopharyngitis,The most common adverse drug,0
ILARIS,nasopharyngitis,with ILARIS,0
ILARIS,influenza,headache and,0
ILARIS,influenza,influenza headache and nausea,1
ILARIS,headache,headache and nausea SJIA The most,1
ILARIS,headache,and nausea SJIA The most common adverse,0
ILARIS,headache,headache and nausea,1
ILARIS,headache,reported by patients with CAPS treated with ILARIS are nasopharyngitis,0
ILARIS,infections,are,0
ILARIS,infections,infections nasopharyngitis and upper respiratory tract,1
ILARIS,infections,infections nasopharyngitis and upper respiratory,1
ILARIS,nasopharyngitis,nasopharyngitis,1
ILARIS,nasopharyngitis,infections nasopharyngitis and upper respiratory,1
ILARIS,nasopharyngitis,nasopharyngitis,1
ILARIS,nasopharyngitis,are nasopharyngitis and upper respiratory,1
ILARIS,nasopharyngitis,nasopharyngitis,1
ILARIS,nasopharyngitis,treated with ILARIS are nasopharyngitis,1
ILARIS,nasopharyngitis,nasopharyngitis,1
ILARIS,nasopharyngitis,SJIA treated with,0
ILARIS,nasopharyngitis,tract infections abdominal pain,0
ILARIS,nasopharyngitis,pain and injection site reactions,0
ILARIS,nasopharyngitis,drug reactions greater than reported by patients with SJIA treated with ILARIS,0
ILARIS,nasopharyngitis,nasopharyngitis and,1
ILARIS,upper respiratory tract infections,infections nasopharyngitis upper respiratory tract infections,1
ILARIS,upper respiratory tract infections,nasopharyngitis and,1
ILARIS,upper respiratory tract infections,site reactions To report SUSPECTED,0
ILARIS,upper respiratory tract infections,upper respiratory tract infections abdominal pain and injection,1
ILARIS,upper respiratory tract infections,SJIA treated with ILARIS are infections,0
ILARIS,upper respiratory tract infections,SJIA treated with ILARIS are infections nasopharyngitis,0
ILARIS,upper respiratory tract infections,by patients with SJIA treated with ILARIS are infections nasopharyngitis and,0
ILARIS,abdominal pain,site reactions To,0
ILARIS,abdominal pain,and upper respiratory tract abdominal pain and injection,1
ILARIS,abdominal pain,site reactions To,0
ILARIS,abdominal pain,To report SUSPECTED,0
ILARIS,abdominal pain,with ILARIS are infections nasopharyngitis and upper respiratory tract,0
ILARIS,abdominal pain,upper respiratory tract abdominal,1
ILARIS,injection site reactions,Novartis,0
ILARIS,vertigo,intraabdominal abscess following,0
ILARIS,vertigo,CAPS patients Among these vertigo patients infections patients including intraabdominal,1
ILARIS,vertigo,intraabdominal abscess following,0
ILARIS,infections,including,0
ILARIS,infections,infections patients including intraabdominal,1
ILARIS,infections,vertigo,0
ILARIS,infections,Among these were vertigo infections,1
ILARIS,infections,vertigo,0
ILARIS,infections,infections patients including intraabdominal abscess following,1
ILARIS,infections,vertigo infections patients,1
ILARIS,infections,infections patients including intraabdominal abscess following,1
ILARIS,infections,infections patients including intraabdominal,1
ILARIS,infections,infections patients including intraabdominal abscess,1
ILARIS,infections,infections patients,1
ILARIS,infections,vertigo infections patients including,1
ILARIS,infections,infections patients,1
ILARIS,intra-abdominal abscess,infections patients intra-abdominal abscess following appendectomy patient,1
ILARIS,intra-abdominal abscess,infections patients,1
ILARIS,nasopharyngitis,with ILARIS treatment in the,0
ILARIS,nasopharyngitis,patients nasopharyngitis diarrhea influenza,1
ILARIS,nasopharyngitis,with ILARIS treatment in the,0
ILARIS,diarrhea,the CAPS patients were diarrhea,1
ILARIS,diarrhea,with ILARIS treatment in the,0
ILARIS,diarrhea,diarrhea influenza headache,1
ILARIS,diarrhea,treatment,0
ILARIS,diarrhea,were diarrhea influenza headache and nausea,1
ILARIS,diarrhea,treatment,0
ILARIS,diarrhea,diarrhea influenza,1
ILARIS,diarrhea,diarrhea influenza headache and nausea One,1
ILARIS,influenza,headache and nausea One patient discontinued treatment,0
ILARIS,influenza,due,0
ILARIS,influenza,influenza headache and nausea One patient,1
ILARIS,influenza,to potential,0
ILARIS,headache,in the,0
ILARIS,headache,headache and nausea,1
ILARIS,headache,with ILARIS treatment in,0
ILARIS,headache,headache and nausea One,1
ILARIS,headache,patients were nasopharyngitis diarrhea headache and nausea One patient,1
ILARIS,headache,headache and nausea One,1
ILARIS,nausea,investigated the,0
ILARIS,nausea,due,0
ILARIS,nausea,One patient discontinued treatment due to potential infection CAPS Study investigated the,0
ILARIS,nausea,nasopharyngitis diarrhea influenza headache nausea,1
ILARIS,nausea,One patient discontinued treatment due to potential infection CAPS Study investigated the,0
ILARIS,nausea,CAPS patients were nasopharyngitis diarrhea influenza,0
ILARIS,nausea,nausea One patient,1
ILARIS,nausea,the CAPS patients,0
ILARIS,nausea,headache nausea One patient discontinued treatment,1
ILARIS,nausea,the CAPS patients,0
ILARIS,nausea,nausea One patient,1
ILARIS,infection,in an week openlabel period Part follo,0
ILARIS,infection,CAPS Study investigated the safety of ILARIS in an week openlabel period,0
ILARIS,infection,openlabel period Part follo,0
ILARIS,infection,infection CAPS Study investigated the safety,1
ILARIS,infection,infection CAPS Study,1
ILARIS,infection,infection CAPS Study investigated the safety,1
ILARIS,infection,infection CAPS Study investigated the safety,1
ILARIS,Nasopharyngitis,Adverse Nasopharyngitis,1
ILARIS,Nasopharyngitis,infection CAPS Study investigated the safety,1
ILARIS,Nasopharyngitis,Nasopharyngitis Diarrhea,1
ILARIS,Nasopharyngitis,ferred Term ILARISNn n of Patients with Adverse,0
ILARIS,Nasopharyngitis,Nasopharyngitis Diarrhea,1
ILARIS,Nasopharyngitis,with Adverse Nasopharyngitis Diarrhea,1
ILARIS,Nasopharyngitis,Nasopharyngitis Diarrhea,1
ILARIS,Diarrhea,Events Diarrhea,1
ILARIS,Diarrhea,Nasopharyngitis Diarrhea,1
ILARIS,Diarrhea,Diarrhea Influenza,1
ILARIS,Diarrhea,Diarrhea,1
ILARIS,Diarrhea,Diarrhea Influenza,1
ILARIS,Diarrhea,Diarrhea,1
ILARIS,Diarrhea,Diarrhea Influenza Rhinitis,1
ILARIS,Diarrhea,with Adverse,0
ILARIS,Influenza,Nasopharyngitis Influenza,1
ILARIS,Influenza,with Adverse,0
ILARIS,Influenza,Influenza,1
ILARIS,Influenza,Nasopharyngitis Influenza Rhinitis Nausea,1
ILARIS,Influenza,Influenza,1
ILARIS,Influenza,Influenza Rhinitis,1
ILARIS,Rhinitis,Rhinitis Nausea Headache,1
ILARIS,Rhinitis,Diarrhea Rhinitis,1
ILARIS,Rhinitis,Rhinitis Nausea Headache,1
ILARIS,Rhinitis,Rhinitis Nausea Headache,1
ILARIS,Rhinitis,Diarrhea Rhinitis,1
ILARIS,Rhinitis,Rhinitis Nausea Headache,1
ILARIS,Rhinitis,Diarrhea Influenza,0
ILARIS,Nausea,Nausea Headache Bronchitis,1
ILARIS,Nausea,Nausea Headache,1
ILARIS,Nausea,Influenza Rhinitis,0
ILARIS,Nausea,Influenza Nausea Headache Bronchitis,1
ILARIS,Nausea,Influenza Rhinitis,0
ILARIS,Nausea,Nausea Headache,1
ILARIS,Nausea,Nausea Headache Bronchitis,1
ILARIS,Headache,Headache,1
ILARIS,Headache,Nausea,0
ILARIS,Headache,Rhinitis Nausea,0
ILARIS,Headache,Headache,1
ILARIS,Headache,Rhinitis Nausea,0
ILARIS,Headache,Nausea,0
ILARIS,Headache,Headache Bronchitis,1
ILARIS,Headache,Headache,1
ILARIS,Headache,Nausea,0
ILARIS,Headache,Rhinitis Headache Bronchitis Gastroenteritis,1
ILARIS,Headache,Nausea,0
ILARIS,Bronchitis,Bronchitis Gastroenteritis,1
ILARIS,Bronchitis,Bronchitis Gastroenteritis Pharyngitis,1
ILARIS,Bronchitis,Bronchitis Gastroenteritis,1
ILARIS,Gastroenteritis,Bronchitis,0
ILARIS,Gastroenteritis,Headache Gastroenteritis Pharyngitis Weight increased,1
ILARIS,Gastroenteritis,Bronchitis,0
ILARIS,Gastroenteritis,Headache,0
ILARIS,Gastroenteritis,Gastroenteritis Pharyngitis Weight,1
ILARIS,Gastroenteritis,Bronchitis,0
ILARIS,Gastroenteritis,Bronchitis,0
ILARIS,Pharyngitis,Bronchitis Gastroenteritis,0
ILARIS,Pharyngitis,Bronchitis Pharyngitis Weight increased Musculoskeletal pain,1
ILARIS,Pharyngitis,Bronchitis Gastroenteritis,0
ILARIS,Pharyngitis,Pharyngitis Weight,1
ILARIS,Pharyngitis,Bronchitis Gastroenteritis,0
ILARIS,Pharyngitis,increased Musculoskeletal,0
ILARIS,Pharyngitis,Gastroenteritis,0
ILARIS,Pharyngitis,Gastroenteritis,0
ILARIS,Weight increased,Weight increased Musculoskeletal pain,1
ILARIS,Weight increased,Gastroenteritis Weight,1
ILARIS,Weight increased,Gastroenteritis,0
ILARIS,Musculoskeletal pain,Vertigo has been,0
ILARIS,Musculoskeletal pain,Musculoskeletal pain Vertigo Vertigo Vertigo has,1
ILARIS,Vertigo,Vertigo Vertigo Vertigo has,1
ILARIS,Vertigo,Vertigo Vertigo Vertigo has been reported,1
ILARIS,Vertigo,Musculoskeletal Vertigo Vertigo Vertigo has been reported,1
ILARIS,Vertigo,Vertigo Vertigo Vertigo has been reported,1
ILARIS,Vertigo,reported in to of patie,0
ILARIS,Vertigo,CAPS studies exclusively in,0
ILARIS,Vertigo,Vertigo,1
ILARIS,Vertigo,CAPS studies exclusively in,0
ILARIS,Vertigo,Vertigo has been reported in,1
ILARIS,Vertigo,Vertigo Vertigo has,1
ILARIS,Vertigo,Vertigo has been reported in,1
ILARIS,Vertigo,sculoskeletal pain Vertigo Vertigo,0
ILARIS,Vertigo,sculoskeletal pain,0
ILARIS,Vertigo,Vertigo,0
ILARIS,Vertigo,sculoskeletal,0
ILARIS,Vertigo,Vertigo,0
ILARIS,Vertigo,sculoskeletal,0
ILARIS,subcutaneous injection site reactions,reactions in Part one patient,0
ILARIS,subcutaneous injection site reactions,were observed in of,0
ILARIS,subcutaneous injection site reactions,In CAPS subcutaneous injection site reactions were observed in,1
ILARIS,subcutaneous injection site reactions,were observed in of,0
ILARIS,subcutaneous injection site reactions,Site Reactions In CAPS subcutaneous injection site reactions were,1
ILARIS,subcutaneous injection site reactions,were observed in of,0
ILARIS,local tolerability reaction,local tolerability reaction No severe injectionsite,1
ILARIS,local tolerability reaction,Part one patient,0
ILARIS,local tolerability reaction,local tolerability reaction No severe injectionsite,1
ILARIS,local tolerability reaction,Part one patient,0
ILARIS,local tolerability reaction,a moderate tolerability reaction and in Part one patient had a mild,0
ILARIS,local tolerability reaction,patient had a local,1
ILARIS,local tolerability reaction,tolerability reaction No,1
ILARIS,local tolerability reaction,a local tolerability reaction,1
ILARIS,local tolerability reaction,reported and none led to discontinuation of,0
ILARIS,injection-site reactions,injection-site reactions were reported and none,1
ILARIS,injection-site reactions,mild local,0
ILARIS,injection-site reactions,reported,0
ILARIS,injection-site reactions,reaction No injection-site reactions,1
ILARIS,injection-site reactions,reported and,0
ILARIS,injection-site reactions,patient had a mild local,0
ILARIS,infections,infections abdominal,1
ILARIS,infections,patient had a mild local,0
ILARIS,infections,treatment in SJIA patients infections abdominal,1
ILARIS,infections,patient had a mild local,0
ILARIS,infections,patients,0
ILARIS,infections,infections abdominal,1
ILARIS,infections,site,0
ILARIS,infections,infections abdominal pain and injection site,1
ILARIS,infections,infections abdominal pain and injection site,1
ILARIS,infections,and injection site reactions Serious infections eg,0
ILARIS,infections,injection site reactions Serious infections,0
ILARIS,infections,both trials The adverse drug reactions associated with ILARIS treatment in SJIA,0
ILARIS,abdominal pain,were abdominal pain and injection site,1
ILARIS,abdominal pain,both trials The adverse drug reactions associated with ILARIS treatment in SJIA,0
ILARIS,abdominal pain,varicella gastroenteritis,0
ILARIS,abdominal pain,were infections,0
ILARIS,abdominal pain,in SJIA patients were abdominal pain and injection site,1
ILARIS,abdominal pain,were infections,0
ILARIS,abdominal pain,associated with ILARIS treatment in SJIA,0
ILARIS,abdominal pain,were abdominal pain,1
ILARIS,abdominal pain,associated with ILARIS treatment in SJIA,0
ILARIS,abdominal pain,patients were abdominal,1
ILARIS,abdominal pain,SJIA patients were infections,0
ILARIS,abdominal pain,site reactions Serious infections eg pneumonia varicella gastroenteritis,0
ILARIS,infections,sepsis otitis,0
ILARIS,pneumonia,site reactions Serious infections pneumonia varicella gastroenteritis measles sepsis otitis,1
ILARIS,pneumonia,sepsis otitis,0
ILARIS,pneumonia,infections pneumonia varicella,1
ILARIS,pneumonia,sepsis otitis,0
ILARIS,pneumonia,pneumonia varicella gastroenteritis measles,1
ILARIS,pneumonia,pneumonia,1
ILARIS,pneumonia,pneumonia varicella gastroenteritis measles,1
ILARIS,pneumonia,pneumonia varicella,1
ILARIS,pneumonia,infections pneumonia varicella gastroenteritis measles sepsis,1
ILARIS,pneumonia,pneumonia varicella,1
ILARIS,pneumonia,pneumonia varicella gastroenteritis measles sepsis,1
ILARIS,pneumonia,site reactions Serious infections pneumonia varicella gastroenteritis,1
ILARIS,pneumonia,pneumonia varicella gastroenteritis measles sepsis,1
ILARIS,pneumonia,sepsis otitis media sinusitis adenovirus lymph node absce,0
ILARIS,varicella,varicella gastroenteritis measles sepsis,1
ILARIS,varicella,measles sepsis otitis,0
ILARIS,varicella,infections eg varicella gastroenteritis,1
ILARIS,varicella,measles sepsis otitis,0
ILARIS,varicella,reactions Serious infections eg varicella,1
ILARIS,varicella,measles sepsis otitis,0
ILARIS,varicella,sepsis otitis media,0
ILARIS,varicella,were infections abdominal pain and injection site reactions Serious,0
ILARIS,varicella,sepsis otitis media,0
ILARIS,varicella,gastroenteritis measles sepsis otitis media sinusitis adenovirus lymph node abscess,0
ILARIS,varicella,varicella gastroenteritis,1
ILARIS,measles,media sinusitis adenovirus lymph,0
ILARIS,measles,eg pneumonia varicella measles sepsis otitis media,1
ILARIS,measles,media sinusitis adenovirus lymph,0
ILARIS,measles,varicella measles sepsis otitis media sinusitis,1
ILARIS,measles,media sinusitis adenovirus lymph,0
ILARIS,measles,measles sepsis otitis media,1
ILARIS,measles,media sinusitis adenovirus lymph,0
ILARIS,measles,eg pneumonia varicella gastroenteritis,0
ILARIS,measles,infections eg pneumonia varicella measles sepsis,1
ILARIS,measles,eg pneumonia varicella gastroenteritis,0
ILARIS,sepsis,node abscess,0
ILARIS,sepsis,Serious infections eg pneumonia varicella,0
ILARIS,sepsis,sepsis otitis,1
ILARIS,sepsis,injection site,0
ILARIS,sepsis,sepsis otitis media sinusitis,1
ILARIS,sepsis,lymph node abscess pharyngitis were observed in,0
ILARIS,sepsis,sepsis otitis,1
ILARIS,sepsis,lymph node abscess pharyngitis were observed in,0
ILARIS,otitis media,site reactions Serious infections eg pneumonia varicella gastroenteritis measles,0
ILARIS,otitis media,measles otitis media sinusitis,1
ILARIS,otitis media,site reactions Serious infections eg pneumonia varicella gastroenteritis measles,0
ILARIS,otitis media,lymph node abscess pharyngitis were observed in approximately to,0
ILARIS,otitis media,gastroenteritis measles otitis media sinusitis,1
ILARIS,otitis media,lymph node abscess pharyngitis were observed in approximately to,0
ILARIS,otitis media,measles otitis media sinusitis adenovirus lymph,1
ILARIS,otitis media,lymph node abscess pharyngitis were observed in approximately to,0
ILARIS,otitis media,were observed in approximately,0
ILARIS,otitis media,were observed in approximately,0
ILARIS,adenovirus,adenovirus lymph node abscess pharyngitis were,1
ILARIS,adenovirus,were observed,0
ILARIS,adenovirus,approximately to to per pat,0
ILARIS,adenovirus,gastroenteritis measles,0
ILARIS,adenovirus,adenovirus lymph node abscess pharyngitis,1
ILARIS,lymph node abscess,gastroenteritis measles,0
ILARIS,lymph node abscess,media,0
ILARIS,lymph node abscess,in approximately to to per,0
ILARIS,lymph node abscess,pharyngitis were observed in,0
ILARIS,lymph node abscess,sinusitis lymph node abscess pharyngitis,1
ILARIS,lymph node abscess,pharyngitis were observed in,0
ILARIS,lymph node abscess,media sinusitis lymph node abscess,1
ILARIS,lymph node abscess,patientdays,0
ILARIS,lymph node abscess,sepsis otitis media sinusitis lymph node abscess,1
ILARIS,lymph node abscess,patientdays,0
ILARIS,lymph node abscess,otitis media sinusitis lymph,1
ILARIS,pharyngitis,lymph node pharyngitis were observed in approximately,1
ILARIS,pharyngitis,otitis media sinusitis lymph,1
ILARIS,Infections,Infections eg nasopharyngitis,1
ILARIS,nasopharyngitis,and infestations All Infections nasopharyngitis viral upper respiratory tract,1
ILARIS,nasopharyngitis,Infections eg nasopharyngitis,1
ILARIS,nasopharyngitis,tract infection pneumonia,0
ILARIS,nasopharyngitis,and infestations All Infections nasopharyngitis viral upper respiratory tract,1
ILARIS,nasopharyngitis,tract infection pneumonia,0
ILARIS,nasopharyngitis,nasopharyngitis viral upper,1
ILARIS,nasopharyngitis,pneumonia rhinitis pharyngitis tonsillitis sinusiti,0
ILARIS,nasopharyngitis,ISNn IR PlaceboNn IR,0
ILARIS,pneumonia,upper respiratory tract infection,0
ILARIS,pneumonia,pneumonia rhinitis pharyngitis tonsillitis,1
ILARIS,pneumonia,pneumonia,1
ILARIS,pneumonia,pneumonia rhinitis,1
ILARIS,pneumonia,pneumonia rhinitis pharyngitis tonsillitis sinusitis,1
ILARIS,pneumonia,tract pneumonia rhinitis pharyngitis,1
ILARIS,pneumonia,pneumonia rhinitis pharyngitis tonsillitis sinusitis,1
ILARIS,pneumonia,viral,0
ILARIS,pneumonia,nasopharyngitis,0
ILARIS,rhinitis,rhinitis pharyngitis tonsillitis sinusitis,1
ILARIS,pharyngitis,eg nasopharyngitis viral,0
ILARIS,pharyngitis,respiratory tract infection pneumonia pharyngitis tonsillitis sinusitis urinary tract,1
ILARIS,pharyngitis,eg nasopharyngitis viral,0
ILARIS,pharyngitis,pharyngitis tonsillitis sinusitis urinary,1
ILARIS,pharyngitis,pharyngitis tonsillitis,1
ILARIS,tonsillitis,tonsillitis,1
ILARIS,tonsillitis,viral upper respiratory tract,0
ILARIS,tonsillitis,urinary,0
ILARIS,tonsillitis,tonsillitis sinusitis urinary,1
ILARIS,tonsillitis,infection gastroenteritis,0
ILARIS,tonsillitis,tonsillitis sinusitis urinary tract infection gastroenteritis,1
ILARIS,tonsillitis,tonsillitis sinusitis urinary tract infection,1
ILARIS,sinusitis,sinusitis urinary tract infection gastroenteritis,1
ILARIS,sinusitis,sinusitis,1
ILARIS,sinusitis,sinusitis urinary tract infection gastroenteritis,1
ILARIS,sinusitis,urinary tract infection gastroenteritis,0
ILARIS,sinusitis,tract infection pneumonia rhinitis,0
ILARIS,sinusitis,sinusitis urinary tract,1
ILARIS,sinusitis,sinusitis urinary tract infection,1
ILARIS,sinusitis,tract infection,0
ILARIS,urinary tract infection,tonsillitis urinary tract infection gastroenteritis viral,1
ILARIS,urinary tract infection,tract infection,0
ILARIS,gastroenteritis,urinary tract gastroenteritis viral,1
ILARIS,gastroenteritis,tract infection,0
ILARIS,gastroenteritis,sinusitis urinary tract gastroenteritis,1
ILARIS,gastroenteritis,tract infection,0
ILARIS,gastroenteritis,sinusitis urinary tract gastroenteritis,1
ILARIS,gastroenteritis,tract infection,0
ILARIS,gastroenteritis,gastroenteritis viral,1
ILARIS,gastroenteritis,gastroenteritis,1
ILARIS,gastroenteritis,gastroenteritis viral,1
ILARIS,gastroenteritis,gastroenteritis,1
ILARIS,gastroenteritis,tract infection,0
ILARIS,anaphylactic reactions,Hypersensitivity During clinical trials anaphylactic reactions,1
ILARIS,anaphylactic reactions,tract infection,0
ILARIS,anaphylactic reactions,During clinical trials anaphylactic reactions have been reported In CAPS,1
ILARIS,anaphylactic reactions,tract infection,0
ILARIS,hypersensitivity reactions,discontinued due,0
ILARIS,hypersensitivity reactions,hypersensitivity reactions,1
ILARIS,hypersensitivity reactions,no patients discontinued due hypersensitivity,1
ILARIS,hypersensitivity reactions,due hypersensitivity,1
ILARIS,hypersensitivity reactions,discontinued due hypersensitivity reactions ILARIS should,1
ILARIS,hypersensitivity reactions,due hypersensitivity,1
ILARIS,hypersensitivity reactions,discontinued due hypersensitivity reactions,1
ILARIS,hypersensitivity reactions,due hypersensitivity,1
ILARIS,hypersensitivity reactions,to any patients with known clinical hypersensitivity,0
ILARIS,hypersensitivity reactions,hypersensitivity reactions ILARIS should not be administered,1
ILARIS,hypersensitivity reactions,to any patients with known clinical hypersensitivity,0
ILARIS,hypersensitivity reactions,no patients discontinued due hypersensitivity,1
ILARIS,decreased white blood cell counts,portion of SJIA decreased white blood cell counts WBC less than,1
ILARIS,decreased white blood cell counts,no patients discontinued due hypersensitivity,1
ILARIS,decreased white blood cell counts,decreased white blood cell counts WBC less,1
ILARIS,decreased white blood cell counts,randomized placebocontrolled portion of SJIA,0
ILARIS,decreased white blood cell counts,decreased white blood cell counts WBC,1
ILARIS,decreased white blood cell counts,randomized placebocontrolled portion of SJIA,0
ILARIS,decreases in absolute neutrophil count,group,0
ILARIS,ANC less than 0.5x10 9 /L,than 0.5x10 9 /L,1
ILARIS,ANC less than 0.5x10 9 /L,placebo group One case ANC less than 0.5x10  9  /L,1
ILARIS,ANC less than 0.5x10 9 /L,than 0.5x10 9 /L,1
ILARIS,ANC less than 0.5x10 9 /L,One case ANC less than 0.5x10  9  /L was observed in the ILARIS,1
ILARIS,ANC less than 0.5x10 9 /L,than 0.5x10 9 /L,1
ILARIS,ANC less than 0.5x10 9 /L,placebo group Mild less,0
ILARIS,ANC less than 0.5x10 9 /L,in the,0
ILARIS,ANC less than 0.5x10 9 /L,than 0.5x10 9 /L was,1
ILARIS,ANC less than 0.5x10 9 /L,placebo group One case ANC less than 0.5x10  9  /L was observed in the ILARIS,1
ILARIS,ANC less than 0.5x10 9 /L,than 0.5x10 9 /L was,1
ILARIS,decreases in platelet counts,platelet counts were observed in,1
ILARIS,Elevations of transaminases,placebotreated patient Hepatic Elevations of transaminases,1
ILARIS,Elevations of transaminases,platelet counts were observed in,1
ILARIS,Elevations of transaminases,patient Hepatic Elevations of transaminases have,1
ILARIS,Elevations of transaminases,platelet counts were observed in,1
ILARIS,Elevations of transaminases,placebotreated patient Hepatic Elevations of transaminases have been observed,1
ILARIS,Elevations of transaminases,platelet counts were observed in,1
ILARIS,high ALT,SJIA Study,0
ILARIS,high ALT,Study,0
ILARIS,high ALT,high ALT andor,1
ILARIS,high ALT,high ALT,1
ILARIS,high ALT,Study,0
ILARIS,high ALT,high ALT andor,1
ILARIS,high ALT,andor AST greater than or equal to times upper limit of normal ULN were reported in,0
ILARIS,high ALT,high ALT andor AST greater than or,1
ILARIS,high ALT,high ALT andor AST,1
ILARIS,high ALT,or,0
ILARIS,elevations of serum bilirubin,elevations of serum bilirubin,1
ILARIS,elevations of serum bilirubin,or,0
ILARIS,elevations of serum bilirubin,Asymptomatic and elevations of serum,1
ILARIS,infections,upper respiratory tract The majority of the events,0
ILARIS,infections,were in fections,1
ILARIS,infections,upper respiratory tract The of,1
ILARIS,infections,respiratory tract The of the eve,1
ILARIS,infections,infections nasopharyngitis and upper respiratory,0
ILARIS,infections,tract inf ections abdominal pain,1
ILARIS,infections,and upper  tract inf ections,1
ILARIS,infections,tract inf ections abdominal pain,1
ILARIS,infections,ections abdominal pain and injection site,0
ILARIS,infections,and upper  tract inf,1
ILARIS,infections,ections abdominal pain and injection site,0
ILARIS,infections,tract inf ections abdominal pain and,1
ILARIS,Infections,ls of a dr ug cannot be directly,1
ILARIS,Infections,tract inf ections abdominal pain and,1
ILARIS,Infections,observed in the clinical ls of a dr ug cannot,1
ILARIS,Infections,tract inf ections abdominal pain and,1
ILARIS,Infections,ls of,1
ILARIS,Infections,clinical ls,1
ILARIS,Infections,reaction,0
ILARIS,Infections,in the clinical ls of a dr,1
ILARIS,Infections,reaction,0
ILARIS,Infections,ls of a dr ug cannot be directly,1
ILARIS,Infections,observed in the clinical ls of a,1
ILARIS,Infections,varying,0
ILARIS,Infections,conditions adverse,0
ILARIS,Infections,clinical trials of another,0
ILARIS,Infections,clinical ls of a dr ug cannot be directly compared,1
ILARIS,Infections,clinical trials of another,0
ILARIS,Infections,another drug and may not reflect,0
ILARIS,Infections,widely varying conditions adverse reaction,0
ILARIS,infections,reflect,0
ILARIS,infections,"


   Trea tment of CAPS The data",1
ILARIS,infections,"


   Trea tment of CAPS The",1
ILARIS,infections,"


   Trea tment",1
ILARIS,infections,in,0
ILARIS,opportunistic infections,104 adult and,1
ILARIS,opportunistic infections,CAPS,0
ILARIS,opportunistic infections,e,1
ILARIS,opportunistic infections,to ILARIS in 104 adult and pediatric CAPS,1
ILARIS,aspergillosis,in adult and iatric CAPS p atients,1
ILARIS,aspergillosis,to ILARIS in 104 adult and pediatric CAPS,1
ILARIS,aspergillosis,MWS,0
ILARIS,aspergillosis,Onset Multisystem,0
ILARIS,aspergillosis,ILARIS in adult and iatric CAPS,1
ILARIS,aspergillosis,CAPS p,1
ILARIS,atypical mycobacterial infections,"ients, including 20 FCAS, 72 MWS,",1
ILARIS,atypical mycobacterial infections,CAPS p,1
ILARIS,atypical mycobacterial infections,"ients, including 20",1
ILARIS,atypical mycobacterial infections,"20 FCAS, 72 MWS, MWSNOMID Neonatal Onset Multisystem Inflammatory",1
ILARIS,herpes zoster,Onset Mu ltisystem Inflammatory,1
ILARIS,herpes zoster,atal Onset Mu ltisystem,1
ILARIS,herpes zoster,Onset Mu ltisystem Inflammatory,1
ILARIS,herpes zoster,including FCAS MWS MWSNOMID atal Onset Mu,1
ILARIS,herpes zoster,atal Onset,1
ILARIS,herpes zoster,and misdiagnosed in,0
ILARIS,herpes zoster,Onset Mu ltisystem,1
ILARIS,herpes zoster,atal Onset Mu ltisystem Inflammatory,1
ILARIS,infections,least s. A total of serious adverse,1
ILARIS,infections,atal Onset Mu ltisystem Inflammatory,1
ILARIS,infections,least s. A total of serious adverse reactions,1
ILARIS,infections,atal Onset Mu ltisystem Inflammatory,1
ILARIS,infections,A total of serious adverse,1
ILARIS,infections,year,0
ILARIS,reactivation of tuberculosis,period Part followed,0
ILARIS,reactivation of tuberculosis,"openlabel iod (Part 1), followed by a ",1
ILARIS,reactivation of tuberculosis,period Part followed,0
ILARIS,reactivation of tuberculosis,period Part followed by,0
ILARIS,reactivation of tuberculosis,an week,0
ILARIS,reactivation of tuberculosis,CAPS Study investigated the safety of ILARIS in,0
ILARIS,reactivation of tuberculosis,followed by a,0
ILARIS,reactivation of tuberculosis,in an week openlabel per,0
ILARIS,reactivation of tuberculosis,ILARIS in an week,0
ILARIS,opportunistic infections,"a , randomized withdrawal  period Part followed by",1
ILARIS,opportunistic infections,ILARIS in an week,0
ILARIS,opportunistic infections,"by a ,",1
ILARIS,opportunistic infections,"followed by a , randomized",1
ILARIS,opportunistic infections,randomized withdrawal period Part followed by,1
ILARIS,opportunistic infections,randomized withdrawal,1
ILARIS,opportunistic infections,"a , randomized withdrawal  period Part followed by a",1
ILARIS,opportunistic infections,randomized withdrawal,1
ILARIS,opportunistic infections,period Part followed by a week,0
ILARIS,malignancies,Weight increased M,0
ILARIS,malignancies,Weight,0
ILARIS,Hypersensitivity reactions,Weight increased Musculoskeletal pain 4,1
ILARIS,Hypersensitivity reactions,4 (11) Vertigo Vertigo,1
ILARIS,Hypersensitivity reactions,Weight increased Musculoskeletal pain 4,1
ILARIS,Hypersensitivity reactions,"Weight increased Musculoskeletal pain        4 (11)            
 Vertigo Vertigo has been reported",1
ILARIS,Hypersensitivity reactions,Weight increased Musculoskeletal pain 4,1
ILARIS,Hypersensitivity reactions,pain Vertigo,0
ILARIS,Hypersensitivity reactions,4 (11) Vertigo Vertigo has,1
ILARIS,Hypersensitivity reactions,4 (11) Vertigo Vertigo has been,1
ILARIS,Hypersensitivity reactions,4 (11) Vertigo Vertigo has been reported,1
ILARIS,Hypersensitivity reactions,reported in to of patients in CAPS,0
ILARIS,Hypersensitivity reactions,4 (11) Vertigo,1
ILARIS,anaphylactic reactions,has been reported,0
ILARIS,anaphylactic reactions,to of tients in CAPS studies,1
ILARIS,anaphylactic reactions,a serious adverse event in two cases All,0
ILARIS,anaphylactic reactions,adverse event in two cases All events reso,0
ILARIS,anaphylactic reactions,CAPS studies exclusively in MWS patients and,1
ILARIS,interfere with normal immune response,have received ILARIS in trials. The safety of,1
ILARIS,interfere with normal immune response,received ILARIS in  trials. The safety of ILARIS compare,1
ILARIS,interfere with normal immune response,have received ILARIS in trials. The safety of,1
ILARIS,MAS,"is, adenovirus",1
ILARIS,MAS,dve rse,1
ILARIS,MAS,both studies dve,1
ILARIS,MAS,dve rse,1
ILARIS,MAS,dve rse reactions are listed,1
ILARIS,MAS,ILARIS in both studies dve rse reactions are listed according,1
ILARIS,MAS,dve rse reactions are listed,1
AMPYRA,Seizures,Seizures Anaphylaxis and,1
AMPYRA,Seizures,the Seizures Anaphylaxis and Urinary Tract Infections,1
AMPYRA,Seizures,Seizures Anaphylaxis and,1
AMPYRA,Seizures,Seizures,1
AMPYRA,Seizures,Seizures,1
AMPYRA,Seizures,Seizures Anaphylaxis and Urinary,1
AMPYRA,Seizures,common adverse,0
AMPYRA,Seizures,Seizures,1
AMPYRA,Seizures,the Seizures Anaphylaxis,1
AMPYRA,Seizures,Seizures,1
AMPYRA,Seizures,and Urinary Tract,0
AMPYRA,Anaphylaxis,the label Anaphylaxis and Urinary Tract Infections EXCERPT,1
AMPYRA,Anaphylaxis,and Urinary Tract,0
AMPYRA,Anaphylaxis,Anaphylaxis,1
AMPYRA,Urinary Tract Infections,Seizures Anaphylaxis Urinary,1
AMPYRA,Urinary Tract Infections,Anaphylaxis,0
AMPYRA,Urinary Tract Infections,the label Seizures Anaphylaxis Urinary Tract Infections,1
AMPYRA,Urinary Tract Infections,Anaphylaxis Urinary Tract Infections,1
AMPYRA,Urinary Tract Infections,the label Seizures Anaphylaxis Urinary Tract Infections,1
AMPYRA,Urinary Tract Infections,Anaphylaxis Urinary Tract Infections EXCERPT The,1
AMPYRA,Urinary Tract Infections,the label Seizures Anaphylaxis Urinary Tract Infections,1
AMPYRA,urinary tract infection,nausea asthenia back pain balance disorder,0
AMPYRA,urinary tract infection,tract infection insomnia dizziness headache,1
AMPYRA,insomnia,insomnia dizziness headache,1
AMPYRA,insomnia,insomnia dizziness headache nausea,1
AMPYRA,insomnia,tract insomnia dizziness headache nausea asthenia,1
AMPYRA,insomnia,insomnia dizziness headache nausea,1
AMPYRA,insomnia,placebo rate for AMPYRA were urinary,0
AMPYRA,dizziness,dizziness,1
AMPYRA,dizziness,were urinary tract infection dizziness headache nausea asthenia,1
AMPYRA,dizziness,dizziness,1
AMPYRA,dizziness,asthenia back pain balance disorder multiple sclerosis relapse,0
AMPYRA,dizziness,sclerosis relapse,0
AMPYRA,dizziness,were urinary tract infection dizziness headache nausea asthenia back pain,1
AMPYRA,dizziness,sclerosis relapse,0
AMPYRA,dizziness,dizziness,1
AMPYRA,dizziness,sclerosis relapse,0
AMPYRA,dizziness,asthenia back pain balance disorder multiple sclerosis relapse,0
AMPYRA,dizziness,were urinary tract infection dizziness headache,1
AMPYRA,dizziness,asthenia back pain balance disorder multiple sclerosis relapse,0
AMPYRA,dizziness,urinary tract infection dizziness headache,1
AMPYRA,dizziness,asthenia back pain balance disorder multiple sclerosis relapse,0
AMPYRA,headache,a rate greater than the placebo rate for AMPYRA were urinary,0
AMPYRA,headache,headache nausea asthenia,1
AMPYRA,headache,back pain balance disorder multiple sclerosis relapse,0
AMPYRA,headache,headache nausea asthenia,1
AMPYRA,headache,back pain balance disorder multiple sclerosis relapse,0
AMPYRA,headache,headache nausea,1
AMPYRA,nausea,insomnia dizziness headache,0
AMPYRA,nausea,pain,0
AMPYRA,nausea,nausea,1
AMPYRA,nausea,asthenia back pain balance disorder multiple sclerosis relapse,0
AMPYRA,nausea,nausea asthenia back pain balance disorder,1
AMPYRA,asthenia,asthenia back pain balance,1
AMPYRA,asthenia,asthenia,1
AMPYRA,asthenia,rate for AMPYRA,0
AMPYRA,asthenia,back pain balance disorder multiple,0
AMPYRA,asthenia,relapse paresthesia nasopharyngitis constipatio,0
AMPYRA,asthenia,asthenia back,1
AMPYRA,asthenia,asthenia back,1
AMPYRA,back pain,back pain balance disorder multiple,1
AMPYRA,back pain,nausea back pain,1
AMPYRA,back pain,back pain balance disorder multiple,1
AMPYRA,back pain,headache nausea back pain,1
AMPYRA,back pain,back pain balance,1
AMPYRA,back pain,ebo rate for AMPYRA were urinary,0
AMPYRA,balance disorder,nausea asthenia back balance disorder multiple sclerosis relapse,1
AMPYRA,balance disorder,ebo rate for AMPYRA were urinary,0
AMPYRA,balance disorder,nausea asthenia back balance,1
AMPYRA,balance disorder,tract,0
AMPYRA,balance disorder,headache nausea asthenia back balance disorder multiple sclerosis relapse,1
AMPYRA,balance disorder,tract,0
AMPYRA,multiple sclerosis relapse,pain balance multiple sclerosis relapse,1
AMPYRA,multiple sclerosis relapse,paresthesia nasopharyngitis constipation dyspepsia and,0
AMPYRA,multiple sclerosis relapse,balance multiple sclerosis relapse paresthesia nasopharyngitis constipation,1
AMPYRA,multiple sclerosis relapse,paresthesia nasopharyngitis constipation dyspepsia and,0
AMPYRA,multiple sclerosis relapse,infection insomnia dizziness headache nausea asthenia,0
AMPYRA,multiple sclerosis relapse,pain balance multiple sclerosis relapse paresthesia nasopharyngitis constipation dyspepsia and,1
AMPYRA,multiple sclerosis relapse,infection insomnia dizziness headache nausea asthenia,0
AMPYRA,multiple sclerosis relapse,pharyngolaryngeal pain,0
AMPYRA,multiple sclerosis relapse,pharyngolaryngeal pain,0
AMPYRA,multiple sclerosis relapse,asthenia back pain balance multiple sclerosis,1
AMPYRA,paresthesia,back pain,0
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia,1
AMPYRA,nasopharyngitis,multiple sclerosis relapse paresthesia,0
AMPYRA,nasopharyngitis,nausea asthenia back pain balance disorder multiple,0
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia and pharyngolaryngeal pain,1
AMPYRA,nasopharyngitis,sclerosis relapse paresthesia,0
AMPYRA,nasopharyngitis,nasopharyngitis,1
AMPYRA,nasopharyngitis,nasopharyngitis constipation dyspepsia,1
AMPYRA,nasopharyngitis,nasopharyngitis,1
AMPYRA,constipation,constipation dyspepsia and pharyngolaryngeal pain,1
AMPYRA,constipation,constipation dyspepsia and,1
AMPYRA,constipation,multiple sclerosis relapse paresthesia constipation dyspepsia and pharyngolaryngeal pain,1
AMPYRA,constipation,constipation dyspepsia and,1
AMPYRA,constipation,nasopharyngitis,0
AMPYRA,constipation,pain To report SUSPECTED ADVERSE REACTIONS contact A,0
AMPYRA,dyspepsia,relapse,0
AMPYRA,dyspepsia,paresthesia nasopharyngitis constipation,0
AMPYRA,dyspepsia,and pharyngolaryngeal pain To report,0
AMPYRA,dyspepsia,pain balance disorder multiple sclerosis relapse paresthesia nasopharyngitis,0
AMPYRA,dyspepsia,relapse paresthesia nasopharyngitis dyspepsia and pharyngolaryngeal,1
AMPYRA,dyspepsia,pain balance disorder multiple sclerosis relapse paresthesia nasopharyngitis,0
AMPYRA,dyspepsia,multiple sclerosis relapse,0
AMPYRA,dyspepsia,nasopharyngitis dyspepsia and pharyngolaryngeal pain To,1
AMPYRA,dyspepsia,multiple sclerosis relapse,0
AMPYRA,dyspepsia,and pharyngolaryngeal pain To report SUSPECTED ADVERSE,0
AMPYRA,dyspepsia,pharyngolaryngeal pain To report SUSPECTED ADVERSE REACTIONS contact Acorda Thera,0
AMPYRA,pharyngolaryngeal pain,dyspepsia pharyngolaryngeal pain,1
AMPYRA,pharyngolaryngeal pain,pharyngolaryngeal pain To report SUSPECTED ADVERSE REACTIONS contact Acorda Thera,0
AMPYRA,pharyngolaryngeal pain,pharyngolaryngeal pain,1
AMPYRA,pharyngolaryngeal pain,pharyngolaryngeal pain To report SUSPECTED ADVERSE REACTIONS contact Acorda Thera,0
AMPYRA,pharyngolaryngeal pain,constipation dyspepsia pharyngolaryngeal pain To,1
AMPYRA,pharyngolaryngeal pain,pharyngolaryngeal pain To report SUSPECTED ADVERSE REACTIONS contact Acorda Thera,0
AMPYRA,pharyngolaryngeal pain,contact Acorda Therapeutics at or,0
AMPYRA,headache,frequently compared to placebo headache AMPYRA placebo,1
AMPYRA,headache,contact Acorda Therapeutics at or,0
AMPYRA,headache,AMPYRA and that led to discontinuation more frequently compared to,0
AMPYRA,dizziness,dizziness AMPYRA placebo and confusional,1
AMPYRA,dizziness,placebo balance disorder,0
AMPYRA,dizziness,dizziness,1
AMPYRA,confusional state,confusional state AMPYRA placebo Table lists adverse,1
AMPYRA,confusional state,confusional state AMPYRA placebo Table lists,1
AMPYRA,confusional state,confusional state AMPYRA placebo,1
AMPYRA,confusional state,confusional,1
AMPYRA,confusional state,confusional state AMPYRA placebo Table,1
AMPYRA,confusional state,AMPYRA placebo confusional,1
AMPYRA,confusional state,confusional state AMPYRA placebo Table lists,1
AMPYRA,confusional state,confusional state AMPYRA placebo Table lists,1
AMPYRA,seizures,seizures has been observed in,1
AMPYRA,seizures,seizures has been observed,1
AMPYRA,seizures,openlabel,0
AMPYRA,seizures,clinical trials As in controlled clinical trials,0
AMPYRA,seizures,the,0
AMPYRA,seizures,has,0
AMPYRA,seizures,seizures has been observed in,1
AMPYRA,seizures,seizures,1
AMPYRA,seizures,"conducted under widely varying itions,  adverse reaction",1
AMPYRA,seizures,seizures,1
AMPYRA,anaphylaxis,label Seizures Anaphylaxis and,0
AMPYRA,anaphylaxis,rnings and,1
AMPYRA,anaphylaxis,in the rnings and ,1
AMPYRA,anaphylaxis,rnings and,1
AMPYRA,seizures,adverse events >=2%,1
AMPYRA,seizures,events >=2%,1
AMPYRA,seizures,"sia, nas",1
AMPYRA,seizures,sclerosis,0
AMPYRA,seizures,To report SUSPECTED AD,0
AMPYRA,seizures,"sclerosis relapse sia, nas opharyngitis",1
AMPYRA,seizures,To report SUSPECTED AD,0
AMPYRA,seizures,iness headache nausea asthenia back pain,0
AMPYRA,seizures,pain To report SUSPECTED,0
AMPYRA,seizures,"multiple sclerosis relapse sia, nas opharyngitis",1
AMPYRA,seizures,pain To report SUSPECTED,0
AMPYRA,seizures,"sclerosis relapse sia,",1
AMPYRA,seizures,FDA at FDA or ww.fda.g,1
AMPYRA,seizures,"sclerosis relapse sia,",1
AMPYRA,seizures,ovmedwatch Controlled Clinical Trials,0
AMPYRA,seizures,In three,0
AMPYRA,seizures,FDA at FDA or ww.fda.g,1
AMPYRA,seizures,In three,0
AMPYRA,seizures,ww.fda.g ovmedwatch Controlled,1
AMPYRA,seizures,at FDA or ww.fda.g ovmedwatch Controlled Clinical Trials Experience,1
AMPYRA,seizures,ww.fda.g ovmedwatch Controlled,1
AMPYRA,seizures,ww.fda.g ovmedwatch Controlled Clinical,1
AMPYRA,seizures,ww.fda.g ovmedwatch Controlled Clinical,1
AMPYRA,seizures,or wwwfdagovmedwatch  Clinica,1
AMPYRA,seizures,ww.fda.g ovmedwatch Controlled Clinical,1
AMPYRA,seizures,In three placebocontrolled clinical trials of,0
AMPYRA,seizures,placebocontrolled clinical trials,0
AMPYRA,seizures,wwwfdagovmedwatch  Clinica,1
AMPYRA,seizures,placebocontrolled clinical trials,0
AMPYRA,seizures,three,0
AMPYRA,seizures, Clinica l Trials Experience In three,1
AMPYRA,seizures,or wwwfdagovmedwatch  Clinica l Trials Experience In,1
AMPYRA,seizures, Clinica l Trials Experience In three,1
AMPYRA,allergic reactions,Back pain,0
AMPYRA,allergic reactions,pain,0
AMPYRA,allergic reactions,                   Balance,1
AMPYRA,allergic reactions,Back,0
AMPYRA,allergic reactions,                   Balance disorder,1
AMPYRA,allergic reactions,Back,0
AMPYRA,respiratory compromise,Back                  5%    Balance disorder,1
AMPYRA,respiratory compromise,Back,0
AMPYRA,respiratory compromise,                 5%    Balance,1
AMPYRA,respiratory compromise,                 5%    Balance disorder,1
AMPYRA,respiratory compromise,                 5%    Balance,1
AMPYRA,respiratory compromise,                 5%    Balance,1
AMPYRA,urticaria,Back           Balance,1
AMPYRA,urticaria,                 5%    Balance,1
AMPYRA,urticaria,Back           Balance,1
AMPYRA,urticaria,                 5%    Balance,1
AMPYRA,urticaria,          Balance disorder,1
AMPYRA,urticaria,Back pain,0
AMPYRA,urticaria,          Balance,1
AMPYRA,urticaria,         ,1
SIRTURO,Increased mortality,the,0
SIRTURO,Increased mortality,Increased,1
SIRTURO,Increased mortality,elsewhere in the Increased mortality,1
SIRTURO,Increased mortality,following serious adverse reactions are discussed elsewhere in,0
SIRTURO,Increased mortality,elsewhere in the Increased mortality,1
SIRTURO,Increased mortality,QT Prolongation see Warnings and,0
SIRTURO,Increased mortality,QT Prolongation see Warnings and,0
SIRTURO,Increased mortality,following serious adverse,0
SIRTURO,QT Prolongation,mortality see Warnings and QT Prolongation see Warnings and Precautions,1
SIRTURO,QT Prolongation,following serious adverse,0
SIRTURO,QT Prolongation,see Warnings and Precautions,0
SIRTURO,QT Prolongation,elsewhere in the labeling Increased mortality see Warnings and,0
SIRTURO,QT Prolongation,elsewhere in the labeling Increased mortality,0
SIRTURO,QT Prolongation,mortality see Warnings,0
SIRTURO,QT Prolongation,QT Prolongation see Warnings and Precautions,1
SIRTURO,QT Prolongation,mortality see Warnings,0
SIRTURO,QT Prolongation,Precautions,0
SIRTURO,QT Prolongation,QT Prolongation,1
SIRTURO,nausea,patients treated with SIRTURO nausea arthralgia headache hemoptysis and,1
SIRTURO,nausea,QT Prolongation,1
SIRTURO,nausea,patients treated with SIRTURO nausea arthralgia,1
SIRTURO,nausea,QT Prolongation,1
SIRTURO,nausea,To report,0
SIRTURO,nausea,nausea arthralgia,1
SIRTURO,nausea,nausea,1
SIRTURO,nausea,headache hemoptysis and chest,0
SIRTURO,nausea,nausea arthralgia headache hemoptysis and,1
SIRTURO,nausea,reported in or more of patients treated with SIRTURO,0
SIRTURO,nausea,SIRTURO were,0
SIRTURO,nausea,and chest pain,0
SIRTURO,arthralgia,EXCERPT To,0
SIRTURO,arthralgia,were,0
SIRTURO,arthralgia,of patients,0
SIRTURO,arthralgia,arthralgia headache hemoptysis and,1
SIRTURO,arthralgia,treated with SIRTURO were arthralgia headache hemoptysis and,1
SIRTURO,arthralgia,arthralgia headache hemoptysis and,1
SIRTURO,arthralgia,arthralgia headache hemoptysis,1
SIRTURO,arthralgia,arthralgia headache hemoptysis,1
SIRTURO,arthralgia,nausea,0
SIRTURO,arthralgia,and,0
SIRTURO,headache,headache hemoptysis,1
SIRTURO,headache,headache hemoptysis and chest pain EXCERPT,1
SIRTURO,headache,headache hemoptysis,1
SIRTURO,hemoptysis,hemoptysis and,1
SIRTURO,hemoptysis,actions reported in or more of patients treated,0
SIRTURO,hemoptysis,arthralgia,0
SIRTURO,hemoptysis,hemoptysis and chest,1
SIRTURO,hemoptysis,were nausea arthralgia hemoptysis and,1
SIRTURO,hemoptysis,hemoptysis and chest,1
SIRTURO,hemoptysis,hemoptysis and chest pain EXCERPT To,1
SIRTURO,hemoptysis,nausea arthralgia headache,0
SIRTURO,hemoptysis,arthralgia hemoptysis,1
SIRTURO,hemoptysis,nausea arthralgia headache,0
SIRTURO,hemoptysis,To report SUSPECTED,0
SIRTURO,hemoptysis,arthralgia hemoptysis and chest,1
SIRTURO,hemoptysis,To report SUSPECTED,0
SIRTURO,aminotransferase elevations,normal developed more,0
SIRTURO,aminotransferase elevations,Studies,0
SIRTURO,aminotransferase elevations,Study In both Studies aminotransferase elevations,1
SIRTURO,aminotransferase elevations,Adverse Reactions were identified from the uncontrolled,0
SIRTURO,increased mortality,increased mortality risk by Week in,1
SIRTURO,increased mortality,there was a statistically increased mortality,1
SIRTURO,increased mortality,increased mortality risk by Week in,1
SIRTURO,increased mortality,treatment group compared to,0
SIRTURO,deaths,Five of the deaths and the,1
SIRTURO,deaths,treatment group compared to,0
SIRTURO,deaths,deaths and the,1
SIRTURO,deaths,deaths and the,1
SIRTURO,deaths,difference Five of,0
SIRTURO,deaths,deaths and the deaths were tuberculosisrelated One,1
SIRTURO,deaths,difference Five of,0
SIRTURO,deaths,deaths and the deaths were tuberculosisrelated One death occurred,1
SIRTURO,deaths,difference Five of,0
SIRTURO,deaths,deaths were tuberculosisrelated One death occurred,1
SIRTURO,deaths,of the difference Five of the SIRTURO deaths,0
SIRTURO,deaths,deaths were tuberculosisrelated One,1
SIRTURO,death,The median time to death,0
SIRTURO,death,death,1
SIRTURO,death,placebo deaths were tuberculosisrelated death,1
SIRTURO,death,death,1
SIRTURO,death,tuberculosisrelated death occurred during the,1
SIRTURO,death,death,1
SIRTURO,death,median time to,0
SIRTURO,death,death occurred during the week SIRTURO,1
SIRTURO,death,death,1
SIRTURO,death,intake of S,0
SIRTURO,deaths,unexplained,0
SIRTURO,deaths,The imbalance deaths is unexplained no discernible pattern,1
SIRTURO,deaths,unexplained,0
SIRTURO,deaths,last intake,0
SIRTURO,deaths,deaths is,1
SIRTURO,deaths,SIRTURO The imbalance deaths is unexplained no discernible,1
SIRTURO,deaths,deaths is,1
SIRTURO,deaths,in,0
SIRTURO,deaths,deaths,1
SIRTURO,death,treat tuberculosis HIV status,0
SIRTURO,death,unexplained no discernible pattern death and,1
SIRTURO,death,treat tuberculosis HIV status,0
SIRTURO,death,death and sputum,1
SIRTURO,death,death,1
SIRTURO,death,discernible pattern death and sputum conversion relapse,1
SIRTURO,death,death,1
SIRTURO,death,death and sputum conversion relapse sensitivity,1
SIRTURO,death,drugs used,0
SIRTURO,death,death and sputum conversion relapse sensitivity,1
SIRTURO,death,death and sputum conversion relapse sensitivity,1
SIRTURO,death,death,1
SIRTURO,died,observed In the openlabel,0
SIRTURO,died,died The most common,1
SIRTURO,died,died The,1
SIRTURO,died,died,1
SIRTURO,died,died The most,1
SIRTURO,died,died,1
SIRTURO,died,died The,1
SIRTURO,died,died The most common cause,1
SIRTURO,death,but,0
SIRTURO,death,one subject who died of TB,0
SIRTURO,death,most common cause death,1
SIRTURO,death,one subject who died of TB,0
SIRTURO,death,death as reported by the,1
SIRTURO,death,death as reported by the investigator,1
SIRTURO,death,death as reported by the,1
SIRTURO,death,cause death as reported by the,1
SIRTURO,death,death as reported by the,1
SIRTURO,death,died of TB had not con,0
SIRTURO,died,not converted,0
SIRTURO,died,subject,0
SIRTURO,died,died,1
SIRTURO,died,died of TB,1
SIRTURO,death,causes death,1
SIRTURO,death,died of TB,1
SIRTURO,death,not,0
SIRTURO,death,TB had not converted or,0
SIRTURO,death,All but one subject who died of TB had not converted,0
SIRTURO,death,remaining subjects varied,0
SIRTURO,death,in,0
SIRTURO,death,relapsed The causes death in the remaining,1
SIRTURO,death,in,0
SIRTURO,death,in the,0
SIRTURO,INCREASED MORTALITY,REACTIONS following serious a,1
SIRTURO,INCREASED MORTALITY,ADVERSE REACTIONS following serious a,1
SIRTURO,INCREASED MORTALITY,reactions are discussed elsewhere in,0
SIRTURO,INCREASED MORTALITY,ADVERSE REACTIONS following serious a dverse reactions are,1
SIRTURO,INCREASED MORTALITY,reactions are discussed elsewhere in,0
SIRTURO,INCREASED MORTALITY,following serious a dverse reactions,1
SIRTURO,INCREASED MORTALITY,reactions are discussed elsewhere in,0
SIRTURO,INCREASED MORTALITY,following serious a dverse,1
SIRTURO,INCREASED MORTALITY,ADVERSE REACTIONS following serious a dverse,1
SIRTURO,INCREASED MORTALITY,following serious a dverse,1
SIRTURO,INCREASED MORTALITY,dverse reactions,0
SIRTURO,QT PROLONGATION,* In creased mortality,1
SIRTURO,QT PROLONGATION,serious adverse,0
SIRTURO,QT PROLONGATION,* In creased mortality see,1
SIRTURO,QT PROLONGATION,discussed elsewhere in the ling: * In,1
SIRTURO,QT PROLONGATION,"elsewhere in the ling:



 *  In creased mortality see Warnings and",1
SIRTURO,QT PROLONGATION,discussed elsewhere in the ling: * In,1
SIRTURO,QT PROLONGATION,adverse reactions are discussed elsewhere in,0
SIRTURO,QT PROLONGATION,"the ling:



 *  In creased mortality see",1
SIRTURO,QT PROLONGATION,adverse reactions are discussed elsewhere in,0
SIRTURO,QT PROLONGATION,"the ling:



 *  In creased mortality",1
SIRTURO,QT PROLONGATION,adverse reactions are discussed elsewhere in,0
SIRTURO,QT PROLONGATION,"in the ling:



 *  In creased mortality",1
SIRTURO,QT PROLONGATION,adverse reactions are discussed elsewhere in,0
SIRTURO,INCREASED MORTALITY,and Precaut ions QT,1
SIRTURO,INCREASED MORTALITY,labeling Increased mortality see arnings and Precaut ions QT Prolongation see,1
SIRTURO,INCREASED MORTALITY,and Precaut ions QT,1
SIRTURO,INCREASED MORTALITY,and Clinical,0
SIRTURO,INCREASED MORTALITY,see arnings and Precaut ions QT Prolongation see Warnings,1
SIRTURO,INCREASED MORTALITY,and Clinical,0
SIRTURO,INCREASED MORTALITY,Warnings and Precautions,0
SIRTURO,INCREASED MORTALITY,and Precautions and,0
SIRTURO,INCREASED MORTALITY,Increased mortality see arnings and Precaut ions QT Prolongation see,1
SIRTURO,INCREASED MORTALITY,and Precautions and,0
SIRTURO,QT PROLONGATION,"mortality see Warnings and ns (5.1)  ]  
 ",1
SIRTURO,QT PROLONGATION,and Precautions and,0
SIRTURO,QT PROLONGATION,and ns (5.1),1
SIRTURO,QT PROLONGATION,Prolongation,0
SIRTURO,death,nings and Precautions Drug Interactions,1
SIRTURO,death,nings and,1
SIRTURO,death,nings and Precautions Drug Interactions,1
SIRTURO,death,and,0
SIRTURO,death,War,0
SIRTURO,death,Clinical,0
SIRTURO,death,Warnings and,0
SIRTURO,death,Precautions Drug,0
SIRTURO,death,nings,1
SIRTURO,death,Hepatotoxicity see nings,1
SIRTURO,death,nings,1
SIRTURO,QT prolongation,pain,0
SIRTURO,QT prolongation,SUSPECTED ADVERSE REACTIONS contact Janssen Therapeutics Division of,0
SIRTURO,QT prolongation,      EXCERPT: ,1
SIRTURO,QT prolongation,chest       EXCERPT:  To report SUSPECTED,1
SIRTURO,QT prolongation,      EXCERPT: ,1
SIRTURO,QT prolongation,Therapeutics Division,0
SIRTURO,QT prolongation,"Janssen Therapeutics Division of ssen Products,  LP at JANSSEN or",1
SIRTURO,QT prolongation,Therapeutics Division,0
SIRTURO,QT prolongation,"Division of ssen Products,  LP at JANSSEN",1
SIRTURO,QT prolongation,Therapeutics Division,0
SIRTURO,QT prolongation,Therapeutics Division of ssen,1
SIRTURO,QT prolongation,ssen,1
SIRTURO,QT prolongation,"Division of ssen Products,",1
SIRTURO,QT prolongation,"ssen Products, LP at JANSSEN or FDA",1
SIRTURO,QT prolongation,"ssen Products, LP at JANSSEN",1
SIRTURO,QT prolongation,FDA at FDA or wwwfdagovmedwatch,0
SIRTURO,death,clinical studies are ducte d under,1
SIRTURO,death,FDA at FDA or wwwfdagovmedwatch,0
SIRTURO,death,ducte d under,1
SIRTURO,death,ducte d under widely varying conditions,1
SIRTURO,death,ducte,1
SIRTURO,death,clinical,0
SIRTURO,QT prolongation,from the pooled safety  from 335 SIRTU ROexposed patients who received,1
SIRTURO,QT prolongation,clinical,0
SIRTURO,QT prolongation,reactions for SIRTURO were identified from,0
SIRTURO,QT prolongation,pooled,0
SIRTURO,QT prolongation,335 SIRTU ROexposed patients who received weeks,1
SIRTURO,QT prolongation,pooled safety from 335,1
SIRTURO,QT prolongation,practice Adverse,0
SIRTURO,QT prolongation,safety  from 335 SIRTU,1
SIRTURO,QT prolongation,practice Adverse,0
SIRTURO,QT prolongation,discussed,0
SIRTURO,QT prolongation,discussed elsewhere,0
SIRTURO,QT prolongation,erse reactions are discussed,1
SIRTURO,QT prolongation,REACTIONS The following serious erse reactions ,1
SIRTURO,QT prolongation,erse reactions are discussed,1
SIRTURO,QT prolongation,REACTIONS The following serious erse reactions  are,1
SIRTURO,QT prolongation,erse reactions are discussed,1
SIRTURO,QT prolongation,adv,0
SIRTURO,QT prolongation,erse reactions are discussed elsewhere in the,1
SIRTURO,QT prolongation,erse reactions are discussed elsewhere,1
SIRTURO,Hepatotoxicity,reased mortality see Warnings and Precautions QT Prolongation see Warnings and,0
SIRTURO,Hepatotoxicity,ecautions,1
SIRTURO,Hepatotoxicity,see Warnings and,0
SIRTURO,Hepatotoxicity,Prolongation see Warnings and ecautions (5.2 and,1
SIRTURO,Hepatotoxicity,see Warnings and,0
SIRTURO,Hepatotoxicity,and Clinical,0
SIRTURO,Hepatotoxicity,and ecautions (5.2,1
SIRTURO,Hepatotoxicity,Pr,0
SIRTURO,Hepatotoxicity,ecautions (5.2 and Clinical,1
SIRTURO,Hepatotoxicity,Precautions QT Prolongation see Warnings and,0
SIRTURO,Hepatotoxicity,Prolongation see Warnings and ecautions,1
SIRTURO,death,ommon adverse reactions reported in or,1
SIRTURO,death,ommon adverse reactions reported in or,1
SIRTURO,death,were,0
SIRTURO,death,ommon adverse reactions,1
SIRTURO,death,ommon adverse reactions,1
SIRTURO,death,REACTIONS contact Janssen Therapeutics Division of Janssen Products LP,0
SIRTURO,death,ECTED ADVERSE,1
SIRTURO,death,report ECTED ADVERSE REACTIONS contact,1
SIRTURO,death,ECTED ADVERSE,1
SIRTURO,death,To report ECTED ADVERSE REACTIONS contact Janssen Therapeutics,1
SIRTURO,death,ECTED ADVERSE,1
SIRTURO,death,ECTED ADVERSE,1
SIRTURO,death,ECTED ADVERSE,1
SIRTURO,deaths,Product,0
SIRTURO,deaths,"s, LP at JANSSEN or",1
SIRTURO,deaths,ADVERSE REACTIONS contact Janssen Therapeutics,0
SIRTURO,deaths,"s, LP  at JANSSEN or",1
SIRTURO,deaths,ADVERSE REACTIONS contact Janssen Therapeutics,0
SIRTURO,deaths,"s, LP ",1
SIRTURO,deaths,ADVERSE REACTIONS contact Janssen Therapeutics,0
SIRTURO,deaths,"s, LP  at JANSSEN or FDA",1
SIRTURO,deaths,ADVERSE REACTIONS contact Janssen Therapeutics,0
SIRTURO,deaths,Therapeutics Division of Janssen Product,0
SIRTURO,deaths,"Janssen s, LP",1
SIRTURO,death,LP at JANSSEN or at 1-,1
SIRTURO,death,at JANSSEN or at,1
SIRTURO,death,at 1- FDA or wwwfdagovmedwatch,1
SIRTURO,death,at 1-,1
SIRTURO,death,LP at JANSSEN or at 1- FDA or,1
SIRTURO,death,at 1-,1
SIRTURO,prolongs the QT interval,another,0
SIRTURO,prolongs the QT interval,clinical studies of another dr,0
SIRTURO,prolongs the QT interval,not reflect t,1
SIRTURO,prolongs the QT interval,reactions for SIRTURO,0
SIRTURO,prolongs the QT interval,of another ug and may not reflect t he rates observed in,1
SIRTURO,prolongs the QT interval,reactions for SIRTURO,0
SIRTURO,prolongs the QT interval,may not reflect t,1
SIRTURO,prolongs the QT interval,Adverse drug reactions,0
SIRTURO,prolongs the QT interval,reflect t he rates observed in,1
SIRTURO,prolongs the QT interval,drug cannot be directly compared to the rates in the clinical,0
ADREVIEW,hypersensitivity reactions,ADVERSE REACTIONS EXCERPT Serious,0
ADREVIEW,hypersensitivity reactions,hypersensitivity,1
ADREVIEW,hypersensitivity reactions,reported,0
ADREVIEW,hypersensitivity reactions,Serious,0
ADREVIEW,hypersensitivity reactions,REACTIONS EXCERPT Serious,0
ADREVIEW,hypersensitivity reactions,REACTIONS EXCERPT,0
ADREVIEW,hypersensitivity reactions,EXCERPT hypersensitivity reactions have been reported,1
ADREVIEW,hypersensitivity reactions,REACTIONS EXCERPT,0
ADREVIEW,hypersensitivity reactions,following AdreView administration The most,0
ADREVIEW,hypersensitivity reactions,EXCERPT Serious,0
ADREVIEW,hypersensitivity reactions,REACTIONS EXCERPT Serious,0
ADREVIEW,dizziness,site,0
ADREVIEW,dizziness,dizziness,1
ADREVIEW,dizziness,The most common adverse dizziness rash pruritis flushing,1
ADREVIEW,dizziness,dizziness,1
ADREVIEW,dizziness,dizziness rash pruritis flushing,1
ADREVIEW,dizziness,The most common adverse reactions,0
ADREVIEW,dizziness,hemorrhage occurred in of,0
ADREVIEW,rash,rash pruritis flushing,1
ADREVIEW,rash,rash pruritis flushing headache and,1
ADREVIEW,rash,rash pruritis flushing,1
ADREVIEW,rash,rash pruritis flushing headache and,1
ADREVIEW,rash,dizziness,0
ADREVIEW,pruritis,hemorrhage occurred in of,0
ADREVIEW,pruritis,pruritis,1
ADREVIEW,pruritis,injection site hemorrhage occurred,0
ADREVIEW,flushing,pruritis,0
ADREVIEW,flushing,administration The most common,0
ADREVIEW,flushing,dizziness rash flushing headache and injection,1
ADREVIEW,flushing,administration The most common,0
ADREVIEW,flushing,adverse reactions dizziness rash,0
ADREVIEW,flushing,flushing,1
ADREVIEW,flushing,flushing headache,1
ADREVIEW,flushing,flushing,1
ADREVIEW,flushing,in of,0
ADREVIEW,flushing,pruritis,0
ADREVIEW,flushing,common,0
ADREVIEW,injection site hemorrhage,rash pruritis flushing headache and,0
ADREVIEW,injection site hemorrhage,injection site hemorrhage,1
ADREVIEW,injection site hemorrhage,flushing headache injection site hemorrhage,1
ADREVIEW,injection site hemorrhage,ministration The most common adverse reactions dizziness rash pruritis flushing,0
ADREVIEW,injection site hemorrhage,in,0
ADREVIEW,injection site hemorrhage,injection site hemorrhage occurred in of patients To,1
ADREVIEW,injection site hemorrhage,rash pruritis flushing headache injection site hemorrhage,1
ADREVIEW,injection site hemorrhage,injection site hemorrhage occurred in of patients To,1
ADREVIEW,injection site hemorrhage,flushing headache injection site hemorrhage occurred in of patients,1
ADREVIEW,injection site hemorrhage,injection site hemorrhage occurred in of patients To,1
ADREVIEW,injection site hemorrhage,and,0
ADREVIEW,injection site hemorrhage,headache injection,1
ADREVIEW,dizziness,Congestive Heart Failure No,0
ADREVIEW,dizziness,were predominantly isolated occurrences patients of one of the following reactions,0
ADREVIEW,dizziness,following dizziness rash,1
ADREVIEW,dizziness,were predominantly isolated occurrences patients of one of the following reactions,0
ADREVIEW,dizziness,dizziness rash pruritus flushing or,1
ADREVIEW,dizziness,dizziness,1
ADREVIEW,rash,isolated,0
ADREVIEW,pruritus,patients of one of the following reactions dizziness rash,0
ADREVIEW,flushing,flushing or injection,1
ADREVIEW,injection site hemorrhage,injection site hemorrhage,1
ADREVIEW,injection site hemorrhage,flushing or injection,1
ADREVIEW,injection site hemorrhage,injection site hemorrhage Congestive Heart Failure No,1
ADREVIEW,injection site hemorrhage,flushing or injection,1
ADREVIEW,injection site hemorrhage,currences patients of one of the following reactions dizziness rash pruritus flushing,0
ADREVIEW,injection site hemorrhage,Heart Failure No serious adverse reactions to AdreView were,0
ADREVIEW,injection site hemorrhage,flushing injection site hemorrhage,1
ADREVIEW,injection site hemorrhage,Heart Failure No serious adverse reactions to AdreView were,0
ADREVIEW,injection site hemorrhage,dizziness rash pruritus flushing injection site hemorrhage Congestive,1
ADREVIEW,injection site hemorrhage,Heart Failure No serious adverse reactions to AdreView were,0
ADREVIEW,injection site hemorrhage,rash pruritus flushing injection,1
ADREVIEW,injection site hemorrhage,injection site hemorrhage Congestive Heart Failure No serious,1
ADREVIEW,headache,reactions were predominantly of mild to moderate intensity,0
ADREVIEW,headache,mild to moderate intensity,0
ADREVIEW,headache,headache The adverse,1
ADREVIEW,headache,other most,0
ADREVIEW,headache,headache The adverse reactions were predominantly,1
ADREVIEW,headache,headache,1
ADREVIEW,headache,of mild,0
ADREVIEW,headache,mild,0
ADREVIEW,headache,and bruising The other most common reactions were flushing,0
ADREVIEW,Hypersensitivity reactions,Hypersensitivity reactions have,1
ADREVIEW,Hypersensitivity reactions,drug exposure,0
ADREVIEW,Hypersensitivity reactions,to drug Hypersensitivity reactions,1
ADREVIEW,Hypersensitivity reactions,to drug Hypersensitivity reactions have,1
ADREVIEW,Hypersensitivity reactions,to drug Hypersensitivity reactions,1
ADREVIEW,Hypersensitivity reactions,to drug Hypersensitivity reactions,1
ADREVIEW,Hypersensitivity reactions,Serious,0
ADREVIEW,Hypersensitivity reactions,adverse reactions,0
ADREVIEW,Hypersensitivity reactions,ensitivity,1
ADREVIEW,Hypersensitivity reactions,REACTIONS EXCERPT Serious ensitivity,1
ADREVIEW,Hypersensitivity reactions,EXCERPT Serious,0
ADREVIEW,Hypersensitivity reactions,following AdreView administration The,0
ADREVIEW,Hypersensitivity reactions,ensitivity reactions have been reported following AdreView administration,1
ADREVIEW,Hypersensitivity reactions,hypers,0
ADREVIEW,Hypersensitivity reactions,EXCERPT Serious ensitivity reactions have,1
ADREVIEW,Hypersensitivity reactions,"with heart ure, and 110 control patie nts All patients",1
ADREVIEW,Hypersensitivity reactions,EXCERPT Serious ensitivity reactions have,1
ADREVIEW,Hypersensitivity reactions,"neuroblastoma patients with heart ure, and 110 control patie nts",1
ADREVIEW,Hypersensitivity reactions,EXCERPT Serious ensitivity reactions have,1
ARCAPTA,asthma,asthma related death ARCAPTA NEOHALER is,1
ARCAPTA,asthma,of asthma,0
ARCAPTA,asthma,risk,0
ARCAPTA,asthma,asthma related death ARCAPTA NEOHALER,1
ARCAPTA,asthma,of,0
ARCAPTA,death,death,1
ARCAPTA,death,treatment of asthma See B,0
ARCAPTA,death,for the treatment of asthma See,0
ARCAPTA,death,death ARCAPTA NEOHALER is not indicated,1
ARCAPTA,death,for the treatment of asthma See,0
ARCAPTA,death,the treatment of asthma See B oxed,0
ARCAPTA,death,the risk of death ARCAPTA,1
ARCAPTA,death,the treatment of asthma See B oxed,0
ARCAPTA,death,death ARCAPTA NEOHALER is not indicated,1
ARCAPTA,death,of death ARCAPTA NEOHALER is not indicated,1
ARCAPTA,death,death ARCAPTA NEOHALER is not indicated,1
ARCAPTA,death,treatment of asthma See B oxed,0
ARCAPTA,oropharyngeal pain,oropharyngeal pain nasopharyngitis headache and nausea To,1
ARCAPTA,oropharyngeal pain,nausea To report SUSPECTED ADVERSE REACTIONS,0
ARCAPTA,oropharyngeal pain,than placebo are oropharyngeal,1
ARCAPTA,oropharyngeal pain,are oropharyngeal pain,1
ARCAPTA,oropharyngeal pain,than placebo are oropharyngeal,1
ARCAPTA,oropharyngeal pain,EXCERPT,0
ARCAPTA,oropharyngeal pain,oropharyngeal pain nasopharyngitis,1
ARCAPTA,nasopharyngitis,are,0
ARCAPTA,nasopharyngitis,report SUSPECTED ADVERSE REACTIONS contact,0
ARCAPTA,nasopharyngitis,SUSPECTED ADVERSE REACTIONS contact Novartis,0
ARCAPTA,nasopharyngitis,are cough oropharyngeal nasopharyngitis,1
ARCAPTA,nasopharyngitis,SUSPECTED ADVERSE REACTIONS contact Novartis,0
ARCAPTA,nasopharyngitis,nasopharyngitis headache and nausea To report,1
ARCAPTA,nasopharyngitis,are cough oropharyngeal nasopharyngitis headache and nausea To,1
ARCAPTA,nasopharyngitis,nasopharyngitis headache and nausea To report,1
ARCAPTA,nasopharyngitis,nasopharyngitis headache and nausea To report,1
ARCAPTA,headache,headache and nausea To report,1
ARCAPTA,headache,cough oropharyngeal pain headache and,1
ARCAPTA,headache,headache and nausea To report,1
ARCAPTA,headache,headache,1
ARCAPTA,headache,headache and nausea To report,1
ARCAPTA,headache,and more common than placebo are,0
ARCAPTA,headache,nausea To report SUSPECTED ADVERSE,0
ARCAPTA,headache,headache,1
ARCAPTA,headache,nausea To report SUSPECTED ADVERSE,0
ARCAPTA,headache,cough oropharyngeal pain headache,1
ARCAPTA,headache,nausea To report SUSPECTED ADVERSE,0
ARCAPTA,nausea,pain nasopharyngitis headache nausea To report SUSPECTED ADVERSE REACTIONS,1
ARCAPTA,nausea,nausea To report SUSPECTED ADVERSE,0
ARCAPTA,nausea,pain nasopharyngitis headache nausea To report SUSPECTED,1
ARCAPTA,nausea,nausea To report SUSPECTED ADVERSE,0
ARCAPTA,nausea,nausea To report,1
ARCAPTA,nausea,Novartis,0
ARCAPTA,nausea,pain nasopharyngitis headache nausea To report SUSPECTED,1
ARCAPTA,nausea,Novartis,0
ARCAPTA,nausea,pain nasopharyngitis headache nausea To report,1
ARCAPTA,nausea,Novartis,0
ARCAPTA,nausea,headache nausea To report SUSPECTED ADVERSE,1
ARCAPTA,nausea,Novartis,0
ARCAPTA,nausea,nausea To report SUSPECTED,1
ARCAPTA,nausea,Novartis,0
ARCAPTA,nausea,common than,0
ARCAPTA,nausea,nausea To report SUSPECTED ADVERSE REACTIONS,1
ARCAPTA,COPD,of ARCAPTA NEOHALER COPD and dyspnea The,1
ARCAPTA,COPD,nausea To report SUSPECTED ADVERSE REACTIONS,1
ARCAPTA,COPD,COPD,0
ARCAPTA,COPD,d patients The most common,0
ARCAPTA,COPD,NEOHALER COPD and dyspnea The most,1
ARCAPTA,COPD,d patients The most common,0
ARCAPTA,dyspnea,dyspnea The most,1
ARCAPTA,dyspnea,The most common adverse reactions that lead to discontinuation of ARCAPTA NEOHALER were COPD,0
ARCAPTA,dyspnea,dyspnea The most,1
ARCAPTA,dyspnea,The most common adverse reactions that lead to discontinuation of ARCAPTA NEOHALER were COPD,0
ARCAPTA,dyspnea,COPD dyspnea The most common,1
ARCAPTA,dyspnea,The most common adverse reactions that lead to discontinuation of ARCAPTA NEOHALER were COPD,0
ARCAPTA,dyspnea,dyspnea The,1
ARCAPTA,dyspnea,discontinuation of ARCAPTA,0
ARCAPTA,dyspnea,COPD dyspnea The most common,1
ARCAPTA,dyspnea,discontinuation of ARCAPTA,0
ARCAPTA,dyspnea,adverse reactions were COPD exacerbation pneumonia angina,0
ARCAPTA,dyspnea,dyspnea The most common,1
ARCAPTA,COPD exacerbation,ation of ARCAPTA NEOHALER were COPD and,0
ARCAPTA,pneumonia,adverse reactions were COPD pneumonia angina pectoris and atrial fibrillation,1
ARCAPTA,pneumonia,ation of ARCAPTA NEOHALER were COPD and,0
ARCAPTA,pneumonia,and dyspnea The most common serious adverse reactions were COPD,0
ARCAPTA,angina pectoris,common serious adverse,0
ARCAPTA,angina pectoris,at,0
ARCAPTA,angina pectoris,angina,1
ARCAPTA,angina pectoris,angina pectoris and atrial fibrillation,1
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris atrial fibrillation which occurred at similar rates,1
ARCAPTA,atrial fibrillation,angina pectoris and atrial fibrillation,1
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris atrial fibrillation which occurred at similar rates,1
ARCAPTA,atrial fibrillation,angina pectoris and atrial fibrillation,1
ARCAPTA,atrial fibrillation,common serious,0
ARCAPTA,atrial fibrillation,adverse,0
ARCAPTA,atrial fibrillation,treatment groups Table,0
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris atrial fibrillation,1
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris atrial fibrillation which,1
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris atrial fibrillation,1
ARCAPTA,atrial fibrillation,pneumonia angina pectoris atrial fibrillation which occurred,1
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris atrial fibrillation,1
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris and,0
ARCAPTA,atrial fibrillation,angina pectoris atrial fibrillation,1
ARCAPTA,atrial fibrillation,exacerbation pneumonia angina pectoris and,0
ARCAPTA,Cough,Cough Oropharyngeal pain,1
ARCAPTA,Nasopharyngitis,and Nasopharyngitis Nervous system disorders,1
ARCAPTA,Nasopharyngitis,Cough Oropharyngeal pain,1
ARCAPTA,Nasopharyngitis,Nasopharyngitis Nervous system disorders,1
ARCAPTA,Nasopharyngitis,Nasopharyngitis,1
ARCAPTA,Nasopharyngitis,system disorders,0
ARCAPTA,Headache,system disorders,0
ARCAPTA,Headache,Headache,1
ARCAPTA,Headache,system disorders,0
ARCAPTA,Nausea,Nausea,1
ARCAPTA,Nausea,disorders,0
ARCAPTA,Nausea,Gastrointestinal Nausea In these trials the,1
ARCAPTA,Nausea,disorders,0
ARCAPTA,Nausea,Nausea In these trials the,1
ARCAPTA,Nausea,Nausea In,1
ARCAPTA,Nausea,Headache,0
ARCAPTA,muscle spasm,tissue muscle,1
ARCAPTA,musculoskeletal pain,disorders muscle musculoskeletal,1
ARCAPTA,musculoskeletal pain,muscle musculoskeletal pain General disorders and administration site,1
ARCAPTA,musculoskeletal pain,disorders muscle musculoskeletal,1
ARCAPTA,musculoskeletal pain,and administration site conditions edema peripheral Metabolism and,0
ARCAPTA,musculoskeletal pain,musculoskeletal pain General disorders,1
ARCAPTA,edema peripheral,and administration site edema peripheral,1
ARCAPTA,edema peripheral,musculoskeletal pain General disorders,1
ARCAPTA,edema peripheral,disorders and administration site edema peripheral,1
ARCAPTA,edema peripheral,edema peripheral Metabolism and nutrition disorder diabetes,1
ARCAPTA,edema peripheral,and administration site conditions,0
ARCAPTA,edema peripheral,disorder diabetes mellitus,0
ARCAPTA,edema peripheral,Infections and,0
ARCAPTA,edema peripheral,musculoskeletal pain General disorders and administration site conditions,0
ARCAPTA,edema peripheral,site edema peripheral,1
ARCAPTA,edema peripheral,disorders and administration site edema,1
ARCAPTA,edema peripheral,edema peripheral Metabolism and nutrition disorder diabetes,1
ARCAPTA,diabetes mellitus,upper respiratory tract infection,0
ARCAPTA,diabetes mellitus,and nutrition diabetes mellitus,1
ARCAPTA,diabetes mellitus,nutrition diabetes mellitus,1
ARCAPTA,diabetes mellitus,and nutrition diabetes mellitus,1
ARCAPTA,diabetes mellitus,disorder,0
ARCAPTA,diabetes mellitus,and administration,0
ARCAPTA,diabetes mellitus,and infestations,0
ARCAPTA,hyperglycemia,upper respiratory tract,0
ARCAPTA,hyperglycemia,hyperglycemia Infections and infestations,1
ARCAPTA,hyperglycemia,and nutrition disorder diabetes mellitus,0
ARCAPTA,hyperglycemia,mellitus,0
ARCAPTA,hyperglycemia,tract infection C ough,0
ARCAPTA,hyperglycemia,infection C,0
ARCAPTA,hyperglycemia,hyperglycemia Infections and infestations sinusitis,1
ARCAPTA,hyperglycemia,hyperglycemia Infections and infestations sinusitis,1
ARCAPTA,hyperglycemia,mellitus,0
ARCAPTA,hyperglycemia,hyperglycemia Infections,1
ARCAPTA,sinusitis,experienced p ost,0
ARCAPTA,sinusitis,sinusitis upper respiratory,1
ARCAPTA,sinusitis,Infections and sinusitis upper respiratory,1
ARCAPTA,sinusitis,sinusitis upper respiratory,1
ARCAPTA,sinusitis,sinusitis upper respiratory tract infection C,1
ARCAPTA,sinusitis,and nutrition disorder diabetes mellitus hyperglycemia Infections and,0
ARCAPTA,sinusitis,mellitus hyperglycemia Infections and sinusitis,1
ARCAPTA,sinusitis,and nutrition disorder diabetes mellitus hyperglycemia Infections and,0
ARCAPTA,upper respiratory tract infection,infestations upper respiratory tract infection,1
ARCAPTA,upper respiratory tract infection,mellitus hyperglycemia Infections and infestations,0
ARCAPTA,upper respiratory tract infection,upper respiratory tract infection C ough experienced p ost,1
ARCAPTA,upper respiratory tract infection,mellitus hyperglycemia Infections and infestations,0
ARCAPTA,upper respiratory tract infection,infestations upper respiratory tract infection C ough experienced,1
ARCAPTA,upper respiratory tract infection,mellitus hyperglycemia Infections and infestations,0
ARCAPTA,upper respiratory tract infection,infestations upper respiratory tract infection C ough experienced,1
ARCAPTA,upper respiratory tract infection,mellitus hyperglycemia Infections and infestations,0
ARCAPTA,cough,of,0
ARCAPTA,cough,on at least of visits following inhalation of the,0
ARCAPTA,cough,inhalation of the recommended mcg dose of,0
ARCAPTA,cough,patients experienced cough on,1
ARCAPTA,cough,inhalation of the recommended mcg dose of,0
ARCAPTA,cough,dose of,0
ARCAPTA,cough,to of,0
ARCAPTA,cough,placebo cough usually occurred,1
ARCAPTA,cough,to of,0
ARCAPTA,cough,cough usually occurred within,1
ARCAPTA,cough,within seconds following inhalation and lasted for no more than seconds Cou,0
ARCAPTA,cough,f,0
ARCAPTA,cough,inhalation and lasted for no,0
ARCAPTA,cough,cough usually occurred,1
ARCAPTA,cough,cough usually,1
ARCAPTA,Cough,within seconds following inhalation and lasted for no more than,0
ARCAPTA,Cough,Cough,1
ARCAPTA,Cough,Cough following inhalation in clinical trials,1
ARCAPTA,Cough,Cough following,1
ARCAPTA,Cough,was not associated,0
ARCAPTA,Cough,Cough following inhalation,1
ARCAPTA,Cough,Cough following inhalation in clinical trials,1
ARCAPTA,Cough,Cough following inhalation,1
ARCAPTA,bronchospasm,associated bronchospasm exacerbations deteriorations of,1
ARCAPTA,bronchospasm,Cough following inhalation,1
ARCAPTA,bronchospasm,bronchospasm,1
ARCAPTA,bronchospasm,Cough following inhalation,1
ARCAPTA,bronchospasm,bronchospasm exacerbations,1
ARCAPTA,loss of efficacy,disease loss of efficacy Clinical Trials Experience,1
ARCAPTA,loss of efficacy,bronchospasm exacerbations,1
ARCAPTA,loss of efficacy,exacerbations deteriorations of disease,0
ARCAPTA,loss of efficacy,of efficacy Clinical Trials,1
ARCAPTA,loss of efficacy,n clinical trials was not associated with bronchospasm exacerbations deteriorations of,0
ARCAPTA,loss of efficacy,deteriorations of disease loss of efficacy,1
ARCAPTA,loss of efficacy,of efficacy Clinical Trials Experience in,1
ARCAPTA,deaths,dose group There were deaths in the,1
ARCAPTA,deaths,of efficacy Clinical Trials Experience in,1
ARCAPTA,deaths,in the ARCAPTA NEOHALER mcg dose group or in the,0
ARCAPTA,deaths,were deaths in,1
ARCAPTA,deaths,in the ARCAPTA NEOHALER mcg dose group or in the,0
ARCAPTA,deaths,dose group There were deaths in the ARCAPTA NEOHALER,1
ARCAPTA,deaths,in the ARCAPTA NEOHALER mcg dose group or in the,0
ARCAPTA,deaths,there were respiratoryrelated deaths in the ARCAPTA NEOHALER mcg,0
ARCAPTA,deaths,respiratoryrelated deaths in the ARCAPTA NEOHALER mcg dose group There were no,0
ARCAPTA,deaths,deaths,1
ARCAPTA,deaths,deaths in the,1
ARCAPTA,asthma exacerbation,asthma exacerbation,1
ARCAPTA,asthma exacerbation,the indacaterol mcg group patients in,0
ARCAPTA,asthma exacerbation,were reported for,0
ARCAPTA,asthma exacerbation,adverse reactions related asthma exacerbation were reported,1
ARCAPTA,asthma exacerbation,were reported for,0
ARCAPTA,asthma exacerbation,mcg group,0
ARCAPTA,deaths,inhaled corticosteroids deaths intubations or,1
ARCAPTA,deaths,mcg group,0
ARCAPTA,deaths,deaths intubations,1
ARCAPTA,deaths,inhaled corticosteroids deaths intubations or serious adverse,1
ARCAPTA,deaths,deaths intubations,1
ARCAPTA,deaths,reactions related,0
ARCAPTA,paradoxical bronchospasm,reactions are hypersensitivity paradoxical bronchospasm,1
ARCAPTA,paradoxical bronchospasm,hypersensitivity paradoxical,1
ARCAPTA,paradoxical bronchospasm,paradoxical bronchospasm tachycardiaheart,1
ARCAPTA,paradoxical bronchospasm,hypersensitivity paradoxical,1
ARCAPTA,paradoxical bronchospasm,paradoxical bronchospasm tachycardiaheart,1
ARCAPTA,tachycardia,tachycardia heart rate increasepalpitations pruritusrash,1
ARCAPTA,tachycardia,tachycardia heart,1
ARCAPTA,tachycardia,hypersensitivity reactions paradoxical tachycardia heart rate increasepalpitations,1
ARCAPTA,tachycardia,tachycardia heart,1
ARCAPTA,tachycardia,tachycardia heart rate,1
ARCAPTA,heart rate increase,heart rate increase palpitations pruritusrash and dizziness,1
ARCAPTA,heart rate increase,tachycardia heart rate,1
ARCAPTA,palpitations,bronchospasm tachycardiaheart rate increase,0
ARCAPTA,palpitations,rate palpitations,1
ARCAPTA,palpitations,bronchospasm tachycardiaheart rate increase,0
ARCAPTA,palpitations,pruritusrash and dizziness,0
ARCAPTA,palpitations,pruritusrash,0
ARCAPTA,palpitations,palpitations pruritusrash,1
ARCAPTA,palpitations,paradoxical bronchospasm,0
ARCAPTA,palpitations,pruritusrash and,0
ARCAPTA,palpitations,paradoxical bronchospasm tachycardiaheart rate palpitations pruritusrash and,1
ARCAPTA,palpitations,pruritusrash and,0
ARCAPTA,pruritus,rash and dizziness,0
ARCAPTA,pruritus,paradoxical bronchospasm,0
ARCAPTA,pruritus,reactions paradoxical bronchospasm,0
ARCAPTA,pruritus,tachycardiaheart rate pruritus,1
ARCAPTA,pruritus,reactions paradoxical bronchospasm,0
ARCAPTA,pruritus,pruritus rash,1
ARCAPTA,pruritus,pruritus,1
ARCAPTA,pruritus,rash and dizziness,0
ARCAPTA,pruritus,rash and dizziness,0
ARCAPTA,pruritus,pruritus rash,1
ARCAPTA,rash,bronchospasm tachycardiaheart rate increasepalpitations rash and dizziness,1
ARCAPTA,rash,pruritus rash,1
ARCAPTA,rash,rash and,1
ARCAPTA,rash,bronchospasm tachycardiaheart rate,0
ARCAPTA,rash,tachycardiaheart rate increasepalpitations rash and,1
ARCAPTA,rash,bronchospasm tachycardiaheart rate,0
ARCAPTA,rash,reactions paradoxical bronchospasm tachycardiaheart rate,0
ARCAPTA,rash,tachycardiaheart rate,0
ARCAPTA,DEATH,    -,1
ARCAPTA,DEATH,REACTIONS L,0
ARCAPTA,DEATH,REACTIONS L ong,0
ARCAPTA,DEATH,ADVERSE REACTIONS,0
ARCAPTA,DEATH,as A RCAPTA NEOHALER,0
ARCAPTA,DEATH,    - acting beta,1
ARCAPTA,DEATH,ong,0
ARCAPTA,DEATH,acting,0
ARCAPTA,DEATH,increase the risk,0
ARCAPTA,DEATH,beta c ago nists such as,1
ARCAPTA,DEATH,increase the risk,0
ARCAPTA,DEATH,acting beta c ago,1
ARCAPTA,DEATH,ong acting beta c,1
ARCAPTA,DEATH,ong acting beta c ago,1
ARCAPTA,DEATH,c ago nists such as,1
ARCAPTA,DEATH,acting beta c,1
ARCAPTA,death,of asthma See,0
ARCAPTA,death,is,1
ARCAPTA,death,W,0
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and,1
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and nausea,1
ARCAPTA,deaths,EXCERPT Most common adverse reactions and more common than placebo are cough orophar,0
ARCAPTA,deaths,yngeal pain nasopharyngitis,1
ARCAPTA,deaths,EXCERPT Most common adverse reactions and more common than placebo are cough orophar,0
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and nausea,1
ARCAPTA,deaths,cough,0
ARCAPTA,deaths,yngeal pain nasopharyngitis headache and,1
ARCAPTA,deaths,To report SUSPECTED ADVERSE REACTIONS,0
ARCAPTA,deaths,yngeal,1
ARCAPTA,DEATH,practice The ARCAPTA NEOHALER safety database reflects,0
ARCAPTA,DEATH,The ARCAPTA NEOHALER,0
ARCAPTA,death,ALER safety,0
ARCAPTA,death,or eater for at,1
ARCAPTA,death,ALER safety,0
ARCAPTA,death,or,0
ARCAPTA,death,of mcg or eater,1
ARCAPTA,death,or,0
ARCAPTA,death,and,0
ARCAPTA,death,least weeks in,0
ARCAPTA,death,weeks in six confirmatory randomized doubleblind placebo and activecontrolled,0
ARCAPTA,deaths,see,0
ARCAPTA,deaths,randomized,0
ARCAPTA,deaths, trial s patients were exposed to,1
ARCAPTA,deaths,placebo and,0
ARCAPTA,deaths,doubleblind placebo and activecontrolled clinical trials see Section In these,0
ARCAPTA,deaths,see,0
ARCAPTA,death,respectively Overall pa,0
ARCAPTA,death,months and d 425 COPD patients were,1
ARCAPTA,death,respectively Overall pa,0
ARCAPTA,death,recommended,0
ARCAPTA,death,were exposed to the recommended dose of mcg,0
ARCAPTA,death,exposed to the recommended dose of mcg for up to months and,0
ARCAPTA,death,d 425 COPD patients were exposed,1
ARCAPTA,cardiovascular effects,nausea To report,0
ARCAPTA,cardiovascular effects,"are cough, or",1
ARCAPTA,cardiovascular effects,"cough, or opharyngeal pain nasopharyngitis",1
ARCAPTA,cardiovascular effects,and more common placebo),1
ARCAPTA,cardiovascular effects,placebo),1
ARCAPTA,cardiovascular effects,ecautions EXCERPT Most common adverse reactions and,0
ARCAPTA,cardiovascular effects,than,0
ARCAPTA,cardiovascular effects,"reactions and more common placebo) are cough, or opharyngeal",1
ARCAPTA,cardiovascular effects,than,0
ARCAPTA,cardiovascular effects,reactions,0
ARCAPTA,cardiovascular effects,"more common placebo) are cough, or opharyngeal",1
ARCAPTA,cardiovascular effects,reactions,0
ARCAPTA,hypersensitivity reactions,placebo are cough oropharyngeal pain nasopharyngitis,0
ARCAPTA,hypersensitivity reactions,nasopharyngitis and,1
ARCAPTA,hypersensitivity reactions," and nausea. (  6  ) 



  To",1
ARCAPTA,hypersensitivity reactions,nasopharyngitis and,1
ARCAPTA,hypersensitivity reactions,"oropharyngeal pain nasopharyngitis  and nausea. (  6  ) 



  To report SUSPECTED ADVERSE REACTIONS",1
ARCAPTA,hypersensitivity reactions,nasopharyngitis and,1
ARCAPTA,hypersensitivity reactions,oropharyngeal pain nasopharyngitis and nausea. (,1
ARCAPTA,hypersensitivity reactions,SUSPECTED,0
ARCAPTA,hypersensitivity reactions,"oropharyngeal pain nasopharyngitis  and nausea. (  6  ) 



  To report SUSPECTED ADVERSE REACTIONS",1
ARCAPTA,hypersensitivity reactions,SUSPECTED,0
ARCAPTA,hypersensitivity reactions,placebo are cough oropharyngeal pain,0
ARCAPTA,hypersensitivity reactions,eactions and more common than placebo are cough oropharyngeal pain nasopharyngitis,0
ARCAPTA,paradoxical bronchospasm,REACTIONS contact Novartis cals Corporation at 1-88 or FDA at,1
ARCAPTA,paradoxical bronchospasm,eactions and more common than placebo are cough oropharyngeal pain nasopharyngitis,0
ARCAPTA,death,EOHAL ER,1
ARCAPTA,death,the rates observed in practice The ARCAPTA,0
ARCAPTA,deaths,of or mcg,0
ARCAPTA,deaths,were e xposed to a,1
ARCAPTA,deaths,of or mcg,0
ARCAPTA,death,n age of patients,1
ARCAPTA,death,of The n age of patients,1
ARCAPTA,death,n age of patients,1
ARCAPTA,death,of The n age,1
ARCAPTA,death,mea,0
ARCAPTA,death,on,1
ARCAPTA,death,that,0
ARCAPTA,death,and for placebotreated patients,0
ARCAPTA,hypersensitivity reactions,"iated with bronchospasm, e",1
ARCAPTA,hypersensitivity reactions,"not iated with bronchospasm, e",1
ARCAPTA,hypersensitivity reactions,trials was not iated,1
ARCAPTA,hypersensitivity reactions,"iated with bronchospasm, e xacerbations deteriorations",1
ARCAPTA,hypersensitivity reactions,"not iated with bronchospasm, e",1
ARCAPTA,hypersensitivity reactions,"iated with bronchospasm, e xacerbations deteriorations",1
ARCAPTA,hypersensitivity reactions,clinical trials was not,0
ARCAPTA,hypersensitivity reactions,"with bronchospasm, e xacerbations deteriorations of disease",1
ARCAPTA,hypersensitivity reactions,efficacy Clinical Trials,0
ARCAPTA,hypersensitivity reactions,of efficacy,0
ARCAPTA,paradoxical bronchospasm,Of these pati,1
ARCAPTA,paradoxical bronchospasm,concomitant with inhaled corticosteroids which were,0
ARCAPTA,paradoxical bronchospasm,andomized. Of these pati ents there,1
ARCAPTA,paradoxical bronchospasm,concomitant with inhaled corticosteroids which were,0
ARCAPTA,paradoxical bronchospasm,n,0
ARCAPTA,increases in pulse rate,in the indacaterol mcg,0
ARCAPTA,increases in pulse rate,600 mcg gr oup and,1
ARCAPTA,increases in pulse rate,600 mcg gr,1
ARCAPTA,increases in pulse rate,mcg group patients in  indacaterol 600 mcg gr,1
ARCAPTA,increases in pulse rate,600 mcg gr,1
ARCAPTA,ECG changes,mild persistent asthma inhaled cor ticosteroids No deaths intubations or,1
ARCAPTA,ECG changes,600 mcg gr,1
ARCAPTA,ECG changes,with mild persistent asthma,0
ARCAPTA,ECG changes,to asthma exacerbation,0
ARCAPTA,ECG changes,asthma exacerbation we,0
ARCAPTA,ECG changes,conducted in,0
ARCAPTA,ECG changes,asthma inhaled cor ticosteroids,1
ARCAPTA,ECG changes,conducted in,0
ARCAPTA,flattening of the T wave,"taking inhaled ds. No deaths, intubatio ns or",1
ARCAPTA,flattening of the T wave,conducted in,0
ARCAPTA,flattening of the T wave,"asthma taking inhaled ds. No deaths, intubatio",1
ARCAPTA,flattening of the T wave,conducted in,0
ARCAPTA,flattening of the T wave,taking inhaled ds. No,1
ARCAPTA,flattening of the T wave,"No deaths, intubatio ns",1
ARCAPTA,flattening of the T wave,serious adverse,0
ARCAPTA,flattening of the T wave,reported,0
ARCAPTA,flattening of the T wave,"inhaled ds. No deaths, intubatio ns or serious adverse reactions",1
ARCAPTA,flattening of the T wave,reported,0
ARCAPTA,flattening of the T wave,"inhaled ds. No deaths, intubatio ns or serious adverse",1
ARCAPTA,flattening of the T wave,reported,0
ARCAPTA,flattening of the T wave,adverse reactions,0
ARCAPTA,flattening of the T wave,g trial was conducted in adult patients with mild persistent asthma,0
ARCAPTA,prolongation of the QTc interval,"corticosteroids No deaths ,",1
ARCAPTA,prolongation of the QTc interval,No deaths,0
ARCAPTA,prolongation of the QTc interval,mild persistent asthma taking inhaled corticosteroids,0
ARCAPTA,prolongation of the QTc interval,"corticosteroids No deaths , or serious adverse reactions r elated to asthma exacerbation",1
ARCAPTA,prolongation of the QTc interval,mild persistent asthma taking inhaled corticosteroids,0
ARCAPTA,prolongation of the QTc interval,corticosteroids No,0
ARCAPTA,prolongation of the QTc interval,reactions r,1
ARCAPTA,prolongation of the QTc interval,"inhaled corticosteroids No deaths , or serious adverse reactions r elated to asthma exacerbation were",1
ARCAPTA,prolongation of the QTc interval,reactions r,1
ARCAPTA,prolongation of the QTc interval,inhaled corticosteroids,0
ARCAPTA,prolongation of the QTc interval,reactions r elated to asthma exacerbation were,1
ARCAPTA,prolongation of the QTc interval,reactions r elated to asthma,1
ARCAPTA,ST segment depression,serious adverse reactions to asthma,1
INTELENCE,hypersensitivity reactions,reactions are described in greater detail in other sections Severe skin,0
INTELENCE,hypersensitivity reactions,hypersensitivity reactions see Warnings,1
INTELENCE,hypersensitivity reactions,hypersensitivity reactions see Warnings and Precautions EXCERPT,1
INTELENCE,hypersensitivity reactions,hypersensitivity reactions,1
INTELENCE,hypersensitivity reactions,hypersensitivity,1
INTELENCE,rash,than placebo in adults are,0
INTELENCE,diarrhea,in at least,0
INTELENCE,diarrhea,in at least,0
INTELENCE,diarrhea,diarrhea To report SUSPECTED ADVERSE REACTIONS,1
INTELENCE,diarrhea,rash diarrhea To report SUSPECTED,1
INTELENCE,diarrhea,diarrhea To report SUSPECTED ADVERSE REACTIONS,1
INTELENCE,rash,Grade in,0
INTELENCE,rash,rash StevensJohnson syndrome,1
INTELENCE,rash,Grade in,0
INTELENCE,rash,rash,1
INTELENCE,rash,rash,1
INTELENCE,rash,rash StevensJohnson syndrome drug hypersensitivity reaction,1
INTELENCE,rash,the placebo arm The most frequently reported ADR at least Grade in severity was,0
INTELENCE,rash,rash StevensJohnson,1
INTELENCE,rash,and,0
INTELENCE,rash,The most frequently reported ADR at,0
INTELENCE,Stevens-Johnson syndrome,reported ADR at least Grade in severity was rash,0
INTELENCE,Stevens-Johnson syndrome,Stevens-Johnson,1
INTELENCE,Stevens-Johnson syndrome,in,0
INTELENCE,Stevens-Johnson syndrome,rash,0
INTELENCE,Stevens-Johnson syndrome,Stevens-Johnson syndrome drug hypersensitivity,1
INTELENCE,Stevens-Johnson syndrome,Stevens-Johnson syndrome drug,1
INTELENCE,hypersensitivity,reaction and erythema multiforme were reported in less than,0
INTELENCE,hypersensitivity,reported ADR at least Grade in severity was rash StevensJohnson syndrome,0
INTELENCE,hypersensitivity,hypersensitivity reaction,1
INTELENCE,hypersensitivity,hypersensitivity reaction and erythema multiforme,1
INTELENCE,hypersensitivity,at least Grade in severity,0
INTELENCE,erythema multiforme,than of subjects during clinical development with INTELENCE r,0
INTELENCE,erythema multiforme,hypersensitivity reaction erythema multiforme were,1
INTELENCE,erythema multiforme,than of subjects during clinical development with INTELENCE r,0
INTELENCE,rash,rash In general in,1
INTELENCE,rash,rash In general in clinical trials,1
INTELENCE,rash,rash,1
INTELENCE,rash,r discontinued due,0
INTELENCE,rash,was mild to moderate occurred primarily in the,0
INTELENCE,rash,discontinued due rash In,1
INTELENCE,rash,was mild to moderate occurred primarily in the,0
INTELENCE,rash,rash In general in clinical,1
INTELENCE,rash,rash,1
INTELENCE,rash,rash In general in,1
INTELENCE,rash,rash In general in clinical,1
INTELENCE,rash,trials,0
INTELENCE,rash,discontinued due to rash In general in clinical trials,0
INTELENCE,Rash,Rash generally resolved within to weeks,1
INTELENCE,Rash,occurred primarily in the second week of therapy and was infrequent,0
INTELENCE,Rash,was infrequent after Rash,1
INTELENCE,Rash,occurred primarily in the second week of therapy and was infrequent,0
INTELENCE,Rash,and was infrequent after Rash generally resolved within to weeks,1
INTELENCE,Rash,occurred primarily in the second week of therapy and was infrequent,0
INTELENCE,Rash,Rash generally resolved within to,1
INTELENCE,Rash,in the second week of therapy and was infrequent,0
INTELENCE,Rash,was,0
INTELENCE,Rash,infrequent after Rash generally resolved within to,1
INTELENCE,Rash,was,0
INTELENCE,Rash,Rash generally resolved within to,1
INTELENCE,Rash,on continued therapy The incidence,0
INTELENCE,rash,Week Rash generally resolved within to weeks on,0
INTELENCE,rash,therapy The incidence rash was higher in,1
INTELENCE,rash,Week Rash generally resolved within to weeks on,0
INTELENCE,rash,men in the INTELENCE r arm in,0
INTELENCE,rash,rash was higher in,1
INTELENCE,rash,men in the INTELENCE r arm in,0
INTELENCE,rash,within to weeks on continued therapy The incidence,0
INTELENCE,rash,rash was higher in women compared,1
INTELENCE,rash,the Phase trials rash,0
INTELENCE,rash,therapy The incidence rash was higher in women compared,1
INTELENCE,rash,the Phase trials rash,0
INTELENCE,rash,r arm in the Phase trials,0
INTELENCE,rash,arm in the,0
INTELENCE,rash,in the Phase rash,1
INTELENCE,rash,arm in the,0
INTELENCE,rash,rash Grade,1
INTELENCE,rash,rash Grade was,1
INTELENCE,rash,reported in,0
INTELENCE,rash,rash Grade was reported,1
INTELENCE,rash,rash Grade was reported in,1
INTELENCE,rash,rash Grade was reported,1
INTELENCE,rash,was higher in women compared to men,0
INTELENCE,rash,rash,1
INTELENCE,rash,in women versus men see Warnings and,0
INTELENCE,rash,a history of rash did not appear to be,1
INTELENCE,rash,in women versus men see Warnings and,0
INTELENCE,rash,be at increased risk for the development of INTELENCE,0
INTELENCE,rash,r related rash,0
INTELENCE,rash,a history of,0
INTELENCE,rash,rash compared,1
INTELENCE,rash,did not appear,0
INTELENCE,rash,rash compared to,1
INTELENCE,rash,rash compared,1
INTELENCE,rash,to be at increased risk for the development of INTELENCE r,0
INTELENCE,rash,rash Common Adverse Reactions,1
INTELENCE,rash,rash Common Adverse Reactions Clinical,1
INTELENCE,rash,rash Common Adverse Reactions,1
INTELENCE,rash,greater,0
INTELENCE,rash,rash Common Adverse Reactions,1
INTELENCE,rash,without a history of rash Common Adverse Reactions Clinical ADRs,1
INTELENCE,rash,rash Common Adverse Reactions,1
INTELENCE,Peripheral neuropathy,System,0
INTELENCE,Peripheral neuropathy,Peripheral neuropathy,1
INTELENCE,Peripheral neuropathy,Disorders,0
INTELENCE,Peripheral neuropathy,Disorders,0
INTELENCE,Peripheral neuropathy,System Disorders,0
INTELENCE,Peripheral neuropathy,Skin and,0
INTELENCE,Peripheral neuropathy,System Peripheral,1
INTELENCE,Peripheral neuropathy,ground regimen Nervous System Peripheral neuropathy,1
INTELENCE,Peripheral neuropathy,Peripheral neuropathy Skin and,1
INTELENCE,Peripheral neuropathy,regimen Nervous System Peripheral neuropathy,1
INTELENCE,Peripheral neuropathy,Peripheral neuropathy Skin and,1
INTELENCE,angina pectoris,Eye Disorders,0
INTELENCE,angina pectoris,myocardial angina pectoris,1
INTELENCE,angina pectoris,Eye Disorders,0
INTELENCE,angina pectoris,angina pectoris atrial fibrillation Ear and,1
INTELENCE,angina pectoris,Eye Disorders,0
INTELENCE,angina pectoris,fibrillation Ear and Labyrinth Disorders,0
INTELENCE,angina pectoris,Disorders vertigo Eye Disorders blurred vi,0
INTELENCE,atrial fibrillation,blurred,0
INTELENCE,atrial fibrillation,atrial fibrillation Ear and,1
INTELENCE,atrial fibrillation,blurred,0
INTELENCE,atrial fibrillation,atrial fibrillation Ear and Labyrinth,1
INTELENCE,atrial fibrillation,blurred,0
INTELENCE,atrial fibrillation,infarction angina atrial fibrillation Ear and Labyrinth Disorders vertigo,1
INTELENCE,atrial fibrillation,blurred,0
INTELENCE,atrial fibrillation,infarction,0
INTELENCE,atrial fibrillation,Eye Disorders blurred,0
INTELENCE,atrial fibrillation,atrial fibrillation Ear and Labyrinth Disorders,1
INTELENCE,atrial fibrillation,Eye Disorders blurred,0
INTELENCE,atrial fibrillation,angina,0
INTELENCE,atrial fibrillation,angina pectoris,0
INTELENCE,vertigo,fibrillation Ear and Labyrinth,0
INTELENCE,vertigo,vertigo Eye Disorders blurred vision,1
INTELENCE,vertigo,vertigo,1
INTELENCE,vertigo,Ear and Labyrinth vertigo,1
INTELENCE,vertigo,vertigo,1
INTELENCE,vertigo,blurred vision Gastrointestinal Disorders gastroesophageal reflux,0
INTELENCE,vertigo,Eye,0
INTELENCE,vertigo,vertigo Eye,1
INTELENCE,vertigo,vertigo Eye Disorders,1
INTELENCE,vertigo,blurred vision Gastrointestinal Disorders gastroesophageal,0
INTELENCE,vertigo,vertigo Eye Disorders,1
INTELENCE,blurred vision,Disorders,0
INTELENCE,blurred vision,Disorders gastroesophageal,0
INTELENCE,blurred vision,blurred vision Gastrointestinal,1
INTELENCE,blurred vision,blurred vision Gastrointestinal Disorders gastroesophageal reflux,1
INTELENCE,gastroesophageal reflux disease,gastroesophageal reflux disease,1
INTELENCE,gastroesophageal reflux disease,Gastrointestinal gastroesophageal,1
INTELENCE,gastritis,gastritis abdominal distension pancreatitis constipation,1
INTELENCE,gastritis,gastritis abdominal,1
INTELENCE,gastritis,gastritis abdominal distension pancreatitis,1
INTELENCE,pancreatitis,distension,0
INTELENCE,pancreatitis,pancreatitis,1
INTELENCE,pancreatitis,distension,0
INTELENCE,pancreatitis,pancreatitis constipation dry mouth hematemesis retching,1
INTELENCE,pancreatitis,pancreatitis constipation dry,1
INTELENCE,constipation,abdominal distension constipation dry mouth,1
INTELENCE,constipation,pancreatitis constipation dry,1
INTELENCE,constipation,dry mouth hematemesis retching stomatitis General Disorders and,0
INTELENCE,constipation,dry mouth hematemesis retching stomatitis General Disorders and Administration Site,0
INTELENCE,constipation,flatulence gastritis abdominal distension constipation dry,1
INTELENCE,constipation,dry mouth hematemesis retching stomatitis General Disorders and Administration Site,0
INTELENCE,constipation,stomatitis General Disorders and Administration,0
INTELENCE,constipation,gastritis abdominal distension constipation dry mouth,1
INTELENCE,constipation,stomatitis General Disorders and Administration,0
INTELENCE,constipation,retching stomatitis,0
INTELENCE,constipation,constipation dry mouth,1
INTELENCE,constipation,flatulence gastritis abdominal,0
INTELENCE,hematemesis,hematemesis,1
INTELENCE,hematemesis,dry hematemesis retching stomatitis General Disorders and,1
INTELENCE,hematemesis,hematemesis,1
INTELENCE,hematemesis,hematemesis retching stomatitis General,1
INTELENCE,hematemesis,hematemesis retching stomatitis General,1
INTELENCE,hematemesis,Disorders and Administration Site Conditions,0
INTELENCE,hematemesis,hematemesis retching stomatitis General Disorders and,1
INTELENCE,hematemesis,distension pancreatitis constipation dry,0
INTELENCE,retching,e flatulence,0
INTELENCE,retching,Administration,0
INTELENCE,retching,retching stomatitis General Disorders,1
INTELENCE,retching,retching stomatitis,1
INTELENCE,retching,dry mouth retching stomatitis General Disorders and Administration,1
INTELENCE,retching,retching stomatitis,1
INTELENCE,retching,Site,0
INTELENCE,retching,retching stomatitis General Disorders and,1
INTELENCE,retching,dry mouth retching stomatitis General Disorders and,1
INTELENCE,retching,retching stomatitis General Disorders and,1
INTELENCE,retching,constipation dry mouth retching,1
INTELENCE,retching,retching stomatitis General Disorders and,1
INTELENCE,retching,retching stomatitis General Disorders and,1
INTELENCE,sluggishness,Hepatobiliary Disorders hepatic failure h,0
INTELENCE,sluggishness,sluggishness,1
INTELENCE,sluggishness,sluggishness,1
INTELENCE,sluggishness,Hepatobiliary Disorders,0
INTELENCE,sluggishness,Administration Site sluggishness Hematologic Disorders hemolytic anemia Hepatobiliary,1
INTELENCE,sluggishness,Hepatobiliary Disorders,0
INTELENCE,sluggishness,and Administration,0
INTELENCE,hemolytic anemia,Conditions sluggishness Hematologic hemolytic anemia Hepatobiliary Disorders,1
INTELENCE,hemolytic anemia,and Administration,0
INTELENCE,hemolytic anemia,and,0
INTELENCE,hemolytic anemia,hemolytic anemia Hepatobiliary,1
INTELENCE,hemolytic anemia,and,0
INTELENCE,hemolytic anemia,hepatitis hepatic steato,0
INTELENCE,hemolytic anemia,Hepatobiliary Disorders hepatic failure,0
INTELENCE,hemolytic anemia,hemolytic anemia Hepatobiliary Disorders hepatic,1
INTELENCE,hepatic failure,ns sluggishness,0
INTELENCE,hepatic failure,hepatic failure hepatomegaly cytolytic hepatitis,1
INTELENCE,hepatomegaly,Immune System Disorders drug hypersensi,0
INTELENCE,cytolytic hepatitis,Hepatobiliary Disorders hepatic failure cytolytic hepatitis,1
INTELENCE,cytolytic hepatitis,Disorders hepatic failure cytolytic,1
INTELENCE,cytolytic hepatitis,logic Disorders hemolytic anemia Hepatobiliary Disorders,0
INTELENCE,cytolytic hepatitis,Hepatobiliary Disorders hepatic failure cytolytic hepatitis,1
INTELENCE,cytolytic hepatitis,Immune System Disorders drug hypersensitivity,0
INTELENCE,cytolytic hepatitis,hepatic failure cytolytic hepatitis,1
INTELENCE,cytolytic hepatitis,cytolytic hepatitis,1
INTELENCE,hepatic steatosis,hepatic steatosis hepatitis Immune System Disorders drug,1
INTELENCE,hepatic steatosis,hepatomegaly cytolytic,0
INTELENCE,hepatic steatosis,failure hepatomegaly cytolytic hepatic steatosis hepatitis Immune System Disorders,1
INTELENCE,hepatic steatosis,hepatomegaly cytolytic,0
INTELENCE,hepatic steatosis,hepatic steatosis hepatitis Immune System Disorders,1
INTELENCE,hepatitis,Disorders hepatic failure hepatomegaly cytolytic hepatitis,0
INTELENCE,hepatitis,hepatitis,1
INTELENCE,hepatitis,System Disorders drug hypersensitivity immune reconstitution syndrome Metabo,0
INTELENCE,hepatitis,hepatitis Immune System,1
INTELENCE,hepatitis,hepatitis Immune System Disorders drug hypersensitivity,1
INTELENCE,hepatitis,hepatic steatosis,0
INTELENCE,hepatitis,hepatitis Immune System Disorders drug hypersensitivity,1
INTELENCE,hepatitis,hepatic steatosis,0
INTELENCE,drug hypersensitivity,drug hypersensitivity immune reconstitution,1
INTELENCE,drug hypersensitivity,drug hypersensitivity immune reconstitution syndrome Metabolism and,1
INTELENCE,drug hypersensitivity,drug hypersensitivity immune reconstitution,1
INTELENCE,drug hypersensitivity,drug hypersensitivity immune reconstitution syndrome,1
INTELENCE,drug hypersensitivity,drug,1
INTELENCE,drug hypersensitivity,steatosis hepatitis Immune,0
INTELENCE,drug hypersensitivity,drug,1
INTELENCE,drug hypersensitivity,immune reconstitution syndrome Metabolism and Nutrition Disorders diabetes mellitus anor,0
INTELENCE,drug hypersensitivity,hepatomegaly cytolytic hepatitis hepatic steatosis hepatitis,0
INTELENCE,drug hypersensitivity,drug hypersensitivity immune,1
INTELENCE,drug hypersensitivity,drug,1
INTELENCE,immune reconstitution syndrome,Disorders drug immune reconstitution,1
INTELENCE,immune reconstitution syndrome,diabetes mellitus anorexia dyslipidemia,0
INTELENCE,immune reconstitution syndrome,Immune System Disorders drug immune reconstitution syndrome Metabolism and,1
INTELENCE,immune reconstitution syndrome,diabetes mellitus anorexia dyslipidemia,0
INTELENCE,immune reconstitution syndrome,reconstitution syndrome Metabolism and Nutrition Disorders,1
INTELENCE,immune reconstitution syndrome,Disorders drug immune reconstitution syndrome,1
INTELENCE,immune reconstitution syndrome,drug immune reconstitution syndrome,1
INTELENCE,immune reconstitution syndrome,drug,0
INTELENCE,immune reconstitution syndrome,drug immune reconstitution syndrome Metabolism and,1
INTELENCE,immune reconstitution syndrome,drug,0
INTELENCE,immune reconstitution syndrome,System Disorders drug hypersensitivity,0
INTELENCE,diabetes mellitus,somnolence convulsion hyp,0
INTELENCE,diabetes mellitus,Metabolism and Nutrition diabetes,1
INTELENCE,diabetes mellitus,and Nutrition diabetes mellitus anorexia dyslipidemia Nervous System,1
INTELENCE,diabetes mellitus,Metabolism and Nutrition diabetes,1
INTELENCE,diabetes mellitus,dyslipidemia Nervous System Disorders paraesthesia,0
INTELENCE,diabetes mellitus,syndrome Metabolism and Nutrition diabetes mellitus anorexia dyslipidemia Nervous System Disorders,1
INTELENCE,diabetes mellitus,dyslipidemia Nervous System Disorders paraesthesia,0
INTELENCE,diabetes mellitus,Metabolism and Nutrition diabetes mellitus anorexia dyslipidemia Nervous System,1
INTELENCE,diabetes mellitus,dyslipidemia Nervous System Disorders paraesthesia,0
INTELENCE,diabetes mellitus,and Nutrition diabetes mellitus,1
INTELENCE,diabetes mellitus,diabetes mellitus,1
INTELENCE,diabetes mellitus,Nutrition diabetes mellitus,1
INTELENCE,anorexia,diabetes anorexia dyslipidemia Nervous,1
INTELENCE,anorexia,Nutrition diabetes mellitus,1
INTELENCE,anorexia,immune reconstitution syndrome Metabolism and,0
INTELENCE,anorexia,anorexia dyslipidemia Nervous System Disorders,1
INTELENCE,anorexia,anorexia dyslipidemia Nervous System Disorders paraesthesia,1
INTELENCE,anorexia,Disorders diabetes,0
INTELENCE,anorexia,dyslipidemia,0
INTELENCE,anorexia,and Nutrition Disorders diabetes anorexia dyslipidemia,1
INTELENCE,anorexia,dyslipidemia,0
INTELENCE,anorexia,immune reconstitution syndrome Metabolism and Nutrition Disorders diabetes,0
INTELENCE,anorexia,and Nutrition,0
INTELENCE,dyslipidemia,Disorders diabetes mellitus dyslipidemia Nervous,1
INTELENCE,dyslipidemia,and Nutrition,0
INTELENCE,dyslipidemia,Disorders diabetes mellitus dyslipidemia Nervous,1
INTELENCE,dyslipidemia,and Nutrition,0
INTELENCE,dyslipidemia,Nervous System,0
INTELENCE,paraesthesia,convulsion hypoesthesia amnesia syncope disturbance in attention,0
INTELENCE,paraesthesia,paraesthesia somnolence convulsion hypoesthesia amnesia,1
INTELENCE,paraesthesia,paraesthesia somnolence convulsion,1
INTELENCE,paraesthesia,convulsion hypoesthesia amnesia syncope disturbance in attention hypersomnia tre,0
INTELENCE,paraesthesia,paraesthesia somnolence convulsion hypoesthesia amnesia,1
INTELENCE,paraesthesia,paraesthesia,1
INTELENCE,paraesthesia,paraesthesia somnolence convulsion hypoesthesia amnesia syncope,1
INTELENCE,paraesthesia,Disorders,0
INTELENCE,paraesthesia,paraesthesia somnolence,1
INTELENCE,paraesthesia,Disorders,0
INTELENCE,somnolence,System Disorders somnolence convulsion hypoesthesia amnesia,1
INTELENCE,somnolence,Disorders,0
INTELENCE,somnolence,somnolence convulsion hypoesthesia,1
INTELENCE,somnolence,convulsion,0
INTELENCE,somnolence,somnolence convulsion hypoesthesia amnesia syncope,1
INTELENCE,somnolence,convulsion,0
INTELENCE,somnolence,dyslipidemia Nervous System Disorders somnolence convulsion hypoesthesia amnesia,1
INTELENCE,somnolence,convulsion,0
INTELENCE,somnolence,Nervous System Disorders somnolence convulsion hypoesthesia amnesia syncope disturbance,1
INTELENCE,somnolence,convulsion,0
INTELENCE,somnolence,somnolence convulsion,1
INTELENCE,somnolence,somnolence convulsion hypoesthesia amnesia,1
INTELENCE,somnolence,somnolence convulsion hypoesthesia,1
INTELENCE,somnolence,somnolence convulsion hypoesthesia amnesia,1
INTELENCE,convulsion,attention hypersomnia,0
INTELENCE,convulsion,paraesthesia,0
INTELENCE,convulsion,convulsion,1
INTELENCE,hypoesthesia,hypoesthesia,1
INTELENCE,hypoesthesia,attention hypersomnia tremor,0
INTELENCE,hypoesthesia,hypoesthesia amnesia syncope disturbance in,1
INTELENCE,hypoesthesia,hypoesthesia amnesia syncope disturbance,1
INTELENCE,hypoesthesia,syncope disturbance in attention,0
INTELENCE,amnesia,attention hypersomnia,0
INTELENCE,amnesia,in attention hypersomnia tremor Psychiatric Disorders,0
INTELENCE,amnesia,Nervous System,0
INTELENCE,amnesia,dyslipidemia Nervous System Disorders paraesthesia somnolence,0
INTELENCE,amnesia,attention hypersomnia tremor Psychiatric Disorders anxiety sle,0
INTELENCE,amnesia,amnesia,1
INTELENCE,amnesia,attention hypersomnia tremor Psychiatric Disorders anxiety sle,0
INTELENCE,syncope,somnolence convulsion hypoesthesia syncope,1
INTELENCE,syncope,attention hypersomnia tremor Psychiatric Disorders anxiety sle,0
INTELENCE,syncope,syncope disturbance in attention hypersomnia tremor,1
INTELENCE,syncope,syncope disturbance,1
INTELENCE,syncope,syncope disturbance in attention hypersomnia tremor,1
INTELENCE,syncope,syncope,1
INTELENCE,syncope,syncope disturbance in attention hypersomnia,1
INTELENCE,syncope,amnesia,0
INTELENCE,disturbance in attention,Disorders paraesthesia,0
INTELENCE,disturbance in attention,abnormal dreams,0
INTELENCE,disturbance in attention,sleep,0
INTELENCE,disturbance in attention,sleep disorders abnormal,0
INTELENCE,disturbance in attention,hypersomnia tremor Psychiatric Disorders anxiety sleep disorders abnormal dreams,0
INTELENCE,disturbance in attention,disturbance in attention hypersomnia,1
INTELENCE,disturbance in attention,in attention,1
INTELENCE,disturbance in attention,hypoesthesia amnesia disturbance,1
INTELENCE,disturbance in attention,convulsion hypoesthesia amnesia disturbance in,1
INTELENCE,hypersomnia,hypersomnia tremor,1
INTELENCE,hypersomnia,hypersomnia tremor Psychiatric Disorders,1
INTELENCE,hypersomnia,hypersomnia tremor,1
INTELENCE,tremor,tremor,1
INTELENCE,tremor,syncope disturbance in attention tremor,1
INTELENCE,tremor,tremor,1
INTELENCE,tremor,disorders abnormal dreams confusional state,0
INTELENCE,tremor,attention hypersomnia,0
INTELENCE,anxiety,state disorientation nervousness nightmares,0
INTELENCE,anxiety,attention,0
INTELENCE,anxiety,anxiety sleep disorders abnormal dreams,1
INTELENCE,anxiety,disorders abnormal dreams confusional state,0
INTELENCE,anxiety,disorientation nervousness,0
INTELENCE,anxiety,anxiety sleep disorders abnormal dreams confusional,1
INTELENCE,anxiety,confusional,0
INTELENCE,anxiety,attention hypersomnia tremor Psychiatric anxiety sleep disorders abnormal dreams confusional,1
INTELENCE,anxiety,confusional,0
INTELENCE,anxiety,anxiety sleep disorders,1
INTELENCE,anxiety,anxiety,1
INTELENCE,sleep disorders,sleep disorders abnormal dreams,1
INTELENCE,abnormal dreams,confusional,0
INTELENCE,abnormal dreams,Psychiatric,0
INTELENCE,abnormal dreams,sleep abnormal dreams confusional state disorientation,1
INTELENCE,abnormal dreams,Psychiatric,0
INTELENCE,abnormal dreams,Disorders anxiety sleep abnormal,1
INTELENCE,abnormal dreams,nightmares,0
INTELENCE,abnormal dreams,in attention hypersomnia tremor Psychiatric Disorders anxiety sleep disorders,0
INTELENCE,abnormal dreams,abnormal dreams confusional state disorientation nervousness,1
INTELENCE,abnormal dreams,abnormal dreams confusional,1
INTELENCE,abnormal dreams,Disorders anxiety sleep abnormal dreams confusional state disorientation,1
INTELENCE,abnormal dreams,abnormal dreams confusional,1
INTELENCE,abnormal dreams,abnormal dreams confusional state,1
INTELENCE,confusional state,nervousness nightmares Renal and Urinary,0
INTELENCE,confusional state,acute,0
INTELENCE,confusional state,confusional state,1
INTELENCE,confusional state,confusional,1
INTELENCE,confusional state,confusional state disorientation,1
INTELENCE,confusional state,anxiety sleep disorders abnormal,0
INTELENCE,confusional state,Disorders anxiety sleep disorders abnormal,0
INTELENCE,confusional state,anxiety sleep disorders abnormal confusional state disorientation,1
INTELENCE,confusional state,Disorders anxiety sleep disorders abnormal,0
INTELENCE,confusional state,Renal,0
INTELENCE,disorientation,disorientation nervousness nightmares Renal and Urinary,1
INTELENCE,disorientation,Renal,0
INTELENCE,disorientation,disorientation nervousness nightmares,1
INTELENCE,disorientation,disorientation nervousness nightmares Renal and,1
INTELENCE,disorientation,disorientation nervousness,1
INTELENCE,disorientation,confusional disorientation nervousness nightmares Renal and,1
INTELENCE,disorientation,disorientation nervousness,1
INTELENCE,disorientation,disorientation,1
INTELENCE,disorientation,abnormal dreams confusional disorientation,1
INTELENCE,disorientation,disorientation,1
INTELENCE,nervousness,failure Reproductive System,0
INTELENCE,nervousness,nervousness,1
INTELENCE,nightmares,acute renal failure Reproductive,0
INTELENCE,nightmares,nightmares Renal and,1
INTELENCE,nightmares,disorders abnormal dreams confusional state,0
INTELENCE,nightmares,nightmares Renal and Urinary Disorders acute,1
INTELENCE,nightmares,rders anxiety sleep,0
INTELENCE,nightmares,dreams confusional state disorientation nightmares Renal,1
INTELENCE,nightmares,rders anxiety sleep,0
INTELENCE,acute renal failure,Urinary acute renal failure Reproductive,1
INTELENCE,acute renal failure,rders anxiety sleep,0
INTELENCE,acute renal failure,Breast,0
INTELENCE,acute renal failure,acute renal,1
INTELENCE,acute renal failure,Renal and Urinary acute renal failure Reproductive System and Breast Disorders,1
INTELENCE,acute renal failure,acute renal,1
INTELENCE,acute renal failure,Disorders gynecomastia RespiratoryThoracic,0
INTELENCE,acute renal failure,Breast Disorders,0
INTELENCE,acute renal failure,state disorientation nervousness,0
INTELENCE,acute renal failure,Renal and Urinary acute,1
INTELENCE,acute renal failure,renal failure,1
INTELENCE,gynecomastia,gynecomastia RespiratoryThoracic,1
INTELENCE,gynecomastia,and,0
INTELENCE,gynecomastia,exertional dyspnea bronchospasm Skin,0
INTELENCE,gynecomastia,gynecomastia RespiratoryThoracic and Mediastinal Disorders,1
INTELENCE,gynecomastia,exertional dyspnea bronchospasm Skin,0
INTELENCE,gynecomastia,Reproductive System and Breast,0
INTELENCE,gynecomastia,gynecomastia RespiratoryThoracic and Mediastinal Disorders,1
INTELENCE,gynecomastia,gynecomastia RespiratoryThoracic,1
INTELENCE,gynecomastia,Disorders,0
INTELENCE,gynecomastia,and Mediastinal,0
INTELENCE,gynecomastia,Breast Disorders,0
INTELENCE,gynecomastia,gynecomastia RespiratoryThoracic and,1
INTELENCE,gynecomastia,gynecomastia,1
INTELENCE,gynecomastia,Breast gynecomastia,1
INTELENCE,gynecomastia,gynecomastia,1
INTELENCE,gynecomastia,System and Breast Disorders,0
INTELENCE,gynecomastia,dyspnea,0
INTELENCE,gynecomastia,gynecomastia RespiratoryThoracic,1
INTELENCE,exertional dyspnea,Mediastinal exertional dyspnea bronchospasm Skin and Subcutaneous,1
INTELENCE,exertional dyspnea,gynecomastia RespiratoryThoracic,1
INTELENCE,exertional dyspnea,exertional dyspnea,1
INTELENCE,exertional dyspnea,RespiratoryThoracic and Mediastinal exertional dyspnea,1
INTELENCE,exertional dyspnea,gynecomastia RespiratoryThoracic and Mediastinal exertional dyspnea,1
INTELENCE,exertional dyspnea,Tissue Disorders night sweats,0
INTELENCE,exertional dyspnea,exertional dyspnea bronchospasm,1
INTELENCE,exertional dyspnea,gynecomastia RespiratoryThoracic and Mediastinal exertional dyspnea,1
INTELENCE,exertional dyspnea,System and Breast Disorders gynecomastia RespiratoryThoracic and Mediastinal,0
INTELENCE,exertional dyspnea,exertional dyspnea bronchospasm Skin and Subcutaneous,1
INTELENCE,exertional dyspnea,and Mediastinal exertional dyspnea bronchospasm Skin and Subcutaneous Tissue,1
INTELENCE,exertional dyspnea,exertional dyspnea bronchospasm Skin and Subcutaneous,1
INTELENCE,night sweats,lipohypertrophy prurigo,0
INTELENCE,night sweats,Skin and Subcutaneous Tissue night,1
INTELENCE,lipohypertrophy,exertional dyspnea bronchospasm Skin and,0
INTELENCE,lipohypertrophy,sweats,0
INTELENCE,lipohypertrophy,lipohypertrophy prurigo hyperhidrosis dry skin,1
INTELENCE,lipohypertrophy,Disorders night lipohypertrophy,1
INTELENCE,lipohypertrophy,lipohypertrophy prurigo hyperhidrosis dry skin,1
INTELENCE,lipohypertrophy,lipohypertrophy prurigo hyperhidrosis dry,1
INTELENCE,lipohypertrophy,Disorders night sweats,0
INTELENCE,lipohypertrophy,Subcutaneous Tissue Disorders night lipohypertrophy prurigo hyperhidrosis,1
INTELENCE,lipohypertrophy,Disorders night sweats,0
INTELENCE,lipohypertrophy,Tissue Disorders night sweats,0
INTELENCE,lipohypertrophy,hyperhidrosis dry skin swelling face Additional ADRs of at least moderate,0
INTELENCE,prurigo,prurigo hyperhidrosis dry skin swelling face,1
INTELENCE,prurigo,prurigo hyperhidrosis dry skin swelling face,1
INTELENCE,prurigo,prurigo hyperhidrosis dry skin swelling,1
INTELENCE,prurigo,prurigo hyperhidrosis,1
INTELENCE,hyperhidrosis,lipohypertrophy prurigo,0
INTELENCE,swelling face,swelling face,1
INTELENCE,swelling face,lipohypertrophy prurigo hyperhidrosis dry swelling face,1
INTELENCE,swelling face,Tissue Disorders night sweats lipohypertrophy prurigo hyperhidrosis dry skin,0
INTELENCE,swelling face,lipohypertrophy prurigo hyperhidrosis dry,0
INTELENCE,swelling face,hyperhidrosis,0
INTELENCE,swelling face,Disorders night sweats lipohypertrophy prurigo hyperhidrosis dry skin,0
INTELENCE,swelling face,d Subcutaneous Tissue Disorders night,0
INTELENCE,acquired lipodystrophy,of at least moderate,0
INTELENCE,acquired lipodystrophy,haemorrhagic stroke each reported in no,0
INTELENCE,acquired lipodystrophy,observed in other trials acquired lipodystrophy angioneurotic edema erythema multiforme and,1
INTELENCE,acquired lipodystrophy,haemorrhagic stroke each reported in no,0
INTELENCE,acquired lipodystrophy,stroke each reported in no,0
INTELENCE,angioneurotic edema,were acquired angioneurotic edema erythema multiforme and haemorrhagic stroke,1
INTELENCE,angioneurotic edema,stroke each reported in no,0
INTELENCE,angioneurotic edema,observed in other trials were acquired,0
INTELENCE,angioneurotic edema,stroke each reported in no more,0
INTELENCE,angioneurotic edema,acquired angioneurotic edema,1
INTELENCE,angioneurotic edema,angioneurotic edema erythema multiforme and,1
INTELENCE,angioneurotic edema,acquired angioneurotic edema,1
INTELENCE,angioneurotic edema,other trials were acquired angioneurotic,1
INTELENCE,angioneurotic edema,other trials were acquired angioneurotic edema,1
INTELENCE,angioneurotic edema,other trials were acquired angioneurotic,1
INTELENCE,angioneurotic edema,angioneurotic edema erythema multiforme,1
INTELENCE,erythema multiforme,were acquired lipodystrophy angioneurotic erythema multiforme,1
INTELENCE,erythema multiforme,erythema multiforme and haemorrhagic stroke,1
INTELENCE,erythema multiforme,no more than of subjects Laboratory Abnorma,0
INTELENCE,erythema multiforme,observed in other trials were,0
INTELENCE,erythema multiforme,observed in other trials were acquired lipodystrophy angioneurotic edema,0
INTELENCE,erythema multiforme,were acquired lipodystrophy angioneurotic erythema multiforme,1
INTELENCE,erythema multiforme,erythema multiforme and haemorrhagic,1
INTELENCE,erythema multiforme,erythema multiforme,1
INTELENCE,ALT abnormalities,enroll AST,0
INTELENCE,ALT abnormalities,ALT abnormalities occurred more frequently,1
INTELENCE,ALT abnormalities,ALT abnormalities occurred more frequently in,1
INTELENCE,ALT abnormalities,ALT abnormalities occurred more frequently,1
INTELENCE,ALT abnormalities,and,0
INTELENCE,ALT abnormalities,ALT abnormalities occurred more frequently in hepatitis,1
INTELENCE,ALT abnormalities,to enroll AST ALT abnormalities,1
INTELENCE,rash,rash which was observed more,1
INTELENCE,rash,subjects The most common adverse drug,0
INTELENCE,rash,adult subjects except for,0
INTELENCE,rash,least of pediatric subjects rash and diarrhea Rash,1
INTELENCE,rash,adult subjects except for,0
INTELENCE,rash,rash and diarrhea Rash was reported,1
INTELENCE,rash,subjects rash and diarrhea Rash was reported,1
INTELENCE,rash,rash and diarrhea Rash was reported,1
INTELENCE,rash,subjects,0
INTELENCE,rash,in male subjects rash,0
INTELENCE,rash,more frequently in,0
INTELENCE,diarrhea,Grade was,0
INTELENCE,diarrhea,diarrhea Rash was,1
INTELENCE,diarrhea,common adverse drug reactions in at least of pediatric subjects were,0
INTELENCE,diarrhea,pediatric subjects were rash diarrhea Rash was reported more,1
INTELENCE,diarrhea,common adverse drug reactions in at least of pediatric subjects were,0
INTELENCE,diarrhea,diarrhea Rash was,1
INTELENCE,diarrhea,diarrhea Rash was reported,1
INTELENCE,diarrhea,diarrhea Rash was,1
INTELENCE,diarrhea,male subjects,0
INTELENCE,diarrhea,diarrhea Rash was reported more frequently,1
INTELENCE,diarrhea,diarrhea Rash was,1
INTELENCE,diarrhea,diarrhea Rash was reported more,1
INTELENCE,Rash,Rash,1
INTELENCE,Rash,of pediatric subjects were,0
INTELENCE,Rash,and Rash was reported more frequently,1
INTELENCE,Rash,of pediatric subjects were,0
INTELENCE,Rash,rash and Rash was reported more frequently,1
INTELENCE,Rash,of pediatric subjects were,0
INTELENCE,Rash,of pediatric subjects were rash and,0
INTELENCE,Rash,of pediatric subjects were rash and,0
INTELENCE,Rash,Rash,1
INTELENCE,rash,females versus males,0
INTELENCE,rash,versus males discontinuations,0
INTELENCE,rash,rash Grade was reported,1
INTELENCE,rash,versus males discontinuations,0
INTELENCE,rash,subjects than,0
INTELENCE,rash,rash Grade was reported in females,1
INTELENCE,rash,rash Grade was reported in,1
INTELENCE,rash,diarrhea Rash was reported more frequently in female subjects than in male,0
INTELENCE,rash,frequently in female subjects than in,0
INTELENCE,rash,rash Grade was reported in females,1
INTELENCE,rash,males discontinuations due,0
INTELENCE,rash,rash were reported,1
INTELENCE,Rash,in females versus Rash greater than or equal,1
INTELENCE,Rash,rash were reported,1
INTELENCE,Rash,versus Rash greater than or,1
INTELENCE,Rash,rash were reported,1
INTELENCE,Rash,Rash greater than,1
INTELENCE,Rash,than or equal to Grade occurred,0
INTELENCE,rash,of therapy Rash was,0
INTELENCE,rash,rash,1
INTELENCE,Rash,the second week of Rash was,1
INTELENCE,Rash,rash,1
INTELENCE,Rash,Rash was selflimiting,1
INTELENCE,Rash,Rash was selflimiting and generally resolved,1
INTELENCE,Rash,Rash was selflimiting and generally resolved,1
INTELENCE,Rash,week of Rash was,1
INTELENCE,Rash,Rash was selflimiting and generally resolved,1
INTELENCE,Rash,mild to moderate of,0
INTELENCE,hypersensitivity,hypersensitivity reactions including DRESS and cases,1
INTELENCE,DRESS,DRESS and cases of,1
INTELENCE,DRESS,DRESS and,1
INTELENCE,DRESS,DRESS and cases of,1
INTELENCE,DRESS,DRESS and cases of,1
INTELENCE,DRESS,see Warnings and Precautions,0
INTELENCE,DRESS,been reported,0
INTELENCE,DRESS,reactions,0
INTELENCE,DRESS,have been,0
INTELENCE,DRESS,Severe hypersensitivity reactions including,0
INTELENCE,hepatic failure,System,0
INTELENCE,hepatic failure,including DRESS,0
INTELENCE,hepatic failure,and cases hepatic,1
INTELENCE,hepatic failure,including DRESS and cases hepatic failure have,1
INTELENCE,hepatic failure,and cases hepatic,1
INTELENCE,hepatic failure,hepatic failure have been,1
INTELENCE,rhabdomyolysis,Subcutaneous Tissue,0
INTELENCE,rhabdomyolysis,rhabdomyolysis Skin,1
INTELENCE,rhabdomyolysis,Tissue Disorders Fatal cases of toxic epidermal necrolysis have,0
INTELENCE,rhabdomyolysis,rhabdomyolysis Skin and Subcutaneous,1
INTELENCE,Fatal,Fatal cases of toxic epidermal necrolysis,1
INTELENCE,Fatal,been reported see Warnings and Precautions,0
INTELENCE,Fatal,Skin and Subcutaneous Tissue Fatal cases of toxic,1
INTELENCE,Fatal,been reported see Warnings and Precautions,0
INTELENCE,toxic epidermal necrolysis,toxic epidermal necrolysis have been,1
INTELENCE,toxic epidermal necrolysis,toxic epidermal necrolysis have been reported,1
INTELENCE,toxic epidermal necrolysis,Disorders Fatal cases toxic epidermal,1
INTELENCE,toxic epidermal necrolysis,epidermal necrolysis have been reported see Warnings,1
INTELENCE,toxic epidermal necrolysis,have been,0
INTELENCE,fatal,are described in greater il,1
INTELENCE,fatal,are described in greater il in other,1
INTELENCE,fatal,are described in greater il,1
INTELENCE,fatal,described in,0
INTELENCE,fatal,The following adverse reactions are,0
INTELENCE,fatal,in greater il,1
INTELENCE,skin reactions,reactions are described in greater,0
INTELENCE,skin reactions,other sections Severe skin and hypersensitivity reactions,1
INTELENCE,skin reactions,described in greater detail in,0
INTELENCE,skin reactions,in greater detail other sections Severe skin and hypersensitivity,1
INTELENCE,skin reactions,described in greater detail in,0
INTELENCE,skin reactions,greater detail other,1
INTELENCE,skin reactions,in greater detail other sections,1
INTELENCE,skin reactions,greater detail other,1
INTELENCE,Stevens-Johnson syndrome,hypersensitivity actions [ see  Warnings  and Precautions EXCERPT,1
INTELENCE,Stevens-Johnson syndrome,greater detail other,1
INTELENCE,Stevens-Johnson syndrome,actions [ see Warnings and Precautions EXCERPT The,1
INTELENCE,Stevens-Johnson syndrome,skin and hypersensitivity actions [ see  Warnings  and Precautions EXCERPT The most,1
INTELENCE,Stevens-Johnson syndrome,actions [ see Warnings and Precautions EXCERPT The,1
INTELENCE,Stevens-Johnson syndrome,[ see Warnings and Precautions,1
INTELENCE,Stevens-Johnson syndrome,Precautions EXCERPT The most common adverse drug,0
INTELENCE,Stevens-Johnson syndrome,other sections Severe skin and,0
INTELENCE,Stevens-Johnson syndrome,Precautions EXCERPT,0
INTELENCE,hypersensitivity reaction,d Precautions (5.1),1
INTELENCE,hypersensitivity reaction,Precautions (5.1) ]. EXCERPT The most common,1
INTELENCE,hypersensitivity reaction,an,0
INTELENCE,hypersensitivity reaction,The most common,0
INTELENCE,hypersensitivity reaction,d Precautions (5.1) ]. EXCERPT The,1
INTELENCE,hypersensitivity reaction,see Warnings d Precautions (5.1)   ]. ,1
INTELENCE,hypersensitivity reaction,d Precautions (5.1) ]. EXCERPT The,1
INTELENCE,hypersensitivity reaction,adverse drug reactions of moderate to severe,0
INTELENCE,hypersensitivity reaction,sections Severe skin,0
INTELENCE,hypersensitivity reaction,sections,0
INTELENCE,hypersensitivity reaction,of moderate to severe intensity,0
INTELENCE,toxic epidermal necrolysis,The most c,1
INTELENCE,toxic epidermal necrolysis,skin and,0
INTELENCE,toxic epidermal necrolysis,least which occurred at,0
INTELENCE,erythema multiforme,drug react ions of moderate to severe,1
INTELENCE,erythema multiforme,adverse drug react ions of moderate to,1
INTELENCE,erythema multiforme,EXCERPT The,0
INTELENCE,erythema multiforme,adverse drug,1
INTELENCE,erythema multiforme,reactions,0
INTELENCE,erythema multiforme,Precautions EXCERPT The most common,0
INTELENCE,fatal,"ts, L P at JANSSEN",1
INTELENCE,fatal,"ts, L P",1
INTELENCE,fatal,"ts, L P at JANSSEN",1
INTELENCE,fatal,"ADVERSE REACTIONS contact Janssen ts,",1
INTELENCE,skin reactions,report SUSPECTED ADVERSE REACTIONS contact,0
INTELENCE,Stevens-Johnson syndrome,Products LP at JANSSEN or FDA at FDA,0
INTELENCE,Stevens-Johnson syndrome,contact Janssen Products LP at JANSSEN or,0
INTELENCE,Stevens-Johnson syndrome,clinical trials are conducted u,0
INTELENCE,toxic epidermal necrolysis,at FDA,0
INTELENCE,toxic epidermal necrolysis,or tch . 6.1,1
INTELENCE,toxic epidermal necrolysis,Experience Adults Because clinical trials are,0
INTELENCE,toxic epidermal necrolysis,"or tch  .  



 

  6.1 Clini cal",1
INTELENCE,toxic epidermal necrolysis,Experience Adults Because clinical trials are,0
INTELENCE,toxic epidermal necrolysis,"or tch  .  



 

  6.1 Clini cal Trials",1
INTELENCE,toxic epidermal necrolysis,Experience Adults Because clinical trials are,0
INTELENCE,toxic epidermal necrolysis,"or tch  .  



 

  6.1 Clini cal Trials Experience Adults Because",1
INTELENCE,toxic epidermal necrolysis,Experience Adults Because clinical trials are,0
INTELENCE,toxic epidermal necrolysis,. 6.1 Clini cal Trials Experience,1
INTELENCE,toxic epidermal necrolysis,"tch  .  



 

  6.1 Clini cal Trials Experience Adults",1
INTELENCE,toxic epidermal necrolysis,. 6.1 Clini cal Trials Experience,1
INTELENCE,erythema multiforme,or FDA,0
INTELENCE,erythema multiforme,Experience: A dults,1
INTELENCE,erythema multiforme,wwwfdagovmedwatch Clinical rials Experience: A,1
INTELENCE,erythema multiforme,Experience: A dults,1
INTELENCE,Hypersensitivity reactions,Experience lts Because clinical tr,1
INTELENCE,Hypersensitivity reactions,Clinical Trials Experience,0
INTELENCE,Hypersensitivity reactions,FDA or wwwfdagovmedwatch Clinical,0
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"under widely varying conditions, adverse reaction rates observed",1
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,are co,0
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,drug cannot be directly compared,0
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"are nducted under widely varying conditions, adverse ",1
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,drug cannot be directly compared,0
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,clinical trials are nducted under,1
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"widely varying conditions, adverse reaction",1
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,"varying conditions, adverse reaction rates observed in",1
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,Because clinical trials are nducted under widely,1
INTELENCE,Drug Rash with Eosinophilia and Systemic Symptoms,are co,0
INTELENCE,DRESS,adverse actio n rates observed in,1
INTELENCE,DRESS,are co,0
INTELENCE,rash,nnot be directly compared to rates,1
INTELENCE,rash,nnot be directly compared to,1
INTELENCE,rash,under widely varying,0
INTELENCE,rash,nnot,1
INTELENCE,rash,a drug nnot,1
INTELENCE,rash,nnot,1
INTELENCE,rash,and,0
INTELENCE,rash,ca,0
INTELENCE,hepatic failure,of another and may not ref lect the rates,1
INTELENCE,hepatic failure,ca,0
INTELENCE,hepatic failure,another and,1
INTELENCE,hepatic failure,a drug cannot be directly compared to rates in the clinical trials of,0
INTELENCE,hepatic failure,safety assessment is based on all data,0
INTELENCE,hepatic failure,may not ref lect the rates observed in,1
INTELENCE,hepatic failure,trials of another and may not ref lect the rates observed in,1
INTELENCE,hepatic failure,may not ref lect the rates observed in,1
INTELENCE,hepatic failure,trials of another and may not,1
INTELENCE,rash,mg twice daily In these,0
INTELENCE,rash,trials the median exposure,0
INTELENCE,rash,whom received INTELENCE r mg twice daily In these pooled trials the,0
INTELENCE,rash,twice daily,0
INTELENCE,rash,HIVinfected,0
INTELENCE,rash, of  whom received INTELENCE r mg,1
INTELENCE,rash,HIVinfected,0
INTELENCE,Rash,g tw ice daily,1
INTELENCE,Rash,INTELENCE r arm and,0
INTELENCE,Rash,treatmentexperienced HIVinfected adult subjects of,0
INTELENCE,Rash,g tw ice daily In these,1
INTELENCE,Rash,g tw ice daily In these,1
INTELENCE,Rash,g tw ice daily In these,1
INTELENCE,rash,mg twice daily In these pooled trials the median exposure for,0
INTELENCE,rash,TELE NCE r,1
INTELENCE,rash,daily In these pooled trials the median exposure for,0
INTELENCE,rash,TELE NCE r,1
INTELENCE,rash,the TELE NCE r arm,1
INTELENCE,rash,TELE NCE r,1
INTELENCE,rash,TELE NCE r,1
INTELENCE,rash,r mg twice daily In these pooled trials the,0
INTELENCE,accumulation of body fat,to weeks,0
INTELENCE,accumulation of body fat,to moderate red primarily in the sec ond,1
INTELENCE,accumulation of body fat,to weeks,0
INTELENCE,accumulation of body fat,moderate red primarily in the,1
INTELENCE,accumulation of body fat,to moderate red primarily in the sec,1
INTELENCE,accumulation of body fat,moderate red primarily in the,1
INTELENCE,accumulation of body fat,in clinical trials rash was mild to moderate occur,0
INTELENCE,accumulation of body fat,moderate,0
INTELENCE,central obesity,"therapy, and",1
INTELENCE,central obesity,"therapy, and wa s",1
INTELENCE,central obesity,second week of,0
INTELENCE,central obesity,"second week therapy, and wa",1
INTELENCE,central obesity,second week of,0
INTELENCE,central obesity,"the second week therapy, and wa s infrequent after",1
INTELENCE,central obesity,second week of,0
INTELENCE,central obesity,"therapy, and wa s infrequent after",1
INTELENCE,central obesity,second week of,0
INTELENCE,dorsocervical fat enlargement,incidence of rash was,0
INTELENCE,dorsocervical fat enlargement,therapy The,0
INTELENCE,dorsocervical fat enlargement,incidence of,0
INTELENCE,dorsocervical fat enlargement,The incidence of rash was higher,0
INTELENCE,dorsocervical fat enlargement,and infrequent,1
INTELENCE,dorsocervical fat enlargement,4. Rash generally,1
INTELENCE,dorsocervical fat enlargement,incidence of rash was,0
INTELENCE,dorsocervical fat enlargement,Week 4. Rash generally resolved within to,1
INTELENCE,dorsocervical fat enlargement,mild to moderate occurred,0
INTELENCE,buffalo hump,enerally,1
INTELENCE,buffalo hump,enerally res olved within to,1
INTELENCE,buffalo hump,Week Rash enerally res olved within to weeks,1
INTELENCE,buffalo hump,enerally res olved within to,1
INTELENCE,buffalo hump,Week Rash enerally res,1
INTELENCE,buffalo hump,higher,0
INTELENCE,buffalo hump,Week Rash enerally res olved within to,1
INTELENCE,buffalo hump,higher,0
INTELENCE,facial wasting,within to ks on continue,1
INTELENCE,facial wasting,generally resolved within to,0
INTELENCE,facial wasting,ks on continue,1
INTELENCE,breast enlargement,within to weeks on therapy. The,1
INTELENCE,breast enlargement,on therapy. The incid ence of rash was higher,1
INTELENCE,breast enlargement,within to weeks on therapy. The,1
INTELENCE,breast enlargement,within to weeks on therapy. The,1
INTELENCE,cushingoid appearance,continued therapy The incidence  rash was higher in w omen compared to men in,1
INTELENCE,cushingoid appearance,within to weeks on therapy. The,1
INTELENCE,cushingoid appearance,The incidence  rash was higher in w omen compared to men in,1
INTELENCE,cushingoid appearance,within to weeks on therapy. The,1
INTELENCE,cushingoid appearance, rash was higher in w omen compared to men in,1
INTELENCE,cushingoid appearance,within to weeks on therapy. The,1
INTELENCE,cushingoid appearance,therapy The incidence rash was higher in w,1
INTELENCE,cushingoid appearance,rash was higher in,1
INTELENCE,Immune reconstitution syndrome,Patients with a history of NNRTIrelated rash did,0
INTELENCE,inflammatory response,"dverse Reactions  


",1
INTELENCE,inflammatory response,Patients with a history of NNRTIrelated rash did,0
INTELENCE,inflammatory response,rash Common dverse,1
INTELENCE,inflammatory response,of NNRTIrelated rash Common dverse Reactions,1
INTELENCE,opportunistic infections,te intensity or greater greater,1
INTELENCE,opportunistic infections,Reactions Clinical ADRs of te intensity or greater,1
INTELENCE,opportunistic infections,of te intensity or greater  greater than or equal to,1
INTELENCE,opportunistic infections,Reactions Clinical ADRs of te intensity or greater,1
INTELENCE,opportunistic infections,history of,0
INTELENCE,opportunistic infections,Grade and reported in at,0
INTELENCE,opportunistic infections,of te intensity or,1
INTELENCE,opportunistic infections,intensity or greater greater than or equal to,1
INTELENCE,opportunistic infections,hout a history,0
INTELENCE,Mycobacterium avium infection,r and occurring at a higher rate,0
INTELENCE,Mycobacterium avium infection,or greater greater han or equal to Grade 2) and r eported in at least of,1
INTELENCE,Mycobacterium avium infection,r and occurring at a higher rate,0
INTELENCE,cytomegalovirus,equal to Grade and orted in at lea st of,1
INTELENCE,cytomegalovirus,r and occurring at a higher rate,0
INTELENCE,cytomegalovirus,to Grade and orted in at lea st of,1
INTELENCE,cytomegalovirus,r and occurring at a higher rate,0
INTELENCE,cytomegalovirus,to Grade and orted in at lea st of subjects treated with,1
INTELENCE,cytomegalovirus,r and occurring at a higher rate,0
INTELENCE,cytomegalovirus,at lea st of,1
INTELENCE,cytomegalovirus,equal to Grade and orted in at lea st of subjects,1
INTELENCE,cytomegalovirus,at lea st of,1
INTELENCE,cytomegalovirus,equal,0
INTELENCE,PCP,ENC,1
INTELENCE,Autoimmune disorders,abnormalities considered ADRs are,0
INTELENCE,Autoimmune disorders,excess of are esented in Table 1.  Laboratory abnormalities considered ADRs are,1
INTELENCE,Autoimmune disorders,abnormalities considered ADRs are,0
INTELENCE,Autoimmune disorders,are esented in Table 1.  Laboratory,1
INTELENCE,Autoimmune disorders,abnormalities considered ADRs are,0
INTELENCE,Autoimmune disorders,included in Table,0
INTELENCE,Autoimmune disorders,to placebo excess of are,0
INTELENCE,Autoimmune disorders,Table 1. Laboratory abnormalities,1
INTELENCE,Autoimmune disorders,of are esented in Table 1. ,1
INTELENCE,Autoimmune disorders,Table 1. Laboratory abnormalities,1
INTELENCE,Graves' disease,TreatmentEmergent Adverse,0
INTELENCE,Graves' disease, abnormalities  considered ADRs,1
INTELENCE,Graves' disease,Table Table TreatmentEmergent Adverse ReactionsIncludes,0
INTELENCE,Graves' disease, abnormalities  considered ADRs,1
INTELENCE,polymyositis,Table Laboratory abnormalities nsidered ADR s are included in,1
INTELENCE,polymyositis, abnormalities  considered ADRs,1
INTELENCE,polymyositis,nsidered ADR s,1
INTELENCE,polymyositis,are presented in Table Laboratory abnormalities co,0
INTELENCE,polymyositis,nsidered ADR,1
INTELENCE,Guillain-Barre syndrome,to placebo excess of are presented in Table Laboratory abnormalities considered ADRs are,0
INTELENCE,Guillain-Barre syndrome,Table TreatmentEmergent Adverse ReactionsIncludes adverse reactions at least possibly,0
INTELENCE,Guillain-Barre syndrome,Table 2.,1
INTELENCE,Guillain-Barre syndrome,abnormalities considered ADRs included,1
INTELENCE,Guillain-Barre syndrome,adverse reactions at least,0
INTELENCE,Guillain-Barre syndrome,are,0
PICATO,Ophthalmic Adverse Reaction,discussed in more detail in other,0
PICATO,Ophthalmic Adverse Reaction,other sections of the Ophthalmic Adverse Reaction see Warnings and Precautions,1
PICATO,Ophthalmic Adverse Reaction,discussed in more detail in other,0
PICATO,Ophthalmic Adverse Reaction,other sections of the Ophthalmic Adverse Reaction,1
PICATO,Ophthalmic Adverse Reaction,discussed in more detail in other,0
PICATO,Ophthalmic Adverse Reaction,Ophthalmic Adverse Reaction see Warnings,1
PICATO,Ophthalmic Adverse Reaction,Adverse Reaction see,1
PICATO,Ophthalmic Adverse Reaction,the Ophthalmic Adverse Reaction,1
PICATO,Ophthalmic Adverse Reaction,Adverse Reaction see,1
PICATO,Ophthalmic Adverse Reaction,sections of the Ophthalmic Adverse Reaction see Warnings,1
PICATO,Ophthalmic Adverse Reaction,Adverse Reaction see,1
PICATO,Ophthalmic Adverse Reaction,sections of the Ophthalmic Adverse Reaction,1
PICATO,Ophthalmic Adverse Reaction,Adverse Reaction see,1
PICATO,Ophthalmic Adverse Reaction,the Ophthalmic Adverse,1
PICATO,Ophthalmic Adverse Reaction,detail in,0
PICATO,Hypersensitivity Reactions,EXCERPT The most common adverse reactions,0
PICATO,Hypersensitivity Reactions,and Precautions EXCERPT The most common adverse reactions,0
PICATO,Hypersensitivity Reactions,Hypersensitivity Reactions see Warnings and,1
PICATO,Hypersensitivity Reactions,and Hypersensitivity Reactions,1
PICATO,Hypersensitivity Reactions,Hypersensitivity Reactions see Warnings and,1
PICATO,Hypersensitivity Reactions,EXCERPT The most common adverse,0
PICATO,Hypersensitivity Reactions,and Precautions,0
PICATO,local skin reactions,adverse reactions local skin,1
PICATO,local skin reactions,gs and Precautions EXCERPT The most,0
PICATO,local skin reactions,skin reactions application site pain application,1
PICATO,local skin reactions,local skin reactions application site pain application site,1
PICATO,local skin reactions,skin reactions application site pain application,1
PICATO,application site pain,EXCERPT The most common,0
PICATO,application site pain,skin application site,1
PICATO,application site pain,skin application site pain,1
PICATO,application site pruritus,application site irritation application site infection periorbital edema nasopharyngitis,0
PICATO,application site pruritus,reactions,0
PICATO,application site pruritus,skin reactions application site application site pruritus,1
PICATO,application site pruritus,application site pruritus application site irritation application,1
PICATO,application site pruritus,infection periorbital,0
PICATO,application site pruritus,skin reactions application site application site pruritus application site irritation application site,1
PICATO,application site pruritus,infection periorbital,0
PICATO,application site irritation,infection periorbital edema nasopharyngitis and,0
PICATO,application site irritation,application site irritation application site infection periorbital,1
PICATO,application site irritation,infection periorbital edema nasopharyngitis and,0
PICATO,application site irritation,site irritation application,1
PICATO,application site irritation,site irritation application site infection periorbital,1
PICATO,application site irritation,pain application site pruritus,0
PICATO,application site infection,To report SUSPECTED ADVERSE R,0
PICATO,periorbital edema,periorbital edema,1
PICATO,nasopharyngitis,lication site pruritus application site irritation,0
PICATO,nasopharyngitis,LEO Pharma Inc,0
PICATO,nasopharyngitis,nasopharyngitis,1
PICATO,nasopharyngitis,nasopharyngitis,1
PICATO,nasopharyngitis,application site irritation application site,0
PICATO,nasopharyngitis,and headache To report SUSPECTED ADVERSE REACTIONS contact LEO Pharma Inc at,0
PICATO,nasopharyngitis,nasopharyngitis and headache To,1
PICATO,nasopharyngitis,SUSPECTED ADVERSE REACTIONS contact LEO Pharma Inc,0
PICATO,headache,headache To,1
PICATO,headache,REACTIONS contact LEO Pharma Inc,0
PICATO,headache,nasopharyngitis,0
PICATO,headache,periorbital edema nasopharyngitis headache To,1
PICATO,headache,nasopharyngitis,0
PICATO,Local skin reactions,consecutive Local skin reactions including,1
PICATO,Local skin reactions,nasopharyngitis,0
PICATO,Local skin reactions,Local skin reactions including erythema,1
PICATO,Local Skin Reactions,Assessment of,0
PICATO,Local Skin Reactions,Local Skin Reactions in the Treatment Area during,1
PICATO,Local Skin Reactions,of Local,1
PICATO,Local Skin Reactions,Skin Reactions in,1
PICATO,Local Skin Reactions,Area during,0
PICATO,Local Skin Reactions,Investigator Assessment of Local,1
PICATO,Local Skin Reactions,Table Investigator Assessment of Local Skin,1
PICATO,Local Skin Reactions,Investigator Assessment of Local Skin,1
PICATO,Local Skin Reactions,Assessment of,0
PICATO,Local skin reactions,Severe Local skin reactions,1
PICATO,Local skin reactions,Severe grade,0
PICATO,Local skin reactions,within day of treatment initiation peaked in,0
PICATO,Local skin reactions,Local skin reactions typically occurred within,1
PICATO,Local skin reactions,Severe Local skin reactions typically occurred within day,1
PICATO,Local skin reactions,Local skin reactions typically occurred within,1
PICATO,Local skin reactions,peaked in intensity,0
PICATO,Application Site Pain,gel N Vehicle Application Site,1
PICATO,Application Site Pain,Vehicle Application,1
PICATO,Application Site Pain,Application Site Pain Application Site Pruritus,1
PICATO,Application Site Pain,N,0
PICATO,Application Site Pain,Application Site Pain Application Site Pruritus,1
PICATO,Application Site Pain,N,0
PICATO,Application Site Pain,Vehicle Application Site Pain Application,1
PICATO,Application Site Pain,N,0
PICATO,Application Site Pruritus,Application Site Pruritus,1
PICATO,Application Site Pruritus,N,0
PICATO,Application Site Pruritus,Site Application Site Pruritus Application Site Infection,1
PICATO,Application Site Pruritus,N,0
PICATO,Application Site Pruritus,Application Site Application Site,1
PICATO,Application Site Pruritus,Application,1
PICATO,Application Site Pruritus,Application,0
PICATO,Application Site Pruritus,Application Site Infection,0
PICATO,Application Site Infection,Application Site Application,1
PICATO,Application Site Infection,Application Site Application Site Infection Periorbital,1
PICATO,Application Site Infection,Application Site Application,1
PICATO,Application Site Infection,Application Site Infection Periorbital,1
PICATO,Application Site Infection,Application Site Application,1
PICATO,Headache,Headache,1
PICATO,Headache,Headache Table,1
PICATO,Headache,Headache,1
PICATO,Headache,Edema,0
PICATO,Headache,Periorbital Headache Table Adver,1
PICATO,Headache,Edema,0
PICATO,Headache,Headache Table,1
PICATO,Headache,Headache Table Adver,1
PICATO,Headache,Headache Table,1
PICATO,Headache,Periorbital Headache,1
PICATO,Headache,Headache Table,1
PICATO,Headache,Headache Table Adver,1
PICATO,Headache,Headache Table,1
PICATO,Application Site Pruritus,N,0
PICATO,Application Site Pruritus,Picator gel N Vehicle Application,1
PICATO,Application Site Pruritus,Application Site,1
PICATO,Application Site Pruritus,Vehicle N,0
PICATO,Application Site Pruritus,Picator gel N Vehicle N,0
PICATO,Application Site Pruritus,N Vehicle Application Site,1
PICATO,Application Site Pruritus,Vehicle N,0
PICATO,Nasopharyngitis,Application Site Pain,0
PICATO,Nasopharyngitis,Nasopharyngitis Application,1
PICATO,Nasopharyngitis,Application Site Pain,0
PICATO,Nasopharyngitis,Application Site,0
PICATO,Nasopharyngitis,Application Site Pain,0
PICATO,Nasopharyngitis,Nasopharyngitis,1
PICATO,Nasopharyngitis,Nasopharyngitis Application Site Pain,1
PICATO,Nasopharyngitis,Application,0
PICATO,Nasopharyngitis,Nasopharyngitis Application Site,1
PICATO,Nasopharyngitis,Nasopharyngitis Application Site,1
PICATO,eyelid edema,with Picato,0
PICATO,eyelid edema,r eyelid edema eye pain conjunctivitis A,1
PICATO,eyelid edema,with Picato,0
PICATO,eyelid edema,Picato r eyelid edema,1
PICATO,eyelid edema,eyelid edema eye pain conjunctivitis,1
PICATO,eye pain,r included eyelid eye pain conjunctivitis A total of subjects,1
PICATO,eye pain,eyelid edema eye pain conjunctivitis,1
PICATO,eye pain,eyelid edema,0
PICATO,eye pain,gel on,0
PICATO,eye pain,included eyelid eye pain conjunctivitis,1
PICATO,eye pain,gel on,0
PICATO,conjunctivitis,conjunctivitis A total,1
PICATO,conjunctivitis,eyelid edema eye pain,0
PICATO,conjunctivitis,conjunctivitis,1
PICATO,conjunctivitis,conjunctivitis,1
PICATO,conjunctivitis,edema eye conjunctivitis,1
PICATO,conjunctivitis,conjunctivitis,1
PICATO,conjunctivitis,r,0
PICATO,conjunctivitis,of subjects treated with Picato r,0
PICATO,conjunctivitis,total of subjects treated with Picato,0
PICATO,conjunctivitis,eye conjunctivitis A total of subjects treated,1
PICATO,conjunctivitis,total of subjects treated with Picato,0
PICATO,conjunctivitis,with Picato,0
PICATO,hypersensitivity,hypersensitivity allergic contact dermatitis herpes,1
PICATO,hypersensitivity,gel hypersensitivity allergic contact,1
PICATO,hypersensitivity,hypersensitivity allergic contact dermatitis herpes,1
PICATO,hypersensitivity,mebutate,0
PICATO,hypersensitivity,r ingenol mebutate gel hypersensitivity,1
PICATO,hypersensitivity,mebutate,0
PICATO,allergic contact dermatitis,Picato r ingenol mebutate gel and,0
PICATO,allergic contact dermatitis,zoster chemical conjunctivitis and corneal burn Because these,0
PICATO,allergic contact dermatitis,allergic contact dermatitis herpes zoster chemical conjunctivitis,1
PICATO,allergic contact dermatitis,uring post approval use of Picato r ingenol mebutate gel and,0
PICATO,herpes zoster,allergic contact dermatitis,0
PICATO,herpes zoster,allergic contact herpes zoster,1
PICATO,herpes zoster,contact herpes zoster,1
PICATO,herpes zoster,these,0
PICATO,herpes zoster,and hypersensitivity allergic contact herpes zoster chemical conjunctivitis and,1
PICATO,herpes zoster,these,0
PICATO,herpes zoster,conjunctivitis and corneal burn Because,0
PICATO,herpes zoster,herpes zoster chemical conjunctivitis and,1
PICATO,herpes zoster,allergic contact herpes zoster chemical,1
PICATO,herpes zoster,herpes zoster chemical conjunctivitis and,1
PICATO,herpes zoster,herpes,1
PICATO,herpes zoster,hypersensitivity allergic contact herpes,1
PICATO,chemical conjunctivitis,and corneal burn Because these reactions are reported voluntarily from a population of,0
PICATO,chemical conjunctivitis,herpes chemical conjunctivitis,1
PICATO,chemical conjunctivitis,and corneal burn Because these reactions are reported voluntarily from a population of,0
PICATO,chemical conjunctivitis,are reported voluntarily from,0
PICATO,chemical conjunctivitis,dermatitis herpes chemical conjunctivitis and corneal,1
PICATO,chemical conjunctivitis,are reported voluntarily from,0
PICATO,chemical conjunctivitis,chemical conjunctivitis and corneal burn,1
PICATO,chemical conjunctivitis,are reported voluntarily,0
PICATO,chemical conjunctivitis,dermatitis herpes chemical conjunctivitis and,1
PICATO,chemical conjunctivitis,are reported voluntarily,0
PICATO,chemical conjunctivitis,allergic contact dermatitis herpes chemical conjunctivitis,1
PICATO,chemical conjunctivitis,are reported voluntarily,0
PICATO,chemical conjunctivitis,allergic contact dermatitis herpes chemical conjunctivitis and corneal burn Because these,1
PICATO,chemical conjunctivitis,are reported voluntarily,0
PICATO,corneal burn,conjunctivitis corneal burn,1
PICATO,corneal burn,herpes zoster chemical conjunctivitis corneal burn Because these,1
PICATO,corneal burn,conjunctivitis corneal burn,1
PICATO,corneal burn,from a,0
PICATO,corneal burn,corneal burn Because these reactions are,1
PICATO,corneal burn,chemical conjunctivitis,0
PICATO,corneal burn,corneal burn,1
PICATO,corneal burn,a population,0
PICATO,corneal burn,conjunctivitis,0
PICATO,Eye disorders,are discus,0
PICATO,Eye disorders,Reaction see Warnings a,0
PICATO,Eye disorders,of the labeling Ophthalmic Adverse Reaction see,0
PICATO,corneal burn,of the *,1
PICATO,corneal burn,ious,0
PICATO,corneal burn,the * Ophthalmi,1
PICATO,eyelid edema,other,0
PICATO,eyelid edema,sections of the labeling Adverse Reac tion,1
PICATO,eyelid edema,other,0
PICATO,eyelid ptosis,ngs and Precautions Hypersensitivity,0
PICATO,eyelid ptosis,Adverse on [see Warni,1
PICATO,eyelid ptosis,ngs and Precautions Hypersensitivity,0
PICATO,eyelid ptosis,Ophthalmic Adverse on [see Warni ngs and Precautions Hypersensitivity Reactions,1
PICATO,eyelid ptosis,ngs and Precautions Hypersensitivity,0
PICATO,eyelid ptosis,Ophthalmic Adverse on [see,1
PICATO,eyelid ptosis,in other sections of the labeling Ophthalmic,0
PICATO,eyelid ptosis,detail in other sections of the labeling Ophthalmic,0
PICATO,Eye disorders,Experience cause,1
PICATO,Eye disorders,Experience cause,1
PICATO,Eye disorders,wwwfdagovmedwatch Clinical Trials Experience cause clinica l trials are conducted under,1
PICATO,Eye disorders,Experience cause,1
PICATO,Eye disorders,cause clinica,1
PICATO,Eye disorders,cause clinica l trials are,1
PICATO,Eye disorders,Trials Experience cause clinica,1
PICATO,Eye disorders,cause clinica l trials,1
PICATO,Eye disorders,Trials Experience cause clinica,1
PICATO,Eye disorders,Experience cause clinica,1
PICATO,eye pain,Because,0
PICATO,eye pain,ted unde r widely,1
PICATO,eye pain,are ted unde r widely varying conditions,1
PICATO,eye pain,ted unde r widely,1
PICATO,eye pain,ted unde r widely varying,1
PICATO,chemical conjunctivitis,trials,0
PICATO,chemical conjunctivitis,widely varying conditio,1
PICATO,chemical conjunctivitis,varying conditio ns adverse,1
PICATO,chemical conjunctivitis,varying conditio ns adverse,1
PICATO,chemical conjunctivitis,varying conditio,1
PICATO,chemical conjunctivitis,clinical trials are conducted widely varying conditio ns adverse,1
PICATO,chemical conjunctivitis,varying conditio,1
PICATO,chemical conjunctivitis,medwatch Clinical Trials Experience,0
PICATO,chemical conjunctivitis,varying conditio ns,1
PICATO,chemical conjunctivitis,trials are conducted widely varying,1
PICATO,corneal burn,adverse re,1
PICATO,corneal burn,widely varying conditions,0
PICATO,eyelid edema,varying,0
PICATO,eyelid edema,tion rates o bserved in,1
PICATO,eyelid edema,rates o bserved in the clinical trials,1
PICATO,eyelid edema,in the clinical trials of a drug cannot be directly,0
PICATO,eyelid ptosis,erved in,1
PICATO,eyelid ptosis,conditions adverse reaction rates erved in the  clinical,1
PICATO,eyelid ptosis,erved in,1
PICATO,eyelid ptosis,rates erved in the ,1
PICATO,eyelid ptosis,erved in,1
PICATO,eyelid ptosis,clinical trials of a drug cannot be directly compared to rates in the clinical,0
PICATO,eyelid ptosis,erved in the clinical,1
PICATO,eyelid ptosis,in the clinical,1
PICATO,eyelid ptosis,under widely varying conditions adverse reaction rates,0
PICATO,eyelid ptosis,reaction rates erved in the  clinical trials of,1
PICATO,eyelid ptosis,under widely varying conditions adverse reaction rates,0
PICATO,periorbital edema,inical trials of a drug cannot,1
PICATO,periorbital edema,the inical trials of  a drug cannot be directly,1
PICATO,periorbital edema,inical trials of a drug cannot,1
PICATO,periorbital edema,inical trials of a drug,1
PICATO,periorbital edema,rates in the clinical trials of another drug and,0
PICATO,periorbital edema,inical trials of ,1
PICATO,periorbital edema,rates in the clinical trials of another drug and,0
PICATO,periorbital edema,conditions adverse reaction rates observed in,0
PICATO,periorbital edema,inical trials of,1
PICATO,Hypersensitivity reactions,"for 3 consecutive days,",1
PICATO,Hypersensitivity reactions,"of once for 3 consecutive days, an",1
PICATO,Hypersensitivity reactions,"for 3 consecutive days, an d subjects",1
PICATO,Hypersensitivity reactions,for 3,1
PICATO,Hypersensitivity reactions,treatment skin area,0
PICATO,Hypersensitivity reactions,"for 3 consecutive days, an d subjects exposed",1
PICATO,Hypersensitivity reactions,"for 3 consecutive days, an d subjects exposed",1
PICATO,Hypersensitivity reactions,"for 3 consecutive days, an d subjects exposed",1
PICATO,Hypersensitivity reactions,field treatment skin,0
PICATO,Hypersensitivity reactions,"concentration of once for 3 consecutive days, an d subjects exposed",1
PICATO,Hypersensitivity reactions,field treatment skin,0
PICATO,Hypersensitivity reactions,once for,1
PICATO,anaphylaxis,scalp regions at a concentration of once daily for consecutive,0
PICATO,anaphylaxis,trunk or,0
PICATO,anaphylaxis,extremities regions at,0
PICATO,anaphylaxis,cm in the trunk or extremities,0
PICATO,allergic contact dermatitis,at a concentration of once,0
PICATO,allergic contact dermatitis,trunk,0
PICATO,allergic contact dermatitis,cato (r) gel field treatm ent skin,1
PICATO,skin reactions in the treated area,were within the selected treatment,1
PICATO,skin reactions in the treated area,of represented no,0
PICATO,skin reactions in the treated area,treatment area and graded by,1
PICATO,skin reactions in the treated area,erosionulceration,0
PICATO,skin reactions in the treated area,investigator,0
PICATO,skin reactions in the treated area,within,1
PICATO,skin reactions in the treated area,vesiculationpustulation and erosionulceration were within the selected,1
PICATO,skin reactions in the treated area,swelling vesiculationpustulation and erosionulceration were assessed,0
PICATO,skin reactions in the treated area,within the selected treatment area and graded by the investigator,1
PICATO,skin reactions in the treated area,swelling vesiculationpustulation and erosionulceration were assessed,0
PICATO,skin reactions in the treated area,within the selected treatment area and graded by the investigator,1
VIZAMYL,flushing,flushing headache increased blood,1
VIZAMYL,flushing,flushing headache,1
VIZAMYL,flushing,dizziness To repor,0
VIZAMYL,flushing,nausea,0
VIZAMYL,headache,headache increased blood pressure nausea,1
VIZAMYL,headache,headache increased,1
VIZAMYL,headache,headache increased blood pressure nausea,1
VIZAMYL,headache,reactions were headache,1
VIZAMYL,headache,headache increased blood pressure nausea,1
VIZAMYL,nausea,nausea and,1
VIZAMYL,nausea,nausea and dizziness To report,1
VIZAMYL,nausea,dizziness To report,0
VIZAMYL,nausea,blood nausea and dizziness To,1
VIZAMYL,nausea,dizziness To report,0
VIZAMYL,nausea,ADVERSE REACTIONS contact GE Healthcare at,0
VIZAMYL,dizziness,blood pressure nausea dizziness To report SUSPECTED ADVERSE REACTIONS,1
VIZAMYL,dizziness,ADVERSE REACTIONS contact GE Healthcare at,0
VIZAMYL,dizziness,blood pressure nausea dizziness To,1
VIZAMYL,dizziness,ADVERSE REACTIONS contact GE Healthcare at,0
VIZAMYL,dizziness,increased,0
VIZAMYL,dizziness,contact,0
VIZAMYL,dizziness,dizziness To,1
VIZAMYL,dizziness,pressure nausea dizziness To report,1
VIZAMYL,dizziness,dizziness To,1
VIZAMYL,dizziness,and,0
VIZAMYL,hypersensitivity reaction,experienced a hypersensitivity reaction with flushing dyspnea and chest,1
VIZAMYL,hypersensitivity reaction,and,0
VIZAMYL,hypersensitivity reaction,Vizamyl experienced a hypersensitivity reaction with flushing dyspnea,1
VIZAMYL,hypersensitivity reaction,and,0
VIZAMYL,hypersensitivity reaction,dyspnea and chest pressure within minutes following Vizamyl administration and,0
VIZAMYL,hypersensitivity reaction,ed a dose,0
VIZAMYL,flushing,experienced a serious hypersensitivity reaction,0
VIZAMYL,flushing,administered Vizamyl experienced a serious hypersensitivity reaction with,0
VIZAMYL,flushing,following Vizamyl administration and recovered with trea,0
VIZAMYL,dyspnea,dyspnea,1
VIZAMYL,dyspnea,dyspnea and,1
VIZAMYL,dyspnea,and recovered,0
VIZAMYL,dyspnea,reaction with,0
VIZAMYL,dyspnea,serious hypersensitivity reaction with dyspnea and chest pressure,1
VIZAMYL,dyspnea,reaction with,0
VIZAMYL,dyspnea,a,0
VIZAMYL,dyspnea,dyspnea and chest pressure within,1
VIZAMYL,dyspnea,with dyspnea and chest,1
VIZAMYL,dyspnea,dyspnea and chest pressure within,1
VIZAMYL,dyspnea,dyspnea and,1
VIZAMYL,chest pressure,administration and,0
VIZAMYL,chest pressure,chest pressure,1
VIZAMYL,chest pressure,with treatment,0
VIZAMYL,chest pressure,flushing dyspnea chest pressure within minutes following Vizamyl administration,1
VIZAMYL,chest pressure,with treatment,0
VIZAMYL,chest pressure,chest pressure,1
VIZAMYL,chest pressure,chest pressure within,1
VIZAMYL,chest pressure,with flushing,0
VIZAMYL,chest pressure,serious hypersensitivity reaction with flushing,0
VIZAMYL,chest pressure,chest pressure within,1
VIZAMYL,Hypersensitivity reactions,commonly,0
VIZAMYL,Hypersensitivity reactions,reported adverse reactions were flushing headache increased,1
VIZAMYL,Hypersensitivity reactions,ADVERSE REACTIONS EXCERPT Most reported,1
VIZAMYL,Radiation risk,Experience Clinical trials are conducted under,0
VIZAMYL,Radiation risk,conducted under widely ying,1
VIZAMYL,Radiation risk,trials are conducted under widely var,0
VIZAMYL,long-term cumulative radiation exposure,trials of Vizamyl not be directly compared to,1
VIZAMYL,long-term cumulative radiation exposure,conditions and adverse reaction rates observed in the clinical trials of Vizamyl can,0
VIZAMYL,long-term cumulative radiation exposure,the rates observed in clinical practice,0
VIZAMYL,long-term cumulative radiation exposure,not be directly,1
VIZAMYL,long-term cumulative radiation exposure,not be directly compared to rates in,1
VIZAMYL,Hypersensitivity reactions,and women Caucasian th a mean age of 62 years,1
VIZAMYL,flushing,Most subjects received a dose of MBq mCi One,0
VIZAMYL,flushing,of years -93 year,1
VIZAMYL,flushing,mCi,0
VIZAMYL,flushing,-93 year,1
VIZAMYL,flushing,of years -93,1
VIZAMYL,flushing,a mean age of years,0
POTIGA,Retinal abnormalities,Warnings and Precautions section of the,0
POTIGA,Retinal abnormalities,of the Retinal abnormalities and potential vision loss,1
POTIGA,Retinal abnormalities,Warnings and Precautions section of the,0
POTIGA,Retinal abnormalities,Retinal abnormalities,1
POTIGA,Retinal abnormalities,potential vision loss see Warnings and Precautions Urinary retention,0
POTIGA,Retinal abnormalities,Warnings,0
POTIGA,Retinal abnormalities,and Precautions section,0
POTIGA,Retinal abnormalities,more detail in,0
POTIGA,Retinal abnormalities,Retinal abnormalities,1
POTIGA,vision loss,and Precautions Urinary retention see Warnings and Precautions,0
POTIGA,vision loss,vision loss see Warnings and,1
POTIGA,vision loss,and vision loss see Warnings and Precautions Urinary,1
POTIGA,vision loss,vision loss see Warnings and,1
POTIGA,vision loss,and,0
POTIGA,vision loss,Warnings and Precautions section of the label Retinal abnormalities and,0
POTIGA,vision loss,of the label Retinal abnormalities and,0
POTIGA,vision loss,vision loss see,1
POTIGA,vision loss,and vision loss,1
POTIGA,vision loss,and Precautions section of the,0
POTIGA,Urinary retention,Urinary retention see Warnings,1
POTIGA,Urinary retention,see Warnings and Precautions,0
POTIGA,Urinary retention,Precautions Skin,0
POTIGA,Urinary retention,and Urinary,1
POTIGA,Urinary retention,Precautions,0
POTIGA,Urinary retention,see Warnings and Urinary,1
POTIGA,Urinary retention,see Warnings and Urinary retention,1
POTIGA,Urinary retention,and Precautions Skin discoloration see,0
POTIGA,Urinary retention,see Warnings and Urinary,1
POTIGA,Skin discoloration,Warnings and Skin discoloration,1
POTIGA,Skin discoloration,and Skin,1
POTIGA,Skin discoloration,Warnings and Precautions Neuropsychiatric,0
POTIGA,Skin discoloration,retention see Warnings and Skin,1
POTIGA,Skin discoloration,Warnings and Skin discoloration,1
POTIGA,Skin discoloration,retention see Warnings and Skin,1
POTIGA,Skin discoloration,Skin discoloration see Warnings and Precautions Neuropsychiatric,1
POTIGA,Skin discoloration,and Skin discoloration see Warnings,1
POTIGA,Skin discoloration,Skin discoloration see Warnings and Precautions Neuropsychiatric,1
POTIGA,Skin discoloration,and Precautions Neuropsychiatric symptoms see Warnings and Precaution,0
POTIGA,Skin discoloration,retention see Warnings and Skin discoloration see,1
POTIGA,Skin discoloration,and Precautions Neuropsychiatric symptoms see Warnings and Precaution,0
POTIGA,Neuropsychiatric symptoms,Warnings and Neuropsychiatric symptoms see,1
POTIGA,Neuropsychiatric symptoms,and Precautions Neuropsychiatric symptoms see Warnings and Precaution,0
POTIGA,Neuropsychiatric symptoms,Warnings and,0
POTIGA,Neuropsychiatric symptoms,Neuropsychiatric symptoms see Warnings and Precautions,1
POTIGA,Neuropsychiatric symptoms,Warnings and,0
POTIGA,Neuropsychiatric symptoms,discoloration see Warnings and Neuropsychiatric symptoms see Warnings and Precautions,1
POTIGA,Neuropsychiatric symptoms,Warnings and,0
POTIGA,Neuropsychiatric symptoms,see,0
POTIGA,Neuropsychiatric symptoms,and somnolence see Warnings and Precautions,0
POTIGA,Neuropsychiatric symptoms,see Warnings and Neuropsychiatric,1
POTIGA,Dizziness,Dizziness and,1
POTIGA,Dizziness,d Precautions,0
POTIGA,Dizziness,and Precautions,0
POTIGA,Dizziness,Warnings and Dizziness and,1
POTIGA,Dizziness,and Precautions,0
POTIGA,somnolence,somnolence see Warnings and Precautions QT,1
POTIGA,somnolence,see,0
POTIGA,QT interval effect,QT interval effect see Warnings and,1
POTIGA,QT interval effect,and QT interval effect see,1
POTIGA,QT interval effect,QT interval effect see Warnings and,1
POTIGA,QT interval effect,Warnings,0
POTIGA,QT interval effect,QT interval effect see Warnings and Precautions,1
POTIGA,QT interval effect,Warnings,0
POTIGA,QT interval effect,and Precautions,0
POTIGA,QT interval effect,somnolence see Warnings and QT interval effect,1
POTIGA,QT interval effect,and ideation see Warnings,0
POTIGA,QT interval effect,Warnings and,0
POTIGA,Suicidal behavior,effect see Warnings and Suicidal behavior,1
POTIGA,Suicidal behavior,Suicidal behavior and,1
POTIGA,Suicidal behavior,see Warnings and Suicidal behavior,1
POTIGA,Suicidal behavior,Suicidal behavior and,1
POTIGA,Suicidal behavior,see,0
POTIGA,Suicidal behavior,Withdrawal seizures see Warnings,0
POTIGA,Withdrawal seizures,Warnings and Withdrawal seizures see Warnings,1
POTIGA,Withdrawal seizures,Withdrawal seizures see Warnings,0
POTIGA,Withdrawal seizures,Warnings and Withdrawal seizures see Warnings and Precautions,1
POTIGA,Withdrawal seizures,Withdrawal seizures see Warnings,0
POTIGA,Withdrawal seizures,and Precautions,0
POTIGA,Withdrawal seizures,ideation see Warnings and Withdrawal seizures,1
POTIGA,Withdrawal seizures,and,0
POTIGA,Withdrawal seizures,Withdrawal seizures see Warnings,1
POTIGA,Withdrawal seizures,cautions Suicidal behavior and ideation see Warnings and Precautions,0
POTIGA,dizziness,common adverse reactions incidence and twice,0
POTIGA,somnolence,confusional state vertigo tremor abnormal coordination diplopia,0
POTIGA,somnolence,somnolence fatigue confusional,1
POTIGA,somnolence,were somnolence fatigue confusional,1
POTIGA,somnolence,somnolence fatigue confusional,1
POTIGA,somnolence,and twice placebo were somnolence fatigue confusional state,1
POTIGA,somnolence,somnolence fatigue confusional,1
POTIGA,somnolence,placebo were somnolence fatigue confusional state,1
POTIGA,somnolence,somnolence fatigue confusional,1
POTIGA,somnolence,tremor abnormal coordination diplopia disturbance in,0
POTIGA,somnolence,somnolence fatigue,1
POTIGA,fatigue,placebo were dizziness fatigue,1
POTIGA,fatigue,somnolence fatigue,1
POTIGA,confusional state,confusional,1
POTIGA,confusional state,were dizziness somnolence confusional state vertigo tremor abnormal coordination diplopia,1
POTIGA,confusional state,confusional,1
POTIGA,confusional state,were dizziness somnolence confusional state,1
POTIGA,confusional state,twice placebo were dizziness,0
POTIGA,confusional state,abnormal,0
POTIGA,confusional state,tremor abnormal coordination diplopia disturbance in attention memory impairment ast,0
POTIGA,confusional state,abnormal,0
POTIGA,confusional state,confusional state vertigo tremor abnormal coordination,1
POTIGA,confusional state,confusional state vertigo tremor abnormal coordination diplopia,1
POTIGA,confusional state,vertigo tremor,0
POTIGA,vertigo,vertigo tremor abnormal coordination,1
POTIGA,vertigo,vertigo tremor abnormal coordination diplopia disturbance,1
POTIGA,tremor,tremor,1
POTIGA,tremor,tremor abnormal coordination,1
POTIGA,tremor,tremor abnormal,1
POTIGA,tremor,tremor abnormal,1
POTIGA,tremor,in attention memory impairment,0
POTIGA,diplopia,diplopia disturbance in,1
POTIGA,diplopia,in attention memory impairment,0
POTIGA,diplopia,diplopia disturbance in attention memory,1
POTIGA,diplopia,diplopia,1
POTIGA,diplopia,diplopia,1
POTIGA,diplopia,diplopia,1
POTIGA,diplopia,diplopia disturbance,1
POTIGA,disturbance in attention,coordination diplopia,0
POTIGA,memory impairment,memory impairment asthenia blurred,1
POTIGA,memory impairment,diplopia disturbance in memory impairment asthenia blurred vision,1
POTIGA,memory impairment,memory impairment asthenia blurred,1
POTIGA,asthenia,asthenia blurred vision gait disturbance aphasia,1
POTIGA,asthenia,asthenia blurred vision gait disturbance,1
POTIGA,asthenia,asthenia blurred,1
POTIGA,asthenia,asthenia blurred vision,1
POTIGA,asthenia,asthenia blurred vision,1
POTIGA,blurred vision,gait disturbance aphasia dysarthria,0
POTIGA,gait disturbance,report SUSPECTED ADVERSE,0
POTIGA,gait disturbance,report,0
POTIGA,gait disturbance,gait disturbance aphasia dysarthria and,1
POTIGA,gait disturbance,impairment asthenia blurred gait,1
POTIGA,aphasia,balance disorder To report SUSPECTED ADVERSE,0
POTIGA,aphasia,aphasia dysarthria and balance disorder,1
POTIGA,aphasia,SUSPECTED ADVERSE REACTIONS contact G,0
POTIGA,aphasia,disorder To report SUSPECTED ADVERSE REACTIONS,0
POTIGA,aphasia,aphasia,1
POTIGA,aphasia,aphasia dysarthria and balance disorder To,1
POTIGA,aphasia,REACTIONS contact G,0
POTIGA,aphasia,disorder To report SUSPECTED ADVERSE REACTIONS,0
POTIGA,dysarthria,dysarthria and balance disorder,1
POTIGA,balance disorder,disturbance aphasia dysarthria balance disorder,1
POTIGA,balance disorder,balance disorder To,1
POTIGA,balance disorder,disturbance aphasia dysarthria balance disorder,1
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,dizziness confusional state fatigue and somnolence,1
POTIGA,dizziness,The most,0
POTIGA,dizziness,confusional state fatigue and somnolence Common Adverse Reactions,0
POTIGA,dizziness,reactions leading to withdrawal,0
POTIGA,confusional state,Adverse Reactions in,0
POTIGA,confusional state,patients receiving POTIGA were confusional state fatigue and,1
POTIGA,confusional state,Adverse Reactions in,0
POTIGA,confusional state,to withdrawal in patients receiving POTIGA were,0
POTIGA,confusional state,patients receiving POTIGA were confusional,1
POTIGA,confusional state,confusional state,1
POTIGA,fatigue,Adverse,0
POTIGA,fatigue,fatigue and somnolence Common Adverse,1
POTIGA,fatigue,confusional state,0
POTIGA,somnolence,somnolence Common Adverse Reactions in All,1
POTIGA,dizziness,dizziness somnolence fatigue confusional state vertigo,1
POTIGA,dizziness,rate,0
POTIGA,dizziness,dizziness somnolence,1
POTIGA,dizziness,placebo rate dizziness somnolence,1
POTIGA,dizziness,dizziness somnolence,1
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,dizziness somnolence fatigue confusional state vertigo,1
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,dizziness,1
POTIGA,dizziness,occurring approximately twice,0
POTIGA,vertigo,placebo rate were,0
POTIGA,vertigo,vertigo tremor abnormal coordination diplopia,1
POTIGA,vertigo,in attention memory,0
POTIGA,vertigo,vertigo tremor abnormal coordination diplopia disturbance,1
POTIGA,vertigo,dizziness somnolence fatigue confusional vertigo,1
POTIGA,vertigo,vertigo tremor abnormal coordination diplopia disturbance,1
POTIGA,vertigo,state,0
POTIGA,vertigo,dizziness somnolence,0
POTIGA,vertigo,placebo rate were,0
POTIGA,tremor,tremor,1
POTIGA,tremor,diplopia disturbance,0
POTIGA,tremor,in attention memory impairment,0
POTIGA,tremor,state tremor,1
POTIGA,tremor,in attention memory impairment,0
POTIGA,tremor,in attention memory,0
POTIGA,tremor,tremor,1
POTIGA,tremor,tremor,1
POTIGA,tremor,state vertigo,0
POTIGA,tremor,tremor abnormal coordination diplopia,1
POTIGA,abnormal coordination,tremor,0
POTIGA,abnormal coordination,abnormal coordination diplopia disturbance in,1
POTIGA,abnormal coordination,diplopia disturbance in attention,0
POTIGA,abnormal coordination,vertigo,0
POTIGA,abnormal coordination,in attention,0
POTIGA,abnormal coordination,state vertigo abnormal coordination diplopia,1
POTIGA,abnormal coordination,in attention,0
POTIGA,diplopia,diplopia disturbance in attention memory impairment,1
POTIGA,disturbance in attention,blurred vision,0
POTIGA,disturbance in attention,impairment,0
POTIGA,disturbance in attention,in attention memory impairment asthenia,1
POTIGA,disturbance in attention,tremor abnormal coordination disturbance,1
POTIGA,disturbance in attention,vertigo tremor abnormal coordination disturbance,1
POTIGA,disturbance in attention,vertigo tremor abnormal coordination disturbance in attention,1
POTIGA,memory impairment,coordination diplopia disturbance in,0
POTIGA,memory impairment,memory impairment asthenia,1
POTIGA,memory impairment,coordination diplopia disturbance in,0
POTIGA,asthenia,asthenia,1
POTIGA,asthenia,memory asthenia blurred vision gait disturbance aphasia,1
POTIGA,asthenia,asthenia,1
POTIGA,asthenia,in attention memory asthenia blurred vision gait,1
POTIGA,asthenia,asthenia,1
POTIGA,asthenia,asthenia blurred,1
POTIGA,asthenia,and balance,0
POTIGA,asthenia,asthenia blurred,1
POTIGA,asthenia,aphasia dysarthria and,0
POTIGA,asthenia,asthenia blurred vision gait,1
POTIGA,asthenia,aphasia dysarthria and,0
POTIGA,blurred vision,attention memory impairment blurred vision gait disturbance aphasia dysarthria,1
POTIGA,blurred vision,aphasia dysarthria and,0
POTIGA,blurred vision,in attention memory impairment asthenia,0
POTIGA,blurred vision,blurred vision,1
POTIGA,blurred vision,impairment,0
POTIGA,gait disturbance,ia disturbance in attention memory,0
POTIGA,gait disturbance,memory impairment asthenia blurred gait disturbance,1
POTIGA,gait disturbance,gait disturbance,1
POTIGA,gait disturbance,memory impairment asthenia blurred gait disturbance,1
POTIGA,gait disturbance,impairment asthenia blurred gait disturbance aphasia dysarthria and,1
POTIGA,gait disturbance,memory impairment asthenia blurred gait disturbance,1
POTIGA,gait disturbance,gait disturbance,1
POTIGA,gait disturbance,blurred gait,1
POTIGA,gait disturbance,impairment asthenia blurred gait disturbance aphasia dysarthria and balance,1
POTIGA,gait disturbance,blurred gait,1
POTIGA,gait disturbance,Table,0
POTIGA,gait disturbance,attention memory impairment asthenia,0
POTIGA,gait disturbance,gait disturbance aphasia dysarthria,1
POTIGA,aphasia,aphasia,1
POTIGA,aphasia,cases the reactions were of,0
POTIGA,aphasia,aphasia dysarthria,1
POTIGA,aphasia,aphasia dysarthria,1
POTIGA,aphasia,gait aphasia dysarthria and,1
POTIGA,aphasia,aphasia dysarthria,1
POTIGA,aphasia,aphasia dysarthria and balance disorder,1
POTIGA,aphasia,reactions were,0
POTIGA,aphasia,aphasia dysarthria,1
POTIGA,dysarthria,the reactions were,0
POTIGA,dysarthria,dysarthria and balance,1
POTIGA,dysarthria,dysarthria and balance,1
POTIGA,dysarthria,dysarthria and,1
POTIGA,dysarthria,dysarthria and,1
POTIGA,dysarthria,memory impairment asthenia blurred vision,0
POTIGA,dysarthria,disturbance dysarthria and,1
POTIGA,dysarthria,memory impairment asthenia blurred vision,0
POTIGA,dysarthria,of mild,0
POTIGA,dysarthria,disturbance dysarthria and balance disorder,1
POTIGA,dysarthria,of mild,0
POTIGA,dysarthria,gait disturbance aphasia,0
POTIGA,increased appetite,and,0
POTIGA,increased appetite,placebo increased,1
POTIGA,increased appetite,dysphagia hyperhydrosis,0
POTIGA,increased appetite,increased appetite hallucinations myoclonus peripheral edema,1
POTIGA,increased appetite,POTIGA and numerically greater than placebo,0
POTIGA,hallucinations,hallucinations myoclonus peripheral edema,1
POTIGA,hallucinations,n of patients treated,0
POTIGA,hallucinations,placebo were increased appetite,0
POTIGA,hallucinations,hypokinesia dry,0
POTIGA,hallucinations,n of patients treated with POTIGA,0
POTIGA,hallucinations,hallucinations myoclonus peripheral,1
POTIGA,hallucinations,were increased hallucinations myoclonus peripheral edema hypokinesia dry,1
POTIGA,hallucinations,hallucinations myoclonus peripheral,1
POTIGA,myoclonus,myoclonus peripheral edema,1
POTIGA,myoclonus,were increased appetite hallucinations,0
POTIGA,myoclonus,mouth dysphagia hyperhydrosis urinary retention malaise an,0
POTIGA,myoclonus,myoclonus peripheral edema hypokinesia dry mouth,1
POTIGA,myoclonus,mouth dysphagia hyperhydrosis urinary retention malaise an,0
POTIGA,myoclonus,treated with,0
POTIGA,myoclonus,myoclonus peripheral edema hypokinesia dry,1
POTIGA,peripheral edema,appetite hallucinations peripheral edema hypokinesia dry,1
POTIGA,peripheral edema,myoclonus peripheral edema hypokinesia dry,1
POTIGA,peripheral edema,hallucinations peripheral edema,1
POTIGA,peripheral edema,appetite hallucinations peripheral edema,1
POTIGA,hypokinesia,dysphagia hyperhydrosis urinary,0
POTIGA,hypokinesia,peripheral hypokinesia dry mouth,1
POTIGA,hypokinesia,dysphagia hyperhydrosis urinary,0
POTIGA,hypokinesia,myoclonus peripheral,0
POTIGA,hypokinesia,myoclonus peripheral hypokinesia dry mouth dysphagia,1
POTIGA,hypokinesia,myoclonus peripheral,0
POTIGA,hypokinesia,hypokinesia dry,1
POTIGA,dry mouth,appetite hallucinations myoclonus peripheral edema hypokinesia,0
POTIGA,dry mouth,dry mouth dysphagia hyperhydrosis urinary retention malaise,1
POTIGA,dry mouth,appetite hallucinations myoclonus peripheral edema hypokinesia,0
POTIGA,dry mouth,myoclonus peripheral edema hypokinesia,0
POTIGA,dry mouth,retention malaise and,0
POTIGA,dry mouth,peripheral edema,0
POTIGA,dysphagia,dysphagia hyperhydrosis,1
POTIGA,dysphagia,Most of the adverse,0
POTIGA,dysphagia,appetite hallucinations myoclonus peripheral,0
POTIGA,hyperhydrosis,hallucinations myoclonus peripheral,0
POTIGA,hyperhydrosis,hyperhydrosis urinary retention malaise,1
POTIGA,hyperhydrosis,hyperhydrosis urinary,1
POTIGA,hyperhydrosis,retention malaise and increased liver enzymes Most of the adverse reactions,0
POTIGA,hyperhydrosis,peripheral edema hypokinesia,0
POTIGA,hyperhydrosis,hyperhydrosis urinary retention malaise and increased,1
POTIGA,hyperhydrosis,mouth hyperhydrosis urinary retention malaise and increased,1
POTIGA,hyperhydrosis,hyperhydrosis urinary retention malaise and increased,1
POTIGA,hyperhydrosis,hyperhydrosis urinary,1
POTIGA,hyperhydrosis,hyperhydrosis urinary retention malaise and increased,1
POTIGA,urinary retention,urinary retention malaise and increased liver enzymes,1
POTIGA,urinary retention,hyperhydrosis urinary retention malaise and increased,1
POTIGA,malaise,hyperhydrosis urinary malaise,1
POTIGA,malaise,hyperhydrosis urinary retention malaise and increased,1
POTIGA,malaise,malaise and increased liver enzymes Most,1
POTIGA,malaise,hyperhydrosis urinary retention malaise and increased,1
POTIGA,malaise,malaise,1
POTIGA,malaise,enzymes Most of the adverse reactions appear to be,0
POTIGA,malaise,malaise and increased liver,1
POTIGA,malaise,dysphagia hyperhydrosis urinary retention,0
POTIGA,malaise,mouth dysphagia,0
POTIGA,malaise,retention,0
POTIGA,malaise,malaise and increased,1
POTIGA,malaise,Most of the adverse reactions appear to,0
POTIGA,increased liver enzymes,those classified as psychi,0
POTIGA,increased liver enzymes,malaise increased,1
POTIGA,increased liver enzymes,and,0
POTIGA,increased liver enzymes,hypokinesia dry mouth dysphagia hyperhydrosis urinary retention malaise and,0
POTIGA,increased liver enzymes,the adverse reactions appear to be dose related,0
POTIGA,increased liver enzymes,reactions appear to be dose related especially,0
POTIGA,increased liver enzymes,liver enzymes Most of,1
POTIGA,dizziness,blurred,0
POTIGA,dizziness,and nervous system symptoms dizziness somnolence confusional state,1
POTIGA,dizziness,blurred,0
POTIGA,dizziness,memory impairment blurred,0
POTIGA,dizziness,dizziness somnolence confusional,1
POTIGA,dizziness,and nervous system symptoms dizziness somnolence confusional state tremor,1
POTIGA,dizziness,dizziness somnolence confusional,1
POTIGA,dizziness,dizziness somnolence,1
POTIGA,dizziness,symptoms dizziness somnolence confusional state,1
POTIGA,dizziness,dizziness somnolence,1
POTIGA,dizziness,dizziness somnolence confusional state,1
POTIGA,dizziness,dizziness somnolence confusional state,1
POTIGA,dizziness,tremor abnormal coordination memory,0
POTIGA,somnolence,nervous system symptoms including somnolence confusional state tremor abnormal coordination,1
POTIGA,somnolence,tremor abnormal coordination memory,0
POTIGA,somnolence,as psychiatric,0
POTIGA,somnolence,symptoms including dizziness,0
POTIGA,somnolence,somnolence,1
POTIGA,somnolence,symptoms including dizziness,0
POTIGA,somnolence,coordination memory impairment,0
POTIGA,somnolence,system symptoms including dizziness,0
POTIGA,somnolence,nervous system symptoms including somnolence confusional state tremor abnormal,1
POTIGA,somnolence,system symptoms including dizziness,0
POTIGA,somnolence,somnolence confusional state,1
POTIGA,somnolence,somnolence confusional state tremor abnormal coordination,1
POTIGA,somnolence,coordination memory,0
POTIGA,confusional state,symptoms including dizziness confusional state tremor,1
POTIGA,confusional state,coordination memory,0
POTIGA,confusional state,dizziness confusional state,1
POTIGA,confusional state,psychiatric and nervous system,0
POTIGA,confusional state,symptoms including dizziness confusional state,1
POTIGA,tremor,tremor abnormal coordination memory impairment blurred,1
POTIGA,tremor,somnolence confusional tremor abnormal coordination memory impairment,1
POTIGA,tremor,tremor abnormal coordination memory impairment blurred,1
POTIGA,tremor,tremor,1
POTIGA,tremor,tremor abnormal,1
POTIGA,tremor,abnormal coordination memory impairment blurred,0
POTIGA,tremor,tremor abnormal coordination memory impairment,1
POTIGA,abnormal coordination,somnolence confusional state,0
POTIGA,abnormal coordination,balance disorder constipation dysu,0
POTIGA,abnormal coordination,balance,0
POTIGA,abnormal coordination,state abnormal coordination memory impairment blurred vision,1
POTIGA,abnormal coordination,balance,0
POTIGA,abnormal coordination,confusional,0
POTIGA,abnormal coordination,abnormal coordination memory,1
POTIGA,abnormal coordination,confusional,0
POTIGA,abnormal coordination,including dizziness,0
POTIGA,abnormal coordination,state tremor,0
POTIGA,abnormal coordination,aphasia balance disorder constipation,0
POTIGA,memory impairment,memory,1
POTIGA,memory impairment,memory impairment blurred vision,1
POTIGA,memory impairment,memory,1
POTIGA,memory impairment,tremor,0
POTIGA,memory impairment,aphasia balance,0
POTIGA,blurred vision,blurred vision gait disturbance aphasia balance disorder,1
POTIGA,blurred vision,blurred vision,1
POTIGA,blurred vision,abnormal coordination memory blurred vision gait disturbance aphasia,1
POTIGA,blurred vision,blurred vision,1
POTIGA,blurred vision,blurred vision gait disturbance,1
POTIGA,blurred vision,abnormal coordination memory blurred vision gait disturbance aphasia balance disorder,1
POTIGA,blurred vision,blurred vision gait disturbance,1
POTIGA,blurred vision,somnolence confusional state tremor abnormal coordination memory,0
POTIGA,blurred vision,abnormal coordination memory blurred vision,1
POTIGA,blurred vision,abnormal coordination memory blurred,1
POTIGA,blurred vision,coordination memory blurred vision,1
POTIGA,gait disturbance,coordination memory impairment blurred gait,1
POTIGA,gait disturbance,vision,0
POTIGA,gait disturbance,state tremor abnormal coordination memory impairment,0
POTIGA,gait disturbance,gait disturbance aphasia,1
POTIGA,gait disturbance,gait disturbance aphasia balance disorder,1
POTIGA,gait disturbance,memory impairment blurred gait disturbance aphasia balance disorder,1
POTIGA,gait disturbance,gait disturbance aphasia balance disorder,1
POTIGA,gait disturbance,was,0
POTIGA,gait disturbance,was,0
POTIGA,gait disturbance,gait,1
POTIGA,aphasia,memory impairment blurred,0
POTIGA,aphasia,aphasia balance disorder,1
POTIGA,balance disorder,balance disorder constipation dysuria and chromaturia,1
POTIGA,balance disorder,aphasia balance disorder,1
POTIGA,balance disorder,disturbance balance,1
POTIGA,balance disorder,with doserelated weight,0
POTIGA,balance disorder,disturbance balance disorder,1
POTIGA,balance disorder,associated,0
POTIGA,balance disorder,disturbance balance disorder constipation dysuria and chromaturia,1
POTIGA,balance disorder,associated,0
POTIGA,balance disorder,balance disorder,1
POTIGA,constipation,with mean weigh,0
POTIGA,constipation,constipation dysuria and chromaturia,1
POTIGA,constipation,constipation dysuria and chromaturia POTIGA,1
POTIGA,constipation,constipation dysuria,1
POTIGA,constipation,constipation dysuria and chromaturia POTIGA,1
POTIGA,constipation,ormal coordination memory impairment blurred vision gait disturbance aphasia balance disorder,0
POTIGA,constipation,gain with,0
POTIGA,constipation,constipation dysuria and,1
POTIGA,constipation,gait,0
POTIGA,constipation,constipation dysuria and chromaturia,1
POTIGA,chromaturia,chromaturia POTIGA,1
POTIGA,chromaturia,and,0
POTIGA,chromaturia,associated with doserelated weight gain with mean weight,0
POTIGA,chromaturia,chromaturia POTIGA was associated with doserelated,1
POTIGA,chromaturia,associated with doserelated weight gain with mean weight,0
POTIGA,chromaturia,mean weight increasing by kg,0
POTIGA,chromaturia,chromaturia POTIGA was associated,1
POTIGA,chromaturia,chromaturia,1
POTIGA,chromaturia,with doserelated weight gain with mean weight increasing,0
POTIGA,chromaturia,disturbance aphasia balance disorder constipation dysuria,0
POTIGA,weight gain,POTIGA was associated with weight gain,1
POTIGA,weight gain,disturbance aphasia balance disorder constipation dysuria,0
POTIGA,weight gain,weight gain with mean weight increasing,1
POTIGA,weight gain,associated with doserelated,0
POTIGA,weight gain,weight gain with,1
POTIGA,weight gain,was associated with weight,1
POTIGA,weight increasing,per day,0
POTIGA,rash,syncope,0
POTIGA,nystagmus,during all clinical trials nystagmus dyspnea leukopenia muscle spasms alopecia,1
POTIGA,nystagmus,syncope,0
POTIGA,nystagmus,nystagmus dyspnea leukopenia muscle,1
POTIGA,nystagmus,rash,0
POTIGA,nystagmus,dyspnea leukopenia muscle spasms alopecia,0
POTIGA,nystagmus,nystagmus dyspnea leukopenia,1
POTIGA,nystagmus,nystagmus dyspnea leukopenia,1
POTIGA,nystagmus,nystagmus dyspnea,1
POTIGA,nystagmus,muscle,0
POTIGA,dyspnea,neutropenia,0
POTIGA,dyspnea,alopecia nephrolithiasis syncope,0
POTIGA,dyspnea,dyspnea leukopenia muscle spasms,1
POTIGA,dyspnea,dyspnea leukopenia muscle spasms alopecia,1
POTIGA,leukopenia,leukopenia muscle spasms,1
POTIGA,leukopenia,leukopenia muscle spasms alopecia nephrolithiasis syncope,1
POTIGA,leukopenia,trials rash nystagmus leukopenia muscle spasms alopecia nephrolithiasis,1
POTIGA,leukopenia,leukopenia muscle spasms alopecia nephrolithiasis syncope,1
POTIGA,leukopenia,leukopenia muscle spasms alopecia nephrolithiasis syncope,1
POTIGA,leukopenia,euphoric mood,0
POTIGA,leukopenia,leukopenia muscle,1
POTIGA,leukopenia,trials rash nystagmus leukopenia muscle spasms alopecia nephrolithiasis,1
POTIGA,leukopenia,leukopenia muscle,1
POTIGA,muscle spasms,dyspnea muscle spasms,1
POTIGA,muscle spasms,trials rash nystagmus dyspnea muscle spasms alopecia nephrolithiasis syncope neutropenia,1
POTIGA,muscle spasms,dyspnea muscle spasms,1
POTIGA,alopecia,alopecia nephrolithiasis syncope,1
POTIGA,alopecia,leukopenia muscle alopecia,1
POTIGA,alopecia,alopecia nephrolithiasis syncope,1
POTIGA,alopecia,alopecia nephrolithiasis syncope,1
POTIGA,alopecia,alopecia nephrolithiasis,1
POTIGA,alopecia,alopecia nephrolithiasis syncope,1
POTIGA,alopecia,alopecia nephrolithiasis syncope neutropenia thrombocytopenia euphoric,1
POTIGA,alopecia,alopecia nephrolithiasis syncope neutropenia thrombocytopenia euphoric,1
POTIGA,nephrolithiasis,nephrolithiasis syncope neutropenia,1
POTIGA,nephrolithiasis,syncope neutropenia,0
POTIGA,nephrolithiasis,clinical,0
POTIGA,nephrolithiasis,spasms nephrolithiasis,1
POTIGA,nephrolithiasis,clinical,0
POTIGA,nephrolithiasis,syncope neutropenia thrombocytopenia,0
POTIGA,nephrolithiasis,nephrolithiasis syncope,1
POTIGA,nephrolithiasis,nephrolithiasis syncope neutropenia thrombocytopenia,1
POTIGA,nephrolithiasis,dyspnea leukopenia muscle spasms nephrolithiasis syncope neutropenia thrombocytopenia euphoric mood,1
POTIGA,nephrolithiasis,nephrolithiasis syncope neutropenia thrombocytopenia,1
POTIGA,nephrolithiasis,thrombocytopenia euphoric mood renal colic,0
POTIGA,nephrolithiasis,nephrolithiasis syncope,1
POTIGA,syncope,syncope neutropenia thrombocytopenia euphoric mood renal,1
POTIGA,syncope,syncope neutropenia thrombocytopenia euphoric mood,1
POTIGA,syncope,syncope neutropenia thrombocytopenia euphoric mood renal,1
POTIGA,neutropenia,neutropenia thrombocytopenia,1
POTIGA,neutropenia,neutropenia thrombocytopenia euphoric mood renal,1
POTIGA,neutropenia,neutropenia thrombocytopenia euphoric mood renal colic,1
POTIGA,neutropenia,neutropenia thrombocytopenia euphoric,1
POTIGA,neutropenia,neutropenia thrombocytopenia euphoric mood,1
POTIGA,neutropenia,neutropenia,1
POTIGA,neutropenia,rash nystagmus dyspnea leukopenia muscle spasms alopecia,0
POTIGA,neutropenia,neutropenia,1
POTIGA,thrombocytopenia,dyspnea leukopenia muscle spasms,0
POTIGA,thrombocytopenia,thrombocytopenia euphoric mood renal colic coma,1
POTIGA,thrombocytopenia,thrombocytopenia euphoric mood renal,1
POTIGA,thrombocytopenia,thrombocytopenia,1
POTIGA,thrombocytopenia,syncope neutropenia,0
POTIGA,thrombocytopenia,thrombocytopenia euphoric mood renal,1
POTIGA,thrombocytopenia,thrombocytopenia euphoric mood renal colic,1
POTIGA,thrombocytopenia,thrombocytopenia euphoric mood renal colic coma,1
POTIGA,euphoric mood,spasms alopecia nephrolithiasis syncope,0
POTIGA,euphoric mood,syncope neutropenia euphoric mood renal colic,1
POTIGA,euphoric mood,spasms alopecia nephrolithiasis syncope,0
POTIGA,euphoric mood,neutropenia thrombocytopenia,0
POTIGA,euphoric mood,leukopenia muscle spasms alopecia nephrolithiasis syncope,0
POTIGA,euphoric mood,euphoric mood renal colic coma encephalopathy,1
POTIGA,euphoric mood,The,0
POTIGA,renal colic,syncope neutropenia thrombocytopenia euphoric renal,1
POTIGA,renal colic,a muscle spasms alopecia nephrolithiasis syncope neutropenia thrombocytopenia euphoric mood,0
POTIGA,renal colic,thrombocytopenia euphoric renal,1
POTIGA,renal colic,overall adverse reaction,0
POTIGA,renal colic,renal colic coma encephalopathy Comparison of,1
POTIGA,renal colic,euphoric renal colic,1
POTIGA,renal colic,mood,0
POTIGA,renal colic,neutropenia thrombocytopenia euphoric renal colic coma encephalopathy Comparison,1
POTIGA,renal colic,mood,0
POTIGA,encephalopathy,encephalopathy Comparison,1
POTIGA,encephalopathy,encephalopathy Comparison of Gender Age and,1
POTIGA,encephalopathy,encephalopathy Comparison,1
POTIGA,encephalopathy,Comparison of,0
POTIGA,encephalopathy,colic encephalopathy,1
POTIGA,encephalopathy,Comparison of,0
POTIGA,encephalopathy,encephalopathy Comparison of Gender Age,1
POTIGA,encephalopathy,thrombocytopenia euphoric mood,0
POTIGA,encephalopathy,and Race The overall,0
POTIGA,encephalopathy,euphoric mood renal colic encephalopathy,1
POTIGA,encephalopathy,and Race The overall,0
POTIGA,encephalopathy,overall adverse reaction profile of POTIGA was,0
POTIGA,RETINAL ABNORMALITIES,REACTIONS,0
POTIGA,RETINAL ABNORMALITIES,REACTIONS The,0
POTIGA,RETINAL ABNORMALITIES,are described in more detail in the Warnings and Precautions section,0
POTIGA,RETINAL ABNORMALITIES,The,0
POTIGA,RETINAL ABNORMALITIES, following adverse re actions are described,1
POTIGA,RETINAL ABNORMALITIES,The,0
POTIGA,RETINAL ABNORMALITIES,ADVERSE REACTIONS  following adverse re actions are described in more,1
POTIGA,RETINAL ABNORMALITIES,The,0
POTIGA,RETINAL ABNORMALITIES,described in more detail,0
POTIGA,RETINAL ABNORMALITIES,REACTIONS following adverse re,1
POTIGA,VISION LOSS,reactions are cribed in m,1
POTIGA,RETINAL ABNORMALITIES,the Warnings and,1
POTIGA,RETINAL ABNORMALITIES, the  Warnings and Pr ecautions section of the,1
POTIGA,RETINAL ABNORMALITIES,the Warnings and,1
POTIGA,RETINAL ABNORMALITIES,and Pr ecautions section,1
POTIGA,RETINAL ABNORMALITIES,more detail,0
POTIGA,RETINAL ABNORMALITIES,ecautions section of the label Retinal abnormalities,0
POTIGA,RETINAL ABNORMALITIES,are described in more detail,0
POTIGA,RETINAL ABNORMALITIES, the  Warnings and Pr ecautions,1
POTIGA,RETINAL ABNORMALITIES,are described in more detail,0
POTIGA,RETINAL ABNORMALITIES,Warnings and Pr ecautions,1
POTIGA,RETINAL ABNORMALITIES,the Warnings and Pr ecautions section of,1
POTIGA,VISION LOSS,Warnings and Precautions ion,1
POTIGA,retinal abnormalities,loss see Warnings and Precautions Urinary retention see,0
POTIGA,retinal abnormalities,label Retinal,0
POTIGA,retinal abnormalities,abnormalities and po tential vision loss,1
POTIGA,retinal abnormalities,abnormalities and po,1
POTIGA,retinal abnormalities,abnormalities and po tential,1
POTIGA,retinal abnormalities,section of the label  abnormalities and po tential vision,1
POTIGA,retinal abnormalities,abnormalities and po tential,1
POTIGA,retinal abnormalities,and po tential,1
POTIGA,retinal abnormalities,of,0
POTIGA,retinal abnormalities,section of the label  abnormalities and po,1
POTIGA,retinal abnormalities,of,0
POTIGA,retinal abnormalities,Retinal,0
POTIGA,damage to the photoreceptors,* Skin disco loration see,1
POTIGA,vision loss,Warnings and,0
POTIGA,vision loss,Warnings and Precautions Skin ion [see,1
POTIGA,vision loss,Skin ion,1
POTIGA,vision loss,ion [see Wa rnings and Precautions,1
POTIGA,retinal abnormalities,see Warnings an,0
POTIGA,retinal abnormalities,* Neuropsychia,1
POTIGA,abnormal visual acuity,Neuropsychiatric symptoms see Warnin,0
POTIGA,abnormal visual acuity,and Precautions (5. Dizziness and somnolence see,1
POTIGA,abnormal visual acuity,symptoms see gs and Precautions (5.,1
POTIGA,abnormal visual acuity,Dizziness and somnolence see Warnings,0
POTIGA,abnormal visual acuity,see Warnings and Precautions QT interval effect,0
POTIGA,abnormal visual acuity,gs and Precautions (5. Dizziness and somnolence see,1
POTIGA,abnormal visual acuity,see Warnings and Precautions QT interval effect,0
POTIGA,abnormal visual acuity,QT interval effect,0
POTIGA,abnormal visual acuity,gs and Precautions (5. Dizziness and somnolence see,1
POTIGA,decreased visual acuity,somnolence see,0
POTIGA,retinal pigmentary abnormalities,adverse react,1
POTIGA,retinal pigmentary abnormalities,adverse react ions incidence,1
POTIGA,retinal pigmentary abnormalities,see Warnings and Precautions RPT:   Most common adverse react ions incidence,1
POTIGA,retinal pigmentary abnormalities,adverse react ions incidence,1
POTIGA,retinal pigmentary abnormalities,RPT:   Most common adverse react ions incidence,1
POTIGA,retinal pigmentary abnormalities,adverse react ions incidence,1
POTIGA,retinal abnormalities,"ce, fatigue, confusio",1
POTIGA,retinal abnormalities,"ce, fatigue, confusio nal",1
POTIGA,retinal abnormalities,abnormal,0
POTIGA,retinal abnormalities,"placebo were dizziness ce, fatigue, confusio nal state",1
POTIGA,retinal abnormalities,abnormal,0
POTIGA,retinal abnormalities,coordination diplopia disturbance in attention,0
POTIGA,retinal abnormalities,incidence and twice,0
POTIGA,retinal abnormalities,"were dizziness ce, fatigue, confusio",1
POTIGA,retinal abnormalities,tremor abnormal coordination diplopia disturbance in attention memory,0
POTIGA,retinal abnormalities,"were dizziness ce, fatigue, confusio nal state vertigo tremor",1
POTIGA,retinal abnormalities,tremor abnormal coordination diplopia disturbance in attention memory,0
POTIGA,retinal abnormalities,"in  memory impairment, a sthenia blurred vision gait disturbance",1
POTIGA,retinal abnormalities,tremor abnormal coordination diplopia disturbance in attention memory,0
POTIGA,retinal abnormalities,igue confusional state vertigo tremor abnormal coordination diplopia disturbance in,0
POTIGA,retinal abnormalities,disturbance,0
POTIGA,retinal abnormalities,tremor abnormal coordination diplopia disturbance in attention,0
POTIGA,retinal abnormalities,"disturbance in  memory impairment, a sthenia blurred vision",1
POTIGA,retinal abnormalities,tremor abnormal coordination diplopia disturbance in attention,0
POTIGA,retinal abnormalities,"memory impairment, a sthenia",1
POTIGA,RETINAL ABNORMALITIES,"Discontinuation in All Controlled  Studies  



 In the randomized",1
POTIGA,RETINAL ABNORMALITIES,"memory impairment, a sthenia",1
POTIGA,RETINAL ABNORMALITIES,in All Controlled,0
POTIGA,RETINAL ABNORMALITIES,for at least years Adverse Reactions Leading to Discontinuation,0
POTIGA,RETINAL ABNORMALITIES,doubleblind placebocontrolled studies of patients receiving,0
POTIGA,RETINAL ABNORMALITIES,Studies In the,1
POTIGA,RETINAL ABNORMALITIES,Studies In the randomized doubleblind placebocontrolled,1
POTIGA,VISION LOSS,All Controlled Clinical Studies In,0
POTIGA,VISION LOSS,and,0
POTIGA,VISION LOSS,double-blin d placebocontrolled studies of,1
POTIGA,VISION LOSS,double-blin d,1
POTIGA,VISION LOSS,In the double-blin d placebocontrolled studies of,1
POTIGA,VISION LOSS,double-blin d,1
POTIGA,VISION LOSS,Clinical Studies In the double-blin d placebocontrolled studies of patients,1
POTIGA,VISION LOSS,double-blin d,1
POTIGA,retinal abnormalities,and,0
POTIGA,retinal abnormalities,receiving POTIGA and of ts (11%) receiving,1
POTIGA,retinal abnormalities,ts (11%) receiving pl acebo,1
POTIGA,retinal abnormalities,(11%) receiving pl acebo,1
POTIGA,retinal abnormalities,reactions The most common adverse,0
POTIGA,retinal abnormalities,reactions The most,0
POTIGA,retinal abnormalities,(11%) receiving pl acebo discontinued,1
POTIGA,retinal abnormalities,acebo discontinued treatment because of adverse reactions,0
POTIGA,retinal abnormalities,and of,0
POTIGA,damage to the photoreceptors,reactions The most common,0
POTIGA,damage to the photoreceptors,reactions leading to awal in patients receiving P OTIGA were,1
POTIGA,damage to the photoreceptors,reactions The most common,0
POTIGA,damage to the photoreceptors,adverse reactions leading to awal,1
POTIGA,damage to the photoreceptors,withdr,0
POTIGA,damage to the photoreceptors,state fatigue and,0
POTIGA,damage to the photoreceptors,leading to awal in patients receiving P OTIGA were,1
POTIGA,damage to the photoreceptors,state fatigue and,0
POTIGA,damage to the photoreceptors,awal in patients receiving P,1
POTIGA,damage to the photoreceptors,OTIGA were dizziness confusional state fatigue and somnolence,0
POTIGA,damage to the photoreceptors,awal in patients receiving P OTIGA,1
POTIGA,damage to the photoreceptors,OTIGA were dizziness confusional state fatigue and somnolence,0
POTIGA,damage to the photoreceptors,fatigue,0
POTIGA,vision loss,Common Adverse,0
POTIGA,vision loss,withdrawal in patients receiving were dizzi,1
POTIGA,vision loss,in patients receiving were,1
POTIGA,vision loss,receiving were dizzi,1
POTIGA,vision loss,POTIGA,0
POTIGA,vision loss,in patients receiving  were dizzi ness,1
POTIGA,vision loss,POTIGA,0
POTIGA,vision loss,receiving  were dizzi ness confusional state fatigue,1
POTIGA,vision loss,POTIGA,0
POTIGA,vision loss,in patients receiving  were dizzi ness,1
POTIGA,vision loss,POTIGA,0
POTIGA,vision loss,leading,0
POTIGA,Urinary retention,ions are describe d,1
POTIGA,Urinary retention,leading,0
POTIGA,skin discoloration,the label Retinal ities and potentia l vision loss see,1
POTIGA,skin discoloration,leading,0
POTIGA,skin discoloration,Warnings,0
POTIGA,skin discoloration,Urinary retention see,0
POTIGA,skin discoloration,label Retinal ities and potentia,1
POTIGA,skin discoloration,ities and potentia l vision loss see Warnings,1
POTIGA,skin discoloration,label Retinal ities and potentia,1
POTIGA,skin discoloration,Warnings and Precautions section of,0
POTIGA,skin discoloration,in the Warnings and Precautions section of,0
POTIGA,skin discoloration,ities and potentia l vision loss see Warnings,1
POTIGA,skin discoloration,in the Warnings and Precautions section of,0
POTIGA,skin discoloration,ities and potentia l vision loss see Warnings,1
POTIGA,skin discoloration,in the Warnings and Precautions section of,0
POTIGA,Neuropsychiatric symptoms,s and Precautions Neuropsychiatric,0
POTIGA,Neuropsychiatric symptoms,symptoms see Warnings,0
POTIGA,Neuropsychiatric symptoms,retention see,0
POTIGA,Neuropsychiatric symptoms,iscoloration [see Warning s and Precautions,1
POTIGA,Neuropsychiatric symptoms,retention see,0
POTIGA,Neuropsychiatric symptoms,iscoloration [see Warning,1
POTIGA,Neuropsychiatric symptoms,retention see Warnings,0
POTIGA,Neuropsychiatric symptoms,symptoms see Warnings and,0
POTIGA,Neuropsychiatric symptoms,iscoloration [see Warning s and Precautions Neuropsychiatric,1
POTIGA,Neuropsychiatric symptoms,Skin iscoloration [see,1
POTIGA,QT prolongation,an,0
POTIGA,QT prolongation,Precautions ( QT interval effect see Warnings,1
POTIGA,abnormalities of the retina,"were zziness, somnolence, fatigu e confusional state",1
POTIGA,abnormalities of the retina,Precautions ( QT interval effect see Warnings,1
POTIGA,abnormalities of the retina,were,0
POTIGA,abnormalities of the retina,and twice placebo were di,0
POTIGA,abnormalities of the retina,vertigo tremor abnormal coordination,0
POTIGA,abnormalities of the retina,"twice placebo were zziness, somnolence, fatigu e confusional",1
POTIGA,abnormalities of the retina,vertigo tremor abnormal coordination,0
POTIGA,abnormalities of the retina,"somnolence, fatigu e",1
POTIGA,abnormalities of the retina,"placebo were zziness, somnolence, fatigu e confusional state vertigo",1
POTIGA,abnormalities of the retina,"somnolence, fatigu e",1
POTIGA,abnormalities of the retina,"zziness, somnolence, fatigu e confusional state",1
POTIGA,damage to photoreceptors,"vision gait disturbance asia, dysarthria,",1
POTIGA,damage to photoreceptors,To report,0
POTIGA,damage to photoreceptors,"gait disturbance asia, dysarthria,",1
POTIGA,damage to photoreceptors,"asia, dysarthria,",1
POTIGA,vision loss,dysarthria and  disorder.  To,1
POTIGA,vision loss,"asia, dysarthria,",1
POTIGA,vision loss,memory impairment asthenia blurred vision gait disturbance aphasia,0
POTIGA,vision loss, disorder.  To report SUSPECTED ADVERSE,1
POTIGA,vision loss, disorder.  To report,1
POTIGA,vision loss, disorder.  To report SUSPECTED ADVERSE,1
POTIGA,vision loss, disorder.  To report SUSPECTED ADVERSE,1
POTIGA,vision loss, disorder.  To,1
POTIGA,vision loss,balance,0
POTIGA,vision loss,dysarthria and  disorder. ,1
POTIGA,vision loss,balance,0
POTIGA,vision loss, disorder.  To report SUSPECTED,1
POTIGA,vision loss, disorder.  To report SUSPECTED,1
POTIGA,retinal abnormalities,"and balance  

   To report SUSPE CTED ADVERSE",1
POTIGA,retinal abnormalities, disorder.  To report SUSPECTED,1
POTIGA,retinal abnormalities,dysarthria and balance To report,1
POTIGA,retinal abnormalities,balance disorder,0
POTIGA,retinal abnormalities,To report SUSPE CTED ADVERSE REACTIONS,1
POTIGA,retinal abnormalities,REACTIONS contact GlaxoSmithKline at,0
POTIGA,retinal abnormalities,GlaxoSmithKline at or,0
POTIGA,retinal abnormalities,To,1
POTIGA,retinal pigmentary abnormalities,of a drug cannot,0
POTIGA,retinal abnormalities,POTIGA was nistered as adjunctiv e therapy to patients,1
POTIGA,retinal abnormalities,of a drug cannot,0
POTIGA,retinal abnormalities,practice POTIGA was nistered,1
POTIGA,retinal abnormalities,drug and may not reflect the rates observed in,0
POTIGA,retinal abnormalities,and may not reflect the rates observed in practice,0
POTIGA,retinal abnormalities,in practice POTIGA was nistered as adjunctiv,1
POTIGA,retinal abnormalities,and may not reflect the rates observed in practice,0
POTIGA,retinal abnormalities,practice POTIGA was nistered as,1
POTIGA,retinal abnormalities,practice POTIGA was nistered as adjunctiv,1
POTIGA,retinal abnormalities,nistered,1
POTIGA,mucous membrane discoloration,clinical studies ng the premarketing developme,1
POTIGA,mucous membrane discoloration,nistered,1
POTIGA,mucous membrane discoloration,nt A,0
POTIGA,discoloration,longer,0
POTIGA,discoloration,treated for year,0
POTIGA,discoloration,least months patients were treated for year or longer and patients,0
POTIGA,discoloration,of patients were reated for at least months patients were,1
POTIGA,discoloration,least months patients were treated for year or longer and patients,0
POTIGA,discoloration,patients were reated for at,1
POTIGA,discoloration,during the premarketing development A total of patients,0
POTIGA,discoloration,t,0
POTIGA,retinal abnormalities,"at least , 585 patients were",1
POTIGA,retinal abnormalities,months,0
POTIGA,retinal pigmentary abnormalities,Reactions Lea ding,1
POTIGA,retinal pigmentary abnormalities,at least ars. Adverse,1
POTIGA,retinal pigmentary abnormalities,Adverse Reactions Lea ding,1
POTIGA,retinal pigmentary abnormalities,ars. Adverse Reactions Lea,1
POTIGA,retinal pigmentary abnormalities,"least ars.



   Adverse Reactions Lea",1
POTIGA,retinal pigmentary abnormalities,ars. Adverse Reactions Lea,1
POTIGA,retinal pigmentary abnormalities,Studies In the randomized doubleblind,0
POTIGA,retinal pigmentary abnormalities,for at least ars. Adverse Reactions,1
POTIGA,retinal pigmentary abnormalities,ars.,1
POTIGA,retinal pigmentary abnormalities,patients were treated for at least,0
POTIGA,discoloration,were treated for at,0
POTIGA,discoloration,ntinuation in All Controlled,1
POTIGA,discoloration,to ntinuation in All Controlled,1
POTIGA,discoloration,ntinuation in All Controlled,1
POTIGA,discoloration,Reactions Leading to ntinuation,1
POTIGA,discoloration,to ntinuation in,1
POTIGA,discoloration,ntinuation in All Controlled Clinical Studies In,1
POTIGA,discoloration,to ntinuation in,1
POTIGA,discoloration,ntinuation in All,1
POTIGA,discoloration,to ntinuation in,1
POTIGA,discoloration,Reactions Leading to ntinuation in,1
POTIGA,discoloration,were treated for at least years Adverse,0
POTIGA,discoloration,ntinuation in All,1
POTIGA,discoloration,were treated for at least years Adverse,0
POTIGA,Funduscopic abnormalities,ontrolled Clinical Studie s,1
POTIGA,Funduscopic abnormalities,were treated for at least years Adverse,0
POTIGA,Funduscopic abnormalities,in All,0
POTIGA,Funduscopic abnormalities,Clinical Studie,1
POTIGA,Funduscopic abnormalities,ontrolled Clinical Studie s In,1
POTIGA,Funduscopic abnormalities,Clinical Studie,1
POTIGA,focal retinal pigment epithelium clumping,of ients (11%) receiving,1
POTIGA,focal retinal pigment epithelium clumping,ients (11%) receiving placebo discontinue,1
POTIGA,retinal abnormalities,of adverse ons. The most,1
POTIGA,retinal abnormalities,because of adverse reacti,0
POTIGA,retinal abnormalities,leading to,0
POTIGA,retinal abnormalities,of adverse ons. The most common  adverse reactions leading to,1
POTIGA,retinal abnormalities,leading to,0
POTIGA,retinal abnormalities,of adverse ons. The most common,1
POTIGA,retinal abnormalities,receiving,0
POTIGA,retinal abnormalities,treatment because of adverse ons. The most common  adverse reactions leading to withdrawal,1
POTIGA,retinal abnormalities,receiving,0
POTIGA,retinal abnormalities,adverse ons. The most,1
POTIGA,abnormal visual acuity,receiving POTIGA were,0
POTIGA,abnormal visual acuity,in pati ents receiving POTIGA were,1
POTIGA,abnormal visual acuity,in pati ents receiving POTIGA were,1
POTIGA,retinal abnormalities,"Overall, th e",1
POTIGA,retinal abnormalities,"Clinical ies  



 Overall, th e most",1
POTIGA,retinal abnormalities,"Overall, th e",1
POTIGA,retinal abnormalities,"in All Controlled Clinical ies Overall, th",1
POTIGA,retinal dystrophy,occurring approximately  the placebo rate were dizziness,1
POTIGA,retinal dystrophy,"in All Controlled Clinical ies Overall, th",1
POTIGA,retinal dystrophy,POTIGA and,0
POTIGA,retinal dystrophy,the placebo rate,1
POTIGA,abnormalities in the electroretinogram,"somnolence (22%), fatigue confusional state vertigo tremor abnormal",1
POTIGA,abnormalities in the electroretinogram,confusional state vertigo,0
POTIGA,abnormalities in the electroretinogram,"placebo rate were ness (23%), somnolence (22%), fatigue  confusional state vertigo tremor abnormal",1
POTIGA,abnormalities in the electroretinogram,confusional state vertigo,0
POTIGA,abnormalities in the electroretinogram,"were ness (23%), somnolence (22%), fatigue  confusional state vertigo tremor abnormal",1
POTIGA,abnormalities in the electroretinogram,confusional state vertigo,0
POTIGA,abnormal fluorescein angiography,fatigue confusional state,0
POTIGA,retinal abnormalities,asthenia ed,1
POTIGA,retinal abnormalities,"ed vision (5%), gait disturbance aphasia dysarthria",1
POTIGA,retinal abnormalities,disorder,0
POTIGA,retinal abnormalities,see,0
POTIGA,retinal abnormalities,"ed vision (5%), gait disturbance",1
POTIGA,suicides,these studies  of pati,1
POTIGA,suicides,"ed vision (5%), gait disturbance",1
POTIGA,suicides,of pati ents treated,1
POTIGA,suicides,reported in these studies  of pati ents treated with,1
POTIGA,suicides,of pati ents treated,1
POTIGA,suicide,"dry uth, dy",1
POTIGA,suicide,"peripheral edema hypokinesia dry uth, dy",1
POTIGA,suicide,"dry uth, dy",1
POTIGA,suicide,"edema hypokinesia dry uth,",1
POTIGA,suicide,liver enzymes Most of the adv,0
POTIGA,suicidal thoughts,"ary retention, ma laise and",1
POTIGA,suicidal thoughts,"ary retention, ma laise and increased",1
POTIGA,suicidal thoughts,"ary retention, ma laise and",1
POTIGA,suicidal thoughts,increased liver enzymes Most of the adverse,0
POTIGA,suicidal thoughts,"mouth dysphagia hyperhydrosis ary retention,",1
POTIGA,suicidal thoughts,hypokinesia dry mouth dysphagia hyperhydrosis,0
POTIGA,suicidal thoughts,and increased liver enzymes Most of,0
POTIGA,suicidal thoughts,"ary retention, ma laise and",1
POTIGA,suicidal thoughts,"vision gait disturbance aphasia ance disorder,",1
POTIGA,suicidal thoughts,was associated with doserelated weight gain with,0
POTIGA,suicidal thoughts,"ance disorder, co",1
POTIGA,suicidal thoughts,"vision gait disturbance aphasia ance disorder, co",1
POTIGA,suicidal thoughts,"ance disorder, co nstipation dysuria and chromaturia",1
POTIGA,Suicidal Thoughts,by patients,0
POTIGA,Suicidal Thoughts,"rash, n ystagmus dyspnea leukopenia muscle",1
POTIGA,Suicidal Thoughts,list of adverse reactions reported by patients treated with POTIGA during all clinica,0
POTIGA,Suicidal Thoughts,Following is a list of adverse reactions reported by patients treated with POTIGA,0
POTIGA,Suicidal Thoughts,"l trials: rash, n ystagmus",1
POTIGA,Suicidal Thoughts,"trials: rash, n ystagmus dyspnea leukopenia",1
BREO,death,death Currently available data are inadequate,1
BREO,death,determine,0
BREO,deaths,deaths in,1
BREO,deaths,in deaths in subjects receiving salmeterol,1
BREO,deaths,deaths in,1
BREO,deaths,in subjects,0
BREO,deaths,Precautions,0
BREO,deaths,in,0
BREO,deaths,deaths in subjects receiving,1
BREO,deaths,salmeterol See Warnings,0
BREO,deaths,deaths in subjects receiving,1
BREO,deaths,salmeterol or placebo added to usual,0
BREO,deaths,in deaths in subjects receiving salmeterol See,1
BREO,deaths,salmeterol or placebo added to usual,0
BREO,Candida albicans infection,pneumonia in COPD see Warnings and,0
BREO,pneumonia,Warnings and,0
BREO,pneumonia,pneumonia in COPD see,1
BREO,pneumonia,Precautions Increased risk pneumonia in COPD,1
BREO,pneumonia,pneumonia in COPD see,1
BREO,pneumonia,pneumonia in COPD,1
BREO,Immunosuppression,risk of pneumonia in COPD,0
BREO,Immunosuppression,Immunosuppression see Warnings and Precautions Hypercorticism,1
BREO,Immunosuppression,Warnings and Precautions,0
BREO,Immunosuppression,Immunosuppression,1
BREO,Immunosuppression,Hypercorticism and adrenal suppression,0
BREO,Immunosuppression,Immunosuppression,1
BREO,Immunosuppression,Immunosuppression see,1
BREO,Hypercorticism,Warnings and Precautions Reduction in bone,0
BREO,adrenal suppression,ns Immunosuppression see Warnings and Precautions Hypercorticism and,0
BREO,adrenal suppression,Precautions Hypercorticism adrenal,1
BREO,adrenal suppression,density see Warnings,0
BREO,adrenal suppression,Warnings and Precautions Hypercorticism adrenal,1
BREO,adrenal suppression,Hypercorticism adrenal suppression,1
BREO,adrenal suppression,Warnings and Precautions Hypercorticism adrenal,1
BREO,adrenal suppression,adrenal suppression see Warnings and,1
BREO,adrenal suppression,Warnings and Precautions Hypercorticism adrenal suppression see Warnings and Precautions,1
BREO,adrenal suppression,adrenal suppression see Warnings and,1
BREO,adrenal suppression,Hypercorticism adrenal,1
BREO,adrenal suppression,see Warnings and Precautions,0
BREO,Reduction in bone mineral density,bone mineral density see Warnings and Precautions Because,1
BREO,nasopharyngitis,nasopharyngitis upper respiratory tract infection headache,1
BREO,upper respiratory tract infection,Most common,0
BREO,headache,headache and,1
BREO,headache,Most common,0
BREO,headache,headache and oral candidiasis,1
BREO,headache,headache and oral candidiasis Asthma,1
BREO,headache,headache and oral,1
BREO,oral candidiasis,oral candidiasis Asthma,1
BREO,oral candidiasis,oral candidiasis Asthma Most common,1
BREO,oral candidiasis,upper respiratory tract infection headache,0
BREO,nasopharyngitis,candidiasis headache influenza upper respiratory tract infection bronchitis sinusitis,0
BREO,nasopharyngitis,adverse reactions incidence greater than or,0
BREO,oral candidiasis,respiratory tract infection bronchitis sinusitis,0
BREO,oral candidiasis,incidence greater than or equal,0
BREO,oral candidiasis,nasopharyngitis,0
BREO,oral candidiasis,influenza upper respiratory tract infection bronchitis,0
BREO,oral candidiasis,sinusitis,0
BREO,oral candidiasis,to are oral candidiasis,1
BREO,oral candidiasis,oral candidiasis headache,1
BREO,oral candidiasis,reactions incidence,0
BREO,headache,headache influenza,1
BREO,headache,headache,1
BREO,headache,headache influenza,1
BREO,headache,headache influenza upper respiratory tract infection,1
BREO,headache,headache influenza upper,1
BREO,influenza,respiratory tract infection bronchitis sinusitis oropharyngeal pain dysphonia and,0
BREO,influenza,influenza upper respiratory tract infection bronchitis,1
BREO,influenza,nasopharyngitis oral candidiasis influenza upper,1
BREO,influenza,influenza upper respiratory tract infection bronchitis,1
BREO,influenza,candidiasis influenza upper respiratory tract,1
BREO,influenza,influenza upper respiratory tract infection bronchitis,1
BREO,influenza,influenza upper respiratory tract,1
BREO,influenza,oral candidiasis influenza upper respiratory tract,1
BREO,influenza,influenza upper respiratory tract,1
BREO,upper respiratory tract infection,candidiasis headache upper respiratory tract infection bronchitis sinusitis oropharyngeal pain,1
BREO,upper respiratory tract infection,influenza upper respiratory tract,1
BREO,upper respiratory tract infection,candidiasis headache upper respiratory,1
BREO,upper respiratory tract infection,nasopharyngitis oral candidiasis headache upper respiratory tract infection bronchitis sinusitis oropharyngeal,1
BREO,upper respiratory tract infection,candidiasis headache upper respiratory,1
BREO,upper respiratory tract infection,pain dysphonia and cough,0
BREO,upper respiratory tract infection,or,0
BREO,upper respiratory tract infection,candidiasis headache upper,1
BREO,upper respiratory tract infection,candidiasis headache upper respiratory tract infection bronchitis sinusitis oropharyngeal pain,1
BREO,upper respiratory tract infection,candidiasis headache upper,1
BREO,bronchitis,To report SUSPECTED ADVERSE,0
BREO,bronchitis,bronchitis sinusitis oropharyngeal pain dysphonia and,1
BREO,bronchitis,bronchitis sinusitis oropharyngeal pain,1
BREO,bronchitis,influenza upper respiratory tract,0
BREO,sinusitis,sinusitis oropharyngeal pain dysphonia and cough,1
BREO,sinusitis,sinusitis oropharyngeal,1
BREO,sinusitis,sinusitis,1
BREO,sinusitis,infection sinusitis,1
BREO,sinusitis,sinusitis,1
BREO,sinusitis,infection sinusitis oropharyngeal pain dysphonia and cough,1
BREO,sinusitis,sinusitis,1
BREO,oropharyngeal pain,oropharyngeal pain dysphonia and,1
BREO,oropharyngeal pain,and cough To report SUSPECTED,0
BREO,cough,sinusitis,0
BREO,cough,infection bronchitis sinusitis,0
BREO,cough,cough To report,1
BREO,cough,infection bronchitis sinusitis,0
BREO,cough,cough,1
BREO,cough,cough To report SUSPECTED ADVERSE,1
BREO,cough,cough,1
BREO,cough,pain dysphonia cough,1
BREO,cough,cough,1
BREO,cough,cough To report SUSPECTED,1
BREO,cough,cough To report SUSPECTED ADVERSE REACTIONS,1
BREO,cough,respiratory tract infection bronchitis sinusitis oropharyngeal,0
BREO,oral candidiasis,a oral candidiasis,1
BREO,oropharyngeal candidiasis,oropharyngeal,1
BREO,oropharyngeal candidiasis,oral oropharyngeal candidiasis candidiasis and fungal oropharyngitis,1
BREO,oropharyngeal candidiasis,oropharyngeal,1
BREO,fungal oropharyngitis,candidiasis oropharyngeal candidiasis candidiasis fungal,1
BREO,fungal oropharyngitis,safety data is based,0
BREO,fungal oropharyngitis,candidiasis fungal oropharyngitis,1
BREO,fungal oropharyngitis,candidiasis oropharyngeal candidiasis candidiasis fungal oropharyngitis,1
BREO,fungal oropharyngitis,Includes oral candidiasis oropharyngeal,0
BREO,back pain,back pain pneumonia see Warnings,1
BREO,back pain,back pain pneumonia see Warnings,1
BREO,back pain,treated with BREO ELLIPTA n for months,0
BREO,back pain,cough oropharyngeal pai,0
BREO,pneumonia,cough oropharyngeal pain,0
BREO,pneumonia,sinusitis cough oropharyngeal,0
BREO,bronchitis,oropharyngeal pain arthralgia,0
BREO,bronchitis,bronchitis sinusitis cough oropharyngeal,1
BREO,bronchitis,see Warnings and bronchitis,1
BREO,bronchitis,bronchitis sinusitis cough oropharyngeal,1
BREO,bronchitis,Warnings and bronchitis sinusitis,1
BREO,bronchitis,bronchitis sinusitis cough oropharyngeal,1
BREO,bronchitis,see,0
BREO,bronchitis,bronchitis sinusitis cough oropharyngeal pain arthralgia,1
BREO,bronchitis,see Warnings and bronchitis sinusitis cough oropharyngeal,1
BREO,bronchitis,bronchitis sinusitis cough oropharyngeal pain arthralgia,1
BREO,bronchitis,bronchitis sinusitis cough oropharyngeal pain arthralgia,1
BREO,bronchitis,Warnings and,0
BREO,sinusitis,see Warnings,0
BREO,sinusitis,pain arthralgia influenza pharyngitis and pyrexia,0
BREO,cough,bronchitis cough oropharyngeal pain arthralgia influenza,1
BREO,cough,pain arthralgia influenza pharyngitis and pyrexia,0
BREO,cough,cough oropharyngeal,1
BREO,cough,arthralgia influenza pharyngitis,0
BREO,cough,cough oropharyngeal pain arthralgia,1
BREO,cough,and Precautions bronchitis cough oropharyngeal pain arthralgia,1
BREO,cough,cough oropharyngeal pain arthralgia,1
BREO,cough,oropharyngeal,0
BREO,cough,sinusitis,0
BREO,cough,pain pneumonia,0
BREO,cough,cough oropharyngeal pain arthralgia,1
BREO,cough,pain pneumonia,0
BREO,cough,bronchitis cough oropharyngeal,1
BREO,cough,pain pneumonia,0
BREO,oropharyngeal pain,bronchitis sinusitis,0
BREO,oropharyngeal pain,and pyrexia Clinical Trials,0
BREO,oropharyngeal pain,oropharyngeal pain,1
BREO,arthralgia,cough oropharyngeal arthralgia influenza,1
BREO,arthralgia,oropharyngeal pain,1
BREO,arthralgia,Trials Experience in,0
BREO,arthralgia,arthralgia influenza pharyngitis and pyrexia Clinical,1
BREO,arthralgia,arthralgia influenza pharyngitis and pyrexia Clinical,1
BREO,arthralgia,cough oropharyngeal pain,0
BREO,arthralgia,cough oropharyngeal arthralgia influenza pharyngitis and,1
BREO,arthralgia,cough oropharyngeal pain,0
BREO,pharyngitis,pharyngitis and pyrexia Clinical,1
BREO,pyrexia,BREO ELLIPTA for the treatment of asthma,0
BREO,pyrexia,pyrexia Clinical Trials Experience,1
BREO,pyrexia,and,0
BREO,oral candidiasis,Includes,0
BREO,oral candidiasis,a oral candidiasis,1
BREO,oral candidiasis,a,0
BREO,oral candidiasis,Includes,0
BREO,oral candidiasis,a oral,1
BREO,oral candidiasis,Includes,0
BREO,oral candidiasis,a,0
BREO,oral candidiasis,a oral candidiasis,1
BREO,oral candidiasis,a,0
BREO,oral candidiasis,oral candidiasis and oropharyngeal candidiasis Trial was,1
BREO,oral candidiasis,oral candidiasis and oropharyngeal,1
BREO,oral candidiasis,oral candidiasis and oropharyngeal candidiasis Trial was,1
BREO,oropharyngeal candidiasis,candidiasis oropharyngeal candidiasis Trial was a week trial,1
BREO,oropharyngeal candidiasis,oral candidiasis and oropharyngeal candidiasis Trial was,1
BREO,arthralgia,pharyngitis pyrexia arthralgia Month Trial Longterm safety,1
BREO,arthralgia,oral candidiasis and oropharyngeal candidiasis Trial was,1
BREO,pyrexia,pyrexia back,1
BREO,pyrexia,pyrexia back pain extrasystoles,1
BREO,back pain,pain respiratory tract infection allergic rhinitis,0
BREO,back pain,tract infection allergic,0
BREO,extrasystoles,rhinitis pharyngitis rhinitis,0
BREO,extrasystoles,extrasystoles upper,1
BREO,extrasystoles,upper abdominal pain respiratory tract infection allergic,0
BREO,extrasystoles,rhinitis,0
BREO,extrasystoles,pharyngitis rhinitis,0
BREO,extrasystoles,extrasystoles upper abdominal,1
BREO,extrasystoles,extrasystoles upper abdominal pain respiratory tract,1
BREO,extrasystoles,back extrasystoles upper abdominal,1
BREO,extrasystoles,extrasystoles upper abdominal pain respiratory tract,1
BREO,extrasystoles,extrasystoles upper,1
BREO,upper abdominal pain,upper abdominal pain respiratory tract infection,1
BREO,upper abdominal pain,upper abdominal pain respiratory tract,1
BREO,upper abdominal pain,upper abdominal pain respiratory tract infection,1
BREO,upper abdominal pain,pyrexia back pain upper,1
BREO,upper abdominal pain,pyrexia back,0
BREO,upper abdominal pain,upper abdominal pain respiratory,1
BREO,upper abdominal pain,pyrexia back,0
BREO,upper abdominal pain,rhinitis,0
BREO,upper abdominal pain,abdominal pain respiratory tract infection allergic rhinitis,1
BREO,upper abdominal pain,pain upper,1
BREO,upper abdominal pain,back pain upper abdominal pain,1
BREO,respiratory tract infection,upper abdominal,0
BREO,respiratory tract infection,allergic rhinitis pharyngitis,0
BREO,respiratory tract infection,pain extrasystoles upper abdominal respiratory tract infection allergic rhinitis,1
BREO,respiratory tract infection,allergic rhinitis pharyngitis,0
BREO,respiratory tract infection,ELLIPTA,0
BREO,respiratory tract infection,allergic,0
BREO,respiratory tract infection,abdominal pain,0
BREO,respiratory tract infection,abdominal respiratory,1
BREO,respiratory tract infection,respiratory tract infection allergic rhinitis pharyngitis rhinitis arthralgia,1
BREO,respiratory tract infection,abdominal respiratory tract infection allergic,1
BREO,respiratory tract infection,respiratory tract infection allergic rhinitis pharyngitis rhinitis arthralgia,1
BREO,respiratory tract infection,extrasystoles,0
BREO,allergic rhinitis,tract allergic rhinitis pharyngitis rhinitis,1
BREO,allergic rhinitis,extrasystoles,0
BREO,allergic rhinitis,pain respiratory tract allergic,1
BREO,allergic rhinitis,rhinitis arthralgia supraventricular extrasystoles,0
BREO,allergic rhinitis,nths included pyrexia back pain extrasystoles upper abdominal pain respiratory tract,0
BREO,allergic rhinitis,abdominal pain respiratory tract allergic rhinitis pharyngitis rhinitis,1
BREO,allergic rhinitis,nths included pyrexia back pain extrasystoles upper abdominal pain respiratory tract,0
BREO,allergic rhinitis,tract allergic rhinitis pharyngitis,1
BREO,allergic rhinitis,nths included pyrexia back pain extrasystoles upper abdominal pain respiratory tract,0
BREO,allergic rhinitis,arthralgia supraventricular extrasystoles ventricular extrasystoles,0
BREO,allergic rhinitis,allergic rhinitis pharyngitis rhinitis arthralgia supraventricular extrasystoles,1
BREO,pharyngitis,pharyngitis rhinitis arthralgia,1
BREO,pharyngitis,pharyngitis rhinitis arthralgia supraventricular extrasystoles ventricular,1
BREO,pharyngitis,pharyngitis rhinitis,1
BREO,pharyngitis,pharyngitis rhinitis,1
BREO,pharyngitis,pharyngitis rhinitis arthralgia supraventricular,1
BREO,pharyngitis,upper abdominal pain respiratory tract,0
BREO,pharyngitis,back pain,0
BREO,pharyngitis,pharyngitis rhinitis,1
BREO,pharyngitis,pharyngitis,1
BREO,pharyngitis,arthralgia supraventricular extrasystoles ventricular,0
BREO,rhinitis,respiratory tract infection allergic rhinitis pharyngitis,0
BREO,rhinitis,infection allergic rhinitis rhinitis arthralgia supraventricular extrasystoles ventricular extrasystoles,1
BREO,rhinitis,respiratory tract infection allergic rhinitis pharyngitis,0
BREO,rhinitis,allergic rhinitis rhinitis arthralgia supraventricular extrasystoles ventricular extrasystoles,1
BREO,rhinitis,respiratory tract infection allergic rhinitis pharyngitis,0
BREO,rhinitis,rhinitis arthralgia supraventricular extrasystoles,1
BREO,rhinitis,upper abdominal pain respiratory,0
BREO,rhinitis,rhinitis arthralgia supraventricular extrasystoles ventricular,1
BREO,rhinitis,rhinitis,1
BREO,rhinitis,rhinitis arthralgia supraventricular extrasystoles ventricular,1
BREO,arthralgia,arthralgia supraventricular extrasystoles ventricular,1
BREO,arthralgia,rhinitis pharyngitis,0
BREO,arthralgia,arthralgia supraventricular extrasystoles ventricular extrasystoles acute,1
BREO,arthralgia,arthralgia supraventricular extrasystoles ventricular extrasystoles,1
BREO,supraventricular extrasystoles,Exacerbation Trial In a,0
BREO,supraventricular extrasystoles,Trial,0
BREO,supraventricular extrasystoles,rhinitis pharyngitis rhinitis supraventricular extrasystoles,1
BREO,supraventricular extrasystoles,rhinitis supraventricular extrasystoles,1
BREO,supraventricular extrasystoles,supraventricular extrasystoles ventricular,1
BREO,supraventricular extrasystoles,supraventricular extrasystoles,1
BREO,supraventricular extrasystoles,pain respiratory tract,0
BREO,supraventricular extrasystoles,extrasystoles acute sinusitis and pneumonia Exacerbation Trial In a,0
BREO,ventricular extrasystoles,ventricular extrasystoles acute sinusitis and,1
BREO,acute sinusitis,rhinitis,0
BREO,acute sinusitis,pharyngitis rhinitis arthralgia,0
BREO,acute sinusitis,Exacerbation Trial In a to week trial subjects received BREO EL,0
BREO,acute sinusitis,arthralgia supraventricular,0
BREO,acute sinusitis,In a to week trial subjects received BREO,0
BREO,pneumonia,ventricular extrasystoles acute sinusitis pneumonia,1
BREO,pneumonia,In a to week trial subjects received BREO,0
BREO,deaths,deaths or asthmarelated intubations,1
BREO,deaths,trial,0
BREO,deaths,were no,0
BREO,deaths,with subjects treated with fluticasone furoate mcg n There were no,0
BREO,Palpitations,Palpitations tachycardia Immune System Disorders,1
BREO,Palpitations,Palpitations tachycardia,1
BREO,Palpitations,Palpitations tachycardia Immune System Disorders,1
BREO,Palpitations,Hypersensitivity,0
BREO,Palpitations,tachycardia Immune System Disorders Hypersensitivity reactions including anaphylaxis,0
BREO,tachycardia,tachycardia Immune System,1
BREO,tachycardia,these factors Cardiac Disorders tachycardia Immune System Disorders,1
BREO,tachycardia,tachycardia Immune System,1
BREO,tachycardia,tachycardia Immune System Disorders Hypersensitivity,1
BREO,tachycardia,tachycardia Immune System,1
BREO,tachycardia,of these,0
BREO,tachycardia,tachycardia Immune System,1
BREO,Hypersensitivity reactions,Hypersensitivity reactions,1
BREO,Hypersensitivity reactions,tachycardia Immune System Disorders,0
BREO,Hypersensitivity reactions,Immune System Hypersensitivity reactions including anaphylaxis angioedema,1
BREO,Hypersensitivity reactions,tachycardia Immune System Disorders,0
BREO,Hypersensitivity reactions,tachycardia Immune System Disorders,0
BREO,angioedema,Disorders Hypersensitivity reactions including angioedema,1
BREO,angioedema,tachycardia Immune System Disorders,0
BREO,angioedema,angioedema rash and urticaria Musculoskeletal,1
BREO,rash,Musculoskeletal and Connective Tissue Disorders Muscle,0
BREO,rash,rash and urticaria Musculoskeletal and,1
BREO,rash,including anaphylaxis rash and urticaria Musculoskeletal and Connective,1
BREO,rash,rash and urticaria Musculoskeletal and,1
BREO,rash,rash,1
BREO,rash,Hypersensitivity reactions including anaphylaxis angioedema,0
BREO,urticaria,urticaria,1
BREO,urticaria,Connective Tissue Disorders Muscle,0
BREO,urticaria,anaphylaxis angioedema rash urticaria Musculoskeletal and,1
BREO,urticaria,Connective Tissue Disorders Muscle,0
BREO,urticaria,including anaphylaxis angioedema rash urticaria Musculoskeletal,1
BREO,urticaria,Connective Tissue Disorders Muscle,0
BREO,urticaria,rash urticaria Musculoskeletal and,1
BREO,urticaria,Connective Tissue Disorders Muscle,0
BREO,Muscle spasms,and urticaria Musculoskeletal and Connective,0
BREO,Muscle spasms,Connective Tissue Muscle spasms Nervous System Disorders,1
BREO,Muscle spasms,and urticaria Musculoskeletal and Connective,0
BREO,Tremor,Psychiatric Disorders Nervousness,0
BREO,Tremor,Nervous System,0
BREO,Tremor,spasms Nervous System Disorders,0
BREO,Tremor,Psychiatric Disorders Nervousness,0
BREO,Tremor,Psychiatric Disorders,0
BREO,Tremor,Nervous System Tremor Psychiatric Disorders Nervousness,1
BREO,Tremor,Psychiatric Disorders,0
BREO,Tremor,Muscle spasms Nervous System Disorders,0
BREO,Tremor,Tremor Psychiatric Disorders,1
BREO,DEATH,lante rol one,1
BREO,DEATH,LABA such as lante rol one,1
BREO,DEATH,lante rol one,1
BREO,DEATH,lante,1
BREO,DEATH,rol one of,0
BREO,DEATH,lante rol one,1
BREO,DEATH,rol one of,0
BREO,DEATH,lante rol,1
BREO,DEATH,REACTIONS LABA such as lante rol one,1
BREO,DEATH,lante rol,1
BREO,DEATH,death Currently available data are inadequat,0
BREO,DEATH,increase the risk of,0
BREO,DEATH,active,0
BREO,DEATH,REACTIONS LABA such,0
BREO,DEATH,ingre,0
BREO,DEATH,the active dient s in BREO,1
BREO,DEATH,ingre,0
BREO,DEATH,REACTIONS LABA such as,0
BREO,DEATH,such as vilanterol,0
BREO,DEATH,one of,0
BREO,death,oster oids or,1
BREO,death,oster oids or other,1
BREO,death,oster oids or,1
BREO,death,cortic,0
BREO,death,oids or other longterm asthma control drugs mitigates the increased,0
BREO,death,use of inhaled oster oids or other longterm asthma,1
BREO,death,oids or other longterm asthma control drugs mitigates the increased,0
BREO,death,oster oids,1
BREO,death,oster,1
BREO,death,of asthmarelated death,0
BREO,death,to determine whether,0
BREO,deaths,suggest that LABA  the r isk,1
BREO,deaths,to determine whether,0
BREO,deaths,arelated death from LABA Available data from controlled,0
BREO,deaths,LABA,0
BREO,deaths,the r,1
BREO,deaths,that,0
BREO,death,salmeterol ee,1
BREO,death,ee Wa rnings and Precautions Systemic and,1
BREO,death,Systemic and local corticosteroid use,0
BREO,death,may result in,0
BREO,death,subjects receiving,0
BREO,death,increase in asthmarelated deaths in subjects receiving salmeterol,0
BREO,death,salmeterol ee Wa,1
BREO,death,in asthmarelated,0
BREO,death,deaths,0
BREO,death,and,0
BREO,DEATH,and oral candidiasis Asthma,0
BREO,DEATH,incidence greater than,0
BREO,DEATH,eacti ons incidence greater,1
BREO,DEATH,adverse r,0
BREO,DEATH,eacti ons incidence greater than,1
BREO,DEATH,Asthma Most common adverse r,0
BREO,death,report SUSPECTED ADVERSE REACTIONS contact,0
BREO,death,"oropharyngeal n, dy",1
BREO,death,bronchitis sinusitis oropharyngeal,0
BREO,death,and cough To report SUSPECTED ADVERSE,0
BREO,death,"bronchitis sinusitis oropharyngeal n, dy",1
BREO,death,infection bronchitis sinusitis oropharyngeal pai,0
BREO,death,ADVERSE REACTIONS,0
BREO,deaths,FDA at FDA or wwwfdagovmedwatch Clinical,0
BREO,death,in BREO LIPTA increase,1
BREO,death,FDA at FDA or wwwfdagovmedwatch Clinical,0
BREO,Candida albicans infection of the mouth,from controlled clinical trials suggest,0
BREO,Candida albicans infection of the mouth,LABA Available data from controlled clinical trials suggest that LABA increase the risk,0
BREO,Candida albicans infection of the mouth,increase the risk f asthma-related hospitalization in ped iatric,1
BREO,Candida albicans infection of the mouth,LABA Available data from controlled clinical trials suggest that LABA increase the risk,0
BREO,Candida albicans infection of the mouth,f asthma-related hospitalization,1
BREO,Candida albicans infection of the mouth,suggest that LABA increase the risk,0
BREO,Candida albicans infection of the mouth,hospitalization in ped iatric,1
BREO,Candida albicans infection of the mouth,the risk f asthma-related hospitalization in ped iatric and adolescent,1
BREO,Candida albicans infection of the mouth,hospitalization in ped iatric,1
BREO,pneumonia,placebo added to usual asthma therapy showed an increase,0
BREO,pneumonia,lated dea ths in subjects,1
BREO,pneumonia,lated dea,1
BREO,pneumonia,in asthmare,0
BREO,pneumonia,in lated dea,1
BREO,pneumonia,f another LABA salmeterol or placebo added to usual asthma therapy showed an increase in,0
BREO,pneumonia,in lated dea,1
BREO,worsening of infections,in the following Candida albicans infection see,0
BREO,worsening of infections,albicans infection see Warnings and,0
BREO,worsening of infections,the following Candida,0
BREO,worsening of infections,Precautions Systemic and local orticosteroid use may r,1
BREO,worsening of infections,albicans infection,0
BREO,fatal," 
 *  Immunosuppression",1
BREO,fatal,Warnings and,0
BREO,fatal,and Precautions,0
BREO,fatal,"see Warnings and  
 *  Immunosuppression see Warnings and",1
BREO,fatal,and Precautions,0
BREO,fatal," 
 * ",1
BREO,chickenpox,ppression ,1
BREO,chickenpox,ppression  see Warnings and Precautions Hypercorticism,1
BREO,chickenpox,Precautions ppression ,1
BREO,chickenpox,ppression  see Warnings and Precautions Hypercorticism,1
BREO,chickenpox,Precautions ppression  see Warnings,1
BREO,chickenpox,ppression  see Warnings and Precautions Hypercorticism,1
BREO,chickenpox,of pneumonia in COPD see Warnings and,0
BREO,chickenpox,adrenal suppression see Warnings an,0
BREO,chickenpox,ppression  see,1
BREO,chickenpox,see Warnings and Precautions,0
BREO,chickenpox,ppression ,1
BREO,chickenpox,ppression  see Warnings and Precautions,1
BREO,measles, Warnin gs and,1
BREO,measles, Warnin gs and Precautions Hypercorticism and,1
BREO,measles, Warnin gs and,1
BREO,measles, Warnin gs and,1
BREO,measles, Warnin gs and,1
BREO,measles,see,0
BREO,measles,Precautions Immunosuppression  Warnin gs and Precautions,1
BREO,measles,see,0
BREO,measles, Warnin gs,1
BREO,impaired adrenal function,Precautions Hypercorticism and suppression [see Warnings and Precautions Reduction in bone,1
BREO,impaired adrenal function, Warnin gs,1
BREO,impaired adrenal function,suppression [see Warnings and Precautions Reduction,1
BREO,impaired adrenal function,[see Warnings and Precautions Reduction in,1
BREO,impaired adrenal function,suppression [see Warnings,1
BREO,impaired adrenal function,in bone mineral density,0
BREO,impaired adrenal function,and suppression [see,1
BREO,impaired adrenal function,and Precautions Hypercorticism and,0
BREO,Hypercorticism,reaction,0
BREO,death,with COPD in,0
BREO,death,function,0
BREO,death,month exacerbation trials a,0
BREO,death,month exacerbation trials a,0
BREO,death,nclud ed subjects with COPD in,1
BREO,death,two month exacerbation,0
BREO,death,month lung function trials two month exacerbation trials a,0
BREO,death,received at 1 do,1
BREO,death,COPD received at  1 do se of BREO ELLIPTA and,1
BREO,death,received at 1 do,1
BREO,death,1 do se,1
BREO,death,a,0
BREO,death,COPD received at 1,1
BREO,death,COPD received at  1 do,1
BREO,death,COPD received at 1,1
BREO,death,subjects received a higher,0
BREO,death,subjects with COPD received at,0
BREO,death,1 do se of BREO,1
BREO,death,1,1
BREO,deaths,ELLIPTA fluticasone erol 5,1
BREO,deaths,ELLIPTA BREO ELLIPTA fluticasone erol 5 mcg mcg,1
BREO,deaths,ELLIPTA fluticasone erol 5,1
BREO,deaths,erol 5 mcg,1
BREO,death,Obstructive,0
BREO,death,Reactions with BREO,0
BREO,death,ubjects with Chronic,0
BREO,death,in S ubjects with,1
BREO,death,BREO ELLIPTA with Incidence and More Common than,0
BREO,death,than Placebo,0
BREO,death, in S ubjects,1
BREO,death,than Placebo,0
BREO,death,Fluti casone Furoate mcg n Placebo,1
BREO,death,n BREO,0
BREO,death,Furoate mcg n,0
BREO,death,Fluti casone Furoate mcg n,1
BREO,death,Vilanterol,0
BREO,death,n,0
BREO,death,n,0
BREO,death,Furoate mcg n,0
BREO,death,n Vilanterol mcg n,0
BREO,fatalities,thma. BREO ELLIPTA was studied in,1
BREO,fatalities,which enrolled subjects with thma.,1
BREO,fatalities,enrolled subjects with thma. BREO ELLIPTA,1
BREO,fatalities,which enrolled subjects with thma.,1
BREO,fatalities,studied in subjects,0
BREO,pneumonia,Adverse Reaction,0
BREO,pneumonia,")  




  Adverse Reaction",1
BREO,pneumonia,")  




  Adverse Reaction BREO ELLIPTA n",1
BREO,pneumonia,")  




  Adverse Reaction BREO ELLIPTA",1
BREO,pneumonia,ELLIPTA n,0
BREO,pneumonia,than Placebo in Subjects with Asthma Trial,0
BREO,pneumonia,Reaction BREO ELLIPTA n Fluticasone,0
BREO,pneumonia,"with Asthma )  




  Adverse",1
BREO,pneumonia,Reaction BREO ELLIPTA n Fluticasone,0
BREO,pneumonia,with Incidence and More,0
BREO,pneumonias,  Placebo ,1
BREO,pneumonias,  Placebo  n Infections and,1
BREO,pneumonias,Furoate mcg,0
BREO,pneumonias,  Placebo ,1
BREO,infections,and mediastinal disorders,0
BREO,infections,and mediastinal disorders,0
BREO,infections,          ,1
BREO,Chickenpox,           Oropharyngeal pain,1
BREO,Chickenpox,           Oropharyngeal pain,1
BREO,Chickenpox,          ,1
BREO,Chickenpox,thoracic and,0
BREO,Chickenpox,mediastinal            Oropharyngeal,1
BREO,Chickenpox,thoracic and,0
BREO,measles,ediastinal         Oropharyngeal,1
BREO,measles,thoracic and,0
BREO,measles,       ,1
BREO,measles,        Oropharyngeal,1
BREO,HPA dysfunction,and fluti casone,1
BREO,HPA dysfunction,and fluti casone,1
BREO,HPA dysfunction,"ELLIPTA once daily 202), and fluti",1
BREO,HPA dysfunction,"202), and fluti casone",1
BREO,HPA dysfunction,"ELLIPTA once daily 202), and fluti",1
BREO,HPA dysfunction,"daily 202), and fluti casone propionate",1
BREO,HPA dysfunction,"ELLIPTA once daily 202), and fluti",1
BREO,HPA dysfunction,daily n,0
BREO,HPA dysfunction,subjects with asthma,0
BREO,hypercorticism,upper abdominal pain,0
BREO,hypercorticism,act infection allergic rhinitis,0
BREO,hypercorticism,pain extrasystoles upper abdominal respiratory tr act infection,1
BREO,hypercorticism,act infection allergic rhinitis,0
BREO,adrenal suppression,"pain respiratory tract nfection, allergic",1
BREO,adrenal suppression,supraventricular extrasystoles ventricular extrasystol,0
BREO,adrenal suppression,"nfection, allergic",1
BREO,adrenal suppression,"pain respiratory tract nfection, allergic  rhinitis pharyngitis rhinitis arthralgia supraventricular",1
BREO,adrenal suppression,"nfection, allergic",1
BREO,adrenal suppression,for months included pyrexia back pain,0
BREO,adrenal suppression,months,0
BREO,adrenal crisis,"allergic rhinitis aryngitis,",1
BREO,adrenal crisis,extrasystoles,0
BREO,paradoxical bronchospasm,BREO ELLIPTA compared with jects (0.7%),1
BREO,paradoxical bronchospasm,treated wit h fluticasone,1
BREO,paradoxical bronchospasm,jects (0.7%) treated wit h fluticasone furoate,1
BREO,paradoxical bronchospasm,treated wit h fluticasone,1
BREO,paradoxical bronchospasm,jects (0.7%) treated wit h,1
BREO,paradoxical bronchospasm,jects (0.7%),1
BREO,Hypersensitivity reactions,in this 6.3 Postmarketing,1
BREO,Hypersensitivity reactions,observed in this 6.3 Postmarketing Experien,1
BREO,Hypersensitivity reactions,observed in this 6.3 Postmarketing Experien ce In addition to adverse,1
BREO,Hypersensitivity reactions,observed in this 6.3 Postmarketing Experien,1
BREO,Hypersensitivity reactions,intubations observed in this 6.3 Postmarketing Experien ce In addition,1
BREO,Hypersensitivity reactions,observed in this 6.3 Postmarketing Experien,1
BREO,Hypersensitivity reactions,this 6.3 Postmarketing,1
BREO,Hypersensitivity reactions,were no asthmarelated deaths or asthmarelated intubations observed in this,0
BREO,anaphylaxis,have been,0
BREO,anaphylaxis,trials the,0
BREO,anaphylaxis,this trial Postmarketing Experience addition to adverse reactions reported from clinical,1
BREO,anaphylaxis,trials the,0
BREO,anaphylaxis,Experience addition,1
BREO,anaphylaxis,addition to adverse reactions reported,1
BREO,angioedema,addition to dverse rea ctions reported,1
BREO,angioedema,addition to adverse reactions reported,1
BREO,angioedema,have,0
BREO,angioedema,In addition to dverse rea,1
BREO,angioedema,in this trial,0
BREO,angioedema,addition to dverse rea ctions reported from,1
BREO,angioedema,in this trial,0
BREO,angioedema,dverse rea ctions,1
BREO,angioedema,Experience In,0
BREO,angioedema,dverse rea ctions reported from,1
BREO,angioedema,clinical trials the following adverse reactions have been identified during po,0
BREO,angioedema,dverse rea ctions reported from,1
BREO,rash,ions reported from,1
BREO,urticaria,In addition to adverse,0
BREO,urticaria,ted from clinical trials the following,1
BREO,urticaria,ted from,1
BREO,urticaria,ted,1
BREO,urticaria,ted from clinical trials the following,1
BREO,urticaria,ted from clinical,1
BREO,urticaria,postapproval,0
BREO,anaphylactic reactions,ELLIPTA Because,0
BREO,anaphylactic reactions,to,0
BREO,anaphylactic reactions,are reported voluntarily,1
BREO,increases in pulse rate,"Palpitations .



   Immune System D isorders Hypersensitivity reactions including",1
BREO,increases in pulse rate,are reported voluntarily,1
BREO,increases in pulse rate,Palpitations . Immune,1
BREO,increases in pulse rate,Palpitations .,1
BREO,increases in pulse rate,Immune System D isorders,1
BREO,increases in pulse rate,"Cardiac Disorders Palpitations .



   Immune System D isorders Hypersensitivity",1
BREO,increases in pulse rate,Immune System D isorders,1
BREO,increases in pulse rate,Immune System D isorders,1
BREO,increases in pulse rate,Disorders Palpitations . Immune,1
BREO,increases in pulse rate,".



   Immune System D",1
BREO,increases in pulse rate,Disorders Palpitations . Immune,1
BREO,cardiac arrhythmias,Immune System Disorders Hypersensitivity reactions,0
BREO,cardiac arrhythmias,Palpitations tachycardia,0
BREO,cardiac arrhythmias,and urticaria Musculoskeletal and Connective Tissue Disorders,0
BREO,cardiac arrhythmias,"System Disorders Hypersensitivity reactions ing anaphylaxis, an gioedema",1
BREO,cardiac arrhythmias,and urticaria Musculoskeletal and Connective Tissue Disorders,0
BREO,cardiac arrhythmias,tachycardia Immune System Disorders Hypersensitivity reactions includ,0
BREO,cardiac arrhythmias,"Disorders Hypersensitivity reactions ing anaphylaxis, an gioedema rash",1
BREO,cardiac arrhythmias,tachycardia Immune System Disorders Hypersensitivity reactions includ,0
BREO,cardiac arrhythmias,gioedema rash and urticaria Musculoskeletal and,0
BREO,cardiac arrhythmias,"Disorders Hypersensitivity reactions ing anaphylaxis, an gioedema rash and urticaria Musculoskeletal",1
BREO,cardiac arrhythmias,gioedema rash and urticaria Musculoskeletal and,0
BREO,supraventricular tachycardia,Tissue Disorders,0
BREO,supraventricular tachycardia,Muscle spasms Nervous System,0
BREO,supraventricular tachycardia,Nervous System Disorders,0
BREO,supraventricular tachycardia,Immune System Disorders Hypersensitivity reactions,0
BREO,extrasystoles,Connective Tissue Disorders Muscle,0
BREO,extrasystoles,angioedema rash and urticaria oskeletal,1
BREO,extrasystoles,and urticaria oskeletal,1
BREO,extrasystoles,Muscle spasms Nervous,0
BREO,extrasystoles,Tissue Disorders Muscle,0
BREO,extrasystoles,and urticaria oskeletal and,1
BREO,extrasystoles,oskeletal and Connective Tissue Disorders Muscle spasms,1
BREO,extrasystoles,urticaria oskeletal,1
DOTAREM,NSF,associated with a,0
DOTAREM,NSF,has not been reported,0
DOTAREM,NSF,risk,0
DOTAREM,NSF,associated with,0
DOTAREM,NSF,NSF has not been reported,1
DOTAREM,NSF,and NSF has,1
DOTAREM,NSF,NSF has not been reported,1
DOTAREM,NSF,NSF has not been reported in,1
DOTAREM,NSF,NSF,1
DOTAREM,NSF,NSF,1
DOTAREM,NSF,a,0
DOTAREM,NSF,and NSF,1
DOTAREM,NSF,a,0
DOTAREM,NSF,Warnings and NSF has,1
DOTAREM,NSF,a,0
DOTAREM,Hypersensitivity reactions,to DOTAREM Hypersensitivity reactions and,1
DOTAREM,Hypersensitivity reactions,a,0
DOTAREM,Hypersensitivity reactions,DOTAREM Hypersensitivity,1
DOTAREM,Hypersensitivity reactions,alone,0
DOTAREM,Hypersensitivity reactions,to DOTAREM Hypersensitivity reactions,1
DOTAREM,acute kidney injury,alone Hypersensitivity reactions acute,1
DOTAREM,acute kidney injury,in other sections of the labeling,0
DOTAREM,acute kidney injury,reactions acute,1
DOTAREM,acute kidney injury,acute kidney,1
DOTAREM,acute kidney injury,alone Hypersensitivity reactions acute,1
DOTAREM,acute kidney injury,DOTAREM alone Hypersensitivity reactions acute,1
DOTAREM,nausea,nausea headache injection site,1
DOTAREM,nausea,nausea headache injection site pain injection,1
DOTAREM,nausea,nausea headache injection site pain injection,1
DOTAREM,nausea,nausea headache injection site pain injection,1
DOTAREM,nausea,nausea headache injection,1
DOTAREM,nausea,sensation To report,0
DOTAREM,nausea,adverse reactions in clinical studies were,0
DOTAREM,headache,EXCERPT The most frequent,0
DOTAREM,headache,headache,1
DOTAREM,headache,most frequent adverse reactions in clinical studies were,0
DOTAREM,headache,clinical studies were headache injection site,1
DOTAREM,headache,most frequent adverse reactions in clinical studies were,0
DOTAREM,injection site pain,injection site coldness and burning,0
DOTAREM,injection site pain,injection site pain injection,1
DOTAREM,injection site pain,clinical studies were nausea injection site pain injection site,1
DOTAREM,injection site pain,injection site pain injection,1
DOTAREM,injection site pain,injection site pain injection site coldness,1
DOTAREM,injection site pain,injection site pain injection,1
DOTAREM,injection site pain,clinical studies were nausea injection site pain,1
DOTAREM,injection site pain,were nausea injection site pain injection site coldness and,1
DOTAREM,injection site pain,clinical studies were nausea injection site pain,1
DOTAREM,injection site pain,studies were nausea headache,0
DOTAREM,injection site pain,SUSPECTED,0
DOTAREM,injection site coldness,injection site injection site,1
DOTAREM,injection site coldness,site coldness and,1
DOTAREM,injection site coldness,sensation To report SUSPECTED ADVERSE REACTIONS contact GUERBET LLC,0
DOTAREM,injection site coldness,headache injection site,0
DOTAREM,injection site coldness,site pain,0
DOTAREM,injection site coldness,injection site coldness and,1
DOTAREM,injection site coldness,ADVERSE REACTIONS contact,0
DOTAREM,injection site coldness,injection site coldness and,1
DOTAREM,injection site coldness,injection site coldness and burning sensation To,1
DOTAREM,burning sensation,burning sensation To report SUSPECTED ADVERSE REACTIONS,1
DOTAREM,burning sensation,injection site coldness and burning sensation To,1
DOTAREM,burning sensation,burning sensation To report SUSPECTED ADVERSE,1
DOTAREM,burning sensation,clinical,0
DOTAREM,burning sensation,injection site coldness burning,1
DOTAREM,burning sensation,injection site coldness burning sensation,1
DOTAREM,burning sensation,injection site coldness burning,1
DOTAREM,feeling cold,patients who received DOTAREM feeling cold,1
DOTAREM,feeling cold,injection site coldness burning,1
DOTAREM,feeling cold,that occurred with a frequency in patients,0
DOTAREM,rash,received DOTAREM,0
DOTAREM,rash,rash somnolence fatigue dizziness,1
DOTAREM,somnolence,paresthesia dysgeusia pain in extremity anxiety hypert,0
DOTAREM,somnolence,feeling cold somnolence fatigue dizziness vomiting,1
DOTAREM,somnolence,paresthesia dysgeusia pain in extremity anxiety hypert,0
DOTAREM,somnolence,received DOTAREM include feeling cold,0
DOTAREM,somnolence,somnolence fatigue dizziness vomiting pruritus,1
DOTAREM,somnolence,received DOTAREM include feeling cold,0
DOTAREM,somnolence,include feeling cold somnolence,1
DOTAREM,somnolence,received DOTAREM include feeling cold,0
DOTAREM,somnolence,somnolence fatigue dizziness,1
DOTAREM,somnolence,vomiting pruritus paresthesia dysgeusia pain in,0
DOTAREM,somnolence,a,0
DOTAREM,somnolence,somnolence,1
DOTAREM,somnolence,somnolence,1
DOTAREM,fatigue,pruritus paresthesia,0
DOTAREM,fatigue,fatigue dizziness vomiting pruritus,1
DOTAREM,fatigue,a frequency in patients who received DOTAREM include,0
DOTAREM,fatigue,fatigue dizziness vomiting pruritus,1
DOTAREM,fatigue,a frequency in patients who received DOTAREM include,0
DOTAREM,fatigue,fatigue dizziness vomiting pruritus,1
DOTAREM,fatigue,in,0
DOTAREM,fatigue,cold,0
DOTAREM,fatigue,dizziness vomiting pruritus,0
DOTAREM,dizziness,extremity anxiety hypertension,0
DOTAREM,dizziness,dizziness vomiting pruritus paresthesia,1
DOTAREM,vomiting,vomiting pruritus paresthesia dysgeusia,1
DOTAREM,vomiting,dizziness vomiting pruritus paresthesia,1
DOTAREM,vomiting,rash somnolence fatigue vomiting pruritus paresthesia,1
DOTAREM,vomiting,dizziness vomiting pruritus paresthesia,1
DOTAREM,vomiting,DOTAREM include,0
DOTAREM,vomiting,vomiting pruritus paresthesia dysgeusia pain,1
DOTAREM,vomiting,vomiting pruritus,1
DOTAREM,vomiting,vomiting pruritus paresthesia dysgeusia,1
DOTAREM,pruritus,pruritus paresthesia,1
DOTAREM,pruritus,feeling cold rash somnolence,0
DOTAREM,pruritus,in extremity anxiety hypertension palpitations,0
DOTAREM,pruritus,pruritus paresthesia dysgeusia pain in,1
DOTAREM,paresthesia,cold rash somnolence fatigue dizziness vomiting,0
DOTAREM,paresthesia,fatigue dizziness,0
DOTAREM,paresthesia,dizziness vomiting paresthesia dysgeusia pain,1
DOTAREM,paresthesia,fatigue dizziness,0
DOTAREM,paresthesia,paresthesia dysgeusia,1
DOTAREM,paresthesia,paresthesia dysgeusia pain in,1
DOTAREM,paresthesia,dysgeusia pain in extremity anxiety hypertension palpitations oropharyngeal discomfort,0
DOTAREM,dysgeusia,anxiety hypertension palpitations oropharyngeal discomfort serum creatinine,0
DOTAREM,dysgeusia,fatigue dizziness vomiting pruritus dysgeusia pain in extremity anxiety hypertension,1
DOTAREM,dysgeusia,anxiety hypertension palpitations oropharyngeal discomfort serum creatinine,0
DOTAREM,dysgeusia,feeling cold rash somnolence fatigue dizziness vomiting pruritus,0
DOTAREM,dysgeusia,dysgeusia pain,1
DOTAREM,dysgeusia,dysgeusia pain in extremity,1
DOTAREM,pain in extremity,discomfort serum creatinine increased and,0
DOTAREM,hypertension,hypertension palpitations oropharyngeal discomfort serum,1
DOTAREM,hypertension,discomfort serum creatinine,0
DOTAREM,hypertension,site,0
DOTAREM,hypertension,hypertension palpitations oropharyngeal,1
DOTAREM,hypertension,hypertension palpitations oropharyngeal,1
DOTAREM,hypertension,vomiting pruritus paresthesia dysgeusia pain in,0
DOTAREM,hypertension,hypertension palpitations oropharyngeal,1
DOTAREM,hypertension,hypertension,1
DOTAREM,hypertension,creatinine increased and injection site reactions,0
DOTAREM,hypertension,discomfort serum creatinine increased and injection site reactions,0
DOTAREM,palpitations,vomiting,0
DOTAREM,palpitations,palpitations,1
DOTAREM,palpitations,creatinine increased,0
DOTAREM,palpitations,creatinine increased and injection site reactions including site,0
DOTAREM,palpitations,dizziness vomiting pruritus paresthesia dysgeusia pain,0
DOTAREM,oropharyngeal discomfort,oropharyngeal discomfort serum creatinine increased and injection,1
DOTAREM,serum creatinine increased,hypertension palpitations oropharyngeal serum creatinine increased and injection site,1
DOTAREM,serum creatinine increased,oropharyngeal discomfort serum creatinine increased and injection,1
DOTAREM,serum creatinine increased,extravasation,0
DOTAREM,serum creatinine increased,pruritus,0
DOTAREM,serum creatinine increased,pain,0
DOTAREM,injection site reactions,mity anxiety hypertension,0
DOTAREM,injection site reactions,including site inflammation extravasation pruritus,0
DOTAREM,injection site reactions,serum creatinine increased injection,1
DOTAREM,injection site reactions,oropharyngeal,0
DOTAREM,injection site reactions,palpitations oropharyngeal discomfort,0
DOTAREM,injection site reactions,creatinine increased injection site reactions including,1
DOTAREM,injection site reactions,palpitations oropharyngeal discomfort,0
DOTAREM,headache,reported adverse reaction headache,1
DOTAREM,headache,palpitations oropharyngeal discomfort,0
DOTAREM,headache,frequently reported adverse reaction headache,1
DOTAREM,headache,palpitations oropharyngeal discomfort,0
DOTAREM,headache,headache Most adverse events were mild,1
DOTAREM,headache,was,0
DOTAREM,headache,headache Most adverse events were mild,1
DOTAREM,headache,headache Most,1
DOTAREM,bradycardia,Cardiac,0
DOTAREM,bradycardia,action Cardiac bradycardia tachycardia,1
DOTAREM,bradycardia,Cardiac,0
DOTAREM,bradycardia,bradycardia tachycardia arrhythmia Immune,1
DOTAREM,bradycardia,bradycardia tachycardia arrhythmia,1
DOTAREM,bradycardia,Cardiac Disorders,0
DOTAREM,bradycardia,bradycardia tachycardia arrhythmia,1
DOTAREM,bradycardia,bradycardia tachycardia arrhythmia Immune,1
DOTAREM,bradycardia,bradycardia tachycardia arrhythmia,1
DOTAREM,bradycardia,System Disorders hype,0
DOTAREM,bradycardia,bradycardia tachycardia arrhythmia Immune System Disorders,1
DOTAREM,bradycardia,System Disorders hype,0
DOTAREM,tachycardia,tachycardia arrhythmia Immune System Disorders hypersensitivity,1
DOTAREM,tachycardia,Disorders tachycardia arrhythmia Immune System Disorders hypersensitivity,1
DOTAREM,tachycardia,tachycardia arrhythmia Immune System Disorders hypersensitivity,1
DOTAREM,tachycardia,Disorders tachycardia arrhythmia Immune System,1
DOTAREM,tachycardia,tachycardia arrhythmia Immune System Disorders hypersensitivity,1
DOTAREM,tachycardia,tachycardia arrhythmia Immune System Disorders,1
DOTAREM,tachycardia,Cardiac Disorders bradycardia,0
DOTAREM,tachycardia,Cardiac Disorders bradycardia,0
DOTAREM,tachycardia,System Disorders hypersensitivity,0
DOTAREM,arrhythmia,Disorders,0
DOTAREM,arrhythmia,arrhythmia,1
DOTAREM,arrhythmia,bradycardia,0
DOTAREM,hypersensitivity,arrest respiratory arrest cyanosis pharyngeal edema,0
DOTAREM,hypersensitivity,hypersensitivity anaphylactoid,1
DOTAREM,hypersensitivity,arrest respiratory arrest cyanosis pharyngeal edema,0
DOTAREM,hypersensitivity,hypersensitivity,1
DOTAREM,hypersensitivity,arrhythmia Immune System hypersensitivity anaphylactoid reactions including,1
DOTAREM,hypersensitivity,hypersensitivity,1
DOTAREM,anaphylactoid reactions,arrest cyanosis,0
DOTAREM,anaphylactoid reactions,anaphylactoid,1
DOTAREM,anaphylactoid reactions,arrest cyanosis pharyngeal,0
DOTAREM,anaphylactoid reactions,System Disorders anaphylactoid reactions including cardiac arrest respiratory,1
DOTAREM,anaphylactoid reactions,arrest cyanosis pharyngeal,0
DOTAREM,anaphylactoid reactions,hypersensitivity,0
DOTAREM,anaphylactoid reactions,anaphylactoid reactions including,1
DOTAREM,anaphylactoid reactions,arrhythmia Immune System Disorders anaphylactoid,1
DOTAREM,anaphylactoid reactions,pharyngeal edema laryngospasm,0
DOTAREM,anaphylactoid reactions,Immune System Disorders anaphylactoid reactions including cardiac,1
DOTAREM,anaphylactoid reactions,pharyngeal edema laryngospasm,0
DOTAREM,respiratory arrest,anaphylactoid reactions including cardiac respiratory arrest,1
DOTAREM,respiratory arrest,anaphylactoid reactions,0
DOTAREM,respiratory arrest,bronchospasm angioedema conjunctivitis ocular hyperemi,0
DOTAREM,respiratory arrest,Disorders hypersensitivity anaphylactoid reactions,0
DOTAREM,respiratory arrest,including cardiac respiratory arrest,1
DOTAREM,respiratory arrest,anaphylactoid,0
DOTAREM,cyanosis,cyanosis pharyngeal edema laryngospasm,1
DOTAREM,cyanosis,cyanosis,1
DOTAREM,cyanosis,bronchospasm angioedema conjunctivitis ocular hyperemia eyelid,0
DOTAREM,cyanosis,ocular hyperemia,0
DOTAREM,cyanosis,cyanosis,1
DOTAREM,cyanosis,cardiac arrest respiratory arrest,0
DOTAREM,pharyngeal edema,pharyngeal edema,1
DOTAREM,pharyngeal edema,pharyngeal edema laryngospasm bronchospasm angioedema conjunctivitis ocular,1
DOTAREM,pharyngeal edema,arrest cyanosis,0
DOTAREM,pharyngeal edema,arrest respiratory arrest pharyngeal,1
DOTAREM,pharyngeal edema,respiratory,0
DOTAREM,pharyngeal edema,hyperemia eyelid edema,0
DOTAREM,pharyngeal edema,reactions including cardiac,0
DOTAREM,pharyngeal edema,laryngospasm bronchospasm angioedema conjunctivitis ocular hyperemia eyelid edema,0
DOTAREM,pharyngeal edema,pharyngeal edema laryngospasm bronchospasm angioedema conjunctivitis,1
DOTAREM,pharyngeal edema,eyelid edema lacrimatio,0
DOTAREM,laryngospasm,cyanosis pharyngeal laryngospasm bronchospasm,1
DOTAREM,laryngospasm,eyelid edema lacrimatio,0
DOTAREM,laryngospasm,laryngospasm bronchospasm angioedema conjunctivitis ocular hyperemia,1
DOTAREM,laryngospasm,cyanosis pharyngeal laryngospasm bronchospasm,1
DOTAREM,laryngospasm,laryngospasm bronchospasm angioedema conjunctivitis ocular hyperemia,1
DOTAREM,laryngospasm,laryngospasm,1
DOTAREM,laryngospasm,eyelid edema lacrimation increased h,0
DOTAREM,bronchospasm,edema bronchospasm angioedema conjunctivitis,1
DOTAREM,bronchospasm,eyelid edema lacrimation increased h,0
DOTAREM,bronchospasm,edema bronchospasm angioedema conjunctivitis,1
DOTAREM,bronchospasm,eyelid edema lacrimation increased h,0
DOTAREM,bronchospasm,bronchospasm angioedema conjunctivitis ocular,1
DOTAREM,angioedema,angioedema,1
DOTAREM,conjunctivitis,pharyngeal edema laryngospasm bronchospasm conjunctivitis,1
DOTAREM,conjunctivitis,angioedema,1
DOTAREM,conjunctivitis,conjunctivitis,1
DOTAREM,conjunctivitis,laryngospasm bronchospasm conjunctivitis,1
DOTAREM,conjunctivitis,conjunctivitis,1
DOTAREM,conjunctivitis,diac arrest respiratory arrest cyanosis pharyngeal edema laryngospasm,0
DOTAREM,conjunctivitis,ocular hyperemia eyelid edema,0
DOTAREM,conjunctivitis,conjunctivitis ocular,1
DOTAREM,conjunctivitis,ocular hyperemia eyelid edema,0
DOTAREM,ocular hyperemia,bronchospasm angioedema ocular hyperemia eyelid edema lacrimation,1
DOTAREM,ocular hyperemia,ocular hyperemia eyelid edema,0
DOTAREM,ocular hyperemia,conjunctivitis,0
DOTAREM,ocular hyperemia,ocular hyperemia eyelid edema lacrimation increased,1
DOTAREM,ocular hyperemia,angioedema conjunctivitis,0
DOTAREM,ocular hyperemia,laryngospasm bronchospasm angioedema,0
DOTAREM,ocular hyperemia,edema laryngospasm bronchospasm,0
DOTAREM,ocular hyperemia,ocular hyperemia,1
DOTAREM,eyelid edema,Nervous,0
DOTAREM,eyelid edema,eyelid edema lacrimation increased hyperhidrosis urticaria,1
DOTAREM,lacrimation increased,coma convulsion syncope,0
DOTAREM,lacrimation increased,hyperemia eyelid lacrimation increased,1
DOTAREM,hyperhidrosis,coma convulsion syncope,0
DOTAREM,hyperhidrosis,hyperhidrosis urticaria Nervous System Disorders,1
DOTAREM,hyperhidrosis,lacrimation hyperhidrosis urticaria Nervous System Disorders coma,1
DOTAREM,hyperhidrosis,hyperhidrosis urticaria Nervous System Disorders,1
DOTAREM,hyperhidrosis,hyperhidrosis urticaria,1
DOTAREM,hyperhidrosis,coma,0
DOTAREM,urticaria,urticaria Nervous System,1
DOTAREM,urticaria,coma,0
DOTAREM,urticaria,System Disorders coma convulsion syncope presyncope,0
DOTAREM,urticaria,urticaria,1
DOTAREM,urticaria,urticaria Nervous,1
DOTAREM,coma,coma convulsion syncope presyncope parosmia,1
DOTAREM,coma,coma convulsion syncope,1
DOTAREM,coma,coma convulsion syncope presyncope parosmia tremor,1
DOTAREM,coma,coma convulsion syncope,1
DOTAREM,coma,urticaria Nervous System Disorders,0
DOTAREM,coma,coma convulsion syncope,1
DOTAREM,coma,parosmia tremor Musculoskeletal,0
DOTAREM,coma,coma convulsion syncope presyncope parosmia,1
DOTAREM,coma,System Disorders,0
DOTAREM,convulsion,convulsion syncope presyncope parosmia,1
DOTAREM,convulsion,convulsion syncope presyncope,1
DOTAREM,convulsion,urticaria Nervous System Disorders coma,0
DOTAREM,convulsion,increased hyperhidrosis urticaria,0
DOTAREM,convulsion,urticaria Nervous System Disorders convulsion syncope presyncope parosmia tremor,1
DOTAREM,convulsion,increased hyperhidrosis urticaria,0
DOTAREM,convulsion,presyncope parosmia tremor Musculoskeletal,0
DOTAREM,convulsion,Musculoskeletal and,0
DOTAREM,syncope,syncope presyncope parosmia,1
DOTAREM,syncope,Musculoskeletal and,0
DOTAREM,presyncope,Connective Tissue Disorders,0
DOTAREM,presyncope,Disorders,0
DOTAREM,presyncope,presyncope parosmia tremor Musculoskeletal,1
DOTAREM,parosmia,coma convulsion syncope,0
DOTAREM,parosmia,syncope presyncope,0
DOTAREM,parosmia,System Disorders coma convulsion syncope,0
DOTAREM,parosmia,Musculoskeletal and,0
DOTAREM,parosmia,muscle contracture,0
DOTAREM,parosmia,convulsion syncope parosmia tremor Musculoskeletal and Connective,1
DOTAREM,parosmia,muscle contracture,0
DOTAREM,parosmia,parosmia tremor Musculoskeletal,1
DOTAREM,parosmia,convulsion syncope parosmia,1
DOTAREM,parosmia,parosmia tremor Musculoskeletal,1
DOTAREM,tremor,tremor,1
DOTAREM,tremor,tremor Musculoskeletal and Connective Tissue Disorders,1
DOTAREM,tremor,Disorders coma,0
DOTAREM,tremor,convulsion syncope presyncope tremor Musculoskeletal,1
DOTAREM,tremor,Disorders coma,0
DOTAREM,tremor,and Connective,0
DOTAREM,tremor,Disorders muscle contracture muscle,0
DOTAREM,tremor,Disorders coma,0
DOTAREM,tremor,tremor Musculoskeletal and Connective Tissue,1
DOTAREM,tremor,Musculoskeletal and Connective Tissue Disorders,0
DOTAREM,tremor,coma convulsion syncope presyncope tremor Musculoskeletal and Connective,1
DOTAREM,tremor,Musculoskeletal and Connective Tissue Disorders,0
DOTAREM,muscle contracture,Tissue,0
DOTAREM,muscle contracture,muscle contracture muscle,1
DOTAREM,muscle contracture,Connective Tissue muscle contracture,1
DOTAREM,muscle contracture,weakness Gastrointestinal Disorders diarrhea s,0
DOTAREM,muscle contracture,and Connective Tissue muscle contracture muscle weakness Gastrointestinal Disorders diarrhea,1
DOTAREM,muscle contracture,weakness Gastrointestinal Disorders diarrhea s,0
DOTAREM,muscle contracture,muscle contracture,1
DOTAREM,muscle contracture,muscle contracture muscle weakness,1
DOTAREM,muscle contracture,muscle contracture,1
DOTAREM,muscle contracture,parosmia,0
DOTAREM,muscle weakness,Tissue Disorders muscle muscle,1
DOTAREM,muscle weakness,muscle weakness,1
DOTAREM,muscle weakness,Tissue Disorders muscle muscle,1
DOTAREM,muscle weakness,muscle muscle,1
DOTAREM,muscle weakness,Gastrointestinal Disorders,0
DOTAREM,muscle weakness,Tissue Disorders muscle muscle weakness Gastrointestinal,1
DOTAREM,muscle weakness,Gastrointestinal Disorders,0
DOTAREM,muscle weakness,muscle weakness Gastrointestinal Disorders,1
DOTAREM,salivary hypersecretion,and Administration Site Conditions,0
DOTAREM,salivary hypersecretion,Gastrointestinal Disorders diarrhea,0
DOTAREM,salivary hypersecretion,muscle weakness Gastrointestinal Disorders diarrhea,0
DOTAREM,salivary hypersecretion,Gastrointestinal Disorders salivary hypersecretion General Disorders and Administration Site,1
DOTAREM,salivary hypersecretion,muscle weakness Gastrointestinal Disorders diarrhea,0
DOTAREM,salivary hypersecretion,salivary,1
DOTAREM,malaise,Site Conditions,0
DOTAREM,malaise,malaise fever Skin and Subcutaneous Tissue,1
DOTAREM,malaise,malaise fever Skin and,1
DOTAREM,malaise,Administration Site,0
DOTAREM,malaise,Conditions,0
DOTAREM,malaise,Subcutaneous,0
DOTAREM,malaise,malaise fever Skin,1
DOTAREM,malaise,Subcutaneous,0
DOTAREM,malaise,malaise fever Skin,1
DOTAREM,malaise,malaise,1
DOTAREM,fever,fever Skin and Subcutaneous Tissue,1
DOTAREM,fever,fever Skin and Subcutaneous Tissue,1
DOTAREM,fever,fever Skin and Subcutaneous Tissue,1
DOTAREM,NSF,Tissue NSF in patients,1
DOTAREM,NSF,fever Skin and Subcutaneous Tissue,1
DOTAREM,NSF,Subcutaneous Tissue NSF,1
DOTAREM,NSF,fever Skin and Subcutaneous Tissue,1
DOTAREM,NSF,were confounded by the receipt of other GBCAs or in,0
DOTAREM,NSF,NSF,1
DOTAREM,NSF,NSF have been reported,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,GBC,0
DOTAREM,NSF,with a,0
DOTAREM,NSF,with ris k for,1
DOTAREM,NSF,with a,0
DOTAREM,NSF,have been associated with ris k for NSF see Warnings,1
DOTAREM,NSF,with a,0
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,has not been reported,0
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,e Warnings,1
DOTAREM,NSF,.1 ,1
DOTAREM,NSF,Warnings and .1 ,1
DOTAREM,NSF,.1 ,1
DOTAREM,NSF,of xpo sure to,1
DOTAREM,NSF,.1 ,1
DOTAREM,NSF,xpo sure to DOTAREM alone Hypersensitivity,1
DOTAREM,NSF,been reported in patients with,0
DOTAREM,NSF,DOTAREM alone Hypersensitivity reactions,0
DOTAREM,NSF,xpo sure to,1
DOTAREM,NSF,xpo sure to DOTAREM alone,1
DOTAREM,NSF,xpo sure,1
DOTAREM,NSF,xpo sure to DOTAREM alone,1
DOTAREM,NSF,are described in other,0
DOTAREM,NSF,EXCERPT,0
DOTAREM,NSF,Precautions and EXCERPT he  most frequent,1
DOTAREM,NSF,EXCERPT,0
DOTAREM,NSF,frequent adverse,0
DOTAREM,NSF,he  most frequent adverse,1
DOTAREM,NSF,he  most frequent adverse reactions,1
DOTAREM,NSF,in clinical studies,0
DOTAREM,NSF,see Warnings and,0
DOTAREM,NSF,he  most,1
DOTAREM,NSF,EXCERPT,0
DOTAREM,fatal,>= 0. adverse reactions in clinical,1
DOTAREM,fatal,Precautions,0
DOTAREM,fatal,EXCERPT The most >= 0. adverse reactions in,1
DOTAREM,fatal,Precautions,0
DOTAREM,fibrosis,and burning se,0
DOTAREM,fibrosis,and EXCERPT,0
DOTAREM,fibrosis,Precautions and,0
DOTAREM,NSF,clinical studies were nausea headache,0
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,where ethnicity was recorded,1
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,Black and,0
DOTAREM,NEPHROGENIC SYSTEMIC FIBROSIS,and pediatric patients Overall of,0
DOTAREM,NSF,he  ethnic distribution was Caucasian,1
DOTAREM,NSF,he  ethnic distribution was Caucasian Asian,1
DOTAREM,NSF,ethnicity was recorded,0
DOTAREM,NSF,years,0
DOTAREM,NSF,reaction,0
DOTAREM,NSF,immediately,0
DOTAREM,NSF,"to years l,  of patients reported at",1
DOTAREM,NSF,immediately,0
DOTAREM,NSF,and transient in Tab le lists adverse reactions that,1
DOTAREM,NSF,immediately,0
DOTAREM,NSF,Tab le lists,1
DOTAREM,NSF,patients who,0
DOTAREM,NSF,transient in Tab,1
DOTAREM,NSF,patients who,0
DOTAREM,NSF,Tab le lists,1
DOTAREM,Nephrogenic Systemic Fibrosis,REACTIONS GBCAs have been associated,0
DOTAREM,Nephrogenic Systemic Fibrosis,have been with a,1
DOTAREM,Nephrogenic Systemic Fibrosis,GBCAs have been with a risk for NSF [see War,1
DOTAREM,Nephrogenic Systemic Fibrosis,REACTIONS GBCAs have been,0
DOTAREM,Nephrogenic Systemic Fibrosis,REACTIONS GBCAs have been with a risk for NSF  [see War nings and,1
DOTAREM,Nephrogenic Systemic Fibrosis,REACTIONS GBCAs have been,0
DOTAREM,Nephrogenic Systemic Fibrosis,NSF [see War nings and Precautions,1
DOTAREM,Hypersensitivity,s and acute kidn ey,1
DOTAREM,Hypersensitivity,clear history of exposure to DOTAREM alone Hypersensitivity,0
DOTAREM,Hypersensitivity,the,0
DOTAREM,Hypersensitivity,Hypersensitivity s,1
DOTAREM,Hypersensitivity,to DOTAREM alone Hypersensitivity s and acute kidn ey injury are described in,1
DOTAREM,Hypersensitivity,Hypersensitivity s,1
DOTAREM,anaphylactic reactions,are scribed in,1
DOTAREM,anaphylactic reactions,injury are scribed,1
DOTAREM,anaphylactic reactions,labeling see Warnings and Precautions and,0
DOTAREM,anaphylactic reactions,other secti ons of,1
DOTAREM,anaphylactic reactions,history of exposure to DOTAREM alone Hypersensitivity reactions and acute kidney injury are,0
DOTAREM,death,st fr equent adverse reactions in clinical,1
DOTAREM,death,st fr,1
DOTAREM,death,st fr equent adverse,1
DOTAREM,death,Precautions and EXCERPT The st fr,1
DOTAREM,death,injection site,0
DOTAREM,death,Precautions and EXCERPT The st fr equent,1
DOTAREM,death,injection site,0
DOTAREM,death,st fr equent adverse reactions in clinical,1
DOTAREM,death,Warnings,0
DOTAREM,nephrogenic systemic fibrosis,ADVERSE REACTIONS contact GUERBET LLC at,0
DOTAREM,nephrogenic systemic fibrosis,at,0
DOTAREM,nephrogenic systemic fibrosis,wwwfdagovmedwatch Clinical Studies Experience Because clinical trials,0
DOTAREM,nephrogenic systemic fibrosis,trials are con,0
DOTAREM,nephrogenic systemic fibrosis,REACTIONS contact GUERBET LLC,0
DOTAREM,nephrogenic systemic fibrosis,GUERBET LLC 679 or,1
DOTAREM,nephrogenic systemic fibrosis,REACTIONS contact GUERBET LLC 679 or FDA at 1-800-FDA-1088  or wwwfdagovmedwatch Clinical Studies,1
DOTAREM,nephrogenic systemic fibrosis,GUERBET LLC 679 or,1
DOTAREM,NSF,SUSPECTED ADVERSE REACTIONS,0
DOTAREM,NSF,Because clinical,0
DOTAREM,NSF,at FDA  ww wfdagovmedwatch Clinical Studies,1
DOTAREM,NSF,Because clinical,0
DOTAREM,NSF, ww wfdagovmedwatch,1
DOTAREM,NSF, ww wfdagovmedwatch,1
DOTAREM,NSF, ww wfdagovmedwatch Clinical Studies Experience,1
DOTAREM,NSF,wfdagovmedwatch Clinical Studies Experience Because,0
DOTAREM,NSF,asian Asian,0
DOTAREM,NSF,auc asian Asian Black and,1
DOTAREM,NSF,auc asian Asian,1
DOTAREM,NSF,distribution was auc asian Asian Black,1
DOTAREM,NSF,auc asian Asian,1
DOTAREM,NSF,the ethnic distribution was auc asian,1
DOTAREM,NSF,auc asian Asian,1
DOTAREM,NSF,others The,0
DOTAREM,NSF,ethnic distribution was,0
DOTAREM,NSF,others The,0
DOTAREM,NSF,auc asian Asian Black,1
DOTAREM,fatal,"n, 4% Black and",1
DOTAREM,fatal,"distribution was Caucasian n, 4% Black and others The average",1
DOTAREM,fatal,"n, 4% Black and",1
DOTAREM,fatal,others,0
DOTAREM,fatal,range from,0
DOTAREM,fatal,others The average age was years range from to,0
DOTAREM,fatal,others The average age was years range from to years Overall,0
DOTAREM,fatal,was recorded the,0
DOTAREM,fatal,"n, 4% Black and",1
DOTAREM,fatal,"Caucasian n,",1
DOTAREM,fatal,average,0
DOTAREM,fibrosis,ere,0
DOTAREM,fibrosis,to years Overall of patients,0
DOTAREM,fibrosis,thers. T,1
DOTAREM,anaphylactoid reactions,received DOTAREM Overall pediatric patients re,0
DOTAREM,anaphylactoid reactions,"aged 2 - 5 years, aged years and aged",1
DOTAREM,anaphylactoid reactions,"pediatric patients aged s, 33 aged 2 - 5 years, aged years and aged",1
DOTAREM,anaphylactoid reactions,"aged 2 - 5 years, aged years and aged",1
DOTAREM,anaphylactoid reactions,"trials pediatric patients aged s, 33 aged 2 - 5 years, aged",1
DOTAREM,anaphylactoid reactions,"aged 2 - 5 years, aged years and aged",1
DOTAREM,anaphylactoid reactions,"patients aged s, 33 aged 2 - 5 years, aged years and",1
DOTAREM,anaphylactoid reactions,"aged 2 - 5 years, aged years and aged",1
DOTAREM,anaphylactoid reactions,"s, 33 aged 2 - 5 years, aged years and",1
DOTAREM,anaphylactoid reactions,"aged 2 - 5 years, aged years and aged",1
DOTAREM,anaphylactoid reactions,During,0
DOTAREM,anaphylactoid reactions,pediatric patients,0
DOTAREM,anaphylactoid reactions,"patients aged s, 33 aged 2",1
DOTAREM,circulatory collapse,tion following DOTAR EM administration The,1
DOTAREM,circulatory collapse,adverse tion following DOTAR EM administration The most,1
DOTAREM,circulatory collapse,tion following DOTAR EM administration The,1
DOTAREM,circulatory collapse,EM administration The most frequently reported adverse,0
DOTAREM,circulatory collapse,one adverse tion following DOTAR,1
DOTAREM,circulatory collapse,EM administration The most frequently reported adverse,0
DOTAREM,circulatory collapse,Most adverse e,0
DOTAREM,died,pediatric patients reported at least one adverse reaction,0
DOTAREM,died,Overall pediatric patients reported at least one adverse reaction,0
DOTAREM,died,mini stration The most frequently,1
DOTAREM,died,Overall pediatric patients reported at least one adverse reaction,0
DOTAREM,died,mini,1
DOTAREM,hypersensitivity reaction,reactions are ted voluntarily,1
DOTAREM,hypersensitivity reaction,possible to reliably estimate their frequency or,0
DOTAREM,hypersensitivity reaction,reactions are ted voluntarily from a po pulation of uncertain size it,1
DOTAREM,hypersensitivity reaction,possible to reliably estimate their frequency or,0
DOTAREM,hypersensitivity reaction,a po pulation of uncertain size it,1
DOTAREM,hypersensitivity reaction,eactions have been identified during postmarketing use of DOTAREM Because these reactions are repor,0
DOTAREM,hypersensitivity reaction,are repor,0
DOTAREM,acute kidney injury,bradycardia,0
DOTAREM,acute kidney injury,diac Disorders bradycardia tachycardia Immune System D,1
DOTAREM,acute kidney injury,isorders hypersensitivity anaphylactoid reactions including,0
DOTAREM,acute kidney injury,System D,1
DOTAREM,acute kidney injury,Immune System D,1
NESINA,headache,headache and,1
NESINA,headache,in,0
NESINA,pancreatitis,in of patients receiving,0
NESINA,pancreatitis,NESINA,0
NESINA,pancreatitis,trial,0
NESINA,pancreatitis,pancreatitis was reported,1
NESINA,pancreatitis,pancreatitis was reported in of,1
NESINA,pancreatitis,the clinical,0
NESINA,pancreatitis,pancreatitis was reported in,1
NESINA,pancreatitis,the clinical,0
NESINA,pancreatitis,to five of,0
NESINA,hypersensitivity reactions,compared to with all comparators A single event of serum,0
NESINA,hypersensitivity reactions,the overall incidence hypersensitivity reactions,1
NESINA,serum sickness,event serum sickness,1
NESINA,serum sickness,serum,1
NESINA,serum sickness,mg Hypoglycemia,0
NESINA,serum sickness,serum sickness was,1
NESINA,serum sickness,serum sickness was reported in,1
NESINA,serum sickness,serum sickness was,1
NESINA,serum sickness,A single event serum sickness was reported in,1
NESINA,serum sickness,serum sickness was,1
NESINA,serum sickness,single event serum sickness,1
NESINA,serum sickness,serum sickness was,1
NESINA,Hypoglycemic events,treated with NESINA mg Hypoglycemic events were documented based,1
NESINA,Hypoglycemic events,serum sickness was,1
NESINA,Hypoglycemic events,a blood,0
NESINA,Hypoglycemic events,with NESINA mg Hypoglycemic events,1
NESINA,Hypoglycemic events,mg Hypoglycemic events were documented based upon a,1
NESINA,Hypoglycemic events,with NESINA mg Hypoglycemic events,1
NESINA,Hypoglycemic events,treated with NESINA mg Hypoglycemic events were documented based upon a,1
NESINA,Hypoglycemic events,with NESINA mg Hypoglycemic events,1
NESINA,Hypoglycemic events,symptoms of,0
NESINA,Hypoglycemic events,Hypoglycemic events were documented based upon a,1
NESINA,Hypoglycemic events,were documented based upon a blood glucose value andor clinical signs,0
NESINA,Hypoglycemic events,Hypoglycemic events were documented based upon a,1
NESINA,Hypoglycemic events,were documented based upon a blood glucose value andor clinical signs,0
NESINA,Hypoglycemic events,with NESINA mg Hypoglycemic events,1
NESINA,hypoglycemia,hypoglycemia In the monotherapy,1
NESINA,hypoglycemia,hypoglycemia In the,1
NESINA,hypoglycemia,hypoglycemia In the monotherapy study,1
NESINA,hypoglycemia,hypoglycemia In the monotherapy,1
NESINA,hypoglycemia,hypoglycemia,0
NESINA,hypoglycemia,hypoglycemia In the,1
NESINA,hypoglycemia,hypoglycemia In the,1
NESINA,hypoglycemia,hypoglycemia In,1
NESINA,hypoglycemia,hypoglycemia was in,1
NESINA,hypoglycemia,the monotherapy study the incidence,0
NESINA,hypoglycemia,hypoglycemia was in,1
NESINA,hypoglycemia,in elderly patients,0
NESINA,hypoglycemia,hypoglycemia compared to placebo In,1
NESINA,hypoglycemia,hypoglycemia compared to placebo In,1
NESINA,hypoglycemia,as addon therapy to glyburide or insulin did not increase the,0
NESINA,hypoglycemia,increase the incidence,0
NESINA,hypoglycemia,patients the incidence,0
NESINA,hypoglycemia,monotherapy study comparing NESINA,0
NESINA,hypoglycemia,hypoglycemia was with NESINA compared to,1
NESINA,hypoglycemia,with glipizide Table,0
NESINA,Hypoglycemia,and,0
NESINA,Hypoglycemia,NESINA compared to with glipizide Table Table,0
NESINA,Hypoglycemia,compared to with glipizide,0
NESINA,Hypoglycemia,Hypoglycemia Adverse reactions of,1
NESINA,Hypoglycemia,compared to with glipizide,0
NESINA,Hypoglycemia,Hypoglycemia Adverse reactions of hypoglycemia,1
NESINA,Hypoglycemia,Hypoglycemia Adverse reactions of hypoglycemia were,1
NESINA,Hypoglycemia,Hypoglycemia Adverse reactions of,1
NESINA,Hypoglycemia,Hypoglycemia Adverse reactions of hypoglycemia were,1
NESINA,Hypoglycemia,Hypoglycemia Adverse reactions of hypoglycemia were,1
NESINA,hypoglycemia,Rate of HypoglycemiaAdverse reactions hypoglycemia were,1
NESINA,hypoglycemia,Hypoglycemia Adverse reactions of hypoglycemia were,1
NESINA,hypoglycemia,hypoglycemia were,1
NESINA,hypoglycemia,hypoglycemia were,1
NESINA,hypoglycemia,hypoglycemia were based on,1
NESINA,hypoglycemia,hypoglycemia a concurrent,1
NESINA,hypoglycemia,symptomatic and hypoglycemia a concurrent glucose measurement,1
NESINA,hypoglycemia,hypoglycemia a concurrent,1
NESINA,hypoglycemia,symptomatic and hypoglycemia a concurrent glucose measurement was,1
NESINA,hypoglycemia,hypoglycemia a concurrent,1
NESINA,hypoglycemia,and,0
NESINA,hypoglycemia,intenttotreat population in Placebo and,0
NESINA,hypoglycemia,events requiring medical assistance or exhibiting,0
NESINA,hypoglycemia,hypoglycemia were,1
NESINA,hypoglycemia,medical,0
NESINA,hypoglycemia,Severe events hypoglycemia,1
NESINA,hypoglycemia,medical,0
NESINA,hypoglycemia,hypoglycemia were defined as those events,1
NESINA,changes in vital signs,observed in patients treated with NESINA Laboratory,0
NESINA,changes in vital signs,changes in vital signs or in,1
NESINA,changes in vital signs,observed in patients treated with NESINA Laboratory,0
NESINA,changes in vital signs,Signs No,0
NESINA,changes in vital signs,Signs No clinically changes in,1
NESINA,changes in vital signs,Vital Signs No clinically meaningful,0
NESINA,changes in vital signs,observed in patients treated with NESINA,0
NESINA,changes in vital signs,changes in vital signs or in,1
NESINA,changes in vital signs,observed in patients treated with NESINA,0
NESINA,Hypersensitivity reactions,Hypersensitivity reactions including,1
NESINA,Hypersensitivity reactions,adverse reactions,0
NESINA,anaphylaxis,including StevensJohnson synd,0
NESINA,anaphylaxis,anaphylaxis angioedema rash,1
NESINA,anaphylaxis,including StevensJohnson synd,0
NESINA,anaphylaxis,or establish,0
NESINA,anaphylaxis,anaphylaxis,1
NESINA,anaphylaxis,or establish,0
NESINA,anaphylaxis,anaphylaxis angioedema rash urticaria,1
NESINA,anaphylaxis,anaphylaxis,1
NESINA,angioedema,rash urticaria and severe cutaneous adverse reactions including StevensJohnson syndrome,0
NESINA,angioedema,angioedema,1
NESINA,angioedema,including StevensJohnson,0
NESINA,angioedema,exposure Hypersensitivity reactions including angioedema rash urticaria and,1
NESINA,angioedema,including StevensJohnson,0
NESINA,angioedema,rash urticaria and severe cutaneous adverse reactions,0
NESINA,angioedema,exposure Hypersensitivity reactions including angioedema rash urticaria,1
NESINA,angioedema,rash urticaria and severe cutaneous adverse reactions,0
NESINA,urticaria,urticaria and severe,1
NESINA,urticaria,urticaria and severe cutaneous adverse reactions,1
NESINA,cutaneous adverse reactions,cutaneous adverse reactions including StevensJohnson syndrome,1
NESINA,cutaneous adverse reactions,StevensJohnson syndrome hepatic enzyme elevations fulminant hepatic failure severe,0
NESINA,cutaneous adverse reactions,angioedema rash urticaria and cutaneous adverse reactions including StevensJohnson syndrome hepatic enzyme,1
NESINA,cutaneous adverse reactions,StevensJohnson syndrome hepatic enzyme elevations fulminant hepatic failure severe,0
NESINA,cutaneous adverse reactions,osure Hypersensitivity reactions including anaphylaxis angioedema,0
NESINA,cutaneous adverse reactions,urticaria and cutaneous adverse reactions including StevensJohnson syndrome hepatic enzyme,1
NESINA,cutaneous adverse reactions,osure Hypersensitivity reactions including anaphylaxis angioedema,0
NESINA,cutaneous adverse reactions,adverse reactions including StevensJohnson syndrome hepatic,1
NESINA,cutaneous adverse reactions,and cutaneous,1
NESINA,cutaneous adverse reactions,enzyme,0
NESINA,cutaneous adverse reactions,syndrome hepatic enzyme,0
NESINA,hepatic enzyme elevations,StevensJohnson hepatic enzyme elevations,1
NESINA,hepatic enzyme elevations,StevensJohnson hepatic enzyme elevations fulminant hepatic failure,1
NESINA,hepatic enzyme elevations,StevensJohnson hepatic enzyme elevations,1
NESINA,hepatic enzyme elevations,acute pancreatitis,0
NESINA,hepatic enzyme elevations,hepatic enzyme elevations fulminant hepatic failure severe and,1
NESINA,hepatic enzyme elevations,acute pancreatitis,0
NESINA,fulminant hepatic failure,fulminant hepatic failure severe,1
NESINA,fulminant hepatic failure,fulminant hepatic failure severe and disabling arthralgia,1
NESINA,fulminant hepatic failure,syndrome hepatic enzyme,0
NESINA,fulminant hepatic failure,StevensJohnson syndrome hepatic enzyme fulminant hepatic,1
NESINA,fulminant hepatic failure,StevensJohnson syndrome hepatic enzyme fulminant hepatic,1
NESINA,arthralgia,enzyme elevations fulminant hepatic failure,0
NESINA,arthralgia,acute pancreatitis see Warnings and,0
NESINA,arthralgia,arthralgia,1
NESINA,arthralgia,arthralgia,1
NESINA,acute pancreatitis,hepatic enzyme elevations fulminant hepatic failure severe and disabling arthralgia,0
NESINA,acute pancreatitis,see,0
NESINA,acute pancreatitis,see,0
NESINA,acute pancreatitis,acute pancreatitis see Warnings and Precautions,1
NESINA,acute pancreatitis,enzyme elevations fulminant hepatic,0
NESINA,acute pancreatitis,acute pancreatitis,1
NESINA,Acute pancreatitis,of patients treated with NESINA mg and more frequently than in patients who received,0
NESINA,Acute pancreatitis,patients treated with NESINA mg and more frequently than in patients,0
NESINA,Acute pancreatitis,reactions (report,1
NESINA,Acute pancreatitis,reactions (report ed in of patients treated,1
NESINA,Acute pancreatitis,Common reactions (report,1
NESINA,Acute pancreatitis,ADVERSE REACTIONS EXCERPT Common  reactions (report ed in,1
NESINA,Acute pancreatitis,Common reactions (report,1
NESINA,Acute pancreatitis,EXCERPT Common  reactions (report ed in of patients,1
NESINA,Acute pancreatitis,Common reactions (report,1
NESINA,Acute pancreatitis,Common reactions (report,1
NESINA,acute pancreatitis,adverse reactions reported in,0
NESINA,acute pancreatitis,25 mg and more fre,1
NESINA,acute pancreatitis,adverse reactions reported in,0
NESINA,acute pancreatitis,and more fre quently than,1
NESINA,acute pancreatitis,patients treated with 25 mg and more fre quently,1
NESINA,acute pancreatitis,and more fre quently than,1
NESINA,acute pancreatitis,patients treated with 25 mg and more fre quently than in,1
NESINA,acute pancreatitis,and more fre quently than,1
NESINA,acute pancreatitis,received placebo,0
NESINA,acute pancreatitis,patients treated with 25 mg and more fre quently than in patients,1
NESINA,acute pancreatitis,received placebo,0
NESINA,Hypersensitivity,upper re,1
NESINA,Hypersensitivity,REACTIONS contact Takeda P,0
NESINA,hypersensitivity reactions,ort SUSPECTED ADVERSE REAC TIONS contact Takeda Pharmaceuticals,1
NESINA,hypersensitivity reactions,ort SUSPECTED ADVERSE REAC,1
NESINA,hypersensitivity reactions,infection To ort SUSPECTED ADVERSE REAC TIONS,1
NESINA,hypersensitivity reactions,ort SUSPECTED ADVERSE REAC,1
NESINA,hypersensitivity reactions,SUSPECTED ADVERSE REAC,1
NESINA,hypersensitivity reactions,infection,0
NESINA,hypersensitivity reactions,infection To ort SUSPECTED,1
NESINA,hypersensitivity reactions,To ort SUSPECTED ADVERSE,1
NESINA,hypersensitivity reactions,upper respiratory tract infection To,0
NESINA,hypersensitivity reactions,upper respiratory tract,0
NESINA,anaphylaxis,contact Takeda Pharmaceuticals 1-877-TAKED A,1
NESINA,anaphylaxis,upper respiratory tract,0
NESINA,anaphylaxis,FDA or,0
NESINA,anaphylaxis,at FDA or wwwfdagovmedwatch,0
NESINA,anaphylaxis,1-877-TAKED A,1
NESINA,anaphylaxis,FDA or wwwfdagovmedwatch,0
NESINA,anaphylaxis,REACTIONS contact Takeda Pharmaceuticals at,0
NESINA,anaphylaxis,at FDA,0
NESINA,anaphylaxis,or wwwfdagovmedwatch Clini,0
NESINA,anaphylaxis,1-877-TAKED A,1
NESINA,angioedema,SUSPECTED ADVERSE REACTIONS contact,0
NESINA,angioedema,7 (1-877-8,1
NESINA,cutaneous adverse reactions,FDA at 1-800-FDA-1088 or ww wfdagovmedwatch Clinical Studies Experience,1
NESINA,cutaneous adverse reactions,7 (1-877-8,1
NESINA,cutaneous adverse reactions,or ww wfdagovmedwatch Clinical Studies,1
NESINA,cutaneous adverse reactions,at 1-800-FDA-1088 or ww wfdagovmedwatch Clinical,1
NESINA,cutaneous adverse reactions,FDA at 1-800-FDA-1088 or,1
NESINA,Hepatic effects,cal trials of a drug cannot be directly compared,1
NESINA,Hepatic effects,observed in the cal trials of a drug cannot be directly,1
NESINA,Hepatic effects,cal trials of a drug cannot be directly compared,1
NESINA,Hepatic effects,observed in the cal trials of a drug cannot be directly,1
NESINA,Hepatic effects,cal trials of a drug cannot be directly compared,1
NESINA,Hepatic effects,trials of a drug,1
NESINA,Hepatic effects,cal trials,1
NESINA,Hepatic effects,in,0
NESINA,hepatic failure,directly mpared to rates in the clinical trials,1
NESINA,hepatic failure,in,0
NESINA,hepatic failure,trials,0
NESINA,hepatic failure,not reflect the rates,0
NESINA,hepatic failure,drug cannot be directly mpared,1
NESINA,hepatic failure,and may not reflect the rates observed in clinical,0
NESINA,hepatic failure,drug,0
NESINA,fatal,ical  trials,1
NESINA,fatal,ical  trials,1
NESINA,fatal,ical  trials of another,1
NESINA,fatal,ical  trials of another drug,1
NESINA,fatal,ical ,1
NESINA,fatal,ical  trials,1
NESINA,fatal,rates in the ical  trials of,1
NESINA,fatal,ical  trials,1
NESINA,fatal,the ical  trials of another,1
NESINA,fatal,ical  trials,1
NESINA,fatal,ical  trials of,1
NESINA,arthralgia,"farction,  had a history of unstable",1
NESINA,arthralgia,"farction,  had a history of unstable",1
NESINA,arthralgia,"farction, ",1
NESINA,arthralgia,had a,0
NESINA,acute pancreatitis,placebocontrolled addon combination therapy,0
NESINA,hypersensitivity reactions,metformin therapy ee active-controlled trial s of weeks in,1
NESINA,hypersensitivity reactions,placebocontrolled addon combination therapy,0
NESINA,hypersensitivity reactions,ee active-controlled trial s of weeks in,1
NESINA,hypersensitivity reactions,s of,0
NESINA,hypersensitivity reactions,background of metformin therapy ee active-controlled trial s of,1
NESINA,hypersensitivity reactions,s of,0
NESINA,hypersensitivity reactions,therapy ee active-controlled,1
NESINA,hypersensitivity reactions,ee active-controlled trial s of weeks in duration,1
NESINA,angioedema,itazone an d,1
NESINA,angioedema,itazone an d metformin in combination,1
NESINA,angioedema,treated with itazone an d metformin,1
NESINA,angioedema,itazone an d metformin in combination,1
NESINA,angioedema,in patients treated with itazone an d metformin in combination,1
NESINA,angioedema,itazone an d metformin in combination,1
NESINA,cutaneous adverse reactions,pooled analysis of,0
NESINA,cutaneous adverse reactions,treated with pioglitazone and  in combination with metfor min and as monotherapy,1
NESINA,cutaneous adverse reactions,pooled analysis of,0
NESINA,cutaneous adverse reactions,in patients,0
NESINA,cutaneous adverse reactions,treated with pioglitazone and  in combination with metfor min and as monotherapy compared,1
NESINA,cutaneous adverse reactions,in patients,0
NESINA,Stevens-Johnson syndrome,metformin and as onotherapy compared to g lipizide,1
NESINA,Stevens-Johnson syndrome,in patients,0
NESINA,Stevens-Johnson syndrome,with metformin and as onotherapy compared to g lipizide In,1
NESINA,Stevens-Johnson syndrome,in patients,0
NESINA,Stevens-Johnson syndrome,and as onotherapy compared,1
NESINA,Stevens-Johnson syndrome,onotherapy,1
NESINA,Stevens-Johnson syndrome,combination with metformin and,0
NESINA,Stevens-Johnson syndrome,onotherapy compared to g lipizide In a,1
NESINA,Stevens-Johnson syndrome,pioglitazone and metformin in combination with,0
NESINA,Stevens-Johnson syndrome,as onotherapy compared,1
NESINA,fatal,of patients treated with NESINA mg and,0
NESINA,fatal,treated with NESINA mg more  frequently than in patients,1
NESINA,fatal,of patients treated with NESINA mg and,0
NESINA,fatal,more  frequently than in,1
NESINA,hepatic failure,frequently n in patients w ho received placebo are summarized,1
NESINA,hepatic failure,more  frequently than in,1
NESINA,hepatic failure,in patients w ho,1
NESINA,hepatic failure,frequently n in patients w ho received,1
NESINA,hepatic failure,in patients w ho,1
NESINA,hepatic failure,and more frequently n in,1
NESINA,hepatic failure,frequently n in patients w ho received,1
NESINA,hepatic failure,and more frequently n in,1
NESINA,hepatic failure,Adverse reactions reported,0
NESINA,hepatic failure,n in patients w ho received placebo are,1
NESINA,hepatic failure,Adverse reactions reported,0
NESINA,hepatic failure,n in patients w ho received placebo are summarized,1
NESINA,hepatic failure,more frequently tha,0
NESINA,hepatic failure,summarized in Table Table Adverse Reactions Reported,0
NESINA,hepatic failure,mg and more frequently,0
NESINA,arthralgia,y comparin,1
NESINA,arthralgia,did not increase the,0
NESINA,arthralgia,placebo In a monotherapy y,1
NESINA,arthralgia,NESINA to a sulfonylurea in elderly patients the incidence of hypoglycemia was with NESINA c,0
NESINA,arthralgia,sulfonylurea in elderly patients the,0
NESINA,arthralgia,a monotherapy y comparin g NESINA to a,1
NESINA,arthralgia,sulfonylurea in elderly patients the,0
NESINA,arthralgia,y comparin,1
NESINA,arthralgia,monotherapy y comparin g NESINA to,1
NESINA,arthralgia,y comparin,1
NESINA,arthralgia,y comparin g,1
NESINA,arthralgia,compared to placebo,0
EYLEA,Endophthalmitis,intraocular pressure,0
EYLEA,Endophthalmitis,Endophthalmitis and retinal detachments Increased intraocular,1
EYLEA,Endophthalmitis,Endophthalmitis,1
EYLEA,retinal detachments,retinal detachments,1
EYLEA,retinal detachments,Endophthalmitis,1
EYLEA,retinal detachments,retinal detachments Increased intraocular pressure,1
EYLEA,retinal detachments,the labeling Endophthalmitis retinal detachments,1
EYLEA,retinal detachments,section of the labeling,0
EYLEA,retinal detachments,retinal detachments Increased intraocular pressure Thromboembolic,1
EYLEA,retinal detachments,retinal detachments Increased intraocular,1
EYLEA,retinal detachments,of the labeling Endophthalmitis retinal detachments,1
EYLEA,retinal detachments,retinal detachments Increased intraocular,1
EYLEA,retinal detachments,the labeling Endophthalmitis,0
EYLEA,retinal detachments,intraocular pressure Thromboembolic,0
EYLEA,Increased intraocular pressure,and retinal Increased,1
EYLEA,Increased intraocular pressure,Endophthalmitis and retinal Increased intraocular pressure Thromboembolic,1
EYLEA,Increased intraocular pressure,and retinal Increased,1
EYLEA,Thromboembolic events,detachments Increased intraocular Thromboembolic,1
EYLEA,conjunctival hemorrhage,receiving EYLEA conjunctival hemorrhage eye pain cataract vitreous floaters,1
EYLEA,conjunctival hemorrhage,detachments Increased intraocular Thromboembolic,1
EYLEA,conjunctival hemorrhage,receiving EYLEA conjunctival hemorrhage eye,1
EYLEA,conjunctival hemorrhage,detachments Increased intraocular Thromboembolic,1
EYLEA,eye pain,conjunctival eye pain cataract,1
EYLEA,eye pain,detachments Increased intraocular Thromboembolic,1
EYLEA,eye pain,eye pain cataract vitreous,1
EYLEA,eye pain,reported in patients receiving EYLEA were conjunctival hemorrhage,0
EYLEA,eye pain,reactions reported in,0
EYLEA,eye pain,eye pain cataract vitreous,1
EYLEA,eye pain,eye pain cataract vitreous floaters,1
EYLEA,eye pain,eye pain cataract vitreous,1
EYLEA,cataract,cataract vitreous floaters intraocular pressure,1
EYLEA,cataract,receiving EYLEA,0
EYLEA,cataract,increased and vitreous,0
EYLEA,cataract,pain,0
EYLEA,cataract,cataract,1
EYLEA,cataract,cataract vitreous floaters,1
EYLEA,cataract,vitreous detachment To report,0
EYLEA,cataract,verse reactions reported in patients,0
EYLEA,intraocular pressure increased,vitreous intraocular pressure increased and vitreous detachment,1
EYLEA,intraocular pressure increased,verse reactions reported in patients,0
EYLEA,intraocular pressure increased,eye pain cataract vitreous intraocular pressure increased,1
EYLEA,intraocular pressure increased,verse reactions reported in patients,0
EYLEA,vitreous detachment,increased vitreous detachment,1
EYLEA,vitreous detachment,REACTIONS,0
EYLEA,vitreous detachment,intraocular pressure increased vitreous,1
EYLEA,vitreous detachment,conjunctival hemorrhage,0
EYLEA,vitreous detachment,vitreous detachment To report SUSPECTED,1
EYLEA,vitreous detachment,vitreous detachment To report SUSPECTED ADVERSE REACTIONS,1
EYLEA,vitreous detachment,report SUSPECTED ADVERSE REACTIONS contact Regeneron at or,0
EYLEA,vitreous detachment,report SUSPECTED ADVERSE REACTIONS contact,0
EYLEA,vitreous detachment,increased,0
EYLEA,endophthalmitis,endophthalmitis and retinal,1
EYLEA,endophthalmitis,adverse reactions,0
EYLEA,retinal detachment,retinal detachment The most common adverse,1
EYLEA,retinal detachment,in of intravitreal,0
EYLEA,retinal detachment,including endophthalmitis retinal detachment The most,1
EYLEA,retinal detachment,in of intravitreal,0
EYLEA,conjunctival hemorrhage,EYLEA conjunctival hemorrhage,1
EYLEA,conjunctival hemorrhage,conjunctival hemorrhage eye pain,1
EYLEA,conjunctival hemorrhage,EYLEA conjunctival hemorrhage,1
EYLEA,conjunctival hemorrhage,The most common adverse reactions reported in patients receiving EYLEA,0
EYLEA,conjunctival hemorrhage,conjunctival,1
EYLEA,conjunctival hemorrhage,intraocular pressure,0
EYLEA,conjunctival hemorrhage,receiving EYLEA conjunctival,1
EYLEA,conjunctival hemorrhage,receiving EYLEA conjunctival hemorrhage,1
EYLEA,eye pain,reported in patients receiving EYLEA were,0
EYLEA,eye pain,eye pain cataract vitreous floaters intraocular pressure,1
EYLEA,eye pain,EYLEA were conjunctival eye pain,1
EYLEA,eye pain,eye pain,1
EYLEA,eye pain,receiving EYLEA were conjunctival eye pain cataract vitreous floaters intraocular,1
EYLEA,eye pain,eye pain,1
EYLEA,eye pain,conjunctival eye pain,1
EYLEA,eye pain,eye pain,1
EYLEA,cataract,cataract vitreous floaters intraocular pressure increased,1
EYLEA,cataract,intraocular pressure increased,0
EYLEA,cataract,cataract vitreous floaters intraocular pressure,1
EYLEA,cataract,cataract,1
EYLEA,vitreous floaters,pain vitreous,1
EYLEA,vitreous floaters,in patients,0
EYLEA,vitreous floaters,EYLEA were conjunctival hemorrhage eye pain,0
EYLEA,vitreous floaters,conjunctival hemorrhage eye pain vitreous floaters,1
EYLEA,vitreous floaters,and,0
EYLEA,vitreous floaters,Wet AgeRelated Mac,0
EYLEA,vitreous floaters,cataract,0
EYLEA,vitreous floaters,pain vitreous floaters intraocular pressure increased,1
EYLEA,vitreous floaters,cataract,0
EYLEA,intraocular pressure increased,vitreous intraocular pressure increased and,1
EYLEA,intraocular pressure increased,cataract,0
EYLEA,intraocular pressure increased,Neovascular Wet AgeRelated Macular Degeneration,0
EYLEA,intraocular pressure increased,Neovascular Wet AgeRelated Macular Degeneration,0
EYLEA,intraocular pressure increased,cataract vitreous intraocular pressure increased and vitreous,1
EYLEA,intraocular pressure increased,Neovascular Wet AgeRelated Macular Degeneration,0
EYLEA,intraocular pressure increased,pressure increased,1
EYLEA,intraocular pressure increased,vitreous,0
EYLEA,intraocular pressure increased,pressure increased and vitreous,1
EYLEA,intraocular pressure increased,intraocular pressure,1
EYLEA,intraocular pressure increased,floaters,0
EYLEA,intraocular pressure increased,cataract vitreous,0
EYLEA,vitreous detachment,intraocular pressure increased vitreous,1
EYLEA,vitreous detachment,vitreous detachment Neovascular Wet AgeRelated,1
EYLEA,vitreous detachment,described below,0
EYLEA,Conjunctival hemorrhage,Active Control Conjunctival hemorrhage Eye,1
EYLEA,Conjunctival hemorrhage,described below,0
EYLEA,Conjunctival hemorrhage,Conjunctival hemorrhage,1
EYLEA,Conjunctival hemorrhage,Conjunctival hemorrhage Eye,1
EYLEA,Conjunctival hemorrhage,Conjunctival hemorrhage,1
EYLEA,Conjunctival hemorrhage,EYLEAN Active Control Conjunctival hemorrhage,1
EYLEA,Conjunctival hemorrhage,Active Control Conjunctival hemorrhage Eye pain,1
EYLEA,Conjunctival hemorrhage,EYLEAN Active Control Conjunctival hemorrhage,1
EYLEA,Detachment of the retinal pigment epithelium,pithelium,0
EYLEA,Detachment of the retinal pigment epithelium,Detachment of,1
EYLEA,Detachment of the retinal pigment epithelium,retinal pigment epithelium Injection,1
EYLEA,Detachment of the retinal pigment epithelium,the retinal pigment epithelium Injection,1
EYLEA,Detachment of the retinal pigment epithelium,Detachment of,1
EYLEA,Detachment of the retinal pigment epithelium,retinal pigment epithelium Injection site pain,1
EYLEA,Detachment of the retinal pigment epithelium,the retinal pigment epithelium Injection,1
EYLEA,Detachment of the retinal pigment epithelium,pithelium Detachment of the retinal pigment epithelium Injection site,1
EYLEA,Detachment of the retinal pigment epithelium,the retinal pigment epithelium Injection,1
EYLEA,Detachment of the retinal pigment epithelium,Injection site,0
EYLEA,Detachment of the retinal pigment epithelium,Detachment of the retinal pigment epithelium Injection,1
EYLEA,Detachment of the retinal pigment epithelium,Injection site,0
EYLEA,Injection site pain,site pain Foreign,1
EYLEA,Injection site pain,epithelium,0
EYLEA,Injection site pain,retinal pigment Injection site pain,1
EYLEA,Injection site pain,epithelium,0
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in eyes,1
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in,1
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in eyes,1
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in,1
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in eyes Lacrimation,1
EYLEA,Foreign body sensation in eyes,site Foreign body sensation in,1
EYLEA,Lacrimation increased,in Lacrimation increased Vision,1
EYLEA,Lacrimation increased,site Foreign body sensation in,1
EYLEA,Lacrimation increased,in Lacrimation,1
EYLEA,Lacrimation increased,in Lacrimation increased Vision,1
EYLEA,Lacrimation increased,in Lacrimation,1
EYLEA,Lacrimation increased,ody sensation in Lacrimation increased,1
EYLEA,Lacrimation increased,Lacrimation increased Vision blurr,1
EYLEA,Lacrimation increased,ody sensation in Lacrimation increased,1
EYLEA,Lacrimation increased,Lacrimation increased Vision,1
EYLEA,Retinal pigment epithelium tear,Injection site hemorrh,0
EYLEA,Retinal pigment epithelium tear,ar Retinal pigment epithelium tear Injection site,1
EYLEA,Retinal pigment epithelium tear,Injection site hemorrh,0
EYLEA,Retinal pigment epithelium tear,inflammation,0
EYLEA,Retinal pigment epithelium tear,ar,0
EYLEA,Retinal pigment epithelium tear,ar,0
EYLEA,Retinal pigment epithelium tear,Retinal pigment epithelium tear,1
EYLEA,Retinal pigment epithelium tear,inflammation,0
EYLEA,Retinal pigment epithelium tear,epithelium tear,1
EYLEA,Retinal pigment epithelium tear,epithelium tear Injection site hemorrh,1
EYLEA,Injection site hemorrhage,igment epithelium Injection site hemorrhage Eyelid,1
EYLEA,Injection site hemorrhage,epithelium tear Injection site hemorrh,1
EYLEA,Injection site hemorrhage,igment epithelium tear,0
EYLEA,Injection site hemorrhage,Injection site hemorrhage Eyelid edema,1
EYLEA,hypersensitivity,Macular Edema Following Retinal,0
EYLEA,hypersensitivity,serious adverse reactions reported in of,0
EYLEA,hypersensitivity,and endophthalmitis Macular Edema Following Retinal,0
EYLEA,hypersensitivity,hypersensitivity retinal detachment retinal,1
EYLEA,hypersensitivity,hypersensitivity retinal detachment retinal tear,1
EYLEA,hypersensitivity,hypersensitivity,1
EYLEA,hypersensitivity,endophthalmitis Macular Edema Following Retinal Vei,0
EYLEA,hypersensitivity,hypersensitivity retinal detachment retinal,1
EYLEA,hypersensitivity,endophthalmitis Macular Edema Following Retinal Vei,0
EYLEA,hypersensitivity,reactions reported in of the,0
EYLEA,hypersensitivity,hypersensitivity retinal detachment,1
EYLEA,hypersensitivity,reactions reported in of the,0
EYLEA,retinal detachment,Retinal Vein Occlusion RVO,0
EYLEA,retinal detachment,endophthalmitis Macular Edema Following Retinal,0
EYLEA,retinal detachment,retinal detachment retinal tear and endophthalmitis Macular,1
EYLEA,retinal detachment,endophthalmitis Macular Edema Following Retinal,0
EYLEA,retinal tear,retinal retinal,1
EYLEA,retinal tear,hypersensitivity retinal detachment,0
EYLEA,retinal tear,EYLEA were hypersensitivity retinal retinal,1
EYLEA,retinal tear,retinal,0
EYLEA,retinal tear,EYLEA were hypersensitivity retinal retinal,1
EYLEA,endophthalmitis,endophthalmitis Macular Edema Following Retinal,1
EYLEA,endophthalmitis,Vein Occlusion RVO The data,0
EYLEA,endophthalmitis,endophthalmitis Macular,1
EYLEA,endophthalmitis,RVO The data described below,0
EYLEA,endophthalmitis,EYLEA,0
EYLEA,Corneal epithelium defect,ressure increased,0
EYLEA,Corneal epithelium defect,epithelium defect Vitreous flo,1
EYLEA,Corneal epithelium defect,increased,0
EYLEA,Corneal epithelium defect,Corneal epithelium defect,1
EYLEA,Corneal epithelium defect,increased,0
EYLEA,Corneal epithelium defect,Corneal epithelium defect Vitreous flo,1
EYLEA,Corneal epithelium defect,increased,0
EYLEA,corneal edema,corneal edema retinal tear,1
EYLEA,corneal edema,CRVO studies corneal,1
EYLEA,corneal edema,corneal edema retinal tear hypersensitivity and endophthalmitis,1
EYLEA,corneal edema,corneal edema retinal tear hypersensitivity and,1
EYLEA,corneal edema,with,0
EYLEA,corneal edema,studies corneal edema,1
EYLEA,corneal edema,studies corneal,1
EYLEA,corneal edema,Diabetic,0
EYLEA,retinal tear,corneal retinal tear hypersensitivity,1
EYLEA,retinal tear,Diabetic,0
EYLEA,retinal tear,the CRVO,0
EYLEA,retinal tear,studies were corneal retinal tear hypersensitivity and endophthalmitis,1
EYLEA,retinal tear,the CRVO,0
EYLEA,retinal tear,retinal tear hypersensitivity and,1
EYLEA,retinal tear,the CRVO,0
EYLEA,retinal tear,retinal tear hypersensitivity,1
EYLEA,retinal tear,retinal tear,1
EYLEA,retinal tear,retinal tear hypersensitivity,1
EYLEA,retinal tear,studies were corneal retinal tear hypersensitivity and,1
EYLEA,retinal tear,retinal tear hypersensitivity,1
EYLEA,retinal tear,CRVO studies,0
EYLEA,hypersensitivity,hypersensitivity and endophthalmitis Diabetic Macular,1
EYLEA,hypersensitivity,CRVO studies,0
EYLEA,hypersensitivity,hypersensitivity and,1
EYLEA,hypersensitivity,The,0
EYLEA,hypersensitivity,hypersensitivity and,1
EYLEA,hypersensitivity,were corneal edema retinal hypersensitivity and endophthalmitis Diabetic,1
EYLEA,hypersensitivity,hypersensitivity and,1
EYLEA,hypersensitivity,were corneal edema retinal hypersensitivity,1
EYLEA,hypersensitivity,hypersensitivity and,1
EYLEA,hypersensitivity,edema retinal hypersensitivity,1
EYLEA,hypersensitivity,hypersensitivity and,1
EYLEA,hypersensitivity,below reflect e,0
EYLEA,hypersensitivity,hypersensitivity and endophthalmitis Diabetic,1
EYLEA,hypersensitivity,Diabetic Macular Edema,0
EYLEA,endophthalmitis,treated with EYLEA in the,0
EYLEA,endophthalmitis,studies were corneal,0
EYLEA,endophthalmitis,endophthalmitis,1
EYLEA,endophthalmitis,endophthalmitis Diabetic Macular Edema DME The,1
EYLEA,endophthalmitis,in,0
EYLEA,endophthalmitis,Diabetic Macular,0
EYLEA,endophthalmitis,endophthalmitis Diabetic Macular Edema DME,1
EYLEA,endophthalmitis,hypersensitivity endophthalmitis Diabetic Macular Edema DME The,1
EYLEA,endophthalmitis,endophthalmitis Diabetic Macular Edema DME,1
EYLEA,endophthalmitis,and,0
EYLEA,Conjunctival hemorrhage,Conjunctival hemorrhage Eye pain,1
EYLEA,Conjunctival hemorrhage,ControlN,0
EYLEA,Conjunctival hemorrhage,EYLEAN ControlN EYLEAN Conjunctival,1
EYLEA,Intraocular pressure increased,Intraocular pressure increased,1
EYLEA,Intraocular pressure increased,Intraocular pressure increased Ocular hyperemia,1
EYLEA,Intraocular pressure increased,Intraocular pressure increased,1
EYLEA,Intraocular pressure increased,Intraocular pressure increased,1
EYLEA,Intraocular pressure increased,Intraocular pressure increased,1
EYLEA,Lacrimation increased,Lacrimation increased Vision,1
EYLEA,Lacrimation increased,sensation,0
EYLEA,Lacrimation increased,in Lacrimation,1
EYLEA,Lacrimation increased,Lacrimation increased Vision b,1
EYLEA,Lacrimation increased,Lacrimation increased Vision b,1
EYLEA,Lacrimation increased,in Lacrimation increased,1
EYLEA,Lacrimation increased,Lacrimation increased Vision b,1
EYLEA,Lacrimation increased,Lacrimation increased Vision b,1
EYLEA,Lacrimation increased,Lacrimation increased Vision b,1
EYLEA,hypersensitivity,hypersensitivity retinal detachment retinal tear,1
EYLEA,retinal detachment,retinal tear corneal edema and injection site hemorrhage Immunogenicity As with al,0
EYLEA,retinal detachment,were retinal detachment retinal,1
EYLEA,retinal detachment,retinal tear corneal edema and injection site hemorrhage Immunogenicity As with al,0
EYLEA,retinal detachment,As with al,0
EYLEA,retinal detachment,retinal detachment retinal,1
EYLEA,retinal detachment,were retinal detachment,1
EYLEA,retinal detachment,were retinal detachment retinal tear corneal,1
EYLEA,retinal detachment,were retinal detachment,1
EYLEA,retinal detachment,treated with EYLEA were retinal detachment retinal tear corneal edema and,1
EYLEA,retinal detachment,were retinal detachment,1
EYLEA,retinal tear,injection site hemorrhage Immunogenicity As with all,0
EYLEA,retinal tear,hypersensitivity retinal retinal tear corneal edema and injection site,1
EYLEA,retinal tear,injection site hemorrhage Immunogenicity As with all,0
EYLEA,retinal tear,corneal edema and injection site hemorrhage Immunogenicity,0
EYLEA,retinal tear,EYLEA were hypersensitivity retinal,0
EYLEA,retinal tear,EYLEA were hypersensitivity retinal,0
EYLEA,retinal tear,retinal retinal,1
EYLEA,corneal edema,corneal edema and,1
EYLEA,corneal edema,treated with EYLEA were hypersensitivity,0
EYLEA,injection site hemorrhage,and,0
EYLEA,injection site hemorrhage,injection site hemorrhage,1
EYLEA,injection site hemorrhage,injection site hemorrhage Immunogenicity As with all therapeutic,1
EYLEA,injection site hemorrhage,therapeutic proteins there is a,0
EYLEA,injection site hemorrhage,with all therapeutic proteins there is,0
EYLEA,injection site hemorrhage,proteins there is a potential for an,0
EYLEA,injection site hemorrhage,retinal tear corneal edema injection site hemorrhage Immunogenicity As,1
EYLEA,injection site hemorrhage,proteins there is a potential for an,0
EYLEA,Endophthalmitis,adverse eactions,1
EYLEA,Endophthalmitis,are di scussed in greater detail in,1
EYLEA,Endophthalmitis,scussed in greater detail in the Warnings and Precautions section of,0
EYLEA,Endophthalmitis,are di scussed in greater,1
EYLEA,Endophthalmitis,ADVERSE REACTIONS The following adverse r,0
EYLEA,Endophthalmitis,The following adverse eactions are,1
EYLEA,retinal detachments,in greater detai l in the,1
EYLEA,retinal detachments,are ed in greater,1
EYLEA,retinal detachments,The following adverse reactions are discuss,0
EYLEA,retinal detachments,are ed in greater,1
EYLEA,retinal detachments,reactions are ed in,1
EYLEA,retinal detachments,in the Warnings and Precautions section of the labeling,0
EYLEA,Increases in intraocular pressure,EXCERPT The most common rse reactions,1
EYLEA,Increases in intraocular pressure,common rse reactions (>=5%),1
EYLEA,Increases in intraocular pressure,most common rse reactions (>=5%) reported in  patients receiving EYLEA,1
EYLEA,Increases in intraocular pressure,common rse reactions (>=5%),1
EYLEA,arterial thromboembolic events,pain cataract vitreous,0
EYLEA,arterial thromboembolic events,and vitr eous,1
EYLEA,arterial thromboembolic events,"pain cataract vitreous floaters r pressure increased,",1
EYLEA,arterial thromboembolic events,ADVERSE REACTIONS contact Regeneron,0
EYLEA,arterial thromboembolic events,pain cataract vitreous floaters r pressure,1
EYLEA,endophthalmitis,wwwfdagovmedwatch Clinical Trials,0
EYLEA,endophthalmitis,"Clinical Trials perience

  Bec ause",1
EYLEA,endophthalmitis,wwwfdagovmedwatch Clinical Trials,0
EYLEA,endophthalmitis,Trials perience Bec,1
EYLEA,endophthalmitis,"or wwwfdagovmedwatch Clinical Trials perience

  Bec ause clinical trials",1
EYLEA,endophthalmitis,Trials perience Bec,1
EYLEA,endophthalmitis,"Trials perience

  Bec ause clinical trials are conducted",1
EYLEA,endophthalmitis,Trials perience Bec,1
EYLEA,endophthalmitis,or wwwfdagovmedwatch Clinical Trials perience Bec,1
EYLEA,endophthalmitis,perience Bec ause clinical trials,1
EYLEA,endophthalmitis,"Clinical Trials perience

  Bec ause clinical trials",1
EYLEA,endophthalmitis,perience Bec ause clinical trials,1
EYLEA,endophthalmitis,wwwfdagovmedwatch Clinical Trials perience Bec,1
EYLEA,retinal detachments,trials are conducted under widely varying conditions,1
EYLEA,retinal detachments,in the clinical trials o,0
EYLEA,Acute increases in intraocular pressure,patients were d with the recommended dose of 2 mg. Se rious adverse reactions related to,1
EYLEA,Acute increases in intraocular pressure,in the clinical trials o,0
EYLEA,Acute increases in intraocular pressure,Among those patients were d with,1
EYLEA,Acute increases in intraocular pressure,recommended dose of 2 mg. Se rious,1
EYLEA,Acute increases in intraocular pressure,dose of 2 mg. Se rious,1
EYLEA,Acute increases in intraocular pressure,2 mg. Se rious adverse reactions related,1
EYLEA,Sustained increases in intraocular pressure,of intravitreal injections with LEA including endophthalmitis and retinal d etachment,1
EYLEA,Sustained increases in intraocular pressure,2 mg. Se rious adverse reactions related,1
EYLEA,Sustained increases in intraocular pressure,procedure have occurred,0
EYLEA,Sustained increases in intraocular pressure,adverse reactions reported in patients receiving EYLEA were conjun,0
EYLEA,Sustained increases in intraocular pressure,adverse reactions reported,0
EYLEA,arterial thromboembolic events,with wet AMD including patients treated with,1
EYLEA,arterial thromboembolic events,The data described below reflect exposure to EYLEA,0
EYLEA,arterial thromboembolic events,in 1824 patients,1
EYLEA,arterial thromboembolic events,Wet AgeRelated Macular Degeneration AMD The data described below reflect exposure,0
EYLEA,arterial thromboembolic events,below reflect exposure to in,1
EYLEA,arterial thromboembolic events,to in 1824 patients with,1
EYLEA,arterial thromboembolic events,reflect exposure to  in 1824 patients with wet AMD including patients treated with,1
EYLEA,arterial thromboembolic events,to in 1824 patients with,1
EYLEA,arterial thromboembolic events,Degeneration AMD,0
EYLEA,arterial thromboembolic events,The,0
EYLEA,ATEs,incl uding,1
EYLEA,ATEs,incl uding patients treated with the,1
EYLEA,ATEs,with wet incl uding patients,1
EYLEA,ATEs,incl uding patients treated with the,1
EYLEA,thromboembolic events,Reactions,0
EYLEA,thromboembolic events,Vitreous detachment,0
EYLEA,thromboembolic events,                      Vitreous floaters,1
EYLEA,thromboembolic events,Vitreous detachment,0
EYLEA,thromboembolic events,detachment,0
EYLEA,thromboembolic events,Vitreous                      ,1
EYLEA,thromboembolic events,detachment,0
EYLEA,thromboembolic events,                     ,1
EYLEA,thromboembolic events,Vitreous                      ,1
EYLEA,thromboembolic events,                     ,1
EYLEA,thromboembolic events,                      Vitreous,1
TECFIDERA,Anaphylaxis,Progressive,0
TECFIDERA,Anaphylaxis,described elsewhere in Anaphylaxis and Angioedema see,1
TECFIDERA,Anaphylaxis,Progressive,0
TECFIDERA,Anaphylaxis,Anaphylaxis,1
TECFIDERA,Anaphylaxis,Anaphylaxis and Angioedema see Warnings,1
TECFIDERA,Anaphylaxis,in labeling,0
TECFIDERA,Progressive multifocal leukoencephalopathy,Warnings and Precautions Lymphopenia see Warnings and,0
TECFIDERA,Progressive multifocal leukoencephalopathy,see Warnings and Progressive,1
TECFIDERA,Progressive multifocal leukoencephalopathy,and,0
TECFIDERA,Progressive multifocal leukoencephalopathy,Warnings,0
TECFIDERA,Lymphopenia,Lymphopenia see,1
TECFIDERA,Lymphopenia,Lymphopenia see Warnings,1
TECFIDERA,Lymphopenia,leukoencephalopathy see Warnings and Lymphopenia see,1
TECFIDERA,Lymphopenia,Lymphopenia see Warnings,1
TECFIDERA,Lymphopenia,and,0
TECFIDERA,Flushing,Flushing see Warnings,1
TECFIDERA,Flushing,Lymphopenia see Warnings,0
TECFIDERA,Flushing,Flushing see Warnings and Precautions EXCERPT,1
TECFIDERA,Flushing,Flushing,1
TECFIDERA,flushing,diarrhea and nausea To report,0
TECFIDERA,flushing,common,0
TECFIDERA,flushing,flushing abdominal pain diarrhea,1
TECFIDERA,flushing,flushing abdominal pain,1
TECFIDERA,flushing,flushing abdominal pain diarrhea,1
TECFIDERA,abdominal pain,report,0
TECFIDERA,abdominal pain,abdominal pain diarrhea and nausea,1
TECFIDERA,abdominal pain,report,0
TECFIDERA,diarrhea,abdominal diarrhea and nausea To report,1
TECFIDERA,diarrhea,report,0
TECFIDERA,diarrhea,To report SUSPECTED ADVERSE,0
TECFIDERA,diarrhea,and placebo were flushing,0
TECFIDERA,diarrhea,diarrhea,1
TECFIDERA,diarrhea,diarrhea and,1
TECFIDERA,diarrhea,diarrhea,1
TECFIDERA,nausea,nausea,1
TECFIDERA,nausea,contact Biogen,0
TECFIDERA,nausea,nausea To report,1
TECFIDERA,nausea,nausea,1
TECFIDERA,nausea,nausea To report SUSPECTED,1
TECFIDERA,flushing,flushing abdominal pain diarrhea and nausea,1
TECFIDERA,flushing,pain diarrhea and,0
TECFIDERA,flushing,flushing abdominal pain diarrhea and,1
TECFIDERA,flushing,diarrhea and nausea Adverse Reactions in PlaceboControlled,0
TECFIDERA,flushing,for TECFIDERA flushing,1
TECFIDERA,flushing,diarrhea and nausea Adverse Reactions in PlaceboControlled,0
TECFIDERA,flushing,flushing,1
TECFIDERA,flushing,flushing abdominal,1
TECFIDERA,flushing,flushing,1
TECFIDERA,flushing,and more than placebo,0
TECFIDERA,flushing,diarrhea and nausea Adverse Reactions,0
TECFIDERA,abdominal pain,were abdominal pain diarrhea and nausea Adverse Reactions,1
TECFIDERA,abdominal pain,diarrhea and nausea Adverse Reactions,0
TECFIDERA,diarrhea,diarrhea and nausea,1
TECFIDERA,diarrhea,in PlaceboControlled Trials,0
TECFIDERA,nausea,diarrhea nausea Adverse Reactions in PlaceboControlled Trials,1
TECFIDERA,nausea,in PlaceboControlled Trials,0
TECFIDERA,GI events,Gastrointestinal TECFIDERA GI events,1
TECFIDERA,GI events,TECFIDERA caused,0
TECFIDERA,GI events,TECFIDERA GI,1
TECFIDERA,GI events,TECFIDERA GI events,1
TECFIDERA,GI events,TECFIDERA GI events,1
TECFIDERA,nausea,nausea vomiting diarrhea abdominal pain and,1
TECFIDERA,nausea,nausea,1
TECFIDERA,nausea,The incidence,0
TECFIDERA,nausea,caused,0
TECFIDERA,nausea,eg,0
TECFIDERA,nausea,events nausea vomiting diarrhea abdominal pain and,1
TECFIDERA,nausea,eg,0
TECFIDERA,nausea,TECFIDERA caused GI events,0
TECFIDERA,vomiting,vomiting diarrhea abdominal pain and dyspepsia,1
TECFIDERA,vomiting,higher early in,0
TECFIDERA,vomiting,events was higher,0
TECFIDERA,vomiting,vomiting diarrhea abdominal pain and dyspepsia,1
TECFIDERA,vomiting,vomiting diarrhea abdominal pain,1
TECFIDERA,vomiting,vomiting diarrhea abdominal,1
TECFIDERA,vomiting,events eg vomiting diarrhea,1
TECFIDERA,vomiting,vomiting diarrhea abdominal,1
TECFIDERA,vomiting,abdominal,0
TECFIDERA,vomiting,higher,0
TECFIDERA,vomiting,vomiting diarrhea abdominal,1
TECFIDERA,diarrhea,diarrhea abdominal pain and dyspepsia The,1
TECFIDERA,abdominal pain,and dyspepsia The incidence of,0
TECFIDERA,abdominal pain,abdominal pain and dyspepsia The incidence of,1
TECFIDERA,abdominal pain,abdominal pain and,1
TECFIDERA,abdominal pain,abdominal pain,1
TECFIDERA,abdominal pain,abdominal pain and,1
TECFIDERA,abdominal pain,caused GI events eg nausea vomiting,0
TECFIDERA,abdominal pain,vomiting abdominal pain and dyspepsia,1
TECFIDERA,abdominal pain,caused GI events eg nausea vomiting,0
TECFIDERA,abdominal pain,vomiting abdominal pain,1
TECFIDERA,abdominal pain,dyspepsia The incidence of GI events was higher early in the course,0
TECFIDERA,dyspepsia,events was higher early in the,0
TECFIDERA,dyspepsia,pain,0
TECFIDERA,dyspepsia,pain dyspepsia The incidence of GI,1
TECFIDERA,dyspepsia,pain,0
TECFIDERA,dyspepsia,diarrhea abdominal,0
TECFIDERA,dyspepsia,incidence of GI events was higher early in the course of treatment primarily in month,0
TECFIDERA,dyspepsia,events was higher early in the,0
TECFIDERA,dyspepsia,pain dyspepsia The incidence of GI,1
TECFIDERA,dyspepsia,events was higher early in the,0
TECFIDERA,dyspepsia,dyspepsia The incidence of GI events,1
TECFIDERA,dyspepsia,abdominal pain dyspepsia The incidence of,1
TECFIDERA,dyspepsia,dyspepsia The incidence of GI events,1
TECFIDERA,GI events,dyspepsia The incidence GI events,1
TECFIDERA,GI events,GI,1
TECFIDERA,GI events,diarrhea abdominal pain and dyspepsia The incidence,0
TECFIDERA,GI events,The incidence,0
TECFIDERA,GI events,GI events was,1
TECFIDERA,GI events,incidence GI,1
TECFIDERA,GI events,primarily in month and usually decreased,0
TECFIDERA,GI events,early in the course of treatment,0
TECFIDERA,GI events,of,0
TECFIDERA,gastrointestinal events,patients discontinued due gastrointestinal events,1
TECFIDERA,gastrointestinal events,of,0
TECFIDERA,gastrointestinal events,placebo patients discontinued due gastrointestinal events The incidence of,1
TECFIDERA,gastrointestinal events,of,0
TECFIDERA,gastrointestinal events,TECFIDERA Hepatic,0
TECFIDERA,gastrointestinal events,placebo,0
TECFIDERA,gastrointestinal events,was,0
TECFIDERA,gastrointestinal events,incidence of serious GI events was in,0
TECFIDERA,gastrointestinal events,discontinued due gastrointestinal,1
TECFIDERA,gastrointestinal events,due gastrointestinal,1
TECFIDERA,gastrointestinal events,of placebo patients discontinued due,0
TECFIDERA,gastrointestinal events,gastrointestinal events,1
TECFIDERA,GI events,in,0
TECFIDERA,GI events,patients treated with,0
TECFIDERA,GI events,was in patients,0
TECFIDERA,GI events,to gastrointestinal events The incidence of,0
TECFIDERA,GI events,in patients treated with TECFIDERA Hepatic Transaminases An increased inciden,0
TECFIDERA,Elevations of alanine aminotransferase,to times the ULN occurred in,0
TECFIDERA,Elevations of alanine aminotransferase,ULN,0
TECFIDERA,Elevations of alanine aminotransferase,Elevations of alanine aminotransferase,1
TECFIDERA,Elevations of alanine aminotransferase,upper limit of normal Elevations of alanine aminotransferase and aspartate aminotransferase,1
TECFIDERA,Elevations of alanine aminotransferase,Elevations of alanine aminotransferase,1
TECFIDERA,Elevations of alanine aminotransferase,normal Elevations of alanine aminotransferase and aspartate,1
TECFIDERA,Elevations of alanine aminotransferase,Elevations of alanine aminotransferase,1
TECFIDERA,Elevations of alanine aminotransferase,small,0
TECFIDERA,Elevations of alanine aminotransferase,upper limit of,0
TECFIDERA,Elevations of alanine aminotransferase,ULN occurred in a,0
TECFIDERA,elevations in transaminases,elevations in transaminases,1
TECFIDERA,elevations in transaminases,There were elevations in transaminases,1
TECFIDERA,elevations in transaminases,were elevations,1
TECFIDERA,elevations in transaminases,elevations in transaminases times the ULN,1
TECFIDERA,elevations in transaminases,in total bilirubin,0
TECFIDERA,elevations in transaminases,were elevations in transaminases,1
TECFIDERA,elevations in transaminases,in total bilirubin,0
TECFIDERA,elevations in transaminases,and,0
TECFIDERA,elevations in transaminases,groups There were elevations in,1
TECFIDERA,elevations in transaminases,elevations in transaminases times the,1
TECFIDERA,elevations in transaminases,elevations in transaminases,1
TECFIDERA,elevations in total bilirubin,elevations in,0
TECFIDERA,elevations in total bilirubin,the,0
TECFIDERA,elevations in total bilirubin,elevations in total bilirubin times the,1
TECFIDERA,elevations in total bilirubin,total bilirubin times,1
TECFIDERA,elevations in total bilirubin,elevations,1
TECFIDERA,elevations in total bilirubin,total bilirubin times the ULN Discontinuations due,1
TECFIDERA,elevations in total bilirubin,in total bilirubin,1
TECFIDERA,elevations in total bilirubin,ULN with elevations in total bilirubin,1
TECFIDERA,elevations in total bilirubin,in total bilirubin,1
TECFIDERA,elevations in total bilirubin,hepatic transaminases were and were simila,0
TECFIDERA,elevated hepatic transaminases,Discontinuations due elevated hepatic transaminases,1
TECFIDERA,elevated hepatic transaminases,elevated hepatic transaminases were and,1
TECFIDERA,elevated hepatic transaminases,elevated hepatic transaminases,1
TECFIDERA,increase in mean eosinophil counts,in patients treated with TECFIDERA or placebo Eosinophilia A transient,0
TECFIDERA,increase in mean eosinophil counts,or placebo Eosinophilia A increase in mean eosinophil counts was seen,1
TECFIDERA,increase in mean eosinophil counts,in patients treated with TECFIDERA or placebo Eosinophilia A transient,0
TECFIDERA,increase in mean eosinophil counts,TECFIDERA,0
TECFIDERA,increase in mean eosinophil counts,increase in mean,1
TECFIDERA,increase in mean eosinophil counts,A increase,1
TECFIDERA,increase in mean eosinophil counts,A increase in mean eosinophil counts was,1
TECFIDERA,increase in mean eosinophil counts,A increase,1
TECFIDERA,increase in mean eosinophil counts,or placebo Eosinophilia A increase in mean eosinophil counts was seen during the,1
TECFIDERA,increase in mean eosinophil counts,A increase,1
TECFIDERA,Anaphylaxis,described elsewhere in labeling Anaphylaxis and Angioedema see Warnings,0
TECFIDERA,Anaphylaxis,important dverse reac,1
TECFIDERA,Anaphylaxis,important dverse,1
TECFIDERA,Anaphylaxis,dverse reac,1
TECFIDERA,Anaphylaxis,important dverse,1
TECFIDERA,angioedema,Angioedema,0
TECFIDERA,angioedema,see Warnings,0
TECFIDERA,angioedema,important adverse are,1
TECFIDERA,angioedema,adverse  are descr ibed,1
TECFIDERA,angioedema,important adverse are,1
TECFIDERA,angioedema,adverse,0
TECFIDERA,Progressive multifocal leukoencephalopathy,ssive multifocal leukoencephalopathy see,0
TECFIDERA,Progressive multifocal leukoencephalopathy,and Angioedema,0
TECFIDERA,Progressive multifocal leukoencephalopathy,and Precautions ( 5.1 )]. * Progre ssive multifocal,1
TECFIDERA,Progressive multifocal leukoencephalopathy,"Angioedema see s and Precautions (  5.1  )].  
 *  Progre ssive",1
TECFIDERA,Progressive multifocal leukoencephalopathy,and Precautions ( 5.1 )]. * Progre ssive multifocal,1
TECFIDERA,Progressive multifocal leukoencephalopathy,Precautions,0
TECFIDERA,Progressive multifocal leukoencephalopathy,leukoencephalopathy,0
TECFIDERA,Progressive multifocal leukoencephalopathy,labeling Anaphylaxis and Angioedema see Warning,0
TECFIDERA,Progressive multifocal leukoencephalopathy,dverse,0
TECFIDERA,Progressive multifocal leukoencephalopathy,and Angioedema see,0
TECFIDERA,Progressive multifocal leukoencephalopathy,described elsewhere in labeling Anaphylaxis and Angioedema see Warning,0
TECFIDERA,PML,see,0
TECFIDERA,PML,ive multifocal,1
TECFIDERA,Lymphopenia,Lymph,0
TECFIDERA,Lymphopenia,Precautions Flushing,0
TECFIDERA,Lymphopenia,Precautions openia [see,1
TECFIDERA,Lymphopenia,Warnings and,0
TECFIDERA,Lymphopenia,Warnings and Precautions openia [see Warnings and,1
TECFIDERA,Lymphopenia,Warnings and,0
TECFIDERA,Lymphopenia,Precautions Flushing,0
TECFIDERA,Lymphopenia,openia [see Warnings and,1
TECFIDERA,Lymphopenia,openia [see Warnings and Precautions Flushing,1
TECFIDERA,Lymphopenia,and Precautions,0
TECFIDERA,Lymphopenia,Flushing,0
TECFIDERA,angioedema,Biogen at or FDA -800-FDA-1 or wwwfdagovmedwatch Clinical Trials Experience,1
TECFIDERA,angioedema,Flushing,0
TECFIDERA,angioedema,-800-FDA-1,1
TECFIDERA,angioedema,Experience Because clinical,0
TECFIDERA,angioedema,-800-FDA-1 or wwwfdagovmedwatch Clinical Trials Experience,1
TECFIDERA,angioedema,at or FDA -800-FDA-1 or wwwfdagovmedwatch Clinical,1
TECFIDERA,angioedema,-800-FDA-1 or wwwfdagovmedwatch Clinical Trials Experience,1
TECFIDERA,angioedema,Because clinical trials,0
TECFIDERA,angioedema,Clinical Trials Experience Because clinical,0
TECFIDERA,angioedema,-800-FDA-1 or wwwfdagovmedwatch Clinical,1
TECFIDERA,angioedema,clinical,0
TECFIDERA,angioedema,-800-FDA-1,1
TECFIDERA,difficulty breathing,rates observed,0
TECFIDERA,difficulty breathing,or wwwfdagovmedwatch Clinical Trials,0
TECFIDERA,difficulty breathing,varying conditions adverse,0
TECFIDERA,difficulty breathing,l trials are conduct ed,1
TECFIDERA,difficulty breathing,Because l trials are conduct ed under widely varying conditions,1
TECFIDERA,difficulty breathing,l trials are conduct ed,1
TECFIDERA,difficulty breathing,Experience Because clinica,0
TECFIDERA,difficulty breathing,rates observed,0
TECFIDERA,difficulty breathing,Because clinica,0
TECFIDERA,difficulty breathing,l trials are conduct ed under widely,1
TECFIDERA,swelling of the throat,"arying conditions, adv",1
TECFIDERA,swelling of the throat,"under widely arying conditions,",1
TECFIDERA,swelling of the throat,"arying conditions, adv erse reaction rates observed",1
TECFIDERA,swelling of the throat,Because,0
TECFIDERA,swelling of the throat,cannot be directly,0
TECFIDERA,swelling of the throat,"arying conditions, adv erse",1
TECFIDERA,swelling of the throat,"under widely arying conditions, adv erse reaction rates observed in",1
TECFIDERA,swelling of the throat,"arying conditions, adv erse",1
TECFIDERA,swelling of the throat,"widely arying conditions, adv",1
TECFIDERA,swelling of the throat,"arying conditions, adv erse",1
TECFIDERA,fatal,than placebo for TECFIDERA were,0
TECFIDERA,fatal,ence  and,1
TECFIDERA,fatal,ence  and more than,1
TECFIDERA,progressive multifocal leukoencephalopathy,in PlaceboControlled Tr,0
TECFIDERA,progressive multifocal leukoencephalopathy,reactions incidence and,0
TECFIDERA,progressive multifocal leukoencephalopathy,than placebo) for TECFIDERA wer e flushing abdominal pain,1
TECFIDERA,progressive multifocal leukoencephalopathy,more than placebo) for TECFIDERA wer e,1
TECFIDERA,progressive multifocal leukoencephalopathy,diarrhea,0
TECFIDERA,progressive multifocal leukoencephalopathy,The most common adverse reactions incidence and,0
TECFIDERA,progressive multifocal leukoencephalopathy,in clinical,0
TECFIDERA,progressive multifocal leukoencephalopathy,clinical practice The most common,0
TECFIDERA,progressive multifocal leukoencephalopathy,common adverse reactions incidence,0
TECFIDERA,PML,than placebo for TECFIDERA flu shing abdominal pain diarrhea,1
TECFIDERA,PML,common adverse reactions incidence,0
TECFIDERA,PML,pain diarrhea and nausea Adverse Reactions in PlaceboControlled Trials,0
TECFIDERA,PML,TECFIDERA,0
TECFIDERA,PML,flu shing abdominal,1
TECFIDERA,PML,diarrhea,0
TECFIDERA,PML,than placebo for TECFIDERA flu shing abdominal pain,1
TECFIDERA,PML,diarrhea,0
TECFIDERA,PML,than placebo for TECFIDERA flu shing abdominal pain,1
TECFIDERA,PML,diarrhea,0
TECFIDERA,PML,flu,1
TECFIDERA,PML,common adverse reactions incidence and more than,0
TECFIDERA,PML,flu shing abdominal pain diarrhea and,1
TECFIDERA,lymphopenia,ation from  patients treated with TECFIDERA,1
TECFIDERA,lymphopenia,flu shing abdominal pain diarrhea and,1
TECFIDERA,lymphopenia,TECFIDERA mg,0
TECFIDERA,lymphopenia,twice a,0
TECFIDERA,lymphopenia,in Study and ed for TECF IDERA mg BID,1
TECFIDERA,lymphopenia,twice a,0
TECFIDERA,lymphopenia,ed for TECF IDERA mg BID at higher,1
TECFIDERA,lymphopenia,ed for TECF IDERA mg BID at higher,1
TECFIDERA,lymphopenia,ed for TECF,1
TECFIDERA,lymphopenia,ed for TECF IDERA mg BID at higher,1
TECFIDERA,prolonged lymphopenia,caused GI events (e.g nausea vomiting diarrhea abdominal pain,1
TECFIDERA,prolonged lymphopenia,Gastrointestinal caused GI events (e.g nausea vomiting diarrhea abdominal,1
TECFIDERA,prolonged lymphopenia,caused GI events (e.g nausea vomiting diarrhea abdominal pain,1
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,TECFIDERA and less,0
TECFIDERA,lymphocyte counts <0.5 x 10 9 /L,compared with placebo Four percent of patients treated with TECFIDERA and less than,0
TECFIDERA,flushing,ansient  increase in mean,1
TECFIDERA,flushing,ansient  increase in,1
TECFIDERA,warmth,in me an eosinophil,1
TECFIDERA,warmth,seen during the first,0
TECFIDERA,redness,in  eosino phil counts was seen during,1
TECFIDERA,redness,seen during the first,0
TECFIDERA,redness, eosino phil counts was seen during,1
TECFIDERA,redness, eosino phil,1
TECFIDERA,redness, eosino phil counts was seen during,1
TECFIDERA,redness, eosino phil counts was,1
TECFIDERA,redness,of,0
TECFIDERA,redness,Adverse,0
TECFIDERA,redness, eosino,1
TECFIDERA,redness, eosino phil counts was seen,1
TECFIDERA,redness, eosino phil,1
TECFIDERA,itching,or placebo Eosinophilia A transient increase in mean,0
TECFIDERA,itching,il,1
TECFIDERA,itching,in mean il coun,1
TECFIDERA,itching,Reactions in PlaceboControlled an,0
TECFIDERA,itching,mean il coun ts was,1
TECFIDERA,itching,Reactions in PlaceboControlled an,0
TECFIDERA,itching,il coun,1
TECFIDERA,itching,mean il coun ts was seen during,1
TECFIDERA,itching,il coun,1
TECFIDERA,itching,il coun,1
TECFIDERA,itching,il coun ts,1
TECFIDERA,burning sensation,was en during the fir,1
TECFIDERA,burning sensation,in PlaceboControlled and,0
TECFIDERA,burning sensation,during the fir st months of therapy Adverse,1
TECFIDERA,burning sensation,en during,1
TECFIDERA,burning sensation,counts was en,1
TECFIDERA,burning sensation,and Uncontrolled,0
TECFIDERA,burning sensation,en during the fir st months,1
TECFIDERA,burning sensation,counts was en during the fir st months of therapy,1
TECFIDERA,burning sensation,en during the fir st months,1
TECFIDERA,flushing,Studies In placebocontrolled and,0
TECFIDERA,flushing,ed and U,1
TECFIDERA,flushing,ed and U,1
TECFIDERA,flushing,therapy Adverse Reactions in ed and U,1
TECFIDERA,flushing,Adverse Reactions in ed and U ncontrolled,1
TECFIDERA,flushing,therapy Adverse Reactions in ed and U,1
TECFIDERA,flushing,In placebocontrolled and uncontrolled clinical,0
TECFIDERA,flushing,ed,1
TECFIDERA,flushing,Reactions in ed and,1
TECFIDERA,Flushing,in PlaceboControlled and ontrolle d Studies In placebocontrolled and,1
TECFIDERA,Flushing,Reactions in ed and,1
TECFIDERA,Flushing,ontrolle d Studies In placebocontrolled,1
TECFIDERA,Flushing,ontrolle d,1
TECFIDERA,Flushing,in PlaceboControlled and ontrolle d,1
TECFIDERA,Flushing,ontrolle d,1
TECFIDERA,Flushing,uncontrolled clinical,0
TECFIDERA,Flushing,a total of patients,0
TECFIDERA,Flushing,ontrolle d Studies In placebocontrolled and,1
TECFIDERA,Flushing,ontrolle d Studies In,1
TECFIDERA,Flushing,In placebocontrolled,0
TECFIDERA,flushing,and been followed for riods up,1
TECFIDERA,flushing,In placebocontrolled,0
TECFIDERA,flushing,followed for riods up,1
TECFIDERA,flushing,clinical studies a total,0
TECFIDERA,flushing,exposure of personyears,0
TECFIDERA,flushing,riods up to years,1
TECFIDERA,flushing,been followed for riods up to,1
TECFIDERA,flushing,riods up to years,1
TECFIDERA,flushing,TECFIDERA and been followed for pe,0
TECFIDERA,flushing,for pe,0
TECFIDERA,flushing,placebo- controlled,1
TECFIDERA,flushing,placebo- controlled clinical,1
TECFIDERA,flushing,with the experience in placebo-,1
TECFIDERA,flushing,placebo- controlled clinical,1
TECFIDERA,flushing,studies was consistent with the,0
TECFIDERA,flushing,the experience in placebo- controlled clinical,1
TECFIDERA,flushing,studies was consistent with the,0
TECFIDERA,flushing,controlled clinical,0
TECFIDERA,flushing,placebo-,1
TECFIDERA,flushing,controlled clinical trials,0
TREANDA,Myelosuppression,Precautions Infections see Warnings and,0
TREANDA,Infections,Infections see Warnings,1
TREANDA,Infections,Infections,1
TREANDA,Infections,Infections,1
TREANDA,Infections,Infections,1
TREANDA,Infections,Infections,1
TREANDA,Infections,see Warnings and Infections see Warnings and,1
TREANDA,Infections,Infections,1
TREANDA,Infusion Reactions,Precautions Anaphylaxis Infusion Reactions see Warnings and,1
TREANDA,Infusion Reactions,Infections,1
TREANDA,Infusion Reactions,see,0
TREANDA,Infusion Reactions,Precautions Anaphylaxis Infusion,1
TREANDA,Infusion Reactions,Precautions Anaphylaxis Infusion Reactions see Warnings and,1
TREANDA,Infusion Reactions,Precautions Anaphylaxis Infusion,1
TREANDA,Infusion Reactions,and Precautions Anaphylaxis Infusion Reactions see Warnings and Precautions Tumor,1
TREANDA,Infusion Reactions,Precautions Anaphylaxis Infusion,1
TREANDA,Infusion Reactions,see Warnings and Precautions Tumor Lysis Syndrome see Warnings and Precauti,0
TREANDA,Infusion Reactions,and Precautions Anaphylaxis Infusion Reactions,1
TREANDA,Infusion Reactions,Warnings and Precautions Anaphylaxis Infusion Reactions,1
TREANDA,Tumor Lysis Syndrome,Lysis Syndrome see,1
TREANDA,Tumor Lysis Syndrome,Lysis Syndrome see,1
TREANDA,Skin Reactions,Skin Reactions see,1
TREANDA,Skin Reactions,Syndrome see Warnings and Precautions,0
TREANDA,Malignancies,Malignancies see Warnings and Precautions Extravasation,1
TREANDA,Extravasation injury,Warnings and Precautions,0
TREANDA,Extravasation injury,Extravasation injury see Warnings,1
TREANDA,pyrexia,nonhematologic adverse reactions,0
TREANDA,pyrexia,pyrexia nausea,1
TREANDA,pyrexia,reactions for CLL frequency pyrexia nausea,1
TREANDA,pyrexia,pyrexia nausea,1
TREANDA,pyrexia,nonhematologic adverse reactions,0
TREANDA,pyrexia,CLL frequency pyrexia nausea and,1
TREANDA,pyrexia,nonhematologic adverse reactions,0
TREANDA,pyrexia,Most common nonhematologic adverse reactions for NHL,0
TREANDA,pyrexia,pyrexia nausea and vomiting Most,1
TREANDA,pyrexia,for CLL frequency pyrexia nausea,1
TREANDA,pyrexia,pyrexia nausea and vomiting Most,1
TREANDA,nausea,nausea and vomiting Most common nonhematologic,1
TREANDA,vomiting,pyrexia nausea vomiting Most common nonhematologic adverse,1
TREANDA,vomiting,nausea and vomiting Most common nonhematologic,1
TREANDA,nausea,nausea,1
TREANDA,nausea,nausea,1
TREANDA,nausea,nausea fatigue vomiting,1
TREANDA,nausea,nausea,1
TREANDA,fatigue,fatigue vomiting,1
TREANDA,fatigue,nausea,1
TREANDA,fatigue,nausea,0
TREANDA,fatigue,headache weight decreased,0
TREANDA,fatigue,fatigue vomiting diarrhea pyrexia constipation anorexia,1
TREANDA,fatigue,fatigue vomiting diarrhea pyrexia constipation,1
TREANDA,fatigue,frequency are nausea,0
TREANDA,fatigue,weight,0
TREANDA,fatigue,weight,0
TREANDA,fatigue,fatigue vomiting diarrhea pyrexia constipation,1
TREANDA,fatigue,adverse reactions for NHL frequency,0
TREANDA,vomiting,anorexia,0
TREANDA,vomiting,vomiting diarrhea pyrexia constipation anorexia cough,1
TREANDA,vomiting,vomiting diarrhea pyrexia constipation,1
TREANDA,vomiting,are nausea vomiting diarrhea pyrexia constipation anorexia,1
TREANDA,vomiting,vomiting diarrhea pyrexia constipation,1
TREANDA,vomiting,nausea vomiting,1
TREANDA,vomiting,vomiting diarrhea pyrexia constipation,1
TREANDA,vomiting,nonhematologic adverse reactions for NHL frequency are nausea,0
TREANDA,diarrhea,diarrhea pyrexia constipation,1
TREANDA,diarrhea,nonhematologic adverse reactions for NHL frequency are nausea,0
TREANDA,diarrhea,diarrhea pyrexia constipation,1
TREANDA,pyrexia,pyrexia constipation anorexia cough headache weight,1
TREANDA,pyrexia,headache weight decreased dyspnea rash and,0
TREANDA,pyrexia,reactions for NHL frequency are nausea fatigue vomiting,0
TREANDA,pyrexia,dyspnea rash and,0
TREANDA,pyrexia,nhematologic adverse reactions for NHL frequency are nausea fatigue vomiting,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,nhematologic adverse reactions for NHL frequency are nausea fatigue vomiting,0
TREANDA,pyrexia,pyrexia constipation,1
TREANDA,pyrexia,nausea fatigue vomiting pyrexia constipation anorexia,1
TREANDA,pyrexia,pyrexia constipation,1
TREANDA,pyrexia,headache weight decreased dyspnea rash and stomatitis,0
TREANDA,constipation,are nausea fatigue vomiting diarrhea pyrexia,0
TREANDA,constipation,weight decreased dyspnea rash,0
TREANDA,constipation,constipation anorexia,1
TREANDA,constipation,constipation anorexia,1
TREANDA,constipation,are nausea fatigue vomiting,0
TREANDA,constipation,diarrhea pyrexia,0
TREANDA,constipation,fatigue vomiting diarrhea constipation anorexia cough headache,1
TREANDA,constipation,diarrhea pyrexia,0
TREANDA,constipation,constipation anorexia,1
TREANDA,constipation,nausea fatigue vomiting diarrhea constipation,1
TREANDA,constipation,constipation anorexia,1
TREANDA,constipation,for NHL frequency,0
TREANDA,anorexia,anorexia cough headache weight,1
TREANDA,anorexia,for NHL frequency,0
TREANDA,anorexia,anorexia,1
TREANDA,anorexia,constipation,0
TREANDA,anorexia,pyrexia,0
TREANDA,anorexia,NHL,0
TREANDA,headache,constipation,0
TREANDA,headache,headache weight decreased,1
TREANDA,headache,dyspnea rash,0
TREANDA,headache,constipation anorexia headache weight,1
TREANDA,headache,dyspnea rash,0
TREANDA,headache,Most common hematologic,0
TREANDA,headache,headache weight decreased,1
TREANDA,headache,headache weight decreased dyspnea rash,1
TREANDA,headache,headache weight decreased dyspnea,1
TREANDA,headache,vomiting,0
TREANDA,headache,constipation,0
TREANDA,weight decreased,anorexia cough weight decreased dyspnea rash and stomatitis,1
TREANDA,weight decreased,constipation,0
TREANDA,weight decreased,pyrexia constipation anorexia cough weight decreased,1
TREANDA,weight decreased,abnormalities for,0
TREANDA,weight decreased,weight decreased dyspnea rash and,1
TREANDA,weight decreased,pyrexia constipation anorexia cough weight decreased dyspnea,1
TREANDA,weight decreased,weight decreased dyspnea rash and,1
TREANDA,weight decreased,pyrexia constipation anorexia cough weight decreased dyspnea rash and stomatitis,1
TREANDA,weight decreased,weight decreased dyspnea rash and,1
TREANDA,weight decreased,common,0
TREANDA,weight decreased,weight decreased dyspnea,1
TREANDA,weight decreased,common,0
TREANDA,weight decreased,cough weight,1
TREANDA,rash,cough headache weight decreased rash and stomatitis,1
TREANDA,rash,cough weight,1
TREANDA,rash,vomiting diarrhea pyrexia constipation anorexia cough headache weight decreased dyspnea,0
TREANDA,rash,weight decreased rash and stomatitis Most,1
TREANDA,rash,vomiting diarrhea pyrexia constipation anorexia cough headache weight decreased dyspnea,0
TREANDA,rash,decreased rash and stomatitis Most common,1
TREANDA,rash,vomiting diarrhea pyrexia constipation anorexia cough headache weight decreased dyspnea,0
TREANDA,stomatitis,weight decreased dyspnea rash stomatitis Most common hematologic abnormalities for,1
TREANDA,stomatitis,vomiting diarrhea pyrexia constipation anorexia cough headache weight decreased dyspnea,0
TREANDA,stomatitis,stomatitis,1
TREANDA,stomatitis,vomiting diarrhea pyrexia constipation anorexia cough headache weight decreased dyspnea,0
TREANDA,stomatitis,common hematologic abnormalities for both indications frequency,0
TREANDA,stomatitis,stomatitis Most common hematologic abnormalities for,1
TREANDA,stomatitis,stomatitis Most,1
TREANDA,stomatitis,hematologic abnormalities,0
TREANDA,stomatitis,rash stomatitis,1
TREANDA,stomatitis,hematologic abnormalities,0
TREANDA,stomatitis,weight decreased dyspnea rash and,0
TREANDA,stomatitis,both,0
TREANDA,hematologic abnormalities,frequency are,0
TREANDA,hematologic abnormalities,rash and stomatitis Most hematologic,1
TREANDA,hematologic abnormalities,hematologic abnormalities for both,1
TREANDA,hematologic abnormalities,rash and stomatitis Most hematologic,1
TREANDA,hematologic abnormalities,leukopenia thrombocytopenia and,0
TREANDA,hematologic abnormalities,and stomatitis Most hematologic abnormalities,1
TREANDA,hematologic abnormalities,and stomatitis Most hematologic abnormalities,1
TREANDA,lymphopenia,abnormalities for both,0
TREANDA,lymphopenia,lymphopenia anemia leukopenia,1
TREANDA,lymphopenia,neutropenia EXCERPT To,0
TREANDA,lymphopenia,lymphopenia anemia leukopenia thrombocytopenia,1
TREANDA,lymphopenia,lymphopenia anemia leukopenia thrombocytopenia and neutropenia,1
TREANDA,lymphopenia,lymphopenia anemia leukopenia thrombocytopenia and neutropenia,1
TREANDA,lymphopenia,and neutropenia,0
TREANDA,lymphopenia,lymphopenia anemia leukopenia thrombocytopenia and,1
TREANDA,lymphopenia,both,0
TREANDA,anemia,and neutropenia EXCERPT,0
TREANDA,anemia,thrombocytopenia and neutropenia EXCERPT To report SUSPECTED A,0
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia EXCERPT To,1
TREANDA,thrombocytopenia,frequency are lymphopenia anemia thrombocytopenia and,1
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia EXCERPT To,1
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia EXCERPT,1
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia,1
TREANDA,thrombocytopenia,thrombocytopenia,1
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia EXCERPT To report,1
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia EXCERPT To,1
TREANDA,thrombocytopenia,thrombocytopenia and neutropenia EXCERPT,1
TREANDA,neutropenia,neutropenia EXCERPT,1
TREANDA,neutropenia,neutropenia EXCERPT To report SUSPECTED,1
TREANDA,neutropenia,anemia leukopenia thrombocytopenia neutropenia EXCERPT To report,1
TREANDA,neutropenia,neutropenia EXCERPT To report SUSPECTED,1
TREANDA,neutropenia,SUSPECTED ADVERSE REACTIONS,0
TREANDA,neutropenia,neutropenia EXCERPT To,1
TREANDA,neutropenia,anemia leukopenia thrombocytopenia neutropenia EXCERPT To report,1
TREANDA,neutropenia,neutropenia EXCERPT To,1
TREANDA,neutropenia,anemia leukopenia,0
TREANDA,pyrexia,one or mo,0
TREANDA,pyrexia,greater than pyrexia nausea and vomiting,1
TREANDA,pyrexia,one or mo,0
TREANDA,pyrexia,a frequency greater than pyrexia nausea,1
TREANDA,pyrexia,one or mo,0
TREANDA,nausea,frequency,0
TREANDA,nausea,a frequency greater than were,0
TREANDA,nausea,were nausea and,1
TREANDA,nausea,a frequency greater than were,0
TREANDA,vomiting,were pyrexia nausea vomiting Other,1
TREANDA,vomiting,a frequency greater than were,0
TREANDA,vomiting,or more,0
TREANDA,asthenia,asthenia,1
TREANDA,asthenia,asthenia fatigue,1
TREANDA,asthenia,or more studies,0
TREANDA,fatigue,fatigue malaise and weakness dry,1
TREANDA,fatigue,fatigue malaise and weakness dry,1
TREANDA,fatigue,or more studies included asthenia,0
TREANDA,fatigue,mouth somnolence cough constipation headache mucosal inflammation,0
TREANDA,fatigue,more studies included fatigue malaise,1
TREANDA,fatigue,mouth somnolence cough constipation headache mucosal inflammation,0
TREANDA,fatigue,weakness dry mouth somnolence cough constipation,0
TREANDA,fatigue,fatigue malaise and weakness dry,1
TREANDA,fatigue,fatigue malaise and,1
TREANDA,fatigue,included fatigue malaise and,1
TREANDA,fatigue,fatigue malaise and,1
TREANDA,malaise,headache mucosal inflammation and,0
TREANDA,malaise,fatigue,0
TREANDA,malaise,mucosal inflammation and,0
TREANDA,weakness,weakness dry mouth somnolence cough constipation,1
TREANDA,weakness,somnolence cough constipation headache mucosal inflammation,0
TREANDA,dry mouth,dry mouth,1
TREANDA,dry mouth,somnolence cough constipation headache mucosal inflammation,0
TREANDA,dry mouth,weakness,0
TREANDA,dry mouth,dry mouth somnolence,1
TREANDA,dry mouth,dry mouth somnolence cough constipation headache,1
TREANDA,somnolence,frequently in one or more studies,0
TREANDA,somnolence,mucosal inflammation and,0
TREANDA,cough,included asthenia fatigue,0
TREANDA,cough,fatigue,0
TREANDA,constipation,and stomatitis Worsening hypertension was reported,0
TREANDA,headache,cough headache mucosal inflammation and stomatitis,1
TREANDA,headache,and stomatitis Worsening hypertension was reported,0
TREANDA,headache,mouth somnolence cough headache,1
TREANDA,headache,and stomatitis Worsening hypertension was reported,0
TREANDA,headache,was reported in patients treate,0
TREANDA,headache,mouth somnolence cough headache mucosal inflammation and stomatitis Worsening,1
TREANDA,headache,was reported in patients treate,0
TREANDA,headache,hypertension was reported in,0
TREANDA,headache,mouth somnolence cough headache mucosal inflammation and stomatitis,1
TREANDA,headache,hypertension was reported in,0
TREANDA,headache,headache,1
TREANDA,headache,cough headache mucosal,1
TREANDA,headache,headache,1
TREANDA,mucosal inflammation,mucosal inflammation and,1
TREANDA,mucosal inflammation,mucosal inflammation and stomatitis Worsening,1
TREANDA,mucosal inflammation,mucosal inflammation,1
TREANDA,mucosal inflammation,reported in patients,0
TREANDA,mucosal inflammation,mucosal inflammation and stomatitis Worsening hypertension,1
TREANDA,stomatitis,stomatitis Worsening hypertension was reported,1
TREANDA,stomatitis,stomatitis Worsening hypertension,1
TREANDA,stomatitis,stomatitis,1
TREANDA,stomatitis,inflammation,0
TREANDA,stomatitis,and,0
TREANDA,stomatitis,stomatitis Worsening hypertension was reported in,1
TREANDA,stomatitis,constipation headache mucosal inflammation stomatitis Worsening,1
TREANDA,stomatitis,stomatitis Worsening hypertension was reported in,1
TREANDA,stomatitis,stomatitis Worsening hypertension was reported,1
TREANDA,Worsening hypertension,Worsening hypertension was reported,1
TREANDA,hypersensitivity,leading to study withdrawal for patients receiving TREANDA,0
TREANDA,hypersensitivity,were,0
TREANDA,hypersensitivity,contains the treatment emergent adverse,0
TREANDA,hypersensitivity,pyrexia Table contains the treatment emergent adverse reactions,0
TREANDA,hypersensitivity,hypersensitivity and pyrexia Table contains the,1
TREANDA,hypersensitivity,patients receiving TREANDA hypersensitivity and pyrexia,1
TREANDA,hypersensitivity,hypersensitivity and pyrexia Table contains the,1
TREANDA,hypersensitivity,hypersensitivity and pyrexia Table contains the,1
TREANDA,hypersensitivity,hypersensitivity and pyrexia Table contains the,1
TREANDA,hypersensitivity,receiving TREANDA hypersensitivity and pyrexia Table contains the,1
TREANDA,hypersensitivity,hypersensitivity and pyrexia Table contains the,1
TREANDA,hypersensitivity,hypersensitivity,1
TREANDA,hypersensitivity,receiving TREANDA hypersensitivity and pyrexia,1
TREANDA,hypersensitivity,hypersensitivity,1
TREANDA,pyrexia,pyrexia Table contains,1
TREANDA,pyrexia,pyrexia Table contains the treatment,1
TREANDA,pyrexia,pyrexia Table contains the treatment,1
TREANDA,pyrexia,were,0
TREANDA,pyrexia,emergent adverse reactions regardless of,0
TREANDA,pyrexia,Table contains the treatment emergent adverse reactions regardless of,0
TREANDA,pyrexia,TREANDA were hypersensitivity pyrexia Table contains the treatment,1
TREANDA,pyrexia,Table contains the treatment emergent adverse reactions regardless of,0
TREANDA,pyrexia,receiving TREANDA were hypersensitivity pyrexia,1
TREANDA,pyrexia,Table contains the treatment emergent adverse reactions regardless of,0
TREANDA,pyrexia,pyrexia,1
TREANDA,myelosuppressive effects,myelosuppressive effects seen in patients treated with,1
TREANDA,myelosuppressive effects,confirm myelosuppressive effects,1
TREANDA,myelosuppressive effects,myelosuppressive effects seen in patients treated with,1
TREANDA,myelosuppressive effects,Table These findings confirm myelosuppressive,1
TREANDA,Hemoglobin Decreased,Grade n,0
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased,1
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased Platelets Decreased,1
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased Platelets Decreased,1
TREANDA,Platelets Decreased,Platelets Decreased Leukocytes,1
TREANDA,Platelets Decreased,Hemoglobin Decreased Platelets Decreased,1
TREANDA,Leukocytes Decreased,Leukocytes,1
TREANDA,Leukocytes Decreased,Leukocytes Decreased Lymphocytes,1
TREANDA,Leukocytes Decreased,Leukocytes Decreased,1
TREANDA,Leukocytes Decreased,Leukocytes Decreased Lymphocytes Decreased,1
TREANDA,Leukocytes Decreased,Leukocytes Decreased,1
TREANDA,Leukocytes Decreased,Platelets Decreased,0
TREANDA,Leukocytes Decreased,Decreased,0
TREANDA,Leukocytes Decreased,Platelets Decreased,0
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Neutrophils Decreased,1
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Neutrophils,1
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Neutrophils Decreased,1
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Neutrophils,1
TREANDA,Lymphocytes Decreased,Leukocytes Lymphocytes,1
TREANDA,Lymphocytes Decreased,Leukocytes Lymphocytes,1
TREANDA,bilirubin elevations,bilirubin elevations,1
TREANDA,bilirubin elevations,trial of patients bilirubin,1
TREANDA,bilirubin elevations,CLL trial of patients bilirubin elevations some without,1
TREANDA,bilirubin elevations,trial of patients bilirubin,1
TREANDA,bilirubin elevations,of patients bilirubin,1
TREANDA,bilirubin elevations,of patients bilirubin elevations some without associated significant,1
TREANDA,bilirubin elevations,of patients bilirubin,1
TREANDA,bilirubin elevations,CLL,0
TREANDA,bilirubin elevations,of patients bilirubin elevations some without associated significant elevations,1
TREANDA,bilirubin elevations,CLL,0
TREANDA,bilirubin elevations,trial of patients bilirubin,1
TREANDA,bilirubin elevations,patients bilirubin elevations some without associated significant elevations,1
TREANDA,bilirubin elevations,trial of patients bilirubin,1
TREANDA,bilirubin elevations,CLL trial of patients bilirubin elevations,1
TREANDA,elevations in AST,associated elevations,1
TREANDA,elevations in AST,elevations in AST and ALT Grade or increased,1
TREANDA,elevations in AST,associated elevations,1
TREANDA,increased bilirubin,increased bilirubin occurred in of,1
TREANDA,increased bilirubin,AST and ALT Grade increased bilirubin,1
TREANDA,increased bilirubin,and ALT Grade increased,1
TREANDA,increased bilirubin,AST and ALT Grade increased bilirubin occurred in of,1
TREANDA,increased bilirubin,and ALT Grade increased,1
TREANDA,increased bilirubin,increased bilirubin,1
TREANDA,increased bilirubin,increased bilirubin occurred in,1
TREANDA,increased bilirubin,in of patients Increases in AST and ALT of,0
TREANDA,Increases in AST,Increases in AST and ALT of Grade or,1
TREANDA,Increases in AST,Grade or increased,0
TREANDA,Increases in AST,in,0
TREANDA,Increases in AST,bilirubin occurred in of Increases in AST,1
TREANDA,Increases in AST,in,0
TREANDA,Increases in AST,occurred in of Increases in,1
TREANDA,nausea,nonhematologic adverse reactions nausea fatigue vomiting diarrhea and,1
TREANDA,nausea,occurred in of Increases in,1
TREANDA,nausea,The most,0
TREANDA,nausea,most common nonhemato,0
TREANDA,nausea,nonhematologic adverse reactions nausea fatigue vomiting diarrhea and pyrexia,1
TREANDA,nausea,most common nonhemato,0
TREANDA,nausea,nausea fatigue,1
TREANDA,nausea,were,0
TREANDA,fatigue,fatigue vomiting diarrhea and,1
TREANDA,fatigue,fatigue vomiting diarrhea and,1
TREANDA,fatigue,fatigue vomiting diarrhea,1
TREANDA,fatigue,fatigue vomiting,1
TREANDA,fatigue,fatigue vomiting,1
TREANDA,fatigue,common nonhematologic,0
TREANDA,fatigue,fatigue vomiting diarrhea and pyrexia The,1
TREANDA,vomiting,vomiting diarrhea and pyrexia,1
TREANDA,vomiting,vomiting,1
TREANDA,vomiting,fatigue,0
TREANDA,vomiting,vomiting diarrhea and pyrexia The most,1
TREANDA,diarrhea,fatigue diarrhea and pyrexia The,1
TREANDA,diarrhea,vomiting diarrhea and pyrexia The most,1
TREANDA,diarrhea,diarrhea,1
TREANDA,diarrhea,were nausea fatigue diarrhea,1
TREANDA,diarrhea,diarrhea,1
TREANDA,diarrhea,diarrhea and pyrexia The,1
TREANDA,diarrhea,reactions were nausea fatigue,0
TREANDA,diarrhea,diarrhea and pyrexia,1
TREANDA,diarrhea,nausea,0
TREANDA,pyrexia,common nonhematologic Grade or,0
TREANDA,pyrexia,adverse reactions were nausea fatigue vomiting diarrhea and,0
TREANDA,pyrexia,were,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,were,0
TREANDA,pyrexia,were,0
TREANDA,pyrexia,reactions were nausea fatigue vomiting diarrhea,0
TREANDA,pyrexia,pyrexia,1
TREANDA,pyrexia,reactions,0
TREANDA,pyrexia,vomiting diarrhea pyrexia The most common nonhematologic,1
TREANDA,pyrexia,reactions,0
TREANDA,pyrexia,The most common nonhematologic Grade or adverse reactions were,0
TREANDA,fatigue,febrile neutropenia and pneumonia,0
TREANDA,fatigue,fatigue febrile neutropenia and,1
TREANDA,fatigue,fatigue,1
TREANDA,febrile neutropenia,febrile,1
TREANDA,febrile neutropenia,febrile neutropenia,1
TREANDA,febrile neutropenia,and pneumonia hypokalemia and dehydration each,0
TREANDA,febrile neutropenia,The most common nonhematologic Grade or adverse reactions were,0
TREANDA,febrile neutropenia,adverse reactions were febrile neutropenia and,1
TREANDA,febrile neutropenia,The most common nonhematologic Grade or adverse reactions were,0
TREANDA,febrile neutropenia,and pneumonia hypokalemia and,0
TREANDA,pneumonia,pneumonia hypokalemia and dehydration each reported,1
TREANDA,pneumonia,febrile neutropenia pneumonia hypokalemia and,1
TREANDA,pneumonia,pneumonia hypokalemia and dehydration each reported,1
TREANDA,pneumonia,neutropenia pneumonia hypokalemia and dehydration each reported,1
TREANDA,pneumonia,pneumonia hypokalemia and dehydration each reported,1
TREANDA,pneumonia,and dehydration each reported in,0
TREANDA,pneumonia,fatigue febrile,0
TREANDA,pneumonia,dehydration each reported in of patients Table,0
TREANDA,hypokalemia,were fatigue febrile neutropenia and pneumonia,0
TREANDA,dehydration,dehydration,1
TREANDA,dehydration,pneumonia hypokalemia dehydration each reported in of,1
TREANDA,dehydration,dehydration,1
TREANDA,dehydration,dehydration each reported in of patients,1
TREANDA,dehydration,dehydration each reported in of patients,1
TREANDA,dehydration,neutropenia and pneumonia hypokalemia and,0
TREANDA,dehydration,dehydration each reported in of,1
TREANDA,dehydration,dehydration each reported in,1
TREANDA,Abdominal distension,Abdominal distension,1
TREANDA,Abdominal distension,Abdominal distension,1
TREANDA,Abdominal distension,Abdominal distension General disorder,1
TREANDA,Abdominal distension,l pain upper,0
TREANDA,Abdominal distension,pain Abdominal distension General,1
TREANDA,Abdominal distension,l pain upper,0
TREANDA,Abdominal distension,l pain Abdominal distension,1
TREANDA,Hematologic toxicities,system organ class Hematologic,1
TREANDA,Hematologic toxicities,values and CTC grade in NHL patients,0
TREANDA,Hematologic toxicities,in each,0
TREANDA,Hematologic toxicities,each system organ class Hematologic toxicities based on laboratory values,1
TREANDA,Hematologic toxicities,in each,0
TREANDA,Hematologic toxicities,nly once in each preferred term category and once,0
TREANDA,Hematologic toxicities,each system organ class Hematologic toxicities,1
TREANDA,Hematologic toxicities,once in each preferred term category and once in each system organ,0
TREANDA,Hematologic toxicities,on laboratory values and CTC grade in NHL patients treated in both single arm,0
TREANDA,Hematologic toxicities,organ class Hematologic toxicities based on laboratory values and,1
TREANDA,Hematologic toxicities,on laboratory values and CTC grade in NHL patients treated in both single arm,0
TREANDA,hyperglycemia,at,0
TREANDA,hyperglycemia,hyperglycemia elevated creatinine hyponatremia,1
TREANDA,hyperglycemia,hyperglycemia elevated creatinine,1
TREANDA,elevated creatinine,were elevated creatinine hyponatremia and hypocalcemia Table Incidence,1
TREANDA,elevated creatinine,hyperglycemia elevated creatinine,1
TREANDA,elevated creatinine,elevated creatinine hyponatremia and hypocalcemia Table Incidence,1
TREANDA,elevated creatinine,combined were elevated creatinine hyponatremia,1
TREANDA,elevated creatinine,elevated creatinine hyponatremia and hypocalcemia Table Incidence,1
TREANDA,hyponatremia,elevated hyponatremia and hypocalcemia,1
TREANDA,hyponatremia,elevated creatinine hyponatremia and hypocalcemia Table Incidence,1
TREANDA,hyponatremia,hyponatremia and hypocalcemia Table,1
TREANDA,hypocalcemia,hypocalcemia Table,1
TREANDA,hypocalcemia,hyponatremia and hypocalcemia Table,1
TREANDA,hypocalcemia,arm studies combined were hyperglycemia,0
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased,1
TREANDA,Lymphocytes Decreased,patients Hematology variable All Grades,0
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Leukocytes Decreased Hemog,1
TREANDA,Lymphocytes Decreased,patients Hematology variable All Grades,0
TREANDA,Lymphocytes Decreased,variable All Grades Lymphocytes Decreased,1
TREANDA,Lymphocytes Decreased,Percent,0
TREANDA,Lymphocytes Decreased,Lymphocytes Decreased Leukocytes,1
TREANDA,Lymphocytes Decreased,Leukocytes,0
TREANDA,Lymphocytes Decreased,Grades Lymphocytes Decreased Leukocytes,1
TREANDA,Lymphocytes Decreased,Leukocytes,0
TREANDA,Leukocytes Decreased,Hemoglobin Decreased,0
TREANDA,Leukocytes Decreased,Grades Lymphocytes Leukocytes Decreased,1
TREANDA,Leukocytes Decreased,Grades,0
TREANDA,Leukocytes Decreased,Leukocytes Decreased,1
TREANDA,Leukocytes Decreased,Grades,0
TREANDA,Leukocytes Decreased,Grades Grades Lymphocytes Leukocytes,1
TREANDA,Leukocytes Decreased,Grades Grades Lymphocytes,0
TREANDA,Leukocytes Decreased,Leukocytes Decreased Hemoglobin Decreased Neut,1
TREANDA,Leukocytes Decreased,Hemoglobin Decreased Neut,0
TREANDA,Leukocytes Decreased,Grades Grades Lymphocytes,0
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased,1
TREANDA,Hemoglobin Decreased,Grades Grades Lymphocytes,0
TREANDA,Hemoglobin Decreased,eased Leukocytes Hemoglobin Decreased Neutrophils,1
TREANDA,Hemoglobin Decreased,Grades Grades Lymphocytes,0
TREANDA,Hemoglobin Decreased,Leukocytes Hemoglobin,1
TREANDA,Hemoglobin Decreased,eased Leukocytes Hemoglobin Decreased,1
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased Neutrophils Decreased Plat,1
TREANDA,Hemoglobin Decreased,Hemoglobin,1
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased Neutrophils Decreased Plat,1
TREANDA,Hemoglobin Decreased,Leukocytes Hemoglobin Decreased,1
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased Neutrophils Decreased,1
TREANDA,Hemoglobin Decreased,Leukocytes Hemoglobin Decreased,1
TREANDA,Hemoglobin Decreased,Hemoglobin Decreased Neutrophils Decreased,1
TREANDA,Neutrophils Decreased,Hemoglobin,0
TREANDA,Neutrophils Decreased,Neutrophils Decreased Platelets Decreased,1
TREANDA,Platelets Decreased,In both studies serious adverse reactions regardless,0
TREANDA,Platelets Decreased,Neutrophils,0
TREANDA,Platelets Decreased,Platelets,1
TREANDA,Platelets Decreased,Platelets Decreased In both studies,1
TREANDA,Platelets Decreased,both studies serious adverse reactions,0
TREANDA,Platelets Decreased,Platelets Decreased In both studies,1
TREANDA,Platelets Decreased,Platelets Decreased,1
TREANDA,febrile neutropenia,patients febrile neutropenia,1
TREANDA,febrile neutropenia,febrile neutropenia and pneumonia,1
TREANDA,febrile neutropenia,febrile neutropenia,1
TREANDA,febrile neutropenia,occurring in of patients febrile,1
TREANDA,pneumonia,pneumonia,1
TREANDA,pneumonia,pneumonia Other,1
TREANDA,pneumonia,pneumonia Other important serious adverse reactions,1
TREANDA,pneumonia,pneumonia Other important,1
TREANDA,pneumonia,adverse reactions occurring in of patients were febrile neutropenia,0
TREANDA,pneumonia,pneumonia Other important serious adverse,1
TREANDA,pneumonia,pneumonia Other important serious,1
TREANDA,cardiac failure,acute renal cardiac,1
TREANDA,cardiac failure,cardiac failure hypersensitivity skin reactions pulmonary fibrosis,1
TREANDA,cardiac failure,cardiac failure hypersensitivity,1
TREANDA,cardiac failure,cardiac failure hypersensitivity skin reactions pulmonary fibrosis,1
TREANDA,cardiac failure,andor postmarketing experience were acute,0
TREANDA,cardiac failure,pulmonary fibrosis and,0
TREANDA,cardiac failure,cardiac failure hypersensitivity skin,1
TREANDA,cardiac failure,andor postmarketing experience were acute renal failure,0
TREANDA,hypersensitivity,fibrosis and myelodysplastic syndrome Serious drugrelated adverse,0
TREANDA,hypersensitivity,acute renal failure cardiac hypersensitivity skin reactions pulmonary fibrosis,1
TREANDA,hypersensitivity,fibrosis and myelodysplastic syndrome Serious drugrelated adverse,0
TREANDA,hypersensitivity,renal failure cardiac hypersensitivity skin,1
TREANDA,hypersensitivity,fibrosis and myelodysplastic syndrome Serious drugrelated adverse,0
TREANDA,hypersensitivity,cardiac hypersensitivity,1
TREANDA,hypersensitivity,fibrosis and myelodysplastic syndrome Serious drugrelated adverse,0
TREANDA,hypersensitivity,skin reactions pulmonary fibrosis and myelodysplastic syndrome Serious,0
TREANDA,hypersensitivity,hypersensitivity skin reactions pulmonary,1
TREANDA,hypersensitivity,Serious drugrelated,0
TREANDA,skin reactions,experience were acute renal failure,0
TREANDA,skin reactions,cardiac failure skin reactions,1
TREANDA,skin reactions,skin reactions pulmonary,1
TREANDA,skin reactions,drugrelated,0
TREANDA,skin reactions,failure cardiac failure skin reactions,1
TREANDA,skin reactions,cardiac failure skin reactions pulmonary,1
TREANDA,skin reactions,failure cardiac failure skin reactions,1
TREANDA,skin reactions,skin reactions pulmonary fibrosis and myelodysplastic syndrome,1
TREANDA,skin reactions,skin reactions,1
TREANDA,pulmonary fibrosis,drugrelated adverse reactions reported,0
TREANDA,pulmonary fibrosis,myelodysplastic syndrome Serious,0
TREANDA,pulmonary fibrosis,pulmonary fibrosis and,1
TREANDA,pulmonary fibrosis,pulmonary fibrosis and myelodysplastic syndrome Serious,1
TREANDA,pulmonary fibrosis,cardiac failure hypersensitivity skin pulmonary fibrosis and myelodysplastic syndrome Serious,1
TREANDA,pulmonary fibrosis,pulmonary fibrosis and myelodysplastic syndrome Serious,1
TREANDA,pulmonary fibrosis,hypersensitivity skin pulmonary,1
TREANDA,pulmonary fibrosis,cardiac failure hypersensitivity skin reactions,0
TREANDA,myelodysplastic syndrome,fibrosis myelodysplastic,1
TREANDA,myelodysplastic syndrome,pulmonary,0
TREANDA,myelodysplastic syndrome,reactions reported in clinical trials included myelosuppression,0
TREANDA,myelodysplastic syndrome,hypersensitivity skin reactions pulmonary fibrosis and,0
TREANDA,myelodysplastic syndrome,failure cardiac,0
TREANDA,myelodysplastic syndrome,reactions pulmonary fibrosis myelodysplastic,1
TREANDA,myelodysplastic syndrome,pulmonary fibrosis myelodysplastic syndrome Serious drugrelated adverse reactions,1
TREANDA,myelodysplastic syndrome,reactions pulmonary fibrosis myelodysplastic,1
TREANDA,myelodysplastic syndrome,myelodysplastic syndrome Serious drugrelated,1
TREANDA,myelosuppression,included,0
TREANDA,myelosuppression,pneumonia tumor lysis syndrome and,0
TREANDA,myelosuppression,myelosuppression infection,1
TREANDA,myelosuppression,reactions see Warnings and,0
TREANDA,myelosuppression,syndrome Serious drugrelated adverse reactions reported in clinical,0
TREANDA,infection,lysis syndrome,0
TREANDA,infection,infection pneumonia tumor,1
TREANDA,infection,clinical trials included infection pneumonia tumor lysis,1
TREANDA,infection,infection pneumonia tumor,1
TREANDA,infection,and infusion reactions see Warnings and Precautions,0
TREANDA,infection,syndrome and infusion reactions see Warnings and Precautions,0
TREANDA,pneumonia,Precautions,0
TREANDA,pneumonia,pneumonia tumor lysis,1
TREANDA,pneumonia,pneumonia tumor lysis syndrome and infusion,1
TREANDA,pneumonia,pneumonia,1
TREANDA,tumor lysis syndrome,reported in clinical,0
TREANDA,tumor lysis syndrome,included myelosuppression infection tumor lysis,1
TREANDA,tumor lysis syndrome,myelosuppression infection tumor lysis,1
TREANDA,infusion reactions,reactions occurring less,0
TREANDA,infusion reactions,and,0
TREANDA,infusion reactions,tumor lysis syndrome infusion reactions,1
TREANDA,infusion reactions,and,0
TREANDA,infusion reactions,infusion reactions,1
TREANDA,infusion reactions,pneumonia tumor lysis syndrome infusion reactions see Warnings and Precautions Adverse,1
TREANDA,infusion reactions,infusion reactions,1
TREANDA,infusion reactions,syndrome infusion,1
TREANDA,infusion reactions,tumor lysis syndrome infusion reactions,1
TREANDA,infusion reactions,syndrome infusion,1
TREANDA,hemolysis,Adverse reactions occurring,0
TREANDA,hemolysis,to TREANDA treatment hemolysis,1
TREANDA,hemolysis,Adverse reactions occurring,0
TREANDA,hemolysis,hemolysis dysgeusiataste disorder,1
TREANDA,hemolysis,hemolysis dysgeusiataste,1
TREANDA,hemolysis,hemolysis dysgeusiataste disorder atypical,1
TREANDA,hemolysis,hemolysis dysgeusiataste,1
TREANDA,hemolysis,possibly related to TREANDA,0
TREANDA,hemolysis,hemolysis dysgeusiataste disorder,1
TREANDA,dysgeusia,dysgeusia taste disorder atypical pneumonia sepsis,1
TREANDA,dysgeusia,TREANDA,0
TREANDA,taste disorder,herpes zoster,0
TREANDA,taste disorder,hemolysis taste,1
TREANDA,taste disorder,hemolysis taste,1
TREANDA,taste disorder,TREANDA treatment were hemolysis taste disorder,1
TREANDA,taste disorder,taste disorder,1
TREANDA,atypical pneumonia,hemolysis dysgeusiataste atypical pneumonia sepsis,1
TREANDA,atypical pneumonia,taste disorder,1
TREANDA,atypical pneumonia,skin necrosis Postmarketing,0
TREANDA,atypical pneumonia,possibly related to TREANDA,0
TREANDA,atypical pneumonia,treatment were hemolysis dysgeusiataste atypical pneumonia sepsis herpes zoster,1
TREANDA,atypical pneumonia,possibly related to TREANDA,0
TREANDA,atypical pneumonia,were hemolysis dysgeusiataste,0
TREANDA,atypical pneumonia,were hemolysis dysgeusiataste atypical pneumonia,1
TREANDA,sepsis,zoster erythema dermatitis and skin necrosis Postmarketing Experience,0
TREANDA,sepsis,sepsis herpes zoster erythema dermatitis,1
TREANDA,sepsis,disorder atypical sepsis herpes zoster erythema,1
TREANDA,sepsis,sepsis herpes zoster erythema dermatitis,1
TREANDA,sepsis,and skin necrosis Postmarketing Experience,0
TREANDA,herpes zoster,related to,0
TREANDA,herpes zoster,and skin necrosis,0
TREANDA,herpes zoster,pneumonia herpes zoster erythema dermatitis and skin,1
TREANDA,herpes zoster,and skin necrosis,0
TREANDA,herpes zoster,atypical pneumonia herpes zoster erythema,1
TREANDA,herpes zoster,and skin necrosis,0
TREANDA,herpes zoster,pneumonia herpes,1
TREANDA,erythema,erythema dermatitis and skin necrosis Postmarketing,1
TREANDA,erythema,erythema dermatitis and skin necrosis Postmarketing,1
TREANDA,erythema,sepsis herpes zoster,0
TREANDA,erythema,erythema dermatitis and,1
TREANDA,erythema,sepsis herpes zoster,0
TREANDA,erythema,dysgeusiataste disorder atypical pneumonia sepsis herpes,0
TREANDA,erythema,pneumonia sepsis herpes erythema dermatitis and,1
TREANDA,erythema,dysgeusiataste disorder atypical pneumonia sepsis herpes,0
TREANDA,dermatitis,sepsis herpes zoster dermatitis and skin necrosis,1
TREANDA,dermatitis,dysgeusiataste disorder atypical pneumonia sepsis herpes,0
TREANDA,dermatitis,dermatitis and,1
TREANDA,dermatitis,Postmarketing Experience The,0
TREANDA,dermatitis,Postmarketing Experience The,0
TREANDA,dermatitis,dermatitis and skin necrosis Postmarketing Experience,1
TREANDA,anaphylaxis,to reliably estimate their,0
TREANDA,anaphylaxis,establish a,0
TREANDA,anaphylaxis,their frequency or,0
TREANDA,anaphylaxis,anaphylaxis and injection or,1
TREANDA,anaphylaxis,anaphylaxis and injection or infusion,1
TREANDA,anaphylaxis,or infusion site reactions including,0
TREANDA,infusion site reactions,or,0
TREANDA,infusion site reactions,injection,0
TREANDA,infusion site reactions,injection infusion,1
TREANDA,infusion site reactions,infusion site reactions including phlebitis pruritus irritation,1
TREANDA,infusion site reactions,injection infusion,1
TREANDA,infusion site reactions,site reactions including,1
TREANDA,pneumocystis jiroveci pneumonia,irritation,0
TREANDA,pneumocystis jiroveci pneumonia,pneumocystis jiroveci pneumonia and pneumonitis Skin,1
TREANDA,pneumocystis jiroveci pneumonia,irritation,0
TREANDA,pneumocystis jiroveci pneumonia,and pneumocystis jiroveci pneumonia and,1
TREANDA,pneumocystis jiroveci pneumonia,irritation,0
TREANDA,pneumonitis,when TREANDA was administered,0
TREANDA,Skin reactions,pneumonia and Skin reactions including SJS and,1
TREANDA,Skin reactions,when TREANDA was administered,0
TREANDA,Skin reactions,Skin reactions including SJS and TEN have,1
TREANDA,Skin reactions,Skin,1
TREANDA,SJS,TEN have occurred when TREANDA was administered concomitantly with allopurinol and,0
TREANDA,SJS,pneumocystis jiroveci pneumonia,0
TREANDA,SJS,SJS,1
TREANDA,SJS,SJS and TEN have occurred when,1
TREANDA,SJS,swelling pneumocystis jiroveci,0
TREANDA,SJS,Skin reactions including,0
TREANDA,TEN,TEN have,1
TREANDA,TEN,Skin reactions including,0
TREANDA,TEN,TEN have occurred when TREANDA,1
TREANDA,TEN,Skin reactions including,0
TREANDA,TEN,and pneumonitis Skin,0
TREANDA,Myelosuppression,REACTIONS The following serious se reactions hav,1
TREANDA,myelosuppression,of the abel. *,1
TREANDA,myelosuppression,Warnings,0
TREANDA,death,label on [s,1
TREANDA,death,label on,1
TREANDA,death,of the label on [s,1
TREANDA,death,on [s ee,1
TREANDA,Infections,see Warnings and ecautions ,1
TREANDA,Infections,on [s ee,1
TREANDA,Infections,Infections see Warnings and,0
TREANDA,Infections,ecautions  Infections see,1
TREANDA,Infections,see Warnings and,0
TREANDA,Infections,ecautions  Infections,1
TREANDA,Infections,ecautions  Infections see Warnings and,1
TREANDA,Infections,other sections of,0
TREANDA,Infections,ecautions ,1
TREANDA,Infections,ecautions  Infections see,1
TREANDA,Anaphylaxis,Warnings and Precautions ylaxis,1
TREANDA,Anaphylaxis,see Warnings and Precautions ylaxis,1
TREANDA,Anaphylaxis,ylaxis and Infusion Reactions see Warnings,1
TREANDA,Anaphylaxis,ylaxis and  Infusion Reactions see Warnings and,1
TREANDA,Anaphylaxis,ylaxis and Infusion Reactions see Warnings,1
TREANDA,Anaphylaxis,ylaxis and Infusion Reactions see,1
TREANDA,Anaphylaxis,Warnings and Precautions ylaxis and  Infusion Reactions see Warnings,1
TREANDA,Anaphylaxis,ylaxis and Infusion Reactions see,1
TREANDA,Infusion Reactions,and ion Reactions [see Warnings and Precautions,1
TREANDA,Infusion Reactions,ylaxis and Infusion Reactions see,1
TREANDA,Infusion Reactions,see,0
TREANDA,Infusion Reactions,Infections see Warnings and Precautions Anaphylaxis and,0
TREANDA,Infusion Reactions,and Precautions Tumor Lysis Syndrome see Warnings and,0
TREANDA,Infusion Reactions,Anaphylaxis and ion Reactions [see Warnings and Precautions Tumor Lysis,1
TREANDA,Infusion Reactions,and Precautions Tumor Lysis Syndrome see Warnings and,0
TREANDA,Infusion Reactions,Anaphylaxis and ion Reactions [see Warnings and Precautions Tumor Lysis,1
TREANDA,Infusion Reactions,and Precautions Tumor Lysis Syndrome see Warnings and,0
TREANDA,anaphylactic reactions,and Precautions Anaphylaxis and Infusion,0
TREANDA,anaphylactic reactions,see Warnings d Precautions (,1
TREANDA,anaphylactic reactions,see Warnings d Precautions  (  5.3  Tumor,1
TREANDA,anaphylactic reactions,see Warnings d Precautions (,1
TREANDA,anaphylactic reactions,see Warnings,0
TREANDA,anaphylactic reactions,Warnings an,0
TREANDA,anaphylactic reactions,and Infusion Reactions see Warnings,0
TREANDA,anaphylactic reactions,Warnings and Precautions Skin Reactions,0
TREANDA,anaphylactic reactions,Precautions ( 5.3,1
TREANDA,anaphylactic reactions,Precautions,0
TREANDA,anaphylactic reactions,Warnings d Precautions,1
TREANDA,Acute renal failure,Other,0
TREANDA,Acute renal failure,Warnings and Precautions,0
TREANDA,Acute renal failure,and Precautions Malignancies,1
TREANDA,Acute renal failure,Warnings and Precautions Malignancies [see   Warnings and Precautions Extravasation,1
TREANDA,Acute renal failure,and Precautions Malignancies,1
TREANDA,Acute renal failure,see Warnings and Precautions Malignancies [see,1
TREANDA,death,ngs a nd Precautions Extravasation,1
TREANDA,death,see Warnings and Precautions Malignancies [see,1
TREANDA,death,and Precautions Other Malignancies see,0
TREANDA,death,ngs a nd Precautions,1
TREANDA,death,Precautions Other Malignancies see ngs a,1
TREANDA,death,Warnings and,0
TREANDA,death,Extravasation injury see Warnings and,0
TREANDA,death,Other Malignancies see Warni,0
TREANDA,death,nd Precautions Extravasation injury see Warnings and,0
TREANDA,death,ngs a nd,1
TREANDA,death,and Precautions Other Malignancies see,0
TREANDA,Skin Reactions,see Warnings and Precautions,0
TREANDA,Skin Reactions,Extravasation injury e  Warnings an d Precautions,1
TREANDA,Skin Reactions,see Warnings and Precautions,0
TREANDA,Skin Reactions,e  Warnings an d Precautions,1
TREANDA,Skin Reactions,see Warnings and Precautions,0
TREANDA,Skin Reactions,e Warnings an d Precautions,1
TREANDA,SJS,mon nonhematologic adverse reactions for,1
TREANDA,SJS,Most com,0
TREANDA,SJS,mon nonhematologic adverse reactions,1
TREANDA,SJS,and Precautions Most mon,1
TREANDA,SJS,mon nonhematologic adverse reactions,1
TREANDA,SJS,nausea and vomiting,0
TREANDA,SJS,CLL frequency are pyrexia,0
TREANDA,TEN,Most common non,0
TREANDA,TEN,atologic adverse reactions for CLL frequency are pyrexia,0
TREANDA,TEN,hem atologic adverse,1
TREANDA,fatal,c adv erse reactions for CLL frequency,1
TREANDA,fatal,hem atologic adverse,1
TREANDA,fatal,nausea and vomiting Most,0
TREANDA,fatal,pyrexia nausea and vomiting Most,0
TREANDA,fatal,CLL frequency are pyrexia nausea and vomiting Most,0
TREANDA,fatal,erse reactions for,0
TREANDA,fatal,Precautions Most common c adv,1
TREANDA,fatal,erse reactions for,0
TREANDA,fatal,and,0
TREANDA,Malignancies,y >=,1
TREANDA,malignant diseases,"are nausea fatigue omiting,",1
TREANDA,malignant diseases,"frequency are nausea fatigue omiting,",1
TREANDA,malignant diseases,"fatigue omiting, diarrhea, pyrexia constipation anorexia",1
TREANDA,malignant diseases,"frequency are nausea fatigue omiting,",1
TREANDA,malignant diseases,nausea,0
TREANDA,malignant diseases,Most common nonhematologic adverse reactions for NHL frequency are nausea,0
TREANDA,malignant diseases,"omiting, diarrhea, pyrexia constipation",1
TREANDA,Extravasation,"diarrhea pyrexia constipation anorexia h, headache,  weight decreased dyspnea",1
TREANDA,Extravasation,"omiting, diarrhea, pyrexia constipation",1
TREANDA,Extravasation,coug,0
TREANDA,Extravasation,and stomatitis Most common,0
TREANDA,Extravasation,weight decreased dyspnea rash and stomatitis Most common hematologic abnorma,0
TREANDA,Embryo-fetal toxicity,stomatitis Most common hematologic es for both indicatio,1
TREANDA,Embryo-fetal toxicity,leukopenia thrombocytopenia,0
TREANDA,Embryo-fetal toxicity,for both indicatio ns frequency are lymphopenia anemia,1
TREANDA,Embryo-fetal toxicity,leukopenia thrombocytopenia,0
TREANDA,Embryo-fetal toxicity,stomatitis Most common hematologic es for both indicatio,1
TREANDA,Fetal harm,(frequency are lymphopenia anemia leukopenia thrombocytopenia,1
TREANDA,Fetal harm,(frequency are lymphopenia anemia leukopenia,1
TREANDA,Fetal harm,abnormalities for both (frequency are,1
TREANDA,Fetal harm,(frequency are lymphopenia anemia leukopenia,1
TREANDA,Fetal harm,(frequency are lymphopenia anemia leukopenia thrombocytopenia,1
TREANDA,Fetal harm,(frequency are,1
TREANDA,Fetal harm,(frequency are,1
TREANDA,Fetal harm,both indications,0
TREANDA,Fetal harm,(frequency are lymphopenia anemia,1
TREANDA,myelosuppression,at 1-800-FDA-108 or wwwfdagovmedwatch Clinical,1
TREANDA,myelosuppression,(frequency are lymphopenia anemia,1
TREANDA,myelosuppression,Teva Pharmaceuticals at or at,1
TREANDA,myelosuppression,Teva Pharmaceuticals at or at 1-800-FDA-108 or wwwfdagovmedwatch,1
TREANDA,myelosuppression,Teva Pharmaceuticals at or at,1
TREANDA,myelosuppression,Because,0
TREANDA,myelosuppression,at 1-800-FDA-108,1
TREANDA,myelosuppression,SUSPECTED ADVERSE,0
TREANDA,myelosuppression,at 1-800-FDA-108 or,1
TREANDA,myelosuppression,SUSPECTED ADVERSE,0
TREANDA,died,Clinical Trials Experience Because ical trials are conducted under,1
TREANDA,died,SUSPECTED ADVERSE,0
TREANDA,died,Clinical Trials Experience,0
TREANDA,died,Because,0
TREANDA,died,Clinical Trials Experience Because ical trials are conducted,1
TREANDA,died,Because,0
TREANDA,died,ical trials,1
TREANDA,myelosuppression-related adverse reactions,clinical,0
TREANDA,myelosuppression-related adverse reactions,Because clinical trial,0
TREANDA,myelosuppression-related adverse reactions,s are conducted under widely varying condi tions adverse reaction,1
TREANDA,myelosuppression-related adverse reactions,Because clinical trial,0
TREANDA,myelosuppression-related adverse reactions,clinical s are conducted under widely varying condi tions,1
TREANDA,myelosuppression-related adverse reactions,Because clinical trial,0
TREANDA,myelosuppression-related adverse reactions,clinical s are conducted under widely varying condi,1
TREANDA,neutropenic sepsis,conditions adverse eaction rates obse,1
TREANDA,neutropenic sepsis,conditions adverse eaction rates obse rved in the,1
TREANDA,neutropenic sepsis,conditions adverse eaction rates obse,1
TREANDA,diffuse alveolar hemorrhage,adverse,0
TREANDA,thrombocytopenia,drug,0
TREANDA,pneumonia,be directly  to rates,1
TREANDA,pneumonia,drug,0
TREANDA,opportunistic infection,in the linical trials of anoth er drug and,1
TREANDA,opportunistic infection,drug,0
TREANDA,opportunistic infection,trials of anoth er drug,1
TREANDA,opportunistic infection,of anoth er drug,1
TREANDA,Infection,vomiting Other adverse ons seen  frequently in,1
TREANDA,Infection,of anoth er drug,1
TREANDA,Infection,reacti,0
TREANDA,Infection,Other adverse ons seen ,1
TREANDA,Infection,reacti,0
TREANDA,Infection,vomiting Other,0
TREANDA,Infection,dry mouth somn,0
TREANDA,Infection,ons seen frequently in one or more,1
TREANDA,pneumonia,more,0
TREANDA,pneumonia,frequently i,0
TREANDA,pneumonia,n one or more,1
TREANDA,sepsis,weakness dry mouth somnolence cough constipation,0
TREANDA,sepsis,re stu dies included asthenia fatigue,1
TREANDA,sepsis,re stu dies,1
TREANDA,sepsis,re stu dies included asthenia fatigue,1
TREANDA,sepsis,frequently in one or re stu dies included asthenia,1
TREANDA,sepsis,re stu dies included asthenia fatigue,1
TREANDA,sepsis,frequently in one or re stu dies,1
TREANDA,sepsis,re stu dies included asthenia fatigue,1
TREANDA,sepsis,and vomiting Other adverse reactions,0
TREANDA,sepsis,asthenia fatigue malaise,0
TREANDA,sepsis,one or re,1
TREANDA,sepsis,adverse reactions seen frequently,0
TREANDA,septic shock,constipation,0
TREANDA,septic shock,studi,0
TREANDA,septic shock,cough constipation headache,0
TREANDA,septic shock,mouth somnolence cough constipation headache muco,0
TREANDA,septic shock,in one or more es included,1
TREANDA,septic shock,more es included ,1
TREANDA,septic shock,in one or more es included,1
TREANDA,septic shock,or more es included  asthenia,1
TREANDA,septic shock,in one or more es included,1
TREANDA,septic shock,es included asthenia,1
TREANDA,septic shock,or more es included  asthenia,1
TREANDA,septic shock,es included asthenia,1
TREANDA,death,"ia, f atigue",1
TREANDA,death,"included ia, f atigue malaise and weakness",1
TREANDA,death,"ia, f atigue",1
TREANDA,death,"ia, f atigue malaise and",1
TREANDA,death,"studies included ia, f atigue malaise",1
TREANDA,death,"ia, f atigue malaise and",1
TREANDA,death,reactions seen frequently in,0
TREANDA,death,"ia, f atigue malaise and",1
TREANDA,death,"more studies included ia, f",1
TREANDA,death,"ia, f atigue malaise and weakness dry",1
TREANDA,myelosuppression,in patients treated with TREANDA,0
TREANDA,infections,with TREA NDA in,1
TREANDA,infections,stomatitis Worsening hypertension was reported in patients,0
TREANDA,infections,with chlorambucil Three,0
TREANDA,infections,and,0
TREANDA,infections,with TREA NDA,1
TREANDA,infections,in patients with TREA,1
TREANDA,infections,with TREA NDA in the CLL trial,1
TREANDA,infections,these adverse reactions,0
TREANDA,Infusion reactions,The most freq uent adverse reactions leading,1
TREANDA,fever,g TRE ANDA,1
TREANDA,fever,g TRE ANDA were,1
TREANDA,fever,receivin,0
TREANDA,fever,study withdrawal for patients g TRE,1
TREANDA,fever,receivin,0
TREANDA,chills,DA wer e,1
TREANDA,chills,pyrexia Table contains the treatment emergent adverse,0
TREANDA,chills,DA wer e hypersensitivity,1
TREANDA,chills,DA wer,1
TREANDA,chills,DA wer,1
TREANDA,chills,e hypersensitivity and pyrexia,0
TREANDA,pruritus,emergent,0
TREANDA,pruritus,for patients receiving TREANDA hypersen sitivity and pyrexia,1
TREANDA,pruritus,emergent,0
TREANDA,rash,TREANDA were ity  and pyrexia Table,1
TREANDA,rash,emergent,0
TREANDA,rash,ity  and pyrexia,1
TREANDA,rash,Table contains,0
TREANDA,rash,were ity  and pyrexia Table contains,1
TREANDA,rash,Table contains,0
TREANDA,anaphylactoid reactions,the,1
TREANDA,anaphylactoid reactions,patients receiving TREANDA were hypersensitivity and pyrexia Table,0
TREANDA,anaphylactoid reactions,the treatment emergent adverse reactions,1
TREANDA,anaphylactoid reactions,treatment emergent adverse reactions regardless,1
TREANDA,SJS,infestat,0
TREANDA,SJS,Infections and ion,1
TREANDA,SJS,infestat,0
TREANDA,SJS,ion,1
TREANDA,SJS,infestat,0
TREANDA,myelodysplastic syndrome,5,1
TREANDA,myelodysplastic syndrome,Weight   5 (3)         0        Metabolism and nutrition,1
TREANDA,myelodysplastic syndrome,5,1
TREANDA,myelodysplastic syndrome,Weight decreased,0
TREANDA,myelodysplastic syndrome,Metabolism,0
TREANDA,myelodysplastic syndrome,Metabolism and,0
TREANDA,myelodysplastic syndrome,Metabolism,0
TREANDA,myeloproliferative disorders,on,0
ELIQUIS,thrombotic events,information Increased risk thrombotic events after premature,1
ELIQUIS,thrombotic events,on,0
ELIQUIS,thrombotic events,prescribing information Increased risk thrombotic events,1
ELIQUIS,thrombotic events,thrombotic,1
ELIQUIS,thrombotic events,thrombotic events after premature discontinuation seeWarnings,1
ELIQUIS,thrombotic events,the prescribing information Increased,0
ELIQUIS,thrombotic events,Increased risk thrombotic events,1
ELIQUIS,thrombotic events,premature discontinuation seeWarnings and,0
ELIQUIS,thrombotic events,thrombotic,1
ELIQUIS,Bleeding,or puncture seeWarnings,0
ELIQUIS,Bleeding,or puncture,0
ELIQUIS,Bleeding,Bleeding seeWarnings and Precautions Spinalepidural,1
ELIQUIS,Bleeding,Bleeding seeWarnings,1
ELIQUIS,Bleeding,Bleeding seeWarnings and Precautions Spinalepidural,1
ELIQUIS,Bleeding,Bleeding seeWarnings,1
ELIQUIS,bleeding-related adverse reactions,studies was bleeding-related adverse reactions in,1
ELIQUIS,bleeding-related adverse reactions,Bleeding seeWarnings,1
ELIQUIS,bleeding,least one,0
ELIQUIS,bleeding,bleeding during,1
ELIQUIS,bleeding,of patients experiencing bleeding during the treatment period and,1
ELIQUIS,bleeding,bleeding during,1
ELIQUIS,bleeding,bleeding during the treatment,1
ELIQUIS,bleeding,and bleeding,1
ELIQUIS,bleeding,bleeding during the treatment,1
ELIQUIS,bleeding,bleeding rate,1
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,bleeding rate percentage of subjects with,1
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,of subjects with at least one bleeding event per,0
ELIQUIS,bleeding,bleeding rate percentage of subjects,1
ELIQUIS,bleeding,subjects with at least one bleeding event per patientyears in ARISTOTLE a,0
ELIQUIS,bleeding,treatment period and bleeding rate percentage,1
ELIQUIS,bleeding,subjects with at least one bleeding event per patientyears in ARISTOTLE a,0
ELIQUIS,bleeding,bleeding rate,1
ELIQUIS,bleeding,bleeding event per patientyears,1
ELIQUIS,bleeding,bleeding event,1
ELIQUIS,bleeding,rate percentage of subjects with at least,0
ELIQUIS,bleeding,at least,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,bleeding event per patientyears in ARISTOTLE,1
ELIQUIS,Bleeding,Bleeding Events,1
ELIQUIS,Bleeding,Bleeding Events in Patients with,1
ELIQUIS,Bleeding,Bleeding Events in Patients,1
ELIQUIS,Bleeding,Ratio,0
ELIQUIS,Bleeding,were counted once per subject but subjects may,0
ELIQUIS,Bleeding,subject but subjects may have contributed,0
ELIQUIS,Bleeding,Bleeding events were counted,1
ELIQUIS,Bleeding,subject but subjects may have contributed,0
ELIQUIS,Bleeding,to,0
ELIQUIS,Bleeding,Bleeding events were,1
ELIQUIS,Bleeding,treatment ontreatment per,0
ELIQUIS,Bleeding,were counted during treatment or within days,0
ELIQUIS,Bleeding,Bleeding events were,1
ELIQUIS,Bleeding,stopping,0
ELIQUIS,Bleeding,treatment ontreatment,0
ELIQUIS,Bleeding,Bleeding events were counted,1
ELIQUIS,bleeding,of stopping study treatment,0
ELIQUIS,bleeding,ontreatment period Defined,0
ELIQUIS,bleeding,period Defined as clinically bleeding accompanied,1
ELIQUIS,bleeding,ontreatment period Defined,0
ELIQUIS,bleeding,one or more of the following a decrease in hemoglobin of gdL a,0
ELIQUIS,bleeding,decrease in hemoglobin of gdL a,0
ELIQUIS,bleeding,of the following a decrease in hemoglobin of gdL a transfusion,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,decrease in hemoglobin,in hemoglobin,1
ELIQUIS,decrease in hemoglobin,following decrease in hemoglobin,1
ELIQUIS,decrease in hemoglobin,in hemoglobin,1
ELIQUIS,decrease in hemoglobin,a transfusion of or more units of packed red blood cells bleeding,0
ELIQUIS,decrease in hemoglobin,in hemoglobin of,1
ELIQUIS,decrease in hemoglobin,more of the following decrease in hemoglobin of gdL a transfusion,1
ELIQUIS,decrease in hemoglobin,in hemoglobin of,1
ELIQUIS,decrease in hemoglobin,the following decrease in hemoglobin of gdL a transfusion of,1
ELIQUIS,decrease in hemoglobin,in hemoglobin of,1
ELIQUIS,decrease in hemoglobin,of the following decrease in hemoglobin,1
ELIQUIS,decrease in hemoglobin,in hemoglobin of,1
ELIQUIS,decrease in hemoglobin,following decrease in hemoglobin of gdL a transfusion of,1
ELIQUIS,decrease in hemoglobin,in hemoglobin of,1
ELIQUIS,bleeding at a critical site,critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,bleeding at a critical site,bleeding at a critical site intracranial,1
ELIQUIS,bleeding at a critical site,critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,bleeding at a critical site,of packed red blood,0
ELIQUIS,bleeding at a critical site,of,0
ELIQUIS,bleeding at a critical site,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,bleeding at a critical site,bleeding at a critical site,1
ELIQUIS,bleeding at a critical site,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,bleeding at a critical site,red blood bleeding at a critical site intracranial,1
ELIQUIS,bleeding at a critical site,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,bleeding at a critical site,of packed red blood bleeding at a critical site intracranial intraspinal intraocular,1
ELIQUIS,bleeding at a critical site,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,compartment syndrome,pericardial intraarticular intramuscular compartment syndrome retroperitoneal or with fatal,1
ELIQUIS,compartment syndrome,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,compartment syndrome,intraocular pericardial intraarticular intramuscular compartment syndrome retroperitoneal or with fatal outcome,1
ELIQUIS,compartment syndrome,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,compartment syndrome,compartment syndrome retroperitoneal or with fatal outcome,1
ELIQUIS,compartment syndrome,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,fatal outcome,or fatal outcome Intracranial bleed includes intracerebral intraventricular,1
ELIQUIS,fatal outcome,at a critical site intracranial intraspinal intraocular pericardial intraarticular,1
ELIQUIS,fatal outcome,retroperitoneal,0
ELIQUIS,fatal outcome,fatal outcome,1
ELIQUIS,Intracranial bleed,fatal Intracranial bleed includes intracerebral intraventricular subdural and,1
ELIQUIS,Intracranial bleed,fatal outcome,1
ELIQUIS,Intracranial bleed,fatal,0
ELIQUIS,Intracranial bleed,intracerebral intraventricular subdural and subarachnoid bleeding,0
ELIQUIS,Intracranial bleed,subdural and,0
ELIQUIS,Intracranial bleed,outcome,0
ELIQUIS,Intracranial bleed,Intracranial bleed includes intracerebral,1
ELIQUIS,Intracranial bleed,Intracranial bleed,1
ELIQUIS,Intracranial bleed,with fatal Intracranial bleed includes intracerebral,1
ELIQUIS,Intracranial bleed,Intracranial bleed,1
ELIQUIS,subarachnoid bleeding,hemorrhagic stroke was adjudicated and counted as an,0
ELIQUIS,subarachnoid bleeding,counted as an intracranial,0
ELIQUIS,subarachnoid bleeding,intracerebral intraventricular subdural subarachnoid bleeding,1
ELIQUIS,subarachnoid bleeding,intraventricular subdural subarachnoid bleeding Any type,1
ELIQUIS,subarachnoid bleeding,intracerebral intraventricular subdural subarachnoid bleeding,1
ELIQUIS,subarachnoid bleeding,subarachnoid bleeding Any type of hemorrhagic,1
ELIQUIS,hemorrhagic stroke,and subarachnoid,0
ELIQUIS,hemorrhagic stroke,Any type hemorrhagic,1
ELIQUIS,hemorrhagic stroke,hemorrhagic,1
ELIQUIS,hemorrhagic stroke,hemorrhagic stroke was adjudicated and counted as,1
ELIQUIS,hemorrhagic stroke,type hemorrhagic stroke was adjudicated and,1
ELIQUIS,hemorrhagic stroke,hemorrhagic stroke was adjudicated and counted as,1
ELIQUIS,GI bleed,based on the safety population,0
ELIQUIS,GI bleed,GI bleed,1
ELIQUIS,GI bleed,based on the safety population,0
ELIQUIS,GI bleed,Fatal bleeding is,0
ELIQUIS,GI bleed,bleeding Fatal bleeding is an,0
ELIQUIS,rectal bleeding,rectal bleeding Fatal,1
ELIQUIS,rectal bleeding,GI rectal bleeding Fatal bleeding is an adjudicated,1
ELIQUIS,rectal bleeding,rectal bleeding Fatal,1
ELIQUIS,rectal bleeding,lower GI rectal bleeding Fatal bleeding is,1
ELIQUIS,rectal bleeding,rectal bleeding Fatal,1
ELIQUIS,rectal bleeding,upper GI lower GI rectal bleeding,1
ELIQUIS,rectal bleeding,rectal bleeding Fatal,1
ELIQUIS,rectal bleeding,Section GI bleed includes upper GI lower,0
ELIQUIS,rectal bleeding,lower GI,0
ELIQUIS,rectal bleeding,death as intracranial,0
ELIQUIS,Fatal,rectal Fatal bleeding is an,1
ELIQUIS,Fatal,death as intracranial,0
ELIQUIS,Fatal,GI and rectal bleeding,0
ELIQUIS,Fatal,GI and rectal Fatal,1
ELIQUIS,Fatal,GI and rectal bleeding,0
ELIQUIS,Fatal,death as intracranial,0
ELIQUIS,Fatal,adjudicated death with the primary cause of death,0
ELIQUIS,Fatal,Section GI bleed includes upper GI lower GI,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,GI and,0
ELIQUIS,bleeding,GI and rectal bleeding bleeding is an,1
ELIQUIS,bleeding,GI and,0
ELIQUIS,bleeding,bleeding is an adjudicated death with,1
ELIQUIS,death,is an death with the primary cause,1
ELIQUIS,death,bleeding is an adjudicated death with,1
ELIQUIS,death,Fatal bleeding is an death with the primary,1
ELIQUIS,death,bleeding is an adjudicated death with,1
ELIQUIS,death,Fatal bleeding is an death with the primary cause,1
ELIQUIS,death,bleeding is an adjudicated death with,1
ELIQUIS,death,death with the primary cause of,1
ELIQUIS,death,death with,1
ELIQUIS,death,death with the primary cause,1
ELIQUIS,death,death with the primary cause of,1
ELIQUIS,death,bleeding Fatal bleeding is an adjudicated,0
ELIQUIS,death,death as intracranial,1
ELIQUIS,death,death as,1
ELIQUIS,death,and rectal bleeding Fatal bleeding is an adjudicated death with,0
ELIQUIS,intracranial bleeding,primary cause of death intracranial bleeding or nonintracranial,1
ELIQUIS,intracranial bleeding,and rectal bleeding Fatal bleeding is an adjudicated death with,0
ELIQUIS,intracranial bleeding,intracranial bleeding or,1
ELIQUIS,intracranial bleeding,intracranial bleeding or,1
ELIQUIS,intracranial bleeding,intracranial bleeding or,1
ELIQUIS,intracranial bleeding,ontreatment period Major,0
ELIQUIS,intracranial bleeding,primary cause of,0
ELIQUIS,intracranial bleeding,of death intracranial bleeding,1
ELIQUIS,intracranial bleeding,intracranial bleeding or nonintracranial bleeding during the,1
ELIQUIS,intracranial bleeding,bleeding during the,0
ELIQUIS,intracranial bleeding,intracranial bleeding or nonintracranial bleeding,1
ELIQUIS,intracranial bleeding,the primary cause,0
ELIQUIS,non-intracranial bleeding,as intracranial bleeding non-intracranial bleeding,1
ELIQUIS,non-intracranial bleeding,the primary cause,0
ELIQUIS,non-intracranial bleeding,bleeding non-intracranial bleeding during,1
ELIQUIS,non-intracranial bleeding,the primary cause,0
ELIQUIS,non-intracranial bleeding,non-intracranial bleeding during the ontreatment period Major,1
ELIQUIS,bleeding,bleeding were generally consistent,1
ELIQUIS,bleeding,bleeding were,1
ELIQUIS,bleeding,bleeding were,1
ELIQUIS,bleeding,bleeding were generally consistent across,1
ELIQUIS,bleeding,bleeding were,1
ELIQUIS,bleeding,ARISTOTLE the results for major,0
ELIQUIS,bleeding,bleeding were generally,1
ELIQUIS,bleeding,bleeding were generally,1
ELIQUIS,bleeding,bleeding were generally,1
ELIQUIS,bled,apixaban with bled more per,1
ELIQUIS,bled,bleeding were generally,1
ELIQUIS,bled,Subjects treated with apixaban with,0
ELIQUIS,bled,bled more per,1
ELIQUIS,bled,bled,1
ELIQUIS,bled,bled more per year than,1
ELIQUIS,bled,region and,0
ELIQUIS,bled,per year than did subjects without diabetes per year,0
ELIQUIS,bled,Figure Subjects treated with,0
ELIQUIS,Bleeding,Bleeding Hazard Ratios by,1
ELIQUIS,Bleeding,Bleeding Hazard Ratios by Baseline,1
ELIQUIS,Bleeding,Bleeding Hazard Ratios by,1
ELIQUIS,Bleeding,Figure Bleeding Hazard Ratios by,1
ELIQUIS,Bleeding,Bleeding Hazard Ratios by,1
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,Figure Bleeding Hazard Ratios by,1
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,year Figure Bleeding Hazard Ratios,1
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,Bleeding Hazard Ratios by,1
ELIQUIS,Bleeding,Bleeding Hazard,1
ELIQUIS,Bleeding,did subjects without diabetes per year Figure Major,0
ELIQUIS,Bleeding,Bleeding Hazard Ratios by,1
ELIQUIS,Bleeding,did subjects without diabetes per year Figure Major,0
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,be,0
ELIQUIS,Bleeding,overinterpreted Bleeding Events,1
ELIQUIS,Bleeding,be,0
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,be,0
ELIQUIS,Bleeding,not be overinterpreted Bleeding Events in Patients with Nonvalvular,1
ELIQUIS,Bleeding,be,0
ELIQUIS,Bleeding,pparent homogeneity or heterogeneity among groups should,0
ELIQUIS,Bleeding,Bleeding Events in Patients with,1
ELIQUIS,Bleeding,Bleeding Forest Plot Other Adverse Reactions,1
ELIQUIS,Bleeding,Bleeding Forest Plot,1
ELIQUIS,Bleeding,ARISTOTLE,0
ELIQUIS,Bleeding,Major,0
ELIQUIS,Hypersensitivity reactions,Hypersensitivity reactions including,1
ELIQUIS,Hypersensitivity reactions,Hypersensitivity reactions including drug hypersensitivity such,1
ELIQUIS,Hypersensitivity reactions,Adverse Hypersensitivity reactions including,1
ELIQUIS,Hypersensitivity reactions,Hypersensitivity reactions including drug hypersensitivity such,1
ELIQUIS,Hypersensitivity reactions,Reactions,0
ELIQUIS,Hypersensitivity reactions,such,0
ELIQUIS,drug hypersensitivity,and syncope were reported,0
ELIQUIS,drug hypersensitivity,Plot Other Adverse,0
ELIQUIS,drug hypersensitivity,rash,0
ELIQUIS,drug hypersensitivity,skin rash and anaphylactic reactions,0
ELIQUIS,drug hypersensitivity,drug hypersensitivity such as skin rash and,1
ELIQUIS,drug hypersensitivity,Reactions Hypersensitivity reactions drug,1
ELIQUIS,drug hypersensitivity,drug hypersensitivity such as skin rash,1
ELIQUIS,drug hypersensitivity,including,0
ELIQUIS,skin rash,reactions such as allergic edema and,0
ELIQUIS,skin rash,such skin,1
ELIQUIS,skin rash,skin rash and anaphylactic,1
ELIQUIS,skin rash,including drug,0
ELIQUIS,skin rash,such as allergic edema and syncope were reported in of,0
ELIQUIS,skin rash,skin rash,1
ELIQUIS,skin rash,hypersensitivity such skin,1
ELIQUIS,skin rash,in of patients r,0
ELIQUIS,skin rash,in,0
ELIQUIS,anaphylactic reactions,as skin rash anaphylactic reactions,1
ELIQUIS,anaphylactic reactions,anaphylactic reactions such,1
ELIQUIS,allergic edema,syncope were reported in of patients receiving ELIQUIS Prophylaxis of,0
ELIQUIS,allergic edema,anaphylactic reactions such allergic,1
ELIQUIS,allergic edema,including drug hypersensitivity such as skin,0
ELIQUIS,allergic edema,anaphylactic reactions such allergic,1
ELIQUIS,allergic edema,skin,0
ELIQUIS,allergic edema,reactions,0
ELIQUIS,syncope,syncope were reported in,1
ELIQUIS,syncope,as allergic edema syncope,1
ELIQUIS,syncope,syncope were reported in,1
ELIQUIS,syncope,in of patients receiving ELIQUIS Prophylaxis of Deep Vein,0
ELIQUIS,syncope,were reported in of patients receiving ELIQUIS Prophylaxis of,0
ELIQUIS,syncope,syncope were reported in of patients,1
ELIQUIS,syncope,syncope were reported,1
ELIQUIS,syncope,syncope were reported in of patients,1
ELIQUIS,syncope,Vein Thrombosis,0
ELIQUIS,Bleeding,Bleeding results,1
ELIQUIS,Bleeding,patients treated with ELIQUIS mg twice daily experienced,0
ELIQUIS,Bleeding,Bleeding results during,1
ELIQUIS,Bleeding,Bleeding results during the treatment,1
ELIQUIS,Bleeding,Bleeding results during,1
ELIQUIS,Bleeding,adverse Bleeding results during the treatment,1
ELIQUIS,Bleeding,Bleeding results during,1
ELIQUIS,Bleeding,in the Phase III studies are shown in Table,0
ELIQUIS,Bleeding,patients,0
ELIQUIS,Bleeding,Bleeding results during the,1
ELIQUIS,Bleeding,mg twice daily experienced,0
ELIQUIS,Bleeding,Bleeding was assessed,1
ELIQUIS,Bleeding,mg twice daily experienced,0
ELIQUIS,Bleeding,are,0
ELIQUIS,Bleeding,Replacement Surgery Ble,0
ELIQUIS,Bleeding,with the,0
ELIQUIS,Bleeding,Table,0
ELIQUIS,Bleeding,in each,0
ELIQUIS,Bleeding,assessed in each study beginning with the first dose of,0
ELIQUIS,bleeding,Surgery bleeding,1
ELIQUIS,bleeding,assessed in each study beginning with the first dose of,0
ELIQUIS,bleeding,Includes subjects with,0
ELIQUIS,bleeding,bleeding criteria,1
ELIQUIS,surgical site bleeding,Surgery All bleeding criteria surgical site bleeding,1
ELIQUIS,surgical site bleeding,bleeding criteria,1
ELIQUIS,surgical site bleeding,surgical site bleeding,1
ELIQUIS,bleeding,bleeding events,1
ELIQUIS,bleeding,bleeding events that,1
ELIQUIS,bleeding,bleeding events that occurred,1
ELIQUIS,bleeding,bleeding events that occurred before the,1
ELIQUIS,bleeding,bleeding Includes subjects with major,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,subjects with major,0
ELIQUIS,bleeding,hours post surgery,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,subjects with bleeding events that occurred,1
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,to hours,0
ELIQUIS,bleeding,bleeding events that occurred before,1
ELIQUIS,bleeding,hours,0
ELIQUIS,bleeding,of apixaban administered to hours post surgery,0
ELIQUIS,bleeding,bleeding events that occurred before,1
ELIQUIS,bleeding,bleeding events that occurred before the,1
ELIQUIS,bleeding,bleeding events that occurred before,1
ELIQUIS,Bleeding into an operated joint,this category of,0
ELIQUIS,Bleeding into an operated joint,all patients with this category of bleeding,0
ELIQUIS,bleeding,Events and event rates include one enoxaparintreated patient in ADVANCE who also,0
ELIQUIS,bleeding,was present,0
ELIQUIS,bleeding,bleeding Events,1
ELIQUIS,bleeding,present in all patients with this category of,0
ELIQUIS,bleeding,bleeding Events,1
ELIQUIS,bleeding,bleeding Events and event rates include,1
ELIQUIS,bleeding,category of,0
ELIQUIS,bleeding,and event rates,0
ELIQUIS,bleeding,bleeding Events and event,1
ELIQUIS,intracranial hemorrhage,also intracranial hemorrhage CRNM clinically,1
ELIQUIS,intracranial hemorrhage,bleeding Events and event,1
ELIQUIS,intracranial hemorrhage,mg po,0
ELIQUIS,intracranial hemorrhage,relevant,0
ELIQUIS,intracranial hemorrhage,include one enoxaparintreated patient in ADVANCE who,0
ELIQUIS,hemorrhagic anemia,postoperative hemorrhagic,1
ELIQUIS,hemorrhagic anemia,postoperative and,0
ELIQUIS,hematoma,hematoma and vaginal and urethral hemorrhage,1
ELIQUIS,hematoma,postoperative and,0
ELIQUIS,hematoma,Hemorrhage hematoma and vaginal and,1
ELIQUIS,hematoma,postoperative and,0
ELIQUIS,hematoma,hematoma and,1
ELIQUIS,urethral hemorrhage,Postprocedural hemorrhage including postpr,0
ELIQUIS,urethral hemorrhage,hematoma and vaginal urethral hemorrhage Postprocedural hemorrhage including,1
ELIQUIS,urethral hemorrhage,Postprocedural hemorrhage including postpr,0
ELIQUIS,urethral hemorrhage,Postprocedural hemorrhage including postpr,0
ELIQUIS,urethral hemorrhage,and vaginal urethral hemorrhage Postprocedural,1
ELIQUIS,urethral hemorrhage,Postprocedural hemorrhage including postpr,0
ELIQUIS,urethral hemorrhage,vaginal urethral hemorrhage,1
ELIQUIS,urethral hemorrhage,and vaginal urethral hemorrhage Postprocedural hemorrhage,1
ELIQUIS,urethral hemorrhage,vaginal urethral hemorrhage,1
ELIQUIS,urethral hemorrhage,vaginal urethral hemorrhage Postprocedural hemorrhage including,1
ELIQUIS,urethral hemorrhage,vaginal urethral hemorrhage,1
ELIQUIS,Postprocedural hemorrhage,vaginal,0
ELIQUIS,Postprocedural hemorrhage,urethral Postprocedural,1
ELIQUIS,Postprocedural hemorrhage,matoma and vaginal and urethral hemorrhage,0
ELIQUIS,Postprocedural hemorrhage,and urethral Postprocedural hemorrhage including postprocedural hematoma,1
ELIQUIS,Postprocedural hemorrhage,matoma and vaginal and urethral hemorrhage,0
ELIQUIS,Postprocedural hemorrhage,urethral Postprocedural hemorrhage including postprocedural hematoma wound hemorrhage,1
ELIQUIS,Postprocedural hemorrhage,matoma and vaginal and urethral hemorrhage,0
ELIQUIS,Postprocedural hemorrhage,site hematoma and,0
ELIQUIS,postprocedural hematoma,hemorrhage including,0
ELIQUIS,postprocedural hematoma,and catheter site,0
ELIQUIS,wound hemorrhage,wound hemorrhage vessel,1
ELIQUIS,wound hemorrhage,wound hemorrhage,1
ELIQUIS,wound hemorrhage,postprocedural wound,1
ELIQUIS,wound hemorrhage,puncture site hematoma and catheter site,0
ELIQUIS,wound hemorrhage,wound hemorrhage vessel puncture,1
ELIQUIS,wound hemorrhage,wound hemorrhage vessel puncture site,1
ELIQUIS,wound hemorrhage,hemorrhage including postprocedural wound hemorrhage vessel puncture,1
ELIQUIS,wound hemorrhage,wound hemorrhage vessel puncture site,1
ELIQUIS,catheter site hemorrhage,site hemorrhage Transaminases increased including,1
ELIQUIS,catheter site hemorrhage,catheter site hemorrhage Transaminases increased including alanine,1
ELIQUIS,catheter site hemorrhage,hematoma catheter site hemorrhage,1
ELIQUIS,catheter site hemorrhage,increased,0
ELIQUIS,catheter site hemorrhage,catheter site hemorrhage Transaminases increased,1
ELIQUIS,catheter site hemorrhage,postprocedural hematoma,0
ELIQUIS,catheter site hemorrhage,puncture site hematoma catheter,1
ELIQUIS,catheter site hemorrhage,hemorrhage vessel puncture site hematoma and,0
ELIQUIS,Transaminases increased,alanine aminotransferase,0
ELIQUIS,Transaminases increased,and catheter site Transaminases,1
ELIQUIS,Transaminases increased,Transaminases increased including alanine aminotransferase increased,1
ELIQUIS,Transaminases increased,including alanine,0
ELIQUIS,Transaminases increased,hematoma and catheter site,0
ELIQUIS,Transaminases increased,Transaminases increased including,1
ELIQUIS,Transaminases increased,alanine,0
ELIQUIS,Transaminases increased,Transaminases increased including alanine aminotransferase,1
ELIQUIS,Transaminases increased,Transaminases increased including,1
ELIQUIS,alanine aminotransferase increased,morrhage Transaminases increased,0
ELIQUIS,alanine aminotransferase increased,and alanine aminotransferase abnormal Aspar,0
ELIQUIS,alanine aminotransferase increased,alanine aminotransferase increased and alanine,1
ELIQUIS,alanine aminotransferase increased,alanine,0
ELIQUIS,alanine aminotransferase abnormal,alanine aminotransferase abnormal Aspartate,1
ELIQUIS,alanine aminotransferase abnormal,aminotransferase,0
ELIQUIS,alanine aminotransferase abnormal,including alanine aminotransferase increased and,0
ELIQUIS,alanine aminotransferase abnormal,Aspartate,0
ELIQUIS,alanine aminotransferase abnormal,alanine aminotransferase increased alanine aminotransferase abnormal,1
ELIQUIS,alanine aminotransferase abnormal,Aspartate,0
ELIQUIS,Aspartate aminotransferase increased,eased and alanine aminotransferase Aspartate aminotransferase,1
ELIQUIS,Aspartate aminotransferase increased,aminotransferase increased Gammaglutamyltransferase i,1
ELIQUIS,Aspartate aminotransferase increased,and alanine aminotransferase Aspartate aminotransferase increased Gammaglutamyltransferase,1
ELIQUIS,Aspartate aminotransferase increased,aminotransferase increased Gammaglutamyltransferase i,1
ELIQUIS,Aspartate aminotransferase increased,aminotransferase increased Gammaglutamyltransferase i,1
ELIQUIS,Aspartate aminotransferase increased,aminotransferase increased,1
ELIQUIS,thrombocytopenia,system thrombocytopenia including platelet count decreases Vascular,1
ELIQUIS,thrombocytopenia,aminotransferase increased,1
ELIQUIS,thrombocytopenia,thrombocytopenia including platelet,1
ELIQUIS,thrombocytopenia,disorders,0
ELIQUIS,thrombocytopenia,Blood and lymphatic system thrombocytopenia including platelet count decreases Vascular,1
ELIQUIS,thrombocytopenia,disorders,0
ELIQUIS,thrombocytopenia,thrombocytopenia including platelet count decreases Vascular,1
ELIQUIS,thrombocytopenia,and lymphatic,0
ELIQUIS,thrombocytopenia,Blood and lymphatic system thrombocytopenia,1
ELIQUIS,thrombocytopenia,and lymphatic,0
ELIQUIS,thrombocytopenia,thrombocytopenia,1
ELIQUIS,platelet count decreases,count decreases Vascular disorders hypotension including,1
ELIQUIS,platelet count decreases,disorders thrombocytopenia platelet count decreases,1
ELIQUIS,platelet count decreases,of to Blood and lymphatic system disorders,0
ELIQUIS,platelet count decreases,thrombocytopenia platelet count decreases Vascular disorders,1
ELIQUIS,platelet count decreases,of to Blood and lymphatic system disorders,0
ELIQUIS,platelet count decreases,platelet count decreases Vascular disorders hypotension including procedural,1
ELIQUIS,platelet count decreases,thrombocytopenia platelet count decreases,1
ELIQUIS,platelet count decreases,platelet count decreases Vascular disorders hypotension including procedural,1
ELIQUIS,platelet count decreases,disorders,0
ELIQUIS,platelet count decreases,platelet count decreases Vascular,1
ELIQUIS,platelet count decreases,and lymphatic system,0
ELIQUIS,platelet count decreases,to Blood and lymphatic,0
ELIQUIS,hypotension,hypotension including procedural hypotension Respiratory thoracic,1
ELIQUIS,hypotension,thoracic and mediastinal disorders,0
ELIQUIS,hypotension,hypotension including,1
ELIQUIS,hypotension,Respiratory thoracic and mediastinal disorders epistax,0
ELIQUIS,hypotension,and mediastinal disorders,0
ELIQUIS,hypotension,hypotension including,1
ELIQUIS,hypotension,decreases,0
ELIQUIS,hypotension,Vascular hypotension including procedural hypotension Respiratory,1
ELIQUIS,hypotension,decreases,0
ELIQUIS,procedural hypotension,hypotension procedural hypotension Respiratory thoracic and mediastinal,1
ELIQUIS,procedural hypotension,decreases,0
ELIQUIS,procedural hypotension,procedural hypotension Respiratory,1
ELIQUIS,procedural hypotension,procedural hypotension,1
ELIQUIS,procedural hypotension,procedural hypotension Respiratory thoracic,1
ELIQUIS,procedural hypotension,platelet count decreases,0
ELIQUIS,procedural hypotension,procedural hypotension Respiratory thoracic and mediastinal disorders,1
ELIQUIS,procedural hypotension,decreases Vascular disorders hypotension procedural hypotension Respiratory thoracic and,1
ELIQUIS,procedural hypotension,procedural hypotension Respiratory thoracic and mediastinal disorders,1
ELIQUIS,epistaxis,epistaxis Gastrointestinal disorders gastrointestinal hemorrhage,1
ELIQUIS,epistaxis,disorders,0
ELIQUIS,epistaxis,epistaxis Gastrointestinal disorders gastrointestinal hemorrhage including,1
ELIQUIS,epistaxis,epistaxis Gastrointestinal disorders gastrointestinal hemorrhage including,1
ELIQUIS,gastrointestinal hemorrhage,disorders epistaxis Gastrointestinal disorders,0
ELIQUIS,gastrointestinal hemorrhage,Hepatobiliary,0
ELIQUIS,gastrointestinal hemorrhage,hematochezia Hepatobiliary disorders liver function tes,0
ELIQUIS,gastrointestinal hemorrhage,and melena hematochezia Hepatobiliary disorders,0
ELIQUIS,hematemesis,gastrointestinal hemorrhage hematemesis,1
ELIQUIS,hematemesis,and melena hematochezia Hepatobiliary disorders,0
ELIQUIS,hematemesis,gastrointestinal hemorrhage hematemesis,1
ELIQUIS,hematemesis,and melena hematochezia Hepatobiliary disorders,0
ELIQUIS,hematemesis,hematemesis and melena hematochezia,1
ELIQUIS,hematemesis,hematemesis and melena hematochezia Hepatobiliary disorders,1
ELIQUIS,hematemesis,gastrointestinal hemorrhage hematemesis and,1
ELIQUIS,hematemesis,hematemesis and melena hematochezia Hepatobiliary disorders,1
ELIQUIS,hematemesis,hematemesis,1
ELIQUIS,hematemesis,hematemesis and melena hematochezia Hepatobiliary disorders,1
ELIQUIS,hematemesis,hematemesis,1
ELIQUIS,hematemesis,hematemesis and melena hematochezia,1
ELIQUIS,melena,melena hematochezia Hepatobiliary disorders,1
ELIQUIS,melena,hematemesis and melena hematochezia,1
ELIQUIS,melena,hematemesis melena hematochezia Hepatobiliary disorders liver function,1
ELIQUIS,melena,hematemesis and melena hematochezia,1
ELIQUIS,melena,epistaxis Gastrointestinal disorders,0
ELIQUIS,melena,melena,1
ELIQUIS,melena,melena hematochezia Hepatobiliary disorders liver function,1
ELIQUIS,melena,melena hematochezia Hepatobiliary,1
ELIQUIS,hematochezia,including hematemesis and melena,0
ELIQUIS,liver function test abnormal,increased,0
ELIQUIS,liver function test abnormal,and urinary,0
ELIQUIS,liver function test abnormal,Renal and urinary disorders,0
ELIQUIS,liver function test abnormal,melena hematochezia,0
ELIQUIS,blood alkaline phosphatase increased,liver function test blood alkaline phosphatase increased,1
ELIQUIS,blood alkaline phosphatase increased,function test blood alkaline phosphatase increased,1
ELIQUIS,blood alkaline phosphatase increased,phosphatase increased blood bilirubin increased Renal and,1
ELIQUIS,blood bilirubin increased,bilirubin increased Renal and urinary,1
ELIQUIS,blood bilirubin increased,blood,1
ELIQUIS,blood bilirubin increased,bilirubin increased,1
ELIQUIS,blood bilirubin increased,Hepatobiliary disorders liver function,0
ELIQUIS,hematuria,blood bilirubin increased Renal,0
ELIQUIS,hematuria,hematuria,1
ELIQUIS,wound secretion,procedural complications,0
ELIQUIS,wound secretion,parameters Injury poisoning,0
ELIQUIS,wound secretion,including incisionsite hematoma operative hemorrhage Less,0
ELIQUIS,wound secretion,wound secretion,1
ELIQUIS,incision-site hemorrhage,incision-site hemorrhage including incisionsite hematoma operative hemorrhage,1
ELIQUIS,incision-site hemorrhage,wound secretion,1
ELIQUIS,incision-site hemorrhage,and procedural complications wound incision-site hemorrhage,1
ELIQUIS,incision-site hemorrhage,incision-site hemorrhage,1
ELIQUIS,incision-site hemorrhage,incision-site hemorrhage including incisionsite hematoma,1
ELIQUIS,incision-site hemorrhage,incision-site hemorrhage,1
ELIQUIS,incision-site hemorrhage,complications wound incision-site,1
ELIQUIS,incision-site hematoma,incision-site hematoma operative,1
ELIQUIS,incision-site hematoma,incision-site hematoma operative hemorrhage Less common,1
ELIQUIS,incision-site hematoma,incision-site hematoma operative,1
ELIQUIS,incision-site hematoma,operative hemorrhage Less common,0
ELIQUIS,incision-site hematoma,operative hemorrhage Less common adverse reactions in apixabantreated,0
ELIQUIS,incision-site hematoma,common adverse reactions in apixabantreated patients undergoing hi,0
ELIQUIS,incision-site hematoma,hemorrhage incision-site hematoma operative hemorrhage Less,1
ELIQUIS,incision-site hematoma,common adverse reactions in apixabantreated patients undergoing hi,0
ELIQUIS,incision-site hematoma,incision-site hematoma operative hemorrhage Less,1
ELIQUIS,incision-site hematoma,incision-site hematoma operative hemorrhage Less common adverse,1
ELIQUIS,incision-site hematoma,incision-site hematoma operative hemorrhage Less,1
ELIQUIS,incision-site hematoma,secretion incisionsite hemorrhage,0
ELIQUIS,operative hemorrhage,operative hemorrhage,1
ELIQUIS,operative hemorrhage,patients,0
ELIQUIS,operative hemorrhage,hip or,0
ELIQUIS,hemoptysis,hypersensitivity muscle hemorrhage ocular hemorrhage including,0
ELIQUIS,hemoptysis,hypersensitivity,0
ELIQUIS,hemoptysis,of Gingival bleeding,0
ELIQUIS,hemoptysis,hemorrhage including conjunctival,0
ELIQUIS,hemoptysis,of Gingival hemoptysis hypersensitivity muscle hemorrhage,1
ELIQUIS,hemoptysis,hemorrhage including conjunctival,0
ELIQUIS,hemoptysis,of Gingival hemoptysis,1
ELIQUIS,hemoptysis,hemorrhage including conjunctival,0
ELIQUIS,hypersensitivity,hypersensitivity,1
ELIQUIS,hypersensitivity,frequency of Gingival bleeding,0
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage ocular,1
ELIQUIS,hypersensitivity,Gingival bleeding hypersensitivity,1
ELIQUIS,hypersensitivity,hypersensitivity muscle hemorrhage ocular,1
ELIQUIS,hypersensitivity,hypersensitivity,1
ELIQUIS,muscle hemorrhage,Treatment,0
ELIQUIS,muscle hemorrhage,hemoptysis muscle hemorrhage,1
ELIQUIS,muscle hemorrhage,muscle hemorrhage ocular hemorrhage including conjunctival,1
ELIQUIS,muscle hemorrhage,hemoptysis muscle hemorrhage ocular hemorrhage including,1
ELIQUIS,muscle hemorrhage,muscle hemorrhage ocular hemorrhage including conjunctival,1
ELIQUIS,muscle hemorrhage,Gingival,0
ELIQUIS,ocular hemorrhage,and PE,0
ELIQUIS,ocular hemorrhage,ocular hemorrhage,1
ELIQUIS,ocular hemorrhage,ocular,1
ELIQUIS,ocular hemorrhage,bleeding hemoptysis hypersensitivity muscle ocular,1
ELIQUIS,conjunctival hemorrhage,muscle hemorrhage ocular hemorrhage conjunctival hemorrhage rectal hemorrhage Treatment,1
ELIQUIS,conjunctival hemorrhage,bleeding hemoptysis hypersensitivity muscle ocular,1
ELIQUIS,conjunctival hemorrhage,ocular hemorrhage conjunctival hemorrhage rectal,1
ELIQUIS,conjunctival hemorrhage,bleeding hemoptysis hypersensitivity muscle ocular,1
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage,1
ELIQUIS,conjunctival hemorrhage,ocular hemorrhage conjunctival,1
ELIQUIS,conjunctival hemorrhage,Gingival bleeding hemoptysis hypersensitivity muscle hemorrhage ocular hemorrhage,0
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage rectal hemorrhage Treatment,1
ELIQUIS,conjunctival hemorrhage,Gingival bleeding hemoptysis hypersensitivity muscle hemorrhage ocular hemorrhage,0
ELIQUIS,conjunctival hemorrhage,hemoptysis hypersensitivity muscle hemorrhage ocular,0
ELIQUIS,conjunctival hemorrhage,hemorrhage conjunctival hemorrhage rectal hemorrhage Treatment of DVT,1
ELIQUIS,conjunctival hemorrhage,hemoptysis hypersensitivity muscle hemorrhage ocular,0
ELIQUIS,conjunctival hemorrhage,Gingival bleeding hemoptysis hypersensitivity muscle hemorrhage ocular hemorrhage including,0
ELIQUIS,rectal hemorrhage,rectal hemorrhage Treatment of DVT,1
ELIQUIS,rectal hemorrhage,muscle hemorrhage ocular hemorrhage,0
ELIQUIS,rectal hemorrhage,including conjunctival,0
ELIQUIS,epistaxis,epistaxis contusion,1
ELIQUIS,epistaxis,including conjunctival,0
ELIQUIS,epistaxis,to ELIQUIS mg twice daily Common adverse,0
ELIQUIS,epistaxis,epistaxis contusion hematuria rectal hemorrhage,1
ELIQUIS,contusion,epistaxis,0
ELIQUIS,contusion,were gingival bleeding contusion,1
ELIQUIS,contusion,epistaxis,0
ELIQUIS,contusion,hemoptysis AMPLIFY Study,0
ELIQUIS,contusion,menorrhagia,0
ELIQUIS,contusion,and,0
ELIQUIS,contusion,contusion hematuria rectal hemorrhage,1
ELIQUIS,hematuria,hematuria rectal hemorrhage hematoma menorrhagia,1
ELIQUIS,hematuria,hemoptysis AMPLIFY Study The,0
ELIQUIS,hematuria,hematuria,1
ELIQUIS,hematuria,hematuria,1
ELIQUIS,hematuria,hematuria,1
ELIQUIS,hematuria,epistaxis hematuria rectal hemorrhage hematoma,1
ELIQUIS,hematuria,hematuria,1
ELIQUIS,hematuria,were gingival bleeding epistaxis,0
ELIQUIS,rectal hemorrhage,bleeding epistaxis contusion hematuria,0
ELIQUIS,rectal hemorrhage,Study The mean duration of,0
ELIQUIS,rectal hemorrhage,rectal hemorrhage,1
ELIQUIS,rectal hemorrhage,epistaxis contusion rectal hemorrhage,1
ELIQUIS,rectal hemorrhage,were gingival bleeding,0
ELIQUIS,rectal hemorrhage,hemoptysis AMPLIFY Study The mean duration of,0
ELIQUIS,rectal hemorrhage,duration of exposure to ELI,0
ELIQUIS,rectal hemorrhage,were,0
ELIQUIS,rectal hemorrhage,rectal,1
ELIQUIS,hematoma,epistaxis contusion hematuria rectal hemorrhage,0
ELIQUIS,menorrhagia,hematuria rectal,0
ELIQUIS,menorrhagia,rectal hemorrhage,0
ELIQUIS,menorrhagia,gingival bleeding epistaxis contusion hematuria rectal hemorrhage hematoma,0
ELIQUIS,menorrhagia,hemorrhage hematoma,0
ELIQUIS,menorrhagia,contusion hematuria rectal hemorrhage menorrhagia and hemoptysis AMPLIFY,1
ELIQUIS,menorrhagia,hemorrhage hematoma,0
ELIQUIS,menorrhagia,menorrhagia and hemoptysis AMPLIFY Study,1
ELIQUIS,hemoptysis,menorrhagia,0
ELIQUIS,hemoptysis,hemoptysis,1
ELIQUIS,hemoptysis,epistaxis contusion hematuria rectal hemorrhage hematoma menorrhagia and,0
ELIQUIS,hemoptysis,hemoptysis AMPLIFY Study,1
ELIQUIS,hemoptysis,hemoptysis,1
ELIQUIS,bleeding,was days in,0
ELIQUIS,bleeding,compared,0
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,in the AMPLIFY study Adverse reactions related to,0
ELIQUIS,bleeding,reactions related bleeding occurred in ELIQUIStreated,1
ELIQUIS,bleeding,in the AMPLIFY study Adverse reactions related to,0
ELIQUIS,bleeding,occurred in ELIQUIStreated,0
ELIQUIS,bleeding,Adverse reactions related bleeding occurred in,1
ELIQUIS,bleeding,occurred in ELIQUIStreated,0
ELIQUIS,bleeding,bleeding occurred in ELIQUIStreated patients compared,1
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,rate due to,0
ELIQUIS,bleeding,the ELIQUIStreated,0
ELIQUIS,bleeding,CI Pvalue,0
ELIQUIS,Bleeding,Bleeding results from the AMPLIFY,1
ELIQUIS,Bleeding,y safety endpoint of major bleeding relative risk CI Pvalue,0
ELIQUIS,Bleeding,bleeding relative risk CI Bleeding results from the,1
ELIQUIS,Bleeding,y safety endpoint of major bleeding relative risk CI Pvalue,0
ELIQUIS,Bleeding,bleeding relative risk CI Bleeding results,1
ELIQUIS,Bleeding,y safety endpoint of major bleeding relative risk CI Pvalue,0
ELIQUIS,Bleeding,Bleeding Results in the AMPLIFY Study,1
ELIQUIS,Bleeding,AMPLIFY Study,0
ELIQUIS,Bleeding,Bleeding Results in,1
ELIQUIS,Bleeding,Bleeding,1
ELIQUIS,Bleeding,Bleeding Results,1
ELIQUIS,Bleeding,Table Bleeding Results,1
ELIQUIS,Bleeding,Bleeding Results,1
ELIQUIS,Bleeding,in,0
ELIQUIS,Bleeding,are summarized in Table Bleeding Results in,1
ELIQUIS,Bleeding,in,0
ELIQUIS,Bleeding,Bleeding Results in,1
ELIQUIS,CRNM,Risk CI,0
ELIQUIS,CRNM,CRNM clinically relevant nonmajor bleedingEvents associated,1
ELIQUIS,CRNM,ELIQUISNn EnoxaparinWarfarinNn Relative Risk CRNM clinically relevant,1
ELIQUIS,CRNM,CRNM clinically relevant nonmajor bleedingEvents associated,1
ELIQUIS,CRNM,EnoxaparinWarfarinNn Relative Risk CRNM clinically relevant,1
ELIQUIS,CRNM,CRNM clinically relevant nonmajor bleedingEvents associated,1
ELIQUIS,clinically relevant nonmajor bleeding,IQUISNn EnoxaparinWarfarinNn Relative Risk CI CRNM,0
ELIQUIS,clinically relevant nonmajor bleeding,Relative Risk CI clinically,1
ELIQUIS,clinically relevant nonmajor bleeding,clinically relevant nonmajor bleeding Events associated with each,1
ELIQUIS,clinically relevant nonmajor bleeding,relevant nonmajor bleeding Events associated with each endpoint,1
ELIQUIS,clinically relevant nonmajor bleeding,per,0
ELIQUIS,clinically relevant nonmajor bleeding,once per subject but subjects may,0
ELIQUIS,clinically relevant nonmajor bleeding,nonmajor bleeding Events associated,1
ELIQUIS,clinically relevant nonmajor bleeding,Risk CI clinically relevant nonmajor,1
ELIQUIS,bleeding,Adverse reactions related bleeding occurred in ELIQUIStreated patients compared,1
ELIQUIS,bleeding,Risk CI clinically relevant nonmajor,1
ELIQUIS,bleeding,in ELIQUIStreated patients compared to,0
ELIQUIS,bleeding,Adverse reactions related bleeding occurred in ELIQUIStreated,1
ELIQUIS,bleeding,in ELIQUIStreated patients compared to,0
ELIQUIS,bleeding,ELIQUIStreated patients compared to,0
ELIQUIS,bleeding,occurred in ELIQUIStreated patients compared to placebotreated patients,0
ELIQUIS,bleeding,bleeding events was approximately in,1
ELIQUIS,bleeding,to,0
ELIQUIS,bleeding,bleeding events was,1
ELIQUIS,bleeding,bleeding,1
ELIQUIS,bleeding,approximately in the ELIQUIStreated patients compared to in those patients in,0
ELIQUIS,bleeding,bleeding events was approximately,1
ELIQUIS,bleeding,approximately in the ELIQUIStreated patients compared to in those patients in,0
ELIQUIS,bleeding,was,0
ELIQUIS,bleeding,bleeding events was approximately in,1
ELIQUIS,Bleeding,Bleeding results from the,1
ELIQUIS,Bleeding,Bleeding results from the AMPLIFYEXT study,1
ELIQUIS,Bleeding,Table Table Bleeding,0
ELIQUIS,Bleeding,results from the AMPLIFYEXT study are summarized in Table,0
ELIQUIS,Bleeding,Table Bleeding Results in the AMPLIFYEXT Study,1
ELIQUIS,Bleeding,results from the AMPLIFYEXT study are summarized in Table,0
ELIQUIS,Bleeding,the AMPLIFYEXT Study ELIQUIS mg bidNn,0
ELIQUIS,CRNM,bidNn,0
ELIQUIS,CRNM,CRNM clinically relevant,1
ELIQUIS,CRNM,CRNM clinically relevant,1
ELIQUIS,CRNM,counted,0
ELIQUIS,CRNM,CRNM,1
ELIQUIS,CRNM,CRNM clinically relevant nonmajor bleedingEvents,1
ELIQUIS,clinically relevant nonmajor bleeding,may,0
ELIQUIS,clinically relevant nonmajor bleeding,ELIQUIS mg bidNn PlaceboNn clinically relevant,1
ELIQUIS,hemorrhagic anemia,system hemorrhagic anemia,1
ELIQUIS,hematochezia,hemorrhagic anemia,0
ELIQUIS,hematochezia,hematochezia hemorrhoidal hemorrhage gastrointestinal,1
ELIQUIS,hematochezia,hematochezia,1
ELIQUIS,hematochezia,hemorrhoidal hemorrhage gastrointestinal hemorrhage hematemesis melena anal,0
ELIQUIS,hematochezia,hematochezia hemorrhoidal hemorrhage gastrointestinal hemorrhage,1
ELIQUIS,hematochezia,hematochezia hemorrhoidal hemorrhage,1
ELIQUIS,hematochezia,hemorrhagic anemia Gastrointestinal hematochezia hemorrhoidal hemorrhage gastrointestinal,1
ELIQUIS,hematochezia,hematochezia hemorrhoidal hemorrhage,1
ELIQUIS,hematochezia,gastrointestinal hemorrhage hematemesis melena anal hemorrhage,0
ELIQUIS,hemorrhoidal hemorrhage,hemorrhoidal hemorrhage,1
ELIQUIS,hemorrhoidal hemorrhage,hemorrhoidal hemorrhage,1
ELIQUIS,hemorrhoidal hemorrhage,hemorrhoidal hemorrhage,1
ELIQUIS,gastrointestinal hemorrhage,gastrointestinal hemorrhage hematemesis melena,1
ELIQUIS,gastrointestinal hemorrhage,anal,0
ELIQUIS,hematemesis,hemorrhage,0
ELIQUIS,melena,gastrointestinal hemorrhage melena anal hemorrhage,1
ELIQUIS,melena,hemorrhage,0
ELIQUIS,melena,melena anal hemorrhage Injury,1
ELIQUIS,melena,melena anal hemorrhage Injury poisoning,1
ELIQUIS,melena,melena anal hemorrhage,1
ELIQUIS,melena,Injury poisoning and procedural complications,0
ELIQUIS,melena,melena anal,1
ELIQUIS,melena,hemorrhoidal hemorrhage gastrointestinal hemorrhage melena,1
ELIQUIS,melena,melena anal,1
ELIQUIS,anal hemorrhage,anal hemorrhage Injury poisoning and,1
ELIQUIS,anal hemorrhage,melena anal,1
ELIQUIS,anal hemorrhage,gastrointestinal hemorrhage hematemesis anal,1
ELIQUIS,anal hemorrhage,gastrointestinal hemorrhage hematemesis anal hemorrhage,1
ELIQUIS,anal hemorrhage,gastrointestinal hemorrhage hematemesis anal,1
ELIQUIS,anal hemorrhage,anal hemorrhage Injury poisoning and procedural complications,1
ELIQUIS,anal hemorrhage,hemorrhage gastrointestinal hemorrhage hematemesis anal hemorrhage Injury poisoning and procedural,1
ELIQUIS,anal hemorrhage,anal hemorrhage Injury poisoning and procedural complications,1
ELIQUIS,anal hemorrhage,anal hemorrhage Injury,1
ELIQUIS,wound hemorrhage,poisoning and procedural,0
ELIQUIS,wound hemorrhage,hematoma periorbital hematoma Musculoskeletal and conn,0
ELIQUIS,traumatic hematoma,tissue disorders,0
ELIQUIS,traumatic hematoma,disorders muscle,0
ELIQUIS,traumatic hematoma,traumatic hematoma periorbital hematoma,1
ELIQUIS,traumatic hematoma,postprocedural traumatic hematoma periorbital hematoma,1
ELIQUIS,traumatic hematoma,traumatic hematoma periorbital hematoma,1
ELIQUIS,traumatic hematoma,complications wound hemorrhage postprocedural traumatic,1
ELIQUIS,traumatic hematoma,traumatic hematoma periorbital,1
ELIQUIS,traumatic hematoma,postprocedural traumatic hematoma periorbital hematoma,1
ELIQUIS,traumatic hematoma,traumatic hematoma periorbital,1
ELIQUIS,periorbital hematoma,hemorrhage postprocedural hemorrhage traumatic periorbital,1
ELIQUIS,periorbital hematoma,disorders muscle hemorrhage,0
ELIQUIS,muscle hemorrhage,connective tissue muscle,1
ELIQUIS,muscle hemorrhage,and connective tissue muscle hemorrhage Reproductive system,1
ELIQUIS,muscle hemorrhage,connective tissue muscle,1
ELIQUIS,muscle hemorrhage,tissue muscle hemorrhage,1
ELIQUIS,muscle hemorrhage,connective tissue muscle,1
ELIQUIS,muscle hemorrhage,disorders vaginal,0
ELIQUIS,muscle hemorrhage,tissue muscle hemorrhage Reproductive system and,1
ELIQUIS,muscle hemorrhage,disorders vaginal,0
ELIQUIS,muscle hemorrhage,muscle hemorrhage Reproductive,1
ELIQUIS,muscle hemorrhage,disorders vaginal,0
ELIQUIS,muscle hemorrhage,traumatic hematoma,0
ELIQUIS,muscle hemorrhage,Musculoskeletal and connective tissue muscle hemorrhage Reproductive,1
ELIQUIS,muscle hemorrhage,traumatic hematoma,0
ELIQUIS,muscle hemorrhage,and breast disorders vaginal hemorrhage metrorrhagia menometrorrhagia,0
ELIQUIS,vaginal hemorrhage,Reproductive system and breast vaginal hemorrhage metrorrhagia menometrorrhagia,1
ELIQUIS,vaginal hemorrhage,and breast disorders vaginal hemorrhage metrorrhagia menometrorrhagia,0
ELIQUIS,vaginal hemorrhage,breast vaginal hemorrhage,1
ELIQUIS,vaginal hemorrhage,system and breast vaginal hemorrhage,1
ELIQUIS,metrorrhagia,hemorrhage,0
ELIQUIS,metrorrhagia,metrorrhagia menometrorrhagia genital hemorrhage Vascular,1
ELIQUIS,metrorrhagia,metrorrhagia menometrorrhagia genital hemorrhage Vascular,1
ELIQUIS,metrorrhagia,hemorrhage,0
ELIQUIS,metrorrhagia,metrorrhagia menometrorrhagia genital,1
ELIQUIS,metrorrhagia,hemorrhage,0
ELIQUIS,metrorrhagia,genital hemorrhage,0
ELIQUIS,metrorrhagia,metrorrhagia menometrorrhagia genital,1
ELIQUIS,metrorrhagia,metrorrhagia menometrorrhagia genital hemorrhage,1
ELIQUIS,menometrorrhagia,disorders vaginal hemorrhage,0
ELIQUIS,menometrorrhagia,breast disorders vaginal hemorrhage menometrorrhagia genital hemorrhage Vascular,1
ELIQUIS,menometrorrhagia,disorders vaginal hemorrhage,0
ELIQUIS,menometrorrhagia,disorders vaginal hemorrhage menometrorrhagia genital hemorrhage Vascular,1
ELIQUIS,menometrorrhagia,disorders vaginal hemorrhage,0
ELIQUIS,menometrorrhagia,and subcutaneous tissue,0
ELIQUIS,menometrorrhagia,subcutaneous,0
ELIQUIS,menometrorrhagia,vaginal hemorrhage menometrorrhagia genital,1
ELIQUIS,menometrorrhagia,subcutaneous,0
ELIQUIS,menometrorrhagia,uscle hemorrhage Reproductive system and breast,0
ELIQUIS,menometrorrhagia,vaginal hemorrhage,0
ELIQUIS,menometrorrhagia,menometrorrhagia genital hemorrhage Vascular disorders hemorrhage,1
ELIQUIS,menometrorrhagia,menometrorrhagia,1
ELIQUIS,genital hemorrhage,and subcutaneous,0
ELIQUIS,genital hemorrhage,genital hemorrhage Vascular disorders,1
ELIQUIS,genital hemorrhage,vaginal hemorrhage metrorrhagia genital hemorrhage Vascular,1
ELIQUIS,genital hemorrhage,genital hemorrhage Vascular disorders,1
ELIQUIS,hemorrhage,hemorrhage,0
ELIQUIS,ecchymosis,tissue ecchymosis skin hemorrhage petechiae,1
ELIQUIS,ecchymosis,hemorrhage,0
ELIQUIS,ecchymosis,ecchymosis skin hemorrhage petechiae Eye,1
ELIQUIS,skin hemorrhage,tissue disorders skin,1
ELIQUIS,skin hemorrhage,disorders,0
ELIQUIS,skin hemorrhage,and subcutaneous tissue disorders skin hemorrhage petechiae Eye disorders conjunctival hemorrhage,1
ELIQUIS,skin hemorrhage,disorders,0
ELIQUIS,skin hemorrhage,skin hemorrhage petechiae Eye disorders,1
ELIQUIS,skin hemorrhage,tissue disorders skin hemorrhage petechiae Eye disorders conjunctival hemorrhage,1
ELIQUIS,skin hemorrhage,skin hemorrhage petechiae Eye disorders,1
ELIQUIS,skin hemorrhage,e Vascular disorders hemorrhage Skin and subcutaneous,0
ELIQUIS,skin hemorrhage,conjunctival hemorrhage retinal hemorrhage,0
ELIQUIS,skin hemorrhage,tissue disorders skin hemorrhage,1
ELIQUIS,skin hemorrhage,conjunctival hemorrhage retinal hemorrhage,0
ELIQUIS,petechiae,petechiae Eye disorders,1
ELIQUIS,petechiae,Skin and subcutaneous tissue disorders ecchymosis,0
ELIQUIS,conjunctival hemorrhage,tissue disorders ecchymosis skin hemorrhage petechiae,0
ELIQUIS,conjunctival hemorrhage,urine,0
ELIQUIS,conjunctival hemorrhage,eye hemorrhage,0
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage retinal,1
ELIQUIS,conjunctival hemorrhage,eye hemorrhage,0
ELIQUIS,conjunctival hemorrhage,and,0
ELIQUIS,conjunctival hemorrhage,skin hemorrhage petechiae Eye conjunctival,1
ELIQUIS,conjunctival hemorrhage,hemorrhage petechiae Eye conjunctival hemorrhage,1
ELIQUIS,conjunctival hemorrhage,skin hemorrhage petechiae Eye conjunctival,1
ELIQUIS,conjunctival hemorrhage,conjunctival hemorrhage retinal hemorrhage eye hemorrhage Investigations,1
ELIQUIS,conjunctival hemorrhage,Eye conjunctival,1
ELIQUIS,retinal hemorrhage,hemorrhage,0
ELIQUIS,eye hemorrhage,eye hemorrhage Investigations blood,1
ELIQUIS,eye hemorrhage,hemorrhage retinal eye hemorrhage Investigations blood,1
ELIQUIS,eye hemorrhage,eye hemorrhage Investigations blood,1
ELIQUIS,eye hemorrhage,eye hemorrhage Investigations,1
ELIQUIS,blood urine present,urine present occult blood positive occult blood,1
ELIQUIS,occult blood positive,disorders,0
ELIQUIS,occult blood positive,Investigations blood urine occult blood positive occult blood red blood cells,1
ELIQUIS,occult blood positive,disorders,0
ELIQUIS,occult blood positive,present,0
ELIQUIS,occult blood positive,Investigations blood urine occult blood positive occult blood,1
ELIQUIS,occult blood positive,present,0
ELIQUIS,occult blood positive,blood positive,1
ELIQUIS,occult blood positive,red blood,0
ELIQUIS,occult blood positive,blood,0
ELIQUIS,occult blood positive,urine occult blood positive occult,1
ELIQUIS,occult blood positive,blood,0
ELIQUIS,occult blood,occult blood occult blood,1
ELIQUIS,occult blood,blood,0
ELIQUIS,occult blood,occult blood,1
ELIQUIS,red blood cells urine positive,blood cells urine positive General disorders and,1
ELIQUIS,injection-site hematoma,vessel,0
ELIQUIS,injection-site hematoma,vessel,0
ELIQUIS,injection-site hematoma,vessel puncturesite hematoma,0
ELIQUIS,injection-site hematoma,and administrationsite injection-site hematoma,1
ELIQUIS,injection-site hematoma,General disorders and administrationsite injection-site hematoma vessel puncturesite hematoma,1
ELIQUIS,injection-site hematoma,and administrationsite injection-site hematoma,1
ELIQUIS,injection-site hematoma,vessel,0
ELIQUIS,injection-site hematoma,disorders and,0
ELIQUIS,injection-site hematoma,vessel puncturesite,0
ELIQUIS,injection-site hematoma,injection-site hematoma vessel puncturesite hematoma,1
ELIQUIS,injection-site hematoma,injection-site hematoma vessel puncturesite,1
ELIQUIS,THROMBOTIC EVENTS,of,0
ELIQUIS,THROMBOTIC EVENTS,discussed in greater etail in other,1
ELIQUIS,THROMBOTIC EVENTS,other se ctions of the prescribing information,1
ELIQUIS,THROMBOTIC EVENTS,in other se ctions of the,1
ELIQUIS,THROMBOTIC EVENTS,in other se ctions,1
ELIQUIS,THROMBOTIC EVENTS,etail in other se,1
ELIQUIS,THROMBOTIC EVENTS,other se ctions of the,1
ELIQUIS,THROMBOTIC EVENTS,d,0
ELIQUIS,EPIDURAL HEMATOMA,greater detail in,0
ELIQUIS,EPIDURAL HEMATOMA,he prescribing in formation Increased,1
ELIQUIS,EPIDURAL HEMATOMA,greater detail in,0
ELIQUIS,EPIDURAL HEMATOMA,he prescribing in formation Increased,1
ELIQUIS,EPIDURAL HEMATOMA,greater detail in,0
ELIQUIS,THROMBOTIC EVENTS,premature,0
ELIQUIS,THROMBOTIC EVENTS,after premature,0
ELIQUIS,THROMBOTIC EVENTS,and Precautions Bleeding seeWarnings and Precautions Spina,0
ELIQUIS,THROMBOTIC EVENTS,after premature continuation [see Warnings and Precautions Bleeding,1
ELIQUIS,THROMBOTIC EVENTS,and Precautions Bleeding seeWarnings and Precautions Spina,0
ELIQUIS,THROMBOTIC EVENTS,continuation [see Warnings and Precautions Bleeding seeWarnings,1
ELIQUIS,THROMBOTIC EVENTS,after premature continuation,1
ELIQUIS,EPIDURAL HEMATOMA,Precautions Spinalepidural anesthesia or,0
ELIQUIS,EPIDURAL HEMATOMA,risk of thrombotic events after premature discontinuation seeWarnings,0
ELIQUIS,EPIDURAL HEMATOMA,after premature discontinuation seeWarnings d,1
ELIQUIS,EPIDURAL HEMATOMA,discontinuation seeWarnings d Precautions (5.,1
ELIQUIS,EPIDURAL HEMATOMA,Precautions (5.,1
ELIQUIS,THROMBOTIC EVENTS,inal/epidural ane sthesia or puncture seeWarnings,1
ELIQUIS,THROMBOTIC EVENTS,Precautions EXCERPT,0
ELIQUIS,THROMBOTIC EVENTS,seeWarnings and Precautions inal/epidural ane,1
ELIQUIS,thrombotic events,adverse s (>1%) are,1
ELIQUIS,thrombotic events,s (>1%) are relat ed to,1
ELIQUIS,thrombotic events,s,1
ELIQUIS,thrombotic events,common adverse s (>1%) are relat,1
ELIQUIS,spinal hematomas,trials of a g,1
ELIQUIS,spinal hematomas,of a g cannot be dire ctly compared to rates,1
ELIQUIS,spinal hematomas,trials of a g,1
ELIQUIS,spinal hematomas,clinical,0
ELIQUIS,hematomas,"

   Redu ction of",1
ELIQUIS,hematomas,clinical,0
ELIQUIS,hematomas,"

   Redu ction",1
ELIQUIS,hematomas,"

   Redu ction of Risk of",1
ELIQUIS,hematomas,in Patients with Nonvalvular Atrial Fibrillation,0
ELIQUIS,hematomas,in,0
ELIQUIS,hematomas,reflect the rates observed,0
ELIQUIS,hematomas,observed in,0
ELIQUIS,hematomas,with Nonvalvular,0
ELIQUIS,hematomas,Embolism in,0
ELIQUIS,hematomas,of another drug and may not reflect the rates observed,0
ELIQUIS,permanent paralysis,and,0
ELIQUIS,permanent paralysis,Risk of Stroke Systemic Embolism i,1
ELIQUIS,permanent paralysis,and,0
ELIQUIS,permanent paralysis,Embolism i,1
ELIQUIS,permanent paralysis,was evaluated in,0
ELIQUIS,permanent paralysis,safety of ELIQUIS was evaluated,0
ELIQUIS,permanent paralysis,ELIQUIS was evaluated,0
ELIQUIS,permanent paralysis,The safety of,0
ELIQUIS,permanent paralysis,of Stroke Systemic Embolism i n Patients with Nonvalvular Atrial,1
ELIQUIS,permanent paralysis,The safety of,0
ELIQUIS,spinal hematomas,seeCl,0
ELIQUIS,spinal hematomas,ARISTOTLE and AVERROES studies inical Studies ( including patients exposed to ELIQUIS,1
ELIQUIS,spinal hematomas,seeCl,0
ELIQUIS,spinal hematomas,to ELIQUIS mg twice daily and patients,0
ELIQUIS,spinal hematomas,daily and patients,0
ELIQUIS,spinal hematomas,AVERROES studies inical Studies ( including patients exposed to,1
ELIQUIS,spinal hematomas,daily and patients,0
ELIQUIS,spinal hematomas,twice daily and patients,0
ELIQUIS,THROMBOTIC EVENTS,bleeding during the treatment period and the bleeding rate percentage,0
ELIQUIS,THROMBOTIC EVENTS,and,0
ELIQUIS,THROMBOTIC EVENTS,rate  of subjects with at,1
ELIQUIS,THROMBOTIC EVENTS,and,0
ELIQUIS,THROMBOTIC EVENTS,subjects with at least one bleeding event,1
ELIQUIS,THROMBOTIC EVENTS,the bleeding rate of,1
ELIQUIS,THROMBOTIC EVENTS,bleeding rate  of subjects with at least one,1
ELIQUIS,THROMBOTIC EVENTS,the bleeding rate of,1
ELIQUIS,THROMBOTIC EVENTS,of subjects with at least one,1
ELIQUIS,EPIDURAL HEMATOMA,ne bleeding event,1
ELIQUIS,EPIDURAL HEMATOMA,bleeding event per patientyears in ARISTOTLE,1
ELIQUIS,EPIDURAL HEMATOMA,treatment period and the bleeding,0
ELIQUIS,EPIDURAL HEMATOMA,with at least ne,1
ELIQUIS,THROMBOTIC EVENTS,ARI,0
ELIQUIS,THROMBOTIC EVENTS,"Fibrillation in STOTLE* 
         ELIQUISNn per ptyear WarfarinNn per",1
ELIQUIS,THROMBOTIC EVENTS,ARI,0
ELIQUIS,THROMBOTIC EVENTS,Patients with,0
ELIQUIS,thrombotic events,ELIQUISNn per ptyear,0
ELIQUIS,thrombotic events,per ptyear Ratio(95%,1
ELIQUIS,thrombotic events,ptyear Ratio(95% CI),1
ELIQUIS,thrombotic events,WarfarinNn per ptyear Ratio(95% CI),1
ELIQUIS,thrombotic events,per ptyear Hazard,0
ELIQUIS,thrombotic events,Ratio(95% CI) P-,1
ELIQUIS,thrombotic events,per ptyear Ratio(95% CI)  P- value Bleeding events,1
ELIQUIS,thrombotic events,Ratio(95% CI) P-,1
ELIQUIS,spinal hematomas,treatment or within days of stopping study treatment ontrea,0
ELIQUIS,spinal hematomas,study treatment tment period).   Defined as clinically overt,1
ELIQUIS,spinal hematomas,treatment or within days of stopping study treatment ontrea,0
ELIQUIS,spinal hematomas,stopping study treatment tment period).,1
ELIQUIS,spinal hematomas,more of the following a decrease,0
ELIQUIS,spinal hematomas,treatment,0
ELIQUIS,spinal hematomas,stopping study treatment tment period).   Defined as clinically overt,1
ELIQUIS,spinal hematomas,treatment,0
ELIQUIS,spinal hematomas,tment period).   Defined as clinically overt,1
ELIQUIS,spinal hematomas,treatment,0
ELIQUIS,spinal hematomas,tment period).,1
ELIQUIS,spinal hematomas,tment period).,1
ELIQUIS,spinal hematomas,tment period).   Defined as clinically overt bleeding,1
ELIQUIS,spinal hematomas,tment period).,1
ELIQUIS,hematomas,units of packed red blood cells bleeding at a critical site intracranial,0
ELIQUIS,hematomas,"hemoglobin of /dL, a tr",1
ELIQUIS,hematomas,"decrease in hemoglobin of /dL,",1
ELIQUIS,hematomas,"decrease in hemoglobin of /dL, a",1
ELIQUIS,hematomas,"of /dL, a tr",1
ELIQUIS,hematomas,"decrease in hemoglobin of /dL, a",1
ELIQUIS,hematomas,at a critical,0
ELIQUIS,hematomas,a tr ansfusion of or more units,1
ELIQUIS,hematomas,"of /dL, a tr ansfusion of or",1
ELIQUIS,hematomas,a tr ansfusion of or more units,1
ELIQUIS,permanent paralysis,transfusion of or more  of packed red bloo,1
ELIQUIS,permanent paralysis,a tr ansfusion of or more units,1
ELIQUIS,permanent paralysis,or more of packed,1
ELIQUIS,permanent paralysis,of packed red bloo d cells bleeding at a,1
ELIQUIS,fatal,detai l in other sections of,1
ELIQUIS,thrombotic events,ed to bleeding.(6,1
ELIQUIS,stroke,PECTED ADVERSE REACTIONS,1
ELIQUIS,stroke,ed to bleeding.(6,1
ELIQUIS,stroke,PECTED ADVERSE REACTIONS contact BristolMyers Squibb,1
ELIQUIS,stroke,PECTED ADVERSE REACTIONS contact BristolMyers,1
ELIQUIS,stroke,PECTED ADVERSE REACTIONS contact,1
ELIQUIS,stroke,bleeding To report PECTED ADVERSE REACTIONS contact BristolMyers Squibb,1
ELIQUIS,stroke,PECTED ADVERSE REACTIONS contact,1
ELIQUIS,stroke,ADVERSE REACTIONS contact BristolMyers Squibb at or FDA at FDA or,0
ELIQUIS,stroke,adverse reactions are related to bleeding To report SUS,0
ELIQUIS,stroke,BristolMyers Squibb at,0
ELIQUIS,stroke,To report PECTED ADVERSE REACTIONS contact BristolMyers,1
ELIQUIS,stroke,BristolMyers Squibb at,0
ELIQUIS,stroke,BristolMyers Squibb at or FDA at FDA or ww,0
ELIQUIS,bleeding,and may not ect the,1
ELIQUIS,bleeding,ect the ,1
ELIQUIS,bleeding,and may not ect the,1
ELIQUIS,bleeding,and may not ect the  rates observed in,1
ELIQUIS,bleeding,and may not ect the,1
ELIQUIS,bleeding,refl,0
ELIQUIS,fatal,   Re duction of Risk of Stroke,1
ELIQUIS,fatal,   Re duction of Risk,1
ELIQUIS,fatal,   Re duction of Risk of,1
ELIQUIS,fatal,   Re duction of Risk of,1
ELIQUIS,fatal,in,0
ELIQUIS,fatal,observed in    Re,1
ELIQUIS,fatal,in,0
ELIQUIS,fatal,   Re duction of Risk of,1
ELIQUIS,fatal,rates,0
ELIQUIS,bleeding,ction of Risk of Stroke and,1
ELIQUIS,bleeding,Embolism in Patients with Nonvalvular Atrial,0
ELIQUIS,bleeding,in practice ction,1
ELIQUIS,bleeding,in practice ction,1
ELIQUIS,bleeding,rates observed in practice ction of Risk of Stroke,1
ELIQUIS,bleeding,in practice ction,1
ELIQUIS,bleeding,rates observed in practice ction of,1
ELIQUIS,bleeding,rates observed in practice Redu,0
ELIQUIS,bleeding,ction of,1
ELIQUIS,bleeding,exposed to ELIQUIS mg twice,0
ELIQUIS,bleeding,and VERROES  studies seeClinical Studies including,1
ELIQUIS,bleeding,exposed to ELIQUIS mg twice,0
ELIQUIS,permanent paralysis,"intraarticular intramuscular with ent syndrome, retro peritoneal or with fatal",1
ELIQUIS,permanent paralysis,exposed to ELIQUIS mg twice,0
ELIQUIS,permanent paralysis,"syndrome, retro peritoneal or with",1
ELIQUIS,permanent paralysis,"intraarticular intramuscular with ent syndrome,",1
ELIQUIS,permanent paralysis,"intramuscular with ent syndrome, retro",1
ELIQUIS,permanent paralysis,Intracranial bleed includes,0
ELIQUIS,permanent paralysis,or with fatal,0
ELIQUIS,permanent paralysis,ent,1
ELIQUIS,permanent paralysis,outcome Intracranial bleed,0
BOSULIF,Myelosuppression,Warnings and Precautions Hepatic toxici,0
BOSULIF,Myelosuppression,Myelosuppression see Dosage and,1
BOSULIF,Myelosuppression,and Warnings and Precautions,0
BOSULIF,Myelosuppression,Myelosuppression see Dosage and Administration,1
BOSULIF,Hepatic toxicity,Warnings and Hepatic toxicity see Dosage and,1
BOSULIF,Hepatic toxicity,Myelosuppression see Dosage and Administration,1
BOSULIF,Hepatic toxicity,Hepatic toxicity see,1
BOSULIF,Hepatic toxicity,and Hepatic toxicity,1
BOSULIF,Hepatic toxicity,Hepatic toxicity see,1
BOSULIF,Fluid retention,Fluid retention see Warnings and Precautions,1
BOSULIF,Fluid retention,Precautions Renal,0
BOSULIF,Fluid retention,and Fluid,1
BOSULIF,Fluid retention,Fluid retention see Warnings and,1
BOSULIF,Fluid retention,Warnings and Fluid retention,1
BOSULIF,Fluid retention,Fluid retention see Warnings and,1
BOSULIF,Fluid retention,Fluid retention see Warnings and,1
BOSULIF,Renal toxicity,see Warnings and Precautions EXCERPT Most common adverse,0
BOSULIF,Renal toxicity,and Renal toxicity,1
BOSULIF,Renal toxicity,Renal toxicity see Warnings and,1
BOSULIF,Renal toxicity,Renal toxicity see,1
BOSULIF,diarrhea,anemia,0
BOSULIF,diarrhea,diarrhea nausea,1
BOSULIF,diarrhea,abdominal pain rash anemia pyrexia and,0
BOSULIF,nausea,fatigue To,0
BOSULIF,nausea,nausea,1
BOSULIF,nausea,fatigue To,0
BOSULIF,nausea,are nausea,1
BOSULIF,nausea,fatigue To,0
BOSULIF,nausea,incidence greater than are nausea thrombocytopenia vomiting abdominal,1
BOSULIF,nausea,fatigue To,0
BOSULIF,nausea,common adverse reactions incidence greater than,0
BOSULIF,nausea,nausea thrombocytopenia,1
BOSULIF,nausea,incidence greater than are nausea thrombocytopenia vomiting,1
BOSULIF,nausea,nausea thrombocytopenia,1
BOSULIF,thrombocytopenia,thrombocytopenia vomiting abdominal pain,1
BOSULIF,thrombocytopenia,incidence greater than are,0
BOSULIF,thrombocytopenia,thrombocytopenia,1
BOSULIF,thrombocytopenia,fatigue To report SUSPECTED ADVE,0
BOSULIF,thrombocytopenia,EXCERPT Most common,0
BOSULIF,thrombocytopenia,vomiting abdominal,0
BOSULIF,thrombocytopenia,than are diarrhea thrombocytopenia vomiting abdominal pain,1
BOSULIF,thrombocytopenia,vomiting abdominal,0
BOSULIF,vomiting,vomiting abdominal pain rash anemia,1
BOSULIF,vomiting,than are diarrhea nausea vomiting abdominal,1
BOSULIF,vomiting,vomiting abdominal pain rash anemia,1
BOSULIF,vomiting,are diarrhea nausea vomiting,1
BOSULIF,vomiting,vomiting abdominal pain rash anemia,1
BOSULIF,abdominal pain,abdominal pain rash,1
BOSULIF,abdominal pain,abdominal pain,1
BOSULIF,rash,thrombocytopenia vomiting abdominal rash anemia pyrexia and fatigue,1
BOSULIF,rash,abdominal pain,1
BOSULIF,rash,pain,0
BOSULIF,rash,rash anemia,1
BOSULIF,rash,thrombocytopenia vomiting abdominal rash anemia pyrexia and fatigue To,1
BOSULIF,rash,rash anemia,1
BOSULIF,rash,To report SUSPECTED ADVERSE REACTIONS,0
BOSULIF,rash,rash anemia pyrexia and fatigue To,1
BOSULIF,rash,rash anemia pyrexia and fatigue To,1
BOSULIF,rash,rash,1
BOSULIF,rash,rash,1
BOSULIF,anemia,anemia pyrexia and,1
BOSULIF,anemia,anemia,1
BOSULIF,anemia,anemia,1
BOSULIF,anemia,abdominal pain anemia pyrexia and,1
BOSULIF,anemia,anemia,1
BOSULIF,anemia,anemia pyrexia and fatigue To,1
BOSULIF,anemia,nausea thrombocytopenia vomiting,0
BOSULIF,pyrexia,pyrexia and fatigue To,1
BOSULIF,pyrexia,ADVERSE,0
BOSULIF,pyrexia,fatigue To,0
BOSULIF,pyrexia,pyrexia,1
BOSULIF,pyrexia,fatigue To,0
BOSULIF,pyrexia,vomiting abdominal pain rash pyrexia,1
BOSULIF,pyrexia,fatigue To,0
BOSULIF,pyrexia,anemia,0
BOSULIF,pyrexia,abdominal pain rash pyrexia and fatigue To report,1
BOSULIF,pyrexia,anemia,0
BOSULIF,pyrexia,pyrexia and fatigue,1
BOSULIF,pyrexia,pyrexia and,1
BOSULIF,pyrexia,contact Pfizer,0
BOSULIF,fatigue,vomiting abdominal pain rash anemia pyrexia,0
BOSULIF,fatigue,fatigue To report SUSPECTED ADVERSE,1
BOSULIF,fatigue,anemia pyrexia fatigue To,1
BOSULIF,fatigue,fatigue To report SUSPECTED ADVERSE,1
BOSULIF,fatigue,fatigue To report SUSPECTED ADVERSE,1
BOSULIF,fatigue,fatigue To report,1
BOSULIF,fatigue,fatigue To report,1
BOSULIF,anaphylactic shock,and may not reflect the,0
BOSULIF,anaphylactic shock,see Contraindications myelosuppression,0
BOSULIF,anaphylactic shock,reported anaphylactic,1
BOSULIF,anaphylactic shock,anaphylactic shock,1
BOSULIF,anaphylactic shock,anaphylactic shock,1
BOSULIF,anaphylactic shock,adverse reactions reported anaphylactic shock see,1
BOSULIF,anaphylactic shock,anaphylactic shock,1
BOSULIF,anaphylactic shock,reported include,0
BOSULIF,anaphylactic shock,reactions reported anaphylactic shock see Contraindications,1
BOSULIF,anaphylactic shock,reported include,0
BOSULIF,anaphylactic shock,the rates,0
BOSULIF,myelosuppression,shock see,0
BOSULIF,myelosuppression,shock see myelosuppression gastrointestinal toxicity diarrhea fluid,1
BOSULIF,myelosuppression,shock see,0
BOSULIF,myelosuppression,shock,0
BOSULIF,gastrointestinal toxicity,of any toxicity grade r,0
BOSULIF,gastrointestinal toxicity,fluid retention hepatotoxicity and rash Adverse,0
BOSULIF,gastrointestinal toxicity,shock see Contraindications gastrointestinal toxicity diarrhea fluid,1
BOSULIF,gastrointestinal toxicity,fluid retention hepatotoxicity and rash Adverse,0
BOSULIF,gastrointestinal toxicity,Adverse reactions of any toxicity grade r,0
BOSULIF,gastrointestinal toxicity,gastrointestinal toxicity diarrhea fluid retention hepatotoxicity and,1
BOSULIF,diarrhea,myelosuppression gastrointestinal diarrhea,1
BOSULIF,diarrhea,gastrointestinal toxicity diarrhea fluid retention hepatotoxicity and,1
BOSULIF,diarrhea,diarrhea fluid retention hepatotoxicity,1
BOSULIF,diarrhea,myelosuppression gastrointestinal toxicity,0
BOSULIF,diarrhea,anaphylactic shock,0
BOSULIF,diarrhea,diarrhea fluid,1
BOSULIF,diarrhea,of any toxicity grade reported,0
BOSULIF,diarrhea,diarrhea fluid,1
BOSULIF,diarrhea,gastrointestinal diarrhea fluid retention,1
BOSULIF,diarrhea,diarrhea fluid,1
BOSULIF,diarrhea,diarrhea fluid retention hepatotoxicity and,1
BOSULIF,diarrhea,diarrhea fluid retention hepatotoxicity and,1
BOSULIF,diarrhea,diarrhea fluid retention hepatotoxicity and,1
BOSULIF,fluid retention,rash Adverse reactions of,0
BOSULIF,fluid retention,hepatotoxicity and rash Adverse reactions of,0
BOSULIF,fluid retention,toxicity fluid retention,1
BOSULIF,fluid retention,fluid retention hepatotoxicity and rash Adverse,1
BOSULIF,fluid retention,of any,0
BOSULIF,fluid retention,fluid retention hepatotoxicity and rash Adverse,1
BOSULIF,fluid retention,fluid retention,1
BOSULIF,fluid retention,fluid retention hepatotoxicity,1
BOSULIF,fluid retention,fluid retention hepatotoxicity and rash Adverse reactions,1
BOSULIF,hepatotoxicity,hepatotoxicity and rash Adverse reactions,1
BOSULIF,hepatotoxicity,hepatotoxicity,1
BOSULIF,hepatotoxicity,diarrhea fluid hepatotoxicity and,1
BOSULIF,hepatotoxicity,hepatotoxicity,1
BOSULIF,hepatotoxicity,hepatotoxicity,1
BOSULIF,hepatotoxicity,hepatotoxicity,1
BOSULIF,hepatotoxicity,diarrhea fluid,0
BOSULIF,hepatotoxicity,hepatotoxicity,1
BOSULIF,hepatotoxicity,toxicity grade reported for greater than,0
BOSULIF,rash,and,0
BOSULIF,rash,rash Adverse reactions of any toxicity,1
BOSULIF,rash,rash Adverse reactions of any,1
BOSULIF,rash,toxicity diarrhea fluid retention,0
BOSULIF,rash,diarrhea,0
BOSULIF,rash,rash Adverse,1
BOSULIF,rash,rash Adverse reactions of any toxicity,1
BOSULIF,rash,rash Adverse reactions of any toxicity,1
BOSULIF,rash,rash Adverse reactions of any toxicity,1
BOSULIF,diarrhea,diarrhea nausea,1
BOSULIF,diarrhea,abdominal,0
BOSULIF,nausea,were nausea thrombocytopenia vomiting abdominal pain,1
BOSULIF,nausea,abdominal,0
BOSULIF,nausea,population n were nausea thrombocytopenia,1
BOSULIF,nausea,abdominal,0
BOSULIF,nausea,nausea,1
BOSULIF,nausea,were nausea thrombocytopenia vomiting abdominal pain,1
BOSULIF,nausea,nausea,1
BOSULIF,nausea,abdominal pain rash anemia,0
BOSULIF,nausea,nausea thrombocytopenia vomiting,1
BOSULIF,nausea,safety population n were nausea thrombocytopenia vomiting,1
BOSULIF,nausea,nausea thrombocytopenia vomiting,1
BOSULIF,nausea,population n were nausea,1
BOSULIF,nausea,nausea thrombocytopenia vomiting,1
BOSULIF,thrombocytopenia,rash,0
BOSULIF,thrombocytopenia,abdominal,0
BOSULIF,thrombocytopenia,anemia,0
BOSULIF,thrombocytopenia,thrombocytopenia vomiting abdominal pain,1
BOSULIF,thrombocytopenia,nausea,0
BOSULIF,thrombocytopenia,anemia pyrexia,0
BOSULIF,thrombocytopenia,pyrexia and,0
BOSULIF,thrombocytopenia,thrombocytopenia vomiting abdominal pain rash,1
BOSULIF,thrombocytopenia,thrombocytopenia vomiting abdominal pain rash,1
BOSULIF,thrombocytopenia,thrombocytopenia vomiting abdominal pain rash,1
BOSULIF,thrombocytopenia,Phase safety population,0
BOSULIF,rash,rash anemia pyrexia and fatigue see,1
BOSULIF,rash,rash anemia pyrexia and,1
BOSULIF,rash,rash anemia,1
BOSULIF,rash,rash anemia pyrexia and,1
BOSULIF,rash,anemia pyrexia and fatigue see Clinical,0
BOSULIF,rash,thrombocytopenia vomiting abdominal rash anemia pyrexia and fatigue see,1
BOSULIF,rash,anemia pyrexia and fatigue see Clinical,0
BOSULIF,rash,vomiting,0
BOSULIF,anemia,rash,0
BOSULIF,anemia,anemia pyrexia and fatigue see,1
BOSULIF,anemia,anemia,1
BOSULIF,anemia,pain,0
BOSULIF,anemia,abdominal pain anemia pyrexia and,1
BOSULIF,anemia,pain,0
BOSULIF,pyrexia,pyrexia,1
BOSULIF,pyrexia,pyrexia and fatigue see Clinical Studies,1
BOSULIF,pyrexia,pyrexia,1
BOSULIF,pyrexia,Studies Adverse,0
BOSULIF,pyrexia,anemia,0
BOSULIF,pyrexia,pyrexia,1
BOSULIF,pyrexia,thrombocytopenia,0
BOSULIF,pyrexia,and fatigue see Clinical Studies Adverse Reactions in,0
BOSULIF,pyrexia,vomiting abdominal,0
BOSULIF,fatigue,cytopenia vomiting abdominal pain rash anemia,0
BOSULIF,fatigue,fatigue see,1
BOSULIF,fatigue,fatigue see Clinical,1
BOSULIF,fatigue,fatigue see,1
BOSULIF,fatigue,fatigue see,1
BOSULIF,fatigue,fatigue see,1
BOSULIF,fatigue,Studies Adverse,0
BOSULIF,fatigue,see Clinical Studies Adverse Reactions in Patients,0
BOSULIF,fatigue,fatigue see Clinical Studies Adverse,1
BOSULIF,QTcF interval of greater than 500 milliseconds,disease including QT interval,0
BOSULIF,QTcF interval of greater than 500 milliseconds,one patient QTcF interval,1
BOSULIF,QTcF interval of greater than 500 milliseconds,Phase clinical trial one,0
BOSULIF,QTcF interval of greater than 500 milliseconds,interval of greater than 500 milliseconds,1
BOSULIF,QTcF interval of greater than 500 milliseconds,one patient QTcF interval of greater than,1
BOSULIF,QTcF interval of greater than 500 milliseconds,trial,0
BOSULIF,QTcF interval of greater than 500 milliseconds,clinical trial one patient QTcF interval of greater than 500 milliseconds Patients with uncontrolled or significant,1
BOSULIF,QTcF interval of greater than 500 milliseconds,trial,0
BOSULIF,QTcF interval of greater than 500 milliseconds,500 milliseconds Patients,1
BOSULIF,QTcF interval of greater than 500 milliseconds,trial one patient QTcF interval of greater than 500 milliseconds Patients with uncontrolled or,1
BOSULIF,QTcF interval of greater than 500 milliseconds,500 milliseconds Patients,1
BOSULIF,QTcF interval of greater than 500 milliseconds,trial one patient QTcF interval of greater than 500 milliseconds,1
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,less than 1*10 9 /L Hemoglobin,1
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,Low less than Absolute Neutrophil Count less than 1*10  9  /L Hemoglobin,1
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,less than 1*10 9 /L Hemoglobin,1
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,than Absolute Neutrophil Count less than 1*10  9  /L Hemoglobin,1
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,less than 1*10 9 /L Hemoglobin,1
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,Hemoglobin Low,0
BOSULIF,Absolute Neutrophil Count less than 1*10 9 /L,less than,0
BOSULIF,ALT greater than 5.0*ULN,Biochemistry Parameters ALT greater than 5.0*ULN SGOTAST greater t,1
BOSULIF,ALT greater than 5.0*ULN,less than,0
BOSULIF,ALT greater than 5.0*ULN,Biochemistry,0
BOSULIF,AST greater than 5.0*ULN,ULN AST greater,1
BOSULIF,Lipase greater than 2*ULN,Lipase greater than 2*ULN,1
BOSULIF,Lipase greater than 2*ULN,than Lipase greater than,1
BOSULIF,Lipase greater than 2*ULN,ULN,0
BOSULIF,Lipase greater than 2*ULN,eater than ULN,0
BOSULIF,Lipase greater than 2*ULN,greater than 2*ULN Phosphorus Lo,1
BOSULIF,Total Bilirubin greater than 3.0*ULN,Low less than Total Bilirubin greater than 3.0*ULN Additional Adv,1
BOSULIF,Total Bilirubin greater than 3.0*ULN,greater than 2*ULN Phosphorus Lo,1
BOSULIF,Total Bilirubin greater than 3.0*ULN,mmolL,0
BOSULIF,Total Bilirubin greater than 3.0*ULN,Low less than Total Bilirubin greater than 3.0*ULN,1
BOSULIF,Total Bilirubin greater than 3.0*ULN,mmolL,0
BOSULIF,Total Bilirubin greater than 3.0*ULN,than Total Bilirubin greater than 3.0*ULN,1
BOSULIF,Total Bilirubin greater than 3.0*ULN,Low less than Total Bilirubin greater than,1
BOSULIF,Total Bilirubin greater than 3.0*ULN,than mmolL,0
BOSULIF,febrile neutropenia,System Disorders and less febrile neutropenia Cardiac Disorders and less,1
BOSULIF,febrile neutropenia,than mmolL,0
BOSULIF,febrile neutropenia,System Disorders and,0
BOSULIF,febrile neutropenia,System Disorders and less febrile,1
BOSULIF,febrile neutropenia,less febrile neutropenia,1
BOSULIF,febrile neutropenia,and less febrile neutropenia,1
BOSULIF,febrile neutropenia,Disorders and less febrile neutropenia,1
BOSULIF,febrile neutropenia,Disorders and less than,0
BOSULIF,febrile neutropenia,less febrile neutropenia,1
BOSULIF,febrile neutropenia,System Disorders and less,0
BOSULIF,febrile neutropenia,category Blood,0
BOSULIF,pericardial effusion,pericardial effusion and,1
BOSULIF,pericardial effusion,and less than pericarditis Ear and,0
BOSULIF,pericardial effusion,pericardial effusion and,1
BOSULIF,pericardial effusion,less than pericarditis Ear and Labyrinth Disorders and less than,0
BOSULIF,pericardial effusion,less pericardial effusion,1
BOSULIF,pericardial effusion,less than pericarditis Ear and Labyrinth Disorders and less than,0
BOSULIF,pericardial effusion,pericardial effusion,1
BOSULIF,pericardial effusion,pericardial effusion,1
BOSULIF,pericardial effusion,Disorders and less pericardial,1
BOSULIF,pericardial effusion,less than pericarditis Ear and Labyrinth Disorders and,0
BOSULIF,pericardial effusion,and,0
BOSULIF,pericarditis,pericarditis Ear and Labyrinth,1
BOSULIF,pericarditis,than tinnitus,0
BOSULIF,tinnitus,tinnitus Gastrointestinal,1
BOSULIF,tinnitus,and less tinnitus Gastrointestinal Disorders,1
BOSULIF,tinnitus,tinnitus Gastrointestinal,1
BOSULIF,tinnitus,tinnitus Gastrointestinal,1
BOSULIF,tinnitus,tinnitus Gastrointestinal,1
BOSULIF,tinnitus,tinnitus Gastrointestinal,1
BOSULIF,gastritis,gastritis and,1
BOSULIF,gastritis,tinnitus Gastrointestinal,1
BOSULIF,acute pancreatitis,acute pancreatitis gastrointestinal,1
BOSULIF,acute pancreatitis,acute pancreatitis gastrointestinal hemorrhage includes gastrointestinal hemorrhage,1
BOSULIF,acute pancreatitis,than gastritis and less than,0
BOSULIF,acute pancreatitis,acute pancreatitis gastrointestinal hemorrhage includes gastrointestinal hemorrhage,1
BOSULIF,acute pancreatitis,gastritis and less acute pancreatitis,1
BOSULIF,acute pancreatitis,includes,0
BOSULIF,acute pancreatitis,and less acute,1
BOSULIF,gastrointestinal hemorrhage,and less than gastritis,0
BOSULIF,gastrointestinal hemorrhage,less than gastritis and less than acute pancreatitis,0
BOSULIF,gastrointestinal hemorrhage,Disorders and,0
BOSULIF,gastrointestinal hemorrhage,than acute gastrointestinal hemorrhage includes gastrointestinal,1
BOSULIF,gastrointestinal hemorrhage,Disorders and,0
BOSULIF,gastrointestinal hemorrhage,hemorrhage gastric,0
BOSULIF,gastrointestinal hemorrhage,gastrointestinal,1
BOSULIF,gastrointestinal hemorrhage,hemorrhage gastric hemorrhage upper gastrointestinal hemorrhage,0
BOSULIF,gastrointestinal hemorrhage,acute pancreatitis gastrointestinal hemorrhage gastrointestinal hemorrhage,1
BOSULIF,gastrointestinal hemorrhage,and less than acute pancreatitis gastrointestinal hemorrhage includes,0
BOSULIF,gastrointestinal hemorrhage,pancreatitis gastrointestinal hemorrhage gastrointestinal hemorrhage gastric,1
BOSULIF,gastrointestinal hemorrhage,and less than acute pancreatitis gastrointestinal hemorrhage includes,0
BOSULIF,gastric hemorrhage,and Administrative Site,0
BOSULIF,gastric hemorrhage,hemorrhage includes gastrointestinal gastric hemorrhage,1
BOSULIF,gastric hemorrhage,s than acute pancreatitis gastrointestinal hemorrhage includes gastrointestinal,0
BOSULIF,gastric hemorrhage,gastric hemorrhage upper gastrointestinal,1
BOSULIF,gastric hemorrhage,gastrointestinal hemorrhage General,0
BOSULIF,gastric hemorrhage,s than acute pancreatitis gastrointestinal hemorrhage includes gastrointestinal,0
BOSULIF,gastric hemorrhage,gastrointestinal hemorrhage includes gastrointestinal gastric hemorrhage upper gastrointestinal,1
BOSULIF,gastric hemorrhage,s than acute pancreatitis gastrointestinal hemorrhage includes gastrointestinal,0
BOSULIF,gastric hemorrhage,upper gastrointestinal hemorrhage General Disorders and Administrative,0
BOSULIF,upper gastrointestinal hemorrhage,hemorrhage,0
BOSULIF,upper gastrointestinal hemorrhage,gastrointestinal hemorrhage General,1
BOSULIF,upper gastrointestinal hemorrhage,gastrointestinal hemorrhage General,1
BOSULIF,chest pain,chest pain,1
BOSULIF,chest pain,Disorders and,0
BOSULIF,chest pain,and less than,0
BOSULIF,chest pain,chest pain and chest discomfort pain,1
BOSULIF,chest pain,less than chest pain chest,1
BOSULIF,chest pain,than chest pain chest,1
BOSULIF,chest pain,than chest pain chest pain and chest discomfort,1
BOSULIF,chest pain,than chest pain chest,1
BOSULIF,pain,pain Hepatobiliary Disorders and less,1
BOSULIF,pain,and chest,0
BOSULIF,pain,chest pain Hepatobiliary Disorders and less than,1
BOSULIF,pain,and chest,0
BOSULIF,pain,than hepatotoxicity includes hepatotoxicity,0
BOSULIF,hepatotoxicity,and less than,0
BOSULIF,hepatotoxicity,hepatotoxicity includes,1
BOSULIF,hepatotoxicity,and less than,0
BOSULIF,hepatotoxicity,hepatotoxicity toxic hepatitis and,0
BOSULIF,hepatotoxicity,and,0
BOSULIF,hepatotoxicity,hepatotoxicity includes hepatotoxicity,1
BOSULIF,hepatotoxicity,hepatic function,0
BOSULIF,hepatotoxicity,Hepatobiliary Disorders and less hepatotoxicity includes,1
BOSULIF,hepatotoxicity,hepatic function,0
BOSULIF,hepatotoxicity,chest pain,0
BOSULIF,hepatotoxicity,cytolytic hepatitis,0
BOSULIF,hepatotoxicity,hepatotoxicity toxic,1
BOSULIF,hepatotoxicity,than hepatotoxicity hepatotoxicity toxic hepatitis and,1
BOSULIF,hepatotoxicity,hepatotoxicity toxic,1
BOSULIF,hepatotoxicity,hepatotoxicity,1
BOSULIF,hepatotoxicity,hepatotoxicity toxic hepatitis and cytolytic hepatitis,1
BOSULIF,toxic hepatitis,hepatitis abnormal hepatic function includes abnormal hepatic,0
BOSULIF,cytolytic hepatitis,cytolytic,1
BOSULIF,cytolytic hepatitis,hepatotoxicity toxic hepatitis cytolytic,1
BOSULIF,cytolytic hepatitis,abnormal hepatic function includes abnormal hepatic function liver,0
BOSULIF,cytolytic hepatitis,cytolytic hepatitis abnormal hepatic,1
BOSULIF,cytolytic hepatitis,cytolytic hepatitis abnormal hepatic,1
BOSULIF,abnormal hepatic function,hepatic function includes,1
BOSULIF,abnormal hepatic function,hepatic function abnormal,1
BOSULIF,abnormal hepatic function,abnormal hepatic function,1
BOSULIF,abnormal hepatic function,than,0
BOSULIF,abnormal hepatic function,hepatic,0
BOSULIF,abnormal hepatic function,abnormal hepatic function abnormal,1
BOSULIF,abnormal hepatic function,hepatitis abnormal hepatic function abnormal,1
BOSULIF,abnormal hepatic function,abnormal hepatic function liver disorder,1
BOSULIF,liver disorder,liver disorder and less,1
BOSULIF,liver disorder,abnormal hepatic function liver disorder,1
BOSULIF,liver disorder,includes abnormal hepatic,0
BOSULIF,liver injury,disorder and,0
BOSULIF,liver injury,liver injury Immune System Disorders and less,1
BOSULIF,liver injury,drug hypersensitivity,0
BOSULIF,drug hypersensitivity,Disorders and less drug hypersensitivity,1
BOSULIF,drug hypersensitivity,than anaphylactic shock,0
BOSULIF,drug hypersensitivity,Infestations and less,0
BOSULIF,drug hypersensitivity,than,0
BOSULIF,drug hypersensitivity,drug hypersensitivity and less,1
BOSULIF,drug hypersensitivity,drug hypersensitivity,1
BOSULIF,anaphylactic shock,anaphylactic shock Infections and Infestations and,1
BOSULIF,anaphylactic shock,than,0
BOSULIF,anaphylactic shock,anaphylactic shock Infections and Infestations,1
BOSULIF,anaphylactic shock,less than pneumonia includes pneumonia,0
BOSULIF,anaphylactic shock,includes,0
BOSULIF,anaphylactic shock,less anaphylactic,1
BOSULIF,anaphylactic shock,and less anaphylactic shock Infections and Infestations and less,1
BOSULIF,anaphylactic shock,less anaphylactic,1
BOSULIF,anaphylactic shock,less anaphylactic shock Infections,1
BOSULIF,anaphylactic shock,less anaphylactic,1
BOSULIF,pneumonia,Infections,0
BOSULIF,pneumonia,and Infestations and less than,0
BOSULIF,pneumonia,pneumonia includes pneumonia bronchopneumonia lobar pneumonia,1
BOSULIF,pneumonia,pneumonia includes pneumonia bronchopneumonia lobar,1
BOSULIF,pneumonia,pneumonia includes,1
BOSULIF,pneumonia,primary atypical pneumonia influenza bro,0
BOSULIF,pneumonia,pneumonia includes pneumonia,1
BOSULIF,pneumonia,lobar pneumonia,0
BOSULIF,pneumonia,primary,0
BOSULIF,pneumonia,and less than,0
BOSULIF,pneumonia,pneumonia,1
BOSULIF,pneumonia,shock Infections and Infestations and less than pneumonia,0
BOSULIF,pneumonia,bronchopneumonia lobar pneumonia primary atypical pneumonia influenza bronchitis Invest,0
BOSULIF,lobar pneumonia,includes pneumonia lobar pneumonia,1
BOSULIF,lobar pneumonia,lobar pneumonia,1
BOSULIF,lobar pneumonia,includes pneumonia bronchopneumonia,0
BOSULIF,lobar pneumonia,and less,0
BOSULIF,lobar pneumonia,lobar,1
BOSULIF,lobar pneumonia,atypical pneumonia influenza bronchitis Investigations and less,0
BOSULIF,lobar pneumonia,than pneumonia includes pneumonia lobar pneumonia primary atypical pneumonia influenza,1
BOSULIF,lobar pneumonia,atypical pneumonia influenza bronchitis Investigations and less,0
BOSULIF,lobar pneumonia,primary atypical pneumonia influenza bronchitis Investigations and,0
BOSULIF,lobar pneumonia,pneumonia lobar,1
BOSULIF,lobar pneumonia,lobar pneumonia primary atypical,1
BOSULIF,primary atypical pneumonia,lobar primary atypical pneumonia,1
BOSULIF,primary atypical pneumonia,primary atypical pneumonia influenza bronchitis Investigations and,1
BOSULIF,primary atypical pneumonia,lobar primary,1
BOSULIF,primary atypical pneumonia,bronchopneumonia lobar primary atypical pneumonia,1
BOSULIF,primary atypical pneumonia,Investigations and less,0
BOSULIF,bronchitis,bronchitis Investigations and less,1
BOSULIF,bronchitis,bronchitis Investigations and less than,1
BOSULIF,bronchitis,primary,0
BOSULIF,bronchitis,primary atypical pneumonia influenza,0
BOSULIF,electrocardiogram QT prolonged,Metabolism,0
BOSULIF,electrocardiogram QT prolonged,electrocardiogram QT prolonged,1
BOSULIF,electrocardiogram QT prolonged,Metabolism,0
BOSULIF,electrocardiogram QT prolonged,influenza bronchitis Investigations and less than,0
BOSULIF,electrocardiogram QT prolonged,less,0
BOSULIF,electrocardiogram QT prolonged,electrocardiogram QT prolonged increased blood creatine,1
BOSULIF,electrocardiogram QT prolonged,Investigations and less electrocardiogram QT prolonged,1
BOSULIF,electrocardiogram QT prolonged,Investigations and less electrocardiogram QT prolonged,1
BOSULIF,electrocardiogram QT prolonged,Investigations and less electrocardiogram QT prolonged,1
BOSULIF,increased blood creatine phosphokinase,electrocardiogram QT increased blood creatine,1
BOSULIF,increased blood creatine phosphokinase,increased blood,0
BOSULIF,increased blood creatine phosphokinase,creatine phosphokinase increased blood creatinine,1
BOSULIF,increased blood creatine phosphokinase,Metabolism and Nutrition Disorder,0
BOSULIF,increased blood creatine phosphokinase,prolonged,0
BOSULIF,increased blood creatine phosphokinase,than electrocardiogram QT increased blood creatine phosphokinase increased blood creatinine Metabolism,1
BOSULIF,increased blood creatine phosphokinase,prolonged,0
BOSULIF,increased blood creatinine,increased blood creatinine Metabolism and Nutrition Disorder,1
BOSULIF,increased blood creatinine,and less than electrocardiogram QT prolonged,0
BOSULIF,dehydration,dehydration Musculoskeletal and Connective,1
BOSULIF,dehydration,dehydration Musculoskeletal and Connective Tissue Disorder,1
BOSULIF,dehydration,dehydration Musculoskeletal and,1
BOSULIF,dehydration,less than,0
BOSULIF,dehydration,than,0
BOSULIF,myalgia,myalgia Nervous System Disorders,1
BOSULIF,myalgia,myalgia Nervous System,1
BOSULIF,myalgia,myalgia Nervous,1
BOSULIF,myalgia,Tissue Disorder and less myalgia,1
BOSULIF,myalgia,myalgia Nervous,1
BOSULIF,myalgia,Tissue Disorder and less than,0
BOSULIF,myalgia,Musculoskeletal and Connective,0
BOSULIF,myalgia,myalgia,1
BOSULIF,myalgia,Musculoskeletal and Connective,0
BOSULIF,myalgia,Disorder and less myalgia,1
BOSULIF,myalgia,Musculoskeletal and Connective,0
BOSULIF,myalgia,myalgia Nervous System,1
BOSULIF,dysgeusia,dysgeusia Renal and Urinary,1
BOSULIF,dysgeusia,dysgeusia Renal and Urinary Disorders and,1
BOSULIF,dysgeusia,dysgeusia Renal and Urinary,1
BOSULIF,acute renal failure,renal failure renal failure Respiratory Thoracic and,1
BOSULIF,acute renal failure,dysgeusia Renal and Urinary Disorders and less,0
BOSULIF,acute renal failure,than,0
BOSULIF,acute renal failure,acute renal failure renal,1
BOSULIF,renal failure,acute renal,0
BOSULIF,renal failure,than acute renal renal failure Respiratory Thoracic and Mediastinal Disorders,1
BOSULIF,renal failure,acute renal,0
BOSULIF,renal failure,than pleural,0
BOSULIF,renal failure,renal failure Respiratory Thoracic and,1
BOSULIF,pleural effusion,edema,0
BOSULIF,pleural effusion,pleural effusion and,1
BOSULIF,pleural effusion,pleural effusion and less than acute pulmonary,1
BOSULIF,pleural effusion,pleural effusion and less than acute,1
BOSULIF,pleural effusion,and less than acute pulmonary edema respiratory,0
BOSULIF,pleural effusion,than,0
BOSULIF,pleural effusion,Disorders and less pleural effusion and less than acute,1
BOSULIF,pleural effusion,than,0
BOSULIF,pleural effusion,and,0
BOSULIF,acute pulmonary edema,acute pulmonary edema respiratory failure pulmonary,1
BOSULIF,acute pulmonary edema,and less acute pulmonary edema respiratory,1
BOSULIF,acute pulmonary edema,acute pulmonary edema respiratory failure pulmonary,1
BOSULIF,acute pulmonary edema,pulmonary edema respiratory failure,1
BOSULIF,acute pulmonary edema,less acute pulmonary edema,1
BOSULIF,acute pulmonary edema,pulmonary edema respiratory failure pulmonary hypertension,1
BOSULIF,acute pulmonary edema,Skin and Subcutaneous Disorders,0
BOSULIF,acute pulmonary edema,c and Mediastinal Disorders and,0
BOSULIF,acute pulmonary edema,less acute pulmonary edema respiratory failure pulmonary hypertension Skin,1
BOSULIF,acute pulmonary edema,c and Mediastinal Disorders and,0
BOSULIF,respiratory failure,effusion and less than acute pulmonary edema,0
BOSULIF,respiratory failure,less than,0
BOSULIF,respiratory failure,Subcutaneous Disorders and,0
BOSULIF,respiratory failure,respiratory failure,1
BOSULIF,pulmonary hypertension,acute pulmonary edema respiratory,0
BOSULIF,pulmonary hypertension,pulmonary hypertension Skin,1
BOSULIF,pulmonary hypertension,respiratory pulmonary hypertension,1
BOSULIF,pulmonary hypertension,acute pulmonary edema respiratory pulmonary hypertension Skin and,1
BOSULIF,pulmonary hypertension,respiratory pulmonary hypertension,1
BOSULIF,pulmonary hypertension,Subcutaneous Disorders,0
BOSULIF,pulmonary hypertension,Skin and Subcutaneous Disorders and less than,0
BOSULIF,pulmonary hypertension,pulmonary,0
BOSULIF,pulmonary hypertension,pulmonary edema respiratory pulmonary hypertension,1
BOSULIF,pulmonary hypertension,pulmonary,0
BOSULIF,pulmonary hypertension,failure,0
BOSULIF,urticaria,urticaria pruritus acne and less,1
BOSULIF,urticaria,urticaria pruritus acne and,1
BOSULIF,urticaria,failure pulmonary hypertension Skin and Subcutaneous Disorders and less than,0
BOSULIF,urticaria,urticaria pruritus acne and,1
BOSULIF,urticaria,urticaria pruritus acne and,1
BOSULIF,pruritus,less than pruritus acne,1
BOSULIF,pruritus,urticaria pruritus acne and,1
BOSULIF,erythema multiforme,pruritus acne and less erythema multiforme exfoliative rash drug eruption,1
BOSULIF,erythema multiforme,urticaria pruritus acne and,1
BOSULIF,exfoliative rash,exfoliative rash drug eruption,1
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in,1
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in g reater detail,1
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in,1
BOSULIF,Gastrointestinal Toxicity,adverse ctions are discussed in g reater,1
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in,1
BOSULIF,Gastrointestinal Toxicity,REACTIONS The following adverse ctions are discussed in g reater,1
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in,1
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in g reater detail in other,1
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in,1
BOSULIF,Gastrointestinal Toxicity,REACTIONS The following adverse ctions are discussed in g,1
BOSULIF,Gastrointestinal Toxicity,ctions are discussed in g reater detail in other sections,1
BOSULIF,Gastrointestinal Toxicity,REACTIONS The following adverse ctions are discussed in g reater detail in other sections,1
BOSULIF,Gastrointestinal Toxicity,ctions are discussed in g reater detail in other sections,1
BOSULIF,Gastrointestinal Toxicity,ctions are discussed,1
BOSULIF,Gastrointestinal Toxicity,The following adverse ctions are discussed in g,1
BOSULIF,Hepatic Toxicity,sage and Adminis tration and Warnings and,1
BOSULIF,Hepatic Toxicity,The following adverse ctions are discussed in g,1
BOSULIF,Hepatic Toxicity,sage and Adminis,1
BOSULIF,Hepatic Toxicity,The following adverse ctions are discussed in g,1
BOSULIF,Hepatic Toxicity,Precautions Myelosuppression see sage and,1
BOSULIF,Hepatic Toxicity,Precautions Myelosuppression see sage and Adminis tration and,1
BOSULIF,Hepatic Toxicity,Precautions Myelosuppression see sage and,1
BOSULIF,Hepatic Toxicity,Precautions Hepatic toxicity see Dosage and Admin,0
BOSULIF,Hepatic Toxicity,see sage and,1
BOSULIF,Fluid Retention,Dosage and Administration and Warnings,0
BOSULIF,Fluid Retention,] . *,1
BOSULIF,Fluid Retention,Administration and Warnings and ] .,1
BOSULIF,Fluid Retention,Hepatic toxicity see Dosage and Administration and Warnings and,0
BOSULIF,Embryofetal Toxicity,vomiting dominal,1
BOSULIF,Embryofetal Toxicity,"dominal pain, rash,  anemia pyrexia and fatigue",1
BOSULIF,Embryofetal Toxicity,vomiting dominal,1
BOSULIF,Embryofetal Toxicity,"dominal pain, rash,",1
BOSULIF,Embryofetal Toxicity,thrombocytopenia vomiting ab,0
BOSULIF,Embryofetal Toxicity,nausea thrombocytopenia vomiting dominal,1
BOSULIF,fetal harm,"xia, and f atigue To report SUSPECTED",1
BOSULIF,fetal harm,"xia, and f atigue To",1
BOSULIF,fetal harm,contact Pfizer,0
BOSULIF,fetal harm,and f,1
BOSULIF,fetal harm,"xia, and f atigue To",1
BOSULIF,fetal harm,and f,1
BOSULIF,fetal harm,"pain rash anemia xia, and f atigue",1
BOSULIF,fetal harm,and f,1
BOSULIF,fetal harm,"abdominal pain rash anemia xia, and f atigue",1
BOSULIF,fetal harm,and f,1
BOSULIF,fetal harm,"pain rash anemia xia, and f",1
BOSULIF,fetal harm,and f,1
BOSULIF,Diarrhea,"

  6.1 ",1
BOSULIF,Diarrhea,"

  6.1  Clinical Trials Experience Because clinical",1
BOSULIF,nausea,Trials Experience,0
BOSULIF,nausea,or wwwfdagovmedwatch inical Trials Experience,1
BOSULIF,nausea,Trials Experience,0
BOSULIF,nausea,inical Trials Experience,1
BOSULIF,nausea,inical Trials,1
BOSULIF,nausea,at FDA or wwwfdagovmedwatch inical Trials,1
BOSULIF,nausea,inical Trials,1
BOSULIF,nausea,are conducted under widely varying conditions adverse,0
BOSULIF,nausea,trials are conducted under widely,0
BOSULIF,vomiting,or wwwfdagovmedwatch Clinical rials Ex perience Because clinical,1
BOSULIF,vomiting,trials are conducted under widely,0
BOSULIF,vomiting,rials Ex perience,1
BOSULIF,vomiting,rials Ex,1
BOSULIF,vomiting,rials Ex perience,1
BOSULIF,vomiting,perience Because clinical trials are,0
BOSULIF,vomiting,FDA or wwwfdagovmedwatch Clinical rials Ex,1
BOSULIF,abdominal pain,or,0
BOSULIF,abdominal pain,or FDA at,0
BOSULIF,abdominal pain,"wwwfdagovmedwatch Clinical Trials ce

  Because  clinical trials",1
BOSULIF,abdominal pain,or FDA at,0
BOSULIF,abdominal pain,ce Because clinical trials,1
BOSULIF,Thrombocytopenia,pain,0
BOSULIF,Thrombocytopenia,"were diarrhea nausea thrombocytopenia ing (39%), abdom inal pain",1
BOSULIF,Thrombocytopenia,pain,0
BOSULIF,Thrombocytopenia,"nausea thrombocytopenia ing (39%), abdom inal pain rash anemia pyrexia",1
BOSULIF,Thrombocytopenia,pain,0
BOSULIF,Thrombocytopenia,"were diarrhea nausea thrombocytopenia ing (39%), abdom inal",1
BOSULIF,Thrombocytopenia,pain,0
BOSULIF,Thrombocytopenia,"ing (39%), abdom inal pain",1
BOSULIF,Thrombocytopenia,"(39%), abdom inal pain rash",1
BOSULIF,Thrombocytopenia,anemia pyrexia and,0
BOSULIF,anemia,al pai n rash anemia pyrexia and,1
BOSULIF,anemia,n were diarrhea nausea,0
BOSULIF,anemia,vomiting al pai n rash,1
BOSULIF,anemia,n were diarrhea nausea,0
BOSULIF,anemia,opulation n,0
BOSULIF,anemia,al pai n rash anemia pyrexia,1
BOSULIF,neutropenia,anemia pyrexia,0
BOSULIF,neutropenia,Clinical Studies Adver,0
BOSULIF,neutropenia,diarrhea nausea thrombocytopenia,0
BOSULIF,neutropenia,anemia pyrexia and fatigue see,0
BOSULIF,neutropenia,"%), rash",1
BOSULIF,neutropenia,diarrhea nausea thrombocytopenia vomiting abdominal,0
BOSULIF,neutropenia,n were diarrhea nausea thrombocytopenia vomiting,0
BOSULIF,neutropenia,"nausea thrombocytopenia vomiting abdominal %), rash",1
BOSULIF,neutropenia,rash (3 anemia pyrexia and fatigue,1
BOSULIF,drug induced liver injury,ous leukemia (CML) and wi th resistance or intolerance,1
BOSULIF,drug induced liver injury,blast phase chronic ous leukemia (CML) and wi th resistance or,1
BOSULIF,drug induced liver injury,ous leukemia (CML) and wi th resistance or intolerance,1
BOSULIF,drug induced liver injury,Study enrolled patients with Ph chronic,0
BOSULIF,drug induced liver injury,blast phase chronic ous leukemia (CML) and wi th resistance or intolerance to,1
BOSULIF,drug induced liver injury,Study enrolled patients with Ph chronic,0
BOSULIF,drug induced liver injury,therapy see Clinical Studies The,0
BOSULIF,drug induced liver injury,chronic ous leukemia (CML) and,1
BOSULIF,drug induced liver injury,blast phase chronic ous leukemia (CML) and,1
BOSULIF,elevations in ALT,rapy see Clinical Studies The safety population received,0
BOSULIF,elevations in ALT,Studies The safety population received at least,0
BOSULIF,elevations in ALT,safety population received at,0
BOSULIF,elevations in ALT,with resistance or ance to prior the,1
BOSULIF,elevations in ALT,or blast phase chronic myelogenous leukemia CML and with,0
BOSULIF,total bilirubin greater than 2*ULN,safety population (received at lea st dose of BOSULIF included,1
BOSULIF,total bilirubin greater than 2*ULN,or blast phase chronic myelogenous leukemia CML and with,0
BOSULIF,total bilirubin greater than 2*ULN,population (received at lea st dose of BOSULIF included,1
BOSULIF,total bilirubin greater than 2*ULN,CML patients patients with CP CML,0
BOSULIF,total bilirubin greater than 2*ULN,Clinical Studies safety population (received at lea st,1
BOSULIF,total bilirubin greater than 2*ULN,CML patients patients with CP CML,0
BOSULIF,total bilirubin greater than 2*ULN,safety population (received at lea st dose,1
BOSULIF,total bilirubin greater than 2*ULN,at lea st dose of BOSULIF,1
BOSULIF,total bilirubin greater than 2*ULN,therapy see Clinical Studies safety population,1
BOSULIF,total bilirubin greater than 2*ULN,Clinical Studies safety,1
BOSULIF,total bilirubin greater than 2*ULN,safety population (received at lea st dose of BOSULIF,1
BOSULIF,total bilirubin greater than 2*ULN,of BOSULIF,0
BOSULIF,alkaline phosphatase less than 2*ULN,dose of BOSULIF) included 546 CML pa tients patients with CP CML,1
BOSULIF,alkaline phosphatase less than 2*ULN,of BOSULIF,0
BOSULIF,alkaline phosphatase less than 2*ULN,received at dose of BOSULIF) included 546 CML pa tients,1
BOSULIF,alkaline phosphatase less than 2*ULN,of BOSULIF,0
BOSULIF,alkaline phosphatase less than 2*ULN,dose of BOSULIF) included 546 CML pa tients,1
BOSULIF,alkaline phosphatase less than 2*ULN,had,0
BOSULIF,alkaline phosphatase less than 2*ULN,BOSULIF) included 546 CML pa tients patients with CP CML,1
BOSULIF,alkaline phosphatase less than 2*ULN,at dose of BOSULIF) included 546 CML pa tients patients,1
BOSULIF,alkaline phosphatase less than 2*ULN,BOSULIF) included 546 CML pa tients patients with CP CML,1
BOSULIF,alkaline phosphatase less than 2*ULN,CML pa tients patients,1
BOSULIF,alkaline phosphatase less than 2*ULN,population received at dose of BOSULIF) included 546,1
BOSULIF,AST elevation,d,0
BOSULIF,AST elevation,additional TKI who had,0
BOSULIF,AST elevation,months,0
BOSULIF,AST elevation,a median uration of BO SULIF treatment of months,1
BOSULIF,AST elevation,months,0
BOSULIF,AST elevation,uration of BO SULIF treatment,1
BOSULIF,AST elevation,months,0
BOSULIF,AST elevation,median d,0
BOSULIF,AST elevation,had a median uration of,1
BOSULIF,AST elevation,of BO SULIF treatment of months and,1
BOSULIF,increased ALT,respectively The median dose nsity was 483,1
BOSULIF,increased ALT,nsity was 483,1
BOSULIF,increased ALT,respectively The median dose nsity was,1
BOSULIF,increased ALT,nsity was 483 mgday and,1
BOSULIF,increased ALT,respectively The median dose nsity was,1
BOSULIF,increased ALT,nsity was,1
BOSULIF,increased ALT,AP CML and,0
BOSULIF,increased ALT,respectively The median dose nsity,1
BOSULIF,increased ALT,months respectively The median dose inte,0
BOSULIF,increased ALT,inte,0
BOSULIF,Fluid retention,Advanced Phase CML includes patients with Accelerated Phase and Blast Phase,0
BOSULIF,Fluid retention,CMLN All Grades,0
BOSULIF,Fluid retention,CMLN,0
BOSULIF,Fluid retention,All es(%)           Grade Advanced,1
BOSULIF,Fluid retention,CMLN,0
BOSULIF,pericardial effusion,Advanced Phase L includes patients,1
BOSULIF,pericardial effusion,Phase L includes,1
BOSULIF,pericardial effusion,includes patients,1
BOSULIF,pericardial effusion,Grade Advanced Phase L includes patients  with Accelerated,1
BOSULIF,pericardial effusion,includes patients,1
BOSULIF,pericardial effusion,es Grade All,0
BOSULIF,pericardial effusion,Advanced Phase L includes,1
BOSULIF,pericardial effusion,Grade Advanced Phase L includes patients  with Accelerated Phase and Blast,1
BOSULIF,pericardial effusion,Advanced Phase L includes,1
BOSULIF,pericardial effusion,Grade Advanced Phase,0
BOSULIF,pericardial effusion,Accelerated,0
BOSULIF,pleural effusion,hase and Blast Phase CML,0
BOSULIF,pleural effusion,th Accelerated P,1
BOSULIF,pleural effusion,includes patients th,1
BOSULIF,pleural effusion,Accelerated P hase,1
BOSULIF,pleural effusion,th Accelerated P hase and,1
BOSULIF,pulmonary edema,Pha,0
BOSULIF,pulmonary edema,patients with Accelerated se and Blast Ph ase CML,1
BOSULIF,pulmonary edema,Pha,0
BOSULIF,fetal harm,the c,1
BOSULIF,fetal harm,by protocol Table fies the c linically relevant or severe,1
BOSULIF,fetal harm,the c,1
BOSULIF,fetal harm,including QT interval prolongation were excluded by protocol Table identi,0
BOSULIF,embryofetal toxicities,laboratory test normalities for the,1
BOSULIF,embryofetal toxicities,test normalities for the,1
BOSULIF,embryofetal toxicities,safety,0
BOSULIF,embryofetal toxicities,normalities for the Ph ase,1
BOSULIF,embryofetal toxicities,laboratory test normalities for the,1
BOSULIF,embryofetal toxicities,Grade laboratory test normalities,1
BOSULIF,embryofetal toxicities,the Ph ase,1
BOSULIF,embryofetal toxicities,for the Ph ase CML safety population,1
GILENYA,Bradyarrhythmia,described elsewhere in Bradyarrhythmia and Atrioventricular,1
GILENYA,Bradyarrhythmia,for the Ph ase CML safety population,1
GILENYA,Atrioventricular Blocks,and,0
GILENYA,Atrioventricular Blocks,in labeling Bradyarrhythmia Atrioventricular Blocks see Warnings and Precautions Infections,1
GILENYA,Atrioventricular Blocks,and,0
GILENYA,Atrioventricular Blocks,labeling Bradyarrhythmia,0
GILENYA,Atrioventricular Blocks,elsewhere,0
GILENYA,Infections,see Warnings and Infections see Warnings and Precautions,1
GILENYA,Infections,elsewhere,0
GILENYA,Infections,Infections see,1
GILENYA,Progressive multifocal leukoencephalopathy,multifocal leukoencephalopathy see Warnings and,1
GILENYA,Progressive multifocal leukoencephalopathy,Warnings and Precautions Macular Edema see Warnings,0
GILENYA,Progressive multifocal leukoencephalopathy,Progressive multifocal leukoencephalopathy see Warnings and Precautions,1
GILENYA,Progressive multifocal leukoencephalopathy,Infections see Warnings and Progressive multifocal leukoencephalopathy see Warnings and,1
GILENYA,Progressive multifocal leukoencephalopathy,Progressive multifocal leukoencephalopathy see Warnings and Precautions,1
GILENYA,Progressive multifocal leukoencephalopathy,multifocal leukoencephalopathy,1
GILENYA,Progressive multifocal leukoencephalopathy,Infections see Warnings and Progressive multifocal leukoencephalopathy,1
GILENYA,Progressive multifocal leukoencephalopathy,see Warnings,0
GILENYA,Progressive multifocal leukoencephalopathy,Macular Edema see Warnings and,0
GILENYA,Macular Edema,leukoencephalopathy see Warnings and Macular Edema see Warnings,1
GILENYA,Macular Edema,Macular Edema see Warnings and,0
GILENYA,Macular Edema,Warnings and Macular Edema see Warnings,1
GILENYA,Macular Edema,Macular Edema see Warnings and,0
GILENYA,Macular Edema,Macular Edema see Warnings,1
GILENYA,Macular Edema,Macular Edema see Warnings and,1
GILENYA,Posterior Reversible Encephalopathy Syndrome,Warnings and,0
GILENYA,Posterior Reversible Encephalopathy Syndrome,Precautions Respiratory Effects see Warnings and,0
GILENYA,Posterior Reversible Encephalopathy Syndrome,Edema see Warnings and,0
GILENYA,Posterior Reversible Encephalopathy Syndrome,and Precautions Respiratory Effects see,0
GILENYA,Posterior Reversible Encephalopathy Syndrome,see Warnings,0
GILENYA,Respiratory Effects,Encephalopathy,0
GILENYA,Respiratory Effects,and Respiratory Effects,1
GILENYA,Respiratory Effects,Warnings and Respiratory Effects see Warnings and,1
GILENYA,Respiratory Effects,and Respiratory Effects,1
GILENYA,Respiratory Effects,Respiratory Effects see Warnings and Precautions Liver,1
GILENYA,Respiratory Effects,and Respiratory Effects,1
GILENYA,Respiratory Effects,Respiratory Effects,1
GILENYA,Respiratory Effects,Respiratory Effects see,1
GILENYA,Respiratory Effects,see,0
GILENYA,Respiratory Effects,Respiratory Effects see,1
GILENYA,Liver Injury,Precautions EXCERPT Most common,0
GILENYA,Liver Injury,Liver Injury,1
GILENYA,Liver Injury,Liver Injury see Warnings,1
GILENYA,Liver Injury,adverse reactions,0
GILENYA,Liver Injury,Precautions,0
GILENYA,Liver Injury,and Precautions EXCERPT Most common,0
GILENYA,Liver Injury,Warnings and,0
GILENYA,Liver Injury,Warnings and,0
GILENYA,Headache,adverse reactions incidence and Headache liver transaminase elevation diarrhea,1
GILENYA,Headache,Warnings and,0
GILENYA,Headache,incidence and placebo,0
GILENYA,Headache,common adverse,0
GILENYA,Headache,and,0
GILENYA,Headache,Headache liver transaminase elevation diarrhea,1
GILENYA,Headache,reactions incidence and Headache,1
GILENYA,Headache,Headache liver transaminase elevation diarrhea,1
GILENYA,Headache,Most common,0
GILENYA,Headache,incidence and Headache liver transaminase,1
GILENYA,Headache,Most common,0
GILENYA,Headache,Headache liver transaminase elevation diarrhea,1
GILENYA,Headache,Headache liver transaminase,1
GILENYA,liver transaminase elevation,reactions incidence and placebo liver,1
GILENYA,liver transaminase elevation,and placebo liver transaminase elevation,1
GILENYA,liver transaminase elevation,reactions incidence and placebo liver,1
GILENYA,liver transaminase elevation,cough influenza sinusitis back pain abdominal pain and pain in,0
GILENYA,liver transaminase elevation,EXCERPT Most common adverse reactions,0
GILENYA,liver transaminase elevation,liver transaminase elevation diarrhea cough influenza sinusitis,1
GILENYA,liver transaminase elevation,EXCERPT Most common adverse reactions,0
GILENYA,liver transaminase elevation,pain abdominal pain and pain in extremity,0
GILENYA,liver transaminase elevation,liver transaminase elevation diarrhea cough influenza sinusitis back,1
GILENYA,liver transaminase elevation,transaminase elevation diarrhea cough influenza,1
GILENYA,liver transaminase elevation,cough influenza sinusitis,0
GILENYA,diarrhea,diarrhea cough influenza sinusitis back,1
GILENYA,diarrhea,liver transaminase diarrhea cough influenza sinusitis back pain,1
GILENYA,diarrhea,diarrhea cough influenza sinusitis back,1
GILENYA,diarrhea,diarrhea cough influenza,1
GILENYA,diarrhea,placebo Headache liver transaminase diarrhea cough influenza sinusitis back pain,1
GILENYA,diarrhea,diarrhea cough influenza,1
GILENYA,diarrhea,diarrhea cough influenza sinusitis back pain,1
GILENYA,cough,cough influenza sinusitis back pain,1
GILENYA,cough,back pain abdominal pain and,0
GILENYA,cough,influenza,0
GILENYA,cough,incidence and placebo Headache liver,0
GILENYA,cough,diarrhea,0
GILENYA,cough,cough influenza sinusitis back pain,1
GILENYA,cough,diarrhea,0
GILENYA,cough,influenza sinusitis back pain abdominal pain,0
GILENYA,cough,pain,0
GILENYA,influenza,influenza,1
GILENYA,influenza,elevation diarrhea influenza sinusitis back pain abdominal,1
GILENYA,influenza,influenza,1
GILENYA,influenza,influenza sinusitis,1
GILENYA,influenza,influenza sinusitis back,1
GILENYA,influenza,abdominal,0
GILENYA,influenza,influenza sinusitis back,1
GILENYA,influenza,pain and pain in extremity To report SUSPECTED AD,0
GILENYA,sinusitis,elevation diarrhea,0
GILENYA,sinusitis,sinusitis back pain abdominal,1
GILENYA,back pain,back pain abdominal pain,1
GILENYA,back pain,back pain abdominal pain,1
GILENYA,back pain,back pain abdominal pain,1
GILENYA,abdominal pain,contact,0
GILENYA,abdominal pain,REACTIONS contact Novartis,0
GILENYA,abdominal pain,SUSPECTED ADVERSE REACTIONS contact Novartis,0
GILENYA,abdominal pain,influenza sinusitis back abdominal,1
GILENYA,abdominal pain,back abdominal pain and pain in,1
GILENYA,abdominal pain,influenza sinusitis back abdominal,1
GILENYA,pain in extremity,pain abdominal pain pain in,1
GILENYA,headache,adverse reactions incidence and placebo for GILENYA mg,0
GILENYA,headache,headache,1
GILENYA,headache,influenza sinusitis back pain abdominal pain an,0
GILENYA,headache,influenza sinusitis back,0
GILENYA,headache,headache liver,1
GILENYA,headache,headache liver transaminase elevation,1
GILENYA,headache,headache liver transaminase elevation diarrhea cough,1
GILENYA,headache,headache liver,1
GILENYA,headache,for GILENYA,0
GILENYA,headache,liver transaminase elevation diarrhea cough influenza sinusitis back,0
GILENYA,liver transaminase elevation,liver transaminase elevation diarrhea cough influenza sinusitis,1
GILENYA,liver transaminase elevation,mg were liver transaminase,1
GILENYA,liver transaminase elevation,pain and,0
GILENYA,liver transaminase elevation,pain and pain in extremity,0
GILENYA,liver transaminase elevation,mg were liver transaminase elevation diarrhea cough influenza sinusitis,1
GILENYA,liver transaminase elevation,pain and pain in extremity,0
GILENYA,diarrhea,placebo for GILENYA mg were headache liver transaminase elevation,0
GILENYA,diarrhea,and placebo for GILENYA mg were headache liver transaminase elevation,0
GILENYA,diarrhea,diarrhea cough influenza sinusitis back pain,1
GILENYA,diarrhea,influenza sinusitis back pain abdominal pain and,0
GILENYA,diarrhea,sinusitis back pain abdominal pain and pain in extremity Adverse events,0
GILENYA,cough,dence and placebo for GILENYA mg were headache liver transaminase elevation,0
GILENYA,cough,headache liver transaminase elevation cough influenza sinusitis back pain,1
GILENYA,cough,dence and placebo for GILENYA mg were headache liver transaminase elevation,0
GILENYA,cough,pain abdominal pain and pain,0
GILENYA,cough,cough influenza sinusitis,1
GILENYA,influenza,influenza sinusitis back,1
GILENYA,influenza,mg were headache liver transaminase elevation,0
GILENYA,sinusitis,sinusitis back,1
GILENYA,sinusitis,diarrhea cough sinusitis back pain abdominal pain,1
GILENYA,sinusitis,sinusitis back,1
GILENYA,sinusitis,back,0
GILENYA,back pain,influenza back,1
GILENYA,back pain,in extremity Adverse events that led to treatment,0
GILENYA,back pain,back,1
GILENYA,abdominal pain,sinusitis back abdominal,1
GILENYA,abdominal pain,sinusitis back abdominal pain and pain in,1
GILENYA,abdominal pain,sinusitis back abdominal,1
GILENYA,abdominal pain,abdominal pain and,1
GILENYA,abdominal pain,cough influenza sinusitis back abdominal pain and pain in extremity,1
GILENYA,abdominal pain,abdominal pain and,1
GILENYA,abdominal pain,mg were headache liver transaminase elevation,0
GILENYA,abdominal pain,events that led to treatment discontinuation,0
GILENYA,abdominal pain,cough influenza sinusitis back abdominal pain,1
GILENYA,abdominal pain,abdominal pain,1
GILENYA,pain in extremity,pain abdominal pain pain in extremity Adverse events that led,1
GILENYA,pain in extremity,abdominal pain,1
GILENYA,pain in extremity,and,0
GILENYA,pain in extremity,abdominal pain pain in extremity Adverse events that led to,1
GILENYA,pain in extremity,and,0
GILENYA,pain in extremity,pain in extremity Adverse events that,1
GILENYA,pain in extremity,pain in extremity,1
GILENYA,pain in extremity,back pain,0
GILENYA,serum transaminase elevations,taking GILENYA mg serum transaminase elevations,1
GILENYA,serum transaminase elevations,back pain,0
GILENYA,serum transaminase elevations,to on placebo,0
GILENYA,basal cell carcinoma,cell carcinoma compared to on placebo Table,1
GILENYA,basal cell carcinoma,basal cell carcinoma compared,1
GILENYA,basal cell carcinoma,transaminase elevations compared,0
GILENYA,basal cell carcinoma,cell carcinoma compared to,1
GILENYA,basal cell carcinoma,basal cell,1
GILENYA,basal cell carcinoma,ients taking GILENYA mg were serum transaminase elevations,0
GILENYA,basal cell carcinoma,to on placebo basal cell,1
GILENYA,basal cell carcinoma,basal cell carcinoma compared to on placebo Table,1
GILENYA,basal cell carcinoma,to on placebo basal cell,1
GILENYA,Tinea versicolor,Herpes Tinea,1
GILENYA,Tinea versicolor,Tinea versicolor Cardiac,1
GILENYA,Tinea versicolor,Herpes Tinea,1
GILENYA,Tinea versicolor,Tinea versicolor,1
GILENYA,Tinea versicolor,Herpes Tinea,1
GILENYA,Tinea versicolor,Herpes Tinea versicolor,1
GILENYA,Bradycardia,Disorders,0
GILENYA,Bradycardia,Disorders,0
GILENYA,Bradycardia,Cardiac,0
GILENYA,Bradycardia,Nervous,0
GILENYA,Bradycardia,Bradycardia Nervous system disorders,1
GILENYA,Bradycardia,Nervous system,0
GILENYA,Headache,Headache Migraine,1
GILENYA,Headache,system disorders,0
GILENYA,Headache,Nervous system,0
GILENYA,Headache,disorders,0
GILENYA,Headache,system disorders,0
GILENYA,Asthenia,Asthenia,1
GILENYA,Asthenia,Asthenia Musculoskeletal and connective tissue,1
GILENYA,Asthenia,Asthenia Musculoskeletal,1
GILENYA,Asthenia,Asthenia Musculoskeletal and connective tissue,1
GILENYA,Asthenia,Asthenia Musculoskeletal,1
GILENYA,Asthenia,and,0
GILENYA,Pain in extremity,Pain in,1
GILENYA,Pain in extremity,Pain in extremity Skin and subcutaneous tissue disorders,1
GILENYA,Pain in extremity,in extremity Skin,1
GILENYA,Pain in extremity,Back pain,0
GILENYA,Pain in extremity,subcutaneous,0
GILENYA,Pain in extremity,in extremity Skin and,1
GILENYA,Pain in extremity,in extremity Skin and subcutaneous tissue disorders,1
GILENYA,Pain in extremity,Back Pain in extremity,1
GILENYA,Alopecia,Alopecia Actinic keratosis,1
GILENYA,Alopecia,Back Pain in extremity,1
GILENYA,Alopecia,Alopecia Actinic keratosis,1
GILENYA,Blood triglycerides increased,Blood triglycerides increased,1
GILENYA,Blood triglycerides increased,transaminase elevations Blood triglycerides increased,1
GILENYA,Blood triglycerides increased,thoracic and mediastinal disorders,0
GILENYA,Blood triglycerides increased,transaminase elevations Blood triglycerides increased Respiratory thoracic and mediastinal disorders,1
GILENYA,Blood triglycerides increased,thoracic and mediastinal disorders,0
GILENYA,Blood triglycerides increased,Respiratory thoracic and mediastinal disorders,0
GILENYA,Blood triglycerides increased,Blood,1
GILENYA,Blood triglycerides increased,Liver transaminase elevations Blood triglycerides increased,1
GILENYA,Blood triglycerides increased,Blood,1
GILENYA,Blood triglycerides increased,triglycerides increased Respiratory thoracic,1
GILENYA,Blood triglycerides increased,transaminase elevations Blood triglycerides increased Respiratory thoracic and,1
GILENYA,Blood triglycerides increased,triglycerides increased Respiratory thoracic,1
GILENYA,Blood triglycerides increased,and mediastinal,0
GILENYA,Cough,Cough Dyspnea,1
GILENYA,Cough,Cough Dyspnea E,1
GILENYA,Cough,Cough Dyspnea,1
GILENYA,Cough,Cough Dyspnea E,1
GILENYA,Cough,Cough Dyspnea,1
GILENYA,Cough,Respiratory thoracic and mediastinal Cough,1
GILENYA,Cough,Cough Dyspnea,1
GILENYA,Cough,thoracic and,0
GILENYA,Cough,Cough Dyspnea,1
GILENYA,Cough,mediastinal,0
GILENYA,Cough,disorders,0
GILENYA,Vision blurred,disorders,0
GILENYA,Vision blurred,Vision blurred Vascular,1
GILENYA,Vision blurred,disorders,0
GILENYA,Vision blurred,Vision blurred,1
GILENYA,Vision blurred,Eye Vision blurred,1
GILENYA,Vision blurred,disorders,0
GILENYA,Vision blurred,Vision blurred,1
GILENYA,Hypertension,Hypertension Blood and lymphatic,1
GILENYA,Hypertension,Hypertension Blood and,1
GILENYA,Hypertension,Hypertension Blood and lymphatic,1
GILENYA,Hypertension,disorders,0
GILENYA,Hypertension,Hypertension Blood and lymphatic system,1
GILENYA,Hypertension,Vascular,0
GILENYA,Hypertension,lymphatic system disorders,0
GILENYA,Lymphopenia,and lymphatic system disorders,0
GILENYA,Lymphopenia,system,0
GILENYA,Lymphopenia,Lymphopenia Leukopenia,1
GILENYA,Lymphopenia,system,0
GILENYA,Lymphopenia,Lymphopenia,1
GILENYA,Lymphopenia,and lymphatic system,0
GILENYA,Lymphopenia,Lymphopenia Leukopenia Neop,1
GILENYA,Basal cell carcinoma,papilloma,0
GILENYA,Basal cell carcinoma,Adverse reactions,0
GILENYA,Basal cell carcinoma,papilloma,0
GILENYA,Basal cell carcinoma,Basal cell carcinoma Adverse reactions of dizziness pneumonia,1
GILENYA,Basal cell carcinoma,papilloma,0
GILENYA,Basal cell carcinoma,Basal cell carcinoma Adverse reactions of dizziness,1
GILENYA,Basal cell carcinoma,papilloma,0
GILENYA,dizziness,reported in Studies and but,0
GILENYA,dizziness,reactions of,0
GILENYA,dizziness,dizziness pneumonia eczema and pruritus were,1
GILENYA,dizziness,carcinoma Adverse reactions,0
GILENYA,pneumonia,Adverse reactions of pneumonia eczema,1
GILENYA,pneumonia,carcinoma Adverse reactions,0
GILENYA,pneumonia,reactions of,0
GILENYA,pneumonia,pneumonia eczema and pruritus were also,1
GILENYA,pneumonia,pneumonia,1
GILENYA,pneumonia,of pneumonia eczema and pruritus were also,1
GILENYA,pneumonia,pneumonia,1
GILENYA,pneumonia,carcinoma Adverse reactions,0
GILENYA,pneumonia,in Studies and but did not meet the reporting rate,0
GILENYA,pneumonia,pneumonia eczema and pruritus were also,1
GILENYA,pneumonia,pneumonia eczema and pruritus were,1
GILENYA,pneumonia,Basal cell,0
GILENYA,eczema,not meet the reporting rate criteria for,0
GILENYA,eczema,eczema and pruritus were,1
GILENYA,eczema,eczema and pruritus were also reported,1
GILENYA,eczema,eczema and pruritus were also,1
GILENYA,eczema,eczema and pruritus,1
GILENYA,eczema,eczema and pruritus,1
GILENYA,pruritus,reporting rate criteria for inclusion in,0
GILENYA,pruritus,rate criteria for,0
GILENYA,pruritus,pruritus were also reported,1
GILENYA,pruritus,rate criteria for,0
GILENYA,pruritus,reactions of,0
GILENYA,Vascular events,to those in Studies and,0
GILENYA,Vascular events,Vascular events including ischemic,1
GILENYA,Vascular events,and hemorrhagic strokes and peripheral,0
GILENYA,Vascular events,those in Studies and,0
GILENYA,Vascular events,generally similar to those in,0
GILENYA,Vascular events,study were generally similar,0
GILENYA,peripheral arterial occlusive disease,peripheral arterial occlusive disease were reported in premarketing clinical,1
GILENYA,peripheral arterial occlusive disease,hemorrhagic strokes peripheral arterial occlusive disease were reported,1
GILENYA,peripheral arterial occlusive disease,peripheral arterial occlusive disease were reported in premarketing clinical,1
GILENYA,Bradycardia,in labeling Bradyarrhythmia and Atrioventricular Blocks,0
GILENYA,Bradycardia,labeling Bradyarrhythmia and Atrioventricular Blocks see War,0
GILENYA,Bradycardia,ons are described elsewhere in labeling Bradyarrhythmia and Atrioventricular,0
GILENYA,Bradycardia,ADVERSE,0
GILENYA,atrioventricular conduction,in labe ling Bradyarrhythmia and Atrioventricular,1
GILENYA,atrioventricular conduction,elsewhere in labe ling Bradyarrhythmia,1
GILENYA,atrioventricular conduction,REACTIONS The following serious adverse reactions are,0
GILENYA,atrioventricular conduction,see Warnings and Precautions,0
GILENYA,atrioventricular conduction,Atrioventricular Blocks see,0
GILENYA,atrioventricular conduction,see Warnings and,0
GILENYA,atrioventricular conduction,serious adverse reactions described elsewhere in labe ling Bradyarrhythmia and,1
GILENYA,atrioventricular conduction,see Warnings and,0
GILENYA,atrioventricular conduction,serious adverse reactions,0
GILENYA,atrioventricular conduction,following serious adverse reactions described elsewhere in labe ling Bradyarrhythmia and,1
GILENYA,atrioventricular conduction,serious adverse reactions,0
GILENYA,Infections,described elsewhere in labeling Bradyarrhythmia and Atrioventricular Blocks,0
GILENYA,infections,ections,1
GILENYA,infections,Warnings,0
GILENYA,infections,and Precautions ections [s,1
GILENYA,infections,Precautions ections [s,1
GILENYA,infections,ee Warnings and Precautions Progressive multifocal leukoencephalopathy see Warnings an,0
GILENYA,infections,Precautions ections [s ee Warnings and Precautions Progressive,1
GILENYA,infections,ee Warnings and Precautions Progressive multifocal leukoencephalopathy see Warnings an,0
GILENYA,infections,Precautions Progressive multifocal leukoencephalopathy,0
GILENYA,Progressive multifocal leukoencephalopathy,see Warnings,0
GILENYA,Progressive multifocal leukoencephalopathy,and Pr ecautions,1
GILENYA,Progressive multifocal leukoencephalopathy,cephalopathy Syndrome [see Warnings and Pr,1
GILENYA,Progressive multifocal leukoencephalopathy,and Pr ecautions,1
GILENYA,Progressive multifocal leukoencephalopathy,Respiratory Effects,0
GILENYA,Progressive multifocal leukoencephalopathy,Effects see Warnings and Precautions Liver,0
GILENYA,Progressive multifocal leukoencephalopathy,Precautions Liver Injury,0
GILENYA,Progressive multifocal leukoencephalopathy,Warnings and Pr ecautions Respiratory Effects see Warnings,1
GILENYA,Progressive multifocal leukoencephalopathy,Precautions Liver,0
GILENYA,PML,Syndrome see Warnings and aut ions Respiratory Effects,1
GILENYA,PML,Precautions Liver,0
GILENYA,PML,aut ions Respiratory Effects,1
GILENYA,PML,Respiratory Effects see Warnings and Precautions Liver Injury see,0
GILENYA,Posterior reversible encephalopathy syndrome,pain in extremity ( To report SUSPECTED,1
GILENYA,Posterior reversible encephalopathy syndrome,"back n, abdominal pain, and pain in extremity (  ",1
GILENYA,Posterior reversible encephalopathy syndrome,pain in extremity ( To report SUSPECTED,1
GILENYA,Posterior reversible encephalopathy syndrome,"cough influenza sinusitis back n, abdominal pain, and pain in extremity (   To",1
GILENYA,Posterior reversible encephalopathy syndrome,pain in extremity ( To report SUSPECTED,1
GILENYA,PRES,1 ) To,1
GILENYA,PRES,pain,0
GILENYA,PRES,1 ),1
GILENYA,PRES,1 ) To report SUSPECTED,1
GILENYA,PRES,Pharmaceuticals Corporation at,0
GILENYA,PRES,extremity,0
GILENYA,PRES,in 1,1
GILENYA,Decrease in pulmonary function tests,SUSPECTED ADVERSE,0
GILENYA,Decrease in pulmonary function tests,report SUSPECTED ADVERSE REACTIONS Novartis Pharmaceuticals Corporatio,1
GILENYA,Decrease in pulmonary function tests,report SUSPECTED ADVERSE REACTIONS  Novartis Pharmaceuticals Corporatio n,1
GILENYA,Decrease in pulmonary function tests,report SUSPECTED ADVERSE REACTIONS Novartis Pharmaceuticals Corporatio,1
GILENYA,Decrease in pulmonary function tests,Novartis Pharmaceuticals Corporatio n at,1
GILENYA,Decrease in pulmonary function tests,n at or FDA at FDA,0
GILENYA,Decrease in pulmonary function tests,report SUSPECTED ADVERSE REACTIONS  Novartis Pharmaceuticals Corporatio n at,1
GILENYA,Decrease in pulmonary function tests,n at or FDA at FDA,0
GILENYA,Decrease in pulmonary function tests,Novartis Pharmaceuticals Corporatio n at,1
GILENYA,Liver injury,or medwatch,1
GILENYA,Liver injury,at or FDA,0
GILENYA,Liver injury,medwatch . Clinical Trials Experience Because clinical,1
GILENYA,Liver injury,clinical,0
GILENYA,Liver injury,or medwatch  .  Clinical Trials Experience Because,1
GILENYA,Liver injury,clinical,0
GILENYA,Liver injury,at FDA or medwatch  .  Clinical,1
GILENYA,Liver injury,clinical,0
GILENYA,Liver injury,Novartis Pharmaceuticals Corporation at,0
GILENYA,Liver injury,or FDA at FDA or wwwfdagov,0
GILENYA,heart rate decrease,lled trial (Study 2,1
GILENYA,heart rate decrease,or FDA at FDA or wwwfdagov,0
GILENYA,heart rate decrease,in,0
GILENYA,heart rate decrease,mg in the year lled trial (Study 2 The overall exposure,1
GILENYA,heart rate decrease,in,0
GILENYA,heart rate decrease,trials Studies and and,0
GILENYA,heart rate decrease,who received,0
GILENYA,heart rate decrease,year activecontro,0
GILENYA,heart rate decrease,exposure in the,0
GILENYA,heart rate decrease,mg in the year lled trial (Study 2 The,1
GILENYA,heart rate decrease,exposure in the,0
GILENYA,heart rate decrease,lled trial (Study 2 The overall exposure in the,1
GILENYA,heart rate decrease,the year lled trial (Study 2 The,1
GILENYA,heart rate decrease,lled trial (Study 2 The overall exposure in the,1
GILENYA,decline in heart rate,exposure in the,0
GILENYA,decline in heart rate,equivalent to personyears Approximately patients received,1
GILENYA,decline in heart rate,was equivalent to personyears,1
GILENYA,decline in heart rate,was equivalent to personyears Approximately patients received,1
GILENYA,decline in heart rate,activecontrolled trial Study The,0
GILENYA,decline in heart rate,least years of treatment,0
GILENYA,decline in heart rate,ls was equivalent to personyears,1
GILENYA,decline in heart rate,equivalent to personyears Approximately patients received,1
GILENYA,decline in heart rate,activecontrolled trial Study The,0
GILENYA,heart rate decrease,the xposure to,1
GILENYA,heart rate decrease,to GILENYA mg was,1
GILENYA,heart rate decrease,mg In all clinical studies including uncontrolled extension studies the e,0
GILENYA,heart rate decrease,to GILENYA,1
GILENYA,heart rate decrease,placebo for GILENYA mg were headach,0
GILENYA,heart rate decrease,adverse reactions incidence and placebo for GILENYA,0
GILENYA,heart rate decrease,extension studies,0
GILENYA,heart rate decrease,personyears In o-controlled trials the most frequent adverse reactions,1
GILENYA,heart rate decrease,extension studies,0
GILENYA,heart rate decrease,personyears In o-controlled trials the most frequent adverse reactions,1
GILENYA,heart rate decrease,extension studies,0
GILENYA,heart rate decrease,o-controlled trials,1
GILENYA,Heart rates below 40 beats per minute,back pain abdominal pain and pain in extremity Adverse e,0
GILENYA,Heart rates below 40 beats per minute,and pain in extremity Adverse,0
GILENYA,Heart rates below 40 beats per minute,sinusitis back pain abdominal pain and pain in extremity,0
GILENYA,symptomatic bradycardia,pain and n in extremity. Adverse,1
GILENYA,symptomatic bradycardia,sinusitis back pain abdominal pain and pain in extremity,0
GILENYA,symptomatic bradycardia,and n in extremity. Adverse events that led,1
GILENYA,symptomatic bradycardia,sinusitis back pain abdominal pain and pain in extremity,0
GILENYA,symptomatic bradycardia,pain abdominal pain and n in extremity.,1
GILENYA,symptomatic bradycardia,abdominal pain and n,1
GILENYA,symptomatic bradycardia,elevation diarrhea cough influenza sinusitis,0
GILENYA,symptomatic bradycardia,pain and n in extremity. Adverse,1
GILENYA,symptomatic bradycardia,elevation diarrhea cough influenza sinusitis,0
GILENYA,symptomatic bradycardia,extremity. Adverse events that led to,1
GILENYA,symptomatic bradycardia,abdominal pain,0
GILENYA,symptomatic bradycardia,n in extremity. Adverse events that led to,1
GILENYA,bradycardia,transaminase .7%,1
GILENYA,bradycardia,transaminase .7% compare,1
GILENYA,bradycardia,mg were serum transaminase .7% compare d to,1
GILENYA,bradycardia,transaminase .7% compare,1
GILENYA,bradycardia,d to on placebo and,0
GILENYA,bradycardia,more than,0
GILENYA,bradycardia,patients taking GILENYA mg were serum transaminase,0
GILENYA,bradycardia,.7%,1
GILENYA,bradycardia,serum transaminase .7%,1
GILENYA,hypotension,in of GILENYAtreated patients,0
GILENYA,hypotension,compared 0.5%,1
GILENYA,hypotension,that,0
GILENYA,hypotension,on pl acebo Table lists adverse,1
GILENYA,dizziness,"ebo).



",1
GILENYA,dizziness,"compared to on ebo).



 Table lists adverse",1
GILENYA,dizziness,"ebo).



",1
GILENYA,dizziness,and,0
GILENYA,dizziness,"ebo).



 Table lists adverse reactions",1
GILENYA,dizziness,"to on ebo).



 Table lists adverse reactions that",1
GILENYA,dizziness,"ebo).



 Table lists adverse reactions",1
GILENYA,dizziness,compared to on placebo and basal,0
GILENYA,dizziness,"ebo).



 Table lists adverse reactions",1
GILENYA,fatigue,able 1 lists,1
GILENYA,fatigue,compared to on placebo able 1,1
GILENYA,fatigue,able 1 lists adverse reactions that occurred,1
GILENYA,fatigue,cell carcinoma compared to,0
GILENYA,fatigue,reactions that occurred in,0
GILENYA,palpitations,that occurred in of GILENYAtreated patients and higher rate than for placebo,0
GILENYA,palpitations,compared to on placebo,0
GILENYA,palpitations,to on placebo Table sts adverse  reactions,1
GILENYA,palpitations,compared to on placebo,0
GILENYA,palpitations,patients and higher rate than,0
GILENYA,chest pain,adverse that,1
GILENYA,decrease in heart rate,for placebo Table Adverse tions Reported,1
GILENYA,decrease in heart rate,Adverse tions Reported in Stud ies and Occurring in of,1
GILENYA,decrease in heart rate,for placebo Table Adverse tions Reported,1
GILENYA,decrease in heart rate,placebo Table Adverse tions Reported in Stud ies and Occurring in,1
GILENYA,decrease in heart rate,for placebo Table Adverse tions Reported,1
GILENYA,decrease in heart rate,ies and Occurring in of,0
GILENYA,decrease in heart rate,at Higher Rate,0
GILENYA,AV conduction delays,itis 11,1
GILENYA,AV conduction delays,itis  11             Bronchitis Herpes zoster,1
GILENYA,AV conduction delays,itis 11,1
GILENYA,AV conduction delays,Influenza itis  11             Bronchitis,1
GILENYA,AV conduction delays,itis 11,1
GILENYA,AV conduction delays,itis 11 Bronchitis Herpes zoster,1
GILENYA,AV conduction delays,Sinus,0
GILENYA,AV conduction delays,Influenza itis 11,1
GILENYA,AV conduction delays,itis 11 Bronchitis Herpes,1
GILENYA,AV conduction delays,Influenza itis,1
GILENYA,AV conduction delays,itis 11 Bronchitis Herpes zoster,1
GILENYA,first-degree AV block,Herpes zoster Tinea versic,0
GILENYA,first-degree AV block,chitis 8 Herpes zoster Tinea versic,1
GILENYA,first-degree AV block,chitis  8             Herpes zoster Tinea versic,1
GILENYA,first-degree AV block,chitis 8 Herpes zoster Tinea versic,1
GILENYA,first-degree AV block,chitis 8 Herpes zoster,1
GILENYA,first-degree AV block,Herpes,0
GILENYA,first-degree AV block,chitis 8 Herpes zoster,1
GILENYA,first-degree AV block,zoster,0
GILENYA,second-degree AV blocks,"           
   Nervous  system disorders Headache",1
GILENYA,second-degree AV blocks,"           
   Nervous ",1
GILENYA,second-degree AV blocks,system disorders,0
GILENYA,second-degree AV blocks,"           
   Nervous  system",1
GILENYA,second-degree AV blocks,system disorders Headache,0
GILENYA,second-degree AV blocks,"Disorders            
   Nervous ",1
GILENYA,second-degree AV blocks,system disorders Headache,0
GILENYA,second-degree AV blocks,"           
   Nervous  system disorders",1
GILENYA,second-degree AV blocks,"           
   Nervous  system disorders",1
GILENYA,second-degree AV blocks,"           
   Nervous  system disorders",1
GILENYA,second-degree AV blocks,"           
   Nervous  system disorders",1
GILENYA,second-degree AV blocks,"           
   Nervous ",1
GILENYA,2:1 AV blocks,              Headache Migraine,1
GILENYA,2:1 AV blocks,             ,1
GILENYA,2:1 AV blocks,disorders,0
GILENYA,2:1 AV blocks,system               Headache Migraine,1
GILENYA,2:1 AV blocks,disorders,0
GILENYA,2:1 AV block,ers         ,1
GILENYA,2:1 AV block,Gastrointestinal ers         ,1
GILENYA,2:1 AV block,ers         ,1
GILENYA,2:1 AV block,ers         ,1
GILENYA,2:1 AV block,ers         ,1
GILENYA,conduction abnormalities,disorders an d,1
GILENYA,conduction abnormalities,"Abdominal 
   General disorders an d",1
GILENYA,conduction abnormalities,disorders an d,1
GILENYA,conduction abnormalities,"Abdominal 
   General disorders an d administration site",1
GILENYA,conduction abnormalities,disorders an d,1
GILENYA,conduction abnormalities,disorders an d administration,1
GILENYA,conduction abnormalities,d administration site conditions,0
GILENYA,conduction abnormalities,"
   General disorders an",1
GILENYA,conduction abnormalities,d administration site conditions,0
GILENYA,conduction abnormalities,General,1
GILENYA,third-degree AV block,tissue disorders,0
GILENYA,third-degree AV block,in extremity,0
GILENYA,third-degree AV block,               9      Pain in extremity Skin,1
GILENYA,AV block,Back,0
GILENYA,AV block,"       
 Pain in extremity",1
GILENYA,AV block,ssue disorders Back,0
GILENYA,AV block,"       
 Pain in extremity",1
GILENYA,AV block,and,0
GILENYA,AV block,"ssue disorders Back        
 Pain in extremity",1
GILENYA,AV block,and,0
GILENYA,AV block,"       
",1
GILENYA,AV block,"Back        
 Pain in",1
GILENYA,AV block,"       
",1
GILENYA,AV block,"       
 Pain",1
GILENYA,junctional escape,Pain in extremit,1
GILENYA,junctional escape,Back Pain,1
GILENYA,junctional escape,in extremit,1
GILENYA,junctional escape,Pain in extremit,1
GILENYA,junctional escape,Pain in extremit,1
GILENYA,asystole,ia   3   Actinic keratosis In,1
GILENYA,asystole,Pain in extremit,1
GILENYA,asystole,subcutaneous tissue disorders Alopec,0
GILENYA,asystole,tissue disorders Alopec,0
GILENYA,asystole,tissue disorders ia,1
GILENYA,asystole,ia 3 Actinic keratosis In,1
GILENYA,asystole,Actinic keratosis,0
GILENYA,asystole,ia   3   Actinic,1
GILENYA,asystole,Actinic keratosis,0
GILENYA,asystole,and subcutaneous tissue disorders ia   3   Actinic keratosis,1
GILENYA,asystole,Actinic keratosis,0
GILENYA,death,      Actinic,1
GILENYA,death,     ,1
GILENYA,death,     ,1
GILENYA,death,neous tissue disorders,0
GILENYA,syncope,        Blood triglycerides,1
GILENYA,syncope,Blood,0
GILENYA,syncope,transaminase elevations ALTGGTAST,0
GILENYA,syncope,        Blood,1
GILENYA,syncope,       ,1
GILENYA,syncope,        Blood,1
GILENYA,syncope,Blood,0
GILENYA,reduction in peripheral lymphocyte count,disorders                                Cough Dyspnea,1
GILENYA,sequestration of lymphocytes in lymphoid tissues,9 7,1
GILENYA,infections,Dyspnea Eye            Vision blurred Vascular,1
GILENYA,infections,9 7,1
GILENYA,infections,           Vision blurred Vascular disorders,1
GILENYA,infections,          ,1
GILENYA,infections,Table difference was,0
GILENYA,infections,was less than Adverse reactions with GILENYA mg,0
GILENYA,infections,reactions,0
GILENYA,bronchitis,year activecontrolled versus,0
GILENYA,bronchitis,in Study the year activecontrolled versus interferon beta,0
GILENYA,bronchitis,). Adv erse,1
GILENYA,bronchitis,reactions with GILENYA mg in,0
GILENYA,bronchitis,difference was less ).,1
GILENYA,herpes zoster,in Table,0
GILENYA,herpes zoster,se reactions with,1
GILENYA,herpes zoster,se reactions with GILENYA,1
GILENYA,pneumonia,"in  2, the 1 year activecontrolled versus interferon",1
GILENYA,pneumonia,se reactions with GILENYA,1
GILENYA,herpetic infections,e disease,1
GILENYA,herpetic infections,e disease were repo rted in premarketing clinical,1
GILENYA,herpetic infections,e disease,1
GILENYA,died,received GILENYA mg)  higher than recommended for use,1
GILENYA,died,e disease,1
GILENYA,died,mg)  higher than recommended for use,1
GILENYA,died,received GILENYA mg)  higher than recommended,1
GILENYA,died,mg)  higher than recommended for use,1
GILENYA,died,mg)  higher,1
GILENYA,died,mg)  higher than,1
GILENYA,died,mg)  higher than,1
GILENYA,died,mg)  higher than,1
GILENYA,died,mg)  higher than recommended,1
GILENYA,died,patients who received GILENYA doses,0
GILENYA,died,mg)  higher than recommended,1
GILENYA,died,premarketing clinical trials in patients,0
GILENYA,herpetic infections,in patients who,0
GILENYA,herpetic infections,mg er than recommended,1
GILENYA,herpetic infections,in patients who,0
GILENYA,herpetic infections,doses mg er,1
GILENYA,herpetic infections,Similar events have been,0
GILENYA,herpetic infections,mg er than,1
GILENYA,herpetic infections,er than recommended for,1
GILENYA,herpetic infections,mg er than,1
GILENYA,herpetic infections,than recommended for use in,1
GILENYA,herpetic infections,received GILENYA doses mg er than recommended,1
GILENYA,herpetic infections,than recommended for use in,1
GILENYA,herpetic infections,the postmarketing setting,0
GILENYA,disseminated primary herpes zoster,not been established Lymphomas,0
GILENYA,disseminated primary herpes zoster,the postm arketing setting although,1
GILENYA,disseminated primary herpes zoster,been d with GILENYA 0.5 mg in the postm arketing,1
GILENYA,disseminated primary herpes zoster,the postm arketing setting although,1
GILENYA,disseminated primary herpes zoster,doses mg higher than recommended for,0
GILENYA,disseminated primary herpes zoster,been d with GILENYA 0.5 mg in the postm arketing setting although a,1
GILENYA,disseminated primary herpes zoster,doses mg higher than recommended for,0
GILENYA,disseminated primary herpes zoster,for,0
GILENYA,herpes simplex encephalitis,causal relationsh ip has,1
GILENYA,herpes simplex encephalitis,in the postmarketing setting lthough a causal relationsh ip has not been established,1
GILENYA,herpes simplex encephalitis,causal relationsh ip has,1
GILENYA,herpes simplex encephalitis,in MS Similar events have,0
GILENYA,herpes simplex encephalitis,lthough a causal relationsh ip,1
GILENYA,herpes simplex encephalitis,setting lthough a causal relationsh ip has not been,1
GILENYA,herpes simplex encephalitis,lthough a causal relationsh ip,1
GILENYA,herpes simplex encephalitis,in premarketing,0
GILENYA,herpes simplex encephalitis,setting a,0
BENLYSTA,Mortality,Mortality see Warnings and Precautions,1
BENLYSTA,Mortality,detail in the Warnings,0
BENLYSTA,Mortality,Mortality see,1
BENLYSTA,Mortality,with,0
BENLYSTA,Mortality,section,0
BENLYSTA,Mortality,Mortality see Warnings,1
BENLYSTA,Infections,Infections,1
BENLYSTA,Infections,Infections see Warnings and Precautions Malignancy,1
BENLYSTA,Infections,see,0
BENLYSTA,Infections,Precautions Infections see Warnings and,1
BENLYSTA,Infections,see,0
BENLYSTA,Infections,Infections see Warnings and Precautions Malignancy,1
BENLYSTA,Infections,Infections,1
BENLYSTA,Infections,Infections see Warnings and Precautions Malignancy,1
BENLYSTA,Infections,Infections,1
BENLYSTA,Infections,section Mortality see Warnings and,0
BENLYSTA,Infections,Infections see Warnings and,1
BENLYSTA,Malignancy,Serious Infections see,0
BENLYSTA,Malignancy,Precautions Hypersensitivity Reactions,0
BENLYSTA,Malignancy,Malignancy see Warnings,1
BENLYSTA,Malignancy,see Warnings and Precautions Hypersensitivity Reactions including Anaphylax,0
BENLYSTA,Malignancy,Malignancy see Warnings,1
BENLYSTA,Malignancy,Malignancy see Warnings and Precautions Hypersensitivity,1
BENLYSTA,Malignancy,Hypersensitivity Reactions including Anaphylax,0
BENLYSTA,Malignancy,see,0
BENLYSTA,Anaphylaxis,Anaphylaxis see Warnings and,1
BENLYSTA,Anaphylaxis,Anaphylaxis see,1
BENLYSTA,Anaphylaxis,and Precautions Infusion Reactions see Warnings and Precau,0
BENLYSTA,Anaphylaxis,Infusion Reactions see Warnings and,0
BENLYSTA,Anaphylaxis,Anaphylaxis see,1
BENLYSTA,Anaphylaxis,Anaphylaxis see Warnings and Precautions,1
BENLYSTA,Anaphylaxis,Anaphylaxis see,1
BENLYSTA,Depression,Depression see,1
BENLYSTA,Depression,EXCERPT Common adverse,0
BENLYSTA,Depression,Common adverse reactions,0
BENLYSTA,Depression,Infusion Reactions see Warnings and Precautions,0
BENLYSTA,Depression,Reactions see Warnings and Depression see Warnings and,1
BENLYSTA,Depression,Infusion Reactions see Warnings and Precautions,0
BENLYSTA,Depression,Depression see Warnings,1
BENLYSTA,Depression,Depression,1
BENLYSTA,Depression,Depression,1
BENLYSTA,Depression,and Precautions,0
BENLYSTA,Depression,Depression see Warnings and Precautions,1
BENLYSTA,nausea,trials were,0
BENLYSTA,diarrhea,diarrhea pyrexia nasopharyngitis bronchitis insomnia,1
BENLYSTA,diarrhea,diarrhea pyrexia nasopharyngitis,1
BENLYSTA,diarrhea,diarrhea,1
BENLYSTA,diarrhea,diarrhea pyrexia nasopharyngitis bronchitis,1
BENLYSTA,diarrhea,clinical trials were,0
BENLYSTA,diarrhea,diarrhea,1
BENLYSTA,diarrhea,diarrhea pyrexia nasopharyngitis,1
BENLYSTA,diarrhea,depression migraine and,0
BENLYSTA,diarrhea,clinical trials were diarrhea pyrexia nasopharyngitis,1
BENLYSTA,diarrhea,depression migraine and,0
BENLYSTA,pyrexia,pyrexia nasopharyngitis,1
BENLYSTA,pyrexia,pyrexia nasopharyngitis bronchitis insomnia pain,1
BENLYSTA,pyrexia,adverse,0
BENLYSTA,pyrexia,were nausea diarrhea,0
BENLYSTA,nasopharyngitis,trials were nausea diarrhea nasopharyngitis bronchitis insomnia pain,1
BENLYSTA,nasopharyngitis,were nausea diarrhea,0
BENLYSTA,nasopharyngitis,diarrhea nasopharyngitis bronchitis insomnia pain in,1
BENLYSTA,nasopharyngitis,were nausea diarrhea,0
BENLYSTA,bronchitis,bronchitis insomnia pain in,1
BENLYSTA,bronchitis,in clinical trials were nausea diarrhea pyrexia,0
BENLYSTA,bronchitis,nausea diarrhea pyrexia bronchitis,1
BENLYSTA,bronchitis,in clinical trials were nausea diarrhea pyrexia,0
BENLYSTA,bronchitis,nasopharyngitis,0
BENLYSTA,bronchitis,bronchitis insomnia,1
BENLYSTA,bronchitis,nasopharyngitis,0
BENLYSTA,bronchitis,bronchitis insomnia pain in extremity depression,1
BENLYSTA,bronchitis,nausea diarrhea pyrexia bronchitis insomnia pain in,1
BENLYSTA,bronchitis,bronchitis insomnia pain in extremity depression,1
BENLYSTA,bronchitis,diarrhea,0
BENLYSTA,insomnia,pyrexia,0
BENLYSTA,insomnia,clinical trials were,0
BENLYSTA,insomnia,in extremity depression migraine and,0
BENLYSTA,insomnia,diarrhea pyrexia nasopharyngitis insomnia,1
BENLYSTA,insomnia,in extremity depression migraine and,0
BENLYSTA,insomnia,pain in extremity depression migraine and pharyngitis To report SUSPECTED,0
BENLYSTA,insomnia,clinical trials were nausea diarrhea pyrexia,0
BENLYSTA,insomnia,pharyngitis To report SUSPECTED ADVE,0
BENLYSTA,insomnia,e reactions in,0
BENLYSTA,insomnia,pharyngitis To,0
BENLYSTA,insomnia,pyrexia nasopharyngitis bronchitis,0
BENLYSTA,pain in extremity,nausea diarrhea,0
BENLYSTA,pain in extremity,in extremity depression migraine and pharyngitis,1
BENLYSTA,pain in extremity,bronchitis pain in extremity depression migraine,1
BENLYSTA,pain in extremity,in extremity depression migraine and pharyngitis,1
BENLYSTA,pain in extremity,diarrhea pyrexia,0
BENLYSTA,pain in extremity,pain in,1
BENLYSTA,pain in extremity,ADVERSE REACTIONS cont,0
BENLYSTA,migraine,nasopharyngitis bronchitis insomnia pain in extremity,0
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,migraine and pharyngitis To report SUSPECTED,1
BENLYSTA,migraine,pharyngitis To report SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline,0
BENLYSTA,migraine,migraine and pharyngitis,1
BENLYSTA,migraine,pharyngitis To report SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline,0
BENLYSTA,migraine,depression,0
BENLYSTA,pharyngitis,pain in extremity depression migraine and,0
BENLYSTA,pharyngitis,depression migraine pharyngitis To report,1
BENLYSTA,pharyngitis,pain in extremity depression migraine and,0
BENLYSTA,pharyngitis,pyrexia nasopharyngitis bronchitis insomnia pain in extremity,0
BENLYSTA,pharyngitis,depression migraine pharyngitis To report SUSPECTED ADVERSE,1
BENLYSTA,pharyngitis,pyrexia nasopharyngitis bronchitis insomnia pain in extremity,0
BENLYSTA,pharyngitis,nasopharyngitis bronchitis insomnia,0
BENLYSTA,pharyngitis,depression migraine pharyngitis To report SUSPECTED,1
BENLYSTA,pharyngitis,nasopharyngitis bronchitis insomnia,0
BENLYSTA,pharyngitis,pharyngitis To report,1
BENLYSTA,pharyngitis,ADVERSE REACTIONS contact,0
BENLYSTA,pharyngitis,pharyngitis To report SUSPECTED ADVERSE REACTIONS,1
BENLYSTA,infections,with treated with placebo The most common serious adverse,0
BENLYSTA,infections,and in the groups receiving BENLYSTA and placebo respectively see Warnings and,0
BENLYSTA,infections,infections and in the,1
BENLYSTA,infections,and in the groups receiving BENLYSTA and placebo respectively see Warnings and,0
BENLYSTA,infections,and in the groups receiving BENLYSTA and placebo respectively see Warnings and,0
BENLYSTA,infections,infections,1
BENLYSTA,nausea,nausea diarrhea,1
BENLYSTA,nausea,infections,1
BENLYSTA,nausea,nausea diarrhea pyrexia,1
BENLYSTA,nausea,trials nausea diarrhea pyrexia,1
BENLYSTA,nausea,nausea diarrhea pyrexia,1
BENLYSTA,nausea,clinical trials nausea diarrhea,1
BENLYSTA,nausea,nausea diarrhea pyrexia,1
BENLYSTA,nausea,in clinical trials nausea diarrhea pyrexia,1
BENLYSTA,nausea,nausea diarrhea pyrexia,1
BENLYSTA,nausea,nausea diarrhea pyrexia nasopharyngitis bronchitis insomnia,1
BENLYSTA,nausea,patients in clinical trials nausea,1
BENLYSTA,nausea,nausea diarrhea pyrexia nasopharyngitis bronchitis insomnia,1
BENLYSTA,nausea,in clinical trials nausea diarrhea pyrexia nasopharyngitis,1
BENLYSTA,nausea,nausea diarrhea pyrexia nasopharyngitis bronchitis insomnia,1
BENLYSTA,nausea,bronchitis insomnia,0
BENLYSTA,nausea,reactions occurring in of,0
BENLYSTA,diarrhea,insomnia pain in extremity depression migraine,0
BENLYSTA,diarrhea,diarrhea pyrexia,1
BENLYSTA,pyrexia,were nausea pyrexia nasopharyngitis bronchitis insomnia pain,1
BENLYSTA,pyrexia,diarrhea pyrexia,1
BENLYSTA,pyrexia,pyrexia nasopharyngitis bronchitis insomnia,1
BENLYSTA,pyrexia,pyrexia nasopharyngitis bronchitis,1
BENLYSTA,nasopharyngitis,adverse reactions occurring in of patients in clinical trials were nausea,0
BENLYSTA,nasopharyngitis,reactions occurring in of patients in,0
BENLYSTA,bronchitis,in extremity depression migraine,0
BENLYSTA,bronchitis,bronchitis insomnia pain in extremity,1
BENLYSTA,bronchitis,nausea diarrhea pyrexia bronchitis insomnia pain,1
BENLYSTA,bronchitis,bronchitis insomnia pain in extremity,1
BENLYSTA,insomnia,patients who,0
BENLYSTA,insomnia,insomnia,1
BENLYSTA,insomnia,insomnia pain in extremity depression migraine,1
BENLYSTA,insomnia,pharyngitis The proportion of,0
BENLYSTA,insomnia,nasopharyngitis insomnia pain in extremity depression migraine,1
BENLYSTA,insomnia,pharyngitis The proportion of,0
BENLYSTA,insomnia,in extremity depression migraine and pharyngitis The proportion of patients,0
BENLYSTA,insomnia,pain in extremity depression migraine and pharyngitis The proportion of patients who disco,0
BENLYSTA,insomnia,insomnia pain in extremity depression migraine,1
BENLYSTA,insomnia,pain in extremity depression migraine and pharyngitis The proportion of patients who disco,0
BENLYSTA,pain in extremity,bronchitis pain in extremity,1
BENLYSTA,pain in extremity,pain in extremity depression migraine and pharyngitis The proportion of patients who disco,0
BENLYSTA,pain in extremity,The proportion of patients who discontinued treatment d,0
BENLYSTA,pain in extremity,migraine and pharyngitis The proportion of patients,0
BENLYSTA,pain in extremity,who discontinued treatment,0
BENLYSTA,pain in extremity,pyrexia nasopharyngitis bronchitis pain in extremity depression,1
BENLYSTA,pain in extremity,who discontinued treatment,0
BENLYSTA,pain in extremity,insomnia,0
BENLYSTA,pain in extremity,pyrexia nasopharyngitis bronchitis pain in extremity,1
BENLYSTA,pain in extremity,who,0
BENLYSTA,pain in extremity,nasopharyngitis bronchitis pain in extremity,1
BENLYSTA,pain in extremity,who,0
BENLYSTA,depression,depression migraine and pharyngitis The proportion,1
BENLYSTA,depression,depression migraine and pharyngitis,1
BENLYSTA,depression,bronchitis insomnia pain in depression migraine and pharyngitis The,1
BENLYSTA,depression,depression migraine and pharyngitis,1
BENLYSTA,depression,depression migraine and pharyngitis The,1
BENLYSTA,migraine,pain in extremity migraine and pharyngitis The,1
BENLYSTA,migraine,depression migraine and pharyngitis The,1
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,in extremity migraine and pharyngitis The proportion of,1
BENLYSTA,migraine,migraine,1
BENLYSTA,migraine,migraine and,1
BENLYSTA,pharyngitis,due to any adverse,0
BENLYSTA,pharyngitis,who discontinued treatment due to any adverse reaction during the c,0
BENLYSTA,pharyngitis,pyrexia nasopharyngitis bronchitis insomnia pain in,0
BENLYSTA,pharyngitis,adverse reaction during the,0
BENLYSTA,pharyngitis,pharyngitis The,1
BENLYSTA,pharyngitis,pharyngitis The proportion,1
BENLYSTA,pharyngitis,pharyngitis The proportion of,1
BENLYSTA,pharyngitis,pharyngitis The proportion of patients who,1
BENLYSTA,pharyngitis,pharyngitis The proportion of patients who,1
BENLYSTA,pharyngitis,patients who discontinued treatment due to any adverse,0
BENLYSTA,infusion reactions,nephritis BENLYSTA and placebo and infections,0
BENLYSTA,lupus nephritis,and infections BENLYSTA and,0
BENLYSTA,lupus nephritis,BENLYSTA and lupus nephritis,1
BENLYSTA,lupus nephritis,BENLYSTA or placebo were infusion reactions BENLYSTA,0
BENLYSTA,infections,lists adverse reactions regardless,0
BENLYSTA,infections,infections BENLYSTA,1
BENLYSTA,infections,BENLYSTA and placebo,0
BENLYSTA,infusion reactions,infusion reactions of nausea erythematous rash pruritus,1
BENLYSTA,infusion reactions,patients receiving BENLYSTA mgkg Three patients with antibelimumab antibodies experienced,0
BENLYSTA,infusion reactions,experienced infusion reactions,1
BENLYSTA,infusion reactions,experienced infusion reactions,1
BENLYSTA,infusion reactions,experienced infusion reactions,1
BENLYSTA,infusion reactions,antibelimumab antibodies experienced infusion reactions,1
BENLYSTA,infusion reactions,and,0
BENLYSTA,infusion reactions,pruritus eyelid edema headache and dyspnea none of the reactions,0
BENLYSTA,infusion reactions,with antibelimumab antibodies experienced infusion,1
BENLYSTA,infusion reactions,with antibelimumab antibodies experienced infusion,1
BENLYSTA,nausea,nausea erythematous,1
BENLYSTA,nausea,experienced mild infusion reactions nausea erythematous,1
BENLYSTA,nausea,nausea erythematous,1
BENLYSTA,nausea,experienced mild infusion reactions nausea erythematous rash pruritus,1
BENLYSTA,nausea,nausea erythematous,1
BENLYSTA,nausea,nausea erythematous rash,1
BENLYSTA,nausea,nausea erythematous rash pruritus eyelid edema,1
BENLYSTA,nausea,nausea erythematous rash,1
BENLYSTA,erythematous rash,headache and dyspnea none of the reactions was,0
BENLYSTA,pruritus,nausea erythematous pruritus eyelid edema,1
BENLYSTA,pruritus,headache and dyspnea none of the reactions was,0
BENLYSTA,pruritus,pruritus,1
BENLYSTA,pruritus,pruritus,1
BENLYSTA,pruritus,pruritus eyelid edema,1
BENLYSTA,pruritus,pruritus eyelid,1
BENLYSTA,pruritus,pruritus eyelid edema headache and,1
BENLYSTA,pruritus,erythematous rash,0
BENLYSTA,pruritus,mild infusion reactions of,0
BENLYSTA,eyelid edema,eyelid edema headache and dyspnea none,1
BENLYSTA,eyelid edema,eyelid edema headache and,1
BENLYSTA,headache,and,0
BENLYSTA,headache,headache and dyspnea none of,1
BENLYSTA,headache,headache,1
BENLYSTA,headache,experienced,0
BENLYSTA,headache,infusion reactions of nausea erythematous,0
BENLYSTA,headache,erythematous rash pruritus eyelid headache and dyspnea none of the,1
BENLYSTA,headache,infusion reactions of nausea erythematous,0
BENLYSTA,headache,eyelid headache and dyspnea none of the,1
BENLYSTA,headache,infusion reactions of nausea erythematous,0
BENLYSTA,headache,edema,0
BENLYSTA,headache,was lifethreatening The,0
BENLYSTA,headache,reactions of nausea erythematous rash pruritus eyelid edema,0
BENLYSTA,dyspnea,headache,0
BENLYSTA,dyspnea,of the presence,0
BENLYSTA,dyspnea,headache dyspnea none of the,1
BENLYSTA,dyspnea,of the presence,0
BENLYSTA,dyspnea,eyelid edema headache,0
BENLYSTA,dyspnea,the presence of,0
BENLYSTA,dyspnea,none of the reactions was lifethreatening The clinical relevance of the,0
BENLYSTA,dyspnea,edema headache dyspnea,1
BENLYSTA,dyspnea,none of the reactions was lifethreatening The clinical relevance of the,0
BENLYSTA,dyspnea,the reactions was lifethreatening The clinical relevance of the presence,0
BENLYSTA,Fatal,see Warnings,0
BENLYSTA,Fatal,frequency or establish a causal relationship to,0
BENLYSTA,anaphylaxis,anaphylaxis see Warnings and,1
BENLYSTA,anaphylaxis,drug exposure Fatal,0
BENLYSTA,Mortality,conditions,0
BENLYSTA,deaths,under widely ying c,1
BENLYSTA,deaths,widely ying c onditions adverse reaction rates observed,1
BENLYSTA,deaths,under widely ying c,1
BENLYSTA,deaths,clinical trials are conducted under widely,0
BENLYSTA,deaths,conducted under widely ying c onditions adverse reaction,1
BENLYSTA,deaths,clinical trials are conducted under widely,0
BENLYSTA,deaths,widely ying c,1
BENLYSTA,deaths,clinical trials are conducted under widely,0
BENLYSTA,deaths,observed in the clinical trials of a drug,0
BENLYSTA,Infections,n the clin ical,1
BENLYSTA,Infections,the clin ical trials,1
BENLYSTA,Infections,n the clin ical trials of,1
BENLYSTA,Infections,with rates n,1
BENLYSTA,Infections,the clinical trials of a drug cannot be,0
BENLYSTA,Infections,directly compared with rates,0
BENLYSTA,fatal,rug a nd may not,1
BENLYSTA,fatal,another rug a,1
BENLYSTA,fatal,of another rug a,1
BENLYSTA,fatal,of a drug,0
BENLYSTA,fatal,practice The following have been observed with,0
BENLYSTA,fatal,compared with rates in,0
BENLYSTA,infections,d,1
BENLYSTA,infections,trials of another drug d may not  reflect the,1
BENLYSTA,infections,d,1
BENLYSTA,infections,may not reflect the,1
BENLYSTA,infections,of another drug d may not  reflect the rates observed,1
BENLYSTA,infections,may not reflect the,1
BENLYSTA,infections,rates observed in practice The following have,0
BENLYSTA,infections,in practice The following have been,0
BENLYSTA,PML,Precautions [ s,1
BENLYSTA,PML,in practice The following have been,0
BENLYSTA,PML,[ s ee Warnings and Precautions,1
BENLYSTA,Hypersensitivity Reactions,XCERPT Common adverse,0
BENLYSTA,Hypersensitivity Reactions,trials,0
BENLYSTA,Hypersensitivity Reactions,] E XCERPT Common adverse reactions in,1
BENLYSTA,Hypersensitivity Reactions,autions (5.6) ],1
BENLYSTA,Hypersensitivity Reactions,(5.6) ] E XCERPT Common adverse reactions,1
BENLYSTA,Hypersensitivity Reactions,trials,0
BENLYSTA,Hypersensitivity Reactions,clinical trials were nausea diarrhea,0
BENLYSTA,Hypersensitivity Reactions,autions,1
BENLYSTA,Hypersensitivity Reactions,Depression see Warnings and,0
BENLYSTA,Hypersensitivity Reactions,Depression see Warnings and autions,1
BENLYSTA,Anaphylaxis,mmon advers e reactions in,1
BENLYSTA,Anaphylaxis,and Precautions,0
BENLYSTA,Anaphylaxis,e reactions in,0
BENLYSTA,Anaphylaxis,were nausea diarrhea,0
BENLYSTA,Anaphylaxis,reactions in clinical trials were nausea,0
BENLYSTA,Anaphylaxis,mmon advers,1
BENLYSTA,Anaphylaxis,mmon advers e reactions in clinical,1
BENLYSTA,Anaphylaxis,Precautions EXCERPT,0
BENLYSTA,Anaphylaxis,Warnings and Precautions EXCERPT mmon,1
BENLYSTA,fatal,insomnia pain,0
BENLYSTA,fatal,Common adverse =5%)  in,1
BENLYSTA,fatal,insomnia pain,0
BENLYSTA,Depression,report SUSPECTED ADVERSE REACTIONS,0
BENLYSTA,Depression,REACTIONS contact,0
BENLYSTA,Depression,ADVERSE REACTIONS contact,0
BENLYSTA,Depression,REACTIONS contact GlaxoSmithKline -6597,1
BENLYSTA,Depression,SUSPECTED ADVERSE,0
BENLYSTA,Depression,The data d,0
BENLYSTA,Depression,GlaxoSmithKline -6597 or,1
BENLYSTA,Depression,-6597 or F DA at,1
BENLYSTA,Depression,FDA or wwwfdagovmedwatch,0
BENLYSTA,Depression,The data described,0
BENLYSTA,Depression,REACTIONS contact GlaxoSmithKline at or FDA,0
BENLYSTA,Depression,at 1-800- FDA,1
BENLYSTA,Depression,contact GlaxoSmithKline at or at 1-800-,1
BENLYSTA,Depression,GlaxoSmithKline at or at 1-800-,1
BENLYSTA,Depression,GlaxoSmithKline at or  at 1-800- FDA or wwwfdagovmedwatch,1
BENLYSTA,Depression,GlaxoSmithKline at or at 1-800-,1
BENLYSTA,Depression,or FDA,0
BENLYSTA,suicidality,at or FDA at 088 or www.,1
BENLYSTA,suicidality,FDA at 088,1
BENLYSTA,suicidality,088,1
BENLYSTA,suicidality,or www. fdagovmedwatch Clinical Trials,1
BENLYSTA,suicidality,088 or,1
BENLYSTA,deaths,= 675) intravenously over a,1
BENLYSTA,deaths,= 675) intravenously over a hour period,1
BENLYSTA,deaths,of the trials T,0
BENLYSTA,deaths,at doses of mgkg N mgkg N Trial only or mgkg N or,0
BENLYSTA,deaths,was given,0
BENLYSTA,deaths,", whil e in the other",1
BENLYSTA,deaths,in the,0
BENLYSTA,deaths,no apparent ose-re lated,1
BENLYSTA,deaths,in the,0
BENLYSTA,deaths,ose-re lated increase in the majority,1
BENLYSTA,deaths,ose-re lated,1
BENLYSTA,deaths,see Clinical Studies Because there was no apparent,0
BENLYSTA,deaths,the safety data,0
BENLYSTA,deaths,BENLYSTA,0
BENLYSTA,death,data summarized below are presented for th,0
BENLYSTA,death,3 d oses pooled,1
BENLYSTA,death,presented for e 3,1
BENLYSTA,death,for e 3 d,1
BENLYSTA,death,presented for e 3,1
BENLYSTA,death,presented for e 3,1
BENLYSTA,death,e 3 d oses pooled,1
BENLYSTA,death,for e 3 d oses pooled,1
BENLYSTA,death,e 3 d oses pooled,1
BENLYSTA,infection,ated; the adverse,1
BENLYSTA,infection,e 3 d oses pooled,1
BENLYSTA,infection,ated; the,1
BENLYSTA,infection,ated; the adverse reaction table displays,1
BENLYSTA,infection,ated; the,1
BENLYSTA,infection,recommended dose of mgkg compared with plac,0
BENLYSTA,infection,results for the recommended dose,0
BENLYSTA,infection,of mgkg compared with plac,0
BENLYSTA,infection,presented,0
BENLYSTA,infection,ated; the adverse reaction table,1
BENLYSTA,infection,unless otherwise ated; the,1
BENLYSTA,cardiovascular disease,the dverse reaction table  displays the,1
BENLYSTA,cardiovascular disease,unless otherwise ated; the,1
BENLYSTA,cardiovascular disease,indicated the dverse reaction table  displays,1
BENLYSTA,cardiovascular disease,unless otherwise ated; the,1
BENLYSTA,cardiovascular disease,doses pooled unless otherwise,0
BENLYSTA,suicide,reaction table,0
BENLYSTA,fatal,place bo The population had a,1
BENLYSTA,fatal,bo The population had a mean age of range to were,0
BENLYSTA,fatal,compared place bo The population had,1
BENLYSTA,fatal,bo The population had a mean age of range to were,0
BENLYSTA,fatal,compared place bo The population had,1
BENLYSTA,fatal,bo The population had a mean age of range to were,0
BENLYSTA,fatal,dose of mgkg compared place bo The population,1
BENLYSTA,fatal,bo The population had a mean age of range to were,0
BENLYSTA,fatal,place bo The population had,1
BENLYSTA,fatal,bo The population had a mean age of range to were,0
BENLYSTA,infections,of mgkg compared with o.,1
BENLYSTA,infections,with o. The,1
BENLYSTA,infections,placeb,0
BENLYSTA,infections,o. The population had,1
BENLYSTA,infections,and,0
BENLYSTA,infections,"with o.



 The population had a mean age",1
BENLYSTA,infections,and,0
BENLYSTA,infections,population had a mean age of range to were,0
BENLYSTA,infections,o. The,1
BENLYSTA,infections,female,0
BENLYSTA,infections,o. The population had a,1
BENLYSTA,infections,compared with o. The,1
BENLYSTA,infections,o. The population had a,1
BENLYSTA,infections,"diarrhea,  pyrexia",1
BENLYSTA,infections,"in clinical trials were diarrhea,  pyrexia nasopharyngitis bronchitis",1
BENLYSTA,infections,"diarrhea,  pyrexia",1
BENLYSTA,infections,"diarrhea,  pyrexia nasopharyngitis bronchitis insomnia",1
BENLYSTA,infections,reactions occurring in,0
BENLYSTA,infections,clinical trials were nausea,0
BENLYSTA,infections,and pharyngitis  proportio,1
BENLYSTA,infections,clinical trials were nausea,0
BENLYSTA,infections,pain in extremity depression migraine and pharyngitis,0
BENLYSTA,infections,The,0
BENLYSTA,infections,and pharyngitis The,0
BENLYSTA,infections,discontinued treatment due to any adverse reaction during the controlled,0
BENLYSTA,infections, proportio n of patients who,1
BENLYSTA,infections,discontinued treatment due to any adverse reaction during the controlled,0
BENLYSTA,infections, proportio n of patients,1
BENLYSTA,infections,discontinued treatment due to any adverse reaction during the,0
BENLYSTA,infections,and pharyngitis,0
BENLYSTA,upper respiratory tract infection,adverse reaction during,1
BENLYSTA,upper respiratory tract infection,e to any adverse reaction during  the controlled clinical trials was,1
BENLYSTA,upper respiratory tract infection,adverse reaction during,1
BENLYSTA,upper respiratory tract infection,for patients,0
BENLYSTA,upper respiratory tract infection,pharyngitis The proportion of patients who discontinued,0
BENLYSTA,upper respiratory tract infection,e to any adverse reaction during,1
BENLYSTA,upper respiratory tract infection,reaction during the,1
BENLYSTA,upper respiratory tract infection,discontinued treatment e to any adverse reaction during  the controlled clinical,1
BENLYSTA,upper respiratory tract infection,reaction during the,1
BENLYSTA,upper respiratory tract infection,discontinued treatment e to any adverse reaction during  the controlled,1
BENLYSTA,upper respiratory tract infection,reaction during the,1
BENLYSTA,upper respiratory tract infection,treatment e,1
BENLYSTA,upper respiratory tract infection,proportion of patients who,0
BENLYSTA,urinary tract infection,placebo The,0
BENLYSTA,urinary tract infection,patients receiving placebo The most,0
BENLYSTA,urinary tract infection,patients who discontinued,0
BENLYSTA,urinary tract infection,e controlled clinical t rials was for patients,1
BENLYSTA,urinary tract infection,patients receiving placebo The most com,0
BENLYSTA,urinary tract infection,BENLYSTA and for patients receiving placebo The,0
BENLYSTA,urinary tract infection,reaction during e controlled clinical t rials was for patients,1
BENLYSTA,urinary tract infection,BENLYSTA and for patients receiving placebo The,0
BENLYSTA,urinary tract infection,controlled clinical t rials was for patients receiving,1
BENLYSTA,nasopharyngitis,was 6.2% fo r patients receiving,1
BENLYSTA,nasopharyngitis,clinical als was,1
BENLYSTA,nasopharyngitis,receiving placebo The most common adverse,0
BENLYSTA,nasopharyngitis,treatment due,0
BENLYSTA,nasopharyngitis,clinical tri,0
BENLYSTA,nasopharyngitis,als was 6.2% fo r patients receiving,1
BENLYSTA,nasopharyngitis,during the controlled clinical als was 6.2% fo r patients receiving BENLYSTA,1
BENLYSTA,nasopharyngitis,als was 6.2% fo r patients receiving,1
BENLYSTA,nasopharyngitis,als was 6.2% fo r,1
BENLYSTA,nasopharyngitis,als was 6.2% fo r patients receiving,1
BENLYSTA,bronchitis,receiving placebo The most common adverse,0
BENLYSTA,bronchitis,patients ceiving BE NLYSTA,1
BENLYSTA,bronchitis,receiving placebo The most common adverse,0
BENLYSTA,bronchitis,the controlled clinical trials,0
BENLYSTA,bronchitis,adverse reaction during the,0
BENLYSTA,bronchitis,to any adverse reaction,0
BENLYSTA,bronchitis,ceiving BE,1
BENLYSTA,influenza,trials was for,0
BENLYSTA,influenza, and 7.1%,1
BENLYSTA,influenza,trials was for,0
BENLYSTA,influenza,receiving  and 7.1% for patients receiving placebo The,1
BENLYSTA,influenza,trials was for,0
BENLYSTA,influenza,was for patients receiving  and 7.1% for,1
BENLYSTA,influenza,trials was for,0
BENLYSTA,influenza,and 7.1% for,1
BENLYSTA,influenza,was for patients receiving and,1
BENLYSTA,influenza,controlled,0
BENLYSTA,influenza,trials was for patients receiving,0
BENLYSTA,infections,during the controlled,0
BENLYSTA,infections,A or place bo were infusion reactions,1
BENLYSTA,infections,during the controlled,0
BENLYSTA,infections,mmon adverse reactions resulting in discontinuation,0
BENLYSTA,infections,treatment of patients receiving A or,1
BENLYSTA,infections,bo were infusion reactions BENLYSTA and placebo lupus nephritis BENLYSTA,0
BENLYSTA,pneumonia,placebo were nfusion r,1
BENLYSTA,pneumonia,in discontinuation of treatment,0
BENLYSTA,bronchitis,and lupus neph,1
BENLYSTA,bronchitis,and lupus neph,1
BENLYSTA,bronchitis,BENLYSTA and lupus,1
BENLYSTA,bronchitis,and placebo,0
BENLYSTA,bronchitis,and,0
BENLYSTA,bronchitis,ritis,0
BENLYSTA,bronchitis,BENLYSTA,0
BENLYSTA,bronchitis,BENLYSTA and,0
BENLYSTA,bronchitis,reactions BENLYSTA and lupus neph,1
BENLYSTA,Infections,lupus tis (0.7%  BENLYSTA and placebo and,1
BENLYSTA,Infections,reactions BENLYSTA and lupus neph,1
BENLYSTA,Infections,infections BENLYSTA and placebo Table lists ad,0
BENLYSTA,Infections,tis (0.7% BENLYSTA,1
BENLYSTA,Infections,lupus tis (0.7%  BENLYSTA and,1
BENLYSTA,Infections,tis (0.7% BENLYSTA,1
BENLYSTA,Infections,with SLE who,0
BENLYSTA,Infections,lists adverse reactions regardless f causalit y occurring in,1
BENLYSTA,Infections,with SLE who,0
BENLYSTA,Infections,adverse reactions regardless f causalit,1
BENLYSTA,Infections,lists adverse reactions regardless f causalit y,1
BENLYSTA,Infections,adverse reactions regardless f causalit,1
BENLYSTA,Infections,f causalit y,1
BENLYSTA,Infections,reactions regardless f causalit,1
BENLYSTA,Infections,adverse reactions regardless f causalit,1
BENLYSTA,Infections,received BENLYSTA mgkg and at an incidence,0
BENLYSTA,Infections,f causalit y occurring in at least,1
BENLYSTA,Infections,who,0
BENLYSTA,JC virus,controlled studies,0
BENLYSTA,JC virus,studies Table Inciden,0
BENLYSTA,JC virus,occurring in at Least of Patients Treated,0
BENLYSTA,JC virus,of Ad verse,1
BENLYSTA,JC virus,t least greater than that observed with placebo in the controlled studies,0
BENLYSTA,JC virus,greater than that observed with placebo in the controlled,0
BENLYSTA,JC virus,Table ce of,1
BENLYSTA,JC virus,controlled studies Table ce of Ad,1
BENLYSTA,JC virus,controlled studies Table ce of Ad verse,1
BENLYSTA,JC virus,controlled studies Table ce of Ad,1
BENLYSTA,JC virus,controlled studies Table ce of,1
BENLYSTA,PML,ons occurring in at Least,1
BENLYSTA,PML,ons occurring,1
BENLYSTA,PML,ons occurring in at Least,1
BENLYSTA,PML,ons occurring in at Least of,1
BENLYSTA,neurological deficits,mgkg plus Standard of Care and,0
BENLYSTA,neurological deficits,Adverse Reactions occurring at,1
BENLYSTA,neurological deficits,ts Treated with BENLYSTA mgkg plus Standard of Care and at Least More Frequently than in,0
BENLYSTA,fatal,Least,0
BENLYSTA,fatal,Least of Patients Treated ith B,1
BENLYSTA,fatal,Patients Treated ith B,1
BENLYSTA,fatal,Treated,0
BENLYSTA,fatal,of Adverse Reactions,0
BENLYSTA,fatal,ith B ENLYSTA mgkg plus Standard of,1
BENLYSTA,fatal,of Adverse Reactions,0
BENLYSTA,hypersensitivity reactions,in of patients receiving  mg/kg and in 27 of 559 (4 patients receiving BENLYSTA mgkg The,1
BENLYSTA,hypersensitivity reactions,of Adverse Reactions,0
BENLYSTA,hypersensitivity reactions,for the group receiving mgkg ma,0
BENLYSTA,hypersensitivity reactions,mg/kg and in,1
BENLYSTA,hypersensitivity reactions,in of patients receiving BENLYSTA,0
BENLYSTA,hypersensitivity reactions, mg/kg and in 27 of 559 (4 patients receiving BENLYSTA mgkg The,1
BENLYSTA,hypersensitivity reactions,in of patients receiving BENLYSTA,0
BENLYSTA,hypersensitivity reactions,27 of 559 (4 patients,1
BENLYSTA,hypersensitivity reactions,receiving,0
BENLYSTA,hypersensitivity reactions,of patients receiving mg/kg and in,1
BENLYSTA,hypersensitivity reactions,frequency for the group receiving,0
BENLYSTA,hypersensitivity reactions,patients receiving,0
BENLYSTA,Anaphylaxis,ass,0
BENLYSTA,Anaphylaxis,to lower ay,1
BENLYSTA,Anaphylaxis,frequency due to lower ay sensitiv,1
BENLYSTA,hypotension,patients wi th antibelimumab antibodies experienced mild,1
BENLYSTA,hypotension,patients wi th antibelimumab,1
BENLYSTA,hypotension,receiving BENLYSTA mgkg patients wi th,1
BENLYSTA,hypotension,patients wi th antibelimumab,1
BENLYSTA,hypotension,patients wi th,1
BENLYSTA,hypotension,patients receiving BENLYSTA mgkg patients wi,1
BENLYSTA,angioedema, anti-beli mumab antibodies experienced mild,1
BENLYSTA,angioedema,antibodies were detected in patients,0
BENLYSTA,angioedema, anti-beli,1
BENLYSTA,urticaria,rash pruritus eyelid edema,0
BENLYSTA,urticaria,in patients receiving BENLYSTA mgkg Three,0
BENLYSTA,urticaria,mild infusion reactions of nausea erythematous rash pruritus eyelid,0
BENLYSTA,urticaria,mab antib odies experienced mild,1
BENLYSTA,rash,rien ced,1
BENLYSTA,rash,rien ced mild infusion reactions,1
BENLYSTA,rash,rien,1
BENLYSTA,rash,mgkg Three patients with antibelimumab,0
BENLYSTA,rash,antibelimumab antibodies rien ced mild,1
BENLYSTA,rash,mgkg Three patients with antibelimumab,0
BENLYSTA,rash,mild infusion reactions of nausea erythematous rash pruritus,0
BENLYSTA,rash,edema headache and dysp,0
BENLYSTA,rash,edema headache,0
BENLYSTA,rash,rien,1
BENLYSTA,rash,edema headache,0
BENLYSTA,pruritus,edema headache,0
BENLYSTA,pruritus,d mild i,1
BENLYSTA,dyspnea,erythematous rash pruritus eyelid edema headache,0
BENLYSTA,dyspnea,n react,1
BENLYSTA,dyspnea,mild n react,1
BENLYSTA,dyspnea,n react,1
BENLYSTA,dyspnea,n react ions of,1
BENLYSTA,dyspnea,n react,1
BENLYSTA,hypersensitivity reactions,one of the reactions was l,1
BENLYSTA,hypersensitivity reactions,of the reactions was l,1
BENLYSTA,hypersensitivity reactions,the presence of antibelimumab antibodies is not known,0
BENLYSTA,hypersensitivity reactions,ld infusion reactions of nausea erythematous rash pruritus eyelid edema headache and,0
BENLYSTA,hypersensitivity reactions,presence of antibelimumab,0
BENLYSTA,hypersensitivity reactions,of the reactions was l ifethreatening The clinical relevance,1
BENLYSTA,infusion reactions,eyelid edema headache and dyspnea,0
BENLYSTA,infusion reactions,reactions was,0
BENLYSTA,infusion reactions,hreatening. The cl inical,1
BENLYSTA,infusion reactions,hreatening. The cl inical relevance of the presence,1
BENLYSTA,infusion reactions,reactions was hreatening. The,1
BENLYSTA,infusion reactions,is not known The data reflect the,0
BENLYSTA,adverse events associated with the infusion,a causal relationship to drug exp osure Fatal,1
BENLYSTA,adverse events associated with the infusion,frequency establish a causal relationship to drug exp osure Fatal,1
BENLYSTA,adverse events associated with the infusion,a causal relationship to drug exp osure Fatal,1
BENLYSTA,adverse events associated with the infusion,a causal relationship to drug exp,1
BENLYSTA,adverse events associated with the infusion,their frequency,0
BENLYSTA,adverse events associated with the infusion,reliably estimate their frequency establish a causal relationship to drug exp,1
BENLYSTA,adverse events associated with the infusion,see Warnings and Precautions,0
BENLYSTA,adverse events associated with the infusion,of uncertain size it is not,0
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions,1
XALKORI,Hepatotoxicity,of uncertain size it is not,0
XALKORI,Hepatotoxicity,Hepatotoxicity see,1
XALKORI,Hepatotoxicity,Hepatotoxicity,1
XALKORI,Hepatotoxicity,see Warnings and Precautions,0
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions Interstitial,1
XALKORI,Hepatotoxicity,sections of the Hepatotoxicity see Warnings and Precautions Interstitial,1
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions Interstitial,1
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions,1
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings and,1
XALKORI,Hepatotoxicity,Hepatotoxicity see Warnings,1
XALKORI,Hepatotoxicity,Hepatotoxicity,1
XALKORI,Interstitial Lung Disease,QT Interval,0
XALKORI,Interstitial Lung Disease,sections of the labeling Hepatotoxicity,0
XALKORI,Interstitial Lung Disease,and Interstitial Lung Disease Pneumonitis see Warnings and,1
XALKORI,Interstitial Lung Disease,sections of the labeling Hepatotoxicity,0
XALKORI,Interstitial Lung Disease,and Interstitial,1
XALKORI,Pneumonitis,see Warnings and,0
XALKORI,Pneumonitis,Pneumonitis see Warnings,1
XALKORI,Pneumonitis,Interstitial Lung Pneumonitis see Warnings and,1
XALKORI,Pneumonitis,Pneumonitis see Warnings,1
XALKORI,Pneumonitis,Precautions Interstitial Lung Pneumonitis see Warnings and Precautions QT,1
XALKORI,Pneumonitis,Pneumonitis see Warnings,1
XALKORI,QT Interval Prolongation,DiseasePneumonitis see,0
XALKORI,Bradycardia,Bradycardia see,1
XALKORI,Bradycardia,and Precautions,0
XALKORI,Bradycardia,see Warnings and Bradycardia see Warnings and Precautions Severe,1
XALKORI,Bradycardia,and Precautions,0
XALKORI,Visual Loss,The,0
XALKORI,Visual Loss,Warnings and Precautions Visual Loss see Warnings and,1
XALKORI,Visual Loss,The,0
XALKORI,Visual Loss,Visual Loss see,1
XALKORI,Visual Loss,The,0
XALKORI,Visual Loss,Visual Loss,1
XALKORI,Visual Loss,and Precautions Visual Loss,1
XALKORI,Visual Loss,Visual Loss,1
XALKORI,Visual Loss,Visual Loss,1
XALKORI,vision disorders,vision,1
XALKORI,vision disorders,most common adverse reactions vision disorders,1
XALKORI,vision disorders,vision,1
XALKORI,vision disorders,vision disorders,1
XALKORI,vision disorders,vision disorders diarrhea nausea,1
XALKORI,vision disorders,EXCERPT The most common adverse,0
XALKORI,vision disorders,most common adverse reactions vision disorders,1
XALKORI,diarrhea,edema elevated transaminases upper,0
XALKORI,diarrhea,vision diarrhea nausea,1
XALKORI,diarrhea,edema elevated transaminases upper,0
XALKORI,diarrhea,diarrhea nausea,1
XALKORI,diarrhea,diarrhea nausea vomiting constipation,1
XALKORI,diarrhea,vision diarrhea,1
XALKORI,diarrhea,diarrhea nausea vomiting constipation,1
XALKORI,diarrhea,diarrhea nausea,1
XALKORI,diarrhea,transaminases upper respiratory,0
XALKORI,diarrhea,vision diarrhea nausea vomiting constipation edema,1
XALKORI,diarrhea,transaminases upper respiratory,0
XALKORI,diarrhea,diarrhea nausea vomiting constipation edema elevated,1
XALKORI,diarrhea,diarrhea nausea vomiting,1
XALKORI,nausea,transaminases upper respiratory infection,0
XALKORI,nausea,nausea vomiting constipation edema,1
XALKORI,nausea,vomiting constipation edema elevated transaminases upper respiratory infection decreased,0
XALKORI,nausea,elevated transaminases,0
XALKORI,nausea,nausea vomiting constipation edema elevated,1
XALKORI,nausea,nausea vomiting constipation edema,1
XALKORI,vomiting,disorders diarrhea vomiting constipation edema elevated transaminases,1
XALKORI,vomiting,nausea vomiting constipation edema,1
XALKORI,vomiting,vomiting,1
XALKORI,vomiting,diarrhea vomiting constipation edema elevated transaminases upper,1
XALKORI,vomiting,vomiting,1
XALKORI,vomiting,decreased,0
XALKORI,vomiting,vomiting,1
XALKORI,vomiting,constipation edema elevated,0
XALKORI,vomiting,are vision disorders diarrhea vomiting constipation edema elevated transaminases,1
XALKORI,vomiting,constipation edema elevated,0
XALKORI,vomiting,decreased appetite and,0
XALKORI,vomiting,transaminases upper respiratory infection,0
XALKORI,vomiting,vomiting constipation edema elevated transaminases upper,1
XALKORI,constipation,decreased appetite and dysgeusia,0
XALKORI,edema,vomiting edema elevated transaminases,1
XALKORI,edema,decreased appetite and dysgeusia,0
XALKORI,edema,edema elevated transaminases upper respiratory,1
XALKORI,edema,disorders diarrhea nausea vomiting edema elevated transaminases upper respiratory infection,1
XALKORI,edema,edema elevated transaminases upper respiratory,1
XALKORI,elevated transaminases,decreased appetite and dysgeusia,0
XALKORI,elevated transaminases,elevated transaminases upper respiratory infection decreased,1
XALKORI,elevated transaminases,To,0
XALKORI,elevated transaminases,vomiting,0
XALKORI,elevated transaminases,diarrhea nausea vomiting constipation elevated transaminases,1
XALKORI,elevated transaminases,constipation elevated transaminases upper,1
XALKORI,elevated transaminases,diarrhea nausea vomiting constipation elevated transaminases,1
XALKORI,elevated transaminases,elevated transaminases upper respiratory infection,1
XALKORI,elevated transaminases,elevated transaminases,1
XALKORI,elevated transaminases,elevated transaminases upper respiratory infection,1
XALKORI,elevated transaminases,diarrhea nausea vomiting constipation elevated,1
XALKORI,elevated transaminases,elevated transaminases,1
XALKORI,upper respiratory infection,diarrhea nausea vomiting constipation edema,0
XALKORI,upper respiratory infection,and,0
XALKORI,upper respiratory infection,upper respiratory infection decreased,1
XALKORI,upper respiratory infection,and,0
XALKORI,upper respiratory infection,upper respiratory infection,1
XALKORI,upper respiratory infection,upper respiratory infection decreased appetite and,1
XALKORI,upper respiratory infection,upper respiratory infection,1
XALKORI,upper respiratory infection,elevated,0
XALKORI,upper respiratory infection,upper respiratory infection decreased appetite,1
XALKORI,upper respiratory infection,upper respiratory infection decreased appetite and,1
XALKORI,upper respiratory infection,upper respiratory infection decreased appetite,1
XALKORI,upper respiratory infection,disorders diarrhea nausea vomiting constipation edema elevated,0
XALKORI,decreased appetite,decreased appetite and dysgeusia To report SUSPECTED,1
XALKORI,decreased appetite,arrhea,0
XALKORI,decreased appetite,edema elevated transaminases,0
XALKORI,decreased appetite,decreased appetite,1
XALKORI,decreased appetite,decreased appetite and dysgeusia To report,1
XALKORI,decreased appetite,elevated transaminases upper respiratory decreased appetite and dysgeusia,1
XALKORI,decreased appetite,decreased appetite and dysgeusia To report,1
XALKORI,decreased appetite,REACTIONS contact Pfizer Inc at,0
XALKORI,dysgeusia,dysgeusia To report SUSPECTED,1
XALKORI,dysgeusia,dysgeusia To report SUSPECTED,1
XALKORI,dysgeusia,dysgeusia To report SUSPECTED,1
XALKORI,dysgeusia,report SUSPECTED ADVERSE,0
XALKORI,dysgeusia,respiratory infection decreased appetite dysgeusia To report,1
XALKORI,dysgeusia,report SUSPECTED ADVERSE,0
XALKORI,dysgeusia,infection decreased appetite and,0
XALKORI,dysgeusia,dysgeusia To report SUSPECTED,1
XALKORI,vision disorders,adverse reactions of XALKORI in,0
XALKORI,vision disorders,vision disorders,1
XALKORI,vision disorders,Studies and vision,1
XALKORI,vision disorders,transaminases upper respiratory infecti,0
XALKORI,vision disorders,vision disorders diarrhea nausea vomiting constipation edema,1
XALKORI,diarrhea,diarrhea,1
XALKORI,diarrhea,reactions of XALKORI,0
XALKORI,diarrhea,diarrhea nausea vomiting constipation edema elevated,1
XALKORI,diarrhea,nausea vomiting constipation edema elevated transaminases upper,0
XALKORI,diarrhea,diarrhea,1
XALKORI,diarrhea,nausea vomiting constipation edema elevated transaminases upper respiratory infection decrea,0
XALKORI,diarrhea,diarrhea nausea vomiting constipation edema,1
XALKORI,diarrhea,diarrhea nausea vomiting constipation edema elevated,1
XALKORI,diarrhea,diarrhea nausea vomiting constipation edema,1
XALKORI,nausea,nausea vomiting constipation edema,1
XALKORI,vomiting,vomiting,1
XALKORI,vomiting,vision disorders diarrhea nausea,0
XALKORI,vomiting,nausea,0
XALKORI,constipation,are vision disorders diarrhea nausea vomiting,0
XALKORI,constipation,constipation edema elevated transaminases upper,1
XALKORI,constipation,nausea vomiting,0
XALKORI,constipation,vomiting,0
XALKORI,constipation,constipation edema elevated transaminases upper,1
XALKORI,constipation,appetite and,0
XALKORI,constipation,disorders diarrhea nausea constipation,1
XALKORI,constipation,appetite and,0
XALKORI,constipation,constipation edema elevated transaminases upper,1
XALKORI,elevated transaminases,elevated transaminases upper respiratory infection,1
XALKORI,elevated transaminases,appetite and dysgeusia Previously,0
XALKORI,elevated transaminases,elevated transaminases upper,1
XALKORI,elevated transaminases,constipation elevated transaminases upper respiratory infection decreased appetite,1
XALKORI,elevated transaminases,elevated transaminases upper,1
XALKORI,elevated transaminases,diarrhea nausea vomiting constipation elevated,1
XALKORI,elevated transaminases,edema,0
XALKORI,elevated transaminases,nausea vomiting constipation elevated transaminases upper respiratory infection decreased,1
XALKORI,elevated transaminases,edema,0
XALKORI,elevated transaminases,Studies and are vision,0
XALKORI,upper respiratory infection,edema elevated upper respiratory infection decreased appetite and dysgeusia Previously,1
XALKORI,upper respiratory infection,Studies and are vision,0
XALKORI,upper respiratory infection,constipation edema elevated upper respiratory,1
XALKORI,upper respiratory infection,constipation edema elevated upper,1
XALKORI,upper respiratory infection,respiratory infection decreased appetite and,1
XALKORI,dysgeusia,and,0
XALKORI,dysgeusia,dysgeusia Previously Untreated,1
XALKORI,dyspnea,dyspnea and pulmonary embolism,1
XALKORI,dyspnea,treated with XALKORI dyspnea and pulmonary embolism Fatal adverse,1
XALKORI,dyspnea,dyspnea and pulmonary embolism,1
XALKORI,dyspnea,dyspnea and pulmonary embolism Fatal adverse,1
XALKORI,pulmonary embolism,were dyspnea pulmonary embolism Fatal,1
XALKORI,pulmonary embolism,dyspnea and pulmonary embolism Fatal adverse,1
XALKORI,pulmonary embolism,pulmonary embolism Fatal adverse events,1
XALKORI,pulmonary embolism,XALKORI were dyspnea pulmonary embolism Fatal,1
XALKORI,pulmonary embolism,pulmonary embolism Fatal adverse events,1
XALKORI,pulmonary embolism,pulmonary,1
XALKORI,pulmonary embolism,patients consisting of,0
XALKORI,pulmonary embolism,pulmonary embolism Fatal adverse,1
XALKORI,pulmonary embolism,serious adverse events,0
XALKORI,pulmonary embolism,pulmonary embolism Fatal adverse events in,1
XALKORI,pulmonary embolism,events reported in,0
XALKORI,pulmonary embolism,Fatal adverse events in XALKORItreated patients occurred in patients,0
XALKORI,Fatal,were dyspnea and pulmonary Fatal adverse,1
XALKORI,Fatal,Fatal adverse events in XALKORItreated patients occurred in patients,0
XALKORI,Fatal,Fatal adverse events in,1
XALKORI,septic shock,septic shock,1
XALKORI,septic shock,adverse events in XALKORItreated patients occurred in patients consisting of,0
XALKORI,septic shock,Fatal adverse events in XALKORItreated patients occurred in,0
XALKORI,septic shock,reductions due to adverse reactions,0
XALKORI,septic shock,Fatal adverse events in XALKORItreated,0
XALKORI,septic shock,occurred in patients consisting septic shock,1
XALKORI,septic shock,septic shock,1
XALKORI,septic shock,septic shock acute respiratory,1
XALKORI,septic shock,septic shock acute respiratory,1
XALKORI,acute respiratory failure,of septic acute respiratory failure,1
XALKORI,acute respiratory failure,septic shock acute respiratory,1
XALKORI,acute respiratory failure,and diabetic ketoacidosis Dose reductions due to adverse reactions were,0
XALKORI,acute respiratory failure,patients consisting of,0
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis,1
XALKORI,diabetic ketoacidosis,respiratory failure diabetic ketoacidosis Dose reductions due to adverse,1
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis,1
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis Dose reductions,1
XALKORI,diabetic ketoacidosis,failure diabetic ketoacidosis,1
XALKORI,diabetic ketoacidosis,shock acute respiratory failure diabetic,1
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis Dose reductions due,1
XALKORI,diabetic ketoacidosis,shock acute respiratory failure diabetic,1
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis Dose reductions due to,1
XALKORI,diabetic ketoacidosis,diabetic ketoacidosis Dose,1
XALKORI,nausea,nausea and elevated transaminases,1
XALKORI,nausea,dose reduction in these patients,0
XALKORI,nausea,discontinuation,0
XALKORI,nausea,nausea and,1
XALKORI,nausea,nausea and elevated transaminases,1
XALKORI,elevated transaminases,discontinuation in XALKORItreated,0
XALKORI,elevated transaminases,discontinuation in XALKORItreated patients elevated,1
XALKORI,elevated transaminases,discontinuation in XALKORItreated patients elevated transaminases,1
XALKORI,hepatotoxicity,hepatotoxicity and ILD Tables and,1
XALKORI,hepatotoxicity,hepatotoxicity and ILD Tables and,1
XALKORI,hepatotoxicity,hepatotoxicity and ILD,1
XALKORI,hepatotoxicity,in XALKORItreated patients,0
XALKORI,hepatotoxicity,hepatotoxicity and ILD Tables and summarize,1
XALKORI,nausea,neuropathy which,0
XALKORI,nausea,nausea decreased appetite fatigue neuropathy,1
XALKORI,nausea,at an overall incidence between and in patients treated with XALKORI included,0
XALKORI,nausea,patients treated with XALKORI nausea decreased appetite fatigue,1
XALKORI,nausea,at an overall incidence between and in patients treated with XALKORI included,0
XALKORI,nausea,an,0
XALKORI,decreased appetite,decreased appetite fatigue neuropathy which included,1
XALKORI,decreased appetite,treated with XALKORI included,0
XALKORI,decreased appetite,with XALKORI included decreased,1
XALKORI,decreased appetite,hypoaesthesia muscular,0
XALKORI,decreased appetite,decreased,1
XALKORI,decreased appetite,included gait disturbance hypoaesthesia muscular,0
XALKORI,decreased appetite,included,0
XALKORI,decreased appetite,XALKORI included decreased appetite fatigue neuropathy which included,1
XALKORI,decreased appetite,included,0
XALKORI,fatigue,neuropathy which included gait disturbance hypoaesthesia,0
XALKORI,fatigue,fatigue neuropathy which included,1
XALKORI,fatigue,treated with,0
XALKORI,fatigue,XALKORI included nausea,0
XALKORI,fatigue,included nausea decreased fatigue neuropathy,1
XALKORI,fatigue,XALKORI included nausea,0
XALKORI,neuropathy,with XALKORI included nausea decreased appetite,0
XALKORI,neuropathy,neuropathy which included gait disturbance,1
XALKORI,neuropathy,gait disturbance hypoaesthesia muscular weakness,0
XALKORI,neuropathy,hypoaesthesia muscular weakness neuralgia neuropathy peri,0
XALKORI,hypoaesthesia,included gait hypoaesthesia muscular weakness neuralgia,1
XALKORI,hypoaesthesia,hypoaesthesia muscular weakness neuralgia neuropathy peri,0
XALKORI,hypoaesthesia,paraesthesia,0
XALKORI,hypoaesthesia,hypoaesthesia muscular weakness neuralgia neuropathy peripheral,1
XALKORI,hypoaesthesia,which,0
XALKORI,hypoaesthesia,hypoaesthesia muscular weakness neuralgia,1
XALKORI,hypoaesthesia,included,0
XALKORI,muscular weakness,muscular weakness,1
XALKORI,muscular weakness,disturbance muscular weakness,1
XALKORI,muscular weakness,muscular weakness,1
XALKORI,muscular weakness,muscular weakness,1
XALKORI,muscular weakness,sed appetite,0
XALKORI,muscular weakness,which included gait disturbance muscular weakness neuralgia neuropathy,1
XALKORI,muscular weakness,sed appetite,0
XALKORI,muscular weakness,fatigue neuropathy which included,0
XALKORI,muscular weakness,muscular weakness neuralgia neuropathy,1
XALKORI,muscular weakness,peripheral,0
XALKORI,muscular weakness,muscular weakness,1
XALKORI,neuralgia,hypoaesthesia muscular neuralgia neuropathy peripheral,1
XALKORI,neuralgia,muscular weakness,1
XALKORI,neuralgia,neuralgia neuropathy peripheral,1
XALKORI,neuralgia,neuralgia neuropathy peripheral paraesthesia peripheral,1
XALKORI,neuralgia,neuralgia neuropathy peripheral,1
XALKORI,neuralgia,disturbance hypoaesthesia muscular,0
XALKORI,neuralgia,which included gait disturbance hypoaesthesia,0
XALKORI,neuralgia,hypoaesthesia muscular neuralgia neuropathy peripheral paraesthesia peripheral sensory,1
XALKORI,neuralgia,which included gait disturbance hypoaesthesia,0
XALKORI,neuralgia,hypoaesthesia muscular neuralgia neuropathy peripheral paraesthesia peripheral sensory,1
XALKORI,neuralgia,which included gait disturbance hypoaesthesia,0
XALKORI,neuralgia,paraesthesia peripheral sensory neuropathy,0
XALKORI,neuralgia,fatigue neuropathy which included gait disturbance,0
XALKORI,neuralgia,peripheral sensory neuropathy polyneuropathy sensory distur,0
XALKORI,neuropathy peripheral,neuropathy peripheral paraesthesia peripheral sensory neuropathy,1
XALKORI,neuropathy peripheral,disturbance hypoaesthesia muscular weakness neuropathy peripheral,1
XALKORI,neuropathy peripheral,disturbance rash ren,0
XALKORI,neuropathy peripheral,peripheral sensory neuropathy polyneuropathy sensory,0
XALKORI,neuropathy peripheral,weakness neuropathy peripheral paraesthesia peripheral,1
XALKORI,neuropathy peripheral,peripheral sensory neuropathy polyneuropathy sensory,0
XALKORI,neuropathy peripheral,hypoaesthesia muscular weakness neuropathy peripheral,1
XALKORI,paraesthesia,muscular weakness neuralgia neuropathy,0
XALKORI,paraesthesia,neuralgia neuropathy peripheral,0
XALKORI,paraesthesia,weakness neuralgia neuropathy,0
XALKORI,paraesthesia,disturbance rash renal,0
XALKORI,paraesthesia,paraesthesia,1
XALKORI,polyneuropathy,polyneuropathy,1
XALKORI,polyneuropathy,peripheral paraesthesia peripheral,0
XALKORI,polyneuropathy,rash renal cyst,0
XALKORI,polyneuropathy,sensory polyneuropathy sensory disturbance rash renal cyst,1
XALKORI,polyneuropathy,rash renal cyst,0
XALKORI,polyneuropathy,polyneuropathy sensory,1
XALKORI,polyneuropathy,ILD ILD,0
XALKORI,sensory disturbance,sensory disturbance rash,1
XALKORI,rash,disturbance,0
XALKORI,rash,rash renal cyst,1
XALKORI,rash,disturbance,0
XALKORI,rash,rash renal cyst ILD ILD,1
XALKORI,renal cyst,renal cyst,1
XALKORI,renal cyst,syncope,0
XALKORI,renal cyst,renal cyst ILD ILD,1
XALKORI,renal cyst,disturbance renal cyst ILD ILD pneumonitis,1
XALKORI,renal cyst,renal cyst ILD ILD,1
XALKORI,renal cyst,sensory disturbance renal cyst ILD ILD pneumonitis,1
XALKORI,renal cyst,renal cyst ILD ILD,1
XALKORI,renal cyst,pneumonitis,0
XALKORI,renal cyst,disturbance renal cyst ILD ILD pneumonitis,1
XALKORI,renal cyst,pneumonitis,0
XALKORI,renal cyst,peripheral sensory neuropathy,0
XALKORI,ILD,ILD ILD pneumonitis,1
XALKORI,ILD,sensory,0
XALKORI,ILD,ILD pneumonitis and syncope,1
XALKORI,ILD,renal,0
XALKORI,pneumonitis,rash renal cyst ILD pneumonitis and,1
XALKORI,pneumonitis,renal,0
XALKORI,pneumonitis,rash renal cyst ILD,0
XALKORI,pneumonitis,rash,0
XALKORI,pneumonitis,renal cyst ILD ILD,0
XALKORI,pneumonitis,pneumonitis and syncope Table Summary of,1
XALKORI,syncope,syncope Table,1
XALKORI,syncope,TreatmentEmergent Laboratory,0
XALKORI,syncope,ILD ILD pneumonitis syncope Table Summary of TreatmentEmergent,1
XALKORI,syncope,TreatmentEmergent Laboratory,0
XALKORI,syncope,syncope,1
XALKORI,syncope,TreatmentEmergent Laboratory,0
XALKORI,syncope,syncope,1
XALKORI,syncope,disturbance rash renal cyst ILD ILD,0
XALKORI,syncope,cyst ILD ILD pneumonitis syncope Table Summary of,1
XALKORI,syncope,disturbance rash renal cyst ILD ILD,0
XALKORI,syncope,cyst ILD ILD pneumonitis syncope Table Summary of,1
XALKORI,syncope,disturbance rash renal cyst ILD ILD,0
XALKORI,syncope,Laboratory Abnormalities,0
XALKORI,pneumonia,adverse reactions reported in patients,0
XALKORI,pneumonia,adverse reactions,0
XALKORI,pneumonia,pneumonia pulmonary embolism,1
XALKORI,pneumonia,reactions in,0
XALKORI,pulmonary embolism,reported in patients,0
XALKORI,dyspnea,in XALKORItreated patients in Study,0
XALKORI,dyspnea,dyspnea and ILD Fatal adverse reactions,1
XALKORI,dyspnea,were pneumonia pulmonary dyspnea,1
XALKORI,dyspnea,dyspnea and ILD Fatal adverse reactions,1
XALKORI,ILD,were pneumonia pulmonary embolism,0
XALKORI,ILD,ILD,1
XALKORI,Fatal,adverse reactions in XALKORItreated patients in,0
XALKORI,Fatal,Fatal adverse,1
XALKORI,Fatal,XALKORItreated patients in Study occurred,0
XALKORI,Fatal,Fatal adverse reactions in,1
XALKORI,Fatal,Fatal adverse reactions in XALKORItreated patients,1
XALKORI,Fatal,in Study,0
XALKORI,Fatal,Fatal adverse reactions,1
XALKORI,Fatal,in Study,0
XALKORI,Fatal,Fatal adverse reactions,1
XALKORI,Fatal,Fatal adverse reactions in XALKORItreated patients,1
XALKORI,acute respiratory distress syndrome,occurred in patients consisting acute respiratory distress syndrome,1
XALKORI,acute respiratory distress syndrome,consisting acute respiratory distress syndrome arrhythmia dyspnea pneumonia pneumonitis pulmonary,1
XALKORI,acute respiratory distress syndrome,occurred in patients consisting acute respiratory distress syndrome,1
XALKORI,acute respiratory distress syndrome,of,0
XALKORI,acute respiratory distress syndrome,patients consisting acute respiratory distress,1
XALKORI,acute respiratory distress syndrome,distress syndrome arrhythmia dyspnea,1
XALKORI,acute respiratory distress syndrome,dyspnea pneumonia pneumonitis pulmonary embolism ILD respiratory,0
XALKORI,acute respiratory distress syndrome,patients consisting acute respiratory distress syndrome arrhythmia dyspnea pneumonia,1
XALKORI,acute respiratory distress syndrome,dyspnea pneumonia pneumonitis pulmonary embolism ILD respiratory,0
XALKORI,acute respiratory distress syndrome,patients consisting acute respiratory distress syndrome arrhythmia dyspnea pneumonia pneumonitis,1
XALKORI,acute respiratory distress syndrome,dyspnea pneumonia pneumonitis pulmonary embolism ILD respiratory,0
XALKORI,acute respiratory distress syndrome,ILD respiratory failure,0
XALKORI,acute respiratory distress syndrome,occurred in patients consisting acute respiratory,1
XALKORI,arrhythmia,pneumonitis pulmonary embolism ILD,0
XALKORI,arrhythmia,syndrome,0
XALKORI,arrhythmia,arrhythmia,1
XALKORI,arrhythmia,arrhythmia dyspnea,1
XALKORI,arrhythmia,arrhythmia,1
XALKORI,pneumonia,pneumonia pneumonitis,1
XALKORI,pneumonia,in patients consisting,0
XALKORI,pneumonia,pneumonia,1
XALKORI,pneumonia,pneumonia pneumonitis pulmonary embolism ILD respiratory,1
XALKORI,pneumonia,syndrome,0
XALKORI,pneumonia,pneumonia,1
XALKORI,pneumonia,of acute,0
XALKORI,pneumonia,pneumonia pneumonitis pulmonary embolism,1
XALKORI,pneumonia,pneumonia pneumonitis pulmonary embolism ILD respiratory,1
XALKORI,pneumonitis,pneumonitis pulmonary embolism ILD,1
XALKORI,pneumonitis,pneumonitis pulmonary embolism,1
XALKORI,pneumonitis,arrhythmia dyspnea pneumonia,0
XALKORI,pneumonitis,dyspnea pneumonia,0
XALKORI,pneumonitis,reductions due,0
XALKORI,pneumonitis,pneumonitis pulmonary embolism,1
XALKORI,pneumonitis,pneumonitis pulmonary embolism ILD respiratory failure,1
XALKORI,pneumonitis,due to,0
XALKORI,pneumonitis,pneumonitis pulmonary embolism ILD respiratory failure,1
XALKORI,pulmonary embolism,pulmonary embolism,1
XALKORI,pulmonary embolism,pulmonary embolism ILD respiratory failure,1
XALKORI,pulmonary embolism,distress syndrome arrhythmia,0
XALKORI,pulmonary embolism,dyspnea pneumonia pulmonary embolism ILD respiratory failure and,1
XALKORI,pulmonary embolism,distress syndrome arrhythmia,0
XALKORI,pulmonary embolism,pulmonary embolism ILD respiratory failure and sepsis,1
XALKORI,pulmonary embolism,pneumonia pulmonary embolism ILD respiratory,1
XALKORI,pulmonary embolism,pulmonary embolism ILD respiratory failure and sepsis,1
XALKORI,pulmonary embolism,pneumonia pulmonary embolism,1
XALKORI,pulmonary embolism,pulmonary embolism ILD respiratory failure and sepsis,1
XALKORI,pulmonary embolism,syndrome arrhythmia dyspnea pneumonia pulmonary embolism ILD respiratory failure and sepsis,1
XALKORI,pulmonary embolism,pulmonary embolism ILD respiratory failure and sepsis,1
XALKORI,pulmonary embolism,to adverse,0
XALKORI,ILD,ILD respiratory failure,1
XALKORI,ILD,to adverse,0
XALKORI,ILD,dyspnea pneumonia pneumonitis pulmonary ILD respiratory failure and sepsis,1
XALKORI,ILD,to adverse,0
XALKORI,ILD,ILD respiratory failure and sepsis,1
XALKORI,ILD,pneumonia pneumonitis pulmonary,0
XALKORI,ILD,ILD respiratory failure and,1
XALKORI,ILD,pneumonia pneumonitis pulmonary ILD respiratory failure and sepsis Dose,1
XALKORI,ILD,ILD respiratory failure and,1
XALKORI,ILD,pneumonitis pulmonary ILD respiratory failure,1
XALKORI,ILD,ILD respiratory failure and,1
XALKORI,ILD,pneumonia pneumonitis pulmonary ILD respiratory,1
XALKORI,ILD,ILD respiratory failure and,1
XALKORI,respiratory failure,pneumonia pneumonitis pulmonary embolism respiratory failure,1
XALKORI,respiratory failure,respiratory failure,1
XALKORI,respiratory failure,dyspnea pneumonia pneumonitis pulmonary embolism ILD,0
XALKORI,respiratory failure,pulmonary embolism respiratory failure and sepsis Dose reductions due,1
XALKORI,respiratory failure,dyspnea pneumonia pneumonitis pulmonary embolism ILD,0
XALKORI,respiratory failure,pneumonia pneumonitis pulmonary embolism respiratory failure and,1
XALKORI,respiratory failure,dyspnea pneumonia pneumonitis pulmonary embolism ILD,0
XALKORI,respiratory failure,respiratory failure and,1
XALKORI,respiratory failure,respiratory failure and sepsis Dose reductions due,1
XALKORI,sepsis,sepsis Dose reductions,1
XALKORI,QTc prolongation,neutropenia XALKORI was discontinued for adverse reactions in,0
XALKORI,QTc prolongation,concurrent aspartate aminotransferase,0
XALKORI,QTc prolongation,QTc prolongation and neutropenia XALKORI was discontinued,1
XALKORI,QTc prolongation,elevation,0
XALKORI,neutropenia,elevation QTc prolongation neutropenia XALKORI was discontinued for adverse,1
XALKORI,neutropenia,elevation,0
XALKORI,neutropenia,neutropenia XALKORI was discontinued for,1
XALKORI,neutropenia,e patients with concurrent aspartate aminotransferase AST elevation QTc prolongation and,0
XALKORI,ILD,ALT and AST elevation,0
XALKORI,ILD,ILD ALT and AST elevation,1
XALKORI,ILD,ILD ALT and,1
XALKORI,ILD,ILD,1
XALKORI,ILD,ILD ALT and AST elevation,1
XALKORI,ILD,ILD,1
XALKORI,ILD,ILD ALT and,1
XALKORI,ILD,AST elevation dyspnea and pulmonary embolism,0
XALKORI,ILD,ILD ALT and AST elevation,1
XALKORI,AST elevation,XALKORI were ILD ALT AST elevation dyspnea and pulmonary,1
XALKORI,AST elevation,ILD ALT and AST elevation,1
XALKORI,dyspnea,AST,0
XALKORI,dyspnea,dyspnea and pulmonary embolism Tables and,1
XALKORI,dyspnea,dyspnea and pulmonary embolism,1
XALKORI,dyspnea,and AST,0
XALKORI,dyspnea,ILD ALT and AST dyspnea and pulmonary,1
XALKORI,dyspnea,and AST,0
XALKORI,dyspnea,dyspnea and pulmonary embolism Tables and,1
XALKORI,dyspnea,were ILD ALT,0
XALKORI,pulmonary embolism,pulmonary embolism Tables,1
XALKORI,pulmonary embolism,adverse,0
XALKORI,pulmonary embolism,pulmonary embolism Tables and summarize common,1
XALKORI,pulmonary embolism,common,0
XALKORI,pulmonary embolism,discontinuation of XALKORI were ILD,0
XALKORI,pulmonary embolism,AST elevation dyspnea pulmonary embolism Tables and,1
XALKORI,pulmonary embolism,discontinuation of XALKORI were ILD,0
XALKORI,Upper respiratory infection,Upper respiratory infection,1
XALKORI,Upper respiratory infection,discontinuation of XALKORI were ILD,0
XALKORI,Upper respiratory infection,Upper respiratory infection,1
XALKORI,Upper respiratory infection,discontinuation of XALKORI were ILD,0
XALKORI,Upper respiratory infection,Upper,1
XALKORI,Upper respiratory infection,Infestations,0
XALKORI,Upper respiratory infection,d Infestations,0
XALKORI,neuropathy,included neuropathy dysesthesia gait disturbance hypoesthesia muscular,1
XALKORI,neuropathy,d Infestations,0
XALKORI,neuropathy,XALKORI included neuropathy dysesthesia gait disturbance hypoesthesia muscular,1
XALKORI,neuropathy,d Infestations,0
XALKORI,neuropathy,neuropathy dysesthesia gait disturbance,1
XALKORI,neuropathy,neuropathy dysesthesia gait,1
XALKORI,neuropathy,XALKORI included,0
XALKORI,neuropathy,patients treated with XALKORI included fatigue,0
XALKORI,neuropathy,treated with XALKORI,0
XALKORI,neuropathy,neuropathy dysesthesia gait disturbance hypoesthesia,1
XALKORI,neuropathy,neuropathy dysesthesia,1
XALKORI,neuropathy,with,0
XALKORI,dysesthesia,dysesthesia gait,1
XALKORI,dysesthesia,patients treated,0
XALKORI,dysesthesia,weakness neuralgia peripheral neuropathy,0
XALKORI,dysesthesia,neuralgia peripheral neuropathy parasthesia,0
XALKORI,dysesthesia,with XALKORI,0
XALKORI,dysesthesia,dysesthesia gait disturbance,1
XALKORI,dysesthesia,weakness neuralgia peripheral neuropathy,0
XALKORI,dysesthesia,dysesthesia,1
XALKORI,dysesthesia,neuropathy,0
XALKORI,hypoesthesia,hypoesthesia muscular weakness,1
XALKORI,hypoesthesia,hypoesthesia muscular weakness neuralgia peripheral neuropathy,1
XALKORI,hypoesthesia,dysesthesia gait disturbance,0
XALKORI,hypoesthesia,hypoesthesia muscular weakness neuralgia peripheral neuropathy,1
XALKORI,muscular weakness,gait disturbance muscular weakness,1
XALKORI,muscular weakness,dysesthesia gait disturbance muscular,1
XALKORI,muscular weakness,disturbance muscular weakness neuralgia,1
XALKORI,muscular weakness,dysesthesia gait disturbance muscular,1
XALKORI,muscular weakness,dysesthesia gait disturbance muscular weakness neuralgia peripheral,1
XALKORI,muscular weakness,dysesthesia gait disturbance muscular,1
XALKORI,muscular weakness,muscular weakness neuralgia peripheral neuropathy parasthesia,1
XALKORI,muscular weakness,muscular weakness neuralgia peripheral neuropathy,1
XALKORI,muscular weakness,muscular,1
XALKORI,muscular weakness,gait disturbance muscular weakness,1
XALKORI,neuralgia,neuralgia peripheral,1
XALKORI,neuralgia,gait disturbance muscular weakness,1
XALKORI,neuralgia,gait disturbance hypoesthesia muscular neuralgia peripheral,1
XALKORI,neuralgia,gait disturbance muscular weakness,1
XALKORI,neuralgia,peripheral neuropathy parasthesia peripheral sensory neuropathy polyneuropathy burning sensati,0
XALKORI,neuralgia,disturbance hypoesthesia muscular weakness,0
XALKORI,neuralgia,disturbance hypoesthesia,0
XALKORI,neuralgia,hypoesthesia muscular neuralgia peripheral neuropathy,1
XALKORI,neuralgia,disturbance hypoesthesia,0
XALKORI,neuralgia,neuralgia peripheral,1
XALKORI,neuralgia,sensory neuropathy polyneuropathy,0
XALKORI,neuralgia,fatigue neuropathy,0
XALKORI,neuralgia,neuralgia peripheral neuropathy,1
XALKORI,peripheral neuropathy,weakness peripheral,1
XALKORI,peripheral neuropathy,muscular weakness peripheral,1
XALKORI,peripheral neuropathy,neuralgia,0
XALKORI,peripheral neuropathy,peripheral neuropathy parasthesia peripheral sensory neuropathy,1
XALKORI,peripheral neuropathy,peripheral neuropathy,1
XALKORI,peripheral neuropathy,hypoesthesia muscular,0
XALKORI,parasthesia,muscular weakness neuralgia peripheral,0
XALKORI,parasthesia,in skin rash,0
XALKORI,parasthesia,parasthesia peripheral sensory neuropathy,1
XALKORI,parasthesia,parasthesia peripheral sensory,1
XALKORI,parasthesia,parasthesia,1
XALKORI,parasthesia,parasthesia peripheral sensory,1
XALKORI,parasthesia,neuropathy polyneuropathy burning,0
XALKORI,parasthesia,parasthesia peripheral sensory neuropathy polyneuropathy burning,1
XALKORI,parasthesia,hypoesthesia muscular weakness neuralgia peripheral neuropathy,0
XALKORI,peripheral sensory neuropathy,sensation in skin,0
XALKORI,peripheral sensory neuropathy,sensory neuropathy polyneuropathy,1
XALKORI,peripheral sensory neuropathy,neuropathy peripheral sensory neuropathy polyneuropathy,1
XALKORI,peripheral sensory neuropathy,sensory neuropathy polyneuropathy,1
XALKORI,peripheral sensory neuropathy,polyneuropathy burning sensation,0
XALKORI,peripheral sensory neuropathy,neuropathy peripheral sensory neuropathy polyneuropathy,1
XALKORI,peripheral sensory neuropathy,polyneuropathy burning sensation,0
XALKORI,polyneuropathy,skin rash ILD acute respiratory distress syndrome ILD pneumoni,0
XALKORI,polyneuropathy,skin rash ILD acute respiratory,0
XALKORI,polyneuropathy,polyneuropathy burning sensation,1
XALKORI,polyneuropathy,skin rash ILD acute respiratory,0
XALKORI,polyneuropathy,parasthesia peripheral sensory polyneuropathy burning sensation,1
XALKORI,polyneuropathy,skin rash ILD acute respiratory,0
XALKORI,polyneuropathy,neuropathy parasthesia peripheral,0
XALKORI,polyneuropathy,skin rash ILD acute respiratory distress syndrome ILD,0
XALKORI,burning sensation in skin,rash ILD,0
XALKORI,burning sensation in skin,in skin rash ILD,1
XALKORI,burning sensation in skin,in skin rash ILD,1
XALKORI,burning sensation in skin,ILD pneumonitis renal cyst and,0
XALKORI,burning sensation in skin,neuropathy burning sensation in,1
XALKORI,burning sensation in skin,burning sensation in skin,1
XALKORI,burning sensation in skin,neuropathy burning sensation in,1
XALKORI,burning sensation in skin,parasthesia peripheral sensory neuropathy burning sensation in skin,1
XALKORI,burning sensation in skin,rash ILD acute respiratory distress syndrome ILD pneumonitis,0
XALKORI,rash,neuropathy polyneuropathy burning sensation,0
XALKORI,rash,parasthesia peripheral sensory neuropathy,0
XALKORI,rash,peripheral sensory neuropathy polyneuropathy burning sensation in,0
XALKORI,rash,distress syndrome ILD,0
XALKORI,ILD,ILD acute,1
XALKORI,ILD,ILD acute respiratory,1
XALKORI,ILD,rash,0
XALKORI,ILD,peripheral sensory neuropathy polyneuropathy burning sensation in,0
XALKORI,ILD,rash,0
XALKORI,ILD,ILD,1
XALKORI,acute respiratory distress syndrome,sensation in skin rash acute respiratory distress syndrome ILD,1
XALKORI,acute respiratory distress syndrome,ILD,1
XALKORI,acute respiratory distress syndrome,sensation in skin rash acute respiratory distress syndrome ILD pneumonitis,1
XALKORI,acute respiratory distress syndrome,ILD,1
XALKORI,acute respiratory distress syndrome,rash acute respiratory distress,1
XALKORI,acute respiratory distress syndrome,sensory neuropathy polyneuropathy burning sensation in,0
XALKORI,acute respiratory distress syndrome,neuropathy polyneuropathy burning sensation in skin rash,0
XALKORI,acute respiratory distress syndrome,sensory,0
XALKORI,acute respiratory distress syndrome,sensation in skin rash acute respiratory distress,1
XALKORI,acute respiratory distress syndrome,acute respiratory distress syndrome,1
XALKORI,ILD,syndrome,0
XALKORI,ILD,ILD pneumonitis renal cyst and,1
XALKORI,pneumonitis,acute respiratory distress syndrome pneumonitis renal cyst,1
XALKORI,pneumonitis,ILD pneumonitis renal cyst and,1
XALKORI,pneumonitis,pneumonitis renal cyst,1
XALKORI,pneumonitis,pneumonitis renal cyst,1
XALKORI,pneumonitis,pneumonitis renal cyst,1
XALKORI,pneumonitis,syndrome,0
XALKORI,pneumonitis,syndrome pneumonitis,1
XALKORI,pneumonitis,syndrome,0
XALKORI,pneumonitis,syndrome,0
XALKORI,pneumonitis,pneumonitis,1
XALKORI,pneumonitis,and hepatic failure Table Summary of,0
XALKORI,renal cyst,renal cyst and hepatic failure Table Summary,1
XALKORI,renal cyst,TreatmentEmergent,0
XALKORI,renal cyst,skin rash ILD,0
XALKORI,renal cyst,renal cyst,1
XALKORI,renal cyst,skin rash ILD acute,0
XALKORI,Vision disorders,Adverse Drug Reactions Vision Vision disorders,1
XALKORI,Vision disorders,skin rash ILD acute,0
XALKORI,Vision disorders,blurred vision or vitreous,0
XALKORI,Vision disorders,Vision,1
XALKORI,visual impairment,visual impairment photopsia blurred vision,1
XALKORI,visual impairment,photopsia blurred vision or vitreous floaters occurred in of patients The majo,0
XALKORI,visual impairment,visual impairment photopsia,1
XALKORI,visual impairment,vision or,0
XALKORI,photopsia,photopsia blurred,1
XALKORI,vitreous floaters,vitreous floaters occurred in of,1
XALKORI,vitreous floaters,these,0
XALKORI,visual adverse reactions,patients with Grade and patients with Grade visual impairment,0
XALKORI,visual adverse reactions,these patients had visual,1
XALKORI,visual adverse reactions,of these patients had visual adverse reactions,1
XALKORI,visual adverse reactions,these patients had visual,1
XALKORI,visual adverse reactions,occurred in,0
XALKORI,visual adverse reactions,patients had visual adverse reactions There were,1
XALKORI,visual adverse reactions,occurred in,0
XALKORI,visual adverse reactions,patients The majority of these,0
XALKORI,visual impairment,Visual Symptom Assessment Questionnaire VSAQALK,0
XALKORI,visual impairment,and patients with Grade,0
XALKORI,visual impairment,and patients with visual impairment,1
XALKORI,visual impairment,and patients with Grade,0
XALKORI,visual impairment,with Grade,0
XALKORI,visual impairment,visual impairment Based on the,1
XALKORI,visual impairment,patients treated with XALKORI,0
XALKORI,visual impairment,and patients with visual impairment Based on the,1
XALKORI,visual impairment,patients treated with XALKORI,0
XALKORI,visual impairment,adverse reactions There were patients,0
XALKORI,visual impairment,visual impairment Based,1
XALKORI,visual impairment,patients with visual impairment,1
XALKORI,visual impairment,and patients with visual impairment Based on the,1
XALKORI,visual impairment,patients with visual impairment,1
XALKORI,visual impairment,with visual impairment,1
XALKORI,visual disturbances,incidence visual,1
XALKORI,vision disorder,with chemotherapy The onset vision,1
XALKORI,vision disorder,on the XALKORI,0
XALKORI,vision disorder,vision disorder generally was within the first,1
XALKORI,vision disorder,onset vision disorder,1
XALKORI,vision disorder,vision disorder,1
XALKORI,visual disturbances,Studies and visual,1
XALKORI,visual disturbances,The majority of patients on the XALKORI arms in Studies and reported,0
XALKORI,visual disturbances,Studies and visual disturbances,1
XALKORI,visual disturbances,patients on the XALKORI arms,0
XALKORI,visual disturbances,visual,1
XALKORI,visual disturbances,visual disturbances which occurred at,1
XALKORI,visual disturbances,visual,1
XALKORI,visual disturbances,and visual disturbances,1
XALKORI,Renal cysts,in patients,0
XALKORI,Renal cysts,Grade in severity Renal,0
XALKORI,Renal cysts,in severity Renal Renal cysts were experienced by of,1
XALKORI,Renal cysts,Grade in severity Renal,0
XALKORI,Renal cysts,Renal cysts were experienced by of,1
XALKORI,Renal cysts,Renal cysts were experienced by of patients,1
XALKORI,Renal cysts,Renal cysts were experienced by of patients,1
XALKORI,Renal cysts,in severity Renal Renal cysts,1
XALKORI,Renal cysts,Renal cysts were experienced by of,1
XALKORI,Renal cysts,Grade in severity Renal Renal cysts,1
XALKORI,Renal cysts,occurred in patients treated with XALKORI and patient treated with chemotherapy in St,0
XALKORI,Renal cysts,Renal Cysts Renal cysts,0
XALKORI,Renal cysts,were experienced by of Renal cysts,1
XALKORI,Renal cysts,Renal Cysts Renal cysts,0
XALKORI,Renal cysts,Renal cysts occurred,1
XALKORI,Renal cysts,with chemotherapy in St,0
XALKORI,Renal cysts,Renal cysts occurred in patients treated,1
XALKORI,Renal cysts,in Renal cysts occurred,1
XALKORI,Renal cysts,Renal cysts occurred in patients treated,1
XALKORI,Renal cysts,Renal cysts occurred,1
XALKORI,Renal cysts,chemotherapy in Renal cysts,1
XALKORI,Renal cysts,with chemotherapy in Renal cysts,1
XALKORI,Renal cysts,chemotherapy in Renal cysts,1
XALKORI,renal cysts,complex Local cystic invasion beyond the kidney occurred in some,0
XALKORI,renal cysts,renal cysts in XALKORItreated,1
XALKORI,Local cystic invasion beyond the kidney,Local cystic invasion beyond the kidney occurred,1
XALKORI,Local cystic invasion beyond the kidney,the kidney occurred in some,1
XALKORI,Local cystic invasion beyond the kidney,XALKORItreated patients were Local cystic invasion beyond the kidney occurred,1
XALKORI,Local cystic invasion beyond the kidney,the kidney occurred in some,1
XALKORI,Local cystic invasion beyond the kidney,Local cystic invasion beyond the kidney occurred in some,1
XALKORI,Local cystic invasion beyond the kidney,the kidney occurred in some,1
XALKORI,renal abscesses,trials no,0
XALKORI,renal abscesses,by,0
XALKORI,Hepatotoxicity,are dis cussed in greater detail in,1
XALKORI,Hepatotoxicity,following adverse ctions are dis cussed in greater,1
XALKORI,Hepatotoxicity,are dis cussed in greater detail in,1
XALKORI,Hepatotoxicity,labeling,0
XALKORI,Hepatotoxicity,are dis cussed in greater detail,1
XALKORI,Hepatotoxicity,REACTIONS The following adverse ctions are dis,1
XALKORI,Hepatotoxicity,The following adverse ctions are,1
XALKORI,Hepatotoxicity,are dis cussed in greater,1
XALKORI,Hepatotoxicity,of the labeling Hepatotoxicity see Warnings and,0
XALKORI,Hepatotoxicity,ADVERSE REACTIONS,0
XALKORI,Hepatotoxicity,in greater detail in other sections of the labeling Hepatotoxicity see Warnings and,0
XALKORI,Fatal,of the labeling Hepatotoxicity see Warnings,0
XALKORI,hepatotoxicity,in other sections,0
XALKORI,hepatotoxicity,i,0
XALKORI,hepatotoxicity,n greater,1
XALKORI,hepatotoxicity,Hepatotoxicity,0
XALKORI,hepatotoxicity,following adverse,0
XALKORI,hepatotoxicity,n greater deta il in,1
XALKORI,hepatotoxicity,following adverse,0
XALKORI,Interstitial Lung Disease,Lung DiseasePneumonitis see nings and Precautions (5. QT Interval Prolongation see Warnings,1
XALKORI,Interstitial Lung Disease,following adverse,0
XALKORI,Interstitial Lung Disease,and,0
XALKORI,Interstitial Lung Disease,Interstitial Lung DiseasePneumonitis see nings and Precautions (5. QT,1
XALKORI,Interstitial Lung Disease,and,0
XALKORI,Interstitial Lung Disease,Lung DiseasePneumonitis,0
XALKORI,Interstitial Lung Disease,Precautions Bradycardia,0
XALKORI,Interstitial Lung Disease,War,0
XALKORI,ILD,  ] QT Interval Prolongation,1
XALKORI,ILD,  ],1
XALKORI,ILD,QT,0
XALKORI,ILD,and,0
XALKORI,Pneumonitis,see Warnings and * QT,1
XALKORI,Pneumonitis,"and 
 *  QT Int",1
XALKORI,Pneumonitis,see Warnings and * QT,1
XALKORI,Pneumonitis,Precautions,0
XALKORI,Pneumonitis,* QT Int erval Prolongation see Warnings and,1
XALKORI,Pneumonitis,DiseasePneumonitis see Warnings and * QT Int,1
XALKORI,Pneumonitis,and,0
XALKORI,Pneumonitis,"and 
 *  QT Int",1
XALKORI,Pneumonitis,and,0
XALKORI,Pneumonitis,see Warnings,0
XALKORI,QT Interval Prolongation,ns (5.4) ] * Severe,1
XALKORI,QT Interval Prolongation,Bradycardia see Warnings and Precautio,0
XALKORI,QT Interval Prolongation,"Bradycardia see Warnings and ns (5.4)  ]  
 *  Severe Visual Loss see",1
XALKORI,QT Interval Prolongation,Bradycardia see Warnings and Precautio,0
XALKORI,QT Interval Prolongation,Warnings and ns (5.4) ] * Severe,1
XALKORI,Bradycardia,decreased appetite and To report S USPECTED,1
XALKORI,Bradycardia,Warnings and ns (5.4) ] * Severe,1
XALKORI,Bradycardia,decreased appetite and To report S USPECTED ADVERSE,1
XALKORI,Bradycardia,Warnings and ns (5.4) ] * Severe,1
XALKORI,Bradycardia,REACTIONS contact Pfizer Inc at or FDA at,0
XALKORI,Bradycardia,decreased appetite and dysgeusia,0
XALKORI,Bradycardia,FDA or wwwf,0
XALKORI,Bradycardia,appetite and To report S USPECTED ADVERSE,1
XALKORI,Bradycardia,FDA or wwwf,0
XALKORI,bradycardia,"report SUSPECTED ADVERSE CTIONS,",1
XALKORI,bradycardia,"CTIONS, con tact",1
XALKORI,Visual Loss,are conducted under widely varying conditions,0
XALKORI,Visual Loss,conducted under widely varying conditions adverse reaction rates observed in the,0
XALKORI,Visual Loss,or wwwfdagovmedwatch Clinical Trials Experience,0
XALKORI,Visual Loss,Because nical trial s are conducted under widely,1
XALKORI,Visual Loss,or wwwfdagovmedwatch Clinical Trials Experience,0
XALKORI,Visual Loss,Experience Because nical trial s,1
XALKORI,Visual Loss,or wwwfdagovmedwatch Clinical Trials Experience,0
XALKORI,Visual Loss,Because nical trial s are conducted under,1
XALKORI,Visual Loss,or wwwfdagovmedwatch Clinical Trials Experience,0
XALKORI,Visual Loss,nical trial s,1
XALKORI,Visual Loss,nical trial s,1
XALKORI,Embryofetal Toxicity,rates in the clinic al trials,1
XALKORI,Embryofetal Toxicity,drug cannot be directly,0
XALKORI,Embryofetal Toxicity,compared  rates in the clinic al,1
XALKORI,Embryofetal Toxicity,drug cannot be directly,0
XALKORI,Embryofetal Toxicity,in the clinic al trials,1
XALKORI,Embryofetal Toxicity,the clinic al,1
XALKORI,Embryofetal Toxicity,compared  rates in the clinic al trials of another,1
XALKORI,Embryofetal Toxicity,the clinic al,1
XALKORI,Embryofetal Toxicity, rates in the clinic al trials of another,1
XALKORI,Embryofetal Toxicity,the clinic al,1
XALKORI,fetal harm, another d rug and may not reflect,1
XALKORI,fetal harm,the clinic al,1
XALKORI,fetal harm,not reflect the rates observed in clinical practice,0
XALKORI,fetal harm,trials  another d,1
XALKORI,fetal harm,not reflect the rates observed in clinical practice,0
XALKORI,hepatotoxicity,daily i n,1
XALKORI,hepatotoxicity,twice,1
XALKORI,hepatotoxicity,who,0
XALKORI,hepatotoxicity,XALKORI twice,1
XALKORI,hepatotoxicity,NSCLC who received XALKORI twice,1
XALKORI,hepatotoxicity,XALKORI twice daily,1
XALKORI,hepatotoxicity,based primarily on patients with ALKpositive,0
XALKORI,hepatotoxicity, twice daily i n two openlabel randomized,1
XALKORI,hepatotoxicity,based primarily on patients with ALKpositive,0
XALKORI,fatal,This,0
XALKORI,fatal,in two,0
XALKORI,fatal,trials,0
XALKORI,fatal,open- label randomized,1
XALKORI,fatal,open- label,1
XALKORI,fatal,open- label randomized activecontrolled trials Studies,1
XALKORI,fatal,twice daily in open- label randomized activecontrolled trials,1
XALKORI,fatal,open- label randomized activecontrolled trials Studies,1
XALKORI,elevations in alanine aminotransferase,adverse drug reactions 1326 patients with,1
XALKORI,elevations in alanine aminotransferase,Studies and,0
XALKORI,elevations in alanine aminotransferase,on adverse drug reactions 1326 patients with ALK-positive,1
XALKORI,elevations in alanine aminotransferase,on adverse drug reactions 1326 patients with ALK-positive metast atic,1
XALKORI,elevations in alanine aminotransferase,on adverse drug reactions 1326 patients with ALK-positive,1
XALKORI,elevations in alanine aminotransferase,ALK-positive metast atic NSCLC who received XALKORI,1
XALKORI,elevations in alanine aminotransferase,1326 patients with ALK-positive metast,1
XALKORI,elevations in alanine aminotransferase,ALK-positive metast atic NSCLC who received XALKORI,1
XALKORI,elevations in alanine aminotransferase,drug,0
XALKORI,elevations in ALT,"constipation a, elevated trans aminases",1
XALKORI,elevations in ALT,drug,0
XALKORI,elevations in ALT,"nausea vomiting constipation a,",1
XALKORI,elevations in ALT,constipation,0
XALKORI,elevations in ALT,"a, elevated trans aminases",1
XALKORI,elevations in ALT,constipation,0
XALKORI,elevations in ALT,"constipation a, elevated trans aminases upper",1
XALKORI,elevations in ALT,constipation,0
XALKORI,elevations in ALT,and are vision disorders diarrhea,0
XALKORI,elevations in ALT,"vomiting constipation a,",1
XALKORI,elevations in ALT,upper respiratory infection decreased appetite and,0
XALKORI,elevations in ALT,and dysgeusia Previously,0
XALKORI,elevations in ALT,diarrhea nausea,0
XALKORI,elevated transaminases,are derived from 340 patients,1
XALKORI,elevated transaminases, are derived from 340  patients with ALKpositive metastatic NSCLC,1
XALKORI,elevated transaminases,are derived from 340 patients,1
XALKORI,elevated transaminases,data in are derived from,1
XALKORI,Transaminase elevations,not received previous systemic treatment for advanced,0
XALKORI,Transaminase elevations,with ALK-positiv e metastatic,1
XALKORI,Transaminase elevations,tients with ALK-positiv e,1
XALKORI,Transaminase elevations,are derived from tients with ALK-positiv e metastatic NSCLC who,1
XALKORI,Transaminase elevations,tients with ALK-positiv e,1
XALKORI,Transaminase elevations,Table are derived from tients with,1
XALKORI,Transaminase elevations,Table are derived from tients with ALK-positiv e metastatic NSCLC,1
XALKORI,Transaminase elevations,Table are derived from tients with,1
XALKORI,fatal,UC) o f or,1
XALKORI,fatal,UC) o f or mgminmL,1
XALKORI,fatal,A,0
XALKORI,fatal,for up to,0
XALKORI,fatal,the concentrationtime curve UC) o,1
XALKORI,fatal,was given by intravenous infusion every weeks for up,0
XALKORI,fatal,every,0
XALKORI,fatal,under the concentrationtime curve UC) o f,1
XALKORI,fatal,every,0
XALKORI,fatal,was given by intravenous infusion every weeks for up,0
XALKORI,interstitial lung disease,concentrationtime curve AUC  5 or 6 mg?min/mL (n=78). Chemotherapy,1
XALKORI,interstitial lung disease,was given by intravenous infusion every weeks for up,0
XALKORI,interstitial lung disease,cycles in the absence of,0
XALKORI,interstitial lung disease,6 mg?min/mL (n=78). Chemotherapy was given by,1
XALKORI,interstitial lung disease,was given by intravenous infusion every weeks,0
XALKORI,interstitial lung disease,concentrationtime curve AUC  5 or 6 mg?min/mL (n=78). Chemotherapy was given,1
XALKORI,interstitial lung disease,was given by intravenous infusion every weeks,0
XALKORI,interstitial lung disease,curve AUC  5 or 6 mg?min/mL (n=78). Chemotherapy was given by intravenous,1
XALKORI,interstitial lung disease,was given by intravenous infusion every weeks,0
XALKORI,interstitial lung disease,5 or 6 mg?min/mL (n=78). Chemotherapy was,1
XALKORI,interstitial lung disease,in the absence of,0
XALKORI,interstitial lung disease,or 6 mg?min/mL (n=78). Chemotherapy was given by intravenous,1
XALKORI,ILD,the absence of,0
XALKORI,ILD,hem,1
XALKORI,ILD,hem otherapy was given by intravenous,1
XALKORI,ILD,of or mgminmL n hem otherapy was given by,1
XALKORI,ILD,hem otherapy was given by intravenous,1
XALKORI,ILD,curve AUC of or,0
XALKORI,ILD,or mgminmL n hem otherapy was given by,1
XALKORI,ILD,curve AUC of or,0
XALKORI,ILD,hem otherapy was,1
XALKORI,ILD,hem otherapy was given by,1
XALKORI,ILD,calculated to produce,0
XALKORI,ILD,hem,1
XALKORI,ILD,hem otherapy was given by intravenous,1
XALKORI,ILD,intravenous infusion every weeks for up to cycles in the absence,0
XALKORI,ILD,hem,1
XALKORI,ILD,cycles in the absence of dose,0
XALKORI,ILD,or mgminmL n C,0
XALKORI,ILD,of or mgminmL n hem otherapy was given by intravenous,1
XALKORI,ILD,or mgminmL n C,0
XALKORI,pneumonitis,of or mgminmL n,0
XALKORI,pneumonitis,of,0
XALKORI,pneumonitis,an area under the concentrationtime curve AUC of or mgminmL n Chemot,0
XALKORI,pneumonitis,herapy was given by intravenous infusion,1
XALKORI,pneumonitis,mgminmL n herapy was  given by intravenous infusion,1
XALKORI,pneumonitis,herapy was given by intravenous infusion,1
XALKORI,pneumonitis,herapy,1
XALKORI,pneumonitis,Chemot,0
XALKORI,pneumonitis,herapy was given by intravenous,1
XALKORI,pneumonitis,mgminmL n herapy,1
XALKORI,pneumonitis,herapy was,1
XALKORI,pneumonitis,or,0
XALKORI,pneumonitis,herapy was given by intravenous infusion,1
XALKORI,pneumonitis,n herapy was,1
XALKORI,ILD,tox icities After cycles,1
XALKORI,ILD,infusion every weeks for up to cycles in the absence of,0
XALKORI,ILD,remained on study with,0
XALKORI,ILD,the absence of,0
XALKORI,ILD,patients remained on  wi th no additional anticancer,1
XALKORI,ILD,the absence of,0
XALKORI,ILD,on  wi,1
XALKORI,ILD,the absence of,0
XALKORI,ILD, wi th no,1
XALKORI,ILD,absence,0
XALKORI,ILD, wi,1
XALKORI,ILD,absence,0
XALKORI,ILD,doselimiting chemotherapyrelated toxicities After cycles patients remained,0
XALKORI,ILD, wi th,1
XALKORI,ILD,doselimiting chemotherapyrelated toxicities After cycles patients remained,0
XALKORI,ILD, wi,1
XALKORI,ILD,treatment and tumor assessments continued until documented disease,0
XALKORI,ILD,treatment and tumor assessments continued until documented disease prog,0
XALKORI,fatal,treat ment and tumor assessments continued,1
XALKORI,fatal,no additional treat ment and tumor assessments continued,1
XALKORI,fatal,treat ment and tumor assessments continued,1
XALKORI,fatal,treat ment and,1
XALKORI,fatal,cycles patients remained on study,0
XALKORI,ILD,ent and tumor assessments,1
XALKORI,ILD,additional anticancer,0
XALKORI,QTc prolongation,of patients were,1
XALKORI,QTc prolongation,additional anticancer,0
XALKORI,QTc prolongation,than years A total of of patients were female and were Asian Serious adverse,0
XALKORI,QTc prolongation,in,0
XALKORI,QTc prolongation,were,0
XALKORI,QTc prolongation,of patients were,1
XALKORI,QTc prolongation,of,0
XALKORI,Symptomatic bradycardia,for,0
XALKORI,Symptomatic bradycardia,XALKORIN Chemotherapy PemetrexedCis,0
XALKORI,Symptomatic bradycardia,than Chemotherapy in Study Adverse,1
XALKORI,Symptomatic bradycardia,for Grades with KORI than Chemotherapy  in Study Adverse,1
XALKORI,Symptomatic bradycardia,than Chemotherapy in Study Adverse,1
XALKORI,Symptomatic bradycardia,KORI than Chemotherapy in Study Adverse Reaction XALKORIN,1
XALKORI,bradycardia,Adverse Reaction,0
XALKORI,bradycardia,XALKORI,0
XALKORI,bradycardia,or PemetrexedCarboplatinN All Grades,0
XALKORI,bradycardia,71) Chemo therapy PemetrexedCisplatin or,1
XALKORI,bradycardia,Reaction 71),1
XALKORI,bradycardia,therapy PemetrexedCisplatin or PemetrexedCarboplatinN All,0
XALKORI,bradycardia,71) Chemo therapy PemetrexedCisplatin or,1
XALKORI,bradycardia,Study Adverse Reaction 71)   Chemo therapy PemetrexedCisplatin or PemetrexedCarboplatinN,1
XALKORI,bradycardia,71) Chemo therapy PemetrexedCisplatin or,1
XALKORI,bradycardia,71) Chemo therapy PemetrexedCisplatin or,1
XALKORI,bradycardia,71) Chemo,1
XALKORI,heart rate less than 50 beats per minute,PemetrexedCisplatin,0
XALKORI,heart rate less than 50 beats per minute,PemetrexedCisplatin or PemetrexedCarboplatinN All Grade 3/4(%) All,1
XALKORI,heart rate less than 50 beats per minute,PemetrexedCarboplatinN All Grade 3/4(%) All Grades(%),1
XALKORI,syncope,All Grades Grade des,1
XALKORI,syncope,des cas es,1
XALKORI,syncope,Grade Inclu,0
XALKORI,syncope,des cas es reported within the clustered,1
XALKORI,syncope,reported within the clustered,0
XALKORI,syncope,des cas es reported within,1
XALKORI,syncope,des cas es reported within the,1
XALKORI,syncope,Grades Grade,0
XALKORI,syncope,des cas es reported,1
XALKORI,embryotoxicity,increased,0
XALKORI,embryotoxicity,"          
   ",1
XALKORI,embryotoxicity,and Connective Tissue,0
XALKORI,embryotoxicity,increased,0
XALKORI,embryotoxicity,"Weight           
   ",1
XALKORI,embryotoxicity,increased,0
CLEVIPREX,Hypotension,Hypotension and Reflex Tachycardia see,1
CLEVIPREX,Hypotension,in the,0
CLEVIPREX,Hypotension,Tachycardia see Warnings and Precautions EXCERPT Most common adve,0
CLEVIPREX,Hypotension,discussed elsewhere in the labeling,0
CLEVIPREX,Hypotension,Warnings and Precautions EXCERPT Most common adve,0
CLEVIPREX,Hypotension,the labeling,0
CLEVIPREX,Reflex Tachycardia,Reflex Tachycardia see,1
CLEVIPREX,Reflex Tachycardia,the labeling,0
CLEVIPREX,Reflex Tachycardia,Hypotension Reflex Tachycardia,1
CLEVIPREX,Reflex Tachycardia,Hypotension Reflex,1
CLEVIPREX,headache,reactions headache nausea and vomiting To report,1
CLEVIPREX,headache,Hypotension Reflex,1
CLEVIPREX,headache,see Warnings and Precautions EXCERPT Most common adverse reactions are,0
CLEVIPREX,headache,reactions headache nausea and vomiting To,1
CLEVIPREX,headache,see Warnings and Precautions EXCERPT Most common adverse reactions are,0
CLEVIPREX,headache,EXCERPT,0
CLEVIPREX,headache,SUSPECTED ADVERSE REACTIONS,0
CLEVIPREX,headache,headache nausea and vomiting To report,1
CLEVIPREX,headache,headache nausea and vomiting To report,1
CLEVIPREX,headache,Warnings and Precautions EXCERPT Most common,0
CLEVIPREX,headache,nausea and vomiting To report,0
CLEVIPREX,nausea,SUSPECTED ADVERSE REACTIONS contact The Medicines,0
CLEVIPREX,nausea,nausea and,1
CLEVIPREX,nausea,nausea and vomiting To report SUSPECTED,1
CLEVIPREX,nausea,and vomiting To,0
CLEVIPREX,nausea,reactions are nausea and vomiting To report,1
CLEVIPREX,nausea,and vomiting To,0
CLEVIPREX,vomiting,are headache nausea vomiting To report,1
CLEVIPREX,vomiting,and vomiting To,0
CLEVIPREX,vomiting,vomiting,1
CLEVIPREX,vomiting,headache nausea vomiting To,1
CLEVIPREX,vomiting,vomiting,1
CLEVIPREX,vomiting,vomiting To report SUSPECTED ADVERSE REACTIONS,1
CLEVIPREX,vomiting,vomiting,1
CLEVIPREX,vomiting,are headache nausea and,0
CLEVIPREX,vomiting,nausea,0
CLEVIPREX,vomiting,headache nausea and,0
CLEVIPREX,vomiting,vomiting To report SUSPECTED,1
CLEVIPREX,headache,vomiting The incidence of adverse events,0
CLEVIPREX,headache,incidence,0
CLEVIPREX,headache,headache nausea and,1
CLEVIPREX,headache,Cleviprex in severe hypertension headache nausea and vomiting The incidence,1
CLEVIPREX,headache,headache nausea and,1
CLEVIPREX,headache,headache nausea and vomiting The,1
CLEVIPREX,headache,Cleviprex in severe hypertension headache nausea and,1
CLEVIPREX,headache,headache nausea and vomiting The,1
CLEVIPREX,headache,incidence of adverse events,0
CLEVIPREX,headache,in severe hypertension headache nausea and vomiting The incidence,1
CLEVIPREX,headache,incidence of adverse events,0
CLEVIPREX,headache,headache nausea and,1
CLEVIPREX,headache,headache nausea and vomiting The incidence,1
CLEVIPREX,nausea,included nausea and vomiting The incidence,1
CLEVIPREX,nausea,headache nausea and vomiting The incidence,1
CLEVIPREX,nausea,severe hypertension included nausea and,1
CLEVIPREX,nausea,headache nausea and vomiting The incidence,1
CLEVIPREX,nausea,Cleviprex,0
CLEVIPREX,nausea,vomiting The incidence of adverse events,0
CLEVIPREX,nausea,severe hypertension included,0
CLEVIPREX,nausea,severe hypertension included nausea and vomiting The,1
CLEVIPREX,nausea,severe hypertension included,0
CLEVIPREX,vomiting,incidence of adverse events,0
CLEVIPREX,vomiting,in severe,0
CLEVIPREX,vomiting,vomiting The incidence,1
CLEVIPREX,vomiting,Cleviprex in,0
CLEVIPREX,myocardial infarction,severe or essential hypertension myocardial infarction,1
CLEVIPREX,myocardial infarction,Cleviprex in,0
CLEVIPREX,myocardial infarction,or essential hypertension myocardial infarction,1
CLEVIPREX,myocardial infarction,cardiac,0
CLEVIPREX,myocardial infarction,syncopeRespiratory dyspnea PostMarketing and Other,0
CLEVIPREX,myocardial infarction,cardiac arrestNervous,0
CLEVIPREX,myocardial infarction,hypertension myocardial infarction,1
CLEVIPREX,myocardial infarction,cardiac arrestNervous,0
CLEVIPREX,myocardial infarction,severe or essential hypertension myocardial infarction cardiac,1
CLEVIPREX,myocardial infarction,cardiac arrestNervous,0
CLEVIPREX,myocardial infarction,or essential hypertension myocardial infarction cardiac arrestNervous system syncopeRespiratory,1
CLEVIPREX,myocardial infarction,cardiac arrestNervous,0
CLEVIPREX,cardiac arrest,Nervous system syncopeRespiratory dyspnea PostMarketing and Other Clinical,0
CLEVIPREX,cardiac arrest,myocardial cardiac arrest,1
CLEVIPREX,cardiac arrest,dyspnea,0
CLEVIPREX,cardiac arrest,hypertension includedCardiac myocardial cardiac arrest Nervous system syncopeRespiratory dyspnea PostMarketing,1
CLEVIPREX,cardiac arrest,dyspnea,0
CLEVIPREX,cardiac arrest,Nervous system syncopeRespiratory dyspnea PostMarketing and,0
CLEVIPREX,syncope,essential hypertension includedCardiac myocardial infarction cardiac arrestNervous system,0
CLEVIPREX,syncope,syncope Respiratory dyspnea PostMarketing and Other,1
CLEVIPREX,syncope,cardiac arrestNervous,0
CLEVIPREX,syncope,syncope Respiratory,1
CLEVIPREX,syncope,syncope Respiratory dyspnea,1
CLEVIPREX,syncope,re or essential hypertension includedCardiac myocardial infarction cardiac,0
CLEVIPREX,syncope,myocardial infarction cardiac arrestNervous,0
CLEVIPREX,syncope,syncope,1
CLEVIPREX,syncope,syncope Respiratory,1
CLEVIPREX,dyspnea,dyspnea PostMarketing and Other,1
CLEVIPREX,dyspnea,syncope Respiratory,1
CLEVIPREX,dyspnea,dyspnea PostMarketing and Other,1
CLEVIPREX,increased blood triglycerides,postapproval use of increased blood triglycerides ileus hypersensitivity hypotension nausea,1
CLEVIPREX,increased blood triglycerides,dyspnea PostMarketing and Other,1
CLEVIPREX,increased blood triglycerides,ileus hypersensitivity hypotension nausea,0
CLEVIPREX,increased blood triglycerides,blood triglycerides ileus hypersensitivity hypotension,1
CLEVIPREX,increased blood triglycerides,possible pulmonary,0
CLEVIPREX,increased blood triglycerides,postapproval use of increased blood triglycerides,1
CLEVIPREX,increased blood triglycerides,increased blood triglycerides ileus hypersensitivity,1
CLEVIPREX,ileus,hypersensitivity hypotension nausea decreased oxygen saturation possible pulmonary,0
CLEVIPREX,ileus,ileus hypersensitivity hypotension nausea decreased,1
CLEVIPREX,hypersensitivity,oxygen saturation possible pulmonary shunting and,0
CLEVIPREX,hypersensitivity,increased blood,0
CLEVIPREX,hypersensitivity,hypersensitivity hypotension nausea,1
CLEVIPREX,hypersensitivity,increased blood,0
CLEVIPREX,hypotension,hypotension nausea decreased oxygen,1
CLEVIPREX,hypotension,hypotension nausea decreased oxygen saturation possible,1
CLEVIPREX,hypotension,triglycerides ileus hypotension,1
CLEVIPREX,hypotension,hypotension nausea decreased oxygen saturation possible,1
CLEVIPREX,nausea,nausea decreased oxygen saturation possible,1
CLEVIPREX,nausea,nausea decreased oxygen saturation,1
CLEVIPREX,nausea,nausea decreased,1
CLEVIPREX,nausea,saturation possible,0
CLEVIPREX,nausea,nausea,1
CLEVIPREX,nausea,nausea decreased oxygen saturation,1
CLEVIPREX,nausea,hypersensitivity nausea decreased oxygen saturation possible pulmonary,1
CLEVIPREX,nausea,nausea decreased oxygen saturation,1
CLEVIPREX,nausea,of Cleviprex increased blood triglycerides ileus,0
CLEVIPREX,nausea,possible pulmonary,0
CLEVIPREX,nausea,oxygen,0
CLEVIPREX,pulmonary shunting,nausea decreased oxygen saturation pulmonary,1
CLEVIPREX,pulmonary shunting,pulmonary shunting,1
CLEVIPREX,pulmonary shunting,and reflex,0
CLEVIPREX,pulmonary shunting,pulmonary shunting and reflex,1
CLEVIPREX,pulmonary shunting,and reflex,0
CLEVIPREX,Hypotension,Warnings and ecautions (,1
CLEVIPREX,Hypotension,headache nausea and vomiting,0
CLEVIPREX,reflex tachycardia,"    
      EXCERPT Most common adverse",1
CLEVIPREX,reflex tachycardia,"    
      EXCERPT",1
CLEVIPREX,reflex tachycardia,"    
      EXCERPT Most common",1
CLEVIPREX,reflex tachycardia,"    
      EXCERPT Most",1
CLEVIPREX,reflex tachycardia,"    
      EXCERPT Most common",1
CLEVIPREX,reflex tachycardia,Most common adverse reactions are,0
CLEVIPREX,negative inotropic effects,report SUSPECTED ADVERSE REACTIONS ct The Medicines Company a t MDCO or FDA,1
CLEVIPREX,negative inotropic effects,Most common adverse reactions are,0
CLEVIPREX,negative inotropic effects,Company a t MDCO or FDA,1
CLEVIPREX,negative inotropic effects,SUSPECTED ADVERSE REACTIONS ct The Medicines Company a t,1
CLEVIPREX,negative inotropic effects,Company a t MDCO or FDA,1
CLEVIPREX,negative inotropic effects,ct The Medicines Company a t MDCO or FDA,1
CLEVIPREX,negative inotropic effects,ADVERSE REACTIONS ct The Medicines Company a t MDCO or FDA,1
CLEVIPREX,negative inotropic effects,ct The Medicines Company a t MDCO or FDA,1
CLEVIPREX,negative inotropic effects,ADVERSE REACTIONS ct The Medicines,1
CLEVIPREX,negative inotropic effects,ct The Medicines Company a t MDCO or,1
CLEVIPREX,negative inotropic effects,ADVERSE REACTIONS ct The Medicines,1
CLEVIPREX,exacerbate heart failure,88-977-MDCO (6326) or FD A at FDA or,1
CLEVIPREX,exacerbate heart failure,ADVERSE REACTIONS ct The Medicines,1
CLEVIPREX,exacerbate heart failure,88-977-MDCO (6326) or FD,1
CLEVIPREX,exacerbate heart failure,ADVERSE REACTIONS ct The Medicines,1
CLEVIPREX,exacerbate heart failure,at FDA or wwwfdagovmedwatch,0
CLEVIPREX,exacerbate heart failure,contact The Medicines Company 88-977-MDCO (6326) or FD,1
CLEVIPREX,exacerbate heart failure,at FDA or wwwfdagovmedwatch,0
CLEVIPREX,exacerbate heart failure,or FD A at FDA or,1
CLEVIPREX,exacerbate heart failure,wwwfdagovmedwatch Clinical Trials,0
CLEVIPREX,exacerbate heart failure,Company 88-977-MDCO (6326) or FD A at FDA or wwwfdagovmedwatch,1
CLEVIPREX,exacerbate heart failure,wwwfdagovmedwatch Clinical Trials,0
CLEVIPREX,exacerbate heart failure,contact The Medicines Company 88-977-MDCO (6326),1
CLEVIPREX,reflex tachycardia,in an additional patients r durations betwee n and hours Because,1
CLEVIPREX,reflex tachycardia,contact The Medicines Company 88-977-MDCO (6326),1
CLEVIPREX,reflex tachycardia,additional patients r,1
CLEVIPREX,reflex tachycardia,trials are conducted,0
CLEVIPREX,reflex tachycardia,in an additional patients r durations betwee,1
CLEVIPREX,reflex tachycardia,trials are conducted,0
CLEVIPREX,reflex tachycardia,jority of patients n it was infused as a continuous infusion in,0
CLEVIPREX,reflex tachycardia,conducted under widely varying conditions advers,0
CLEVIPREX,reflex tachycardia,patients r durations betwee n and hours,1
CLEVIPREX,reflex tachycardia,conducted under widely varying conditions advers,0
CLEVIPREX,reflex tachycardia,fo,0
CLEVIPREX,negative inotropic effects,reactions Table Common adverse ctions in,1
CLEVIPREX,negative inotropic effects,ctions in placebo-controll ed perioperative studies ESCAPE ESCAPE,1
CLEVIPREX,negative inotropic effects,ctions in placebo-controll ed,1
CLEVIPREX,negative inotropic effects,ctions in placebo-controll ed perioperative studies ESCAPE ESCAPE,1
CLEVIPREX,negative inotropic effects,perioperative studies ESCAPE,0
CLEVIPREX,negative inotropic effects,Common adverse ctions,1
CLEVIPREX,negative inotropic effects,reactions Table Common adverse ctions in placebo-controll,1
CLEVIPREX,negative inotropic effects,Common adverse ctions,1
CLEVIPREX,negative inotropic effects,by at,0
CLEVIPREX,negative inotropic effects,in placebo-controll ed perioperative studies ESCAPE,1
CLEVIPREX,negative inotropic effects,ctions,1
CLEVIPREX,negative inotropic effects,Common adverse ctions,1
CLEVIPREX,exacerbate heart failure,in placebocontrolled rioperative,1
CLEVIPREX,exacerbate heart failure,placebocontrolled,0
CLEVIPREX,exacerbate heart failure,"reactions in placebocontrolled rioperative studies. 
   ESCAPE ESCAPE",1
CLEVIPREX,exacerbate heart failure,placebocontrolled,0
CLEVIPREX,exacerbate heart failure,rioperative studies.,1
LUMIZYME,hypersensitivity reactions,trials hypersensitivity reactions and,1
LUMIZYME,hypersensitivity reactions,rioperative studies.,1
LUMIZYME,hypersensitivity reactions,EXCERPT The,0
LUMIZYME,anaphylaxis,anaphylaxis rash,1
LUMIZYME,anaphylaxis,anaphylaxis rash,1
LUMIZYME,anaphylaxis,hypersensitivity reactions and anaphylaxis rash pyrexia,1
LUMIZYME,anaphylaxis,anaphylaxis rash,1
LUMIZYME,anaphylaxis,and anaphylaxis rash,1
LUMIZYME,anaphylaxis,anaphylaxis rash,1
LUMIZYME,anaphylaxis,trials were,0
LUMIZYME,anaphylaxis,anaphylaxis rash,1
LUMIZYME,anaphylaxis,urticaria headache hyperhidrosis,0
LUMIZYME,rash,hyperhidrosis nausea cough,0
LUMIZYME,rash,hypersensitivity reactions and,0
LUMIZYME,rash,hyperhidrosis nausea cough decreased oxygen,0
LUMIZYME,rash,reactions in clinical,0
LUMIZYME,pyrexia,included anaphylaxis pyrexia flushingfeeling hot,1
LUMIZYME,pyrexia,reactions in clinical,0
LUMIZYME,pyrexia,reactions,0
LUMIZYME,pyrexia,nausea cough decreased oxygen saturati,0
LUMIZYME,pyrexia,headache hyperhidrosis nausea cough decreased,0
LUMIZYME,pyrexia,pyrexia flushingfeeling hot,1
LUMIZYME,pyrexia,reactions and included anaphylaxis pyrexia flushingfeeling,1
LUMIZYME,pyrexia,pyrexia flushingfeeling hot,1
LUMIZYME,pyrexia,cough decreased oxygen saturati,0
LUMIZYME,pyrexia,included anaphylaxis,0
LUMIZYME,pyrexia,pyrexia,1
LUMIZYME,flushing,in clinical trials were hypersensitivity reactions,0
LUMIZYME,flushing,flushing,1
LUMIZYME,flushing,pyrexia,0
LUMIZYME,flushing,hypersensitivity reactions and included,0
LUMIZYME,flushing,flushing,1
LUMIZYME,flushing,flushing feeling,1
LUMIZYME,flushing,flushing feeling hot urticaria headache hyperhidrosis,1
LUMIZYME,feeling hot,nausea cough decreased,0
LUMIZYME,feeling hot,headache hyperhidrosis nausea cough decreased oxygen saturation tachycardia tachy,0
LUMIZYME,feeling hot,headache hyperhidrosis nausea cough decreased oxygen,0
LUMIZYME,feeling hot,feeling hot urticaria headache hyperhidrosis,1
LUMIZYME,feeling hot,rash,0
LUMIZYME,feeling hot,reactions,0
LUMIZYME,feeling hot,pyrexia feeling hot,1
LUMIZYME,urticaria,urticaria headache hyperhidrosis nausea cough decreased,1
LUMIZYME,headache,hot headache hyperhidrosis nausea,1
LUMIZYME,headache,urticaria headache hyperhidrosis nausea cough decreased,1
LUMIZYME,headache,headache hyperhidrosis,1
LUMIZYME,headache,headache,1
LUMIZYME,headache,headache hyperhidrosis nausea cough,1
LUMIZYME,hyperhidrosis,urticaria hyperhidrosis nausea cough decreased oxygen saturation,1
LUMIZYME,hyperhidrosis,headache hyperhidrosis nausea cough,1
LUMIZYME,hyperhidrosis,hyperhidrosis nausea cough decreased oxygen,1
LUMIZYME,nausea,nausea cough,1
LUMIZYME,nausea,discomfort dizziness muscle,0
LUMIZYME,cough,hyperhidrosis cough decreased oxygen,1
LUMIZYME,cough,discomfort dizziness muscle,0
LUMIZYME,cough,cough decreased oxygen saturation tachycardia,1
LUMIZYME,cough,cough decreased,1
LUMIZYME,cough,anaphylaxis rash pyrexia,0
LUMIZYME,cough,oxygen saturation tachycardia tachypnea,0
LUMIZYME,cough,cough decreased oxygen saturation tachycardia tachypnea,1
LUMIZYME,cough,headache hyperhidrosis cough decreased oxygen saturation tachycardia tachypnea,1
LUMIZYME,cough,cough decreased oxygen saturation tachycardia tachypnea,1
LUMIZYME,cough,cough decreased oxygen saturation tachycardia tachypnea,1
LUMIZYME,cough,cough decreased oxygen saturation tachycardia tachypnea,1
LUMIZYME,decreased oxygen saturation,urticaria headache hyperhidrosis nausea decreased,1
LUMIZYME,decreased oxygen saturation,chest discomfort dizziness,0
LUMIZYME,decreased oxygen saturation,decreased oxygen,1
LUMIZYME,decreased oxygen saturation,tachycardia tachypnea chest discomfort dizziness muscle twitching agitation cyanosis erythe,0
LUMIZYME,decreased oxygen saturation,hot urticaria headache,0
LUMIZYME,decreased oxygen saturation,urticaria headache hyperhidrosis nausea decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,rash pyrexia flushingfeeling hot urticaria headache hyperhidrosis nausea cough,0
LUMIZYME,decreased oxygen saturation,pyrexia flushingfeeling hot urticaria headache hyperhidrosis,0
LUMIZYME,decreased oxygen saturation,discomfort dizziness muscle twitching agitation cyanosis erythe,0
LUMIZYME,decreased oxygen saturation,headache hyperhidrosis nausea decreased oxygen saturation tachycardia tachypnea chest discomfort,1
LUMIZYME,decreased oxygen saturation,discomfort dizziness muscle twitching agitation cyanosis erythe,0
LUMIZYME,tachycardia,tachycardia tachypnea,1
LUMIZYME,tachycardia,muscle,0
LUMIZYME,tachycardia,dizziness,0
LUMIZYME,tachycardia,twitching,0
LUMIZYME,tachycardia,tachycardia,1
LUMIZYME,tachycardia,twitching,0
LUMIZYME,chest discomfort,cough decreased oxygen saturation tachycardia,0
LUMIZYME,chest discomfort,decreased oxygen saturation tachycardia chest discomfort dizziness muscle twitching agitation cyanosis,1
LUMIZYME,chest discomfort,cough decreased oxygen saturation tachycardia,0
LUMIZYME,chest discomfort,saturation tachycardia tachypnea,0
LUMIZYME,chest discomfort,chest discomfort dizziness muscle twitching agitation,1
LUMIZYME,chest discomfort,agitation,0
LUMIZYME,dizziness,chest dizziness muscle twitching agitation,1
LUMIZYME,dizziness,agitation,0
LUMIZYME,dizziness,dizziness muscle twitching,1
LUMIZYME,dizziness,saturation tachycardia tachypnea chest dizziness muscle twitching agitation cyanosis,1
LUMIZYME,dizziness,dizziness muscle twitching,1
LUMIZYME,dizziness,chest dizziness muscle twitching agitation,1
LUMIZYME,dizziness,dizziness muscle twitching,1
LUMIZYME,dizziness,dizziness muscle,1
LUMIZYME,dizziness,dizziness muscle twitching,1
LUMIZYME,dizziness,cyanosis,0
LUMIZYME,dizziness,dizziness muscle twitching agitation cyanosis,1
LUMIZYME,dizziness,oxygen saturation tachycardia tachypnea chest,0
LUMIZYME,muscle twitching,dizziness,0
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis erythema,1
LUMIZYME,muscle twitching,tachypnea chest discomfort muscle twitching agitation cyanosis,1
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis erythema,1
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis erythema,1
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis erythema,1
LUMIZYME,muscle twitching,tachypnea chest discomfort muscle twitching agitation cyanosis erythema hypertensionincreased blood,1
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis erythema,1
LUMIZYME,muscle twitching,tachypnea chest,0
LUMIZYME,muscle twitching,chest discomfort,0
LUMIZYME,muscle twitching,cough decreased oxygen saturation tachycardia tachypnea chest discomfort,0
LUMIZYME,agitation,agitation cyanosis erythema hypertensionincreased blood,1
LUMIZYME,agitation,agitation cyanosis erythema hypertensionincreased blood pressure,1
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,agitation cyanosis erythema hypertensionincreased blood pressure,1
LUMIZYME,cyanosis,cyanosis erythema hypertensionincreased blood pressure pallor,1
LUMIZYME,cyanosis,cyanosis erythema hypertensionincreased blood pressure pallor,1
LUMIZYME,cyanosis,cyanosis erythema hypertensionincreased blood pressure,1
LUMIZYME,cyanosis,cyanosis erythema,1
LUMIZYME,erythema,erythema hypertensionincreased,1
LUMIZYME,erythema,muscle twitching agitation erythema hypertensionincreased blood pressure pallor,1
LUMIZYME,erythema,erythema hypertensionincreased,1
LUMIZYME,erythema,agitation erythema hypertensionincreased blood pressure pallor,1
LUMIZYME,erythema,erythema hypertensionincreased,1
LUMIZYME,erythema,cyanosis,0
LUMIZYME,erythema,erythema,1
LUMIZYME,erythema,cyanosis,0
LUMIZYME,hypertension,pressure pallor,0
LUMIZYME,hypertension,hypertension increased blood pressure pallor,1
LUMIZYME,hypertension,hypertension increased blood pressure pallor,1
LUMIZYME,hypertension,pallor rigors tremor,0
LUMIZYME,hypertension,hypertension increased blood pressure pallor rigors,1
LUMIZYME,hypertension,hypertension increased blood,1
LUMIZYME,hypertension,twitching agitation cyanosis hypertension increased blood pressure pallor,1
LUMIZYME,hypertension,hypertension increased blood,1
LUMIZYME,hypertension,hypertension increased blood pressure pallor,1
LUMIZYME,increased blood pressure,blood pressure pallor rigors tremor,1
LUMIZYME,increased blood pressure,SUSPECTED ADVERSE,0
LUMIZYME,increased blood pressure,chest discomfort dizziness muscle,0
LUMIZYME,pallor,blood pallor rigors tremor,1
LUMIZYME,pallor,chest discomfort dizziness muscle,0
LUMIZYME,pallor,and myalgia,0
LUMIZYME,pallor,blood pallor rigors tremor vomiting fatigue and,1
LUMIZYME,pallor,and myalgia,0
LUMIZYME,pallor,pallor rigors tremor vomiting,1
LUMIZYME,pallor,pallor,1
LUMIZYME,pallor,pallor rigors tremor vomiting,1
LUMIZYME,pallor,pallor rigors tremor vomiting fatigue,1
LUMIZYME,pallor,pallor rigors tremor vomiting fatigue and,1
LUMIZYME,pallor,erythema hypertensionincreased blood,0
LUMIZYME,tremor,tremor vomiting fatigue and myalgia To,1
LUMIZYME,tremor,tremor vomiting fatigue and,1
LUMIZYME,tremor,tremor vomiting fatigue,1
LUMIZYME,tremor,hypertensionincreased blood pressure pallor tremor vomiting fatigue,1
LUMIZYME,tremor,tremor vomiting fatigue,1
LUMIZYME,tremor,tremor,1
LUMIZYME,tremor,tremor vomiting fatigue,1
LUMIZYME,tremor,tremor,1
LUMIZYME,tremor,tremor,1
LUMIZYME,tremor,tremor,1
LUMIZYME,tremor,myalgia To report,0
LUMIZYME,tremor,blood pressure pallor tremor vomiting,1
LUMIZYME,tremor,myalgia To report,0
LUMIZYME,vomiting,vomiting fatigue and myalgia To,1
LUMIZYME,vomiting,vomiting fatigue and,1
LUMIZYME,vomiting,ADVERSE,0
LUMIZYME,vomiting,vomiting fatigue and myalgia,1
LUMIZYME,vomiting,ADVERSE,0
LUMIZYME,vomiting,vomiting fatigue and myalgia,1
LUMIZYME,vomiting,vomiting fatigue and myalgia To,1
LUMIZYME,vomiting,erythema hypertensionincreased blood pressure pallor rigors tremor,0
LUMIZYME,vomiting,agitation cyanosis erythema hypertensionincreased blood pressure pallor rigors tremor,0
LUMIZYME,fatigue,report,0
LUMIZYME,myalgia,myalgia,1
LUMIZYME,myalgia,myalgia,1
LUMIZYME,myalgia,myalgia,1
LUMIZYME,myalgia,Genzyme at or,0
LUMIZYME,myalgia,vomiting,0
LUMIZYME,myalgia,myalgia To report SUSPECTED,1
LUMIZYME,myalgia,myalgia To report SUSPECTED,1
LUMIZYME,myalgia,myalgia To report SUSPECTED,1
LUMIZYME,myalgia,myalgia To report SUSPECTED,1
LUMIZYME,myalgia,myalgia To report SUSPECTED,1
LUMIZYME,myalgia,rigors,0
LUMIZYME,myalgia,myalgia To report,1
LUMIZYME,myalgia,rigors,0
LUMIZYME,anaphylaxis,hypersensitivity reactions and anaphylaxis rash pyrexia flushingfeeling hot urticaria,1
LUMIZYME,anaphylaxis,rigors,0
LUMIZYME,anaphylaxis,pyrexia flushingfeeling hot urticaria,0
LUMIZYME,anaphylaxis,anaphylaxis rash pyrexia flushingfeeling hot urticaria,1
LUMIZYME,anaphylaxis,anaphylaxis rash pyrexia,1
LUMIZYME,anaphylaxis,alglucosidase alfa treatment,0
LUMIZYME,anaphylaxis,headache hyperhidrosis,0
LUMIZYME,anaphylaxis,and,0
LUMIZYME,rash,nausea cough decreased oxygen,0
LUMIZYME,rash,rash,1
LUMIZYME,rash,cough decreased oxygen,0
LUMIZYME,rash,rash pyrexia flushingfeeling,1
LUMIZYME,rash,reactions and included rash pyrexia,1
LUMIZYME,rash,rash pyrexia flushingfeeling,1
LUMIZYME,rash,rash pyrexia flushingfeeling,1
LUMIZYME,pyrexia,pyrexia flushingfeeling,1
LUMIZYME,pyrexia,included anaphylaxis pyrexia,1
LUMIZYME,pyrexia,pyrexia flushingfeeling,1
LUMIZYME,pyrexia,reactions and included anaphylaxis rash,0
LUMIZYME,pyrexia,and included anaphylaxis rash,0
LUMIZYME,flushing,flushing feeling hot,1
LUMIZYME,flushing,decreased,0
LUMIZYME,flushing,flushing,1
LUMIZYME,flushing,rash flushing feeling hot urticaria headache hyperhidrosis,1
LUMIZYME,flushing,flushing,1
LUMIZYME,flushing,hypersensitivity reactions and included,0
LUMIZYME,flushing,flushing feeling hot,1
LUMIZYME,flushing,included anaphylaxis rash flushing feeling hot urticaria headache hyperhidrosis,1
LUMIZYME,flushing,flushing feeling hot,1
LUMIZYME,feeling hot,headache hyperhidrosis nausea cough decreased oxygen saturation tachycardia,0
LUMIZYME,feeling hot,feeling hot urticaria,1
LUMIZYME,feeling hot,anaphylaxis rash pyrexia feeling hot,1
LUMIZYME,feeling hot,included anaphylaxis rash pyrexia feeling hot,1
LUMIZYME,urticaria,urticaria,1
LUMIZYME,urticaria,cough decreased oxygen saturation tachycardia tachypnea chest,0
LUMIZYME,urticaria,urticaria headache hyperhidrosis,1
LUMIZYME,urticaria,urticaria headache hyperhidrosis nausea,1
LUMIZYME,urticaria,hot,0
LUMIZYME,urticaria,urticaria headache,1
LUMIZYME,headache,urticaria,0
LUMIZYME,headache,nausea cough decreased oxygen saturation tachycardia tachypnea,0
LUMIZYME,headache,included anaphylaxis,0
LUMIZYME,headache,persensitivity reactions and included anaphylaxis,0
LUMIZYME,headache,hyperhidrosis nausea cough decreased,0
LUMIZYME,headache,headache hyperhidrosis nausea,1
LUMIZYME,headache,hot headache,1
LUMIZYME,headache,headache hyperhidrosis nausea,1
LUMIZYME,headache,headache hyperhidrosis nausea,1
LUMIZYME,headache,oxygen saturation tachycardia tachypnea chest,0
LUMIZYME,hyperhidrosis,headache,0
LUMIZYME,hyperhidrosis,hyperhidrosis nausea cough,1
LUMIZYME,hyperhidrosis,hyperhidrosis nausea,1
LUMIZYME,hyperhidrosis,included anaphylaxis,0
LUMIZYME,hyperhidrosis,chest discomfort,0
LUMIZYME,hyperhidrosis,flushingfeeling hot urticaria,0
LUMIZYME,hyperhidrosis,hyperhidrosis nausea cough decreased,1
LUMIZYME,hyperhidrosis,hyperhidrosis nausea cough decreased oxygen saturation,1
LUMIZYME,hyperhidrosis,oxygen saturation tachycardia tachypnea chest discomfort,0
LUMIZYME,nausea,nausea cough decreased oxygen saturation,1
LUMIZYME,nausea,hyperhidrosis,0
LUMIZYME,nausea,anaphylaxis rash pyrexia flushingfeeling,0
LUMIZYME,cough,cough decreased oxygen saturation tachycardia,1
LUMIZYME,cough,anaphylaxis rash pyrexia flushingfeeling,0
LUMIZYME,cough,headache,0
LUMIZYME,cough,cough decreased oxygen,1
LUMIZYME,cough,flushingfeeling hot urticaria headache hyperhidrosis nausea,0
LUMIZYME,cough,dizziness muscle twitching,0
LUMIZYME,cough,anaphylaxis rash,0
LUMIZYME,cough,nausea,0
LUMIZYME,cough,discomfort dizziness muscle,0
LUMIZYME,cough,cough,1
LUMIZYME,decreased oxygen saturation,oxygen saturation tachycardia tachypnea chest discomfort dizziness,1
LUMIZYME,decreased oxygen saturation,nausea decreased oxygen,1
LUMIZYME,decreased oxygen saturation,urticaria headache hyperhidrosis nausea decreased oxygen saturation tachycardia tachypnea chest discomfort dizziness,1
LUMIZYME,decreased oxygen saturation,nausea decreased oxygen,1
LUMIZYME,decreased oxygen saturation,decreased oxygen saturation tachycardia tachypnea chest discomfort,1
LUMIZYME,decreased oxygen saturation,nausea decreased oxygen,1
LUMIZYME,decreased oxygen saturation,hyperhidrosis nausea decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,headache hyperhidrosis nausea decreased oxygen saturation tachycardia tachypnea chest discomfort dizziness,1
LUMIZYME,decreased oxygen saturation,hyperhidrosis nausea decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,oxygen saturation tachycardia tachypnea,1
LUMIZYME,decreased oxygen saturation,nausea cough,0
LUMIZYME,tachycardia,dizziness,0
LUMIZYME,tachycardia,nausea cough decreased oxygen tachycardia tachypnea chest,1
LUMIZYME,tachycardia,dizziness,0
LUMIZYME,tachycardia,hyperhidrosis nausea cough,0
LUMIZYME,tachycardia,dizziness muscle twitching agitation cyanosis,0
LUMIZYME,tachycardia,tachycardia,1
LUMIZYME,tachycardia,dizziness muscle twitching agitation cyanosis,0
LUMIZYME,tachycardia,cyanosis,0
LUMIZYME,tachycardia,decreased oxygen tachycardia tachypnea chest,1
LUMIZYME,tachycardia,cyanosis,0
LUMIZYME,tachycardia,tachycardia tachypnea chest discomfort dizziness muscle,1
LUMIZYME,tachycardia,cyanosis erythema hypertens,0
LUMIZYME,tachycardia,cough decreased oxygen tachycardia tachypnea chest discomfort dizziness,1
LUMIZYME,tachycardia,cyanosis erythema hypertens,0
LUMIZYME,tachypnea,tachypnea chest discomfort,1
LUMIZYME,tachypnea,tachypnea chest discomfort dizziness muscle,1
LUMIZYME,tachypnea,oxygen saturation tachypnea chest discomfort dizziness muscle twitching,1
LUMIZYME,tachypnea,tachypnea chest discomfort dizziness muscle,1
LUMIZYME,tachypnea,saturation tachycardia,0
LUMIZYME,tachypnea,twitching,0
LUMIZYME,tachypnea,tachypnea chest discomfort dizziness,1
LUMIZYME,tachypnea,twitching,0
LUMIZYME,chest discomfort,saturation tachycardia chest discomfort dizziness muscle twitching agitation,1
LUMIZYME,chest discomfort,twitching,0
LUMIZYME,chest discomfort,decreased oxygen saturation tachycardia chest,1
LUMIZYME,dizziness,dizziness muscle twitching agitation cyanosis erythema,1
LUMIZYME,dizziness,hypertensionincreased blood pressure,0
LUMIZYME,dizziness,dizziness muscle,1
LUMIZYME,dizziness,dizziness muscle,1
LUMIZYME,dizziness,dizziness,1
LUMIZYME,dizziness,dizziness muscle twitching,1
LUMIZYME,dizziness,saturation,0
LUMIZYME,muscle twitching,chest discomfort,0
LUMIZYME,muscle twitching,muscle twitching agitation,1
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis erythema,1
LUMIZYME,muscle twitching,tachypnea chest discomfort muscle twitching agitation cyanosis erythema hypertensionincreased,1
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis erythema,1
LUMIZYME,muscle twitching,blood pressure pallor rigors tremor,0
LUMIZYME,muscle twitching,muscle twitching,1
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis,1
LUMIZYME,muscle twitching,muscle twitching,1
LUMIZYME,muscle twitching,muscle twitching agitation cyanosis,1
LUMIZYME,muscle twitching,saturation tachycardia tachypnea,0
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,agitation cyanosis,1
LUMIZYME,agitation,muscle agitation cyanosis erythema hypertensionincreased,1
LUMIZYME,agitation,agitation cyanosis,1
LUMIZYME,agitation,agitation cyanosis erythema,1
LUMIZYME,agitation,dizziness muscle agitation cyanosis erythema hypertensionincreased blood pressure,1
LUMIZYME,agitation,agitation cyanosis erythema,1
LUMIZYME,agitation,agitation cyanosis,1
LUMIZYME,agitation,agitation,1
LUMIZYME,agitation,agitation cyanosis erythema hypertensionincreased blood pressure,1
LUMIZYME,agitation,agitation cyanosis,1
LUMIZYME,agitation,agitation,1
LUMIZYME,cyanosis,cyanosis erythema hypertensionincreased,1
LUMIZYME,cyanosis,agitation,0
LUMIZYME,cyanosis,pressure pallor rigors tremor,0
LUMIZYME,cyanosis,cyanosis erythema hypertensionincreased blood pressure,1
LUMIZYME,cyanosis,rigors tremor vomiting fatigue,0
LUMIZYME,erythema,erythema hypertensionincreased blood pressure,1
LUMIZYME,erythema,erythema hypertensionincreased blood,1
LUMIZYME,erythema,ration tachycardia tachypnea chest discomfort dizziness,0
LUMIZYME,erythema,muscle twitching agitation cyanosis,0
LUMIZYME,erythema,dizziness muscle twitching agitation erythema hypertensionincreased blood,1
LUMIZYME,erythema,muscle twitching agitation cyanosis,0
LUMIZYME,erythema,twitching agitation erythema hypertensionincreased blood pressure,1
LUMIZYME,erythema,muscle twitching agitation cyanosis,0
LUMIZYME,erythema,tremor vomiting fatigue and,0
LUMIZYME,erythema,hypertensionincreased blood pressure pallor rigors tremor vomiting fatigue and myalgia,0
LUMIZYME,erythema,discomfort dizziness muscle twitching,0
LUMIZYME,hypertension,hypertension,1
LUMIZYME,hypertension,tachypnea,0
LUMIZYME,hypertension,cyanosis hypertension increased blood pressure pallor,1
LUMIZYME,hypertension,tachypnea,0
LUMIZYME,hypertension,and myalgia Clinical,0
LUMIZYME,hypertension,hypertension increased blood pressure pallor rigors,1
LUMIZYME,hypertension,cyanosis erythema,0
LUMIZYME,hypertension,cyanosis erythema,0
LUMIZYME,hypertension,cyanosis hypertension increased blood,1
LUMIZYME,hypertension,cyanosis erythema,0
LUMIZYME,hypertension,pallor rigors tremor vomiting fatigue and myalgia,0
LUMIZYME,increased blood pressure,cyanosis erythema increased blood pressure pallor,1
LUMIZYME,increased blood pressure,pallor rigors tremor vomiting fatigue and myalgia,0
LUMIZYME,increased blood pressure,blood pressure pallor rigors tremor vomiting fatigue,1
LUMIZYME,increased blood pressure,twitching agitation cyanosis erythema,0
LUMIZYME,tremor,pressure pallor tremor vomiting fatigue and myalgia,1
LUMIZYME,tremor,twitching agitation cyanosis erythema,0
LUMIZYME,tremor,Clinical Trials in InfantileOnset and JuvenileOnset,0
LUMIZYME,tremor,twitching agitation cyanosis erythema hypertensionincreased blood,0
LUMIZYME,tremor,and myalgia,0
LUMIZYME,tremor,InfantileOnset and JuvenileOnset,0
LUMIZYME,tremor,hypertensionincreased blood pressure,0
LUMIZYME,tremor,tremor vomiting fatigue and,1
LUMIZYME,tremor,tremor vomiting fatigue,1
LUMIZYME,fatigue,fatigue and myalgia,1
LUMIZYME,myalgia,myalgia,1
LUMIZYME,anaphylaxis,anaphylaxis and acute cardiorespiratory failure The,1
LUMIZYME,anaphylaxis,most serious,0
LUMIZYME,anaphylaxis,acute cardiorespiratory failure The most common adverse reactions,0
LUMIZYME,anaphylaxis,alfa treatment included,0
LUMIZYME,anaphylaxis,alfa treatment anaphylaxis and acute cardiorespiratory failure The,1
LUMIZYME,anaphylaxis,alfa treatment included,0
LUMIZYME,anaphylaxis,anaphylaxis and acute cardiorespiratory,1
LUMIZYME,anaphylaxis,included,0
LUMIZYME,anaphylaxis,anaphylaxis and acute cardiorespiratory failure,1
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,acute cardiorespiratory failure,included anaphylaxis acute cardiorespiratory,1
LUMIZYME,acute cardiorespiratory failure,most common adverse,0
LUMIZYME,acute cardiorespiratory failure,cardiorespiratory failure The most common,1
LUMIZYME,acute cardiorespiratory failure,reactions reported,0
LUMIZYME,acute cardiorespiratory failure,treatment included anaphylaxis acute cardiorespiratory failure The most common adverse reactions,1
LUMIZYME,acute cardiorespiratory failure,reactions reported,0
LUMIZYME,acute cardiorespiratory failure,treatment included anaphylaxis acute cardiorespiratory failure The,1
LUMIZYME,acute cardiorespiratory failure,reactions reported,0
LUMIZYME,acute cardiorespiratory failure,anaphylaxis acute cardiorespiratory failure The most common adverse,1
LUMIZYME,acute cardiorespiratory failure,reactions reported,0
LUMIZYME,hypersensitivity reactions,in clinical trials hypersensitivity,1
LUMIZYME,hypersensitivity reactions,intervention in clinical trials hypersensitivity,1
LUMIZYME,hypersensitivity reactions,trials hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,in clinical trials hypersensitivity,1
LUMIZYME,hypersensitivity reactions,atory failure The most,0
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,alfa and included rash,0
LUMIZYME,rash,pyrexia urticaria flushing decreased oxygen saturation cough tachypnea tachycardia hyperten,0
LUMIZYME,rash,rash pyrexia urticaria flushing,1
LUMIZYME,rash,rash pyrexia urticaria flushing decreased oxygen,1
LUMIZYME,rash,cough tachypnea,0
LUMIZYME,rash,rash,1
LUMIZYME,pyrexia,pyrexia urticaria flushing decreased,1
LUMIZYME,pyrexia,cough tachypnea tachycardia hypertensionincr,0
LUMIZYME,pyrexia,occurring in of patients treated with alglucosidase alfa and included rash,0
LUMIZYME,pyrexia,and included pyrexia urticaria flushing decreased oxygen,1
LUMIZYME,pyrexia,occurring in of patients treated with alglucosidase alfa and included rash,0
LUMIZYME,urticaria,urticaria flushing decreased,1
LUMIZYME,flushing,of patients treated with alglucosidase alfa and included rash,0
LUMIZYME,flushing,alfa and,0
LUMIZYME,flushing,cough tachypnea,0
LUMIZYME,decreased oxygen saturation,tachycardia hypertensionincreased blood pressure pallor rigors vomiting,0
LUMIZYME,decreased oxygen saturation,urticaria decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,pyrexia urticaria decreased oxygen saturation cough tachypnea tachycardia hypertensionincreased blood,1
LUMIZYME,decreased oxygen saturation,decreased oxygen saturation,1
LUMIZYME,decreased oxygen saturation,decreased oxygen,1
LUMIZYME,decreased oxygen saturation,pressure pallor rigors vomiting cy,0
LUMIZYME,cough,cough tachypnea tachycardia,1
LUMIZYME,cough,saturation,0
LUMIZYME,cough,cough tachypnea tachycardia hypertensionincreased blood pressure,1
LUMIZYME,cough,cough tachypnea tachycardia,1
LUMIZYME,cough,urticaria flushing decreased oxygen cough tachypnea tachycardia,1
LUMIZYME,cough,cough tachypnea tachycardia,1
LUMIZYME,cough,oxygen,0
LUMIZYME,cough,hypertensionincreased blood pressure pallor,0
LUMIZYME,tachypnea,tachycardia hypertensionincreased blood pressure pallor rigors vomiting cyanosis agitation,0
LUMIZYME,tachypnea,tachypnea tachycardia hypertensionincreased blood pressure,1
LUMIZYME,tachypnea,tachypnea tachycardia hypertensionincreased blood,1
LUMIZYME,tachypnea,flushing,0
LUMIZYME,tachypnea,decreased oxygen saturation tachypnea tachycardia hypertensionincreased,1
LUMIZYME,tachypnea,flushing,0
LUMIZYME,tachypnea,tachypnea tachycardia hypertensionincreased blood,1
LUMIZYME,tachycardia,tachycardia hypertensionincreased,1
LUMIZYME,tachycardia,tachycardia hypertensionincreased blood pressure pallor rigors,1
LUMIZYME,hypertension,hypertension increased blood pressure pallor,1
LUMIZYME,hypertension,hypertension increased blood,1
LUMIZYME,hypertension,hypertension increased blood pressure pallor,1
LUMIZYME,hypertension,hypertension increased,1
LUMIZYME,increased blood pressure,vomiting,0
LUMIZYME,increased blood pressure,tachycardia increased blood pressure pallor rigors,1
LUMIZYME,increased blood pressure,vomiting,0
LUMIZYME,increased blood pressure,oxygen saturation cough,0
LUMIZYME,increased blood pressure,increased blood pressure pallor rigors vomiting,1
LUMIZYME,increased blood pressure,oxygen saturation cough,0
LUMIZYME,increased blood pressure,saturation cough tachypnea tachycardia,0
LUMIZYME,increased blood pressure,cough tachypnea tachycardia hypertension,0
LUMIZYME,increased blood pressure,cough tachypnea tachycardia increased blood,1
LUMIZYME,increased blood pressure,rigors vomiting cyanosis agitation and tremor These reactions were more likely,0
LUMIZYME,increased blood pressure,rigors vomiting cyanosis agitation and,0
LUMIZYME,pallor,tachypnea tachycardia hypertensionincreased blood pallor rigors vomiting cyanosis,1
LUMIZYME,pallor,rigors vomiting cyanosis agitation and,0
LUMIZYME,pallor,pallor,1
LUMIZYME,pallor,tachycardia hypertensionincreased blood pallor,1
LUMIZYME,pallor,pallor,1
LUMIZYME,pallor,were more likely to occur,0
LUMIZYME,pallor,pallor,1
LUMIZYME,pallor,saturation cough tachypnea,0
LUMIZYME,pallor,hypertensionincreased blood pallor rigors vomiting,1
LUMIZYME,pallor,saturation cough tachypnea,0
LUMIZYME,pallor,pallor rigors vomiting cyanosis,1
LUMIZYME,pallor,pallor rigors vomiting cyanosis agitation,1
LUMIZYME,rigors,more,0
LUMIZYME,rigors,tremor These reactions were more likely to occur with higher i,0
LUMIZYME,rigors,rigors vomiting cyanosis agitation,1
LUMIZYME,rigors,hypertensionincreased blood pressure rigors vomiting cyanosis agitation and,1
LUMIZYME,rigors,rigors vomiting cyanosis agitation,1
LUMIZYME,rigors,likely,0
LUMIZYME,rigors,rigors vomiting cyanosis,1
LUMIZYME,rigors,pressure rigors,1
LUMIZYME,rigors,rigors vomiting cyanosis,1
LUMIZYME,rigors,were more likely to,0
LUMIZYME,rigors,pressure rigors vomiting cyanosis,1
LUMIZYME,rigors,were more likely to,0
LUMIZYME,vomiting,vomiting cyanosis,1
LUMIZYME,vomiting,hypertensionincreased blood,0
LUMIZYME,vomiting,vomiting,1
LUMIZYME,vomiting,vomiting cyanosis agitation and tremor,1
LUMIZYME,vomiting,vomiting cyanosis agitation,1
LUMIZYME,vomiting,vomiting cyanosis agitation and,1
LUMIZYME,vomiting,vomiting cyanosis,1
LUMIZYME,vomiting,n saturation cough tachypnea tachycardia hypertensionincreased blood,0
LUMIZYME,vomiting,vomiting cyanosis,1
LUMIZYME,vomiting,hypertensionincreased blood pressure pallor vomiting cyanosis agitation,1
LUMIZYME,vomiting,vomiting cyanosis,1
LUMIZYME,cyanosis,cyanosis agitation,1
LUMIZYME,agitation,agitation and tremor These reactions were,1
LUMIZYME,tremor,tremor These reactions,1
LUMIZYME,tremor,blood,0
LUMIZYME,tremor,Some patients,0
LUMIZYME,tremor,tremor These,1
LUMIZYME,tremor,more likely to occur with higher infusion rates Some patients,0
LUMIZYME,tremor,pallor rigors vomiting,0
LUMIZYME,tremor,tremor These reactions were,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions Table summarizes,1
LUMIZYME,hypersensitivity reactions,Table summarizes all adverse reactions occurring in of patients or more patients,0
LUMIZYME,hypersensitivity reactions,reactions occurring in of,0
LUMIZYME,hypersensitivity reactions,of patients or more,0
LUMIZYME,hypersensitivity reactions,corticosteroids still experienced,0
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions Table summarizes all adverse,1
LUMIZYME,hypersensitivity reactions,all,0
LUMIZYME,hypersensitivity reactions,patients or more patients,0
LUMIZYME,rash erythematous,Rash including,0
LUMIZYME,rash erythematous,including,0
LUMIZYME,rash erythematous,rash,1
LUMIZYME,rash erythematous,rash macular and maculopapular,0
LUMIZYME,rash erythematous,including,0
LUMIZYME,rash erythematous,rash erythematous rash macular and,1
LUMIZYME,rash erythematous,Rash rash erythematous rash macular and maculopapular Pyrexia,1
LUMIZYME,rash erythematous,rash erythematous rash macular and,1
LUMIZYME,rash erythematous,rash,1
LUMIZYME,rash erythematous,including,0
LUMIZYME,rash macular,and maculopapular,0
LUMIZYME,rash macular,rash macular and maculopapular Pyrexia,1
LUMIZYME,rash macular,Rash including rash rash,1
LUMIZYME,rash macular,rash macular,1
LUMIZYME,rash macular,and,0
LUMIZYME,rash macular,and maculopapular,0
LUMIZYME,rash macular,including rash rash macular and maculopapular,1
LUMIZYME,rash macular,and maculopapular,0
LUMIZYME,rash macular,Rash including rash rash,1
LUMIZYME,livedo reticularis,with alglucosidase alfa livedo,1
LUMIZYME,livedo reticularis,alglucosidase,0
LUMIZYME,livedo reticularis,trials and expanded access programs with alglucosidase alfa included,0
LUMIZYME,livedo reticularis,in other clinical trials and,0
LUMIZYME,livedo reticularis,in other clinical trials and expanded access programs,0
LUMIZYME,livedo reticularis,ventricular extrasystoles nodal rhythm rales,0
LUMIZYME,irritability,irritability retching increased lacrimation,1
LUMIZYME,irritability,included livedo irritability retching increased,1
LUMIZYME,irritability,irritability retching increased lacrimation,1
LUMIZYME,irritability,irritability retching increased lacrimation ventricular extrasystoles,1
LUMIZYME,irritability,irritability,1
LUMIZYME,irritability,irritability retching increased lacrimation ventricular,1
LUMIZYME,irritability,irritability retching increased,1
LUMIZYME,irritability,irritability,1
LUMIZYME,irritability,livedo irritability retching,1
LUMIZYME,irritability,irritability,1
LUMIZYME,retching,and expanded access programs with alglucosidase alfa included,0
LUMIZYME,retching,expanded access programs with alglucosidase alfa included livedo,0
LUMIZYME,retching,and expanded access programs with,0
LUMIZYME,retching,and expanded access programs with alglucosidase alfa included livedo,0
LUMIZYME,retching,rhythm rales respiratory tract,0
LUMIZYME,retching,included livedo reticularis retching increased lacrimation ventricular extrasystoles,1
LUMIZYME,retching,rhythm rales respiratory tract,0
LUMIZYME,ventricular extrasystoles,ventricular extrasystoles nodal rhythm rales respiratory tract,1
LUMIZYME,ventricular extrasystoles,alfa included livedo,0
LUMIZYME,ventricular extrasystoles,ventricular extrasystoles nodal rhythm rales respiratory,1
LUMIZYME,ventricular extrasystoles,rales respiratory tract irritation and cold sweat,0
LUMIZYME,ventricular extrasystoles,increased ventricular extrasystoles nodal rhythm rales respiratory tract,1
LUMIZYME,ventricular extrasystoles,rales respiratory tract irritation and cold sweat,0
LUMIZYME,nodal rhythm,nodal rhythm rales respiratory tract irritation and,1
LUMIZYME,nodal rhythm,rales respiratory tract irritation and cold sweat,0
LUMIZYME,nodal rhythm,increased lacrimation ventricular nodal rhythm rales respiratory tract,1
LUMIZYME,nodal rhythm,rales respiratory tract irritation and cold sweat,0
LUMIZYME,nodal rhythm,cold,0
LUMIZYME,nodal rhythm,sweat Safety was also evaluated,0
LUMIZYME,nodal rhythm,increased lacrimation ventricular nodal rhythm,1
LUMIZYME,nodal rhythm,increased lacrimation,0
LUMIZYME,nodal rhythm,lacrimation ventricular nodal rhythm rales respiratory,1
LUMIZYME,nodal rhythm,increased lacrimation,0
LUMIZYME,nodal rhythm,retching increased lacrimation ventricular nodal,1
LUMIZYME,rales,lacrimation ventricular extrasystoles nodal rales,1
LUMIZYME,rales,retching increased lacrimation ventricular nodal,1
LUMIZYME,rales,rales respiratory tract irritation and,1
LUMIZYME,rales,rales respiratory tract irritation and,1
LUMIZYME,rales,rales,1
LUMIZYME,rales,rales respiratory tract irritation and cold,1
LUMIZYME,rales,rales respiratory tract irritation,1
LUMIZYME,rales,rales,1
LUMIZYME,respiratory tract irritation,extrasystoles,0
LUMIZYME,cold sweat,nodal rhythm rales respiratory tract,0
LUMIZYME,cold sweat,cold sweat Safety was also evaluated,1
LUMIZYME,cold sweat,cold sweat Safety was also evaluated,1
LUMIZYME,cold sweat,rhythm rales respiratory tract irritation,0
LUMIZYME,cold sweat,cold sweat,1
LUMIZYME,cold sweat,also evaluated in patients male females,0
LUMIZYME,cold sweat,irritation,0
LUMIZYME,cold sweat,females with Pompe disease in,0
LUMIZYME,cold sweat,respiratory tract irritation cold sweat Safety,1
LUMIZYME,cold sweat,females with Pompe disease in,0
LUMIZYME,cold sweat,tract irritation cold sweat,1
LUMIZYME,anaphylactic reactions,anaphylactic reactions Serious adverse reactions reported,1
LUMIZYME,anaphylactic reactions,Two patients receiving alglucosidase alfa discontinued the trial,0
LUMIZYME,anaphylactic reactions,trial due anaphylactic reactions,1
LUMIZYME,anaphylactic reactions,discontinued the trial due anaphylactic reactions,1
LUMIZYME,anaphylaxis,included,0
LUMIZYME,anaphylaxis,anaphylaxis which presented as angioedema throat,1
LUMIZYME,anaphylaxis,anaphylaxis which,1
LUMIZYME,anaphylaxis,with alglucosidase alfa anaphylaxis which presented as angioedema throat,1
LUMIZYME,anaphylaxis,anaphylaxis which,1
LUMIZYME,anaphylaxis,anaphylaxis which presented as angioedema throat,1
LUMIZYME,anaphylaxis,alglucosidase alfa anaphylaxis which,1
LUMIZYME,anaphylaxis,anaphylaxis which presented as angioedema throat,1
LUMIZYME,anaphylaxis,which presented,0
LUMIZYME,anaphylaxis,paindiscomfort,0
LUMIZYME,angioedema,alfa,0
LUMIZYME,angioedema,angioedema throat tightness and,1
LUMIZYME,angioedema,angioedema throat tightness and chest paindiscomfort,1
LUMIZYME,angioedema,angioedema throat,1
LUMIZYME,angioedema,which presented angioedema,1
LUMIZYME,angioedema,angioedema throat,1
LUMIZYME,angioedema,angioedema throat tightness and chest paindiscomfort,1
LUMIZYME,angioedema,alfa included anaphylaxis,0
LUMIZYME,angioedema,angioedema,1
LUMIZYME,angioedema,anaphylaxis which presented angioedema throat tightness and chest paindiscomfort,1
LUMIZYME,angioedema,angioedema,1
LUMIZYME,throat tightness,which presented as throat tightness and chest paindiscomfort,1
LUMIZYME,throat tightness,angioedema,1
LUMIZYME,throat tightness,anaphylaxis which presented as throat tightness and chest paindiscomfort One patient,1
LUMIZYME,throat tightness,angioedema,1
LUMIZYME,chest pain,a serious,0
LUMIZYME,chest pain,tightness chest pain discomfort One patient with,1
LUMIZYME,chest pain,a serious,0
LUMIZYME,chest pain,history of WolffParkinsonWhite,0
LUMIZYME,chest pain,chest pain discomfort One patient,1
LUMIZYME,chest pain,throat tightness and,0
LUMIZYME,chest pain,of WolffParkinsonWhite syndrome experienced a serious,0
LUMIZYME,chest pain,chest,1
LUMIZYME,chest pain,and,0
LUMIZYME,chest pain,as angioedema throat tightness chest,1
LUMIZYME,supraventricular tachycardia,a serious adverse reaction supraventricular,1
LUMIZYME,supraventricular tachycardia,most common adverse reactions,0
LUMIZYME,hypersensitivity reactions,headache nausea urticaria,0
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions and included anaphylaxis,1
LUMIZYME,anaphylaxis,and anaphylaxis headache nausea,1
LUMIZYME,anaphylaxis,hypersensitivity reactions and included anaphylaxis,1
LUMIZYME,anaphylaxis,anaphylaxis headache,1
LUMIZYME,anaphylaxis,nausea,0
LUMIZYME,anaphylaxis,nausea urticaria dizziness chest discomfort vomiting hyperhidrosis flushingfeelin,0
LUMIZYME,anaphylaxis,hypersensitivity reactions,0
LUMIZYME,anaphylaxis,anaphylaxis headache,1
LUMIZYME,anaphylaxis,anaphylaxis headache nausea urticaria dizziness chest,1
LUMIZYME,anaphylaxis,anaphylaxis headache,1
LUMIZYME,anaphylaxis,anaphylaxis headache nausea,1
LUMIZYME,anaphylaxis,hypersensitivity reactions and included,0
LUMIZYME,anaphylaxis,dizziness,0
LUMIZYME,headache,anaphylaxis,0
LUMIZYME,headache,reactions and,0
LUMIZYME,headache,headache nausea urticaria dizziness,1
LUMIZYME,headache,reactions and,0
LUMIZYME,dizziness,included anaphylaxis headache nausea dizziness chest discomfort,1
LUMIZYME,dizziness,reactions and,0
LUMIZYME,dizziness,dizziness chest discomfort vomiting,1
LUMIZYME,dizziness,dizziness chest discomfort vomiting hyperhidrosis flushingfeeling,1
LUMIZYME,chest discomfort,nausea urticaria chest discomfort vomiting hyperhidrosis flushingfeeling,1
LUMIZYME,chest discomfort,dizziness chest discomfort vomiting hyperhidrosis flushingfeeling,1
LUMIZYME,chest discomfort,hypersensitivity reactions and included anaphylaxis headache nausea,0
LUMIZYME,chest discomfort,urticaria chest discomfort vomiting hyperhidrosis flushingfeeling hot increased,1
LUMIZYME,chest discomfort,hypersensitivity reactions and included anaphylaxis headache nausea,0
LUMIZYME,chest discomfort,chest discomfort vomiting hyperhidrosis flushingfeeling,1
LUMIZYME,chest discomfort,chest discomfort vomiting hyperhidrosis flushingfeeling hot,1
LUMIZYME,chest discomfort,nausea urticaria chest discomfort,1
LUMIZYME,vomiting,pressure paresthesia pyrexia,0
LUMIZYME,vomiting,vomiting,1
LUMIZYME,vomiting,vomiting hyperhidrosis flushingfeeling hot increased blood,1
LUMIZYME,vomiting,vomiting,1
LUMIZYME,hyperhidrosis,nausea,0
LUMIZYME,hyperhidrosis,discomfort hyperhidrosis flushingfeeling hot increased,1
LUMIZYME,hyperhidrosis,nausea,0
LUMIZYME,hyperhidrosis,hyperhidrosis flushingfeeling hot increased blood,1
LUMIZYME,hyperhidrosis,dizziness chest,0
LUMIZYME,hyperhidrosis,hyperhidrosis flushingfeeling,1
LUMIZYME,flushing,flushing feeling hot,1
LUMIZYME,flushing,flushing feeling,1
LUMIZYME,flushing,flushing feeling,1
LUMIZYME,flushing,dizziness chest,0
LUMIZYME,flushing,flushing,1
LUMIZYME,flushing,flushing feeling,1
LUMIZYME,flushing,anaphylaxis headache nausea urticaria dizziness chest discomfort,0
LUMIZYME,feeling hot,chest discomfort vomiting hyperhidrosis feeling hot,1
LUMIZYME,feeling hot,vomiting hyperhidrosis feeling,1
LUMIZYME,feeling hot,chest discomfort vomiting hyperhidrosis feeling,1
LUMIZYME,feeling hot,vomiting hyperhidrosis feeling hot,1
LUMIZYME,feeling hot,vomiting hyperhidrosis feeling hot increased blood pressure paresthesia,1
LUMIZYME,feeling hot,vomiting hyperhidrosis feeling hot,1
LUMIZYME,increased blood pressure,flushingfeeling increased blood pressure,1
LUMIZYME,increased blood pressure,vomiting hyperhidrosis feeling hot,1
LUMIZYME,increased blood pressure,blood pressure paresthesia,1
LUMIZYME,increased blood pressure,and throat,0
LUMIZYME,increased blood pressure,hyperhidrosis flushingfeeling increased blood pressure paresthesia pyrexia local,1
LUMIZYME,increased blood pressure,and throat,0
LUMIZYME,increased blood pressure,hyperhidrosis flushingfeeling increased blood pressure paresthesia pyrexia,1
LUMIZYME,increased blood pressure,and throat,0
LUMIZYME,increased blood pressure,chest discomfort vomiting hyperhidrosis,0
LUMIZYME,paresthesia,paresthesia pyrexia,1
LUMIZYME,paresthesia,paresthesia pyrexia,1
LUMIZYME,paresthesia,increased blood paresthesia pyrexia local swelling,1
LUMIZYME,paresthesia,paresthesia pyrexia,1
LUMIZYME,paresthesia,paresthesia,1
LUMIZYME,paresthesia,paresthesia pyrexia local swelling diarrhea,1
LUMIZYME,paresthesia,paresthesia pyrexia local swelling diarrhea pruritus,1
LUMIZYME,paresthesia,pruritus rash and throat tightness Delayedonset,0
LUMIZYME,paresthesia,discomfort vomiting hyperhidrosis flushingfeeling,0
LUMIZYME,paresthesia,paresthesia,1
LUMIZYME,paresthesia,blood paresthesia pyrexia local,1
LUMIZYME,paresthesia,paresthesia,1
LUMIZYME,pyrexia,pyrexia local swelling,1
LUMIZYME,pyrexia,pressure pyrexia local,1
LUMIZYME,pyrexia,pyrexia local swelling,1
LUMIZYME,local swelling,local swelling diarrhea pruritus,1
LUMIZYME,local swelling,local swelling diarrhea pruritus rash and,1
LUMIZYME,local swelling,paresthesia local swelling,1
LUMIZYME,local swelling,local swelling diarrhea pruritus rash and,1
LUMIZYME,local swelling,local swelling diarrhea,1
LUMIZYME,local swelling,increased blood pressure paresthesia local swelling diarrhea pruritus rash and throat,1
LUMIZYME,local swelling,local swelling diarrhea,1
LUMIZYME,local swelling,local swelling diarrhea pruritus,1
LUMIZYME,local swelling,local swelling diarrhea,1
LUMIZYME,local swelling,local swelling diarrhea pruritus rash and throat,1
LUMIZYME,pruritus,hot increased,0
LUMIZYME,pruritus,Delayedonset reactions defined as,0
LUMIZYME,pruritus,paresthesia pyrexia local swelling pruritus,1
LUMIZYME,pruritus,Delayedonset reactions defined as,0
LUMIZYME,pruritus,reactions defined,0
LUMIZYME,pruritus,Delayedonset reactions defined as adverse reactions occurring,0
LUMIZYME,rash,rash and throat tightness Delayedonset,1
LUMIZYME,rash,rash and throat,1
LUMIZYME,rash,rash and throat tightness,1
LUMIZYME,throat tightness,swelling diarrhea pruritus rash throat tightness,1
LUMIZYME,throat tightness,rash and throat tightness,1
LUMIZYME,throat tightness,throat tightness Delayedonset reactions,1
LUMIZYME,throat tightness,rash and throat tightness,1
LUMIZYME,throat tightness,paresthesia pyrexia local swelling,0
LUMIZYME,throat tightness,throat tightness Delayedonset reactions defined as,1
LUMIZYME,throat tightness,diarrhea pruritus rash,0
LUMIZYME,hyperhidrosis,the controlled trial hyperhidrosis Additional delayedonset reactions occurring in,1
LUMIZYME,hyperhidrosis,diarrhea pruritus rash,0
LUMIZYME,hyperhidrosis,hyperhidrosis Additional,1
LUMIZYME,hyperhidrosis,hyperhidrosis Additional,1
LUMIZYME,hyperhidrosis,hyperhidrosis Additional delayedonset reactions occurring in,1
LUMIZYME,fatigue,delayedonset reactions occurring in alglucosidase,0
LUMIZYME,fatigue,in alglucosidase alfatreated patients fatigue myalgia and nausea,1
LUMIZYME,fatigue,delayedonset reactions occurring in alglucosidase,0
LUMIZYME,fatigue,delayedonset,0
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,fatigue myalgia and nausea,1
LUMIZYME,fatigue,in alglucosidase,0
LUMIZYME,fatigue,about the,0
LUMIZYME,fatigue,fatigue,1
LUMIZYME,fatigue,fatigue myalgia and nausea,1
LUMIZYME,fatigue,fatigue myalgia and nausea Patients,1
LUMIZYME,myalgia,possibility of delayedonset hypersensitivity r,0
LUMIZYME,nausea,nausea Patients should be counseled about,1
LUMIZYME,nausea,of delayedonset hypersensitivity reactions and,0
LUMIZYME,anaphylaxis,anaphylaxis and hypersensitivity,1
LUMIZYME,anaphylaxis,anaphylaxis and hypersensitivity reactions,1
LUMIZYME,anaphylaxis,infusion interruption decreased infusion,0
LUMIZYME,anaphylaxis,anaphylaxis and hypersensitivity reactions,1
LUMIZYME,anaphylaxis,clinical trials,0
LUMIZYME,anaphylaxis,anaphylaxis,1
LUMIZYME,anaphylaxis,anaphylaxis and hypersensitivity reactions were managed,1
LUMIZYME,anaphylaxis,trials,0
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions were,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions were managed with infusion,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions were,1
LUMIZYME,hypersensitivity reactions,In clinical trials anaphylaxis hypersensitivity reactions were managed with infusion,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions were,1
LUMIZYME,hypersensitivity reactions,trials anaphylaxis and,0
LUMIZYME,hypersensitivity reactions,infusion rate administration of,0
LUMIZYME,IgG antibody titers with inhibitory activity,IgG antibody titers with inhibitory activity Alglucosidase alfatreated,1
LUMIZYME,IgG antibody titers with inhibitory activity,infusion rate administration of,0
LUMIZYME,IgG antibody titers with inhibitory activity,inhibitory activity Alglucosidase alfatreated,1
LUMIZYME,IgG antibody titers with inhibitory activity,presence of high IgG,1
LUMIZYME,IgG antibody titers with inhibitory activity,decrease in motor function should be,0
LUMIZYME,IgG antibody titers with inhibitory activity,the presence of high IgG antibody titers with inhibitory,1
LUMIZYME,IgG antibody titers with inhibitory activity,sustained,0
LUMIZYME,recurrent hypersensitivity reactions,to severe recurrent hypersensitivity reactions for which,1
LUMIZYME,recurrent hypersensitivity reactions,sustained,0
LUMIZYME,recurrent hypersensitivity reactions,for which mastcell activation was suspected Some of the patients who tested positive for,0
LUMIZYME,recurrent hypersensitivity reactions,hypersensitivity reactions for which mastcell activation,1
LUMIZYME,recurrent hypersensitivity reactions,hypersensitivity reactions for which,1
LUMIZYME,recurrent hypersensitivity reactions,recurrent hypersensitivity reactions for which mastcell activation,1
LUMIZYME,recurrent hypersensitivity reactions,hypersensitivity reactions for which,1
LUMIZYME,recurrent hypersensitivity reactions,experienced moderate to severe recurrent hypersensitivity,1
LUMIZYME,recurrent hypersensitivity reactions,recurrent hypersensitivity reactions for which mastcell,1
LUMIZYME,recurrent hypersensitivity reactions,moderate to severe,0
LUMIZYME,recurrent hypersensitivity reactions,hypersensitivity reactions for which mastcell activation was,1
LUMIZYME,hypersensitivity reactions,hypersensitivity,1
LUMIZYME,hypersensitivity reactions,moderate to severe or hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,to severe or hypersensitivity reactions for which mastcell activation,1
LUMIZYME,hypersensitivity reactions,moderate to severe or hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,patients,0
LUMIZYME,anaphylactic reactions,alglucosidase alfaspecific IgE antibodies anaphylactic reactions seeBoxed,1
LUMIZYME,anaphylactic reactions,patients,0
LUMIZYME,anaphylactic reactions,anaphylactic reactions,1
LUMIZYME,anaphylactic reactions,anaphylactic reactions seeBoxed WarningandWarnings,1
LUMIZYME,anaphylactic reactions,anaphylactic reactions seeBoxed WarningandWarnings,1
LUMIZYME,anaphylactic reactions,IgE antibodies anaphylactic reactions seeBoxed WarningandWarnings and,1
LUMIZYME,anaphylactic reactions,anaphylactic reactions seeBoxed WarningandWarnings,1
LUMIZYME,anaphylactic reactions,anaphylactic reactions seeBoxed WarningandWarnings,1
LUMIZYME,anaphylactic reactions,the patients who tested positive for alglucosidase alfaspecific IgE antibodies experienced,0
LUMIZYME,hypersensitivity reactions,using a slower infusion rate at,0
LUMIZYME,hypersensitivity reactions,alfaspecific IgE antibodies and hypersensitivity reactions were able to,1
LUMIZYME,hypersensitivity reactions,using a slower infusion rate at,0
LUMIZYME,hypersensitivity reactions,alfa using a slower infusion rate at lower,0
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions,1
LUMIZYME,anaphylaxis,anaphylaxis seeBoxed WarningandWarnings and,1
LUMIZYME,anaphylaxis,anaphylaxis seeBoxed WarningandWarnings,1
LUMIZYME,Acute cardiorespiratory failure,Acute cardiorespiratory failure possibly,1
LUMIZYME,Acute cardiorespiratory failure,in infantileonset Pompe disease patien,0
LUMIZYME,Acute cardiorespiratory failure,cardiorespiratory failure possibly associated with,1
LUMIZYME,Acute cardiorespiratory failure,Acute cardiorespiratory failure possibly associated with,1
LUMIZYME,Acute cardiorespiratory failure,cardiorespiratory failure possibly associated with,1
LUMIZYME,Acute cardiorespiratory failure,infantileonset Pompe disease,0
LUMIZYME,Acute cardiorespiratory failure,anaphylaxis seeBoxed WarningandWarnings and Acute cardiorespiratory failure possibly associated with fluid,1
LUMIZYME,Acute cardiorespiratory failure,infantileonset Pompe disease,0
LUMIZYME,Acute cardiorespiratory failure,WarningandWarnings and Acute,1
LUMIZYME,Acute cardiorespiratory failure,WarningandWarnings and Acute cardiorespiratory failure,1
LUMIZYME,Acute cardiorespiratory failure,WarningandWarnings and Acute,1
LUMIZYME,Acute cardiorespiratory failure,in infantileonset Pompe,0
LUMIZYME,fluid overload,with,0
LUMIZYME,fluid overload,patients with preexisting hypertrophic cardiom,0
LUMIZYME,fluid overload,fluid overload has,1
LUMIZYME,fluid overload,cardiorespiratory failure possibly associated fluid overload has been reported,1
LUMIZYME,fluid overload,fluid overload has,1
LUMIZYME,fluid overload,failure possibly associated fluid overload has been,1
LUMIZYME,fluid overload,fluid overload has,1
LUMIZYME,flu-like illness,seeBoxed WarningandWarning and Precautions Recurrent reactions,0
LUMIZYME,flu-like illness,Recurrent reactions consisting flu-like illness or a combination,1
LUMIZYME,flu-like illness,seeBoxed WarningandWarning and Precautions Recurrent reactions,0
LUMIZYME,flu-like illness,flu-like illness or a combination,1
LUMIZYME,flu-like illness,seeBoxed WarningandWarning and Precautions Recurrent reactions,0
LUMIZYME,flu-like illness,flu-like illness or a,1
LUMIZYME,flu-like illness,seeBoxed WarningandWarning and Precautions Recurrent reactions,0
LUMIZYME,flu-like illness,flu-like illness or a,1
LUMIZYME,flu-like illness,flu-like,1
LUMIZYME,pyrexia,pyrexia chills,1
LUMIZYME,pyrexia,pyrexia chills myalgia arthralgia pain or,1
LUMIZYME,pyrexia,pyrexia chills myalgia arthralgia pain,1
LUMIZYME,pyrexia,after completion of infusions,0
LUMIZYME,chills,consisting of flulike illness or a combination of events,0
LUMIZYME,chills,chills myalgia arthralgia pain,1
LUMIZYME,chills,consisting of flulike illness or a combination of events,0
LUMIZYME,chills,chills myalgia arthralgia pain or fatigue,1
LUMIZYME,chills,events such,0
LUMIZYME,chills,arthralgia pain or fatigue occurring after completion of,0
LUMIZYME,chills,chills myalgia,1
LUMIZYME,chills,infusions and,0
LUMIZYME,myalgia,fatigue occurring after,0
LUMIZYME,myalgia,myalgia arthralgia,1
LUMIZYME,myalgia,such as pyrexia chills,0
LUMIZYME,myalgia,occurring after completion of infusions and lasting,0
LUMIZYME,myalgia,flulike illness or a combination of events such as,0
LUMIZYME,myalgia,myalgia arthralgia pain or fatigue occurring,1
LUMIZYME,myalgia,flulike illness or a combination of events such as,0
LUMIZYME,myalgia,urrent reactions consisting of flulike illness or,0
LUMIZYME,arthralgia,occurring after completion of infusions and lasting usually for days have b,0
LUMIZYME,arthralgia,chills arthralgia,1
LUMIZYME,arthralgia,occurring after completion of infusions and lasting usually for days have b,0
LUMIZYME,arthralgia,arthralgia pain or,1
LUMIZYME,arthralgia,arthralgia pain or fatigue occurring,1
LUMIZYME,arthralgia,arthralgia pain or,1
LUMIZYME,arthralgia,arthralgia pain or,1
LUMIZYME,arthralgia,arthralgia,1
LUMIZYME,arthralgia,for days have b,0
LUMIZYME,arthralgia,after completion of infusions,0
LUMIZYME,arthralgia,arthralgia,1
LUMIZYME,pain,pain,1
LUMIZYME,pain,have been ob,0
LUMIZYME,pain,as pyrexia chills myalgia pain or fatigue occurring,1
LUMIZYME,pain,have been ob,0
LUMIZYME,pain,events such as,0
LUMIZYME,pain,as pyrexia chills myalgia pain,1
LUMIZYME,pain,events such as,0
LUMIZYME,pain,pyrexia chills myalgia arthralgia,0
LUMIZYME,pain,or fatigue occurring after completion of infusions and lasting usually,0
LUMIZYME,pain,pain or,1
LUMIZYME,pain,chills myalgia pain or fatigue occurring after completion,1
LUMIZYME,pain,pain or,1
LUMIZYME,pain,pain or fatigue occurring after,1
LUMIZYME,fatigue,fatigue occurring,1
LUMIZYME,fatigue,such as pyrexia chills myalgia,0
LUMIZYME,hypersensitivity reactions,in clinical trials seeAdverse Reactions the following hypersensitivity reactio,0
LUMIZYME,hypersensitivity reactions,in clinical trials seeAdverse Reactions the following hypersensitivity reactio,0
LUMIZYME,hypersensitivity reactions,and,0
LUMIZYME,hypersensitivity reactions,In addition to,0
LUMIZYME,hypersensitivity reactions,addition to hypersensitivity,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions reported in clinical trials seeAdverse,1
LUMIZYME,hypersensitivity reactions,In addition to hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,to the,0
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions reported,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions reported,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions have been reported,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions reported,1
LUMIZYME,hypersensitivity reactions,trials seeAdverse Reactions the hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,hypersensitivity reactions reported,1
LUMIZYME,hypersensitivity reactions,Reactions the hypersensitivity reactions,1
LUMIZYME,hypersensitivity reactions,trials seeAdverse Reactions the,0
LUMIZYME,hypersensitivity reactions,have been reported in at,0
LUMIZYME,hypersensitivity reactions,the hypersensitivity reactions have,1
LUMIZYME,hypersensitivity reactions,have been reported in at,0
LUMIZYME,anaphylactic shock,at least patients and anaphylactic shock,1
LUMIZYME,anaphylactic shock,and anaphylactic shock respiratory failure respiratory,1
LUMIZYME,anaphylactic shock,at least patients and anaphylactic shock,1
LUMIZYME,respiratory failure,patients and included anaphylactic respiratory failure,1
LUMIZYME,respiratory failure,at least patients and anaphylactic shock,1
LUMIZYME,respiratory failure,anaphylactic respiratory failure,1
LUMIZYME,respiratory failure,respiratory failure respiratory,1
LUMIZYME,respiratory failure,anaphylactic respiratory failure,1
LUMIZYME,respiratory failure,respiratory failure respiratory,1
LUMIZYME,respiratory arrest,anaphylactic shock respiratory respiratory arrest,1
LUMIZYME,respiratory arrest,anaphylactic shock respiratory respiratory arrest cardiac arrest hypoxia,1
LUMIZYME,respiratory arrest,anaphylactic shock respiratory respiratory arrest,1
LUMIZYME,respiratory arrest,shock respiratory respiratory arrest,1
LUMIZYME,respiratory arrest,anaphylactic shock respiratory respiratory arrest,1
LUMIZYME,respiratory arrest,have been reported in at least patients and,0
LUMIZYME,respiratory arrest,respiratory respiratory arrest cardiac arrest hypoxia,1
LUMIZYME,respiratory arrest,have been reported in at least patients and,0
LUMIZYME,respiratory arrest,respiratory arrest cardiac arrest,1
LUMIZYME,respiratory arrest,cardiac arrest hypoxia dyspnea wheezing convulsions peripheral coldness restlessness nervou,0
LUMIZYME,respiratory arrest,arrest hypoxia dyspnea wheezing convulsions peripheral coldness,0
LUMIZYME,respiratory arrest,included anaphylactic shock respiratory respiratory,1
LUMIZYME,cardiac arrest,dyspnea wheezing convulsions,0
LUMIZYME,cardiac arrest,respiratory cardiac,1
LUMIZYME,cardiac arrest,wheezing convulsions,0
LUMIZYME,cardiac arrest,cardiac arrest hypoxia dyspnea wheezing convulsions peripheral,1
LUMIZYME,cardiac arrest,failure respiratory cardiac arrest,1
LUMIZYME,cardiac arrest,in at least,0
LUMIZYME,cardiac arrest,shock respiratory failure respiratory cardiac arrest hypoxia dyspnea wheezing,1
LUMIZYME,cardiac arrest,in at least,0
LUMIZYME,cardiac arrest,least patients and included,0
LUMIZYME,cardiac arrest,cardiac arrest hypoxia dyspnea wheezing,1
LUMIZYME,hypoxia,hypoxia dyspnea wheezing convulsions peripheral,1
LUMIZYME,hypoxia,hypoxia dyspnea wheezing convulsions peripheral coldness,1
LUMIZYME,hypoxia,arrest cardiac arrest,0
LUMIZYME,dyspnea,dyspnea,1
LUMIZYME,convulsions,convulsions,1
LUMIZYME,convulsions,cardiac arrest hypoxia,0
LUMIZYME,convulsions,pain,0
LUMIZYME,convulsions,convulsions peripheral coldness restlessness nervousness,1
LUMIZYME,peripheral coldness,peripheral coldness restlessness nervousness back,1
LUMIZYME,peripheral coldness,arrest hypoxia dyspnea wheezing peripheral coldness restlessness nervousness,1
LUMIZYME,peripheral coldness,peripheral coldness restlessness nervousness back,1
LUMIZYME,restlessness,restlessness nervousness back,1
LUMIZYME,restlessness,back pain stridor pharyngeal edema abdominal pain apnea muscle spasm and,0
LUMIZYME,restlessness,restlessness nervousness back pain stridor,1
LUMIZYME,restlessness,nervousness back pain,0
LUMIZYME,restlessness,restlessness nervousness,1
LUMIZYME,restlessness,restlessness nervousness back pain stridor,1
LUMIZYME,restlessness,respiratory arrest,0
LUMIZYME,restlessness,peripheral restlessness nervousness back,1
LUMIZYME,restlessness,respiratory arrest,0
LUMIZYME,nervousness,cardiac arrest hypoxia dyspnea wheezing convulsions,0
LUMIZYME,nervousness,peripheral coldness nervousness back pain stridor,1
LUMIZYME,nervousness,cardiac arrest hypoxia dyspnea wheezing convulsions,0
LUMIZYME,nervousness,nervousness back,1
LUMIZYME,back pain,coldness restlessness back pain,1
LUMIZYME,back pain,nervousness back,1
LUMIZYME,back pain,back pain stridor pharyngeal edema abdominal,1
LUMIZYME,back pain,pharyngeal edema abdominal pain apnea muscle spasm and conjunctivitis,0
LUMIZYME,back pain,stridor pharyngeal edema abdominal pain apnea muscle spasm,0
LUMIZYME,back pain,arrest hypoxia dyspnea wheezing convulsions peripheral,0
LUMIZYME,back pain,apnea muscle spasm and conjunctivitis In addition,0
LUMIZYME,back pain,apnea muscle spasm and,0
LUMIZYME,stridor,nervousness back,0
LUMIZYME,stridor,stridor,1
LUMIZYME,stridor,stridor pharyngeal edema abdominal,1
LUMIZYME,stridor,stridor pharyngeal edema abdominal pain,1
LUMIZYME,pharyngeal edema,back pain pharyngeal,1
LUMIZYME,pharyngeal edema,pharyngeal edema abdominal pain apnea,1
LUMIZYME,pharyngeal edema,pharyngeal edema abdominal pain apnea muscle,1
LUMIZYME,pharyngeal edema,pain,0
LUMIZYME,pharyngeal edema,dyspnea wheezing convulsions peripheral coldness restlessness nervousness back,0
LUMIZYME,pharyngeal edema,pharyngeal edema,1
LUMIZYME,pharyngeal edema,conjunctivitis In addition one case of,0
LUMIZYME,abdominal pain,of,0
LUMIZYME,abdominal pain,abdominal pain apnea muscle,1
LUMIZYME,abdominal pain,convulsions peripheral coldness restlessness nervousness,0
LUMIZYME,apnea,In addition one case of hyperparathyroidism has been reported,0
LUMIZYME,apnea,apnea muscle spasm and conjunctivitis,1
LUMIZYME,apnea,In addition one case of hyperparathyroidism has been reported,0
LUMIZYME,apnea,nervousness back pain stridor,0
LUMIZYME,apnea,abdominal,0
LUMIZYME,apnea,apnea muscle,1
LUMIZYME,conjunctivitis,conjunctivitis In addition one,1
LUMIZYME,conjunctivitis,conjunctivitis,1
LUMIZYME,conjunctivitis,conjunctivitis In,1
LUMIZYME,conjunctivitis,conjunctivitis In,1
LUMIZYME,conjunctivitis,abdominal pain apnea muscle spasm,0
LUMIZYME,conjunctivitis,pain apnea muscle,0
LUMIZYME,conjunctivitis,conjunctivitis In addition one,1
LUMIZYME,conjunctivitis,conjunctivitis,1
LUMIZYME,conjunctivitis,conjunctivitis In addition one,1
LUMIZYME,conjunctivitis,conjunctivitis In addition,1
LUMIZYME,hyperparathyroidism,hyperparathyroidism has been reported Systemic,1
LUMIZYME,hyperparathyroidism,hyperparathyroidism,1
LUMIZYME,proteinuria,necrotizing skin lesions,0
LUMIZYME,proteinuria,erparathyroidism has been reported Systemic and,0
LUMIZYME,proteinuria,proteinuria and nephrotic,1
LUMIZYME,proteinuria,proteinuria,1
LUMIZYME,proteinuria,and cutaneous immunemediated reactions proteinuria and nephrotic syndrome,1
LUMIZYME,proteinuria,proteinuria,1
LUMIZYME,proteinuria,membranous glomerulonephritis,0
LUMIZYME,proteinuria,Systemic,0
LUMIZYME,proteinuria,immunemediated reactions proteinuria and nephrotic syndrome,1
LUMIZYME,proteinuria,Systemic,0
LUMIZYME,proteinuria,skin lesions,0
LUMIZYME,proteinuria,reactions proteinuria and nephrotic syndrome secondary to,1
LUMIZYME,proteinuria,skin lesions,0
LUMIZYME,nephrotic syndrome,proteinuria,0
LUMIZYME,nephrotic syndrome,including proteinuria nephrotic,1
LUMIZYME,nephrotic syndrome,nephrotic syndrome secondary,1
LUMIZYME,nephrotic syndrome,nephrotic syndrome secondary,1
LUMIZYME,nephrotic syndrome,nephrotic syndrome secondary,1
LUMIZYME,nephrotic syndrome,to membranous glomerulonephritis and necrotizing skin lesions have been reported,0
LUMIZYME,nephrotic syndrome,nephrotic syndrome secondary to membranous glomerulonephritis,1
LUMIZYME,nephrotic syndrome,nephrotic syndrome secondary to,1
LUMIZYME,membranous glomerulonephritis,membranous glomerulonephritis and necrotizing skin,1
LUMIZYME,membranous glomerulonephritis,and nephrotic syndrome secondary membranous,1
LUMIZYME,membranous glomerulonephritis,postmarketing safety,0
LUMIZYME,membranous glomerulonephritis,syndrome secondary to,0
LUMIZYME,membranous glomerulonephritis,necrotizing skin lesions have been reported in postmarketing safety experience with alglucosid,0
LUMIZYME,membranous glomerulonephritis,membranous glomerulonephritis and necrotizing skin lesions have,1
LUMIZYME,membranous glomerulonephritis,syndrome secondary membranous glomerulonephritis,1
LUMIZYME,membranous glomerulonephritis,membranous glomerulonephritis and necrotizing skin lesions have,1
LUMIZYME,membranous glomerulonephritis,and nephrotic syndrome secondary membranous glomerulonephritis and necrotizing skin,1
LUMIZYME,membranous glomerulonephritis,membranous glomerulonephritis and necrotizing skin lesions have,1
LUMIZYME,necrotizing skin lesions,membranous glomerulonephritis necrotizing skin lesions,1
LUMIZYME,necrotizing skin lesions,to membranous glomerulonephritis necrotizing skin lesions have been reported in postmarketing,1
LUMIZYME,necrotizing skin lesions,membranous glomerulonephritis necrotizing skin lesions,1
LUMIZYME,necrotizing skin lesions,secondary to membranous glomerulonephritis necrotizing skin,1
LUMIZYME,ANAPHYLAXIS, *  The mos t,1
LUMIZYME,ANAPHYLAXIS,secondary to membranous glomerulonephritis necrotizing skin,1
LUMIZYME,ANAPHYLAXIS,clinical trials were hypersensitivity,0
LUMIZYME,ANAPHYLAXIS,ADVERSE REACTIONS *,1
LUMIZYME,ANAPHYLAXIS,REACTIONS  *  The mos t frequently reported adverse,1
LUMIZYME,ANAPHYLAXIS,ADVERSE REACTIONS *,1
LUMIZYME,ANAPHYLAXIS,* The mos,1
LUMIZYME,ANAPHYLAXIS,ADVERSE REACTIONS  *  The mos t frequently reported adverse,1
LUMIZYME,ANAPHYLAXIS,* The mos,1
LUMIZYME,ANAPHYLAXIS,ADVERSE REACTIONS * The mos,1
LUMIZYME,ANAPHYLAXIS,REACTIONS EXCERPT,0
LUMIZYME,ANAPHYLAXIS,* The mos,1
LUMIZYME,HYPERSENSITIVITY,ADVERSE REACTIONS EXCERPT,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,trials,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,dverse reactions (>= 5%) in clinical trials were hypersensitivity,1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,The most frequently reported,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,frequently reported dverse,1
LUMIZYME,ANAPHYLAXIS,reactions and : anaphylax is rash pyrexia flushingfeeling,1
LUMIZYME,ANAPHYLAXIS,frequently reported dverse,1
LUMIZYME,ANAPHYLAXIS,adverse reactions in clinical trials were hypersensitivity reactions,0
LUMIZYME,ANAPHYLAXIS,y reported adverse reactions,0
LUMIZYME,ANAPHYLAXIS,were hypersensitivity reactions and :,1
LUMIZYME,ANAPHYLAXIS,hypersensitivity reactions and : anaphylax is rash pyrexia flushingfeeling,1
LUMIZYME,ANAPHYLAXIS,were hypersensitivity reactions and :,1
LUMIZYME,ANAPHYLAXIS,: anaphylax is rash pyrexia flushingfeeling hot,1
LUMIZYME,HYPERSENSITIVITY,hyperhidrosis nausea cough decreased oxygen saturatio,0
LUMIZYME,HYPERSENSITIVITY,urticaria headache hyperhidrosis nausea cough decreased oxygen,0
LUMIZYME,HYPERSENSITIVITY,hypersensitivity reactions,0
LUMIZYME,HYPERSENSITIVITY,"rash, pyrexia, flushingfeeling hot urticaria headache hyperhidrosis",1
LUMIZYME,HYPERSENSITIVITY,headache hyperhidrosis nausea,0
LUMIZYME,HYPERSENSITIVITY,", rash, pyrexia, flushingfeeling hot",1
LUMIZYME,HYPERSENSITIVITY,"included , rash, pyrexia, flushingfeeling hot urticaria headache hyperhidrosis",1
LUMIZYME,HYPERSENSITIVITY,", rash, pyrexia, flushingfeeling hot",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hing/feeling hot, urticar ia headache",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,", rash, pyrexia, flushingfeeling hot",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,clinical trials were hypersensitivity reactions and included,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hing/feeling hot, urticar",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,decreased oxygen,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,pyrexia flus,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,rash pyrexia hing/feeling,1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,rash pyrexia hing/feeling,1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,headache hyperhidrosis nausea cough decreased oxygen saturation,0
LUMIZYME,hypersensitivity reactions,tachypnea,0
LUMIZYME,hypersensitivity reactions,"st discomfort, dizziness,  muscle twitching agitation",1
LUMIZYME,hypersensitivity reactions,tachypnea,0
LUMIZYME,hypersensitivity reactions,saturation tachycardia tachypnea st,1
LUMIZYME,hypersensitivity reactions,hypertensionincreased blood pressure pallor rigo,0
LUMIZYME,hypersensitivity reactions,"st discomfort, dizziness, muscle twitching agitation cyanosis",1
LUMIZYME,hypersensitivity reactions,hypertensionincreased blood pressure pallor,0
LUMIZYME,hypersensitivity reactions,"st discomfort, dizziness, muscle twitching agitation cyanosis erythema",1
LUMIZYME,respiratory distress,"discomfort dizziness muscle , agitation, cyanosi s erythema",1
LUMIZYME,respiratory distress,"st discomfort, dizziness, muscle twitching agitation cyanosis erythema",1
LUMIZYME,respiratory distress,tremor vomiting,0
LUMIZYME,respiratory distress,"discomfort dizziness muscle , agitation, cyanosi s erythema hypertensionincreased blood pressure",1
LUMIZYME,respiratory distress,tremor vomiting,0
LUMIZYME,respiratory distress,"dizziness muscle , agitation, cyanosi",1
LUMIZYME,respiratory distress,twitching,0
LUMIZYME,respiratory distress,", agitation,",1
LUMIZYME,respiratory distress,pressure pallor rigors tremor vomiting fatigue and m,0
LUMIZYME,respiratory distress,"dizziness muscle , agitation, cyanosi",1
LUMIZYME,hypoxia,chest discomfort dizziness muscle twitching,0
LUMIZYME,apnea,"twitching agitation cyanosis , hyp",1
LUMIZYME,dyspnea,cyanosis erythema tension,1
LUMIZYME,dyspnea,"twitching agitation cyanosis , hyp",1
LUMIZYME,dyspnea,agitation cyanosis,0
LUMIZYME,bradycardia,ncreased bl ood,1
LUMIZYME,bradycardia,agitation cyanosis,0
LUMIZYME,bradycardia,ncreased bl,1
LUMIZYME,bradycardia,agitation cyanosis,0
LUMIZYME,bradycardia,tremor vomiting fatigue,0
LUMIZYME,bradycardia,chest discomfort dizziness muscle twitching agitation,0
LUMIZYME,bradycardia,rigors tremor vomiting fatigue and myalgia To report SUSPECT,0
LUMIZYME,bronchospasm,"hypertensionincreased blood pressure allor, rigor",1
LUMIZYME,bronchospasm,"erythema hypertensionincreased blood pressure allor,",1
LUMIZYME,bronchospasm,s tremor vomiting fatigue and myalgia To report SUSPECTED ADVERSE REACTIONS,0
LUMIZYME,bronchospasm,"pressure allor,",1
LUMIZYME,bronchospasm,"allor, rigor s",1
LUMIZYME,bronchospasm,"pressure allor,",1
LUMIZYME,bronchospasm,agitation cyanosis erythema hypertensionincreased blood,0
LUMIZYME,bronchospasm,"hypertensionincreased blood pressure allor, rigor s tremor vomiting",1
LUMIZYME,bronchospasm,agitation cyanosis erythema hypertensionincreased blood,0
LUMIZYME,bronchospasm,and myalgia To,0
LUMIZYME,throat tightness,"hypertensionincreased blood pressure pallor  tremor, vomitin",1
LUMIZYME,throat tightness,and myalgia To,0
LUMIZYME,throat tightness,cyanosis erythema hypertensionincreased blood pressure,0
LUMIZYME,throat tightness,rigors,0
LUMIZYME,throat tightness,"blood pressure pallor tremor,",1
LUMIZYME,throat tightness,"blood pressure pallor tremor, vomitin",1
LUMIZYME,throat tightness,rigors,0
LUMIZYME,throat tightness,and myalgia To report SUSPECTED ADVERSE REACTIONS contact Genzyme at,0
LUMIZYME,hypotension,"pallor rigors tremor fatigue, a",1
LUMIZYME,hypotension,"pallor rigors tremor fatigue, a",1
LUMIZYME,hypotension,erythema,0
LUMIZYME,hypotension,"pressure pallor rigors tremor fatigue,",1
LUMIZYME,hypotension,"pressure pallor rigors tremor fatigue,",1
LUMIZYME,hypotension,"rigors tremor fatigue, a",1
LUMIZYME,hypotension,"pallor rigors tremor fatigue, a",1
LUMIZYME,hypotension,"fatigue, a nd myalgia To report",1
LUMIZYME,angioedema,contact Genzyme at,0
LUMIZYME,angioedema,fatigue  myalgia ( To,1
LUMIZYME,angioedema,contact Genzyme at,0
LUMIZYME,angioedema,myalgia (,1
LUMIZYME,angioedema,tremor vomiting fatigue  myalgia (,1
LUMIZYME,angioedema,myalgia (,1
LUMIZYME,angioedema,myalgia (,1
LUMIZYME,angioedema,myalgia ( To report,1
LUMIZYME,angioedema,ADVERSE REACTIONS contact Genzyme,0
LUMIZYME,angioedema,fatigue,0
LUMIZYME,angioedema,tremor vomiting fatigue  myalgia ( To report SUSPECTED ADVERSE REACTIONS,1
LUMIZYME,angioedema,fatigue,0
LUMIZYME,angioedema,REACTIONS contact Genzyme,0
LUMIZYME,lip swelling,DVERSE REACTIONS contact,0
LUMIZYME,lip swelling,eased blood,0
LUMIZYME,periorbital edema,at or FDA at FDA or wwwfdagovmedwatch Clin,0
LUMIZYME,periorbital edema,or FDA at FDA or wwwfdagovmedwatch Clin,0
LUMIZYME,periorbital edema,"ERSE REACTIONS, c",1
LUMIZYME,periorbital edema,rigors tremor vomiting fatigue and myalgia To report,0
LUMIZYME,periorbital edema,"myalgia To report SUSPECTED ERSE REACTIONS,",1
LUMIZYME,periorbital edema,"ERSE REACTIONS, c",1
LUMIZYME,periorbital edema,"myalgia To report SUSPECTED ERSE REACTIONS,",1
LUMIZYME,periorbital edema,"ERSE REACTIONS, c ontact Genzyme",1
LUMIZYME,periorbital edema,FDA or wwwfdagovmedwatch,0
LUMIZYME,periorbital edema,vomiting fatigue and myalgia To report SUSPECTED ADV,0
LUMIZYME,periorbital edema,"SUSPECTED ERSE REACTIONS, c ontact Genzyme at or FDA",1
LUMIZYME,periorbital edema,vomiting fatigue and myalgia To report SUSPECTED ADV,0
LUMIZYME,face edema,at FDA,0
LUMIZYME,face edema,ADVERSE REACTIONS Genzyme a,1
LUMIZYME,face edema, Genzyme a t or FDA at FDA,1
LUMIZYME,face edema,ADVERSE REACTIONS Genzyme a,1
LUMIZYME,Immune-mediated reactions,"wwwfdagovmedwatch Clinical Trials xperience

  Because clin ical trials are conducted",1
LUMIZYME,Immune-mediated reactions,ADVERSE REACTIONS Genzyme a,1
LUMIZYME,Immune-mediated reactions,"Trials xperience

  Because clin ical trials",1
LUMIZYME,Immune-mediated reactions,ADVERSE REACTIONS Genzyme a,1
LUMIZYME,Immune-mediated reactions,Trials xperience Because,1
LUMIZYME,Immune-mediated reactions,under widely varying conditions adverse reaction rates observed in the cl,0
LUMIZYME,Immune-mediated reactions,xperience Because clin ical trials are conducted under,1
LUMIZYME,Immune-mediated reactions,adverse,0
LUMIZYME,Immune-mediated reactions,or FDA at FDA or wwwfdagovmedwatch Clinical Trials E,0
LUMIZYME,Immune-mediated reactions,adverse reaction,0
LUMIZYME,Immune-mediated reactions,Because clin ical,1
LUMIZYME,Immune-mediated reactions,Clinical Trials xperience Because,1
LUMIZYME,proteinuria, conducted  under widely varying,1
LUMIZYME,proteinuria,of,0
LUMIZYME,proteinuria,clinical trials,0
LUMIZYME,proteinuria, conducted  under,1
LUMIZYME,proteinuria, conducted  under widely,1
LUMIZYME,nephrotic syndrome,Experience Because,0
LUMIZYME,necrotizing skin lesions,Clinical Trials Experience Because clinical trials are conducted under widely,0
LUMIZYME,necrotizing skin lesions,of a drug,0
LUMIZYME,necrotizing skin lesions,"conducted under widely varying tions, adverse reaction  rates observed in the clinical",1
LUMIZYME,necrotizing skin lesions,of a drug,0
LUMIZYME,necrotizing skin lesions,"tions, adverse reaction rates observed in",1
LUMIZYME,necrotizing skin lesions,clinical trials of a drug,0
LUMIZYME,necrotizing skin lesions,"tions, adverse reaction rates observed",1
LUMIZYME,fluid overload,"saturation achycardia,",1
LUMIZYME,fluid overload,shingfeeling hot,0
LUMIZYME,fluid overload,urticaria headache hyperhidrosis,0
LUMIZYME,fluid overload,"saturation achycardia, ta chypnea chest discomfort dizziness muscle",1
LUMIZYME,fluid overload,urticaria headache hyperhidrosis,0
LUMIZYME,fluid overload,"achycardia, ta chypnea",1
LUMIZYME,fluid overload,"achycardia, ta",1
LUMIZYME,ANAPHYLAXIS,blood p ressure pallor rigors tremor,1
LUMIZYME,ANAPHYLAXIS,fatigue and myalgia,0
LUMIZYME,ANAPHYLAXIS,erythema sed,1
LUMIZYME,ANAPHYLAXIS,cyanosis erythema hypertensionincrea,0
LUMIZYME,ANAPHYLAXIS,sed blood p ressure pallor rigors tremor vomiting,1
LUMIZYME,ANAPHYLAXIS,cyanosis erythema hypertensionincrea,0
LUMIZYME,HYPERSENSITIVITY,igors tremor vomiting fatigue and myalgia Clinical Trials,0
LUMIZYME,HYPERSENSITIVITY,omfort dizziness muscle twitching agitation cyanosis erythema,0
LUMIZYME,HYPERSENSITIVITY,"hypertensionincreased blood ssure, pallor, r",1
LUMIZYME,HYPERSENSITIVITY,"blood ssure, pallor, r igors",1
LUMIZYME,HYPERSENSITIVITY,"hypertensionincreased blood ssure, pallor, r",1
LUMIZYME,HYPERSENSITIVITY,"ssure, pallor, r",1
LUMIZYME,HYPERSENSITIVITY,"hypertensionincreased blood ssure, pallor, r",1
LUMIZYME,HYPERSENSITIVITY,hypertensionincreased blood pre,0
LUMIZYME,HYPERSENSITIVITY,"ssure, pallor, r igors tremor",1
LUMIZYME,HYPERSENSITIVITY,dizziness muscle twitching agitation cyanosis,0
LUMIZYME,HYPERSENSITIVITY,"cyanosis erythema hypertensionincreased blood ssure, pallor, r",1
LUMIZYME,HYPERSENSITIVITY,dizziness muscle twitching agitation cyanosis,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hypertensionincreased blood pressure pallor , tremor, vomiting, fatig ue",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,dizziness muscle twitching agitation cyanosis,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"pressure pallor , tremor, vomiting, fatig",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"hypertensionincreased blood pressure pallor ,",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,blood,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"blood pressure pallor , tremor, vomiting, fatig ue and myalgia Clinical",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,blood,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,",",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"pallor , tremor,",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,and JuvenileOnset Pompe,0
LUMIZYME,IMMUNE-MEDIATED REACTIONS,"vomiting, fatig ue",1
LUMIZYME,IMMUNE-MEDIATED REACTIONS,and myalgia Clinical Trials in InfantileOnset and JuvenileOnset Pompe Disease T,0
LUMIZYME,CARDIORESPIRATORY FAILURE,Clinical Trial s in InfantileOnset and JuvenileOnset,1
LUMIZYME,anaphylactic reactions,Disease Two multicenter openlabel al,1
LUMIZYME,anaphylactic reactions,openlabel al trials were conduct,1
LUMIZYME,hypersensitivity reactions,conducted in,0
LUMIZYME,hypersensitivity reactions,conducted in antile-onset Pompe disease patients ages month to,1
LUMIZYME,hypersensitivity reactions,conducted in,0
LUMIZYME,hypersensitivity reactions,Pompe disease patients ages month to,1
LUMIZYME,hypersensitivity reactions,conducted in antile-onset,1
LUMIZYME,hypersensitivity reactions,antile-onset Pompe disease,1
LUMIZYME,hypersensitivity reactions,conducted in antile-onset,1
LUMIZYME,hypersensitivity reactions,openlabel clinical trials were conducted in inf,0
LUMIZYME,hypersensitivity reactions,antile-onset Pompe disease patients,1
LUMIZYME,Immune-mediated reactions,Approximately half of the 4%) were male. Patients w,1
LUMIZYME,Immune-mediated reactions,antile-onset Pompe disease patients,1
LUMIZYME,Immune-mediated reactions,alfa or mgkg,0
LUMIZYME,proteinuria,were treated h,1
LUMIZYME,proteinuria,treated h alglucosi dase,1
LUMIZYME,proteinuria,were treated h,1
LUMIZYME,proteinuria,Patients were treated h alglucosi dase alfa or,1
LUMIZYME,proteinuria,were treated h,1
LUMIZYME,proteinuria,other,0
LUMIZYME,nephrotic syndrome,were treated with se,1
LUMIZYME,nephrotic syndrome,se alfa 20,1
LUMIZYME,nephrotic syndrome,to weeks mean,0
LUMIZYME,nephrotic syndrome,se alfa 20,1
LUMIZYME,necrotizing skin lesions,alfa or mgkg very other week for peri ods ranging from to,1
LUMIZYME,necrotizing skin lesions,se alfa 20,1
LUMIZYME,necrotizing skin lesions,mgkg very other week,1
LUMIZYME,necrotizing skin lesions,very other week for peri ods ranging from to,1
LUMIZYME,necrotizing skin lesions,mgkg very other week,1
LUMIZYME,necrotizing skin lesions,alglucosidase alfa or mgkg very other week for peri ods,1
LUMIZYME,necrotizing skin lesions,mgkg very other week,1
LUMIZYME,necrotizing skin lesions,for peri ods ranging from,1
LUMIZYME,necrotizing skin lesions,very other week for,1
LUMIZYME,necrotizing skin lesions,treated with alglucosidase alfa,0
LUMIZYME,fluid overload,These reactions were more kely to occur,1
LUMIZYME,fluid overload,with higher infusion rates Some patients who were pretreated with antihistamines,0
LUMIZYME,Hypersensitivity Reactions,most frequently rted adverse reactions (>= in clinical trials,1
LUMIZYME,Hypersensitivity Reactions,with higher infusion rates Some patients who were pretreated with antihistamines,0
LUMIZYME,Hypersensitivity Reactions,trials were hypersensitivity,0
LUMIZYME,anaphylaxis,ials were h,1
LUMIZYME,anaphylaxis,trials were hypersensitivity,0
LUMIZYME,anaphylaxis,in clinical ials were h,1
LUMIZYME,anaphylaxis,trials were hypersensitivity,0
LUMIZYME,anaphylaxis,and included anaphylaxis rash pyrexia flushingfeeling hot,0
LUMIZYME,anaphylaxis,ypersensitivity reactions and included anaphylaxis rash pyrexia flushingfeeling hot,0
LUMIZYME,anaphylaxis,reactions in clinical ials,1
LUMIZYME,anaphylaxis,reported,0
LUMIZYME,anaphylaxis,frequently reported,0
LUMIZYME,hypersensitivity reactions,and i,1
LUMIZYME,hypersensitivity reactions,reactions and i ncluded anaphylaxis rash pyrexia flushingfeeling,1
LUMIZYME,hypersensitivity reactions,were hypers,0
LUMIZYME,Immune-Mediated Reactions,myalgia To report SPECTED ADVERSE REACTIONS contact Genzyme at,1
LUMIZYME,Immune-Mediated Reactions,were hypers,0
LUMIZYME,Immune-Mediated Reactions,fatigue,0
LUMIZYME,Immune-Mediated Reactions,ADVERSE REACTIONS contact Genzyme,1
LUMIZYME,Immune-Mediated Reactions,report SPECTED ADVERSE,1
LUMIZYME,Immune-Mediated Reactions,SPECTED ADVERSE REACTIONS contact Genzyme,1
LUMIZYME,Immune-Mediated Reactions,or wwwfdagovmedwatch,0
LUMIZYME,Immune-Mediated Reactions,ADVERSE REACTIONS contact Genzyme at or,1
LUMIZYME,acute cardiorespiratory failure,trials of a drug canno,1
LUMIZYME,acute cardiorespiratory failure,inical,0
LUMIZYME,acute cardiorespiratory failure,in,0
LUMIZYME,acute cardiorespiratory failure,drug canno,1
LUMIZYME,acute cardiorespiratory failure,drug canno t be directly,1
LUMIZYME,acute cardiorespiratory failure,clinical,1
LUMIZYME,acute cardiorespiratory failure,rates observed in clinical,1
LUMIZYME,acute cardiorespiratory failure,clinical trials of a drug canno t be directly compared to,1
LUMIZYME,acute cardiorespiratory failure,rates observed in clinical,1
LUMIZYME,acute cardiorespiratory failure,be directly compared to,0
LUMIZYME,acute cardiorespiratory failure,drug canno t,1
LUMIZYME,Cardiac Arrhythmia,Precautions In clinical,0
LUMIZYME,Sudden Cardiac Death,the labeling Anaphylaxis hypersensitivity rea,1
LUMIZYME,Sudden Cardiac Death,Anaphylaxis hypersensitivity rea ctions seeWarnings and,1
LUMIZYME,Sudden Cardiac Death,the labeling Anaphylaxis hypersensitivity rea,1
LUMIZYME,Sudden Cardiac Death,most common adverse reacti,0
LUMIZYME,Sudden Cardiac Death,hypersensitivity rea ctions seeWarnings and Precautions In,1
LUMIZYME,Sudden Cardiac Death,most common adverse reacti,0
LUMIZYME,Sudden Cardiac Death,and Precautions In clinical trials the most common,0
LUMIZYME,Sudden Cardiac Death,hypersensitivity rea,1
LUMIZYME,Sudden Cardiac Death,and Precautions In clinical trials the most common,0
LUMIZYME,Anaphylaxis,hot urticaria headache hyperhidrosis,0
LUMIZYME,Anaphylaxis,"nausea, cou gh",1
LUMIZYME,Anaphylaxis,"urticaria headache nausea, cou",1
LUMIZYME,Anaphylaxis,"nausea, cou gh",1
LUMIZYME,Anaphylaxis,included,0
LUMIZYME,Anaphylaxis,discomfort dizziness muscle,0
LUMIZYME,hypersensitivity reactions,cough ecreased oxygen saturation tachycardia tachypnea,1
LUMIZYME,hypersensitivity reactions,discomfort dizziness muscle,0
LUMIZYME,hypersensitivity reactions,d,0
LUMIZYME,hypersensitivity reactions,oxygen saturation tachycardia tachypnea chest,1
LUMIZYME,hypersensitivity reactions,nausea cough ecreased oxygen saturation tachycardia tachypnea chest discomfort,1
LUMIZYME,hypersensitivity reactions,oxygen saturation tachycardia tachypnea chest,1
LUMIZYME,hypersensitivity reactions,hyperhidrosis nausea cough ecreased oxygen,1
LUMIZYME,hypersensitivity reactions,hyperhidrosis nausea cough ecreased oxygen saturation,1
LUMIZYME,hypersensitivity reactions,headache hyperhidrosis nausea cough ecreased oxygen,1
LUMIZYME,anaphylactic shock,"rigors, tremor, vomiting",1
LUMIZYME,anaphylactic shock,", rigors, tremor, vomiting fatigue",1
LUMIZYME,anaphylactic shock,blood pressure,0
LUMIZYME,anaphylactic shock,vomiting fatigue and myalgia Clinical Trials in,0
LUMIZYME,anaphylactic shock,"pressure , rigors, tremor,  vomiting",1
LUMIZYME,anaphylactic shock,vomiting fatigue and myalgia Clinical Trials in,0
LUMIZYME,anaphylactic shock,",",1
LUMIZYME,anaphylactic shock,erythema,0
LUMIZYME,anaphylactic shock,in,0
LUMIZYME,cardiac arrest,"miting,",1
LUMIZYME,cardiac arrest,"pallor rigors tremor miting,",1
LUMIZYME,cardiac arrest,JuvenileOnset Pompe Disease Tw,0
LUMIZYME,cardiac arrest,"miting, fatigu e and",1
LUMIZYME,cardiac arrest,JuvenileOnset Pompe Disease Tw,0
LUMIZYME,cardiac arrest,myalgia Clinical Trials in InfantileOnset and JuvenileOnset Pompe Disease,0
LUMIZYME,respiratory arrest,pallor rigors tremor vomiting and myalgia.,1
LUMIZYME,respiratory arrest,and myalgia. Clinical Trials in InfantileOnset,1
LUMIZYME,respiratory arrest,rigors tremor vomiting,0
LUMIZYME,respiratory arrest," and myalgia.
 

  Clinical Trials in",1
LUMIZYME,respiratory arrest,rigors tremor vomiting,0
LUMIZYME,respiratory arrest,"pallor rigors tremor vomiting  and myalgia.
 

  Clinical Trials in InfantileOnset and",1
LUMIZYME,respiratory arrest,rigors tremor vomiting,0
LUMIZYME,respiratory arrest,"tremor vomiting  and myalgia.
 

  Clinical",1
LUMIZYME,respiratory arrest,rigors tremor vomiting,0
LUMIZYME,respiratory arrest,in,0
LUMIZYME,respiratory arrest,and,0
LUMIZYME,respiratory arrest,"rigors tremor vomiting  and myalgia.
 

  Clinical Trials in InfantileOnset and",1
LUMIZYME,respiratory arrest,and,0
LUMIZYME,respiratory distress,pallor rigors tremor vomiting fatigue and,0
LUMIZYME,respiratory distress,vomiting fatigue and,0
LUMIZYME,respiratory distress,and   Clinical Trials in InfantileOnset and JuvenileOnset,1
LUMIZYME,respiratory distress,vomiting fatigue and,0
LUMIZYME,respiratory distress,tremor vomiting fatigue and Clinical Trials,1
LUMIZYME,respiratory distress,Clinical Trials in,1
LUMIZYME,hypoxia,and JuvenileOnset Pompe Disease,0
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,in nfantil,1
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe,1
LUMIZYME,hypoxia,Disease Two multicenter openlabel clinical,0
LUMIZYME,hypoxia,tremor vomiting fatigue and myalgia,0
LUMIZYME,hypoxia,JuvenileOnset Pompe Disease Two multicenter,0
LUMIZYME,hypoxia,multicenter,0
LUMIZYME,hypoxia,nfantil eOnset,1
LUMIZYME,hypoxia,pallor rigors tremor vomiting fatigue and myalgia Clinical Trials in I,0
LUMIZYME,hypoxia,nfantil eOnset,1
LUMIZYME,hypoxia,pallor rigors tremor vomiting fatigue and myalgia Clinical Trials in I,0
LUMIZYME,hypoxia,nfantil eOnset and JuvenileOnset Pompe Disease,1
LUMIZYME,apnea,vomiting fatigue,0
LUMIZYME,apnea,Disease Two multicenter openlabel clinical,0
LUMIZYME,apnea,Trials in Onset and JuvenileOnset,1
LUMIZYME,apnea,Disease Two multicenter openlabel clinical,0
LUMIZYME,apnea,Onset,1
LUMIZYME,apnea,Onset and JuvenileOnset Pompe,1
LUMIZYME,dyspnea,nd,1
LUMIZYME,dyspnea,in InfantileOnset nd Juve,1
LUMIZYME,dyspnea,nd,1
LUMIZYME,dyspnea,Clinical Trials in InfantileOnset nd Juve,1
LUMIZYME,dyspnea,nd,1
LUMIZYME,dyspnea,in InfantileOnset nd Juve nileOnset Pompe Disease,1
LUMIZYME,dyspnea,nd,1
LUMIZYME,dyspnea,Clinical Trials in InfantileOnset nd,1
LUMIZYME,dyspnea,Disease Two multicenter openlabel clinical trials were conducted,0
LUMIZYME,dyspnea,Clinical Trials in InfantileOnset a,0
LUMIZYME,dyspnea,nd Juve nileOnset Pompe,1
LUMIZYME,dyspnea,openlabel clinical trials were,0
LUMIZYME,bradycardia,multicenter openlabel clinical trials were conducted in,0
LUMIZYME,bradycardia,le-Onset Po,1
LUMIZYME,bradycardia,and le-Onset Po mpe Disease,1
LUMIZYME,bradycardia,le-Onset Po,1
LUMIZYME,bradycardia,clinical trials were conducted in infantileonset P,0
LUMIZYME,bradycardia,le-Onset Po mpe,1
LUMIZYME,bradycardia,Trials in InfantileOnset and le-Onset,1
LUMIZYME,bradycardia,le-Onset Po mpe,1
LUMIZYME,bradycardia,InfantileOnset and le-Onset Po mpe Disease Two multicenter,1
LUMIZYME,bradycardia,le-Onset Po mpe,1
LUMIZYME,bradycardia,and le-Onset Po,1
LUMIZYME,bradycardia,were conducted in,0
LUMIZYME,bradycardia,and le-Onset,1
LUMIZYME,bradycardia,le-Onset Po,1
LUMIZYME,tachycardia,vomiting,0
LUMIZYME,tachycardia,InfantileOnset and JuvenileOnset e,1
LUMIZYME,tachycardia,and JuvenileOnset e Disease,1
LUMIZYME,tachycardia,JuvenileOnset e Disease  ,1
LUMIZYME,tachycardia,and JuvenileOnset e Disease,1
LUMIZYME,tachycardia,in InfantileOnset and JuvenileOnset e Disease,1
LUMIZYME,tachycardia,Clinical Trials in InfantileOnset and,0
LUMIZYME,tachycardia,and JuvenileOnset e Disease,1
LUMIZYME,tachycardia,clinical trials were conducted in infantileonset Pompe disease,0
LUMIZYME,tachycardia,e Disease Two multicenter openlabel,1
LUMIZYME,tachycardia,and JuvenileOnset e Disease   Two multicenter openlabel,1
LUMIZYME,tachycardia,e Disease Two multicenter openlabel,1
LUMIZYME,bronchospasm,Clinical,0
LUMIZYME,bronchospasm,infantileonset Pompe disease patients,0
LUMIZYME,bronchospasm,"JuvenileOnset Pompe 

 Two multi center openlabel clinical trials were",1
LUMIZYME,bronchospasm,infantileonset Pompe disease patients,0
LUMIZYME,bronchospasm,in infantileonset Pompe disease patients ages,0
LUMIZYME,bronchospasm,Pompe,0
LUMIZYME,bronchospasm,"

 Two multi center openlabel",1
LUMIZYME,bronchospasm,Pompe,0
LUMIZYME,bronchospasm,Two multi center openlabel,1
LUMIZYME,bronchospasm,"and JuvenileOnset Pompe 

 Two multi center openlabel clinical",1
LUMIZYME,bronchospasm,Two multi center openlabel,1
LUMIZYME,throat tightness,JuvenileOnset,0
LUMIZYME,throat tightness,"nter, open-label clinical trials were",1
LUMIZYME,throat tightness,in infantileonset Pompe,0
LUMIZYME,throat tightness,"JuvenileOnset Pompe Disease Two nter, open-label",1
LUMIZYME,throat tightness,in InfantileOnset and JuvenileOnset Pompe,0
LUMIZYME,throat tightness,Pompe Disease Two multice,0
LUMIZYME,hypotension,linical tri,1
LUMIZYME,hypotension,linical tri als were conducted,1
LUMIZYME,hypotension,linical tri als were conducted in infantileonset,1
LUMIZYME,hypotension,Trials in InfantileOnset and,0
LUMIZYME,hypotension,disease patients ages month to years,0
LUMIZYME,hypotension,linical tri als,1
LUMIZYME,hypotension,linical tri als were,1
LUMIZYME,hypotension,Disease Two multicenter openlabel linical tri als were,1
LUMIZYME,hypotension,linical tri als were,1
LUMIZYME,angioedema,openlabel clinical s were con,1
LUMIZYME,angioedema,s were con,1
LUMIZYME,angioedema,patients ages month to years old,0
LUMIZYME,lip swelling,patients ages month to years old Approximately half,0
LUMIZYME,lip swelling,-onset Pompe disease patients ages,1
LUMIZYME,lip swelling,years old Approximately,0
LUMIZYME,lip swelling,-onset Pompe disease patients,1
LUMIZYME,lip swelling,in -onset,1
LUMIZYME,lip swelling,disease,0
LUMIZYME,lip swelling,-onset Pompe disease patients ages,1
LUMIZYME,lip swelling,disease,0
LUMIZYME,periorbital edema,sease Two,0
LUMIZYME,periorbital edema,"isease patients,  ages month to years old",1
LUMIZYME,periorbital edema,sease Two,0
LUMIZYME,periorbital edema,"conducted in infantileonset Pompe isease patients,",1
LUMIZYME,periorbital edema,sease Two multicenter openlabel clinical trials were conducted in infantileonset Pompe d,0
LUMIZYME,periorbital edema,"infantileonset Pompe isease patients,  ages month to years old",1
LUMIZYME,periorbital edema,sease Two multicenter openlabel clinical trials were conducted in infantileonset Pompe d,0
LUMIZYME,periorbital edema,Pompe d,0
LUMIZYME,periorbital edema,openlabel clinical trials were conducted,0
LUMIZYME,periorbital edema,"infantileonset Pompe isease patients,",1
LUMIZYME,periorbital edema,the patients were male Patients,0
LUMIZYME,face edema,month to years,1
LUMIZYME,face edema,years old Approximately half of the patients were male Patients,0
LUMIZYME,face edema,Pompe,0
LUMIZYME,face edema,trials were conducted in infantileonset Pompe,0
LUMIZYME,face edema,the patients were male,0
LUMIZYME,face edema,were treated,0
LUMIZYME,face edema,patients ages,0
LUMIZYME,face edema,month to years old Approximately half,1
LUMIZYME,face edema,month to,1
LUMIZYME,face edema,the patients were male Patients were,0
LUMIZYME,face edema,Patients were treated,0
LUMIZYME,face edema,month to years old Approximately,1
LUMIZYME,face edema,month to years old Approximately half of,1
LUMIZYME,face edema,clinical trials were conducted in infantileonset Pompe disease,0
LUMIZYME,face edema,disease patients month,1
LUMIZYME,face edema,month to years old,1
LUMIZYME,urticaria,month to rs old. A,1
LUMIZYME,urticaria,male Patients were treated with,0
LUMIZYME,urticaria,treated with,0
LUMIZYME,urticaria,to rs old. A,1
LUMIZYME,urticaria,with alglucosidase alfa,0
LUMIZYME,urticaria,month to rs old. A pproximately half,1
LUMIZYME,urticaria,with alglucosidase alfa,0
LUMIZYME,urticaria,rs old. A,1
LUMIZYME,urticaria,month to rs old. A pproximately half of the,1
LUMIZYME,urticaria,rs old. A,1
LUMIZYME,urticaria,month to rs old.,1
LUMIZYME,urticaria,in infantileonset Pompe disease patients ages month,0
LUMIZYME,urticaria,patients ages month to rs old.,1
LUMIZYME,urticaria,rs old. A pproximately half of,1
LUMIZYME,urticaria,pproximately half,0
LUMIZYME,urticaria,to rs old. A pproximately,1
LUMIZYME,urticaria,pproximately half,0
LUMIZYME,chest discomfort,Pompe disease patients ages month to years old Approximately half,0
LUMIZYME,chest discomfort,periods ranging from,0
LUMIZYME,chest discomfort,Approximately half of the were male. Patie nts,1
LUMIZYME,chest discomfort,periods ranging from,0
LUMIZYME,chest discomfort,half of the were male. Patie,1
LUMIZYME,chest discomfort,the were male. Patie nts were treated with alglucosidase,1
LUMIZYME,chest discomfort,half of the were male. Patie,1
LUMIZYME,chest discomfort,patients,0
LUMIZYME,chest discomfort,were male. Patie nts were treated,1
LUMIZYME,chest discomfort,patients,0
LUMIZYME,chest discomfort,of the were male. Patie nts were,1
LUMIZYME,chest discomfort,patients,0
LUMIZYME,chest discomfort,male. Patie nts were treated with,1
LUMIZYME,chest discomfort,treated with alglucosidase alfa or,0
LUMIZYME,wheezing,old Approximately half of the patients were male,0
LUMIZYME,wheezing,wer,0
LUMIZYME,wheezing,alglucosidase alfa or mgkg every other week for periods ranging from to weeks,0
LUMIZYME,wheezing,Patients,0
LUMIZYME,wheezing,the patients were male,0
LUMIZYME,wheezing,patients were male Patients e treate,1
LUMIZYME,wheezing,the patients were male,0
LUMIZYME,wheezing,of,0
LUMIZYME,wheezing,patients were male Patients e treate d,1
LUMIZYME,wheezing,of,0
LUMIZYME,tachypnea,Patients were,0
LUMIZYME,tachypnea,the patients were,0
LUMIZYME,tachypnea,or mgkg every other week for periods ranging,0
LUMIZYME,tachypnea,with algl ucosidase alfa or mgkg every,1
LUMIZYME,tachypnea,were male Patients were with algl,1
LUMIZYME,tachypnea,to weeks mean,0
LUMIZYME,tachypnea,every other week for periods,0
LUMIZYME,cyanosis,weeks,0
LUMIZYME,cyanosis,years old Approximately half of the patients were male,0
LUMIZYME,cyanosis,osidase  alfa or mgkg every,1
LUMIZYME,cyanosis,osidase  alfa or mgkg,1
LUMIZYME,cyanosis,were male Patients,0
LUMIZYME,cyanosis,mgkg every other week for periods ranging from to,0
LUMIZYME,cyanosis,osidase  alfa or mgkg,1
LUMIZYME,cyanosis,mgkg every other week for periods ranging from to,0
LUMIZYME,decreased oxygen saturation,with alglucosidase fa 20 or 40 mg/kg every oth er week,1
LUMIZYME,decreased oxygen saturation,mgkg every other week for periods ranging from to,0
LUMIZYME,decreased oxygen saturation,were treated with alglucosidase fa 20 or 40 mg/kg every oth er week for periods ranging,1
LUMIZYME,decreased oxygen saturation,mgkg every other week for periods ranging from to,0
LUMIZYME,decreased oxygen saturation,with alglucosidase fa 20 or 40 mg/kg every oth er week for periods ranging,1
LUMIZYME,decreased oxygen saturation,mgkg every other week for periods ranging from to,0
LUMIZYME,decreased oxygen saturation,20 or 40 mg/kg every oth er week for periods ranging,1
LUMIZYME,decreased oxygen saturation,treated with alglucosidase fa 20,1
LUMIZYME,decreased oxygen saturation,treated with alglucosidase fa,1
LUMIZYME,convulsions,most serious,0
LUMIZYME,convulsions,mgkg every  week for p eriods ranging from,1
LUMIZYME,convulsions,most serious,0
LUMIZYME,convulsions,week,1
LUMIZYME,convulsions,alglucosidase alfa or,0
LUMIZYME,convulsions,for p eriods ranging from to weeks,1
LUMIZYME,convulsions,week for p,1
LUMIZYME,convulsions,weeks mean weeks The most serious,0
LUMIZYME,pruritus,from to weeks mean weeks The most serious adverse reactions,0
LUMIZYME,pruritus,other week for iods ran,1
LUMIZYME,pruritus,for iods ran,1
LUMIZYME,pruritus,iods ran ging,1
LUMIZYME,hyperhidrosis,to 106 we eks mean weeks,1
LUMIZYME,hyperhidrosis,periods ranging m 1 to 106 we eks,1
LUMIZYME,hyperhidrosis,to 106 we eks mean weeks,1
LUMIZYME,hyperhidrosis,1 to 106 we,1
LUMIZYME,hyperhidrosis,weeks,0
LUMIZYME,hyperhidrosis,periods ranging m 1 to 106,1
LUMIZYME,hyperhidrosis,m 1 to 106 we eks mean weeks The,1
LUMIZYME,hyperhidrosis,periods ranging m 1 to 106,1
LUMIZYME,hyperhidrosis,with alglucosidase,0
LUMIZYME,nausea,periods ranging from to s (mea n,1
LUMIZYME,nausea,with alglucosidase,0
LUMIZYME,nausea,The most serious adverse reactions reported with alglucosidase alfa treatment incl,0
LUMIZYME,nausea,week,0
LUMIZYME,nausea,weeks The most serious adverse reactions reported with,0
LUMIZYME,nausea,ranging from to s (mea,1
LUMIZYME,nausea,adverse reactions reported with alglucosidase,0
LUMIZYME,dizziness,alglucosidase,0
LUMIZYME,dizziness,ranging from,0
LUMIZYME,dizziness,serious adverse reactions reported with,0
LUMIZYME,dizziness,alfa,0
LUMIZYME,dizziness,ranging from to weeks  61 weeks,1
LUMIZYME,dizziness,alfa,0
LUMIZYME,dizziness,61 weeks The most serious,1
LUMIZYME,dizziness,61 weeks,1
LUMIZYME,dizziness,reported with alglucosidase alfa treatment,0
LUMIZYME,dizziness,treatment included,0
LUMIZYME,hypertension,"to weeks mean 



 The mos t serious adverse reactions reported",1
LUMIZYME,hypertension,treatment included,0
LUMIZYME,hypertension,adverse reactions reported with alglucosidase alfa treatment included anaphylaxis and acut,0
LUMIZYME,increased blood pressure,serious adverse reactio,1
LUMIZYME,increased blood pressure,serious adverse reactio ns reported,1
LUMIZYME,increased blood pressure,weeks The serious adverse reactio,1
LUMIZYME,increased blood pressure,to weeks mean weeks The most,0
LUMIZYME,flushing,periods ranging from,0
LUMIZYME,flushing,The most serious adverse  reporte,1
LUMIZYME,flushing,periods ranging from,0
LUMIZYME,flushing,with alglucosidase alfa treatment included anaphylaxis and,0
LUMIZYME,feeling hot,with alglu cosidase alfa treatment included,1
LUMIZYME,feeling hot,serious adverse reactions  with alglu cosidase alfa,1
LUMIZYME,feeling hot,with alglu cosidase alfa treatment included,1
LUMIZYME,feeling hot,most serious adverse reactions  with alglu cosidase,1
LUMIZYME,feeling hot,with alglu cosidase alfa treatment included,1
LUMIZYME,erythema,sidase a lfa treatment,1
LUMIZYME,erythema,most,0
LUMIZYME,pallor,treatme,0
LUMIZYME,pallor,nt inc luded anaphylaxis and,1
LUMIZYME,pallor,with alglucosidase alfa nt inc luded anaphylaxis and,1
LUMIZYME,pallor,nt inc luded anaphylaxis and,1
LUMIZYME,pallor,alfa nt inc luded anaphylaxis and,1
LUMIZYME,pallor,nt inc luded anaphylaxis and,1
LUMIZYME,pallor,nt inc luded,1
LUMIZYME,pallor,nt inc luded,1
LUMIZYME,pallor,failure The,0
LUMIZYME,restlessness,cute cardior,1
LUMIZYME,restlessness,anaphylaxis and cute,1
LUMIZYME,restlessness,intervention in,0
LUMIZYME,restlessness,treatment,0
LUMIZYME,restlessness,cute,1
LUMIZYME,restlessness,included anaphylaxis and cute cardior,1
LUMIZYME,restlessness,anaphylaxis and cute cardior,1
LUMIZYME,nervousness,treatment included anaphylaxis and acute,0
LUMIZYME,nervousness,and acute cardiores,0
LUMIZYME,nervousness,requiring intervention in clinical trials were hypersen,0
LUMIZYME,nervousness,anaphylaxis and acute piratory,1
LUMIZYME,headache,"ure.



 The most common adverse reactions",1
LUMIZYME,headache,"ure.



 The",1
LUMIZYME,headache,"ure.



 The most common adverse reactions",1
LUMIZYME,headache,"acute cardiorespiratory ure.



 The most common",1
LUMIZYME,headache,"ure.



 The most common adverse reactions",1
LUMIZYME,headache,"ure.



 The most common",1
LUMIZYME,back pain,most c ommon adverse reactions requiring intervention,1
LUMIZYME,back pain,treatment included anaphylaxis and,0
LUMIZYME,back pain,most c ommon adverse reactions requiring,1
LUMIZYME,back pain,he most c,1
LUMIZYME,back pain,he most c ommon,1
LUMIZYME,back pain,ommon adverse reactions requiring intervention in clinical trials were hypersensitivity reactions,0
LUMIZYME,paresthesia,most adverse,1
LUMIZYME,paresthesia,cardiorespiratory failure The most adverse,1
LUMIZYME,paresthesia,intervention in clinical trials were hypersensitivity reactions occurring,0
LUMIZYME,paresthesia,common,0
LUMIZYME,paresthesia,clinical trials were hypersensitivity reactions occurring in of,0
LUMIZYME,paresthesia,The most adverse rea ctions requiring intervention in,1
LUMIZYME,paresthesia,clinical trials were hypersensitivity reactions occurring in of,0
LUMIZYME,paresthesia,acute,0
LUMIZYME,paresthesia,cardiorespiratory failure The most adverse rea ctions requiring intervention in clinical,1
LUMIZYME,paresthesia,acute,0
LUMIZYME,paresthesia,failure The most adverse rea,1
LUMIZYME,Immune-mediated cutaneous reactions,ythematous rash macular and maculopapular,0
LUMIZYME,Immune-mediated cutaneous reactions,Adverse Rash (including rash er,1
LUMIZYME,Immune-mediated cutaneous reactions,Adverse Rash (including rash er,1
LUMIZYME,pyrexia,ensionIncreased Blood  Decrea,1
LUMIZYME,pyrexia,Adverse Rash (including rash er,1
LUMIZYME,pyrexia,sed,0
LUMIZYME,pyrexia,sed Oxygen,0
LUMIZYME,pyrexia,sed Oxygen,0
LUMIZYME,pyrexia,Pressure,0
LUMIZYME,pyrexia,Blood  Decrea sed,1
LUMIZYME,pyrexia,Pressure,0
LUMIZYME,pyrexia, Decrea sed Oxygen Saturation,1
LUMIZYME,pyrexia,ensionIncreased Blood  Decrea,1
LUMIZYME,pyrexia, Decrea sed Oxygen Saturation,1
LUMIZYME,pyrexia, Decrea sed Oxygen,1
LUMIZYME,pyrexia,sed,0
LUMIZYME,Acute cardiorespiratory failure,n infantile-onset Pompe disease patients treated in,1
LUMIZYME,Acute cardiorespiratory failure,sed,0
LUMIZYME,Acute cardiorespiratory failure,observed n,1
LUMIZYME,Acute cardiorespiratory failure,Additional hypersensitivity reactions observed n,1
LUMIZYME,Acute cardiorespiratory failure,infantile-onset Pompe disease patients,1
LUMIZYME,Acute cardiorespiratory failure,expanded access programs,0
LUMIZYME,Acute cardiorespiratory failure,Pompe disease patients treated in other clinical,1
LUMIZYME,fluid overload,", irritability retching increased",1
LUMIZYME,fluid overload,", irritability retching increased",1
LUMIZYME,fluid overload,"alfa included livedo , irritability",1
LUMIZYME,fluid overload,", irritability retching increased lacrimation ventricular extrasystoles",1
LUMIZYME,fluid overload,"alfa included livedo , irritability retching increased lacrimation",1
LUMIZYME,fluid overload,", irritability retching increased lacrimation ventricular extrasystoles",1
LUMIZYME,fluid overload,"alglucosidase alfa included livedo , irritability retching increased",1
LUMIZYME,fluid overload,", irritability retching increased lacrimation ventricular extrasystoles",1
LUMIZYME,fluid overload,and expanded access programs with alglucosidase alfa included livedo reticularis,0
LUMIZYME,Ventricular arrhythmias,18 years with a m edian duration of treatment of,1
LUMIZYME,Ventricular arrhythmias,with a m edian duration of,1
LUMIZYME,Ventricular arrhythmias,alfa Patients were  1 to 18 years with a m edian duration of treatment,1
LUMIZYME,Ventricular arrhythmias,with a m edian duration of,1
LUMIZYME,bradycardia,years with a  duration o f treatment,1
LUMIZYME,bradycardia,with a m edian duration of,1
LUMIZYME,bradycardia,a duration,1
LUMIZYME,bradycardia,days No,0
LUMIZYME,cardiac arrest,duration of treatment 437 days (rang e,1
LUMIZYME,cardiac arrest,days No,0
LUMIZYME,cardiac arrest,437 days (rang,1
LUMIZYME,cardiac arrest,days No,0
LUMIZYME,cardiac arrest,Patients were aged to years with a median duration of treatment of,0
LUMIZYME,cardiac arrest,of treatment 437 days (rang e to days,1
LUMIZYME,cardiac arrest,Patients were aged to years with a median duration of treatment of,0
LUMIZYME,cardiac arrest,a median duration of treatment,0
LUMIZYME,cardiac arrest,duration of treatment 437 days (rang,1
LUMIZYME,cardiac arrest,e to days No new safety findings were,0
LUMIZYME,cardiac arrest,437 days (rang e to days No,1
LUMIZYME,cardiac arrest,median duration of treatment 437 days (rang,1
LUMIZYME,cardiac arrest,of treatment 437,1
LUMIZYME,death,to 4,1
LUMIZYME,death,findings were,0
LUMIZYME,death,to 4,1
LUMIZYME,death,treatment of days  to 4 days,1
LUMIZYME,death,to 4,1
LUMIZYME,death,to,0
LUMIZYME,death,to 4 days No new safety,1
LUMIZYME,reduced clinical efficacy,years of age and the youngest placebotreated patient was years of,0
LUMIZYME,reduced clinical efficacy,patients were,0
LUMIZYME,reduced clinical efficacy,nai,0
LUMIZYME,reduced clinical efficacy,to enzyme replacement therapy,1
LUMIZYME,reduced clinical efficacy,All patients were ve to enzyme,1
LUMIZYME,reduced clinical efficacy,ve to enzyme replacement  therapy Patients,1
LUMIZYME,reduced clinical efficacy,All patients were ve to enzyme,1
LUMIZYME,loss of motor function,received al glucosidase alfa or placebo,1
LUMIZYME,loss of motor function,ratio and received al glucosidase alfa or,1
LUMIZYME,death,every other week,1
CERDELGA,fatigue,most common adverse reactions fatigue headache nausea diarrhea,1
CERDELGA,fatigue,every other week,1
CERDELGA,fatigue,fatigue headache nausea diarrhea back,1
CERDELGA,fatigue,common adverse reactions fatigue headache nausea,1
CERDELGA,fatigue,fatigue headache nausea diarrhea back,1
CERDELGA,fatigue,most common adverse reactions fatigue,1
CERDELGA,fatigue,fatigue headache nausea diarrhea back,1
CERDELGA,fatigue,diarrhea back pain pain in extremities and upper abdominal,0
CERDELGA,fatigue,fatigue,1
CERDELGA,fatigue,diarrhea back pain pain in extremities and upper abdominal,0
CERDELGA,fatigue,reactions,0
CERDELGA,fatigue,adverse reactions,0
CERDELGA,headache,common adverse reactions are headache nausea diarrhea,1
CERDELGA,headache,adverse reactions,0
CERDELGA,headache,headache nausea diarrhea back,1
CERDELGA,headache,headache nausea diarrhea back pain,1
CERDELGA,headache,are headache nausea diarrhea back,1
CERDELGA,headache,headache nausea diarrhea back pain,1
CERDELGA,headache,adverse reactions are headache nausea diarrhea back pain pain,1
CERDELGA,headache,headache nausea diarrhea back pain,1
CERDELGA,headache,in extremities,0
CERDELGA,headache,diarrhea back pain pain in extremities and upper abdominal pain To report,0
CERDELGA,headache,headache nausea,1
CERDELGA,nausea,ADVERSE REACTIONS EXCERPT,0
CERDELGA,nausea,fatigue nausea,1
CERDELGA,nausea,ADVERSE REACTIONS EXCERPT,0
CERDELGA,nausea,To,0
CERDELGA,nausea,nausea,1
CERDELGA,diarrhea,most common adverse reactions are fatigue headache,0
CERDELGA,diarrhea,diarrhea back pain pain,1
CERDELGA,diarrhea,diarrhea back pain pain,1
CERDELGA,diarrhea,diarrhea back pain pain,1
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,back pain,fatigue headache nausea back,1
CERDELGA,back pain,back pain,1
CERDELGA,back pain,headache nausea back,1
CERDELGA,back pain,diarrhea,0
CERDELGA,back pain,headache nausea back,1
CERDELGA,back pain,fatigue headache nausea back pain,1
CERDELGA,back pain,headache nausea back,1
CERDELGA,back pain,reactions are fatigue headache nausea,0
CERDELGA,back pain,and upper abdominal pain To report SUSPECTED,0
CERDELGA,back pain,back pain,1
CERDELGA,back pain,nausea back pain,1
CERDELGA,pain in extremities,back pain in extremities,1
CERDELGA,pain in extremities,nausea back pain,1
CERDELGA,pain in extremities,upper abdominal pain To report SUSPECTED,0
CERDELGA,pain in extremities,contact,0
CERDELGA,upper abdominal pain,diarrhea back pain,0
CERDELGA,upper abdominal pain,upper abdominal pain To,1
CERDELGA,upper abdominal pain,extremities upper abdominal,1
CERDELGA,upper abdominal pain,pain in extremities upper abdominal pain To report SUSPECTED ADVERSE,1
CERDELGA,upper abdominal pain,extremities upper abdominal,1
CERDELGA,upper abdominal pain,abdominal pain To report SUSPECTED,1
CERDELGA,upper abdominal pain,are,0
CERDELGA,upper abdominal pain,report SUSPECTED ADVERSE REACTIONS contact Genzyme Corporation at or,0
CERDELGA,upper abdominal pain,contact,0
CERDELGA,upper abdominal pain,abdominal pain To report SUSPECTED ADVERSE REACTIONS,1
CERDELGA,upper abdominal pain,pain pain in extremities upper,1
CERDELGA,fatigue,fatigue,1
CERDELGA,headache,across Trials and were,0
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,nausea,of the GD,0
CERDELGA,nausea,across Trials and were fatigue,0
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,nausea,nausea diarrhea back pain pain in,1
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,nausea,nausea diarrhea,1
CERDELGA,diarrhea,diarrhea back,1
CERDELGA,diarrhea,nausea diarrhea,1
CERDELGA,diarrhea,were fatigue headache diarrhea back pain pain in,1
CERDELGA,diarrhea,nausea diarrhea,1
CERDELGA,diarrhea,the GD patients,0
CERDELGA,diarrhea,diarrhea back pain pain in,1
CERDELGA,diarrhea,fatigue headache diarrhea back,1
CERDELGA,diarrhea,diarrhea back pain pain in,1
CERDELGA,diarrhea,diarrhea back pain pain,1
CERDELGA,back pain,diarrhea,0
CERDELGA,back pain,Trials and were fatigue,0
CERDELGA,back pain,were fatigue headache nausea back,1
CERDELGA,back pain,nausea diarrhea,0
CERDELGA,back pain,Trials and were fatigue headache nausea,0
CERDELGA,back pain,back,1
CERDELGA,upper abdominal pain,two,0
CERDELGA,upper abdominal pain,is based on two controlled,0
CERDELGA,upper abdominal pain,Trials and were fatigue headache nausea diarrhea back pain pain in extremities and,0
CERDELGA,upper abdominal pain,upper abdominal pain The adverse reaction profile of,1
CERDELGA,upper abdominal pain,Trials and were fatigue headache nausea diarrhea back pain pain in extremities and,0
CERDELGA,upper abdominal pain,upper abdominal pain The,1
CERDELGA,upper abdominal pain,upper abdominal pain The adverse reaction profile,1
CERDELGA,upper abdominal pain,upper abdominal pain,1
CERDELGA,upper abdominal pain,studies Trials and,0
CERDELGA,upper abdominal pain,in extremities upper abdominal pain,1
CERDELGA,upper abdominal pain,studies Trials and,0
CERDELGA,upper abdominal pain,upper abdominal pain,1
CERDELGA,ECG Changes,adverse r,1
CERDELGA,ECG Changes,EXCERPT The most n adverse r eactions are fatigue headache nausea,1
CERDELGA,ECG Changes,adverse r,1
CERDELGA,ECG Changes,adverse r,1
CERDELGA,ECG Changes,pain in,0
CERDELGA,ECG Changes,n adverse,1
CERDELGA,Cardiac Arrhythmias,"most common adverse reactions e: fatigue, headach e nausea diarrhea back pain",1
CERDELGA,Cardiac Arrhythmias,n adverse,1
CERDELGA,Cardiac Arrhythmias,adverse,0
CERDELGA,Cardiac Arrhythmias,extremities and,0
CERDELGA,Cardiac Arrhythmias,"reactions e: fatigue,",1
CERDELGA,Cardiac Arrhythmias,"reactions e: fatigue, headach e nausea diarrhea back pain",1
CERDELGA,Cardiac Arrhythmias,"reactions e: fatigue,",1
CERDELGA,Cardiac Arrhythmias,EXCERPT The most common adverse,0
CERDELGA,Cardiac Arrhythmias,extremities and upper abdominal pain To,0
CERDELGA,Cardiac Arrhythmias,e:,1
CERDELGA,Cardiac Arrhythmias,most common adverse reactions e:,1
CERDELGA,cardiac arrhythmias, clinical trials of another drug,1
CERDELGA,cardiac arrhythmias,most common adverse reactions e:,1
CERDELGA,cardiac arrhythmias,and may,0
CERDELGA,cardiac arrhythmias,clinical trials of another drug and may not,1
NEURACEQ,injection site reaction,most commonly reported adverse reactions,0
NEURACEQ,injection site reaction,pain To report SUSPECTED ADV,0
NEURACEQ,injection site reaction,reactions,0
NEURACEQ,injection site reaction,adverse reactions injection site reaction consisting of,1
NEURACEQ,injection site reaction,reactions,0
NEURACEQ,injection site reaction,injection site reaction consisting of erythema irritation and,1
NEURACEQ,injection site reactions,mild to moderate in,0
NEURACEQ,application site erythema,application site erythema Injection site,1
NEURACEQ,application site erythema,mild to moderate in,0
NEURACEQ,application site erythema,in,0
NEURACEQ,application site erythema,irritation Injection s,0
NEURACEQ,application site erythema,application site erythema Injection,1
NEURACEQ,Injection site irritation,site Injection site irritation Injection,1
NEURACEQ,Injection site irritation,application site erythema Injection,1
NEURACEQ,Injection site irritation,Injection,0
NEURACEQ,Injection site irritation,Injection application site Injection site irritation,1
NEURACEQ,Injection site irritation,Injection,0
NEURACEQ,Injection site irritation,n Injection application site Injection site irritation Injection site pain,1
NEURACEQ,Injection site irritation,Injection,0
NEURACEQ,Injection site irritation,site irritation Injection,1
NEURACEQ,Injection site irritation,site irritation Injection,1
NEURACEQ,Injection site irritation,site Injection site irritation Injection site,1
NEURACEQ,Injection site irritation,site irritation Injection,1
NEURACEQ,Injection site irritation,Injection site,0
NEURACEQ,Injection site irritation,Injection site,0
NEURACEQ,Injection site irritation,Injection,0
NEURACEQ,long-term cumulative radiation exposure,of erythema irritation and pain,0
NEURACEQ,long-term cumulative radiation exposure,tion consisting of erythema irritation and pain To report,0
NEURACEQ,long-term cumulative radiation exposure,"To report  ADVERSE REACTIONS, contact Piramal at  or FDA",1
NEURACEQ,long-term cumulative radiation exposure,tion consisting of erythema irritation and pain To report,0
NEURACEQ,long-term cumulative radiation exposure,"and pain To report ADVERSE REACTIONS, contact Piramal at",1
NEURACEQ,long-term cumulative radiation exposure,e drug,1
NEURACEQ,long-term cumulative radiation exposure,Injection,0
NEURACEQ,long-term cumulative radiation exposure,n Administrations in Subjects e drug reaction      n (%)              Injection application site erythema Injection,1
NEURACEQ,long-term cumulative radiation exposure,Injection,0
NEURACEQ,long-term cumulative radiation exposure,Injection application site erythema,0
NEURACEQ,long-term cumulative radiation exposure,Injection application site erythema,0
NEURACEQ,long-term cumulative radiation exposure,n (%) Injection,1
NEURACEQ,long-term cumulative radiation exposure,erythema Injection,0
NEURACEQ,long-term cumulative radiation exposure,e drug reaction      n (%)              Injection application site erythema,1
NEURACEQ,long-term cumulative radiation exposure,erythema Injection,0
NEURACEQ,Long-term cumulative radiation exposure,Administrations in Subjects Adverse drug,0
NEURACEQ,Long-term cumulative radiation exposure,n,0
NEURACEQ,Long-term cumulative radiation exposure,site irritation,0
NEURACEQ,cancer,ection site irritation Injection site,1
NEURACEQ,cancer,site irritation,0
NEURACEQ,cancer,n Injection application site erythema Inj,0
NEURACEQ,cancer,ection site irritation,1
NEURACEQ,cancer,ection site irritation,1
NEURACEQ,cancer,ection site irritation Injection site pain,1
NEURACEQ,cancer,ection,1
NEURACEQ,cancer,site erythema ection,1
NEURACEQ,cancer,ection,1
NEURACEQ,cancer,ection site irritation Injection site pain,1
NEURACEQ,cancer,irritation Injection,0
PROLIA,Hypocalcemia,Hypocalcemia see Warnings and Precautions Serious,1
PROLIA,Hypocalcemia,are discussed below and also,0
PROLIA,Hypocalcemia,Hypocalcemia see Warnings,1
PROLIA,Hypocalcemia,Hypocalcemia see Warnings and Precautions,1
PROLIA,Infections,Infections see Warnings,1
PROLIA,Infections,Infections see Warnings,1
PROLIA,Infections,see,0
PROLIA,Infections,Infections see Warnings and Precautions Dermatologic,1
PROLIA,Infections,Warnings and Precautions Infections see Warnings and,1
PROLIA,Infections,Infections see Warnings and Precautions Dermatologic,1
PROLIA,Infections,Warnings and,0
PROLIA,Infections,Infections,1
PROLIA,Infections,Infections see Warnings and,1
PROLIA,Infections,Infections see Warnings and Precautions Dermatologic,1
PROLIA,Infections,Infections see Warnings,1
PROLIA,Dermatologic Adverse Reactions,see Warnings and Dermatologic Adverse Reactions see Warnings and Precautions Osteonecrosis,1
PROLIA,Dermatologic Adverse Reactions,Infections see Warnings,1
PROLIA,Dermatologic Adverse Reactions,Dermatologic Adverse Reactions see Warnings and Precautions,1
PROLIA,Dermatologic Adverse Reactions,Infections see Warnings,1
PROLIA,Dermatologic Adverse Reactions,Dermatologic Adverse Reactions,1
PROLIA,Dermatologic Adverse Reactions,Infections see Warnings and Dermatologic Adverse Reactions see Warnings and Precautions,1
PROLIA,Dermatologic Adverse Reactions,Dermatologic Adverse Reactions,1
PROLIA,Dermatologic Adverse Reactions,Adverse Reactions see,1
PROLIA,Dermatologic Adverse Reactions,and Precautions Osteonecrosis of the Jaw,0
PROLIA,Dermatologic Adverse Reactions,Precautions Serious Infections,0
PROLIA,Dermatologic Adverse Reactions,Warnings and,0
PROLIA,Dermatologic Adverse Reactions,Warnings and,0
PROLIA,Osteonecrosis of the Jaw,Precautions,0
PROLIA,back pain,The most common a,0
PROLIA,back pain,patients,0
PROLIA,pain in extremity,pain,0
PROLIA,pain in extremity,in extremity musculoskeletal pain,1
PROLIA,pain in extremity,in extremity musculoskeletal pain hypercholesterolemia,1
PROLIA,pain in extremity,osteoporosis are back pain in extremity,1
PROLIA,pain in extremity,in extremity musculoskeletal pain hypercholesterolemia,1
PROLIA,pain in extremity,pain in extremity musculoskeletal pain,1
PROLIA,musculoskeletal pain,with,0
PROLIA,musculoskeletal pain,pain pain in musculoskeletal pain hypercholesterolemia,1
PROLIA,musculoskeletal pain,with,0
PROLIA,musculoskeletal pain,Prolia in patients with postmenopausal osteoporosis are back pain pain in extremity,0
PROLIA,musculoskeletal pain,in patients with postmenopausal osteoporosis are back pain,0
PROLIA,musculoskeletal pain,musculoskeletal pain hypercholesterolemia and,1
PROLIA,musculoskeletal pain,adverse reactions reported with Prolia,0
PROLIA,musculoskeletal pain,and cystitis The,0
PROLIA,musculoskeletal pain,musculoskeletal pain hypercholesterolemia,1
PROLIA,musculoskeletal pain,pain pain in musculoskeletal pain,1
PROLIA,cystitis,osteoporosis are back pain,0
PROLIA,cystitis,cystitis The most common adverse reactions,1
PROLIA,cystitis,cystitis The most common adverse,1
PROLIA,cystitis,cystitis The most common adverse reactions,1
PROLIA,cystitis,cystitis The,1
PROLIA,cystitis,cystitis The most common adverse reactions,1
PROLIA,cystitis,cystitis The most common adverse reactions,1
PROLIA,back pain,osteoporosis back pain arthralgia and nasopharyngitis,1
PROLIA,back pain,cystitis The most common adverse reactions,1
PROLIA,arthralgia,most common adverse reactions reported with Prolia in men with osteoporosis,0
PROLIA,arthralgia,Prolia in men with osteoporosis are back pain,0
PROLIA,arthralgia,and nasopharyngitis The most common,0
PROLIA,arthralgia,per patient incidence adverse reactions reported,0
PROLIA,arthralgia,arthralgia,1
PROLIA,arthralgia,arthralgia and nasopharyngitis The most,1
PROLIA,arthralgia,arthralgia,1
PROLIA,arthralgia,are back arthralgia and nasopharyngitis The,1
PROLIA,arthralgia,arthralgia,1
PROLIA,arthralgia,with Prolia in men with,0
PROLIA,arthralgia,reactions reported with Prolia,0
PROLIA,nasopharyngitis,nasopharyngitis The,1
PROLIA,nasopharyngitis,are back pain arthralgia nasopharyngitis,1
PROLIA,nasopharyngitis,nasopharyngitis The,1
PROLIA,nasopharyngitis,Prolia in,0
PROLIA,nasopharyngitis,most common per patient incidence adverse reactions reported with Prolia in,0
PROLIA,nasopharyngitis,nasopharyngitis The,1
PROLIA,nasopharyngitis,nasopharyngitis The most common,1
PROLIA,nasopharyngitis,pain arthralgia nasopharyngitis The most common per,1
PROLIA,nasopharyngitis,nasopharyngitis The most common,1
PROLIA,nasopharyngitis,back pain arthralgia and,0
PROLIA,nasopharyngitis,common,0
PROLIA,arthralgia,been reported in clinical tria,0
PROLIA,arthralgia,cancer are,0
PROLIA,arthralgia,arthralgia and back,1
PROLIA,back pain,arthralgia and,0
PROLIA,musculoskeletal pain,musculoskeletal pain have also been reported in,1
PROLIA,musculoskeletal pain,arthralgia and,0
PROLIA,back pain,back pain and,1
PROLIA,back pain,The Prolia Postmarketing Active Safety Surveillance,0
PROLIA,back pain,are,0
PROLIA,back pain,with,0
PROLIA,back pain,patients,0
PROLIA,constipation,discontinuation of Prolia,0
PROLIA,constipation,with postmenopausal osteoporosis,0
PROLIA,constipation,to collect,0
PROLIA,constipation,Prolia Postmarketing Active Safety Surveillance Program is available,0
PROLIA,constipation,constipation,1
PROLIA,constipation,constipation The Prolia,1
PROLIA,constipation,patients with postmenopausal osteoporosis are back,0
PROLIA,constipation,with postmenopausal osteoporosis are,0
PROLIA,constipation,constipation,1
PROLIA,constipation,constipation The Prolia Postmarketing Active Safety,1
PROLIA,pain in extremity,in extremity hypercholesterolemia,1
PROLIA,hypercholesterolemia,hypercholesterolemia musculoskeletal pain and cystitis,1
PROLIA,hypercholesterolemia,pain in hypercholesterolemia musculoskeletal pain and,1
PROLIA,hypercholesterolemia,hypercholesterolemia musculoskeletal pain and cystitis,1
PROLIA,hypercholesterolemia,back pain pain in hypercholesterolemia musculoskeletal pain and,1
PROLIA,hypercholesterolemia,hypercholesterolemia musculoskeletal pain and cystitis,1
PROLIA,hypercholesterolemia,in hypercholesterolemia musculoskeletal,1
PROLIA,hypercholesterolemia,hypercholesterolemia musculoskeletal pain and cystitis,1
PROLIA,hypercholesterolemia,more common than placebo were back pain pain in extremity,0
PROLIA,hypercholesterolemia,in clinical trials,0
PROLIA,hypercholesterolemia,been reported in clinical,0
PROLIA,hypercholesterolemia,placebo were,0
PROLIA,hypercholesterolemia,cystitis Pancreatitis,0
PROLIA,hypercholesterolemia,hypercholesterolemia musculoskeletal,1
PROLIA,musculoskeletal pain,musculoskeletal pain and cystitis Pancreatitis has been,1
PROLIA,musculoskeletal pain,extremity musculoskeletal pain and cystitis Pancreatitis has been,1
PROLIA,musculoskeletal pain,musculoskeletal pain and cystitis Pancreatitis has been,1
PROLIA,musculoskeletal pain,pain in extremity,0
PROLIA,musculoskeletal pain,extremity musculoskeletal pain and cystitis Pancreatitis has,1
PROLIA,musculoskeletal pain,pain in extremity,0
PROLIA,musculoskeletal pain,pain in extremity musculoskeletal pain and cystitis Pancreatitis has,1
PROLIA,musculoskeletal pain,pain in extremity,0
PROLIA,musculoskeletal pain,and more common than placebo were back,0
PROLIA,cystitis,been,0
PROLIA,cystitis,cystitis Pancreatitis,1
PROLIA,cystitis,cystitis,1
PROLIA,Pancreatitis,Pancreatitis has been reported,1
PROLIA,Pancreatitis,Pancreatitis has been reported,1
PROLIA,Pancreatitis,hypercholesterolemia musculoskeletal pain and Pancreatitis has,1
PROLIA,Pancreatitis,Pancreatitis has been reported,1
PROLIA,Pancreatitis,Pancreatitis has been reported in,1
PROLIA,Pancreatitis,and cystitis,0
PROLIA,Pancreatitis,Pancreatitis has been reported in,1
PROLIA,Pancreatitis,and cystitis,0
PROLIA,Pancreatitis,Osteoporosis,0
PROLIA,Pancreatitis,Pancreatitis has been,1
PROLIA,back pain,than placebo back,1
PROLIA,back pain,ablation for cancer,0
PROLIA,back pain,hormone,0
PROLIA,back pain,placebo back pain arthralgia,1
PROLIA,back pain,hormone,0
PROLIA,back pain,back pain arthralgia and nasopharyngitis Bone loss,1
PROLIA,back pain,and more common than,0
PROLIA,back pain,common than placebo back pain,1
PROLIA,back pain,back pain arthralgia,1
PROLIA,back pain,loss due to hormone ablation,0
PROLIA,arthralgia,cancer,0
PROLIA,nasopharyngitis,nasopharyngitis Bone loss due,1
PROLIA,nasopharyngitis,loss due to hormone ablation for cancer Most common adverse,0
PROLIA,nasopharyngitis,nasopharyngitis Bone loss due,1
PROLIA,nasopharyngitis,nasopharyngitis Bone loss due to,1
PROLIA,nasopharyngitis,nasopharyngitis,1
PROLIA,nasopharyngitis,nasopharyngitis Bone loss,1
PROLIA,nasopharyngitis,and more common than placebo,0
PROLIA,nasopharyngitis,back pain arthralgia nasopharyngitis Bone loss due to,1
PROLIA,nasopharyngitis,and more common than placebo,0
PROLIA,nasopharyngitis,arthralgia,0
PROLIA,arthralgia,extremity and musculoskeletal pain have,0
PROLIA,arthralgia,placebo arthralgia and,1
PROLIA,arthralgia,extremity and musculoskeletal pain have,0
PROLIA,arthralgia,arthralgia,1
PROLIA,arthralgia,arthralgia and back pain Pain,1
PROLIA,arthralgia,extremity and musculoskeletal pain have also been reported in,0
PROLIA,arthralgia,Pain in extremity and musculoskeletal pain have also been reported in,0
PROLIA,arthralgia,arthralgia and back pain Pain,1
PROLIA,arthralgia,common than placebo arthralgia and back pain,1
PROLIA,arthralgia,arthralgia and back pain Pain,1
PROLIA,arthralgia,extremity and musculoskeletal,0
PROLIA,Pain in extremity,back Pain in extremity and musculoskeletal pain,1
PROLIA,Pain in extremity,extremity and musculoskeletal,0
PROLIA,Pain in extremity,and back Pain in extremity and musculoskeletal pain have,1
PROLIA,Pain in extremity,extremity and musculoskeletal,0
PROLIA,Pain in extremity,Pain in extremity,1
PROLIA,Pain in extremity,extremity and musculoskeletal,0
PROLIA,Pain in extremity,Pain in extremity and musculoskeletal,1
PROLIA,mortality,incidence of mortality was n in,1
PROLIA,mortality,Pain in extremity and musculoskeletal,1
PROLIA,mortality,mortality was n in,1
PROLIA,mortality,mortality was n,1
PROLIA,mortality,and IU of vitamin D supplementation per day,0
PROLIA,mortality,mortality,1
PROLIA,Anemia,Anemia CARDIAC DISORDERS,1
PROLIA,Anemia,Anemia,1
PROLIA,Anemia,CARDIAC DISORDERS,0
PROLIA,Angina pectoris,EAR AND,0
PROLIA,Angina pectoris,AND LABYRINTH D,0
PROLIA,Angina pectoris,CARDIAC,0
PROLIA,Angina pectoris,Atrial fibrillation EAR,0
PROLIA,Angina pectoris,AND,0
PROLIA,Atrial fibrillation,LABYRINTH DISORDERS Vertigo,0
PROLIA,Atrial fibrillation,Atrial fibrillation EAR AND LABYRINTH DISORDERS,1
PROLIA,Atrial fibrillation,Angina Atrial fibrillation,1
PROLIA,Atrial fibrillation,Atrial fibrillation EAR AND LABYRINTH DISORDERS,1
PROLIA,Atrial fibrillation,AND LABYRINTH,0
PROLIA,Atrial fibrillation,Atrial fibrillation EAR AND,1
PROLIA,Vertigo,Vertigo GASTROINTESTINAL,1
PROLIA,Vertigo,Vertigo GASTROINTESTINAL,1
PROLIA,Vertigo,AND LABYRINTH Vertigo GASTROINTESTINAL DISORDERS Abdominal,1
PROLIA,Vertigo,Vertigo GASTROINTESTINAL,1
PROLIA,Vertigo,AND LABYRINTH DISORDERS,0
PROLIA,Vertigo,DISORDERS,0
PROLIA,Vertigo,LABYRINTH DISORDERS,0
PROLIA,Vertigo,LABYRINTH Vertigo GASTROINTESTINAL DISORDERS,1
PROLIA,Vertigo,LABYRINTH DISORDERS,0
PROLIA,Abdominal pain upper,Vertigo GASTROINTESTINAL Abdominal pain upper Flatulence Gastroesophageal reflux di,1
PROLIA,Abdominal pain upper,LABYRINTH DISORDERS,0
PROLIA,Abdominal pain upper,pain upper,1
PROLIA,Abdominal pain upper,pain upper,1
PROLIA,Abdominal pain upper,Flatulence Gastroesophageal reflux di,0
PROLIA,Flatulence,DISORDERS Abdominal pain upper,0
PROLIA,Flatulence,GASTROINTESTINAL DISORDERS Abdominal pain Flatulence Gastroesophageal reflux disease,1
PROLIA,Flatulence,DISORDERS Abdominal pain upper,0
PROLIA,Flatulence,Flatulence Gastroesophageal,1
PROLIA,Flatulence,reflux disease,0
PROLIA,Flatulence,Flatulence Gastroesophageal,1
PROLIA,Flatulence,GASTROINTESTINAL DISORDERS Abdominal pain Flatulence Gastroesophageal reflux disease GENERAL,1
PROLIA,Flatulence,Flatulence Gastroesophageal,1
PROLIA,Gastroesophageal reflux disease,reflux disease GENERAL DISORDERS AND ADMINISTRATION,1
PROLIA,Gastroesophageal reflux disease,upper Gastroesophageal,1
PROLIA,Gastroesophageal reflux disease,reflux disease GENERAL DISORDERS AND ADMINISTRATION,1
PROLIA,Gastroesophageal reflux disease,upper Gastroesophageal reflux,1
PROLIA,Gastroesophageal reflux disease,Abdominal pain upper Flatulence,0
PROLIA,Gastroesophageal reflux disease,Abdominal,0
PROLIA,Gastroesophageal reflux disease,pain upper Gastroesophageal reflux disease GENERAL DISORDERS,1
PROLIA,Gastroesophageal reflux disease,Abdominal,0
PROLIA,Gastroesophageal reflux disease,upper Gastroesophageal reflux disease GENERAL DISORDERS,1
PROLIA,Gastroesophageal reflux disease,Abdominal,0
PROLIA,Gastroesophageal reflux disease,upper Gastroesophageal reflux disease,1
PROLIA,Edema peripheral,ADMINISTRATION SITE Edema peripheral Asthenia INFECTIONS AND INFESTATIONS,1
PROLIA,Edema peripheral,upper Gastroesophageal reflux disease,1
PROLIA,Edema peripheral,SITE Edema peripheral,1
PROLIA,Edema peripheral,AND ADMINISTRATION SITE Edema peripheral,1
PROLIA,Edema peripheral,Edema peripheral Asthenia,1
PROLIA,Edema peripheral,Edema peripheral Asthenia INFECTIONS,1
PROLIA,Edema peripheral,Edema peripheral Asthenia,1
PROLIA,Edema peripheral,INFECTIONS,0
PROLIA,Edema peripheral,DISORDERS AND ADMINISTRATION SITE Edema peripheral,1
PROLIA,Asthenia,SITE CONDITIONS Edema,0
PROLIA,Asthenia,peripheral,0
PROLIA,Asthenia,INFECTIONS,0
PROLIA,Asthenia,Asthenia INFECTIONS,1
PROLIA,Asthenia,INFECTIONS AND INFESTATIONS,0
PROLIA,Cystitis,Cystitis,1
PROLIA,Cystitis,AND INFESTATIONS,0
PROLIA,Cystitis,Cystitis Upper respiratory tract infection P,1
PROLIA,Cystitis,Asthenia INFECTIONS AND Cystitis Upper respiratory tract,1
PROLIA,Cystitis,Cystitis Upper respiratory tract infection P,1
PROLIA,Cystitis,tract,0
PROLIA,Cystitis,INFECTIONS AND Cystitis Upper respiratory tract infection,1
PROLIA,Cystitis,tract,0
PROLIA,Upper respiratory tract infection,AND INFESTATIONS Upper respiratory,1
PROLIA,Upper respiratory tract infection,AND INFESTATIONS Cystitis,0
PROLIA,Upper respiratory tract infection,Cystitis,0
PROLIA,Upper respiratory tract infection,INFECTIONS AND INFESTATIONS Upper respiratory tract infection,1
PROLIA,Upper respiratory tract infection,Cystitis,0
PROLIA,Upper respiratory tract infection,Cystitis,0
PROLIA,Upper respiratory tract infection,respiratory tract infection Pneumonia,1
PROLIA,Upper respiratory tract infection,AND INFESTATIONS,0
PROLIA,Pneumonia,Pneumonia Pharyngitis Herpes zoster,1
PROLIA,Pneumonia,AND INFESTATIONS,0
PROLIA,Pneumonia,respiratory tract Pneumonia Pharyngitis Herpes zoster,1
PROLIA,Pneumonia,AND INFESTATIONS,0
PROLIA,Pneumonia,respiratory tract Pneumonia,1
PROLIA,Pneumonia,AND INFESTATIONS,0
PROLIA,Pneumonia,respiratory tract Pneumonia,1
PROLIA,Pneumonia,AND INFESTATIONS,0
PROLIA,Pharyngitis,infection Pneumonia,0
PROLIA,Pharyngitis,Pharyngitis Herpes zoster METABOLISM AND NUTRITION,1
PROLIA,Pharyngitis,spiratory tract infection Pharyngitis Herpes zoster METABOLISM AND NUTRITION,1
PROLIA,Pharyngitis,Pharyngitis Herpes zoster METABOLISM AND NUTRITION,1
PROLIA,Pharyngitis,METABOLISM,0
PROLIA,Pharyngitis,Pharyngitis Herpes zoster METABOLISM,1
PROLIA,Pharyngitis,METABOLISM,0
PROLIA,Pharyngitis,tract infection Pharyngitis,1
PROLIA,Pharyngitis,METABOLISM,0
PROLIA,Pharyngitis,tract,0
PROLIA,Pharyngitis,Pharyngitis Herpes,1
PROLIA,Pharyngitis,Pharyngitis,1
PROLIA,Pharyngitis,Pneumonia,0
PROLIA,Hypercholesterolemia,AND NUTRITION Hypercholesterolemia MUSCULOSKELETAL AND,1
PROLIA,Hypercholesterolemia,Pneumonia,0
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL AND CONNECTIVE TISSUE,1
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL AND CONNECTIVE,1
PROLIA,Hypercholesterolemia,CONNECTIVE,0
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL,1
PROLIA,Hypercholesterolemia,Hypercholesterolemia MUSCULOSKELETAL AND CONNECTIVE TISSUE,1
PROLIA,Hypercholesterolemia,DISORDERS,0
PROLIA,Back pain,DISORDERS,0
PROLIA,Back pain,sterolemia MUSCULOSKELETAL AND CONNECTIVE,0
PROLIA,Back pain,CONNECTIVE TISSUE Back,1
PROLIA,Back pain,TISSUE Back pain,1
PROLIA,Back pain,Back pain,1
PROLIA,Pain in extremity,TISSUE DISORDERS Back Pain in extremity Musculoskeletal pain Bone pain,1
PROLIA,Pain in extremity,Back pain,1
PROLIA,Pain in extremity,Pain in extremity,1
PROLIA,Pain in extremity,Musculoskeletal pain Bone pain,0
PROLIA,Pain in extremity,Back pain,0
PROLIA,Pain in extremity,in extremity Musculoskeletal pain,1
PROLIA,Pain in extremity,Musculoskeletal pain,0
PROLIA,Pain in extremity,DISORDERS Back Pain in extremity,1
PROLIA,Pain in extremity,pain Bone,0
PROLIA,Musculoskeletal pain,Bone,0
PROLIA,Musculoskeletal pain,in Musculoskeletal,1
PROLIA,Musculoskeletal pain,Back,0
PROLIA,Musculoskeletal pain,extremity,0
PROLIA,Musculoskeletal pain,Musculoskeletal pain Bone,1
PROLIA,Musculoskeletal pain,in Musculoskeletal pain Bone,1
PROLIA,Musculoskeletal pain,Musculoskeletal pain Bone,1
PROLIA,Musculoskeletal pain,Back pain Pain in Musculoskeletal pain,1
PROLIA,Bone pain,extremity Musculoskeletal Bone pain,1
PROLIA,Bone pain,Back pain Pain in Musculoskeletal pain,1
PROLIA,Bone pain,Musculoskeletal Bone pain Myalgia,1
PROLIA,Bone pain,Back pain Pain in Musculoskeletal pain,1
PROLIA,Bone pain,Bone pain Myalgia,1
PROLIA,Bone pain,Back pain Pain in Musculoskeletal pain,1
PROLIA,Bone pain,Bone pain Myalgia Spinal,1
PROLIA,Bone pain,Musculoskeletal Bone pain Myalgia,1
PROLIA,Bone pain,Bone pain Myalgia Spinal,1
PROLIA,Bone pain,Musculoskeletal Bone pain Myalgia Spinal osteoarthritis,1
PROLIA,Bone pain,Bone pain Myalgia Spinal,1
PROLIA,Myalgia,Myalgia Spinal osteoarthritis NERVOUS SYSTEM DI,1
PROLIA,Myalgia,Myalgia Spinal osteoarthritis NERVOUS,1
PROLIA,Myalgia,osteoarthritis,0
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM DISORDERS,1
PROLIA,Spinal osteoarthritis,osteoarthritis,0
PROLIA,Spinal osteoarthritis,Myalgia,0
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM,1
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM DISORDERS Sciatica,1
PROLIA,Spinal osteoarthritis,pain Spinal osteoarthritis NERVOUS SYSTEM,1
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM DISORDERS Sciatica,1
PROLIA,Spinal osteoarthritis,Bone pain Myalgia,0
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS SYSTEM DISORDERS Sciatica,1
PROLIA,Spinal osteoarthritis,SYSTEM DISORDERS Sciatica,0
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis NERVOUS,1
PROLIA,Spinal osteoarthritis,Spinal osteoarthritis,1
PROLIA,Sciatica,SYSTEM Sciatica PSYCHIATRIC DISORDERS,1
PROLIA,Sciatica,Spinal osteoarthritis,1
PROLIA,Sciatica,PSYCHIATRIC DISORDERS Insomnia,0
PROLIA,Sciatica,osteoarthritis NERVOUS SYSTEM DISORDERS,0
PROLIA,Sciatica,Sciatica PSYCHIATRIC,1
PROLIA,Sciatica,Sciatica PSYCHIATRIC,1
PROLIA,Sciatica,Sciatica PSYCHIATRIC,1
PROLIA,Rash,Pruritus,0
PROLIA,Rash,Pruritus,0
PROLIA,Rash,Insomnia SKIN,0
PROLIA,Rash,SUBCUTANEOUS,0
PROLIA,Rash,SUBCUTANEOUS TISSUE Rash Pruritus,1
PROLIA,Rash,SUBCUTANEOUS,0
PROLIA,Rash,Rash,1
PROLIA,Rash,Pruritus Hypocalcemia Decreases,0
PROLIA,Pruritus,Pruritus Hypocalcemia Decreases,1
PROLIA,Hypocalcemia,Hypocalcemia Decreases in serum calcium,1
PROLIA,Hypocalcemia,Rash,0
PROLIA,Hypocalcemia,Decreases,0
PROLIA,Hypocalcemia,Hypocalcemia Decreases in,1
PROLIA,Hypocalcemia,Rash Pruritus,0
PROLIA,Decreases in serum calcium levels,visit were reported in women in the placebo group,0
PROLIA,Decreases in serum calcium levels,Decreases in,1
PROLIA,Decreases in serum calcium levels,Rash Pruritus Decreases in serum calcium levels to less,1
PROLIA,Decreases in serum calcium levels,Decreases in,1
PROLIA,Decreases in serum calcium levels,Rash Pruritus Decreases in serum calcium levels to less than mgdL at,1
PROLIA,Decreases in serum calcium levels,Decreases in,1
PROLIA,Decreases in serum calcium levels,Rash Pruritus Hypocalcemia,0
PROLIA,Decreases in serum calcium levels,Decreases in serum calcium levels,1
PROLIA,Decreases in serum calcium levels,calcium levels to,1
PROLIA,Decreases in serum calcium levels,Pruritus Decreases in serum calcium levels to less than mgdL,1
PROLIA,Decreases in serum calcium levels,calcium levels to,1
PROLIA,Decreases in serum calcium levels,Decreases in serum calcium levels to,1
PROLIA,Decreases in serum calcium levels,calcium levels to,1
PROLIA,infection,may increase the risk infection In the clinical,1
PROLIA,infection,calcium levels to,1
PROLIA,infection,risk infection In the,1
PROLIA,infection,calcium levels to,1
PROLIA,infection,of postmenopausal women,0
PROLIA,infections,postmenopausal women with osteoporosis the incidence of,0
PROLIA,infections,with osteoporosis the incidence of,0
PROLIA,infections,infections resulting in death,1
PROLIA,infections,the incidence infections resulting in,1
PROLIA,infections,infections resulting in death,1
PROLIA,infections,with osteoporosis the,0
PROLIA,infections,infections resulting in,1
PROLIA,death,the incidence of nonfatal,0
PROLIA,death,incidence of infections resulting death,1
PROLIA,death,the incidence of nonfatal,0
PROLIA,death,incidence of infections resulting death was in both placebo and,1
PROLIA,death,the incidence of nonfatal,0
PROLIA,infections,due to,0
PROLIA,infections,infections was in the,1
PROLIA,infections,of nonfatal infections was in the placebo and,1
PROLIA,infections,infections was in the,1
PROLIA,infections,infections was in the,1
PROLIA,infections,of nonfatal,0
PROLIA,infections,the incidence of nonfatal infections was in,1
PROLIA,infections,of nonfatal,0
PROLIA,infections,infections was in the placebo and,1
PROLIA,Endocarditis,Prolia,0
PROLIA,Endocarditis,Endocarditis was reported in no,1
PROLIA,Endocarditis,receiving Prolia Skin infections,0
PROLIA,Endocarditis,Endocarditis was reported,1
PROLIA,Endocarditis,Endocarditis,1
PROLIA,Endocarditis,Endocarditis was reported,1
PROLIA,Endocarditis,Endocarditis,1
PROLIA,Endocarditis,Prolia were Endocarditis,1
PROLIA,Endocarditis,Endocarditis,1
PROLIA,Endocarditis,Endocarditis was reported in,1
PROLIA,Endocarditis,Endocarditis was reported in no,1
PROLIA,Skin infections,Skin infections,1
PROLIA,Skin infections,Endocarditis was reported in no,1
PROLIA,Skin infections,reported Endocarditis was reported in no placebo patients and,0
PROLIA,Skin infections,Skin infections including erysipelas and cellulitis leading,1
PROLIA,Skin infections,frequently in p,0
PROLIA,Skin infections,Skin infections including erysipelas and cellulitis,1
PROLIA,Skin infections,no placebo patients and,0
PROLIA,Skin infections,reported Endocarditis was reported,0
PROLIA,Skin infections,receiving Skin infections including erysipelas and,1
PROLIA,Skin infections,reported Endocarditis was reported,0
PROLIA,erysipelas,erysipelas and,1
PROLIA,erysipelas,receiving Prolia Skin infections erysipelas,1
PROLIA,erysipelas,erysipelas and,1
PROLIA,erysipelas,Skin infections erysipelas and cellulitis,1
PROLIA,erysipelas,erysipelas and,1
PROLIA,erysipelas,Prolia Skin infections erysipelas and,1
PROLIA,erysipelas,erysipelas and,1
PROLIA,cellulitis,cellulitis leading to hospitalization were,1
PROLIA,cellulitis,cellulitis leading to,1
PROLIA,cellulitis,cellulitis leading to hospitalization were,1
PROLIA,cellulitis,cellulitis leading to,1
PROLIA,cellulitis,infections,0
PROLIA,cellulitis,and,0
PROLIA,cellulitis,and patients receiving Prolia Skin,0
PROLIA,cellulitis,with Prolia p,0
PROLIA,cellulitis,cellulitis leading to hospitalization were reported,1
PROLIA,dermal adverse events,eczema and rashes with these events reported in of the,0
PROLIA,dermal adverse events,epidermal dermal adverse events,1
PROLIA,dermal adverse events,in of the placebo and,0
PROLIA,dermal adverse events,in,0
PROLIA,dermal adverse events,events reported in of the placebo and,0
PROLIA,dermatitis,events,0
PROLIA,dermatitis,dermatitis eczema,1
PROLIA,dermatitis,dermatitis eczema and rashes,1
PROLIA,dermatitis,of the,0
PROLIA,dermatitis,treated with Prolia developed epidermal and,0
PROLIA,dermatitis,these events reported in of the,0
PROLIA,dermatitis,and rashes with these events reported in of,0
PROLIA,eczema,eczema and rashes,1
PROLIA,eczema,eczema and rashes with these,1
PROLIA,eczema,eczema and rashes with these events,1
PROLIA,eczema,eczema and rashes with these,1
PROLIA,rashes,dermal adverse events such as dermatitis eczema,0
PROLIA,rashes,rashes with,1
PROLIA,rashes,events,0
PROLIA,rashes,with these events reported in of the placebo and of the Prolia groups p Mo,0
PROLIA,rashes,rashes with these events reported,1
PROLIA,rashes,rashes with these events reported in,1
PROLIA,rashes,rashes with,1
PROLIA,rashes,rashes with,1
PROLIA,ONJ,Warnings and Precautions Osteonecrosis of the,0
PROLIA,ONJ,Jaw,0
PROLIA,ONJ,been reported in the osteoporosis,0
PROLIA,atypical femoral fractures,osteoporosis clinical trial atypical femoral,1
PROLIA,atypical femoral fractures,trial atypical femoral fractures were,1
PROLIA,atypical femoral fractures,osteoporosis clinical trial atypical femoral,1
PROLIA,atypical femoral fractures,atypical femoral fractures were,1
PROLIA,atypical femoral fracture,atypical femoral fracture diagnosis,1
PROLIA,atypical femoral fracture,was,0
PROLIA,atypical femoral fracture,Prolia exposure,0
PROLIA,atypical femoral fracture,early as years see Warnings and,0
PROLIA,atypical femoral fracture,Prolia exposure to time atypical,1
PROLIA,atypical femoral fracture,Prolia exposure to time atypical femoral fracture diagnosis was as early,1
PROLIA,atypical femoral fracture,Prolia exposure to time atypical,1
PROLIA,Pancreatitis,Pancreatitis was reported,1
PROLIA,Pancreatitis,Pancreatitis was,1
PROLIA,Pancreatitis,Pancreatitis,1
PROLIA,Pancreatitis,Pancreatitis was,1
PROLIA,Pancreatitis,Pancreatitis was reported in,1
PROLIA,Pancreatitis,agnosis was,0
PROLIA,Pancreatitis,as years,0
PROLIA,death,in the placebo group and all patients in,0
PROLIA,malignancies,and in the Prolia,0
PROLIA,malignancies,placebo and in the Prolia groups New,0
PROLIA,malignancies,occurrence was variable New Malignancies,0
PROLIA,malignancies,malignancies,1
PROLIA,malignancies,malignancies was,1
PROLIA,malignancies,was in the placebo and in the Prolia groups,0
PROLIA,malignancies,Prolia groups,0
PROLIA,mortality,The incidence of allcause,0
PROLIA,mortality,group The incidence of,0
PROLIA,mortality,vitamin D supplementation per day The,0
PROLIA,mortality,mortality was n,1
PROLIA,mortality,the placebo group and,0
PROLIA,mortality,mortality was n in the placebo,1
PROLIA,mortality,The incidence of mortality was n,1
PROLIA,mortality,mortality was n in the placebo,1
PROLIA,back pain,back pain,1
PROLIA,back pain,back,1
PROLIA,back pain,Prolia than,0
PROLIA,back pain,with osteoporosis and more frequently with Prolia than,0
PROLIA,back pain,arthralgia,0
PROLIA,back pain,back pain placebo vs Prolia,1
PROLIA,back pain,arthralgia,0
PROLIA,arthralgia,the placebotreated patients were back,0
PROLIA,arthralgia,Prolia,0
PROLIA,arthralgia,vs,0
PROLIA,arthralgia,back pain placebo vs arthralgia,1
PROLIA,arthralgia,vs,0
PROLIA,arthralgia,arthralgia placebo vs Prolia and nasopharyngitis,1
PROLIA,arthralgia,arthralgia placebo vs,1
PROLIA,arthralgia,nasopharyngitis placebo vs Prolia,0
PROLIA,arthralgia,arthralgia,1
PROLIA,nasopharyngitis,arthralgia placebo vs Prolia nasopharyngitis placebo vs Prolia Serious Infections,1
PROLIA,nasopharyngitis,arthralgia,1
PROLIA,nasopharyngitis,nasopharyngitis placebo vs Prolia Serious,1
PROLIA,nasopharyngitis,vs Prolia nasopharyngitis placebo vs Prolia,1
PROLIA,nasopharyngitis,nasopharyngitis placebo vs Prolia Serious,1
PROLIA,nasopharyngitis,was reported in,0
PROLIA,nasopharyngitis,nasopharyngitis placebo vs Prolia Serious Infections,1
PROLIA,nasopharyngitis,nasopharyngitis placebo vs Prolia Serious,1
PROLIA,nasopharyngitis,nasopharyngitis placebo vs Prolia Serious,1
PROLIA,infection,no,0
PROLIA,infection,S infection was reported,1
PROLIA,infection,no,0
PROLIA,infection,infection was reported in patient in,1
PROLIA,infection,Prolia,0
PROLIA,infection,Prolia,0
PROLIA,infection,in patient in,0
PROLIA,infection,Serious Infections S erious,0
PROLIA,infection,infection was reported,1
PROLIA,infection,Prolia Serious Infections,0
PROLIA,dermatitis,the Prolia group Dermatologic Reactions Epidermal and dermal adverse,0
PROLIA,dermatitis,dermatitis,1
PROLIA,dermatitis,placebo group,0
PROLIA,dermatitis,dermatitis eczema and rashes were reported,1
PROLIA,dermatitis,dermatitis eczema and rashes were,1
PROLIA,dermatitis,dermatitis,1
PROLIA,dermatitis,group and,0
PROLIA,dermatitis,dermatitis eczema and,1
PROLIA,dermatitis,group and,0
PROLIA,dermatitis,dermatitis eczema and,1
PROLIA,dermatitis,group and,0
PROLIA,dermatitis,Reactions Epidermal and,0
PROLIA,eczema,eczema and rashes were,1
PROLIA,rashes,as dermatitis eczema rashes were reported in,1
PROLIA,rashes,eczema and rashes were,1
PROLIA,rashes,events,0
PROLIA,rashes,dermal adverse events such as dermatitis eczema and,0
PROLIA,rashes,rashes were reported in patients in,1
PROLIA,rashes,as dermatitis,0
PROLIA,rashes,the placebo group and patients in the Prolia,0
PROLIA,rashes,the Prolia group,0
PROLIA,rashes,rashes were reported in patients,1
PROLIA,ONJ,the Jaw No cases ONJ were reported Pancreatitis Pancreatitis was,1
PROLIA,ONJ,rashes were reported in patients,1
PROLIA,Pancreatitis,patient in the,0
PROLIA,Pancreatitis,Pancreatitis was reported in patient,1
PROLIA,malignancies,group New Malignancies malignancies were reported,1
PROLIA,malignancies,Pancreatitis was reported in patient,1
PROLIA,malignancies,Prolia group New Malignancies,0
PROLIA,malignancies,Prolia group New Malignancies malignancies,1
PROLIA,malignancies,Prolia group New Malignancies,0
PROLIA,malignancies,Malignancies malignancies were reported in no,1
PROLIA,malignancies,Prolia group New Malignancies,0
PROLIA,malignancies,group New,0
PROLIA,malignancies,were reported in no patients in the placebo group,0
PROLIA,prostate cancers,the placebo group and prostate,1
PROLIA,prostate cancers,malignancies were reported in no patients in the placebo group and patients,0
PROLIA,prostate cancers,of Bone,0
PROLIA,prostate cancers,prostate cancers basal cell carcinoma in the,1
PROLIA,prostate cancers,group,0
PROLIA,basal cell carcinoma,Receiving Androgen,0
PROLIA,basal cell carcinoma,and patients prostate basal,1
PROLIA,basal cell carcinoma,prostate basal cell carcinoma in the Prolia group,1
PROLIA,basal cell carcinoma,and patients prostate basal,1
PROLIA,basal cell carcinoma,in the placebo,0
PROLIA,basal cell carcinoma,of Bone Loss in Patients,0
PROLIA,basal cell carcinoma,group and patients prostate basal,1
PROLIA,arthralgia,therapy for breast cancer and more frequently than in the placebotreated patients,0
PROLIA,back pain,equently than in the placebotreated patients were arthralgia placebo vs,0
PROLIA,back pain,back pain placebo,1
PROLIA,back pain,back pain placebo vs Prolia Pain,1
PROLIA,back pain,back pain placebo,1
PROLIA,back pain,than in the,0
PROLIA,back pain,Prolia,0
PROLIA,back pain,back pain placebo,1
PROLIA,back pain,back pain placebo vs Prolia Pain,1
PROLIA,Pain in extremity,Prolia and musculoskeletal pain,0
PROLIA,Pain in extremity,pain placebo vs Pain in extremity placebo vs Prolia and musculoskeletal,1
PROLIA,Pain in extremity,Prolia and musculoskeletal pain,0
PROLIA,Pain in extremity,and musculoskeletal,0
PROLIA,Pain in extremity,pain,0
PROLIA,Pain in extremity,in extremity placebo vs Prolia and musculoskeletal,1
PROLIA,Pain in extremity,s were arthralgia placebo vs Prolia and back pain placebo vs,0
PROLIA,Pain in extremity,Pain in extremity placebo,1
PROLIA,Pain in extremity,back pain placebo vs Pain,1
PROLIA,Pain in extremity,Pain in extremity placebo vs Prolia,1
PROLIA,Pain in extremity,and musculoskeletal pain placebo vs Prolia have also be,0
PROLIA,musculoskeletal pain,musculoskeletal pain,1
PROLIA,musculoskeletal pain,extremity placebo vs Prolia musculoskeletal,1
PROLIA,musculoskeletal pain,Prolia have also,0
PROLIA,musculoskeletal pain,clinical trials Additionally in,0
PROLIA,musculoskeletal pain,clinical trials Additionally in Proliat,0
PROLIA,musculoskeletal pain,reported in,0
PROLIA,musculoskeletal pain,back pain placebo vs Prolia Pain in extremity,0
PROLIA,musculoskeletal pain,musculoskeletal pain placebo,1
PROLIA,musculoskeletal pain,trials Additionally,0
PROLIA,musculoskeletal pain,musculoskeletal pain placebo vs Prolia,1
PROLIA,cataracts,serum calcium mgdL was,0
PROLIA,cataracts,vs Prolia Hypocalcemia,0
PROLIA,cataracts,cataracts was,1
PROLIA,cataracts,ADT a greater incidence cataracts was observed placebo vs Prolia,1
PROLIA,cataracts,cataracts was,1
PROLIA,cataracts,serum calcium mgdL was reported,0
PROLIA,cataracts,cataracts was,1
PROLIA,Hypocalcemia,Hypocalcemia serum calcium,1
PROLIA,Hypocalcemia,vs at,0
PROLIA,Hypocalcemia,observed placebo vs Hypocalcemia serum calcium mgdL was reported,1
PROLIA,Hypocalcemia,vs at,0
PROLIA,Hypocalcemia,Hypocalcemia serum,1
PROLIA,Hypocalcemia,Hypocalcemia serum calcium mgdL,1
PROLIA,Hypocalcemia,calcium mgdL was reported only,0
PROLIA,Hypocalcemia,was observed placebo vs,0
PROLIA,Hypocalcemia,vs Hypocalcemia serum,1
PROLIA,Hypocalcemia,was observed placebo vs,0
PROLIA,hypersensitivity reactions,use,0
PROLIA,hypersensitivity reactions,use of,0
PROLIA,hypersensitivity reactions,hypersensitivity reactions,1
PROLIA,hypersensitivity reactions,of Prolia hypersensitivity reactions anaphylaxis,1
PROLIA,hypersensitivity reactions,hypersensitivity reactions,1
PROLIA,hypersensitivity reactions,wing adverse reactions have been identified during post approval use of,0
PROLIA,hypersensitivity reactions,Prolia hypersensitivity,1
PROLIA,hypersensitivity reactions,use of Prolia hypersensitivity reactions anaphylaxis rash,1
PROLIA,hypersensitivity reactions,Prolia hypersensitivity,1
PROLIA,hypersensitivity reactions,swelling,0
PROLIA,anaphylaxis,anaphylaxis rash urticaria,1
PROLIA,anaphylaxis,anaphylaxis rash urticaria,1
PROLIA,anaphylaxis,of Prolia Drugrelated hypersensitivity anaphylaxis,1
PROLIA,anaphylaxis,anaphylaxis rash urticaria,1
PROLIA,anaphylaxis,Drugrelated hypersensitivity anaphylaxis rash urticaria facial swelling and,1
PROLIA,anaphylaxis,anaphylaxis rash urticaria,1
PROLIA,anaphylaxis,hypersensitivity anaphylaxis rash,1
PROLIA,anaphylaxis,anaphylaxis rash urticaria,1
PROLIA,rash,rash urticaria facial,1
PROLIA,rash,rash urticaria facial,1
PROLIA,rash,reactions rash urticaria facial swelling and,1
PROLIA,rash,rash urticaria facial,1
PROLIA,rash,of Prolia Drugrelated hypersensitivity reactions anaphylaxis,0
PROLIA,rash,severe,0
PROLIA,rash,Prolia Drugrelated hypersensitivity reactions rash urticaria facial swelling,1
PROLIA,rash,severe,0
PROLIA,rash,reactions rash urticaria facial swelling and erythema,1
PROLIA,rash,severe,0
PROLIA,rash,reactions rash urticaria facial swelling and erythema,1
PROLIA,rash,severe,0
PROLIA,rash,urticaria facial swelling,0
PROLIA,rash,Prolia Drugrelated hypersensitivity reactions rash urticaria,1
PROLIA,rash,urticaria facial swelling,0
PROLIA,urticaria,severe symptomatic hypocalcemia,0
PROLIA,urticaria,anaphylaxis,0
PROLIA,facial swelling,urticaria,0
PROLIA,facial swelling,rash facial swelling,1
PROLIA,facial swelling,reactions anaphylaxis rash urticaria,0
PROLIA,facial swelling,reactions anaphylaxis rash facial swelling,1
PROLIA,facial swelling,reactions anaphylaxis rash urticaria,0
PROLIA,facial swelling,facial swelling,1
PROLIA,facial swelling,facial swelling and,1
PROLIA,facial swelling,reactions,0
PROLIA,facial swelling,facial swelling and,1
PROLIA,facial swelling,urticaria,0
PROLIA,facial swelling,facial swelling and erythema Hypocalcemia severe,1
PROLIA,erythema,swelling and,0
PROLIA,erythema,facial swelling erythema,1
PROLIA,erythema,swelling and,0
PROLIA,erythema,erythema Hypocalcemia severe symptomatic hypocalcemia,1
PROLIA,erythema,Hypocalcemia severe,0
PROLIA,erythema,Musculoskeletal pain including severe,0
PROLIA,erythema,erythema Hypocalcemia severe symptomatic hypocalcemia Musculoskeletal,1
PROLIA,erythema,swelling erythema Hypocalcemia severe,1
PROLIA,erythema,erythema Hypocalcemia severe symptomatic hypocalcemia Musculoskeletal,1
PROLIA,Hypocalcemia,facial swelling and Hypocalcemia severe symptomatic hypocalcemia,1
PROLIA,Hypocalcemia,erythema Hypocalcemia severe symptomatic hypocalcemia Musculoskeletal,1
PROLIA,symptomatic hypocalcemia,severe cases Parathyroid Hormone PTH,0
PROLIA,symptomatic hypocalcemia,and erythema Hypocalcemia symptomatic hypocalcemia Musculoskeletal pain including,1
PROLIA,symptomatic hypocalcemia,severe cases Parathyroid Hormone PTH,0
PROLIA,symptomatic hypocalcemia,symptomatic hypocalcemia,1
PROLIA,symptomatic hypocalcemia,pain including severe cases Parathyroid Hormone PTH,0
PROLIA,symptomatic hypocalcemia,erythema Hypocalcemia symptomatic,1
PROLIA,symptomatic hypocalcemia,Hypocalcemia,0
PROLIA,hypocalcemia,severe cases Parathyroid Hormone,0
PROLIA,hypocalcemia,hypocalcemia,1
PROLIA,hypocalcemia,hypocalcemia Musculoskeletal pain including severe cases,1
PROLIA,hypocalcemia,hypocalcemia Musculoskeletal pain including severe,1
PROLIA,hypocalcemia,hypocalcemia Musculoskeletal,1
PROLIA,hypocalcemia,severe,0
PROLIA,hypocalcemia,cases Parathyroid Hormone PTH,0
PROLIA,hypocalcemia,hypocalcemia Musculoskeletal pain including severe,1
PROLIA,hypocalcemia,anaphylaxis rash,0
PROLIA,Musculoskeletal pain,Musculoskeletal pain including severe cases Parathyroid Hormone,1
PROLIA,Musculoskeletal pain,Marked,0
PROLIA,Musculoskeletal pain,facial swelling and erythema Hypocalcemia severe symptomatic hypocalcemia,0
PROLIA,Musculoskeletal pain,Musculoskeletal pain including severe,1
PROLIA,Musculoskeletal pain,Hypocalcemia severe symptomatic Musculoskeletal pain including,1
PROLIA,Musculoskeletal pain,Musculoskeletal pain including severe,1
PROLIA,Musculoskeletal pain,symptomatic Musculoskeletal pain,1
PROLIA,Musculoskeletal pain,facial swelling and,0
PROLIA,Musculoskeletal pain,Musculoskeletal pain including severe,1
PROLIA,Musculoskeletal pain,symptomatic Musculoskeletal pain,1
PROLIA,elevation in serum PTH,elevation,1
PROLIA,elevation in serum PTH,Hormone PTH elevation in serum PTH,1
PROLIA,elevation in serum PTH,Marked,0
PROLIA,elevation in serum PTH,cases Parathyroid Hormone PTH elevation,1
PROLIA,elevation in serum PTH,Hormone PTH elevation in serum PTH,1
PROLIA,elevation in serum PTH,cases Parathyroid Hormone PTH elevation,1
PROLIA,elevation in serum PTH,in patients with severe renal,0
PROLIA,elevation in serum PTH,elevation in serum PTH in patients,1
PROLIA,elevation in serum PTH,in patients with severe renal,0
PROLIA,elevation in serum PTH,Parathyroid Hormone,0
PROLIA,elevation in serum PTH,Hormone PTH elevation in serum PTH in,1
PROLIA,elevation in serum PTH,Parathyroid Hormone,0
PROLIA,elevation in serum PTH,in serum PTH in patients with severe renal,1
PROLIA,toxicity,altered pharmacokinetic toxicity profile or clinical,1
PROLIA,toxicity,in serum PTH in patients with severe renal,1
PROLIA,toxicity,toxicity,1
PROLIA,Hypersensitivity,Warnings and Pre cautions,1
PROLIA,Hypersensitivity,elsewhere in the labeling Hypocalcemia see,0
PROLIA,Hypersensitivity,Warnings and Pre cautions Serious Infections,1
PROLIA,Hypersensitivity,elsewhere in the labeling Hypocalcemia see,0
PROLIA,Hypersensitivity,discussed below and also elsewhere in the labeling,0
PROLIA,anaphylactic reactions,Adverse Reactions,0
PROLIA,anaphylactic reactions,* Serious Infections see Warnings,1
PROLIA,anaphylactic reactions,Hypocalcemia see Warnings and 5.3 )] *,1
PROLIA,anaphylactic reactions,"and  5.3  )]  
 *  Serious",1
PROLIA,anaphylactic reactions,Hypocalcemia see Warnings and 5.3 )] *,1
PROLIA,anaphylactic reactions,)] * Serious Infections see Warnings,1
PROLIA,anaphylactic reactions,)] * Serious Infections,1
PROLIA,anaphylactic reactions,5.3 )] *,1
PROLIA,Hypocalcemia,Warnings and Precautions Osteonecrosis of,1
PROLIA,Hypocalcemia,the Jaw see,0
PROLIA,Hypocalcemia,rious Infections see Warnings and Precautions Dermatologic Adverse,0
PROLIA,Hypocalcemia,Warnings and Precautions Dermatologic Adverse,0
PROLIA,Hypocalcemia,Adverse Reactions Warnings,1
PROLIA,Osteonecrosis of the jaw,and Diaphyseal,0
PROLIA,Osteonecrosis of the jaw,see Warnings and,0
PROLIA,Osteonecrosis of the jaw,with Prolia in patients with postmenopausal,0
PROLIA,Osteonecrosis of the jaw,( 5.5 )] The most,1
PROLIA,Osteonecrosis of the jaw,Precautions ( 5.5 )] The most common adverse,1
PROLIA,Atypical femoral fractures,with postmenopausal os teoporosis are,1
PROLIA,Atypical femoral fractures,patie,0
PROLIA,infections,men with osteoporosis are back pain arthralgia,0
PROLIA,infections,mon advers e reactions reported,1
PROLIA,infections,in men with osteoporosis are back pain arthralgia and nasopharyng,0
PROLIA,infections,and cystitis The,0
PROLIA,infections,mon advers e reactions reported with Prolia,1
PROLIA,infections,The most mon,1
PROLIA,infections,The most mon,1
PROLIA,infections,and cystitis The most mon advers e reactions reported with Prolia,1
PROLIA,infections,The most mon,1
PROLIA,infections,mon advers e reactions,1
PROLIA,skin infections,The most common adverse reported,1
PROLIA,Dermatologic reactions,in patients with e loss receiving,1
PROLIA,Dermatologic reactions,in patients with e loss receiving andro gen,1
PROLIA,Dermatologic reactions,in patients with e loss receiving,1
PROLIA,Dermatologic reactions,e loss receiving andro gen deprivation therapy for,1
PROLIA,Dermatologic reactions,in patients with e loss receiving,1
PROLIA,Dermatologic reactions,in patients with e loss receiving andro gen deprivation therapy for prostate,1
PROLIA,Dermatologic reactions,in patients with e loss receiving,1
PROLIA,Dermatologic reactions,with e loss receiving,1
PROLIA,Dermatologic reactions,patients with bon,0
PROLIA,Dermatologic reactions,patients with e loss receiving andro gen deprivation therapy for prostate,1
PROLIA,Dermatologic reactions,patients with bon,0
PROLIA,Dermatologic reactions,receiving andro gen deprivation therapy for,1
PROLIA,Dermatologic reactions,loss receiving andro gen,1
PROLIA,Dermatitis,n deprivat ion therapy,1
PROLIA,Dermatitis,n deprivat ion,1
PROLIA,Dermatitis,with bone loss receiving n deprivat ion therapy for prostate cancer,1
PROLIA,Dermatitis,n deprivat ion,1
PROLIA,Dermatitis,with bone loss receiving n,1
PROLIA,Dermatitis,or adjuvant aromatase inhibitor,0
PROLIA,Dermatitis,receiving n deprivat ion therapy for,1
PROLIA,Dermatitis,or adjuvant aromatase inhibitor,0
PROLIA,Dermatitis,loss receiving n deprivat ion therapy,1
PROLIA,Dermatitis,or adjuvant aromatase inhibitor,0
PROLIA,Dermatitis,with bone loss receiving n deprivat ion,1
PROLIA,Dermatitis,or adjuvant aromatase inhibitor,0
PROLIA,Dermatitis,ncidence adverse reactions,0
PROLIA,rashes,n ther apy for,1
PROLIA,rashes,ncidence adverse reactions,0
PROLIA,rashes,receiving androgen n ther apy,1
PROLIA,rashes,ncidence adverse reactions,0
PROLIA,rashes,bone loss receiving androgen,0
PROLIA,rashes,loss receiving androgen n ther,1
PROLIA,eczema,androgen deprivation therapy r pros,1
PROLIA,Muscle Pain,emity and m usculoskeletal pain have also been,1
PROLIA,Muscle Pain,androgen deprivation therapy r pros,1
PROLIA,Muscle Pain,pain Pain in emity and m usculoskeletal pain,1
PROLIA,Muscle Pain,androgen deprivation therapy r pros,1
PROLIA,Muscle Pain,in clinical,0
PROLIA,Muscle Pain,pain Pain in emity and m usculoskeletal pain,1
PROLIA,Muscle Pain,in clinical,0
PROLIA,Muscle Pain,pain have also been reported in clinical trials The most,0
PROLIA,Muscle Pain,pain Pain in emity and,1
PROLIA,Muscle Pain,emity and m usculoskeletal pain have,1
PROLIA,Muscle Pain,Pain in emity and m usculoskeletal pain have,1
PROLIA,Muscle Pain,emity and m usculoskeletal pain have,1
PROLIA,Suppression of bone turnover,he most common,1
PROLIA,hypersensitivity,thi,0
PROLIA,hypersensitivity,s program. EXCERPT Postmenopausal,1
PROLIA,hypersensitivity,more information about s,1
PROLIA,anaphylaxis,this program     *  Post,1
PROLIA,anaphylaxis,more information about s,1
PROLIA,anaphylaxis,* Post menopausal osteoporosis Most common,1
PROLIA,hypotension,back pain pain in extremity hypercholesterolemia musculoskeletal,0
PROLIA,hypotension,back pain pain in extremity hypercholesterolemia musculoskeletal,0
PROLIA,hypotension,common adverse (> 5% and m ore common than placebo,1
PROLIA,hypotension,back pain pain in extremity hypercholesterolemia musculoskeletal,0
PROLIA,hypotension,and m ore common,1
PROLIA,hypotension,adverse (> 5% and,1
PROLIA,hypotension,5% and m ore common than placebo,1
PROLIA,hypotension,out this program EXCERPT Postmenopausal osteoporosis Most common,0
PROLIA,hypotension,were back pain pain,0
PROLIA,dyspnea,e commo n,1
PROLIA,dyspnea,common adverse reactions and e commo n than placebo were,1
PROLIA,dyspnea,e commo n,1
PROLIA,dyspnea,and e,1
PROLIA,dyspnea,e commo n than placebo,1
PROLIA,throat tightness,more than placebo),1
PROLIA,throat tightness,than placebo) we re back pain pain,1
PROLIA,upper airway edema,Pancreatitis,0
PROLIA,upper airway edema,pain in extremit y,1
PROLIA,upper airway edema,common adverse reactions and more common than placebo were back,0
PROLIA,upper airway edema,common,0
PROLIA,upper airway edema,in extremit,1
PROLIA,upper airway edema,pain in extremit y hypercholesterolemia musculoskeletal pain,1
PROLIA,upper airway edema,pain in extremit y hypercholesterolemia musculoskeletal pain and,1
PROLIA,upper airway edema,"than placebo were back , pain",1
PROLIA,pruritus,pain pain in  hyperch,1
PROLIA,pruritus,"than placebo were back , pain",1
PROLIA,pruritus, hyperch olesterolemia musculoskeletal pain and cystitis,1
PROLIA,pruritus, hyperch olesterolemia musculoskeletal pain,1
PROLIA,pruritus, hyperch olesterolemia,1
PROLIA,pruritus, hyperch olesterolemia musculoskeletal pain,1
PROLIA,urticaria,musculoskeletal pain and cystitis Pancreatitis has been,0
PROLIA,urticaria,than placebo were back pain pain in extremity,0
PROLIA,urticaria,"rolemia,  musculoskeletal pain",1
PROLIA,urticaria,than placebo were back pain pain in extremity,0
PROLIA,urticaria,in clinical trials,0
PROLIA,urticaria,"rolemia,  musculoskeletal pain and cystitis",1
PROLIA,urticaria,"rolemia, ",1
PROLIA,urticaria,"rolemia, ",1
PROLIA,hypocalcemia,drug cannot be directly pared to rat es in the,1
PROLIA,hypocalcemia,"rolemia, ",1
PROLIA,hypocalcemia,be directly pared to rat es in the clinical studies,1
PROLIA,hypocalcemia,"rolemia, ",1
PROLIA,hypocalcemia,the clinical studies,0
PROLIA,hypocalcemia,to rat es,1
PROLIA,Hypocalcemia,Women ith,1
PROLIA,Hypocalcemia,not reflect the rates observed in clinical practice Treatment of Postmenopausal Women w,0
PROLIA,Hypocalcemia,Women ith Osteopor osis,1
PROLIA,Hypocalcemia,not reflect the rates observed in clinical practice Treatment of Postmenopausal Women w,0
PROLIA,Hypocalcemia,Treatment of Postmenopausal Women ith Osteopor,1
PROLIA,Hypocalcemia,not reflect the rates observed in clinical practice Treatment of Postmenopausal Women w,0
PROLIA,Hypocalcemia,postmenopausal osteoporosis was assessed in a,0
PROLIA,Hypocalcemia,Postmenopausal Women ith,1
PROLIA,Hypocalcemia,practice Treatment of,0
PROLIA,Hypocalcemia,Postmenopausal Women ith Osteopor,1
PROLIA,Hypocalcemia,practice Treatment of,0
PROLIA,Hypocalcemia,osteoporosis was assessed in,0
PROLIA,elevations of serum parathyroid hormone,study of l women aged 60 to 91 years. A total of women were,1
PROLIA,elevations of serum parathyroid hormone,osteoporosis was assessed in,0
PROLIA,elevations of serum parathyroid hormone,doubleblind placebocontrolled multinational study,0
PROLIA,elevations of serum parathyroid hormone,placebocontrolled multinational study of l women aged 60 to 91 years. A total of women were exposed,1
PROLIA,elevations of serum parathyroid hormone,doubleblind placebocontrolled multinational study,0
PROLIA,elevations of serum parathyroid hormone,aged 60 to 91 years. A total of women were,1
PROLIA,elevations of serum parathyroid hormone,were exposed,0
PROLIA,elevations of serum parathyroid hormone,postmenopausa,0
PROLIA,ONJ,adverse events was,0
PROLIA,ONJ,events was and for,0
PROLIA,ONJ,was and for the placebo and Prolia groups respectively Adverse reac,0
PROLIA,ONJ,postmenopausal women with osteoporosis and more frequently,0
PROLIA,ONJ,ns,0
PROLIA,ONJ,tio ns,1
PROLIA,ONJ,tio ns reported in of postmenopausal,1
PROLIA,ONJ,tio ns,1
PROLIA,ONJ,tio ns reported in,1
PROLIA,Atypical femoral fractures,(2.0) Pruritus Hypocalcemia Decreases in serum calcium,1
PROLIA,Atypical femoral fractures,"SUBCUTANEOUS TISSUE DISORDERS  (2.0)   
     Pruritus    Hypocalcemia Decreases in",1
PROLIA,Atypical femoral fractures,(2.0) Pruritus Hypocalcemia Decreases in serum calcium,1
PROLIA,thigh pain,in  Prolia gr oup The nadir in serum,1
PROLIA,thigh pain,(2.0) Pruritus Hypocalcemia Decreases in serum calcium,1
PROLIA,thigh pain,the,0
PROLIA,thigh pain,in the placebo group and,0
PROLIA,thigh pain,nadir in serum calcium level occurs at approximately day after Prolia dosing in subjects,0
PROLIA,thigh pain, Prolia gr oup The nadir,1
PROLIA,thigh pain,nadir in serum calcium level occurs at approximately day after Prolia dosing in subjects,0
PROLIA,thigh pain,group and women in Prolia gr,1
PROLIA,thigh pain,women in Prolia gr,1
PROLIA,thigh pain,in women in the,0
PROLIA,skin infections,vs n subjects with,1
PROLIA,skin infections,in women in the,0
PROLIA,skin infections,subjects with creatinine clearance mLmin Serious Infections,1
PROLIA,skin infections,creatinine clearance mLmin vs n subjects,1
PROLIA,skin infections,n subjects with creatinine clearance mLmin Serious Infections,1
PROLIA,skin infections,creatinine clearance mLmin vs n subjects,1
PROLIA,skin infections,clearance,0
PROLIA,skin infections,n subjects with creatinine clearance,1
PROLIA,skin infections,Prolia dosing was in subjects with creatinine clearance mLmin,0
PROLIA,infections of the abdomen,RANKL is expressed,0
PROLIA,infections of the abdomen,ligand RANKL is expressed on,0
PROLIA,infections of the abdomen,with creatinine learance >=,1
PROLIA,Endocarditis,kappaB RANKL) is ex,1
PROLIA,Endocarditis,with creatinine learance >=,1
PROLIA,Endocarditis,nuclear factor kappaB RANKL) is ex pressed on activated T and,1
PROLIA,Endocarditis,with creatinine learance >=,1
PROLIA,opportunistic infections,and B lymphocytes and,0
PROLIA,infections,menopausal women with osteoporosis,1
PROLIA,infections,the clinical study of,0
PROLIA,infections,the,0
PROLIA,infections,(0.7% pl acebo vs Prolia,1
PROLIA,infections,in the n (0.7% pl acebo vs Prolia,1
PROLIA,infections,(0.7% pl acebo vs Prolia,1
PROLIA,infections,n (0.7% pl acebo vs Prolia,1
PROLIA,dermal adverse events,that reported with,0
PROLIA,dermal adverse events,(< 0.1% placebo vs Prolia The,1
PROLIA,dermal adverse events,The incidence of opportunistic infections was,0
PROLIA,dermal adverse events,to that reported with p,0
PROLIA,dermal adverse events,in patients treated with rolia (<,1
PROLIA,dermal adverse events,rolia (< 0.1% placebo,1
PROLIA,dermal adverse events,rolia,1
PROLIA,dermal adverse events,The incidence of opportunistic infections was similar to that,0
PROLIA,dermatitis," Prolia).
 The incidence of opportunistic",1
PROLIA,dermatitis,vs,0
PROLIA,dermatitis," Prolia).
",1
PROLIA,dermatitis,"Prolia placebo  Prolia).
 The incidence of",1
PROLIA,dermatitis," Prolia).
",1
PROLIA,dermatitis," Prolia).
 The incidence of",1
PROLIA,dermatitis,with Prolia placebo,0
PROLIA,dermatitis," Prolia).
 The incidence of opportunistic",1
PROLIA,dermatitis,"treated with Prolia placebo  Prolia).
",1
PROLIA,dermatitis," Prolia).
 The incidence of opportunistic",1
PROLIA,dermatitis,"with Prolia placebo  Prolia).
",1
PROLIA,dermatitis," Prolia).
 The incidence of opportunistic",1
PROLIA,eczema,frequently in patients treated,0
PROLIA,eczema,of opportunistic infections was,0
PROLIA,rashes,The nce,1
PROLIA,muscle pain,events were not pecific to  the injection,1
PROLIA,muscle pain,The nce,1
PROLIA,muscle pain,were not pecific,1
PROLIA,suppression of bone remodeling,Prolia The duration of ia exposure to time of atypica,1
PROLIA,suppression of bone remodeling,Warnings and,0
PROLIA,suppression of bone remodeling,treated with Prolia,0
PROLIA,suppression of bone remodeling,ia exposure to time of atypica l femoral fracture,1
PROLIA,suppression of bone remodeling,treated with Prolia,0
PROLIA,suppression of bone remodeling,was as early as years,0
PROLIA,suppression of bone remodeling,of atypica l,1
PROLIA,suppression of bone remodeling,in the Prolia group had serious,1
PROLIA,suppression of bone remodeling,group and 8,1
PROLIA,suppression of bone remodeling,in,0
PROLIA,suppression of bone remodeling,and all,0
PROLIA,suppression of bone remodeling,and all,0
PROLIA,osteonecrosis of the jaw,the,0
PROLIA,osteonecrosis of the jaw,group eral,1
PROLIA,osteonecrosis of the jaw,Prolia,0
PROLIA,osteonecrosis of the jaw,group eral patients,1
PROLIA,osteonecrosis of the jaw,history of pancreatitis The time from product administration to event,0
PROLIA,osteonecrosis of the jaw,of pancreatitis The time from product,0
PROLIA,atypical fractures,of pancrea titis The,1
PROLIA,atypical fractures,of pancrea titis The time,1
PROLIA,atypical fractures,a history of pancrea titis The time,1
PROLIA,atypical fractures,of pancrea titis The time,1
PROLIA,delayed fracture healing,of The time,1
PROLIA,delayed fracture healing,product a dministration to event occurrence,1
PROLIA,delayed fracture healing,from product a dministration to event occurrence was,1
PROLIA,delayed fracture healing,group Several patients had a prior history,0
FANAPT,dizziness,fatigue nasal,0
FANAPT,dizziness,adverse reactions incidence and fold greater than placebo were,0
FANAPT,dizziness,tachycardia and weight,0
FANAPT,dry mouth,dry mouth,1
FANAPT,dry mouth,greater than placebo,0
FANAPT,dry mouth,than placebo were dry mouth fatigue nasal,1
FANAPT,dry mouth,greater than placebo,0
FANAPT,dry mouth,dry mouth,1
FANAPT,dry mouth,greater than placebo,0
FANAPT,dry mouth,observed adverse reactions incidence and fold greater,0
FANAPT,dry mouth,were dry mouth,1
FANAPT,dry mouth,dry mouth fatigue nasal congestion orthostatic,1
FANAPT,dry mouth,were dry mouth,1
FANAPT,fatigue,dizziness dry fatigue nasal congestion,1
FANAPT,fatigue,were dry mouth,1
FANAPT,fatigue,dizziness dry fatigue nasal congestion,1
FANAPT,fatigue,were dry mouth,1
FANAPT,nasal congestion,and weight,0
FANAPT,nasal congestion,dizziness dry mouth nasal,1
FANAPT,nasal congestion,orthostatic hypotension somnolence tachycardia and,0
FANAPT,nasal congestion,tachycardia and,0
FANAPT,nasal congestion,and fold greater than placebo,0
FANAPT,nasal congestion,increased,0
FANAPT,nasal congestion,dizziness dry mouth nasal,1
FANAPT,somnolence,somnolence tachycardia and weight,1
FANAPT,somnolence,nasal congestion orthostatic somnolence tachycardia,1
FANAPT,somnolence,somnolence tachycardia and weight,1
FANAPT,somnolence,somnolence tachycardia and weight increased,1
FANAPT,tachycardia,tachycardia and weight increased To report,1
FANAPT,weight increased,REACTIONS contact Novartis Pharmaceuticals Corporatio,0
FANAPT,weight increased,Novartis Pharmaceuticals,0
FANAPT,weight increased,weight increased,1
FANAPT,weight increased,somnolence,0
FANAPT,Weight Increased,Musculoskeletal Weight Increased,1
FANAPT,Weight Increased,somnolence,0
FANAPT,Weight Increased,Weight Increased Cardiac,1
FANAPT,Weight Increased,somnolence,0
FANAPT,Weight Increased,Musculoskeletal Stiffness,0
FANAPT,Weight Increased,Weight Increased Cardiac Disorders,1
FANAPT,Weight Increased,Weight Increased Cardiac Disorders,1
FANAPT,Weight Increased,Weight Increased Cardiac Disorders,1
FANAPT,Weight Increased,Weight Increased,1
FANAPT,Weight Increased,Musculoskeletal Weight Increased Cardiac Disorders,1
FANAPT,Weight Increased,Weight Increased,1
FANAPT,Weight Increased,Weight Increased Cardiac,1
FANAPT,Weight Increased,Weight Increased Cardiac,1
FANAPT,Vision Blurred,Eye Vision Blurred Gastrointestinal,1
FANAPT,Vision Blurred,Weight Increased Cardiac,1
FANAPT,Vision Blurred,Vision Blurred,1
FANAPT,Vision Blurred,Vision Blurred,1
FANAPT,Vision Blurred,Vision Blurred,1
FANAPT,Nausea,Gastrointestinal Nausea,1
FANAPT,Nausea,Vision Blurred,1
FANAPT,Diarrhea,Dry Diarrhea,1
FANAPT,Diarrhea,Vision Blurred,1
FANAPT,Hypotension,Hypotension Table includes adverse,1
FANAPT,Hypotension,Hypotension,1
FANAPT,Hypotension,Hypotension Table includes adverse,1
FANAPT,Hypotension,Hypotension Table includes adverse,1
FANAPT,Hypotension,Table includes adverse reactions,0
FANAPT,Hypotension,Hypotension Table includes adverse reactions,1
FANAPT,Hypotension,Hypotension Table,1
FANAPT,Hypotension,Hypotension,0
FANAPT,Hypotension,Hypotension Table includes,1
FANAPT,Hypotension,Orthostatic Hypotension,0
FANAPT,Hypotension,includes adverse,0
FANAPT,abdominal discomfort,to mgday abdominal discomfort dizziness hypotension,1
FANAPT,abdominal discomfort,includes adverse,0
FANAPT,dizziness,tachycardia and weight,0
FANAPT,dizziness,dizziness hypotension musculoskeletal stiffness tachycardia and,1
FANAPT,dizziness,dizziness hypotension,1
FANAPT,dizziness,Common and,0
FANAPT,dizziness,stiffness tachycardia,0
FANAPT,dizziness,dizziness hypotension musculoskeletal,1
FANAPT,dizziness,dizziness,1
FANAPT,hypotension,increased Common and DrugRelated,0
FANAPT,hypotension,and DrugRelated,0
FANAPT,hypotension,hypotension musculoskeletal stiffness tachycardia and weight,1
FANAPT,hypotension,weight increased Common,0
FANAPT,hypotension,hypotension musculoskeletal stiffness tachycardia and weight,1
FANAPT,musculoskeletal stiffness,musculoskeletal stiffness tachycardia,1
FANAPT,musculoskeletal stiffness,musculoskeletal stiffness tachycardia and weight increased Common,1
FANAPT,musculoskeletal stiffness,musculoskeletal stiffness tachycardia,1
FANAPT,musculoskeletal stiffness,were abdominal discomfort dizziness musculoskeletal,1
FANAPT,tachycardia,discomfort dizziness,0
FANAPT,tachycardia,and DrugRelated Adverse Reactions in Clinical Trials Ba,0
FANAPT,tachycardia,tachycardia and weight increased Common and,1
FANAPT,tachycardia,abdominal discomfort dizziness hypotension musculoskeletal stiffness,0
FANAPT,tachycardia,dizziness hypotension musculoskeletal tachycardia and weight increased,1
FANAPT,tachycardia,abdominal discomfort dizziness hypotension musculoskeletal stiffness,0
FANAPT,tachycardia,tachycardia and weight increased,1
FANAPT,tachycardia,tachycardia and,1
FANAPT,tachycardia,weight increased Common and DrugRelated Adverse Reactions in,0
FANAPT,weight increased,weight increased Common and,1
FANAPT,weight increased,weight increased,1
FANAPT,weight increased,weight increased Common and DrugRelated Adverse,1
FANAPT,weight increased,weight increased Common,1
FANAPT,weight increased,day were abdominal discomfort dizziness hypotension musculoskeletal stiffness tachycardia,0
FANAPT,weight increased,stiffness tachycardia weight,1
FANAPT,weight increased,dizziness hypotension musculoskeletal,0
FANAPT,dizziness,dizziness dry,1
FANAPT,dizziness,dizziness hypotension musculoskeletal,0
FANAPT,dizziness,dizziness dry mouth fatigue nasal,1
FANAPT,dry mouth,for at least dose dry,1
FANAPT,dry mouth,least dose dry mouth fatigue nasal congestion,1
FANAPT,dry mouth,for at least dose dry,1
FANAPT,dry mouth,tachycardia orthostatic hypotension and weight increased,0
FANAPT,fatigue,fatigue nasal congestion somnolence,1
FANAPT,fatigue,fatigue nasal congestion somnolence tachycardia orthostatic,1
FANAPT,fatigue,fatigue nasal congestion somnolence,1
FANAPT,fatigue,orthostatic hypotension,0
FANAPT,fatigue,somnolence,0
FANAPT,fatigue,dry fatigue nasal congestion,1
FANAPT,fatigue,somnolence,0
FANAPT,nasal congestion,increased,0
FANAPT,nasal congestion,nasal congestion somnolence tachycardia orthostatic hypotension and,1
FANAPT,nasal congestion,nasal congestion somnolence tachycardia,1
FANAPT,nasal congestion,for at least dose dizziness dry mouth fatigue,0
FANAPT,nasal congestion,dry mouth nasal congestion somnolence tachycardia orthostatic hypotension and,1
FANAPT,nasal congestion,for at least dose dizziness dry mouth fatigue,0
FANAPT,nasal congestion,dry mouth nasal congestion somnolence tachycardia orthostatic hypotension and,1
FANAPT,nasal congestion,for at least dose dizziness dry mouth fatigue,0
FANAPT,nasal congestion,weight increased,0
FANAPT,nasal congestion,dose dizziness dry mouth nasal congestion,1
FANAPT,somnolence,for,0
FANAPT,somnolence,fatigue nasal somnolence,1
FANAPT,somnolence,for,0
FANAPT,somnolence,and weight increased Dizziness tachycardia and,0
FANAPT,somnolence,fatigue nasal somnolence,1
FANAPT,somnolence,and weight increased Dizziness tachycardia and,0
FANAPT,tachycardia,tachycardia orthostatic,1
FANAPT,tachycardia,and weight increased Dizziness tachycardia and,0
FANAPT,tachycardia,dose dizziness dry,0
FANAPT,tachycardia,tachycardia orthostatic hypotension and,1
FANAPT,tachycardia,hypotension and weight increased Dizziness tachycardia and weight increased were a,0
FANAPT,tachycardia,tachycardia orthostatic hypotension,1
FANAPT,tachycardia,tachycardia orthostatic hypotension,1
FANAPT,tachycardia,placebo rate for,0
FANAPT,tachycardia,mouth fatigue nasal congestion tachycardia orthostatic hypotension and weight increased,1
FANAPT,tachycardia,placebo rate for,0
FANAPT,tachycardia,congestion tachycardia orthostatic hypotension and,1
FANAPT,tachycardia,placebo rate for,0
FANAPT,orthostatic hypotension,nasal congestion somnolence orthostatic hypotension,1
FANAPT,orthostatic hypotension,placebo rate for,0
FANAPT,orthostatic hypotension,tachycardia,0
FANAPT,orthostatic hypotension,for at least dose dizziness dry,0
FANAPT,orthostatic hypotension,somnolence orthostatic hypotension,1
FANAPT,weight increased,weight increased Dizziness,1
FANAPT,weight increased,weight increased Dizziness tachycardia,1
FANAPT,weight increased,hypotension weight increased Dizziness tachycardia and,1
FANAPT,weight increased,weight increased Dizziness tachycardia,1
FANAPT,weight increased,somnolence tachycardia orthostatic hypotension weight,1
FANAPT,weight increased,orthostatic hypotension weight increased,1
FANAPT,weight increased,somnolence tachycardia orthostatic hypotension weight,1
FANAPT,weight increased,fatigue,0
FANAPT,weight increased,weight increased Dizziness tachycardia,1
FANAPT,tachycardia,were at least twice as common on to mgday as on to,0
FANAPT,tachycardia,tachycardia and,1
FANAPT,tachycardia,were at least twice as common on to mgday as on to,0
FANAPT,tachycardia,weight increased,0
FANAPT,tachycardia,tachycardia,1
FANAPT,tachycardia,common on to mgday as on to,0
FANAPT,tachycardia,were at least twice as common,0
FANAPT,tachycardia,tachycardia,1
FANAPT,tachycardia,tachycardia and weight increased,1
FANAPT,weight increased,increased Dizziness tachycardia weight increased,1
FANAPT,weight increased,tachycardia weight increased,1
FANAPT,weight increased,increased Dizziness tachycardia weight increased,1
FANAPT,weight increased,increased Dizziness tachycardia,0
FANAPT,weight increased,to mgday as,0
FANAPT,weight increased,weight increased were at least twice,1
FANAPT,weight increased,weight increased Dizziness tachycardia weight increased,1
FANAPT,weight increased,weight increased,1
FANAPT,EPS-related adverse events,event,0
FANAPT,EPS-related adverse events,event data collected from those trials showed,0
FANAPT,EPS-related adverse events,adverse events as shown in Table Table,1
FANAPT,EPS-related adverse events,rates EPS-related adverse events as,1
FANAPT,EPS-related adverse events,adverse events as shown in Table Table,1
FANAPT,EPS-related adverse events,adverse events as shown in Table Table,1
FANAPT,EPS-related adverse events,of,0
FANAPT,EPS,EPSrelated adverse events as shown,0
FANAPT,EPS,EPS Compared to,1
FANAPT,anemia,anemia iron deficiency,1
FANAPT,anemia,anemia iron deficiency anemia,1
FANAPT,anemia,anemia iron,1
FANAPT,anemia,and Lymphatic Disorders,0
FANAPT,anemia,and Lymphatic Disorders,0
FANAPT,anemia,and Lymphatic Disorders anemia iron deficiency,1
FANAPT,anemia,and Lymphatic Disorders,0
FANAPT,anemia,anemia iron deficiency anemia Rare leukopenia,1
FANAPT,anemia,anemia iron,1
FANAPT,anemia,Blood and,0
FANAPT,iron deficiency anemia,Cardiac Disorders Frequent palpitations,0
FANAPT,iron deficiency anemia,Disorders,0
FANAPT,iron deficiency anemia,in fewer than patients Blood and,0
FANAPT,iron deficiency anemia,iron deficiency anemia,1
FANAPT,iron deficiency anemia,in fewer than patients Blood and Lymphatic Disorders Infrequent anemia,0
FANAPT,iron deficiency anemia,iron deficiency anemia Rare leukopenia,1
FANAPT,iron deficiency anemia,Frequent palpitations Rare arrhythmia atriov,0
FANAPT,iron deficiency anemia,Infrequent iron deficiency anemia Rare leukopenia Cardiac Disorders,1
FANAPT,iron deficiency anemia,Frequent palpitations Rare arrhythmia atriov,0
FANAPT,iron deficiency anemia,in fewer than patients Blood and Lymphatic Disorders Infrequent,0
FANAPT,leukopenia,leukopenia Cardiac Disorders,1
FANAPT,palpitations,Cardiac Disorders palpitations,1
FANAPT,palpitations,leukopenia Cardiac Disorders,1
FANAPT,arrhythmia,arrhythmia atrioventricular block first degree,1
FANAPT,arrhythmia,deficiency anemia Rare leukopenia Cardiac Disorders Frequent palpitations,0
FANAPT,arrhythmia,first degree cardiac failure including,0
FANAPT,arrhythmia,Rare leukopenia,0
FANAPT,arrhythmia,Disorders Frequent palpitations arrhythmia atrioventricular block first,1
FANAPT,arrhythmia,Rare leukopenia,0
FANAPT,atrioventricular block,Cardiac Disorders,0
FANAPT,atrioventricular block,anemia,0
FANAPT,atrioventricular block,atrioventricular block first,1
FANAPT,vertigo,cardiac failure,0
FANAPT,vertigo,vertigo tinnitus Endocrine Disorders,1
FANAPT,vertigo,vertigo tinnitus Endocrine,1
FANAPT,vertigo,Eye Disorders,0
FANAPT,vertigo,vertigo tinnitus Endocrine,1
FANAPT,vertigo,acute Ear and Labyrinth,0
FANAPT,vertigo,Eye,0
FANAPT,vertigo,Labyrinth Disorders vertigo tinnitus Endocrine Disorders,1
FANAPT,vertigo,Eye,0
FANAPT,vertigo,tinnitus Endocrine Disorders,0
FANAPT,vertigo,vertigo tinnitus Endocrine Disorders Infrequent hypothyroidism,1
FANAPT,tinnitus,Endocrine Disorders Infrequent hypothyroidism,0
FANAPT,tinnitus,Disorders Infrequent tinnitus Endocrine Disorders Infrequent hypothyroidism Eye,1
FANAPT,tinnitus,Endocrine Disorders Infrequent hypothyroidism,0
FANAPT,tinnitus,Infrequent hypothyroidism Eye Disorders Frequent,0
FANAPT,tinnitus,tinnitus Endocrine Disorders Infrequent hypothyroidism,1
FANAPT,tinnitus,Disorders Infrequent tinnitus Endocrine Disorders Infrequent hypothyroidism Eye,1
FANAPT,tinnitus,tinnitus Endocrine Disorders Infrequent hypothyroidism,1
FANAPT,hypothyroidism,hypothyroidism Eye Disorders,1
FANAPT,hypothyroidism,Endocrine Disorders hypothyroidism,1
FANAPT,hypothyroidism,hypothyroidism Eye Disorders,1
FANAPT,hypothyroidism,hypothyroidism Eye Disorders Frequent conjunctivitis,1
FANAPT,hypothyroidism,dry,0
FANAPT,hypothyroidism,dry,0
FANAPT,hypothyroidism,hypothyroidism Eye Disorders Frequent conjunctivitis including,1
FANAPT,hypothyroidism,tinnitus Endocrine Disorders hypothyroidism,1
FANAPT,hypothyroidism,hypothyroidism Eye Disorders Frequent conjunctivitis including,1
FANAPT,hypothyroidism,hypothyroidism Eye Disorders Frequent conjunctivitis including,1
FANAPT,hypothyroidism,Infrequent,0
FANAPT,hypothyroidism,hypothyroidism Eye Disorders,1
FANAPT,conjunctivitis,conjunctivitis including allergic Infrequent,1
FANAPT,conjunctivitis,conjunctivitis including allergic,1
FANAPT,conjunctivitis,Infrequent hypothyroidism,0
FANAPT,conjunctivitis,conjunctivitis,1
FANAPT,dry eye,cataract hyperemia including,0
FANAPT,dry eye,dry eye blepharitis eyelid edema,1
FANAPT,dry eye,including allergic dry eye,1
FANAPT,dry eye,conjunctivitis including allergic dry,1
FANAPT,dry eye,Disorders,0
FANAPT,dry eye,allergic dry eye,1
FANAPT,dry eye,Disorders,0
FANAPT,dry eye,blepharitis eyelid,0
FANAPT,blepharitis,eyelid edema eye,0
FANAPT,blepharitis,cataract hyperemia,0
FANAPT,blepharitis,blepharitis eyelid edema eye,1
FANAPT,eye swelling,conjunctivitis including allergic Infrequent dry eye blepharitis eyelid edema,0
FANAPT,eye swelling,dry eye blepharitis eyelid eye swelling lenticular opacities,1
FANAPT,eye swelling,conjunctivitis including allergic Infrequent dry eye blepharitis eyelid edema,0
FANAPT,eye swelling,cataract hyperemia including conjunctival,0
FANAPT,lenticular opacities,lenticular opacities,1
FANAPT,lenticular opacities,Infrequent dry,0
FANAPT,lenticular opacities,lenticular opacities cataract hyperemia including conjunctival,1
FANAPT,lenticular opacities,hyperemia including conjunctival,0
FANAPT,lenticular opacities,including conjunctival Gastrointestinal Disorders Infrequent gastr,0
FANAPT,lenticular opacities,lenticular opacities,1
FANAPT,cataract,hyperemia including conjunctival Gastrointestinal Disorders Infrequent,0
FANAPT,cataract,cataract hyperemia including conjunctival Gastrointestinal Disorders,1
FANAPT,cataract,cataract hyperemia including conjunctival Gastrointestinal,1
FANAPT,cataract,cataract hyperemia,1
FANAPT,hyperemia,swelling lenticular opacities hyperemia including,1
FANAPT,hyperemia,cataract hyperemia,1
FANAPT,gastritis,gastritis salivary hypersecretion fecal,1
FANAPT,gastritis,ities,0
FANAPT,gastritis,gastritis salivary hypersecretion fecal incontinence,1
FANAPT,gastritis,hypersecretion fecal,0
FANAPT,salivary hypersecretion,Rare aphthous stomatitis,0
FANAPT,salivary hypersecretion,salivary hypersecretion,1
FANAPT,salivary hypersecretion,ulceration Rare,0
FANAPT,salivary hypersecretion,salivary hypersecretion fecal incontinence mouth ulceration,1
FANAPT,salivary hypersecretion,Disorders Infrequent salivary hypersecretion fecal incontinence mouth ulceration,1
FANAPT,salivary hypersecretion,salivary hypersecretion fecal incontinence mouth ulceration,1
FANAPT,salivary hypersecretion,ulcer,0
FANAPT,salivary hypersecretion,conjunctival Gastrointestinal Disorders Infrequent salivary hypersecretion fecal incontinence,1
FANAPT,salivary hypersecretion,ulcer,0
FANAPT,salivary hypersecretion,conjunctival Gastrointestinal Disorders Infrequent salivary hypersecretion fecal incontinence mouth ulceration Rare,1
FANAPT,salivary hypersecretion,ulcer,0
FANAPT,salivary hypersecretion,conjunctival Gastrointestinal Disorders Infrequent salivary hypersecretion fecal incontinence mouth ulceration Rare,1
FANAPT,salivary hypersecretion,ulcer,0
FANAPT,fecal incontinence,conjunctival Gastrointestinal Disorders Infrequent,0
FANAPT,fecal incontinence,duodenal,0
FANAPT,fecal incontinence,stomatitis duodenal ulcer hiatus hernia,0
FANAPT,fecal incontinence,Infrequent gastritis salivary hypersecretion,0
FANAPT,fecal incontinence,fecal incontinence mouth,1
FANAPT,fecal incontinence,hypersecretion,0
FANAPT,fecal incontinence,stomatitis duodenal ulcer hiatus,0
FANAPT,fecal incontinence,Gastrointestinal Disorders Infrequent,0
FANAPT,fecal incontinence,salivary,0
FANAPT,mouth ulceration,mouth ulceration Rare aphthous stomatitis,1
FANAPT,mouth ulceration,salivary,0
FANAPT,mouth ulceration,mouth ulceration Rare,1
FANAPT,mouth ulceration,hypersecretion fecal incontinence,0
FANAPT,mouth ulceration,mouth ulceration Rare aphthous,1
FANAPT,mouth ulceration,mouth ulceration Rare aphthous stomatitis duodenal ulcer,1
FANAPT,mouth ulceration,fecal mouth ulceration,1
FANAPT,mouth ulceration,mouth ulceration Rare aphthous stomatitis duodenal ulcer,1
FANAPT,mouth ulceration,hyperchlorhydria lip ulceration,0
FANAPT,aphthous stomatitis,mouth ulceration aphthous stomatitis,1
FANAPT,aphthous stomatitis,hyperchlorhydria lip ulceration,0
FANAPT,aphthous stomatitis,hyperchlorhydria lip,0
FANAPT,aphthous stomatitis,ulceration aphthous,1
FANAPT,aphthous stomatitis,hiatus hernia hyperchlorhydria lip ulceration reflux,0
FANAPT,aphthous stomatitis,ulceration Rare,0
FANAPT,aphthous stomatitis,incontinence mouth ulceration aphthous,1
FANAPT,aphthous stomatitis,incontinence mouth ulceration aphthous stomatitis,1
FANAPT,aphthous stomatitis,incontinence mouth ulceration aphthous,1
FANAPT,duodenal ulcer,ulceration reflux esophagitis,0
FANAPT,duodenal ulcer,mouth ulceration Rare aphthous duodenal,1
FANAPT,duodenal ulcer,Rare aphthous duodenal ulcer,1
FANAPT,duodenal ulcer,duodenal ulcer hiatus,1
FANAPT,duodenal ulcer,hypersecretion,0
FANAPT,duodenal ulcer,stomatitis,0
FANAPT,hiatus hernia,duodenal hiatus hernia,1
FANAPT,hiatus hernia,ulceration Rare aphthous,0
FANAPT,hiatus hernia,hiatus hernia hyperchlorhydria lip ulceration reflux,1
FANAPT,hyperchlorhydria,stomatitis duodenal ulcer hiatus hyperchlorhydria,1
FANAPT,hyperchlorhydria,hiatus hernia hyperchlorhydria lip ulceration reflux,1
FANAPT,hyperchlorhydria,hyperchlorhydria lip,1
FANAPT,hyperchlorhydria,stomatitis duodenal ulcer hiatus hyperchlorhydria lip ulceration,1
FANAPT,hyperchlorhydria,hyperchlorhydria lip,1
FANAPT,lip ulceration,stomatitis duodenal ulcer,0
FANAPT,lip ulceration,Rare aphthous stomatitis,0
FANAPT,lip ulceration,duodenal ulcer hiatus hernia lip,1
FANAPT,lip ulceration,duodenal ulcer hiatus hernia lip ulceration reflux esophagitis,1
FANAPT,lip ulceration,duodenal ulcer hiatus hernia lip,1
FANAPT,lip ulceration,lip ulceration,1
FANAPT,lip ulceration,stomatitis,0
FANAPT,reflux esophagitis,reflux esophagitis stomatitis,1
FANAPT,reflux esophagitis,stomatitis,0
FANAPT,reflux esophagitis,hiatus hernia hyperchlorhydria lip reflux esophagitis stomatitis General Disorders and Administrative,1
FANAPT,reflux esophagitis,stomatitis,0
FANAPT,reflux esophagitis,reflux esophagitis stomatitis General Disorders,1
FANAPT,reflux esophagitis,Conditions Infrequent edema genera,0
FANAPT,reflux esophagitis,Site Conditions Infrequent edema genera,0
FANAPT,reflux esophagitis,reflux esophagitis stomatitis General Disorders and Administrative,1
FANAPT,reflux esophagitis,reflux esophagitis stomatitis General Disorders,1
FANAPT,reflux esophagitis,hiatus hernia hyperchlorhydria lip reflux esophagitis stomatitis General Disorders,1
FANAPT,reflux esophagitis,reflux esophagitis stomatitis General Disorders,1
FANAPT,stomatitis,ulceration reflux stomatitis General Disorders,1
FANAPT,stomatitis,reflux esophagitis stomatitis General Disorders,1
FANAPT,edema,to cardiac disease difficulty in walking,0
FANAPT,edema,thirst,0
FANAPT,edema,edema general pitting due to cardiac,1
FANAPT,edema,general pitting due to cardiac,0
FANAPT,difficulty in walking,to cardiac difficulty in,1
FANAPT,difficulty in walking,to cardiac difficulty,1
FANAPT,difficulty in walking,due to cardiac disease,0
FANAPT,difficulty in walking,difficulty in walking thirst Rare hyperthermia,1
FANAPT,difficulty in walking,due to cardiac disease,0
FANAPT,difficulty in walking,Infrequent cholelithiasis In,0
FANAPT,difficulty in walking,difficulty in walking thirst Rare,1
FANAPT,difficulty in walking,edema general pitting,0
FANAPT,difficulty in walking,in walking thirst Rare hyperthermia,1
FANAPT,thirst,thirst Rare,1
FANAPT,thirst,in walking thirst Rare hyperthermia,1
FANAPT,thirst,thirst Rare hyperthermia Hepatobiliary Disorders Infrequent,1
FANAPT,thirst,thirst,1
FANAPT,thirst,Infrequent cholelithiasis,0
FANAPT,thirst,walking,0
FANAPT,thirst,Disorders,0
FANAPT,thirst,hyperthermia Hepatobiliary Disorders Infrequent,0
FANAPT,cholelithiasis,decreased Infrequent,0
FANAPT,cholelithiasis,cholelithiasis Investigations,1
FANAPT,cholelithiasis,cholelithiasis Investigations,1
FANAPT,cholelithiasis,cholelithiasis Investigations,1
FANAPT,cholelithiasis,difficulty in walking thirst Rare hyperthermia Hepatobiliary Disorders,0
FANAPT,cholelithiasis,decreased Infrequent,0
FANAPT,cholelithiasis,cholelithiasis Investigations Frequent weight,1
FANAPT,cholelithiasis,Investigations Frequent,0
FANAPT,cholelithiasis,Rare hyperthermia Hepatobiliary Disorders cholelithiasis Investigations Frequent weight,1
FANAPT,cholelithiasis,Investigations Frequent,0
FANAPT,cholelithiasis,cholelithiasis Investigations Frequent,1
FANAPT,cholelithiasis,Investigations Frequent,0
FANAPT,weight decreased,count increased hematocrit decreased,0
FANAPT,weight decreased,cholelithiasis Investigations weight,1
FANAPT,weight decreased,neutrophil,0
FANAPT,weight decreased,Disorders Infrequent cholelithiasis Investigations weight,1
FANAPT,weight decreased,weight decreased Infrequent hemoglobin decreased neutrophil,1
FANAPT,weight decreased,count increased,0
FANAPT,weight decreased,weight decreased Infrequent,1
FANAPT,weight decreased,weight decreased Infrequent hemoglobin decreased,1
FANAPT,weight decreased,weight decreased Infrequent,1
FANAPT,hemoglobin decreased,decreased hemoglobin,1
FANAPT,hemoglobin decreased,hemoglobin decreased neutrophil count increased,1
FANAPT,hemoglobin decreased,rs Infrequent cholelithiasis Investigations Frequent weight,0
FANAPT,hemoglobin decreased,decreased Metabolism and Nutrition,0
FANAPT,hemoglobin decreased,count increased,0
FANAPT,hemoglobin decreased,neutrophil count increased,0
FANAPT,neutrophil count increased,neutrophil count increased hematocrit decreased,1
FANAPT,neutrophil count increased,neutrophil count,1
FANAPT,neutrophil count increased,hemoglobin neutrophil count,1
FANAPT,neutrophil count increased,neutrophil count increased,1
FANAPT,neutrophil count increased,hemoglobin neutrophil count increased hematocrit decreased Metabolism and Nutrition,1
FANAPT,neutrophil count increased,neutrophil count increased,1
FANAPT,neutrophil count increased,weight decreased Infrequent hemoglobin neutrophil count increased,1
FANAPT,neutrophil count increased,neutrophil count increased,1
FANAPT,neutrophil count increased,neutrophil count increased,1
FANAPT,neutrophil count increased,neutrophil count increased,1
FANAPT,hematocrit decreased,neutrophil count hematocrit decreased Metabolism and Nutrition Disorders Infrequent,1
FANAPT,hematocrit decreased,neutrophil count increased,1
FANAPT,hematocrit decreased,appetite,0
FANAPT,hematocrit decreased,count hematocrit,1
FANAPT,hematocrit decreased,count hematocrit decreased Metabolism and Nutrition,1
FANAPT,hematocrit decreased,count hematocrit,1
FANAPT,increased appetite,and Nutrition Disorders increased appetite,1
FANAPT,increased appetite,increased appetite,1
FANAPT,increased appetite,fluid retention Musculoskeletal,0
FANAPT,increased appetite,hematocrit decreased Metabolism and,0
FANAPT,increased appetite,Nutrition Disorders Infrequent,0
FANAPT,increased appetite,Connective,0
FANAPT,dehydration,Infrequent increased dehydration hypokalemia fluid retention,1
FANAPT,dehydration,Connective,0
FANAPT,dehydration,dehydration,1
FANAPT,dehydration,dehydration hypokalemia,1
FANAPT,dehydration,dehydration hypokalemia fluid,1
FANAPT,dehydration,dehydration hypokalemia fluid retention,1
FANAPT,hypokalemia,hypokalemia fluid retention Musculoskeletal,1
FANAPT,hypokalemia,hypokalemia fluid retention Musculoskeletal and Connective,1
FANAPT,hypokalemia,hypokalemia,1
FANAPT,hypokalemia,hypokalemia fluid retention Musculoskeletal,1
FANAPT,hypokalemia,hypokalemia fluid retention Musculoskeletal and Connective,1
FANAPT,hypokalemia,hypokalemia fluid retention,1
FANAPT,fluid retention,fluid,1
FANAPT,fluid retention,Nutrition Disorders Infrequent increased appetite dehydration,0
FANAPT,fluid retention,appetite dehydration fluid retention Musculoskeletal and Connective Tissue,1
FANAPT,fluid retention,Nutrition Disorders Infrequent increased appetite dehydration,0
FANAPT,fluid retention,fluid retention Musculoskeletal and,1
FANAPT,myalgia,myalgia muscle spasms Rare torticollis Nervous,1
FANAPT,myalgia,Infrequent paresthesia ps,0
FANAPT,myalgia,myalgia muscle spasms Rare torticollis,1
FANAPT,myalgia,myalgia muscle spasms,1
FANAPT,myalgia,and Connective Tissue Disorders myalgia muscle spasms Rare torticollis,1
FANAPT,myalgia,myalgia muscle spasms,1
FANAPT,myalgia,myalgia muscle spasms Rare torticollis,1
FANAPT,myalgia,myalgia muscle spasms,1
FANAPT,myalgia,myalgia muscle spasms Rare,1
FANAPT,myalgia,myalgia muscle spasms Rare torticollis,1
FANAPT,myalgia,Disorders myalgia muscle spasms,1
FANAPT,myalgia,myalgia muscle spasms Rare torticollis,1
FANAPT,torticollis,torticollis Nervous System Disorders Infrequent,1
FANAPT,torticollis,Disorders Infrequent paresthesia,0
FANAPT,torticollis,torticollis Nervous System,1
FANAPT,torticollis,myalgia muscle spasms torticollis Nervous System Disorders Infrequent,1
FANAPT,torticollis,torticollis Nervous System,1
FANAPT,torticollis,torticollis Nervous,1
FANAPT,torticollis,torticollis Nervous System,1
FANAPT,torticollis,Disorders Frequent myalgia,0
FANAPT,paresthesia,Infrequent,0
FANAPT,paresthesia,System Disorders paresthesia psychomotor hyperactivity,1
FANAPT,paresthesia,Infrequent,0
FANAPT,paresthesia,paresthesia psychomotor,1
FANAPT,paresthesia,System Disorders paresthesia psychomotor hyperactivity restlessness,1
FANAPT,paresthesia,paresthesia psychomotor,1
FANAPT,paresthesia,torticollis Nervous System Disorders paresthesia psychomotor hyperactivity restlessness amnesia nystagmus,1
FANAPT,paresthesia,paresthesia psychomotor,1
FANAPT,paresthesia,psychomotor hyperactivity restlessness amnesia nystagmus Rare restless,0
FANAPT,paresthesia,paresthesia psychomotor hyperactivity restlessness,1
FANAPT,psychomotor hyperactivity,torticollis Nervous System Disorders Infrequent,0
FANAPT,restlessness,Rare restless legs,0
FANAPT,restlessness,restlessness,1
FANAPT,restlessness,restlessness amnesia nystagmus,1
FANAPT,restlessness,restlessness amnesia nystagmus Rare restless legs,1
FANAPT,restlessness,Disorders Infrequent paresthesia psychomotor restlessness amnesia nystagmus Rare restless,1
FANAPT,restlessness,restlessness amnesia nystagmus Rare restless legs,1
FANAPT,restlessness,Rare restless legs,0
FANAPT,amnesia,Psychiatric Disorders,0
FANAPT,amnesia,paresthesia psychomotor hyperactivity amnesia nystagmus Rare restless,1
FANAPT,amnesia,Psychiatric Disorders,0
FANAPT,amnesia,restlessness,0
FANAPT,amnesia,Infrequent paresthesia psychomotor hyperactivity amnesia nystagmus Rare,1
FANAPT,amnesia,restlessness,0
FANAPT,amnesia,amnesia,1
FANAPT,amnesia,psychomotor hyperactivity amnesia nystagmus Rare restless legs,1
FANAPT,amnesia,amnesia,1
FANAPT,restless legs syndrome,restlessness amnesia nystagmus restless legs syndrome Psychiatric,1
FANAPT,restless legs syndrome,amnesia,1
FANAPT,restless legs syndrome,hyperactivity restlessness amnesia nystagmus restless,1
FANAPT,restless legs syndrome,amnesia nystagmus restless legs syndrome Psychiatric Disorders Frequent,1
FANAPT,restless legs syndrome,hyperactivity restlessness amnesia nystagmus restless,1
FANAPT,restless legs syndrome,legs syndrome Psychiatric Disorders Frequent,1
FANAPT,restless legs syndrome,restlessness amnesia nystagmus restless legs,1
FANAPT,restless legs syndrome,nystagmus restless legs syndrome,1
FANAPT,restless legs syndrome,restlessness amnesia nystagmus,0
FANAPT,restless legs syndrome,restless,1
FANAPT,restless legs syndrome,hyperactivity restlessness,0
FANAPT,aggression,confusional state man,0
FANAPT,aggression,Psychiatric Disorders Frequent aggression delusion Infrequent hostility,1
FANAPT,aggression,confusional state man,0
FANAPT,aggression,aggression delusion Infrequent hostility,1
FANAPT,delusion,delusion Infrequent hostility,1
FANAPT,delusion,legs,0
FANAPT,delusion,libido,0
FANAPT,delusion,restless legs syndrome Psychiatric Disorders Frequent,0
FANAPT,delusion,delusion Infrequent hostility libido decreased,1
FANAPT,delusion,Disorders Frequent restlessness,0
FANAPT,hostility,libido decreased paranoia anorgasmia confusional state,0
FANAPT,hostility,hostility libido decreased,1
FANAPT,hostility,hostility,1
FANAPT,hostility,hostility,1
FANAPT,hostility,Frequent restlessness aggression delusion hostility libido decreased,1
FANAPT,hostility,hostility,1
FANAPT,hostility,hostility libido decreased paranoia,1
FANAPT,hostility,delusion hostility libido decreased paranoia anorgasmia,1
FANAPT,hostility,hostility libido decreased paranoia,1
FANAPT,libido decreased,restlessness aggression delusion Infrequent libido decreased paranoia anorgasmia confusional state,1
FANAPT,libido decreased,hostility libido decreased paranoia,1
FANAPT,libido decreased,panic attack,0
FANAPT,paranoia,attack obsessivecompulsive,0
FANAPT,paranoia,paranoia anorgasmia,1
FANAPT,paranoia,paranoia anorgasmia confusional state mania catatonia,1
FANAPT,anorgasmia,decreased anorgasmia confusional state,1
FANAPT,anorgasmia,paranoia anorgasmia confusional state mania catatonia,1
FANAPT,anorgasmia,equent restlessness aggression delusion Infrequent,0
FANAPT,confusional state,swings panic attack obsessivecompulsive,0
FANAPT,confusional state,confusional state mania catatonia mood,1
FANAPT,confusional state,swings panic attack obsessivecompulsive,0
FANAPT,confusional state,stlessness aggression delusion Infrequent hostility,0
FANAPT,confusional state,paranoia confusional state mania catatonia mood swings panic,1
FANAPT,confusional state,stlessness aggression delusion Infrequent hostility,0
FANAPT,confusional state,confusional state mania catatonia mood,1
FANAPT,confusional state,bulimia nervosa delir,0
FANAPT,confusional state,hostility libido decreased paranoia confusional state,1
FANAPT,confusional state,bulimia nervosa delir,0
FANAPT,confusional state,anorgasmia,0
FANAPT,confusional state,paranoia confusional state,1
FANAPT,mania,mania catatonia mood swings panic attack,1
FANAPT,mania,paranoia anorgasmia confusional mania catatonia mood swings panic,1
FANAPT,mania,mania catatonia mood swings panic attack,1
FANAPT,mania,mania catatonia mood swings panic attack,1
FANAPT,mania,paranoia,0
FANAPT,mania,mood swings panic attack obsessivecompulsive disorder bulimia nervosa delirium,0
FANAPT,mania,delusion Infrequent hostility libido decreased paranoia anorgasmia,0
FANAPT,catatonia,catatonia mood swings,1
FANAPT,catatonia,libido decreased,0
FANAPT,catatonia,catatonia,1
FANAPT,catatonia,confusional state catatonia,1
FANAPT,catatonia,catatonia,1
FANAPT,catatonia,mood swings panic attack obsessivecompulsive disorder,0
FANAPT,catatonia,catatonia mood,1
FANAPT,catatonia,lusion Infrequent hostility,0
FANAPT,mood swings,delirium,0
FANAPT,mood swings,mood swings panic,1
FANAPT,mood swings,delirium,0
FANAPT,mood swings,bulimia nervosa delirium,0
FANAPT,mood swings,nervosa delirium polydipsia psychogenic,0
FANAPT,mood swings,mood swings panic attack,1
FANAPT,mood swings,polydipsia,0
FANAPT,mood swings,nervosa delirium polydipsia psychogenic,0
FANAPT,mood swings,delirium polydipsia psychogenic im,0
FANAPT,mood swings,bulimia nervosa delirium polydipsia psychogenic im,0
FANAPT,panic attack,obsessivecompulsive disorder bulimia,0
FANAPT,panic attack,panic attack obsessivecompulsive,1
FANAPT,panic attack,panic attack obsessivecompulsive,1
FANAPT,obsessive-compulsive disorder,obsessive-compulsive disorder bulimia nervosa,1
FANAPT,obsessive-compulsive disorder,panic attack obsessivecompulsive,1
FANAPT,obsessive-compulsive disorder,panic attack,0
FANAPT,delirium,bulimia nervosa,0
FANAPT,delirium,polydipsia psychogenic impulsecontrol disorder major depression Renal and Urinary Disorde,0
FANAPT,delirium,impulsecontrol,0
FANAPT,delirium,Renal,0
FANAPT,delirium,state mania catatonia mood swings panic,0
FANAPT,delirium,delirium polydipsia psychogenic impulsecontrol,1
FANAPT,delirium,disorder major depression Renal and Urinary,0
FANAPT,delirium,delirium polydipsia,1
FANAPT,delirium,delirium polydipsia,1
FANAPT,delirium,delirium polydipsia,1
FANAPT,delirium,delirium polydipsia,1
FANAPT,polydipsia psychogenic,bulimia nervosa polydipsia psychogenic impulsecontrol disorder,1
FANAPT,polydipsia psychogenic,delirium polydipsia,1
FANAPT,polydipsia psychogenic,disorder bulimia nervosa polydipsia psychogenic impulsecontrol disorder major,1
FANAPT,polydipsia psychogenic,delirium polydipsia,1
FANAPT,polydipsia psychogenic,and Urinary,0
FANAPT,polydipsia psychogenic,polydipsia psychogenic impulsecontrol disorder major,1
FANAPT,polydipsia psychogenic,nervosa polydipsia,1
FANAPT,polydipsia psychogenic,polydipsia psychogenic impulsecontrol disorder,1
FANAPT,polydipsia psychogenic,disorder bulimia nervosa polydipsia psychogenic,1
FANAPT,impulse-control disorder,bulimia nervosa delirium polydipsia impulse-control disorder major depression Renal,1
FANAPT,impulse-control disorder,disorder bulimia nervosa polydipsia psychogenic,1
FANAPT,major depression,impulsecontrol major depression Renal and,1
FANAPT,major depression,disorder bulimia nervosa polydipsia psychogenic,1
FANAPT,major depression,psychogenic impulsecontrol major,1
FANAPT,major depression,major depression Renal and Urinary Disorders Frequent,1
FANAPT,major depression,delirium polydipsia,0
FANAPT,major depression,major depression Renal,1
FANAPT,major depression,impulsecontrol major,1
FANAPT,major depression,psychogenic impulsecontrol major depression Renal and Urinary Disorders Frequent,1
FANAPT,major depression,impulsecontrol major,1
FANAPT,major depression,Urinary Disorders Frequent urinary,0
FANAPT,major depression,major depression Renal and,1
FANAPT,major depression,Urinary Disorders Frequent urinary incontinence Infrequent dysuria,0
FANAPT,urinary incontinence,depression Renal and,0
FANAPT,urinary incontinence,impulsecontrol disorder major depression,0
FANAPT,urinary incontinence,Frequent,0
FANAPT,dysuria,depression,0
FANAPT,dysuria,incontinence dysuria pollakiuria,1
FANAPT,dysuria,depression,0
FANAPT,dysuria,incontinence Infrequent,0
FANAPT,dysuria,dysuria pollakiuria,1
FANAPT,dysuria,urinary incontinence dysuria pollakiuria,1
FANAPT,dysuria,dysuria pollakiuria,1
FANAPT,dysuria,dysuria pollakiuria enuresis nephrolithiasis,1
FANAPT,pollakiuria,renal failure acute Reproductive,0
FANAPT,pollakiuria,pollakiuria enuresis,1
FANAPT,pollakiuria,urinary incontinence Infrequent pollakiuria enuresis nephrolithiasis Rare urinary retention,1
FANAPT,pollakiuria,pollakiuria enuresis,1
FANAPT,pollakiuria,incontinence Infrequent pollakiuria enuresis nephrolithiasis,1
FANAPT,pollakiuria,pollakiuria enuresis,1
FANAPT,pollakiuria,pollakiuria enuresis nephrolithiasis Rare urinary retention,1
FANAPT,pollakiuria,pollakiuria enuresis nephrolithiasis,1
FANAPT,pollakiuria,urinary incontinence Infrequent pollakiuria enuresis nephrolithiasis Rare,1
FANAPT,pollakiuria,pollakiuria enuresis nephrolithiasis,1
FANAPT,pollakiuria,pollakiuria enuresis,1
FANAPT,enuresis,enuresis nephrolithiasis Rare urinary retention,1
FANAPT,enuresis,enuresis nephrolithiasis,1
FANAPT,enuresis,enuresis nephrolithiasis Rare urinary,1
FANAPT,enuresis,enuresis nephrolithiasis Rare urinary,1
FANAPT,enuresis,failure acute Reproductive System and Bre,0
FANAPT,enuresis,incontinence Infrequent dysuria enuresis nephrolithiasis Rare,1
FANAPT,enuresis,failure acute Reproductive System and Bre,0
FANAPT,nephrolithiasis,retention renal,0
FANAPT,nephrolithiasis,incontinence Infrequent dysuria pollakiuria nephrolithiasis Rare urinary retention renal,1
FANAPT,nephrolithiasis,retention renal,0
FANAPT,nephrolithiasis,nephrolithiasis Rare,1
FANAPT,nephrolithiasis,pollakiuria nephrolithiasis Rare urinary retention,1
FANAPT,nephrolithiasis,nephrolithiasis Rare,1
FANAPT,nephrolithiasis,nephrolithiasis Rare urinary retention renal,1
FANAPT,nephrolithiasis,nephrolithiasis Rare,1
FANAPT,urinary retention,dysuria pollakiuria enuresis nephrolithiasis urinary retention renal failure acute Reproductive,1
FANAPT,urinary retention,nephrolithiasis Rare,1
FANAPT,urinary retention,urinary retention,1
FANAPT,urinary retention,pollakiuria enuresis nephrolithiasis urinary retention renal failure acute Reproductive System,1
FANAPT,urinary retention,urinary retention,1
FANAPT,urinary retention,urinary retention renal failure,1
FANAPT,urinary retention,urinary retention renal failure acute Reproductive,1
FANAPT,urinary retention,Frequent erectile dysfuncti,0
FANAPT,urinary retention,Frequent erectile,0
FANAPT,erectile dysfunction,pain amenorrhea breast pain,0
FANAPT,erectile dysfunction,and Breast Disorders erectile dysfunction,1
FANAPT,erectile dysfunction,erectile dysfunction Infrequent testicular pain amenorrhea breast,1
FANAPT,erectile dysfunction,breast pain Rare,0
FANAPT,erectile dysfunction,Breast Disorders erectile dysfunction Infrequent,1
FANAPT,erectile dysfunction,breast pain Rare,0
FANAPT,erectile dysfunction,failure acute Reproductive System and Breast,0
FANAPT,erectile dysfunction,erectile dysfunction,1
FANAPT,testicular pain,Frequent,0
FANAPT,testicular pain,testicular pain amenorrhea breast,1
FANAPT,testicular pain,testicular pain amenorrhea breast pain Rare,1
FANAPT,testicular pain,Infrequent,0
FANAPT,testicular pain,Disorders Frequent erectile dysfunction testicular pain amenorrhea breast pain Rare,1
FANAPT,testicular pain,Infrequent,0
FANAPT,amenorrhea,amenorrhea breast pain Rare,1
FANAPT,amenorrhea,amenorrhea breast pain,1
FANAPT,amenorrhea,erectile dysfunction,0
FANAPT,breast pain,testicular pain breast,1
FANAPT,breast pain,metrorrhagia postmenopausal,0
FANAPT,breast pain,menstruation irregular gynecomastia menorrhagia,0
FANAPT,breast pain,breast pain Rare menstruation irregular gynecomastia,1
FANAPT,breast pain,dysfunction Infrequent testicular,0
FANAPT,breast pain,Rare menstruation irregular gynecomastia menorrhagia metrorrhagia postmenopausal hemorrha,0
FANAPT,breast pain,and Breast Disorders,0
FANAPT,breast pain,Infrequent testicular pain breast pain,1
FANAPT,breast pain,testicular pain breast pain Rare menstruation irregular gynecomastia menorrhagia,1
FANAPT,breast pain,Infrequent testicular pain breast pain,1
FANAPT,breast pain,dysfunction Infrequent testicular pain breast,1
FANAPT,menstruation irregular,menstruation irregular gynecomastia menorrhagia,1
FANAPT,menstruation irregular,menstruation irregular gynecomastia menorrhagia metrorrhagia postmenopausal hemorrhage,1
FANAPT,menstruation irregular,pain amenorrhea breast pain menstruation irregular gynecomastia menorrhagia metrorrhagia,1
FANAPT,menstruation irregular,menstruation irregular gynecomastia menorrhagia metrorrhagia postmenopausal hemorrhage,1
FANAPT,menstruation irregular,menstruation,1
FANAPT,menstruation irregular,pain amenorrhea breast pain,0
FANAPT,menstruation irregular,postmenopausal,0
FANAPT,menstruation irregular,menstruation irregular gynecomastia,1
FANAPT,menstruation irregular,postmenopausal hemorrhage prostatitis,0
FANAPT,menstruation irregular,menstruation irregular gynecomastia menorrhagia metrorrhagia,1
FANAPT,gynecomastia,gynecomastia,1
FANAPT,gynecomastia,gynecomastia menorrhagia metrorrhagia postmenopausal,1
FANAPT,gynecomastia,pain Rare menstruation gynecomastia,1
FANAPT,gynecomastia,gynecomastia menorrhagia metrorrhagia postmenopausal,1
FANAPT,gynecomastia,breast pain Rare menstruation gynecomastia,1
FANAPT,gynecomastia,gynecomastia menorrhagia metrorrhagia postmenopausal,1
FANAPT,metrorrhagia,menorrhagia,0
FANAPT,metrorrhagia,metrorrhagia postmenopausal hemorrhage,1
FANAPT,metrorrhagia,postmenopausal,0
FANAPT,metrorrhagia,Thoracic and Mediastinal Disorders Inf,0
FANAPT,metrorrhagia,menorrhagia,0
FANAPT,postmenopausal hemorrhage,Disorders Infrequent epistaxis,0
FANAPT,postmenopausal hemorrhage,postmenopausal hemorrhage prostatitis Respiratory Thoracic,1
FANAPT,postmenopausal hemorrhage,postmenopausal hemorrhage prostatitis Respiratory Thoracic and,1
FANAPT,prostatitis,prostatitis Respiratory,1
FANAPT,prostatitis,prostatitis Respiratory,1
FANAPT,prostatitis,Respiratory Thoracic and,0
FANAPT,prostatitis,prostatitis Respiratory Thoracic and Mediastinal,1
FANAPT,prostatitis,menorrhagia metrorrhagia postmenopausal prostatitis,1
FANAPT,prostatitis,prostatitis Respiratory Thoracic and Mediastinal,1
FANAPT,prostatitis,Thoracic,0
FANAPT,prostatitis,prostatitis Respiratory Thoracic and Mediastinal,1
FANAPT,prostatitis,Thoracic,0
FANAPT,epistaxis,Disorders epistaxis asthma rhinorrhea sinus,1
FANAPT,epistaxis,Thoracic,0
FANAPT,asthma,asthma rhinorrhea sinus congestion,1
FANAPT,asthma,asthma,1
FANAPT,asthma,asthma rhinorrhea sinus congestion,1
FANAPT,rhinorrhea,rhinorrhea sinus congestion nasal dryness Rare,1
FANAPT,rhinorrhea,asthma rhinorrhea sinus congestion,1
FANAPT,rhinorrhea,rhinorrhea sinus congestion nasal,1
FANAPT,rhinorrhea,rhinorrhea sinus,1
FANAPT,sinus congestion,Infrequent epistaxis asthma sinus congestion nasal dryness Rare dry throat,1
FANAPT,sinus congestion,rhinorrhea sinus,1
FANAPT,sinus congestion,asthma sinus congestion nasal dryness Rare dry throat,1
FANAPT,sinus congestion,rhinorrhea sinus,1
FANAPT,sinus congestion,Infrequent epistaxis asthma sinus congestion nasal dryness Rare dry,1
FANAPT,sinus congestion,rhinorrhea sinus,1
FANAPT,sinus congestion,sinus congestion nasal dryness Rare dry throat,1
FANAPT,sinus congestion,epistaxis asthma sinus congestion,1
FANAPT,sinus congestion,syndrome dyspnea,0
FANAPT,sinus congestion,sleep,0
FANAPT,sinus congestion,sinus congestion nasal dryness Rare dry throat,1
FANAPT,sinus congestion,Thoracic,0
FANAPT,sinus congestion,asthma sinus congestion,1
FANAPT,nasal dryness,dry,0
FANAPT,nasal dryness,dry throat sleep apnea syndrome dyspnea exertional Postmarketing,0
FANAPT,dry throat,sinus congestion nasal dryness dry,1
FANAPT,dry throat,dryness dry throat sleep apnea,1
FANAPT,dry throat,sinus congestion nasal dryness dry,1
FANAPT,dry throat,Experience The following a,0
FANAPT,dry throat,nasal dryness dry throat sleep apnea syndrome,1
FANAPT,dry throat,Experience The following a,0
FANAPT,sleep apnea syndrome,Infrequent epistaxis asthma,0
FANAPT,sleep apnea syndrome,apnea syndrome dyspnea exertional Postmarketing Experience,1
FANAPT,sleep apnea syndrome,rhinorrhea sinus congestion nasal dryness Rare dry,0
FANAPT,sleep apnea syndrome,adverse reactions,0
FANAPT,sleep apnea syndrome,dry sleep apnea syndrome dyspnea exertional Postmarketing Experience The,1
FANAPT,sleep apnea syndrome,adverse reactions,0
FANAPT,sleep apnea syndrome,following,0
FANAPT,sleep apnea syndrome,dryness Rare dry sleep apnea,1
FANAPT,sleep apnea syndrome,asthma rhinorrhea,0
FANAPT,sleep apnea syndrome,dryness Rare dry sleep apnea syndrome,1
FANAPT,sleep apnea syndrome,dryness Rare dry throat,0
FANAPT,dyspnea exertional,throat sleep apnea dyspnea exertional Postmarketing Experience The following adverse,1
FANAPT,dyspnea exertional,dryness Rare dry throat,0
FANAPT,dyspnea exertional,Experience The following adverse reactions have been identified,0
FANAPT,dyspnea exertional,dry throat sleep apnea dyspnea exertional,1
FANAPT,dyspnea exertional,Experience The following adverse reactions have been identified,0
FANAPT,retrograde ejaculation,of FANAPT,0
FANAPT,retrograde ejaculation,of FANAPT,0
FANAPT,retrograde ejaculation,of FANAPT,0
FANAPT,retrograde ejaculation,use of,0
FANAPT,retrograde ejaculation,of retrograde,1
FANAPT,retrograde ejaculation,identified during postapproval,0
FANAPT,retrograde ejaculation,retrograde ejaculation Because these reactions were,1
FANAPT,retrograde ejaculation,identified during postapproval,0
FANAPT,retrograde ejaculation,of,0
FANAPT,MORTALITY,were: di zziness dry mouth fatigue,1
FANAPT,death,erien ce Because clinical trials are,1
FANAPT,death,clinical trial database for FANAPT consisting of patients exposed to FANAPT at,0
FANAPT,death,ow is,1
FANAPT,death,FANAPT consisting of patients exposed to,0
FANAPT,death,ow,1
FANAPT,deaths,a clinical rial d,1
FANAPT,deaths,clinical rial d atabase for FANAPT,1
FANAPT,deaths,a clinical rial d,1
FANAPT,sudden death,patients exposed to NAPT,1
FANAPT,sudden death,of patients exposed to NAPT at dose s of mgday,1
FANAPT,sudden death,patients exposed to NAPT,1
FANAPT,sudden death,of patients exposed to NAPT at dose s of mgday or,1
FANAPT,sudden death,patients exposed to NAPT,1
FANAPT,sudden death,FANAPT for at,0
FANAPT,sudden death,patients exposed to NAPT at dose s of mgday or,1
FANAPT,sudden death,FANAPT for at,0
FANAPT,sudden death,patients exposed to NAPT at dose,1
FANAPT,sudden death,of patients exposed to NAPT at dose s of,1
FANAPT,sudden death,patients exposed to NAPT at dose,1
FANAPT,sudden death,patients exposed to NAPT,1
FANAPT,sudden death,of patients exposed to NAPT,1
FANAPT,pneumonia,for,0
FANAPT,pneumonia,database for FANAPT consisting of patients exposed to FANAPT at doses of mgday or,0
FANAPT,MORTALITY,reactions during re were o btained by general inquiry and,1
FANAPT,MORTALITY,database for FANAPT consisting of patients exposed to FANAPT at doses of mgday or,0
FANAPT,MORTALITY,re were o,1
FANAPT,MORTALITY,exposure Adverse reactions during re were o,1
FANAPT,MORTALITY,investigators using their own terminology Conse,0
FANAPT,MORTALITY,own terminology,0
FANAPT,MORTALITY,and recorded by,0
FANAPT,death, cate gories using MedDRA terminology The,1
FANAPT,death,proportion of individuals experiencing adverse reactions,0
FANAPT,death, cate gories using MedDRA,1
FANAPT,death, cate gories using,1
FANAPT,death, cate gories using,1
FANAPT,death, cate gories using MedDRA terminology The,1
FANAPT,cerebrovascular-related adverse events,fold greater than placebo were dizziness dry mouth fatigue nasal,0
FANAPT,cerebrovascular-related adverse events,"nasal congestion hypotension, somnolence,",1
FANAPT,cerebrovascular-related adverse events,ADVERSE,0
FANAPT,cerebrovascular-related adverse events,"somnolence, tachycardia, and weight",1
FANAPT,cerebrovascular-related adverse events,"hypotension, somnolence, tachycardia,",1
FANAPT,cerebrovascular-related adverse events,"somnolence, tachycardia, and weight increased",1
FANAPT,cerebrovascular-related adverse events,"nasal congestion hypotension, somnolence, tachycardia,",1
FANAPT,QT prolongation,and weight increased,0
FANAPT,QT prolongation,or FDA at,0
FANAPT,QT prolongation,contact Novartis,0
FANAPT,Prolongs QT interval,ADVERSE REACTIO NS,1
FANAPT,Prolongs QT interval,CTED ADVERSE REACTIO,1
FANAPT,Prolongs QT interval,report CTED ADVERSE REACTIO NS contact Novartis,1
FANAPT,Prolongs QT interval,CTED ADVERSE REACTIO,1
FANAPT,arrhythmia,euticals C orporation at or,1
FANAPT,arrhythmia,CTED ADVERSE REACTIO,1
FANAPT,arrhythmia,euticals C orporation at or FDA,1
FANAPT,arrhythmia,ADVERSE REACTIONS contact Novartis euticals,1
FANAPT,arrhythmia,euticals C orporation at,1
FANAPT,arrhythmia,SUSPECTED ADVERSE REACTIONS,0
FANAPT,arrhythmia,at or FDA at FDA or,0
FANAPT,arrhythmia,weight increased To,0
FANAPT,sudden death,Novartis Pharmaceuticals ation at 1-8 or,1
FANAPT,sudden death,weight increased To,0
FANAPT,sudden death,contact Novartis Pharmaceuticals ation at 1-8 or FDA at FDA or,1
FANAPT,sudden death,weight increased To,0
FANAPT,sudden death,contact Novartis Pharmaceuticals ation at 1-8 or FDA,1
FANAPT,sudden death,weight increased To,0
FANAPT,sudden death,contact Novartis Pharmaceuticals ation at 1-8,1
FANAPT,sudden death,report SUSPECTED ADVERSE REACTIONS contact Novartis Pharmaceuticals,0
FANAPT,sudden death,wwwfdagovmedwatch Clinical,0
FANAPT,sudden death,or wwwfdagovmedwatch Clinical Studies,0
FANAPT,Neuroleptic Malignant Syndrome,patients exposed to FANAPT a,0
FANAPT,Neuroleptic Malignant Syndrome,clinical actice. The information below,1
FANAPT,Neuroleptic Malignant Syndrome,clinical pr,0
FANAPT,Tardive dyskinesia,trial database for FANAPT,0
FANAPT,Tardive dyskinesia,to FANAPT at do,1
FANAPT,Tardive dyskinesia,FANAPT at do,1
FANAPT,Tardive dyskinesia,received FANAPT for,0
FANAPT,Tardive dyskinesia,consisting of patients ed to FANAPT at do ses of mgday,1
FANAPT,Tardive dyskinesia,received FANAPT for,0
FANAPT,Hyperglycemia,of nia. Of these received,1
FANAPT,Hyperglycemia,received FANAPT for,0
FANAPT,Hyperglycemia,treatment of nia.,1
FANAPT,Hyperglycemia,nia. Of these received,1
FANAPT,Hyperglycemia,the treatment of nia. Of these received,1
FANAPT,Hyperglycemia,nia. Of these received,1
FANAPT,Hyperglycemia,Of these received FANAPT,1
FANAPT,Hyperglycemia,nia. Of these,1
FANAPT,Hyperglycemia,for the treatment of nia. Of,1
FANAPT,Hyperglycemia,least,0
FANAPT,Hyperglycemia,FANAPT for at,0
FANAPT,diabetes mellitus,treatment of schizophrenia Of  received FANAPT ,1
FANAPT,diabetes mellitus,FANAPT for at,0
FANAPT,diabetes mellitus,received FANAPT for at least months,1
FANAPT,diabetes mellitus,for the treatment,0
FANAPT,diabetes mellitus,least,0
FANAPT,diabetes mellitus,Of  received FANAPT  for,1
FANAPT,diabetes mellitus,least,0
FANAPT,diabetes mellitus,of schizophrenia Of  received FANAPT  for,1
FANAPT,diabetes mellitus,least,0
FANAPT,diabetes mellitus,received FANAPT for at,1
FANAPT,diabetes mellitus,months,0
FANAPT,Dyslipidemia,categories openlabel and d,0
FANAPT,Dyslipidemia,trials The and,1
FANAPT,Weight Gain,and flexibledose studies and shortterm and longer,0
FANAPT,Weight Gain,phases of studies inpatients and outpatients fixeddose,1
FANAPT,Weight Gain,phases of studies inpatients and outpatients,1
FANAPT,Weight Gain,openlabel and  phases of  studies inpatients and,1
FANAPT,Weight Gain,phases of studies inpatients and outpatients,1
FANAPT,Weight Gain,phases of studies inpatients,1
FANAPT,Metabolic Changes,flexibledos,0
FANAPT,Metabolic Changes,"e studies, and sh ortterm and longerterm exposure Adverse",1
FANAPT,Metabolic Changes,flexibledos,0
FANAPT,Metabolic Changes,fixeddose and e,1
FANAPT,Metabolic Changes,flexibledos,0
FANAPT,Metabolic Changes,outpatients fixeddose and flexibledos,0
FANAPT,Metabolic Changes,reactions during,0
FANAPT,cerebrovascular risk,general inquiry d recorded by clinic al,1
FANAPT,cerebrovascular risk,reactions during,0
FANAPT,cerebrovascular risk,obtained by general inquiry d recorded by clinic al investigators using their own,1
FANAPT,cerebrovascular risk,reactions during,0
FANAPT,metabolic changes,clinical tigators using th eir own,1
FANAPT,metabolic changes,reactions during,0
FANAPT,metabolic changes,tigators using th eir own terminology Consequently,1
FANAPT,metabolic changes,Consequently to provide a meaningful,0
FANAPT,metabolic changes,eir own terminology Consequently to provide a meaningful estimate of,0
FANAPT,metabolic changes,by clinical,0
FANAPT,metabolic changes,and recorded by clinical tigators using,1
FANAPT,hyperglycemia,investigators using their own erminology.,1
FANAPT,hyperglycemia,own erminology.,1
FANAPT,hyperglycemia,erminology. C onsequently to provide a meaningful,1
FANAPT,hyperglycemia,own erminology. C onsequently to provide a meaningful,1
FANAPT,hyperglycemia,erminology. C onsequently to provide a meaningful,1
FANAPT,hyperglycemia,obtained by general inquiry and recorded,0
FANAPT,hyperglycemia,erminology. C,1
FANAPT,hyperglycemia,erminology.,1
FANAPT,hyperglycemia,investigators using their own erminology.,1
FANAPT,dyslipidemia,"sequently, t o provide a meaningful estimate",1
FANAPT,dyslipidemia,investigators using their own erminology.,1
FANAPT,dyslipidemia,their own terminology Con,0
FANAPT,dyslipidemia,"their own terminology sequently, t o",1
FANAPT,dyslipidemia,their own terminology Con,0
FANAPT,dyslipidemia,experiencing adverse reactions,0
FANAPT,dyslipidemia,using their own terminology Con,0
FANAPT,dyslipidemia,"own terminology sequently,",1
FANAPT,weight gain,ide a meani,1
FANAPT,weight gain,terminology Consequently to ide a meani,1
FANAPT,weight gain,proportion of individuals experiencing adverse,0
FANAPT,weight gain,own terminology Consequently to ide,1
FANAPT,weight gain,estimate of the proportion of individuals,0
FANAPT,Seizures,meaningful estimate the prop ortion of individuals,1
FANAPT,Seizures,estimate of the proportion of individuals,0
FANAPT,Seizures,the prop ortion of individuals,1
FANAPT,Seizures,grouped,0
FANAPT,Seizures,estimate of,0
FANAPT,Orthostatic hypotension,categories using MedDRA inology.,1
FANAPT,Orthostatic hypotension,"inology.



 The stated",1
FANAPT,Orthostatic hypotension,categories using MedDRA inology.,1
FANAPT,Orthostatic hypotension,grouped,0
FANAPT,Orthostatic hypotension,standardized categories,0
FANAPT,Dizziness,requencie,1
FANAPT,Dizziness,requencie s of adverse reactions represent,1
FANAPT,tachycardia,of adverse,1
FANAPT,tachycardia,terminology The stated of,1
FANAPT,tachycardia,of adverse reactions represent the proportions of,1
FANAPT,tachycardia,terminology The stated of adverse  reactions represent the proportions of,1
FANAPT,tachycardia,of adverse reactions represent the proportions of,1
FANAPT,tachycardia,of adverse reactions represent the proportions,1
FANAPT,tachycardia,The stated,0
FANAPT,tachycardia,of adverse,1
FANAPT,tachycardia,terminology The stated of adverse,1
FANAPT,tachycardia,were grouped in standardized categories using MedDRA terminology The,0
FANAPT,syncope,stated frequencies of adverse ons rep,1
FANAPT,syncope,were grouped in standardized categories using MedDRA terminology The,0
FANAPT,syncope,reacti,0
FANAPT,syncope,stated frequencies of adverse ons rep resent the proportions of individuals,1
FANAPT,syncope,reacti,0
FANAPT,syncope,of adverse ons rep,1
FANAPT,syncope,ons rep,1
FANAPT,syncope,of adverse ons rep,1
FANAPT,syncope,terminology The stated frequencies,0
FANAPT,syncope,treatmentemergent adverse reaction of,0
FANAPT,syncope,adverse ons rep resent the proportions of,1
FANAPT,syncope,treatmentemergent adverse reaction of,0
FANAPT,syncope,ons rep resent the proportions of individuals,1
FANAPT,syncope,treatmentemergent adverse,0
FANAPT,Leukopenia,experience d a,1
FANAPT,Leukopenia,experience d a treatmentemergent adverse reaction,1
FANAPT,Leukopenia,experience d a,1
FANAPT,Leukopenia,experience d a,1
FANAPT,Leukopenia,individuals experience d a treatmentemergent,1
FANAPT,Leukopenia,experience d a,1
FANAPT,Leukopenia,treatmentemergent adverse reaction of the type listed A reaction,0
FANAPT,Leukopenia,of individuals experience d a treatmentemergent adverse,1
FANAPT,Leukopenia,treatmentemergent adverse reaction of the type listed A reaction,0
FANAPT,Leukopenia,frequencies,0
FANAPT,Neutropenia,who a treatment,1
FANAPT,Neutropenia,frequencies,0
FANAPT,Suicide,Adverse Reactions Occurring at an Incidence of or More,0
FANAPT,Suicide,doses n,1
FANAPT,Suicide,patients who received FANAPT at daily doses withi,0
FANAPT,Suicide,ge of to mg n Adverse Reactions Occurring,0
FANAPT,Suicide,Incidence of or More among,0
FANAPT,Suicide,fixed or flexibledose studies,0
FANAPT,Priapism,eived FANAPT at daily doses within a range of to mg n Adverse Reactions,0
FANAPT,Priapism,n Adverse Reactions g at an  Incidence of or More among,1
FANAPT,Priapism,eived FANAPT at daily doses within a range of to mg n Adverse Reactions,0
FANAPT,Priapism,at an Incidence,1
FANAPT,Priapism,mg n Adverse Reactions g,1
FANAPT,Priapism,and More,0
FANAPT,Priapism,g at an,1
FANAPT,motor impairment,than Placebo able 7 enumerate s the,1
FANAPT,motor impairment,g at an,1
FANAPT,motor impairment,able 7 enumerate s the pooled,1
FANAPT,motor impairment,7 enumerate s the pooled,1
FANAPT,motor impairment,More Frequent,0
FANAPT,motor impairment,T,0
FANAPT,motor impairment,Placebo able,1
FANAPT,motor impairment,able,1
FANAPT,cerebrovascular adverse events,Term    (N=483)          (N=391)    Body as a Whole Arthralgia,1
FANAPT,cerebrovascular adverse events,able,1
FANAPT,cerebrovascular adverse events,FANAPT mgday Dictionaryderived Term N,0
FANAPT,cerebrovascular adverse events,   (N=483)          (N=391)    Body as a Whole,1
FANAPT,cerebrovascular adverse events,FANAPT mgday Dictionaryderived Term N,0
FANAPT,cerebrovascular adverse events,N,0
FANAPT,fatalities,N N Body as,0
FANAPT,QTc prolongation,Cardiac Disorde rs Tachycardia,1
FANAPT,QTcF increase,"Gastrointestinal   
       Nau sea Dry Mouth",1
FANAPT,QTcF increase,Cardiac Disorde rs Tachycardia,1
FANAPT,QTcF increase,sea,0
FANAPT,QTcF increase,"  
       Nau sea Dry",1
FANAPT,Neuroleptic Malignant Syndrome,patients,0
FANAPT,Neuroleptic Malignant Syndrome,the incidence in patients reated with,1
FANAPT,Neuroleptic Malignant Syndrome,abdominal discomfort dizziness hypotension,0
FANAPT,Neuroleptic Malignant Syndrome,with FANAPT 10 to 16 mg day were,1
FANAPT,Neuroleptic Malignant Syndrome,patients treated with FANAPT to mgday were twice than the incidence,0
FANAPT,Neuroleptic Malignant Syndrome,stiffness tachycardia,0
FANAPT,Neuroleptic Malignant Syndrome,incidence in patients reated with FANAPT 10 to 16 mg day were,1
FANAPT,Neuroleptic Malignant Syndrome,stiffness tachycardia,0
FANAPT,Neuroleptic Malignant Syndrome,treated with FANAPT to mgday were twice,0
FANAPT,NMS,ay  were abdominal discomfort,1
FANAPT,NMS,dizziness hypotension,0
FANAPT,NMS,tachycardia,0
FANAPT,NMS,FANAPT to ay  were abdominal discomfort dizziness hypotension,1
FANAPT,NMS,tachycardia,0
FANAPT,hyperpyrexia,stiffness,0
FANAPT,hyperpyrexia,Common nd,1
FANAPT,hyperpyrexia,nd Drug-Rela ted Adverse Reactions in Clinical,1
FANAPT,muscle rigidity,d Adverse React ions in Clinical Trials,1
FANAPT,muscle rigidity,ions in Clinical Trials Based on the,0
FANAPT,altered mental status,ns in Clinical Trials,1
FANAPT,altered mental status,DrugRelated Adverse ns in Clinical Trials,1
FANAPT,altered mental status,Common and DrugRelated Adverse ns in Clinical Trials,1
FANAPT,altered mental status,ns in Clinical Trials Based on,1
FANAPT,altered mental status,DrugRelated Adverse ns in Clinical Trials Based on the pooled data,1
FANAPT,altered mental status,ns in Clinical Trials Based on,1
FANAPT,altered mental status,the pooled,0
FANAPT,altered mental status,tachycardia and weight,0
FANAPT,altered mental status,the pooled data from placebocontrolled or week fixed or flexibledose,0
FANAPT,catatonic signs,weight increased Common and DrugRelated Adverse Reactions in Clinical Trials Based,0
FANAPT,catatonic signs,in Clinical Trials on the pooled,1
FANAPT,catatonic signs,on the pooled data,1
FANAPT,catatonic signs,Reactions in Clinical Trials  on the pooled  data,1
FANAPT,catatonic signs,on the pooled data,1
FANAPT,catatonic signs,Clinical Trials on,1
FANAPT,catatonic signs,in Clinical Trials on,1
FANAPT,autonomic instability,flexibledose studies the following adverse reactions occurred in incidence,0
FANAPT,autonomic instability,"from o-controlled, 4-",1
FANAPT,autonomic instability,"o-controlled, 4- or 6 week fixed or",1
FANAPT,autonomic instability,"from o-controlled, 4-",1
FANAPT,autonomic instability,"the pooled data from o-controlled,",1
FANAPT,autonomic instability,4- or 6 week fixed or,1
FANAPT,autonomic instability,in,0
FANAPT,autonomic instability,4- or 6 week fixed,1
FANAPT,autonomic instability,adverse,0
FANAPT,autonomic instability,4- or 6 week fixed or flexibledose studies,1
FANAPT,irregular pulse,the following adverse reactions occurred in incidence,0
FANAPT,irregular pulse,"data from placebocontrolled or eek, fixed- or ",1
FANAPT,irregular pulse,the following adverse reactions occurred in incidence,0
FANAPT,irregular pulse,"eek, fixed- or  flexibledose",1
FANAPT,irregular pulse,the following adverse reactions occurred in incidence,0
FANAPT,irregular pulse,"eek, fixed- or flexibledose studies the following",1
FANAPT,irregular pulse,"eek, fixed- or flexibledose studies the following",1
FANAPT,irregular pulse,"eek, fixed- or flexibledose studies",1
FANAPT,irregular pulse,placebocontrolled,0
FANAPT,tachycardia,Based on the pooled,0
FANAPT,tachycardia,incidence in,0
FANAPT,tachycardia,reactions occurred in incidence in the patients treated with FANAPT and at,0
FANAPT,tachycardia,"week fixed or flexibledose s, the foll",1
FANAPT,tachycardia,reactions occurred in incidence in the patients treated with FANAPT and at,0
FANAPT,tachycardia,owing adverse reactions occurred in incidence in the,0
FANAPT,tachycardia,"s, the foll owing adverse reactions occurred",1
FANAPT,tachycardia,"fixed or flexibledose s, the foll owing adverse reactions occurred",1
FANAPT,tachycardia,"s, the foll owing adverse reactions occurred",1
FANAPT,tachycardia,"s, the foll",1
FANAPT,tachycardia,"flexibledose s, the foll owing adverse",1
FANAPT,tachycardia,"s, the foll",1
FANAPT,tachycardia,"fixed or flexibledose s, the",1
FANAPT,diaphoresis,ing adverse reactions occurred,1
FANAPT,diaphoresis,ing adverse,1
FANAPT,diaphoresis,in incidence in the patients treated,0
FANAPT,diaphoresis,studies the ing adverse,1
FANAPT,diaphoresis,or flexibledose studies the ing adverse reactions occurred in,1
FANAPT,diaphoresis,studies the ing adverse,1
FANAPT,diaphoresis,from placebocontrolled or week fixed or flexibledose studies the follow,0
FANAPT,diaphoresis,ing adverse reactions occurred in,1
FANAPT,diaphoresis,ing adverse reactions,1
FANAPT,diaphoresis,ing adverse reactions occurred in,1
FANAPT,diaphoresis,data from placebocontrolled or,0
FANAPT,diaphoresis,ing adverse reactions occurred in incidence in,1
FANAPT,cardiac dysrhythmia,occurred in >= incidence,1
FANAPT,cardiac dysrhythmia,rom placebocontrolled or week fixed or flexibledose studies,0
FANAPT,cardiac dysrhythmia,ions occurred in >= incidence in the patients,1
FANAPT,cardiac dysrhythmia,with FANAPT and at least twice the placebo rate for at,0
FANAPT,cardiac dysrhythmia,following adverse,0
FANAPT,cardiac dysrhythmia,ions occurred in >= incidence in the,1
FANAPT,myoglobinuria,ce the placeb,1
FANAPT,myoglobinuria,ions occurred in >= incidence in the,1
FANAPT,myoglobinuria,adverse reactions occurred in incidence in the,0
FANAPT,myoglobinuria,patients treated with FANAPT and,0
FANAPT,myoglobinuria,FANAPT and at least ce the placeb,1
FANAPT,myoglobinuria,at least ce the placeb,1
FANAPT,myoglobinuria,FANAPT and at least ce the placeb,1
FANAPT,myoglobinuria,the placeb o rate for at least,1
FANAPT,myoglobinuria,and at least ce the placeb o rate for at,1
FANAPT,myoglobinuria,the placeb o rate for at least,1
FANAPT,myoglobinuria,the patients treated with FANAPT and at,0
FANAPT,myoglobinuria,the placeb,1
FANAPT,myoglobinuria,fatigue nasal,0
FANAPT,rhabdomyolysis,at least twice,0
FANAPT,rhabdomyolysis,rate for at,1
FANAPT,rhabdomyolysis,least twice the rate,1
FANAPT,rhabdomyolysis,tions occurred in incidence in the patients treated with FANAPT and at,0
FANAPT,rhabdomyolysis,rate for at le ast dose dizziness dry,1
FANAPT,rhabdomyolysis,for at le ast dose,1
FANAPT,rhabdomyolysis,congestion somnolence tachycardia,0
FANAPT,rhabdomyolysis,placebo,0
FANAPT,acute renal failure,"rate for at least ose: dizziness,",1
FANAPT,acute renal failure,"rate for at least ose: dizziness, dry",1
FANAPT,acute renal failure,"rate for at least ose: dizziness,",1
FANAPT,acute renal failure,"rate for at least ose: dizziness, dry mouth fatigue nasal congestion somnolence",1
FANAPT,acute renal failure,"rate for at least ose: dizziness,",1
FANAPT,Tardive dyskinesia,     1.9           Adverse Reactions,1
FANAPT,Tardive dyskinesia,     1.9           Adverse Reactions Associated,1
FANAPT,Tardive dyskinesia,Parkinsonism      1.9          ,1
FANAPT,Tardive dyskinesia,     1.9           Adverse Reactions Associated,1
FANAPT,Tardive dyskinesia,Tremor,0
FANAPT,Tardive dyskinesia,Associated with,0
FANAPT,Tardive dyskinesia,     1.9           Adverse,1
FANAPT,Tardive dyskinesia,Associated with,0
FANAPT,Tardive dyskinesia,Parkinsonism,0
FANAPT,Tardive dyskinesia,     1.9           Adverse Reactions Associated,1
FANAPT,"involuntary, dyskinetic movements",erse Reactions,1
FANAPT,"involuntary, dyskinetic movements",Associated with Di scontinuation of,1
FANAPT,"involuntary, dyskinetic movements",Treatment in Clinical Trials Based on,0
FANAPT,"involuntary, dyskinetic movements",Tremor erse Reactions Associated with Di scontinuation,1
FANAPT,"involuntary, dyskinetic movements",Treatment in Clinical Trials Based on,0
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated,1
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated with Di scontinuation of Treatment in Clinical,1
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated,1
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated with Di scontinuation of Treatment in,1
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated,1
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated with Di scontinuation of Treatment in,1
FANAPT,"involuntary, dyskinetic movements",erse Reactions Associated,1
FANAPT,"involuntary, dyskinetic movements",with Di scontinuation of Treatment in,1
FANAPT,hyperglycemia,listed in order of decreasing,0
FANAPT,hyperglycemia,by it. R eactions,1
FANAPT,hyperglycemia,"were not necessarily  by it.



 R eactions are further",1
FANAPT,hyperglycemia,by it. R eactions,1
FANAPT,hyperglycemia,were not necessarily by,1
FANAPT,hyperglycemia,necessarily by,1
FANAPT,dyslipidemia,ctions are f urther categorized by MedDRA,1
FANAPT,dyslipidemia,it ctions are,1
FANAPT,dyslipidemia,in,0
FANAPT,dyslipidemia,necessarily caused by it ctions are f urther categorized by MedDRA system,1
FANAPT,dyslipidemia,in,0
FANAPT,dyslipidemia,categorized by MedDRA system organ class and listed,0
FANAPT,body weight gain,frequency according,0
FANAPT,body weight gain,decreasing,0
FANAPT,body weight gain,it Reactions are categorized,1
FANAPT,body weight gain,categorized by MedDRA system organ class and,1
FANAPT,body weight gain,categorized by MedDRA system organ,1
FANAPT,body weight gain,treatment with FANAPT they were not necessarily caused by,0
FANAPT,body weight gain,further,0
FANAPT,body weight gain, categorized by  MedDRA system organ class,1
FANAPT,body weight gain,further,0
FANAPT,body weight gain,it Reactions are  categorized by  MedDRA system,1
FANAPT,body weight gain,further,0
FANAPT,body weight gain,were not necessarily caused by it Reactions,0
FANAPT,Hyperglycemia,requent adver se,1
FANAPT,Hyperglycemia,requent adver se reactions are,1
FANAPT,Hyperglycemia,in Table appear in this,0
FANAPT,Hyperglycemia,listed in Table appear in,0
FANAPT,Hyperglycemia,requent adver se reactions are those,1
FANAPT,Hyperglycemia,appear in this listing requent,1
FANAPT,Hyperglycemia,requent adver se,1
FANAPT,ketoacidosis,those occurring in  1/1000 pati ents rare,1
FANAPT,ketoacidosis,requent adver se,1
FANAPT,ketoacidosis,events are those occurring,0
FANAPT,ketoacidosis,those occurring in 1/1000 pati,1
FANAPT,ketoacidosis,are those,0
FANAPT,ketoacidosis,those,0
FANAPT,ketoacidosis,1/1000 pati ents rare,1
FANAPT,ketoacidosis,Blood and Lymphatic,0
FANAPT,ketoacidosis,Blood,0
FANAPT,ketoacidosis,in,0
FANAPT,ketoacidosis, 1/1000 pati ents,1
FANAPT,ketoacidosis,in,0
FANAPT,hyperosmolar coma,patients Blood,0
FANAPT,hyperosmolar coma,in to ; rare events are,1
FANAPT,hyperosmolar coma,; rare events are those occurring,1
FANAPT,hyperosmolar coma,in to ; rare events are,1
FANAPT,hyperosmolar coma,; rare events are those occurring in fewer,1
FANAPT,hyperosmolar coma,in to ; rare events are,1
FANAPT,hyperosmolar coma,Blood,0
FANAPT,hyperosmolar coma,events are those occurring in fewer,1
FANAPT,hyperosmolar coma,occurring in to ; rare events are those occurring in fewer,1
FANAPT,hyperosmolar coma,events are those occurring in fewer,1
FANAPT,hyperosmolar coma,to ; rare events are those occurring in,1
FANAPT,hyperosmolar coma,events are those occurring in fewer,1
FANAPT,hyperosmolar coma,; rare events are those,1
FANAPT,death,se oc curring,1
FANAPT,death,se oc curring in,1
FANAPT,death,rare events are se oc,1
FANAPT,death,se oc curring in,1
FANAPT,death,se oc,1
FANAPT,death,se oc curring in fewer than,1
FANAPT,death,curring in fewer than patients,0
FANAPT,death,patients rare events are se oc,1
FANAPT,death,curring in fewer than patients,0
FANAPT,death,those occurring in to patients rare events are,0
FANAPT,hyperglycemia-related adverse events,"opacities cataract hyperemia ncluding conjunctival)



   Gastroi ntestinal Disorders Infrequent gastritis salivary",1
FANAPT,hyperglycemia-related adverse events,those occurring in to patients rare events are,0
FANAPT,hyperglycemia-related adverse events,cataract hyperemia ncluding,1
FANAPT,hyperglycemia-related adverse events,"opacities cataract hyperemia ncluding conjunctival)



   Gastroi ntestinal Disorders Infrequent gastritis salivary",1
FANAPT,hyperglycemia-related adverse events,cataract hyperemia ncluding,1
FANAPT,hyperglycemia-related adverse events,"ncluding conjunctival)



   Gastroi ntestinal Disorders Infrequent gastritis salivary",1
FANAPT,hyperglycemia-related adverse events,cataract hyperemia ncluding,1
FANAPT,hyperglycemia-related adverse events,swelling lenticular,0
FANAPT,hyperglycemia-related adverse events,"lenticular opacities cataract hyperemia ncluding conjunctival)



   Gastroi ntestinal Disorders Infrequent gastritis",1
FANAPT,hyperglycemia-related adverse events,swelling lenticular,0
FANAPT,hyperglycemia-related adverse events,lenticular opacities cataract hyperemia ncluding,1
FANAPT,hyperglycemia-related adverse events,"cataract hyperemia ncluding conjunctival)



   Gastroi ntestinal Disorders Infrequent gastritis salivary",1
FANAPT,hyperglycemia-related adverse events,lenticular opacities cataract hyperemia ncluding,1
FULYZAQ,Upper respiratory tract infection,tract infection Bronchitis,1
FULYZAQ,Upper respiratory tract infection,n PlaceboN Upper respiratory tract infection Bronchitis,1
FULYZAQ,Upper respiratory tract infection,tract infection Bronchitis,1
FULYZAQ,Upper respiratory tract infection,respiratory tract infection,1
FULYZAQ,Bronchitis,Upper respiratory tract infection,0
FULYZAQ,Bronchitis,n Upper respiratory tract infection,0
FULYZAQ,Bronchitis,Upper respiratory tract Bronchitis,1
FULYZAQ,Bronchitis,n Upper respiratory tract infection,0
FULYZAQ,Bronchitis,Bronchitis Cough,1
FULYZAQ,Bronchitis,Bronchitis Cough,1
FULYZAQ,Bronchitis,tract Bronchitis Cough,1
FULYZAQ,Bronchitis,Bronchitis Cough,1
FULYZAQ,Bronchitis,Bronchitis Cough,1
FULYZAQ,Bronchitis,Bronchitis Cough,1
FULYZAQ,Flatulence,Flatulence Increased bilirubin,1
FULYZAQ,Flatulence,Bronchitis Cough,1
FULYZAQ,Nausea,Nausea,1
FULYZAQ,Nausea,Bronchitis Cough,1
FULYZAQ,Nausea,Nausea Back,1
FULYZAQ,Nausea,Increased Nausea Back,1
FULYZAQ,Nausea,Nausea Back,1
FULYZAQ,Nausea,bilirubin,0
FULYZAQ,Nausea,Increased,0
FULYZAQ,Nausea,Nausea Back,1
FULYZAQ,Back pain,Back pain,1
FULYZAQ,Back pain,Back pain Arthralgia,1
FULYZAQ,Back pain,Back pain,1
FULYZAQ,Back pain,Nausea,0
FULYZAQ,Arthralgia,Arthralgia Urinary tract infection,1
FULYZAQ,Arthralgia,Arthralgia,1
FULYZAQ,Arthralgia,Arthralgia,1
FULYZAQ,Arthralgia,Arthralgia,1
FULYZAQ,Arthralgia,Urinary,0
FULYZAQ,Arthralgia,Arthralgia Urinary,1
FULYZAQ,Arthralgia,Urinary,0
FULYZAQ,Urinary tract infection,Urinary,1
FULYZAQ,Urinary tract infection,n Urinary tract,1
FULYZAQ,Urinary tract infection,n,0
FULYZAQ,Urinary tract infection,n Urinary tract,1
FULYZAQ,Nasopharyngitis,Urinary,0
FULYZAQ,Nasopharyngitis,tract Nasopharyngitis,1
FULYZAQ,Nasopharyngitis,Urinary,0
FULYZAQ,Nasopharyngitis,tract infection,0
FULYZAQ,Nasopharyngitis,tract Nasopharyngitis Musculoskeletal,1
FULYZAQ,Nasopharyngitis,tract infection,0
FULYZAQ,Nasopharyngitis,Urinary tract,0
FULYZAQ,Nasopharyngitis,Nasopharyngitis,1
FULYZAQ,Nasopharyngitis,Nasopharyngitis Musculoskeletal,1
FULYZAQ,Musculoskeletal pain,Musculoskeletal pain,1
FULYZAQ,Musculoskeletal pain,Nasopharyngitis,0
FULYZAQ,Musculoskeletal pain,Musculoskeletal pain Hemorrhoids Giard,1
FULYZAQ,Hemorrhoids,Musculoskeletal Hemorrhoids Giardiasis,1
FULYZAQ,Hemorrhoids,Musculoskeletal pain Hemorrhoids Giard,1
FULYZAQ,Giardiasis,Giardiasis Anxiety In,1
FULYZAQ,Giardiasis,Giardiasis,1
FULYZAQ,Giardiasis,pain Giardiasis Anxiety In,1
FULYZAQ,Giardiasis,Giardiasis,1
FULYZAQ,Giardiasis,Giardiasis Anxiety In,1
FULYZAQ,Giardiasis,Giardiasis Anxiety In,1
FULYZAQ,Giardiasis,Giardiasis Anxiety In,1
FULYZAQ,Giardiasis,Giardiasis,1
FULYZAQ,Giardiasis,pain Giardiasis Anxiety In,1
FULYZAQ,Giardiasis,Giardiasis,1
FULYZAQ,Increased alanine aminotransferase,is Increased alanine aminotransferase Abdominal distension,1
FULYZAQ,Increased alanine aminotransferase,Giardiasis,1
FULYZAQ,Increased alanine aminotransferase,alanine aminotransferase Abdominal distension,1
FULYZAQ,abdominal pain,bilirubin increased,0
FULYZAQ,acne,FULYZAQ were abdominal acne increased aspartate aminotransferase,1
FULYZAQ,acne,bilirubin increased,0
FULYZAQ,increased aspartate aminotransferase,pain increased,1
FULYZAQ,increased aspartate aminotransferase,abdominal pain acne,0
FULYZAQ,increased aspartate aminotransferase,bilirubin increased unconjugated blood bilirubin constipation,0
FULYZAQ,increased aspartate aminotransferase,abdominal pain increased aspartate aminotransferase increased conjugated,1
FULYZAQ,increased aspartate aminotransferase,bilirubin increased unconjugated blood bilirubin constipation,0
FULYZAQ,increased aspartate aminotransferase,increased aspartate aminotransferase increased conjugated bilirubin increased,1
FULYZAQ,increased conjugated bilirubin,increased aspartate increased conjugated bilirubin,1
FULYZAQ,increased conjugated bilirubin,increased aspartate aminotransferase increased conjugated bilirubin increased,1
FULYZAQ,increased conjugated bilirubin,increased conjugated bilirubin increased unconjugated,1
FULYZAQ,increased conjugated bilirubin,increased aspartate,0
FULYZAQ,increased conjugated bilirubin,increased aspartate increased,1
FULYZAQ,increased conjugated bilirubin,aspartate increased conjugated bilirubin,1
FULYZAQ,increased conjugated bilirubin,increased aspartate increased,1
FULYZAQ,increased conjugated bilirubin,blood bilirubin constipation depression dermatitis dizziness,0
FULYZAQ,increased conjugated bilirubin,increased aspartate,0
FULYZAQ,increased unconjugated blood bilirubin,increased unconjugated blood bilirubin constipation depression dermatitis dizziness dry,1
FULYZAQ,increased unconjugated blood bilirubin,increased aspartate,0
FULYZAQ,increased unconjugated blood bilirubin,increased unconjugated,1
FULYZAQ,increased unconjugated blood bilirubin,were abdominal pain acne increased aspartate aminotransferase,0
FULYZAQ,increased unconjugated blood bilirubin,increased unconjugated,1
FULYZAQ,increased unconjugated blood bilirubin,conjugated increased,1
FULYZAQ,increased unconjugated blood bilirubin,aminotransferase increased conjugated bilirubin,0
FULYZAQ,increased unconjugated blood bilirubin,aspartate aminotransferase increased conjugated increased unconjugated,1
FULYZAQ,depression,conjugated bilirubin increased unconjugated blood bilirubin constipation,0
FULYZAQ,depression,depression dermatitis dizziness dry,1
FULYZAQ,depression,depression,1
FULYZAQ,depression,bilirubin depression dermatitis,1
FULYZAQ,depression,depression,1
FULYZAQ,dermatitis,depression,0
FULYZAQ,dermatitis,unconjugated blood bilirubin constipation dermatitis dizziness dry mouth dyspepsia gastroenteritis,1
FULYZAQ,dermatitis,depression,0
FULYZAQ,dermatitis,constipation dermatitis dizziness dry mouth,1
FULYZAQ,dermatitis,depression,0
FULYZAQ,dermatitis,blood bilirubin constipation dermatitis dizziness dry mouth dyspepsia gastroenteritis,1
FULYZAQ,dermatitis,depression,0
FULYZAQ,dermatitis,mouth dyspepsia gastroenteritis herpes,0
FULYZAQ,dermatitis,conjugated bilirubin increased unconjugated,0
FULYZAQ,dermatitis,dermatitis dizziness dry mouth,1
FULYZAQ,dermatitis,unconjugated blood bilirubin constipation depression,0
FULYZAQ,dermatitis,increased unconjugated blood bilirubin,0
FULYZAQ,dermatitis,dermatitis dizziness dry mouth dyspepsia,1
FULYZAQ,dry mouth,dermatitis dry mouth dyspepsia gastroenteritis herpes,1
FULYZAQ,dry mouth,dermatitis dizziness dry mouth dyspepsia,1
FULYZAQ,dry mouth,dermatitis dry mouth dyspepsia gastroenteritis herpes,1
FULYZAQ,dry mouth,dermatitis dizziness dry mouth dyspepsia,1
FULYZAQ,dry mouth,constipation depression dermatitis dry mouth,1
FULYZAQ,dyspepsia,dry dyspepsia gastroenteritis herpes zoster,1
FULYZAQ,dyspepsia,constipation depression dermatitis dry mouth,1
FULYZAQ,dyspepsia,gastroenteritis herpes zoster nephrolithiasis pain in extremity pollakiuria procedural,0
FULYZAQ,gastroenteritis,gastroenteritis herpes zoster nephrolithiasis pain in,1
FULYZAQ,herpes zoster,mouth dyspepsia herpes zoster nephrolithiasis pain in extremity pollakiuria,1
FULYZAQ,herpes zoster,gastroenteritis herpes zoster nephrolithiasis pain in,1
FULYZAQ,herpes zoster,mouth dyspepsia herpes,1
FULYZAQ,herpes zoster,mouth,0
FULYZAQ,herpes zoster,dizziness dry mouth dyspepsia herpes,1
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis,1
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain,1
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain in extremity,1
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis,1
FULYZAQ,herpes zoster,herpes zoster nephrolithiasis pain in,1
FULYZAQ,herpes zoster,depression dermatitis dizziness dry mouth,0
FULYZAQ,nephrolithiasis,nephrolithiasis pain in extremity pollakiuria,1
FULYZAQ,nephrolithiasis,nephrolithiasis pain in,1
FULYZAQ,nephrolithiasis,allergy sinusitis and decreased white b,0
FULYZAQ,nephrolithiasis,mouth dyspepsia gastroenteritis herpes nephrolithiasis pain in,1
FULYZAQ,nephrolithiasis,allergy sinusitis and decreased white b,0
FULYZAQ,pain in extremity,dermatitis dizziness dry mouth dyspepsia gastroenteritis herpes zoster nephrolithiasis,0
FULYZAQ,pollakiuria,dry mouth dyspepsia gastroenteritis herpes zoster nephrolithiasis pain in,0
FULYZAQ,pollakiuria,pain in pollakiuria procedural,1
FULYZAQ,pollakiuria,dry mouth dyspepsia gastroenteritis herpes zoster nephrolithiasis pain in,0
FULYZAQ,procedural pain,procedural pain,1
FULYZAQ,procedural pain,seasonal allergy sinusitis and decreased white blood,0
FULYZAQ,seasonal allergy,seasonal allergy sinusitis and decreased,1
FULYZAQ,seasonal allergy,in extremity pollakiuria procedural seasonal allergy sinusitis and,1
FULYZAQ,seasonal allergy,seasonal allergy sinusitis and decreased,1
FULYZAQ,seasonal allergy,seasonal allergy sinusitis and,1
FULYZAQ,seasonal allergy,decreased,0
FULYZAQ,seasonal allergy,were similar,0
FULYZAQ,sinusitis,patients who received d,0
FULYZAQ,sinusitis,sinusitis and decreased white,1
FULYZAQ,sinusitis,sinusitis and decreased white blood cell,1
FULYZAQ,sinusitis,sinusitis and decreased,1
FULYZAQ,sinusitis,pollakiuria procedural pain seasonal sinusitis and decreased white blood cell,1
FULYZAQ,sinusitis,sinusitis and decreased,1
FULYZAQ,sinusitis,sinusitis and,1
FULYZAQ,decreased white blood cell count,pain in extremity pollakiuria procedural pain seasonal allergy sinusitis and,0
FULYZAQ,upper respiratory tract infection,upper respiratory tract infection bronchitis,1
FULYZAQ,upper respiratory tract infection,pain in extremity pollakiuria procedural pain seasonal allergy sinusitis and,0
FULYZAQ,upper respiratory tract infection,tract infection bronchitis,1
FULYZAQ,upper respiratory tract infection,mg daily EXCERPT Most common adverse,0
FULYZAQ,upper respiratory tract infection,upper respiratory tract infection bronchitis cough flatulence,1
FULYZAQ,upper respiratory tract infection,adverse reactions incidence upper respiratory tract infection bronchitis cough,1
FULYZAQ,upper respiratory tract infection,upper respiratory tract infection bronchitis cough flatulence,1
FULYZAQ,upper respiratory tract infection,common adverse reactions incidence,0
FULYZAQ,upper respiratory tract infection,To report SUSPECTED ADVERSE R,0
FULYZAQ,upper respiratory tract infection,reactions incidence upper respiratory tract infection bronchitis cough flatulence and,1
FULYZAQ,upper respiratory tract infection,To report SUSPECTED ADVERSE R,0
FULYZAQ,bronchitis,bronchitis,1
FULYZAQ,bronchitis,tract,0
FULYZAQ,bronchitis,incidence are upper respiratory,0
FULYZAQ,bronchitis,bronchitis cough flatulence and,1
FULYZAQ,bronchitis,report SUSPECTED ADVERSE,0
FULYZAQ,bronchitis,adverse reactions incidence are upper respiratory tract infection,0
FULYZAQ,bronchitis,are upper respiratory,0
FULYZAQ,flatulence,flatulence and increased bilirubin To,1
FULYZAQ,increased bilirubin,tract,0
FULYZAQ,increased bilirubin,are upper respiratory tract infection bronchitis cough,0
FULYZAQ,increased bilirubin,contact Salix,0
FULYZAQ,increased bilirubin,flatulence increased,1
FULYZAQ,increased bilirubin,respiratory tract infection,0
FULYZAQ,increased bilirubin,and,0
FULYZAQ,increased bilirubin,flatulence increased,1
FULYZAQ,increased bilirubin,tract,0
FULYZAQ,increased bilirubin,infection bronchitis cough flatulence increased bilirubin To report SUSPECTED ADVERSE,1
FULYZAQ,increased bilirubin,tract,0
FULYZAQ,increased bilirubin,are upper,0
EOVIST,Nephrogenic systemic fibrosis,elsewhere in the Nephrogenic,1
EOVIST,Nephrogenic systemic fibrosis,in the Nephrogenic systemic fibrosis,1
EOVIST,Nephrogenic systemic fibrosis,the,0
EOVIST,Nephrogenic systemic fibrosis,and Warnings and Precautions Hypersensitivity,0
EOVIST,Nephrogenic systemic fibrosis,reactionsare,0
EOVIST,Nephrogenic systemic fibrosis,Warning and,0
EOVIST,Nephrogenic systemic fibrosis,Boxed,0
EOVIST,Nephrogenic systemic fibrosis,elsewhere in the Nephrogenic systemic fibrosis,1
EOVIST,NSF,NSF see Boxed Warning,1
EOVIST,NSF,systemic NSF see Boxed,1
EOVIST,NSF,NSF see Boxed Warning,1
EOVIST,NSF,NSF see Boxed Warning and,1
EOVIST,NSF,and Precautions,0
EOVIST,Hypersensitivity reactions,and Hypersensitivity,1
EOVIST,Hypersensitivity reactions,EXCERPT Most,0
EOVIST,Hypersensitivity reactions,Hypersensitivity reactions see Contraindications,1
EOVIST,Hypersensitivity reactions,EXCERPT Most,0
EOVIST,Hypersensitivity reactions,and Hypersensitivity,1
EOVIST,Hypersensitivity reactions,fibrosis NSF,0
EOVIST,Hypersensitivity reactions,see Contraindications and Warnings and Precautions EXCERPT Most comm,0
EOVIST,Hypersensitivity reactions,Warning and Warnings and Hypersensitivity reactions,1
EOVIST,nausea,nausea headache feeling hot dizziness,1
EOVIST,headache,headache feeling hot dizziness and back,1
EOVIST,feeling hot,feeling hot,1
EOVIST,feeling hot,feeling,1
EOVIST,feeling hot,SUSPECTED ADVERSE REACTIONS contact,0
EOVIST,feeling hot,feeling hot dizziness,1
EOVIST,feeling hot,adverse reactions incidence are,0
EOVIST,feeling hot,back pain,0
EOVIST,feeling hot,are nausea feeling hot dizziness and back,1
EOVIST,feeling hot,back pain,0
EOVIST,feeling hot,nausea feeling hot,1
EOVIST,feeling hot,pain To report SUSPECTED ADVERSE REACTIONS contact,0
EOVIST,dizziness,dizziness and,1
EOVIST,dizziness,common adverse reactions incidence,0
EOVIST,back pain,reactions incidence are nausea headache feeling,0
EOVIST,back pain,common,0
EOVIST,back pain,feeling hot dizziness back,1
EOVIST,back pain,dizziness back pain To,1
EOVIST,back pain,feeling hot dizziness back,1
EOVIST,back pain,dizziness back pain To report,1
EOVIST,back pain,feeling hot dizziness back,1
EOVIST,back pain,headache feeling hot dizziness back pain To,1
EOVIST,back pain,feeling hot dizziness back,1
EOVIST,nausea,frequent adverse reactions,0
EOVIST,nausea,mild to,0
EOVIST,headache,with the use of,0
EOVIST,headache,headache feeling hot dizziness and back,1
EOVIST,headache,headache feeling,1
EOVIST,dizziness,reactions were predominantly of mild to moderate severity,0
EOVIST,dizziness,feeling dizziness and back pain Adverse reactions,1
EOVIST,dizziness,reactions were predominantly of mild to moderate severity,0
EOVIST,dizziness,pain Adverse reactions,0
EOVIST,dizziness,dizziness and back pain Adverse,1
EOVIST,back pain,reactions were predominantly of mild to moderate severity Table lists adverse react,0
EOVIST,Dizziness,Dizziness Back,1
EOVIST,Vomiting,Vomiting Blood pressure,1
EOVIST,Vomiting,Vomiting Blood,1
EOVIST,Vomiting,Vomiting Blood pressure,1
EOVIST,Vomiting,Vomiting Blood,1
EOVIST,Vomiting,Vomiting Blood pressure,1
EOVIST,Vomiting,Vomiting Blood,1
EOVIST,Vomiting,Blood pressure,0
EOVIST,Vomiting,Blood pressure increased,0
EOVIST,Vomiting,Back Vomiting,1
EOVIST,Vomiting,Blood pressure increased,0
EOVIST,Vomiting,Blood pressure increased,0
EOVIST,Injection site reactions,pressure,0
EOVIST,Injection site reactions,increased,0
EOVIST,Injection site reactions,Blood pressure Injection site reactions pain burning,1
EOVIST,Injection site reactions,increased,0
EOVIST,Injection site reactions,coldness extravasation,0
EOVIST,Injection site reactions,Blood pressure increased,0
EOVIST,Injection site reactions,Injection site reactions,1
EOVIST,Injection site reactions,pressure,0
EOVIST,Injection site reactions,pressure,0
EOVIST,Injection site reactions,pressure Injection site reactions,1
EOVIST,Rash,Rash Respiratory disorders dyspnea,1
EOVIST,Rash,pressure Injection site reactions,1
EOVIST,dyspnea,dyspnea,1
EOVIST,dyspnea,respiratory distress Fatigue,0
EOVIST,dyspnea,respiratory distress Fatigue,0
EOVIST,respiratory distress,disorders respiratory,1
EOVIST,respiratory distress,Rash Respiratory disorders respiratory distress,1
EOVIST,respiratory distress,Rash Respiratory disorders respiratory distress Fatigue,1
EOVIST,respiratory distress,Rash Respiratory disorders respiratory distress,1
EOVIST,respiratory distress,Respiratory disorders,0
EOVIST,respiratory distress,Respiratory disorders respiratory,1
EOVIST,respiratory distress,Rash Respiratory disorders respiratory distress,1
EOVIST,respiratory distress,Respiratory disorders respiratory,1
EOVIST,respiratory distress,respiratory distress Fatigue,1
EOVIST,Fatigue,Fatigue Chest,1
EOVIST,Fatigue,Fatigue Chest,1
EOVIST,Fatigue,Fatigue,1
EOVIST,Fatigue,Fatigue Chest,1
EOVIST,Fatigue,Fatigue Chest pain,1
EOVIST,Fatigue,Fatigue Chest pain,1
EOVIST,Fatigue,Fatigue Chest,1
EOVIST,Fatigue,Fatigue Chest pain,1
EOVIST,Vertigo,Vertigo Dry,1
EOVIST,Vertigo,Fatigue Chest pain,1
EOVIST,Vertigo,Chest,0
EOVIST,Vertigo,Vertigo Dry,1
EOVIST,Vertigo,Vertigo Dry mouth,1
EOVIST,Vertigo,Vertigo,1
EOVIST,Vertigo,Chest pain,0
EOVIST,Vertigo,Chest Vertigo,1
EOVIST,Vertigo,Chest pain,0
EOVIST,Vertigo,Vertigo,1
EOVIST,Chills,Chills Feeling abnormal,1
EOVIST,Chills,mouth,0
EOVIST,Chills,Chills Feeling abnormal,1
EOVIST,Chills,mouth,0
EOVIST,Chills,Dry,0
EOVIST,Chills,mouth,0
EOVIST,Chills,Chills,1
EOVIST,Chills,Chills Feeling,1
EOVIST,Chills,Dry mouth,0
EOVIST,akathisia,EOVIST include akathisia bundle branch block palpitation oral,1
EOVIST,akathisia,Dry mouth,0
EOVIST,akathisia,include akathisia,1
EOVIST,akathisia,Dry mouth,0
EOVIST,akathisia,discomfort salivary hypersecretion maculopapular rash,0
EOVIST,akathisia,occurred with a,0
EOVIST,bundle branch block,include tremor akathisia,0
EOVIST,bundle branch block,hypersecretion maculopapular,0
EOVIST,bundle branch block,branch block palpitation oral discomfort salivary hypersecretion,1
EOVIST,bundle branch block,bundle branch block,1
EOVIST,bundle branch block,palpitation oral discomfort salivary hypersecretion maculopapular rash,0
EOVIST,bundle branch block,tremor bundle branch,1
EOVIST,bundle branch block,occurred with a frequency of,0
EOVIST,bundle branch block,discomfort salivary,0
EOVIST,palpitation,palpitation,1
EOVIST,oral discomfort,akathisia bundle branch,0
EOVIST,oral discomfort,hyperhidrosis,0
EOVIST,oral discomfort,oral discomfort salivary hypersecretion maculopapular rash hyperhidrosis,1
EOVIST,oral discomfort,branch block oral discomfort salivary hypersecretion maculopapular rash,1
EOVIST,oral discomfort,oral discomfort salivary hypersecretion maculopapular rash hyperhidrosis,1
EOVIST,oral discomfort,maculopapular rash hyperhidrosis discomfort and malaise,0
EOVIST,oral discomfort,EOVIST include tremor akathisia bundle branch block,0
EOVIST,oral discomfort,block,0
EOVIST,oral discomfort,bundle branch block oral discomfort salivary hypersecretion maculopapular rash hyperhidrosis,1
EOVIST,oral discomfort,block,0
EOVIST,oral discomfort,akathisia bundle branch block oral discomfort salivary hypersecretion maculopapular rash hyperhidrosis,1
EOVIST,oral discomfort,block,0
EOVIST,salivary hypersecretion,Elevation of serum iron,0
EOVIST,salivary hypersecretion,include tremor akathisia bundle branch block,0
EOVIST,salivary hypersecretion,discomfort and malaise Elevation of serum iron values and,0
EOVIST,salivary hypersecretion,discomfort,0
EOVIST,salivary hypersecretion,hyperhidrosis discomfort and malaise Elevation of serum iron,0
EOVIST,salivary hypersecretion,block palpitation oral salivary hypersecretion maculopapular rash hyperhidrosis discomfort and,1
EOVIST,salivary hypersecretion,hyperhidrosis discomfort and malaise Elevation of serum iron,0
EOVIST,salivary hypersecretion,Elevation of serum iron values,0
EOVIST,maculopapular rash,salivary,0
EOVIST,maculopapular rash,maculopapular rash,1
EOVIST,maculopapular rash,serum iron,0
EOVIST,maculopapular rash,oral discomfort salivary,0
EOVIST,maculopapular rash,discomfort salivary maculopapular rash,1
EOVIST,maculopapular rash,palpitation oral discomfort salivary maculopapular rash hyperhidrosis discomfort and malaise,1
EOVIST,maculopapular rash,discomfort salivary maculopapular rash,1
EOVIST,maculopapular rash,bundle branch block palpitation oral discomfort salivary,0
EOVIST,maculopapular rash,bundle branch block palpitation,0
EOVIST,discomfort,discomfort and malaise Elevation of,1
EOVIST,discomfort,salivary hypersecretion maculopapular rash discomfort and malaise Elevation of,1
EOVIST,discomfort,discomfort and malaise Elevation of,1
EOVIST,discomfort,discomfort and malaise Elevation,1
EOVIST,malaise,malaise Elevation of serum,1
EOVIST,malaise,Elevation of serum iron values and serum bilirubin laboratory values,0
EOVIST,Elevation of serum iron,malaise,0
EOVIST,Hypersensitivity reactions,causal relationship to drug Hypersensitivity reactions anaphylacticshock hypotension pharyngolaryngeal,1
EOVIST,Hypersensitivity reactions,malaise,0
EOVIST,Hypersensitivity reactions,Hypersensitivity reactions,1
EOVIST,Hypersensitivity reactions,drug exposure,0
EOVIST,Hypersensitivity reactions,to,0
EOVIST,anaphylacticshock,anaphylacticshock hypotension pharyngolaryngeal edema,1
EOVIST,hypotension,relationship,0
EOVIST,hypotension,hypotension pharyngolaryngeal edema urticaria,1
EOVIST,hypotension,hypotension pharyngolaryngeal,1
EOVIST,hypotension,drug exposure Hypersensitivity reactions hypotension pharyngolaryngeal edema urticaria face,1
EOVIST,hypotension,hypotension pharyngolaryngeal,1
EOVIST,pharyngolaryngeal edema,Hypersensitivity reactions anaphylacticshock pharyngolaryngeal,1
EOVIST,urticaria,reactions anaphylacticshock hypotension pharyngolaryngeal urticaria face edema rhinitis,1
EOVIST,urticaria,Hypersensitivity reactions anaphylacticshock pharyngolaryngeal,1
EOVIST,face edema,face edema rhinitis conjunctivitis,1
EOVIST,face edema,face edema,1
EOVIST,rhinitis,rhinitis conjunctivitis abdominal pain,1
EOVIST,rhinitis,rhinitis conjunctivitis abdominal pain,1
EOVIST,rhinitis,cough and pallor see Warnings,0
EOVIST,conjunctivitis,conjunctivitis,1
EOVIST,conjunctivitis,pharyngolaryngeal,0
EOVIST,conjunctivitis,cough and pallor,0
EOVIST,abdominal pain,abdominal pain hypoesthesia sneezing cough,1
EOVIST,abdominal pain,abdominal pain hypoesthesia,1
EOVIST,hypoesthesia,conjunctivitis abdominal hypoesthesia sneezing cough and pallor see,1
EOVIST,hypoesthesia,abdominal pain hypoesthesia,1
EOVIST,hypoesthesia,hypoesthesia sneezing cough and,1
EOVIST,hypoesthesia,hypoesthesia sneezing cough and pallor see,1
EOVIST,hypoesthesia,hypoesthesia sneezing cough and pallor see,1
EOVIST,hypoesthesia,pallor see Warnings and Precautions Tachycardia,0
EOVIST,hypoesthesia,edema urticaria face edema,0
EOVIST,hypoesthesia,Warnings and,0
EOVIST,hypoesthesia,hypoesthesia sneezing,1
EOVIST,hypoesthesia,conjunctivitis,0
EOVIST,hypoesthesia,hypoesthesia sneezing cough and,1
EOVIST,sneezing,and pallor,0
EOVIST,sneezing,sneezing cough and pallor see,1
EOVIST,sneezing,abdominal pain sneezing cough and pallor,1
EOVIST,sneezing,sneezing cough and pallor see,1
EOVIST,sneezing,urticaria,0
EOVIST,cough,abdominal pain hypoesthesia cough and pallor see Warnings,1
EOVIST,cough,urticaria,0
EOVIST,cough,cough and pallor see,1
EOVIST,cough,cough and,1
EOVIST,cough,and,0
EOVIST,cough,hypoesthesia,0
EOVIST,cough,pain hypoesthesia cough and pallor see Warnings and,1
EOVIST,cough,hypoesthesia,0
EOVIST,pallor,pallor,1
EOVIST,pallor,sneezing cough pallor see Warnings and,1
EOVIST,pallor,pallor,1
EOVIST,pallor,hypoesthesia sneezing cough pallor see Warnings,1
EOVIST,pallor,pallor,1
EOVIST,pallor,pain,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,adverse re actionsare discussed,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,elsewhere,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,REACTIONS The,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,ADVERSE REACTIONS  following serious adverse re actionsare discussed,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,REACTIONS The,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,fibrosis,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,labeling Nephrogenic systemic fibrosis,0
EOVIST,NSF,tio nsare discussed elsewhere in the,1
EOVIST,NSF,following serious adverse tio nsare discussed elsewhere,1
EOVIST,NSF,tio nsare discussed elsewhere in the,1
EOVIST,NSF,tio nsare discussed elsewhere,1
EOVIST,NSF,serious adverse tio nsare,1
EOVIST,NSF,tio nsare discussed elsewhere,1
EOVIST,NSF,The following serious adverse tio nsare discussed elsewhere in the,1
EOVIST,NSF,tio nsare discussed elsewhere,1
EOVIST,NSF,REACTIONS The following serious,0
EOVIST,NSF,tio nsare discussed elsewhere,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,see Boxed Warning and,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,the labeling:,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,"adverse reactionsare d elsewhere in the labeling:
 Nephrogenic",1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,the labeling:,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,discusse,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,discusse,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,serious adverse reactionsare d,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,in the labeling:,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,serious adverse reactionsare d elsewhere in the labeling:,1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,REACTIONS The following serious,0
EOVIST,NSF,"
 * Nephrogenic",1
EOVIST,NSF,in the labeling,0
EOVIST,NSF,"
 * Nephrogenic systemic fibrosis",1
EOVIST,NSF,in the labeling,0
EOVIST,NSF,"
 *",1
EOVIST,NSF,"
 * Nephrogenic systemic fibrosis NSF",1
EOVIST,NSF,"elsewhere in the 
 * Nephrogenic",1
EOVIST,NSF,"
 * Nephrogenic systemic fibrosis NSF",1
EOVIST,NSF,"the 
 *",1
EOVIST,NSF,"
 * Nephrogenic systemic fibrosis NSF",1
EOVIST,NSF,"
 * Nephrogenic",1
EOVIST,NSF,ERSE REACTIONS The following serious adverse reactionsare discussed,0
EOVIST,NSF,"the 
 * Nephrogenic systemic fibrosis NSF",1
EOVIST,NSF,ERSE REACTIONS The following serious adverse reactionsare discussed,0
EOVIST,NSF,see Boxed Warning and s a nd Precautions Hypersensitivity,1
EOVIST,NSF,ERSE REACTIONS The following serious adverse reactionsare discussed,0
EOVIST,NSF,see,0
EOVIST,NSF,Precautions,0
EOVIST,NSF,e n ausea headache feeling,1
EOVIST,NSF,headache feeling hot dizziness and back pain To,0
EOVIST,fatal,", fee ling hot dizziness and",1
EOVIST,fatal,"incidence are nausea ,",1
EOVIST,fatal,"nausea , fee",1
EOVIST,fatal,"are nausea ,",1
EOVIST,fatal,", fee ling hot dizziness and",1
EOVIST,fatal,"incidence are nausea , fee",1
EOVIST,fibrosis,"ss, and back pain To report SUSPECTED",1
EOVIST,fibrosis,"feeling hot ss, and",1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,", 22% Asian, 3% Hispanic, 2%  Black and of",1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,"feeling hot ss, and",1
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,was years age,0
EOVIST,NEPHROGENIC SYSTEMIC FIBROSIS,were men and the ethnic distribution was,0
EOVIST,NSF,ack,1
EOVIST,NSF,ack and,1
EOVIST,NSF,Hispanic ack and,1
EOVIST,NSF,ack and,1
EOVIST,NSF,Caucasian Asian Hispanic ack and of,1
EOVIST,NSF,ack and,1
EOVIST,NSF,Caucasian Asian Hispanic ack,1
EOVIST,NSF,ack and,1
EOVIST,NSF,age range,0
EOVIST,NSF,rea,1
EOVIST,NSF,rea,1
EOVIST,NSF,rea ctions,1
EOVIST,Nephrogenic Systemic Fibrosis,The following serious,0
EOVIST,Nephrogenic Systemic Fibrosis,systemic,0
EOVIST,Nephrogenic Systemic Fibrosis,serious se reactionsare discussed els ewhere,1
EOVIST,Nephrogenic Systemic Fibrosis,systemic,0
EOVIST,hypersensitivity reactions,incidence,0
EOVIST,cutaneous manifestations,and Precautions EXCERPT ost common adverse react,1
EOVIST,shock,ling  hot dizziness and back pain,1
EOVIST,shock,ling  hot dizziness and back pain,1
EOVIST,shock,hot dizziness and back,0
EOVIST,shock,headache fee,0
EOVIST,shock,ling  hot dizziness,1
EOVIST,shock,ling  hot dizziness and,1
EOVIST,shock,ling  hot dizziness and back pain,1
EOVIST,shock,ling  hot dizziness and,1
EOVIST,shock,ling  hot dizziness and back pain,1
EOVIST,shock,ling  hot dizziness and,1
EOVIST,shock,adverse reactions incidence are nausea headache fee,0
EOVIST,shock,contact Bayer Healt,0
EOVIST,nephrogenic systemic fibrosis,Clinical Trials E xperience Because clinical trials are,1
EOVIST,nephrogenic systemic fibrosis,FDA at FDA or 6.1 Clinical,1
EOVIST,nephrogenic systemic fibrosis,6.1,1
EOVIST,nephrogenic systemic fibrosis,"or 


 

  6.1 Clinical Trials E xperience Because clinical trials",1
EOVIST,nephrogenic systemic fibrosis,6.1,1
EOVIST,nephrogenic systemic fibrosis,at,0
EOVIST,nephrogenic systemic fibrosis,6.1 Clinical Trials E xperience Because clinical,1
EOVIST,NSF,eri ence,1
EOVIST,NSF,6.1 Clinical Trials E xperience Because clinical,1
EOVIST,NSF,eri ence Because clinical,1
EOVIST,NSF,conducted under widely varying conditions adverse reaction,0
EOVIST,NSF,eri ence Because clinical,1
EOVIST,NSF,reactions described in,0
EOVIST,NSF,fle ct the,1
EOVIST,NSF,in clinical practice The,0
EOVIST,NSF,fle ct the rates,1
EOVIST,NSF,fle ct the,1
EOVIST,NSF,fle ct the rates,1
EOVIST,NSF,fle ct the rates observed in,1
EOVIST,NSF,fle ct the rates observed,1
EOVIST,NSF,fle ct the rates,1
EOVIST,NSF, of other ethnic groups,1
EOVIST,NSF,subjects,0
EOVIST,NSF, of other,1
EOVIST,NSF,average age was years age range,0
EOVIST,NSF,was,0
EOVIST,fatal,roups The average,1
EOVIST,fatal,The average age was years age range from to years Overall of subjects,0
EOVIST,fatal,consisted of other ethnic roups The average age was years,1
EOVIST,fatal,The average age was years age range from to years Overall of subjects,0
EOVIST,fatal,roups,1
EOVIST,fatal,roups The,1
EOVIST,fatal,roups The average age,1
EOVIST,fatal,g,0
EOVIST,fatal,other ethnic roups The average,1
EOVIST,fatal,g,0
EOVIST,fatal,other,0
EOVIST,fatal,roups The average,1
EOVIST,fibrosis,average  was 57 ,1
EOVIST,fibrosis,roups The average,1
EOVIST,fibrosis,The average was 57,1
EOVIST,fibrosis,average  was 57  years age range,1
EOVIST,fibrosis,The average was 57,1
EOVIST,fibrosis,was,1
EOVIST,fibrosis,was 57 years age range,1
EOVIST,fibrosis,Overall,0
EOVIST,hypersensitivity reactions,n                         ,1
EOVIST,hypersensitivity reactions,Vertigo,0
EOVIST,hypersensitivity reactions,n                          Vertigo,1
EOVIST,hypersensitivity reactions,n                          Vertigo Dry,1
EOVIST,hypersensitivity reactions,n                          Vertigo Dry,1
EOVIST,hypersensitivity reactions,Vertigo Dry mou,0
EOVIST,hypersensitivity reactions,s Fatigue,0
EOVIST,hypersensitivity reactions,n                          Vertigo Dry mou,1
EOVIST,cutaneous manifestations,Dry,0
EOVIST,cutaneous manifestations,Vertigo,0
EOVIST,cutaneous manifestations,Vertigo,0
EOVIST,cutaneous manifestations,Chest pain Vertigo,0
EOVIST,cutaneous manifestations,                        ,1
EOVIST,cutaneous manifestations,                         Dry mouth Chill,1
EOVIST,cutaneous manifestations,Dry mouth,0
EOVIST,hypersensitivity reaction,"received EOVIST include  akathisia, bundle branch block palpitation",1
EOVIST,hypersensitivity reaction,Dry mouth,0
EOVIST,hypersensitivity reaction,"received EOVIST include akathisia, bundle branch",1
EOVIST,hypersensitivity reaction,bundle branch block palpitation oral,1
EOVIST,hypersensitivity reaction,"akathisia, bundle branch block palpitation oral",1
EOVIST,hypersensitivity reaction,a frequency of in subjects who received EOVIST include tremor,0
EOVIST,hypersensitivity reaction,of in subjects who received EOVIST include tremor,0
EOVIST,hypersensitivity reaction,occurred with a frequency of,0
EOVIST,hypersensitivity reaction,bundle branch block palpitation oral discomfort salivary,1
EOVIST,hypersensitivity reaction,"akathisia, bundle branch",1
EOVIST,hypersensitivity reaction,"who received EOVIST include akathisia, bundle branch",1
EOVIST,acute kidney injury,uncertain size it is not possible to,1
EOVIST,acute kidney injury,uncertain size it,1
EOVIST,acute kidney injury,causal,0
EOVIST,acute kidney injury,reported voluntarily from a n of uncertain size it,1
EOVIST,acute kidney injury,causal,0
EOVIST,acute kidney injury,from a n of uncertain size it is,1
EOVIST,acute kidney injury,causal,0
EOVIST,acute kidney injury,reported voluntarily from a n of,1
EOVIST,acute kidney injury,hypotension pharyngolaryngeal edema,0
EOVIST,acute kidney injury,ship to drug exposu re Hypersensitivity,1
EOVIST,acute kidney injury,hypotension pharyngolaryngeal edema,0
EOVIST,acute kidney injury,not possible to reliably estimate their frequency,0
EOVIST,acute kidney injury,drug exposu re Hypersensitivity reactions anaphylacticshock hypotension,1
ONFI,Somnolence,Somnolence,1
ONFI,Somnolence,Somnolence or Sedation see Warnings and,1
ONFI,Somnolence,sections of the labeling include the following,0
ONFI,Somnolence,other sections of the labeling include the,0
ONFI,Somnolence,Precautions Potentiation of Sedation from Concomitan,0
ONFI,Somnolence,Somnolence or Sedation see Warnings,1
ONFI,Somnolence,Somnolence or Sedation see Warnings,1
ONFI,Somnolence,icant adverse reactions that appear in other sections,0
ONFI,Somnolence,Somnolence or Sedation see Warnings and,1
ONFI,Somnolence,Somnolence or,1
ONFI,Sedation,Sedation,1
ONFI,Sedation,Somnolence Sedation see Warnings and Precautions Potentiation,1
ONFI,Sedation,Sedation,1
ONFI,Sedation,Sedation see Warnings,1
ONFI,Potentiation of Sedation,with,0
ONFI,Potentiation of Sedation,Nervous System Depressants see Warnings and,0
ONFI,Dermatological Reactions,Contraindications Warnings,0
ONFI,Dermatological Reactions,see Warnings and Precautions Serious,0
ONFI,Dermatological Reactions,Precautions Dermatological,1
ONFI,Dermatological Reactions,Dermatological Reactions see,1
ONFI,Dermatological Reactions,Precautions Dermatological Reactions,1
ONFI,Psychological Dependence,Warnings and Precautions Physical Psychological,1
ONFI,Psychological Dependence,and Precautions Physical Psychological Dependence,1
ONFI,Psychological Dependence,and Precautions Physical Psychological,1
ONFI,Psychological Dependence,Warnings and Precautions Physical and,0
ONFI,Psychological Dependence,see Warnings and,0
ONFI,Suicidal Behavior,Suicidal Behavior and Ideation,1
ONFI,Suicidal Behavior,Dependence see Warnings and Suicidal Behavior,1
ONFI,Suicidal Behavior,Suicidal Behavior and,1
ONFI,Suicidal Behavior,see Warnings and Suicidal Behavior,1
ONFI,Suicidal Behavior,Suicidal Behavior and,1
ONFI,Suicidal Behavior,Suicidal Behavior and Ideation,1
ONFI,Suicidal Behavior,and Precautions EXCERPT,0
ONFI,constipation,in any ONFI dose constipation,1
ONFI,constipation,and Precautions EXCERPT,0
ONFI,constipation,constipation somnolence or sedation pyrexia lethargy,1
ONFI,constipation,and Precautions EXCERPT,0
ONFI,constipation,in any ONFI dose constipation somnolence or sedation pyrexia lethargy,1
ONFI,constipation,and Precautions EXCERPT,0
ONFI,somnolence,somnolence or sedation,1
ONFI,somnolence,somnolence or sedation pyrexia,1
ONFI,somnolence,somnolence or,1
ONFI,somnolence,included somnolence or sedation pyrexia lethargy and,1
ONFI,somnolence,somnolence or,1
ONFI,somnolence,sedation,0
ONFI,somnolence,constipation,0
ONFI,sedation,dose included constipation somnolence sedation pyrexia lethargy and drooling,1
ONFI,sedation,constipation,0
ONFI,sedation,sedation pyrexia lethargy and drooling To,1
ONFI,sedation,in any ONFI dose,0
ONFI,pyrexia,pyrexia lethargy,1
ONFI,drooling,drooling To report SUSPECTED ADVERSE,1
ONFI,drooling,pyrexia lethargy,1
ONFI,drooling,any ONFI,0
ONFI,lethargy,Common Adverse Reactions in an L,0
ONFI,lethargy,lethargy somnolence ataxia aggression fatigue and,1
ONFI,lethargy,fatigue and insomnia Most Common,0
ONFI,somnolence,somnolence ataxia aggression fatigue and,1
ONFI,somnolence,somnolence ataxia aggression fatigue and,1
ONFI,somnolence,in an,0
ONFI,ataxia,ataxia aggression fatigue and,1
ONFI,ataxia,ataxia aggression fatigue,1
ONFI,ataxia,in an LGS,0
ONFI,ataxia,Reactions,0
ONFI,ataxia,ataxia aggression fatigue and,1
ONFI,ataxia,order,0
ONFI,ataxia,ataxia aggression fatigue,1
ONFI,aggression,aggression,1
ONFI,aggression,aggression fatigue,1
ONFI,aggression,lethargy somnolence aggression fatigue and insomnia Most,1
ONFI,aggression,aggression fatigue,1
ONFI,fatigue,order of frequency,0
ONFI,fatigue,frequency included lethargy somnolence,0
ONFI,fatigue,fatigue and insomnia Most,1
ONFI,fatigue,lethargy somnolence ataxia fatigue and,1
ONFI,fatigue,fatigue and insomnia Most,1
ONFI,fatigue,fatigue and insomnia Most,1
ONFI,fatigue,lethargy somnolence ataxia fatigue and insomnia Most Common,1
ONFI,fatigue,fatigue and insomnia Most,1
ONFI,fatigue,order of frequency included lethargy somnolence,0
ONFI,insomnia,Most,0
ONFI,insomnia,insomnia Most Common Adverse Reactions,1
ONFI,insomnia,insomnia Most Common Adverse,1
ONFI,Somnolence,Nervous System Disorders,0
ONFI,Somnolence,Somnolence or,1
ONFI,Somnolence,Somnolence or Sedation,1
ONFI,Somnolence,Somnolence,1
ONFI,Somnolence,Nervous System Somnolence or,1
ONFI,Somnolence,Somnolence,1
ONFI,Anemia,Anemia eosinophilia leukopenia thrombocytopenia Eye Disorders,1
ONFI,Anemia,Somnolence,1
ONFI,Anemia,organ,0
ONFI,Anemia,Anemia eosinophilia leukopenia thrombocytopenia Eye,1
ONFI,Anemia,Anemia eosinophilia leukopenia thrombocytopenia,1
ONFI,Anemia,Disorders Diplopia vision blurred Gastro,0
ONFI,Anemia,categorized by system organ class,0
ONFI,Anemia,Anemia eosinophilia leukopenia thrombocytopenia,1
ONFI,eosinophilia,eosinophilia leukopenia,1
ONFI,eosinophilia,eosinophilia leukopenia thrombocytopenia Eye Disorders,1
ONFI,eosinophilia,Blood Disorders Anemia,0
ONFI,eosinophilia,system organ class Blood Disorders Anemia,0
ONFI,eosinophilia,Disorders eosinophilia leukopenia,1
ONFI,eosinophilia,system organ class Blood Disorders Anemia,0
ONFI,eosinophilia,eosinophilia leukopenia thrombocytopenia Eye Disorders Diplopia,1
ONFI,leukopenia,leukopenia thrombocytopenia Eye Disorders,1
ONFI,leukopenia,Eye Disorders Diplopia vision blurred,0
ONFI,thrombocytopenia,thrombocytopenia Eye Disorders Diplopia vision blurred,1
ONFI,Hepatic enzyme increased,enzyme increased Musculoskeletal Muscle spasms Psychiatric Disorders,1
ONFI,Agitation,Agitation anxiety apathy,1
ONFI,Agitation,Agitation anxiety,1
ONFI,Agitation,Agitation anxiety apathy,1
ONFI,Agitation,Hepatic enzyme increased Musculoskeletal Muscle spasms Psychiatric Disorders,0
ONFI,Agitation,Disorders,0
ONFI,Agitation,Agitation anxiety apathy confusional,1
ONFI,Agitation,delusion hallucination,0
ONFI,Agitation,Agitation anxiety,1
ONFI,Agitation,Agitation,1
ONFI,Agitation,Agitation anxiety,1
ONFI,anxiety,anxiety,1
ONFI,anxiety,anxiety,1
ONFI,anxiety,and Urinary Diso,0
ONFI,anxiety,anxiety apathy confusional state depression delirium,1
ONFI,anxiety,anxiety apathy confusional state,1
ONFI,anxiety,anxiety apathy confusional state,1
ONFI,confusional state,Musculoskeletal Muscle spasms Psychiatric Disorders Agitation,0
ONFI,confusional state,confusional state depression delirium delusion,1
ONFI,confusional state,Musculoskeletal Muscle spasms Psychiatric Disorders Agitation,0
ONFI,confusional state,Disorders Agitation anxiety confusional state depression delirium delusion hallucination Renal,1
ONFI,confusional state,Musculoskeletal Muscle spasms Psychiatric Disorders Agitation,0
ONFI,confusional state,Urinary Disorders Urinary retention,0
ONFI,confusional state,confusional state depression delirium delusion hallucination,1
ONFI,confusional state,Disorders Agitation anxiety confusional state depression delirium delusion,1
ONFI,confusional state,confusional state depression delirium delusion hallucination,1
ONFI,confusional state,anxiety,0
ONFI,confusional state,depression delirium delusion hallucination,0
ONFI,confusional state,confusional state,1
ONFI,confusional state,delusion hallucination Renal and,0
ONFI,depression,depression,1
ONFI,depression,depression,1
ONFI,depression,Urinary Disorders Urinary retention Respirat,0
ONFI,delirium,anxiety apathy confusional state delirium,1
ONFI,delirium,Urinary Disorders Urinary retention Respirat,0
ONFI,delirium,hallucination Renal and,0
ONFI,delirium,Agitation anxiety apathy,0
ONFI,delirium,delirium delusion hallucination,1
ONFI,delirium,Agitation anxiety apathy,0
ONFI,delirium,delirium delusion hallucination Renal and,1
ONFI,delusion,delusion hallucination Renal,1
ONFI,hallucination,hallucination Renal,1
ONFI,hallucination,state depression delirium hallucination Renal and Urinary Disorders,1
ONFI,hallucination,hallucination Renal,1
ONFI,hallucination,depression delirium hallucination Renal and Urinary,1
ONFI,hallucination,hallucination Renal,1
ONFI,hallucination,hallucination,1
ONFI,hallucination,Urinary,0
ONFI,Aspiration,Aspiration respiratory depression Skin and,1
ONFI,Aspiration,Aspiration,1
ONFI,Aspiration,Disorders,0
ONFI,Aspiration,and Subcutaneous Tissue Disorders Rash urticaria,0
ONFI,Aspiration,Urinary retention Respiratory Aspiration respiratory depression Skin and,1
ONFI,Aspiration,and Subcutaneous Tissue Disorders Rash urticaria,0
ONFI,Aspiration,Rash urticaria,0
ONFI,Aspiration,Aspiration respiratory,1
ONFI,Aspiration,Respiratory Aspiration respiratory,1
ONFI,Aspiration,Aspiration respiratory,1
ONFI,respiratory depression,respiratory depression Skin and Subcutaneous Tissue,1
ONFI,respiratory depression,Urinary retention Respiratory Disorders respiratory depression,1
ONFI,respiratory depression,respiratory depression Skin and Subcutaneous Tissue,1
ONFI,respiratory depression,Urinary retention Respiratory Disorders respiratory,1
ONFI,respiratory depression,angioedema,0
ONFI,respiratory depression,respiratory depression Skin and Subcutaneous Tissue Disorders,1
ONFI,respiratory depression,retention Respiratory Disorders respiratory,1
ONFI,respiratory depression,Respiratory,0
ONFI,respiratory depression,angioedema and,0
ONFI,respiratory depression,Urinary retention Respiratory Disorders respiratory depression Skin and Subcutaneous Tissue Disorders,1
ONFI,respiratory depression,angioedema and,0
ONFI,Rash,Rash urticaria angioedema and facial,1
ONFI,Rash,Tissue Rash urticaria angioedema and facial and,1
ONFI,Rash,Rash urticaria angioedema and facial,1
ONFI,Rash,Subcutaneous Tissue,0
ONFI,Rash,Subcutaneous,0
ONFI,Rash,Rash urticaria angioedema and,1
ONFI,urticaria,Subcutaneous Tissue Disorders urticaria angioedema,1
ONFI,urticaria,Rash urticaria angioedema and,1
ONFI,urticaria,urticaria angioedema and,1
ONFI,urticaria,urticaria angioedema and facial and,1
ONFI,angioedema,angioedema and facial and lip edema,1
ONFI,angioedema,Subcutaneous Tissue Disorders Rash angioedema and facial,1
ONFI,angioedema,angioedema and facial and lip edema,1
ONFI,angioedema,Tissue Disorders Rash angioedema and facial and lip edema,1
ONFI,angioedema,angioedema and facial and lip edema,1
ONFI,angioedema,Subcutaneous Tissue Disorders Rash angioedema and facial and,1
ONFI,angioedema,angioedema and facial and lip edema,1
ONFI,angioedema,and,0
ONFI,angioedema,angioedema,1
ONFI,angioedema,angioedema and facial and lip edema,1
ONFI,angioedema,Rash,0
ONFI,angioedema,Subcutaneous Tissue Disorders Rash angioedema and facial and,1
ONFI,angioedema,Rash,0
ONFI,angioedema,facial,0
ONFI,Sedation,ns that  appear in other sections,1
ONFI,Sedation,facial,0
ONFI,Dermatological Reactions,Warnings and Precautions Serious Dermatological Reactions see,0
ONFI,Dermatological Reactions,Symptoms [see Warnings and Precautions Serious,1
ONFI,Dermatological Reactions,Precautions ithdrawal,1
ONFI,Dermatological Reactions,see Warnings and Precautions ithdrawal Symptoms [see  Warnings and Precautions Serious,1
ONFI,Dermatological Reactions,Precautions ithdrawal,1
ONFI,Dermatological Reactions,ithdrawal Symptoms [see Warnings and Precautions Serious,1
ONFI,Dermatological Reactions,Symptoms [see,1
ONFI,Dermatological Reactions,ithdrawal Symptoms [see Warnings and Precautions,1
ONFI,Dermatological Reactions,Warnings and Precautions W,0
ONFI,Dermatological Reactions,Precautions ithdrawal Symptoms,1
ONFI,Dermatological Reactions,Warnings and Precautions ithdrawal Symptoms [see  Warnings and,1
ONFI,Dermatological Reactions,Precautions ithdrawal Symptoms,1
ONFI,Stevens-Johnson syndrome,Withdrawal Symptoms see Warnings d Precautions (    5.3   Serious Dermatological Reactions see Contraindications,1
ONFI,Stevens-Johnson syndrome,Precautions ithdrawal Symptoms,1
ONFI,Stevens-Johnson syndrome,Symptoms see Warnings,0
ONFI,Stevens-Johnson syndrome,Serious,0
ONFI,Stevens-Johnson syndrome,Symptoms see Warnings d Precautions (    5.3   Serious Dermatological,1
ONFI,Stevens-Johnson syndrome,Serious,0
ONFI,Stevens-Johnson syndrome,Symptoms,0
ONFI,Stevens-Johnson syndrome,Symptoms see Warnings d Precautions (    5.3   Serious,1
ONFI,Stevens-Johnson syndrome,Symptoms,0
ONFI,Stevens-Johnson syndrome,Precautions Withdrawal Symptoms see Warnings,0
ONFI,Stevens-Johnson syndrome,see Contraindications,0
ONFI,Stevens-Johnson syndrome,Withdrawal Symptoms see Warnings d Precautions (    5.3   Serious Dermatological Reactions see,1
ONFI,Stevens-Johnson syndrome,see Contraindications,0
ONFI,Stevens-Johnson syndrome,( 5.3 Serious,1
ONFI,toxic epidermal necrolysis,Warnings and Precautions,0
ONFI,toxic epidermal necrolysis," 
 *  Serious Dermatologic",1
ONFI,toxic epidermal necrolysis,Warnings and Precautions,0
ONFI,toxic epidermal necrolysis,and Precautions Physical,0
ONFI,toxic epidermal necrolysis,"Warnings and  
 *  Serious Dermatologic",1
ONFI,toxic epidermal necrolysis,and Precautions Physical,0
ONFI,toxic epidermal necrolysis,s and Precautions,0
ONFI,toxic epidermal necrolysis,Precautions,0
ONFI,toxic epidermal necrolysis,"Warnings and  
 *  Serious Dermatologic al",1
ONFI,toxic epidermal necrolysis,Precautions,0
ONFI,toxic epidermal necrolysis,see Contraindications,0
ONFI,toxic epidermal necrolysis,"and  
 *  Serious Dermatologic al Reactions",1
ONFI,toxic epidermal necrolysis,see Contraindications,0
ONFI,toxic epidermal necrolysis,"Warnings and  
 *  Serious Dermatologic al Reactions",1
ONFI,toxic epidermal necrolysis,see Contraindications,0
ONFI,Psychological Dependence,see,0
ONFI,Psychological Dependence,and cal,1
ONFI,Psychological Dependence,Warnings and,0
ONFI,Psychological Dependence,see Contraindications Warnings and Precautions,0
ONFI,Suicidal Behavior,and,0
ONFI,Suicidal Behavior,EXCERPT: Ad,1
ONFI,Suicidal Behavior,Warnings and EXCERPT: Ad,1
ONFI,Suicidal Behavior,Ideation see Warnings and EXCERPT:,1
ONFI,Suicidal Behavior,EXCERPT: Ad,1
ONFI,Suicidal Behavior,    EXCERPT:   Ad verse reactions,1
ONFI,Suicidal Behavior,EXCERPT: Ad,1
ONFI,Suicidal Behavior,and,0
ONFI,somnolence,"edation, p",1
ONFI,somnolence,"edation, p yrexia lethargy and",1
ONFI,somnolence,"sedation pyrexia lethargy and .1  )   
  To",1
ONFI,somnolence,"edation, p yrexia lethargy and",1
ONFI,somnolence,"sedation pyrexia lethargy and .1  )   
 ",1
ONFI,somnolence,"edation, p yrexia lethargy and",1
ONFI,somnolence,pyrexia lethargy,0
ONFI,somnolence,sedation pyrexia lethargy and .1,1
ONFI,somnolence,lethargy and .1,1
ONFI,somnolence,"pyrexia lethargy and .1  )   
  To report SUSPECTED",1
ONFI,somnolence,lethargy and .1,1
ONFI,sedation,To repo rt SUSPECTED ADVERSE REACTIONS,1
ONFI,sedation,and  To repo rt SUSPECTED,1
ONFI,sedation,To repo rt SUSPECTED ADVERSE REACTIONS,1
ONFI,sedation,drooling,0
ONFI,sedation,and To,1
ONFI,sedation,FDA at FDA,0
ONFI,somnolence,t 1-800-FD A,1
ONFI,sedation,wwwfdagovmedwatch Clinical Trials Experience,0
ONFI,sedation,8 or wwwfdagovmedwatch Clinical Trials,1
ONFI,sedation,or FDA at 8 or     wwwfdagovmedwatch Clinical Trials,1
ONFI,sedation,8 or wwwfdagovmedwatch Clinical Trials,1
ONFI,sedation,SUSPECTED ADVERSE REACTIONS contact Lundbeck at or FDA,0
ONFI,sedation,at 8,1
ONFI,sedation,at 8 or    ,1
ONFI,sedation,at 8,1
ONFI,skin reactions,dose of mg for g body weight; mg for,1
ONFI,skin reactions,at 8,1
ONFI,skin reactions,body weight; mg for,1
ONFI,skin reactions,g body weight;,1
ONFI,skin reactions,kg body weight mg for kg body weight c Maximum daily dose of,0
ONFI,skin reactions,for kg body weight c Maximum daily dose,0
ONFI,skin reactions,mg for g,1
ONFI,skin reactions,for g body weight; mg for kg,1
ONFI,skin reactions,mg for g,1
ONFI,skin reactions,for g body weight;,1
ONFI,Stevens-Johnson syndrome,All ONFI N,0
ONFI,Stevens-Johnson syndrome,body weight Placebo N ONFI Dose,1
ONFI,Stevens-Johnson syndrome,body weight,0
ONFI,Stevens-Johnson syndrome,mg for kg body,0
ONFI,SJS,    Placebo N ONFI Dose,1
ONFI,SJS,   ,1
ONFI,SJS,mg,0
ONFI,SJS,kg body     Placebo N ONFI Dose,1
ONFI,SJS,mg,0
ONFI,toxic epidermal necrolysis,for kg body Placebo N=59,1
ONFI,toxic epidermal necrolysis,body           Placebo    N=59  ONFI Dose Level All ONFI,1
ONFI,toxic epidermal necrolysis,for kg body Placebo N=59,1
ONFI,toxic epidermal necrolysis,mg for kg body Placebo,1
ONFI,toxic epidermal necrolysis,Placebo N=59,1
ONFI,toxic epidermal necrolysis,kg body weight mg,0
ONFI,toxic epidermal necrolysis,Placebo N=59 ONFI Dose Level All,1
ONFI,toxic epidermal necrolysis,body           Placebo    N=59  ONFI,1
ONFI,toxic epidermal necrolysis,Placebo N=59 ONFI Dose Level All,1
ONFI,toxic epidermal necrolysis,Low a N Medium b,0
ONFI,TEN,body weight Placebo     ONFI Dose Level,1
ONFI,TEN,Low a N Medium b,0
ONFI,TEN,    ONFI Dose Level All ONFI,1
ONFI,TEN,    ONFI,1
ONFI,TEN,   ,1
ONFI,TEN,body weight Placebo     ONFI Dose Level All,1
ONFI,TEN,   ,1
ONFI,TEN,weight Placebo     ONFI Dose Level All,1
ONFI,TEN,   ,1
ONFI,TEN,body weight Placebo     ONFI,1
ONFI,TEN,   ,1
ONFI,TEN,for,0
ONFI,TEN,    ONFI Dose Level,1
ONFI,suicidal behavior,olence,0
ONFI,suicidal behavior,"     
       Somn olence or Sedation",1
ONFI,suicidal behavior,"     
       Somn olence",1
ONFI,suicidal behavior,"     
       Somn",1
ONFI,suicidal thoughts,Disorders Aspiration,0
ONFI,suicidal thoughts,llucination Re nal and,1
ONFI,suicidal thoughts,depression delirium,0
ONFI,suicidal thoughts,state depression delirium delusion llucination    Re nal and Urinary,1
ONFI,suicidal thoughts,depression delirium,0
ONFI,suicidal thoughts,and Urinary Disorders Urinary retention Respiratory,0
ONFI,suicidal thoughts,llucination Re,1
ONFI,suicidal thoughts,llucination Re nal,1
ONFI,suicidal thoughts,Disorders Aspiration,0
COMETRIQ,Perforations,Boxed Warning Warnings and Precautions Hemorrhage see B,0
COMETRIQ,Perforations,adverse reactions are discussed elsewhere in the label,0
COMETRIQ,Perforations,Fistula see,0
COMETRIQ,Perforations,serious adverse reactions are discussed elsewhere in the,0
COMETRIQ,Perforations,Hemorrhage see,0
COMETRIQ,Perforations,and Fistula see Boxed Warning Warnings and Precautions Hemorrhage see B,0
COMETRIQ,Perforations,Perforations,1
COMETRIQ,Perforations,Fistula see Boxed Warning Warnings,0
COMETRIQ,Perforations,Fistula see Boxed Warning,0
COMETRIQ,Hemorrhage,Warnings and Hemorrhage see Boxed,1
COMETRIQ,Hemorrhage,Fistula see Boxed Warning,0
COMETRIQ,Hemorrhage,and,0
COMETRIQ,Thromboembolic Events,Thromboembolic Events see Warnings and Precautions,1
COMETRIQ,Thromboembolic Events,and Thromboembolic Events see,1
COMETRIQ,Thromboembolic Events,Thromboembolic Events see Warnings and Precautions,1
COMETRIQ,Thromboembolic Events,Thromboembolic Events see Warnings and Precautions,1
COMETRIQ,Thromboembolic Events,Warning Warnings and Thromboembolic Events see Warnings and,1
COMETRIQ,Thromboembolic Events,Thromboembolic Events see Warnings and Precautions,1
COMETRIQ,Thromboembolic Events,Thromboembolic Events,1
COMETRIQ,Thromboembolic Events,Precautions,0
COMETRIQ,Thromboembolic Events,Complications see Warnings and,0
COMETRIQ,Thromboembolic Events,Precautions,0
COMETRIQ,Thromboembolic Events,Precautions,0
COMETRIQ,Wound Complications,see Warnings and Wound Complications,1
COMETRIQ,Hypertension,see Warnings and Hypertension see,1
COMETRIQ,Hypertension,see Warnings and Wound Complications,1
COMETRIQ,Hypertension,Precautions Wound Complications see Warnings and Precautions,0
COMETRIQ,Hypertension,and,0
COMETRIQ,Osteonecrosis of the Jaw,Warnings and Osteonecrosis,1
COMETRIQ,Osteonecrosis of the Jaw,and Osteonecrosis of the Jaw see,1
COMETRIQ,Osteonecrosis of the Jaw,Warnings and Osteonecrosis,1
COMETRIQ,Osteonecrosis of the Jaw,gs and,0
COMETRIQ,Osteonecrosis of the Jaw,and Precautions,0
COMETRIQ,Osteonecrosis of the Jaw,Warnings and Osteonecrosis of the Jaw see Warnings and Precautions Palmarplantar,1
COMETRIQ,Osteonecrosis of the Jaw,and Precautions,0
COMETRIQ,Osteonecrosis of the Jaw,and Osteonecrosis of the,1
COMETRIQ,Osteonecrosis of the Jaw,erythrodysesthesia syndrome see,0
COMETRIQ,Osteonecrosis of the Jaw,Warnings,0
COMETRIQ,Osteonecrosis of the Jaw,and,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Jaw see Warnings and Palmar-plantar,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,see Warnings and Palmar-plantar erythrodysesthesia syndrome see Warnings and,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Jaw see Warnings and Palmar-plantar,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome see Warnings and Precautions Proteinuria,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,see Warnings and Palmar-plantar,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,Palmar-plantar erythrodysesthesia syndrome see Warnings,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,and Palmar-plantar,1
COMETRIQ,Proteinuria,Warnings and Proteinuria see Warnings and Precautions,1
COMETRIQ,Proteinuria,and Palmar-plantar,1
COMETRIQ,Proteinuria,Proteinuria,1
COMETRIQ,Proteinuria,and Proteinuria see Warnings,1
COMETRIQ,Proteinuria,Proteinuria,1
COMETRIQ,Proteinuria,Precautions Reversible Posterior,0
COMETRIQ,Proteinuria,see Warnings and Precautions Reversible Posterior,0
COMETRIQ,Proteinuria,Proteinuria,1
COMETRIQ,Proteinuria,Proteinuria see Warnings,1
COMETRIQ,Proteinuria,Proteinuria,1
COMETRIQ,Proteinuria,Proteinuria see Warnings and Precautions,1
COMETRIQ,Proteinuria,Warnings and Proteinuria see Warnings and,1
COMETRIQ,Proteinuria,Proteinuria see Warnings and Precautions,1
COMETRIQ,Proteinuria,syndrome see Warnings and Proteinuria see Warnings,1
COMETRIQ,Proteinuria,Proteinuria see Warnings and Precautions,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Reversible Posterior,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Proteinuria see Warnings and Reversible Posterior Leukoencephalopathy Syndrome see Warnings and Precautions EXCERPT,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Reversible Posterior,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Leukoencephalopathy Syndrome see Warnings and Precautions EXCERPT,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Posterior Leukoencephalopathy Syndrome see Warnings,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Leukoencephalopathy Syndrome see Warnings and,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Proteinuria see Warnings and Reversible Posterior Leukoencephalopathy,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Reversible Posterior Leukoencephalopathy Syndrome,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Proteinuria see Warnings and Reversible Posterior Leukoencephalopathy,1
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,most commonly reported adverse,0
COMETRIQ,Reversible Posterior Leukoencephalopathy Syndrome,Reversible Posterior Leukoencephalopathy Syndrome see Warnings and Precautions EXCERPT,1
COMETRIQ,diarrhea,syndrome PPES,0
COMETRIQ,diarrhea,diarrhea stomatitis palmarplantar,1
COMETRIQ,diarrhea,reported adverse drug reactions diarrhea stomatitis palmarplantar erythrodysesthesia syndrome PPES,1
COMETRIQ,diarrhea,diarrhea stomatitis palmarplantar,1
COMETRIQ,diarrhea,EXCERPT The most commonly reported adverse drug,0
COMETRIQ,diarrhea,palmarplantar erythrodysesthesia syndrome PPES decreased,0
COMETRIQ,diarrhea,EXCERPT The most commonly,0
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,commonly reported,0
COMETRIQ,diarrhea,diarrhea stomatitis,1
COMETRIQ,stomatitis,adverse drug reactions are stomatitis palmarplantar erythrodysesthesia,1
COMETRIQ,stomatitis,diarrhea stomatitis,1
COMETRIQ,stomatitis,reactions are stomatitis palmarplantar erythrodysesthesia syndrome PPES decreased,1
COMETRIQ,stomatitis,diarrhea stomatitis,1
COMETRIQ,stomatitis,stomatitis,1
COMETRIQ,stomatitis,erythrodysesthesia syndrome PPES decreased weight decreased appetite nausea,0
COMETRIQ,stomatitis,weight decreased appetite nausea,0
COMETRIQ,stomatitis,PPES decreased weight,0
COMETRIQ,stomatitis,decreased appetite nausea f,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,appetite nausea fatigue oral pain hair color,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,reactions are diarrhea,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,are diarrhea palmar-plantar erythrodysesthesia syndrome,1
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,reactions are diarrhea,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,adverse drug reactions,0
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,are diarrhea palmar-plantar,1
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,appetite nausea fatigue oral pain hair color changes,0
COMETRIQ,PPES,PPES decreased weight,1
COMETRIQ,decreased weight,syndrome,0
COMETRIQ,decreased weight,drug reactions are diarrhea stomatitis,0
COMETRIQ,decreased weight,decreased weight,1
COMETRIQ,decreased weight,reactions are diarrhea stomatitis palmarplantar erythrodysesthesia syndrome PPES,0
COMETRIQ,decreased weight,erythrodysesthesia syndrome PPES,0
COMETRIQ,decreased appetite,decreased appetite,1
COMETRIQ,decreased appetite,erythrodysesthesia syndrome PPES,0
COMETRIQ,nausea,decreased,0
COMETRIQ,nausea,fatigue oral pain hair color changes dysgeusia hypertension abdominal pain and constipation,0
COMETRIQ,fatigue,erythrodysesthesia syndrome PPES decreased,0
COMETRIQ,fatigue,abdominal pain and constipation,0
COMETRIQ,fatigue,oral pain hair color,0
COMETRIQ,oral pain,oral pain hair color,1
COMETRIQ,oral pain,oral pain hair color,0
COMETRIQ,oral pain,oral pain hair color changes dysgeusia,1
COMETRIQ,oral pain,oral pain hair color changes dysgeusia hypertension,1
COMETRIQ,hair color changes,decreased weight decreased appetite nausea fatigue oral pain,0
COMETRIQ,hair color changes,nausea fatigue oral hair color,1
COMETRIQ,hair color changes,hair color changes dysgeusia hypertension abdominal pain,1
COMETRIQ,hair color changes,nausea fatigue oral hair color,1
COMETRIQ,hair color changes,decreased weight decreased appetite nausea fatigue,0
COMETRIQ,hair color changes,hair color changes dysgeusia hypertension abdominal pain and,1
COMETRIQ,hair color changes,pain and constipation The most common laboratory abnormalitie,0
COMETRIQ,dysgeusia,dysgeusia,1
COMETRIQ,dysgeusia,dysgeusia hypertension abdominal,1
COMETRIQ,hypertension,hypertension abdominal pain and constipation,1
COMETRIQ,hypertension,hypertension abdominal pain and constipation,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,most common laboratory abnormalities,0
COMETRIQ,hypertension,hypertension abdominal pain and constipation The,1
COMETRIQ,hypertension,appetite nausea fatigue,0
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,laboratory,0
COMETRIQ,abdominal pain,abnormalities are increased,0
COMETRIQ,abdominal pain,pain,0
COMETRIQ,abdominal pain,color changes dysgeusia abdominal pain and,1
COMETRIQ,abdominal pain,pain,0
COMETRIQ,abdominal pain,abdominal pain,1
COMETRIQ,constipation,The most,0
COMETRIQ,constipation,constipation The most common laboratory,1
COMETRIQ,constipation,hair,0
COMETRIQ,constipation,abnormalities are increased AST,0
COMETRIQ,constipation,most common laboratory abnormalities are increased AST,0
COMETRIQ,constipation,constipation The most common,1
COMETRIQ,increased AST,abnormalities increased AST,1
COMETRIQ,increased AST,constipation The most common,1
COMETRIQ,increased AST,increased AST increased ALT,1
COMETRIQ,increased AST,constipation The most common,1
COMETRIQ,increased AST,hypocalcemia neutropenia,0
COMETRIQ,increased AST,common laboratory abnormalities increased,1
COMETRIQ,increased AST,increased AST,1
COMETRIQ,increased AST,phosphatase hypocalcemia neutropenia thrombocyto,0
COMETRIQ,increased AST,laboratory abnormalities increased AST,1
COMETRIQ,increased AST,abnormalities increased AST increased ALT lymphopenia increased alkaline,1
COMETRIQ,increased AST,laboratory abnormalities increased AST,1
COMETRIQ,increased AST,increased AST increased ALT lymphopenia increased,1
COMETRIQ,increased ALT,lymphopenia increased alkaline phosphatase hypocalcemia neutropenia thrombocytopenia,0
COMETRIQ,increased ALT,common,0
COMETRIQ,increased ALT,neutropenia thrombocytopenia hypophos,0
COMETRIQ,increased ALT,increased increased ALT lymphopenia increased alkaline phosphatase,1
COMETRIQ,increased ALT,neutropenia thrombocytopenia hypophos,0
COMETRIQ,increased ALT,constipation The most,0
COMETRIQ,increased ALT,increased increased ALT,1
COMETRIQ,increased ALT,phosphatase hypocalcemia neutropenia thrombocytopenia hypophos,0
COMETRIQ,increased ALT,abnormalities,0
COMETRIQ,increased ALT,are increased increased ALT lymphopenia,1
COMETRIQ,increased ALT,abnormalities,0
COMETRIQ,lymphopenia,phosphatase,0
COMETRIQ,lymphopenia,lymphopenia increased alkaline phosphatase hypocalcemia neutropenia,1
COMETRIQ,lymphopenia,lymphopenia,1
COMETRIQ,lymphopenia,nd constipation The,0
COMETRIQ,lymphopenia,The most common laboratory,0
COMETRIQ,increased alkaline phosphatase,hypocalcemia neutropenia thrombocytopenia hypophosphatemia,0
COMETRIQ,increased alkaline phosphatase,increased AST increased ALT increased alkaline phosphatase,1
COMETRIQ,increased alkaline phosphatase,increased AST increased ALT increased,1
COMETRIQ,increased alkaline phosphatase,neutropenia thrombocytopenia hypophosphatemia and,0
COMETRIQ,increased alkaline phosphatase,increased,1
COMETRIQ,increased alkaline phosphatase,increased AST increased ALT increased alkaline,1
COMETRIQ,increased alkaline phosphatase,increased ALT increased,1
COMETRIQ,increased alkaline phosphatase,increased alkaline phosphatase hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,increased alkaline phosphatase,neutropenia thrombocytopenia hypophosphatemia and,0
COMETRIQ,hypocalcemia,hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,hypocalcemia,hypocalcemia neutropenia,1
COMETRIQ,hypocalcemia,bnormalities are increased AST increased ALT lymphopenia increased,0
COMETRIQ,hypocalcemia,ALT lymphopenia increased alkaline,0
COMETRIQ,hypocalcemia,lymphopenia increased,0
COMETRIQ,hypocalcemia,alkaline hypocalcemia neutropenia thrombocytopenia hypophosphatemia and,1
COMETRIQ,hypocalcemia,lymphopenia increased,0
COMETRIQ,hypocalcemia,increased alkaline hypocalcemia neutropenia thrombocytopenia,1
COMETRIQ,hypocalcemia,lymphopenia increased,0
COMETRIQ,hypocalcemia,alkaline hypocalcemia neutropenia thrombocytopenia hypophosphatemia and,1
COMETRIQ,hypocalcemia,lymphopenia increased,0
COMETRIQ,hypocalcemia,hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,neutropenia,To report,0
COMETRIQ,neutropenia,hypophosphatemia and hyperbilirubinemia To report SUSPECTED AD,0
COMETRIQ,neutropenia,lymphopenia increased,0
COMETRIQ,neutropenia,neutropenia thrombocytopenia,1
COMETRIQ,neutropenia,neutropenia thrombocytopenia,1
COMETRIQ,neutropenia,increased ALT,0
COMETRIQ,thrombocytopenia,phosphatase hypocalcemia thrombocytopenia,1
COMETRIQ,thrombocytopenia,increased ALT,0
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia and hyperbilirubinemia,1
COMETRIQ,thrombocytopenia,phosphatase hypocalcemia thrombocytopenia hypophosphatemia and hyperbilirubinemia,1
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia and hyperbilirubinemia,1
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia and hyperbilirubinemia To,1
COMETRIQ,hypophosphatemia,neutropenia,0
COMETRIQ,hypophosphatemia,alkaline phosphatase hypocalcemia neutropenia hypophosphatemia and hyperbilirubinemia,1
COMETRIQ,hypophosphatemia,neutropenia,0
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia To report,1
COMETRIQ,hypophosphatemia,hypophosphatemia and,1
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia To report SUSPECTED ADVERSE REACTIONS,1
COMETRIQ,hyperbilirubinemia,SUSPECTED ADVERSE REACTIONS contact Exelixis,0
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia To report SUSPECTED ADVERSE REACTIONS,1
COMETRIQ,hyperbilirubinemia,phosphatase hypocalcemia neutropenia thrombocytopenia hypophosphatemia and,0
COMETRIQ,hyperbilirubinemia,To report SUSPECTED ADVERSE,0
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia To report SUSPECTED ADVERSE REACTIONS,1
COMETRIQ,hyperbilirubinemia,alkaline phosphatase hypocalcemia neutropenia thrombocytopenia,0
COMETRIQ,hyperbilirubinemia,ADVERSE,0
COMETRIQ,hyperbilirubinemia,SUSPECTED ADVERSE REACTIONS contact,0
COMETRIQ,diarrhea,diarrhea stomatitis palmarplantar erythrodysesthesia syndrome,1
COMETRIQ,diarrhea,diarrhea stomatitis palmarplantar erythrodysesthesia,1
COMETRIQ,diarrhea,decreasing diarrhea,1
COMETRIQ,diarrhea,diarrhea stomatitis palmarplantar erythrodysesthesia,1
COMETRIQ,diarrhea,of decreasing diarrhea,1
COMETRIQ,diarrhea,diarrhea stomatitis palmarplantar erythrodysesthesia,1
COMETRIQ,stomatitis,palmarplantar erythrodysesthesia syndrome PPES,0
COMETRIQ,stomatitis,stomatitis palmarplantar erythrodysesthesia syndrome PPES decreased,1
COMETRIQ,stomatitis,of decreasing,0
COMETRIQ,stomatitis,stomatitis,1
COMETRIQ,stomatitis,order of decreasing frequency stomatitis palmarplantar erythrodysesthesia,1
COMETRIQ,stomatitis,stomatitis,1
COMETRIQ,stomatitis,stomatitis palmarplantar,1
COMETRIQ,stomatitis,of decreasing frequency stomatitis palmarplantar erythrodysesthesia,1
COMETRIQ,stomatitis,stomatitis palmarplantar,1
COMETRIQ,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome PPES decreased,1
COMETRIQ,PPES,order of,0
COMETRIQ,PPES,order of decreasing frequency diarrhea stomatitis palmarplantar erythrodysesthesia,0
COMETRIQ,PPES,PPES decreased,1
COMETRIQ,PPES,erythrodysesthesia PPES decreased weight decreased,1
COMETRIQ,PPES,PPES decreased,1
COMETRIQ,PPES,PPES decreased weight decreased appetite,1
COMETRIQ,PPES,pain hair color changes dysgeusia,0
COMETRIQ,PPES,in,0
COMETRIQ,PPES,decreased appetite nausea fatigue oral pain hair color changes dysgeusia,0
COMETRIQ,PPES,palmarplantar erythrodysesthesia PPES,1
COMETRIQ,PPES,decreased appetite nausea fatigue oral pain hair color changes dysgeusia,0
COMETRIQ,decreased weight,decreasing frequency,0
COMETRIQ,decreased weight,erythrodysesthesia syndrome decreased weight decreased appetite,1
COMETRIQ,decreased weight,decreasing frequency,0
COMETRIQ,decreased appetite,decreased appetite nausea fatigue oral pain hair,1
COMETRIQ,decreased appetite,syndrome PPES decreased decreased appetite nausea fatigue oral,1
COMETRIQ,decreased appetite,decreased appetite nausea fatigue oral pain hair,1
COMETRIQ,nausea,weight decreased nausea fatigue,1
COMETRIQ,nausea,decreased appetite nausea fatigue oral pain hair,1
COMETRIQ,nausea,hair color changes dysgeusia,0
COMETRIQ,nausea,oral pain,0
COMETRIQ,fatigue,fatigue oral pain hair,1
COMETRIQ,oral pain,appetite nausea oral pain,1
COMETRIQ,hair color changes,color changes dysgeusia hypertension abdominal pain and,1
COMETRIQ,hair color changes,common laboratory,0
COMETRIQ,hair color changes,hair color changes dysgeusia,1
COMETRIQ,hair color changes,common laboratory,0
COMETRIQ,hair color changes,The most common,0
COMETRIQ,dysgeusia,color dysgeusia hypertension abdominal pain,1
COMETRIQ,dysgeusia,The most common,0
COMETRIQ,hypertension,color changes hypertension abdominal pain,1
COMETRIQ,hypertension,The most common,0
COMETRIQ,abdominal pain,color changes dysgeusia abdominal pain,1
COMETRIQ,abdominal pain,The most common,0
COMETRIQ,abdominal pain,color changes dysgeusia abdominal pain,1
COMETRIQ,abdominal pain,changes,0
COMETRIQ,abdominal pain,dysgeusia abdominal pain,1
COMETRIQ,increased AST,increased AST,1
COMETRIQ,increased AST,increased AST increased ALT,1
COMETRIQ,increased AST,laboratory abnormalities increased AST,1
COMETRIQ,increased AST,common laboratory abnormalities increased AST increased ALT,1
COMETRIQ,increased AST,laboratory abnormalities increased AST,1
COMETRIQ,increased AST,laboratory abnormalities increased AST,1
COMETRIQ,increased AST,laboratory abnormalities increased AST,1
COMETRIQ,increased AST,most common laboratory,0
COMETRIQ,increased AST,hypocalcemia neutropenia,0
COMETRIQ,increased AST,The,0
COMETRIQ,increased AST,abnormalities increased,1
COMETRIQ,increased AST,increased AST increased,1
COMETRIQ,increased ALT,laboratory abnormalities were increased increased,1
COMETRIQ,increased ALT,laboratory abnormalities were increased increased ALT lymphopenia increased ALP hypocalcemia,1
COMETRIQ,increased ALT,laboratory abnormalities were increased increased,1
COMETRIQ,increased ALT,abnormalities were increased increased ALT,1
COMETRIQ,increased ALT,laboratory abnormalities were increased increased,1
COMETRIQ,lymphopenia,lymphopenia increased ALP hypocalcemia neutropenia,1
COMETRIQ,lymphopenia,lymphopenia increased ALP hypocalcemia,1
COMETRIQ,lymphopenia,laboratory abnormalities,0
COMETRIQ,lymphopenia,thrombocytopenia,0
COMETRIQ,lymphopenia,lymphopenia increased ALP,1
COMETRIQ,lymphopenia,ALT,0
COMETRIQ,lymphopenia,lymphopenia increased ALP hypocalcemia,1
COMETRIQ,lymphopenia,increased AST increased lymphopenia increased ALP hypocalcemia neutropenia thrombocytopenia,1
COMETRIQ,lymphopenia,lymphopenia increased ALP hypocalcemia,1
COMETRIQ,increased ALP,increased AST increased ALT increased ALP hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,increased ALP,lymphopenia increased ALP hypocalcemia,1
COMETRIQ,increased ALP,increased ALP hypocalcemia,1
COMETRIQ,increased ALP,laboratory abnormalities were increased,0
COMETRIQ,increased ALP,increased,1
COMETRIQ,increased ALP,increased ALT increased ALP hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,increased ALP,increased,1
COMETRIQ,increased ALP,ALT increased ALP hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,increased ALP,increased,1
COMETRIQ,increased ALP,increased ALP,1
COMETRIQ,increased ALP,increased AST increased ALT increased,1
COMETRIQ,increased ALP,increased ALP hypocalcemia neutropenia thrombocytopenia hypophosphatemia and,1
COMETRIQ,increased ALP,increased ALT lymphopenia,0
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,hypocalcemia,hypophosphatemia and,0
COMETRIQ,hypocalcemia,mmon laboratory abnormalities were increased AST increased ALT lymphopenia,0
COMETRIQ,hypocalcemia,hypocalcemia neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,hypocalcemia,mmon laboratory abnormalities were increased AST increased ALT lymphopenia,0
COMETRIQ,neutropenia,hypocalcemia,0
COMETRIQ,neutropenia,neutropenia thrombocytopenia,1
COMETRIQ,neutropenia,and hyperbilirubinemia,0
COMETRIQ,neutropenia,hypocalcemia,0
COMETRIQ,neutropenia,ALT lymphopenia increased ALP neutropenia thrombocytopenia hypophosphatemia and,1
COMETRIQ,neutropenia,hypocalcemia,0
COMETRIQ,neutropenia,neutropenia thrombocytopenia hypophosphatemia and,1
COMETRIQ,neutropenia,hyperbilirubinemia Grade adverse reactions,0
COMETRIQ,neutropenia,neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,neutropenia,lymphopenia increased ALP neutropenia thrombocytopenia hypophosphatemia and,1
COMETRIQ,neutropenia,neutropenia thrombocytopenia hypophosphatemia,1
COMETRIQ,neutropenia,neutropenia thrombocytopenia hypophosphatemia and hyperbilirubinemia Grade,1
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia,1
COMETRIQ,thrombocytopenia,thrombocytopenia,1
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia and,1
COMETRIQ,thrombocytopenia,Grade adverse,0
COMETRIQ,thrombocytopenia,thrombocytopenia hypophosphatemia and hyperbilirubinemia Grade,1
COMETRIQ,thrombocytopenia,and hyperbilirubinemia Grade adverse,0
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia,1
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia Grade adverse reactions,1
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia Grade adverse,1
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia Grade adverse,1
COMETRIQ,hypophosphatemia,hypophosphatemia and hyperbilirubinemia Grade adverse,1
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia,1
COMETRIQ,hyperbilirubinemia,occurred,0
COMETRIQ,hyperbilirubinemia,abnormalities which occurred,0
COMETRIQ,hyperbilirubinemia,hypophosphatemia hyperbilirubinemia Grade adverse reactions and,1
COMETRIQ,hyperbilirubinemia,abnormalities which occurred,0
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia Grade adverse reactions and,1
COMETRIQ,hyperbilirubinemia,hypophosphatemia hyperbilirubinemia Grade adverse reactions,1
COMETRIQ,hyperbilirubinemia,hyperbilirubinemia Grade adverse reactions and,1
COMETRIQ,diarrhea,diarrhea PPES lymphopenia hypocalcemia,1
COMETRIQ,diarrhea,of decreasing diarrhea PPES lymphopenia hypocalcemia fatigue,1
COMETRIQ,diarrhea,diarrhea PPES lymphopenia hypocalcemia,1
COMETRIQ,diarrhea,asthenia increased ALT,0
COMETRIQ,diarrhea,included,0
COMETRIQ,diarrhea,difference of included in order of,0
COMETRIQ,diarrhea,fatigue hypertension asthenia increased ALT,0
COMETRIQ,diarrhea,diarrhea PPES lymphopenia,1
COMETRIQ,diarrhea,in order of decreasing diarrhea PPES lymphopenia hypocalcemia,1
COMETRIQ,diarrhea,diarrhea PPES lymphopenia,1
COMETRIQ,PPES,frequency PPES lymphopenia hypocalcemia,1
COMETRIQ,PPES,diarrhea PPES lymphopenia,1
COMETRIQ,lymphopenia,of decreasing frequency,0
COMETRIQ,lymphopenia,lymphopenia hypocalcemia fatigue hypertension,1
COMETRIQ,lymphopenia,ALT decreased weight stomatitis and de,0
COMETRIQ,lymphopenia,lymphopenia hypocalcemia fatigue hypertension,1
COMETRIQ,lymphopenia,a betweenarm difference of included in order of decreasing,0
COMETRIQ,lymphopenia,decreasing frequency diarrhea lymphopenia hypocalcemia fatigue,1
COMETRIQ,lymphopenia,a betweenarm difference of included in order of decreasing,0
COMETRIQ,lymphopenia,lymphopenia hypocalcemia fatigue hypertension asthenia,1
COMETRIQ,lymphopenia,of decreasing frequency diarrhea lymphopenia hypocalcemia fatigue,1
COMETRIQ,lymphopenia,lymphopenia hypocalcemia fatigue hypertension asthenia,1
COMETRIQ,hypocalcemia,diarrhea PPES hypocalcemia fatigue hypertension,1
COMETRIQ,hypocalcemia,lymphopenia hypocalcemia fatigue hypertension asthenia,1
COMETRIQ,hypocalcemia,diarrhea PPES hypocalcemia fatigue hypertension asthenia increased ALT,1
COMETRIQ,hypocalcemia,lymphopenia hypocalcemia fatigue hypertension asthenia,1
COMETRIQ,hypocalcemia,frequency diarrhea PPES hypocalcemia,1
COMETRIQ,hypocalcemia,lymphopenia hypocalcemia fatigue hypertension asthenia,1
COMETRIQ,hypocalcemia,increased ALT decreased weight stomatitis and,0
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,fatigue,fatigue hypertension asthenia increased ALT,1
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,frequency diarrhea PPES lymphopenia fatigue hypertension asthenia increased ALT decreased,1
COMETRIQ,fatigue,fatigue,1
COMETRIQ,fatigue,order of decreasing frequency diarrhea PPES,0
COMETRIQ,fatigue,fatigue hypertension,1
COMETRIQ,fatigue,fatigue hypertension asthenia increased,1
COMETRIQ,fatigue,PPES lymphopenia fatigue hypertension asthenia increased ALT decreased,1
COMETRIQ,fatigue,fatigue hypertension asthenia increased,1
COMETRIQ,fatigue,and decreased appetite,0
COMETRIQ,fatigue,frequency diarrhea PPES lymphopenia fatigue hypertension asthenia increased ALT,1
COMETRIQ,fatigue,and decreased appetite,0
COMETRIQ,fatigue,in order of decreasing,0
COMETRIQ,hypertension,weight,0
COMETRIQ,hypertension,hypertension asthenia increased ALT decreased weight,1
COMETRIQ,hypertension,hypocalcemia hypertension,1
COMETRIQ,hypertension,hypertension asthenia increased ALT decreased weight,1
COMETRIQ,hypertension,hypertension asthenia increased ALT decreased,1
COMETRIQ,hypertension,hypertension asthenia increased,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,asthenia,order of,0
COMETRIQ,asthenia,increased,0
COMETRIQ,asthenia,increased ALT,0
COMETRIQ,asthenia,asthenia increased ALT decreased weight stomatitis,1
COMETRIQ,increased ALT,increased ALT,1
COMETRIQ,increased ALT,increased ALT decreased weight stomatitis and decreased,1
COMETRIQ,stomatitis,stomatitis and decreased,1
COMETRIQ,stomatitis,increased ALT decreased stomatitis,1
COMETRIQ,stomatitis,stomatitis and decreased,1
COMETRIQ,stomatitis,asthenia increased ALT decreased stomatitis and,1
COMETRIQ,stomatitis,stomatitis and decreased,1
COMETRIQ,stomatitis,asthenia increased ALT decreased stomatitis and,1
COMETRIQ,stomatitis,stomatitis and decreased,1
COMETRIQ,stomatitis,stomatitis,1
COMETRIQ,stomatitis,stomatitis and decreased appetite see Table,1
COMETRIQ,decreased appetite,decreased appetite see,1
COMETRIQ,decreased appetite,of patients receiving COME,0
COMETRIQ,decreased appetite,decreased appetite see Table Table,1
COMETRIQ,decreased appetite,weight stomatitis decreased appetite,1
COMETRIQ,decreased appetite,decreased appetite see Table Table Fatal adverse,1
COMETRIQ,decreased appetite,decreased appetite see,1
COMETRIQ,Fatal,Fatal adverse reactions occurred,1
COMETRIQ,Fatal,Table Fatal adverse reactions occurred in of,1
COMETRIQ,Fatal,Fatal adverse reactions occurred,1
COMETRIQ,Fatal,appetite see Table Fatal adverse reactions occurred,1
COMETRIQ,Fatal,Fatal adverse reactions occurred,1
COMETRIQ,Fatal,appetite see Table Fatal adverse reactions,1
COMETRIQ,Fatal,Fatal adverse reactions occurred,1
COMETRIQ,Fatal,Fatal adverse reactions occurred,1
COMETRIQ,Fatal,see Table Fatal adverse reactions occurred in,1
COMETRIQ,Fatal,Fatal adverse reactions occurred,1
COMETRIQ,Fatal,decreased appetite see Table Fatal adverse reactions occurred in of,1
COMETRIQ,Fatal,Fatal adverse reactions occurred,1
COMETRIQ,Fatal,occurred in of patients receiving COMETRIQ,0
COMETRIQ,Fatal,Table Fatal,1
COMETRIQ,Fatal,occurred in of patients receiving COMETRIQ,0
COMETRIQ,Fatal,occurred in of patients receiving COMETRIQ and,0
COMETRIQ,hemorrhage,septicemia fistulas,0
COMETRIQ,hemorrhage,e Fatal adverse reactions occurred in of,0
COMETRIQ,hemorrhage,receiving COMETRIQ and resulted hemorrhage pneumonia septicemia fistulas,1
COMETRIQ,hemorrhage,e Fatal adverse reactions occurred in of,0
COMETRIQ,hemorrhage,COMETRIQ and resulted hemorrhage pneumonia septicemia fistulas cardiac,1
COMETRIQ,hemorrhage,e Fatal adverse reactions occurred in of,0
COMETRIQ,hemorrhage,and,0
COMETRIQ,hemorrhage,occurred in of patients receiving COMETRIQ and,0
COMETRIQ,hemorrhage,resulted hemorrhage pneumonia,1
COMETRIQ,hemorrhage,occurred in of patients receiving COMETRIQ and,0
COMETRIQ,hemorrhage,pneumonia septicemia fistulas cardiac,0
COMETRIQ,hemorrhage,and,0
COMETRIQ,hemorrhage,receiving COMETRIQ and,0
COMETRIQ,pneumonia,fistulas cardiac arrest respiratory failure and unspecified death,0
COMETRIQ,pneumonia,failure and unspecified death Fatal,0
COMETRIQ,pneumonia,death,0
COMETRIQ,pneumonia,pneumonia septicemia fistulas cardiac arrest,1
COMETRIQ,pneumonia,COMETRIQ and resulted from pneumonia septicemia fistulas,1
COMETRIQ,pneumonia,pneumonia septicemia fistulas cardiac arrest,1
COMETRIQ,pneumonia,from pneumonia septicemia fistulas cardiac arrest,1
COMETRIQ,pneumonia,pneumonia septicemia fistulas cardiac arrest,1
COMETRIQ,pneumonia,pneumonia septicemia fistulas cardiac arrest respiratory,1
COMETRIQ,septicemia,arrest respiratory,0
COMETRIQ,septicemia,hemorrhage septicemia fistulas cardiac arrest,1
COMETRIQ,septicemia,arrest respiratory,0
COMETRIQ,septicemia,septicemia fistulas,1
COMETRIQ,fistulas,fistulas,1
COMETRIQ,fistulas,fistulas cardiac arrest respiratory failure,1
COMETRIQ,fistulas,of patients,0
COMETRIQ,fistulas,fistulas cardiac arrest respiratory failure and,1
COMETRIQ,fistulas,failure and unspecified death Fatal adverse,0
COMETRIQ,cardiac arrest,cardiac arrest respiratory failure and unspecified death,1
COMETRIQ,cardiac arrest,cardiac arrest respiratory,1
COMETRIQ,respiratory failure,respiratory failure and unspecified death Fatal,1
COMETRIQ,respiratory failure,arrest,0
COMETRIQ,respiratory failure,pneumonia septicemia fistulas cardiac respiratory failure,1
COMETRIQ,respiratory failure,Fatal adverse reactions occurred in of patients receiving,0
COMETRIQ,respiratory failure,cardiac respiratory failure,1
COMETRIQ,respiratory failure,respiratory failure,1
COMETRIQ,respiratory failure,fistulas cardiac,0
COMETRIQ,death,death Fatal adverse reactions occurred,1
COMETRIQ,death,fistulas cardiac,0
COMETRIQ,death,death Fatal,1
COMETRIQ,death,occurred in of patients receiving,0
COMETRIQ,death,death Fatal adverse reactions occurred in,1
COMETRIQ,death,death Fatal,1
COMETRIQ,death,reactions occurred in of patients receiving placebo and,0
COMETRIQ,death,and death Fatal adverse reactions occurred,1
COMETRIQ,death,reactions occurred in of patients receiving placebo and,0
COMETRIQ,death,occurred in of,0
COMETRIQ,Fatal,Fatal adverse reactions occurred in of,1
COMETRIQ,Fatal,respiratory failure,0
COMETRIQ,Fatal,septicemia fistulas cardiac,0
COMETRIQ,Fatal,Fatal adverse reactions occurred in,1
COMETRIQ,Fatal,respiratory failure and unspecified Fatal adverse reactions occurred in,1
COMETRIQ,Fatal,Fatal adverse reactions occurred in,1
COMETRIQ,Fatal,receiving placebo and resulted,0
COMETRIQ,Fatal,Fatal adverse reactions,1
COMETRIQ,pneumonia,and resulted from septicemia,0
COMETRIQ,pneumonia,pneumonia and,1
COMETRIQ,pneumonia,pneumonia and general deterioration The,1
COMETRIQ,pneumonia,from,0
COMETRIQ,pneumonia,and resulted from pneumonia and general deterioration The dose,1
COMETRIQ,pneumonia,from,0
COMETRIQ,general deterioration,in of patients receiving COMETRIQ compared,0
COMETRIQ,general deterioration,from septicemia pneumonia general deterioration The dose was reduced,1
COMETRIQ,general deterioration,in of patients receiving COMETRIQ compared,0
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,hypocalcemia,treated with COMETRIQ hypocalcemia increased lipase PPES,1
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,hypocalcemia,hypocalcemia increased lipase PPES diarrhea fatigue,1
COMETRIQ,hypocalcemia,hypocalcemia increased lipase,1
COMETRIQ,hypocalcemia,hypocalcemia increased lipase PPES diarrhea,1
COMETRIQ,hypocalcemia,hypocalcemia increased lipase,1
COMETRIQ,hypocalcemia,hypocalcemia,1
COMETRIQ,increased lipase,increased lipase PPES diarrhea fatigue hypertension nausea,1
COMETRIQ,increased lipase,patients treated with,0
COMETRIQ,increased lipase,COMETRIQ were increased lipase PPES diarrhea fatigue hypertension nausea,1
COMETRIQ,increased lipase,patients treated with,0
COMETRIQ,increased lipase,increased lipase,1
COMETRIQ,PPES,fatigue hypertension,0
COMETRIQ,PPES,tracheal,0
COMETRIQ,PPES,discontinuation in patients treated with COMETRIQ were hypocalcemia increased lipase,0
COMETRIQ,PPES,PPES diarrhea fatigue hypertension nausea pancreatitis,1
COMETRIQ,PPES,PPES,1
COMETRIQ,diarrhea,diarrhea fatigue hypertension nausea pancreatitis tracheal,1
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,increased lipase diarrhea,1
COMETRIQ,diarrhea,diarrhea,1
COMETRIQ,diarrhea,were hypocalcemia increased,0
COMETRIQ,diarrhea,diarrhea fatigue hypertension nausea pancreatitis tracheal,1
COMETRIQ,diarrhea,diarrhea fatigue hypertension nausea,1
COMETRIQ,fatigue,and vomiting Increased,0
COMETRIQ,fatigue,increased,0
COMETRIQ,fatigue,fatigue hypertension nausea,1
COMETRIQ,fatigue,in patients treated with COMETRIQ were hypocalcemia increased lipase PPES,0
COMETRIQ,fatigue,pancreatitis tracheal fistula formation and vomiting Increased,0
COMETRIQ,fatigue,hypertension nausea pancreatitis tracheal fistula,0
COMETRIQ,fatigue,fatigue hypertension nausea,1
COMETRIQ,hypertension,increased lipase PPES diarrhea hypertension nausea pancreatitis tracheal fistula,1
COMETRIQ,hypertension,fatigue hypertension nausea,1
COMETRIQ,hypertension,diarrhea hypertension nausea,1
COMETRIQ,hypertension,fatigue hypertension nausea,1
COMETRIQ,hypertension,hypertension nausea pancreatitis tracheal fistula formation,1
COMETRIQ,hypertension,and vomiting Increased levels,0
COMETRIQ,hypertension,formation and,0
COMETRIQ,hypertension,hypertension nausea pancreatitis tracheal,1
COMETRIQ,nausea,nausea pancreatitis tracheal fistula formation and,1
COMETRIQ,nausea,nausea pancreatitis tracheal fistula formation and,1
COMETRIQ,nausea,nausea pancreatitis tracheal,1
COMETRIQ,nausea,vomiting Increased levels of thyroid stimulating,0
COMETRIQ,nausea,and,0
COMETRIQ,nausea,nausea pancreatitis,1
COMETRIQ,nausea,formation and vomiting,0
COMETRIQ,nausea,nausea pancreatitis,1
COMETRIQ,nausea,PPES diarrhea fatigue nausea pancreatitis,1
COMETRIQ,nausea,nausea pancreatitis,1
COMETRIQ,nausea,nausea pancreatitis tracheal fistula,1
COMETRIQ,nausea,nausea pancreatitis,1
COMETRIQ,pancreatitis,pancreatitis tracheal fistula formation,1
COMETRIQ,pancreatitis,pancreatitis tracheal fistula formation and,1
COMETRIQ,tracheal fistula formation,were hypocalcemia increased lipase PPES,0
COMETRIQ,Peripheral neuropathy,sensory Peripheral neuropathy,1
COMETRIQ,Peripheral neuropathy,were hypocalcemia increased lipase PPES,0
COMETRIQ,elevated blood pressure,COMETRIQtreated,0
COMETRIQ,elevated blood pressure,blood pressure and there was a,1
COMETRIQ,elevated blood pressure,in COMETRIQtreated patients,0
COMETRIQ,hypertension,hypertension in,1
COMETRIQ,hypertension,hypertension in COMETRIQtreated patients,1
COMETRIQ,hypertension,of,0
COMETRIQ,hypertension,COMETRIQtreated patients over placebotreated patients vs according to,0
COMETRIQ,hypertension,overt,0
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,the incidence of hypertension in COMETRIQtreated patients over,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,hypertension,1
COMETRIQ,hypertension,was a doubling in the incidence,0
COMETRIQ,hypertension,the incidence of hypertension in COMETRIQtreated patients,1
COMETRIQ,hypertension,was a doubling in the incidence,0
COMETRIQ,malignant hypertension,patients malignant hypertension Table,1
COMETRIQ,malignant hypertension,was a doubling in the incidence,0
COMETRIQ,malignant hypertension,Table PerPatient Incidence of Hypertension in Protocol XL Hypertension,0
COMETRIQ,malignant hypertension,PerPatient Incidence of Hypertension in Protocol,0
COMETRIQ,malignant hypertension,and Treatment of High Blood Pressure JNC staging,0
COMETRIQ,malignant hypertension,staging,0
COMETRIQ,malignant hypertension,malignant hypertension Table PerPatient Incidence,1
COMETRIQ,malignant hypertension,PerPatient Incidence,0
COMETRIQ,malignant hypertension,staging criteria No patients malignant hypertension,1
COMETRIQ,Hypertension,in Protocol XL,0
COMETRIQ,Hypertension,Hypertension in Protocol,1
COMETRIQ,Hypertension,Hypertension in Protocol,1
COMETRIQ,Pre-hypertension,Pre-hypertension Systolic,1
COMETRIQ,Pre-hypertension,Pre-hypertension Systolic mmHg or,1
COMETRIQ,Pre-hypertension,mmHg and Diastolic Pre-hypertension Systolic,1
COMETRIQ,Pre-hypertension,Pre-hypertension Systolic mmHg or,1
COMETRIQ,Pre-hypertension,Diastolic,0
COMETRIQ,Pre-hypertension,mmHg,0
COMETRIQ,PERFORATIONS,following s erious,1
COMETRIQ,FISTULAS,Perforations and,0
COMETRIQ,HEMORRHAGE,The following serious adverse tions,1
COMETRIQ,HEMORRHAGE,ADVERSE REACTIONS The following serious adverse,0
COMETRIQ,HEMORRHAGE,REACTIONS,0
COMETRIQ,HEMORRHAGE,adverse,0
COMETRIQ,PERFORATIONS,adverse reactions are discussed ewhere in,1
COMETRIQ,PERFORATIONS,discussed ewhere in th e,1
COMETRIQ,PERFORATIONS,adverse reactions are discussed ewhere in,1
COMETRIQ,PERFORATIONS,ewhere,1
COMETRIQ,PERFORATIONS,ewhere in th,1
COMETRIQ,PERFORATIONS,ewhere,1
COMETRIQ,PERFORATIONS,discussed ewhere in th e,1
COMETRIQ,PERFORATIONS,ewhere,1
COMETRIQ,PERFORATIONS,discussed ewhere in th,1
COMETRIQ,PERFORATIONS,Fistula see Boxed Warning Warnings and Precautions,0
COMETRIQ,FISTULAS,Fistula see Boxed Warning Warnings and Precautions Hemo,0
COMETRIQ,FISTULAS,"el:



  Perforations",1
COMETRIQ,FISTULAS,serious adverse reactions are discussed elsewhere,0
COMETRIQ,FISTULAS,"the el:



  Perforations and Fistula see Boxed",1
COMETRIQ,FISTULAS,serious adverse reactions are discussed elsewhere,0
COMETRIQ,FISTULAS,"elsewhere in the el:



 ",1
COMETRIQ,FISTULAS,serious adverse reactions are discussed elsewhere,0
COMETRIQ,FISTULAS,"el:



  Perforations and Fistula see Boxed",1
COMETRIQ,FISTULAS,"in the el:



  Perforations",1
COMETRIQ,FISTULAS,"el:



  Perforations and Fistula see Boxed",1
COMETRIQ,FISTULAS,are discussed elsewhere in the lab,0
COMETRIQ,HEMORRHAGE,Boxed Warning,0
COMETRIQ,HEMORRHAGE,EACTIONS,0
COMETRIQ,HEMORRHAGE,forations  and Fistula see Boxed,1
COMETRIQ,HEMORRHAGE,and Fistula see Boxed Warning,0
COMETRIQ,HEMORRHAGE,reactions are discussed,0
COMETRIQ,HEMORRHAGE,see Boxed Warning,0
COMETRIQ,Perforations,[ see,1
COMETRIQ,Perforations,the label Perforations and stula [ see ,1
COMETRIQ,Perforations,[ see,1
COMETRIQ,Perforations,Perforations and Fi,0
COMETRIQ,fistulas,see Boxe,0
COMETRIQ,fistulas,see,0
COMETRIQ,fistulas,d Warnin g,1
COMETRIQ,fistulas,see,0
COMETRIQ,fistulas,Fistula see d Warnin,1
COMETRIQ,fistulas,d Warnin g Warnings,1
COMETRIQ,fistulas,Boxe,0
COMETRIQ,fistulas,elsewhere in the label Perforations and Fistula see,0
COMETRIQ,fistulas,and Fistula see d Warnin g Warnings,1
COMETRIQ,fistulas,elsewhere in the label Perforations and Fistula see,0
COMETRIQ,fistulas,Fistula see d Warnin,1
COMETRIQ,Gastrointestinal perforations,label Perforations and Fistula see Boxed,0
COMETRIQ,Gastrointestinal perforations,"see Boxed  ,  Warnings and Precautions  Hemorrhage see",1
COMETRIQ,Gastrointestinal perforations,label Perforations and Fistula see Boxed,0
COMETRIQ,Gastrointestinal perforations,the,0
COMETRIQ,Gastrointestinal perforations,Fistula see,0
COMETRIQ,Gastrointestinal perforations,Boxed,0
COMETRIQ,Gastrointestinal perforations,see,0
COMETRIQ,fistula formation,Warnings and Precautions morrhage [ see  B oxed Warning,1
COMETRIQ,fistula formation,see,0
COMETRIQ,Hemorrhage,Complications see ings and,1
COMETRIQ,Hemorrhage,ings and P recautions Hypertension,1
COMETRIQ,Hemorrhage,Warnings and Precautions Wound Complications see Warn,0
COMETRIQ,Hemorrhage,ings and P recautions Hypertension,1
COMETRIQ,Hemorrhage,Precautions Wound Complications see ings and P,1
COMETRIQ,Hemorrhage,ings and P recautions Hypertension,1
COMETRIQ,Hemorrhage,see ings and P,1
COMETRIQ,Hemorrhage,and P recautions,1
COMETRIQ,fatal,"Warnings and ) ] 
 Hypertension",1
COMETRIQ,fatal,and P recautions,1
COMETRIQ,fatal,Complications see Warnings and Precautions,0
COMETRIQ,fatal,") ] 
 Hypertension",1
COMETRIQ,fatal,Complications see Warnings and Precautions,0
COMETRIQ,fatal,the Jaw see W,0
COMETRIQ,fatal,Wound Complications,0
COMETRIQ,fatal,of,0
COMETRIQ,fatal,Complications see Warnings and ),1
COMETRIQ,fatal,) ] Hypertension,1
COMETRIQ,hemorrhage,  Hyperten sion see Warnings and,1
COMETRIQ,hemorrhage,Warnings and   Hyperten sion see Warnings and Precautions,1
COMETRIQ,hemorrhage,  Hyperten sion see Warnings and,1
COMETRIQ,hemorrhage,and Precautions Osteonecrosis of the Jaw see Warnings and,0
COMETRIQ,hemorrhage,of,0
COMETRIQ,hemorrhage,Precautions Wound Complications,0
COMETRIQ,hemorrhage,Warnings,0
COMETRIQ,hemorrhage,  Hyperten sion see Warnings,1
COMETRIQ,hemorrhage,Complications,0
COMETRIQ,hemorrhage,the,0
COMETRIQ,hemorrhage,  Hyperten sion see Warnings,1
COMETRIQ,hemorrhage,  Hyperten sion see Warnings and,1
COMETRIQ,hemorrhage,d Precautions Wound Complications see Warnings,0
COMETRIQ,hemoptysis, Warnings  and,1
COMETRIQ,gastrointestinal hemorrhage,"and recautions  (  5.5  ) ] 
 * Osteonecrosis of",1
COMETRIQ,gastrointestinal hemorrhage, Warnings  and,1
COMETRIQ,gastrointestinal hemorrhage,of the Jaw see Warnings and Precautions Palmarplantar erythrod,0
COMETRIQ,gastrointestinal hemorrhage,see Warnings,0
COMETRIQ,gastrointestinal hemorrhage,"Warnings and recautions  (  5.5  ) ] 
 * Osteonecrosis of the",1
COMETRIQ,gastrointestinal hemorrhage,see Warnings,0
COMETRIQ,PERFORATIONS,Reversible sterior Leuk,1
COMETRIQ,FISTULAS,phalopat hy,1
COMETRIQ,FISTULAS,and Precautions EXCERPT The most,0
COMETRIQ,FISTULAS,Warnings,0
COMETRIQ,FISTULAS,Precautions EXCERPT The most,0
COMETRIQ,FISTULAS,phalopat hy Syndrome see,1
COMETRIQ,FISTULAS,phalopat hy Syndrome see Warnings,1
COMETRIQ,FISTULAS,Precautions Reversible Posterior phalopat hy Syndrome see Warnings and,1
COMETRIQ,FISTULAS,phalopat hy Syndrome see Warnings,1
COMETRIQ,HEMORRHAGE,[ s ee Warnings and Precautions,1
COMETRIQ,HEMORRHAGE,ndrome,1
COMETRIQ,HEMORRHAGE,and Precautions,0
COMETRIQ,HEMORRHAGE,Reversible Posterior Leukoencephalopathy ndrome [ s,1
COMETRIQ,HEMORRHAGE,and Precautions,0
COMETRIQ,HEMORRHAGE,The,0
COMETRIQ,HEMORRHAGE,Precautions Reversible Posterior Leukoencephalopathy Sy,0
COMETRIQ,HEMORRHAGE,Leukoencephalopathy ndrome [ s ee Warnings and Precautions EXCERPT,1
COMETRIQ,HEMORRHAGE,Precautions Reversible Posterior Leukoencephalopathy Sy,0
COMETRIQ,HEMORRHAGE,ndrome [ s ee Warnings and,1
COMETRIQ,Perforations,are diarrhea stomatitis palmarplantar erythrodysesthesia syndrome PPE,0
COMETRIQ,Perforations,EXCERPT The most commonly eported adve rse,1
COMETRIQ,Perforations,are diarrhea stomatitis palmarplantar erythrodysesthesia syndrome PPE,0
COMETRIQ,Perforations,eported adve,1
COMETRIQ,Fistulas,rug reac tions are diarrhea stomatitis palmarplantar,1
COMETRIQ,Fistulas,eported adve,1
COMETRIQ,Fistulas,most commonly reported adverse rug reac,1
COMETRIQ,Fistulas,tions are diarrhea stomatitis palmarplantar erythrodysesthesia syndrome PPES,0
COMETRIQ,Fistulas,rug reac tions are diarrhea,1
COMETRIQ,Fistulas,erythrodysesthesia syndrome,0
COMETRIQ,Fistulas,rug reac tions are diarrhea stomatitis palmarplantar,1
COMETRIQ,Fistulas,adverse rug reac,1
COMETRIQ,Fistulas,rug reac tions are diarrhea stomatitis palmarplantar,1
COMETRIQ,Gastrointestinal perforations,"reported adverse drug ons (>=25%) are diarrhea, sto matitis palmarplantar erythrodysesthesia syndrome",1
COMETRIQ,Gastrointestinal perforations,rug reac tions are diarrhea stomatitis palmarplantar,1
COMETRIQ,Gastrointestinal perforations,"reported adverse drug ons (>=25%) are diarrhea, sto matitis palmarplantar erythrodysesthesia",1
COMETRIQ,Gastrointestinal perforations,rug reac tions are diarrhea stomatitis palmarplantar,1
COMETRIQ,Gastrointestinal perforations,"commonly reported adverse drug ons (>=25%) are diarrhea,",1
COMETRIQ,Gastrointestinal perforations,reported adverse drug,0
COMETRIQ,Gastrointestinal perforations,syndrome PPES decreased weight,0
COMETRIQ,Gastrointestinal perforations,reported adverse drug ons (>=25%),1
COMETRIQ,Gastrointestinal perforations,palmarplantar erythrodysesthesia syndrome PPES decreased,0
COMETRIQ,Gastrointestinal perforations,syndrome PPES decreased weight,0
COMETRIQ,fistula formation,reactions are diarrhea stomatitis tar erythrodysest hesia syndrome PPES,1
COMETRIQ,fistula formation,syndrome PPES decreased weight,0
COMETRIQ,fistula formation,tar erythrodysest hesia syndrome PPES decreased,1
COMETRIQ,fistula formation,are diarrhea stomatitis tar erythrodysest,1
COMETRIQ,fistula formation,are diarrhea stomatitis,0
COMETRIQ,fistula formation,stomatitis tar erythrodysest hesia syndrome,1
COMETRIQ,fistula formation,are diarrhea stomatitis,0
COMETRIQ,fistula formation,nausea fatigue oral,0
COMETRIQ,fistula formation,tar erythrodysest hesia syndrome PPES,1
COMETRIQ,fistula formation,tar,1
COMETRIQ,fistula formation,tar erythrodysest,1
COMETRIQ,fatal,changes dysgeusia hypertension nal p ain and constipation,1
COMETRIQ,fatal,tar erythrodysest,1
COMETRIQ,fatal,and constipation The most common laboratory abnormalities,0
COMETRIQ,fatal,color changes dysgeusia hypertension nal p ain and constipation The,1
COMETRIQ,fatal,and constipation The most common laboratory abnormalities,0
COMETRIQ,fatal,and constipation The most common laboratory abnormalities are increased AST,0
COMETRIQ,fatal,nal p ain and,1
COMETRIQ,fatal,most common,0
COMETRIQ,fatal,hair color changes,0
COMETRIQ,fatal,dysgeusia hypertension nal p ain,1
COMETRIQ,fatal,hair color changes,0
COMETRIQ,hemorrhage,and con stipation The most common laboratory,1
COMETRIQ,hemorrhage,"dysgeusia hypertension abdominal n, and con",1
COMETRIQ,hemorrhage,"n,",1
COMETRIQ,hemorrhage,"n, and con stipation The most common laboratory",1
COMETRIQ,hemorrhage,hypertension abdominal,0
COMETRIQ,hemorrhage,nausea fatigue,0
COMETRIQ,hemorrhage,and con stipation The most,1
COMETRIQ,hemorrhage,pain hair color changes dysgeusia hypertension abdominal pai,0
COMETRIQ,hemorrhage,"hypertension abdominal n, and",1
COMETRIQ,hemorrhage,hypertension abdominal pai,0
COMETRIQ,hemorrhage,"n, and con",1
COMETRIQ,hemorrhage,"n, and con stipation The most common",1
COMETRIQ,hemorrhage,"n, and con stipation The most common",1
COMETRIQ,hemorrhage,"n, and con stipation The most common",1
COMETRIQ,hemorrhage,sed appetite nausea,0
COMETRIQ,hemorrhage,common laboratory abnormalities are increased AST increased ALT,0
COMETRIQ,hemorrhage,laboratory abnormalities are increased AST,0
COMETRIQ,gastrointestinal hemorrhage,most  laboratory abnormalities ( are increased AST increased,1
COMETRIQ,gastrointestinal hemorrhage,laboratory abnormalities are increased AST,0
COMETRIQ,gastrointestinal hemorrhage,most laboratory abnormalities,1
COMETRIQ,gastrointestinal hemorrhage,The most common,0
COMETRIQ,gastrointestinal hemorrhage,constipation The most  laboratory abnormalities ( are increased AST,1
COMETRIQ,gastrointestinal hemorrhage,The most common,0
COMETRIQ,Thrombotic Events,The following serious,0
COMETRIQ,Thrombotic Events,erse reactions ar e discussed,1
COMETRIQ,Thrombotic Events,REACTIONS The following serious erse reactions ar e,1
COMETRIQ,Thrombotic Events,erse reactions ar e discussed,1
COMETRIQ,Thrombotic Events,Perforations and Fistula,0
COMETRIQ,Thrombotic Events,and Fistula see Boxed Warning Warning,0
COMETRIQ,Wound Complications,[ see Boxed Warning Warnings,1
COMETRIQ,Wound Complications,Precautions,0
COMETRIQ,Wound Complications,Hemorrhage [ see Boxed Warning,1
COMETRIQ,Wound Complications,and  Hemorrhage [ see   Boxed Warning Warnings and,1
COMETRIQ,Wound Complications,Hemorrhage [ see Boxed Warning,1
COMETRIQ,Wound Complications,Thromboembolic Events see,0
COMETRIQ,Wound Complications,see Boxed Warning,0
COMETRIQ,Wound Complications,Fistula see,0
COMETRIQ,Wound Complications,Hemorrhage [ see,1
COMETRIQ,Wound Complications,Warning,0
COMETRIQ,Wound Complications,[ see Boxed Warning Warnings and,1
COMETRIQ,Hypertension,Warnings and Precautions,0
COMETRIQ,Hypertension,Wound Complications,0
COMETRIQ,Hypertension,Precautions Thromboembolic Events,0
COMETRIQ,Hypertension,and Precauti,1
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,Warnings and Precautions ecrosis of the,1
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,syndrome see Warnings and,0
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,and Pre cautions Palmarplantar erythrodysesthesia,1
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,and Precautions ecrosis of the Jaw [ see  Warnings and Pre cautions Palmarplantar erythrodysesthesia,1
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,and Pre cautions Palmarplantar erythrodysesthesia,1
COMETRIQ,Palmar-plantar Erythrodysesthesia syndrome,Warnings and Pre,1
COMETRIQ,Proteinuria,a syndrome see Warnings and Precautions,1
COMETRIQ,Proteinuria,a syndrome,1
COMETRIQ,Proteinuria,the Jaw see Warnings and,0
COMETRIQ,Proteinuria,a,1
COMETRIQ,Proteinuria,Precautions Palmarplantar a,1
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,"s and Precautions  (  5.8  ) ] 
 *  Reversible Po sterior Leukoencephalopathy Syndrome see",1
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,Precautions Palmarplantar a,1
COMETRIQ,Reversible posterior leukoencephalopathy syndrome,Proteinuria see s and Precautions ( 5.8 ) ] *,1
COMETRIQ,RPLS,Precautions Reversible,0
COMETRIQ,RPLS,see Warnings,0
COMETRIQ,RPLS,ions,0
COMETRIQ,RPLS,Precautions Reversible erio r,1
COMETRIQ,RPLS,ions,0
COMETRIQ,RPLS,erio r Leukoencephalopathy Syndrome see Warnings,1
COMETRIQ,RPLS,erio,1
COMETRIQ,RPLS,Leukoencephalopathy Syndrome see,0
COMETRIQ,RPLS,Leukoencephalopathy Syndrome see Warnings and Precautions EXCERPT The mo,0
COMETRIQ,Embryofetal toxicity,drug reactions,0
COMETRIQ,Embryofetal toxicity,rnings and Precautio ns,1
COMETRIQ,Embryofetal toxicity,drug reactions,0
COMETRIQ,Embryofetal toxicity,and Precautio ns EXCERPT The most commonly,1
COMETRIQ,Embryofetal toxicity,Posterior Leukoencephalopathy Syndrome see rnings and Precautio ns,1
COMETRIQ,Embryofetal toxicity,and Precautio ns EXCERPT The most commonly,1
COMETRIQ,Embryofetal toxicity,Leukoencephalopathy Syndrome,0
COMETRIQ,Embryofetal toxicity,and Precautio ns EXCERPT,1
COMETRIQ,Embryofetal toxicity,The most commonly reported adverse drug reactions,0
COMETRIQ,Embryofetal toxicity,most commonly reported adverse drug reactions are,0
COMETRIQ,Embryofetal toxicity,and Precautions Reversible Posterior Leukoencephalopathy Syndrome see,0
COMETRIQ,fetal harm,) ] EXCERPT,1
COMETRIQ,fetal harm,Warnings and ) ],1
COMETRIQ,fetal harm,Reversible Posterior Leukoencephalopathy Syndrome,0
COMETRIQ,GI fistula,"hair color changes dysgeusia n,",1
COMETRIQ,GI fistula,pain and constipation The most common laboratory abnormalities,0
COMETRIQ,GI fistula,"dysgeusia n, abdomin",1
COMETRIQ,GI fistula,abnormalities,0
COMETRIQ,GI fistula,"color changes dysgeusia n,",1
COMETRIQ,GI fistula,are increased,0
COMETRIQ,GI fistula,"n, abdomin al pain",1
COMETRIQ,GI fistula,are increased,0
COMETRIQ,GI fistula,"n, abdomin al pain and constipation The",1
COMETRIQ,GI fistula,"color changes dysgeusia n, abdomin",1
COMETRIQ,fatal,"dysgeusia hypertension abdominal in, a nd constipation The most",1
COMETRIQ,fatal,"color changes dysgeusia n, abdomin",1
COMETRIQ,fatal,"dysgeusia hypertension abdominal in, a nd constipation The most",1
COMETRIQ,fatal,"color changes dysgeusia n, abdomin",1
COMETRIQ,fatal,"in, a",1
COMETRIQ,fatal,"color changes dysgeusia n, abdomin",1
COMETRIQ,fatal,common,0
COMETRIQ,fatal,abdominal pa,0
COMETRIQ,Non-GI fistulas,and pation. The mos t common laboratory abnormalities are,1
COMETRIQ,Non-GI fistulas,abdominal pa,0
COMETRIQ,Non-GI fistulas,pain and,0
COMETRIQ,Non-GI fistulas,pation.,1
COMETRIQ,Non-GI fistulas,pain and consti,0
COMETRIQ,Non-GI fistulas,The mos,1
COMETRIQ,Non-GI fistulas,The mos t common,1
COMETRIQ,Non-GI fistulas,dysgeusia hypertension abdominal,0
COMETRIQ,Non-GI fistulas,The mos t common laboratory abnormalities,1
COMETRIQ,Non-GI fistulas,abdominal pain and pation. The mos t common laboratory,1
COMETRIQ,Non-GI fistulas,The mos t common laboratory abnormalities,1
COMETRIQ,fatal,ALT lymphopenia increased ine,1
COMETRIQ,fatal,ine p hosphatase hypocalcemia neutropenia thrombocytopenia,1
COMETRIQ,fatal,ALT lymphopenia increased ine,1
COMETRIQ,fatal,Inc 935 o,1
COMETRIQ,fatal,ALT lymphopenia increased ine,1
COMETRIQ,fatal,REACTIONS contact Exelixis Inc 935 o r FDA,1
COMETRIQ,fatal,ALT lymphopenia increased ine,1
COMETRIQ,fatal,935 o r FDA at,1
COMETRIQ,fatal,REACTIONS contact Exelixis Inc 935 o r FDA,1
COMETRIQ,fatal,935 o r FDA at,1
COMETRIQ,fatal,Inc,0
COMETRIQ,hemorrhage,FDA at 1- FDA or wwwfdagovmedwatch Clinical Trial,1
COMETRIQ,hemorrhage,contact Exelixis Inc at  FDA at 1- FDA,1
COMETRIQ,hemorrhage,FDA at 1- FDA or wwwfdagovmedwatch Clinical Trial,1
COMETRIQ,hemorrhage,Exelixis Inc,0
COMETRIQ,hemorrhage, FDA at 1- FDA or wwwfdagovmedwatch Clinical,1
COMETRIQ,hemorrhage,Exelixis Inc,0
COMETRIQ,hemorrhage,at  FDA at 1- FDA or wwwfdagovmedwatch Clinical Trial,1
COMETRIQ,hemorrhage,Exelixis Inc,0
COMETRIQ,hemorrhage,at 1-,1
COMETRIQ,hemorrhage,Exelixis Inc,0
COMETRIQ,hemorrhage,at 1- FDA,1
COMETRIQ,hemorrhage,at,0
COMETRIQ,hemorrhage,FDA at 1- FDA or,1
COMETRIQ,hemorrhage, FDA at 1- FDA or,1
COMETRIQ,hemorrhage,FDA at 1- FDA or,1
COMETRIQ,hemorrhagic events,Clinical Tr,1
COMETRIQ,hemorrhagic events,or 6.1,1
COMETRIQ,hemorrhagic events,clinical trials are conducted under widely varying conditions,0
COMETRIQ,hemorrhagic events,FDA at FDA or 6.1,1
COMETRIQ,hemorrhagic events,conducted under widely,0
COMETRIQ,thrombotic events,of COMETRIQ was,0
COMETRIQ,thrombotic events,ice The safety of COMETRIQ was evaluated in,0
COMETRIQ,thrombotic events,not reflect the observed in,1
COMETRIQ,thrombotic events,not reflect the observed in,1
COMETRIQ,venous thromboembolism,of C OMETRIQ,1
COMETRIQ,venous thromboembolism,safety of C OMETRIQ was evaluated,1
COMETRIQ,venous thromboembolism,rates observed in e. The,1
COMETRIQ,venous thromboembolism,ed to,0
COMETRIQ,venous thromboembolism,rates observed in e. The safety,1
COMETRIQ,venous thromboembolism,observed in practic,0
COMETRIQ,arterial thromboembolism,330 patients wi th progressive metastatic medullary thyroid,1
COMETRIQ,arterial thromboembolism,330 patients wi th progressive metastatic medullary,1
COMETRIQ,arterial thromboembolism,COMETRIQ,0
COMETRIQ,arterial thromboembolism,not reflect the rates,0
COMETRIQ,Wound complications,See Clinical Studies,0
COMETRIQ,Wound complications,Clinical 4) .] The,1
COMETRIQ,Wound complications,Clinical 4) .],1
COMETRIQ,Wound complications,below reflect a median,0
COMETRIQ,hypertension,frequency diarrhea stomatitis palmarplantar sthesia synd rome PPES decreased weight decreased,1
COMETRIQ,hypertension,below reflect a median,0
COMETRIQ,hypertension,fatigue oral,0
COMETRIQ,hypertension,hair,0
COMETRIQ,hypertension,sthesia synd rome,1
COMETRIQ,hypertension,sthesia synd rome,1
COMETRIQ,hypertension,sthesia synd rome,1
COMETRIQ,hypertension,rome PPES decreased weight decreased appetite nausea fatigue oral pain hair color,0
COMETRIQ,hypertension,diarrhea stomatitis palmarplantar sthesia,1
COMETRIQ,hypertension,order of decreasing frequency diarrhea stomatitis palmarplantar erythrodyse,0
COMETRIQ,hypertension,sthesia synd,1
COMETRIQ,hypertension,petite nausea fatigue oral pain hair color changes dysgeusia,0
COMETRIQ,hypertension, constipatio n The most,1
COMETRIQ,hypertension, constipatio,1
COMETRIQ,hypertension, constipatio n,1
COMETRIQ,Osteonecrosis of the jaw,"PPES lymphopenia hypocalcemia fatigue ypertension, asthenia, i",1
COMETRIQ,Osteonecrosis of the jaw, constipatio n,1
COMETRIQ,Osteonecrosis of the jaw,"asthenia, i ncreased ALT decreased weight stomatitis",1
COMETRIQ,Osteonecrosis of the jaw,"asthenia, i",1
COMETRIQ,Osteonecrosis of the jaw,"asthenia, i ncreased ALT decreased",1
COMETRIQ,Osteonecrosis of the jaw,and decreased appetite see Table Table,0
COMETRIQ,Osteonecrosis of the jaw,"ypertension, asthenia, i ncreased",1
COMETRIQ,Osteonecrosis of the jaw,and decreased appetite see Table Table,0
COMETRIQ,Osteonecrosis of the jaw,stomatitis and decreased appetite see Table Table,0
COMETRIQ,ONJ,see Table Table Fata,0
COMETRIQ,ONJ,rea sed ALT decreased weight,1
COMETRIQ,ONJ,rea sed ALT decreased,1
COMETRIQ,ONJ,fatigue hypertension asthenia inc,0
COMETRIQ,ONJ,rea sed ALT decreased weight stomatitis,1
COMETRIQ,ONJ,rea sed ALT decreased weight,1
COMETRIQ,ONJ,PPES lymphopenia,0
COMETRIQ,ONJ,rea sed ALT decreased weight stomatitis,1
COMETRIQ,ONJ,PPES lymphopenia,0
COMETRIQ,ONJ,occurred in of patients,0
COMETRIQ,ONJ,eas ed appetite,1
COMETRIQ,ONJ,eas ed appetite see Table Table,1
COMETRIQ,jaw pain,stomatitis and decreased appetite Table,1
COMETRIQ,jaw pain,decreased appetite Table,1
COMETRIQ,jaw pain,decreased appetite  Table 1 Table Fatal,1
COMETRIQ,jaw pain,decreased appetite Table,1
COMETRIQ,jaw pain,Fatal adverse reactions occurred in,0
COMETRIQ,jaw pain, Table 1 Table Fatal adverse reactions,1
COMETRIQ,jaw pain,Fatal adverse reactions occurred in,0
COMETRIQ,jaw pain,Table 1 Table,1
COMETRIQ,jaw pain,and decreased appetite Table 1,1
COMETRIQ,jaw pain,stomatitis and decreased appetite  Table 1 Table Fatal adverse,1
COMETRIQ,jaw pain,and decreased appetite Table 1,1
COMETRIQ,jaw pain,Fatal adverse reactions occurred in of patients receiving COMETRIQ,0
COMETRIQ,jaw pain,stomatitis and decreased appetite  Table 1 Table Fatal adverse reactions occurred,1
COMETRIQ,jaw pain,Fatal adverse reactions occurred in of patients receiving COMETRIQ,0
COMETRIQ,osteomyelitis,"decreased appetite see ,  Table 2  ) Fatal",1
COMETRIQ,osteomyelitis,Fatal adverse reactions occurred in of patients receiving COMETRIQ,0
COMETRIQ,osteomyelitis,and,0
COMETRIQ,osteomyelitis,"decreased appetite see , Table",1
COMETRIQ,osteomyelitis,"decreased appetite see , Table",1
COMETRIQ,osteitis,"


 Fata",1
COMETRIQ,osteitis,from,0
COMETRIQ,osteitis,decreased appetite see Table Table,0
COMETRIQ,bone erosion,adverse reac tions occurred in,1
COMETRIQ,bone erosion,occurred in of patients receiving COMETRIQ and resulted from,0
COMETRIQ,bone erosion,see Table Table adverse reac tions occurred in of patients,1
COMETRIQ,bone erosion,occurred in of patients receiving COMETRIQ and resulted from,0
COMETRIQ,bone erosion,see Table Table adverse,1
COMETRIQ,bone erosion,ALT decreased,0
COMETRIQ,bone erosion,Table Table adverse reac tions occurred,1
COMETRIQ,bone erosion,ALT decreased,0
COMETRIQ,bone erosion,adverse reac,1
COMETRIQ,bone erosion,Table Table adverse,1
COMETRIQ,bone erosion,appetite see Table Table adverse reac tions occurred in of,1
COMETRIQ,bone erosion,Table Table adverse,1
COMETRIQ,bone erosion,adverse reac tions occurred in of,1
COMETRIQ,periodontal infection,6% of patients receiving COMETRIQ,1
COMETRIQ,periodontal infection,stomatitis and,0
COMETRIQ,periodontal infection,COMETRIQ,0
COMETRIQ,periodontal infection,6% of patients receiving,1
COMETRIQ,periodontal infection,resulted from,0
COMETRIQ,periodontal infection,reactions red in,1
COMETRIQ,periodontal infection,adverse reactions red in 6% of patients,1
COMETRIQ,periodontal infection,reactions red in,1
COMETRIQ,toothache,eceiving  COMETRIQ and resulted,1
COMETRIQ,toothache,in of patients eceiving  COMETRIQ and resulted,1
COMETRIQ,toothache,eceiving  COMETRIQ and resulted,1
COMETRIQ,toothache,COMETRIQ and resulted from hemorrhage pneumonia septicemia fistulas cardiac arrest respiratory,0
COMETRIQ,toothache,occurred in of patients eceiving  COMETRIQ,1
COMETRIQ,toothache,COMETRIQ and resulted from hemorrhage pneumonia septicemia fistulas cardiac arrest respiratory,0
COMETRIQ,toothache,ased appetite see,0
COMETRIQ,toothache,and resulted from hemorrhage pneumonia septicemia fistulas cardiac,0
COMETRIQ,toothache,eceiving  COMETRIQ and resulted from,1
COMETRIQ,toothache,occurred in of patients eceiving  COMETRIQ and resulted from,1
COMETRIQ,toothache,eceiving  COMETRIQ and resulted from,1
COMETRIQ,gingival ulceration,adverse reactions occurred in of patients receiving CO,0
COMETRIQ,persistent jaw pain,"COMETRIQ and resulted from age, pneumonia, sep ticemia fistulas cardiac",1
COMETRIQ,persistent jaw pain,adverse reactions occurred in of patients receiving CO,0
COMETRIQ,persistent jaw pain,death Fatal adverse reactio,0
COMETRIQ,persistent jaw pain,hemorrh,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,discontinuation in,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,receiving Q compared to none in patients receiving p lacebo Adverse,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,discontinuation in,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,in patients receiving p lacebo Adverse reactions led to,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,receiving Q compared to none in patients,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,led to study,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,one in patients receiving Q compared to none in patients receiving p lacebo Adverse,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,led to study,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,patients receiving Q compared to none in patients receiving p,1
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,led to study,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,receiving placebo The median,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,receiving COMETRI,0
COMETRIQ,Palmar-plantar erythrodysesthesia syndrome,discontinuation in,0
COMETRIQ,PPES,none in patients receiving cebo Adverse reactions led to study,1
COMETRIQ,PPES,discontinuation in,0
COMETRIQ,PPES,patients,0
COMETRIQ,PPES,patients receiving cebo Adverse,1
COMETRIQ,PPES,patients,0
COMETRIQ,PPES,of patients,0
COMETRIQ,PPES,cebo Adverse reactions led to study,1
COMETRIQ,PPES,of patients,0
COMETRIQ,PPES,cebo Adverse,1
COMETRIQ,PPES,cebo,1
COMETRIQ,PPES,compared to none in,0
COMETRIQ,PPES,led to study treatment discontinuation in,0
COMETRIQ,PPES,cebo Adverse,1
COMETRIQ,PPES,cebo Adverse reactions led,1
COMETRIQ,PPES,cebo Adverse reactions led to study,1
COMETRIQ,PPES,r of dosing delays was one in patients receiving COMETRIQ compared,0
COMETRIQ,PPES,cebo Adverse,1
COMETRIQ,Proteinuria,"increased ase, PPES, ",1
COMETRIQ,Proteinuria,cebo Adverse,1
COMETRIQ,Proteinuria,"were hypocalcemia increased ase, PPES,",1
COMETRIQ,Proteinuria,"increased ase, PPES,  diarrhea fatigue hypertension nausea",1
COMETRIQ,Proteinuria,"were hypocalcemia increased ase, PPES,",1
COMETRIQ,Proteinuria,pancreatitis tracheal fistula formation and vomiting,0
COMETRIQ,Proteinuria,fistula formation and,0
COMETRIQ,Proteinuria,"ase, PPES, diarrhea",1
COMETRIQ,Proteinuria,"hypocalcemia increased ase, PPES,  diarrhea fatigue hypertension nausea pancreatitis",1
COMETRIQ,Proteinuria,"ase, PPES, diarrhea",1
COMETRIQ,Proteinuria,"were hypocalcemia increased ase, PPES,  diarrhea",1
COMETRIQ,Proteinuria,"ase, PPES, diarrhea",1
COMETRIQ,Proteinuria,"were hypocalcemia increased ase, PPES,",1
COMETRIQ,Proteinuria,"increased ase, PPES,  diarrhea fatigue hypertension nausea pancreatitis",1
COMETRIQ,Proteinuria,"were hypocalcemia increased ase, PPES,",1
COMETRIQ,RPLS,prior thyroidectomy d 89 were taking thyroid,1
COMETRIQ,RPLS,"were hypocalcemia increased ase, PPES,",1
COMETRIQ,RPLS,d 89 were taking thyroid hormone replacement,1
COMETRIQ,subcortical vasogenic edema,and,0
COMETRIQ,subcortical vasogenic edema,of Selected Adverse Reactions,0
COMETRIQ,subcortical vasogenic edema,arm had a prior thyroidectomy,0
NULOJIX,PTLD,PTLD predominantly CNS PTLD and other,1
NULOJIX,PTLD,PTLD predominantly,1
NULOJIX,PTLD,PTLD predominantly CNS PTLD and other,1
NULOJIX,PTLD,reactions reported with NULOJIX PTLD,1
NULOJIX,PTLD,PTLD predominantly CNS PTLD and other,1
NULOJIX,PTLD,with NULOJIX PTLD predominantly CNS PTLD,1
NULOJIX,PTLD,PTLD predominantly CNS PTLD and other,1
NULOJIX,PTLD,NULOJIX,0
NULOJIX,CNS PTLD,CNS PTLD and other malignancies,1
NULOJIX,CNS PTLD,CNS PTLD and other malignancies see,1
NULOJIX,CNS PTLD,CNS PTLD and other malignancies,1
NULOJIX,CNS PTLD,are PTLD CNS PTLD and other malignancies see,1
NULOJIX,CNS PTLD,CNS PTLD and other malignancies,1
NULOJIX,CNS PTLD,CNS PTLD,1
NULOJIX,CNS PTLD,malignancies see Boxed Warning and,0
NULOJIX,CNS PTLD,malignancies see Boxed Warning and Warnings,0
NULOJIX,CNS PTLD,CNS,1
NULOJIX,malignancies,Boxed,0
NULOJIX,malignancies,Precautions,0
NULOJIX,malignancies,malignancies,1
NULOJIX,malignancies,malignancies see Boxed Warning,1
NULOJIX,malignancies,Precautions Serious,0
NULOJIX,malignancies,and malignancies see Boxed,1
NULOJIX,malignancies,Precautions Serious,0
NULOJIX,malignancies,malignancies see Boxed,1
NULOJIX,malignancies,malignancies see Boxed,1
NULOJIX,malignancies,with NULOJIX are PTLD predominantly CNS PTLD and other,0
NULOJIX,infections,see,0
NULOJIX,JC virus,JC virus associated PML,1
NULOJIX,JC virus,and Precautions Serious,0
NULOJIX,JC virus,see Warnings and Precautions,0
NULOJIX,PML,Serious infections,0
NULOJIX,PML,PML,1
NULOJIX,PML,JC PML,1
NULOJIX,PML,PML,1
NULOJIX,PML,PML and,1
NULOJIX,PML,PML and polyoma virus nephropathy,1
NULOJIX,PML,PML and,1
NULOJIX,PML,PML and polyoma,1
NULOJIX,PML,and,0
NULOJIX,PML,see Warnings,0
NULOJIX,PML,infections including JC PML and polyoma virus,1
NULOJIX,PML,see Warnings,0
NULOJIX,PML,Serious infections including,0
NULOJIX,polyoma virus nephropathy,polyoma virus nephropathy see Warnings and Precautions EXCERPT,1
NULOJIX,polyoma virus nephropathy,PML polyoma virus,1
NULOJIX,polyoma virus nephropathy,PML polyoma,1
NULOJIX,polyoma virus nephropathy,and,0
NULOJIX,polyoma virus nephropathy,EXCERPT Most common adverse,0
NULOJIX,polyoma virus nephropathy,Precautions EXCERPT Most common adverse rea,0
NULOJIX,polyoma virus nephropathy,PML,0
NULOJIX,polyoma virus nephropathy,polyoma virus nephropathy see Warnings and,1
NULOJIX,anemia,anemia diarrhea urinary tract infection peripheral,1
NULOJIX,diarrhea,treatment are diarrhea urinary tract infection peripheral edema,1
NULOJIX,diarrhea,anemia diarrhea urinary tract infection peripheral,1
NULOJIX,diarrhea,reactions on NULOJIX treatment are,0
NULOJIX,diarrhea,NULOJIX,0
NULOJIX,diarrhea,diarrhea urinary tract infection peripheral,1
NULOJIX,diarrhea,NULOJIX,0
NULOJIX,diarrhea,urinary tract,0
NULOJIX,diarrhea,treatment,0
NULOJIX,diarrhea,are diarrhea urinary tract infection peripheral,1
NULOJIX,diarrhea,treatment,0
NULOJIX,diarrhea,Most common adverse reactions on NULOJIX treatment,0
NULOJIX,urinary tract infection,NULOJIX treatment are anemia urinary tract infection,1
NULOJIX,urinary tract infection,graft,0
NULOJIX,urinary tract infection,dysfunction cough nausea,0
NULOJIX,urinary tract infection,are anemia urinary tract infection peripheral,1
NULOJIX,urinary tract infection,dysfunction cough nausea,0
NULOJIX,urinary tract infection,urinary tract infection,1
NULOJIX,urinary tract infection,reactions on,0
NULOJIX,peripheral edema,peripheral edema constipation hypertension,1
NULOJIX,peripheral edema,peripheral edema constipation hypertension,1
NULOJIX,peripheral edema,urinary tract peripheral edema constipation hypertension pyrexia,1
NULOJIX,peripheral edema,peripheral edema constipation hypertension,1
NULOJIX,peripheral edema,peripheral edema,1
NULOJIX,peripheral edema,urinary tract peripheral edema constipation hypertension,1
NULOJIX,peripheral edema,peripheral edema,1
NULOJIX,constipation,cough nausea vomiting,0
NULOJIX,constipation,constipation hypertension pyrexia graft dysfunction cough,1
NULOJIX,constipation,constipation hypertension pyrexia,1
NULOJIX,constipation,urinary tract infection peripheral constipation hypertension pyrexia graft dysfunction,1
NULOJIX,constipation,constipation hypertension pyrexia,1
NULOJIX,hypertension,hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,pyrexia,0
NULOJIX,hypertension,hyperkalemia and leuk,0
NULOJIX,hypertension,graft dysfunction cough,0
NULOJIX,hypertension,hypertension,1
NULOJIX,hypertension,hypertension pyrexia graft dysfunction cough nausea,1
NULOJIX,hypertension,hypertension pyrexia graft,1
NULOJIX,hypertension,infection peripheral edema hypertension pyrexia graft,1
NULOJIX,hypertension,hypertension pyrexia graft,1
NULOJIX,hypertension,hypertension pyrexia graft dysfunction cough nausea,1
NULOJIX,hypertension,tract infection peripheral edema hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,hypertension pyrexia graft dysfunction cough nausea,1
NULOJIX,pyrexia,urinary tract infection peripheral edema,0
NULOJIX,pyrexia,hyperkalemia and leukopenia,0
NULOJIX,pyrexia,tract infection peripheral edema,0
NULOJIX,pyrexia,anemia diarrhea urinary tract,0
NULOJIX,graft dysfunction,graft dysfunction,1
NULOJIX,graft dysfunction,hypertension graft dysfunction cough nausea vomiting,1
NULOJIX,graft dysfunction,graft dysfunction,1
NULOJIX,graft dysfunction,graft dysfunction cough,1
NULOJIX,graft dysfunction,urinary tract infection peripheral edema constipation,0
NULOJIX,graft dysfunction,graft dysfunction,1
NULOJIX,graft dysfunction,graft,1
NULOJIX,graft dysfunction,leukopenia,0
NULOJIX,graft dysfunction,constipation hypertension graft dysfunction,1
NULOJIX,graft dysfunction,hypertension graft dysfunction cough,1
NULOJIX,graft dysfunction,constipation hypertension graft dysfunction,1
NULOJIX,cough,cough nausea vomiting,1
NULOJIX,cough,cough nausea vomiting headache,1
NULOJIX,cough,pyrexia graft cough nausea,1
NULOJIX,cough,cough nausea vomiting headache,1
NULOJIX,cough,edema,0
NULOJIX,cough,cough,1
NULOJIX,nausea,nausea vomiting headache hypokalemia,1
NULOJIX,nausea,cough,1
NULOJIX,nausea,headache hypokalemia hyperkalemia,0
NULOJIX,nausea,nausea vomiting headache hypokalemia hyperkalemia,1
NULOJIX,nausea,graft dysfunction nausea vomiting headache hypokalemia,1
NULOJIX,nausea,nausea vomiting headache hypokalemia hyperkalemia,1
NULOJIX,nausea,y tract infection,0
NULOJIX,nausea,nausea vomiting headache,1
NULOJIX,nausea,leukopenia To,0
NULOJIX,vomiting,pyrexia graft dysfunction cough vomiting,1
NULOJIX,vomiting,leukopenia To,0
NULOJIX,vomiting,headache hypokalemia hyperkalemia and leukopenia To report SUSPECTED,0
NULOJIX,vomiting,vomiting headache hypokalemia,1
NULOJIX,vomiting,vomiting headache hypokalemia,1
NULOJIX,vomiting,vomiting headache hypokalemia,1
NULOJIX,vomiting,pyrexia graft dysfunction cough vomiting headache hypokalemia,1
NULOJIX,vomiting,vomiting headache hypokalemia,1
NULOJIX,vomiting,vomiting,1
NULOJIX,vomiting,vomiting headache hypokalemia,1
NULOJIX,vomiting,vomiting,1
NULOJIX,vomiting,pyrexia graft dysfunction cough vomiting headache hypokalemia hyperkalemia and leukopenia,1
NULOJIX,vomiting,vomiting,1
NULOJIX,hypokalemia,cough nausea vomiting hypokalemia hyperkalemia,1
NULOJIX,hypokalemia,vomiting,1
NULOJIX,hypokalemia,hypokalemia hyperkalemia and leukopenia To report,1
NULOJIX,hypokalemia,vomiting hypokalemia hyperkalemia and leukopenia,1
NULOJIX,hypokalemia,hypokalemia hyperkalemia and leukopenia To report,1
NULOJIX,hypokalemia,dysfunction cough nausea vomiting hypokalemia,1
NULOJIX,hypokalemia,hypokalemia hyperkalemia and leukopenia To report,1
NULOJIX,hypokalemia,hypokalemia hyperkalemia and leukopenia To,1
NULOJIX,hypokalemia,hypokalemia,1
NULOJIX,hyperkalemia,hypertension pyrexia graft dysfunction,0
NULOJIX,hyperkalemia,hypertension pyrexia,0
NULOJIX,hyperkalemia,tipation hypertension pyrexia graft,0
NULOJIX,hyperkalemia,leukopenia To report SUSPECTED,0
NULOJIX,hyperkalemia,hyperkalemia and leukopenia To report SUSPECTED,1
NULOJIX,hyperkalemia,report SUSPECTED ADVERSE REACTIONS,0
NULOJIX,hyperkalemia,hyperkalemia and leukopenia,1
NULOJIX,hyperkalemia,report SUSPECTED ADVERSE REACTIONS,0
NULOJIX,hyperkalemia,hyperkalemia and leukopenia To,1
NULOJIX,leukopenia,leukopenia,1
NULOJIX,leukopenia,leukopenia To report SUSPECTED,1
NULOJIX,leukopenia,report SUSPECTED ADVERSE REACTIONS contact,0
NULOJIX,leukopenia,leukopenia,1
NULOJIX,leukopenia,leukopenia,1
NULOJIX,leukopenia,and,0
NULOJIX,leukopenia,leukopenia To report SUSPECTED ADVERSE REACTIONS,1
NULOJIX,leukopenia,dysfunction cough nausea,0
NULOJIX,leukopenia,nausea vomiting headache hypokalemia,0
NULOJIX,CNS PTLD,for CNS PTLD,1
NULOJIX,CNS PTLD,CNS PTLD PML and,1
NULOJIX,CNS PTLD,treated and followed for CNS,1
NULOJIX,CNS PTLD,and followed for CNS PTLD PML and other CNS infections,1
NULOJIX,CNS PTLD,treated and followed for CNS,1
NULOJIX,PML,PML,1
NULOJIX,PML,PML and other CNS infections were,1
NULOJIX,PML,PML,1
NULOJIX,PML,CNS PML,1
NULOJIX,PML,PML,1
NULOJIX,PML,PML and other CNS,1
NULOJIX,PML,PML,1
NULOJIX,CNS infections,association with a NULOJIX regimen of,0
NULOJIX,CNS infections,CNS infections were more frequently,1
NULOJIX,CNS infections,association with a NULOJIX regimen of,0
NULOJIX,anemia,and frequency of NULOJIX anemia diarrhea urinary tract,1
NULOJIX,anemia,association with a NULOJIX regimen of,0
NULOJIX,anemia,anemia diarrhea urinary tract,1
NULOJIX,anemia,anemia diarrhea urinary,1
NULOJIX,anemia,anemia diarrhea urinary,1
NULOJIX,anemia,anemia diarrhea,1
NULOJIX,anemia,frequency of NULOJIX anemia diarrhea urinary tract,1
NULOJIX,anemia,anemia diarrhea,1
NULOJIX,anemia,patients treated with the recommended dose and,0
NULOJIX,diarrhea,infection peripheral edema,0
NULOJIX,urinary tract infection,edema constipation hypertension pyrexia graft dysfunction,0
NULOJIX,peripheral edema,recommended,0
NULOJIX,peripheral edema,NULOJIX were anemia diarrhea urinary,0
NULOJIX,peripheral edema,diarrhea urinary tract peripheral edema constipation hypertension pyrexia graft,1
NULOJIX,peripheral edema,NULOJIX were anemia diarrhea urinary,0
NULOJIX,peripheral edema,graft dysfunction cough,0
NULOJIX,peripheral edema,peripheral edema constipation,1
NULOJIX,peripheral edema,graft dysfunction cough,0
NULOJIX,peripheral edema,diarrhea urinary tract peripheral,1
NULOJIX,peripheral edema,cough nausea,0
NULOJIX,peripheral edema,urinary tract infection,0
NULOJIX,peripheral edema,cough nausea vomiting headache,0
NULOJIX,constipation,constipation hypertension pyrexia,1
NULOJIX,constipation,constipation hypertension,1
NULOJIX,constipation,infection peripheral constipation hypertension pyrexia graft,1
NULOJIX,constipation,constipation hypertension,1
NULOJIX,constipation,constipation hypertension pyrexia graft dysfunction,1
NULOJIX,constipation,constipation hypertension pyrexia graft,1
NULOJIX,constipation,constipation hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,infection peripheral edema hypertension pyrexia graft dysfunction cough nausea,1
NULOJIX,hypertension,constipation hypertension pyrexia graft dysfunction,1
NULOJIX,hypertension,edema,0
NULOJIX,hypertension,hypertension pyrexia,1
NULOJIX,pyrexia,pyrexia graft dysfunction,1
NULOJIX,pyrexia,hypertension pyrexia,1
NULOJIX,pyrexia,hyperkalemia and,0
NULOJIX,pyrexia,pyrexia graft dysfunction cough nausea,1
NULOJIX,pyrexia,urinary tract infection,0
NULOJIX,pyrexia,pyrexia graft dysfunction cough,1
NULOJIX,pyrexia,LOJIX were anemia diarrhea urinary tract infection peripheral edema,0
NULOJIX,pyrexia,LOJIX were anemia diarrhea urinary tract infection peripheral edema constipation hypertension,0
NULOJIX,pyrexia,pyrexia graft dysfunction cough,1
NULOJIX,pyrexia,were,0
NULOJIX,pyrexia,pyrexia graft dysfunction cough nausea,1
NULOJIX,graft dysfunction,edema,0
NULOJIX,graft dysfunction,graft,1
NULOJIX,cough,cough nausea vomiting,1
NULOJIX,cough,dysfunction,0
NULOJIX,cough,hyperkalemia,0
NULOJIX,cough,hypertension pyrexia graft cough nausea,1
NULOJIX,cough,hyperkalemia,0
NULOJIX,cough,pyrexia graft cough nausea vomiting headache,1
NULOJIX,cough,hyperkalemia,0
NULOJIX,cough,graft cough nausea,1
NULOJIX,cough,hyperkalemia,0
NULOJIX,cough,and leukopenia The proportion,0
NULOJIX,cough,pyrexia,0
NULOJIX,cough,cough,1
NULOJIX,cough,The proportion of,0
NULOJIX,nausea,vomiting,0
NULOJIX,nausea,infection peripheral,0
NULOJIX,nausea,nausea vomiting headache hypokalemia,1
NULOJIX,nausea,nausea vomiting headache,1
NULOJIX,nausea,nausea vomiting headache hypokalemia,1
NULOJIX,nausea,nausea vomiting headache,1
NULOJIX,nausea,nausea vomiting headache hypokalemia hyperkalemia,1
NULOJIX,nausea,headache hypokalemia hyperkalemia and leukopenia The proportion of patients,0
NULOJIX,nausea,nausea vomiting headache hypokalemia hyperkalemia and,1
NULOJIX,vomiting,vomiting,1
NULOJIX,vomiting,headache hypokalemia,0
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia,1
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia and leukopenia,1
NULOJIX,vomiting,vomiting headache hypokalemia hyperkalemia,1
NULOJIX,vomiting,vomiting headache,1
NULOJIX,vomiting,patients who,0
NULOJIX,vomiting,vomiting headache,1
NULOJIX,vomiting,cough vomiting headache hypokalemia hyperkalemia and leukopenia,1
NULOJIX,vomiting,vomiting headache,1
NULOJIX,vomiting,graft dysfunction cough vomiting,1
NULOJIX,vomiting,vomiting headache,1
NULOJIX,headache,of patients who,0
NULOJIX,headache,pyrexia graft,0
NULOJIX,headache,headache hypokalemia,1
NULOJIX,headache,dysfunction cough nausea headache hypokalemia hyperkalemia and leukopenia,1
NULOJIX,headache,headache hypokalemia,1
NULOJIX,headache,The proportion of patients who discontinued,0
NULOJIX,headache,headache,1
NULOJIX,headache,headache hypokalemia hyperkalemia and leukopenia,1
NULOJIX,headache,headache,1
NULOJIX,headache,dysfunction cough nausea headache hypokalemia hyperkalemia and leukopenia,1
NULOJIX,headache,headache,1
NULOJIX,headache,who discontinued treatme,0
NULOJIX,hypokalemia,headache,0
NULOJIX,hypokalemia,leukopenia The proportion of patients who discontinued treatment due to adv,0
NULOJIX,hypokalemia,dysfunction cough nausea vomiting hypokalemia hyperkalemia,1
NULOJIX,hypokalemia,leukopenia The proportion of patients who discontinued treatment due to adv,0
NULOJIX,hyperkalemia,hyperkalemia and leukopenia The,1
NULOJIX,hyperkalemia,hyperkalemia and leukopenia,1
NULOJIX,hyperkalemia,hyperkalemia and leukopenia The proportion of,1
NULOJIX,hyperkalemia,treatment due to,0
NULOJIX,leukopenia,sion pyrexia graft dysfunction,0
NULOJIX,leukopenia,sion,0
NULOJIX,leukopenia,leukopenia,1
NULOJIX,leukopenia,sion,0
NULOJIX,leukopenia,headache hypokalemia hyperkalemia leukopenia The proportion of,1
NULOJIX,leukopenia,sion,0
NULOJIX,leukopenia,of patients who discontinued treatment due to adverse,0
NULOJIX,leukopenia,was,0
NULOJIX,leukopenia,dysfunction cough nausea vomiting headache hypokalemia hyperkalemia,0
NULOJIX,leukopenia,leukopenia The proportion of,1
NULOJIX,leukopenia,nausea,0
NULOJIX,leukopenia,leukopenia The proportion of patients who,1
NULOJIX,cytomegalovirus infection,cytomegalovirus infection and complications of transplanted kidney,1
NULOJIX,cytomegalovirus infection,leukopenia The proportion of patients who,1
NULOJIX,cytomegalovirus infection,to discontinuation in NULOJIXtreated,0
NULOJIX,cytomegalovirus infection,cytomegalovirus infection,1
NULOJIX,cytomegalovirus infection,cytomegalovirus infection,1
NULOJIX,cytomegalovirus infection,transplanted kidney,0
NULOJIX,cytomegalovirus infection,cytomegalovirus infection,1
NULOJIX,cytomegalovirus infection,most common adverse reactions leading to discontinuation in NULOJIXtreated patients,0
NULOJIX,cytomegalovirus infection,Information on selected,0
NULOJIX,complications of transplanted kidney,patients were cytomegalovirus infection complications of transplanted kidney,1
NULOJIX,complications of transplanted kidney,complications of transplanted kidney Information,1
NULOJIX,complications of transplanted kidney,patients were cytomegalovirus infection complications of transplanted kidney,1
NULOJIX,complications of transplanted kidney,infection complications of transplanted kidney Information on selected,1
NULOJIX,complications of transplanted kidney,patients were cytomegalovirus infection complications of transplanted kidney,1
NULOJIX,complications of transplanted kidney,clinical,0
NULOJIX,complications of transplanted kidney,Information on selected significant adverse reactions observed during clinical trials i,0
NULOJIX,complications of transplanted kidney,infection complications of,1
NULOJIX,complications of transplanted kidney,transplanted kidney,1
NULOJIX,complications of transplanted kidney,leading to discontinuation in NULOJIXtreated patients were cytomegalovirus,0
NULOJIX,complications of transplanted kidney,cytomegalovirus infection complications of transplanted kidney Information on selected significant adverse,1
NULOJIX,complications of transplanted kidney,leading to discontinuation in NULOJIXtreated patients were cytomegalovirus,0
NULOJIX,complications of transplanted kidney,patients were,0
NULOJIX,post-transplant lymphoproliferative disorder,Disorder Reported cases,0
NULOJIX,post-transplant lymphoproliferative disorder,PostTransplant Lymphoproliferative Disorder Reported cases of,0
NULOJIX,post-transplant lymphoproliferative disorder,of,0
NULOJIX,post-transplant lymphoproliferative disorder,were obtained for NULOJIX by,0
NULOJIX,post-transplant lymphoproliferative disorder,Disorder Reported cases post-transplant lymphoproliferative disorder PTLD up,1
NULOJIX,post-transplant lymphoproliferative disorder,were obtained for NULOJIX by,0
NULOJIX,post-transplant lymphoproliferative disorder,Lymphoproliferative Disorder Reported cases post-transplant lymphoproliferative disorder PTLD,1
NULOJIX,post-transplant lymphoproliferative disorder,were obtained for NULOJIX by,0
NULOJIX,post-transplant lymphoproliferative disorder,Reported cases post-transplant lymphoproliferative disorder PTLD up to months,1
NULOJIX,post-transplant lymphoproliferative disorder,were obtained for NULOJIX by,0
NULOJIX,PTLD,Lymphoproliferative Disorder,0
NULOJIX,PTLD,PTLD up to,1
NULOJIX,PTLD,Lymphoproliferative Disorder,0
NULOJIX,PTLD,PTLD up to months post,1
NULOJIX,PTLD,lymphoproliferative PTLD up to months post transplant,1
NULOJIX,PTLD,PTLD up to months post,1
NULOJIX,PTLD,for NULOJIX by pooling both dosage,0
NULOJIX,PTLD,PTLD up to months post,1
NULOJIX,PTLD,posttransplant lymphoproliferative PTLD up to months,1
NULOJIX,PTLD,PTLD up to months post,1
NULOJIX,PTLD,there were cases PTLD in EBV seropositive,1
NULOJIX,PTLD,PTLD up to months post,1
NULOJIX,PTLD,PTLD in EBV seropositive,1
NULOJIX,PTLD,PTLD in EBV seropositive patients and,1
NULOJIX,PTLD,PTLD,1
NULOJIX,PTLD,PTLD without,1
NULOJIX,PTLD,treated with,0
NULOJIX,PTLD,PTLD without,1
NULOJIX,PTLD,PTLD without CNS involvement All cases,1
NULOJIX,PTLD,PTLD without CNS involvement All cases,1
NULOJIX,PTLD,to,0
NULOJIX,PTLD,PTLD reported up to months,1
NULOJIX,PTLD,All cases PTLD reported,1
NULOJIX,PTLD,PTLD reported up to months,1
NULOJIX,PTLD,of,0
NULOJIX,PTLD,PTLD reported up to,1
NULOJIX,PTLD,PTLD reported up to,1
NULOJIX,PTLD,PTLD reported up to,1
NULOJIX,PTLD,PTLD reported up to,1
NULOJIX,PTLD,PTLD reported,1
NULOJIX,PTLD,PTLD reported up to months post,1
NULOJIX,PTLD,PTLD reported up,1
NULOJIX,PTLD,PTLD in patients,1
NULOJIX,PTLD,PTLD,1
NULOJIX,PTLD,PTLD Reported,1
NULOJIX,PTLD,Contraindications Table Summary PTLD,1
NULOJIX,PTLD,PTLD Reported,1
NULOJIX,PTLD,Contraindications Table Summary PTLD Reported in Studies and,1
NULOJIX,PTLD,PTLD Reported,1
NULOJIX,PTLD,Reported in Studies and Through Three,0
NULOJIX,PTLD,PTLD Reported in Studies,1
NULOJIX,PTLD,Reported in Studies and Through Three Years of Treatment NULOJIX No,0
NULOJIX,PTLD,PTLD compared to of,1
NULOJIX,PTLD,PTLD compared to of CMV seropositive,1
NULOJIX,PTLD,PTLD compared to of,1
NULOJIX,PTLD,PTLD compared to,1
NULOJIX,PTLD,EBV seropositive recipients tr,0
NULOJIX,PTLD,CMV seronegative,0
NULOJIX,PTLD,PTLD cases,1
NULOJIX,PTLD,regimen of NULOJIX three,0
NULOJIX,PTLD,dosage regimen,0
NULOJIX,PTLD,PTLD remains to be determined,1
NULOJIX,PTLD,a risk factor,0
NULOJIX,PTLD,PTLD,1
NULOJIX,PTLD,factor for,0
NULOJIX,PTLD,risk factor PTLD remains to be determined however,1
NULOJIX,PTLD,factor for,0
NULOJIX,PTLD,prescribing NULOJIX se,0
NULOJIX,Malignancies,were reported in Study,0
NULOJIX,Malignancies,Malignancies excluding nonmelanoma,1
NULOJIX,Malignancies,Malignancies,0
NULOJIX,Malignancies,skin cancer and PTLD were reported in Study and Study in,0
NULOJIX,non-melanoma skin cancer,skin cancer,1
NULOJIX,non-melanoma skin cancer,Precautions Other Malignancies Malignancies non-melanoma skin,1
NULOJIX,non-melanoma skin cancer,non-melanoma,1
NULOJIX,non-melanoma skin cancer,Other Malignancies Malignancies non-melanoma skin cancer and PTLD,1
NULOJIX,non-melanoma skin cancer,non-melanoma,1
NULOJIX,non-melanoma skin cancer,in Study and Study,0
NULOJIX,non-melanoma skin cancer,skin cancer and,1
NULOJIX,non-melanoma skin cancer,non-melanoma skin cancer,1
NULOJIX,PTLD,skin cancer PTLD were reported in,1
NULOJIX,PTLD,non-melanoma skin cancer,1
NULOJIX,PTLD,PTLD were,1
NULOJIX,PTLD,PTLD were reported in,1
NULOJIX,PTLD,utions,0
NULOJIX,PTLD,cancer PTLD were reported in Study,1
NULOJIX,PTLD,utions,0
NULOJIX,PTLD,PTLD were reported in Study and,1
NULOJIX,PTLD,PTLD were reported in Study and,1
NULOJIX,PTLD,excluding nonmelanoma skin,0
NULOJIX,PTLD,PTLD were reported,1
NULOJIX,PTLD,PTLD were reported in Study and,1
NULOJIX,Non-melanoma skin cancer,skin cancer was reported in of,1
NULOJIX,Non-melanoma skin cancer,with the cyclosporine control Non-melanoma skin cancer,1
NULOJIX,Non-melanoma skin cancer,with,0
NULOJIX,Non-melanoma skin cancer,Non-melanoma skin cancer was reported in of,1
NULOJIX,Non-melanoma skin cancer,skin cancer was reported,1
NULOJIX,fatal,fatal,1
NULOJIX,fatal,reported among,0
NULOJIX,fatal,progressive multifocal,0
NULOJIX,fatal,Multifocal Leukoencephalopathy Two,0
NULOJIX,progressive multifocal leukoencephalopathy,been reported among patients treated with a,0
NULOJIX,progressive multifocal leukoencephalopathy,and Precautions Progressive Multifocal Leukoencephalopathy,0
NULOJIX,progressive multifocal leukoencephalopathy,progressive multifocal leukoencephalopathy PML have,1
NULOJIX,progressive multifocal leukoencephalopathy,and Precautions Progressive Multifocal Leukoencephalopathy,0
NULOJIX,PML,PML have been,1
NULOJIX,PML,cases of progressive,0
NULOJIX,PML,PML have,1
NULOJIX,PML,of progressive multifocal leukoencephalopathy,0
NULOJIX,PML,PML have been reported among,1
NULOJIX,PML,ve Multifocal Leukoencephalopathy Two fatal cases of progressive multifocal,0
NULOJIX,PML,cases of progressive multifocal,0
NULOJIX,PML,PML have been,1
NULOJIX,PML,cases of progressive multifocal,0
NULOJIX,PML,PML have been,1
NULOJIX,PML,liver transplant,0
NULOJIX,PML,PML were reported,1
NULOJIX,PML,PML were,1
NULOJIX,PML,PML were reported,1
NULOJIX,PML,PML,1
NULOJIX,PML,PML were reported in patients treated,1
NULOJIX,PML,trial of,0
NULOJIX,infectious etiology,infectious etiology were reported based,1
NULOJIX,infectious etiology,clinical assessment,0
NULOJIX,infectious etiology,infectious etiology were reported based on clinical,1
NULOJIX,infectious etiology,Adverse reactions infectious,1
NULOJIX,infectious etiology,organisms for,0
NULOJIX,infectious etiology,reactions infectious etiology,1
NULOJIX,infectious etiology,Viral and,0
NULOJIX,infections,number infections serious infections and select,1
NULOJIX,infections,Viral and,0
NULOJIX,infections,patients treated,0
NULOJIX,infections,in patients treated wi,0
NULOJIX,infections,number of infections infections and select,1
NULOJIX,infections,in patients treated wi,0
NULOJIX,infections,infections and select infections,1
NULOJIX,infections,the NULOJIX,0
NULOJIX,infections,of infections,0
NULOJIX,infections,and infections with identified etiology reported in,1
NULOJIX,infections,of infections,0
NULOJIX,infections,etiology reported in patients treated with the NULOJIX recommended regimen or the,0
NULOJIX,infections,infections with,1
NULOJIX,infections,when provided by,0
NULOJIX,infections,serious infections and infections with,1
NULOJIX,infections,when provided by,0
NULOJIX,infections,select,0
NULOJIX,Fungal infections,patients,0
NULOJIX,Fungal infections,Fungal infections,1
NULOJIX,Fungal infections,Fungal infections were,1
NULOJIX,Fungal infections,to receiving cyclosporine,0
NULOJIX,Fungal infections,receiving NULOJIX compared to receiving cyclosporine,0
NULOJIX,Fungal infections,Fungal infections were reported,1
NULOJIX,Fungal infections,in Fungal,1
NULOJIX,Fungal infections,NULOJIX compared,0
NULOJIX,Fungal infections,in Fungal infections were reported in,1
NULOJIX,Fungal infections,NULOJIX compared,0
NULOJIX,mucocutaneous fungal infections,due to skin mucocutaneous fungal infections Tuberculosis and herpes infections,1
NULOJIX,mucocutaneous fungal infections,NULOJIX compared,0
NULOJIX,mucocutaneous fungal infections,cyclosporine primarily due,0
NULOJIX,mucocutaneous fungal infections,of,0
NULOJIX,mucocutaneous fungal infections,reported more frequently in patients receiving,0
NULOJIX,mucocutaneous fungal infections,to skin and,0
NULOJIX,herpes infections,fungal infections Tuberculosis herpes infections,1
NULOJIX,herpes infections,receiving cyclosporine primarily,0
NULOJIX,tuberculosis,but one NULOJIX patient lived in countries with a high prevalence,0
NULOJIX,tuberculosis,the patients who,0
NULOJIX,tuberculosis,rted more frequently in patients receiving NULOJIX than cyclosporine Of the,0
NULOJIX,tuberculosis,than,0
NULOJIX,tuberculosis,the patients who tuberculosis through years all,1
NULOJIX,tuberculosis,than,0
NULOJIX,tuberculosis,than cyclosporine Of,0
NULOJIX,tuberculosis,tuberculosis through years,1
NULOJIX,tuberculosis,tuberculosis through years,1
NULOJIX,Infections,Select Infections with,0
NULOJIX,Infections,Infections and,1
NULOJIX,Infections,Three Years of,0
NULOJIX,Infections,a high prevalence of tuberculosis see Warnings and,0
NULOJIX,Infections,Infections with Identified Etiology by Treatment,1
NULOJIX,Infections,Infections with Identified Etiology,1
NULOJIX,Infections,Infections with,1
NULOJIX,Infections,following One and Three Years of,0
NULOJIX,Infections,and Three Years of Treatment,0
NULOJIX,Infections,Overall Infections and Infections with Identified Etiology,1
NULOJIX,Infections,and Three Years of Treatment,0
NULOJIX,Infections,Table Overall Infections,0
NULOJIX,Infections,Table Overall Infections and Infections with Identified Etiology,1
NULOJIX,Infections,Table Overall Infections,0
NULOJIX,infections,reactions the,0
NULOJIX,infectious adverse reactions,fungal and other organisms infectious adverse,1
NULOJIX,death,in,0
NULOJIX,death,may be lifethreatening,0
NULOJIX,death,death or hospitalization or prolongation of,1
NULOJIX,death,or result in,0
NULOJIX,Infections,Infections not meeting,1
NULOJIX,Infections,are,0
NULOJIX,Infections,are considered nonserious BK virusassociated nephropathy was,0
NULOJIX,Infections,meeting these criteria are considered nonserious BK virusassociated nephropathy was re,0
NULOJIX,Infections,of,0
NULOJIX,Infections,Infections not meeting these criteria are,1
NULOJIX,Infections,of,0
NULOJIX,BK virus-associated nephropathy,reported in NULOJIX patients of which resulted in,0
NULOJIX,BK virus-associated nephropathy,BK virus-associated nephropathy was reported,1
NULOJIX,BK virus-associated nephropathy,virus-associated nephropathy was reported in NULOJIX,1
NULOJIX,BK virus-associated nephropathy,virus-associated nephropathy,1
NULOJIX,BK virus-associated nephropathy,existing,0
NULOJIX,herpes infections,discontinuation All infections,0
NULOJIX,herpes infections,treatment discontinuation All infections,0
NULOJIX,herpes infections,in graft,0
NULOJIX,herpes infections,nonserious and led to treatment discontinuation,0
NULOJIX,herpes infections,herpes infections were,1
NULOJIX,herpes infections,Year herpes infections,1
NULOJIX,herpes infections,graft loss by Year herpes infections,1
NULOJIX,herpes infections,and led to treatment discontinuation All,0
NULOJIX,herpes infections,discontinuation,0
NULOJIX,herpes infections,loss by Year herpes infections,1
NULOJIX,herpes infections,nonserious,0
NULOJIX,herpes infections,herpes infections were,1
NULOJIX,herpes infections,cyclosporine,0
NULOJIX,cryptococcal meningitis,cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,Infections Reported in the CNS Following three,0
NULOJIX,cryptococcal meningitis,Studies cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,cryptococcal meningitis was reported in,1
NULOJIX,cryptococcal meningitis,cryptococcal,1
NULOJIX,CNS infections,CNS infections including,1
NULOJIX,CNS infections,Studies and were reported to have developed,0
NULOJIX,CNS infections,case of Chagas encephalitis with,0
NULOJIX,CNS infections,with cryptococcal,0
NULOJIX,CNS infections,were reported to have CNS infections including cases of cryptococcal,1
NULOJIX,CNS infections,with cryptococcal,0
NULOJIX,CNS infections,to have CNS infections,1
NULOJIX,CNS infections,to have CNS infections including cases of,1
NULOJIX,CNS infections,to have CNS infections,1
NULOJIX,CNS infections,CNS infections including cases,1
NULOJIX,cryptococcal meningitis,cryptococcal meningitis one case of Chagas encephalitis,1
NULOJIX,cryptococcal meningitis,infections including cases cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,cryptococcal meningitis one case of Chagas encephalitis,1
NULOJIX,cryptococcal meningitis,cryptococcal meningitis one case of Chagas encephalitis,1
NULOJIX,cryptococcal meningitis,cryptococcal meningitis one case of Chagas encephalitis,1
NULOJIX,cryptococcal meningitis,one case of Chagas encephalitis,0
NULOJIX,cryptococcal meningitis,cases cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,encephalitis with cryptococcal meningitis one case of,0
NULOJIX,cryptococcal meningitis,cryptococcal meningitis one case,1
NULOJIX,Chagas encephalitis,meningitis one case Chagas encephalitis,1
NULOJIX,cryptococcal meningitis,encephalitis cryptococcal meningitis one case of cerebral,1
NULOJIX,cryptococcal meningitis,meningitis one case Chagas encephalitis,1
NULOJIX,cryptococcal meningitis,cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,of Chagas encephalitis cryptococcal meningitis one case of,1
NULOJIX,cryptococcal meningitis,cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,case of,0
NULOJIX,cryptococcal meningitis,cryptococcal,1
NULOJIX,cryptococcal meningitis,one case,0
NULOJIX,cryptococcal meningitis,cases of cryptococcal,0
NULOJIX,cryptococcal meningitis,of Chagas encephalitis cryptococcal meningitis,1
NULOJIX,cryptococcal meningitis,of Chagas encephalitis cryptococcal meningitis one,1
NULOJIX,cryptococcal meningitis,of Chagas encephalitis cryptococcal meningitis,1
NULOJIX,cerebral aspergillosis,cerebral aspergillosis one case of West,1
NULOJIX,cerebral aspergillosis,cerebral,1
NULOJIX,cerebral aspergillosis,one case of West Nile encephalitis and one case of PML discussed above,0
NULOJIX,cerebral aspergillosis,meningitis one case cerebral aspergillosis,1
NULOJIX,cerebral aspergillosis,cerebral aspergillosis,1
NULOJIX,PML,There were,0
NULOJIX,PML,PML discussed above Infusion Reactions There,1
NULOJIX,PML,There were,0
NULOJIX,PML,above Infusion,0
NULOJIX,PML,PML,1
NULOJIX,anaphylaxis,PML discussed above,0
NULOJIX,anaphylaxis,in,0
NULOJIX,anaphylaxis,case of PML discussed,0
NULOJIX,anaphylaxis,Studies and through three years,0
NULOJIX,anaphylaxis,discussed above Infusion Reactions There were no reports,0
NULOJIX,anaphylaxis,anaphylaxis,1
NULOJIX,anaphylaxis,discussed above Infusion Reactions There were no reports,0
NULOJIX,anaphylaxis,anaphylaxis or drug hypersensitivity in patients,1
NULOJIX,anaphylaxis,anaphylaxis or drug hypersensitivity in patients,1
NULOJIX,anaphylaxis,anaphylaxis or,1
NULOJIX,anaphylaxis,anaphylaxis or drug hypersensitivity in patients,1
NULOJIX,drug hypersensitivity,or,0
NULOJIX,drug hypersensitivity,anaphylaxis drug,1
NULOJIX,drug hypersensitivity,reports,0
NULOJIX,drug hypersensitivity,three years,0
NULOJIX,drug hypersensitivity,drug hypersensitivity,1
NULOJIX,drug hypersensitivity,no reports of anaphylaxis drug hypersensitivity in patients,1
NULOJIX,drug hypersensitivity,drug hypersensitivity,1
NULOJIX,drug hypersensitivity,Reactions,0
NULOJIX,drug hypersensitivity,drug hypersensitivity in patients treated,1
NULOJIX,drug hypersensitivity,drug hypersensitivity in patients treated with NULOJIX,1
NULOJIX,drug hypersensitivity,drug hypersensitivity in patients treated with,1
NULOJIX,Infusion-related reactions,Infusion-related reactions,1
NULOJIX,Infusion-related reactions,and through three Infusion-related reactions within,1
NULOJIX,Infusion-related reactions,Infusion-related reactions,1
NULOJIX,Infusion-related reactions,through three Infusion-related reactions within one hour of infusion,1
NULOJIX,Infusion-related reactions,Infusion-related reactions,1
NULOJIX,Infusion-related reactions,through three Infusion-related reactions,1
NULOJIX,Infusion-related reactions,Infusion-related reactions,1
NULOJIX,Infusion-related reactions,within,0
NULOJIX,Infusion-related reactions,recommended,0
NULOJIX,Infusion-related reactions,infusion were reported in of patients treated with the recommended dose,0
NULOJIX,Infusion-related reactions,Infusion-related reactions within one,1
NULOJIX,Infusion-related reactions,infusion were reported in of patients treated with the recommended dose,0
NULOJIX,hypotension,hypotension and hypertension Proteinuria,1
NULOJIX,hypotension,Year The most frequent reactions,0
NULOJIX,proteinuria,the frequency proteinuria,1
NULOJIX,proteinuria,Year The most frequent reactions,0
NULOJIX,proteinuria,frequency proteinuria on urine dipstick,1
NULOJIX,proteinuria,Year The most frequent reactions,0
NULOJIX,proteinuria,on urine dipstick in,0
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,Studies and the frequency proteinuria on urine,1
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,ars after transplantation in,0
NULOJIX,proteinuria,The clinical,0
NULOJIX,proteinuria,occurrence proteinuria in both,1
NULOJIX,proteinuria,The clinical,0
NULOJIX,proteinuria,occurrence of,0
NULOJIX,proteinuria,occurrence proteinuria,1
NULOJIX,proteinuria,occurrence of,0
NULOJIX,proteinuria,proteinuria in,1
NULOJIX,proteinuria,proteinuria,1
NULOJIX,proteinuria,differences in the occurrence,0
NULOJIX,proteinuria,in the occurrence,0
NULOJIX,proteinuria,proteinuria The clinical,1
NULOJIX,proteinuria,both studies at any,0
NULOJIX,proteinuria,proteinuria The,1
NULOJIX,early proteinuria,early proteinuria is unknown Immunogenicity Antibodies,1
NULOJIX,early proteinuria,this increase early proteinuria,1
NULOJIX,early proteinuria,early proteinuria is unknown Immunogenicity Antibodies,1
NULOJIX,early proteinuria,against,0
NULOJIX,early proteinuria,of this increase early proteinuria,1
NULOJIX,early proteinuria,and no patients experienced,0
NULOJIX,new-onset diabetes after transplantation,Transplantation The incidence new-onset diabetes after transplantation,1
NULOJIX,new-onset diabetes after transplantation,diabetes after transplantation NODAT was defined in Studies,1
NULOJIX,NODAT,in,0
NULOJIX,NODAT,NODAT by the end of one,1
NULOJIX,NODAT,NULOJIX,0
NULOJIX,NODAT,year compared to of patients on the cyclosporine control regimen Ho,0
NULOJIX,NODAT,NODAT by the end,1
NULOJIX,NODAT,year compared to of patients on the cyclosporine control regimen Ho,0
NULOJIX,NODAT,NODAT by the end,1
NULOJIX,NODAT,NODAT by the end,1
NULOJIX,NODAT,NULOJIX recommended regimen NODAT by the end,1
NULOJIX,NODAT,NODAT by the end,1
NULOJIX,NODAT,NODAT by,1
NULOJIX,NODAT,NODAT by the,1
NULOJIX,NODAT,NULOJIX recommended regimen NODAT by the end of,1
NULOJIX,NODAT,NODAT by the,1
NULOJIX,NODAT,patients treated with,0
NULOJIX,NODAT,NODAT was,1
NULOJIX,NODAT,NULOJIX recommended regimen and in,0
NULOJIX,NODAT,NODAT was,1
NULOJIX,NODAT,incidence NODAT was in patients treated with,1
NULOJIX,NODAT,NODAT was,1
NULOJIX,Hypertension,Hypertension was reported as an,1
NULOJIX,Hypertension,Hypertension was reported as an,1
NULOJIX,Hypertension,were mmHg lower in NULOJIXtreated patients compared,0
NULOJIX,Hypertension,and,0
NULOJIX,Hypertension,compared to cyclosporinetreated Hypertension,1
NULOJIX,Hypertension,and,0
NULOJIX,Urinary tract infection,d Urinary,1
NULOJIX,Guillain-Barre syndrome,Infestations see Table,0
NULOJIX,Guillain-Barre syndrome,listed below Immune System Guillain-Barre,1
NULOJIX,stomatitis,see Table Gastrointestinal stomatitis including,1
NULOJIX,stomatitis,listed below Immune System Guillain-Barre,1
NULOJIX,stomatitis,Disorders,0
NULOJIX,stomatitis,stomatitis including aphthous,1
NULOJIX,stomatitis,stomatitis including aphthous stomatitis Injury,1
NULOJIX,stomatitis,Complications,0
NULOJIX,stomatitis,stomatitis including aphthous,1
NULOJIX,stomatitis,stomatitis including aphthous,1
NULOJIX,stomatitis,stomatitis,1
NULOJIX,aphthous stomatitis,including,0
NULOJIX,aphthous stomatitis,aphthous stomatitis Injury Poisoning and,1
NULOJIX,aphthous stomatitis,aphthous stomatitis,1
NULOJIX,aphthous stomatitis,aphthous stomatitis,1
NULOJIX,chronic allograft nephropathy,chronic allograft,1
NULOJIX,chronic allograft nephropathy,Injury Poisoning and Procedural chronic allograft nephropathy complications of transplanted,1
NULOJIX,chronic allograft nephropathy,chronic allograft,1
NULOJIX,complications of transplanted kidney,complications of transplanted kidney including wound dehiscence,1
NULOJIX,complications of transplanted kidney,Complications chronic,0
NULOJIX,complications of transplanted kidney,complications of transplanted kidney including wound dehiscence arteriovenous fistula,1
NULOJIX,complications of transplanted kidney,complications of transplanted kidney,1
NULOJIX,complications of transplanted kidney,complications of transplanted kidney,1
NULOJIX,complications of transplanted kidney,complications of transplanted kidney,1
NULOJIX,complications of transplanted kidney,complications of,1
NULOJIX,wound dehiscence,complications of transplanted,0
NULOJIX,wound dehiscence,Lymphatic System,0
NULOJIX,arteriovenous fistula thrombosis,allograft nephropathy complications of transplanted kidney including wound,0
NULOJIX,arteriovenous fistula thrombosis,and,0
NULOJIX,arteriovenous fistula thrombosis,arteriovenous fistula thrombosis,1
NULOJIX,neutropenia,renal failure renal artery s,0
NULOJIX,neutropenia,renal impairment including acute renal failure renal artery,0
NULOJIX,neutropenia,Urinary Disorders renal impairment including acute renal failure renal artery s,0
NULOJIX,neutropenia,Blood and Lymphatic System neutropenia Renal and Urinary Disorders,1
NULOJIX,neutropenia,Urinary Disorders renal impairment including acute renal failure renal artery s,0
NULOJIX,neutropenia,neutropenia Renal and,1
NULOJIX,neutropenia,Urinary Disorders renal impairment including acute renal failure renal artery s,0
NULOJIX,neutropenia,neutropenia Renal and Urinary,1
NULOJIX,neutropenia,neutropenia Renal and Urinary Disorders renal,1
NULOJIX,neutropenia,neutropenia Renal and Urinary,1
NULOJIX,neutropenia,neutropenia,1
NULOJIX,neutropenia,Disorders renal impairment including acute renal failure renal artery,0
NULOJIX,neutropenia,ing wound dehiscence arteriovenous,0
NULOJIX,renal impairment,Urinary,0
NULOJIX,renal artery stenosis,renal renal artery stenosis urinary incontinence hydronephrosis Vascular Disorders,1
NULOJIX,renal artery stenosis,Urinary,0
NULOJIX,renal artery stenosis,renal artery stenosis urinary,1
NULOJIX,renal artery stenosis,including acute renal renal artery stenosis urinary incontinence,1
NULOJIX,renal artery stenosis,renal artery stenosis urinary,1
NULOJIX,urinary incontinence,hydronephrosis Vascular,0
NULOJIX,urinary incontinence,failure renal artery urinary incontinence,1
NULOJIX,urinary incontinence,hydronephrosis,0
NULOJIX,urinary incontinence,hematoma lymphocele Musculoskeletal and,0
NULOJIX,urinary incontinence,urinary incontinence hydronephrosis Vascular,1
NULOJIX,urinary incontinence,renal artery urinary,1
NULOJIX,hydronephrosis,stenosis urinary hydronephrosis Vascular,1
NULOJIX,hydronephrosis,renal artery urinary,1
NULOJIX,hydronephrosis,artery stenosis urinary hydronephrosis Vascular Disorders hematoma lymphocele Musculoskeletal,1
NULOJIX,hydronephrosis,renal artery urinary,1
NULOJIX,hydronephrosis,hydronephrosis Vascular Disorders hematoma lymphocele Musculoskeletal,1
NULOJIX,hydronephrosis,Disorders hematoma lymphocele Musculoskeletal,0
NULOJIX,hydronephrosis,hydronephrosis Vascular Disorders hematoma lymphocele Musculoskeletal,1
NULOJIX,lymphocele,hydronephrosis,0
NULOJIX,lymphocele,lymphocele,1
NULOJIX,lymphocele,incontinence hydronephrosis Vascular Disorders lymphocele Musculoskeletal,1
NULOJIX,lymphocele,lymphocele,1
NULOJIX,lymphocele,and Connective Tissue Disorders musculoskeletal pain Skin and,0
NULOJIX,lymphocele,lymphocele Musculoskeletal and Connective Tissue Disorders,1
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal,1
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal pain,1
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal,1
NULOJIX,musculoskeletal pain,Connective Tissue musculoskeletal pain Skin and Subcutaneous Tissue Disorders,1
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal,1
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal pain Skin and Subcutaneous,1
NULOJIX,musculoskeletal pain,and Connective Tissue musculoskeletal,1
NULOJIX,musculoskeletal pain,Connective Tissue,0
NULOJIX,musculoskeletal pain,hyperhidrosis Cardiac Disorders at,0
NULOJIX,musculoskeletal pain,musculoskeletal pain Skin and Subcutaneous,1
NULOJIX,alopecia,alopecia hyperhidrosis Cardiac Disorders atrial,1
NULOJIX,alopecia,hyperhidrosis Cardiac Disorders atrial,0
NULOJIX,alopecia,Skin and Subcutaneous Tissue alopecia hyperhidrosis Cardiac Disorders,1
NULOJIX,alopecia,hyperhidrosis Cardiac Disorders atrial,0
NULOJIX,hyperhidrosis,Cardiac,0
NULOJIX,hyperhidrosis,Cardiac Disorders atrial fibrillation,0
NULOJIX,hyperhidrosis,hyperhidrosis Cardiac,1
NULOJIX,hyperhidrosis,hyperhidrosis,1
NULOJIX,hyperhidrosis,Disorders atrial fibrillation,0
NULOJIX,hyperhidrosis,hyperhidrosis Cardiac Disorders,1
NULOJIX,hyperhidrosis,hyperhidrosis Cardiac Disorders atrial fibrillation,1
NULOJIX,hyperhidrosis,hyperhidrosis Cardiac,1
NULOJIX,hyperhidrosis,hyperhidrosis,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,most serious adverse reactions reported wit h NULOJIX are PTLD,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,The,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, most serious adverse reactions reported wit h,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,The,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,ADVERSE REACTIONS most serious adverse reactions,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,REACTIONS most serious adverse reactions reported wit,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,predominantly CNS,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,REACTIONS most serious adverse reactions reported wit,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,h,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,most,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,reactions reported wit h NULOJIX are,1
NULOJIX,MALIGNANCIES,"reactions reported with X are:



 * PTLD predominantly CNS PTLD",1
NULOJIX,MALIGNANCIES,reactions reported wit h NULOJIX are,1
NULOJIX,MALIGNANCIES,reported with X are:,1
NULOJIX,MALIGNANCIES,adverse reactions reported with,0
NULOJIX,MALIGNANCIES,other malignancies see Boxed Warning,0
NULOJIX,MALIGNANCIES,malignancies see Boxed Warning and Warnings and,0
NULOJIX,MALIGNANCIES,CNS PTLD and other malignancies see Boxed Warning,0
NULOJIX,MALIGNANCIES,"reactions reported with X are:



 * PTLD predominantly CNS PTLD and",1
NULOJIX,MALIGNANCIES,CNS PTLD and other malignancies see Boxed Warning,0
NULOJIX,INFECTIONS,ominantly  CNS PTLD,1
NULOJIX,INFECTIONS,ominantly  CNS PTLD,1
NULOJIX,INFECTIONS,ominantly  CNS,1
NULOJIX,INFECTIONS,ominantly  CNS PTLD,1
NULOJIX,INFECTIONS,ominantly  CNS PTLD,1
NULOJIX,INFECTIONS,ominantly  CNS PTLD and,1
NULOJIX,INFECTIONS,ominantly  CNS PTLD,1
NULOJIX,INFECTIONS,ominantly  CNS PTLD,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,CNS PTLD  other malignancies [see   Boxed Warning   a,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,ominantly  CNS PTLD,1
NULOJIX,INFECTIONS,", 5.3) Serious infections including",1
NULOJIX,INFECTIONS,Boxed Warning and,0
NULOJIX,INFECTIONS,polyoma virus nephropathy see,0
NULOJIX,INFECTIONS,and Warnings and Precautions,0
NULOJIX,INFECTIONS,"  ,  5.3)  Serious infections",1
NULOJIX,INFECTIONS,and Warnings and Precautions,0
NULOJIX,INFECTIONS,"Warning and Warnings and ,",1
NULOJIX,INFECTIONS,"and ,",1
NULOJIX,INFECTIONS,", 5.3) Serious infections including",1
NULOJIX,INFECTIONS,Serious infections including JC virusassociated PML and polyoma virus nephropathy,0
NULOJIX,post-transplant lymphoproliferative disorder,ding JC virus-associated PML and polyoma,1
NULOJIX,post-transplant lymphoproliferative disorder,polyoma vir us nephropathy see Warnings and,1
NULOJIX,post-transplant lymphoproliferative disorder,Warning and Warnings and Precautions Serious infections inclu,0
NULOJIX,post-transplant lymphoproliferative disorder,and Precautions EXCERPT,0
NULOJIX,post-transplant lymphoproliferative disorder,infections ding JC virus-associated,1
NULOJIX,post-transplant lymphoproliferative disorder,PML and polyoma vir us nephropathy see,1
NULOJIX,post-transplant lymphoproliferative disorder,Serious infections ding JC virus-associated PML and polyoma vir us nephropathy see,1
NULOJIX,post-transplant lymphoproliferative disorder,PML and polyoma vir us nephropathy see,1
NULOJIX,post-transplant lymphoproliferative disorder,Warnings and Precautions Serious,0
NULOJIX,PTLD, nep hropathy see Warnings and Precautions,1
NULOJIX,PTLD,see Warnings and Precautions EXCERPT Most,0
NULOJIX,PTLD,hropathy see Warnings,0
NULOJIX,PTLD, nep hropathy see Warnings,1
NULOJIX,PTLD, nep hropathy see Warnings and,1
NULOJIX,PTLD, nep hropathy see Warnings,1
NULOJIX,PTLD, nep hropathy see,1
NULOJIX,PTLD, nep hropathy see,1
NULOJIX,PTLD, nep hropathy see Warnings,1
NULOJIX,PTLD, nep hropathy see,1
NULOJIX,PTLD, nep hropathy,1
NULOJIX,PTLD, nep hropathy see Warnings,1
NULOJIX,Increased susceptibility to infection,a total of patients t,0
NULOJIX,Increased susceptibility to infection,Administration in a total  patients compared to a cyclosporine  control,1
NULOJIX,Increased susceptibility to infection,a total of patients t,0
NULOJIX,Increased susceptibility to infection,Administration in a total  patients compared to a cyclosporine  control,1
NULOJIX,Increased susceptibility to infection,a total of patients t,0
NULOJIX,Increased susceptibility to infection,total patients compared to a cyclosporine,1
NULOJIX,Increased susceptibility to infection,a total  patients compared to a cyclosporine  control regimen in a,1
NULOJIX,Increased susceptibility to infection,total patients compared to a cyclosporine,1
NULOJIX,Increased susceptibility to infection,frequency see Dosage,0
NULOJIX,Increased susceptibility to infection,in a total patients,1
NULOJIX,malignancies,in a total patients. T,1
NULOJIX,malignancies,patients. T hese two trials also,1
NULOJIX,malignancies,patients. T,1
NULOJIX,malignancies,patients. T hese two,1
NULOJIX,malignancies,two trials also included,0
NULOJIX,malignancies,regimen in a total patients.,1
NULOJIX,malignancies,regimen in a total patients. T,1
NULOJIX,malignancies,in a total patients.,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,"and corticosteroids ts were treated and followed for 3 years.


 CNS PTLD PML and",1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,in a total patients.,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,mycophenolate mofetil and,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,"ts were treated and followed for 3 years.


 CNS PTLD PML",1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,mycophenolate mofetil and,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,All patients also,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,PTLD PML and other CNS infections were more frequently observed in association,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,All,0
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,followed for 3 years. CNS,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,and corticosteroids ts were treated and followed for,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,"ts were treated and followed for 3 years.


 CNS PTLD PML",1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,and corticosteroids ts were treated and followed for,1
NULOJIX,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER,ts were treated and followed for 3 years.,1
NULOJIX,MALIGNANCIES,"LD, PML, and other CNS",1
NULOJIX,MALIGNANCIES,"LD, PML, and other",1
NULOJIX,MALIGNANCIES,frequently observed in association with a,0
NULOJIX,MALIGNANCIES,"LD, PML, and other CNS infections were",1
NULOJIX,MALIGNANCIES,frequently observed in association with a,0
NULOJIX,MALIGNANCIES,"years CNS LD, PML, and",1
NULOJIX,MALIGNANCIES,"LD, PML, and other CNS infections were",1
NULOJIX,MALIGNANCIES,"CNS LD, PML, and other CNS",1
NULOJIX,MALIGNANCIES,"LD, PML, and other CNS infections were",1
NULOJIX,MALIGNANCIES,were more frequently observed in association with a NULOJIX,0
NULOJIX,MALIGNANCIES,in association,0
NULOJIX,INFECTIONS,ections we re more frequently,1
NULOJIX,INFECTIONS,ections we re more frequently,1
NULOJIX,INFECTIONS,PML and other CNS ections we re more frequently,1
NULOJIX,INFECTIONS,ections we re more frequently,1
NULOJIX,INFECTIONS,PML and other CNS ections we re more frequently observed,1
NULOJIX,INFECTIONS,ections we re more frequently,1
NULOJIX,INFECTIONS,NULOJIX regimen of higher cumulative dose and,0
NULOJIX,post-transplant lymphoproliferative disorder,to the recommended regimen; t,1
NULOJIX,PTLD,more,0
NULOJIX,PTLD,refo,1
NULOJIX,PTLD,NULOJIX is,0
NULOJIX,PTLD,the recommended regimen refo re,1
NULOJIX,PTLD,NULOJIX is,0
NULOJIX,PTLD,dosing compared,0
NULOJIX,PTLD,refo re,1
NULOJIX,Increased susceptibility to infection,from the d States and 75% from other countries Because clinical trials are conducted,1
NULOJIX,Increased susceptibility to infection,refo re,1
NULOJIX,Increased susceptibility to infection,conducted under widely varying conditions the adverse,0
NULOJIX,Increased susceptibility to infection,d States and 75% from other countries Because clinical,1
NULOJIX,malignancies,trials are,0
NULOJIX,malignancies,conducted u nder,1
NULOJIX,malignancies,nder widely varying conditions the adverse reaction rates observed cannot be directly,0
NULOJIX,malignancies,trials conducted,1
NULOJIX,malignancies,Because clinical trials conducted u,1
NULOJIX,malignancies,directly,0
NULOJIX,malignancies,trials conducted,1
NULOJIX,Post-Transplant Lymphoproliferative Disorder,with NULOJIX are: * P TLD predominantly,1
NULOJIX,PTLD,"with NULOJIX are D, p",1
NULOJIX,PTLD,with NULOJIX are: * P TLD predominantly,1
NULOJIX,PTLD,"with NULOJIX are D, p redominantly",1
NULOJIX,PTLD,with NULOJIX are: * P TLD predominantly,1
NULOJIX,PTLD,"NULOJIX are D, p",1
NULOJIX,PTLD,with NULOJIX are: * P TLD predominantly,1
NULOJIX,PTLD,"D, p",1
NULOJIX,malignancies, nephropathy,1
NULOJIX,malignancies,polyoma,0
NULOJIX,malignancies,including JC virusassociated PML and polyoma virus,0
NULOJIX,malignancies, nephropathy see Warnings and Precautions,1
NULOJIX,malignancies,polyoma virus,0
NULOJIX,malignancies,and Precautions EXCERPT,0
NULOJIX,malignancies, nephropathy see Warnings and Precautions,1
NULOJIX,malignancies, nephropathy see,1
NULOJIX,malignancies,and,0
NULOJIX,Progressive Multifocal Leukoencephalopathy,"are anemia diarrhea  tract infection, peripheral edema, consti pation hypertension pyrexia graft dysfunction",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,and,0
NULOJIX,Progressive Multifocal Leukoencephalopathy,"edema, consti pation hypertension pyrexia graft",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"tract infection, peripheral",1
NULOJIX,Progressive Multifocal Leukoencephalopathy," tract infection, peripheral edema, consti",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"tract infection, peripheral",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,cough nausea vomiting headache hypokalemia,0
NULOJIX,Progressive Multifocal Leukoencephalopathy,anemia diarrhea,0
NULOJIX,Progressive Multifocal Leukoencephalopathy,"anemia diarrhea tract infection, peripheral edema, consti",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"edema, consti",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"infection, peripheral edema, consti pation hypertension pyrexia graft dysfunction",1
NULOJIX,Progressive Multifocal Leukoencephalopathy," tract infection, peripheral edema, consti",1
NULOJIX,Progressive Multifocal Leukoencephalopathy,"infection, peripheral edema, consti pation hypertension pyrexia graft dysfunction",1
NULOJIX,PML,nausea vomiting headache hypokalemia,0
NULOJIX,PML,tio n hypertension pyrexia graft,1
NULOJIX,PML,tio n hypertension pyrexia graft dysfunction,1
NULOJIX,PML,diarrhea urinary tract infection,0
NULOJIX,PML,edema constipa,0
NULOJIX,PML,treatment are anemia diarrhea urinary tract infection peripheral edema,0
NULOJIX,PML,tio n hypertension pyrexia graft,1
NULOJIX,PML,edema tio n,1
NULOJIX,PML,tio n hypertension pyrexia graft,1
NULOJIX,PML,infection peripheral edema tio n hypertension pyrexia graft,1
NULOJIX,PML,tio n hypertension pyrexia graft,1
NULOJIX,PML,tio n hypertension,1
NULOJIX,infections,Experience The data described belo,0
NULOJIX,infections,wwwfdagovmedwatch Clinical Studies Experience The data described belo,0
NULOJIX,infections,-FDA-1088 ,1
NULOJIX,infections,wwwfdagovmedwatch Clinical Studies Experience The data described belo,0
NULOJIX,infections,Squibb at,0
NULOJIX,infections,-FDA-1088  or,1
NULOJIX,infections,-FDA-1088 ,1
NULOJIX,infections,-FDA-1088 ,1
NULOJIX,infections,Clinical Studies,0
NULOJIX,infections,at or FDA at,0
NULOJIX,infections,-FDA-1088  or wwwfdagovmedwatch,1
NULOJIX,infections,at or FDA at,0
NULOJIX,protozoal infections,cal Studies Experien,1
NULOJIX,protozoal infections,at or FDA at,0
NULOJIX,protozoal infections,cal Studies Experien,1
NULOJIX,protozoal infections,wwwfdagovmedwatch cal,1
NULOJIX,protozoal infections,wwwfdagovmedwatch cal Studies Experien,1
NULOJIX,protozoal infections,wwwfdagovmedwatch cal,1
NULOJIX,protozoal infections,FDA at FDA or wwwfdagovmedwatch Clini,0
NULOJIX,protozoal infections,FDA at,0
NULOJIX,protozoal infections,Studies Experien ce The data described,1
NULOJIX,opportunistic infections,trials,0
NULOJIX,opportunistic infections,ta described below prima rily derive from two randomized,1
NULOJIX,opportunistic infections,trials,0
NULOJIX,opportunistic infections,trials of NULOJIX in,0
NULOJIX,opportunistic infections,below prima rily,1
NULOJIX,opportunistic infections,described below prima,1
NULOJIX,opportunistic infections,Experience The ta described below,1
NULOJIX,opportunistic infections,Clinical Studies Experience The ta described below prima rily,1
NULOJIX,opportunistic infections,Experience The ta described below,1
NULOJIX,tuberculosis,The data described below derive from,1
NULOJIX,tuberculosis,below derive from ,1
NULOJIX,tuberculosis,The data described below derive from,1
NULOJIX,tuberculosis,derive from two randomized activecontrolled threeyear trials,1
NULOJIX,tuberculosis,below derive,1
NULOJIX,tuberculosis,Experience The,0
NULOJIX,tuberculosis,data described below derive from,1
NULOJIX,infections,in,0
NULOJIX,infections,"derive from two domized, a ctivecontrolled threeyear trials",1
NULOJIX,infections,in,0
NULOJIX,infections,de novo kidney transplant patients In,0
NULOJIX,infections,trials of NULOJIX in de novo kidney transplant patients In Study,0
NULOJIX,infections,Experience,0
NULOJIX,infections,"domized, a",1
NULOJIX,infections,derive from two ran,0
NULOJIX,infections,data,0
NULOJIX,infections,kidney transplant patients In Study,0
NULOJIX,fatal,contr,1
NULOJIX,fatal,contr olled threeyear trials of NULOJIX,1
NULOJIX,fatal,derive from two randomized contr,1
NULOJIX,fatal,contr olled threeyear trials of NULOJIX,1
NULOJIX,Polyoma virus-associated nephropathy,Experience The data described below primarily derive,0
NULOJIX,Polyoma virus-associated nephropathy,below primarily derive from,0
NULOJIX,Polyoma virus-associated nephropathy,kidney transplant patients In Study and Study NULOJIX was studied at the recommended,0
NULOJIX,Polyoma virus-associated nephropathy,from two randomized led three-year,1
NULOJIX,kidney graft loss,activecontrolled threeyear trials of NULOJIX in de novo kid,0
NULOJIX,kidney graft loss,de novo ney transplant pa tients In Study and Study,1
NULOJIX,kidney graft loss,activecontrolled threeyear trials of NULOJIX in de novo kid,0
NULOJIX,kidney graft loss,threeyear trials of NULOJIX in de,0
NULOJIX,kidney graft loss,novo ney transplant,1
NULOJIX,kidney graft loss,novo ney transplant,1
NULOJIX,Graft Loss,ulative,1
NULOJIX,Graft Loss,ulative do se and more frequent dosing,1
NULOJIX,post-transplant lymphoproliferative disorder,and more frequent dosing compared to the r ecommended,1
NULOJIX,PTLD,omme nded regimen therefore administration of,1
NULOJIX,PTLD,higher,0
NULOJIX,PTLD,administration of higher than,0
NULOJIX,PTLD,omme,1
NULOJIX,PTLD,the,0
NULOJIX,PTLD,regimen therefore administration,0
NULOJIX,PTLD,may not reflect,0
NULOJIX,PTLD,ed c,1
NULOJIX,PTLD,ed c annot be directly compared to,1
NULOJIX,PTLD,ed c annot,1
NULOJIX,PTLD,ed c annot be directly compared to,1
NULOJIX,PTLD,use clinical trials are conducted under widely varying conditions the adverse,0
NULOJIX,PTLD,of PTLD in EBV seropositive,0
NULOJIX,PTLD,PTLD in,0
NULOJIX,PTLD,regimen of higher ativ e dose and more,1
NULOJIX,PTLD,PTLD in,0
NULOJIX,PTLD,ativ e dose and more frequent,1
NULOJIX,PTLD,ativ e,1
NULOJIX,PTLD,ativ e dose and more frequent,1
NULOJIX,PTLD,ativ e,1
NULOJIX,PML,patients treated with cyclosporine developed PTLD without CNS involvement,0
NULOJIX,PML,l c ases of PTLD,1
NULOJIX,PML,patients treated with cyclosporine developed PTLD without CNS involvement,0
NULOJIX,PVAN,Amo,0
NULOJIX,PVAN,Subpopulation Amo,0
NULOJIX,PVAN,Subpopulation ng,1
NULOJIX,PVAN,ng t he EBV seropositive,1
NULOJIX,PVAN,Seropositive Subpopulation ng t,1
NULOJIX,PVAN,ng t he EBV seropositive,1
NULOJIX,PVAN,EBV seropositive,0
NULOJIX,PVAN,ng,1
NULOJIX,deteriorating renal function,CMV seronegative patients deve,0
NULOJIX,deteriorating renal function,serostatus treated with eith er NULOJIX regimen,1
NULOJIX,deteriorating renal function,and,0
NULOJIX,deteriorating renal function,CMV seronegative,0
NULOJIX,deteriorating renal function,serostatus treated with eith er NULOJIX regimen in,1
NULOJIX,deteriorating renal function,seropositive patients with known serostatus treated with eith er NULOJIX regimen in Studies,1
NULOJIX,deteriorating renal function,serostatus treated with eith er NULOJIX regimen in,1
NULOJIX,deteriorating renal function,with eith er NULOJIX regimen in Studies,1
NULOJIX,deteriorating renal function,with known serostatus treated with eith er NULOJIX regimen,1
NULOJIX,deteriorating renal function,with eith er NULOJIX regimen in Studies,1
NULOJIX,graft loss,and Stu dy,1
NULOJIX,graft loss,1 and,1
NULOJIX,graft loss,1 and Stu dy in of patients treated,1
NULOJIX,graft loss,were reported in  1 and Stu dy,1
NULOJIX,graft loss,1 and Stu dy in of patients treated,1
NULOJIX,death,in Study and,0
NULOJIX,death,reported in Study and,0
NULOJIX,death,with,0
NULOJIX,death,Study and in,1
NULOJIX,death,in Study and in 3. of patients treated,1
NULOJIX,death,Study and in,1
NULOJIX,death,in 3.,1
NULOJIX,death,reported in Study and in 3.,1
NULOJIX,death,in 3. of,1
NULOJIX,PTLD, and of patients treated,1
NULOJIX,PTLD, and of patients treated,1
NULOJIX,PTLD, and of patients treated with the,1
NULOJIX,PTLD, and of patients treated,1
NULOJIX,PTLD, and,1
NULOJIX,PTLD,with the recommended NULOJIX  and,1
NULOJIX,PTLD, and,1
NULOJIX,fatal,skin cancer was,0
NULOJIX,fatal,patients treated ith,1
NULOJIX,fatal,treated ith t he cyclosporine,1
NULOJIX,fatal,patients treated ith,1
NULOJIX,fatal,patients,0
NULOJIX,fatal,and of patients treated ith t he cyclosporine control regimen Nonmelanoma,1
NULOJIX,fatal,patients,0
NULOJIX,fatal,ith t he cyclosporine control,1
NULOJIX,fatal,orine control regimen Nonmelanoma skin,1
NULOJIX,PML,reg,1
NULOJIX,PTLD,patients,0
NULOJIX,PTLD,of patients d,1
NULOJIX,PTLD,th the recommended NULOJIX regimen and in of patients treated,0
NULOJIX,PTLD,cancer was reported in of patients,0
NULOJIX,fatal,ted with cyclosporine,0
NULOJIX,fatal, trea ted with cyclosporine,1
NULOJIX,fatal, trea ted,1
NULOJIX,fatal,of patients,0
NULOJIX,fatal,in,0
NULOJIX,fatal, trea ted with cyclosporine see Warnings,1
NULOJIX,PML,in of patients treated cyc losporine see,1
NULOJIX,PML, trea ted with cyclosporine see Warnings,1
NULOJIX,PML,treated with,0
NULOJIX,PML,Warnings and Precautions Progressive,0
NULOJIX,PML,of patients treated cyc losporine see Warnings and,1
NULOJIX,PML,Warnings and Precautions Progressive,0
NULOJIX,PML,cyc losporine see Warnings and Precautions,1
NULOJIX,PML,patients treated with the recommended NULOJIX regimen and in of patients,0
NULOJIX,PML,in of patients treated cyc losporine,1
NULOJIX,PML,patients treated with the recommended NULOJIX regimen and in of patients,0
NULOJIX,PML,cyc losporine see Warnings and Precautions,1
NULOJIX,PML,patients treated with the recommended NULOJIX regimen and in of patients,0
NULOJIX,PML,Precautions Progressive Multifocal Leukoencephalopa,0
NULOJIX,PML,cyc losporine,1
NULOJIX,Graft loss,treated with the,0
NULOJIX,Graft loss,nt recipie nt was treated with,1
NULOJIX,Graft loss,treated with the,0
NULOJIX,Graft loss,nt recipie nt,1
NULOJIX,Graft loss,kidney nt recipie,1
NULOJIX,Graft loss,nt recipie nt,1
NULOJIX,Graft loss,trials The kidney nt recipie nt was treated,1
NULOJIX,Graft loss,nt recipie nt,1
NULOJIX,Graft loss,regimen or the control regimen in these trials The kidney transpla,0
GILOTRIF,Diarrhea,Diarrhea,1
GILOTRIF,Diarrhea,Diarrhea see Warnings and Precautions,1
GILOTRIF,Diarrhea,other sections of the Diarrhea see,1
GILOTRIF,Diarrhea,Diarrhea see Warnings and Precautions,1
GILOTRIF,Diarrhea,Diarrhea,1
GILOTRIF,Diarrhea,llowing adverse reactions are discussed in greater detail in other sections of the labeling,0
GILOTRIF,Diarrhea,Diarrhea,1
GILOTRIF,Diarrhea,Diarrhea,1
GILOTRIF,Diarrhea,Diarrhea,1
GILOTRIF,Exfoliative Skin Disorders,Warnings and Precautions,0
GILOTRIF,Exfoliative Skin Disorders,Bullous Exfoliative Skin Disorders see Warnings and Precautions,1
GILOTRIF,Exfoliative Skin Disorders,Warnings and Precautions,0
GILOTRIF,Exfoliative Skin Disorders,Precautions Bullous Exfoliative Skin,1
GILOTRIF,Exfoliative Skin Disorders,and Precautions Bullous Exfoliative Skin Disorders see,1
GILOTRIF,Exfoliative Skin Disorders,Precautions Bullous Exfoliative Skin,1
GILOTRIF,Exfoliative Skin Disorders,Precautions Bullous Exfoliative Skin Disorders see Warnings,1
GILOTRIF,Exfoliative Skin Disorders,Precautions Bullous Exfoliative Skin,1
GILOTRIF,Exfoliative Skin Disorders,Skin Disorders see,1
GILOTRIF,Exfoliative Skin Disorders,Warnings,0
GILOTRIF,Exfoliative Skin Disorders,Skin Disorders see Warnings and Precautions,1
GILOTRIF,Interstitial Lung Disease,Bullous and Exfoliative Skin Disorders see Warnings and,0
GILOTRIF,Interstitial Lung Disease,Precautions,0
GILOTRIF,Interstitial Lung Disease,Skin Disorders,0
GILOTRIF,Interstitial Lung Disease,Warnings and Precautions,0
GILOTRIF,Interstitial Lung Disease,Precautions Hepatic Toxicity see Warnings and Precautions,0
GILOTRIF,Interstitial Lung Disease,see,0
GILOTRIF,Hepatic Toxicity,Hepatic Toxicity,1
GILOTRIF,Hepatic Toxicity,see Warnings and Hepatic Toxicity see Warnings and Precautions,1
GILOTRIF,Hepatic Toxicity,Hepatic Toxicity,1
GILOTRIF,Hepatic Toxicity,and,0
GILOTRIF,Hepatic Toxicity,Keratitis see,0
GILOTRIF,Hepatic Toxicity,see Warnings and Hepatic Toxicity,1
GILOTRIF,Hepatic Toxicity,Keratitis see,0
GILOTRIF,Hepatic Toxicity,and Hepatic,1
GILOTRIF,Hepatic Toxicity,Keratitis see Warnings,0
GILOTRIF,Keratitis,Keratitis see Warnings and Precautions EXCERPT,1
GILOTRIF,Keratitis,Keratitis see Warnings and Precautions,1
GILOTRIF,Keratitis,Keratitis see Warnings and Precautions EXCERPT,1
GILOTRIF,Keratitis,Keratitis see Warnings and Precautions,1
GILOTRIF,Keratitis,Keratitis,1
GILOTRIF,Keratitis,and Keratitis see Warnings and Precautions EXCERPT,1
GILOTRIF,Keratitis,Keratitis,1
GILOTRIF,Keratitis,Precautions EXCERPT Most common adverse,0
GILOTRIF,Keratitis,Warnings,0
GILOTRIF,Keratitis,Warnings and Precautions EXCERPT Most common adverse,0
GILOTRIF,Keratitis,Precautions,0
GILOTRIF,Keratitis,and Precautions EXCERPT,0
GILOTRIF,diarrhea,diarrhea rashdermatitis acneiform stomatitis paronychia dry,1
GILOTRIF,diarrhea,decreased appetite nausea,0
GILOTRIF,diarrhea,common adverse reactions diarrhea rashdermatitis,1
GILOTRIF,diarrhea,decreased appetite nausea,0
GILOTRIF,diarrhea,diarrhea rashdermatitis acneiform stomatitis,1
GILOTRIF,diarrhea,diarrhea rashdermatitis acneiform stomatitis,1
GILOTRIF,diarrhea,diarrhea rashdermatitis,1
GILOTRIF,diarrhea,diarrhea rashdermatitis acneiform,1
GILOTRIF,diarrhea,see Warnings and Precautions,0
GILOTRIF,dermatitis acneiform,dermatitis acneiform stomatitis paronychia,1
GILOTRIF,dermatitis acneiform,are diarrhea rash,0
GILOTRIF,dermatitis acneiform,dermatitis acneiform,1
GILOTRIF,dermatitis acneiform,and Precautions EXCERPT Most common adverse reactions are diarrhea,0
GILOTRIF,dermatitis acneiform,nausea,0
GILOTRIF,paronychia,report SUSPECTED ADVERSE R,0
GILOTRIF,paronychia,To report SUSPECTED ADVERSE,0
GILOTRIF,paronychia,paronychia dry skin decreased appetite,1
GILOTRIF,paronychia,paronychia dry,1
GILOTRIF,paronychia,report SUSPECTED ADVERSE,0
GILOTRIF,paronychia,paronychia dry skin,1
GILOTRIF,paronychia,acneiform paronychia dry,1
GILOTRIF,paronychia,paronychia dry skin,1
GILOTRIF,paronychia,acneiform,0
GILOTRIF,dry skin,diarrhea rashdermatitis acneiform stomatitis dry skin decreased appetite nausea vomiting pruritus,1
GILOTRIF,dry skin,acneiform,0
GILOTRIF,dry skin,acneiform stomatitis paronychia,0
GILOTRIF,decreased appetite,pruritus To report SUSPECTED ADVERSE REACTIONS contact,0
GILOTRIF,decreased appetite,stomatitis paronychia dry decreased appetite,1
GILOTRIF,decreased appetite,REACTIONS contact Boehringer I,0
GILOTRIF,decreased appetite,report SUSPECTED ADVERSE REACTIONS contact,0
GILOTRIF,decreased appetite,acneiform stomatitis paronychia dry decreased,1
GILOTRIF,decreased appetite,acneiform stomatitis paronychia dry decreased appetite,1
GILOTRIF,decreased appetite,acneiform stomatitis paronychia dry decreased,1
GILOTRIF,decreased appetite,rashdermatitis,0
GILOTRIF,decreased appetite,acneiform stomatitis paronychia dry decreased appetite nausea,1
GILOTRIF,decreased appetite,rashdermatitis,0
GILOTRIF,decreased appetite,dry decreased appetite,1
GILOTRIF,decreased appetite,rashdermatitis,0
GILOTRIF,nausea,decreased nausea vomiting pruritus,1
GILOTRIF,nausea,rashdermatitis,0
GILOTRIF,nausea,skin decreased,0
GILOTRIF,nausea,vomiting pruritus To report SUSPECTED ADVERSE,0
GILOTRIF,nausea,nausea vomiting pruritus,1
GILOTRIF,nausea,vomiting pruritus To report SUSPECTED ADVERSE,0
GILOTRIF,nausea,paronychia dry skin decreased nausea vomiting pruritus To,1
GILOTRIF,nausea,vomiting pruritus To report SUSPECTED ADVERSE,0
GILOTRIF,nausea,SUSPECTED,0
GILOTRIF,nausea,nausea vomiting pruritus To,1
GILOTRIF,nausea,nausea vomiting pruritus To report SUSPECTED,1
GILOTRIF,vomiting,Boehringer Ingelheim Pharmaceu,0
GILOTRIF,vomiting,skin decreased appetite vomiting pruritus,1
GILOTRIF,vomiting,Boehringer Ingelheim Pharmaceu,0
GILOTRIF,vomiting,vomiting pruritus To report SUSPECTED,1
GILOTRIF,vomiting,To report SUSPECTED ADVERSE REACTIONS contact,0
GILOTRIF,vomiting,decreased appetite vomiting pruritus To report SUSPECTED,1
GILOTRIF,vomiting,To report SUSPECTED ADVERSE REACTIONS contact,0
GILOTRIF,vomiting,ADVERSE REACTIONS,0
GILOTRIF,vomiting,decreased appetite vomiting pruritus To,1
GILOTRIF,vomiting,ADVERSE REACTIONS,0
GILOTRIF,pruritus,pruritus To report,1
GILOTRIF,pruritus,SUSPECTED ADVERSE REACTIONS contact Boehringer Ingelheim Pharmaceuticals,0
GILOTRIF,pruritus,pruritus To report SUSPECTED ADVERSE REACTIONS,1
GILOTRIF,pruritus,acneiform stomatitis paronychia dry,0
GILOTRIF,pruritus,pruritus To,1
GILOTRIF,pruritus,pruritus To report SUSPECTED,1
GILOTRIF,pruritus,pruritus,1
GILOTRIF,pruritus,pruritus To report SUSPECTED ADVERSE,1
GILOTRIF,pruritus,acneiform stomatitis paronychia dry skin decreased,0
GILOTRIF,pruritus,pruritus To report SUSPECTED ADVERSE,1
GILOTRIF,pruritus,acneiform stomatitis paronychia dry skin decreased,0
GILOTRIF,diarrhea,adverse reactions reported in patients treated with,0
GILOTRIF,diarrhea,diarrhea vomiting,1
GILOTRIF,diarrhea,diarrhea vomiting and,1
GILOTRIF,diarrhea,diarrhea vomiting,1
GILOTRIF,diarrhea,with GILOTRIF diarrhea vomiting and,1
GILOTRIF,diarrhea,diarrhea vomiting,1
GILOTRIF,vomiting,vomiting,1
GILOTRIF,vomiting,treated with GILOTRIF were vomiting and dyspnea fatigue and hypokalemia,1
GILOTRIF,vomiting,vomiting,1
GILOTRIF,vomiting,hypokalemia each Fatal adverse reactions,0
GILOTRIF,vomiting,vomiting and dyspnea,1
GILOTRIF,vomiting,reactions in GILOTRIFtrea,0
GILOTRIF,vomiting,GILOTRIF were vomiting and dyspnea fatigue,1
GILOTRIF,vomiting,reactions in GILOTRIFtrea,0
GILOTRIF,vomiting,reactions reported,0
GILOTRIF,dyspnea,Fatal adverse,0
GILOTRIF,dyspnea,dyspnea fatigue and hypokalemia each,1
GILOTRIF,fatigue,fatigue and hypokalemia each Fatal,1
GILOTRIF,fatigue,fatigue and hypokalemia each Fatal,1
GILOTRIF,fatigue,fatigue and hypokalemia each Fatal,1
GILOTRIF,fatigue,fatigue,1
GILOTRIF,fatigue,fatigue and hypokalemia,1
GILOTRIF,fatigue,reactions in GILOTRIFtreated patients in,0
GILOTRIF,fatigue,and fatigue,1
GILOTRIF,fatigue,reactions in GILOTRIFtreated patients in,0
GILOTRIF,Fatal,and dyspnea fatigue and,0
GILOTRIF,Fatal,Fatal,1
GILOTRIF,Fatal,Fatal adverse reactions in,1
GILOTRIF,Fatal,pulmonary,0
GILOTRIF,Fatal,dyspnea fatigue,0
GILOTRIF,Fatal,dyspnea fatigue and hypokalemia Fatal adverse,1
GILOTRIF,Fatal,dyspnea fatigue,0
GILOTRIF,Fatal,each,0
GILOTRIF,Fatal,Fatal adverse reactions in,1
GILOTRIF,Fatal,Fatal adverse,1
GILOTRIF,ILD-like adverse reactions,pulmonary ILD-like adverse reactions,1
GILOTRIF,ILD-like adverse reactions,adverse reactions sepsis and pneumonia Dose,1
GILOTRIF,ILD-like adverse reactions,to adverse reactions were re,0
GILOTRIF,ILD-like adverse reactions,ILD-like adverse reactions sepsis and pneumonia Dose,1
GILOTRIF,ILD-like adverse reactions,pulmonary ILD-like,1
GILOTRIF,ILD-like adverse reactions,adverse reactions sepsis and pneumonia Dose,1
GILOTRIF,ILD-like adverse reactions,Dose reductions due to,0
GILOTRIF,ILD-like adverse reactions,in Study included pulmonary ILD-like,1
GILOTRIF,ILD-like adverse reactions,ILD-like adverse reactions sepsis and pneumonia,1
GILOTRIF,ILD-like adverse reactions,in Study included pulmonary ILD-like,1
GILOTRIF,sepsis,toxicityILDlike adverse sepsis and pneumonia Dose reductions due,1
GILOTRIF,sepsis,in Study included pulmonary ILD-like,1
GILOTRIF,sepsis,to adverse reactions,0
GILOTRIF,sepsis,reductions due to adverse,0
GILOTRIF,sepsis,adverse sepsis and pneumonia,1
GILOTRIF,sepsis,reductions due to adverse,0
GILOTRIF,sepsis,GILOTRIFtreated patients in Study included,0
GILOTRIF,sepsis,GILOTRIFtreated patients in,0
GILOTRIF,sepsis,sepsis and pneumonia,1
GILOTRIF,pneumonia,reactions sepsis pneumonia Dose,1
GILOTRIF,pneumonia,sepsis and pneumonia,1
GILOTRIF,pneumonia,and,0
GILOTRIF,pneumonia,pneumonia Dose reductions,1
GILOTRIF,pneumonia,pneumonia Dose,1
GILOTRIF,pneumonia,pneumonia,1
GILOTRIF,diarrhea,were,0
GILOTRIF,diarrhea,diarrhea rashacne paronychia and stomatitis,1
GILOTRIF,diarrhea,the,0
GILOTRIF,diarrhea,diarrhea,1
GILOTRIF,diarrhea,diarrhea rashacne paronychia and,1
GILOTRIF,diarrhea,diarrhea rashacne paronychia and stomatitis,1
GILOTRIF,rash,rash acne paronychia and stomatitis,1
GILOTRIF,rash,GILOTRIF,0
GILOTRIF,rash,with GILOTRIF were rash,1
GILOTRIF,rash,GILOTRIF,0
GILOTRIF,rash,rash acne paronychia and,1
GILOTRIF,rash,rash acne paronychia and stomatitis Discontinuation,1
GILOTRIF,rash,acne paronychia and stomatitis Discontinuation of therapy in,0
GILOTRIF,rash,rash,1
GILOTRIF,rash,and stomatitis Discontinuation of therapy,0
GILOTRIF,acne,acne paronychia and stomatitis Discontinuation,1
GILOTRIF,acne,acne paronychia and,1
GILOTRIF,acne,treated with GILOTRIF,0
GILOTRIF,acne,stomatitis Discontinuation of therapy in,0
GILOTRIF,paronychia,of,0
GILOTRIF,paronychia,diarrhea paronychia and stomatitis Discontinuation of therapy,1
GILOTRIF,paronychia,of,0
GILOTRIF,paronychia,Discontinuation of therapy in GILOTRIFtreated,0
GILOTRIF,paronychia,GILOTRIFtreated patients,0
GILOTRIF,paronychia,paronychia and stomatitis,1
GILOTRIF,paronychia,reduction in the patients treated with,0
GILOTRIF,paronychia,stomatitis Discontinuation of therapy in,0
GILOTRIF,paronychia,Discontinuation,0
GILOTRIF,paronychia,patients,0
GILOTRIF,stomatitis,stomatitis,1
GILOTRIF,stomatitis,of therapy in GILOTRIFtreated patients for adverse reactions was,0
GILOTRIF,stomatitis,for adverse,0
GILOTRIF,stomatitis,treated,0
GILOTRIF,stomatitis,stomatitis Discontinuation of,1
GILOTRIF,stomatitis,for,0
GILOTRIF,stomatitis,stomatitis,1
GILOTRIF,stomatitis,stomatitis Discontinuation,1
GILOTRIF,stomatitis,patients treated with GILOTRIF were diarrhea,0
GILOTRIF,stomatitis,were diarrhea,0
GILOTRIF,diarrhea,excluded patients with a,0
GILOTRIF,diarrhea,diarrhea ILD,1
GILOTRIF,diarrhea,diarrhea ILD,1
GILOTRIF,diarrhea,diarrhea ILD and paronychia,1
GILOTRIF,diarrhea,diarrhea ILD,1
GILOTRIF,diarrhea,in GILOTRIFtreated patients diarrhea ILD and paronychia Clinical,1
GILOTRIF,diarrhea,diarrhea ILD,1
GILOTRIF,ILD,that led to discontinuation in GILOTRIFtreated patients were diarrhea,0
GILOTRIF,ILD,ILD and paronychia Clinical trials of,1
GILOTRIF,ILD,Clinical,0
GILOTRIF,ILD,an abnormal,0
GILOTRIF,ILD,reactions that led to discontinuation in GILOTRIFtreated patients,0
GILOTRIF,paronychia,patients,0
GILOTRIF,paronychia,paronychia Clinical trials,1
GILOTRIF,paronychia,ILD and,0
GILOTRIF,ventricular dysfunction,More GILOTRIFtreated patients n ventricular,1
GILOTRIF,diastolic dysfunction,defined diastolic,1
GILOTRIF,diastolic dysfunction,or ventricular dilation all Grade compared,0
GILOTRIF,diastolic dysfunction,Grade compared to chemotherapytre,0
GILOTRIF,diastolic dysfunction,as,0
GILOTRIF,diastolic dysfunction,dilation all,0
GILOTRIF,diastolic dysfunction,diastolic dysfunction left ventricular dysfunction or ventricular,1
GILOTRIF,diastolic dysfunction,diastolic dysfunction,1
GILOTRIF,left ventricular dysfunction,left,1
GILOTRIF,left ventricular dysfunction,dysfunction defined as diastolic left,1
GILOTRIF,stomatitis,stomatitis one patient on GILOTRIF were,1
GILOTRIF,stomatitis,Patients in Study,0
GILOTRIF,stomatitis,table stomatitis one patient,1
GILOTRIF,stomatitis,Patients in Study,0
GILOTRIF,stomatitis,stomatitis one,1
GILOTRIF,stomatitis,stomatitis one patient,1
GILOTRIF,stomatitis,stomatitis one,1
GILOTRIF,stomatitis,stomatitis one patient on GILOTRIF were,1
GILOTRIF,stomatitis,stomatitis one patient on,1
GILOTRIF,stomatitis,this table stomatitis one patient,1
GILOTRIF,stomatitis,stomatitis one patient on,1
GILOTRIF,stomatitis,in severity Includes stomatitis aphthous,0
GILOTRIF,stomatitis,stomatitis one patient on,1
GILOTRIF,aphthous stomatitis,aphthous stomatitis mucosal,1
GILOTRIF,mucosal inflammation,on GILOTRIF were,0
GILOTRIF,mucosal inflammation,mucosal inflammation mouth ulceration oral mucosa erosion,1
GILOTRIF,mucosal inflammation,stomatitis,0
GILOTRIF,mucosal inflammation,Grade in severity Includes stomatitis aphthous,0
GILOTRIF,mucosal inflammation,mucosal inflammation,1
GILOTRIF,mucosal inflammation,Includes stomatitis aphthous mucosal inflammation,1
GILOTRIF,mucosal inflammation,mucosal inflammation,1
GILOTRIF,mucosal inflammation,stomatitis aphthous mucosal inflammation mouth ulceration oral mucosa erosion,1
GILOTRIF,mucosal inflammation,mucosal inflammation,1
GILOTRIF,mucosal inflammation,on GILOTRIF were Grade in severity,0
GILOTRIF,mucosal inflammation,mucosal inflammation mouth ulceration oral mucosa erosion,1
GILOTRIF,mouth ulceration,stomatitis mucosal mouth,1
GILOTRIF,mouth ulceration,stomatitis mucosal mouth,1
GILOTRIF,mouth ulceration,mucosal inflammation,0
GILOTRIF,oral mucosa erosion,preferred,0
GILOTRIF,oral mucosa erosion,mucosa erosion,1
GILOTRIF,mucosal erosion,mucosal erosion mucosal ulceration,1
GILOTRIF,mucosal erosion,oral mucosa erosion,0
GILOTRIF,mucosal erosion,ulceration oral mucosa mucosal erosion mucosal,1
GILOTRIF,mucosal erosion,oral mucosa erosion,0
GILOTRIF,mucosal erosion,mucosal erosion mucosal,1
GILOTRIF,mucosal erosion,ulceration oral mucosa mucosal,1
GILOTRIF,mucosal erosion,erosion,0
GILOTRIF,mucosal erosion,oral mucosa mucosal,1
GILOTRIF,mucosal ulceration,Includes group of rash preferred terms acne acne,0
GILOTRIF,mucosal ulceration,oral mucosa erosion mucosal mucosal,1
GILOTRIF,mucosal ulceration,preferred terms acne acne,0
GILOTRIF,mucosal ulceration,mucosal ulceration Includes group of rash preferred,1
GILOTRIF,mucosal ulceration,mucosal ulceration Includes group,1
GILOTRIF,mucosal ulceration,mucosal ulceration Includes group of,1
GILOTRIF,mucosal ulceration,mucosal ulceration Includes group,1
GILOTRIF,mucosal ulceration,mucosal,1
GILOTRIF,mucosal ulceration,ulceration oral,0
GILOTRIF,rash,ulceration Includes group rash preferred terms acne,1
GILOTRIF,rash,ulceration oral,0
GILOTRIF,rash,rash preferred terms acne acne pustular,1
GILOTRIF,rash,preferred terms acne,0
GILOTRIF,acne,pustular dermatitis acneiform Includes paronychia nail,0
GILOTRIF,acne,preferred acne,1
GILOTRIF,acne,pustular dermatitis acneiform Includes paronychia nail,0
GILOTRIF,acne,preferred acne acne,1
GILOTRIF,acne,pustular dermatitis acneiform Includes paronychia nail,0
GILOTRIF,acne,preferred acne acne,1
GILOTRIF,acne,pustular dermatitis acneiform Includes paronychia nail,0
GILOTRIF,acne pustular,acne pustular,1
GILOTRIF,acne pustular,pustular dermatitis acneiform Includes paronychia nail,0
GILOTRIF,acne pustular,acne pustular,1
GILOTRIF,acne pustular,nail,0
GILOTRIF,acne pustular,acneiform Includes paronychia nail infection nail,0
GILOTRIF,acne pustular,preferred terms acne pustular,1
GILOTRIF,paronychia,paronychia nail infection nail bed,1
GILOTRIF,nail infection,terms acne acne pustular dermatitis,0
GILOTRIF,nail infection,dermatitis acneiform Includes nail infection nail bed infection GILOTRIFn,1
GILOTRIF,nail infection,terms acne acne pustular dermatitis,0
GILOTRIF,nail infection,acneiform Includes nail,1
GILOTRIF,nail infection,Includes nail infection nail bed infection,1
GILOTRIF,nail infection,acneiform Includes nail,1
GILOTRIF,nail infection,Includes nail infection nail,1
GILOTRIF,nail infection,acneiform Includes nail,1
GILOTRIF,nail infection,nail infection nail,1
GILOTRIF,nail infection,nail infection nail,1
GILOTRIF,nail infection,group of rash preferred,0
GILOTRIF,nail infection,infection,0
GILOTRIF,nail infection,nail infection nail,1
GILOTRIF,nail bed infection,PemetrexedCisplatinn Adverse,0
GILOTRIF,nail bed infection,GILOTRIFn,0
GILOTRIF,Rash,disorders,0
GILOTRIF,Rash,subcutaneous,0
GILOTRIF,Pruritus,atitis Pruritus Dry,1
GILOTRIF,Pruritus,subcutaneous,0
GILOTRIF,Pruritus,Pruritus,1
GILOTRIF,Pruritus,Pruritus Dry skin,1
GILOTRIF,Decreased appetite,and nutrition,0
GILOTRIF,Pyrexia,Pyrexia Eye,1
GILOTRIF,Pyrexia,Pyrexia Eye,1
GILOTRIF,Pyrexia,Pyrexia,1
GILOTRIF,Pyrexia,Pyrexia Eye disorders,1
GILOTRIF,Pyrexia,conditions,0
GILOTRIF,Pyrexia,Pyrexia Eye,1
GILOTRIF,Pyrexia,and administration site Pyrexia Eye disorders,1
GILOTRIF,Pyrexia,Pyrexia Eye,1
GILOTRIF,Pyrexia,Pyrexia Eye disorders,1
GILOTRIF,Pyrexia,Pyrexia Eye disorders,1
GILOTRIF,Conjunctivitis,Table,0
GILOTRIF,Conjunctivitis,Conjunctivitis Table Adverse Reactio,1
GILOTRIF,blood potassium decreased,igations SOC Reported in,0
GILOTRIF,blood potassium decreased,class GILOTRIFn PemetrexedCisplatinn,0
GILOTRIF,Hypokalemia,Hypokalemia Aspartate aminotransfe,1
GILOTRIF,Diarrhea,adverse reactions a,0
GILOTRIF,Diarrhea,The following adverse reactions a,0
GILOTRIF,Diarrhea,re discu,1
GILOTRIF,Diarrhea,re,1
GILOTRIF,Diarrhea,see Warnings,0
GILOTRIF,dehydration,other sections of the labeling Diarrhea,0
GILOTRIF,dehydration,detail in,1
GILOTRIF,dehydration, detail in  other sections of the,1
GILOTRIF,dehydration,detail in,1
GILOTRIF,renal failure,in,0
GILOTRIF,renal failure,greater detail in sections,1
GILOTRIF,renal failure,and,0
GILOTRIF,Interstitial lung disease,ions Keratitis see Warnings and,0
GILOTRIF,Interstitial lung disease,common rse,1
GILOTRIF,Interstitial lung disease,see Warnings and Precautions EXCERPT Most common adve,0
GILOTRIF,Interstitial lung disease,common rse reactions (>=20%),1
GILOTRIF,Interstitial lung disease,Precautions EXCERPT Most common rse,1
GILOTRIF,Interstitial lung disease,Precautions EXCERPT Most common rse reactions (>=20%) are diarrhea,1
GILOTRIF,Interstitial lung disease,Precautions EXCERPT Most common rse,1
GILOTRIF,ILD,iar rhea rashdermatitis acneiform,1
GILOTRIF,ILD,dry skin,0
GILOTRIF,ILD,common adverse reactions are iar rhea rashdermatitis acneiform stomatitis paronychia,1
GILOTRIF,ILD,dry skin,0
GILOTRIF,ILD,iar rhea rashdermatitis acneiform,1
GILOTRIF,ILD,dry skin,0
GILOTRIF,Hepatic toxicity,To report SUSPECTED ADVERSE,0
GILOTRIF,Hepatic toxicity,"TIONS, contact",1
GILOTRIF,Fatal,vomiting pruritus To report SUSPECTED ADVERSE REACTIONS contact,0
GILOTRIF,Fatal,Boe,0
GILOTRIF,Fatal,report SUSPECTED,0
GILOTRIF,Fatal,Pharmaceuticals Inc at or,0
GILOTRIF,Fatal,hring er Ingelheim Pharmaceuticals Inc at,1
GILOTRIF,Fatal,Pharmaceuticals Inc at or,0
GILOTRIF,Fatal,hring er Ingelheim Pharmaceuticals Inc,1
GILOTRIF,Fatal,Pharmaceuticals Inc at or,0
GILOTRIF,hepatic impairment,contact,0
GILOTRIF,hepatic impairment,r Ingelheim Pharma,1
GILOTRIF,hepatic impairment,SUSPECTED ADVERSE REACTIONS contact r Ingelheim Pharma ceuticals Inc,1
GILOTRIF,hepatic impairment,r Ingelheim Pharma,1
GILOTRIF,hepatic impairment,pruritus To,0
GILOTRIF,hepatic impairment,at,0
GILOTRIF,hepatic impairment,Inc at or TTY or FDA at FDA orwwwfdagovmedwa,0
GILOTRIF,hepatic impairment,ADVERSE REACTIONS contact r Ingelheim,1
GILOTRIF,hepatic impairment,or,0
GILOTRIF,Keratitis,FDA at FDA orwwwfdagovmedwatch Clinical Trials,0
GILOTRIF,Keratitis,reaction rates observed,0
GILOTRIF,Keratitis,reaction,0
GILOTRIF,Embryofetal toxicity,and may not reflect the rates observed in,0
GILOTRIF,Embryofetal toxicity,es in the clinical t rials of another drug and,1
GILOTRIF,Embryofetal toxicity,and may not reflect the rates observed in,0
GILOTRIF,Embryofetal toxicity,the rates observed in practice The,0
GILOTRIF,Embryofetal toxicity,es in the clinical t rials,1
GILOTRIF,Embryofetal toxicity,compared to es in the clinical t,1
GILOTRIF,Embryofetal toxicity,es in the clinical t rials,1
GILOTRIF,Embryofetal toxicity,in the clinical,0
GILOTRIF,Embryofetal toxicity,es in the clinical,1
GILOTRIF,fetal harm,compared to rates in the clinical trials of,0
GILOTRIF,Diarrhea,more 00,1
GILOTRIF,Diarrhea,from more 00 patie,1
GILOTRIF,Diarrhea,more 00,1
GILOTRIF,Diarrhea,the data from more 00 patie,1
GILOTRIF,Diarrhea,more 00,1
GILOTRIF,Diarrhea,is based on the data from,0
GILOTRIF,Diarrhea,more 00 patie,1
GILOTRIF,Diarrhea,data from more 00,1
GILOTRIF,Diarrhea,data from more 00,1
GILOTRIF,Diarrhea,observed in practice,0
GILOTRIF,Diarrhea,00 patie nts,1
GILOTRIF,Diarrhea,observed in practice,0
GILOTRIF,dehydration,at or above,0
GILOTRIF,dehydration,from more than patients 35 NSCLC pa tients receiving,1
GILOTRIF,dehydration,at or above,0
GILOTRIF,dehydration,NSCLC pa tients receiving,1
GILOTRIF,dehydration,at or above the recommended dose Controlled Study,0
GILOTRIF,dehydration,35 NSCLC pa,1
GILOTRIF,renal impairment,Tables and below refl,0
GILOTRIF,renal impairment,GILOTRIF monothe,1
GILOTRIF,renal impairment,including NSCLC patients GILOTRIF monothe rapy at,1
GILOTRIF,renal impairment,GILOTRIF monothe,1
GILOTRIF,renal impairment,Tables and,0
GILOTRIF,renal impairment,GILOTRIF monothe rapy at or,1
GILOTRIF,fatal,n patients including NSCLC patients receiving,0
GILOTRIF,fatal,n patients including NSCLC patients receiving GILOTRIF,0
GILOTRIF,fatal,and below reflect,0
GILOTRIF,fatal,ended dose Controlled,1
GILOTRIF,diarrhea,ontrolle d Study The data in,1
GILOTRIF,diarrhea,recommended dose ontrolle d Study The,1
GILOTRIF,diarrhea,ontrolle d Study The data in,1
GILOTRIF,diarrhea,ontrolle d Study,1
GILOTRIF,diarrhea,ontrolle,1
GILOTRIF,diarrhea,and below,0
GILOTRIF,diarrhea,ontrolle d Study The data in,1
GILOTRIF,diarrhea,cluding NSCLC patients receiving GILOTRIF monotherapy at or above the,0
GILOTRIF,diarrhea,C,0
GILOTRIF,diarrhea,ontrolle d Study The,1
GILOTRIF,diarrhea,reflect,0
GILOTRIF,diarrhea,ontrolle d,1
GILOTRIF,diarrhea,above the recommended dose ontrolle d Study The data in,1
GILOTRIF,diarrhea,ontrolle d,1
GILOTRIF,diarrhea,at or above the recommended dose,0
GILOTRIF,diarrhea,ontrolle d Study,1
GILOTRIF,diarrhea,ontrolle d Study The,1
GILOTRIF,diarrhea,above the recommended dose ontrolle d Study,1
GILOTRIF,diarrhea,ontrolle d Study The,1
GILOTRIF,Renal impairment,a ra ndomized multicenter openlabel trial Study,1
GILOTRIF,Renal impairment,patients,0
GILOTRIF,Renal impairment,enrolled,1
GILOTRIF,Renal impairment,a ra ndomized,1
GILOTRIF,Renal impairment,in a ra,1
GILOTRIF,Renal impairment,enrolled in a ra ndomized multicenter,1
GILOTRIF,Renal impairment,FRTKI naive GILOTRIFtreated patients with,0
GILOTRIF,Renal impairment,naive GILOTRIFtreated patients with EGFR mutationpositive metastatic nonsquamous,0
GILOTRIF,Renal impairment,mutationpositive metastatic nonsquamous enrolled in a,1
GILOTRIF,Renal impairment,daily,0
GILOTRIF,Renal impairment,Study Patients received GILOTRIF mg,0
GILOTRIF,Renal impairment,EGFR mutationpositive metastatic nonsquamous enrolled in,1
GILOTRIF,Renal impairment,ndomized multicenter openlabel trial Study Patients received GILOTRIF mg daily,0
GILOTRIF,Renal impairment,nonsquamous NSCLC,0
GILOTRIF,Renal impairment,multicenter openlabel trial Study Patients,0
GILOTRIF,cutaneous reactions,patients in the,0
GILOTRIF,cutaneous reactions,A total of of patients on GILOTRIF,1
GILOTRIF,cutaneous reactions,A total of of,1
GILOTRIF,cutaneous reactions,years. A total of of,1
GILOTRIF,cutaneous reactions,were female More than,0
GILOTRIF,cutaneous reactions,the pemetrexedcisplatin arm were younger than,0
GILOTRIF,cutaneous reactions,of patients on GILOTRIF and,0
GILOTRIF,cutaneous reactions,patients,0
GILOTRIF,cutaneous reactions,arm were younger years.,1
GILOTRIF,cutaneous reactions,years. A total,1
GILOTRIF,exfoliating lesions,and,0
GILOTRIF,exfoliating lesions,Asia GILOTRIF,0
GILOTRIF,cutaneous reactions,reactions were reported % of patients treat ed with,1
GILOTRIF,cutaneous reactions,Asia GILOTRIF,0
GILOTRIF,cutaneous reactions,reported % of patients treat ed with GILOTRIF The most,1
GILOTRIF,cutaneous reactions,Asia GILOTRIF,0
GILOTRIF,rash,F. T,1
GILOTRIF,rash,F. T he most frequent serious adverse,1
GILOTRIF,rash,treated with F.,1
GILOTRIF,erythema,patients treated with GILOTRIF were diarrhea,0
GILOTRIF,erythema,reported in patients treated,0
GILOTRIF,erythema,most fr equent serious adverse reactions reported,1
GILOTRIF,erythema,treated with GILOTRIF most fr,1
GILOTRIF,erythema,reactions were reported,0
GILOTRIF,erythema,treated with GILOTRIF most fr,1
GILOTRIF,erythema,reactions,0
GILOTRIF,erythema,most fr equent serious adverse reactions,1
GILOTRIF,erythema,with GILOTRIF  most fr equent,1
GILOTRIF,erythema,most fr equent serious adverse reactions,1
GILOTRIF,acneiform rash,with GILOTRIF The most  serious adver se reactions reported in,1
GILOTRIF,acneiform rash,most fr equent serious adverse reactions,1
GILOTRIF,acneiform rash,most  serious adver se reactions,1
GILOTRIF,acneiform rash,most fr equent serious adverse reactions,1
GILOTRIF,acneiform rash,reactions were reported in of patients treated with GILOTRIF,0
GILOTRIF,acneiform rash,GILOTRIF The most serious,1
GILOTRIF,acneiform rash,serious adver se,1
GILOTRIF,acneiform rash,The most  serious adver se reactions reported,1
GILOTRIF,acneiform rash,serious adver se,1
GILOTRIF,acneiform rash,most serious,1
GILOTRIF,cutaneous reactions,ed,1
GILOTRIF,cutaneous reactions,reported in patients ed with GILOTRIF we re,1
GILOTRIF,cutaneous reactions,ed,1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"diarrhea vomiting and fatigue,",1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,and hypokalemia (1.7% each). Fata,1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,patients in Study included pulmonary toxicityILDlike,0
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"fatigue, and hypokalemia (1.7% each).",1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"fatigue, and hypokalemia (1.7% each). Fata l adverse reactions in GILOTRIFtreated",1
GILOTRIF,palmar-plantar erythrodysesthesia syndrome,"fatigue, and hypokalemia (1.7% each).",1
GILOTRIF,ILD,was The most,1
GILOTRIF,ILD,"fatigue, and hypokalemia (1.7% each).",1
GILOTRIF,ILD,was The most,1
GILOTRIF,ILD,was The most frequent adverse reactions,1
GILOTRIF,ILD,patients for adverse was The,1
GILOTRIF,ILD,was The most frequent adverse reactions,1
GILOTRIF,ILD,Discontinuation of therapy in,0
GILOTRIF,ILD,was The most frequent adverse reactions,1
GILOTRIF,ILD,was The most frequent adverse,1
GILOTRIF,ILD,adverse was The most frequent adverse,1
GILOTRIF,ILD,was The most frequent adverse,1
GILOTRIF,lung infiltration,that led to discontinuation in GILOTRIFtreated patients,1
GILOTRIF,lung infiltration,tions that led to discontinuation in GILOTRIFtreated,1
GILOTRIF,lung infiltration,that led to discontinuation in GILOTRIFtreated patients,1
GILOTRIF,pneumonitis,iscontinuat ion in GILOTRIFtreated patients,1
GILOTRIF,pneumonitis,diarrhea,0
GILOTRIF,pneumonitis,in GILOTRIFtreated patients were diarrhea ILD and,0
GILOTRIF,pneumonitis,iscontinuat ion in,1
GILOTRIF,acute respiratory distress syndrome,patients were diarrhea ILD and,1
GILOTRIF,acute respiratory distress syndrome,ILD,0
GILOTRIF,acute respiratory distress syndrome,reactions that led to n in GILOTRIF-treated patients were diarrhea ILD,1
GILOTRIF,acute respiratory distress syndrome,ILD,0
GILOTRIF,acute respiratory distress syndrome,led to discontinuatio,0
GILOTRIF,acute respiratory distress syndrome,n in GILOTRIF-treated patients were diarrhea ILD,1
GILOTRIF,fatal,LVEF ie below the institutional lower limit of,0
GILOTRIF,fatal,icula r ejection,1
GILOTRIF,ILD,ejection  (L VEF ie,1
GILOTRIF,ILD,icula r ejection,1
GILOTRIF,ILD, (L VEF ie below the,1
GILOTRIF,ILD,fraction,0
GILOTRIF,ILD,left ventricular ejection  (L VEF ie below,1
GILOTRIF,ILD,fraction,0
GILOTRIF,ILD, (L VEF ie below the institutional,1
GILOTRIF,ILD,of GILOTRIF excluded patients,0
GILOTRIF,ILD,excluded patients with an,0
GILOTRIF,ILD,ejection  (L VEF,1
GILOTRIF,ILD,excluded patients with an,0
GILOTRIF,ILD,patients with an abnormal left,0
GILOTRIF,ILD,eek s,1
GILOTRIF,ILD,patients with an abnormal left,0
GILOTRIF,ILD,eek s thereafter,1
GILOTRIF,ILD,eek,1
GILOTRIF,ILD,eek s thereafter in the,1
GILOTRIF,ILD,eek s thereafter in the GILOTRIFtreated,1
GILOTRIF,ILD,eek s thereafter in the GILOTRIFtreated,1
GILOTRIF,ILD,eek s thereafter in the,1
GILOTRIF,death,weeks thereafter in the IF-tr eated group and,1
GILOTRIF,death,eek s thereafter in the,1
GILOTRIF,death,group and as needed in the,0
GILOTRIF,death,and as needed in the pemetrexedcisplatin group More GILOTRIFtreated patients,0
GILOTRIF,death,in the IF-tr eated,1
GILOTRIF,death,and as needed in the pemetrexedcisplatin group More GILOTRIFtreated patients,0
GILOTRIF,death,IF-tr eated group and,1
GILOTRIF,death,IF-tr eated group,1
GILOTRIF,death,thereafter in the IF-tr eated group and as,1
GILOTRIF,death,IF-tr eated group,1
GILOTRIF,death,pemetrexedcisplatin group More GILOTRIFtreated patients,0
GILOTRIF,liver test abnormalities,chemotherapytreated patients n 1 Adverse Reactions Repo rted in of,1
GILOTRIF,liver test abnormalities,pemetrexedcisplatin group More GILOTRIFtreated patients,0
GILOTRIF,liver test abnormalities,of GILOTRIFTreated Patients in Study None,0
GILOTRIF,liver test abnormalities,all Grade compared to chemotherapytreated patients n,0
GILOTRIF,liver test abnormalities,n 1 Adverse Reactions Repo,1
GILOTRIF,fatal,GILOTRIF,0
GILOTRIF,fatal,of the adverse reactions in this,0
GILOTRIF,fatal,Reactions Reported in of Treat,1
GILOTRIF,fatal,of the adverse reactions in this,0
GILOTRIF,fatal,of GILOTRIF,0
GILOTRIF,fatal,patients n Table Adverse Reactions Reported in,0
GILOTRIF,fatal,in of Treat ed Patients in Study None,1
GILOTRIF,fatal,patients n Table Adverse Reactions Reported in,0
GILOTRIF,fatal,Treat ed Patients in Study None,1
GILOTRIF,fatal,Treat ed Patients in,1
GILOTRIF,fatal,Treat ed,1
GILOTRIF,fatal,Reported in of Treat ed Patients in Study None,1
GILOTRIF,fatal,Treat ed,1
GILOTRIF,liver test abnormalities,GILOTRIFTreated Patients in,0
GILOTRIF,liver test abnormalities,Study 1 *None of the adverse reactions,1
GILOTRIF,liver test abnormalities,"in of GILOTRIFTreated Patients  Study 1 

 *None of the",1
GILOTRIF,liver test abnormalities,Study 1 *None of the adverse reactions,1
GILOTRIF,liver test abnormalities,of GILOTRIFTreated Patients Study,1
GILOTRIF,liver test abnormalities,in of GILOTRIFTreated Patients,0
GILOTRIF,liver test abnormalities,in of GILOTRIFTreated Patients Study 1 *None,1
GILOTRIF,liver test abnormalities," Study 1 

 *None of the adverse reactions in this",1
GILOTRIF,liver test abnormalities,in of GILOTRIFTreated Patients Study 1 *None,1
GILOTRIF,worsening eye inflammation,acneiform Includes paronychia nail infection nail,0
GILOTRIF,worsening eye inflammation,infection nail bed infection TRIFn=229      Pemetrexed/ Cisplatinn,1
GILOTRIF,worsening eye inflammation,acneiform Includes paronychia nail infection nail,0
GILOTRIF,light sensitivity,"    
   Adverse R eaction All Grades",1
GILOTRIF,light sensitivity,acneiform Includes paronychia nail infection nail,0
GILOTRIF,light sensitivity,bed infection,0
GILOTRIF,blurred vision,GILOTRIFn PemetrexedCisplatinn Adverse ction All,1
GILOTRIF,blurred vision,GILOTRIFn PemetrexedCisplatinn Adverse ction All,1
GILOTRIF,blurred vision,Grade Gastrointestinal,0
GILOTRIF,blurred vision,ction All Grades Grade,1
GILOTRIF,blurred vision,ction All Grades Grade All Grades Grade,1
GILOTRIF,eye pain,rades(%) Grade All,1
GILOTRIF,eye pain,Grade,0
GILOTRIF,red eye,de 3*(% All,1
GILOTRIF,red eye,Grade,0
GILOTRIF,red eye,de 3*(% All Grades,1
GILOTRIF,fetal harm,           Infections and infestations,1
GILOTRIF,fetal harm,           Infections and infestations,1
GILOTRIF,fetal harm,           Infections and infestations,1
GILOTRIF,fetal harm,           Infections and infestations,1
GILOTRIF,fetal harm,Infections and infestations,0
GILOTRIF,fetal harm,Dry            Infections,1
GILOTRIF,fetal harm,Infections and infestations,0
GILOTRIF,fetal harm,skin,0
GILOTRIF,fetal harm,           Infections and infestations Paronychia,1
GILOTRIF,fetal harm,skin,0
GILOTRIF,embryotoxic,"   
       ",1
GILOTRIF,embryotoxic,"   
        Paronychia Cystit",1
GILOTRIF,embryotoxic,infestations,0
GILOTRIF,embryotoxic,"   
        Paronychia",1
GILOTRIF,embryotoxic,and infestations,0
GILOTRIF,abortions at late gestational stages,Paronychia,0
GILOTRIF,abortions at late gestational stages,and,0
DATSCAN,Hypersensitivity,EXCERPT,0
DATSCAN,Hypersensitivity,ADVERSE REACTIONS,0
DATSCAN,Hypersensitivity,EXCERPT,0
DATSCAN,Hypersensitivity,Hypersensitivity,1
DATSCAN,Hypersensitivity,Hypersensitivity and injection,1
DATSCAN,Hypersensitivity,Hypersensitivity and injection site reactions,1
DATSCAN,Hypersensitivity,Hypersensitivity and injection site reactions,1
DATSCAN,Hypersensitivity,Hypersensitivity and injection site reactions,1
DATSCAN,Hypersensitivity,Hypersensitivity and injection site reactions have,1
DATSCAN,Hypersensitivity,Hypersensitivity and injection site reactions,1
DATSCAN,Hypersensitivity,REACTIONS Hypersensitivity,1
DATSCAN,Hypersensitivity,Hypersensitivity and injection site reactions,1
DATSCAN,injection site reactions,Hypersensitivity injection site reactions,1
DATSCAN,injection site reactions,injection site reactions have been reported following DaTscan,1
DATSCAN,injection site reactions,ADVERSE REACTIONS EXCERPT Hypersensitivity injection site,1
DATSCAN,headache,most common adverse headache nausea vertigo dry mouth,1
DATSCAN,headache,ADVERSE REACTIONS EXCERPT Hypersensitivity injection site,1
DATSCAN,headache,headache nausea,1
DATSCAN,headache,headache nausea vertigo dry,1
DATSCAN,headache,headache nausea vertigo dry mouth or,1
DATSCAN,headache,headache nausea vertigo dry,1
DATSCAN,headache,headache nausea vertigo dry mouth or,1
DATSCAN,headache,headache nausea vertigo dry,1
DATSCAN,headache,the most common adverse headache nausea vertigo dry,1
DATSCAN,headache,headache nausea vertigo dry,1
DATSCAN,headache,common,0
DATSCAN,headache,headache,1
DATSCAN,vertigo,vertigo dry mouth or,1
DATSCAN,vertigo,headache,1
DATSCAN,vertigo,report,0
DATSCAN,vertigo,vertigo dry mouth,1
DATSCAN,vertigo,vertigo dry,1
DATSCAN,vertigo,mouth or,0
DATSCAN,vertigo,vertigo dry mouth or dizziness occurred,1
DATSCAN,vertigo,reactions headache vertigo dry,1
DATSCAN,vertigo,vertigo dry mouth or dizziness occurred,1
DATSCAN,vertigo,occurred,0
DATSCAN,vertigo,dry mouth or dizziness occurred in of subjects To report SUSPECTED,0
DATSCAN,dry mouth,dry mouth or dizziness occurred,1
DATSCAN,dry mouth,report SUSPECTED ADVERSE REACTIONS,0
DATSCAN,dry mouth,dry mouth,1
DATSCAN,dry mouth,dry mouth or dizziness,1
DATSCAN,dry mouth,dry mouth or dizziness,1
DATSCAN,dry mouth,nausea dry mouth or dizziness occurred in,1
DATSCAN,dry mouth,dry mouth or dizziness,1
DATSCAN,dizziness,headache,0
DATSCAN,dizziness,adverse,0
DATSCAN,dizziness,vertigo dry mouth dizziness occurred in of subjects,1
DATSCAN,dizziness,adverse,0
DATSCAN,dizziness,vertigo dry mouth dizziness occurred,1
DATSCAN,dizziness,adverse,0
DATSCAN,dizziness,contact,0
DATSCAN,headache,headache nausea vertigo dry mouth or,1
DATSCAN,headache,rate of or less and the,0
DATSCAN,nausea,These reactions were of,0
DATSCAN,nausea,of nausea vertigo,1
DATSCAN,nausea,These reactions were of,0
DATSCAN,nausea,nausea vertigo dry mouth,1
DATSCAN,nausea,the reported events consisted of,0
DATSCAN,nausea,events consisted of nausea vertigo dry,1
DATSCAN,nausea,the reported events consisted of,0
DATSCAN,nausea,reactions were of mild,0
DATSCAN,nausea,nausea vertigo dry mouth or dizziness,1
DATSCAN,nausea,of nausea vertigo dry mouth or dizziness,1
DATSCAN,nausea,nausea vertigo dry mouth or dizziness,1
DATSCAN,nausea,a rate of or less and the reported events consisted,0
DATSCAN,vertigo,vertigo dry mouth or dizziness These,1
DATSCAN,vertigo,vertigo,1
DATSCAN,vertigo,vertigo dry mouth or,1
DATSCAN,vertigo,mouth or dizziness,0
DATSCAN,vertigo,e reactions,0
DATSCAN,vertigo,vertigo,1
DATSCAN,vertigo,vertigo dry mouth,1
DATSCAN,vertigo,events consisted of,0
DATSCAN,vertigo,were of,0
DATSCAN,dizziness,mild to,0
DATSCAN,dizziness,to moderate severity Postmarketing Experience Because,0
DATSCAN,dizziness,nausea vertigo dry mouth dizziness These reactions were,1
DATSCAN,dizziness,to moderate severity Postmarketing Experience Because,0
DATSCAN,dizziness,dizziness These reactions were of mild,1
DATSCAN,hypersensitivity reactions,hypersensitivity reactions have been,1
DATSCAN,hypersensitivity reactions,dizziness These reactions were of mild,1
DATSCAN,hypersensitivity reactions,the postmarketing hypersensitivity reactions have been reported The,1
DATSCAN,hypersensitivity reactions,dizziness These reactions were of mild,1
DATSCAN,hypersensitivity reactions,eir frequency or,0
DATSCAN,hypersensitivity reactions,exposure In the postmarketing hypersensitivity reactions have been reported The reactions,1
DATSCAN,hypersensitivity reactions,eir frequency or,0
DATSCAN,rash,rash,1
DATSCAN,rash,pruritis within minutes of DaTscan administration,0
DATSCAN,rash,The reactions either resolved,0
DATSCAN,rash,rash and,1
DATSCAN,pruritis,hypersensitivity reactions have been reported The,0
DATSCAN,Hypersensitivity reactions,REACTIONS EXCERPT ty and injection site reac tions,1
DATSCAN,Hypersensitivity reactions,hypersensitivity reactions have been reported The,0
DATSCAN,Hypersensitivity reactions,Hypersensitivi,0
DATSCAN,Hypersensitivity reactions,reported following DaTscan administration In,0
DATSCAN,Hypersensitivity reactions,ADVERSE REACTIONS EXCERPT ty and injection site reac tions have been reported following,1
DATSCAN,Hypersensitivity reactions,reported following DaTscan administration In,0
DATSCAN,Hypersensitivity reactions,Hypersensitivi,0
DATSCAN,Hypersensitivity reactions,DaTscan administration In clinical trials the,0
DATSCAN,Hypersensitivity reactions,clinical trials,0
DATSCAN,Hypersensitivity reactions,ADVERSE REACTIONS EXCERPT ty and injection site reac tions have been,1
DATSCAN,Hypersensitivity reactions,clinical trials,0
DATSCAN,Hypersensitivity reactions,DaTscan administration In clinical trials the most co,0
DATSCAN,Hypersensitivity reactions,REACTIONS EXCERPT ty and injection site reac tions have been reported,1
DATSCAN,Hypersensitivity reactions,DaTscan administration In clinical trials the most co,0
DATSCAN,Hypersensitivity reactions,118 or FDA at 1-800-FDA-10 or wwwfdagovmedwatch,1
DATSCAN,Hypersensitivity reactions,DaTscan administration In clinical trials the most co,0
DATSCAN,Hypersensitivity reactions,or FDA at 1-800-FDA-10 or wwwfdagovmedwatch Clinical Study,1
DATSCAN,Hypersensitivity reactions,GE Healthcare 118 or FDA at 1-800-FDA-10 or wwwfdagovmedwatch,1
DATSCAN,Hypersensitivity reactions,or FDA at 1-800-FDA-10 or wwwfdagovmedwatch Clinical Study,1
DATSCAN,Hypersensitivity reactions,contact GE Healthcare 118,1
DATSCAN,Hypersensitivity reactions,contact GE Healthcare 118 or FDA,1
DATSCAN,skin erythema,with a mean age of years range to,0
DATSCAN,pruritis,a mean,1
DATSCAN,pruritis,Study Experience The data from,0
DATSCAN,pruritis,DaTscan in subjects  a mean ,1
DATSCAN,pruritis,Study Experience The data from,0
DATSCAN,pruritis,in subjects a,1
DATSCAN,pruritis, a mean ,1
DATSCAN,pruritis,in subjects a,1
DATSCAN,pruritis,studies reflect exposure to DaTscan in subjects with,0
DATSCAN,pruritis,years Among these subjects were,0
DATSCAN,pruritis,subjects  a mean  age of years,1
DATSCAN,pruritis,years Among these subjects were,0
DATSCAN,pruritis,subjects,0
KALBITOR,Hypersensitivity,Hypersensitivity reactions including,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have occurred,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have occurred,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have occurred,1
KALBITOR,Hypersensitivity,ADVERSE Hypersensitivity reactions including anaphylaxis,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have occurred,1
KALBITOR,Hypersensitivity,ADVERSE Hypersensitivity reactions including anaphylaxis,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have occurred,1
KALBITOR,Hypersensitivity,Hypersensitivity,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have occurred,1
KALBITOR,Hypersensitivity,Hypersensitivity reactions including anaphylaxis have,1
KALBITOR,anaphylaxis,anaphylaxis have occurred in patients treated,1
KALBITOR,anaphylaxis,anaphylaxis,1
KALBITOR,headache,placebo headache,1
KALBITOR,headache,anaphylaxis,1
KALBITOR,headache,headache,1
KALBITOR,headache,headache nausea diarrhea,1
KALBITOR,headache,headache,1
KALBITOR,headache,headache nausea,1
KALBITOR,headache,headache,1
KALBITOR,headache,KALBITORtreated patients and greater than placebo are,0
KALBITOR,headache,headache,1
KALBITOR,headache,headache,1
KALBITOR,headache,headache nausea diarrhea pyrexia injection,1
KALBITOR,nausea,reactions occurring in of KALBITORtreated patients and greater than placebo are,0
KALBITOR,nausea,nausea diarrhea pyrexia injection site,1
KALBITOR,nausea,nausea diarrhea,1
KALBITOR,nausea,headache,0
KALBITOR,nausea,patients,0
KALBITOR,nausea,nausea diarrhea pyrexia,1
KALBITOR,nausea,greater than placebo are,0
KALBITOR,nausea,placebo are nausea diarrhea,1
KALBITOR,nausea,greater than placebo are,0
KALBITOR,nausea,greater than placebo are nausea diarrhea pyrexia injection,1
KALBITOR,nausea,greater than placebo are,0
KALBITOR,diarrhea,diarrhea pyrexia injection site reactions and,1
KALBITOR,diarrhea,than placebo are headache nausea,0
KALBITOR,pyrexia,headache nausea pyrexia injection site reactions and,1
KALBITOR,pyrexia,than placebo are headache nausea,0
KALBITOR,pyrexia,pyrexia injection site reactions and nasopharyngitis,1
KALBITOR,pyrexia,pyrexia injection site reactions and,1
KALBITOR,pyrexia,than placebo are headache nausea,0
KALBITOR,injection site reactions,headache nausea diarrhea injection,1
KALBITOR,injection site reactions,report SUSPECTED ADVERSE REACTIONS contact,0
KALBITOR,injection site reactions,headache nausea,0
KALBITOR,injection site reactions,REACTIONS contact Dyax Corp at,0
KALBITOR,injection site reactions,diarrhea injection,1
KALBITOR,injection site reactions,contact Dyax Corp at,0
KALBITOR,injection site reactions,report,0
KALBITOR,nasopharyngitis,injection site reactions,0
KALBITOR,nasopharyngitis,nasopharyngitis To report,1
KALBITOR,nasopharyngitis,reactions,0
KALBITOR,nasopharyngitis,nasopharyngitis To report SUSPECTED ADVERSE REACTIONS,1
KALBITOR,nasopharyngitis,injection site reactions nasopharyngitis To report SUSPECTED ADVERSE REACTIONS,1
KALBITOR,nasopharyngitis,nasopharyngitis To report SUSPECTED ADVERSE REACTIONS,1
KALBITOR,headache,headache nausea fatigue,1
KALBITOR,headache,reactions in,0
KALBITOR,headache,the most common adverse reactions in patients,0
KALBITOR,headache,headache nausea fatigue diarrhea,1
KALBITOR,headache,diarrhea upper respiratory tract,0
KALBITOR,headache,patients with HAE headache nausea fatigue diarrhea,1
KALBITOR,headache,diarrhea upper respiratory tract,0
KALBITOR,headache,patients with HAE headache,1
KALBITOR,headache,diarrhea upper respiratory tract,0
KALBITOR,headache,headache nausea fatigue diarrhea upper respiratory,1
KALBITOR,headache,patients with HAE headache nausea fatigue,1
KALBITOR,headache,headache nausea fatigue diarrhea upper respiratory,1
KALBITOR,nausea,injection site reacti,0
KALBITOR,nausea,headache,0
KALBITOR,nausea,nausea fatigue diarrhea,1
KALBITOR,nausea,headache,0
KALBITOR,nausea,tract infection injection site,0
KALBITOR,nausea,patients with HAE were nausea fatigue diarrhea,1
KALBITOR,nausea,tract infection injection site,0
KALBITOR,nausea,nausea,1
KALBITOR,nausea,patients with HAE were nausea fatigue diarrhea upper respiratory,1
KALBITOR,nausea,nausea,1
KALBITOR,nausea,nausea fatigue diarrhea upper respiratory,1
KALBITOR,nausea,nausea,1
KALBITOR,fatigue,HAE were headache fatigue diarrhea upper respiratory,1
KALBITOR,fatigue,nausea,1
KALBITOR,fatigue,fatigue diarrhea upper respiratory tract,1
KALBITOR,diarrhea,infection injection site reactions nasopharyngitis,0
KALBITOR,diarrhea,nausea fatigue,0
KALBITOR,diarrhea,diarrhea upper,1
KALBITOR,diarrhea,injection site reactions nasopharyngitis,0
KALBITOR,diarrhea,reactions in patients with HAE,0
KALBITOR,diarrhea,fatigue,0
KALBITOR,diarrhea,diarrhea upper respiratory tract infection injection,1
KALBITOR,diarrhea,were headache,0
KALBITOR,diarrhea,tract infection,0
KALBITOR,diarrhea,diarrhea upper respiratory tract infection,1
KALBITOR,upper respiratory tract infection,upper respiratory tract infection injection site reactions nasopharyngitis vomiting,1
KALBITOR,upper respiratory tract infection,diarrhea upper respiratory tract infection,1
KALBITOR,upper respiratory tract infection,eactions in,0
KALBITOR,upper respiratory tract infection,upper respiratory tract infection injection site reactions,1
KALBITOR,upper respiratory tract infection,fatigue upper respiratory tract infection,1
KALBITOR,upper respiratory tract infection,respiratory tract infection injection site,1
KALBITOR,upper respiratory tract infection,headache nausea fatigue upper respiratory tract,1
KALBITOR,upper respiratory tract infection,were headache nausea fatigue upper respiratory,1
KALBITOR,upper respiratory tract infection,fatigue upper respiratory tract,1
KALBITOR,injection site reactions,upper abdominal,0
KALBITOR,injection site reactions,injection site reactions,1
KALBITOR,injection site reactions,tract injection site reactions,1
KALBITOR,nasopharyngitis,upper abdominal pain,0
KALBITOR,nasopharyngitis,nasopharyngitis vomiting pruritus upper abdominal,1
KALBITOR,nasopharyngitis,upper abdominal pain,0
KALBITOR,nasopharyngitis,nasopharyngitis vomiting,1
KALBITOR,nasopharyngitis,pain and,0
KALBITOR,nasopharyngitis,upper abdominal pain and pyrexia Anaphylaxis wa,0
KALBITOR,nasopharyngitis,tract infection injection site nasopharyngitis vomiting pruritus,1
KALBITOR,nasopharyngitis,upper abdominal pain and pyrexia Anaphylaxis wa,0
KALBITOR,nasopharyngitis,nasopharyngitis,1
KALBITOR,nasopharyngitis,respiratory tract,0
KALBITOR,nasopharyngitis,nasopharyngitis vomiting,1
KALBITOR,nasopharyngitis,respiratory tract,0
KALBITOR,nasopharyngitis,nasopharyngitis vomiting,1
KALBITOR,vomiting,pruritus upper abdominal pain and pyrexia Anaphylaxis,0
KALBITOR,vomiting,vomiting,1
KALBITOR,vomiting,site reactions nasopharyngitis,0
KALBITOR,vomiting,upper abdominal pain,0
KALBITOR,vomiting,vomiting pruritus upper abdominal,1
KALBITOR,vomiting,vomiting pruritus,1
KALBITOR,pruritus,tract infection injection site reactions,0
KALBITOR,pruritus,pruritus upper abdominal,1
KALBITOR,pruritus,nasopharyngitis vomiting,0
KALBITOR,pruritus,was reported,0
KALBITOR,pruritus,pruritus upper abdominal pain and,1
KALBITOR,pruritus,tract,0
KALBITOR,pruritus,injection site,0
KALBITOR,pruritus,pruritus,1
KALBITOR,upper abdominal pain,reactions nasopharyngitis,0
KALBITOR,upper abdominal pain,upper,1
KALBITOR,upper abdominal pain,upper abdominal pain and,1
KALBITOR,upper abdominal pain,nasopharyngitis vomiting upper,1
KALBITOR,upper abdominal pain,nasopharyngitis vomiting upper abdominal pain and pyrexia Anaphylaxis was,1
KALBITOR,upper abdominal pain,nasopharyngitis vomiting upper,1
KALBITOR,pyrexia,pyrexia Anaphylaxis was reported,1
KALBITOR,Anaphylaxis,Anaphylaxis was reported in of patients,1
KALBITOR,Anaphylaxis,Injection,0
KALBITOR,ANAPHYLAXIS,have occurred in patients treated,0
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions,1
KALBITOR,ANAPHYLAXIS,with,0
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions including anaphylaxis have,1
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions including anaphylaxis have,1
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions,1
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions including anaphylaxis,1
KALBITOR,ANAPHYLAXIS,persensitiv ity reactions including anaphylaxis have,1
KALBITOR,ANAPHYLAXIS,see Contraindications,0
KALBITOR,ANAPHYLAXIS,reactions,0
KALBITOR,ANAPHYLAXIS,"REACTIONS Hypersensitivity ,",1
KALBITOR,ANAPHYLAXIS,"ADVERSE REACTIONS Hypersensitivity , including",1
KALBITOR,ANAPHYLAXIS,reactions,0
KALBITOR,ANAPHYLAXIS,"Hypersensitivity ,",1
KALBITOR,ANAPHYLAXIS,", including",1
KALBITOR,ANAPHYLAXIS,"ADVERSE REACTIONS Hypersensitivity , including",1
KALBITOR,ANAPHYLAXIS,", including",1
KALBITOR,Anaphylaxis,"REACTIONS Hypersensitivity reactions including ylaxis, hav",1
KALBITOR,Anaphylaxis,"Hypersensitivity reactions including ylaxis,",1
KALBITOR,ANAPHYLAXIS,t the rates observed in practice The,1
KALBITOR,ANAPHYLAXIS,not t,1
KALBITOR,ANAPHYLAXIS,the rates observed in practice The,1
KALBITOR,ANAPHYLAXIS,not t the rates,1
KALBITOR,ANAPHYLAXIS,the rates observed in practice The,1
KALBITOR,ANAPHYLAXIS,reflec,0
KALBITOR,ANAPHYLAXIS,of another drug and,0
KALBITOR,Anaphylaxis,data described below reflect exposure to KALBITOR in,0
KALBITOR,Anaphylaxis,atients wit h HAE treated,1
KALBITOR,Anaphylaxis,below,0
KALBITOR,Hypersensitivity Reactions,occurred in patients treated,0
KALBITOR,Hypersensitivity Reactions,ADVERSE REACTIONS Hypersensitivity reaction,0
KALBITOR,Hypersensitivity Reactions,treated with KALBITOR see Contraindications,0
KALBITOR,Hypersensitivity Reactions,"s, including anaphylaxis,",1
KALBITOR,Hypersensitivity Reactions,"including anaphylaxis, have occurred in",1
KALBITOR,Hypersensitivity Reactions,"REACTIONS Hypersensitivity s, including",1
KALBITOR,Hypersensitivity Reactions,ADVERSE REACTIONS Hypersensitivity reaction,0
KALBITOR,Anaphylaxis,including anaphylaxis,0
KALBITOR,Anaphylaxis,ed in,1
KALBITOR,Anaphylaxis,reactions including anaphylaxis have ed in,1
KALBITOR,Anaphylaxis,ed in patie nts treated with,1
KALBITOR,Anaphylaxis,reactions including anaphylaxis have ed in,1
KALBITOR,Anaphylaxis,ed in patie,1
KALBITOR,Anaphylaxis,anaphylaxis have occurr,0
KALBITOR,Anaphylaxis,treated w ith KALBITOR,1
KALBITOR,Anaphylaxis,anaphylaxis have occurred in,0
KALBITOR,Anaphylaxis,treated w ith KALBITOR see Contraindications and,1
KALBITOR,Anaphylaxis,and Warnings and Precautions,0
KALBITOR,Anaphylaxis,anaphylaxis have occurred in s treated w,1
KALBITOR,Anaphylaxis,have occurred in s,1
KALBITOR,Anaphylaxis,in,0
KALBITOR,Anaphylaxis,occurred,0
KALBITOR,Anaphylaxis,have occurred,0
KALBITOR,Anaphylaxis,s treated w ith KALBITOR see Contraindications and,1
KALBITOR,hypersensitivity,tact Dyax Corp.  at or FDA,1
KALBITOR,hypersensitivity,s treated w ith KALBITOR see Contraindications and,1
KALBITOR,hypersensitivity,tact Dyax Corp. at or,1
KALBITOR,hypersensitivity,Dyax Corp. at or FDA at,1
KALBITOR,hypersensitivity,con,0
KALBITOR,hypersensitivity,Dyax Corp. at or FDA at FDA,1
KALBITOR,hypersensitivity,SUSPECTED ADVERSE REACTIONS tact Dyax Corp. ,1
KALBITOR,hypersensitivity,Dyax Corp. at or FDA at FDA,1
KALBITOR,anaphylaxis,or DA at,1
KALBITOR,anaphylaxis,or DA at 1-800 FDA or wwwfdagovmedwatch Clinical Trials,1
KALBITOR,anaphylaxis,or DA at,1
KALBITOR,anaphylaxis,Corp at or DA,1
KALBITOR,anaphylaxis,the clinical trials of an,0
KALBITOR,anaphylaxis,of other drug  and may not reflect the,1
KALBITOR,anaphylaxis,the clinical trials of an,0
KALBITOR,anaphylaxis,clinical trials of,0
KALBITOR,anaphylaxis,not reflect the rates observed in practice The safety,0
KALBITOR,anaphylaxis,other drug and may not reflect,1
KALBITOR,flushing,to KALBITOR,0
KALBITOR,flushing,in patients,0
KALBITOR,flushing,practice The safety data cribed b elow reflect exposure,1
KALBITOR,flushing,in patients,0
KALBITOR,flushing,cribed b elow,1
KALBITOR,flushing,The safety data cribed b elow,1
KALBITOR,flushing,cribed b elow,1
KALBITOR,pharyngeal edema,described ow,1
KALBITOR,pharyngeal edema,data described ow reflect,1
KALBITOR,pharyngeal edema,described bel,0
KALBITOR,pharyngeal edema,described,0
KALBITOR,pharyngeal edema,in practice The safety data,0
KALBITOR,pharyngeal edema,The safety data described ow reflect expos ure to KALBITOR in,1
KALBITOR,pharyngeal edema,in practice The safety data,0
KALBITOR,pharyngeal edema,and may not reflect the rates observed,0
KALBITOR,pruritus,described below reflect e to KAL BITOR in patients,1
KALBITOR,pruritus,and may not reflect the rates observed,0
KALBITOR,rhinorrhea,in 255,1
KALBITOR,rhinorrhea,with HAE treated with either intravenous or subcutaneous KALBITOR Of the,0
KALBITOR,rhinorrhea,TOR in 255 patients,1
KALBITOR,rhinorrhea,rates observed in practice The safety,0
KALBITOR,rhinorrhea,in 255 patients with HAE treated,1
KALBITOR,rhinorrhea,to TOR in 255 patients with HAE,1
KALBITOR,rhinorrhea,in 255 patients with HAE treated,1
KALBITOR,sneezing,atients  with HAE treated,1
KALBITOR,sneezing,atients  with HAE treated,1
KALBITOR,sneezing,practice,0
KALBITOR,sneezing,in atients  with HAE treated with,1
KALBITOR,sneezing,practice,0
KALBITOR,sneezing,atients  with HAE treated,1
KALBITOR,sneezing,below reflect exposure,0
KALBITOR,sneezing,KALBITOR in atients  with HAE treated,1
KALBITOR,sneezing,below reflect exposure,0
KALBITOR,sneezing,atients  with HAE treated with either,1
KALBITOR,sneezing,KALBITOR Of the patients of patie,0
KALBITOR,sneezing,intravenous or subcutaneous KALBITOR Of the patients,0
KALBITOR,nasal congestion,to KALBITOR in patients th HAE treated w,1
KALBITOR,nasal congestion,or subcutaneous KALBITOR Of the patients,0
KALBITOR,nasal congestion,KALBITOR in patients th HAE treated w,1
KALBITOR,nasal congestion,or subcutaneous KALBITOR Of the patients,0
KALBITOR,nasal congestion,in patients th HAE treated w,1
KALBITOR,nasal congestion,treated w ith,1
KALBITOR,nasal congestion,were,0
KALBITOR,nasal congestion,ith either intravenous or subcutaneous KALBITOR Of the patients of patients were female,0
KALBITOR,nasal congestion,described below reflect exposure to KALBITOR in patients,0
KALBITOR,throat irritation,either intraven ous or,1
KALBITOR,throat irritation,exposure to KALBITOR in patients with HAE treated wit,0
KALBITOR,throat irritation,treated h either intraven ous or subcutaneous,1
KALBITOR,throat irritation,exposure to KALBITOR in patients with HAE treated wit,0
KALBITOR,throat irritation,Of the patients of patients were female and were,0
KALBITOR,throat irritation,described below reflect exposure to KALBITOR in patients with HAE treated wit,0
KALBITOR,throat irritation,treated h either intraven ous or,1
KALBITOR,throat irritation,described below reflect exposure to KALBITOR in patients with HAE treated wit,0
KALBITOR,throat irritation,KALBITOR Of the patients of,0
KALBITOR,throat irritation,patients with HAE treated h,1
KALBITOR,throat irritation,either intraven ous or subcutaneous,1
KALBITOR,throat irritation,to KALBITOR,0
KALBITOR,urticaria,either s or subc,1
KALBITOR,urticaria,treated with either s or subc utaneous KALBITOR Of,1
KALBITOR,urticaria,either s or subc,1
KALBITOR,urticaria,s or subc,1
KALBITOR,urticaria,either s or subc,1
KALBITOR,wheezing,Of the,0
KALBITOR,wheezing,aneous K ALBITOR Of the patients,1
KALBITOR,wheezing,with HAE,0
KALBITOR,wheezing,either intravenous or aneous K ALBITOR Of the patients of,1
KALBITOR,wheezing,with HAE,0
KALBITOR,wheezing,Of the patients of patients were female and were Caucasian Patients treated,0
KALBITOR,wheezing,aneous K ALBITOR Of the patients,1
KALBITOR,wheezing,the patients of patients were female and were Caucasian,0
KALBITOR,hypotension,with,0
KALBITOR,hypotension,subcutaneous R. Of the 2 patients,1
KALBITOR,hypotension,with,0
KALBITOR,hypotension,the 2 patients,1
KALBITOR,hypotension,or subcutaneous R. Of the 2 patients of patients were female,1
KALBITOR,hypotension,the 2 patients,1
KALBITOR,hypotension,subcutaneous R. Of the 2,1
KALBITOR,hypotension,KALBITO,0
KALBITOR,hypotension,subcutaneous R. Of the 2,1
KALBITOR,hypotension,KALBITO,0
KALBITOR,hypotension,female,0
KALBITOR,hypotension,or subcutaneous R. Of the 2 patients of patients,1
KALBITOR,hypotension,female,0
KALBITOR,hypotension,to KALBITOR in,0
KALBITOR,hypersensitivity,treated with KALBITOR were een the ages,1
KALBITOR,hypersensitivity,and years Overall the most common adverse reactions in patients with HAE were,0
KALBITOR,pruritus,ost comm on adverse,1
KALBITOR,pruritus,with HAE were,0
KALBITOR,pruritus,Overall the ost comm on adverse reactions in patients,1
KALBITOR,pruritus,with HAE were,0
KALBITOR,pruritus,ost comm on adverse reactions,1
KALBITOR,pruritus,the ost,1
KALBITOR,pruritus,and years Overall the ost comm,1
KALBITOR,pruritus,were headache,0
KALBITOR,pruritus,were headache nausea fatigue diar,0
KALBITOR,pruritus,and years Overall the ost comm on adverse reactions in,1
KALBITOR,pruritus,were headache nausea fatigue diar,0
KALBITOR,rash,ts treated with KALBITOR were between the ages,0
KALBITOR,rash,rse  reactions in patients,1
KALBITOR,rash,ts treated with KALBITOR were between the ages,0
KALBITOR,rash,the most common rse  reactions in patients with,1
KALBITOR,rash,ts treated with KALBITOR were between the ages,0
KALBITOR,rash,in,0
KALBITOR,rash,common rse  reactions in patients with,1
KALBITOR,rash,in,0
KALBITOR,rash,rse  reactions in patients,1
KALBITOR,rash,rse ,1
KALBITOR,rash,between the ages of,0
KALBITOR,rash,rse  reactions in patients with,1
KALBITOR,rash,Overall the most common rse ,1
KALBITOR,rash,rse  reactions in patients with,1
KALBITOR,urticaria,n 255 pat ients,1
KALBITOR,urticaria,were headache nausea fatigue diarrhea,0
KALBITOR,urticaria,reactions n,1
KALBITOR,urticaria,reactions i,0
KALBITOR,urticaria,upper respiratory t,0
KALBITOR,urticaria,reactions n 255,1
KALBITOR,urticaria,years Overall,0
APTIOM,Suicidal Behavior,Suicidal Behavior and Ideation see Warnings and,1
APTIOM,Suicidal Behavior,in more,0
APTIOM,Suicidal Behavior,of the Suicidal Behavior,1
APTIOM,Suicidal Behavior,see Warnings and Precautions Serious Dermatologic Reactions see War,0
APTIOM,Suicidal Behavior,Suicidal Behavior and Ideation see Warnings,1
APTIOM,Suicidal Behavior,the Suicidal,1
APTIOM,Suicidal Behavior,section of the Suicidal Behavior,1
APTIOM,Suicidal Behavior,the Suicidal,1
APTIOM,Suicidal Behavior,Suicidal Behavior and,1
APTIOM,Suicidal Behavior,the Suicidal,1
APTIOM,Suicidal Behavior,Precautions section of the Suicidal Behavior,1
APTIOM,Suicidal Behavior,the Suicidal Behavior,1
APTIOM,Dermatologic Reactions,Precautions Drug Reaction with,0
APTIOM,Dermatologic Reactions,Dermatologic Reactions see,1
APTIOM,Dermatologic Reactions,Precautions Dermatologic Reactions see Warnings and Precautions,1
APTIOM,Dermatologic Reactions,Dermatologic Reactions see,1
APTIOM,Dermatologic Reactions,and Precautions Dermatologic Reactions see Warnings and Precautions,1
APTIOM,Dermatologic Reactions,Dermatologic Reactions see,1
APTIOM,Dermatologic Reactions,Warnings and Precautions Drug Reaction,0
APTIOM,Dermatologic Reactions,Dermatologic,1
APTIOM,Dermatologic Reactions,see Warnings and Precautions Serious,0
APTIOM,Dermatologic Reactions,Precautions Dermatologic Reactions,1
APTIOM,Dermatologic Reactions,see Warnings and Precautions Serious,0
APTIOM,Dermatologic Reactions,Warnings and Precautions Dermatologic Reactions see,1
APTIOM,Dermatologic Reactions,see Warnings and Precautions Serious,0
APTIOM,Dermatologic Reactions,see Warnings and Precautions Dermatologic Reactions,1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Warnings and Drug Reaction with Eosinophilia and Systemic Symptoms,1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,see Warnings and Drug Reaction with Eosinophilia and Systemic Symptoms DRESSMultiorgan Hypersensitivity see Warnings,1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Warnings and Drug Reaction with Eosinophilia and Systemic Symptoms,1
APTIOM,DRESS,with Eosinophilia and Systemic DRESS Multiorgan,1
APTIOM,DRESS,Warnings and Drug Reaction with Eosinophilia and Systemic Symptoms,1
APTIOM,DRESS,DRESS,1
APTIOM,DRESS,Warnings and Drug Reaction with Eosinophilia and Systemic Symptoms,1
APTIOM,DRESS,ee Warnings and Precautions Drug Reaction with,0
APTIOM,DRESS,Warnings and Precautions Anaphylactic,0
APTIOM,DRESS,DRESS Multiorgan Hypersensitivity,1
APTIOM,DRESS,DRESS Multiorgan,1
APTIOM,DRESS,and Precautions Drug Reaction with Eosinophilia and,0
APTIOM,Multiorgan Hypersensitivity,and Systemic Symptoms Multiorgan Hypersensitivity,1
APTIOM,Multiorgan Hypersensitivity,Systemic Symptoms Multiorgan,1
APTIOM,Multiorgan Hypersensitivity,and Systemic Symptoms Multiorgan,1
APTIOM,Multiorgan Hypersensitivity,Symptoms Multiorgan Hypersensitivity see Warnings and Precautions Anaphylactic,1
APTIOM,Multiorgan Hypersensitivity,and Systemic Symptoms Multiorgan,1
APTIOM,Multiorgan Hypersensitivity,Drug Reaction with Eosinophilia and Systemic Symptoms DRESS,0
APTIOM,Multiorgan Hypersensitivity,Multiorgan Hypersensitivity see Warnings,1
APTIOM,Multiorgan Hypersensitivity,Drug Reaction with Eosinophilia and Systemic Symptoms DRESS,0
APTIOM,Multiorgan Hypersensitivity,Systemic Symptoms Multiorgan,1
APTIOM,Multiorgan Hypersensitivity,Anaphylactic Reactions and Angioedema see Warnings,0
APTIOM,Multiorgan Hypersensitivity,Eosinophilia and Systemic Symptoms Multiorgan Hypersensitivity see,1
APTIOM,Multiorgan Hypersensitivity,Anaphylactic Reactions and Angioedema see Warnings,0
APTIOM,Multiorgan Hypersensitivity,Multiorgan Hypersensitivity see Warnings and,1
APTIOM,Anaphylactic Reactions,Anaphylactic Reactions,1
APTIOM,Angioedema,Angioedema,1
APTIOM,Angioedema,Reactions,0
APTIOM,Angioedema,Angioedema,1
APTIOM,Angioedema,Angioedema see Warnings and,1
APTIOM,Hyponatremia,see Warnings,0
APTIOM,Hyponatremia,and Hyponatremia,1
APTIOM,Hyponatremia,see Warnings,0
APTIOM,Hyponatremia,Precautions,0
APTIOM,Hyponatremia,Warnings and Precautions Neurological Adverse Reactions see Warnings,0
APTIOM,Hyponatremia,Hyponatremia,1
APTIOM,Hyponatremia,and Precautions Neurological Adverse Reactions see Warnings,0
APTIOM,Hyponatremia,Hyponatremia see Warnings,1
APTIOM,Hyponatremia,and Precautions Neurological Adverse Reactions see Warnings,0
APTIOM,Hyponatremia,and Angioedema see Warnings,0
APTIOM,Hyponatremia,and Hyponatremia see Warnings,1
APTIOM,Hyponatremia,and Angioedema see Warnings,0
APTIOM,Hyponatremia,Precautions Neurological Adverse Reactions see,0
APTIOM,Neurological Adverse Reactions,and Precautions Drug Induced Liver Injury,0
APTIOM,Neurological Adverse Reactions,Hyponatremia see Warnings and Neurological Adverse,1
APTIOM,Neurological Adverse Reactions,see Warnings and Precautions,0
APTIOM,Neurological Adverse Reactions,Neurological Adverse Reactions see Warnings and Precautions,1
APTIOM,Neurological Adverse Reactions,see Warnings and Precautions,0
APTIOM,Neurological Adverse Reactions,Neurological,1
APTIOM,Neurological Adverse Reactions,and Neurological Adverse,1
APTIOM,Drug Induced Liver Injury,and Drug Induced Liver Injury see Warnings and Precautions Abnormal,1
APTIOM,Drug Induced Liver Injury,and Neurological Adverse,1
APTIOM,Drug Induced Liver Injury,Drug Induced Liver Injury see Warnings and Precautions,1
APTIOM,Drug Induced Liver Injury,Tests see Warnings and Pr,0
APTIOM,Abnormal Thyroid Function Tests,see Warnings and Abnormal Thyroid,1
APTIOM,dizziness,diplopia,0
APTIOM,somnolence,placebo somnolence nausea,1
APTIOM,somnolence,diplopia,0
APTIOM,somnolence,greater than placebo,0
APTIOM,somnolence,placebo,0
APTIOM,somnolence,adverse reactions in patients receiving APTIOM and,0
APTIOM,headache,fatigue vertigo ataxia blurred vision and tremor To,0
APTIOM,diplopia,diplopia,1
APTIOM,diplopia,nausea diplopia vomiting fatigue vertigo ataxia,1
APTIOM,diplopia,diplopia,1
APTIOM,diplopia,and,0
APTIOM,diplopia,diplopia vomiting,1
APTIOM,diplopia,diplopia vomiting fatigue vertigo ataxia blurred,1
APTIOM,vomiting,vomiting fatigue vertigo ataxia blurred,1
APTIOM,vomiting,dizziness somnolence nausea headache vomiting fatigue vertigo ataxia blurred,1
APTIOM,vomiting,vomiting fatigue vertigo ataxia blurred,1
APTIOM,vomiting,vomiting fatigue vertigo ataxia blurred vision,1
APTIOM,vomiting,fatigue vertigo ataxia blurred vision and,0
APTIOM,vomiting,nausea headache vomiting fatigue vertigo ataxia,1
APTIOM,vomiting,fatigue vertigo ataxia blurred vision and,0
APTIOM,vomiting,vomiting,1
APTIOM,vomiting,nausea headache vomiting,1
APTIOM,vomiting,vomiting,1
APTIOM,fatigue,fatigue vertigo ataxia,1
APTIOM,vertigo,d greater than placebo dizziness somnolence nausea,0
APTIOM,vertigo,nausea headache diplopia vomiting vertigo ataxia blurred,1
APTIOM,vertigo,d greater than placebo dizziness somnolence nausea,0
APTIOM,vertigo,vertigo ataxia,1
APTIOM,vertigo,To report,0
APTIOM,vertigo,vertigo ataxia,1
APTIOM,vertigo,vertigo ataxia blurred vision,1
APTIOM,vertigo,headache diplopia vomiting vertigo ataxia blurred,1
APTIOM,vertigo,vertigo ataxia blurred vision,1
APTIOM,vertigo,dizziness somnolence nausea headache diplopia vomiting,0
APTIOM,vertigo,vertigo ataxia blurred vision and,1
APTIOM,vertigo,vertigo,1
APTIOM,ataxia,ataxia,1
APTIOM,ataxia,diplopia vomiting fatigue ataxia blurred vision and tremor To,1
APTIOM,ataxia,ataxia,1
APTIOM,ataxia,To report SUSPECTED ADVERSE REACTIONS contact Sunovio,0
APTIOM,ataxia,ataxia blurred vision and,1
APTIOM,ataxia,blurred,0
APTIOM,ataxia,ataxia blurred vision and,1
APTIOM,ataxia,ataxia blurred vision and tremor,1
APTIOM,ataxia,placebo dizziness somnolence nausea headache diplopia vomiting,0
APTIOM,blurred vision,blurred vision and,1
APTIOM,blurred vision,placebo dizziness somnolence nausea headache diplopia vomiting,0
APTIOM,blurred vision,vertigo blurred vision,1
APTIOM,blurred vision,blurred vision,1
APTIOM,blurred vision,vertigo blurred vision,1
APTIOM,blurred vision,blurred vision and tremor,1
APTIOM,blurred vision,blurred vision and tremor To report,1
APTIOM,blurred vision,blurred vision and tremor,1
APTIOM,blurred vision,contact Sunovion,0
APTIOM,blurred vision,vomiting fatigue vertigo ataxia,0
APTIOM,blurred vision,diplopia vomiting fatigue vertigo blurred vision,1
APTIOM,blurred vision,vomiting fatigue vertigo ataxia,0
APTIOM,tremor,vision and,0
APTIOM,tremor,tremor,1
APTIOM,tremor,vision and,0
APTIOM,tremor,tremor To report SUSPECTED,1
APTIOM,tremor,vertigo ataxia blurred vision tremor To report,1
APTIOM,tremor,tremor To report SUSPECTED,1
APTIOM,tremor,ADVERSE REACTIONS contact Sunovion at or,0
APTIOM,tremor,tremor To,1
APTIOM,tremor,ss,0
APTIOM,hyponatremia,hyponatremia Adverse reactions observed,1
APTIOM,hyponatremia,hyponatremia Adverse reactions observed in,1
APTIOM,hyponatremia,hyponatremia Adverse,1
APTIOM,Dizziness,Dizziness nausea somnolence and,1
APTIOM,Dizziness,Dizziness nausea somnolence and fatigue were,1
APTIOM,Dizziness,at,0
APTIOM,Dizziness,Dizziness nausea somnolence and fatigue,1
APTIOM,Dizziness,Dizziness nausea somnolence and fatigue,1
APTIOM,Dizziness,Dizziness nausea somnolence and,1
APTIOM,Dizziness,and fatigue were all reported at lower,0
APTIOM,Dizziness,Dizziness,1
APTIOM,Dizziness,Dizziness nausea somnolence and fatigue were,1
APTIOM,nausea,established,0
APTIOM,somnolence,somnolence,1
APTIOM,somnolence,established Dizziness somnolence and fatigue were,1
APTIOM,somnolence,somnolence,1
APTIOM,fatigue,Dizziness nausea somnolence,0
APTIOM,fatigue,fatigue were all reported at,1
APTIOM,fatigue,nausea somnolence fatigue were all reported,1
APTIOM,fatigue,fatigue were all reported at,1
APTIOM,fatigue,not be established Dizziness nausea,0
APTIOM,fatigue,fatigue,1
APTIOM,fatigue,Dizziness nausea somnolence fatigue were all reported at lower,1
APTIOM,fatigue,fatigue,1
APTIOM,fatigue,and,0
APTIOM,dizziness,dizziness,1
APTIOM,dizziness,dizziness nausea vomiting ataxia diplopia,1
APTIOM,vomiting,headache blurred vision vertigo,0
APTIOM,vomiting,frequency were dizziness vomiting ataxia diplopia,1
APTIOM,vomiting,headache blurred vision vertigo,0
APTIOM,vomiting,vomiting ataxia diplopia,1
APTIOM,vomiting,ataxia diplopia somnolence headache blurred vision vertigo asthenia fatigue,0
APTIOM,vomiting,somnolence headache blurred vision vertigo,0
APTIOM,ataxia,ataxia diplopia somnolence headache blurred,1
APTIOM,ataxia,ataxia diplopia somnolence headache blurred,1
APTIOM,ataxia,ataxia diplopia somnolence headache blurred vision,1
APTIOM,ataxia,descending order of frequency were dizziness nausea vomiting,0
APTIOM,ataxia,ataxia,1
APTIOM,ataxia,ataxia diplopia somnolence,1
APTIOM,ataxia,were dizziness nausea ataxia diplopia,1
APTIOM,ataxia,ataxia diplopia somnolence,1
APTIOM,ataxia,leading to discontinuation in descending order of frequency were dizziness nausea vomiting,0
APTIOM,diplopia,diplopia somnolence headache blurred vision,1
APTIOM,diplopia,vision vertigo asthenia fatigue rash,0
APTIOM,diplopia,diplopia somnolence headache blurred vision vertigo,1
APTIOM,diplopia,diplopia somnolence,1
APTIOM,diplopia,dizziness,0
APTIOM,diplopia,vision vertigo asthenia fatigue rash dysarthria and tremor,0
APTIOM,diplopia,diplopia,1
APTIOM,diplopia,diplopia,1
APTIOM,somnolence,somnolence headache blurred vision vertigo asthenia,1
APTIOM,headache,vertigo asthenia fatigue rash dysarthria and tremor The most,0
APTIOM,headache,headache blurred vision vertigo,1
APTIOM,headache,blurred vision vertigo asthenia fatigue,0
APTIOM,headache,headache blurred vision,1
APTIOM,headache,diplopia,0
APTIOM,blurred vision,blurred vision vertigo asthenia fatigue rash dysarthria,1
APTIOM,blurred vision,diplopia,0
APTIOM,blurred vision,diplopia somnolence blurred vision,1
APTIOM,blurred vision,diplopia,0
APTIOM,blurred vision,most frequently reported adverse,0
APTIOM,blurred vision,blurred vision vertigo,1
APTIOM,blurred vision,diplopia somnolence blurred,1
APTIOM,blurred vision,vomiting ataxia diplopia somnolence blurred vision vertigo asthenia fatigue,1
APTIOM,blurred vision,diplopia somnolence blurred,1
APTIOM,blurred vision,blurred vision vertigo,1
APTIOM,vertigo,vertigo asthenia fatigue,1
APTIOM,vertigo,most frequently reported adverse reaction,0
APTIOM,asthenia,asthenia fatigue rash dysarthria and,1
APTIOM,asthenia,most frequently reported adverse reaction,0
APTIOM,fatigue,vision vertigo fatigue rash dysarthria and,1
APTIOM,fatigue,most frequently reported adverse reaction,0
APTIOM,fatigue,headache blurred vision vertigo fatigue rash dysarthria and,1
APTIOM,fatigue,most frequently reported adverse reaction,0
APTIOM,fatigue,fatigue rash,1
APTIOM,fatigue,most frequently reported adverse reaction,0
APTIOM,fatigue,fatigue rash dysarthria and tremor,1
APTIOM,fatigue,fatigue rash dysarthria and tremor The,1
APTIOM,fatigue,fatigue rash,1
APTIOM,fatigue,most frequently reported,0
APTIOM,fatigue,ataxia diplopia somnolence headache,0
APTIOM,fatigue,fatigue rash dysarthria and,1
APTIOM,fatigue,fatigue rash dysarthria and tremor The,1
APTIOM,fatigue,fatigue rash dysarthria and,1
APTIOM,dysarthria,adverse,0
APTIOM,dysarthria,asthenia fatigue dysarthria and,1
APTIOM,dysarthria,adverse,0
APTIOM,dysarthria,dysarthria and tremor,1
APTIOM,dysarthria,adverse,0
APTIOM,dysarthria,vision vertigo asthenia fatigue dysarthria and tremor The most,1
APTIOM,dysarthria,adverse,0
APTIOM,dysarthria,dysarthria and tremor The most frequently,1
APTIOM,tremor,at doses of mg,0
APTIOM,tremor,vertigo asthenia,0
APTIOM,tremor,tremor The most frequently reported,1
APTIOM,tremor,and,0
APTIOM,tremor,doses of mg,0
APTIOM,tremor,tremor The most frequently,1
APTIOM,tremor,doses of mg,0
APTIOM,tremor,tremor The most frequently,1
APTIOM,tremor,The most frequently reported adverse reactions in patients receiving APTIOM at doses of mg,0
APTIOM,tremor,patients,0
APTIOM,tremor,tremor The most frequently reported,1
APTIOM,dizziness,diplopia vomiting fatigue vertigo ataxia blurred vision and tr,0
APTIOM,dizziness,dizziness,1
APTIOM,dizziness,dizziness,1
APTIOM,dizziness,than placebo dizziness somnolence nausea headache diplopia,1
APTIOM,dizziness,dizziness,1
APTIOM,dizziness,nausea headache diplopia vomiting fatigue vertigo ataxia blurred vision and tr,0
APTIOM,dizziness,n patients receiving APTIOM at doses,0
APTIOM,dizziness,dizziness,1
APTIOM,dizziness,n patients receiving APTIOM at,0
APTIOM,dizziness,placebo dizziness somnolence nausea headache,1
APTIOM,dizziness,n patients receiving APTIOM at,0
APTIOM,dizziness,and greater than placebo dizziness somnolence nausea headache diplopia vomiting,1
APTIOM,dizziness,n patients receiving APTIOM at,0
APTIOM,somnolence,somnolence nausea,1
APTIOM,somnolence,somnolence,1
APTIOM,somnolence,mg and greater than placebo were dizziness,0
APTIOM,somnolence,nausea headache diplopia vomiting fatigue vertigo ataxia blurred vision,0
APTIOM,somnolence,somnolence,1
APTIOM,somnolence,placebo were,0
APTIOM,somnolence,at doses of mg or mg and greater,0
APTIOM,somnolence,somnolence nausea headache diplopia,1
APTIOM,somnolence,placebo were somnolence nausea headache diplopia vomiting fatigue,1
APTIOM,somnolence,somnolence nausea headache diplopia,1
APTIOM,somnolence,diplopia vomiting fatigue vertigo ataxia blurred vision and,0
APTIOM,nausea,placebo were dizziness nausea headache,1
APTIOM,nausea,diplopia vomiting fatigue vertigo ataxia blurred vision and,0
APTIOM,nausea,nausea headache diplopia vomiting fatigue vertigo,1
APTIOM,nausea,were dizziness nausea headache diplopia vomiting fatigue,1
APTIOM,nausea,nausea headache diplopia vomiting fatigue vertigo,1
APTIOM,nausea,nausea headache,1
APTIOM,nausea,headache diplopia vomiting fatigue vertigo ataxia blurred vision,0
APTIOM,headache,headache diplopia vomiting fatigue vertigo,1
APTIOM,headache,Table gives,0
APTIOM,headache,doses,0
APTIOM,headache,headache diplopia vomiting fatigue,1
APTIOM,diplopia,fatigue,0
APTIOM,diplopia,were dizziness somnolence nausea diplopia vomiting,1
APTIOM,diplopia,fatigue,0
APTIOM,diplopia,headache,0
APTIOM,vomiting,the incidence of,0
APTIOM,vomiting,somnolence nausea headache vomiting fatigue vertigo ataxia blurred,1
APTIOM,vomiting,the incidence of,0
APTIOM,vomiting,vomiting fatigue vertigo ataxia blurred vision,1
APTIOM,vomiting,greater than placebo were dizziness somnolence nausea,0
APTIOM,vomiting,vomiting,1
APTIOM,vomiting,vomiting fatigue,1
APTIOM,vomiting,vomiting fatigue vertigo ataxia,1
APTIOM,vomiting,vomiting fatigue,1
APTIOM,vomiting,vomiting fatigue,1
APTIOM,vomiting,vomiting fatigue,1
APTIOM,vomiting,ataxia blurred vision,0
APTIOM,vomiting,nausea headache vomiting fatigue vertigo,1
APTIOM,vomiting,ataxia blurred vision,0
APTIOM,fatigue,fatigue vertigo,1
APTIOM,fatigue,headache diplopia fatigue vertigo ataxia,1
APTIOM,fatigue,fatigue vertigo,1
APTIOM,fatigue,fatigue vertigo ataxia blurred vision,1
APTIOM,fatigue,headache diplopia fatigue vertigo ataxia blurred vision,1
APTIOM,fatigue,fatigue vertigo ataxia blurred vision,1
APTIOM,fatigue,fatigue vertigo ataxia blurred vision and,1
APTIOM,fatigue,fatigue vertigo ataxia blurred vision and,1
APTIOM,fatigue,fatigue vertigo ataxia blurred vision and,1
APTIOM,vertigo,vertigo,1
APTIOM,vertigo,headache diplopia vomiting vertigo ataxia blurred vision and tremor,1
APTIOM,vertigo,vertigo,1
APTIOM,vertigo,nausea headache diplopia vomiting vertigo ataxia blurred vision,1
APTIOM,vertigo,vertigo,1
APTIOM,vertigo,vertigo ataxia,1
APTIOM,vertigo,adverse reactions that o,0
APTIOM,vertigo,and tremor Table,0
APTIOM,vertigo,were dizziness somnolence nausea headache diplopia vomiting,0
APTIOM,vertigo,and tremor Table gives the incidence,0
APTIOM,blurred vision,in of,0
APTIOM,blurred vision,reactions that occurred in,0
APTIOM,blurred vision,vomiting fatigue vertigo blurred vision,1
APTIOM,blurred vision,reactions that occurred in,0
APTIOM,blurred vision,blurred vision and tremor Table gives the,1
APTIOM,blurred vision,blurred vision and tremor Table,1
APTIOM,blurred vision,fatigue vertigo blurred vision,1
APTIOM,blurred vision,vertigo blurred vision,1
APTIOM,blurred vision,ataxia,0
APTIOM,tremor,incidence of adverse reactions that occurred in,0
APTIOM,tremor,nausea headache diplopia vomiting fatigue,0
APTIOM,tremor,tremor,1
APTIOM,tremor,tremor Table gives the incidence,1
APTIOM,tremor,tremor Table gives the,1
APTIOM,Vertigo,Ear and labyrinth Vertigo Eye disorders,1
APTIOM,Vertigo,tremor Table gives the,1
APTIOM,Vertigo,N Ear and labyrinth Vertigo Eye disorders,1
APTIOM,Vertigo,tremor Table gives the,1
APTIOM,Vertigo,Eye disorders,0
APTIOM,Vertigo,Eye disorders Diplopia,0
APTIOM,Vertigo,labyrinth,0
APTIOM,Vertigo,Vertigo Eye,1
APTIOM,Diplopia,Diplopia Blurred vision Visual impairment,1
APTIOM,Diplopia,vision Visual,0
APTIOM,Diplopia,Eye Diplopia Blurred vision Visual,1
APTIOM,Diplopia,vision Visual,0
APTIOM,Diplopia,Blurred,0
APTIOM,Diplopia,Diplopia Blurred vision Visual,1
APTIOM,Diplopia,Vertigo Eye Diplopia Blurred vision Visual impairment,1
APTIOM,Diplopia,Diplopia Blurred vision Visual,1
APTIOM,Diplopia,Diplopia Blurred vision Visual impairment,1
APTIOM,Diplopia,Diplopia Blurred vision Visual,1
APTIOM,Diplopia,Diplopia Blurred,1
APTIOM,Blurred vision,Visual impairment Gastroint,0
APTIOM,Blurred vision,disorders Blurred,1
APTIOM,Blurred vision,Diplopia,0
APTIOM,Blurred vision,Eye disorders Blurred vision Visual impairment Gastroint,1
APTIOM,Blurred vision,Diplopia,0
APTIOM,Blurred vision,Visual,0
APTIOM,Blurred vision,Blurred vision Visual,1
APTIOM,Blurred vision,Eye disorders Blurred vision Visual impairment,1
APTIOM,Blurred vision,Blurred vision Visual,1
APTIOM,Visual impairment,Visual impairment Gastrointestinal,1
APTIOM,Visual impairment,Diplopia,0
APTIOM,Visual impairment,Eye disorders Diplopia Blurred vision,0
APTIOM,Visual impairment,Diplopia Blurred Visual,1
APTIOM,Visual impairment,Visual impairment Gastrointestinal disorders,1
APTIOM,Visual impairment,Diplopia Blurred Visual,1
APTIOM,Visual impairment,disorders,0
APTIOM,Visual impairment,Diplopia Blurred Visual impairment Gastrointestinal,1
APTIOM,Visual impairment,disorders,0
APTIOM,Visual impairment,Visual impairment,1
APTIOM,Visual impairment,disorders,0
APTIOM,Visual impairment,Visual impairment Gastrointestinal disorders,1
APTIOM,Nausea,Nausea Vomiting Diarrhea Constipation,1
APTIOM,Nausea,Nausea Vomiting Diarrhea,1
APTIOM,Nausea,Nausea Vomiting Diarrhea Constipation Abdominal pain,1
APTIOM,Nausea,Nausea Vomiting Diarrhea,1
APTIOM,Nausea,disorders,0
APTIOM,Nausea,Abdominal pain,0
APTIOM,Vomiting,Diarrhea Constipation Abdominal pain,0
APTIOM,Vomiting,Vomiting Diarrhea Constipation Abdominal pain Gastritis,1
APTIOM,Vomiting,Diarrhea Constipation Abdominal pain,0
APTIOM,Diarrhea,Diarrhea Constipation Abdominal,1
APTIOM,Diarrhea,Diarrhea,1
APTIOM,Diarrhea,Diarrhea Constipation Abdominal,1
APTIOM,Constipation,Constipation Abdominal,1
APTIOM,Constipation,Constipation Abdominal pain Gastritis,1
APTIOM,Constipation,Constipation Abdominal,1
APTIOM,Constipation,Constipation Abdominal pain Gastritis,1
APTIOM,Abdominal pain,Nausea Vomiting Diarrhea Abdominal pain Gastritis,1
APTIOM,Abdominal pain,Constipation Abdominal pain Gastritis,1
APTIOM,Abdominal pain,Nausea Vomiting Diarrhea Abdominal pain Gastritis General disorders,1
APTIOM,Abdominal pain,Constipation Abdominal pain Gastritis,1
APTIOM,Abdominal pain,Diarrhea Constipation,0
APTIOM,Abdominal pain,Constipation,0
APTIOM,Gastritis,Gastritis General disorders,1
APTIOM,Gastritis,Gastritis General disorders and administr,1
APTIOM,Gastritis,disorders and administr,0
APTIOM,Gastritis,pain,0
APTIOM,Fatigue,Fatigue Asthenia Gait,1
APTIOM,Fatigue,Fatigue Asthenia Gait disturbance,1
APTIOM,Fatigue,Fatigue Asthenia,1
APTIOM,Fatigue,Gait disturbance Peripheral,0
APTIOM,Fatigue,Fatigue Asthenia Gait,1
APTIOM,Fatigue,Fatigue Asthenia Gait disturbance Peripheral edema,1
APTIOM,Fatigue,Fatigue Asthenia Gait disturbance,1
APTIOM,Fatigue,Fatigue,1
APTIOM,Fatigue,Fatigue Asthenia Gait disturbance,1
APTIOM,Fatigue,Gait disturbance Peripheral,0
APTIOM,Asthenia,disturbance Peripheral,0
APTIOM,Gait disturbance,Fatigue Gait,1
APTIOM,Gait disturbance,Fatigue Gait disturbance Peripheral edema,1
APTIOM,Gait disturbance,Fatigue Gait,1
APTIOM,Gait disturbance,s Fatigue Gait disturbance Peripheral,1
APTIOM,Gait disturbance,Fatigue Gait,1
APTIOM,Gait disturbance,s,0
APTIOM,Gait disturbance,Fatigue,0
APTIOM,Gait disturbance,Fatigue Gait disturbance,1
APTIOM,Gait disturbance,Fatigue,0
APTIOM,Gait disturbance,Gait,1
APTIOM,Peripheral edema,Peripheral edema,1
APTIOM,Dizziness,Ataxia Balance disorder,0
APTIOM,Somnolence,Somnolence Headache Ataxia Balance,1
APTIOM,Somnolence,Ataxia Balance disorder,0
APTIOM,Somnolence,Somnolence Headache Ataxia Balance disorder,1
APTIOM,Somnolence,Somnolence Headache Ataxia,1
APTIOM,Somnolence,Somnolence Headache Ataxia Balance disorder,1
APTIOM,Somnolence,Somnolence Headache Ataxia,1
APTIOM,Somnolence,disorder Tremor Dysarthria Memory impairment,0
APTIOM,Somnolence,Tremor Dysarthria,0
APTIOM,Headache,Headache Ataxia Balance,1
APTIOM,Ataxia,Ataxia Balance disorder Tremor Dysarthria,1
APTIOM,Ataxia,Ataxia Balance disorder Tremor Dysarthria Memory,1
APTIOM,Ataxia,Headache,0
APTIOM,Balance disorder,Balance disorder Tremor,1
APTIOM,Balance disorder,Dysarthria Memory impairment Nystagmus,0
APTIOM,Balance disorder,Headache Balance disorder,1
APTIOM,Balance disorder,disorders Dizziness Somnolence Headache,0
APTIOM,Tremor,Somnolence Headache Ataxia Balance Tremor,1
APTIOM,Tremor,disorders Dizziness Somnolence Headache,0
APTIOM,Tremor,Tremor Dysarthria Memory impairment Nystagmus,1
APTIOM,Dysarthria,Headache Ataxia Balance disorder Dysarthria,1
APTIOM,Dysarthria,Tremor Dysarthria Memory impairment Nystagmus,1
APTIOM,Dysarthria,Memory impairment Nystagmus,0
APTIOM,Dysarthria,Memory,0
APTIOM,Memory impairment,disorder Tremor Memory,1
APTIOM,Memory impairment,disorder Tremor,0
APTIOM,Memory impairment,Nystagmus Psychiatric disor,0
APTIOM,Memory impairment,Tremor Dysarthria,0
APTIOM,Nystagmus,Psychiatric,0
APTIOM,Nystagmus,Nystagmus Psychiatric,1
APTIOM,Depression,Psychiatric Depression,1
APTIOM,Depression,Nystagmus Psychiatric,1
APTIOM,Depression,agmus,0
APTIOM,Insomnia,Insomnia,1
APTIOM,Insomnia,thoracic and,0
APTIOM,Insomnia,Psychiatric,0
APTIOM,Insomnia,Insomnia,1
APTIOM,Insomnia,Insomnia Respiratory thoracic and,1
APTIOM,Insomnia,Insomnia Respiratory thoracic,1
APTIOM,Insomnia,Insomnia Respiratory,1
APTIOM,Rash,Rash Vascular,1
APTIOM,Rash,disorders,0
APTIOM,Rash,Vascular disorders Hyperten,0
APTIOM,Rash,disorders,0
APTIOM,Hypertension,Hypertension Other,1
APTIOM,Hypertension,disorders,0
APTIOM,Hypertension,Hypertension Other,1
APTIOM,Hypertension,Hypertension,1
APTIOM,Hypertension,Vascular disorders,0
APTIOM,Hypertension,Vascular,0
APTIOM,Hypertension,Vascular disorders,0
APTIOM,Suicidal Behavior,more detail in the Warnings and Precautions section,0
APTIOM,Suicidal Behavior,The following adverse ctions are descri,1
APTIOM,Suicidal Behavior,more detail in the Warnings and Precautions section,0
APTIOM,Suicidal Behavior,in the Warnings and Precautions section of the label,0
APTIOM,Suicidal Behavior,adverse ctions are descri bed,1
APTIOM,Suicidal Behavior,in the Warnings and Precautions section of the label,0
APTIOM,Suicidal Behavior,are descri bed in more detail,1
APTIOM,Suicidal Behavior,of the,0
APTIOM,Dermatologic Reactions,of the  Suicidal Behavior and Ideation see Warnings and Precautions,1
APTIOM,Dermatologic Reactions,of the,0
APTIOM,Dermatologic Reactions,section of the Suicidal Behavior,1
APTIOM,Dermatologic Reactions,Serious Dermatologic,0
APTIOM,Dermatologic Reactions,the  Suicidal Behavior and,1
APTIOM,Dermatologic Reactions,Serious Dermatologic,0
APTIOM,Dermatologic Reactions,more detail in the Warnings and Precautions section of,0
APTIOM,Dermatologic Reactions,Suicidal Behavior and,1
APTIOM,Dermatologic Reactions,Reactions,0
APTIOM,Dermatologic Reactions,Suicidal Behavior and Ideation see Warnings and,1
APTIOM,Dermatologic Reactions,the Suicidal Behavior,1
APTIOM,Dermatologic Reactions,section of the Suicidal Behavior,1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Serious Dermatologic Reactions see Warnings and Precautions Drug Reaction with,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,"label Suicidal Behavior and deation [see Warnings and Precautions (  5.1  )]  
 *",1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Serious Dermatologic Reactions see Warnings and Precautions Drug Reaction with,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,in the Warnings and Precautions section of the label Suicidal Behavior and,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,and Precautions section of the label Suicidal Behavior and I,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,in the Warnings and Precautions section of the label Suicidal Behavior and,0
APTIOM,DRESS,of the label Suicidal Behavior,0
APTIOM,DRESS,see Warnings and Precautions,0
APTIOM,DRESS,Serio us Dermatologic Reactions,1
APTIOM,Anaphylactic Reactions,and Systemic Symptom,0
APTIOM,Anaphylactic Reactions,Warnings and Precautions Dermatologic,1
APTIOM,Angioedema,Precautions Serious Dermatologic Reactions  Warnings  and Precautions Drug,1
APTIOM,Angioedema,Warnings and Precautions Dermatologic,1
APTIOM,Angioedema, Warnings  and Precautions Drug Reaction,1
APTIOM,Angioedema,Warnings and,0
APTIOM,Angioedema,and Ideation see Warnings and Precautions Serious Dermatologic,0
APTIOM,Angioedema, Warnings  and,1
APTIOM,Angioedema, Warnings  and Precautions,1
APTIOM,Angioedema, Warnings  and Precautions Drug,1
APTIOM,Angioedema,Precautions Serious Dermatologic Reactions  Warnings ,1
APTIOM,Angioedema, Warnings  and Precautions Drug,1
APTIOM,Angioedema,with Eosinophilia and Systemic Symptoms,0
APTIOM,Neurological Adverse Reactions,Precautions Neurological,0
APTIOM,Neurological Adverse Reactions,see nings and Precautions (  5.4   Hyponatremia see Warnings,1
APTIOM,Neurological Adverse Reactions,Precautions Neurological,0
APTIOM,Neurological Adverse Reactions,Hyponatremia see Warnings,0
APTIOM,Neurological Adverse Reactions,Warnings and Precautions,0
APTIOM,Neurological Adverse Reactions,Precautions Neurological Adverse,0
APTIOM,Neurological Adverse Reactions,Angioedema see nings and Precautions,1
APTIOM,Neurological Adverse Reactions,Precautions ( 5.4 Hyponatremia see Warnings and,1
APTIOM,Neurological Adverse Reactions,see nings and Precautions (  5.4   Hyponatremia,1
APTIOM,Neurological Adverse Reactions,Precautions ( 5.4 Hyponatremia see Warnings and,1
APTIOM,Drug Induced Liver Injury,nausea,0
APTIOM,Drug Induced Liver Injury,common adverse ons in patients receiving APTIOM and,1
APTIOM,Drug Induced Liver Injury,nausea,0
APTIOM,Drug Induced Liver Injury,reacti,0
APTIOM,Drug Induced Liver Injury,and greater than placebo dizziness somnolence nausea,0
APTIOM,Drug Induced Liver Injury,greater than placebo dizziness somnolence nausea headache diplopia,0
APTIOM,Drug Induced Liver Injury,somnolence nausea headache diplopia,0
APTIOM,Drug Induced Liver Injury,patients receiving APTIOM and greater,1
APTIOM,suicidal thoughts,report SUSPECTED ADVERSE,0
APTIOM,suicidal thinking,"Clinical Studies patients received IOM, of whom 225",1
APTIOM,suicidal thinking,whom 225,1
APTIOM,suicidal thinking,"patients received IOM,",1
APTIOM,suicidal thinking,"Clinical Studies patients received IOM, of whom 225  were treated for longer than",1
APTIOM,suicidal thinking,"patients received IOM,",1
APTIOM,suicidal thinking,whom 225 were treated for,1
APTIOM,suicidal thinking,Studies patients,0
APTIOM,suicidal thinking,and for longer than months Of the patients,0
APTIOM,suicidal thinking,longer,0
APTIOM,suicidal thinking,were,1
APTIOM,suicidal thinking,received APTIOM of were treated for,1
APTIOM,suicidal thinking,were treated for  longer,1
APTIOM,suicidal thinking,received APTIOM of were treated for,1
APTIOM,suicidal thinking,of were treated for  longer,1
APTIOM,suicidal thinking,received APTIOM of were treated for,1
APTIOM,suicidal thinking,of were treated for,1
APTIOM,suicidal thinking,treated for,1
APTIOM,suicides,e placeb o,1
APTIOM,suicides,treated for,1
APTIOM,suicides,APTIOM of whom were treated,0
APTIOM,suicides,longer than,0
APTIOM,suicidal thoughts,in those trials approximately e between 18 and,1
APTIOM,suicidal thoughts,approximately e between 18 and ,1
APTIOM,suicidal thoughts,in those trials approximately e between 18 and,1
APTIOM,suicidal thoughts,in those trials approximately e between 18 and  years old approximately were male,1
APTIOM,suicidal thoughts,in those trials approximately e between 18 and,1
APTIOM,suicidal thoughts,in those trials approximately e between 18 and  years old approximately,1
APTIOM,suicidal thoughts,in those trials approximately e between 18 and,1
APTIOM,suicidal thoughts,APTIOM Of,0
APTIOM,suicidal thoughts,e between 18 and  years old approximately were male,1
APTIOM,suicidal thoughts,APTIOM Of,0
APTIOM,suicidal thoughts,between 18 and years old approximately were male,1
APTIOM,suicidal thoughts,between 18 and years old approximately were,1
APTIOM,suicidal thoughts,those trials approximately e between 18 and  years old approximately were,1
APTIOM,suicidal thoughts,between 18 and years old approximately were,1
APTIOM,suicidal thoughts,in those trials,0
APTIOM,suicidal thoughts,at the recommend ed doses of,1
APTIOM,suicidal thoughts,at the recommend ed doses of mg and,1
APTIOM,suicidal thoughts,and mg once daily discontinued from the,0
APTIOM,suicidal thoughts,randomized to receive at,1
APTIOM,suicidal thoughts,APTIOM,0
APTIOM,suicidal thoughts,of,0
APTIOM,suicidal thoughts,as a result o f an adverse,1
APTIOM,Suicidal Thoughts,fatigue were all reported at,0
APTIOM,Suicidal Thoughts,Titration Phase,0
APTIOM,Suicidal Thoughts,incidences durin g the AED Withdrawal,1
APTIOM,Suicidal Thoughts,incidences durin g,1
APTIOM,Suicidal Thoughts,Phase compared with the Titration,0
APTIOM,Suicidal Thoughts,and fatigue were all reported at lower,0
APTIOM,Suicidal Thoughts,Withdrawal Phase,0
APTIOM,suicidal thoughts,than,0
APTIOM,suicidal thoughts,than ebo) were dizzine ss somnolence nausea,1
APTIOM,suicidal thoughts,than,0
APTIOM,suicidal thoughts,ebo) were dizzine ss somnolence nausea,1
APTIOM,suicidal thoughts,mg and greater than ebo),1
APTIOM,suicidal thoughts,greater than,0
APTIOM,suicidal thoughts,receiving,0
APTIOM,mortality,initial dose mg for 1  week and,1
APTIOM,mortality,receiving,0
APTIOM,mortality,for 1 week and then increased,1
APTIOM,mortality,and then increased to mg compared to patients who initiated therapy at mg,0
APTIOM,mortality,mg for 1 week and,1
APTIOM,suicidal thoughts,and then increased  800 mg compared  to patients who,1
APTIOM,suicidal thoughts,mg for 1 week and,1
APTIOM,suicidal thoughts,and,0
APTIOM,suicidal thoughts,then increased 800 mg,1
APTIOM,suicidal thoughts,patients who began therapy at an initial dose of mg for week,0
APTIOM,suicidal thoughts,then increased  800 mg compared  to patients who initiated therapy,1
APTIOM,suicidal thoughts,patients who began therapy at an initial dose of mg for week,0
APTIOM,suicidal thoughts,dose of mg for week and,0
APTIOM,suicidal thoughts,mg for week,0
APTIOM,suicidal thoughts,then increased 800 mg,1
APTIOM,suicidal thoughts,800 mg compared,1
APTIOM,suicidal thoughts,therapy at mg Table Adverse Reactions Incidence in Pooled,0
APTIOM,dermatologic reactions,disorders Diplopia Blurred vision Visual,0
APTIOM,dermatologic reactions,      1151             Gastrointestinal disorders,1
APTIOM,dermatologic reactions,disorders Diplopia Blurred vision Visual,0
APTIOM,dermatologic reactions,ye disorders Diplopia Blurred vision,0
APTIOM,dermatologic reactions,      1151             Gastrointestinal disorders,1
APTIOM,Stevens-Johnson Syndrome,Gastrointestinal disor,1
APTIOM,Stevens-Johnson Syndrome,"rred vision Visual 
 Gastrointestinal disor ders",1
APTIOM,Stevens-Johnson Syndrome,Gastrointestinal disor,1
APTIOM,Stevens-Johnson Syndrome,vision,0
APTIOM,Stevens-Johnson Syndrome,Gastrointestinal disor ders,1
APTIOM,Stevens-Johnson Syndrome,Visual,0
APTIOM,SJS,rs ,1
APTIOM,fatal,Constipation,0
APTIOM,fatal,      Nausea Vomiting Diarrhea Constipation Abdominal,1
APTIOM,fatal,      Nausea Vomiting,1
APTIOM,fatal,      Nausea Vomiting Diarrhea Constipation Abdominal,1
APTIOM,fatal,Nausea Vomiting Diarrhea Constipation,0
APTIOM,fatal,Diarrhea Constipation,0
APTIOM,fatal,strointestinal       Nausea Vomiting Diarrhea Constipation,1
APTIOM,fatal,Diarrhea Constipation,0
APTIOM,fatal,disorders,0
APTIOM,fatal,Constipation Abdominal pain Gastritis,0
APTIOM,fatal,      Nausea,1
APTIOM,fatal,Constipation Abdominal pain,0
APTIOM,dermatologic reactions,Nausea Vomit,1
APTIOM,dermatologic reactions,testinal       Nausea     Vomit ing Diarrhea Constipation Abdominal pain,1
APTIOM,dermatologic reactions,Nausea Vomit,1
APTIOM,dermatologic reactions,Diarrhea Constipation Abdominal,0
APTIOM,dermatologic reactions,testinal       Nausea     Vomit,1
APTIOM,dermatologic reactions,Diarrhea Constipation Abdominal,0
APTIOM,dermatologic reactions,      Nausea     Vomit,1
APTIOM,dermatologic reactions,Diarrhea Constipation Abdominal,0
APTIOM,dermatologic reactions,Nausea Vomit ing Diarrhea Constipation Abdominal,1
APTIOM,toxic epidermal necrolysis,Nausea Vomiting rhea,1
APTIOM,toxic epidermal necrolysis,rhea Constipation,1
APTIOM,toxic epidermal necrolysis,Nausea Vomiting rhea     Constipation     ,1
APTIOM,toxic epidermal necrolysis,rhea Constipation,1
APTIOM,toxic epidermal necrolysis,Nausea Vomiting rhea,1
APTIOM,toxic epidermal necrolysis,Abdominal pain Gastritis,0
APTIOM,toxic epidermal necrolysis,Diar,0
APTIOM,TEN,dom inal pain Gastritis General,1
APTIOM,TEN,dom inal pain Gastritis,1
APTIOM,TEN,Diarrhea,0
APTIOM,TEN,dom inal pain Gastritis General,1
APTIOM,TEN,Diarrhea,0
APTIOM,TEN,inal pain Gastritis General,0
APTIOM,TEN,dom inal pain,1
APTIOM,TEN,Diarrhea Constipation dom inal,1
APTIOM,TEN,dom inal pain,1
APTIOM,TEN,dom inal,1
APTIOM,TEN,dom,1
APTIOM,TEN,dom inal,1
APTIOM,SJS,ain,1
APTIOM,SJS,ain Gastritis General disorders,1
APTIOM,SJS,Gastritis General,0
APTIOM,SJS,ain Gastritis General,1
APTIOM,SJS,Nausea Vomiting,0
APTIOM,SJS,Diarrhea Constipation,0
APTIOM,SJS,Gastritis General disorders,0
APTIOM,SJS,Nausea Vomiting Diarrhea,0
APTIOM,dermatologic reactions,           7321        Infections and Infestations Urinary tract,1
APTIOM,dermatologic reactions,           7321        Infections and Infestations Urinary tract,1
APTIOM,dermatologic reactions,           7321        Infections and Infestations Urinary tract,1
APTIOM,dermatologic reactions,Peripheral            7321       ,1
APTIOM,dermatologic reactions,           7321        Infections and Infestations Urinary tract,1
APTIOM,dermatologic reactions,           7321        Infections,1
APTIOM,dermatologic reactions,Gait disturbance Peripheral            7321        Infections and,1
APTIOM,dermatologic reactions,           7321        Infections,1
APTIOM,dermatologic reactions,Urinary,0
APTIOM,dermatologic reactions,Gait,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,"and nutrition                                 
      Hyponatremia  ",1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,Gait,0
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,"                                
      Hyponatremia   Nervous",1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,"                                
      Hyponatremia   Nervous",1
APTIOM,Drug Reaction with Eosinophilia and Systemic Symptoms,"                                
      Hyponatremia   Nervous",1
APTIOM,DRESS,      Nervous system di,1
APTIOM,DRESS,ders,0
APTIOM,DRESS,      Nervous system,1
APTIOM,DRESS,ders,0
APTIOM,DRESS,      Nervous,1
APTIOM,fatal,ers   Dizziness Somnolence Headache Ataxia,1
APTIOM,fatal,ers   Dizziness Somnolence,1
APTIOM,fatal,system disord,0
APTIOM,fatal,ers   Dizziness Somnolence Headache Ataxia Balance,1
APTIOM,DRESS,lence Headache Ataxia,1
APTIOM,DRESS,Ataxia Balance disorder Tremor Dysarthria,0
APTIOM,DRESS,Dysarthria,0
APTIOM,DRESS,system disorders Dizziness Somno,0
APTIOM,DRESS,system disorders Dizziness lence Headache Ataxia Balance disorder,1
APTIOM,DRESS,system disorders Dizziness Somno,0
APTIOM,fever,emor ,1
APTIOM,fever,emor  Dysarthria,1
APTIOM,fever,emor  Dysarthria Memory,1
APTIOM,fever,emor  Dysarthria Memory,1
APTIOM,fever,Dysarthria Memory,0
APTIOM,fever,disorder Tr,0
APTIOM,rash,Ataxia Balance disorder   Dy sarthria Memory,1
APTIOM,rash,disorder Tr,0
APTIOM,rash,Balance disorder   Dy sarthria Memory impairment Nystagmus,1
APTIOM,rash,disorder Tr,0
APTIOM,lymphadenopathy,Balance disorder,0
APTIOM,lymphadenopathy,disorder Tremor Memory impa,1
APTIOM,hepatitis,Memory,0
APTIOM,hepatitis,disorders Depression,0
APTIOM,hepatitis,Dysarthria Memory impairment 181563422,1
APTIOM,hepatitis,disorders Depression,0
APTIOM,hepatitis,181563422 Psychiatric,1
APTIOM,hepatitis,Memory impairment 181563422 Psychiatric disorders Depression,1
APTIOM,hepatitis,181563422 Psychiatric,1
APTIOM,hepatitis,181563422 Psychiatric,1
APTIOM,hepatitis,181563422,1
APTIOM,hepatitis,Psychiatric,0
APTIOM,nephritis,          Psychiatric disorders,1
APTIOM,nephritis,          Psychiatric disorders,1
APTIOM,nephritis,disorders Depression,0
APTIOM,nephritis,Memory impairment           Psychiatric disorders Depression Insomnia,1
APTIOM,nephritis,disorders Depression,0
APTIOM,nephritis,          Psychiatric,1
APTIOM,nephritis,          Psychiatric disorders,1
APTIOM,nephritis,Memory impairment           Psychiatric disorders Depression,1
APTIOM,nephritis,          Psychiatric disorders,1
APTIOM,nephritis,          Psychiatric disorders,1
APTIOM,hematological abnormalities,Psychiatric disorders Depression Insomnia,1
APTIOM,hematological abnormalities,"   
 Psychiatric disorders ",1
APTIOM,hematological abnormalities,Psychiatric disorders Depression Insomnia,1
APTIOM,myocarditis,disorders,0
APTIOM,myocarditis,  Depressio n,1
APTIOM,myocarditis,  Depressio n Insomnia Respiratory thor,1
APTIOM,myocarditis,Psychiatric   Depressio n,1
APTIOM,myocarditis,  Depressio n Insomnia Respiratory thor,1
APTIOM,myocarditis,  Depressio,1
APTIOM,myocarditis,stagmus Psychiatric,0
APTIOM,myocarditis,  Depressio n Insomnia,1
APTIOM,myocarditis,  Depressio n Insomnia Respiratory thor,1
APTIOM,myocarditis,stagmus Psychiatric   Depressio n Insomnia,1
APTIOM,myocarditis,  Depressio n Insomnia Respiratory thor,1
APTIOM,myocarditis,  Depressio n,1
APTIOM,myositis, Insomni,1
APTIOM,myositis,  Depressio n,1
APTIOM,myositis, Insomni,1
APTIOM,myositis,Respiratory thoracic and,0
APTIOM,myositis,Psychiatric disorders,0
APTIOM,myositis,Depression,0
APTIOM,myositis, Insomni a Respiratory thoracic,1
APTIOM,myositis,a,0
APTIOM,Eosinophilia,disorders Depression              Respiratory thoracic,1
APTIOM,Eosinophilia,a,0
APTIOM,Eosinophilia,Insomnia,0
APTIOM,Eosinophilia,Psychiatric disorders Depression              Respiratory thoracic and mediastinal disorders,1
APTIOM,Eosinophilia,Insomnia,0
APTIOM,Eosinophilia,             Respiratory thoracic and,1
APTIOM,Eosinophilia,             Respiratory thoracic and mediastinal,1
APTIOM,Eosinophilia,and mediastinal,0
APTIOM,Eosinophilia,             Respiratory thoracic,1
APTIOM,Eosinophilia,disorders,0
APTIOM,Eosinophilia,Insomnia,0
APTIOM,Eosinophilia,and mediastinal disorders,0
APTIOM,rash,sue disorders Rash Vascular,0
APTIOM,angioedema,in creatin,1
APTIOM,angioedema,in hemoglobin and,0
APTIOM,angioedema,in creatin e phosphokinase Adverse Reactions Based,1
APTIOM,angioedema,triglycerides and LDL and in creatin e phosphokinase Adverse Reactions,1
APTIOM,angioedema,in creatin e phosphokinase Adverse Reactions Based,1
APTIOM,angioedema,hemoglobin and hematocrit,0
APTIOM,angioedema,gender differences,0
APTIOM,angioedema,reactions,0
APTIOM,angioedema,"Race  



",1
APTIOM,angioedema,phosphokinase Adverse Reactions Based on Gender and,0
APTIOM,angioedema,"Based on Gender Race  



 No significant",1
APTIOM,angioedema,phosphokinase Adverse Reactions Based on Gender and,0
APTIOM,angioedema,"Race  



 No significant gender differences",1
APTIOM,angioedema,reactions,0
APTIOM,angioedema,"Race  



 No significant gender",1
APTIOM,laryngeal edema,of adverse reactions Although there were few,0
APTIOM,laryngeal edema,and Race No significant ender differenc,1
APTIOM,laryngeal edema,in the incidence of adverse reactions Although there were few nonCaucasian,0
APTIOM,laryngeal edema,ender,1
APTIOM,fatal,Although there were few,0
APTIOM,fatal,noted in,1
APTIOM,fatal,noted in the incidence,1
APTIOM,fatal,noted in the incidence,1
APTIOM,fatal,noted in the incidence,1
APTIOM,fatal,No significant,0
DUAVEE,Cardiovascular Disorders,of the Cardiovascular Disorders see Warnings,1
DUAVEE,Cardiovascular Disorders,No significant,0
DUAVEE,Cardiovascular Disorders,discussed in greater,0
DUAVEE,Cardiovascular Disorders,Cardiovascular Disorders see Warnings,1
DUAVEE,Cardiovascular Disorders,in greater,0
DUAVEE,Cardiovascular Disorders,see Warnings and Precautions Malignant,0
DUAVEE,Malignant Neoplasms,Malignant,1
DUAVEE,Malignant Neoplasms,and Malignant Neoplasms,1
DUAVEE,Malignant Neoplasms,Precautions,0
DUAVEE,Malignant Neoplasms,and Precautions Gallbladder Disease see,0
DUAVEE,Malignant Neoplasms,and Precautions Gallbladder Disease see Warnings and Precautions,0
DUAVEE,Malignant Neoplasms,Cardiovascular Disorders see,0
DUAVEE,Malignant Neoplasms,Disorders see Warnings and Malignant Neoplasms,1
DUAVEE,Malignant Neoplasms,Malignant Neoplasms,1
DUAVEE,Malignant Neoplasms,Warnings and Malignant,1
DUAVEE,Gallbladder Disease,Warnings and Precautions,0
DUAVEE,Gallbladder Disease,and Gallbladder,1
DUAVEE,Gallbladder Disease,Malignant Neoplasms,0
DUAVEE,Gallbladder Disease,Precautions,0
DUAVEE,Gallbladder Disease,Gallbladder Disease,1
DUAVEE,Gallbladder Disease,gs and Precautions Malignant Neoplasms see Warnings,0
DUAVEE,Gallbladder Disease,see Warnings and Gallbladder Disease see Warnings and,1
DUAVEE,Gallbladder Disease,gs and Precautions Malignant Neoplasms see Warnings,0
DUAVEE,Gallbladder Disease,Gallbladder Disease,1
DUAVEE,Hypertriglyceridemia,see Warnings and Precautions EXCERPT In four,0
DUAVEE,muscle spasms,incidence were,0
DUAVEE,muscle spasms,reactions incidence,0
DUAVEE,muscle spasms,abdominal pain upper oropharyngeal,0
DUAVEE,muscle spasms,incidence muscle spasms nausea diarrhea,1
DUAVEE,muscle spasms,abdominal pain upper oropharyngeal,0
DUAVEE,muscle spasms,reactions incidence muscle spasms nausea diarrhea,1
DUAVEE,muscle spasms,abdominal pain upper oropharyngeal,0
DUAVEE,nausea,nausea diarrhea dyspepsia abdominal pain,1
DUAVEE,nausea,the common adverse reactions incidence were muscle spasms,0
DUAVEE,nausea,incidence were muscle nausea diarrhea,1
DUAVEE,nausea,the common adverse reactions incidence were muscle spasms,0
DUAVEE,nausea,pain upper,0
DUAVEE,nausea,nausea diarrhea dyspepsia abdominal,1
DUAVEE,nausea,incidence were muscle spasms,0
DUAVEE,nausea,pain upper oropharyngeal pain dizziness and neck pain,0
DUAVEE,nausea,nausea diarrhea dyspepsia abdominal,1
DUAVEE,diarrhea,diarrhea dyspepsia abdominal,1
DUAVEE,diarrhea,muscle spasms,0
DUAVEE,dyspepsia,dyspepsia,1
DUAVEE,abdominal pain upper,nausea diarrhea abdominal pain,1
DUAVEE,abdominal pain upper,als the common adverse reactions incidence were muscle spasms nausea,0
DUAVEE,abdominal pain upper,diarrhea abdominal,1
DUAVEE,abdominal pain upper,neck pain,0
DUAVEE,abdominal pain upper,and neck,0
DUAVEE,abdominal pain upper,report SUSPECTED,0
DUAVEE,abdominal pain upper,als the common adverse reactions incidence were muscle spasms nausea,0
DUAVEE,abdominal pain upper,diarrhea abdominal pain upper oropharyngeal,1
DUAVEE,abdominal pain upper,als the common adverse reactions incidence were muscle spasms nausea,0
DUAVEE,abdominal pain upper,diarrhea dyspepsia,0
DUAVEE,oropharyngeal pain,oropharyngeal pain dizziness and neck pain To,1
DUAVEE,oropharyngeal pain,contact Pfizer Inc,0
DUAVEE,oropharyngeal pain,report SUSPECTED,0
DUAVEE,oropharyngeal pain,oropharyngeal pain,1
DUAVEE,oropharyngeal pain,report SUSPECTED,0
DUAVEE,oropharyngeal pain,abdominal pain oropharyngeal pain,1
DUAVEE,oropharyngeal pain,report SUSPECTED,0
DUAVEE,oropharyngeal pain,abdominal pain oropharyngeal pain dizziness and neck pain,1
DUAVEE,oropharyngeal pain,report SUSPECTED,0
DUAVEE,oropharyngeal pain,reactions incidence,0
DUAVEE,dizziness,dizziness,1
DUAVEE,dizziness,dizziness and neck pain,1
DUAVEE,dizziness,dizziness,1
DUAVEE,dizziness,dizziness and neck pain To,1
DUAVEE,dizziness,dizziness and neck pain To,1
DUAVEE,neck pain,dizziness and,0
DUAVEE,mortality,was in the DUAVEE group and in the placebo group The incidence of,0
DUAVEE,mortality,was in the DUAVEE group and in the,0
DUAVEE,hot flush,commonly observed adverse,0
DUAVEE,hot flush,most commonly observed adverse,0
DUAVEE,hot flush,observed adverse reactions,0
DUAVEE,hot flush,The most common,0
DUAVEE,hot flush,nausea,0
DUAVEE,hot flush,and in the placebo group The most common adverse reactions leading to,0
DUAVEE,hot flush,reactions leading to discontinuation hot flush,1
DUAVEE,abdominal pain upper,most common adverse reactions leading to discontinuation were hot flush,0
DUAVEE,abdominal pain upper,were hot abdominal pain upper,1
DUAVEE,abdominal pain upper,leading to discontinuation were hot,0
DUAVEE,abdominal pain upper,observed,0
DUAVEE,abdominal pain upper,abdominal pain upper and nausea The,1
DUAVEE,abdominal pain upper,pain upper and nausea,1
DUAVEE,abdominal pain upper,adverse reactions incidence,0
DUAVEE,abdominal pain upper,discontinuation were hot,0
DUAVEE,abdominal pain upper,abdominal pain upper and nausea,1
DUAVEE,abdominal pain upper,hot abdominal pain,1
DUAVEE,nausea,pain upper nausea The,1
DUAVEE,nausea,hot abdominal pain,1
DUAVEE,nausea,frequently reported in wom,0
DUAVEE,nausea,upper,0
DUAVEE,venous thromboembolism,venous thromboembolism deep venous thrombosis,1
DUAVEE,venous thromboembolism,venous thromboembolism deep,1
DUAVEE,venous thromboembolism,venous thromboembolism deep venous thrombosis,1
DUAVEE,venous thromboembolism,venous thromboembolism deep venous,1
DUAVEE,venous thromboembolism,venous thromboembolism deep venous thrombosis,1
DUAVEE,venous thromboembolism,Venous thromboembolism In the clinical studies,0
DUAVEE,venous thromboembolism,embolism and retinal vein thrombosis were low in,0
DUAVEE,venous thromboembolism,and retinal vein thrombosis were low in all,0
DUAVEE,venous thromboembolism,for,0
DUAVEE,venous thromboembolism,the reporting rates venous thromboembolism deep,1
DUAVEE,venous thromboembolism,for,0
DUAVEE,deep venous thrombosis,venous deep,1
DUAVEE,deep venous thrombosis,deep venous,1
DUAVEE,deep venous thrombosis,for venous deep venous thrombosis,1
DUAVEE,deep venous thrombosis,deep venous,1
DUAVEE,deep venous thrombosis,rates for venous deep,1
DUAVEE,deep venous thrombosis,thromboembolism,0
DUAVEE,deep venous thrombosis,treatment groups Adverse reactio,0
DUAVEE,deep venous thrombosis,groups,0
DUAVEE,deep venous thrombosis,for venous deep venous thrombosis,1
DUAVEE,venous thromboembolism,treatment groups Adverse reactions venous thromboembolism,1
DUAVEE,venous thromboembolism,Adverse reactions venous,1
DUAVEE,venous thromboembolism,treatment groups,0
DUAVEE,venous thromboembolism,that the risk venous thromboembolism,1
DUAVEE,venous thromboembolism,treatment groups,0
DUAVEE,venous thromboembolism,not possible to conclude,0
DUAVEE,venous thromboembolism,venous thromboembolism with DUAVEE is different from,1
DUAVEE,venous thromboembolism,risk venous thromboembolism with,1
DUAVEE,venous thromboembolism,venous thromboembolism with DUAVEE is different from,1
DUAVEE,venous thromboembolism,conclude that the risk venous thromboembolism with,1
DUAVEE,venous thromboembolism,venous thromboembolism with DUAVEE is different from,1
DUAVEE,venous thromboembolism,that seen with other estrogen therapies see Warnings,0
DUAVEE,venous thromboembolism,the risk venous thromboembolism with DUAVEE is different from,1
DUAVEE,venous thromboembolism,that seen with other estrogen therapies see Warnings,0
DUAVEE,ENDOMETRIAL CANCER,following adverse reactions are discussed in greater,1
DUAVEE,ENDOMETRIAL CANCER,REACTIONS  following adverse,1
DUAVEE,ENDOMETRIAL CANCER,following adverse reactions are discussed in greater,1
DUAVEE,ENDOMETRIAL CANCER,are discussed in greater detail in other sections of the label Cardiovascular,0
DUAVEE,ENDOMETRIAL CANCER, following adverse reactions,1
DUAVEE,ENDOMETRIAL CANCER,are discussed in greater detail in other sections of the label Cardiovascular,0
DUAVEE,ENDOMETRIAL CANCER,detail in other sections of,0
DUAVEE,CARDIOVASCULAR DISORDERS,following adverse eactions are discussed i n,1
DUAVEE,CARDIOVASCULAR DISORDERS,detail in other sections of,0
DUAVEE,CARDIOVASCULAR DISORDERS,REACTIONS The following adverse eactions are discussed i n greater detail,1
DUAVEE,CARDIOVASCULAR DISORDERS,detail in other sections of,0
DUAVEE,CARDIOVASCULAR DISORDERS,adverse eactions are discussed i n greater detail in,1
DUAVEE,CARDIOVASCULAR DISORDERS,detail in other sections of,0
DUAVEE,CARDIOVASCULAR DISORDERS,the label Cardiovascular Disorders see Warnings and,0
DUAVEE,CARDIOVASCULAR DISORDERS,adverse,0
DUAVEE,CARDIOVASCULAR DISORDERS,following adverse eactions are,1
DUAVEE,DEMENTIA,following adverse reactions are discussed,0
DUAVEE,DEMENTIA,l in oth er sections of,1
DUAVEE,DEMENTIA,in,0
DUAVEE,DEMENTIA,REACTIONS The following adverse,0
DUAVEE,DEMENTIA,in oth er sections,1
DUAVEE,DEMENTIA,are discussed in greater l in oth er sections of the,1
DUAVEE,DEMENTIA,in oth er sections,1
DUAVEE,DEMENTIA,l in oth,1
DUAVEE,DEMENTIA,detai,0
DUAVEE,ENDOMETRIAL CANCER,of he label:,1
DUAVEE,CARDIOVASCULAR DISORDERS,the label,0
DUAVEE,CARDIOVASCULAR DISORDERS,diovascular Disorders [s ee,1
DUAVEE,DEMENTIA,see Warnings,0
DUAVEE,DEMENTIA,d Precau,1
DUAVEE,DEMENTIA,in,0
DUAVEE,endometrial hyperplasia,"mized, placebo-controll",1
DUAVEE,endometrial hyperplasia,"EXCERPT In four prospective mized, placebo-controll",1
DUAVEE,endometrial hyperplasia,"mized, placebo-controll ed trials the common adverse",1
DUAVEE,endometrial hyperplasia,"mized, placebo-controll",1
DUAVEE,endometrial hyperplasia,ed,0
DUAVEE,endometrial hyperplasia,"prospective mized,",1
DUAVEE,stroke,drug and may not reflect the rates observed in clinical practice The safety of conjug,0
DUAVEE,stroke,safety of,0
DUAVEE,stroke,drug cannot be directly compared to rates in,0
DUAVEE,stroke,and may not reflect the rates observed in clinical practice The safety of,0
DUAVEE,stroke,the rates observed in clinical practice The,0
DUAVEE,stroke,ials o f another drug,1
DUAVEE,stroke,in the clinical trials of a drug cannot be directly compared,0
DUAVEE,stroke,trials,0
DUAVEE,stroke,observed in clinical practice The,0
DUAVEE,deep vein thrombosis,in clinical practice The safety of,0
DUAVEE,deep vein thrombosis,the clinical trials of ther drug and may no t reflect the rates,1
DUAVEE,deep vein thrombosis,in clinical practice The safety of,0
DUAVEE,deep vein thrombosis,ther drug and may no t reflect the,1
DUAVEE,deep vein thrombosis,ano,0
DUAVEE,deep vein thrombosis,observed in clinical practice The safety of conjugated,0
DUAVEE,deep vein thrombosis,observed in clinical practice The safety,0
DUAVEE,deep vein thrombosis,reflect the rates,0
DUAVEE,DVT,ref lect the rates observed in,1
DUAVEE,DVT,ref lect,1
DUAVEE,dementia,treated ,1
DUAVEE,dementia,treated  with DUAVEE and patients received,1
DUAVEE,dementia,of patients treated  with DUAVEE and,1
DUAVEE,dementia,treated  with DUAVEE and patients received,1
DUAVEE,dementia,treated  with,1
DUAVEE,dementia,treated  with DUAVEE and patients received,1
DUAVEE,dementia,A total of patients treated  with DUAVEE and patients,1
DUAVEE,dementia,treated  with DUAVEE and patients received,1
DUAVEE,dementia,treated  with DUAVEE and patients received,1
DUAVEE,dementia,were,0
DUAVEE,ENDOMETRIAL CANCER,upper and,0
DUAVEE,ENDOMETRIAL CANCER,common adverse eactions leading t,1
DUAVEE,ENDOMETRIAL CANCER,upper and,0
DUAVEE,ENDOMETRIAL CANCER,most common adverse eactions leading,1
DUAVEE,CARDIOVASCULAR DISORDERS,reactions leading discontinuation were hot flush abdominal pain,1
DUAVEE,CARDIOVASCULAR DISORDERS,most common adverse eactions leading,1
DUAVEE,CARDIOVASCULAR DISORDERS,adverse reactions leading discontinuation were hot,1
DUAVEE,CARDIOVASCULAR DISORDERS,discontinuation were hot flush,1
DUAVEE,CARDIOVASCULAR DISORDERS,adverse reactions leading discontinuation were hot,1
DUAVEE,CARDIOVASCULAR DISORDERS,leading discontinuation were,1
DUAVEE,CARDIOVASCULAR DISORDERS,common adverse reactions leading discontinuation were hot,1
DUAVEE,CARDIOVASCULAR DISORDERS,were hot,1
DUAVEE,CARDIOVASCULAR DISORDERS,common adverse reactions leading discontinuation were,1
DUAVEE,DEMENTIA,adverse reactions,0
DUAVEE,endometrial cancer,"in .



 Table 1: Adv erse",1
DUAVEE,endometrial cancer,adverse reactions,0
DUAVEE,endometrial cancer,Table 1: Adv erse Reactions Incidence,1
DUAVEE,endometrial cancer,DUAVEE than placebo are presented in,0
DUAVEE,endometrial cancer,placebo are presented in Table,0
DUAVEE,endometrial cancer,Group in Placebocontrolled,0
DUAVEE,venous thromboembolism,Warnings a nd Precautions,1
DUAVEE,venous thromboembolism,and Precautions Malignant,0
DUAVEE,venous thromboembolism,Warnings and Precautions Malignant lasms [see,1
DUAVEE,venous thromboembolism,and Precautions Malignant lasms [see,1
DUAVEE,venous thromboembolism,Malignant lasms [see Warnings,1
DUAVEE,pulmonary embolism,Malignant Neoplasms see Warnings Precautions (5.3),1
DUAVEE,pulmonary embolism,cular Disorders see Warnings,0
DUAVEE,pulmonary embolism,Precautions (5.3) Gallbladder Disease see Warnings,1
DUAVEE,pulmonary embolism,Neoplasms see Warnings  Precautions (5.3) Gallbladder Disease,1
DUAVEE,pulmonary embolism,Precautions (5.3) Gallbladder Disease see Warnings,1
DUAVEE,stroke,Warnings and Precautions Malignant Neoplasms see,0
DUAVEE,stroke,Warnings and ] *,1
DUAVEE,stroke,and ],1
DUAVEE,retinal vascular thrombosis,[see Warni ngs,1
DUAVEE,retinal vascular thrombosis,[see Warni ngs,1
DUAVEE,retinal vascular thrombosis,Precautions bladder Disease [see  Warni,1
DUAVEE,retinal vascular thrombosis,[see Warni ngs,1
DUAVEE,retinal vascular thrombosis,Warnings and Precautions bladder Disease [see  Warni ngs and Precautions,1
DUAVEE,retinal vascular thrombosis,[see Warni ngs,1
DUAVEE,retinal vascular thrombosis,[see Warni ngs and Precautions Hypertriglyceridemia see,1
DUAVEE,retinal vascular thrombosis,and Precautions bladder Disease [see  Warni ngs and,1
DUAVEE,retinal vascular thrombosis,[see Warni ngs and Precautions Hypertriglyceridemia see,1
DUAVEE,retinal vascular thrombosis,see Warnings and Precautions bladder Disease [see  Warni ngs and Precautions Hypertriglyceridemia see,1
DUAVEE,retinal vascular thrombosis,[see Warni ngs and Precautions Hypertriglyceridemia see,1
DUAVEE,retinal vascular thrombosis,bladder Disease [see  Warni ngs and Precautions Hypertriglyceridemia,1
DUAVEE,retinal vascular thrombosis,[see Warni ngs and Precautions Hypertriglyceridemia see,1
DUAVEE,Malignant neoplasms,"see Warnings and )  ]  
 *  Hypertri glyceridemia see",1
DUAVEE,Malignant neoplasms,[see Warni ngs and Precautions Hypertriglyceridemia see,1
DUAVEE,Malignant neoplasms,Warnings and,0
DUAVEE,Malignant neoplasms,Disease,0
DUAVEE,Malignant neoplasms,* Hypertri glyceridemia see Warnings and,1
DUAVEE,Malignant neoplasms,"and )  ]  
 *  Hypertri glyceridemia see Warnings and Precautions",1
DUAVEE,Malignant neoplasms,* Hypertri glyceridemia see Warnings and,1
DUAVEE,Malignant neoplasms,Warnings and Precautions EXCERPT In four,0
DUAVEE,Malignant neoplasms,Precautions Gallbladder,0
DUAVEE,Malignant neoplasms,] * Hypertri glyceridemia see,1
DUAVEE,endometrial cancer,Warnings an d Precautions EXCERPT In,1
DUAVEE,endometrial cancer,and Precautions  [see  Warnings an d Precautions EXCERPT In four,1
DUAVEE,endometrial cancer,Warnings an d Precautions EXCERPT In,1
DUAVEE,endometrial cancer,and Precautions Hypertriglyceridemia,0
DUAVEE,endometrial cancer,Warnings an d Precautions EXCERPT In four,1
DUAVEE,endometrial cancer,d Precautions EXCERPT In four,0
DUAVEE,endometrial cancer,Precautions,0
DUAVEE,endometrial cancer,Precautions EXCERPT In,0
DUAVEE,endometrial cancer,Warnings an d Precautions EXCERPT,1
DUAVEE,endometrial cancer,Precautions EXCERPT In,0
DUAVEE,endometrial cancer,Warnings and Precautions [see Warnings an,1
DUAVEE,breast cancer,Warnings Precautions (,1
DUAVEE,breast cancer,Warnings and Precautions [see Warnings an,1
DUAVEE,breast cancer,Precautions ( EXCERPT,1
DUAVEE,ovarian cancer,] EXCE RPT,1
DUAVEE,ovarian cancer,"Hypertriglyceridemia see Warnings and ]  
      EXCE",1
DUAVEE,ovarian cancer,] EXCE RPT,1
DUAVEE,gallbladder disease,-controlled trials the,1
DUAVEE,VTE,enrolling postmenopausal,0
DUAVEE,VTE, 3  clinical trials ranging from,1
DUAVEE,VTE,and enrolling,0
DUAVEE,VTE, 3  clinical trials,1
DUAVEE,VTE, 3  clinical trials ranging from weeks,1
DUAVEE,VTE,was evaluated in four  3  clinical trials ranging from weeks,1
DUAVEE,VTE, 3  clinical trials ranging from weeks,1
DUAVEE,VTE,in duration and enrolling postmenopausal,0
DUAVEE,VTE, 3  clinical trials ranging,1
DUAVEE,VTE, 3  clinical,1
DUAVEE,VTE, 3  clinical trials ranging from weeks,1
DUAVEE,stroke,in duration and enrolling postmenopausal women age,0
DUAVEE,stroke,clinical trials ranging,0
DUAVEE,stroke,Phase clinical trials ranging m 12 w eeks to,1
DUAVEE,stroke,clinical trials ranging,0
DUAVEE,stroke,trials ranging m 12,1
DUAVEE,stroke,12 w eeks to months in duration,1
DUAVEE,stroke,of conjugated estrogensbazedoxifene was evaluated in four,0
DUAVEE,stroke,m,1
DUAVEE,DVT,duration and enrolling postmenopausal women age to years,0
DUAVEE,DVT,njugated estrogensbazedoxifene was evaluated in four Phase,0
DUAVEE,DVT,to ,1
DUAVEE,DVT,to ,1
DUAVEE,DVT,to  months in duration,1
DUAVEE,DVT,to  months in duration and enrolling,1
DUAVEE,DVT,njugated estrogensbazedoxifene was evaluated in four,0
DUAVEE,stroke,The incidence,0
DUAVEE,stroke,adverse reactions ce >=  more,1
DUAVEE,stroke,The incidence,0
DUAVEE,stroke,than placebo are,0
DUAVEE,stroke,ce >=,1
DUAVEE,stroke,nausea The most commonly observed adverse reactions,0
DUAVEE,stroke,commonly observed adverse reactions ce >= ,1
DUAVEE,stroke,nausea The most commonly observed adverse reactions,0
DUAVEE,stroke,nausea The most commonly observed adverse reactions,0
DUAVEE,stroke,ce >= more frequently reported,1
DUAVEE,VTE,10 ,1
DUAVEE,PE,disorders Muscle spasms,0
KALYDECO,Transaminase Elevations,Transaminase Elevations see Warnings and Precautions,1
KALYDECO,Transaminase Elevations,the Transaminase,1
KALYDECO,Transaminase Elevations,label,0
KALYDECO,Transaminase Elevations,other sections of the Transaminase Elevations,1
KALYDECO,Transaminase Elevations,sections of the Transaminase Elevations,1
KALYDECO,Transaminase Elevations,adverse reaction is discussed in greater detail in other sections of the label,0
KALYDECO,Transaminase Elevations,sections of the Transaminase Elevations see Warnings and,1
KALYDECO,Transaminase Elevations,adverse reaction is discussed in greater detail in other sections of the label,0
KALYDECO,Transaminase Elevations,most common adverse drug,0
KALYDECO,Transaminase Elevations,sections of the Transaminase,1
KALYDECO,headache,headache oropharyngeal,1
KALYDECO,headache,headache oropharyngeal,1
KALYDECO,headache,headache oropharyngeal pain upper,1
KALYDECO,headache,were,0
KALYDECO,headache,congestion,0
KALYDECO,oropharyngeal pain,were oropharyngeal pain upper respiratory tract infection,1
KALYDECO,oropharyngeal pain,congestion,0
KALYDECO,oropharyngeal pain,oropharyngeal pain upper respiratory tract infection nasal,1
KALYDECO,oropharyngeal pain,oropharyngeal,1
KALYDECO,oropharyngeal pain,gene were oropharyngeal pain,1
KALYDECO,oropharyngeal pain,oropharyngeal,1
KALYDECO,oropharyngeal pain,oropharyngeal pain upper respiratory tract infection nasal,1
KALYDECO,oropharyngeal pain,oropharyngeal pain upper respiratory tract infection nasal,1
KALYDECO,oropharyngeal pain,oropharyngeal pain upper respiratory tract infection nasal,1
KALYDECO,oropharyngeal pain,the CFTR gene were oropharyngeal pain,1
KALYDECO,oropharyngeal pain,CFTR gene were oropharyngeal pain,1
KALYDECO,oropharyngeal pain,the CFTR gene were oropharyngeal pain,1
KALYDECO,oropharyngeal pain,upper respiratory tract infection nasal congestion abdominal pain nasopharyngitis diarrhea,0
KALYDECO,upper respiratory tract infection,a GD mutation in,0
KALYDECO,upper respiratory tract infection,tract infection nasal congestion abdominal,1
KALYDECO,upper respiratory tract infection,gene were headache oropharyngeal upper respiratory tract infection nasal congestion abdominal pain nasopharyngitis,1
KALYDECO,upper respiratory tract infection,tract infection nasal congestion abdominal,1
KALYDECO,upper respiratory tract infection,tract infection nasal congestion,1
KALYDECO,nasal congestion,respiratory tract nasal congestion abdominal pain nasopharyngitis diarrhea rash,1
KALYDECO,nasal congestion,tract infection nasal congestion,1
KALYDECO,nasal congestion,pain upper respiratory tract nasal congestion,1
KALYDECO,nasal congestion,tract infection nasal congestion,1
KALYDECO,nasal congestion,upper respiratory tract nasal,1
KALYDECO,nasal congestion,nasopharyngitis diarrhea rash,0
KALYDECO,nasal congestion,rash nausea and dizziness To,0
KALYDECO,nasal congestion,pain,0
KALYDECO,nasal congestion,pain upper respiratory,0
KALYDECO,nasal congestion,respiratory tract,0
KALYDECO,nasal congestion,nasal congestion abdominal pain,1
KALYDECO,abdominal pain,headache,0
KALYDECO,abdominal pain,tract infection nasal abdominal pain nasopharyngitis,1
KALYDECO,abdominal pain,headache,0
KALYDECO,abdominal pain,respiratory tract infection nasal abdominal,1
KALYDECO,abdominal pain,diarrhea rash,0
KALYDECO,abdominal pain,abdominal pain,1
KALYDECO,abdominal pain,abdominal pain,1
KALYDECO,nasopharyngitis,tract infection nasal congestion,0
KALYDECO,nasopharyngitis,nasopharyngitis diarrhea rash,1
KALYDECO,nasopharyngitis,abdominal pain,0
KALYDECO,nasopharyngitis,nasal congestion abdominal nasopharyngitis diarrhea rash nausea,1
KALYDECO,nasopharyngitis,abdominal pain,0
KALYDECO,nasopharyngitis,nasopharyngitis diarrhea rash nausea and,1
KALYDECO,nasopharyngitis,nasopharyngitis diarrhea,1
KALYDECO,nasopharyngitis,report SUSPECTED ADVERSE,0
KALYDECO,nasopharyngitis,and,0
KALYDECO,nasopharyngitis,SUSPECTED ADVERSE REACTIONS,0
KALYDECO,nasopharyngitis,nasopharyngitis diarrhea,1
KALYDECO,diarrhea,pain diarrhea rash nausea and dizziness To,1
KALYDECO,diarrhea,nasopharyngitis diarrhea,1
KALYDECO,diarrhea,nasal congestion,0
KALYDECO,rash,congestion abdominal pain nasopharyngitis rash nausea and dizziness To report,1
KALYDECO,rash,nasal congestion,0
KALYDECO,rash,rash nausea and,1
KALYDECO,rash,nasal congestion abdominal pain nasopharyngitis diarrhea,0
KALYDECO,rash,infection nasal congestion abdominal pain nasopharyngitis diarrhea,0
KALYDECO,rash,rash,1
KALYDECO,nausea,nausea and dizziness To report,1
KALYDECO,dizziness,nasopharyngitis diarrhea rash,0
KALYDECO,increased hepatic enzymes,KALYDECOtreated patients included abdominal increased hepatic enzymes,1
KALYDECO,increased hepatic enzymes,adverse,0
KALYDECO,increased hepatic enzymes,more frequently in,0
KALYDECO,increased hepatic enzymes,hepatic enzymes and hypoglycemia The most,1
KALYDECO,increased hepatic enzymes,in KALYDECOtreated patients included,0
KALYDECO,increased hepatic enzymes,abdominal increased hepatic,1
KALYDECO,hypoglycemia,increased hepatic enzymes,0
KALYDECO,hypoglycemia,patients treated with KALYDECO were headache,0
KALYDECO,hypoglycemia,KALYDECO were,0
KALYDECO,hypoglycemia,the patients treated with KALYDECO were,0
KALYDECO,hypoglycemia,hypoglycemia The most common adverse,1
KALYDECO,hypoglycemia,KALYDECOtreated patients included abdominal pain increased hepatic,0
KALYDECO,hypoglycemia,hypoglycemia,1
KALYDECO,hypoglycemia,KALYDECOtreated patients included abdominal pain increased hepatic,0
KALYDECO,hypoglycemia,hypoglycemia The most common,1
KALYDECO,headache,headache upper respiratory tract infection,1
KALYDECO,headache,with KALYDECO were,0
KALYDECO,headache,the patients treated,0
KALYDECO,headache,hypoglycemia,0
KALYDECO,headache,headache upper respiratory tract,1
KALYDECO,upper respiratory tract infection,upper respiratory tract infection nasal congestion nausea rash rhinitis,1
KALYDECO,upper respiratory tract infection,upper respiratory tract infection nasal congestion nausea rash rhinitis,1
KALYDECO,nasal congestion,dizziness arthralgia and bacteria,0
KALYDECO,nasal congestion,upper respiratory tract nasal congestion,1
KALYDECO,nasal congestion,nasal congestion nausea rash rhinitis dizziness,1
KALYDECO,nausea,nausea rash rhinitis dizziness arthralgia and,1
KALYDECO,nausea,nausea rash rhinitis,1
KALYDECO,nausea,nausea rash rhinitis,1
KALYDECO,nausea,KALYDECO were headache upper respiratory tract infection nasal congestion,0
KALYDECO,nausea,nausea rash rhinitis,1
KALYDECO,rash,rash rhinitis dizziness,1
KALYDECO,rash,infection nasal congestion rash rhinitis,1
KALYDECO,rash,rash rhinitis dizziness,1
KALYDECO,rash,congestion nausea,0
KALYDECO,rash,sputum The inciden,0
KALYDECO,rash,sputum The inciden,0
KALYDECO,rash,rash rhinitis dizziness arthralgia and,1
KALYDECO,rash,tract infection nasal congestion,0
KALYDECO,rhinitis,rhinitis dizziness arthralgia and bacteria,1
KALYDECO,rhinitis,rhinitis dizziness arthralgia and bacteria,1
KALYDECO,rhinitis,dizziness arthralgia and bacteria,0
KALYDECO,rhinitis,rhinitis dizziness arthralgia and,1
KALYDECO,dizziness,dizziness,1
KALYDECO,dizziness,The incidence of adverse reactions below is,0
KALYDECO,dizziness,dizziness arthralgia and bacteria in sputum,1
KALYDECO,dizziness,in sputum The incidence of adverse reactions below is,0
KALYDECO,dizziness,and bacteria in sputum The incidence of adverse reactions below is,0
KALYDECO,bacteria in sputum,in sputum The incidence of adverse,1
KALYDECO,bacteria in sputum,rash rhinitis dizziness arthralgia bacteria in sputum The,1
KALYDECO,bacteria in sputum,in sputum The incidence of adverse,1
KALYDECO,bacteria in sputum,in sputum The incidence,1
KALYDECO,rhinitis,rhinitis,1
KALYDECO,rhinitis,rhinitis Investigations aspartate aminotransferase increased bacteria,1
KALYDECO,rhinitis,in the placebo group include Infections and infestations,0
KALYDECO,rhinitis,exceeded that in the,0
KALYDECO,rhinitis,rhinitis,1
KALYDECO,rhinitis,rhinitis,1
KALYDECO,bacteria in sputum,bacteria in sputum blood,1
KALYDECO,bacteria in sputum,rhinitis,1
KALYDECO,bacteria in sputum,connective,0
KALYDECO,bacteria in sputum,glucose increased hepatic enzyme,0
KALYDECO,bacteria in sputum,increased hepatic,0
KALYDECO,bacteria in sputum,rhinitis Investigations aspartate,0
KALYDECO,bacteria in sputum,aminotransferase,0
KALYDECO,blood glucose increased,in blood,1
KALYDECO,blood glucose increased,enzyme increased Musculoskeletal,0
KALYDECO,blood glucose increased,disorders,0
KALYDECO,hepatic enzyme increased,and connective tissue disorders arthralgia musculoskeletal chest,0
KALYDECO,hepatic enzyme increased,hepatic enzyme increased Musculoskeletal,1
KALYDECO,hepatic enzyme increased,and connective tissue disorders arthralgia musculoskeletal chest,0
KALYDECO,hepatic enzyme increased,glucose increased,0
KALYDECO,hepatic enzyme increased,enzyme increased Musculoskeletal and connective tissue disorders,1
KALYDECO,hepatic enzyme increased,glucose increased,0
KALYDECO,hepatic enzyme increased,in sputum blood,0
KALYDECO,hepatic enzyme increased,chest pain m,0
KALYDECO,hepatic enzyme increased,sputum blood glucose hepatic enzyme increased,1
KALYDECO,arthralgia,arthralgia musculoskeletal chest pain myalgia,1
KALYDECO,arthralgia,tissue disorders,0
KALYDECO,arthralgia,Musculoskeletal and connective tissue,0
KALYDECO,arthralgia,disorders,0
KALYDECO,arthralgia,arthralgia musculoskeletal,1
KALYDECO,arthralgia,connective,0
KALYDECO,arthralgia,tissue arthralgia musculoskeletal chest pain,1
KALYDECO,arthralgia,connective,0
KALYDECO,arthralgia,Musculoskeletal and connective tissue,0
KALYDECO,arthralgia,arthralgia musculoskeletal chest pain myalgia Nervous,1
KALYDECO,musculoskeletal chest pain,and connective tissue disorders musculoskeletal chest pain myalgia Nervous,1
KALYDECO,musculoskeletal chest pain,arthralgia musculoskeletal chest pain myalgia Nervous,1
KALYDECO,musculoskeletal chest pain,musculoskeletal chest pain,1
KALYDECO,musculoskeletal chest pain,sinus,0
KALYDECO,musculoskeletal chest pain,musculoskeletal chest pain myalgia Nervous,1
KALYDECO,musculoskeletal chest pain,sinus,0
KALYDECO,musculoskeletal chest pain,myalgia Nervous system disorders sinus headache Respiratory,0
KALYDECO,musculoskeletal chest pain,and,0
KALYDECO,musculoskeletal chest pain,and connective tissue disorders musculoskeletal chest pain,1
KALYDECO,musculoskeletal chest pain,tissue disorders arthralgia,0
KALYDECO,musculoskeletal chest pain,sinus headache,0
KALYDECO,myalgia,musculoskeletal chest myalgia Nervous system disorders sinus headache,1
KALYDECO,myalgia,sinus headache,0
KALYDECO,myalgia,arthralgia musculoskeletal chest myalgia,1
KALYDECO,myalgia,sinus headache,0
KALYDECO,sinus headache,Nervous system sinus headache Respiratory thoracic and mediastinal disorders,1
KALYDECO,sinus headache,sinus headache,0
KALYDECO,sinus headache,sinus headache,1
KALYDECO,sinus headache,Nervous system sinus headache Respiratory thoracic and,1
KALYDECO,sinus headache,sinus headache,1
KALYDECO,pharyngeal erythema,Respiratory thoracic,0
KALYDECO,pharyngeal erythema,sinus,0
KALYDECO,pleuritic pain,pleuritic pain sinus congestion,1
KALYDECO,pleuritic pain,tissue disorders acne The safety p,0
KALYDECO,pleuritic pain,disorders pharyngeal pleuritic pain sinus,1
KALYDECO,pleuritic pain,tissue disorders acne The safety p,0
KALYDECO,pleuritic pain,ders,0
KALYDECO,pleuritic pain,pleuritic pain sinus,1
KALYDECO,pleuritic pain,pleuritic pain sinus congestion,1
KALYDECO,pleuritic pain,and mediastinal disorders pharyngeal pleuritic,1
KALYDECO,sinus congestion,sinus congestion wheezing,1
KALYDECO,sinus congestion,sinus congestion wheezing Skin and subcutaneous,1
KALYDECO,sinus congestion,and mediastinal disorders pharyngeal erythema,0
KALYDECO,wheezing,sinus wheezing,1
KALYDECO,wheezing,and mediastinal disorders pharyngeal erythema,0
KALYDECO,wheezing,pleuritic pain sinus wheezing Skin,1
KALYDECO,wheezing,and mediastinal disorders pharyngeal erythema,0
KALYDECO,acne,clinical,0
KALYDECO,acne,and subcutaneous tissue acne,1
KALYDECO,acne,clinical,0
KALYDECO,elevated transaminases,to have serious adverse reactions,0
KALYDECO,elevated transaminases,patients treated with KALYDECO,0
KALYDECO,elevated transaminases,adverse,0
KALYDECO,elevated transaminases,have serious,0
KALYDECO,elevated transaminases,elevated transaminases all,1
KALYDECO,elevated transaminases,elevated transaminases all ULN,1
KALYDECO,elevated transaminases,elevated transaminases all,1
KALYDECO,elevated liver transaminases,elevated liver transaminases compared to none,1
KALYDECO,elevated liver transaminases,have serious adverse reactions elevated,1
KALYDECO,transaminase elevations,transaminase elevations ALT,1
KALYDECO,transaminase elevations,incidence of patients,0
KALYDECO,transaminase elevations,transaminase elevations ALT,1
KALYDECO,transaminase elevations,daily the incidence of patients experiencing,0
KALYDECO,transaminase elevations,of patients transaminase,1
KALYDECO,transaminase elevations,transaminase elevations ALT or AST,1
KALYDECO,transaminase elevations,the incidence of patients transaminase elevations ALT or AST,1
KALYDECO,transaminase elevations,transaminase elevations ALT or AST,1
KALYDECO,AST levels >8 * ULN,which returned,0
KALYDECO,AST levels >8 * ULN,baseline levels following interruption of KALYDECO dosing,0
KALYDECO,AST levels >8 * ULN,g transaminase elevations ALT or AST ULN was All patients had maximum ALT,0
KALYDECO,AST levels >8 * ULN,had maximum ALT,0
KALYDECO,AST levels >8 * ULN,* ULN which returned to baseline levels,1
KALYDECO,Elevated transaminases,sections of the label Transaminase Elevations,0
KALYDECO,Elevated transaminases,ction is,1
KALYDECO,Elevated transaminases,REACTIONS The following adverse ction is discussed in  greater detail in,1
KALYDECO,Elevated transaminases,ction is,1
KALYDECO,Elevated transaminases,rea,0
KALYDECO,Elevated transaminases,ction is discussed in greater,1
KALYDECO,Elevated transaminases,detail in other sections of the label,0
KALYDECO,Elevated transaminases,The following adverse ction is discussed,1
KALYDECO,Elevated transaminases,adverse rea,0
KALYDECO,Cataracts,practice. The,1
KALYDECO,Cataracts,practice. The overall,1
KALYDECO,Cataracts,on pooled data from three,0
KALYDECO,Non-congenital lens opacities,observed in,0
KALYDECO,Non-congenital lens opacities,overall safety profile of KALYDECO is,1
KALYDECO,Elevated transaminases,GD mutation,0
KALYDECO,Elevated transaminases,for the Fdel n (Trial 3). In additi on,1
KALYDECO,Elevated transaminases,GD mutation,0
KALYDECO,Elevated transaminases,n (Trial 3). In additi on the,1
KALYDECO,Elevated transaminases,the Fdel n (Trial 3). In additi on the following clinical trials,1
KALYDECO,Elevated transaminases,n (Trial 3). In additi on the,1
KALYDECO,Elevated transaminases,the Fdel n (Trial 3). In,1
KALYDECO,Elevated transaminases,n (Trial 3). In,1
KALYDECO,Elevated transaminases,n (Trial 3). In additi on,1
KALYDECO,Elevated transaminases,were homozygous for the Fdel mutatio,0
KALYDECO,non-congenital lens opacities,patients Serious adverse reactions,0
KALYDECO,non-congenital lens opacities,and for placebotreated patients Serious adverse reactions,0
AMYVID,headache,adverse reaction headache occurring in of,1
AMYVID,headache,and for placebotreated patients Serious adverse reactions,0
AMYVID,musculoskeletal pain,musculoskeletal,1
AMYVID,musculoskeletal pain,increased fatigue,0
AMYVID,musculoskeletal pain,patients followed musculoskeletal pain,1
AMYVID,musculoskeletal pain,in of patients followed musculoskeletal pain blood pressure,1
AMYVID,musculoskeletal pain,patients followed musculoskeletal pain,1
AMYVID,musculoskeletal pain,of patients followed musculoskeletal pain blood pressure,1
AMYVID,musculoskeletal pain,patients followed musculoskeletal pain,1
AMYVID,musculoskeletal pain,in of pa,0
AMYVID,musculoskeletal pain,followed,0
AMYVID,musculoskeletal pain,followed musculoskeletal pain blood pressure increased fatigue nausea,1
AMYVID,musculoskeletal pain,followed,0
AMYVID,blood pressure increased,blood pressure increased fatigue nausea and injection,1
AMYVID,blood pressure increased,followed,0
AMYVID,fatigue,patients,0
AMYVID,fatigue,pressure fatigue nausea and injection site reaction,1
AMYVID,fatigue,patients,0
AMYVID,fatigue,fatigue nausea and injection site reaction,1
AMYVID,fatigue,pressure,0
AMYVID,fatigue,all occurring in of patients To report SUS,0
AMYVID,fatigue,fatigue nausea,1
AMYVID,fatigue,fatigue nausea and injection site,1
AMYVID,fatigue,fatigue nausea and injection site reaction,1
AMYVID,fatigue,of patients To,0
AMYVID,fatigue,fatigue nausea and injection site,1
AMYVID,nausea,patients followed by musculoskeletal pain blood pressure increased fatigue,0
AMYVID,nausea,of patients,0
AMYVID,nausea,nausea and injection site reaction all,1
AMYVID,nausea,pressure increased fatigue,0
AMYVID,nausea,followed by musculoskeletal pain blood pressure,0
AMYVID,nausea,fatigue,0
AMYVID,injection site reaction,occurring,0
AMYVID,injection site reaction,and,0
AMYVID,injection site reaction,in,0
AMYVID,injection site reaction,nausea injection site reaction,1
AMYVID,injection site reaction,in,0
AMYVID,blood pressure increased,Includes the blood pressure,1
AMYVID,blood pressure increased,the blood pressure,1
AMYVID,blood pressure increased,pressure increased and hypertension b Includes the,1
AMYVID,blood pressure increased,blood pressure increased and hypertension,1
AMYVID,blood pressure increased,Table Adverse Reactions Reported in Clinical Trials N patients a Includes,0
AMYVID,blood pressure increased,Reactions Reported in Clinical,0
AMYVID,hypertension,hypertension,1
AMYVID,hypertension,hypertension b Includes the terms,1
AMYVID,hypertension,patients a Includes the terms blood pressure increased,0
AMYVID,hypertension,hypertension b,1
AMYVID,hypertension,a,0
AMYVID,hypertension,hypertension b Includes the,1
AMYVID,hypertension,terms blood pressure increased hypertension b Includes,1
AMYVID,hypertension,hypertension b Includes the,1
AMYVID,hypertension,blood pressure increased,0
AMYVID,hypertension,hypertension b,1
AMYVID,hypertension,the terms injection,0
AMYVID,injection site haemorrhage,the,0
AMYVID,injection site haemorrhage,hypertension b Includes the injection,1
AMYVID,injection site haemorrhage,injection site haemorrhage injection site irritation and,1
AMYVID,injection site haemorrhage,the terms blood pressure increased,0
AMYVID,injection site haemorrhage,cold and,0
AMYVID,injection site haemorrhage,the terms,0
AMYVID,injection site haemorrhage,Includes the terms,0
AMYVID,injection site haemorrhage,Includes the injection site,1
AMYVID,injection site haemorrhage,injection site haemorrhage injection site irritation and injection,1
AMYVID,injection site haemorrhage,injection site,1
AMYVID,injection site irritation,pain c Includes the terms feeling cold,0
AMYVID,injection site irritation,injection site irritation and injection,1
AMYVID,injection site irritation,pain c Includes the terms feeling cold,0
AMYVID,injection site irritation,injection site irritation and,1
AMYVID,injection site irritation,pain c Includes the terms feeling cold,0
AMYVID,injection site irritation,blood pressure,0
AMYVID,injection site irritation,b,0
AMYVID,injection site irritation,site irritation and injection,1
AMYVID,injection site irritation,injection,0
AMYVID,injection site irritation,the terms injection site injection site irritation and,1
AMYVID,injection site irritation,injection,0
AMYVID,injection site pain,haemorrhage,0
AMYVID,injection site pain,hypertension b Includes,0
AMYVID,injection site pain,haemorrhage injection site irritation injection site pain c Includes the,1
AMYVID,injection site pain,hypertension b Includes,0
AMYVID,injection site pain,Includes the terms injection site haemorrhage injection site irritation and,0
AMYVID,injection site pain,site pain c Includes the terms,1
AMYVID,injection site pain,terms injection site,0
AMYVID,injection site pain,the terms injection site haemorrhage injection site irritation,0
AMYVID,injection site pain,terms injection site haemorrhage,0
AMYVID,injection site pain,site pain c Includes the terms,1
AMYVID,injection site pain,site pain c Includes,1
AMYVID,feeling cold,Reactions N Percent of,0
AMYVID,feeling cold,feeling cold and chills,1
AMYVID,feeling cold,the feeling cold and chills Adverse Reactions,1
AMYVID,feeling cold,feeling cold and chills,1
AMYVID,feeling cold,feeling cold and chills Adverse Reactions,1
AMYVID,feeling cold,feeling cold and chills Adverse,1
AMYVID,feeling cold,c Includes the feeling cold,1
AMYVID,chills,and injection site pain c Includes,0
AMYVID,chills,chills,1
AMYVID,chills,Reactions N Percent of,0
AMYVID,chills,chills Adverse Reactions N,1
AMYVID,chills,Reactions N Percent of,0
AMYVID,chills,Percent,0
AMYVID,chills,chills Adverse,1
AMYVID,chills,chills Adverse,1
AMYVID,Blood pressure increased,pain,0
AMYVID,infusion site rash,infusion site rash dysgeusia pruritis,1
AMYVID,infusion site rash,and infusion site rash dysgeusia,1
AMYVID,infusion site rash,infusion site rash dysgeusia pruritis,1
AMYVID,infusion site rash,and infusion site rash,1
AMYVID,infusion site rash,infusion site rash dysgeusia pruritis urticaria and,1
AMYVID,infusion site rash,and infusion site rash,1
AMYVID,infusion site rash,occurred at lower frequencies and,0
AMYVID,infusion site rash,infusion site rash dysgeusia,1
AMYVID,infusion site rash,pruritis urticaria and,0
AMYVID,infusion site rash,urticaria,0
AMYVID,infusion site rash,infusion site rash dysgeusia pruritis urticaria and flushing,1
AMYVID,pruritis,pruritis urticaria and flushing,1
AMYVID,pruritis,infusion,0
AMYVID,pruritis,pruritis urticaria and flushing,1
AMYVID,urticaria,pruritis,0
AMYVID,urticaria,dysgeusia urticaria and,1
AMYVID,urticaria,pruritis,0
AMYVID,urticaria,site rash dysgeusia urticaria,1
AMYVID,urticaria,pruritis,0
AMYVID,urticaria,site rash dysgeusia urticaria and flushing,1
AMYVID,urticaria,pruritis,0
AMYVID,Radiation risk,"of patients followed by eletal pain,",1
AMYVID,Radiation risk,musculosk,0
AMYVID,Radiation risk,"pain, b lood",1
AMYVID,Radiation risk,patients followed by eletal,1
AMYVID,Radiation risk,"pain, b lood",1
AMYVID,Radiation risk,"pain, b lood",1
AMYVID,Radiation risk,of patients followed by eletal,1
AMYVID,Radiation risk,"eletal pain, b lood pressure increased fatigue",1
AMYVID,long-term cumulative radiation exposure,"and injection site reaction  occurring in <1% of patients (  6  ).
 To report SUSPECTED ADVERSE REACTIONS",1
AMYVID,long-term cumulative radiation exposure,"eletal pain, b lood pressure increased fatigue",1
AMYVID,long-term cumulative radiation exposure,fatigue nausea and,0
AMYVID,long-term cumulative radiation exposure,6 ). To report SUSPECTED,1
AMYVID,long-term cumulative radiation exposure,patients ( 6 ).,1
AMYVID,long-term cumulative radiation exposure,site pain c,0
AMYVID,long-term cumulative radiation exposure,injection site,0
AMYVID,long-term cumulative radiation exposure,terms feel,0
AMYVID,long-term cumulative radiation exposure,c Includes the terms,0
AMYVID,long-term cumulative radiation exposure,e Reactions N Percent of patients He,0
AMYVID,long-term cumulative radiation exposure,Percent of,0
AMYVID,long-term cumulative radiation exposure,"Includes the terms ing cold and chills.      
  
   Advers",1
AMYVID,long-term cumulative radiation exposure,Percent of,0
AMYVID,long-term cumulative radiation exposure,Percent,0
AMYVID,long-term cumulative radiation exposure,of patients He,0
AMYVID,Long-term cumulative radiation exposure,chills Reactions                              ,1
AMYVID,Long-term cumulative radiation exposure,of patients He,0
AMYVID,Long-term cumulative radiation exposure,and chills Reactions                               N Percent,1
AMYVID,Long-term cumulative radiation exposure,of patients He,0
AMYVID,Long-term cumulative radiation exposure,Reactions                               N Percent of patients Headache,1
AMYVID,Long-term cumulative radiation exposure,Reactions                               N,1
AMYVID,Long-term cumulative radiation exposure,Reactions                               N,1
AMYVID,Long-term cumulative radiation exposure,Reactions                               N,1
AMYVID,Long-term cumulative radiation exposure,Reactions                               N,1
AMYVID,Long-term cumulative radiation exposure,Reactions                               N,1
TIVICAY,Hypersensitivity,biochemistries in,0
TIVICAY,Hypersensitivity,Hypersensitivity reactions,1
TIVICAY,Hypersensitivity,related by the investigator or ADRs are,0
TIVICAY,Hypersensitivity,Warnings and Precautions,0
TIVICAY,Fat Redistribution,coinfection see Warnings and Fat Redistribution see Warnings and Precautions Immune,1
TIVICAY,Fat Redistribution,Warnings and Precautions,0
TIVICAY,Fat Redistribution,and Precautions Immune Reconstitution,0
TIVICAY,Immune Reconstitution Syndrome,Precautions,0
TIVICAY,Immune Reconstitution Syndrome,and Immune Reconstitution Syndrome see Warnings and Precautions,1
TIVICAY,Immune Reconstitution Syndrome,Precautions,0
TIVICAY,Immune Reconstitution Syndrome,under,0
TIVICAY,Immune Reconstitution Syndrome,Reconstitution Syndrome see,1
TIVICAY,insomnia,insomnia fatigue and,1
TIVICAY,insomnia,one adult trial insomnia fatigue,1
TIVICAY,insomnia,insomnia fatigue and,1
TIVICAY,insomnia,insomnia,1
TIVICAY,insomnia,insomnia fatigue and,1
TIVICAY,fatigue,contact ViiV Healthcare,0
TIVICAY,headache,headache To,1
TIVICAY,headache,adult trial,0
TIVICAY,headache,insomnia fatigue headache,1
TIVICAY,headache,adult trial,0
TIVICAY,rash,rash rash generalized rash macular rash,1
TIVICAY,rash,rash rash generalized,1
TIVICAY,rash,rash rash generalized rash macular rash,1
TIVICAY,rash,pooled,0
TIVICAY,rash,eruption In,0
TIVICAY,rash,rash rash generalized rash macular rash,1
TIVICAY,rash,rash maculopapular rash pruritic and,0
TIVICAY,rash generalized,Includes pooled terms,0
TIVICAY,rash generalized,rash generalized rash macular rash maculopapular,1
TIVICAY,rash generalized,drug eruption In addition Grade inso,0
TIVICAY,rash generalized,Includes pooled terms rash generalized,1
TIVICAY,rash generalized,pooled terms rash,0
TIVICAY,rash generalized,a Includes pooled terms rash generalized,1
TIVICAY,rash generalized,rash generalized rash,1
TIVICAY,rash macular,rash macular rash maculopapular rash,1
TIVICAY,rash macular,rash rash,0
TIVICAY,rash macular,pooled terms rash rash rash,1
TIVICAY,rash macular,Grade,0
TIVICAY,rash macular,rash macular,1
TIVICAY,rash macular,rash macular rash maculopapular,1
TIVICAY,rash maculo-papular,rash rash generalized rash rash maculo-papular rash pruritic and drug,1
TIVICAY,rash maculo-papular,rash macular rash maculopapular,1
TIVICAY,rash maculo-papular,rash maculo-papular rash,1
TIVICAY,rash maculo-papular,macular,0
TIVICAY,rash maculo-papular,rash,1
TIVICAY,rash maculo-papular,rash maculo-papular rash pruritic and,1
TIVICAY,rash maculo-papular,rash,1
TIVICAY,rash maculo-papular,rash generalized rash rash maculo-papular rash pruritic and drug eruption,1
TIVICAY,rash maculo-papular,rash,1
TIVICAY,rash maculo-papular,rash rash generalized rash rash maculo-papular,1
TIVICAY,rash maculo-papular,macular,0
TIVICAY,rash maculo-papular,by and less th,0
TIVICAY,rash pruritic,macular rash rash,1
TIVICAY,drug eruption,drug eruption,1
TIVICAY,drug eruption,addition Grade insomnia was reported by and less than of subjects,0
TIVICAY,insomnia,insomnia was reported,1
TIVICAY,insomnia,insomnia was reported,1
TIVICAY,insomnia,of subjects receiving TIVICAY and raltegravir,0
TIVICAY,insomnia,insomnia was reported by,1
TIVICAY,diarrhea,diarrhea,1
TIVICAY,diarrhea,insomnia was reported by,1
TIVICAY,diarrhea,diarrhea of in subjects receiving TIVICAY,1
TIVICAY,diarrhea,diarrhea of in subjects receiving,1
TIVICAY,diarrhea,diarrhea of in subjects receiving TIVICAY,1
TIVICAY,diarrhea,severe intensity with at,0
TIVICAY,diarrhea,mg once,0
TIVICAY,diarrhea,diarrhea of in subjects receiving TIVICAY,1
TIVICAY,diarrhea,diarrhea,1
TIVICAY,diarrhea,at,0
TIVICAY,Abdominal pain,Abdominal pain abdominal discomfort flatulence upper,1
TIVICAY,abdominal discomfort,relationship Gastrointestinal Disorders Abdominal abdominal,1
TIVICAY,abdominal discomfort,relationship Gastrointestinal Disorders Abdominal abdominal discomfort flatulence,1
TIVICAY,abdominal discomfort,relationship Gastrointestinal Disorders Abdominal abdominal,1
TIVICAY,abdominal discomfort,relationship Gastrointestinal Disorders Abdominal abdominal,1
TIVICAY,abdominal discomfort,pain vomiting Hepatobiliary Disorders,0
TIVICAY,abdominal discomfort,abdominal discomfort,1
TIVICAY,abdominal discomfort,pain vomiting Hepatobiliary Disorders,0
TIVICAY,abdominal discomfort,relationship Gastrointestinal Disorders Abdominal abdominal discomfort flatulence upper abdominal pain vomiting,1
TIVICAY,abdominal discomfort,pain vomiting Hepatobiliary Disorders,0
TIVICAY,flatulence,flatulence upper abdominal pain vomiting,1
TIVICAY,flatulence,pain vomiting Hepatobiliary Disorders,0
TIVICAY,flatulence,pain,0
TIVICAY,flatulence,pain vomiting Hepatobiliary Disorders Hepatitis Musculoskeletal,0
TIVICAY,flatulence,flatulence upper abdominal pain vomiting,1
TIVICAY,flatulence,Hepatobiliary Disorders Hepatitis,0
TIVICAY,upper abdominal pain,abdominal discomfort upper,1
TIVICAY,vomiting,vomiting Hepatobiliary Disorders Hepatitis,1
TIVICAY,vomiting,abdominal pain,0
TIVICAY,vomiting,vomiting,1
TIVICAY,vomiting,Disorders Hepatitis Musculoskeletal Disorders,0
TIVICAY,vomiting,abdominal vomiting Hepatobiliary Disorders Hepatitis Musculoskeletal Disorders,1
TIVICAY,vomiting,Disorders Hepatitis Musculoskeletal Disorders,0
TIVICAY,vomiting,discomfort flatulence upper abdominal pain,0
TIVICAY,vomiting,Disorders Abdominal,0
TIVICAY,Hepatitis,discomfort flatulence upper,0
TIVICAY,Hepatitis,pain vomiting Hepatobiliary Hepatitis Musculoskeletal Disorders Myositis Psychiatric,1
TIVICAY,Hepatitis,discomfort flatulence upper,0
TIVICAY,Hepatitis,flatulence upper abdominal pain vomiting,0
TIVICAY,Myositis,ideation attempt behavior or completion,0
TIVICAY,Myositis,Myositis Psychiatric Disorders Suicidal ideation,1
TIVICAY,Myositis,Myositis Psychiatric Disorders Suicidal,1
TIVICAY,Myositis,Myositis Psychiatric Disorders Suicidal ideation,1
TIVICAY,Myositis,Myositis Psychiatric Disorders,1
TIVICAY,Myositis,Disorders Suicidal ideation,0
TIVICAY,Myositis,Myositis,1
TIVICAY,Myositis,Musculoskeletal,0
TIVICAY,Myositis,Myositis Psychiatric,1
TIVICAY,Myositis,Myositis Psychiatric Disorders Suicidal ideation,1
TIVICAY,Suicidal ideation,Suicidal ideation attempt behavior or completion These,1
TIVICAY,Suicidal ideation,Disorders Myositis Psychiatric Suicidal,1
TIVICAY,Renal impairment,eexisting history of depression or other psychiatric illness Renal and Urinary,0
TIVICAY,Renal impairment,Subcutaneous,0
TIVICAY,Renal impairment,Renal impairment,1
TIVICAY,Renal impairment,Renal impairment Skin and,1
TIVICAY,Renal impairment,Urinary Renal,1
TIVICAY,Renal impairment,illness Renal and,0
TIVICAY,Pruritus,Pruritus,1
TIVICAY,Pruritus,Pruritus Laboratory Abnormalities Treatmentnaive Subjects,1
TIVICAY,Pruritus,Tissue Pruritus Laboratory,1
TIVICAY,Pruritus,Pruritus Laboratory Abnormalities Treatmentnaive Subjects,1
TIVICAY,Pruritus,Pruritus,1
TIVICAY,Pruritus,Subcutaneous Tissue Pruritus Laboratory Abnormalities Treatmentnaive Subjects Selected,1
TIVICAY,Pruritus,Pruritus,1
TIVICAY,Pruritus,Pruritus Laboratory Abnormalities,1
TIVICAY,Pruritus,Selected laboratory abnormaliti,0
TIVICAY,Pruritus,Renal and Urinary Disorders Renal impairment Skin and Subcutaneous Tissue Disorders,0
TIVICAY,Pruritus,and Subcutaneous Tissue,0
TIVICAY,elevated ALT,combined observed in,0
TIVICAY,hyperglycemia,ALT AST cholesterol creatine hyperglycemia and lipase Two,1
TIVICAY,hyperglycemia,combined observed in,0
TIVICAY,hyperglycemia,of subjects had a Grade to treatmentemergent,0
TIVICAY,hyperglycemia,creatine hyperglycemia and lipase,1
TIVICAY,hyperglycemia,of subjects had a Grade to treatmentemergent,0
TIVICAY,hyperglycemia,at Week were,0
TIVICAY,hyperglycemia,AST cholesterol creatine hyperglycemia,1
TIVICAY,hyperglycemia,at Week were,0
TIVICAY,hyperglycemia,hyperglycemia and lipase Two,1
TIVICAY,hyperglycemia,Grade,0
TIVICAY,hyperglycemia,and lipase Two percent of of subjects had a Grade to treatmentemergent h,0
TIVICAY,hyperglycemia,Two percent of of subjects had a Grade to treatmentemergent,0
TIVICAY,neutropenia,hematology laboratory abnormality neutropenia of,1
TIVICAY,neutropenia,Two percent of of subjects had a Grade to treatmentemergent,0
TIVICAY,neutropenia,hematology,0
TIVICAY,neutropenia,laboratory abnormality neutropenia,1
TIVICAY,neutropenia,hematology,0
TIVICAY,neutropenia,most frequently,0
TIVICAY,ALT abnormalities,and,0
TIVICAY,ALT abnormalities,rates of AST ALT abnormalities were higher in the,1
TIVICAY,ALT abnormalities,and,0
TIVICAY,ALT abnormalities,B andor C virus coinfection,0
TIVICAY,ALT abnormalities,andor C virus coinfection for all treatment,0
TIVICAY,ALT abnormalities,rates of AST ALT,1
TIVICAY,ALT abnormalities,AST ALT abnormalities,1
TIVICAY,ALT abnormalities,ALT abnormalities were,1
TIVICAY,ALT abnormalities,that observed in subjects without hepatitis B or C coinfection,0
TIVICAY,ALT abnormalities,ALT abnormalities,1
TIVICAY,ALT abnormalities,subgroup with hepatitis B andor,0
TIVICAY,Liver chemistry elevations,vs with,0
TIVICAY,Liver chemistry elevations,Liver chemistry elevations consistent with immune,1
TIVICAY,Liver chemistry elevations,immune,0
TIVICAY,Liver chemistry elevations,with hepatitis B and,0
TIVICAY,Liver chemistry elevations,in,0
TIVICAY,immune reconstitution syndrome,reconstitution syndrome,1
TIVICAY,immune reconstitution syndrome,chemistry elevations consistent immune reconstitution,1
TIVICAY,immune reconstitution syndrome,consistent immune reconstitution syndrome,1
TIVICAY,increase serum creatinine,has been shown increase serum creatinine due,1
TIVICAY,increase serum creatinine,consistent immune reconstitution syndrome,1
TIVICAY,increase serum creatinine,serum creatinine due to,1
TIVICAY,increase serum creatinine,increase serum creatinine,1
TIVICAY,increase serum creatinine,increase serum creatinine due to inhibition of tubular,1
TIVICAY,increase serum creatinine,increase serum creatinine,1
TIVICAY,increase serum creatinine,Dolutegravir has been shown increase serum,1
TIVICAY,increase serum creatinine,increase serum creatinine due to inhibition of,1
TIVICAY,increase serum creatinine,Dolutegravir has been shown increase serum,1
TIVICAY,increase serum creatinine,shown increase serum,1
TIVICAY,increase serum creatinine,Dolutegravir has been shown to,0
TIVICAY,Increases in serum creatinine,to,0
TIVICAY,Creatinine increases,were comparable,0
TIVICAY,Creatinine increases,weeks of Creatinine increases,1
TIVICAY,Creatinine increases,were comparable,0
TIVICAY,Creatinine increases,weeks of Creatinine increases were comparable,1
TIVICAY,Creatinine increases,were comparable,0
TIVICAY,Creatinine increases,by background NRTIs and,0
TIVICAY,Creatinine increases,dL to mg per dL was observed after weeks of treatment,0
TIVICAY,Creatinine increases,similar in treatmentexperienced subjects,0
TIVICAY,Creatinine increases,Creatinine increases,1
TIVICAY,Creatinine increases,similar in treatmentexperienced subjects,0
TIVICAY,rash,rash n abdominal pain n and,1
TIVICAY,abdominal pain,ADRs reported in at least subject were rash n,0
TIVICAY,abdominal pain,subject were rash n,0
TIVICAY,diarrhea,abdominal pain,0
TIVICAY,diarrhea,diarrhea n No Grade or,1
TIVICAY,diarrhea,laboratory abnormalities were,0
TIVICAY,diarrhea,were reported The Grade laboratory abnormalities,0
TIVICAY,diarrhea,diarrhea n No Grade,1
TIVICAY,diarrhea,diarrhea n No,1
TIVICAY,diarrhea,Grade or ADRs were reported The Grade laboratory abnormalities were elevated,0
TIVICAY,diarrhea,Grade ADRs reported,0
TIVICAY,diarrhea,diarrhea n No,1
TIVICAY,diarrhea,laboratory abnormalities were elevated tot,0
TIVICAY,elevated total bilirubin,The Grade laboratory abnormalities elevated total bilirubin,1
TIVICAY,Hypersensitivity reactions,adverse reactions (adverse,1
TIVICAY,Hypersensitivity reactions,REACTIONS The following adverse reactions (adverse events  assessed as causally,1
TIVICAY,Hypersensitivity reactions,adverse reactions (adverse,1
TIVICAY,Hypersensitivity reactions,The following adverse reactions (adverse events ,1
TIVICAY,Hypersensitivity reactions,adverse reactions (adverse,1
TIVICAY,Hypersensitivity reactions,reactions (adverse events,1
TIVICAY,Hypersensitivity reactions,reactions (adverse events assessed as causally,1
TIVICAY,Hypersensitivity reactions,(adverse events,1
TIVICAY,rash,ly r elated by,1
TIVICAY,rash,ly r,1
TIVICAY,rash,ly r elated by,1
TIVICAY,rash,ly r elated by,1
TIVICAY,rash,ly r elated by,1
TIVICAY,rash,ly r,1
TIVICAY,rash,ly r,1
TIVICAY,rash,ly r,1
TIVICAY,rash,ly r,1
TIVICAY,rash,as ly r,1
TIVICAY,rash,The following adverse drug,0
TIVICAY,rash,as ly r elated by the investigator or,1
TIVICAY,rash,The following adverse drug,0
TIVICAY,rash,events assessed as ly r,1
TIVICAY,organ dysfunction,in other sections of,1
TIVICAY,liver injury,discussed in other sections the labelin,1
TIVICAY,liver injury,other sections the labelin,1
TIVICAY,liver injury,g Hypersensitivity reactions see Warnings and Precautions Effects on,0
TIVICAY,liver injury,the labelin,1
TIVICAY,liver injury,Precautions,0
TIVICAY,liver injury,other,0
TIVICAY,liver injury,and,0
TIVICAY,liver injury,in other sections the,1
TIVICAY,liver injury,in other sections the labelin,1
TIVICAY,liver injury,discussed in other sections  the labelin g Hypersensitivity reactions,1
TIVICAY,liver injury,in other sections the labelin,1
TIVICAY,transaminase elevations,recautions (5.4)] . Because clinical trials are conducted,1
TIVICAY,transaminase elevations,"Warnings and recautions (5.4)] . 
   Because clinical trials are",1
TIVICAY,transaminase elevations,recautions (5.4)] . Because clinical trials are conducted,1
TIVICAY,transaminase elevations,"Warnings and recautions (5.4)] . 
   Because",1
TIVICAY,transaminase elevations,recautions (5.4)] . Because clinical trials are conducted,1
TIVICAY,transaminase elevations,see Warnings and recautions (5.4)] .,1
TIVICAY,transaminase elevations,Warnings and recautions (5.4)] .,1
TIVICAY,transaminase elevations,widely varying conditions adverse reaction,0
TIVICAY,transaminase elevations,see Warnings and recautions (5.4)],1
TIVICAY,transaminase elevations,Warnings and recautions (5.4)],1
TIVICAY,transaminase elevations,(5.4)] . Because clinical trials are conducted,1
TIVICAY,accumulation of body fat,incidence at least in tho,0
TIVICAY,accumulation of body fat,actice. EXCERPT: The most common adverse reactions,1
TIVICAY,accumulation of body fat,actice. EXCERPT: The,1
TIVICAY,accumulation of body fat,actice. EXCERPT: The most common adverse reactions,1
TIVICAY,accumulation of body fat,intensity and incidence at least,0
TIVICAY,accumulation of body fat,actice. EXCERPT:,1
TIVICAY,accumulation of body fat,in,0
TIVICAY,accumulation of body fat,"observed in actice.
 

   EXCERPT:  ",1
TIVICAY,accumulation of body fat,in,0
TIVICAY,Hypersensitivity,insomnia fatigue,0
TIVICAY,Hypersensitivity,"fatigue and (  6.1  )



    To report SUSPECTED ADVERSE",1
TIVICAY,Hypersensitivity,insomnia fatigue,0
TIVICAY,Hypersensitivity,adult trial are insomnia fatigue and headache,0
TIVICAY,Hypersensitivity,and ( 6.1,1
TIVICAY,Hypersensitivity,(,1
TIVICAY,Hypersensitivity,6.1 ) To report SUSPECTED ADVERSE,1
TIVICAY,rash,thca re,1
TIVICAY,rash,contact ViiV thca re at or FDA at,1
TIVICAY,rash,thca re,1
TIVICAY,organ dysfunction,at 1088 or  www.fda. govmedwatch,1
TIVICAY,organ dysfunction,thca re,1
TIVICAY,organ dysfunction,at or FDA at 1088 or  www.fda.,1
TIVICAY,organ dysfunction,thca re,1
TIVICAY,organ dysfunction,Clinical Trials,0
TIVICAY,organ dysfunction,at 1088 or,1
TIVICAY,organ dysfunction,ViiV Healthcare at or FDA at,0
TIVICAY,organ dysfunction,FDA,0
TIVICAY,organ dysfunction,at or FDA at 1088 or www.fda.,1
TIVICAY,liver injury,"    



 

  Clinical Trials",1
TIVICAY,liver injury,FDA at,0
TIVICAY,liver injury,"    



 

  Clinical Trials Experience",1
TIVICAY,liver injury,"FDA at FDA or     



 

 ",1
TIVICAY,liver injury,"    



 

  Clinical Trials Experience",1
TIVICAY,transaminase elevations,dose of ther TIVICAY 50 mg with fixeddose,1
TIVICAY,transaminase elevations,"    



 

  Clinical Trials Experience",1
TIVICAY,transaminase elevations,dose of ther TIVICAY 50 mg with fixeddose,1
TIVICAY,transaminase elevations,"    



 

  Clinical Trials Experience",1
TIVICAY,transaminase elevations,50 mg with fixeddose,1
TIVICAY,transaminase elevations,dose of ther TIVICAY 50 mg,1
TIVICAY,transaminase elevations,ther,1
TIVICAY,transaminase elevations,daily or,0
TIVICAY,transaminase elevations,TIVICAY 50 mg with fixeddose abacavir sulfate and lamivudine,1
TIVICAY,transaminase elevations,mg with fixeddose,1
TIVICAY,elevations in transaminases,either TIVICAY mg,0
TIVICAY,elevations in transaminases,d-dose efavirenz/emtricitab inetenofovir,1
TIVICAY,elevations in transaminases,sulfate and lamivudine EPZICOM once daily or fixe,0
TIVICAY,elevations in transaminases,or d-dose efavirenz/emtricitab inetenofovir ATRIPLA r once,1
TIVICAY,elevations in transaminases,sulfate and lamivudine EPZICOM once daily or fixe,0
TIVICAY,immune reconstitution syndrome,discontinuation were in subjects receiving TIVICA,0
TIVICAY,immune reconstitution syndrome,daily or fixeddose efavirenzemtricitabinetenofovir (r) ) once daily. Through,1
TIVICAY,immune reconstitution syndrome,efavirenzemtricitabinetenofovir (r) ) once daily. Through,1
TIVICAY,immune reconstitution syndrome,Through 9 weeks,1
TIVICAY,immune reconstitution syndrome,efavirenzemtricitabinetenofovir   (r)  ) once daily. Through 9 weeks,1
TIVICAY,immune reconstitution syndrome,Through 9 weeks,1
TIVICAY,immune reconstitution syndrome,efavirenzemtricitabinetenofovir (r) ),1
TIVICAY,immune reconstitution syndrome,) once daily. Through 9 weeks the,1
TIVICAY,immune reconstitution syndrome,weeks the rates,0
TIVICAY,immune reconstitution syndrome,subjects,0
TIVICAY,immune reconstitution syndrome,  (r)  ) once daily. Through 9 weeks the rates of,1
TIVICAY,immune reconstitution syndrome,subjects,0
TIVICAY,hepatitis B reactivation,"daily Through eks, the rates of advers e events leading",1
TIVICAY,hepatitis B reactivation,subjects,0
TIVICAY,hepatitis B reactivation,events,0
TIVICAY,hepatitis B reactivation,"daily Through eks, the rates",1
TIVICAY,hepatitis B reactivation,"once daily Through eks, the rates",1
TIVICAY,hepatitis B reactivation,"daily Through eks, the rates of",1
TIVICAY,central obesity,simplify resentation; di,1
TIVICAY,central obesity,resentation; di,1
TIVICAY,central obesity,SPRING and SINGLE trials are provided,0
TIVICAY,central obesity,resentation; di rect comparisons across trials,1
TIVICAY,central obesity,resentation; di rect comparisons across trials should,1
TIVICAY,central obesity,resentation; di rect comparisons across trials,1
TIVICAY,central obesity,is to simplify resentation;,1
TIVICAY,central obesity,simplify resentation; di,1
TIVICAY,central obesity,is to simplify resentation;,1
TIVICAY,dorsocervical fat enlargement,designs Table,0
TIVICAY,dorsocervical fat enlargement,across trials should not be made due,1
TIVICAY,buffalo hump,direct comparisons across trials ould not be ,1
TIVICAY,buffalo hump,across trials should not be made due,1
TIVICAY,facial wasting,rial,1
TIVICAY,facial wasting,Drug Reactions,0
TIVICAY,facial wasting,differing t,0
TIVICAY,facial wasting,be,0
TIVICAY,facial wasting,rial designs. Table Treatmentemergent Adverse Drug,1
TIVICAY,breast enlargement,"to differing trial 
 Table 2. Treatme ntemergent Adverse Drug",1
TIVICAY,breast enlargement,rial designs. Table Treatmentemergent Adverse Drug,1
TIVICAY,breast enlargement,at,0
TIVICAY,breast enlargement,"due to differing trial 
 Table 2. Treatme ntemergent",1
TIVICAY,breast enlargement,at,0
TIVICAY,breast enlargement,should not be made due to differing trial,0
TIVICAY,breast enlargement,trials should not be made due,0
TIVICAY,breast enlargement,trial designs,0
TIVICAY,breast enlargement,"trial 
 Table 2. Treatme ntemergent Adverse Drug",1
TIVICAY,breast enlargement,trial designs,0
TIVICAY,Immune reconstitution syndrome,+ 2 NRTIs,1
TIVICAY,Immune reconstitution syndrome,NRTIs n,0
TIVICAY,Immune reconstitution syndrome,Preferred Term SPRING TIVICAY 50,1
TIVICAY,Immune reconstitution syndrome,mg Once Daily + 2 NRTIs,1
TIVICAY,Immune reconstitution syndrome,  TIVICAY 50 mg Once Daily + 2 NRTIs n Raltegravir,1
TIVICAY,Immune reconstitution syndrome,mg Once Daily + 2 NRTIs,1
TIVICAY,polymyositis,      <1%    Nervous System,1
TIVICAY,Guillain-Barre syndrome,Abnormal            <1%         ,1
TIVICAY,Guillain-Barre syndrome,      <1%    Nervous System,1
TIVICAY,Guillain-Barre syndrome,           <1%         ,1
TIVICAY,Guillain-Barre syndrome,           <1%          Nervous System,1
TIVICAY,Guillain-Barre syndrome,dreams,0
TIVICAY,Guillain-Barre syndrome,dreams,0
TIVICAY,Guillain-Barre syndrome,Abnormal            <1%          Nervous,1
TIVICAY,Guillain-Barre syndrome,dreams,0
TIVICAY,Guillain-Barre syndrome,           <1%          Nervous,1
TIVICAY,Guillain-Barre syndrome,Abnormal dreams,0
ULESFIA,ocular irritation,with ocular irritation,1
ULESFIA,ocular irritation,Abnormal dreams,0
ULESFIA,ocular irritation,ocular irritation application site irritation and application,1
ULESFIA,ocular irritation,than with ocular irritation application site,1
ULESFIA,ocular irritation,ocular irritation application site irritation and application,1
ULESFIA,ocular irritation,ocular irritation application,1
ULESFIA,ocular irritation,more common than with ocular irritation,1
ULESFIA,ocular irritation,than with ocular irritation application site,1
ULESFIA,ocular irritation,more common than with ocular irritation,1
ULESFIA,ocular irritation,irritation and application site anesthesia and,0
ULESFIA,ocular irritation,site irritation and application site anesthesia and hypoesthesia To re,0
ULESFIA,ocular irritation,application site anesthesia and hypoesthesia To re,0
ULESFIA,application site irritation,application site irritation and application site anesthesia,1
ULESFIA,application site irritation,application site anesthesia and hypoesthesia To re,0
ULESFIA,application site irritation,site irritation and application,1
ULESFIA,application site irritation,and application site anesthesia and hypoesthesia To report SUSPECTED ADVERSE REACTI,0
ULESFIA,application site irritation,site irritation and application site anesthesia,1
ULESFIA,application site irritation,placebo ocular application site irritation,1
ULESFIA,application site irritation,ocular application site,1
ULESFIA,application site irritation,ocular irritation,0
ULESFIA,application site irritation,application,1
ULESFIA,application site irritation,irritation,0
ULESFIA,application site anesthesia,application site anesthesia,1
ULESFIA,application site anesthesia,with placebo ocular irritation application site irritation,0
ULESFIA,application site anesthesia,contact,0
ULESFIA,application site anesthesia,and more common than with placebo,0
ULESFIA,application site anesthesia,site irritation application site anesthesia and hypoesthesia To report SUSPECTED,1
ULESFIA,application site anesthesia,and more common than with placebo,0
ULESFIA,Application site Irritation,Application,0
ULESFIA,Application site Irritation,Application,0
ULESFIA,Application site Irritation,Application site Irritation Application,1
ULESFIA,Application site anesthesia,site anesthesia hypoesthesia Pain,1
ULESFIA,Application site anesthesia,Lotion Vehicle Application site Application,1
ULESFIA,Application site anesthesia,Vehicle,0
ULESFIA,Application site anesthesia,site anesthesia hypoesthesia Pain,1
ULESFIA,Application site anesthesia,Application site anesthesia hypoesthesia,1
ULESFIA,Application site anesthesia,site Application site anesthesia,1
ULESFIA,Pain,subjects who did not h,0
ULESFIA,Pain,Pain The subset of,1
ULESFIA,Pain,Pain The subset of subjects,1
ULESFIA,Pain,anesthesia hypoesthesia,0
ULESFIA,Pain,hypoesthesia,0
ULESFIA,Pain,hypoesthesia,0
ULESFIA,Pain,Pain The subset of,1
ULESFIA,Pain,hypoesthesia,0
ULESFIA,Pain,did,0
ULESFIA,Pruritus,Monitored Adverse Pruritus Erythema Pyoderma,1
ULESFIA,Pruritus,did,0
ULESFIA,Pruritus,Treatment,0
ULESFIA,Pruritus,Table Monitored Adverse,0
ULESFIA,Pruritus,Pruritus Erythema Pyoderma and Ocular Irritation,1
ULESFIA,Pruritus,Irritation with,0
ULESFIA,Erythema,Erythema Pyoderma and Ocular Irritation,1
ULESFIA,Erythema,and Ocular Irritation with Onset After Treatment SignsSymptoms ULESFIA r,0
ULESFIA,Erythema,Table Monitored Adverse Reactions Erythema Pyoderma and,1
ULESFIA,Erythema,and Ocular Irritation with Onset After Treatment SignsSymptoms ULESFIA r,0
ULESFIA,Erythema,Erythema Pyoderma and Ocular Irritation with,1
ULESFIA,Pyoderma,Pyoderma,1
ULESFIA,Pyoderma,After Treatment SignsSymptoms ULESFIA r,0
ULESFIA,Ocular Irritation,Ocular Irritation,1
ULESFIA,Ocular Irritation,Pyoderma Ocular,1
ULESFIA,Ocular Irritation,Ocular Irritation,1
ULESFIA,Ocular Irritation,and,0
ULESFIA,Ocular Irritation,Ocular Irritation with Onset After Treatment SignsSymptoms,1
ULESFIA,Ocular Irritation,with Onset After Treatment SignsSymptoms ULESFIA r Lotion Vehicle Pruritu,0
ULESFIA,Ocular Irritation,and,0
ULESFIA,Ocular Irritation,Ocular Irritation with,1
ULESFIA,application site dryness,site dermatitis,0
ULESFIA,application site dryness,site dryness,1
ULESFIA,application site dryness,order of application site dryness,1
ULESFIA,application site dryness,of application site dryness,1
ULESFIA,application site dryness,in decreasing order of application,1
ULESFIA,application site dryness,were in decreasing order of,0
ULESFIA,application site excoriation,application site excoriation paraesthesia application site,1
ULESFIA,application site excoriation,site excoriation paraesthesia application,1
ULESFIA,application site excoriation,site excoriation paraesthesia,1
ULESFIA,application site excoriation,excoriation thermal burn,0
ULESFIA,application site excoriation,thermal,0
ULESFIA,application site excoriation,excoriation thermal burn,0
ULESFIA,application site excoriation,application site application site excoriation,1
ULESFIA,paraesthesia,paraesthesia application site dermatitis excoriation thermal,1
ULESFIA,paraesthesia,paraesthesia application site dermatitis excoriation thermal,1
ULESFIA,paraesthesia,site paraesthesia application,1
ULESFIA,paraesthesia,paraesthesia application site dermatitis excoriation thermal,1
ULESFIA,paraesthesia,paraesthesia application site,1
ULESFIA,application site dermatitis,dryness,0
ULESFIA,application site dermatitis,site excoriation application site,1
ULESFIA,application site dermatitis,excoriation application site,1
ULESFIA,application site dermatitis,site dermatitis excoriation thermal burn,1
ULESFIA,application site dermatitis,excoriation application site,1
ULESFIA,application site dermatitis,site excoriation application site dermatitis excoriation thermal burn dandruff,1
ULESFIA,application site dermatitis,excoriation application site,1
ULESFIA,application site dermatitis,application site dermatitis excoriation thermal,1
ULESFIA,application site dermatitis,thermal burn,0
ULESFIA,excoriation,thermal burn dandruff erythema rash and skin,0
ULESFIA,excoriation,excoriation thermal,1
ULESFIA,excoriation,thermal burn dandruff erythema rash and skin,0
ULESFIA,excoriation,excoriation thermal burn dandruff,1
ULESFIA,thermal burn,thermal burn dandruff erythema rash and skin,1
ULESFIA,thermal burn,thermal burn dandruff erythema rash and,1
ULESFIA,thermal burn,paraesthesia application site dermatitis thermal burn dandruff erythema rash and skin,1
ULESFIA,thermal burn,thermal burn dandruff erythema rash and,1
ULESFIA,thermal burn,site dermatitis thermal burn dandruff erythema rash and,1
ULESFIA,thermal burn,thermal burn dandruff erythema rash and,1
ULESFIA,dandruff,dandruff erythema rash and skin,1
ULESFIA,dandruff,erythema rash and skin,0
ULESFIA,erythema,rash,0
ULESFIA,erythema,dermatitis excoriation thermal,0
ULESFIA,erythema,thermal burn,0
ULESFIA,erythema,erythema,1
ULESFIA,erythema,dermatitis excoriation thermal burn erythema rash and skin exfoliation,1
ULESFIA,erythema,erythema,1
ULESFIA,erythema,dermatitis excoriation thermal burn erythema rash and skin,1
ULESFIA,erythema,erythema,1
ULESFIA,erythema,thermal burn erythema rash and,1
ULESFIA,erythema,erythema,1
ULESFIA,erythema,dermatitis excoriation thermal burn erythema rash,1
ULESFIA,erythema,erythema,1
ULESFIA,erythema,dandruff,0
ULESFIA,rash,rash,1
ULESFIA,rash,rash and,1
ULESFIA,rash,rash,1
ULESFIA,rash,rash,1
ULESFIA,rash,rash and,1
ULESFIA,rash,rash and skin exfoliation,1
ULESFIA,rash,paraesthesia application site dermatitis excoriation thermal burn dandruff,0
ULESFIA,rash,rash and skin exfoliation,1
ULESFIA,rash,excoriation thermal,0
ULESFIA,rash,site dermatitis excoriation,0
ULESFIA,Neonatal toxicity,common,0
ULESFIA,gasping syndrome,more common th an with,1
ULESFIA,gasping syndrome,and application site anesthesia,0
ULESFIA,gasping syndrome,irritation application site irritation and application site anesthesia,0
ULESFIA,gasping syndrome,common th an with placebo ocular,1
ULESFIA,gasping syndrome,an,0
ULESFIA,Eye irritation,"irritation application site rritation, and application site anesthesia and hypoesthesia",1
ULESFIA,Eye irritation,an,0
ULESFIA,Eye irritation,with placebo ocular irritation,0
ULESFIA,Eye irritation,"rritation, and application site anesthesia and hypoesthesia",1
ULESFIA,Eye irritation,"rritation,",1
ULESFIA,Eye irritation,placebo ocular irritation application site,0
ULESFIA,Eye irritation,"rritation, and application site anesthesia and",1
ULESFIA,Eye irritation,"irritation application site rritation,",1
ULESFIA,Eye irritation,"rritation, and application site anesthesia",1
ULESFIA,Eye irritation,"site rritation, and application site anesthesia and hypoesthesia",1
ULESFIA,Eye irritation,"rritation, and application site anesthesia",1
ULESFIA,Contact dermatitis,at 1 or FDA,1
ULESFIA,Contact dermatitis,and hypoesthesia To report,0
ULESFIA,Contact dermatitis,"uticals, LLC. at 1",1
ULESFIA,Contact dermatitis,and hypoesthesia To report,0
ULESFIA,neonatal gasping syndrome,to rates in the clinical trials of another drug and may not,0
ULESFIA,neonatal gasping syndrome,observed in clini cal practice The,1
ULESFIA,neonatal gasping syndrome,may not reflect e rates observed in clini,1
ULESFIA,neonatal gasping syndrome,compared to rates in the clinical trials of another drug and may not reflect,0
ULESFIA,neonatal gasping syndrome,not reflect e rates observed in,1
ULESFIA,neonatal gasping syndrome,and may,0
ULESFIA,neonatal gasping syndrome,and may not reflect e rates observed in clini cal practice The rates,1
ULESFIA,neonatal gasping syndrome,and may,0
ULESFIA,metabolic acidosis,rates of adv,1
ULESFIA,metabolic acidosis,rates of adv erse reactions,1
ULESFIA,metabolic acidosis,clinical The rates of,1
ULESFIA,metabolic acidosis,clinical The rates of,1
ULESFIA,metabolic acidosis,clinical   The rates of adv erse reactions below were derived,1
ULESFIA,metabolic acidosis,clinical The rates of,1
ULESFIA,metabolic acidosis,rates of adv erse reactions below were,1
ULESFIA,metabolic acidosis,of adv erse reactions below were derived,1
ULESFIA,progressive hypotension,of adverse reactions below e,1
ULESFIA,seizures,trials and one openlabel study,0
ULESFIA,seizures,"derived from two ized, mu lticenter vehiclecontrolled clinical trials and",1
ULESFIA,seizures,trials and one openlabel study,0
ULESFIA,seizures,The rates of adverse reactions,0
ULESFIA,seizures,study in subjects,0
ULESFIA,seizures,"ized, mu lticenter vehiclecontrolled clinical trials",1
ULESFIA,seizures,with,0
ULESFIA,seizures,clinical practice The rates of adverse reactions below,0
ULESFIA,seizures,"two ized, mu lticenter vehiclecontrolled clinical trials and",1
ULESFIA,seizures,clinical practice The rates of adverse reactions below,0
ULESFIA,central nervous system depression,rates of adverse reactions below,0
ULESFIA,central nervous system depression,"i-center, vehicle-controlled clin ical trials",1
ULESFIA,central nervous system depression,"i-center, vehicle-controlled clin ical",1
ULESFIA,central nervous system depression,openlabel study in subjects with head lice infestation,0
ULESFIA,central nervous system depression,"randomized i-center, vehicle-controlled clin",1
ULESFIA,central nervous system depression,"i-center, vehicle-controlled",1
ULESFIA,central nervous system depression,with head lice infestation Skin scalp,0
ULESFIA,intraventricular hemorrhage,and one open-labe l study in subjects with,1
ULESFIA,intraventricular hemorrhage,multicenter vehiclecontrolled al trials and one,1
ULESFIA,intraventricular hemorrhage,two randomized multicenter vehiclecontrolled al trials and,1
ULESFIA,death,y in,1
ULESFIA,gasping syndrome,about the presence of n and scalp symp toms the results,1
ULESFIA,gasping syndrome,y in,1
ULESFIA,gasping syndrome,results are presented in Table Table Monitored Adverse,0
ULESFIA,gasping syndrome,n,1
ULESFIA,gasping syndrome,scalp symp toms the,1
ULESFIA,gasping syndrome,clinical trials All,0
ULESFIA,gasping syndrome,presented,0
ULESFIA,eye irritation,Application site /478),1
ULESFIA,eye irritation,Lotion Vehicle Application site /478),1
ULESFIA,eye irritation,Application site anesthesia,0
ULESFIA,eye irritation,Lotion Vehicle Application site /478) 1%,1
ULESFIA,eye irritation,/478) 1%,1
ULESFIA,eye irritation,/478) 1% Application,1
ULESFIA,eye irritation,/478)      1% ,1
ULESFIA,eye irritation,/478) 1% Application,1
ULESFIA,eye irritation,Irritation,0
ULESFIA,eye irritation,/478) 1% Application site anesthesia hypoesthesia,1
JUBLIA,ingrown toenails,ingrown toenails application site dermatitis application site,1
JUBLIA,ingrown toenails,/478) 1% Application site anesthesia hypoesthesia,1
JUBLIA,ingrown toenails,most common adverse reactions incidence,0
JUBLIA,ingrown toenails,ingrown toenails application site dermatitis application,1
JUBLIA,ingrown toenails,most common adverse reactions incidence,0
JUBLIA,ingrown toenails,EXCERPT,0
JUBLIA,ingrown toenails,ADVERSE REACTIONS,0
JUBLIA,ingrown toenails,ingrown toenails,1
JUBLIA,application site dermatitis,most common adverse reactions incidence were ingrown,0
JUBLIA,application site dermatitis,most,0
JUBLIA,application site vesicles,application site vesicles and application site pain To,1
JUBLIA,application site vesicles,e most common adverse reactions incidence were ingrown toenails application site dermatitis,0
JUBLIA,application site vesicles,site,0
JUBLIA,Ingrown toenail,n JUBLIAN Ingrown,1
JUBLIA,Ingrown toenail,JUBLIAN Ingrown toenail Application site dermatitis,1
JUBLIA,Ingrown toenail,n JUBLIAN Ingrown,1
JUBLIA,Ingrown toenail,Adverse Event n,0
JUBLIA,Ingrown toenail,Application site,0
JUBLIA,Application site dermatitis,Application site dermatitis,1
JUBLIA,Application site dermatitis,Application site dermatitis Application site vesicles,1
JUBLIA,Application site dermatitis,Application site vesicles,0
JUBLIA,Application site dermatitis,Ingrown Application site dermatitis,1
JUBLIA,Application site dermatitis,Application site vesicles,0
JUBLIA,Application site vesicles,Application site Application,1
TRULICITY,Thyroid C-cell Tumors,prescribing information Risk Thyroid C-cell Tumors see Warnings and,1
TRULICITY,Thyroid C-cell Tumors,Application site Application,1
TRULICITY,Thyroid C-cell Tumors,C-cell Tumors see,1
TRULICITY,Thyroid C-cell Tumors,Thyroid C-cell Tumors,1
TRULICITY,Thyroid C-cell Tumors,Thyroid C-cell Tumors see Warnings,1
TRULICITY,Thyroid C-cell Tumors,are,0
TRULICITY,Thyroid C-cell Tumors,see Warnings,0
TRULICITY,Pancreatitis,Warnings and Precautions Hypoglycemia with Concomitant Use,0
TRULICITY,Pancreatitis,Pancreatitis,1
TRULICITY,Pancreatitis,Warnings and Precautions Hypoglycemia with Concomitant Use,0
TRULICITY,Pancreatitis,Use,0
TRULICITY,Hypoglycemia,see Warnings and Precautions,0
TRULICITY,Hypoglycemia,Hypoglycemia,1
TRULICITY,Hypoglycemia,Insulin see Warnings and Precautions,0
TRULICITY,Hypersensitivity,impairment see Warnings,0
TRULICITY,Hypersensitivity,and Precautions,0
TRULICITY,Hypersensitivity,Hypersensitivity reactions see Warnings and,1
TRULICITY,Hypersensitivity,and Precautions,0
TRULICITY,Hypersensitivity,Secretagogues or Insulin see Warnings,0
TRULICITY,Hypersensitivity,Hypersensitivity reactions see Warnings and Precautions,1
TRULICITY,Hypersensitivity,impairment see Warnings,0
TRULICITY,Hypersensitivity,Hypersensitivity reactions see Warnings and Precautions,1
TRULICITY,Renal impairment,Renal impairment,1
TRULICITY,Renal impairment,Renal impairment see Warnings and Precautions,1
TRULICITY,Gastrointestinal Disease,Gastrointestinal Disease see,1
TRULICITY,Gastrointestinal Disease,Renal impairment see Warnings and Precautions,1
TRULICITY,Gastrointestinal Disease,and Precautions EXCERPT The most common adverse reactions repo,0
TRULICITY,nausea,nausea diarrhea vomiting,1
TRULICITY,nausea,and Precautions EXCERPT The most common adverse reactions repo,0
TRULICITY,nausea,nausea,1
TRULICITY,diarrhea,diarrhea,1
TRULICITY,diarrhea,diarrhea vomiting abdominal,1
TRULICITY,diarrhea,The most common adverse reactions reported in of patients treated,0
TRULICITY,diarrhea,diarrhea,1
TRULICITY,diarrhea,are diarrhea vomiting,1
TRULICITY,diarrhea,diarrhea,1
TRULICITY,diarrhea,common adverse reactions reported in of,0
TRULICITY,diarrhea,nausea,0
TRULICITY,diarrhea,treated with TRULICITY are diarrhea vomiting abdominal,1
TRULICITY,diarrhea,nausea,0
TRULICITY,diarrhea,treated with TRULICITY are diarrhea vomiting abdominal,1
TRULICITY,diarrhea,nausea,0
TRULICITY,diarrhea,The most common adverse reactions reported in,0
TRULICITY,vomiting,reported in of patients treated with TRULICITY are,0
TRULICITY,vomiting,ommon adverse reactions reported in of patients treated with TRULICITY are nausea,0
TRULICITY,vomiting,reported in of patients,0
TRULICITY,abdominal pain,patients treated with,0
TRULICITY,abdominal pain,are nausea diarrhea abdominal pain,1
TRULICITY,decreased appetite,abdominal pain decreased appetite,1
TRULICITY,decreased appetite,patients,0
TRULICITY,decreased appetite,decreased appetite To,1
TRULICITY,decreased appetite,Lilly and Company,0
TRULICITY,decreased appetite,treated with TRULICITY are nausea diarrhea vomiting,0
TRULICITY,decreased appetite,abdominal pain and,0
TRULICITY,decreased appetite,abdominal pain decreased appetite To report,1
TRULICITY,decreased appetite,abdominal pain and,0
TRULICITY,decreased appetite,decreased appetite To report SUSPECTED ADVERSE,1
TRULICITY,decreased appetite,and Company at Lill,0
TRULICITY,hypoglycemia,common adverse reactions hypoglycemia,1
TRULICITY,hypoglycemia,and Company at Lill,0
TRULICITY,diarrhea,diarrhea fecal volume,1
TRULICITY,diarrhea,a diarrhea fecal volume,1
TRULICITY,diarrhea,diarrhea fecal volume,1
TRULICITY,diarrhea,Includes retching vomiting vomiting pr,0
TRULICITY,diarrhea,increased frequent bowel movements b Includes retching vomiting,0
TRULICITY,diarrhea,Reported in of TRULICITYTreated Patients a,0
TRULICITY,diarrhea,diarrhea fecal volume increased frequent bowel,1
TRULICITY,fecal volume increased,Includes fecal,1
TRULICITY,fecal volume increased,b Includes retching,0
TRULICITY,fecal volume increased,Includes fecal,1
TRULICITY,fecal volume increased,fecal volume increased,1
TRULICITY,fecal volume increased,Patients,0
TRULICITY,fecal volume increased,vomiting vomiting projectile,0
TRULICITY,fecal volume increased,Includes fecal volume increased,1
TRULICITY,fecal volume increased,vomiting vomiting projectile,0
TRULICITY,fecal volume increased,in,0
TRULICITY,fecal volume increased,in of TRULICITYTreated Patients a Includes,0
TRULICITY,frequent bowel movements,Reported in,0
TRULICITY,retching,movements b retching vomiting vomiting projectile c Includes,1
TRULICITY,retching,Reported in,0
TRULICITY,retching,retching vomiting vomiting projectile c Includes,1
TRULICITY,retching,retching vomiting vomiting projectile c,1
TRULICITY,retching,bowel movements b retching vomiting vomiting,1
TRULICITY,retching,retching vomiting vomiting projectile c,1
TRULICITY,retching,retching,1
TRULICITY,retching,retching,1
TRULICITY,retching,frequent bowel movements b retching vomiting vomiting,1
TRULICITY,retching,retching,1
TRULICITY,vomiting,Includes,0
TRULICITY,vomiting,vomiting vomiting projectile c Includes,1
TRULICITY,vomiting,movements b Includes vomiting vomiting,1
TRULICITY,vomiting,vomiting vomiting projectile c Includes,1
TRULICITY,vomiting,projectile c Includes abdominal discomfort abdominal,0
TRULICITY,vomiting,abdominal pain,0
TRULICITY,vomiting,vomiting vomiting projectile c,1
TRULICITY,vomiting,increased frequent bowel movements b Includes,0
TRULICITY,vomiting,vomiting,1
TRULICITY,vomiting projectile,abdominal pain abdominal pain lower abdominal pain upper,0
TRULICITY,vomiting projectile,abdominal discomfort abdominal pain abdominal pain lower abdominal,0
TRULICITY,vomiting projectile,vomiting,1
TRULICITY,vomiting projectile,abdominal discomfort abdominal pain abdominal pain lower,0
TRULICITY,abdominal discomfort,abdominal discomfort abdominal pain,1
TRULICITY,abdominal discomfort,abdominal discomfort abdominal pain abdominal pain lower,0
TRULICITY,abdominal discomfort,upper,0
TRULICITY,abdominal discomfort,abdominal discomfort abdominal pain abdominal,1
TRULICITY,abdominal discomfort,vomiting vomiting projectile,0
TRULICITY,abdominal discomfort,vomiting projectile c abdominal discomfort abdominal pain abdominal,1
TRULICITY,abdominal discomfort,vomiting vomiting projectile,0
TRULICITY,abdominal discomfort,projectile c abdominal,1
TRULICITY,abdominal discomfort,projectile c abdominal discomfort,1
TRULICITY,abdominal discomfort,c abdominal discomfort abdominal pain abdominal pain,1
TRULICITY,abdominal discomfort,projectile c abdominal discomfort,1
TRULICITY,abdominal discomfort,c abdominal,1
TRULICITY,abdominal pain,gastrointestinal,0
TRULICITY,abdominal pain,projectile c Includes abdominal abdominal pain,1
TRULICITY,abdominal pain,abdominal pain,0
TRULICITY,abdominal pain,abdominal abdominal,1
TRULICITY,abdominal pain,abdominal pain abdominal,1
TRULICITY,abdominal pain,abdominal pain abdominal pain,1
TRULICITY,abdominal pain,abdominal pain abdominal pain,1
TRULICITY,abdominal pain,vomiting projectile c,0
TRULICITY,abdominal pain lower,abdominal pain lower abdominal pain upper,1
TRULICITY,abdominal pain lower,abdominal pain lower abdominal,1
TRULICITY,abdominal pain lower,pain upper abdominal tenderness gastrointestinal,0
TRULICITY,abdominal pain lower,abdominal discomfort,0
TRULICITY,abdominal pain lower,discomfort abdominal abdominal pain lower,1
TRULICITY,abdominal pain lower,Includes abdominal discomfort abdominal abdominal pain,1
TRULICITY,abdominal pain lower,Includes abdominal discomfort abdominal abdominal,1
TRULICITY,abdominal pain lower,abdominal pain lower abdominal pain upper abdominal tenderness,1
TRULICITY,abdominal pain lower,abdominal abdominal pain lower abdominal pain upper abdominal,1
TRULICITY,abdominal pain lower,abdominal pain lower abdominal pain upper abdominal tenderness,1
TRULICITY,abdominal pain lower,abdominal abdominal pain lower,1
TRULICITY,abdominal pain upper,vomiting projectile c Includes abdominal,0
TRULICITY,abdominal pain upper,fatigue,0
TRULICITY,abdominal pain upper,abdominal pain abdominal pain upper abdominal tenderness gastrointestinal,1
TRULICITY,abdominal pain upper,fatigue,0
TRULICITY,abdominal tenderness,lower abdominal pain abdominal tenderness,1
TRULICITY,abdominal tenderness,abdominal tenderness gastrointestinal pain d Includes,1
TRULICITY,abdominal tenderness,lower abdominal pain abdominal tenderness,1
TRULICITY,abdominal tenderness,malaise Note Percentages refl,0
TRULICITY,abdominal tenderness,Includes fatigue asthenia malaise Note,0
TRULICITY,abdominal tenderness,pain abdominal tenderness gastrointestinal pain d Includes fatigue,1
TRULICITY,abdominal tenderness,Includes fatigue asthenia malaise Note,0
TRULICITY,abdominal tenderness,abdominal pain abdominal tenderness gastrointestinal pain d,1
TRULICITY,abdominal tenderness,Includes fatigue asthenia malaise Note,0
TRULICITY,gastrointestinal pain,pain upper abdominal gastrointestinal pain d Includes,1
TRULICITY,gastrointestinal pain,Includes fatigue asthenia malaise Note,0
TRULICITY,gastrointestinal pain,pain upper abdominal gastrointestinal pain d Includes fatigue asthenia,1
TRULICITY,gastrointestinal pain,Includes fatigue asthenia malaise Note,0
TRULICITY,gastrointestinal pain,d Includes fatigue asthenia malaise Note Percentages reflect the,0
TRULICITY,gastrointestinal pain,upper abdominal gastrointestinal pain d Includes fatigue asthenia malaise,1
TRULICITY,gastrointestinal pain,d Includes fatigue asthenia malaise Note Percentages reflect the,0
TRULICITY,gastrointestinal pain,d Includes fatigue asthenia malaise Note Percentages reflect the number of patie,0
TRULICITY,gastrointestinal pain,upper abdominal gastrointestinal pain d Includes,1
TRULICITY,gastrointestinal pain,d Includes fatigue asthenia malaise Note Percentages reflect the number of patie,0
TRULICITY,gastrointestinal pain,d Includes fatigue asthenia malaise Note,0
TRULICITY,gastrointestinal pain,gastrointestinal pain d Includes fatigue,1
TRULICITY,gastrointestinal pain,reflect the number,0
TRULICITY,gastrointestinal pain,gastrointestinal pain d Includes fatigue asthenia malaise,1
TRULICITY,fatigue,Includes,0
TRULICITY,fatigue,pain lower,0
TRULICITY,fatigue,pain upper abdominal tenderness gastrointestinal pain d,0
TRULICITY,fatigue,d fatigue,1
TRULICITY,fatigue,pain upper abdominal tenderness gastrointestinal pain d,0
TRULICITY,fatigue,fatigue,1
TRULICITY,fatigue,tenderness gastrointestinal pain d fatigue asthenia malaise,1
TRULICITY,fatigue,fatigue,1
TRULICITY,fatigue,fatigue,1
TRULICITY,asthenia,asthenia malaise Note Percentages reflect the,1
TRULICITY,asthenia,asthenia malaise Note Percentages reflect,1
TRULICITY,asthenia,patients that,0
TRULICITY,asthenia,asthenia,1
TRULICITY,malaise,fatigue malaise Note Percentages reflect the,1
TRULICITY,malaise,asthenia,1
TRULICITY,gastrointestinal adverse reactions,frequently among patients,0
TRULICITY,gastrointestinal adverse reactions,pool of placebocontrolled gastrointestinal adverse,1
TRULICITY,gastrointestinal adverse reactions,placebocontrolled gastrointestinal adverse,1
TRULICITY,gastrointestinal adverse reactions,placebocontrolled gastrointestinal adverse reactions,1
TRULICITY,gastrointestinal adverse reactions,placebocontrolled gastrointestinal adverse,1
TRULICITY,gastrointestinal adverse reactions,discontinued treatment due gastrointestinal adverse reactions,1
TRULICITY,gastrointestinal adverse reactions,discontinued treatment due gastrointestinal,1
TRULICITY,gastrointestinal adverse reactions,due gastrointestinal,1
TRULICITY,gastrointestinal adverse reactions,mg discontinued,0
TRULICITY,gastrointestinal adverse reactions,gastrointestinal adverse,1
TRULICITY,gastrointestinal adverse reactions,of gastrointestinal,0
TRULICITY,gastrointestinal adverse reactions,adverse reactions than patients,1
TRULICITY,gastrointestinal adverse reactions,mg discontinued treatment due gastrointestinal adverse reactions than patients receiving,1
TRULICITY,gastrointestinal adverse reactions,adverse reactions than patients,1
TRULICITY,gastrointestinal adverse reactions,severity of,0
TRULICITY,gastrointestinal adverse reactions,and TRULICITY mg discontinued treatment,0
TRULICITY,gastrointestinal adverse reactions,adverse reactions occurring on mg,1
TRULICITY,gastrointestinal adverse reactions,mg of TRULICITY as mild in and of cases respectively,0
TRULICITY,gastrointestinal adverse reactions,Investigators graded the severity gastrointestinal adverse reactions occurring on,1
TRULICITY,gastrointestinal adverse reactions,mg of TRULICITY as mild in and of cases respectively,0
TRULICITY,gastrointestinal adverse reactions,gastrointestinal adverse reactions occurring on,1
TRULICITY,gastrointestinal adverse reactions,mg of TRULICITY as mild in and of cases respectively,0
TRULICITY,constipation,than placebo frequencies,0
TRULICITY,constipation,constipation flatulence abdominal,1
TRULICITY,constipation,than placebo frequencies listed respectively as placebo mg mg,0
TRULICITY,constipation,respectively as placebo,0
TRULICITY,constipation,frequencies listed respectively as placebo,0
TRULICITY,abdominal distension,as placebo mg mg constipation flatulence,0
TRULICITY,abdominal distension,disease and eructation,0
TRULICITY,abdominal distension,constipation abdominal distension gastroesophageal reflux disease,1
TRULICITY,abdominal distension,disease and eructation,0
TRULICITY,abdominal distension,disease and eructation,0
TRULICITY,abdominal distension,disease,0
TRULICITY,gastroesophageal reflux disease,distension,0
TRULICITY,gastroesophageal reflux disease,abdominal gastroesophageal,1
TRULICITY,eructation,eructation Pool of Placebo and,1
TRULICITY,eructation,eructation Pool of Placebo,1
TRULICITY,hypoglycemia,common adverse reactions,0
TRULICITY,hypoglycemia,were similar to those listed in Table,0
TRULICITY,hypoglycemia,hypoglycemia,1
TRULICITY,hypoglycemia,adverse reactions hypoglycemia were similar to those,1
TRULICITY,hypoglycemia,hypoglycemia,1
TRULICITY,hypoglycemia,similar to those listed in Table Other,0
TRULICITY,hypoglycemia,hypoglycemia were similar to those listed,1
TRULICITY,hypoglycemia,Table Other Adverse,0
TRULICITY,hypoglycemia,hypoglycemia were similar to those listed,1
TRULICITY,hypoglycemia,hypoglycemia were similar to those listed,1
TRULICITY,hypoglycemia,hypoglycemia in the,1
TRULICITY,hypoglycemia,hypoglycemia,1
TRULICITY,hypoglycemia,hypoglycemia in the,1
TRULICITY,hypoglycemia,glucose threshold and hypoglycemia,1
TRULICITY,hypoglycemia,hypoglycemia in the,1
TRULICITY,hypoglycemia,hypoglycemia in,1
TRULICITY,Hypoglycemia,PlaceboControlled Trials Placebo,0
TRULICITY,Hypoglycemia,Hypoglycemia Adverse Reactions,1
TRULICITY,Hypoglycemia,PlaceboControlled Trials Placebo,0
TRULICITY,Hypoglycemia,Documented Symptomatic and Hypoglycemia Adverse Reactions in PlaceboControlled Trials,1
TRULICITY,Hypoglycemia,PlaceboControlled Trials Placebo,0
TRULICITY,Hypoglycemia,Hypoglycemia,1
TRULICITY,hypoglycemia,hypoglycemia occurred in and of,1
TRULICITY,hypoglycemia,Hypoglycemia,1
TRULICITY,hypoglycemia,patients when TRULICITY mg and mg respectively was,0
TRULICITY,hypoglycemia,coadministered with a sulfonylurea hypoglycemia occurred in,1
TRULICITY,hypoglycemia,patients when TRULICITY mg and mg respectively was,0
TRULICITY,hypoglycemia,hypoglycemia occurred in and of patients,1
TRULICITY,symptomatic hypoglycemia,mg and mg respectively was coadministered,0
TRULICITY,symptomatic hypoglycemia,sulfonylurea symptomatic hypoglycemia,1
TRULICITY,symptomatic hypoglycemia,symptomatic,1
TRULICITY,symptomatic hypoglycemia,sulfonylurea symptomatic,1
TRULICITY,symptomatic hypoglycemia,of patients when TRULICITY,0
TRULICITY,hypoglycemia,hypoglycemia occurred in and of,1
TRULICITY,hypoglycemia,insulin,0
TRULICITY,hypoglycemia,prandial insulin hypoglycemia occurred in and of patients,1
TRULICITY,hypoglycemia,insulin,0
TRULICITY,hypoglycemia,with prandial insulin hypoglycemia occurred in and of,1
TRULICITY,hypoglycemia,insulin,0
TRULICITY,increase in heart rate,in heart rate HR,1
TRULICITY,increase in heart rate,a,0
TRULICITY,increase in heart rate,have not b,0
TRULICITY,increase in heart rate,increase in heart rate HR of beats per minute,1
TRULICITY,increase in heart rate,have not b,0
TRULICITY,increase in heart rate,increase in HR have,0
TRULICITY,increase in heart rate,mg resulted in a increase in heart rate,1
TRULICITY,increase in HR,rate HR of beats per minute bpm The longterm clinical effects of the,0
TRULICITY,increase in HR,established see Warnings,0
TRULICITY,increase in HR,clinical effects of increase in HR have not been established see,1
TRULICITY,increase in HR,established see Warnings,0
TRULICITY,increase in HR,of,0
TRULICITY,increase in HR,increase in HR have not been established,1
TRULICITY,increase in HR,longterm clinical effects of increase,1
TRULICITY,increase in HR,longterm clinical effects of increase in HR,1
TRULICITY,increase in HR,longterm clinical effects of increase,1
TRULICITY,increase in HR,of increase in HR have not been established,1
TRULICITY,increase in HR,longterm clinical effects of increase,1
TRULICITY,Sinus tachycardia,with placebo TRULICITY mg and,0
TRULICITY,Persistence of sinus tachycardia,TRULICITY mg Persistence of sinus tachycardia reported at more than,1
TRULICITY,Persistence of sinus tachycardia,with placebo TRULICITY mg and,0
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity,1
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions sometimes,1
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity,1
TRULICITY,Systemic hypersensitivity,other products Systemic,1
TRULICITY,Systemic hypersensitivity,other products,0
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions,1
TRULICITY,Systemic hypersensitivity,other products,0
TRULICITY,Systemic hypersensitivity,other products,0
TRULICITY,Systemic hypersensitivity,products Systemic hypersensitivity,1
TRULICITY,Systemic hypersensitivity,other products,0
TRULICITY,Systemic hypersensitivity,products Systemic,1
TRULICITY,Systemic hypersensitivity,other products Systemic hypersensitivity adverse,1
TRULICITY,Systemic hypersensitivity,products Systemic,1
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions,1
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions sometimes severe,1
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions,1
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions sometimes severe,1
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse,1
TRULICITY,Systemic hypersensitivity,Systemic hypersensitivity adverse reactions sometimes severe,1
TRULICITY,Systemic hypersensitivity,products Systemic hypersensitivity,1
TRULICITY,urticaria,Systemic hypersensitivity adverse reactions sometimes severe,0
TRULICITY,urticaria,in of patients on TRULICITY in,0
TRULICITY,urticaria,rash,0
TRULICITY,urticaria,urticaria systemic rash,1
TRULICITY,urticaria,patients on TRULICITY in,0
TRULICITY,urticaria,Hypersensitivity Systemic hypersensitivity adverse,0
TRULICITY,systemic rash,eg severe systemic,1
TRULICITY,systemic rash,severe eg severe urticaria,0
TRULICITY,systemic rash,severe systemic rash,1
TRULICITY,systemic rash,severe systemic rash facial,1
TRULICITY,systemic rash,severe systemic rash,1
TRULICITY,systemic rash,facial edema lip swelling occurred in,0
TRULICITY,systemic rash,systemic rash facial,1
TRULICITY,systemic rash,severe systemic,1
TRULICITY,systemic rash,severe systemic rash,1
TRULICITY,systemic rash,systemic rash facial,1
TRULICITY,systemic rash,severe systemic rash,1
TRULICITY,facial edema,urticaria,0
TRULICITY,facial edema,facial,1
TRULICITY,facial edema,adverse reactions sometimes severe eg,0
TRULICITY,facial edema,adverse reactions sometimes severe eg severe urticaria systemic rash,0
TRULICITY,facial edema,facial edema,1
TRULICITY,facial edema,in of patients on TRULICITY,0
TRULICITY,lip swelling,rash facial lip,1
TRULICITY,injection-site reactions,the placebocontrolled injection-site reactions eg injectionsite rash erythema were,1
TRULICITY,injection-site reactions,rash facial lip,1
TRULICITY,injection-site reactions,patients and,0
TRULICITY,injection-site reactions,five Phase studies Injectionsite Reactions In the placebocontrolled studies,0
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite rash,1
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite rash erythema were,1
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite rash,1
TRULICITY,injection-site reactions,injection-site reactions eg,1
TRULICITY,injection-site reactions,injection-site reactions eg injectionsite rash,1
TRULICITY,injection-site reactions,injection-site reactions,1
TRULICITY,injection-site reactions,patients,0
TRULICITY,injection-site rash,reactions injection-site rash erythema were reported in,1
TRULICITY,injection-site rash,patients,0
TRULICITY,injection-site rash,and in of placebotreated patie,0
TRULICITY,PR interval increase,and of patients,0
TRULICITY,PR interval increase,respectively On electrocardiograms PR interval increase to at least,1
TRULICITY,PR interval increase,and of patients,0
TRULICITY,PR interval increase,patients treated with placebo,0
TRULICITY,PR interval increase,PR interval increase to at least milliseconds was,1
TRULICITY,PR interval increase,patients,0
TRULICITY,PR interval increase,PR interval increase to,1
TRULICITY,PR interval increase,On electrocardiograms PR interval,1
TRULICITY,PR interval increase,of,0
TRULICITY,THYROID C-CELL TUMORS,the prescribing,0
TRULICITY,THYROID C-CELL TUMORS,Thyroid Ccell Tumor,0
TRULICITY,THYROID C-CELL TUMORS,REACTIONS The ng serious,1
TRULICITY,THYROID C-CELL TUMORS,REACTIONS The ng serious reactions  are described below or,1
TRULICITY,THYROID C-CELL TUMORS,REACTIONS The ng serious,1
TRULICITY,THYROID C-CELL TUMORS,information Risk of Thyroid Ccell,0
TRULICITY,THYROID C-CELL TUMORS,reactions are described below elsewhere in the pres cribing,1
TRULICITY,THYROID C-CELL TUMORS,information Risk of Thyroid Ccell,0
TRULICITY,THYROID C-CELL TUMORS,described below,0
TRULICITY,THYROID C-CELL TUMORS,information Risk of,0
TRULICITY,THYROID C-CELL TUMORS,elsewhere in the pres cribing information Risk of,1
TRULICITY,THYROID C-CELL TUMORS,information Risk of,0
TRULICITY,thyroid C-cell tumors,( 5. Hypoglycemia with Concomitant Use,1
TRULICITY,thyroid C-cell tumors,( 5. Hypoglycemia,1
TRULICITY,thyroid C-cell tumors,see and Precautions,1
TRULICITY,thyroid C-cell tumors,and Precautions Hypersensitivity reactions see Warnings and,1
TRULICITY,thyroid C-cell tumors,Insulin Secretagogues,0
TRULICITY,thyroid C-cell tumors,Hypersensitivity reactions see Warnings and,0
TRULICITY,thyroid C-cell tumors,with Concomitant Use,0
TRULICITY,thyroid C-cell tumors,Insulin see ings,1
TRULICITY,thyroid C-cell tumors,see ings and Precautions,1
TRULICITY,thyroid C-cell tumors,see,0
TRULICITY,thyroid C-cell tumors,see ings and Precautions,1
TRULICITY,thyroid C-cell tumors,ings and Precautions Hypersensitivity reactions,1
TRULICITY,thyroid C-cell tumors,ings and Precautions  Hypersensitivity reactions,1
TRULICITY,thyroid C-cell tumors,ings and Precautions Hypersensitivity reactions,1
TRULICITY,medullary thyroid carcinoma,ions see,0
TRULICITY,medullary thyroid carcinoma,and Precautions,0
TRULICITY,medullary thyroid carcinoma,"Insulin see Warnings and 
 *  Hypersensitivity react ions see Warnings",1
TRULICITY,medullary thyroid carcinoma,and Precautions,0
TRULICITY,medullary thyroid carcinoma,or,0
TRULICITY,MTC,ns  see Warnings and,1
TRULICITY,MTC,and Precautions Renal impairment,0
TRULICITY,MTC,Secretagogues or Insulin see Warnings and Precautions Hypersensitivity reactio,0
TRULICITY,MTC,ns  see Warnings and Precautions,1
TRULICITY,MTC,ns  see Warnings and,1
TRULICITY,MTC,ns  see Warnings,1
TRULICITY,MTC,Secretagogues or Insulin,0
TRULICITY,MTC,and Precautions Hypersensitivity,0
TRULICITY,MTC,ns  see Warnings,1
TRULICITY,thyroid C-cell tumors,and Precautions Renal t [see Warnings,1
TRULICITY,thyroid C-cell tumors,and P recautions,1
TRULICITY,thyroid C-cell tumors,and Precautions Renal t [see Warnings and P recautions Severe,1
TRULICITY,thyroid C-cell tumors,and P recautions,1
TRULICITY,thyroid C-cell tumors,Warnings and Precautions,0
TRULICITY,thyroid C-cell tumors,t [see Warnings and P recautions,1
TRULICITY,thyroid C-cell tumors,Warnings and Precautions,0
TRULICITY,thyroid C-cell tumors,t [see Warnings and P recautions Severe,1
TRULICITY,thyroid C-cell tumors,Warnings and Precautions,0
TRULICITY,thyroid C-cell tumors,Renal t [see Warnings and P recautions Severe Gastrointestinal,1
TRULICITY,thyroid C-cell tumors,Warnings and Precautions,0
TRULICITY,thyroid C-cell tumors,in able,1
TRULICITY,thyroid C-cell tumors,from the placebocontrolled trials see Clinical,0
TRULICITY,thyroid C-cell tumors,)] . These,1
TRULICITY,thyroid C-cell tumors,patients to TRULICITY and a,0
TRULICITY,thyroid C-cell tumors,Studies ( 14 )] . These,1
TRULICITY,medullary thyroid carcinoma,These ta reflect exposure of,1
TRULICITY,medullary thyroid carcinoma,exposure of 1670 patients to TRULICITY and,1
TRULICITY,medullary thyroid carcinoma,see Clinical Studies These ta reflect exposure of,1
TRULICITY,medullary thyroid carcinoma,see Clinical Studies These ta reflect exposure of 1670 patients to TRULICITY and,1
TRULICITY,medullary thyroid carcinoma,see Clinical Studies These ta reflect exposure of,1
TRULICITY,medullary thyroid carcinoma,see Clinical Studies These ta reflect exposure of,1
TRULICITY,MTC,ati ents to TRULICITY and a,1
TRULICITY,MTC,data,0
TRULICITY,MTC,ati,1
TRULICITY,thyroid C-cell tumors,exposure to TRULICITY of,0
TRULICITY,Thyroid C-cell Tumors,tions are described b elow or elsewhere in,1
TRULICITY,Thyroid C-cell Tumors,are described b elow,1
TRULICITY,Thyroid C-cell Tumors,tions are described b elow or elsewhere in the,1
TRULICITY,Thyroid C-cell Tumors,following serious tions,1
TRULICITY,Thyroid C-cell Tumors,serious tions are described b elow or elsewhere,1
TRULICITY,Thyroid C-cell Tumors,following serious tions,1
TRULICITY,Thyroid C-cell Tumors,serious tions are described b elow or,1
TRULICITY,Thyroid C-cell Tumors,following serious tions,1
TRULICITY,Thyroid C-cell Tumors,tions are described b elow or elsewhere,1
TRULICITY,Thyroid C-cell Tumors,The following serious tions are,1
TRULICITY,Pancreatitis,information: Risk of Thyroid Ccell,1
TRULICITY,Hypoglycemia, Precautions Hypersensitivity reactions see,1
TRULICITY,Hypoglycemia,see Warnings  Precautions,1
TRULICITY,Hypoglycemia, Precautions Hypersensitivity reactions see,1
TRULICITY,Hypoglycemia, Precautions Hypersensitivity reactions see Warnings,1
TRULICITY,Hypoglycemia, Precautions Hypersensitivity reactions see,1
TRULICITY,Hypoglycemia,Insulin see Warnings  Precautions Hypersensitivity reactions see,1
TRULICITY,Hypoglycemia, Precautions Hypersensitivity reactions see,1
TRULICITY,Hypoglycemia,and Precautions,0
TRULICITY,Hypoglycemia,see Warnings and,0
TRULICITY,Hypoglycemia, Precautions Hypersensitivity reactions,1
TRULICITY,Hypoglycemia,Concomitant Use,0
TRULICITY,Hypersensitivity,Disease see gs and Precautio ns EXCERPT The most common,1
TRULICITY,Hypersensitivity,Concomitant Use,0
TRULICITY,Hypersensitivity,Precautions,0
TRULICITY,Hypersensitivity,Disease see gs,1
TRULICITY,Hypersensitivity,Gastrointestinal Disease see gs and Precautio,1
TRULICITY,Hypersensitivity,reactions reported in,0
TRULICITY,Hypersensitivity,Severe Gastrointestinal Disease,0
TRULICITY,Renal Impairment,decreased appetite To report SUSPECTED ADVERSE REACTIONS contact,0
TRULICITY,Renal Impairment,"nausea diarrhea iting,",1
TRULICITY,Renal Impairment,"iting, abdominal pain and decreased appetite",1
TRULICITY,Renal Impairment,"are nausea diarrhea iting, abdominal",1
TRULICITY,Renal Impairment,"iting, abdominal pain and decreased appetite",1
TRULICITY,Renal Impairment,"TRULICITY are nausea diarrhea iting,",1
TRULICITY,Renal Impairment,"TRULICITY are nausea diarrhea iting,",1
TRULICITY,Renal Impairment,vom,0
TRULICITY,thyroid C-cell adenomas,Clinical,0
TRULICITY,thyroid C-cell adenomas,The data in Table are derived,0
TRULICITY,thyroid C-cell adenomas,( 14 )] . These data reflect exposure of patients,1
TRULICITY,thyroid C-cell adenomas,Clinical (,1
TRULICITY,thyroid C-cell adenomas,placebocontrolled trials see Clinical ( 14 )] . These,1
TRULICITY,thyroid C-cell adenomas,placebocontrolled trials,0
TRULICITY,thyroid C-cell adenomas,trials see Clinical ( 14,1
TRULICITY,thyroid C-cell tumors,exposure,0
TRULICITY,thyroid C-cell tumors,. Across the treatmen,1
TRULICITY,thyroid C-cell tumors,TRULICITY of . Across the treatmen t arms the mean,1
TRULICITY,thyroid C-cell tumors,. Across the treatmen,1
TRULICITY,thyroid C-cell tumors,to TRULICITY of,0
TRULICITY,thyroid C-cell tumors,the treatmen,1
TRULICITY,thyroid C-cell tumors,exposure to TRULICITY of . Across the,1
TRULICITY,medullary thyroid carcinoma,population in these,0
TRULICITY,medullary thyroid carcinoma,of patients was 56 years were years,1
TRULICITY,medullary thyroid carcinoma,age of patients was 56 years were years or older,1
TRULICITY,medullary thyroid carcinoma,mean age of patients was 56 years,1
TRULICITY,medullary thyroid carcinoma,age of patients was 56 years,1
TRULICITY,medullary thyroid carcinoma,were years or older and,0
TRULICITY,MTC,ear s were years or older,1
TRULICITY,MTC,ear s were,1
TRULICITY,MTC,ear,1
TRULICITY,MTC,ear,1
TRULICITY,thyroid C-cell tumors,hese studies,1
TRULICITY,thyroid C-cell tumors,in hese studies was 69%  White Black or,1
TRULICITY,thyroid C-cell tumors,hese studies,1
TRULICITY,thyroid C-cell tumors,of Hispanic or Latino ethnicity At baselin,0
TRULICITY,thyroid C-cell tumors,Black or African American Asian were of Hispanic or Latino ethnicity At baselin,0
TRULICITY,thyroid C-cell tumors,was 69% White Black,1
TRULICITY,thyroid C-cell tumors,studies was 69% White Black or African American,1
TRULICITY,thyroid C-cell tumors,hese studies was 69%  White Black,1
TRULICITY,thyroid C-cell tumors,studies was 69% White Black or African American,1
TRULICITY,thyroid C-cell tumors,of patients was years were years or older and were male The population in,0
TRULICITY,thyroid C-cell tumors,The population in hese studies,1
TRULICITY,MTC,n;  were of Hispanic or Latino,1
TRULICITY,MTC,or African American n;  were of Hispanic or Latino,1
TRULICITY,MTC,n;  were of Hispanic or Latino,1
TRULICITY,MTC,n;  were of Hispanic or,1
TRULICITY,MTC,n;  were of,1
TRULICITY,MTC,n; ,1
TRULICITY,MTC,studies was White Black or African American,0
TRULICITY,MTC,n;  were of Hispanic,1
TRULICITY,MTC,Black or African American n;  were,1
TRULICITY,MTC,n;  were of Hispanic,1
TRULICITY,MTC,n;  were of Hispanic or Latino,1
TRULICITY,MTC,retinopathy Baseline,0
TRULICITY,MTC,he  population reported retinopathy,1
TRULICITY,MTC,he ,1
TRULICITY,MTC,he  population reported retinopathy Baseline estimated,1
TRULICITY,MTC,estimated renal function was normal or mildly impaired eG,0
TRULICITY,MTC,he  population reported,1
TRULICITY,MTC,he  population reported retinopathy Baseline estimated,1
TRULICITY,MTC,of he  population reported,1
TRULICITY,MTC,he  population reported retinopathy Baseline estimated,1
TRULICITY,MTC,lud ing hypoglycemia,1
TRULICITY,MTC,lud ing hypoglycemia associated with the,1
TRULICITY,MTC,lud ing hypoglycemia associated,1
TRULICITY,MTC,lud ing,1
TRULICITY,MTC,lud,1
TRULICITY,MTC,lud ing,1
TRULICITY,MTC,lud,1
TRULICITY,pancreatitis,             Vomiting,1
TRULICITY,pancreatitis,lud,1
TRULICITY,pancreatitis,             Vomiting,1
TRULICITY,pancreatitis,             Vomiting,1
TRULICITY,pancreatitis,a,0
TRULICITY,pancreatitis,             Vomiting,1
TRULICITY,pancreatitis,Diarrhea,0
TRULICITY,pancreatitis,             Vomiting b,1
TRULICITY,hypoglycemia,ULICITY 1.5 mg discontinued treatment due to,1
TRULICITY,hypoglycemia,TRULICITY mg and ULICITY 1.5 ,1
TRULICITY,hypoglycemia,ULICITY 1.5 mg discontinued treatment due to,1
TRULICITY,hypoglycemia,gastrointestinal adverse reactions,0
TRULICITY,hypoglycemia,ULICITY 1.5 mg discontinued treatment due,1
TRULICITY,hypoglycemia,receiving TRULICITY,0
TRULICITY,hypoglycemia,ULICITY 1.5 mg,1
TRULICITY,hypoglycemia,ULICITY 1.5 mg discontinued treatment due,1
TRULICITY,hypoglycemia,receiving TRULICITY mg and ULICITY,1
TRULICITY,hypoglycemia,TRULICITY mg and,0
TRULICITY,hypoglycemia,TRULICITY mg and ULICITY 1.5  mg discontinued treatment due to,1
TRULICITY,hypoglycemia,TRULICITY mg and,0
TRULICITY,Systemic hypersensitivity,"of cases, respectively, or severe in and",1
TRULICITY,Systemic hypersensitivity,"cases respectively moderate in % of cases, respectively, or severe",1
TRULICITY,Systemic hypersensitivity,"of cases, respectively, or severe in and",1
TRULICITY,Systemic hypersensitivity,"of cases, respectively, or severe in and of",1
TRULICITY,Systemic hypersensitivity,cases respectively In addition to the,0
TRULICITY,Systemic hypersensitivity,%,1
TRULICITY,Systemic hypersensitivity,"cases respectively moderate in % of cases,",1
TRULICITY,Systemic hypersensitivity,in %,1
TRULICITY,Systemic hypersensitivity,"in % of cases, respectively, or severe in",1
TRULICITY,Systemic hypersensitivity,in %,1
TRULICITY,Systemic hypersensitivity,"respectively moderate in % of cases,",1
TRULICITY,acute renal failure,abdominal disten,0
TRULICITY,chronic renal failure,distension gastroesopha,0
TRULICITY,chronic renal failure,reflux disease ( and,1
TRULICITY,chronic renal failure,geal reflux,1
TRULICITY,chronic renal failure,Pool of Placebo and,0
TRULICITY,chronic renal failure,disease ( and,1
TRULICITY,chronic renal failure,abdominal,0
TRULICITY,chronic renal failure,flatulence,0
TRULICITY,nausea, type ,1
TRULICITY,nausea, type  diabetes participating in placebo,1
TRULICITY,nausea, type  diabetes participating in,1
TRULICITY,nausea, type  diabetes participating in placebo and,1
TRULICITY,nausea, type ,1
TRULICITY,nausea, type  diabetes participating in placebo,1
TRULICITY,nausea, type ,1
TRULICITY,nausea,use of,0
TRULICITY,vomiting,a larger,0
TRULICITY,vomiting,diabetes participating in placebo,1
TRULICITY,vomiting,diabetes participating,1
TRULICITY,vomiting,diabetes participating in placebo,1
TRULICITY,diarrhea,evaluated in a larger pool of patients with type diabetes,0
TRULICITY,diarrhea,use of TRULICITY as monotherapy,0
TRULICITY,diarrhea,articipa,1
TRULICITY,dehydration,patients with type diabetes in 6 placeb o and activecontrolled trials,1
TRULICITY,dehydration,articipa,1
TRULICITY,dehydration,type diabetes in 6 placeb o and activecontrolled,1
TRULICITY,dehydration,articipa,1
TRULICITY,gastrointestinal adverse reactions,"American, 11% Asian; 32% w ere of Hispanic",1
TRULICITY,gastrointestinal adverse reactions,"African American, 11% Asian; 32% w ere of Hispanic",1
TRULICITY,gastrointestinal adverse reactions,"American, 11% Asian; 32% w ere of Hispanic",1
TRULICITY,gastrointestinal adverse reactions,"studies was White Black African American,",1
TRULICITY,gastrointestinal adverse reactions,"African American, 11% Asian; 32% w ere of Hispanic or",1
TRULICITY,gastrointestinal adverse reactions,"studies was White Black African American,",1
TRULICITY,gastrointestinal adverse reactions,The population in these studies was White Black or,0
TRULICITY,gastrointestinal adverse reactions,Asian; 32% w,1
TRULICITY,gastrointestinal adverse reactions,"American, 11% Asian; 32% w ere",1
TRULICITY,gastrointestinal adverse reactions,"American, 11% Asian; 32% w ere of Hispanic or Latino",1
TRULICITY,gastrointestinal adverse reactions,"African American, 11% Asian; 32% w ere of Hispanic or",1
TRULICITY,gastrointestinal adverse reactions,"American, 11% Asian; 32% w ere of Hispanic or Latino",1
TRULICITY,gastrointestinal adverse reactions,Asian; 32% w ere of Hispanic or Latino,1
TRULICITY,gastrointestinal adverse reactions,population had diabetes,0
TRULICITY,gastrointestinal adverse reactions,"Black African American, 11% Asian; 32%",1
TRULICITY,gastrointestinal adverse reactions,Black or,0
TRULICITY,gastrointestinal adverse reactions,"was White Black African American, 11% Asian; 32% w ere of Hispanic or Latino",1
TRULICITY,gastrointestinal adverse reactions,Black or,0
TRULICITY,gastrointestinal adverse reactions,Latino ethnicity At baseline the population had diabetes for,0
TRULICITY,gastrointestinal adverse reactions,"studies was White Black African American, 11% Asian;",1
TRULICITY,gastrointestinal adverse reactions,ethnicity At baseline the population,0
TEFLARO,Hypersensitivity Reactions,and Precautions Hypersensitivity,1
TEFLARO,Hypersensitivity Reactions,Hypersensitivity,1
TEFLARO,Hypersensitivity Reactions,and Precautions Hypersensitivity,1
TEFLARO,Hypersensitivity Reactions,diarrhea see War,0
TEFLARO,Hypersensitivity Reactions,and Precautions Hypersensitivity Reactions see Warnings and Precautions,1
TEFLARO,Hypersensitivity Reactions,diarrhea see War,0
TEFLARO,Hypersensitivity Reactions,Hypersensitivity Reactions see,1
TEFLARO,Hypersensitivity Reactions,difficile Associated,0
TEFLARO,Hypersensitivity Reactions,Hypersensitivity Reactions,1
TEFLARO,Clostridium difficile -Associated diarrhea,Seroconversion see,0
TEFLARO,Clostridium difficile -Associated diarrhea,Reactions see Warnings and Clostridium,1
TEFLARO,Clostridium difficile -Associated diarrhea,see Warnings and Clostridium,1
TEFLARO,Clostridium difficile -Associated diarrhea,see Warnings and Clostridium difficile -Associated,1
TEFLARO,Clostridium difficile -Associated diarrhea,Hypersensitivity Reactions see,0
TEFLARO,Clostridium difficile -Associated diarrhea,Reactions see Warnings and Precautions,0
TEFLARO,nausea,nausea,1
TEFLARO,rash,rash To,1
TEFLARO,rash,occurring in of patients are diarrhea nausea and,0
TEFLARO,rash,rash To report SUSPECTED ADVERSE REACTIONS,1
TEFLARO,rash,To report SUSPECTED ADVERSE REACTIONS,0
TEFLARO,rash,of patients are,0
TEFLARO,rash,rash To report SUSPECTED ADVERSE,1
TEFLARO,rash,patients are diarrhea nausea rash To report,1
TEFLARO,rash,rash To report SUSPECTED ADVERSE,1
TEFLARO,rash,patients are diarrhea nausea rash,1
TEFLARO,rash,rash To report SUSPECTED ADVERSE,1
TEFLARO,diarrhea,diarrhea nausea and rash,1
TEFLARO,diarrhea,diarrhea nausea and,1
TEFLARO,diarrhea,diarrhea,1
TEFLARO,diarrhea,trials diarrhea nausea,1
TEFLARO,diarrhea,diarrhea,1
TEFLARO,diarrhea,reactions occurring in,0
TEFLARO,diarrhea,diarrhea nausea and rash,1
TEFLARO,diarrhea,lists,0
TEFLARO,nausea,the pooled,0
TEFLARO,nausea,were nausea and,1
TEFLARO,nausea,the pooled,0
TEFLARO,nausea,of patients receiving Teflaro in the pooled phase clinical trials were diarrhea,0
TEFLARO,nausea,trials were nausea,1
TEFLARO,nausea,of patients receiving Teflaro in the pooled phase clinical trials were diarrhea,0
TEFLARO,nausea,lists,0
TEFLARO,nausea,nausea and rash Table lists adverse,1
TEFLARO,nausea,phase clinical trials were nausea and rash Table lists adverse,1
TEFLARO,nausea,nausea and rash Table lists adverse,1
TEFLARO,nausea,nausea and rash Table lists adverse,1
TEFLARO,nausea,nausea and rash Table lists adverse,1
TEFLARO,nausea,and rash Table lists adverse reactions occurring,0
TEFLARO,rash,receiving Teflaro in the pooled phase clinical trials,0
TEFLARO,rash,phase clinical trials were diarrhea nausea,0
TEFLARO,rash,nausea rash Table lists,1
TEFLARO,rash,phase clinical trials were diarrhea nausea,0
TEFLARO,Increased transaminases,Increased transaminases Metabolism,1
TEFLARO,Increased transaminases,Increased transaminases,1
TEFLARO,Increased transaminases,Increased transaminases Metabolism,1
TEFLARO,Increased transaminases,Laboratory,0
TEFLARO,Increased transaminases,Increased transaminases Metabolism and,1
TEFLARO,Anemia,Thrombocytopenia Cardiac,0
TEFLARO,Eosinophilia,Eosinophilia Neutropenia Thrombocytopenia Cardiac disorders Bradycardia,1
TEFLARO,Eosinophilia,Thrombocytopenia Cardiac,0
TEFLARO,Eosinophilia,and lymphatic system disorders,0
TEFLARO,Eosinophilia,system disorders Eosinophilia Neutropenia,1
TEFLARO,Eosinophilia,and lymphatic system disorders,0
TEFLARO,Eosinophilia,Eosinophilia Neutropenia Thrombocytopenia Cardiac,1
TEFLARO,Eosinophilia,Eosinophilia Neutropenia Thrombocytopenia Cardiac,1
TEFLARO,Neutropenia,Blood and lymphatic system disorders Anemia Eosinophilia,0
TEFLARO,Neutropenia,and lymphatic system disorders Anemia Eosinophilia,0
TEFLARO,Neutropenia,Thrombocytopenia Cardiac disorders,0
TEFLARO,Thrombocytopenia,disorders Anemia Eosinophilia Thrombocytopenia,1
TEFLARO,Thrombocytopenia,Thrombocytopenia Cardiac disorders,0
TEFLARO,Thrombocytopenia,Thrombocytopenia,1
TEFLARO,Thrombocytopenia,Thrombocytopenia Cardiac,1
TEFLARO,Thrombocytopenia,system disorders Anemia Eosinophilia,0
TEFLARO,Bradycardia,Neutropenia Thrombocytopenia Cardiac Bradycardia Palpitations,1
TEFLARO,Bradycardia,system disorders Anemia Eosinophilia,0
TEFLARO,Bradycardia,Bradycardia,1
TEFLARO,Bradycardia,pain General disorders and,0
TEFLARO,Bradycardia,Cardiac disorders,0
TEFLARO,Bradycardia,Bradycardia,1
TEFLARO,Palpitations,Palpitations Gastrointestinal disorders Abdominal pain,1
TEFLARO,Palpitations,Bradycardia,1
TEFLARO,Palpitations,disorders Palpitations Gastrointestinal,1
TEFLARO,Palpitations,Bradycardia,1
TEFLARO,Palpitations,Gastrointestinal,0
TEFLARO,Palpitations,Palpitations Gastrointestinal disorders,1
TEFLARO,Palpitations,Eosinophilia,0
TEFLARO,Palpitations,Thrombocytopenia Cardiac disorders Palpitations Gastrointestinal disorders,1
TEFLARO,Palpitations,Eosinophilia,0
TEFLARO,Palpitations,Palpitations Gastrointestinal,1
TEFLARO,Palpitations,Eosinophilia,0
TEFLARO,Palpitations,Cardiac disorders Palpitations Gastrointestinal,1
TEFLARO,Palpitations,Eosinophilia,0
TEFLARO,Palpitations,and administration site,0
TEFLARO,Abdominal pain,administration site conditions,0
TEFLARO,Abdominal pain,Gastrointestinal Abdominal,1
TEFLARO,Abdominal pain,Bradycardia Palpitations Gastrointestinal Abdominal pain,1
TEFLARO,Abdominal pain,disorders Bradycardia,0
TEFLARO,Abdominal pain,Abdominal pain,1
TEFLARO,Abdominal pain,Gastrointestinal,0
TEFLARO,Abdominal pain,Gastrointestinal Abdominal pain,1
TEFLARO,Abdominal pain,disorders Bradycardia Palpitations,0
TEFLARO,Abdominal pain,Bradycardia Palpitations Gastrointestinal Abdominal pain General disorders and administration,1
TEFLARO,Abdominal pain,disorders Bradycardia Palpitations,0
TEFLARO,Pyrexia,Hepatitis Immune system disorders Hypersensitivity,0
TEFLARO,Pyrexia,site Pyrexia Hepatobiliary disorders Hepatitis Immune system,1
TEFLARO,Pyrexia,Hepatitis Immune system disorders Hypersensitivity,0
TEFLARO,Hepatitis,disorders Hypersensitivity Anaphylaxis Infections and infestations,0
TEFLARO,Hepatitis,Immune system,0
TEFLARO,Hypersensitivity,conditions Pyrexia,0
TEFLARO,Hypersensitivity,difficile colitis,0
TEFLARO,Hypersensitivity,difficile,0
TEFLARO,Hypersensitivity,Hepatitis Immune,0
TEFLARO,Anaphylaxis,and infestations Clostridium,0
TEFLARO,Anaphylaxis,disorders Anaphylaxis Infections,1
TEFLARO,Anaphylaxis,and infestations Clostridium,0
TEFLARO,Anaphylaxis,system disorders Anaphylaxis Infections and infestations Clostridium difficile,1
TEFLARO,Anaphylaxis,and infestations Clostridium,0
TEFLARO,Anaphylaxis,Anaphylaxis Infections and infestations Clostridium,1
TEFLARO,Clostridium difficile colitis,Clostridium,1
TEFLARO,Clostridium difficile colitis,and Clostridium,1
TEFLARO,Clostridium difficile colitis,difficile colitis Metabolism,1
TEFLARO,Clostridium difficile colitis,and Clostridium difficile  colitis Metabolism and,1
TEFLARO,Clostridium difficile colitis,difficile colitis Metabolism,1
TEFLARO,Clostridium difficile colitis,Immune system disorders Hypersensitivity Anaphylaxis Infections and infestations,0
TEFLARO,Clostridium difficile colitis,Clostridium difficile  colitis Metabolism and nutrition disorders,1
TEFLARO,Clostridium difficile colitis,Immune system disorders Hypersensitivity Anaphylaxis Infections and infestations,0
TEFLARO,Clostridium difficile colitis,Anaphylaxis Infections and Clostridium difficile colitis,1
TEFLARO,Hyperglycemia,and,0
TEFLARO,Hyperglycemia,Hyperglycemia Hyperkalemia Nervous system,1
TEFLARO,Hyperglycemia,Hyperglycemia Hyperkalemia,1
TEFLARO,Hyperkalemia,disorders Dizziness Convulsion Renal and urinary disorders,0
TEFLARO,Hyperkalemia,Convulsion Renal,0
TEFLARO,Hyperkalemia,tions Clostridium difficile colitis Metabolism,0
TEFLARO,Hyperkalemia,disorders,0
TEFLARO,Hyperkalemia,Hyperkalemia Nervous system disorders,1
TEFLARO,Dizziness,Dizziness Convulsion Renal,1
TEFLARO,Dizziness,Nervous system Dizziness Convulsion Renal and urinary disorders,1
TEFLARO,Dizziness,Dizziness Convulsion Renal,1
TEFLARO,Dizziness,Dizziness Convulsion Renal,1
TEFLARO,Dizziness,Dizziness Convulsion Renal and urinary disorders,1
TEFLARO,Dizziness,Dizziness Convulsion Renal and,1
TEFLARO,Dizziness,Dizziness,1
TEFLARO,Dizziness,failure Skin and subcutaneous,0
TEFLARO,Convulsion,Convulsion Renal and urinary,1
TEFLARO,Convulsion,Dizziness,0
TEFLARO,Convulsion,Convulsion Renal and urinary,1
TEFLARO,Convulsion,Nervous system disorders Convulsion Renal and urinary,1
TEFLARO,Convulsion,Convulsion Renal and urinary,1
TEFLARO,Convulsion,Convulsion Renal and urinary,1
TEFLARO,Convulsion,Convulsion,1
TEFLARO,Convulsion,Convulsion,1
TEFLARO,Renal failure,Renal and urinary disorders,0
TEFLARO,Renal failure,and,0
TEFLARO,Renal failure,Renal failure Skin and subcutaneous,1
TEFLARO,Renal failure,Renal and urinary disorders,0
TEFLARO,Renal failure,urinary Renal failure,1
TEFLARO,Renal failure,Renal and urinary disorders,0
TEFLARO,Renal failure,Convulsion Renal and urinary Renal failure Skin and subcutaneous tissue,1
TEFLARO,Renal failure,Renal and urinary disorders,0
TEFLARO,Renal failure,Convulsion Renal and urinary,0
TEFLARO,Renal failure,Skin and,0
TEFLARO,Renal failure,urinary Renal,1
TEFLARO,Urticaria,Experience The following adverse reaction has been,0
TEFLARO,Urticaria,reaction,0
TEFLARO,Urticaria,Skin and subcutaneous tissue Urticaria Postmarketing Experience The following,1
TEFLARO,Urticaria,reaction,0
TEFLARO,Urticaria,Skin and,0
TEFLARO,Urticaria,Urticaria Postmarketing Experience,1
TEFLARO,Urticaria,Urticaria,1
TEFLARO,Urticaria,tissue Urticaria,1
TEFLARO,Urticaria,Urticaria,1
TEFLARO,Urticaria,Urticaria Postmarketing Experience The,1
TEFLARO,Urticaria,Urticaria Postmarketing Experience,1
TEFLARO,Urticaria,adverse reaction has,0
TEFLARO,Clostridium difficile -associated diarrhea,diarrhea [see Warnings and Precautions (,1
TEFLARO,Clostridium difficile -associated diarrhea,Warnings and Precautions E,0
TEFLARO,Clostridium difficile -associated diarrhea,and Precautions E,0
TEFLARO,Clostridium difficile -associated diarrhea,[see Warnings and Precautions (,1
TEFLARO,CDAD,.2   Direct Coombs Test Seroconversion,1
TEFLARO,CDAD,.2   Direct,1
TEFLARO,fatal,idely varying,1
TEFLARO,fatal,idely varying,1
TEFLARO,fatal,drug cannot,0
TEFLARO,fatal,Experience Because clinical trials are conducted under w,0
TEFLARO,fatal,conducted under idely varying conditions adverse,1
TEFLARO,fatal,Experience Because clinical trials are conducted under w,0
TEFLARO,fatal,idely varying conditions adverse reaction rates,1
TEFLARO,skin reactions,conducted under widely varying conditions adverse reaction,0
TEFLARO,skin reactions,clinical tria ls of,1
TEFLARO,skin reactions,adverse reaction rates observed clinical tria,1
TEFLARO,skin reactions,reaction rates observed  clinical tria,1
TEFLARO,skin reactions,adverse reaction rates observed clinical tria,1
TEFLARO,skin reactions,clinical,0
TEFLARO,skin reactions,rates observed clinical,1
TEFLARO,skin reactions,directly to rates from clinical trials of,0
TEFLARO,skin reactions,directly,0
TEFLARO,skin reactions,clinical tria ls of,1
TEFLARO,skin reactions,ls of a drug cannot be,0
TEFLARO,CDAD,Caucasian Serious Adverse s,1
TEFLARO,CDAD,s an d Adverse Reactions,1
TEFLARO,CDAD,s an d Adverse Reactions,1
TEFLARO,diarrhea,in of patients receiving Teflaro and of patients receiving,0
TEFLARO,diarrhea,Teflaro and of,0
TEFLARO,diarrhea,s (SARs),1
TEFLARO,diarrhea,clinical trials serious adverse s (SARs) occurred in of,1
TEFLARO,diarrhea,s (SARs),1
TEFLARO,diarrhea,serious adverse s (SARs) occurred in of patients,1
TEFLARO,diarrhea,s (SARs),1
TEFLARO,diarrhea,s (SARs),1
TEFLARO,diarrhea,s (SARs),1
TEFLARO,diarrhea,s (SARs) occurred in of patients receiving,1
TEFLARO,fatal,of patients receiving Teflaro and of patients receiving comparato,0
TEFLARO,fatal,patients receiving comparato,0
TEFLARO,fatal,reactions SARs urred in of,1
TEFLARO,fatal,patients receiving comparato,0
TEFLARO,fatal,pooled Phase clinical trials serious adverse reactions SARs,0
TEFLARO,fatal,urred in of patients receiving Teflaro,1
TEFLARO,fatal,urred in of patients receiving,1
TEFLARO,fatal,In the four,0
TEFLARO,fatal,adverse,0
TEFLARO,colitis,reactions SARs in,1
TEFLARO,colitis,in 98/1,1
TEFLARO,colitis,reactions SARs in,1
TEFLARO,colitis,Phase,0
TEFLARO,colitis,patients receiving,0
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,h in the Phase CABP trials Adverse,0
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,gram IV very 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI,1
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,Phase,0
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,IV very 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trial s and ceftriaxone,1
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,Phase,0
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,included vancomycin gram IV very 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trial s and ceftriaxone gram IV,1
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,Phase,0
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,IV very 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI,1
TEFLARO,Seroconversion from a negative to a positive direct Coombs' test result,in the Phase CABP trials Adverse,0
JARDIANCE,Hypotension,Renal Function see Warnings and Preca,0
JARDIANCE,Hypotension,Hypotension see Warnings and Precautions Impairment,1
JARDIANCE,Hypotension,Hypotension see Warnings and Precautions,1
JARDIANCE,Hypotension,the Hypotension,1
JARDIANCE,Hypotension,Hypotension see Warnings and Precautions,1
JARDIANCE,Impairment in Renal Function,Precautions,0
JARDIANCE,Impairment in Renal Function,and elsewhere in the,0
JARDIANCE,Hypoglycemia,Warnings,0
JARDIANCE,Genital Mycotic Infections,Genital Mycotic Infections see Warnings and,1
JARDIANCE,Genital Mycotic Infections,Mycotic Infections see Warnings,1
JARDIANCE,Urinary Tract Infections,Warnings and Urinary,1
JARDIANCE,Urinary Tract Infections,Warnings and Urinary Tract,1
JARDIANCE,Urinary Tract Infections,Urinary Tract Infections see Warnings and Precautions Increased,1
JARDIANCE,Urinary Tract Infections,Warnings and Urinary Tract,1
JARDIANCE,Urinary Tract Infections,Infections see Warnings and,0
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,see Warnings and Increased Low-Density Lipoprotein,1
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,Increased Low-Density Lipoprotein Cholesterol LDLC see Warnings,1
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,and Increased Low-Density Lipoprotein,1
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,recautions Urinary Tract,0
JARDIANCE,Increased Low-Density Lipoprotein Cholesterol,see Warnings and Precautions The most common adverse,0
JARDIANCE,urinary tract infections,greater incidence urinary tract infections,1
JARDIANCE,urinary tract infections,The most common adverse reactions associated with JARDIANCE or,0
JARDIANCE,urinary tract infections,or greater,0
JARDIANCE,genital mycotic infections,To report SUSPECTED ADVERSE REACTIONS,0
JARDIANCE,genital mycotic infections,and genital mycotic infections EXCERPT To report,1
JARDIANCE,genital mycotic infections,To report SUSPECTED ADVERSE REACTIONS,0
JARDIANCE,genital mycotic infections,incidence were urinary tract infections,0
JARDIANCE,genital mycotic infections,mycotic infections,1
JARDIANCE,genital mycotic infections,tract infections and genital mycotic,1
JARDIANCE,genital mycotic infections,genital mycotic infections,1
JARDIANCE,genital mycotic infections,tract infections and genital mycotic,1
JARDIANCE,genital mycotic infections,ADVERSE REACTIONS contact,0
JARDIANCE,genital mycotic infections,genital mycotic infections,1
JARDIANCE,hypoglycemia,eGFR mLmin m,0
JARDIANCE,urinary tract infection,but not limited urinary,1
JARDIANCE,urinary tract infection,tract infection asymptomatic bacteriuria cystitis b,1
JARDIANCE,urinary tract infection,infections,0
JARDIANCE,asymptomatic bacteriuria,limited to urinary tract asymptomatic,1
JARDIANCE,asymptomatic bacteriuria,urinary tract,0
JARDIANCE,asymptomatic bacteriuria,infections include the following,0
JARDIANCE,asymptomatic bacteriuria,asymptomatic bacteriuria cystitis b Female genital,1
JARDIANCE,asymptomatic bacteriuria,asymptomatic bacteriuria cystitis,1
JARDIANCE,cystitis,cystitis,1
JARDIANCE,Female genital mycotic infections,genital mycotic infections include the following adverse reactions,1
JARDIANCE,Female genital mycotic infections,Female genital mycotic infections include the following,1
JARDIANCE,Female genital mycotic infections,cystitis,0
JARDIANCE,Female genital mycotic infections,cystitis Female genital mycotic infections include the following adverse reactions,1
JARDIANCE,Female genital mycotic infections,cystitis,0
JARDIANCE,Female genital mycotic infections,vulvovaginal mycotic,0
JARDIANCE,Female genital mycotic infections,vulvovaginal,0
JARDIANCE,Female genital mycotic infections,asymptomatic bacteriuria cystitis b,0
JARDIANCE,vulvovaginal mycotic infection,include,0
JARDIANCE,vulvovaginal mycotic infection,infections include the following,0
JARDIANCE,vulvovaginal mycotic infection,adverse vulvovaginal mycotic infection,1
JARDIANCE,vulvovaginal mycotic infection,the,0
JARDIANCE,vulvovaginal mycotic infection,Female genital mycotic infections include the following,0
JARDIANCE,vulvovaginal mycotic infection,adverse,0
JARDIANCE,vulvovaginal mycotic infection,vulvovaginal mycotic infection vaginal infection vulvitis,1
JARDIANCE,vulvovaginal mycotic infection,adverse,0
JARDIANCE,vulvovaginal mycotic infection,vulvovaginal mycotic infection vaginal infection,1
JARDIANCE,vulvovaginal mycotic infection,infection genital candidiasis gen,0
JARDIANCE,vulvitis,ections include the following adverse reactions vulvovaginal,0
JARDIANCE,vulvovaginal candidiasis,vulvovaginal candidiasis genital,1
JARDIANCE,vulvovaginal candidiasis,vulvovaginal candidiasis genital infection genital,1
JARDIANCE,vulvovaginal candidiasis,vaginal infection vulvovaginal candidiasis genital infection,1
JARDIANCE,vulvovaginal candidiasis,vulvovaginal candidiasis genital infection genital,1
JARDIANCE,vulvovaginal candidiasis,genital infection fungal genitourinary tract,0
JARDIANCE,vulvovaginal candidiasis,fungal genitourinary tract infection,0
JARDIANCE,vulvovaginal candidiasis,infection fungal genitourinary tract,0
JARDIANCE,vulvovaginal candidiasis,mycotic infection vaginal infection vulvovaginal,1
JARDIANCE,vulvovaginal candidiasis,mycotic infection,0
JARDIANCE,vulvovaginal candidiasis,vulvovaginal candidiasis genital infection,1
JARDIANCE,genital infection,genital infection fungal genitourinary tract infection vulvovaginitis cerv,0
JARDIANCE,genital infection,infection fungal genitourinary,0
JARDIANCE,genital infection,vulvitis vulvovaginal genital infection genital candidiasis genital infection fungal,1
JARDIANCE,genital infection,infection fungal genitourinary,0
JARDIANCE,genital infection,vulvitis vulvovaginal genital infection genital candidiasis genital,1
JARDIANCE,genital infection,infection fungal genitourinary,0
JARDIANCE,genital infection,infection vulvovaginitis,0
JARDIANCE,genital infection,genital infection,1
JARDIANCE,genital infection,vaginal infection vulvitis vulvovaginal genital infection,1
JARDIANCE,genital infection,e reactions vulvovaginal mycotic infection vaginal infection vulvitis vulvovaginal candidiasis,0
JARDIANCE,genital infection,genital infection genital candidiasis genital infection,1
JARDIANCE,genital candidiasis,genital,1
JARDIANCE,genital candidiasis,genital candidiasis genital infection fungal genitourinary tract,1
JARDIANCE,genital candidiasis,vulvovaginal candidiasis genital genital candidiasis genital infection fungal genitourinary,1
JARDIANCE,genital candidiasis,genital candidiasis genital infection fungal genitourinary tract,1
JARDIANCE,genital candidiasis,genital candidiasis genital infection fungal,1
JARDIANCE,genital candidiasis,genital candidiasis genital infection fungal genitourinary tract,1
JARDIANCE,genital infection fungal,candidiasis,0
JARDIANCE,genital infection fungal,genital infection fungal genitourinary tract infection vulvovaginitis,1
JARDIANCE,genital infection fungal,genital infection fungal,1
JARDIANCE,genital infection fungal,genital infection fungal genitourinary tract infection vulvovaginitis,1
JARDIANCE,genital infection fungal,genital infection fungal,1
JARDIANCE,genital infection fungal,genitourinary tract infection vulvovaginitis cervicitis urogenital infection fungal vaginitis,0
JARDIANCE,genital infection fungal,infection fungal genitourinary,1
JARDIANCE,genitourinary tract infection,genitourinary tract infection vulvovaginitis cervicitis urogenital infection fungal,1
JARDIANCE,genitourinary tract infection,genital infection genitourinary tract infection,1
JARDIANCE,vulvovaginitis,vaginitis bacterial Percentages calculated with,0
JARDIANCE,vulvovaginitis,infection genital candidiasis genital,0
JARDIANCE,vulvovaginitis,genitourinary tract,0
JARDIANCE,vulvovaginitis,vulvovaginitis cervicitis urogenital infection fungal,1
JARDIANCE,vulvovaginitis,vulvovaginitis cervicitis urogenital,1
JARDIANCE,vulvovaginitis,genitourinary tract vulvovaginitis,1
JARDIANCE,vulvovaginitis,vulvovaginitis cervicitis urogenital,1
JARDIANCE,vulvovaginitis,vaginitis,0
JARDIANCE,vulvovaginitis,genital infection fungal genitourinary tract,0
JARDIANCE,vulvovaginitis,infection fungal genitourinary tract vulvovaginitis cervicitis urogenital,1
JARDIANCE,vulvovaginitis,genital infection fungal genitourinary tract,0
JARDIANCE,vulvovaginitis,genital,0
JARDIANCE,cervicitis,cervicitis urogenital infection fungal vaginitis,1
JARDIANCE,cervicitis,fungal genitourinary tract infection vulvovaginitis,0
JARDIANCE,cervicitis,cervicitis,1
JARDIANCE,cervicitis,urogenital infection fungal,0
JARDIANCE,cervicitis,cervicitis urogenital infection fungal,1
JARDIANCE,cervicitis,calculated with the number,0
JARDIANCE,urogenital infection fungal,urogenital infection fungal,1
JARDIANCE,urogenital infection fungal,calculated with the number,0
JARDIANCE,urogenital infection fungal,l candidiasis genital,0
JARDIANCE,urogenital infection fungal,vulvovaginitis,0
JARDIANCE,urogenital infection fungal,infection fungal vaginitis bacterial Percentages,1
JARDIANCE,urogenital infection fungal,vulvovaginitis urogenital infection fungal,1
JARDIANCE,urogenital infection fungal,genital infection,0
JARDIANCE,urogenital infection fungal,genitourinary tract infection vulvovaginitis cervicitis,0
JARDIANCE,urogenital infection fungal,group,0
JARDIANCE,vaginitis bacterial,urogenital infection vaginitis,1
JARDIANCE,vaginitis bacterial,infection vaginitis bacterial,1
JARDIANCE,polyuria,polyuria,1
JARDIANCE,polyuria,polyuria pollakiuria and nocturia d,1
JARDIANCE,polyuria,polyuria pollakiuria and nocturia,1
JARDIANCE,polyuria,polyuria,1
JARDIANCE,polyuria,polyuria pollakiuria and nocturia,1
JARDIANCE,pollakiuria,pollakiuria and nocturia,1
JARDIANCE,pollakiuria,pollakiuria,1
JARDIANCE,pollakiuria,pollakiuria and nocturia d Male,1
JARDIANCE,pollakiuria,pollakiuria,1
JARDIANCE,pollakiuria,limited to pollakiuria and nocturia,1
JARDIANCE,pollakiuria,pollakiuria,1
JARDIANCE,pollakiuria,to pollakiuria and nocturia,1
JARDIANCE,pollakiuria,pollakiuria,1
JARDIANCE,pollakiuria,pollakiuria and nocturia d Male genital,1
JARDIANCE,balanoposthitis,candida scrotal ab,0
JARDIANCE,balanoposthitis,include the following adverse balanoposthitis,1
JARDIANCE,balanoposthitis,candida scrotal ab,0
JARDIANCE,balanoposthitis,balanoposthitis balanitis genital infections fungal genitourinary,1
JARDIANCE,balanoposthitis,balanoposthitis balanitis genital infections fungal,1
JARDIANCE,balanoposthitis,include the following adverse balanoposthitis balanitis genital infections fungal genitourinary,1
JARDIANCE,balanoposthitis,balanoposthitis balanitis genital infections fungal,1
JARDIANCE,balanoposthitis,balanoposthitis balanitis genital infections fungal genitourinary,1
JARDIANCE,balanoposthitis,infections fungal genitourinary tract infection balanitis,0
JARDIANCE,balanoposthitis,genital infections fungal genitourinary tract infection balanitis,0
JARDIANCE,balanoposthitis,adverse balanoposthitis balanitis genital infections,1
JARDIANCE,balanoposthitis,genital infections fungal genitourinary tract infection balanitis,0
JARDIANCE,balanoposthitis,reactions,0
JARDIANCE,balanitis,balanitis,1
JARDIANCE,balanitis,balanitis,1
JARDIANCE,balanitis,balanitis genital infections fungal genitourinary tract,1
JARDIANCE,balanitis,the following adverse reactions balanitis,1
JARDIANCE,balanitis,balanitis genital infections fungal genitourinary tract,1
JARDIANCE,genital infections fungal,ale genital mycotic infections include,0
JARDIANCE,genital infections fungal,adverse reactions balanoposthitis genital,1
JARDIANCE,genitourinary tract infection,candida scrotal abscess,0
JARDIANCE,genitourinary tract infection,penile,0
JARDIANCE,genitourinary tract infection,infections genitourinary tract infection balanitis,1
JARDIANCE,genitourinary tract infection,penile,0
JARDIANCE,genitourinary tract infection,with the,0
JARDIANCE,genitourinary tract infection,genitourinary tract infection balanitis,1
JARDIANCE,genitourinary tract infection,with the,0
JARDIANCE,genitourinary tract infection,genitourinary tract infection,1
JARDIANCE,genitourinary tract infection,balanitis genital infections genitourinary tract,1
JARDIANCE,balanitis candida,Percentages calculated with the number of male subjects in each,0
JARDIANCE,balanitis candida,genitourinary tract balanitis candida,1
JARDIANCE,balanitis candida,infection,0
JARDIANCE,balanitis candida,balanitis candida scrotal abscess penile infection,1
JARDIANCE,balanitis candida,with,0
JARDIANCE,balanitis candida,genitourinary tract balanitis candida scrotal abscess penile infection Percentages,1
JARDIANCE,balanitis candida,with,0
JARDIANCE,scrotal abscess,scrotal abscess penile infection Percentages,1
JARDIANCE,scrotal abscess,scrotal abscess penile infection Percentages,1
JARDIANCE,scrotal abscess,genitourinary tract infection balanitis candida,0
JARDIANCE,scrotal abscess,tract,0
JARDIANCE,scrotal abscess,genitourinary tract,0
JARDIANCE,scrotal abscess,scrotal,1
JARDIANCE,scrotal abscess,balanitis candida,0
JARDIANCE,scrotal abscess,balanitis scrotal abscess penile infection Percentages,1
JARDIANCE,scrotal abscess,balanitis candida,0
JARDIANCE,scrotal abscess,candida,0
JARDIANCE,penile infection,penile infection Percentages calculated with,1
JARDIANCE,penile infection,scrotal penile infection Percentages calculated,1
JARDIANCE,penile infection,penile infection Percentages calculated with,1
JARDIANCE,penile infection,infections fungal genitourinary tract infection,0
JARDIANCE,penile infection,Percentages calculated,0
JARDIANCE,penile infection,scrotal penile infection Percentages calculated with the,1
JARDIANCE,penile infection,Percentages calculated,0
JARDIANCE,penile infection,penile infection Percentages calculated,1
JARDIANCE,penile infection,balanitis candida scrotal penile,1
JARDIANCE,Urinary tract infection,PlaceboN JARDIANCE mgN JARDIANCE mgN,0
JARDIANCE,Urinary tract infection,JARDIANCE mgN JARDIANCE Urinary tract infection,1
JARDIANCE,Urinary tract infection,tract infection a Female genit,1
JARDIANCE,Urinary tract infection,JARDIANCE Urinary tract,1
JARDIANCE,Urinary tract infection,tract infection,1
JARDIANCE,Urinary tract infection,JARDIANCE mgN JARDIANCE,0
JARDIANCE,Female genital mycotic infections,Female genital mycotic infections b Upper,1
JARDIANCE,Female genital mycotic infections,JARDIANCE mgN JARDIANCE,0
JARDIANCE,Female genital mycotic infections,b,0
JARDIANCE,Female genital mycotic infections,infection a,0
JARDIANCE,Upper respiratory tract infection,mycotic infections Upper respiratory tract infection,1
JARDIANCE,Upper respiratory tract infection,infections b,0
JARDIANCE,Upper respiratory tract infection,Upper respiratory tract infection,1
JARDIANCE,Upper respiratory tract infection,infections Upper respiratory tract,1
JARDIANCE,Upper respiratory tract infection,infections Upper respiratory,1
JARDIANCE,Upper respiratory tract infection,Upper respiratory tract infection Increased urination,1
JARDIANCE,Increased urination,ratory tract,0
JARDIANCE,Increased urination,tract Increased urination,1
JARDIANCE,Increased urination,Increased urination,1
JARDIANCE,Increased urination,infection,0
JARDIANCE,Increased urination,Increased urination c Dyslipid,1
JARDIANCE,polydipsia,in and for placebo JARDIANCE mg and,0
JARDIANCE,polydipsia,and,0
JARDIANCE,polydipsia,JARDIANCE mg,0
JARDIANCE,polydipsia,JARDIANCE mg respectively,0
JARDIANCE,polydipsia,polydipsia was reported in,1
JARDIANCE,polydipsia,polydipsia was reported in and for,1
JARDIANCE,osmotic diuresis,JARDIANCE causes osmotic diuresis which may lead to,1
JARDIANCE,osmotic diuresis,polydipsia was reported in and for,1
JARDIANCE,osmotic diuresis,JARDIANCE,0
JARDIANCE,osmotic diuresis,osmotic diuresis which may lead to intravascular,1
JARDIANCE,osmotic diuresis,Volume Depletion JARDIANCE causes osmotic diuresis which may lead,1
JARDIANCE,osmotic diuresis,osmotic diuresis which may lead to intravascular,1
JARDIANCE,volume depletion,volume depletion In the,1
JARDIANCE,volume depletion,to volume,0
JARDIANCE,volume depletion,of five placebocontrolled clinical trials adverse,0
JARDIANCE,volume depletion,volume depletion eg blood pressure,1
JARDIANCE,volume depletion,reactions related volume depletion,1
JARDIANCE,volume depletion,blood pressure systolic decreased dehydration,0
JARDIANCE,volume depletion,volume depletion eg,1
JARDIANCE,volume depletion,adverse reactions related volume depletion,1
JARDIANCE,volume depletion,pressure ambulatory,0
JARDIANCE,volume depletion,related volume depletion eg blood pressure,1
JARDIANCE,volume depletion,pressure ambulatory,0
JARDIANCE,volume depletion,decreased,0
JARDIANCE,volume depletion,related volume depletion,1
JARDIANCE,blood pressure systolic decreased,related to,0
JARDIANCE,blood pressure systolic decreased,ambulatory blood pressure,1
JARDIANCE,blood pressure systolic decreased,volume depletion eg blood,0
JARDIANCE,blood pressure systolic decreased,depletion eg blood pressure,0
JARDIANCE,blood pressure systolic decreased,eg blood,0
JARDIANCE,blood pressure systolic decreased,depletion eg,0
JARDIANCE,blood pressure systolic decreased,dehydration hypotension,0
JARDIANCE,dehydration,eg,0
JARDIANCE,dehydration,hypotension hypovolemia orthostatic hypotension and syncope,0
JARDIANCE,hypotension,ambulatory decreased blood pressure systolic,0
JARDIANCE,hypotension,decreased hypotension hypovolemia orthostatic hypotension and syncope,1
JARDIANCE,hypotension,ambulatory decreased blood pressure systolic,0
JARDIANCE,hypotension,blood pressure systolic decreased,0
JARDIANCE,hypotension,hypotension hypovolemia orthostatic hypotension and,1
JARDIANCE,hypotension,reported by and of patien,0
JARDIANCE,hypotension,pressure systolic decreased,0
JARDIANCE,hypotension,hypotension hypovolemia orthostatic hypotension,1
JARDIANCE,hypotension,orthostatic hypotension,0
JARDIANCE,hypotension,pressure systolic decreased hypotension hypovolemia orthostatic hypotension and,1
JARDIANCE,hypotension,orthostatic hypotension,0
JARDIANCE,hypotension,pressure systolic decreased hypotension hypovolemia orthostatic hypotension,1
JARDIANCE,hypotension,orthostatic hypotension,0
JARDIANCE,hypovolemia,blood pressure,0
JARDIANCE,hypovolemia,pressure systolic decreased dehydration hypotension,0
JARDIANCE,hypovolemia,hypotension,0
JARDIANCE,hypovolemia,blood pressure systolic,0
JARDIANCE,hypovolemia,decreased,0
JARDIANCE,hypovolemia,decreased dehydration hypovolemia orthostatic hypotension and,1
JARDIANCE,hypovolemia,decreased,0
JARDIANCE,hypovolemia,hypovolemia orthostatic hypotension and,1
JARDIANCE,orthostatic hypotension,orthostatic hypotension and syncope were reported,1
JARDIANCE,orthostatic hypotension,orthostatic hypotension and,1
JARDIANCE,orthostatic hypotension,hypotension orthostatic hypotension,1
JARDIANCE,orthostatic hypotension,and of patients treated with placebo,0
JARDIANCE,orthostatic hypotension,hypotension,0
JARDIANCE,orthostatic hypotension,systolic,0
JARDIANCE,orthostatic hypotension,decreased blood pressure systolic decreased dehydration hypotension,0
JARDIANCE,orthostatic hypotension,and of patients treated with placebo JARDIANCE,0
JARDIANCE,orthostatic hypotension,decreased dehydration,0
JARDIANCE,orthostatic hypotension,orthostatic,1
JARDIANCE,syncope,syncope were reported,1
JARDIANCE,syncope,hypovolemia orthostatic hypotension,0
JARDIANCE,syncope,by and,0
JARDIANCE,hypotension,hypotension in patients at,1
JARDIANCE,hypotension,hypotension in patients at risk for,1
JARDIANCE,hypotension,and JARDIANCE mg respectively JARDIANCE may increase,0
JARDIANCE,hypotension,respectively,0
JARDIANCE,hypotension,contraction,0
JARDIANCE,hypotension,hypotension in,1
JARDIANCE,hypotension,hypotension in patients at risk,1
JARDIANCE,hypotension,hypotension in patients,1
JARDIANCE,hypotension,hypotension in patients,1
JARDIANCE,hypotension,increase the risk,0
JARDIANCE,Increased Urination,Use in Specific,0
JARDIANCE,Increased Urination,Specific Increased Urination,1
JARDIANCE,Increased Urination,Increased Urination In,1
JARDIANCE,increased urination,increased urination eg polyuria pollakiuria and nocturia,1
JARDIANCE,increased urination,eg polyuria pollakiuria and nocturia,0
JARDIANCE,increased urination,increased urination eg polyuria pollakiuria and nocturia,1
JARDIANCE,increased urination,eg polyuria pollakiuria and nocturia,0
JARDIANCE,increased urination,JARDIANCE than,0
JARDIANCE,increased urination,trials adverse reactions increased,1
JARDIANCE,increased urination,increased urination eg,1
JARDIANCE,increased urination,increased urination,1
JARDIANCE,polyuria,polyuria pollakiuria and nocturia occurred,1
JARDIANCE,polyuria,pool of five placebocontrolled clinical trials adverse reactions,0
JARDIANCE,polyuria,on JARDIANCE,0
JARDIANCE,polyuria,on JARDIANCE than,0
JARDIANCE,pollakiuria,pollakiuria,1
JARDIANCE,pollakiuria,urination eg pollakiuria and,1
JARDIANCE,pollakiuria,pollakiuria,1
JARDIANCE,pollakiuria,pollakiuria,1
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,adverse reactions of increased urination,0
JARDIANCE,nocturia,nocturia occurred more frequently on,1
JARDIANCE,nocturia,polyuria pollakiuria and,0
JARDIANCE,nocturia,adverse reactions of increased urination eg polyuria pollakiuria and,0
JARDIANCE,nocturia,nocturia was reported by and of,1
JARDIANCE,nocturia,placebo see Table nocturia,1
JARDIANCE,nocturia,nocturia was reported by and of,1
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,nocturia,1
JARDIANCE,nocturia,and of patients treated,0
JARDIANCE,nocturia,nocturia was reported by and of,1
JARDIANCE,Impairment in Renal Function,Impairment in Renal Function Use,1
JARDIANCE,Impairment in Renal Function,nocturia was reported by and of,1
JARDIANCE,Impairment in Renal Function,in serum creatinine,0
JARDIANCE,Impairment in Renal Function,eGFR,0
JARDIANCE,Impairment in Renal Function,patients treated with placebo JARDIANCE mg,0
JARDIANCE,Impairment in Renal Function,and JARDIANCE mg Impairment,1
JARDIANCE,Impairment in Renal Function,associated with increases in,0
JARDIANCE,Impairment in Renal Function,creatinine and decreases,0
JARDIANCE,Impairment in Renal Function,and,0
JARDIANCE,Impairment in Renal Function,with,0
JARDIANCE,increases in serum creatinine,JARDIANCE,0
JARDIANCE,increases in serum creatinine,Impairment in,0
JARDIANCE,decreases in eGFR,decreases in eGFR see Table Patients with moderate,1
JARDIANCE,decreases in eGFR,renal impairment at baseline had larger mean,0
JARDIANCE,eGFR 30 to less than 60 mL/min/1.73 m 2,study eGFR 30 to less than 60 mL/min/1.73 m  2 Pool,1
JARDIANCE,eGFR 30 to less than 60 mL/min/1.73 m 2,renal impairment at baseline had larger mean,0
JARDIANCE,eGFR 30 to less than 60 mL/min/1.73 m 2,less than 60 mL/min/1.73 m 2 Pool of Week PlaceboControlled,1
JARDIANCE,Hypoglycemia,Hypoglycemia The incidence of hypoglycemia,1
JARDIANCE,Hypoglycemia,Hypoglycemia,1
JARDIANCE,Hypoglycemia,R mLmin,0
JARDIANCE,Hypoglycemia,Hypoglycemia,1
JARDIANCE,Hypoglycemia,R mLmin Hypoglycemia The,1
JARDIANCE,Hypoglycemia,Hypoglycemia,1
JARDIANCE,Hypoglycemia,Hypoglycemia The incidence of hypoglycemia,1
JARDIANCE,Hypoglycemia,Hypoglycemia,1
JARDIANCE,hypoglycemia,hypoglycemia,1
JARDIANCE,hypoglycemia,was administered with,0
JARDIANCE,hypoglycemia,by study is shown in Table,0
JARDIANCE,Hypoglycemic Events,and Precautions Table Incidence of Overalla,0
JARDIANCE,Hypoglycemic Events,and Hypoglycemic Events in PlaceboControlled Clinical Studies,1
JARDIANCE,Hypoglycemic Events,and Precautions Table Incidence of Overalla,0
JARDIANCE,Hypoglycemic Events,hypoglycemic events plasma or capillary,0
JARDIANCE,Hypoglycemic Events,of,0
JARDIANCE,Hypoglycemic Events,Overall,0
JARDIANCE,Hypoglycemic Events,Incidence of Overalla and Hypoglycemic Events,1
JARDIANCE,Hypoglycemic Events,or capillary,0
JARDIANCE,Hypoglycemic Events,and Hypoglycemic Events,1
JARDIANCE,Hypoglycemic Events,of Overalla and Hypoglycemic,1
JARDIANCE,Hypoglycemic Events,Overalla and Severeb,0
JARDIANCE,Hypoglycemic Events,Hypoglycemic Events in PlaceboControlled Clinical Studies,1
JARDIANCE,Hypoglycemic Events,Hypoglycemic Events in PlaceboControlled,1
JARDIANCE,Hypoglycemic Events,Hypoglycemic Events in PlaceboControlled Clinical Studies,1
JARDIANCE,hypoglycemic events,Studies,0
JARDIANCE,hypoglycemic events,Studies a hypoglycemic events,1
JARDIANCE,hypoglycemic events,hypoglycemic events plasma,1
JARDIANCE,hypoglycemic events,and Severeb Hypoglycemic Events in,0
JARDIANCE,hypoglycemic events,hypoglycemic events plasma or capillary glucose of,1
JARDIANCE,hypoglycemic events,Clinical Studies a hypoglycemic events plasma or,1
JARDIANCE,hypoglycemic events,hypoglycemic events plasma or capillary glucose of,1
JARDIANCE,hypoglycemic events,Overalla and Severeb Hypoglycemic Events in PlaceboControlled Clinical,0
JARDIANCE,hypoglycemic events,Studies a hypoglycemic events plasma or capillary,1
JARDIANCE,hypoglycemic events,Overalla and Severeb Hypoglycemic Events in PlaceboControlled Clinical,0
JARDIANCE,hypoglycemic events,hypoglycemic,1
JARDIANCE,hypoglycemic events,hypoglycemic events plasma or capillary glucose of,1
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,Overall hypoglycemic events plasma capillary,1
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,glucose c Insu,0
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,70 mg/dL b Severe hypoglycemic,1
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,requiring assistance regardless,0
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,than or equal to 70 mg/dL b,1
JARDIANCE,capillary glucose of less than or equal to 70 mg/dL,events plasma capillary glucose of less than or equal to 70 mg/dL,1
JARDIANCE,hypoglycemic events,Severe,0
JARDIANCE,hypoglycemic events,to mgdL b hypoglycemic,1
JARDIANCE,hypoglycemic events,equal to mgdL b hypoglycemic,1
JARDIANCE,hypoglycemic events,hypoglycemic events requiring,1
JARDIANCE,hypoglycemic events,equal to mgdL b hypoglycemic,1
JARDIANCE,genital mycotic infections,infection vaginal infection genital infection fungal vulvovaginal candidi,0
JARDIANCE,genital mycotic infections,genital infection fungal,0
JARDIANCE,genital mycotic infections,clinical trials the incidence genital,1
JARDIANCE,genital mycotic infections,genital mycotic infections,1
JARDIANCE,genital mycotic infections,incidence,0
JARDIANCE,genital mycotic infections,vaginal mycotic infection vaginal infection genital infection fungal vulvovaginal,0
JARDIANCE,genital mycotic infections,mycotic infections eg vaginal mycotic,1
JARDIANCE,vaginal mycotic infection,vaginal mycotic infection,1
JARDIANCE,vaginal mycotic infection,mycotic infections vaginal mycotic infection vaginal infection genital,1
JARDIANCE,vaginal mycotic infection,vaginal mycotic infection,1
JARDIANCE,vaginal mycotic infection,infections vaginal mycotic infection,1
JARDIANCE,vaginal mycotic infection,mycotic infection vaginal infection genital infection fungal,1
JARDIANCE,vaginal infection,genital infection fungal vulvovaginal candidiasis and vulvitis,0
JARDIANCE,vaginal infection,mycotic infection,0
JARDIANCE,vaginal infection,was,0
JARDIANCE,vaginal infection,was,0
JARDIANCE,vaginal infection,vaginal mycotic vaginal,1
JARDIANCE,vaginal infection,infections eg vaginal mycotic vaginal,1
JARDIANCE,genital infection fungal,vaginal mycotic infection vaginal genital infection,1
JARDIANCE,genital infection fungal,treated with JARDIANCE,0
JARDIANCE,genital infection fungal,mycotic,0
JARDIANCE,genital infection fungal,vaginal mycotic infection vaginal,0
JARDIANCE,genital infection fungal,vaginal mycotic infection vaginal genital infection fungal,1
JARDIANCE,genital infection fungal,candidiasis and vulvitis was increased in patients treated,0
JARDIANCE,genital infection fungal,vaginal mycotic infection,0
JARDIANCE,genital infection fungal,genital infection fungal vulvovaginal candidiasis and vulvitis,1
JARDIANCE,vulvovaginal candidiasis,infection vulvovaginal candidiasis and,1
JARDIANCE,vulvovaginal candidiasis,genital infection fungal vulvovaginal candidiasis and vulvitis,1
JARDIANCE,vulvovaginal candidiasis,eg vaginal mycotic infection,0
JARDIANCE,vulvovaginal candidiasis,and vulvitis was increased in patients treated,0
JARDIANCE,vulvovaginal candidiasis,mycotic infections eg vaginal mycotic infection vaginal infection genital infection,0
JARDIANCE,vulvitis,vulvitis was,1
JARDIANCE,vulvitis,fungal vulvovaginal candidiasis vulvitis was,1
JARDIANCE,vulvitis,vulvitis was,1
JARDIANCE,vulvitis,vulvitis was increased in patients treated,1
JARDIANCE,vulvitis,vulvitis was,1
JARDIANCE,genital infection,genital infection,1
JARDIANCE,genital infection,Discontinuation from study due genital infection occurred in of placebotreated patients,1
JARDIANCE,genital infection,genital infection,1
JARDIANCE,genital infection,occurred in of placebotreated patients and of patients treated with,0
JARDIANCE,genital infection,genital infection,1
JARDIANCE,genital infection,occurred in of placebotreated patients and of patients treated with,0
JARDIANCE,genital infection,JARDIANCE mg respectively Discontinuation from study due to,0
JARDIANCE,genital infection,Discontinuation from study due genital infection,1
JARDIANCE,genital infection,Discontinuation from study due genital infection occurred in of placebotreated patients,1
JARDIANCE,genital infection,Discontinuation from study due genital infection,1
JARDIANCE,genital infection,from study due genital infection,1
JARDIANCE,genital infection,genital infection occurred in of placebotreated patients,1
JARDIANCE,Phimosis,less,0
JARDIANCE,Phimosis,Phimosis occurred more,1
JARDIANCE,Phimosis,male patients see Phimosis occurred more,1
JARDIANCE,Phimosis,Phimosis occurred more,1
JARDIANCE,Phimosis,Phimosis occurred,1
JARDIANCE,Phimosis,see,0
JARDIANCE,Phimosis,Phimosis occurred more,1
JARDIANCE,Phimosis,occurred more frequently,0
JARDIANCE,Phimosis,Phimosis occurred,1
JARDIANCE,Urinary Tract Infections,Urinary Tract,1
JARDIANCE,Urinary Tract Infections,less than,0
JARDIANCE,Urinary Tract Infections,JARDIANCE mg than Urinary,1
JARDIANCE,Urinary Tract Infections,Urinary Tract Infections In,1
JARDIANCE,Urinary Tract Infections,mg than Urinary Tract Infections,1
JARDIANCE,Urinary Tract Infections,clinical trials the,0
JARDIANCE,Urinary Tract Infections,Urinary Tract Infections In the pool of five,1
JARDIANCE,Urinary Tract Infections,JARDIANCE mg than Urinary Tract Infections In,1
JARDIANCE,Urinary Tract Infections,Urinary Tract Infections In the pool of five,1
JARDIANCE,Urinary Tract Infections,Tract Infections In the pool of,1
JARDIANCE,urinary tract infections,Urinary Tract Infections In the pool,0
JARDIANCE,urinary tract infections,trials the incidence urinary,1
JARDIANCE,urinary tract infections,clinical trials the incidence urinary tract infections eg urinary tract,1
JARDIANCE,urinary tract infections,trials the incidence urinary,1
JARDIANCE,urinary tract infections,urinary,1
JARDIANCE,urinary tract infections,the incidence urinary tract infections eg urinary tract,1
JARDIANCE,urinary tract infections,urinary,1
JARDIANCE,urinary tract infections,bacteriuria and cystitis was increased in patients,0
JARDIANCE,urinary tract infections,clinical trials the incidence urinary,1
JARDIANCE,urinary tract infections,increased in,0
JARDIANCE,urinary tract infection,bacteriuria and cystitis was increased in patients treated,0
JARDIANCE,urinary tract infection,patients,0
JARDIANCE,urinary tract infection,e pool of five placebocontrolled,0
JARDIANCE,urinary tract infection,infections urinary tract infection asymptomatic bacteriuria and cystitis was,1
JARDIANCE,urinary tract infection,e pool of five placebocontrolled,0
JARDIANCE,urinary tract infection,tract infections urinary tract infection asymptomatic bacteriuria and cystitis,1
JARDIANCE,urinary tract infection,e pool of five placebocontrolled,0
JARDIANCE,asymptomatic bacteriuria,asymptomatic bacteriuria,1
JARDIANCE,asymptomatic bacteriuria,asymptomatic bacteriuria and cystitis was increased,1
JARDIANCE,asymptomatic bacteriuria,treated with JARDIANCE compared to placebo see Table,0
JARDIANCE,asymptomatic bacteriuria,eg urinary tract asymptomatic,1
JARDIANCE,cystitis,patients treated with JARDIANCE compared to placebo see Table,0
JARDIANCE,cystitis,compared to placebo see,0
JARDIANCE,cystitis,to placebo see Table Patients,0
JARDIANCE,cystitis,to placebo see Table,0
JARDIANCE,cystitis,cystitis was increased in patients treated,1
JARDIANCE,urinary tract infection,experience urinary tract,1
JARDIANCE,urinary tract infection,urinary tract infection The,1
JARDIANCE,urinary tract infection,experience urinary tract,1
JARDIANCE,urinary tract infection,urinary tract infection The rate of treatment,1
JARDIANCE,urinary tract infection,experience urinary tract,1
JARDIANCE,urinary tract infection,likely to experience urinary tract infection,1
JARDIANCE,urinary tract infections,treatment discontinuation due to,0
JARDIANCE,urinary tract infections,urinary,0
JARDIANCE,urinary tract infections,urinary tract infections was and for placebo,1
JARDIANCE,urinary tract infections,infection,0
JARDIANCE,urinary tract infections,treatment discontinuation due urinary tract infections was and for placebo,1
JARDIANCE,urinary tract infections,infection,0
JARDIANCE,Urinary tract infections,mg Urinary tract infections occurred more frequently in female,1
JARDIANCE,Urinary tract infections,infection,0
JARDIANCE,Urinary tract infections,tract infections,1
JARDIANCE,Urinary tract infections,and for placebo JARDIANCE mg and JARDIANCE,0
JARDIANCE,Urinary tract infections,tract infections occurred more frequently in female,1
JARDIANCE,urinary tract infections,patients The incidence urinary tract infections,1
JARDIANCE,urinary tract infections,placebo,0
JARDIANCE,urinary tract infections,Urinary tract infections occurred more frequently in female patients,0
JARDIANCE,urinary tract infections,patients The incidence urinary,1
JARDIANCE,urinary tract infections,tract infections in,1
JARDIANCE,urinary tract infections,patients The incidence urinary,1
JARDIANCE,urinary tract infections,urinary tract infections,1
JARDIANCE,urinary tract infections,JARDIANCE mg,0
JARDIANCE,urinary tract infections,of,0
JARDIANCE,Increase in Low-Density Lipoprotein Cholesterol,Tests,0
JARDIANCE,Increase in Low-Density Lipoprotein Cholesterol,Specific Populations Laboratory Increase in,1
JARDIANCE,Increase in Low-Density Lipoprotein Cholesterol,Specific Populations Laboratory Increase in Low-Density Lipoprotein Cholesterol,1
JARDIANCE,Increase in Low-Density Lipoprotein Cholesterol,Specific Populations Laboratory Increase in,1
JARDIANCE,increases in low-density lipoprotein cholesterol,LowDensity Lipoprotein Cholesterol LDLC increases in low-density lipoprotein cholesterol LDLC were observed in,1
JARDIANCE,increases in low-density lipoprotein cholesterol,Specific Populations Laboratory Increase in,1
JARDIANCE,increases in low-density lipoprotein cholesterol,increases in low-density lipoprotein cholesterol LDLC were observed in patients,1
JARDIANCE,increases in low-density lipoprotein cholesterol,LowDensity,0
JARDIANCE,increases in low-density lipoprotein cholesterol,in LowDensity Lipoprotein Cholesterol LDLC Doserelated,0
JARDIANCE,Increase in Hematocrit,to mgdL across treatment Increase in,1
JARDIANCE,hematocrit decreased,hematocrit decreased by,1
JARDIANCE,hematocrit decreased,groups Increase in Hematocrit In a pool of four placebocontrolled studies,0
JARDIANCE,hematocrit decreased,hematocrit decreased by,1
JARDIANCE,hematocrit decreased,placebocontrolled studies hematocrit decreased by in placebo and,1
JARDIANCE,hematocrit decreased,hematocrit decreased by,1
JARDIANCE,hematocrit decreased,placebocontrolled studies,0
JARDIANCE,hematocrit decreased,studies hematocrit decreased,1
JARDIANCE,hematocrit decreased,placebocontrolled studies,0
JARDIANCE,hematocrit decreased,of four placebocontrolled studies hematocrit decreased,1
JARDIANCE,hematocrit decreased,of four placebocontrolled studies hematocrit decreased,1
JARDIANCE,Hypotension,important verse react ions,1
JARDIANCE,Hypotension,of four placebocontrolled studies hematocrit decreased,1
JARDIANCE,Hypotension,The following,0
JARDIANCE,Hypotension,following important verse react,1
JARDIANCE,Hypotension,The following,0
JARDIANCE,Hypotension,and elsewhere in the labeling Hypotension see Warnings and,0
JARDIANCE,Hypotension,the labeling Hypotension see Warnings,0
JARDIANCE,Hypotension,labeling Hypotension see Warnings and,0
JARDIANCE,Hypotension,in the labeling Hypotension see,0
JARDIANCE,Hypotension,important verse react,1
JARDIANCE,Hypotension,below and,0
JARDIANCE,Hypotension,The following important verse react ions are described below,1
JARDIANCE,Hypotension,below and,0
JARDIANCE,Impairment in renal function,Precautions Genital Mycotic Infections see Warnings and,0
JARDIANCE,Impairment in renal function,Precautions Hypoglycemia with Concomitant Use with Insulin and,0
JARDIANCE,Impairment in renal function,Genital Mycotic Infections see,0
JARDIANCE,Impairment in renal function,Mycotic Infections see Warnings,0
JARDIANCE,Impairment in renal function,see Warnings and Precautions,0
JARDIANCE,Impairment in renal function,Precautions,0
JARDIANCE,Impairment in renal function,[see Wa rnings and Precautions Genital Mycotic,1
JARDIANCE,Impairment in renal function,Precautions Genital Mycotic Infections see Warnings and,0
JARDIANCE,Impairment in renal function,nsulin,1
JARDIANCE,Genital mycotic infections,ommon adverse reactions as sociated with JARDIANCE or greater,1
JARDIANCE,Genital mycotic infections,most ommon adverse,1
JARDIANCE,Urinary tract infections,ere urinary tract infect,1
JARDIANCE,Urinary tract infections,or greater incidence ere urinary,1
JARDIANCE,Urinary tract infections,incidence ere urinary tract infect ions and female,1
JARDIANCE,Urinary tract infections,or greater incidence ere urinary,1
JARDIANCE,Urinary tract infections,female genital mycotic infections EXCERPT To report SUSPECTED,0
JARDIANCE,Urinary tract infections,EXCERPT To report,0
JARDIANCE,Urinary tract infections,ere urinary tract infect ions,1
JARDIANCE,Urinary tract infections,EXCERPT To report,0
JARDIANCE,Urinary tract infections,ere,1
JARDIANCE,Urinary tract infections,greater incidence ere urinary tract infect ions and female genital,1
JARDIANCE,Urinary tract infections,ere,1
JARDIANCE,Urinary tract infections,EXCERPT To report SUSPECTED,0
JARDIANCE,Urinary tract infections,incidence,0
JARDIANCE,Increased LDL-C,female genital,0
JARDIANCE,Increased LDL-C,) EXCERP T To report SUSPECTED,1
JARDIANCE,intravascular volume contraction,Trials Experience Because clinical ials,1
JARDIANCE,Symptomatic hypotension,Because,0
JARDIANCE,Symptomatic hypotension,"rying conditions, adver se reaction rates observed in",1
JARDIANCE,Symptomatic hypotension,"under widely rying conditions, adver",1
JARDIANCE,Symptomatic hypotension,"conditions, adver se reaction",1
JARDIANCE,Symptomatic hypotension,the clinical trials,0
JARDIANCE,Symptomatic hypotension,in the clinical trials of,0
JARDIANCE,Symptomatic hypotension,"rying conditions,",1
JARDIANCE,Symptomatic hypotension,"rying conditions, adver se reaction rates observed",1
JARDIANCE,decreases eGFR,received,0
JARDIANCE,decreases eGFR,JARDIANCE mg,0
JARDIANCE,impaired renal function,placebo (N=995) JARDIANCE mg N or,1
JARDIANCE,impaired renal function,of approximately weeks Patients eceived placebo (N=995),1
JARDIANCE,impaired renal function,eceived placebo (N=995) JARDIANCE mg N or JARDIANCE,1
JARDIANCE,impaired renal function,of the population,0
JARDIANCE,impaired renal function,of approximately weeks,0
JARDIANCE,hypoglycemia,"nephropathy pathy (8%),",1
JARDIANCE,hypoglycemia,"pathy (8%), or neuropathy Baseline renal function",1
JARDIANCE,hypoglycemia,"included diabetic nephropathy pathy (8%), ",1
JARDIANCE,hypoglycemia,"pathy (8%), or neuropathy Baseline renal function",1
JARDIANCE,hypoglycemia,in of patients and,0
JARDIANCE,hypoglycemia,"pathy (8%), or neuropathy Baseline renal function",1
JARDIANCE,hypoglycemia,nephropathy retino,0
JARDIANCE,hypoglycemia,diabetes at baseline included,0
JARDIANCE,hypoglycemia,pathy,1
JARDIANCE,hypoglycemia,neuropathy Baseline renal function was normal or mildly impaired,0
JARDIANCE,genital mycotic infections,occurred in greate r than or,1
JARDIANCE,genital mycotic infections,JARDIANCE mg Table,0
JARDIANCE,genital mycotic infections,r than or equal to of patients treated with JARDIANCE mg or JARDIANCE,0
JARDIANCE,genital mycotic infections,ebo and,1
JARDIANCE,mycotic genital infections,or JARDIANCE mg Table Adverse Reactions Reported in of,0
JARDIANCE,mycotic genital infections,with JARDIANCE an d Greater than Placebo in,1
JARDIANCE,mycotic genital infections,Reported in of Treated,1
JARDIANCE,mycotic genital infections,in of  Treated with JARDIANCE an d Greater than,1
JARDIANCE,mycotic genital infections,Reported in of Treated,1
JARDIANCE,mycotic genital infections,in of  Treated with JARDIANCE an d Greater than,1
JARDIANCE,mycotic genital infections,Reported in of Treated,1
JARDIANCE,mycotic genital infections,Treated,1
JARDIANCE,mycotic genital infections,Reported in of Treated with,1
JARDIANCE,mycotic genital infections,Reactions Reported in of  Treated with JARDIANCE an d Greater than Placebo,1
JARDIANCE,mycotic genital infections,Reported in of Treated with,1
JARDIANCE,mycotic genital infections,than Placebo in Pooled PlaceboControlled Clinical Studies of JARDIANCE Monotherapy,0
JARDIANCE,mycotic genital infections,with JARDIANCE an d Greater,1
JARDIANCE,urinary tract infections,"Combination herapy 
   a  Predefined adverse event grouping including",1
JARDIANCE,urinary tract infections,with JARDIANCE an d Greater,1
JARDIANCE,urinary tract infections,Monotherapy or Combination herapy a Predefined,1
JARDIANCE,urinary tract infections,limited to urinary tract,0
JARDIANCE,urinary tract infections,Monotherapy or Combination herapy a Predefined,1
JARDIANCE,urinary tract infections,tract,0
JARDIANCE,urinary tract infections,JARDIANCE Monotherapy or Combination herapy a Predefined,1
JARDIANCE,urinary tract infections,herapy a Predefined adverse,1
JARDIANCE,urinary tract infections,of JARDIANCE,0
JARDIANCE,urinary tract infections,Placebo in Pooled,0
JARDIANCE,Increases in LDL-C,genital cotic infections i nclude the following adverse,1
JARDIANCE,Increases in LDL-C,Placebo in Pooled,0
JARDIANCE,Increases in LDL-C,Female genital cotic infections i nclude the following adverse,1
JARDIANCE,Increases in LDL-C,Placebo in Pooled,0
JARDIANCE,Increases in LDL-C,cystitis b,0
JARDIANCE,Increases in LDL-C,cotic,1
JARDIANCE,Increases in LDL-C,cystitis b Female genital cotic,1
ULORIC,liver function abnormalities,least greater than placebo liver function abnormalities nausea arthralgia and rash To,1
ULORIC,liver function abnormalities,cystitis b Female genital cotic,1
ULORIC,liver function abnormalities,greater than placebo liver function abnormalities nausea arthralgia and,1
ULORIC,liver function abnormalities,cystitis b Female genital cotic,1
ULORIC,nausea,nausea,1
ULORIC,nausea,nausea arthralgia and rash To report,1
ULORIC,nausea,nausea,1
ULORIC,nausea,nausea arthralgia and rash To,1
ULORIC,arthralgia,abnormalities nausea,0
ULORIC,arthralgia,arthralgia and,1
ULORIC,arthralgia,arthralgia and rash To,1
ULORIC,arthralgia,arthralgia and rash To,1
ULORIC,arthralgia,at least greater,0
ULORIC,arthralgia,arthralgia,1
ULORIC,arthralgia,rash To report SUSPECTED ADVERSE,0
ULORIC,arthralgia,function abnormalities arthralgia and rash To,1
ULORIC,arthralgia,rash To report SUSPECTED ADVERSE,0
ULORIC,arthralgia,greater than placebo are,0
ULORIC,rash,To report SUSPECTED ADVERSE REACTIONS contact Takeda Pharmaceuticals,0
ULORIC,rash,Takeda,0
ULORIC,rash,SUSPECTED ADVERSE REACTIONS,0
ULORIC,liver function abnormalities,liver function abnormalities in of,1
ULORIC,liver function abnormalities,was,0
ULORIC,liver function abnormalities,to discontinuation from therapy liver function abnormalities,1
ULORIC,liver function abnormalities,was,0
ULORIC,liver function abnormalities,liver,1
ULORIC,liver function abnormalities,discontinuation from therapy liver function abnormalities in of ULORIC mg,1
ULORIC,liver function abnormalities,liver,1
ULORIC,liver function abnormalities,from therapy liver function abnormalities,1
ULORIC,liver function abnormalities,liver,1
ULORIC,liver function abnormalities,reaction,0
ULORIC,liver function abnormalities,in of ULORIC mg of ULORIC mg and in of allopurinoltreated subjects In,0
ULORIC,liver function abnormalities,function abnormalities in of ULORIC,1
ULORIC,dizziness,presented in dizziness was reported in,1
ULORIC,dizziness,function abnormalities in of ULORIC,1
ULORIC,dizziness,rate more than,0
ULORIC,dizziness,dizziness,1
ULORIC,dizziness,Table,0
ULORIC,dizziness,reactions presented in dizziness was reported in more,1
ULORIC,dizziness,Table,0
ULORIC,dizziness,of allopurinoltreated subjects In addition,0
ULORIC,dizziness,dizziness was reported in more than,1
ULORIC,dizziness,dizziness was reported,1
ULORIC,dizziness,dizziness was reported,1
ULORIC,dizziness,dizziness was reported,1
ULORIC,anemia,anemia idiopathic,1
ULORIC,anemia,thrombocytopenic purpura leukocytosisleukopenia neutropenia pancytopenia splenomeg,0
ULORIC,anemia,and Lymphatic System anemia idiopathic thrombocytopenic,1
ULORIC,anemia,thrombocytopenic purpura leukocytosisleukopenia neutropenia pancytopenia splenomeg,0
ULORIC,anemia,from Warnings and Precautions Blood,0
ULORIC,idiopathic thrombocytopenic purpura,System Disorders idiopathic thrombocytopenic,1
ULORIC,idiopathic thrombocytopenic purpura,neutropenia pancytopenia,0
ULORIC,idiopathic thrombocytopenic purpura,idiopathic thrombocytopenic purpura,1
ULORIC,leukocytosis,Cardiac,0
ULORIC,leukocytosis,splenomegaly thrombocytopenia,0
ULORIC,leukocytosis,and Lymphatic System Disorders anemia,0
ULORIC,leukocytosis,leukocytosis leukopenia,1
ULORIC,leukocytosis,leukocytosis leukopenia neutropenia pancytopenia splenomegaly,1
ULORIC,leukocytosis,leukocytosis leukopenia neutropenia pancytopenia,1
ULORIC,leukocytosis,Cardiac Disorders,0
ULORIC,leukocytosis,leukocytosis leukopenia neutropenia pancytopenia splenomegaly,1
ULORIC,leukopenia,idiopathic thrombocytopenic purpura leukopenia,1
ULORIC,leukopenia,leukocytosis leukopenia neutropenia pancytopenia splenomegaly,1
ULORIC,leukopenia,leukopenia neutropenia pancytopenia splenomegaly,1
ULORIC,leukopenia,and Lymphatic System Disorders anemia idiopathic thrombocytopenic,0
ULORIC,leukopenia,anemia,0
ULORIC,leukopenia,Blood and,0
ULORIC,leukopenia,thrombocytopenia Cardiac Disorders angina,0
ULORIC,leukopenia,leukopenia,1
ULORIC,leukopenia,anemia,0
ULORIC,leukopenia,leukopenia neutropenia,1
ULORIC,leukopenia,idiopathic thrombocytopenic purpura,0
ULORIC,neutropenia,neutropenia pancytopenia,1
ULORIC,neutropenia,System Disorders anemia,0
ULORIC,neutropenia,neutropenia pancytopenia splenomegaly,1
ULORIC,pancytopenia,tem Disorders anemia idiopathic thrombocytopenic,0
ULORIC,pancytopenia,Disorders angina,0
ULORIC,pancytopenia,pancytopenia splenomegaly thrombocytopenia,1
ULORIC,pancytopenia,Disorders angina,0
ULORIC,pancytopenia,angina pectoris atrial fibrillationfl,0
ULORIC,splenomegaly,atrial fibrillationflutter cardiac,0
ULORIC,splenomegaly,angina pectoris atrial,0
ULORIC,splenomegaly,purpura leukocytosisleukopenia neutropenia splenomegaly thrombocytopenia,1
ULORIC,splenomegaly,angina pectoris atrial,0
ULORIC,splenomegaly,splenomegaly thrombocytopenia Cardiac Disorders angina,1
ULORIC,splenomegaly,thrombocytopenia Cardiac Disorders angina pectoris,0
ULORIC,splenomegaly,splenomegaly thrombocytopenia Cardiac Disorders angina pectoris,1
ULORIC,thrombocytopenia,neutropenia pancytopenia thrombocytopenia Cardiac,1
ULORIC,thrombocytopenia,splenomegaly thrombocytopenia Cardiac Disorders angina pectoris,1
ULORIC,angina pectoris,fibrillationflutter cardiac murmur ECG,0
ULORIC,angina pectoris,pancytopenia splenomegaly thrombocytopenia Cardiac angina pectoris,1
ULORIC,angina pectoris,ECG abnormal palpitations,0
ULORIC,angina pectoris,Cardiac angina pectoris,1
ULORIC,angina pectoris,angina pectoris atrial fibrillationflutter cardiac murmur ECG,1
ULORIC,atrial fibrillation,tachycardia,0
ULORIC,atrial fibrillation,atrial fibrillation,1
ULORIC,atrial fibrillation,tachycardia Ear,0
ULORIC,atrial fibrillation,Cardiac Disorders angina atrial fibrillation,1
ULORIC,atrial fibrillation,angina atrial fibrillation,1
ULORIC,atrial fibrillation,splenomegaly thrombocytopenia Cardiac Disorders angina,0
ULORIC,atrial fibrillation,atrial fibrillation flutter,1
ULORIC,atrial fibrillation,splenomegaly thrombocytopenia Cardiac Disorders angina,0
ULORIC,cardiac murmur,atrial,0
ULORIC,cardiac murmur,cardiac murmur ECG abnormal palpitations sinus bradycardia,1
ULORIC,cardiac murmur,atrial,0
ULORIC,cardiac murmur,palpitations sinus bradycardia tachycardia Ear and Labyrinth Disorders,0
ULORIC,cardiac murmur,pectoris atrial cardiac murmur ECG abnormal palpitations,1
ULORIC,cardiac murmur,palpitations sinus bradycardia tachycardia Ear and Labyrinth Disorders,0
ULORIC,cardiac murmur,cardiac murmur ECG abnormal palpitations sinus,1
ULORIC,cardiac murmur,cardiac murmur ECG abnormal palpitations sinus bradycardia,1
ULORIC,cardiac murmur,Ear and Labyrinth Disorders d,0
ULORIC,ECG abnormal,pectoris atrial fibrillationflutter cardiac ECG,1
ULORIC,ECG abnormal,ECG abnormal palpitations sinus bradycardia tachycardia,1
ULORIC,ECG abnormal,sinus bradycardia tachycardia Ear and Labyrinth Disorders deafness,0
ULORIC,ECG abnormal,Cardiac,0
ULORIC,ECG abnormal,ECG abnormal palpitations,1
ULORIC,ECG abnormal,ECG abnormal,1
ULORIC,ECG abnormal,angina pectoris atrial,0
ULORIC,ECG abnormal,cytopenia,0
ULORIC,ECG abnormal,Disorders deafness,0
ULORIC,palpitations,palpitations sinus bradycardia tachycardia Ear,1
ULORIC,sinus bradycardia,Labyrinth Disorders deafness,0
ULORIC,sinus bradycardia,angina pectoris atrial fibrillationflutter cardiac murmur,0
ULORIC,sinus bradycardia,ECG abnormal sinus bradycardia,1
ULORIC,sinus bradycardia,murmur ECG,0
ULORIC,sinus bradycardia,cardiac murmur ECG abnormal sinus,1
ULORIC,sinus bradycardia,Disorders deafness tinnitus,0
ULORIC,sinus bradycardia,murmur ECG abnormal sinus bradycardia tachycardia Ear,1
ULORIC,sinus bradycardia,Disorders deafness tinnitus,0
ULORIC,sinus bradycardia,abnormal sinus bradycardia tachycardia Ear,1
ULORIC,sinus bradycardia,Disorders deafness tinnitus,0
ULORIC,tachycardia,ECG abnormal,0
ULORIC,tachycardia,deafness tinnitus vertigo Eye Disorders,0
ULORIC,tachycardia,tinnitus vertigo Eye Disorders vision bl,0
ULORIC,tachycardia,abnormal palpitations sinus tachycardia Ear and Labyrinth Disorders deafness,1
ULORIC,tachycardia,tinnitus vertigo Eye Disorders vision bl,0
ULORIC,tachycardia,sinus,0
ULORIC,tachycardia,ctoris atrial,0
ULORIC,deafness,deafness,1
ULORIC,deafness,deafness tinnitus vertigo Eye Disorders vision,1
ULORIC,deafness,Gastrointestinal,0
ULORIC,deafness,and,0
ULORIC,tinnitus,blurred,0
ULORIC,tinnitus,Disorders tinnitus vertigo Eye Disorders vision,1
ULORIC,tinnitus,blurred,0
ULORIC,tinnitus,tinnitus vertigo Eye Disorders,1
ULORIC,tinnitus,tinnitus vertigo,1
ULORIC,vertigo,deafness vertigo Eye,1
ULORIC,vertigo,tinnitus vertigo,1
ULORIC,vertigo,Disorders deafness vertigo Eye,1
ULORIC,vertigo,tinnitus vertigo,1
ULORIC,vision blurred,vertigo Eye,0
ULORIC,vision blurred,Eye vision,1
ULORIC,vision blurred,Labyrinth Disorders deafness,0
ULORIC,vision blurred,vision blurred Gastrointestinal Disorders,1
ULORIC,vision blurred,pain constipation dry,0
ULORIC,vision blurred,constipation,0
ULORIC,vision blurred,vertigo Eye,0
ULORIC,vision blurred,vision blurred Gastrointestinal Disorders abdominal,1
ULORIC,vision blurred,distention abdominal pain constipation dry mouth,0
ULORIC,vision blurred,tinnitus vertigo Eye vision,1
ULORIC,abdominal distention,abdominal pain constipation dry mouth dyspepsia flatulence frequent stools,0
ULORIC,abdominal distention,abdominal,1
ULORIC,abdominal distention,Disorders vision blurred Gastrointestinal abdominal,1
ULORIC,abdominal distention,abdominal distention abdominal pain constipation dry,1
ULORIC,abdominal distention,constipation dry,0
ULORIC,abdominal distention,abdominal distention abdominal pain constipation dry,1
ULORIC,abdominal distention,Disorders vision,0
ULORIC,constipation,flatulence,0
ULORIC,constipation,constipation dry,1
ULORIC,constipation,abdominal distention abdominal constipation dry,1
ULORIC,constipation,constipation dry,1
ULORIC,constipation,dry mouth dyspepsia flatulence frequent,0
ULORIC,dry mouth,Disorders abdominal distention abdominal pain constipation,0
ULORIC,dyspepsia,frequent stools gastritis,0
ULORIC,dyspepsia,abdominal pain constipation dry dyspepsia,1
ULORIC,dyspepsia,frequent stools gastritis,0
ULORIC,flatulence,dry mouth flatulence frequent stools gastritis gastroesophageal,1
ULORIC,flatulence,frequent stools gastritis,0
ULORIC,flatulence,constipation dry mouth flatulence frequent stools,1
ULORIC,flatulence,frequent stools gastritis,0
ULORIC,flatulence,flatulence frequent stools gastritis gastroesophageal reflux,1
ULORIC,flatulence,flatulence,1
ULORIC,flatulence,constipation dry mouth flatulence,1
ULORIC,flatulence,flatulence,1
ULORIC,flatulence,flatulence,1
ULORIC,flatulence,rointestinal Disorders abdominal distention abdominal pain,0
ULORIC,flatulence,abdominal,0
ULORIC,flatulence,dry mouth flatulence frequent stools,1
ULORIC,flatulence,abdominal,0
ULORIC,flatulence,Disorders,0
ULORIC,frequent stools,gingival pain haematemes,0
ULORIC,frequent stools,frequent stools,1
ULORIC,gastritis,stools,0
ULORIC,gastritis,mouth dyspepsia flatulence frequent gastritis gastroesophageal reflux,1
ULORIC,gastritis,stools,0
ULORIC,gastritis,dyspepsia flatulence frequent gastritis gastroesophageal reflux disease,1
ULORIC,gastritis,stools,0
ULORIC,gastritis,gastrointestinal discomfort gingival pain,0
ULORIC,gastritis,constipation dry mouth dyspepsia flatulence,0
ULORIC,gastritis,frequent gastritis gastroesophageal reflux disease gastrointestinal,1
ULORIC,gastritis,constipation dry mouth dyspepsia flatulence,0
ULORIC,gastritis,gastroesophageal reflux disease gastrointestinal,0
ULORIC,gastritis,gastritis gastroesophageal,1
ULORIC,gastritis,pain haematemesis,0
ULORIC,gastritis,gastritis gastroesophageal reflux disease gastrointestinal discomfort,1
ULORIC,gastroesophageal reflux disease,reflux disease gastrointestinal discomfort,1
ULORIC,gastroesophageal reflux disease,gastroesophageal reflux disease gastrointestinal discomfort gingival pain,1
ULORIC,gastroesophageal reflux disease,mouth dyspepsia flatulence frequent,0
ULORIC,gastroesophageal reflux disease,reflux disease gastrointestinal discomfort,1
ULORIC,gastrointestinal discomfort,gastritis gastroesophageal reflux gastrointestinal,1
ULORIC,gastrointestinal discomfort,disease,0
ULORIC,gingival pain,gingival pain,1
ULORIC,gingival pain,gastroesophageal reflux disease gastrointestinal gingival pain,1
ULORIC,gingival pain,discomfort,0
ULORIC,gingival pain,hematochezia mouth ulceration pancreatitis,0
ULORIC,haematemesis,ent stools gastritis gastroesophageal reflux disease,0
ULORIC,haematemesis,mouth ulceration,0
ULORIC,haematemesis,hematochezia mouth ulceration pancreatitis peptic,0
ULORIC,haematemesis,pain,0
ULORIC,haematemesis,haematemesis hyperchlorhydria hematochezia,1
ULORIC,haematemesis,haematemesis hyperchlorhydria hematochezia mouth ulceration,1
ULORIC,haematemesis,discomfort gingival,0
ULORIC,hyperchlorhydria,ulceration pancreatitis peptic ulcer vomiting,0
ULORIC,mouth ulceration,mouth ulceration,1
ULORIC,mouth ulceration,hyperchlorhydria hematochezia,0
ULORIC,mouth ulceration,Administration Site,0
ULORIC,mouth ulceration,hyperchlorhydria hematochezia,0
ULORIC,mouth ulceration,mouth ulceration,1
ULORIC,mouth ulceration,mouth ulceration,1
ULORIC,mouth ulceration,pancreatitis peptic ulcer vomiting General Disorders,0
ULORIC,pancreatitis,pancreatitis peptic ulcer vomiting General Disorders,1
ULORIC,pancreatitis,pancreatitis peptic ulcer vomiting General Disorders,0
ULORIC,pancreatitis,and Administration,0
ULORIC,pancreatitis,hematochezia mouth,0
ULORIC,peptic ulcer,peptic ulcer,1
ULORIC,peptic ulcer,hematochezia mouth,0
ULORIC,peptic ulcer,ulceration peptic ulcer vomiting General Disorders and Administration,1
ULORIC,peptic ulcer,hematochezia mouth,0
ULORIC,peptic ulcer,hyperchlorhydria hematochezia mouth ulceration peptic ulcer vomiting General Disorders and,1
ULORIC,peptic ulcer,hematochezia mouth,0
ULORIC,peptic ulcer,peptic ulcer,1
ULORIC,vomiting,pancreatitis peptic vomiting General Disorders and,1
ULORIC,vomiting,peptic ulcer,1
ULORIC,vomiting,vomiting General Disorders and,1
ULORIC,vomiting,pancreatitis peptic vomiting General Disorders and Administration,1
ULORIC,vomiting,vomiting General Disorders and,1
ULORIC,vomiting,vomiting General Disorders,1
ULORIC,vomiting,haematemesis hyperchlorhydria hematochezia,0
ULORIC,vomiting,and Administration Site Conditions asthenia chest,0
ULORIC,vomiting,hyperchlorhydria hematochezia mouth ulceration pancreatitis peptic,0
ULORIC,vomiting,mouth ulceration pancreatitis,0
ULORIC,vomiting,pancreatitis peptic vomiting General,1
ULORIC,vomiting,mouth ulceration pancreatitis,0
ULORIC,vomiting,pancreatitis peptic vomiting General Disorders and,1
ULORIC,vomiting,mouth ulceration pancreatitis,0
ULORIC,asthenia,vomiting,0
ULORIC,asthenia,ulcer vomiting General Disorders and Administration Site,0
ULORIC,asthenia,asthenia chest paindiscomfort edema,1
ULORIC,asthenia,Administration Site asthenia chest paindiscomfort edema fatigue feeling,1
ULORIC,asthenia,asthenia chest paindiscomfort edema,1
ULORIC,asthenia,gait,0
ULORIC,asthenia,asthenia chest paindiscomfort edema,1
ULORIC,asthenia,asthenia chest paindiscomfort edema fatigue feeling,1
ULORIC,asthenia,Disorders and Administration Site asthenia chest,1
ULORIC,asthenia,asthenia chest paindiscomfort edema fatigue feeling,1
ULORIC,chest pain,chest pain discomfort,1
ULORIC,chest pain,asthenia chest paindiscomfort edema fatigue feeling,1
ULORIC,chest pain,Site Conditions asthenia,0
ULORIC,chest pain,chest pain,1
ULORIC,chest pain,gait,0
ULORIC,chest pain,Administration Site Conditions chest pain discomfort edema,1
ULORIC,chest pain,gait,0
ULORIC,chest pain,chest pain discomfort edema fatigue feeling,1
ULORIC,chest pain,Site Conditions chest pain discomfort,1
ULORIC,chest pain,chest pain discomfort edema fatigue feeling,1
ULORIC,chest pain,Administration Site Conditions chest,1
ULORIC,chest pain,Administration Site Conditions chest pain,1
ULORIC,chest pain,Administration Site Conditions chest,1
ULORIC,edema,edema fatigue feeling abnormal gait,1
ULORIC,edema,edema fatigue feeling,1
ULORIC,fatigue,asthenia chest,0
ULORIC,fatigue,fatigue feeling abnormal,1
ULORIC,fatigue,paindiscomfort,0
ULORIC,fatigue,fatigue feeling abnormal,1
ULORIC,fatigue,fatigue feeling,1
ULORIC,fatigue,fatigue feeling abnormal gait disturbance,1
ULORIC,fatigue,fatigue feeling,1
ULORIC,fatigue,fatigue feeling abnormal gait,1
ULORIC,fatigue,fatigue feeling,1
ULORIC,feeling abnormal,edema feeling abnormal gait,1
ULORIC,feeling abnormal,fatigue feeling,1
ULORIC,feeling abnormal,influenzalike symptoms,0
ULORIC,feeling abnormal,edema fatigue,0
ULORIC,feeling abnormal,feeling abnormal gait disturbance influenzalike symptoms mass,1
ULORIC,gait disturbance,thirst Hepatobiliary Disorders,0
ULORIC,influenza-like symptoms,chest paindiscomfort edema fatigue feeling abnormal gait,0
ULORIC,influenza-like symptoms,influenza-like symptoms mass pain,1
ULORIC,mass,mass pain thirst Hepatobiliary,1
ULORIC,pain,disturbance influenzalike symptoms pain thirst Hepatobiliary Disorders cholelithiasischolecystitis hepatic,1
ULORIC,pain,mass pain thirst Hepatobiliary,1
ULORIC,pain,pain thirst Hepatobiliary Disorders,1
ULORIC,pain,pain,1
ULORIC,pain,pain thirst Hepatobiliary Disorders,1
ULORIC,pain,pain thirst Hepatobiliary,1
ULORIC,pain,pain thirst Hepatobiliary,1
ULORIC,pain,pain,1
ULORIC,pain,pain thirst Hepatobiliary Disorders,1
ULORIC,thirst,hepatic steatosis hepatitis,0
ULORIC,thirst,disturbance influenzalike symptoms mass thirst Hepatobiliary,1
ULORIC,thirst,hepatic steatosis hepatitis,0
ULORIC,thirst,thirst Hepatobiliary,1
ULORIC,thirst,pain,0
ULORIC,thirst,disturbance influenzalike symptoms mass thirst Hepatobiliary Disorders,1
ULORIC,thirst,pain,0
ULORIC,thirst,thirst Hepatobiliary Disorders cholelithiasischolecystitis,1
ULORIC,cholelithiasis,hepatomegaly Immune,0
ULORIC,cholelithiasis,Immune System Disorder hypersen,0
ULORIC,cholelithiasis,cholelithiasis cholecystitis,1
ULORIC,cholelithiasis,Immune System,0
ULORIC,cholelithiasis,cholelithiasis cholecystitis,1
ULORIC,cholelithiasis,hepatomegaly Immune System Disorder hypersen,0
ULORIC,cholelithiasis,Hepatobiliary cholelithiasis,1
ULORIC,cholelithiasis,hepatomegaly Immune System Disorder hypersen,0
ULORIC,cholelithiasis,cholelithiasis cholecystitis,1
ULORIC,cholelithiasis,thirst Hepatobiliary cholelithiasis,1
ULORIC,cholelithiasis,cholelithiasis cholecystitis,1
ULORIC,cholelithiasis,thirst Hepatobiliary cholelithiasis cholecystitis hepatic steatosis hepatitis hepatomegaly,1
ULORIC,cholelithiasis,cholelithiasis cholecystitis,1
ULORIC,cholecystitis,System,0
ULORIC,cholecystitis,Disorders cholecystitis hepatic steatosis hepatitis hepatomegaly Immune,1
ULORIC,cholecystitis,System,0
ULORIC,cholecystitis,hepatomegaly Immune System Disorder,0
ULORIC,hepatic steatosis,thirst Hepatobiliary Disorders hepatic steatosis hepatitis hepatomegaly Immune,1
ULORIC,hepatic steatosis,hepatomegaly Immune System Disorder,0
ULORIC,hepatic steatosis,Immune,0
ULORIC,hepatic steatosis,thirst Hepatobiliary Disorders hepatic steatosis,1
ULORIC,hepatic steatosis,Immune,0
ULORIC,hepatic steatosis,Disorder,0
ULORIC,hepatic steatosis,pain thirst Hepatobiliary Disorders hepatic steatosis,1
ULORIC,hepatic steatosis,pain thirst Hepatobiliary Disorders hepatic steatosis hepatitis hepatomegaly Immune,1
ULORIC,hepatic steatosis,pain thirst Hepatobiliary Disorders hepatic steatosis,1
ULORIC,hepatitis,hepatitis hepatomegaly Immune System Disorder hypersensitivity,1
ULORIC,hepatomegaly,hepatomegaly Immune System Disorder hypersensitivity Infections,1
ULORIC,hepatomegaly,hepatomegaly,1
ULORIC,hepatomegaly,hepatic steatosis hepatomegaly Immune,1
ULORIC,hepatomegaly,hepatomegaly,1
ULORIC,hepatomegaly,hepatomegaly Immune System Disorder hypersensitivity Infections,1
ULORIC,hepatomegaly,hepatomegaly,1
ULORIC,hepatomegaly,cholelithiasischolecystitis hepatic steatosis hepatitis,0
ULORIC,hepatomegaly,hepatomegaly,1
ULORIC,hepatomegaly,cholelithiasischolecystitis hepatic steatosis hepatomegaly Immune System Disorder,1
ULORIC,hepatomegaly,hepatomegaly,1
ULORIC,hepatomegaly,hepatic steatosis,0
ULORIC,hypersensitivity,hypersensitivity Infections and Infestations herpes,1
ULORIC,hypersensitivity,hypersensitivity Infections and Infestations herpes,1
ULORIC,hypersensitivity,and Infestations,0
ULORIC,hypersensitivity,hypersensitivity,1
ULORIC,hypersensitivity,herpes zoster,0
ULORIC,hypersensitivity,hepatic steatosis hepatitis hepatomegaly Immune System,0
ULORIC,hypersensitivity,hepatitis hepatomegaly Immune System,0
ULORIC,hypersensitivity,Immune System hypersensitivity Infections,1
ULORIC,hypersensitivity,hepatitis hepatomegaly Immune System,0
ULORIC,hypersensitivity,hypersensitivity Infections,1
ULORIC,contusion,contusion Metabolism,1
ULORIC,contusion,zoster Procedural contusion Metabolism,1
ULORIC,contusion,contusion Metabolism,1
ULORIC,contusion,Infections and Infestations herpes,0
ULORIC,contusion,contusion Metabolism,1
ULORIC,contusion,contusion,1
ULORIC,contusion,contusion Metabolism,1
ULORIC,contusion,Complications,0
ULORIC,contusion,zoster Procedural Complications,0
ULORIC,anorexia,anorexia appetite,1
ULORIC,anorexia,contusion,0
ULORIC,anorexia,anorexia,1
ULORIC,anorexia,anorexia,1
ULORIC,anorexia,mellitus hypercholesterolemia,0
ULORIC,anorexia,anorexia appetite decreasedincreased dehydration diabetes,1
ULORIC,anorexia,anorexia appetite decreasedincreased dehydration diabetes mellitus,1
ULORIC,anorexia,anorexia appetite decreasedincreased dehydration diabetes mellitus,1
ULORIC,anorexia,anorexia,1
ULORIC,anorexia,anorexia appetite decreasedincreased dehydration diabetes mellitus,1
ULORIC,anorexia,and,0
ULORIC,appetite decreased,Nutrition Disorders appetite decreased increased dehydration diabetes mellitus,1
ULORIC,appetite decreased,and,0
ULORIC,appetite decreased,Nutrition,0
ULORIC,appetite decreased,appetite decreased increased dehydration diabetes mellitus,1
ULORIC,appetite decreased,Metabolism and Nutrition Disorders appetite decreased increased dehydration diabetes mellitus,1
ULORIC,appetite decreased,appetite decreased increased dehydration diabetes mellitus,1
ULORIC,dehydration,anorexia appetite dehydration diabetes mellitus hypercholesterolemia,1
ULORIC,dehydration,appetite decreased increased dehydration diabetes mellitus,1
ULORIC,diabetes mellitus,Disorders anorexia,0
ULORIC,diabetes mellitus,diabetes mellitus hypercholesterolemia hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia,1
ULORIC,diabetes mellitus,diabetes mellitus hypercholesterolemia hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia,1
ULORIC,diabetes mellitus,hyperlipidemia hypertriglyceridemia hypokalemia,0
ULORIC,diabetes mellitus,Disorders anorexia appetite decreasedincreased diabetes,1
ULORIC,diabetes mellitus,diabetes mellitus hypercholesterolemia hyperglycemia,1
ULORIC,diabetes mellitus,hyperglycemia hyperlipidemia,0
ULORIC,diabetes mellitus,n Metabolism and Nutrition,0
ULORIC,hypercholesterolemia,hypercholesterolemia hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia,1
ULORIC,hypercholesterolemia,diabetes,0
ULORIC,hypercholesterolemia,hypercholesterolemia,1
ULORIC,hyperglycemia,hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia,1
ULORIC,hyperglycemia,rs anorexia appetite decreasedincreased dehydration diabetes mellitus hypercholesterolemia,0
ULORIC,hyperglycemia,hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia,1
ULORIC,hyperglycemia,dehydration diabetes,0
ULORIC,hyperglycemia,hyperglycemia hyperlipidemia hypertriglyceridemia hypokalemia,1
ULORIC,hyperlipidemia,hyperlipidemia,1
ULORIC,hyperlipidemia,hypokalemia weight decreasedincreased Musculoskeletal and,0
ULORIC,hyperlipidemia,hyperlipidemia,1
ULORIC,hyperlipidemia,hyperlipidemia hypertriglyceridemia,1
ULORIC,hyperlipidemia,hyperlipidemia hypertriglyceridemia hypokalemia,1
ULORIC,hyperlipidemia,hyperlipidemia hypertriglyceridemia hypokalemia weight,1
ULORIC,hyperlipidemia,diabetes mellitus hypercholesterolemia hyperlipidemia,1
ULORIC,hyperlipidemia,hyperlipidemia hypertriglyceridemia hypokalemia weight,1
ULORIC,hyperlipidemia,decreasedincreased Musculoskeletal and Connectiv,0
ULORIC,hypertriglyceridemia,dehydration diabetes mellitus hypercholesterolemia hyperglycemia,0
ULORIC,hypertriglyceridemia,and,0
ULORIC,hypertriglyceridemia,mellitus hypercholesterolemia hyperglycemia hyperlipidemia,0
ULORIC,hypertriglyceridemia,decreasedincreased Musculoskeletal and Connective,0
ULORIC,hypertriglyceridemia,weight decreasedincreased Musculoskeletal and Connective,0
ULORIC,hypertriglyceridemia,hypertriglyceridemia,1
ULORIC,hypertriglyceridemia,weight decreasedincreased Musculoskeletal and Connective,0
ULORIC,hypertriglyceridemia,hyperglycemia hyperlipidemia,0
ULORIC,hypertriglyceridemia,diabetes mellitus hypercholesterolemia hyperglycemia hypertriglyceridemia hypokalemia weight decreasedincreased,1
ULORIC,hypertriglyceridemia,hyperglycemia hyperlipidemia,0
ULORIC,hypokalemia,hypokalemia weight decreasedincreased Musculoskeletal and Connective,1
ULORIC,hypokalemia,and Connective,0
ULORIC,hypokalemia,decreasedincreased Musculoskeletal and Connective Tissue Disorders arthritis jo,0
ULORIC,hypokalemia,hyperlipidemia hypokalemia weight decreasedincreased Musculoskeletal,1
ULORIC,hypokalemia,decreasedincreased Musculoskeletal and Connective Tissue Disorders arthritis jo,0
ULORIC,hypokalemia,hyperglycemia,0
ULORIC,hypokalemia,Disorders arthritis,0
ULORIC,hypokalemia,hypokalemia,1
ULORIC,hypokalemia,Disorders arthritis,0
ULORIC,hypokalemia,mellitus,0
ULORIC,hypokalemia,hypokalemia,1
ULORIC,arthritis,joint stiffness joint swelling muscle,0
ULORIC,arthritis,stiffness joint,0
ULORIC,arthritis,and Connective Tissue arthritis joint stiffness joint swelling muscle,1
ULORIC,arthritis,stiffness joint,0
ULORIC,arthritis,joint,0
ULORIC,arthritis,Disorders,0
ULORIC,arthritis,stiffness joint swelling muscle,0
ULORIC,arthritis,arthritis joint,1
ULORIC,arthritis,and Connective Tissue arthritis joint stiffness joint,1
ULORIC,arthritis,arthritis joint,1
ULORIC,arthritis,arthritis joint stiffness joint swelling muscle,1
ULORIC,joint stiffness,arthritis,0
ULORIC,joint stiffness,Tissue,0
ULORIC,joint stiffness,Connective Tissue Disorders joint stiffness joint swelling muscle spasmstwitchingtightnessweakness musculoskeletal,1
ULORIC,joint stiffness,Tissue,0
ULORIC,joint stiffness,Connective Tissue Disorders joint stiffness joint swelling muscle spasmstwitchingtightnessweakness,1
ULORIC,joint stiffness,Tissue,0
ULORIC,joint stiffness,and Connective Tissue Disorders joint,1
ULORIC,joint swelling,joint swelling muscle,1
ULORIC,joint swelling,Tissue Disorders arthritis joint joint swelling muscle spasmstwitchingtightnessweakness musculoskeletal painstiffness myalgia,1
ULORIC,joint swelling,joint swelling muscle,1
ULORIC,joint swelling,joint swelling,1
ULORIC,joint swelling,muscle,0
ULORIC,joint swelling,arthritis joint stiffness,0
ULORIC,joint swelling,arthritis joint joint swelling muscle spasmstwitchingtightnessweakness,1
ULORIC,joint swelling,arthritis joint stiffness,0
ULORIC,joint swelling,joint swelling muscle,1
ULORIC,joint swelling,Tissue Disorders arthritis joint,0
ULORIC,joint swelling,painstiffness myalgia Nervous,0
ULORIC,muscle spasms,painstiffness myalgia Nervous System,0
ULORIC,muscle spasms,joint muscle spasms twitchingtightnessweakness musculoskeletal painstiffness myalgia,1
ULORIC,muscle spasms,painstiffness myalgia Nervous System,0
ULORIC,muscle spasms,musculoskeletal painstiffness myalgia,0
ULORIC,muscle spasms,muscle spasms twitchingtightnessweakness musculoskeletal painstiffness myalgia,1
ULORIC,muscle spasms,stiffness joint muscle spasms,1
ULORIC,musculoskeletal pain,musculoskeletal,1
ULORIC,musculoskeletal pain,musculoskeletal pain stiffness myalgia,1
ULORIC,myalgia,myalgia Nervous System Disorders,1
ULORIC,myalgia,myalgia Nervous System Disorders altered taste,1
ULORIC,myalgia,ffness joint,0
ULORIC,altered taste,altered taste balance,1
ULORIC,altered taste,musculoskeletal painstiffness myalgia Nervous System,0
ULORIC,altered taste,altered taste,1
ULORIC,altered taste,musculoskeletal painstiffness myalgia Nervous System,0
ULORIC,altered taste,GuillainBarre,0
ULORIC,altered taste,musculoskeletal,0
ULORIC,balance disorder,headache hemiparesis,0
ULORIC,balance disorder,balance disorder cerebrovascular accident GuillainBarre syndrome,1
ULORIC,balance disorder,syndrome headache hemiparesis,0
ULORIC,balance disorder,Disorders altered balance disorder cerebrovascular accident GuillainBarre,1
ULORIC,balance disorder,syndrome headache hemiparesis,0
ULORIC,cerebrovascular accident,hypoesthesia hyposmia lacunar infarction,0
ULORIC,cerebrovascular accident,Nervous System Disorders altered,0
ULORIC,cerebrovascular accident,altered taste balance cerebrovascular accident GuillainBarre syndrome headache,1
ULORIC,cerebrovascular accident,Nervous System Disorders altered,0
ULORIC,cerebrovascular accident,Disorders altered taste balance cerebrovascular accident GuillainBarre syndrome,1
ULORIC,cerebrovascular accident,Nervous System Disorders altered,0
ULORIC,Guillain-Barre syndrome,taste balance disorder cerebrovascular Guillain-Barre,1
ULORIC,Guillain-Barre syndrome,altered taste balance disorder cerebrovascular accident,0
ULORIC,Guillain-Barre syndrome,cerebrovascular Guillain-Barre syndrome headache hemiparesis hypoesthesia hyposmia lacunar,1
ULORIC,Guillain-Barre syndrome,altered taste balance disorder cerebrovascular accident,0
ULORIC,Guillain-Barre syndrome,cerebrovascular Guillain-Barre syndrome,1
ULORIC,Guillain-Barre syndrome,cerebrovascular,0
ULORIC,Guillain-Barre syndrome,balance disorder cerebrovascular Guillain-Barre syndrome,1
ULORIC,Guillain-Barre syndrome,Guillain-Barre syndrome headache hemiparesis hypoesthesia hyposmia lacunar,1
ULORIC,Guillain-Barre syndrome,balance disorder cerebrovascular Guillain-Barre syndrome,1
ULORIC,headache,headache hemiparesis hypoesthesia hyposmia,1
ULORIC,headache,Disorders altered taste balance,0
ULORIC,headache,headache hemiparesis hypoesthesia hyposmia,1
ULORIC,headache,headache,1
ULORIC,headache,headache hemiparesis hypoesthesia hyposmia,1
ULORIC,headache,balance disorder cerebrovascular accident GuillainBarre,0
ULORIC,headache,hypoesthesia hyposmia lacunar infarction lethargy mental impairment migraine pa,0
ULORIC,headache,cerebrovascular accident,0
ULORIC,headache,infarction lethargy mental impairment migraine pa,0
ULORIC,headache,headache hemiparesis hypoesthesia hyposmia lacunar,1
ULORIC,headache,em Disorders altered taste balance disorder cerebrovascular,0
ULORIC,hemiparesis,accident GuillainBarre,0
ULORIC,hemiparesis,rs altered taste balance disorder cerebrovascular,0
ULORIC,hemiparesis,lethargy mental impairment migraine,0
ULORIC,hemiparesis,hemiparesis hypoesthesia,1
ULORIC,hemiparesis,syndrome,0
ULORIC,hemiparesis,headache,0
ULORIC,hypoesthesia,taste balance disorder cerebrovascular accident GuillainBarre syndrome,0
ULORIC,hyposmia,hemiparesis hyposmia lacunar,1
ULORIC,hyposmia,taste balance disorder cerebrovascular accident GuillainBarre syndrome,0
ULORIC,hyposmia,hyposmia lacunar,1
ULORIC,hyposmia,paresthesia somnolence,0
ULORIC,hyposmia,GuillainBarre syndrome headache hemiparesis hyposmia lacunar infarction lethargy,1
ULORIC,hyposmia,paresthesia somnolence,0
ULORIC,hyposmia,hyposmia,1
ULORIC,hyposmia,paresthesia somnolence,0
ULORIC,hyposmia,hyposmia lacunar infarction lethargy mental impairment,1
ULORIC,hyposmia,mental impairment migraine paresthesia somnolence transient,0
ULORIC,hyposmia,hyposmia lacunar infarction lethargy mental impairment,1
ULORIC,lacunar infarction,hemiparesis hypoesthesia lacunar infarction,1
ULORIC,lacunar infarction,headache hemiparesis hypoesthesia lacunar infarction,1
ULORIC,lacunar infarction,syndrome headache hemiparesis hypoesthesia lacunar infarction lethargy mental,1
ULORIC,lacunar infarction,headache hemiparesis hypoesthesia lacunar infarction,1
ULORIC,lacunar infarction,syndrome headache hemiparesis hypoesthesia lacunar infarction lethargy mental impairment migraine,1
ULORIC,lacunar infarction,headache hemiparesis hypoesthesia lacunar infarction,1
ULORIC,lacunar infarction,migraine paresthesia,0
ULORIC,lacunar infarction,impairment migraine paresthesia somnolence transient ischemic attack tremor,0
ULORIC,lacunar infarction,syndrome headache hemiparesis hypoesthesia lacunar infarction,1
ULORIC,lacunar infarction,hypoesthesia lacunar infarction,1
ULORIC,lacunar infarction,headache hemiparesis,0
ULORIC,lacunar infarction,lacunar infarction lethargy mental impairment migraine paresthesia,1
ULORIC,lethargy,lethargy mental impairment,1
ULORIC,lethargy,lethargy mental,1
ULORIC,lethargy,GuillainBarre syndrome headache hemiparesis hypoesthesia hyposmia,0
ULORIC,lethargy,lethargy mental impairment migraine,1
ULORIC,lethargy,headache hemiparesis hypoesthesia hyposmia lacunar,0
ULORIC,mental impairment,hyposmia lacunar infarction mental impairment migraine paresthesia somnolence transient ischemic,1
ULORIC,mental impairment,headache hemiparesis hypoesthesia hyposmia lacunar,0
ULORIC,mental impairment,hemiparesis,0
ULORIC,mental impairment,hypoesthesia hyposmia lacunar infarction mental impairment,1
ULORIC,mental impairment,lethargy,0
ULORIC,mental impairment,hyposmia lacunar infarction,0
ULORIC,mental impairment,hypoesthesia hyposmia lacunar infarction mental impairment migraine paresthesia somnolence transient ischemic,1
ULORIC,mental impairment,hyposmia lacunar infarction,0
ULORIC,mental impairment,mental impairment migraine paresthesia somnolence,1
ULORIC,mental impairment,mental,1
ULORIC,migraine,migraine,1
ULORIC,migraine,mental,1
ULORIC,migraine,impairment,0
ULORIC,migraine,ischemic,0
ULORIC,migraine,migraine paresthesia,1
ULORIC,migraine,lethargy,0
ULORIC,migraine,transient ischemic attack,0
ULORIC,migraine,migraine,1
ULORIC,migraine,attack tremor,0
ULORIC,migraine,migraine paresthesia somnolence transient,1
ULORIC,migraine,migraine paresthesia somnolence transient,1
ULORIC,migraine,migraine paresthesia somnolence transient,1
ULORIC,paresthesia,infarction lethargy mental impairment paresthesia somnolence transient,1
ULORIC,paresthesia,migraine paresthesia somnolence transient,1
ULORIC,paresthesia,paresthesia,1
ULORIC,paresthesia,transient,0
ULORIC,paresthesia,lethargy mental impairment paresthesia somnolence transient ischemic attack tremor,1
ULORIC,paresthesia,transient,0
ULORIC,paresthesia,paresthesia,1
ULORIC,paresthesia,paresthesia somnolence,1
ULORIC,paresthesia,paresthesia,1
ULORIC,paresthesia,paresthesia somnolence,1
ULORIC,transient ischemic attack,infarction lethargy mental,0
ULORIC,transient ischemic attack,paresthesia,0
ULORIC,transient ischemic attack,ischemic attack tremor,1
ULORIC,transient ischemic attack,hyposmia lacunar infarction lethargy mental impairment migraine paresthesia,0
ULORIC,transient ischemic attack,Disorders agitation,0
ULORIC,tremor,ischemic tremor,1
ULORIC,tremor,Disorders agitation,0
ULORIC,tremor,insomnia irritability libido,0
ULORIC,tremor,ischemic tremor Psychiatric,1
ULORIC,tremor,insomnia irritability libido,0
ULORIC,tremor,tremor Psychiatric Disorders,1
ULORIC,tremor,mental impairment migraine,0
ULORIC,tremor,impairment migraine paresthesia somnolence,0
ULORIC,tremor,Disorders,0
ULORIC,tremor,tremor Psychiatric Disorders agitation anxiety,1
ULORIC,tremor,Disorders,0
ULORIC,tremor,attack,0
ULORIC,agitation,ischemic attack tremor Psychiatric agitation,1
ULORIC,agitation,attack,0
ULORIC,agitation,insomnia,0
ULORIC,agitation,Psychiatric agitation,1
ULORIC,agitation,insomnia,0
ULORIC,agitation,agitation,1
ULORIC,agitation,irritability libido decreased nervousness panic attack,0
ULORIC,agitation,anxiety depression,0
ULORIC,agitation,tremor Psychiatric agitation anxiety depression,1
ULORIC,agitation,anxiety depression,0
ULORIC,agitation,anxiety depression insomnia irritability libido decreased,0
ULORIC,agitation,attack tremor,0
ULORIC,anxiety,attack tremor Psychiatric Disorders anxiety depression insomnia,1
ULORIC,anxiety,attack tremor,0
ULORIC,anxiety,tremor,0
ULORIC,depression,depression,1
ULORIC,depression,anxiety,0
ULORIC,depression,panic attack personality,0
ULORIC,insomnia,insomnia irritability libido decreased nervousness,1
ULORIC,insomnia,Disorders agitation anxiety insomnia irritability libido decreased nervousness panic,1
ULORIC,insomnia,insomnia irritability libido decreased nervousness,1
ULORIC,irritability,personality change,0
ULORIC,irritability,irritability libido decreased nervousness panic,1
ULORIC,irritability,attack,0
ULORIC,irritability,irritability,1
ULORIC,irritability,attack tremor Psychiatric Disorders agitation anxiety depression,0
ULORIC,irritability,Renal and Urinary Disorders,0
ULORIC,libido decreased,insomnia libido decreased,1
ULORIC,libido decreased,anxiety depression insomnia libido decreased,1
ULORIC,libido decreased,libido decreased,1
ULORIC,libido decreased,anxiety depression insomnia libido decreased,1
ULORIC,libido decreased,depression insomnia,0
ULORIC,libido decreased,depression insomnia libido decreased,1
ULORIC,libido decreased,Disorders hematuria,0
ULORIC,libido decreased,libido decreased nervousness panic attack,1
ULORIC,libido decreased,libido decreased,1
ULORIC,libido decreased,libido decreased nervousness panic attack,1
ULORIC,libido decreased,libido decreased,1
ULORIC,nervousness,panic attack personality change Renal and Urinary,0
ULORIC,nervousness,change Renal and Urinary,0
ULORIC,nervousness,and,0
ULORIC,nervousness,nervousness panic attack,1
ULORIC,nervousness,nervousness panic attack,1
ULORIC,panic attack,nervousness,0
ULORIC,panic attack,irritability libido decreased panic attack personality change Renal and,1
ULORIC,panic attack,nervousness,0
ULORIC,panic attack,Disorders hematuria,0
ULORIC,personality change,personality change Renal and Urinary Disorders hematuria,1
ULORIC,personality change,nervousness panic personality change Renal,1
ULORIC,personality change,personality change Renal and Urinary Disorders hematuria,1
ULORIC,personality change,hematuria nephrolithiasis pollakiuria proteinuria,0
ULORIC,personality change,Renal and Urinary Disorders hematuria,0
ULORIC,personality change,decreased nervousness panic,0
ULORIC,hematuria,Urinary hematuria nephrolithiasis pollakiuria proteinuria,1
ULORIC,hematuria,decreased nervousness panic,0
ULORIC,hematuria,hematuria nephrolithiasis,1
ULORIC,hematuria,renal insufficiency,0
ULORIC,hematuria,hematuria nephrolithiasis pollakiuria,1
ULORIC,hematuria,hematuria nephrolithiasis pollakiuria proteinuria,1
ULORIC,hematuria,hematuria,1
ULORIC,hematuria,pollakiuria proteinuria renal,0
ULORIC,hematuria,pollakiuria,0
ULORIC,nephrolithiasis,nephrolithiasis,1
ULORIC,nephrolithiasis,urgency,0
ULORIC,nephrolithiasis,and Urinary Disorders nephrolithiasis pollakiuria proteinuria renal,1
ULORIC,nephrolithiasis,urgency,0
ULORIC,nephrolithiasis,change Renal and Urinary,0
ULORIC,nephrolithiasis,urgency incontinence Reprodu,0
ULORIC,nephrolithiasis,renal,0
ULORIC,nephrolithiasis,nephrolithiasis pollakiuria proteinuria renal failure,1
ULORIC,nephrolithiasis,renal,0
ULORIC,nephrolithiasis,panic attack,0
ULORIC,nephrolithiasis,nephrolithiasis pollakiuria proteinuria renal failure,1
ULORIC,pollakiuria,pollakiuria proteinuria renal failure,1
ULORIC,pollakiuria,pollakiuria proteinuria,1
ULORIC,pollakiuria,pollakiuria proteinuria renal failure,1
ULORIC,pollakiuria,nephrolithiasis,0
ULORIC,pollakiuria,Disorders,0
ULORIC,pollakiuria,Urinary Disorders hematuria,0
ULORIC,pollakiuria,pollakiuria proteinuria,1
ULORIC,pollakiuria,Renal and Urinary,0
ULORIC,proteinuria,Urinary Disorders,0
ULORIC,proteinuria,nephrolithiasis proteinuria renal failure renal insufficiency,1
ULORIC,proteinuria,Urinary Disorders,0
ULORIC,proteinuria,pollakiuria,0
ULORIC,proteinuria,Urinary Disorders hematuria nephrolithiasis proteinuria renal failure,1
ULORIC,proteinuria,pollakiuria,0
ULORIC,proteinuria,proteinuria renal failure renal insufficiency,1
ULORIC,proteinuria,renal insufficiency urgency incontinence Reproductive System and Breast Ch,0
ULORIC,proteinuria,nephrolithiasis,0
ULORIC,proteinuria,Renal and,0
ULORIC,renal failure,renal failure renal insufficiency urgency incontinence Reproductive,1
ULORIC,renal failure,renal,1
ULORIC,renal failure,Renal and Urinary,0
ULORIC,renal failure,pollakiuria renal failure,1
ULORIC,renal failure,Renal and Urinary,0
ULORIC,renal failure,hematuria nephrolithiasis pollakiuria renal failure renal insufficiency,1
ULORIC,renal failure,Renal and Urinary,0
ULORIC,renal failure,Reproductive System and Breast,0
ULORIC,renal failure,renal failure renal insufficiency,1
ULORIC,renal failure,pollakiuria,0
ULORIC,renal insufficiency,pollakiuria proteinuria renal failure,0
ULORIC,renal insufficiency,pollakiuria proteinuria renal renal insufficiency urgency incontinence Reproductive System and,1
ULORIC,renal insufficiency,pollakiuria proteinuria renal failure,0
ULORIC,renal insufficiency,renal insufficiency urgency incontinence Reproductive System and,1
ULORIC,renal insufficiency,Renal and Urinary Disorders hematuria nephrolithiasis pollakiuria proteinuria renal failure,0
ULORIC,renal insufficiency,breast pain erectile,0
ULORIC,breast pain,and Breast breast,1
ULORIC,breast pain,and Breast Changes,0
ULORIC,breast pain,Mediastinal Disorders bronc,0
ULORIC,breast pain,System and Breast breast pain,1
ULORIC,breast pain,Mediastinal Disorders bronc,0
ULORIC,breast pain,dysfunction gynecomastia Respiratory Thoracic and,0
ULORIC,breast pain,Breast breast pain,1
ULORIC,breast pain,System and Breast breast,1
ULORIC,breast pain,gynecomastia Respiratory Thoracic and Mediastinal Disorders,0
ULORIC,breast pain,ailure renal insufficiency urgency incontinence Reproductive System and,0
ULORIC,breast pain,Changes,0
ULORIC,erectile dysfunction,Respiratory Thoracic and,0
ULORIC,erectile dysfunction,Respiratory Thoracic and Mediastinal,0
ULORIC,erectile dysfunction,Thoracic and Mediastinal Disorders bronchitis,0
ULORIC,erectile dysfunction,breast erectile dysfunction gynecomastia,1
ULORIC,erectile dysfunction,Thoracic and Mediastinal Disorders bronchitis,0
ULORIC,erectile dysfunction,Changes breast erectile dysfunction,1
ULORIC,erectile dysfunction,Thoracic and Mediastinal Disorders bronchitis cough,0
ULORIC,erectile dysfunction,erectile dysfunction,1
ULORIC,erectile dysfunction,erectile dysfunction,1
ULORIC,gynecomastia,dysfunction,0
ULORIC,bronchitis,bronchitis cough dyspnea epistaxis,1
ULORIC,bronchitis,Disorders,0
ULORIC,bronchitis,Respiratory Thoracic and Mediastinal Disorders,0
ULORIC,bronchitis,Mediastinal,0
ULORIC,bronchitis,bronchitis cough,1
ULORIC,bronchitis,bronchitis cough dyspnea epistaxis,1
ULORIC,bronchitis,bronchitis cough dyspnea epistaxis nasal dryness,1
ULORIC,cough,cough dyspnea epistaxis nasal,1
ULORIC,cough,cough dyspnea epistaxis nasal,1
ULORIC,dyspnea,dyspnea epistaxis nasal dryness,1
ULORIC,dyspnea,and Mediastinal Disorders bronchitis dyspnea epistaxis nasal dryness paranasal,1
ULORIC,dyspnea,dyspnea epistaxis nasal dryness,1
ULORIC,dyspnea,dyspnea epistaxis nasal dryness paranasal,1
ULORIC,dyspnea,dyspnea epistaxis nasal dryness paranasal sinus,1
ULORIC,dyspnea,hypersecretion pharyngeal edema,0
ULORIC,dyspnea,dyspnea epistaxis nasal dryness paranasal,1
ULORIC,dyspnea,and Mediastinal Disorders bronchitis dyspnea epistaxis nasal dryness,1
ULORIC,dyspnea,dyspnea epistaxis nasal dryness paranasal,1
ULORIC,dyspnea,bronchitis cough,0
ULORIC,epistaxis,pharyngeal edema respiratory tract congestion sne,0
ULORIC,epistaxis,tract,0
ULORIC,epistaxis,epistaxis,1
ULORIC,epistaxis,epistaxis nasal dryness paranasal sinus hypersecretion,1
ULORIC,epistaxis,bronchitis cough epistaxis nasal dryness paranasal sinus,1
ULORIC,epistaxis,epistaxis nasal dryness paranasal sinus hypersecretion,1
ULORIC,epistaxis,epistaxis nasal dryness paranasal,1
ULORIC,epistaxis,Mediastinal Disorders bronchitis cough epistaxis nasal dryness paranasal,1
ULORIC,epistaxis,epistaxis nasal dryness paranasal,1
ULORIC,epistaxis,Disorders bronchitis cough epistaxis nasal dryness paranasal sinus hypersecretion,1
ULORIC,epistaxis,epistaxis nasal dryness paranasal,1
ULORIC,nasal dryness,Disorders bronchitis cough dyspnea nasal dryness,1
ULORIC,paranasal sinus hypersecretion,paranasal sinus hypersecretion pharyngeal,1
ULORIC,paranasal sinus hypersecretion,upper respiratory,0
ULORIC,pharyngeal edema,nasal,0
ULORIC,pharyngeal edema,paranasal sinus pharyngeal edema respiratory tract congestion sneezing,1
ULORIC,pharyngeal edema,nasal,0
ULORIC,respiratory tract congestion,paranasal sinus hypersecretion pharyngeal respiratory tract congestion sneezing,1
ULORIC,respiratory tract congestion,nasal,0
ULORIC,respiratory tract congestion,pharyngeal respiratory tract congestion sneezing throat irritation upper respiratory,1
ULORIC,respiratory tract congestion,nasal,0
ULORIC,sneezing,pharyngeal edema respiratory tract sneezing throat,1
ULORIC,sneezing,nasal,0
ULORIC,sneezing,respiratory tract sneezing throat irritation upper respiratory tract,1
ULORIC,sneezing,nasal,0
ULORIC,sneezing,sneezing throat irritation upper respiratory,1
ULORIC,sneezing,hypersecretion pharyngeal edema,0
ULORIC,sneezing,sneezing throat irritation,1
ULORIC,sneezing,hypersecretion pharyngeal edema,0
ULORIC,sneezing,sneezing throat irritation upper respiratory tract,1
ULORIC,sneezing,sneezing throat,1
ULORIC,sneezing,irritation upper respiratory tract infection Skin and Subcutaneous,0
ULORIC,sneezing,congestion,0
ULORIC,sneezing,sneezing throat,1
ULORIC,throat irritation,Tissue Disorders,0
ULORIC,throat irritation,congestion throat irritation upper respiratory tract,1
ULORIC,throat irritation,Tissue Disorders,0
ULORIC,upper respiratory tract infection,tract infection Skin and Subcutaneous Tissue Disorders,1
ULORIC,upper respiratory tract infection,throat,0
ULORIC,alopecia,alopecia,1
ULORIC,alopecia,alopecia angioedema dermatitis dermographism ecchymosis eczema,1
ULORIC,alopecia,alopecia angioedema dermatitis dermographism ecchymosis eczema,1
ULORIC,alopecia,eczema hair,0
ULORIC,alopecia,tract infection Skin and Subcutaneous,0
ULORIC,alopecia,alopecia angioedema dermatitis dermographism ecchymosis,1
ULORIC,alopecia,alopecia angioedema dermatitis dermographism ecchymosis eczema,1
ULORIC,alopecia,alopecia angioedema dermatitis dermographism ecchymosis,1
ULORIC,alopecia,alopecia,1
ULORIC,alopecia,changes hair growth,0
ULORIC,angio-edema,angio-edema dermatitis dermographism,1
ULORIC,angio-edema,color changes hair growth abnormal,0
ULORIC,angio-edema,angio-edema dermatitis dermographism ecchymosis eczema hair,1
ULORIC,angio-edema,and Subcutaneous,0
ULORIC,angio-edema,Skin and,0
ULORIC,angio-edema,alopecia,0
ULORIC,angio-edema,Disorders,0
ULORIC,dermatitis,abnormal hyperhidrosis,0
ULORIC,dermatitis,Tissue Disorders alopecia dermatitis dermographism ecchymosis eczema hair color,1
ULORIC,dermatitis,abnormal hyperhidrosis,0
ULORIC,dermatitis,dermatitis dermographism ecchymosis eczema hair color,1
ULORIC,dermatitis,changes hair growth,0
ULORIC,dermatitis,ecchymosis eczema,0
ULORIC,dermatitis,hair growth abnormal,0
ULORIC,dermatitis,dermatitis,1
ULORIC,dermatitis,dermatitis dermographism ecchymosis,1
ULORIC,dermatitis,dermatitis,1
ULORIC,dermatitis,dermatitis,1
ULORIC,dermographism,dermographism ecchymosis eczema hair color,1
ULORIC,dermographism,dermatitis,1
ULORIC,dermographism,dermographism ecchymosis,1
ULORIC,dermographism,dermographism ecchymosis eczema,1
ULORIC,dermographism,angioedema dermographism,1
ULORIC,dermographism,dermographism ecchymosis eczema,1
ULORIC,dermographism,eczema,0
ULORIC,dermographism,dermographism ecchymosis eczema hair color,1
ULORIC,ecchymosis,ecchymosis eczema,1
ULORIC,eczema,dermatitis dermographism eczema hair color changes hair growth,1
ULORIC,eczema,ecchymosis eczema,1
ULORIC,eczema,angioedema dermatitis dermographism eczema hair,1
ULORIC,eczema,ecchymosis eczema,1
ULORIC,eczema,eczema hair color changes hair growth,1
ULORIC,eczema,eczema hair,1
ULORIC,eczema,eczema hair color changes hair growth,1
ULORIC,eczema,eczema hair color changes,1
ULORIC,eczema,eczema hair color changes hair growth,1
ULORIC,eczema,growth abnormal,0
ULORIC,eczema,eczema hair color changes hair growth,1
ULORIC,eczema,changes hair growth abnormal hyperhidrosis peeling,0
ULORIC,eczema,Disorders alopecia angioedema dermatitis,0
ULORIC,eczema,eczema,1
ULORIC,hair color changes,ecchymosis hair color changes,1
ULORIC,hair color changes,eczema,1
ULORIC,hair color changes,skin petechiae,0
ULORIC,hair color changes,photosensitivity,0
ULORIC,hair color changes,hair color,1
ULORIC,hair color changes,growth abnormal hyperhidrosis peeling skin,0
ULORIC,hair color changes,dermatitis dermographism ecchymosis,0
ULORIC,hair color changes,hair color changes hair growth,1
ULORIC,hair color changes,cutaneous,0
ULORIC,hyperhidrosis,hyperhidrosis peeling skin petechiae,1
ULORIC,hyperhidrosis,hyperhidrosis peeling skin petechiae photosensitivity,1
ULORIC,hyperhidrosis,pruritus purpura skin discolorationaltered pigmen,0
ULORIC,hyperhidrosis,hyperhidrosis peeling,1
ULORIC,hyperhidrosis,hyperhidrosis peeling skin,1
ULORIC,hyperhidrosis,hyperhidrosis peeling skin petechiae,1
ULORIC,peeling skin,peeling skin petechiae photosensitivity pruritus,1
ULORIC,peeling skin,peeling skin petechiae photosensitivity,1
ULORIC,peeling skin,peeling skin petechiae photosensitivity pruritus,1
ULORIC,peeling skin,discolorationaltered pigmentation skin,0
ULORIC,peeling skin,peeling,1
ULORIC,petechiae,petechiae photosensitivity,1
ULORIC,petechiae,hism ecchymosis eczema hair color changes hair,0
ULORIC,petechiae,petechiae photosensitivity,1
ULORIC,petechiae,pigmentation,0
ULORIC,petechiae,hyperhidrosis peeling skin,0
ULORIC,petechiae,purpura skin discolorationaltered pigmentation skin,0
ULORIC,petechiae,growth abnormal hyperhidrosis peeling petechiae photosensitivity pruritus,1
ULORIC,petechiae,purpura skin discolorationaltered pigmentation skin,0
ULORIC,petechiae,photosensitivity,0
ULORIC,petechiae,abnormal hyperhidrosis peeling petechiae photosensitivity pruritus purpura skin discolorationaltered,1
ULORIC,petechiae,photosensitivity,0
ULORIC,pruritus,skin petechiae pruritus purpura,1
ULORIC,pruritus,photosensitivity,0
ULORIC,pruritus,pruritus purpura skin discolorationaltered pigmentation skin,1
ULORIC,pruritus,petechiae pruritus,1
ULORIC,pruritus,pruritus purpura skin discolorationaltered pigmentation skin,1
ULORIC,purpura,purpura,1
ULORIC,skin discoloration,petechiae photosensitivity pruritus skin,1
ULORIC,skin discoloration,skin discoloration altered,1
ULORIC,skin discoloration,skin discoloration altered pigmentation skin lesion,1
ULORIC,skin discoloration,skin discoloration altered,1
ULORIC,skin lesion,pigmentation,0
ULORIC,skin lesion,discolorationaltered skin,1
ULORIC,skin lesion,flush hypertension,0
ULORIC,skin odor abnormal,skin odor abnormal urticaria,1
ULORIC,skin odor abnormal,discolorationaltered pigmentation skin skin odor abnormal urticaria Vascular Disorders,1
ULORIC,skin odor abnormal,skin odor abnormal urticaria,1
ULORIC,skin odor abnormal,pigmentation skin skin odor abnormal,1
ULORIC,skin odor abnormal,skin odor abnormal urticaria,1
ULORIC,skin odor abnormal,skin lesion,0
ULORIC,skin odor abnormal,flush hypertension hypotension Labor,0
ULORIC,skin odor abnormal,urticaria Vascular Disorders flushing,0
ULORIC,skin odor abnormal,purpura skin discolorationaltered pigmentation skin,0
ULORIC,skin odor abnormal,discolorationaltered,0
ULORIC,skin odor abnormal,pruritus purpura skin discolorationaltered pigmentation skin,0
ULORIC,urticaria,skin lesion skin odor urticaria Vascular Disorders flushing hot,1
ULORIC,urticaria,pruritus purpura skin discolorationaltered pigmentation skin,0
ULORIC,urticaria,odor urticaria Vascular Disorders flushing,1
ULORIC,urticaria,pruritus purpura skin discolorationaltered pigmentation skin,0
ULORIC,hot flush,urticaria Vascular Disorders hot flush,1
ULORIC,hot flush,urticaria Vascular Disorders,0
ULORIC,hot flush,Disorders hot,1
ULORIC,hot flush,Disorders hot flush,1
ULORIC,hot flush,Parameters activated partial thromboplastin time pro,0
ULORIC,hot flush,abnormal urticaria Vascular Disorders hot flush hypertension hypotension Laboratory Parameters,1
ULORIC,hot flush,Parameters activated partial thromboplastin time pro,0
ULORIC,hot flush,hot flush hypertension,1
ULORIC,hot flush,urticaria Vascular Disorders hot flush,1
ULORIC,hot flush,hot flush hypertension,1
ULORIC,hypertension,flushing,0
ULORIC,hypertension,hypertension hypotension Laboratory Parameters activated partial,1
ULORIC,hypertension,hypertension hypotension Laboratory Parameters,1
ULORIC,hypertension,hypertension hypotension Laboratory Parameters activated partial,1
ULORIC,hypertension,hypertension hypotension Laboratory Parameters activated,1
ULORIC,hypertension,hot flush,0
ULORIC,hypertension,hypertension hypotension Laboratory,1
ULORIC,hypertension,hypertension hypotension Laboratory Parameters activated,1
ULORIC,hypertension,hypertension hypotension Laboratory Parameters,1
ULORIC,hypertension,hypertension hypotension Laboratory Parameters activated partial,1
ULORIC,hypertension,hypertension hypotension Laboratory Parameters,1
ULORIC,hypotension,time prolonged creatine increased,0
ULORIC,hypotension,prolonged,0
ULORIC,hypotension,hypotension Laboratory Parameters activated partial thromboplastin,1
ULORIC,hypotension,hypotension,1
ULORIC,hypotension,hypotension Laboratory Parameters activated partial thromboplastin,1
ULORIC,hypotension,Parameters activated,0
ULORIC,hypotension,hypotension Laboratory Parameters activated,1
ULORIC,activated partial thromboplastin time prolonged,Parameters,0
ULORIC,activated partial thromboplastin time prolonged,flushing hot flush hypertension hypotension Laboratory,0
ULORIC,activated partial thromboplastin time prolonged,Laboratory,0
ULORIC,activated partial thromboplastin time prolonged,activated partial thromboplastin time prolonged creatine increased bicarbonate,1
ULORIC,activated partial thromboplastin time prolonged,Laboratory,0
ULORIC,activated partial thromboplastin time prolonged,partial thromboplastin time prolonged creatine increased bicarbonate decreased,1
ULORIC,activated partial thromboplastin time prolonged,activated partial thromboplastin time prolonged creatine increased,1
ULORIC,activated partial thromboplastin time prolonged,partial thromboplastin time prolonged creatine increased bicarbonate decreased,1
ULORIC,activated partial thromboplastin time prolonged,Laboratory activated partial thromboplastin time,1
ULORIC,activated partial thromboplastin time prolonged,hypertension hypotension Laboratory activated partial thromboplastin time prolonged creatine increased bicarbonate decreased,1
ULORIC,activated partial thromboplastin time prolonged,Laboratory activated partial thromboplastin time,1
ULORIC,activated partial thromboplastin time prolonged,increased bicarbonate decreased,0
ULORIC,creatine increased,decreased sodium increased EEG abnormal glucose,0
ULORIC,bicarbonate decreased,glucose increased cholesterol increased triglycerides increased,0
ULORIC,bicarbonate decreased,cholesterol increased triglycerides,0
ULORIC,bicarbonate decreased,creatine,0
ULORIC,bicarbonate decreased,time prolonged creatine bicarbonate decreased,1
ULORIC,bicarbonate decreased,time prolonged creatine bicarbonate,1
ULORIC,bicarbonate decreased,cholesterol increased triglycerides increased,0
ULORIC,sodium increased,creatine increased bicarbonate sodium increased,1
ULORIC,sodium increased,cholesterol increased triglycerides increased,0
ULORIC,EEG abnormal,EEG abnormal,1
ULORIC,EEG abnormal,increased bicarbonate decreased sodium EEG abnormal,1
ULORIC,EEG abnormal,EEG abnormal,1
ULORIC,EEG abnormal,partial thromboplastin,0
ULORIC,EEG abnormal,EEG abnormal glucose increased,1
ULORIC,EEG abnormal,EEG abnormal glucose increased cholesterol,1
ULORIC,EEG abnormal,EEG abnormal glucose increased,1
ULORIC,EEG abnormal,EEG abnormal glucose increased cholesterol,1
ULORIC,EEG abnormal,bicarbonate,0
ULORIC,glucose increased,sodium increased EEG glucose increased cholesterol increased triglycerides increased,1
ULORIC,glucose increased,bicarbonate,0
ULORIC,glucose increased,glucose increased cholesterol,1
ULORIC,glucose increased,glucose increased cholesterol increased,1
ULORIC,glucose increased,glucose increased cholesterol,1
ULORIC,glucose increased,increased amylase increased potassium increased,0
ULORIC,glucose increased,glucose increased cholesterol increased,1
ULORIC,cholesterol increased,cholesterol increased,1
ULORIC,cholesterol increased,cholesterol,1
ULORIC,cholesterol increased,EEG abnormal glucose cholesterol increased,1
ULORIC,cholesterol increased,EEG abnormal glucose cholesterol increased triglycerides increased amylase,1
ULORIC,cholesterol increased,EEG abnormal glucose cholesterol increased,1
ULORIC,cholesterol increased,abnormal glucose cholesterol increased,1
ULORIC,cholesterol increased,sodium increased EEG abnormal,0
ULORIC,cholesterol increased,cholesterol increased triglycerides increased amylase increased,1
ULORIC,cholesterol increased,cholesterol increased triglycerides increased amylase increased,1
ULORIC,cholesterol increased,increased EEG abnormal glucose cholesterol increased triglycerides increased amylase increased,1
ULORIC,cholesterol increased,cholesterol increased triglycerides increased amylase increased,1
ULORIC,cholesterol increased,increased platelet,0
ULORIC,triglycerides increased,bicarbonate decreased sodium increased EEG abnormal glucose increased cholesterol increased,0
ULORIC,triglycerides increased,platelet count decreased hematocrit decrea,0
ULORIC,triglycerides increased,triglycerides increased amylase increased,1
ULORIC,amylase increased,increased triglycerides increased,0
ULORIC,amylase increased,amylase,1
ULORIC,amylase increased,amylase increased potassium increased,1
ULORIC,amylase increased,increased cholesterol increased,0
ULORIC,amylase increased,triglycerides amylase increased,1
ULORIC,amylase increased,EEG abnormal glucose increased cholesterol increased triglycerides increased,0
ULORIC,amylase increased,increased platelet count decreased hematocrit decreased,0
ULORIC,potassium increased,potassium,1
ULORIC,potassium increased,increased triglycerides increased amylase potassium,1
ULORIC,potassium increased,potassium increased TSH increased,1
ULORIC,potassium increased,amylase potassium increased,1
ULORIC,potassium increased,amylase potassium increased TSH increased,1
ULORIC,potassium increased,amylase potassium increased,1
ULORIC,potassium increased,EEG abnormal glucose increased cholesterol increased triglycerides,0
ULORIC,platelet count decreased,increased TSH platelet count,1
ULORIC,hematocrit decreased,hematocrit decreased hemoglobin decreased MCV,1
ULORIC,hematocrit decreased,hemoglobin decreased MCV increased RBC decreased creatinine increased blood urea increased,0
ULORIC,hematocrit decreased,increased platelet count hematocrit,1
ULORIC,hematocrit decreased,platelet count hematocrit,1
ULORIC,hematocrit decreased,hematocrit decreased hemoglobin decreased MCV,1
ULORIC,hematocrit decreased,blood urea increased BU,0
ULORIC,hematocrit decreased,count hematocrit decreased hemoglobin decreased MCV,1
ULORIC,hematocrit decreased,blood urea increased BU,0
ULORIC,hematocrit decreased,hematocrit decreased hemoglobin decreased,1
ULORIC,hematocrit decreased,hematocrit decreased hemoglobin decreased MCV,1
ULORIC,hemoglobin decreased,hematocrit hemoglobin,1
ULORIC,hemoglobin decreased,increased,0
ULORIC,hemoglobin decreased,increased BUNcreatinine,0
ULORIC,hemoglobin decreased,hemoglobin decreased,1
ULORIC,hemoglobin decreased,hemoglobin decreased MCV increased RBC decreased,1
ULORIC,MCV increased,MCV increased RBC decreased creatinine increased,1
ULORIC,MCV increased,MCV increased RBC decreased creatinine,1
ULORIC,MCV increased,MCV increased,1
ULORIC,MCV increased,hemoglobin MCV increased RBC decreased creatinine increased,1
ULORIC,MCV increased,MCV increased,1
ULORIC,MCV increased,increased blood,0
ULORIC,RBC decreased,decreased,0
ULORIC,creatinine increased,MCV increased RBC creatinine increased blood urea increased,1
ULORIC,creatinine increased,decreased,0
ULORIC,creatinine increased,creatinine increased blood urea increased,1
ULORIC,blood urea increased,decreased creatinine,0
ULORIC,blood urea increased,blood urea increased BUNcreatinine ratio increased,1
ULORIC,blood urea increased,decreased,0
ULORIC,blood urea increased,increased,0
ULORIC,blood urea increased,increased,0
ULORIC,BUN/creatinine ratio increased,hemoglobin decreased MCV increased,0
ULORIC,BUN/creatinine ratio increased,hemoglobin decreased MCV increased RBC decreased creatinine,0
ULORIC,BUN/creatinine ratio increased,hemoglobin decreased MCV increased RBC decreased creatinine increased,0
ULORIC,BUN/creatinine ratio increased,creatinine increased blood urea BUN/creatinine ratio,1
ULORIC,BUN/creatinine ratio increased,BUN/creatinine ratio increased,1
ULORIC,BUN/creatinine ratio increased,phosphokinase CPK,0
ULORIC,alkaline phosphatase increased,increased creatine phosphokinase CPK alkaline phosphatase increased LDH increased,1
ULORIC,alkaline phosphatase increased,phosphokinase CPK,0
ULORIC,alkaline phosphatase increased,phosphokinase CPK,0
ULORIC,alkaline phosphatase increased,increased urine,0
ULORIC,urine output increased,decreased lymphocyte count,0
ULORIC,urine output increased,eatine phosphokinase CPK increased alkaline phosphatase increased,0
ULORIC,urine output increased,decreased WBC increaseddecreased coagula,0
ULORIC,urine output increased,increased PSA urine output increased decreased lymphocyte count,1
ULORIC,urine output increased,decreased WBC increaseddecreased coagula,0
ULORIC,urine output increased,PSA increased,0
ULORIC,urine output increased,urine output increased decreased lymphocyte count decreased neutrophil,1
ULORIC,urine output increased,urine output increased decreased lymphocyte,1
ULORIC,urine output increased,increased PSA urine output,1
ULORIC,lymphocyte count decreased,increased LDH increased,0
ULORIC,lymphocyte count decreased,neutrophil count decreased WBC increaseddecreased,0
ULORIC,lymphocyte count decreased,ed alkaline phosphatase increased LDH increased PSA increased urine output increaseddecreased,0
ULORIC,lymphocyte count decreased,abnormal low,0
ULORIC,lymphocyte count decreased,lymphocyte count decreased,1
ULORIC,lymphocyte count decreased,urine output lymphocyte count decreased neutrophil count decreased WBC,1
ULORIC,lymphocyte count decreased,lymphocyte count decreased,1
ULORIC,WBC increased,WBC increased,1
ULORIC,WBC increased,test abnormal low density lipoprotein LDL,0
ULORIC,WBC increased,WBC increased decreased coagulation test abnormal,1
ULORIC,WBC increased,output increaseddecreased lymphocyte count decreased,0
ULORIC,WBC increased,decreased neutrophil count WBC,1
ULORIC,WBC increased,count decreased neutrophil count WBC increased,1
ULORIC,WBC increased,WBC increased decreased,1
ULORIC,WBC increased,count decreased neutrophil count WBC increased,1
ULORIC,coagulation test abnormal,creaseddecreased lymphocyte,0
ULORIC,coagulation test abnormal,density lipoprotein LDL increased prothrombin time prolonged urinary casts urine positive,0
ULORIC,coagulation test abnormal,prothrombin time prolonged urinary casts urine positive,0
ULORIC,coagulation test abnormal,decreased WBC coagulation test abnormal low density lipoprotein,1
ULORIC,coagulation test abnormal,prothrombin time prolonged urinary casts urine positive,0
ULORIC,coagulation test abnormal,test abnormal low density lipoprotein,1
ULORIC,prothrombin time prolonged,prothrombin time prolonged urinary casts urine positive for,1
ULORIC,urine positive for white blood cells,test abnormal low density lipoprotein LDL increased prothrombin time prolonged urinary casts,0
ULORIC,Cardiovascular events,Cardiovascular,1
ULORIC,Cardiovascular events,were adjudicated to one of the predefined endpoints from the AntiPlatelet Trialists,0
ULORIC,Cardiovascular events,protein Cardiovascular Cardiovascular events,1
ULORIC,Cardiovascular events,protein Cardiovascular Cardiovascular events,1
ULORIC,Cardiovascular events,the predefined endpoints from the AntiPlatelet Trialists,0
ULORIC,cardiovascular death,cardiovascular death nonfatal myocardial infarction and,1
ULORIC,cardiovascular death,Trialists Collaborations cardiovascular death,1
ULORIC,cardiovascular death,from the AntiPlatelet Trialists Collaborations APTC,0
ULORIC,cardiovascular death,myocardial infarction,0
ULORIC,cardiovascular death,cardiovascular death,1
ULORIC,cardiovascular death,Trialists Collaborations APTC,0
ULORIC,cardiovascular death,cardiovascular death nonfatal myocardial infarction and,1
ULORIC,cardiovascular death,to one,0
ULORIC,myocardial infarction,APTC cardiovascular death myocardial infarction,1
ULORIC,myocardial infarction,and,0
ULORIC,myocardial infarction,cardiovascular death myocardial infarction and,1
ULORIC,myocardial infarction,and,0
ULORIC,myocardial infarction,myocardial infarction and nonfatal stroke in,1
ULORIC,myocardial infarction,myocardial infarction and nonfatal stroke,1
ULORIC,myocardial infarction,myocardial infarction and nonfatal stroke in the,1
ULORIC,myocardial infarction,myocardial infarction and,1
ULORIC,myocardial infarction,myocardial infarction and nonfatal stroke in the,1
ULORIC,myocardial infarction,longterm extension studies,0
ULORIC,myocardial infarction,studies In,0
ULORIC,stroke,and,0
ULORIC,stroke,stroke in the randomized controlled and,1
ULORIC,stroke,randomized controlled and,0
ULORIC,stroke,stroke in the,1
ULORIC,stroke,and,0
ULORIC,stroke,alists Collaborations APTC cardiovascular death,0
ULORIC,stroke,stroke,1
ULORIC,stroke,myocardial infarction and stroke in the,1
ULORIC,stroke,stroke,1
ULORIC,hepatic failure,hepatic failure some fatal jaundice serious cases,1
ULORIC,hepatic failure,function test results liver disorder,0
ULORIC,hepatic failure,causal relationship Hepatobiliary hepatic failure some fatal jaundice serious cases,1
ULORIC,hepatic failure,function test results liver disorder,0
ULORIC,hepatic failure,liably estimate their frequency or establish,0
ULORIC,hepatic failure,frequency or establish a causal relationship Hepatobiliary Disorders,0
ULORIC,hepatic failure,results liver,0
ULORIC,hepatic failure,hepatic failure,1
ULORIC,fatal,fatal jaundice serious cases of abnormal,1
ULORIC,fatal,fatal,1
ULORIC,fatal,disorder,0
ULORIC,fatal,Hepatobiliary Disorders hepatic failure fatal jaundice serious cases of abnormal,1
ULORIC,fatal,disorder,0
ULORIC,fatal,fatal jaundice serious cases,1
ULORIC,jaundice,jaundice serious cases of abnormal,1
ULORIC,jaundice,jaundice serious cases of,1
ULORIC,jaundice,jaundice serious,1
ULORIC,jaundice,jaundice serious,1
ULORIC,jaundice,jaundice serious,1
ULORIC,jaundice,jaundice,1
ULORIC,jaundice,jaundice serious cases of,1
ULORIC,abnormal liver function,fatal,0
ULORIC,liver disorder,function test liver,1
ULORIC,liver disorder,results,0
ULORIC,liver disorder,System Disorders anaphylaxis,0
ULORIC,liver disorder,liver disorder Immune System Disorders anaphylaxis anaphylactic,1
ULORIC,liver disorder,liver disorder Immune System Disorders anaphylaxis anaphylactic,1
ULORIC,liver disorder,anaphylactic reaction Musculoskeletal and Conn,0
ULORIC,liver disorder,test liver disorder Immune,1
ULORIC,liver disorder,anaphylactic reaction Musculoskeletal and Conn,0
ULORIC,anaphylaxis,Musculoskeletal and Connective Tissue Disorders,0
ULORIC,anaphylaxis,reaction Musculoskeletal and Connective Tissue Disorders,0
ULORIC,anaphylaxis,Tissue Disorders,0
ULORIC,anaphylactic reaction,Immune System Disorders anaphylactic reaction Musculoskeletal and Connective,1
ULORIC,anaphylactic reaction,Tissue Disorders,0
ULORIC,anaphylactic reaction,Disorders anaphylactic reaction Musculoskeletal,1
ULORIC,anaphylactic reaction,Tissue Disorders,0
ULORIC,anaphylactic reaction,disorder Immune,0
ULORIC,anaphylactic reaction,results liver disorder Immune System Disorders anaphylaxis,0
ULORIC,anaphylactic reaction,rhabdomyolysis,0
ULORIC,rhabdomyolysis,Musculoskeletal and Connective Tissue rhabdomyolysis Psychiatric Disorders psychotic behavior,1
ULORIC,rhabdomyolysis,rhabdomyolysis,0
ULORIC,rhabdomyolysis,Connective Tissue rhabdomyolysis Psychiatric,1
ULORIC,rhabdomyolysis,rhabdomyolysis,0
ULORIC,rhabdomyolysis,rhabdomyolysis Psychiatric Disorders psychotic behavior,1
ULORIC,rhabdomyolysis,rhabdomyolysis,0
ULORIC,rhabdomyolysis,rhabdomyolysis Psychiatric Disorders,1
ULORIC,rhabdomyolysis,rhabdomyolysis,1
ULORIC,rhabdomyolysis,Connective Tissue Disorders,0
ULORIC,rhabdomyolysis,rhabdomyolysis Psychiatric Disorders psychotic,1
ULORIC,rhabdomyolysis,rhabdomyolysis Psychiatric Disorders psychotic,1
ULORIC,rhabdomyolysis,rhabdomyolysis Psychiatric Disorders psychotic,1
ULORIC,psychotic behavior,Tissue Disorders rhabdomyolysis Psychiatric psychotic behavior,1
ULORIC,psychotic behavior,psychotic behavior,1
ULORIC,psychotic behavior,rhabdomyolysis Psychiatric psychotic behavior including aggressive thoughts Renal and,1
ULORIC,psychotic behavior,psychotic behavior,1
ULORIC,psychotic behavior,psychotic,1
ULORIC,psychotic behavior,Tissue Disorders rhabdomyolysis Psychiatric psychotic,1
ULORIC,psychotic behavior,rhabdomyolysis Psychiatric,0
ULORIC,psychotic behavior,aggressive thoughts Renal and Urinary,0
ULORIC,psychotic behavior,Tissue Disorders rhabdomyolysis Psychiatric psychotic behavior including aggressive thoughts,1
ULORIC,psychotic behavior,aggressive thoughts Renal and Urinary,0
ULORIC,psychotic behavior,Renal and,0
ULORIC,psychotic behavior,psychotic behavior,1
ULORIC,tubulointerstitial nephritis,tubulointerstitial nephritis Skin and Subcutaneous Tissue,1
ULORIC,tubulointerstitial nephritis,Renal and Urinary,0
ULORIC,tubulointerstitial nephritis,tubulointerstitial nephritis,1
ULORIC,tubulointerstitial nephritis,tubulointerstitial nephritis Skin and Subcutaneous,1
ULORIC,tubulointerstitial nephritis,tubulointerstitial nephritis Skin and,1
ULORIC,tubulointerstitial nephritis,Renal and Urinary tubulointerstitial nephritis,1
ULORIC,tubulointerstitial nephritis,Johnson,0
ULORIC,tubulointerstitial nephritis,Urinary tubulointerstitial nephritis Skin and Subcutaneous Tissue Disorders,1
ULORIC,tubulointerstitial nephritis,Johnson,0
ULORIC,tubulointerstitial nephritis,Disorders psychotic behavior including aggressive thoughts Renal and Urinary Disorders,0
ULORIC,tubulointerstitial nephritis,Subcutaneous Tissue Disorders generalized rash Stevens Johnson,0
ULORIC,generalized rash,generalized rash Stevens Johnson Syndrome hypersensitivity skin,1
ULORIC,generalized rash,Stevens,0
ULORIC,generalized rash,Skin and Subcutaneous Tissue generalized rash Stevens Johnson,1
ULORIC,generalized rash,Stevens,0
ULORIC,generalized rash,generalized rash Stevens Johnson Syndrome hypersensitivity,1
ULORIC,generalized rash,Stevens,0
ULORIC,generalized rash,Skin and Subcutaneous Tissue generalized,1
ULORIC,generalized rash,generalized rash Stevens,1
ULORIC,generalized rash,Skin and Subcutaneous Tissue generalized rash Stevens Johnson Syndrome hypersensitivity skin,1
ULORIC,generalized rash,generalized rash Stevens,1
ULORIC,Stevens Johnson Syndrome,hypersensitivity skin,0
ULORIC,Stevens Johnson Syndrome,hypersensitivity,0
ULORIC,Stevens Johnson Syndrome,hypersensitivity skin,0
ULORIC,Stevens Johnson Syndrome,and Subcutaneous Tissue,0
ULORIC,Gout Flare,Adverse  occurring in at least of ULORICtreated,1
ULORIC,Gout Flare,and Subcutaneous Tissue,0
ULORIC,Gout Flare, occurring in at least of,1
ULORIC,Gout Flare, occurring in at least of,1
ULORIC,Gout Flare,EXCERPT Adverse  occurring in at least of,1
ULORIC,Gout Flare, occurring in at least of,1
ULORIC,Gout Flare, occurring in at least,1
ULORIC,Gout Flare, occurring in at least of,1
ULORIC,Gout Flare,are liver,0
ULORIC,Gout Flare,least greater than placebo are liver,0
ULORIC,Gout Flare,of ULORICtreated patients and at,0
ULORIC,Gout Flare, occurring in at,1
ULORIC,Gout Flare,ADVERSE REACTIONS EXCERPT Adverse  occurring in at least of,1
ULORIC,Gout Flare, occurring in at,1
ULORIC,gout flares, ULORIC-tre,1
ULORIC,gout flares, ULORIC-tre ated patients,1
ULORIC,gout flares,least  ULORIC-tre,1
ULORIC,gout flares, ULORIC-tre ated patients,1
ULORIC,gout flares, ULORIC-tre ated patients and at least,1
ULORIC,Cardiovascular Events,wwwfdagovmedwatch Clinical Trials Experience ause clinical trials  are,1
ULORIC,Cardiovascular Events, ULORIC-tre ated patients and at least,1
ULORIC,Cardiovascular Events,ause clinical,1
ULORIC,Cardiovascular Events,Clinical Trials Experience ause clinical,1
ULORIC,Cardiovascular Events,Clinical Trials Experience ause clinical trials,1
ULORIC,Cardiovascular Events,wwwfdagovmedwatch Clinical Trials Experience ause clinical,1
ULORIC,Cardiovascular Events,observed in the clinical trial,0
ULORIC,cardiovascular thromboembolic events,"conditions, adverse r",1
ULORIC,Hepatic Effects,to rates in the,0
ULORIC,Hepatic Effects,the rates obs erved in practice,1
ULORIC,Hepatic Effects,total of subjects with hyperuricemia and gout were treated with ULORIC,0
ULORIC,Hepatic Effects,clinical trials of another drug,0
ULORIC,Hepatic Effects,drug and may not t the rates obs erved in practice A total,1
ULORIC,Hepatic Effects,clinical trials of another drug,0
ULORIC,hepatic failure,tal of 2757 sub jects with hyperuricemia and gout,1
ULORIC,hepatic failure,observed in practice A to,0
ULORIC,hepatic failure,practice A tal of,1
ULORIC,hepatic failure,in practice A tal,1
ULORIC,fatal,yperu ricemia and gout were,1
ULORIC,fatal,in practice A tal,1
ULORIC,fatal,another drug and may not reflect the rates observed in practice A total of subjects with,0
ULORIC,fatal,and gout were treated with ULORIC mg or mg daily in clinical studies For ULORIC,0
ULORIC,gout flares,controlled linical stu,1
ULORIC,gout flares,linical stu,1
ULORIC,gout flares,In three randomized controlled linical stu dies Studies,1
ULORIC,gout flares,linical stu,1
ULORIC,cardiovascular thromboembolic events,Placebo ULORIC allopurinolO,0
ULORIC,cardiovascular thromboembolic events,Greater than Seen in Receiving Placebo in Controlled Stud ies Adverse,1
ULORIC,cardiovascular thromboembolic events,Placebo ULORIC allopurinolO,0
ULORIC,cardiovascular thromboembolic events,Greater than Seen in Receiving Placebo,1
ULORIC,cardiovascular deaths,Controlled s Adverse React,1
ULORIC,cardiovascular deaths,ions Placebo ULORIC allopurinolOf,0
ULORIC,cardiovascular deaths,in Controlled s,1
ULORIC,cardiovascular deaths,s Adverse React,1
ULORIC,myocardial infarctions,Studies Adverse       Placebo          ULORIC allopurinolOf the subjects,1
ULORIC,myocardial infarctions,s Adverse React,1
ULORIC,myocardial infarctions,ULORIC allopurinolOf,0
ULORIC,myocardial infarctions,allopurinolOf,0
ULORIC,myocardial infarctions,      Placebo          ULORIC,1
ULORIC,myocardial infarctions,Patients Receiving,0
ULORIC,myocardial infarctions,      Placebo          ULORIC allopurinolOf the subjects,1
ULORIC,myocardial infarctions,Adverse,0
ULORIC,myocardial infarctions,      Placebo          ULORIC allopurinolOf the,1
ULORIC,myocardial infarctions,Placebo in Controlled,0
ULORIC,strokes,Placebo LORIC   allopurinolOf,1
ULORIC,strokes,Placebo in Controlled,0
ULORIC,strokes,Controlled Studies Adverse Reactions,0
ULORIC,strokes,Adverse Reactions Placebo LORIC   allopurinolOf the subjects who,1
ULORIC,strokes,Controlled Studies Adverse Reactions,0
ULORIC,strokes,allopurinol received mg received,0
ULORIC,strokes,U,0
ULORIC,strokes,received mg received mg,0
ULORIC,strokes,allopurinol,0
ULORIC,strokes,received allopurinol received mg,0
ULORIC,strokes,LORIC  ,1
ULORIC,strokes,received allopurinol received mg,0
KYPROLIS,Cardiac Toxicities,Cardiac Toxicities see Warnings and,1
KYPROLIS,Cardiac Toxicities,other sections of the Cardiac Toxicities see Warnings and Precautions Acute,1
KYPROLIS,Cardiac Toxicities,Cardiac Toxicities see Warnings and,1
KYPROLIS,Cardiac Toxicities,sections of the,0
KYPROLIS,Cardiac Toxicities,in other,0
KYPROLIS,Cardiac Toxicities,other sections of the Cardiac Toxicities,1
KYPROLIS,Cardiac Toxicities,in other,0
KYPROLIS,Cardiac Toxicities,Cardiac Toxicities see,1
KYPROLIS,Cardiac Toxicities,Cardiac Toxicities see,1
KYPROLIS,Cardiac Toxicities,Cardiac,1
KYPROLIS,Cardiac Toxicities,the Cardiac,1
KYPROLIS,Cardiac Toxicities,sections of the Cardiac Toxicities,1
KYPROLIS,Cardiac Toxicities,the Cardiac,1
KYPROLIS,Acute Renal Failure,Toxicities see Warnings and Acute Renal Failure,1
KYPROLIS,Acute Renal Failure,the Cardiac,1
KYPROLIS,Acute Renal Failure,Renal Failure see Warnings,1
KYPROLIS,Acute Renal Failure,Warnings and Acute Renal Failure see,1
KYPROLIS,Acute Renal Failure,Renal Failure see Warnings,1
KYPROLIS,Acute Renal Failure,Acute Renal Failure see Warnings and Precautions,1
KYPROLIS,Acute Renal Failure,Renal Failure see Warnings,1
KYPROLIS,Acute Renal Failure,Precautions,0
KYPROLIS,Acute Renal Failure,see Warnings and Precautio,0
KYPROLIS,Tumor Lysis Syndrome,and Tumor Lysis Syndrome see Warnings and Precautions,1
KYPROLIS,Tumor Lysis Syndrome,see Warnings and Precautio,0
KYPROLIS,Tumor Lysis Syndrome,Warnings and Precautions,0
KYPROLIS,Tumor Lysis Syndrome,Warnings and Tumor Lysis Syndrome see,1
KYPROLIS,Tumor Lysis Syndrome,Warnings and Precautions,0
KYPROLIS,Tumor Lysis Syndrome,Warnings and Precautions,0
KYPROLIS,Tumor Lysis Syndrome,and,0
KYPROLIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings,1
KYPROLIS,Pulmonary Toxicity,Warnings and Pulmonary Toxicity see,1
KYPROLIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings,1
KYPROLIS,Pulmonary Toxicity,Hypertension see Warnings and Precaut,0
KYPROLIS,Pulmonary Toxicity,see Warnings and,0
KYPROLIS,Pulmonary Toxicity,Syndrome see Warnings and Pulmonary Toxicity,1
KYPROLIS,Pulmonary Toxicity,see Warnings and Pulmonary,1
KYPROLIS,Pulmonary Toxicity,Syndrome see Warnings and Pulmonary,1
KYPROLIS,Pulmonary Toxicity,Pulmonary,1
KYPROLIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and Precautions,1
KYPROLIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and,1
KYPROLIS,Pulmonary Hypertension,Toxicity see Warnings and Pulmonary,1
KYPROLIS,Pulmonary Hypertension,and Pulmonary Hypertension,1
KYPROLIS,Pulmonary Hypertension,Pulmonary Hypertension see Warnings and,1
KYPROLIS,Pulmonary Hypertension,Pulmonary Hypertension see Warnings and Precautions,1
KYPROLIS,Pulmonary Hypertension,Precautions Dyspnea see Warnings and,0
KYPROLIS,Pulmonary Hypertension,and Pulmonary,1
KYPROLIS,Pulmonary Hypertension,Warnings,0
KYPROLIS,Dyspnea,Dyspnea see Warnings and,1
KYPROLIS,Dyspnea,Hypertension,0
KYPROLIS,Dyspnea,Dyspnea see,1
KYPROLIS,Hypertension,Hypertension see,1
KYPROLIS,Hypertension,Warnings and Precautions,0
KYPROLIS,Hypertension,Dyspnea see Warnings and Hypertension see Warnings and Precautions Venous,1
KYPROLIS,Hypertension,Warnings and Precautions,0
KYPROLIS,Hypertension,Hypertension,1
KYPROLIS,Hypertension,Dyspnea see,0
KYPROLIS,Hypertension,Hypertension see Warnings and Precautions,1
KYPROLIS,Hypertension,Dyspnea see,0
KYPROLIS,Hypertension,Hypertension see Warnings and,1
KYPROLIS,Hypertension,Hypertension see Warnings and Precautions Venous,1
KYPROLIS,Hypertension,Hypertension see Warnings and,1
KYPROLIS,Venous Thrombosis,see Warnings and Venous Thrombosis,1
KYPROLIS,Venous Thrombosis,Hypertension see Warnings and,1
KYPROLIS,Venous Thrombosis,Venous Thrombosis,1
KYPROLIS,Infusion Reactions,see Warnings,0
KYPROLIS,Infusion Reactions,Venous Thrombosis see Warnings and,0
KYPROLIS,Thrombocytopenia,Reactions see Warnings and Thrombocytopenia see Warnings and Precautions,1
KYPROLIS,Thrombocytopenia,Venous Thrombosis see Warnings and,0
KYPROLIS,Thrombocytopenia,Thrombocytopenia see Warnings,1
KYPROLIS,Hepatic Toxicity,Hepatic Toxicity and Hepatic Failure,1
KYPROLIS,Hepatic Toxicity,see Warnings and Hepatic,1
KYPROLIS,Hepatic Toxicity,Hepatic Toxicity and Hepatic Failure,1
KYPROLIS,Hepatic Toxicity,see Warnings and Hepatic Toxicity and Hepatic Failure,1
KYPROLIS,Hepatic Toxicity,Hepatic Toxicity and Hepatic Failure,1
KYPROLIS,Hepatic Toxicity,Warnings and Hepatic Toxicity,1
KYPROLIS,Hepatic Toxicity,Hepatic Toxicity and Hepatic Failure,1
KYPROLIS,Hepatic Toxicity,Hepatic Toxicity and Hepatic,1
KYPROLIS,Hepatic Toxicity,cautions Thrombocytopenia see Warnings and Precautions,0
KYPROLIS,Hepatic Toxicity,Thrombocytopenia see Warnings and Hepatic Toxicity,1
KYPROLIS,Hepatic Failure,Toxicity Hepatic Failure,1
KYPROLIS,Hepatic Failure,Toxicity,0
KYPROLIS,Hepatic Failure,see Warnings and,0
KYPROLIS,Thrombotic Thrombocytopenic Purpura,see Warnings and Thrombotic Thrombocytopenic Purpura,1
KYPROLIS,Thrombotic Thrombocytopenic Purpura,see Warnings and,0
KYPROLIS,Hemolytic Uremic Syndrome,see Warnings and Precautions Thrombotic Thrombocytopenic Purpura,0
KYPROLIS,Hemolytic Uremic Syndrome,and Precautions Posterior Reversible,0
KYPROLIS,Hemolytic Uremic Syndrome,Warnings and,0
KYPROLIS,Hemolytic Uremic Syndrome,Thrombocytopenic Hemolytic Uremic,1
KYPROLIS,Hemolytic Uremic Syndrome,Hemolytic Uremic Syndrome see,1
KYPROLIS,Hemolytic Uremic Syndrome,Hemolytic Uremic,1
KYPROLIS,Hemolytic Uremic Syndrome,and Precautions Thrombotic Thrombocytopenic Hemolytic Uremic Syndrome see Warnings and Precautions,1
KYPROLIS,Hemolytic Uremic Syndrome,Hemolytic Uremic,1
KYPROLIS,Hemolytic Uremic Syndrome,Failure see Warnings and Precautions,0
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,most common adverse event,0
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,The,0
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Precautions,0
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,and Precautions,0
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,The most common adverse,0
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Posterior Reversible Encephalopathy,1
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Precautions,0
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Syndrome see Warnings and Posterior Reversible Encephalopathy Syndrome,1
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Precautions,0
KYPROLIS,Posterior Reversible Encephalopathy Syndrome,Posterior Reversible Encephalopathy Syndrome PRES see Warnings and,1
KYPROLIS,PRES,common adverse events occu,0
KYPROLIS,fatigue,fatigue thrombocytopenia,1
KYPROLIS,fatigue,common adverse events occu,0
KYPROLIS,fatigue,fatigue,1
KYPROLIS,fatigue,thrombocytopenia nausea pyrexia decreased platelets dyspnea diarrhea,0
KYPROLIS,fatigue,fatigue thrombocytopenia nausea pyrexia,1
KYPROLIS,thrombocytopenia,thrombocytopenia nausea pyrexia decreased platelets dyspnea,1
KYPROLIS,thrombocytopenia,nausea pyrexia decreased platelets dyspnea diarrhea decreased lymphocyte headache decreased,0
KYPROLIS,thrombocytopenia,thrombocytopenia nausea pyrexia decreased,1
KYPROLIS,thrombocytopenia,thrombocytopenia nausea,1
KYPROLIS,thrombocytopenia,thrombocytopenia,1
KYPROLIS,thrombocytopenia,anemia thrombocytopenia,1
KYPROLIS,thrombocytopenia,thrombocytopenia,1
KYPROLIS,nausea,nausea pyrexia decreased platelets dyspnea diarrhea,1
KYPROLIS,nausea,nausea pyrexia,1
KYPROLIS,nausea,monotherapy trials anemia fatigue nausea pyrexia decreased platelets,1
KYPROLIS,nausea,nausea pyrexia,1
KYPROLIS,nausea,nausea,1
KYPROLIS,nausea,diarrhea decreased lymphocyte,0
KYPROLIS,pyrexia,anemia fatigue thrombocytopenia pyrexia decreased platelets dyspnea diarrhea,1
KYPROLIS,pyrexia,diarrhea decreased lymphocyte,0
KYPROLIS,pyrexia,headache,0
KYPROLIS,pyrexia,lymphocyte headache,0
KYPROLIS,decreased platelets,hemoglobin cough edema,0
KYPROLIS,decreased platelets,dyspnea diarrhea decreased,0
KYPROLIS,decreased platelets,thrombocytopenia nausea decreased platelets dyspnea diarrhea decreased lymphocyte headache,1
KYPROLIS,decreased platelets,dyspnea diarrhea decreased,0
KYPROLIS,decreased platelets,Kyprolis,0
KYPROLIS,decreased platelets,decreased platelets dyspnea diarrhea decreased lymphocyte,1
KYPROLIS,decreased platelets,Kyprolis,0
KYPROLIS,decreased platelets,thrombocytopenia nausea decreased platelets dyspnea diarrhea decreased,1
KYPROLIS,decreased platelets,Kyprolis,0
KYPROLIS,decreased platelets,decreased platelets dyspnea diarrhea decreased lymphocyte headache,1
KYPROLIS,decreased platelets,hemoglobin cough,0
KYPROLIS,decreased platelets,decreased platelets dyspnea diarrhea,1
KYPROLIS,decreased platelets,decreased platelets dyspnea diarrhea,1
KYPROLIS,dyspnea,dyspnea diarrhea decreased,1
KYPROLIS,dyspnea,dyspnea diarrhea decreased,1
KYPROLIS,dyspnea,pyrexia decreased dyspnea diarrhea,1
KYPROLIS,dyspnea,dyspnea diarrhea decreased,1
KYPROLIS,dyspnea,decreased dyspnea diarrhea decreased lymphocyte,1
KYPROLIS,dyspnea,dyspnea diarrhea decreased,1
KYPROLIS,dyspnea,pyrexia,0
KYPROLIS,diarrhea,thrombocytopenia nausea pyrexia decreased platelets dyspnea,0
KYPROLIS,diarrhea,decreased hemoglobin cough edema peripheral The,0
KYPROLIS,diarrhea,notherapy trials anemia fatigue thrombocytopenia nausea pyrexia,0
KYPROLIS,diarrhea,edema peripheral The,0
KYPROLIS,diarrhea,diarrhea decreased lymphocyte headache,1
KYPROLIS,diarrhea,diarrhea decreased lymphocyte headache decreased hemoglobin,1
KYPROLIS,diarrhea,pyrexia decreased platelets diarrhea decreased lymphocyte headache decreased,1
KYPROLIS,diarrhea,diarrhea decreased lymphocyte headache decreased hemoglobin,1
KYPROLIS,decreased lymphocyte,headache decreased hemoglobin cough edema,0
KYPROLIS,decreased lymphocyte,decreased lymphocyte headache,1
KYPROLIS,decreased lymphocyte,common adverse even,0
KYPROLIS,decreased lymphocyte,decreased lymphocyte,1
KYPROLIS,decreased lymphocyte,decreased lymphocyte headache decreased hemoglobin cough edema,1
KYPROLIS,decreased lymphocyte,most common adverse even,0
KYPROLIS,decreased lymphocyte,platelets dyspnea decreased lymphocyte headache,1
KYPROLIS,decreased lymphocyte,most common adverse even,0
KYPROLIS,headache,headache decreased hemoglobin cough edema,1
KYPROLIS,headache,decreased headache decreased hemoglobin,1
KYPROLIS,headache,headache decreased hemoglobin cough edema,1
KYPROLIS,headache,headache,1
KYPROLIS,headache,decreased,0
KYPROLIS,headache,adverse,0
KYPROLIS,headache,headache,1
KYPROLIS,headache,edema peripheral The most common,0
KYPROLIS,decreased hemoglobin,at least of,0
KYPROLIS,decreased hemoglobin,edema peripheral The most common adverse,0
KYPROLIS,decreased hemoglobin,lymphocyte decreased hemoglobin cough edema,1
KYPROLIS,decreased hemoglobin,edema peripheral The most common adverse,0
KYPROLIS,decreased hemoglobin,decreased hemoglobin cough edema peripheral The most,1
KYPROLIS,cough,headache decreased cough edema peripheral The,1
KYPROLIS,cough,decreased hemoglobin cough edema peripheral The most,1
KYPROLIS,cough,cough edema peripheral The most,1
KYPROLIS,cough,decreased hemoglobin cough edema peripheral The most,1
KYPROLIS,edema peripheral,decreased hemoglobin edema peripheral,1
KYPROLIS,edema peripheral,decreased hemoglobin cough edema peripheral The most,1
KYPROLIS,edema peripheral,hemoglobin edema peripheral The most common,1
KYPROLIS,edema peripheral,decreased hemoglobin cough edema peripheral The most,1
KYPROLIS,edema peripheral,The most common adverse events occurring in at least of,0
KYPROLIS,decreased lymphocytes,neutropenia decreased total,0
KYPROLIS,decreased absolute neutrophil count,the combination therapy trial decreased,0
KYPROLIS,decreased absolute neutrophil count,patients treated with Kyprolis in,0
KYPROLIS,decreased phosphorus,platelets diarrhea fatigu,0
KYPROLIS,decreased phosphorus,decreased phosphorus,1
KYPROLIS,decreased phosphorus,platelets diarrhea fatigu,0
KYPROLIS,decreased phosphorus,lymphocytes decreased absolute neutrophil decreased phosphorus anemia neutropenia,1
KYPROLIS,decreased phosphorus,platelets diarrhea fatigu,0
KYPROLIS,decreased phosphorus,decreased phosphorus anemia neutropenia decreased total,1
KYPROLIS,decreased phosphorus,decreased total white blood cell count decreased platelets,0
KYPROLIS,decreased phosphorus,neutropenia decreased total white blood cell count,0
KYPROLIS,decreased phosphorus,decreased phosphorus anemia neutropenia decreased total,1
KYPROLIS,decreased phosphorus,decreased,1
KYPROLIS,anemia,anemia neutropenia decreased total white,1
KYPROLIS,anemia,decreased,1
KYPROLIS,anemia,count decreased anemia neutropenia decreased total white blood,1
KYPROLIS,anemia,decreased,1
KYPROLIS,neutropenia,anemia,0
KYPROLIS,neutropenia,count decreased,0
KYPROLIS,decreased total white blood cell count,neutrophil count decreased phosphorus anemia neutropenia,0
KYPROLIS,decreased platelets,decreased platelets,1
KYPROLIS,decreased platelets,neutrophil count decreased phosphorus anemia neutropenia,0
KYPROLIS,decreased platelets,cell decreased platelets diarrhea fatigue,1
KYPROLIS,decreased platelets,neutrophil count decreased phosphorus anemia neutropenia,0
KYPROLIS,decreased platelets,total white blood cell decreased,1
KYPROLIS,decreased platelets,eutrophil,0
KYPROLIS,decreased platelets,cell decreased platelets diarrhea fatigue thrombocytopenia,1
KYPROLIS,decreased platelets,eutrophil,0
KYPROLIS,decreased platelets,count,0
KYPROLIS,decreased platelets,cough upper respiratory tract infecti,0
KYPROLIS,decreased platelets,decreased platelets diarrhea,1
KYPROLIS,decreased platelets,cough upper respiratory tract infecti,0
KYPROLIS,decreased platelets,blood cell decreased,1
KYPROLIS,decreased platelets,cell decreased,1
KYPROLIS,diarrhea,decreased,0
KYPROLIS,diarrhea,count decreased,0
KYPROLIS,diarrhea,diarrhea fatigue thrombocytopenia,1
KYPROLIS,diarrhea,diarrhea fatigue,1
KYPROLIS,fatigue,cough,0
KYPROLIS,fatigue,fatigue thrombocytopenia pyrexia,1
KYPROLIS,fatigue,fatigue thrombocytopenia,1
KYPROLIS,fatigue,thrombocytopenia pyrexia muscle spasm cough upper respiratory tract infection,0
KYPROLIS,fatigue,respiratory tract infection decreased hemog,0
KYPROLIS,fatigue,cough upper respiratory,0
KYPROLIS,thrombocytopenia,thrombocytopenia pyrexia muscle spasm,1
KYPROLIS,thrombocytopenia,count decreased platelets diarrhea thrombocytopenia pyrexia muscle,1
KYPROLIS,thrombocytopenia,thrombocytopenia pyrexia muscle spasm,1
KYPROLIS,thrombocytopenia,thrombocytopenia pyrexia muscle spasm,1
KYPROLIS,thrombocytopenia,decreased platelets diarrhea thrombocytopenia pyrexia muscle spasm,1
KYPROLIS,thrombocytopenia,thrombocytopenia pyrexia muscle spasm,1
KYPROLIS,thrombocytopenia,decreased hemoglobin hypokalemia,0
KYPROLIS,pyrexia,pyrexia muscle,1
KYPROLIS,pyrexia,cough upper respiratory,0
KYPROLIS,pyrexia,platelets diarrhea fatigue pyrexia muscle spasm cough,1
KYPROLIS,pyrexia,cough upper respiratory,0
KYPROLIS,pyrexia,pyrexia muscle spasm,1
KYPROLIS,pyrexia,decreased platelets diarrhea fatigue thrombocytopenia,0
KYPROLIS,pyrexia,muscle spasm cough upper respiratory tract infection decreased hemoglobin hypokalemia,0
KYPROLIS,pyrexia,pyrexia muscle,1
KYPROLIS,muscle spasm,muscle spasm,1
KYPROLIS,muscle spasm,diarrhea fatigue thrombocytopenia muscle spasm cough upper respiratory,1
KYPROLIS,muscle spasm,muscle spasm,1
KYPROLIS,muscle spasm,diarrhea fatigue thrombocytopenia muscle spasm cough,1
KYPROLIS,muscle spasm,muscle spasm,1
KYPROLIS,muscle spasm,hemoglobin,0
KYPROLIS,muscle spasm,muscle spasm cough upper respiratory tract,1
KYPROLIS,muscle spasm,hemoglobin,0
KYPROLIS,muscle spasm,diarrhea fatigue thrombocytopenia muscle spasm,1
KYPROLIS,cough,To report,0
KYPROLIS,cough,cough upper,1
KYPROLIS,cough,To report,0
KYPROLIS,cough,diarrhea fatigue thrombocytopenia pyrexia muscle spasm,0
KYPROLIS,cough,cough upper respiratory,1
KYPROLIS,cough,count decreased platelets diarrhea fatigue thrombocytopenia pyrexia muscle,0
KYPROLIS,upper respiratory tract infection,muscle spasm upper respiratory tract infection decreased,1
KYPROLIS,upper respiratory tract infection,count decreased platelets diarrhea fatigue thrombocytopenia pyrexia muscle,0
KYPROLIS,upper respiratory tract infection,thrombocytopenia pyrexia muscle spasm upper respiratory tract infection,1
KYPROLIS,upper respiratory tract infection,count decreased platelets diarrhea fatigue thrombocytopenia pyrexia muscle,0
KYPROLIS,upper respiratory tract infection,muscle spasm upper respiratory tract infection,1
KYPROLIS,upper respiratory tract infection,thrombocytopenia pyrexia muscle spasm upper respiratory tract infection decreased hemoglobin hypokalemia To,1
KYPROLIS,upper respiratory tract infection,muscle spasm upper respiratory tract infection,1
KYPROLIS,upper respiratory tract infection,upper respiratory,1
KYPROLIS,upper respiratory tract infection,decreased hemoglobin,0
KYPROLIS,upper respiratory tract infection,muscle spasm upper respiratory tract infection,1
KYPROLIS,upper respiratory tract infection,decreased hemoglobin,0
KYPROLIS,upper respiratory tract infection,diarrhea fatigue,0
KYPROLIS,upper respiratory tract infection,SUSPECTED ADVERSE REACTIONS contact,0
KYPROLIS,upper respiratory tract infection,thrombocytopenia pyrexia muscle spasm upper respiratory tract infection decreased,1
KYPROLIS,upper respiratory tract infection,SUSPECTED ADVERSE REACTIONS contact,0
KYPROLIS,decreased hemoglobin,spasm cough,0
KYPROLIS,hypokalemia,hypokalemia To report SUSPECTED ADVERSE REACTIONS,1
KYPROLIS,hypokalemia,hypokalemia To report,1
KYPROLIS,Deaths,Rd Deaths due to,1
KYPROLIS,Deaths,hypokalemia To report,1
KYPROLIS,Deaths,Deaths due,1
KYPROLIS,Deaths,Deaths due to,1
KYPROLIS,Deaths,Deaths due to adverse,1
KYPROLIS,Deaths,Deaths due to,1
KYPROLIS,died,died due to,1
KYPROLIS,died,with patients died due to adverse events,1
KYPROLIS,died,died due to,1
KYPROLIS,died,died due to adverse,1
KYPROLIS,died,died,1
KYPROLIS,died,who,0
KYPROLIS,died,arm occurred in patients,0
KYPROLIS,died,patients died,1
KYPROLIS,died,arm occurred in patients,0
KYPROLIS,deaths,the last dose of any Rd therapy The,0
KYPROLIS,deaths,deaths occurring,1
KYPROLIS,deaths,of,0
KYPROLIS,deaths,cause deaths occurring,1
KYPROLIS,deaths,of,0
KYPROLIS,deaths,deaths occurring in patients in the,1
KYPROLIS,deaths,any Rd therapy The most,0
KYPROLIS,deaths,of the last dose of,0
KYPROLIS,deaths,Rd therapy The most common,0
KYPROLIS,pneumonia,pneumonia versus respiratory tract infection versus,1
KYPROLIS,pneumonia,arm pneumonia versus,1
KYPROLIS,pneumonia,pneumonia versus respiratory tract infection versus,1
KYPROLIS,pneumonia,pneumonia versus respiratory tract infection,1
KYPROLIS,pneumonia,pneumonia versus respiratory tract infection,1
KYPROLIS,pneumonia,events reported in the KRd arm as compared with the Rd,0
KYPROLIS,pneumonia,common serious adverse events reported in,0
KYPROLIS,pneumonia,arm pneumonia versus respiratory,1
KYPROLIS,pneumonia,common serious adverse events reported in,0
KYPROLIS,pneumonia,tract infection versus,0
KYPROLIS,pneumonia,pneumonia versus,1
KYPROLIS,pneumonia,infection versus pyrexia,0
KYPROLIS,respiratory tract infection,respiratory tract infection versus,1
KYPROLIS,pyrexia,infection,0
KYPROLIS,pyrexia,infection pyrexia versus and pulmonary,1
KYPROLIS,pyrexia,infection,0
KYPROLIS,pyrexia,tract,0
KYPROLIS,pyrexia,pyrexia,1
KYPROLIS,pyrexia,tract,0
KYPROLIS,pyrexia,infection pyrexia versus and,1
KYPROLIS,pyrexia,tract,0
KYPROLIS,pyrexia,pyrexia versus and pulmonary embolism,1
KYPROLIS,pyrexia,tract,0
KYPROLIS,pyrexia,tract infection pyrexia versus and pulmonary,1
KYPROLIS,pyrexia,tract,0
KYPROLIS,pyrexia,pyrexia versus and pulmonary,1
KYPROLIS,pulmonary embolism,event occurred in,0
KYPROLIS,pulmonary embolism,pulmonary embolism versus Discontinuation due to,1
KYPROLIS,pulmonary embolism,infection versus pyrexia versus pulmonary,1
KYPROLIS,pulmonary embolism,infection versus pyrexia versus pulmonary embolism,1
KYPROLIS,pulmonary embolism,versus,0
KYPROLIS,pneumonia,pneumonia myocardial,1
KYPROLIS,pneumonia,pneumonia myocardial infarction and,1
KYPROLIS,myocardial infarction,myocardial infarction and upper respiratory,1
KYPROLIS,myocardial infarction,pneumonia myocardial infarction and,1
KYPROLIS,myocardial infarction,myocardial infarction and upper,1
KYPROLIS,myocardial infarction,of Kyprolis occurred,0
KYPROLIS,myocardial infarction,common events included myocardial infarction,1
KYPROLIS,myocardial infarction,included myocardial infarction and upper respiratory,1
KYPROLIS,myocardial infarction,common events included myocardial infarction,1
KYPROLIS,myocardial infarction,and the most common events included pneumonia,0
KYPROLIS,myocardial infarction,most common events included myocardial infarction and upper respiratory,1
KYPROLIS,myocardial infarction,and the most common events included pneumonia,0
KYPROLIS,myocardial infarction,tract infection Common,0
KYPROLIS,myocardial infarction,common events included myocardial infarction,1
KYPROLIS,upper respiratory tract infection,and,0
KYPROLIS,upper respiratory tract infection,included pneumonia myocardial infarction upper respiratory tract,1
KYPROLIS,upper respiratory tract infection,patients,0
KYPROLIS,upper respiratory tract infection,respiratory tract infection Common Adverse Events The adverse,1
KYPROLIS,upper respiratory tract infection,most,0
KYPROLIS,upper respiratory tract infection,upper respiratory tract infection Common,1
KYPROLIS,upper respiratory tract infection,most,0
KYPROLIS,Pneumonia,lenalidomide and,0
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,Pneumonia,Pneumonia includes preferred terms,1
KYPROLIS,Pneumonia,Pneumonia includes preferred,1
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,Pneumonia,Pneumonia includes,1
KYPROLIS,Pneumonia,dexamethasone Pneumonia includes preferred terms of pneumonia,1
KYPROLIS,Pneumonia,Pneumonia includes,1
KYPROLIS,Pneumonia,lenalidomide and lowdose dexamethasone a,0
KYPROLIS,Pneumonia,Pneumonia includes preferred terms of,1
KYPROLIS,Pneumonia,includes preferred,0
KYPROLIS,pneumonia,Pneumonia includes preferred terms pneumonia bronchopneumonia,1
KYPROLIS,pneumonia,includes preferred,0
KYPROLIS,pneumonia,Rd lenalidomide and lowdose dexamethasone a Pneumonia includes,0
KYPROLIS,pneumonia,pneumonia bronchopneumonia b Peripheral,1
KYPROLIS,pneumonia,pneumonia bronchopneumonia,1
KYPROLIS,pneumonia,pneumonia bronchopneumonia b,1
KYPROLIS,bronchopneumonia,includes preferred terms of bronchopneumonia,1
KYPROLIS,bronchopneumonia,pneumonia bronchopneumonia b,1
KYPROLIS,Peripheral neuropathies NEC,neuropathies NEC includes preferred terms,1
KYPROLIS,Peripheral neuropathies NEC,terms,0
KYPROLIS,Peripheral neuropathies NEC,peripheral neuropathies NEC,0
KYPROLIS,Peripheral neuropathies NEC,pneumonia bronchopneumonia Peripheral neuropathies,1
KYPROLIS,Peripheral neuropathies NEC,pneumonia bronchopneumonia Peripheral,1
KYPROLIS,Peripheral neuropathies NEC,Peripheral neuropathies NEC includes preferred terms under HLT,1
KYPROLIS,Peripheral neuropathies NEC,Peripheral neuropathies NEC includes preferred terms under,1
KYPROLIS,Peripheral neuropathies NEC,Peripheral neuropathies NEC includes preferred terms under HLT,1
KYPROLIS,Peripheral neuropathies NEC,Peripheral neuropathies NEC includes,1
KYPROLIS,Peripheral neuropathies NEC,pneumonia,0
KYPROLIS,Peripheral neuropathies NEC,terms of pneumonia bronchopneumonia Peripheral neuropathies NEC,1
KYPROLIS,peripheral neuropathies NEC,b Peripheral neuropathies NEC,0
KYPROLIS,peripheral neuropathies NEC,d Embolic,0
KYPROLIS,peripheral neuropathies NEC,includes preferred terms under,0
KYPROLIS,peripheral neuropathies NEC,neuropathies NEC c Dyspnea includes,1
KYPROLIS,peripheral neuropathies NEC,includes preferred terms of dyspnea dyspnea exertional,0
KYPROLIS,Dyspnea,d,0
KYPROLIS,Dyspnea,Dyspnea includes preferred terms of,1
KYPROLIS,Dyspnea,Dyspnea includes,1
KYPROLIS,Dyspnea,includes preferred terms under HLT peripheral neuropathies,0
KYPROLIS,Dyspnea,Dyspnea includes,1
KYPROLIS,Dyspnea,Dyspnea includes,1
KYPROLIS,Dyspnea,terms of dyspnea dyspnea exertional d Embolic and thrombotic events,0
KYPROLIS,Dyspnea,peripheral neuropathies,0
KYPROLIS,Dyspnea,preferred terms under HLT peripheral neuropathies NEC c,0
KYPROLIS,Dyspnea,Dyspnea,1
KYPROLIS,Dyspnea,preferred terms under HLT peripheral neuropathies NEC c,0
KYPROLIS,dyspnea,preferred terms under HLT peripheral neuropathies NEC c Dyspnea includes preferred,0
KYPROLIS,dyspnea,events venous include,0
KYPROLIS,dyspnea,dyspnea dyspnea exertional d Embolic and,1
KYPROLIS,dyspnea,dyspnea dyspnea exertional,1
KYPROLIS,dyspnea,dyspnea dyspnea exertional d Embolic and,1
KYPROLIS,dyspnea exertional,NEC c Dyspnea includes preferred,0
KYPROLIS,dyspnea exertional,thrombotic events venous include preferred terms,0
KYPROLIS,dyspnea exertional,terms of dyspnea exertional d,1
KYPROLIS,dyspnea exertional,thrombotic events venous include preferred terms,0
KYPROLIS,dyspnea exertional,dyspnea exertional d Embolic and thrombotic events,1
KYPROLIS,dyspnea exertional,terms of dyspnea exertional d Embolic,1
KYPROLIS,dyspnea exertional,dyspnea exertional d Embolic and thrombotic events,1
KYPROLIS,"Embolic and thrombotic events, venous",Embolic and thrombotic,1
KYPROLIS,"embolic and thrombotic events, venous",terms in MedDRA,0
KYPROLIS,"embolic and thrombotic events, venous",hypertensive,0
KYPROLIS,"embolic and thrombotic events, venous",preferred terms,0
KYPROLIS,"embolic and thrombotic events, venous","events, venous e",1
KYPROLIS,"embolic and thrombotic events, venous","thrombotic events, venous e Hypertension includes preferred",1
KYPROLIS,"embolic and thrombotic events, venous","embolic and thrombotic events, venous e Hypertension includes",1
KYPROLIS,"embolic and thrombotic events, venous","thrombotic events, venous e Hypertension includes preferred",1
KYPROLIS,Hypertension,venous Hypertension includes preferred terms of hypertension,1
KYPROLIS,Hypertension,"thrombotic events, venous e Hypertension includes preferred",1
KYPROLIS,Hypertension,of hypertension hypertensive,0
KYPROLIS,Hypertension,events venous Hypertension includes preferred terms of,1
KYPROLIS,Hypertension,of hypertension hypertensive,0
KYPROLIS,Hypertension,Hypertension,1
KYPROLIS,Hypertension,of hypertension hypertensive,0
KYPROLIS,Hypertension,venous Hypertension includes preferred,1
KYPROLIS,Hypertension,of hypertension hypertensive,0
KYPROLIS,Hypertension,preferred terms in MedDRA SMQ,0
KYPROLIS,Hypertension,crisis,0
KYPROLIS,Hypertension,hypertensive,0
KYPROLIS,Hypertension,Hypertension,1
KYPROLIS,Hypertension,hypertensive,0
KYPROLIS,Hypertension,Hypertension includes preferred terms of,1
KYPROLIS,hypertensive crisis,venous e,0
KYPROLIS,hypertensive emergency,ArmN Rd ArmN,0
KYPROLIS,hypertensive emergency,hypertensive emergency System Organ Class KRd ArmN,1
KYPROLIS,hypertensive emergency,hypertensive emergency,1
KYPROLIS,hypertensive emergency,hypertensive hypertensive,1
KYPROLIS,hypertensive emergency,venous e,0
KYPROLIS,hypertensive emergency,preferred,0
KYPROLIS,hypertensive emergency,Class,0
KYPROLIS,hypertensive emergency,KRd ArmN Rd,0
KYPROLIS,hypertensive emergency,hypertension hypertensive crisis,0
KYPROLIS,lymphopenia,failure cardiac failure congestive,0
KYPROLIS,cardiac arrest,Cardiac cardiac arrest cardiac failure cardiac,1
KYPROLIS,cardiac arrest,failure cardiac failure congestive,0
KYPROLIS,cardiac arrest,lymphopenia Cardiac cardiac arrest cardiac failure cardiac failure,1
KYPROLIS,cardiac arrest,failure cardiac failure congestive,0
KYPROLIS,cardiac failure,myocardial ischemia,0
KYPROLIS,cardiac failure,cardiac cardiac failure cardiac failure congestive myocardial infarction,1
KYPROLIS,cardiac failure,myocardial ischemia,0
KYPROLIS,cardiac failure,cardiac cardiac failure cardiac failure congestive,1
KYPROLIS,cardiac failure,myocardial ischemia,0
KYPROLIS,cardiac failure congestive,cardiac arrest cardiac cardiac,1
KYPROLIS,cardiac failure congestive,arrest,0
KYPROLIS,myocardial infarction,arrest,0
KYPROLIS,myocardial infarction,cardiac failure cardiac failure congestive,0
KYPROLIS,myocardial infarction,cardiac failure myocardial,1
KYPROLIS,myocardial infarction,cardiac failure,0
KYPROLIS,myocardial infarction,cardiac arrest cardiac failure,0
KYPROLIS,myocardial infarction,blurred Gastrointestinal,0
KYPROLIS,myocardial infarction,ischemia,0
KYPROLIS,myocardial infarction,failure cardiac failure myocardial infarction,1
KYPROLIS,myocardial infarction,ischemia,0
KYPROLIS,myocardial infarction,lymphopenia Cardiac disorders cardiac arrest cardiac failure cardiac,0
KYPROLIS,myocardial ischemia,myocardial,0
KYPROLIS,myocardial ischemia,myocardial ischemia Eye disorders cataract,1
KYPROLIS,myocardial ischemia,myocardial ischemia Eye disorders cataract vision,1
KYPROLIS,myocardial ischemia,Eye disorders cataract vision blurred Gastrointestinal,0
KYPROLIS,myocardial ischemia,cataract,0
KYPROLIS,myocardial ischemia,myocardial ischemia Eye disorders cataract vision,1
KYPROLIS,myocardial ischemia,myocardial ischemia Eye disorders cataract vision blurred,1
KYPROLIS,myocardial ischemia,vision blurred Gastrointestinal disorders,0
KYPROLIS,cataract,lure cardiac failure congestive myocardial infarction myocardial ischemia Eye disorders,0
KYPROLIS,cataract,ischemia Eye cataract vision blurred Gastrointestinal disorders abdominal,1
KYPROLIS,cataract,lure cardiac failure congestive myocardial infarction myocardial ischemia Eye disorders,0
KYPROLIS,cataract,cataract vision blurred Gastrointestinal disorders abdominal,1
KYPROLIS,vision blurred,vision blurred Gastrointestinal disorders,1
KYPROLIS,abdominal pain upper,abdominal pain upper dyspepsia toothache,1
KYPROLIS,abdominal pain upper,vision blurred Gastrointestinal disorders,1
KYPROLIS,abdominal pain upper,abdominal abdominal pain upper,1
KYPROLIS,abdominal pain upper,disorders abdominal abdominal pain,1
KYPROLIS,abdominal pain upper,abdominal pain,1
KYPROLIS,abdominal pain upper,Gastrointestinal disorders abdominal abdominal pain upper dyspepsia toothache General,1
KYPROLIS,abdominal pain upper,abdominal pain,1
KYPROLIS,abdominal pain upper,Gastrointestinal disorders abdominal abdominal pain upper,1
KYPROLIS,abdominal pain upper,conditions,0
KYPROLIS,abdominal pain upper,and administration,0
KYPROLIS,dyspepsia,dyspepsia toothache General,1
KYPROLIS,toothache,upper toothache,1
KYPROLIS,toothache,dyspepsia toothache General,1
KYPROLIS,toothache,toothache,1
KYPROLIS,toothache,toothache General disorders and administration site,1
KYPROLIS,chills,chills infusion site reaction,1
KYPROLIS,chills,and administration site chills infusion site reaction,1
KYPROLIS,chills,chills infusion site reaction,1
KYPROLIS,chills,and infestations influenza,0
KYPROLIS,chills,conditions,0
KYPROLIS,chills,chills infusion,1
KYPROLIS,infusion site reaction,infusion site reaction,1
KYPROLIS,infusion site reaction,site reaction,1
KYPROLIS,infusion site reaction,infusion site reaction multiorgan failure pain Infections and,1
KYPROLIS,infusion site reaction,and administration site conditions infusion site reaction multiorgan,1
KYPROLIS,infusion site reaction,infusion site reaction multiorgan failure pain Infections and,1
KYPROLIS,infusion site reaction,conditions infusion site reaction multiorgan failure,1
KYPROLIS,infusion site reaction,infusion site reaction multiorgan failure pain Infections and,1
KYPROLIS,infusion site reaction,infusion site reaction multiorgan failure pain Infections and,1
KYPROLIS,infusion site reaction,urinary tract in,0
KYPROLIS,infusion site reaction,conditions infusion site reaction,1
KYPROLIS,infusion site reaction,administration site conditions infusion site reaction multiorgan failure,1
KYPROLIS,infusion site reaction,conditions infusion site reaction,1
KYPROLIS,multi-organ failure,chills infusion site multi-organ failure pain Infections and infestations,1
KYPROLIS,multi-organ failure,conditions infusion site reaction,1
KYPROLIS,pain,pain Infections and,1
KYPROLIS,pain,conditions infusion site reaction,1
KYPROLIS,pain,pain Infections,1
KYPROLIS,pain,multiorgan pain Infections and infestations influenza sepsis,1
KYPROLIS,pain,pain Infections,1
KYPROLIS,pain,failure,0
KYPROLIS,influenza,influenza sepsis urinary tract infection viral,1
KYPROLIS,influenza,Infections and influenza sepsis urinary tract,1
KYPROLIS,influenza,influenza sepsis urinary tract infection viral,1
KYPROLIS,influenza,influenza sepsis urinary tract,1
KYPROLIS,influenza,influenza sepsis urinary tract infection viral,1
KYPROLIS,influenza,infusion site reaction multiorgan failure pain,0
KYPROLIS,influenza,Infections and influenza sepsis urinary,1
KYPROLIS,influenza,infusion site reaction multiorgan failure pain,0
KYPROLIS,sepsis,Infections and infestations sepsis urinary tract infection,1
KYPROLIS,sepsis,infusion site reaction multiorgan failure pain,0
KYPROLIS,sepsis,urinary tract infection viral infection Metabolism,0
KYPROLIS,sepsis,infestations sepsis urinary tract,1
KYPROLIS,sepsis,urinary tract infection viral infection Metabolism,0
KYPROLIS,sepsis,site,0
KYPROLIS,sepsis,sepsis urinary tract infection viral infection,1
KYPROLIS,sepsis,site reaction,0
KYPROLIS,viral infection,viral infection Metabolism and nutrition disorders dehydration,1
KYPROLIS,viral infection,viral infection Metabolism and nutrition disorders,1
KYPROLIS,viral infection,dehydration,0
KYPROLIS,viral infection,nutrition disorders dehydration hyperkalemia hyperuricemia,0
KYPROLIS,viral infection,sepsis,0
KYPROLIS,viral infection,pain Infections and infestations influenza sepsis urinary tract infection,0
KYPROLIS,viral infection,and nutrition disorders dehydration,0
KYPROLIS,viral infection,viral infection Metabolism and nutrition disorders,1
KYPROLIS,viral infection,and nutrition disorders dehydration,0
KYPROLIS,viral infection,infestations influenza sepsis urinary tract,0
KYPROLIS,viral infection,hyperkalemia hyperuricemia hypoalbuminem,0
KYPROLIS,dehydration,dehydration hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,dehydration,hypoalbuminemia,0
KYPROLIS,dehydration,dehydration,1
KYPROLIS,dehydration,dehydration hyperkalemia,1
KYPROLIS,dehydration,nutrition,0
KYPROLIS,dehydration,nutrition dehydration,1
KYPROLIS,dehydration,nutrition,0
KYPROLIS,dehydration,dehydration hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,dehydration,dehydration hyperkalemia hyperuricemia hypoalbuminemia hyponatremia,1
KYPROLIS,dehydration,tumor,0
KYPROLIS,dehydration,hyperkalemia hyperuricemia,0
KYPROLIS,hyperkalemia,tumor lysis syndrome Musculoskeletal and,0
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia hyponatremia tumor lysis,1
KYPROLIS,hyperkalemia,urinary tract infection viral,0
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia hyponatremia tumor lysis,1
KYPROLIS,hyperkalemia,tract infection viral infection,0
KYPROLIS,hyperkalemia,Musculoskeletal and con,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperuricemia,disorders dehydration hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperuricemia,dehydration hyperkalemia,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hyponatremia tumor lysis syndrome,1
KYPROLIS,hyperuricemia,disorders dehydration hyperuricemia hypoalbuminemia hyponatremia tumor lysis,1
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hyponatremia tumor lysis syndrome,1
KYPROLIS,hyperuricemia,and connective tissue,0
KYPROLIS,hyperuricemia,lysis syndrome Musculoskeletal and connective tissue,0
KYPROLIS,hyperuricemia,and nutrition disorders dehydration hyperuricemia,1
KYPROLIS,hyperuricemia,lysis syndrome Musculoskeletal and connective tissue,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia,1
KYPROLIS,hypoalbuminemia,hypoalbuminemia hyponatremia tumor lysis syndrome Musculoskeletal,1
KYPROLIS,hypoalbuminemia,and connective,0
KYPROLIS,hyponatremia,syndrome Musculoskeletal and connective tissue,0
KYPROLIS,hyponatremia,hyponatremia tumor lysis,1
KYPROLIS,hyponatremia,Musculoskeletal and connective tissue disorders muscular,0
KYPROLIS,hyponatremia,hyponatremia tumor,1
KYPROLIS,tumor lysis syndrome,tumor lysis syndrome,1
KYPROLIS,tumor lysis syndrome,tumor lysis syndrome,1
KYPROLIS,tumor lysis syndrome,hyperuricemia hypoalbuminemia tumor,1
KYPROLIS,tumor lysis syndrome,weakness myalgia,0
KYPROLIS,tumor lysis syndrome,hyperuricemia hypoalbuminemia tumor lysis syndrome Musculoskeletal and connective,1
KYPROLIS,tumor lysis syndrome,weakness myalgia,0
KYPROLIS,tumor lysis syndrome,tumor lysis syndrome Musculoskeletal and connective tissue,1
KYPROLIS,tumor lysis syndrome,weakness myalgia,0
KYPROLIS,muscular weakness,Nervous system disorders,0
KYPROLIS,muscular weakness,disorders,0
KYPROLIS,muscular weakness,connective tissue muscular,1
KYPROLIS,myalgia,myalgia Nervous system disorders hypoesthesia,1
KYPROLIS,myalgia,connective tissue disorders muscular myalgia Nervous,1
KYPROLIS,myalgia,myalgia Nervous system disorders hypoesthesia,1
KYPROLIS,myalgia,myalgia Nervous system,1
KYPROLIS,myalgia,connective tissue disorders muscular myalgia,1
KYPROLIS,myalgia,myalgia Nervous system,1
KYPROLIS,hypoesthesia,and connective tissue disorders muscular weakness myalgia Nervous system disorders,0
KYPROLIS,hypoesthesia,hypoesthesia paresthesia deafness Psychiatric,1
KYPROLIS,hypoesthesia,hypoesthesia paresthesia deafness,1
KYPROLIS,hypoesthesia,hypoesthesia paresthesia deafness Psychiatric,1
KYPROLIS,hypoesthesia,hypoesthesia paresthesia deafness Psychiatric,1
KYPROLIS,hypoesthesia,hypoesthesia paresthesia deafness Psychiatric,1
KYPROLIS,paresthesia,paresthesia deafness Psychiatric disorders anxiety,1
KYPROLIS,paresthesia,paresthesia deafness,1
KYPROLIS,paresthesia,paresthesia,1
KYPROLIS,paresthesia,ective tissue disorders muscular weakness myalgia Nervous system disorders hypoesthesia,0
KYPROLIS,paresthesia,paresthesia deafness Psychiatric disorders anxiety,1
KYPROLIS,paresthesia,weakness myalgia Nervous,0
KYPROLIS,paresthesia,ective tissue disorders muscular weakness myalgia,0
KYPROLIS,paresthesia,paresthesia deafness Psychiatric,1
KYPROLIS,anxiety,Nervous system disorders hypoesthesia,0
KYPROLIS,renal failure,and urinary renal,1
KYPROLIS,renal failure acute,thoracic,0
KYPROLIS,renal impairment,Renal,0
KYPROLIS,renal impairment,renal impairment,1
KYPROLIS,renal impairment,renal failure renal,1
KYPROLIS,renal impairment,renal impairment,1
KYPROLIS,renal impairment,renal impairment Respiratory thoracic and,1
KYPROLIS,renal impairment,renal impairment,1
KYPROLIS,renal impairment,thoracic,0
KYPROLIS,renal impairment,disorders dysphonia epistaxis oropharyngeal,0
KYPROLIS,renal impairment,renal impairment Respiratory,1
KYPROLIS,epistaxis,epistaxis oropharyngeal pain pulmonary,1
KYPROLIS,epistaxis,epistaxis oropharyngeal pain,1
KYPROLIS,epistaxis,epistaxis oropharyngeal pain pulmonary embolism pulmonary,1
KYPROLIS,epistaxis,impairment Respiratory thoracic and mediastinal disorders dysphonia,0
KYPROLIS,epistaxis,epistaxis oropharyngeal pain pulmonary embolism pulmonary,1
KYPROLIS,epistaxis,epistaxis oropharyngeal pain,1
KYPROLIS,oropharyngeal pain,and mediastinal disorders dysphonia oropharyngeal pain pulmonary,1
KYPROLIS,oropharyngeal pain,epistaxis oropharyngeal pain,1
KYPROLIS,oropharyngeal pain,te renal impairment Respiratory thoracic and mediastinal disorders,0
KYPROLIS,oropharyngeal pain,thoracic and mediastinal disorders dysphonia,0
KYPROLIS,oropharyngeal pain,dysphonia oropharyngeal pain,1
KYPROLIS,oropharyngeal pain,thoracic,0
KYPROLIS,oropharyngeal pain,oropharyngeal pain pulmonary embolism pulmonary edema,1
KYPROLIS,oropharyngeal pain,mediastinal disorders dysphonia oropharyngeal pain pulmonary embolism pulmonary edema,1
KYPROLIS,oropharyngeal pain,oropharyngeal pain pulmonary embolism pulmonary edema,1
KYPROLIS,oropharyngeal pain,dysphonia oropharyngeal pain pulmonary embolism,1
KYPROLIS,oropharyngeal pain,oropharyngeal pain pulmonary embolism pulmonary edema,1
KYPROLIS,oropharyngeal pain,disorders dysphonia oropharyngeal pain pulmonary embolism pulmonary edema Skin,1
KYPROLIS,oropharyngeal pain,oropharyngeal pain pulmonary embolism pulmonary edema,1
KYPROLIS,oropharyngeal pain,oropharyngeal pain pulmonary embolism pulmonary edema,1
KYPROLIS,pulmonary embolism,oropharyngeal pulmonary embolism,1
KYPROLIS,pulmonary edema,pain,0
KYPROLIS,pulmonary edema,subcutaneous tissue disorders erythema hyperhidrosis pruritus Vascular,0
KYPROLIS,erythema,and subcutaneous tissue erythema hyperhidrosis pruritus Vascular disorders deep,1
KYPROLIS,erythema,subcutaneous tissue disorders erythema hyperhidrosis pruritus Vascular,0
KYPROLIS,erythema,disorders deep vein,0
KYPROLIS,erythema,erythema hyperhidrosis pruritus Vascular disorders deep,1
KYPROLIS,erythema,disorders deep vein,0
KYPROLIS,erythema,erythema hyperhidrosis pruritus Vascular disorders,1
KYPROLIS,erythema,and subcutaneous,0
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus,1
KYPROLIS,hyperhidrosis,disorders erythema,0
KYPROLIS,hyperhidrosis,and,0
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus,1
KYPROLIS,hyperhidrosis,deep vein thrombosis hypotension,0
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus Vascular disorders deep,1
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus Vascular disorders,1
KYPROLIS,hyperhidrosis,hyperhidrosis pruritus Vascular disorders deep,1
KYPROLIS,hyperhidrosis,disorders deep vein thrombosis hypotension Grade,0
KYPROLIS,pruritus,pruritus Vascular,1
KYPROLIS,deep vein thrombosis,occurred during Cycles with a subs,0
KYPROLIS,deep vein thrombosis,vein thrombosis hypotension Grade and,1
KYPROLIS,deep vein thrombosis,disorders erythema hyperhidrosis pruritus Vascular,0
KYPROLIS,hypotension,hypotension Grade and higher,1
KYPROLIS,hypotension,and higher adverse reactions that occurred during,0
KYPROLIS,hypotension,hypotension Grade and higher,1
KYPROLIS,neutropenia,difference between the two,0
KYPROLIS,neutropenia,arms,0
KYPROLIS,neutropenia,neutropenia thrombocytopenia,1
KYPROLIS,neutropenia,two arms neutropenia thrombocytopenia hypokalemia and hypophosphatemia Laboratory,1
KYPROLIS,neutropenia,neutropenia thrombocytopenia,1
KYPROLIS,thrombocytopenia,thrombocytopenia hypokalemia and,1
KYPROLIS,thrombocytopenia,thrombocytopenia hypokalemia and hypophosphatemia Laboratory,1
KYPROLIS,thrombocytopenia,thrombocytopenia,1
KYPROLIS,thrombocytopenia,thrombocytopenia hypokalemia and,1
KYPROLIS,hypophosphatemia,the,0
KYPROLIS,hypophosphatemia,Grade laboratory abnormalities r,0
KYPROLIS,Decreased Lymphocytes,Decreased Lymphocytes Decreased Ab,1
KYPROLIS,Decreased Lymphocytes,Decreased Lymphocytes Decreased,1
KYPROLIS,Decreased Lymphocytes,y Abnormality KRd N Decreased Lymphocytes Decreased Ab,1
KYPROLIS,Decreased Lymphocytes,Decreased Lymphocytes Decreased,1
KYPROLIS,Decreased Lymphocytes,N Decreased Lymphocytes Decreased,1
KYPROLIS,Decreased Lymphocytes,Decreased Lymphocytes Decreased,1
KYPROLIS,Decreased Lymphocytes,Abnormality KRd N Decreased Lymphocytes,1
KYPROLIS,Decreased Lymphocytes,N RdN,0
KYPROLIS,Decreased Lymphocytes,KRd N,0
KYPROLIS,Decreased Phosphorus,Neutrophil Count,0
KYPROLIS,Decreased Phosphorus,Neutrophil Decreased,1
KYPROLIS,Decreased Phosphorus,Decreased Phosphorus,1
KYPROLIS,Decreased Hemoglobin,Blood Cell Decreased Hemoglobin,1
KYPROLIS,Decreased Hemoglobin,Decreased Hemoglobin,1
KYPROLIS,Decreased Hemoglobin,Blood Cell Decreased Hemoglobin,1
KYPROLIS,Decreased Hemoglobin,White Blood Cell Decreased Hemoglobin,1
KYPROLIS,Decreased Hemoglobin,Blood Cell Decreased Hemoglobin,1
KYPROLIS,Decreased Hemoglobin,White Blood Cell Decreased,1
KYPROLIS,Decreased Hemoglobin,Decreased Hemoglobin Decreased,1
KYPROLIS,Decreased Hemoglobin,Decreased Hemoglobin,1
KYPROLIS,Decreased Hemoglobin,Blood Cell,0
KYPROLIS,Decreased Hemoglobin,Decreased Hemoglobin Decreased,1
KYPROLIS,Decreased Hemoglobin,White Blood Cell,0
KYPROLIS,pneumonia,pneumonia acute renal failure,1
KYPROLIS,pneumonia,pneumonia acute renal failure disease,1
KYPROLIS,pneumonia,progression pyrexia hypercalcemia congest,0
KYPROLIS,pneumonia,pneumonia acute renal,1
KYPROLIS,acute renal failure,acute renal failure disease,1
KYPROLIS,acute renal failure,pneumonia acute renal,1
KYPROLIS,acute renal failure,were acute renal failure,1
KYPROLIS,disease progression,pneumonia acute renal disease,1
KYPROLIS,pyrexia,failure multiple,0
KYPROLIS,pyrexia,pyrexia hypercalcemia congestive,1
KYPROLIS,pyrexia,failure disease pyrexia hypercalcemia congestive heart,1
KYPROLIS,pyrexia,pyrexia hypercalcemia congestive,1
KYPROLIS,pyrexia,failure multiple myeloma,0
KYPROLIS,pyrexia,were pneumonia acute renal,0
KYPROLIS,congestive heart failure,disease,0
KYPROLIS,congestive heart failure,progression pyrexia congestive heart failure,1
KYPROLIS,congestive heart failure,pyrexia congestive heart failure multiple myeloma anemia and,1
KYPROLIS,congestive heart failure,progression pyrexia congestive heart failure,1
KYPROLIS,multiple myeloma,incidence of,0
KYPROLIS,anemia,anemia and dyspnea,1
KYPROLIS,anemia,anemia and dyspnea In,1
KYPROLIS,anemia,pyrexia,0
KYPROLIS,Deaths,Deaths due to adverse,1
KYPROLIS,Deaths,Deaths due to adverse events within,1
KYPROLIS,Deaths,years old and in those years old see,0
KYPROLIS,Deaths,Deaths due to adverse events within,1
KYPROLIS,Deaths,events within,0
KYPROLIS,Deaths,Geriatric Deaths due to adverse events,1
KYPROLIS,Deaths,events within,0
KYPROLIS,Deaths,old see Geriatric Deaths due to adverse events,1
KYPROLIS,Deaths,events within,0
KYPROLIS,Deaths,of Kyprolis occurred in patients,0
KYPROLIS,Deaths,see Geriatric Deaths,1
KYPROLIS,Deaths,of Kyprolis occurred in patients,0
KYPROLIS,Deaths,and in those,0
KYPROLIS,cardiac disorders,These,0
KYPROLIS,cardiac disorders,events were related cardiac disorders in,1
KYPROLIS,cardiac disorders,These,0
KYPROLIS,cardiac disorders,patients renal disorders in patients and,0
KYPROLIS,cardiac disorders,related cardiac disorders,1
KYPROLIS,cardiac disorders,in,0
KYPROLIS,cardiac disorders,patients,0
KYPROLIS,renal disorders,renal disorders,1
KYPROLIS,renal disorders,patients infections in renal disorders,1
KYPROLIS,renal disorders,in renal,1
KYPROLIS,renal disorders,in renal disorders in patients and other adverse,1
KYPROLIS,renal disorders,in renal,1
KYPROLIS,renal disorders,in renal disorders in patients,1
KYPROLIS,renal disorders,in renal,1
KYPROLIS,renal disorders,in renal disorders,1
KYPROLIS,mortality,mortality was higher in the patients,1
KYPROLIS,mortality,the control,0
KYPROLIS,mortality,and refractory multiple mortality,1
KYPROLIS,mortality,the control,0
KYPROLIS,mortality,mortality was,1
KYPROLIS,acute renal failure,renal failure The common adverse,1
KYPROLIS,acute renal failure,adverse event acute renal failure,1
KYPROLIS,acute renal failure,greater with Kyprolis,0
KYPROLIS,acute renal failure,adverse events occurring at a rate,0
KYPROLIS,acute renal failure,event acute renal failure The common,1
KYPROLIS,acute renal failure,adverse events occurring at a rate,0
KYPROLIS,acute renal failure,acute,1
KYPROLIS,Pneumonia,Pneumonia includes the preferred terms,1
KYPROLIS,Pneumonia,a,0
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,Pneumonia,Kyprolis Monotherapy Pneumonia includes the preferred,1
KYPROLIS,Pneumonia,Pneumonia,1
KYPROLIS,pneumonia,neuropathies NEC includes,0
KYPROLIS,Peripheral neuropathies NEC,terms of pneumonia bronchopneumonia Peripheral neuropathies NEC includes,1
KYPROLIS,Peripheral neuropathies NEC,neuropathies NEC includes,0
KYPROLIS,peripheral neuropathies NEC,eumonia,0
KYPROLIS,peripheral neuropathies NEC,exertional d Hypertension,0
KYPROLIS,peripheral neuropathies NEC,includes the preferred terms under HLT,0
KYPROLIS,peripheral neuropathies NEC,peripheral neuropathies,1
KYPROLIS,peripheral neuropathies NEC,NEC includes,0
KYPROLIS,peripheral neuropathies NEC,HLT,0
KYPROLIS,Dyspnea,neuropathies,0
KYPROLIS,Dyspnea,Dyspnea,1
KYPROLIS,Dyspnea,of dyspnea dyspnea exertional d Hypertension includes,0
KYPROLIS,Dyspnea,the preferred terms,0
KYPROLIS,Dyspnea,includes the preferred,0
KYPROLIS,Dyspnea,NEC includes the preferred terms under HLT,0
KYPROLIS,Dyspnea,Dyspnea includes,1
KYPROLIS,Dyspnea,Dyspnea includes the preferred,1
KYPROLIS,Dyspnea,neuropathies,0
KYPROLIS,dyspnea,exertional d Hypertension includes the preferred terms of hypertension hypertensive,0
KYPROLIS,dyspnea exertional,the preferred terms of dyspnea,1
KYPROLIS,dyspnea exertional,preferred terms of dyspnea exertional d Hypertension includes,1
KYPROLIS,dyspnea exertional,the preferred terms of dyspnea,1
KYPROLIS,dyspnea exertional,dyspnea exertional d Hypertension includes the,1
KYPROLIS,dyspnea exertional,the preferred terms of dyspnea,1
KYPROLIS,dyspnea exertional,the preferred,0
KYPROLIS,dyspnea exertional,HLT peripheral neuropathies NEC c Dyspnea includes the preferred terms of dyspnea,0
KYPROLIS,Hypertension,Hypertension includes the preferred terms,1
KYPROLIS,Hypertension,HLT peripheral neuropathies NEC c Dyspnea includes the preferred terms of dyspnea,0
KYPROLIS,Hypertension,preferred terms of dyspnea dyspnea,0
KYPROLIS,Hypertension,and,0
KYPROLIS,Hypertension,preferred,0
KYPROLIS,Hypertension,dyspnea dyspnea exertional Hypertension,1
KYPROLIS,Hypertension,preferred,0
KYPROLIS,Hypertension,preferred terms of hypertension hypertensive crisis and hypertensive,0
KYPROLIS,Hypertension,hypertensive crisis and hypertensive,0
KYPROLIS,Hypertension,neuropathies NEC c Dyspnea,0
KYPROLIS,hypertension,hypertension hypertensive crisis and hypertensive,1
KYPROLIS,hypertensive crisis,hypertensive crisis and hypertensive emergency Kyprol,1
KYPROLIS,hypertensive crisis,hypertension hypertensive crisis and hypertensive,1
KYPROLIS,hypertensive crisis,hypertensive crisis,1
KYPROLIS,hypertensive crisis,hypertensive crisis and hypertensive,1
KYPROLIS,hypertensive crisis,dyspnea exertional d Hypertension includes the,0
KYPROLIS,hypertensive crisis,hypertensive crisis and hypertensive emergency,1
KYPROLIS,hypertensive crisis,terms of hypertensive crisis,1
KYPROLIS,hypertensive crisis,hypertensive crisis and hypertensive emergency Kyprol,1
KYPROLIS,hypertensive crisis,preferred terms of hypertensive,1
KYPROLIS,hypertensive emergency,d Hypertension includes the,0
KYPROLIS,hypertensive emergency,of hypertension hypertensive crisis hypertensive emergency Kyprolis,1
KYPROLIS,hypertensive emergency,d Hypertension includes the,0
KYPROLIS,hypertensive emergency,Kyprolis,0
KYPROLIS,hypertensive emergency,hypertensive crisis hypertensive,1
KYPROLIS,hypertensive emergency,of hypertension hypertensive crisis hypertensive,1
KYPROLIS,hypertensive emergency,hypertension hypertensive crisis and,0
KYPROLIS,Pneumonia,Pneumonia a,1
KYPROLIS,Pneumonia,hypertension hypertensive crisis and,0
KYPROLIS,Pneumonia,piratory,0
KYPROLIS,Pneumonia,piratory Tract Pneumonia a Met,1
KYPROLIS,Pneumonia,piratory,0
KYPROLIS,Pneumonia,piratory,0
KYPROLIS,Pneumonia,Pneumonia a,1
KYPROLIS,Pneumonia,Pneumonia a,1
KYPROLIS,Pneumonia,Pneumonia a,1
KYPROLIS,febrile neutropenia,febrile neutropenia,1
KYPROLIS,febrile neutropenia,Reactions Occurring at a Frequency of Blood and lymphatic,0
KYPROLIS,febrile neutropenia,Reactions,0
KYPROLIS,febrile neutropenia,disorders cardiac arrest cardiac failure congestive myocardial,0
KYPROLIS,febrile neutropenia,at a Frequency of Blood and lymphatic system,0
KYPROLIS,febrile neutropenia,febrile neutropenia Cardiac,1
KYPROLIS,febrile neutropenia,arrest cardiac failure congestive myocardial,0
KYPROLIS,febrile neutropenia,febrile neutropenia Cardiac,1
KYPROLIS,febrile neutropenia,febrile neutropenia Cardiac disorders,1
KYPROLIS,febrile neutropenia,and lymphatic system febrile neutropenia,1
KYPROLIS,cardiac arrest,Blood and lymphatic system disorders febrile,0
KYPROLIS,cardiac arrest,disorders febrile neutropenia Cardiac cardiac arrest cardiac failure congestive myocardial infarction,1
KYPROLIS,cardiac arrest,Blood and lymphatic system disorders febrile,0
KYPROLIS,cardiac arrest,disorders,0
KYPROLIS,cardiac arrest,cardiac arrest cardiac failure congestive,1
KYPROLIS,cardiac arrest,congestive myocardial,0
KYPROLIS,cardiac arrest,neutropenia Cardiac cardiac arrest cardiac,1
KYPROLIS,cardiac arrest,congestive myocardial,0
KYPROLIS,cardiac arrest,disorders febrile neutropenia Cardiac cardiac arrest,1
KYPROLIS,cardiac arrest,lymphatic system,0
KYPROLIS,cardiac arrest,disorders febrile neutropenia Cardiac cardiac,1
KYPROLIS,cardiac arrest,ischemia,0
KYPROLIS,cardiac failure congestive,Eye disorders cataract,0
KYPROLIS,cardiac failure congestive,disorders cardiac cardiac failure,1
KYPROLIS,cardiac failure congestive,disorders cardiac cardiac failure congestive myocardial infarction,1
KYPROLIS,cardiac failure congestive,disorders cardiac cardiac failure,1
KYPROLIS,cardiac failure congestive,cardiac failure congestive,1
KYPROLIS,cardiac failure congestive,neutropenia Cardiac disorders cardiac cardiac failure congestive,1
KYPROLIS,cardiac failure congestive,myocardial infarction myocardial,0
KYPROLIS,cardiac failure congestive,Cardiac disorders cardiac cardiac failure congestive myocardial infarction,1
KYPROLIS,cardiac failure congestive,myocardial infarction myocardial,0
KYPROLIS,cardiac failure congestive,cardiac failure congestive,1
KYPROLIS,cardiac failure congestive,failure congestive myocardial infarction myocardial,1
KYPROLIS,cardiac failure congestive,disorders cardiac cardiac failure congestive myocardial infarction myocardial ischemia,1
KYPROLIS,cardiac failure congestive,failure congestive myocardial infarction myocardial,1
KYPROLIS,myocardial ischemia,congestive myocardial myocardial ischemia,1
KYPROLIS,myocardial ischemia,cardiac arrest cardiac failure,0
KYPROLIS,blurred vision,blurred vision Gastrointestinal disorders abdominal pain,1
KYPROLIS,blurred vision,Eye disorders blurred,1
KYPROLIS,blurred vision,failure congestive myocardial infarction,0
KYPROLIS,blurred vision,Eye disorders blurred vision Gastrointestinal disorders,1
KYPROLIS,blurred vision,failure congestive myocardial infarction,0
KYPROLIS,blurred vision,myocardial ischemia Eye disorders blurred vision,1
KYPROLIS,blurred vision,disorders blurred vision Gastrointestinal disorders abdominal,1
KYPROLIS,blurred vision,myocardial ischemia Eye disorders blurred vision,1
KYPROLIS,blurred vision,myocardial ischemia Eye disorders blurred,1
KYPROLIS,blurred vision,disorders blurred vision Gastrointestinal,1
KYPROLIS,blurred vision,myocardial ischemia Eye disorders blurred,1
KYPROLIS,blurred vision,Gastrointestinal disorders abdominal pain,0
KYPROLIS,blurred vision,blurred,1
KYPROLIS,abdominal pain,Gastrointestinal disorders,0
KYPROLIS,abdominal pain,abdominal pain abdominal pain upper dyspepsia,1
KYPROLIS,abdominal pain,and administration,0
KYPROLIS,abdominal pain upper,vision Gastrointestinal,0
KYPROLIS,abdominal pain upper,vision Gastrointestinal disorders abdominal abdominal pain upper dyspepsia toothache General disorders,1
KYPROLIS,abdominal pain upper,vision Gastrointestinal,0
KYPROLIS,abdominal pain upper,Eye disorders cataract blurred vision Gastrointestinal disorders abdominal,0
KYPROLIS,abdominal pain upper,Gastrointestinal disorders abdominal abdominal pain upper dyspepsia toothache General disorders,1
KYPROLIS,abdominal pain upper,Eye disorders cataract blurred vision Gastrointestinal disorders abdominal,0
KYPROLIS,abdominal pain upper,blurred,0
KYPROLIS,abdominal pain upper,vision Gastrointestinal disorders abdominal abdominal pain upper dyspepsia toothache,1
KYPROLIS,abdominal pain upper,blurred,0
KYPROLIS,abdominal pain upper,abdominal,0
KYPROLIS,abdominal pain upper,abdominal pain upper,1
KYPROLIS,abdominal pain upper,cataract blurred vision Gastrointestinal disorders,0
KYPROLIS,dyspepsia,dyspepsia,1
KYPROLIS,toothache,infusion site reaction multiorgan f,0
KYPROLIS,toothache,reaction multiorgan,0
KYPROLIS,toothache,pain abdominal pain upper toothache General disorders and administration,1
KYPROLIS,toothache,reaction multiorgan,0
KYPROLIS,toothache,toothache General disorders and,1
KYPROLIS,toothache,site,0
KYPROLIS,toothache,site reaction multiorgan f,0
KYPROLIS,toothache,disorders abdominal pain,0
KYPROLIS,infusion site reaction,hepatic,0
KYPROLIS,infusion site reaction,site reaction multiorgan failure,1
KYPROLIS,infusion site reaction,administration site infusion site reaction,1
KYPROLIS,infusion site reaction,site reaction multiorgan failure,1
KYPROLIS,multi-organ failure,and administration site conditions infusion,0
KYPROLIS,multi-organ failure,site multi-organ,1
KYPROLIS,multi-organ failure,multi-organ failure pain,1
KYPROLIS,multi-organ failure,multi-organ failure pain,1
KYPROLIS,multi-organ failure,site conditions infusion site multi-organ failure,1
KYPROLIS,multi-organ failure,site multi-organ failure,1
KYPROLIS,multi-organ failure,site conditions infusion site multi-organ failure,1
KYPROLIS,multi-organ failure,multi-organ failure,1
KYPROLIS,multi-organ failure,multi-organ failure pain Hepatobiliary,1
KYPROLIS,multi-organ failure,infusion site multi-organ failure,1
KYPROLIS,pain,disorders hepatic failure Infections and infestations bronchitis i,0
KYPROLIS,pain,multiorgan pain Hepatobiliary disorders,1
KYPROLIS,pain,disorders hepatic failure Infections and infestations bronchitis i,0
KYPROLIS,bronchitis,Hepatobiliary disorders hepatic failure Infections and,0
KYPROLIS,bronchitis,Hepatobiliary disorders hepatic failure Infections,0
KYPROLIS,bronchitis,bronchitis influenza nasopharyngitis respiratory,1
KYPROLIS,bronchitis,bronchitis influenza nasopharyngitis respiratory,1
KYPROLIS,bronchitis,tract,0
KYPROLIS,nasopharyngitis,nasopharyngitis respiratory,1
KYPROLIS,respiratory tract infection,respiratory tract infection sepsis urinary tract infection,1
KYPROLIS,respiratory tract infection,influenza respiratory tract infection,1
KYPROLIS,respiratory tract infection,respiratory tract infection sepsis urinary tract infection,1
KYPROLIS,respiratory tract infection,influenza,0
KYPROLIS,sepsis,nasopharyngitis respiratory tract sepsis urinary tract,1
KYPROLIS,sepsis,influenza,0
KYPROLIS,sepsis,and nutrition,0
KYPROLIS,sepsis,urinary tract infection Metabolism and nutrition disorders hyperglycemia,0
KYPROLIS,sepsis,nutrition disorders hyperglycemia,0
KYPROLIS,sepsis,nutrition disorders hyperglycemia,0
KYPROLIS,sepsis,sepsis urinary tract infection,1
KYPROLIS,sepsis,nasopharyngitis respiratory tract infection,0
KYPROLIS,sepsis,and infestations bronchitis influenza nasopharyngitis respiratory tract infection,0
KYPROLIS,sepsis,sepsis urinary,1
KYPROLIS,urinary tract infection,tract infection urinary tract infection,1
KYPROLIS,urinary tract infection,ions and,0
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia,1
KYPROLIS,hyperglycemia,Metabolism and nutrition hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia,1
KYPROLIS,hyperglycemia,nutrition disorders,0
KYPROLIS,hyperglycemia,ratory tract infection sepsis urinary tract infection,0
KYPROLIS,hyperglycemia,and nutrition hyperglycemia hyperkalemia hyperuricemia,1
KYPROLIS,hyperglycemia,ratory tract infection sepsis urinary tract infection,0
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia,1
KYPROLIS,hyperglycemia,hypoalbuminemia hypocalcemia hypomagnesemia,0
KYPROLIS,hyperglycemia,tract infection,0
KYPROLIS,hyperkalemia,urinary tract,0
KYPROLIS,hyperkalemia,hyperkalemia,1
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia,1
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia,1
KYPROLIS,hyperkalemia,hyperuricemia hypoalbuminemia,0
KYPROLIS,hyperkalemia,hypomagnesemia hyponatremia hypophosphatemia tumo,0
KYPROLIS,hyperkalemia,fection,0
KYPROLIS,hyperkalemia,hyperkalemia,1
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia hypomagnesemia hyponatremia,1
KYPROLIS,hyperuricemia,hypocalcemia hypomagnesemia hyponatremia,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hypocalcemia hypomagnesemia hyponatremia,1
KYPROLIS,hyperuricemia,urinary tract infection Metabolism and nutrition,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hypocalcemia hypomagnesemia hyponatremia hypophosphatemia,1
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hypocalcemia,1
KYPROLIS,hyperuricemia,hypophosphatemia tumor lysis,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hypocalcemia hypomagnesemia hyponatremia,1
KYPROLIS,hypoalbuminemia,hypoalbuminemia hypocalcemia,1
KYPROLIS,hypoalbuminemia,hypomagnesemia hyponatremia hypophosphatemia tumor lysis,0
KYPROLIS,hypoalbuminemia,hypocalcemia hypomagnesemia hyponatremia hypophosphatemia,0
KYPROLIS,hypoalbuminemia,hypomagnesemia hyponatremia hypophosphatemia tumor lysis syndrome,0
KYPROLIS,hypocalcemia,syndrome,0
KYPROLIS,hypocalcemia,hypocalcemia hypomagnesemia hyponatremia hypophosphatemia tumor lysis,1
KYPROLIS,hypocalcemia,syndrome,0
KYPROLIS,hypocalcemia,lysis,0
KYPROLIS,hypomagnesemia,hypomagnesemia hyponatremia hypophosphatemia tumor lysis,1
KYPROLIS,hypomagnesemia,and connective tissue,0
KYPROLIS,hypomagnesemia,hypomagnesemia hyponatremia,1
KYPROLIS,hypomagnesemia,hypomagnesemia hyponatremia hypophosphatemia tumor lysis syndrome,1
KYPROLIS,hypomagnesemia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypomagnesemia hyponatremia,1
KYPROLIS,hypomagnesemia,hypomagnesemia hyponatremia hypophosphatemia tumor lysis syndrome,1
KYPROLIS,hypomagnesemia,hypomagnesemia hyponatremia hypophosphatemia,1
KYPROLIS,hyponatremia,and connective tissue,0
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia,1
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia tumor lysis,1
KYPROLIS,hyponatremia,Musculoskeletal and connective tissue,0
KYPROLIS,hyponatremia,hypophosphatemia tumor lysis syndrome Musculoskeletal and,0
KYPROLIS,hyponatremia,hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia tumor,1
KYPROLIS,hyponatremia,hypophosphatemia tumor lysis syndrome Musculoskeletal and,0
KYPROLIS,hyponatremia,syndrome Musculoskeletal and connective tissue disorders,0
KYPROLIS,tumor lysis syndrome,hypoalbuminemia hypocalcemia hypomagnesemia hyponatremia tumor lysis syndrome Musculoskeletal and connective tissue,1
KYPROLIS,tumor lysis syndrome,syndrome Musculoskeletal and connective tissue disorders,0
KYPROLIS,tumor lysis syndrome,tumor lysis syndrome Musculoskeletal and connective,1
KYPROLIS,tumor lysis syndrome,hyponatremia tumor lysis,1
KYPROLIS,tumor lysis syndrome,hypomagnesemia,0
KYPROLIS,musculoskeletal chest pain,disorders,0
KYPROLIS,musculoskeletal chest pain,disorders hypoesthesia paresthesia Psychiatric,0
KYPROLIS,musculoskeletal chest pain,hypophosphatemia tumor lysis syndrome Musculoskeletal and connective,0
KYPROLIS,musculoskeletal chest pain,Musculoskeletal and connective tissue musculoskeletal,1
KYPROLIS,myalgia,myalgia Nervous system disorders hypoesthesia paresthesia,1
KYPROLIS,myalgia,myalgia Nervous system disorders hypoesthesia,1
KYPROLIS,myalgia,myalgia Nervous system disorders hypoesthesia paresthesia,1
KYPROLIS,myalgia,chest pain,0
KYPROLIS,myalgia,chest myalgia Nervous system disorders hypoesthesia paresthesia,1
KYPROLIS,myalgia,chest pain,0
KYPROLIS,myalgia,myalgia,1
KYPROLIS,myalgia,musculoskeletal chest myalgia Nervous system,1
KYPROLIS,myalgia,myalgia,1
KYPROLIS,myalgia,myalgia Nervous system,1
KYPROLIS,myalgia,tissue disorders musculoskeletal chest myalgia Nervous system disorders hypoesthesia,1
KYPROLIS,myalgia,myalgia Nervous system,1
KYPROLIS,myalgia,musculoskeletal chest myalgia Nervous,1
KYPROLIS,myalgia,myalgia Nervous system,1
KYPROLIS,hypoesthesia,hypoesthesia paresthesia Psychiatric,1
KYPROLIS,paresthesia,paresthesia Psychiatric disorders anxiety Renal,1
KYPROLIS,paresthesia,paresthesia Psychiatric disorders,1
KYPROLIS,paresthesia,paresthesia,1
KYPROLIS,paresthesia,paresthesia Psychiatric disorders,1
KYPROLIS,paresthesia,paresthesia Psychiatric,1
KYPROLIS,paresthesia,paresthesia Psychiatric,1
KYPROLIS,paresthesia,myalgia Nervous system,0
KYPROLIS,paresthesia,system,0
KYPROLIS,paresthesia,paresthesia,1
KYPROLIS,paresthesia,Psychiatric disorders anxiety Renal,0
KYPROLIS,paresthesia,chest pain myalgia,0
KYPROLIS,anxiety,and urinary disorders renal impairment,0
KYPROLIS,dysphonia,and,0
KYPROLIS,dysphonia,mediastinal dysphonia oropharyngeal pain pulmonary edema Skin,1
KYPROLIS,dysphonia,and,0
KYPROLIS,dysphonia,disorders renal impairment Respiratory thoracic and,0
KYPROLIS,dysphonia,mediastinal dysphonia oropharyngeal pain pulmonary,1
KYPROLIS,dysphonia,disorders renal impairment Respiratory thoracic and,0
KYPROLIS,dysphonia,urinary disorders renal impairment Respiratory thoracic and,0
KYPROLIS,dysphonia,subcutaneous tissue disorders erythema hype,0
KYPROLIS,dysphonia,dysphonia oropharyngeal pain pulmonary,1
KYPROLIS,dysphonia,dysphonia oropharyngeal pain pulmonary edema Skin,1
KYPROLIS,dysphonia,pain pulmonary edema Skin and subcutaneous tissue disorders erythema,0
KYPROLIS,oropharyngeal pain,disorders,0
KYPROLIS,pulmonary edema,oropharyngeal pulmonary edema Skin and subcutaneous tissue,1
KYPROLIS,pulmonary edema,disorders,0
KYPROLIS,pulmonary edema,erythema hyperhidrosis,0
KYPROLIS,pulmonary edema,subcutaneous tissue disorders erythema hyperhidrosis pruritus rash Vas,0
KYPROLIS,pulmonary edema,mediastinal disorders dysphonia oropharyngeal pulmonary,1
KYPROLIS,pulmonary edema,oropharyngeal pulmonary edema Skin and subcutaneous tissue disorders,1
KYPROLIS,pulmonary edema,mediastinal disorders dysphonia oropharyngeal pulmonary,1
KYPROLIS,pulmonary edema,mediastinal disorders dysphonia oropharyngeal,0
KYPROLIS,pulmonary edema,disorders dysphonia oropharyngeal pulmonary edema,1
KYPROLIS,pulmonary edema,pulmonary edema Skin,1
KYPROLIS,pulmonary edema,disorders dysphonia oropharyngeal pulmonary edema Skin,1
KYPROLIS,pulmonary edema,pulmonary edema Skin,1
KYPROLIS,pulmonary edema,pulmonary edema Skin,1
KYPROLIS,pulmonary edema,pulmonary edema Skin,1
KYPROLIS,erythema,erythema hyperhidrosis pruritus,1
KYPROLIS,pruritus,pruritus rash,1
KYPROLIS,pruritus,disorders embolic and thrombotic events venous including deep vein thromb,0
KYPROLIS,pruritus,pruritus rash Vascular disorders embolic,1
KYPROLIS,pruritus,tissue disorders erythema pruritus rash Vascular,1
KYPROLIS,pruritus,pruritus rash Vascular disorders embolic,1
KYPROLIS,pruritus,disorders erythema pruritus rash Vascular disorders embolic,1
KYPROLIS,pruritus,pruritus rash Vascular disorders embolic,1
KYPROLIS,pruritus,pruritus rash Vascular disorders,1
KYPROLIS,pruritus,tissue disorders erythema pruritus,1
KYPROLIS,pruritus,pruritus rash Vascular disorders,1
KYPROLIS,rash,rash Vascular disorders embolic and thrombotic,1
KYPROLIS,rash,edema Skin,0
KYPROLIS,rash,pruritus,0
KYPROLIS,rash,thrombotic events venous including deep vein,0
KYPROLIS,rash,rash,1
KYPROLIS,rash,and,0
KYPROLIS,rash,tissue disorders,0
KYPROLIS,"embolic and thrombotic events, venous","embolic and thrombotic events, venous",1
KYPROLIS,deep vein thrombosis,drosis pruritus rash Vascular disorders,0
KYPROLIS,deep vein thrombosis,vein thrombosis and pulmonary,1
KYPROLIS,deep vein thrombosis,and higher adverse reactions occurring at an,0
KYPROLIS,deep vein thrombosis,thrombotic events venous deep vein thrombosis,1
KYPROLIS,deep vein thrombosis,events venous deep vein thrombosis and,1
KYPROLIS,deep vein thrombosis,thrombotic events venous deep vein thrombosis,1
KYPROLIS,deep vein thrombosis,deep,1
KYPROLIS,deep vein thrombosis,vein thrombosis and,1
KYPROLIS,deep vein thrombosis,deep vein,1
KYPROLIS,pulmonary embolism,pulmonary embolism hypotension Grade,1
KYPROLIS,pulmonary embolism,deep vein,1
KYPROLIS,pulmonary embolism,including deep vein thrombosis pulmonary,1
KYPROLIS,pulmonary embolism,thrombosis,0
KYPROLIS,pulmonary embolism,at an incidence of include,0
KYPROLIS,pulmonary embolism,pulmonary embolism hypotension Grade and higher,1
KYPROLIS,pulmonary embolism,deep vein,0
KYPROLIS,pulmonary embolism,pulmonary,1
KYPROLIS,pulmonary embolism,including deep vein thrombosis pulmonary embolism hypotension Grade and,1
KYPROLIS,pulmonary embolism,pulmonary,1
KYPROLIS,pulmonary embolism,deep vein thrombosis pulmonary embolism hypotension Grade and,1
KYPROLIS,pulmonary embolism,pulmonary,1
KYPROLIS,hypotension,hypotension Grade,1
KYPROLIS,febrile neutropenia,cardiac arrest cardiac failure congestive pain sepsis urinary tract infection hyperglycemia,0
KYPROLIS,febrile neutropenia,febrile neutropenia cardiac arrest cardiac,1
KYPROLIS,febrile neutropenia,at an incidence of febrile neutropenia cardiac,1
KYPROLIS,febrile neutropenia,febrile neutropenia cardiac arrest cardiac,1
KYPROLIS,cardiac failure congestive,include febrile neutropenia cardiac cardiac failure congestive,1
KYPROLIS,pain,arrest cardiac failure pain,1
KYPROLIS,pain,include febrile neutropenia cardiac cardiac failure congestive,1
KYPROLIS,pain,pain sepsis urinary tract,1
KYPROLIS,pain,pain,1
KYPROLIS,pain,sepsis urinary tract,0
KYPROLIS,pain,febrile neutropenia cardiac arrest cardiac,0
KYPROLIS,pain,failure,0
KYPROLIS,pain,pain sepsis urinary tract,1
KYPROLIS,sepsis,hyperuricemia hypoalbuminemia,0
KYPROLIS,sepsis,infection hyperglycemia hyperkalemia hyperuricemia,0
KYPROLIS,sepsis,sepsis urinary tract,1
KYPROLIS,sepsis,sepsis urinary,1
KYPROLIS,sepsis,sepsis urinary tract,1
KYPROLIS,sepsis,sepsis urinary,1
KYPROLIS,sepsis,sepsis urinary tract,1
KYPROLIS,urinary tract infection,congestive pain urinary tract infection,1
KYPROLIS,urinary tract infection,failure congestive pain,0
KYPROLIS,urinary tract infection,sepsis,0
KYPROLIS,urinary tract infection,pain urinary tract infection,1
KYPROLIS,urinary tract infection,sepsis,0
KYPROLIS,urinary tract infection,tract infection hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia,1
KYPROLIS,urinary tract infection,pain urinary,1
KYPROLIS,hyperglycemia,hyperglycemia,1
KYPROLIS,hyperglycemia,urinary tract hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia,1
KYPROLIS,hyperglycemia,hyperglycemia,1
KYPROLIS,hyperglycemia,urinary tract hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia hyponatremia,1
KYPROLIS,hyperglycemia,hyperglycemia,1
KYPROLIS,hyperglycemia,tract hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperglycemia,hyperglycemia,1
KYPROLIS,hyperglycemia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperkalemia,hyponatremia hypophosphatemia renal failure,0
KYPROLIS,hyperkalemia,hypophosphatemia renal failure renal,0
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia,1
KYPROLIS,hyperkalemia,hyperkalemia hyperuricemia hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia,1
KYPROLIS,hyperuricemia,urinary tract,0
KYPROLIS,hyperuricemia,cardiac failure congestive pain sepsis urinary,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia,1
KYPROLIS,hyperuricemia,renal failure acute,0
KYPROLIS,hyperuricemia,hyperuricemia hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia renal,1
KYPROLIS,hyperuricemia,hypoalbuminemia hypocalcemia hyponatremia,0
KYPROLIS,hypoalbuminemia,tract infection,0
KYPROLIS,hyponatremia,pulmonary,0
KYPROLIS,hyponatremia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hyponatremia,1
KYPROLIS,hyponatremia,pulmonary,0
KYPROLIS,hyponatremia,hyperglycemia hyperkalemia hyperuricemia hypoalbuminemia hyponatremia hypophosphatemia renal,1
KYPROLIS,hyponatremia,pulmonary,0
KYPROLIS,hyponatremia,hyponatremia,1
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia renal failure renal failure,1
KYPROLIS,hyponatremia,hypoalbuminemia hyponatremia hypophosphatemia renal failure renal failure,1
KYPROLIS,hyponatremia,hyponatremia hypophosphatemia renal failure renal failure,1
KYPROLIS,hypophosphatemia,hyperuricemia hypoalbuminemia hypocalcemia hypophosphatemia renal failure,1
KYPROLIS,hypophosphatemia,hyponatremia hypophosphatemia renal failure renal failure,1
KYPROLIS,hypophosphatemia,hypophosphatemia renal failure,1
KYPROLIS,hypophosphatemia,hypophosphatemia renal,1
KYPROLIS,hypophosphatemia,acute renal,0
KYPROLIS,hypophosphatemia,infection hyperglycemia hyperkalemia hyperuricemia,0
KYPROLIS,renal failure,hypoalbuminemia hypocalcemia hyponatremia renal failure renal,1
KYPROLIS,renal failure,infection hyperglycemia hyperkalemia hyperuricemia,0
KYPROLIS,renal failure,renal impairment pulmonary edema and,0
KYPROLIS,renal failure,renal failure renal failure,1
KYPROLIS,renal failure,and hypotension,0
KYPROLIS,renal failure,hyperuricemia hypoalbuminemia hypocalcemia hyponatremia hypophosphatemia,0
KYPROLIS,renal failure,renal failure renal failure acute,1
KYPROLIS,renal failure,renal,1
KYPROLIS,renal failure acute,renal failure acute renal impairment pulmonary,1
KYPROLIS,renal failure acute,renal failure acute renal impairment pulmonary edema and,1
KYPROLIS,renal impairment,failure renal failure renal impairment pulmonary,1
KYPROLIS,renal impairment,renal failure acute renal impairment pulmonary edema and,1
KYPROLIS,renal impairment,failure,0
KYPROLIS,renal impairment,renal impairment pulmonary edema and hypotension Laboratory,1
KYPROLIS,renal impairment,failure renal failure renal impairment,1
KYPROLIS,pulmonary edema,pulmonary edema and hypotension Laboratory Abnormalities Table,1
KYPROLIS,pulmonary edema,describes,0
KYPROLIS,pulmonary edema,and hypotension Laboratory Abnormalities Table describes,0
KYPROLIS,pulmonary edema,pulmonary edema and hypotension,1
KYPROLIS,pulmonary edema,renal failure,0
KYPROLIS,pulmonary edema,Laboratory Abnormalities Table describes,0
KYPROLIS,pulmonary edema,impairment,0
KYPROLIS,hypotension,Table describes Grade laboratory abnormalities,0
KYPROLIS,hypotension,Laboratory Abnormalities Table describes Grade laboratory abnormalities,0
KYPROLIS,hypotension,failure renal failure acute renal impairment pulmonary edema and,0
KYPROLIS,hypotension,edema hypotension Laboratory Abnormalities Table describes Grade,1
KYPROLIS,hypotension,failure renal failure acute renal impairment pulmonary edema and,0
KYPROLIS,hypotension,hypotension Laboratory Abnormalities Table,1
KYPROLIS,hypotension,hypotension Laboratory Abnormalities,1
KYPROLIS,hypotension,hypotension,1
KYPROLIS,hypotension,Laboratory,0
KYPROLIS,hypotension,Abnormalities Table describes Grade laboratory abnormalities r,0
KYPROLIS,Decreased Platelets,Reaction KyprolisN,0
KYPROLIS,Decreased Hemoglobin,Lymphocytes,0
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Decreased Total White Blood Cell Count Decreased Sodium,1
KYPROLIS,Decreased Total White Blood Cell Count,Lymphocytes,0
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Hemoglobin,0
KYPROLIS,Decreased Total White Blood Cell Count,Total White Blood Cell Count Decreased Sodium,1
KYPROLIS,Decreased Total White Blood Cell Count,Hemoglobin,0
KYPROLIS,Decreased Total White Blood Cell Count,Hemoglobin,0
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Decreased Total White Blood,1
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Total White Blood Cell Count Decreased,1
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Decreased Total White Blood,1
KYPROLIS,Decreased Total White Blood Cell Count,Decreased Total White Blood Cell Count,1
KYPROLIS,Decreased Sodium,White Blood Cell Decreased Sodium Decreased Absolute,1
KYPROLIS,Decreased Sodium,Decreased Total White Blood Cell Count,1
KYPROLIS,Decreased Sodium,Decreased Sodium,1
KYPROLIS,Decreased Sodium,Decreased Absolute Neu,0
KYPROLIS,Decreased Sodium,Decreased Absolute,0
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased,0
KYPROLIS,Decreased Absolute Neutrophil Count,Sodium,0
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Decreased Absolute Neutrophil,1
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Absolute Neutrophil Count Postmarketing Experience,1
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Decreased Absolute Neutrophil Count,1
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Absolute Neutrophil Count Postmarketing Experience,1
KYPROLIS,Decreased Absolute Neutrophil Count,Neutrophil Count Postmarketing Experience,1
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Decreased Absolute Neutrophil Count Postmarketing,1
KYPROLIS,Decreased Absolute Neutrophil Count,Neutrophil Count Postmarketing Experience,1
KYPROLIS,Decreased Absolute Neutrophil Count,Decreased Absolute,1
KYPROLIS,dehydration,dehydration thrombotic thrombocytopenic purpurahemolytic uremic,1
KYPROLIS,dehydration,or establish a causal relationship to,0
KYPROLIS,dehydration,exposure,0
KYPROLIS,dehydration,dehydration thrombotic,1
KYPROLIS,thrombotic thrombocytopenic purpura,establish a causal relationship,0
KYPROLIS,thrombotic thrombocytopenic purpura,or establish a causal relationship to,0
KYPROLIS,thrombotic thrombocytopenic purpura,causal relationship to drug exposure dehydration,0
KYPROLIS,thrombotic thrombocytopenic purpura,thrombocytopenic purpura hemolytic uremic,1
KYPROLIS,thrombotic thrombocytopenic purpura,thrombotic thrombocytopenic,1
KYPROLIS,thrombotic thrombocytopenic purpura,relationship to drug exposure thrombotic,1
KYPROLIS,hemolytic uremic syndrome,syndrome including fatal outcomes and posterior reversible encephalopathy,0
KYPROLIS,hemolytic uremic syndrome,dehydration thrombotic thrombocytopenic hemolytic uremic,1
KYPROLIS,hemolytic uremic syndrome,exposure dehydration thrombotic thrombocytopenic hemolytic,1
KYPROLIS,hemolytic uremic syndrome,to drug,0
KYPROLIS,hemolytic uremic syndrome,exposure dehydration thrombotic thrombocytopenic hemolytic uremic syndrome TTPHUS tumor lysis syndrome,1
KYPROLIS,hemolytic uremic syndrome,to drug,0
KYPROLIS,hemolytic uremic syndrome,thrombocytopenic hemolytic uremic,1
KYPROLIS,TTP,syndrome,0
KYPROLIS,TTP,TTP HUS,1
KYPROLIS,TTP,drug exposure dehydration thrombotic,0
KYPROLIS,TTP,TTP,1
KYPROLIS,TTP,dehydration thrombotic thrombocytopenic purpurahemolytic uremic,0
KYPROLIS,TTP,purpurahemolytic uremic TTP HUS tumor lysis syndrome including,1
KYPROLIS,TTP,dehydration thrombotic thrombocytopenic purpurahemolytic uremic,0
KYPROLIS,TTP,syndrome,0
KYPROLIS,TTP,TTP HUS tumor lysis,1
KYPROLIS,TTP,syndrome,0
KYPROLIS,tumor lysis syndrome,uremic,0
KYPROLIS,tumor lysis syndrome,lysis syndrome including fatal,1
KYPROLIS,tumor lysis syndrome,purpurahemolytic uremic syndrome tumor lysis syndrome including fatal outcomes and,1
KYPROLIS,tumor lysis syndrome,lysis syndrome including fatal,1
KYPROLIS,tumor lysis syndrome,rug exposure dehydration thrombotic,0
KYPROLIS,tumor lysis syndrome,lysis syndrome including fatal outcomes and posterior,1
KYPROLIS,tumor lysis syndrome,purpurahemolytic uremic syndrome tumor lysis syndrome,1
KYPROLIS,tumor lysis syndrome,lysis syndrome including fatal outcomes and posterior,1
KYPROLIS,tumor lysis syndrome,lysis syndrome including fatal outcomes and,1
KYPROLIS,fatal,fatal outcomes and posterior,1
KYPROLIS,fatal,thrombocytopenic purpurahemolytic uremic syndrome TTPHUS tumor,0
KYPROLIS,fatal,outcomes and posterior reversible encephalopathy syndrome,0
KYPROLIS,fatal,and posterior reversible encephalopathy syndrome PRES,0
KYPROLIS,fatal,outcomes and posterior reversible encephalopathy syndrome,0
KYPROLIS,fatal,reversible encephalopathy syndrome,0
KYPROLIS,fatal,uremic syndrome TTPHUS,0
KYPROLIS,Cardiac toxicities,ions are discussed,1
KYPROLIS,Cardiac toxicities,ions are discussed in,1
KYPROLIS,Cardiac toxicities,ions are discussed,1
KYPROLIS,Cardiac toxicities,sections of the labeling,0
KYPROLIS,Cardiac toxicities,are discussed in,1
KYPROLIS,Cardiac toxicities,ions are discussed in greater detail in other,1
KYPROLIS,Cardiac toxicities,are discussed in,1
KYPROLIS,cardiac failure,adverse reactions are discussed in great,0
KYPROLIS,myocardial infarction,ections,1
KYPROLIS,myocardial infarction,detail in other ections of the,1
KYPROLIS,myocardial infarction,and Precautions,0
KYPROLIS,myocardial infarction,ections of the labeli,1
KYPROLIS,myocardial infarction,and Precautions,0
KYPROLIS,myocardial infarction,Precautions Acute,0
KYPROLIS,myocardial infarction,discussed in,0
KYPROLIS,myocardial infarction,other ections of the labeli ng Cardiac Toxicities,1
KYPROLIS,myocardial infarction,discussed in,0
KYPROLIS,myocardial infarction,detail in other ections of the labeli ng Cardiac Toxicities see Warnings,1
KYPROLIS,myocardial infarction,discussed in,0
KYPROLIS,myocardial infarction,see Warnings and Precautions Acute,0
KYPROLIS,fatal,"
 *   Cardiac Toxicities see Warnings and",1
KYPROLIS,fatal,labeling,0
KYPROLIS,fatal,labeling,0
KYPROLIS,fatal,"other sections of the 
 *   Cardiac Toxicities see Warnings and",1
KYPROLIS,fatal,labeling,0
KYPROLIS,fatal,"
 *   Cardiac Toxicities see",1
KYPROLIS,fatal,the labeling,0
KYPROLIS,myocardial ischemia,Precautions Acute Renal Failure see Warnings and,0
KYPROLIS,myocardial ischemia,of the labeling Cardiac cities [ see Warnin,1
KYPROLIS,myocardial ischemia,labeling Cardiac cities [ see Warnin gs and Precautions,1
KYPROLIS,myocardial ischemia,of the labeling Cardiac cities [ see Warnin,1
KYPROLIS,myocardial ischemia,Renal Failure see Warnings,0
KYPROLIS,myocardial ischemia,gs and Precautions Acute Renal Failure,0
KYPROLIS,Acute Renal Failure,Failure,0
KYPROLIS,Acute Renal Failure,Lysis Syndrome see Warnings and,0
KYPROLIS,Acute Renal Failure,Syndrome see Warnings and Precautions,0
KYPROLIS,Acute Renal Failure,Renal see Warnings and Pr ecautions Tumor,1
KYPROLIS,Acute Renal Failure,Syndrome see Warnings and Precautions,0
KYPROLIS,Acute Renal Failure,and Pr ecautions Tumor Lysis Syndrome see,1
KYPROLIS,Acute Renal Failure,Failure,0
KYPROLIS,Acute Renal Failure,see Warnings and Precautions,0
KYPROLIS,Tumor Lysis Syndrome,Precautions Tumor Lysis Syndrome e,1
KYPROLIS,Tumor Lysis Syndrome,utions Pulmonary Toxicity see Warnings and,0
KYPROLIS,Tumor Lysis Syndrome,Precautions Tumor Lysis Syndrome e Warnings and Preca utions Pulmonary Toxicity see,1
KYPROLIS,Tumor Lysis Syndrome,utions Pulmonary Toxicity see Warnings and,0
KYPROLIS,Tumor Lysis Syndrome,Renal,0
KYPROLIS,Tumor Lysis Syndrome,and Preca utions Pulmonary Toxicity see Warnings,1
KYPROLIS,Tumor Lysis Syndrome,and Precautions Pulmo,0
KYPROLIS,Tumor Lysis Syndrome,Syndrome e Warnings and Preca utions,1
KYPROLIS,Tumor Lysis Syndrome,and Precautions Pulmo,0
KYPROLIS,Tumor Lysis Syndrome,Syndrome se,0
KYPROLIS,Tumor Lysis Syndrome,Tumor Lysis Syndrome e Warnings and Preca utions,1
KYPROLIS,Tumor Lysis Syndrome,Syndrome se,0
KYPROLIS,Tumor Lysis Syndrome,Renal Failure see Warnings and Precautions Tumor Lysis Syndrome,0
KYPROLIS,TLS,ion,1
KYPROLIS,TLS,s Pulmonary,0
KYPROLIS,Pulmonary Toxicity,Hypertension see Warnings d Precautions (,1
KYPROLIS,Pulmonary Toxicity,Warnings d Precautions (  5 Dyspnea see,1
KYPROLIS,Pulmonary Toxicity,Hypertension see Warnings d Precautions (,1
KYPROLIS,Acute Respiratory Distress Syndrome,[ see Warnings and Preca utions Hypertension see Warnings and,1
KYPROLIS,Acute Respiratory Distress Syndrome,utions Hypertension see Warnings and Precautions Venous Thro,0
KYPROLIS,Acute Respiratory Distress Syndrome,see Warnings and Preca utions Hypertension see Warnings,1
KYPROLIS,Acute Respiratory Distress Syndrome,Dyspnea [ see Warnings and Preca utions,1
KYPROLIS,Acute Respiratory Distress Syndrome,Warnings and    Dyspnea [ see Warnings and Preca utions Hypertension,1
KYPROLIS,Acute Respiratory Distress Syndrome,Dyspnea [ see Warnings and Preca utions,1
KYPROLIS,Acute Respiratory Distress Syndrome,see,0
KYPROLIS,Acute Respiratory Distress Syndrome,Warnings and    Dyspnea [ see Warnings and Preca utions Hypertension see,1
KYPROLIS,Acute Respiratory Distress Syndrome,see,0
KYPROLIS,acute respiratory failure,* H ypertension,1
KYPROLIS,acute respiratory failure,] * H ypertension,1
KYPROLIS,acute respiratory failure,) ] * H ypertension see Warnings and,1
KYPROLIS,acute respiratory failure,Warnings,0
KYPROLIS,acute respiratory failure,Warnings and ions ( 5.6 ),1
KYPROLIS,acute respiratory failure,* H ypertension see Warnings,1
KYPROLIS,acute respiratory failure,"see Warnings and ions (  5.6  ) ] 
 *    H ypertension",1
KYPROLIS,acute respiratory failure,* H ypertension see Warnings,1
KYPROLIS,acute respiratory failure,* H,1
KYPROLIS,acute respiratory failure,ions ( 5.6 ) ],1
KYPROLIS,acute diffuse infiltrative pulmonary disease,nsion,1
KYPROLIS,acute diffuse infiltrative pulmonary disease,and Precautions ( 5.7 Venous Thrombosis,1
KYPROLIS,Pulmonary Hypertension,nfusion Reactions see Warnings and,0
KYPROLIS,Pulmonary Hypertension,Warnings and,0
KYPROLIS,Pulmonary Hypertension,"s (  5.8  ) ] 
 *    I nfusion",1
KYPROLIS,Pulmonary Hypertension,Warnings and,0
KYPROLIS,Pulmonary Hypertension,Warnings and s ( 5.8,1
KYPROLIS,Pulmonary Hypertension,"see Warnings and s (  5.8  ) ] 
 *    I nfusion Reactions",1
KYPROLIS,Pulmonary Hypertension,Warnings and s ( 5.8,1
KYPROLIS,Pulmonary Hypertension,"s (  5.8  ) ] 
 *    I nfusion Reactions see Warnings",1
KYPROLIS,Pulmonary Hypertension,Warnings and s ( 5.8,1
KYPROLIS,Pulmonary Hypertension,Warnings and s ( 5.8 ),1
KYPROLIS,Pulmonary Hypertension,see Warnings,0
KYPROLIS,Pulmonary Hypertension,s ( 5.8 ) ] * I,1
KYPROLIS,Hypertension,and Precautions Toxicity and Hepatic Failure,1
KYPROLIS,Hypertension,s ( 5.8 ) ] * I,1
KYPROLIS,hypertensive crisis,and Hepatic,0
KYPROLIS,hypertensive crisis,Warnings,0
KYPROLIS,Infusion Reactions,5.13 )],1
KYPROLIS,Infusion Reactions,Warnings and Precaution,0
KYPROLIS,Infusion Reactions,PRES see Warnings and Precaution,0
KYPROLIS,Infusion Reactions,most common adverse events occurring in at least of patients treated with Ky,0
KYPROLIS,Thrombocytopenia,anemia,0
KYPROLIS,Thrombocytopenia,common adverse events occurring at least 20%,1
KYPROLIS,Hepatic Toxicity,"d platelets, dys pnea",1
KYPROLIS,Hepatic Toxicity,"thrombocytopenia nausea pyrexia d platelets, dys",1
KYPROLIS,Hepatic Toxicity,"d platelets, dys pnea",1
KYPROLIS,Hepatic Toxicity,pnea diarrhea decreased lymphocyte headache decreased hemoglobin cough edema,0
KYPROLIS,Hepatic Toxicity,"d platelets, dys",1
KYPROLIS,Hepatic Toxicity,"fatigue thrombocytopenia nausea pyrexia d platelets, dys",1
KYPROLIS,Hepatic Toxicity,anemia,0
KYPROLIS,Hepatic Toxicity,pyrexia,0
KYPROLIS,Hepatic Toxicity,pnea,0
KYPROLIS,Hepatic Failure,lymphocyte headache decreased hemoglobin cough,0
KYPROLIS,Hepatic Failure,"nausea pyrexia decreased platelets  diarrhea, decr",1
KYPROLIS,Hepatic Failure,lymphocyte headache decreased hemoglobin cough,0
KYPROLIS,Hepatic Failure,anemia fatigue thrombocytopenia nausea pyrexia decreased,0
KYPROLIS,Hepatic Failure,onotherapy trials anemia fatigue thrombocytopenia nausea pyrexia decreased platelets,0
KYPROLIS,Thrombotic thrombocytopenic purpura,patients treated,0
KYPROLIS,Thrombotic thrombocytopenic purpura,6 ) The most common advers e events occurring in,1
KYPROLIS,Thrombotic thrombocytopenic purpura,dyspnea diarrhea decreased,0
KYPROLIS,Thrombotic thrombocytopenic purpura,cough edema,0
KYPROLIS,Thrombotic thrombocytopenic purpura,The most common advers e events occurring,1
KYPROLIS,Thrombotic thrombocytopenic purpura,most common advers e events occurring in at,1
KYPROLIS,Thrombotic thrombocytopenic purpura,dyspnea diarrhea decreased lymphocyte headache decreased hemoglobin cough,0
KYPROLIS,Thrombotic thrombocytopenic purpura,in the combination therapy tria,0
KYPROLIS,hemolytic uremic syndrome,peripheral The most common events,1
KYPROLIS,hemolytic uremic syndrome,The most common  events occurring in at l east,1
KYPROLIS,hemolytic uremic syndrome,peripheral The most common events,1
KYPROLIS,hemolytic uremic syndrome,most common events occurring in,1
KYPROLIS,hemolytic uremic syndrome,with Kyprolis in the combination,0
KYPROLIS,hemolytic uremic syndrome,in at l east of,1
KYPROLIS,hemolytic uremic syndrome,events,1
KYPROLIS,hemolytic uremic syndrome,The most common events,1
KYPROLIS,hemolytic uremic syndrome,headache decreased hemoglobin cough edema peripheral The most,0
KYPROLIS,HUS,at 0%  of patients treated with Kyprolis,1
KYPROLIS,HUS,headache decreased hemoglobin cough edema peripheral The most,0
KYPROLIS,Posterior reversible encephalopathy syndrome,therapy trial decreased lymphocytes d absolute neutrophil,1
KYPROLIS,Posterior reversible encephalopathy syndrome,decreased total white blood cell count,0
KYPROLIS,PRES,white blood,0
KYPROLIS,PRES,"rus, anemia neutropenia decreased total",1
KYPROLIS,PRES,"rus, anemia neutropenia decreased",1
KYPROLIS,PRES,"decreased rus, anemia neutropenia",1
KYPROLIS,PRES,"rus, anemia neutropenia decreased",1
KYPROLIS,PRES,"rus, anemia neutropenia",1
KYPROLIS,PRES,"decreased rus, anemia",1
KYPROLIS,PRES,"rus, anemia neutropenia",1
KYPROLIS,PRES,ination,0
KYPROLIS,PRES,phospho,0
KYPROLIS,PRES,total white blood cell count decreased,0
KYPROLIS,Embryo-fetal Toxicity,"pyrexia muscle spasm ough, upper respirato ry tract infection decreased hemoglobin",1
KYPROLIS,Embryo-fetal Toxicity,total white blood cell count decreased,0
KYPROLIS,worsening of pre-existing cardiac failure,conducted under widely varying,0
KYPROLIS,worsening of pre-existing cardiac failure,AMGEN or FDA at A-1088 or,1
KYPROLIS,congestive heart failure,6.1 Clinical Trials Expe rience Because clinical trials are,1
KYPROLIS,congestive heart failure,AMGEN or FDA at A-1088 or,1
KYPROLIS,congestive heart failure,6.1 Clinical Trials Expe rience Because clinical trials,1
KYPROLIS,congestive heart failure,AMGEN or FDA at FDA,0
KYPROLIS,congestive heart failure,6.1 Clinical Trials Expe rience Because,1
KYPROLIS,pulmonary edema,Clinical,0
KYPROLIS,pulmonary edema,"ence

  Because",1
KYPROLIS,pulmonary edema,Clinical,0
KYPROLIS,pulmonary edema,adverse reaction rates observed,0
KYPROLIS,pulmonary edema,at FDA or wwwfdagovmedwatch,0
KYPROLIS,pulmonary edema,clinical trials are conducted under,0
KYPROLIS,pulmonary edema,"Trials ence

  Because clinical trials are conducted",1
KYPROLIS,pulmonary edema,clinical trials are conducted under,0
KYPROLIS,pulmonary edema,Clinical Trials ence Because,1
KYPROLIS,pulmonary edema,at FDA or wwwfdagovmedwatch Clinical,0
KYPROLIS,pulmonary edema,ence Because clinical trials are,1
KYPROLIS,pulmonary edema,"Trials ence

  Because clinical trials are conducted under",1
KYPROLIS,pulmonary edema,ence Because clinical trials are,1
KYPROLIS,decreased ejection fraction,d under widely,0
KYPROLIS,myocardial ischemia,Experience,0
KYPROLIS,myocardial ischemia,of a drug cannot be directly compared with rates,0
KYPROLIS,myocardial ischemia,adverse reactio n rates observed in the,1
KYPROLIS,myocardial ischemia,adverse reactio,1
KYPROLIS,myocardial ischemia,"under widely varying ns, adverse",1
KYPROLIS,myocardial ischemia,adverse reactio n,1
KYPROLIS,myocardial ischemia,"ns, adverse reactio",1
KYPROLIS,myocardial ischemia,rates in the clin,0
KYPROLIS,myocardial infarction,reaction s observed in the cli,1
KYPROLIS,myocardial infarction,widely,0
KYPROLIS,myocardial infarction,trials are conducted under widely varying conditions adverse,0
KYPROLIS,myocardial infarction,be directly compared with rates in the clinical trials of another drug,0
KYPROLIS,myocardial infarction,drug cannot be directly compared with rates in the clinical trials of another drug,0
KYPROLIS,myocardial infarction,s observed in the cli nical trials,1
KYPROLIS,myocardial infarction,in the cli nical trials of a drug,1
KYPROLIS,myocardial infarction,reaction s observed in the cli nical trials of a drug,1
KYPROLIS,myocardial infarction,in the cli nical trials of a drug,1
KYPROLIS,myocardial infarction,in the cli nical trials of a,1
KYPROLIS,fatalities,rates in the clinical trials of another drug,0
KYPROLIS,fatalities,observed in the clinical s of a dru g,1
KYPROLIS,fatalities,rates in the clinical trials of another drug,0
KYPROLIS,fatalities,of another drug and may,0
KYPROLIS,fatalities,s of a dru,1
KYPROLIS,fatalities,s of a dru,1
KYPROLIS,Death,Safety Experience ith K yprolis in Combination with Lenalidomide,1
KYPROLIS,Death,s of a dru,1
KYPROLIS,Death,Patients with Multiple Myeloma,0
KYPROLIS,Death,ith K yprolis in Combination,1
KYPROLIS,Death,ith K,1
KYPROLIS,Death,practice Safety Experience ith K,1
KYPROLIS,cardiac arrest,Multiple Myeloma The,0
KYPROLIS,acute renal failure,arm were pneumoni a,1
KYPROLIS,acute renal failure,in the Rd arm The most common,0
KYPROLIS,acute renal failure,the KRd arm as,0
KYPROLIS,acute renal failure,with the d arm,1
KYPROLIS,acute renal failure,with the d arm were pneumoni a,1
KYPROLIS,acute renal failure,with the d arm,1
KYPROLIS,acute renal failure,infection versus,0
KYPROLIS,acute renal failure,events reported in the KRd arm as,0
KYPROLIS,acute renal failure,tract infection versus pyrexia,0
KYPROLIS,Renal insufficiency adverse events,arm as compared with the Rd arm were pneumonia versus respiratory tract infection,0
KYPROLIS,Renal insufficiency adverse events,embolism versus Discontinuation due to any,0
KYPROLIS,Renal insufficiency adverse events,pyrexia (4% ver sus and pulmonary embolism,1
KYPROLIS,Renal insufficiency adverse events,"versus respiratory tract (4% versus 1.5%), pyrexia (4%",1
KYPROLIS,Renal insufficiency adverse events,infection,0
KYPROLIS,Renal insufficiency adverse events,tract (4% versus,1
KYPROLIS,Renal insufficiency adverse events,event,0
KYPROLIS,renal impairment,"s 2%), and pulmo nary embolism versus Discontinuation due",1
KYPROLIS,renal impairment,event,0
KYPROLIS,renal impairment,respiratory tract,0
KYPROLIS,renal impairment,versus pyrexia s,1
KYPROLIS,renal impairment,respiratory tract infection,0
KYPROLIS,acute renal failure,(3% ver sus,1
KYPROLIS,acute renal failure,versus pyrexia versus and ry embolism,1
KYPROLIS,acute renal failure,embolism (3% ver sus,1
KYPROLIS,acute renal failure,infection,0
KYPROLIS,acute renal failure,versus respiratory tract infection versus pyrexia versus,0
KYPROLIS,acute renal failure,arm,0
KYPROLIS,acute renal failure,ry embolism (3% ver sus Discontinuation,1
KYPROLIS,acute renal failure,ry embolism (3% ver sus Discontinuation due to,1
KYPROLIS,acute renal failure,versus pyrexia versus and ry embolism (3% ver,1
KYPROLIS,acute renal failure,versus pyrexia versus and ry embolism (3%,1
KYPROLIS,renal failure,infection versus pyrexia versus,0
KYPROLIS,renal failure,embolism,0
KYPROLIS,renal failure,event occurred in in the KRd arm,0
KYPROLIS,renal failure,embolism s 2%). Discon tinuation due to any,1
KYPROLIS,renal failure,event occurred in in the KRd arm,0
KYPROLIS,renal failure,s 2%). Discon tinuation due to any,1
KYPROLIS,renal failure,event occurred in in the KRd arm,0
KYPROLIS,renal failure,2%). Discon tinuation,1
KYPROLIS,renal failure,s 2%). Discon,1
KYPROLIS,renal failure,arm versus in,0
KYPROLIS,renal failure,and pulmonary embolism s 2%). Discon tinuation due to any adverse,1
KYPROLIS,renal failure,arm versus in,0
KYPROLIS,renal failure,s 2%). Discon tinuation due to any,1
KYPROLIS,renal failure,arm versus in,0
KYPROLIS,Acute renal failure,versus in the Rd rm. Adverse events  leading to discontinuation of,1
KYPROLIS,Acute renal failure,arm versus in,0
KYPROLIS,Acute renal failure,Rd rm. Adverse,1
KYPROLIS,Acute renal failure,patients and the most common,0
KYPROLIS,Acute renal failure,the KRd arm versus,0
KYPROLIS,Acute renal failure,the Rd rm.,1
KYPROLIS,Acute renal failure,any adverse event occurred in in the KRd arm versus in the Rd,0
KYPROLIS,Acute renal failure,rm. Adverse events leading to discontinuation,1
KYPROLIS,TLS,lenalidomideand lowdose,0
KYPROLIS,TLS,Kyprolis lenalidomideand lowdose has one Rd lenalidomide,1
KYPROLIS,TLS,lenalidomideand lowdose,0
KYPROLIS,TLS,has one Rd lenalidomide and,1
KYPROLIS,TLS,lenalidomideand lowdose,0
KYPROLIS,TLS,has one Rd lenalidomide and lowdose,1
KYPROLIS,TLS,has one Rd lenalidomide,1
KYPROLIS,fatal,Pneumonia includes preferred terms,0
KYPROLIS,fatal,alido mide and lowdose,1
KYPROLIS,fatal,lenalidomideand lowdose dexamethasone Rd len,0
KYPROLIS,fatal,alido mide and lowdose dexamethasone a,1
KYPROLIS,fatal,of,0
KYPROLIS,Acute Respiratory Distress Syndrome,Grade Grade Any,0
KYPROLIS,Acute Respiratory Distress Syndrome,Preferred Term Any Grade Grade Any Grade,1
KYPROLIS,Acute Respiratory Distress Syndrome,Class KRd ArmN Rd 389),1
KYPROLIS,Acute Respiratory Distress Syndrome,Any Grade Grade Any Grade,0
KYPROLIS,Acute Respiratory Distress Syndrome,"389)    
  Preferred Term           Any",1
KYPROLIS,Acute Respiratory Distress Syndrome,Any Grade Grade Any Grade,0
KYPROLIS,Acute Respiratory Distress Syndrome,Organ Class,0
KYPROLIS,Acute Respiratory Distress Syndrome,Preferred Term Any Grade,1
KYPROLIS,Acute Respiratory Distress Syndrome,"KRd ArmN Rd 389)    
  Preferred Term           Any Grade Grade",1
KYPROLIS,Acute Respiratory Distress Syndrome,Preferred Term Any Grade,1
KYPROLIS,Acute Respiratory Distress Syndrome,Rd 389) Preferred Term,1
KYPROLIS,ARDS,Grade,0
KYPROLIS,ARDS,     Any,1
KYPROLIS,ARDS,    ,1
KYPROLIS,ARDS,Grade Grade,0
KYPROLIS,ARDS,Any Grade Grade Blood,0
KYPROLIS,acute respiratory failure,ArmN Preferred,0
KYPROLIS,acute respiratory failure,Any Grad e,1
KYPROLIS,acute respiratory failure,Preferred Term,0
KYPROLIS,acute respiratory failure,Any Grad e Grade Any,1
KYPROLIS,acute respiratory failure,Any Grad,1
KYPROLIS,acute respiratory failure,Any Grade Grade Blood and Lymphatic,0
KYPROLIS,acute respiratory failure,Rd ArmN Preferred                  Any Grad,1
KYPROLIS,acute respiratory failure,Any Grade Grade Blood and Lymphatic,0
KYPROLIS,acute respiratory failure,Rd ArmN,0
KYPROLIS,acute respiratory failure,Grade Any Grade Grade Blood and Lymphatic System,0
KYPROLIS,acute respiratory failure,Grade Any Grade Grade Blood and Lymphatic,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,Term,0
KYPROLIS,acute diffuse infiltrative pulmonary disease,Term Any >=,1
KYPROLIS,acute diffuse infiltrative pulmonary disease,>= Grade 3 Any Grade >= Grade Blood and Lymphatic System,1
KYPROLIS,acute diffuse infiltrative pulmonary disease,Grade 3 Any Grade >=,1
KYPROLIS,acute diffuse infiltrative pulmonary disease,and Lymphatic,0
KYPROLIS,pneumonitis,"Grade Any Grade      
  Blo od and Lymphatic System",1
KYPROLIS,pneumonitis,and Lymphatic,0
KYPROLIS,interstitial lung disease,d Lymphatic System Disord ers,1
KYPROLIS,interstitial lung disease,Any,0
KYPROLIS,syncope,Tissue Disorders Muscle,0
KYPROLIS,syncope,onnecti ve Tissue Disorders Muscle,1
KYPROLIS,syncope,onnecti,1
KYPROLIS,syncope,and onnecti ve,1
KYPROLIS,syncope,onnecti,1
KYPROLIS,syncope,onnecti ve,1
KYPROLIS,syncope,C,0
KYPROLIS,syncope,onnecti ve Tissue,1
KYPROLIS,syncope,and onnecti ve Tissue Disorders,1
KYPROLIS,syncope,onnecti ve Tissue,1
KYPROLIS,syncope,Musculoskeletal and C,0
KYPROLIS,chest tightness,Musculoskeletal and Tissue Disorde,1
KYPROLIS,chest tightness,Musculoskeletal and Tissue Disorde,1
KYPROLIS,chest tightness,Musculoskeletal and  Tissue Disorde rs,1
KYPROLIS,chest tightness,Musculoskeletal and Tissue Disorde,1
KYPROLIS,chest tightness,Tissue Disorde rs,1
KYPROLIS,chest tightness,rs Muscle Spasms,0
KYPROLIS,angina,       Muscle Spasms,1
KYPROLIS,angina,       Muscle,1
KYPROLIS,angina,       Muscle Spasms,1
KYPROLIS,angina,and Connective Tissue        Muscle Spasms,1
KYPROLIS,angina,       Muscle Spasms,1
KYPROLIS,angina,       Muscle,1
KYPROLIS,PRES,neutropenia lymphopenia Cardiac s: c,1
KYPROLIS,PRES,ardiac arrest cardiac failure cardiac failure,0
KYPROLIS,PRES,s: c ardiac arrest,1
KYPROLIS,PRES,cardiac failure cardiac failure congestive myocardial infarction myocardial,0
KYPROLIS,PRES,neutropenia lymphopenia Cardiac s: c ardiac arrest cardiac,1
KYPROLIS,PRES,cardiac failure cardiac failure congestive myocardial infarction myocardial,0
KYPROLIS,PRES,Cardiac s: c ardiac arrest cardiac,1
KYPROLIS,PRES,cardiac failure cardiac failure congestive myocardial infarction myocardial,0
KYPROLIS,PRES,febrile neutropenia lymphopenia Cardiac s: c,1
KYPROLIS,PRES,s: c ardiac arrest cardiac failure cardiac,1
KYPROLIS,PRES,febrile neutropenia lymphopenia Cardiac s: c,1
KYPROLIS,fetal harm,and connective tissue disorders lar,1
KYPROLIS,embryo-fetal toxicity,"failure te, renal impairment  Respiratory thoracic",1
KYPROLIS,embryo-fetal toxicity,and connective tissue disorders lar,1
KYPROLIS,embryo-fetal toxicity,"renal failure te, renal impairment",1
KYPROLIS,embryo-fetal toxicity,"renal failure renal failure te,",1
KYPROLIS,embryo-fetal toxicity,"te, renal impairment  Respiratory",1
KYPROLIS,embryo-fetal toxicity,"renal failure renal failure te,",1
KYPROLIS,embryo-fetal toxicity,"renal failure renal failure te, renal impairment",1
KYPROLIS,embryo-fetal toxicity,"failure renal failure te, renal impairment ",1
KYPROLIS,embryo-fetal toxicity,"renal failure renal failure te, renal impairment",1
KYPROLIS,embryo-fetal toxicity,acu,0
KYPROLIS,embryo-fetal toxicity,renal impairment Respiratory thoracic and,1
KYPROLIS,embryo-fetal toxicity,mediastinal disorders dysphonia,0
YERVOY,Immune-mediated hepatitis,Immune-mediated hepatitis see,1
YERVOY,Immune-mediated hepatitis,Immune-mediated hepatitis see Warnings and Precautions Immunemediated,1
YERVOY,Immune-mediated hepatitis,Immune-mediated hepatitis,1
YERVOY,Immune-mediated hepatitis,Immune-mediated hepatitis,1
YERVOY,Immune-mediated hepatitis,Immunemediated dermatitis see Warnings,0
YERVOY,Immune-mediated hepatitis,labeling Immunemediated enterocolitis see,0
YERVOY,Immune-mediated hepatitis,Warnings and Immune-mediated hepatitis see Warnings and Precautions,1
YERVOY,Immune-mediated hepatitis,labeling Immunemediated enterocolitis see,0
YERVOY,Immune-mediated hepatitis,Immune-mediated hepatitis see,1
YERVOY,Immune-mediated neuropathies,Immune-mediated neuropathies see Warnings and Precautions Immunemediated,1
YERVOY,Immune-mediated neuropathies,ons Immunemediated dermatitis see Warnings and Precautions,0
YERVOY,Immune-mediated neuropathies,see Warnings and,0
YERVOY,Immune-mediated neuropathies,see Warnings and Immune-mediated,1
YERVOY,Immune-mediated neuropathies,Precautions Immunemediated endocrinopathies,0
YERVOY,Immune-mediated neuropathies,Warnings and Precautions Immunemediated,0
YERVOY,Immune-mediated neuropathies,Warnings and Precautions Immunemediated,0
YERVOY,Immune-mediated neuropathies,Precautions Immunemediated endocrinopathies see Warnings,0
YERVOY,Immune-mediated neuropathies,dermatitis see Warnings and Immune-mediated,1
YERVOY,Immune-mediated endocrinopathies,and Precautions,0
YERVOY,Immune-mediated endocrinopathies,Precautions,0
YERVOY,Immune-mediated endocrinopathies,Other immunemediated adverse reactions,0
YERVOY,Immune-mediated endocrinopathies,see Warnings and Immune-mediated endocrinopathies,1
YERVOY,Immune-mediated endocrinopathies,Immune-mediated endocrinopathies see Warnings,1
YERVOY,Immune-mediated endocrinopathies,neuropathies see Warnings and Immune-mediated endocrinopathies,1
YERVOY,Immune-mediated endocrinopathies,Warnings and,0
YERVOY,immune-mediated adverse reactions,and Precautions immune-mediated adverse reactions,1
YERVOY,immune-mediated adverse reactions,Precautions immune-mediated adverse reactions,1
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions including ocular,1
YERVOY,immune-mediated adverse reactions,Precautions immune-mediated adverse reactions including,1
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions including ocular,1
YERVOY,immune-mediated adverse reactions,and Precautions immune-mediated adverse reactions including,1
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions including ocular,1
YERVOY,immune-mediated adverse reactions,Warnings and Precautions immune-mediated adverse reactions,1
YERVOY,immune-mediated adverse reactions,and Precautions,0
YERVOY,ocular manifestations,ocular manifestations see Warnings and Precautions,1
YERVOY,ocular manifestations,ocular manifestations see,1
YERVOY,ocular manifestations,Other immunemediated adverse reactions,0
YERVOY,ocular manifestations,ocular manifestations see Warnings,1
YERVOY,ocular manifestations,adverse,0
YERVOY,ocular manifestations,adverse reactions ocular manifestations,1
YERVOY,ocular manifestations,immunemediated adverse reactions ocular manifestations see Warnings,1
YERVOY,ocular manifestations,adverse reactions ocular manifestations,1
YERVOY,ocular manifestations,Precautions EXCERPT Most common adverse reactions ar,0
YERVOY,ocular manifestations,immunemediated adverse reactions ocular,1
YERVOY,fatigue,fatigue diarrhea pruritus rash and,1
YERVOY,fatigue,immunemediated adverse reactions ocular,1
YERVOY,fatigue,fatigue,1
YERVOY,fatigue,fatigue diarrhea pruritus rash and colitis,1
YERVOY,diarrhea,diarrhea pruritus rash and colitis To,1
YERVOY,diarrhea,EXCERPT Most,0
YERVOY,rash,rash and colitis To,1
YERVOY,rash,EXCERPT Most,0
YERVOY,rash,fatigue diarrhea,0
YERVOY,rash,report SUSPECTED ADVERSE REACTIONS,0
YERVOY,rash,rash and colitis To report SUSPECTED,1
YERVOY,rash,reactions are fatigue diarrhea rash and colitis To report,1
YERVOY,rash,rash and colitis To report SUSPECTED,1
YERVOY,rash,rash and colitis To,1
YERVOY,rash,rash and colitis To report SUSPECTED,1
YERVOY,rash,rash and colitis To report,1
YERVOY,rash,report,0
YERVOY,rash,reactions are fatigue diarrhea rash and colitis To,1
YERVOY,rash,report,0
YERVOY,colitis,colitis,1
YERVOY,colitis,colitis To report SUSPECTED ADVERSE REACTIONS,1
YERVOY,colitis,colitis To report SUSPECTED ADVERSE REACTIONS,1
YERVOY,colitis,and,0
YERVOY,colitis,pruritus rash colitis To report SUSPECTED,1
YERVOY,colitis,and,0
YERVOY,colitis,fatigue diarrhea,0
YERVOY,colitis,colitis To report SUSPECTED,1
YERVOY,colitis,rash colitis To,1
YERVOY,colitis,colitis To report SUSPECTED,1
YERVOY,fatigue,common adverse,0
YERVOY,fatigue,most common adverse,0
YERVOY,fatigue,at mgkg fatigue diarrhea,1
YERVOY,fatigue,most common adverse,0
YERVOY,diarrhea,mgkg were diarrhea pruritus,1
YERVOY,diarrhea,most common adverse,0
YERVOY,diarrhea,The,0
YERVOY,pruritus,pruritus rash and,1
YERVOY,pruritus,Table presents selected adverse reactions from,0
YERVOY,pruritus,pruritus rash,1
YERVOY,pruritus,who received,0
YERVOY,pruritus,and colitis Table,0
YERVOY,pruritus,pruritus rash,1
YERVOY,pruritus,mgkg were,0
YERVOY,rash,rash,1
YERVOY,rash,rash and colitis,1
YERVOY,rash,rash and colitis Table,1
YERVOY,rash,rash,1
YERVOY,rash,were fatigue diarrhea pruritus,0
YERVOY,rash,were fatigue diarrhea rash and colitis Table presents,1
YERVOY,rash,were fatigue diarrhea pruritus,0
YERVOY,rash,rash and colitis Table presents selected,1
YERVOY,rash,were fatigue diarrhea rash and colitis Table presents,1
YERVOY,rash,rash and colitis Table presents selected,1
YERVOY,rash,colitis Table presents selected adverse reactions from Study which occurred in at le,0
YERVOY,rash,were fatigue diarrhea rash,1
YERVOY,rash,colitis Table presents selected adverse reactions from Study which occurred in at le,0
YERVOY,colitis,diarrhea,0
YERVOY,fatal,severe lifethreatening fatal immunemediated adverse reactions,1
YERVOY,fatal,diarrhea,0
YERVOY,fatal,lifethreatening or,0
YERVOY,fatal,lifethreatening,0
YERVOY,fatal,fatal immunemediated,1
YERVOY,fatal,fatal immunemediated adverse,1
YERVOY,fatal,severe lifethreatening fatal immunemediated adverse reactions from,1
YERVOY,fatal,fatal immunemediated adverse,1
YERVOY,fatal,of severe lifethreatening fatal immunemediated,1
YERVOY,fatal,fatal immunemediated adverse,1
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions from Study Table Severe,1
YERVOY,immune-mediated adverse reactions,of severe lifethreatening or immune-mediated adverse reactions,1
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions from Study Table Severe,1
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions from Study Table,1
YERVOY,immune-mediated adverse reactions,Fatal Immunemediated Adverse Reactions in Study,0
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions,1
YERVOY,immune-mediated adverse reactions,severe lifethreatening or immune-mediated adverse reactions from,1
YERVOY,immune-mediated adverse reactions,immune-mediated adverse reactions,1
YERVOY,Fatal,Adverse Reactions,0
YERVOY,Fatal,to,0
YERVOY,Fatal,Fatal Immunemediated Adverse Reactions,1
YERVOY,Fatal,adverse reactions from Study Table,0
YERVOY,Fatal,fethreatening or fatal immunemediated,0
YERVOY,Fatal,Fatal Immunemediated Adverse Reactions,1
YERVOY,Fatal,fethreatening or fatal immunemediated,0
YERVOY,Fatal,Study Table Severe Fatal Immunemediated Adverse Reactions,1
YERVOY,Fatal,fethreatening or fatal immunemediated,0
YERVOY,Fatal,from Study Table,0
YERVOY,Fatal,Table,0
YERVOY,Fatal,Including fatal outcome b,0
YERVOY,Immune-mediated Adverse Reactions,adverse,0
YERVOY,Immune-mediated Adverse Reactions,Adverse Reactions in Study,1
YERVOY,Immune-mediated Adverse Reactions,in Study a,0
YERVOY,Immune-mediated Adverse Reactions,Table,0
YERVOY,Immune-mediated Adverse Reactions,in Study a Including fatal outcome b Including intestinal perforation c,0
YERVOY,Immune-mediated Adverse Reactions,Adverse Reactions in Study,1
YERVOY,Immune-mediated Adverse Reactions,Severe to Immune-mediated Adverse,1
YERVOY,Immune-mediated Adverse Reactions,Study Table Severe,0
YERVOY,Immune-mediated Adverse Reactions,from Study Table Severe to Fatal,0
YERVOY,Immune-mediated Adverse Reactions,Fatal,0
YERVOY,fatal,a fatal outcome b Including intestinal perforation,1
YERVOY,fatal,Fatal,0
YERVOY,fatal,Reactions in,0
YERVOY,fatal,fatal outcome b,1
YERVOY,fatal,fatal outcome b,1
YERVOY,fatal,fatal outcome b,1
YERVOY,fatal,Severe to Fatal Immunemediated Adverse Reactions in Study,0
YERVOY,fatal,fatal outcome b Including,1
YERVOY,fatal,Reactions in Study a fatal outcome b Including intestinal perforation,1
YERVOY,fatal,fatal outcome b Including,1
YERVOY,fatal,fatal outcome b Including intestinal,1
YERVOY,fatal,fatal outcome b Including,1
YERVOY,fatal,Reactions,0
YERVOY,fatal,to Fatal Immunemediated Adverse,0
YERVOY,intestinal perforation,b intestinal perforation c Underlying,1
YERVOY,intestinal perforation,to Fatal Immunemediated Adverse,0
YERVOY,intestinal perforation,intestinal perforation c Underlying,1
YERVOY,intestinal perforation,etiology not established Perc,0
YERVOY,intestinal perforation,intestinal perforation c Underlying etiology not established,1
YERVOY,intestinal perforation,outcome b intestinal,1
YERVOY,intestinal perforation,intestinal perforation c Underlying etiology,1
YERVOY,Enterocolitis,Adverse Reaction,0
YERVOY,Enterocolitis,Adverse Enterocolitis ab,1
YERVOY,Enterocolitis,Adverse Reaction,0
YERVOY,Enterocolitis,Adverse Enterocolitis ab Hepa,1
YERVOY,Enterocolitis,Adverse Reaction,0
YERVOY,Enterocolitis,Enterocolitis ab Hepa,1
YERVOY,Enterocolitis,Enterocolitis ab,1
YERVOY,Enterocolitis,Enterocolitis,1
YERVOY,Enterocolitis,Enterocolitis ab,1
YERVOY,Enterocolitis,emediated Adverse Reaction,0
YERVOY,Enterocolitis,Reaction,0
YERVOY,urticaria,urticaria large intestinal,1
YERVOY,urticaria,urticaria large intestinal ulcer,1
YERVOY,esophagitis,noted urticaria large intestinal ulcer,0
YERVOY,esophagitis,esophagitis acute respiratory distress,1
YERVOY,esophagitis,and infusion reaction Based on the,0
YERVOY,acute respiratory distress syndrome,ulcer acute respiratory,1
YERVOY,acute respiratory distress syndrome,large intestinal ulcer acute respiratory distress,1
YERVOY,acute respiratory distress syndrome,distress syndrome,1
YERVOY,acute respiratory distress syndrome,distress syndrome renal failure and infusion reaction,1
YERVOY,acute respiratory distress syndrome,urticaria large intestinal ulcer acute respiratory,1
YERVOY,acute respiratory distress syndrome,urticaria large intestinal ulcer acute respiratory distress syndrome renal failure,1
YERVOY,acute respiratory distress syndrome,urticaria large intestinal ulcer acute respiratory,1
YERVOY,acute respiratory distress syndrome,respiratory distress syndrome renal failure and infusion reaction,1
YERVOY,infusion reaction,the incidence and,0
YERVOY,enterocolitis,enterocolitis and hepatitis,1
YERVOY,hepatitis,appear to be,0
YERVOY,Drug reaction with eosinophilia and systemic symptoms,DRESS,0
YERVOY,Drug reaction with eosinophilia and systemic symptoms,reaction with eosinophilia and systemic symptoms DRESS,1
YERVOY,Drug reaction with eosinophilia and systemic symptoms,Skin and Subcutaneous Tissue Drug reaction with eosinophilia and systemic symptoms,1
YERVOY,Drug reaction with eosinophilia and systemic symptoms,and Subcutaneous Tissue Drug reaction with eosinophilia and systemic symptoms DRESS syndrome Immunogenicity,1
YERVOY,Drug reaction with eosinophilia and systemic symptoms,Skin and Subcutaneous Tissue Drug reaction with eosinophilia and systemic symptoms,1
YERVOY,Drug reaction with eosinophilia and systemic symptoms,Drug reaction with eosinophilia and systemic symptoms DRESS syndrome,1
YERVOY,Drug reaction with eosinophilia and systemic symptoms,Skin and Subcutaneous Tissue Drug reaction with eosinophilia and systemic symptoms,1
YERVOY,Drug reaction with eosinophilia and systemic symptoms,clinical studies of,0
YERVOY,DRESS syndrome,and systemic DRESS,1
YERVOY,DRESS syndrome,Drug reaction with eosinophilia and,0
YERVOY,DRESS syndrome,eosinophilia and systemic DRESS syndrome Immunogenicity,1
YERVOY,DRESS syndrome,Drug reaction with eosinophilia and,0
YERVOY,peri-infusional reactions,peri-infusional reactions,1
YERVOY,peri-infusional reactions,peri-infusional reactions consistent with hypersensitivity,1
YERVOY,peri-infusional reactions,peri-infusional reactions,1
YERVOY,peri-infusional reactions,ipilimumab Infusionrelated peri-infusional,1
YERVOY,peri-infusional reactions,ipilimumab Infusionrelated peri-infusional reactions consistent with,1
YERVOY,peri-infusional reactions,ipilimumab Infusionrelated peri-infusional,1
YERVOY,peri-infusional reactions,peri-infusional reactions consistent with hypersensitivity or anaphylaxis,1
YERVOY,peri-infusional reactions,in these patients,0
YERVOY,peri-infusional reactions,peri-infusional reactions consistent with hypersensitivity,1
YERVOY,hypersensitivity,or periinfusional reactions consistent,0
YERVOY,hypersensitivity,periinfusional reactions consistent with,0
YERVOY,anaphylaxis,anaphylaxis were not,1
YERVOY,anaphylaxis,periinfusional reactions consistent with,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,of the labeling Immunemediated,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse reactions a re discussed in greater,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,of the labeling Immunemediated,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,detail in,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse reactions a,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,detail in,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,other sections,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,Warnings and Precautions,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,in other sectio ns,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,in greater detail in other sectio ns,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,adverse reactions are in greater detail in other sectio ns of the,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,in greater detail in other sectio ns,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,are in greater detail in,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,in greater detail in other sectio,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,are in greater detail in,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,in greater detail in other sectio ns of the,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,reactions are in greater detail in other sectio ns of the labeling,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,The following adverse,0
YERVOY,immune-mediated adverse reactions,the labeling d enterocolitis [see Warnings,1
YERVOY,immune-mediated adverse reactions,the labeling d enterocolitis,1
YERVOY,immune-mediated adverse reactions,sections of the labeling Immunemediate,0
YERVOY,immune-mediated adverse reactions,of the labeling d enterocolitis [see  Warnings an d,1
YERVOY,immune-mediated adverse reactions,sections of the labeling Immunemediate,0
YERVOY,immune-mediated adverse reactions,labeling d enterocolitis [see  Warnings an d Precautions Immunemediated hepatitis,1
YERVOY,immune-mediated adverse reactions,sections of the labeling Immunemediate,0
YERVOY,immune-mediated adverse reactions,other sections,0
YERVOY,immune-mediated adverse reactions,d enterocolitis [see,1
YERVOY,immune-mediated reactions,patitis [see Warnings an,1
YERVOY,immune-mediated reactions,Immunemediated dermatitis see Warnings,0
YERVOY,immune-mediated reactions,Precautions Immunemediated patitis [see,1
YERVOY,immune-mediated reactions,and Precautions Immunemediated patitis [see Warnings an,1
YERVOY,immune-mediated reactions,Precautions Immunemediated,0
YERVOY,immune-mediated reactions,d Precautions Immunemediated dermatitis,0
YERVOY,immune-mediated reactions,Warnings and,0
YERVOY,immune-mediated reactions,see Warnings and,0
YERVOY,immune-mediated reactions,Immunemediated dermatitis see Warnings,0
YERVOY,immune-mediated reactions,see Warnings,0
YERVOY,immune-mediated adverse reactions,Precautions (5.3) Immunemediated neuropathies see,1
YERVOY,immune-mediated adverse reactions,Immunemediated,0
YERVOY,immune-mediated adverse reactions,Precautions (5.3) Immunemediated neuropathies see,1
YERVOY,immune-mediated adverse reactions,Warnings,0
YERVOY,immune-mediated adverse reactions,see Warnings,0
YERVOY,immune-mediated adverse reactions,Immunemediated dermatitis e  Warnings and Precautions (5.3) Immunemediated,1
YERVOY,immune-mediated adverse reactions,see Warnings,0
YERVOY,immune-mediated adverse reactions,and Precautions (5.3),1
YERVOY,immune-mediated adverse reactions,Precautions Immunemediated,0
YERVOY,immune-mediated adverse reactions,and Precautions (5.3) Immunemediated neuropathies see Warnings and,1
YERVOY,enterocolitis,"Warnings and  
 *  ?  Immu nemediated neuropathies see Warnings",1
YERVOY,enterocolitis,and Precautions (5.3) Immunemediated neuropathies see Warnings and,1
YERVOY,enterocolitis,and Precautions Immunemediated,0
YERVOY,enterocolitis,dermatitis see Warnings and,0
YERVOY,hepatitis,-mediated neuropathies see Warnings,1
YERVOY,hepatitis,see Warnings and Precautions Immunemediated,0
YERVOY,hepatitis,Warnings,0
YERVOY,hepatitis,Warnings and Precautions,0
YERVOY,dermatitis,Warnings and Precautions Immunemediated europathie s see Warnings and Precautions,1
YERVOY,dermatitis,Warnings and Precautions,0
YERVOY,dermatitis,n,0
YERVOY,dermatitis,and Precautions Immunemediated europathie s,1
YERVOY,dermatitis,n,0
YERVOY,dermatitis,see Warnings and,0
YERVOY,dermatitis,europathie s see Warnings and Precautions,1
YERVOY,dermatitis,Precautions,0
YERVOY,dermatitis,europathie s see,1
YERVOY,toxic epidermal necrolysis,ings and,1
YERVOY,toxic epidermal necrolysis,and Precautions Immunemediated neuropathies,0
YERVOY,toxic epidermal necrolysis,ings and Precautions (5.4) Immunemediated endocrinopathies see Warnings and,1
YERVOY,toxic epidermal necrolysis,and Precautions Immunemediated neuropathies,0
YERVOY,toxic epidermal necrolysis,Precautions Immunemediated neuropathies see ings,1
YERVOY,toxic epidermal necrolysis,and,0
YERVOY,neuropathy,"see Warnings and  . 
 *  ?  Immunemediated endocrinopathies see Warnings",1
YERVOY,neuropathy,and,0
YERVOY,neuropathy,and Precautions Other,0
YERVOY,neuropathy,* ? Immunemediated endocrinopathies see,1
YERVOY,neuropathy,Precautions Other,0
YERVOY,neuropathy,. * ? Immunemediated endocrinopathies see,1
YERVOY,neuropathy,and .,1
YERVOY,neuropathy,"and  . 
 *  ?  Immunemediated endocrinopathies see",1
YERVOY,neuropathy,and .,1
YERVOY,endocrinopathy,see Warnings,0
YERVOY,endocrinopathy,e-mediated end ocrinopathies see Warnings and Precautions,1
YERVOY,endocrinopathy,neuropathies see Warnings and Precautions,0
YERVOY,endocrinopathy,neuropathies see Warnings and Precautions Immun,0
YERVOY,endocrinopathy,and Precautions e-mediated end ocrinopathies see Warnings,1
YERVOY,endocrinopathy,neuropathies see Warnings and Precautions Immun,0
YERVOY,endocrinopathy,Precautions e-mediated end ocrinopathies see Warnings and Precautions,1
YERVOY,endocrinopathy,neuropathies see Warnings and Precautions Immun,0
YERVOY,endocrinopathy,immunemediated adverse,0
YERVOY,endocrinopathy,Warnings and Precautions e-mediated end ocrinopathies,1
YERVOY,endocrinopathy,immunemediated adverse,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,experience with therapeutics n the same class and may not,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,the same class and may not refl,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,and may not refl ect the rates,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,n the,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,or experience with therapeutics n the same class and may not refl,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,practice The,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,directly compared with rates in other clinical trials or,0
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,experience with therapeutics n the same class and may not refl,1
YERVOY,IMMUNE-MEDIATED ADVERSE REACTIONS,directly compared with rates in other clinical trials or,0
YERVOY,fatal,program,0
YERVOY,fatal,ive a utoimmune disease or those receiving,1
YERVOY,fatal,for organ transplantation Exposure,0
YERVOY,fatal,organ transplantation,0
YERVOY,fatal,with,0
YERVOY,fatal,those receiving systemic immunosuppression for organ transplantation Exposure,0
YERVOY,fatal,ive a utoimmune disease or those,1
YERVOY,fatal,those receiving systemic immunosuppression for organ transplantation Exposure,0
YERVOY,immune-mediated adverse reactions,toimmune disease or those receivi ng,1
YERVOY,immune-mediated adverse reactions,those receiving systemic immunosuppression for organ transplantation Exposure,0
YERVOY,immune-mediated adverse reactions,ng systemic immunosuppression for organ transplantation Exposure to YERVOY,0
YERVOY,immune-mediated adverse reactions,or those receivi ng systemic immunosuppression for,1
YERVOY,immune-mediated adverse reactions,in clinical practice The clinical development program excluded patients with active au,0
YERVOY,immune-mediated adverse reactions,or those receivi ng systemic immunosuppression for organ,1
YERVOY,immune-mediated adverse reactions,patients with active toimmune disease or those receivi ng systemic immunosuppression,1
YERVOY,immune-mediated adverse reactions,or those receivi ng systemic immunosuppression for organ,1
YERVOY,immune-mediated adverse reactions,mgkg,0
YERVOY,immune-mediated adverse reactions,toimmune disease or those receivi ng systemic,1
YERVOY,immune-mediated adverse reactions,Exposure to YERVOY mgkg for doses given by intravenous,0
YERVOY,immune-mediated adverse reactions,study,0
YERVOY,enterocolitis,unresectable metastatic,1
YERVOY,enterocolitis,in previously treated patients with,0
YERVOY,enterocolitis,unresectable metastatic m,1
YERVOY,enterocolitis,metastatic m elanoma was assessed,1
YERVOY,enterocolitis,previously,0
YERVOY,enterocolitis,treated patients with unresectable  metastatic m elanoma was assessed,1
YERVOY,enterocolitis,previously,0
YERVOY,enterocolitis,unresectable metastatic,1
YERVOY,enterocolitis,with unresectable metastatic,1
YERVOY,enterocolitis,metastatic m elanoma was assessed in a,1
YERVOY,enterocolitis,randomized doubleblind clinical study,0
YERVOY,hepatitis,anoma was assessed in a randomized,1
YERVOY,hepatitis,with unresectable or metastatic anoma was,1
YERVOY,hepatitis,or metastatic anoma was assessed in,1
YERVOY,hepatitis,with unresectable or metastatic anoma was,1
YERVOY,hepatitis,with unresectable or metastatic anoma was,1
YERVOY,dermatitis,previously treated patients with unresectable or metastatic melanoma,0
YERVOY,dermatitis,ssessed in a randomized doubleblind,1
YERVOY,dermatitis,metastatic melanoma was ssessed in,1
YERVOY,dermatitis,melanoma was ssessed,1
YERVOY,toxic epidermal necrolysis,double-blind clinical s tudy Study See Clinical Studies,1
YERVOY,endocrinopathy,ee,1
YERVOY,endocrinopathy,or metastatic melanoma was assessed in a randomized doubleblind,0
YERVOY,endocrinopathy,One hundred thirtyone patients median age,0
YERVOY,endocrinopathy,Study,0
YERVOY,endocrinopathy,clinical study Study ee  Clinical S,1
YERVOY,endocrinopathy,Study,0
YERVOY,endocrinopathy,study Study ee,1
YERVOY,endocrinopathy,study Study ee  Clinical S tudies One hundred,1
YERVOY,endocrinopathy,study Study ee,1
YERVOY,immune-mediated reactions,See Clinical Studies One dred thirty-one patients  median age years male,1
YERVOY,immune-mediated reactions,study Study ee,1
YERVOY,immune-mediated reactions,agent patients median age,0
YERVOY,immune-mediated reactions,as,0
YERVOY,immune-mediated reactions,randomized doubleblind clinical study Study See Clinical Studies,0
YERVOY,fatal,adverse reactions are ssed  in greater detail in other,1
YERVOY,fatal,randomized doubleblind clinical study Study See Clinical Studies,0
YERVOY,fatal,ssed  in,1
YERVOY,fatal,the labeling Immunemediated enterocolitis see W,0
YERVOY,fatal,ssed  in greater detail in,1
YERVOY,fatal,ssed  in greater detail in other,1
YERVOY,fatal,in other sections of,0
YERVOY,immune-mediated reactions,reactions are discussed n greater detail in other,1
YERVOY,immune-mediated reactions,reactions are discussed n,1
YERVOY,immune-mediated reactions,ADVERSE REACTIONS The following adverse reactions are discussed,0
YERVOY,immune-mediated reactions,n greater detail in other,1
YERVOY,immune-mediated reactions,reactions are,0
YERVOY,immune-mediated reactions,adverse reactions are,0
YERVOY,Immune-mediated hepatitis,fatigue diarrhea,0
YERVOY,Immune-mediated endocrinopathies,(6.1) To report SU SPECTED,1
YERVOY,Immune-mediated endocrinopathies,diarrhea pruritus rash and tis. (6.1) To,1
YERVOY,diarrhea,varying conditions the,0
YERVOY,diarrhea,cannot be directly pared wi th rates in other,1
YERVOY,diarrhea,varying conditions the,0
YERVOY,diarrhea,under widely varying conditions the adverse reaction rates observed cannot,0
YERVOY,diarrhea,with therapeutics in the same class and may,0
YERVOY,diarrhea,clinical trials or experience with therapeutics in the same class and may,0
YERVOY,diarrhea,in the same,0
YERVOY,diarrhea,conditions the adverse reaction rates observed cannot be directly com,0
YERVOY,fever,other clinical trials exper ience with,1
YERVOY,fever,conditions the adverse reaction rates observed cannot be directly com,0
YERVOY,fever,in other clinical trials exper ience,1
YERVOY,fever,conditions the adverse reaction rates observed cannot be directly com,0
YERVOY,fever,exper ience,1
YERVOY,fever,not reflect the rates observed in clinical practic,0
YERVOY,fever,exper,1
YERVOY,fever,observed in clinical,0
YERVOY,fever,in clinical,0
YERVOY,fever,observed,0
YERVOY,fever,the rates observed,0
YERVOY,ileus,the rates observed,0
YERVOY,ileus,or nce w ith,1
YERVOY,ileus,the rates observed,0
YERVOY,ileus,nce w,1
YERVOY,ileus,in clinical practice,0
YERVOY,ileus,other clinical trials or nce w ith therapeutics in the,1
YERVOY,ileus,in clinical practice,0
YERVOY,peritoneal signs,or experience h therapeutics i n the,1
YERVOY,peritoneal signs,in clinical practice,0
YERVOY,immune-mediated enterocolitis,same ass and may not,1
YERVOY,immune-mediated enterocolitis,therapeutics in the same ass and may not reflect the r,1
YERVOY,immune-mediated enterocolitis,same ass and may not,1
YERVOY,immune-mediated enterocolitis,may not reflect the r ates observed in clinical,1
YERVOY,immune-mediated enterocolitis,same ass and may not reflect the r ates observed in,1
YERVOY,immune-mediated enterocolitis,may not reflect the r ates observed in clinical,1
YERVOY,immune-mediated enterocolitis,same ass and may not reflect the r ates,1
YERVOY,immune-mediated enterocolitis,may not reflect the r ates observed in clinical,1
YERVOY,immune-mediated enterocolitis,ass and may not reflect the,1
YERVOY,immune-mediated enterocolitis,in the same ass and may not reflect the r ates observed in clinical practice,1
YERVOY,immune-mediated enterocolitis,ass and may not reflect the,1
YERVOY,immune-mediated enterocolitis,experience with therapeutics in,0
YERVOY,immune-mediated enterocolitis,therapeutics in the same ass and may not reflect the r ates observed in clinical practice,1
YERVOY,immune-mediated enterocolitis,experience with therapeutics in,0
YERVOY,immune-mediated enterocolitis,therapeutics in the same ass and may not reflect the r ates observed,1
YERVOY,immune-mediated enterocolitis,experience with therapeutics in,0
YERVOY,diarrhea,ment,1
YERVOY,diarrhea,ment pro,1
YERVOY,diarrhea,ment,1
YERVOY,diarrhea,practice The clinical ment pro gram excluded patients with active,1
YERVOY,diarrhea,ment,1
YERVOY,diarrhea,ment pro gram excluded patients with,1
YERVOY,diarrhea,ment pro gram excluded patients,1
YERVOY,diarrhea,patients with active autoimmune disease,0
YERVOY,diarrhea,ment pro gram excluded patients,1
YERVOY,diarrhea,practice The clinical ment pro gram,1
YERVOY,diarrhea,ment pro gram excluded patients,1
YERVOY,abdominal pain,to YERVOY,0
YERVOY,abdominal pain,program excluded patients,0
YERVOY,abdominal pain,toimmune disea se or,1
YERVOY,abdominal pain,program excluded patients,0
YERVOY,abdominal pain,toimmune disea,1
YERVOY,abdominal pain,clinical development program excluded patients with active au,0
YERVOY,abdominal pain,organ transplantation Exposure to,0
YERVOY,abdominal pain,development,0
YERVOY,abdominal pain,toimmune disea se or those receiving,1
YERVOY,abdominal pain,development,0
YERVOY,abdominal pain,clinical,0
YERVOY,abdominal pain,patients with active toimmune disea se or,1
YERVOY,abdominal pain,clinical,0
YERVOY,blood in stool,development program,0
YERVOY,blood in stool,receiving sys temic immunosuppression for,1
YERVOY,blood in stool,receiving sys temic immunosuppression for organ,1
YERVOY,blood in stool,tice The,0
YERVOY,blood in stool,active autoimmune disease or receiving,1
YERVOY,blood in stool,active autoimmune disease or  receiving sys temic immunosuppression for,1
YERVOY,blood in stool,active autoimmune disease or receiving,1
YERVOY,blood in stool,active autoimmune disease or receiving sys,1
YERVOY,enterocolitis,receiving systemic osuppression  for,1
YERVOY,enterocolitis,active autoimmune disease or receiving sys,1
YERVOY,enterocolitis,transplantation Exposure to,0
YERVOY,enterocolitis,osuppression  for organ transplantation Exposure,1
YERVOY,enterocolitis,osuppression  for organ transplantation Exposure to,1
YERVOY,enterocolitis,osuppression  for organ transplantation Exposure,1
YERVOY,enterocolitis,organ transplantation Exposure to YERVOY mgkg for doses given by intravenous infusion in p,0
YERVOY,intestinal perforation,patients with unrese ctable or,1
YERVOY,intestinal perforation,clinical,0
YERVOY,intestinal perforation,lantation Exposure to YERVOY mgkg for doses given by intravenous infusion in previously,0
YERVOY,died,metastatic,0
YERVOY,enterocolitis,Clinical Stu dies,1
YERVOY,enterocolitis,One hundred thirtyone,0
YERVOY,enterocolitis,hundred thirtyone patients,0
YERVOY,enterocolitis,with an investigational gp peptide vaccine gp and patients,0
YERVOY,enterocolitis,with an investigational gp,0
YERVOY,enterocolitis,received YERVOY as a single,0
YERVOY,enterocolitis,an investigational,0
YERVOY,enterocolitis,ale) received YERVOY with an investigational,1
YERVOY,enterocolitis,median age years ale) received,1
YERVOY,enterocolitis,ale) received YERVOY with,1
YERVOY,enterocolitis,vestigational gp peptide,1
YERVOY,enterocolitis,years,0
YERVOY,enterocolitis,vestigational gp peptide vaccine,1
YERVOY,enterocolitis,male received gp pept,0
YERVOY,enterocolitis,vestigational gp peptide vaccine,1
YERVOY,enterocolitis,vestigational gp peptide vaccine gp and,1
YERVOY,enterocolitis,patients median age years male received,0
YERVOY,enterocolitis,with an vestigational gp peptide vaccine gp and,1
YERVOY,enterocolitis,patients median age years male received,0
YERVOY,enterocolitis,the study received,0
YERVOY,enterocolitis,male received gp peptide vaccine alone Patients in the study received a median of doses,0
YERVOY,enterocolitis,"7 years, 54% male received gp peptide vaccine",1
YERVOY,enterocolitis,"median 7 years,",1
YERVOY,enterocolitis,age,0
YERVOY,enterocolitis,"patients median 7 years,",1
YERVOY,enterocolitis,median of doses,0
YERVOY,enterocolitis,patients who received,0
YERVOY,enterocolitis,"hea, pruritus",1
YERVOY,enterocolitis,"hea, pruritus rash",1
YERVOY,enterocolitis,"hea, pruritus",1
YERVOY,enterocolitis,"were fatigue hea, pruritus rash and colitis",1
YERVOY,enterocolitis,"hea, pruritus",1
YERVOY,enterocolitis,reactions,0
YERVOY,enterocolitis,fatigue diarr,0
YERVOY,immune-mediated enterocolitis,regardless of,0
YERVOY,immune-mediated enterocolitis,events regardless,0
YERVOY,immune-mediated enterocolitis,Reactions in 1 a,1
YERVOY,immune-mediated enterocolitis,"1 
   a     Incidences presen ted in this table are",1
YERVOY,immune-mediated enterocolitis,Reactions in 1 a,1
YERVOY,immune-mediated enterocolitis,"in 1 
   a     Incidences presen ted in",1
YERVOY,immune-mediated enterocolitis,Reactions in 1 a,1
YERVOY,immune-mediated enterocolitis,1 a Incidences presen ted in,1
YERVOY,enterocolitis,are based,0
YERVOY,enterocolitis,              Percentage of Patientsa YERVOY,1
YERVOY,enterocolitis,of Patientsa YERVOY,0
YERVOY,enterocolitis,              Percentage of Patientsa YERVOY,1
YERVOY,enterocolitis,of Patientsa YERVOY,0
YERVOY,enterocolitis,              Percentage of Patientsa,1
YERVOY,enterocolitis,             ,1
YERVOY,enterocolitis,presented in this,0
YERVOY,enterocolitis,adverse events,0
YERVOY,enterocolitis,of Patientsa YERVOY,0
YERVOY,enterocolitis,ntsa YERVOY,0
YERVOY,enterocolitis,"YERVOY mgkggpn 00n=132    
 ",1
YERVOY,enterocolitis,ntsa YERVOY,0
YERVOY,enterocolitis,"00n=132    
  System",1
YERVOY,enterocolitis,"00n=132    
  System",1
YERVOY,enterocolitis,"00n=132    
  System",1
YERVOY,enterocolitis,"mgkgn YERVOY mgkggpn 00n=132    
  System Organ",1
YERVOY,enterocolitis,"00n=132    
  System",1
YERVOY,enterocolitis,"00n=132    
  System",1
YERVOY,hepatotoxicity,n. c Unde rlying etiology not established,1
YERVOY,hepatotoxicity,rlying,0
YERVOY,hepatotoxicity,intestinal n.  c     Unde rlying etiology not established,1
YERVOY,hepatotoxicity,rlying,0
YERVOY,hepatotoxicity,n. c,1
YERVOY,hepatotoxicity,outcome b Including intestinal n. c,1
YERVOY,hepatotoxicity,outcome b Including intestinal n. c Unde,1
YERVOY,hepatotoxicity,outcome b Including intestinal n.  c     Unde,1
YERVOY,hepatotoxicity,outcome b Including intestinal n. c Unde,1
YERVOY,hepatotoxicity,intestinal n.  c     Unde rlying etiology not,1
YERVOY,hepatotoxicity,outcome b Including intestinal n. c Unde,1
YERVOY,ALT elevations,perforation c Underlying iology not est,1
YERVOY,ALT elevations,outcome b Including intestinal n. c Unde,1
YERVOY,ALT elevations,ablished Percentage of,0
YERVOY,ALT elevations,Percentage of,0
YERVOY,ALT elevations,iology not est ablished,1
YERVOY,ALT elevations,Percentage,0
YERVOY,ALT elevations,iology not est ablished Percentage of,1
YERVOY,ALT elevations,Percentage,0
YERVOY,total bilirubin elevations,c Underlying etiology not          Percentage (%) of Patients YERVOY,1
YERVOY,total bilirubin elevations,Percentage,0
YERVOY,total bilirubin elevations,(%) of Patients YERVOY,1
YERVOY,total bilirubin elevations,(%) of Patients YERVOY mgkgn,1
YERVOY,hepatic failure,mgkgn YERVOY mgkggpn,0
YERVOY,hepatic failure,Any Immunemediated,0
YERVOY,hepatic failure,"=380        
   Any Immunemediated",1
YERVOY,hepatic failure,"YERVOY =380        
   Any Immunemediated Adverse",1
YERVOY,hepatic failure,"=380        
   Any Immunemediated",1
YERVOY,increases in transaminases,s were also reported (inci dence less than unless,1
YERVOY,increases in transaminases,from to mgkg the following adverse reaction,0
YERVOY,increases in transaminases,unless otherwise noted urticaria large,0
YERVOY,increases in transaminases,less than unless otherwise noted urticaria large intestinal,0
YERVOY,increases in transaminases,were also reported (inci dence,1
YERVOY,increases in transaminases,s were also reported (inci dence,1
YERVOY,increases in transaminases,s were also reported (inci dence less than unless otherwise,1
YERVOY,increases in transaminases,s were also reported (inci dence,1
YERVOY,increases in transaminases,less than unless otherwise noted urticaria,0
YERVOY,increases in transaminases,dence less than unless otherwise noted urticaria large intestinal ulcer esophagitis acu,0
YERVOY,increases in transaminases,were also reported (inci dence less than unless otherwise,1
YERVOY,increases in total bilirubin,noted): urticaria (2% large intestinal ulcer esophagitis acute,1
YERVOY,increases in total bilirubin,intestinal ulcer esophagitis acute respiratory,0
YERVOY,increases in total bilirubin,urticaria (2% large intestinal,1
YERVOY,increases in total bilirubin,reactions were also reported incidence less than unless,0
YERVOY,increases in total bilirubin,unless erwise noted): urticaria (2% large intestinal ulcer,1
YERVOY,increases in total bilirubin,reactions were also reported incidence less than unless,0
YERVOY,increases in total bilirubin,urticaria (2% large,1
YERVOY,fatal, and  severity of enterocolitis,1
YERVOY,immune-mediated dermatitis,melanoma the incidence and everity of enterocolitis a,1
YERVOY,immune-mediated dermatitis, and  severity of enterocolitis,1
YERVOY,Stevens-Johnson syndrome,severity of enterocolitis and atitis appear to be dose dependent Postmarketing Experience The,1
YERVOY,Stevens-Johnson syndrome, and  severity of enterocolitis,1
YERVOY,Stevens-Johnson syndrome,Postmarketing Experience The,0
YERVOY,Stevens-Johnson syndrome,for melanoma the incidence and severity,0
YERVOY,Stevens-Johnson syndrome,and atitis appear to be dose dependent Postmarketing Experience,1
YERVOY,Stevens-Johnson syndrome,for melanoma the incidence and severity,0
YERVOY,toxic epidermal necrolysis,enterocolitis and hepatitis,0
YERVOY,toxic epidermal necrolysis,"appear to be dose ependent.



   6.2   Post",1
YERVOY,toxic epidermal necrolysis,enterocolitis and hepatitis,0
YERVOY,toxic epidermal necrolysis,identified during postapproval,0
YERVOY,rash,be dose dependent ting Experience The following adverse,1
YERVOY,rash,identified during postapproval,0
YERVOY,rash,following adverse reactions have been identified during postapproval use of YERVO,0
YERVOY,rash,ting Experience The following adverse reactions,1
YERVOY,rash,ting Experience The following adverse reactions,1
YERVOY,rash,The following adverse reactions have been identified during,0
YERVOY,rash,to be dose dependent ting Experience The following adverse,1
YERVOY,rash,The following adverse reactions have been identified during,0
YERVOY,rash,enterocolitis and hepatitis appear,0
YERVOY,rash,to be dose dependent ting Experience The following,1
YERVOY,rash,enterocolitis and hepatitis appear,0
YERVOY,rash,severity of enterocolitis and hepatitis appear to be dose dependent,0
YERVOY,rash,ting,1
YERVOY,dermal ulceration,following,0
YERVOY,dermal ulceration,verse reactions h,1
YERVOY,dermal ulceration,following ad,0
YERVOY,dermal ulceration,The following verse reactions h ave been,1
YERVOY,dermal ulceration,following ad,0
YERVOY,dermal ulceration,identified,0
YERVOY,dermal ulceration,hepatitis appear to be dose dependent Postmarketing Experience The following,0
YERVOY,died,of YERVOY Because these reactions are reported voluntarily from,0
YERVOY,died,of in,1
YERVOY,died,use of YERVOY Because these reactions are reported voluntarily,0
YERVOY,died,estimate their frequency or establish a causal,0
YERVOY,died,in s ize it is not always,1
YERVOY,died,in,1
YERVOY,died,uncerta,0
YERVOY,died,population of in,1
YERVOY,died,these reactions are reported voluntarily from a population of,0
YERVOY,toxic epidermal necrolysis,not lways possible to reliably estimate their,1
YERVOY,toxic epidermal necrolysis,these reactions are reported voluntarily from a population of,0
YERVOY,toxic epidermal necrolysis,not lways possible to reliably estimate,1
YERVOY,toxic epidermal necrolysis,these reactions are reported voluntarily from a population of,0
YERVOY,toxic epidermal necrolysis,a population of uncertain,0
YERVOY,toxic epidermal necrolysis,size it is not lways,1
YERVOY,toxic epidermal necrolysis,or establish a causal relationship to drug exposure Skin,0
YERVOY,toxic epidermal necrolysis,or establish a causal relationship to drug exposure Skin and Subcut,0
YERVOY,toxic epidermal necrolysis,possible to reliably,1
YERVOY,dermatitis,relationship drug expos ure Skin and Subcutaneous Tissue,1
YERVOY,dermatitis,possible to reliably,1
YERVOY,dermatitis,ure Skin and Subcutaneous Tissue Disorders Drug reaction,0
YERVOY,dermatitis,causal relationship drug expos ure Skin,1
YERVOY,dermatitis,ure Skin and Subcutaneous Tissue Disorders Drug reaction,0
YERVOY,dermatitis,a causal relationship drug expos,1
YERVOY,dermatitis,drug expos ure Skin and Subcutaneous,1
YERVOY,dermatitis,and systemic,0
YERVOY,dermatitis,Immunogenicity In,0
YERVOY,dermatitis,and,0
YERVOY,dermatitis,g reaction with eosinophilia and,1
YERVOY,dermatitis,to drug exposure,0
YERVOY,dermatitis,Disorders g reaction,1
YERVOY,dermatitis,to drug exposure,0
YERVOY,dermatitis,and Subcutaneous Tissue Disorders g reaction with eosinophilia and systemic,1
YERVOY,dermatitis,to drug exposure,0
YERVOY,dermatitis,Tissue Disorders g reaction with eosinophilia and systemic,1
YERVOY,dermatitis,to drug exposure,0
YERVOY,dermatitis,and systemic symptoms DRESS,0
YERVOY,dermatitis,Disorders g reaction,1
YERVOY,dermatitis,Subcutaneous Tissue Disorders g reaction with eosinophilia and systemic symptoms,1
YERVOY,dermatitis,Disorders g reaction,1
YERVOY,immune-mediated dermatitis,"symptoms DRESS syndrome munogenicity

  In clinica l studies",1
YERVOY,immune-mediated dermatitis,Disorders g reaction,1
YERVOY,immune-mediated dermatitis,binding,0
YERVOY,immune-mediated dermatitis,Drug reaction with eosinophilia,0
YERVOY,immune-mediated dermatitis,syndrome munogenicity,1
YERVOY,immune-mediated dermatitis,munogenicity In clinica l studies of evaluable patients,1
YERVOY,immune-mediated dermatitis,In clinica l studies of evaluable,1
YERVOY,immune-mediated dermatitis,"systemic symptoms DRESS syndrome munogenicity

  In clinica l studies of evaluable patients",1
YERVOY,immune-mediated dermatitis,In clinica l studies of evaluable,1
YERVOY,immune-mediated dermatitis,In clinica l studies of evaluable,1
YERVOY,immune-mediated dermatitis,l,0
YERVOY,dermatitis,against ipilimumab in an cent (ECL),1
YERVOY,dermatitis,based assay This assay has substantial limitations in detecting,0
YERVOY,dermatitis,cent (ECL) based,1
YERVOY,dermatitis,cent (ECL) based,1
YERVOY,dermatitis,cent (ECL),1
YERVOY,dermatitis,an cent (ECL),1
YERVOY,dermatitis,cent (ECL),1
YERVOY,dermatitis,interfere with,0
YERVOY,dermatitis,tralizing  antibodies against ipilimumab detected Because,1
YERVOY,dermatitis,were not reported in these patients nor were,0
YERVOY,dermatitis,tralizing ,1
YERVOY,dermatitis,tralizing  antibodies against ipilimumab detected Because,1
YERVOY,dermatitis,tralizing ,1
YERVOY,dermatitis,were,0
YERVOY,dermatitis,nor were tralizing ,1
YERVOY,dermatitis,were,0
YERVOY,dermatitis,tralizing  antibodies against ipilimumab detected,1
YERVOY,dermatitis,of ipilimumab interfere with the,0
GADAVIST,Nephrogenic Systemic Fibrosis,reactions are discussed elsewhere in labeling,0
GADAVIST,Nephrogenic Systemic Fibrosis,following serious adverse reactions are discussed elsewhere in,0
GADAVIST,Nephrogenic Systemic Fibrosis,in Nephrogenic Systemic Fibrosis NSF see,1
GADAVIST,Nephrogenic Systemic Fibrosis,following serious adverse reactions are discussed elsewhere in,0
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF see Boxed,1
GADAVIST,Nephrogenic Systemic Fibrosis,see Boxed Warning and Warnings and,0
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF see Boxed Warning,1
GADAVIST,Nephrogenic Systemic Fibrosis,see Boxed Warning and Warnings and,0
GADAVIST,Nephrogenic Systemic Fibrosis,are,0
GADAVIST,Nephrogenic Systemic Fibrosis,are discussed elsewhere in Nephrogenic,1
GADAVIST,NSF,in labeling Nephrogenic Systemic NSF see Boxed Warning,1
GADAVIST,NSF,are discussed elsewhere in Nephrogenic,1
GADAVIST,NSF,NSF see Boxed Warning,1
GADAVIST,NSF,adverse,0
GADAVIST,NSF,NSF see Boxed Warning and,1
GADAVIST,NSF,are,0
GADAVIST,NSF,NSF see,1
GADAVIST,Hypersensitivity reactions,see Boxed Warning and Warnings and,0
GADAVIST,Hypersensitivity reactions,Warning,0
GADAVIST,headache,REACTIONS contact,0
GADAVIST,headache,reactions incidence headache nausea and dizziness To report,1
GADAVIST,headache,REACTIONS contact,0
GADAVIST,headache,headache,1
GADAVIST,headache,incidence headache nausea and dizziness To,1
GADAVIST,headache,headache,1
GADAVIST,headache,reactions incidence,0
GADAVIST,headache,headache nausea and dizziness To,1
GADAVIST,headache,SUSPECTED ADVERSE REACTIONS,0
GADAVIST,headache,common adverse reactions incidence are,0
GADAVIST,headache,reactions incidence headache nausea and dizziness To,1
GADAVIST,headache,common adverse reactions incidence are,0
GADAVIST,nausea,nausea,1
GADAVIST,nausea,incidence,0
GADAVIST,nausea,are nausea,1
GADAVIST,nausea,incidence,0
GADAVIST,nausea,are,0
GADAVIST,nausea,nausea and,1
GADAVIST,dizziness,reactions incidence are headache nausea and,0
GADAVIST,dizziness,dizziness,1
GADAVIST,dizziness,Most common adverse reactions incidence are headache nausea,0
GADAVIST,dizziness,dizziness To,1
GADAVIST,dizziness,dizziness,1
GADAVIST,dizziness,SUSPECTED ADVERSE REACTIONS contact Bayer HealthCare Pharmaceuticals In,0
GADAVIST,dizziness,dizziness To report SUSPECTED ADVERSE REACTIONS,1
GADAVIST,dizziness,headache nausea dizziness To report SUSPECTED ADVERSE REACTIONS,1
GADAVIST,dizziness,dizziness To report SUSPECTED ADVERSE REACTIONS,1
GADAVIST,dizziness,dizziness To,1
GADAVIST,dizziness,REACTIONS contact Bayer HealthCare Pharmaceuticals In,0
GADAVIST,Pruritus,Pruritus,1
GADAVIST,Pruritus,includes generalized Erythe,0
GADAVIST,hypotension,anaphylactoid reaction,0
GADAVIST,hypotension,hypotension,1
GADAVIST,hypotension,hypotension,1
GADAVIST,hypotension,hypotension urticaria,1
GADAVIST,hypotension,hypotension urticaria face edema eyelid,1
GADAVIST,hypotension,face edema eyelid edema,0
GADAVIST,hypotension,reactions for hypotension urticaria face,1
GADAVIST,hypotension,face edema eyelid edema,0
GADAVIST,hypotension,for example,0
GADAVIST,hypotension,the following,0
GADAVIST,hypotension,hypotension urticaria face edema eyelid edema,1
GADAVIST,urticaria,adverse reactions for example hypotension,0
GADAVIST,urticaria,urticaria face edema eyelid edema,1
GADAVIST,urticaria,eyelid edema,0
GADAVIST,face edema,occurred with a frequency of in,0
GADAVIST,face edema,adverse reactions for example,0
GADAVIST,face edema,of the following adverse reactions for example,0
GADAVIST,face edema,hypotension face,1
GADAVIST,face edema,of,0
GADAVIST,face edema,for example hypotension face edema,1
GADAVIST,face edema,of,0
GADAVIST,face edema,hypotension face edema eyelid edema flushing,1
GADAVIST,face edema,of,0
GADAVIST,face edema,for example hypotension face,1
GADAVIST,face edema,reactions for example hypotension,0
GADAVIST,eyelid edema,eyelid edema flushing Adverse reactions that,1
GADAVIST,eyelid edema,face eyelid edema,1
GADAVIST,eyelid edema,eyelid edema flushing Adverse reactions that,1
GADAVIST,eyelid edema,eyelid edema,1
GADAVIST,flushing,flushing Adverse reactions that occurred,1
GADAVIST,flushing,eyelid edema,1
GADAVIST,flushing,of the following,0
GADAVIST,flushing,flushing Adverse reactions that,1
GADAVIST,flushing,flushing Adverse reactions that,1
GADAVIST,flushing,in subjects who,0
GADAVIST,loss of consciousness,of consciousness convulsion parosmia tachycardia palpitation,1
GADAVIST,loss of consciousness,with a frequency of,0
GADAVIST,loss of consciousness,subjects who received Gadavist loss of consciousness convulsion parosmia tachycardia palpitation dry,1
GADAVIST,loss of consciousness,with a frequency of,0
GADAVIST,loss of consciousness,occurred with a frequency of in subjects who received,0
GADAVIST,loss of consciousness,of consciousness convulsion,1
GADAVIST,loss of consciousness,who received Gadavist loss of consciousness convulsion parosmia tachycardia palpitation,1
GADAVIST,loss of consciousness,of consciousness convulsion,1
GADAVIST,loss of consciousness,Gadavist loss of,1
GADAVIST,loss of consciousness,frequency of in subjects who,0
GADAVIST,loss of consciousness,loss of consciousness convulsion parosmia tachycardia palpitation dry,1
GADAVIST,loss of consciousness,frequency of in subjects who,0
GADAVIST,convulsion,tachycardia palpitation dry mouth,0
GADAVIST,convulsion,palpitation dry mouth malaise and,0
GADAVIST,convulsion,Gadavist include loss of convulsion,1
GADAVIST,convulsion,palpitation dry mouth malaise and,0
GADAVIST,convulsion,convulsion parosmia tachycardia palpitation,1
GADAVIST,parosmia,include loss of consciousness parosmia tachycardia palpitation dry,1
GADAVIST,parosmia,convulsion parosmia tachycardia palpitation,1
GADAVIST,parosmia,parosmia tachycardia palpitation dry,1
GADAVIST,parosmia,convulsion parosmia tachycardia palpitation,1
GADAVIST,parosmia,parosmia tachycardia,1
GADAVIST,parosmia,parosmia tachycardia palpitation dry mouth malaise,1
GADAVIST,parosmia,consciousness parosmia tachycardia palpitation dry mouth,1
GADAVIST,parosmia,parosmia tachycardia palpitation dry mouth malaise,1
GADAVIST,parosmia,parosmia,1
GADAVIST,parosmia,tachycardia palpitation dry mouth,0
GADAVIST,parosmia,mouth malaise and feeling cold Postmarketing,0
GADAVIST,parosmia,loss,0
GADAVIST,tachycardia,subjects who received Gadavist include loss of consciousness convulsion,0
GADAVIST,tachycardia,tachycardia palpitation dry mouth malaise,1
GADAVIST,tachycardia,tachycardia palpitation,1
GADAVIST,tachycardia,tachycardia,1
GADAVIST,tachycardia,tachycardia palpitation dry,1
GADAVIST,tachycardia,parosmia,0
GADAVIST,tachycardia,tachycardia palpitation,1
GADAVIST,tachycardia,parosmia,0
GADAVIST,tachycardia,Experience The,0
GADAVIST,tachycardia,tachycardia,1
GADAVIST,tachycardia,Experience The,0
GADAVIST,palpitation,Postmarketing Experience The following additiona,0
GADAVIST,palpitation,include,0
GADAVIST,dry mouth,The following additional,0
GADAVIST,dry mouth,consciousness convulsion parosmia tachycardia dry mouth malaise and feeling cold Postmarketing,1
GADAVIST,dry mouth,The following additional,0
GADAVIST,malaise,dry mouth,0
GADAVIST,malaise,malaise and feeling cold Postmarketing,1
GADAVIST,malaise,malaise and feeling cold,1
GADAVIST,malaise,malaise and,1
GADAVIST,malaise,tachycardia,0
GADAVIST,malaise,cold Postmarketing Experience,0
GADAVIST,malaise,malaise,1
GADAVIST,malaise,dry malaise and feeling cold Postmarketing Experience,1
GADAVIST,malaise,malaise,1
GADAVIST,feeling cold,feeling cold Postmarketing Experience The,1
GADAVIST,feeling cold,malaise,1
GADAVIST,feeling cold,feeling cold Postmarketing Experience,1
GADAVIST,feeling cold,feeling cold,1
GADAVIST,feeling cold,consciousness convulsion parosmia,0
GADAVIST,feeling cold,adverse reactions have been reporte,0
GADAVIST,feeling cold,feeling cold Postmarketing Experience,1
GADAVIST,feeling cold,palpitation dry mouth malaise feeling cold Postmarketing Experience The following,1
GADAVIST,feeling cold,feeling cold Postmarketing Experience,1
GADAVIST,feeling cold,parosmia tachycardia palpitation dry mouth malaise,0
GADAVIST,feeling cold,palpitation dry mouth malaise feeling cold Postmarketing Experience,1
GADAVIST,feeling cold,parosmia tachycardia palpitation dry mouth malaise,0
GADAVIST,feeling cold,consciousness convulsion parosmia,0
GADAVIST,Cardiac arrest,Cardiac arrest Nephrogenic Systemic Fibrosis,1
GADAVIST,Cardiac arrest,Systemic Fibrosis NSF Hypersensitivity,0
GADAVIST,Cardiac arrest,to reliably estimate their frequency or establish,0
GADAVIST,Cardiac arrest,Cardiac arrest Nephrogenic Systemic Fibrosis,1
GADAVIST,Cardiac arrest,to reliably estimate their frequency or establish,0
GADAVIST,Cardiac arrest,Cardiac arrest Nephrogenic Systemic,1
GADAVIST,Nephrogenic Systemic Fibrosis,exposure Cardiac Nephrogenic Systemic Fibrosis,1
GADAVIST,Nephrogenic Systemic Fibrosis,Cardiac arrest Nephrogenic Systemic,1
GADAVIST,Nephrogenic Systemic Fibrosis,Cardiac Nephrogenic Systemic Fibrosis NSF Hypersensitivity reactions,1
GADAVIST,Nephrogenic Systemic Fibrosis,Cardiac arrest Nephrogenic Systemic,1
GADAVIST,Nephrogenic Systemic Fibrosis,drug exposure Cardiac Nephrogenic Systemic Fibrosis,1
GADAVIST,Nephrogenic Systemic Fibrosis,Cardiac arrest Nephrogenic Systemic,1
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF Hypersensitivity reactions anaphylactic,1
GADAVIST,Nephrogenic Systemic Fibrosis,drug exposure Cardiac Nephrogenic Systemic Fibrosis NSF,1
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF Hypersensitivity reactions anaphylactic,1
GADAVIST,Nephrogenic Systemic Fibrosis,exposure Cardiac Nephrogenic Systemic Fibrosis NSF,1
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF Hypersensitivity reactions anaphylactic,1
GADAVIST,Nephrogenic Systemic Fibrosis,Cardiac Nephrogenic Systemic Fibrosis NSF Hypersensitivity reactions anaphylactic,1
GADAVIST,Nephrogenic Systemic Fibrosis,Nephrogenic Systemic Fibrosis NSF Hypersensitivity reactions anaphylactic,1
GADAVIST,NSF,collapse respiratory arrest p,0
GADAVIST,NSF,Nephrogenic Systemic NSF Hypersensitivity reactions,1
GADAVIST,NSF,collapse respiratory arrest p,0
GADAVIST,NSF,NSF Hypersensitivity,1
GADAVIST,NSF,NSF Hypersensitivity,1
GADAVIST,NSF,Nephrogenic Systemic NSF Hypersensitivity reactions anaphylactic shock,1
GADAVIST,NSF,NSF Hypersensitivity,1
GADAVIST,NSF,Systemic NSF Hypersensitivity reactions anaphylactic,1
GADAVIST,NSF,NSF Hypersensitivity,1
GADAVIST,NSF,NSF Hypersensitivity reactions anaphylactic shock,1
GADAVIST,NSF,NSF Hypersensitivity reactions,1
GADAVIST,Hypersensitivity reactions,Fibrosis Hypersensitivity reactions,1
GADAVIST,Hypersensitivity reactions,Fibrosis Hypersensitivity reactions anaphylactic shock circulatory,1
GADAVIST,Hypersensitivity reactions,Fibrosis Hypersensitivity reactions,1
GADAVIST,Hypersensitivity reactions,edema bronchospasm cyano,0
GADAVIST,anaphylactic shock,pulmonary edema,0
GADAVIST,anaphylactic shock,NSF Hypersensitivity anaphylactic,1
GADAVIST,anaphylactic shock,anaphylactic shock circulatory collapse,1
GADAVIST,circulatory collapse,Hypersensitivity reactions anaphylactic circulatory collapse respiratory arrest pulmonary edema bronchospasm,1
GADAVIST,circulatory collapse,anaphylactic shock circulatory collapse,1
GADAVIST,circulatory collapse,NSF Hypersensitivity reactions anaphylactic circulatory collapse respiratory,1
GADAVIST,circulatory collapse,anaphylactic shock circulatory collapse,1
GADAVIST,circulatory collapse,NSF Hypersensitivity reactions,0
GADAVIST,circulatory collapse,circulatory collapse,1
GADAVIST,circulatory collapse,Fibrosis NSF Hypersensitivity reactions anaphylactic,0
GADAVIST,circulatory collapse,circulatory collapse respiratory arrest pulmonary edema bronchospasm,1
GADAVIST,circulatory collapse,anaphylactic circulatory collapse,1
GADAVIST,circulatory collapse,circulatory collapse respiratory arrest pulmonary edema bronchospasm,1
GADAVIST,circulatory collapse,circulatory collapse respiratory,1
GADAVIST,respiratory arrest,bronchospasm cyanosis oropharyngeal,0
GADAVIST,respiratory arrest,circulatory respiratory arrest pulmonary edema bronchospasm cyanosis,1
GADAVIST,respiratory arrest,bronchospasm cyanosis oropharyngeal,0
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema bronchospasm cyanosis oropharyngeal,1
GADAVIST,respiratory arrest,bronchospasm cyanosis oropharyngeal,0
GADAVIST,respiratory arrest,reactions anaphylactic shock circulatory respiratory arrest,1
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema,1
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema bronchospasm,1
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema bronchospasm cyanosis oropharyngeal,1
GADAVIST,respiratory arrest,anaphylactic shock circulatory respiratory arrest,1
GADAVIST,respiratory arrest,respiratory arrest pulmonary edema bronchospasm cyanosis oropharyngeal,1
GADAVIST,pulmonary edema,pulmonary edema bronchospasm cyanosis oropharyngeal swelling laryngeal,1
GADAVIST,pulmonary edema,shock circulatory collapse respiratory,0
GADAVIST,pulmonary edema,Hypersensitivity,0
GADAVIST,pulmonary edema,anaphylactic shock circulatory collapse respiratory,0
GADAVIST,pulmonary edema,F Hypersensitivity reactions anaphylactic shock circulatory,0
GADAVIST,pulmonary edema,shock circulatory collapse respiratory pulmonary edema bronchospasm cyanosis,1
GADAVIST,pulmonary edema,F Hypersensitivity reactions anaphylactic shock circulatory,0
GADAVIST,pulmonary edema,pulmonary edema bronchospasm,1
GADAVIST,pulmonary edema,collapse respiratory arrest,0
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal,1
GADAVIST,bronchospasm,pulmonary,0
GADAVIST,bronchospasm,shock circulatory,0
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal swelling,1
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal swelling laryngeal,1
GADAVIST,bronchospasm,edema blood pressure increased,0
GADAVIST,bronchospasm,nsitivity reactions anaphylactic,0
GADAVIST,bronchospasm,bronchospasm cyanosis oropharyngeal swelling laryngeal edema,1
GADAVIST,cyanosis,cyanosis oropharyngeal swelling,1
GADAVIST,cyanosis,laryngeal edema blood pressure increased,0
GADAVIST,cyanosis,respiratory arrest pulmonary edema cyanosis oropharyngeal swelling laryngeal,1
GADAVIST,cyanosis,laryngeal edema blood pressure increased,0
GADAVIST,cyanosis,arrest,0
GADAVIST,cyanosis,blood pressure increased,0
GADAVIST,cyanosis,cyanosis oropharyngeal swelling laryngeal,1
GADAVIST,cyanosis,cyanosis oropharyngeal swelling laryngeal edema blood,1
GADAVIST,oropharyngeal swelling,circulatory collapse respiratory arrest,0
GADAVIST,oropharyngeal swelling,circulatory collapse respiratory arrest pulmonary edema bronchospasm,0
GADAVIST,oropharyngeal swelling,edema,0
GADAVIST,oropharyngeal swelling,bronchospasm cyanosis,0
GADAVIST,oropharyngeal swelling,arrest pulmonary edema bronchospasm oropharyngeal,1
GADAVIST,oropharyngeal swelling,oropharyngeal swelling laryngeal edema blood pressure increased,1
GADAVIST,oropharyngeal swelling,bronchospasm,0
GADAVIST,oropharyngeal swelling,oropharyngeal swelling laryngeal edema,1
GADAVIST,oropharyngeal swelling,bronchospasm,0
GADAVIST,oropharyngeal swelling,arrest pulmonary edema bronchospasm oropharyngeal,1
GADAVIST,oropharyngeal swelling,pulmonary edema,0
GADAVIST,laryngeal edema,bronchospasm cyanosis oropharyngeal laryngeal,1
GADAVIST,laryngeal edema,oropharyngeal laryngeal,1
GADAVIST,laryngeal edema,hyperhidrosis,0
GADAVIST,laryngeal edema,collapse respiratory arrest pulmonary edema bronchospasm cyanosis oropharyngeal swelling,0
GADAVIST,laryngeal edema,pressure,0
GADAVIST,laryngeal edema,arrest pulmonary edema bronchospasm cyanosis,0
GADAVIST,laryngeal edema,oropharyngeal laryngeal edema blood pressure increased,1
GADAVIST,laryngeal edema,arrest pulmonary edema bronchospasm cyanosis,0
GADAVIST,laryngeal edema,laryngeal edema blood,1
GADAVIST,blood pressure increased,blood pressure increased chest pain angioedema,1
GADAVIST,blood pressure increased,cyanosis oropharyngeal swelling,0
GADAVIST,blood pressure increased,swelling laryngeal blood pressure increased chest pain angioedema conjunctivitis hyperhidrosis,1
GADAVIST,blood pressure increased,cyanosis oropharyngeal swelling,0
GADAVIST,blood pressure increased,pressure increased chest pain angioedema,1
GADAVIST,blood pressure increased,blood pressure,1
GADAVIST,blood pressure increased,laryngeal edema,0
GADAVIST,blood pressure increased,pressure increased chest pain,1
GADAVIST,blood pressure increased,sneezing burning sensation and pal,0
GADAVIST,chest pain,pressure chest pain,1
GADAVIST,chest pain,sneezing burning sensation and pal,0
GADAVIST,chest pain,bronchospasm cyanosis oropharyngeal swelling laryngeal edema blood,0
GADAVIST,chest pain,chest pain,1
GADAVIST,chest pain,bronchospasm cyanosis oropharyngeal swelling laryngeal edema blood,0
GADAVIST,chest pain,hyperhidrosis cough sneezing burning sensation and pallor see,0
GADAVIST,chest pain,edema blood pressure chest,1
GADAVIST,chest pain,burning sensation,0
GADAVIST,chest pain,cyanosis oropharyngeal swelling laryngeal edema blood pressure increased,0
GADAVIST,chest pain,pressure chest pain,1
GADAVIST,chest pain,cyanosis oropharyngeal swelling laryngeal edema blood pressure increased,0
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis cough,1
GADAVIST,angioedema,see Warnings and,0
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis,1
GADAVIST,angioedema,increased chest angioedema,1
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis,1
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis cough sneezing,1
GADAVIST,angioedema,angioedema conjunctivitis hyperhidrosis cough sneezing burning,1
GADAVIST,conjunctivitis,Warnings,0
GADAVIST,hyperhidrosis,hyperhidrosis cough sneezing burning sensation and,1
GADAVIST,hyperhidrosis,hyperhidrosis cough sneezing burning,1
GADAVIST,cough,cough sneezing burning sensation and pallor,1
GADAVIST,cough,cough sneezing burning sensation and,1
GADAVIST,cough,cough sneezing,1
GADAVIST,cough,cough sneezing burning sensation,1
GADAVIST,cough,cough sneezing burning sensation,1
GADAVIST,burning sensation,cough burning sensation and pallor see Warnings and,1
GADAVIST,burning sensation,cough sneezing burning sensation,1
GADAVIST,burning sensation,and pallor see,0
GADAVIST,burning sensation,cough burning sensation,1
GADAVIST,burning sensation,hyperhidrosis cough,0
GADAVIST,burning sensation,conjunctivitis hyperhidrosis cough sneezing,0
GADAVIST,burning sensation,pain angioedema conjunctivitis hyperhidrosis cough,0
GADAVIST,pallor,Warnings,0
GADAVIST,pallor,pain angioedema conjunctivitis hyperhidrosis cough,0
GADAVIST,pallor,pallor see Warnings and Precautions,1
GADAVIST,pallor,pallor see Warnings,1
GADAVIST,pallor,pallor see Warnings and,1
GADAVIST,pallor,pallor see Warnings and,1
GADAVIST,pallor,pallor see Warnings,1
GADAVIST,pallor,see Warnings,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,The following serious,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,The following serious adv,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,The following serious adv erse reactions are,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,The following serious,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,ADVERSE The following serious adv,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,ADVERSE The following serious adv,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,The following serious adv,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,discussed elsewhere in labeling Nephrogenic Systemic,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,following serious adverse s are discussed elsewhere in ,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,discussed elsewhere in labeling Nephrogenic Systemic,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,Nephrogenic Systemic Fibrosis NSF see Boxed Warning,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,serious adverse s are discussed elsewhere in  labeling Nephrogenic Systemic,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,Nephrogenic Systemic Fibrosis NSF see Boxed Warning,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,Boxed Warning and Warnings,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,following serious adverse s are discussed elsewhere in ,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,Boxed Warning and Warnings,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,serious adverse s are discussed elsewhere in,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,are discussed elsewhere in labeling Nephrogenic Systemic,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,adverse s are discussed elsewhere in  labeling Nephrogenic Systemic Fibrosis NSF,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,are discussed elsewhere in labeling Nephrogenic Systemic,1
GADAVIST,NSF,nin g and,1
GADAVIST,NSF,adverse reactions nci dence are headache nausea,1
GADAVIST,NSF,nin g and,1
GADAVIST,NSF,nci,1
GADAVIST,NSF,nci dence are headache nausea,1
GADAVIST,NSF,and dizziness,0
GADAVIST,NSF,nci dence,1
GADAVIST,NSF,and Warnings and,0
GADAVIST,NSF,nci dence are,1
GADAVIST,NSF,Precautions EXCERPT Most common adverse,0
GADAVIST,fatal,common adverse reactions are h,1
GADAVIST,fatal,are h,1
GADAVIST,fatal,are h eadache nausea,1
GADAVIST,fatal,reactions are,1
GADAVIST,fatal,Most common adverse reactions are h eadache nausea and,1
GADAVIST,fatal,reactions are,1
GADAVIST,fatal,are h eadache nausea and dizziness,1
GADAVIST,fatal,report SUSPECTED ADVERSE REACTIONS contact,0
GADAVIST,fatal,are h eadache nausea and,1
GADAVIST,fatal,nausea and dizziness To report SUSPECTED,0
GADAVIST,fatal,are h,1
GADAVIST,fibrosis,and dizz iness To report,1
GADAVIST,fibrosis,reactions incidence are headache and dizz,1
GADAVIST,fibrosis,headache and,1
GADAVIST,fibrosis,nausea,0
GADAVIST,fibrosis,incidence are headache and,1
GADAVIST,fibrosis,are headache and,1
GADAVIST,NSF, Ba yer HealthCare,1
GADAVIST,NSF, Ba yer HealthCare Pharmaceuticals,1
GADAVIST,NSF, Ba yer,1
GADAVIST,NSF,ADVERSE REACTIONS  Ba,1
GADAVIST,NSF, Ba yer,1
GADAVIST,NSF,REACTIONS contact,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,Hispanic Black and patients of other ethnic groups The,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,subjects,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,subjects were male nd the ethnic distribution wa s,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,subjects,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,male nd the ethnic,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,the majority receiving the recommended dose Approximately of the subjects were male,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,subjects were male nd the ethnic distribution wa s Caucasian,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,the majority receiving the recommended dose Approximately of the subjects were male,0
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,male nd the ethnic distribution wa,1
GADAVIST,NEPHROGENIC SYSTEMIC FIBROSIS,the majority receiving the recommended dose Approximately of the subjects were male,0
GADAVIST,NSF,60% Caucasian Asian Hispanic Black and,1
GADAVIST,NSF,the majority receiving the recommended dose Approximately of the subjects were male,0
GADAVIST,NSF,ethnic groups The average ag,0
GADAVIST,NSF,distribution 60% Caucasian Asian Hispanic Black,1
GADAVIST,NSF,ethnic groups The average ag,0
GADAVIST,NSF,60% Caucasian Asian Hispanic,1
GADAVIST,NSF,60% Caucasian Asian,1
GADAVIST,NSF,the ethnic distribution 60% Caucasian Asian Hispanic Black,1
GADAVIST,NSF,60% Caucasian Asian,1
GADAVIST,NSF,week yea rs Overall approximately,1
GADAVIST,NSF,60% Caucasian Asian,1
GADAVIST,NSF,from,0
GADAVIST,NSF,yea rs,1
GADAVIST,NSF,week yea rs Overall approximately of subjects,1
GADAVIST,NSF,yea rs,1
GADAVIST,NSF,week,0
GADAVIST,NSF,groups The average age was years range from week to,0
GADAVIST,NSF,reactions associated with,0
GADAVIST,NSF,Table,0
GADAVIST,NSF,of  Gadavist were usually mild,1
GADAVIST,NSF,of  Gadavist,1
GADAVIST,NSF,of  Gadavist were usually,1
GADAVIST,NSF,moderate in severity and transient in nature Table lists,0
GADAVIST,NSF,the of ,1
GADAVIST,NSF,moderate in severity and transient in nature Table lists,0
GADAVIST,NSF,of  Gadavist were usually mild,1
GADAVIST,NSF,of ,1
GADAVIST,NSF,transient in nature Table,0
GADAVIST,Nephrogenic Systemic Fibrosis,The following s,1
GADAVIST,Nephrogenic Systemic Fibrosis,ADVERSE REACTIONS The following s adverse reactions are discu ssed elsewhere in labeling,1
GADAVIST,Nephrogenic Systemic Fibrosis,The following s,1
GADAVIST,Nephrogenic Systemic Fibrosis,REACTIONS The following s adverse reactions are discu ssed elsewhere in,1
GADAVIST,Nephrogenic Systemic Fibrosis,The following s,1
GADAVIST,Nephrogenic Systemic Fibrosis,REACTIONS The following,0
GADAVIST,hypersensitivity reactions,Hypersensitivity reactions,0
GADAVIST,hypersensitivity reactions,ations (4) and Warnings an d Precautions EXCERPT Most,1
GADAVIST,hypersensitivity reactions,Hypersensitivity reactions,0
GADAVIST,hypersensitivity reactions,Precautions EXCERPT Most common,0
GADAVIST,hypersensitivity reactions,and Warnings and Precautions,0
GADAVIST,hypersensitivity reactions,ations (4) and Warnings an d Precautions EXCERPT Most,1
GADAVIST,hypersensitivity reactions,and Precautions Hypersensitivity reactions,0
GADAVIST,hypersensitivity reactions,see ations (4) and Warnings an,1
GADAVIST,hypersensitivity reactions,Contraindic,0
GADAVIST,cutaneous manifestations,* Most comm on adverse reactions incidence,1
GADAVIST,cutaneous manifestations,Most comm on adverse reactions incidence,1
GADAVIST,cutaneous manifestations,CERPT:    *    Most comm,1
GADAVIST,cutaneous manifestations,Most comm on adverse reactions incidence,1
GADAVIST,cutaneous manifestations,Warnings and,0
GADAVIST,cutaneous manifestations,Contraindications and Warnings,0
GADAVIST,death,reactions are h eadache nausea and dizziness To,1
GADAVIST,death,Contraindications and Warnings,0
GADAVIST,death,are h,1
GADAVIST,death,are h eadache nausea and,1
GADAVIST,death,common adverse reactions are,1
GADAVIST,death,common adverse reactions are h,1
GADAVIST,death,common adverse reactions are,1
GADAVIST,nephrogenic systemic fibrosis,"at FDA or 
  6.1 Clinical Trials Experi",1
GADAVIST,nephrogenic systemic fibrosis,common adverse reactions are,1
GADAVIST,nephrogenic systemic fibrosis,Inc at or FDA at,0
GADAVIST,nephrogenic systemic fibrosis,6.1 Clinical Trials Experi,1
GADAVIST,nephrogenic systemic fibrosis,Because clinical trials are conducted,0
GADAVIST,nephrogenic systemic fibrosis,Trials Experi,1
GADAVIST,nephrogenic systemic fibrosis,"at FDA or 
  6.1 Clinical Trials Experi ence Because clinical",1
GADAVIST,nephrogenic systemic fibrosis,Trials Experi,1
GADAVIST,NSF,"ce
",1
GADAVIST,NSF,conditions,0
GADAVIST,NSF,or FDA at FDA or wwwfdagovmedwatch,0
GADAVIST,NSF,"ce
 Because clinical trials",1
GADAVIST,NSF,"ce
 Because",1
GADAVIST,NSF,"wwwfdagovmedwatch Clinical Trials ce
 Because clinical trials are conducted",1
GADAVIST,NSF,"ce
 Because",1
GADAVIST,NSF,"ce
",1
GADAVIST,NSF,"ce
 Because",1
GADAVIST,NSF,drug and may t,1
GADAVIST,NSF,and,0
GADAVIST,NSF,t r,1
GADAVIST,NSF,rates in the clinical,0
GADAVIST,NSF,His panic Black,1
GADAVIST,NSF,rates in the clinical,0
GADAVIST,NSF,His panic Black and,1
GADAVIST,NSF,His panic Black and patients of,1
GADAVIST,NSF,His panic Black and,1
GADAVIST,NSF,His panic Black and,1
GADAVIST,NSF,The average age was years range from w,0
GADAVIST,NSF,patients of other ethnic groups The average age was years range,0
GADAVIST,NSF,range,0
GADAVIST,NSF,of other ethnic groups The average age was years range from,0
GADAVIST,NSF,ethnic distribution was Caucasian His panic Black and patients,1
GADAVIST,NSF,of other ethnic groups The average age was years range from,0
GADAVIST,NSF,ethnic distribution was Caucasian His panic,1
GADAVIST,NSF,of other ethnic groups The average age was years range from,0
GADAVIST,fatal,e subjects were male and the ethnic distribution was,0
GADAVIST,fatal,"was Caucasian Asian Hispanic ,",1
GADAVIST,fatal,"Caucasian Asian Hispanic , and",1
GADAVIST,fatal,"Caucasian Asian Hispanic ,",1
GADAVIST,fatal,week to years,0
GADAVIST,fatal,Hispanic Black,0
GADAVIST,fibrosis,week to years Overall approximately,0
GADAVIST,fibrosis,and patients of ther,1
GADAVIST,acute kidney injury,genic Systemic Fibr,1
GADAVIST,acute kidney injury,and patients of ther,1
GADAVIST,acute kidney injury,arrest genic Systemic Fibr osis NSF Hypersensitivity,1
GADAVIST,acute kidney injury,and patients of ther,1
GADAVIST,acute kidney injury,osis NSF,0
GADAVIST,acute kidney injury,Systemic Fibr osis NSF Hypersensitivity,1
GADAVIST,acute kidney injury,Cardiac arrest genic Systemic Fibr osis NSF Hypersensitivity,1
GADAVIST,acute kidney injury,Systemic Fibr osis NSF Hypersensitivity,1
GADAVIST,acute kidney injury,relationship to drug,0
GADAVIST,acute kidney injury,genic Systemic,1
GADAVIST,acute kidney injury,circulatory,0
OTEZLA,diarrhea,most common,0
OTEZLA,diarrhea,reactions diarrhea nausea and headache Psoriasis,1
OTEZLA,diarrhea,most common,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,The most common adverse reactions are,0
OTEZLA,diarrhea,headache Psoriasis The,0
OTEZLA,diarrhea,diarrhea nausea and headache Psoriasis,1
OTEZLA,diarrhea,diarrhea nausea and headache Psoriasis,1
OTEZLA,diarrhea,adverse,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,adverse reactions are diarrhea nausea,0
OTEZLA,diarrhea,common adverse reactions diarrhea nausea upper,1
OTEZLA,diarrhea,adverse reactions are diarrhea nausea,0
OTEZLA,diarrhea,diarrhea nausea and headache Psoriasis The most common,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,Psoriasis The most,0
OTEZLA,diarrhea,tract infection and headache including tension,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,tract infection and headache including tension headache,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,tract infection and headache including tension headache,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,nausea,nausea upper,1
OTEZLA,nausea,nausea upper respiratory tract infection,1
OTEZLA,nausea,nausea upper respiratory,1
OTEZLA,nausea,are,0
OTEZLA,nausea,common adverse reactions are diarrhea,0
OTEZLA,nausea,including tension,0
OTEZLA,nausea,most common adverse,0
OTEZLA,upper respiratory tract infection,diarrhea nausea,0
OTEZLA,upper respiratory tract infection,headache To report SUSPECTED ADVERSE,0
OTEZLA,upper respiratory tract infection,upper respiratory tract infection and headache including tension headache,1
OTEZLA,upper respiratory tract infection,diarrhea upper respiratory tract,1
OTEZLA,upper respiratory tract infection,adverse reactions are diarrhea upper respiratory tract infection,1
OTEZLA,upper respiratory tract infection,diarrhea upper respiratory tract,1
OTEZLA,upper respiratory tract infection,adverse reactions are,0
OTEZLA,upper respiratory tract infection,headache including tension headache To report SUSPECTED ADVERSE,0
OTEZLA,upper respiratory tract infection,tract infection and,1
OTEZLA,upper respiratory tract infection,most common adverse reactions are diarrhea,0
OTEZLA,upper respiratory tract infection,tract infection and headache,1
OTEZLA,headache,infection headache including tension headache To,1
OTEZLA,headache,tract infection and headache,1
OTEZLA,headache,headache including tension,1
OTEZLA,headache,tract infection and headache,1
OTEZLA,headache,respiratory tract infection,0
OTEZLA,headache,REACTIONS contact,0
OTEZLA,headache,e most common adverse reactions,0
OTEZLA,headache,headache including tension headache To,1
OTEZLA,headache,headache including tension headache To report,1
OTEZLA,headache,headache including,1
OTEZLA,tension headache,infection and headache tension,1
OTEZLA,tension headache,tension headache To report,1
OTEZLA,tension headache,e reactions are diarrhea nausea upper respiratory,0
OTEZLA,tension headache,report SUSPECTED ADVERSE REACTIONS contact,0
OTEZLA,tension headache,infection and headache tension,1
OTEZLA,tension headache,infection and headache tension headache To report SUSPECTED,1
OTEZLA,tension headache,infection and headache tension,1
OTEZLA,tension headache,report SUSPECTED,0
OTEZLA,Diarrhea,treatment and tended to resolve over time with,0
OTEZLA,Diarrhea,time with,0
OTEZLA,Diarrhea,the first weeks of treatment,0
OTEZLA,Diarrhea,time with continued dosing,0
OTEZLA,headache,tended to resolve over time with,0
OTEZLA,headache,Diarrhea,0
OTEZLA,headache,headache and,1
OTEZLA,headache,headache,1
OTEZLA,headache,and nausea were the,0
OTEZLA,headache,headache and nausea were,1
OTEZLA,headache,headache and nausea were the,1
OTEZLA,headache,headache and nausea were,1
OTEZLA,headache,The most common adverse reactions,0
OTEZLA,headache,headache and,1
OTEZLA,headache,time with continued dosing headache and nausea,1
OTEZLA,headache,headache and,1
OTEZLA,nausea,and tended to resolve over time with continued dosing Diarrhea headache,0
OTEZLA,nausea,nausea were,1
OTEZLA,nausea,tended,0
OTEZLA,nausea,nausea were the most,1
OTEZLA,nausea,nausea were the most commonly reported,1
OTEZLA,nausea,nausea were,1
OTEZLA,nausea,continued dosing Diarrhea headache nausea,1
OTEZLA,nausea,nausea were,1
OTEZLA,nausea,headache nausea were,1
OTEZLA,nausea,nausea were,1
OTEZLA,nausea,reactions The most common adverse reactions,0
OTEZLA,nausea,nausea were the most commonly reported,1
OTEZLA,nausea,for patients taking OTEZLA nausea diarrhea,1
OTEZLA,nausea,nausea were the most commonly reported,1
OTEZLA,nausea,discontinuation for patients,0
OTEZLA,nausea,adverse reactions leading to discontinuation for patients,0
OTEZLA,headache,were nausea diarrhea headache The,1
OTEZLA,headache,adverse reactions leading to discontinuation for patients,0
OTEZLA,headache,headache The proportion of,1
OTEZLA,headache,diarrhea headache The proportion of patients,1
OTEZLA,headache,headache The proportion of,1
OTEZLA,headache,who discontinued treatment,0
OTEZLA,headache,headache The proportion of patients with,1
OTEZLA,headache,headache The proportion,1
OTEZLA,headache,were nausea diarrhea headache,1
OTEZLA,headache,headache The proportion,1
OTEZLA,gastrointestinal adverse reactions,Patients on Placebo for up to Day Week,0
OTEZLA,gastrointestinal adverse reactions,up to Day Week a Of the reported,0
OTEZLA,gastrointestinal adverse reactions,Of the gastrointestinal adverse reactions,1
OTEZLA,gastrointestinal adverse reactions,on Placebo for,0
OTEZLA,gastrointestinal adverse reactions,the gastrointestinal adverse reactions,1
OTEZLA,gastrointestinal adverse reactions,Of the gastrointestinal adverse,1
OTEZLA,gastrointestinal adverse reactions,the gastrointestinal adverse reactions,1
OTEZLA,gastrointestinal adverse reactions,Of the gastrointestinal adverse,1
OTEZLA,gastrointestinal adverse reactions,a serious adverse reaction of,0
OTEZLA,gastrointestinal adverse reactions,gastrointestinal adverse reactions subject experienced a serious,1
OTEZLA,gastrointestinal adverse reactions,a serious adverse reaction of,0
OTEZLA,gastrointestinal adverse reactions,Week a Of the gastrointestinal adverse reactions,1
OTEZLA,gastrointestinal adverse reactions,a serious adverse reaction of,0
OTEZLA,nausea,nausea,1
OTEZLA,nausea,nausea and vomiting in,1
OTEZLA,nausea,nausea and vomiting in OTEZLA mg,1
OTEZLA,nausea,reaction nausea,1
OTEZLA,nausea,nausea and vomiting in OTEZLA mg,1
OTEZLA,nausea,a serious adverse reaction nausea and vomiting in OTEZLA,1
OTEZLA,nausea,nausea and vomiting in OTEZLA mg,1
OTEZLA,nausea,nausea and vomiting in OTEZLA mg,1
OTEZLA,nausea,twice daily,0
OTEZLA,nausea,nausea and,1
OTEZLA,nausea,and vomiting in OTEZLA mg,0
OTEZLA,vomiting,vomiting in OTEZLA mg twice,1
OTEZLA,vomiting,vomiting in OTEZLA mg twice daily,1
OTEZLA,vomiting,vomiting in OTEZLA mg twice,1
OTEZLA,vomiting,of nausea vomiting in OTEZLA mg,1
OTEZLA,vomiting,vomiting in OTEZLA mg twice,1
OTEZLA,vomiting,vomiting in OTEZLA mg,1
OTEZLA,vomiting,gastrointestinal adverse reactions subject,0
OTEZLA,vomiting,vomiting in OTEZLA mg,1
OTEZLA,vomiting,of nausea vomiting in OTEZLA mg twice,1
OTEZLA,vomiting,vomiting in OTEZLA mg,1
OTEZLA,vomiting,vomiting in OTEZLA mg twice daily,1
OTEZLA,vomiting,adverse reaction of nausea vomiting in OTEZLA mg twice daily,1
OTEZLA,vomiting,vomiting in OTEZLA mg twice daily,1
OTEZLA,diarrhea,adverse reaction of headache,0
OTEZLA,diarrhea,subject treated with OTEZLA mg twice daily experienced a serious adverse reaction,0
OTEZLA,diarrhea,a,0
OTEZLA,diarrhea,diarrhea patient treated with,1
OTEZLA,diarrhea,serious adverse reaction of headache,0
OTEZLA,diarrhea,diarrhea patient treated with,1
OTEZLA,diarrhea,serious adverse reaction of headache,0
OTEZLA,diarrhea,diarrhea patient treated with,1
OTEZLA,diarrhea,diarrhea patient treated with OTEZLA mg,1
OTEZLA,diarrhea,diarrhea patient treated with,1
OTEZLA,headache,a serious adverse reaction headache b Of,1
OTEZLA,headache,diarrhea patient treated with,1
OTEZLA,headache,headache b,1
OTEZLA,headache,headache b Of the reported,1
OTEZLA,headache,reported adverse drug reactions none were serious c n indicates number,0
OTEZLA,headache,headache,1
OTEZLA,Hypersensitivity,Hypersensitivity Investigations Weight decrease Gastrointestinal Disorders,1
OTEZLA,Hypersensitivity,clinical,0
OTEZLA,Hypersensitivity,Disorders Frequent bowel movement gastroesop,0
OTEZLA,Hypersensitivity,clinical studies,0
OTEZLA,Weight decrease,Weight decrease Gastrointestinal Disorders Frequent bowel,1
OTEZLA,Weight decrease,Frequent bowel movement,0
OTEZLA,Frequent bowel movement,Nutrition,0
OTEZLA,Frequent bowel movement,decrease Gastrointestinal Frequent bowel,1
OTEZLA,Frequent bowel movement,Disorders Decreased appetit,0
OTEZLA,Frequent bowel movement,Frequent bowel movement gastroesophageal,1
OTEZLA,Frequent bowel movement,Investigations Weight decrease Gastrointestinal Frequent bowel movement gastroesophageal,1
OTEZLA,Frequent bowel movement,Frequent bowel movement gastroesophageal,1
OTEZLA,Frequent bowel movement,Disorders,0
OTEZLA,Frequent bowel movement,bowel movement gastroesophageal reflux disease dyspepsia,1
OTEZLA,Frequent bowel movement,Gastrointestinal Frequent bowel movement gastroesophageal reflux disease dyspepsia Metabolism,1
OTEZLA,Frequent bowel movement,bowel movement gastroesophageal reflux disease dyspepsia,1
OTEZLA,Frequent bowel movement,Hypersensitivity Investigations Weight,0
OTEZLA,gastroesophageal reflux disease,Disorders Decreased appetite,0
OTEZLA,gastroesophageal reflux disease,ensitivity Investigations Weight decrease,0
OTEZLA,gastroesophageal reflux disease,Gastrointestinal Disorders Frequent bowel gastroesophageal reflux disease dyspepsia Metabolism,1
OTEZLA,gastroesophageal reflux disease,ensitivity Investigations Weight decrease,0
OTEZLA,gastroesophageal reflux disease,reflux disease dyspepsia Metabolism and,1
OTEZLA,gastroesophageal reflux disease,gastroesophageal reflux disease dyspepsia Metabolism and,1
OTEZLA,gastroesophageal reflux disease,reflux disease dyspepsia,1
OTEZLA,gastroesophageal reflux disease,Frequent bowel,0
OTEZLA,dyspepsia,gastroesophageal reflux dyspepsia,1
OTEZLA,dyspepsia,Frequent bowel,0
OTEZLA,dyspepsia,Disorders Migraine Res,0
OTEZLA,dyspepsia,gastroesophageal reflux,0
OTEZLA,dyspepsia,bowel movement gastroesophageal,0
OTEZLA,dyspepsia,reflux dyspepsia Metabolism and Nutrition Disorders,1
OTEZLA,dyspepsia,bowel movement gastroesophageal,0
OTEZLA,dyspepsia,reflux,0
OTEZLA,Migraine,Migraine Respiratory Thoracic,1
OTEZLA,Migraine,Migraine Respiratory,1
OTEZLA,Migraine,appetite Nervous System Migraine Respiratory Thoracic and Mediastinal Disorders,1
OTEZLA,Migraine,Migraine Respiratory,1
OTEZLA,Cough,Cough Skin and Subcutaneous,1
OTEZLA,Cough,Migraine Respiratory,1
OTEZLA,Cough,System Disorders Migraine Respiratory,0
OTEZLA,Cough,treated with OTEZLA mg twice daily,0
OTEZLA,Cough,Cough Skin,1
OTEZLA,Cough,Mediastinal Cough Skin and Subcutaneous Tissue,1
OTEZLA,Cough,Cough Skin,1
OTEZLA,Cough,and Subcutaneous Tissue Disorders Rash,0
OTEZLA,Cough,OTEZLA mg,0
OTEZLA,Cough,Nervous System Disorders Migraine Respiratory,0
OTEZLA,Cough,Cough Skin and,1
OTEZLA,Cough,Cough Skin and,1
OTEZLA,Diarrhea,overall median,0
OTEZLA,Diarrhea,Diarrhea nausea and upper respiratory,1
OTEZLA,Diarrhea,Diarrhea nausea,1
OTEZLA,Diarrhea,of Diarrhea nausea,1
OTEZLA,Diarrhea,Diarrhea nausea,1
OTEZLA,Diarrhea,overall median age of Diarrhea,1
OTEZLA,Diarrhea,Diarrhea nausea,1
OTEZLA,Diarrhea,Diarrhea nausea and upper respiratory,1
OTEZLA,Diarrhea,Diarrhea nausea and upper respiratory,1
OTEZLA,Diarrhea,an overall median age of years,0
OTEZLA,Diarrhea,commonly reported,0
OTEZLA,nausea,of years nausea and upper,1
OTEZLA,nausea,commonly reported,0
OTEZLA,nausea,nausea and upper,1
OTEZLA,nausea,years nausea and upper,1
OTEZLA,nausea,nausea and upper,1
OTEZLA,nausea,Diarrhea,0
OTEZLA,nausea,and upper respiratory tract,0
OTEZLA,nausea,nausea and upper,1
OTEZLA,nausea,reactions leading to discontinuation for,0
OTEZLA,nausea,subjects taking OTEZLA,0
OTEZLA,nausea,nausea diarrhea,1
OTEZLA,diarrhea,nausea,0
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,diarrhea,1
OTEZLA,diarrhea,subjects taking OTEZLA,0
OTEZLA,diarrhea,discontinued,0
OTEZLA,diarrhea,with psoriasis,0
OTEZLA,diarrhea,diarrhea and headache The proportion of,1
OTEZLA,diarrhea,discontinued treatment d,0
OTEZLA,headache,diarrhea headache,1
OTEZLA,headache,discontinued treatment d,0
OTEZLA,headache,who discontinued,0
OTEZLA,headache,headache The proportion of subjects with,1
OTEZLA,headache,headache The proportion of subjects,1
OTEZLA,headache,headache The proportion of subjects with,1
OTEZLA,headache,headache The proportion of subjects with,1
OTEZLA,headache,nausea diarrhea,0
OTEZLA,headache,ions leading to discontinuation for subjects taking OTEZLA were nausea diarrhea and,0
OTEZLA,headache,with,0
OTEZLA,abdominal pain,reaction abdominal pain,1
OTEZLA,abdominal pain,abdominal pain Preferred Term Placebo Nn OTEZLA,1
OTEZLA,abdominal pain,abdominal pain Preferred Term Placebo Nn OTEZLA,1
OTEZLA,abdominal pain,adverse reaction abdominal pain,1
OTEZLA,abdominal pain,abdominal pain Preferred Term Placebo Nn OTEZLA,1
OTEZLA,abdominal pain,reaction abdominal pain,1
OTEZLA,abdominal pain,abdominal pain Preferred Term Placebo Nn OTEZLA,1
OTEZLA,abdominal pain,Placebo Nn OTEZLA mg BID Nn Diarrhea,0
OTEZLA,abdominal pain,abdominal pain Preferred,1
OTEZLA,abdominal pain,Placebo Nn OTEZLA mg BID Nn Diarrhea,0
OTEZLA,abdominal pain,Placebo Nn OTEZLA,0
OTEZLA,Nausea,Nausea Upper,1
OTEZLA,Nausea,Upper,0
OTEZLA,Nausea,Nn Nausea Upper,1
OTEZLA,Nausea,Upper,0
OTEZLA,Nausea,Nausea,1
OTEZLA,Nausea,Diarrhea,0
OTEZLA,Nausea,mg BID Nn Diarrhea,0
OTEZLA,Nausea,Nn Nausea Upper respiratory tract,1
OTEZLA,Nausea,mg BID Nn Diarrhea,0
OTEZLA,Headache,headache,0
OTEZLA,Headache,Headache,1
OTEZLA,Headache,headache,0
OTEZLA,Headache,Tension,0
OTEZLA,Headache,Headache Abdominal pain,1
OTEZLA,Headache,Tension,0
OTEZLA,Headache,headache,0
OTEZLA,Headache,Tension Headache Abdominal pain,1
OTEZLA,Headache,headache,0
OTEZLA,Insomnia,Insomnia Back,1
OTEZLA,Insomnia,Insomnia Back pain,1
OTEZLA,Insomnia,Insomnia Back pain,1
OTEZLA,Insomnia,Insomnia Back pain,1
OTEZLA,Insomnia,Insomnia Back,1
OTEZLA,Insomnia,Insomnia Back pain,1
OTEZLA,Insomnia,Insomnia Back,1
OTEZLA,Insomnia,Insomnia Back pain,1
OTEZLA,Insomnia,Insomnia Back pain,1
OTEZLA,Insomnia,Insomnia Back pain,1
OTEZLA,Migraine,Frequent bowel,0
OTEZLA,Folliculitis,Folliculitis,1
OTEZLA,Folliculitis,Folliculitis,1
OTEZLA,Folliculitis,Tooth,0
OTEZLA,Folliculitis,Folliculitis Sinus headache,1
OTEZLA,Folliculitis,Folliculitis Sinus headache,1
OTEZLA,Weight Decrease,at FDA r www.fda.gov/m edwatch Clinical Trials,1
OTEZLA,Weight Decrease,Folliculitis Sinus headache,1
OTEZLA,Weight Decrease,trials are conducted,0
OTEZLA,Weight Decrease,Celgene Corporation at or FDA at FDA,0
OTEZLA,Weight Decrease,r www.fda.gov/m edwatch,1
OTEZLA,Weight Decrease,or FDA at FDA r,1
OTEZLA,Weight Decrease,are conducted under widely,0
OTEZLA,Weight Decrease,FDA at FDA,0
OTEZLA,Weight Decrease,are conducted,0
OTEZLA,depression,doubleblind placebocontrolled [Studies P sA PsA,1
OTEZLA,depression,are conducted,0
OTEZLA,depression,placebocontrolled [Studies P,1
OTEZLA,depression,arthritis see Cl,0
OTEZLA,depression,common e reaction,1
OTEZLA,depression,resolve,0
OTEZLA,depression,e reaction s presented inTable occurred,1
OTEZLA,depression,resolve,0
OTEZLA,depression,of the most,0
OTEZLA,depression,e reaction,1
OTEZLA,depression,inTable occurred,0
OTEZLA,depressed mood,adverse reactions esented inTabl e occurred within,1
OTEZLA,depressed mood,inTable occurred,0
OTEZLA,depressed mood,common adverse reactions esented inTabl e occurred,1
OTEZLA,depressed mood,inTable occurred,0
OTEZLA,depressed mood,of treatment and tended to,0
OTEZLA,depressed mood,reactions esented,1
OTEZLA,depressed mood,reactions esented inTabl e occurred within,1
OTEZLA,depressed mood,reactions esented,1
OTEZLA,depressed mood,common adverse reactions esented inTabl e occurred within,1
OTEZLA,depressed mood,reactions esented,1
OTEZLA,depressed mood,an overall median age of years The majority of the most common,0
OTEZLA,depressed mood,common adverse reactions esented inTabl,1
OTEZLA,depressed mood,esented inTabl,1
OTEZLA,depressed mood,common adverse reactions esented inTabl,1
OTEZLA,depressed mood,most common adverse reactions esented,1
OTEZLA,depression,mmonly rep orted adverse reactions The,1
OTEZLA,depression,mmonly,1
OTEZLA,depression,nausea were the most mmonly rep,1
OTEZLA,depression,tended to resolve over time with continued dosing Diarrhea headache,0
OTEZLA,depression,common adverse,0
OTEZLA,depression,mmonly rep orted adverse reactions,1
OTEZLA,depression,the most mmonly,1
OTEZLA,depression,the most mmonly rep,1
OTEZLA,depression,mmonly rep orted adverse reactions The most,1
OTEZLA,depressed mood,for patients,0
OTEZLA,depressed mood,were the most commonly d adverse,1
OTEZLA,depressed mood,Diarrhea headache and nausea were,0
OTEZLA,depressed mood,d,1
OTEZLA,depressed mood,most commonly d adverse reac,1
OTEZLA,depressed mood,were the most commonly d,1
OTEZLA,depressed mood,d adverse reac tions The most common adverse,1
OTEZLA,depressed mood,and,0
OTEZLA,depressed mood,adverse reac tions The most common,1
OTEZLA,depressed mood,commonly d,1
OTEZLA,Depression,common adverse reactions leading to disco,0
OTEZLA,Depression,ntinuation for,1
OTEZLA,Depression,common adverse reactions leading to disco,0
OTEZLA,Depression,were nausea diarrhea and,0
OTEZLA,Depression,ntinuation for patients taking OTEZLA were,1
OTEZLA,Depression,ntinuation for patients taking OTEZLA,1
OTEZLA,Depression,ntinuation,1
OTEZLA,Depression,ntinuation for,1
OTEZLA,Depression,ntinuation for patients taking OTEZLA,1
OTEZLA,suicidal ideation,The proportion of patients with psoriatic,0
OTEZLA,suicide,on OTEZLA mg wice Da,1
OTEZLA,suicide,Reported in of Patients,0
OTEZLA,suicide,wice Da ily and Than That Observed,1
OTEZLA,suicide,Reported in of Patients,0
OTEZLA,suicide,wice Da ily and,1
OTEZLA,suicide,Reported in of Patients,0
OTEZLA,depression,miting in  OTEZLA mg,1
OTEZLA,depression,Reported in of Patients,0
OTEZLA,depression,of nausea and miting in  OTEZLA mg,1
OTEZLA,depression,Reported in of Patients,0
OTEZLA,depression,of nausea and miting,1
OTEZLA,depression,twice daily,0
OTEZLA,depression,twice daily experienced a serious adve,0
OTEZLA,depression,and miting in ,1
OTEZLA,depression,twice daily experienced a serious adve,0
OTEZLA,depression,miting in OTEZLA mg twice daily,1
OTEZLA,depression,miting in  OTEZLA mg twice daily subject,1
OTEZLA,depression,miting in OTEZLA mg twice daily,1
OTEZLA,depression,and miting in,1
OTEZLA,depression,ZLA 30 mg,1
OTEZLA,Depression,patient treated with OTEZLA mg twice daily experienced a serious adverse,0
OTEZLA,Depression,arrhea patient treated with,0
OTEZLA,Depression,twice daily experienced a,0
OTEZLA,Depression,serious adverse reaction of adache.   ,1
OTEZLA,Depression,twice daily experienced a,0
OTEZLA,Depression,of he,0
OTEZLA,Depression,patient treated with OTEZLA mg twice daily experienced a,0
OTEZLA,Depression,adache.    b Of the reported,1
OTEZLA,Depression,adache.    b Of the reported adverse,1
OTEZLA,Depression,adache.    b Of,1
OTEZLA,Depression,adverse reaction of adache.    b Of the,1
OTEZLA,Depression,adache.    b Of,1
OTEZLA,suicidal behavior,patients and                 P lacebo OTEZLA mg BID,1
OTEZLA,suicidal behavior,adache.    b Of,1
OTEZLA,attempted suicide,12(N=493)n (%) Diarrhea a,1
OTEZLA,attempted suicide,Day to Nn c Day to Day Nn Day to Nn Day,0
OTEZLA,attempted suicide,12(N=493)n (%) Diarrhea a,1
OTEZLA,suicide,        Nausea,1
OTEZLA,suicide,        Nausea a,1
OTEZLA,suicide,       ,1
OTEZLA,suicide,        Nausea a,1
OTEZLA,suicide,       ,1
OTEZLA,weight decrease,spiratory tract infection b,1
OTEZLA,weight decrease,spiratory tract infection b,1
OTEZLA,weight decrease,spiratory tract infection b,1
OTEZLA,weight decrease,spiratory,1
DYSPORT,Distant Spread of Toxin Effect,in Distant Spread of,1
DYSPORT,Spread of Effects from Toxin,Toxin Products seeWarnings,0
DYSPORT,Spread of Effects from Toxin,Toxin Products seeWarnings and Spread of Effects from Toxin seeWarnings and,1
DYSPORT,Spread of Effects from Toxin,Toxin Products seeWarnings,0
DYSPORT,Spread of Effects from Toxin,Products seeWarnings and Spread of Effects from Toxin seeWarnings and Precautions,1
DYSPORT,Spread of Effects from Toxin,Toxin Products seeWarnings,0
DYSPORT,Spread of Effects from Toxin,between Botulinum,0
DYSPORT,Spread of Effects from Toxin,Effects from Toxin seeWarnings and,1
DYSPORT,Spread of Effects from Toxin,Difficulties seeWarnings and,0
DYSPORT,Spread of Effects from Toxin,ck of Interchangeability between Botulinum Toxin Products seeWarnings,0
DYSPORT,Dysphagia,from Toxin seeWarnings and,0
DYSPORT,Dysphagia,Toxin seeWarnings and Dysphagia and Breathing Difficulties seeWarnings and,1
DYSPORT,Dysphagia,from Toxin seeWarnings and,0
DYSPORT,Dysphagia,from Toxin seeWarnings and Precautions,0
DYSPORT,Dysphagia,from Toxin seeWarnings and Dysphagia and Breathing Difficulties seeWarnings,1
DYSPORT,Dysphagia,from Toxin seeWarnings and Precautions,0
DYSPORT,Dysphagia,Dysphagia and Breathing Difficulties,1
DYSPORT,Dysphagia,Toxin seeWarnings and Precautions,0
DYSPORT,Dysphagia,Spread of,0
DYSPORT,Dysphagia,Dysphagia,1
DYSPORT,Dysphagia,Spread of,0
DYSPORT,Breathing Difficulties,Dysphagia Breathing Difficulties,1
DYSPORT,Breathing Difficulties,Spread of,0
DYSPORT,Breathing Difficulties,Toxin seeWarnings and Precautions Dysphagia and,0
DYSPORT,Breathing Difficulties,Precautions,0
DYSPORT,Breathing Difficulties,Breathing Difficulties seeWarnings and Precautions Facial Anatomy,1
DYSPORT,Breathing Difficulties,Precautions,0
DYSPORT,Breathing Difficulties,Dysphagia,0
DYSPORT,Breathing Difficulties,Precautions Dysphagia Breathing,1
DYSPORT,Breathing Difficulties,Breathing Difficulties seeWarnings and Precautions,1
DYSPORT,Intradermal Immune Reaction,Albumin seeWarnings,0
DYSPORT,muscular weakness,dysphagia dry mouth injection site discomfort,0
DYSPORT,muscular weakness,of patients muscular weakness,1
DYSPORT,muscular weakness,reactions of patients muscular weakness dysphagia,1
DYSPORT,muscular weakness,of patients muscular weakness,1
DYSPORT,muscular weakness,of patients muscular weakness,1
DYSPORT,muscular weakness,muscular weakness dysphagia dry mouth,1
DYSPORT,muscular weakness,muscular weakness dysphagia dry mouth injection site,1
DYSPORT,muscular weakness,adverse reactions of patients muscular,1
DYSPORT,muscular weakness,muscular weakness dysphagia dry mouth injection site,1
DYSPORT,muscular weakness,mouth injection site discomfort fatigue headache neck pain musculoskeletal,0
DYSPORT,dysphagia,are muscular dysphagia dry,1
DYSPORT,dysphagia,mouth injection site discomfort fatigue headache neck pain musculoskeletal,0
DYSPORT,dysphagia,injection site discomfort fatigue headache,0
DYSPORT,dysphagia,pain,0
DYSPORT,dysphagia,neck pain musculoskeletal,0
DYSPORT,dysphagia,are muscular dysphagia dry mouth,1
DYSPORT,dysphagia,neck pain musculoskeletal,0
DYSPORT,dysphagia,weakness,0
DYSPORT,dysphagia,of patients are muscular weakness,0
DYSPORT,dysphagia,dysphagia dry mouth injection site discomfort,1
DYSPORT,dysphagia,of patients are muscular dysphagia dry mouth,1
DYSPORT,dysphagia,dysphagia dry mouth injection site discomfort,1
DYSPORT,dry mouth,are muscular,0
DYSPORT,injection site discomfort,of patients are muscular weakness,0
DYSPORT,injection site discomfort,pain musculoskeletal pain dysphonia injection site pain,0
DYSPORT,injection site discomfort,pain dysphonia injection site pain and,0
DYSPORT,fatigue,fatigue headache,1
DYSPORT,headache,headache neck pain musculoskeletal pain,1
DYSPORT,headache,headache neck pain musculoskeletal pain dysphonia,1
DYSPORT,headache,are muscular,0
DYSPORT,headache,headache neck,1
DYSPORT,neck pain,neck pain musculoskeletal pain dysphonia injection,1
DYSPORT,neck pain,fatigue neck pain musculoskeletal pain dysphonia injection site,1
DYSPORT,neck pain,neck pain musculoskeletal pain dysphonia injection,1
DYSPORT,neck pain,discomfort fatigue neck pain musculoskeletal pain,1
DYSPORT,neck pain,neck pain musculoskeletal pain dysphonia injection,1
DYSPORT,neck pain,fatigue neck pain musculoskeletal pain,1
DYSPORT,neck pain,neck pain musculoskeletal pain dysphonia injection,1
DYSPORT,neck pain,discomfort fatigue,0
DYSPORT,neck pain,injection site discomfort fatigue neck pain,1
DYSPORT,musculoskeletal pain,musculoskeletal pain,1
DYSPORT,musculoskeletal pain,discomfort,0
DYSPORT,musculoskeletal pain,Lines,0
DYSPORT,musculoskeletal pain,musculoskeletal pain,1
DYSPORT,musculoskeletal pain,discomfort fatigue headache neck musculoskeletal pain,1
DYSPORT,musculoskeletal pain,musculoskeletal pain dysphonia injection site pain and,1
DYSPORT,musculoskeletal pain,discomfort fatigue headache neck musculoskeletal pain,1
DYSPORT,musculoskeletal pain,musculoskeletal pain dysphonia injection site pain and,1
DYSPORT,musculoskeletal pain,headache neck,0
DYSPORT,musculoskeletal pain,fatigue headache neck musculoskeletal pain,1
DYSPORT,dysphonia,headache neck pain musculoskeletal dysphonia injection site,1
DYSPORT,dysphonia,fatigue headache neck musculoskeletal pain,1
DYSPORT,dysphonia,dysphonia injection site pain and eye,1
DYSPORT,dysphonia,dysphonia injection site pain,1
DYSPORT,dysphonia,Glabellar Lines The most,0
DYSPORT,injection site pain,injection site pain and eye,1
DYSPORT,injection site pain,Glabellar Lines The most,0
DYSPORT,injection site pain,pain injection,1
DYSPORT,injection site pain,pain dysphonia,0
DYSPORT,injection site pain,pain musculoskeletal pain injection site pain and eye disorders Glabellar,1
DYSPORT,injection site pain,pain dysphonia,0
DYSPORT,injection site pain,injection site pain and eye disorders,1
DYSPORT,injection site pain,injection site pain and eye,1
DYSPORT,injection site pain,injection site pain and eye disorders,1
DYSPORT,eye disorders,eye disorders Glabellar,1
DYSPORT,nasopharyngitis,are,0
DYSPORT,headache,frequently reported adverse reactions are nasopharyngitis,0
DYSPORT,headache,headache injection site pain,1
DYSPORT,headache,are headache injection site pain injection site,1
DYSPORT,headache,headache injection site pain,1
DYSPORT,headache,headache injection,1
DYSPORT,headache,The most frequently reported adverse reactions,0
DYSPORT,headache,nasopharyngitis,0
DYSPORT,injection site pain,are nasopharyngitis injection site pain injection,1
DYSPORT,injection site pain,nasopharyngitis,0
DYSPORT,injection site pain,site pain injection site reaction,1
DYSPORT,injection site pain,Lines The most,0
DYSPORT,injection site reaction,nasopharyngitis headache injection site injection site,1
DYSPORT,injection site reaction,nasopharyngitis headache injection site injection site reaction upper,1
DYSPORT,injection site reaction,nasopharyngitis headache injection site injection site,1
DYSPORT,injection site reaction,site,0
DYSPORT,injection site reaction,site injection site reaction upper respiratory tract infection,1
DYSPORT,injection site reaction,site,0
DYSPORT,injection site reaction,ptosis sinusitis,0
DYSPORT,injection site reaction,sinusitis,0
DYSPORT,injection site reaction,headache injection site injection site reaction upper respiratory tract,1
DYSPORT,injection site reaction,sinusitis,0
DYSPORT,injection site reaction,reactions are nasopharyngitis headache injection site,0
DYSPORT,injection site reaction,injection site injection site reaction upper,1
DYSPORT,injection site reaction,reactions are nasopharyngitis headache injection site,0
DYSPORT,injection site reaction,site injection site,1
DYSPORT,upper respiratory tract infection,pain injection site upper respiratory tract infection,1
DYSPORT,upper respiratory tract infection,site injection site,1
DYSPORT,eyelid edema,respiratory tract,0
DYSPORT,eyelid edema,reaction upper respiratory tract eyelid edema,1
DYSPORT,eyelid edema,respiratory tract,0
DYSPORT,eyelid edema,eyelid edema eyelid ptosis sinusitis,1
DYSPORT,eyelid edema,upper respiratory tract eyelid edema eyelid ptosis sinusitis and,1
DYSPORT,eyelid edema,eyelid edema eyelid ptosis sinusitis,1
DYSPORT,eyelid edema,ptosis sinusitis and nausea Upper Limb Spasticity The most,0
DYSPORT,eyelid edema,tract infection,0
DYSPORT,sinusitis,most frequently reported adverse reactions,0
DYSPORT,sinusitis,sinusitis and nausea Upper,1
DYSPORT,urinary tract infection,reactions urinary tract infection nasopharyngitis muscular,1
DYSPORT,urinary tract infection,sinusitis and nausea Upper,1
DYSPORT,nasopharyngitis,nasopharyngitis muscular weakness,1
DYSPORT,nasopharyngitis,musculoskeletal pain dizziness fall,0
DYSPORT,nasopharyngitis,nasopharyngitis muscular weakness musculoskeletal,1
DYSPORT,nasopharyngitis,nasopharyngitis muscular weakness musculoskeletal,1
DYSPORT,nasopharyngitis,The most frequently reported adverse,0
DYSPORT,nasopharyngitis,muscular weakness musculoskeletal pain dizziness fall and depression To report SUSP,0
DYSPORT,nasopharyngitis,nasopharyngitis muscular weakness musculoskeletal pain,1
DYSPORT,nasopharyngitis,muscular weakness musculoskeletal pain dizziness fall and depression To report SUSP,0
DYSPORT,muscular weakness,frequently reported adverse reactions are,0
DYSPORT,muscular weakness,are urinary tract infection muscular weakness musculoskeletal pain dizziness,1
DYSPORT,muscular weakness,frequently reported adverse reactions are,0
DYSPORT,muscular weakness,muscular weakness musculoskeletal pain dizziness,1
DYSPORT,muscular weakness,frequently reported adverse reactions are,0
DYSPORT,muscular weakness,muscular weakness musculoskeletal,1
DYSPORT,muscular weakness,SUSPECTED ADVERSE REACT,0
DYSPORT,dizziness,SUSPECTED ADVERSE REACTIONS contact Ipsen Biopharmaceut,0
DYSPORT,dizziness,dizziness,1
DYSPORT,dizziness,dizziness fall,1
DYSPORT,dizziness,musculoskeletal dizziness fall,1
DYSPORT,dizziness,dizziness fall,1
DYSPORT,dizziness,dizziness fall and,1
DYSPORT,dizziness,dizziness fall and depression To,1
DYSPORT,dizziness,dizziness fall and,1
DYSPORT,dizziness,REACTIONS contact Ipsen Biopharmaceut,0
DYSPORT,dizziness,musculoskeletal dizziness,1
DYSPORT,dizziness,REACTIONS contact Ipsen Biopharmaceut,0
DYSPORT,dizziness,SUSPECTED,0
DYSPORT,fall,fall and depression To,1
DYSPORT,fall,SUSPECTED,0
DYSPORT,fall,and depression To report SUSPECTED ADVERSE,0
DYSPORT,fall,muscular weakness musculoskeletal,0
DYSPORT,fall,fall and depression To report SUSPECTED,1
DYSPORT,muscular weakness,muscular weakness dysphagia,1
DYSPORT,muscular weakness,fall and depression To report SUSPECTED,1
DYSPORT,muscular weakness,site discomfort fatigue headache neck pain musculoskeletal pai,0
DYSPORT,muscular weakness,dry mouth injection site discomfort fatigue headache neck,0
DYSPORT,muscular weakness,cervical dystonia patients muscular weakness,1
DYSPORT,muscular weakness,of DYSPORT r in the placebo controlled clinical trials in cervical dystonia,0
DYSPORT,muscular weakness,muscular weakness dysphagia dry mouth injection,1
DYSPORT,muscular weakness,muscular weakness dysphagia dry mouth injection,1
DYSPORT,muscular weakness,muscular weakness dysphagia dry mouth injection,1
DYSPORT,dysphagia,patients were,0
DYSPORT,dry mouth,pain musculoskeletal pain dysphonia,0
DYSPORT,dry mouth,in cervical dystonia patients were muscular weakness,0
DYSPORT,fatigue,site fatigue headache neck pain musculoskeletal pain,1
DYSPORT,fatigue,in cervical dystonia patients were muscular weakness,0
DYSPORT,fatigue,mouth injection site fatigue headache,1
DYSPORT,fatigue,in cervical dystonia patients were muscular weakness,0
DYSPORT,fatigue,fatigue headache neck,1
DYSPORT,fatigue,dry mouth injection site fatigue headache neck pain musculoskeletal,1
DYSPORT,fatigue,fatigue headache neck,1
DYSPORT,fatigue,fatigue headache,1
DYSPORT,headache,eye disorders consisting,0
DYSPORT,neck pain,pain dysphonia,0
DYSPORT,neck pain,injection site discomfort fatigue neck pain musculoskeletal,1
DYSPORT,neck pain,pain dysphonia,0
DYSPORT,neck pain,discomfort fatigue neck pain,1
DYSPORT,musculoskeletal pain,dry mouth injection site,0
DYSPORT,musculoskeletal pain,musculoskeletal pain dysphonia injection site pain,1
DYSPORT,dysphonia,dry mouth injection,0
DYSPORT,dysphonia,dysphonia,1
DYSPORT,dysphonia,dry mouth injection,0
DYSPORT,dysphonia,dysphonia injection site pain,1
DYSPORT,dysphonia,dysphonia injection site,1
DYSPORT,dysphonia,pain musculoskeletal pain,0
DYSPORT,dysphonia,dysphonia injection site pain and,1
DYSPORT,dysphonia,disorders,0
DYSPORT,dysphonia,dysphonia injection site pain,1
DYSPORT,dysphonia,eye disorders consisting of,0
DYSPORT,injection site pain,pain musculoskeletal pain injection site pain and eye disorders consisting,1
DYSPORT,injection site pain,eye disorders consisting of,0
DYSPORT,injection site pain,disorders consisting of blurred vision diplopia and reduced visual,0
DYSPORT,injection site pain,of blurred vision diplopia and reduced,0
DYSPORT,injection site pain,and reduced visual acuity and,0
DYSPORT,injection site pain,headache neck,0
DYSPORT,injection site pain,neck pain musculoskeletal pain injection site pain and eye disorders consisting of,1
DYSPORT,injection site pain,headache neck,0
DYSPORT,eye disorders,pain eye disorders consisting of blurred vision,1
DYSPORT,eye disorders,headache neck,0
DYSPORT,eye disorders,pain eye disorders,1
DYSPORT,eye disorders,headache neck,0
DYSPORT,eye disorders,site pain eye disorders,1
DYSPORT,eye disorders,injection site pain eye disorders consisting,1
DYSPORT,eye disorders,site pain eye disorders,1
DYSPORT,eye disorders,eye disorders consisting of blurred,1
DYSPORT,eye disorders,site pain eye disorders,1
DYSPORT,eye disorders,fatigue headache neck pain musculoskeletal pain dysphonia,0
DYSPORT,eye disorders,eye disorders consisting,1
DYSPORT,diplopia,of blurred vision,0
DYSPORT,diplopia,and accommodation Other than,0
DYSPORT,diplopia,diplopia and reduced visual acuity and,1
DYSPORT,diplopia,blurred diplopia and reduced visual,1
DYSPORT,diplopia,diplopia and reduced visual acuity and,1
DYSPORT,diplopia,and eye disorders consisting of blurred,0
DYSPORT,reduced visual acuity,of blurred vision diplopia and,0
DYSPORT,reduced visual acuity,reduced visual acuity,1
DYSPORT,reduced visual acuity,blurred vision diplopia reduced visual acuity,1
DYSPORT,reduced visual acuity,reduced visual acuity,1
DYSPORT,reduced visual acuity,Other than injection site,0
DYSPORT,reduced visual acuity,reduced visual acuity and accommodation Other than injection,1
DYSPORT,reduced visual acuity,diplopia reduced visual acuity and accommodation,1
DYSPORT,reduced visual acuity,reduced visual acuity and accommodation Other than injection,1
DYSPORT,injection site reactions,accommodation Other injection site reactions most adverse reactions,1
DYSPORT,injection site reactions,reduced visual acuity and accommodation Other than injection,1
DYSPORT,injection site reactions,and accommodation Other injection,1
DYSPORT,injection site reactions,injection site reactions most adverse reactions became,1
DYSPORT,injection site reactions,injection,1
DYSPORT,injection site reactions,and accommodation Other injection site reactions most adverse reactions became,1
DYSPORT,injection site reactions,injection,1
DYSPORT,injection site reactions,injection site reactions,1
DYSPORT,injection site reactions,became noticeable about one week after treatment and lasted several weeks,0
DYSPORT,injection site reactions,reactions became noticeable about one,0
DYSPORT,disturbance in attention,patient,0
DYSPORT,disturbance in attention,One patient,0
DYSPORT,disturbance in attention,withdrawal One,0
DYSPORT,disturbance in attention,disorder feeling abnormal and headache and one patient experienced dysphagia Table,0
DYSPORT,disturbance in attention,adverse reactions leading to,0
DYSPORT,disturbance in attention,to,0
DYSPORT,disturbance in attention,feeling abnormal and headache,0
DYSPORT,eyelid disorder,one patient experienced dysphagia Table compares the inc,0
DYSPORT,eyelid disorder,experienced disturbance in eyelid disorder feeling abnormal and headache,1
DYSPORT,eyelid disorder,one patient experienced dysphagia Table compares the inc,0
DYSPORT,feeling abnormal,feeling abnormal and headache and one,1
DYSPORT,feeling abnormal,disturbance in attention eyelid feeling,1
DYSPORT,feeling abnormal,eyelid feeling abnormal and headache,1
DYSPORT,feeling abnormal,disturbance in attention eyelid feeling,1
DYSPORT,feeling abnormal,feeling abnormal and headache,1
DYSPORT,feeling abnormal,feeling abnormal and headache and one,1
DYSPORT,feeling abnormal,attention eyelid feeling,1
DYSPORT,feeling abnormal,disorder,0
DYSPORT,feeling abnormal,experienced disturbance,0
DYSPORT,feeling abnormal,eyelid feeling abnormal,1
DYSPORT,feeling abnormal,headache and one patient experienced dysphagia Table compares the,0
DYSPORT,headache,One patient,0
DYSPORT,headache,headache and,1
DYSPORT,headache,headache and one patient,1
DYSPORT,headache,dysphagia Table,0
DYSPORT,headache,feeling abnormal,0
DYSPORT,headache,disorder feeling abnormal headache and,1
DYSPORT,headache,feeling abnormal,0
DYSPORT,headache,most frequent adv,0
DYSPORT,headache,disorder feeling abnormal headache and one patient,1
DYSPORT,headache,most frequent adv,0
DYSPORT,headache,feeling abnormal headache,1
DYSPORT,headache,most frequent adv,0
DYSPORT,dysphagia,compares the incidence of,0
DYSPORT,dysphagia,dysphagia Table compares the,1
DYSPORT,dysphagia,dysphagia,1
DYSPORT,dysphagia,dysphagia,1
DYSPORT,dysphagia,dysphagia Table compares the incidence of,1
DYSPORT,dysphagia,and one patient dysphagia Table compares the incidence,1
DYSPORT,dysphagia,dysphagia Table compares the incidence of,1
DYSPORT,Injection site discomfort,Injection site discomfort and injection site,1
DYSPORT,Injection site discomfort,Injection,1
DYSPORT,Injection site discomfort,Site Injection site discomfort and injection site,1
DYSPORT,Injection site discomfort,Injection,1
DYSPORT,Injection site discomfort,Injection Site Injection site discomfort and injection,1
DYSPORT,Injection site discomfort,Injection,1
DYSPORT,Injection site discomfort,Injection Site Reactions,0
DYSPORT,injection site pain,site discomfort injection site pain were common,1
DYSPORT,injection site pain,Injection Site Reactions,0
DYSPORT,injection site pain,Reactions Injection site discomfort injection site pain,1
DYSPORT,injection site pain,Injection site discomfort injection site,1
DYSPORT,injection site pain,discomfort injection site pain were common adverse reactions following,1
DYSPORT,injection site pain,Injection site discomfort injection site,1
DYSPORT,injection site pain,following DYSPORT r administration Less Common,0
DYSPORT,injection site pain,Injection Site,0
DYSPORT,injection site pain,site pain were common adverse reactions following,1
DYSPORT,injection site pain,Injection site discomfort injection site pain were common adverse,1
DYSPORT,injection site pain,site pain were common adverse reactions following,1
DYSPORT,injection site pain,discomfort injection site pain were common adverse reactions following,1
DYSPORT,injection site pain,site pain were common adverse reactions following,1
DYSPORT,injection site pain,site discomfort,0
DYSPORT,dyspnea,mainly dyspnea,1
DYSPORT,dyspnea,site discomfort,0
DYSPORT,dyspnea,dyspnea The median,1
DYSPORT,dyspnea,dyspnea,1
DYSPORT,dyspnea,from last dose of DYSPORT r was approximately one week and the m,0
DYSPORT,dyspnea,dyspnea The median,1
DYSPORT,dyspnea,of,0
DYSPORT,dyspnea,These consisted mainly dyspnea The median,1
DYSPORT,dyspnea,of,0
DYSPORT,dyspnea,time,0
DYSPORT,dizziness,dizziness,1
DYSPORT,dizziness,dizziness in of DYSPORT r,1
DYSPORT,dizziness,phase of clinical trials dizziness in of DYSPORT r treated,1
DYSPORT,dizziness,dizziness in of DYSPORT r,1
DYSPORT,muscle atrophy,muscle atrophy in of,1
DYSPORT,muscle atrophy,of the placebotreated patients L,0
DYSPORT,muscle atrophy,muscle atrophy in of DYSPORT r,1
DYSPORT,muscle atrophy,muscle atrophy,1
DYSPORT,muscle atrophy,r,0
DYSPORT,muscle atrophy,patients muscle atrophy in of DYSPORT r,1
DYSPORT,muscle atrophy,r,0
DYSPORT,reduction in heart rate,study showed a statistically reduction in heart rate compared to baseline averaging,1
DYSPORT,reduction in heart rate,r,0
DYSPORT,reduction in heart rate,heart rate compared to baseline,1
DYSPORT,reduction in heart rate,showed a statistically reduction in,1
DYSPORT,reduction in heart rate,thirty minutes after injecti,0
DYSPORT,nasopharyngitis,nasopharyngitis headache injection site,1
DYSPORT,nasopharyngitis,injection,0
DYSPORT,nasopharyngitis,following injection of DYSPORT,0
DYSPORT,nasopharyngitis,nasopharyngitis headache injection site pain,1
DYSPORT,nasopharyngitis,of DYSPORT r nasopharyngitis headache injection site pain injection,1
DYSPORT,nasopharyngitis,nasopharyngitis headache injection site pain,1
DYSPORT,nasopharyngitis,injection of DYSPORT r nasopharyngitis headache injection site,1
DYSPORT,nasopharyngitis,nasopharyngitis headache injection site pain,1
DYSPORT,headache,nasopharyngitis,0
DYSPORT,headache,headache injection site,1
DYSPORT,headache,of DYSPORT,0
DYSPORT,headache,headache injection site pain injection,1
DYSPORT,injection site pain,headache,0
DYSPORT,injection site pain,DYSPORT,0
DYSPORT,injection site reaction,respiratory tract infection eyelid edema eyelid ptosis sinusitis and,0
DYSPORT,injection site reaction,site pain,0
DYSPORT,injection site reaction,injection,1
DYSPORT,upper respiratory tract infection,pain injection site upper respiratory tract infection,1
DYSPORT,upper respiratory tract infection,site pain injection site,0
DYSPORT,upper respiratory tract infection,to DYSPORT r,0
DYSPORT,upper respiratory tract infection,tract infection,1
DYSPORT,upper respiratory tract infection,site pain injection site upper respiratory,1
DYSPORT,upper respiratory tract infection,eyelid edema eyelid ptosis sinusitis and nausea Table reflects exposure to,0
DYSPORT,upper respiratory tract infection,upper respiratory tract infection eyelid edema eyelid,1
DYSPORT,upper respiratory tract infection,r were,0
DYSPORT,upper respiratory tract infection,upper respiratory tract infection eyelid edema eyelid ptosis,1
DYSPORT,upper respiratory tract infection,r were,0
DYSPORT,eyelid edema,tract eyelid edema eyelid ptosis sinusitis,1
DYSPORT,eyelid edema,r were,0
DYSPORT,eyelid ptosis,eyelid ptosis sinusitis and nausea,1
DYSPORT,sinusitis,eyelid edema eyelid sinusitis and,1
DYSPORT,sinusitis,eyelid ptosis sinusitis and nausea,1
DYSPORT,sinusitis,infection eyelid edema eyelid sinusitis and nausea Table reflects,1
DYSPORT,sinusitis,eyelid ptosis sinusitis and nausea,1
DYSPORT,nausea,years,0
DYSPORT,nausea,nausea Table reflects,1
DYSPORT,nausea,nausea,1
DYSPORT,nausea,sinusitis nausea Table,1
DYSPORT,nausea,nausea,1
DYSPORT,nausea,nausea Table,1
DYSPORT,nausea,exposure to DYSPORT r in patients to years,0
DYSPORT,nausea,nausea Table reflects exposure to,1
DYSPORT,nausea,nausea Table reflects,1
DYSPORT,nausea,DYSPORT r in patients to years of age,0
DYSPORT,nausea,ptosis,0
DYSPORT,Injection Site Reaction,Site Injection Site Reaction,1
DYSPORT,Injection Site Reaction,ptosis,0
DYSPORT,headache,headache nasopharyngitis injection,1
DYSPORT,headache,reported of these adverse reactions were,0
DYSPORT,headache,headache,1
DYSPORT,headache,headache nasopharyngitis injection,1
DYSPORT,headache,headache,1
DYSPORT,headache,these adverse reactions headache nasopharyngitis injection site pain sinusitis,1
DYSPORT,headache,headache,1
DYSPORT,sinusitis,these adverse reactions were headache nasopharyngitis injection site,0
DYSPORT,sinusitis,nasopharyngitis injection site sinusitis URI injection site,1
DYSPORT,sinusitis,these adverse reactions were headache nasopharyngitis injection site,0
DYSPORT,sinusitis,sinusitis,1
DYSPORT,sinusitis,headache nasopharyngitis injection site sinusitis URI injection site,1
DYSPORT,sinusitis,sinusitis,1
DYSPORT,sinusitis,site pain,0
DYSPORT,sinusitis,nasopharyngitis,0
DYSPORT,sinusitis,sinusitis URI injection,1
DYSPORT,URI,discomfort erythema tenderness,0
DYSPORT,URI,URI injection site bruising and injection,1
DYSPORT,URI,discomfort erythema,0
DYSPORT,URI,URI injection,1
DYSPORT,URI,bruising,0
DYSPORT,URI,were,0
DYSPORT,URI,nasopharyngitis injection site pain URI injection,1
DYSPORT,URI,were,0
DYSPORT,URI,numbness discomfort erythema tenderness,0
DYSPORT,URI,of these adverse reactions were headache,0
DYSPORT,URI,discomfort erythema tenderness,0
DYSPORT,injection site bruising,injection site bruising and injection site reaction,1
DYSPORT,injection site bruising,pain sinusitis injection site bruising,1
DYSPORT,injection site reaction,injection site reaction,1
DYSPORT,injection site reaction,injection site reaction numbness discomfort erythema tenderness tingling,1
DYSPORT,injection site reaction,injection site reaction,1
DYSPORT,injection site reaction,injection site reaction numbness discomfort erythema tenderness,1
DYSPORT,bronchitis,pain cough contact dermatitis,0
DYSPORT,bronchitis,of the population bronchitis influenza pharyngolaryngeal pain,1
DYSPORT,bronchitis,pain cough contact dermatitis,0
DYSPORT,bronchitis,bronchitis influenza,1
DYSPORT,bronchitis,of the population bronchitis influenza pharyngolaryngeal pain cough contact,1
DYSPORT,bronchitis,bronchitis influenza,1
DYSPORT,bronchitis,the,0
DYSPORT,bronchitis,of the population,0
DYSPORT,bronchitis,bronchitis influenza pharyngolaryngeal,1
DYSPORT,bronchitis,bronchitis influenza pharyngolaryngeal pain cough contact,1
DYSPORT,bronchitis,repeated injections in of the population,0
DYSPORT,influenza,influenza pharyngolaryngeal pain,1
DYSPORT,influenza,swelling,0
DYSPORT,influenza,influenza pharyngolaryngeal pain cough,1
DYSPORT,influenza,pharyngolaryngeal,0
DYSPORT,influenza,influenza pharyngolaryngeal pain cough contact,1
DYSPORT,influenza,influenza pharyngolaryngeal pain,1
DYSPORT,influenza,site swelling and injection,0
DYSPORT,influenza,influenza pharyngolaryngeal pain,1
DYSPORT,influenza,included influenza pharyngolaryngeal pain cough contact,1
DYSPORT,influenza,influenza pharyngolaryngeal pain,1
DYSPORT,pharyngolaryngeal pain,dermatitis injection site swelling and injection site,0
DYSPORT,pharyngolaryngeal pain,bronchitis pharyngolaryngeal pain cough contact dermatitis injection site,1
DYSPORT,pharyngolaryngeal pain,dermatitis injection site swelling and injection site,0
DYSPORT,pharyngolaryngeal pain,pharyngolaryngeal pain cough,1
DYSPORT,pharyngolaryngeal pain,influenza,0
DYSPORT,pharyngolaryngeal pain,pharyngolaryngeal pain cough,1
DYSPORT,pharyngolaryngeal pain,included bronchitis pharyngolaryngeal,1
DYSPORT,pharyngolaryngeal pain,contact dermatitis injection site swelling and injection site discomfort The,0
DYSPORT,pharyngolaryngeal pain,bronchitis pharyngolaryngeal pain cough contact,1
DYSPORT,pharyngolaryngeal pain,contact dermatitis injection site swelling and injection site discomfort The,0
DYSPORT,pharyngolaryngeal pain,injection site swelling and injection site,0
DYSPORT,cough,included bronchitis influenza pharyngolaryngeal cough contact dermatitis injection site,1
DYSPORT,cough,injection site swelling and injection site,0
DYSPORT,contact dermatitis,population included bronchitis influenza pharyngolaryngeal pain,0
DYSPORT,contact dermatitis,bronchitis,0
DYSPORT,contact dermatitis,contact,1
DYSPORT,contact dermatitis,contact dermatitis injection site swelling and injection,1
DYSPORT,contact dermatitis,influenza pharyngolaryngeal pain contact dermatitis injection site swelling and,1
DYSPORT,contact dermatitis,contact dermatitis injection site swelling and injection,1
DYSPORT,contact dermatitis,contact dermatitis injection,1
DYSPORT,contact dermatitis,contact dermatitis injection site swelling and injection,1
DYSPORT,injection site swelling,incidence of,0
DYSPORT,injection site swelling,The,0
DYSPORT,injection site swelling,site swelling and injection site discomfort,1
DYSPORT,injection site swelling,injection site discomfort The incidence of eyelid ptosis did not,0
DYSPORT,injection site swelling,population included bronchitis influenza,0
DYSPORT,eyelid ptosis,of,0
DYSPORT,eyelid ptosis,The incidence,0
DYSPORT,eyelid ptosis,eyelid ptosis did not increase in the,1
DYSPORT,eyelid ptosis,dermatitis injection,0
DYSPORT,eyelid ptosis,The incidence eyelid ptosis,1
DYSPORT,eyelid ptosis,discomfort The incidence eyelid ptosis,1
DYSPORT,eyelid ptosis,site discomfort The incidence eyelid,1
DYSPORT,eyelid ptosis,h contact,0
DYSPORT,eyelid ptosis,eyelid ptosis,1
DYSPORT,eyelid ptosis,moderate in severity and resolved over,0
DYSPORT,eyelid ptosis,multiple retreatments at intervals three months The majority of the reports of,0
DYSPORT,eyelid ptosis,ty studies with multiple,0
DYSPORT,eyelid ptosis,eyelid ptosis were mild,1
DYSPORT,eyelid ptosis,retreatments at,0
DYSPORT,eyelid ptosis,eyelid ptosis were mild to,1
DYSPORT,eyelid ptosis,intervals,0
DYSPORT,eyelid ptosis,eyelid,1
DYSPORT,eyelid ptosis,ty studies with multiple retreatments at intervals,0
DYSPORT,eyelid ptosis,eyelid ptosis were mild to moderate,1
DYSPORT,eyelid ptosis,to moderate in severity and resolved over several weeks,0
DYSPORT,Muscular weakness,and connective tissue disorders,0
DYSPORT,Muscular weakness,etal and connective tissue Muscular weakness Pain i,1
DYSPORT,Muscular weakness,and connective tissue disorders,0
DYSPORT,Muscular weakness,Muscular weakness Pain i,1
DYSPORT,Muscular weakness,Muscular weakness Pain,1
DYSPORT,Muscular weakness,tissue Muscular weakness,1
DYSPORT,Muscular weakness,Muscular weakness Pain,1
DYSPORT,Injection site reactions,Injection site reactions eg,1
DYSPORT,Injection site reactions,Reactions,0
DYSPORT,Injection site reactions,Injection Site Injection site reactions,1
DYSPORT,Injection site reactions,site reactions eg pain bruising haemorrhage injection,1
DYSPORT,Injection site reactions,Injection site reactions eg pain bruising haemorrhage,1
DYSPORT,Injection site reactions,site reactions eg pain bruising haemorrhage injection,1
DYSPORT,Injection site reactions,Site Injection site,1
DYSPORT,injection site erythema,haematoma etc have occurred,0
DYSPORT,injection site erythema,pain bruising haemorrhage,0
DYSPORT,injection site erythema,Injection Site Reactions Injection site,0
DYSPORT,injection site erythema,reactions eg pain bruising injection site,1
DYSPORT,dysphagia,treatment groups dysphagia gait disturbance hypertonia,1
DYSPORT,dysphagia,reactions eg pain bruising injection site,1
DYSPORT,gait disturbance,included gait,1
DYSPORT,gait disturbance,r treatment groups included,0
DYSPORT,gait disturbance,groups included gait,1
DYSPORT,gait disturbance,sensation of,0
DYSPORT,gait disturbance,Postmarketing,0
DYSPORT,gait disturbance,groups included gait,1
DYSPORT,gait disturbance,incidence of less than reported,0
DYSPORT,gait disturbance,gait disturbance,1
DYSPORT,gait disturbance,heaviness,0
DYSPORT,hypertonia,dysphagia gait hypertonia and sensation of heaviness Postmarketing,1
DYSPORT,hypertonia,heaviness,0
DYSPORT,hypertonia,dysphagia gait hypertonia and sensation of,1
DYSPORT,hypertonia,heaviness,0
DYSPORT,hypertonia,hypertonia and sensation of heaviness,1
DYSPORT,hypertonia,hypertonia,1
DYSPORT,sensation of heaviness,gait disturbance hypertonia sensation of heaviness Postmarketing Experience Because,1
DYSPORT,sensation of heaviness,hypertonia,1
DYSPORT,sensation of heaviness,gait disturbance hypertonia sensation of heaviness Postmarketing Experience Because adverse reactions,1
DYSPORT,sensation of heaviness,hypertonia,1
DYSPORT,sensation of heaviness,adverse reactions are,0
DYSPORT,sensation of heaviness,gait disturbance hypertonia sensation of heaviness Postmarketing Experience Because adverse reactions,1
DYSPORT,sensation of heaviness,adverse reactions are,0
DYSPORT,sensation of heaviness,included dysphagia gait disturbance hypertonia,0
DYSPORT,sensation of heaviness,included dysphagia gait disturbance hypertonia and,0
DYSPORT,sensation of heaviness,reported voluntarily,0
DYSPORT,sensation of heaviness,are reported voluntarily from,0
DYSPORT,sensation of heaviness,sensation of,1
DYSPORT,vertigo,use of DYSPORT vertigo,1
DYSPORT,vertigo,sensation of,1
DYSPORT,vertigo,facial paresis,0
DYSPORT,photophobia,paresis hypoesthesia,0
DYSPORT,photophobia,paresis hypoesthesia erythema and,0
DYSPORT,photophobia,r vertigo,0
DYSPORT,photophobia,photophobia influenzalike illness amyotrophy burning,1
DYSPORT,photophobia,during postapproval use of DYSPORT,0
DYSPORT,photophobia,DYSPORT r photophobia influenzalike illness,1
DYSPORT,photophobia,during postapproval use of DYSPORT,0
DYSPORT,photophobia,photophobia,1
DYSPORT,photophobia,DYSPORT r photophobia,1
DYSPORT,photophobia,photophobia,1
DYSPORT,influenza-like illness,of DYSPORT r vertigo influenza-like illness amyotrophy burning,1
DYSPORT,influenza-like illness,photophobia,1
DYSPORT,amyotrophy,amyotrophy burning sensation,1
DYSPORT,amyotrophy,use of,0
DYSPORT,amyotrophy,photophobia influenzalike,0
DYSPORT,amyotrophy,amyotrophy burning,1
DYSPORT,amyotrophy,amyotrophy burning sensation facial,1
DYSPORT,amyotrophy,amyotrophy,1
DYSPORT,amyotrophy,facial paresis hypoesthesia erythema,0
DYSPORT,amyotrophy,paresis hypoesthesia,0
DYSPORT,burning sensation,illness burning sensation,1
DYSPORT,burning sensation,paresis hypoesthesia,0
DYSPORT,burning sensation,excessive granulation,0
DYSPORT,burning sensation,excessive granulation tissue,0
DYSPORT,burning sensation,hypoesthesia erythema and excessive,0
DYSPORT,burning sensation,photophobia influenzalike illness burning sensation facial paresis hypoesthesia erythema,1
DYSPORT,burning sensation,hypoesthesia erythema and excessive,0
DYSPORT,facial paresis,burning sensation,0
DYSPORT,facial paresis,amyotrophy burning facial paresis hypoesthesia erythema and,1
DYSPORT,facial paresis,burning sensation,0
DYSPORT,hypoesthesia,amyotrophy burning sensation facial hypoesthesia erythema and excessive granulation tissue,1
DYSPORT,hypoesthesia,burning sensation,0
DYSPORT,hypoesthesia,paresis,0
DYSPORT,hypoesthesia,tissue Immunogenicity As with all therapeutic pr,0
DYSPORT,hypoesthesia,hypoesthesia erythema and,1
DYSPORT,hypoesthesia,photophobia influenzalike illness amyotrophy burning sensation facial paresis,0
DYSPORT,hypoesthesia,amyotrophy burning sensation facial hypoesthesia erythema,1
DYSPORT,hypoesthesia,photophobia influenzalike illness amyotrophy burning sensation facial paresis,0
DYSPORT,hypoesthesia,hypoesthesia,1
DYSPORT,hypoesthesia,hypoesthesia erythema and,1
DYSPORT,hypoesthesia,with,0
DYSPORT,hypoesthesia,amyotrophy burning sensation facial hypoesthesia erythema,1
DYSPORT,hypoesthesia,with,0
DYSPORT,erythema,illness amyotrophy burning,0
DYSPORT,erythema,tissue Immunogenicity As,0
DYSPORT,erythema,erythema and excessive granulation tissue Immunogenicity,1
DYSPORT,erythema,erythema,1
DYSPORT,erythema,erythema and excessive granulation,1
DYSPORT,erythema,erythema and excessive granulation,1
DYSPORT,erythema,erythema and excessive,1
DYSPORT,erythema,and excessive granulation,0
DYSPORT,erythema,facial paresis erythema and excessive granulation,1
DYSPORT,erythema,and excessive granulation,0
DYSPORT,erythema,erythema and excessive granulation tissue,1
DYSPORT,excessive granulation tissue,hypoesthesia erythema excessive granulation tissue,1
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,elsewhere in labeling Distant Spread of Toxin Effect seeBoxe,0
DYSPORT,generalized muscle weakness,utions (5.2) ] * Dysphag,1
DYSPORT,generalized muscle weakness,] * Dysphag ia and Breathing Difficulties seeWarnings,1
DYSPORT,generalized muscle weakness,from Toxin seeWarnings and utions (5.2) ] *,1
DYSPORT,generalized muscle weakness,Precautions,0
DYSPORT,generalized muscle weakness,Toxin seeWarnings and utions,1
DYSPORT,generalized muscle weakness,seeWarnings and utions (5.2) ] *,1
DYSPORT,diplopia,Precautions Facial Anatomy in the,0
DYSPORT,diplopia,seeWarnings and Precautions  and Bre athing,1
DYSPORT,diplopia,Precautions Facial Anatomy in the,0
DYSPORT,blurred vision,hing Difficult,1
DYSPORT,blurred vision,and Precautions Dysphagia and hing Difficult ies,1
DYSPORT,blurred vision,hing Difficult,1
DYSPORT,blurred vision,Precautions Dysphagia,0
DYSPORT,blurred vision,Breat,0
DYSPORT,blurred vision,Precautions Dysphagia and hing,1
DYSPORT,blurred vision,Treatment of Glabellar Lines,0
DYSPORT,ptosis,s [see,1
DYSPORT,ptosis,Precautions Dysphagia and Breathing s [see Warnings and Precautions Facial,1
DYSPORT,ptosis,s [see,1
DYSPORT,ptosis,Breathing Difficultie,0
DYSPORT,ptosis,Precautions Dysphagia and Breathing,0
DYSPORT,ptosis,the Treatment of Glabellar Lines,0
DYSPORT,ptosis,Precautions Dysphagia and Breathing s,1
DYSPORT,dysphagia,Breathing Difficulties seeWa,0
DYSPORT,dysphagia,Breathing Difficulties rnings,1
DYSPORT,dysphagia,Breathing Difficulties rnings,1
DYSPORT,dysphonia,Precautio ns Facial Anatomy in,1
DYSPORT,dysphonia,Precautio,1
DYSPORT,dysphonia,Precautio,1
DYSPORT,dysarthria,"seeWarnings and  (5.3)]  
 Facial Anatomy in the Treatment",1
DYSPORT,dysarthria,Precautio,1
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy",1
DYSPORT,dysarthria,"Difficulties seeWarnings and  (5.3)]  
 Facial",1
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy",1
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy in the Treatment",1
DYSPORT,dysarthria,"Difficulties seeWarnings and  (5.3)]  
 Facial Anatomy in the Treatment",1
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy in the Treatment",1
DYSPORT,dysarthria,"Breathing Difficulties seeWarnings and  (5.3)]  
 Facial Anatomy in the Treatment",1
DYSPORT,dysarthria," (5.3)]  
 Facial Anatomy in the Treatment",1
DYSPORT,urinary incontinence,Glabellar Lines seeWarnings,0
DYSPORT,urinary incontinence,Difficulties seeWarnings and Facial Anatomy in,1
DYSPORT,urinary incontinence,Facial Anatomy in the,1
DYSPORT,urinary incontinence,Breathing Difficulties seeWarnings and,0
DYSPORT,urinary incontinence,  Facial Anatomy in ,1
DYSPORT,urinary incontinence,Breathing Difficulties seeWarnings and,0
DYSPORT,urinary incontinence,Difficulties seeWarnings and Facial Anatomy in,1
DYSPORT,urinary incontinence,Anatomy in the Treatment of Glabellar,1
DYSPORT,urinary incontinence,Glabellar Lines seeWarnings and Precautions,0
DYSPORT,urinary incontinence,Glabellar Lines seeWarnings and Precautions,0
DYSPORT,urinary incontinence,Anatomy in,1
DYSPORT,breathing difficulties,Disorders seeWarnings an,0
DYSPORT,breathing difficulties,the,0
DYSPORT,breathing difficulties,Lines seeWarnings and Precautions Preexisting Neuromuscular Disorders seeWarnings,0
DYSPORT,breathing difficulties,Facial Anatomy in the reatment,1
DYSPORT,breathing difficulties,Anatomy in the reatment of Glabellar  Lines seeWarnings and Precautions Preexisting,1
DYSPORT,breathing difficulties,Facial Anatomy in the reatment,1
DYSPORT,breathing difficulties,Preexisting,0
DYSPORT,breathing difficulties,Precautions Preexisting Neuromuscular s [seeWarnings and Pre cautions Human Albumin,1
DYSPORT,breathing difficulties,Preexisting,0
DYSPORT,breathing difficulties,and Precautions Preexisting Neuromuscular s [seeWarnings and Pre cautions,1
DYSPORT,breathing difficulties,Preexisting,0
DYSPORT,death,cauti ons Intradermal,1
DYSPORT,death,Human Albumin,0
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,respiratory tract infect ion eyelid,1
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,reactions are nasopharyngitis headache injection site pain,0
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,site upper respiratory tract,1
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,reaction,0
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,ion eyelid edema eyelid ptosis sinusitis and nausea Upper Limb Spasticity,0
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,site upper respiratory tract,1
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,injection,0
DYSPORT,DISTANT SPREAD OF TOXIN EFFECT,site,0
DYSPORT,breathing difficulties,"SUSPECTED ADVERSE IONS, contact Ipsen Bi",1
DYSPORT,breathing difficulties,"SUSPECTED ADVERSE IONS,",1
DYSPORT,breathing difficulties,or,0
DYSPORT,death,DA-10,1
DYSPORT,death,REACTIONS contact Ipsen Biopharmaceuticals,0
DYSPORT,death,DA-10 or wwwfdagovmedwatch Clinical Trials Experience,1
DYSPORT,death,Because clinical trials are c,0
DYSPORT,death,Biopharmaceuticals Inc at or,0
DYSPORT,death,USPECTED ADVERSE REACTIONS contact Ipsen Biopharmaceuticals Inc,0
DYSPORT,Creutzfeldt-Jakob disease,observed,0
DYSPORT,CJD,ion s EXCERPT Cervical,1
DYSPORT,CJD,observed,0
DYSPORT,CJD,ion s EXCERPT Cervical,1
DYSPORT,CJD,ion s EXCERPT,1
DYSPORT,CJD,Dystonia Most,0
DYSPORT,CJD,ion s EXCERPT Cervical Dystonia Most,1
DYSPORT,CJD,Dystonia Most,0
DYSPORT,CJD,ion,1
DYSPORT,CJD,ion s EXCERPT Cervical,1
DYSPORT,CJD,Immune Reaction seeWarnings and ion s EXCERPT Cervical Dystonia Most,1
DYSPORT,CJD,ion s EXCERPT Cervical,1
DYSPORT,CJD,and Precaut,0
DYSPORT,CJD,ion s EXCERPT Cervical Dystonia Most,1
DYSPORT,viral diseases,patients are muscular weakness dysphagia dry,0
DYSPORT,viral diseases,Precautions,0
DYSPORT,viral diseases," Dystonia  
 
",1
DYSPORT,viral diseases,muscular weakness dysphagia,0
DYSPORT,viral diseases,weakness,0
DYSPORT,viral diseases,seeWarnings and Precautions EXCERPT,0
DYSPORT,viral diseases,Cervical,0
DYSPORT,viral diseases," Dystonia  
 
 Most commonly observed adverse reactions",1
DYSPORT,viral diseases,muscular weakness dysphagia,0
DYSPORT,CJD,st ,1
DYSPORT,CJD,st  commonly observed adverse reactions of,1
DYSPORT,CJD,st  commonly observed adverse,1
DYSPORT,CJD,seeWarnings and Precautions,0
DYSPORT,CJD,st  commonly observed,1
DYSPORT,CJD,st  commonly,1
DYSPORT,CJD,Precautions EXCERPT Cervical Dystonia st ,1
DYSPORT,CJD,st  commonly,1
DYSPORT,CJD,st  commonly observed,1
DYSPORT,asthenia,conducted under,0
DYSPORT,asthenia,at FDA or .fda.gov medwatch Clinical Trials,1
DYSPORT,asthenia,conducted under,0
DYSPORT,asthenia,FDA or .fda.gov medwatch Clinical Trials Experience Because,1
DYSPORT,asthenia,conducted under,0
DYSPORT,asthenia,FDA or .fda.gov,1
DYSPORT,asthenia,conducted under,0
DYSPORT,asthenia,.fda.gov medwatch,1
DYSPORT,asthenia,conducted under,0
DYSPORT,asthenia,.fda.gov medwatch Clinical,1
DYSPORT,asthenia,or .fda.gov medwatch,1
DYSPORT,asthenia,.fda.gov medwatch Clinical,1
DYSPORT,asthenia,.fda.gov medwatch,1
DYSPORT,generalized muscle weakness,or,0
DYSPORT,generalized muscle weakness,6.1 Clini,1
DYSPORT,generalized muscle weakness,FDA at FDA or edwatch 6.1,1
DYSPORT,generalized muscle weakness,under widely varying conditions,0
DYSPORT,generalized muscle weakness,FDA or wwwfdagovm,0
DYSPORT,generalized muscle weakness,at or FDA at FDA,0
DYSPORT,generalized muscle weakness,Trials Experience Because clinical trials are,0
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch l Trials,1
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch l Trials Experience Because clinical trials are,1
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch l Trials,1
DYSPORT,diplopia,wwwfdagovmedwatch l Trials,1
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch l Trials,1
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch l,1
DYSPORT,diplopia,l Trials,1
DYSPORT,diplopia,FDA or wwwfdagovmedwatch l Trials Experience Because clinical,1
DYSPORT,diplopia,l Trials,1
DYSPORT,diplopia,or FDA at FDA,0
DYSPORT,diplopia,FDA at FDA,0
DYSPORT,diplopia,at FDA or wwwfdagovmedwatch,0
DYSPORT,blurred vision,clinical trials are conducted under widely varying conditions adverse reaction rates,0
DYSPORT,blurred vision,xperience B ecause clinical trials are conducted,1
DYSPORT,blurred vision,"xperience

  B ecause",1
DYSPORT,blurred vision,xperience B ecause clinical trials are conducted,1
DYSPORT,ptosis,Experience ause c linical trials are,1
DYSPORT,ptosis,xperience B ecause clinical trials are conducted,1
DYSPORT,ptosis,Trials Experience,0
DYSPORT,ptosis,FDA or wwwfdagovmedwatch Clinical Trials Experience,0
DYSPORT,ptosis,Experience ause c,1
DYSPORT,ptosis,Clinical Trials Experience ause c,1
DYSPORT,ptosis,Experience ause c,1
DYSPORT,ptosis,Clinical Trials,0
DYSPORT,ptosis,are conducted under widely varying conditions,0
DYSPORT,ptosis,Experience ause,1
DYSPORT,ptosis,ause c,1
DYSPORT,ptosis,reaction rates observed in,0
DYSPORT,dysphagia,Clinical Trials Experience Because nical tri als,1
DYSPORT,dysphagia,reaction rates observed in,0
DYSPORT,dysphagia,at FDA or wwwfdagovmedwatch Clinical Trials,0
DYSPORT,dysphagia,nical tri als are conducted under,1
DYSPORT,dysphonia,Experience Because clinical trial,0
DYSPORT,dysphonia,are con ducted under,1
DYSPORT,dysphonia,Because clinical s are con ducted,1
DYSPORT,dysphonia,are con ducted under,1
DYSPORT,dysphonia,trials,0
DYSPORT,dysarthria,clinical trials are cted under,1
DYSPORT,dysarthria,trials are cted under,1
DYSPORT,dysarthria,clinical trials are cted under,1
DYSPORT,urinary incontinence,cannot be directly compared t,0
DYSPORT,urinary incontinence,conducted under idely varying condit ions adverse,1
DYSPORT,urinary incontinence,cannot be directly compared t,0
DYSPORT,breathing difficulties,under widely varying conditions,0
DYSPORT,breathing difficulties,reaction rate s observed in the,1
DYSPORT,breathing difficulties,reaction rate s observed,1
DYSPORT,breathing difficulties,compared to rates in,0
DYSPORT,breathing difficulties,directly compared to rates the clinical,1
DYSPORT,breathing difficulties,may not reflect the rates observed in practice Cervical Dystonia T,0
DYSPORT,death,described below reflect exposure to DYSPORT,0
DYSPORT,death,another drug and may not reflect the rates observed,0
DYSPORT,spread of toxin effects,the,0
DYSPORT,spread of toxin effects,to DYSPORT,0
DYSPORT,spread of toxin effects,"  Cervical Dystonia  

",1
DYSPORT,spread of toxin effects,to DYSPORT,0
DYSPORT,spread of toxin effects,"observed in   Cervical Dystonia  

",1
DYSPORT,spread of toxin effects,to DYSPORT,0
DYSPORT,spread of toxin effects,data described below reflect exposure,0
DYSPORT,spread of toxin effects,"in   Cervical Dystonia  

 The data",1
DYSPORT,spread of toxin effects,data described below reflect exposure,0
DYSPORT,spread of toxin effects,es in the clinical trials of another drug and may not reflect the,0
DYSPORT,spread of toxin effects,The data described,0
DYSPORT,spread of toxin effect,y Caucasian with a median age of years range years Most,0
DYSPORT,spread of toxin effect,Caucasian with a median age of years range years Most,0
DYSPORT,breathing difficulties,reactions occurring in re than 5% of patients who received Units of,1
DYSPORT,breathing difficulties,Caucasian with a median age of years range years Most,0
DYSPORT,breathing difficulties,the placebo controlled clinical,0
DYSPORT,breathing difficulties,received Units of DYSPORT r in the placebo,0
DYSPORT,breathing difficulties,adverse reactions occurring in re than 5%,1
DYSPORT,breathing difficulties,reactions occurring in re than 5% of patients,1
DYSPORT,breathing difficulties,reactions occurring in re than 5% of patients,1
DYSPORT,breathing difficulties,adverse reactions occurring in re than 5% of patients who received Units,1
DYSPORT,breathing difficulties,reactions occurring in re than 5% of patients,1
DYSPORT,breathing difficulties,DYSPORT r in the placebo controlled,0
DYSPORT,Deaths,injection site reactions most adverse reactions became noticeable,0
DYSPORT,Deaths,commod ation Other,1
DYSPORT,Deaths,disorders,0
DYSPORT,Deaths,commod ation Other than,1
DYSPORT,Deaths,visual acuity and ac,0
DYSPORT,Deaths,commod ation Other than,1
DYSPORT,Deaths,and commod ation Other,1
DYSPORT,Deaths,commod ation Other than,1
DYSPORT,Deaths,of blurred vision diplopia and,0
DYSPORT,Deaths,commod ation Other than injection site,1
DYSPORT,dysphagia,of blurred vision diplopia and reduced visual acuity,0
DYSPORT,dysphagia,after treatment,0
DYSPORT,dysphagia,Other than site reac tions most adverse,1
DYSPORT,dysphagia,after treatment,0
DYSPORT,dysphagia,noticeable about one week after treatment and,0
DYSPORT,dysphagia,about one,0
DYSPORT,dysphagia,vision diplopia and reduced visual acuity,0
DYSPORT,dysphagia,tions most adverse reactions became noticeable about one,0
DYSPORT,dysphagia,acuity and accommodation Other,0
DYSPORT,Dysphagia,reactions became noticeable about,0
DYSPORT,Dysphagia,reactions became noticeable about week afte,1
DYSPORT,Dysphagia,reactions became noticeable about,0
DYSPORT,Dysphagia,week afte r treatment and,1
DYSPORT,Dysphagia,reactions became noticeable about,0
DYSPORT,Dysphagia,noticeable about week,1
DYSPORT,Dysphagia,and lasted several weeks The rates,0
DYSPORT,Dysphagia,week afte r treatment and lasted,1
DYSPORT,Dysphagia,weeks The rates of adverse,0
DYSPORT,Dysphagia,about week,1
DYSPORT,Aspiration,than in the placebocontrolled trials During the clinical,0
DYSPORT,Aspiration,and open-l,1
DYSPORT,Aspiration,the combined and open-l abel experience than in,1
DYSPORT,Aspiration,and open-l,1
DYSPORT,Aspiration,and open-l,1
DYSPORT,Aspiration,the clinical studies,0
DYSPORT,dysphagia,experienced adverse reactions,0
DYSPORT,dysphagia,the place bocontrolled trials During the clinical,1
DYSPORT,dysphagia,and openlabel experience,0
DYSPORT,dysphagia,the clinical studies two patients experienced adverse reactions,0
DYSPORT,dysphagia,than in,0
DYSPORT,weaken neck muscles,"id disorder, feelin",1
DYSPORT,weaken neck muscles,than in,0
DYSPORT,weaken neck muscles,in attention id,1
DYSPORT,weaken neck muscles,"attention id disorder, feelin g abnormal and",1
DYSPORT,weaken neck muscles,in attention id,1
DYSPORT,weaken neck muscles,to withdrawal One patient,0
DYSPORT,weaken neck muscles,"id disorder, feelin g abnormal and headache",1
DYSPORT,weaken neck muscles,to withdrawal One patient,0
DYSPORT,weaken neck muscles,"disturbance in attention id disorder, feelin g abnormal and headache and",1
DYSPORT,weaken neck muscles,to withdrawal One patient,0
DYSPORT,loss of breathing capacity,pares the incidence of,1
DYSPORT,loss of breathing capacity,elid disorder feeling abnormal and headache and,0
DYSPORT,loss of breathing capacity,from a single,0
DYSPORT,loss of breathing capacity,patient experienced dysphagia Table pares the incidence of the most frequent,1
DYSPORT,loss of breathing capacity,from a single,0
DYSPORT,loss of breathing capacity,disorder feeling abnormal and headache and one patient experienced dysphagia Table,0
DYSPORT,loss of breathing capacity,Table pares the incidence of the,1
DYSPORT,loss of breathing capacity,disorder feeling abnormal and headache and one patient experienced dysphagia Table,0
DYSPORT,loss of breathing capacity,dysphagia Table pares the incidence of the most frequent adverse reactions from,1
DYSPORT,loss of breathing capacity,disorder feeling abnormal and headache and one patient experienced dysphagia Table,0
DYSPORT,breathing difficulties,placebo seeClinical Table 3: Most,1
DYSPORT,breathing difficulties,placebo seeClinical Table,1
DYSPORT,breathing difficulties,3: Most Com mon Adverse Reactions and,1
DYSPORT,breathing difficulties,placebo,0
DYSPORT,breathing difficulties,of Clinical T,0
DYSPORT,breathing difficulties,seeClinical Studies,0
DYSPORT,breathing difficulties,Table 3: Most Com mon Adverse,1
DYSPORT,breathing difficulties,"compared to placebo seeClinical 



 Table 3: Most Com mon",1
DYSPORT,breathing difficulties,Table 3: Most Com mon Adverse,1
DYSPORT,respiratory failure,Reactions (>5%) and Greater than Placebo in the,1
DYSPORT,respiratory failure,Table 3: Most Com mon Adverse,1
DYSPORT,respiratory failure,Studies Table Most Common Reactions (>5%) and,1
DYSPORT,respiratory failure,Studies Table Most Common Adverse,0
DYSPORT,respiratory failure,(>5%) and Greater than Placebo in,1
DYSPORT,dysphagia,      7   Nervous system,1
DYSPORT,dysphagia,(>5%) and Greater than Placebo in,1
DYSPORT,dysphagia,Nervous system,0
DYSPORT,respiratory compromise,Nervous sy,1
DYSPORT,respiratory compromise,"        
   Nervous sy stem disorders",1
DYSPORT,respiratory compromise,Nervous sy,1
DYSPORT,respiratory compromise,stem disorders H,0
DYSPORT,respiratory compromise,mouth,0
DYSPORT,respiratory compromise,Nervous sy stem disorders H,1
DYSPORT,respiratory compromise,Nervous sy stem disorders,1
DYSPORT,respiratory compromise,Nervous sy stem disorders H,1
DYSPORT,viral diseases,       9       Respiratory thoracic and mediastinal,1
DYSPORT,viral diseases,       9       Respiratory thoracic and mediastinal disorders,1
DYSPORT,CJD,ders    ,1
DYSPORT,CJD,       9       Respiratory thoracic and mediastinal disorders,1
DYSPORT,CJD,    Eye Disorders,1
DYSPORT,CJD,       9       Respiratory thoracic and mediastinal disorders,1
DYSPORT,CJD,ders,0
FIRAZYR,injection site reactions,reported adverse reactions injection site reactions,1
FIRAZYR,injection site reactions,adverse reactions injection site reactions which occurred,1
FIRAZYR,injection site reactions,reported adverse reactions injection site reactions,1
FIRAZYR,injection site reactions,injection site reactions which,1
FIRAZYR,injection site reactions,reported adverse reactions injection site reactions,1
FIRAZYR,injection site reactions,site reactions which occurred in almost,1
FIRAZYR,injection site reactions,injection site reactions which occurred in almost all,1
FIRAZYR,injection site reactions,site reactions which occurred in almost,1
FIRAZYR,injection site reactions,commonly reported adverse reactions injection site reactions which,1
FIRAZYR,injection site reactions,site reactions which occurred in almost,1
FIRAZYR,injection site reactions,adverse reactions injection site reactions,1
FIRAZYR,injection site reactions,in almost all patients in clinical trials,0
FIRAZYR,injection site reactions,reported adverse reactions injection site reactions which occurred,1
FIRAZYR,injection site reactions,in almost all patients in clinical trials,0
FIRAZYR,injection site reactions,commonly reported adverse reactions injection site reactions which occurred in,1
FIRAZYR,injection site reactions,in almost all patients in clinical trials,0
FIRAZYR,transaminase increase,patients included transaminase,1
FIRAZYR,transaminase increase,included transaminase increase,1
FIRAZYR,rash,rash To report SUSPECTED,1
FIRAZYR,rash,included transaminase increase,1
FIRAZYR,rash,ADVERSE REACTIONS contact Shire Human Genetic,0
FIRAZYR,rash,rash To,1
FIRAZYR,rash,reactions reported rash nausea and,1
FIRAZYR,rash,rash To,1
FIRAZYR,nausea,nausea and headache,1
FIRAZYR,nausea,reactions reported included nausea and headache,1
FIRAZYR,nausea,nausea and headache,1
FIRAZYR,nausea,controlled phase of the trials Other adverse reactions reported included,0
FIRAZYR,headache,in the controlled phase of the trials Other adverse reactions reported included rash nausea,0
FIRAZYR,headache,was evaluated in a separate,0
FIRAZYR,headache,to FIRAZYR The safety of,0
FIRAZYR,headache,was,0
FIRAZYR,headache,headache,1
FIRAZYR,headache,evaluated in a,0
FIRAZYR,headache,nausea and,0
FIRAZYR,headache,headache in,1
FIRAZYR,hypersensitivity,hypersensitivity or anaphylactic,1
FIRAZYR,hypersensitivity,hypersensitivity or anaphylactic reactions,1
FIRAZYR,hypersensitivity,hypersensitivity or anaphylactic reactions were reported,1
FIRAZYR,hypersensitivity,antiicatibant antibodies Three of these patients,0
FIRAZYR,anaphylactic reactions,No hypersensitivity anaphylactic reactions were reported,1
FIRAZYR,anaphylactic reactions,antiicatibant antibodies Three of these patients,0
FIRAZYR,anaphylactic reactions,had subsequent tests which were negative No hypersensitivity or,0
INVOKANA,Hypotension,Function see Warnings and,0
INVOKANA,Hypotension,Hypotension see Warnings and,1
INVOKANA,Hypotension,Hypotension,1
INVOKANA,Hypotension,Warnings and,0
INVOKANA,Hypotension,elsewhere in the Hypotension see,1
INVOKANA,Hypotension,Warnings and,0
INVOKANA,Hypotension,the labeling,0
INVOKANA,Hypotension,Hypotension see Warnings and,1
INVOKANA,Impairment in Renal Function,Warnings and Impairment in Renal Function,1
INVOKANA,Impairment in Renal Function,Hypotension see Warnings and,1
INVOKANA,Impairment in Renal Function,Impairment in Renal Function see Warnings and Precautions Hyperkalemia,1
INVOKANA,Impairment in Renal Function,Hypotension see Warnings and,1
INVOKANA,Impairment in Renal Function,Warnings and Precautions,0
INVOKANA,Impairment in Renal Function,Impairment in Renal Function,1
INVOKANA,Impairment in Renal Function,see Warnings and Impairment in Renal Function see Warnings and Precautions,1
INVOKANA,Impairment in Renal Function,Impairment in Renal Function,1
INVOKANA,Impairment in Renal Function,and Impairment,1
INVOKANA,Hyperkalemia,Warnings and Hyperkalemia see Warnings and,1
INVOKANA,Hyperkalemia,and Impairment,1
INVOKANA,Hyperkalemia,see Warnings and Precautions Hypoglycemia with Concomitant Use with Insulin and In,0
INVOKANA,Hyperkalemia,Warnings and Precautions Hypoglycemia with Concomitant Use with,0
INVOKANA,Hyperkalemia,and Hyperkalemia see,1
INVOKANA,Hyperkalemia,Warnings and Precautions Hypoglycemia with Concomitant Use with,0
INVOKANA,Hyperkalemia,Hypoglycemia with Concomitant Use with,0
INVOKANA,Hyperkalemia,Precautions,0
INVOKANA,Hyperkalemia,Hyperkalemia see Warnings and,1
INVOKANA,Hypoglycemia,Secretagogues see Warnings and,0
INVOKANA,Hypoglycemia,Use with Insulin and Insulin Secretagogues see Warnings and,0
INVOKANA,Genital Mycotic Infections,Warnings and Genital Mycotic,1
INVOKANA,Genital Mycotic Infections,Warnings and Precautions Hypersensitivity Reactions,0
INVOKANA,Genital Mycotic Infections,Reactions see Warnings,0
INVOKANA,Genital Mycotic Infections,and Genital Mycotic Infections,1
INVOKANA,Genital Mycotic Infections,see Warnings and Genital,1
INVOKANA,Genital Mycotic Infections,Warnings,0
INVOKANA,Genital Mycotic Infections,see Warnings and Precautions Hypersensitivity Reactions see Warnings and,0
INVOKANA,Genital Mycotic Infections,Warnings and Genital Mycotic,1
INVOKANA,Hypersensitivity Reactions,and Hypersensitivity Reactions see Warnings and Precautions,1
INVOKANA,Hypersensitivity Reactions,Warnings and Genital Mycotic,1
INVOKANA,Hypersensitivity Reactions,see Warnings and Hypersensitivity Reactions,1
INVOKANA,Hypersensitivity Reactions,Hypersensitivity Reactions see Warnings and Precautions,1
INVOKANA,Hypersensitivity Reactions,Hypersensitivity Reactions see Warnings and Precautions,1
INVOKANA,Hypersensitivity Reactions,Fracture,0
INVOKANA,Hypersensitivity Reactions,Hypersensitivity Reactions see,1
INVOKANA,Hypersensitivity Reactions,Fracture,0
INVOKANA,Hypersensitivity Reactions,Warnings and Precautions,0
INVOKANA,Bone Fracture,Warnings and Precautions,0
INVOKANA,Bone Fracture,LowDensity,0
INVOKANA,Bone Fracture,Bone Fracture see Warnings and Precautions Increases,1
INVOKANA,Bone Fracture,Bone,1
INVOKANA,Bone Fracture,Bone Fracture see Warnings and Precautions Increases,1
INVOKANA,Bone Fracture,see Warnings,0
INVOKANA,Bone Fracture,Precautions Hypersensitivity Reactions see Warnings and,0
INVOKANA,Bone Fracture,and,0
INVOKANA,Bone Fracture,Bone Fracture see Warnings and Precautions,1
INVOKANA,Bone Fracture,and,0
INVOKANA,Bone Fracture,LDLC,0
INVOKANA,Increases in Low-Density Lipoprotein,in Low-Density Lipoprotein LDLC see Warnings,1
INVOKANA,Increases in Low-Density Lipoprotein,Increases in Low-Density Lipoprotein LDLC see,1
INVOKANA,Increases in Low-Density Lipoprotein,Low-Density Lipoprotein LDLC see,1
INVOKANA,Increases in Low-Density Lipoprotein,LDLC see Warnings and Precautions Most,0
INVOKANA,Increases in Low-Density Lipoprotein,adverse reactions,0
INVOKANA,Increases in Low-Density Lipoprotein,Bone Fracture see,0
INVOKANA,female genital mycotic infections,female,1
INVOKANA,female genital mycotic infections,tract infection and increased,0
INVOKANA,female genital mycotic infections,infection and increased urination EXCERPT To,0
INVOKANA,female genital mycotic infections,greater,0
INVOKANA,female genital mycotic infections,or greater female genital mycotic infections urinary tract infection and,1
INVOKANA,female genital mycotic infections,greater,0
INVOKANA,female genital mycotic infections,tract infection and increased urination EXCERPT To report SUSPECTED,0
INVOKANA,female genital mycotic infections,greater female genital mycotic infections urinary tract,1
INVOKANA,female genital mycotic infections,tract infection and increased urination EXCERPT To report SUSPECTED,0
INVOKANA,female genital mycotic infections,mycotic infections urinary,1
INVOKANA,female genital mycotic infections,EXCERPT To report,0
INVOKANA,urinary tract infection,urinary tract infection and increased urination,1
INVOKANA,urinary tract infection,reactions,0
INVOKANA,urinary tract infection,associated with INVOKANA,0
INVOKANA,urinary tract infection,mycotic,0
INVOKANA,urinary tract infection,urinary tract infection and increased urination EXCERPT To,1
INVOKANA,urinary tract infection,mycotic,0
INVOKANA,urinary tract infection,urinary tract infection and increased urination,1
INVOKANA,urinary tract infection,mycotic,0
INVOKANA,urinary tract infection,reactions associated,0
INVOKANA,urinary tract infection,ADVERSE REACTIONS,0
INVOKANA,increased urination,ADVERSE REACTIONS contact Janssen,0
INVOKANA,increased urination,infections urinary tract infection increased urination EXCERPT To report SUSPECTED ADVERSE,1
INVOKANA,increased urination,ADVERSE REACTIONS contact Janssen,0
INVOKANA,increased urination,infections urinary tract infection increased urination EXCERPT To report SUSPECTED ADVERSE,1
INVOKANA,increased urination,ADVERSE REACTIONS contact Janssen,0
INVOKANA,increased urination,infections urinary tract infection increased urination,1
INVOKANA,increased urination,contact Janssen,0
INVOKANA,increased urination,greater incidence female genital mycotic infections urinary tract infection,0
INVOKANA,increased urination,urinary tract infection increased,1
INVOKANA,Female genital mycotic infections,mgN INVOKANA Female genital,1
INVOKANA,Female genital mycotic infections,INVOKANA Female genital mycotic infections,1
INVOKANA,Female genital mycotic infections,PlaceboN INVOKANA mgN INVOKANA Female genital mycotic,1
INVOKANA,Female genital mycotic infections,Urinary tract infectio,0
INVOKANA,Female genital mycotic infections,PlaceboN INVOKANA mgN INVOKANA Female genital mycotic infections,1
INVOKANA,Female genital mycotic infections,Urinary tract infectio,0
INVOKANA,Female genital mycotic infections,mgN INVOKANA Female genital,1
INVOKANA,Female genital mycotic infections,mgN INVOKANA,0
INVOKANA,Female genital mycotic infections,INVOKANA mgN INVOKANA Female genital mycotic infections,1
INVOKANA,Female genital mycotic infections,mgN INVOKANA,0
INVOKANA,Female genital mycotic infections,mgN INVOKANA Female genital mycotic,1
INVOKANA,Urinary tract infections,mycotic Urinary tract infections,1
INVOKANA,Urinary tract infections,mgN INVOKANA Female genital mycotic,1
INVOKANA,Urinary tract infections,mycotic Urinary,1
INVOKANA,Urinary tract infections,tract infections,1
INVOKANA,Urinary tract infections,mycotic,0
INVOKANA,Urinary tract infections,Urinary tract infections,1
INVOKANA,Urinary tract infections,infections,0
INVOKANA,Urinary tract infections,mycotic Urinary tract infections,1
INVOKANA,Increased urination,ct Increased,1
INVOKANA,Increased urination,Increased urination Male,1
INVOKANA,Increased urination,Increased urination Male,1
INVOKANA,Increased urination,Increased urination Male,1
INVOKANA,fatigue,fatigue,1
INVOKANA,fatigue,INVOKANA,0
INVOKANA,fatigue,fatigue with comparator with INVOKANA,1
INVOKANA,fatigue,those listed in,0
INVOKANA,fatigue,fatigue with,1
INVOKANA,fatigue,reactions fatigue with comparator with INVOKANA,1
INVOKANA,fatigue,fatigue with,1
INVOKANA,fatigue,loss,0
INVOKANA,fatigue,with comparator with INVOKANA,0
INVOKANA,loss of strength,loss,1
INVOKANA,loss of strength,mg loss,1
INVOKANA,loss of strength,INVOKANA mg loss of strength or energy,1
INVOKANA,loss of strength,mg loss,1
INVOKANA,asthenia,asthenia,1
INVOKANA,asthenia,mg loss,1
INVOKANA,asthenia,asthenia with comparator with INVOKANA,1
INVOKANA,asthenia,with INVOKANA,0
INVOKANA,asthenia,INVOKANA mg and loss of,0
INVOKANA,asthenia,of strength or energy asthenia with comparator with INVOKANA,1
INVOKANA,asthenia,INVOKANA mg and loss of,0
INVOKANA,asthenia,asthenia with comparator with INVOKANA mg,1
INVOKANA,asthenia,asthenia with comparator with,1
INVOKANA,asthenia,with comparator with INVOKANA mg and,0
INVOKANA,hypersensitivity-related adverse reactions,occurred in,0
INVOKANA,hypersensitivity-related adverse reactions,eight clinical hypersensitivity-related adverse reactions,1
INVOKANA,hypersensitivity-related adverse reactions,and INVOKANA,0
INVOKANA,erythema,erythema rash pruritus urticaria and angioedema,1
INVOKANA,erythema,erythema rash,1
INVOKANA,erythema,hypersensitivityrelated adverse reactions erythema rash,1
INVOKANA,erythema,erythema rash,1
INVOKANA,erythema,hypersensitivityrelated adverse reactions erythema rash pruritus,1
INVOKANA,erythema,erythema rash,1
INVOKANA,erythema,and of,0
INVOKANA,erythema,hypersensitivityrelated,0
INVOKANA,erythema,reactions erythema rash pruritus urticaria and angioedema,1
INVOKANA,erythema,hypersensitivityrelated,0
INVOKANA,erythema,erythema rash pruritus urticaria and angioedema,1
INVOKANA,erythema,erythema rash pruritus urticaria and,1
INVOKANA,rash,rash pruritus urticaria and angioedema,1
INVOKANA,pruritus,erythema pruritus,1
INVOKANA,pruritus,rash pruritus urticaria and angioedema,1
INVOKANA,pruritus,and angioedema,0
INVOKANA,pruritus,pruritus urticaria and angioedema occurred,1
INVOKANA,pruritus,pruritus urticaria and angioedema occurred in,1
INVOKANA,pruritus,pruritus urticaria,1
INVOKANA,pruritus,pruritus urticaria and angioedema occurred,1
INVOKANA,urticaria,receiving comparator,0
INVOKANA,urticaria,urticaria and,1
INVOKANA,urticaria,erythema,0
INVOKANA,urticaria,clinical trials hypersensitivityrelated adverse,0
INVOKANA,urticaria,rash,0
INVOKANA,angioedema,angioedema occurred in and of,1
INVOKANA,angioedema,hypersensitivityrelated adverse reactions including erythema rash pruritus,0
INVOKANA,angioedema,angioedema occurred in and of patients,1
INVOKANA,angioedema,hypersensitivityrelated adverse reactions including erythema rash pruritus,0
INVOKANA,hypersensitivity,adverse reactions of,0
INVOKANA,hypersensitivity,hypersensitivity with INVOKANA which,1
INVOKANA,hypersensitivity,hypersensitivity with INVOKANA which included patients,1
INVOKANA,hypersensitivity,adverse reactions hypersensitivity with INVOKANA which,1
INVOKANA,hypersensitivity,hypersensitivity with INVOKANA which included patients,1
INVOKANA,hypersensitivity,hypersensitivity,1
INVOKANA,hypersensitivity,hypersensitivity with INVOKANA which included,1
INVOKANA,urticaria,urticaria and patient with a,1
INVOKANA,urticaria,included patients urticaria and patient,1
INVOKANA,urticaria,urticaria and patient with a,1
INVOKANA,urticaria,with,0
INVOKANA,urticaria,INVOKANA which included patients urticaria and patient,1
INVOKANA,urticaria,with,0
INVOKANA,urticaria,INVOKANA which included patients urticaria and patient with,1
INVOKANA,urticaria,with,0
INVOKANA,urticaria,urticaria and patient with a,1
INVOKANA,urticaria,urticaria occurring within hours of exposure,0
INVOKANA,urticaria,INVOKANA which included,0
INVOKANA,urticaria,urticaria and patient with a,1
INVOKANA,urticaria,rash and urticaria occurring within hours of exposure to,0
INVOKANA,diffuse rash,diffuse rash,1
INVOKANA,diffuse rash,and patient with diffuse rash,1
INVOKANA,diffuse rash,and patient with diffuse rash and,1
INVOKANA,diffuse rash,and patient with diffuse rash,1
INVOKANA,diffuse rash,exposure to INVOKANA,0
INVOKANA,urticaria,to INVOKANA Among these patients patients,0
INVOKANA,urticaria,of exposure to INVOKANA Among these patients patients discontinued,0
INVOKANA,urticaria,urticaria and patient with a diffuse rash,0
INVOKANA,urticaria,rash urticaria,1
INVOKANA,urticaria,urticaria and patient with a diffuse rash,0
INVOKANA,urticaria,urticaria occurring within,1
INVOKANA,urticaria,reinitiated,0
INVOKANA,urticaria,to INVOKANA,0
INVOKANA,urticaria,was reinitiated,0
INVOKANA,Photosensitivity-related adverse reactions,patient with,0
INVOKANA,photosensitivity reaction,photosensitivity reaction polymorphic,1
INVOKANA,photosensitivity reaction,INVOKANA was reinitiated Photosensitivityrelated adverse reactions including,0
INVOKANA,photosensitivity reaction,light eruption and sunburn occurred in and of patients receiving co,0
INVOKANA,photosensitivity reaction,photosensitivity reaction polymorphic light eruption and sunburn,1
INVOKANA,polymorphic light eruption,photosensitivity polymorphic,1
INVOKANA,polymorphic light eruption,including photosensitivity polymorphic,1
INVOKANA,polymorphic light eruption,light eruption and,1
INVOKANA,polymorphic light eruption,including photosensitivity polymorphic,1
INVOKANA,polymorphic light eruption,of patients receiving comparator INVOKANA mg a,0
INVOKANA,polymorphic light eruption,light eruption and,1
INVOKANA,polymorphic light eruption,photosensitivity reaction,0
INVOKANA,polymorphic light eruption,Photosensitivityrelated adverse reactions including photosensitivity reaction,0
INVOKANA,sunburn,eruption sunburn occurred in and of,1
INVOKANA,sunburn,Photosensitivityrelated adverse reactions including photosensitivity reaction,0
INVOKANA,sunburn,comparator INVOKANA mg,0
INVOKANA,sunburn,sunburn occurred in and of,1
INVOKANA,sunburn,sunburn occurred in,1
INVOKANA,sunburn,receiving,0
INVOKANA,sunburn,sunburn occurred,1
INVOKANA,sunburn,light eruption sunburn,1
INVOKANA,sunburn,sunburn occurred,1
INVOKANA,osmotic diuresis,results in osmotic diuresis which,1
INVOKANA,osmotic diuresis,sunburn occurred,1
INVOKANA,osmotic diuresis,in osmotic,1
INVOKANA,osmotic diuresis,intravascular volume In clinical studies,0
INVOKANA,osmotic diuresis,in osmotic diuresis which may lead to,1
INVOKANA,osmotic diuresis,intravascular volume In clinical studies,0
INVOKANA,osmotic diuresis,INVOKANA results in osmotic,1
INVOKANA,osmotic diuresis,treatment with INVOKANA,0
INVOKANA,reductions in intravascular volume,reductions in intravascular volume In,1
INVOKANA,reductions in intravascular volume,treatment with INVOKANA,0
INVOKANA,reductions in intravascular volume,may lead reductions in intravascular volume In clinical studies treatment,1
INVOKANA,reductions in intravascular volume,treatment with INVOKANA,0
INVOKANA,reductions in intravascular volume,osmotic diuresis which,0
INVOKANA,reductions in intravascular volume,studies treatment with INVOKANA was associated with,0
INVOKANA,reductions in intravascular volume,Adverse Reactions INVOKANA results in an,0
INVOKANA,reductions in intravascular volume,may lead reductions in intravascular volume In clinical,1
INVOKANA,reductions in intravascular volume,Adverse Reactions INVOKANA results in an,0
INVOKANA,reductions in intravascular volume,intravascular volume In clinical studies treatment with,1
INVOKANA,hypotension,hypotension,1
INVOKANA,hypotension,volume depletionrelated adverse reactions hypotension postural dizziness orthostatic,1
INVOKANA,hypotension,hypotension,1
INVOKANA,postural dizziness,syncope and dehydration An increased incidence was,0
INVOKANA,postural dizziness,postural dizziness orthostatic hypotension syncope,1
INVOKANA,postural dizziness,syncope and dehydration An increased incidence was,0
INVOKANA,postural dizziness,reactions eg postural dizziness,1
INVOKANA,postural dizziness,increased incidence was,0
INVOKANA,postural dizziness,depletionrelated adverse reactions eg postural dizziness,1
INVOKANA,postural dizziness,increased incidence was,0
INVOKANA,postural dizziness,postural dizziness orthostatic,1
INVOKANA,postural dizziness,increased incidence was,0
INVOKANA,postural dizziness,eg postural dizziness,1
INVOKANA,orthostatic hypotension,eg hypotension postural orthostatic hypotension,1
INVOKANA,orthostatic hypotension,eg hypotension postural orthostatic hypotension syncope,1
INVOKANA,orthostatic hypotension,eg hypotension postural orthostatic hypotension,1
INVOKANA,orthostatic hypotension,orthostatic hypotension,1
INVOKANA,orthostatic hypotension,patients on the,0
INVOKANA,orthostatic hypotension,eg hypotension postural orthostatic hypotension,1
INVOKANA,orthostatic hypotension,dizziness,0
INVOKANA,orthostatic hypotension,postural dizziness,0
INVOKANA,orthostatic hypotension,of,0
INVOKANA,orthostatic hypotension,adverse reactions eg hypotension,0
INVOKANA,orthostatic hypotension,orthostatic hypotension,1
INVOKANA,dehydration,dehydration An increased,1
INVOKANA,dehydration,dehydration An,1
INVOKANA,dehydration,dehydration An increased,1
INVOKANA,dehydration,dehydration An,1
INVOKANA,dehydration,An increased incidence was observed,0
INVOKANA,dehydration,the mg dose The,0
INVOKANA,dehydration,dehydration,1
INVOKANA,dehydration,dehydration An increased,1
INVOKANA,dehydration,mg,0
INVOKANA,volume depletion-related adverse reactions,increase,0
INVOKANA,volume depletion-related adverse reactions,volume depletion-related adverse reactions were the use of,1
INVOKANA,volume depletion-related adverse reactions,moderate renal impairment eGFR to less than mLmin,0
INVOKANA,volume depletion-related adverse reactions,to less,0
INVOKANA,volume depletion-related adverse reactions,adverse reactions,1
INVOKANA,volume depletion-related adverse reactions,the largest increase volume,1
INVOKANA,volume depletion-related adverse reactions,the largest,0
INVOKANA,volume depletion-related adverse reactions,increase in,0
INVOKANA,Volume Depletion-Related Adverse Reaction,and Table Proportion of Patients,0
INVOKANA,Volume Depletion-Related Adverse Reaction,Trials Baseline Characteristic Comparator Gro,0
INVOKANA,Volume Depletion-Related Adverse Reaction,Trials Baseline,0
INVOKANA,Volume Depletion-Related Adverse Reaction,Results from Clinical Trials Baseline Characteristic Comparator Gro,0
INVOKANA,Volume Depletion-Related Adverse Reaction,at Least Volume Depletion-Related Adverse Reaction,1
INVOKANA,Volume Depletion-Related Adverse Reaction,Results from Clinical Trials Baseline Characteristic Comparator Gro,0
INVOKANA,Volume Depletion-Related Adverse Reaction,Patients With at Least Volume Depletion-Related Adverse Reaction,1
INVOKANA,Volume Depletion-Related Adverse Reaction,Results from Clinical Trials Baseline Characteristic Comparator Gro,0
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,less than 60 mL/min/1.73 m 2 Use of,1
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,of,0
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,eGFR less than 60 mL/min/1.73 m  2 Use of,1
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,of,0
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,Use of loop,0
INVOKANA,eGFR less than 60 mL/min/1.73 m 2,Use of loop diuretic,0
INVOKANA,falls,falls was and with,1
INVOKANA,falls,falls was,1
INVOKANA,falls,proportion of patients who falls was and with comparator,1
INVOKANA,falls,falls was,1
INVOKANA,falls,falls was and with comparator,1
INVOKANA,falls,falls was,1
INVOKANA,falls,who experienced,0
INVOKANA,falls,falls was and with comparator INVOKANA,1
INVOKANA,falls,of patients who falls was and with,1
INVOKANA,falls,falls was and with comparator INVOKANA,1
INVOKANA,falls,falls for patients,1
INVOKANA,increase in serum creatinine,increase,1
INVOKANA,fall in estimated GFR,renal impairment at,0
INVOKANA,renal function decline,patients who experienced at least one,0
INVOKANA,renal function decline,renal function decline defined as an,1
INVOKANA,renal function decline,least one event of renal function,1
INVOKANA,renal function decline,and lower than baseline was,0
INVOKANA,renal function decline,of renal function,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,mL/min/1.73 m 2 and,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,mg and with INVOK,0
INVOKANA,eGFR below 80 mL/min/1.73 m 2,as eGFR below 80 mL/min/1.73 m,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,function decline defined as eGFR below 80 mL/min/1.73 m  2 and lower than,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,as eGFR below 80 mL/min/1.73 m,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,m 2 and lower than,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,decline defined as eGFR below 80 mL/min/1.73 m  2 and,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,m 2 and lower than,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,eGFR below 80 mL/min/1.73 m  2 and lower,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,m 2 and lower than,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,function decline defined as eGFR below 80 mL/min/1.73 m  2,1
INVOKANA,eGFR below 80 mL/min/1.73 m 2,m 2 and lower than,1
INVOKANA,renal function decline,renal function decline,1
INVOKANA,renal function decline,m 2 and lower than,1
INVOKANA,renal function decline,renal function decline,1
INVOKANA,renal function decline,INVOKANA mg had a renal function,1
INVOKANA,renal function decline,renal function decline,1
INVOKANA,renal function decline,renal function decline In a trial,1
INVOKANA,renal function decline,renal function decline,1
INVOKANA,renal function decline,out in patients with moderate renal impairment with a baseline eGFR of,0
INVOKANA,renal function decline,INVOKANA mg had a renal function,1
INVOKANA,renal function decline,event of renal function decline defined as an,1
INVOKANA,renal function decline,INVOKANA mg had a renal function,1
INVOKANA,renal function decline,experienced at least,0
INVOKANA,renal function decline,function decline defined as an eGFR,1
INVOKANA,renal function decline,of renal function,1
INVOKANA,renal function decline,of renal function decline defined as an eGFR,1
INVOKANA,renal function decline,of renal function,1
INVOKANA,renal function decline,renal function decline defined as an,1
INVOKANA,renal function decline,least one event of renal function,1
INVOKANA,renal function decline,one event of renal function decline,1
INVOKANA,renal function decline,of renal function decline defined as an eGFR,1
INVOKANA,renal function decline,one event of renal function decline,1
INVOKANA,renal function decline,of renal function decline,1
INVOKANA,eGFR 30% lower than baseline,with INVOKANA mg and with INVOKANA,0
INVOKANA,eGFR 30% lower than baseline,function decline defined as eGFR,1
INVOKANA,eGFR 30% lower than baseline,function decline defined as eGFR 30% lower than baseline was with placebo,1
INVOKANA,eGFR 30% lower than baseline,function decline defined as eGFR,1
INVOKANA,eGFR 30% lower than baseline,function decline defined as eGFR 30%,1
INVOKANA,eGFR 30% lower than baseline,lower than baseline was with placebo with INVOKANA,1
INVOKANA,eGFR 30% lower than baseline,patients who experienced at least one event of significant renal function decline defined as,0
INVOKANA,eGFR 30% lower than baseline,defined as eGFR,1
INVOKANA,eGFR 30% lower than baseline,decline defined,0
INVOKANA,renal function decline,with INVOKANA mg and with,0
INVOKANA,renal function decline,INVOKANA mg had a renal function,1
INVOKANA,renal function decline,a renal function decline In a,1
INVOKANA,renal function decline,INVOKANA mg had a renal function,1
INVOKANA,renal function decline,significant,0
INVOKANA,renal function decline,a,0
INVOKANA,renal function decline,INVOKANA mg had a renal function decline In,1
INVOKANA,renal function decline,a,0
INVOKANA,renal function decline,had,0
INVOKANA,renal function decline,renal function decline In a pooled population,1
INVOKANA,renal function decline,renal function decline In a pooled population,1
INVOKANA,renal function decline,of significant,0
INVOKANA,renal function decline,of significant,0
INVOKANA,renal function decline,episodes of renal,1
INVOKANA,renal-related adverse reactions,with,0
INVOKANA,renal-related adverse reactions,renal-related adverse reactions eg increased blood creatinine,1
INVOKANA,renal-related adverse reactions,with,0
INVOKANA,renal-related adverse reactions,glomerular,0
INVOKANA,renal-related adverse reactions,renal-related,1
INVOKANA,renal-related adverse reactions,filtration rate,0
INVOKANA,renal-related adverse reactions,Use of,0
INVOKANA,renal-related adverse reactions,incidence renal-related adverse reactions eg increased blood creatinine decreased,1
INVOKANA,renal-related adverse reactions,Use of,0
INVOKANA,increased blood creatinine,reactions increased blood,1
INVOKANA,decreased glomerular filtration rate,decreased glomerular filtration rate renal impairment and acute renal,1
INVOKANA,decreased glomerular filtration rate,incidence of renalrelated adverse reactions,0
INVOKANA,decreased glomerular filtration rate,increased blood decreased glomerular filtration rate renal impairment and acute renal,1
INVOKANA,decreased glomerular filtration rate,incidence of renalrelated adverse reactions,0
INVOKANA,decreased glomerular filtration rate,of renalrelated adverse reactions,0
INVOKANA,decreased glomerular filtration rate,decreased glomerular filtration rate,1
INVOKANA,decreased glomerular filtration rate,decreased,1
INVOKANA,decreased glomerular filtration rate,reactions eg increased blood decreased glomerular filtration rate renal impairment and,1
INVOKANA,decreased glomerular filtration rate,decreased,1
INVOKANA,decreased glomerular filtration rate,increased blood decreased,1
INVOKANA,decreased glomerular filtration rate,decreased glomerular filtration rate renal,1
INVOKANA,decreased glomerular filtration rate,renalrelated adverse reactions eg increased blood creatinine,0
INVOKANA,renal impairment,increased blood creatinine decreased glomerular filtration rate,0
INVOKANA,renal impairment,in patients with moderate renal impairment In the,0
INVOKANA,acute renal failure,blood creatinine decreased glomerular filtration rate renal impairment and,0
INVOKANA,acute renal failure,filtration rate renal impairment acute renal failure particularly,1
INVOKANA,acute renal failure,blood creatinine decreased glomerular filtration rate renal impairment and,0
INVOKANA,acute renal failure,acute renal failure,1
INVOKANA,acute renal failure,particularly in patients with moderate renal impairment,0
INVOKANA,acute renal failure,acute renal failure,1
INVOKANA,acute renal failure,renal failure particularly in patients with,1
INVOKANA,acute renal failure,renal impairment In,0
INVOKANA,acute renal failure,eg increased blood creatinine decreased glomerular filtration,0
INVOKANA,acute renal failure,acute renal failure,1
INVOKANA,acute renal failure,eg increased blood creatinine decreased glomerular filtration,0
INVOKANA,acute renal failure,acute renal failure,1
INVOKANA,renal-related adverse reactions,was with,0
INVOKANA,renal-related adverse reactions,adverse reactions was,1
INVOKANA,renal-related adverse reactions,with placebo with,0
INVOKANA,renal-related adverse events,with INVOKANA mg Discontinuations due,0
INVOKANA,renal-related adverse events,mg Discontinuations due renal-related adverse events occurred in,1
INVOKANA,renal-related adverse events,with INVOKANA mg Discontinuations due,0
INVOKANA,female genital mycotic infections,vulvovaginal mycotic,0
INVOKANA,female genital mycotic infections,female genital mycotic infections eg vulvovaginal mycotic infection vulvovaginal,1
INVOKANA,female genital mycotic infections,female genital mycotic infections eg vulvovaginal,1
INVOKANA,female genital mycotic infections,female genital mycotic infections eg vulvovaginal mycotic infection,1
INVOKANA,vulvovaginal mycotic infection,pool of four placebocontrolled clinical trials female,0
INVOKANA,vulvovaginal mycotic infection,vulvovaginitis occurred in and of females treate,0
INVOKANA,vulvovaginal mycotic infection,genital mycotic infections,0
INVOKANA,vulvovaginal candidiasis,infections eg vulvovaginal mycotic vulvovaginal candidiasis and vulvovaginitis occurred,1
INVOKANA,vulvovaginal candidiasis,genital mycotic infections,0
INVOKANA,vulvovaginitis,mycotic infection vulvovaginal,0
INVOKANA,vulvovaginitis,vulvovaginal candidiasis vulvovaginitis,1
INVOKANA,vulvovaginitis,mycotic infection vulvovaginal,0
INVOKANA,vulvovaginitis,ale genital mycotic infections eg vulvovaginal mycotic infection vulvovaginal candidiasis,0
INVOKANA,vulvovaginitis,vulvovaginitis occurred in and,1
INVOKANA,genital mycotic infections,more likely to,0
INVOKANA,genital mycotic infections,likely to genital,1
INVOKANA,candidal balanitis,mycotic infections candidal balanitis,1
INVOKANA,candidal balanitis,likely to genital,1
INVOKANA,candidal balanitis,candidal balanitis balanoposthitis occurred in and,1
INVOKANA,candidal balanitis,candidal balanitis balanoposthitis occurred in and of,1
INVOKANA,candidal balanitis,candidal balanitis balanoposthitis occurred,1
INVOKANA,candidal balanitis,male genital mycotic infections candidal balanitis balanoposthitis occurred in,1
INVOKANA,candidal balanitis,candidal balanitis balanoposthitis occurred,1
INVOKANA,candidal balanitis,infections candidal balanitis balanoposthitis,1
INVOKANA,candidal balanitis,candidal balanitis balanoposthitis occurred,1
INVOKANA,candidal balanitis,infections candidal balanitis,1
INVOKANA,candidal balanitis,candidal balanitis balanoposthitis occurred,1
INVOKANA,candidal balanitis,male genital mycotic infections candidal,1
INVOKANA,balanoposthitis,balanoposthitis occurred in,1
INVOKANA,balanoposthitis,balanoposthitis occurred in and of males,1
INVOKANA,balanoposthitis,balanoposthitis occurred,1
INVOKANA,balanoposthitis,treated with,0
INVOKANA,Male genital mycotic infections,and INVOKANA mg Male genital mycotic infections,1
INVOKANA,Male genital mycotic infections,males with,0
INVOKANA,Male genital mycotic infections,prior history of balanitis or bal,0
INVOKANA,phimosis,phimosis was reported in of,1
INVOKANA,phimosis,analysis of controlled phimosis,1
INVOKANA,phimosis,phimosis was reported in of,1
INVOKANA,phimosis,pooled analysis of controlled phimosis was reported in,1
INVOKANA,phimosis,phimosis was reported in of,1
INVOKANA,phimosis,phimosis was reported,1
INVOKANA,phimosis,Precautions Hypoglycemia,0
INVOKANA,phimosis,phimosis see Warnings and Precautions Hypoglycemia,1
INVOKANA,phimosis,In all clinical trials,0
INVOKANA,phimosis,circumcision to treat phimosis see Warnings and,1
INVOKANA,phimosis,In all clinical trials,0
INVOKANA,phimosis,phimosis,1
INVOKANA,phimosis,circumcision to treat phimosis see,1
INVOKANA,phimosis,phimosis,1
INVOKANA,phimosis,treat,0
INVOKANA,phimosis,phimosis see Warnings,1
INVOKANA,phimosis,all clinical trials hypo,0
INVOKANA,hypoglycemia,hypoglycemia occurred at a higher rate,1
INVOKANA,Hypoglycemia,Table Incidence,0
INVOKANA,Hypoglycemia,Hypoglycemia Number,1
INVOKANA,Hypoglycemia,Table Incidence,0
INVOKANA,Hypoglycemia,Hypoglycemia Number,1
INVOKANA,Hypoglycemia,Table Incidence,0
INVOKANA,hypoglycemia,hypoglycemia based on either biochemically documented,1
INVOKANA,hypoglycemic events,biochemically documented episodes or hypoglycemic events,1
INVOKANA,hypoglycemic events,hypoglycemic,1
INVOKANA,hypoglycemic events,hypoglycemic events in the,1
INVOKANA,hypoglycemic events,intenttotreat,0
INVOKANA,hypoglycemic events,documented episodes or hypoglycemic,1
INVOKANA,hypoglycemic events,episodes or hypoglycemic,1
INVOKANA,hypoglycemic events,the intenttotreat population in,0
INVOKANA,bone fractures,rates of bone fractures,1
INVOKANA,bone fractures,The,0
INVOKANA,bone fractures,incidence rates of bone,1
INVOKANA,bone fractures,INVOKANA mg,0
INVOKANA,bone fractures,bone fractures were and per,1
INVOKANA,bone fractures,of exposure to INVOKANA of weeks,0
INVOKANA,bone fractures,bone fractures were and,1
INVOKANA,Fractures,Fractures were,1
INVOKANA,Fractures,bone fractures were and,1
INVOKANA,Fractures,entyears of exposure in the comparator INVOKANA mg and INVOKANA mg,0
INVOKANA,Fractures,observed as,0
INVOKANA,Fractures,weeks after treatment initiation and were more likely,0
INVOKANA,Fractures,mg groups Fractures were observed,1
INVOKANA,Fractures,weeks after treatment initiation and were more likely,0
INVOKANA,Fractures,Fractures were observed as early,1
INVOKANA,Fractures,Fractures were observed as,1
INVOKANA,Fractures,INVOKANA mg groups,0
INVOKANA,Fractures,respectively,0
INVOKANA,Fractures,Fractures were observed as early as,1
INVOKANA,Fractures,respectively,0
INVOKANA,Fractures,in the comparator,0
INVOKANA,Fractures,observed as early as weeks after treatment initiation and were,0
INVOKANA,Fractures,observed,0
INVOKANA,Fractures,INVOKANA mg groups Fractures were observed,1
INVOKANA,Fractures,observed,0
INVOKANA,Fractures,exposure in the comparator INVOKANA,0
INVOKANA,Fractures,Fractures,1
INVOKANA,Fractures,initiation and were more,0
INVOKANA,increases in serum potassium,than mLmin increases in serum potassium to greater than mEqL,1
INVOKANA,increases in serum potassium,initiation and were more,0
INVOKANA,increases in serum potassium,and of patients,0
INVOKANA,increases in serum potassium,than mLmin increases,1
INVOKANA,increases in serum potassium,than mLmin increases in serum potassium,1
INVOKANA,increases in serum potassium,than mLmin increases,1
INVOKANA,increases in serum potassium,mLmin increases in,1
INVOKANA,increases in serum potassium,to less than mLmin increases in,1
INVOKANA,increases in serum potassium,less than mLmin increases in serum potassium to greater than mEqL,1
INVOKANA,increases in serum potassium,to less than mLmin increases in,1
INVOKANA,increases in serum potassium,than mLmin increases in serum potassium,1
INVOKANA,increases in serum potassium,increases,1
INVOKANA,increases in serum potassium,and above baseline occurred in and of patients treat,0
INVOKANA,increases in serum potassium,above baseline occurred in,0
INVOKANA,increases in serum potassium,than mLmin increases in serum,1
INVOKANA,increases in serum potassium,greater than mEqL and above baseline occurred in and,0
INVOKANA,increases in serum potassium,greater than mEqL and above baseline occurred in and,0
INVOKANA,increases in serum potassium,less than mLmin increases in serum potassium to greater than mEqL,1
INVOKANA,increases in serum potassium,greater than mEqL and above baseline occurred in and,0
INVOKANA,increases in serum potassium,to less than mLmin increases in serum potassium to greater than mEqL and,1
INVOKANA,increases in serum potassium,greater than mEqL and above baseline occurred in and,0
INVOKANA,increases in potassium,potassium at baseline Among patients with,0
INVOKANA,increases in potassium,INVOKANA mg In these increases in potassium were more commonly,1
INVOKANA,increases in potassium,potassium at baseline Among patients with,0
INVOKANA,increases in serum magnesium,in serum magnesium were,1
INVOKANA,increases in serum magnesium,serum magnesium were observed,1
INVOKANA,serum magnesium levels increased,levels increased by and,1
INVOKANA,serum magnesium levels increased,impairment see Clinical serum magnesium,1
INVOKANA,serum magnesium levels increased,magnesium levels increased by,1
INVOKANA,serum magnesium levels increased,see Clinical serum,1
INVOKANA,serum magnesium levels increased,magnesium levels increased by,1
INVOKANA,serum magnesium levels increased,Clinical serum,1
INVOKANA,serum magnesium levels increased,In a trial,0
INVOKANA,serum magnesium levels increased,impairment see Clinical serum magnesium levels increased,1
INVOKANA,serum magnesium levels increased,In a trial,0
INVOKANA,serum magnesium levels increased,renal impairment see Clinical serum magnesium,1
INVOKANA,serum magnesium levels increased,renal impairment see Clinical serum magnesium levels increased by and with placebo INVOKANA,1
INVOKANA,serum magnesium levels increased,renal impairment see Clinical serum magnesium,1
INVOKANA,increases in serum phosphate,INVOKANA mg respectively Increases in Serum Phosphate Doserelated,0
INVOKANA,increases in serum phosphate,increases in serum phosphate,1
INVOKANA,increases in serum phosphate,INVOKANA mg respectively Increases in Serum Phosphate Doserelated,0
INVOKANA,increases in serum phosphate,increases in serum phosphate levels,1
INVOKANA,increases in serum phosphate,INVOKANA mg respectively Increases in Serum Phosphate Doserelated,0
INVOKANA,increases in serum phosphate,serum phosphate levels,1
INVOKANA,increases in serum phosphate,Phosphate increases in serum,1
INVOKANA,increases in serum phosphate,were observed with INVOKANA,0
INVOKANA,increases in serum phosphate,Increases in Serum Phosphate increases in serum phosphate levels were,1
INVOKANA,increases in serum phosphate,were observed with INVOKANA,0
INVOKANA,change in serum phosphate levels,the mean change in serum phosphate levels were and with INVOKANA,1
INVOKANA,change in serum phosphate levels,were observed with INVOKANA,0
INVOKANA,change in serum phosphate levels,mean change in serum phosphate levels were and,1
INVOKANA,change in serum phosphate levels,were observed with INVOKANA,0
INVOKANA,change in serum phosphate levels,serum phosphate levels were and with INVOKANA,1
INVOKANA,change in serum phosphate levels,the mean change in serum phosphate levels were and with INVOKANA,1
INVOKANA,change in serum phosphate levels,serum phosphate levels were and with INVOKANA,1
INVOKANA,change in serum phosphate levels,controlled trials the mean change,1
INVOKANA,change in serum phosphate levels,in serum phosphate levels,1
INVOKANA,change in serum phosphate levels,in serum phosphate levels were and with INVOKANA,1
INVOKANA,change in serum phosphate levels,phosphate levels,1
INVOKANA,change in serum phosphate levels,controlled trials the mean change in serum,1
INVOKANA,increases in LDL-C,Cholesterol nonHDLC In the pool of four placebocontrolled trials doserelated,0
INVOKANA,increases in LDL-C,increases in LDL-C with,1
INVOKANA,increases in non-HDL-C,percent changes,0
INVOKANA,hemoglobin above the upper limit of normal,and INVOKANA mg respectively had,0
INVOKANA,hemoglobin above the upper limit of normal,INVOKANA mg respectively hemoglobin above the upper limit of normal Decreases in,1
INVOKANA,hemoglobin above the upper limit of normal,and INVOKANA mg respectively had,0
INVOKANA,hemoglobin above the upper limit of normal,INVOKANA mg respectively hemoglobin above the upper limit of normal Decreases in,1
INVOKANA,hemoglobin above the upper limit of normal,and INVOKANA mg respectively had,0
INVOKANA,hemoglobin above the upper limit of normal,had,0
INVOKANA,hemoglobin above the upper limit of normal,Density Bone mineral density BMD was,0
INVOKANA,hemoglobin above the upper limit of normal,upper limit of normal Decreases in Bone Mineral Density,1
INVOKANA,declines in BMD at the total hip,and respectively Additionall,0
INVOKANA,declines in BMD at the total hip,mg had declines in,1
INVOKANA,Hypotension,dverse reac tions,1
INVOKANA,Hypotension,dverse reac tions,1
INVOKANA,Hypotension,following important dverse reac,1
INVOKANA,Hypotension,dverse reac tions,1
INVOKANA,Hypotension,The following,0
INVOKANA,Hypotension,are described below and elsewhere in the labeling,0
INVOKANA,Impairment in Renal Function,emia,1
INVOKANA,Impairment in Renal Function,Hypoglyc,0
INVOKANA,Impairment in Renal Function,s and Precautions Hyperkalemia see Warnings and,0
INVOKANA,Impairment in Renal Function,Use wi th Insulin,1
INVOKANA,Impairment in Renal Function,Use wi th Insulin,1
INVOKANA,Impairment in Renal Function,and Precautions emia with Concomitant,1
INVOKANA,Impairment in Renal Function,Insulin Secretagogues,0
INVOKANA,Impairment in Renal Function,Warnings and Precautions Genital Mycotic I,0
INVOKANA,Impairment in Renal Function,and Precautions,0
INVOKANA,Impairment in Renal Function,Precautions Hyperkalemia see Warnings and Precautions,0
INVOKANA,Hyperkalemia,Genital Mycotic,0
INVOKANA,Hyperkalemia,] * H ypersensitivity Reactions,1
INVOKANA,Hyperkalemia,and ),1
INVOKANA,Hyperkalemia,and Precautions Genital Mycotic Infections see,0
INVOKANA,Hyperkalemia,"and )  ]  
 *  H ypersensitivity Reactions see",1
INVOKANA,Hyperkalemia,and Precautions Genital Mycotic Infections see,0
INVOKANA,Hyperkalemia,"Warnings and )  ]  
 *  H ypersensitivity Reactions see",1
INVOKANA,Hyperkalemia,and Precautions Genital Mycotic Infections see,0
INVOKANA,Hyperkalemia,* H ypersensitivity Reactions see,1
INVOKANA,Hyperkalemia,* H ypersensitivity,1
INVOKANA,Hypoglycemia,Precautions Increases in nsity Lipopr,1
INVOKANA,Hypoglycemia,in nsity Lipopr,1
INVOKANA,Hypoglycemia,nsity Lipopr otein LDLC see Warnings,1
INVOKANA,Hypoglycemia,adverse,0
INVOKANA,Hypoglycemia,Bone Fracture see,0
INVOKANA,Hypoglycemia,nsity Lipopr otein,1
INVOKANA,Hypoglycemia,Bone Fracture see,0
INVOKANA,Hypoglycemia,LowDe,0
INVOKANA,Hypoglycemia,and Precautions Increases in nsity Lipopr,1
INVOKANA,Hypoglycemia,otein LDLC see Warnings and,0
INVOKANA,Genital mycotic infections,reactions associated with,0
INVOKANA,Genital mycotic infections,"or greater incidence female enital mycotic infections,",1
INVOKANA,Genital mycotic infections,enital,1
INVOKANA,Genital mycotic infections,tract,0
INVOKANA,Genital mycotic infections,infection and increased urination EXCERPT,0
INVOKANA,Genital mycotic infections,associated with INVOKANA,0
INVOKANA,Genital mycotic infections,increased urination EXCERPT To,0
INVOKANA,Hypersensitivity reactions,"infection and increased n (  6.1  ) 
      EXCERPT To report SUSPECTED ADVERSE",1
INVOKANA,Hypersensitivity reactions,increased urination EXCERPT To,0
INVOKANA,Hypersensitivity reactions,eater incidence female genital mycotic infections urinary tract,0
INVOKANA,Hypersensitivity reactions,tract infection and increased n ( 6.1,1
INVOKANA,Hypersensitivity reactions,REACTIONS contact Janssen,0
INVOKANA,Hypersensitivity reactions,) EXCERPT,1
INVOKANA,Hypersensitivity reactions,"increased n (  6.1  ) 
      EXCERPT To",1
INVOKANA,Hypersensitivity reactions,) EXCERPT,1
INVOKANA,Hypersensitivity reactions,"increased n (  6.1  ) 
      EXCERPT To report",1
INVOKANA,Hypersensitivity reactions,) EXCERPT,1
INVOKANA,Hypersensitivity reactions,"n (  6.1  ) 
      EXCERPT To report SUSPECTED ADVERSE",1
INVOKANA,Hypersensitivity reactions,) EXCERPT,1
INVOKANA,Hypersensitivity reactions,"n (  6.1  ) 
      EXCERPT To report",1
INVOKANA,Hypersensitivity reactions,) EXCERPT,1
INVOKANA,Hypersensitivity reactions,infection and increased n (,1
INVOKANA,Bone fracture,Pharmaceuticals at,1
INVOKANA,Bone fracture,Pharmaceuticals Inc,0
INVOKANA,Bone fracture,at 1-800-526- or,1
INVOKANA,Bone fracture,Pharmaceuticals Inc,0
INVOKANA,Bone fracture,Janssen Pharmaceuticals at,1
INVOKANA,Bone fracture,or FDA at FDA or wwwfdagovmedwatch Clinical,0
INVOKANA,Bone fracture,Pharmaceuticals Inc,0
INVOKANA,Bone fracture,contact Janssen Pharmaceuticals at 1-800-526-,1
INVOKANA,Bone fracture,Pharmaceuticals Inc,0
INVOKANA,Bone fracture,Pharmaceuticals at 1-800-526- or FDA,1
INVOKANA,Bone fracture,Pharmaceuticals Inc,0
INVOKANA,Increased LDL-C,Clinical Studies ience,1
INVOKANA,Increased LDL-C,"ience

  Becaus e",1
INVOKANA,Increased LDL-C,Clinical Studies ience,1
INVOKANA,Increased LDL-C,wwwfdagovmedwatch Clinical,0
INVOKANA,Increased LDL-C,Studies ience,1
INVOKANA,intravascular volume contraction,widely varying conditions adverse reaction rates,0
INVOKANA,intravascular volume contraction,the clinical trials of a drug ca nnot be,1
INVOKANA,intravascular volume contraction,varying conditions adverse reaction rates,0
INVOKANA,Symptomatic hypotension,drug ot be directly compared,1
INVOKANA,Symptomatic hypotension,varying conditions adverse reaction rates,0
INVOKANA,Symptomatic hypotension,be directly compared,1
INVOKANA,Symptomatic hypotension,a drug ot,1
INVOKANA,Symptomatic hypotension,trials of a drug ot be,1
INVOKANA,Symptomatic hypotension,be directly compared to the,1
INVOKANA,increases serum creatinine,years and were older than,0
INVOKANA,increases serum creatinine,. Fifty percent (50%),1
INVOKANA,decreases eGFR,age Fifty percent of the po,0
INVOKANA,decreases eGFR,and were Black or African American At,0
INVOKANA,decreases eGFR,pulation was m ale and were Caucasian were,1
INVOKANA,Renal function abnormalities,of,0
INVOKANA,Renal function abnormalities,population was male and were Caucasian were Asian and were Black,0
INVOKANA,Renal function abnormalities,were Black or an American. At baseline the population had,1
INVOKANA,Renal function abnormalities,population was male and were Caucasian were Asian and were Black,0
INVOKANA,hyperkalemia,f diabetes Baseline renal,0
INVOKANA,hyperkalemia,INVOKANA mg or 300,1
INVOKANA,hyperkalemia,either INVOKANA mg or 300,1
INVOKANA,hyperkalemia," 300 mg.



 Table Adverse Reactions From Pool",1
INVOKANA,hyperkalemia,either INVOKANA mg or 300,1
INVOKANA,hyperkalemia,either INVOKANA mg or 300,1
INVOKANA,hyperkalemia,300 mg. Table Adverse Reactions,1
INVOKANA,hyperkalemia,Pool of Four Week PlaceboControlled Studies,0
INVOKANA,hyperkalemia,treated,0
INVOKANA,hyperkalemia,at least of patients treated with either INVOKANA mg or INVOKANA,0
INVOKANA,hyperkalemia,Pool of Four Week PlaceboControlled,0
INVOKANA,hyperkalemia,Table Adverse Reactions From,0
INVOKANA,hypoglycemia,2%           Urinary tract infections,1
INVOKANA,hypoglycemia,2%           Urinary,1
INVOKANA,hypoglycemia,2%          ,1
INVOKANA,hypoglycemia,Female genital mycotic infections,0
INVOKANA,hypoglycemia,Urinary tract,0
INVOKANA,hypoglycemia,2%          ,1
INVOKANA,hypoglycemia,Urinary tract,0
INVOKANA,hypoglycemia,Female genital mycotic 2%           Urinary tract,1
INVOKANA,hypoglycemia,Urinary tract,0
INVOKANA,genital mycotic infections,infections,0
INVOKANA,genital mycotic infections,genital,0
INVOKANA,bone fracture,than in patients taking placebo Pool of Placebo and,0
INVOKANA,bone fracture,of,0
INVOKANA,bone fracture,for canagliflozin was evaluated in a larger pool of,0
INVOKANA,bone fracture,rolled Trials The occurrence of adverse reactions,1
INVOKANA,bone fracture,Placebo,0
INVOKANA,increases in LDL-C,Studies and,0
INVOKANA,increases in LDL-C,was weeks,0
INVOKANA,increases in LDL-C,to INVOKANA The ean,1
XTANDI,Seizure,Seizure see,1
XTANDI,Seizure,Seizure see Warnings and Precautions EXCERPT,1
XTANDI,fatigue,are fatigue back pain decreased appetite,1
XTANDI,fatigue,Seizure see Warnings and Precautions EXCERPT,1
XTANDI,fatigue,appetite constipation,0
XTANDI,fatigue,fatigue back pain,1
XTANDI,back pain,back pain decreased appetite,1
XTANDI,back pain,reactions are back pain,1
XTANDI,back pain,common adverse reactions are back pain decreased appetite,1
XTANDI,back pain,reactions are back pain,1
XTANDI,back pain,hot flush upper respiratory tract,0
XTANDI,back pain,astheniafatigue,0
XTANDI,back pain,are back pain decreased appetite constipation,1
XTANDI,back pain,astheniafatigue,0
XTANDI,back pain,back pain decreased appetite,1
XTANDI,back pain,back pain decreased appetite constipation arthralgia,1
XTANDI,back pain,back pain decreased appetite,1
XTANDI,back pain,arthralgia diarrhea hot flush,0
XTANDI,decreased appetite,back decreased appetite,1
XTANDI,decreased appetite,decreased appetite constipation arthralgia,1
XTANDI,decreased appetite,reactions are astheniafatigue back decreased,1
XTANDI,decreased appetite,are astheniafatigue back decreased appetite constipation arthralgia,1
XTANDI,decreased appetite,reactions are astheniafatigue back decreased,1
XTANDI,decreased appetite,decreased appetite constipation arthralgia diarrhea hot flush,1
XTANDI,decreased appetite,decreased appetite constipation,1
XTANDI,decreased appetite,common adverse reactions are astheniafatigue back,0
XTANDI,decreased appetite,reactions are astheniafatigue back decreased appetite constipation arthralgia,1
XTANDI,decreased appetite,common adverse reactions are astheniafatigue back,0
XTANDI,constipation,constipation arthralgia diarrhea hot flush upper,1
XTANDI,constipation,back pain decreased,0
XTANDI,constipation,constipation arthralgia diarrhea hot flush upper,1
XTANDI,constipation,upper respiratory tract infection peripheral,0
XTANDI,constipation,decreased constipation arthralgia diarrhea hot flush,1
XTANDI,constipation,upper respiratory tract infection peripheral,0
XTANDI,arthralgia,arthralgia diarrhea hot flush upper,1
XTANDI,diarrhea,diarrhea hot flush,1
XTANDI,diarrhea,peripheral edema dyspnea,0
XTANDI,diarrhea,diarrhea hot,1
XTANDI,diarrhea,diarrhea hot,1
XTANDI,hot flush,tract infection peripheral edema dyspnea musculoskeletal pain,0
XTANDI,hot flush,astheniafatigue back pain decreased appetite constipation arthralgia diarrhea,0
XTANDI,hot flush,pain,0
XTANDI,hot flush,decreased appetite constipation arthralgia hot flush,1
XTANDI,hot flush,pain,0
XTANDI,hot flush,upper respiratory tract infection peripheral edema dyspnea musculoskeletal pain weight decreas,0
XTANDI,hot flush,pain decreased,0
XTANDI,hot flush,back pain decreased appetite constipation arthralgia diarrhea,0
XTANDI,hot flush,peripheral edema dyspnea,0
XTANDI,hot flush,s are,0
XTANDI,hot flush,infection peripheral edema dyspnea musculoskeletal pain weight,0
XTANDI,upper respiratory tract infection,diarrhea hot,0
XTANDI,upper respiratory tract infection,decreased appetite constipation arthralgia diarrhea,0
XTANDI,upper respiratory tract infection,diarrhea hot upper respiratory tract infection peripheral edema dyspnea musculoskeletal pain,1
XTANDI,upper respiratory tract infection,decreased appetite constipation arthralgia diarrhea,0
XTANDI,upper respiratory tract infection,constipation arthralgia diarrhea hot upper respiratory tract infection peripheral edema dyspnea musculoskeletal pain,1
XTANDI,upper respiratory tract infection,decreased appetite constipation arthralgia diarrhea,0
XTANDI,upper respiratory tract infection,upper respiratory tract infection peripheral edema dyspnea musculoskeletal pain,1
XTANDI,upper respiratory tract infection,decreased appetite constipation arthralgia diarrhea,0
XTANDI,upper respiratory tract infection,hot upper respiratory,1
XTANDI,upper respiratory tract infection,flush,0
XTANDI,upper respiratory tract infection,arthralgia diarrhea hot upper,1
XTANDI,peripheral edema,peripheral edema dyspnea,1
XTANDI,peripheral edema,tract peripheral edema dyspnea musculoskeletal pain weight,1
XTANDI,peripheral edema,peripheral edema dyspnea,1
XTANDI,peripheral edema,flush upper respiratory tract peripheral,1
XTANDI,dyspnea,dyspnea musculoskeletal pain,1
XTANDI,dyspnea,dyspnea musculoskeletal pain weight decreased headache,1
XTANDI,dyspnea,dyspnea musculoskeletal pain weight decreased,1
XTANDI,dyspnea,edema,0
XTANDI,dyspnea,infection peripheral dyspnea musculoskeletal,1
XTANDI,dyspnea,edema,0
XTANDI,dyspnea,musculoskeletal pain weight decreased headache,0
XTANDI,dyspnea,dyspnea musculoskeletal pain weight decreased,1
XTANDI,musculoskeletal pain,peripheral edema musculoskeletal pain,1
XTANDI,musculoskeletal pain,musculoskeletal pain,1
XTANDI,musculoskeletal pain,headache hypertension and dizzinessvertigo To report SUSPECT,0
XTANDI,musculoskeletal pain,decreased headache hypertension and dizzinessvertigo To,0
XTANDI,musculoskeletal pain,arthralgia diarrhea hot,0
XTANDI,weight decreased,hot flush,0
XTANDI,weight decreased,dizzinessvertigo,0
XTANDI,headache,headache,1
XTANDI,headache,headache,1
XTANDI,headache,headache,1
XTANDI,hypertension,pain,0
XTANDI,hypertension,hypertension and,1
XTANDI,hypertension,hypertension and dizzinessvertigo,1
XTANDI,hypertension,tract infection peripheral edema dyspnea musculoskeletal pain weight decreased,0
XTANDI,hypertension,pain weight decreased hypertension and dizzinessvertigo To report,1
XTANDI,hypertension,tract infection peripheral edema dyspnea musculoskeletal pain weight decreased,0
XTANDI,hypertension,headache,0
XTANDI,hypertension,REACTIONS contact Astellas Pha,0
XTANDI,hypertension,weight decreased hypertension and dizzinessvertigo To report,1
XTANDI,hypertension,REACTIONS contact Astellas Pha,0
XTANDI,hypertension,hypertension and dizzinessvertigo To report,1
XTANDI,hypertension,hypertension and,1
XTANDI,dizziness,dizziness vertigo To report SUSPECTED,1
XTANDI,dizziness,dizziness vertigo,1
XTANDI,dizziness,weight decreased headache,0
XTANDI,dizziness,decreased headache hypertension dizziness,1
XTANDI,dizziness,weight decreased headache,0
XTANDI,dizziness,weight decreased headache hypertension and,0
XTANDI,vertigo,and vertigo To report SUSPECTED,1
XTANDI,vertigo,weight decreased headache hypertension and,0
XTANDI,vertigo,pain weight decreased,0
XTANDI,vertigo,vertigo To report SUSPECTED,1
XTANDI,vertigo,pain weight decreased,0
XTANDI,vertigo,vertigo,1
XTANDI,vertigo,US Inc at,0
XTANDI,vertigo,dyspnea musculoskeletal pain weight decreased headache,0
XTANDI,vertigo,vertigo To,1
XTANDI,vertigo,musculoskeletal pain weight,0
XTANDI,vertigo,vertigo To report SUSPECTED ADVERSE,1
XTANDI,asthenia,over placebo in the XTANDItreated patients,0
XTANDI,asthenia,asthenia fatigue back pain decreased appetite,1
XTANDI,asthenia,asthenia,1
XTANDI,asthenia,asthenia fatigue back pain decreased,1
XTANDI,asthenia,decreased appetite constipation arthralgia diarrhea hot,0
XTANDI,fatigue,clinical trials were fatigue,1
XTANDI,fatigue,decreased appetite constipation arthralgia diarrhea hot,0
XTANDI,fatigue,fatigue back pain decreased appetite constipation,1
XTANDI,back pain,clinical trials were back pain,1
XTANDI,back pain,fatigue back pain decreased appetite constipation,1
XTANDI,back pain,back pain,1
XTANDI,back pain,fatigue back pain decreased appetite constipation,1
XTANDI,back pain,were back,1
XTANDI,back pain,back pain decreased appetite constipation,1
XTANDI,back pain,trials were back pain,1
XTANDI,back pain,back pain decreased appetite constipation,1
XTANDI,back pain,the two randomized clinical trials were astheniafatigue,0
XTANDI,back pain,back pain decreased appetite constipation,1
XTANDI,decreased appetite,were astheniafatigue back decreased,1
XTANDI,decreased appetite,decreased appetite constipation arthralgia,1
XTANDI,decreased appetite,were astheniafatigue back decreased,1
XTANDI,decreased appetite,infection peripheral,0
XTANDI,decreased appetite,e XTANDItreated patients from the two randomized clinical trials were astheniafatigue back pain,0
XTANDI,decreased appetite,flush upper respiratory tract infection peripheral,0
XTANDI,constipation,back pain decreased constipation arthralgia diarrhea hot flush upper,1
XTANDI,constipation,flush upper respiratory tract infection peripheral,0
XTANDI,constipation,edema,0
XTANDI,constipation,constipation arthralgia diarrhea hot flush upper,1
XTANDI,constipation,decreased,0
XTANDI,constipation,constipation arthralgia diarrhea hot flush,1
XTANDI,constipation,constipation arthralgia,1
XTANDI,constipation,arthralgia diarrhea hot flush upper respiratory tract infection peripheral edema dyspnea mus,0
XTANDI,arthralgia,arthralgia,1
XTANDI,arthralgia,trials,0
XTANDI,arthralgia,two randomized clinical trials were,0
XTANDI,arthralgia,diarrhea hot flush upper respiratory tract infection peripheral edema,0
XTANDI,arthralgia,arthralgia diarrhea hot flush upper respiratory,1
XTANDI,hot flush,astheniafatigue back,0
XTANDI,hot flush,musculoskeletal,0
XTANDI,hot flush,arthralgia hot flush upper,1
XTANDI,hot flush,musculoskeletal,0
XTANDI,hot flush,appetite constipation arthralgia hot,1
XTANDI,hot flush,arthralgia hot flush upper,1
XTANDI,hot flush,appetite constipation arthralgia hot,1
XTANDI,hot flush,appetite constipation arthralgia hot flush upper respiratory tract,1
XTANDI,hot flush,appetite constipation arthralgia hot,1
XTANDI,upper respiratory tract infection,arthralgia diarrhea hot upper respiratory tract infection peripheral edema dyspnea,1
XTANDI,upper respiratory tract infection,appetite constipation arthralgia hot,1
XTANDI,upper respiratory tract infection,diarrhea hot upper,1
XTANDI,upper respiratory tract infection,tract infection peripheral edema,1
XTANDI,upper respiratory tract infection,hypertension and,0
XTANDI,upper respiratory tract infection,diarrhea hot upper respiratory tract infection,1
XTANDI,upper respiratory tract infection,astheniafatigue,0
XTANDI,upper respiratory tract infection,diarrhea hot upper respiratory,1
XTANDI,upper respiratory tract infection,constipation arthralgia diarrhea hot upper,1
XTANDI,upper respiratory tract infection,upper respiratory tract infection peripheral edema dyspnea,1
XTANDI,peripheral edema,tract infection,0
XTANDI,peripheral edema,respiratory tract peripheral edema dyspnea musculoskeletal pain weight,1
XTANDI,peripheral edema,tract infection,0
XTANDI,peripheral edema,musculoskeletal pain weight decreased headache hypertension and,0
XTANDI,peripheral edema,pain weight decreased headache,0
XTANDI,peripheral edema,hot flush upper respiratory,0
XTANDI,peripheral edema,flush upper respiratory tract peripheral,1
XTANDI,peripheral edema,upper respiratory tract,0
XTANDI,peripheral edema,peripheral,1
XTANDI,peripheral edema,peripheral edema,1
XTANDI,peripheral edema,diarrhea hot flush,0
XTANDI,dyspnea,dyspnea musculoskeletal,1
XTANDI,dyspnea,dyspnea musculoskeletal pain,1
XTANDI,dyspnea,dyspnea musculoskeletal pain weight decreased headache,1
XTANDI,dyspnea,flush upper respiratory tract infection peripheral edema,0
XTANDI,dyspnea,dyspnea musculoskeletal pain weight decreased,1
XTANDI,musculoskeletal pain,edema,0
XTANDI,musculoskeletal pain,musculoskeletal pain,1
XTANDI,weight decreased,weight decreased headache hypertension and dizzinessvertigo Study,1
XTANDI,weight decreased,weight decreased headache hypertension and dizzinessvertigo Study,1
XTANDI,weight decreased,dizzinessvertigo,0
XTANDI,weight decreased,weight decreased,1
XTANDI,headache,dyspnea musculoskeletal pain weight,0
XTANDI,headache,headache hypertension and,1
XTANDI,headache,dyspnea musculoskeletal pain weight,0
XTANDI,headache,weight,0
XTANDI,headache,edema dyspnea,0
XTANDI,headache,weight headache hypertension,1
XTANDI,headache,edema dyspnea,0
XTANDI,hypertension,Prostate Cancer,0
XTANDI,hypertension,hypertension and dizzinessvertigo Study Metastatic CastrationResistant,1
XTANDI,hypertension,decreased hypertension and,1
XTANDI,hypertension,hypertension and dizzinessvertigo Study Metastatic CastrationResistant,1
XTANDI,hypertension,Study Metastatic,0
XTANDI,hypertension,pain weight decreased hypertension and,1
XTANDI,hypertension,Study Metastatic,0
XTANDI,dizziness,dizziness vertigo Study Metastatic,1
XTANDI,dizziness,CastrationResistant,0
XTANDI,vertigo,headache,0
XTANDI,vertigo,vertigo Study Metastatic CastrationResistant Prostate,1
XTANDI,vertigo,Chemotherapy,0
XTANDI,vertigo,vertigo Study Metastatic CastrationResistant,1
XTANDI,vertigo,pain weight,0
XTANDI,vertigo,headache hypertension and,0
XTANDI,vertigo,hypertension and,0
XTANDI,vertigo,vertigo Study Metastatic CastrationResistant Prostate Cancer,1
XTANDI,seizure,seizure which occurred,1
XTANDI,seizure,seizure which occurred in,1
XTANDI,seizure,which occurred in of the XTANDItreated patients compared to,0
XTANDI,seizure,treatment discontinuation,0
XTANDI,seizure,leading to treatment discontinuation seizure which occurred in,1
XTANDI,seizure,treatment discontinuation,0
XTANDI,seizure,patients compared to none of the,0
XTANDI,seizure,seizure which occurred,1
XTANDI,seizure,adverse,0
XTANDI,seizure,seizure,1
XTANDI,seizure,adverse,0
XTANDI,Asthenic Conditions,Grade Grade General Disorders,0
XTANDI,Asthenic Conditions,Asthenic Conditions b,1
XTANDI,Asthenic Conditions,Grade Grade Grade General Asthenic Conditions b,1
XTANDI,Asthenic Conditions,Asthenic Conditions b,1
XTANDI,Asthenic Conditions,Asthenic,1
XTANDI,Asthenic Conditions,Grade Grade General Asthenic Conditions b Peripher,1
XTANDI,Asthenic Conditions,Asthenic,1
XTANDI,Asthenic Conditions,General Asthenic Conditions,1
XTANDI,Upper Respiratory Tract Infection,e,0
XTANDI,Upper Respiratory Tract Infection,Upper Respiratory Tract,1
XTANDI,Upper Respiratory Tract Infection,Tract Infection e Lower,1
XTANDI,Upper Respiratory Tract Infection,Infestations,0
XTANDI,Upper Respiratory Tract Infection,Upper Respiratory Tract,1
XTANDI,Upper Respiratory Tract Infection,Tract Infection e Lower Respir,1
XTANDI,Lung Infection,Lower Respiratory Tract Lung Infection,1
XTANDI,asthenia,and vertigod Includes amnesia memory,0
XTANDI,fatigue,fatigue c Includes dizziness,1
XTANDI,fatigue,and vertigod Includes amnesia memory,0
XTANDI,fatigue,c Includes dizziness and vertigod,0
XTANDI,fatigue,Includes amnesia memory impairment cognitive disorder,0
XTANDI,fatigue,fatigue c Includes dizziness and vertigod,1
XTANDI,fatigue,amnesia memory impairment cognitive disorder a,0
XTANDI,fatigue,CTCAE vb Includes,0
XTANDI,fatigue,fatigue c Includes dizziness and,1
XTANDI,fatigue,CTCAE vb Includes,0
XTANDI,fatigue,CTCAE vb Includes asthenia fatigue c Includes dizziness and,1
XTANDI,fatigue,CTCAE vb Includes,0
XTANDI,fatigue,a CTCAE vb Includes,0
XTANDI,dizziness,dizziness,1
XTANDI,dizziness,a CTCAE vb Includes,0
XTANDI,dizziness,asthenia and fatiguec dizziness and vertigod Includes amnesia,1
XTANDI,dizziness,a CTCAE vb Includes,0
XTANDI,dizziness,asthenia and fatiguec dizziness and vertigod Includes,1
XTANDI,dizziness,a CTCAE vb Includes,0
XTANDI,dizziness,memory impairment cognitive disorder,0
XTANDI,dizziness,disturbance in attent,0
XTANDI,dizziness,fatiguec,0
XTANDI,dizziness,asthenia and fatiguec dizziness and vertigod Includes amnesia memory,1
XTANDI,dizziness,fatiguec,0
XTANDI,dizziness,CTCAE vb Includes asthenia and,0
XTANDI,dizziness,a CTCAE vb Includes asthenia and fatiguec,0
XTANDI,vertigo,Includes asthenia and fatiguec Includes dizziness,0
XTANDI,vertigo,and fatiguec Includes dizziness vertigo d Includes,1
XTANDI,vertigo,Includes asthenia and fatiguec Includes dizziness,0
XTANDI,vertigo,vertigo d Includes amnesia memory impairment,1
XTANDI,vertigo,vertigo,1
XTANDI,vertigo,Includes dizziness vertigo d Includes amnesia memory,1
XTANDI,vertigo,vertigo,1
XTANDI,vertigo,Includes amnesia,0
XTANDI,vertigo,vb Includes asthenia and,0
XTANDI,amnesia,disturbance in attentione Includes nasopharyngitis,0
XTANDI,amnesia,memory impairment cognitive disorder,0
XTANDI,amnesia,Includes,0
XTANDI,amnesia,and vertigod Includes,0
XTANDI,amnesia,amnesia memory impairment cognitive disorder and,1
XTANDI,amnesia,amnesia memory impairment cognitive disorder,1
XTANDI,amnesia,amnesia memory impairment cognitive,1
XTANDI,amnesia,amnesia memory impairment cognitive,1
XTANDI,amnesia,amnesia memory impairment cognitive,1
XTANDI,amnesia,amnesia memory impairment cognitive disorder and,1
XTANDI,memory impairment,Includes memory impairment,1
XTANDI,cognitive disorder,cognitive disorder and disturbance in attentione Includes,1
XTANDI,cognitive disorder,nasopharyngitis upper respiratory tract infection,0
XTANDI,cognitive disorder,cognitive disorder and disturbance in,1
XTANDI,cognitive disorder,vertigod Includes,0
XTANDI,cognitive disorder,cognitive disorder and,1
XTANDI,cognitive disorder,attentione Includes nasopharyngitis upper respiratory,0
XTANDI,cognitive disorder,vertigod Includes amnesia memory cognitive disorder and disturbance in attentione Includes,1
XTANDI,cognitive disorder,attentione Includes nasopharyngitis upper respiratory,0
XTANDI,cognitive disorder,amnesia memory,0
XTANDI,disturbance in attention,impairment cognitive disorder disturbance in attention e Includes,1
XTANDI,disturbance in attention,amnesia memory,0
XTANDI,disturbance in attention,disturbance in attention,1
XTANDI,disturbance in attention,amnesia memory,0
XTANDI,disturbance in attention,Includes nasopharyngitis upper respiratory tract infection sinusitis rhinitis pharyngitis,0
XTANDI,disturbance in attention,tract infection sinusitis rhinitis,0
XTANDI,nasopharyngitis,disturbance in attentione nasopharyngitis upper,1
XTANDI,nasopharyngitis,tract infection sinusitis rhinitis,0
XTANDI,nasopharyngitis,and disturbance,0
XTANDI,nasopharyngitis,nasopharyngitis upper respiratory tract infection sinusitis,1
XTANDI,nasopharyngitis,nasopharyngitis upper respiratory tract infection,1
XTANDI,nasopharyngitis,amnesia,0
XTANDI,nasopharyngitis,and,0
XTANDI,nasopharyngitis,nasopharyngitis upper respiratory tract,1
XTANDI,nasopharyngitis,respiratory tract infection sinusitis rhinitis pharyngitis and,0
XTANDI,nasopharyngitis,nasopharyngitis upper respiratory,1
XTANDI,nasopharyngitis,disorder and disturbance in attentione,0
XTANDI,upper respiratory tract infection,disturbance in attentione Includes,0
XTANDI,sinusitis,pneumonia lower respiratory,0
XTANDI,sinusitis,and disturbance in attentione Includes nasopharyngitis upper respiratory,0
XTANDI,sinusitis,respiratory tract sinusitis rhinitis pharyngitis and,1
XTANDI,sinusitis,and disturbance in attentione Includes nasopharyngitis upper respiratory,0
XTANDI,sinusitis,upper respiratory tract sinusitis rhinitis pharyngitis and laryngitisf Includes,1
XTANDI,sinusitis,and disturbance in attentione Includes nasopharyngitis upper respiratory,0
XTANDI,sinusitis,sinusitis rhinitis pharyngitis and laryngitisf,1
XTANDI,sinusitis,tract sinusitis rhinitis pharyngitis,1
XTANDI,sinusitis,sinusitis rhinitis pharyngitis and laryngitisf,1
XTANDI,sinusitis,sinusitis rhinitis pharyngitis and laryngitisf Includes,1
XTANDI,sinusitis,Includes,0
XTANDI,sinusitis,tract sinusitis rhinitis pharyngitis and laryngitisf Includes,1
XTANDI,sinusitis,Includes,0
XTANDI,rhinitis,respiratory tract infection,0
XTANDI,rhinitis,rhinitis,1
XTANDI,rhinitis,rhinitis pharyngitis and laryngitisf Includes,1
XTANDI,rhinitis,upper,0
XTANDI,rhinitis,rhinitis pharyngitis and,1
XTANDI,rhinitis,rhinitis pharyngitis and,1
XTANDI,pharyngitis,pharyngitis and,1
XTANDI,pharyngitis,pharyngitis and laryngitisf Includes pneumonia lower,1
XTANDI,pharyngitis,pharyngitis and laryngitisf Includes pneumonia lower,1
XTANDI,pharyngitis,nasopharyngitis upper respiratory tract infection,0
XTANDI,laryngitis,upper respiratory tract infection sinusitis rhinitis pharyngitis,0
XTANDI,laryngitis,laryngitis f Includes pneumonia lower respiratory,1
XTANDI,laryngitis,laryngitis,1
XTANDI,laryngitis,tract infection sinusitis rhinitis pharyngitis and,0
XTANDI,laryngitis,laryngitis f Includes,1
XTANDI,pneumonia,pneumonia lower respiratory tract infection,1
XTANDI,pneumonia,lung infection Study Chemo,0
XTANDI,pneumonia,pharyngitis and laryngitisf pneumonia lower respiratory,1
XTANDI,pneumonia,lung infection Study Chemo,0
XTANDI,pneumonia,sinusitis rhinitis pharyngitis,0
XTANDI,pneumonia,upper,0
XTANDI,pneumonia,upper respiratory tract infection sinusitis rhinitis pharyngitis and,0
XTANDI,pneumonia,pneumonia lower respiratory tract,1
XTANDI,pneumonia,pneumonia,1
XTANDI,pneumonia,rhinitis pharyngitis and laryngitisf pneumonia lower respiratory tract infection,1
XTANDI,pneumonia,pneumonia,1
XTANDI,bronchitis,lung infection Study Chemotherapynaive Metastatic CastrationResistant,0
XTANDI,lung infection,lung infection Study Chemotherapynaive,1
XTANDI,lung infection,lung infection Study Chemotherapynaive Metastatic CastrationResistant,0
XTANDI,fatigue,treatment discontinuation fatigue asthenia which occurred in,1
XTANDI,fatigue,lung infection Study Chemotherapynaive Metastatic CastrationResistant,0
XTANDI,fatigue,leading to treatment discontinuation fatigue asthenia which occurred,1
XTANDI,fatigue,lung infection Study Chemotherapynaive Metastatic CastrationResistant,0
XTANDI,fatigue,fatigue asthenia which,1
XTANDI,fatigue,reaction leading to,0
XTANDI,fatigue,in of patients on each treatment arm,0
XTANDI,fatigue,fatigue,1
XTANDI,fatigue,fatigue asthenia which occurred in,1
XTANDI,asthenia,asthenia which,1
XTANDI,asthenia,to treatment discontinuation was asthenia which,1
XTANDI,asthenia,asthenia which,1
XTANDI,asthenia,common,0
XTANDI,asthenia,in of patients on each treatment arm Table includes adverse reactions repor,0
XTANDI,Asthenic Conditions,Asthenic Conditions b Periphe,1
XTANDI,Restless Legs Syndrome,Restless Legs Syndrome,1
XTANDI,Restless Legs Syndrome,Asthenic Conditions b Periphe,1
XTANDI,Restless Legs Syndrome,Disordersd,0
XTANDI,Restless Legs Syndrome,nt Restless Legs Syndrome,1
XTANDI,Restless Legs Syndrome,Disordersd,0
XTANDI,Restless Legs Syndrome,Restless Legs Syndrome Respiratory,1
XTANDI,Restless Legs Syndrome,Restless Legs Syndrome Respiratory,1
XTANDI,Restless Legs Syndrome,nt,0
XTANDI,Upper Respiratory Tract Infection,Upper Respiratory Tract Infection f Lower,1
XTANDI,Upper Respiratory Tract Infection,Infections And Upper Respiratory Tract     Infection f,1
XTANDI,Upper Respiratory Tract Infection,Upper Respiratory Tract Infection f Lower,1
XTANDI,Upper Respiratory Tract Infection,Infestations,0
XTANDI,Upper Respiratory Tract Infection,Tract Infection f,1
XTANDI,Upper Respiratory Tract Infection,And Upper Respiratory Tract,1
XTANDI,Upper Respiratory Tract Infection,Infections And Infestations,0
XTANDI,Upper Respiratory Tract Infection,Upper,1
XTANDI,Upper Respiratory Tract Infection,f Lower Respir,0
XTANDI,Upper Respiratory Tract Infection,f,0
XTANDI,Upper Respiratory Tract Infection,And Upper Respiratory,1
XTANDI,asthenia,fatiguec Includes dizziness and vertigod Includes,0
XTANDI,asthenia,a CTCAE vb asthenia and fatiguec Includes dizziness,1
XTANDI,asthenia,fatiguec Includes dizziness and vertigod Includes,0
XTANDI,fatigue,fatigue c Includes dizziness and,1
XTANDI,fatigue,c,0
XTANDI,fatigue,fatigue c Includes,1
XTANDI,fatigue,fatigue c Includes,1
XTANDI,fatigue,CTCAE vb Includes asthenia fatigue c Includes dizziness,1
XTANDI,fatigue,fatigue c Includes,1
XTANDI,fatigue,vertigod Includes amnesia memory impairment cognitive disorder,0
XTANDI,dizziness,dizziness and vertigod,1
XTANDI,dizziness,dizziness,1
XTANDI,vertigo,Includes dizziness,0
XTANDI,vertigo,disorder and disturbance,0
XTANDI,vertigo,a CTCAE vb Includes asthenia,0
XTANDI,vertigo,a CTCAE vb Includes asthenia,0
XTANDI,vertigo,dizziness vertigo d,1
XTANDI,vertigo,a CTCAE vb Includes asthenia,0
XTANDI,vertigo,vertigo d,1
XTANDI,vertigo,vertigo d Includes amnesia memory impairment,1
XTANDI,vertigo,Includes dizziness vertigo d Includes amnesia,1
XTANDI,vertigo,vertigo d Includes amnesia memory impairment,1
XTANDI,vertigo,fatiguec,0
XTANDI,vertigo,Includes,0
XTANDI,amnesia,dizziness and vertigod amnesia,1
XTANDI,amnesia,Includes,0
XTANDI,amnesia,amnesia memory impairment cognitive disorder,1
XTANDI,amnesia,amnesia memory,1
XTANDI,amnesia,and fatiguec Includes dizziness and vertigod,0
XTANDI,amnesia,vb Includes asthenia and fatiguec Includes dizziness,0
XTANDI,amnesia,Includes dizziness and vertigod amnesia memory,1
XTANDI,amnesia,vb Includes asthenia and fatiguec Includes dizziness,0
XTANDI,amnesia,attentione,0
XTANDI,amnesia,and vertigod amnesia memory,1
XTANDI,amnesia,attentione,0
XTANDI,memory impairment,vertigod Includes memory impairment,1
XTANDI,memory impairment,attentione,0
XTANDI,memory impairment,in attentione Includes dyspnea exertional,0
XTANDI,memory impairment,vertigod Includes memory impairment cognitive disorder,1
XTANDI,memory impairment,in attentione Includes dyspnea exertional,0
XTANDI,memory impairment,and vertigod Includes memory impairment,1
XTANDI,memory impairment,in attentione Includes dyspnea exertional,0
XTANDI,memory impairment,memory impairment cognitive disorder and disturbance,1
XTANDI,memory impairment,in attentione Includes dyspnea exertional,0
XTANDI,memory impairment,memory impairment cognitive disorder and,1
XTANDI,memory impairment,and disturbance in attentione Includes,0
XTANDI,exertional dyspnea,exertional dyspnea and dyspnea at,1
XTANDI,exertional dyspnea,disturbance in attentione Includes exertional dyspnea,1
XTANDI,exertional dyspnea,exertional dyspnea and dyspnea at,1
XTANDI,exertional dyspnea,memory impairment cognitive disorder and disturbance in,0
XTANDI,exertional dyspnea,in attentione Includes exertional,1
XTANDI,dyspnea at rest,upper respiratory tract infection sinusitis,0
XTANDI,dyspnea at rest,exertional dyspnea dyspnea at rest f Includes nasopharyngitis upper,1
XTANDI,dyspnea at rest,upper respiratory tract infection sinusitis,0
XTANDI,nasopharyngitis,at restf nasopharyngitis upper,1
XTANDI,nasopharyngitis,upper respiratory tract infection sinusitis,0
XTANDI,nasopharyngitis,restf nasopharyngitis upper,1
XTANDI,nasopharyngitis,upper respiratory tract infection sinusitis,0
XTANDI,upper respiratory tract infection,at restf Includes upper respiratory tract infection sinusitis rhinitis pharyngitis,1
XTANDI,upper respiratory tract infection,upper respiratory tract infection sinusitis,0
XTANDI,upper respiratory tract infection,tract infection,1
XTANDI,rhinitis,respiratory tract infection bronchitis,0
XTANDI,rhinitis,pneumonia lower respiratory,0
XTANDI,rhinitis,rhinitis,1
XTANDI,rhinitis,rhinitis pharyngitis and laryngitisg,1
XTANDI,rhinitis,rhinitis pharyngitis and laryngitisg Includes,1
XTANDI,pharyngitis,infection,0
XTANDI,pharyngitis,pharyngitis and laryngitisg Includes pneumonia,1
XTANDI,laryngitis,laryngitis g Includes pneumonia,1
XTANDI,laryngitis,respiratory tract infection bronchitis and,0
XTANDI,laryngitis,laryngitis g Includes pneumonia lower,1
XTANDI,laryngitis,upper respiratory tract,0
XTANDI,laryngitis,laryngitis g Includes pneumonia lower,1
XTANDI,laryngitis,laryngitis g Includes pneumonia,1
XTANDI,laryngitis,laryngitis g Includes,1
XTANDI,pneumonia,and,0
XTANDI,pneumonia,pneumonia lower respiratory tract,1
XTANDI,pneumonia,pneumonia lower respiratory tract infection bronchitis,1
XTANDI,pneumonia,pneumonia lower respiratory tract,1
XTANDI,lower respiratory tract infection,and laryngitisg Includes lower respiratory tract infection,1
XTANDI,lower respiratory tract infection,laryngitisg,0
XTANDI,lower respiratory tract infection,the two randomized,0
XTANDI,lower respiratory tract infection,lung infection Laboratory,0
XTANDI,lower respiratory tract infection,and laryngitisg Includes lower respiratory tract infection,1
XTANDI,lower respiratory tract infection,tract infection bronchitis and lung,1
XTANDI,lower respiratory tract infection,sinusitis rhinitis pharyngitis,0
XTANDI,lower respiratory tract infection,Laboratory Abnormalities In the two randomized,0
XTANDI,bronchitis,bronchitis and,1
XTANDI,bronchitis,bronchitis and lung infection Laboratory Abnormalities,1
XTANDI,bronchitis,bronchitis and lung infection Laboratory Abnormalities,1
XTANDI,bronchitis,lower respiratory tract,0
XTANDI,bronchitis,bronchitis and lung infection Laboratory,1
XTANDI,bronchitis,respiratory tract bronchitis and,1
XTANDI,bronchitis,bronchitis and lung infection Laboratory,1
XTANDI,bronchitis,lower respiratory tract,0
XTANDI,bronchitis,and lung infection Laboratory Abnormalities,0
XTANDI,bronchitis,bronchitis and lung infection Laboratory Abnormalities,1
XTANDI,bronchitis,bronchitis and lung infection,1
XTANDI,neutropenia,neutropenia occurred in of patients,1
XTANDI,neutropenia,neutropenia occurred in,1
XTANDI,neutropenia,neutropenia,1
XTANDI,neutropenia,trials neutropenia,1
XTANDI,neutropenia,neutropenia,1
XTANDI,neutropenia,neutropenia occurred in of patients treated,1
XTANDI,neutropenia,neutropenia,1
XTANDI,neutropenia,neutropenia occurred in of patients treated,1
XTANDI,neutropenia,with XTANDI Grade and in of patients,0
XTANDI,neutropenia,neutropenia,1
XTANDI,neutropenia,clinical trials neutropenia occurred in of patients treated,1
XTANDI,neutropenia,neutropenia,1
XTANDI,neutropenia,treated with,0
XTANDI,neutropenia,patients,0
XTANDI,neutropenia,In the two randomized clinical trials Grade,0
XTANDI,neutropenia,trials neutropenia occurred in,1
XTANDI,neutropenia,In the two randomized clinical trials Grade,0
XTANDI,neutropenia,neutropenia occurred in of patients treated,1
XTANDI,neutropenia,In the two randomized clinical trials Grade,0
XTANDI,thrombocytopenia,thrombocytopenia was of patients,1
XTANDI,thrombocytopenia,with placebo Grade,0
XTANDI,thrombocytopenia,XTANDI,0
XTANDI,thrombocytopenia,treated with XTANDI Grade and of patients treated,0
XTANDI,thrombocytopenia,The incidence of thrombocytopenia was of,1
XTANDI,thrombocytopenia,treated with XTANDI Grade and of patients treated,0
XTANDI,thrombocytopenia,thrombocytopenia was of patients treated with,1
XTANDI,thrombocytopenia,with XTANDI Grade and of patients,0
XTANDI,thrombocytopenia,Grade,0
XTANDI,thrombocytopenia,treated with placebo,0
XTANDI,thrombocytopenia,of,0
XTANDI,elevations in ALT,elevations in ALT occurred,1
XTANDI,elevations in ALT,XTANDI Grade and of patients treated,0
XTANDI,elevations in ALT,placebo Grade Grade,0
XTANDI,elevations in ALT,in ALT occurred in of,1
XTANDI,elevations in ALT,placebo Grade elevations in ALT occurred in,1
XTANDI,elevations in ALT,in ALT occurred in of,1
XTANDI,elevations in ALT,and of patients treated with p,0
XTANDI,elevations in ALT,Grade elevations in ALT occurred in of patients treated,1
XTANDI,elevations in ALT,and of patients treated with p,0
XTANDI,elevations in ALT,and of,0
XTANDI,elevations in ALT,placebo,0
XTANDI,elevations in ALT,placebo Grade elevations,1
XTANDI,elevations in ALT,in ALT occurred in,1
XTANDI,elevations in ALT,treated,0
XTANDI,elevations in ALT,treated with placebo Grade elevations in ALT,1
XTANDI,elevations in ALT,placebo Grade elevations in ALT,1
XTANDI,elevations in ALT,placebo Grade elevations in ALT occurred in of,1
XTANDI,elevations in ALT,placebo Grade elevations in ALT,1
XTANDI,elevations in bilirubin,in bilirubin occurred in,1
XTANDI,elevations in bilirubin,with placebo Grade elevations in bilirubin occurred in of patients treated,1
XTANDI,elevations in bilirubin,in bilirubin occurred in,1
XTANDI,elevations in bilirubin,elevations in bilirubin,1
XTANDI,elevations in bilirubin,patients treated with XTANDI Grade and of,0
XTANDI,elevations in bilirubin,and of patients treated with placebo Grade Grade,0
XTANDI,elevations in bilirubin,in bilirubin occurred in of patients,1
XTANDI,elevations in bilirubin,elevations,1
XTANDI,elevations in bilirubin,placebo Grade elevations in bilirubin occurred in,1
XTANDI,elevations in bilirubin,elevations,1
XTANDI,elevations in bilirubin,of patients treated with pla,0
XTANDI,elevations in bilirubin,in bilirubin occurred in of,1
XTANDI,elevations in bilirubin,placebo Grade elevations in bilirubin occurred,1
XTANDI,elevations in bilirubin,in bilirubin occurred in of,1
XTANDI,elevations in bilirubin,elevations in bilirubin occurred in of patients,1
XTANDI,elevations in bilirubin,patients treated with,0
XTANDI,elevations in bilirubin,Grade,0
XTANDI,elevations in bilirubin,treated with,0
XTANDI,elevations in bilirubin,XTANDI Grade,0
XTANDI,elevations in bilirubin,of patients treated with placebo Grade,0
XTANDI,elevations in bilirubin,elevations in bilirubin occurred in of patients treated,1
XTANDI,elevations in bilirubin,of patients treated with placebo Grade,0
XTANDI,elevations in bilirubin,treated with placebo Grade elevations in bilirubin,1
XTANDI,died,in each treatment group had an infection re,0
XTANDI,died,patients treated with died from infections or sepsis In,1
XTANDI,died,in each treatment group had an infection re,0
XTANDI,infections,infections or sepsis In,1
XTANDI,infections,infections or sepsis In Study patient,1
XTANDI,infections,placebo died infections or sepsis,1
XTANDI,infections,infections or sepsis In Study patient,1
XTANDI,infections,XTANDI compared,0
XTANDI,infections,patients treated with XTANDI,0
XTANDI,infections,infections or sepsis,1
XTANDI,infections,patients treated with XTANDI,0
XTANDI,sepsis,from,0
XTANDI,sepsis,group had an infection resulting in death,0
XTANDI,sepsis,compared to,0
XTANDI,sepsis,sepsis In Study,1
XTANDI,sepsis,compared to,0
XTANDI,sepsis,treated with placebo died from infections,0
XTANDI,sepsis,sepsis In Study patient in,1
XTANDI,infection,infection resulting in death Falls,1
XTANDI,infection,group had,0
XTANDI,infection,infection resulting in death,1
XTANDI,infection,infection resulting in death Falls,1
XTANDI,death,death Falls and Fallrelated Injuries,1
XTANDI,death,had an infection resulting death,1
XTANDI,death,death Falls and Fallrelated Injuries,1
XTANDI,death,an infection resulting death Falls and,1
XTANDI,death,death Falls and Fallrelated Injuries,1
XTANDI,death,resulting death Falls and Fallrelated Injuries,1
XTANDI,death,death Falls and Fallrelated Injuries,1
XTANDI,death,two randomized clinical trials falls,0
XTANDI,death,an infection resulting death Falls and,1
XTANDI,death,two randomized clinical trials falls,0
XTANDI,death,randomized clinical trials falls,0
XTANDI,death,an infection resulting death Falls and Fallrelated Injuries In,1
XTANDI,death,randomized clinical trials falls,0
XTANDI,death,death Falls and Fallrelated,1
XTANDI,death,two randomized clinical trials,0
XTANDI,falls,falls including fallrelated injuries occurred,1
XTANDI,falls,falls,1
XTANDI,falls,falls including,1
XTANDI,falls,two randomized,0
XTANDI,falls,compared,0
XTANDI,falls,falls including,1
XTANDI,falls,trials,0
XTANDI,fall-related injuries,the two randomized clinical trials falls including,0
XTANDI,fall-related injuries,compared to of patients treated with placebo,0
XTANDI,fall-related injuries,clinical trials falls fall-related injuries occurred in of patients treated,1
XTANDI,fall-related injuries,compared to of patients treated with placebo,0
XTANDI,fall-related injuries,fall-related injuries occurred in of patients,1
XTANDI,fall-related injuries,falls fall-related injuries,1
XTANDI,fall-related injuries,fall-related injuries occurred in of patients,1
XTANDI,fall-related injuries,and Fallrelated Injuries In the two randomized clinical trials falls,0
XTANDI,loss of consciousness,loss of consciousness,1
XTANDI,loss of consciousness,loss of consciousness,1
XTANDI,loss of consciousness,associated loss of consciousness or seizure Fallrelated,1
XTANDI,loss of consciousness,loss of consciousness,1
XTANDI,loss of consciousness,seizure Fallrelated injuries were more severe in patients treated with XTANDI and,0
XTANDI,loss of consciousness,of consciousness or seizure Fallrelated injuries were,1
XTANDI,loss of consciousness,of consciousness,1
XTANDI,loss of consciousness,were more severe in patients,0
XTANDI,seizure,Falls were not associated with loss,0
XTANDI,seizure,treated with XTANDI and included nonpathologic,0
XTANDI,seizure,with placebo Falls were not associated with loss of consciousness or,0
XTANDI,seizure,consciousness seizure,1
XTANDI,seizure,with placebo Falls were not associated with loss of consciousness or,0
XTANDI,seizure,injuries were more severe in patients treated with XTANDI and included,0
XTANDI,seizure,severe in patients treated with XTANDI and included nonpathologic,0
XTANDI,seizure,consciousness seizure,1
XTANDI,seizure,severe in patients treated with XTANDI and included nonpathologic,0
XTANDI,seizure,in patients treated with XTANDI,0
XTANDI,Fall-related injuries,Fall-related injuries were more,1
XTANDI,Fall-related injuries,of consciousness or,0
XTANDI,Fall-related injuries,or Fall-related,1
XTANDI,non-pathologic fractures,non-pathologic fractures joint injuries and hematomas,1
XTANDI,non-pathologic fractures,XTANDI and non-pathologic fractures,1
XTANDI,non-pathologic fractures,non-pathologic fractures joint injuries and hematomas,1
XTANDI,non-pathologic fractures,non-pathologic fractures joint injuries,1
XTANDI,non-pathologic fractures,non-pathologic fractures joint injuries and hematomas,1
XTANDI,non-pathologic fractures,patients,0
XTANDI,non-pathologic fractures,randomized trials hypertension was,0
XTANDI,non-pathologic fractures,and hematomas Hypertension In the,0
XTANDI,non-pathologic fractures,XTANDI and non-pathologic,1
XTANDI,joint injuries,joint injuries and hematomas Hypertension In,1
XTANDI,joint injuries,XTANDI and non-pathologic,1
XTANDI,joint injuries,more severe in patients,0
XTANDI,joint injuries,joint injuries,1
XTANDI,joint injuries,and,0
XTANDI,joint injuries,joint injuries,1
XTANDI,joint injuries,and,0
XTANDI,joint injuries,XTANDI and included nonpathologic,0
XTANDI,joint injuries,included nonpathologic,0
XTANDI,joint injuries,and included nonpathologic joint injuries and,1
XTANDI,joint injuries,included nonpathologic,0
XTANDI,Hypertension,Hypertension In the two randomized trials,1
XTANDI,Hypertension,and,0
XTANDI,Hypertension,hypertension was reported in of,0
XTANDI,Hypertension,Hypertension,1
XTANDI,Hypertension,Hypertension,1
XTANDI,Hypertension,trials hypertension was reported in of patients receiving XTANDI and,0
XTANDI,Hypertension,Hypertension In the,1
XTANDI,Hypertension,trials hypertension was reported in of patients receiving XTANDI and,0
XTANDI,hypertension,hypertension was reported in of patients,1
XTANDI,hypertension,hypertension,1
XTANDI,hypertension,hypertension was reported in of patients,1
XTANDI,hypertension,hypertension was reported in of,1
XTANDI,hypertension,placebo No patients,0
XTANDI,hypertensive crisis,receiving placebo No patients hypertensive,1
XTANDI,hypertensive crisis,Hypertension led to,0
XTANDI,hypertensive crisis,hypertensive crisis,1
XTANDI,hypertensive crisis,hypertensive crisis Medical history,1
XTANDI,hypertensive crisis,hypertensive crisis Medical history of hypertension,1
XTANDI,hypertensive crisis,receiving placebo No patients hypertensive,1
XTANDI,hypertensive crisis,to study discontinuati,0
XTANDI,Hypertension,Hypertension,1
XTANDI,Seizure,cussed  in more,1
XTANDI,Seizure,cussed ,1
XTANDI,Seizure,The following is cussed ,1
XTANDI,Seizure,cussed ,1
XTANDI,seizure,"NS, con tact Astellas",1
XTANDI,seizure,"NS, con tact Astellas",1
XTANDI,seizure,"report SUSPECTED ADVERSE NS,",1
XTANDI,seizure,Pharma US Inc at or FDA at FDA,0
XTANDI,seizure,"report SUSPECTED ADVERSE NS, con",1
XTANDI,seizure,"ADVERSE NS, con",1
XTANDI,seizure,"NS, con tact Astellas Pharma",1
XTANDI,seizure,"NS, con tact Astellas Pharma US",1
XTANDI,seizure,DA at 1 FDA or wwwfdagovmedwatch Clinical Trial,1
XTANDI,Seizure,Because clinical tri,0
XTANDI,Seizure,Inc at or FDA,0
XTANDI,Seizure,Experience,0
XTANDI,Seizure,wwwfdagovmedwatch,0
XTANDI,Seizure,00-FDA- or wwwfdagovmedwatch,1
XTANDI,Seizure,00-FDA- or wwwfdagovmedwatch Clinical Trial,1
XTANDI,Seizure,at or FDA at,0
XTANDI,Seizure,00-FDA-,1
XTANDI,Seizure,Because clinical,0
XTANDI,Seizure,00-FDA-,1
XTANDI,seizure, trials of a drug cannot,1
XTANDI,seizure, trials of a drug,1
XTANDI,seizure,reaction rates observed in,0
XTANDI,seizure,the  trials of a drug cannot,1
XTANDI,seizure,reaction rates observed in,0
XTANDI,seizure, trials of,1
XTANDI,seizure, trials,1
XTANDI,seizure,rates observed in the  trials of a drug cannot be,1
XTANDI,seizure, trials,1
XTANDI,seizure,drug cannot be ectly c ompared,1
XTANDI,seizure, trials,1
XTANDI,seizure,cannot be ectly c ompared to rates in the,1
XTANDI,seizure, trials,1
XTANDI,seizure,observed in pr,0
XTANDI,seizure,a drug cannot be ectly c ompared to rates,1
XTANDI,seizure,observed in pr,0
XTANDI,seizure,cannot be ectly c,1
XTANDI,seizure,ectly c ompared to rates,1
XTANDI,seizure,ectly c ompared to rates,1
XTANDI,seizure,ectly c ompared to rates,1
XTANDI,seizure,a drug cannot be ectly c,1
XTANDI,seizure,ectly c ompared to rates,1
AFINITOR,Infections,Infections see Warnings,1
AFINITOR,Infections,see Warnings and Infections see Warnings and,1
AFINITOR,Infections,Infections see Warnings,1
AFINITOR,Infections,Warnings and Infections see Warnings and Precautions Angioedema,1
AFINITOR,Infections,Infections see Warnings,1
AFINITOR,Infections,and Infections see Warnings and,1
AFINITOR,Infections,Infections see Warnings,1
AFINITOR,Infections,see Warnings and Infections see Warnings and Precautions,1
AFINITOR,Infections,Infections see Warnings,1
AFINITOR,Infections,Infections see Warnings,1
AFINITOR,Infections,Infections see,1
AFINITOR,Angioedema,Angioedema,1
AFINITOR,Oral ulceration,Warnings,0
AFINITOR,Impaired wound healing,Impaired wound healing,1
AFINITOR,Impaired wound healing,Impaired wound healing see Warnings and Precautions,1
AFINITOR,Impaired wound healing,Impaired wound healing,1
AFINITOR,Impaired wound healing,Because clinical trials are conducted,0
AFINITOR,Impaired wound healing,Impaired,1
AFINITOR,Impaired wound healing,see Warnings and Precautions,0
AFINITOR,Impaired wound healing,Renal failure,0
AFINITOR,Impaired wound healing,wound healing see Warnings and Precautions Because,1
AFINITOR,Impaired wound healing,Impaired wound healing see Warnings and Precautions Because,1
AFINITOR,Impaired wound healing,Renal failure,0
AFINITOR,Impaired wound healing,Impaired wound healing see Warnings and Precautions,1
AFINITOR,stomatitis,stomatitis infections rash,1
AFINITOR,stomatitis,stomatitis infections rash fatigue diarrhea,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis infections rash,1
AFINITOR,stomatitis,reactions,0
AFINITOR,stomatitis,stomatitis infections,1
AFINITOR,stomatitis,stomatitis infections rash fatigue,1
AFINITOR,stomatitis,adverse reactions incidence stomatitis infections rash fatigue,1
AFINITOR,stomatitis,stomatitis infections rash fatigue,1
AFINITOR,stomatitis,stomatitis infections rash fatigue diarrhea,1
AFINITOR,stomatitis,fatigue,0
AFINITOR,infections,infections rash fatigue diarrhea edema,1
AFINITOR,infections,infections rash,1
AFINITOR,infections,cough,0
AFINITOR,infections,infections rash fatigue diarrhea edema abdominal,1
AFINITOR,infections,cough,0
AFINITOR,infections,infections rash fatigue diarrhea edema,1
AFINITOR,infections,cough,0
AFINITOR,rash,adverse,0
AFINITOR,rash,include,0
AFINITOR,rash,include stomatitis rash fatigue diarrhea edema abdominal pain,1
AFINITOR,rash,include,0
AFINITOR,rash,abdominal pain nausea fever asthenia cough headache,0
AFINITOR,fatigue,fatigue diarrhea edema abdominal pain nausea,1
AFINITOR,fatigue,fatigue,1
AFINITOR,diarrhea,cough headache and,0
AFINITOR,diarrhea,RCC Most common adverse reactions,0
AFINITOR,edema,nausea fever asthenia cough headache and decreased appetite,0
AFINITOR,edema,include stomatitis infections,0
AFINITOR,edema,edema abdominal pain nausea,1
AFINITOR,edema,fatigue edema abdominal pain nausea,1
AFINITOR,edema,edema abdominal pain nausea,1
AFINITOR,edema,infections rash fatigue edema abdominal pain nausea,1
AFINITOR,edema,edema abdominal pain nausea,1
AFINITOR,edema,diarrhea,0
AFINITOR,edema,edema abdominal pain nausea,1
AFINITOR,edema,edema abdominal pain nausea fever asthenia,1
AFINITOR,edema,common adverse,0
AFINITOR,edema,stomatitis infections rash fatigue edema abdominal pain nausea fever asthenia,1
AFINITOR,edema,common adverse,0
AFINITOR,abdominal pain,abdominal pain nausea fever asthenia cough,1
AFINITOR,abdominal pain,diarrhea edema,0
AFINITOR,abdominal pain,fatigue diarrhea edema,0
AFINITOR,abdominal pain,fatigue diarrhea abdominal pain,1
AFINITOR,nausea,nausea fever asthenia cough headache,1
AFINITOR,nausea,rash fatigue diarrhea edema,0
AFINITOR,nausea,nausea fever,1
AFINITOR,nausea,rash fatigue diarrhea edema,0
AFINITOR,nausea,abdominal nausea fever asthenia,1
AFINITOR,nausea,rash fatigue diarrhea edema,0
AFINITOR,nausea,diarrhea edema,0
AFINITOR,nausea,nausea fever asthenia cough headache and,1
AFINITOR,nausea,pain,0
AFINITOR,nausea,fatigue diarrhea edema abdominal nausea fever,1
AFINITOR,nausea,pain,0
AFINITOR,nausea,asthenia cough headache and decreased appetite Renal,0
AFINITOR,asthenia,and decreased appetite,0
AFINITOR,asthenia,angiomyolipoma,0
AFINITOR,asthenia,asthenia cough,1
AFINITOR,cough,diarrhea edema abdominal pain nausea fever asthenia,0
AFINITOR,cough,nausea fever cough,1
AFINITOR,cough,diarrhea edema abdominal pain nausea fever asthenia,0
AFINITOR,headache,with,0
AFINITOR,headache,headache and decreased appetite,1
AFINITOR,headache,headache and decreased appetite Renal angiomyolipoma,1
AFINITOR,headache,headache and decreased appetite Renal angiomyolipoma,1
AFINITOR,headache,headache and decreased appetite Renal angiomyolipoma,1
AFINITOR,headache,atitis infections rash fatigue diarrhea edema abdominal pain nausea fever asthenia cough,0
AFINITOR,headache,fatigue diarrhea edema abdominal pain nausea fever,0
AFINITOR,headache,diarrhea edema abdominal pain nausea fever,0
AFINITOR,stomatitis,adverse reactions incidence,0
AFINITOR,stomatitis,stomatitis SEGA with,1
AFINITOR,stomatitis,reactions,0
AFINITOR,stomatitis,with TSC Most,0
AFINITOR,stomatitis,stomatitis SEGA,1
AFINITOR,stomatitis,Renal angiomyolipoma with TSC Most common adverse reaction,0
AFINITOR,stomatitis,incidence stomatitis SEGA,1
AFINITOR,stomatitis,Renal angiomyolipoma with TSC Most common adverse reaction,0
AFINITOR,stomatitis,SEGA with TSC Most common adverse,0
AFINITOR,stomatitis,respiratory tract infection To,0
AFINITOR,stomatitis,adverse reactions incidence stomatitis and respiratory tract,1
AFINITOR,stomatitis,respiratory tract infection To,0
AFINITOR,stomatitis,stomatitis and respiratory tract infection,1
AFINITOR,respiratory tract infection,REACTIONS contact,0
AFINITOR,stomatitis,stomatitis infections,1
AFINITOR,stomatitis,stomatitis infections,1
AFINITOR,stomatitis,stomatitis infections rash,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis infections rash,1
AFINITOR,stomatitis,stomatitis infections rash fatigue diarrhea and,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,of approximately months The most,0
AFINITOR,stomatitis,stomatitis infections rash fatigue diarrhea,1
AFINITOR,infections,infections rash fatigue,1
AFINITOR,infections,infections rash fatigue diarrhea and decreased,1
AFINITOR,infections,common Grade,0
AFINITOR,infections,adverse,0
AFINITOR,rash,stomatitis infections,0
AFINITOR,rash,rash,1
AFINITOR,rash,rash fatigue diarrhea and decreased appetite,1
AFINITOR,rash,reactions incidence were stomatitis infections,0
AFINITOR,rash,rash fatigue diarrhea,1
AFINITOR,rash,reactions incidence were stomatitis infections,0
AFINITOR,rash,rash,1
AFINITOR,rash,were stomatitis rash fatigue diarrhea and decreased,1
AFINITOR,rash,rash,1
AFINITOR,rash,rash fatigue diarrhea and decreased appetite,1
AFINITOR,rash,rash fatigue,1
AFINITOR,rash,reactions incidence were stomatitis rash fatigue diarrhea,1
AFINITOR,rash,rash fatigue,1
AFINITOR,fatigue,fatigue diarrhea and decreased appetite The,1
AFINITOR,diarrhea,diarrhea and decreased,1
AFINITOR,diarrhea,diarrhea and decreased appetite,1
AFINITOR,diarrhea,diarrhea and decreased appetite The,1
AFINITOR,diarrhea,common adverse reactions incidence,0
AFINITOR,diarrhea,diarrhea and decreased appetite The,1
AFINITOR,diarrhea,were stomatitis infections rash diarrhea and decreased appetite The most,1
AFINITOR,diarrhea,diarrhea and decreased appetite The,1
AFINITOR,diarrhea,stomatitis infections rash diarrhea and decreased appetite The most,1
AFINITOR,diarrhea,diarrhea and decreased appetite The,1
AFINITOR,diarrhea,Grade,0
AFINITOR,decreased appetite,reactions incidence were stomatitis,0
AFINITOR,decreased appetite,rash fatigue diarrhea decreased appetite The most common Grade adverse,1
AFINITOR,decreased appetite,reactions incidence were stomatitis,0
AFINITOR,decreased appetite,decreased appetite The most common,1
AFINITOR,decreased appetite,decreased appetite The most common Grade adverse,1
AFINITOR,decreased appetite,fatigue diarrhea decreased appetite The most common Grade adverse,1
AFINITOR,decreased appetite,decreased appetite The most common Grade adverse,1
AFINITOR,decreased appetite,and,0
AFINITOR,decreased appetite,The most common Grade adverse reactions incidence,0
AFINITOR,stomatitis,stomatitis infections,1
AFINITOR,stomatitis,The most common Grade adverse reactions incidence,0
AFINITOR,stomatitis,stomatitis infections hyperglycemia fatigue,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,The most common,0
AFINITOR,stomatitis,pneumonitis and diarrhea The most common,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis infections hyperglycemia fatigue,1
AFINITOR,infections,pneumonitis and diarrhea The most common laboratory abnormaliti,0
AFINITOR,infections,infections hyperglycemia,1
AFINITOR,infections,fatigue dyspnea pneumonitis and diarrhea,0
AFINITOR,infections,decreased appetite The most,0
AFINITOR,infections,decreased appetite The most common Grade adverse reactions incidence,0
AFINITOR,infections,most common Grade,0
AFINITOR,infections,and diarrhea The most common laboratory abnormaliti,0
AFINITOR,infections,pneumonitis and diarrhea The,0
AFINITOR,hyperglycemia,hyperglycemia fatigue dyspnea,1
AFINITOR,hyperglycemia,were stomatitis hyperglycemia fatigue dyspnea pneumonitis and,1
AFINITOR,hyperglycemia,hyperglycemia fatigue dyspnea,1
AFINITOR,hyperglycemia,hyperglycemia fatigue,1
AFINITOR,hyperglycemia,were stomatitis hyperglycemia fatigue,1
AFINITOR,hyperglycemia,hyperglycemia fatigue,1
AFINITOR,hyperglycemia,common laboratory,0
AFINITOR,hyperglycemia,hyperglycemia fatigue dyspnea pneumonitis and diarrhea,1
AFINITOR,hyperglycemia,were stomatitis hyperglycemia fatigue dyspnea pneumonitis,1
AFINITOR,hyperglycemia,hyperglycemia fatigue dyspnea pneumonitis and diarrhea,1
AFINITOR,hyperglycemia,laboratory abnormalities,0
AFINITOR,dyspnea,hyperglycemia,0
AFINITOR,dyspnea,infections,0
AFINITOR,pneumonitis,pneumonitis and diarrhea The most common,1
AFINITOR,pneumonitis,laboratory abnormalities incidence were,0
AFINITOR,diarrhea,abnormalities,0
AFINITOR,diarrhea,diarrhea,1
AFINITOR,diarrhea,fatigue dyspnea pneumonitis diarrhea The most common laboratory,1
AFINITOR,diarrhea,diarrhea,1
AFINITOR,diarrhea,diarrhea The,1
AFINITOR,diarrhea,diarrhea The,1
AFINITOR,diarrhea,fatigue dyspnea pneumonitis diarrhea The most,1
AFINITOR,diarrhea,diarrhea The,1
AFINITOR,diarrhea,hyperglycemia fatigue dyspnea pneumonitis diarrhea The most common laboratory,1
AFINITOR,diarrhea,diarrhea The,1
AFINITOR,diarrhea,diarrhea The most common laboratory abnormalities,1
AFINITOR,diarrhea,diarrhea The most common laboratory,1
AFINITOR,hypercholesterolemia,common laboratory abnormalities incidence were,0
AFINITOR,hypercholesterolemia,aspartate transaminase AST,0
AFINITOR,hypercholesterolemia,hypercholesterolemia hyperglycemia,1
AFINITOR,hypercholesterolemia,transaminase AST,0
AFINITOR,hypercholesterolemia,hypercholesterolemia hyperglycemia increased aspartate transaminase AST,1
AFINITOR,hyperglycemia,leukopenia thrombocytopenia lymphopenia,0
AFINITOR,hyperglycemia,hypercholesterolemia,0
AFINITOR,increased aspartate transaminase,e most common laboratory,0
AFINITOR,anemia,transaminase anemia leukopenia thrombocytopenia lymphopenia,1
AFINITOR,anemia,e most common laboratory,0
AFINITOR,anemia,aspartate transaminase,0
AFINITOR,anemia,hyperglycemia increased aspartate transaminase,0
AFINITOR,anemia,thrombocytopenia lymphopenia,0
AFINITOR,anemia,anemia leukopenia thrombocytopenia,1
AFINITOR,anemia,thrombocytopenia lymphopenia,0
AFINITOR,anemia,anemia leukopenia thrombocytopenia,1
AFINITOR,anemia,AST,0
AFINITOR,anemia,aspartate,0
AFINITOR,anemia,anemia,1
AFINITOR,anemia,AST,0
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,transaminase AST leukopenia thrombocytopenia lymphopenia increased alanine,1
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,leukopenia thrombocytopenia,1
AFINITOR,leukopenia,leukopenia thrombocytopenia lymphopenia increased,1
AFINITOR,leukopenia,aspartate transaminase AST leukopenia thrombocytopenia lymphopenia,1
AFINITOR,leukopenia,leukopenia thrombocytopenia lymphopenia increased,1
AFINITOR,thrombocytopenia,thrombocytopenia lymphopenia increased,1
AFINITOR,thrombocytopenia,aspartate transaminase AST anemia thrombocytopenia lymphopenia,1
AFINITOR,thrombocytopenia,thrombocytopenia lymphopenia increased,1
AFINITOR,thrombocytopenia,most common Grade,0
AFINITOR,thrombocytopenia,thrombocytopenia,1
AFINITOR,thrombocytopenia,thrombocytopenia lymphopenia,1
AFINITOR,lymphopenia,and hypertriglyceridemia The most common,0
AFINITOR,lymphopenia,lymphopenia increased alanine transaminase ALT and,1
AFINITOR,lymphopenia,and hypertriglyceridemia The most common,0
AFINITOR,lymphopenia,lymphopenia increased alanine,1
AFINITOR,lymphopenia,lymphopenia increased,1
AFINITOR,lymphopenia,most common,0
AFINITOR,lymphopenia,lymphopenia increased alanine transaminase ALT,1
AFINITOR,lymphopenia,transaminase AST anemia leukopenia lymphopenia increased alanine transaminase,1
AFINITOR,lymphopenia,lymphopenia increased alanine transaminase ALT,1
AFINITOR,lymphopenia,lymphopenia increased alanine,1
AFINITOR,increased alanine transaminase,ALT and,0
AFINITOR,increased alanine transaminase,laboratory abnormalities incidence,0
AFINITOR,increased alanine transaminase,alanine transaminase ALT and hypertriglyceridemia The,1
AFINITOR,increased alanine transaminase,AST anemia leukopenia thrombocytopenia increased alanine transaminase ALT and hypertriglyceridemia The,1
AFINITOR,increased alanine transaminase,alanine transaminase ALT and hypertriglyceridemia The,1
AFINITOR,lymphopenia,were,0
AFINITOR,lymphopenia,potassium increased AST increased ALT and,0
AFINITOR,lymphopenia,incidence lymphopenia hyperglycemia,1
AFINITOR,lymphopenia,potassium increased AST increased ALT and,0
AFINITOR,lymphopenia,AST increased ALT and thrombocytopenia,0
AFINITOR,lymphopenia,Grade laboratory abnormalities incidence lymphopenia hyperglycemia anemia decreased potassium,1
AFINITOR,lymphopenia,AST increased ALT and thrombocytopenia,0
AFINITOR,lymphopenia,AST increased,0
AFINITOR,lymphopenia,Grade laboratory,0
AFINITOR,hyperglycemia,abnormalities incidence were hyperglycemia anemia decreased potassium increased,1
AFINITOR,hyperglycemia,Grade laboratory,0
AFINITOR,hyperglycemia,ALT and thrombocytopenia,0
AFINITOR,hyperglycemia,were,0
AFINITOR,hyperglycemia,hyperglycemia anemia decreased potassium increased,1
AFINITOR,hyperglycemia,hyperglycemia anemia decreased potassium,1
AFINITOR,hyperglycemia,anemia decreased potassium increased AST,0
AFINITOR,anemia,abnormalities,0
AFINITOR,anemia,anemia decreased,1
AFINITOR,anemia,lymphopenia anemia decreased potassium increased AST increased,1
AFINITOR,anemia,anemia decreased,1
AFINITOR,anemia,increased AST increased ALT and,0
AFINITOR,anemia,anemia,1
AFINITOR,anemia,ALT and thrombocytopenia Fatal adverse reactio,0
AFINITOR,anemia,anemia decreased potassium increased,1
AFINITOR,anemia,AST increased ALT and,0
AFINITOR,decreased potassium,lymphopenia hyperglycemia decreased potassium increased AST increased ALT,1
AFINITOR,decreased potassium,AST increased ALT and,0
AFINITOR,decreased potassium,decreased potassium,1
AFINITOR,decreased potassium,reactions occurred,0
AFINITOR,decreased potassium,AST,0
AFINITOR,decreased potassium,decreased potassium increased AST,1
AFINITOR,decreased potassium,decreased potassium increased,1
AFINITOR,decreased potassium,decreased potassium increased AST,1
AFINITOR,decreased potassium,ommon Grade,0
AFINITOR,decreased potassium,adverse reactions occurred more,0
AFINITOR,increased AST,hyperglycemia anemia decreased increased AST increased ALT,1
AFINITOR,increased AST,adverse reactions occurred more,0
AFINITOR,increased AST,hyperglycemia anemia decreased increased AST,1
AFINITOR,increased AST,anemia,0
AFINITOR,increased AST,atory abnormalities incidence were,0
AFINITOR,increased AST,thrombocytopenia Fatal,0
AFINITOR,increased ALT,patients who,0
AFINITOR,increased ALT,increased ALT,1
AFINITOR,increased ALT,decreased potassium increased increased ALT,1
AFINITOR,increased ALT,anemia decreased potassium increased increased ALT and thrombocytopenia Fatal adverse reactions,1
AFINITOR,increased ALT,decreased potassium increased increased ALT,1
AFINITOR,increased ALT,decreased potassium increased increased ALT and thrombocytopenia,1
AFINITOR,increased ALT,decreased potassium increased increased ALT,1
AFINITOR,thrombocytopenia,Fatal adverse reactions occurred,0
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse reactions occurred more,1
AFINITOR,thrombocytopenia,increased AST increased ALT thrombocytopenia Fatal adverse,1
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse reactions occurred more,1
AFINITOR,thrombocytopenia,potassium increased AST increased ALT,0
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse reactions,1
AFINITOR,thrombocytopenia,decreased potassium,0
AFINITOR,thrombocytopenia,decreased potassium increased AST increased,0
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse,1
AFINITOR,thrombocytopenia,AST increased ALT thrombocytopenia,1
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse,1
AFINITOR,thrombocytopenia,thrombocytopenia Fatal adverse reactions occurred more,1
AFINITOR,Fatal,received AFINITOR plus exemestane c,0
AFINITOR,Fatal,AFINITOR plus exemestane,0
AFINITOR,Fatal,Fatal adverse reactions,1
AFINITOR,stomatitis,b stomatitis,1
AFINITOR,stomatitis,Fatal adverse reactions,1
AFINITOR,stomatitis,stomatitis mouth ulceration aphthous stomatitis glossodynia,1
AFINITOR,stomatitis,stomatitis mouth ulceration aphthous,1
AFINITOR,stomatitis,gingival pain glossitis and lip,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis mouth ulceration,1
AFINITOR,aphthous stomatitis,a period of weeks a Exemestane mgday b Includes stomatitis mouth ulceration,0
AFINITOR,aphthous stomatitis,ulceration c Includes,0
AFINITOR,aphthous stomatitis,aphthous stomatitis glossodynia gingival,1
AFINITOR,aphthous stomatitis,y for a period,0
AFINITOR,aphthous stomatitis,Includes stomatitis mouth aphthous stomatitis glossodynia gingival pain glossitis,1
AFINITOR,aphthous stomatitis,y for a period,0
AFINITOR,aphthous stomatitis,aphthous stomatitis glossodynia,1
AFINITOR,aphthous stomatitis,aphthous stomatitis glossodynia gingival pain,1
AFINITOR,aphthous stomatitis,aphthous stomatitis glossodynia,1
AFINITOR,aphthous stomatitis,gingival,0
AFINITOR,aphthous stomatitis,Includes stomatitis mouth aphthous stomatitis glossodynia gingival pain,1
AFINITOR,aphthous stomatitis,gingival,0
AFINITOR,aphthous stomatitis,ulceration,0
AFINITOR,glossodynia,Includes stomatitis,0
AFINITOR,glossodynia,ulceration aphthous glossodynia gingival pain glossitis and,1
AFINITOR,glossodynia,Includes stomatitis,0
AFINITOR,glossodynia,b Includes stomatitis mouth,0
AFINITOR,glossodynia,glossodynia gingival pain glossitis and,1
AFINITOR,glossodynia,a Exemestane,0
AFINITOR,glossodynia,Includes,0
AFINITOR,glossodynia,mgday b Includes stomatitis,0
AFINITOR,glossodynia,glossodynia gingival pain glossitis and lip,1
AFINITOR,glossodynia,stomatitis mouth ulceration aphthous glossodynia gingival,1
AFINITOR,glossodynia,glossodynia gingival pain glossitis and lip,1
AFINITOR,gingival pain,gingival pain glossitis and lip ulceration c,1
AFINITOR,gingival pain,aphthous stomatitis gingival,1
AFINITOR,gingival pain,stomatitis mouth ulceration aphthous stomatitis,0
AFINITOR,gingival pain,ulceration c Includes all preferred terms within the infections and,0
AFINITOR,gingival pain,preferred terms within the infections and,0
AFINITOR,gingival pain,gingival pain glossitis and lip ulceration,1
AFINITOR,gingival pain,stomatitis gingival pain,1
AFINITOR,gingival pain,mouth,0
AFINITOR,gingival pain,and lip,0
AFINITOR,glossitis,and,0
AFINITOR,glossitis,gingival glossitis and lip ulceration c,1
AFINITOR,glossitis,and,0
AFINITOR,glossitis,glossitis,1
AFINITOR,lip ulceration,aphthous stomatitis,0
AFINITOR,lip ulceration,glossitis lip,1
AFINITOR,lip ulceration,and infestations system organ class the,0
AFINITOR,lip ulceration,stomatitis glossodynia,0
AFINITOR,lip ulceration,pain glossitis lip ulceration c,1
AFINITOR,lip ulceration,stomatitis glossodynia,0
AFINITOR,lip ulceration,glossodynia gingival pain glossitis lip,1
AFINITOR,lip ulceration,pain glossitis lip ulceration,1
AFINITOR,lip ulceration,glossodynia gingival pain glossitis lip,1
AFINITOR,lip ulceration,lip ulceration c Includes all preferred terms,1
AFINITOR,nasopharyngitis,urinary tract infection upper,0
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract infection,1
AFINITOR,nasopharyngitis,the most,0
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract infection upper respiratory,1
AFINITOR,nasopharyngitis,class,0
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract,1
AFINITOR,nasopharyngitis,nasopharyngitis urinary tract infection upper,1
AFINITOR,urinary tract infection,being,0
AFINITOR,urinary tract infection,being urinary tract infection upper respiratory tract infection,1
AFINITOR,urinary tract infection,being,0
AFINITOR,urinary tract infection,common being urinary tract,1
AFINITOR,urinary tract infection,infections and infestations system organ class,0
AFINITOR,urinary tract infection,urinary tract infection upper respiratory tract infection,1
AFINITOR,upper respiratory tract infection,the most common being nasopharyngitis urinary tract,0
AFINITOR,upper respiratory tract infection,being,0
AFINITOR,upper respiratory tract infection,organ class the most,0
AFINITOR,upper respiratory tract infection,upper,1
AFINITOR,upper respiratory tract infection,being nasopharyngitis urinary tract upper respiratory tract infection,1
AFINITOR,upper respiratory tract infection,cystitis sinusitis and also including candidiasi,0
AFINITOR,upper respiratory tract infection,tract upper respiratory,1
AFINITOR,upper respiratory tract infection,system organ class the most common being nasopharyngitis,0
AFINITOR,upper respiratory tract infection,nasopharyngitis urinary tract upper,1
AFINITOR,pneumonia,pneumonia bronchitis cystitis,1
AFINITOR,pneumonia,infection upper respiratory tract pneumonia bronchitis,1
AFINITOR,pneumonia,pneumonia bronchitis cystitis,1
AFINITOR,pneumonia,infection upper,0
AFINITOR,pneumonia,tract pneumonia,1
AFINITOR,pneumonia,infection upper,0
AFINITOR,pneumonia,infection,0
AFINITOR,pneumonia,pneumonia bronchitis cystitis sinusitis,1
AFINITOR,pneumonia,infection upper respiratory tract pneumonia bronchitis cystitis sinusitis and,1
AFINITOR,pneumonia,pneumonia bronchitis cystitis sinusitis,1
AFINITOR,pneumonia,pneumonia bronchitis cystitis,1
AFINITOR,pneumonia,and also including,0
AFINITOR,pneumonia,infection,0
AFINITOR,bronchitis,bronchitis cystitis sinusitis and also including,1
AFINITOR,bronchitis,bronchitis cystitis sinusitis and also,1
AFINITOR,bronchitis,bronchitis cystitis sinusitis and also including,1
AFINITOR,bronchitis,including,0
AFINITOR,cystitis,tract infection pneumonia cystitis sinusitis and also including,1
AFINITOR,cystitis,including,0
AFINITOR,cystitis,upper respiratory tract infection pneumonia,0
AFINITOR,cystitis,pneumonia bronchitis,0
AFINITOR,cystitis,candidiasis and,0
AFINITOR,cystitis,cystitis sinusitis and,1
AFINITOR,cystitis,cystitis sinusitis and also including,1
AFINITOR,cystitis,cystitis sinusitis and,1
AFINITOR,cystitis,cystitis sinusitis,1
AFINITOR,cystitis,cystitis sinusitis and,1
AFINITOR,sinusitis,sinusitis and also including candidiasis and,1
AFINITOR,sinusitis,cystitis,0
AFINITOR,sinusitis,pneumonia,0
AFINITOR,sinusitis,hepatitis C d,0
AFINITOR,sinusitis,C,0
AFINITOR,sinusitis,pneumonia bronchitis cystitis,0
AFINITOR,sinusitis,also including candidiasis and sepsis and hepatitis,0
AFINITOR,sinusitis,pneumonia,0
AFINITOR,candidiasis,also candidiasis,1
AFINITOR,candidiasis,pneumonia,0
AFINITOR,candidiasis,also candidiasis and sepsis and,1
AFINITOR,candidiasis,pneumonia,0
AFINITOR,candidiasis,candidiasis and,1
AFINITOR,candidiasis,hepatitis,0
AFINITOR,candidiasis,sinusitis and also candidiasis and sepsis and hepatitis C,1
AFINITOR,candidiasis,hepatitis,0
AFINITOR,sepsis,candidiasis sepsis and hepatitis C d,1
AFINITOR,sepsis,hepatitis,0
AFINITOR,sepsis,including candidiasis sepsis and hepatitis,1
AFINITOR,sepsis,hepatitis,0
AFINITOR,sepsis,including candidiasis sepsis and,1
AFINITOR,sepsis,hepatitis,0
AFINITOR,sepsis,candidiasis sepsis and hepatitis C d,1
AFINITOR,sepsis,hepatitis,0
AFINITOR,sepsis,sepsis and hepatitis,1
AFINITOR,sepsis,interstitial,0
AFINITOR,sepsis,sepsis and hepatitis C d,1
AFINITOR,sepsis,and hepatitis C d Includes pneumonitis interstitial lung disease,0
AFINITOR,hepatitis C,lung,0
AFINITOR,pneumonitis,pneumonitis interstitial lung,1
AFINITOR,pneumonitis,lung,0
AFINITOR,pneumonitis,d pneumonitis interstitial lung,1
AFINITOR,pneumonitis,lung,0
AFINITOR,pneumonitis,C d pneumonitis interstitial,1
AFINITOR,pneumonitis,lung,0
AFINITOR,pneumonitis,interstitial lung disease lung infiltration and,0
AFINITOR,pneumonitis,sepsis and,0
AFINITOR,pneumonitis,and also including candidiasis and sepsis and hepatitis C,0
AFINITOR,pneumonitis,pneumonitis interstitial lung,1
AFINITOR,pneumonitis,pneumonitis interstitial lung disease lung,1
AFINITOR,pneumonitis,Exposure,0
AFINITOR,interstitial lung disease,interstitial lung disease lung,1
AFINITOR,interstitial lung disease,Includes interstitial lung disease lung infiltration and,1
AFINITOR,interstitial lung disease,interstitial lung disease lung,1
AFINITOR,interstitial lung disease,interstitial lung,1
AFINITOR,interstitial lung disease,d Includes interstitial lung,1
AFINITOR,interstitial lung disease,Includes interstitial lung disease lung infiltration and pulmonary,1
AFINITOR,interstitial lung disease,d Includes interstitial lung,1
AFINITOR,interstitial lung disease,C d Includes interstitial,1
AFINITOR,interstitial lung disease,lung infiltration and pulmonary,0
AFINITOR,interstitial lung disease,interstitial lung disease lung infiltration and,1
AFINITOR,interstitial lung disease,hepatitis C d Includes interstitial,1
AFINITOR,lung infiltration,Includes pneumonitis interstitial lung lung infiltration,1
AFINITOR,lung infiltration,hepatitis C d Includes interstitial,1
AFINITOR,lung infiltration,lung infiltration and pulmonary fibrosis e,1
AFINITOR,lung infiltration,lung disease,0
AFINITOR,lung infiltration,lung infiltration,1
AFINITOR,lung infiltration,lung infiltration and pulmonary,1
AFINITOR,lung infiltration,interstitial lung lung infiltration,1
AFINITOR,lung infiltration,lung lung infiltration,1
AFINITOR,pulmonary fibrosis,pulmonary fibrosis,1
AFINITOR,pulmonary fibrosis,infiltration and,0
AFINITOR,pulmonary fibrosis,disease lung infiltration pulmonary fibrosis,1
AFINITOR,pulmonary fibrosis,pulmonary,1
AFINITOR,pulmonary fibrosis,pneumonitis,0
AFINITOR,pulmonary fibrosis,pneumonitis interstitial lung disease lung infiltration,0
AFINITOR,pulmonary fibrosis,disease lung infiltration pulmonary fibrosis,1
AFINITOR,pulmonary fibrosis,infiltration pulmonary,1
AFINITOR,anemia,reports of,0
AFINITOR,anemia,Reflects corresponding adverse drug,0
AFINITOR,anemia,collectively as pancytopenia,0
AFINITOR,anemia,reports anemia leukopenia lymphopenia neutropenia and,1
AFINITOR,anemia,collectively as pancytopenia,0
AFINITOR,anemia,and thrombocytopenia,0
AFINITOR,anemia,anemia leukopenia lymphopenia neutropenia and thrombocytopenia,1
AFINITOR,anemia,and thrombocytopenia,0
AFINITOR,anemia,anemia leukopenia lymphopenia neutropenia and,1
AFINITOR,anemia,and thrombocytopenia collectively as pancytopenia which,0
AFINITOR,anemia,thrombocytopenia collectively as pancytopenia which o,0
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,leukopenia lymphopenia,1
AFINITOR,leukopenia,as pancytopenia which occurred at l,0
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,leukopenia lymphopenia neutropenia and thrombocytopenia,1
AFINITOR,leukopenia,anemia,0
AFINITOR,leukopenia,neutropenia and thrombocytopenia collectively as pancytopenia which,0
AFINITOR,leukopenia,reports,0
AFINITOR,leukopenia,reports of leukopenia lymphopenia neutropenia and,1
AFINITOR,leukopenia,reports,0
AFINITOR,leukopenia,neutropenia and thrombocytopenia collectively,0
AFINITOR,lymphopenia,reports of anemia lymphopenia,1
AFINITOR,lymphopenia,neutropenia and thrombocytopenia collectively,0
AFINITOR,lymphopenia,pancytopenia which,0
AFINITOR,lymphopenia,Reflects corresponding adverse drug reaction reports,0
AFINITOR,lymphopenia,lymphopenia neutropenia and thrombocytopenia collectively,1
AFINITOR,lymphopenia,lymphopenia neutropenia and thrombocytopenia,1
AFINITOR,lymphopenia,lymphopenia neutropenia and thrombocytopenia collectively,1
AFINITOR,neutropenia,neutropenia and thrombocytopenia collectively as,1
AFINITOR,neutropenia,occurred at lower frequency,0
AFINITOR,neutropenia,b Reflects corresponding adverse drug reaction reports,0
AFINITOR,neutropenia,reports of,0
AFINITOR,neutropenia,anemia leukopenia neutropenia and thrombocytopenia collectively as,1
AFINITOR,neutropenia,reports of,0
AFINITOR,neutropenia,neutropenia and thrombocytopenia collectively as,1
AFINITOR,neutropenia,reports of,0
AFINITOR,neutropenia,at lower frequency,0
AFINITOR,neutropenia,at lower frequency L,0
AFINITOR,neutropenia,gday b Reflects corresponding adverse drug reaction,0
AFINITOR,neutropenia,neutropenia and thrombocytopenia collectively,1
AFINITOR,thrombocytopenia,anemia leukopenia lymphopenia neutropenia thrombocytopenia collectively as pancytopenia which,1
AFINITOR,thrombocytopenia,neutropenia and thrombocytopenia collectively,1
AFINITOR,thrombocytopenia,thrombocytopenia collectively,1
AFINITOR,thrombocytopenia,thrombocytopenia,1
AFINITOR,thrombocytopenia,thrombocytopenia,1
AFINITOR,thrombocytopenia,leukopenia lymphopenia neutropenia and,0
AFINITOR,thrombocytopenia,which occurred,0
AFINITOR,thrombocytopenia,thrombocytopenia collectively,1
AFINITOR,thrombocytopenia,thrombocytopenia collectively as pancytopenia,1
AFINITOR,thrombocytopenia,thrombocytopenia collectively as,1
AFINITOR,thrombocytopenia,thrombocytopenia collectively as pancytopenia,1
AFINITOR,thrombocytopenia,thrombocytopenia,1
AFINITOR,pancytopenia,pancytopenia which occurred at,1
AFINITOR,pancytopenia,pancytopenia which occurred at lower,1
AFINITOR,pancytopenia,pancytopenia which occurred at,1
AFINITOR,pancytopenia,thrombocytopenia collectively pancytopenia which occurred at,1
AFINITOR,pancytopenia,pancytopenia which occurred at,1
AFINITOR,rash,headache The most common Grade,0
AFINITOR,rash,rash diarrhea fatigue edema abdominal pain,1
AFINITOR,diarrhea,diarrhea,1
AFINITOR,diarrhea,and headache The most common Grade adverse rea,0
AFINITOR,diarrhea,nausea fever,0
AFINITOR,diarrhea,diarrhea fatigue edema,1
AFINITOR,diarrhea,stomatitis diarrhea fatigue edema abdominal pain nausea,1
AFINITOR,diarrhea,diarrhea fatigue edema,1
AFINITOR,diarrhea,nausea fever and headache The most common,0
AFINITOR,diarrhea,The most common adverse reactions incidence,0
AFINITOR,diarrhea,diarrhea fatigue edema abdominal pain nausea,1
AFINITOR,diarrhea,The most common adverse reactions incidence,0
AFINITOR,diarrhea,diarrhea fatigue edema abdominal,1
AFINITOR,diarrhea,The most common adverse reactions incidence,0
AFINITOR,fatigue,fatigue,1
AFINITOR,fatigue,fatigue,1
AFINITOR,fatigue,fatigue edema abdominal pain nausea,1
AFINITOR,fatigue,abdominal pain nausea fever,0
AFINITOR,fatigue,adverse reactions incidence,0
AFINITOR,fatigue,fatigue,1
AFINITOR,fatigue,rash,0
AFINITOR,fatigue,fatigue edema abdominal pain,1
AFINITOR,edema,fatigue,0
AFINITOR,abdominal pain,abdominal,1
AFINITOR,abdominal pain,reactions incidence,0
AFINITOR,abdominal pain,stomatitis rash diarrhea fatigue abdominal pain nausea fever and headache,1
AFINITOR,abdominal pain,reactions incidence,0
AFINITOR,abdominal pain,Grade adverse reactions,0
AFINITOR,abdominal pain,abdominal,1
AFINITOR,abdominal pain,diarrhea fatigue abdominal pain,1
AFINITOR,abdominal pain,most common Grade adverse reactions incidence,0
AFINITOR,abdominal pain,rash diarrhea fatigue abdominal,1
AFINITOR,nausea,nausea fever and,1
AFINITOR,nausea,incidence were,0
AFINITOR,nausea,nausea,1
AFINITOR,nausea,fatigue edema abdominal nausea fever and headache The most,1
AFINITOR,nausea,nausea,1
AFINITOR,nausea,edema abdominal nausea,1
AFINITOR,nausea,nausea,1
AFINITOR,nausea,nausea fever and headache The most,1
AFINITOR,nausea,diarrhea fatigue edema abdominal nausea fever and headache,1
AFINITOR,nausea,nausea fever and headache The most,1
AFINITOR,nausea,edema abdominal nausea fever and headache The most,1
AFINITOR,nausea,nausea fever and headache The most,1
AFINITOR,nausea,pain,0
AFINITOR,nausea,nausea fever and,1
AFINITOR,nausea,pain,0
AFINITOR,fever,Grade,0
AFINITOR,fever,fever,1
AFINITOR,fever,were stomatitis rash diarrhea fatigue edema,0
AFINITOR,fever,fatigue edema abdominal pain fever and headache The most,1
AFINITOR,fever,were stomatitis rash diarrhea fatigue edema,0
AFINITOR,fever,fever and headache,1
AFINITOR,fever,fever,1
AFINITOR,fever,fever and headache The most,1
AFINITOR,headache,headache The,1
AFINITOR,headache,pain nausea fever and,0
AFINITOR,headache,fever,0
AFINITOR,headache,adverse,0
AFINITOR,headache,abdominal pain nausea,0
AFINITOR,diarrhea,er and headache The most common Grade adverse reactions,0
AFINITOR,diarrhea,diarrhea The most,1
AFINITOR,diarrhea,were stomatitis and,0
AFINITOR,decreased hemoglobin,were stomatitis and,0
AFINITOR,decreased hemoglobin,decreased hemoglobin hyperglycemia alkaline phosphatase increased,1
AFINITOR,decreased hemoglobin,were stomatitis and,0
AFINITOR,decreased hemoglobin,decreased hemoglobin hyperglycemia alkaline phosphatase,1
AFINITOR,hyperglycemia,hyperglycemia alkaline phosphatase,1
AFINITOR,hyperglycemia,abnormalities incidence were decreased hyperglycemia alkaline phosphatase increased hypercholesterolemia bicarbonate,1
AFINITOR,hyperglycemia,hyperglycemia alkaline phosphatase,1
AFINITOR,hyperglycemia,common laboratory abnormalities incidence were decreased,0
AFINITOR,hyperglycemia,hyperglycemia alkaline phosphatase increased,1
AFINITOR,hyperglycemia,hyperglycemia alkaline,1
AFINITOR,hyperglycemia,bicarbonate decreased,0
AFINITOR,hyperglycemia,abnormalities incidence were decreased hyperglycemia,1
AFINITOR,hyperglycemia,bicarbonate decreased,0
AFINITOR,hyperglycemia,hyperglycemia alkaline,1
AFINITOR,hyperglycemia,hyperglycemia,1
AFINITOR,hypercholesterolemia,phosphatase hypercholesterolemia,1
AFINITOR,hypercholesterolemia,hyperglycemia,1
AFINITOR,hypercholesterolemia,decreased hemoglobin hyperglycemia alkaline phosphatase,0
AFINITOR,hypercholesterolemia,alkaline phosphatase increased,0
AFINITOR,hypercholesterolemia,hypercholesterolemia bicarbonate,1
AFINITOR,hypercholesterolemia,lities incidence were decreased hemoglobin hyperglycemia,0
AFINITOR,hypercholesterolemia,hypercholesterolemia,1
AFINITOR,increased aspartate transaminase,hypercholesterolemia bicarbonate decreased increased aspartate transaminase AST The most common Grade,1
AFINITOR,increased aspartate transaminase,hypercholesterolemia,1
AFINITOR,increased aspartate transaminase,abnormalities,0
AFINITOR,increased aspartate transaminase,hypercholesterolemia bicarbonate decreased increased aspartate transaminase AST The most common,1
AFINITOR,increased aspartate transaminase,abnormalities,0
AFINITOR,increased aspartate transaminase,aspartate transaminase,1
AFINITOR,increased aspartate transaminase,aspartate transaminase,1
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST The most common Grade,1
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST The,1
AFINITOR,increased aspartate transaminase,phosphatase increased,0
AFINITOR,increased aspartate transaminase,aspartate transaminase AST,1
AFINITOR,increased aspartate transaminase,decreased increased aspartate transaminase,1
AFINITOR,increased aspartate transaminase,aspartate transaminase AST,1
AFINITOR,hyperglycemia,hyperglycemia lymphopenia decreased hemoglobin hypophosphatemia,1
AFINITOR,hyperglycemia,hyperglycemia lymphopenia decreased hemoglobin,1
AFINITOR,lymphopenia,were lymphopenia decreased hemoglobin hypophosphatemia increased,1
AFINITOR,lymphopenia,hyperglycemia lymphopenia decreased hemoglobin,1
AFINITOR,lymphopenia,lymphopenia decreased hemoglobin hypophosphatemia increased alkaline,1
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,decreased hemoglobin,increased aspartate,0
AFINITOR,decreased hemoglobin,laboratory,0
AFINITOR,decreased hemoglobin,were hyperglycemia lymphopenia,0
AFINITOR,decreased hemoglobin,lymphopenia,0
AFINITOR,decreased hemoglobin,decreased hemoglobin,1
AFINITOR,decreased hemoglobin,were hyperglycemia decreased hemoglobin hypophosphatemia,1
AFINITOR,decreased hemoglobin,decreased hemoglobin,1
AFINITOR,hypophosphatemia,hypophosphatemia,1
AFINITOR,hypophosphatemia,hypophosphatemia increased alkaline phosphatase neutropenia increased,1
AFINITOR,hypophosphatemia,hypophosphatemia increased alkaline phosphatase neutropenia,1
AFINITOR,hypophosphatemia,decreased hypophosphatemia increased alkaline phosphatase neutropenia increased,1
AFINITOR,hypophosphatemia,hypophosphatemia increased alkaline phosphatase neutropenia,1
AFINITOR,hypophosphatemia,hyperglycemia lymphopenia decreased hypophosphatemia increased alkaline phosphatase neutropenia increased,1
AFINITOR,hypophosphatemia,hypophosphatemia increased alkaline phosphatase neutropenia,1
AFINITOR,hypophosphatemia,lymphopenia decreased hypophosphatemia increased alkaline phosphatase neutropenia increased,1
AFINITOR,hypophosphatemia,hypophosphatemia increased alkaline phosphatase neutropenia,1
AFINITOR,hypophosphatemia,were hyperglycemia lymphopenia decreased hypophosphatemia increased alkaline phosphatase neutropenia,1
AFINITOR,hypophosphatemia,hypophosphatemia increased alkaline phosphatase neutropenia,1
AFINITOR,increased alkaline phosphatase,increased alkaline phosphatase neutropenia increased aspartate transaminase,1
AFINITOR,increased alkaline phosphatase,hypophosphatemia increased alkaline phosphatase neutropenia,1
AFINITOR,increased alkaline phosphatase,hemoglobin increased alkaline,1
AFINITOR,increased alkaline phosphatase,increased alkaline phosphatase neutropenia increased,1
AFINITOR,increased alkaline phosphatase,hemoglobin increased,1
AFINITOR,increased alkaline phosphatase,increased aspartate transaminase,0
AFINITOR,increased alkaline phosphatase,decreased,0
AFINITOR,increased alkaline phosphatase,incidence were,0
AFINITOR,increased alkaline phosphatase,AST potassium decreased,0
AFINITOR,increased alkaline phosphatase,lymphopenia decreased hemoglobin increased,1
AFINITOR,neutropenia,hypophosphatemia increased alkaline,0
AFINITOR,neutropenia,neutropenia increased aspartate transaminase,1
AFINITOR,neutropenia,hypophosphatemia increased alkaline,0
AFINITOR,neutropenia,decreased hemoglobin hypophosphatemia,0
AFINITOR,neutropenia,decreased hemoglobin,0
AFINITOR,neutropenia,thrombocytopenia,0
AFINITOR,neutropenia,and thrombocytopenia Deaths during,0
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST potassium decreased,1
AFINITOR,increased aspartate transaminase,phosphatase,0
AFINITOR,increased aspartate transaminase,phosphatase,0
AFINITOR,increased aspartate transaminase,decreased and thrombocytopenia Deaths during doubleblind treatment where an ad,0
AFINITOR,increased aspartate transaminase,increased aspartate transaminase AST potassium decreased and thrombocytopenia,1
AFINITOR,thrombocytopenia,potassium decreased thrombocytopenia Deaths during doubleblind,1
AFINITOR,thrombocytopenia,increased aspartate transaminase AST potassium decreased and thrombocytopenia,1
AFINITOR,thrombocytopenia,potassium decreased thrombocytopenia Deaths during doubleblind treatment where,1
AFINITOR,thrombocytopenia,increased aspartate transaminase AST potassium decreased and thrombocytopenia,1
AFINITOR,death,death on the,1
AFINITOR,death,death on the,1
AFINITOR,death,placebo Causes death on,1
AFINITOR,death,death on the,1
AFINITOR,death,death on the AFINITOR arm,1
AFINITOR,death,death on,1
AFINITOR,death,death on the AFINITOR arm,1
AFINITOR,death,death on the AFINITOR arm included,1
AFINITOR,death,death on the AFINITOR arm,1
AFINITOR,acute renal failure,of the acute renal failure acute respiratory distress cardiac,1
AFINITOR,acute renal failure,death on the AFINITOR arm,1
AFINITOR,acute renal failure,the following,0
AFINITOR,acute renal failure,acute,1
AFINITOR,acute renal failure,renal failure,1
AFINITOR,acute renal failure,renal failure acute respiratory,1
AFINITOR,acute respiratory distress,acute renal,0
AFINITOR,acute respiratory distress,respiratory distress cardiac,1
AFINITOR,acute respiratory distress,on the AFINITOR arm included one case,0
AFINITOR,acute respiratory distress,case,0
AFINITOR,acute respiratory distress,following acute renal failure,0
AFINITOR,acute respiratory distress,following acute renal acute respiratory distress cardiac arrest,1
AFINITOR,acute respiratory distress,following acute renal failure,0
AFINITOR,acute respiratory distress,and sepsis There,0
AFINITOR,acute respiratory distress,pneumonia and sepsis There,0
AFINITOR,acute respiratory distress,auses of death on the AFINITOR,0
AFINITOR,cardiac arrest,failure pneumonia and sepsis There,0
AFINITOR,death,due to,0
AFINITOR,death,death cause,1
AFINITOR,death,pneumonia and sepsis There was one death due to,0
AFINITOR,death,due to,0
AFINITOR,death,death cause unknown hepatic,1
AFINITOR,death,to pulmonary embol,0
AFINITOR,death,death cause,1
AFINITOR,hepatic failure,distress cardiac,0
AFINITOR,hepatic failure,and sepsis There was one death due to pulmonary embolism on,0
AFINITOR,hepatic failure,renal,0
AFINITOR,hepatic failure,hepatic failure pneumonia,1
AFINITOR,hepatic failure,renal,0
AFINITOR,hepatic failure,cause hepatic,1
AFINITOR,hepatic failure,was one,0
AFINITOR,pneumonia,unknown hepatic,0
AFINITOR,pneumonia,death,0
AFINITOR,pneumonia,cause unknown hepatic pneumonia and sepsis There was one,1
AFINITOR,pneumonia,death,0
AFINITOR,pneumonia,pneumonia and,1
AFINITOR,sepsis,sepsis There was one death,1
AFINITOR,sepsis,on the placebo arm After crossover,0
AFINITOR,sepsis,pneumonia and,0
AFINITOR,death,crossover to openlabel AFINITOR there,0
AFINITOR,death,cardiac arrest death cause unknown hepatic failure pneumonia and,0
AFINITOR,death,and sepsis There was death due to pulmonary embolism on,1
AFINITOR,death,cardiac arrest death cause unknown hepatic failure pneumonia and,0
AFINITOR,death,There was death,1
AFINITOR,death,cardiac arrest death cause unknown hepatic failure pneumonia and,0
AFINITOR,deaths,there were three,0
AFINITOR,deaths,patient with insulinoma,0
AFINITOR,deaths,deaths one due,1
AFINITOR,deaths,deaths one due to hypoglycemia and,1
AFINITOR,hypoglycemia,hypoglycemia and cardiac,1
AFINITOR,hypoglycemia,three additional deaths one due to,0
AFINITOR,hypoglycemia,hypoglycemia,1
AFINITOR,hypoglycemia,were three additional deaths,0
AFINITOR,hypoglycemia,hypoglycemia and cardiac arrest,1
AFINITOR,hypoglycemia,to,0
AFINITOR,hypoglycemia,AFINITOR there were three additional,0
AFINITOR,hypoglycemia,hypoglycemia and cardiac arrest in,1
AFINITOR,cardiac arrest,cardiac arrest in,1
AFINITOR,cardiac arrest,openlabel AFINITOR there were three additional deaths one due to,0
AFINITOR,cardiac arrest,due to,0
AFINITOR,cardiac arrest,hypoglycemia cardiac arrest in a,1
AFINITOR,cardiac arrest,due to,0
AFINITOR,cardiac arrest,to hypoglycemia cardiac arrest in,1
AFINITOR,cardiac arrest,due to,0
AFINITOR,cardiac arrest,patient with insulinoma one due to myocardial infarction with congestive heart failure and,0
AFINITOR,myocardial infarction,in a patient with insulinoma,0
AFINITOR,myocardial infarction,insulinoma one due myocardial infarction,1
AFINITOR,myocardial infarction,myocardial infarction with congestive,1
AFINITOR,myocardial infarction,The rates of treatmentemergent,0
AFINITOR,myocardial infarction,due,0
AFINITOR,myocardial infarction,congestive heart,0
AFINITOR,congestive heart failure,congestive heart failure and the,1
AFINITOR,congestive heart failure,congestive heart,0
AFINITOR,congestive heart failure,other due to sudden death The rates of treatmentemergent,0
AFINITOR,sudden death,of treatmentemergent,0
AFINITOR,sudden death,sudden death The rates,1
AFINITOR,sudden death,congestive heart failure and,0
AFINITOR,sudden death,sudden death The rates,1
AFINITOR,sudden death,treatmentemergent adverse events resulting,0
AFINITOR,renal failure,placebo patients renal failure,1
AFINITOR,renal failure,renal failure occurred in six patients,1
AFINITOR,renal failure,placebo patients renal failure,1
AFINITOR,renal failure,everolimus patients,0
AFINITOR,renal failure,of placebo patients renal,1
AFINITOR,renal failure,renal failure occurred in six,1
AFINITOR,renal failure,renal,1
AFINITOR,renal failure,renal failure occurred,1
AFINITOR,renal failure,and of placebo patients renal failure occurred in six,1
AFINITOR,renal failure,renal failure occurred,1
AFINITOR,renal failure,placebo patients renal,1
AFINITOR,pulmonary embolus,pulmonary embolus in the,1
AFINITOR,thrombosis,thrombosis in the everolimus arm and,1
AFINITOR,thrombosis,patients with,0
AFINITOR,thrombosis,compares,0
AFINITOR,thrombosis,thrombosis in the everolimus,1
AFINITOR,thrombosis,patients thrombosis,1
AFINITOR,thrombosis,thrombosis in the everolimus,1
AFINITOR,thrombosis,arm and two in the placebo arm Table compares the incidence of treatmente,0
AFINITOR,thrombosis,in the placebo arm,0
AFINITOR,thrombosis,arm as,0
AFINITOR,stomatitis,gingival,0
AFINITOR,stomatitis,lip,0
AFINITOR,stomatitis,stomatitis aphthous stomatitis,1
AFINITOR,stomatitis,Version a stomatitis aphthous stomatitis,1
AFINITOR,stomatitis,stomatitis aphthous stomatitis,1
AFINITOR,stomatitis,stomatitis aphthous stomatitis gingival painswellingulceration,1
AFINITOR,stomatitis,Patients with Advanced PNET Grading according,0
AFINITOR,stomatitis,stomatitis aphthous stomatitis gingival painswellingulceration,1
AFINITOR,stomatitis,stomatitis aphthous stomatitis gingival painswellingulceration glossitis,1
AFINITOR,aphthous stomatitis,PNET Grading according to,0
AFINITOR,aphthous stomatitis,Version a,0
AFINITOR,aphthous stomatitis,a Includes aphthous stomatitis gingival painswellingulceration glossitis glossodynia lip,1
AFINITOR,aphthous stomatitis,Version a,0
AFINITOR,aphthous stomatitis,aphthous stomatitis gingival painswellingulceration glossitis,1
AFINITOR,aphthous stomatitis,Version a,0
AFINITOR,aphthous stomatitis,ulceration mouth,0
AFINITOR,aphthous stomatitis,Version a Includes aphthous stomatitis gingival painswellingulceration glossitis glossodynia,1
AFINITOR,aphthous stomatitis,ulceration mouth,0
AFINITOR,gingival pain,aphthous,0
AFINITOR,gingival pain,gingival pain swellingulceration glossitis glossodynia lip ulceration,1
AFINITOR,gingival pain,aphthous,0
AFINITOR,glossitis,ulceration mouth ulceration tongue ulceration and,0
AFINITOR,glossitis,stomatitis aphthous stomatitis gingival painswellingulceration,0
AFINITOR,glossitis,gingival glossitis glossodynia lip,1
AFINITOR,glossitis,stomatitis aphthous stomatitis gingival painswellingulceration,0
AFINITOR,glossitis,glossitis glossodynia,1
AFINITOR,glossitis,aphthous stomatitis gingival glossitis glossodynia lip ulceration mouth,1
AFINITOR,glossitis,glossitis glossodynia,1
AFINITOR,glossitis,mouth ulceration tongue ulceration and mucosal inflammation,0
AFINITOR,glossitis,stomatitis aphthous stomatitis gingival glossitis glossodynia lip,1
AFINITOR,glossitis,mouth ulceration tongue ulceration and mucosal inflammation,0
AFINITOR,glossitis,glossitis glossodynia lip,1
AFINITOR,glossodynia,painswellingulceration glossitis,0
AFINITOR,glossodynia,ulceration mouth,0
AFINITOR,glossodynia,inflammation b Includes diarr,0
AFINITOR,glossodynia,glossodynia lip ulceration mouth ulceration,1
AFINITOR,glossodynia,glossodynia lip,1
AFINITOR,glossodynia,glossodynia lip ulceration mouth ulceration tongue,1
AFINITOR,glossodynia,Includes stomatitis aphthous stomatitis gingival,0
AFINITOR,glossodynia,glossodynia lip ulceration mouth,1
AFINITOR,glossodynia,gingival painswellingulceration glossitis,0
AFINITOR,lip ulceration,stomatitis gingival painswellingulceration,0
AFINITOR,lip ulceration,lip ulceration mouth,1
AFINITOR,lip ulceration,painswellingulceration glossitis lip,1
AFINITOR,lip ulceration,ncludes stomatitis aphthous stomatitis,0
AFINITOR,lip ulceration,lip ulceration mouth ulceration,1
AFINITOR,lip ulceration,lip ulceration mouth ulceration tongue ulceration,1
AFINITOR,lip ulceration,ulceration,0
AFINITOR,lip ulceration,gingival painswellingulceration glossitis lip ulceration,1
AFINITOR,mouth ulceration,painswellingulceration,0
AFINITOR,mouth ulceration,mouth ulceration tongue ulceration,1
AFINITOR,tongue ulceration,lip ulceration mouth tongue ulceration,1
AFINITOR,tongue ulceration,mouth ulceration tongue ulceration,1
AFINITOR,tongue ulceration,tongue ulceration and mucosal inflammation b Includes,1
AFINITOR,tongue ulceration,mouth ulceration tongue ulceration,1
AFINITOR,tongue ulceration,mouth tongue ulceration,1
AFINITOR,tongue ulceration,mouth tongue ulceration and mucosal inflammation,1
AFINITOR,tongue ulceration,mouth tongue ulceration,1
AFINITOR,tongue ulceration,tongue ulceration,1
AFINITOR,tongue ulceration,ulceration mouth tongue,1
AFINITOR,mucosal inflammation,mucosal inflammation b Includes diarrhea,1
AFINITOR,mucosal inflammation,ulceration mucosal inflammation b,1
AFINITOR,mucosal inflammation,mucosal inflammation b Includes diarrhea,1
AFINITOR,mucosal inflammation,mucosal inflammation b Includes diarrhea enteritis enterocolitis,1
AFINITOR,mucosal inflammation,mucosal inflammation b Includes diarrhea,1
AFINITOR,mucosal inflammation,ulceration tongue ulceration mucosal inflammation b,1
AFINITOR,mucosal inflammation,mucosal inflammation b Includes diarrhea,1
AFINITOR,mucosal inflammation,glossitis glossodynia,0
AFINITOR,mucosal inflammation,and,0
AFINITOR,mucosal inflammation,mucosal inflammation b Includes diarrhea enteritis enterocolitis,1
AFINITOR,mucosal inflammation,mouth ulceration tongue ulceration mucosal inflammation,1
AFINITOR,enteritis,enteritis enterocolitis,1
AFINITOR,enteritis,enteritis enterocolitis colitis,1
AFINITOR,enteritis,steatorrhea c Includes pneumonitis,0
AFINITOR,enteritis,enteritis enterocolitis colitis defecation urgency and,1
AFINITOR,enteritis,ulceration tongue ulceration and mucosal inflammation b,0
AFINITOR,enteritis,Includes enteritis enterocolitis colitis defecation,1
AFINITOR,enteritis,ulceration tongue ulceration and mucosal inflammation b,0
AFINITOR,enterocolitis,steatorrhea c,0
AFINITOR,enterocolitis,Includes diarrhea enteritis,0
AFINITOR,enterocolitis,and,0
AFINITOR,enterocolitis,steatorrhea c Includes pneumonitis,0
AFINITOR,enterocolitis,enterocolitis colitis defecation urgency,1
AFINITOR,enterocolitis,colitis defecation,0
AFINITOR,colitis,colitis defecation urgency,1
AFINITOR,colitis,colitis defecation,1
AFINITOR,colitis,c Includes pneumonitis,0
AFINITOR,colitis,colitis defecation urgency and,1
AFINITOR,colitis,interstitial lung,0
AFINITOR,colitis,colitis,1
AFINITOR,colitis,colitis,1
AFINITOR,colitis,colitis,1
AFINITOR,defecation urgency,and steatorrhea c Includes pneumonitis interstitial lung disease,0
AFINITOR,defecation urgency,enteritis enterocolitis defecation urgency,1
AFINITOR,steatorrhea,steatorrhea c Includes pneumonitis,1
AFINITOR,steatorrhea,steatorrhea c Includes pneumonitis,1
AFINITOR,steatorrhea,steatorrhea c Includes pneumonitis interstitial,1
AFINITOR,steatorrhea,steatorrhea c Includes pneumonitis,1
AFINITOR,steatorrhea,steatorrhea c,1
AFINITOR,steatorrhea,urgency,0
AFINITOR,steatorrhea,colitis,0
AFINITOR,steatorrhea,steatorrhea,1
AFINITOR,pneumonitis,pneumonitis interstitial lung disease,1
AFINITOR,pneumonitis,and steatorrhea c pneumonitis interstitial lung,1
AFINITOR,pneumonitis,pneumonitis interstitial lung disease,1
AFINITOR,pneumonitis,pneumonitis interstitial lung disease,1
AFINITOR,pneumonitis,interstitial,0
AFINITOR,pneumonitis,disease pulmonary fibrosis and,0
AFINITOR,pneumonitis,pneumonitis,1
AFINITOR,pneumonitis,pneumonitis interstitial lung disease pulmonary,1
AFINITOR,pneumonitis,steatorrhea c pneumonitis interstitial lung disease pulmonary fibrosis,1
AFINITOR,pneumonitis,pneumonitis interstitial lung disease pulmonary,1
AFINITOR,pneumonitis,pneumonitis interstitial lung disease pulmonary,1
AFINITOR,pneumonitis,udes diarrhea enteritis enterocolitis colitis defecation urgency and steatorrhea,0
AFINITOR,interstitial lung disease,Includes interstitial lung disease pulmonary fibrosis and restrictive pulmonary,1
AFINITOR,interstitial lung disease,udes diarrhea enteritis enterocolitis colitis defecation urgency and steatorrhea,0
AFINITOR,interstitial lung disease,interstitial,1
AFINITOR,interstitial lung disease,pulmonary disease,0
AFINITOR,pulmonary fibrosis,N Placebo N,0
AFINITOR,pulmonary fibrosis,N Placebo N,0
AFINITOR,pulmonary fibrosis,pulmonary fibrosis and restrictive,1
AFINITOR,pulmonary fibrosis,steatorrhea c Includes pneumonitis interstitial lung disease,0
AFINITOR,restrictive pulmonary disease,lung disease pulmonary fibrosis restrictive pulmonary disease,1
AFINITOR,restrictive pulmonary disease,fibrosis restrictive pulmonary disease,1
AFINITOR,Cough,Cough productive,1
AFINITOR,Cough,Cough productive cough,1
AFINITOR,irregular menstruation,irregular menstruation occurred in of AFINITORtreated,1
AFINITOR,irregular menstruation,patients aged to irregular,1
AFINITOR,irregular menstruation,none of,0
AFINITOR,irregular menstruation,of AFINITORtreated females and none of the females in,0
AFINITOR,irregular menstruation,patients aged to years,0
AFINITOR,irregular menstruation,aged to irregular menstruation occurred in,1
AFINITOR,irregular menstruation,patients aged to years,0
AFINITOR,irregular menstruation,female patients aged to irregular menstruation occurred in,1
AFINITOR,irregular menstruation,patients aged to years,0
AFINITOR,Lymphocytes decreased,decreased,0
AFINITOR,Lymphocytes decreased,Hemoglobin decreased,0
AFINITOR,Lymphocytes decreased,Hemoglobin Lymphocytes decreased,1
AFINITOR,Lymphocytes decreased,Hemoglobin decreased,0
AFINITOR,Lymphocytes decreased,Lymphocytes decreased Platelets,1
AFINITOR,Lymphocytes decreased,Hemoglobin,0
AFINITOR,Lymphocytes decreased,Lymphocytes decreased Platelets decreased,1
AFINITOR,Lymphocytes decreased,Hemoglobin Lymphocytes decreased Platelets,1
AFINITOR,Lymphocytes decreased,Lymphocytes decreased Platelets decreased,1
AFINITOR,Platelets decreased,Lymphocytes Platelets decreased,1
AFINITOR,WBC decreased,WBC decreased,1
AFINITOR,WBC decreased,WBC decreased,1
AFINITOR,WBC decreased,WBC decreased Neutrophils,1
AFINITOR,WBC decreased,WBC decreased,1
AFINITOR,WBC decreased,WBC decreased,1
AFINITOR,WBC decreased,WBC decreased,1
AFINITOR,WBC decreased,WBC decreased Neutrophils,1
AFINITOR,WBC decreased,WBC decreased Neutrophils,1
AFINITOR,Alkaline phosphatase increased,nical Alkaline phosphatase,1
AFINITOR,Alkaline phosphatase increased,Alkaline phosphatase increased Glucose fasting inc,1
AFINITOR,Alkaline phosphatase increased,nical Alkaline phosphatase,1
AFINITOR,Alkaline phosphatase increased,Alkaline phosphatase increased,1
AFINITOR,Alkaline phosphatase increased,Glucose fasting inc,0
AFINITOR,Alkaline phosphatase increased,nical Alkaline phosphatase increased Glucose fasting,1
AFINITOR,Alkaline phosphatase increased,Glucose fasting inc,0
AFINITOR,Alkaline phosphatase increased,Glucose fasting,0
AFINITOR,Alkaline phosphatase increased,phosphatase increased Glucose fasting inc,1
AFINITOR,Alkaline phosphatase increased,nical Alkaline phosphatase increased Glucose fasting,1
AFINITOR,Alkaline phosphatase increased,phosphatase increased Glucose fasting inc,1
AFINITOR,Cholesterol increased,e fasting Cholesterol,1
AFINITOR,Cholesterol increased,fasting increased,0
AFINITOR,Cholesterol increased,e fasting Cholesterol increased Bicarbonate decreased,1
AFINITOR,Cholesterol increased,fasting increased,0
AFINITOR,Cholesterol increased,Cholesterol increased Bicarbonate,1
AFINITOR,Cholesterol increased,increased,0
AFINITOR,Cholesterol increased,Cholesterol increased Bicarbonate decreased,1
AFINITOR,Cholesterol increased,fasting Cholesterol,1
AFINITOR,Cholesterol increased,Cholesterol increased,1
AFINITOR,Bicarbonate decreased,Bicarbonate decreased,1
AFINITOR,Phosphate decreased,increased,0
AFINITOR,Phosphate decreased,ALT,0
AFINITOR,Phosphate decreased,Phosphate decreased Triglycerides increas,1
AFINITOR,Phosphate decreased,Phosphate decreased,1
AFINITOR,Triglycerides increased,Phosphate Triglycerides increased,1
AFINITOR,Triglycerides increased,Phosphate Triglycerides increased,1
AFINITOR,Triglycerides increased,decreased,0
AFINITOR,Triglycerides increased,decreased,0
AFINITOR,Triglycerides increased,Phosphate decreased,0
AFINITOR,Triglycerides increased,Triglycerides,1
AFINITOR,Calcium decreased,Calcium decreased,1
AFINITOR,Calcium decreased,Triglycerides,1
AFINITOR,Calcium decreased,Calcium decreased Potassium,1
AFINITOR,Calcium decreased,Calcium decreased,1
AFINITOR,Calcium decreased,Calcium,1
AFINITOR,Calcium decreased,Calcium decreased,1
AFINITOR,Potassium decreased,Calcium Potassium,1
AFINITOR,Potassium decreased,Calcium Potassium decreased Creatinine increased,1
AFINITOR,Potassium decreased,Calcium Potassium,1
AFINITOR,Potassium decreased,Calcium,0
AFINITOR,Potassium decreased,decreased,0
AFINITOR,Potassium decreased,decreased,0
AFINITOR,Creatinine increased,Potassium decreased,0
AFINITOR,Creatinine increased,Creatinine increased Sodium decreased,1
AFINITOR,Creatinine increased,Potassium decreased,0
AFINITOR,Creatinine increased,Creatinine increased Sodium,1
AFINITOR,Creatinine increased,Potassium decreased,0
AFINITOR,Creatinine increased,Creatinine increased Sodium,1
AFINITOR,Albumin decreased,Sodium Albumin decreased,1
AFINITOR,Albumin decreased,Creatinine increased Sodium,1
AFINITOR,Albumin decreased,Albumin decreased,1
AFINITOR,Bilirubin increased,Albumin Bilirubin increased,1
AFINITOR,Bilirubin increased,Albumin decreased,1
AFINITOR,Bilirubin increased,Bilirubin,1
AFINITOR,Bilirubin increased,Albumin decreased,0
AFINITOR,stomatitis,stomatitis infections asthenia fatigue cough and,1
AFINITOR,stomatitis,stomatitis infections asthenia fatigue,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis infections asthenia fatigue,1
AFINITOR,stomatitis,placebo The most common adverse,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,most common Grade adverse reactions,0
AFINITOR,stomatitis,common adverse reactions incidence stomatitis infections,1
AFINITOR,stomatitis,most common Grade adverse reactions,0
AFINITOR,infections,asthenia fatigue cough and,0
AFINITOR,infections,incidence were infections asthenia fatigue cough and diarrhea,1
AFINITOR,infections,asthenia fatigue cough and,0
AFINITOR,infections,reactions incidence were infections asthenia,1
AFINITOR,infections,asthenia fatigue cough and,0
AFINITOR,asthenia,incidence,0
AFINITOR,asthenia,asthenia fatigue cough and,1
AFINITOR,asthenia,asthenia fatigue,1
AFINITOR,asthenia,asthenia fatigue cough and diarrhea,1
AFINITOR,asthenia,asthenia fatigue cough and diarrhea The,1
AFINITOR,asthenia,asthenia fatigue cough and,1
AFINITOR,fatigue,fatigue cough and diarrhea The,1
AFINITOR,cough,reactions incidence were infections,0
AFINITOR,cough,were stomatitis infections asthenia cough and diarrhea The most,1
AFINITOR,cough,reactions incidence were infections,0
AFINITOR,cough,and diarrhea,0
AFINITOR,cough,The most common Grade,0
AFINITOR,diarrhea,asthenia fatigue cough diarrhea The most common Grade adverse,1
AFINITOR,diarrhea,The most common Grade,0
AFINITOR,diarrhea,diarrhea The most common,1
AFINITOR,infections,infections dyspnea,1
AFINITOR,infections,infections dyspnea fatigue stomatitis dehydration pneumonitis,1
AFINITOR,infections,infections dyspnea fatigue stomatitis dehydration pneumonitis,1
AFINITOR,infections,most common Grade adverse reactions incidence,0
AFINITOR,infections,infections dyspnea fatigue stomatitis dehydration pneumonitis,1
AFINITOR,dyspnea,adverse reactions incidence were dyspnea fatigue stomatitis,1
AFINITOR,dyspnea,infections dyspnea fatigue stomatitis dehydration pneumonitis,1
AFINITOR,dyspnea,dyspnea fatigue stomatitis,1
AFINITOR,dyspnea,dyspnea fatigue,1
AFINITOR,dyspnea,adverse reactions incidence were dyspnea fatigue stomatitis,1
AFINITOR,dyspnea,dyspnea fatigue,1
AFINITOR,dyspnea,diarrhea The most common Grade adverse reactions incidence,0
AFINITOR,dyspnea,fatigue stomatitis dehydration pneumonitis abdominal pain and asthenia,0
AFINITOR,fatigue,infections dyspnea,0
AFINITOR,fatigue,fatigue stomatitis dehydration,1
AFINITOR,fatigue,infections fatigue stomatitis,1
AFINITOR,fatigue,fatigue stomatitis dehydration,1
AFINITOR,fatigue,abdominal pain and asthenia,0
AFINITOR,fatigue,fatigue stomatitis dehydration pneumonitis,1
AFINITOR,fatigue,The,0
AFINITOR,stomatitis,adverse,0
AFINITOR,stomatitis,dyspnea stomatitis dehydration pneumonitis abdominal pain and,1
AFINITOR,stomatitis,adverse,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis dehydration pneumonitis abdominal pain,1
AFINITOR,stomatitis,stomatitis dehydration,1
AFINITOR,stomatitis,were infections dyspnea fatigue,0
AFINITOR,stomatitis,pneumonitis abdominal pain and asthenia The most common,0
AFINITOR,dehydration,dyspnea fatigue dehydration pneumonitis abdominal,1
AFINITOR,dehydration,pneumonitis abdominal pain and asthenia The most common,0
AFINITOR,dehydration,laboratory,0
AFINITOR,dehydration,were,0
AFINITOR,dehydration,dehydration pneumonitis abdominal pain and,1
AFINITOR,dehydration,dehydration pneumonitis abdominal pain,1
AFINITOR,dehydration,and asthenia The most common laboratory,0
AFINITOR,pneumonitis,abdominal pain,0
AFINITOR,pneumonitis,stomatitis pneumonitis abdominal,1
AFINITOR,pneumonitis,abdominal pain,0
AFINITOR,asthenia,anemia hypercholesterolemia,0
AFINITOR,asthenia,pneumonitis abdominal pain asthenia,1
AFINITOR,asthenia,anemia hypercholesterolemia,0
AFINITOR,asthenia,pain asthenia The,1
AFINITOR,asthenia,anemia hypercholesterolemia,0
AFINITOR,asthenia,pneumonitis abdominal pain asthenia The most common laboratory,1
AFINITOR,asthenia,anemia hypercholesterolemia,0
AFINITOR,asthenia,anemia,0
AFINITOR,asthenia,asthenia The most common,1
AFINITOR,asthenia,asthenia The,1
AFINITOR,asthenia,asthenia,1
AFINITOR,asthenia,common laboratory abnormalities incidence were,0
AFINITOR,anemia,anemia hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,1
AFINITOR,anemia,anemia hypercholesterolemia hypertriglyceridemia,1
AFINITOR,anemia,and,0
AFINITOR,anemia,anemia hypercholesterolemia hypertriglyceridemia hyperglycemia,1
AFINITOR,anemia,anemia hypercholesterolemia hypertriglyceridemia,1
AFINITOR,anemia,tis abdominal pain and asthenia The most common laboratory abnormalities,0
AFINITOR,anemia,hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,0
AFINITOR,anemia,and asthenia The most common laboratory,0
AFINITOR,hypercholesterolemia,The most common,0
AFINITOR,hypercholesterolemia,abnormalities incidence were hypercholesterolemia,1
AFINITOR,hypercholesterolemia,The most common,0
AFINITOR,hypercholesterolemia,and,0
AFINITOR,hypercholesterolemia,hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and increased,1
AFINITOR,hypercholesterolemia,were anemia,0
AFINITOR,hypercholesterolemia,incidence were hypercholesterolemia hypertriglyceridemia hyperglycemia,1
AFINITOR,hypercholesterolemia,were anemia,0
AFINITOR,hypercholesterolemia,were hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,1
AFINITOR,hypercholesterolemia,were anemia,0
AFINITOR,hypercholesterolemia,hypercholesterolemia,1
AFINITOR,hypercholesterolemia,hypercholesterolemia hypertriglyceridemia,1
AFINITOR,hyperglycemia,anemia hypercholesterolemia hyperglycemia lymphopenia and increased creatinine,1
AFINITOR,hyperglycemia,hypercholesterolemia hypertriglyceridemia,1
AFINITOR,hyperglycemia,hyperglycemia lymphopenia and increased,1
AFINITOR,hyperglycemia,aboratory,0
AFINITOR,hyperglycemia,laboratory abnormalities inciden,0
AFINITOR,hyperglycemia,creatinine The most common Grade laboratory abnormalities inciden,0
AFINITOR,hyperglycemia,hyperglycemia lymphopenia and increased,1
AFINITOR,lymphopenia,lymphopenia and increased,1
AFINITOR,lymphopenia,lymphopenia and increased creatinine The,1
AFINITOR,lymphopenia,anemia,0
AFINITOR,lymphopenia,lymphopenia and,1
AFINITOR,lymphopenia,creatinine The,0
AFINITOR,lymphopenia,creatinine The most common Grade laboratory abnormalities,0
AFINITOR,increased creatinine,anemia hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,0
AFINITOR,increased creatinine,lymphopenia increased creatinine The most,1
AFINITOR,increased creatinine,anemia hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,0
AFINITOR,increased creatinine,hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia increased creatinine The most common Grade laboratory,1
AFINITOR,increased creatinine,anemia hypercholesterolemia hypertriglyceridemia hyperglycemia lymphopenia and,0
AFINITOR,increased creatinine,increased creatinine,1
AFINITOR,increased creatinine,increased creatinine The,1
AFINITOR,increased creatinine,hyperglycemia lymphopenia increased creatinine,1
AFINITOR,increased creatinine,lymphopenia increased,1
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,lymphopenia,lymphopenia hyperglycemia,1
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,lymphopenia,incidence lymphopenia,1
AFINITOR,lymphopenia,lymphopenia,1
AFINITOR,lymphopenia,lymphopenia hyperglycemia,1
AFINITOR,lymphopenia,lymphopenia hyperglycemia anemia,1
AFINITOR,hyperglycemia,due to acute respiratory failure,0
AFINITOR,anemia,and hypercholesterolemia Deaths due,0
AFINITOR,anemia,and hypercholesterolemia Deaths due to acute,0
AFINITOR,anemia,anemia,1
AFINITOR,anemia,Deaths due to acute respiratory failure infect,0
AFINITOR,anemia,abnormalities incidence were lymphopenia anemia hypophosphatemia and,1
AFINITOR,anemia,Deaths due to acute respiratory failure infect,0
AFINITOR,hypophosphatemia,due to acute respiratory failure infection and,0
AFINITOR,hypophosphatemia,hypophosphatemia,1
AFINITOR,hypophosphatemia,incidence were lymphopenia hyperglycemia hypophosphatemia and hypercholesterolemia Deaths due,1
AFINITOR,hypophosphatemia,hypophosphatemia,1
AFINITOR,hypophosphatemia,were,0
AFINITOR,hypercholesterolemia,hypercholesterolemia Deaths due to,1
AFINITOR,hypercholesterolemia,were,0
AFINITOR,hypercholesterolemia,lymphopenia hyperglycemia anemia hypophosphatemia hypercholesterolemia Deaths due to acute respiratory,1
AFINITOR,hypercholesterolemia,were,0
AFINITOR,Deaths,Deaths due,1
AFINITOR,Deaths,Deaths due,1
AFINITOR,acute respiratory failure,hypercholesterolemia Deaths due acute,1
AFINITOR,acute respiratory failure,acute respiratory failure infection,1
AFINITOR,acute respiratory failure,hypercholesterolemia Deaths due acute,1
AFINITOR,acute respiratory failure,lymphopenia hyperglycemia anemia hypophosphatemia and hypercholesterolemia,0
AFINITOR,acute respiratory failure,acute respiratory failure,1
AFINITOR,acute respiratory failure,respiratory failure infection and,1
AFINITOR,acute respiratory failure,hypercholesterolemia Deaths due acute respiratory failure infection and acute renal,1
AFINITOR,acute respiratory failure,respiratory failure infection and,1
AFINITOR,acute respiratory failure,acute respiratory failure,1
AFINITOR,acute respiratory failure,hyperglycemia anemia hypophosphatemia and hypercholesterolemia,0
AFINITOR,infection,infection and,1
AFINITOR,infection,hyperglycemia anemia hypophosphatemia and hypercholesterolemia,0
AFINITOR,infection,infection and acute renal,1
AFINITOR,infection,infection and acute,1
AFINITOR,infection,infection and acute renal,1
AFINITOR,infection,infection and acute renal failure,1
AFINITOR,infection,infection,1
AFINITOR,acute renal failure,renal failure were observed on the AFINITOR,1
AFINITOR,acute renal failure,rates,0
AFINITOR,acute renal failure,on the AFINITOR arm but none on the placebo arm The,0
AFINITOR,acute renal failure,respiratory failure infection acute renal failure,1
AFINITOR,acute renal failure,acute renal failure were,1
AFINITOR,acute renal failure,respiratory failure infection acute renal failure,1
AFINITOR,acute renal failure,renal failure,1
AFINITOR,acute renal failure,respiratory failure infection acute renal,1
AFINITOR,pneumonitis,and dyspnea Infections stomatitis,0
AFINITOR,dyspnea,for treatment delay or,0
AFINITOR,dyspnea,dyspnea,1
AFINITOR,dyspnea,pneumonitis and,0
AFINITOR,dyspnea,discontinuation were,0
AFINITOR,dyspnea,dyspnea Infections stomatitis,1
AFINITOR,dyspnea,and,0
AFINITOR,dyspnea,dyspnea Infections stomatitis and,1
AFINITOR,dyspnea,of,0
AFINITOR,dyspnea,pneumonitis dyspnea Infections stomatitis,1
AFINITOR,dyspnea,of,0
AFINITOR,dyspnea,dyspnea Infections stomatitis and pneumonitis were,1
AFINITOR,Infections,Infections stomatitis,1
AFINITOR,Infections,of causality leading to,0
AFINITOR,Infections,Infections stomatitis and pneumonitis,1
AFINITOR,Infections,reasons for treatment delay or dose,0
AFINITOR,Infections,Infections stomatitis,1
AFINITOR,Infections,Infections stomatitis and,1
AFINITOR,Infections,pneumonitis and Infections stomatitis and,1
AFINITOR,Infections,Infections stomatitis and,1
AFINITOR,Infections,Infections stomatitis and pneumonitis,1
AFINITOR,Infections,discontinuation were pneumonitis and Infections,1
AFINITOR,Infections,Infections stomatitis and pneumonitis,1
AFINITOR,Infections,pneumonitis were the most common reasons for treatment,0
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,pneumonitis were the most common reasons for treatment,0
AFINITOR,stomatitis,stomatitis and pneumonitis,1
AFINITOR,stomatitis,stomatitis and,1
AFINITOR,infections,infections anemia,1
AFINITOR,infections,infections anemia and stomatitis,1
AFINITOR,infections,were infections anemia and stomatitis Table,1
AFINITOR,infections,infections anemia and stomatitis,1
AFINITOR,infections,the incidence of treatmentemergent,0
AFINITOR,infections,during AFINITOR treatment were infections,1
AFINITOR,infections,the incidence of treatmentemergent,0
AFINITOR,infections,infections anemia and stomatitis,1
AFINITOR,anemia,anemia and stomatitis,1
AFINITOR,anemia,infections anemia and stomatitis,1
AFINITOR,anemia,anemia and stomatitis,1
AFINITOR,anemia,anemia and stomatitis Table compares the,1
AFINITOR,anemia,interventions required during,0
AFINITOR,anemia,anemia and stomatitis,1
AFINITOR,stomatitis,adverse reactions reported with an,0
AFINITOR,stomatitis,stomatitis Table compares,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,were,0
AFINITOR,Stomatitis,than in the Placebo Arm Grading according to CTCAE Version a,0
AFINITOR,Stomatitis,Stomatitis including aphthous stomatitis and mouth,1
AFINITOR,aphthous stomatitis,according to CTCAE Version a Stomatitis including,0
AFINITOR,aphthous stomatitis,Version a Stomatitis aphthous stomatitis and mouth and tongue,1
AFINITOR,aphthous stomatitis,according to CTCAE Version a Stomatitis including,0
AFINITOR,aphthous stomatitis,Stomatitis,0
AFINITOR,aphthous stomatitis,aphthous stomatitis and mouth and,1
AFINITOR,aphthous stomatitis,the Placebo Arm Grading according to CTCAE Version a Stomatitis including,0
AFINITOR,aphthous stomatitis,Stomatitis including,0
AFINITOR,aphthous stomatitis,aphthous stomatitis,1
AFINITOR,aphthous stomatitis,aphthous stomatitis and mouth and tongue ulceration,1
AFINITOR,aphthous stomatitis,aphthous stomatitis,1
AFINITOR,aphthous stomatitis,CTCAE Version a Stomatitis aphthous,1
AFINITOR,tongue ulceration,a Stomatitis including aphthous,0
AFINITOR,tongue ulceration,a Stomatitis including aphthous stomatitis and,0
AFINITOR,tongue ulceration,mouth,0
AFINITOR,tongue ulceration,stomatitis and mouth and,0
AFINITOR,nasopharyngitis,being,0
AFINITOR,nasopharyngitis,the most common nasopharyngitis pneumonia urinary tract infection bronchitis,1
AFINITOR,nasopharyngitis,being,0
AFINITOR,nasopharyngitis,nasopharyngitis pneumonia urinary,1
AFINITOR,nasopharyngitis,and,0
AFINITOR,nasopharyngitis,nasopharyngitis pneumonia urinary tract,1
AFINITOR,nasopharyngitis,urinary tract,0
AFINITOR,nasopharyngitis,nasopharyngitis pneumonia urinary,1
AFINITOR,nasopharyngitis,nasopharyngitis,1
AFINITOR,nasopharyngitis,nasopharyngitis pneumonia urinary tract,1
AFINITOR,nasopharyngitis,nasopharyngitis,1
AFINITOR,pneumonia,the most common being pneumonia urinary tract infection,1
AFINITOR,pneumonia,nasopharyngitis,1
AFINITOR,pneumonia,pneumonia urinary tract infection bronchitis,1
AFINITOR,pneumonia,nasopharyngitis,1
AFINITOR,pneumonia,most common being pneumonia urinary tract,1
AFINITOR,pneumonia,nasopharyngitis,1
AFINITOR,pneumonia,organ class the most common,0
AFINITOR,pneumonia,class the,0
AFINITOR,urinary tract infection,urinary tract infection bronchitis and,1
AFINITOR,urinary tract infection,being nasopharyngitis urinary,1
AFINITOR,urinary tract infection,urinary,1
AFINITOR,urinary tract infection,being nasopharyngitis urinary,1
AFINITOR,urinary tract infection,nasopharyngitis urinary tract infection bronchitis and,1
AFINITOR,urinary tract infection,being nasopharyngitis urinary,1
AFINITOR,urinary tract infection,tract infection,1
AFINITOR,bronchitis,bronchitis and sinusitis and also,1
AFINITOR,bronchitis,bronchitis and sinusitis and also including,1
AFINITOR,bronchitis,urinary tract bronchitis and sinusitis and,1
AFINITOR,bronchitis,bronchitis and sinusitis and also including,1
AFINITOR,bronchitis,urinary tract bronchitis and sinusitis and also,1
AFINITOR,bronchitis,bronchitis and sinusitis and also including,1
AFINITOR,bronchitis,being nasopharyngitis pneumonia urinary tract,0
AFINITOR,sinusitis,being nasopharyngitis pneumonia urinary tract infection,0
AFINITOR,sinusitis,pneumonia urinary tract infection bronchitis and,0
AFINITOR,sinusitis,sinusitis and,1
AFINITOR,sinusitis,pneumonia urinary tract infection bronchitis and,0
AFINITOR,aspergillosis,and also aspergillosis candidiasis,1
AFINITOR,aspergillosis,pneumonia urinary tract infection bronchitis and,0
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c,1
AFINITOR,aspergillosis,and sinusitis and also aspergillosis candidiasis,1
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c,1
AFINITOR,aspergillosis,and also aspergillosis candidiasis and sepsis,1
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c,1
AFINITOR,aspergillosis,tract infection bronchitis and,0
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c Includes,1
AFINITOR,aspergillosis,tract infection bronchitis and,0
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c,1
AFINITOR,aspergillosis,and also aspergillosis candidiasis and sepsis,1
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c,1
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c Includes,1
AFINITOR,aspergillosis,and also aspergillosis candidiasis and sepsis c Includes,1
AFINITOR,aspergillosis,aspergillosis candidiasis and sepsis c Includes,1
AFINITOR,candidiasis,candidiasis and sepsis c,1
AFINITOR,candidiasis,also including candidiasis and,1
AFINITOR,candidiasis,candidiasis and sepsis c,1
AFINITOR,sepsis,also including aspergillosis candidiasis sepsis c Includes,1
AFINITOR,sepsis,candidiasis and sepsis c,1
AFINITOR,sepsis,c Includes pneumonitis interstitial lung disease lung infiltration pulmonary,0
AFINITOR,sepsis,sepsis c,1
AFINITOR,sepsis,pneumonitis interstitial lung disease lung infiltration pulmonary alveolar,0
AFINITOR,sepsis,also including aspergillosis candidiasis sepsis c Includes,1
AFINITOR,sepsis,pneumonitis interstitial lung disease lung infiltration pulmonary alveolar,0
AFINITOR,sepsis,sepsis c Includes,1
AFINITOR,sepsis,pulmonary alveolar h,0
AFINITOR,sepsis,aspergillosis candidiasis sepsis c Includes pneumonitis interstitial lung,1
AFINITOR,sepsis,pulmonary alveolar h,0
AFINITOR,lung infiltration,and sepsis c Includes,0
AFINITOR,lung infiltration,pneumonitis interstitial lung lung infiltration,1
AFINITOR,lung infiltration,and sepsis c Includes,0
AFINITOR,lung infiltration,interstitial lung lung infiltration pulmonary alveolar hemorrhage pulmonary toxicity,1
AFINITOR,lung infiltration,and sepsis c Includes,0
AFINITOR,lung infiltration,pneumonitis interstitial lung,0
AFINITOR,lung infiltration,interstitial lung lung infiltration pulmonary alveolar hemorrhage,1
AFINITOR,lung infiltration,pneumonitis interstitial lung,0
AFINITOR,lung infiltration,lung disease,0
AFINITOR,lung infiltration,toxicity and alveolitis,0
AFINITOR,pulmonary alveolar hemorrhage,interstitial,0
AFINITOR,pulmonary alveolar hemorrhage,alveolar hemorrhage pulmonary toxicity and alveolitis,1
AFINITOR,pulmonary alveolar hemorrhage,pulmonary alveolar hemorrhage,1
AFINITOR,pulmonary alveolar hemorrhage,lung pulmonary alveolar hemorrhage pulmonary toxicity and alveolitis AFINITOR,1
AFINITOR,pulmonary alveolar hemorrhage,pulmonary alveolar hemorrhage,1
AFINITOR,pulmonary alveolar hemorrhage,lung pulmonary alveolar hemorrhage pulmonary toxicity and alveolitis,1
AFINITOR,pulmonary alveolar hemorrhage,pulmonary alveolar hemorrhage,1
AFINITOR,pulmonary toxicity,alveolar,0
AFINITOR,pulmonary toxicity,lung infiltration pulmonary alveolar hemorrhage,0
AFINITOR,pulmonary toxicity,pulmonary alveolar pulmonary toxicity,1
AFINITOR,pulmonary toxicity,pulmonary alveolar pulmonary toxicity,1
AFINITOR,pulmonary toxicity,AFINITOR,0
AFINITOR,pulmonary toxicity,pulmonary toxicity and alveolitis AFINITOR mgday,1
AFINITOR,pulmonary toxicity,pulmonary toxicity and alveolitis AFINITOR,1
AFINITOR,pulmonary toxicity,infiltration pulmonary alveolar,0
AFINITOR,alveolitis,alveolitis,1
AFINITOR,alveolitis,pulmonary toxicity alveolitis AFINITOR mgday N Placebo N,1
AFINITOR,alveolitis,alveolitis,1
AFINITOR,Abdominal pain,Abdominal pain,1
AFINITOR,Abdominal pain,Gastrointestinal Abdominal pain dry mouth hemorrhoids,1
AFINITOR,Abdominal pain,Abdominal pain,1
AFINITOR,Abdominal pain,incidence of include Gastrointestinal disorders,0
AFINITOR,Abdominal pain,General disorders and administrati,0
AFINITOR,Abdominal pain,include Gastrointestinal Abdominal,1
AFINITOR,Abdominal pain,an incidence of,0
AFINITOR,Abdominal pain,Abdominal,1
AFINITOR,Abdominal pain,include Gastrointestinal Abdominal pain,1
AFINITOR,Abdominal pain,of include Gastrointestinal Abdominal,1
AFINITOR,dry mouth,dry mouth hemorrhoids dysphagia General disorders and,1
AFINITOR,dry mouth,Abdominal dry mouth,1
AFINITOR,dry mouth,dysphagia General disorders and administration,0
AFINITOR,dry mouth,Gastrointestinal disorders Abdominal dry mouth hemorrhoids,1
AFINITOR,dry mouth,dysphagia General disorders and administration,0
AFINITOR,dry mouth,disorders Abdominal,0
AFINITOR,dry mouth,Abdominal dry mouth,1
AFINITOR,dry mouth,Abdominal dry mouth,1
AFINITOR,dry mouth,dry mouth,1
AFINITOR,hemorrhoids,administration site conditions Weight,0
AFINITOR,hemorrhoids,hemorrhoids dysphagia General disorders and administration,1
AFINITOR,hemorrhoids,hemorrhoids,1
AFINITOR,hemorrhoids,dry hemorrhoids,1
AFINITOR,hemorrhoids,hemorrhoids,1
AFINITOR,hemorrhoids,dysphagia General disorders,0
AFINITOR,hemorrhoids,mouth,0
AFINITOR,hemorrhoids,hemorrhoids dysphagia,1
AFINITOR,dysphagia,Weight decreased,0
AFINITOR,dysphagia,dysphagia General disorders and,1
AFINITOR,dysphagia,Weight decreased chest,0
AFINITOR,dysphagia,dysphagia General disorders and administration site,1
AFINITOR,dysphagia,dysphagia General disorders and,1
AFINITOR,dysphagia,dysphagia General disorders and administration,1
AFINITOR,dysphagia,dysphagia General,1
AFINITOR,dysphagia,Gastrointestinal disorders Abdominal pain dry,0
AFINITOR,dysphagia,dysphagia General disorders and administration site,1
AFINITOR,Weight decreased,pain chills impaired wound healing Respiratory thoracic a,0
AFINITOR,Weight decreased,administration site Weight,1
AFINITOR,Weight decreased,site Weight decreased chest pain chills,1
AFINITOR,Weight decreased,administration site Weight,1
AFINITOR,Weight decreased,site Weight decreased,1
AFINITOR,chest pain,thoracic,0
AFINITOR,chest pain,chest pain chills impaired wound healing,1
AFINITOR,chest pain,thoracic and,0
AFINITOR,chest pain,chest pain,1
AFINITOR,chest pain,chest pain,1
AFINITOR,chest pain,conditions Weight chest pain chills,1
AFINITOR,chest pain,chest pain,1
AFINITOR,chest pain,chest pain chills impaired wound healing,1
AFINITOR,chills,General disorders,0
AFINITOR,chills,chills impaired wound healing,1
AFINITOR,chills,chest,0
AFINITOR,chills,chills impaired wound healing Respiratory,1
AFINITOR,chills,chills impaired wound healing Respiratory thoracic,1
AFINITOR,chills,Weight decreased chest chills impaired wound,1
AFINITOR,chills,chills impaired wound healing Respiratory thoracic,1
AFINITOR,impaired wound healing,disorders and administration site conditions Weight decreased chest pain chills,0
AFINITOR,impaired wound healing,and mediastinal disorders Pleural effusion pharyngola,0
AFINITOR,impaired wound healing,impaired wound healing Respiratory thoracic and mediastinal,1
AFINITOR,impaired wound healing,disorders and administration,0
AFINITOR,impaired wound healing,decreased chest pain,0
AFINITOR,Pleural effusion,Pleural effusion pharyngolaryngeal pain rhinorrhea,1
AFINITOR,Pleural effusion,Respiratory thoracic,0
AFINITOR,Pleural effusion,Respiratory thoracic and mediastinal disorders,0
AFINITOR,Pleural effusion,Respiratory thoracic and mediastinal Pleural effusion pharyngolaryngeal pain,1
AFINITOR,Pleural effusion,Respiratory thoracic and mediastinal disorders,0
AFINITOR,Pleural effusion,subcutaneous,0
AFINITOR,Pleural effusion,Respiratory thoracic and mediastinal Pleural effusion,1
AFINITOR,Pleural effusion,mediastinal Pleural effusion pharyngolaryngeal pain,1
AFINITOR,Pleural effusion,Respiratory thoracic and mediastinal Pleural effusion,1
AFINITOR,Pleural effusion,Pleural effusion pharyngolaryngeal pain,1
AFINITOR,Pleural effusion,Pleural,1
AFINITOR,Pleural effusion,and mediastinal Pleural,1
AFINITOR,pharyngolaryngeal pain,disorders Handfoot syndrome reporte,0
AFINITOR,pharyngolaryngeal pain,and,0
AFINITOR,pharyngolaryngeal pain,and subcutaneous tissue disorders Handfoot syndrome,0
AFINITOR,pharyngolaryngeal pain,pharyngolaryngeal,1
AFINITOR,rhinorrhea,rhinorrhea Skin and subcutaneous tissue,1
AFINITOR,rhinorrhea,effusion pharyngolaryngeal rhinorrhea Skin and subcutaneous,1
AFINITOR,rhinorrhea,rhinorrhea Skin and subcutaneous tissue,1
AFINITOR,rhinorrhea,and mediastinal disorders Pleural effusion pharyngolaryngeal pain,0
AFINITOR,Hand-foot syndrome,nail disorder erythema,0
AFINITOR,Hand-foot syndrome,subcutaneous tissue Hand-foot syndrome,1
AFINITOR,Hand-foot syndrome,nail disorder erythema,0
AFINITOR,Hand-foot syndrome,syndrome nail disorder,0
AFINITOR,Hand-foot syndrome,and subcutaneous tissue disorders,0
AFINITOR,Hand-foot syndrome,Hand-foot syndrome reported as palmarplantar erythrodysesthesia syndrome,1
AFINITOR,Hand-foot syndrome,Hand-foot,1
AFINITOR,Hand-foot syndrome,palmarplantar,0
AFINITOR,Hand-foot syndrome,and subcutaneous tissue Hand-foot syndrome,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,Handfoot syndrome reported palmar-plantar erythrodysesthesia syndrome,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,reported palmar-plantar erythrodysesthesia syndrome,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,reported palmar-plantar erythrodysesthesia syndrome nail disorder erythema,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome nail disorder erythema onychoclasis skin,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,erythrodysesthesia syndrome,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,Handfoot syndrome reported palmar-plantar erythrodysesthesia,1
AFINITOR,palmar-plantar erythrodysesthesia syndrome,subcutaneous tissue,0
AFINITOR,palmar-plantar erythrodysesthesia syndrome,palmar-plantar erythrodysesthesia syndrome nail disorder,1
AFINITOR,nail disorder,reported as palmarplantar erythrodysesthesia nail disorder erythema onychoclasis,1
AFINITOR,nail disorder,palmar-plantar erythrodysesthesia syndrome nail disorder,1
AFINITOR,nail disorder,nail disorder,1
AFINITOR,erythema,palmarplantar erythrodysesthesia syndrome nail erythema onychoclasis skin lesion acneiform,1
AFINITOR,erythema,nail disorder,1
AFINITOR,onychoclasis,angioedema Metabolism and,0
AFINITOR,onychoclasis,disorder,0
AFINITOR,onychoclasis,nail disorder onychoclasis skin lesion,1
AFINITOR,onychoclasis,disorder,0
AFINITOR,onychoclasis,onychoclasis skin lesion acneiform dermatitis,1
AFINITOR,onychoclasis,as palmarplantar erythrodysesthesia syndrome nail disorder,0
AFINITOR,onychoclasis,onychoclasis skin,1
AFINITOR,onychoclasis,onychoclasis skin lesion acneiform dermatitis,1
AFINITOR,skin lesion,erythema skin lesion,1
AFINITOR,skin lesion,skin lesion,1
AFINITOR,acneiform dermatitis,syndrome nail disorder erythema onychoclasis,0
AFINITOR,acneiform dermatitis,and nutrition disorders Exacerbation of preexisting d,0
AFINITOR,acneiform dermatitis,acneiform dermatitis angioedema Metabolism and,1
AFINITOR,acneiform dermatitis,and,0
AFINITOR,acneiform dermatitis,onychoclasis skin,0
AFINITOR,acneiform dermatitis,skin acneiform dermatitis,1
AFINITOR,acneiform dermatitis,erythema onychoclasis skin acneiform,1
AFINITOR,angioedema,skin lesion acneiform angioedema,1
AFINITOR,angioedema,erythema onychoclasis skin acneiform,1
AFINITOR,angioedema,lesion acneiform angioedema Metabolism and nutrition,1
AFINITOR,angioedema,erythema onychoclasis skin acneiform,1
AFINITOR,angioedema,skin lesion acneiform angioedema Metabolism and,1
AFINITOR,angioedema,erythema onychoclasis skin acneiform,1
AFINITOR,angioedema,and nutrition disorders Exacerbation of,0
AFINITOR,angioedema,angioedema Metabolism,1
AFINITOR,new onset of diabetes mellitus,Exacerbation of preexisting diabetes new onset of diabetes mellitus Psychiatric disorders,1
AFINITOR,new onset of diabetes mellitus,angioedema Metabolism,1
AFINITOR,new onset of diabetes mellitus,new onset of diabetes mellitus Psychiatric,1
AFINITOR,new onset of diabetes mellitus,angioedema Metabolism,1
AFINITOR,new onset of diabetes mellitus,preexisting diabetes new,1
AFINITOR,new onset of diabetes mellitus,Exacerbation of preexisting diabetes new onset of,1
AFINITOR,new onset of diabetes mellitus,mellitus,0
AFINITOR,new onset of diabetes mellitus,Insomnia Nervous system,0
AFINITOR,new onset of diabetes mellitus,of preexisting diabetes new onset,1
AFINITOR,Insomnia,Insomnia Nervous,1
AFINITOR,Insomnia,Insomnia Nervous system,1
AFINITOR,Insomnia,Insomnia Nervous,1
AFINITOR,Insomnia,system disorders,0
AFINITOR,Insomnia,system disorders Dizziness paresthesia Eye,0
AFINITOR,Insomnia,Insomnia Nervous system disorders,1
AFINITOR,Insomnia,system disorders Dizziness paresthesia,0
AFINITOR,Insomnia,Insomnia Nervous system,1
AFINITOR,Insomnia,Insomnia Nervous system disorders Dizziness,1
AFINITOR,Insomnia,of diabetes mellitus Psychiatric Insomnia Nervous,1
AFINITOR,Insomnia,Insomnia Nervous system disorders Dizziness,1
AFINITOR,Insomnia,Insomnia Nervous system,1
AFINITOR,Dizziness,Dizziness paresthesia,1
AFINITOR,Dizziness,Dizziness paresthesia Eye,1
AFINITOR,Dizziness,Dizziness paresthesia Eye,1
AFINITOR,paresthesia,Insomnia Nervous system disorders paresthesia Eye disorders Eyelid edema,1
AFINITOR,paresthesia,Dizziness paresthesia Eye,1
AFINITOR,paresthesia,paresthesia,1
AFINITOR,paresthesia,system disorders paresthesia Eye disorders Eyelid edema,1
AFINITOR,paresthesia,paresthesia,1
AFINITOR,paresthesia,paresthesia Eye,1
AFINITOR,paresthesia,paresthesia Eye,1
AFINITOR,Eyelid edema,disorders,0
AFINITOR,Eyelid edema,disorders Dizziness paresthesia,0
AFINITOR,Eyelid edema,disorders Dizziness paresthesia Eye Eyelid edema conjunctivitis Vascular disorders Hypertension deep,1
AFINITOR,Eyelid edema,disorders Dizziness paresthesia,0
AFINITOR,conjunctivitis,conjunctivitis,1
AFINITOR,conjunctivitis,conjunctivitis Vascular disorders Hypertension,1
AFINITOR,conjunctivitis,Eye disorders Eyelid conjunctivitis,1
AFINITOR,conjunctivitis,conjunctivitis Vascular disorders Hypertension,1
AFINITOR,conjunctivitis,Dizziness paresthesia,0
AFINITOR,conjunctivitis,conjunctivitis Vascular disorders Hypertension deep vein,1
AFINITOR,conjunctivitis,conjunctivitis Vascular disorders Hypertension deep vein,1
AFINITOR,conjunctivitis,Hypertension deep vein,0
AFINITOR,conjunctivitis,conjunctivitis Vascular disorders Hypertension deep vein,1
AFINITOR,conjunctivitis,disorders Dizziness,0
AFINITOR,Hypertension,Hypertension deep,1
AFINITOR,Hypertension,disorders,0
AFINITOR,Hypertension,Hypertension,1
AFINITOR,Hypertension,Hypertension deep,1
AFINITOR,Hypertension,Hypertension,1
AFINITOR,Hypertension,edema conjunctivitis Vascular,0
AFINITOR,Hypertension,Hypertension deep vein thrombosis Renal,1
AFINITOR,Hypertension,edema conjunctivitis Vascular,0
AFINITOR,Hypertension,Hypertension deep vein thrombosis Renal,1
AFINITOR,Hypertension,Eyelid edema conjunctivitis Vascular disorders,0
AFINITOR,Hypertension,vein thrombosis,0
AFINITOR,Tachycardia,Tachycardia congestive,1
AFINITOR,congestive cardiac failure,urinary disorders Renal,0
AFINITOR,congestive cardiac failure,disorders,0
AFINITOR,congestive cardiac failure,failure Cardiac disorders congestive cardiac failure,1
AFINITOR,congestive cardiac failure,disorders,0
AFINITOR,congestive cardiac failure,disorders congestive cardiac failure Musculoskeletal and connective tissue,1
AFINITOR,congestive cardiac failure,disorders,0
AFINITOR,Hemorrhage,Hematologic Hemorrhage Key,1
AFINITOR,Hemorrhage,disorders,0
AFINITOR,Hemorrhage,Table Key,0
AFINITOR,Hemorrhage,Hemorrhage,1
AFINITOR,Hemorrhage,Hemorrhage Key laboratory abnormalities,1
AFINITOR,Hemorrhage,Hemorrhage,1
AFINITOR,Hemorrhage,Jaw pain Hematologic Hemorrhage Key laboratory abnormalities are presented,1
AFINITOR,Hemorrhage,Hemorrhage,1
AFINITOR,Hemorrhage,Table Key,0
AFINITOR,Hemorrhage,disorders,0
AFINITOR,Hemorrhage,pain Hematologic Hemorrhage Key,1
AFINITOR,Hemorrhage,disorders,0
AFINITOR,Hemorrhage,Hemorrhage Key laboratory,1
AFINITOR,Hemorrhage,Jaw pain Hematologic disorders,0
AFINITOR,anemia,reports anemia leukopenia lymphopenia neutropenia and thrombocytopenia,1
AFINITOR,anemia,Jaw pain Hematologic disorders,0
AFINITOR,anemia,pancytopenia which occu,0
AFINITOR,anemia,reports of,0
AFINITOR,anemia,anemia leukopenia lymphopenia,1
AFINITOR,anemia,reports anemia leukopenia lymphopenia,1
AFINITOR,anemia,anemia leukopenia lymphopenia,1
AFINITOR,anemia,of,0
AFINITOR,anemia,drug reaction reports anemia leukopenia lymphopenia,1
AFINITOR,anemia,of,0
AFINITOR,leukopenia,leukopenia lymphopenia neutropenia and,1
AFINITOR,leukopenia,of leukopenia lymphopenia neutropenia and thrombocytopenia,1
AFINITOR,leukopenia,leukopenia lymphopenia neutropenia and,1
AFINITOR,leukopenia,of leukopenia lymphopenia,1
AFINITOR,leukopenia,leukopenia lymphopenia neutropenia and,1
AFINITOR,leukopenia,leukopenia lymphopenia neutropenia and thrombocytopenia,1
AFINITOR,leukopenia,leukopenia lymphopenia neutropenia,1
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,reports of leukopenia,1
AFINITOR,leukopenia,leukopenia,1
AFINITOR,leukopenia,occurred,0
AFINITOR,leukopenia,anemia,0
AFINITOR,leukopenia,leukopenia lymphopenia,1
AFINITOR,leukopenia,anemia,0
AFINITOR,lymphopenia,lymphopenia neutropenia and thrombocytopenia,1
AFINITOR,lymphopenia,lymphopenia neutropenia and thrombocytopenia collectively,1
AFINITOR,lymphopenia,of anemia lymphopenia neutropenia and thrombocytopenia,1
AFINITOR,lymphopenia,lymphopenia neutropenia and thrombocytopenia collectively,1
AFINITOR,lymphopenia,leukopenia,0
AFINITOR,lymphopenia,reaction reports of anemia lymphopenia neutropenia and thrombocytopenia collectively pancytopenia,1
AFINITOR,lymphopenia,leukopenia,0
AFINITOR,neutropenia,leukopenia,0
AFINITOR,neutropenia,thrombocytopenia collectively,0
AFINITOR,neutropenia,neutropenia and,1
AFINITOR,neutropenia,neutropenia and thrombocytopenia,1
AFINITOR,neutropenia,pancytopenia which occurred,0
AFINITOR,neutropenia,drug,0
AFINITOR,neutropenia,anemia leukopenia neutropenia and,1
AFINITOR,neutropenia,drug,0
AFINITOR,neutropenia,anemia leukopenia neutropenia and thrombocytopenia collectively,1
AFINITOR,neutropenia,drug,0
AFINITOR,pancytopenia,arameter,0
AFINITOR,stomatitis,incidence stomatitis The most common Grade adverse,1
AFINITOR,stomatitis,arameter,0
AFINITOR,stomatitis,for AFINITOR,0
AFINITOR,stomatitis,adverse reactions incidence were stomatitis and amenorrhea The,0
AFINITOR,stomatitis,were stomatitis and amenorrhea The,0
AFINITOR,stomatitis,stomatitis The most common,1
AFINITOR,stomatitis,stomatitis The most common Grade adverse,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,adverse reaction reported for AFINITOR,0
AFINITOR,stomatitis,Grade adverse reactions incidence,0
AFINITOR,stomatitis,stomatitis and,1
AFINITOR,stomatitis,stomatitis and amenorrhea,1
AFINITOR,amenorrhea,common laboratory abnormalities incidence,0
AFINITOR,amenorrhea,incidence,0
AFINITOR,hypertriglyceridemia,hypertriglyceridemia and anemia The most common,1
AFINITOR,hypertriglyceridemia,amenorrhea The most common laboratory abnormalities incidence,0
AFINITOR,anemia,anemia The most common Grade,1
AFINITOR,anemia,anemia The most common,1
AFINITOR,anemia,were,0
AFINITOR,anemia,laboratory abnormalities,0
AFINITOR,anemia,The most,0
AFINITOR,anemia,laboratory abnormality incidence was hypophosphatemia The r,0
AFINITOR,anemia,hypertriglyceridemia anemia The most,1
AFINITOR,anemia,laboratory abnormality incidence was hypophosphatemia The r,0
AFINITOR,anemia,The most common Grade laboratory abnormality incidence was hypophosphatemia The,0
AFINITOR,anemia,hypertriglyceridemia anemia The most common,1
AFINITOR,anemia,The most common Grade laboratory abnormality incidence was hypophosphatemia The,0
AFINITOR,hypophosphatemia,triglyceridemia and anemia The most common Grade laboratory abnormality incidence,0
AFINITOR,hypophosphatemia,hypophosphatemia The,1
AFINITOR,hypophosphatemia,hypophosphatemia The rate of,1
AFINITOR,hypophosphatemia,hypophosphatemia The,1
AFINITOR,hypophosphatemia,hypophosphatemia The rate of adverse reactions,1
AFINITOR,hypophosphatemia,hypophosphatemia The rate of adverse reactions,1
AFINITOR,hypophosphatemia,discontinuation,0
AFINITOR,hypophosphatemia,hypophosphatemia The rate of,1
AFINITOR,hypophosphatemia,The most common Grade laboratory abnormality incidence was,0
AFINITOR,hypophosphatemia,hypophosphatemia The,1
AFINITOR,hypersensitivity,convulsion and hypophosphatemia Dose adjustments interruptions or reduc,0
AFINITOR,hypersensitivity,hypersensitivity angioedemabronchospasm convulsion,1
AFINITOR,hypersensitivity,patients Adverse reactions leading to permanent discontinuation,0
AFINITOR,hypersensitivity,hypersensitivity angioedemabronchospasm convulsion,1
AFINITOR,hypersensitivity,interruptions or,0
AFINITOR,hypersensitivity,patients Adverse,0
AFINITOR,hypersensitivity,hypersensitivity angioedemabronchospasm convulsion and hypophosphatemia Dose,1
AFINITOR,hypersensitivity,hypersensitivity angioedemabronchospasm,1
AFINITOR,hypersensitivity,and hypophosphatemia Dose adjustments,0
AFINITOR,angioedema,convulsion and hypophosphatemia Dose adjustments interruptions or reductions,0
AFINITOR,angioedema,hypophosphatemia Dose,0
AFINITOR,bronchospasm,bronchospasm convulsion and hypophosphatemia,1
AFINITOR,bronchospasm,permanent discontinuation,0
AFINITOR,bronchospasm,bronchospasm convulsion and hypophosphatemia Dose adjustments,1
AFINITOR,bronchospasm,AFINITOR,0
AFINITOR,bronchospasm,bronchospasm convulsion,1
AFINITOR,bronchospasm,bronchospasm convulsion and hypophosphatemia Dose,1
AFINITOR,bronchospasm,bronchospasm convulsion,1
AFINITOR,bronchospasm,bronchospasm convulsion and,1
AFINITOR,convulsion,ing to,0
AFINITOR,convulsion,were convulsion and,1
AFINITOR,convulsion,ing to,0
AFINITOR,convulsion,the AFINITOR arm were convulsion and hypophosphatemia,1
AFINITOR,convulsion,ing to,0
AFINITOR,convulsion,hypersensitivityangioedemabronchospasm,0
AFINITOR,convulsion,convulsion and hypophosphatemia Dose adjustments interruptions,1
AFINITOR,convulsion,the AFINITOR arm were convulsion and,1
AFINITOR,convulsion,convulsion and hypophosphatemia Dose adjustments interruptions,1
AFINITOR,convulsion,arm were convulsion and hypophosphatemia Dose,1
AFINITOR,convulsion,convulsion and hypophosphatemia Dose adjustments interruptions,1
AFINITOR,convulsion,adjustments interruptions or reductions,0
AFINITOR,convulsion,discontinuation in the AFINITOR,0
AFINITOR,convulsion,convulsion and hypophosphatemia Dose adjustments,1
AFINITOR,hypophosphatemia,hypersensitivityangioedemabronchospasm,0
AFINITOR,hypophosphatemia,hypophosphatemia Dose adjustments interruptions or,1
AFINITOR,hypophosphatemia,hypophosphatemia Dose adjustments,1
AFINITOR,hypophosphatemia,hypophosphatemia Dose,1
AFINITOR,hypophosphatemia,hypophosphatemia Dose adjustments,1
AFINITOR,stomatitis,stomatitis Table compares the incidence,1
AFINITOR,aphthous stomatitis,Angiomyolipoma Grading according to,0
AFINITOR,aphthous stomatitis,and glossodynia,0
AFINITOR,aphthous stomatitis,gingival,0
AFINITOR,aphthous stomatitis,gingival,0
AFINITOR,aphthous stomatitis,CTCAE Version a Includes aphthous stomatitis mouth,1
AFINITOR,aphthous stomatitis,gingival,0
AFINITOR,aphthous stomatitis,aphthous,1
AFINITOR,aphthous stomatitis,stomatitis,0
AFINITOR,aphthous stomatitis,aphthous stomatitis mouth ulceration gingival pain glossitis,1
AFINITOR,mouth ulceration,and glossodynia AFINITOR N,0
AFINITOR,mouth ulceration,glossitis and glossodynia AFINITOR,0
AFINITOR,gingival pain,N,0
AFINITOR,gingival pain,a,0
AFINITOR,gingival pain,stomatitis aphthous stomatitis mouth gingival pain glossitis and glossodynia,1
AFINITOR,gingival pain,a,0
AFINITOR,gingival pain,AFINITOR N Placebo N,0
AFINITOR,gingival pain,stomatitis aphthous stomatitis mouth gingival,1
AFINITOR,gingival pain,mouth gingival pain,1
AFINITOR,gingival pain,gingival pain,1
AFINITOR,gingival pain,aphthous stomatitis mouth gingival pain glossitis and glossodynia,1
AFINITOR,gingival pain,gingival pain,1
AFINITOR,glossitis,ulceration gingival glossitis and,1
AFINITOR,glossitis,gingival pain,1
AFINITOR,glossitis,glossitis and,1
AFINITOR,glossitis,stomatitis mouth,0
AFINITOR,glossitis,glossitis and glossodynia AFINITOR N Placebo,1
AFINITOR,glossitis,aphthous,0
AFINITOR,glossitis,and,0
AFINITOR,glossitis,Includes stomatitis aphthous stomatitis mouth ulceration gingival,0
AFINITOR,glossitis,ulceration gingival glossitis and,1
AFINITOR,glossitis,Includes stomatitis aphthous stomatitis mouth ulceration gingival,0
AFINITOR,glossitis,glossitis and glossodynia AFINITOR N,1
AFINITOR,glossitis,Includes stomatitis aphthous stomatitis mouth ulceration gingival,0
AFINITOR,glossodynia,stomatitis aphthous stomatitis mouth,0
AFINITOR,glossodynia,Includes stomatitis aphthous stomatitis mouth,0
AFINITOR,glossodynia,glossodynia AFINITOR N Placebo,1
AFINITOR,glossodynia,Includes stomatitis aphthous stomatitis mouth,0
AFINITOR,glossodynia,Includes stomatitis aphthous stomatitis,0
AFINITOR,glossodynia,gingival pain glossitis and,0
AFINITOR,glossodynia,glossodynia AFINITOR,1
AFINITOR,glossodynia,glossodynia AFINITOR N,1
AFINITOR,glossodynia,glossodynia AFINITOR,1
AFINITOR,menorrhagia,menorrhagia,1
AFINITOR,menorrhagia,menorrhagia menstrual irregularities and vaginal,1
AFINITOR,menorrhagia,the placebo group Other adverse reactions involving the,0
AFINITOR,menorrhagia,in the placebo group Other adverse reactions involving the female reproductive,0
AFINITOR,menorrhagia,system menorrhagia menstrual irregularities,1
AFINITOR,menorrhagia,in the placebo group Other adverse reactions involving the female reproductive,0
AFINITOR,menorrhagia,following,0
AFINITOR,menorrhagia,reactions involving the female,0
AFINITOR,menorrhagia,females in the placebo,0
AFINITOR,menstrual irregularities,menstrual irregularities and vaginal hemorrhage,1
AFINITOR,menstrual irregularities,were menstrual irregularities and,1
AFINITOR,menstrual irregularities,menstrual irregularities and vaginal hemorrhage,1
AFINITOR,menstrual irregularities,menstrual irregularities and vaginal,1
AFINITOR,menstrual irregularities,menstrual irregularities and vaginal hemorrhage,1
AFINITOR,menstrual irregularities,reactions occurred in less,0
AFINITOR,menstrual irregularities,menstrual irregularities and vaginal hemorrhage,1
AFINITOR,menstrual irregularities,involving the,0
AFINITOR,vaginal hemorrhage,vaginal,1
AFINITOR,vaginal hemorrhage,The following additional,0
AFINITOR,vaginal hemorrhage,irregularities vaginal hemorrhage The following additional,1
AFINITOR,vaginal hemorrhage,The following additional,0
AFINITOR,vaginal hemorrhage,additional adverse reactions occurred,0
AFINITOR,epistaxis,epistaxis decreased,1
AFINITOR,epistaxis,abnormal,0
AFINITOR,epistaxis,abnormal,0
AFINITOR,epistaxis,epistaxis decreased appetite otitis media,1
AFINITOR,epistaxis,epistaxis decreased,1
AFINITOR,epistaxis,than of AFINITOR treated epistaxis decreased appetite otitis media depression,1
AFINITOR,epistaxis,epistaxis decreased,1
AFINITOR,epistaxis,epistaxis decreased appetite otitis media depression,1
AFINITOR,epistaxis,epistaxis decreased,1
AFINITOR,epistaxis,epistaxis decreased appetite,1
AFINITOR,epistaxis,treated epistaxis,1
AFINITOR,epistaxis,epistaxis decreased appetite,1
AFINITOR,decreased appetite,decreased appetite otitis media depression abnormal taste,1
AFINITOR,decreased appetite,AFINITOR treated patients decreased,1
AFINITOR,decreased appetite,decreased appetite otitis media depression abnormal,1
AFINITOR,otitis media,otitis media depression abnormal taste increased,1
AFINITOR,otitis media,otitis,1
AFINITOR,otitis media,decreased otitis media,1
AFINITOR,otitis media,otitis media,1
AFINITOR,otitis media,hormone LH levels,0
AFINITOR,depression,AFINITOR treated patients epistaxis decreased appetite otitis,0
AFINITOR,depression,depression abnormal taste increased blood luteinizing,1
AFINITOR,depression,abnormal taste,0
AFINITOR,depression,increased blood fo,0
AFINITOR,depression,depression,1
AFINITOR,abnormal taste,abnormal taste increased blood luteinizing hormone LH,1
AFINITOR,abnormal taste,depression,0
AFINITOR,abnormal taste,abnormal taste increased blood luteinizing hormone,1
AFINITOR,abnormal taste,abnormal taste,1
AFINITOR,abnormal taste,increased blood follicle stimulating,0
AFINITOR,abnormal taste,abnormal taste,1
AFINITOR,abnormal taste,increased blood follicle stimulating,0
AFINITOR,abnormal taste,appetite otitis media abnormal taste increased blood luteinizing hormone LH,1
AFINITOR,abnormal taste,increased blood follicle stimulating,0
AFINITOR,abnormal taste,media abnormal taste increased,1
AFINITOR,abnormal taste,increased blood follicle stimulating,0
AFINITOR,abnormal taste,abnormal taste increased blood luteinizing hormone,1
AFINITOR,abnormal taste,otitis media abnormal taste increased blood luteinizing,1
AFINITOR,abnormal taste,abnormal taste increased blood luteinizing hormone,1
AFINITOR,hypersensitivity,teinizing hormone LH levels increased blood follicle stimulating hormone,0
AFINITOR,hypersensitivity,hypersensitivity ovarian cyst,1
AFINITOR,hypersensitivity,angioedema Table Key Laboratory Abnorma,0
AFINITOR,hypersensitivity,hormone FSH hypersensitivity ovarian,1
AFINITOR,hypersensitivity,angioedema Table Key Laboratory Abnorma,0
AFINITOR,hypersensitivity,hypersensitivity ovarian,1
AFINITOR,hypersensitivity,hypersensitivity ovarian cyst pneumonitis and angioedema,1
AFINITOR,hypersensitivity,ovarian cyst,0
AFINITOR,hypersensitivity,hormone FSH hypersensitivity ovarian cyst,1
AFINITOR,hypersensitivity,ovarian cyst,0
AFINITOR,ovarian cyst,levels ovarian cyst pneumonitis and angioedema Table,1
AFINITOR,ovarian cyst,ovarian cyst,0
AFINITOR,ovarian cyst,angioedema Table Key Laboratory Abnormalities Reported,0
AFINITOR,ovarian cyst,levels ovarian cyst,1
AFINITOR,ovarian cyst,FSH levels ovarian,1
AFINITOR,ovarian cyst,ovarian cyst,1
AFINITOR,ovarian cyst,Abnormalities Reported,0
AFINITOR,ovarian cyst,angioedema Table,0
AFINITOR,ovarian cyst,Key,0
AFINITOR,pneumonitis,levels hypersensitivity,0
AFINITOR,pneumonitis,hormone FSH levels,0
AFINITOR,pneumonitis,hormone FSH levels,0
AFINITOR,pneumonitis,hypersensitivity ovarian pneumonitis and angioedema,1
AFINITOR,pneumonitis,hormone FSH levels,0
AFINITOR,pneumonitis,FSH levels hypersensitivity ovarian pneumonitis and angioedema Table Key Laboratory,1
AFINITOR,pneumonitis,hormone FSH levels,0
AFINITOR,pneumonitis,pneumonitis and angioedema Table,1
AFINITOR,angioedema,levels hypersensitivity ovarian cyst pneumonitis,0
AFINITOR,angioedema,angioedema Table Key,1
AFINITOR,angioedema,Reported in,0
AFINITOR,stomatitis,for,0
AFINITOR,stomatitis,incidence,0
AFINITOR,stomatitis,tract infection The most common,0
AFINITOR,stomatitis,stomatitis and respiratory,1
AFINITOR,stomatitis,stomatitis and,1
AFINITOR,stomatitis,The,0
AFINITOR,stomatitis,stomatitis and respiratory,1
AFINITOR,stomatitis,and respiratory tract infection,0
AFINITOR,stomatitis,stomatitis and,1
AFINITOR,stomatitis,tract infection The most common Grade adverse reactions,0
AFINITOR,respiratory tract infection,were stomatitis pyrexia pneumonia,0
AFINITOR,respiratory tract infection,respiratory tract infection The most common Grade adverse,1
AFINITOR,respiratory tract infection,incidence were stomatitis and,0
AFINITOR,respiratory tract infection,AFINITOR incidence were stomatitis respiratory tract infection,1
AFINITOR,respiratory tract infection,stomatitis,0
AFINITOR,respiratory tract infection,respiratory tract infection The,1
AFINITOR,respiratory tract infection,most common adverse reactions reported for AFINITOR incidence were stomatitis,0
AFINITOR,stomatitis,stomatitis pyrexia pneumonia,1
AFINITOR,stomatitis,most common adverse reactions reported for AFINITOR incidence were stomatitis,0
AFINITOR,stomatitis,pneumonia gastroenteritis aggression agitation and,0
AFINITOR,stomatitis,stomatitis pyrexia pneumonia gastroenteritis aggression agitation,1
AFINITOR,stomatitis,stomatitis pyrexia pneumonia,1
AFINITOR,stomatitis,stomatitis pyrexia pneumonia gastroenteritis aggression agitation,1
AFINITOR,stomatitis,stomatitis pyrexia pneumonia gastroenteritis aggression,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,adverse reactions incidence stomatitis pyrexia pneumonia,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,pyrexia,most common key laboratory,0
AFINITOR,pyrexia,adverse reactions incidence were pyrexia pneumonia gastroenteritis aggression agitation and,1
AFINITOR,pyrexia,most common key laboratory,0
AFINITOR,pyrexia,pyrexia pneumonia gastroenteritis,1
AFINITOR,pyrexia,most,0
AFINITOR,pyrexia,aggression agitation and,0
AFINITOR,pyrexia,adverse,0
AFINITOR,pneumonia,pneumonia gastroenteritis aggression agitation and amenorrhea,1
AFINITOR,gastroenteritis,The most common,0
AFINITOR,gastroenteritis,key laboratory abnormalities incidence,0
AFINITOR,gastroenteritis,gastroenteritis aggression agitation and amenorrhea,1
AFINITOR,gastroenteritis,gastroenteritis aggression agitation and,1
AFINITOR,gastroenteritis,gastroenteritis,1
AFINITOR,gastroenteritis,most common,0
AFINITOR,gastroenteritis,were stomatitis pyrexia pneumonia,0
AFINITOR,gastroenteritis,Grade,0
AFINITOR,gastroenteritis,amenorrhea The most common key,0
AFINITOR,aggression,Grade adverse,0
AFINITOR,aggression,aggression agitation and,1
AFINITOR,aggression,The,0
AFINITOR,agitation,agitation and amenorrhea The most common,1
AFINITOR,agitation,abnormalities incidence were hypercholeste,0
AFINITOR,amenorrhea,amenorrhea The most,1
AFINITOR,amenorrhea,amenorrhea The most common,1
AFINITOR,amenorrhea,aggression agitation amenorrhea The most common,1
AFINITOR,amenorrhea,amenorrhea The most common,1
AFINITOR,amenorrhea,gastroenteritis aggression agitation amenorrhea The most common,1
AFINITOR,amenorrhea,amenorrhea The most common,1
AFINITOR,amenorrhea,amenorrhea,1
AFINITOR,amenorrhea,amenorrhea The,1
AFINITOR,amenorrhea,most,0
AFINITOR,amenorrhea,key laboratory,0
AFINITOR,amenorrhea,hypercholesterolemia and,0
AFINITOR,hypercholesterolemia,on agitation and amenorrhea The,0
AFINITOR,hypercholesterolemia,incidence hypercholesterolemia and,1
AFINITOR,hypercholesterolemia,on agitation and amenorrhea The,0
AFINITOR,hypercholesterolemia,The,0
AFINITOR,hypercholesterolemia,The most common Grade laboratory abnormality inciden,0
AFINITOR,hypercholesterolemia,hypercholesterolemia and elevated partial thromboplastin,1
AFINITOR,hypercholesterolemia,hypercholesterolemia and elevated,1
AFINITOR,hypercholesterolemia,hypercholesterolemia,1
AFINITOR,hypercholesterolemia,hypercholesterolemia and elevated partial thromboplastin,1
AFINITOR,elevated partial thromboplastin time,common key laboratory abnormalities,0
AFINITOR,elevated partial thromboplastin time,rhea The most common key laboratory abnormalities incidence were hypercholesterolemia,0
AFINITOR,elevated partial thromboplastin time,rhea The most common key laboratory abnormalities incidence were hypercholesterolemia and,0
AFINITOR,elevated partial thromboplastin time,rhea The most common key laboratory abnormalities,0
AFINITOR,elevated partial thromboplastin time,The most common key laboratory abnormalities incidence were hypercholesterolemia and,0
AFINITOR,elevated partial thromboplastin time,common key,0
AFINITOR,elevated partial thromboplastin time,abnormalities incidence were hypercholesterolemia elevated partial thromboplastin time The,1
AFINITOR,elevated partial thromboplastin time,common key,0
AFINITOR,elevated partial thromboplastin time,key laboratory abnormalities incidence were hypercholesterolemia,0
AFINITOR,elevated partial thromboplastin time,elevated partial thromboplastin time The most common Grade laboratory,1
AFINITOR,elevated partial thromboplastin time,key laboratory abnormalities incidence were hypercholesterolemia,0
AFINITOR,elevated partial thromboplastin time,elevated partial thromboplastin time The most,1
AFINITOR,elevated partial thromboplastin time,key laboratory abnormalities incidence were hypercholesterolemia,0
AFINITOR,neutropenia,permanent discontinuation Dose adjustments inte,0
AFINITOR,neutropenia,There were no,0
AFINITOR,neutropenia,no adverse reactions resulting in permanent discontinuation Dose adjustments,0
AFINITOR,neutropenia,incidence neutropenia There,1
AFINITOR,neutropenia,no adverse reactions resulting in permanent discontinuation Dose adjustments,0
AFINITOR,neutropenia,in permanent discontinuation Dose adjustments,0
AFINITOR,stomatitis,stomatitis Table,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis Table,1
AFINITOR,stomatitis,stomatitis Table compares the incidence,1
AFINITOR,stomatitis,of adverse reactions,0
AFINITOR,stomatitis,stomatitis Table compares the incidence,1
AFINITOR,stomatitis,the,0
AFINITOR,stomatitis,stomatitis Table compares the,1
AFINITOR,mouth ulceration,mouth ulceration stomatitis and lip ulceration b,1
AFINITOR,mouth ulceration,Version a mouth ulceration stomatitis and lip ulceration,1
AFINITOR,mouth ulceration,mouth ulceration stomatitis and lip ulceration b,1
AFINITOR,mouth ulceration,mouth ulceration stomatitis and lip ulceration,1
AFINITOR,mouth ulceration,to CTCAE Version,0
AFINITOR,mouth ulceration,Grading according to CTCAE Version,0
AFINITOR,mouth ulceration,Version a mouth ulceration,1
AFINITOR,stomatitis,stomatitis and lip ulceration b Includes,1
AFINITOR,stomatitis,stomatitis and lip ulceration b Includes,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,stomatitis and lip ulceration,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,stomatitis,Includes mouth stomatitis and lip ulceration b Includes,1
AFINITOR,stomatitis,stomatitis,1
AFINITOR,lip ulceration,stomatitis lip,1
AFINITOR,respiratory tract infection,lip ulceration b respiratory tract infection upper respiratory tract,1
AFINITOR,respiratory tract infection,stomatitis lip,1
AFINITOR,respiratory tract infection,respiratory tract infection upper,1
AFINITOR,respiratory tract infection,stomatitis lip,1
AFINITOR,respiratory tract infection,ulceration b respiratory tract infection,1
AFINITOR,respiratory tract infection,lip ulceration b Includes,0
AFINITOR,respiratory tract infection,lip ulceration b respiratory tract infection upper respiratory,1
AFINITOR,respiratory tract infection,lip ulceration b Includes,0
AFINITOR,respiratory tract infection,ulceration stomatitis and lip,0
AFINITOR,respiratory tract infection,respiratory tract infection upper respiratory tract,1
AFINITOR,respiratory tract infection,ulceration stomatitis and lip,0
AFINITOR,upper respiratory tract infection,and lip,0
AFINITOR,upper respiratory tract infection,stomatitis and lip ulceration b Includes,0
AFINITOR,upper respiratory tract infection,Includes mouth ulceration stomatitis and lip ulceration,0
AFINITOR,upper respiratory tract infection,c Includes gastroenteritis gastroenteritis viral and gas,0
AFINITOR,respiratory tract infection viral,infection respiratory tract infection,1
AFINITOR,respiratory tract infection viral,respiratory tract infection viral c Includes gastroenteritis gastroenteritis,1
AFINITOR,respiratory tract infection viral,infection respiratory tract infection,1
AFINITOR,respiratory tract infection viral,respiratory tract infection respiratory tract infection viral,1
AFINITOR,respiratory tract infection viral,infection respiratory tract infection,1
AFINITOR,respiratory tract infection viral,tract infection viral c Includes,1
AFINITOR,respiratory tract infection viral,tract infection viral c,1
AFINITOR,respiratory tract infection viral,respiratory tract infection viral c,1
AFINITOR,respiratory tract infection viral,tract infection viral c,1
AFINITOR,respiratory tract infection viral,infection viral c Includes gastroenteritis gastroenteritis,1
AFINITOR,respiratory tract infection viral,c Includes gastroenteritis gastroenteritis viral and,0
AFINITOR,gastroenteritis,gastroenteritis gastroenteritis viral and,1
AFINITOR,gastroenteritis,gastroenteritis gastroenteritis viral and gastrointestinal,1
AFINITOR,gastroenteritis,gastroenteritis gastroenteritis,1
AFINITOR,gastroenteritis,gastroenteritis,1
AFINITOR,gastroenteritis,and gastrointestinal infection d,0
AFINITOR,gastroenteritis,gastroenteritis viral and gastrointestinal infection d Includes agitation anxiety panic attac,0
AFINITOR,gastroenteritis,infection viral c Includes,0
AFINITOR,gastroenteritis,c Includes,0
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal infection,1
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal infection d,1
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal infection,1
AFINITOR,gastroenteritis viral,c Includes gastroenteritis viral and gastrointestinal,1
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal infection,1
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal infection,1
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal infection,1
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal,1
AFINITOR,gastroenteritis viral,gastroenteritis viral and gastrointestinal infection,1
AFINITOR,gastroenteritis viral,gastroenteritis viral,1
AFINITOR,gastroenteritis viral,d,0
AFINITOR,gastrointestinal infection,tract infection viral c Includes gastroenteritis gastroenteritis viral and,0
AFINITOR,gastrointestinal infection,gastrointestinal infection,1
AFINITOR,gastrointestinal infection,gastrointestinal infection,1
AFINITOR,gastrointestinal infection,anxiety panic attack aggression abnormal behavior and,0
AFINITOR,gastrointestinal infection,Includes gastroenteritis gastroenteritis viral gastrointestinal infection,1
AFINITOR,gastrointestinal infection,Includes gastroenteritis gastroenteritis viral gastrointestinal infection d Includes agitation anxiety panic,1
AFINITOR,gastrointestinal infection,Includes gastroenteritis gastroenteritis viral gastrointestinal infection,1
AFINITOR,gastrointestinal infection,gastrointestinal infection,1
AFINITOR,gastrointestinal infection,gastroenteritis gastroenteritis viral gastrointestinal infection,1
AFINITOR,agitation,agitation anxiety panic,1
AFINITOR,agitation,agitation anxiety panic attack,1
AFINITOR,agitation,anxiety panic attack,0
AFINITOR,agitation,and gastrointestinal infection d agitation,1
AFINITOR,agitation,anxiety panic attack,0
AFINITOR,agitation,agitation anxiety panic attack aggression,1
AFINITOR,anxiety,anxiety panic attack aggression,1
AFINITOR,anxiety,panic attack,0
AFINITOR,anxiety,aggression abnormal behavior and,0
AFINITOR,anxiety,anxiety,1
AFINITOR,anxiety,anxiety panic attack,1
AFINITOR,anxiety,viral and gastrointestinal infection d,0
AFINITOR,anxiety,infection d Includes anxiety panic attack aggression abnormal behavior,1
AFINITOR,anxiety,viral and gastrointestinal infection d,0
AFINITOR,anxiety,and obsessive,0
AFINITOR,anxiety,anxiety panic attack aggression abnormal behavior,1
AFINITOR,panic attack,infection d Includes agitation panic,1
AFINITOR,panic attack,d Includes agitation panic attack,1
AFINITOR,panic attack,infection d Includes agitation panic,1
AFINITOR,panic attack,infection d Includes agitation panic attack,1
AFINITOR,panic attack,gastrointestinal,0
AFINITOR,panic attack,panic attack aggression,1
AFINITOR,panic attack,gastrointestinal,0
AFINITOR,panic attack,abnormal behavior and obsessive compulsive disorder e Includes rash rash,0
AFINITOR,panic attack,behavior and obsessive compulsive disorder,0
AFINITOR,panic attack,d Includes agitation panic attack,1
AFINITOR,panic attack,behavior and obsessive compulsive disorder,0
AFINITOR,panic attack,panic attack aggression abnormal behavior,1
AFINITOR,panic attack,behavior and obsessive compulsive disorder,0
AFINITOR,panic attack,panic attack aggression abnormal behavior,1
AFINITOR,aggression,Includes agitation anxiety panic aggression,1
AFINITOR,aggression,panic attack aggression abnormal behavior,1
AFINITOR,aggression,Includes agitation anxiety panic aggression abnormal behavior and obsessive,1
AFINITOR,aggression,panic attack aggression abnormal behavior,1
AFINITOR,aggression,aggression,1
AFINITOR,aggression,anxiety panic attack,0
AFINITOR,abnormal behavior,abnormal behavior and obsessive compulsive,1
AFINITOR,abnormal behavior,Includes rash rash generalized,0
AFINITOR,abnormal behavior,is viral and gastrointestinal infection d,0
AFINITOR,obsessive compulsive disorder,generalized rash macular rash maculopapular rash papular dermatitis al,0
AFINITOR,obsessive compulsive disorder,abnormal behavior obsessive compulsive disorder e Includes rash rash,1
AFINITOR,obsessive compulsive disorder,generalized rash macular rash maculopapular rash papular dermatitis al,0
AFINITOR,obsessive compulsive disorder,compulsive disorder e,1
AFINITOR,obsessive compulsive disorder,abnormal behavior obsessive compulsive disorder e Includes rash rash generalized,1
AFINITOR,obsessive compulsive disorder,compulsive disorder e,1
AFINITOR,obsessive compulsive disorder,and,0
AFINITOR,obsessive compulsive disorder,Includes rash rash generalized rash macular rash,0
AFINITOR,obsessive compulsive disorder,rash rash generalized rash macular,0
AFINITOR,obsessive compulsive disorder,obsessive compulsive disorder,1
AFINITOR,obsessive compulsive disorder,estinal infection d Includes agitation anxiety panic,0
AFINITOR,rash,rash rash,1
AFINITOR,rash,rash rash generalized rash,1
AFINITOR,rash,disorder e rash rash generalized rash,1
AFINITOR,rash,rash rash generalized rash,1
AFINITOR,rash,rash rash generalized rash macular,1
AFINITOR,rash,rash rash,1
AFINITOR,rash,rash rash generalized rash macular rash,1
AFINITOR,rash,rash rash,1
AFINITOR,rash generalized,papular dermatitis,0
AFINITOR,rash generalized,Includes,0
AFINITOR,rash generalized,e Includes rash generalized rash,1
AFINITOR,rash generalized,Includes,0
AFINITOR,rash generalized,panic attack aggression abnormal behavior,0
AFINITOR,rash macular,rash rash macular rash maculopapular rash papular dermatitis,1
AFINITOR,rash macular,panic attack aggression abnormal behavior,0
AFINITOR,rash macular,e Includes rash rash rash macular rash maculopapular rash papular dermatitis,1
AFINITOR,rash macular,panic attack aggression abnormal behavior,0
AFINITOR,rash macular,behavior and obsessive compulsive disorder e Includes,0
AFINITOR,rash macular,maculopapular rash papular dermatitis allergic and,0
AFINITOR,rash macular,Includes rash rash rash macular rash maculopapular rash papular,1
AFINITOR,rash macular,maculopapular rash papular dermatitis allergic and,0
AFINITOR,rash maculo-papular,disorder e Includes rash rash,0
AFINITOR,rash maculo-papular,rash rash generalized rash rash maculo-papular rash,1
AFINITOR,rash maculo-papular,disorder e Includes rash rash,0
AFINITOR,rash maculo-papular,rash maculo-papular rash,1
AFINITOR,rash maculo-papular,and obsessive compulsive disorder e Includes,0
AFINITOR,rash maculo-papular,rash macular,0
AFINITOR,rash maculo-papular,rash maculo-papular,1
AFINITOR,rash maculo-papular,rash rash generalized rash rash,1
AFINITOR,rash maculo-papular,rash rash,1
AFINITOR,rash papular,rash papular dermatitis allergic and urticaria AFINITOR,1
AFINITOR,rash papular,rash rash,1
AFINITOR,rash papular,rash macular rash rash papular dermatitis allergic and urticaria AFINITOR,1
AFINITOR,rash papular,rash rash,1
AFINITOR,rash papular,rash macular rash rash papular dermatitis allergic and urticaria AFINITOR,1
AFINITOR,rash papular,rash rash,1
AFINITOR,rash papular,rash papular,1
AFINITOR,rash papular,rash papular dermatitis,1
AFINITOR,rash papular,generalized rash macular rash rash papular,1
AFINITOR,rash papular,rash macular rash rash papular,1
AFINITOR,rash papular,generalized rash macular rash rash papular,1
AFINITOR,rash papular,rash papular,1
AFINITOR,rash papular,rash papular,1
AFINITOR,dermatitis allergic,rash dermatitis allergic,1
AFINITOR,dermatitis allergic,rash papular,1
AFINITOR,urticaria,urticaria AFINITOR N Placebo N All,1
AFINITOR,urticaria,urticaria AFINITOR N Placebo N All,1
AFINITOR,urticaria,N All,0
AFINITOR,urticaria,allergic urticaria AFINITOR,1
AFINITOR,urticaria,N All,0
AFINITOR,menstrual abnormalities,the menstrual abnormalities were reported dysmenorrhea menorrhagia,1
AFINITOR,menstrual abnormalities,N All,0
AFINITOR,dysmenorrhea,abnormalities were dysmenorrhea menorrhagia metrorrhagia and unspecified menstrual,1
AFINITOR,dysmenorrhea,N All,0
AFINITOR,dysmenorrhea,dysmenorrhea menorrhagia metrorrhagia and unspecified menstrual,1
AFINITOR,dysmenorrhea,r this same group of AFINITORtreated females the following menstrual,0
AFINITOR,dysmenorrhea,dysmenorrhea menorrhagia metrorrhagia,1
AFINITOR,menorrhagia,menorrhagia metrorrhagia,1
AFINITOR,menorrhagia,f AFINITORtreated females the,0
AFINITOR,menorrhagia,abnormalities were reported menorrhagia metrorrhagia,1
AFINITOR,menorrhagia,f AFINITORtreated females the,0
AFINITOR,metrorrhagia,were reported dysmenorrhea metrorrhagia and unspecified,1
AFINITOR,metrorrhagia,f AFINITORtreated females the,0
AFINITOR,metrorrhagia,were reported dysmenorrhea metrorrhagia and unspecified menstrual irregularity The,1
AFINITOR,metrorrhagia,f AFINITORtreated females the,0
AFINITOR,metrorrhagia,abnormalities were reported dysmenorrhea menorrhagia,0
AFINITOR,metrorrhagia,metrorrhagia and unspecified,1
AFINITOR,metrorrhagia,were reported dysmenorrhea metrorrhagia and unspecified menstrual irregularity The,1
AFINITOR,metrorrhagia,metrorrhagia and unspecified,1
AFINITOR,metrorrhagia,menorrhagia,0
AFINITOR,metrorrhagia,the following,0
AFINITOR,metrorrhagia,reported dysmenorrhea metrorrhagia and,1
AFINITOR,metrorrhagia,the following,0
AFINITOR,unspecified menstrual irregularity,adverse reactions occurred in less than,0
AFINITOR,unspecified menstrual irregularity,metrorrhagia unspecified,1
AFINITOR,unspecified menstrual irregularity,unspecified,1
AFINITOR,unspecified menstrual irregularity,menstrual irregularity The,1
AFINITOR,unspecified menstrual irregularity,dysmenorrhea menorrhagia metrorrhagia unspecified,1
AFINITOR,unspecified menstrual irregularity,menstrual abnormalities were reported dysmenorrhea menorrhagia metrorrhagia and,0
AFINITOR,unspecified menstrual irregularity,unspecified menstrual irregularity The following,1
AFINITOR,unspecified menstrual irregularity,unspecified menstrual irregularity,1
AFINITOR,unspecified menstrual irregularity,menstrual irregularity The following additional adverse reactions,1
AFINITOR,nausea,nausea pain in extremity,1
AFINITOR,nausea,patients,0
AFINITOR,nausea,adverse reactions occurred in less than of AFINITORtreated,0
AFINITOR,nausea,nausea pain,1
AFINITOR,nausea,nausea pain in extremity insomnia,1
AFINITOR,nausea,nausea,1
AFINITOR,pain in extremity,insomnia pneumonia epistaxis hypersensitivity increased blood luteini,0
AFINITOR,pain in extremity,insomnia pneumonia epistaxis hypersensitivity,0
AFINITOR,pain in extremity,of AFINITORtreated patients pain in extremity,1
AFINITOR,insomnia,insomnia pneumonia epistaxis hypersensitivity,1
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity,1
AFINITOR,pneumonia,nausea pain in extremity pneumonia epistaxis hypersensitivity,1
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity,1
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity increased blood,1
AFINITOR,pneumonia,extremity pneumonia,1
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity increased blood,1
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity,1
AFINITOR,pneumonia,hypersensitivity increased blood luteinizing hormone LH,0
AFINITOR,pneumonia,luteinizing hormone,0
AFINITOR,pneumonia,pneumonia epistaxis hypersensitivity increased blood,1
AFINITOR,epistaxis,hormone LH levels and pneumonitis,0
AFINITOR,hypersensitivity,hypersensitivity increased,1
AFINITOR,hypersensitivity,hormone LH levels and pneumonitis Table,0
AFINITOR,hypersensitivity,levels and pneumonitis Table,0
AFINITOR,hypersensitivity,hypersensitivity increased blood luteinizing,1
AFINITOR,hypersensitivity,hormone LH levels and pneumonitis,0
AFINITOR,hypersensitivity,pneumonia hypersensitivity increased blood luteinizing hormone LH,1
AFINITOR,hypersensitivity,hormone LH levels and pneumonitis,0
AFINITOR,hypersensitivity,in extremity insomnia pneumonia epistaxis,0
AFINITOR,hypersensitivity,hypersensitivity increased blood luteinizing hormone,1
AFINITOR,pneumonitis,Table,0
AFINITOR,pneumonitis,Laboratory Abnormalities Reported in AFINITORtreated,0
AFINITOR,pneumonitis,pneumonitis Table Key Laboratory Abnormalities Reported,1
AFINITOR,pneumonitis,Abnormalities Reported in AFINITORtreated Patients with SEGA in,0
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated creatinine,1
AFINITOR,cellulitis,and elevated creatinine,0
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated,1
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated creatinine Postmarketing,1
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated creatinine,1
AFINITOR,cellulitis,key laboratory cellulitis,1
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated creatinine,1
AFINITOR,cellulitis,laboratory cellulitis hyperglycemia and,1
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated creatinine,1
AFINITOR,cellulitis,key laboratory cellulitis,1
AFINITOR,cellulitis,cellulitis hyperglycemia and elevated creatinine,1
AFINITOR,elevated creatinine,key laboratory abnormalities cellulitis,0
AFINITOR,elevated creatinine,elevated creatinine Postmarketing Experience The following adverse,1
AFINITOR,elevated creatinine,hyperglycemia elevated creatinine,1
AFINITOR,elevated creatinine,abnormalities cellulitis,0
AFINITOR,elevated creatinine,elevated creatinine Postmarketing,1
AFINITOR,elevated creatinine,abnormalities cellulitis,0
AFINITOR,acute pancreatitis,to drug acute,1
AFINITOR,acute pancreatitis,acute pancreatitis cholecystitis cholelithiasis arterial,1
AFINITOR,acute pancreatitis,to drug acute,1
AFINITOR,acute pancreatitis,arterial thrombotic,0
AFINITOR,acute pancreatitis,to reliably estimate frequency,0
AFINITOR,acute pancreatitis,causal,0
AFINITOR,acute pancreatitis,reflex sympathetic,0
AFINITOR,acute pancreatitis,drug acute pancreatitis cholecystitis,1
AFINITOR,acute pancreatitis,reflex sympathetic,0
AFINITOR,acute pancreatitis,causal relationship to drug acute,1
AFINITOR,cholelithiasis,thrombotic events and,0
AFINITOR,cholelithiasis,cholelithiasis arterial thrombotic events and reflex,1
AFINITOR,cholelithiasis,cholelithiasis,1
AFINITOR,cholelithiasis,cholelithiasis arterial thrombotic events and,1
AFINITOR,arterial thrombotic events,thrombotic events and reflex,1
AFINITOR,Non-infectious pneumonitis,reactions are discuss ed in,1
AFINITOR,Non-infectious pneumonitis,reactions are discuss,1
AFINITOR,Non-infectious pneumonitis,serious adv,0
AFINITOR,Non-infectious pneumonitis,serious erse reactions are discuss ed,1
AFINITOR,Non-infectious pneumonitis,serious adv,0
AFINITOR,Non-infectious pneumonitis,following serious erse reactions are discuss ed,1
AFINITOR,Non-infectious pneumonitis,serious adv,0
AFINITOR,fatal,of the label e War nings and Precautions Noninfectious,1
AFINITOR,fatal,serious adv,0
AFINITOR,fatal,in greater,0
AFINITOR,Infections,utions (5. Angioedema with concomitant use,1
AFINITOR,Infections,utions (5. Angioedema with concomitant use of,1
AFINITOR,Infections,Infections see Warnings and utions (5.,1
AFINITOR,Infections,see Warnings and utions (5.,1
AFINITOR,Infections,see Warnings and utions (5. Angioedema with concomitant use of,1
AFINITOR,Infections,see Warnings and utions (5.,1
AFINITOR,Infections,utions (5. Angioedema with,1
AFINITOR,Infections,Warnings and Preca,0
AFINITOR,Infections,Precautions Infections see Warnings and,0
AFINITOR,Infections,with concomitant use,0
AFINITOR,infections,Warnings and Precautions a,1
AFINITOR,infections,with con comitant use of,1
AFINITOR,infections,Warnings and Precautions a,1
AFINITOR,infections,Precautions Infections,0
AFINITOR,infections,Precautions a with con,1
AFINITOR,infections,see,0
AFINITOR,infections,see Warnings and Precautions Oral ulceration see Warn,0
AFINITOR,Angioedema,lceration  see Warnings,1
AFINITOR,Angioedema,Precautions Oral lceration  see,1
AFINITOR,Angioedema,lceration  see Warnings,1
AFINITOR,Angioedema,failure see,0
AFINITOR,Angioedema,u,0
AFINITOR,Angioedema,see Warnings and Precautions Renal,0
AFINITOR,Angioedema,lceration  see Warnings and,1
AFINITOR,Angioedema,see,0
AFINITOR,Oral ulceration,wound healin,1
AFINITOR,Mouth ulcers,and Precautions Impaired wound,0
AFINITOR,Mouth ulcers,Precautions Because clinical trials are conducted,0
AFINITOR,Mouth ulcers,clinical trials are conducted under widely varying,0
AFINITOR,stomatitis,wound healing see and Precau tions Because clinical trials,1
AFINITOR,stomatitis,clinical trials are conducted under widely varying,0
AFINITOR,stomatitis,and Precau tions Because clinical trials,1
AFINITOR,stomatitis,and Precau tions Because clinical trials are,1
AFINITOR,stomatitis,and Precau tions,1
AFINITOR,stomatitis,wound healing see and Precau tions Because clinical,1
AFINITOR,stomatitis,and Precau tions,1
AFINITOR,stomatitis,wound healing see and Precau,1
AFINITOR,stomatitis,and Precau tions Because clinical trials are,1
AFINITOR,Renal failure,Because clinical trials,0
AFINITOR,Renal failure,may not reflect the rates,0
AFINITOR,Renal failure,eaction rates observed cannot,1
AFINITOR,Renal failure,are conducted under widely varying conditions the adverse,0
AFINITOR,renal failure,may not reflect the rates observed,0
AFINITOR,renal failure,reaction rates observed c,0
AFINITOR,renal failure,to rates in other trials and may,0
AFINITOR,renal failure,annot be dire ctly compared to,1
AFINITOR,renal failure,to rates in other trials and may,0
AFINITOR,fatal, not  reflect the rates observed,1
AFINITOR,fatal,in other trials and  not  reflect the rates,1
AFINITOR,fatal, not  reflect the rates observed,1
AFINITOR,fatal,the,0
AFINITOR,fatal, not  reflect the,1
AFINITOR,fatal, not ,1
AFINITOR,fatal, not  reflect the rates observed in,1
AFINITOR,fatal,compared to rates,0
AFINITOR,fatal,directly compared to rates in other trials and may,0
AFINITOR,fatal, not  reflect the rates observed,1
AFINITOR,fatal,trials and  not  reflect the rates observed,1
AFINITOR,fatal, not  reflect the rates observed,1
AFINITOR,Impaired wound healing,EXCERPT: A dvanced HR BC advanced PNET,1
AFINITOR,Impaired wound healing,reactions incidence include,0
AFINITOR,Impaired wound healing,PNET,0
AFINITOR,Impaired wound healing,clinical ce.,1
AFINITOR,Impaired wound healing,may not reflect the rates observed in,0
AFINITOR,Impaired wound healing,ce. EXCERPT: A dvanced HR BC,1
AFINITOR,wound-related complications,reflect the rates observed in clinical practice EXCERPT Advanced,0
AFINITOR,wound-related complications,"PNET, advanced RCC: Mo st common adverse reactions incidence",1
AFINITOR,wound-related complications,advanced RCC: Mo st common adverse,1
AFINITOR,wound-related complications,common adverse reactions incidence include stomatitis infections,0
AFINITOR,wound-related complications,rash fatigue diarrhe,0
AFINITOR,Elevations of serum creatinine,cough,0
AFINITOR,Elevations of serum creatinine,headache and decreased,0
AFINITOR,Elevations of serum creatinine,"nausea, fever, asthenia, cough",1
AFINITOR,Elevations of serum creatinine,rash fatigue diarrhea edema,0
AFINITOR,Elevations of serum creatinine,"edema pain, nausea, fever,",1
AFINITOR,Elevations of serum creatinine,rash fatigue diarrhea,0
AFINITOR,Decreases in hemoglobin,", 6.3 ) Renal an giomyolipoma with TSC Most",1
AFINITOR,Decreases in hemoglobin,"cough headache and decreased  ,  6.3  )



 Renal an giomyolipoma with",1
AFINITOR,Decreases in hemoglobin,", 6.3 ) Renal an giomyolipoma with TSC Most",1
AFINITOR,Decreases in hemoglobin,nausea fever asthenia cough,0
AFINITOR,Decreases in hemoglobin,adverse reaction incidence is,0
AFINITOR,Embryo-fetal toxicity,To report SUSPECTED ADVERSE REACTIONS contact Novartis Pharmaceut,0
AFINITOR,Embryo-fetal toxicity,contact Novartis icals Corporation at ,1
AFINITOR,Embryo-fetal toxicity,To report SUSPECTED ADVERSE REACTIONS contact Novartis Pharmaceut,0
AFINITOR,Embryo-fetal toxicity,icals Corporation at ,1
AFINITOR,Embryo-fetal toxicity,To report SUSPECTED ADVERSE REACTIONS contact Novartis Pharmaceut,0
AFINITOR,Embryo-fetal toxicity,ADVERSE REACTIONS contact Novartis,0
AFINITOR,Embryo-fetal toxicity,REACTIONS contact Novartis icals Corporation at ,1
AFINITOR,Embryo-fetal toxicity,ADVERSE REACTIONS contact Novartis,0
AFINITOR,Embryo-fetal toxicity,ADVERSE REACTIONS contact Novartis icals Corporation at  or FDA at FDA or,1
AFINITOR,Embryo-fetal toxicity,ADVERSE REACTIONS contact Novartis,0
AFINITOR,Non-infectious pneumonitis,AFINITOR mgday plus exemestane mgday n versus,0
AFINITOR,Non-infectious pneumonitis,Breast,0
AFINITOR,Non-infectious pneumonitis,placebo plus exemestane,0
AFINITOR,Non-infectious pneumonitis,ancer The efficacy and safety,0
AFINITOR,non-infectious pneumonitis,hormone receptorpositive  breast cancer. The median age of patients was,1
AFINITOR,non-infectious pneumonitis,ancer The efficacy and safety,0
AFINITOR,non-infectious pneumonitis,hormone receptorpositive  breast cancer. The median,1
AFINITOR,non-infectious pneumonitis,ancer The efficacy and safety,0
AFINITOR,non-infectious pneumonitis,or metastatic hormone receptorpositive  breast cancer. The median age of patients was years,1
AFINITOR,non-infectious pneumonitis,ancer The efficacy and safety,0
AFINITOR,non-infectious pneumonitis,in patients with advanced or metastatic hormone receptorpositive HERnegative,0
AFINITOR,non-infectious pneumonitis,or metastatic hormone receptorpositive  breast cancer. The median,1
AFINITOR,non-infectious pneumonitis,in patients with advanced or metastatic hormone receptorpositive HERnegative,0
AFINITOR,non-infectious pneumonitis,receptorpositive breast cancer.,1
AFINITOR,non-infectious pneumonitis,metastatic hormone receptorpositive  breast cancer. The median age of patients was years,1
AFINITOR,non-infectious pneumonitis,receptorpositive breast cancer.,1
AFINITOR,non-infectious pneumonitis,receptorpositive  breast cancer. The median,1
AFINITOR,non-infectious pneumonitis,receptorpositive breast cancer.,1
AFINITOR,non-infectious pneumonitis,cancer. The median age of patients,1
AFINITOR,non-infectious pneumonitis,controlled trial in patients with advanced or metastatic hormone receptorpositive,0
AFINITOR,non-infectious pneumonitis,hormone receptorpositive  breast cancer. The median age,1
AFINITOR,non-infectious pneumonitis,controlled trial in patients with advanced or metastatic hormone receptorpositive,0
AFINITOR,non-infectious pneumonitis,or metastatic hormone receptorpositive breast cancer. The,1
AFINITOR,pneumonitis, stomatitis,1
AFINITOR,pneumonitis,lip ulceration c,0
AFINITOR,pneumonitis,and,0
AFINITOR,pneumonitis,mouth ulceration aphthous stomatitis glossodynia gingival pain glossitis and lip ulceration c,0
AFINITOR,pneumonitis, stomatitis mouth ulceration aphthous,1
AFINITOR,pneumonitis,a Exemestane mgday b  stomatitis mouth ulceration aphthous stomatitis,1
AFINITOR,pneumonitis, stomatitis mouth ulceration aphthous,1
AFINITOR,pneumonitis,lip ulceration c,0
AFINITOR,pneumonitis,mgday b  stomatitis,1
AFINITOR,pneumonitis,lip ulceration c,0
AFINITOR,pneumonitis, stomatitis mouth,1
AFINITOR,pneumonitis,Exemestane mgday b  stomatitis,1
AFINITOR,pneumonitis, stomatitis mouth,1
AFINITOR,protozoal infections,tract infection upper respiratory tract infe,0
AFINITOR,protozoal infections,em,1
AFINITOR,protozoal infections,and,0
AFINITOR,protozoal infections,tract infection upper respiratory tract,0
AFINITOR,protozoal infections,em,1
AFINITOR,protozoal infections,and infestations em,1
AFINITOR,protozoal infections,within the infections,0
AFINITOR,protozoal infections,"em organ class,",1
AFINITOR,protozoal infections,infection upper respiratory,0
AFINITOR,infections with opportunistic pathogens,upper,0
AFINITOR,infections with opportunistic pathogens,"being nasopharyngitis (10%), urinary tr act infection upper respiratory",1
AFINITOR,infections with opportunistic pathogens,upper,0
AFINITOR,infections with opportunistic pathogens,"organ class the most being nasopharyngitis (10%), urinary tr act infection upper",1
AFINITOR,infections with opportunistic pathogens,upper,0
AFINITOR,infections with opportunistic pathogens,infections and infestations,0
AFINITOR,infections with opportunistic pathogens,act infection upper respiratory tract infection pneumonia bronchitis,0
AFINITOR,pneumonia,and sepsis and,0
AFINITOR,pneumonia,candidiasis and,0
AFINITOR,pneumonia,tract infection,0
AFINITOR,mycobacterial infections,"bronchitis cystitis inusitis (3%), and also  including",1
AFINITOR,mycobacterial infections,tract infection,0
AFINITOR,mycobacterial infections,C d Includes pneumonitis inte,0
AFINITOR,mycobacterial infections,cystitis s,0
AFINITOR,mycobacterial infections,"bronchitis cystitis inusitis (3%), and also  including candidiasis",1
AFINITOR,mycobacterial infections,cystitis s,0
AFINITOR,mycobacterial infections,d Includes pneumonitis inte,0
AFINITOR,mycobacterial infections,"pneumonia bronchitis cystitis inusitis (3%), and also  including candidiasis and sepsis and",1
AFINITOR,mycobacterial infections,d Includes pneumonitis inte,0
AFINITOR,mycobacterial infections,"infection pneumonia bronchitis cystitis inusitis (3%), and also  including candidiasis and sepsis and",1
AFINITOR,mycobacterial infections,d Includes pneumonitis inte,0
AFINITOR,mycobacterial infections,bronchitis,0
AFINITOR,mycobacterial infections,infection pneumonia bronchitis cystitis inusitis,1
AFINITOR,bacterial infections,"g candidiasis (<1%), and sepsis and hepatitis C",1
AFINITOR,bacterial infections,"g candidiasis (<1%),",1
AFINITOR,bacterial infections,"also g candidiasis (<1%), and sepsis",1
AFINITOR,bacterial infections,"g candidiasis (<1%),",1
AFINITOR,bacterial infections,"also g candidiasis (<1%), and",1
AFINITOR,bacterial infections,"g candidiasis (<1%),",1
AFINITOR,bacterial infections,cystitis sinusitis and also,0
AFINITOR,invasive fungal infections,"also including candidiasis nd sepsis (<1%), and hepat itis C d Includes",1
AFINITOR,invasive fungal infections,cystitis sinusitis and also,0
AFINITOR,invasive fungal infections,"including candidiasis nd sepsis (<1%), and hepat itis C",1
AFINITOR,invasive fungal infections,cystitis sinusitis and also,0
AFINITOR,invasive fungal infections,candidiasis a,0
AFINITOR,aspergillosis,d Inclu des,1
AFINITOR,aspergillosis,des pneumonitis interstitial lung disease lung infiltration and pulmonary fibrosis e Exposure,0
AFINITOR,aspergillosis,%). d,1
AFINITOR,candidiasis,s pneumonit,1
AFINITOR,candidiasis,s pneumonit is,1
AFINITOR,candidiasis,s pneumonit,1
AFINITOR,candidiasis,s pneumonit is interstitial lung disease,1
AFINITOR,candidiasis,s pneumonit is,1
AFINITOR,candidiasis,d s pneumonit is interstitial lung disease lung,1
AFINITOR,candidiasis,s pneumonit is,1
AFINITOR,pneumocystis jiroveci pneumonia,"disease, lung",1
AFINITOR,pneumocystis jiroveci pneumonia,"Includes pneumonitis nterstitial lung disease,",1
AFINITOR,pneumocystis jiroveci pneumonia,i,0
AFINITOR,pneumocystis jiroveci pneumonia,so including candidiasis and,0
AFINITOR,pneumocystis jiroveci pneumonia,pneumonitis,0
AFINITOR,pneumocystis jiroveci pneumonia,nterstitial lung,1
AFINITOR,pneumocystis jiroveci pneumonia,pulmonary,0
AFINITOR,PJP,fil,1
AFINITOR,PJP,nd sepsis and hepatitis C d Includes,0
AFINITOR,PJP,pulmonary fibrosis,0
AFINITOR,PJP,fil tration and pulmonary,1
AFINITOR,PJP,pulmonary fibrosis,0
AFINITOR,PJP,and pulmonary,0
AFINITOR,viral infections,"disease lung n, and pulmonary fibrosis e Exposure to AFINITOR",1
AFINITOR,viral infections,and pulmonary,0
AFINITOR,viral infections,and pulmonary,1
AFINITOR,viral infections,or placebo AFINITOR mgday ex,0
AFINITOR,reactivation of hepatitis B virus,infiltration and pulmonary e Exposure to AFINITOR,1
AFINITOR,reactivation of hepatitis B virus,or placeb o AFINITOR mgday,1
AFINITOR,sepsis,mgday exemestane,0
AFINITOR,sepsis,exemestane a N Placebo ane  a,1
AFINITOR,sepsis,mgday exemestane,0
AFINITOR,sepsis,ane a N All grades,1
AFINITOR,sepsis,Grade Grade All grades,0
AFINITOR,sepsis,ane a,1
AFINITOR,sepsis,mgday exemestane a,0
AFINITOR,sepsis,Grade Grade All,0
AFINITOR,hepatic failure,a                 All grades Grade,1
AFINITOR,hepatic failure,Grade Grade All,0
AFINITOR,fatal,rades Grade Grade All grades,0
AFINITOR,fatal,Placebo exemestane a All g rades Grade Grade All grades,1
AFINITOR,fatal,rades Grade Grade All grades,0
AFINITOR,angioedema,and administration site condi,0
AFINITOR,angioedema,       7   General disorders,1
AFINITOR,angioedema,       7   General disorders and administration,1
AFINITOR,angioedema,       7   General disorders,1
AFINITOR,angioedema,mouth,0
AFINITOR,angioedema,       7   General disorders and,1
AFINITOR,angioedema,and administration,0
AFINITOR,swelling of the airways,site,0
AFINITOR,swelling of the airways,      0                 General disorders,1
AFINITOR,swelling of the airways,      0                 General disorders,1
AFINITOR,swelling of the airways,      0                 General,1
AFINITOR,swelling of the airways,      0                ,1
AFINITOR,swelling of the airways,      0                 General,1
AFINITOR,swelling of the airways,Dry       0                 General disorders,1
AFINITOR,swelling of the airways,      0                 General,1
AFINITOR,swelling of the airways,mouth,0
AFINITOR,swelling of the airways,Dry,0
AFINITOR,angioedema,site conditions      27    Edema peripheral,1
AFINITOR,angioedema,Dry,0
AFINITOR,angioedema,     27    Edema peripheral,1
AFINITOR,angioedema,     27   ,1
AFINITOR,angioedema,     27   ,1
AFINITOR,angioedema,     27    Edema peripheral,1
AFINITOR,angioedema,Fatigue,0
AFINITOR,renal failure,and,0
AFINITOR,renal failure,and nutrition disorders,0
AFINITOR,renal failure,disorders,0
AFINITOR,renal failure,and nutrition,0
AFINITOR,renal failure,nutrition disorders,0
AFINITOR,renal failure,"  
       Dec reased appetite",1
AFINITOR,wound-related complications,Musculoskeletal d connective tissue,1
AFINITOR,wound-related complications,d connective tissue disorde,1
AFINITOR,wound-related complications,Musculoskeletal d connective tissue,1
AFINITOR,incisional hernia,   0.8           ,1
AFINITOR,incisional hernia,   0.8            Back,1
AFINITOR,lymphocele, 0        ,1
AFINITOR,seroma,disorders   17   Back pain,1
AFINITOR,seroma, 0        ,1
AFINITOR,seroma,  17  ,1
AFINITOR,Decreased hemoglobin,weeks weeks Key observed laboratory abnormalities are,0
AFINITOR,Decreased hemoglobin,abnormalities are resented in,1
AFINITOR,Decreased hemoglobin,Key observed laboratory abnormalities,0
AFINITOR,Decreased hemoglobin,are resented in,1
AFINITOR,Decreased hemoglobin,Table 3. Table,1
AFINITOR,Decreased hemoglobin,resented in Table 3. Table Key Laboratory Abnormalities Reported,1
AFINITOR,Decreased hemoglobin,Table 3. Table,1
AFINITOR,Decreased hemoglobin,in Table 3. Table Key Laboratory Abnormalities Reported,1
AFINITOR,Decreased hemoglobin,observed laboratory abnormalities are resented in Table 3. Table Key Laboratory,1
AFINITOR,Decreased hemoglobin,in Table 3. Table Key Laboratory Abnormalities Reported,1
AFINITOR,hepatic impairment,          5       ,1
AFINITOR,hepatic impairment,in Table 3. Table Key Laboratory Abnormalities Reported,1
AFINITOR,hepatic impairment,decreased,0
AFINITOR,hepatic impairment,          5        Platelets,1
AFINITOR,hepatic impairment,WBC           5        Platelets,1
AFINITOR,hepatic impairment,          5        Platelets,1
AFINITOR,hepatic impairment,          5        Platelets,1
AFINITOR,hepatic impairment,          5        Platelets decreased,1
AFINITOR,hepatic impairment,WBC           5       ,1
AFINITOR,hepatic impairment,          5        Platelets decreased,1
AFINITOR,fetal harm,AFINITOR,0
AFINITOR,fetal harm,with advanced PNET the,0
AFINITOR,fetal harm,a random ized controlled trial,1
AFINITOR,fetal harm,a random ized controlled trial,1
AFINITOR,embryo-fetal toxicities,AFINITOR (n=204) versus placebo n in,1
AFINITOR,embryo-fetal toxicities,with,0
AFINITOR,embryo-fetal toxicities,al of AFINITOR (n=204),1
AFINITOR,embryo-fetal toxicities,controlled al of,1
AFINITOR,embryo-fetal toxicities,randomized controlled al of AFINITOR (n=204) ,1
AFINITOR,embryo-fetal toxicities,controlled al of,1
AFINITOR,embryo-fetal toxicities,al of AFINITOR (n=204)  versus placebo n in patients,1
AFINITOR,embryo-fetal toxicities,controlled al of,1
AFINITOR,embryo-fetal toxicities,a randomized controlled al of AFINITOR (n=204)  versus placebo n in patients,1
AFINITOR,embryo-fetal toxicities,controlled al of,1
AFINITOR,embryo-fetal toxicities,of AFINITOR (n=204) versus placebo,1
ENTEREG,dyspepsia,dyspepsia To report SUSPECTED ADVERSE REACTIONS,1
ENTEREG,dyspepsia,included a bowel resection dyspepsia To report SUSPECTED,1
ENTEREG,dyspepsia,dyspepsia To report SUSPECTED ADVERSE REACTIONS,1
ENTEREG,dyspepsia,dyspepsia To,1
ENTEREG,dyspepsia,dyspepsia To report SUSPECTED ADVERSE REACTIONS,1
ENTEREG,dyspepsia,dyspepsia To,1
ENTEREG,dyspepsia,dyspepsia To report SUSPECTED ADVERSE REACTIONS,1
ENTEREG,dyspepsia,dyspepsia To report SUSPECTED ADVERSE REACTIONS,1
ENTEREG,dyspepsia,Sharp Dohme,0
ENTEREG,dyspepsia,after the first dose,0
ENTEREG,dyspepsia,that occurred after the first,0
ENTEREG,MYOCARDIAL INFARCTION,c,0
ENTEREG,MYOCARDIAL INFARCTION,REACTIONS EXCERPT The most ommon,1
ENTEREG,MYOCARDIAL INFARCTION,most ommon adverse reactio n,1
ENTEREG,MYOCARDIAL INFARCTION,REACTIONS EXCERPT The most ommon,1
ENTEREG,myocardial infarction,"dyspepsia To report SUSPECTED VERSE REACTIONS,",1
ENTEREG,myocardial infarction,"To report SUSPECTED VERSE REACTIONS, cont",1
ENTEREG,myocardial infarction,VERSE,1
ENTEREG,myocardial infarction,varying co nditions adverse,1
ENTEREG,MYOCARDIAL INFARCTION,reflect e to ENTEREG 12 mg,1
ENTEREG,MYOCARDIAL INFARCTION,reflect e to ENTEREG 12 mg,1
ENTEREG,MYOCARDIAL INFARCTION,e to ENTEREG 12 mg in patients,1
ENTEREG,MYOCARDIAL INFARCTION,reflect e to ENTEREG 12 mg,1
ENTEREG,myocardial infarction,a ery that,1
ENTEREG,myocardial infarction,Caucasian were undergoing a ery,1
ENTEREG,myocardial infarctions,common adverse n (incidence >=1.5%) o ccurring with a,1
ENTEREG,myocardial infarctions,Caucasian were undergoing a ery,1
ENTEREG,abdominal pain,or wwwfdagovmedwatch Clinical Trials,0
ENTEREG,abdominal pain,varying conditions adverse reaction rates observed,0
ENTEREG,abdominal pain,wwwfdagovmedwatch Clinical Trials Experience clinical,1
ENTEREG,abdominal pain,FDA or wwwfdagovmedwatch Clinical Trials,0
ENTEREG,abdominal pain,clinical,1
ENTEREG,abdominal pain,rates observed in the,0
ENTEREG,abdominal pain,clinical tria ls are conducted under widely,1
ENTEREG,abdominal pain,Experience clinical,1
ENTEREG,abdominal pain,conditions,0
ENTEREG,vomiting,are ted unde r,1
ENTEREG,vomiting,conditions,0
ENTEREG,vomiting,widely varying conditions adverse,0
ENTEREG,vomiting,ted unde r widely varying conditions,1
ENTEREG,vomiting,widely varying conditions adverse,0
ENTEREG,vomiting,Clinical Trials Experience Because,0
ENTEREG,vomiting,are ted unde,1
ENTEREG,vomiting,wwwfdagovmedwatch Clinical Trials Experience Because,0
ENTEREG,vomiting,trials are ted unde,1
ENTEREG,vomiting,clinical trials are ted,1
ENTEREG,myocardial infarctions,exposure to ENTEREG mg patients in 10 placebo,1
ENTEREG,myocardial infarctions,clinical trials are ted,1
ENTEREG,myocardial infarctions,daily until hospital discharge or for a maximum of days,0
ENTEREG,myocardial infarctions,or for a maximum of days of,0
ENTEREG,myocardial infarctions,the scheduled of surgery and,1
ENTEREG,myocardial infarctions,surgery and then t wice,1
ENTEREG,myocardial infarctions,of surgery and then t,1
ENTEREG,myocardial infarctions,a maximum,0
ENTEREG,myocardial infarctions,or for a maximum of,0
ENTEREG,myocardial infarctions,the scheduled  of surgery and then t,1
ENTEREG,myocardial infarctions,or for a maximum of,0
COARTEM,anorexia,anorexia dizziness asthenia arthralgia and,1
COARTEM,anorexia,reactions in adults are anorexia dizziness asthenia,1
COARTEM,anorexia,anorexia dizziness asthenia arthralgia and,1
COARTEM,anorexia,anorexia dizziness asthenia,1
COARTEM,anorexia,most common adverse,0
COARTEM,anorexia,asthenia,0
COARTEM,anorexia,most common adverse reactions in,0
COARTEM,anorexia,arthralgia,0
COARTEM,anorexia,anorexia dizziness asthenia arthralgia and myalgia,1
COARTEM,anorexia,and myalgia The most common adverse,0
COARTEM,anorexia,anorexia dizziness asthenia arthralgia,1
COARTEM,dizziness,adults are headache dizziness asthenia,1
COARTEM,dizziness,anorexia dizziness asthenia arthralgia,1
COARTEM,asthenia,adverse reactions in adults,0
COARTEM,asthenia,children,0
COARTEM,asthenia,headache anorexia dizziness,0
COARTEM,asthenia,asthenia arthralgia and myalgia,1
COARTEM,asthenia,adults are headache anorexia asthenia arthralgia and myalgia The most,1
COARTEM,asthenia,asthenia arthralgia and myalgia,1
COARTEM,asthenia,in adults are,0
COARTEM,asthenia,asthenia arthralgia and myalgia,1
COARTEM,asthenia,asthenia arthralgia,1
COARTEM,arthralgia,arthralgia,1
COARTEM,arthralgia,arthralgia and myalgia The most,1
COARTEM,arthralgia,arthralgia,1
COARTEM,arthralgia,headache anorexia dizziness arthralgia and myalgia The,1
COARTEM,arthralgia,arthralgia,1
COARTEM,myalgia,myalgia The,1
COARTEM,myalgia,myalgia,1
COARTEM,myalgia,myalgia The most common adverse,1
COARTEM,myalgia,myalgia The,1
COARTEM,myalgia,myalgia The,1
COARTEM,myalgia,myalgia The most,1
COARTEM,myalgia,myalgia The most common adverse,1
COARTEM,myalgia,most common,0
COARTEM,pyrexia,and myalgia The most common adverse reactions in children are,0
COARTEM,pyrexia,reactions in children pyrexia cough vomiting anorexia and,1
COARTEM,pyrexia,and myalgia The most common adverse reactions in children are,0
COARTEM,pyrexia,adverse,0
COARTEM,cough,cough vomiting anorexia and headache,1
COARTEM,cough,cough vomiting anorexia and headache To,1
COARTEM,cough,REACTIONS,0
COARTEM,cough,cough vomiting anorexia,1
COARTEM,cough,REACTIONS,0
COARTEM,cough,The most common adverse reactions in,0
COARTEM,cough,cough vomiting anorexia,1
COARTEM,cough,cough vomiting anorexia and headache To,1
COARTEM,cough,and headache To,0
COARTEM,anorexia,pyrexia,0
COARTEM,anorexia,pyrexia cough anorexia,1
COARTEM,anorexia,pyrexia,0
COARTEM,anorexia,To report SUSPECTED ADVERSE REACTIONS contact,0
COARTEM,anorexia,To report SUSPECTED ADVERSE REACTIONS contact Novartis Pharmaceuticals,0
COARTEM,anorexia,anorexia and headache To,1
COARTEM,anorexia,anorexia and headache To,1
COARTEM,anorexia,anorexia and headache To,1
COARTEM,anorexia,common adverse reactions in children,0
COARTEM,Hypersensitivity Reactions,Hypersensitivity Reactions see Contraindications and Adverse Reactions,1
COARTEM,Hypersensitivity Reactions,Hypersensitivity Reactions see Contraindications,1
COARTEM,anorexia,adverse reactions were anorexia dizziness and asthenia,1
COARTEM,anorexia,Hypersensitivity Reactions see Contraindications,1
COARTEM,dizziness,the most frequently reported,0
COARTEM,dizziness,were headache dizziness and asthenia In children,1
COARTEM,dizziness,the most frequently reported,0
COARTEM,dizziness,reactions,0
COARTEM,dizziness,children the adverse,0
COARTEM,dizziness,the most frequently reported,0
COARTEM,dizziness,adverse reactions were headache dizziness and,1
COARTEM,dizziness,the most frequently reported,0
COARTEM,dizziness,dizziness and asthenia In children the,1
COARTEM,dizziness,dizziness and,1
COARTEM,dizziness,headache,0
COARTEM,asthenia,dizziness asthenia In children,1
COARTEM,asthenia,headache,0
COARTEM,asthenia,frequently reported adverse reactions,0
COARTEM,asthenia,headache,0
COARTEM,asthenia,reactions were headache anorexia,0
COARTEM,asthenia,asthenia In children the,1
COARTEM,asthenia,cough vomiting anorexia and headache Most adv,0
COARTEM,asthenia,anorexia dizziness asthenia In children the adverse,1
COARTEM,asthenia,cough vomiting anorexia and headache Most adv,0
COARTEM,asthenia,asthenia In children,1
COARTEM,asthenia,headache anorexia dizziness asthenia In,1
COARTEM,asthenia,asthenia In children,1
COARTEM,pyrexia,lead to,0
COARTEM,pyrexia,reactions were headache anorexia dizziness and asthenia In children the adverse reactions were,0
COARTEM,cough,adverse reactions were mild did not,0
COARTEM,cough,cough vomiting anorexia,1
COARTEM,cough,reactions were cough vomiting anorexia and headache,1
COARTEM,cough,cough vomiting anorexia,1
COARTEM,cough,cough vomiting anorexia,1
COARTEM,cough,mild did not lead to discontinuatio,0
COARTEM,cough,cough vomiting anorexia,1
COARTEM,cough,were cough vomiting anorexia and,1
COARTEM,cough,cough vomiting anorexia,1
COARTEM,cough,were headache anorexia dizziness and asthenia In children,0
COARTEM,cough,anorexia and headache Most adverse reactions were mild did not lead,0
COARTEM,vomiting,asthenia In children the adverse,0
COARTEM,vomiting,vomiting,1
COARTEM,vomiting,vomiting,1
COARTEM,vomiting,pyrexia vomiting anorexia and,1
COARTEM,vomiting,vomiting,1
COARTEM,vomiting,were pyrexia,0
COARTEM,anorexia,not,0
COARTEM,anorexia,anorexia and,1
COARTEM,headache,medication and,0
COARTEM,headache,ness and asthenia In children the adverse,0
COARTEM,headache,headache Most adverse reactions,1
COARTEM,headache,reactions were mild did not lead to discontinuation,0
COARTEM,headache,vomiting anorexia headache Most adverse,1
COARTEM,headache,reactions were mild did not lead to discontinuation,0
COARTEM,headache,pyrexia cough vomiting anorexia headache Most adverse,1
COARTEM,headache,reactions were mild did not lead to discontinuation,0
COARTEM,headache,headache Most adverse reactions were mild,1
COARTEM,Headache,N Nervous system Headache,1
COARTEM,Headache,headache Most adverse reactions were mild,1
COARTEM,Headache,Metabolism,0
COARTEM,Headache,N Nervous system,0
COARTEM,Headache,Headache Dizziness,1
COARTEM,Arthralgia,Arthralgia,1
COARTEM,Arthralgia,and connective tissue Arthralgia Myalgia,1
COARTEM,Arthralgia,Arthralgia,1
COARTEM,Arthralgia,Arthralgia Myalgia Gastrointestinal,1
COARTEM,Arthralgia,Arthralgia,1
COARTEM,Arthralgia,tissue Arthralgia,1
COARTEM,Arthralgia,Arthralgia,1
COARTEM,Arthralgia,and connective tissue disorders,0
COARTEM,Arthralgia,Myalgia Gastrointestinal di,0
COARTEM,Myalgia,tissue disorders Myalgia Gastrointestinal,1
COARTEM,Myalgia,Myalgia Gastrointestinal di,0
COARTEM,Myalgia,connective tissue disorders Myalgia Gastrointestinal disorders Nausea,1
COARTEM,Myalgia,Myalgia Gastrointestinal di,0
COARTEM,Vomiting,Gastrointestinal disorders Vomiting Abdominal pain,1
COARTEM,Vomiting,Myalgia Gastrointestinal di,0
COARTEM,Vomiting,Vomiting Abdominal,1
COARTEM,Vomiting,Vomiting Abdominal,1
COARTEM,Vomiting,Vomiting Abdominal,1
COARTEM,Vomiting,Nausea,0
COARTEM,Vomiting,Nausea,0
COARTEM,Vomiting,Nausea,0
COARTEM,Vomiting,Vomiting Abdominal,1
COARTEM,Diarrhea,Diarrhea Psychiatric disorders Sleep,1
COARTEM,Diarrhea,Diarrhea Psychiatric,1
COARTEM,Diarrhea,Diarrhea Psychiatric,1
COARTEM,Diarrhea,Diarrhea Psychiatric disorders Sleep,1
COARTEM,Diarrhea,Abdominal Diarrhea Psychiatric disorders Sleep,1
COARTEM,Diarrhea,Diarrhea Psychiatric disorders Sleep,1
COARTEM,Diarrhea,Abdominal,0
COARTEM,Sleep disorder,Psychiatric Sleep disorder Insomnia Cardiac disorders Palp,1
COARTEM,Sleep disorder,Abdominal,0
COARTEM,Sleep disorder,Sleep disorder,1
COARTEM,Sleep disorder,Cardiac disorders Palp,0
COARTEM,Sleep disorder,Psychiatric Sleep disorder,1
COARTEM,Sleep disorder,Cardiac disorders Palp,0
COARTEM,Sleep disorder,Diarrhea,0
COARTEM,Sleep disorder,Diarrhea,0
COARTEM,Sleep disorder,disorders,0
COARTEM,Sleep disorder,Sleep disorder Insomnia Cardiac disorders,1
COARTEM,Sleep disorder,disorders,0
COARTEM,Sleep disorder,Sleep disorder Insomnia Cardiac disorders,1
COARTEM,Insomnia,Palpitations,0
COARTEM,Insomnia,Insomnia Cardiac disorders Palpitations Hepatobiliary,1
COARTEM,Insomnia,Sleep Insomnia Cardiac disorders Palpitations,1
COARTEM,Insomnia,Insomnia Cardiac disorders Palpitations Hepatobiliary,1
COARTEM,Insomnia,Sleep Insomnia,1
COARTEM,Insomnia,Insomnia Cardiac disorders Palpitations Hepatobiliary,1
COARTEM,Insomnia,Sleep,0
COARTEM,Insomnia,Insomnia,1
COARTEM,Insomnia,Sleep,0
COARTEM,Insomnia,Insomnia Cardiac disorders Palpitations Hepatobiliary d,1
COARTEM,Insomnia,Sleep,0
COARTEM,Insomnia,Insomnia Cardiac disorders Palpitations Hepatobiliary d,1
COARTEM,Palpitations,Palpitations Hepatobiliary disorders Hepatomegaly Blood and,1
COARTEM,Palpitations,Insomnia Cardiac disorders Palpitations Hepatobiliary d,1
COARTEM,Palpitations,Insomnia,0
COARTEM,Palpitations,rder Insomnia Cardiac,0
COARTEM,Palpitations,Hepatobiliary disorders Hepatomegaly Blood and,0
COARTEM,Palpitations,Palpitations,1
COARTEM,Palpitations,Hepatobiliary disorders Hepatomegaly Blood,0
COARTEM,Hepatomegaly,Hepatomegaly,1
COARTEM,Hepatomegaly,Hepatobiliary,0
COARTEM,Hepatomegaly,Hepatomegaly Blood,1
COARTEM,Hepatomegaly,Hepatomegaly Blood and,1
COARTEM,Hepatomegaly,system,0
COARTEM,Hepatomegaly,Hepatomegaly Blood and lymphatic,1
COARTEM,Splenomegaly,Anemia,0
COARTEM,Splenomegaly,Anemia Respiratory thoracic,0
COARTEM,Splenomegaly,Splenomegaly,1
COARTEM,Splenomegaly,system disorders,0
COARTEM,Splenomegaly,Anemia Respiratory,0
COARTEM,Anemia,system,0
COARTEM,Anemia,Anemia Respiratory thoracic and mediastinal,1
COARTEM,Anemia,system,0
COARTEM,Anemia,Anemia Respiratory thoracic and mediastinal disorders,1
COARTEM,Anemia,lymphatic system disorders Anemia,1
COARTEM,Anemia,Anemia Respiratory thoracic and mediastinal disorders,1
COARTEM,Anemia,Anemia Respiratory,1
COARTEM,Anemia,Anemia Respiratory thoracic and mediastinal,1
COARTEM,Anemia,lymphatic system disorders Anemia,1
COARTEM,Anemia,Anemia Respiratory thoracic and mediastinal,1
COARTEM,Anemia,and lymphatic,0
COARTEM,Anemia,Anemia Respiratory,1
COARTEM,Anemia,and,0
COARTEM,Cough,Cough Skin and,1
COARTEM,Cough,Cough Skin,1
COARTEM,Cough,Cough Skin and subcutaneous tissue disorders,1
COARTEM,Cough,and subcutaneous tissue disorders,0
COARTEM,Cough,Cough Skin,1
COARTEM,Cough,Cough Skin and subcutaneous tissue disorders,1
COARTEM,Cough,Cough Skin and subcutaneous tissue disorders,1
COARTEM,Cough,and mediastinal Cough Skin and subcutaneous,1
COARTEM,Cough,Cough Skin and subcutaneous tissue disorders,1
COARTEM,Cough,Respiratory thoracic and mediastinal Cough,1
COARTEM,Cough,Cough Skin and subcutaneous tissue disorders,1
COARTEM,Pruritus,Pruritus Rash,1
COARTEM,Pruritus,Cough Skin and subcutaneous tissue disorders,1
COARTEM,Rash,Rash,1
COARTEM,Rash,Rash Ear and labyrinth,1
COARTEM,Rash,Pruritus,0
COARTEM,Rash,subcutaneous,0
COARTEM,Rash,and subcutaneous tissue disorders Rash Ear and labyrinth,1
COARTEM,Rash,subcutaneous,0
COARTEM,Vertigo,and labyrinth disorders,0
COARTEM,Vertigo,Vertigo Infections and infestations,1
COARTEM,Vertigo,Ear and labyrinth Vertigo,1
COARTEM,Vertigo,Vertigo Infections and infestations,1
COARTEM,Vertigo,Infections and,0
COARTEM,Vertigo,Ear and labyrinth Vertigo Infections and infestations Malaria,1
COARTEM,Vertigo,Infections and,0
COARTEM,Vertigo,Vertigo Infections and,1
COARTEM,Vertigo,Vertigo Infections and infestations,1
COARTEM,Vertigo,Vertigo Infections and,1
COARTEM,Vertigo,labyrinth Vertigo Infections and infestations Malaria,1
COARTEM,Vertigo,Vertigo Infections and,1
COARTEM,Malaria,disorders Vertigo Infections and Malaria Nasopharyngitis Adult,1
COARTEM,Malaria,Vertigo Infections and,1
COARTEM,Malaria,and infestations,0
COARTEM,Nasopharyngitis,Infections and infestations Malaria,0
COARTEM,Nasopharyngitis,Infections and infestations Nasopharyngitis,1
COARTEM,Nasopharyngitis,Infections and infestations Malaria,0
COARTEM,Nasopharyngitis,Table Adverse,0
COARTEM,Nasopharyngitis,infestations Nasopharyngitis Adult patients,1
COARTEM,Nasopharyngitis,Table Adverse,0
COARTEM,Nasopharyngitis,Nasopharyngitis Adult patients defined as years,1
COARTEM,Nasopharyngitis,Nasopharyngitis Adult patients defined as years,1
COARTEM,Nasopharyngitis,and infestations Nasopharyngitis Adult patients defined as years,1
COARTEM,Nasopharyngitis,Nasopharyngitis Adult patients defined as years,1
COARTEM,Nasopharyngitis,and infestations Nasopharyngitis,1
COARTEM,Nasopharyngitis,Nasopharyngitis Adult patients defined as years,1
COARTEM,Nasopharyngitis,Malaria,0
COARTEM,Nasopharyngitis,Nasopharyngitis Adult patients defined as,1
COARTEM,Cough,Cough Gastrointestinal disorders Vomiting,1
COARTEM,Cough,Cough,1
COARTEM,Cough,mediastinal Cough Gastrointestinal disorders Vomiting,1
COARTEM,Cough,Cough,1
COARTEM,Cough,and,0
COARTEM,Cough,and mediastinal Cough Gastrointestinal,1
COARTEM,Cough,and,0
COARTEM,Cough,Cough,1
COARTEM,Vomiting,Vomiting Abdominal,1
COARTEM,Vomiting,Vomiting Abdominal pain,1
COARTEM,Vomiting,Vomiting Abdominal,1
COARTEM,Vomiting,Vomiting,1
COARTEM,Vomiting,Vomiting Abdominal,1
COARTEM,Vomiting,Vomiting Abdominal pain,1
COARTEM,Vomiting,mediastinal disorders Cough,0
COARTEM,Vomiting,mediastinal disorders Cough,0
COARTEM,Vomiting,Cough,0
COARTEM,Abdominal pain,Abdominal pain,1
COARTEM,Diarrhea,Infections and in,0
COARTEM,Diarrhea,Diarrhea Nausea Infections,1
COARTEM,Diarrhea,Infections and in,0
COARTEM,Diarrhea,Diarrhea Nausea Infections and,1
COARTEM,Diarrhea,Abdominal pain,0
COARTEM,Diarrhea,Nausea Infections,0
COARTEM,Diarrhea,Diarrhea Nausea,1
COARTEM,Diarrhea,Abdominal,0
COARTEM,Diarrhea,Diarrhea Nausea Infections and,1
COARTEM,Diarrhea,Abdominal,0
COARTEM,Nausea,Nausea,1
COARTEM,Nausea,Nausea Infections and,1
COARTEM,Nausea,Plasmodium,0
COARTEM,Nausea,Nausea Infections and infestations Plasmodium falciparum,1
COARTEM,Plasmodium falciparum infection,Metabolism and,0
COARTEM,Plasmodium falciparum infection,and infestations,0
COARTEM,Plasmodium falciparum infection,Rhinitis Metabolism and,0
COARTEM,Plasmodium falciparum infection,Infections and Plasmodium falciparum,1
COARTEM,Plasmodium falciparum infection,Nausea Infections and Plasmodium falciparum  infection Rhinitis Metabolism and,1
COARTEM,Plasmodium falciparum infection,Infections and Plasmodium falciparum,1
COARTEM,Plasmodium falciparum infection,and Plasmodium falciparum  infection,1
COARTEM,Plasmodium falciparum infection,Infections and Plasmodium falciparum,1
COARTEM,Plasmodium falciparum infection,Nausea Infections and Plasmodium,1
COARTEM,Rhinitis,Plasmodium falciparum Rhinitis Metabolism and,1
COARTEM,Rhinitis,Nausea Infections and Plasmodium,1
COARTEM,Rhinitis,infestations Plasmodium falciparum Rhinitis,1
COARTEM,Rhinitis,Nausea Infections and Plasmodium,1
COARTEM,Rhinitis,infestations Plasmodium falciparum Rhinitis Metabolism and nutrition,1
COARTEM,Rhinitis,Nausea Infections and Plasmodium,1
COARTEM,Rhinitis,Metabolism,0
COARTEM,Rhinitis,Rhinitis Metabolism and,1
COARTEM,Rhinitis,Rhinitis Metabolism and,1
COARTEM,Rhinitis,and infestations,0
COARTEM,Rhinitis,infestations Plasmodium falciparum Rhinitis Metabolism and nutrition disorders,1
COARTEM,Rhinitis,and infestations,0
COARTEM,Dizziness,lymphatic system,0
COARTEM,Dizziness,Dizziness,1
COARTEM,Dizziness,Nervous system disorders Headache,0
COARTEM,Dizziness,disorders Dizziness Blood and lymphatic system disorders,1
COARTEM,Dizziness,Nervous system disorders Headache,0
COARTEM,Dizziness,Dizziness,1
COARTEM,Dizziness,Dizziness Blood,1
COARTEM,Splenomegaly,lymphatic system Splenomegaly Anemia Hepatobiliary disorde,1
COARTEM,Splenomegaly,Dizziness Blood,1
COARTEM,Splenomegaly,Splenomegaly Anemia Hepatobiliary disorde,1
COARTEM,Splenomegaly,Splenomegaly Anemia,1
COARTEM,Splenomegaly,Splenomegaly Anemia Hepatobiliary disorde,1
COARTEM,Splenomegaly,Splenomegaly Anemia Hepatobiliary,1
COARTEM,Splenomegaly,system Splenomegaly Anemia Hepatobiliary,1
COARTEM,Splenomegaly,Splenomegaly Anemia Hepatobiliary,1
COARTEM,Splenomegaly,lymphatic system disorders,0
COARTEM,Splenomegaly,Splenomegaly Anemia Hepatobiliary disorde,1
COARTEM,Anemia,Anemia Hepatobiliary,1
COARTEM,Anemia,Anemia,1
COARTEM,Anemia,and lymphatic system disorders Anemia Hepatobiliary disorders Hepatomegaly,1
COARTEM,Anemia,Anemia,1
COARTEM,Anemia,Anemia Hepatobiliary disorders,1
COARTEM,Anemia,Anemia Hepatobiliary disorders Hepatomegaly Investi,1
COARTEM,Anemia,Hepatobiliary disorders Hepatomegaly,0
COARTEM,Anemia,Blood,0
COARTEM,Anemia,system disorders Anemia Hepatobiliary disorders Hepatomegaly,1
COARTEM,Anemia,Blood,0
COARTEM,Anemia,and lymphatic system disorders,0
COARTEM,Anemia,lymphatic system disorders Anemia Hepatobiliary disorders Hepatomegaly,1
COARTEM,Anemia,and lymphatic system disorders,0
COARTEM,Hepatomegaly,Hepatobiliary,0
COARTEM,Hepatomegaly,Hepatomegaly Investigations,1
COARTEM,Aspartate aminotransferase increased,Aspartate aminotransferase increased Musculoskeletal and,1
COARTEM,Arthralgia,Arthralgia Myalgia Skin,1
COARTEM,Arthralgia,Musculoskeletal and connective tissue Arthralgia Myalgia Skin and,1
COARTEM,Arthralgia,Arthralgia Myalgia Skin,1
COARTEM,Arthralgia,Arthralgia Myalgia,1
COARTEM,Arthralgia,Arthralgia Myalgia Skin and,1
COARTEM,Arthralgia,increased Musculoskeletal and,0
COARTEM,Arthralgia,increased Musculoskeletal and,0
COARTEM,Arthralgia,Musculoskeletal and connective tissue,0
COARTEM,Arthralgia,Skin and,0
COARTEM,Arthralgia,Myalgia,0
COARTEM,Arthralgia,Arthralgia Myalgia Skin and subcutaneo,1
COARTEM,Myalgia,tissue disorders Rash,0
COARTEM,Myalgia,and,0
COARTEM,Myalgia,Skin and subcutaneous tissue,0
COARTEM,Myalgia,Myalgia Skin and subcutaneous,1
COARTEM,Myalgia,Arthralgia,0
COARTEM,Myalgia,Myalgia Skin and subcutaneous tissue,1
COARTEM,Myalgia,Myalgia Skin,1
COARTEM,Myalgia,Myalgia Skin and subcutaneous tissue disorders,1
COARTEM,Myalgia,Myalgia Skin and subcutaneous tissue,1
COARTEM,Myalgia,tissue disorders,0
COARTEM,Rash,Rash Children defined as patients years,1
COARTEM,Rash,Myalgia,0
COARTEM,Rash,patients years of,0
COARTEM,Rash,Myalgia,0
COARTEM,eosinophilia,and lymphatic system eosinophilia Ear and labyrinth disorders,1
COARTEM,eosinophilia,Myalgia,0
COARTEM,tinnitus,tinnitus Eye disorders conjunctivitis Gastrointestinal,1
COARTEM,tinnitus,lymphatic system,0
COARTEM,tinnitus,tinnitus Eye disorders conjunctivitis,1
COARTEM,conjunctivitis,constipation dyspepsia dysphagia peptic ulcer,0
COARTEM,conjunctivitis,conjunctivitis Gastrointestinal disorders constipation dyspepsia,1
COARTEM,conjunctivitis,conjunctivitis Gastrointestinal,1
COARTEM,conjunctivitis,tinnitus Eye conjunctivitis Gastrointestinal disorders constipation dyspepsia dysphagia,1
COARTEM,conjunctivitis,conjunctivitis Gastrointestinal,1
COARTEM,constipation,constipation,1
COARTEM,dyspepsia,innitus Eye disorders conjunctivitis,0
COARTEM,peptic ulcer,peptic,1
COARTEM,peptic ulcer,Gastrointestinal disorders constipation dyspepsia peptic,1
COARTEM,peptic ulcer,peptic ulcer,1
COARTEM,peptic ulcer,peptic ulcer,1
COARTEM,peptic ulcer,peptic ulcer,1
COARTEM,peptic ulcer,disorders gait,0
COARTEM,abscess,abscess acrodermatitis bronchitis ear,1
COARTEM,abscess,abscess acrodermatitis bronchitis ear,1
COARTEM,abscess,acrodermatitis bronchitis ear infection gastroenteritis helminthic,0
COARTEM,abscess,abscess acrodermatitis,1
COARTEM,abscess,ear infection,0
COARTEM,abscess,and abscess,1
COARTEM,abscess,ear infection,0
COARTEM,abscess,abscess acrodermatitis bronchitis ear infection gastroenteritis,1
COARTEM,abscess,disorders gait,0
COARTEM,bronchitis,bronchitis ear infection,1
COARTEM,bronchitis,abscess bronchitis ear infection gastroenteritis helminthic,1
COARTEM,bronchitis,bronchitis ear infection,1
COARTEM,bronchitis,bronchitis ear infection,1
COARTEM,bronchitis,helminthic infection hookworm infection impetigo influenza,0
COARTEM,bronchitis,bronchitis ear infection gastroenteritis,1
COARTEM,bronchitis,helminthic infection hookworm infection impetigo influenza,0
COARTEM,bronchitis,Infections and infestations abscess acrodermatitis,0
COARTEM,bronchitis,bronchitis,1
COARTEM,bronchitis,Infections and infestations abscess bronchitis ear infection gastroenteritis helminthic,1
COARTEM,bronchitis,bronchitis,1
COARTEM,bronchitis,bronchitis ear,1
COARTEM,bronchitis,infestations abscess bronchitis,1
COARTEM,bronchitis,bronchitis ear,1
COARTEM,ear infection,ear infection gastroenteritis helminthic infection hookworm,1
COARTEM,ear infection,abscess acrodermatitis ear,1
COARTEM,ear infection,abscess acrodermatitis ear,1
COARTEM,ear infection,infestations abscess,0
COARTEM,ear infection,infestations abscess acrodermatitis ear infection gastroenteritis helminthic infection hookworm,1
COARTEM,ear infection,infestations abscess,0
COARTEM,ear infection,infection impetigo influenza,0
COARTEM,ear infection,ear infection gastroenteritis helminthic,1
COARTEM,ear infection,abscess acrodermatitis,0
COARTEM,ear infection,abscess acrodermatitis ear infection,1
COARTEM,ear infection,gait disturbance Infections and infestations abscess,0
COARTEM,gastroenteritis,Infections and infestations abscess acrodermatitis bronchitis,0
COARTEM,gastroenteritis,acrodermatitis bronchitis ear gastroenteritis helminthic,1
COARTEM,gastroenteritis,Infections and infestations abscess acrodermatitis bronchitis,0
COARTEM,gastroenteritis,gastroenteritis helminthic infection,1
COARTEM,gastroenteritis,ear gastroenteritis helminthic infection,1
COARTEM,gastroenteritis,gastroenteritis helminthic infection,1
COARTEM,gastroenteritis,gastroenteritis,1
COARTEM,gastroenteritis,bronchitis ear infection,0
COARTEM,gastroenteritis,ear gastroenteritis helminthic infection,1
COARTEM,gastroenteritis,bronchitis ear infection,0
COARTEM,gastroenteritis,ear gastroenteritis helminthic infection hookworm infection impetigo,1
COARTEM,gastroenteritis,bronchitis ear infection,0
COARTEM,gastroenteritis,Infections and infestations,0
COARTEM,gastroenteritis,infection,0
COARTEM,helminthic infection,helminthic infection hookworm infection impetigo influenza,1
COARTEM,helminthic infection,lower respiratory tract infection malaria,0
COARTEM,helminthic infection,and infestations abscess acrodermatitis bronchitis ear,0
COARTEM,helminthic infection,bronchitis ear infection helminthic      infection hookworm infection impetigo influenza lower,1
COARTEM,helminthic infection,and infestations abscess acrodermatitis bronchitis ear,0
COARTEM,helminthic infection,ear infection helminthic,1
COARTEM,helminthic infection,bronchitis ear infection helminthic      infection hookworm infection impetigo influenza lower,1
COARTEM,helminthic infection,ear infection helminthic,1
COARTEM,hookworm infection,lower respiratory tract,0
COARTEM,hookworm infection,impetigo influenza lower respiratory tract infection malaria nasopharyngitis,0
COARTEM,impetigo,hookworm impetigo,1
COARTEM,impetigo,impetigo influenza lower respiratory tract infection malaria nasopharyngitis,0
COARTEM,impetigo,impetigo influenza lower respiratory tract infection,1
COARTEM,impetigo,impetigo influenza lower respiratory tract infection malaria nasopharyngitis,0
COARTEM,impetigo,ear,0
COARTEM,impetigo,infection,0
COARTEM,impetigo,impetigo influenza lower respiratory,1
COARTEM,impetigo,respiratory tract infection malaria,0
COARTEM,impetigo,gastroenteritis helminthic infection hookworm impetigo influenza,1
COARTEM,impetigo,respiratory tract infection malaria,0
COARTEM,impetigo,impetigo influenza lower,1
COARTEM,impetigo,impetigo influenza lower respiratory tract infection,1
COARTEM,impetigo,impetigo influenza lower,1
COARTEM,influenza,influenza lower respiratory tract,1
COARTEM,influenza,influenza lower respiratory tract infection malaria,1
COARTEM,influenza,ronchitis ear infection gastroenteritis helminthic infection hookworm infection,0
COARTEM,influenza,infection hookworm,0
COARTEM,influenza,respiratory tract infection malaria nasopharyngitis oral herpes,0
COARTEM,lower respiratory tract infection,infection impetigo lower respiratory tract infection malaria nasopharyngitis oral herpes pneumonia,1
COARTEM,lower respiratory tract infection,respiratory tract infection malaria nasopharyngitis oral herpes,0
COARTEM,lower respiratory tract infection,influenza,0
COARTEM,lower respiratory tract infection,malaria nasopharyngitis oral herpes pneumonia respiratory,0
COARTEM,lower respiratory tract infection,nasopharyngitis oral herpes,0
COARTEM,malaria,malaria nasopharyngitis,1
COARTEM,malaria,pneumonia respiratory,0
COARTEM,malaria,tract,0
COARTEM,malaria,malaria nasopharyngitis oral,1
COARTEM,malaria,nasopharyngitis oral herpes pneumonia respiratory tract infection subcutaneous abscess,0
COARTEM,malaria,malaria,1
COARTEM,malaria,hookworm infection impetigo influenza lower respiratory tract,0
COARTEM,malaria,infection hookworm infection impetigo influenza lower respiratory tract,0
COARTEM,malaria,minthic infection hookworm infection impetigo,0
COARTEM,nasopharyngitis,oral herpes pneumonia respiratory tract infection subcutaneous abscess upper,0
COARTEM,nasopharyngitis,subcutaneous abscess upper,0
COARTEM,nasopharyngitis,nasopharyngitis oral herpes pneumonia respiratory tract,1
COARTEM,nasopharyngitis,pneumonia,0
COARTEM,nasopharyngitis,nasopharyngitis oral herpes pneumonia respiratory tract,1
COARTEM,nasopharyngitis,hookworm infection impetigo influenza lower respiratory,0
COARTEM,nasopharyngitis,nasopharyngitis oral herpes pneumonia respiratory tract,1
COARTEM,nasopharyngitis,influenza lower respiratory tract infection,0
COARTEM,pneumonia,oral,0
COARTEM,pneumonia,pneumonia respiratory tract infection,1
COARTEM,pneumonia,oral,0
COARTEM,pneumonia,pneumonia respiratory tract infection subcutaneous abscess,1
COARTEM,pneumonia,influenza lower respiratory tract,0
COARTEM,pneumonia,tract infection,0
COARTEM,respiratory tract infection,oral herpes respiratory tract infection,1
COARTEM,respiratory tract infection,subcutaneous abscess,0
COARTEM,respiratory tract infection,malaria nasopharyngitis oral herpes respiratory tract,1
COARTEM,respiratory tract infection,nfluenza lower respiratory tract infection,0
COARTEM,respiratory tract infection,pneumonia,0
COARTEM,respiratory tract infection,herpes respiratory tract infection subcutaneous abscess upper respiratory,1
COARTEM,respiratory tract infection,pneumonia,0
COARTEM,respiratory tract infection,respiratory tract infection subcutaneous abscess,1
COARTEM,respiratory tract infection,pneumonia,0
COARTEM,subcutaneous abscess,herpes pneumonia respiratory tract subcutaneous abscess,1
COARTEM,subcutaneous abscess,herpes pneumonia respiratory tract subcutaneous abscess upper respiratory tract,1
COARTEM,subcutaneous abscess,herpes pneumonia respiratory tract subcutaneous abscess,1
COARTEM,subcutaneous abscess,subcutaneous abscess upper respiratory,1
COARTEM,subcutaneous abscess,herpes pneumonia respiratory tract subcutaneous abscess,1
COARTEM,upper respiratory tract infection,respiratory,0
COARTEM,upper respiratory tract infection,respiratory tract infection urinary,1
COARTEM,upper respiratory tract infection,a nasopharyngitis oral herpes pneumonia respiratory,0
COARTEM,upper respiratory tract infection,infection,0
COARTEM,urinary tract infection,urinary tract infection Investigations alanine aminotransferase increased,1
COARTEM,urinary tract infection,urinary tract,1
COARTEM,urinary tract infection,infection subcutaneous abscess upper,0
COARTEM,urinary tract infection,tract infection Investigations alanine aminotransferase,1
COARTEM,urinary tract infection,upper respiratory,0
COARTEM,urinary tract infection,abscess upper respiratory tract urinary tract,1
COARTEM,urinary tract infection,infection subcutaneous abscess upper respiratory tract infection,0
COARTEM,urinary tract infection,respiratory tract urinary tract infection Investigations alanine aminotransferase,1
COARTEM,urinary tract infection,infection subcutaneous abscess upper respiratory tract infection,0
COARTEM,urinary tract infection,tract urinary tract infection Investigations,1
COARTEM,urinary tract infection,infection subcutaneous abscess upper respiratory tract infection,0
COARTEM,urinary tract infection,tract infection Investigations alanine aminotransferase increased aspartate,1
COARTEM,alanine aminotransferase increased,upper respiratory,0
COARTEM,alanine aminotransferase increased,infection,0
COARTEM,alanine aminotransferase increased,infection Investigations,0
COARTEM,aspartate aminotransferase increased,urinary tract infection,0
COARTEM,aspartate aminotransferase increased,ct infection urinary tract infection,0
COARTEM,aspartate aminotransferase increased,aspartate aminotransferase increased hematocrit,1
COARTEM,aspartate aminotransferase increased,count decreased platelet,0
COARTEM,aspartate aminotransferase increased,alanine aminotransferase aspartate aminotransferase increased hematocrit decreased lymphocyte morphology abnormal,1
COARTEM,aspartate aminotransferase increased,count decreased platelet,0
COARTEM,aspartate aminotransferase increased,hematocrit decreased lymphocyte morphology,0
COARTEM,hematocrit decreased,Investigations,0
COARTEM,hematocrit decreased,increased,0
COARTEM,hematocrit decreased,increased,0
COARTEM,hematocrit decreased,increased,0
COARTEM,hematocrit decreased,abnormal platelet,0
COARTEM,hematocrit decreased,aspartate aminotransferase hematocrit      decreased lymphocyte morphology abnormal,1
COARTEM,hematocrit decreased,abnormal platelet,0
COARTEM,hematocrit decreased,Investigations,0
COARTEM,hematocrit decreased,hematocrit      decreased lymphocyte morphology abnormal platelet,1
COARTEM,hematocrit decreased,Investigations,0
COARTEM,hematocrit decreased,aminotransferase increased aspartate aminotransferase hematocrit      decreased lymphocyte morphology,1
COARTEM,hematocrit decreased,Investigations,0
COARTEM,hematocrit decreased,aspartate aminotransferase,0
COARTEM,lymphocyte morphology abnormal,decreased,0
COARTEM,lymphocyte morphology abnormal,lymphocyte morphology abnormal,1
COARTEM,lymphocyte morphology abnormal,decreased,0
COARTEM,lymphocyte morphology abnormal,lymphocyte morphology,1
COARTEM,lymphocyte morphology abnormal,increased white blood cell count decreased,0
COARTEM,lymphocyte morphology abnormal,aminotransferase increased hematocrit lymphocyte,1
COARTEM,platelet count increased,count increased,0
COARTEM,platelet count increased,cell count decreased,0
COARTEM,platelet count increased,abnormal platelet,0
COARTEM,platelet count increased,cell count decreased white blood cell count increased,0
COARTEM,white blood cell count decreased,white blood cell count increased Metabolism and nutrition disorders hypokalemia,0
COARTEM,white blood cell count decreased,white,1
COARTEM,white blood cell count decreased,cell count decreased white,1
COARTEM,white blood cell count decreased,blood cell count decreased white blood cell count,1
COARTEM,white blood cell count decreased,decreased platelet count white blood cell,1
COARTEM,white blood cell count decreased,increased Metabolism and nutrition,0
COARTEM,white blood cell count decreased,Metabolism and,0
COARTEM,white blood cell count decreased,decreased platelet,0
COARTEM,white blood cell count increased,hypokalemia Musculoskeletal and,0
COARTEM,white blood cell count increased,white blood,1
COARTEM,hypokalemia,hypokalemia Musculoskeletal and connective,1
COARTEM,back pain,nutrition disorders hypokalemia Musculoskeletal and connective tissue disorders,0
COARTEM,back pain,disorders,0
COARTEM,back pain,connective tissue back pain Nervous system,1
COARTEM,back pain,disorders,0
COARTEM,back pain,disorders,0
COARTEM,back pain,connective tissue back pain Nervous,1
COARTEM,back pain,disorders,0
COARTEM,back pain,tissue back pain,1
COARTEM,back pain,back pain Nervous system,1
COARTEM,back pain,back pain Nervous system disorders,1
COARTEM,back pain,back pain Nervous system,1
COARTEM,ataxia,connective tissue disorders back pain,0
COARTEM,ataxia,ataxia clonus,1
COARTEM,ataxia,connective tissue disorders back pain,0
COARTEM,ataxia,ataxia clonus fine motor,1
COARTEM,ataxia,and connective,0
COARTEM,ataxia,motor delay,0
COARTEM,ataxia,hyperreflexia hypoesthesia nystagmus tremor Psychiatri,0
COARTEM,ataxia,system,0
COARTEM,ataxia,back pain,0
COARTEM,ataxia,ataxia clonus fine,1
COARTEM,ataxia,fine motor delay hyperreflexia hypoesthesia,0
COARTEM,clonus,clonus,1
COARTEM,fine motor delay,disorders ataxia fine motor delay hyperreflexia,1
COARTEM,fine motor delay,clonus,1
COARTEM,fine motor delay,clonus,0
COARTEM,fine motor delay,motor delay hyperreflexia,1
COARTEM,fine motor delay,fine,1
COARTEM,hyperreflexia,system disorders ataxia clonus fine,0
COARTEM,hyperreflexia,Psychiatric,0
COARTEM,hyperreflexia,agitation,0
COARTEM,hyperreflexia,hyperreflexia hypoesthesia nystagmus,1
COARTEM,hyperreflexia,disorders agitation mood,0
COARTEM,hyperreflexia,ataxia clonus fine motor hyperreflexia hypoesthesia nystagmus tremor Psychiatric,1
COARTEM,hyperreflexia,disorders agitation mood,0
COARTEM,hyperreflexia,ataxia clonus fine motor hyperreflexia hypoesthesia nystagmus tremor Psychiatric,1
COARTEM,hyperreflexia,disorders agitation mood,0
COARTEM,hyperreflexia,hyperreflexia hypoesthesia nystagmus tremor Psychiatric,1
COARTEM,hyperreflexia,hyperreflexia,1
COARTEM,hypoesthesia,motor delay,0
COARTEM,hypoesthesia,pain Nervous system disorders ataxia,0
COARTEM,hypoesthesia,hypoesthesia nystagmus tremor Psychiatric,1
COARTEM,nystagmus,nystagmus tremor,1
COARTEM,nystagmus,nystagmus tremor Psychiatric disorders agitation,1
COARTEM,nystagmus,delay hyperreflexia,0
COARTEM,nystagmus,system disorders ataxia clonus fine motor delay hyperreflexia hypoesthesia,0
COARTEM,tremor,and,0
COARTEM,tremor,tremor Psychiatric disorders,1
COARTEM,tremor,disorders agitation mood,0
COARTEM,agitation,motor delay,0
COARTEM,agitation,agitation mood swings Renal and urinary,1
COARTEM,agitation,disorders hematuria proteinuria,0
COARTEM,agitation,agitation mood swings Renal and urinary,1
COARTEM,mood swings,hyperreflexia hypoesthesia nystagmus tremor Psychiatric disorders,0
COARTEM,mood swings,mood swings Renal and urinary,1
COARTEM,mood swings,mood swings Renal and urinary disorders hematuria,1
COARTEM,mood swings,mood swings Renal and,1
COARTEM,mood swings,nystagmus tremor Psychiatric disorders mood swings,1
COARTEM,mood swings,mood swings Renal and,1
COARTEM,mood swings,mood swings Renal and urinary disorders hematuria,1
COARTEM,mood swings,agitation,0
COARTEM,mood swings,disorders mood swings,1
COARTEM,mood swings,Psychiatric disorders mood swings,1
COARTEM,mood swings,disorders mood swings,1
COARTEM,mood swings,disorders mood swings,1
COARTEM,hematuria,Renal and urinary hematuria,1
COARTEM,hematuria,disorders mood swings,1
COARTEM,hematuria,swings Renal and urinary hematuria,1
COARTEM,hematuria,disorders mood swings,1
COARTEM,hematuria,and urinary hematuria proteinuria,1
COARTEM,hematuria,disorders mood swings,1
COARTEM,hematuria,urinary,0
COARTEM,hematuria,thoracic and,0
COARTEM,hematuria,Respiratory thoracic and mediastinal disorders,0
COARTEM,hematuria,agitation mood swings Renal and urinary,0
COARTEM,hematuria,thoracic and mediastinal disorders,0
COARTEM,hematuria,hematuria proteinuria,1
COARTEM,hematuria,disorders,0
COARTEM,asthma,asthma pharyngolaryngeal pain Skin and subcutaneous,1
COARTEM,asthma,pharyngolaryngeal pain Skin and subcutaneous tissue,0
COARTEM,pharyngo-laryngeal pain,urticaria,0
COARTEM,pharyngo-laryngeal pain,pharyngo-laryngeal pain Skin and subcutaneous tissue disorders,1
COARTEM,pharyngo-laryngeal pain,disorders,0
COARTEM,pharyngo-laryngeal pain,subcutaneous,0
COARTEM,urticaria,and subcutaneous tissue urticaria Postmarketing Experience The,1
COARTEM,urticaria,subcutaneous,0
COARTEM,urticaria,been identified,0
COARTEM,urticaria,have,0
COARTEM,urticaria,Skin and,0
COARTEM,anaphylaxis,Hypersensitivity,0
COARTEM,anaphylaxis,drug exposure Hypersensitivity anaphylaxis urticaria angioedema and serious,1
COARTEM,anaphylaxis,Hypersensitivity,0
COARTEM,anaphylaxis,Hypersensitivity anaphylaxis urticaria angioedema and serious,1
COARTEM,anaphylaxis,Hypersensitivity,0
COARTEM,anaphylaxis,bullous eruption,0
COARTEM,urticaria,urticaria angioedema and serious skin,1
COARTEM,urticaria,urticaria angioedema and serious skin,1
COARTEM,urticaria,Hypersensitivity reactions,0
COARTEM,urticaria,to drug exposure Hypersensitivity reactions,0
COARTEM,urticaria,urticaria angioedema and serious,1
COARTEM,urticaria,urticaria angioedema and serious skin reactions,1
COARTEM,urticaria,urticaria angioedema,1
COARTEM,urticaria,and serious skin,0
COARTEM,urticaria,urticaria,1
COARTEM,urticaria,skin reactions bullous eruption have been reported,0
COARTEM,angioedema,angioedema and serious skin,1
COARTEM,angioedema,relationship to drug exposure,0
COARTEM,angioedema,Hypersensitivity,0
COARTEM,angioedema,angioedema and serious skin reactions bullous,1
COARTEM,skin reactions,and skin,1
COARTEM,skin reactions,urticaria angioedema and skin,1
COARTEM,skin reactions,angioedema and,0
COARTEM,skin reactions,skin reactions,1
COARTEM,bullous eruption,bullous,1
COARTEM,bullous eruption,skin bullous,1
COARTEM,bullous eruption,skin bullous eruption,1
COARTEM,bullous eruption,have,0
COARTEM,bullous eruption,angioedema and serious skin bullous eruption,1
COARTEM,bullous eruption,angioedema and serious skin bullous eruption have,1
COARTEM,bullous eruption,angioedema and serious skin bullous eruption,1
COARTEM,bullous eruption,have been reported,0
COARTEM,prolongation of the QT interval,sure to a 6-dose regimen of Coa,1
COARTEM,prolongation of the QT interval,have been reported,0
COARTEM,prolongation of the QT interval,data described below reflect,0
COARTEM,prolongation of the QT interval,of Coa rtem Tablets in patients,1
COARTEM,prolongation of the QT interval,sure,1
COARTEM,prolongation of the QT interval,described below reflect sure to a 6-dose regimen of Coa rtem Tablets,1
COARTEM,prolongation of the QT interval,sure,1
COARTEM,prolongation of the QT interval,and children,0
COARTEM,QT prolongation,Hepatomegaly,0
COARTEM,QT prolongation,Blood and ly,1
COARTEM,QT prolongation,"disorders  
 Blood and ly mphatic system",1
COARTEM,QT prolongation,Blood and ly,1
COARTEM,QT prolongation,Blood and ly,1
COARTEM,QT prolongation,system disorders Splenomegaly Anemia,0
COARTEM,QT prolongation,Blood and ly mphatic system,1
COARTEM,QT prolongation,Hepatobiliary disorders Hepatomegaly,0
COARTEM,QT prolongation,Hepatomegaly,0
COARTEM,QT prolongation,disorders Blood and ly,1
COARTEM,QT prolongation,and ly mphatic system,1
DALVANCE,nausea,nausea,1
DALVANCE,nausea,with DALVANCE nausea headache,1
DALVANCE,nausea,nausea,1
DALVANCE,nausea,nausea headache and diarrhea,1
DALVANCE,headache,headache and diarrhea,1
DALVANCE,diarrhea,were nausea headache and,0
DALVANCE,diarrhea,reactions in patients treated with DALVANCE were,0
DALVANCE,diarrhea,REACTIONS,0
DALVANCE,diarrhea,diarrhea To report SUSPECTED ADVERSE,1
DALVANCE,diarrhea,and,0
DALVANCE,diarrhea,diarrhea To report,1
DALVANCE,nausea,with DALVANCE nausea headache and,1
DALVANCE,nausea,diarrhea To report,1
DALVANCE,nausea,patients treated with,0
DALVANCE,nausea,nausea headache,1
DALVANCE,headache,headache and diarrhea The,1
DALVANCE,headache,with DALVANCE were headache and diarrhea,1
DALVANCE,headache,headache and diarrhea The,1
DALVANCE,headache,DALVANCE were headache and diarrhea,1
DALVANCE,headache,headache and diarrhea The,1
DALVANCE,headache,headache,1
DALVANCE,headache,with DALVANCE,0
DALVANCE,headache,were headache and diarrhea,1
DALVANCE,headache,with DALVANCE,0
DALVANCE,headache,headache and diarrhea The median,1
DALVANCE,headache,with DALVANCE were headache and,1
DALVANCE,headache,headache and diarrhea The median,1
DALVANCE,headache,headache and diarrhea The median duration,1
DALVANCE,headache,headache,1
DALVANCE,diarrhea,were nausea headache diarrhea The median duration of,1
DALVANCE,diarrhea,headache,1
DALVANCE,diarrhea,diarrhea The,1
DALVANCE,diarrhea,headache,1
DALVANCE,diarrhea,diarrhea The median duration,1
DALVANCE,diarrhea,nausea headache diarrhea The,1
DALVANCE,diarrhea,diarrhea The median duration,1
DALVANCE,diarrhea,diarrhea The,1
DALVANCE,anemia,anemia hemorrhagic,1
DALVANCE,anemia,anemia,1
DALVANCE,hemorrhagic anemia,trials Blood and lymphatic system disorders,0
DALVANCE,hemorrhagic anemia,hemorrhagic anemia,1
DALVANCE,hemorrhagic anemia,hemorrhagic anemia leucopenia neutropenia thrombocytopenia,1
DALVANCE,hemorrhagic anemia,Blood and,0
DALVANCE,leucopenia,lymphatic system,0
DALVANCE,leucopenia,eosinophilia thrombocytosis Gastrointestinal diso,0
DALVANCE,leucopenia,anemia hemorrhagic leucopenia neutropenia thrombocytopenia petechiae eosinophilia,1
DALVANCE,leucopenia,eosinophilia thrombocytosis Gastrointestinal diso,0
DALVANCE,leucopenia,hemorrhagic leucopenia neutropenia thrombocytopenia petechiae eosinophilia,1
DALVANCE,leucopenia,eosinophilia thrombocytosis Gastrointestinal diso,0
DALVANCE,neutropenia,Blood and lymphatic system,0
DALVANCE,thrombocytopenia,thrombocytopenia petechiae eosinophilia thrombocytosis Gastrointestinal,1
DALVANCE,thrombocytopenia,disorders anemia,0
DALVANCE,thrombocytopenia,thrombocytopenia petechiae eosinophilia thrombocytosis Gastrointestinal disorders,1
DALVANCE,thrombocytopenia,thrombocytopenia petechiae eosinophilia thrombocytosis Gastrointestinal disorders,1
DALVANCE,thrombocytopenia,thrombocytosis Gastrointestinal disorders,0
DALVANCE,thrombocytopenia,thrombocytopenia petechiae,1
DALVANCE,thrombocytopenia,thrombocytopenia,1
DALVANCE,petechiae,petechiae eosinophilia thrombocytosis Gastrointestinal disorders gastrointestinal,1
DALVANCE,eosinophilia,eosinophilia thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage,1
DALVANCE,eosinophilia,hemorrhage melena,0
DALVANCE,eosinophilia,eosinophilia thrombocytosis Gastrointestinal,1
DALVANCE,eosinophilia,anemia,0
DALVANCE,eosinophilia,eosinophilia thrombocytosis Gastrointestinal disorders gastrointestinal,1
DALVANCE,eosinophilia,anemia hemorrhagic anemia leucopenia neutropenia thrombocytopenia petechiae,0
DALVANCE,eosinophilia,eosinophilia thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage,1
DALVANCE,eosinophilia,eosinophilia thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage,1
DALVANCE,eosinophilia,eosinophilia thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage,1
DALVANCE,thrombocytosis,hemorrhage melena,0
DALVANCE,thrombocytosis,thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage melena,1
DALVANCE,thrombocytosis,thrombocytosis,1
DALVANCE,thrombocytosis,thrombocytosis Gastrointestinal,1
DALVANCE,thrombocytosis,thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage,1
DALVANCE,gastrointestinal hemorrhage,Gastrointestinal gastrointestinal hemorrhage melena hematochezia abdominal pain General,1
DALVANCE,gastrointestinal hemorrhage,thrombocytosis Gastrointestinal disorders gastrointestinal hemorrhage,1
DALVANCE,gastrointestinal hemorrhage,petechiae eosinophilia thrombocytosis,0
DALVANCE,gastrointestinal hemorrhage,administration site,0
DALVANCE,gastrointestinal hemorrhage,gastrointestinal hemorrhage,1
DALVANCE,gastrointestinal hemorrhage,petechiae eosinophilia thrombocytosis Gastrointestinal gastrointestinal hemorrhage melena,1
DALVANCE,gastrointestinal hemorrhage,gastrointestinal hemorrhage,1
DALVANCE,gastrointestinal hemorrhage,eosinophilia thrombocytosis Gastrointestinal gastrointestinal hemorrhage melena hematochezia abdominal,1
DALVANCE,gastrointestinal hemorrhage,gastrointestinal hemorrhage,1
DALVANCE,gastrointestinal hemorrhage,hematochezia abdominal pain General disorders,0
DALVANCE,melena,melena,1
DALVANCE,hematochezia,hematochezia abdominal pain General disorders,1
DALVANCE,abdominal pain,melena,0
DALVANCE,abdominal pain,hemorrhage melena abdominal pain General disorders,1
DALVANCE,abdominal pain,melena,0
DALVANCE,abdominal pain,melena abdominal pain,1
DALVANCE,infusion-related reactions,infusion-related reactions,1
DALVANCE,infusion-related reactions,disorders anaphylactoid reac,0
DALVANCE,infusion-related reactions,administration site infusion-related,1
DALVANCE,infusion-related reactions,General disorders and,0
DALVANCE,infusion-related reactions,site,0
DALVANCE,infusion-related reactions,and administration site infusion-related,1
DALVANCE,infusion-related reactions,infusion-related reactions Hepatobiliary disorders,1
DALVANCE,infusion-related reactions,site infusion-related reactions Hepatobiliary disorders,1
DALVANCE,infusion-related reactions,infusion-related reactions Hepatobiliary disorders,1
DALVANCE,infusion-related reactions,and administration site infusion-related reactions Hepatobiliary disorders,1
DALVANCE,infusion-related reactions,infusion-related reactions Hepatobiliary disorders,1
DALVANCE,hepatotoxicity,and,0
DALVANCE,anaphylactoid reaction,anaphylactoid reaction Infections and infestations Clostridium,1
DALVANCE,anaphylactoid reaction,and infestations Clostridium difficile,0
DALVANCE,oral candidiasis,and,0
DALVANCE,oral candidiasis,and infestations Clostridium difficile,0
DALVANCE,oral candidiasis,and infestations Clostridium difficile oral candidiasis,1
DALVANCE,oral candidiasis,Clostridium difficile oral candidiasis,1
DALVANCE,oral candidiasis,difficile oral candidiasis,1
DALVANCE,oral candidiasis,difficile oral candidiasis vulvovaginal mycotic infection Investigations,1
DALVANCE,oral candidiasis,difficile oral candidiasis,1
DALVANCE,oral candidiasis,Clostridium difficile,0
DALVANCE,oral candidiasis,Investigations hepatic transaminases increased blood,0
DALVANCE,oral candidiasis,infestations,0
DALVANCE,vulvovaginal mycotic infection,vulvovaginal mycotic infection Investigations hepatic transaminases increased,1
DALVANCE,vulvovaginal mycotic infection,mycotic infection Investigations hepatic,1
DALVANCE,vulvovaginal mycotic infection,vulvovaginal mycotic infection Investigations hepatic transaminases increased,1
DALVANCE,vulvovaginal mycotic infection,colitis oral vulvovaginal,1
DALVANCE,vulvovaginal mycotic infection,vulvovaginal mycotic,1
DALVANCE,vulvovaginal mycotic infection,and infestations,0
DALVANCE,vulvovaginal mycotic infection,blood alkaline phosphatase,0
DALVANCE,vulvovaginal mycotic infection,difficile colitis oral vulvovaginal mycotic infection Investigations hepatic transaminases,1
DALVANCE,vulvovaginal mycotic infection,blood alkaline phosphatase,0
DALVANCE,hepatic transaminases increased,candidiasis vulvovaginal mycotic infection hepatic transaminases increased,1
DALVANCE,hepatic transaminases increased,blood alkaline phosphatase,0
DALVANCE,hepatic transaminases increased,transaminases increased blood alkaline phosphatase increased international,1
DALVANCE,hepatic transaminases increased,ridium difficile colitis oral candidiasis,0
DALVANCE,hepatic transaminases increased,normalized ratio,0
DALVANCE,hepatic transaminases increased,mycotic infection hepatic transaminases increased blood alkaline,1
DALVANCE,hepatic transaminases increased,normalized ratio,0
DALVANCE,blood alkaline phosphatase increased,alkaline phosphatase increased international normalized ratio increased,1
DALVANCE,blood alkaline phosphatase increased,infection,0
DALVANCE,blood alkaline phosphatase increased,alkaline phosphatase increased international normalized ratio,1
DALVANCE,international normalized ratio increased,Metabolism and nutrition disorders hypoglycemia,0
DALVANCE,international normalized ratio increased,tion,0
DALVANCE,international normalized ratio increased,phosphatase international normalized ratio increased Metabolism and nutrition disorders hypoglycemia,1
DALVANCE,international normalized ratio increased,tion,0
DALVANCE,international normalized ratio increased,increased blood alkaline phosphatase international normalized ratio increased Metabolism and,1
DALVANCE,international normalized ratio increased,tion,0
DALVANCE,international normalized ratio increased,phosphatase international normalized ratio increased,1
DALVANCE,international normalized ratio increased,tion,0
DALVANCE,international normalized ratio increased,ratio increased,1
DALVANCE,hypoglycemia,hypoglycemia,1
DALVANCE,hypoglycemia,and mediastinal,0
DALVANCE,hypoglycemia,international normalized ratio increased Metabolism,0
DALVANCE,hypoglycemia,hypoglycemia Nervous System,1
DALVANCE,dizziness,dizziness Respiratory thoracic and mediastinal disorders,1
DALVANCE,dizziness,disorders hypoglycemia,0
DALVANCE,bronchospasm,bronchospasm Skin,1
DALVANCE,bronchospasm,bronchospasm Skin and Subcutaneous,1
DALVANCE,bronchospasm,bronchospasm,1
DALVANCE,bronchospasm,bronchospasm Skin and Subcutaneous,1
DALVANCE,bronchospasm,and mediastinal bronchospasm Skin,1
DALVANCE,bronchospasm,bronchospasm Skin and Subcutaneous,1
DALVANCE,bronchospasm,disorders flushing phl,0
DALVANCE,bronchospasm,bronchospasm,1
DALVANCE,bronchospasm,bronchospasm Skin and Subcutaneous,1
DALVANCE,bronchospasm,bronchospasm Skin and,1
DALVANCE,bronchospasm,disorders,0
DALVANCE,bronchospasm,bronchospasm Skin and Subcutaneous,1
DALVANCE,urticaria,Subcutaneous Tissue urticaria,1
DALVANCE,urticaria,bronchospasm Skin and Subcutaneous,1
DALVANCE,urticaria,disorders,0
DALVANCE,urticaria,urticaria,1
DALVANCE,urticaria,Tissue urticaria Vascular,1
DALVANCE,urticaria,urticaria,1
DALVANCE,urticaria,disorders bronchospasm Skin and Subcutaneous,0
DALVANCE,urticaria,thoracic,0
DALVANCE,urticaria,urticaria Vascular disorders flushing phlebitis wound,1
DALVANCE,urticaria,urticaria Vascular,1
DALVANCE,urticaria,urticaria Vascular disorders,1
DALVANCE,urticaria,Subcutaneous Tissue urticaria Vascular disorders flushing phlebitis wound,1
DALVANCE,urticaria,urticaria Vascular disorders,1
DALVANCE,flushing,spontaneous hematoma Alanine Aminotransferase,0
DALVANCE,flushing,flushing,1
DALVANCE,flushing,flushing phlebitis wound hemorrhage spontaneous,1
DALVANCE,flushing,Vascular flushing phlebitis wound hemorrhage,1
DALVANCE,flushing,flushing phlebitis wound hemorrhage spontaneous,1
DALVANCE,flushing,flushing,1
DALVANCE,phlebitis,urticaria Vascular disorders phlebitis wound,1
DALVANCE,phlebitis,flushing,1
DALVANCE,phlebitis,Alanine Aminotransferase,0
DALVANCE,wound hemorrhage,Vascular disorders flushing wound hemorrhage,1
DALVANCE,wound hemorrhage,disorders flushing wound hemorrhage spontaneous hematoma Alanine Aminotransferase ALT,1
DALVANCE,wound hemorrhage,Vascular disorders flushing wound hemorrhage,1
DALVANCE,wound hemorrhage,urticaria Vascular disorders flushing wound hemorrhage spontaneous hematoma,1
DALVANCE,wound hemorrhage,Vascular disorders flushing wound hemorrhage,1
DALVANCE,wound hemorrhage,urticaria Vascular disorders flushing wound hemorrhage spontaneous hematoma Alanine Aminotransferase,1
DALVANCE,wound hemorrhage,Vascular disorders flushing wound hemorrhage,1
DALVANCE,wound hemorrhage,wound hemorrhage spontaneous hematoma Alanine Aminotransferase,1
DALVANCE,wound hemorrhage,Vascular disorders flushing wound hemorrhage,1
DALVANCE,wound hemorrhage,Vascular disorders flushing wound,1
DALVANCE,wound hemorrhage,flushing phlebitis,0
DALVANCE,wound hemorrhage,spontaneous hematoma Alanine Aminotransferase ALT,0
DALVANCE,spontaneous hematoma,Vascular disorders,0
DALVANCE,spontaneous hematoma,wound spontaneous hematoma,1
DALVANCE,spontaneous hematoma,disorders flushing phlebitis wound spontaneous hematoma,1
DALVANCE,spontaneous hematoma,disorders flushing phlebitis wound spontaneous hematoma Alanine Aminotransferase ALT Elevations,1
DALVANCE,spontaneous hematoma,disorders flushing phlebitis wound spontaneous hematoma,1
DALVANCE,spontaneous hematoma,flushing phlebitis wound spontaneous hematoma Alanine Aminotransferase,1
DALVANCE,spontaneous hematoma,disorders flushing phlebitis wound spontaneous hematoma,1
DALVANCE,spontaneous hematoma,spontaneous hematoma,1
DALVANCE,spontaneous hematoma,with normal baseline,0
DALVANCE,spontaneous hematoma,Elevations Among patients with,0
DALVANCE,spontaneous hematoma,Elevations Among patients with,0
DALVANCE,ALT elevations,patients had ALT,1
DALVANCE,ALT elevations,ALT,1
DALVANCE,ALT elevations,than comparatortreated patients had,0
DALVANCE,ALT elevations,ALT elevations greater than times the,1
DALVANCE,ALT values greater than 10 times ULN,Eight of patients treated with,0
DALVANCE,ALT values greater than 10 times ULN,than 10 times ULN Eight of patients,1
DALVANCE,ALT values greater than 10 times ULN,had underlying conditions,0
DALVANCE,ALT values greater than 10 times ULN,respectively including three subjects,0
DALVANCE,ALT values greater than 10 times ULN,10 times ULN Eight of patients,1
DALVANCE,ALT values greater than 10 times ULN,ALT values greater than 10 times ULN Eight of,1
DALVANCE,ALT values greater than 10 times ULN,three subjects with ALT values greater than 10 times ULN Eight of patients,1
DALVANCE,ALT values greater than 10 times ULN,ALT values greater than 10 times ULN Eight of,1
DALVANCE,ALT values greater than 10 times ULN,subjects with ALT values,1
DALVANCE,ALT values greater than 10 times ULN,ULN vs respectively including,0
DALVANCE,ALT values greater than 10 times ULN,including three subjects,0
DALVANCE,ALT elevations,ALT elevations greater than,1
DALVANCE,ALT elevations,ALT elevations were reversible in all subjects No comparatortreated,0
DALVANCE,ALT elevations,addition one DALVANCEtreated subject in,0
DALVANCE,ALT elevations,alcohol abuse In addition one DALVANCEtreated subject in a,0
DALVANCE,ALT elevations,Phase trial had ALT elevations greater than times ULN,1
DALVANCE,ALT elevations,alcohol abuse In addition one DALVANCEtreated subject in a,0
DALVANCE,ALT elevations,ALT elevations,0
DALVANCE,ALT elevations,ALT elevations were reversible,1
DALVANCE,ALT elevations,a Phase,0
DALVANCE,ALT elevations,ALT elevations were reversible in,1
DALVANCE,ALT elevations,elevations greater than times ALT elevations,1
DALVANCE,ALT elevations,times ULN,0
DALVANCE,ALT elevations,ALT elevations were reversible in all subjects,1
DALVANCE,ALT elevations,comparatortreated subject with normal,0
DALVANCE,ALT elevation,baseline transaminases had ALT elevation,1
DALVANCE,ALT elevation,had,0
DALVANCE,skin reactions,rates in the clini,0
DALVANCE,skin reactions,rates observed in clinical trials of DALVANCE cannot,0
DALVANCE,skin reactions,"under widely varying ,",1
DALVANCE,skin reactions,", adverse reac tion",1
DALVANCE,skin reactions,", adverse",1
DALVANCE,skin reactions,"varying , adverse reac tion rates observed in",1
DALVANCE,skin reactions,", adverse",1
DALVANCE,skin reactions,widely,0
DALVANCE,ALT elevations,"with DALVANCE were a (5.5%), head",1
DALVANCE,ALT elevations,"treated with DALVANCE were a (5.5%), head",1
DALVANCE,ALT elevations,REACTIONS contact,0
DALVANCE,Clostridium difficile -associated diarrhea,"SUSPECTED ADVERSE ACTIONS,",1
DALVANCE,Clostridium difficile -associated diarrhea,"SUSPECTED ADVERSE ACTIONS, contact Durata Therapeutics, Inc.",1
DALVANCE,Clostridium difficile -associated diarrhea,To report,0
DALVANCE,Clostridium difficile -associated diarrhea,"SUSPECTED ADVERSE ACTIONS, contact Durata Therapeutics, Inc. at or FDA",1
DALVANCE,Clostridium difficile -associated diarrhea,To report,0
DALVANCE,Red-Man Syndrome,patients and comparator was,1
DALVANCE,Red-Man Syndrome,an adverse,0
DALVANCE,Red-Man Syndrome,and comparator,1
DALVANCE,Red-Man Syndrome,comparator was discontinued due to an,1
DALVANCE,Red-Man Syndrome,in patients and comparator was,1
DALVANCE,flushing of the upper body,the comparator was due to an adverse reaction in patients Most Common,1
DALVANCE,flushing of the upper body,in patients and comparator was,1
DALVANCE,urticaria,n 35/1224 patients Most Common,1
DALVANCE,urticaria,in patients and comparator was,1
DALVANCE,urticaria,reaction n 35/1224 patients Most Common Adverse Reactions,1
DALVANCE,urticaria,in patients and comparator was,1
DALVANCE,pruritus,2.8%) pa tients Most,1
DALVANCE,pruritus,reaction 2.8%) pa tients Most Common Adverse,1
DALVANCE,pruritus,2.8%) pa tients Most,1
DALVANCE,pruritus,reactions in patients,0
DALVANCE,pruritus,common adverse reactions in patients trea,0
DALVANCE,pruritus,an adverse reaction 2.8%) pa,1
DALVANCE,pruritus,2.8%) pa tients Most Common Adverse,1
DALVANCE,rash,discontinued due to an,0
DALVANCE,rash,due to an,0
DALVANCE,rash,"

   Most Common Adverse Reactions The",1
DALVANCE,rash,discontinued due to an,0
DALVANCE,rash,"

   Most Common",1
DALVANCE,rash,atients and the comparator was discontinued due to an adverse reaction,0
DALVANCE,rash,in,0
DALVANCE,rash,Adverse Reactions The most common,0
DALVANCE,Clostridium difficile -associated diarrhea,N a           98 (5.5)         78 (6.4)       Vomiting,1
DALVANCE,Clostridium difficile -associated diarrhea,Adverse Reactions The most common,0
DALVANCE,Clostridium difficile -associated diarrhea,a           98 (5.5)         78 (6.4)      ,1
DALVANCE,Clostridium difficile -associated diarrhea,Adverse Reactions The most common,0
DALVANCE,Clostridium difficile -associated diarrhea,Comparator N N a           98 (5.5)         78 (6.4)      ,1
DALVANCE,Clostridium difficile -associated diarrhea,Adverse Reactions The most common,0
DALVANCE,Clostridium difficile -associated diarrhea,Comparator N N a           98 (5.5)         78 (6.4)      ,1
DALVANCE,Clostridium difficile -associated diarrhea,Adverse Reactions The most common,0
DALVANCE,Clostridium difficile -associated diarrhea,Dalbavancin Comparator N N a,1
DALVANCE,Clostridium difficile -associated diarrhea,78 (6.4) Vomiting Diarrhea,1
DALVANCE,Clostridium difficile -associated diarrhea,Nause,0
DALVANCE,Clostridium difficile -associated diarrhea,N N a 98,1
DALVANCE,CDAD," 
   Vomiting Diarrhea",1
DALVANCE,CDAD," 
  ",1
DALVANCE,diarrhea,Headache,0
DALVANCE,diarrhea,Diarrhea 83 (4.7),1
DALVANCE,fatal,Diarrhea Headache,0
DALVANCE,colitis,Headache,0
DALVANCE,colitis,9 (4.8) Rash Pruritus,1
DALVANCE,colitis,9 (4.8),1
FERRIPROX,chromaturia,pain alanine aminotransferase increased,0
FERRIPROX,chromaturia,The most common adverse reactions are incidence,0
FERRIPROX,chromaturia,chromaturia,1
FERRIPROX,chromaturia,REACTIONS EXCERPT,0
FERRIPROX,chromaturia,chromaturia nausea vomiting and abdominal,1
FERRIPROX,chromaturia,chromaturia nausea vomiting and abdominal,1
FERRIPROX,vomiting,vomiting and,1
FERRIPROX,vomiting,vomiting and abdominal pain alanine aminotransferase,1
FERRIPROX,vomiting,vomiting and,1
FERRIPROX,vomiting,reactions are incidence chromaturia vomiting and,1
FERRIPROX,vomiting,vomiting and,1
FERRIPROX,vomiting,most common adverse reactions are incidence chromaturia nausea,0
FERRIPROX,abdominal pain,vomiting abdominal pain alanine,1
FERRIPROX,abdominal pain,most common adverse reactions are incidence chromaturia nausea,0
FERRIPROX,abdominal pain,abdominal pain alanine aminotransferase increased arthralgia and,1
FERRIPROX,alanine aminotransferase increased,SUSPECTED ADVERSE REACTIONS,0
FERRIPROX,alanine aminotransferase increased,alanine aminotransferase increased arthralgia and neutropenia To,1
FERRIPROX,alanine aminotransferase increased,abdominal alanine aminotransferase increased arthralgia and neutropenia To,1
FERRIPROX,alanine aminotransferase increased,alanine aminotransferase increased arthralgia and neutropenia To,1
FERRIPROX,alanine aminotransferase increased,alanine aminotransferase increased arthralgia,1
FERRIPROX,alanine aminotransferase increased,vomiting and abdominal alanine aminotransferase increased arthralgia and neutropenia To report,1
FERRIPROX,alanine aminotransferase increased,alanine aminotransferase increased arthralgia,1
FERRIPROX,alanine aminotransferase increased,abdominal alanine aminotransferase increased arthralgia and neutropenia,1
FERRIPROX,alanine aminotransferase increased,alanine aminotransferase increased arthralgia,1
FERRIPROX,alanine aminotransferase increased,ADVERSE,0
FERRIPROX,alanine aminotransferase increased,arthralgia and neutropenia To report SUSPECTED,0
FERRIPROX,arthralgia,arthralgia and,1
FERRIPROX,arthralgia,arthralgia and,1
FERRIPROX,arthralgia,arthralgia and,1
FERRIPROX,arthralgia,arthralgia,1
FERRIPROX,arthralgia,arthralgia and neutropenia To report SUSPECTED,1
FERRIPROX,arthralgia,arthralgia and neutropenia,1
FERRIPROX,arthralgia,aminotransferase arthralgia,1
FERRIPROX,arthralgia,arthralgia and neutropenia,1
FERRIPROX,neutropenia,neutropenia To report SUSPECTED ADVERSE,1
FERRIPROX,neutropenia,neutropenia,1
FERRIPROX,Agranulocytosis,other sections of the Agranulocytosis Neutropenia see Warnings,1
FERRIPROX,Agranulocytosis,neutropenia,1
FERRIPROX,Agranulocytosis,sections of the Agranulocytosis,1
FERRIPROX,Agranulocytosis,neutropenia,1
FERRIPROX,Agranulocytosis,ALT,0
FERRIPROX,Agranulocytosis,are also discussed in other sections,0
FERRIPROX,Agranulocytosis,Agranulocytosis Neutropenia see Warnings,1
FERRIPROX,Agranulocytosis,Neutropenia,0
FERRIPROX,Agranulocytosis,Agranulocytosis Neutropenia see Warnings and,1
FERRIPROX,Agranulocytosis,Agranulocytosis Neutropenia see Warnings,1
FERRIPROX,Neutropenia,discussed in other sections,0
FERRIPROX,Neutropenia,sections of the labeling Neutropenia see Warnings and Precautions,1
FERRIPROX,Neutropenia,discussed in other sections,0
FERRIPROX,Neutropenia,Elevated,0
FERRIPROX,Neutropenia,Neutropenia see Warnings and Precautions,1
FERRIPROX,Neutropenia,also discussed in other sections of the labeling Agranulocytosis,0
FERRIPROX,Neutropenia,in,0
FERRIPROX,Neutropenia,labeling Neutropenia,1
FERRIPROX,Neutropenia,in,0
FERRIPROX,Elevated ALT,Elevated ALT Decreased plasma zinc,1
FERRIPROX,Elevated ALT,see Warnings and Elevated ALT Decreased plasma zinc concentrations,1
FERRIPROX,Elevated ALT,Elevated ALT Decreased plasma zinc,1
FERRIPROX,Elevated ALT,see Warnings and Elevated ALT,1
FERRIPROX,Elevated ALT,zinc concentrations Because,0
FERRIPROX,Elevated ALT,trials,0
FERRIPROX,Elevated ALT,see Warnings and Elevated ALT,1
FERRIPROX,Elevated ALT,trials,0
FERRIPROX,Elevated ALT,Precautions,0
FERRIPROX,Elevated ALT,AgranulocytosisNeutropenia see Warnings and Elevated ALT Decreased plasma zinc,1
FERRIPROX,Elevated ALT,Precautions,0
FERRIPROX,Elevated ALT,Elevated ALT Decreased plasma zinc concentrations Because,1
FERRIPROX,Decreased plasma zinc concentrations,Precautions Elevated Decreased plasma zinc concentrations,1
FERRIPROX,Decreased plasma zinc concentrations,Elevated ALT Decreased plasma zinc concentrations Because,1
FERRIPROX,agranulocytosis,Ferriprox agranulocytosis see Warnings and Precautions The,1
FERRIPROX,agranulocytosis,Elevated ALT Decreased plasma zinc concentrations Because,1
FERRIPROX,agranulocytosis,with Ferriprox agranulocytosis see,1
FERRIPROX,agranulocytosis,Elevated ALT Decreased plasma zinc concentrations Because,1
FERRIPROX,agranulocytosis,agranulocytosis see,1
FERRIPROX,agranulocytosis,agranulocytosis see Warnings and Precautions The,1
FERRIPROX,agranulocytosis,agranulocytosis see Warnings,1
FERRIPROX,agranulocytosis,agranulocytosis see Warnings and Precautions The,1
FERRIPROX,agranulocytosis,agranulocytosis see Warnings,1
FERRIPROX,agranulocytosis,agranulocytosis see Warnings and Precautions The,1
FERRIPROX,agranulocytosis,agranulocytosis see Warnings and Precautions,1
FERRIPROX,agranulocytosis,clinical trials with Ferriprox agranulocytosis see,1
FERRIPROX,agranulocytosis,agranulocytosis see Warnings and Precautions,1
FERRIPROX,chromaturia,during clinical,0
FERRIPROX,chromaturia,chromaturia nausea vomiting,1
FERRIPROX,chromaturia,reported during clinical trials chromaturia nausea vomiting abdominal,1
FERRIPROX,chromaturia,chromaturia nausea vomiting,1
FERRIPROX,nausea,reactions reported during clinical,0
FERRIPROX,nausea,alanine aminotransferase increased,0
FERRIPROX,nausea,adverse reactions,0
FERRIPROX,nausea,aminotransferase increased,0
FERRIPROX,vomiting,vomiting abdominal,1
FERRIPROX,vomiting,vomiting,1
FERRIPROX,vomiting,were chromaturia vomiting,1
FERRIPROX,vomiting,vomiting,1
FERRIPROX,abdominal pain,abdominal pain alanine aminotransferase increased,1
FERRIPROX,abdominal pain,The,0
FERRIPROX,abdominal pain,abdominal pain alanine aminotransferase increased arthralgia and,1
FERRIPROX,abdominal pain,most common adverse reactions reported,0
FERRIPROX,abdominal pain,nausea vomiting,0
FERRIPROX,abdominal pain,abdominal pain alanine aminotransferase increased arthralgia,1
FERRIPROX,arthralgia,abdominal pain alanine aminotransferase,0
FERRIPROX,neutropenia,nausea,0
FERRIPROX,neutropenia,pain alanine aminotransferase increased,0
FERRIPROX,neutropenia,neutropenia The table below,1
FERRIPROX,neutropenia,the,0
FERRIPROX,neutropenia,neutropenia The table below,1
FERRIPROX,neutropenia,increased arthralgia neutropenia The table below lists the,1
FERRIPROX,neutropenia,neutropenia The table below,1
FERRIPROX,Nausea,Nausea Abdominal paindiscomf,1
FERRIPROX,Neutrophil count decreased,Alanine Aminotransferase Neutrophil count,1
FERRIPROX,Neutrophil count decreased,Aminotransferase Neutrophil count decreased Weight increased,1
FERRIPROX,Neutrophil count decreased,Alanine Aminotransferase Neutrophil count,1
FERRIPROX,Neutrophil count decreased,Neutrophil count decreased,1
FERRIPROX,Neutrophil count decreased,count decreased Weight increased,1
FERRIPROX,Neutrophil count decreased,Neutrophil count decreased,1
FERRIPROX,Neutrophil count decreased,count decreased Weight increased,1
FERRIPROX,Weight increased,Weight increased Aspartate Aminotransferase incre,1
FERRIPROX,Aspartate Aminotransferase increased,Weight Aspartate Aminotransferase,1
FERRIPROX,Aspartate Aminotransferase increased,AND,0
FERRIPROX,Aspartate Aminotransferase increased,AND NUTRITION DISORDERS,0
FERRIPROX,Aspartate Aminotransferase increased,Weight,0
FERRIPROX,Aspartate Aminotransferase increased,Aspartate Aminotransferase increased METABOLISM AND,1
FERRIPROX,Aspartate Aminotransferase increased,METABOLISM AND,0
FERRIPROX,Increased appetite,Increased appetite Decreased,1
FERRIPROX,Increased appetite,NUTRITION Increased appetite Decreased,1
FERRIPROX,Increased appetite,Increased appetite Decreased,1
FERRIPROX,Increased appetite,Increased appetite Decreased appetite,1
FERRIPROX,Increased appetite,NUTRITION,0
FERRIPROX,Increased appetite,AND NUTRITION Increased,1
FERRIPROX,Increased appetite,METABOLISM AND NUTRITION,0
FERRIPROX,Increased appetite,Increased appetite,1
FERRIPROX,Decreased appetite,AND CONNECTIVE TISSUE,0
FERRIPROX,Decreased appetite,appetite,0
FERRIPROX,Decreased appetite,Decreased appetite MUSCULOSKELETAL,1
FERRIPROX,Decreased appetite,appetite,0
FERRIPROX,Decreased appetite,Decreased appetite MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,1
FERRIPROX,Decreased appetite,Increased,0
FERRIPROX,Decreased appetite,Increased,0
FERRIPROX,Decreased appetite,Decreased appetite MUSCULOSKELETAL AND,1
FERRIPROX,Decreased appetite,Increased,0
FERRIPROX,Decreased appetite,Decreased appetite MUSCULOSKELETAL AND CONNECTIVE,1
FERRIPROX,Arthropathy,Arthropathy NERVOUS SYSTEM,1
FERRIPROX,Arthropathy,NERVOUS,0
FERRIPROX,Arthropathy,Arthropathy NERVOUS SYSTEM DISORDERS,1
FERRIPROX,Arthropathy,NERVOUS SYSTEM DISORDERS,0
FERRIPROX,Arthropathy,Pain in Arthropathy NERVOUS,1
FERRIPROX,Arthropathy,NERVOUS SYSTEM DISORDERS,0
FERRIPROX,Arthropathy,NERVOUS SYSTEM DISORDERS,0
FERRIPROX,Arthropathy,in,0
FERRIPROX,Headache,Headache URINARY,1
FERRIPROX,Headache,in,0
FERRIPROX,Headache,Headache URINARY,1
FERRIPROX,Headache,Headache,1
FERRIPROX,Headache,Headache URINARY,1
FERRIPROX,Headache,SYSTEM Headache,1
FERRIPROX,Headache,Headache URINARY,1
FERRIPROX,Headache,Headache,1
FERRIPROX,Headache,Headache URINARY DISORDERS,1
FERRIPROX,Headache,DISORDERS,0
FERRIPROX,Headache,SYSTEM Headache,1
FERRIPROX,Headache,DISORDERS,0
FERRIPROX,Headache,Headache URINARY DISORDERS,1
FERRIPROX,Headache,DISORDERS,0
FERRIPROX,Chromaturia,Chromaturia,1
FERRIPROX,nausea,nausea vomiting and abdominal pain,1
FERRIPROX,nausea,symptoms,0
FERRIPROX,nausea,symptoms such nausea vomiting and abdominal,1
FERRIPROX,nausea,symptoms,0
FERRIPROX,nausea,nausea,1
FERRIPROX,nausea,symptoms,0
FERRIPROX,nausea,the most frequent adverse reactions reported by patients,0
FERRIPROX,nausea,nausea vomiting,1
FERRIPROX,nausea,such,0
FERRIPROX,nausea,Chromaturia Gastrointestinal symptoms such,0
FERRIPROX,nausea,Chromaturia Gastrointestinal symptoms such nausea vomiting and,1
FERRIPROX,nausea,Chromaturia Gastrointestinal symptoms such,0
FERRIPROX,vomiting,maturia Gastrointestinal,0
FERRIPROX,vomiting,as nausea,0
FERRIPROX,vomiting,vomiting,1
FERRIPROX,abdominal pain,nausea vomiting abdominal pain,1
FERRIPROX,abdominal pain,vomiting,1
FERRIPROX,abdominal pain,abdominal,1
FERRIPROX,abdominal pain,as,0
FERRIPROX,abdominal pain,nausea vomiting abdominal,1
FERRIPROX,abdominal pain,abdominal pain were the most,1
FERRIPROX,abdominal pain,nausea vomiting abdominal pain,1
FERRIPROX,abdominal pain,were the most frequent adverse reactions reported by patients,0
FERRIPROX,abdominal pain,Gastrointestinal symptoms such as nausea vomiting,0
FERRIPROX,abdominal pain,abdominal pain,1
FERRIPROX,abdominal pain,nausea,0
FERRIPROX,Chromaturia,in the,0
FERRIPROX,Chromaturia,urine is a result,0
FERRIPROX,Chromaturia,of the urine is,0
FERRIPROX,Chromaturia,Chromaturia reddishbrown discoloration of,1
FERRIPROX,Chromaturia,of,0
FERRIPROX,Chromaturia,in of Chromaturia reddishbrown discoloration of,1
FERRIPROX,Chromaturia,of,0
FERRIPROX,Chromaturia,Chromaturia reddishbrown discoloration,1
FERRIPROX,thrombocytosis,thrombocytosis pancytopenia,1
FERRIPROX,thrombocytosis,Blood and lymphatic system thrombocytosis,1
FERRIPROX,thrombocytosis,thrombocytosis pancytopenia,1
FERRIPROX,thrombocytosis,Blood and,0
FERRIPROX,thrombocytosis,fibrillation cardiac failure,0
FERRIPROX,thrombocytosis,thrombocytosis pancytopenia Cardiac disorders atrial fibrillation,1
FERRIPROX,pancytopenia,pancytopenia Cardiac disorders atrial fibrillation,1
FERRIPROX,atrial fibrillation,disorders thrombocytosis pancytopenia Cardiac atrial fibrillation cardiac failure Congenital familial and,1
FERRIPROX,atrial fibrillation,pancytopenia Cardiac disorders atrial fibrillation,1
FERRIPROX,atrial fibrillation,atrial fibrillation,1
FERRIPROX,atrial fibrillation,Cardiac atrial fibrillation,1
FERRIPROX,atrial fibrillation,atrial,1
FERRIPROX,atrial fibrillation,atrial fibrillation cardiac failure Congenital familial,1
FERRIPROX,atrial fibrillation,atrial,1
FERRIPROX,atrial fibrillation,pancytopenia Cardiac atrial fibrillation,1
FERRIPROX,atrial fibrillation,Cardiac disorders,0
FERRIPROX,atrial fibrillation,cardiac failure,0
FERRIPROX,cardiac failure,disorders,0
FERRIPROX,cardiac failure,and genetic,0
FERRIPROX,cardiac failure,disorders atrial,0
FERRIPROX,hypospadias,hypospadias Eye disorders,1
FERRIPROX,hypospadias,papilledema,0
FERRIPROX,hypospadias,familial and genetic disorders,0
FERRIPROX,hypospadias,hypospadias Eye disorders diplopia papilledema,1
FERRIPROX,hypospadias,orders atrial fibrillation cardiac,0
FERRIPROX,diplopia,Eye diplopia papilledema retinal toxicity,1
FERRIPROX,diplopia,orders atrial fibrillation cardiac,0
FERRIPROX,diplopia,enterocolitis rectal hemorrhag,0
FERRIPROX,diplopia,and genetic disorders,0
FERRIPROX,diplopia,diplopia papilledema,1
FERRIPROX,diplopia,and genetic disorders,0
FERRIPROX,diplopia,and,0
FERRIPROX,diplopia,disorders,0
FERRIPROX,diplopia,genetic disorders hypospadias Eye diplopia papilledema,1
FERRIPROX,diplopia,disorders,0
FERRIPROX,papilledema,papilledema retinal,1
FERRIPROX,papilledema,Congenital familial and genetic disorders,0
FERRIPROX,retinal toxicity,diplopia retinal,1
FERRIPROX,retinal toxicity,disorders diplopia retinal,1
FERRIPROX,retinal toxicity,hypospadias Eye disorders diplopia retinal toxicity,1
FERRIPROX,retinal toxicity,retinal toxicity Gastrointestinal disorders enterocolitis,1
FERRIPROX,retinal toxicity,hypospadias Eye disorders diplopia retinal toxicity,1
FERRIPROX,retinal toxicity,retinal toxicity Gastrointestinal disorders,1
FERRIPROX,enterocolitis,enterocolitis rectal hemorrhage gastric,1
FERRIPROX,enterocolitis,enterocolitis,1
FERRIPROX,enterocolitis,enterocolitis rectal,1
FERRIPROX,enterocolitis,enterocolitis rectal hemorrhage gastric ulcer,1
FERRIPROX,enterocolitis,Gastrointestinal enterocolitis rectal hemorrhage,1
FERRIPROX,enterocolitis,enterocolitis rectal hemorrhage gastric ulcer,1
FERRIPROX,enterocolitis,papilledema retinal toxicity Gastrointestinal enterocolitis rectal hemorrhage gastric,1
FERRIPROX,enterocolitis,enterocolitis rectal hemorrhage gastric ulcer,1
FERRIPROX,rectal hemorrhage,pancreatitis parotid gland enlargement,0
FERRIPROX,rectal hemorrhage,parotid gland enlargement,0
FERRIPROX,rectal hemorrhage,rectal hemorrhage gastric ulcer pancreatitis parotid gland,1
FERRIPROX,rectal hemorrhage,rectal hemorrhage gastric ulcer pancreatitis,1
FERRIPROX,rectal hemorrhage,rectal hemorrhage gastric,1
FERRIPROX,rectal hemorrhage,rectal hemorrhage gastric ulcer pancreatitis,1
FERRIPROX,rectal hemorrhage,papilledema retinal,0
FERRIPROX,rectal hemorrhage,Gastrointestinal disorders rectal hemorrhage gastric ulcer pancreatitis,1
FERRIPROX,rectal hemorrhage,papilledema retinal,0
FERRIPROX,rectal hemorrhage,retinal,0
FERRIPROX,rectal hemorrhage,retinal toxicity Gastrointestinal disorders rectal hemorrhage gastric,1
FERRIPROX,rectal hemorrhage,retinal,0
FERRIPROX,rectal hemorrhage,toxicity Gastrointestinal disorders rectal hemorrhage,1
FERRIPROX,gastric ulcer,gastric ulcer pancreatitis parotid gland,1
FERRIPROX,gastric ulcer,enlargement General,0
FERRIPROX,gastric ulcer,toxicity Gastrointestinal disorders enterocolitis rectal hemorrhage,0
FERRIPROX,pancreatitis,pancreatitis parotid gland enlargement General,1
FERRIPROX,pancreatitis,rectal hemorrhage gastric ulcer,0
FERRIPROX,pancreatitis,hemorrhage gastric pancreatitis,1
FERRIPROX,pancreatitis,rectal hemorrhage gastric ulcer,0
FERRIPROX,pancreatitis,pancreatitis parotid gland enlargement General,1
FERRIPROX,pancreatitis,pancreatitis parotid,1
FERRIPROX,pancreatitis,pancreatitis parotid,1
FERRIPROX,pancreatitis,pancreatitis parotid gland enlargement General disorders,1
FERRIPROX,pancreatitis,pancreatitis parotid gland enlargement General,1
FERRIPROX,pancreatitis,disorders and,0
FERRIPROX,pancreatitis,gland enlargement General disorders and administration site conditions,0
FERRIPROX,parotid gland enlargement,gastric ulcer parotid gland enlargement General disorders and administration site,1
FERRIPROX,parotid gland enlargement,gland enlargement General disorders and administration site conditions,0
FERRIPROX,parotid gland enlargement,rectal hemorrhage gastric ulcer parotid gland enlargement General disorders and,1
FERRIPROX,parotid gland enlargement,gland enlargement General disorders and administration site conditions,0
FERRIPROX,parotid gland enlargement,pyrexia edema peripheral m,0
FERRIPROX,parotid gland enlargement,conditions chills pyrexia edema peripheral m,0
FERRIPROX,chills,failure,0
FERRIPROX,chills,and administration site chills pyrexia edema peripheral,1
FERRIPROX,chills,failure,0
FERRIPROX,chills,and administration site,0
FERRIPROX,chills,disorders,0
FERRIPROX,chills,chills pyrexia edema peripheral,1
FERRIPROX,chills,conditions,0
FERRIPROX,chills,edema peripheral multiorgan failure,0
FERRIPROX,edema peripheral,edema peripheral,1
FERRIPROX,edema peripheral,conditions chills edema peripheral multiorgan failure Hepatobiliary disorders,1
FERRIPROX,edema peripheral,edema peripheral,1
FERRIPROX,edema peripheral,chills edema,1
FERRIPROX,edema peripheral,edema peripheral multiorgan failure Hepatobiliary disorders jaundice,1
FERRIPROX,jaundice,anaphylactic shock hypersensitivity,0
FERRIPROX,jaundice,shock hypersensitivity,0
FERRIPROX,hepatomegaly,Hepatobiliary disorders,0
FERRIPROX,hepatomegaly,jaundice,0
FERRIPROX,hepatomegaly,hepatomegaly Immune system disorders anaphylactic shock,1
FERRIPROX,hepatomegaly,jaundice,0
FERRIPROX,hepatomegaly,Hepatobiliary disorders,0
FERRIPROX,hepatomegaly,hepatomegaly Immune system disorders anaphylactic shock,1
FERRIPROX,hepatomegaly,hepatomegaly Immune,1
FERRIPROX,hepatomegaly,hepatomegaly,1
FERRIPROX,hepatomegaly,hepatomegaly Immune system disorders anaphylactic,1
FERRIPROX,hepatomegaly,disorders hepatomegaly Immune system disorders,1
FERRIPROX,hepatomegaly,hepatomegaly Immune system disorders anaphylactic,1
FERRIPROX,hepatomegaly,peripheral multiorgan failure Hepatobiliary disorders,0
FERRIPROX,anaphylactic shock,Immune system anaphylactic,1
FERRIPROX,anaphylactic shock,system anaphylactic shock hypersensitivity I nfections and infestations,1
FERRIPROX,anaphylactic shock,Immune system anaphylactic,1
FERRIPROX,anaphylactic shock,jaundice hepatomegaly Immune system anaphylactic shock hypersensitivity I nfections and infestations,1
FERRIPROX,anaphylactic shock,Immune system anaphylactic,1
FERRIPROX,anaphylactic shock,system anaphylactic shock,1
FERRIPROX,hypersensitivity,hypersensitivity I nfections and infestations,1
FERRIPROX,cryptococcal cutaneous infection,and,0
FERRIPROX,enteroviral encephalitis,cryptococcal cutaneous enteroviral encephalitis,1
FERRIPROX,enteroviral encephalitis,pharyngitis pneumonia sepsis furuncle infectious hepatitis,0
FERRIPROX,enteroviral encephalitis,enteroviral,1
FERRIPROX,enteroviral encephalitis,enteroviral encephalitis pharyngitis pneumonia sepsis,1
FERRIPROX,enteroviral encephalitis,enteroviral,1
FERRIPROX,pharyngitis,furuncle infectious hepatitis rash pustular subcutaneous abscess Inve,0
FERRIPROX,pharyngitis,infection enteroviral pharyngitis pneumonia sepsis furuncle infectious hepatitis,1
FERRIPROX,pharyngitis,furuncle infectious hepatitis rash pustular subcutaneous abscess Inve,0
FERRIPROX,pharyngitis,pharyngitis pneumonia sepsis furuncle infectious,1
FERRIPROX,pneumonia,ctions and infestations cryptococcal cutaneous infection enteroviral,0
FERRIPROX,pneumonia,pneumonia sepsis furuncle infectious hepatitis rash,1
FERRIPROX,pneumonia,pneumonia sepsis furuncle infectious hepatitis rash,1
FERRIPROX,pneumonia,encephalitis pneumonia sepsis furuncle infectious hepatitis rash,1
FERRIPROX,pneumonia,pneumonia sepsis furuncle infectious hepatitis rash,1
FERRIPROX,pneumonia,pneumonia sepsis,1
FERRIPROX,pneumonia,enteroviral encephalitis pneumonia sepsis,1
FERRIPROX,pneumonia,pneumonia sepsis,1
FERRIPROX,pneumonia,pneumonia sepsis furuncle infectious hepatitis rash,1
FERRIPROX,pneumonia,pneumonia,1
FERRIPROX,pneumonia,pneumonia sepsis furuncle infectious hepatitis rash,1
FERRIPROX,pneumonia,pneumonia sepsis furuncle,1
FERRIPROX,pneumonia,pneumonia sepsis furuncle infectious hepatitis rash,1
FERRIPROX,pneumonia,pneumonia sepsis furuncle,1
FERRIPROX,sepsis,sepsis furuncle infectious hepatitis rash pustular,1
FERRIPROX,sepsis,pneumonia sepsis furuncle,1
FERRIPROX,sepsis,sepsis furuncle infectious hepatitis rash,1
FERRIPROX,sepsis,sepsis furuncle infectious,1
FERRIPROX,sepsis,cryptococcal cutaneous infection enteroviral encephalitis,0
FERRIPROX,furuncle,furuncle infectious hepatitis rash pustular subcutaneous,1
FERRIPROX,furuncle,furuncle infectious hepatitis rash,1
FERRIPROX,furuncle,enteroviral encephalitis pharyngitis pneumonia furuncle infectious hepatitis rash pustular,1
FERRIPROX,furuncle,furuncle infectious hepatitis rash,1
FERRIPROX,furuncle,enteroviral encephalitis pharyngitis pneumonia furuncle infectious,1
FERRIPROX,furuncle,furuncle infectious hepatitis rash,1
FERRIPROX,furuncle,hepatitis rash pustular,0
FERRIPROX,infectious hepatitis,increased blood crea,0
FERRIPROX,infectious hepatitis,rash pustular,0
FERRIPROX,infectious hepatitis,infectious hepatitis rash,1
FERRIPROX,infectious hepatitis,rash pustular,0
FERRIPROX,infectious hepatitis,infectious hepatitis rash pustular,1
FERRIPROX,infectious hepatitis,infectious hepatitis,1
FERRIPROX,infectious hepatitis,infectious hepatitis rash pustular subcutaneous abscess Investigations,1
FERRIPROX,infectious hepatitis,sepsis furuncle,0
FERRIPROX,infectious hepatitis,subcutaneous abscess Investigations blood bilirubin increased,0
FERRIPROX,infectious hepatitis,infectious hepatitis,1
FERRIPROX,rash pustular,rash pustular subcutaneous abscess Investigations blood bilirubin,1
FERRIPROX,rash pustular,infectious hepatitis,1
FERRIPROX,rash pustular,blood,0
FERRIPROX,rash pustular,rash pustular subcutaneous abscess Investigations blood bilirubin,1
FERRIPROX,rash pustular,blood,0
FERRIPROX,rash pustular,blood,0
FERRIPROX,rash pustular,infectious rash pustular subcutaneous abscess Investigations blood bilirubin,1
FERRIPROX,rash pustular,blood,0
FERRIPROX,rash pustular,rash pustular subcutaneous abscess Investigations blood bilirubin,1
FERRIPROX,rash pustular,Investigations blood bilirubin increased,0
FERRIPROX,rash pustular,furuncle infectious rash pustular,1
FERRIPROX,rash pustular,Investigations blood bilirubin increased,0
FERRIPROX,rash pustular,abscess Investigations blood bilirubin increased blood creatinine phosphok,0
FERRIPROX,rash pustular,rash pustular subcutaneous abscess Investigations,1
FERRIPROX,subcutaneous abscess,subcutaneous abscess,1
FERRIPROX,subcutaneous abscess,infectious,0
FERRIPROX,subcutaneous abscess,infectious hepatitis rash subcutaneous,1
FERRIPROX,blood creatinine phosphokinase increased,Investigations blood bilirubin blood creatinine phosphokinase increased Metabolism,1
FERRIPROX,blood creatinine phosphokinase increased,infectious hepatitis rash subcutaneous,1
FERRIPROX,blood creatinine phosphokinase increased,blood,1
FERRIPROX,blood creatinine phosphokinase increased,blood creatinine phosphokinase increased,1
FERRIPROX,blood creatinine phosphokinase increased,disorders metabolic acidosis dehydration,0
FERRIPROX,blood creatinine phosphokinase increased,and,0
FERRIPROX,blood creatinine phosphokinase increased,disorders,0
FERRIPROX,metabolic acidosis,nutrition disorders,0
FERRIPROX,metabolic acidosis,Musculoskeletal and,0
FERRIPROX,metabolic acidosis,nutrition metabolic,1
FERRIPROX,metabolic acidosis,metabolic acidosis dehydration Musculoskeletal and connective tissue,1
FERRIPROX,metabolic acidosis,and nutrition metabolic acidosis dehydration Musculoskeletal and connective,1
FERRIPROX,metabolic acidosis,metabolic acidosis dehydration Musculoskeletal and connective tissue,1
FERRIPROX,dehydration,phosphokinase increased Metabolism and nutrition disorders,0
FERRIPROX,dehydration,dehydration Musculoskeletal,1
FERRIPROX,dehydration,connective tissue disorders,0
FERRIPROX,dehydration,Musculoskeletal and connective tissue disorders myositis chondropathy trismus Ne,0
FERRIPROX,dehydration,dehydration Musculoskeletal and connective tissue disorders,1
FERRIPROX,dehydration,dehydration Musculoskeletal and connective tissue,1
FERRIPROX,myositis,and connective,0
FERRIPROX,myositis,myositis chondropathy trismus,1
FERRIPROX,myositis,system disorders cerebellar syndrome,0
FERRIPROX,myositis,myositis chondropathy trismus,1
FERRIPROX,myositis,and connective tissue myositis chondropathy trismus Nervous,1
FERRIPROX,myositis,myositis chondropathy trismus,1
FERRIPROX,myositis,myositis,1
FERRIPROX,myositis,myositis chondropathy,1
FERRIPROX,myositis,connective,0
FERRIPROX,chondropathy,chondropathy trismus Nervous,1
FERRIPROX,chondropathy,tissue,0
FERRIPROX,chondropathy,chondropathy trismus Nervous system,1
FERRIPROX,chondropathy,metabolic acidosis dehydration Musculoskeletal,0
FERRIPROX,trismus,convulsion gait distu,0
FERRIPROX,cerebellar syndrome,system disorders,0
FERRIPROX,cerebral hemorrhage,cerebral hemorrhage,1
FERRIPROX,cerebral hemorrhage,system disorders,0
FERRIPROX,cerebral hemorrhage,disorders cerebellar cerebral hemorrhage convulsion,1
FERRIPROX,cerebral hemorrhage,system disorders,0
FERRIPROX,cerebral hemorrhage,Nervous system,0
FERRIPROX,cerebral hemorrhage,isorders myositis chondropathy trismus Nervous system,0
FERRIPROX,gait disturbance,gait disturbance intracranial pressure increased psychomotor skills,1
FERRIPROX,gait disturbance,gait disturbance intracranial pressure increased psychomotor skills,1
FERRIPROX,gait disturbance,intracranial pressure increased psychomotor skills impaired pyramidal tract syndrome somnolence,0
FERRIPROX,gait disturbance,intracranial pressure increased psychomotor skills impaired pyramidal tract syndrome somnolence,0
FERRIPROX,gait disturbance,hemorrhage convulsion,0
FERRIPROX,gait disturbance,syndrome cerebral hemorrhage gait disturbance intracranial pressure increased,1
FERRIPROX,gait disturbance,hemorrhage convulsion,0
FERRIPROX,intracranial pressure increased,gait intracranial pressure,1
FERRIPROX,intracranial pressure increased,intracranial pressure increased psychomotor skills impaired pyramidal,1
FERRIPROX,intracranial pressure increased,psychomotor skills impaired pyramidal tract syndrome somnolence Psychiatric disorders,0
FERRIPROX,intracranial pressure increased,tract syndrome somnolence Psychiatric,0
FERRIPROX,intracranial pressure increased,convulsion gait,0
FERRIPROX,intracranial pressure increased,skills impaired pyramidal,0
FERRIPROX,intracranial pressure increased,convulsion gait intracranial,1
FERRIPROX,pyramidal tract syndrome,bruxism,0
FERRIPROX,pyramidal tract syndrome,bruxism,0
FERRIPROX,pyramidal tract syndrome,pyramidal tract,1
FERRIPROX,pyramidal tract syndrome,disorders,0
FERRIPROX,somnolence,somnolence,1
FERRIPROX,somnolence,Psychiatric,0
FERRIPROX,somnolence,somnolence Psychiatric disorders bruxism,1
FERRIPROX,somnolence,somnolence Psychiatric disorders,1
FERRIPROX,somnolence,impaired pyramidal tract somnolence Psychiatric disorders,1
FERRIPROX,somnolence,somnolence Psychiatric disorders,1
FERRIPROX,somnolence,somnolence,1
FERRIPROX,somnolence,pyramidal tract somnolence,1
FERRIPROX,somnolence,somnolence,1
FERRIPROX,somnolence,pressure increased psychomotor skills impaired pyramidal tract,0
FERRIPROX,somnolence,disorders,0
FERRIPROX,bruxism,Psychiatric bruxism depression,1
FERRIPROX,bruxism,disorders,0
FERRIPROX,bruxism,disorders glycosuria,0
FERRIPROX,bruxism,bruxism depression obsessivecompulsive disorder Renal,1
FERRIPROX,bruxism,disorder Renal,0
FERRIPROX,bruxism,somnolence Psychiatric bruxism depression obsessivecompulsive disorder Renal,1
FERRIPROX,bruxism,disorder Renal,0
FERRIPROX,bruxism,bruxism depression obsessivecompulsive disorder Renal,1
FERRIPROX,bruxism,Renal disorders glycosuria,0
FERRIPROX,bruxism,disorders glycosuria hemoglobinuria,0
FERRIPROX,bruxism,bruxism depression obsessivecompulsive disorder Renal disorders,1
FERRIPROX,depression,depression obsessivecompulsive disorder Renal,1
FERRIPROX,obsessive-compulsive disorder,obsessive-compulsive disorder,1
FERRIPROX,obsessive-compulsive disorder,obsessive-compulsive disorder Renal disorders glycosuria,1
FERRIPROX,obsessive-compulsive disorder,Renal disorders,0
FERRIPROX,obsessive-compulsive disorder,Psychiatric disorders,0
FERRIPROX,obsessive-compulsive disorder,syndrome somnolence Psychiatric disorders bruxism,0
FERRIPROX,obsessive-compulsive disorder,Psychiatric disorders bruxism obsessive-compulsive disorder,1
FERRIPROX,obsessive-compulsive disorder,bruxism depression,0
FERRIPROX,glycosuria,glycosuria,1
FERRIPROX,glycosuria,glycosuria hemoglobinuria Respiratory,1
FERRIPROX,glycosuria,glycosuria,1
FERRIPROX,glycosuria,glycosuria hemoglobinuria Respiratory thoracic and mediastinal,1
FERRIPROX,glycosuria,glycosuria hemoglobinuria Respiratory thoracic and,1
FERRIPROX,glycosuria,hemoglobinuria Respiratory thoracic and mediastinal disorders acute respiratory,0
FERRIPROX,hemoglobinuria,hemoglobinuria Respiratory,1
FERRIPROX,hemoglobinuria,hemoglobinuria Respiratory thoracic and,1
FERRIPROX,acute respiratory distress syndrome,respiratory distress syndrome epistaxis hemoptysis pulmonary embolism Skin,1
FERRIPROX,acute respiratory distress syndrome,mediastinal acute,1
FERRIPROX,acute respiratory distress syndrome,acute respiratory distress syndrome epistaxis,1
FERRIPROX,acute respiratory distress syndrome,mediastinal acute,1
FERRIPROX,acute respiratory distress syndrome,acute respiratory distress syndrome epistaxis hemoptysis,1
FERRIPROX,acute respiratory distress syndrome,mediastinal acute,1
FERRIPROX,acute respiratory distress syndrome,respiratory distress syndrome epistaxis hemoptysis pulmonary embolism,1
FERRIPROX,acute respiratory distress syndrome,mediastinal disorders,0
FERRIPROX,acute respiratory distress syndrome,hemoglobinuria Respiratory thoracic,0
FERRIPROX,acute respiratory distress syndrome,respiratory distress syndrome epistaxis hemoptysis,1
FERRIPROX,acute respiratory distress syndrome,thoracic and mediastinal acute respiratory distress syndrome epistaxis hemoptysis pulmonary embolism,1
FERRIPROX,acute respiratory distress syndrome,respiratory distress syndrome epistaxis hemoptysis,1
FERRIPROX,acute respiratory distress syndrome,glycosuria hemoglobinuria Respiratory thoracic and mediastinal,0
FERRIPROX,epistaxis,disorders acute respiratory distress epistaxis hemoptysis pulmonary embolism Skin,1
FERRIPROX,epistaxis,glycosuria hemoglobinuria Respiratory thoracic and mediastinal,0
FERRIPROX,epistaxis,disorders acute respiratory distress epistaxis hemoptysis pulmonary embolism Skin subcutaneous,1
FERRIPROX,epistaxis,glycosuria hemoglobinuria Respiratory thoracic and mediastinal,0
FERRIPROX,epistaxis,embolism Skin,0
FERRIPROX,epistaxis,epistaxis hemoptysis pulmonary embolism Skin subcutaneous,1
FERRIPROX,epistaxis,thoracic and mediastinal disorders acute respiratory distress,0
FERRIPROX,epistaxis,respiratory distress epistaxis hemoptysis pulmonary embolism,1
FERRIPROX,epistaxis,thoracic and mediastinal disorders acute respiratory distress,0
FERRIPROX,hemoptysis,Respiratory thoracic and mediastinal disorders acute respiratory distress,0
FERRIPROX,hemoptysis,hemoptysis pulmonary embolism Skin subcutaneous,1
FERRIPROX,hemoptysis,hemoptysis pulmonary embolism Skin subcutaneous,1
FERRIPROX,hemoptysis,hemoptysis pulmonary embolism Skin subcutaneous,1
FERRIPROX,pulmonary embolism,syndrome epistaxis,0
FERRIPROX,pulmonary embolism,pulmonary embolism Skin,1
FERRIPROX,pulmonary embolism,respiratory distress syndrome epistaxis pulmonary embolism,1
FERRIPROX,pulmonary embolism,epistaxis pulmonary,1
FERRIPROX,pulmonary embolism,Skin subcutaneous tissue,0
FERRIPROX,hyperhidrosis,ss syndrome epistaxis hemoptysis pulmonary,0
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital edema photosensitivity reaction pruritis,1
FERRIPROX,hyperhidrosis,photosensitivity reaction pruritis urticaria,0
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital edema photosensitivity reaction,1
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital edema,1
FERRIPROX,hyperhidrosis,edema photosensitivity reaction pruritis urticaria rash HenochSchonlein,0
FERRIPROX,hyperhidrosis,subcutaneous tissue hyperhidrosis periorbital edema photosensitivity,1
FERRIPROX,hyperhidrosis,edema photosensitivity reaction pruritis urticaria rash HenochSchonlein,0
FERRIPROX,hyperhidrosis,hyperhidrosis periorbital edema photosensitivity reaction pruritis,1
FERRIPROX,photosensitivity reaction,photosensitivity reaction,1
FERRIPROX,photosensitivity reaction,disorders,0
FERRIPROX,photosensitivity reaction,hyperhidrosis periorbital,0
FERRIPROX,photosensitivity reaction,hyperhidrosis periorbital photosensitivity,1
FERRIPROX,photosensitivity reaction,disorders hypotension,0
FERRIPROX,pruritis,Vascular disorders hypotension,0
FERRIPROX,pruritis,Skin subcutaneous tissue disorders hyperhidrosis,0
FERRIPROX,pruritis,periorbital edema photosensitivity pruritis urticaria rash HenochSchonlein,1
FERRIPROX,pruritis,Skin subcutaneous tissue disorders hyperhidrosis,0
FERRIPROX,pruritis,edema photosensitivity pruritis urticaria,1
FERRIPROX,pruritis,Skin subcutaneous tissue disorders hyperhidrosis,0
FERRIPROX,pruritis,HenochSchonlein purpura Vascular disorders hypotension hypertension,0
FERRIPROX,urticaria,Vascular disorders hypotension,0
FERRIPROX,urticaria,periorbital edema photosensitivity reaction urticaria rash HenochSchonlein,1
FERRIPROX,urticaria,Vascular disorders hypotension,0
FERRIPROX,rash,reaction pruritis rash HenochSchonlein purpura Vascular disorders hypotension,1
FERRIPROX,rash,Vascular disorders hypotension,0
FERRIPROX,rash,reaction pruritis rash HenochSchonlein purpura Vascular,1
FERRIPROX,rash,Vascular disorders hypotension,0
FERRIPROX,rash,rash HenochSchonlein purpura Vascular,1
FERRIPROX,rash,pruritis rash HenochSchonlein purpura Vascular,1
FERRIPROX,rash,rash HenochSchonlein purpura Vascular,1
FERRIPROX,rash,photosensitivity reaction,0
FERRIPROX,rash,pruritis rash HenochSchonlein,1
FERRIPROX,rash,photosensitivity reaction,0
FERRIPROX,rash,rash HenochSchonlein,1
FERRIPROX,rash,photosensitivity reaction,0
FERRIPROX,Henoch-Schonlein purpura,pruritis urticaria Henoch-Schonlein,1
FERRIPROX,Henoch-Schonlein purpura,pruritis urticaria Henoch-Schonlein,1
FERRIPROX,Henoch-Schonlein purpura,pruritis urticaria Henoch-Schonlein purpura,1
FERRIPROX,Henoch-Schonlein purpura,urticaria Henoch-Schonlein purpura,1
FERRIPROX,Henoch-Schonlein purpura,disorders hypotension,0
FERRIPROX,Henoch-Schonlein purpura,Henoch-Schonlein purpura Vascular,1
FERRIPROX,Henoch-Schonlein purpura,Henoch-Schonlein purpura Vascular disorders hypotension hypertension,1
FERRIPROX,Henoch-Schonlein purpura,Henoch-Schonlein purpura Vascular disorders hypotension hypertension,1
FERRIPROX,Henoch-Schonlein purpura,Henoch-Schonlein purpura,1
FERRIPROX,AGRANULOCYTOSIS,ADVERSE EXCERPT:    *   The most common,1
FERRIPROX,AGRANULOCYTOSIS,Henoch-Schonlein purpura,1
FERRIPROX,AGRANULOCYTOSIS,ADVERSE EXCERPT:    *   The most common adverse reactions,1
FERRIPROX,AGRANULOCYTOSIS,Henoch-Schonlein purpura,1
FERRIPROX,NEUTROPENIA,T,0
FERRIPROX,NEUTROPENIA,and abdominal,0
FERRIPROX,NEUTROPENIA,EXCERPT he most com mon adverse reactions,1
FERRIPROX,NEUTROPENIA,and abdominal,0
FERRIPROX,NEUTROPENIA,reactions are incidence,0
FERRIPROX,NEUTROPENIA,he most com mon adverse,1
FERRIPROX,NEUTROPENIA,reactions are incidence,0
FERRIPROX,NEUTROPENIA,ADVERSE REACTIONS EXCERPT he most com,1
FERRIPROX,NEUTROPENIA,reactions are incidence,0
FERRIPROX,NEUTROPENIA,EXCERPT he most com mon,1
FERRIPROX,NEUTROPENIA,reactions are incidence,0
FERRIPROX,AGRANULOCYTOSIS,adverse eactions are (i,1
FERRIPROX,AGRANULOCYTOSIS,reactions are incidence,0
FERRIPROX,AGRANULOCYTOSIS,alanine aminotransferase increased,0
FERRIPROX,NEUTROPENIA,ADVERSE REACTIONS EXCERPT The,0
FERRIPROX,NEUTROPENIA,adverse reactions are cidence,1
FERRIPROX,NEUTROPENIA,are cidence >=  chromaturia,1
FERRIPROX,NEUTROPENIA,adverse reactions are cidence,1
FERRIPROX,NEUTROPENIA,cidence >=,1
FERRIPROX,NEUTROPENIA,cidence >= chromaturia nausea vomiting,1
FERRIPROX,agranulocytosis,pain alanine aminotransferase increased arthralgia,0
FERRIPROX,agranulocytosis,nal,0
FERRIPROX,agranulocytosis,pain alanine aminotransferase increased,0
FERRIPROX,infections,abdominal pain alanine nsferase i ncreased arthralgia and,1
FERRIPROX,infections,pain alanine aminotransferase increased,0
FERRIPROX,Neutropenia,aminotransferase increased thralgia,1
FERRIPROX,Neutropenia,thralgia an,1
FERRIPROX,Neutropenia,nausea vomiting and abdominal,0
FERRIPROX,Neutropenia,alanine aminotransferase increased,0
FERRIPROX,Neutropenia,increased thralgia an,1
FERRIPROX,Neutropenia,thralgia an d neutropenia To report SUSPECTED,1
FERRIPROX,Neutropenia,and,0
FERRIPROX,agranulocytosis,ADVERSE REACTIONS contact,0
FERRIPROX,agranulocytosis,To re,1
FERRIPROX,AGRANULOCYTOSIS,varying conditions e reaction rate s observed in the clinical,1
FERRIPROX,AGRANULOCYTOSIS,To re,1
FERRIPROX,AGRANULOCYTOSIS,Because clinical,0
FERRIPROX,AGRANULOCYTOSIS,under widely varying conditions e reaction rate,1
FERRIPROX,AGRANULOCYTOSIS,e reaction rate s observed in,1
FERRIPROX,AGRANULOCYTOSIS,under widely varying conditions e reaction rate,1
FERRIPROX,AGRANULOCYTOSIS,varying conditions e reaction rate s observed in the clinical,1
FERRIPROX,AGRANULOCYTOSIS,under widely varying conditions e reaction rate,1
FERRIPROX,AGRANULOCYTOSIS,under widely varying conditions e reaction rate s observed in the,1
FERRIPROX,AGRANULOCYTOSIS,under widely varying conditions e reaction rate,1
FERRIPROX,NEUTROPENIA,the clinical trials of another d,0
FERRIPROX,NEUTROPENIA,erved in th,1
FERRIPROX,NEUTROPENIA,erved,1
FERRIPROX,NEUTROPENIA,adverse reaction rates erved in th e clinical trials of a,1
FERRIPROX,NEUTROPENIA,erved,1
FERRIPROX,NEUTROPENIA,adverse,0
FERRIPROX,NEUTROPENIA,rates erved in,1
FERRIPROX,agranulocytosis,rug and may not reflect the rates observed,1
FERRIPROX,agranulocytosis,rates erved in,1
FERRIPROX,agranulocytosis,may not,1
FERRIPROX,agranulocytosis,of another rug and may not reflect the rates observed,1
FERRIPROX,agranulocytosis,may not,1
FERRIPROX,agranulocytosis,and may not reflect the rates observed in,1
FERRIPROX,agranulocytosis,rug and may not,1
FERRIPROX,agranulocytosis,and may not reflect the rates observed in,1
FERRIPROX,agranulocytosis,Ferriprox represents,0
FERRIPROX,agranulocytosis,another rug and may not reflect the rates observed in,1
FERRIPROX,agranulocytosis,Ferriprox represents,0
FERRIPROX,agranulocytosis,the clinical trials of,0
FERRIPROX,infections,d in pract ice Adverse reaction,1
FERRIPROX,infections,not reflect the rates d in pract ice Adverse reaction information for,1
FERRIPROX,infections,d in pract ice Adverse reaction,1
FERRIPROX,infections,and may not reflect the rates,0
FERRIPROX,infections,drug and may not reflect the rates observe,0
FERRIPROX,infections,d in,1
FERRIPROX,infections,Ferriprox represents the pooled data,0
FERRIPROX,infections,rates d in,1
FERRIPROX,infections,reaction information,0
FERRIPROX,infections,rates d in,1
FERRIPROX,death,rates in the clinical trials of another drug and may not reflect the rates,0
FERRIPROX,Neutropenia,Ferriprox represents the pooled data collected from patients,0
FERRIPROX,Neutropenia,rates observed in practice erse reacti on information for,1
FERRIPROX,Neutropenia,Ferriprox represents the pooled data collected from patients,0
FERRIPROX,Neutropenia,practice erse,1
FERRIPROX,Neutropenia,data collected from patients,0
FERRIPROX,Neutropenia,observed in practice erse reacti,1
FERRIPROX,Neutropenia,erse reacti,1
FERRIPROX,Neutropenia,observed in practice erse,1
FERRIPROX,agranulocytosis,for Ferriprox resents the poo led,1
FERRIPROX,agranulocytosis,observed in practice erse,1
FERRIPROX,agranulocytosis,information for Ferriprox resents the poo,1
FERRIPROX,agranulocytosis,or activecontrolled clinical,0
FERRIPROX,fetal harm,ADVERSE REACTIONS contact A,0
FERRIPROX,Fatal,REACTIONS contact ApoPharma Inc at Telephone Email,0
FERRIPROX,Fatal,medic alsafetyapopharmacom or FDA,1
FERRIPROX,Fatal,medic alsafetyapopharmacom or FDA at,1
FERRIPROX,Fatal,medic alsafetyapopharmacom or FDA,1
FERRIPROX,Fatal,medic alsafetyapopharmacom or FDA at FDA,1
FERRIPROX,Fatal,at Telephone medic alsafetyapopharmacom or,1
FERRIPROX,Fatal,medic alsafetyapopharmacom or FDA at FDA,1
FERRIPROX,agranulocytosis,lsafety@apophar macom or FDA,1
FERRIPROX,agranulocytosis,lsafety@apophar macom,1
FERRIPROX,agranulocytosis,ApoPharma,0
FERRIPROX,agranulocytosis,lsafety@apophar,1
FERRIPROX,agranulocytosis,Email medica,0
FERRIPROX,agranulocytosis,Inc at,0
FERRIPROX,agranulocytosis,CTED,0
FERRIPROX,agranulocytosis,lsafety@apophar macom or FDA,1
FERRIPROX,agranulocytosis,lsafety@apophar macom or FDA at FDA,1
FERRIPROX,neutropenia,/medwatch   Clinical Trial,1
FERRIPROX,neutropenia,/medwatch   Clinical Trial,1
FERRIPROX,neutropenia,wwwfdagov,0
FERRIPROX,neutropenia,/medwatch   Clinical Trial,1
FERRIPROX,neutropenia,/medwatch   Clinical Trial,1
FERRIPROX,neutropenia,adverse reactions are also discussed in o,0
FERRIPROX,neutropenia,Experience The following adverse reactions are,0
FERRIPROX,neutropenia,or /medwatch   Clinical Trial Experience,1
FERRIPROX,neutropenia,Experience The following adverse reactions are,0
FERRIPROX,neutropenia,FDA at FDA or,0
FERRIPROX,agranulocytosis,adverse,0
FERRIPROX,agranulocytosis,at FDA or wwwfdagovmedwatch l Trial,1
FERRIPROX,agranulocytosis,FDA or wwwfdagovmedwatch Clinica,0
FERRIPROX,agranulocytosis,Trial Experie,1
FERRIPROX,agranulocytosis,or FDA at,0
FERRIPROX,agranulocytosis,reactions are,0
FERRIPROX,agranulocytosis,l,1
FERRIPROX,agranulocytosis,l Trial Experie nce The following adverse reactions,1
FERRIPROX,agranulocytosis,l,1
FERRIPROX,agranulocytosis,the rates observed,0
FERRIPROX,agranulocytosis,pooled data collected from,0
FERRIPROX,agranulocytosis,pooled data col lected,1
FERRIPROX,agranulocytosis,from patients who participated in single arm or activecontrolled,0
FERRIPROX,agranulocytosis,information for Ferriprox represents pooled data,1
FERRIPROX,agranulocytosis,clinical,0
FERRIPROX,agranulocytosis,who participated in single arm or,0
FERRIPROX,agranulocytosis,information for Ferriprox represents pooled data col,1
FERRIPROX,agranulocytosis,in,0
FERRIPROX,Agranulocytosis,data collected from,0
FERRIPROX,neutropenia,represents the pooled data collected from patients who,0
FERRIPROX,agranulocytosis,studies The,0
FERRIPROX,agranulocytosis,clinical trials with Ferriprox was agranulocytosis see,0
FERRIPROX,agranulocytosis,or activecontrolled clinical studies The most serious adverse rea,0
FERRIPROX,agranulocytosis,rea,0
FERRIPROX,agranulocytosis,serious adverse ction,1
FERRIPROX,agranulocytosis,serious adverse ction reported  in clinical trials with,1
FERRIPROX,agranulocytosis,serious adverse ction,1
FERRIPROX,agranulocytosis,see,0
FERRIPROX,agranulocytosis,participated in single arm or activecontrolled clinical studies The most serious adverse,0
FERRIPROX,agranulocytosis,ction reported in,1
FERRIPROX,agranulocytosis,ction reported in clinical trials with,1
FERRIPROX,death,trial s,1
FERRIPROX,death,trial,1
FERRIPROX,death,trial s with Ferriprox,1
FERRIPROX,death,trial,1
FERRIPROX,death,trial s with Ferriprox was,1
FERRIPROX,embryofetal death,                  INVESTIGATIONS Alanine Amino,1
FERRIPROX,embryofetal death,Diarrhea Dyspepsia,0
FERRIPROX,embryofetal death,Diarrhea Dyspepsia,0
FERRIPROX,embryofetal death,INVESTIGATIONS Alanine Amino,0
FERRIPROX,embryofetal death,INVESTIGATIONS Alanine,0
FERRIPROX,embryofetal death,Diarrhea,0
FERRIPROX,embryofetal death,                  INVESTIGATIONS,1
FERRIPROX,embryofetal death,Diarrhea Dyspepsia,0
FERRIPROX,increased serum ALT,NECTIVE TISSUE DISO,1
FERRIPROX,increased serum ALT,AND,0
FERRIPROX,increased serum ALT,AND CON,0
FERRIPROX,increased serum ALT,NECTIVE TISSUE DISO,1
FERRIPROX,increased serum ALT,MUSCULOSKELETAL AND CON,0
FERRIPROX,increased serum ALT,appetite MUSCULOSKELETAL AND NECTIVE TISSUE DISO RDERS,1
FERRIPROX,increased serum ALT,MUSCULOSKELETAL AND CON,0
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS SYSTEM DISORDERS,1
FERRIPROX,Decreased plasma zinc concentrations,NERVOUS SYSTEM,0
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS SYSTEM DISORDERS Hea,1
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS,1
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS SYSTEM DISORDERS Hea,1
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS,1
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy         ,1
FERRIPROX,Decreased plasma zinc concentrations,                Arthropathy          NERVOUS SYSTEM DISORDERS,1
FERRIPROX,Decreased plasma zinc concentrations,in,0
FERRIPROX,Decreased plasma zinc concentrations,Pain in                 Arthropathy          NERVOUS SYSTEM DISORDERS Hea,1
FERRIPROX,Decreased plasma zinc concentrations,in,0
PRADAXA,bleeding,reactions reported,0
PRADAXA,bleeding,bleeding see Warnings and,1
PRADAXA,bleeding,PRADAXA were related bleeding see Warnings,1
PRADAXA,bleeding,bleeding see Warnings and,1
PRADAXA,bleeding,common adverse reactions a,0
PRADAXA,bleeding,and Precautions EXCERPT Most,0
PRADAXA,bleeding,bleeding see,1
PRADAXA,bleeding,bleeding see Warnings and Precautions,1
PRADAXA,bleeding,ADVERSE REACTIONS The most serious adverse reactions reported with PRADAXA were related,0
PRADAXA,bleeding,The most serious adverse reactions reported with PRADAXA were,0
PRADAXA,bleeding,EXCERPT Most,0
PRADAXA,gastritis,and,0
PRADAXA,gastritis,reactions gastritis like symptoms,1
PRADAXA,gastritis,and,0
PRADAXA,gastritis,gastritis like symptoms and,1
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,adverse reactions gastritis like symptoms and bleeding To,1
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,Warnings and Precautions EXCERPT Most,0
PRADAXA,gastritis,gastritis,1
PRADAXA,gastritis,ADVERSE REACTIONS contact Boehring,0
PRADAXA,gastritis,reactions gastritis like symptoms and,1
PRADAXA,gastritis,ADVERSE REACTIONS contact Boehring,0
PRADAXA,bleeding,To,0
PRADAXA,bleeding,contact,0
PRADAXA,bleeding,bleeding To report SUSPECTED ADVERSE,1
PRADAXA,bleeding,are gastritislike symptoms bleeding To report SUSPECTED,1
PRADAXA,bleeding,bleeding To report SUSPECTED ADVERSE,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,symptoms bleeding To report SUSPECTED ADVERSE REACTIONS,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding To,1
PRADAXA,bleeding,SUSPECTED ADVERSE REACTIONS contact Boehringer Ingelheim Pharmaceutical,0
PRADAXA,bleeding,To report SUSPECTED ADVERSE REACTIONS contact Boehringer,0
PRADAXA,bleeding,bleeding and gastrointestinal events,1
PRADAXA,bleeding,bleeding and gastrointestinal,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding and gastrointestinal events,1
PRADAXA,bleeding,gastrointestinal events ie dyspepsia nausea upper abdominal pain gastrointestinal,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,to discontinuation of PRADAXA bleeding and gastrointestinal events,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,for warfarin The most frequent adverse,0
PRADAXA,bleeding,nausea upper abdominal pain,0
PRADAXA,bleeding,nausea upper abdominal pain gastrointestinal hemorr,0
PRADAXA,gastrointestinal events,gastrointestinal events ie dyspepsia nausea upper,1
PRADAXA,gastrointestinal events,nausea upper abdominal pain gastrointestinal hemorr,0
PRADAXA,gastrointestinal events,gastrointestinal,0
PRADAXA,gastrointestinal events,to discontinuation of PRADAXA were bleeding and,0
PRADAXA,gastrointestinal events,of PRADAXA were bleeding gastrointestinal events ie,1
PRADAXA,gastrointestinal events,to discontinuation of PRADAXA were bleeding and,0
PRADAXA,gastrointestinal events,of PRADAXA were bleeding gastrointestinal events,1
PRADAXA,gastrointestinal events,were bleeding and,0
PRADAXA,dyspepsia,bleeding and gastrointestinal events dyspepsia nausea,1
PRADAXA,dyspepsia,were bleeding and,0
PRADAXA,dyspepsia,upper abdominal pain,0
PRADAXA,dyspepsia,dyspepsia nausea upper abdominal pain gastrointestinal,1
PRADAXA,dyspepsia,dyspepsia nausea upper,1
PRADAXA,dyspepsia,leading to discontinuation of,0
PRADAXA,dyspepsia,dyspepsia nausea upper abdominal,1
PRADAXA,dyspepsia,leading to discontinuation of,0
PRADAXA,dyspepsia,abdominal pain gastrointestinal,0
PRADAXA,dyspepsia,and diarrhea Bleeding,0
PRADAXA,dyspepsia,dyspepsia,1
PRADAXA,nausea,events ie nausea upper abdominal pain,1
PRADAXA,nausea,dyspepsia,1
PRADAXA,nausea,ie nausea,1
PRADAXA,nausea,dyspepsia,1
PRADAXA,nausea,and diarrhea Bleeding,0
PRADAXA,nausea,nausea upper,1
PRADAXA,nausea,nausea upper abdominal pain gastrointestinal,1
PRADAXA,nausea,discontinuation of PRADAXA were bleeding and,0
PRADAXA,nausea,leading to discontinuation of PRADAXA were,0
PRADAXA,nausea,of PRADAXA were bleeding and gastrointestinal events ie,0
PRADAXA,upper abdominal pain,gastrointestinal events ie dyspepsia upper,1
PRADAXA,upper abdominal pain,gastrointestinal events ie,0
PRADAXA,gastrointestinal hemorrhage,ie dyspepsia nausea upper abdominal,0
PRADAXA,gastrointestinal hemorrhage,Warnings and Precautions T,0
PRADAXA,gastrointestinal hemorrhage,Bleeding see Warnings and Precautions T,0
PRADAXA,diarrhea,dyspepsia nausea upper abdominal pain gastrointestinal hemorrhage,0
PRADAXA,bleeding,events during the,0
PRADAXA,bleeding,bleeding events during the treatment period,1
PRADAXA,bleeding,see Warnings and Precautions Table shows the number of adjudicated major,0
PRADAXA,bleeding,bleeding events during the treatment period,1
PRADAXA,bleeding,bleeding events during the treatment period,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,events during the treatment period in the RELY study with the,0
PRADAXA,bleeding,bleeding events during,1
PRADAXA,bleeding,the,0
PRADAXA,bleeding,bleeding rate per subjectyears Major bleeding,1
PRADAXA,bleeding,bleeding rate per subjectyears Major,1
PRADAXA,bleeding,the RELY study with bleeding,1
PRADAXA,bleeding,bleeding rate per subjectyears Major,1
PRADAXA,bleeding,bleeding rate,1
PRADAXA,bleeding,per,0
PRADAXA,bleeding,in,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,the RELY study with,0
PRADAXA,bleeding,gdL a transfusion of,0
PRADAXA,bleeding,gdL a transfusion,0
PRADAXA,bleeding,bleeding accompanied,1
PRADAXA,bleeding,the bleeding rate per subjectyears,0
PRADAXA,bleeding at a critical site,packed,0
PRADAXA,bleeding at a critical site,blood bleeding at,1
PRADAXA,bleeding at a critical site,bleeding at a critical site or with a fatal outcome,1
PRADAXA,bleeding at a critical site,blood bleeding at,1
PRADAXA,bleeding at a critical site,a transfusion of,0
PRADAXA,bleeding at a critical site,a critical site or with a fatal outcome,1
PRADAXA,bleeding at a critical site,of packed red blood bleeding at a critical site,1
PRADAXA,bleeding at a critical site,cells,0
PRADAXA,fatal,bleeding at a,0
PRADAXA,Intracranial hemorrhage,Intracranial hemorrhage included intracerebral,1
PRADAXA,Intracranial hemorrhage,fatal Intracranial hemorrhage included intracerebral hemorrhagic,1
PRADAXA,Intracranial hemorrhage,Intracranial hemorrhage included intracerebral,1
PRADAXA,Intracranial hemorrhage,or,0
PRADAXA,hemorrhagic stroke,critical site or with a fatal outcome,0
PRADAXA,subdural bleeds,subdural bleeds Table Adjudicated Major Bleeding,1
PRADAXA,subdural bleeds,subdural bleeds Table,1
PRADAXA,subdural bleeds,subarachnoid subdural,1
PRADAXA,subdural bleeds,aPatients during treatment o,0
PRADAXA,subdural bleeds,Table Adjudicated Major,0
PRADAXA,subdural bleeds,subdural bleeds Table Adjudicated Major,1
PRADAXA,subdural bleeds,tal outcome Intracranial hemorrhage included intracerebral hemorrhagic stroke,0
PRADAXA,subdural bleeds,Events in Treated Patientsa aPatients during,0
PRADAXA,subdural bleeds,in Treated,0
PRADAXA,subdural bleeds,hemorrhagic stroke subarachnoid subdural bleeds,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,bleeds Table Adjudicated Bleeding Events,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,bleeds Table Adjudicated Bleeding Events in Treated,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,subdural bleeds Table Adjudicated Bleeding Events in,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Bleeding Events in Treated Patientsa,1
PRADAXA,Bleeding,bleeds Table Adjudicated,0
PRADAXA,Bleeding,Bleeding Events in Treated,1
PRADAXA,Bleeding,bleeds Table Adjudicated Bleeding Events in,1
PRADAXA,Bleeding,Bleeding Events in Treated,1
PRADAXA,Bleeding,stroke subarachnoid,0
PRADAXA,Bleeding,ntracerebral hemorrhagic stroke subarachnoid,0
PRADAXA,decrease in hemoglobin,was considered cDefined as bleeding accompanied by one or more of the,0
PRADAXA,decrease in hemoglobin,in hemoglobin of gdL a transfusion of,1
PRADAXA,decrease in hemoglobin,was considered cDefined as bleeding accompanied,0
PRADAXA,decrease in hemoglobin,the following decrease in hemoglobin,1
PRADAXA,decrease in hemoglobin,or more units of,0
PRADAXA,decrease in hemoglobin,following decrease in,1
PRADAXA,decrease in hemoglobin,of the following decrease in hemoglobin of gdL,1
PRADAXA,decrease in hemoglobin,following decrease in,1
PRADAXA,decrease in hemoglobin,of the following decrease,1
PRADAXA,decrease in hemoglobin,bleeding accompanied,0
PRADAXA,bleeding at a critical site,packed red blood bleeding,1
PRADAXA,bleeding at a critical site,blood bleeding at a critical,1
PRADAXA,bleeding at a critical site,bleeding,1
PRADAXA,bleeding at a critical site,bleeding at a critical,1
PRADAXA,bleeding at a critical site,blood bleeding at,1
PRADAXA,bleeding at a critical site,a critical site or with fatal outcome,1
PRADAXA,fatal,or fatal outcome dIntracranial bleed included,1
PRADAXA,fatal,a critical site or with fatal outcome,1
PRADAXA,fatal,fatal outcome dIntracranial,1
PRADAXA,fatal,dL a transfusion of or more units of packed red blood cells,0
PRADAXA,fatal,or more units of packed red blood,0
PRADAXA,fatal,a critical site or fatal outcome,1
PRADAXA,fatal,or more units of packed red blood,0
PRADAXA,fatal,a critical,0
PRADAXA,fatal,critical site or fatal outcome dIntracranial bleed included intracerebral,1
PRADAXA,fatal,a critical,0
PRADAXA,fatal,fatal outcome dIntracranial,1
PRADAXA,Intracranial bleed,outcome Intracranial bleed included intracerebral,1
PRADAXA,Intracranial bleed,fatal outcome dIntracranial,1
PRADAXA,Intracranial bleed,with fatal outcome Intracranial,1
PRADAXA,Intracranial bleed,fatal outcome Intracranial,1
PRADAXA,Intracranial bleed,Intracranial bleed included intracerebral hemorrhagic stroke subarachnoid,1
PRADAXA,Intracranial bleed,fatal outcome Intracranial,1
PRADAXA,Intracranial bleed,Intracranial bleed included intracerebral,1
PRADAXA,Intracranial bleed,outcome Intracranial bleed included,1
PRADAXA,Intracranial bleed,Intracranial bleed included intracerebral,1
PRADAXA,hemorrhagic stroke,on the,0
PRADAXA,hemorrhagic stroke,intracerebral,0
PRADAXA,hemorrhagic stroke,bleed included hemorrhagic,1
PRADAXA,hemorrhagic stroke,analysis based on the,0
PRADAXA,hemorrhagic stroke,on the safety population,0
PRADAXA,hemorrhagic stroke,hemorrhagic,1
PRADAXA,hemorrhagic stroke,dIntracranial bleed included hemorrhagic stroke,1
PRADAXA,subdural bleeds,stroke subarachnoid subdural bleeds eOntreatment analysis based on the,1
PRADAXA,subdural bleeds,dIntracranial bleed included hemorrhagic stroke,1
PRADAXA,subdural bleeds,subdural bleeds eOntreatment analysis based,1
PRADAXA,subdural bleeds,subdural bleeds eOntreatment analysis,1
PRADAXA,subdural bleeds,safety population,0
PRADAXA,subdural bleeds,subdural,1
PRADAXA,subdural bleeds,subdural bleeds eOntreatment analysis,1
PRADAXA,Fatal,Studies Fatal bleed Adjudicated,1
PRADAXA,Fatal,subdural bleeds eOntreatment analysis,1
PRADAXA,Fatal,as defined above with investigator,0
PRADAXA,Fatal,Fatal,1
PRADAXA,Fatal,in Section Clinical Studies Fatal,1
PRADAXA,Fatal,Fatal,1
PRADAXA,Fatal,as defined above with investigator,0
PRADAXA,Fatal,Fatal bleed,1
PRADAXA,Fatal,Fatal bleed Adjudicated major bleed,1
PRADAXA,Fatal,in Section Clinical Studies Fatal bleed Adjudicated major bleed as,1
PRADAXA,Fatal,Fatal bleed Adjudicated major bleed,1
PRADAXA,Fatal,Fatal bleed Adjudicated major bleed,1
PRADAXA,Fatal,in Section Clinical Studies Fatal,1
PRADAXA,Fatal,Fatal bleed Adjudicated major bleed,1
PRADAXA,bleed,bleed Adjudicated major bleed,1
PRADAXA,bleed,Fatal bleed Adjudicated major bleed,1
PRADAXA,bleed,bleed Adjudicated major bleed,1
PRADAXA,bleed,in Section Clinical Studies bleed Adjudicated major bleed,1
PRADAXA,bleed,bleed Adjudicated major bleed,1
PRADAXA,bleed,bleed,1
PRADAXA,bleed,bleed Adjudicated major bleed,1
PRADAXA,bleed,as defined above with investigator reported,0
PRADAXA,bleed,ITT analysis presented in Section Clinical Studies fFatal bleed Adjudicated major,0
PRADAXA,bleed,fFatal bleed,0
PRADAXA,bleed,bleed as defined above with investigator,1
PRADAXA,bleed,bleed as defined above with,1
PRADAXA,bleed,bleed as defined above with investigator,1
PRADAXA,bleed,fFatal bleed Adjudicated bleed as defined above,1
PRADAXA,bleed,bleed as defined above with investigator,1
PRADAXA,bleed,bleed as defined,1
PRADAXA,bleed,fatal outcome and,0
PRADAXA,bleed,bleed as,1
PRADAXA,death,fatal outcome and death with primary cause from,1
PRADAXA,death,bleed as,1
PRADAXA,death,death with primary cause from bleeding,1
PRADAXA,death,death with,1
PRADAXA,death,reported fatal outcome and death with primary cause from bleeding,1
PRADAXA,death,death with,1
PRADAXA,bleeding,bleeding gNonintracranial fatal bleed,1
PRADAXA,bleeding,as,0
PRADAXA,bleeding,and,0
PRADAXA,bleeding,bleeding gNonintracranial fatal bleed Adjudicated major,1
PRADAXA,bleeding,with investigator reported fatal outcome and adjudicated death with primary cause from,0
PRADAXA,bleeding,bleeding,1
PRADAXA,fatal,fatal bleed Adjudicated,1
PRADAXA,fatal,primary cause from bleeding gNonintracranial,0
PRADAXA,fatal,above and adjudicated death,0
PRADAXA,fatal,fatal bleed Adjudicated,1
PRADAXA,fatal,primary cause from bleeding fatal bleed Adjudicated major bleed,1
PRADAXA,fatal,fatal bleed Adjudicated,1
PRADAXA,fatal,fatal bleed Adjudicated major,1
PRADAXA,fatal,from bleeding fatal bleed Adjudicated major,1
PRADAXA,fatal,fatal bleed Adjudicated major,1
PRADAXA,fatal,fatal bleed Adjudicated major bleed as,1
PRADAXA,fatal,fatal bleed Adjudicated major,1
PRADAXA,fatal,bleeding fatal bleed Adjudicated major bleed as,1
PRADAXA,fatal,fatal bleed Adjudicated major,1
PRADAXA,bleed,from bleeding gNonintracranial fatal,0
PRADAXA,death,above and death with primary cause from bleeding,1
PRADAXA,death,from bleeding gNonintracranial fatal,0
PRADAXA,death,death with primary cause from bleeding,1
PRADAXA,death,without symptomatic,0
PRADAXA,death,death with primary cause from,1
PRADAXA,death,gNonintracranial fatal bleed Adjudicated major,0
PRADAXA,death,fatal bleed Adjudicated major,0
PRADAXA,death,death with,1
PRADAXA,death,major bleed as defined above,0
PRADAXA,death,death with,1
PRADAXA,bleeding,cause bleeding,1
PRADAXA,bleeding,death with,1
PRADAXA,bleeding,bleed,0
PRADAXA,bleeding,bleeding but without symptomatic intracranial,1
PRADAXA,bleeding,bleeding but without symptomatic intracranial,1
PRADAXA,bleeding,bleeding but without symptomatic intracranial bleed,1
PRADAXA,bleeding,bleeding but,1
PRADAXA,bleeding,death with primary cause bleeding but,1
PRADAXA,bleeding,bleeding but,1
PRADAXA,bleeding,bleeding but without symptomatic,1
PRADAXA,bleeding,bleeding but without symptomatic,1
PRADAXA,symptomatic intracranial bleed,symptomatic intracranial bleed,1
PRADAXA,ICH,ICH,1
PRADAXA,Hemorrhagic Stroke,CH Hemorrhagic Stroke e,1
PRADAXA,Hemorrhagic Stroke,ICH,1
PRADAXA,Hemorrhagic Stroke,Hemorrhagic Stroke e Oth,1
PRADAXA,Hemorrhagic Stroke,CH Hemorrhagic,1
PRADAXA,gastrointestinal bleeds,a higher rate of gastrointestinal,1
PRADAXA,gastrointestinal bleeds,of gastrointestinal,1
PRADAXA,gastrointestinal bleeds,of gastrointestinal,1
PRADAXA,gastrointestinal bleeds,than,0
PRADAXA,gastrointestinal bleeds,patients receiving,0
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in,1
PRADAXA,gastrointestinal bleeds,any,0
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients,1
PRADAXA,bleeds,major subgroups defined by,0
PRADAXA,bleeds,bleeds was similar with PRADAXA,1
PRADAXA,bleeds,receiving warfarin vs respectively The risk,0
PRADAXA,bleeds,risk of bleeds was similar with,1
PRADAXA,bleeds,receiving warfarin vs respectively The risk,0
PRADAXA,bleeds,bleeds was similar with PRADAXA,1
PRADAXA,bleeding,bleeding on PRADAXA hazard ratio,1
PRADAXA,bleeding,bleeding on PRADAXA hazard ratio CI,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,to for,0
PRADAXA,bleeding,ratio CI to for patients years of age Figure Ad,0
PRADAXA,bleeding,bleeding on PRADAXA hazard,1
PRADAXA,bleeding,ratio CI to for patients years of age Figure Ad,0
PRADAXA,bleeding,higher incidence,0
PRADAXA,bleeding,bleeding on PRADAXA,1
PRADAXA,bleeding,bleeding on PRADAXA,1
PRADAXA,Bleeding,Major,0
PRADAXA,Bleeding,age Figure Adjudicated Bleeding by Baseline Characteristics Including Hemorrhagic,1
PRADAXA,Bleeding,Major,0
PRADAXA,Bleeding,Adjudicated Bleeding,1
PRADAXA,Bleeding,Major,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,Major,0
PRADAXA,gastrointestinal adverse reactions,incidence gastrointestinal,1
PRADAXA,gastrointestinal adverse reactions,on,0
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions vs on warfarin These were,1
PRADAXA,gastrointestinal adverse reactions,on,0
PRADAXA,gastrointestinal adverse reactions,increased incidence gastrointestinal adverse reactions vs on warfarin These were,1
PRADAXA,gastrointestinal adverse reactions,on,0
PRADAXA,gastrointestinal adverse reactions,incidence gastrointestinal adverse,1
PRADAXA,gastrointestinal adverse reactions,adverse reactions,1
PRADAXA,dyspepsia,dyspepsia including abdominal pain upper,1
PRADAXA,dyspepsia,on warfarin These were dyspepsia including abdominal pain upper abdominal,1
PRADAXA,dyspepsia,dyspepsia including abdominal pain upper,1
PRADAXA,abdominal pain upper,abdominal pain upper abdominal pain,1
PRADAXA,abdominal pain upper,abdominal pain upper,1
PRADAXA,abdominal pain upper,abdominal pain upper abdominal pain abdominal discomfort and,1
PRADAXA,abdominal pain upper,discomfort and gastritislike symptoms incl,0
PRADAXA,abdominal pain upper,abdominal,1
PRADAXA,abdominal pain,commonly dyspepsia including abdominal,0
PRADAXA,abdominal pain,abdominal pain abdominal pain,1
PRADAXA,abdominal pain,abdominal pain abdominal discomfort and,1
PRADAXA,abdominal pain,abdominal pain abdominal pain,1
PRADAXA,abdominal pain,and gastritislike,0
PRADAXA,abdominal pain,dyspepsia including abdominal pain abdominal pain,1
PRADAXA,abdominal pain,pain upper,0
PRADAXA,abdominal pain,abdominal pain abdominal,1
PRADAXA,abdominal pain,abdominal pain abdominal discomfort and,1
PRADAXA,abdominal discomfort,abdominal discomfort and epigastric,1
PRADAXA,abdominal discomfort,abdominal discomfort and epigastric discomfort and,1
PRADAXA,abdominal discomfort,abdominal discomfort and,1
PRADAXA,abdominal discomfort,abdominal discomfort and epigastric discomfort and,1
PRADAXA,abdominal discomfort,upper abdominal abdominal,1
PRADAXA,abdominal discomfort,s on warfarin,0
PRADAXA,gastritis,discomfort and,0
PRADAXA,gastritis,symptoms including GERD esophagitis erosive gastritis gastric hemorrhage hemorrhagic gast,0
PRADAXA,gastritis,gastritis like symptoms including,1
PRADAXA,gastritis,symptoms including GERD esophagitis erosive gastritis gastric hemorrhage hemorrhagic gast,0
PRADAXA,gastritis,discomfort and epigastric discomfort gastritis like symptoms,1
PRADAXA,gastritis,symptoms including GERD esophagitis erosive gastritis gastric hemorrhage hemorrhagic gast,0
PRADAXA,gastritis,and epigastric discomfort gastritis like symptoms including GERD esophagitis,1
PRADAXA,gastritis,symptoms including GERD esophagitis erosive gastritis gastric hemorrhage hemorrhagic gast,0
PRADAXA,gastritis,discomfort gastritis like symptoms including,1
PRADAXA,gastritis,symptoms including GERD esophagitis erosive gastritis gastric hemorrhage hemorrhagic gast,0
PRADAXA,gastritis,and epigastric discomfort,0
PRADAXA,gastritis,and epigastric discomfort,0
PRADAXA,GERD,gastritis,0
PRADAXA,GERD,gastritislike symptoms including,0
PRADAXA,GERD,GERD esophagitis,1
PRADAXA,GERD,gastritislike symptoms including,0
PRADAXA,GERD,GERD esophagitis erosive gastritis gastric hemorrhage,1
PRADAXA,esophagitis,gastritis,0
PRADAXA,esophagitis,hemorrhagic erosive gastritis and,0
PRADAXA,esophagitis,esophagitis erosive gastritis gastric,1
PRADAXA,esophagitis,abdominal discomfort and epigastric,0
PRADAXA,esophagitis,erosive gastritis gastric hemorrhage hemorrhagic,0
PRADAXA,esophagitis,gastritislike symptoms including esophagitis erosive gastritis gastric hemorrhage,1
PRADAXA,esophagitis,erosive gastritis gastric hemorrhage hemorrhagic,0
PRADAXA,erosive gastritis,erosive gastritis gastric hemorrhage,1
PRADAXA,erosive gastritis,gastric hemorrhage,0
PRADAXA,erosive gastritis,including GERD esophagitis,0
PRADAXA,erosive gastritis,erosive gastritis,1
PRADAXA,erosive gastritis,hemorrhagic gastritis hemorrhagic,0
PRADAXA,erosive gastritis,erosive gastritis gastric,1
PRADAXA,erosive gastritis,symptoms including GERD erosive gastritis gastric hemorrhage hemorrhagic gastritis,1
PRADAXA,erosive gastritis,erosive gastritis gastric,1
PRADAXA,erosive gastritis,and epigastric,0
PRADAXA,erosive gastritis,symptoms including GERD erosive gastritis gastric,1
PRADAXA,erosive gastritis,and epigastric,0
PRADAXA,erosive gastritis,and,0
PRADAXA,gastric hemorrhage,hemorrhagic,0
PRADAXA,gastric hemorrhage,esophagitis erosive gastric,1
PRADAXA,gastric hemorrhage,gastric hemorrhage hemorrhagic gastritis hemorrhagic,1
PRADAXA,gastric hemorrhage,gastric hemorrhage hemorrhagic gastritis hemorrhagic erosive gastritis,1
PRADAXA,gastric hemorrhage,gastric hemorrhage hemorrhagic,1
PRADAXA,gastric hemorrhage,gastritis hemorrhagic erosive,0
PRADAXA,gastric hemorrhage,symptoms including GERD esophagitis erosive gastritis,0
PRADAXA,gastric hemorrhage,gastritislike symptoms including,0
PRADAXA,gastric hemorrhage,erosive,0
PRADAXA,hemorrhagic gastritis,hemorrhagic gastritis hemorrhagic,1
PRADAXA,hemorrhagic gastritis,hemorrhagic gastritis hemorrhagic erosive gastritis,1
PRADAXA,hemorrhagic gastritis,hemorrhagic gastritis hemorrhagic erosive gastritis and gastrointestinal,1
PRADAXA,hemorrhagic gastritis,hemorrhagic gastritis hemorrhagic erosive gastritis,1
PRADAXA,hemorrhagic erosive gastritis,gastritis gastric hemorrhage hemorrhagic hemorrhagic erosive gastritis,1
PRADAXA,hemorrhagic erosive gastritis,hemorrhagic gastritis hemorrhagic erosive gastritis,1
PRADAXA,hemorrhagic erosive gastritis,gastric hemorrhage,0
PRADAXA,hemorrhagic erosive gastritis,gastric hemorrhage hemorrhagic hemorrhagic erosive gastritis and gastrointestinal,1
PRADAXA,hemorrhagic erosive gastritis,gastric hemorrhage,0
PRADAXA,hemorrhagic erosive gastritis,gastritis gastric hemorrhage hemorrhagic hemorrhagic erosive gastritis and gastrointestinal ulcer Hypersensitivity Reactions,1
PRADAXA,hemorrhagic erosive gastritis,gastric hemorrhage,0
PRADAXA,hemorrhagic erosive gastritis,hemorrhage hemorrhagic hemorrhagic erosive gastritis and gastrointestinal ulcer,1
PRADAXA,hemorrhagic erosive gastritis,gastric hemorrhage,0
PRADAXA,hemorrhagic erosive gastritis,ulcer Hypersensitivity Reactions In the,0
PRADAXA,hemorrhagic erosive gastritis,hemorrhagic erosive gastritis and gastrointestinal ulcer Hypersensitivity Reactions,1
PRADAXA,hemorrhagic erosive gastritis,hemorrhage hemorrhagic hemorrhagic erosive,1
PRADAXA,gastrointestinal ulcer,gastrointestinal ulcer Hypersensitivity Reactions In the,1
PRADAXA,gastrointestinal ulcer,the RELY,0
PRADAXA,urticaria,hypersensitivity including,0
PRADAXA,urticaria,urticaria rash and pruritus,1
PRADAXA,urticaria,urticaria,1
PRADAXA,urticaria,urticaria rash and pruritus,1
PRADAXA,urticaria,edema anaphylactic reaction and anaphylactic shock were,0
PRADAXA,urticaria,were reported i,0
PRADAXA,urticaria,urticaria rash and pruritus allergic edema,1
PRADAXA,urticaria,urticaria rash and pruritus allergic,1
PRADAXA,rash,were reported in,0
PRADAXA,rash,including,0
PRADAXA,rash,rash and pruritus allergic edema,1
PRADAXA,rash,drug hypersensitivity including,0
PRADAXA,rash,drug hypersensitivity,0
PRADAXA,rash,drug hypersensitivity including rash and pruritus allergic edema,1
PRADAXA,rash,drug hypersensitivity,0
PRADAXA,pruritus,reported in,0
PRADAXA,pruritus,rash pruritus allergic edema,1
PRADAXA,pruritus,reported in,0
PRADAXA,pruritus,pruritus allergic edema anaphylactic,1
PRADAXA,pruritus,reaction and,0
PRADAXA,pruritus,including urticaria rash pruritus allergic edema anaphylactic reaction,1
PRADAXA,pruritus,reaction and,0
PRADAXA,pruritus,pruritus allergic edema anaphylactic reaction and,1
PRADAXA,allergic edema,allergic edema anaphylactic,1
PRADAXA,allergic edema,rash,0
PRADAXA,anaphylactic reaction,and pruritus allergic anaphylactic,1
PRADAXA,anaphylactic reaction,rash and pruritus allergic edema,0
PRADAXA,anaphylactic reaction,including urticaria rash,0
PRADAXA,anaphylactic reaction,anaphylactic reaction and anaphylactic shock,1
PRADAXA,anaphylactic reaction,including urticaria rash,0
PRADAXA,anaphylactic reaction,receiving PRADAXA,0
PRADAXA,anaphylactic reaction,including urticaria rash and pruritus allergic edema,0
PRADAXA,anaphylactic shock,receiving PRADAXA,0
PRADAXA,anaphylactic shock,PRADAXA Treatment and,0
PRADAXA,anaphylactic shock,allergic edema,0
PRADAXA,anaphylactic shock,rash,0
PRADAXA,bleeding,the following criteria applied fatal,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,CrCl of mLmin Bleeding events,0
PRADAXA,fatal,fatal bleeding,1
PRADAXA,fatal,fatal bleeding symptomatic bleeding in a,1
PRADAXA,fatal,critical area or,0
PRADAXA,fatal,fatal bleeding symptomatic bleeding in,1
PRADAXA,fatal,at least one,0
PRADAXA,fatal,fatal bleeding symptomatic,1
PRADAXA,fatal,fatal bleeding,1
PRADAXA,fatal,the following criteria fatal bleeding,1
PRADAXA,fatal,fatal bleeding,1
PRADAXA,fatal,a critical,0
PRADAXA,fatal,bleeding,0
PRADAXA,bleeding,applied fatal,0
PRADAXA,bleeding,the following criteria applied bleeding symptomatic bleeding in a critical,1
PRADAXA,bleeding,applied fatal,0
PRADAXA,symptomatic bleeding in a critical area,critical area or organ,1
PRADAXA,symptomatic bleeding in a critical area,fatal symptomatic bleeding in a critical area or organ intraocular intracranial intraspinal,1
PRADAXA,symptomatic bleeding in a critical area,critical area or organ,1
PRADAXA,compartment syndrome,in a,0
PRADAXA,retroperitoneal bleeding,intramuscular with compartment retroperitoneal,1
PRADAXA,retroperitoneal bleeding,bleeding causing a fall in hemoglobin level,0
PRADAXA,retroperitoneal bleeding,retroperitoneal,1
PRADAXA,retroperitoneal bleeding,or organ intraocular intracranial intraspinal or intramuscular with compartment syndrome,0
PRADAXA,retroperitoneal bleeding,or pericardial bleeding bleeding,0
PRADAXA,retroperitoneal bleeding,compartment retroperitoneal bleeding intraarticular bleeding or pericardial,1
PRADAXA,retroperitoneal bleeding,or pericardial bleeding bleeding,0
PRADAXA,retroperitoneal bleeding,retroperitoneal bleeding intraarticular bleeding or,1
PRADAXA,intra-articular bleeding,retroperitoneal,0
PRADAXA,intra-articular bleeding,bleeding,0
PRADAXA,intra-articular bleeding,with compartment syndrome retroperitoneal intra-articular bleeding or pericardial bleeding bleeding,1
PRADAXA,intra-articular bleeding,bleeding,0
PRADAXA,pericardial bleeding,syndrome retroperitoneal bleeding intraarticular bleeding or,0
PRADAXA,pericardial bleeding,or leading to trans,0
PRADAXA,pericardial bleeding,pericardial bleeding,1
PRADAXA,pericardial bleeding,retroperitoneal bleeding intraarticular bleeding pericardial,1
PRADAXA,pericardial bleeding,pericardial bleeding bleeding causing a fall in,1
PRADAXA,pericardial bleeding,pericardial bleeding,1
PRADAXA,pericardial bleeding,pericardial bleeding bleeding causing a fall in,1
PRADAXA,pericardial bleeding,bleeding intraarticular bleeding pericardial,1
PRADAXA,bleeding,mmolL,0
PRADAXA,bleeding,gdL,0
PRADAXA,bleeding,or,0
PRADAXA,fall in hemoglobin level,or,0
PRADAXA,fall in hemoglobin level,in hemoglobin level of,1
PRADAXA,fall in hemoglobin level,causing fall in hemoglobin level,1
PRADAXA,fall in hemoglobin level,bleeding causing fall in hemoglobin level of gdL,1
PRADAXA,fall in hemoglobin level,causing fall in hemoglobin level,1
PRADAXA,fall in hemoglobin level,fall in hemoglobin level,1
PRADAXA,fall in hemoglobin level,pericardial bleeding bleeding causing fall in hemoglobin level of gdL mmolL,1
PRADAXA,fall in hemoglobin level,fall in hemoglobin level,1
PRADAXA,fall in hemoglobin level,fall in hemoglobin level of gdL,1
PRADAXA,fall in hemoglobin level,fall in hemoglobin level,1
PRADAXA,bleeding,the number of patients bleeding events in the pooled,1
PRADAXA,bleeding,fall in hemoglobin level,1
PRADAXA,bleeding,studies,0
PRADAXA,bleeding,during the full treatment includi,0
PRADAXA,Bleeding,Note MBE can belong to more,0
PRADAXA,Bleeding,treatment periods,0
PRADAXA,Bleeding,Bleeding Events in RECOVER,1
PRADAXA,Bleeding,RECOVER II Treated Patients Note MBE can belong to more,0
PRADAXA,Bleeding,randomization,0
PRADAXA,MBE,MBE b,1
PRADAXA,MBE,than one site of,0
PRADAXA,MBE,MBE,1
PRADAXA,MBE,MBE b Bleeding site based,1
PRADAXA,MBE,MBE b Bleeding site based on,1
PRADAXA,MBE,MBE b Bleeding site based,1
PRADAXA,MBE,MBE b,1
PRADAXA,MBE,one,0
PRADAXA,MBE,MBE b Bleeding,1
PRADAXA,MBE,MBE b Bleeding site based on,1
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,based on investigator assessment Patients can have more than one site,0
PRADAXA,Bleeding,one MBE Bleeding site based,1
PRADAXA,Bleeding,based on investigator assessment Patients can have more than one site,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,Bleeding,with at least one MBE b,0
PRADAXA,bleeding,than one site,0
PRADAXA,bleeding,ne MBE b Bleeding site based on investigator assessment Patients can have more than,0
PRADAXA,bleeding,bleeding c Confidence interval Patients Major,1
PRADAXA,bleeding,bleeding c Confidence interval Patients,1
PRADAXA,bleeding,Confidence interval Patients bleeding,1
PRADAXA,bleeding,bleeding c Confidence interval Patients,1
PRADAXA,bleeding,bleeding event a Bleeding sites,1
PRADAXA,bleeding,bleeding event a Bleeding sites for,1
PRADAXA,bleeding,c Confidence interval Patients,0
PRADAXA,bleeding,event,0
PRADAXA,bleeding,interval Patients bleeding event a,1
PRADAXA,bleeding,event,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,Patients,0
PRADAXA,Bleeding,Bleeding sites for MBE,1
PRADAXA,Bleeding,bleeding,0
PRADAXA,bleeding,bleeding The rate of any gastrointestinal bleeds,0
PRADAXA,bleeding,Clinically,0
PRADAXA,bleeding,bleeding The rate,0
PRADAXA,bleeding,bleeding Any bleeding The,1
PRADAXA,bleeding,bleeding Any bleeding The rate,1
PRADAXA,bleeding,bleeding Any bleeding The rate,1
PRADAXA,bleeding,bleeding Any bleeding,1
PRADAXA,bleeding,relevant nonmajor,0
PRADAXA,bleeding,relevant nonmajor,0
PRADAXA,bleeding,Clinically relevant nonmajor bleeding bleeding,1
PRADAXA,bleeding,relevant nonmajor,0
PRADAXA,bleeding,bleeding The rate of any,1
PRADAXA,bleeding,nonmajor,0
PRADAXA,bleeding,bleeding The,1
PRADAXA,bleeding,any gastrointestinal bleeds in patients receiving,0
PRADAXA,bleeding,bleeding The,1
PRADAXA,bleeding,gastrointestinal bleeds,0
PRADAXA,bleeding,rate of any gastrointestinal bleeds in patients receiving PRADAXA mg in the full,0
PRADAXA,gastrointestinal bleeds,The rate of gastrointestinal bleeds in patients,1
PRADAXA,gastrointestinal bleeds,rate of any gastrointestinal bleeds in patients receiving PRADAXA mg in the full,0
PRADAXA,gastrointestinal bleeds,of gastrointestinal,1
PRADAXA,bleeding,bleeding events,1
PRADAXA,bleeding,bleeding events in the,1
PRADAXA,bleeding,bleeding events in,1
PRADAXA,bleeding,days Table shows the,0
PRADAXA,bleeding,bleeding events in,1
PRADAXA,bleeding,number of patients bleeding events in the study Table,1
PRADAXA,bleeding,bleeding events in,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,of days Table shows the number of patients experiencing,0
PRADAXA,bleeding,mean exposure of days Table shows,0
PRADAXA,bleeding,bleeding events,1
PRADAXA,Bleeding,Note MBE can belong to more than one criterion,0
PRADAXA,Bleeding,belong to more,0
PRADAXA,Bleeding,Bleeding,1
PRADAXA,MBE,MBE b,1
PRADAXA,Bleeding,investigator assessment Patients,0
PRADAXA,bleeding,bleeding c Confidence interval,1
PRADAXA,bleeding,bleeding c Confidence interval Patients Major,1
PRADAXA,bleeding,bleeding c Confidence,1
PRADAXA,bleeding,bleeding c Confidence interval Patients,1
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,Confidence interval Patients Major,0
PRADAXA,bleeding,sites for MBE,0
PRADAXA,bleeding,bleeding event a Bleeding,1
PRADAXA,bleeding,event a Bleeding,0
PRADAXA,bleeding,bleeding Any,0
PRADAXA,bleeding,bleeding In the REMEDY study the,1
PRADAXA,bleeding,bleeding In the REMEDY,1
PRADAXA,bleeding,bleeding In the REMEDY study the,1
PRADAXA,bleeding,bleeding In the REMEDY,1
PRADAXA,bleeding,bleeding In the,1
PRADAXA,bleeding,Clinically relevant nonmajor bleeding bleeding In,1
PRADAXA,bleeding,bleeding In the,1
PRADAXA,bleeding,bleeding In the REMEDY study the,1
PRADAXA,bleeding,REMEDY study the,0
PRADAXA,bleeding,bleeding bleeding In the,1
PRADAXA,bleeding,REMEDY study the,0
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients,1
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients receiving,1
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients,1
PRADAXA,gastrointestinal bleeds,rate of gastrointestinal bleeds,1
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients receiving PRADAXA,1
PRADAXA,gastrointestinal bleeds,rate of gastrointestinal bleeds,1
PRADAXA,gastrointestinal bleeds,PRADAXA mg,0
PRADAXA,bleeding,of patients bleeding events in the,1
PRADAXA,bleeding,PRADAXA mg,0
PRADAXA,bleeding,bleeding events in the,1
PRADAXA,bleeding,bleeding events in the study,1
PRADAXA,bleeding,bleeding events,1
PRADAXA,Bleeding,study Bleeding Events in RESONATE Treated,1
PRADAXA,Bleeding,bleeding events,1
PRADAXA,Bleeding,can,0
PRADAXA,Bleeding,Bleeding Events in RESONATE Treated,1
PRADAXA,MBE,MBE can belong to,1
PRADAXA,MBE,MBE b Bleeding site,1
PRADAXA,MBE,MBE b Bleeding site,1
PRADAXA,MBE,on investigator assessment Patients can have more than one site,0
PRADAXA,MBE,on investigator assessment Patients can have more than one,0
PRADAXA,MBE,MBE b,1
PRADAXA,MBE,on investigator assessment Patients can have more than one,0
PRADAXA,MBE,one site of,0
PRADAXA,MBE,can belong,0
PRADAXA,MBE,MBE b Bleeding site,1
PRADAXA,Bleeding,based on investigator assessment Patients can have more,0
PRADAXA,Bleeding,investigator assessment Patients can have more than one site,0
PRADAXA,Bleeding,Bleeding site based on,1
PRADAXA,bleeding,site bleeding c Confidence interval Patients,1
PRADAXA,bleeding,Bleeding site based on,1
PRADAXA,bleeding,interval Patients Major bleeding,0
PRADAXA,bleeding,interval Patients bleeding event a Clinically,1
PRADAXA,bleeding,interval Patients Major bleeding,0
PRADAXA,bleeding,Clinically relevant,0
PRADAXA,bleeding,c Confidence interval Patients,0
PRADAXA,bleeding,bleeding,1
PRADAXA,bleeding,bleeding event a Clinically,1
PRADAXA,bleeding,Patients bleeding event a Clinically relevant,1
PRADAXA,bleeding,bleeding event a Clinically,1
PRADAXA,bleeding,bleeding event,1
PRADAXA,bleeding,relevant nonmajor,0
PRADAXA,bleeding,bleeding Any,1
PRADAXA,bleeding,bleeding Any bleeding In the,1
PRADAXA,bleeding,bleeding In the RESONATE,1
PRADAXA,bleeding,bleeding In the RESONATE study,1
PRADAXA,bleeding,nonmajor bleeding bleeding In,1
PRADAXA,bleeding,bleeding In the RESONATE study,1
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients receiving PRADAXA mg,1
PRADAXA,gastrointestinal bleeds,the rate of gastrointestinal bleeds,1
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients receiving,1
PRADAXA,gastrointestinal bleeds,the rate of gastrointestinal bleeds,1
PRADAXA,gastrointestinal bleeds,nonmajor bleeding Any bleeding In the RESONATE study the rate of any,0
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients,1
PRADAXA,gastrointestinal bleeds,nonmajor bleeding Any bleeding In the RESONATE study the rate of any,0
PRADAXA,gastrointestinal bleeds,rate of gastrointestinal,1
PRADAXA,gastrointestinal bleeds,study the rate of gastrointestinal,1
PRADAXA,gastrointestinal bleeds,in patients receiving PRADAXA mg was,0
PRADAXA,gastrointestinal bleeds,gastrointestinal bleeds in patients,1
PRADAXA,myocardial infarction,myocardial infarction was reported,1
PRADAXA,myocardial infarction,gastrointestinal bleeds in patients,1
PRADAXA,myocardial infarction,myocardial infarction was reported in patients who,1
PRADAXA,fatal,myocardial infarction was reported,0
PRADAXA,fatal,the placebocontrolled study a similar rate of,0
PRADAXA,fatal,fatal clinical myocardial infarction was reported,1
PRADAXA,fatal,rate of nonfatal fatal clinical myocardial infarction,1
PRADAXA,fatal,fatal clinical myocardial infarction was reported,1
PRADAXA,fatal,was reported in patients,0
PRADAXA,fatal,of,0
PRADAXA,fatal,infarction was reported in patients who received PRADAXA per patie,0
PRADAXA,fatal,fatal clinical myocardial infarction,1
PRADAXA,fatal,patients who,0
PRADAXA,myocardial infarction,nonfatal and fatal myocardial infarction,1
PRADAXA,myocardial infarction,fatal myocardial infarction was reported in patients,1
PRADAXA,myocardial infarction,nonfatal and fatal myocardial infarction,1
PRADAXA,myocardial infarction,of nonfatal and fatal myocardial infarction,1
PRADAXA,myocardial infarction,nonfatal and fatal myocardial infarction,1
PRADAXA,myocardial infarction,was reported in patients who received PRADAXA per patientyears and in those who,0
PRADAXA,myocardial infarction,in those who,0
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions vs on,1
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions vs on,1
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions vs on,1
PRADAXA,gastrointestinal adverse reactions,had a similar incidence gastrointestinal adverse reactions,1
PRADAXA,gastrointestinal adverse reactions,a similar incidence gastrointestinal adverse reactions,1
PRADAXA,gastrointestinal adverse reactions,had a similar incidence gastrointestinal adverse reactions,1
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions,1
PRADAXA,gastrointestinal adverse reactions,had,0
PRADAXA,gastrointestinal adverse reactions,incidence gastrointestinal adverse reactions,1
PRADAXA,gastrointestinal adverse reactions,had,0
PRADAXA,gastrointestinal adverse reactions,gastrointestinal adverse reactions vs on warfarin Dyspepsia,1
PRADAXA,gastrointestinal adverse reactions,had,0
PRADAXA,Dyspepsia,discomfort and epigastric discomfort o,0
PRADAXA,Dyspepsia,Dyspepsia including abdominal pain upper abdominal,1
PRADAXA,Dyspepsia,Dyspepsia including abdominal pain,1
PRADAXA,abdominal pain upper,Dyspepsia abdominal pain upper,1
PRADAXA,abdominal pain,abdominal pain abdominal discomfort and epigastric,1
PRADAXA,abdominal discomfort,abdominal,0
PRADAXA,abdominal discomfort,on PRADAXA in vs,0
PRADAXA,abdominal discomfort,patients on PRADAXA in vs on warfarin and gastr,0
PRADAXA,epigastric discomfort,gastritislike symptoms includi,0
PRADAXA,epigastric discomfort,and,0
PRADAXA,epigastric discomfort,abdominal pain upper abdominal pain,0
PRADAXA,epigastric discomfort,epigastric discomfort,1
PRADAXA,gastritis,on PRADAXA in,0
PRADAXA,gastritis,gastritis like symptoms including gastritis,1
PRADAXA,gastritis,mfort and epigastric discomfort occurred in patients on,0
PRADAXA,gastritis,gastritis like,1
PRADAXA,gastritis,gastritis and gastric,0
PRADAXA,gastritis,gastritis like symptoms including gastritis GERD,1
PRADAXA,gastritis,warfarin gastritis,1
PRADAXA,gastritis,gastritis like symptoms including gastritis GERD,1
PRADAXA,gastritis,esophagitis,0
PRADAXA,gastritis,gastritis and gastric hemorrhage occurred,0
PRADAXA,gastritis,gastritis GERD esophagitis erosive gastritis and,1
PRADAXA,gastritis,in patients,0
PRADAXA,gastritis,including,0
PRADAXA,gastritis,and gastritislike symptoms gastritis GERD esophagitis erosive gastritis and,1
PRADAXA,gastritis,including,0
PRADAXA,gastritis,hemorrhage occurred at,0
PRADAXA,GERD,GERD esophagitis,1
PRADAXA,GERD,GERD,1
PRADAXA,GERD,gastritislike,0
PRADAXA,esophagitis,esophagitis erosive,1
PRADAXA,esophagitis,occurred,0
PRADAXA,esophagitis,gastritislike symptoms including gastritis esophagitis,1
PRADAXA,esophagitis,occurred,0
PRADAXA,esophagitis,on PRADAXA in vs on warfarin and gastritislike,0
PRADAXA,esophagitis,esophagitis erosive gastritis and gastric,1
PRADAXA,esophagitis,on PRADAXA in vs on warfarin and gastritislike,0
PRADAXA,esophagitis,occurred at vs respectively Hypersens,0
PRADAXA,esophagitis,esophagitis erosive gastritis,1
PRADAXA,esophagitis,esophagitis,1
PRADAXA,erosive gastritis,and gastric hemorrhage occurred at,0
PRADAXA,erosive gastritis,erosive gastritis and gastric hemorrhage occurred,1
PRADAXA,erosive gastritis,on warfarin and gastritislike symptoms including gastritis,0
PRADAXA,erosive gastritis,gastric hemorrhage occurred,0
PRADAXA,erosive gastritis,GERD erosive gastritis and gastric hemorrhage occurred,1
PRADAXA,erosive gastritis,gastric hemorrhage occurred,0
PRADAXA,erosive gastritis,erosive gastritis and gastric hemorrhage occurred at,1
PRADAXA,erosive gastritis,gastric hemorrhage occurred,0
PRADAXA,erosive gastritis,gastric,0
PRADAXA,hypersensitivity,studies,0
PRADAXA,hypersensitivity,the pivotal studies hypersensitivity,1
PRADAXA,hypersensitivity,studies,0
PRADAXA,hypersensitivity,hypersensitivity including urticaria rash,1
PRADAXA,hypersensitivity,hypersensitivity including,1
PRADAXA,hypersensitivity,hypersensitivity including urticaria rash and,1
PRADAXA,hypersensitivity,pruritus allergic edema,0
PRADAXA,urticaria,pivotal studies drug hypersensitivity urticaria rash and pruritus,1
PRADAXA,urticaria,pruritus allergic edema,0
PRADAXA,urticaria,hypersensitivity including,0
PRADAXA,urticaria,urticaria rash and,1
PRADAXA,urticaria,urticaria,1
PRADAXA,urticaria,urticaria rash and,1
PRADAXA,urticaria,pivotal studies drug,0
PRADAXA,urticaria,pivotal studies drug hypersensitivity urticaria rash and pruritus allergic edema,1
PRADAXA,urticaria,pivotal studies drug,0
PRADAXA,urticaria,Hypersensitivity Reactions In the pivotal,0
PRADAXA,rash,and pruritus,0
PRADAXA,rash,rash and pruritus allergic edema anaphylactic,1
PRADAXA,rash,rash and pruritus allergic,1
PRADAXA,rash,shock,0
PRADAXA,rash,anaphylactic shock were,0
PRADAXA,rash,rash and pruritus,1
PRADAXA,rash,anaphylactic shock were,0
PRADAXA,rash,drug hypersensitivity including rash and pruritus allergic,1
PRADAXA,rash,anaphylactic shock were,0
PRADAXA,rash,studies,0
PRADAXA,pruritus,urticaria rash pruritus,1
PRADAXA,pruritus,studies,0
PRADAXA,pruritus,pruritus,1
PRADAXA,pruritus,pruritus allergic,1
PRADAXA,pruritus,reported in of,0
PRADAXA,pruritus,rash and,0
PRADAXA,pruritus,including urticaria rash pruritus allergic edema,1
PRADAXA,pruritus,rash and,0
PRADAXA,pruritus,including urticaria rash pruritus allergic edema anaphylactic reaction and,1
PRADAXA,pruritus,rash and,0
PRADAXA,pruritus,were reported in of patients,0
PRADAXA,pruritus,pruritus allergic edema anaphylactic reaction,1
PRADAXA,pruritus,were reported in of patients,0
PRADAXA,pruritus,were reported in,0
PRADAXA,allergic edema,allergic edema anaphylactic reaction and,1
PRADAXA,anaphylactic reaction,pruritus allergic anaphylactic reaction and anaphylactic shock were reported,1
PRADAXA,anaphylactic reaction,allergic edema anaphylactic reaction and,1
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic reaction and anaphylactic,1
PRADAXA,anaphylactic reaction,allergic edema anaphylactic reaction and,1
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic,1
PRADAXA,anaphylactic reaction,and pruritus allergic anaphylactic reaction and anaphylactic shock,1
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic,1
PRADAXA,anaphylactic reaction,anaphylactic reaction,1
PRADAXA,anaphylactic reaction,rash and pruritus allergic anaphylactic reaction,1
PRADAXA,anaphylactic shock,allergic edema anaphylactic reaction anaphylactic,1
PRADAXA,anaphylactic shock,allergic edema anaphylactic reaction anaphylactic shock,1
PRADAXA,anaphylactic shock,anaphylactic,1
PRADAXA,anaphylactic shock,rash and pruritus,0
PRADAXA,anaphylactic shock,allergic edema anaphylactic reaction,0
PRADAXA,anaphylactic shock,were,0
PRADAXA,angioedema,angioedema thrombocytopenia,1
PRADAXA,angioedema,post approval use of angioedema thrombocytopenia,1
PRADAXA,angioedema,angioedema thrombocytopenia,1
PRADAXA,thrombocytopenia,thrombocytopenia esophageal ulcer,1
PRADAXA,thrombocytopenia,thrombocytopenia,1
PRADAXA,thrombocytopenia,thrombocytopenia esophageal ulcer,1
PRADAXA,thrombocytopenia,approval use of PRADAXA thrombocytopenia,1
PRADAXA,thrombocytopenia,thrombocytopenia esophageal ulcer,1
PRADAXA,thrombocytopenia,of PRADAXA thrombocytopenia esophageal ulcer,1
PRADAXA,thrombocytopenia,thrombocytopenia esophageal ulcer,1
PRADAXA,thrombocytopenia,thrombocytopenia,1
PRADAXA,thrombocytopenia,use of PRADAXA thrombocytopenia,1
PRADAXA,thrombocytopenia,thrombocytopenia,1
PRADAXA,thrombocytopenia,thrombocytopenia esophageal,1
PRADAXA,EPIDURAL HEMATOMA,bleeding see and Precautions,1
PRADAXA,EPIDURAL HEMATOMA,bleeding see  and Precautions  EXCERPT Most common,1
PRADAXA,EPIDURAL HEMATOMA,bleeding see and Precautions,1
PRADAXA,EPIDURAL HEMATOMA,to bleeding see and,1
PRADAXA,EPIDURAL HEMATOMA,see  and Precautions  EXCERPT,1
PRADAXA,EPIDURAL HEMATOMA,to bleeding see and,1
PRADAXA,EPIDURAL HEMATOMA,to bleeding see  and Precautions  EXCERPT,1
PRADAXA,EPIDURAL HEMATOMA,to bleeding see and,1
PRADAXA,EPIDURAL HEMATOMA,reactions are gastritislike symptoms and,0
PRADAXA,EPIDURAL HEMATOMA,see  and Precautions ,1
PRADAXA,EPIDURAL HEMATOMA,reactions are gastritislike symptoms and,0
PRADAXA,EPIDURAL HEMATOMA,see and,1
PRADAXA,EPIDURAL HEMATOMA,to bleeding see and Precautions,1
PRADAXA,EPIDURAL HEMATOMA,are,0
PRADAXA,EPIDURAL HEMATOMA,"  (6.1)  



    ",1
PRADAXA,EPIDURAL HEMATOMA,"  (6.1)  



     To report SUSPECTED ADVERSE",1
PRADAXA,EPIDURAL HEMATOMA,"  (6.1)  



     To report SUSPECTED ADVERSE",1
PRADAXA,EPIDURAL HEMATOMA,"  (6.1)  



     To report SUSPECTED",1
PRADAXA,spinal hematomas,and System ic,1
PRADAXA,spinal hematomas,reflect the rates observed in practice Reduction of Risk of,0
PRADAXA,spinal hematomas,Nonvalvular Atrial Fibrillation The,0
PRADAXA,spinal hematomas,and System ic Embolism in Nonvalvular Atrial,1
PRADAXA,spinal hematomas,and System ic Embolism,1
PRADAXA,hematomas,y) study,1
PRADAXA,hematomas,Anticoagulant y) study  provided,1
PRADAXA,hematomas,y) study,1
PRADAXA,hematomas,y) study  provided safety information on the,1
PRADAXA,hematomas,y) study,1
PRADAXA,hematomas,Anticoagulant y) study,1
PRADAXA,hematomas,y),1
PRADAXA,hematomas,Therap,0
PRADAXA,hematomas,Longterm Anticoagulant y),1
PRADAXA,permanent paralysis,use of two do ses of PRADAXA and warfarin,1
PRADAXA,permanent paralysis,of patients and their e,0
PRADAXA,EPIDURAL HEMATOMA,discontinuation were for XA 150,1
PRADAXA,EPIDURAL HEMATOMA,were for XA 150 mg,1
PRADAXA,EPIDURAL HEMATOMA,treatment discontinuation were for XA 150 mg,1
PRADAXA,EPIDURAL HEMATOMA,and 16% for warfarin The most,1
PRADAXA,EPIDURAL HEMATOMA,discontinuation were for XA 150 mg and 16% ,1
PRADAXA,EPIDURAL HEMATOMA,and 16% for warfarin The most,1
PRADAXA,EPIDURAL HEMATOMA,150 mg and 16% for warfarin,1
PRADAXA,EPIDURAL HEMATOMA,and 16% for,1
PRADAXA,spinal hematomas,or of the following,1
PRADAXA,spinal hematomas,and 16% for,1
PRADAXA,spinal hematomas,accompanied by one or of the following a decrease in hemoglobin,1
PRADAXA,spinal hematomas,and 16% for,1
PRADAXA,spinal hematomas,or of the following a decrease,1
PRADAXA,spinal hematomas,and 16% for,1
PRADAXA,spinal hematomas,of the following a decrease,1
PRADAXA,spinal hematomas,one or of the,1
PRADAXA,spinal hematomas,transfusion of units of packed red blood cells,0
PRADAXA,spinal hematomas,units,0
PRADAXA,hematomas,outcome Intracranial hemorrhage included intracerebral hemorrhagic stroke,0
PRADAXA,hematomas,fatal outcome Intracranial,0
PRADAXA,permanent paralysis,and subdural bleeds Table Adjudicated,0
PRADAXA,permanent paralysis,fatal,0
PRADAXA,permanent paralysis,hemorrhage included,1
PRADAXA,permanent paralysis,hemorrhagic stroke subarachnoid and subdural bleeds,0
PRADAXA,permanent paralysis,hemorrhage included intracerebral hemorrhagic stroke subarachnoid,1
PRADAXA,permanent paralysis,and subdural bleeds Table Adjudicated Majo,0
PRADAXA,Bleeding,reaction s reported with,1
PRADAXA,Bleeding,most serious,0
PRADAXA,Bleeding,serious reaction s reported,1
PRADAXA,Bleeding,most serious,0
PRADAXA,Bleeding,reaction,1
PRADAXA,Bleeding,most serious reaction s reported with PRADAXA,1
PRADAXA,Bleeding,reaction,1
PRADAXA,fatal,to bleeding see,0
PRADAXA,fatal,adverse reactions reported with PRADAXA were rel,0
PRADAXA,fatal,most serious adverse reactions reported with PRADAXA were,0
PRADAXA,fatal,most serious adverse reactions reported,0
PRADAXA,fatal,reported with PRADAXA were ated ,1
PRADAXA,fatal,most serious adverse reactions reported,0
PRADAXA,fatal,with PRADAXA,0
PRADAXA,fatal,ated  to bleeding,1
PRADAXA,bleeding,o bleedi ng see,1
PRADAXA,bleeding,adverse,0
PRADAXA,bleeding,o bleedi ng see Warnings,1
PRADAXA,bleeding,common adverse reactions,0
PRADAXA,bleeding,with PRADAXA were related o bleedi ng see Warnings,1
PRADAXA,bleeding,common adverse reactions,0
PRADAXA,bleeding,see Warnings,0
PRADAXA,bleeding,o bleedi,1
PRADAXA,bleeding,PRADAXA were related o bleedi ng see Warnings,1
PRADAXA,bleeding,o bleedi,1
PRADAXA,bleeding, reflect the rates observed in,1
PRADAXA,fatal,of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation The RELY Ra,0
PRADAXA,fatal,The RELY,0
PRADAXA,fatal,practice ducti,1
PRADAXA,fatal,The RELY,0
PRADAXA,fatal,ducti on of Risk,1
PRADAXA,fatal,Risk,0
PRADAXA,fatal,ducti on,1
PRADAXA,fatal,ducti on of Risk of Stroke,1
PRADAXA,bleeding,n of Ris k of Stroke and Systemic,1
PRADAXA,bleeding,in practice n of Ris,1
PRADAXA,bleeding,n of Ris k of Stroke and Systemic,1
PRADAXA,bleeding,of Ris k of,1
PRADAXA,bleeding,of Stroke and Systemic Embolism in Nonvalvular,0
PRADAXA,bleeding,observed in practice n of Ris,1
PRADAXA,bleeding,n of Ris k of Stroke and Systemic,1
PRADAXA,bleeding,n of Ris,1
PRADAXA,bleeding,reflect,0
PRADAXA,bleeding,Nonvalvular Atrial Fibrillation,0
PRADAXA,bleeding,may not reflect the rates observed in,0
PRADAXA,bleeding,rates observed in practice n of Ris,1
PRADAXA,bleeding,may not reflect the rates observed in,0
PRADAXA,spinal hematoma, gastrointestin al hemorrhage,1
PRADAXA,spinal hematoma,nausea upper abdominal  gastrointestin,1
PRADAXA,spinal hematoma, gastrointestin al hemorrhage,1
PRADAXA,spinal hematoma,see,0
PRADAXA,spinal hematoma,and gastrointestinal events ie dyspepsia nausea upper,0
PRADAXA,spinal hematoma, gastrointestin al hemorrhage and diarrhea,1
PRADAXA,spinal hematoma,nausea upper abdominal  gastrointestin,1
PRADAXA,spinal hematoma, gastrointestin al hemorrhage and diarrhea,1
PRADAXA,spinal hematoma, gastrointestin al hemorrhage and diarrhea,1
PRADAXA,spinal hematoma, gastrointestin,1
PRADAXA,spinal hematoma,nausea upper abdominal,0
PRADAXA,spinal hematoma, gastrointestin al hemorrhage and diarrhea Bleeding,1
PRADAXA,permanent paralysis,"and   

        Bleedin g",1
PRADAXA,permanent paralysis, gastrointestin al hemorrhage and diarrhea Bleeding,1
PRADAXA,permanent paralysis,ie dyspepsia nausea upper abdominal pain gastrointestinal hemorrhage,0
PRADAXA,permanent paralysis,"hemorrhage and   

        Bleedin",1
PRADAXA,permanent paralysis,ie dyspepsia nausea upper abdominal pain gastrointestinal hemorrhage,0
PRADAXA,permanent paralysis,and,0
PRADAXA,permanent paralysis,"  

        Bleedin",1
PRADAXA,permanent paralysis,"pain gastrointestinal hemorrhage and   

        Bleedin g see",1
PRADAXA,permanent paralysis,"  

        Bleedin",1
PRADAXA,permanent paralysis,"pain gastrointestinal hemorrhage and   

        Bleedin g",1
PRADAXA,permanent paralysis,"  

        Bleedin",1
PRADAXA,permanent paralysis,ie dyspepsia nausea upper abdominal pain gastrointestinal,0
PRADAXA,permanent paralysis,and Precautions Table shows the number,0
PRADAXA,permanent paralysis,"  

        Bleedin g see Warnings and",1
PRADAXA,paralysis,  Bleedin g,1
PRADAXA,paralysis,shows the number of,0
PRADAXA,paralysis,  Bleedin g see Warnings,1
PRADAXA,paralysis,  Bleedin g see,1
PRADAXA,paralysis,  Bleedin g see,1
PRADAXA,paralysis,  Bleedin,1
PRADAXA,paralysis,  Bleedin g see,1
PRADAXA,paralysis,  Bleedin g see,1
PRADAXA,paralysis,hemorrhage and   Bleedin g see,1
PRADAXA,paralysis,  Bleedin g see,1
PRADAXA,paralysis,gastrointestinal hemorrhage and,0
PRADAXA,thromboembolic events,above with or reported,1
PRADAXA,thromboembolic events,as defined above with or reported,1
PRADAXA,thromboembolic events,above,0
PRADAXA,thromboembolic events,fatal out come and,1
PRADAXA,thromboembolic events,bleed as,0
PRADAXA,transient ischemic attack,adjudicated death ith primary cause from bl eeding gNonintracranial fatal bleed,1
PRADAXA,transient ischemic attack,bleed as,0
PRADAXA,transient ischemic attack,cause from bl eeding gNonintracranial fatal bleed,1
PRADAXA,transient ischemic attack,cause from bl eeding,1
PRADAXA,transient ischemic attack,and adjudicated death ith primary cause from bl,1
PRADAXA,transient ischemic attack,investigator reported fatal,0
PRADAXA,transient ischemic attack,above,0
PRADAXA,transient ischemic attack,death ith primary cause from bl eeding gNonintracranial fatal bleed,1
PRADAXA,transient ischemic attack,above,0
PRADAXA,transient ischemic attack,with,0
PRADAXA,transient ischemic attack,bleed Adjudicated major bleed as,0
PRADAXA,bleeding,cause from bleeding but,0
PRADAXA,pericardial effusions,fatal bleed Adjudicated major bleed as defined above,0
PRADAXA,pericardial effusions,bleed Adjudicated major bleed as defined above,0
PRADAXA,pericardial effusions,with prim ary cause from bleeding,1
PRADAXA,pericardial effusions,e from bleeding gNonintracranial fatal bleed Adjudicated major bleed as defined above,0
PRADAXA,pericardial effusions,above and cated death with prim,1
PRADAXA,pericardial effusions,defined above and cated death with prim ary cause from bleeding but,1
PRADAXA,pericardial effusions,above and cated death with prim,1
PRADAXA,pericardial effusions,above and cated death with,1
PRADAXA,pericardial effusions,from bleeding gNonintracranial fatal bleed Adjudicated,0
PRADAXA,pericardial effusions,above and cated death with prim ary,1
PRADAXA,pericardial effusions,from bleeding gNonintracranial fatal bleed Adjudicated,0
PRADAXA,pericardial effusions,bleed based,0
PRADAXA,bleeding,         PRADAXA mgN,1
PRADAXA,bleeding,assessment,0
PRADAXA,bleeding,         PRADAXA mgN,1
VORAXAZE,allergic reactions,allergic reactions,1
VORAXAZE,allergic reactions,REACTIONS Serious,0
VORAXAZE,allergic reactions,allergic reactions including anaphylactic,1
VORAXAZE,allergic reactions,allergic reactions,1
VORAXAZE,allergic reactions,allergic reactions including,1
VORAXAZE,anaphylactic reactions,most common adverse reactions incidence with VORAXAZE are paraesthesias,0
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur,1
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur The most,1
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur The most,1
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur The most,1
VORAXAZE,anaphylactic reactions,anaphylactic reactions,1
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur The most common,1
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur The,1
VORAXAZE,anaphylactic reactions,Serious allergic reactions anaphylactic reactions may occur The most,1
VORAXAZE,anaphylactic reactions,anaphylactic reactions may occur The,1
VORAXAZE,paraesthesias,flushing nausea andor,0
VORAXAZE,paraesthesias,The most,0
VORAXAZE,paraesthesias,paraesthesias flushing nausea andor,1
VORAXAZE,paraesthesias,The most,0
VORAXAZE,flushing,with VORAXAZE are flushing,1
VORAXAZE,flushing,The most,0
VORAXAZE,flushing,flushing nausea andor vomiting,1
VORAXAZE,nausea,nausea andor vomiting hypotension and,1
VORAXAZE,nausea,nausea andor vomiting,1
VORAXAZE,nausea,paraesthesias nausea andor vomiting,1
VORAXAZE,nausea,nausea andor vomiting,1
VORAXAZE,nausea,nausea andor,1
VORAXAZE,headache,headache EXCERPT,1
VORAXAZE,headache,vomiting hypotension headache EXCERPT,1
VORAXAZE,headache,headache EXCERPT,1
VORAXAZE,headache,nausea andor vomiting hypotension headache EXCERPT,1
VORAXAZE,headache,headache EXCERPT,1
VORAXAZE,headache,headache EXCERPT In,1
VORAXAZE,headache,In clinical trials the most common related adverse events occurring in of p,0
VORAXAZE,headache,headache EXCERPT In clinical,1
VORAXAZE,headache,headache EXCERPT In clinical trials the,1
VORAXAZE,headache,headache EXCERPT In clinical,1
VORAXAZE,headache,headache,1
VORAXAZE,headache,are paraesthesias flushing nausea andor vomiting,0
VORAXAZE,headache,headache EXCERPT In clinical trials,1
VORAXAZE,paraesthesia,paraesthesia,1
VORAXAZE,paraesthesia,patients paraesthesia flushing nausea,1
VORAXAZE,paraesthesia,paraesthesia,1
VORAXAZE,paraesthesia,related adverse events occurring,0
VORAXAZE,paraesthesia,paraesthesia flushing nausea andor vomiting,1
VORAXAZE,paraesthesia,and headache To report,0
VORAXAZE,paraesthesia,occurring in of patients paraesthesia flushing nausea andor vomiting hypotension,1
VORAXAZE,paraesthesia,and headache To report,0
VORAXAZE,paraesthesia,paraesthesia flushing nausea,1
VORAXAZE,paraesthesia,paraesthesia flushing nausea andor vomiting hypotension,1
VORAXAZE,paraesthesia,paraesthesia flushing nausea,1
VORAXAZE,flushing,flushing nausea andor vomiting,1
VORAXAZE,flushing,flushing nausea,1
VORAXAZE,flushing,flushing,1
VORAXAZE,flushing,flushing nausea andor vomiting hypotension,1
VORAXAZE,flushing,flushing,1
VORAXAZE,flushing,flushing nausea andor vomiting,1
VORAXAZE,flushing,were,0
VORAXAZE,nausea,and headache To report SUSPECTED,0
VORAXAZE,nausea,nausea andor vomiting hypotension and headache,1
VORAXAZE,nausea,were paraesthesia nausea andor vomiting hypotension and headache,1
VORAXAZE,nausea,nausea andor vomiting hypotension and headache,1
VORAXAZE,nausea,were paraesthesia nausea andor vomiting hypotension and headache,1
VORAXAZE,nausea,nausea andor vomiting hypotension and headache,1
VORAXAZE,nausea,flushing,0
VORAXAZE,nausea,and headache,0
VORAXAZE,nausea,nausea andor,1
VORAXAZE,nausea,and headache,0
VORAXAZE,nausea,related adverse events occurring in of patients were,0
VORAXAZE,vomiting,paraesthesia flushing nausea,0
VORAXAZE,vomiting,vomiting hypotension,1
VORAXAZE,vomiting,and headache To report SUSPECTED ADVERSE,0
VORAXAZE,vomiting,SUSPECTED ADVERSE REACTIONS call,0
VORAXAZE,vomiting,andor,0
VORAXAZE,vomiting,vomiting hypotension and headache To,1
VORAXAZE,vomiting,were paraesthesia flushing,0
VORAXAZE,vomiting,vomiting hypotension,1
VORAXAZE,vomiting,To report SUSPECTED,0
VORAXAZE,vomiting,paraesthesia flushing nausea,0
VORAXAZE,hypotension,hypotension and headache To report,1
VORAXAZE,hypotension,hypotension and headache To report,1
VORAXAZE,hypotension,hypotension,1
VORAXAZE,headache,headache To report SUSPECTED,1
VORAXAZE,headache,headache To report SUSPECTED,1
VORAXAZE,headache,contact FDA at,0
VORAXAZE,headache,report SUSPECTED ADVERSE REACTIONS call or contact,0
VORAXAZE,headache,headache To,1
VORAXAZE,headache,contact FDA at,0
VORAXAZE,headache,REACTIONS,0
VORAXAZE,headache,headache To report,1
VORAXAZE,headache,nausea andor vomiting hypotension headache To,1
VORAXAZE,headache,headache To report,1
VORAXAZE,flushing,experienced related flushing The most common,1
VORAXAZE,flushing,headache To report,1
VORAXAZE,flushing,or renal events were,0
VORAXAZE,flushing,flushing The most common related,1
VORAXAZE,paresthesia,each occurred,0
VORAXAZE,flushing,flushing and nausea andor vomiting which,1
VORAXAZE,flushing,events were flushing and nausea,1
VORAXAZE,flushing,flushing and nausea andor vomiting which,1
VORAXAZE,vomiting,vomiting which each occurred in of,1
VORAXAZE,vomiting,vomiting which each occurred,1
VORAXAZE,vomiting,of,0
VORAXAZE,vomiting,occurred in of patients,0
VORAXAZE,vomiting,or renal events were paresthesia flushing and,0
VORAXAZE,vomiting,ns that were not hematologic hepatic or renal events were paresthesia flushing,0
VORAXAZE,vomiting,vomiting which each occurred in of,1
VORAXAZE,vomiting,vomiting which each,1
VORAXAZE,flushing,classified as Grade in,0
VORAXAZE,flushing,the following flushing feeling hot burning sensation One,1
VORAXAZE,flushing,classified as Grade in,0
VORAXAZE,feeling hot,Hepatic or Renal,0
VORAXAZE,feeling hot,feeling hot burning sensation One of these,1
VORAXAZE,feeling hot,following terms feeling,1
VORAXAZE,feeling hot,or Renal Adverse Reactions This incidence,0
VORAXAZE,burning sensation,following terms flushing feeling burning sensation One of these reactions,1
VORAXAZE,burning sensation,or Renal Adverse Reactions This incidence,0
VORAXAZE,burning sensation,This incidence includes the following terms flushing feeling,0
VORAXAZE,burning sensation,terms flushing feeling burning sensation One of these reactions,1
VORAXAZE,burning sensation,This incidence includes the following terms flushing feeling,0
VORAXAZE,burning sensation,One of,0
VORAXAZE,burning sensation,Adverse Reactions This incidence includes the following terms flushing feeling,0
VORAXAZE,burning sensation,terms flushing feeling hot,0
VORAXAZE,burning sensation,burning sensation,1
VORAXAZE,burning sensation,flushing feeling burning sensation,1
VORAXAZE,burning sensation,feeling burning sensation One of these,1
VORAXAZE,burning sensation,flushing feeling burning sensation,1
VORAXAZE,Vomiting,Vomiting Headache H,1
VORAXAZE,Vomiting,Nausea,0
VORAXAZE,Vomiting,Flushing,0
VORAXAZE,Vomiting,Flushing Vomiting Headache,1
VORAXAZE,Vomiting,Flushing,0
VORAXAZE,Vomiting,Vomiting Headache,1
VORAXAZE,Vomiting,Flushing,0
VORAXAZE,Hypotension,Hypotension Blurred Vision,1
VORAXAZE,Hypotension,Hypotension,1
VORAXAZE,Hypotension,Hypotension Blurred,1
VORAXAZE,Hypotension,Hypotension Blurred,1
VORAXAZE,Rash,Rash,1
VORAXAZE,Rash,Hypotension Blurred,1
VORAXAZE,Rash,Rash Throat irritationThroat,1
VORAXAZE,Rash,Throat irritationThroat,0
VORAXAZE,Rash,Rash Throat irritationThroat tightness,1
VORAXAZE,Rash,ty Rash Throat,1
VORAXAZE,Rash,Rash Throat irritationThroat tightness,1
VORAXAZE,Rash,ty,0
VORAXAZE,Rash,Hypertension,0
VORAXAZE,Rash,Rash Throat irritationThroat tightness,1
VORAXAZE,Tremor,Immunogenicity As with all th,0
VORAXAZE,Tremor,Tremor Immunogenicity As,1
VORAXAZE,Tremor,Tremor Immunogenicity,1
VORAXAZE,Tremor,Tremor Immunogenicity As with all th,1
VORAXAZE,Tremor,tightness,0
VORAXAZE,Tremor,Immunogenicity As with,0
VORAXAZE,Tremor,tightness,0
VORAXAZE,Tremor,Immunogenicity As,0
VORAXAZE,Tremor,irritationThroat Tremor Immunogenicity As with all,1
VORAXAZE,Tremor,Immunogenicity As,0
VORAXAZE,allergic reactions,with VORAXAZE are paraesthesi,0
VORAXAZE,allergic reactions,most common adverse,0
VORAXAZE,allergic reactions,common adverse reactions incidence with VORAXAZE,0
VORAXAZE,allergic reactions,REACTIONS Serious allergic reactions ing anaphylactic r eactions may,1
VORAXAZE,allergic reactions,common adverse reactions incidence with VORAXAZE,0
VORAXAZE,allergic reactions,reactions ing anaphylactic r eactions may occur The,1
VORAXAZE,allergic reactions,common adverse reactions incidence with VORAXAZE,0
VORAXAZE,allergic reactions,REACTIONS Serious allergic reactions ing anaphylactic r eactions may,1
VORAXAZE,allergic reactions,common adverse reactions incidence with VORAXAZE,0
VORAXAZE,allergic reactions,ing anaphylactic r,1
VORAXAZE,anaphylactic reactions,anaphylactic reactions y occur. The most comm on adverse reactions incidence,1
VORAXAZE,anaphylactic reactions,ing anaphylactic r,1
VORAXAZE,anaphylactic reactions,VORAXAZE are paraesthesias flushing nausea andor vomiti,0
VORAXAZE,anaphylactic reactions,are paraesthesias flushing nausea,0
VORAXAZE,anaphylactic reactions,y occur. The most comm on,1
VORAXAZE,anaphylactic reactions,are paraesthesias flushing nausea,0
VORAXAZE,anaphylactic reactions,The most comm on,1
VORAXAZE,anaphylactic reactions,reactions y occur. The most comm,1
VORAXAZE,anaphylactic reactions,incidence with VORAXAZE are paraesthesias flushing nausea andor,0
VORAXAZE,anaphylactic reactions,y occur. The most,1
VORAXAZE,allergic reactions,drugs,0
HORIZANT,Somnolence,Somnolence sedation and dizziness see Warnings,1
HORIZANT,Somnolence,and dizziness see Warnings and Precautions,0
HORIZANT,Somnolence,in more detail in the Warnings and Precautions,0
HORIZANT,Somnolence,ctions are described in,0
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,sedation,section of the label sedation and dizziness see Warnings,1
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,sedation,and,0
HORIZANT,sedation,sedation,1
HORIZANT,sedation,the label Somnolence,0
HORIZANT,dizziness,see Warnings and Precautions RLS Most common adverse,0
HORIZANT,dizziness,dizziness,1
HORIZANT,dizziness,the label Somnolencesedation dizziness see Warnings and Precautions,1
HORIZANT,dizziness,dizziness,1
HORIZANT,dizziness,label Somnolencesedation,0
HORIZANT,dizziness,dizziness see,1
HORIZANT,somnolence,somnolence,1
HORIZANT,somnolence,of placebo somnolence sedation and,1
HORIZANT,somnolence,somnolence,1
HORIZANT,somnolence,adverse reactions,0
HORIZANT,somnolence,somnolence sedation and,1
HORIZANT,somnolence,sedation and dizziness PHN Most common adverse reactions and,0
HORIZANT,somnolence,somnolence sedation and dizziness,1
HORIZANT,sedation,were,0
HORIZANT,sedation,somnolence,0
HORIZANT,sedation,placebo were sedation and dizziness,1
HORIZANT,sedation,somnolence,0
HORIZANT,sedation,placebo were sedation and dizziness,1
HORIZANT,sedation,somnolence,0
HORIZANT,sedation,common adverse,0
HORIZANT,dizziness,Most common adverse reactions and greater than placebo,0
HORIZANT,dizziness,dizziness somnolence and headache EXCERPT To,1
HORIZANT,dizziness,To,0
HORIZANT,dizziness,dizziness somnolence and headache,1
HORIZANT,dizziness,and greater than placebo dizziness somnolence,1
HORIZANT,dizziness,dizziness somnolence and headache,1
HORIZANT,dizziness,reactions and greater,0
HORIZANT,dizziness,placebo,0
HORIZANT,somnolence,dizziness,0
HORIZANT,somnolence,somnolence,1
HORIZANT,somnolence,greater than placebo,0
HORIZANT,somnolence,placebo were somnolence and headache EXCERPT To report,1
HORIZANT,somnolence,greater than placebo,0
HORIZANT,somnolence,REACTIONS contact XenoP,0
HORIZANT,somnolence,were somnolence,1
HORIZANT,somnolence,REACTIONS contact XenoP,0
HORIZANT,somnolence,somnolence,1
HORIZANT,somnolence,dizziness,0
HORIZANT,somnolence,somnolence and headache,1
HORIZANT,somnolence,dizziness,0
HORIZANT,headache,PHN Most common adverse reactions and greater than,0
HORIZANT,headache,headache EXCERPT,1
HORIZANT,headache,Most common adverse,0
HORIZANT,headache,reactions and greater than placebo,0
HORIZANT,somnolence,somnolence sedation and dizziness see,1
HORIZANT,somnolence,somnolence sedation and dizziness see,1
HORIZANT,somnolence,dose of HORIZANT somnolence sedation and,1
HORIZANT,somnolence,somnolence sedation and dizziness see,1
HORIZANT,sedation,sedation and dizziness see,1
HORIZANT,sedation,sedation and dizziness,1
HORIZANT,sedation,sedation and,1
HORIZANT,sedation,mg,0
HORIZANT,sedation,placebo in these trials for the,0
HORIZANT,sedation,mg dose of HORIZANT were somnolence,0
HORIZANT,dizziness,were somnolencesedation and,0
HORIZANT,balance disorder,greater than placebo balance disorder blurred,1
HORIZANT,balance disorder,were somnolencesedation and,0
HORIZANT,blurred vision,following,0
HORIZANT,blurred vision,atients treated with,0
HORIZANT,blurred vision,vertigo The,0
HORIZANT,blurred vision,feeling drunk lethargy and vertigo,0
HORIZANT,blurred vision,than placebo were balance blurred vision,1
HORIZANT,blurred vision,feeling drunk lethargy and vertigo,0
HORIZANT,blurred vision,and numerically greater than placebo were,0
HORIZANT,blurred vision,numerically greater than placebo were balance disorder,0
HORIZANT,blurred vision,following adverse reactions were dos,0
HORIZANT,disorientation,disorder blurred disorientation,1
HORIZANT,disorientation,following adverse reactions were dos,0
HORIZANT,disorientation,were balance disorder blurred disorientation feeling drunk lethargy and,1
HORIZANT,disorientation,following adverse reactions were dos,0
HORIZANT,disorientation,blurred vision,0
HORIZANT,disorientation,disorientation,1
HORIZANT,disorientation,disorientation feeling drunk lethargy and,1
HORIZANT,disorientation,disorientation feeling drunk,1
HORIZANT,disorientation,disorientation feeling drunk lethargy,1
HORIZANT,disorientation,disorientation feeling drunk lethargy,1
HORIZANT,disorientation,vertigo The following adverse reactions were doserelated somno,0
HORIZANT,feeling drunk,than placebo were balance disorder blurred vision,0
HORIZANT,lethargy,lethargy and vertigo The following adverse,1
HORIZANT,lethargy,lethargy,1
HORIZANT,lethargy,disorientation feeling lethargy and vertigo The following,1
HORIZANT,lethargy,lethargy,1
HORIZANT,lethargy,placebo were balance disorder blurred,0
HORIZANT,lethargy,lethargy and vertigo The following adverse,1
HORIZANT,vertigo,feeling drunk lethargy vertigo The following adverse reactions were,1
HORIZANT,vertigo,lethargy and vertigo The following adverse,1
HORIZANT,vertigo,vertigo The following adverse,1
HORIZANT,vertigo,vertigo,1
HORIZANT,vertigo,vertigo The following adverse,1
HORIZANT,vertigo,vertigo,1
HORIZANT,vertigo,than placebo,0
HORIZANT,somnolence,somnolence sedation dizziness feeling drunk libido,1
HORIZANT,somnolence,somnolence sedation dizziness feeling drunk libido,1
HORIZANT,somnolence,reactions were somnolence sedation dizziness feeling,1
HORIZANT,somnolence,somnolence sedation dizziness feeling drunk libido,1
HORIZANT,somnolence,reactions,0
HORIZANT,somnolence,decreased depression headache,0
HORIZANT,somnolence,somnolence sedation dizziness feeling,1
HORIZANT,somnolence,feeling,0
HORIZANT,somnolence,somnolence sedation dizziness feeling,1
HORIZANT,sedation,sedation dizziness feeling drunk libido,1
HORIZANT,dizziness,vertigo,0
HORIZANT,dizziness,edema,0
HORIZANT,dizziness,dizziness feeling drunk libido decreased,1
HORIZANT,dizziness,drunk libido decreased depression headache peripheral edema and,0
HORIZANT,feeling drunk,and vertigo Postherpetic,0
HORIZANT,feeling drunk,depression headache peripheral edema and vertigo,0
HORIZANT,feeling drunk,headache,0
HORIZANT,feeling drunk,depression headache,0
HORIZANT,feeling drunk,feeling drunk libido decreased depression headache peripheral,1
HORIZANT,feeling drunk,depression headache,0
HORIZANT,feeling drunk,peripheral,0
HORIZANT,libido decreased,somnolencesedation dizziness feeling libido decreased,1
HORIZANT,libido decreased,peripheral,0
HORIZANT,libido decreased,edema and vertigo Postherpetic Neuralgia,0
HORIZANT,libido decreased,libido decreased,1
HORIZANT,depression,depression headache peripheral edema and vertigo,1
HORIZANT,depression,and vertigo Postherpetic Neuralgia The,0
HORIZANT,depression,depression,1
HORIZANT,depression,depression headache peripheral edema and vertigo,1
HORIZANT,headache,drunk libido decreased,0
HORIZANT,headache,decreased headache peripheral,1
HORIZANT,headache,drunk libido decreased,0
HORIZANT,headache,Postherpetic Neuralgia The exposure to HORIZANT,0
HORIZANT,headache,headache peripheral edema and vertigo,1
HORIZANT,headache,Postherpetic Neuralgia The exposure to HORIZANT,0
HORIZANT,headache,somnolencesedation dizziness feeling drunk libido decreased,0
HORIZANT,headache,depression,0
HORIZANT,headache,headache peripheral edema and vertigo,1
HORIZANT,peripheral edema,Postherpetic Neuralgia The exposure to HORIZANT,0
HORIZANT,peripheral edema,dizziness feeling drunk,0
HORIZANT,peripheral edema,peripheral edema and vertigo Postherpetic,1
HORIZANT,peripheral edema,peripheral,1
HORIZANT,peripheral edema,dizziness feeling drunk,0
HORIZANT,peripheral edema,decreased depression peripheral edema and vertigo Postherpetic Neuralgia The,1
HORIZANT,peripheral edema,dizziness feeling drunk,0
HORIZANT,peripheral edema,depression peripheral,1
HORIZANT,vertigo,peripheral edema vertigo Postherpetic Neuralgia The exposure,1
HORIZANT,vertigo,depression peripheral,1
HORIZANT,vertigo,libido decreased,0
HORIZANT,vertigo,headache peripheral edema vertigo Postherpetic Neuralgia The exposure,1
HORIZANT,vertigo,libido decreased,0
HORIZANT,vertigo,with PHN,0
HORIZANT,vertigo,vertigo Postherpetic Neuralgia The exposure to,1
HORIZANT,vertigo,libido decreased depression headache peripheral edema,0
HORIZANT,vertigo,and,0
HORIZANT,vertigo,vertigo Postherpetic Neuralgia,1
HORIZANT,dizziness,for the mg,0
HORIZANT,dizziness,dizziness,1
HORIZANT,dizziness,of,0
HORIZANT,dizziness,dizziness somnolence,1
HORIZANT,dizziness,dizziness somnolence and headache see,1
HORIZANT,somnolence,for the mg dose of HORIZANT were dizziness,0
HORIZANT,somnolence,somnolence and,1
HORIZANT,somnolence,for,0
HORIZANT,headache,headache,1
HORIZANT,headache,Table lists treatmentemergent adverse reactions that occurred in of,0
HORIZANT,headache,headache,1
HORIZANT,confusional state,dry mouth flatulence,0
HORIZANT,confusional state,balance,0
HORIZANT,confusional state,mgday balance confusional,1
HORIZANT,confusional state,dry,0
HORIZANT,confusional state,flatulence increased,0
HORIZANT,dry mouth,confusional state dry mouth flatulence increased appetite irritability,1
HORIZANT,dry mouth,flatulence increased,0
HORIZANT,dry mouth,mgday balance disorder confusional,0
HORIZANT,dry mouth,dry mouth flatulence,1
HORIZANT,dry mouth,appetite irritability and,0
HORIZANT,dry mouth,but were,0
HORIZANT,dry mouth,balance disorder confusional state dry mouth flatulence increased appetite irritability and,1
HORIZANT,dry mouth,but were,0
HORIZANT,dry mouth,dry,1
HORIZANT,dry mouth,confusional state dry,1
HORIZANT,dry mouth,dry mouth flatulence increased,1
HORIZANT,increased appetite,mouth increased appetite,1
HORIZANT,increased appetite,increased appetite,1
HORIZANT,increased appetite,vertigo Dizziness somnolence,0
HORIZANT,increased appetite,mouth increased appetite,1
HORIZANT,increased appetite,dry mouth,0
HORIZANT,increased appetite,dry mouth flatulence,0
HORIZANT,increased appetite,mouth increased appetite irritability and,1
HORIZANT,increased appetite,dry mouth flatulence,0
HORIZANT,increased appetite,increased appetite irritability and,1
HORIZANT,increased appetite,dry mouth flatulence,0
HORIZANT,irritability,irritability and vertigo Dizziness,1
HORIZANT,irritability,mouth flatulence increased irritability and vertigo Dizziness somnolence fatigue,1
HORIZANT,irritability,irritability and vertigo Dizziness,1
HORIZANT,irritability,flatulence increased irritability and vertigo Dizziness somnolence fatigue,1
HORIZANT,irritability,irritability and vertigo Dizziness,1
HORIZANT,irritability,irritability and vertigo Dizziness,1
HORIZANT,irritability,mouth flatulence increased irritability,1
HORIZANT,irritability,irritability and vertigo Dizziness,1
HORIZANT,irritability,irritability and vertigo Dizziness somnolence,1
HORIZANT,irritability,irritability and vertigo Dizziness,1
HORIZANT,irritability,flatulence increased irritability and vertigo,1
HORIZANT,irritability,irritability and vertigo Dizziness,1
HORIZANT,irritability,irritability and vertigo Dizziness,1
HORIZANT,irritability,flatulence increased irritability,1
HORIZANT,irritability,irritability and vertigo Dizziness,1
HORIZANT,irritability,and insomnia appeared to,0
HORIZANT,vertigo,vertigo Dizziness somnolence,1
HORIZANT,vertigo,vertigo,1
HORIZANT,vertigo,and insomnia appeared to show a,0
HORIZANT,Dizziness,Dizziness,1
HORIZANT,Dizziness,relationship Adverse Events A,0
HORIZANT,Dizziness,a dose relationship Adverse Events A,0
HORIZANT,somnolence,somnolence fatigue and insomnia,1
HORIZANT,somnolence,irritability and vertigo somnolence fatigue and,1
HORIZANT,somnolence,somnolence fatigue and insomnia,1
HORIZANT,somnolence,depression dry mouth flatulence increased appetite,0
HORIZANT,somnolence,somnolence fatigue,1
HORIZANT,somnolence,irritability and vertigo somnolence fatigue and insomnia appeared,1
HORIZANT,somnolence,somnolence fatigue,1
HORIZANT,somnolence,somnolence fatigue and insomnia,1
HORIZANT,insomnia,insomnia appeared to,1
HORIZANT,insomnia,somnolence fatigue insomnia appeared to,1
HORIZANT,insomnia,insomnia appeared to,1
HORIZANT,insomnia,insomnia appeared,1
HORIZANT,insomnia,and vertigo Dizziness,0
HORIZANT,insomnia,Adverse Events Associated,0
HORIZANT,insomnia,insomnia appeared to show a dose,1
HORIZANT,insomnia,and,0
HORIZANT,insomnia,irritability and vertigo Dizziness somnolence,0
HORIZANT,insomnia,Events Associated With Gabapentin The,0
HORIZANT,insomnia,insomnia appeared to show a,1
HORIZANT,breast enlargement,have been,0
HORIZANT,breast enlargement,breast enlargement gynecomastia and elevated creatine kinase,1
HORIZANT,gynecomastia,and elevated,0
HORIZANT,gynecomastia,in clinical,0
HORIZANT,gynecomastia,gynecomastia,1
HORIZANT,gynecomastia,trials or postmarketing breast gynecomastia and elevated creatine kinase,1
HORIZANT,gynecomastia,gynecomastia,1
HORIZANT,gynecomastia,gynecomastia and elevated,1
HORIZANT,Driving impairment,REACTIONS The following adverse ons,1
HORIZANT,Driving impairment,the label,0
HORIZANT,Driving impairment,and Precautions section of,0
HORIZANT,Driving impairment,label Somnolencesedation a,0
HORIZANT,Somnolence,RLS: Mos t common adverse reactions,1
HORIZANT,Somnolence,dizziness see Warnings and   RLS: Mos,1
HORIZANT,Somnolence,RLS: Mos t common adverse reactions,1
HORIZANT,Somnolence,Warnings and RLS: Mos,1
HORIZANT,Somnolence,placebo,0
HORIZANT,Somnolence,dizziness see Warnings and RLS: Mos,1
HORIZANT,Somnolence,RLS: Mos t common,1
HORIZANT,Somnolence,Warnings and   RLS: Mos t common,1
HORIZANT,Somnolence,RLS: Mos t common,1
HORIZANT,sedation,see,0
HORIZANT,sedation,RLS Most,0
HORIZANT,sedation, common  adverse,1
HORIZANT,sedation,times the rate of placebo were,0
HORIZANT,sedation,Warnings and Precautions RLS  common  adverse,1
HORIZANT,sedation,times the rate of placebo were,0
HORIZANT,dizziness,times the rate of placebo,0
HORIZANT,Suicidal thoughts,and greater,0
HORIZANT,suicidal thoughts,ADVERSE REACTIO,0
HORIZANT,suicidal thoughts,"NS, contact XenoP ort",1
HORIZANT,suicidal thoughts,To,0
HORIZANT,suicidal thoughts,somnolence and headache EXCERPT To report SUSPECTED ADVERSE REACTIO,0
HORIZANT,suicidal thoughts,"ADVERSE NS, contact XenoP ort at XENOPRT or",1
HORIZANT,suicidal thoughts,somnolence and headache EXCERPT To report SUSPECTED ADVERSE REACTIO,0
HORIZANT,driving impairment,reaction rates observed in the clinical trials of a,0
HORIZANT,driving impairment,or wwwfdagovmedwatch Clinical Trials Experience,0
HORIZANT,driving impairment,clinical trials,0
HORIZANT,driving impairment,trials are co nducted under widely varying,1
HORIZANT,driving impairment,ical trials are co nducted under widely varying conditions,1
HORIZANT,driving impairment,trials are co nducted under widely varying,1
HORIZANT,driving impairment,Experience Because ical trials are co,1
HORIZANT,driving impairment,trials are co nducted under widely varying,1
HORIZANT,driving impairment,varying conditions,0
HORIZANT,driving impairment,are co,1
HORIZANT,driving impairment,Because ical trials are co,1
HORIZANT,driving impairment,are co,1
HORIZANT,driving impairment,with rates in the clinical trials of,0
HORIZANT,somnolence,for at least year HORIZANT in the treatment,0
HORIZANT,somnolence,included,0
HORIZANT,somnolence,at least year HORIZANT in the treatment of RLS was studied p,0
HORIZANT,somnolence,osed for a t least months and,1
HORIZANT,somnolence,at least year HORIZANT in the treatment of RLS was studied p,0
HORIZANT,somnolence,least months and exposed for at least year HORIZANT in the,0
HORIZANT,somnolence,RLS included osed for a t least,1
HORIZANT,somnolence,least months and exposed for at least year HORIZANT in the,0
HORIZANT,somnolence,t least,0
HORIZANT,somnolence,patients with RLS included osed for a,1
HORIZANT,somnolence,trials n nd in long,1
HORIZANT,somnolence,was studied primarily in placebocontrolled,0
HORIZANT,somnolence,nd in long term followup studies The population,1
HORIZANT,somnolence,in long term followup studies The population,1
HORIZANT,somnolence,in placebocontrolled trials n nd in long term followup,1
HORIZANT,somnolence,in long term followup studies The population,1
HORIZANT,sedation,population with RLS ranged,0
HORIZANT,sedation,and in term fol lowup studies,1
HORIZANT,sedation,population with RLS ranged,0
HORIZANT,sedation,RLS ranged from to years,0
HORIZANT,sedation,ranged from,0
HORIZANT,sedation,term fol lowup studies The,1
HORIZANT,sedation,in term fol,1
HORIZANT,sedation,term fol lowup,1
HORIZANT,sedation,in term fol,1
HORIZANT,dizziness,in longterm p studies,1
HORIZANT,dizziness,in longterm p studies,1
HORIZANT,somnolence,treated with mg of HORIZANT disconti,0
HORIZANT,somnolence,with RLS in double blind placebocontrolled week clinical trials The,0
HORIZANT,sedation,ied in,1
HORIZANT,sedation,in 2 of the studies Eleven out,1
HORIZANT,sedation,in 2 of the studies Eleven,1
HORIZANT,sedation,The mg dose was ied in,1
HORIZANT,sedation,dose was ied in,1
HORIZANT,sedation,mg dose was ied in 2 of,1
HORIZANT,sedation,dose was ied in,1
HORIZANT,sedation,Eleven out of patients treated with mg of,0
HORIZANT,sedation,mg dose was ied in 2 of,1
HORIZANT,sedation,Eleven out of patients treated with mg of,0
HORIZANT,sedation,trials,0
HORIZANT,sedation,ied in 2 of the studies Eleven out,1
HORIZANT,somnolence,who received ebo.,1
HORIZANT,somnolence,patients who received ebo.,1
HORIZANT,somnolence,ebo. T he most commonly,1
HORIZANT,somnolence,"ebo.



 T he most commonly observed adverse",1
HORIZANT,somnolence,ebo. T he most commonly,1
HORIZANT,Dizziness,of placebo in these for the 6 mg dose of,1
HORIZANT,Dizziness,ebo. T he most commonly,1
HORIZANT,Dizziness,observed adverse reactions and at least times the rate,0
HORIZANT,Dizziness,in these for the 6 mg dose of HORIZANT,1
HORIZANT,Dizziness,observed adverse reactions and at least times the rate,0
HORIZANT,Dizziness,in these for the 6 mg,1
HORIZANT,Dizziness,observed adverse reactions and at least times the rate,0
HORIZANT,Dizziness,reactions and at least times,0
HORIZANT,Dizziness,of placebo in these for,1
HORIZANT,Dizziness,for the 6 mg dose,1
HORIZANT,dizziness,LS treate d with HORIZANT and numerically,1
HORIZANT,dizziness,in of patients with LS treate d with HORIZANT and numerically,1
HORIZANT,dizziness,LS treate d with HORIZANT and numerically,1
HORIZANT,dizziness,in of patients with LS treate d with HORIZANT,1
HORIZANT,dizziness,LS treate d with HORIZANT and numerically,1
HORIZANT,Somnolence,than . Tabl,1
HORIZANT,Somnolence,occurred in of patients with RLS treated with,0
HORIZANT,Somnolence,.,1
HORIZANT,Somnolence,than . Tabl,1
HORIZANT,Somnolence,. Tabl e Incidence,1
HORIZANT,Somnolence,. Tabl,1
HORIZANT,Somnolence,of Patients Treated With,0
HORIZANT,Somnolence,with HORIZANT and numerically greater than,0
HORIZANT,sedation,4. Inci dence of Adverse,1
HORIZANT,sedation,numerically,0
HORIZANT,Dizziness,Reactions in Week RLS Studies Reported,0
HORIZANT,Dizziness,Patie,0
HORIZANT,Dizziness,nts Treat ed With,1
HORIZANT,Dizziness, administ ration,1
HORIZANT,Dizziness, administ ration site conditions,1
HORIZANT,Dizziness, administ ration,1
HORIZANT,Dizziness, administ ration site conditions,1
HORIZANT,Dizziness, administ ration,1
HORIZANT,Dizziness,ration,0
HORIZANT,Dizziness, administ ration site,1
HORIZANT,Dizziness, administ ration site,1
HORIZANT,Dizziness, administ ration,1
HORIZANT,Dizziness, administ ration site,1
HORIZANT,Dizziness, administ ration site,1
HORIZANT,Dizziness,General disorders  administ ration,1
HORIZANT,Dizziness, administ ration site,1
HORIZANT,suicidal thoughts,                  Weight,1
HORIZANT,suicidal thoughts,nutritional disorders,0
HORIZANT,suicidal behavior,Libido                 2 a Placebo was a treatment,1
HORIZANT,suicidal behavior,nutritional disorders,0
HORIZANT,suicidal thinking,ment arm in of the doubleblind placebocontrolled week,0
HORIZANT,suicidal thinking,trials b The mg dose of,0
HORIZANT,suicidal thinking,was a treat,1
HORIZANT,suicidal thinking,The mg d,0
HORIZANT,suicidal thinking,IZANT was a treat ment arm in of the,1
HORIZANT,suicidal thinking,ment arm in of the doubleblind placebocontrolled week,0
HORIZANT,suicidal thinking,in of the doubleblind placebocontrolled week clinical trials c The,0
HORIZANT,suicidal thinking,c The,0
HORIZANT,suicidal thinking,trials c,0
HORIZANT,suicidal thinking,of IZANT was a treat,1
HORIZANT,suicidal thoughts,12 wee k studies,1
HORIZANT,suicidal thoughts,in t,0
HORIZANT,suicidal thoughts,hese three 12 wee k studies in,1
HORIZANT,suicidal thoughts,in t,0
HORIZANT,suicidal thoughts,reactions reported in hese,1
HORIZANT,suicidal thoughts,12 wee k studies in of,1
HORIZANT,suicidal thoughts,"headache, periphe ral edema and",1
HORIZANT,suicidal thoughts,in,0
HORIZANT,suicidal thoughts,"headache, periphe ral",1
HORIZANT,suicidal thoughts,exposure,0
HORIZANT,suicidal thoughts,"feeling drunk libido decreased headache, periphe ral edema and vertigo Postherpetic",1
HORIZANT,suicidal thoughts,exposure,0
HORIZANT,suicidal thoughts,"decreased headache, periphe",1
HORIZANT,suicidal thoughts,exposure,0
HORIZANT,suicidal thoughts,edema and vertigo Postherpetic,0
HORIZANT,suicidal thoughts,"libido decreased headache, periphe ral edema and",1
HORIZANT,suicidal thoughts,edema and vertigo Postherpetic,0
HORIZANT,suicidal thoughts,Numerically r Than the Placeb o Rate Reported in,1
HORIZANT,suicidal thoughts,edema and vertigo Postherpetic,0
HORIZANT,suicidal thoughts,Reactions in At Least,0
HORIZANT,suicidal thoughts,Body SystemAdverse Reaction PlaceboN,0
HORIZANT,suicidal thoughts,r Than,1
HORIZANT,suicidal thoughts,Numerically r Than the Placeb o Rate Reported in All,1
HORIZANT,suicidal thoughts,r Than,1
HORIZANT,suicidal thoughts,of HORIZANT and Numerically r,1
HORIZANT,suicidal thoughts,the Placeb o Rate Reported in,1
HORIZANT,suicidal thoughts,With mgday of HORIZANT and,0
HORIZANT,suicidal thoughts,PHN Study Body SystemAdverse Reaction PlaceboN,0
HORIZANT,suicidal thoughts,SystemAdverse,0
HORIZANT,myositis,nd nutri,1
HORIZANT,myositis,SystemAdverse,0
HORIZANT,Eosinophilia,             Weight,1
HORIZANT,Eosinophilia,            ,1
HORIZANT,Eosinophilia,nutritional             ,1
HORIZANT,Eosinophilia,            ,1
HORIZANT,Eosinophilia,Metabolism and nutritional disorders,0
HORIZANT,Eosinophilia,            ,1
HORIZANT,Eosinophilia,nutritional              Weight,1
HORIZANT,Eosinophilia,            ,1
HORIZANT,rash,disorders,0
STENDRA,headache,back pain To report SUSPECTED,0
STENDRA,headache,greater than or equal to include,0
STENDRA,headache,headache flushing,1
STENDRA,flushing,equal to include flushing nasal congestion nasopharyngitis and back,1
STENDRA,flushing,headache flushing,1
STENDRA,flushing,nasal congestion nasopharyngitis and back pain To,0
STENDRA,flushing,flushing nasal congestion nasopharyngitis and,1
STENDRA,flushing,equal to include flushing nasal congestion nasopharyngitis,1
STENDRA,flushing,flushing nasal congestion nasopharyngitis and,1
STENDRA,nasal congestion,equal to include headache nasal congestion nasopharyngitis and,1
STENDRA,nasal congestion,flushing nasal congestion nasopharyngitis and,1
STENDRA,nasal congestion,nasal congestion nasopharyngitis and,1
STENDRA,nasal congestion,flushing nasal congestion nasopharyngitis and,1
STENDRA,nasal congestion,to include headache nasal,1
STENDRA,nasal congestion,nasal congestion,1
STENDRA,nasal congestion,to include headache nasal congestion nasopharyngitis and,1
STENDRA,nasal congestion,nasal congestion,1
STENDRA,nasal congestion,or,0
STENDRA,nasal congestion,to include headache nasal,1
STENDRA,nasopharyngitis,ADVERSE REACTIONS contact,0
STENDRA,nasopharyngitis,nasopharyngitis,1
STENDRA,nasopharyngitis,report SUSPECTED ADVERSE,0
STENDRA,nasopharyngitis,to include headache flushing nasal congestion,0
STENDRA,nasopharyngitis,pain,0
STENDRA,nasopharyngitis,report SUSPECTED ADVERSE REACTIONS contact or,0
STENDRA,nasopharyngitis,nasopharyngitis and back,1
STENDRA,nasopharyngitis,contact or FDA at,0
STENDRA,nasopharyngitis,SUSPECTED ADVERSE REACTIONS,0
STENDRA,nasopharyngitis,headache flushing nasal nasopharyngitis and back pain To,1
STENDRA,nasopharyngitis,SUSPECTED ADVERSE REACTIONS,0
STENDRA,back pain,back pain To report SUSPECTED ADVERSE,1
STENDRA,back pain,congestion nasopharyngitis back pain To report,1
STENDRA,back pain,back pain To report SUSPECTED ADVERSE,1
STENDRA,back pain,FDA at,0
STENDRA,back pain,or FDA,0
STENDRA,back pain,nasopharyngitis back,1
STENDRA,upper respiratory infection,bronchitis influenza,0
STENDRA,URI,URI bronchitis influenza,1
STENDRA,URI,upper respiratory URI bronchitis influenza sinusitis sinus congestion,1
STENDRA,URI,URI bronchitis influenza,1
STENDRA,bronchitis,bronchitis influenza sinusitis sinus,1
STENDRA,bronchitis,influenza sinusitis sinus congestion hypertension dyspepsia nausea constipation and,0
STENDRA,bronchitis,infection bronchitis influenza sinusitis,1
STENDRA,bronchitis,influenza sinusitis sinus congestion hypertension dyspepsia nausea constipation and,0
STENDRA,bronchitis,bronchitis influenza sinusitis sinus,1
STENDRA,bronchitis,upper respiratory infection bronchitis influenza sinusitis sinus,1
STENDRA,bronchitis,bronchitis influenza sinusitis sinus,1
STENDRA,influenza,upper respiratory infection URI influenza sinusitis sinus congestion hypertension dyspepsia,1
STENDRA,influenza,bronchitis influenza sinusitis sinus,1
STENDRA,sinusitis,infection URI bronchitis sinusitis sinus congestion,1
STENDRA,sinusitis,bronchitis influenza sinusitis sinus,1
STENDRA,sinusitis,sinusitis sinus,1
STENDRA,sinusitis,sinusitis,1
STENDRA,sinus congestion,sinus congestion hypertension dyspepsia nausea constipation and,1
STENDRA,hypertension,sinusitis sinus hypertension,1
STENDRA,hypertension,sinus congestion hypertension dyspepsia nausea constipation and,1
STENDRA,hypertension,an,0
STENDRA,hypertension,hypertension dyspepsia,1
STENDRA,hypertension,hypertension,1
STENDRA,hypertension,rash In an openlabel longterm extension study,0
STENDRA,hypertension,sinusitis sinus hypertension dyspepsia nausea constipation,1
STENDRA,hypertension,rash In an openlabel longterm extension study,0
STENDRA,hypertension,and,0
STENDRA,dyspepsia,dyspepsia nausea constipation and rash In,1
STENDRA,dyspepsia,URI bronchitis,0
STENDRA,dyspepsia,nausea constipation and rash In an openlabel longterm extension study of two of these,0
STENDRA,dyspepsia,dyspepsia nausea,1
STENDRA,dyspepsia,constipation and,0
STENDRA,constipation,influenza sinusitis sinus congestion hypertension dyspepsia,0
STENDRA,constipation,constipation and rash In an openlabel,1
STENDRA,constipation,extension study of two of these randomized doubleblind,0
STENDRA,constipation,fection URI bronchitis influenza sinusitis sinus congestion hypertension dyspepsia,0
STENDRA,constipation,constipation and,1
STENDRA,upper respiratory infection,than of,0
STENDRA,URI,pain arthralgia hypertension and diarrhea,0
STENDRA,URI,sinusitis bronchitis dizziness back pain arthralgia,0
STENDRA,URI,URI influenza sinusitis bronchitis,1
STENDRA,URI,patients,0
STENDRA,URI,study,0
STENDRA,URI,included upper respiratory URI influenza sinusitis bronchitis dizziness,1
STENDRA,URI,study,0
STENDRA,URI,URI,1
STENDRA,URI,patients in the openlabel extension study included upper respiratory infection,0
STENDRA,URI,upper respiratory URI influenza sinusitis bronchitis dizziness,1
STENDRA,URI,patients in the openlabel extension study included upper respiratory infection,0
STENDRA,URI,arthralgia hypertension and,0
STENDRA,influenza,than of patients in the openlabel extension study,0
STENDRA,influenza,arthralgia,0
STENDRA,influenza,influenza sinusitis bronchitis dizziness back pain,1
STENDRA,influenza,influenza,1
STENDRA,sinusitis,sinusitis bronchitis dizziness back pain,1
STENDRA,sinusitis,URI sinusitis bronchitis dizziness,1
STENDRA,sinusitis,sinusitis bronchitis dizziness back pain,1
STENDRA,sinusitis,dizziness back,0
STENDRA,sinusitis,URI,0
STENDRA,bronchitis,events occurred in,0
STENDRA,bronchitis,included upper respiratory infection,0
STENDRA,bronchitis,respiratory infection URI influenza sinusitis,0
STENDRA,bronchitis,bronchitis dizziness,1
STENDRA,bronchitis,respiratory infection URI influenza sinusitis,0
STENDRA,bronchitis,bronchitis dizziness back,1
STENDRA,bronchitis,influenza,0
STENDRA,bronchitis,infection URI influenza bronchitis dizziness,1
STENDRA,bronchitis,influenza,0
STENDRA,bronchitis,bronchitis dizziness back pain,1
STENDRA,bronchitis,bronchitis dizziness back pain arthralgia,1
STENDRA,bronchitis,bronchitis dizziness back pain arthralgia,1
STENDRA,back pain,sinusitis bronchitis back pain,1
STENDRA,back pain,study included upper respiratory infection URI influenza,0
STENDRA,hypertension,hypertension and diarrhea,1
STENDRA,hypertension,er respiratory,0
STENDRA,diarrhea,diarrhea The following events,1
STENDRA,diarrhea,diarrhea,1
STENDRA,diarrhea,ection URI influenza sinusitis bronchitis dizziness back pain,0
STENDRA,diarrhea,diarrhea The,1
STENDRA,diarrhea,diarrhea The following events occurred in,1
STENDRA,diarrhea,diarrhea The,1
STENDRA,diarrhea,diarrhea The following events occurred in,1
STENDRA,diarrhea,diarrhea The following events occurred in,1
STENDRA,diarrhea,diarrhea The following,1
STENDRA,diarrhea,diarrhea The following events occurred in,1
STENDRA,diarrhea,occurred in less than of patients in the,0
STENDRA,edema peripheral,Cardiovascular angina unstable angina deep vein,0
STENDRA,edema peripheral,as a edema peripheral fatigue Cardiovascular angina unstable angina,1
STENDRA,edema peripheral,Cardiovascular angina unstable angina deep vein,0
STENDRA,edema peripheral,a edema,1
STENDRA,edema peripheral,lausible relation to drug use and reports too imprecise to be meaningful Body as a whole,0
STENDRA,edema peripheral,edema peripheral fatigue Cardiovascular,1
STENDRA,edema peripheral,edema peripheral,1
STENDRA,edema peripheral,as a edema peripheral,1
STENDRA,edema peripheral,edema peripheral,1
STENDRA,edema peripheral,edema peripheral fatigue Cardiovascular angina unstable,1
STENDRA,edema peripheral,a edema peripheral,1
STENDRA,edema peripheral,edema peripheral fatigue Cardiovascular angina unstable,1
STENDRA,edema peripheral,as a edema peripheral,1
STENDRA,fatigue,fatigue Cardiovascular,1
STENDRA,fatigue,as a whole edema fatigue Cardiovascular angina,1
STENDRA,fatigue,fatigue Cardiovascular,1
STENDRA,fatigue,as a,0
STENDRA,angina,angina unstable angina,1
STENDRA,angina,as a,0
STENDRA,angina,angina unstable angina,1
STENDRA,angina,a whole,0
STENDRA,angina,a whole edema peripheral fatigue Cardiovascular,0
STENDRA,deep vein thrombosis,edema peripheral fatigue,0
STENDRA,deep vein thrombosis,edema peripheral fatigue,0
STENDRA,deep vein thrombosis,angina unstable deep vein thrombosis palpitations,1
STENDRA,deep vein thrombosis,edema peripheral fatigue,0
STENDRA,deep vein thrombosis,vein thrombosis palpitations,1
STENDRA,deep vein thrombosis,as a whole edema peripheral fatigue,0
STENDRA,deep vein thrombosis,angina unstable deep vein thrombosis,1
STENDRA,deep vein thrombosis,deep vein thrombosis palpitations Digestive gastritis gastroesophageal,1
STENDRA,deep vein thrombosis,angina unstable deep vein thrombosis,1
STENDRA,deep vein thrombosis,palpitations,0
STENDRA,deep vein thrombosis,gastritis,0
STENDRA,deep vein thrombosis,a whole edema,0
STENDRA,palpitations,palpitations Digestive gastritis gastroesophageal reflux,1
STENDRA,palpitations,palpitations,1
STENDRA,palpitations,palpitations Digestive gastritis,1
STENDRA,palpitations,palpitations,1
STENDRA,gastritis,hypoglycemia,0
STENDRA,gastritis,vein thrombosis palpitations,0
STENDRA,gastritis,vein thrombosis palpitations,0
STENDRA,gastritis,Cardiovascular angina unstable angina,0
STENDRA,gastritis,gastritis gastroesophageal reflux,1
STENDRA,gastritis,unstable angina deep vein,0
STENDRA,gastritis,gastritis gastroesophageal reflux disease hypoglycemia,1
STENDRA,gastritis,unstable angina,0
STENDRA,gastroesophageal reflux disease,thrombosis palpitations,0
STENDRA,gastroesophageal reflux disease,gastroesophageal reflux disease hypoglycemia,1
STENDRA,gastroesophageal reflux disease,Digestive gastroesophageal reflux disease hypoglycemia blood glucose increased alanine,1
STENDRA,gastroesophageal reflux disease,gastroesophageal reflux disease hypoglycemia,1
STENDRA,gastroesophageal reflux disease,oropharyngeal pain sto,0
STENDRA,gastroesophageal reflux disease,Digestive gastroesophageal,1
STENDRA,gastroesophageal reflux disease,thrombosis palpitations Digestive gastroesophageal reflux disease hypoglycemia blood,1
STENDRA,gastroesophageal reflux disease,Digestive gastroesophageal,1
STENDRA,hypoglycemia,palpitations,0
STENDRA,hypoglycemia,reflux hypoglycemia blood glucose increased alanine aminotransferase,1
STENDRA,hypoglycemia,palpitations,0
STENDRA,hypoglycemia,palpitations Digestive,0
STENDRA,hypoglycemia,gastroesophageal reflux disease,0
STENDRA,hypoglycemia,vein thrombosis palpitations Digestive gastritis gastroesophageal,0
STENDRA,blood glucose increased,glucose increased alanine aminotransferase,1
STENDRA,blood glucose increased,blood glucose increased alanine aminotransferase increased,1
STENDRA,blood glucose increased,glucose increased alanine aminotransferase increased oropharyngeal,1
STENDRA,blood glucose increased,reflux disease blood glucose increased,1
STENDRA,blood glucose increased,glucose increased alanine aminotransferase increased oropharyngeal,1
STENDRA,blood glucose increased,rombosis palpitations,0
STENDRA,blood glucose increased,Digestive,0
STENDRA,blood glucose increased,gastroesophageal reflux disease,0
STENDRA,blood glucose increased,pain stomach discomfort vomiting Musculo,0
STENDRA,blood glucose increased,gastritis gastroesophageal reflux disease blood glucose increased,1
STENDRA,alanine aminotransferase increased,disease hypoglycemia blood glucose alanine aminotransferase,1
STENDRA,alanine aminotransferase increased,oropharyngeal pain stomach discomfort vomiting,0
STENDRA,alanine aminotransferase increased,hypoglycemia blood glucose alanine aminotransferase increased oropharyngeal pain stomach discomfort,1
STENDRA,alanine aminotransferase increased,oropharyngeal pain stomach discomfort vomiting,0
STENDRA,alanine aminotransferase increased,aminotransferase increased,1
STENDRA,oropharyngeal pain,alanine aminotransferase oropharyngeal,1
STENDRA,oropharyngeal pain,oropharyngeal pain,1
STENDRA,oropharyngeal pain,aminotransferase increased,0
STENDRA,oropharyngeal pain,aminotransferase oropharyngeal pain,1
STENDRA,oropharyngeal pain,ophageal,0
STENDRA,oropharyngeal pain,aminotransferase oropharyngeal pain stomach discomfort vomiting Musculoskeletal muscle,1
STENDRA,oropharyngeal pain,ophageal,0
STENDRA,oropharyngeal pain,hypoglycemia,0
STENDRA,oropharyngeal pain,oropharyngeal pain,1
STENDRA,oropharyngeal pain,aminotransferase oropharyngeal pain stomach discomfort vomiting Musculoskeletal,1
STENDRA,oropharyngeal pain,oropharyngeal pain,1
STENDRA,stomach discomfort,stomach discomfort vomiting,1
STENDRA,stomach discomfort,aminotransferase increased oropharyngeal stomach,1
STENDRA,stomach discomfort,blood glucose increased alanine aminotransferase increased oropharyngeal,0
STENDRA,vomiting,vomiting,1
STENDRA,vomiting,vomiting Musculoskeletal muscle spasms musculoskeletal,1
STENDRA,vomiting,oropharyngeal pain,0
STENDRA,vomiting,stomach vomiting Musculoskeletal muscle spasms musculoskeletal pain,1
STENDRA,vomiting,oropharyngeal pain,0
STENDRA,vomiting,vomiting Musculoskeletal muscle,1
STENDRA,vomiting,vomiting Musculoskeletal muscle spasms musculoskeletal pain,1
STENDRA,muscle spasms,extremity,0
STENDRA,muscle spasms,discomfort vomiting muscle spasms musculoskeletal pain,1
STENDRA,muscle spasms,extremity,0
STENDRA,muscle spasms,in extremity Nervous depression,0
STENDRA,muscle spasms,vomiting muscle spasms musculoskeletal pain,1
STENDRA,muscle spasms,in extremity Nervous depression,0
STENDRA,muscle spasms,Nervous,0
STENDRA,muscle spasms,pain myalgia,0
STENDRA,muscle spasms,pain stomach discomfort vomiting,0
STENDRA,muscle spasms,pain stomach discomfort vomiting muscle spasms,1
STENDRA,muscle spasms,pain stomach discomfort vomiting,0
STENDRA,musculoskeletal pain,depression insomnia somnolence,0
STENDRA,musculoskeletal pain,discomfort vomiting Musculoskeletal muscle musculoskeletal pain,1
STENDRA,myalgia,musculoskeletal,0
STENDRA,myalgia,discomfort vomiting Musculoskeletal muscle spasms musculoskeletal pain,0
STENDRA,myalgia,muscle spasms musculoskeletal myalgia pain in extremity Nervous depression,1
STENDRA,myalgia,discomfort vomiting Musculoskeletal muscle spasms musculoskeletal pain,0
STENDRA,myalgia,myalgia pain in extremity,1
STENDRA,myalgia,myalgia pain,1
STENDRA,myalgia,myalgia pain in,1
STENDRA,myalgia,myalgia pain,1
STENDRA,pain in extremity,spasms musculoskeletal pain myalgia,0
STENDRA,pain in extremity,pain in extremity Nervous depression insomnia somnolence,1
STENDRA,pain in extremity,musculoskeletal pain pain,1
STENDRA,pain in extremity,Nervous depression insomnia somnolence vertigo Respiratory cough dyspnea exer,0
STENDRA,depression,spasms musculoskeletal pain myalgia pain in,0
STENDRA,depression,pain in extremity depression insomnia somnolence vertigo,1
STENDRA,depression,spasms musculoskeletal pain myalgia pain in,0
STENDRA,depression,pain in extremity depression insomnia,1
STENDRA,depression,spasms musculoskeletal pain myalgia pain in,0
STENDRA,depression,depression insomnia somnolence vertigo Respiratory,1
STENDRA,depression,spasms musculoskeletal pain myalgia pain in,0
STENDRA,depression,depression insomnia somnolence vertigo Respiratory,1
STENDRA,depression,depression insomnia somnolence,1
STENDRA,insomnia,Nervous depression,0
STENDRA,insomnia,insomnia somnolence,1
STENDRA,insomnia,Nervous insomnia,1
STENDRA,insomnia,insomnia somnolence,1
STENDRA,insomnia,pain in extremity Nervous insomnia,1
STENDRA,insomnia,insomnia somnolence,1
STENDRA,insomnia,epistaxis,0
STENDRA,insomnia,exertional epistaxis wheezing Skin,0
STENDRA,insomnia,insomnia,1
STENDRA,insomnia,spasms musculoskeletal pain myalgia pain in extremity,0
STENDRA,insomnia,insomnia somnolence vertigo Respiratory cough,1
STENDRA,insomnia,insomnia somnolence,1
STENDRA,somnolence,extremity Nervous depression insomnia,0
STENDRA,somnolence,somnolence vertigo Respiratory cough dyspnea exertional,1
STENDRA,somnolence,vertigo Respiratory cough dyspnea exertional epistaxis,0
STENDRA,somnolence,somnolence vertigo Respiratory cough dyspnea,1
STENDRA,somnolence,depression somnolence,1
STENDRA,somnolence,somnolence vertigo Respiratory cough dyspnea,1
STENDRA,somnolence,pain myalgia pain in extremity Nervous,0
STENDRA,somnolence,depression somnolence vertigo Respiratory cough,1
STENDRA,somnolence,pain myalgia pain in extremity Nervous,0
STENDRA,somnolence,somnolence vertigo,1
STENDRA,somnolence,pain myalgia pain in extremity Nervous,0
STENDRA,somnolence,Respiratory,0
STENDRA,somnolence,Skin,0
STENDRA,cough,somnolence vertigo cough,1
STENDRA,cough,Skin,0
STENDRA,dyspnea exertional,insomnia somnolence vertigo Respiratory dyspnea exertional,1
STENDRA,dyspnea exertional,dyspnea exertional,1
STENDRA,dyspnea exertional,pruritus Urogenital balanitis,0
STENDRA,dyspnea exertional,Respiratory dyspnea exertional epistaxis wheezing Skin and,1
STENDRA,dyspnea exertional,pruritus Urogenital balanitis,0
STENDRA,dyspnea exertional,Skin and Appendages,0
STENDRA,dyspnea exertional,Respiratory,0
STENDRA,dyspnea exertional,Respiratory dyspnea,1
STENDRA,dyspnea exertional,dyspnea,1
STENDRA,epistaxis,epistaxis wheezing Skin and Appendages,1
STENDRA,epistaxis,epistaxis wheezing Skin and Appendages pruritus,1
STENDRA,epistaxis,cough dyspnea epistaxis wheezing,1
STENDRA,epistaxis,epistaxis wheezing Skin and Appendages pruritus,1
STENDRA,epistaxis,epistaxis wheezing,1
STENDRA,wheezing,wheezing Skin and Appendages pruritus,1
STENDRA,wheezing,wheezing Skin and,1
STENDRA,wheezing,pruritus Urogenital balanitis erection,0
STENDRA,wheezing,pruritus Urogenital balanitis,0
STENDRA,pruritus,cough dyspnea exertional epistaxis,0
STENDRA,pruritus,pruritus Urogenital balanitis,1
STENDRA,pruritus,epistaxis wheezing Skin and pruritus Urogenital balanitis erection,1
STENDRA,pruritus,pruritus Urogenital balanitis,1
STENDRA,pruritus,Skin and pruritus Urogenital balanitis,1
STENDRA,pruritus,pruritus Urogenital balanitis,1
STENDRA,pruritus,pruritus Urogenital balanitis,1
STENDRA,pruritus,pruritus Urogenital balanitis erection increased hematuria,1
STENDRA,pruritus,Skin and pruritus,1
STENDRA,pruritus,pruritus Urogenital balanitis erection increased hematuria,1
STENDRA,pruritus,Skin and pruritus Urogenital,1
STENDRA,pruritus,pruritus Urogenital balanitis erection increased hematuria,1
STENDRA,balanitis,balanitis erection increased hematuria nephrolithiasis,1
STENDRA,balanitis,balanitis,1
STENDRA,balanitis,pruritus Urogenital,0
STENDRA,balanitis,tract infection In,0
STENDRA,balanitis,infection In an,0
STENDRA,balanitis,and Appendages,0
STENDRA,balanitis,Appendages pruritus balanitis,1
STENDRA,balanitis,and Appendages,0
STENDRA,balanitis,Urogenital,0
STENDRA,balanitis,exertional epistaxis wheezing Skin,0
STENDRA,erection increased,pruritus Urogenital erection,1
STENDRA,erection increased,erection increased hematuria nephrolithiasis,1
STENDRA,erection increased,pruritus Urogenital erection,1
STENDRA,erection increased,tract infection,0
STENDRA,erection increased,Skin and,0
STENDRA,erection increased,Urogenital erection increased,1
STENDRA,erection increased,Skin and,0
STENDRA,erection increased,tract infection In an additional randomized,0
STENDRA,erection increased,and Appendages pruritus Urogenital erection increased hematuria nephrolithiasis pollakiuria urinary,1
STENDRA,erection increased,tract infection In an additional randomized,0
STENDRA,erection increased,Urogenital erection,1
STENDRA,hematuria,nephrolithiasis pollakiuria urinary tract infection In an additional randomized doubleblin,0
STENDRA,hematuria,hematuria nephrolithiasis pollakiuria urinary tract,1
STENDRA,hematuria,Urogenital,0
STENDRA,hematuria,hematuria nephrolithiasis pollakiuria urinary,1
STENDRA,hematuria,Urogenital,0
STENDRA,hematuria,hematuria nephrolithiasis pollakiuria,1
STENDRA,hematuria,infection In an additional randomized,0
STENDRA,hematuria,In an,0
STENDRA,hematuria,hematuria nephrolithiasis pollakiuria,1
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria urinary tract,1
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria,1
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria urinary tract infection In,1
STENDRA,nephrolithiasis,Urogenital balanitis erection increased nephrolithiasis pollakiuria urinary,1
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria urinary tract infection In,1
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria,1
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria urinary tract infection In,1
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria urinary tract infection In,1
STENDRA,nephrolithiasis,nephrolithiasis,1
STENDRA,nephrolithiasis,nephrolithiasis pollakiuria urinary tract,1
STENDRA,nephrolithiasis,an additional randomized,0
STENDRA,nephrolithiasis,increased nephrolithiasis pollakiuria urinary tract infection In,1
STENDRA,nephrolithiasis,an additional randomized,0
STENDRA,pollakiuria,pollakiuria,1
STENDRA,urinary tract infection,urinary tract infection,1
STENDRA,urinary tract infection,pollakiuria,1
STENDRA,urinary tract infection,tract infection,1
STENDRA,urinary tract infection,urinary tract infection In an,1
STENDRA,urinary tract infection,tract infection In,1
STENDRA,urinary tract infection,randomized,0
STENDRA,urinary tract infection,increased hematuria nephrolithiasis urinary tract,1
STENDRA,change in color vision,STENDRA dose subject reported change in color,1
STENDRA,change in color vision,in color vision Postmarketing Experience Ophthalmologic Nonarteritic anterior,1
STENDRA,change in color vision,a,0
STENDRA,change in color vision,STENDRA dose subject reported change in,1
STENDRA,change in color vision,change in color vision,1
STENDRA,change in color vision,STENDRA dose subject reported change in,1
STENDRA,change in color vision,Postmarketing Experience Ophthalmologic Nonarteritic anterior ischemic optic ne,0
STENDRA,change in color vision,change in color vision Postmarketing Experience Ophthalmologic,1
STENDRA,change in color vision,Postmarketing Experience Ophthalmologic Nonarteritic anterior ischemic optic ne,0
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Non-arteritic anterior ischemic optic neuropathy NAION,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Non-arteritic anterior ischemic optic neuropathy,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,a cause of decreased vision including permanent loss of vision has been reported rarely,0
STENDRA,Non-arteritic anterior ischemic optic neuropathy,of vision has been,0
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Postmarketing Experience Non-arteritic anterior ischemic optic neuropathy NAION a,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,of vision has been,0
STENDRA,Non-arteritic anterior ischemic optic neuropathy,optic neuropathy NAION a cause of decreased,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,Non-arteritic anterior ischemic,1
STENDRA,Non-arteritic anterior ischemic optic neuropathy,permanent loss,0
STENDRA,NAION,Ophthalmologic Nonarteritic anterior,0
STENDRA,decreased vision,ischemic optic neuropathy NAION,0
STENDRA,permanent loss of vision,permanent loss of vision,1
STENDRA,permanent loss of vision,permanent loss of vision has been reported rarely postmarketing,1
STENDRA,permanent loss of vision,decreased vision permanent,1
STENDRA,permanent loss of vision,the use of,0
STENDRA,permanent loss of vision,permanent loss of vision has,1
STENDRA,permanent loss of vision,cause of decreased vision permanent loss of vision has,1
STENDRA,permanent loss of vision,permanent loss of vision has,1
STENDRA,hypotension,the clinical trials f another,1
STENDRA,hypotension,administered to men dur,0
STENDRA,hypotension,clinical trials of a drug cannot be directly compared to,0
STENDRA,hypotension,clinical trials f another d,1
STENDRA,hypotension,clinical trials of a drug cannot be directly compared to,0
STENDRA,hypotension,directly compared to rates in the clinical trials,0
STENDRA,hypotension,in the clinical trials f another d,1
STENDRA,hypotension,directly compared to rates in the clinical trials,0
STENDRA,hypotension,trials f,1
STENDRA,hypotension,another d rug and may not,1
STENDRA,hypotension,f,1
STENDRA,hypotension,another d rug and may,1
STENDRA,cardiac risk,"patients treated with RA 50 mg, 10 mg or mg was and",1
STENDRA,cardiac risk,another d rug and may,1
STENDRA,cardiac risk,respectively compared,0
STENDRA,cardiac risk,discontinuation rate due to adverse reactions for patients,0
STENDRA,cardiac risk,due to adverse reactions for patients treated,0
STENDRA,cardiac risk,"RA 50 mg, 10 mg",1
STENDRA,cardiac risk,due to adverse reactions for patients treated,0
STENDRA,cardiac risk,"RA 50 mg, 10",1
STENDRA,cardiac risk,due to adverse reactions for patients treated,0
STENDRA,cardiac risk,or mg was and respectively compared to for placebotreated,0
STENDRA,cardiac risk,"50 mg, 10 mg or mg was and",1
STENDRA,cardiac risk,RA,1
STENDRA,cardiac risk,"for patients treated with RA 50 mg, 10",1
STENDRA,non-arteritic anterior ischemic optic neuropathy,STENDRA is uncertain. Excluded from this li,1
STENDRA,non-arteritic anterior ischemic optic neuropathy,this li st,1
STENDRA,non-arteritic anterior ischemic optic neuropathy,A causal p to STENDRA is uncertain. Excluded,1
STENDRA,non-arteritic anterior ischemic optic neuropathy,events that,0
STENDRA,non-arteritic anterior ischemic optic neuropathy,uncertain. Excluded from this li st are those events that,1
STENDRA,NAION,lasting months A causal relationship to STENDRA is,0
STENDRA,NAION, are  those events that,1
STENDRA,NAION, are  those events that were,1
STENDRA,NAION, are  those,1
STENDRA,NAION,A,0
STENDRA,NAION, are ,1
STENDRA,NAION,reports too,0
STENDRA,NAION,relationship to STENDRA is uncertain Excluded from this list,0
STENDRA,NAION, are  those events that were minor,1
STENDRA,NAION, are  those,1
STENDRA,decreased vision,with no plausib,1
STENDRA,decreased vision,minor,0
STENDRA,permanent loss of vision,imprecise to be meaningful Body as a,0
STENDRA,permanent loss of vision,"no plausible  to drug use, and report s too imprecise to be",1
STENDRA,permanent loss of vision,imprecise to be meaningful Body as a,0
STENDRA,permanent loss of vision,"no plausible to drug use, and report",1
STENDRA,permanent loss of vision,those,0
STENDRA,NAION,pain,0
STENDRA,NAION,"rt, v omiting Musculoskeletal muscle",1
STENDRA,NAION,"rt, v omiting Musculoskeletal",1
STENDRA,NAION,"pain stomach rt, v omiting Musculoskeletal muscle spasms musculoskeletal",1
STENDRA,NAION,"rt, v omiting Musculoskeletal",1
STENDRA,NAION,Musculoskeletal muscle spasms musculoskeletal,0
STENDRA,NAION,increased,0
STENDRA,NAION,muscle spasms musculoskeletal,0
STENDRA,NAION,"increased oropharyngeal pain stomach rt, v",1
STENDRA,NAION,"musculoskeletal , mya",1
STENDRA,NAION,Musculoskeletal muscle spasms,0
STENDRA,symptomatic hypotension,of an erection sufficient,0
STENDRA,symptomatic hypotension,"time to onset of of STENDRA, defined",1
STENDRA,dizziness,defined as the e to the,1
STENDRA,dizziness,STENDRA defined as the e to the  first occurrence of an,1
STENDRA,dizziness,defined as the e to the,1
STENDRA,lightheadedness,of an erection sufficient for sexual intercourse Table presents the adverse reactions,0
STENDRA,lightheadedness,of STENDRA defined as the time to the,0
STENDRA,lightheadedness,for sexual intercourse Table presents the adverse reactions,0
STENDRA,lightheadedness,to the rst occurrence,1
STENDRA,fainting,to the first occurrence an,1
STENDRA,symptomatic hypotension,Lasting Months o Determine the Time to,1
STENDRA,symptomatic hypotension,Determine the Time to Onset of Effect Study Adverse,1
ADCETRIS,Peripheral Neuropathy,the prescribing Peripheral Neuropathy,1
ADCETRIS,Peripheral Neuropathy,Peripheral,1
ADCETRIS,Peripheral Neuropathy,of the prescribing information,0
ADCETRIS,Peripheral Neuropathy,of the prescribing Peripheral,1
ADCETRIS,Anaphylaxis,Anaphylaxis and,1
ADCETRIS,Anaphylaxis,Infusion,0
ADCETRIS,Anaphylaxis,Anaphylaxis and,1
ADCETRIS,Infusion Reactions,Infusion Reactions see Warnings and Precautions Hematologic,1
ADCETRIS,Infusion Reactions,Neuropathy see,0
ADCETRIS,Infusion Reactions,Anaphylaxis and,0
ADCETRIS,Infusion Reactions,Warnings and Precautions,0
ADCETRIS,Infusion Reactions,Neuropathy see Warnings and,0
ADCETRIS,Hematologic Toxicities,Hematologic Toxicities see Warnings and Precautions Serious,1
ADCETRIS,Infections,and Precautions Infections and Opportunistic Infections see Warnings,1
ADCETRIS,Infections,Hematologic Toxicities see Warnings and Precautions Serious,1
ADCETRIS,Infections,Infections,1
ADCETRIS,Infections,Infections and Opportunistic Infections see,1
ADCETRIS,Infections,Infections and Opportunistic Infections,1
ADCETRIS,Infections,Toxicities see Warnings and Precautions Serious,0
ADCETRIS,Opportunistic Infections,Opportunistic Infections,1
ADCETRIS,Opportunistic Infections,Opportunistic Infections see Warnings and Precautions,1
ADCETRIS,Opportunistic Infections,Opportunistic Infections,1
ADCETRIS,Opportunistic Infections,Precautions Tumor Lysis Syndrome see Warnings and P,0
ADCETRIS,Opportunistic Infections,Precautions Serious Infections,0
ADCETRIS,Opportunistic Infections,Precautions Serious Infections Opportunistic Infections,1
ADCETRIS,Opportunistic Infections,Precautions Serious Infections Opportunistic Infections,1
ADCETRIS,Opportunistic Infections,see Warnings,0
ADCETRIS,Tumor Lysis Syndrome,see Warnings and Tumor Lysis Syndrome see Warnings and Precautions,1
ADCETRIS,Tumor Lysis Syndrome,see Warnings,0
ADCETRIS,Tumor Lysis Syndrome,Presence of,0
ADCETRIS,Tumor Lysis Syndrome,and Tumor,1
ADCETRIS,Tumor Lysis Syndrome,and Tumor Lysis Syndrome see Warnings and,1
ADCETRIS,Tumor Lysis Syndrome,and Tumor,1
ADCETRIS,Tumor Lysis Syndrome,Tumor Lysis Syndrome see,1
ADCETRIS,Tumor Lysis Syndrome,and Tumor,1
ADCETRIS,Tumor Lysis Syndrome,see Warnings and Precautions,0
ADCETRIS,Tumor Lysis Syndrome,Warnings and Tumor Lysis,1
ADCETRIS,Increased Toxicity,and Increased Toxicity in the,1
ADCETRIS,Increased Toxicity,Warnings and Tumor Lysis,1
ADCETRIS,Increased Toxicity,Syndrome see Warnings and Increased Toxicity in the Presence,1
ADCETRIS,Increased Toxicity,Warnings and Tumor Lysis,1
ADCETRIS,Increased Toxicity,Impairment see,0
ADCETRIS,Increased Toxicity,Syndrome see Warnings,0
ADCETRIS,Increased Toxicity,Tumor Lysis Syndrome see,0
ADCETRIS,Increased Toxicity,Presence of Severe Renal,0
ADCETRIS,Increased Toxicity,Syndrome see Warnings and Increased Toxicity in the Presence of,1
ADCETRIS,Increased Toxicity,Presence of Severe Renal,0
ADCETRIS,Increased Toxicity,Syndrome see Warnings,0
ADCETRIS,Increased Toxicity,Lysis Syndrome see,0
ADCETRIS,Increased Toxicity,see Warnings and Increased Toxicity,1
ADCETRIS,Increased Toxicity,Increased Toxicity,1
ADCETRIS,Increased Toxicity,see Warnings and Increased Toxicity,1
ADCETRIS,Increased Toxicity,see Warnings,0
ADCETRIS,Increased Toxicity,Severe Hepatic Impairment,0
ADCETRIS,Increased Toxicity,and Increased Toxicity,1
ADCETRIS,Increased Toxicity,Increased Toxicity in the Presence of Moderate,1
ADCETRIS,Increased Toxicity,of Moderate or,0
ADCETRIS,Increased Toxicity,Increased Toxicity in the,1
ADCETRIS,Increased Toxicity,Increased Toxicity in,1
ADCETRIS,Increased Toxicity,of Moderate,0
ADCETRIS,Increased Toxicity,Severe Hepatic Impairment,0
ADCETRIS,Hepatotoxicity,Warnings and Hepatotoxicity,1
ADCETRIS,Hepatotoxicity,Severe Hepatic Impairment,0
ADCETRIS,Hepatotoxicity,Impairment see Warnings,0
ADCETRIS,Hepatotoxicity,Progressive,0
ADCETRIS,Hepatotoxicity,see Warnings and Precautions Progressive,0
ADCETRIS,Hepatotoxicity,and Hepatotoxicity see Warnings and,1
ADCETRIS,Hepatotoxicity,see Warnings and Precautions Progressive,0
ADCETRIS,Hepatotoxicity,Warnings and Hepatotoxicity see Warnings and Precautions Progressive,1
ADCETRIS,Hepatotoxicity,see Warnings and Precautions Progressive,0
ADCETRIS,Hepatotoxicity,of Moderate or Severe Hepatic Impairment see Warnings and Precautions,0
ADCETRIS,Hepatotoxicity,Hepatotoxicity,1
ADCETRIS,Hepatotoxicity,see Warnings and Precautions,0
ADCETRIS,Hepatotoxicity,see Warnings and Hepatotoxicity see Warnings,1
ADCETRIS,Hepatotoxicity,see Warnings and Precautions,0
ADCETRIS,Progressive Multifocal Leukoencephalopathy,see Warnings and Progressive Multifocal Leukoencephalopathy see,1
ADCETRIS,Progressive Multifocal Leukoencephalopathy,see Warnings and Precautions,0
ADCETRIS,Progressive Multifocal Leukoencephalopathy,see Warnings,0
ADCETRIS,Progressive Multifocal Leukoencephalopathy,Multifocal Leukoencephalopathy see Warnings and Precautions Pulmonary,1
ADCETRIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and,1
ADCETRIS,Pulmonary Toxicity,Warnings and Pulmonary Toxicity,1
ADCETRIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and,1
ADCETRIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and Precautions Serious,1
ADCETRIS,Pulmonary Toxicity,and Pulmonary Toxicity see Warnings and Precautions,1
ADCETRIS,Pulmonary Toxicity,Pulmonary Toxicity see Warnings and Precautions Serious,1
ADCETRIS,Pulmonary Toxicity,see Warnings and Pulmonary Toxicity,1
ADCETRIS,Pulmonary Toxicity,and,0
ADCETRIS,Pulmonary Toxicity,Leukoencephalopathy see Warnings and Pulmonary Toxicity see Warnings and Precautions Serious,1
ADCETRIS,Pulmonary Toxicity,and,0
ADCETRIS,Dermatologic Reactions,see Warnings and Precautions Dermatologic Reactions see Warnings,1
ADCETRIS,Dermatologic Reactions,and,0
ADCETRIS,Dermatologic Reactions,Warnings and Precautions Dermatologic,1
ADCETRIS,Dermatologic Reactions,Dermatologic Reactions see Warnings and Precautions,1
ADCETRIS,Dermatologic Reactions,Warnings and Precautions,0
ADCETRIS,Dermatologic Reactions,and Precautions EXCERPT The most common adverse reactions,0
ADCETRIS,Dermatologic Reactions,Warnings and Precautions Dermatologic Reactions,1
ADCETRIS,Dermatologic Reactions,and Precautions EXCERPT The most common adverse reactions,0
ADCETRIS,Dermatologic Reactions,Precautions,0
ADCETRIS,Dermatologic Reactions,Dermatologic Reactions see,1
ADCETRIS,Dermatologic Reactions,Precautions,0
ADCETRIS,Dermatologic Reactions,Serious,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,Serious,0
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue,1
ADCETRIS,neutropenia,neutropenia peripheral,1
ADCETRIS,neutropenia,HL and relapsed neutropenia peripheral sensory,1
ADCETRIS,neutropenia,neutropenia peripheral,1
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue nausea,1
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue nausea,1
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy,1
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue nausea,1
ADCETRIS,neutropenia,neutropenia peripheral sensory,1
ADCETRIS,neutropenia,sensory neuropathy fatigue nausea anemia upper respiratory,0
ADCETRIS,peripheral sensory neuropathy,HL and relapsed sALCL peripheral,1
ADCETRIS,peripheral sensory neuropathy,diarrhea pyrexia,0
ADCETRIS,peripheral sensory neuropathy,relapsed,0
ADCETRIS,peripheral sensory neuropathy,sALCL peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,relapsed,0
ADCETRIS,fatigue,pyrexia rash,0
ADCETRIS,fatigue,respiratory,0
ADCETRIS,fatigue,rash,0
ADCETRIS,fatigue,sensory fatigue nausea anemia upper respiratory tract,1
ADCETRIS,fatigue,rash,0
ADCETRIS,fatigue,fatigue nausea anemia,1
ADCETRIS,nausea,nausea anemia upper respiratory tract,1
ADCETRIS,nausea,fatigue nausea anemia,1
ADCETRIS,nausea,nausea,1
ADCETRIS,anemia,sensory neuropathy fatigue anemia upper,1
ADCETRIS,anemia,nausea,1
ADCETRIS,anemia,sALCL neutropenia peripheral sensory neuropathy fatigue nausea,0
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,sALCL neutropenia peripheral sensory neuropathy fatigue nausea,0
ADCETRIS,anemia,anemia upper respiratory tract infection diarrhea,1
ADCETRIS,anemia,anemia upper respiratory,1
ADCETRIS,anemia,neuropathy fatigue nausea,0
ADCETRIS,anemia,anemia upper respiratory tract infection diarrhea,1
ADCETRIS,anemia,anemia upper respiratory,1
ADCETRIS,upper respiratory tract infection,peripheral sensory neuropathy,0
ADCETRIS,upper respiratory tract infection,cough and vomiting,0
ADCETRIS,upper respiratory tract infection,pyrexia rash thrombocytopenia,0
ADCETRIS,upper respiratory tract infection,pyrexia rash thrombocytopenia cough,0
ADCETRIS,upper respiratory tract infection,neuropathy fatigue nausea upper respiratory tract infection diarrhea pyrexia rash,1
ADCETRIS,upper respiratory tract infection,pyrexia rash thrombocytopenia cough,0
ADCETRIS,upper respiratory tract infection,upper respiratory tract infection diarrhea,1
ADCETRIS,upper respiratory tract infection,diarrhea pyrexia rash thrombocytopenia cough,0
ADCETRIS,upper respiratory tract infection,upper respiratory tract,1
ADCETRIS,upper respiratory tract infection,upper respiratory tract infection diarrhea pyrexia rash thrombocytopenia cough,1
ADCETRIS,upper respiratory tract infection,upper respiratory tract,1
ADCETRIS,diarrhea,diarrhea pyrexia rash thrombocytopenia cough and,1
ADCETRIS,diarrhea,ropenia peripheral sensory neuropathy,0
ADCETRIS,diarrhea,tract diarrhea,1
ADCETRIS,diarrhea,ropenia peripheral sensory neuropathy,0
ADCETRIS,diarrhea,HL,0
ADCETRIS,diarrhea,diarrhea pyrexia,1
ADCETRIS,diarrhea,diarrhea pyrexia,1
ADCETRIS,diarrhea,diarrhea pyrexia,1
ADCETRIS,diarrhea,infection,0
ADCETRIS,diarrhea,diarrhea pyrexia,1
ADCETRIS,pyrexia,diarrhea,0
ADCETRIS,pyrexia,pyrexia rash thrombocytopenia cough,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,tract infection pyrexia rash thrombocytopenia cough and,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,nausea anemia upper respiratory,0
ADCETRIS,pyrexia,infection pyrexia rash thrombocytopenia cough and vomiting,1
ADCETRIS,pyrexia,nausea anemia upper respiratory,0
ADCETRIS,pyrexia,pyrexia rash,1
ADCETRIS,pyrexia,thrombocytopenia cough and vomiting Classical,0
ADCETRIS,pyrexia,pyrexia rash,1
ADCETRIS,rash,rash thrombocytopenia cough,1
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,thrombocytopenia,pyrexia thrombocytopenia,1
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,thrombocytopenia,thrombocytopenia cough and vomiting Classical,1
ADCETRIS,thrombocytopenia,respiratory tract infection,0
ADCETRIS,thrombocytopenia,pyrexia,0
ADCETRIS,thrombocytopenia,HL,0
ADCETRIS,thrombocytopenia,infection diarrhea pyrexia thrombocytopenia cough and vomiting Classical HL,1
ADCETRIS,thrombocytopenia,HL,0
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,thrombocytopenia,thrombocytopenia cough and,1
ADCETRIS,thrombocytopenia,infection diarrhea pyrexia thrombocytopenia,1
ADCETRIS,thrombocytopenia,thrombocytopenia cough and,1
ADCETRIS,cough,cough and vomiting Classical,1
ADCETRIS,cough,cough and,1
ADCETRIS,cough,cough and vomiting Classical,1
ADCETRIS,vomiting,postautoHSCT consolidation neutropenia peripheral sensory neuropath,0
ADCETRIS,neutropenia,sh thrombocytopenia cough and vomiting Classical HL,0
ADCETRIS,neutropenia,thrombocytopenia cough and vomiting Classical HL,0
ADCETRIS,neutropenia,vomiting Classical HL,0
ADCETRIS,neutropenia,upper respiratory tract,0
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy thrombocytopenia,1
ADCETRIS,neutropenia,upper respiratory tract infection,0
ADCETRIS,neutropenia,neutropenia peripheral sensory,1
ADCETRIS,neutropenia,thrombocytopenia cough and vomiting,0
ADCETRIS,peripheral sensory neuropathy,Classical HL postautoHSCT consolidation peripheral sensory,1
ADCETRIS,peripheral sensory neuropathy,HL postautoHSCT consolidation neutropenia,0
ADCETRIS,thrombocytopenia,HL postautoHSCT consolidation neutropenia,0
ADCETRIS,thrombocytopenia,thrombocytopenia anemia upper respiratory tract,1
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,thrombocytopenia,thrombocytopenia anemia upper respiratory tract,1
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,motor neuropathy nausea,0
ADCETRIS,anemia,anemia upper,1
ADCETRIS,anemia,motor neuropathy nausea,0
ADCETRIS,anemia,anemia upper respiratory,1
ADCETRIS,anemia,anemia upper,1
ADCETRIS,upper respiratory tract infection,neuropathy thrombocytopenia upper respiratory tract,1
ADCETRIS,upper respiratory tract infection,peripheral motor neuropathy nausea cough and,0
ADCETRIS,upper respiratory tract infection,upper respiratory tract infection fatigue peripheral motor,1
ADCETRIS,upper respiratory tract infection,peripheral motor neuropathy nausea cough and,0
ADCETRIS,upper respiratory tract infection,neuropathy thrombocytopenia anemia,0
ADCETRIS,upper respiratory tract infection,upper,1
ADCETRIS,upper respiratory tract infection,thrombocytopenia upper respiratory tract,1
ADCETRIS,upper respiratory tract infection,tract infection fatigue peripheral,1
ADCETRIS,upper respiratory tract infection,sensory neuropathy thrombocytopenia anemia,0
ADCETRIS,upper respiratory tract infection,diarrhea To,0
ADCETRIS,fatigue,respiratory tract fatigue peripheral motor neuropathy nausea cough,1
ADCETRIS,fatigue,diarrhea To,0
ADCETRIS,fatigue,fatigue peripheral motor,1
ADCETRIS,fatigue,openia,0
ADCETRIS,fatigue,fatigue peripheral,1
ADCETRIS,fatigue,To report,0
ADCETRIS,peripheral motor neuropathy,fatigue,0
ADCETRIS,peripheral motor neuropathy,fatigue,0
ADCETRIS,peripheral motor neuropathy,peripheral motor neuropathy nausea cough and diarrhea,1
ADCETRIS,peripheral motor neuropathy,fatigue,0
ADCETRIS,nausea,nausea cough and,1
ADCETRIS,nausea,nausea cough and diarrhea To report,1
ADCETRIS,nausea,fatigue peripheral motor neuropathy,0
ADCETRIS,nausea,nausea cough and diarrhea To,1
ADCETRIS,nausea,nausea cough and diarrhea To,1
ADCETRIS,nausea,infection fatigue peripheral motor nausea cough and diarrhea To report,1
ADCETRIS,nausea,nausea cough and diarrhea To,1
ADCETRIS,nausea,nausea cough,1
ADCETRIS,cough,cough and diarrhea To report,1
ADCETRIS,cough,respiratory tract infection fatigue peripheral motor,0
ADCETRIS,cough,cough and,1
ADCETRIS,cough,tract infection fatigue,0
ADCETRIS,cough,cough and,1
ADCETRIS,cough,cough and diarrhea,1
ADCETRIS,cough,cough and diarrhea To report SUSPECTED,1
ADCETRIS,cough,cough and diarrhea To,1
ADCETRIS,cough,diarrhea To report SUSPECTED ADVERSE REACTIONS contact Seattle,0
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,diarrhea,SUSPECTED ADVERSE REACTIONS,0
ADCETRIS,diarrhea,diarrhea To,1
ADCETRIS,diarrhea,SUSPECTED ADVERSE REACTIONS,0
ADCETRIS,diarrhea,neuropathy,0
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,neutropenia,regardless of,0
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue nausea,1
ADCETRIS,neutropenia,regardless of causality neutropenia peripheral,1
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue nausea,1
ADCETRIS,neutropenia,neutropenia,1
ADCETRIS,neutropenia,causality were,0
ADCETRIS,neutropenia,regardless of causality neutropenia,1
ADCETRIS,neutropenia,causality were,0
ADCETRIS,neutropenia,neutropenia peripheral,1
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,causality were peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,fatigue nausea anemia upper,0
ADCETRIS,peripheral sensory neuropathy,diarrhea pyrexia rash thrombocytope,0
ADCETRIS,peripheral sensory neuropathy,causality were,0
ADCETRIS,peripheral sensory neuropathy,the most common adverse reactions regardless,0
ADCETRIS,peripheral sensory neuropathy,causality were neutropenia,0
ADCETRIS,peripheral sensory neuropathy,anemia upper respiratory tract,0
ADCETRIS,peripheral sensory neuropathy,were peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,anemia upper respiratory tract,0
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy fatigue nausea anemia,1
ADCETRIS,fatigue,of causality,0
ADCETRIS,fatigue,neutropenia peripheral sensory fatigue,1
ADCETRIS,fatigue,of causality,0
ADCETRIS,fatigue,fatigue nausea anemia upper,1
ADCETRIS,fatigue,dverse reactions regardless of causality were neutropenia peripheral sensory,0
ADCETRIS,fatigue,fatigue nausea anemia upper respiratory tract,1
ADCETRIS,fatigue,fatigue nausea anemia upper respiratory tract,1
ADCETRIS,fatigue,sensory fatigue nausea anemia,1
ADCETRIS,fatigue,fatigue nausea anemia upper respiratory tract,1
ADCETRIS,fatigue,pyrexia,0
ADCETRIS,fatigue,fatigue nausea,1
ADCETRIS,nausea,nausea anemia upper respiratory,1
ADCETRIS,nausea,fatigue,0
ADCETRIS,nausea,nausea anemia upper respiratory,1
ADCETRIS,nausea,fatigue,0
ADCETRIS,anemia,neuropathy fatigue anemia upper respiratory tract infection diarrhea,1
ADCETRIS,anemia,fatigue,0
ADCETRIS,anemia,regardless of causality were neutropenia peripheral sensory,0
ADCETRIS,anemia,anemia upper respiratory tract,1
ADCETRIS,anemia,causality,0
ADCETRIS,anemia,infection diarrhea pyrexia rash thrombocytopenia cough,0
ADCETRIS,anemia,anemia,1
ADCETRIS,upper respiratory tract infection,regardless of causality were neutropenia peripheral sensory neuropathy fatigue nausea,0
ADCETRIS,diarrhea,fatigue nausea anemia upper,0
ADCETRIS,diarrhea,diarrhea pyrexia rash thrombocytopenia cough,1
ADCETRIS,diarrhea,thrombocytopenia cough and vomiting The most common,0
ADCETRIS,pyrexia,tract,0
ADCETRIS,pyrexia,pyrexia rash thrombocytopenia,1
ADCETRIS,pyrexia,pyrexia rash,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,tract infection pyrexia rash thrombocytopenia cough,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,pyrexia rash thrombocytopenia,1
ADCETRIS,pyrexia,The most,0
ADCETRIS,pyrexia,diarrhea,0
ADCETRIS,pyrexia,pyrexia rash thrombocytopenia,1
ADCETRIS,rash,tract,0
ADCETRIS,rash,pyrexia,0
ADCETRIS,rash,diarrhea rash,1
ADCETRIS,rash,pyrexia,0
ADCETRIS,rash,diarrhea rash thrombocytopenia cough and,1
ADCETRIS,rash,pyrexia,0
ADCETRIS,rash,rash thrombocytopenia cough,1
ADCETRIS,rash,pyrexia,0
ADCETRIS,rash,rash thrombocytopenia cough and,1
ADCETRIS,rash,pyrexia,0
ADCETRIS,rash,rash,1
ADCETRIS,rash,rash thrombocytopenia cough and vomiting,1
ADCETRIS,thrombocytopenia,thrombocytopenia cough and vomiting The most,1
ADCETRIS,thrombocytopenia,respiratory tract infection diarrhea pyrexia rash,0
ADCETRIS,thrombocytopenia,thrombocytopenia cough and vomiting The,1
ADCETRIS,thrombocytopenia,respiratory tract infection diarrhea pyrexia rash,0
ADCETRIS,thrombocytopenia,thrombocytopenia cough,1
ADCETRIS,thrombocytopenia,diarrhea pyrexia thrombocytopenia cough,1
ADCETRIS,thrombocytopenia,thrombocytopenia cough,1
ADCETRIS,thrombocytopenia,infection diarrhea pyrexia thrombocytopenia cough and,1
ADCETRIS,thrombocytopenia,thrombocytopenia cough,1
ADCETRIS,thrombocytopenia,thrombocytopenia cough and,1
ADCETRIS,cough,cough and,1
ADCETRIS,cough,cough and vomiting The,1
ADCETRIS,cough,anemia upper respiratory tract infection,0
ADCETRIS,cough,least of patients in,0
ADCETRIS,cough,cough and vomiting The most common,1
ADCETRIS,cough,adverse reactions occurring in at least of patients in either,0
ADCETRIS,cough,cough and,1
ADCETRIS,cough,adverse reactions occurring in at least of patients in either,0
ADCETRIS,cough,cough and vomiting,1
ADCETRIS,cough,cough and,1
ADCETRIS,cough,rash thrombocytopenia,0
ADCETRIS,vomiting,infection diarrhea pyrexia rash thrombocytopenia cough,0
ADCETRIS,vomiting,vomiting The most common adverse reactions,1
ADCETRIS,vomiting,vomiting The,1
ADCETRIS,vomiting,most common adverse reactions occurring in at least of patients in either Study or re,0
ADCETRIS,vomiting,occurring in at least of patients,0
ADCETRIS,vomiting,vomiting The,1
ADCETRIS,vomiting,infection diarrhea pyrexia rash,0
ADCETRIS,vomiting,vomiting The most common adverse,1
ADCETRIS,vomiting,vomiting The,1
ADCETRIS,vomiting,anemia upper respiratory tract infection diarrhea pyrexia rash thrombocytopenia,0
ADCETRIS,neutropenia,peripheral sensory neuropathy thrombocytopenia anemia upper respiratory,0
ADCETRIS,peripheral sensory neuropathy,regardless of causality were peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,fatigue peripheral motor,0
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy thrombocytopenia anemia,1
ADCETRIS,peripheral sensory neuropathy,tract infection fatigue peripheral motor,0
ADCETRIS,thrombocytopenia,thrombocytopenia anemia upper respiratory tract infection,1
ADCETRIS,thrombocytopenia,peripheral motor neuropathy nausea cough,0
ADCETRIS,thrombocytopenia,anemia upper respiratory tract infection fatigue peripheral motor neuropathy,0
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,thrombocytopenia,anemia upper respiratory tract infection fatigue peripheral motor neuropathy,0
ADCETRIS,thrombocytopenia,thrombocytopenia anemia,1
ADCETRIS,thrombocytopenia,fatigue peripheral,0
ADCETRIS,thrombocytopenia,thrombocytopenia anemia upper respiratory tract infection,1
ADCETRIS,anemia,neutropenia,0
ADCETRIS,anemia,anemia upper respiratory tract,1
ADCETRIS,anemia,peripheral sensory neuropathy anemia,1
ADCETRIS,anemia,anemia upper respiratory tract,1
ADCETRIS,anemia,nt arm,0
ADCETRIS,anemia,of causality,0
ADCETRIS,anemia,arm regardless of causality,0
ADCETRIS,anemia,arm regardless of causality were neutropenia,0
ADCETRIS,anemia,anemia upper respiratory,1
ADCETRIS,upper respiratory tract infection,respiratory tract infection fatigue,1
ADCETRIS,upper respiratory tract infection,neuropathy thrombocytopenia upper respiratory tract,1
ADCETRIS,fatigue,fatigue peripheral motor neuropathy nausea cough,1
ADCETRIS,fatigue,fatigue peripheral,1
ADCETRIS,fatigue,fatigue peripheral motor,1
ADCETRIS,fatigue,diarrhea,0
ADCETRIS,fatigue,and diarrhea The most common,0
ADCETRIS,peripheral motor neuropathy,infection peripheral motor neuropathy,1
ADCETRIS,peripheral motor neuropathy,motor neuropathy nausea cough and diarrhea,1
ADCETRIS,peripheral motor neuropathy,motor neuropathy nausea cough and diarrhea,1
ADCETRIS,nausea,nausea cough and diarrhea,1
ADCETRIS,nausea,infection fatigue peripheral motor nausea cough and,1
ADCETRIS,nausea,nausea cough and diarrhea,1
ADCETRIS,nausea,occurring in at least of patients,0
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue upper,1
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue upper,1
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy fatigue upper,1
ADCETRIS,peripheral sensory neuropathy,causality were peripheral sensory neuropathy fatigue upper,1
ADCETRIS,peripheral sensory neuropathy,neutropenia peripheral sensory neuropathy fatigue upper,1
ADCETRIS,peripheral sensory neuropathy,peripheral sensory,1
ADCETRIS,peripheral sensory neuropathy,infection nausea,0
ADCETRIS,peripheral sensory neuropathy,upper respiratory tract infection nausea,0
ADCETRIS,peripheral sensory neuropathy,reactions regardless of causality,0
ADCETRIS,peripheral sensory neuropathy,were peripheral sensory neuropathy fatigue upper respiratory tract infection,1
ADCETRIS,peripheral sensory neuropathy,reactions regardless of causality,0
ADCETRIS,peripheral sensory neuropathy,of causality,0
ADCETRIS,peripheral sensory neuropathy,infection nausea diarrhea anemia pyrexia thrombocytopenia,0
ADCETRIS,peripheral sensory neuropathy,peripheral sensory,1
ADCETRIS,fatigue,fatigue,1
ADCETRIS,fatigue,thrombocytopenia,0
ADCETRIS,fatigue,neutropenia peripheral sensory,0
ADCETRIS,fatigue,neutropenia peripheral sensory neuropathy,0
ADCETRIS,fatigue,were neutropenia peripheral sensory fatigue upper respiratory tract infection,1
ADCETRIS,fatigue,neutropenia peripheral sensory neuropathy,0
ADCETRIS,fatigue,reactions regardless of causality were neutropenia peripheral sensory neuropathy,0
ADCETRIS,fatigue,diarrhea anemia,0
ADCETRIS,upper respiratory tract infection,abdominal pain,0
ADCETRIS,upper respiratory tract infection,neuropathy upper respiratory tract infection nausea diarrhea anemia pyrexia,1
ADCETRIS,upper respiratory tract infection,abdominal pain,0
ADCETRIS,upper respiratory tract infection,anemia pyrexia thrombocytopenia,0
ADCETRIS,nausea,respiratory tract nausea diarrhea anemia pyrexia,1
ADCETRIS,nausea,anemia pyrexia thrombocytopenia,0
ADCETRIS,nausea,nausea,1
ADCETRIS,diarrhea,diarrhea anemia pyrexia,1
ADCETRIS,anemia,anemia pyrexia thrombocytopenia rash abdominal pain,1
ADCETRIS,anemia,pain cough and vomiting,0
ADCETRIS,anemia,anemia pyrexia thrombocytopenia,1
ADCETRIS,anemia,cough and vomiting,0
ADCETRIS,anemia,Summary of Clinical,0
ADCETRIS,anemia,anemia pyrexia thrombocytopenia rash,1
ADCETRIS,anemia,anemia pyrexia thrombocytopenia rash abdominal,1
ADCETRIS,anemia,anemia pyrexia thrombocytopenia rash,1
ADCETRIS,anemia,anemia pyrexia thrombocytopenia rash abdominal,1
ADCETRIS,anemia,respiratory tract,0
ADCETRIS,pyrexia,vomiting Summary of Clinical Trial Exp,0
ADCETRIS,pyrexia,sensory neuropathy fatigue upper respiratory tract,0
ADCETRIS,pyrexia,pyrexia thrombocytopenia rash abdominal,1
ADCETRIS,pyrexia,diarrhea pyrexia thrombocytopenia rash abdominal,1
ADCETRIS,pyrexia,pyrexia thrombocytopenia rash abdominal,1
ADCETRIS,pyrexia,nausea diarrhea pyrexia thrombocytopenia,1
ADCETRIS,pyrexia,pyrexia thrombocytopenia rash abdominal,1
ADCETRIS,thrombocytopenia,thrombocytopenia rash abdominal pain cough and,1
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,thrombocytopenia,tract infection nausea diarrhea,0
ADCETRIS,thrombocytopenia,thrombocytopenia rash abdominal pain cough and,1
ADCETRIS,thrombocytopenia,thrombocytopenia,1
ADCETRIS,thrombocytopenia,fatigue upper respiratory tract infection,0
ADCETRIS,thrombocytopenia,thrombocytopenia rash abdominal pain cough and,1
ADCETRIS,thrombocytopenia,nausea diarrhea anemia thrombocytopenia,1
ADCETRIS,thrombocytopenia,thrombocytopenia rash abdominal pain cough and,1
ADCETRIS,thrombocytopenia,and vomiting Summary of Clinical,0
ADCETRIS,rash,of Clinical Trial Experience,0
ADCETRIS,rash,respiratory tract infection nausea diarrhea anemia,0
ADCETRIS,rash,diarrhea anemia pyrexia,0
ADCETRIS,abdominal pain,abdominal pain cough and,1
ADCETRIS,abdominal pain,pyrexia thrombocytopenia abdominal pain cough and,1
ADCETRIS,abdominal pain,abdominal pain cough and,1
ADCETRIS,abdominal pain,anemia pyrexia thrombocytopenia abdominal pain cough and vomiting Summary of,1
ADCETRIS,abdominal pain,abdominal pain cough and,1
ADCETRIS,abdominal pain,abdominal pain cough and vomiting,1
ADCETRIS,abdominal pain,abdominal pain cough and,1
ADCETRIS,cough,cough and,1
ADCETRIS,cough,cough and,1
ADCETRIS,cough,cough,1
ADCETRIS,cough,diarrhea anemia,0
ADCETRIS,cough,tract infection,0
ADCETRIS,cough,nausea diarrhea,0
ADCETRIS,cough,tract infection,0
ADCETRIS,cough,cough and vomiting Summary of,1
ADCETRIS,cough,thrombocytopenia rash abdominal cough and vomiting Summary of,1
ADCETRIS,cough,cough and vomiting Summary of,1
ADCETRIS,vomiting,vomiting,1
ADCETRIS,vomiting,rash abdominal pain cough and,0
ADCETRIS,vomiting,vomiting Summary of Clinical Trial Experience,1
ADCETRIS,vomiting,cough vomiting,1
ADCETRIS,vomiting,vomiting Summary of Clinical Trial Experience,1
ADCETRIS,vomiting,and,0
ADCETRIS,neutropenia,of causality neutropenia anemia,1
ADCETRIS,neutropenia,and,0
ADCETRIS,neutropenia,neutropenia anemia,1
ADCETRIS,neutropenia,neutropenia anemia peripheral,1
ADCETRIS,neutropenia,neutropenia anemia,1
ADCETRIS,neutropenia,most common,0
ADCETRIS,anemia,peripheral sensory neuropathy fatigue nausea pyrexia rash diarrhea and,0
ADCETRIS,anemia,anemia peripheral sensory neuropathy,1
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,regardless of causality were anemia peripheral sensory neuropathy fatigue nausea,1
ADCETRIS,anemia,anemia,1
ADCETRIS,anemia,anemia peripheral sensory,1
ADCETRIS,anemia,anemia peripheral sensory neuropathy fatigue nausea,1
ADCETRIS,anemia,of causality were,0
ADCETRIS,anemia,anemia peripheral sensory neuropathy fatigue,1
ADCETRIS,anemia,neuropathy fatigue nausea pyrexia rash diarrhea and pain Table,0
ADCETRIS,anemia,anemia peripheral sensory neuropathy fatigue,1
ADCETRIS,peripheral sensory neuropathy,neutropenia peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,causality were neutropenia peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,neutropenia peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,Commonly Reported Ad,0
ADCETRIS,peripheral sensory neuropathy,causality were neutropenia anemia,0
ADCETRIS,peripheral sensory neuropathy,neutropenia,0
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral,1
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral sensory neuropathy fatigue,1
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral,1
ADCETRIS,peripheral sensory neuropathy,most common adverse reactions regardless of,0
ADCETRIS,peripheral sensory neuropathy,pain Table,0
ADCETRIS,peripheral sensory neuropathy,Commonly,0
ADCETRIS,fatigue,peripheral sensory neuropathy,0
ADCETRIS,fatigue,anemia peripheral sensory fatigue nausea pyrexia rash diarrhea,1
ADCETRIS,fatigue,peripheral sensory neuropathy,0
ADCETRIS,fatigue,anemia peripheral sensory,0
ADCETRIS,fatigue,anemia peripheral sensory fatigue,1
ADCETRIS,fatigue,anemia peripheral sensory,0
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,anemia peripheral sensory,0
ADCETRIS,nausea,fatigue,0
ADCETRIS,nausea,neuropathy nausea pyrexia rash,1
ADCETRIS,nausea,fatigue,0
ADCETRIS,nausea,nausea pyrexia,1
ADCETRIS,nausea,fatigue,0
ADCETRIS,nausea,nausea pyrexia,1
ADCETRIS,pyrexia,pyrexia rash diarrhea and pain Table,1
ADCETRIS,pyrexia,anemia,0
ADCETRIS,pyrexia,sensory neuropathy fatigue pyrexia rash diarrhea and pain,1
ADCETRIS,pyrexia,anemia,0
ADCETRIS,pyrexia,pyrexia rash diarrhea and pain Table,1
ADCETRIS,pyrexia,Adverse Reactions in,0
ADCETRIS,pyrexia,neuropathy fatigue pyrexia,1
ADCETRIS,pyrexia,Adverse Reactions in,0
ADCETRIS,pyrexia,peripheral,0
ADCETRIS,rash,neuropathy fatigue nausea,0
ADCETRIS,rash,ss,0
ADCETRIS,rash,nausea,0
ADCETRIS,rash,Adverse Reactions in,0
ADCETRIS,rash,rash diarrhea and pain Table Most,1
ADCETRIS,rash,rash diarrhea and pain,1
ADCETRIS,rash,neuropathy fatigue nausea rash diarrhea and,1
ADCETRIS,rash,rash diarrhea and pain,1
ADCETRIS,diarrhea,diarrhea and pain Table Most,1
ADCETRIS,diarrhea,diarrhea,1
ADCETRIS,diarrhea,diarrhea and,1
ADCETRIS,diarrhea,pyrexia diarrhea and pain,1
ADCETRIS,diarrhea,diarrhea and,1
ADCETRIS,diarrhea,pain Table Most Commonly Reported Adverse Reactions in Studies and,0
ADCETRIS,diarrhea,diarrhea and pain Table,1
ADCETRIS,pain,diarrhea pain Table Most Commonly,1
ADCETRIS,pain,diarrhea and pain Table,1
ADCETRIS,pain,anemia peripheral sensory neuropathy fatigue nausea pyrexia,0
ADCETRIS,pain,pain,1
ADCETRIS,pain,Most Commonly Reported Adverse Reactions,0
ADCETRIS,pain,and,0
ADCETRIS,pain,pyrexia rash diarrhea pain,1
ADCETRIS,pain,and,0
ADCETRIS,neuropathy,experienced any grade neuropathy Of these patients,1
ADCETRIS,neuropathy,and,0
ADCETRIS,neuropathy,any,0
ADCETRIS,neuropathy,neuropathy Of these,1
ADCETRIS,neuropathy,neuropathy Of these,1
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,neuropathy Of these patients had,1
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,who neuropathy had residual neuropathy at the,1
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,Of the patients who neuropathy,1
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,neuropathy had residual neuropathy at the,1
ADCETRIS,neuropathy,neuropathy,1
ADCETRIS,neuropathy,the,0
ADCETRIS,neuropathy,residual,0
ADCETRIS,neuropathy,of patients treated with,0
ADCETRIS,neuropathy,In Study of patients treated with ADCETRIS experienced any grade,0
ADCETRIS,neuropathy,patients who neuropathy had complete resolution,1
ADCETRIS,neuropathy,In Study of patients treated with ADCETRIS experienced any grade,0
ADCETRIS,neuropathy,neuropathy had complete resolution and,1
ADCETRIS,neuropathy,had residual neuropathy partial improvement,0
ADCETRIS,neuropathy,improvement no,0
ADCETRIS,neuropathy,had complete resolution and had residual neuropathy partial improvement,0
ADCETRIS,residual neuropathy,the,0
ADCETRIS,residual neuropathy,last evaluation Infusion,0
ADCETRIS,residual neuropathy,and residual neuropathy partial improvement,1
ADCETRIS,residual neuropathy,last evaluation Infusion,0
ADCETRIS,infusion-related reactions,no Grade infusion-related reactions reported,1
ADCETRIS,infusion-related reactions,last evaluation Infusion,0
ADCETRIS,infusion-related reactions,no Grade infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusion-related reactions reported in Studies and,1
ADCETRIS,infusion-related reactions,of anaphylaxis,0
ADCETRIS,infusion-related reactions,most common adverse,0
ADCETRIS,infusion-related reactions,reactions associated infusion-related,1
ADCETRIS,chills,most common adverse reactions associated,0
ADCETRIS,chills,chills nausea dyspnea pruritus pyrexia,1
ADCETRIS,chills,chills,1
ADCETRIS,chills,pruritus pyrexia and cough,0
ADCETRIS,chills,dyspnea pruritus pyrexia and cough In,0
ADCETRIS,chills,chills nausea,1
ADCETRIS,nausea,and,0
ADCETRIS,nausea,nausea dyspnea pruritus pyrexia and,1
ADCETRIS,nausea,pruritus pyrexia and cough In Study,0
ADCETRIS,nausea,with infusionrelated reactions were nausea,1
ADCETRIS,nausea,pruritus pyrexia and cough In Study,0
ADCETRIS,nausea,nausea dyspnea pruritus pyrexia and,1
ADCETRIS,nausea,pruritus pyrexia and cough In Study,0
ADCETRIS,nausea,In Study infusionrelated r,0
ADCETRIS,nausea,nausea dyspnea pruritus pyrexia,1
ADCETRIS,nausea,common adverse reactions associated with infusionrelated,0
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,reactions were nausea dyspnea pruritus pyrexia and cough,1
ADCETRIS,nausea,nausea,1
ADCETRIS,dyspnea,infusionrelated reactions were chills,0
ADCETRIS,dyspnea,adverse reactions associated with infusionrelated reactions were,0
ADCETRIS,dyspnea,with infusionrelated reactions were chills,0
ADCETRIS,dyspnea,reactions were chills dyspnea pruritus pyrexia and,1
ADCETRIS,dyspnea,with infusionrelated reactions were chills,0
ADCETRIS,dyspnea,dyspnea pruritus pyrexia and,1
ADCETRIS,dyspnea,with infusionrelated reactions were chills,0
ADCETRIS,dyspnea,dyspnea,1
ADCETRIS,dyspnea,dyspnea pruritus pyrexia and cough,1
ADCETRIS,pruritus,pruritus,1
ADCETRIS,pruritus,were chills nausea pruritus pyrexia,1
ADCETRIS,pruritus,pruritus,1
ADCETRIS,pruritus,pruritus,1
ADCETRIS,pruritus,were reported in,0
ADCETRIS,pruritus,were reported in,0
ADCETRIS,pyrexia,pyrexia and cough In Study infusionrelated,1
ADCETRIS,pyrexia,pyrexia and cough In Study infusionrelated,1
ADCETRIS,pyrexia,pyrexia and cough In,1
ADCETRIS,pyrexia,pyrexia and cough,1
ADCETRIS,pyrexia,pyrexia and cough,1
ADCETRIS,pyrexia,pyrexia and,1
ADCETRIS,pyrexia,pyrexia and cough In Study,1
ADCETRIS,pyrexia,reactions were chills nausea dyspnea,0
ADCETRIS,pyrexia,nausea dyspnea pyrexia and cough,1
ADCETRIS,pyrexia,reactions were chills nausea dyspnea,0
ADCETRIS,pyrexia,chills,0
ADCETRIS,cough,cough In Study infusionrelated reactions were,1
ADCETRIS,cough,cough In Study infusionrelated reactions were,1
ADCETRIS,cough,cough In Study infusionrelated reactions were,1
ADCETRIS,cough,cough In Study infusionrelated,1
ADCETRIS,cough,cough In,1
ADCETRIS,cough,cough In Study,1
ADCETRIS,cough,dyspnea pruritus,0
ADCETRIS,cough,In Study infusionrelated reactions were reported in patients,0
ADCETRIS,cough,cough In Study infusionrelated reactions were,1
ADCETRIS,cough,and,0
ADCETRIS,cough,pruritus pyrexia cough In,1
ADCETRIS,cough,and,0
ADCETRIS,infusion-related reactions,pyrexia and cough In infusion-related reactions were reported in,1
ADCETRIS,infusion-related reactions,and,0
ADCETRIS,infusion-related reactions,In infusion-related reactions were reported in patients in,1
ADCETRIS,infusion-related reactions,and,0
ADCETRIS,infusion-related reactions,In infusion-related reactions were reported,1
ADCETRIS,infusion-related reactions,and,0
ADCETRIS,infusion-related reactions,patients in the ADCETRIStreated arm,0
ADCETRIS,infusion-related reactions,pyrexia and cough In infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusion-related reactions were,1
ADCETRIS,infusion-related reactions,cough In infusion-related reactions,1
ADCETRIS,infusion-related reactions,dyspnea pruritus pyrexia and cough In,0
ADCETRIS,infusion-related reactions,the ADCETRIStreated arm and patients in the,0
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,the,0
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusionrelated reactions No infusion-related reactions,1
ADCETRIS,infusion-related reactions,infusion-related reactions,1
ADCETRIS,infusion-related reactions,who experienced,0
ADCETRIS,infusion-related reactions,reactions No infusion-related reactions,1
ADCETRIS,infusion-related reactions,who experienced,0
ADCETRIS,infusion-related reactions,infusion-related reactions were reported The,1
ADCETRIS,infusion-related reactions,common adverse,0
ADCETRIS,infusion-related reactions,reactions No infusion-related,1
ADCETRIS,infusion-related reactions,experienced infusionrelated reactions No infusion-related reactions,1
ADCETRIS,infusion-related reactions,No infusion-related,1
ADCETRIS,infusion-related reactions,infusion-related reactions were reported The most common,1
ADCETRIS,infusion-related reactions,infusion-related reactions were nausea chills,1
ADCETRIS,infusion-related reactions,infusion-related,1
ADCETRIS,infusion-related reactions,infusion-related reactions were nausea chills,1
ADCETRIS,infusion-related reactions,infusion-related,1
ADCETRIS,infusion-related reactions,adverse reactions associated infusion-related reactions were nausea chills,1
ADCETRIS,infusion-related reactions,infusion-related,1
ADCETRIS,infusion-related reactions,reactions associated infusion-related reactions were nausea chills dyspnea,1
ADCETRIS,infusion-related reactions,infusion-related,1
ADCETRIS,infusion-related reactions,common adverse,0
ADCETRIS,infusion-related reactions,most common,0
ADCETRIS,nausea,nausea chills dyspnea,1
ADCETRIS,nausea,nausea chills dyspnea headache pruritus,1
ADCETRIS,nausea,nausea chills dyspnea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,associated with infusionrelated reactions nausea chills dyspnea headache pruritus rash,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,nausea,1
ADCETRIS,nausea,infusionrelated,0
ADCETRIS,dyspnea,rash back pain and vomiting,0
ADCETRIS,headache,headache pruritus,1
ADCETRIS,headache,headache pruritus rash,1
ADCETRIS,headache,headache,1
ADCETRIS,headache,pruritus rash back pain and vomiting Pulmonary,0
ADCETRIS,pruritus,headache,0
ADCETRIS,pruritus,pruritus rash back pain and vomiting,1
ADCETRIS,pruritus,chills,0
ADCETRIS,pruritus,pruritus rash,1
ADCETRIS,pruritus,pruritus,1
ADCETRIS,pruritus,pruritus rash back pain,1
ADCETRIS,pruritus,pain and vomiting,0
ADCETRIS,pruritus,pruritus rash,1
ADCETRIS,rash,rash back pain and vomiting,1
ADCETRIS,rash,pruritus rash,1
ADCETRIS,rash,headache pruritus,0
ADCETRIS,rash,headache pruritus,0
ADCETRIS,rash,nausea chills dyspnea headache pruritus,0
ADCETRIS,rash,rash back pain,1
ADCETRIS,back pain,patients with classical HL th,0
ADCETRIS,back pain,back pain and vomiting Pulmonary Toxicity In,1
ADCETRIS,back pain,pruritus back pain and vomiting,1
ADCETRIS,back pain,back pain and vomiting Pulmonary Toxicity In,1
ADCETRIS,back pain,patients with,0
ADCETRIS,back pain,trial in patients,0
ADCETRIS,back pain,back pain,1
ADCETRIS,back pain,reactions were nausea chills,0
ADCETRIS,vomiting,vomiting Pulmonary Toxicity In,1
ADCETRIS,non-infectious pulmonary toxicity,the rate,0
ADCETRIS,non-infectious pulmonary toxicity,rate non-infectious pulmonary toxicity,1
ADCETRIS,non-infectious pulmonary toxicity,rate of,0
ADCETRIS,non-infectious pulmonary toxicity,ABVD adriamycin,0
ADCETRIS,non-infectious pulmonary toxicity,ABVD adriamycin bleomycin vinblastine,0
ADCETRIS,non-infectious pulmonary toxicity,rate of,0
ADCETRIS,non-infectious pulmonary toxicity,regimen the rate non-infectious pulmonary toxicity,1
ADCETRIS,non-infectious pulmonary toxicity,non-infectious pulmonary toxicity was higher than,1
ADCETRIS,cough,with ABVD adriamycin bleomycin vinblastine dacarbazine Patients,0
ADCETRIS,cough,cough and dyspnea Interstitial infiltration,1
ADCETRIS,cough,Patients typically cough,1
ADCETRIS,cough,cough and dyspnea Interstitial infiltration,1
ADCETRIS,cough,cough,1
ADCETRIS,cough,cough,1
ADCETRIS,cough,cough and dyspnea Interstitial infiltration,1
ADCETRIS,cough,bleomycin vinblastine dacarbazine Patients,0
ADCETRIS,cough,cough and dyspnea Interstitial infiltration,1
ADCETRIS,cough,vinblastine dacarbazine Patients typically cough and,1
ADCETRIS,cough,cough and dyspnea Interstitial infiltration,1
ADCETRIS,dyspnea,dyspnea Interstitial infiltration andor inflammation were,1
ADCETRIS,dyspnea,reported,0
ADCETRIS,dyspnea,cough,0
ADCETRIS,dyspnea,reported,0
ADCETRIS,dyspnea,reported cough dyspnea Interstitial,1
ADCETRIS,dyspnea,reported,0
ADCETRIS,dyspnea,adriamycin bleomycin vinblastine dacarbazine Patients,0
ADCETRIS,pulmonary toxicity,contraindicated see Contraindications Cases pulmonary toxicity,1
ADCETRIS,pulmonary toxicity,adriamycin bleomycin vinblastine dacarbazine Patients,0
ADCETRIS,pulmonary toxicity,see Contraindications Cases pulmonary toxicity have also,1
ADCETRIS,pulmonary toxicity,adriamycin bleomycin vinblastine dacarbazine Patients,0
ADCETRIS,pulmonary toxicity,patients,0
ADCETRIS,pulmonary toxicity,see Contraindications Cases pulmonary toxicity have also been,1
ADCETRIS,pulmonary toxicity,patients,0
ADCETRIS,pulmonary toxicity,contraindicated see Contraindications Cases pulmonary,1
ADCETRIS,pulmonary toxicity,pulmonary toxicity have also,1
ADCETRIS,pulmonary toxicity,contraindicated see Contraindications Cases pulmonary,1
ADCETRIS,pulmonary toxicity,with bleomycin is contraindicated see,0
ADCETRIS,pulmonary toxicity,toxicity have also been,0
ADCETRIS,pulmonary toxicity,pulmonary toxicity,1
ADCETRIS,pulmonary toxicity,ADCETRIS In pulmonary toxicity,1
ADCETRIS,pulmonary toxicity,in,0
ADCETRIS,pulmonary toxicity,pulmonary,1
ADCETRIS,pulmonary toxicity,the placebo,0
ADCETRIS,pulmonary toxicity,pulmonary toxicity,1
ADCETRIS,peripheral motor neuropathy,motor neuropathy abdominal pain pulmonary embolism,1
ADCETRIS,abdominal pain,abdominal pain pulmonary embolism pneumonitis,1
ADCETRIS,abdominal pain,motor neuropathy abdominal pain pulmonary embolism,1
ADCETRIS,abdominal pain,embolism,0
ADCETRIS,abdominal pain,peripheral motor abdominal pain pulmonary embolism pneumonitis pneumothorax pyelonephritis,1
ADCETRIS,abdominal pain,embolism,0
ADCETRIS,abdominal pain,peripheral motor abdominal pain,1
ADCETRIS,abdominal pain,embolism,0
ADCETRIS,abdominal pain,peripheral motor abdominal pain,1
ADCETRIS,abdominal pain,HL include peripheral motor abdominal,1
ADCETRIS,pulmonary embolism,peripheral motor,0
ADCETRIS,pulmonary embolism,abdominal pulmonary embolism pneumonitis pneumothorax pyelonephritis and,1
ADCETRIS,pulmonary embolism,peripheral motor,0
ADCETRIS,pulmonary embolism,HL include peripheral motor neuropathy,0
ADCETRIS,pulmonary embolism,neuropathy abdominal pulmonary,1
ADCETRIS,pulmonary embolism,with,0
ADCETRIS,pulmonary embolism,pulmonary embolism pneumonitis pneumothorax pyelonephritis,1
ADCETRIS,pneumonitis,lassical,0
ADCETRIS,pneumonitis,pulmonary embolism,0
ADCETRIS,pneumonitis,pneumonitis pneumothorax pyelonephritis and,1
ADCETRIS,pneumonitis,abdominal pain pulmonary pneumonitis pneumothorax pyelonephritis and pyrexia The,1
ADCETRIS,pneumonitis,pneumonitis pneumothorax pyelonephritis and,1
ADCETRIS,pneumonitis,abdominal pain pulmonary pneumonitis pneumothorax pyelonephritis and pyrexia,1
ADCETRIS,pneumonitis,pneumonitis pneumothorax pyelonephritis and,1
ADCETRIS,pneumonitis,embolism,0
ADCETRIS,pneumonitis,common serious adverse rea,0
ADCETRIS,pneumonitis,pneumonitis pneumothorax pyelonephritis and pyrexia The,1
ADCETRIS,pneumonitis,common serious adverse rea,0
ADCETRIS,pneumothorax,pneumothorax,1
ADCETRIS,pneumothorax,most,0
ADCETRIS,pneumothorax,abdominal pain pulmonary embolism pneumothorax pyelonephritis and,1
ADCETRIS,pneumothorax,most,0
ADCETRIS,pneumothorax,pneumothorax pyelonephritis and,1
ADCETRIS,pneumothorax,abdominal pain pulmonary embolism pneumothorax pyelonephritis,1
ADCETRIS,pneumothorax,pneumothorax pyelonephritis and,1
ADCETRIS,pneumothorax,pneumothorax pyelonephritis and pyrexia The most,1
ADCETRIS,pyelonephritis,adverse reactions,0
ADCETRIS,pyrexia,pneumothorax pyelonephritis and,0
ADCETRIS,pyrexia,pyrexia,1
ADCETRIS,pyrexia,pyrexia The most common serious adverse,1
ADCETRIS,pyrexia,pyrexia The most common serious,1
ADCETRIS,pyrexia,experienced by patients,0
ADCETRIS,pyrexia,and,0
ADCETRIS,pyrexia,pneumothorax pyelonephritis,0
ADCETRIS,pyrexia,pyrexia The most common serious,1
ADCETRIS,septic shock,septic shock supraventricular,1
ADCETRIS,septic shock,extremity and urinary tract infection O,0
ADCETRIS,septic shock,with sALCL,0
ADCETRIS,septic shock,most common serious adverse reactions,0
ADCETRIS,septic shock,patients with sALCL septic,1
ADCETRIS,supraventricular arrhythmia,infection,0
ADCETRIS,supraventricular arrhythmia,most common serious adverse reactions experienced by patients,0
ADCETRIS,supraventricular arrhythmia,important serious,0
ADCETRIS,supraventricular arrhythmia,supraventricular arrhythmia,1
ADCETRIS,supraventricular arrhythmia,with sALCL were septic supraventricular arrhythmia,1
ADCETRIS,supraventricular arrhythmia,were septic supraventricular arrhythmia,1
ADCETRIS,supraventricular arrhythmia,supraventricular arrhythmia pain in,1
ADCETRIS,supraventricular arrhythmia,reactions experienced by patients with sALCL were septic,0
ADCETRIS,supraventricular arrhythmia,with,0
ADCETRIS,pain in extremity,in extremity and urinary tract,1
ADCETRIS,pain in extremity,in extremity and urinary tract infection Other,1
ADCETRIS,pain in extremity,supraventricular pain in extremity and urinary tract infection Other,1
ADCETRIS,pain in extremity,in extremity and urinary tract infection Other,1
ADCETRIS,pain in extremity,serious adverse reactions,0
ADCETRIS,pain in extremity,septic shock supraventricular pain,1
ADCETRIS,pain in extremity,shock supraventricular pain in extremity and urinary tract infection,1
ADCETRIS,pain in extremity,septic shock supraventricular pain,1
ADCETRIS,pain in extremity,septic shock supraventricular pain in extremity and urinary tract,1
ADCETRIS,pain in extremity,septic shock supraventricular pain,1
ADCETRIS,pain in extremity,pain in extremity,1
ADCETRIS,urinary tract infection,urinary tract infection Other important serious adverse reactions,1
ADCETRIS,urinary tract infection,pain in extremity,1
ADCETRIS,urinary tract infection,pain in extremity urinary,1
ADCETRIS,urinary tract infection,extremity and,0
ADCETRIS,urinary tract infection,shock supraventricular arrhythmia pain in extremity,0
ADCETRIS,urinary tract infection,urinary tract,1
ADCETRIS,urinary tract infection,pain in extremity urinary tract,1
ADCETRIS,urinary tract infection,arrhythmia,0
ADCETRIS,urinary tract infection,extremity urinary tract infection,1
ADCETRIS,urinary tract infection,arrhythmia,0
ADCETRIS,PML,PML StevensJohnson syndrome and,1
ADCETRIS,PML,In Study serious adverse,0
ADCETRIS,PML,PML StevensJohnson,1
ADCETRIS,PML,PML StevensJohnson syndrome and tumor lysis,1
ADCETRIS,PML,PML StevensJohnson,1
ADCETRIS,PML,PML StevensJohnson syndrome and tumor,1
ADCETRIS,PML,PML StevensJohnson syndrome and,1
ADCETRIS,PML,PML StevensJohnson syndrome,1
ADCETRIS,Stevens-Johnson syndrome,reported include Stevens-Johnson syndrome,1
ADCETRIS,Stevens-Johnson syndrome,Stevens-Johnson syndrome and tumor lysis,1
ADCETRIS,Stevens-Johnson syndrome,In Study serious,0
ADCETRIS,Stevens-Johnson syndrome,reactions reported include Stevens-Johnson,1
ADCETRIS,Stevens-Johnson syndrome,serious adverse reactions reported include,0
ADCETRIS,Stevens-Johnson syndrome,In Study serious adverse reactions regardless of,0
ADCETRIS,Stevens-Johnson syndrome,reactions reported include Stevens-Johnson,1
ADCETRIS,Stevens-Johnson syndrome,Stevens-Johnson syndrome,1
ADCETRIS,Stevens-Johnson syndrome,and urinary tract infection Other important serious adverse reactions,0
ADCETRIS,tumor lysis syndrome,include PML StevensJohnson syndrome tumor lysis syndrome In Study serious adverse,1
ADCETRIS,tumor lysis syndrome,and urinary tract infection Other important serious adverse reactions,0
ADCETRIS,tumor lysis syndrome,reported,0
ADCETRIS,tumor lysis syndrome,StevensJohnson syndrome tumor lysis syndrome,1
ADCETRIS,tumor lysis syndrome,and,0
ADCETRIS,tumor lysis syndrome,In Study serious adverse reactions,0
ADCETRIS,pneumonia,nausea hepatotoxicity and peripheral,0
ADCETRIS,pneumonia,reactions were,0
ADCETRIS,pyrexia,pyrexia vomiting nausea hepatotoxicity and,1
ADCETRIS,vomiting,were pneumonia vomiting nausea,1
ADCETRIS,vomiting,pyrexia vomiting nausea hepatotoxicity and,1
ADCETRIS,vomiting,vomiting nausea hepatotoxicity and peripheral sensory,1
ADCETRIS,vomiting,vomiting nausea hepatotoxicity and peripheral sensory,1
ADCETRIS,vomiting,pneumonia vomiting nausea,1
ADCETRIS,vomiting,vomiting nausea hepatotoxicity and peripheral sensory,1
ADCETRIS,vomiting,sensory neuropathy,0
ADCETRIS,hepatotoxicity,pyrexia,0
ADCETRIS,hepatotoxicity,hepatotoxicity and,1
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral,1
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral sensory,1
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral,1
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral sensory neuropathy Dose,1
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral sensory,1
ADCETRIS,hepatotoxicity,vomiting,0
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral sensory,1
ADCETRIS,hepatotoxicity,hepatotoxicity and peripheral,1
ADCETRIS,peripheral sensory neuropathy,hepatotoxicity peripheral,1
ADCETRIS,neutropenia,neutropenia and peripheral sensory,1
ADCETRIS,neutropenia,in Studies and neutropenia and peripheral sensory neuropathy,1
ADCETRIS,neutropenia,neutropenia and peripheral sensory,1
ADCETRIS,peripheral sensory neuropathy,neutropenia peripheral sensory,1
ADCETRIS,peripheral sensory neuropathy,and,0
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy see,1
ADCETRIS,peripheral sensory neuropathy,and,0
ADCETRIS,peripheral sensory neuropathy,reactions that led,0
ADCETRIS,peripheral sensory neuropathy,more than of patients in,0
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral sensory neuropathy see,1
ADCETRIS,peripheral sensory neuropathy,more than of patients in,0
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral sensory neuropathy see Dosage,1
ADCETRIS,peripheral sensory neuropathy,more than of patients in,0
ADCETRIS,peripheral sensory neuropathy,and,0
ADCETRIS,peripheral sensory neuropathy,were neutropenia peripheral sensory neuropathy see,1
ADCETRIS,peripheral sensory neuropathy,and,0
ADCETRIS,neutropenia,of,0
ADCETRIS,neutropenia,neutropenia peripheral sensory neuropathy upper,1
ADCETRIS,neutropenia,dose delays in more than of ADCETRIStreated patients in Study,0
ADCETRIS,neutropenia,infection and peripheral,0
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy upper respiratory tract infection and,1
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy upper,1
ADCETRIS,peripheral sensory neuropathy,patients in Study were,0
ADCETRIS,peripheral sensory neuropathy,delays in more than,0
ADCETRIS,peripheral sensory neuropathy,tract infection and peripheral,0
ADCETRIS,peripheral sensory neuropathy,neutropenia,0
ADCETRIS,peripheral sensory neuropathy,Study were peripheral sensory neuropathy upper respiratory tract infection,1
ADCETRIS,peripheral sensory neuropathy,neutropenia,0
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy upper respiratory,1
ADCETRIS,peripheral sensory neuropathy,in Study were peripheral sensory neuropathy,1
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy upper respiratory,1
ADCETRIS,peripheral sensory neuropathy,motor neuropathy see,0
ADCETRIS,upper respiratory tract infection,upper respiratory tract infection and,1
ADCETRIS,upper respiratory tract infection,motor neuropathy see,0
ADCETRIS,upper respiratory tract infection,neuropathy,0
ADCETRIS,upper respiratory tract infection,were neutropenia peripheral sensory upper respiratory tract infection and,1
ADCETRIS,upper respiratory tract infection,neuropathy,0
ADCETRIS,upper respiratory tract infection,Study were neutropenia peripheral,0
ADCETRIS,upper respiratory tract infection,peripheral motor neuropathy see Dosage and Administration,0
ADCETRIS,upper respiratory tract infection,tract infection and peripheral motor,1
ADCETRIS,upper respiratory tract infection,neutropenia peripheral sensory upper respiratory tract infection and peripheral motor neuropathy,1
ADCETRIS,upper respiratory tract infection,tract infection and peripheral motor,1
ADCETRIS,upper respiratory tract infection,were neutropenia peripheral sensory upper respiratory tract,1
ADCETRIS,peripheral motor neuropathy,peripheral,1
ADCETRIS,peripheral motor neuropathy,peripheral sensory neuropathy upper respiratory,0
ADCETRIS,peripheral motor neuropathy,infection peripheral motor neuropathy see Dosage and Administration Discontinuations,1
ADCETRIS,peripheral motor neuropathy,peripheral sensory neuropathy upper respiratory,0
ADCETRIS,peripheral motor neuropathy,Administration Discontinuations Adve,0
ADCETRIS,peripheral motor neuropathy,see Dosage and Administration Discontinuations,0
ADCETRIS,peripheral motor neuropathy,tract infection peripheral motor,1
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy and peripheral motor neuropathy Adverse,1
ADCETRIS,peripheral sensory neuropathy,led to treatment,0
ADCETRIS,peripheral sensory neuropathy,and peripheral motor neuropathy Adverse reactions led to treatment discontinuation i,0
ADCETRIS,peripheral motor neuropathy,motor neuropathy Adverse,1
ADCETRIS,peripheral motor neuropathy,patients with classical HL or sALCL were,0
ADCETRIS,peripheral motor neuropathy,were peripheral sensory neuropathy peripheral motor neuropathy Adverse reactions led to,1
ADCETRIS,peripheral motor neuropathy,patients with classical HL or sALCL were,0
ADCETRIS,peripheral motor neuropathy,sensory neuropathy peripheral motor,1
ADCETRIS,peripheral sensory neuropathy,in or more patients peripheral sensory neuropathy peripheral motor neuropathy,1
ADCETRIS,peripheral sensory neuropathy,sensory neuropathy peripheral motor,1
ADCETRIS,peripheral sensory neuropathy,peripheral sensory neuropathy,1
ADCETRIS,peripheral motor neuropathy,at led to treatment discontinuation in or more patients were peripheral sensory neuropathy,0
ADCETRIS,peripheral motor neuropathy,to treatment discontinuation,0
ADCETRIS,peripheral motor neuropathy,motor neuropathy acute,1
ADCETRIS,peripheral motor neuropathy,peripheral sensory peripheral motor neuropathy acute respiratory,1
ADCETRIS,peripheral motor neuropathy,motor neuropathy acute,1
ADCETRIS,acute respiratory distress syndrome,motor acute respiratory distress syndrome,1
ADCETRIS,acute respiratory distress syndrome,motor neuropathy acute,1
ADCETRIS,acute respiratory distress syndrome,peripheral motor acute respiratory distress syndrome paraesthesia and vomiting,1
ADCETRIS,acute respiratory distress syndrome,motor neuropathy acute,1
ADCETRIS,acute respiratory distress syndrome,respiratory distress syndrome paraesthesia and vomiting Post,1
ADCETRIS,acute respiratory distress syndrome,distress syndrome paraesthesia and vomiting Post Marketing,1
ADCETRIS,acute respiratory distress syndrome,respiratory distress syndrome paraesthesia and,1
ADCETRIS,paraesthesia,paraesthesia and vomiting Post,1
ADCETRIS,paraesthesia,paraesthesia and vomiting Post Marketing,1
ADCETRIS,paraesthesia,paraesthesia and,1
ADCETRIS,paraesthesia,paraesthesia and vomiting Post Marketing,1
ADCETRIS,vomiting,Post Marketing Experience The following adverse reactions have,0
ADCETRIS,vomiting,neuropathy,0
ADCETRIS,vomiting,vomiting Post Marketing Experience,1
ADCETRIS,vomiting,distress syndrome paraesthesia vomiting Post,1
ADCETRIS,vomiting,vomiting Post Marketing Experience,1
ADCETRIS,vomiting,acute respiratory distress,0
ADCETRIS,vomiting,acute respiratory distress syndrome paraesthesia,0
ADCETRIS,vomiting,syndrome paraesthesia vomiting Post Marketing Experience The following,1
ADCETRIS,vomiting,acute respiratory distress syndrome paraesthesia,0
ADCETRIS,vomiting,vomiting Post Marketing,1
ADCETRIS,vomiting,vomiting Post Marketing,1
ADCETRIS,febrile neutropenia,system febrile neutropenia see Warnings,1
ADCETRIS,febrile neutropenia,vomiting Post Marketing,1
ADCETRIS,febrile neutropenia,Hepatobiliary,0
ADCETRIS,febrile neutropenia,drug exposure Blood and lymphatic system,0
ADCETRIS,PML,Warning Warnings and Precautions serious infections,0
ADCETRIS,infections,infections and opportunistic infections see,1
ADCETRIS,infections,infections and opportunistic,1
ADCETRIS,infections,infections and opportunistic infections,1
ADCETRIS,infections,Infections PML see Boxed Warning Warnings and,0
ADCETRIS,infections,Warning Warnings and Precautions serious,0
ADCETRIS,infections,Precautions serious,0
ADCETRIS,opportunistic infections,Warnings and Precautions,0
ADCETRIS,opportunistic infections,opportunistic infections see Warnings,1
ADCETRIS,opportunistic infections,infections opportunistic,1
ADCETRIS,opportunistic infections,and,0
ADCETRIS,opportunistic infections,opportunistic infections see Warnings and Precautions,1
ADCETRIS,opportunistic infections,see Warnings and Precautions Metabolism,0
ADCETRIS,opportunistic infections,infections opportunistic infections see Warnings and,1
ADCETRIS,opportunistic infections,see Warnings and Precautions Metabolism,0
ADCETRIS,Pancreatitis,outcomes Consider the,0
ADCETRIS,Pancreatitis,Pancreatitis including fatal,1
ADCETRIS,Pancreatitis,the diagnosis of pancreatitis for patients presenting,0
ADCETRIS,Pancreatitis,Pancreatitis including fatal,1
ADCETRIS,fatal,fatal,1
ADCETRIS,fatal,with severe,0
ADCETRIS,noninfectious pulmonary toxicity,some with fatal outcomes see,0
ADCETRIS,noninfectious pulmonary toxicity,thoracic and mediastinal noninfectious,1
ADCETRIS,noninfectious pulmonary toxicity,Respiratory thoracic and mediastinal noninfectious pulmonary,1
ADCETRIS,noninfectious pulmonary toxicity,pulmonary toxicity including pneumonitis interstitial lung disease,1
ADCETRIS,pneumonitis,with fatal outcomes,0
ADCETRIS,pneumonitis,pneumonitis interstitial lung,1
ADCETRIS,pneumonitis,Respiratory thoracic and mediastinal disorders noninfectious,0
ADCETRIS,pneumonitis,fatal outcomes see Warnings and,0
ADCETRIS,pneumonitis,pneumonitis,1
ADCETRIS,pneumonitis,pneumonitis interstitial,1
ADCETRIS,pneumonitis,toxicity pneumonitis interstitial lung disease and,1
ADCETRIS,pneumonitis,pneumonitis interstitial,1
ADCETRIS,pneumonitis,disease and ARDS some with fatal outcomes see,0
ADCETRIS,pneumonitis,noninfectious pulmonary toxicity pneumonitis interstitial lung disease and ARDS,1
ADCETRIS,pneumonitis,disease and ARDS some with fatal outcomes see,0
ADCETRIS,pneumonitis,pneumonitis interstitial lung,1
ADCETRIS,interstitial lung disease,and mediastinal,0
ADCETRIS,interstitial lung disease,with fatal outcomes see Warnings and Precautions and Adverse Reactions,0
ADCETRIS,interstitial lung disease,Warnings and Precautions and,0
ADCETRIS,ARDS,ARDS some with fatal outcomes,1
ADCETRIS,ARDS,ARDS some with fatal,1
ADCETRIS,ARDS,outcomes see Warnings,0
ADCETRIS,ARDS,lung disease ARDS some with fatal outcomes see,1
ADCETRIS,ARDS,outcomes see Warnings,0
ADCETRIS,ARDS,ARDS some with,1
ADCETRIS,ARDS,fatal outcomes see Warnings and,0
ADCETRIS,ARDS,and Adverse Reactions,0
ADCETRIS,fatal,and ARDS some fatal outcomes,1
ADCETRIS,fatal,and Adverse Reactions,0
ADCETRIS,fatal,some fatal outcomes see,1
ADCETRIS,fatal,and Adverse Reactions,0
ADCETRIS,fatal,and ARDS,0
ADCETRIS,fatal,fatal outcomes see Warnings,1
ADCETRIS,Toxic epidermal necrolysis,Adverse Reactions Skin,0
ADCETRIS,Toxic epidermal necrolysis,and subcutaneous tissue Toxic,1
ADCETRIS,Toxic epidermal necrolysis,Adverse,0
ADCETRIS,Toxic epidermal necrolysis,subcutaneous tissue Toxic,1
ADCETRIS,Toxic epidermal necrolysis,disorders,0
ADCETRIS,Toxic epidermal necrolysis,tissue Toxic epidermal necrolysis including fatal outcomes,1
ADCETRIS,Toxic epidermal necrolysis,disorders,0
ADCETRIS,Toxic epidermal necrolysis,fatal outcomes see Warnings and,0
ADCETRIS,Toxic epidermal necrolysis,Toxic epidermal necrolysis,1
ADCETRIS,fatal,Precautions Immunogenicity,0
ADCETRIS,fatal,fatal outcomes,1
ADCETRIS,fatal,fatal outcomes see Warnings,1
ADCETRIS,fatal,fatal outcomes,1
ADCETRIS,fatal,disorders Toxic epidermal necrolysis fatal outcomes see,1
ADCETRIS,fatal,fatal outcomes,1
ADCETRIS,fatal,fatal outcomes see Warnings and,1
ADCETRIS,infusion reactions,patients with,0
ADCETRIS,infusion reactions,reactions consistent infusion reactions,1
ADCETRIS,infusion reactions,infusion reactions that,1
ADCETRIS,infusion reactions,led to discontinuation of treatment Overall a higher incidence,0
ADCETRIS,infusion reactions,positive antibodies experienced adverse reactions consistent,0
ADCETRIS,infusion reactions,higher incidence of infusion related reactions,0
ADCETRIS,infusion related reactions,with infusion reactions that led to,0
ADCETRIS,infusion related reactions,a higher incidence of,0
ADCETRIS,infusion related reactions,infusion related reactions was observed in,1
ADCETRIS,infusion related reactions,incidence,0
ADCETRIS,infusion related reactions,a higher incidence infusion related reactions was observed in patients,1
ADCETRIS,infusion related reactions,incidence,0
ADCETRIS,infusion related reactions,infusion reactions that led to discontinuation,0
ADCETRIS,infusion related reactions,higher incidence infusion related reactions was observed in patients who,1
ADCETRIS,infusion related reactions,infusion reactions that led to discontinuation,0
ADCETRIS,infusion related reactions,higher incidence infusion related reactions was observed,1
ADCETRIS,infusion related reactions,infusion reactions that led to discontinuation,0
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,following serious adverse reactions are d iscussed in,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,ADVERSE REACTIONS following serious adverse,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,are d,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,are d iscussed in greater,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,ADVERSE REACTIONS following serious adverse reactions are d,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, following serious adverse reactions are d iscussed in greater detail,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,ADVERSE REACTIONS following serious adverse reactions are d,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,ADVERSE REACTIONS following serious,1
ADCETRIS,PML,cus sed in greater detail in,1
ADCETRIS,PML,cus sed in,1
ADCETRIS,PML,reactions are cus sed,1
ADCETRIS,PML,cus sed in,1
ADCETRIS,PML,dis,0
ADCETRIS,PML,other sections of the prescribing information Peripheral Neuropathy,0
ADCETRIS,PML,sections of,0
ADCETRIS,PML,cus sed in greater detail in,1
ADCETRIS,PML,sections of,0
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,etail in other sections of the prescribing information Peripheral,1
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,sections of,0
ADCETRIS,PML,in greater detail,0
ADCETRIS,PML,the prescribing nfo rmation Peripheral,1
ADCETRIS,PML,in greater detail,0
ADCETRIS,PML,nfo rmation Peripheral Neuropathy see,1
ADCETRIS,JC virus infection,* Peripheral Neuropathy see Warnings and Precautions,1
ADCETRIS,JC virus infection,discussed in greater detail in,0
ADCETRIS,JC virus infection,the prescribing *,1
ADCETRIS,JC virus infection,of the prescribing * Peripheral,1
ADCETRIS,death,see ngs a nd,1
ADCETRIS,death,of the prescribing * Peripheral,1
ADCETRIS,death,Peripheral Neuropathy see ngs,1
ADCETRIS,death,ngs a nd,1
ADCETRIS,death,ngs a nd,1
ADCETRIS,death,see ngs,1
ADCETRIS,death,detail in other sections of,0
ADCETRIS,death,sections of the,0
ADCETRIS,death,nd Precautions Anaphylaxis and Infusion Reactions see,0
ADCETRIS,death,Peripheral Neuropathy see ngs a nd Precautions Anaphylaxis,1
ADCETRIS,death,nd Precautions Anaphylaxis and Infusion Reactions see,0
ADCETRIS,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,Infections and Opportunistic,0
ADCETRIS,PML,rio,1
ADCETRIS,PML,rio us Infections and Opportunistic Infections,1
ADCETRIS,PML,rio us,1
ADCETRIS,JC virus infection,"and 4      )  ]  
 *  ",1
ADCETRIS,JC virus infection,rio us,1
ADCETRIS,JC virus infection,"and 4      )  ]  
 *  ",1
ADCETRIS,JC virus infection,rio us,1
ADCETRIS,JC virus infection,"Warnings and 4      )  ]  
 *  ",1
ADCETRIS,JC virus infection,rio us,1
ADCETRIS,JC virus infection,Infections see,0
ADCETRIS,JC virus infection,Infections see Warnings and Precautions,0
ADCETRIS,death,see   Warnings and Precautions,1
ADCETRIS,death,see   Warnings and Precautions Increased,1
ADCETRIS,death,see   Warnings and Precautions Increased Toxicity,1
ADCETRIS,Peripheral neuropathy,REACTIONS The following serious e reactions are discu,1
ADCETRIS,Peripheral neuropathy,e reactions are discu ssed in greater detail in,1
ADCETRIS,Peripheral neuropathy,REACTIONS The following serious e,1
ADCETRIS,Peripheral neuropathy,following serious e,1
ADCETRIS,Peripheral neuropathy,REACTIONS The following serious e reactions are discu ssed in,1
ADCETRIS,Peripheral neuropathy,following serious e,1
ADCETRIS,Peripheral neuropathy,other sections of the prescribing,0
ADCETRIS,Anaphylaxis,pathy [see Warnings,1
ADCETRIS,infusion reactions,ings,1
ADCETRIS,infusion reactions,information Peripheral Neuropathy see ings and Precautio,1
ADCETRIS,infusion reactions,ter detail in other,0
ADCETRIS,infusion reactions,detail in other sections of,0
ADCETRIS,infusion reactions,information Peripheral Neuropathy see ings,1
ADCETRIS,infusion reactions,see ings and Precautio,1
ADCETRIS,infusion reactions,information Peripheral Neuropathy see ings,1
ADCETRIS,infusion reactions,and Precautio ns Anaphylaxis,1
ADCETRIS,Hematologic toxicities,Warnings and Precautions,0
ADCETRIS,Hematologic toxicities,Precautions,0
ADCETRIS,Hematologic toxicities,gs and Precautions Serious Infections,0
ADCETRIS,Hematologic toxicities,gs and Precautions Serious Infections and Opportunistic Infections,0
ADCETRIS,Hematologic toxicities,and Precautions Hematologic oxicities [see  Warnin gs and,1
ADCETRIS,Hematologic toxicities,gs and Precautions Serious Infections and Opportunistic Infections,0
ADCETRIS,Hematologic toxicities,Precautions Serious Infections and Opportunistic Infections see,0
ADCETRIS,infections,Warnings and Precautions,0
ADCETRIS,infections,Warnings and Precautions,0
ADCETRIS,infections,Increased,0
ADCETRIS,Tumor lysis syndrome,Moderate or,0
ADCETRIS,Tumor lysis syndrome,in the,0
ADCETRIS,Tumor lysis syndrome,the Presence of,0
ADCETRIS,Tumor lysis syndrome,Increased Toxicity in the,0
ADCETRIS,Tumor lysis syndrome,of Moderate Severe Hepatic Impai,1
ADCETRIS,Tumor lysis syndrome,Increased Toxicity in the,0
ADCETRIS,Tumor lysis syndrome,and Precautions Hepatotoxicity see,0
ADCETRIS,Tumor lysis syndrome,see Warnings,0
ADCETRIS,Tumor lysis syndrome,Toxicity in the Presence,0
ADCETRIS,Tumor lysis syndrome,Hepatotoxicity see Warnings,0
ADCETRIS,Hepatotoxicity,see Warnings,0
ADCETRIS,Hepatotoxicity,Precautions Hepatotoxicity see Warnings Precautions (  Progressive Multifocal,1
ADCETRIS,Hepatotoxicity,see Warnings,0
ADCETRIS,Hepatotoxicity,Hepatotoxicity see Warnings Precautions,1
ADCETRIS,Pulmonary Toxicity,atotoxicity see Warnings and Precautions Progressive,0
ADCETRIS,Pulmonary Toxicity,Leukoen,0
ADCETRIS,Pulmonary Toxicity,Precautions Progressive Multifocal cephalopathy,1
ADCETRIS,dermatologic reactions,and Precau tions Serious Dermatologic Reactions see,1
ADCETRIS,dermatologic reactions,Warnings and Precau,1
ADCETRIS,dermatologic reactions,Precautions Pulmonary Toxicity e,1
ADCETRIS,dermatologic reactions,Warnings and Precautions Pulmonary,0
ADCETRIS,dermatologic reactions,e Warnings and Precau tions Serious Dermatologic Reactions,1
ADCETRIS,dermatologic reactions,Warnings and Precau tions Serious Dermatologic Reactions see,1
ADCETRIS,Fetal harm,ost common,1
ADCETRIS,Fetal harm,The ost common adverse reactions were Relapsed classical,1
ADCETRIS,Fetal harm,ost common,1
ADCETRIS,Fetal harm,Dermatologic Reactions see Warnings and Precautions EXCERPT,0
ADCETRIS,Fetal harm,classical HL and relapsed,0
ADCETRIS,peripheral neuropathy,er respiratory tract infection diarrhea pyrexia rash thrombocytopenia,1
ADCETRIS,peripheral neuropathy,pyrexia rash thrombocytopenia,0
ADCETRIS,peripheral neuropathy,nausea anemia er respiratory tract  infection diarrhea pyrexia,1
ADCETRIS,peripheral neuropathy,pyrexia rash thrombocytopenia,0
ADCETRIS,peripheral neuropathy,respiratory tract infection,1
ADCETRIS,peripheral motor neuropathy,"diarrhea pyrexia rash bocytopenia, cough, and vom",1
ADCETRIS,peripheral motor neuropathy,HL postautoHSCT consolidation,0
ADCETRIS,peripheral motor neuropathy,"rash bocytopenia,",1
ADCETRIS,peripheral motor neuropathy,tract infection diarrhea pyrexia,0
ADCETRIS,peripheral motor neuropathy,"bocytopenia, cough,",1
ADCETRIS,peripheral motor neuropathy,fatigue nausea anemia upper,0
ADCETRIS,peripheral neuropathy,-HSCT consolidation: neutropenia peripheral sensory,1
ADCETRIS,neuropathy, periphera l motor neuropathy,1
ADCETRIS,neuropathy, periphera l,1
ADCETRIS,neuropathy, periphera l motor neuropathy,1
ADCETRIS,neuropathy, periphera l motor,1
ADCETRIS,neuropathy,neuropathy thrombocytopenia,0
ADCETRIS,neuropathy,tract infection  periphera l motor neuropathy,1
ADCETRIS,neuropathy,neuropathy thrombocytopenia,0
ADCETRIS,neuropathy,thrombocytopenia anemia,0
ADCETRIS,neuropathy,contact Seattle Genetics Inc t 1-855-47,1
ADCETRIS,neuropathy,Seattle Genetics Inc t 1-855-47 or FDA at,1
ADCETRIS,neuropathy,contact Seattle Genetics Inc t 1-855-47,1
ADCETRIS,neuropathy,Clinical Trial Experience,0
ADCETRIS,neuropathy,t 1-855-47 or FDA at,1
ADCETRIS,neuropathy,t 1-855-47 or FDA at FDA,1
ADCETRIS,neuropathy,t 1-855-47 or FDA at FDA or,1
ADCETRIS,neuropathy,Seattle Genetics Inc t 1-855-47,1
ADCETRIS,neuropathy,at FDA or wwwfdagovmedwatch Clinical Trial Experience,0
ADCETRIS,neuropathy,Inc t 1-855-47,1
ADCETRIS,neuropathy,at FDA or wwwfdagovmedwatch Clinical Trial Experience,0
ADCETRIS,residual neuropathy,Genetics Inc at FDA at,1
ADCETRIS,Infusion-related reactions,in two uncontrolled singlearm,0
ADCETRIS,Infusion-related reactions,HL and systemic stic large cell lymphoma ( sALCL including patients in two,1
ADCETRIS,Infusion-related reactions,in two uncontrolled singlearm,0
ADCETRIS,Infusion-related reactions,cell lymphoma ( sALCL including patients,1
ADCETRIS,Infusion-related reactions,and systemic stic,1
ADCETRIS,anaphylaxis,atients in,0
ADCETRIS,anaphylaxis,large cell lymphoma sALCL uding 160 p atients,1
ADCETRIS,anaphylaxis,atients in,0
ADCETRIS,anaphylaxis,sALCL uding 160 p atients in two uncontrolled,1
ADCETRIS,anaphylaxis,atients in,0
ADCETRIS,anaphylaxis,and and patients,0
ADCETRIS,anaphylaxis,160 p atients in,1
ADCETRIS,anaphylaxis,uding 160 p atients,1
ADCETRIS,anaphylaxis,sALCL uding 160 p atients in two,1
ADCETRIS,anaphylaxis,uding 160 p atients,1
ADCETRIS,neutropenia,in,0
ADCETRIS,neutropenia,Toxicity Criteria CTC Version shown in,1
ADCETRIS,neutropenia,Toxicity Criteria,0
ADCETRIS,neutropenia,Toxicity Criteria CTC Version  shown in   Table In Study,1
ADCETRIS,neutropenia,Toxicity Criteria,0
ADCETRIS,neutropenia,CTC Version  shown in   Table In Study the most,1
ADCETRIS,neutropenia,Toxicity Criteria,0
ADCETRIS,neutropenia,CTC Version  shown in  ,1
ADCETRIS,neutropenia,Toxicity Criteria,0
ADCETRIS,neutropenia,Study the most common,0
ADCETRIS,neutropenia,shown in Table In Study the most,1
ADCETRIS,thrombocytopenia,In,0
ADCETRIS,thrombocytopenia,"In 3, the most",1
ADCETRIS,thrombocytopenia,causality were,0
ADCETRIS,thrombocytopenia,"shown in Table In  3, the most com mon",1
ADCETRIS,thrombocytopenia,causality were,0
ADCETRIS,thrombocytopenia,"3, the most com mon adverse reactions in the",1
ADCETRIS,thrombocytopenia,the most com mon adverse reactions in the,1
ADCETRIS,thrombocytopenia,regardless of,0
ADCETRIS,anemia,advers e,1
ADCETRIS,anemia,advers e,1
ADCETRIS,anemia,advers e,1
ADCETRIS,anemia,advers e reactions in the ADCETRIStreatment,1
ADCETRIS,anemia,advers e reactions,1
ADCETRIS,anemia,advers,1
ADCETRIS,Febrile neutropenia,Study the most common,0
ADCETRIS,Febrile neutropenia,the,0
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment,1
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment arm regardless of,1
ADCETRIS,Febrile neutropenia,common adverse reactions in  ADCETRIS-treatment arm,1
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment arm regardless of,1
ADCETRIS,Febrile neutropenia,arm regardless,0
ADCETRIS,Febrile neutropenia, ADCETRIS-treatment arm regardless,1
ADCETRIS,Febrile neutropenia,arm regardless,0
ADCETRIS,Febrile neutropenia,causality were neutropenia peripheral sensory,0
ADCETRIS,Febrile neutropenia,in  ADCETRIS-treatment,1
ADCETRIS,Febrile neutropenia,causality were neutropenia peripheral sensory,0
ADCETRIS,infections,was mgkg,0
ADCETRIS,infections,lassical H L in a single arm,1
ADCETRIS,infections,lassical H L in a single arm,1
ADCETRIS,infections,studied in patients with lassical,1
ADCETRIS,infections,lassical H L in a single arm,1
ADCETRIS,infections,lassical H,1
ADCETRIS,infections,in Relapsed Classical HL,0
ADCETRIS,opportunistic infections,HL a,1
ADCETRIS,opportunistic infections,clinical tr ial in which,1
ADCETRIS,opportunistic infections,ADCETRIS was studied,0
ADCETRIS,opportunistic infections,classical HL a single arm clinical,1
ADCETRIS,pneumonia,with,0
ADCETRIS,pneumonia,in ich the,1
ADCETRIS,pneumonia,intravenously every weeks,0
ADCETRIS,pneumonia,the r ecommended starting dose,1
ADCETRIS,pneumonia,in ich,1
ADCETRIS,pneumonia,the r,1
ADCETRIS,pneumonia,clinical trial in ich,1
ADCETRIS,pneumonia,ich the r ecommended starting,1
ADCETRIS,pneumonia,clinical trial in ich the,1
ADCETRIS,sepsis,g dose and,1
ADCETRIS,sepsis,which the recommended g dose and schedule was,1
ADCETRIS,sepsis,g dose and,1
ADCETRIS,sepsis,g dose and,1
ADCETRIS,sepsis,g dose and schedule was mgkg,1
ADCETRIS,sepsis,g dose and,1
ADCETRIS,sepsis,in which the recommended g dose and schedule was mgkg,1
ADCETRIS,sepsis,g dose and,1
ADCETRIS,sepsis,recommended g,1
ADCETRIS,sepsis,recommended g dose,1
ADCETRIS,sepsis,in a single arm clinical trial in which the,0
ADCETRIS,sepsis,the recommended g dose and,1
ADCETRIS,sepsis,in a single arm clinical trial in which the,0
ADCETRIS,sepsis,which the recommended g dose and schedule was mgkg,1
ADCETRIS,sepsis,in a single arm clinical trial in which the,0
ADCETRIS,septic shock,arm clinical trial in which the,0
ADCETRIS,septic shock,of treatment was,0
ADCETRIS,septic shock,weeks Median duration of treatment was cycles range,0
ADCETRIS,septic shock,s mgkg intravenously every weeks Median duration of treatment was cycles range s,0
ADCETRIS,septic shock,treatment,0
ADCETRIS,septic shock,schedule wa s mgkg intravenously,1
ADCETRIS,septic shock,starting dose schedule wa,1
ADCETRIS,septic shock,which the,0
ADCETRIS,septic shock,schedule wa s mgkg,1
ADCETRIS,septic shock,recommended starting dose  schedule wa s mgkg,1
ADCETRIS,septic shock,schedule wa s mgkg,1
ADCETRIS,tumor lysis syndrome,"infection nausea diarrhea emia, pyrexia, throm bocytopenia rash",1
ADCETRIS,tumor lysis syndrome,schedule wa s mgkg,1
ADCETRIS,tumor lysis syndrome,neuropathy fatigue upper respiratory tract infection,0
ADCETRIS,deaths,with classical HL at high risk of relapse or progression postautoHSCT in a randomiz,0
ADCETRIS,deaths,died i n patients with classical,1
ADCETRIS,deaths,Study ADCETRIS was died i,1
ADCETRIS,deaths,died i n patients with classical,1
ADCETRIS,deaths,Consolidation Study ADCETRIS was died,1
ADCETRIS,deaths,HL PostautoHSCT,0
ADCETRIS,deaths,at high risk of relapse or progression postautoHSCT,0
ADCETRIS,deaths,died,1
ADCETRIS,deaths,in Classical HL PostautoHSCT Consolidation Study ADCETRIS was stu,0
ADCETRIS,deaths,classical HL at,0
ADCETRIS,deaths,n patients with classical HL at high risk of relapse or,0
ADCETRIS,deaths,  [see,1
ADCETRIS,deaths,  [see Clinical Studies Standard international guidelines,1
ADCETRIS,deaths,ADCETRIStreatment arm received cycles,0
ADCETRIS,deaths,  [see Clinical Studies Standard international,1
ADCETRIS,deaths,  [see Clinical,1
ADCETRIS,deaths,  [see Clinical,1
ADCETRIS,deaths,Studies Standard international guidelines,0
ADCETRIS,deaths,Studies Standard international guidelines were followed,0
ADCETRIS,fatal,VZV prophylaxis with,0
ADCETRIS,fatal,tient s received PCP,1
ADCETRIS,fatal,a median duration of months,0
ADCETRIS,fatal,a median duration,0
ADCETRIS,fatal,tient s received,1
ADCETRIS,fatal,tient,1
ADCETRIS,hepatocellular injury,months range,0
ADCETRIS,hepatocellular injury,"of months 



   Experience in  Systemic",1
ADCETRIS,hepatocellular injury,months range,0
ADCETRIS,hepatocellular injury,median duration,0
ADCETRIS,hepatocellular injury,of months Experience,1
ADCETRIS,elevations of transaminases,Systemic,0
ADCETRIS,elevations of transaminases,Cell Lymphoma Summary of,1
ADCETRIS,elevations of transaminases,Experience in Systemic plastic,1
ADCETRIS,elevations of transaminases,Cell Lymphoma Summary of,1
ADCETRIS,elevations of transaminases,Systemic plastic Large,1
ADCETRIS,elevations of transaminases,Cell Lymphoma Summary of,1
ADCETRIS,elevations of transaminases,ADCETRIS,0
ADCETRIS,JC virus infection,"of causality were , anemia, peripher al sensory neuropathy",1
ADCETRIS,JC virus infection,ADCETRIS,0
ADCETRIS,JC virus infection,"regardless of causality were , anemia, peripher al sensory",1
ADCETRIS,JC virus infection,ADCETRIS,0
ADCETRIS,JC virus infection,most common adverse reactions,0
ADCETRIS,JC virus infection,"causality were , anemia, peripher al",1
ADCETRIS,JC virus infection,most common adverse reactions,0
ADCETRIS,JC virus infection,Table,0
ADCETRIS,JC virus infection,regardless of causality were,0
ADCETRIS,JC virus infection,", anemia, peripher",1
ADCETRIS,JC virus infection,The most common,0
ADCETRIS,PML,neutropenia anemia peripheral sensory rop athy fatigue nausea,1
ADCETRIS,PML,The most common,0
ADCETRIS,PML,Table,0
ADCETRIS,PML,peripheral sensory rop athy fatigue nausea,1
ADCETRIS,PML,Table,0
ADCETRIS,PML,neutropenia anemia,0
ADCETRIS,PML,peripheral sensory neu,0
ADCETRIS,PML,neutropenia,0
ADCETRIS,PML,rop athy fatigue nausea pyrexia,1
ADCETRIS,PML,rop,1
ADCETRIS,Stevens-Johnson syndrome,Peripheral sensory neuropathy,0
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral sensory,1
ADCETRIS,Stevens-Johnson syndrome,                        ,1
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral,1
ADCETRIS,Stevens-Johnson syndrome,Nervous system                         ,1
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral,1
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral sensory neuropathy,1
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral,1
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral sensory,1
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral,1
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral sensory neuropathy,1
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral sensory neuropathy,1
ADCETRIS,Stevens-Johnson syndrome,                         Peripheral sensory neuropathy,1
ADCETRIS,SJS,    Peripheral sensory,1
ADCETRIS,SJS,                         Peripheral sensory neuropathy,1
ADCETRIS,SJS,    Peripheral sensory,1
ADCETRIS,SJS,   ,1
ADCETRIS,SJS,stem     Peripheral sensory,1
ADCETRIS,SJS,   ,1
ADCETRIS,SJS,    Peripheral sensory,1
ADCETRIS,SJS,Peripheral sensory,0
ADCETRIS,SJS,    Peripheral,1
ADCETRIS,SJS,Peripheral,0
ADCETRIS,SJS,Peripheral sensory,0
ADCETRIS,TEN,y   Peripheral,1
ADCETRIS,TEN,neuropath,0
ADCETRIS,TEN,y   Peripheral mot,1
ADCETRIS,TEN,sensory neuropath,0
ADCETRIS,TEN,sensory y   Peripheral,1
ADCETRIS,TEN,sensory neuropath,0
ADCETRIS,TEN,y   Peripheral mot,1
ADCETRIS,fatal,sensory 52    Peripheral motor neuropathy,1
ADCETRIS,fatal,y   Peripheral mot,1
ZERBAXA,Hypersensitivity reactions,in the Warnings and,0
ZERBAXA,Hypersensitivity reactions,Hypersensitivity reactions see Warnings and Precautions,1
ZERBAXA,Hypersensitivity reactions,Hypersensitivity reactions,1
ZERBAXA,Hypersensitivity reactions,Precautions Hypersensitivity reactions,1
ZERBAXA,Hypersensitivity reactions,the Warnings and Precautions Hypersensitivity,1
ZERBAXA,Hypersensitivity reactions,Hypersensitivity reactions see Warnings and,1
ZERBAXA,Hypersensitivity reactions,and Precautions section,0
ZERBAXA,Hypersensitivity reactions,Warnings and Precautions Hypersensitivity reactions see Warnings,1
ZERBAXA,Hypersensitivity reactions,and Precautions section,0
ZERBAXA,Clostridium difficile -associated diarrhea,see Warnings and Clostridium difficile -associated diarrhea,1
ZERBAXA,Clostridium difficile -associated diarrhea,and Precautions section,0
ZERBAXA,nausea,adverse reactions in either indication,0
ZERBAXA,nausea,in either indication nausea diarrhea headache and,1
ZERBAXA,nausea,adverse reactions in either indication,0
ZERBAXA,diarrhea,diarrhea headache,1
ZERBAXA,headache,headache and pyrexia To report SUSPECTED,1
ZERBAXA,pyrexia,report SUSPECTED ADVERSE REACTIONS contact Merck Sharp Dohme Corp,0
ZERBAXA,pyrexia,diarrhea headache pyrexia To report,1
ZERBAXA,pyrexia,report SUSPECTED ADVERSE REACTIONS contact Merck Sharp Dohme Corp,0
ZERBAXA,pyrexia,pyrexia,1
ZERBAXA,pyrexia,nausea diarrhea headache pyrexia,1
ZERBAXA,pyrexia,pyrexia,1
ZERBAXA,pyrexia,pyrexia To report SUSPECTED,1
ZERBAXA,pyrexia,pyrexia To report,1
ZERBAXA,pyrexia,pyrexia To report SUSPECTED,1
ZERBAXA,nausea,nausea diarrhea headache and pyrexia,1
ZERBAXA,nausea,adverse reactions or greater in either indication,0
ZERBAXA,nausea,nausea diarrhea headache and pyrexia Table,1
ZERBAXA,nausea,adverse reactions or greater in either indication,0
ZERBAXA,nausea,in patients receiving ZERBAXA,0
ZERBAXA,nausea,nausea,1
ZERBAXA,nausea,indication occurring in patients receiving,0
ZERBAXA,nausea,were,0
ZERBAXA,diarrhea,diarrhea headache and,1
ZERBAXA,diarrhea,diarrhea headache,1
ZERBAXA,diarrhea,adverse reactions occurring in or greater of patients rece,0
ZERBAXA,diarrhea,diarrhea headache,1
ZERBAXA,diarrhea,diarrhea headache,1
ZERBAXA,diarrhea,headache and pyrexia Table lists adverse reactions occurring in or,0
ZERBAXA,diarrhea,diarrhea headache and pyrexia Table lists,1
ZERBAXA,headache,occurring in or greater of,0
ZERBAXA,headache,either indication occurring in patients receiving ZERBAXA were nausea diarrhea,0
ZERBAXA,headache,headache and pyrexia Table lists adverse,1
ZERBAXA,headache,nausea headache,1
ZERBAXA,headache,headache and pyrexia Table lists adverse,1
ZERBAXA,headache,were nausea headache,1
ZERBAXA,headache,headache and pyrexia Table lists adverse,1
ZERBAXA,headache,headache and pyrexia Table lists,1
ZERBAXA,headache,receiving ZERBAXA were,0
ZERBAXA,headache,headache and pyrexia Table lists adverse,1
ZERBAXA,headache,headache and pyrexia Table lists adverse,1
ZERBAXA,pyrexia,were nausea diarrhea headache pyrexia Table lists adverse reactions,1
ZERBAXA,pyrexia,headache and pyrexia Table lists adverse,1
ZERBAXA,pyrexia,nausea,0
ZERBAXA,pyrexia,pyrexia,1
ZERBAXA,pyrexia,headache,0
ZERBAXA,Renal impairment,receiving comparator Renal impairment,1
ZERBAXA,Renal impairment,comparator drugs,0
ZERBAXA,Renal impairment,receiving comparator Renal impairment including the terms renal,1
ZERBAXA,Renal impairment,comparator drugs,0
ZERBAXA,Renal impairment,patients receiving comparator drugs,0
ZERBAXA,Renal impairment,receiving comparator Renal impairment including the terms,1
ZERBAXA,Renal impairment,patients receiving comparator drugs,0
ZERBAXA,Renal impairment,comparator Renal impairment including the,1
ZERBAXA,Renal impairment,patients receiving comparator drugs,0
ZERBAXA,Renal impairment,patients receiving comparator Renal impairment including,1
ZERBAXA,Renal impairment,patients receiving comparator drugs,0
ZERBAXA,Renal impairment,receiving comparator Renal impairment,1
ZERBAXA,Renal impairment,Renal,1
ZERBAXA,renal impairment,renal impairment renal failure and renal,1
ZERBAXA,renal impairment,patients receiving comparator drugs,0
ZERBAXA,renal impairment,the terms,0
ZERBAXA,renal impairment,impairment,0
ZERBAXA,renal impairment,of patients receiving,0
ZERBAXA,renal impairment,renal impairment renal failure and,1
ZERBAXA,renal impairment,renal impairment renal failure,1
ZERBAXA,renal impairment,to discontinuation,0
ZERBAXA,renal impairment,treatment in,0
ZERBAXA,renal failure,renal renal failure,1
ZERBAXA,renal failure,renal failure and,1
ZERBAXA,renal failure,of,0
ZERBAXA,renal failure acute,renal failure acute,1
ZERBAXA,death,death occurred in of,1
ZERBAXA,death,death occurred in,1
ZERBAXA,death,death occurred in of patients,1
ZERBAXA,death,death occurred in of patients,1
ZERBAXA,death,death varied and,1
ZERBAXA,death,death varied and included worsening andor,1
ZERBAXA,death,death varied and included,1
ZERBAXA,death,death varied and included worsening,1
ZERBAXA,death,death varied and included,1
ZERBAXA,complications of infection,complications of infection,1
ZERBAXA,complications of infection,varied and included worsening complications,1
ZERBAXA,complications of infection,included worsening andor,0
ZERBAXA,complications of infection,varied and included worsening complications,1
ZERBAXA,complications of infection,varied and included worsening complications of infection surgery and underlying,1
ZERBAXA,complications of infection,varied and included worsening complications,1
ZERBAXA,complications of infection,varied and included worsening complications of,1
ZERBAXA,complications of infection,Reactions The,0
ZERBAXA,tachycardia,Cardiac tachycardia,1
ZERBAXA,tachycardia,Reactions The,0
ZERBAXA,tachycardia,in ZERBAXAtreated subjects at a rate of less,0
ZERBAXA,tachycardia,less than Cardiac tachycardia angina pectoris Gastrointestinal disorders ileus,1
ZERBAXA,tachycardia,in ZERBAXAtreated subjects at a rate of less,0
ZERBAXA,angina pectoris,than Cardiac disorders angina pectoris,1
ZERBAXA,angina pectoris,in ZERBAXAtreated subjects at a rate of less,0
ZERBAXA,angina pectoris,angina pectoris,1
ZERBAXA,angina pectoris,Cardiac disorders angina,1
ZERBAXA,angina pectoris,than Cardiac disorders angina pectoris Gastrointestinal disorders,1
ZERBAXA,angina pectoris,Cardiac disorders angina,1
ZERBAXA,ileus,ileus gastritis abdominal distension dyspepsia flatulence,1
ZERBAXA,ileus,ileus paralytic General,0
ZERBAXA,ileus,abdominal,0
ZERBAXA,ileus,ileus,0
ZERBAXA,ileus,tachycardia angina pectoris Gastrointestinal ileus gastritis abdominal distension dyspepsia,1
ZERBAXA,ileus,ileus,0
ZERBAXA,ileus,ileus gastritis abdominal distension dyspepsia flatulence,1
ZERBAXA,ileus,Cardiac disorders tachycardia,0
ZERBAXA,abdominal distension,tachycardia angina pectoris Gastrointestinal disorders ileus,0
ZERBAXA,abdominal distension,ileus paralytic General disorders and,0
ZERBAXA,abdominal distension,tachycardia angina pectoris Gastrointestinal disorders ileus gastritis,0
ZERBAXA,abdominal distension,abdominal distension dyspepsia flatulence ileus,1
ZERBAXA,abdominal distension,abdominal distension dyspepsia flatulence ileus paralytic,1
ZERBAXA,abdominal distension,abdominal distension dyspepsia flatulence ileus paralytic General,1
ZERBAXA,abdominal distension,gastritis,0
ZERBAXA,abdominal distension,disorders ileus abdominal distension dyspepsia flatulence ileus paralytic General,1
ZERBAXA,abdominal distension,gastritis,0
ZERBAXA,abdominal distension,ileus,0
ZERBAXA,dyspepsia,Gastrointestinal disorders ileus gastritis abdominal,0
ZERBAXA,dyspepsia,ileus paralytic General disorders and administration,0
ZERBAXA,dyspepsia,dyspepsia flatulence ileus paralytic General,1
ZERBAXA,dyspepsia,angina pectoris Gastrointestinal disorders ileus gastritis abdominal,0
ZERBAXA,dyspepsia,abdominal,0
ZERBAXA,dyspepsia,disorders ileus gastritis abdominal dyspepsia flatulence ileus paralytic,1
ZERBAXA,dyspepsia,abdominal,0
ZERBAXA,dyspepsia,gastritis abdominal dyspepsia flatulence ileus paralytic,1
ZERBAXA,dyspepsia,abdominal,0
ZERBAXA,dyspepsia,ileus paralytic,0
ZERBAXA,flatulence,na pectoris Gastrointestinal disorders ileus,0
ZERBAXA,flatulence,disorders ileus gastritis abdominal,0
ZERBAXA,ileus paralytic,ileus paralytic,1
ZERBAXA,ileus paralytic,ileus paralytic,1
ZERBAXA,ileus paralytic,ileus paralytic General disorders and administration site,1
ZERBAXA,ileus paralytic,gastritis abdominal distension dyspepsia ileus paralytic,1
ZERBAXA,ileus paralytic,Gastrointestinal disorders ileus,0
ZERBAXA,ileus paralytic,ileus paralytic General disorders and administration,1
ZERBAXA,infusion site reactions,conditions,0
ZERBAXA,infusion site reactions,and infestations candidiasis,0
ZERBAXA,infusion site reactions,conditions,0
ZERBAXA,candidiasis,and administration site conditions infusion,0
ZERBAXA,candidiasis,infection Investigations increased serum gammagluta,0
ZERBAXA,candidiasis,candidiasis oropharyngeal fungal urinary tract,1
ZERBAXA,candidiasis,infection Investigations increased serum gammagluta,0
ZERBAXA,fungal urinary tract infection,candidiasis fungal urinary tract infection Investigations increased serum gammaglutamyl,1
ZERBAXA,fungal urinary tract infection,infection Investigations increased serum gammagluta,0
ZERBAXA,fungal urinary tract infection,GGT increased serum,0
ZERBAXA,fungal urinary tract infection,tract infection Investigations increased,1
ZERBAXA,fungal urinary tract infection,gammaglutamyl transpeptidase GGT increased serum,0
ZERBAXA,fungal urinary tract infection,transpeptidase GGT increased serum,0
ZERBAXA,fungal urinary tract infection,fungal,1
ZERBAXA,fungal urinary tract infection,tract infection Investigations increased,1
ZERBAXA,increased serum gamma-glutamyl transpeptidase,phosphatase positive Coombs test,0
ZERBAXA,increased serum gamma-glutamyl transpeptidase,tract infection increased serum gamma-glutamyl transpeptidase GGT,1
ZERBAXA,increased serum gamma-glutamyl transpeptidase,phosphatase positive Coombs test,0
ZERBAXA,increased serum gamma-glutamyl transpeptidase,fungal urinary tract infection Investigations,0
ZERBAXA,increased serum gamma-glutamyl transpeptidase,infection increased serum,1
ZERBAXA,increased serum gamma-glutamyl transpeptidase,infection increased serum gamma-glutamyl transpeptidase,1
ZERBAXA,increased serum gamma-glutamyl transpeptidase,infection increased serum,1
ZERBAXA,increased serum gamma-glutamyl transpeptidase,gamma-glutamyl transpeptidase GGT increased serum alkaline,1
ZERBAXA,increased serum alkaline phosphatase,transpeptidase GGT,0
ZERBAXA,increased serum alkaline phosphatase,tract,0
ZERBAXA,increased serum alkaline phosphatase,increased serum alkaline phosphatase,1
ZERBAXA,increased serum alkaline phosphatase,increased serum alkaline phosphatase positive Coombs test Metabolism and,1
ZERBAXA,increased serum alkaline phosphatase,increased serum alkaline phosphatase,1
ZERBAXA,increased serum alkaline phosphatase,increased serum alkaline phosphatase positive Coombs,1
ZERBAXA,positive Coombs test,serum alkaline,0
ZERBAXA,positive Coombs test,positive Coombs test Metabolism and nutrition disorders hyperglycemia,1
ZERBAXA,positive Coombs test,positive Coombs test Metabolism and nutrition disorders,1
ZERBAXA,positive Coombs test,positive Coombs test Metabolism and nutrition disorders hyperglycemia,1
ZERBAXA,positive Coombs test,gations increased serum gammaglutamyl transpeptidase GGT increased serum alkaline phosphatase,0
ZERBAXA,positive Coombs test,GGT,0
ZERBAXA,hyperglycemia,hyperglycemia,1
ZERBAXA,hyperglycemia,test Metabolism and nutrition hyperglycemia hypomagnesemia hypophosphatemia,1
ZERBAXA,hyperglycemia,hyperglycemia,1
ZERBAXA,hyperglycemia,hyperglycemia,1
ZERBAXA,hyperglycemia,eased serum alkaline,0
ZERBAXA,hyperglycemia,ischemic stroke Renal,0
ZERBAXA,hyperglycemia,hyperglycemia hypomagnesemia,1
ZERBAXA,hyperglycemia,hyperglycemia hypomagnesemia hypophosphatemia Nervous,1
ZERBAXA,hypomagnesemia,hypomagnesemia,1
ZERBAXA,hypomagnesemia,hyperglycemia hypomagnesemia hypophosphatemia Nervous,1
ZERBAXA,ischemic stroke,Nervous system ischemic stroke Renal,1
ZERBAXA,ischemic stroke,hyperglycemia hypomagnesemia hypophosphatemia Nervous,1
ZERBAXA,ischemic stroke,hypomagnesemia hypophosphatemia Nervous system ischemic stroke Renal and urinary system,1
ZERBAXA,ischemic stroke,hyperglycemia hypomagnesemia hypophosphatemia Nervous,1
ZERBAXA,ischemic stroke,Renal and urinary system,0
ZERBAXA,ischemic stroke,system renal impairment renal failure,0
ZERBAXA,ischemic stroke,hypophosphatemia Nervous system ischemic stroke,1
ZERBAXA,ischemic stroke,ischemic stroke Renal,1
ZERBAXA,ischemic stroke,ischemic,1
ZERBAXA,renal impairment,renal impairment renal failure Respiratory thoracic and,1
ZERBAXA,renal failure,impairment,0
ZERBAXA,renal failure,thoracic and mediastinal disorders dyspnea Skin and,0
ZERBAXA,renal failure,renal renal failure Respiratory thoracic,1
ZERBAXA,renal failure,thoracic and mediastinal disorders dyspnea Skin and,0
ZERBAXA,dyspnea,dyspnea Skin and,1
ZERBAXA,dyspnea,dyspnea Skin and subcutaneous tissue disorders,1
ZERBAXA,dyspnea,and subcutaneous tissue disorders urticaria Vascular disorders,0
ZERBAXA,dyspnea,disorders urticaria Vascular disorders,0
ZERBAXA,dyspnea,dyspnea Skin and,1
ZERBAXA,dyspnea,dyspnea Skin,1
ZERBAXA,dyspnea,disorders urticaria Vascular disorders venous thro,0
ZERBAXA,dyspnea,tissue disorders urticaria Vascular,0
ZERBAXA,dyspnea,and mediastinal,0
ZERBAXA,dyspnea,urticaria Vascular disorders,0
ZERBAXA,urticaria,Vascular disorders,0
ZERBAXA,Clostridium difficile -associated diarrhea,"To report SUSPECTED ADVERSE S, contact Merck Sharp & Dohme Corp., a su",1
ZERBAXA,Clostridium difficile -associated diarrhea,Vascular disorders,0
ZERBAXA,Clostridium difficile -associated diarrhea,"S, contact Merck Sharp & Dohme Corp., a su bsidiary of Merck Co Inc",1
ZERBAXA,Clostridium difficile -associated diarrhea,Vascular disorders,0
ZERBAXA,Clostridium difficile -associated diarrhea,REACTION,0
ZERBAXA,Clostridium difficile -associated diarrhea,bsidiary of Merck Co,0
ZERBAXA,Clostridium difficile -associated diarrhea,"S, contact Merck Sharp & Dohme",1
ZERBAXA,CDAD,idia ry of Merck,1
ZERBAXA,CDAD,"S, contact Merck Sharp & Dohme",1
ZERBAXA,CDAD,or FDA,0
ZERBAXA,CDAD,idia,1
ZERBAXA,CDAD,ADVERSE REACTIONS contact Merck Sharp Dohme Corp a,0
ZERBAXA,fatal,patients receiving ZERBAXA in Phase clinical,0
ZERBAXA,fatal,g in or,1
ZERBAXA,fatal,g in or,1
ZERBAXA,fatal,g in or,1
ZERBAXA,fatal,ZERBAXA in Phase,0
ZERBAXA,fatal,reactions g,1
ZERBAXA,fatal,of patients receiving ZERBAXA in Phase clinical trials Table,0
ZYDELIG,Hepatotoxicity,and are,0
ZYDELIG,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions Severe,1
ZYDELIG,Hepatotoxicity,sections of the prescribing Hepatotoxicity see Warnings and Precautions Severe,1
ZYDELIG,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions Severe,1
ZYDELIG,Hepatotoxicity,Hepatotoxicity see Warnings and,1
ZYDELIG,Hepatotoxicity,sections of the prescribing Hepatotoxicity,1
ZYDELIG,Hepatotoxicity,Hepatotoxicity see Warnings and,1
ZYDELIG,Hepatotoxicity,sections,0
ZYDELIG,Hepatotoxicity,the prescribing Hepatotoxicity see Warnings and,1
ZYDELIG,Hepatotoxicity,sections,0
ZYDELIG,Diarrhea,Diarrhea,1
ZYDELIG,Diarrhea,Pneumonitis see,0
ZYDELIG,Diarrhea,and Precautions Diarrhea or Colitis see Warnings,1
ZYDELIG,Diarrhea,Pneumonitis see,0
ZYDELIG,Colitis,Colitis see,1
ZYDELIG,Colitis,Colitis see Warnings and Precautions Pneumonitis,1
ZYDELIG,Colitis,Precautions Severe Diarrhea Colitis see Warnings,1
ZYDELIG,Colitis,Colitis see Warnings and Precautions Pneumonitis,1
ZYDELIG,Colitis,information Hepatotoxicity see Warnings and,0
ZYDELIG,Colitis,Colitis see Warnings,1
ZYDELIG,Colitis,Colitis see Warnings,1
ZYDELIG,Colitis,and Precautions Severe Diarrhea Colitis see Warnings,1
ZYDELIG,Colitis,Colitis see Warnings,1
ZYDELIG,Colitis,Colitis see Warnings and,1
ZYDELIG,Pneumonitis,Pneumonitis,1
ZYDELIG,Intestinal Perforation,Pneumonitis see Warnings and Intestinal,1
ZYDELIG,Cutaneous Reactions,Cutaneous Reactions see Warnings and Precautions Anaphylaxis,1
ZYDELIG,Cutaneous Reactions,Perforation see Warnings and Precautions Severe,0
ZYDELIG,Cutaneous Reactions,Precautions Severe,0
ZYDELIG,Cutaneous Reactions,Warnings and,0
ZYDELIG,Cutaneous Reactions,see Warnings and Precautions Cutaneous Reactions see,1
ZYDELIG,Cutaneous Reactions,Warnings and,0
ZYDELIG,Cutaneous Reactions,see Warnings and Precautions Cutaneous Reactions,1
ZYDELIG,Cutaneous Reactions,Anaphylaxis see Warnings and,0
ZYDELIG,Anaphylaxis,see Warnings and Precautions Neutropenia see Warnings,0
ZYDELIG,Anaphylaxis,Anaphylaxis,1
ZYDELIG,Anaphylaxis,and Precautions,0
ZYDELIG,Anaphylaxis,Anaphylaxis see Warnings and Precautions Neutropenia,1
ZYDELIG,Anaphylaxis,Reactions see Warnings and Anaphylaxis see Warnings and Precautions Neutropenia,1
ZYDELIG,Anaphylaxis,Anaphylaxis see Warnings and Precautions Neutropenia,1
ZYDELIG,Neutropenia,see Warnings,0
ZYDELIG,Neutropenia,Warnings and Precautions EXCERPT The,0
ZYDELIG,diarrhea,common adverse reactions incidence diarrhea pyrexia fatigue,1
ZYDELIG,diarrhea,Warnings and Precautions EXCERPT The,0
ZYDELIG,diarrhea,nausea cough pneumonia,0
ZYDELIG,diarrhea,incidence,0
ZYDELIG,diarrhea,common adverse reactions incidence are,0
ZYDELIG,diarrhea,diarrhea pyrexia fatigue nausea,1
ZYDELIG,diarrhea,adverse reactions incidence,0
ZYDELIG,diarrhea,diarrhea pyrexia fatigue nausea,1
ZYDELIG,pyrexia,diarrhea,0
ZYDELIG,pyrexia,EXCERPT The most common adverse,0
ZYDELIG,pyrexia,chills and,0
ZYDELIG,pyrexia,pyrexia fatigue nausea,1
ZYDELIG,pyrexia,pyrexia fatigue nausea,1
ZYDELIG,fatigue,rash The most common laborato,0
ZYDELIG,fatigue,fatigue nausea cough pneumonia abdominal,1
ZYDELIG,fatigue,fatigue nausea cough pneumonia,1
ZYDELIG,fatigue,fatigue nausea cough pneumonia abdominal,1
ZYDELIG,fatigue,chills,0
ZYDELIG,nausea,diarrhea pyrexia nausea cough pneumonia abdominal,1
ZYDELIG,nausea,chills,0
ZYDELIG,nausea,nausea,1
ZYDELIG,nausea,chills and rash,0
ZYDELIG,nausea,diarrhea pyrexia nausea,1
ZYDELIG,nausea,chills and rash,0
ZYDELIG,nausea,pain chills and rash The most common laboratory,0
ZYDELIG,nausea,nausea,1
ZYDELIG,nausea,nausea cough pneumonia abdominal,1
ZYDELIG,nausea,reactions incidence,0
ZYDELIG,nausea,most,0
ZYDELIG,nausea,common adverse,0
ZYDELIG,cough,cough pneumonia abdominal pain chills and,1
ZYDELIG,cough,adverse reactions incidence are diarrhea pyrexia fatigue nausea,0
ZYDELIG,cough,The most,0
ZYDELIG,cough,cough,1
ZYDELIG,cough,The most,0
ZYDELIG,cough,cough pneumonia abdominal pain chills,1
ZYDELIG,cough,pneumonia abdominal pain chills and rash The most common laboratory,0
ZYDELIG,cough,chills and rash The most common,0
ZYDELIG,cough,common laboratory,0
ZYDELIG,cough,and rash The most common,0
ZYDELIG,cough,cough pneumonia abdominal pain chills and,1
ZYDELIG,pneumonia,pneumonia abdominal pain chills and rash,1
ZYDELIG,pneumonia,reactions incidence are,0
ZYDELIG,pneumonia,laboratory abnormalities,0
ZYDELIG,abdominal pain,abdominal pain chills and rash The,1
ZYDELIG,abdominal pain,fatigue nausea cough abdominal pain chills and,1
ZYDELIG,abdominal pain,abdominal pain chills and rash The,1
ZYDELIG,abdominal pain,pyrexia fatigue nausea,0
ZYDELIG,abdominal pain,nausea cough abdominal pain,1
ZYDELIG,abdominal pain,pyrexia fatigue nausea,0
ZYDELIG,abdominal pain,cough abdominal,1
ZYDELIG,abdominal pain,abdominal pain chills and rash,1
ZYDELIG,abdominal pain,abdominal pain chills and,1
ZYDELIG,chills,diarrhea pyrexia fatigue nausea cough,0
ZYDELIG,chills,fatigue nausea,0
ZYDELIG,chills,chills and rash The most,1
ZYDELIG,chills,nausea cough pneumonia abdominal chills and rash,1
ZYDELIG,chills,chills and rash The most,1
ZYDELIG,chills,diarrhea pyrexia fatigue nausea cough pneumonia abdominal pain,0
ZYDELIG,chills,chills and,1
ZYDELIG,rash,abdominal pain,0
ZYDELIG,rash,abdominal pain chills rash The most common laboratory,1
ZYDELIG,rash,abdominal pain,0
ZYDELIG,rash,rash The most common,1
ZYDELIG,rash,common laboratory abnormalities incidence are neutropenia hypertri,0
ZYDELIG,rash,pain chills rash The most,1
ZYDELIG,rash,common laboratory abnormalities incidence are neutropenia hypertri,0
ZYDELIG,neutropenia,neutropenia,1
ZYDELIG,neutropenia,common laboratory abnormalities incidence are neutropenia hypertri,0
ZYDELIG,neutropenia,common laboratory abnormalities incidence neutropenia,1
ZYDELIG,neutropenia,common laboratory abnormalities incidence are neutropenia hypertri,0
ZYDELIG,neutropenia,neutropenia,1
ZYDELIG,neutropenia,elevations,0
ZYDELIG,neutropenia,common laboratory abnormalities incidence neutropenia hypertriglyceridemia hyperglycemia,1
ZYDELIG,neutropenia,elevations,0
ZYDELIG,neutropenia,incidence neutropenia hypertriglyceridemia hyperglycemia,1
ZYDELIG,neutropenia,elevations,0
ZYDELIG,neutropenia,common laboratory abnormalities incidence neutropenia hypertriglyceridemia hyperglycemia ALT elevations,1
ZYDELIG,neutropenia,elevations,0
ZYDELIG,neutropenia,neutropenia hypertriglyceridemia hyperglycemia,1
ZYDELIG,hypertriglyceridemia,laboratory abnormalities incidence are hypertriglyceridemia hyperglycemia,1
ZYDELIG,hypertriglyceridemia,neutropenia hypertriglyceridemia hyperglycemia,1
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations and AST,1
ZYDELIG,hypertriglyceridemia,neutropenia hypertriglyceridemia hyperglycemia,1
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations and AST,1
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations and AST,1
ZYDELIG,hypertriglyceridemia,laboratory abnormalities incidence are hypertriglyceridemia hyperglycemia ALT elevations,1
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations and AST,1
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations and,1
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations,1
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia,1
ZYDELIG,hypertriglyceridemia,most common,0
ZYDELIG,hypertriglyceridemia,hypertriglyceridemia hyperglycemia ALT elevations and AST,1
ZYDELIG,hyperglycemia,hyperglycemia,1
ZYDELIG,hyperglycemia,SUSPECTED ADVERSE REACTIONS contact,0
ZYDELIG,hyperglycemia,incidence are neutropenia hypertriglyceridemia,0
ZYDELIG,hyperglycemia,hyperglycemia ALT,1
ZYDELIG,hyperglycemia,hyperglycemia,1
ZYDELIG,ALT elevations,incidence are neutropenia,0
ZYDELIG,AST elevations,and,0
ZYDELIG,AST elevations,incidence are neutropenia hypertriglyceridemia,0
ZYDELIG,AST elevations,Inc,0
ZYDELIG,AST elevations,SUSPECTED ADVERSE REACTIONS contact,0
ZYDELIG,AST elevations,AST elevations To report SUSPECTED ADVERSE REACTIONS,1
ZYDELIG,AST elevations,AST elevations To report SUSPECTED ADVERSE REACTIONS,1
ZYDELIG,AST elevations,hyperglycemia ALT elevations AST elevations To report,1
ZYDELIG,AST elevations,AST elevations To report SUSPECTED ADVERSE REACTIONS,1
ZYDELIG,AST elevations,hyperglycemia ALT elevations AST elevations,1
ZYDELIG,AST elevations,contact,0
ZYDELIG,AST elevations,AST elevations,1
ZYDELIG,pyrexia,were pyrexia,1
ZYDELIG,pyrexia,AST elevations,1
ZYDELIG,pyrexia,treated with Zydelig were pyrexia sepsis,1
ZYDELIG,pyrexia,AST elevations,1
ZYDELIG,pyrexia,febrile neutropenia and diarrhea Adverse reactions that led to discon,0
ZYDELIG,pyrexia,reported for subjects treated with,0
ZYDELIG,sepsis,were pneumonia sepsis febrile neutropenia,1
ZYDELIG,sepsis,reported for subjects treated with,0
ZYDELIG,sepsis,us adverse reactions reported for subjects treated with Zydelig,0
ZYDELIG,sepsis,Zydelig were pneumonia sepsis,1
ZYDELIG,sepsis,us adverse reactions reported for subjects treated with Zydelig,0
ZYDELIG,sepsis,sepsis,1
ZYDELIG,sepsis,for subjects treated,0
ZYDELIG,sepsis,led,0
ZYDELIG,sepsis,pneumonia,0
ZYDELIG,sepsis,Zydelig were pneumonia sepsis febrile neutropenia,1
ZYDELIG,sepsis,pneumonia,0
ZYDELIG,sepsis,Adverse reactions that led to discontinuation,0
ZYDELIG,sepsis,sepsis febrile neutropenia,1
ZYDELIG,diarrhea,febrile neutropenia diarrhea Adverse reactions,1
ZYDELIG,diarrhea,sepsis febrile neutropenia,1
ZYDELIG,diarrhea,with,0
ZYDELIG,diarrhea,diarrhea Adverse reactions that led,1
ZYDELIG,diarrhea,pyrexia sepsis febrile neutropenia and,0
ZYDELIG,diarrhea,diarrhea Adverse reactions that,1
ZYDELIG,diarrhea,diarrhea Adverse reactions,1
ZYDELIG,diarrhea,diarrhea,1
ZYDELIG,diarrhea,Zydelig were pneumonia pyrexia sepsis,0
ZYDELIG,hepatotoxicity,hepatotoxicity and diarrheacolitis Thirtynine subjects had,1
ZYDELIG,hepatotoxicity,Zydelig were pneumonia pyrexia sepsis,0
ZYDELIG,hepatotoxicity,discontinuations hepatotoxicity and diarrheacolitis Thirtynine,1
ZYDELIG,hepatotoxicity,Zydelig were pneumonia pyrexia sepsis,0
ZYDELIG,diarrhea,diarrhea colitis Thirtynine subjects had dose,1
ZYDELIG,diarrhea,common adverse reactions that led to,0
ZYDELIG,colitis,dose,0
ZYDELIG,colitis,and colitis Thirtynine,1
ZYDELIG,colitis,dose,0
ZYDELIG,colitis,to treatment discontinuations were hepatotoxicity and,0
ZYDELIG,colitis,and colitis,1
ZYDELIG,colitis,to treatment discontinuations were hepatotoxicity and,0
ZYDELIG,elevated transaminases,adverse reactions,0
ZYDELIG,elevated transaminases,to adverse reactions or laboratory abnormalities The most common reasons for dose reductions were,0
ZYDELIG,elevated transaminases,reductions elevated transaminases diarrhea or colitis and rash,1
ZYDELIG,elevated transaminases,to adverse reactions or laboratory abnormalities The most common reasons for dose reductions were,0
ZYDELIG,elevated transaminases,adverse reactions and labo,0
ZYDELIG,elevated transaminases,elevated transaminases diarrhea,1
ZYDELIG,elevated transaminases,elevated transaminases diarrhea or colitis,1
ZYDELIG,elevated transaminases,elevated transaminases diarrhea or,1
ZYDELIG,colitis,or,0
ZYDELIG,colitis,colitis and rash Table and Table,1
ZYDELIG,colitis,and Table summarize common adverse reactions,0
ZYDELIG,rash,common reasons for dose reductions were,0
ZYDELIG,rash,or colitis rash,1
ZYDELIG,rash,common reasons for dose reductions were,0
ZYDELIG,rash,rash Table and Table,1
ZYDELIG,rash,rash Table and Table summarize,1
ZYDELIG,rash,rash Table and Table,1
ZYDELIG,rash,rash Table and Table summarize,1
ZYDELIG,rash,abnormalities reported,0
ZYDELIG,rash,abnormalities reported f,0
ZYDELIG,rash,Table summarize,0
ZYDELIG,rash,colitis rash Table and,1
ZYDELIG,rash,Table summarize,0
ZYDELIG,neutrophil count decreased,neutrophil count decreased lymphocyte,1
ZYDELIG,neutrophil count decreased,neutrophil count decreased,1
ZYDELIG,neutrophil count decreased,neutrophil count decreased lymphocyte co,1
ZYDELIG,neutrophil count decreased,version R rituximab Hematology neutrophil count decreased lymphocyte co,1
ZYDELIG,neutrophil count decreased,neutrophil count decreased lymphocyte co,1
ZYDELIG,neutrophil count decreased,R,0
ZYDELIG,lymphocyte count decreased,unt,0
ZYDELIG,lymphocyte count increased,lymphocyte count,1
ZYDELIG,lymphocyte count increased,lymphocyte count increased,1
ZYDELIG,lymphocyte count increased,lymphocyte,1
ZYDELIG,lymphocyte count increased,unt lymphocyte count,1
ZYDELIG,lymphocyte count increased,decreased,0
ZYDELIG,lymphocyte count increased,lymphocyte count increased,1
ZYDELIG,lymphocyte count increased,decreased,0
ZYDELIG,lymphocyte count increased,count increased Serum,1
ZYDELIG,lymphocyte count increased,lymphocyte count increased Serum,1
ZYDELIG,pneumonia,pneumonia diarrhea and pyrexia Adverse,1
ZYDELIG,pneumonia,pneumonia diarrhea,1
ZYDELIG,pneumonia,pneumonia diarrhea and pyrexia Adverse,1
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,reactions that occurred pneumonia,1
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,The,0
ZYDELIG,pneumonia,pneumonia,1
ZYDELIG,pneumonia,pneumonia diarrhea and pyrexia Adverse reactions,1
ZYDELIG,diarrhea,pneumonia,0
ZYDELIG,diarrhea,diarrhea and pyrexia Adverse reactions resulted,1
ZYDELIG,diarrhea,reactions that occurred were diarrhea,1
ZYDELIG,diarrhea,diarrhea and pyrexia Adverse reactions resulted,1
ZYDELIG,diarrhea,diarrhea and,1
ZYDELIG,diarrhea,diarrhea and pyrexia Adverse,1
ZYDELIG,diarrhea,in interruption,0
ZYDELIG,diarrhea,that occurred were diarrhea and pyrexia Adverse,1
ZYDELIG,diarrhea,in interruption,0
ZYDELIG,diarrhea,occurred were diarrhea and,1
ZYDELIG,diarrhea,in interruption,0
ZYDELIG,pyrexia,adverse reactions,0
ZYDELIG,pyrexia,most frequent serious,0
ZYDELIG,pyrexia,interruption or discontinuation for,0
ZYDELIG,pyrexia,pyrexia Adverse reactions resulted in interruption,1
ZYDELIG,diarrhea,for interruption or discontinuations diarrhea pneumonia and elevated,1
ZYDELIG,diarrhea,pyrexia Adverse reactions resulted in interruption,1
ZYDELIG,diarrhea,diarrhea pneumonia and elevated,1
ZYDELIG,diarrhea,discontinuations diarrhea pneumonia and elevated,1
ZYDELIG,diarrhea,diarrhea pneumonia and elevated,1
ZYDELIG,diarrhea,or,0
ZYDELIG,diarrhea,diarrhea pneumonia,1
ZYDELIG,diarrhea,Table provides the adverse reaction,0
ZYDELIG,diarrhea,for interruption or discontinuations were,0
ZYDELIG,diarrhea,ntinuation,0
ZYDELIG,diarrhea,subjects The most common reasons for interruption,0
ZYDELIG,diarrhea,diarrhea pneumonia,1
ZYDELIG,elevated transaminases,pneumonia elevated transaminases Table provides the adverse reactions,1
ZYDELIG,elevated transaminases,diarrhea pneumonia,1
ZYDELIG,elevated transaminases,elevated transaminases Table provides,1
ZYDELIG,elevated transaminases,diarrhea pneumonia,1
ZYDELIG,elevated transaminases,elevated transaminases Table provides the,1
ZYDELIG,elevated transaminases,or discontinuations were diarrhea pneumonia,0
ZYDELIG,elevated transaminases,were diarrhea pneumonia,0
ZYDELIG,elevated transaminases,elevated transaminases Table,1
ZYDELIG,upper respiratory tract infection,Respiratory thoracic,0
ZYDELIG,FATAL,ADVERSE REACTIONS The,0
ZYDELIG,FATAL, foll owing serious adverse reactions,1
ZYDELIG,FATAL,REACTIONS The,0
ZYDELIG,FATAL,The,0
ZYDELIG,FATAL,REACTIONS  foll owing serious,1
ZYDELIG,FATAL,The,0
ZYDELIG,FATAL, foll owing serious,1
ZYDELIG,FATAL,ADVERSE REACTIONS  foll owing,1
ZYDELIG,FATAL, foll owing serious,1
ZYDELIG,FATAL,REACTIONS The,0
ZYDELIG,FATAL, foll owing serious adverse,1
ZYDELIG,FATAL,ADVERSE REACTIONS The,0
ZYDELIG,TOXICITIES,serious,0
ZYDELIG,TOXICITIES,The following,0
ZYDELIG,TOXICITIES,following adverse r,1
ZYDELIG,TOXICITIES,REACTIONS The following  adverse r,1
ZYDELIG,TOXICITIES,following adverse r,1
ZYDELIG,TOXICITIES,following  adverse r eactions have,1
ZYDELIG,TOXICITIES,following adverse r,1
ZYDELIG,TOXICITIES,adverse r eactions have,1
ZYDELIG,TOXICITIES,REACTIONS The following adverse r,1
ZYDELIG,COLITIS,been d with,1
ZYDELIG,COLITIS,are discussed in greater detail in other sections of the,0
ZYDELIG,COLITIS,have been d with  Zydelig in,1
ZYDELIG,COLITIS,are discussed in greater detail in other sections of the,0
ZYDELIG,COLITIS,and are discussed in greater detail in,0
ZYDELIG,COLITIS,d with Zydelig in clinical trials and,1
ZYDELIG,COLITIS,reactions have been d with  Zydelig in,1
ZYDELIG,COLITIS,d with Zydelig in clinical trials and,1
ZYDELIG,COLITIS,d with,1
ZYDELIG,COLITIS,greater detail in,0
ZYDELIG,COLITIS,have been,0
ZYDELIG,PNEUMONITIS,discussed in,0
ZYDELIG,PNEUMONITIS,the prescribing,0
ZYDELIG,PNEUMONITIS,The following serious adverse reactions have been associated,0
ZYDELIG,PNEUMONITIS,adverse reactions have,0
ZYDELIG,PNEUMONITIS,and are discussed in,0
ZYDELIG,PNEUMONITIS,The following serious adverse reactions have been,0
ZYDELIG,INTESTINAL PERFORATION,clinical,0
ZYDELIG,INTESTINAL PERFORATION,trials and are discuss ed,1
ZYDELIG,INTESTINAL PERFORATION,detail in,0
ZYDELIG,INTESTINAL PERFORATION,and are discuss ed,1
ZYDELIG,INTESTINAL PERFORATION,associated with Zydelig in trials and,1
ZYDELIG,INTESTINAL PERFORATION,associated with Zydelig in trials and are,1
ZYDELIG,INTESTINAL PERFORATION,associated with Zydelig in clinical,0
ZYDELIG,INTESTINAL PERFORATION,reactions have been associated with,0
ZYDELIG,INTESTINAL PERFORATION,sections of the prescribing information Hepatotoxicity,0
ZYDELIG,FATAL, deta,1
ZYDELIG,FATAL,sections of the prescribing information Hepatotoxicity,0
ZYDELIG,FATAL,sections of the prescribing information Hepatotoxicity see Warnings and,0
ZYDELIG,FATAL,clinical trials and are discussed in greater,0
ZYDELIG,FATAL,clinical trials and are discussed,0
ZYDELIG,FATAL,information Hepatotoxicity see Warnings and,0
ZYDELIG,FATAL, deta il in other,1
ZYDELIG,FATAL,greater,0
ZYDELIG,FATAL,are discussed in  deta il in other sections,1
ZYDELIG,FATAL,greater,0
ZYDELIG,DIARRHEA,on Hepatotoxicity see Warnings and Precautions Severe,0
ZYDELIG,DIARRHEA,nformati on Hepatotoxicity see Warnings and,1
ZYDELIG,DIARRHEA,in other sections of,0
ZYDELIG,DIARRHEA,detail in other sections of,0
ZYDELIG,DIARRHEA,nformati on Hepatotoxicity see Warnings,1
ZYDELIG,DIARRHEA,of the prescribing nformati on,1
ZYDELIG,DIARRHEA,nformati on Hepatotoxicity see Warnings,1
ZYDELIG,DIARRHEA,Hepatotoxicity see Warnings and Precautions,0
ZYDELIG,COLITIS,"the prescribing .



 * Hepatotoxicity see Warnings and",1
ZYDELIG,COLITIS,Hepatotoxicity see Warnings and Precautions,0
ZYDELIG,PNEUMONITIS,Hepatotoxic ity,1
ZYDELIG,PNEUMONITIS,see Warnings and Prec,0
ZYDELIG,PNEUMONITIS,Hepatotoxic,1
ZYDELIG,PNEUMONITIS,Diarrhea or Colitis see,0
ZYDELIG,PNEUMONITIS,Hepatotoxic ity,1
ZYDELIG,PNEUMONITIS,discussed in greater detail in other,0
ZYDELIG,INTESTINAL PERFORATION,the prescribing information Hepatotoxicity,0
ZYDELIG,INTESTINAL PERFORATION,Hepatotoxicity e Warnings,1
ZYDELIG,INTESTINAL PERFORATION,or,0
ZYDELIG,INTESTINAL PERFORATION,Hepatotoxicity e  Warnings and Precau tions Severe Diarrhea or,1
ZYDELIG,INTESTINAL PERFORATION,or,0
ZYDELIG,INTESTINAL PERFORATION,greater,0
ZYDELIG,INTESTINAL PERFORATION,prescribing information Hepatotoxicity e  Warnings and Precau tions Severe Diarrhea,1
ZYDELIG,INTESTINAL PERFORATION,greater,0
ZYDELIG,Fatal,see,0
ZYDELIG,Fatal,1) ] Severe Diarrhea or Colitis,1
ZYDELIG,Fatal,Precautions Pneumonitis see,0
ZYDELIG,Fatal,and 1),1
ZYDELIG,Fatal,see Warnings and 1)  ],1
ZYDELIG,Fatal,and 1),1
ZYDELIG,hepatotoxicity,Warnings and,0
ZYDELIG,hepatotoxicity,Warnings and Precautions Severe arrhea or Coli tis see Warnings and,1
ZYDELIG,hepatotoxicity,Warnings and,0
ZYDELIG,hepatotoxicity,and,0
ZYDELIG,hepatotoxicity,or Coli tis see Warnings and,1
ZYDELIG,hepatotoxicity,or Coli tis,1
ZYDELIG,hepatotoxicity,Hepatotoxicity,0
ZYDELIG,hepatotoxicity,arrhea or Coli tis,1
ZYDELIG,hepatotoxicity,Hepatotoxicity,0
ZYDELIG,hepatotoxicity,Warnings and Precautions Pneumonitis,0
ZYDELIG,hepatotoxicity,Precautions Pneumonitis see Warnings and,0
ZYDELIG,hepatotoxicity,escribing information Hepatotoxicity see Warnings and Precautions Severe Di,0
ZYDELIG,Fatal,"]  
 ",1
ZYDELIG,Fatal,"Warnings and ]  
  Anaphylaxis see Warnings and Precautions",1
ZYDELIG,Fatal,"]  
 ",1
ZYDELIG,Fatal,"see Warnings and ]  
  Anaphylaxis see Warnings and",1
ZYDELIG,Fatal,"]  
 ",1
ZYDELIG,Fatal,"]  
  Anaphylaxis see",1
ZYDELIG,diarrhea,gs and P recautions Neutropenia see,1
ZYDELIG,diarrhea,"]  
  Anaphylaxis see",1
ZYDELIG,diarrhea,Warnings and Precautions EXCERPT,0
ZYDELIG,diarrhea,Anaphylaxis see gs and P,1
ZYDELIG,diarrhea,and P recautions Neutropenia see Warnings,1
ZYDELIG,diarrhea,recautions Neutropenia,0
ZYDELIG,diarrhea,and P,1
ZYDELIG,diarrhea,Warnings and Precautions,0
ZYDELIG,colitis,see,0
ZYDELIG,Fatal,pneumonia,0
ZYDELIG,Fatal,pain chills and rash he mo,1
ZYDELIG,Fatal,pneumonia,0
ZYDELIG,Fatal,abnormalities incidence,0
ZYDELIG,Fatal,rrhea pyrexia fatigue nausea cough pneumonia abdominal pain,0
ZYDELIG,Fatal,rash he mo st common laboratory,1
ZYDELIG,Fatal,rrhea pyrexia fatigue nausea cough pneumonia abdominal pain,0
ZYDELIG,pneumonitis,tigue nausea cough pneumonia abdominal pain chills and rash The most common,0
ZYDELIG,pneumonitis,oratory abn,1
ZYDELIG,pneumonitis,The most common oratory abn ormalities incidence are neutropenia,1
ZYDELIG,pneumonitis,oratory abn,1
ZYDELIG,pneumonitis,oratory abn ormalities incidence are neutropenia hypertriglyceridemia,1
ZYDELIG,pneumonitis,oratory,1
ZYDELIG,pneumonitis,are neutropenia hypertriglyceridemia,0
ZYDELIG,pneumonitis,oratory abn,1
ZYDELIG,pneumonitis,rash The most common oratory,1
ZYDELIG,pneumonitis,most common oratory abn ormalities incidence are neutropenia hypertriglyceridemia,1
ZYDELIG,pneumonitis,rash The most common oratory,1
ZYDELIG,pneumonitis,neutropenia,0
ZYDELIG,Fatal,To report SUSPECTED,0
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical,1
ZYDELIG,Fatal,contact Gilead Sciences Inc at,0
ZYDELIG,Fatal,or FDA,0
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch,1
ZYDELIG,Fatal,or FDA,0
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical Trial,1
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical,1
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical,1
ZYDELIG,Fatal,00-FD A or wwwfdagovmedwatch Clinical Trial,1
ZYDELIG,intestinal perforation,conducted,0
ZYDELIG,intestinal perforation,".fda.gov/medwatch  


 Clinical Trial",1
ZYDELIG,intestinal perforation,".fda.gov/medwatch  


 Clinical",1
ZYDELIG,FATAL,and may,0
ZYDELIG,FATAL,t be directly compared to rates,0
ZYDELIG,FATAL,rates observed,0
ZYDELIG,FATAL,compared to rates in the clinical trials of another drug and may,0
ZYDELIG,FATAL,be directly compared,0
ZYDELIG,FATAL,widely varying conditions adverse reaction rates observed in the clinical trials of,0
ZYDELIG,FATAL,varying conditions adverse reaction rates observed in the clinical trials of,0
ZYDELIG,FATAL,trials of a canno t be directly,1
ZYDELIG,FATAL,varying conditions adverse reaction rates observed in the clinical trials of,0
ZYDELIG,FATAL,the clinical,0
ZYDELIG,FATAL,clinical trials of another drug and,0
ZYDELIG,TOXICITIES,reflect the rates observed in,0
ZYDELIG,TOXICITIES, compared  to rates,1
ZYDELIG,TOXICITIES, compared  to rates in,1
ZYDELIG,TOXICITIES,ying conditions adverse reaction rates observed in the clinical trials of a drug cannot be,0
ZYDELIG,TOXICITIES, compared  to rates,1
ZYDELIG,TOXICITIES, compared  to rates,1
ZYDELIG,TOXICITIES,ying conditions adverse reaction rates,0
ZYDELIG,TOXICITIES,cannot be  compared  to,1
ZYDELIG,TOXICITIES,ying conditions adverse reaction rates,0
ZYDELIG,DIARRHEA,to rates in the inical t rials of another drug and,1
ZYDELIG,DIARRHEA,ying conditions adverse reaction rates,0
ZYDELIG,DIARRHEA,ction rates observed in the clinical trials of a drug cannot be directly compared to,0
ZYDELIG,DIARRHEA,directly compared to rates in the,0
ZYDELIG,DIARRHEA,a drug cannot be directly compared to rates in,0
ZYDELIG,DIARRHEA,rates in the inical,1
ZYDELIG,DIARRHEA,to rates in the inical t,1
ZYDELIG,DIARRHEA,rates in the inical,1
ZYDELIG,DIARRHEA,trials of a drug cannot be directly compared to rates in,0
ZYDELIG,DIARRHEA,in the inical t rials,1
ZYDELIG,DIARRHEA,trials of a drug cannot be directly compared to rates in,0
ZYDELIG,DIARRHEA,inical t,1
ZYDELIG,COLITIS,rates observed in practice,0
ZYDELIG,COLITIS,the clinical als of ,1
ZYDELIG,COLITIS,rates observed in practice,0
ZYDELIG,COLITIS,als of  another drug and,1
ZYDELIG,COLITIS,rates observed in practice,0
ZYDELIG,COLITIS,als of  another,1
ZYDELIG,COLITIS,rates observed in practice,0
ZYDELIG,COLITIS,in the clinical als,1
ZYDELIG,COLITIS,rates in the clinical als of  another drug,1
ZYDELIG,COLITIS,in the clinical als,1
ZYDELIG,PNEUMONITIS,clinical trials of other drug  and may not reflect the,1
ZYDELIG,PNEUMONITIS,in the clinical als,1
ZYDELIG,INTESTINAL PERFORATION,drug cannot be directly compared to rates in the clinical trials of another drug,0
ZYDELIG,INTESTINAL PERFORATION,and y,1
ZYDELIG,INTESTINAL PERFORATION,Clinical Trials in,0
ZYDELIG,Fatal,Trials in Chronic ic Le ukemia The safety data reflect,1
ZYDELIG,Fatal,Clinical Trials in,0
ZYDELIG,Fatal,ic Le,1
ZYDELIG,Fatal,in,0
ZYDELIG,hepatotoxicity,observed in practice Summary of Clinical Trials in,0
ZYDELIG,hepatotoxicity,Chronic Lymphocytic Leukemia he,1
ZYDELIG,hepatotoxicity,Clinical Trials in Chronic Lymphocytic Leukemia T,0
ZYDELIG,hepatotoxicity,he safety data,1
ZYDELIG,hepatotoxicity,of Clinical Trials in,0
ZYDELIG,hepatotoxicity,T,0
ZYDELIG,hepatotoxicity,in Chronic Lymphocytic Leukemia,0
ZYDELIG,hepatotoxicity,of Clinical Trials in,0
ZYDELIG,Fatal,mg daily The median,1
ZYDELIG,Fatal,of Clinical Trials in,0
ZYDELIG,Fatal,Serious adverse reactions were,0
ZYDELIG,diarrhea,were reported in subjects treated,0
ZYDELIG,diarrhea,of posure,1
ZYDELIG,diarrhea,were reported,0
ZYDELIG,diarrhea,The median duration of posure t o Zydelig was months,1
ZYDELIG,diarrhea,were reported,0
ZYDELIG,diarrhea,The median duration of posure,1
ZYDELIG,diarrhea,duration of posure,1
ZYDELIG,diarrhea,of posure t o Zydelig was months,1
ZYDELIG,diarrhea,duration of posure,1
ZYDELIG,colitis,delig w,1
ZYDELIG,colitis,without Zydelig mg twice daily The median duration of exposure to Zy,0
ZYDELIG,colitis,reactions were reported in subjects treated with Zydelig,0
ZYDELIG,colitis,to,0
ZYDELIG,Fatal,subjects treated with Zydelig were pneumonia pyrexia sepsis,0
ZYDELIG,Fatal,rted  for,1
ZYDELIG,Fatal,adverse reactions rted  for subjects treated,1
ZYDELIG,Fatal,rted  for,1
ZYDELIG,Fatal,rted  for subjects,1
ZYDELIG,Fatal,rted  for subjects treated,1
ZYDELIG,pneumonitis,adverse reactions reported for treated wit,1
ZYDELIG,pneumonitis,for treated wit h Zydelig,1
ZYDELIG,pneumonitis,adverse reactions reported for treated wit,1
ZYDELIG,Fatal,ig oc,1
ZYDELIG,Fatal,to discontinuation of Zydel,0
ZYDELIG,Fatal,led to discontinuation of ig oc,1
ZYDELIG,intestinal perforation,Zydelig occurred (10%) subjects. The mo st common,1
ZYDELIG,intestinal perforation,led to discontinuation of ig oc,1
ZYDELIG,intestinal perforation,The mo st,1
ZYDELIG,intestinal perforation,of Zydelig occurred (10%),1
ZYDELIG,intestinal perforation,diarrhea Adverse reactions that led to discontinuation of Zydelig occurred,0
ZYDELIG,intestinal perforation,occurred,0
ZYDELIG,cutaneous reactions,adverse actions have been a ssociated with,1
ZYDELIG,cutaneous reactions,occurred,0
ZYDELIG,Anaphylaxis,of the ibing infor,1
ZYDELIG,Neutropenia,see Warnings and Severe Dia,1
ZYDELIG,Neutropenia,Hepatotoxicity see Warnings and Severe,1
ZYDELIG,Neutropenia,Severe Dia rrhea or Colitis,1
ZYDELIG,Neutropenia,and  Severe Dia rrhea or Colitis see,1
ZYDELIG,Neutropenia,Severe Dia rrhea or Colitis,1
ZYDELIG,Neutropenia,rrhea or Colitis see,0
ZYDELIG,Embryo-fetal toxicity,see Warnings and,0
ZYDELIG,Embryo-fetal toxicity,and,0
ZYDELIG,Embryo-fetal toxicity,(5.2) ] Pneumonitis see Warnings and Precautions,1
ZYDELIG,Embryo-fetal toxicity,(5.2) ] Pneumonitis,1
ZYDELIG,fetal harm,and Precautions Pneumonit,0
ZYDELIG,fetal harm,and Precautions Intestinal Perforation see,0
ZYDELIG,fetal harm,and Precautions,0
ZYDELIG,fetal harm,is [see  W arnings and,1
ZYDELIG,fetal harm,and Precautions,0
ZYDELIG,Fatal,Precautions Severe Cutaneous [see  Warnings and Precautions Anaphylaxis,1
ZYDELIG,Fatal,and Precautions,0
ZYDELIG,Fatal,Cutaneous [see  Warnings,1
ZYDELIG,Fatal,and Precautions,0
ZYDELIG,Fatal,and Precautions Severe Cutaneous [see  Warnings and Precautions,1
ZYDELIG,Fatal,and Precautions,0
ZYDELIG,Fatal,[see  Warnings and,1
ZYDELIG,Fatal,[see  Warnings and Precautions Anaphylaxis,1
ZYDELIG,Fatal,Severe Cutaneous [see  Warnings and Precautions,1
ZYDELIG,Fatal,[see  Warnings and Precautions Anaphylaxis,1
ZYDELIG,hepatotoxicity,see Warnings and ecautions (5.5,1
ZYDELIG,hepatotoxicity,ecautions,1
ZYDELIG,hepatotoxicity,ecautions (5.5,1
ZYDELIG,hepatotoxicity,ecautions,1
ZYDELIG,hepatotoxicity,see Warnings and ecautions (5.5,1
ZYDELIG,hepatotoxicity,Warnings and Pr,0
ZYDELIG,hepatotoxicity,Reactions see,0
ZYDELIG,Elevations in ALT,Anaphylaxis see Warnings,0
ZYDELIG,Elevations in ALT,ns (5.6) ] * Neutropenia see Warnings and,1
ZYDELIG,Elevations in ALT,Precautio,0
ZYDELIG,Elevations in ALT,"Anaphylaxis see Warnings and ns (5.6)  ]  
 *  Neutropenia see Warnings",1
ZYDELIG,Elevations in ALT,Precautio,0
ZYDELIG,Elevations in ALT,Reactions see Warnings and Precautions Anaphylaxis see Warnings,0
ZYDELIG,Elevations in ALT,ns (5.6),1
ZYDELIG,Elevations in ALT,ns (5.6) ] * Neutropenia see Warnings and Precautions,1
ZYDELIG,Elevations in ALT,ous Reactions see Warnings and Precautions,0
ZYDELIG,Elevations in ALT,Warnings and ns (5.6) ] *,1
ZYDELIG,diarrhea,with relapsed LL recei,1
ZYDELIG,diarrhea,relapsed LL,1
ZYDELIG,diarrhea,LL recei ved up,1
ZYDELIG,diarrhea,to Zydelig,0
ZYDELIG,diarrhea,ved up to doses of,0
ZYDELIG,diarrhea,relapsed LL recei ved up to,1
ZYDELIG,diarrhea,ved up to doses of,0
ZYDELIG,diarrhea,or without Zydelig mg twice daily The median duration of ex,0
ZYDELIG,diarrhea,which subjects with relapsed LL recei ved,1
ZYDELIG,diarrhea,or without Zydelig mg twice daily The median duration of ex,0
ZYDELIG,diarrhea,LL recei,1
ZYDELIG,diarrhea,or without Zydelig mg twice daily The median duration of ex,0
ZYDELIG,diarrhea,rituximab,0
ZYDELIG,colitis,up to 8 doses of rituximab with,1
ZYDELIG,colitis,in,0
ZYDELIG,colitis,relapsed CLL up to 8 doses of rituximab,1
ZYDELIG,colitis,in,0
ZYDELIG,colitis,subjects with relapsed CLL up to 8 doses of rituximab,1
ZYDELIG,colitis,in,0
ZYDELIG,Diarrhea,median duration of exposure to Zydelig was,0
ZYDELIG,Diarrhea,treated with Zydelig were,0
ZYDELIG,Diarrhea,most fre quent,1
ZYDELIG,Diarrhea,with Zydelig rituximab most fre quent serious adverse,1
ZYDELIG,Diarrhea,most fre quent,1
ZYDELIG,Diarrhea,most fre,1
ZYDELIG,Diarrhea,with Zydelig rituximab most fre,1
ZYDELIG,Diarrhea,Zydelig rituximab most fre,1
ZYDELIG,Diarrhea,in subjects treated with,0
ZYDELIG,Diarrhea,most fre quent serious adverse reactions,1
ZYDELIG,Diarrhea,reactions were reported in,0
ZYDELIG,Diarrhea,Zydelig rituximab most fre,1
ZYDELIG,Fatal,tions that led to treatment,1
ZYDELIG,Fatal,reac,0
ZYDELIG,Fatal,that led to treatment discontinuations were hepatotoxicity and diarrheacolitis,0
ZYDELIG,Fatal,tions that led to treatment discontinuations,1
ZYDELIG,Fatal,tions,1
ZYDELIG,pneumonitis,were hepatotoxicity and diarrheacolitis Thirtynine subjects had dose in,0
ZYDELIG,pneumonitis,that led treatment,1
ZYDELIG,pneumonitis,adverse reactions that led treatment d,1
ZYDELIG,pneumonitis,and diarrheacolitis Thirtynine subjects,0
ZYDELIG,pneumonitis,ontinuation of Zydelig occurred in subjects The most common adverse reactions that led,0
ZYDELIG,Fatal,at Higher Incidence n Sub jects Receiving Zydelig Zydelig,1
ZYDELIG,Fatal,ontinuation of Zydelig occurred in subjects The most common adverse reactions that led,0
ZYDELIG,Fatal,Incidence n Sub jects Receiving Zydelig Zydelig RN,1
ZYDELIG,Fatal,ontinuation of Zydelig occurred in subjects The most common adverse reactions that led,0
ZYDELIG,Fatal,at Higher Incidence n Sub,1
ZYDELIG,Fatal,Table Adverse Reactions Reported in of CLL Patients and Occurred,0
ZYDELIG,Fatal,n Sub jects Receiving Zydelig,1
ZYDELIG,Fatal,Table Adverse Reactions Reported in of CLL Patients and Occurred,0
ZYDELIG,Fatal,n Sub jects Receiving Zydelig Zydelig RN,1
ZYDELIG,Fatal,n Sub jects,1
ZYDELIG,Fatal,at Higher Incidence n,1
ZYDELIG,intestinal perforation,Higher Incidence in Subjects ng Zydelig,1
ZYDELIG,intestinal perforation,"in Subjects ng Zydelig 
          ",1
ZYDELIG,intestinal perforation,Higher Incidence in Subjects ng Zydelig,1
ZYDELIG,intestinal perforation,in Subjects ng Zydelig,1
ZYDELIG,diarrhea,         Any Grade,1
ZYDELIG,diarrhea,RN Adverse          Any Grade Grade Any Grade,1
ZYDELIG,diarrhea,         Any Grade,1
ZYDELIG,diarrhea,RN Adverse          Any Grade Grade Any Grade,1
ZYDELIG,diarrhea,         Any Grade,1
ZYDELIG,diarrhea,Reaction,0
ZYDELIG,diarrhea,         Any Grade Grade Any,1
ZYDELIG,diarrhea,Grade Grade Any Grade Grade R rituximab,0
ZYDELIG,anaphylaxis,disorders headache,0
ZYDELIG,anaphylaxis,           ,1
ZYDELIG,anaphylaxis,            General,1
ZYDELIG,anaphylaxis,General,0
ZYDELIG,anaphylaxis,            General disorders and,1
ZYDELIG,anaphylaxis,General,0
ZYDELIG,teratogenic,            nasal congesti,1
SIMPONI,Infections,Infections see Warnings and Precautions,1
SIMPONI,Infections,serious adverse reactions were Infections,1
SIMPONI,Infections,Infections see Warnings and Precautions,1
SIMPONI,Infections,Infections see Warnings and Precautions,1
SIMPONI,Infections,Malignancies see Warnings and Precautions,0
SIMPONI,Infections,Infections see Warnings,1
SIMPONI,Infections,adverse reactions were Infections,1
SIMPONI,Infections,Infections see Warnings,1
SIMPONI,Infections,Precautions,0
SIMPONI,Infections,Infections see Warnings and Precautions,1
SIMPONI,Infections,Infections see Warnings,1
SIMPONI,Infections,ADVERSE REACTIONS The most serious,0
SIMPONI,Malignancies,Malignancies,1
SIMPONI,Malignancies,Most common,0
SIMPONI,upper respiratory tract infection,viral infection bronchitis hypertension and rash,0
SIMPONI,upper respiratory tract infection,reactions,0
SIMPONI,upper respiratory tract infection,upper respiratory tract infection,1
SIMPONI,upper respiratory tract infection,bronchitis,0
SIMPONI,upper respiratory tract infection,upper respiratory tract infection viral infection bronchitis,1
SIMPONI,upper respiratory tract infection,upper respiratory tract infection viral infection,1
SIMPONI,upper respiratory tract infection,common adverse reactions incidence upper respiratory tract infection viral infection,1
SIMPONI,upper respiratory tract infection,upper respiratory tract infection viral infection,1
SIMPONI,upper respiratory tract infection,adverse reactions incidence upper respiratory tract,1
SIMPONI,upper respiratory tract infection,reactions incidence upper respiratory tract infection,1
SIMPONI,viral infection,common adverse reactions incidence are,0
SIMPONI,viral infection,viral infection bronchitis hypertension and,1
SIMPONI,viral infection,viral infection bronchitis hypertension,1
SIMPONI,viral infection,tract viral infection bronchitis hypertension and rash,1
SIMPONI,viral infection,viral infection bronchitis hypertension,1
SIMPONI,viral infection,Most common adverse reactions incidence are upper,0
SIMPONI,viral infection,tract viral infection,1
SIMPONI,viral infection,bronchitis,0
SIMPONI,viral infection,common adverse reactions incidence are upper,0
SIMPONI,viral infection,upper respiratory tract,0
SIMPONI,viral infection,viral infection bronchitis hypertension,1
SIMPONI,bronchitis,bronchitis hypertension and rash,1
SIMPONI,bronchitis,infection viral bronchitis hypertension and,1
SIMPONI,bronchitis,bronchitis hypertension and rash,1
SIMPONI,bronchitis,bronchitis hypertension and rash,1
SIMPONI,bronchitis,respiratory tract infection viral bronchitis hypertension and rash To report,1
SIMPONI,bronchitis,bronchitis hypertension and rash,1
SIMPONI,hypertension,hypertension and,1
SIMPONI,hypertension,To report SUSPECTED,0
SIMPONI,rash,rash,1
SIMPONI,rash,rash To report SUSPECTED ADVERSE REACTIONS,1
SIMPONI,rash,rash To,1
SIMPONI,rash,rash To report SUSPECTED ADVERSE REACTIONS,1
SIMPONI,rash,rash To report,1
SIMPONI,rash,rash To report SUSPECTED ADVERSE REACTIONS,1
SIMPONI,rash,rash To report SUSPECTED,1
SIMPONI,Upper respiratory tract infection,patients and for,0
SIMPONI,Upper respiratory tract infection,placebotreated Upper respiratory tract infection was the most,1
SIMPONI,Upper respiratory tract infection,patients and for,0
SIMPONI,Upper respiratory tract infection,Upper respiratory tract infection was the most,1
SIMPONI,Upper respiratory tract infection,patients and for placebotreated,0
SIMPONI,Upper respiratory tract infection,for placebotreated Upper respiratory tract infection was the,1
SIMPONI,Upper respiratory tract infection,patients and for placebotreated,0
SIMPONI,Upper respiratory tract infection,placebotreated Upper respiratory tract infection was the,1
SIMPONI,Upper respiratory tract infection,patients and for placebotreated,0
SIMPONI,infections,infections observed in SIMPONI ARIAtreated patients,1
SIMPONI,infections,SIMPONI ARIAtreated patients included sepsis pneumonia cellulitis abscess,0
SIMPONI,infections,infections observed in,1
SIMPONI,infections,infections observed in SIMPONI,1
SIMPONI,sepsis,Infections Serious infections observed in,0
SIMPONI,sepsis,sepsis pneumonia,1
SIMPONI,sepsis,sepsis pneumonia,1
SIMPONI,sepsis,ARIAtreated patients,0
SIMPONI,sepsis,sepsis pneumonia cellulitis abscess opportunistic,1
SIMPONI,pneumonia,opportunistic infections tuberculosis TB and invasive,0
SIMPONI,cellulitis,cellulitis abscess opportunistic infections tuberculosis TB,1
SIMPONI,cellulitis,patients included sepsis cellulitis abscess,1
SIMPONI,cellulitis,cellulitis abscess opportunistic infections tuberculosis TB,1
SIMPONI,cellulitis,cellulitis abscess opportunistic infections tuberculosis,1
SIMPONI,cellulitis,ions Serious infections observed in SIMPONI ARIAtreated patients included,0
SIMPONI,cellulitis,cellulitis abscess opportunistic,1
SIMPONI,cellulitis,cellulitis abscess opportunistic infections,1
SIMPONI,cellulitis,cellulitis abscess opportunistic infections,1
SIMPONI,cellulitis,cellulitis abscess opportunistic infections,1
SIMPONI,cellulitis,sepsis pneumonia,0
SIMPONI,cellulitis,cellulitis abscess,1
SIMPONI,cellulitis,cellulitis abscess opportunistic infections tuberculosis,1
SIMPONI,abscess,patients included sepsis pneumonia abscess opportunistic infections,1
SIMPONI,abscess,cellulitis abscess opportunistic infections tuberculosis,1
SIMPONI,abscess,infections tuberculosis TB and invasive,0
SIMPONI,abscess,of TB,0
SIMPONI,opportunistic infections,included sepsis pneumonia cellulitis opportunistic infections,1
SIMPONI,opportunistic infections,opportunistic infections tuberculosis,1
SIMPONI,opportunistic infections,cellulitis abscess,0
SIMPONI,opportunistic infections,pneumonia cellulitis opportunistic,1
SIMPONI,opportunistic infections,cellulitis opportunistic,1
SIMPONI,opportunistic infections,in SIMPONI ARIAtreated,0
SIMPONI,opportunistic infections,opportunistic infections tuberculosis,1
SIMPONI,opportunistic infections,opportunistic infections,1
SIMPONI,opportunistic infections,fungal infections Cases of TB included,0
SIMPONI,tuberculosis,abscess,0
SIMPONI,tuberculosis,extrapulmonary TB The maj,0
SIMPONI,tuberculosis,tuberculosis TB and invasive fungal,1
SIMPONI,tuberculosis,TB,0
SIMPONI,tuberculosis,included pulmonary and extrapulmonary TB The maj,0
SIMPONI,tuberculosis,infections,0
SIMPONI,tuberculosis,and extrapulmonary TB,0
SIMPONI,TB,TB included pulmonary and extrapulmonary,1
SIMPONI,TB,TB included pulmonary and extrapulmonary TB,1
SIMPONI,TB,TB included pulmonary and extrapulmonary TB,1
SIMPONI,TB,TB included,1
SIMPONI,TB,TB included pulmonary and,1
SIMPONI,extrapulmonary TB,infections Cases,0
SIMPONI,extrapulmonary TB,incidence rate,0
SIMPONI,extrapulmonary TB,of the TB,0
SIMPONI,extrapulmonary TB,extrapulmonary TB The majority of,1
SIMPONI,extrapulmonary TB,extrapulmonary TB The,1
SIMPONI,TB,the,0
SIMPONI,TB,TB cases occurred in countries,1
SIMPONI,TB,see Warnings and,0
SIMPONI,TB,Cases of TB included pulmonary and extrapulmonary,0
SIMPONI,TB,The majority of TB cases occurred in countries with,1
SIMPONI,TB,Cases of TB included pulmonary and extrapulmonary,0
SIMPONI,TB,in countries with a high,0
SIMPONI,TB,majority of TB cases,1
SIMPONI,TB,in countries with a high,0
SIMPONI,TB,TB The,0
SIMPONI,TB,cases occurred in countries with a high incidence rate of TB,0
SIMPONI,TB,occurred in countries with a high incidence rate of TB,0
SIMPONI,infections,infections were observed,1
SIMPONI,infections,compared with of controltreated,0
SIMPONI,infections,infections were observed in of SIMPONI,1
SIMPONI,infections,SIMPONI ARIAtreated patients compared with of,0
SIMPONI,infections,patients compared with of controltreated,0
SIMPONI,infections,Precautions In the controlled phase,0
SIMPONI,infections,infections,1
SIMPONI,infections,Precautions In the controlled phase,0
SIMPONI,infections,patients,0
SIMPONI,infections,infections were observed,1
SIMPONI,infections,controltreated patients and infections,1
SIMPONI,infections,infections were observed,1
SIMPONI,infections,controltreated patients and infections were observed in of SIMPONI,1
SIMPONI,infections,infections were observed,1
SIMPONI,infections,controltreated patients and infections were,1
SIMPONI,infections,infections were observed,1
SIMPONI,infections,infections,1
SIMPONI,infections,infections,1
SIMPONI,infections,infections,1
SIMPONI,infections,receiving,0
SIMPONI,infections,patients receiving SIMPONI ARIA,0
SIMPONI,infections,infections was CI in patients,1
SIMPONI,infections,infections was CI in patients,1
SIMPONI,infections,infections was CI in patients,1
SIMPONI,infections,infections was CI in patients,1
SIMPONI,infections,infections was,1
SIMPONI,infections,infections was CI in patients,1
SIMPONI,infections,infections was CI in patients receiving,1
SIMPONI,infections,per patientyears of all infections was CI in patients receiving,1
SIMPONI,infections,infections was CI in patients receiving,1
SIMPONI,active TB,was CI and,0
SIMPONI,active TB,incidence active TB per,1
SIMPONI,active TB,was CI and,0
SIMPONI,opportunistic infections,opportunistic infections per patientyears was CI Malignancies,1
SIMPONI,opportunistic infections,was CI and,0
SIMPONI,opportunistic infections,opportunistic infections per patientyears,1
SIMPONI,opportunistic infections,per patientyears was,0
SIMPONI,opportunistic infections,opportunistic,1
SIMPONI,opportunistic infections,was,0
SIMPONI,malignancy,with SIMPONI ARIA was reported through Week,0
SIMPONI,malignancy,Malignancies One case malignancy other,1
SIMPONI,malignancy,with SIMPONI ARIA was reported through Week,0
SIMPONI,malignancy,CI Malignancies One case malignancy other than,1
SIMPONI,malignancy,with SIMPONI ARIA was reported through Week,0
SIMPONI,malignancy,SIMPONI ARIA,0
SIMPONI,lymphoma,lymphoma,1
SIMPONI,lymphoma,lymphoma and,1
SIMPONI,lymphoma,lymphoma,1
SIMPONI,lymphoma,lymphoma and NMSC,1
SIMPONI,lymphoma,other,0
SIMPONI,lymphoma,through Week during,0
SIMPONI,lymphoma,lymphoma and NMSC with SIMPONI ARIA,1
SIMPONI,NMSC,Malignancies One,0
SIMPONI,malignancies,malignancies per,1
SIMPONI,malignancies,malignancies,1
SIMPONI,malignancies,ial In the controlled and uncontrolled portions through approximately weeks the incidence,0
SIMPONI,malignancies,than lymphoma and NMSC,0
SIMPONI,malignancies,malignancies per patientyears other,1
SIMPONI,malignancies,malignancies per,1
SIMPONI,malignancies,approximately weeks the incidence malignancies per patientyears other than,1
SIMPONI,malignancies,malignancies per,1
SIMPONI,malignancies,NMSC,0
SIMPONI,lymphoma,per patientyears other lymphoma and,1
SIMPONI,lymphoma,NMSC,0
SIMPONI,lymphoma,lymphoma and NMSC in SIMPONI,1
SIMPONI,lymphoma,NMSC,0
SIMPONI,lymphoma,lymphoma and NMSC,1
SIMPONI,lymphoma,NMSC,0
SIMPONI,lymphoma,per patientyears other,0
SIMPONI,lymphoma,the incidence of NMSC,0
SIMPONI,lymphoma,lymphoma and NMSC,1
SIMPONI,lymphoma,lymphoma and NMSC in,1
SIMPONI,lymphoma,SIMPONI ARIAtreated patients was CI and the,0
SIMPONI,NMSC,NMSC in SIMPONI ARIAtreated,1
SIMPONI,NMSC,CI Liver Enzyme Elevations There have been,0
SIMPONI,NMSC,NMSC was CI,1
SIMPONI,NMSC,NMSC was CI,1
SIMPONI,NMSC,incidence,0
SIMPONI,NMSC,There have,0
SIMPONI,NMSC,reports of,0
SIMPONI,NMSC,CI Liver Enzyme Elevations There have,0
SIMPONI,NMSC,NMSC was,1
SIMPONI,NMSC,have,0
SIMPONI,NMSC,Enzyme Elevations,0
SIMPONI,hepatic reactions,s CI Liver Enzyme Elevations There have,0
SIMPONI,hepatic reactions,failure in patients receiving TNFblockers In the controlled phase,0
SIMPONI,acute liver failure,acute liver failure,1
SIMPONI,acute liver failure,in patients receiving TNFblockers In,0
SIMPONI,acute liver failure,patients receiving TNFblockers In the controlled phase of,0
SIMPONI,acute liver failure,severe hepatic reactions acute liver failure in,1
SIMPONI,acute liver failure,patients receiving TNFblockers In the controlled phase of,0
SIMPONI,acute liver failure,hepatic reactions acute,1
SIMPONI,acute liver failure,acute liver failure in,1
SIMPONI,acute liver failure,of severe hepatic reactions acute liver failure in patients receiving TNFblockers In,1
SIMPONI,acute liver failure,acute liver failure in,1
SIMPONI,acute liver failure,acute liver failure in patients receiving TNFblockers In,1
SIMPONI,ALT elevations,receiving TNFblockers In the controlled phase,0
SIMPONI,ALT elevations,ALT elevations,1
SIMPONI,ALT elevations,ALT elevations ULN occurred,1
SIMPONI,ALT elevations,ALT elevations,1
SIMPONI,ALT elevations,of controltreated patients ALT elevations,1
SIMPONI,ALT elevations,ALT elevations ULN occurred in of,1
SIMPONI,ALT elevations,and,0
SIMPONI,ALT elevations,patients,0
SIMPONI,ALT elevations,ARIAtreated patients and,0
SIMPONI,lupus-like syndrome,lupus-like syndrome At Week in Trial,1
SIMPONI,lupus-like syndrome,of control patients were n,0
SIMPONI,lupus-like syndrome,associated with the formation of autoantibodies and rarely,0
SIMPONI,lupus-like syndrome,of,0
SIMPONI,lupus-like syndrome,the development of lupus-like,1
SIMPONI,lupus-like syndrome,of lupus-like syndrome At Week in Trial,1
SIMPONI,lupus-like syndrome,the development of lupus-like,1
SIMPONI,lupus-like syndrome,development,0
SIMPONI,newly ANA-positive,patients,0
SIMPONI,newly positive anti-dsDNA antibodies,no controltreated patients newly positive anti-dsDNA antibodies Administration Reactions,1
SIMPONI,newly positive anti-dsDNA antibodies,patients,0
SIMPONI,infusion reaction,were associated with infusion reaction compared,1
SIMPONI,infusion reaction,patients,0
SIMPONI,infusion reaction,infusions were associated with infusion reaction,1
SIMPONI,infusion reaction,patients,0
SIMPONI,infusion reaction,infusions were,0
SIMPONI,infusion reaction,of infusions,0
SIMPONI,infusion reaction,associated,0
SIMPONI,rash,patients rash No serious infusion reactions,1
SIMPONI,rash,associated,0
SIMPONI,rash,SIMPONI ARIA treated patients rash No serious,1
SIMPONI,rash,associated,0
SIMPONI,rash,rash No serious,1
SIMPONI,rash,SIMPONI ARIA treated patients rash No serious,1
SIMPONI,rash,rash No serious,1
SIMPONI,rash,Immunogenicity Antibodies to,0
SIMPONI,rash,rash No,1
SIMPONI,rash,was,0
SIMPONI,infusion reactions,was rash No infusion,1
SIMPONI,infusion reactions,was rash No infusion reactions were reported Immunogenicity Antibodies,1
SIMPONI,infusion reactions,was rash No infusion,1
SIMPONI,infusion reactions,ARIA were detected,0
SIMPONI,infusion reactions,rash No infusion reactions were reported Immunogenicity,1
SIMPONI,infusion reactions,ARIA were detected,0
SIMPONI,infusion reactions,group The most common infusion reaction in SIMPONI ARIA treated,0
SIMPONI,infusion reactions,infusion reactions were reported Immunogenicity Antibodies,1
SIMPONI,infusion reactions,group The most common infusion reaction in SIMPONI ARIA treated,0
SIMPONI,infusion reactions,No serious,0
SIMPONI,infusion reactions,infusion reactions were,1
SIMPONI,infusion reactions,No serious,0
SIMPONI,Upper respiratory tract infection,and Upper respiratory tract infection,1
SIMPONI,Upper respiratory tract infection,Upper respiratory tract infection such as upper respiratory tract,1
SIMPONI,upper respiratory tract infection,pharyngitis laryngitis,0
SIMPONI,upper respiratory tract infection,respiratory tract infection such upper,1
SIMPONI,upper respiratory tract infection,respiratory tract infection such upper respiratory tract infection nasopharyngitis pharyngitis laryngitis,1
SIMPONI,upper respiratory tract infection,respiratory tract infection such upper,1
SIMPONI,upper respiratory tract infection,upper respiratory tract infection nasopharyngitis,1
SIMPONI,upper respiratory tract infection,such upper respiratory tract infection,1
SIMPONI,upper respiratory tract infection,upper respiratory tract infection nasopharyngitis pharyngitis laryngitis and,1
SIMPONI,upper respiratory tract infection,such upper respiratory tract infection,1
SIMPONI,upper respiratory tract infection,respiratory tract infection such upper respiratory tract infection nasopharyngitis pharyngitis laryngitis and rhinitis,1
SIMPONI,upper respiratory tract infection,such upper respiratory tract infection,1
SIMPONI,upper respiratory tract infection,infection such upper respiratory,1
SIMPONI,upper respiratory tract infection,such as,0
SIMPONI,upper respiratory tract infection,Upper,0
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis and rhinitis,1
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis,1
SIMPONI,nasopharyngitis,pharyngitis,0
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis and,1
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis and rhinitis,1
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis and,1
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis and rhinitis,1
SIMPONI,nasopharyngitis,respiratory tract infection such as upper respiratory,0
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis,1
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis,1
SIMPONI,nasopharyngitis,nasopharyngitis pharyngitis laryngitis,1
SIMPONI,pharyngitis,respiratory,0
SIMPONI,pharyngitis,pharyngitis laryngitis and,1
SIMPONI,pharyngitis,respiratory,0
SIMPONI,pharyngitis,laryngitis and rhinitis Viral infec,0
SIMPONI,pharyngitis,and rhinitis Viral,0
SIMPONI,pharyngitis,pharyngitis laryngitis and rhinitis,1
SIMPONI,pharyngitis,and rhinitis Viral,0
SIMPONI,pharyngitis,pharyngitis laryngitis and rhinitis Viral,1
SIMPONI,pharyngitis,tract infection pharyngitis laryngitis and rhinitis Viral,1
SIMPONI,pharyngitis,pharyngitis laryngitis and rhinitis Viral,1
SIMPONI,laryngitis,respiratory tract infection nasopharyngitis laryngitis and rhinitis,1
SIMPONI,laryngitis,pharyngitis laryngitis and rhinitis Viral,1
SIMPONI,laryngitis,laryngitis and,1
SIMPONI,rhinitis,and,0
SIMPONI,rhinitis,rhinitis Viral infections such as,1
SIMPONI,rhinitis,infection nasopharyngitis pharyngitis laryngitis and,0
SIMPONI,rhinitis,as,0
SIMPONI,rhinitis,rhinitis Viral infections such,1
SIMPONI,rhinitis,and,0
SIMPONI,rhinitis,nasopharyngitis pharyngitis laryngitis rhinitis Viral infections,1
SIMPONI,rhinitis,and,0
SIMPONI,Viral infections,laryngitis and Viral infections,1
SIMPONI,Viral infections,Viral infections such,1
SIMPONI,Viral infections,and,0
SIMPONI,Viral infections,and herpes Bacteri,0
SIMPONI,Viral infections,Viral infections such as influenza,1
SIMPONI,Viral infections,pharyngitis laryngitis,0
SIMPONI,Viral infections,pharyngitis laryngitis and Viral infections,1
SIMPONI,Viral infections,Viral infections such as influenza and,1
SIMPONI,Viral infections,and rhinitis,0
SIMPONI,influenza,herpes Bacterial,0
SIMPONI,influenza,influenza,1
SIMPONI,influenza,nd rhinitis Viral infections,0
SIMPONI,herpes,influenza herpes Bacterial infections,1
SIMPONI,herpes,nd rhinitis Viral infections,0
SIMPONI,herpes,herpes Bacterial infections,1
SIMPONI,Superficial fungal infection,respiratory tract infection pneumonia pyelonephritis,0
SIMPONI,Superficial fungal infection,respiratory tract infection,0
SIMPONI,Superficial fungal infection,fungal infection sinusitis abscess lower,1
SIMPONI,Superficial fungal infection,respiratory tract,0
SIMPONI,sinusitis,sinusitis abscess lower respiratory tract infection,1
SIMPONI,sinusitis,abscess lower respiratory tract infection pneumonia,0
SIMPONI,sinusitis,pneumonia pyelonephritis,0
SIMPONI,sinusitis,and Infestations Superficial fungal sinusitis abscess,1
SIMPONI,sinusitis,pneumonia pyelonephritis,0
SIMPONI,sinusitis,and Infestations Superficial fungal sinusitis,1
SIMPONI,sinusitis,pneumonia pyelonephritis,0
SIMPONI,sinusitis,and Infestations Superficial fungal sinusitis,1
SIMPONI,sinusitis,pneumonia pyelonephritis,0
SIMPONI,sinusitis,sinusitis abscess,1
SIMPONI,sinusitis,abscess lower,0
SIMPONI,sinusitis,sinusitis abscess lower respiratory,1
SIMPONI,sinusitis,and Infestations Superficial fungal sinusitis abscess lower,1
SIMPONI,sinusitis,sinusitis abscess lower respiratory,1
SIMPONI,abscess,Infestations Superficial fungal infection abscess lower,1
SIMPONI,abscess,sinusitis abscess lower respiratory,1
SIMPONI,abscess,pneumonia pyelonephritis,0
SIMPONI,lower respiratory tract infection,Alanine aminotransferase increased aspartate,0
SIMPONI,lower respiratory tract infection,sinusitis lower respiratory tract infection,1
SIMPONI,lower respiratory tract infection,respiratory tract infection pneumonia pyelonephritis Investigations,1
SIMPONI,lower respiratory tract infection,fungal infection sinusitis lower respiratory tract infection,1
SIMPONI,pneumonia,Superficial,0
SIMPONI,pneumonia,aminotransferase increased aspartate,0
SIMPONI,pneumonia,pneumonia pyelonephritis Investigations Alanine aminotransferase increased,1
SIMPONI,pneumonia,pneumonia pyelonephritis Investigations Alanine,1
SIMPONI,pneumonia,pneumonia pyelonephritis Investigations Alanine,1
SIMPONI,pneumonia,pneumonia pyelonephritis Investigations Alanine,1
SIMPONI,pneumonia,Superficial fungal infection sinusitis abscess lower respiratory,0
SIMPONI,pneumonia,sinusitis abscess lower,0
SIMPONI,pneumonia,tract pneumonia pyelonephritis Investigations,1
SIMPONI,pneumonia,sinusitis abscess lower,0
SIMPONI,pyelonephritis,increased aspartate aminotransferase increased n,0
SIMPONI,pyelonephritis,aminotransferase increased n,0
SIMPONI,Alanine aminotransferase increased,infection pneumonia pyelonephritis Alanine aminotransferase,1
SIMPONI,Alanine aminotransferase increased,pyelonephritis Alanine aminotransferase increased,1
SIMPONI,Alanine aminotransferase increased,Alanine aminotransferase increased aspartate aminotransferase increased neutrophil,1
SIMPONI,Alanine aminotransferase increased,Alanine aminotransferase increased aspartate aminotransferase,1
SIMPONI,Alanine aminotransferase increased,aspartate aminotransferase increased neutrophil count decreased Nervous system disorders,0
SIMPONI,aspartate aminotransferase increased,pyelonephritis Investigations Alanine aminotransferase aspartate,1
SIMPONI,aspartate aminotransferase increased,pyelonephritis Investigations Alanine,0
SIMPONI,aspartate aminotransferase increased,disorders Dizziness,0
SIMPONI,aspartate aminotransferase increased,Dizziness,0
SIMPONI,aspartate aminotransferase increased,neutrophil count,0
SIMPONI,aspartate aminotransferase increased,Alanine aminotransferase,0
SIMPONI,aspartate aminotransferase increased,aspartate aminotransferase increased neutrophil count decreased Nervous system,1
SIMPONI,aspartate aminotransferase increased,Alanine aminotransferase,0
SIMPONI,aspartate aminotransferase increased,Alanine aminotransferase increased,0
SIMPONI,aspartate aminotransferase increased,aspartate aminotransferase increased neutrophil count decreased Nervous,1
SIMPONI,aspartate aminotransferase increased,Alanine aminotransferase increased,0
SIMPONI,neutrophil count decreased,aminotransferase,0
SIMPONI,neutrophil count decreased,aspartate aminotransferase neutrophil count decreased,1
SIMPONI,Dizziness,Dizziness,1
SIMPONI,Dizziness,paresthesia,0
SIMPONI,Dizziness,Dizziness paresthesia,1
SIMPONI,Dizziness,neutrophil count decreased,0
SIMPONI,Dizziness,Dizziness paresthesia,1
SIMPONI,Dizziness,Dizziness paresthesia,1
SIMPONI,Dizziness,Dizziness paresthesia,1
SIMPONI,paresthesia,Experience There is,0
SIMPONI,paresthesia,paresthesia Gastrointestinal,1
SIMPONI,paresthesia,Experience There is,0
SIMPONI,paresthesia,paresthesia Gastrointestinal disorders,1
SIMPONI,paresthesia,decreased Nervous system disorders paresthesia Gastrointestinal disorders,1
SIMPONI,paresthesia,paresthesia Gastrointestinal disorders,1
SIMPONI,paresthesia,Gastrointestinal,0
SIMPONI,paresthesia,Constipation Postmarketing Experience There is no,0
SIMPONI,paresthesia,disorders paresthesia Gastrointestinal disorders Constipation Postmarketing Experience,1
SIMPONI,paresthesia,Constipation Postmarketing Experience There is no,0
SIMPONI,paresthesia,decreased Nervous system disorders paresthesia Gastrointestinal disorders Constipation Postmarketing Experience,1
SIMPONI,paresthesia,Constipation Postmarketing Experience There is no,0
SIMPONI,Constipation,Constipation Postmarketing Experience There is no,1
SIMPONI,Constipation,disorders Dizziness paresthesia,0
SIMPONI,Constipation,no postmarketing experience,0
SIMPONI,Constipation,Gastrointestinal Constipation Postmarketing Experience There,1
SIMPONI,Constipation,no postmarketing experience,0
SIMPONI,Melanoma,Melanoma see,1
SIMPONI,Melanoma,no postmarketing experience,0
SIMPONI,Melanoma,Neoplasm Benign and Melanoma see Warnings and Precautions,1
SIMPONI,Melanoma,no postmarketing experience,0
SIMPONI,Melanoma,Malignant,0
SIMPONI,Melanoma,exposure Neoplasm Benign and Melanoma see Warnings and Precautions Immune,1
SIMPONI,Melanoma,Malignant,0
SIMPONI,Melanoma,exposure Neoplasm Benign and Melanoma see Warnings and,1
SIMPONI,Melanoma,Malignant,0
SIMPONI,Melanoma,System Disorders Serious systemic,0
SIMPONI,systemic hypersensitivity reactions,reaction see,0
SIMPONI,systemic hypersensitivity reactions,Disorders systemic hypersensitivity reactions including anaphylactic reaction,1
SIMPONI,systemic hypersensitivity reactions,reaction see,0
SIMPONI,systemic hypersensitivity reactions,Disorders systemic hypersensitivity reactions including anaphylactic reaction,1
SIMPONI,systemic hypersensitivity reactions,reaction see,0
SIMPONI,systemic hypersensitivity reactions,Disorders systemic hypersensitivity reactions including anaphylactic reaction see Warnings,1
SIMPONI,systemic hypersensitivity reactions,reaction see,0
SIMPONI,anaphylactic reaction,hypersensitivity reactions,0
SIMPONI,anaphylactic reaction,hypersensitivity reactions anaphylactic,1
SIMPONI,anaphylactic reaction,hypersensitivity reactions anaphylactic reaction see Warnings and Precautions,1
SIMPONI,anaphylactic reaction,hypersensitivity reactions anaphylactic,1
SIMPONI,anaphylactic reaction,Respiratory thoracic and,0
SIMPONI,anaphylactic reaction,anaphylactic reaction see Warnings and,1
SIMPONI,anaphylactic reaction,reactions anaphylactic reaction,1
SIMPONI,sarcoidosis,sarcoidosis Respiratory thoracic and,1
SIMPONI,sarcoidosis,sarcoidosis Respiratory thoracic and mediastinal,1
SIMPONI,sarcoidosis,sarcoidosis Respiratory thoracic and mediastinal,1
SIMPONI,sarcoidosis,Skin and s,0
SIMPONI,Interstitial lung disease,thoracic and mediastinal Interstitial,1
SIMPONI,Interstitial lung disease,Respiratory thoracic and mediastinal Interstitial lung disease Skin and,1
SIMPONI,Interstitial lung disease,thoracic and mediastinal Interstitial,1
SIMPONI,Interstitial lung disease,Interstitial lung disease Skin and subcutaneous,1
SIMPONI,Interstitial lung disease,and Precautions sarcoidosis,0
SIMPONI,Interstitial lung disease,Skin,0
SIMPONI,Interstitial lung disease,and mediastinal Interstitial lung disease Skin and subcutaneous tissue disorders,1
SIMPONI,Interstitial lung disease,Skin,0
SIMPONI,Interstitial lung disease,and mediastinal Interstitial lung disease Skin and,1
SIMPONI,Interstitial lung disease,Skin,0
SIMPONI,Skin exfoliation,Skin exfoliation bullous skin,1
SIMPONI,Skin exfoliation,bullous,0
SIMPONI,Skin exfoliation,tissue Skin,1
SIMPONI,Skin exfoliation,Skin exfoliation bullous skin,1
SIMPONI,Skin exfoliation,Skin exfoliation,1
SIMPONI,Skin exfoliation,Skin exfoliation bullous skin,1
SIMPONI,Skin exfoliation,Skin exfoliation,1
SIMPONI,Skin exfoliation,Skin and subcutaneous tissue,0
SIMPONI,INFECTIONS,ADVERSE REACTIONS The most rious adve rse reactions were Serious Infections,1
SIMPONI,INFECTIONS,Skin and subcutaneous tissue,0
SIMPONI,INFECTIONS,ections [s,1
SIMPONI,INFECTIONS,Skin and subcutaneous tissue,0
SIMPONI,INFECTIONS,Serious ections [s,1
SIMPONI,INFECTIONS,reactions were Serious ections [s ee Warnings and,1
SIMPONI,INFECTIONS,Serious ections [s,1
SIMPONI,INFECTIONS,ections [s ee,1
SIMPONI,INFECTIONS,Serious ections [s,1
SIMPONI,MALIGNANCY,arnings an d Precautions Malignancies,1
SIMPONI,MALIGNANCY,Precautions Malignancies see Warnings,0
SIMPONI,MALIGNANCY,Serious Infections see arnings an,1
SIMPONI,MALIGNANCY,Infections see arnings an d Precautions Malignancies see Warnings,1
SIMPONI,MALIGNANCY,Serious Infections see arnings an,1
SIMPONI,MALIGNANCY,Precautions Malignancies,0
SIMPONI,MALIGNANCY,arnings an d,1
SIMPONI,INFECTIONS,ancies [se,1
SIMPONI,INFECTIONS,Infections see Warnings and Precautions Malign,0
SIMPONI,MALIGNANCY,rnings and Precautions EXCERPT Most,1
SIMPONI,MALIGNANCY,Infections see Warnings and Precautions Malign,0
SIMPONI,MALIGNANCY,Malignancies see rnings,1
SIMPONI,MALIGNANCY,rnings and Precautions EXCERPT Most common adverse,1
SIMPONI,MALIGNANCY,Malignancies see rnings,1
SIMPONI,MALIGNANCY,Precautions EXCERPT Most common adverse,0
SIMPONI,MALIGNANCY,Precautions EXCERPT Most common adverse,0
SIMPONI,infections,common adverse reactions %) are:,1
SIMPONI,infections,are: up,1
SIMPONI,infections,%) are: up per respiratory,1
SIMPONI,death,", vir al",1
SIMPONI,death,upper respiratory,0
SIMPONI,death,", vir al",1
SIMPONI,death,upper respiratory,0
SIMPONI,death,"upper respiratory tract , vir al",1
SIMPONI,death,upper respiratory,0
SIMPONI,death,bronchitis hypertension and rash,0
SIMPONI,death,", vir al",1
SIMPONI,death,"are upper respiratory tract , vir",1
SIMPONI,tuberculosis,"n, bronchiti s hypertension and rash To",1
SIMPONI,tuberculosis,"n, bronchiti s",1
SIMPONI,tuberculosis,"n, bronchiti s hypertension and rash To",1
SIMPONI,tuberculosis,"n, bronchiti s hypertension and rash",1
SIMPONI,tuberculosis,tract infection,0
SIMPONI,TB,reactions,0
SIMPONI,TB,viral infection  h,1
SIMPONI,TB,reactions,0
SIMPONI,TB,rash To report SUSPECTED ADVERSE REACTIONS contactJanssen Biotech,0
SIMPONI,TB, h ypertension and rash To report,1
SIMPONI,TB,infection viral infection  h ypertension and,1
SIMPONI,TB, h ypertension and rash To report,1
SIMPONI,TB,viral infection  h ypertension and rash To report,1
SIMPONI,TB, h ypertension and rash To report,1
SIMPONI,bacterial sepsis,and ra,1
SIMPONI,bacterial sepsis,"infection bronchitis rtension, and",1
SIMPONI,bacterial sepsis,"infection bronchitis rtension,",1
SIMPONI,bacterial sepsis,contactJanssen Biotech Inc,0
SIMPONI,bacterial sepsis,and ra sh,1
SIMPONI,bacterial sepsis,"infection viral infection bronchitis rtension, and ra sh To",1
SIMPONI,bacterial sepsis,and ra sh,1
SIMPONI,bacterial sepsis,contactJanssen Biotech Inc at,0
SIMPONI,opportunistic infections,contactJanssen Biot ech Inc at JANSSEN or,1
SIMPONI,Lymphoma,and may,0
SIMPONI,Lymphoma,are based on,0
SIMPONI,Lymphoma,eflect t he,1
SIMPONI,Lymphoma,in the clinical trials of another drug and may,0
SIMPONI,Lymphoma,not eflect,1
SIMPONI,Lymphoma,and may not,0
SIMPONI,Lymphoma,may not eflect t,1
SIMPONI,Lymphoma,and may not,0
SIMPONI,Lymphoma,not eflect,1
SIMPONI,Lymphoma,eflect t,1
SIMPONI,malignancies,the rates served in cl inical practice The safety,1
SIMPONI,malignancies,eflect t,1
SIMPONI,malignancies,rates served in cl,1
SIMPONI,malignancies,The safety data described,0
SIMPONI,fatal,observed in pract ice The safety,1
SIMPONI,fatal,The safety data described,0
SIMPONI,fatal,pract,1
SIMPONI,fatal,observed in clinical,0
SIMPONI,fatal,The safety data described below are based on one,0
SIMPONI,fatal,pract ice The safety data,1
SIMPONI,fatal,pract ice The safety data,1
SIMPONI,fatal,rates observed in pract ice The safety data,1
SIMPONI,fatal,pract ice The safety data,1
SIMPONI,infections,patients taking ebo to rec eive treatment,1
SIMPONI,infections,pract ice The safety data,1
SIMPONI,infections,eive treatment with SIMPONI ARIA at Week or,0
SIMPONI,infections,The protocol included provisions for patients taking,0
SIMPONI,infections,provisions for patients taking ebo to rec eive treatment with,1
SIMPONI,infections,The protocol included provisions for patients taking,0
SIMPONI,infections,patients,0
SIMPONI,death,with SIMPONI ARIA at eek,1
SIMPONI,death,by design so,0
SIMPONI,death,receive treatment with SIMPONI ARIA,0
SIMPONI,death,eek 1 or Week either,1
SIMPONI,death,with,0
SIMPONI,death,with SIMPONI ARIA at eek 1 or Week either by patient,1
SIMPONI,death,with,0
SIMPONI,death,with SIMPONI ARIA at eek 1 or,1
SIMPONI,death,with,0
SIMPONI,infections,ONI ARIA at Week or Week either,0
SIMPONI,infections,on uncontrolled disease activity r by desig n so that adverse,1
SIMPONI,infections,ONI ARIA at Week or Week either,0
SIMPONI,infections,disease activity r by desig,1
SIMPONI,infections,by desig,1
SIMPONI,infections,by desig,1
SIMPONI,infections,uncontrolled disease activity r by,1
SIMPONI,infections,Week or Week,0
SIMPONI,Active tuberculosis,(which incl udes controltreated patients,1
SIMPONI,Active tuberculosis,atients (which incl udes controltreated patients who switched,1
SIMPONI,Active tuberculosis,(which incl udes controltreated patients,1
SIMPONI,Active tuberculosis,atients (which incl udes controltreated,1
SIMPONI,Active tuberculosis,patients and SIMPONI ARIAtreated atients (which incl udes controltreated patients,1
SIMPONI,Active tuberculosis,atients (which incl udes controltreated,1
SIMPONI,Active tuberculosis,of exposure,0
SIMPONI,tuberculosis,patients who discontinued treatment due to,0
SIMPONI,tuberculosis,to SIMPONI ARIA at eek 16).,1
SIMPONI,tuberculosis,adverse reactions in,0
SIMPONI,tuberculosis,to SIMPONI ARIA at eek,1
SIMPONI,tuberculosis,reactions in the,0
SIMPONI,tuberculosis,at eek 16).,1
SIMPONI,Invasive fungal infections,respiratory act infection was the,1
SIMPONI,Invasive fungal infections,respiratory act infection was the most common adverse reaction reported,1
SIMPONI,Invasive fungal infections,respiratory act infection was the,1
SIMPONI,Invasive fungal infections,Upper respiratory act infection was the most,1
SIMPONI,Invasive fungal infections,respiratory act infection was the,1
SIMPONI,Invasive fungal infections,was the most common,1
SIMPONI,Invasive fungal infections,patients Upper,0
SIMPONI,Invasive fungal infections,for SIMPONI ARIAtreated patients and for placebotreated patients Upper respiratory tr,0
SIMPONI,Invasive fungal infections,through Week occurring in of,0
SIMPONI,histoplasmosis,the most common rse,1
SIMPONI,histoplasmosis,rse reaction r eported in,1
SIMPONI,histoplasmosis,ts and for placebotreated,0
SIMPONI,histoplasmosis,reaction r eported in the trial through,1
SIMPONI,histoplasmosis,the most common rse reaction r eported in the,1
SIMPONI,histoplasmosis,reaction r eported in the trial through,1
SIMPONI,histoplasmosis,the most common rse reaction r,1
SIMPONI,histoplasmosis,reaction r eported in the trial through,1
SIMPONI,histoplasmosis,Week,0
SIMPONI,histoplasmosis,rse reaction r,1
SIMPONI,histoplasmosis,the most common rse reaction r eported in the,1
SIMPONI,histoplasmosis,rse reaction r,1
SIMPONI,histoplasmosis,the most,0
SIMPONI,coccidioidomycosis,reaction orted in,1
SIMPONI,coccidioidomycosis,rep,0
SIMPONI,coccidioidomycosis,most common adverse reaction orted in the,1
SIMPONI,candidiasis,hrough Week occurring in of,1
SIMPONI,candidiasis,as compared with of,0
SIMPONI,aspergillosis,4 occurring i,1
SIMPONI,aspergillosis,as compared with of,0
SIMPONI,aspergillosis,the trial through Week,0
SIMPONI,aspergillosis,the trial through 4 occurring i n of SIMPONI ARIAtreated,1
SIMPONI,aspergillosis,the trial through Week,0
SIMPONI,aspergillosis,patients,0
SIMPONI,aspergillosis,the trial through 4 occurring i,1
SIMPONI,aspergillosis,infection was,0
SIMPONI,aspergillosis,was the most common adverse reaction reported in,0
SIMPONI,aspergillosis,the trial through 4 occurring i,1
SIMPONI,aspergillosis,4 occurring i n of,1
SIMPONI,aspergillosis,SIMPONI ARIAtreated patients as compared with of,0
SIMPONI,blastomycosis,of SIMPO NI ARIAtreated,1
SIMPONI,blastomycosis,through Week occurring 6.5% of SIMPO NI ARIAtreated patients,1
SIMPONI,blastomycosis,of SIMPO NI ARIAtreated,1
SIMPONI,blastomycosis,of SIMPO NI ARIAtreated,1
SIMPONI,blastomycosis,ARIAtreated patients as compared with,0
SIMPONI,blastomycosis,of SIMPO NI ARIAtreated patients as compared,1
SIMPONI,blastomycosis,Week occurring 6.5% of SIMPO NI ARIAtreated patients as,1
SIMPONI,blastomycosis,of SIMPO NI ARIAtreated patients as compared,1
SIMPONI,blastomycosis,as compared,0
SIMPONI,blastomycosis,trial through Week occurring 6.5% of SIMPO,1
SIMPONI,blastomycosis,as compared,0
SIMPONI,blastomycosis,reaction reported in the,0
SIMPONI,pneumocystosis,adverse reaction reported in,0
SIMPONI,pneumocystosis,IA-treated pat ients as compared with of,1
SIMPONI,pneumocystosis,adverse reaction reported in,0
SIMPONI,pneumocystosis,IA-treated pat,1
SIMPONI,pneumocystosis,IA-treated pat ients as,1
SIMPONI,pneumocystosis,trial through,0
SIMPONI,pneumocystosis,of controltreated patients respectively Infections,0
SIMPONI,pneumocystosis,IA-treated pat ients as compared with of,1
SIMPONI,pneumocystosis,of controltreated patients respectively Infections,0
SIMPONI,pneumocystosis,IA-treated pat,1
SIMPONI,Lymphoma,ortions  of Trial total patientyears of,1
SIMPONI,Lymphoma,of Trial total patientyears of followup with a median followup of approximately weeks,0
SIMPONI,Lymphoma,placebo group In the controlled and uncontrolled p,0
SIMPONI,Lymphoma,patientyears of followup with,0
SIMPONI,Lymphoma,uncontrolled ortions  of Trial,1
SIMPONI,Lymphoma,patientyears of followup with,0
SIMPONI,malignancies,and uncontrolled portions of  958 total p,1
SIMPONI,malignancies,patientyears of followup with,0
SIMPONI,malignancies,portions of  958 total p atientyears of,1
SIMPONI,malignancies,patientyears of followup with,0
SIMPONI,fatal,Trial total years of followup with,1
SIMPONI,fatal,patientyears of followup with,0
SIMPONI,fatal,years of followup with a median,1
SIMPONI,fatal,Trial total years,1
SIMPONI,fatal,years of followup with a median,1
SIMPONI,fatal,of Trial total,0
SIMPONI,fatal,years of followup,1
SIMPONI,fatal,total years of followup with a median,1
SIMPONI,fatal,years of followup,1
SIMPONI,fatal,In the controlled,0
SIMPONI,fatal,of Trial total years of followup with,1
SIMPONI,fatal,In the controlled,0
SIMPONI,infections,see Warnings and Precautions Malignancies see Warnings an,0
SIMPONI,infections,most,0
SIMPONI,infections,"serious adverse s were:


 Serious Infections see Warnings",1
SIMPONI,infections,most,0
SIMPONI,infections,serious adverse s were:,1
SIMPONI,infections,"most serious adverse s were:


 Serious Infections see",1
SIMPONI,infections,serious adverse s were:,1
SIMPONI,infections,reaction,0
SIMPONI,infections,adverse s were:,1
SIMPONI,Invasive fungal infections,infection viral infection bronchitis hypertension and,0
SIMPONI,Invasive fungal infections,Most common adverse ns,1
SIMPONI,Invasive fungal infections,ns (incidence >=3%) are: u pper respiratory tract,1
SIMPONI,Invasive fungal infections,Most common adverse ns,1
SIMPONI,Invasive fungal infections,are: u,1
SIMPONI,Invasive fungal infections,tract infection viral infection bronchitis hypertension and,0
SIMPONI,Hepatitis B reactivation,or FDA at,1
SIMPONI,Hepatitis B reactivation,SUSPECTED ADVERSE REACTIONS contactJanssen Biotech Inc,0
SIMPONI,Hepatitis B reactivation,(1-800-526-7736) or FDA at,1
SIMPONI,Hepatitis B reactivation,REACTIONS contactJanssen Biotech Inc,0
SIMPONI,Hepatitis B reactivation,SUSPECTED ADVERSE,0
SIMPONI,Hepatitis B reactivation,Inc at  (1-800-526-7736) or FDA at,1
SIMPONI,Hepatitis B reactivation,SUSPECTED ADVERSE,0
SIMPONI,Hepatitis B reactivation,Experience Because c,0
SIMPONI,Hepatitis B reactivation,(1-800-526-7736) or FDA,1
SIMPONI,Malignancies,the clinical trials of a drug cannot be directly compared to rates,0
SIMPONI,Malignancies,"nditions, ad",1
SIMPONI,Malignancies,"nditions, ad verse reaction",1
SIMPONI,Malignancies,clinical trials are conducted under widely varying,0
SIMPONI,Malignancies,"nditions, ad verse",1
SIMPONI,Malignancies,verse reaction rates observed,0
SIMPONI,Malignancies,"nditions, ad verse reaction",1
SIMPONI,Malignancies,varying,0
SIMPONI,Malignancies,"varying nditions, ad",1
SIMPONI,lymphoma,varying conditions adverse reaction tes obse,1
SIMPONI,lymphoma,varying conditions adverse reaction tes obse,1
SIMPONI,lymphoma,tes,1
SIMPONI,lymphoma,adverse reaction tes obse rved,1
SIMPONI,lymphoma,tes,1
SIMPONI,lymphoma,in the clinical trials of a drug cannot be directly,0
SIMPONI,lymphoma,tes obse rved in the clinical,1
SIMPONI,lymphoma,tes,1
SIMPONI,lymphoma,to rates in the clinical,0
SIMPONI,lymphoma,under widely varying conditions,0
SIMPONI,lymphoma,reaction tes obse,1
SIMPONI,malignancies,ay not refle ct the rates observed in,1
SIMPONI,malignancies,ay not refle ct the rates,1
SIMPONI,malignancies,another drug and ay not refle ct the rates,1
SIMPONI,malignancies,ay not refle ct the rates,1
SIMPONI,malignancies,another drug and ay not refle,1
SIMPONI,malignancies,ay not refle ct,1
SIMPONI,malignancies,another drug and ay not refle,1
SIMPONI,malignancies,practice,0
SIMPONI,malignancies,clinical trials of another drug,0
SIMPONI,Heart failure,described,0
SIMPONI,Heart failure,not reflect the rates observed in clinical,0
SIMPONI,Heart failure,below are bas ed on,1
SIMPONI,Heart failure,not reflect the rates observed in clinical,0
SIMPONI,Heart failure,safety data below,1
SIMPONI,Heart failure,clinical practice The safety data,0
SIMPONI,Heart failure,data below,1
SIMPONI,Heart failure,below are bas ed on one randomized doubleblind,1
SIMPONI,Heart failure,below are bas ed on,1
SIMPONI,Heart failure,data below are bas ed on one randomized doubleblind,1
SIMPONI,Heart failure,below are bas ed on,1
SIMPONI,Hypersensitivity reactions,Week either by patient response based on,0
SIMPONI,systemic hypersensitivity reactions,uncontrolled disease activity or by design so that adv,0
SIMPONI,systemic hypersensitivity reactions,Week 16 or W,1
SIMPONI,systemic hypersensitivity reactions,based,0
SIMPONI,systemic hypersensitivity reactions,to receive treatmen,0
SIMPONI,systemic hypersensitivity reactions,taking placebo to receive t with SIMPONI ARIA at Week 16 or W,1
SIMPONI,systemic hypersensitivity reactions,16 or W eek either by,1
SIMPONI,systemic hypersensitivity reactions,to receive t with SIMPONI ARIA at Week,1
SIMPONI,anaphylaxis,Week or Week er by patie nt response based on,1
SIMPONI,anaphylaxis,to receive t with SIMPONI ARIA at Week,1
SIMPONI,anaphylaxis,receive,0
SIMPONI,anaphylaxis,isions for patients,0
SIMPONI,anaphylaxis,er by patie,1
SIMPONI,anaphylaxis,Week or Week er by patie,1
SIMPONI,anaphylaxis,activity,0
SIMPONI,anaphylaxis,by patie nt response based on uncontrolled,1
SIMPONI,anaphylaxis,by patie nt response based,1
SIMPONI,anaphylaxis,placebo to receive treatment with,0
SIMPONI,anaphylaxis,by patie nt response based,1
SIMPONI,infections,to a treatment. Comparisons,1
SIMPONI,infections,by patie nt response based,1
SIMPONI,infections,treatment. Comparisons between placebo and SIMPONI,1
SIMPONI,death,first of ex,1
SIMPONI,death,first of ex,1
SIMPONI,death,first of ex,1
SIMPONI,death,first of ex posure Trial included controltreated,1
SIMPONI,death,first of ex,1
SIMPONI,death,based,0
SIMPONI,death,the first,0
SIMPONI,Opportunistic infections,. Trial 1 included 1,1
SIMPONI,Opportunistic infections,.,1
SIMPONI,Opportunistic infections,includes,0
SIMPONI,aspergillosis,includes reated patien,1
SIMPONI,aspergillosis,includes reated,1
SIMPONI,aspergillosis,includes reated patien,1
SIMPONI,aspergillosis,SIMPONI ARIAtreated patients,0
SIMPONI,aspergillosis,of patients who discontinued treatment,0
SIMPONI,aspergillosis,reated patien ts,1
SIMPONI,aspergillosis,controltreated patients and SIMPONI ARIAtreated patients,0
SIMPONI,candidiasis,ARIAtreated patients which includes controltreated patients who switched,0
SIMPONI,candidiasis,o SIMPONI A,1
SIMPONI,candidiasis,controltreated patients who switched o SIMPONI,1
SIMPONI,candidiasis,controltreated patients who switched o SIMPONI A RIA at Week The proportion,1
SIMPONI,candidiasis,controltreated patients who switched o SIMPONI,1
SIMPONI,candidiasis,switched o SIMPONI A,1
SIMPONI,candidiasis,tients and SIMPONI,0
SIMPONI,coccidioidomycosis,who switched to SIMPONI,0
SIMPONI,coccidioidomycosis,SIMPONI A at Week 16). The,1
SIMPONI,coccidioidomycosis,who switched to SIMPONI,0
SIMPONI,coccidioidomycosis,switched to SIMPONI A at Week 16). The proportion of patients who discontinued,1
SIMPONI,coccidioidomycosis,who switched to SIMPONI,0
SIMPONI,coccidioidomycosis,switched to,0
SIMPONI,coccidioidomycosis,SIMPONI A,1
SIMPONI,coccidioidomycosis,SIMPONI A at Week 16). The proportion of,1
SIMPONI,coccidioidomycosis,SIMPONI A,1
SIMPONI,coccidioidomycosis,who switched to SIMPONI A at Week 16). The proportion of,1
SIMPONI,coccidioidomycosis,SIMPONI A,1
SIMPONI,histoplasmosis,who switched to SIMPONI ARIA,0
SIMPONI,histoplasmosis,The,0
SIMPONI,listeriosis,of patients who ntinued,1
SIMPONI,listeriosis,patients who ntinued tre,1
SIMPONI,listeriosis,Trial through Week was for SIMP,0
SIMPONI,listeriosis,of patients who ntinued tre,1
SIMPONI,listeriosis,Trial through Week was for SIMP,0
SIMPONI,listeriosis,who switched to SIMPONI ARIA at Week,0
SIMPONI,pneumocystosis,of patients,0
SIMPONI,pneumocystosis,patients who,0
SIMPONI,pneumocystosis,of patients who discontinued ment,1
SIMPONI,tuberculosis,adverse,0
SIMPONI,tuberculosis,reactions in the controlled phase,1
SIMPONI,tuberculosis,The proportion of patients who discontinued treatment due to,0
SIMPONI,tuberculosis,discontinued,0
SIMPONI,tuberculosis,SIMPONI ARIA at Week The proportion,0
SIMPONI,tuberculosis,SIMPONI ARIAtreated,0
SIMPONI,reactivation of tuberculosis,other opportunistic infections patient-years was 0.42 (95%  CI Malignancies,1
SIMPONI,reactivation of tuberculosis,SIMPONI ARIAtreated,0
SIMPONI,reactivation of tuberculosis,patient-years,1
SIMPONI,reactivation of tuberculosis,patient-years was 0.42 (95% CI Malignancies One case,1
SIMPONI,reactivation of tuberculosis,other opportunistic infections patient-years was,1
SIMPONI,reactivation of tuberculosis,patient-years was 0.42 (95% CI Malignancies,1
SIMPONI,reactivation of tuberculosis,case,0
SIMPONI,reactivation of tuberculosis,patient-years was 0.42 (95%,1
SIMPONI,new tuberculosis infections,"patientyears was 0.11, 1.07).



     Malign ancies",1
SIMPONI,new tuberculosis infections,patient-years was 0.42 (95%,1
SIMPONI,new tuberculosis infections,"0.11, 1.07).",1
SIMPONI,new tuberculosis infections,lymphoma and NMSC with SIMPONI ARIA was,0
SIMPONI,new tuberculosis infections,"0.11, 1.07). Malign ancies One case",1
SIMPONI,reactivation of hepatitis B virus,by,0
SIMPONI,reactivation of hepatitis B virus,golimumab and thus results are an underestimate of t he rate of product,1
SIMPONI,reactivation of hepatitis B virus,by,0
SIMPONI,reactivation of hepatitis B virus,The ELISA,0
SIMPONI,reactivation of hepatitis B virus,and thus results are an underestimate of t he rate of product immunogenicity,1
SIMPONI,reactivation of hepatitis B virus,The ELISA,0
SIMPONI,reactivation of hepatitis B virus,results are an underestimate of t he,1
SIMPONI,reactivation of hepatitis B virus,the sensitivity and specif,0
SIMPONI,reactivation of hepatitis B virus,underestimate of t he,1
SIMPONI,reactivation of hepatitis B virus,copresent golimumab and thus results are an underestimate of t he rate of product immunogenicity,1
SIMPONI,reactivation of hepatitis B virus,underestimate of t he,1
SIMPONI,HBV reactivation,the assay. Addit,1
SIMPONI,HBV reactivation,underestimate of t he,1
SIMPONI,HBV reactivation,and,0
SIMPONI,HBV reactivation,of antibody positivity in an,0
SIMPONI,HBV reactivation,dependent on the sensitivity,0
SIMPONI,HBV reactivation,the assay.,1
SIMPONI,HBV reactivation,the assay. Addit,1
SIMPONI,HBV reactivation,positivity in an assay,0
SIMPONI,HBV reactivation,the assay. Addit,1
SIMPONI,HBV reactivation,specificity,0
SIMPONI,Malignancies,herpes,0
SIMPONI,Malignancies,             Bacterial,1
SIMPONI,Malignancies,herpes,0
SIMPONI,Malignancies,herpes,0
SIMPONI,Malignancies,such as influenza and              Bacterial infections,1
SIMPONI,Malignancies,herpes,0
SIMPONI,fatal,      Bacterial,1
SIMPONI,fatal,     ,1
SIMPONI,fatal,      Bacterial,1
SIMPONI,fatal,Viral infections,0
SIMPONI,fatal,     ,1
SIMPONI,lymphoma,not appear in,0
SIMPONI,lymphoma,section included the lowing e,1
SIMPONI,lymphoma,not appear in,0
SIMPONI,lymphoma,lowing e vents,1
SIMPONI,lymphoma,section included,0
SIMPONI,lymphoma,through Week that do not,0
SIMPONI,lymphoma,There is,0
SIMPONI,lymphoma,"


   Ga",1
SIMPONI,lymphoma,"disorders Dizziness 


   Ga strointestinal disorders Constipation",1
SIMPONI,lymphoma,"


   Ga",1
SIMPONI,lymphoma,Nervous system,0
SIMPONI,lymphoma,increased neutrophil count,0
SIMPONI,chronic leukemia,Experience Th ere,1
SIMPONI,chronic leukemia,Gastrointestinal disorders Constipation Experience Th,1
SIMPONI,hepatosplenic T-cell lymphoma,estimate ir frequency or establish a c,1
SIMPONI,hepatosplenic T-cell lymphoma,Gastrointestinal disorders Constipation Experience Th,1
SIMPONI,hepatosplenic T-cell lymphoma,to golimumab exposure Neoplasm Benign and,0
SIMPONI,hepatosplenic T-cell lymphoma,to reliably estimate ir,1
SIMPONI,hepatosplenic T-cell lymphoma,to reliably estimate ir frequency or establish a c ausal relationship to golimumab,1
SIMPONI,hepatosplenic T-cell lymphoma,to reliably estimate ir,1
SIMPONI,hepatosplenic T-cell lymphoma,establish a c ausal,1
SIMPONI,hepatosplenic T-cell lymphoma,ir frequency or establish a c,1
SIMPONI,hepatosplenic T-cell lymphoma,establish a c ausal,1
SIMPONI,hepatosplenic T-cell lymphoma,reliably estimate ir frequency or establish,1
SIMPONI,HSTCL,sal r elationship to golimumab exposure,1
SIMPONI,HSTCL,sal r elationship to golimumab exposure,1
SIMPONI,HSTCL,is not always possible,0
SIMPONI,rare type of T-cell lymphoma,: Melanoma  [see  Warnings a nd Precautions Immune System Disorders,1
SIMPONI,rare type of T-cell lymphoma,is not always possible,0
SIMPONI,rare type of T-cell lymphoma,Benign and,0
SIMPONI,rare type of T-cell lymphoma,System Disorders Serious systemic hypersensitivity,0
SIMPONI,fatal,System rs :,1
SIMPONI,fatal,Serious systemic hypersensitivity reactions including anaphylactic reaction see Warnings,0
SIMPONI,fatal,rs :,1
SIMPONI,fatal,rs : Serious systemic hypersensitivity reactions including,1
SIMPONI,fatal,rs :,1
BLINCYTO,Cytokine Release Syndrome,Release Syndrome see,1
BLINCYTO,Cytokine Release Syndrome,the label,0
BLINCYTO,Cytokine Release Syndrome,see Warnings,0
BLINCYTO,Cytokine Release Syndrome,Release Syndrome see Warnings and,1
BLINCYTO,Cytokine Release Syndrome,Release Syndrome,1
BLINCYTO,Cytokine Release Syndrome,of the Cytokine,1
BLINCYTO,Cytokine Release Syndrome,discussed in,0
BLINCYTO,Cytokine Release Syndrome,Warnings and,0
BLINCYTO,Cytokine Release Syndrome,the Cytokine Release Syndrome,1
BLINCYTO,Neurological Toxicities,Warnings and Neurological Toxicities,1
BLINCYTO,Neurological Toxicities,and Neurological Toxicities see Warnings and Precautions,1
BLINCYTO,Neurological Toxicities,Warnings and Neurological Toxicities,1
BLINCYTO,Neurological Toxicities,Warnings,0
BLINCYTO,Neurological Toxicities,see Warnings and Precautions Infections see Warnings and,0
BLINCYTO,Neurological Toxicities,Syndrome see Warnings and Neurological Toxicities,1
BLINCYTO,Neurological Toxicities,Cytokine Release Syndrome see Warnings,0
BLINCYTO,Tumor Lysis Syndrome,Warnings,0
BLINCYTO,Tumor Lysis Syndrome,Tumor Lysis Syndrome see,1
BLINCYTO,Tumor Lysis Syndrome,Precautions,0
BLINCYTO,Tumor Lysis Syndrome,Warnings and Tumor Lysis Syndrome see Warnings and,1
BLINCYTO,Tumor Lysis Syndrome,Precautions,0
BLINCYTO,Tumor Lysis Syndrome,Warnings and Tumor Lysis Syndrome,1
BLINCYTO,Tumor Lysis Syndrome,and Febrile Neutropenia see Warnings,0
BLINCYTO,Tumor Lysis Syndrome,Febrile Neutropenia see,0
BLINCYTO,Neutropenia,Syndrome see Warnings and Neutropenia and Febrile Neutropenia,1
BLINCYTO,Neutropenia,Febrile Neutropenia see,0
BLINCYTO,Neutropenia,Febrile Neutropenia see Warnings and Precautions Effects on Ability,0
BLINCYTO,Neutropenia,Effects on Ability to Drive,0
BLINCYTO,Neutropenia,and Precautions,0
BLINCYTO,Neutropenia,Syndrome,0
BLINCYTO,Neutropenia,Neutropenia and,1
BLINCYTO,Neutropenia,Neutropenia and Febrile Neutropenia see,1
BLINCYTO,Neutropenia,Lysis,0
BLINCYTO,Neutropenia,Syndrome see,0
BLINCYTO,Neutropenia,Precautions,0
BLINCYTO,Febrile Neutropenia,Warnings and Precautions Neutropenia Febrile Neutropenia,1
BLINCYTO,Effects on Ability to Drive,Neutropenia and Febrile Neutropenia see Warnings,0
BLINCYTO,Effects on Ability to Drive,and Effects on Ability to,1
BLINCYTO,Effects on Ability to Drive,on Ability to Drive and Use Machines,1
BLINCYTO,Effects on Ability to Drive,Warnings and Effects on,1
BLINCYTO,Effects on Ability to Drive,Enzymes,0
BLINCYTO,Effects on Ability to Drive,Neutropenia see Warnings and Effects on Ability to Drive and Use Machines,1
BLINCYTO,Effects on Ability to Drive,Enzymes,0
BLINCYTO,Elevated Liver Enzymes,Use Machines see,0
BLINCYTO,Elevated Liver Enzymes,on Ability to Drive and Use Machines see Warnings,0
BLINCYTO,Elevated Liver Enzymes,Leukoencephalopathy,0
BLINCYTO,Elevated Liver Enzymes,see Warnings and Elevated Liver Enzymes,1
BLINCYTO,Elevated Liver Enzymes,Warnings and Precautions Leukoencephalopathy see,0
BLINCYTO,Elevated Liver Enzymes,Warnings and Precautions,0
BLINCYTO,Elevated Liver Enzymes,Drive and Use Machines see,0
BLINCYTO,Elevated Liver Enzymes,Elevated Liver Enzymes see Warnings,1
BLINCYTO,Elevated Liver Enzymes,Drive and Use Machines see,0
BLINCYTO,Elevated Liver Enzymes,Elevated Liver Enzymes,1
BLINCYTO,Elevated Liver Enzymes,Drive and Use Machines see,0
BLINCYTO,Elevated Liver Enzymes,Leukoencephalopathy,0
BLINCYTO,Leukoencephalopathy,and Leukoencephalopathy,1
BLINCYTO,Leukoencephalopathy,Leukoencephalopathy,0
BLINCYTO,Leukoencephalopathy,Preparation and Administration Errors,0
BLINCYTO,pyrexia,pyrexia,1
BLINCYTO,pyrexia,Preparation and Administration Errors,0
BLINCYTO,pyrexia,and Precautions The most common adverse reactions were,0
BLINCYTO,headache,common adverse reactions were headache peripheral edema,1
BLINCYTO,headache,and Precautions The most common adverse reactions were,0
BLINCYTO,peripheral edema,common adverse reactions,0
BLINCYTO,peripheral edema,were,0
BLINCYTO,peripheral edema,peripheral edema febrile,1
BLINCYTO,peripheral edema,peripheral edema febrile neutropenia,1
BLINCYTO,peripheral edema,peripheral edema,1
BLINCYTO,peripheral edema,common adverse reactions were pyrexia,0
BLINCYTO,febrile neutropenia,headache peripheral febrile neutropenia,1
BLINCYTO,febrile neutropenia,common adverse reactions were pyrexia,0
BLINCYTO,febrile neutropenia,were pyrexia headache peripheral febrile neutropenia nausea hypokalemia tremor rash,1
BLINCYTO,febrile neutropenia,common adverse reactions were pyrexia,0
BLINCYTO,febrile neutropenia,hypokalemia tremor rash and constipation EXCERPT To r,0
BLINCYTO,febrile neutropenia,febrile neutropenia nausea hypokalemia,1
BLINCYTO,febrile neutropenia,febrile neutropenia nausea hypokalemia tremor,1
BLINCYTO,nausea,nausea,1
BLINCYTO,hypokalemia,n adverse reactions were pyrexia headache peripheral edema,0
BLINCYTO,hypokalemia,neutropenia hypokalemia tremor rash,1
BLINCYTO,hypokalemia,n adverse reactions were pyrexia headache peripheral edema,0
BLINCYTO,hypokalemia,peripheral edema febrile neutropenia hypokalemia tremor rash and constipation EXCERPT,1
BLINCYTO,hypokalemia,n adverse reactions were pyrexia headache peripheral edema,0
BLINCYTO,hypokalemia,and constipation EXCERPT To report,0
BLINCYTO,hypokalemia,febrile,0
BLINCYTO,hypokalemia,headache,0
BLINCYTO,hypokalemia,hypokalemia tremor rash,1
BLINCYTO,hypokalemia,hypokalemia tremor rash and constipation EXCERPT,1
BLINCYTO,hypokalemia,hypokalemia,1
BLINCYTO,tremor,neutropenia nausea tremor rash and constipation,1
BLINCYTO,tremor,hypokalemia,1
BLINCYTO,rash,edema febrile neutropenia nausea hypokalemia tremor,0
BLINCYTO,rash,febrile neutropenia,0
BLINCYTO,rash,tremor,0
BLINCYTO,rash,febrile neutropenia nausea hypokalemia rash and,1
BLINCYTO,rash,tremor,0
BLINCYTO,constipation,constipation EXCERPT To report SUSPECTED,1
BLINCYTO,constipation,REACTIONS contact Amgen,0
BLINCYTO,constipation,constipation EXCERPT To,1
BLINCYTO,constipation,constipation EXCERPT,1
BLINCYTO,pyrexia,pyrexia headache peripheral edema febrile neutropenia,1
BLINCYTO,pyrexia,pyrexia headache,1
BLINCYTO,pyrexia,Black or African,0
BLINCYTO,headache,edema febrile neutropenia nausea hypokalemia and,0
BLINCYTO,headache,hypokalemia and,0
BLINCYTO,headache,febrile,0
BLINCYTO,headache,adverse,0
BLINCYTO,headache,African American The most,0
BLINCYTO,headache,were,0
BLINCYTO,headache,headache peripheral,1
BLINCYTO,headache,were,0
BLINCYTO,peripheral edema,peripheral edema febrile,1
BLINCYTO,peripheral edema,were pyrexia peripheral edema febrile,1
BLINCYTO,peripheral edema,peripheral edema febrile,1
BLINCYTO,peripheral edema,pyrexia peripheral,1
BLINCYTO,peripheral edema,reactions were pyrexia peripheral edema febrile,1
BLINCYTO,peripheral edema,pyrexia peripheral,1
BLINCYTO,febrile neutropenia,pyrexia headache peripheral febrile neutropenia nausea hypokalemia and constipation,1
BLINCYTO,febrile neutropenia,pyrexia peripheral,1
BLINCYTO,febrile neutropenia,most common adverse,0
BLINCYTO,febrile neutropenia,pyrexia headache peripheral febrile neutropenia nausea hypokalemia and,1
BLINCYTO,febrile neutropenia,most common adverse,0
BLINCYTO,febrile neutropenia,febrile neutropenia nausea,1
BLINCYTO,febrile neutropenia,febrile neutropenia nausea hypokalemia,1
BLINCYTO,nausea,febrile nausea hypokalemia and constipation Serious,1
BLINCYTO,nausea,febrile neutropenia nausea hypokalemia,1
BLINCYTO,nausea,nausea hypokalemia and constipation,1
BLINCYTO,nausea,nausea hypokalemia and constipation Serious adverse,1
BLINCYTO,nausea,nausea hypokalemia and constipation,1
BLINCYTO,nausea,were,0
BLINCYTO,nausea,were pyrexia headache peripheral edema febrile,0
BLINCYTO,nausea,nausea hypokalemia and constipation Serious adverse,1
BLINCYTO,nausea,were pyrexia headache peripheral edema febrile,0
BLINCYTO,hypokalemia,ere pyrexia headache peripheral edema febrile,0
BLINCYTO,hypokalemia,edema febrile neutropenia hypokalemia and constipation Serious adverse reactions,1
BLINCYTO,hypokalemia,ere pyrexia headache peripheral edema febrile,0
BLINCYTO,hypokalemia,were reported in,0
BLINCYTO,hypokalemia,edema febrile neutropenia hypokalemia and constipation Serious adverse reactions,1
BLINCYTO,hypokalemia,were reported in,0
BLINCYTO,hypokalemia,adverse reactions were,0
BLINCYTO,hypokalemia,febrile neutropenia hypokalemia and constipation Serious adverse reactions,1
BLINCYTO,hypokalemia,adverse reactions were,0
BLINCYTO,hypokalemia,febrile neutropenia hypokalemia,1
BLINCYTO,hypokalemia,adverse reactions were,0
BLINCYTO,hypokalemia,hypokalemia and,1
BLINCYTO,hypokalemia,adverse reactions were,0
BLINCYTO,hypokalemia,hypokalemia and constipation Serious,1
BLINCYTO,hypokalemia,in of,0
BLINCYTO,febrile neutropenia,common serious adverse reactions,0
BLINCYTO,pyrexia,febrile pyrexia pneumonia sepsis neutropenia,1
BLINCYTO,pyrexia,common serious adverse reactions,0
BLINCYTO,pyrexia,reactions included febrile pyrexia pneumonia sepsis neutropenia devicerelated,1
BLINCYTO,pyrexia,common serious adverse reactions,0
BLINCYTO,pyrexia,pneumonia sepsis neutropenia,0
BLINCYTO,pyrexia,infection,0
BLINCYTO,pyrexia,encephalopathy,0
BLINCYTO,pyrexia,reactions included febrile pyrexia,1
BLINCYTO,pyrexia,encephalopathy,0
BLINCYTO,pyrexia,patients The most common serious adverse reactions included febrile neutropenia,0
BLINCYTO,pyrexia,The most common serious adverse reactions included febrile neutropenia,0
BLINCYTO,pyrexia,in of patients The most common serious adverse reactions included febrile,0
BLINCYTO,pyrexia,pyrexia,1
BLINCYTO,pneumonia,sepsis,0
BLINCYTO,pneumonia,neutropenia pneumonia sepsis neutropenia devicerelated,1
BLINCYTO,pneumonia,sepsis,0
BLINCYTO,pneumonia,pneumonia sepsis,1
BLINCYTO,sepsis,sepsis neutropenia devicerelated infection,1
BLINCYTO,sepsis,sepsis neutropenia devicerelated,1
BLINCYTO,sepsis,encephalopathy infection,0
BLINCYTO,sepsis,sepsis neutropenia devicerelated,1
BLINCYTO,sepsis,infection overdose confusion St,0
BLINCYTO,sepsis,sepsis neutropenia,1
BLINCYTO,sepsis,infection overdose confusion St,0
BLINCYTO,sepsis,sepsis,1
BLINCYTO,neutropenia,neutropenia pyrexia pneumonia sepsis,0
BLINCYTO,neutropenia,neutropenia devicerelated infection tremor encephalopathy infection,1
BLINCYTO,neutropenia,infection,0
BLINCYTO,neutropenia,neutropenia devicerelated infection tremor encephalopathy,1
BLINCYTO,neutropenia,neutropenia pyrexia,0
BLINCYTO,neutropenia,devicerelated infection tremor encephalopathy infection overdose confusion Staphylococcal,0
BLINCYTO,device-related infection,infection overdose,0
BLINCYTO,device-related infection,device-related infection tremor encephalopathy infection overdose,1
BLINCYTO,device-related infection,infection overdose,0
BLINCYTO,device-related infection,overdose,0
BLINCYTO,device-related infection,neutropenia pyrexia pneumonia sepsis device-related infection tremor,1
BLINCYTO,device-related infection,overdose,0
BLINCYTO,device-related infection,Staphylococcal bacteremia and,0
BLINCYTO,tremor,sepsis neutropenia devicerelated tremor encephalopathy infection overdose,1
BLINCYTO,tremor,Staphylococcal bacteremia and,0
BLINCYTO,tremor,sepsis neutropenia,0
BLINCYTO,tremor,confusion Staphylococcal bacteremia and,0
BLINCYTO,encephalopathy,pyrexia pneumonia sepsis neutropenia devicerelated,0
BLINCYTO,encephalopathy,pneumonia sepsis neutropenia devicerelated infection,0
BLINCYTO,encephalopathy,overdose confusion Staphylococcal bacteremia and headache,0
BLINCYTO,encephalopathy,encephalopathy infection overdose,1
BLINCYTO,infection,infection,1
BLINCYTO,infection,infection overdose,1
BLINCYTO,overdose,Adverse,0
BLINCYTO,overdose,overdose confusion Staphylococcal,1
BLINCYTO,overdose,overdose confusion Staphylococcal bacteremia and,1
BLINCYTO,overdose,tremor encephalopathy overdose confusion Staphylococcal,1
BLINCYTO,overdose,overdose confusion Staphylococcal bacteremia and,1
BLINCYTO,overdose,Adverse reactions of Grade,0
BLINCYTO,overdose,overdose confusion Staphylococcal bacteremia and headache,1
BLINCYTO,overdose,devicerelated infection tremor encephalopathy overdose confusion Staphylococcal,1
BLINCYTO,overdose,overdose confusion Staphylococcal bacteremia and headache,1
BLINCYTO,overdose,overdose confusion,1
BLINCYTO,overdose,and headache Adverse reactions,0
BLINCYTO,Staphylococcal bacteremia,infection overdose Staphylococcal  bacteremia and headache Adverse reactions,1
BLINCYTO,Staphylococcal bacteremia,and headache Adverse reactions,0
BLINCYTO,headache,overdose confusion Staphylococcal bacteremia,0
BLINCYTO,encephalopathy,treatment encephalopathy and sepsis Fatal,1
BLINCYTO,encephalopathy,overdose confusion Staphylococcal bacteremia,0
BLINCYTO,encephalopathy,reported most,0
BLINCYTO,sepsis,sepsis Fatal adverse,1
BLINCYTO,sepsis,of,0
BLINCYTO,sepsis,sepsis Fatal adverse events occurred in,1
BLINCYTO,Fatal,Fatal adverse events occurred in of,1
BLINCYTO,Fatal,Fatal adverse events occurred,1
BLINCYTO,Fatal,and Fatal adverse,1
BLINCYTO,Fatal,Fatal adverse events occurred,1
BLINCYTO,Fatal,Fatal adverse events occurred in,1
BLINCYTO,infections,among patients in remission,0
BLINCYTO,infections,events infections No fatal,1
BLINCYTO,infections,among patients in remission,0
BLINCYTO,infections,infections No fatal adverse,1
BLINCYTO,infections,infections No fatal,1
BLINCYTO,infections,Fatal adverse events occurred in of patients,0
BLINCYTO,infections,The,0
BLINCYTO,infections,infections No,1
BLINCYTO,infections,infections No fatal adverse events,1
BLINCYTO,fatal,fatal adverse events occurred on,1
BLINCYTO,fatal,adverse,0
BLINCYTO,fatal,these events were infections fatal adverse events,1
BLINCYTO,fatal,adverse,0
BLINCYTO,fatal,fatal adverse events occurred,1
BLINCYTO,fatal,fatal,1
BLINCYTO,Febrile neutropenia,or Higher Blood and lymphatic,0
BLINCYTO,Febrile neutropenia,Anemia Neutropenia Thrombocytopenia,0
BLINCYTO,Febrile neutropenia,Grade or Higher Blood and,0
BLINCYTO,Febrile neutropenia,Blood and lymphatic system Febrile neutropenia,1
BLINCYTO,Anemia,system disorders Febrile,0
BLINCYTO,Neutropenia,Neutropenia Thrombocytopenia,1
BLINCYTO,Neutropenia,Leukopenia Gastrointestinal d,0
BLINCYTO,Neutropenia,Thrombocytopenia Leukopenia Gastrointestinal,0
BLINCYTO,Neutropenia,Thrombocytopenia Leukopenia Gastrointestinal d,0
BLINCYTO,Neutropenia,Anemia,0
BLINCYTO,Neutropenia,Thrombocytopenia,0
BLINCYTO,Neutropenia,Neutropenia Thrombocytopenia,1
BLINCYTO,Neutropenia,lymphatic,0
BLINCYTO,Neutropenia,disorders Febrile neutropenia Neutropenia Thrombocytopenia Leukopenia,1
BLINCYTO,Neutropenia,lymphatic,0
BLINCYTO,Thrombocytopenia,Thrombocytopenia Leukopenia Gastrointestinal disorders,1
BLINCYTO,Thrombocytopenia,Thrombocytopenia Leukopenia Gastrointestinal disorders,1
BLINCYTO,Thrombocytopenia,Thrombocytopenia,1
BLINCYTO,Thrombocytopenia,Thrombocytopenia Leukopenia Gastrointestinal disorders,1
BLINCYTO,Thrombocytopenia,Leukopenia,0
BLINCYTO,Thrombocytopenia,disorders Febrile neutropenia,0
BLINCYTO,Thrombocytopenia,neutropenia Anemia Neutropenia,0
BLINCYTO,Thrombocytopenia,Gastrointestinal disorders Nausea,0
BLINCYTO,Leukopenia,Gastrointestinal,0
BLINCYTO,Leukopenia,Leukopenia,1
BLINCYTO,Leukopenia,Anemia Neutropenia Leukopenia Gastrointestinal,1
BLINCYTO,Leukopenia,Leukopenia,1
BLINCYTO,Leukopenia,disorders Nausea,0
BLINCYTO,Leukopenia,neutropenia,0
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea includes,1
BLINCYTO,Nausea,Nausea Constipation,1
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea includes,1
BLINCYTO,Nausea,Gastrointestinal,0
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea includes,1
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea includes the,1
BLINCYTO,Nausea,disorders,0
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea includes the,1
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea,1
BLINCYTO,Nausea,Nausea Constipation DiarrheaDiarrhea includes the,1
BLINCYTO,Nausea,openia,0
BLINCYTO,Constipation,disorders Constipation DiarrheaDiarrhea includes the,1
BLINCYTO,Constipation,openia,0
BLINCYTO,Constipation,Leukopenia Gastrointestinal disorders Constipation DiarrheaDiarrhea includes the,1
BLINCYTO,Constipation,openia,0
BLINCYTO,Diarrhea,Nausea Diarrhea Diarrhea includes,1
BLINCYTO,Diarrhea,openia,0
BLINCYTO,Diarrhea,Gastrointestinal disorders Nausea Constipation,0
BLINCYTO,Diarrhea,Gastrointestinal disorders Nausea Diarrhea,1
BLINCYTO,Diarrhea,Gastrointestinal disorders Nausea Constipation,0
BLINCYTO,Diarrhea,Diarrhea Diarrhea includes the,1
BLINCYTO,Diarrhea,Gastrointestinal,0
BLINCYTO,Diarrhea,Nausea Constipation,0
BLINCYTO,Diarrhea,Diarrhea Diarrhea includes the following,1
BLINCYTO,Diarrhea,Nausea Constipation,0
BLINCYTO,Diarrhea,Constipation,0
BLINCYTO,Diarrhea,Diarrhea Diarrhea includes the,1
BLINCYTO,Diarrhea,the following terms colitis,0
BLINCYTO,Diarrhea,Constipation Diarrhea,0
BLINCYTO,Diarrhea,the following terms colitis diarrhea enteritis and neutropenic colitis Abdominal,0
BLINCYTO,Diarrhea,disorders Nausea,0
BLINCYTO,Diarrhea,Diarrhea includes,1
BLINCYTO,Diarrhea,Diarrhea includes the,1
BLINCYTO,Diarrhea,Diarrhea includes,1
BLINCYTO,Diarrhea,Diarrhea includes the,1
BLINCYTO,Diarrhea,colitis diarrhea,0
BLINCYTO,colitis,the following colitis diarrhea enteritis and neutropenic,1
BLINCYTO,colitis,colitis diarrhea,0
BLINCYTO,colitis,colitis,1
BLINCYTO,diarrhea,Abdominal pain Vomiting,0
BLINCYTO,diarrhea,diarrhea enteritis and,1
BLINCYTO,diarrhea,includes the following terms diarrhea,1
BLINCYTO,diarrhea,diarrhea enteritis and,1
BLINCYTO,diarrhea,diarrhea enteritis and neutropenic colitis,1
BLINCYTO,enteritis,following terms colitis enteritis and neutropenic,1
BLINCYTO,enteritis,diarrhea enteritis and neutropenic colitis,1
BLINCYTO,enteritis,and neutropenic colitis,0
BLINCYTO,enteritis,enteritis and neutropenic colitis,1
BLINCYTO,enteritis,and neutropenic colitis,0
BLINCYTO,enteritis,Abdominal pain Vomiting,0
BLINCYTO,enteritis,enteritis and,1
BLINCYTO,neutropenic colitis,neutropenic,1
BLINCYTO,neutropenic colitis,diarrhea enteritis and,0
BLINCYTO,neutropenic colitis,diarrhea enteritis neutropenic colitis Abdominal pain Vomiting General disorders,1
BLINCYTO,neutropenic colitis,diarrhea enteritis and,0
BLINCYTO,neutropenic colitis,neutropenic colitis Abdominal pain Vomiting General disorders,1
BLINCYTO,neutropenic colitis,diarrhea enteritis and,0
BLINCYTO,neutropenic colitis,diarrhea enteritis neutropenic,1
BLINCYTO,Abdominal pain,Abdominal pain Vomiting General disorders and,1
BLINCYTO,Abdominal pain,disorders and administration,0
BLINCYTO,Abdominal pain,enteritis and neutropenic Abdominal pain Vomiting General disorders and administration,1
BLINCYTO,Abdominal pain,disorders and administration,0
BLINCYTO,Abdominal pain,diarrhea enteritis and neutropenic Abdominal pain,1
BLINCYTO,Vomiting,General disorders and,0
BLINCYTO,Vomiting,Vomiting General disorders,1
BLINCYTO,Vomiting,General disorders,0
BLINCYTO,Vomiting,Vomiting General disorders and,1
BLINCYTO,Pyrexia,Fatigue Chills,0
BLINCYTO,Peripheral edema,and,0
BLINCYTO,Peripheral edema,General disorders and administration site conditions,0
BLINCYTO,Peripheral edema,Peripheral edema,1
BLINCYTO,Peripheral edema,Chills Chest pain Immune,0
BLINCYTO,Fatigue,Fatigue Chills Chest pain,1
BLINCYTO,Fatigue,Pyrexia Peripheral Fatigue Chills Chest pain Immune system,1
BLINCYTO,Fatigue,Fatigue Chills Chest pain,1
BLINCYTO,Fatigue,Immune,0
BLINCYTO,Fatigue,site conditions,0
BLINCYTO,Chills,Chills Chest pain Immune system,1
BLINCYTO,Chills,Chills,1
BLINCYTO,Chills,ral disorders and administration,0
BLINCYTO,Chills,Chills,1
BLINCYTO,Chills,Chills Chest pain Immune system disorders,1
BLINCYTO,Chills,Chills,1
BLINCYTO,Chest pain,rs and administration site conditions Pyrexia Peripheral edema,0
BLINCYTO,Chest pain,disorders Cytokine release,0
BLINCYTO,Chest pain,Chest pain Immune system disorders Cytokine release,1
BLINCYTO,Chest pain,Chest pain Immune system disorders Cytokine,1
BLINCYTO,Chest pain,Fatigue Chest,1
BLINCYTO,Chest pain,Pyrexia Peripheral,0
BLINCYTO,Chest pain,system disorders Cytokine release syndrom,0
BLINCYTO,Chest pain,Pyrexia Peripheral edema Fatigue Chest pain,1
BLINCYTO,Chest pain,edema Fatigue Chest pain Immune,1
BLINCYTO,Chest pain,Pyrexia Peripheral edema Fatigue Chest pain,1
BLINCYTO,Cytokine release syndrome,pain Immune system Cytokine release syndrome,1
BLINCYTO,Cytokine release syndrome,system Cytokine release,1
BLINCYTO,Cytokine release syndrome,system Cytokine release syndrome Infections and infestations,1
BLINCYTO,Cytokine release syndrome,system Cytokine release,1
BLINCYTO,Cytokine release syndrome,pain Immune system disorders,0
BLINCYTO,Cytokine release syndrome,infestations,0
BLINCYTO,Cytokine release syndrome,release syndrome Infections,1
BLINCYTO,Cytokine release syndrome,Cytokine release syndrome,1
BLINCYTO,Cytokine release syndrome,system disorders,0
BLINCYTO,Cytokine release syndrome,Cytokine release syndrome Infections and infestations,1
BLINCYTO,Fungal infections,Bacterial,0
BLINCYTO,Fungal infections,pathogen infections Bacterial Fungal infections Viral infections Pneumonia Sepsis Investigation,1
BLINCYTO,Fungal infections,Bacterial,0
BLINCYTO,Fungal infections,infections,0
BLINCYTO,Fungal infections,pathogen infections Bacterial Fungal infections,1
BLINCYTO,Fungal infections,infections,0
BLINCYTO,Fungal infections,pathogen infections Bacterial Fungal infections Viral,1
BLINCYTO,Fungal infections,infections,0
BLINCYTO,Fungal infections,Fungal infections Viral infections Pneumonia Sepsis Investigation,1
BLINCYTO,Fungal infections,Pneumonia Sepsis,0
BLINCYTO,Viral infections,Sepsis,0
BLINCYTO,Viral infections,infections Bacterial infections Fungal Viral infections Pneumonia Sepsis Investigations Increased,1
BLINCYTO,Viral infections,Sepsis,0
BLINCYTO,Viral infections,Viral infections Pneumonia Sepsis Investigations Increased alani,1
BLINCYTO,Viral infections,pathogen infections Bacterial,0
BLINCYTO,Viral infections,Bacterial infections Fungal Viral infections,1
BLINCYTO,Viral infections,Fungal infections,0
BLINCYTO,Viral infections,infections Fungal Viral infections Pneumonia,1
BLINCYTO,Viral infections,Fungal infections,0
BLINCYTO,Pneumonia,Pneumonia Sepsis Investigations Increased alanine,1
BLINCYTO,Pneumonia,Fungal infections Viral Pneumonia Sepsis Investigations,1
BLINCYTO,Pneumonia,Pneumonia Sepsis Investigations Increased alanine,1
BLINCYTO,Pneumonia,Pneumonia Sepsis Investigations,1
BLINCYTO,Pneumonia,Sepsis,0
BLINCYTO,Pneumonia,Pneumonia,1
BLINCYTO,Pneumonia,infections Bacterial infections Fungal infections,0
BLINCYTO,Pneumonia,Sepsis Investigations Increased alanine,0
BLINCYTO,Sepsis,Sepsis Investigations,1
BLINCYTO,Sepsis,Sepsis Investigations Increased alanine,0
BLINCYTO,Sepsis,Fungal infections Viral infections Sepsis Investigations,1
BLINCYTO,Sepsis,Sepsis Investigations Increased alanine,0
BLINCYTO,Sepsis,Sepsis Investigations,1
BLINCYTO,Sepsis,Sepsis Investigations Increased alanine aminotransferase I,1
BLINCYTO,Sepsis,Sepsis Investigations,1
BLINCYTO,Sepsis,Sepsis,1
BLINCYTO,Sepsis,Sepsis Investigations,1
BLINCYTO,Sepsis,Sepsis Investigations Increased alanine aminotransferase,1
BLINCYTO,Increased alanine aminotransferase,Investigations,0
BLINCYTO,Increased alanine aminotransferase,Pneumonia Sepsis Increased alanine,1
BLINCYTO,Increased aspartate aminotransferase,Metabolism and nutrition disorders,0
BLINCYTO,Increased aspartate aminotransferase,aminotransferase,0
BLINCYTO,Increased aspartate aminotransferase,Increased aspartate aminotransferase Increased weight,1
BLINCYTO,Increased aspartate aminotransferase,Investigations Increased alanine Increased aspartate aminotransferase Increased,1
BLINCYTO,Increased aspartate aminotransferase,Increased aspartate aminotransferase Increased weight,1
BLINCYTO,Increased weight,and nutrition disorders Hypokalemia Hypomagnese,0
BLINCYTO,Increased weight,Metabolism,0
BLINCYTO,Increased weight,Increased aspartate aminotransferase,0
BLINCYTO,Increased weight,Increased aspartate Increased weight,1
BLINCYTO,Increased weight,Increased aspartate aminotransferase,0
BLINCYTO,Increased weight,Increased weight Metabolism and nutrition disorders,1
BLINCYTO,Increased weight,Increased weight,1
BLINCYTO,Hypokalemia,Hyperglycemia Decreased appetite Hypophosphatemia,0
BLINCYTO,Hypokalemia,Hypokalemia Hypomagnesemia Hyperglycemia Decreased appetite Hypophosphatemia,1
BLINCYTO,Hypomagnesemia,Metabolism and nutrition,0
BLINCYTO,Hypomagnesemia,Hyperglycemia,0
BLINCYTO,Hypomagnesemia,nutrition disorders Hypomagnesemia Hyperglycemia Decreased appetite Hypophosphatemia,1
BLINCYTO,Hypomagnesemia,Hyperglycemia,0
BLINCYTO,Hypomagnesemia,Hyperglycemia,0
BLINCYTO,Hypomagnesemia,Hypomagnesemia Hyperglycemia Decreased appetite,1
BLINCYTO,Hypomagnesemia,Hypomagnesemia Hyperglycemia Decreased appetite Hypophosphatemia,1
BLINCYTO,Hypomagnesemia,Hypomagnesemia Hyperglycemia Decreased appetite,1
BLINCYTO,Hypomagnesemia,Hypomagnesemia Hyperglycemia,1
BLINCYTO,Hyperglycemia,appetite Hypophosphatemia Musculoske,0
BLINCYTO,Hyperglycemia,nutrition disorders Hypokalemia Hypomagnesemia,0
BLINCYTO,Hyperglycemia,Decreased,0
BLINCYTO,Hyperglycemia,appetite,0
BLINCYTO,Hyperglycemia,nutrition disorders Hypokalemia Hypomagnesemia,0
BLINCYTO,Hyperglycemia,Hyperglycemia Decreased appetite Hypophosphatemia,1
BLINCYTO,Hyperglycemia,nutrition disorders Hypokalemia Hypomagnesemia,0
BLINCYTO,Hyperglycemia,Hyperglycemia Decreased appetite,1
BLINCYTO,Hyperglycemia,Hyperglycemia Decreased appetite Hypophosphatemia Musculoske,1
BLINCYTO,Decreased appetite,nutrition disorders Hypokalemia Hypomagnesemia Decreased,1
BLINCYTO,Decreased appetite,nutrition disorders Hypokalemia Hypomagnesemia Decreased appetite,1
BLINCYTO,Decreased appetite,and connective,0
BLINCYTO,Decreased appetite,Hypokalemia Hypomagnesemia Decreased appetite Hypophosphatemia Musculoskeletal,1
BLINCYTO,Decreased appetite,and connective,0
BLINCYTO,Decreased appetite,Hypokalemia Hypomagnesemia Decreased appetite Hypophosphatemia Musculoskeletal and connective,1
BLINCYTO,Decreased appetite,and connective,0
BLINCYTO,Decreased appetite,Decreased appetite Hypophosphatemia Musculoskeletal,1
BLINCYTO,Decreased appetite,and connective ti,0
BLINCYTO,Decreased appetite,Decreased appetite Hypophosphatemia Musculoskeletal and connective ti,1
BLINCYTO,Back pain,and,0
BLINCYTO,Back pain,tissue Back pain,1
BLINCYTO,Back pain,and,0
BLINCYTO,Back pain,Musculoskeletal and connective tissue Back pain Pain in extremity Bone pain,1
BLINCYTO,Back pain,and,0
BLINCYTO,Back pain,Bone,0
BLINCYTO,Back pain,connective tissue Back pain Pain,1
BLINCYTO,Back pain,Bone,0
BLINCYTO,Back pain,disorders,0
BLINCYTO,Back pain,Back pain,1
BLINCYTO,Back pain,connective tissue Back,1
BLINCYTO,Back pain,Back pain Pain in extremity,1
BLINCYTO,Back pain,Back,1
BLINCYTO,Pain in extremity,connective tissue disorders Back Pain,1
BLINCYTO,Pain in extremity,Back Pain in extremity Bone pain,1
BLINCYTO,Pain in extremity,connective tissue disorders Back Pain,1
BLINCYTO,Bone pain,pain Pain in Bone,1
BLINCYTO,Arthralgia,Arthralgia Nervous system,1
BLINCYTO,Arthralgia,Arthralgia Nervous system,1
BLINCYTO,Arthralgia,Headache,0
BLINCYTO,Arthralgia,extremity Bone Arthralgia Nervous system disorders Headache,1
BLINCYTO,Arthralgia,Headache,0
BLINCYTO,Arthralgia,Headache TremorTremor,0
BLINCYTO,Arthralgia,system disorders Headache TremorTremor inc,0
BLINCYTO,Arthralgia,pain Pain in extremity Bone pain,0
BLINCYTO,Arthralgia,Arthralgia Nervous system disorders Headache,1
BLINCYTO,Arthralgia,in extremity Bone Arthralgia Nervous system disorders Headache TremorTremor,1
BLINCYTO,Arthralgia,Arthralgia Nervous system disorders Headache,1
BLINCYTO,Arthralgia,Arthralgia Nervous,1
BLINCYTO,Headache,system Headache TremorTremor includes the following,1
BLINCYTO,Headache,Arthralgia Nervous,1
BLINCYTO,Headache,Arthralgia Nervous system Headache TremorTremor includes,1
BLINCYTO,Headache,Arthralgia Nervous,1
BLINCYTO,Headache,Headache TremorTremor includes,1
BLINCYTO,Headache,Headache TremorTremor includes the following,1
BLINCYTO,Headache,Headache TremorTremor includes,1
BLINCYTO,Headache,Arthralgia Nervous system Headache,1
BLINCYTO,Headache,Headache TremorTremor includes,1
BLINCYTO,Headache,Headache TremorTremor,1
BLINCYTO,Headache,Arthralgia Nervous system disorders,0
BLINCYTO,Headache,tremor and tremor,0
BLINCYTO,Headache,pain Arthralgia Nervous system disorders,0
BLINCYTO,Headache,Headache TremorTremor includes the,1
BLINCYTO,Tremor,Nervous system,0
BLINCYTO,Tremor,system disorders Tremor Tremor,1
BLINCYTO,Tremor,Nervous system,0
BLINCYTO,Tremor,Tremor Tremor,1
BLINCYTO,Tremor,Tremor Tremor includes the,1
BLINCYTO,Tremor,Tremor Tremor includes the following terms,1
BLINCYTO,Tremor,Nervous system disorders Tremor,1
BLINCYTO,Tremor,Tremor Tremor includes the following terms,1
BLINCYTO,Tremor,Tremor,1
BLINCYTO,Tremor,system disorders Tremor Tremor includes the following terms,1
BLINCYTO,Tremor,Tremor,1
BLINCYTO,Tremor,Tremor Tremor includes the following,1
BLINCYTO,Tremor,disorders,0
BLINCYTO,Tremor,disorders Headache Tremor,1
BLINCYTO,Tremor,disorders,0
BLINCYTO,resting tremor,following resting,1
BLINCYTO,resting tremor,TremorTremor,0
BLINCYTO,resting tremor,resting tremor and tremor Dizziness Psychiatric,1
BLINCYTO,resting tremor,terms,0
BLINCYTO,resting tremor,resting tremor and tremor Dizziness Psychiatric,1
BLINCYTO,resting tremor,terms,0
BLINCYTO,resting tremor,the following resting tremor,1
BLINCYTO,tremor,terms,0
BLINCYTO,tremor,Dizziness,0
BLINCYTO,tremor,Psychiatric disorders,0
BLINCYTO,tremor,tremor Dizziness Psychiatric,1
BLINCYTO,tremor,resting tremor tremor Dizziness,1
BLINCYTO,tremor,tremor Dizziness Psychiatric,1
BLINCYTO,tremor,tremor Dizziness Psychiatric,1
BLINCYTO,tremor,TremorTremor,0
BLINCYTO,tremor,tremor Dizziness Psychiatric,1
BLINCYTO,tremor,and,0
BLINCYTO,Dizziness,Psychiatric disorders,0
BLINCYTO,Dizziness,and Dizziness Psychiatric disorders Insomnia,1
BLINCYTO,Dizziness,Psychiatric disorders,0
BLINCYTO,Insomnia,mediastinal disorders Cough,0
BLINCYTO,Insomnia,thoracic and mediastinal disorders,0
BLINCYTO,Insomnia,Insomnia Respiratory,1
BLINCYTO,Cough,Cough DyspneaDyspnea includes the following terms,1
BLINCYTO,Dyspnea,disorders Dyspnea,1
BLINCYTO,Dyspnea,Cough DyspneaDyspnea includes the following terms,1
BLINCYTO,Dyspnea,omnia Respiratory thoracic and mediastinal disorders Cough,0
BLINCYTO,Dyspnea,mediastinal disorders Dyspnea,1
BLINCYTO,Dyspnea,omnia Respiratory thoracic and mediastinal disorders Cough,0
BLINCYTO,Dyspnea,Dyspnea Dyspnea includes,1
BLINCYTO,Dyspnea,mediastinal,0
BLINCYTO,Dyspnea,bronchial hyperactivity,0
BLINCYTO,Dyspnea,Cough,0
BLINCYTO,Dyspnea,mediastinal disorders Dyspnea Dyspnea includes the,1
BLINCYTO,Dyspnea,Cough,0
BLINCYTO,Dyspnea,thoracic and mediastinal disorders Dyspnea,1
BLINCYTO,Dyspnea,Cough,0
BLINCYTO,Dyspnea,Dyspnea includes,1
BLINCYTO,Dyspnea,thoracic and mediastinal disorders,0
BLINCYTO,acute respiratory failure,DyspneaDyspnea includes the following acute respiratory failure bronchial hyperactivity,1
BLINCYTO,acute respiratory failure,thoracic and mediastinal disorders,0
BLINCYTO,acute respiratory failure,following,0
BLINCYTO,acute respiratory failure,respiratory failure bronchial hyperactivity bronchospasm,1
BLINCYTO,acute respiratory failure,mediastinal,0
BLINCYTO,bronchial hyperactivity,failure and,0
BLINCYTO,bronchial hyperactivity,bronchial hyperactivity,1
BLINCYTO,bronchial hyperactivity,respiratory distress respiratory,0
BLINCYTO,bronchial hyperactivity,following terms acute respiratory bronchial hyperactivity bronchospasm dyspnea dyspnea exertional,1
BLINCYTO,bronchial hyperactivity,respiratory distress respiratory,0
BLINCYTO,bronchospasm,failure bronchial hyperactivity,0
BLINCYTO,dyspnea,failure bronchial hyperactivity dyspnea dyspnea exertional respiratory distress respiratory,1
BLINCYTO,dyspnea,failure bronchial hyperactivity,0
BLINCYTO,dyspnea exertional,failure bronchial hyperactivity bronchospasm dyspnea,1
BLINCYTO,dyspnea exertional,failure bronchial hyperactivity bronchospasm dyspnea,1
BLINCYTO,dyspnea exertional,dyspnea exertional respiratory distress respiratory failure and,1
BLINCYTO,dyspnea exertional,failure bronchial hyperactivity bronchospasm dyspnea,1
BLINCYTO,respiratory distress,bronchospasm dyspnea dyspnea respiratory distress,1
BLINCYTO,respiratory distress,exertional,0
BLINCYTO,respiratory distress,bronchospasm dyspnea dyspnea respiratory,1
BLINCYTO,respiratory distress,bronchial hyperactivity bronchospasm,0
BLINCYTO,respiratory distress,dyspnea respiratory,1
BLINCYTO,respiratory distress,bronchospasm dyspnea dyspnea respiratory distress,1
BLINCYTO,respiratory distress,acute respiratory failure bronchial hyperactivity,0
BLINCYTO,respiratory distress,respiratory distress,1
BLINCYTO,respiratory distress,failure and wheezing Skin and subcutaneous,0
BLINCYTO,respiratory failure,bronchospasm dyspnea dyspnea,0
BLINCYTO,respiratory failure,and subcutaneous tissue disorders,0
BLINCYTO,respiratory failure,hyperactivity bronchospasm dyspnea dyspnea,0
BLINCYTO,respiratory failure,tissue disorders,0
BLINCYTO,respiratory failure,respiratory failure and wheezing Skin and,1
BLINCYTO,respiratory failure,tissue disorders,0
BLINCYTO,respiratory failure,respiratory failure and wheezing,1
BLINCYTO,respiratory failure,respiratory respiratory failure,1
BLINCYTO,respiratory failure,subcutaneous,0
BLINCYTO,respiratory failure,respiratory distress,0
BLINCYTO,respiratory failure,and wheezing Skin and subcutaneous tissue,0
BLINCYTO,wheezing,disorders RashRash includes,0
BLINCYTO,wheezing,wheezing Skin and subcutaneous,1
BLINCYTO,wheezing,wheezing,1
BLINCYTO,wheezing,wheezing Skin and subcutaneous tissue,1
BLINCYTO,Rash,Skin and subcutaneous tissue Rash Rash includes the following terms,1
BLINCYTO,Rash,wheezing Skin and subcutaneous tissue,1
BLINCYTO,Rash,Rash,1
BLINCYTO,Rash,Rash includes the following terms,1
BLINCYTO,Rash,Rash includes the,1
BLINCYTO,Rash,the,0
BLINCYTO,Rash,and subcutaneous tissue disorders Rash,1
BLINCYTO,Rash,the,0
BLINCYTO,Rash,subcutaneous tissue disorders Rash includes the following terms erythema,1
BLINCYTO,Rash,the,0
BLINCYTO,Rash,Rash,1
BLINCYTO,Rash,Rash includes the following terms,1
BLINCYTO,Rash,erythema rash erythematous rash generalized rash,0
BLINCYTO,Rash,Skin and subcutaneous tissue,0
BLINCYTO,erythema,erythema rash,1
BLINCYTO,erythema,the following erythema rash erythematous rash generalized,1
BLINCYTO,erythema,erythema rash,1
BLINCYTO,erythema,erythema rash,1
BLINCYTO,erythema,erythema,1
BLINCYTO,rash,following terms erythema,0
BLINCYTO,rash,tissue disorders,0
BLINCYTO,rash,rash papular rash and,0
BLINCYTO,erythematous rash,Skin,0
BLINCYTO,erythematous rash,erythema erythematous rash generalized rash macular rash,1
BLINCYTO,erythematous rash,Skin,0
BLINCYTO,erythematous rash,Skin and subcutaneous tissue disorders RashRash includes the following,0
BLINCYTO,erythematous rash,erythema erythematous rash,1
BLINCYTO,erythematous rash,Skin and subcutaneous tissue disorders RashRash includes the following,0
BLINCYTO,erythematous rash,erythematous rash generalized rash macular rash,1
BLINCYTO,generalized rash,rash erythematous generalized rash,1
BLINCYTO,generalized rash,erythematous rash generalized rash macular rash,1
BLINCYTO,generalized rash,terms erythema rash erythematous generalized rash,1
BLINCYTO,generalized rash,erythematous rash generalized rash macular rash,1
BLINCYTO,generalized rash,erythematous generalized rash,1
BLINCYTO,generalized rash,generalized rash macular,1
BLINCYTO,generalized rash,generalized rash,1
BLINCYTO,macular rash,papular rash,0
BLINCYTO,macular rash,rash erythematous rash generalized macular rash maculopapular,1
BLINCYTO,macular rash,papular rash,0
BLINCYTO,maculo-papular rash,maculo-papular rash,1
BLINCYTO,maculo-papular rash,papular rash,0
BLINCYTO,maculo-papular rash,maculo-papular,1
BLINCYTO,maculo-papular rash,maculo-papular rash,1
BLINCYTO,maculo-papular rash,maculo-papular,1
BLINCYTO,maculo-papular rash,maculo-papular rash papular rash and vesicular rash,1
BLINCYTO,maculo-papular rash,rash generalized rash,0
BLINCYTO,maculo-papular rash,rash and vesicular rash,0
BLINCYTO,papular rash,rash maculopapular papular,1
BLINCYTO,papular rash,papular,1
BLINCYTO,papular rash,rash maculopapular papular rash,1
BLINCYTO,papular rash,erythema rash,0
BLINCYTO,papular rash,rash macular rash maculopapular papular,1
BLINCYTO,papular rash,rash,0
BLINCYTO,papular rash,vesicular rash Vascular disorders,0
BLINCYTO,papular rash,maculopapular papular rash,1
BLINCYTO,Hypotension,Hypotension Hypertension Additional important,1
BLINCYTO,Hypotension,maculopapular papular rash,1
BLINCYTO,Hypotension,reactions that,0
BLINCYTO,Hypotension,Hypotension Hypertension Additional important,1
BLINCYTO,Hypotension,Hypertension Additional important adverse reactions,0
BLINCYTO,leukocytosis,and lymphatic system,0
BLINCYTO,leukocytosis,lymphopenia Cardiac disorders tachycardia General disorders and admin,0
BLINCYTO,leukocytosis,leukocytosis lymphopenia Cardiac disorders tachycardia,1
BLINCYTO,leukocytosis,leukocytosis lymphopenia,1
BLINCYTO,leukocytosis,leukocytosis lymphopenia Cardiac disorders tachycardia,1
BLINCYTO,leukocytosis,General disorders and,0
BLINCYTO,leukocytosis,disorders,0
BLINCYTO,leukocytosis,lymphatic system leukocytosis lymphopenia Cardiac disorders,1
BLINCYTO,leukocytosis,disorders,0
BLINCYTO,leukocytosis,leukocytosis lymphopenia,1
BLINCYTO,leukocytosis,Cardiac disorders tachycardia General disorders,0
BLINCYTO,leukocytosis,leukocytosis,1
BLINCYTO,lymphopenia,lymphopenia Cardiac disorders,1
BLINCYTO,lymphopenia,system disorders lymphopenia Cardiac disorders tachycardia,1
BLINCYTO,lymphopenia,lymphopenia Cardiac disorders,1
BLINCYTO,lymphopenia,and lymphatic system disorders lymphopenia Cardiac disorders tachycardia,1
BLINCYTO,lymphopenia,lymphopenia Cardiac disorders,1
BLINCYTO,lymphopenia,Table were Blood and lymphatic system disorders,0
BLINCYTO,lymphopenia,disorders lymphopenia Cardiac disorders tachycardia,1
BLINCYTO,lymphopenia,Table were Blood and lymphatic system disorders,0
BLINCYTO,lymphopenia,Cardiac disorders tachycardia General,0
BLINCYTO,lymphopenia,disorders lymphopenia,1
BLINCYTO,lymphopenia,Cardiac disorders tachycardia General,0
BLINCYTO,lymphopenia,tachycardia General disorders,0
BLINCYTO,tachycardia,tachycardia General disorders and administration,1
BLINCYTO,tachycardia,tachycardia General disorders and administration site,1
BLINCYTO,edema,disorders and administration site edema Immune system disorders cytokine storm,1
BLINCYTO,edema,tachycardia General disorders and administration site,1
BLINCYTO,edema,edema Immune system disorders cytokine,1
BLINCYTO,edema,edema,1
BLINCYTO,cytokine storm,edema Immune system disorders,0
BLINCYTO,cytokine storm,cytokine storm Investigations decreased,1
BLINCYTO,cytokine storm,Investigations decreased immunoglobulins increased blood,0
BLINCYTO,cytokine storm,administration site conditions edema Immune system disorders,0
BLINCYTO,cytokine storm,cytokine,1
BLINCYTO,cytokine storm,Investigations,0
BLINCYTO,cytokine storm,system cytokine storm,1
BLINCYTO,cytokine storm,Investigations,0
BLINCYTO,cytokine storm,system cytokine storm Investigations decreased immunoglobulins increased blood,1
BLINCYTO,cytokine storm,Investigations,0
BLINCYTO,cytokine storm,cytokine storm Investigations decreased immunoglobulins increased blood,1
BLINCYTO,cytokine storm,Investigations,0
BLINCYTO,cytokine storm,cytokine storm,1
BLINCYTO,decreased immunoglobulins,cytokine,0
BLINCYTO,decreased immunoglobulins,cytokine storm decreased immunoglobulins increased blood bilirubin,1
BLINCYTO,decreased immunoglobulins,cytokine,0
BLINCYTO,decreased immunoglobulins,increased,0
BLINCYTO,decreased immunoglobulins,disorders cytokine storm,0
BLINCYTO,decreased immunoglobulins,increased gammaglutamyltransferase increased liver,0
BLINCYTO,decreased immunoglobulins,decreased immunoglobulins increased blood,1
BLINCYTO,increased blood bilirubin,Investigations decreased,0
BLINCYTO,increased blood bilirubin,storm Investigations,0
BLINCYTO,increased gamma-glutamyl-transferase,blood increased gamma-glutamyl-transferase,1
BLINCYTO,increased gamma-glutamyl-transferase,storm Investigations,0
BLINCYTO,increased gamma-glutamyl-transferase,increased gamma-glutamyl-transferase increased liver enzymes Metabolism and,1
BLINCYTO,increased gamma-glutamyl-transferase,storm Investigations decreased immunoglobulins increased,0
BLINCYTO,increased gamma-glutamyl-transferase,increased gamma-glutamyl-transferase increased liver enzymes Metabolism,1
BLINCYTO,increased gamma-glutamyl-transferase,increased gamma-glutamyl-transferase increased liver enzymes,1
BLINCYTO,increased gamma-glutamyl-transferase,liver enzymes,0
BLINCYTO,increased gamma-glutamyl-transferase,blood increased gamma-glutamyl-transferase increased,1
BLINCYTO,increased gamma-glutamyl-transferase,liver enzymes,0
BLINCYTO,increased gamma-glutamyl-transferase,increased liver enzymes Metabolism and nutrition disorders,0
BLINCYTO,increased liver enzymes,bilirubin,0
BLINCYTO,increased liver enzymes,bilirubin increased increased liver enzymes Metabolism,1
BLINCYTO,increased liver enzymes,bilirubin,0
BLINCYTO,increased liver enzymes,blood bilirubin increased increased liver enzymes Metabolism and nutrition,1
BLINCYTO,increased liver enzymes,bilirubin,0
BLINCYTO,increased liver enzymes,bilirubin increased increased,1
BLINCYTO,increased liver enzymes,increased liver enzymes Metabolism and nutrition,1
BLINCYTO,increased liver enzymes,increased liver enzymes Metabolism,1
BLINCYTO,increased liver enzymes,gammaglutamyltransferase,0
BLINCYTO,increased liver enzymes,blood bilirubin increased increased,1
BLINCYTO,increased liver enzymes,increased liver enzymes Metabolism and nutrition disorders,1
BLINCYTO,increased liver enzymes,blood bilirubin increased increased,1
BLINCYTO,tumor lysis syndrome,nutrition tumor lysis syndrome hypoalbuminemia Nervous system disorders encephalopathy,1
BLINCYTO,tumor lysis syndrome,blood bilirubin increased increased,1
BLINCYTO,tumor lysis syndrome,lysis syndrome hypoalbuminemia Nervous system disorders,1
BLINCYTO,tumor lysis syndrome,liver enzymes Metabolism,0
BLINCYTO,tumor lysis syndrome,and nutrition tumor lysis syndrome,1
BLINCYTO,tumor lysis syndrome,liver enzymes Metabolism,0
BLINCYTO,hypoalbuminemia,tumor lysis hypoalbuminemia Nervous,1
BLINCYTO,hypoalbuminemia,liver enzymes Metabolism,0
BLINCYTO,hypoalbuminemia,disorders tumor lysis hypoalbuminemia Nervous system disorders encephalopathy paresthesia,1
BLINCYTO,hypoalbuminemia,liver enzymes Metabolism,0
BLINCYTO,hypoalbuminemia,paresthesia,0
BLINCYTO,hypoalbuminemia,paresthesia aphasia,0
BLINCYTO,hypoalbuminemia,tumor,0
BLINCYTO,hypoalbuminemia,hypoalbuminemia Nervous,1
BLINCYTO,hypoalbuminemia,hypoalbuminemia Nervous system disorders encephalopathy paresthesia,1
BLINCYTO,encephalopathy,syndrome hypoalbuminemia Nervous system encephalopathy paresthesia aphasia convulsion memory impairment,1
BLINCYTO,encephalopathy,hypoalbuminemia Nervous system disorders encephalopathy paresthesia,1
BLINCYTO,encephalopathy,system,0
BLINCYTO,encephalopathy,encephalopathy paresthesia,1
BLINCYTO,encephalopathy,system encephalopathy paresthesia aphasia,1
BLINCYTO,encephalopathy,encephalopathy paresthesia,1
BLINCYTO,paresthesia,disorders,0
BLINCYTO,paresthesia,memory impairment cognitive,0
BLINCYTO,paresthesia,paresthesia aphasia,1
BLINCYTO,paresthesia,cognitive disorder speech,0
BLINCYTO,paresthesia,paresthesia aphasia convulsion memory impairment,1
BLINCYTO,paresthesia,lysis,0
BLINCYTO,convulsion,encephalopathy paresthesia,0
BLINCYTO,convulsion,paresthesia convulsion memory impairment cognitive,1
BLINCYTO,convulsion,encephalopathy paresthesia,0
BLINCYTO,convulsion,convulsion,1
BLINCYTO,convulsion,memory impairment,0
BLINCYTO,convulsion,speech disorder Psychiatric dis,0
BLINCYTO,convulsion,convulsion memory impairment cognitive disorder speech,1
BLINCYTO,convulsion,convulsion memory impairment,1
BLINCYTO,cognitive disorder,speech disorder,0
BLINCYTO,cognitive disorder,cognitive disorder speech,1
BLINCYTO,cognitive disorder,disorder Psychiatric disorders confusion,0
BLINCYTO,speech disorder,disorientation Vascular disorders,0
BLINCYTO,speech disorder,memory impairment cognitive speech,1
BLINCYTO,speech disorder,impairment cognitive speech disorder,1
BLINCYTO,speech disorder,speech disorder Psychiatric disorders,1
BLINCYTO,speech disorder,confusion disorientation Vascular,0
BLINCYTO,speech disorder,convulsion,0
BLINCYTO,confusion,confusion disorientation Vascular disorders,1
BLINCYTO,confusion,disorders,0
BLINCYTO,confusion,impairment cognitive,0
BLINCYTO,confusion,confusion disorientation Vascular disorders capillary,1
BLINCYTO,confusion,impairment cognitive,0
BLINCYTO,disorientation,syndrome Hypersensitivity,0
BLINCYTO,disorientation,disorientation Vascular disorders capillary leak syndrome,1
BLINCYTO,capillary leak syndrome,confusion disorientation Vascular disorders,0
BLINCYTO,capillary leak syndrome,leak syndrome,1
BLINCYTO,capillary leak syndrome,Vascular capillary leak syndrome,1
BLINCYTO,capillary leak syndrome,disorders confusion disorientation Vascular capillary leak syndrome,1
BLINCYTO,capillary leak syndrome,disorientation Vascular disorders,0
BLINCYTO,capillary leak syndrome,disorders confusion disorientation Vascular capillary leak syndrome,1
BLINCYTO,capillary leak syndrome,capillary leak syndrome,1
BLINCYTO,Hypersensitivity reactions,Hypersensitivity reactions related to BLINCYTO treatment,1
BLINCYTO,Hypersensitivity reactions,capillary leak Hypersensitivity,1
BLINCYTO,Hypersensitivity reactions,leak Hypersensitivity,1
BLINCYTO,Hypersensitivity reactions,and,0
BLINCYTO,Hypersensitivity reactions,Hypersensitivity reactions related to BLINCYTO treatment,1
BLINCYTO,Hypersensitivity reactions,treatment were hypersensitivity and bronchospasm,0
BLINCYTO,Hypersensitivity reactions,Vascular disorders capillary leak Hypersensitivity reactions,1
BLINCYTO,Hypersensitivity reactions,Hypersensitivity reactions related to BLINCYTO treatment,1
BLINCYTO,Hypersensitivity reactions,disorders capillary leak Hypersensitivity reactions related to BLINCYTO treatment,1
BLINCYTO,Hypersensitivity reactions,Hypersensitivity reactions related to BLINCYTO treatment,1
BLINCYTO,hypersensitivity,to BLINCYTO treatment,0
BLINCYTO,hypersensitivity,hypersensitivity,1
BLINCYTO,bronchospasm,bronchospasm,1
BLINCYTO,bronchospasm,therapeutic proteins there is potential,0
BLINCYTO,bronchospasm,bronchospasm Immunogenicity As with all,1
BLINCYTO,bronchospasm,bronchospasm Immunogenicity As with all,1
BLINCYTO,bronchospasm,proteins there is potential for im,0
BLINCYTO,bronchospasm,bronchospasm Immunogenicity As with all,1
BLINCYTO,bronchospasm,proteins there,0
BLINCYTO,bronchospasm,BLINCYTO treatment were hypersensitivity,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,REACTIONS e following adverse react ions,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,BLINCYTO treatment were hypersensitivity,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,adverse react ions are discussed,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,adverse react,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,of the label Cytokine Release Syn,0
BLINCYTO,NEUROLOGICAL TOXICITIES,The following adverse reactions re discussed,1
BLINCYTO,NEUROLOGICAL TOXICITIES,following adverse,0
BLINCYTO,NEUROLOGICAL TOXICITIES,reactions re,1
BLINCYTO,NEUROLOGICAL TOXICITIES,Cytokine,0
BLINCYTO,NEUROLOGICAL TOXICITIES,re discussed,1
BLINCYTO,NEUROLOGICAL TOXICITIES,of the label Cytokine,0
BLINCYTO,NEUROLOGICAL TOXICITIES,adverse reactions a,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,in r sections of the label:  Cytokine Release Syndrome see,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,adverse reactions a,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,sections of the label: Cytokine,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,see Warnings and Precautions Neurological,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,the label: Cytokine Release,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,see Warnings,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,Cytokine Release Syndrome see Warnings and Precautions Neurological Tox,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,the label: Cytokine Release Syndrome see Warnings,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,see Warnings and Precautions Neurological Tox,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,detail in r sections of the label: ,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,see Warnings and Precautions Neurological Tox,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,in r sections of the label:  Cytokine Release Syndrome see,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,see Warnings and Precautions Neurological Tox,0
BLINCYTO,Cytokine Release Syndrome,Release Syndrome e Warnings and,1
BLINCYTO,CRS,(   Neurological Toxicities,1
BLINCYTO,CRS,(   Neurological Toxicities see,1
BLINCYTO,CRS,(   Neurological Toxicities see Warnings,1
BLINCYTO,CRS,Warnings and Precautions Infections see,0
BLINCYTO,CRS,and Precautions Infections see,0
BLINCYTO,Neurological toxicities,Warnings and Precautions Effects on Ability to Drive and Use,0
BLINCYTO,Neurological toxicities,Febrile Ne utropenia see Warnings and Precautions,1
BLINCYTO,Neurological toxicities,tropenia and Febrile Ne utropenia see,1
BLINCYTO,Neurological toxicities,Febrile Ne utropenia see Warnings and Precautions,1
BLINCYTO,Neurological toxicities,tropenia and Febrile Ne,1
BLINCYTO,Neurological toxicities,Febrile Ne utropenia see Warnings and Precautions,1
BLINCYTO,Neurological toxicities,Tumor Lysis Syndrome see,0
BLINCYTO,Neurological toxicities,Warnings and,0
BLINCYTO,Neurological toxicities,tropenia and Febrile Ne utropenia see Warnings and,1
BLINCYTO,Neurological toxicities,see Warnings and Precautions tropenia and Febrile Ne utropenia see Warnings and,1
BLINCYTO,Neurological toxicities,tropenia and Febrile Ne utropenia see Warnings and,1
BLINCYTO,Neurological toxicities,Warnings and Precautions tropenia,1
BLINCYTO,Neurological toxicities,Precautions tropenia,1
BLINCYTO,Neurological toxicities,Febrile Ne utropenia see,1
BLINCYTO,Neurological toxicities,Febrile Ne,1
BLINCYTO,Neurological toxicities,and,0
BLINCYTO,fatal,Warnings and .5  ),1
BLINCYTO,fatal,and,0
BLINCYTO,fatal,Ability to Drive and Use Machines see Warnings and,0
BLINCYTO,fatal,Drive,0
BLINCYTO,fatal,Precautions,0
BLINCYTO,fatal,Neutropenia see Warnings and .5  ),1
BLINCYTO,fatal,Precautions,0
BLINCYTO,fatal,Warnings and .5  ) Effects on Ability,1
BLINCYTO,fatal,Precautions,0
BLINCYTO,fatal,Neutropenia see Warnings and .5  ) Effects on Ability,1
BLINCYTO,fatal,Precautions,0
BLINCYTO,fatal,.5 ),1
BLINCYTO,fatal,Neutropenia and,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,Leukoencephalopathy e,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,Enzymes see Warnings and,0
BLINCYTO,CYTOKINE RELEASE SYNDROME,e Warnings and Precaution,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,and Precautions Leukoencephalopathy e Warnings and Precaution s Preparation,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,e Warnings and Precaution,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,Leukoencephalopathy e Warnings,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,Warnings and Precautions Leukoencephalopathy e Warnings,1
BLINCYTO,CYTOKINE RELEASE SYNDROME,Warnings and Precaution s Preparation and Administration Errors,1
BLINCYTO,NEUROLOGICAL TOXICITIES,see Warnings and,0
BLINCYTO,NEUROLOGICAL TOXICITIES,* Preparati on,1
BLINCYTO,Cytokine Release Syndrome,The,1
BLINCYTO,Cytokine Release Syndrome,see Warnings and The most,1
BLINCYTO,Cytokine Release Syndrome,most common adverse,1
BLINCYTO,Cytokine Release Syndrome,see Warnings and  The most common adverse  reactions were pyrexia headache,1
BLINCYTO,Cytokine Release Syndrome,most common adverse,1
BLINCYTO,Cytokine Release Syndrome,Errors see Warnings,0
BLINCYTO,Cytokine Release Syndrome,most common adverse reactions were pyrexia,1
BLINCYTO,Cytokine Release Syndrome,see Warnings and The most common adverse,1
BLINCYTO,Cytokine Release Syndrome,The most common adverse reactions were pyrexia,1
BLINCYTO,Cytokine Release Syndrome,and The,1
BLINCYTO,Cytokine Release Syndrome,reactions were pyrexia headache peripheral edema,0
BLINCYTO,Cytokine Release Syndrome,Errors see Warnings and  The most common adverse  reactions were,1
BLINCYTO,Cytokine Release Syndrome,reactions were pyrexia headache peripheral edema,0
BLINCYTO,Cytokine Release Syndrome,The,1
BLINCYTO,CRS,act ions were pyrexia,1
BLINCYTO,CRS,act,1
BLINCYTO,CRS,act ions were pyrexia,1
BLINCYTO,CRS,Errors see Warnings and Precautions The most,0
BLINCYTO,CRS,act ions were,1
BLINCYTO,CRS,The most common adverse act ions were,1
BLINCYTO,CRS,act ions were,1
BLINCYTO,CRS,most common adverse act ions were,1
BLINCYTO,CRS,act ions were,1
BLINCYTO,CRS,most common adverse act ions were,1
BLINCYTO,CRS,act ions were,1
BLINCYTO,CRS,febrile neutropenia,0
BLINCYTO,CRS,act ions were pyrexia headache peripheral,1
BLINCYTO,CRS,act ions were pyrexia headache,1
BLINCYTO,CRS,re,0
BLINCYTO,fatal,", per ipheral edema febrile neutropenia",1
BLINCYTO,fatal,headache,0
BLINCYTO,fatal,"adverse reactions were pyrexia , per",1
BLINCYTO,fatal,hypokalemia tremor rash,0
BLINCYTO,Neurological toxicities,REACTIONS,0
BLINCYTO,Neurological toxicities,"tremor rash and constipation RPT:   

}}        To r eport SUSPECTED ADVERSE REACTIONS",1
BLINCYTO,Neurological toxicities,REACTIONS,0
BLINCYTO,Neurological toxicities,at AMGEN or FDA at,0
BLINCYTO,Neurological toxicities,Inc at,0
BLINCYTO,Neurological toxicities,SUSPECTED ADVERSE REACTIONS contact Amgen Inc at AMGEN or,0
BLINCYTO,Neurological toxicities,}} To r eport SUSPECTED ADVERSE REACTIONS contact,1
BLINCYTO,Neurological toxicities,constipation RPT: }} To,1
BLINCYTO,Neurological toxicities,To r eport SUSPECTED ADVERSE REACTIONS,1
BLINCYTO,Neurological toxicities,RPT: }} To r eport SUSPECTED ADVERSE REACTIONS contact,1
BLINCYTO,Neurological toxicities,RPT: }} To r eport SUSPECTED ADVERSE REACTIONS contact,1
BLINCYTO,Neurological toxicities,To r eport SUSPECTED,1
BLINCYTO,Neurological toxicities,tremor rash and constipation RPT:,1
BLINCYTO,Neurological toxicities,at AMGEN,0
BLINCYTO,fatal,mgen  Inc at,1
BLINCYTO,fatal,mgen  Inc at,1
BLINCYTO,fatal,A,0
BLINCYTO,fatal,SUSPECTED ADVERSE REACTIONS contact mgen  Inc at AMGEN,1
BLINCYTO,fatal,A,0
BLINCYTO,fatal,Inc at AMGEN or FDA at FDA or wwwfdagovmedwatch,0
BLINCYTO,fatal,mgen  Inc,1
BLINCYTO,fatal,mgen  Inc at,1
BLINCYTO,fatal,stipation EXCERPT To report SUSPECTED ADVERSE REACTIONS contact,0
BLINCYTO,fatal,EXCERPT To report SUSPECTED ADVERSE,0
BLINCYTO,fatal,ADVERSE REACTIONS contact mgen  Inc at AMGEN or,1
BLINCYTO,fatal,EXCERPT To report SUSPECTED ADVERSE,0
BLINCYTO,Infections,rea,0
BLINCYTO,Infections,The following adverse rea,0
BLINCYTO,Infections,label Cytokine Release Syndrome s,0
BLINCYTO,Infections,adverse ctions,1
BLINCYTO,Effects on Ability to Drive,Cytokine,0
BLINCYTO,Cytokine Release Syndrome,Machines see Warnings and Elevated Liver Enzymes [s ee Warnings and Precautions Leukoencephalopathy,1
BLINCYTO,Cytokine Release Syndrome,Cytokine,0
BLINCYTO,Cytokine Release Syndrome,Warnings and Elevated Liver Enzymes,1
BLINCYTO,Cytokine Release Syndrome,see,0
BLINCYTO,Cytokine Release Syndrome,Warnings and Elevated Liver Enzymes [s,1
BLINCYTO,Cytokine Release Syndrome,see,0
BLINCYTO,Cytokine Release Syndrome,see,0
BLINCYTO,Cytokine Release Syndrome,Elevated Liver Enzymes [s ee,1
BLINCYTO,Cytokine Release Syndrome,Elevated Liver Enzymes [s ee Warnings and Precautions,1
BLINCYTO,Cytokine Release Syndrome,Elevated Liver Enzymes [s ee,1
BLINCYTO,Cytokine Release Syndrome,Warnings,0
BLINCYTO,Cytokine Release Syndrome,and,0
BLINCYTO,Cytokine Release Syndrome,Elevated Liver Enzymes [s ee Warnings,1
BLINCYTO,Cytokine Release Syndrome,see,0
BLINCYTO,Cytokine Release Syndrome,Warnings,0
BLINCYTO,Cytokine Release Syndrome,Liver Enzymes [s,1
BLINCYTO,Cytokine Release Syndrome,Machines see Warnings and Elevated Liver Enzymes [s ee Warnings and Precautions,1
BLINCYTO,Cytokine Release Syndrome,Liver Enzymes [s,1
BLINCYTO,CRS,to Drive and Use Machines see Warnings and Precautions Elevated Liver,0
BLINCYTO,CRS,Use Machines see Warnings and,0
BLINCYTO,CRS, Wa rnings and Precautions,1
BLINCYTO,CRS, Wa rnings and,1
BLINCYTO,CRS, Wa,1
BLINCYTO,fatal,* L eukoencephalopathy see Warnings and Precautions,1
BLINCYTO,fatal,Enzymes see Warnings and Precautions,0
BLINCYTO,Infusion reactions,Warnings and ( 5.8 )] *,1
BLINCYTO,CRS,peripheral,0
BLINCYTO,CRS,"peripheral ma, febrile neutropenia nausea",1
BLINCYTO,CRS,peripheral,0
BLINCYTO,CRS,rash,0
BLINCYTO,pyrexia,febrile eutrope nia nausea,1
BLINCYTO,pyrexia,rash,0
BLINCYTO,pyrexia,common adverse reactions were pyrexia headache peripheral,0
BLINCYTO,pyrexia,eutrope nia nausea,1
BLINCYTO,pyrexia,pyrexia headache peripheral edema febrile n,0
BLINCYTO,pyrexia,edema febrile eutrope nia nausea hypokalemia tremor,1
BLINCYTO,pyrexia,pyrexia headache peripheral edema febrile n,0
BLINCYTO,headache,"a, nause a hypokalemia tremor rash",1
BLINCYTO,headache,"edema febrile a, nause",1
BLINCYTO,headache,tremor rash and constipation EXCERPT To,0
BLINCYTO,headache,"a, nause",1
BLINCYTO,headache,"febrile a, nause a",1
BLINCYTO,headache,"a, nause",1
BLINCYTO,headache,"headache peripheral edema febrile a,",1
BLINCYTO,headache,"febrile a,",1
BLINCYTO,nausea,adverse reactions,0
BLINCYTO,nausea, hypok alemia tremor rash and,1
BLINCYTO,nausea,edema febrile neutropenia  hypok alemia tremor,1
BLINCYTO,nausea, hypok alemia tremor rash and,1
BLINCYTO,nausea,tremor rash and constipation EXCERPT,0
BLINCYTO,nausea,neutropenia,0
BLINCYTO,asthenia,and constipation,0
BLINCYTO,asthenia,"nausea emia, tr",1
BLINCYTO,asthenia,"emia, tr emor rash and constipation",1
BLINCYTO,asthenia,hypokal,0
BLINCYTO,asthenia,and constipation EXCERPT To report SUSPECTED ADVERSE R,0
BLINCYTO,asthenia,"emia, tr emor rash and",1
BLINCYTO,asthenia,"neutropenia nausea emia, tr emor rash and constipation EXCERPT",1
BLINCYTO,asthenia,"emia, tr emor rash and",1
BLINCYTO,asthenia,nausea,0
BLINCYTO,hypotension,"or, rash,",1
BLINCYTO,hypotension,"or, rash, a nd constipation EXCERPT To report",1
BLINCYTO,hypotension,"hypokalemia or,",1
BLINCYTO,hypotension,neutropenia,0
BLINCYTO,hypotension,edema,0
BLINCYTO,increased alanine aminotransferase,constipation. ( 6.1 ) E,1
BLINCYTO,increased alanine aminotransferase,constipation. ( 6.1 ),1
BLINCYTO,increased alanine aminotransferase,hypokalemia tremor rash constipation. (,1
BLINCYTO,increased alanine aminotransferase,6.1 ) E XCERPT To report SUSPECTED,1
BLINCYTO,increased alanine aminotransferase,Amgen Inc at AMGEN,0
BLINCYTO,increased aspartate aminotransferase,To report SUSPEC,1
BLINCYTO,increased aspartate aminotransferase,To report SUSPEC TED ADVERSE REACTIONS contact,1
BLINCYTO,increased aspartate aminotransferase,To report SUSPEC TED ADVERSE REACTIONS,1
BLINCYTO,increased aspartate aminotransferase,ERPT: }} To report SUSPEC TED,1
BLINCYTO,increased aspartate aminotransferase,"rash and constipation ERPT:   

}}        To report SUSPEC",1
BLINCYTO,increased aspartate aminotransferase,ERPT: }} To report SUSPEC TED,1
BLINCYTO,increased aspartate aminotransferase,report SUSPEC TED ADVERSE REACTIONS,1
BLINCYTO,increased aspartate aminotransferase,febrile neutropenia nausea,0
BLINCYTO,fatal,.gov/ medwatch,1
BLINCYTO,fatal,at FDA,0
BLINCYTO,fatal,contact Amgen Inc at,0
BLINCYTO,fatal,trials,0
BLINCYTO,fatal,or .gov/ medwatch Clinical Trials Experience Because,1
BLINCYTO,fatal,trials,0
BLINCYTO,fatal,FDA at FDA or .gov/ medwatch Clinical Trials Experience Because,1
BLINCYTO,fatal,trials,0
BLINCYTO,fatal,FDA at FDA or .gov/ medwatch Clinical Trials Experience,1
BLINCYTO,fatal,trials,0
BLINCYTO,fatal,REACTIONS contact Amgen Inc at AMGEN or FDA at FDA,0
BLINCYTO,CRS,edw atch Clinical Trials Experience,1
BLINCYTO,CRS,edw,1
BLINCYTO,CRS,clinical trials,0
BLINCYTO,CRS,edw atch Clinical Trials,1
BLINCYTO,CRS,FDA or edw atch Clinical Trials Experience Because,1
BLINCYTO,CRS,edw atch Clinical Trials,1
BLINCYTO,CRS,edw atch Clinical Trials,1
BLINCYTO,CRS,edw atch,1
BLINCYTO,CRS,edw,1
BLINCYTO,CRS,Trials Experience Because clinical trials are conducted un,0
BLINCYTO,CRS,edw atch Clinical Trials,1
BLINCYTO,CRS,clinical,0
BLINCYTO,disseminated intravascular coagulation,Experience,0
BLINCYTO,disseminated intravascular coagulation,Trials Experience Because al trials are conducted under widely v arying conditions adverse reaction rates,1
BLINCYTO,disseminated intravascular coagulation,Experience,0
BLINCYTO,disseminated intravascular coagulation,trials of a drug cannot,0
BLINCYTO,disseminated intravascular coagulation,Because al trials are conducted under widely v arying conditions adverse,1
BLINCYTO,disseminated intravascular coagulation,trials of a drug cannot,0
BLINCYTO,disseminated intravascular coagulation,al trials are conducted under widely v arying conditions adverse,1
BLINCYTO,disseminated intravascular coagulation,trials of a drug cannot,0
BLINCYTO,disseminated intravascular coagulation,clinical trials of a drug cannot,0
BLINCYTO,disseminated intravascular coagulation,Clinical Trials Experience Because al trials are conducted under widely v,1
BLINCYTO,DIC,yin g conditions adverse reaction,1
BLINCYTO,DIC,Clinical Trials Experience Because al trials are conducted under widely v,1
BLINCYTO,DIC,under,0
BLINCYTO,DIC,clinical trials are conducted,0
BLINCYTO,DIC,yin g conditions,1
BLINCYTO,DIC,yin g conditions adverse reaction rates,1
BLINCYTO,DIC,reaction rates observed in the clinical trials of a drug,0
BLINCYTO,DIC,adverse reaction rates observed in the clinical trials of,0
BLINCYTO,DIC,conducted under widely yin g conditions adverse reaction,1
BLINCYTO,DIC,adverse reaction rates observed in the clinical trials of,0
BLINCYTO,DIC,yin g conditions,1
BLINCYTO,DIC,adverse reaction rates observed in the clinical trials of,0
BLINCYTO,DIC,yin,1
BLINCYTO,capillary leak syndrome,varying c,0
BLINCYTO,capillary leak syndrome,"onditions, adverse reac tion rates observed in the",1
BLINCYTO,capillary leak syndrome,"widely varying onditions, adverse",1
BLINCYTO,capillary leak syndrome,"under widely varying onditions, adverse reac tion rates observed",1
BLINCYTO,capillary leak syndrome,"widely varying onditions, adverse",1
BLINCYTO,capillary leak syndrome,"under widely varying onditions, adverse reac",1
BLINCYTO,capillary leak syndrome,varying,0
BLINCYTO,CLS,on  rates,1
BLINCYTO,hemophagocytic lymphohistiocytosis,rates bserved in the clinical,1
BLINCYTO,hemophagocytic lymphohistiocytosis,clinical trials are conducted under widely varying conditions adverse reaction,0
BLINCYTO,hemophagocytic lymphohistiocytosis,bserved in the clinical trials of a drug,1
BLINCYTO,hemophagocytic lymphohistiocytosis,rates,0
BLINCYTO,hemophagocytic lymphohistiocytosis,bserved in the clinical trials of,1
BLINCYTO,hemophagocytic lymphohistiocytosis,e Because clinical trials are conducted under widely varying conditions adverse reaction rates,0
BLINCYTO,macrophage activation syndrome,of drug cannot be directly compa,1
BLINCYTO,macrophage activation syndrome,clinical trials of  drug cannot be directly compa red to,1
BLINCYTO,macrophage activation syndrome,of drug cannot be directly compa,1
BLINCYTO,macrophage activation syndrome,cannot be directly compa red to rates in the,1
BLINCYTO,macrophage activation syndrome,clinical trials of  drug cannot be directly compa red,1
BLINCYTO,macrophage activation syndrome,cannot be directly compa red to rates in the,1
BLINCYTO,HLH,directly d,1
BLINCYTO,HLH,d,1
BLINCYTO,HLH,d t o,1
BLINCYTO,HLH,d,1
BLINCYTO,MAS,clinical trials of another drug and may not reflect the rates observed in practice T,0
BLINCYTO,CRS,rug and,1
BLINCYTO,CRS,rug and may not,1
BLINCYTO,CRS,clinical trials of another rug and may,1
BLINCYTO,CRS,rug and may not,1
BLINCYTO,CRS,The safety data described in this section r,0
BLINCYTO,CRS,rug,1
BLINCYTO,CRS,rug and may not,1
BLINCYTO,CRS,rug and may not,1
BLINCYTO,CRS,rug and may not reflect,1
BLINCYTO,CRS,rug and may not,1
BLINCYTO,neurological toxicities,study,0
BLINCYTO,neurological toxicities, 37 years (range: 18 to years were male,1
BLINCYTO,neurological toxicities,study,0
BLINCYTO,neurological toxicities,(range: 18 to years were male were White,1
BLINCYTO,neurological toxicities,population 37 years (range: 18 to,1
BLINCYTO,neurological toxicities,White were Asian and were Black,0
BLINCYTO,neurological toxicities,population,0
BLINCYTO,neurological toxicities,18 to years were male were White,1
BLINCYTO,neurological toxicities,study population  37 years (range: 18 to,1
BLINCYTO,neurological toxicities,18 to years were male were White,1
BLINCYTO,neurological toxicities,37 years (range: 18 to,1
BLINCYTO,neurological toxicities,years (range: 18 to,1
BLINCYTO,fatal,The,0
BLINCYTO,fatal,", hea dache",1
BLINCYTO,encephalopathy,reported in of patients The most common serious,0
BLINCYTO,encephalopathy,Seri,0
BLINCYTO,encephalopathy,and,0
BLINCYTO,encephalopathy,constipation ous adverse re actions were reported in of,1
BLINCYTO,encephalopathy,and,0
BLINCYTO,speech disorders,patients The most common serious adverse reactions,0
BLINCYTO,speech disorders,reactions were ported in,1
BLINCYTO,speech disorders,Serious adverse reactions were ported in 65% of patients The,1
BLINCYTO,speech disorders,reactions were ported in,1
BLINCYTO,speech disorders,patients The most common serious adverse reactions included,0
BLINCYTO,speech disorders,re,0
BLINCYTO,speech disorders,Serious adverse reactions were ported in 65% of patients The,1
BLINCYTO,speech disorders,re,0
BLINCYTO,speech disorders,were ported,1
BLINCYTO,speech disorders,reactions were ported in 65% of patients The,1
BLINCYTO,speech disorders,were ported,1
BLINCYTO,speech disorders,adverse reactions included,0
BLINCYTO,speech disorders,65% of patients The most common,1
BLINCYTO,disturbances in consciousness,atients.,1
BLINCYTO,disturbances in consciousness,in of atients. The most common seri,1
BLINCYTO,disturbances in consciousness,most common seri,1
BLINCYTO,disturbances in consciousness,atients. The,1
BLINCYTO,disturbances in consciousness,pyrexia pneumonia,0
BLINCYTO,disturbances in consciousness,common seri ous adverse reactions,1
BLINCYTO,disturbances in consciousness,constipation Serious adverse reactions,0
BLINCYTO,confusion,febrile neutropenia pyrexia pneumonia sepsis neutropenia devicerel,0
BLINCYTO,confusion,adverse reactions were reported in,0
BLINCYTO,confusion,s,1
BLINCYTO,disorientation,common serious adverse tions (>=,1
BLINCYTO,disorientation,tions (>= 2%) included febrile neutropenia,1
BLINCYTO,disorientation,sepsis neutropenia,0
BLINCYTO,disorientation,The most common serious,0
BLINCYTO,disorientation,common serious adverse tions (>=,1
BLINCYTO,disorientation,common serious adverse,0
BLINCYTO,disorientation,tions (>= 2%),1
BLINCYTO,disorientation,febrile neutropenia,0
BLINCYTO,balance disorders,"adverse reactions included febrile penia, pyrexia,",1
BLINCYTO,balance disorders,"pyrexia, p neumonia sepsis",1
BLINCYTO,balance disorders,"penia, pyrexia, p neumonia sepsis",1
BLINCYTO,balance disorders,"pyrexia, p neumonia sepsis",1
BLINCYTO,balance disorders,neutropenia devicerelated infection tremor encephalopathy infection overdose,0
BLINCYTO,balance disorders,"febrile penia, pyrexia, p neumonia",1
BLINCYTO,balance disorders,neutropenia devicerelated infection tremor encephalopathy infection overdose,0
BLINCYTO,balance disorders,neutro,0
BLINCYTO,infections,as the reason discontinu,1
BLINCYTO,infections,neutro,0
BLINCYTO,infections,adverse reactions reported,0
BLINCYTO,infections,as the reason discontinu ation of treatment,1
BLINCYTO,infections,adverse reactions reported,0
BLINCYTO,sepsis,for discontinuation treatm ent included encephalopathy,1
BLINCYTO,sepsis,adverse reactions reported,0
BLINCYTO,sepsis,Fatal adverse events,0
BLINCYTO,sepsis,most frequently,0
BLINCYTO,sepsis,as the reason for discontinuation,0
BLINCYTO,sepsis,frequently as the reason,0
BLINCYTO,sepsis,adverse reactions reported most,0
BLINCYTO,sepsis,treatm ent included encephalopathy,1
BLINCYTO,sepsis,reason for discontinuation treatm ent included encephalopathy and sepsis,1
BLINCYTO,sepsis,treatm ent included encephalopathy,1
BLINCYTO,pneumonia,of t include d encephalopathy and sepsis,1
BLINCYTO,pneumonia,treatm ent included encephalopathy,1
BLINCYTO,pneumonia,discontinuation of t include d encephalopathy and sepsis,1
BLINCYTO,pneumonia,treatm ent included encephalopathy,1
BLINCYTO,pneumonia,INCYTO The adverse reactions reported most frequently as the reason for discontinuation of treatmen,0
BLINCYTO,pneumonia,in of patients The majority of these,0
BLINCYTO,pneumonia,for discontinuation of t include d encephalopathy and sepsis Fatal,1
BLINCYTO,pneumonia,in of patients The majority of these,0
BLINCYTO,pneumonia,most frequently as the reason for discontinuation of,0
BLINCYTO,pneumonia,of t include d encephalopathy,1
BLINCYTO,pneumonia,most frequently as the reason for discontinuation of,0
BLINCYTO,pneumonia,discontinuation of t include,1
BLINCYTO,pneumonia,of t include d encephalopathy and sepsis Fatal,1
BLINCYTO,pneumonia,discontinuation of t include,1
BLINCYTO,pneumonia,t include d encephalopathy and sepsis,1
BLINCYTO,pneumonia,reason for discontinuation of t include,1
BLINCYTO,pneumonia,t include d encephalopathy and sepsis,1
BLINCYTO,pneumonia,encephalopathy and,0
BLINCYTO,pneumonia,for discontinuation of t include,1
BLINCYTO,pneumonia,encephalopathy and,0
BLINCYTO,pneumonia,t include d encephalopathy,1
BLINCYTO,pneumonia,encephalopathy and,0
BLINCYTO,bacteremia,encephalop athy and,1
BLINCYTO,opportunistic infections,for discontinuation of treatment included,0
BLINCYTO,opportunistic infections,included hy and,1
BLINCYTO,opportunistic infections,of treatment included hy and,1
BLINCYTO,opportunistic infections,frequently as the reason for,0
BLINCYTO,catheter-site infections,vents occurred in,1
BLINCYTO,catheter-site infections,occurred in 15% of patients The majority,1
BLINCYTO,catheter-site infections,vents occurred,1
BLINCYTO,catheter-site infections,the reason,0
BLINCYTO,catheter-site infections,e,0
BLINCYTO,catheter-site infections,events occurred,0
BLINCYTO,catheter-site infections,Fatal adverse vents occurred,1
BLINCYTO,catheter-site infections,vents occurred in 15% of,1
BLINCYTO,catheter-site infections,Fatal adverse vents occurred in 15% of patients The,1
BLINCYTO,catheter-site infections,vents occurred in 15% of,1
BLINCYTO,catheter-site infections,15% of,1
BLINCYTO,fatal,for any grade,0
BLINCYTO,fatal,in of,0
BLINCYTO,fatal,No fatal adverse events d on,1
BLINCYTO,fatal,No fatal adverse events d on  treatment among patients in remission,1
BLINCYTO,fatal,No fatal adverse events d on,1
BLINCYTO,fatal,No fatal adverse events d on  treatment among,1
BLINCYTO,fatal,No fatal adverse events d on,1
BLINCYTO,fatal,remission The adverse reactions with,0
BLINCYTO,Tumor lysis syndrome,>= 5% Incidence for Grade or Higher N Adverse,1
BLINCYTO,Tumor lysis syndrome,her are summarized in Table Table Adverse Reactions With Incidence for,0
BLINCYTO,Tumor lysis syndrome,>= 5% Incidence,1
BLINCYTO,Tumor lysis syndrome,Any GradeGrading based on NCI Common,0
BLINCYTO,Tumor lysis syndrome,on NCI,0
BLINCYTO,Tumor lysis syndrome,Any Grade  >= 5% Incidence for Grade or Higher,1
BLINCYTO,Tumor lysis syndrome,on NCI,0
BLINCYTO,Tumor lysis syndrome,>= 5%,1
BLINCYTO,Tumor lysis syndrome,Incidence for,1
BLINCYTO,Tumor lysis syndrome,>= 5% Incidence for Grade or Higher N Adverse,1
BLINCYTO,Tumor lysis syndrome,>= 5% Incidence for Grade or Higher,1
BLINCYTO,Tumor lysis syndrome,Grade,0
BLINCYTO,TLS,rad e,1
BLINCYTO,TLS,rad e or Higher,1
BLINCYTO,TLS,for rad e or,1
BLINCYTO,TLS,rad e or Higher,1
BLINCYTO,TLS,Reaction Any,0
BLINCYTO,fatal,eacti on,1
BLINCYTO,fatal,Grade or Incidence for,0
BLINCYTO,fatal,R,0
BLINCYTO,fatal,based on NCI Common Terminology Criteria,0
BLINCYTO,fatal,NCI Common Terminology Criteria,0
BLINCYTO,fatal,eacti on Any,1
BLINCYTO,fatal,eacti on Any GradeGrading based,1
BLINCYTO,fatal,eacti on Any,1
BLINCYTO,fatal,or Higher N Adverse eacti on Any GradeGrading based on,1
BLINCYTO,fatal,eacti on Any,1
BLINCYTO,Neutropenia,neutropenic tis.     Ab dominal pain Vomiting General disorders,1
BLINCYTO,Neutropenia,eacti on Any,1
BLINCYTO,Neutropenia,diarrhea,0
BLINCYTO,Neutropenia,dominal pain Vomiting General,0
BLINCYTO,Neutropenia,tis. Ab dominal pain Vomiting General,1
BLINCYTO,Neutropenia,enteritis and neutropenic tis.     Ab dominal,1
BLINCYTO,Neutropenia,tis. Ab dominal pain Vomiting General,1
BLINCYTO,Neutropenia,tis. Ab,1
BLINCYTO,Neutropenia,General,0
BLINCYTO,Neutropenia,General disorders and,0
BLINCYTO,Neutropenia,tis. Ab dominal pain Vomiting General,1
BLINCYTO,Neutropenia,tis.,1
BLINCYTO,Neutropenia,colitis,0
BLINCYTO,Neutropenia,the following terms colitis diarrhea,0
BLINCYTO,Neutropenia,disorders and,0
BLINCYTO,Neutropenia,tis. Ab,1
BLINCYTO,Neutropenia,tis. Ab dominal pain Vomiting,1
BLINCYTO,Neutropenia,pain Vomiting General disorders and administ,0
BLINCYTO,Neutropenia,dominal pain Vomiting General disorders and,0
BLINCYTO,febrile neutropenia,g General disorders,0
BLINCYTO,febrile neutropenia,al pain     Vomitin g,1
BLINCYTO,febrile neutropenia,g General disorders,0
BLINCYTO,febrile neutropenia,and,0
BLINCYTO,febrile neutropenia,disorders,0
BLINCYTO,febrile neutropenia,General disorders and,0
BLINCYTO,febrile neutropenia,and neutropenic colitis al pain     Vomitin g,1
BLINCYTO,febrile neutropenia,General disorders and,0
BLINCYTO,febrile neutropenia,and neutropenic colitis al pain,1
BLINCYTO,neurologic events,Fungal infections,0
BLINCYTO,neurologic events,and infestations Other pathogen infections Bacte,0
BLINCYTO,neurologic events,Bacte,0
BLINCYTO,seizures,infections Pneumonia,0
BLINCYTO,seizures,Fungal fections Viral infections Pneumonia Sepsis,1
BLINCYTO,seizures,infections Pneumonia,0
BLINCYTO,seizures,fections Viral infections Pneumonia,1
BLINCYTO,loss of consciousness,aminotransferase Increased,0
BLINCYTO,loss of consciousness,alanine aminotransferase Increased aspartate,0
BLINCYTO,loss of consciousness,        4419151397   ,1
BLINCYTO,loss of consciousness,infections Pneumonia Sepsis,0
BLINCYTO,loss of consciousness,        4419151397    Investigations Increased alanine aminotransferase,1
BLINCYTO,loss of consciousness,infections,0
BLINCYTO,elevations in liver enzymes,appetite 60735 Musculoskelet,1
BLINCYTO,CRS,connective,0
BLINCYTO,CRS,    Bone pain Arthralgia Nervous,1
BLINCYTO,CRS,    Bone pain Arthralgia Nervous system,1
BLINCYTO,CRS,    Bone pain Arthralgia Nervous,1
BLINCYTO,CRS,   ,1
BLINCYTO,CRS,pain Arthralgia Nervous system disorders,0
BLINCYTO,CRS,Nervous,0
BLINCYTO,CRS,disorders Back,0
BLINCYTO,CRS,Arthralgia Nervous,0
BLINCYTO,CRS,Back pain Pain in     Bone pain Arthralgia Nervous,1
BLINCYTO,CRS,Arthralgia Nervous,0
BLINCYTO,elevations in liver enzymes,tremor and remor. Dizziness,1
BLINCYTO,elevations in liver enzymes,resting tremor and remor.     Dizziness        Psychiatric disorders,1
BLINCYTO,elevations in liver enzymes,tremor and remor. Dizziness,1
BLINCYTO,CRS,a   Respiratory,1
BLINCYTO,CRS,tremor and remor. Dizziness,1
BLINCYTO,leukoencephalopathy,rash and vesicular .        21       2 Vascular disorders,1
BLINCYTO,leukoencephalopathy,tremor and remor. Dizziness,1
BLINCYTO,leukoencephalopathy,disorders Hypotension,0
NATAZIA,cardiovascular events,cardiovascular events and stroke see,1
NATAZIA,cardiovascular events,labeling Serious,0
NATAZIA,cardiovascular events,and stroke see Boxed,0
NATAZIA,cardiovascular events,cardiovascular events and stroke see,1
NATAZIA,cardiovascular events,elsewhere in the labeling cardiovascular events and,1
NATAZIA,cardiovascular events,cardiovascular events and stroke see,1
NATAZIA,stroke,events stroke see Boxed Warning and Warnings,1
NATAZIA,stroke,cardiovascular events and stroke see,1
NATAZIA,stroke,Warnings,0
NATAZIA,stroke,stroke see Boxed,1
NATAZIA,stroke,events stroke see Boxed Warning and Warnings,1
NATAZIA,stroke,stroke see Boxed,1
NATAZIA,stroke,Boxed Warning and Warnings and Precautions Vascular events see Warnings,0
NATAZIA,stroke,Warnings and Precautions Vascular events see,0
NATAZIA,stroke,stroke see,1
NATAZIA,stroke,stroke,1
NATAZIA,stroke,Warning and Warnings,0
NATAZIA,stroke,stroke see Boxed Warning and Warnings,1
NATAZIA,Irregular uterine bleeding,uterine bleeding Nausea,1
NATAZIA,Irregular uterine bleeding,Nausea Breast tenderness Headache EXCERPT,0
NATAZIA,Irregular uterine bleeding,reported by COC users Irregular uterine,1
NATAZIA,Irregular uterine bleeding,tenderness Headache EXCERPT The,0
NATAZIA,Irregular uterine bleeding,reactions commonly reported by COC users,0
NATAZIA,Nausea,Nausea Breast tenderness Headache EXCERPT,1
NATAZIA,Nausea,EXCERPT The most,0
NATAZIA,Nausea,Nausea Breast tenderness Headache EXCERPT,1
NATAZIA,Nausea,COC users are Irregular uterine,0
NATAZIA,Nausea,Nausea Breast,1
NATAZIA,Nausea,COC users are Irregular uterine,0
NATAZIA,Nausea,The most,0
NATAZIA,Nausea,reactions,0
NATAZIA,Nausea,Adverse reactions commonly reported by COC users are,0
NATAZIA,Nausea,Nausea Breast tenderness,1
NATAZIA,Nausea,Adverse reactions commonly reported by COC users are,0
NATAZIA,Headache,Headache EXCERPT,1
NATAZIA,Headache,common adverse reactions in clinical trials for,0
NATAZIA,Headache,most common adverse reactions in clinical trials for,0
NATAZIA,Headache,uterine bleeding Nausea Breast Headache EXCERPT,1
NATAZIA,Headache,most common adverse reactions in clinical trials for,0
NATAZIA,Headache,reactions,0
NATAZIA,Headache,reactions in clinical,0
NATAZIA,Headache,Nausea Breast Headache,1
NATAZIA,Headache,reactions in clinical,0
NATAZIA,headaches,common adverse reactions in clinical trials for Natazia,0
NATAZIA,headaches,breast tendernesspain,0
NATAZIA,headaches,uterine bleedingheadache including migraines breast,0
NATAZIA,headaches,headaches irregular uterine,1
NATAZIA,headaches,for Natazia headaches irregular uterine,1
NATAZIA,headaches,headaches irregular uterine,1
NATAZIA,headaches,Natazia are,0
NATAZIA,headaches,Natazia headaches irregular uterine,1
NATAZIA,headaches,Natazia are,0
NATAZIA,headaches,headaches irregular uterine,1
NATAZIA,headache,headache including,1
NATAZIA,headache,irregular uterine headache including migraines,1
NATAZIA,headache,headache including,1
NATAZIA,headache,menstrual disorders nausea or,0
NATAZIA,headache,headache including migraines breast tendernesspain menstrual,1
NATAZIA,headache,menstrual disorders nausea or,0
NATAZIA,headache,headache including migraines breast tendernesspain,1
NATAZIA,headache,nausea or,0
NATAZIA,headache,nausea or,0
NATAZIA,headache,headache including migraines breast tendernesspain,1
NATAZIA,headache,bleeding,0
NATAZIA,migraines,migraines breast tendernesspain,1
NATAZIA,migraines,uterine bleedingheadache migraines,1
NATAZIA,migraines,migraines breast tendernesspain,1
NATAZIA,breast tenderness,uterine bleedingheadache including breast tenderness pain menstrual,1
NATAZIA,breast tenderness,migraines breast tendernesspain,1
NATAZIA,breast tenderness,al trials for Natazia are headaches irregular uterine bleedingheadache including migraines,0
NATAZIA,breast tenderness,irregular uterine bleedingheadache including breast tenderness,1
NATAZIA,breast tenderness,bleedingheadache including breast tenderness pain menstrual disorders nausea,1
NATAZIA,breast tenderness,irregular uterine bleedingheadache including breast tenderness,1
NATAZIA,breast tenderness,uterine bleedingheadache including,0
NATAZIA,breast tenderness,pain,0
NATAZIA,breast tenderness,trials for Natazia are,0
NATAZIA,breast tenderness,uterine bleedingheadache including breast tenderness pain,1
NATAZIA,breast tenderness,trials for Natazia are,0
NATAZIA,menstrual disorders,menstrual disorders nausea or vomiting acne,1
NATAZIA,menstrual disorders,migraines breast menstrual disorders,1
NATAZIA,menstrual disorders,menstrual disorders nausea or vomiting acne,1
NATAZIA,menstrual disorders,menstrual disorders nausea or vomiting acne,1
NATAZIA,nausea,vomiting acne mood changes and increased weight,0
NATAZIA,nausea,tendernesspain menstrual disorders,0
NATAZIA,nausea,nausea,1
NATAZIA,nausea,changes and increased weight To report,0
NATAZIA,nausea,increased weight,0
NATAZIA,nausea,nausea or vomiting,1
NATAZIA,acne,acne,1
NATAZIA,acne,acne mood changes and,1
NATAZIA,acne,acne,1
NATAZIA,acne,menstrual disorders nausea or acne mood,1
NATAZIA,acne,acne,1
NATAZIA,acne,acne mood changes and increased,1
NATAZIA,acne,acne mood changes,1
NATAZIA,acne,changes,0
NATAZIA,mood changes,report,0
NATAZIA,mood changes,mood changes,1
NATAZIA,mood changes,or vomiting mood changes and,1
NATAZIA,mood changes,mood changes,1
NATAZIA,mood changes,mood,1
NATAZIA,mood changes,disorders nausea or vomiting mood,1
NATAZIA,mood changes,mood changes and increased weight To,1
NATAZIA,mood changes,disorders nausea or vomiting mood,1
NATAZIA,mood changes,disorders nausea,0
NATAZIA,mood changes,weight To report,0
NATAZIA,increased weight,increased weight To,1
NATAZIA,increased weight,acne mood,0
NATAZIA,increased weight,mood changes increased weight To report SUSPECTED,1
NATAZIA,increased weight,acne mood,0
NATAZIA,increased weight,mood changes increased weight To report SUSPECTED ADVERSE REACTIONS,1
NATAZIA,increased weight,acne mood,0
NATAZIA,increased weight,vomiting acne mood changes and,0
NATAZIA,increased weight,or vomiting acne,0
NATAZIA,increased weight,increased weight To report SUSPECTED ADVERSE REACTIONS,1
NATAZIA,increased weight,increased weight,1
NATAZIA,menstrual disorder,reactions leading,0
NATAZIA,menstrual disorder,genital hemorrhage vaginal,0
NATAZIA,menstrual disorder,menstrual disorder metrorrhagia,1
NATAZIA,menstrual disorder,genital hemorrhage vaginal,0
NATAZIA,menstrual disorder,reactions leading to discontinuation menstrual disorder metrorrhagia menorrhagia menstruation,1
NATAZIA,menstrual disorder,genital hemorrhage vaginal,0
NATAZIA,menstrual disorder,reactions leading to discontinuation menstrual disorder,1
NATAZIA,metrorrhagia,metrorrhagia menorrhagia menstruation irregular,1
NATAZIA,metrorrhagia,metrorrhagia menorrhagia menstruation,1
NATAZIA,metrorrhagia,menstrual,0
NATAZIA,metrorrhagia,the most frequent adverse reactions leading to discontinuation were menstrual,0
NATAZIA,menorrhagia,menorrhagia menstruation irregular genital hemorrhage,1
NATAZIA,menorrhagia,menorrhagia menstruation irregular genital hemorrhage,1
NATAZIA,menorrhagia,menorrhagia menstruation irregular genital hemorrhage,1
NATAZIA,menstruation irregular,menstruation irregular genital hemorrhage,1
NATAZIA,menstruation irregular,menstrual disorder metrorrhagia menorrhagia,0
NATAZIA,menstruation irregular,were menstrual disorder metrorrhagia menstruation irregular genital,1
NATAZIA,menstruation irregular,menstrual disorder metrorrhagia menorrhagia,0
NATAZIA,menstruation irregular,menstrual disorder metrorrhagia menstruation irregular genital hemorrhage vaginal,1
NATAZIA,menstruation irregular,menstrual disorder metrorrhagia menorrhagia,0
NATAZIA,menstruation irregular,were menstrual disorder metrorrhagia menstruation irregular genital hemorrhage vaginal,1
NATAZIA,menstruation irregular,menstrual disorder metrorrhagia menorrhagia,0
NATAZIA,menstruation irregular,leading to discontinuation were,0
NATAZIA,genital hemorrhage,mood changes depression,0
NATAZIA,genital hemorrhage,ding to,0
NATAZIA,genital hemorrhage,genital hemorrhage vaginal hemorrhage dysfunctional,1
NATAZIA,genital hemorrhage,metrorrhagia menorrhagia menstruation genital hemorrhage,1
NATAZIA,genital hemorrhage,ding to discontinuation,0
NATAZIA,genital hemorrhage,genital hemorrhage,1
NATAZIA,genital hemorrhage,menstruation,0
NATAZIA,genital hemorrhage,genital hemorrhage,1
NATAZIA,genital hemorrhage,menorrhagia menstruation genital hemorrhage vaginal hemorrhage dysfunctional uterine,1
NATAZIA,genital hemorrhage,genital hemorrhage,1
NATAZIA,vaginal hemorrhage,genital vaginal hemorrhage dysfunctional uterine bleeding mood,1
NATAZIA,vaginal hemorrhage,genital hemorrhage,1
NATAZIA,vaginal hemorrhage,changes depression mood swings mood altered,0
NATAZIA,vaginal hemorrhage,menorrhagia menstruation,0
NATAZIA,vaginal hemorrhage,changes depression mood,0
NATAZIA,vaginal hemorrhage,disorder metrorrhagia menorrhagia menstruation,0
NATAZIA,dysfunctional uterine bleeding,uterine bleeding mood changes,1
NATAZIA,dysfunctional uterine bleeding,uterine bleeding mood,1
NATAZIA,dysfunctional uterine bleeding,dysfunctional uterine bleeding mood,1
NATAZIA,dysfunctional uterine bleeding,mood,0
NATAZIA,dysfunctional uterine bleeding,vaginal dysfunctional uterine bleeding,1
NATAZIA,mood changes,dysfunctional uterine mood changes depression mood,1
NATAZIA,mood changes,vaginal dysfunctional uterine bleeding,1
NATAZIA,mood changes,dysfunctional uterine mood changes,1
NATAZIA,mood changes,vaginal dysfunctional uterine bleeding,1
NATAZIA,mood changes,mood swings mood altered depressed mood dysthymic disorder,0
NATAZIA,mood changes,mood changes,1
NATAZIA,mood changes,mood swings mood altered depressed mood dysthymic disorder,0
NATAZIA,mood changes,disorder crying acne,0
NATAZIA,mood changes,hemorrhage dysfunctional uterine mood changes depression mood swings,1
NATAZIA,mood changes,disorder crying acne,0
NATAZIA,depression,dysthymic,0
NATAZIA,depression,depression,1
NATAZIA,depression,uterine bleeding mood,0
NATAZIA,mood swings,mood swings mood,1
NATAZIA,mood swings,bleeding mood changes mood,1
NATAZIA,mood swings,uterine bleeding mood changes mood swings mood altered depressed mood,1
NATAZIA,mood swings,bleeding mood changes mood,1
NATAZIA,mood swings,vaginal hemorrhage dysfunctional uterine,0
NATAZIA,mood altered,mood altered depressed mood dysthymic disorder crying,1
NATAZIA,mood altered,mood mood altered,1
NATAZIA,mood altered,depressed mood dysthymic disorder crying acne headache including migraines,0
NATAZIA,depressed mood,mood depressed,1
NATAZIA,crying,crying,1
NATAZIA,crying,crying acne,1
NATAZIA,crying,crying acne headache including,1
NATAZIA,crying,crying acne headache including migraines and,1
NATAZIA,crying,including migraines,0
NATAZIA,crying,migraines,0
NATAZIA,crying,g mood changes depression mood swings mood altered depressed mood dysthymic disorder,0
NATAZIA,crying,crying acne headache,1
NATAZIA,crying,depressed mood dysthymic crying acne,1
NATAZIA,crying,crying acne headache,1
NATAZIA,crying,migraines and weight,0
NATAZIA,acne,disorder crying,0
NATAZIA,weight increased,including migraines weight increased Common Adverse,1
NATAZIA,weight increased,disorder crying,0
NATAZIA,headache,Common Adverse headache including migraines breast,1
NATAZIA,headache,disorder crying,0
NATAZIA,migraines,Common Adverse Reactions headache,0
NATAZIA,migraines,discomfort or tenderness menstrual disorders,0
NATAZIA,migraines,increased Common,0
NATAZIA,migraines,migraines breast pain discomfort or tenderness,1
NATAZIA,breast pain,breast,1
NATAZIA,breast pain,breast pain discomfort or,1
NATAZIA,breast pain,Reactions headache including breast pain,1
NATAZIA,breast pain,breast pain discomfort or,1
NATAZIA,metrorrhagia,menstrual disorders,0
NATAZIA,menstruation irregular,or tenderness menstrual disorders menstruation irregular menorrhagia vaginal hemorrhage,1
NATAZIA,menstruation irregular,menstrual disorders,0
NATAZIA,menstruation irregular,bleeding genital hemorrhage,0
NATAZIA,menstruation irregular,tenderness menstrual disorders menstruation irregular,1
NATAZIA,menstruation irregular,or tenderness menstrual disorders menstruation irregular menorrhagia,1
NATAZIA,menstruation irregular,tenderness menstrual disorders menstruation irregular,1
NATAZIA,menstruation irregular,dysfunctional uterine bleeding genital hemorrhage abnormal,0
NATAZIA,menstruation irregular,menstruation irregular menorrhagia vaginal hemorrhage dysfunctional uterine,1
NATAZIA,menstruation irregular,menstrual disorders menstruation,1
NATAZIA,menstruation irregular,or tenderness menstrual disorders menstruation irregular,1
NATAZIA,menorrhagia,menorrhagia vaginal hemorrhage dysfunctional,1
NATAZIA,menorrhagia,or tenderness menstrual disorders menstruation irregular,1
NATAZIA,menorrhagia,disorders metrorrhagia menstruation menorrhagia vaginal hemorrhage,1
NATAZIA,menorrhagia,or tenderness menstrual disorders menstruation irregular,1
NATAZIA,menorrhagia,pain discomfort or,0
NATAZIA,menorrhagia,disorders metrorrhagia menstruation menorrhagia vaginal hemorrhage dysfunctional uterine bleeding,1
NATAZIA,menorrhagia,pain discomfort or,0
NATAZIA,menorrhagia,hemorrhage abnormal withdrawal bleedi,0
NATAZIA,menorrhagia,menstruation irregular,0
NATAZIA,vaginal hemorrhage,disorders metrorrhagia menstruation irregular vaginal,1
NATAZIA,vaginal hemorrhage,vaginal hemorrhage dysfunctional uterine,1
NATAZIA,vaginal hemorrhage,disorders metrorrhagia menstruation irregular menorrhagia,0
NATAZIA,vaginal hemorrhage,genital hemorrhage abnormal,0
NATAZIA,vaginal hemorrhage,metrorrhagia menstruation irregular vaginal hemorrhage dysfunctional uterine,1
NATAZIA,vaginal hemorrhage,genital hemorrhage abnormal,0
NATAZIA,vaginal hemorrhage,abnormal withdrawal bleeding uterine hemorrha,0
NATAZIA,dysfunctional uterine bleeding,hemorrhage,0
NATAZIA,dysfunctional uterine bleeding,menorrhagia vaginal dysfunctional uterine bleeding,1
NATAZIA,dysfunctional uterine bleeding,hemorrhage,0
NATAZIA,dysfunctional uterine bleeding,dysfunctional uterine bleeding genital hemorrhage abnormal,1
NATAZIA,genital hemorrhage,genital hemorrhage,1
NATAZIA,genital hemorrhage,bleeding,0
NATAZIA,genital hemorrhage,uterine genital,1
NATAZIA,abnormal withdrawal bleeding,hemorrhage nausea or vomiting acne mood changes depression,0
NATAZIA,abnormal withdrawal bleeding,abnormal withdrawal bleeding,1
NATAZIA,abnormal withdrawal bleeding,genital abnormal withdrawal bleeding,1
NATAZIA,abnormal withdrawal bleeding,abnormal withdrawal bleeding,1
NATAZIA,uterine hemorrhage,uterine,1
NATAZIA,uterine hemorrhage,uterine,1
NATAZIA,uterine hemorrhage,hemorrhage abnormal withdrawal uterine hemorrhage nausea or vomiting,1
NATAZIA,uterine hemorrhage,uterine,1
NATAZIA,uterine hemorrhage,genital hemorrhage abnormal withdrawal uterine hemorrhage nausea,1
NATAZIA,uterine hemorrhage,uterine,1
NATAZIA,uterine hemorrhage,abnormal withdrawal uterine,1
NATAZIA,uterine hemorrhage,genital hemorrhage abnormal withdrawal uterine hemorrhage,1
NATAZIA,uterine hemorrhage,uterine hemorrhage,1
NATAZIA,uterine hemorrhage,vomiting acne mood changes depression,0
NATAZIA,uterine hemorrhage,uterine hemorrhage nausea,1
NATAZIA,uterine hemorrhage,vomiting acne mood changes depression,0
NATAZIA,uterine hemorrhage,bleeding,0
NATAZIA,nausea,abnormal withdrawal bleeding uterine nausea or vomiting acne,1
NATAZIA,nausea,bleeding,0
NATAZIA,nausea,nausea or vomiting acne,1
NATAZIA,nausea,nausea or vomiting acne mood,1
NATAZIA,nausea,withdrawal bleeding uterine nausea,1
NATAZIA,nausea,nausea or vomiting acne mood,1
NATAZIA,nausea,nausea or vomiting acne,1
NATAZIA,nausea,uterine bleeding genital hemorrhage abnormal withdrawal,0
NATAZIA,nausea,nausea or vomiting acne mood changes,1
NATAZIA,nausea,nausea or,1
NATAZIA,vomiting,vomiting acne mood changes,1
NATAZIA,vomiting,vomiting acne mood changes depression,1
NATAZIA,vomiting,bleeding uterine hemorrhage nausea vomiting acne mood changes,1
NATAZIA,vomiting,vomiting acne mood changes depression,1
NATAZIA,acne,or vomiting,0
NATAZIA,acne,hemorrhage nausea or acne mood changes depression,1
NATAZIA,acne,or vomiting,0
NATAZIA,mood changes,mood swings depressed,0
NATAZIA,mood changes,depression mood swings,0
NATAZIA,mood changes,hemorrhage nausea or vomiting mood changes,1
NATAZIA,mood changes,depression mood swings,0
NATAZIA,mood changes,hemorrhage nausea or vomiting mood changes,1
NATAZIA,mood changes,acne,0
NATAZIA,mood changes,vomiting acne,0
NATAZIA,depression,disorder crying and,0
NATAZIA,depression,acne mood depression mood swings depressed mood,1
NATAZIA,depression,disorder crying and,0
NATAZIA,depression,depression mood swings depressed mood,1
NATAZIA,depression,depression mood,1
NATAZIA,depression,uterine hemorrhage nausea or,0
NATAZIA,depression,depression mood swings depressed mood,1
NATAZIA,mood swings,mood changes mood,1
NATAZIA,mood swings,vomiting acne mood changes mood swings,1
NATAZIA,mood swings,changes mood swings,1
NATAZIA,mood swings,mood changes,0
NATAZIA,mood swings,ding uterine hemorrhage nausea,0
NATAZIA,mood swings,mood,1
NATAZIA,mood swings,vomiting acne mood changes mood swings depressed mood mood altered,1
NATAZIA,mood swings,mood,1
NATAZIA,depressed mood,depressed mood,1
NATAZIA,depressed mood,lability dysthymic disorder crying,0
NATAZIA,depressed mood,and increased weight,0
NATAZIA,depressed mood,depressed mood mood altered affect,1
NATAZIA,depressed mood,disorder,0
NATAZIA,depressed mood,affect lability dysthymic disorder crying and,0
NATAZIA,depressed mood,mood altered affect,0
NATAZIA,depressed mood,mood changes depression mood depressed mood mood,1
NATAZIA,depressed mood,mood altered affect,0
NATAZIA,depressed mood,dysthymic,0
NATAZIA,mood altered,increased weight Serious,0
NATAZIA,mood altered,disorder crying,0
NATAZIA,mood altered,swings depressed mood altered affect lability,1
NATAZIA,mood altered,disorder crying,0
NATAZIA,mood altered,mood altered affect,1
NATAZIA,mood altered,disorder crying,0
NATAZIA,mood altered,crying,0
NATAZIA,affect lability,Serious,0
NATAZIA,affect lability,mood mood affect,1
NATAZIA,affect lability,affect lability dysthymic disorder crying,1
NATAZIA,affect lability,affect lability dysthymic disorder crying and increased,1
NATAZIA,affect lability,disorder crying and increased weight Serious,0
NATAZIA,crying,crying,1
NATAZIA,crying,Serious Adverse Reactions myocardial infarction,0
NATAZIA,crying,lability dysthymic crying and increased weight,1
NATAZIA,crying,Serious Adverse Reactions myocardial infarction,0
NATAZIA,increased weight,increased weight,1
NATAZIA,increased weight,lability dysthymic disorder crying,0
NATAZIA,increased weight,disorder crying increased weight Serious Adverse Reactions myocardial,1
NATAZIA,increased weight,lability dysthymic disorder crying,0
NATAZIA,increased weight,increased weight Serious Adverse Reactions myocardial,1
NATAZIA,increased weight,myocardial infarction cases,0
NATAZIA,increased weight,increased weight Serious Adverse Reactions myocardial,1
NATAZIA,increased weight,myocardial infarction cases,0
NATAZIA,increased weight,dysthymic disorder crying increased weight Serious Adverse Reactions myocardial infarction,1
NATAZIA,increased weight,myocardial infarction cases,0
NATAZIA,myocardial infarction,myocardial infarction cases ruptured ovarian cyst,1
NATAZIA,ruptured ovarian cyst,infarction ruptured ovarian cyst cases deep vein thrombosis,1
NATAZIA,ruptured ovarian cyst,myocardial infarction cases ruptured ovarian cyst,1
NATAZIA,ruptured ovarian cyst,Reactions myocardial infarction ruptured ovarian cyst,1
NATAZIA,ruptured ovarian cyst,liver,0
NATAZIA,ruptured ovarian cyst,the liver uterine leiomyoma acute,0
NATAZIA,ruptured ovarian cyst,Adverse Reactions myocardial infarction ruptured ovarian cyst,1
NATAZIA,ruptured ovarian cyst,Adverse Reactions myocardial infarction ruptured ovarian cyst,1
NATAZIA,ruptured ovarian cyst,Adverse Reactions myocardial,0
NATAZIA,ruptured ovarian cyst,ovarian cyst,1
NATAZIA,ruptured ovarian cyst,hyperplasia of the liver uterine leiomyoma,0
NATAZIA,deep vein thrombosis,uterine leiomyoma acute cholecystitis and chronic,0
NATAZIA,deep vein thrombosis,cases ruptured ovarian cyst deep vein thrombosis focal nodular hyperplasia of,1
NATAZIA,deep vein thrombosis,uterine leiomyoma acute cholecystitis and chronic,0
NATAZIA,deep vein thrombosis,liver uterine,0
NATAZIA,deep vein thrombosis,ruptured ovarian cyst deep vein thrombosis,1
NATAZIA,deep vein thrombosis,deep vein thrombosis focal nodular,1
NATAZIA,deep vein thrombosis,infarction cases ruptured ovarian cyst,0
NATAZIA,deep vein thrombosis,cyst deep vein,1
NATAZIA,deep vein thrombosis,deep vein thrombosis,1
NATAZIA,deep vein thrombosis,cyst deep vein,1
NATAZIA,deep vein thrombosis,ovarian cyst deep vein thrombosis focal nodular hyperplasia of,1
NATAZIA,deep vein thrombosis,cyst deep vein,1
NATAZIA,focal nodular hyperplasia of the liver,the liver uterine leiomyoma,1
NATAZIA,focal nodular hyperplasia of the liver,and chronic acalculous cholecystitis Postmarket,0
NATAZIA,focal nodular hyperplasia of the liver,cases deep vein focal nodular hyperplasia of the liver,1
NATAZIA,focal nodular hyperplasia of the liver,and chronic acalculous cholecystitis Postmarket,0
NATAZIA,focal nodular hyperplasia of the liver,deep vein focal nodular hyperplasia of the liver uterine leiomyoma acute cholecystitis and,1
NATAZIA,focal nodular hyperplasia of the liver,and chronic acalculous cholecystitis Postmarket,0
NATAZIA,focal nodular hyperplasia of the liver,vein focal nodular hyperplasia of,1
NATAZIA,uterine leiomyoma,the uterine leiomyoma acute cholecystitis,1
NATAZIA,uterine leiomyoma,vein focal nodular hyperplasia of,1
NATAZIA,uterine leiomyoma,uterine leiomyoma acute cholecystitis and chronic,1
NATAZIA,uterine leiomyoma,vein focal nodular hyperplasia of,1
NATAZIA,uterine leiomyoma,Postmarketing Experience,0
NATAZIA,uterine leiomyoma,cholecystitis and chronic acalculous cholecystitis,0
NATAZIA,uterine leiomyoma,nodular hyperplasia of,0
NATAZIA,uterine leiomyoma,hyperplasia of the uterine leiomyoma,1
NATAZIA,acute cholecystitis,liver uterine acute,1
NATAZIA,acute cholecystitis,focal nodular,0
NATAZIA,acute cholecystitis,the liver uterine acute cholecystitis,1
NATAZIA,acute cholecystitis,deep vein thrombosis focal nodular hyperplasia of the liver uterine leiomyoma,0
NATAZIA,acute cholecystitis,acute cholecystitis and chronic acalculous,1
NATAZIA,chronic acalculous cholecystitis,chronic acalculous cholecystitis Postmarketing Experience The following,1
NATAZIA,chronic acalculous cholecystitis,The following adverse reactions have been identified,0
NATAZIA,chronic acalculous cholecystitis,Experience The,0
NATAZIA,chronic acalculous cholecystitis,uterine leiomyoma acute cholecystitis chronic acalculous,1
NATAZIA,chronic acalculous cholecystitis,acalculous cholecystitis,1
NATAZIA,chronic acalculous cholecystitis,acute cholecystitis chronic acalculous cholecystitis,1
NATAZIA,chronic acalculous cholecystitis,acute cholecystitis chronic acalculous cholecystitis Postmarketing Experience,1
NATAZIA,chronic acalculous cholecystitis,acute cholecystitis chronic acalculous cholecystitis,1
NATAZIA,arterial thromboembolic events,thromboembolic events,1
NATAZIA,arterial thromboembolic events,disorders Venous arterial thromboembolic events including pulmonary emboli deep,1
NATAZIA,arterial thromboembolic events,thromboembolic events,1
NATAZIA,arterial thromboembolic events,drug exposure Vascular disorders Venous and,0
NATAZIA,arterial thromboembolic events,myocardial,0
NATAZIA,arterial thromboembolic events,thrombosis cerebral thrombosis myocardial,0
NATAZIA,arterial thromboembolic events,arterial thromboembolic events,1
NATAZIA,arterial thromboembolic events,thromboembolic events including pulmonary emboli deep,1
NATAZIA,arterial thromboembolic events,Venous arterial thromboembolic events including pulmonary emboli deep,1
NATAZIA,arterial thromboembolic events,thromboembolic events including pulmonary emboli deep,1
NATAZIA,pulmonary emboli,pulmonary emboli,1
NATAZIA,pulmonary emboli,thromboembolic events including pulmonary emboli deep,1
NATAZIA,pulmonary emboli,pulmonary emboli deep vein thrombosis,1
NATAZIA,pulmonary emboli,arterial thromboembolic events pulmonary,1
NATAZIA,pulmonary emboli,and arterial thromboembolic events pulmonary emboli deep vein thrombosis cerebral,1
NATAZIA,pulmonary emboli,arterial thromboembolic events pulmonary,1
NATAZIA,pulmonary emboli,events pulmonary,1
NATAZIA,pulmonary emboli,and arterial thromboembolic events pulmonary emboli,1
NATAZIA,pulmonary emboli,events pulmonary,1
NATAZIA,pulmonary emboli,including,0
NATAZIA,pulmonary emboli,exposure Vascular disorders Venous and arterial thromboembolic,0
NATAZIA,deep vein thrombosis,stroke hypertension Hepatobiliary disorders,0
NATAZIA,deep vein thrombosis,arterial,0
NATAZIA,cerebral thrombosis,deep vein cerebral thrombosis myocardial infarction and stroke hypertension,1
NATAZIA,cerebral thrombosis,arterial,0
NATAZIA,cerebral thrombosis,pulmonary emboli,0
NATAZIA,cerebral thrombosis,cerebral thrombosis myocardial infarction and stroke,1
NATAZIA,cerebral thrombosis,emboli deep vein cerebral thrombosis,1
NATAZIA,cerebral thrombosis,cerebral thrombosis myocardial infarction and stroke,1
NATAZIA,cerebral thrombosis,stroke hypertension Hepatobiliary disorders Gallbladder disease,0
NATAZIA,cerebral thrombosis,emboli deep vein cerebral thrombosis myocardial infarction and stroke,1
NATAZIA,cerebral thrombosis,stroke hypertension Hepatobiliary disorders Gallbladder disease,0
NATAZIA,cerebral thrombosis,cerebral thrombosis myocardial infarction and stroke,1
NATAZIA,cerebral thrombosis,pulmonary emboli,0
NATAZIA,myocardial infarction,myocardial infarction and stroke hypertension Hepatobiliary disorders,1
NATAZIA,myocardial infarction,thrombosis cerebral myocardial infarction,1
NATAZIA,myocardial infarction,myocardial infarction and stroke hypertension Hepatobiliary disorders,1
NATAZIA,myocardial infarction,emboli deep,0
NATAZIA,myocardial infarction,myocardial infarction and stroke hypertension Hepatobiliary,1
NATAZIA,myocardial infarction,emboli deep,0
NATAZIA,myocardial infarction,thrombosis cerebral myocardial infarction,1
NATAZIA,stroke,Immune,0
NATAZIA,stroke,stroke hypertension Hepatobiliary disorders,1
NATAZIA,stroke,stroke,1
NATAZIA,stroke,thrombosis,0
NATAZIA,hepatitis,hypertension,0
NATAZIA,hepatitis,hepatitis Immune,1
NATAZIA,Fluid retention,system disorders Dizziness Skin and subcutaneous tissue,0
NATAZIA,Fluid retention,Fluid retention hypertriglyceridemia Nervous system disorders Dizziness,1
NATAZIA,Fluid retention,Dizziness,0
NATAZIA,Fluid retention,disorders Hypersensitivity Metabolism and nutrition disorders,0
NATAZIA,Fluid retention,system disorders Dizziness,0
NATAZIA,Fluid retention,Fluid retention hypertriglyceridemia Nervous system,1
NATAZIA,Fluid retention,and nutrition Fluid retention hypertriglyceridemia Nervous system disorders Dizziness,1
NATAZIA,Fluid retention,Fluid retention hypertriglyceridemia Nervous system,1
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous,1
NATAZIA,hypertriglyceridemia,disorders Fluid retention,0
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous system disorders Dizziness,1
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous,1
NATAZIA,hypertriglyceridemia,nutrition disorders Fluid hypertriglyceridemia,1
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous,1
NATAZIA,hypertriglyceridemia,Fluid hypertriglyceridemia Nervous system,1
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous,1
NATAZIA,hypertriglyceridemia,Immune system disorders Hypersensitivity Metabolism and nutrition disorders Fluid retention,0
NATAZIA,hypertriglyceridemia,Metabolism and nutrition disorders,0
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous system disorders Dizziness Skin,1
NATAZIA,hypertriglyceridemia,hypertriglyceridemia Nervous system,1
NATAZIA,Dizziness,tissue disorders Chloasma angioedema erythema nodosum erythema multif,0
NATAZIA,Dizziness,Dizziness Skin and,1
NATAZIA,Dizziness,Fluid retention hypertriglyceridemia,0
NATAZIA,Chloasma,Chloasma angioedema,1
NATAZIA,Chloasma,Chloasma angioedema erythema,1
NATAZIA,Chloasma,Chloasma angioedema erythema nodosum erythema multiforme,1
NATAZIA,Chloasma,angioedema erythema nodosum erythema multiforme Gastrointestinal disorders,0
NATAZIA,Chloasma,multiforme Gastrointestinal disorders Gastrointestinal,0
NATAZIA,Chloasma,Chloasma angioedema erythema nodosum erythema,1
NATAZIA,Chloasma,Chloasma angioedema erythema,1
NATAZIA,Chloasma,triglyceridemia Nervous system disorders Dizziness Skin,0
NATAZIA,Chloasma,system disorders Dizziness Skin and subcutaneous tissue disorders,0
NATAZIA,Chloasma,Chloasma angioedema erythema nodosum erythema,1
NATAZIA,angioedema,angioedema,1
NATAZIA,angioedema,angioedema erythema,1
NATAZIA,erythema nodosum,Gastrointestinal symptoms for,0
NATAZIA,erythema multiforme,erythema multiforme Gastrointestinal disorders Gastrointestinal,1
NATAZIA,erythema multiforme,disorders Chloasma angioedema erythema erythema,1
NATAZIA,erythema multiforme,erythema erythema,1
NATAZIA,erythema multiforme,erythema,1
NATAZIA,erythema multiforme,erythema erythema multiforme,1
NATAZIA,erythema multiforme,Gastrointestinal,0
NATAZIA,erythema multiforme,disorders Chloasma angioedema erythema erythema multiforme,1
NATAZIA,CARDIOVASCULAR EVENTS,ctions with the use o f COCs are discussed elsewhere,1
NATAZIA,CARDIOVASCULAR EVENTS,disorders Chloasma angioedema erythema erythema multiforme,1
NATAZIA,CARDIOVASCULAR EVENTS,are,0
NATAZIA,CARDIOVASCULAR EVENTS,ing: * Serious cardiovascular,1
NATAZIA,CARDIOVASCULAR EVENTS,elsewhere in the ing: *,1
NATAZIA,CARDIOVASCULAR EVENTS,"in the ing:



 *    Serious cardiovascular events and stroke",1
NATAZIA,CARDIOVASCULAR EVENTS,elsewhere in the ing: *,1
NATAZIA,CARDIOVASCULAR EVENTS,"the ing:



 *    Serious cardiovascular",1
NATAZIA,CARDIOVASCULAR EVENTS,elsewhere in the ing: *,1
NATAZIA,CARDIOVASCULAR EVENTS,Boxed Warning and Warnings and,0
NATAZIA,CARDIOVASCULAR EVENTS,discussed elsewhere in the ing: *,1
NATAZIA,CARDIOVASCULAR EVENTS,elsewhere in the ing: * Serious,1
NATAZIA,cardiovascular events,utions Vascular events see Warnings and,0
NATAZIA,cardiovascular events,see Boxed Warning nd Warnings,1
NATAZIA,cardiovascular events,and Preca utions Vascular events,1
NATAZIA,cardiovascular events,nd Warnings and Preca,1
NATAZIA,cardiovascular events,the labeling Serious cardiovascular events,0
NATAZIA,cardiovascular events,see Boxed,0
NATAZIA,cardiovascular events,and Preca utions Vascular events see Warnings,1
NATAZIA,cardiovascular events,nd Warnings and Preca,1
NATAZIA,cardiovascular events,Boxed Warning nd,1
NATAZIA,cardiovascular events,Warning nd Warnings and Preca,1
NATAZIA,CARDIOVASCULAR EVENTS,common adverse (>= 2%) in,1
NATAZIA,CARDIOVASCULAR EVENTS,trials for Natazia are headaches irregular,0
NATAZIA,CARDIOVASCULAR EVENTS,in clinical trials for Natazia are,1
NATAZIA,CARDIOVASCULAR EVENTS,EXCERPT The,0
NATAZIA,CARDIOVASCULAR EVENTS,adverse (>= 2%),1
NATAZIA,CARDIOVASCULAR EVENTS,2%) in clinical,1
NATAZIA,CARDIOVASCULAR EVENTS,including migraines bre,0
NATAZIA,CARDIOVASCULAR EVENTS,(>= 2%) in clinical trials for Natazia are,1
NATAZIA,cardiovascular events,(3%) and increased weight To report,1
NATAZIA,cardiovascular events,mood es (3%) and increased,1
NATAZIA,cardiovascular events,vomiting acne mood es (3%) and increased weight,1
NATAZIA,cardiovascular events,mood es (3%) and increased,1
NATAZIA,cardiovascular events,(3%) and increased,1
NATAZIA,cardiovascular events,contact Bayer HealthCare Pharmac,0
NATAZIA,cardiovascular events,Bayer HealthCare Pharmac,0
NATAZIA,Liver disease,] *,1
NATAZIA,Liver disease,Precautions,0
NATAZIA,Liver disease,reported by,0
NATAZIA,Liver disease,"see Warnings and ]  
 *    Liv er disease",1
NATAZIA,Liver disease,reported by,0
NATAZIA,Liver disease,events see Warnings and ] * Liv,1
NATAZIA,Liver disease,Precautions Adverse reactions commonly,0
NATAZIA,Liver disease,Precautions Vascular events,0
NATAZIA,Liver disease,disease see Warnings and Precautions Adverse reactions commonly reported,0
NATAZIA,Liver disease,Warnings and ] *,1
NATAZIA,Liver disease,Warnings and Precautions Vascular events see Warnings and,0
NATAZIA,lipid metabolic effects,The most common adverse,1
NATAZIA,lipid metabolic effects,Breast tenderness,0
NATAZIA,lipid metabolic effects,most common adverse reactions in clinical trials,1
NATAZIA,lipid metabolic effects,most common adverse reactions in,1
NATAZIA,lipid metabolic effects,tenderness Headache The most common adverse reactions in clinical,1
NATAZIA,lipid metabolic effects,most common adverse reactions in,1
NATAZIA,lipid metabolic effects,common adverse reactions in clinical trials,1
NATAZIA,lipid metabolic effects,Headache The most common adverse reactions,1
NATAZIA,lipid metabolic effects,common adverse reactions in clinical trials,1
NATAZIA,Headache,breast tendernesspain ual diso rders nausea or,1
NATAZIA,Headache,common adverse reactions in clinical trials,1
NATAZIA,Headache,ual diso rders nausea or vomiting,1
NATAZIA,Headache,common adverse reactions in clinical trials,1
NATAZIA,Headache,including migraines breast tendernesspain ual diso rders nausea or,1
NATAZIA,Headache,common adverse reactions in clinical trials,1
NATAZIA,Headache,migraines breast tendernesspain ual,1
NATAZIA,Headache,mood changes and increased,0
NATAZIA,Headache,including migraines breast tendernesspain ual,1
NATAZIA,Uterine bleeding,mood changes,0
NATAZIA,Uterine bleeding,report SU,1
NATAZIA,Uterine bleeding,mood changes and increased To report,1
NATAZIA,Uterine bleeding,changes,0
NATAZIA,Uterine bleeding,report SU SPECTED ADVERSE,1
NATAZIA,Uterine bleeding,changes and increased,0
NATAZIA,Uterine bleeding,To report SU SPECTED ADVERSE REACTIONS contact,1
NATAZIA,venous thromboembolism,Bleeding Studies,0
NATAZIA,venous thromboembolism,and Heavy Menstrual Bleeding A total,1
NATAZIA,venous thromboembolism,"Heavy Menstrual Bleeding  A total of 2,131 wome n to years of",1
NATAZIA,venous thromboembolism,and Heavy Menstrual Bleeding A total,1
NATAZIA,venous thromboembolism,"Menstrual Bleeding A total of 2,131 wome",1
NATAZIA,venous thromboembolism,Menstrual Bleeding A total of,1
NATAZIA,venous thromboembolism,"Menstrual Bleeding  A total of 2,131 wome n to years of age",1
NATAZIA,venous thromboembolism,Menstrual Bleeding A total of,1
NATAZIA,venous thromboembolism,one dose,1
NATAZIA,venous thromboembolism,dose of Natazia w ere,1
NATAZIA,venous thromboembolism,age who took at one dose,1
NATAZIA,venous thromboembolism,age who took at one dose of Natazia w,1
NATAZIA,venous thromboembolism,ere enrolled in four clinical phase,0
NATAZIA,venous thromboembolism,age who took at one dose of,1
NATAZIA,venous thromboembolism,of age who took,0
NATAZIA,venous thromboembolism,subjects were included in,0
NATAZIA,venous thromboembolism,trials A total of subjects,0
NATAZIA,venous thromboembolism,of Natazia w ere,1
NATAZIA,VTE,two,0
NATAZIA,VTE,al ,1
NATAZIA,VTE,of Natazia were enrolled,0
NATAZIA,VTE,al  of subjects were included in,1
NATAZIA,VTE,of Natazia were enrolled,0
NATAZIA,VTE, up to cycles with,1
NATAZIA,VTE,a treatment  up to cycles,1
NATAZIA,VTE, up to cycles with,1
NATAZIA,VTE,studies with a treatment  up,1
NATAZIA,VTE, up to cycles with,1
NATAZIA,VTE,  1 Adverse,1
NATAZIA,VTE,Clinical,0
NATAZIA,VTE,frequent menstrual bleeding in,0
NATAZIA,VTE,pathology See Clinical,0
NATAZIA,VTE,menstrual bleeding in women without organic pathology See Clinical,0
NATAZIA,VTE,  1 Adverse Reactions Leading,1
NATAZIA,arterial thromboses,nt adverse reaction s leading to,1
NATAZIA,arterial thromboses,  1 Adverse Reactions Leading,1
NATAZIA,arterial thromboses,metrorrhagia,0
NATAZIA,arterial thromboses,the most nt adverse reaction s leading to discontinuation were,1
NATAZIA,arterial thromboses,metrorrhagia,0
NATAZIA,arterial thromboses,nt adverse reaction s leading to,1
NATAZIA,arterial thromboses,metrorrhagia,0
NATAZIA,arterial thromboses,were menstrual disorder metrorrhagia menorrhagia menstruation irregu,0
NATAZIA,arterial thromboses,an adverse,0
NATAZIA,arterial thromboses,most nt adverse reaction,1
NATAZIA,arterial thromboses,reaction the most nt,1
NATAZIA,arterial thromboses,to discontinuation were menstrual disorder metrorrhagia menorrhagia menstruation irregu,0
NATAZIA,strokes,continuation were menstrual disorder metrorrhagia menorrhagia menstruation irregular,0
NATAZIA,strokes,frequent adverse reactions  to dis continuation were,1
NATAZIA,strokes,continuation were menstrual disorder metrorrhagia menorrhagia menstruation irregular,0
NATAZIA,strokes,most frequent adverse reactions to dis,1
NATAZIA,thromboembolic disease,"vaginal hemorrhage,",1
NATAZIA,cerebrovascular events,"uterine hemorrhage nausea or (6.0%), acne",1
NATAZIA,cerebrovascular events,"(6.0%), acne",1
NATAZIA,cerebrovascular events,withdrawal bleeding uterine,0
NATAZIA,cerebrovascular events,"nausea or  (6.0%), acne (3.9%),  mood changes depression",1
NATAZIA,cerebrovascular events,withdrawal bleeding uterine,0
NATAZIA,cerebrovascular events,mood changes depression mood swings,0
NATAZIA,cerebrovascular events,uterine hemorrhage nausea,0
NATAZIA,cerebrovascular events,"or (6.0%),",1
NATAZIA,hemorrhagic strokes,affect lability dysthymic disorder crying and increased,0
NATAZIA,stroke,increased weight Serious Adverse :  myo cardial infarction cases,1
NATAZIA,stroke,affect lability dysthymic disorder crying and increased,0
NATAZIA,stroke,increased weight Serious Adverse :  myo,1
NATAZIA,stroke,affect lability dysthymic disorder crying and increased,0
NATAZIA,stroke,cardial,0
NATAZIA,stroke,: myo,1
NATAZIA,stroke,Serious Adverse,0
NATAZIA,breast cancer,"events including pulmonary , deep vein t hrombosis cerebral",1
NATAZIA,breast cancer,Serious Adverse,0
NATAZIA,breast cancer,Vascular disorders Venous and arterial thromboembolic events including,0
NATAZIA,breast cancer,vein t hrombosis,1
NATAZIA,breast cancer,"including pulmonary , deep vein",1
NATAZIA,breast cancer,"including pulmonary , deep vein t hrombosis cerebral thrombosis myocardial",1
NATAZIA,breast cancer,"including pulmonary , deep vein",1
NATAZIA,breast cancer,disorders Venous and arterial thromboembolic events including,0
NATAZIA,breast cancer,"events including pulmonary , deep vein t hrombosis cerebral thrombosis myocardial",1
NATAZIA,breast cancer,disorders Venous and arterial thromboembolic events including,0
NATAZIA,breast cancer,and stroke hypertension patobiliary d,1
NATAZIA,breast cancer,disorders Hypersensitivity Metabolis,0
NATAZIA,breast cancer,patobiliary d,1
NATAZIA,breast cancer,He,0
NATAZIA,breast cancer,infarction and stroke hypertension patobiliary d,1
NATAZIA,breast cancer,He,0
NATAZIA,breast cancer,patobiliary d isorders Gallbladder,1
NATAZIA,breast cancer,He,0
NATAZIA,breast cancer,infarction and stroke hypertension patobiliary,1
NATAZIA,breast cancer,thrombosis cerebral thrombosis myocardial infarction,0
NATAZIA,breast cancer,myocardial infarction and stroke hypertension,0
NATAZIA,breast cancer,disease hepatitis Immune,0
NATAZIA,cervical cancer,"and nutrition disorders Fluid tion, hypertrig",1
NATAZIA,cervical cancer,"nutrition disorders Fluid tion,",1
NATAZIA,cervical cancer,disorders Dizziness Skin and subcutaneous tissue,0
NATAZIA,cervical cancer,"tion, hypertrig lyceridemia Nervous",1
NATAZIA,cervical cancer,"nutrition disorders Fluid tion, hypertrig lyceridemia Nervous system disorders",1
NATAZIA,cervical cancer,"tion, hypertrig lyceridemia Nervous",1
NATAZIA,cervical cancer,"tion, hypertrig",1
NATAZIA,cervical cancer,"tion, hypertrig lyceridemia Nervous",1
NATAZIA,cervical cancer,Fluid reten,0
NATAZIA,cervical cancer,"tion, hypertrig lyceridemia Nervous system disorders",1
NATAZIA,cervical cancer,"disorders Fluid tion, hypertrig",1
NATAZIA,cervical cancer,"disorders Fluid tion, hypertrig lyceridemia Nervous",1
NATAZIA,cervical cancer,"disorders Fluid tion, hypertrig",1
DIFICID,nausea,adverse reactions nausea vomiting,1
DIFICID,nausea,"disorders Fluid tion, hypertrig",1
DIFICID,nausea,nausea vomiting,1
DIFICID,nausea,adverse reactions nausea,1
DIFICID,nausea,nausea vomiting,1
DIFICID,nausea,nausea vomiting abdominal pain,1
DIFICID,nausea,nausea vomiting abdominal pain,1
DIFICID,vomiting,are vomiting abdominal pain,1
DIFICID,vomiting,nausea vomiting abdominal pain,1
DIFICID,vomiting,EXCERPT,0
DIFICID,vomiting,vomiting abdominal pain gastrointestinal hemorrhage,1
DIFICID,vomiting,vomiting abdominal pain gastrointestinal hemorrhage,1
DIFICID,vomiting,vomiting abdominal,1
DIFICID,vomiting,vomiting abdominal pain,1
DIFICID,abdominal pain,gastrointestinal hemorrhage anemia,0
DIFICID,abdominal pain,abdominal pain gastrointestinal hemorrhage anemia and,1
DIFICID,gastrointestinal hemorrhage,gastrointestinal hemorrhage anemia and neutropenia To report,1
DIFICID,gastrointestinal hemorrhage,nausea vomiting abdominal gastrointestinal,1
DIFICID,anemia,anemia and neutropenia To,1
DIFICID,anemia,nausea vomiting abdominal pain gastrointestinal hemorrhage,0
DIFICID,anemia,gastrointestinal,0
DIFICID,anemia,anemia and,1
DIFICID,neutropenia,neutropenia To,1
DIFICID,neutropenia,neutropenia To report,1
DIFICID,neutropenia,report SUSPECTED ADVERSE,0
DIFICID,abdominal distension,trials,0
DIFICID,abdominal distension,flatulence intestinal,0
DIFICID,abdominal distension,abdominal distension abdominal,1
DIFICID,abdominal distension,flatulence intestinal,0
DIFICID,abdominal distension,Gastrointestinal abdominal,1
DIFICID,abdominal distension,controlled trials Gastrointestinal abdominal,1
DIFICID,abdominal distension,abdominal distension,1
DIFICID,abdominal distension,controlled trials Gastrointestinal abdominal,1
DIFICID,abdominal distension,Gastrointestinal abdominal distension,1
DIFICID,abdominal distension,controlled trials Gastrointestinal abdominal,1
DIFICID,abdominal tenderness,distension,0
DIFICID,abdominal tenderness,intestinal obstruction megacolon Investigations,0
DIFICID,abdominal tenderness,Gastrointestinal Disorders abdominal,0
DIFICID,abdominal tenderness,Gastrointestinal Disorders abdominal abdominal tenderness dyspepsia dysphagia flatulence intestinal,1
DIFICID,abdominal tenderness,Gastrointestinal Disorders abdominal,0
DIFICID,abdominal tenderness,dysphagia flatulence intestinal obstruction megacolon Investigations incre,0
DIFICID,abdominal tenderness,dyspepsia dysphagia,0
DIFICID,abdominal tenderness,Gastrointestinal Disorders abdominal abdominal tenderness dyspepsia,1
DIFICID,abdominal tenderness,dyspepsia dysphagia,0
DIFICID,dyspepsia,dyspepsia dysphagia,1
DIFICID,dyspepsia,abdominal tenderness,0
DIFICID,dyspepsia,Gastrointestinal Disorders abdominal distension abdominal tenderness,0
DIFICID,dyspepsia,abdominal distension abdominal dyspepsia dysphagia flatulence intestinal obstruction megacolon,1
DIFICID,dyspepsia,Gastrointestinal Disorders abdominal distension abdominal tenderness,0
DIFICID,dyspepsia,dyspepsia dysphagia flatulence intestinal obstruction megacolon,1
DIFICID,dyspepsia,dyspepsia,1
DIFICID,dyspepsia,dyspepsia dysphagia,1
DIFICID,dysphagia,Investigations,0
DIFICID,dysphagia,obstruction megacolon Investigations increased blood alkaline,0
DIFICID,flatulence,flatulence intestinal obstruction megacolon,1
DIFICID,flatulence,abdominal tenderness dyspepsia,0
DIFICID,flatulence,flatulence intestinal,1
DIFICID,flatulence,alkaline phosphatase,0
DIFICID,flatulence,tenderness,0
DIFICID,flatulence,flatulence intestinal obstruction,1
DIFICID,flatulence,flatulence intestinal obstruction megacolon Investigations increased,1
DIFICID,intestinal obstruction,abdominal tenderness dyspepsia dysphagia intestinal obstruction,1
DIFICID,intestinal obstruction,intestinal obstruction megacolon Investigations increased blood,1
DIFICID,intestinal obstruction,Disorders abdominal,0
DIFICID,intestinal obstruction,dyspepsia dysphagia intestinal obstruction megacolon Investigations increased blood alkaline,1
DIFICID,intestinal obstruction,Disorders abdominal,0
DIFICID,intestinal obstruction,intestinal obstruction megacolon Investigations,1
DIFICID,intestinal obstruction,dyspepsia dysphagia intestinal,1
DIFICID,megacolon,megacolon,1
DIFICID,megacolon,dyspepsia dysphagia intestinal,1
DIFICID,megacolon,increased blood alkaline phosphatase decreased blood bicarbonate,0
DIFICID,megacolon,megacolon,1
DIFICID,megacolon,flatulence intestinal,0
DIFICID,megacolon,phosphatase decreased blood bicarbonate increas,0
DIFICID,megacolon,dysphagia flatulence,0
DIFICID,megacolon,dominal distension abdominal tenderness dyspepsia dysphagia flatulence intestinal obstruction,0
DIFICID,megacolon,megacolon Investigations increased blood,1
DIFICID,megacolon,dysphagia flatulence intestinal megacolon Investigations,1
DIFICID,megacolon,megacolon Investigations increased blood,1
DIFICID,increased blood alkaline phosphatase,dyspepsia dysphagia flatulence intestinal,0
DIFICID,increased blood alkaline phosphatase,alkaline phosphatase decreased,1
DIFICID,increased blood alkaline phosphatase,alkaline phosphatase decreased,1
DIFICID,increased blood alkaline phosphatase,rness dyspepsia dysphagia flatulence,0
DIFICID,increased blood alkaline phosphatase,obstruction megacolon increased blood alkaline phosphatase,1
DIFICID,increased blood alkaline phosphatase,rness dyspepsia dysphagia flatulence,0
DIFICID,increased blood alkaline phosphatase,increased blood alkaline phosphatase decreased blood bicarbonate increased,1
DIFICID,increased blood alkaline phosphatase,decreased,0
DIFICID,increased blood alkaline phosphatase,platelet count Metabolism,0
DIFICID,increased blood alkaline phosphatase,decreased,0
DIFICID,increased blood alkaline phosphatase,blood alkaline phosphatase decreased blood,1
DIFICID,decreased blood bicarbonate,decreased platelet count,0
DIFICID,decreased blood bicarbonate,e intestinal,0
DIFICID,decreased blood bicarbonate,blood alkaline decreased blood bicarbonate increased hepatic enzymes decreased,1
DIFICID,decreased blood bicarbonate,e intestinal,0
DIFICID,decreased blood bicarbonate,blood alkaline decreased blood bicarbonate increased hepatic enzymes decreased,1
DIFICID,decreased blood bicarbonate,e intestinal,0
DIFICID,increased hepatic enzymes,Disorders hyperglycemia metabolic aci,0
DIFICID,increased hepatic enzymes,Metabolism,0
DIFICID,increased hepatic enzymes,hepatic enzymes decreased,1
DIFICID,increased hepatic enzymes,increased hepatic enzymes decreased,1
DIFICID,increased hepatic enzymes,platelet count Metabolism and Nutrition Disorders hyperglycemia,0
DIFICID,increased hepatic enzymes,phosphatase,0
DIFICID,increased hepatic enzymes,platelet count Metabolism,0
DIFICID,increased hepatic enzymes,phosphatase decreased blood increased hepatic,1
DIFICID,increased hepatic enzymes,decreased blood increased hepatic enzymes,1
DIFICID,decreased platelet count,bicarbonate increased hepatic decreased platelet count Metabolism and,1
DIFICID,decreased platelet count,decreased blood increased hepatic enzymes,1
DIFICID,decreased platelet count,Metabolism and Nutrition,0
DIFICID,decreased platelet count,blood bicarbonate increased hepatic decreased platelet count Metabolism and Nutrition Disorders,1
DIFICID,decreased platelet count,Metabolism and Nutrition,0
DIFICID,decreased platelet count,acidosis Skin and Subcu,0
DIFICID,decreased platelet count,bicarbonate increased hepatic decreased platelet count Metabolism and Nutrition,1
DIFICID,decreased platelet count,acidosis Skin and Subcu,0
DIFICID,decreased platelet count,blood bicarbonate increased hepatic,0
DIFICID,decreased platelet count,Nutrition Disorders hyperglycemia metabolic acidosis Skin and,0
DIFICID,hyperglycemia,count Metabolism and Nutrition,0
DIFICID,hyperglycemia,hyperglycemia,1
DIFICID,hyperglycemia,hyperglycemia metabolic acidosis Skin,1
DIFICID,hyperglycemia,acidosis Skin and Subcutaneous Tissue Disorders drug eruption,0
DIFICID,hyperglycemia,hyperglycemia metabolic,1
DIFICID,hyperglycemia,e increased hepatic enzymes decreased platelet count,0
DIFICID,hyperglycemia,hyperglycemia metabolic acidosis Skin and,1
DIFICID,hyperglycemia,enzymes,0
DIFICID,hyperglycemia,and Subcutaneous Tissue,0
DIFICID,hyperglycemia,Tissue Disorders drug,0
DIFICID,metabolic acidosis,metabolic acidosis Skin,1
DIFICID,metabolic acidosis,Disorders metabolic acidosis Skin and Subcutaneous,1
DIFICID,metabolic acidosis,metabolic acidosis Skin,1
DIFICID,metabolic acidosis,and Nutrition Disorders metabolic acidosis,1
DIFICID,metabolic acidosis,Skin and,0
DIFICID,metabolic acidosis,Nutrition Disorders metabolic acidosis,1
DIFICID,metabolic acidosis,Skin and,0
DIFICID,metabolic acidosis,metabolic acidosis,1
DIFICID,metabolic acidosis,Nutrition Disorders metabolic,1
DIFICID,drug eruption,drug eruption pruritus rash Post,1
DIFICID,drug eruption,drug eruption pruritus rash Post,1
DIFICID,drug eruption,Experience,0
DIFICID,rash,rash Post Marketing Experience Adverse reactions,1
DIFICID,rash,eruption rash Post Marketing Experience Adverse reactions,1
DIFICID,rash,rash Post Marketing Experience Adverse reactions,1
DIFICID,rash,rash Post Marketing,1
DIFICID,rash,eruption rash Post Marketing Experience Adverse,1
DIFICID,rash,rash Post Marketing,1
DIFICID,rash,marketing setting ari,0
DIFICID,rash,rash Post Marketing Experience Adverse,1
DIFICID,angioedema,have,0
DIFICID,angioedema,angioedema rash and,1
DIFICID,rash,always possible Hypersensitivity,0
DIFICID,rash,rash and pruritus have been,1
DIFICID,rash,rash and,1
DIFICID,rash,rash and pruritus have been reported,1
DIFICID,rash,have been reported,0
DIFICID,rash,not always possible Hypersensitivity,0
DIFICID,rash,possible,0
DIFICID,pruritus,possible Hypersensitivity,0
DIFICID,pruritus,pruritus,1
DIFICID,pruritus,rash pruritus,1
DIFICID,pruritus,pruritus,1
DIFICID,pruritus,pruritus have been reported,1
DIFICID,pruritus,pruritus have been reported,1
DIFICID,Acute hypersensitivity reactions,ge anemia,0
DIFICID,Acute hypersensitivity reactions,"nausea vomiting abdominal  (6%), gastrointestinal hemorrha ge anemia and",1
DIFICID,Acute hypersensitivity reactions,ge anemia,0
DIFICID,Acute hypersensitivity reactions,"(6%), gastrointestinal hemorrha",1
DIFICID,angioedema,are nausea vomiting abdominal pain,0
DIFICID,angioedema,"(4%), ane",1
DIFICID,angioedema,"pain gastrointestinal (4%),",1
DIFICID,angioedema,ADVERSE REACTIONS,0
DIFICID,angioedema,"pain gastrointestinal (4%),",1
DIFICID,angioedema,"gastrointestinal  (4%), ane mia and",1
DIFICID,angioedema,"pain gastrointestinal (4%),",1
DIFICID,angioedema,"(4%), ane mia and neutropenia",1
DIFICID,angioedema,"gastrointestinal (4%),",1
DIFICID,angioedema,"vomiting abdominal pain gastrointestinal (4%), ane",1
DIFICID,dyspnea,ctions are nausea vomiting abdominal pain gastrointestinal hemorrhage,0
DIFICID,dyspnea,report SUSPECTED ADVERSE,0
DIFICID,dyspnea,SUSPECTED ADVERSE,0
DIFICID,dyspnea,contact,0
DIFICID,dyspnea,"a (2%), and neutropenia To report",1
DIFICID,pruritus,hemorrhage anemia nd neutr openia To report SUSPECTED,1
DIFICID,pruritus,"a (2%), and neutropenia To report",1
DIFICID,pruritus,gastrointestinal hemorrhage anemia nd neutr openia To report SUSPECTED,1
DIFICID,pruritus,"a (2%), and neutropenia To report",1
DIFICID,pruritus,hemorrhage anemia nd neutr openia To report,1
DIFICID,pruritus,"a (2%), and neutropenia To report",1
DIFICID,rash,hemorrhage anemia and  (2% To report SUSPECTED ADVERSE,1
DIFICID,rash,"a (2%), and neutropenia To report",1
DIFICID,rash, (2% To,1
DIFICID,rash,gastrointestinal hemorrhage anemia and  (2% To,1
DIFICID,rash, (2% To,1
DIFICID,rash, (2% To report SUSPECTED,1
DIFICID,rash,and  (2% To,1
DIFICID,rash, (2% To report SUSPECTED,1
DIFICID,rash,REACTIONS contact,0
DIFICID,rash, (2% To report SUSPECTED ADVERSE REACTIONS,1
DIFICID,rash, (2% To report SUSPECTED ADVERSE,1
DIFICID,Acute hypersensitivity reactions,not ect the rates observed in,1
DIFICID,Acute hypersensitivity reactions,ect the rates observed in practi ce The,1
DIFICID,Acute hypersensitivity reactions,for days was evaluated,0
DIFICID,Acute hypersensitivity reactions,and may not ect the rates observed in practi,1
DIFICID,Acute hypersensitivity reactions,for days was evaluated,0
DIFICID,Acute hypersensitivity reactions,ect the rates observed in practi ce The,1
DIFICID,Acute hypersensitivity reactions,not ect the,1
DIFICID,Acute hypersensitivity reactions,in practi,1
DIFICID,dyspnea,safety  of,1
DIFICID,dyspnea,safety  of DIFICID mg tablets,1
DIFICID,dyspnea,reflect the,0
DIFICID,dyspnea,rates observed in practice safety  of,1
DIFICID,dyspnea,reflect the,0
DIFICID,rash,rates,0
DIFICID,rash, DIF ICID mg tablets taken twice,1
DIFICID,angioedema of the mouth,of DIFICID mg lets,1
DIFICID,hypersensitivity reactions,ithdrew from trials as a r esult of adverse reactions,1
DIFICID,hypersensitivity reactions,of DIFICID mg lets,1
DIFICID,hypersensitivity reactions,ithdrew from trials,1
DIFICID,hypersensitivity reactions,patients receiving DIFICID ithdrew from trials as a r esult of adverse,1
DIFICID,hypersensitivity reactions,ithdrew from trials,1
EDARBI,diarrhea,Pharmaceuticals LLC at,0
EDARBI,diarrhea,diarrhea To report SUSPECTED ADVERSE REACTIONS,1
EDARBI,diarrhea,diarrhea To report,1
EDARBI,diarrhea,diarrhea To,1
EDARBI,diarrhea,diarrhea,1
EDARBI,diarrhea,diarrhea To report SUSPECTED ADVERSE,1
EDARBI,diarrhea,Pharmaceuticals LLC at,0
EDARBI,diarrhea,Arbor Pharmaceuticals LLC,0
EDARBI,hypotension,to hypotension orthostatic hypotension was reported,1
EDARBI,hypotension,Arbor Pharmaceuticals LLC,0
EDARBI,hypotension,hypotension orthostatic hypotension was reported,1
EDARBI,hypotension,hypotension orthostatic hypotension was,1
EDARBI,hypotension,hypotension orthostatic hypotension was reported,1
EDARBI,hypotension,by patients randomized to Edarbi mg,0
EDARBI,hypotension,hypotension orthostatic hypotension,1
EDARBI,hypotension,by patients randomized to Edarbi mg,0
EDARBI,hypotension,hypotension orthostatic hypotension was reported by,1
EDARBI,hypotension,by patients randomized,0
EDARBI,hypotension,event leading to hypotension orthostatic hypotension was,1
EDARBI,hypotension,by patients randomized,0
EDARBI,orthostatic hypotension,leading to discontinuation orthostatic,1
EDARBI,orthostatic hypotension,orthostatic,1
EDARBI,orthostatic hypotension,orthostatic hypotension was reported by patients,1
EDARBI,orthostatic hypotension,discontinuation orthostatic hypotension was reported,1
EDARBI,orthostatic hypotension,orthostatic hypotension was reported by patients,1
EDARBI,orthostatic hypotension,Edarbi,0
EDARBI,orthostatic hypotension,leading to discontinuation orthostatic,1
EDARBI,orthostatic hypotension,leading to discontinuation orthostatic hypotension was reported by,1
EDARBI,orthostatic hypotension,leading to discontinuation orthostatic,1
EDARBI,diarrhea,similar regardless of,0
EDARBI,diarrhea,placebocontrolled,0
EDARBI,diarrhea,treated with Edarbi mg,0
EDARBI,diarrhea,and similar regardless of age gender and race In,0
EDARBI,diarrhea,to in patients,0
EDARBI,diarrhea,diarrhea was,1
EDARBI,diarrhea,to in patients,0
EDARBI,diarrhea,diarrhea was reported,1
EDARBI,diarrhea,age gender and race,0
EDARBI,diarrhea,diarrhea was reported up,1
EDARBI,diarrhea,placebocontrolled monotherapy,0
EDARBI,nausea,listed below Gastrointestinal Disorders,0
EDARBI,nausea,Gastrointestinal nausea General,1
EDARBI,nausea,listed below Gastrointestinal Disorders,0
EDARBI,asthenia,Site asthenia,1
EDARBI,asthenia,listed below Gastrointestinal Disorders,0
EDARBI,muscle spasm,Musculoskeletal and Connective Tissue muscle,1
EDARBI,muscle spasm,Site Conditions asthenia fatigue Musculoskeletal and Connective,0
EDARBI,muscle spasm,and Connective Tissue muscle spasm Nervous,1
EDARBI,muscle spasm,Site Conditions asthenia fatigue Musculoskeletal and Connective,0
EDARBI,muscle spasm,Musculoskeletal and Connective Tissue muscle spasm,1
EDARBI,muscle spasm,muscle spasm Nervous System Disorders,1
EDARBI,muscle spasm,muscle spasm,1
EDARBI,muscle spasm,and Connective Tissue Disorders,0
EDARBI,dizziness,dizziness dizziness postural Respiratory Thoracic,1
EDARBI,dizziness,dizziness dizziness postural Respiratory Thoracic and,1
EDARBI,dizziness,dizziness dizziness postural Respiratory,1
EDARBI,dizziness,Musculoskeletal and Connective Tissue Disorders muscle,0
EDARBI,dizziness,dizziness,1
EDARBI,dizziness postural,Nervous System Disorders dizziness postural Respiratory Thoracic,1
EDARBI,dizziness postural,dizziness,1
EDARBI,dizziness postural,spasm Nervous System Disorders dizziness,1
EDARBI,dizziness postural,Disorders cough,0
EDARBI,dizziness postural,cough Clinical Laboratory Findin,0
EDARBI,dizziness postural,System Disorders dizziness,0
EDARBI,dizziness postural,Respiratory,0
EDARBI,dizziness postural,Nervous System Disorders dizziness postural,1
EDARBI,dizziness postural,Respiratory,0
EDARBI,dizziness postural,System Disorders dizziness postural,1
EDARBI,dizziness postural,Respiratory,0
EDARBI,dizziness postural,System Disorders dizziness,0
EDARBI,cough,cough Clinical,1
EDARBI,cough,cough Clinical Laboratory,1
EDARBI,cough,cough Clinical,1
EDARBI,cough,dizziness postural,0
EDARBI,cough,cough Clinical Laboratory Findings,1
EDARBI,cough,Thoracic and Mediastinal,0
EDARBI,cough,Disorders,0
EDARBI,cough,Findings In controlled clinical trials clinically relevant,0
EDARBI,cough,cough,1
EDARBI,increases in serum creatinine,creatinine Small increases in serum creatinine,1
EDARBI,increases in serum creatinine,Edarbi The increase,0
EDARBI,increases in serum creatinine,seen in patients receiving mg of Edarbi The increase may,0
EDARBI,increases in serum creatinine,larger when coadministered with,0
EDARBI,increases in serum creatinine,Serum creatinine Small increases in serum creatinine are seen in patients,1
EDARBI,increases in serum creatinine,larger when coadministered with,0
EDARBI,increases in serum creatinine,Small increases,1
EDARBI,serum creatinine increases,more likely to serum creatinine increases HemoglobinHematocrit Low,1
EDARBI,serum creatinine increases,Small increases,1
EDARBI,serum creatinine increases,serum creatinine increases,1
EDARBI,serum creatinine increases,more likely to serum,1
EDARBI,serum creatinine increases,serum creatinine increases HemoglobinHematocrit Low hemoglobin,1
EDARBI,serum creatinine increases,more likely to serum,1
EDARBI,serum creatinine increases,serum,1
EDARBI,serum creatinine increases,serum creatinine increases HemoglobinHematocrit,1
EDARBI,serum creatinine increases,creatinine increases HemoglobinHematocrit Low hemoglobin,1
EDARBI,serum creatinine increases,hematocrit and RBC counts were,0
EDARBI,Low hemoglobin,Low hemoglobin hematocrit and RBC,1
EDARBI,Low hemoglobin,report serum creatinine increases Low hemoglobin,1
EDARBI,Low hemoglobin,creatinine increases Low,1
EDARBI,Low hemoglobin,in and of Edarbitreated subjects,0
EDARBI,Low hemoglobin,serum creatinine increases,0
EDARBI,Low hemoglobin,Low hemoglobin hematocrit and RBC,1
EDARBI,Low hemoglobin,creatinine increases Low hemoglobin hematocrit and RBC counts were,1
EDARBI,Low hemoglobin,Low hemoglobin hematocrit and RBC,1
EDARBI,Low hemoglobin,to report serum creatinine increases,0
EDARBI,Nausea,relationship to,0
EDARBI,Nausea,Nausea Muscle spasms Rash Pruritus Angioedema,1
EDARBI,Nausea,spasms Rash,0
EDARBI,Nausea,spasms Rash,0
EDARBI,Nausea,Nausea Muscle spasms Rash Pruritus,1
EDARBI,Nausea,Nausea Muscle,1
EDARBI,Nausea,Nausea Muscle spasms Rash,1
EDARBI,Nausea,drug Nausea Muscle spasms Rash,1
EDARBI,Nausea,Nausea Muscle spasms Rash,1
EDARBI,Nausea,to drug Nausea Muscle spasms,1
EDARBI,Nausea,Nausea Muscle spasms Rash,1
EDARBI,Muscle spasms,exposure Muscle spasms,1
EDARBI,FETAL TOXICITY,REACTIONS ERPT:,1
EDARBI,FETAL TOXICITY,REACTIONS ERPT:   The mo st common,1
EDARBI,FETAL TOXICITY,REACTIONS ERPT:,1
EDARBI,FETAL TOXICITY,REACTIONS ERPT:   The mo st,1
EDARBI,FETAL TOXICITY,REACTIONS ERPT:,1
EDARBI,FETAL TOXICITY,ADVERSE,0
EDARBI,FETAL TOXICITY,common adverse reaction in adults was diarrhea To,0
EDARBI,FETAL TOXICITY,The mo,1
EDARBI,FETAL TOXICITY,common se reaction in adults was diarrhea To report,1
EDARBI,FETAL TOXICITY,The mo,1
EDARBI,FETAL TOXICITY,se reaction in adults was diarrhea To,1
EDARBI,FETAL TOXICITY,The mo,1
EDARBI,FETAL TOXICITY,contact Arbor Pharmace,0
EDARBI,FETAL TOXICITY,EXCERPT The most common se reaction in adults was diarrhea,1
EDARBI,FETAL TOXICITY,contact Arbor Pharmace,0
EDARBI,FETAL TOXICITY,REACTIONS contact Arbor,0
EDARBI,FETAL TOXICITY,To report SUSPECTED ADVERSE REACTIONS contact,0
EDARBI,FETAL TOXICITY,report SUSPECTED ADVERSE REACTIONS contact Arbor,0
EDARBI,FETAL TOXICITY,EXCERPT The most common se reaction in,1
EDARBI,FETAL TOXICITY,most common se reaction in,1
EDARBI,death to the developing fetus,"FDA or wwwfdagovmedwatch nical Trials Experience

  Be cause clinical trials",1
EDARBI,death to the developing fetus,most common se reaction in,1
EDARBI,death to the developing fetus,are conducted under widely,0
EDARBI,death to the developing fetus,"nical Trials Experience

  Be cause clinical",1
EDARBI,death to the developing fetus,are conducted under widely,0
EDARBI,death to the developing fetus,Experience Be cause clinical trials,1
EDARBI,death to the developing fetus,at,0
EDARBI,death to the developing fetus,wwwfdagovmedwatch nical Trials,1
EDARBI,death to the developing fetus,"FDA or wwwfdagovmedwatch nical Trials Experience

  Be cause",1
EDARBI,death to the developing fetus,wwwfdagovmedwatch nical Trials,1
EDARBI,death to the developing fetus,adverse reaction,0
EDARBI,death to the developing fetus,"wwwfdagovmedwatch nical Trials Experience

  Be",1
EDARBI,death to the developing fetus,adverse reaction,0
EDARBI,death to the developing fetus,"nical Trials Experience

  Be cause clinical trials are conducted",1
EDARBI,death to the developing fetus,adverse reaction,0
EDARBI,FETAL TOXICITY,"conditions, ad",1
EDARBI,death to the developing fetus,for safety when treated with Edarbi at doses,1
EDARBI,death to the developing fetus,patients,0
EDARBI,death to the developing fetus,A total of,0
EDARBI,death to the developing fetus,total of patients were for safety when treated with  Edarbi at doses of,1
EDARBI,death to the developing fetus,A total of,0
EDARBI,death to the developing fetus,mg in clinical,0
EDARBI,death to the developing fetus,safety when treated with Edarbi at,1
EDARBI,death to the developing fetus,treated with Edarbi at doses of,1
EDARBI,death to the developing fetus,treated for at,0
EDARBI,death to the developing fetus,for safety when treated with  Edarbi at,1
EDARBI,death to the developing fetus,treated for at,0
EDARBI,reduces fetal renal function,"conditions, adv erse reaction rates observed in",1
EDARBI,reduces fetal renal function,"dely varying conditions, adv erse reaction rates",1
EDARBI,reduces fetal renal function,the clinical trials of a drug cannot be directly compared to rates i,0
EDARBI,reduces fetal renal function,Because clinical trials,0
EDARBI,reduces fetal renal function,"under dely varying conditions, adv",1
EDARBI,reduces fetal renal function,Because clinical trials,0
EDARBI,reduces fetal renal function,"under dely varying conditions, adv erse reaction rates",1
EDARBI,reduces fetal renal function,Because clinical trials,0
EDARBI,reduces fetal renal function,"trials are conducted under dely varying conditions, adv erse reaction",1
EDARBI,reduces fetal renal function,Because clinical trials,0
EDARBI,reduces fetal renal function,wi,0
EDARBI,reduces fetal renal function,the clinical trials of a drug cannot be directly compared,0
EDARBI,reduces fetal renal function,compared to,0
EDARBI,neonatal morbidity,in the clinica l trials,1
EDARBI,neonatal morbidity,conditions adverse reaction rates ved in the clinica,1
EDARBI,neonatal morbidity,rates ved,1
EDARBI,oligohydramnios,be directly compared to rates in the,1
EDARBI,oligohydramnios,drug and may not reflect,0
EDARBI,oligohydramnios,be directly compared to rates,1
EDARBI,oligohydramnios,a drug,0
EDARBI,oligohydramnios,the clinical trials of a drug can,0
EDARBI,oligohydramnios,not be directly compared to,1
EDARBI,oligohydramnios,not be directly,1
EDARBI,oligohydramnios,not be,1
EDARBI,fetal lung hypoplasia,e clinical trials of another drug and,1
EDARBI,fetal lung hypoplasia,trials of another drug,1
EDARBI,fetal lung hypoplasia,reaction rates observed in the clinical trials of a drug cannot be directly compared to rates,0
EDARBI,fetal lung hypoplasia,in e clinical trials of,1
EDARBI,fetal lung hypoplasia,the clinical trials of a drug cannot,0
EDARBI,fetal lung hypoplasia,in e clinical trials of,1
EDARBI,fetal lung hypoplasia,directly compared to,0
EDARBI,fetal lung hypoplasia,to rates in e clinical trials of  another drug and may,1
EDARBI,fetal lung hypoplasia,directly compared to,0
EDARBI,fetal lung hypoplasia,rates in e,1
EDARBI,fetal lung hypoplasia,patients,0
EDARBI,neonatal adverse effects,ates observed in practic e A,1
EDARBI,neonatal adverse effects,Edarbi,0
EDARBI,neonatal adverse effects,not reflect the r,0
EDARBI,neonatal adverse effects,not reflect the ates observed in practic e,1
EDARBI,neonatal adverse effects,not reflect the r,0
EDARBI,neonatal adverse effects,trials of another drug and may not reflect the,0
EDARBI,neonatal adverse effects,the ates observed in practic e,1
EDARBI,neonatal adverse effects,trials of another drug and may not reflect the,0
EDARBI,neonatal adverse effects,e A total of patients were evaluated for safety when,0
EDARBI,neonatal adverse effects,trials of another drug and,0
EDARBI,symptomatic hypotension,acebo-controlled monoth erapy and combination therapy,1
EDARBI,symptomatic hypotension,for Edarbi,0
EDARBI,symptomatic hypotension,adverse reactions similar,0
EDARBI,changes in renal function,Other adverse reactions,0
EDARBI,changes in renal function,treated th Edarbi 80 mg,1
EDARBI,changes in renal function,wi,0
EDARBI,changes in renal function,to in patients treated th Edarbi 80 mg daily com pared with,1
EDARBI,changes in renal function,wi,0
EDARBI,oliguria,fatigue Musculoskeletal and Connective Tissue,0
EDARBI,oliguria,nia fatigue Musculoskeletal and Connective Tissue Disorders muscle spasm Nervous,0
EDARBI,oliguria,and Connective Tissue Disorders,0
EDARBI,oliguria,: asthe nia fatigue,1
EDARBI,oliguria,Disorders and Administration Site :  asthe,1
EDARBI,oliguria,: asthe nia fatigue,1
EDARBI,oliguria,Disorders and Administration Site :,1
EDARBI,oliguria,: asthe nia fatigue Musculoskeletal and,1
EDARBI,oliguria,and Connective Tissue,0
EDARBI,progressive azotemia,Site Conditions,0
EDARBI,progressive azotemia,Conditions fatigue,1
EDARBI,progressive azotemia,and,0
EDARBI,progressive azotemia,"Administration Site Conditions  fatigue



   Muscu loskeletal and",1
EDARBI,progressive azotemia,and,0
EDARBI,progressive azotemia,Site Conditions fatigue Muscu,1
EDARBI,progressive azotemia,Connective Tissue Disorders muscle spasm Nervous,0
EDARBI,progressive azotemia,Site Conditions fatigue Muscu,1
EDARBI,progressive azotemia,Administration Site Conditions fatigue,1
EDARBI,progressive azotemia,and Connective Tissue Disorders,0
EDARBI,acute renal failure,and,0
EDARBI,acute renal failure,fatigue Musculoskeletal and nnective Tissue Dis,1
EDARBI,acute renal failure,spasm Nervous System,0
EDARBI,acute renal failure,and nnective Tissue Dis,1
EDARBI,acute renal failure,spasm Nervous System,0
EDARBI,acute renal failure,nnective Tissue Dis,1
EDARBI,acute renal failure,orders,0
EDARBI,acute renal failure,and nnective Tissue Dis orders muscle spasm Nervous,1
EDARBI,acute renal failure,orders,0
EDARBI,acute renal failure,Musculoskeletal and nnective Tissue,1
EDARBI,acute renal failure,nnective Tissue Dis orders,1
EDARBI,death,Tissue,0
EDARBI,increases in serum creatinine,uncommon with a dministration of Edarbi,1
EDARBI,increases in serum creatinine,standard laboratory rameters,1
EDARBI,increases in serum creatinine,Small reversible increases in,0
EDARBI,increases in serum creatinine,in serum creatini,0
EDARBI,increases in serum creatinine,In controlled clinical trials clinically relevant,0
EDARBI,increases in serum creatinine,in standard laboratory rameters were uncommon with a dministration,1
EDARBI,increases in serum creatinine,In controlled clinical trials clinically relevant,0
EDARBI,increases in serum creatinine,with a dministration,1
EDARBI,increases in serum creatinine,trials clinically relevant changes in standard laboratory,0
EDARBI,increases in serum creatinine,rameters were uncommon with a dministration of Edarbi Serum creatinine,1
EDARBI,increases in serum creatinine,trials clinically relevant changes in standard laboratory,0
IMBRUVICA,Infections,and,0
IMBRUVICA,Infections,the labeling Hemorrhage see Warnings and Precautions,0
IMBRUVICA,Infections,and Infections,1
IMBRUVICA,Infections,the labeling Hemorrhage see Warnings and Precautions,0
IMBRUVICA,Infections,Infections see Warnings,1
IMBRUVICA,Infections,Infections see Warnings and Precautions,1
IMBRUVICA,Infections,Infections see Warnings,1
IMBRUVICA,Infections,Cytopenias see Warnings and Precautions,0
IMBRUVICA,Infections,Warnings and,0
IMBRUVICA,Infections,Infections see Warnings and,1
IMBRUVICA,Cytopenias,Cytopenias see Warnings and Precautions,1
IMBRUVICA,Cytopenias,Warnings and,0
IMBRUVICA,Cytopenias,Cytopenias see Warnings and,1
IMBRUVICA,Cytopenias,and Precautions,0
IMBRUVICA,Atrial Fibrillation,Warnings and Atrial Fibrillation see Warnings and Precautions Second,1
IMBRUVICA,Atrial Fibrillation,and Precautions,0
IMBRUVICA,Atrial Fibrillation,Primary Malignancies see Warnings,0
IMBRUVICA,Atrial Fibrillation,Atrial,1
IMBRUVICA,Atrial Fibrillation,see Warnings and Atrial Fibrillation,1
IMBRUVICA,Atrial Fibrillation,Atrial,1
IMBRUVICA,Atrial Fibrillation,Cytopenias see Warnings and Atrial Fibrillation,1
IMBRUVICA,Atrial Fibrillation,Atrial,1
IMBRUVICA,Atrial Fibrillation,Warnings,0
IMBRUVICA,Second Primary Malignancies,and Second Primary Malignancies,1
IMBRUVICA,Second Primary Malignancies,Warnings,0
IMBRUVICA,Second Primary Malignancies,Warnings and Second Primary Malignancies see,1
IMBRUVICA,Second Primary Malignancies,Warnings,0
IMBRUVICA,Second Primary Malignancies,Second Primary Malignancies,1
IMBRUVICA,Second Primary Malignancies,Second Primary Malignancies see Warnings,1
IMBRUVICA,Tumor Lysis Syndrome,Tumor Lysis Syndrome see Warnings and,1
IMBRUVICA,Tumor Lysis Syndrome,Second Primary Malignancies see Warnings,1
IMBRUVICA,Tumor Lysis Syndrome,Warnings,0
IMBRUVICA,Tumor Lysis Syndrome,trials are conducted under,0
IMBRUVICA,Tumor Lysis Syndrome,Lysis Syndrome see Warnings,1
IMBRUVICA,Tumor Lysis Syndrome,clinical trials are conducted under,0
IMBRUVICA,thrombocytopenia,MCL CLL WM were,0
IMBRUVICA,thrombocytopenia,anemia fatigue musculoskeletal pain bruising,0
IMBRUVICA,thrombocytopenia,thrombocytopenia neutropenia,1
IMBRUVICA,thrombocytopenia,nausea upper respiratory,0
IMBRUVICA,thrombocytopenia,thrombocytopenia neutropenia,1
IMBRUVICA,neutropenia,neutropenia diarrhea,1
IMBRUVICA,neutropenia,reactions in patients with,0
IMBRUVICA,neutropenia,neutropenia diarrhea anemia fatigue,1
IMBRUVICA,neutropenia,with Bcell malignancies MCL CLL WM were,0
IMBRUVICA,neutropenia,reactions in patients with Bcell malignancies MCL CLL WM,0
IMBRUVICA,neutropenia,fatigue musculoskeletal pain bruising nausea upper respiratory tract,0
IMBRUVICA,neutropenia,CLL WM were neutropenia diarrhea,1
IMBRUVICA,neutropenia,fatigue musculoskeletal pain bruising nausea upper respiratory tract,0
IMBRUVICA,neutropenia,patients,0
IMBRUVICA,neutropenia,neutropenia diarrhea anemia fatigue,1
IMBRUVICA,diarrhea,nausea upper respiratory,0
IMBRUVICA,diarrhea,infection,0
IMBRUVICA,diarrhea,respiratory tract,0
IMBRUVICA,anemia,neutropenia,0
IMBRUVICA,anemia,malignancies MCL CLL WM,0
IMBRUVICA,anemia,anemia fatigue musculoskeletal,1
IMBRUVICA,anemia,anemia fatigue musculoskeletal,1
IMBRUVICA,anemia,were thrombocytopenia neutropenia anemia fatigue musculoskeletal pain,1
IMBRUVICA,anemia,anemia fatigue musculoskeletal,1
IMBRUVICA,anemia,neutropenia diarrhea,0
IMBRUVICA,anemia,bruising nausea upper respiratory tract infection and,0
IMBRUVICA,anemia,tract infection,0
IMBRUVICA,anemia,malignancies MCL CLL WM were thrombocytopenia neutropenia diarrhea,0
IMBRUVICA,fatigue,malignancies MCL CLL WM were thrombocytopenia neutropenia diarrhea anemia,0
IMBRUVICA,fatigue,thrombocytopenia neutropenia diarrhea fatigue musculoskeletal pain bruising nausea upper,1
IMBRUVICA,fatigue,malignancies MCL CLL WM were thrombocytopenia neutropenia diarrhea anemia,0
IMBRUVICA,fatigue,diarrhea anemia,0
IMBRUVICA,fatigue,WM were thrombocytopenia neutropenia,0
IMBRUVICA,fatigue,neutropenia,0
IMBRUVICA,fatigue,fatigue musculoskeletal pain bruising,1
IMBRUVICA,musculoskeletal pain,musculoskeletal pain bruising nausea upper respiratory,1
IMBRUVICA,nausea,nausea upper respiratory tract infection,1
IMBRUVICA,nausea,nausea upper,1
IMBRUVICA,upper respiratory tract infection,upper respiratory tract,1
IMBRUVICA,upper respiratory tract infection,pain bruising upper respiratory,1
IMBRUVICA,upper respiratory tract infection,bruising upper respiratory,1
IMBRUVICA,upper respiratory tract infection,ADVERSE REACTIONS,0
IMBRUVICA,upper respiratory tract infection,upper respiratory tract infection and rash To report,1
IMBRUVICA,upper respiratory tract infection,rash To report SUSPECTED,0
IMBRUVICA,upper respiratory tract infection,To report SUSPECTED ADVERSE REACTIONS contact Pharmacyclics,0
IMBRUVICA,upper respiratory tract infection,musculoskeletal pain bruising upper,1
IMBRUVICA,upper respiratory tract infection,pain bruising upper respiratory tract,1
IMBRUVICA,rash,rash To report SUSPECTED,1
IMBRUVICA,rash,rash To report SUSPECTED ADVERSE,1
IMBRUVICA,rash,rash To report SUSPECTED ADVERSE,1
IMBRUVICA,rash,rash To report,1
IMBRUVICA,rash,upper respiratory tract infection rash To report SUSPECTED ADVERSE,1
IMBRUVICA,rash,rash To report,1
IMBRUVICA,rash,tract infection rash To report SUSPECTED ADVERSE REACTIONS,1
IMBRUVICA,rash,rash To report,1
IMBRUVICA,rash,tract infection rash To report,1
IMBRUVICA,rash,rash To report,1
IMBRUVICA,diarrhea,diarrhea neutropenia anemia,1
IMBRUVICA,diarrhea,diarrhea,1
IMBRUVICA,diarrhea,adverse reactions were thrombocytopenia,0
IMBRUVICA,diarrhea,diarrhea neutropenia anemia fatigue musculoskeletal pain,1
IMBRUVICA,diarrhea,diarrhea,1
IMBRUVICA,diarrhea,adverse,0
IMBRUVICA,diarrhea,peripheral edema upper respiratory tract infe,0
IMBRUVICA,neutropenia,edema,0
IMBRUVICA,neutropenia,anemia,0
IMBRUVICA,neutropenia,commonly occurring,0
IMBRUVICA,neutropenia,adverse reactions were thrombocytopenia diarrhea,0
IMBRUVICA,neutropenia,neutropenia anemia fatigue musculoskeletal pain,1
IMBRUVICA,anemia,anemia fatigue,1
IMBRUVICA,anemia,anemia fatigue musculoskeletal pain peripheral edema,1
IMBRUVICA,anemia,anemia fatigue,1
IMBRUVICA,anemia,upper respiratory,0
IMBRUVICA,anemia,anemia fatigue musculoskeletal pain peripheral,1
IMBRUVICA,anemia,reactions were,0
IMBRUVICA,anemia,diarrhea anemia fatigue,1
IMBRUVICA,anemia,reactions were,0
IMBRUVICA,anemia,commonly occurring adverse reactions were,0
IMBRUVICA,anemia,adverse reactions were,0
IMBRUVICA,anemia,pain peripheral edema upper respiratory tract infection,0
IMBRUVICA,fatigue,diarrhea neutropenia fatigue musculoskeletal pain,1
IMBRUVICA,fatigue,pain peripheral edema upper respiratory tract infection,0
IMBRUVICA,musculoskeletal pain,thrombocytopenia diarrhea neutropenia anemia musculoskeletal,1
IMBRUVICA,musculoskeletal pain,thrombocytopenia diarrhea,0
IMBRUVICA,musculoskeletal pain,neutropenia,0
IMBRUVICA,musculoskeletal pain,edema upper respiratory tract,0
IMBRUVICA,musculoskeletal pain,fatigue,0
IMBRUVICA,musculoskeletal pain,thrombocytopenia diarrhea neutropenia anemia,0
IMBRUVICA,musculoskeletal pain,musculoskeletal pain peripheral edema upper respiratory,1
IMBRUVICA,peripheral edema,peripheral,1
IMBRUVICA,peripheral edema,neutropenia anemia fatigue musculoskeletal peripheral edema upper respiratory tract infection,1
IMBRUVICA,peripheral edema,peripheral,1
IMBRUVICA,peripheral edema,anemia fatigue musculoskeletal peripheral edema upper respiratory tract infection,1
IMBRUVICA,peripheral edema,peripheral,1
IMBRUVICA,upper respiratory tract infection,upper respiratory tract infection nausea bruising dyspnea constipation,1
IMBRUVICA,upper respiratory tract infection,peripheral,0
IMBRUVICA,upper respiratory tract infection,e thrombocytopenia diarrhea neutropenia anemia fatigue musculoskeletal pain peripheral edema,0
IMBRUVICA,upper respiratory tract infection,musculoskeletal pain peripheral upper respiratory tract,1
IMBRUVICA,upper respiratory tract infection,anemia fatigue musculoskeletal pain peripheral,0
IMBRUVICA,upper respiratory tract infection,constipation rash abdominal pain vomiting and decreased appetite,0
IMBRUVICA,upper respiratory tract infection,respiratory tract infection nausea bruising dyspnea constipation,1
IMBRUVICA,upper respiratory tract infection,bruising dyspnea constipation rash,0
IMBRUVICA,upper respiratory tract infection,upper respiratory tract infection nausea,1
IMBRUVICA,upper respiratory tract infection,bruising dyspnea constipation rash,0
IMBRUVICA,bruising,pain peripheral edema upper respiratory,0
IMBRUVICA,bruising,respiratory tract infection bruising dyspnea,1
IMBRUVICA,bruising,pain peripheral edema upper respiratory,0
IMBRUVICA,bruising,rash abdominal pain vomiting and decreased,0
IMBRUVICA,bruising,peripheral edema upper respiratory tract,0
IMBRUVICA,bruising,bruising dyspnea constipation rash abdominal pain,1
IMBRUVICA,bruising,pain vomiting and decreased appetite see Tables,0
IMBRUVICA,bruising,and decreased,0
IMBRUVICA,bruising,respiratory tract infection bruising dyspnea constipation rash abdominal,1
IMBRUVICA,bruising,and decreased,0
IMBRUVICA,dyspnea,decreased appetite see,0
IMBRUVICA,dyspnea,musculoskeletal pain peripheral edema upper respiratory tract infection nausea,0
IMBRUVICA,dyspnea,tract infection nausea dyspnea,1
IMBRUVICA,dyspnea,musculoskeletal pain peripheral edema upper respiratory tract infection nausea,0
IMBRUVICA,dyspnea,musculoskeletal pain peripheral edema upper respiratory,0
IMBRUVICA,dyspnea,dyspnea constipation rash abdominal pain vomiting,1
IMBRUVICA,dyspnea,dyspnea constipation rash abdominal,1
IMBRUVICA,dyspnea,dyspnea constipation rash abdominal pain vomiting,1
IMBRUVICA,dyspnea,infection nausea dyspnea constipation,1
IMBRUVICA,dyspnea,dyspnea constipation rash abdominal pain vomiting,1
IMBRUVICA,constipation,respiratory tract infection nausea bruising,0
IMBRUVICA,constipation,and The most comm,0
IMBRUVICA,constipation,constipation rash abdominal pain,1
IMBRUVICA,constipation,constipation rash,1
IMBRUVICA,constipation,and,0
IMBRUVICA,constipation,vomiting and decreased appetite see Tables and The,0
IMBRUVICA,constipation,tract infection nausea bruising constipation,1
IMBRUVICA,constipation,vomiting and decreased appetite see Tables and The,0
IMBRUVICA,constipation,and decreased,0
IMBRUVICA,constipation,tract infection nausea bruising dyspnea,0
IMBRUVICA,rash,infection nausea bruising dyspnea rash abdominal pain vomiting and decreased,1
IMBRUVICA,rash,tract infection nausea bruising dyspnea,0
IMBRUVICA,rash,bruising dyspnea rash,1
IMBRUVICA,rash,tract infection nausea bruising dyspnea,0
IMBRUVICA,rash,respiratory tract infection nausea bruising dyspnea,0
IMBRUVICA,rash,vomiting and decreased appetite see Tables and The,0
IMBRUVICA,rash,rash abdominal pain vomiting,1
IMBRUVICA,rash,Tables and The most common Gra,0
IMBRUVICA,rash,rash abdominal pain vomiting and,1
IMBRUVICA,rash,rash abdominal pain,1
IMBRUVICA,abdominal pain,abdominal pain vomiting and,1
IMBRUVICA,abdominal pain,bruising dyspnea constipation abdominal,1
IMBRUVICA,abdominal pain,Grade or nonhe,0
IMBRUVICA,abdominal pain,abdominal pain vomiting,1
IMBRUVICA,vomiting,vomiting and decreased appetite see,1
IMBRUVICA,vomiting,vomiting and decreased appetite,1
IMBRUVICA,vomiting,and The most common Grade or nonhematologica,0
IMBRUVICA,vomiting,rash abdominal,0
IMBRUVICA,vomiting,vomiting,1
IMBRUVICA,vomiting,constipation rash abdominal vomiting and,1
IMBRUVICA,vomiting,vomiting,1
IMBRUVICA,decreased appetite,nonhematological adverse reactions,0
IMBRUVICA,decreased appetite,vomiting decreased appetite,1
IMBRUVICA,decreased appetite,nonhematological adverse reactions,0
IMBRUVICA,decreased appetite,infection nausea bruising dyspnea,0
IMBRUVICA,decreased appetite,decreased,1
IMBRUVICA,decreased appetite,ratory tract infection nausea bruising,0
IMBRUVICA,decreased appetite,vomiting decreased appetite,1
IMBRUVICA,decreased appetite,infection nausea bruising,0
IMBRUVICA,decreased appetite,decreased appetite,1
IMBRUVICA,decreased appetite,vomiting decreased appetite,1
IMBRUVICA,decreased appetite,decreased appetite,1
IMBRUVICA,pneumonia,pneumonia abdominal pain,1
IMBRUVICA,pneumonia,atrial fibrillation diarrhea,0
IMBRUVICA,pneumonia,nonhematological adverse reactions pneumonia,1
IMBRUVICA,pneumonia,atrial fibrillation diarrhea,0
IMBRUVICA,pneumonia,pneumonia abdominal pain,1
IMBRUVICA,pneumonia,fibrillation diarrhea fatigue and skin infections Fatal and,0
IMBRUVICA,pneumonia,abdominal pain atrial fibrillation diarrhea fatigue and skin infections Fatal and serious,0
IMBRUVICA,pneumonia,adverse reactions,0
IMBRUVICA,pneumonia,nonhematological adverse reactions,0
IMBRUVICA,pneumonia,pneumonia abdominal pain atrial fibrillation diarrhea,1
IMBRUVICA,pneumonia,pneumonia abdominal pain atrial fibrillation diarrhea,1
IMBRUVICA,pneumonia,pneumonia abdominal pain atrial fibrillation diarrhea,1
IMBRUVICA,abdominal pain,were,0
IMBRUVICA,abdominal pain,atrial fibrillation diarrhea fatigue and skin,0
IMBRUVICA,abdominal pain,nonhematological adverse reactions were abdominal pain atrial fibrillation diarrhea fatigue and,1
IMBRUVICA,abdominal pain,atrial fibrillation diarrhea fatigue and skin,0
IMBRUVICA,abdominal pain,most common Grade or,0
IMBRUVICA,abdominal pain,most common Grade or nonhematological adverse reactions were pneumonia,0
IMBRUVICA,abdominal pain,abdominal,1
IMBRUVICA,abdominal pain,nonhematological adverse reactions were abdominal pain,1
IMBRUVICA,abdominal pain,adverse reactions were abdominal pain atrial fibrillation diarrhea fatigue and,1
IMBRUVICA,abdominal pain,nonhematological adverse reactions were abdominal pain,1
IMBRUVICA,abdominal pain,abdominal pain atrial fibrillation diarrhea fatigue,1
IMBRUVICA,abdominal pain,adverse reactions were abdominal,1
IMBRUVICA,diarrhea,of renal failure have occurred with,0
IMBRUVICA,fatigue,adverse reactions were pneumonia abdominal pain atrial fibrillation,0
IMBRUVICA,skin infections,diarrhea fatigue skin,1
IMBRUVICA,skin infections,of,0
IMBRUVICA,skin infections,atrial fibrillation diarrhea fatigue skin infections Fatal and serious cases,1
IMBRUVICA,skin infections,of,0
IMBRUVICA,skin infections,skin,1
IMBRUVICA,skin infections,atrial fibrillation diarrhea fatigue skin infections,1
IMBRUVICA,skin infections,skin,1
IMBRUVICA,Fatal,cases of renal failure,0
IMBRUVICA,Fatal,and serious cases of renal failure have occurred with IMBRUVICA therapy,0
IMBRUVICA,Fatal,Fatal and serious cases of,1
IMBRUVICA,Fatal,Fatal,1
IMBRUVICA,Fatal,Fatal and serious cases,1
IMBRUVICA,renal failure,serious cases renal failure have occurred,1
IMBRUVICA,renal failure,Fatal and serious cases,1
IMBRUVICA,renal failure,have occurred with IMBRUVICA therapy Increases in,0
IMBRUVICA,renal failure,and,0
IMBRUVICA,renal failure,fibrillation diarrhea fatigue and skin infections Fatal,0
IMBRUVICA,renal failure,skin infections Fatal and serious cases,0
IMBRUVICA,renal failure,fibrillation diarrhea fatigue and skin infections Fatal and serious,0
IMBRUVICA,renal failure,Fatal and serious cases renal failure have,1
IMBRUVICA,renal failure,fibrillation diarrhea fatigue and skin infections Fatal and serious,0
IMBRUVICA,renal failure,the upper limit of,0
IMBRUVICA,Increases in creatinine,Increases in creatinine to times the upper limit,1
IMBRUVICA,Increases in creatinine,have occurred,0
IMBRUVICA,Increases in creatinine,times the upper limit of,0
IMBRUVICA,Increases in creatinine,have occurred with IMBRUVICA Increases in creatinine to times the,1
IMBRUVICA,Increases in creatinine,times the upper limit of,0
IMBRUVICA,Increases in creatinine,in creatinine to times the upper,1
IMBRUVICA,Increases in creatinine,times the upper limit,0
IMBRUVICA,Increases in creatinine,in creatinine to times the,1
IMBRUVICA,Increases in creatinine,have occurred with IMBRUVICA Increases in creatinine,1
IMBRUVICA,Upper respiratory tract infection,respiratory tract infection,1
IMBRUVICA,Pneumonia,Pneumonia Skin infections,1
IMBRUVICA,Sinusitis,Sinusitis General disorders,1
IMBRUVICA,Sinusitis,Sinusitis General disorders and a,1
IMBRUVICA,Fatigue,disorders and administrative site Fatigue Peripheral,1
IMBRUVICA,Fatigue,Sinusitis General disorders and a,1
IMBRUVICA,Fatigue,Fatigue,1
IMBRUVICA,Fatigue,Fatigue Peripheral,1
IMBRUVICA,Fatigue,Fatigue,1
IMBRUVICA,Fatigue,Fatigue Peripheral edema,1
IMBRUVICA,Fatigue,Fatigue,1
IMBRUVICA,Musculoskeletal pain,Musculoskeletal and connective tissue Musculoskeletal pain,1
IMBRUVICA,Musculoskeletal pain,disorders,0
IMBRUVICA,Musculoskeletal pain,Musculoskeletal pain Muscle spasms,1
IMBRUVICA,Musculoskeletal pain,disorders,0
IMBRUVICA,Musculoskeletal pain,Musculoskeletal and connective tissue Musculoskeletal,1
IMBRUVICA,Arthralgia,spasms,0
IMBRUVICA,Headache,Headache,1
IMBRUVICA,Headache,disorders,0
IMBRUVICA,Headache,em disorders,0
IMBRUVICA,Headache,Dizziness,0
IMBRUVICA,Headache,Headache Table Treatme,1
IMBRUVICA,Headache,Dizziness,0
IMBRUVICA,Headache,Headache,1
IMBRUVICA,Decrease of Hemoglobin,or Neutrophils,0
IMBRUVICA,Decrease of Hemoglobin,adverse Decrease of Hemoglobin,1
IMBRUVICA,subdural hematoma,reduction occurred,0
IMBRUVICA,subdural hematoma,discontinuation subdural hematoma Adverse reactions leading,1
IMBRUVICA,subdural hematoma,reduction occurred,0
IMBRUVICA,elevated uric acid levels,Forty percent of patients elevated uric acid,1
IMBRUVICA,elevated uric acid levels,Forty percent of patients elevated uric acid levels,1
IMBRUVICA,elevated uric acid levels,elevated uric acid levels on study,1
IMBRUVICA,elevated uric acid levels,Forty percent of patients elevated uric acid levels,1
IMBRUVICA,elevated uric acid levels,percent of patients elevated uric acid levels on study including,1
IMBRUVICA,elevated uric acid levels,Forty percent of patients elevated uric acid levels,1
IMBRUVICA,elevated uric acid levels,percent of patients elevated uric acid,1
IMBRUVICA,elevated uric acid levels,percent of patients elevated uric acid,1
IMBRUVICA,elevated uric acid levels,Adverse reaction of hyperuricemia was,0
IMBRUVICA,hyperuricemia,elevated uric acid levels on study including with values above mgdL,0
IMBRUVICA,hyperuricemia,hyperuricemia,1
IMBRUVICA,hyperuricemia,hyperuricemia,1
IMBRUVICA,hyperuricemia,reaction hyperuricemia was reported for,1
IMBRUVICA,hyperuricemia,hyperuricemia,1
IMBRUVICA,hyperuricemia,levels on study including with values above mgdL Adverse reaction of,0
IMBRUVICA,hyperuricemia,hyperuricemia was reported for of,1
IMBRUVICA,hyperuricemia,mgdL Adverse reaction hyperuricemia was reported for,1
IMBRUVICA,hyperuricemia,hyperuricemia was reported for of,1
IMBRUVICA,thrombocytopenia,thrombocytopenia neutropenia diarrhea anemia fatigue musculoskeletal,1
IMBRUVICA,thrombocytopenia,most commonly occurring adverse reactions in Study,0
IMBRUVICA,thrombocytopenia,thrombocytopenia neutropenia diarrhea,1
IMBRUVICA,neutropenia,neutropenia diarrhea anemia fatigue musculoskeletal pain,1
IMBRUVICA,neutropenia,neutropenia diarrhea anemia fatigue musculoskeletal pain,1
IMBRUVICA,diarrhea,diarrhea,1
IMBRUVICA,diarrhea,thrombocytopenia diarrhea anemia fatigue musculoskeletal,1
IMBRUVICA,diarrhea,diarrhea,1
IMBRUVICA,diarrhea,diarrhea anemia fatigue musculoskeletal pain,1
IMBRUVICA,diarrhea,were thrombocytopenia diarrhea anemia fatigue musculoskeletal pain,1
IMBRUVICA,diarrhea,diarrhea anemia fatigue musculoskeletal pain,1
IMBRUVICA,diarrhea,reactions,0
IMBRUVICA,diarrhea,diarrhea anemia,1
IMBRUVICA,diarrhea,anemia fatigue musculoskeletal pain upper respiratory,0
IMBRUVICA,diarrhea,thrombocytopenia diarrhea anemia fatigue musculoskeletal,1
IMBRUVICA,diarrhea,anemia fatigue musculoskeletal pain upper respiratory,0
IMBRUVICA,diarrhea,diarrhea anemia fatigue musculoskeletal pain upper,1
IMBRUVICA,diarrhea,were thrombocytopenia diarrhea anemia fatigue,1
IMBRUVICA,diarrhea,diarrhea anemia fatigue musculoskeletal pain upper,1
IMBRUVICA,anemia,anemia,1
IMBRUVICA,anemia,adverse reactions in Study and Study were thrombocytopenia neutropenia diarrhea,0
IMBRUVICA,anemia,rash,0
IMBRUVICA,anemia,anemia,1
IMBRUVICA,anemia,anemia fatigue musculoskeletal pain upper respiratory,1
IMBRUVICA,anemia,anemia fatigue musculoskeletal,1
IMBRUVICA,anemia,thrombocytopenia neutropenia anemia fatigue musculoskeletal pain,1
IMBRUVICA,anemia,anemia fatigue musculoskeletal,1
IMBRUVICA,fatigue,fatigue,1
IMBRUVICA,fatigue,and,0
IMBRUVICA,fatigue,fatigue musculoskeletal pain upper,1
IMBRUVICA,fatigue,thrombocytopenia neutropenia diarrhea fatigue musculoskeletal pain upper,1
IMBRUVICA,fatigue,fatigue musculoskeletal pain upper,1
IMBRUVICA,fatigue,diarrhea,0
IMBRUVICA,fatigue,fatigue musculoskeletal pain upper,1
IMBRUVICA,fatigue,upper respiratory tract infection rash nausea and,0
IMBRUVICA,fatigue,rse reactions in Study and Study were thrombocytopenia neutropenia diarrhea,0
IMBRUVICA,fatigue,fatigue musculoskeletal,1
IMBRUVICA,musculoskeletal pain,and Study were,0
IMBRUVICA,musculoskeletal pain,musculoskeletal pain,1
IMBRUVICA,musculoskeletal pain,upper respiratory tract infection rash nausea and pyrexia,0
IMBRUVICA,musculoskeletal pain,musculoskeletal pain upper,1
IMBRUVICA,musculoskeletal pain,diarrhea anemia musculoskeletal pain upper respiratory tract infection,1
IMBRUVICA,musculoskeletal pain,musculoskeletal pain upper,1
IMBRUVICA,musculoskeletal pain,thrombocytopenia neutropenia diarrhea anemia musculoskeletal pain upper respiratory tract infection,1
IMBRUVICA,musculoskeletal pain,musculoskeletal pain upper,1
IMBRUVICA,musculoskeletal pain,upper,0
IMBRUVICA,musculoskeletal pain,infection rash nausea,0
IMBRUVICA,musculoskeletal pain,Study were thrombocytopenia neutropenia diarrhea,0
IMBRUVICA,upper respiratory tract infection,respiratory tract infection,1
IMBRUVICA,upper respiratory tract infection,anemia fatigue,0
IMBRUVICA,upper respiratory tract infection,of patients receiving IMBRUVICA in Study,0
IMBRUVICA,upper respiratory tract infection,rash nausea and pyrexia Approximately five percent of patients receiving IMBRUVICA,0
IMBRUVICA,upper respiratory tract infection,upper respiratory tract,1
IMBRUVICA,upper respiratory tract infection,diarrhea anemia fatigue musculoskeletal upper respiratory tract infection rash nausea,1
IMBRUVICA,upper respiratory tract infection,upper respiratory tract,1
IMBRUVICA,upper respiratory tract infection,diarrhea anemia fatigue musculoskeletal upper,1
IMBRUVICA,upper respiratory tract infection,upper respiratory tract infection rash nausea and pyrexia,1
IMBRUVICA,upper respiratory tract infection,thrombocytopenia neutropenia diarrhea,0
IMBRUVICA,rash,rash,1
IMBRUVICA,rash,anemia fatigue musculoskeletal pain upper respiratory,0
IMBRUVICA,rash,rash nausea and,1
IMBRUVICA,nausea,IMBRUVICA in Study and,0
IMBRUVICA,infections,infections subdural hematomas and diarrhea,1
IMBRUVICA,infections,infections subdural hematomas,1
IMBRUVICA,infections,infections subdural,1
IMBRUVICA,infections,infections subdural hematomas,1
IMBRUVICA,infections,These included,0
IMBRUVICA,infections,infections subdural hematomas and diarrhea Adverse,1
IMBRUVICA,infections,infections subdural hematomas and diarrhea Adverse,1
IMBRUVICA,infections,infections subdural hematomas and diarrhea Adverse,1
IMBRUVICA,infections,infections subdural hematomas and diarrhea Adverse,1
IMBRUVICA,infections,discontinued treatment due to adverse,0
IMBRUVICA,infections,events These infections,1
IMBRUVICA,infections,discontinued treatment due to adverse,0
IMBRUVICA,subdural hematomas,events These included subdural hematomas,1
IMBRUVICA,subdural hematomas,to dose reduction occurred in approximately of,0
IMBRUVICA,subdural hematomas,treatment due to adverse events These included infections,0
IMBRUVICA,subdural hematomas,Study and Study discontinued treatment due to,0
IMBRUVICA,subdural hematomas,These included subdural hematomas,1
IMBRUVICA,subdural hematomas,These included subdural hematomas,1
IMBRUVICA,subdural hematomas,events These included subdural hematomas,1
IMBRUVICA,subdural hematomas,subdural,1
IMBRUVICA,subdural hematomas,adverse events These included subdural hematomas,1
IMBRUVICA,subdural hematomas,subdural hematomas and diarrhea Adverse events,1
IMBRUVICA,diarrhea,Adverse events leading,0
IMBRUVICA,diarrhea,diarrhea Adverse events leading to,1
IMBRUVICA,diarrhea,hematomas,0
IMBRUVICA,diarrhea,diarrhea Adverse,1
IMBRUVICA,diarrhea,to dose reduction occurred in approximately of patients Study,0
IMBRUVICA,diarrhea,diarrhea Adverse events,1
IMBRUVICA,Dyspepsia,Abdominal,0
IMBRUVICA,Dyspepsia,Abdominal Dyspepsia Infections,1
IMBRUVICA,Dyspepsia,Abdominal,0
IMBRUVICA,Dyspepsia,Abdominal Dyspepsia,1
IMBRUVICA,Dyspepsia,Abdominal,0
IMBRUVICA,Dyspepsia,Infections,0
IMBRUVICA,Sinusitis,Upper respiratory tract infection,0
IMBRUVICA,Sinusitis,Sinusitis Skin infection,1
IMBRUVICA,Pneumonia,Pneumonia,1
IMBRUVICA,Pyrexia,Pyrexia,1
IMBRUVICA,Cough,Cough Oropharyngeal,1
IMBRUVICA,Arthralgia,disorders Musculoskeletal Arthralgia Muscle spasms,1
IMBRUVICA,Arthralgia,Cough Oropharyngeal,1
IMBRUVICA,Arthralgia,Musculoskeletal Arthralgia Muscle spasms,1
IMBRUVICA,Arthralgia,Cough Oropharyngeal,1
IMBRUVICA,Arthralgia,Arthralgia,1
IMBRUVICA,Arthralgia,Arthralgia,1
IMBRUVICA,Arthralgia,disorders Musculoskeletal Arthralgia Muscle,1
IMBRUVICA,Arthralgia,Arthralgia,1
IMBRUVICA,Headache,Headache Peripheral neuropat,1
IMBRUVICA,Headache,Dizziness,0
IMBRUVICA,Headache,Headache Peripheral,1
IMBRUVICA,Headache,Headache Peripheral,1
IMBRUVICA,Headache,Headache Peripheral,1
IMBRUVICA,Headache,Headache Peripheral,1
IMBRUVICA,Headache,Headache Peripheral,1
IMBRUVICA,Decreased appetite,Metabolism and nutrition Decreased appetite,1
IMBRUVICA,Second malignancies,Neoplasms benign malignant Second,1
IMBRUVICA,Laceration,Laceration Psychiatric,1
IMBRUVICA,Laceration,Injury poisoning and procedural complications,0
IMBRUVICA,Laceration,Injury poisoning and procedural complications,0
IMBRUVICA,Laceration,Laceration Psychiatric disorders,1
IMBRUVICA,Insomnia,ic disorders Insomnia Vascular disorder,1
IMBRUVICA,Insomnia,Laceration Psychiatric disorders,1
IMBRUVICA,Insomnia,Anxiety,0
IMBRUVICA,Insomnia,ic disorders,0
IMBRUVICA,Insomnia,Insomnia,1
IMBRUVICA,Insomnia,Insomnia Vascular,1
IMBRUVICA,Insomnia,Insomnia Vascular,1
IMBRUVICA,Insomnia,Insomnia,1
IMBRUVICA,Hypertension,Hypertension,1
IMBRUVICA,Hypertension,Insomnia,1
IMBRUVICA,Hypertension,Hypertension Table TreatmentEmerge,1
IMBRUVICA,Decrease of Hemoglobin,and adverse Decrease of Hemoglobin,1
IMBRUVICA,Decrease of Hemoglobin,Hypertension Table TreatmentEmerge,1
IMBRUVICA,Decrease of Hemoglobin,Patients with CLL N in,0
IMBRUVICA,Decrease of Hemoglobin,Study IMBRUVICAN Ofatumu,0
IMBRUVICA,Decrease of Hemoglobin,TreatmentEmergentBased on laboratory measurements per IWCLL criteria,0
IMBRUVICA,Decrease of Hemoglobin,Decrease of Hemoglobin Platelets,1
IMBRUVICA,Decrease of Hemoglobin,Decrease of Hemoglobin Platelets,1
IMBRUVICA,Decrease of Hemoglobin,Decrease of Hemoglobin Platelets,1
IMBRUVICA,neutropenia,trial,0
IMBRUVICA,neutropenia,trial neutropenia,1
IMBRUVICA,neutropenia,trial,0
IMBRUVICA,neutropenia,neutropenia thrombocytopenia diarrhea rash nausea muscle,1
IMBRUVICA,neutropenia,neutropenia thrombocytopenia diarrhea rash nausea muscle,1
IMBRUVICA,neutropenia,the WM trial neutropenia thrombocytopenia diarrhea rash nausea muscle,1
IMBRUVICA,neutropenia,neutropenia thrombocytopenia diarrhea rash nausea muscle,1
IMBRUVICA,neutropenia,neutropenia thrombocytopenia,1
IMBRUVICA,neutropenia,muscle,0
IMBRUVICA,thrombocytopenia,thrombocytopenia diarrhea rash nausea muscle spasms,1
IMBRUVICA,thrombocytopenia,thrombocytopenia,1
IMBRUVICA,thrombocytopenia,thrombocytopenia diarrhea rash nausea,1
IMBRUVICA,thrombocytopenia,thrombocytopenia diarrhea,1
IMBRUVICA,thrombocytopenia,thrombocytopenia,1
IMBRUVICA,thrombocytopenia,thrombocytopenia diarrhea rash nausea,1
IMBRUVICA,thrombocytopenia,thrombocytopenia,1
IMBRUVICA,thrombocytopenia,of patients,0
IMBRUVICA,thrombocytopenia,neutropenia,0
IMBRUVICA,thrombocytopenia,thrombocytopenia diarrhea rash nausea,1
IMBRUVICA,thrombocytopenia,neutropenia,0
IMBRUVICA,diarrhea,neutropenia diarrhea,1
IMBRUVICA,diarrhea,neutropenia,0
IMBRUVICA,diarrhea,in the,0
IMBRUVICA,diarrhea,diarrhea rash nausea muscle,1
IMBRUVICA,diarrhea,in the W,0
IMBRUVICA,rash,rash nausea muscle spasms and,1
IMBRUVICA,rash,trial were neutropenia thrombocytopenia rash nausea muscle spasms and,1
IMBRUVICA,rash,rash nausea muscle spasms and,1
IMBRUVICA,rash,rash nausea muscle,1
IMBRUVICA,nausea,nausea,1
IMBRUVICA,nausea,nausea muscle spasms and fatigue,1
IMBRUVICA,nausea,reactions in the WM,0
IMBRUVICA,nausea,nausea muscle spasms and fatigue,1
IMBRUVICA,nausea,thrombocytopenia diarrhea nausea,1
IMBRUVICA,nausea,nausea muscle spasms and fatigue,1
IMBRUVICA,nausea,muscle spasms and fatigue Six percent of patients receiving IMBRUVICA in the,0
IMBRUVICA,nausea,nausea muscle spasms,1
IMBRUVICA,nausea,rash,0
IMBRUVICA,muscle spasms,rash muscle,1
IMBRUVICA,muscle spasms,receiving IMBRUVICA,0
IMBRUVICA,muscle spasms,muscle spasms and fatigue Six percent,1
IMBRUVICA,muscle spasms,receiving IMBRUVICA,0
IMBRUVICA,muscle spasms,reactions,0
IMBRUVICA,fatigue,neutropenia thrombocytopenia diarrhea,0
IMBRUVICA,Fatigue,Fatigue Musculoskeletal,1
IMBRUVICA,Fatigue,disorders and administrative site Fatigue,1
IMBRUVICA,Fatigue,Fatigue Musculoskeletal,1
IMBRUVICA,Fatigue,Musculoskeletal and connecti,0
IMBRUVICA,Fatigue,and administrative site Fatigue Musculoskeletal and connecti,1
IMBRUVICA,Fatigue,Musculoskeletal and connecti,0
IMBRUVICA,Fatigue,disorders,0
IMBRUVICA,Arthropathy,Arthropathy Infections and infesta,1
IMBRUVICA,Arthropathy,disorders Muscle Arthropathy Infections,1
IMBRUVICA,Arthropathy,Arthropathy Infections and infesta,1
IMBRUVICA,Arthropathy,disorders,0
IMBRUVICA,Arthropathy,Arthropathy Infections,1
IMBRUVICA,Arthropathy,tissue,0
IMBRUVICA,Arthropathy,Arthropathy Infections and infesta,1
IMBRUVICA,Arthropathy,Arthropathy Infections,1
IMBRUVICA,Arthropathy,Muscle Arthropathy Infections and,1
IMBRUVICA,Arthropathy,Arthropathy Infections,1
IMBRUVICA,Cough,Epistaxis,0
IMBRUVICA,Cough,Epistaxis,0
IMBRUVICA,Cough,Nervous system,0
IMBRUVICA,Cough,diastinal disorders Epistaxis,0
IMBRUVICA,Cough,Cough Nervous system d,1
IMBRUVICA,Cough,disorders Epistaxis,0
IMBRUVICA,Cough,Nervous system d,0
IMBRUVICA,Skin cancer,Neoplasms benign malignant and unspecified including cysts and polyps,0
IMBRUVICA,Skin cancer,and Skin cancer,1
IMBRUVICA,Skin cancer,Skin cancer Table TreatmentEmerg,1
IMBRUVICA,Skin cancer,including cysts,0
IMBRUVICA,Skin cancer,Skin cancer,1
IMBRUVICA,Decrease of Hemoglobin,WM N Perc,0
IMBRUVICA,Hypersensitivity reactions,angioedema,0
IMBRUVICA,Hypersensitivity reactions,to drug Hypersensitivity,1
IMBRUVICA,anaphylactic shock,reactions anaphylactic shock fatal urticaria and,1
IMBRUVICA,anaphylactic shock,to drug Hypersensitivity,1
IMBRUVICA,anaphylactic shock,Hypersensitivity reactions anaphylactic,1
IMBRUVICA,anaphylactic shock,establish a causal relationship to,0
IMBRUVICA,anaphylactic shock,reactions anaphylactic shock fatal urticaria and angioedema,1
IMBRUVICA,anaphylactic shock,establish a causal relationship to,0
IMBRUVICA,anaphylactic shock,drug exposure Hypersensitivity reactions,0
IMBRUVICA,anaphylactic shock,Hypersensitivity reactions anaphylactic shock,1
IMBRUVICA,anaphylactic shock,drug exposure Hypersensitivity reactions,0
IMBRUVICA,anaphylactic shock,drug exposure Hypersensitivity reactions anaphylactic shock fatal urticaria and angioedema have,1
IMBRUVICA,anaphylactic shock,drug exposure Hypersensitivity reactions,0
IMBRUVICA,fatal,fatal urticaria and angioedema have been,1
IMBRUVICA,fatal,fatal,1
IMBRUVICA,fatal,and angioedema have been reported,0
IMBRUVICA,angioedema,angioedema,1
IMBRUVICA,angioedema,angioedema,1
IMBRUVICA,angioedema,have,0
IMBRUVICA,Hemorrhage,adverse,0
IMBRUVICA,Hemorrhage,rea,0
IMBRUVICA,Hemorrhage,ctions are discussed,1
IMBRUVICA,Hemorrhage,labeling Hemorrhage see Warnings and Pr,0
IMBRUVICA,Hemorrhage,ctions are discussed in more,1
IMBRUVICA,Hemorrhage,labeling Hemorrhage see Warnings and Pr,0
IMBRUVICA,Hemorrhage,in other sections of the,0
IMBRUVICA,Hemorrhage,following adverse ctions are,1
IMBRUVICA,Hemorrhage,adverse ctions,1
IMBRUVICA,Hemorrhage,ctions are discussed in more detail,1
IMBRUVICA,Infections,detail in other ions of th,1
IMBRUVICA,Infections,ctions are discussed in more detail,1
IMBRUVICA,Infections,other ions of th e labeling,1
IMBRUVICA,Infections,ctions are discussed in more detail,1
IMBRUVICA,Infections,Warnings and Precautions,0
IMBRUVICA,Infections,in other ions of th e labeling Hemorrhage,1
IMBRUVICA,Infections,Warnings and Precautions,0
IMBRUVICA,Infections,ions of th,1
IMBRUVICA,Infections,Warnings and Precautions,0
IMBRUVICA,Atrial Fibrillation,Atrial Fibrillation see Warnings and,0
IMBRUVICA,Atrial Fibrillation,Cytopenias ee Warnings,1
IMBRUVICA,Second Primary Malignancies,see and Precautions (5.4) ],1
IMBRUVICA,Second Primary Malignancies,Fibrillation,0
IMBRUVICA,Second Primary Malignancies,Atrial Fibrillation,0
IMBRUVICA,Second Primary Malignancies,and Precautions Tumor Lysis,0
IMBRUVICA,Second Primary Malignancies,Atrial Fibrillation see and Precautions,1
IMBRUVICA,Second Primary Malignancies,see  and Precautions (5.4)  ]   Second Primary Malignancies see Warnings,1
IMBRUVICA,Second Primary Malignancies,Atrial Fibrillation see and Precautions,1
IMBRUVICA,Second Primary Malignancies,Warnings,0
IMBRUVICA,Second Primary Malignancies,Fibrillation see  and Precautions (5.4)  ]   Second Primary Malignancies see Warnings,1
IMBRUVICA,Second Primary Malignancies,Warnings,0
IMBRUVICA,Second Primary Malignancies,Atrial Fibrillation,0
IMBRUVICA,skin cancers,Precautions Second Primary Malignancies,0
IMBRUVICA,skin cancers,Warnings and Precautions,0
IMBRUVICA,skin cancers,and tions (5.5),1
IMBRUVICA,skin cancers,tions (5.5) Tumor Lysis Syndrome,1
IMBRUVICA,skin cancers,tions (5.5) Tumor Lysis Syndrome see,1
IMBRUVICA,skin cancers,Warnings and tions (5.5)  Tumor Lysis Syndrome see,1
IMBRUVICA,skin cancers,tions (5.5) Tumor Lysis Syndrome see,1
IMBRUVICA,skin cancers,Warnings and tions (5.5)  Tumor,1
IMBRUVICA,skin cancers,tions (5.5) Tumor Lysis Syndrome see,1
IMBRUVICA,skin cancers,tions (5.5) Tumor,1
IMBRUVICA,skin cancers,Tumor Lysis Syndrome,0
IMBRUVICA,Tumor Lysis Syndrome,nings and Precaution s Because clinical trials are,1
IMBRUVICA,Tumor Lysis Syndrome,see nings and Precaution s Because clinical trials,1
IMBRUVICA,Tumor Lysis Syndrome,nings and Precaution s Because clinical trials are,1
IMBRUVICA,Tumor Lysis Syndrome,nings and Precaution s Because clinical trials are,1
IMBRUVICA,Tumor Lysis Syndrome,see nings and Precaution s Because clinical,1
IMBRUVICA,Tumor Lysis Syndrome,nings and Precaution s Because clinical trials are,1
IMBRUVICA,TLS,and,0
IMBRUVICA,TLS,adverse,0
IMBRUVICA,TLS,and (5. Because,1
IMBRUVICA,TLS,adverse,0
IMBRUVICA,TLS,(5.,1
IMBRUVICA,fetal harm,ed in clin,1
IMBRUVICA,fetal harm,(5.,1
IMBRUVICA,fetal harm,under widely variable conditions adverse event rates,0
IMBRUVICA,fetal harm,be directly compared with rates of clinical trials of,0
IMBRUVICA,Fatal, prac tice EXCERPT The most common,1
IMBRUVICA,Fatal,observed  prac tice EXCERPT The most,1
IMBRUVICA,Fatal, prac tice EXCERPT The most common,1
IMBRUVICA,Fatal, prac tice EXCERPT,1
IMBRUVICA,Fatal,drug and may not reflect,0
IMBRUVICA,Fatal,The most common adverse reactions in patients,0
IMBRUVICA,Fatal, prac tice EXCERPT,1
IMBRUVICA,Fatal, prac tice EXCERPT,1
IMBRUVICA,Fatal, prac tice EXCERPT The most common,1
IMBRUVICA,Fatal, prac tice EXCERPT The most,1
IMBRUVICA,Fatal,reflect the rates observed  prac tice EXCERPT The,1
IMBRUVICA,Fatal, prac tice EXCERPT The most,1
IMBRUVICA,bleeding events,and may not reflect the rates observed in pract,0
IMBRUVICA,bleeding events,"the rates observed in ice.
 

   EXCE RPT The most",1
IMBRUVICA,bleeding events,and may not reflect the rates observed in pract,0
IMBRUVICA,bleeding events,in ice. EXCE,1
IMBRUVICA,bleeding events,in patients with ell malignancie,1
IMBRUVICA,bleeding events,WM,0
IMBRUVICA,bleeding events,CLL WM were thrombocytopenia,0
IMBRUVICA,bleeding events,anemia,0
IMBRUVICA,subdural hematoma,"Bcell (MCL,",1
IMBRUVICA,subdural hematoma,"patients with Bcell (MCL, CLL, WM) we",1
IMBRUVICA,subdural hematoma,"Bcell (MCL,",1
IMBRUVICA,subdural hematoma,pain bruising nausea,0
IMBRUVICA,subdural hematoma,WM) we re thrombocytopenia neutropenia diarrhea,1
IMBRUVICA,subdural hematoma,WM) we re thrombocytopenia neutropenia diarrhea,1
IMBRUVICA,subdural hematoma,EXCERPT The most,0
IMBRUVICA,subdural hematoma,in,0
IMBRUVICA,gastrointestinal bleeding,"MCL CLL WM thrombocytopenia,",1
IMBRUVICA,gastrointestinal bleeding,"thrombocytopenia, neutro penia diarrhea anemia",1
IMBRUVICA,gastrointestinal bleeding,"thrombocytopenia, neutro penia diarrhea",1
IMBRUVICA,gastrointestinal bleeding,were,0
IMBRUVICA,gastrointestinal bleeding,"thrombocytopenia, neutro penia diarrhea anemia",1
IMBRUVICA,hematuria,musculoskeletal pain bruising,0
IMBRUVICA,hematuria,"were thrombocytopenia nia, diar",1
IMBRUVICA,hematuria,musculoskeletal pain bruising,0
IMBRUVICA,post procedural hemorrhage,"fatigue, musculos keletal pain bruising nausea upper",1
IMBRUVICA,post procedural hemorrhage,malignancies MCL CLL WM were,0
IMBRUVICA,Bleeding,pain bruising nausea upper piratory tract,1
IMBRUVICA,Bleeding,malignancies MCL CLL WM were,0
IMBRUVICA,Bleeding,REACTIONS contact,0
IMBRUVICA,Bleeding,piratory tract infection,1
IMBRUVICA,Bleeding,upper,0
IMBRUVICA,Bleeding,upper piratory,1
IMBRUVICA,Bleeding,upper,0
IMBRUVICA,Bleeding,fatigue musculoskeletal,0
IMBRUVICA,Bleeding,upper res,0
IMBRUVICA,Bleeding,piratory tract infection and rash To,1
IMBRUVICA,bruising,tract infection and   To rep ort SUSPECTED ADVERSE REACTIONS,1
IMBRUVICA,bruising,piratory tract infection and rash To,1
IMBRUVICA,bruising,ort SUSPECTED ADVERSE REACTIONS contact,0
IMBRUVICA,bruising,Pharmacyclics at or FDA,0
IMBRUVICA,bruising,infection and   To rep ort,1
IMBRUVICA,bruising,Pharmacyclics at or FDA,0
IMBRUVICA,bruising,REACTIONS contact,0
IMBRUVICA,petechiae,To report USPECTED  ADVERSE REACTIONS contact Pharmacyclics at,1
IMBRUVICA,petechiae,REACTIONS contact,0
IMBRUVICA,hemorrhage,"Mantle Cell ma  



 T he data",1
IMBRUVICA,hemorrhage,REACTIONS contact,0
IMBRUVICA,hemorrhage,ma T he data described below,1
IMBRUVICA,hemorrhage,Experience Mantle Cell ma,1
IMBRUVICA,hemorrhage,IMBRUVICA in a clinical trial that,0
IMBRUVICA,hemorrhage,ma T he data described,1
IMBRUVICA,hemorrhage,clinical trial,0
IMBRUVICA,hemorrhage,"Cell ma  



 T he data described below",1
IMBRUVICA,hemorrhage,clinical trial,0
IMBRUVICA,hemorrhage,in a clinical trial that included patients,0
IMBRUVICA,hemorrhage,a clinical trial that included,0
IMBRUVICA,hemorrhage,exposure,0
IMBRUVICA,Fatal,iarrh ea,1
IMBRUVICA,Fatal,upper respiratory,0
IMBRUVICA,Fatal,months The most commonly occurring adverse reactions were thrombocytopenia,0
IMBRUVICA,Fatal,iarrh ea neutropenia anemia fatigue,1
IMBRUVICA,Fatal,iarrh ea neutropenia anemia fatigue,1
IMBRUVICA,Fatal,The most commonly,0
IMBRUVICA,Fatal,edema upper respiratory tract in,0
IMBRUVICA,Fatal,anemia fatigue musculoskeletal pain peripheral edema upper,0
IMBRUVICA,Fatal,thrombocytopenia iarrh ea neutropenia anemia fatigue musculoskeletal,1
IMBRUVICA,Fatal,anemia fatigue musculoskeletal pain peripheral edema upper,0
IMBRUVICA,infections,"thrombocytopenia diarrhea , anemia,  fatigue musculoskeletal pain peripheral edema",1
IMBRUVICA,infections,anemia fatigue musculoskeletal pain peripheral edema upper,0
IMBRUVICA,infections,"were thrombocytopenia diarrhea , anemia,  fatigue",1
IMBRUVICA,infections,anemia fatigue musculoskeletal pain peripheral edema upper,0
IMBRUVICA,infections,commonly occurring adverse reactions,0
IMBRUVICA,infections,", anemia,  fatigue musculoskeletal",1
IMBRUVICA,infections,commonly occurring adverse reactions,0
IMBRUVICA,infections,"diarrhea , anemia,  fatigue musculoskeletal",1
IMBRUVICA,infections,commonly occurring adverse reactions,0
IMBRUVICA,infections,occurring adverse reactions,0
IMBRUVICA,infections,"diarrhea , anemia,  fatigue",1
IMBRUVICA,infections,occurring adverse reactions,0
IMBRUVICA,infections,"were thrombocytopenia diarrhea ,",1
IMBRUVICA,infections,edema upper respiratory,0
IMBRUVICA,infections,diarrhea,0
IMBRUVICA,infections,neutropenia anemia,0
IMBRUVICA,infections,cytopenia diarrhea neutropenia anemia fatigue musculoskeletal pain peripheral,0
IMBRUVICA,infections,bruising dyspnea constipation rash abdominal,0
IMBRUVICA,PML,rash abdominal pain vomiting and decreased appetite,0
IMBRUVICA,PML,most common Grade or nonhematological adverse reactions were,0
IMBRUVICA,PML, an d The most common Grade,1
IMBRUVICA,PML,decreased appetite see  an d The most common Grade,1
IMBRUVICA,PML, an d The most common Grade,1
IMBRUVICA,cytopenias,"fatigue and skin s.



 Fat",1
IMBRUVICA,cytopenias, an d The most common Grade,1
IMBRUVICA,cytopenias,s. Fat al and,1
IMBRUVICA,cytopenias,"and skin s.



 Fat al and",1
IMBRUVICA,cytopenias,s. Fat al and,1
IMBRUVICA,cytopenias,"and skin s.



 Fat al and",1
IMBRUVICA,cytopenias,s. Fat al and,1
IMBRUVICA,cytopenias,s.,1
IMBRUVICA,cytopenias,"fatigue and skin s.



 Fat al and serious cases of",1
IMBRUVICA,cytopenias,s.,1
IMBRUVICA,cytopenias,IMBRUVICA therapy Increases,0
IMBRUVICA,cytopenias,pain atrial fibrillation diarrhea fatigue and skin,0
IMBRUVICA,cytopenias,"diarrhea fatigue and skin s.



 Fat al and serious cases",1
IMBRUVICA,cytopenias,pain atrial fibrillation diarrhea fatigue and skin,0
IMBRUVICA,cytopenias,fatigue and skin s. Fat,1
IMBRUVICA,cytopenias,"diarrhea fatigue and skin s.



 Fat al",1
IMBRUVICA,cytopenias,fatigue and skin s. Fat,1
IMBRUVICA,neutropenia,and ous cases,1
IMBRUVICA,neutropenia,in creatinine to times the upp,0
IMBRUVICA,neutropenia,infections Fatal and ous,1
IMBRUVICA,neutropenia,ous cases,1
IMBRUVICA,neutropenia,ous cases o,1
IMBRUVICA,neutropenia,ous cases,1
IMBRUVICA,neutropenia,Fatal and seri,0
IMBRUVICA,neutropenia,IMBRUVICA therapy Increases in creatinine to times the,0
IMBRUVICA,neutropenia,Fatal and ous,1
IMBRUVICA,anemia,to times the upper limit of,0
IMBRUVICA,anemia,times the upper limit of normal occurred in of patients,0
IMBRUVICA,anemia,es in creatinine to times,1
IMBRUVICA,anemia,es in creatinine,1
IMBRUVICA,Atrial fibrillation,using agent IMBRUVICA 560 mg daily occurring at a,1
IMBRUVICA,Atrial fibrillation,es in creatinine,1
IMBRUVICA,Atrial fibrillation,trial N using agent IMBRUVICA 560 mg daily occurring at a,1
IMBRUVICA,Atrial fibrillation,es in creatinine,1
IMBRUVICA,Atrial fibrillation,occurred in of patients Adverse reactions from the MCL trial N,0
IMBRUVICA,Atrial fibrillation,IMBRUVICA 560,1
IMBRUVICA,Atrial fibrillation,MCL trial N using agent IMBRUVICA 560,1
IMBRUVICA,Atrial fibrillation,agent IMBRUVICA 560 mg,1
IMBRUVICA,Atrial fibrillation,MCL trial N using agent,1
IMBRUVICA,atrial flutter,IMBRUVICA mg aily occurring,1
IMBRUVICA,atrial flutter,agent IMBRUVICA mg aily occurring,1
IMBRUVICA,atrial flutter,IMBRUVICA mg aily occurring,1
IMBRUVICA,atrial flutter,Table Table NonHematologic Adverse Reactions,0
IMBRUVICA,atrial flutter,aily occurring,1
IMBRUVICA,atrial flutter,IMBRUVICA mg aily occurring at a,1
IMBRUVICA,atrial flutter,aily occurring,1
IMBRUVICA,atrial flutter,aily occurring,1
IMBRUVICA,Reduced fetal weights,administrative site conditions,0
IMBRUVICA,Reduced fetal weights,conditions,0
DUREZOL,elevated intraocular pressure,ophthalmic steroids elevated intraocular pressure which may be associated with,1
DUREZOL,elevated intraocular pressure,conditions,0
DUREZOL,elevated intraocular pressure,elevated intraocular,1
DUREZOL,elevated intraocular pressure,steroids elevated intraocular pressure which may be associated,1
DUREZOL,elevated intraocular pressure,elevated intraocular,1
DUREZOL,elevated intraocular pressure,with ophthalmic steroids elevated intraocular pressure which may be associated,1
DUREZOL,elevated intraocular pressure,elevated intraocular,1
DUREZOL,elevated intraocular pressure,associated with ophthalmic steroids elevated,1
DUREZOL,elevated intraocular pressure,elevated intraocular pressure,1
DUREZOL,optic nerve damage,cataract formation,0
DUREZOL,optic nerve damage,associated,0
DUREZOL,optic nerve damage,posterior,0
DUREZOL,optic nerve damage,may be associated optic nerve damage visual acuity,1
DUREZOL,optic nerve damage,posterior,0
DUREZOL,optic nerve damage,secondary,0
DUREZOL,posterior subcapsular cataract formation,posterior subcapsular cataract formation secondary,1
DUREZOL,posterior subcapsular cataract formation,acuity and field posterior subcapsular cataract formation secondary,1
DUREZOL,posterior subcapsular cataract formation,posterior subcapsular cataract formation secondary,1
DUREZOL,secondary ocular infection,optic nerve damage visual acuity and field defects posterior,0
DUREZOL,secondary ocular infection,defects posterior subcapsular cataract secondary,1
DUREZOL,secondary ocular infection,ocular infection from,1
DUREZOL,secondary ocular infection,subcapsular cataract secondary ocular infection,1
DUREZOL,secondary ocular infection,subcapsular cataract formation,0
DUREZOL,perforation of the globe,pathogens including herpes,0
DUREZOL,perforation of the globe,cataract,0
DUREZOL,perforation of the globe,including herpes simplex perforation of the globe,1
DUREZOL,perforation of the globe,cataract,0
DUREZOL,Ocular adverse reactions,Ocular adverse reactions occurring in,1
DUREZOL,Ocular adverse reactions,cornea or sclera Ocular Ocular adverse reactions,1
DUREZOL,Ocular adverse reactions,the cornea or sclera Ocular,0
DUREZOL,Ocular adverse reactions,adverse reactions occurring in of,1
DUREZOL,Ocular adverse reactions,Surgery,0
DUREZOL,Ocular adverse reactions,Ocular Ocular adverse reactions,1
DUREZOL,Ocular adverse reactions,Ocular adverse reactions occurring in of,1
DUREZOL,Ocular adverse reactions,Ocular Ocular adverse reactions,1
DUREZOL,Ocular adverse reactions,cornea or sclera,0
DUREZOL,Ocular adverse reactions,adverse reactions occurring in of,1
DUREZOL,corneal edema,hyperemia eye pain,0
DUREZOL,corneal edema,studies with DUREZOL corneal edema ciliary,1
DUREZOL,corneal edema,hyperemia eye pain,0
DUREZOL,corneal edema,corneal edema,1
DUREZOL,corneal edema,and conjunctival hyperemia eye pain photophobia,0
DUREZOL,corneal edema,studies with DUREZOL corneal edema ciliary,1
DUREZOL,corneal edema,and conjunctival hyperemia eye pain photophobia,0
DUREZOL,conjunctival hyperemia,edema ciliary conjunctival hyperemia eye pain photophobia,1
DUREZOL,conjunctival hyperemia,and conjunctival hyperemia eye pain photophobia,0
DUREZOL,conjunctival hyperemia,corneal edema ciliary conjunctival hyperemia,1
DUREZOL,conjunctival hyperemia,anterior chamber cells anterior,0
DUREZOL,conjunctival hyperemia,edema ciliary conjunctival hyperemia,1
DUREZOL,conjunctival hyperemia,conjunctival hyperemia eye pain photophobia,1
DUREZOL,conjunctival hyperemia,edema ciliary conjunctival hyperemia,1
DUREZOL,conjunctival hyperemia,conjunctival hyperemia eye pain,1
DUREZOL,conjunctival hyperemia,included corneal edema ciliary conjunctival,1
DUREZOL,eye pain,eye pain photophobia posterior capsule opacification anterior,1
DUREZOL,eye pain,corneal edema ciliary and,0
DUREZOL,eye pain,hyperemia,0
DUREZOL,eye pain,anterior chamber cells,0
DUREZOL,photophobia,opacification anterior chamber cells anterior chamber flare,0
DUREZOL,photophobia,conjunctival hyperemia eye photophobia posterior capsule opacification anterior chamber,1
DUREZOL,photophobia,opacification anterior chamber cells anterior chamber flare,0
DUREZOL,photophobia,photophobia,1
DUREZOL,photophobia,studies with DUREZOL included corneal edema,0
DUREZOL,photophobia,photophobia posterior capsule,1
DUREZOL,photophobia,and conjunctival hyperemia eye photophobia posterior capsule opacification anterior chamber,1
DUREZOL,photophobia,photophobia posterior capsule,1
DUREZOL,photophobia,photophobia posterior capsule,1
DUREZOL,posterior capsule opacification,eye pain posterior,1
DUREZOL,posterior capsule opacification,anterior chamber cells anterior chamber flare conjunctival edema and blepharitis Other,0
DUREZOL,anterior chamber cells,conjunctival hyperemia eye pain photophobia,0
DUREZOL,anterior chamber flare,adverse,0
DUREZOL,anterior chamber flare,unctival hyperemia eye pain photophobia posterior capsule opacification,0
DUREZOL,anterior chamber flare,chamber cells,0
DUREZOL,anterior chamber flare,anterior chamber anterior chamber flare,1
DUREZOL,anterior chamber flare,chamber cells,0
DUREZOL,anterior chamber flare,reactions occurring in of subjects,0
DUREZOL,anterior chamber flare,chamber flare,1
DUREZOL,anterior chamber flare,reactions occurring in of subjects,0
DUREZOL,anterior chamber flare,chamber anterior chamber flare,1
DUREZOL,anterior chamber flare,reactions occurring in of subjects,0
DUREZOL,conjunctival edema,anterior chamber conjunctival edema and blepharitis,1
DUREZOL,conjunctival edema,reactions occurring in of subjects,0
DUREZOL,conjunctival edema,occurring in of,0
DUREZOL,blepharitis,blepharitis Other,1
DUREZOL,blepharitis,blepharitis Other ocular adverse reactions,1
DUREZOL,blepharitis,chamber,0
DUREZOL,blepharitis,blepharitis,1
DUREZOL,reduced visual acuity,and blepharitis Other ocular adverse reactions occurring in of,0
DUREZOL,reduced visual acuity,blepharitis Other ocular adverse reactions occurring in of,0
DUREZOL,reduced visual acuity,subjects reduced visual acuity punctate keratitis,1
DUREZOL,reduced visual acuity,blepharitis Other ocular adverse reactions occurring in of,0
DUREZOL,punctate keratitis,inflammation,0
DUREZOL,punctate keratitis,included reduced visual punctate keratitis,1
DUREZOL,punctate keratitis,inflammation,0
DUREZOL,punctate keratitis,adverse reactions occurring in of subjects included app,0
DUREZOL,punctate keratitis,subjects included reduced visual punctate keratitis eye inflammation and,1
DUREZOL,punctate keratitis,adverse reactions occurring in of subjects included app,0
DUREZOL,punctate keratitis,punctate keratitis eye inflammation and iritis,1
DUREZOL,punctate keratitis,subjects included reduced visual punctate keratitis,1
DUREZOL,punctate keratitis,punctate keratitis eye inflammation and iritis,1
DUREZOL,punctate keratitis,punctate keratitis eye inflammation and iritis Ocular,1
DUREZOL,punctate keratitis,subjects included reduced visual punctate keratitis,1
DUREZOL,eye inflammation,acuity punctate eye inflammation,1
DUREZOL,eye inflammation,eye inflammation and iritis Ocular adverse reactions,1
DUREZOL,eye inflammation,punctate eye inflammation,1
DUREZOL,eye inflammation,eye inflammation and iritis Ocular adverse reactions,1
DUREZOL,eye inflammation,subjects included,0
DUREZOL,eye inflammation,in of subjects included reduced visual acuity punctate keratitis,0
DUREZOL,eye inflammation,of subjects included application,0
DUREZOL,eye inflammation,eye inflammation and iritis Ocular,1
DUREZOL,eye inflammation,of subjects included application,0
DUREZOL,eye inflammation,visual acuity punctate eye inflammation,1
DUREZOL,eye inflammation,acuity punctate eye inflammation and iritis Ocular adverse,1
DUREZOL,eye inflammation,visual acuity punctate eye inflammation,1
DUREZOL,iritis,iritis Ocular adverse reactions occurring in,1
DUREZOL,iritis,in of subjects included reduced,0
DUREZOL,iritis,iritis Ocular adverse reactions,1
DUREZOL,application site discomfort,of subjects application site discomfort or,1
DUREZOL,application site discomfort,iritis Ocular adverse reactions,1
DUREZOL,application site discomfort,irritation and c,0
DUREZOL,application site discomfort,subjects application site discomfort or irritation,1
DUREZOL,application site discomfort,irritation and c,0
DUREZOL,application site discomfort,in of subjects application,1
DUREZOL,application site discomfort,site discomfort,1
DUREZOL,application site discomfort,in of subjects application site discomfort or irritation corneal,1
DUREZOL,application site discomfort,site discomfort,1
DUREZOL,application site discomfort,site discomfort or irritation corneal,1
DUREZOL,application site discomfort,and striae episcleritis eye pruritis eyelid irritation and c,0
DUREZOL,corneal pigmentation,discomfort or corneal pigmentation,1
DUREZOL,corneal pigmentation,corneal pigmentation and striae episcleritis,1
DUREZOL,corneal pigmentation,discomfort or corneal pigmentation,1
DUREZOL,corneal pigmentation,corneal pigmentation and striae episcleritis eye,1
DUREZOL,corneal pigmentation,discomfort or corneal,1
DUREZOL,corneal pigmentation,or corneal,1
DUREZOL,corneal pigmentation,corneal pigmentation and striae episcleritis eye,1
DUREZOL,corneal pigmentation,corneal pigmentation,1
DUREZOL,corneal pigmentation,corneal pigmentation and striae episcleritis eye,1
DUREZOL,corneal pigmentation,discomfort or corneal pigmentation and,1
DUREZOL,corneal pigmentation,corneal pigmentation and striae episcleritis eye,1
DUREZOL,episcleritis,corneal pigmentation,0
DUREZOL,episcleritis,corneal pigmentation and episcleritis,1
DUREZOL,episcleritis,corneal pigmentation,0
DUREZOL,eye pruritis,irritation corneal pigmentation and,0
DUREZOL,eye pruritis,eye pruritis eyelid,1
DUREZOL,eye pruritis,eye pruritis eyelid,1
DUREZOL,eye pruritis,pigmentation and striae eye pruritis eyelid irritation and crusting,1
DUREZOL,eye pruritis,eye pruritis eyelid,1
DUREZOL,eye pruritis,corneal pigmentation and striae eye pruritis eyelid irritation and crusting,1
DUREZOL,eye pruritis,eye pruritis eyelid,1
DUREZOL,eye pruritis,increased lacrimation macular edema scle,0
DUREZOL,eye pruritis,and crusting foreign body sensation,0
DUREZOL,eye pruritis,eye pruritis eyelid,1
DUREZOL,eyelid irritation,eyelid irritation and crusting foreign body,1
DUREZOL,eyelid irritation,striae episcleritis eye eyelid irritation,1
DUREZOL,foreign body sensation,these,0
DUREZOL,foreign body sensation,and foreign body,1
DUREZOL,foreign body sensation,foreign,1
DUREZOL,foreign body sensation,pruritis eyelid irritation and foreign body,1
DUREZOL,foreign body sensation,body sensation increased lacrimation macular edema sclera,1
DUREZOL,foreign body sensation,foreign,1
DUREZOL,foreign body sensation,macular edema sclera hyperemia and uveitis Most of these reactions,0
DUREZOL,foreign body sensation,body sensation increased lacrimation macular edema,1
DUREZOL,foreign body sensation,uveitis Most of these reactions,0
DUREZOL,increased lacrimation,body increased lacrimation macular edema sclera hyperemia and,1
DUREZOL,increased lacrimation,uveitis Most of these reactions,0
DUREZOL,increased lacrimation,foreign body increased,1
DUREZOL,increased lacrimation,increased lacrimation macular edema,1
DUREZOL,increased lacrimation,foreign body increased,1
DUREZOL,increased lacrimation,these,0
DUREZOL,increased lacrimation,foreign body increased,1
DUREZOL,increased lacrimation,been,0
DUREZOL,increased lacrimation,increased lacrimation macular,1
DUREZOL,increased lacrimation,and crusting foreign body increased lacrimation macular edema sclera hyperemia,1
DUREZOL,increased lacrimation,increased lacrimation macular,1
DUREZOL,increased lacrimation,increased lacrimation,1
DUREZOL,macular edema,foreign body sensation increased macular edema,1
DUREZOL,macular edema,of these reactions may have,0
DUREZOL,sclera hyperemia,Most of these reactions may have been,0
DUREZOL,sclera hyperemia,sclera hyperemia and uveitis Most of these,1
DUREZOL,sclera hyperemia,Most of these reactions may have been,0
DUREZOL,sclera hyperemia,sclera hyperemia and uveitis Most of these,1
DUREZOL,sclera hyperemia,sclera,1
DUREZOL,sclera hyperemia,increased lacrimation macular sclera,1
DUREZOL,sclera hyperemia,reactions may have been the consequence of the surgical procedure,0
DUREZOL,sclera hyperemia,sclera hyperemia,1
DUREZOL,uveitis,Most of these reactions may have been the consequence,0
DUREZOL,uveitis,uveitis Most of these,1
DUREZOL,uveitis,Most of these reactions may have been the consequence,0
DUREZOL,uveitis,have been,0
DUREZOL,uveitis,sclera hyperemia,0
DUREZOL,uveitis,uveitis Most of these reactions may,1
DUREZOL,uveitis,uveitis Most of these reactions may,1
DUREZOL,blurred vision,eye pain headache increased IOP iritis limbal and conjunctival hyperemia punc,0
DUREZOL,blurred vision,of subjects,0
DUREZOL,eye irritation,eye irritation eye pain,1
DUREZOL,eye irritation,included blurred eye irritation,1
DUREZOL,eye irritation,eye irritation eye pain,1
DUREZOL,eye irritation,eye irritation,1
DUREZOL,eye irritation,increased IOP iritis limbal and conjunctival,0
DUREZOL,eye irritation,and conjunctival,0
DUREZOL,eye irritation,limbal and,0
DUREZOL,eye irritation,of subjects included blurred eye,1
DUREZOL,eye pain,vision eye eye,1
DUREZOL,eye pain,to,0
DUREZOL,eye pain,eye pain headache increased,1
DUREZOL,eye pain,eye pain headache increased IOP,1
DUREZOL,eye pain,eye pain headache increased IOP iritis limbal,1
DUREZOL,eye pain,eye pain headache increased,1
DUREZOL,eye pain,occurring in of subjects included blurred vision,0
DUREZOL,eye pain,vision eye eye pain,1
DUREZOL,eye pain,occurring in of subjects included blurred vision,0
DUREZOL,headache,blurred vision eye irritation eye pain,0
DUREZOL,headache,headache increased IOP iritis,1
DUREZOL,headache,blurred vision eye irritation eye pain,0
DUREZOL,headache,headache increased IOP iritis limbal and,1
DUREZOL,headache,headache increased IOP,1
DUREZOL,headache,eye irritation eye headache,1
DUREZOL,headache,headache increased IOP,1
DUREZOL,headache,and uveitis,0
DUREZOL,headache,headache increased IOP iritis,1
DUREZOL,headache,and uveitis,0
DUREZOL,headache,keratitis and uveitis,0
DUREZOL,headache,in of subjects included blurred,0
DUREZOL,increased IOP,DUREZOL occurring in of,0
DUREZOL,increased IOP,increased IOP iritis,1
DUREZOL,increased IOP,DUREZOL occurring in of,0
DUREZOL,increased IOP,conjunctival hyperemia punctate,0
DUREZOL,iritis,IOP,0
DUREZOL,iritis,conjunctival hyperemia punctate keratitis and uveitis Adverse,0
DUREZOL,iritis,blurred vision eye irritation,0
DUREZOL,iritis,uveitis Adverse reactions occurring,0
DUREZOL,conjunctival hyperemia,increased IOP iritis limbal conjunctival hyperemia punctate keratitis and,1
DUREZOL,conjunctival hyperemia,uveitis Adverse reactions occurring,0
DUREZOL,conjunctival hyperemia,iritis limbal conjunctival,1
DUREZOL,conjunctival hyperemia,IOP iritis limbal conjunctival hyperemia,1
DUREZOL,conjunctival hyperemia,iritis limbal conjunctival hyperemia punctate keratitis and,1
DUREZOL,conjunctival hyperemia,IOP iritis limbal conjunctival hyperemia,1
DUREZOL,conjunctival hyperemia,keratitis and uveitis Adverse,0
DUREZOL,conjunctival hyperemia,limbal conjunctival hyperemia,1
DUREZOL,conjunctival hyperemia,keratitis and uveitis Adverse,0
DUREZOL,conjunctival hyperemia,eye irritation eye,0
DUREZOL,punctate keratitis,subjects included anterior chamber flare,0
DUREZOL,punctate keratitis,conjunctival punctate,1
DUREZOL,uveitis,uveitis,1
DUREZOL,uveitis,uveitis,1
DUREZOL,uveitis,IOP,0
DUREZOL,uveitis,uveitis,1
DUREZOL,uveitis,keratitis uveitis Adverse,1
DUREZOL,uveitis,uveitis,1
DUREZOL,uveitis,uveitis Adverse reactions occurring in of,1
DUREZOL,uveitis,e pain headache increased IOP iritis limbal and conjunctival hyperemia punctate,0
DUREZOL,uveitis,reactions occurring in of subjects included anterior chamber flare corneal edema d,0
DUREZOL,uveitis,uveitis Adverse,1
DUREZOL,corneal edema,included anterior chamber corneal edema dry,1
DUREZOL,corneal edema,uveitis Adverse,1
DUREZOL,corneal edema,occurring in of subjects included anterior chamber flare,0
DUREZOL,corneal edema,eye iridocyclitis photophobia and reduced,0
DUREZOL,corneal edema,flare,0
DUREZOL,dry eye,chamber flare corneal dry eye,1
DUREZOL,dry eye,flare corneal dry eye,1
DUREZOL,dry eye,anterior chamber flare corneal dry eye iridocyclitis,1
DUREZOL,dry eye,flare corneal dry eye,1
DUREZOL,dry eye,anterior chamber flare corneal dry eye,1
DUREZOL,dry eye,and reduced visual acuity,0
DUREZOL,photophobia,eye photophobia and reduced visual,1
DUREZOL,photophobia,and reduced visual acuity,0
DUREZOL,photophobia,eye,0
DUREZOL,glaucoma,ciated w ith optic nerve damage,1
DUREZOL,glaucoma,ciated w,1
DUREZOL,glaucoma,pressure which may be ciated w,1
DUREZOL,glaucoma,ciated w ith optic nerve,1
DUREZOL,damage to the optic nerve,"associated with tic nerve damage, visual  acuity and field defects posterior",1
DUREZOL,damage to the optic nerve,ciated w ith optic nerve,1
DUREZOL,damage to the optic nerve,"may be associated with tic nerve damage, visual",1
DUREZOL,damage to the optic nerve,"may be associated with tic nerve damage,",1
DUREZOL,damage to the optic nerve,"tic nerve damage,",1
DUREZOL,damage to the optic nerve,secondary ocular,0
DUREZOL,damage to the optic nerve,"tic nerve damage, visual",1
DUREZOL,damage to the optic nerve,"tic nerve damage, visual  acuity and",1
DUREZOL,damage to the optic nerve,"tic nerve damage, visual",1
DUREZOL,defects in visual acuity,cataract formation secondary ocular infection,0
DUREZOL,defects in visual acuity,"optic nerve damage visual uity and field defects,  posterior",1
DUREZOL,defects in visual acuity,cataract formation secondary ocular infection,0
DUREZOL,defects in visual acuity,"and field defects, posterior subcapsular cataract",1
DUREZOL,posterior subcapsular cataract,or sclera. 6.1 O cular Surgery Ocular,1
DUREZOL,posterior subcapsular cataract,"of  cornea or sclera.



   6.1 O cular Surgery",1
DUREZOL,posterior subcapsular cataract,or sclera. 6.1 O cular Surgery Ocular,1
DUREZOL,posterior subcapsular cataract,where there is thinning,0
DUREZOL,posterior subcapsular cataract,"thinning of  cornea or sclera.



   6.1 O cular Surgery Ocular",1
DUREZOL,posterior subcapsular cataract,where there is thinning,0
DUREZOL,posterior subcapsular cataract,of cornea or sclera. 6.1 O,1
DUREZOL,posterior subcapsular cataract,sclera. 6.1 O cular Surgery Ocular adverse reactions,1
DUREZOL,posterior subcapsular cataract,adverse reactions occurring in of,0
DUREZOL,delay healing,adverse,0
DUREZOL,delay healing,in clinical studies h DUREZOL,1
DUREZOL,secondary ocular infections,Most of these reactions may have been,0
DUREZOL,secondary ocular infections,"foreign body sensation creased lacrimation, macula",1
DUREZOL,secondary ocular infections,"sensation creased lacrimation, macula r edema sclera hyperemia and",1
DUREZOL,secondary ocular infections,"foreign body sensation creased lacrimation, macula",1
DUREZOL,secondary ocular infections,and striae episcleritis eye pruritis eyelid irritation and crusting foreign body sensation in,0
DUREZOL,secondary ocular infections,"body sensation creased lacrimation, macula r",1
DUREZOL,secondary ocular infections,and striae episcleritis eye pruritis eyelid irritation and crusting foreign body sensation in,0
DUREZOL,secondary ocular infections,"body sensation creased lacrimation, macula",1
DUREZOL,secondary ocular infections,edema sclera hyperemia and uveitis Most of these reactions may have been the,0
DUREZOL,Fungal infections of the cornea,punctate and uveitis. Adverse reaction,1
DUREZOL,Fungal infections of the cornea,conjunctival hyperemia punctate  and uveitis.  Adverse reaction s occurring,1
DUREZOL,Fungal infections of the cornea,punctate and uveitis. Adverse reaction,1
DUREZOL,Fungal infections of the cornea,eye pain headache increased IOP,0
ZYKADIA,Gastrointestinal Toxicity,see Warnings and Precautions Hepatotoxicity,0
ZYKADIA,Gastrointestinal Toxicity,the labeling Severe or Gastrointestinal Toxicity see Warnings and Precautions Hepatotoxicity,1
ZYKADIA,Gastrointestinal Toxicity,see Warnings and Precautions Hepatotoxicity,0
ZYKADIA,Gastrointestinal Toxicity,sections of the labeling Severe or,0
ZYKADIA,Gastrointestinal Toxicity,Gastrointestinal Toxicity,1
ZYKADIA,Gastrointestinal Toxicity,Severe or Gastrointestinal,1
ZYKADIA,Gastrointestinal Toxicity,the labeling Severe or Gastrointestinal Toxicity see,1
ZYKADIA,Gastrointestinal Toxicity,Severe or Gastrointestinal,1
ZYKADIA,Gastrointestinal Toxicity,labeling,0
ZYKADIA,Gastrointestinal Toxicity,or Gastrointestinal,1
ZYKADIA,Hepatotoxicity,Persistent Gastrointestinal Toxicity see Warnings and,0
ZYKADIA,Hepatotoxicity,Warnings and,0
ZYKADIA,Hepatotoxicity,Hepatotoxicity see Warnings and Precautions Interstitial,1
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1
ZYKADIA,Hepatotoxicity,see Warnings and Hepatotoxicity see Warnings and Precautions Interstitial,1
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1
ZYKADIA,Hepatotoxicity,Warnings and Hepatotoxicity see,1
ZYKADIA,Hepatotoxicity,Hepatotoxicity,1
ZYKADIA,Interstitial Lung Disease,and Precautions Hepatotoxicity see Warnings and Precautions,0
ZYKADIA,Interstitial Lung Disease,Interstitial,1
ZYKADIA,Interstitial Lung Disease,Pneumonitis,0
ZYKADIA,Interstitial Lung Disease,Interval Prolongation see Warnings and P,0
ZYKADIA,Pneumonitis,Pneumonitis see Warnings,1
ZYKADIA,Pneumonitis,Precautions QT Interval Prolongation,0
ZYKADIA,Pneumonitis,and Precautions,0
ZYKADIA,Pneumonitis,Pneumonitis see Warnings and Precautions,1
ZYKADIA,Pneumonitis,Interstitial Lung Pneumonitis see Warnings and Precautions,1
ZYKADIA,Pneumonitis,Pneumonitis see Warnings and Precautions,1
ZYKADIA,Pneumonitis,Pneumonitis see,1
ZYKADIA,Pneumonitis,Pneumonitis see Warnings and Precautions,1
ZYKADIA,Pneumonitis,Pneumonitis see,1
ZYKADIA,Pneumonitis,Warnings and Precautions QT Interval Prolongation see Warnings and Precautions,0
ZYKADIA,Pneumonitis,Pneumonitis see Warnings and,1
ZYKADIA,QT Interval Prolongation,Interval Prolongation see Warnings and Precautions,1
ZYKADIA,QT Interval Prolongation,Warnings and Precautions,0
ZYKADIA,Hyperglycemia,Hyperglycemia,1
ZYKADIA,Hyperglycemia,and Precautions and Clinical Hyperglycemia see,1
ZYKADIA,Hyperglycemia,Hyperglycemia,1
ZYKADIA,Hyperglycemia,Warnings and,0
ZYKADIA,Bradycardia,and Bradycardia see Warnings,1
ZYKADIA,Bradycardia,Warnings and,0
ZYKADIA,Bradycardia,see Warnings and,0
ZYKADIA,Bradycardia,Bradycardia,1
ZYKADIA,Bradycardia,Pancreatitis see,0
ZYKADIA,Bradycardia,Hyperglycemia see,0
ZYKADIA,Bradycardia,and Precautions and Clinical Pharmacology Pancreatitis see Warni,0
ZYKADIA,Bradycardia,Clinical Pharmacology Hyperglycemia see Warnings and,0
ZYKADIA,Pancreatitis,and Clinical Pancreatitis see Warnings and Precautions,1
ZYKADIA,Pancreatitis,Clinical Pharmacology Hyperglycemia see Warnings and,0
ZYKADIA,Pancreatitis,and Precautions EXCERPT The most,0
ZYKADIA,Pancreatitis,Pancreatitis see Warnings and,1
ZYKADIA,Pancreatitis,Pancreatitis see Warnings,1
ZYKADIA,Pancreatitis,Warnings and Precautions and Clinical Pharmacology,0
ZYKADIA,diarrhea,diarrhea nausea,1
ZYKADIA,diarrhea,diarrhea nausea elevated,1
ZYKADIA,diarrhea,vomiting abdominal,0
ZYKADIA,nausea,nausea elevated,1
ZYKADIA,nausea,nausea elevated transaminases vomiting,1
ZYKADIA,nausea,nausea elevated,1
ZYKADIA,nausea,transaminases vomiting abdominal pain fatigue,0
ZYKADIA,nausea,vomiting abdominal pain fatigue decreased appetite and,0
ZYKADIA,nausea,of at least are nausea elevated transaminases,1
ZYKADIA,nausea,vomiting abdominal pain fatigue decreased appetite and,0
ZYKADIA,elevated transaminases,appetite and constipation To,0
ZYKADIA,elevated transaminases,are diarrhea nausea,0
ZYKADIA,elevated transaminases,To report,0
ZYKADIA,elevated transaminases,diarrhea elevated,1
ZYKADIA,elevated transaminases,elevated transaminases vomiting abdominal,1
ZYKADIA,elevated transaminases,at least are diarrhea elevated transaminases vomiting abdominal pain,1
ZYKADIA,elevated transaminases,elevated transaminases vomiting abdominal,1
ZYKADIA,vomiting,report SUSPECTED A,0
ZYKADIA,vomiting,elevated transaminases,0
ZYKADIA,vomiting,vomiting abdominal pain fatigue decreased appetite,1
ZYKADIA,vomiting,vomiting abdominal pain fatigue decreased appetite,1
ZYKADIA,vomiting,vomiting abdominal pain fatigue decreased appetite,1
ZYKADIA,vomiting,are diarrhea nausea elevated vomiting,1
ZYKADIA,vomiting,vomiting abdominal pain fatigue decreased appetite,1
ZYKADIA,vomiting,are diarrhea nausea elevated vomiting abdominal pain fatigue decreased appetite,1
ZYKADIA,vomiting,vomiting abdominal pain fatigue decreased appetite,1
ZYKADIA,fatigue,are diarrhea nausea elevated transaminases vomiting,0
ZYKADIA,fatigue,fatigue decreased appetite and,1
ZYKADIA,fatigue,fatigue decreased,1
ZYKADIA,fatigue,vomiting abdominal fatigue decreased appetite and,1
ZYKADIA,fatigue,fatigue decreased,1
ZYKADIA,fatigue,fatigue,1
ZYKADIA,fatigue,abdominal fatigue decreased appetite and constipation To,1
ZYKADIA,fatigue,fatigue,1
ZYKADIA,fatigue,vomiting abdominal fatigue decreased appetite and,1
ZYKADIA,fatigue,fatigue,1
ZYKADIA,fatigue,abdominal fatigue decreased appetite and,1
ZYKADIA,fatigue,fatigue,1
ZYKADIA,fatigue,fatigue decreased appetite,1
ZYKADIA,fatigue,fatigue,1
ZYKADIA,decreased appetite,transaminases vomiting abdominal pain decreased appetite and constipation,1
ZYKADIA,decreased appetite,fatigue,1
ZYKADIA,decreased appetite,decreased appetite and,1
ZYKADIA,decreased appetite,contact,0
ZYKADIA,decreased appetite,vomiting abdominal pain decreased appetite and,1
ZYKADIA,decreased appetite,contact,0
ZYKADIA,decreased appetite,decreased appetite and constipation To report SUSPECTED,1
ZYKADIA,decreased appetite,REACTIONS,0
ZYKADIA,decreased appetite,decreased appetite and constipation To,1
ZYKADIA,decreased appetite,decreased appetite,1
ZYKADIA,decreased appetite,pain decreased appetite and,1
ZYKADIA,decreased appetite,decreased appetite,1
ZYKADIA,decreased appetite,decreased appetite,1
ZYKADIA,constipation,constipation To,1
ZYKADIA,constipation,constipation To report SUSPECTED ADVERSE,1
ZYKADIA,constipation,constipation,1
ZYKADIA,constipation,constipation To,1
ZYKADIA,increased ALT,increased ALT nausea increased AST diarrhea and,1
ZYKADIA,increased ALT,increased AST diarrhea and vomiting Serious adverse drug,0
ZYKADIA,increased ALT,nausea increased AST diarrhea and,0
ZYKADIA,increased ALT,interruptions increased ALT nausea increased AST diarrhea,1
ZYKADIA,increased ALT,nausea increased AST diarrhea and,0
ZYKADIA,increased ALT,of patients that led to dose reductions or interruptions,0
ZYKADIA,nausea,adverse,0
ZYKADIA,nausea,nausea increased AST,1
ZYKADIA,nausea,were increased nausea,1
ZYKADIA,nausea,nausea increased AST,1
ZYKADIA,nausea,nausea increased AST,1
ZYKADIA,nausea,reductions or interruptions,0
ZYKADIA,nausea,were,0
ZYKADIA,increased AST,or interruptions were increased,0
ZYKADIA,increased AST,patients that led to dose reductions or interruptions were increased,0
ZYKADIA,increased AST,increased AST diarrhea,1
ZYKADIA,increased AST,patients that led to dose reductions or interruptions were increased,0
ZYKADIA,increased AST,ALT increased AST,1
ZYKADIA,increased AST,patients that led to dose reductions or interruptions were increased,0
ZYKADIA,increased AST,were increased ALT increased AST,1
ZYKADIA,increased AST,patients that led to dose reductions or interruptions were increased,0
ZYKADIA,increased AST,increased AST diarrhea,1
ZYKADIA,diarrhea,increased ALT nausea increased AST,0
ZYKADIA,diarrhea,diarrhea,1
ZYKADIA,diarrhea,diarrhea,1
ZYKADIA,diarrhea,interruptions were increased ALT nausea,0
ZYKADIA,vomiting,ALT nausea increased,0
ZYKADIA,vomiting,Serious adverse drug reactions reported in or more of,0
ZYKADIA,pneumonia,pneumonia ILDpneumonitis dyspnea dehydration hyperglycemia and,1
ZYKADIA,pneumonia,pneumonia ILDpneumonitis dyspnea dehydration,1
ZYKADIA,pneumonia,pneumonia,1
ZYKADIA,pneumonia,adverse reactions,0
ZYKADIA,pneumonia,Study were pneumonia ILDpneumonitis dyspnea dehydration hyperglycemia,1
ZYKADIA,pneumonia,adverse reactions,0
ZYKADIA,pneumonia,pneumonia ILDpneumonitis dyspnea dehydration,1
ZYKADIA,pneumonia,pneumonia ILDpneumonitis dyspnea dehydration hyperglycemia and,1
ZYKADIA,ILD,ILD pneumonitis dyspnea dehydration hyperglycemia,1
ZYKADIA,ILD,convulsion ILD pneumonitis dyspnea,1
ZYKADIA,ILD,ILD pneumonitis dyspnea dehydration hyperglycemia,1
ZYKADIA,pneumonitis,pneumonitis dyspnea dehydration hyperglycemia and nausea,1
ZYKADIA,pneumonitis,pneumonitis dyspnea,1
ZYKADIA,pneumonitis,pneumonitis dyspnea,1
ZYKADIA,pneumonitis,pneumonitis dyspnea dehydration hyperglycemia,1
ZYKADIA,pneumonitis,pneumonitis dyspnea,1
ZYKADIA,dyspnea,pneumonia dyspnea dehydration hyperglycemia and,1
ZYKADIA,dyspnea,pneumonitis dyspnea,1
ZYKADIA,dyspnea,convulsion,0
ZYKADIA,dyspnea,in or more,0
ZYKADIA,dyspnea,pneumonia dyspnea dehydration hyperglycemia and,1
ZYKADIA,dyspnea,in or more,0
ZYKADIA,dyspnea,were convulsion pneumonia dyspnea dehydration hyperglycemia,1
ZYKADIA,dyspnea,in or more,0
ZYKADIA,dehydration,pneumonia ILDpneumonitis dehydration hyperglycemia and nausea,1
ZYKADIA,dehydration,in or more,0
ZYKADIA,dehydration,reported in or more of patients in Study were convulsion pneumonia ILDpneumonitis,0
ZYKADIA,dehydration,dehydration hyperglycemia and nausea Fatal,1
ZYKADIA,dehydration,in Study were convulsion,0
ZYKADIA,dehydration,reported in or more of patients in,0
ZYKADIA,dehydration,in patients treated with ZYKADIA occurred,0
ZYKADIA,dehydration,dehydration hyperglycemia,1
ZYKADIA,dehydration,were convulsion pneumonia ILDpneumonitis dehydration hyperglycemia and nausea Fatal adverse,1
ZYKADIA,dehydration,dehydration hyperglycemia,1
ZYKADIA,dehydration,or more of patients in Study were convulsion pneumonia,0
ZYKADIA,hyperglycemia,hyperglycemia,1
ZYKADIA,hyperglycemia,hyperglycemia and nausea Fatal,1
ZYKADIA,hyperglycemia,hyperglycemia,1
ZYKADIA,hyperglycemia,were convulsion pneumonia ILDpneumonitis dyspnea dehydration,0
ZYKADIA,hyperglycemia,hyperglycemia and nausea Fatal,1
ZYKADIA,hyperglycemia,dyspnea dehydration,0
ZYKADIA,nausea,nausea Fatal adverse reactions in patients,1
ZYKADIA,nausea,ILDpneumonitis dyspnea dehydration hyperglycemia nausea,1
ZYKADIA,nausea,nausea Fatal adverse reactions in patients,1
ZYKADIA,nausea,nausea Fatal adverse reactions,1
ZYKADIA,nausea,patients consisting of,0
ZYKADIA,nausea,were convulsion pneumonia,0
ZYKADIA,nausea,dyspnea dehydration hyperglycemia,0
ZYKADIA,nausea,ts in,0
ZYKADIA,nausea,of patients consisting of,0
ZYKADIA,Fatal,Fatal adverse reactions,1
ZYKADIA,Fatal,consisting of,0
ZYKADIA,Fatal,hyperglycemia and nausea,0
ZYKADIA,Fatal,udy were convulsion pneumonia ILDpneumonitis dyspnea dehydration hyperglycemia and,0
ZYKADIA,pneumonia,patients treated with ZYKADIA occurred in of patients consisting of,0
ZYKADIA,pneumonia,pneumonia patients respiratory failure ILDpneumonitis,1
ZYKADIA,respiratory failure,of,0
ZYKADIA,respiratory failure,pneumonia respiratory failure,1
ZYKADIA,respiratory failure,of,0
ZYKADIA,respiratory failure,physical health deterioration,0
ZYKADIA,ILD,ILD pneumonitis pneumothorax,1
ZYKADIA,ILD,physical health deterioration pulmonary,0
ZYKADIA,ILD,respiratory ILD pneumonitis,1
ZYKADIA,ILD,physical health deterioration pulmonary,0
ZYKADIA,ILD,pneumonia patients respiratory ILD pneumonitis pneumothorax gastric hemorrhage general,1
ZYKADIA,ILD,physical health deterioration pulmonary,0
ZYKADIA,ILD,pneumonia patients respiratory ILD,1
ZYKADIA,ILD,physical health deterioration pulmonary,0
ZYKADIA,pneumonitis,pneumonitis pneumothorax gastric hemorrhage general,1
ZYKADIA,pneumothorax,pneumothorax gastric,1
ZYKADIA,pneumothorax,pulmonary tuberculosis,0
ZYKADIA,pneumothorax,respiratory failure,0
ZYKADIA,pneumothorax,pneumonia patients respiratory,0
ZYKADIA,pneumothorax,pneumothorax gastric,1
ZYKADIA,gastric hemorrhage,respiratory failure ILDpneumonitis gastric hemorrhage general,1
ZYKADIA,gastric hemorrhage,pneumothorax gastric,1
ZYKADIA,gastric hemorrhage,gastric,1
ZYKADIA,gastric hemorrhage,failure ILDpneumonitis gastric,1
ZYKADIA,gastric hemorrhage,tuberculosis,0
ZYKADIA,gastric hemorrhage,general physical health deterioration pulmonary tuberculosis cardiac tamponade and sepsis pa,0
ZYKADIA,gastric hemorrhage,patients,0
ZYKADIA,gastric hemorrhage,gastric hemorrhage general,1
ZYKADIA,pulmonary tuberculosis,each Discontinuation of therapy due to adverse,0
ZYKADIA,pulmonary tuberculosis,health pulmonary tuberculosis,1
ZYKADIA,pulmonary tuberculosis,and sepsis patient each Discontinuation of,0
ZYKADIA,pulmonary tuberculosis,health pulmonary tuberculosis,1
ZYKADIA,pulmonary tuberculosis,deterioration,0
ZYKADIA,pulmonary tuberculosis,pulmonary tuberculosis cardiac tamponade and sepsis patient,1
ZYKADIA,pulmonary tuberculosis,physical health pulmonary tuberculosis,1
ZYKADIA,pulmonary tuberculosis,deterioration,0
ZYKADIA,pulmonary tuberculosis,health pulmonary,1
ZYKADIA,pulmonary tuberculosis,pneumothorax,0
ZYKADIA,cardiac tamponade,physical health deterioration pulmonary cardiac tamponade and sepsis patient,1
ZYKADIA,cardiac tamponade,pneumothorax,0
ZYKADIA,cardiac tamponade,to adverse reactions occurred,0
ZYKADIA,cardiac tamponade,pulmonary cardiac tamponade,1
ZYKADIA,cardiac tamponade,to adverse reactions occurred,0
ZYKADIA,cardiac tamponade,cardiac tamponade and sepsis patient each Discontinuation,1
ZYKADIA,cardiac tamponade,patient each Discontinuation,0
ZYKADIA,cardiac tamponade,s,0
ZYKADIA,cardiac tamponade,Discontinuation,0
ZYKADIA,cardiac tamponade,each Discontinuation of therapy due to adverse reactions occurred in,0
ZYKADIA,cardiac tamponade,cardiac tamponade,1
ZYKADIA,pneumonia,pneumonia,1
ZYKADIA,pneumonia,patients,0
ZYKADIA,pneumonia,were,0
ZYKADIA,pneumonia,ILDpneumonitis and decreased appetite Tables,0
ZYKADIA,ILD,ILD,1
ZYKADIA,ILD,Tables and summarize the common,0
ZYKADIA,ILD,patients in Study were ILD pneumonitis,1
ZYKADIA,ILD,Tables and summarize the common,0
ZYKADIA,ILD,ILD pneumonitis and decreased appetite Tables,1
ZYKADIA,ILD,ILD pneumonitis,1
ZYKADIA,ILD,ILD pneumonitis and decreased appetite Tables,1
ZYKADIA,pneumonitis,Tables and summarize the common adverse reactions and,0
ZYKADIA,pneumonitis,pneumonitis and decreased,1
ZYKADIA,pneumonitis,pneumonitis and decreased appetite Tables,1
ZYKADIA,pneumonitis,pneumonitis and decreased appetite Tables,1
ZYKADIA,pneumonitis,and decreased appetite Tables,0
ZYKADIA,pneumonitis,pneumonitis and decreased appetite Tables,1
ZYKADIA,decreased appetite,ILDpneumonitis decreased appetite,1
ZYKADIA,decreased appetite,and summarize,0
ZYKADIA,decreased appetite,and summarize the common adverse,0
ZYKADIA,decreased appetite,decreased appetite Tables and summarize the,1
ZYKADIA,decreased appetite,of patients,0
ZYKADIA,decreased appetite,reactions,0
ZYKADIA,decreased appetite,summarize the common adverse reactions and laboratory abnormalities observed in,0
ZYKADIA,decreased appetite,at led to discontinuation in or more of patients in Study were pneumonia ILDpneumonitis and,0
ZYKADIA,decreased appetite,Study were pneumonia ILDpneumonitis decreased appetite Tables,1
ZYKADIA,decreased appetite,at led to discontinuation in or more of patients in Study were pneumonia ILDpneumonitis and,0
ZYKADIA,Abdominal pain,National Cancer Institute Common Terminology Criteria for Adverse Events version,0
ZYKADIA,Abdominal pain,Events version Abdominal,1
ZYKADIA,abdominal pain,Abdominal abdominal pain upper abdominal pain,1
ZYKADIA,abdominal pain,Events version Abdominal,1
ZYKADIA,abdominal pain,abdominal pain upper abdominal pain abdominal,1
ZYKADIA,abdominal pain,a Abdominal abdominal,1
ZYKADIA,abdominal pain,a Abdominal abdominal,1
ZYKADIA,abdominal pain,discomfort b Esophageal disorder dyspep,0
ZYKADIA,abdominal pain,Terminology,0
ZYKADIA,abdominal pain,abdominal pain upper,1
ZYKADIA,abdominal pain,discomfort b,0
ZYKADIA,abdominal pain,abdominal pain,1
ZYKADIA,upper abdominal pain,a Abdominal pain abdominal upper abdominal,1
ZYKADIA,upper abdominal pain,upper,1
ZYKADIA,upper abdominal pain,discomfort epigastric discomfort b Esophageal disorder,0
ZYKADIA,upper abdominal pain,Abdominal pain abdominal upper abdominal pain,1
ZYKADIA,upper abdominal pain,discomfort epigastric discomfort b Esophageal disorder,0
ZYKADIA,upper abdominal pain,Events version,0
ZYKADIA,abdominal discomfort,reflux disease dyspha,0
ZYKADIA,abdominal discomfort,pain abdominal pain upper abdominal pain,0
ZYKADIA,abdominal discomfort,disorder dyspepsia gastroesophageal reflux disease,0
ZYKADIA,abdominal discomfort,upper abdominal abdominal,1
ZYKADIA,abdominal discomfort,upper abdominal abdominal discomfort epigastric discomfort b Esophageal disorder,1
ZYKADIA,abdominal discomfort,upper abdominal abdominal,1
ZYKADIA,abdominal discomfort,abdominal discomfort epigastric discomfort b Esophageal disorder,1
ZYKADIA,abdominal discomfort,abdominal discomfort,1
ZYKADIA,abdominal discomfort,abdominal discomfort,1
ZYKADIA,abdominal discomfort,Adverse,0
ZYKADIA,abdominal discomfort,abdominal discomfort epigastric discomfort b Esophageal,1
ZYKADIA,abdominal discomfort,Adverse,0
ZYKADIA,epigastric discomfort,upper abdominal pain abdominal epigastric,1
ZYKADIA,Esophageal disorder,Esophageal disorder dyspepsia,1
ZYKADIA,dyspepsia,l pain upper abdominal pain abdominal discomfort,0
ZYKADIA,dyspepsia,dyspepsia gastroesophageal reflux disease dysphagia c,1
ZYKADIA,dyspepsia,b,0
ZYKADIA,dyspepsia,Rash,0
ZYKADIA,dyspepsia,disease dysphagia c Fatigue fatigue asthenia d,0
ZYKADIA,gastroesophageal reflux disease,rash maculopapular rash acneiform dermatiti,0
ZYKADIA,gastroesophageal reflux disease,dyspepsia,0
ZYKADIA,gastroesophageal reflux disease,b Esophageal disorder gastroesophageal,1
ZYKADIA,gastroesophageal reflux disease,gastroesophageal reflux disease dysphagia c Fatigue,1
ZYKADIA,gastroesophageal reflux disease,abdominal pain abdominal discomfort epigastric discomfort b Esophageal disorder dyspepsia,0
ZYKADIA,gastroesophageal reflux disease,gastroesophageal,1
ZYKADIA,dysphagia,asthenia d,0
ZYKADIA,dysphagia,c Fatigue fatigue asthenia d,0
ZYKADIA,dysphagia,dysphagia c Fatigue fatigue,1
ZYKADIA,dysphagia,dysphagia c Fatigue fatigue,1
ZYKADIA,dysphagia,disorder dyspepsia gastroesophageal reflux dysphagia c Fatigue fatigue asthenia d,1
ZYKADIA,dysphagia,dysphagia c Fatigue fatigue,1
ZYKADIA,dysphagia,reflux,0
ZYKADIA,Fatigue,rash,0
ZYKADIA,Fatigue,reflux disease dysphagia Fatigue fatigue,1
ZYKADIA,Fatigue,rash,0
ZYKADIA,Fatigue,Fatigue fatigue asthenia d Rash rash,1
ZYKADIA,fatigue,fatigue asthenia,1
ZYKADIA,fatigue,mfort b Esophageal disorder dyspepsia,0
ZYKADIA,asthenia,asthenia d,1
ZYKADIA,asthenia,rash maculopapular rash,0
ZYKADIA,asthenia,fatigue,0
ZYKADIA,asthenia,rash acneiform dermatitis,0
ZYKADIA,asthenia,asthenia d,1
ZYKADIA,asthenia,asthenia d Rash rash,1
ZYKADIA,asthenia,asthenia,1
ZYKADIA,asthenia,asthenia d Rash rash,1
ZYKADIA,asthenia,reflux,0
ZYKADIA,asthenia,disease dysphagia c Fatigue asthenia d Rash rash,1
ZYKADIA,asthenia,reflux,0
ZYKADIA,Rash,rash,0
ZYKADIA,Rash,acneiform dermatitis,0
ZYKADIA,Rash,Rash rash maculopapular rash,1
ZYKADIA,Rash,Rash rash,1
ZYKADIA,Rash,acneiform dermatitis ZYKADIAN,0
ZYKADIA,Rash,Fatigue fatigue asthenia Rash rash maculopapular,1
ZYKADIA,Rash,acneiform dermatitis ZYKADIAN,0
ZYKADIA,Rash,Rash rash maculopapular rash,1
ZYKADIA,rash,fatigue asthenia d rash maculopapular rash acneiform dermatitis ZYKADIAN,1
ZYKADIA,rash,Rash rash maculopapular rash,1
ZYKADIA,rash,rash maculopapular rash acneiform,1
ZYKADIA,rash,rash,1
ZYKADIA,rash,acneiform dermatitis,0
ZYKADIA,rash,fatigue asthenia d rash maculopapular rash acneiform,1
ZYKADIA,rash,acneiform dermatitis,0
ZYKADIA,rash,Fatigue fatigue asthenia d rash maculopapular rash acneiform dermatitis,1
ZYKADIA,rash,acneiform dermatitis,0
ZYKADIA,rash,dysphagia c Fatigue,0
ZYKADIA,rash,Fatigue fatigue asthenia d rash maculopapular rash acneiform dermatitis,1
ZYKADIA,rash,dysphagia c Fatigue,0
ZYKADIA,maculopapular rash,maculopapular rash acneiform dermatitis,1
ZYKADIA,maculopapular rash,d Rash rash,0
ZYKADIA,maculopapular rash,asthenia d Rash maculopapular rash acneiform dermatitis ZYKADIAN All,1
ZYKADIA,maculopapular rash,d Rash rash,0
ZYKADIA,maculopapular rash,acneiform dermatitis,0
ZYKADIA,maculopapular rash,ZYKADIAN,0
ZYKADIA,Constipation,a,0
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Constipation,a,0
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Constipation,Abdominal pain Constipation Esophageal,1
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Constipation,pain Constipation Esophageal disorder b,1
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Constipation,Abdominal pain Constipation,1
ZYKADIA,Constipation,Constipation,1
ZYKADIA,Constipation,Abdominal pain a,0
ZYKADIA,Constipation,pain Constipation Esophageal disorder,1
ZYKADIA,Constipation,Abdominal pain a,0
ZYKADIA,Constipation,Esophageal disorder,0
ZYKADIA,Fatigue,and administration site,0
ZYKADIA,Fatigue,Fatigue c Metabolism,1
ZYKADIA,Decreased appetite,Metabolism,0
ZYKADIA,Decreased appetite,Decreased appetite,1
ZYKADIA,Decreased appetite,Metabolism,0
ZYKADIA,Decreased appetite,Skin and,0
ZYKADIA,Decreased appetite,disorders,0
ZYKADIA,Decreased appetite,Skin and subcutaneous tissue,0
ZYKADIA,Decreased appetite,Skin and subcutaneous tissue disorders,0
ZYKADIA,Decreased appetite,nutrition Decreased appetite Skin and subcutaneous tissue disorders,1
ZYKADIA,Decreased appetite,Skin and subcutaneous tissue disorders,0
ZYKADIA,Decreased appetite,Decreased appetite,1
ZYKADIA,Rash,and subcutaneous tissue Rash,1
ZYKADIA,Rash,Decreased appetite,1
ZYKADIA,Rash,Rash d Respiratory thoracic and,1
ZYKADIA,Rash,disorders,0
ZYKADIA,Rash,Rash d Respiratory thoracic and mediastinal,1
ZYKADIA,Rash,and subcutaneous,0
ZYKADIA,Interstitial lung disease,clinically significant adverse,0
ZYKADIA,Interstitial lung disease,mediastinal disorders,0
ZYKADIA,Interstitial lung disease,thoracic and mediastinal Interstitial lung disease pneumonitis Additional clinically,1
ZYKADIA,Interstitial lung disease,mediastinal disorders,0
ZYKADIA,Interstitial lung disease,Respiratory thoracic and mediastinal Interstitial lung disease,1
ZYKADIA,Interstitial lung disease,mediastinal disorders,0
ZYKADIA,Interstitial lung disease,Respiratory thoracic and mediastinal Interstitial,1
ZYKADIA,Interstitial lung disease,Additional,0
ZYKADIA,pneumonitis,Interstitial lung pneumonitis Additional,1
ZYKADIA,pneumonitis,Additional,0
ZYKADIA,pneumonitis,adverse reactions,0
ZYKADIA,pneumonitis,disorders Interstitial lung pneumonitis Additional,1
ZYKADIA,pneumonitis,adverse reactions,0
ZYKADIA,pneumonitis,clinically significant adverse reactions,0
ZYKADIA,pneumonitis,pneumonitis Additional clinically significant adverse,1
ZYKADIA,pneumonitis,mediastinal disorders Interstitial lung,0
ZYKADIA,pneumonitis,mediastinal disorders,0
ZYKADIA,neuropathy,paresthesia,0
ZYKADIA,neuropathy,lly,0
ZYKADIA,paresthesia,paresthesia muscular,1
ZYKADIA,paresthesia,paresthesia muscular weakness gait disturbance,1
ZYKADIA,paresthesia,paresthesia muscular,1
ZYKADIA,paresthesia,comprised of,0
ZYKADIA,muscular weakness,muscular weakness,1
ZYKADIA,muscular weakness,muscular weakness gait disturbance peripheral,1
ZYKADIA,muscular weakness,of patients treated with,0
ZYKADIA,gait disturbance,gait disturbance peripheral neuropathy hypoesthesia peripheral sensory,1
ZYKADIA,gait disturbance,sensory neuropathy dysesthesia neuralgia,0
ZYKADIA,peripheral neuropathy,included,0
ZYKADIA,peripheral neuropathy,muscular weakness gait peripheral neuropathy hypoesthesia peripheral sensory neuropathy,1
ZYKADIA,peripheral neuropathy,included,0
ZYKADIA,peripheral neuropathy,muscular weakness gait peripheral neuropathy hypoesthesia peripheral sensory neuropathy,1
ZYKADIA,peripheral neuropathy,included,0
ZYKADIA,peripheral neuropathy,peripheral neuropathy hypoesthesia peripheral sensory,1
ZYKADIA,peripheral neuropathy,peripheral neuropathy hypoesthesia,1
ZYKADIA,peripheral neuropathy,peripheral neuropathy,1
ZYKADIA,peripheral neuropathy,gait,0
ZYKADIA,hypoesthesia,peripheral hypoesthesia peripheral sensory neuropathy dysesthesia,1
ZYKADIA,hypoesthesia,gait,0
ZYKADIA,hypoesthesia,hypoesthesia peripheral sensory neuropathy dysesthesia neuralgia,1
ZYKADIA,peripheral sensory neuropathy,peripheral neuropathy peripheral sensory neuropathy dysesthesia neuralgia peripheral motor neuropathy,1
ZYKADIA,peripheral sensory neuropathy,hypoesthesia peripheral sensory neuropathy dysesthesia neuralgia,1
ZYKADIA,peripheral sensory neuropathy,paresthesia muscular weakness gait disturbance peripheral,0
ZYKADIA,peripheral sensory neuropathy,disturbance peripheral neuropathy peripheral sensory neuropathy dysesthesia,1
ZYKADIA,peripheral sensory neuropathy,paresthesia muscular weakness gait disturbance peripheral,0
ZYKADIA,peripheral sensory neuropathy,neuropathy peripheral sensory neuropathy dysesthesia neuralgia peripheral,1
ZYKADIA,peripheral sensory neuropathy,paresthesia muscular weakness gait disturbance peripheral,0
ZYKADIA,peripheral sensory neuropathy,peripheral sensory neuropathy dysesthesia neuralgia,1
ZYKADIA,peripheral sensory neuropathy,peripheral sensory neuropathy dysesthesia,1
ZYKADIA,peripheral sensory neuropathy,neuropathy peripheral sensory,1
ZYKADIA,dysesthesia,dysesthesia neuralgia peripheral motor neuropathy,1
ZYKADIA,neuralgia,neuralgia peripheral motor neuropathy hypotonia,1
ZYKADIA,neuralgia,motor neuropathy hypotonia or polyneuropathy vision disorder comprised,0
ZYKADIA,neuralgia,neuralgia peripheral motor neuropathy,1
ZYKADIA,neuralgia,dysesthesia,0
ZYKADIA,peripheral motor neuropathy,or polyneuropathy vision disorder,0
ZYKADIA,peripheral motor neuropathy,peripheral motor neuropathy hypotonia or,1
ZYKADIA,peripheral motor neuropathy,or polyneuropathy vision disorder,0
ZYKADIA,peripheral motor neuropathy,neuropathy dysesthesia peripheral motor neuropathy hypotonia or,1
ZYKADIA,peripheral motor neuropathy,or polyneuropathy vision disorder,0
ZYKADIA,peripheral motor neuropathy,peripheral motor neuropathy hypotonia or polyneuropathy vision,1
ZYKADIA,peripheral motor neuropathy,or polyneuropathy vision disorder,0
ZYKADIA,peripheral motor neuropathy,motor neuropathy,1
ZYKADIA,peripheral motor neuropathy,dysesthesia peripheral motor neuropathy,1
ZYKADIA,peripheral motor neuropathy,hypotonia or polyneuropathy vision disorder,0
ZYKADIA,polyneuropathy,polyneuropathy vision,1
ZYKADIA,polyneuropathy,polyneuropathy vision,1
ZYKADIA,vision disorder,or vision disorder comprised of,1
ZYKADIA,vision disorder,polyneuropathy vision,1
ZYKADIA,vision disorder,or polyneuropathy,0
ZYKADIA,vision disorder,polyneuropathy,0
ZYKADIA,vision impairment,disorder presbyopia or reduced,0
ZYKADIA,vision impairment,polyneuropathy vision disorder comprised vision impairment blurred vision photopsia accommodation disorder,1
ZYKADIA,vision impairment,disorder presbyopia or reduced,0
ZYKADIA,vision impairment,vision impairment blurred vision photopsia accommodation,1
ZYKADIA,vision impairment,disorder presbyopia or reduced,0
ZYKADIA,blurred vision,prolonged QT interval,0
ZYKADIA,blurred vision,disorder comprised of vision impairment,0
ZYKADIA,photopsia,photopsia,1
ZYKADIA,accommodation disorder,vision impairment blurred vision accommodation,1
ZYKADIA,accommodation disorder,visual,0
ZYKADIA,accommodation disorder,impairment blurred vision accommodation,1
ZYKADIA,accommodation disorder,impairment blurred vision accommodation,1
ZYKADIA,accommodation disorder,accommodation disorder presbyopia or,1
ZYKADIA,accommodation disorder,accommodation disorder presbyopia or reduced visual acuity,1
ZYKADIA,accommodation disorder,accommodation disorder presbyopia or,1
ZYKADIA,accommodation disorder,vision impairment blurred vision accommodation disorder presbyopia or reduced visual,1
ZYKADIA,accommodation disorder,accommodation disorder presbyopia or,1
ZYKADIA,accommodation disorder,presbyopia or,0
ZYKADIA,accommodation disorder,accommodation disorder presbyopia,1
ZYKADIA,accommodation disorder,acuity prolonged QT interval and bradycardia Table,0
ZYKADIA,presbyopia,presbyopia or reduced visual acuity prolonged,1
ZYKADIA,presbyopia,presbyopia or reduced,1
ZYKADIA,presbyopia,presbyopia,1
ZYKADIA,presbyopia,presbyopia,1
ZYKADIA,presbyopia,presbyopia,1
ZYKADIA,presbyopia,disorder,0
ZYKADIA,presbyopia,presbyopia or reduced visual,1
ZYKADIA,presbyopia,presbyopia,1
ZYKADIA,reduced visual acuity,visual acuity prolonged QT interval and,1
ZYKADIA,reduced visual acuity,visual acuity prolonged QT interval and bradycardia,1
ZYKADIA,reduced visual acuity,of vision impairment blurred vision,0
ZYKADIA,reduced visual acuity,presbyopia reduced,1
ZYKADIA,reduced visual acuity,blurred vision photopsia accommodation disorder presbyopia,0
ZYKADIA,reduced visual acuity,impairment blurred vision photopsia accommodation,0
ZYKADIA,reduced visual acuity,reduced visual acuity,1
ZYKADIA,reduced visual acuity,photopsia accommodation disorder presbyopia reduced,1
ZYKADIA,prolonged QT interval,visual prolonged,1
ZYKADIA,prolonged QT interval,bradycardia,0
ZYKADIA,prolonged QT interval,Key Laboratory Abnormalities Occurring in All NCI,0
ZYKADIA,prolonged QT interval,visual prolonged QT interval and bradycardia Table,1
ZYKADIA,prolonged QT interval,Key Laboratory Abnormalities Occurring in All NCI,0
ZYKADIA,prolonged QT interval,prolonged QT,1
ZYKADIA,prolonged QT interval,reduced visual prolonged QT,1
ZYKADIA,prolonged QT interval,QT interval and bradycardia Table Key Laboratory,1
ZYKADIA,prolonged QT interval,disorder presbyopia or,0
ZYKADIA,prolonged QT interval,Abnormalities Occurring in All NCI CT,0
ZYKADIA,Hemoglobin decreased,transaminase,0
ZYKADIA,Hemoglobin decreased,transaminase,0
ZYKADIA,Creatinine increased,Creatinine,1
ZYKADIA,Creatinine increased,Aspartate transaminase AST Creatinine increased Glucose increased,1
ZYKADIA,Creatinine increased,Creatinine,1
ZYKADIA,Creatinine increased,Aspartate,0
ZYKADIA,Creatinine increased,transaminase AST Creatinine,1
ZYKADIA,Creatinine increased,Creatinine,1
ZYKADIA,Creatinine increased,Creatinine increased Glucose,1
ZYKADIA,Creatinine increased,transaminase,0
ZYKADIA,Creatinine increased,transaminase AST Creatinine increased,1
ZYKADIA,Creatinine increased,transaminase,0
ZYKADIA,Creatinine increased,Creatinine increased,1
ZYKADIA,Phosphate decreased,Glucose,0
ZYKADIA,Phosphate decreased,Phosphate decreased,1
ZYKADIA,Phosphate decreased,Phosphate decreased,1
ZYKADIA,Phosphate decreased,Glucose Phosphate,1
ZYKADIA,Phosphate decreased,Glucose,0
ZYKADIA,Phosphate decreased,Phosphate decreased,1
ZYKADIA,Phosphate decreased,increased,0
ZYKADIA,Lipase increased,Phosphate,0
ZYKADIA,Lipase increased,Lipase increased Bilirubin,1
ZYKADIA,Lipase increased,Phosphate,0
ZYKADIA,Lipase increased,Phosphate,0
ZYKADIA,Lipase increased,decreased,0
ZYKADIA,Lipase increased,Bilirubin total,0
ZYKADIA,Lipase increased,Lipase increased Bilirubin total,1
ZYKADIA,diarrhea,other sections of the g: *,1
ZYKADIA,diarrhea,Persistent Gastrointestinal Toxicity,0
ZYKADIA,diarrhea,"other sections of the g:



 * Severe or Persistent Gastrointestinal",1
ZYKADIA,diarrhea,Persistent Gastrointestinal Toxicity,0
ZYKADIA,diarrhea,"sections of the g:



 * Severe",1
ZYKADIA,diarrhea,Persistent Gastrointestinal Toxicity,0
ZYKADIA,diarrhea,Persistent Gastrointestinal,0
ZYKADIA,nausea,Severe or Persistent Gastrointestinal Toxicity see,1
ZYKADIA,nausea,Persistent Gastrointestinal,0
ZYKADIA,nausea,other sections of the Severe or,1
ZYKADIA,nausea,Persistent Gastrointestinal,0
ZYKADIA,vomiting,r Persis tent Gastrointestinal Toxicity see,1
ZYKADIA,vomiting,r Persis tent Gastrointestinal Toxicity see Warnings,1
ZYKADIA,vomiting,r Persis tent Gastrointestinal Toxicity see,1
ZYKADIA,vomiting,Gastrointestinal Toxicity see Warnings and Precautions Hepatotoxicity,0
ZYKADIA,vomiting,Severe r,1
ZYKADIA,vomiting,labeling Severe o,0
ZYKADIA,vomiting,adverse reactions are discussed,0
ZYKADIA,vomiting,r Persis tent,1
ZYKADIA,vomiting,Warnings and Precautions,0
ZYKADIA,vomiting,greater detail in other sections of the labeling,0
ZYKADIA,vomiting,r Persis tent Gastrointestinal Toxicity,1
ZYKADIA,abdominal pain,labeling Severe or Persistent,0
ZYKADIA,abdominal pain, Gastrointesti nal Toxicity see Warnings and,1
ZYKADIA,abdominal pain,or,0
ZYKADIA,abdominal pain, Gastrointesti nal Toxicity see Warnings,1
ZYKADIA,abdominal pain,are discussed in,0
ZYKADIA,abdominal pain, Gastrointesti nal Toxicity see Warnings,1
ZYKADIA,abdominal pain,labeling Severe or  Gastrointesti nal Toxicity,1
ZYKADIA,abdominal pain, Gastrointesti nal Toxicity see Warnings,1
ZYKADIA,abdominal pain,discussed,0
ZYKADIA,Hepatotoxicity,umonitis [see,1
ZYKADIA,Hepatotoxicity,Interval Prolongation see Warnings and Precautions a,0
ZYKADIA,Hepatotoxicity,umonitis [see,1
ZYKADIA,hepatotoxicity,"see Warnings and ons (5.3)]  
  QT Interval",1
ZYKADIA,hepatotoxicity,umonitis [see,1
ZYKADIA,hepatotoxicity,ons (5.3)] QT Interval Prolongation see Warnings,1
ZYKADIA,hepatotoxicity,see Warnings,0
ZYKADIA,hepatotoxicity,ons (5.3)] QT Interval Prolongation,1
ZYKADIA,hepatotoxicity,ons (5.3)] QT Interval Prolongation,1
ZYKADIA,hepatotoxicity,and Precautions Interstitial Lung DiseasePneumonitis see Warnings,0
ZYKADIA,hepatotoxicity,QT Interval Prolongation see Warnings and Precautions and Clinical,0
ZYKADIA,hepatotoxicity,"see Warnings and ons (5.3)]  
  QT Interval Prolongation",1
ZYKADIA,hepatotoxicity,QT Interval Prolongation see Warnings and Precautions and Clinical,0
ZYKADIA,hepatotoxicity,"Warnings and ons (5.3)]  
  QT",1
ZYKADIA,hepatotoxicity,QT Interval Prolongation see Warnings and Precautions and Clinical,0
ZYKADIA,Interstitial Lung Disease,and ecautions,1
ZYKADIA,Interstitial Lung Disease,Hyperglycemia see Warnings and ecautions (5.5)],1
ZYKADIA,Interstitial Lung Disease,"Hyperglycemia see Warnings and ecautions (5.5)]  
 *  Br adycardia see Warnings and",1
ZYKADIA,Interstitial Lung Disease,Hyperglycemia see Warnings and ecautions (5.5)],1
ZYKADIA,Interstitial Lung Disease,"Hyperglycemia see Warnings and ecautions (5.5)]  
 *  Br",1
ZYKADIA,Interstitial Lung Disease,Hyperglycemia see Warnings and ecautions (5.5)],1
ZYKADIA,Interstitial Lung Disease,see Warnings and ecautions (5.5)] *,1
ZYKADIA,Interstitial Lung Disease,Hyperglycemia see Warnings and ecautions (5.5)],1
ZYKADIA,ILD,Warnings and Precautions yca rdia see Warnings and,1
ZYKADIA,ILD,Hyperglycemia see Warnings and ecautions (5.5)],1
ZYKADIA,ILD,yca rdia see,1
ZYKADIA,ILD,yca,1
ZYKADIA,ILD,yca rdia see Warnings and Precautions,1
ZYKADIA,ILD,Warnings and Precautions Brad,0
ZYKADIA,ILD,Clinical Pharmacology Hyperglycemia see Warnings and Precautions Brad,0
ZYKADIA,ILD,yca rdia see Warnings,1
ZYKADIA,Pneumonitis,inical Pharmacology Hyperglycemia see,0
ZYKADIA,Pneumonitis,Hyperglycemia see,0
ZYKADIA,Pneumonitis,ia [see War nings and Precautions,1
ZYKADIA,Pneumonitis,[see War nings and Precautions and,1
ZYKADIA,Pneumonitis,Warnings and Precautions ia [see War nings,1
ZYKADIA,Pneumonitis,[see War nings and Precautions and,1
ZYKADIA,Pneumonitis,Precautions ia [see War nings,1
ZYKADIA,Pneumonitis,[see War nings and Precautions and,1
ZYKADIA,Pneumonitis,see Warnings and P,0
ZYKADIA,Pneumonitis,ia [see War nings and,1
ZYKADIA,Pneumonitis,Warnings and Precautions ia [see War,1
ZYKADIA,Pneumonitis,and Clinical Pharmacology Pancreatitis see Warnings and P,0
ZYKADIA,QT Interval Prolongation,EXCERPT The most mon,1
ZYKADIA,QTc interval prolongation,"25%) are diarrhea, nausea elevated transaminases vomiting abdominal pain",1
ZYKADIA,QTc interval prolongation,decreased,0
ZYKADIA,QTc interval prolongation,reactions incidence of at 25%) are,1
ZYKADIA,QTc interval prolongation,"are diarrhea, nausea elevated",1
ZYKADIA,QTc interval prolongation,least,0
ZYKADIA,QTc interval prolongation,vomiting abdominal pain,0
ZYKADIA,QTc interval prolongation,elevated transaminases vomiting abdominal pain fatigue decreased appetite and,0
ZYKADIA,QTc interval prolongation,"diarrhea, nausea elevated transaminases vomiting abdominal",1
ZYKADIA,Hyperglycemia,Clinical Trials,0
ZYKADIA,Hyperglycemia,"or wwwfdagovmedwatch Clinical  Experience

 Because clinical trials are",1
ZYKADIA,Hyperglycemia,Clinical Trials,0
ZYKADIA,Hyperglycemia," Experience

 Because clinical",1
ZYKADIA,Hyperglycemia," Experience

 Because",1
ZYKADIA,Hyperglycemia," Experience

 Because clinical",1
ZYKADIA,hyperglycemia,Trials Experience Because clinical ials are,1
ZYKADIA,hyperglycemia,clinical ials are cond,1
ZYKADIA,hyperglycemia,Trials Experience Because clinical ials are cond ucted under widely varying conditions,1
ZYKADIA,hyperglycemia,clinical ials are cond,1
ZYKADIA,hyperglycemia,Because clinical ials are cond ucted under widely varying conditions,1
ZYKADIA,hyperglycemia,clinical ials are cond,1
ZYKADIA,hyperglycemia,ials are cond ucted under widely,1
ZYKADIA,hyperglycemia,Trials Experience Because clinical ials,1
ZYKADIA,hyperglycemia,the clinical trials of a,0
ZYKADIA,hyperglycemia,Trials Experience Because clinical ials,1
ZYKADIA,hyperglycemia,in the,0
ZYKADIA,Bradycardia,observed in practice The,0
ZYKADIA,Bradycardia,eval,0
ZYKADIA,Bradycardia,another drug and,0
ZYKADIA,Bradycardia,reflect the rates,0
ZYKADIA,Bradycardia,The safety eval,0
ZYKADIA,bradycardia,ZYKADIA is based 5 ALK-posit ive patients in,1
ZYKADIA,bradycardia,The safety eval,0
ZYKADIA,bradycardia,5 ALK-posit ive patients in,1
ZYKADIA,bradycardia,5 ALK-posit,1
ZYKADIA,bradycardia,not reflect the rates observed,0
ZYKADIA,bradycardia,evaluation of ZYKADIA is,0
ZYKADIA,bradycardia,patients in Study patients with NSCLC and patients with other cancers who,0
ZYKADIA,bradycardia,5 ALK-posit,1
ZYKADIA,bradycardia,is based 5,1
ZYKADIA,bradycardia,safety evaluation of,0
ZYKADIA,Pancreatitis,of mg daily The dian,1
ZYKADIA,Pancreatitis,mg daily The dian duratio,1
ZYKADIA,Pancreatitis,population characteristics were,0
ZYKADIA,Elevations of lipase,duration f exposure to ZYKADI,1
ZYKADIA,Elevations of lipase,population characteristics were,0
ZYKADIA,Elevations of lipase,daily,0
ZYKADIA,Elevations of lipase,f exposure to ZYKADI,1
ZYKADIA,Elevations of lipase,f exposure to ZYKADI A was months The study,1
ZYKADIA,Elevations of lipase,f exposure to ZYKADI,1
ZYKADIA,Elevations of lipase,median duration f exposure to ZYKADI,1
ZYKADIA,Elevations of lipase,The median duration f exposure to,1
ZYKADIA,Elevations of lipase,The median duration f exposure to ZYKADI A was months The study,1
ZYKADIA,Elevations of lipase,The median duration f exposure to,1
ZYKADIA,Elevations of lipase,patients with other cancers who received ZYKADIA at a dose of mg daily The,0
ZYKADIA,Elevations of lipase,median duration f exposure,1
ZYKADIA,Elevations of lipase,daily The median duration f exposure to ZYKADI,1
ZYKADIA,Elevations of lipase,median duration f exposure,1
ZYKADIA,pancreatitis,ZYKADIA was months study popula tion,1
ZYKADIA,pancreatitis,median duration f exposure,1
ZYKADIA,pancreatitis,ZYKADIA was months study popula tion characteristics were median,1
ZYKADIA,pancreatitis,median duration f exposure,1
ZYKADIA,pancreatitis,ZYKADIA was months study popula tion characteristics were median,1
ZYKADIA,pancreatitis,median duration f exposure,1
ZYKADIA,pancreatitis,were median age years age less,0
ZYKADIA,pancreatitis,was months study popula tion characteristics,1
ZYKADIA,pancreatitis,were median age years age less,0
ZYKADIA,pancreatitis,months study popula tion characteristics were median,1
ZYKADIA,pancreatitis,were median age years age less,0
ZYKADIA,Embryofetal Toxicity,less than female Caucasian Asian NSCLC adenocarcinom,0
ZYKADIA,Embryofetal Toxicity,"a histology (90%),",1
ZYKADIA,Embryofetal Toxicity,less,0
ZYKADIA,Embryofetal Toxicity,"female Caucasian Asian NSCLC a histology (90%), n",1
ZYKADIA,Embryofetal Toxicity,less,0
ZYKADIA,Embryofetal Toxicity,"histology (90%), n ever or",1
ZYKADIA,Embryofetal Toxicity,Asian,0
ZYKADIA,Embryofetal Toxicity,"a histology (90%), n ever or former smoker",1
ZYKADIA,Embryofetal Toxicity,female Caucasian Asian NSCLC a histology,1
ZYKADIA,fetal harm,Caucasian Asian NSCLC adenocarcinoma histology,0
ZYKADIA,fetal harm,or brain metastasis and number of prior therapies or more,0
ZYKADIA,fetal harm,"(97%), EC",1
ZYKADIA,fetal harm,or former smoker,0
ZYKADIA,fetal harm,"former (97%), EC",1
ZYKADIA,fetal harm," (97%), EC OG",1
ZYKADIA,fetal harm,"former (97%), EC",1
ZYKADIA,fetal harm,Caucasian Asian NSCLC adenocarcinoma histology never or former,0
ZYKADIA,fetal harm,le,0
ZYKADIA,Diarrhea,h ZYKADI A The most frequent,1
ZYKADIA,Diarrhea,h ZYKADI,1
ZYKADIA,Diarrhea,adverse reactions occurred in of patients treated wit,0
ZYKADIA,Diarrhea,wit,0
ZYKADIA,Diarrhea,treated h,1
ZYKADIA,Diarrhea,h ZYKADI A The most,1
ZYKADIA,Diarrhea,due to adverse reactions occurred in,0
ZYKADIA,nausea,The m ost,1
ZYKADIA,nausea,The m ost frequent adverse,1
ZYKADIA,nausea,least of patients that led to,0
ZYKADIA,nausea, The m ost frequent adverse reactions reported,1
ZYKADIA,nausea,least of patients that led to,0
ZYKADIA,nausea,dose reductions,0
ZYKADIA,nausea,ost frequent adverse reactions reported,0
ZYKADIA,nausea,patients treated with  The m ost frequent adverse,1
ZYKADIA,nausea,ost frequent adverse reactions reported,0
ZYKADIA,nausea,of patients treated with The m,1
ZYKADIA,vomiting,The t,1
ZYKADIA,vomiting,t freque nt adverse reactions reported,1
ZYKADIA,vomiting,t freque nt adverse reactions,1
ZYKADIA,vomiting,t freque nt adverse reactions reported,1
ZYKADIA,vomiting,The mos,0
ZYKADIA,vomiting,The mos,0
ZYKADIA,vomiting,treated with ZYKADIA The t freque,1
ZYKADIA,vomiting,The mos,0
ZYKADIA,vomiting,ZYKADIA The mos,0
ZYKADIA,abdominal pain,adverse reactions occurred in of patients treated with ZYKADIA,0
ZYKADIA,abdominal pain,ZYKADIA The most frequent verse reaction s,1
ZYKADIA,abdominal pain,adverse reactions occurred in of patients treated with ZYKADIA,0
ZYKADIA,abdominal pain,verse reaction s reported in at,1
ZYKADIA,diarrhea,sed AST diarrhea and,1
ZYKADIA,diarrhea,in or more,0
ZYKADIA,diarrhea,sed,1
ZYKADIA,diarrhea,sed AST,1
ZYKADIA,nausea,"6%), d iarrhea and",1
ZYKADIA,vomiting,AST rrhea,1
ZYKADIA,vomiting,rrhea (1,1
ZYKADIA,vomiting,AST rrhea,1
ZYKADIA,vomiting,dia,0
ZYKADIA,vomiting,ALT nausea increased AST rrhea (1,1
ZYKADIA,vomiting,of,0
ZYKADIA,vomiting,nausea increased AST rrhea (1 and,1
ZYKADIA,vomiting,of,0
ZYKADIA,vomiting,in or more,0
ZYKADIA,vomiting,increased ALT nausea increased AST dia,0
ZYKADIA,vomiting,ALT nausea increased AST rrhea (1 and vomiting Serious adverse,1
ZYKADIA,vomiting,increased ALT nausea increased AST dia,0
ZYKADIA,abdominal pain,AST,0
ZYKADIA,abdominal pain,and vomiting,1
ZYKADIA,abdominal pain,and vomiting ( Serious adverse,1
ZYKADIA,abdominal pain,and vomiting,1
ZYKADIA,abdominal pain,vomiting (,1
ZYKADIA,abdominal pain,vomiting ( Serious adverse drug reactions reported,1
ZYKADIA,abdominal pain,nausea,0
ZYKADIA,hepatotoxicity,"ion,",1
ZYKADIA,hepatotoxicity,gastric hemorrhage,0
ZYKADIA,hepatotoxicity,"ion, pulmonary",1
ZYKADIA,Elevations in alanine aminotransferase,and (1 patient each). Discontinuation of,1
ZYKADIA,Elevations in alanine aminotransferase,sepsis,0
ZYKADIA,Elevations in alanine aminotransferase,sepsis,0
ZYKADIA,Elevations in alanine aminotransferase,tuberculosis cardiac tamponade and (1 patient each). Discontinuation of,1
ZYKADIA,Elevations in alanine aminotransferase,and sepsis,0
ZYKADIA,Elevations in alanine aminotransferase,each). Discontinuation of therapy due to,1
ZYKADIA,Elevations in alanine aminotransferase,Discontinuation of therapy due,1
ZYKADIA,Elevations in alanine aminotransferase,cardiac tamponade and  (1 patient each). Discontinuation of  therapy due to adverse,1
ZYKADIA,Elevations in alanine aminotransferase,Discontinuation of therapy due,1
ZYKADIA,Elevations in alanine aminotransferase,patient each). Discontinuation of therapy due to,1
ZYKADIA,elevated transaminases,of,1
ZYKADIA,elevated transaminases,decreased appetite Tables and summarize the common,0
ZYKADIA,elevated transaminases,or  of patients in Study  were pneumonia,1
ZYKADIA,elevated transaminases,decreased appetite Tables and summarize the common,0
ZYKADIA,elevated transaminases,led to,0
ZYKADIA,jaundice, pneumon ia ILDpneumonitis,1
ZYKADIA,jaundice,ILDpneumonitis and decreased appetite,0
ZYKADIA,jaundice, pneumon ia ILDpneumonitis and decreased,1
ZYKADIA,jaundice, pneumon ia ILDpneumonitis and decreased,1
ZYKADIA,jaundice, pneumon,1
ZYKADIA,jaundice, pneumon ia ILDpneumonitis,1
ZYKADIA,jaundice,appetite Tables and summarize the common adverse reactio,0
ZYKADIA,jaundice, pneumon ia ILDpneumonitis,1
ZYKADIA,elevations in ALT,"onitis, and decre ased appetite Tables",1
ZYKADIA,elevations in ALT,adverse reactions and laboratory,0
ZYKADIA,elevations in ALT,"Study were pneumonia onitis, and decre ased appetite Tables and summarize",1
ZYKADIA,elevations in ALT,adverse reactions and laboratory,0
ZYKADIA,ILD,rad,1
ZYKADIA,ILD,dermatitis ZYKADIAN All Grades rad,1
ZYKADIA,ILD,rad,1
ZYKADIA,ILD,e Gastrointestinal disorders,0
ZYKADIA,ILD,rad e Gastrointestinal,1
ZYKADIA,ILD,rad,1
ZYKADIA,ILD,rad e Gastrointestinal,1
ZYKADIA,ILD,e,0
ZYKADIA,ILD,e Gastrointestinal disorders,0
ZYKADIA,ILD,e Gastrointestinal disorders,0
ZYKADIA,ILD,All Grades rad,1
ZYKADIA,ILD,e Gastrointestinal disorders,0
ZYKADIA,ILD,All Grades rad e Gastrointestinal,1
ZYKADIA,ILD,e Gastrointestinal disorders,0
ZYKADIA,ILD,dermatitis ZYKADIAN All Grades rad e Gastrointestinal disorders,1
ZYKADIA,ILD,e Gastrointestinal disorders,0
ZYKADIA,ILD,ZYKADIAN All Grades rad e Gastrointestinal disorders,1
ZYKADIA,ILD,e Gastrointestinal disorders,0
ZYKADIA,ILD,rad e Gastrointestinal disorders,1
ZYKADIA,ILD,rad e Gastrointestinal,1
ZYKADIA,pneumonitis, 3-4       ,1
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis,m dermatitis ZYKADIAN All Grades Grade,0
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis,All Grades Grade,0
ZYKADIA,pneumonitis,dermatitis ZYKADIAN,0
ZYKADIA,pneumonitis,m dermatitis ZYKADIAN All Grades,0
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis, 3-4        Gastrointestinal,1
ZYKADIA,pneumonitis,dermatitis,0
ZYKADIA,pneumonitis,Grade,0
ZYKADIA,pneumonitis,m dermatitis ZYKADIAN All Grades Grade,0
ZYKADIA,pneumonitis, 3-4       ,1
ZYKADIA,pneumonitis, Gastrointe stinal disorders,1
ZYKADIA,pneumonitis, 3-4       ,1
ZYKADIA,pneumonitis,All Grades  Gastrointe stinal disorders,1
ZYKADIA,pneumonitis, 3-4       ,1
ZYKADIA,pneumonitis,Grades,0
ZYKADIA,ILD,    Nausea Vomiting,1
ZYKADIA,ILD,Grades,0
ZYKADIA,ILD,   ,1
ZYKADIA,ILD,    Nausea Vomiting,1
ZYKADIA,ILD,Gastrointestinal,0
ZYKADIA,pneumonitis,Gastrointestinal disorders           6,1
ZYKADIA,pneumonitis,Gastrointestinal,0
ZYKADIA,pneumonitis,          6 Nausea Vomiting,1
ZYKADIA,pneumonitis,Diarrhea,0
ZYKADIA,fatal,Diarrhea Nausea,0
ZYKADIA,fatal,Diarrhea 0     Vomiting Abdominal p,1
ZYKADIA,fatal,Diarrhea Nausea,0
ZYKADIA,fatal,0     Vomiting Abdominal,1
ZYKADIA,fatal,0     Vomiting,1
ZYKADIA,fatal,0     Vomiting Abdominal p,1
ZYKADIA,fatal,0     Vomiting,1
ZYKADIA,fatal,Vomiting Abdominal,0
ZYKADIA,fatal,Diarrhea Nausea,0
ZYKADIA,fatal,0     Vomiting Abdominal,1
ZYKADIA,fatal,0     Vomiting Abdominal p,1
ZYKADIA,fatal,Diarrhea 0     Vomiting Abdominal,1
ZYKADIA,fatal,0     Vomiting Abdominal p,1
ZYKADIA,ILD,   ,1
ZYKADIA,ILD,    Vomiting,1
ZYKADIA,ILD,    Vomiting Abdominal pain,1
ZYKADIA,ILD,    Vomiting Abdominal,1
ZYKADIA,ILD,    Vomiting Abdominal pain,1
ZYKADIA,ILD,    Vomiting,1
ZYKADIA,ILD,Constipation,0
ZYKADIA,ILD,pain    ,1
ZYKADIA,ILD,Constipation,0
ZYKADIA,ILD,Abdominal pain     Constipation,1
ZYKADIA,ILD,Constipation,0
ZYKADIA,ILD,    Constipation Esophageal disorder,1
ZYKADIA,ILD,Vomiting Abdominal,0
ZYKADIA,ILD,Esophageal,0
ZYKADIA,ILD,a,0
ZYKADIA,ILD,a,0
ZYKADIA,ILD,    Constipation Esophageal disorder b,1
ZYKADIA,pneumonitis,            Constipation Esophageal disorder b,1
ZYKADIA,pneumonitis,a,0
ZYKADIA,QTc interval prolongation,nutrition disorders,0
ZYKADIA,QTc interval prolongation,"Metabolism and nutrition            
     Decrease d appetite Skin and subcutaneous",1
ZYKADIA,QTc interval prolongation,nutrition disorders,0
ZYKADIA,QTc interval prolongation,subcutaneous,0
ZYKADIA,QTc interval prolongation,"           
     Decrease d appetite Skin and",1
ZYKADIA,ventricular tachyarrhythmias,rders Decreased Skin,1
ZYKADIA,Torsade de pointes,appetite Skin and subcutaneous tissu,0
ZYKADIA,Torsade de pointes,appetite Skin and subcutaneous e disorders       ,1
ZYKADIA,Torsade de pointes,appetite Skin and subcutaneous tissu,0
ZYKADIA,Torsade de pointes,Skin and subcutaneous e,1
ZYKADIA,Torsade de pointes,Skin and subcutaneous e disorders,1
ZYKADIA,Torsade de pointes,e disorders Rash d Respirator,1
ZYKADIA,sudden death,tissue              Rash d Respiratory,1
ZYKADIA,sudden death,e disorders Rash d Respirator,1
ZYKADIA,sudden death,             Rash d Respiratory thoracic,1
ZYKADIA,QTc interval increase,sorders               Interstitial lung,1
ZYKADIA,QTc interval increase,sorders               Interstitial,1
ZYKADIA,increase from baseline QTc,ZYKADIA included neuropathy omprised of,1
ZYKADIA,increase from baseline QTc,"of paresthesia, m uscular",1
ZYKADIA,increase from baseline QTc,in or more of patients treated with,0
ZYKADIA,increase from baseline QTc,included,0
ZYKADIA,increase from baseline QTc,included neuropathy,0
ZYKADIA,increase from baseline QTc,"neuropathy omprised of paresthesia, m uscular weakness gait",1
ZYKADIA,increase from baseline QTc,included neuropathy,0
ZYKADIA,increase from baseline QTc,hypoesthesia,0
ZYKADIA,increase from baseline QTc,occurring in or more,0
ZYKADIA,increases in the QTc interval,"hypoesthesia peripheral sensory dysesthesia, neuralgia,",1
ZYKADIA,increases in the QTc interval,"dysesthesia, neuralgia, perip",1
ZYKADIA,increases in the QTc interval,"hypoesthesia peripheral sensory dysesthesia, neuralgia,",1
ZYKADIA,Hyperglycemia,ase,0
ZYKADIA,Hyperglycemia,ase increased Bilirubin total increased,0
ZYKADIA,Hyperglycemia,"    
     Lip ase increased Bilirubin total increased",1
ZYKADIA,Hyperglycemia,"    
     Lip",1
ZYKADIA,Hyperglycemia,"    
     Lip ase increased Bilirubin total increased",1
ZYKADIA,Hyperglycemia,"    
     Lip ase increased",1
ZYKADIA,Hyperglycemia,"    
     Lip ase",1
ZYKADIA,Hyperglycemia,"    
     Lip",1
CHOLINE,injection site reaction,adverse reactions to Ccholine have been reported,0
CHOLINE,injection site reaction,an uncommon injection,1
CHOLINE,injection site reaction,an uncommon injection,1
CHOLINE,injection site reaction,uncommon injection,1
CHOLINE,injection site reaction,injection site reaction,1
CHOLINE,injection site reaction,of an uncommon injection site reaction no,1
CHOLINE,injection site reaction,injection site reaction,1
CHOLINE,injection site reaction,rse reactions to Ccholine have been reported,0
CHOLINE,injection site reaction,uncommon injection,1
CHOLINE,injection site reaction,uncommon injection site reaction no other,1
CHOLINE,injection site reaction,uncommon injection,1
CHOLINE,Allergic reactions,reaction no other adverse reactions have been reported To,0
CHOLINE,Radiation risk,been,0
CHOLINE,Radiation risk,adverse reactions have,0
CHOLINE,Radiation risk,mild injection site reaction no other adverse reactions have been reported To report,0
CHOLINE,Radiation risk,Department of,0
CHOLINE,Radiation risk,To SUSPECTED ADV,1
ERWINAZE,Hypersensitivity reactions,the Hypersensitivity reactions,1
ERWINAZE,Hypersensitivity reactions,Hypersensitivity,1
ERWINAZE,Pancreatitis,Pancreatitis,1
ERWINAZE,Glucose intolerance,Pancreatitis see Warnings and Glucose intolerance see Warnings and Precautions Thrombosis,1
ERWINAZE,Glucose intolerance,Pancreatitis,1
ERWINAZE,Glucose intolerance,hemorrhage see Warnings and Precauti,0
ERWINAZE,Glucose intolerance,Pancreatitis see Warnings and Glucose intolerance see Warnings,1
ERWINAZE,Glucose intolerance,hemorrhage see Warnings and Precauti,0
ERWINAZE,Glucose intolerance,see Warnings and Glucose,1
ERWINAZE,Thrombosis,Warnings and Precautions,0
ERWINAZE,Thrombosis,Precautions The most common,0
ERWINAZE,Thrombosis,and Precautions The most,0
ERWINAZE,Thrombosis,Warnings and Thrombosis and hemorrhage,1
ERWINAZE,Thrombosis,and Precautions The most,0
ERWINAZE,Thrombosis,see,0
ERWINAZE,Thrombosis,common,0
ERWINAZE,Thrombosis,Thrombosis and hemorrhage see,1
ERWINAZE,Thrombosis,Thrombosis and hemorrhage see Warnings,1
ERWINAZE,Thrombosis,Thrombosis and hemorrhage see,1
ERWINAZE,hemorrhage,hemorrhage,1
ERWINAZE,hemorrhage,hemorrhage,1
ERWINAZE,hemorrhage,most,0
ERWINAZE,hemorrhage,common adverse reactions incidence or,0
ERWINAZE,hemorrhage,hemorrhage see,1
ERWINAZE,hemorrhage,common adverse reactions incidence or,0
ERWINAZE,hemorrhage,hemorrhage see Warnings and Precautions,1
ERWINAZE,hemorrhage,Warnings and Precautions The,0
ERWINAZE,systemic hypersensitivity,reactions vomiting nausea thr,0
ERWINAZE,systemic hypersensitivity,greater with ERWINAZE treatment systemic,1
ERWINAZE,systemic hypersensitivity,ERWINAZE treatment systemic hypersensitivity,1
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal,1
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal,1
ERWINAZE,systemic hypersensitivity,greater with ERWINAZE treatment systemic hypersensitivity hyperglycemia,1
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal,1
ERWINAZE,systemic hypersensitivity,ERWINAZE treatment systemic hypersensitivity hyperglycemia transaminases abnormal fever pancreatitis,1
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal,1
ERWINAZE,systemic hypersensitivity,ERWINAZE,0
ERWINAZE,systemic hypersensitivity,greater with ERWINAZE treatment systemic,1
ERWINAZE,systemic hypersensitivity,abnormal fever pancreatitis local,0
ERWINAZE,hyperglycemia,abnormal fever pancreatitis local reactions,0
ERWINAZE,hyperglycemia,systemic hyperglycemia transaminases,1
ERWINAZE,hyperglycemia,abnormal fever pancreatitis local reactions,0
ERWINAZE,hyperglycemia,greater with ERWINAZE,0
ERWINAZE,hyperglycemia,are systemic hyperglycemia transaminases abnormal,1
ERWINAZE,hyperglycemia,greater with ERWINAZE,0
ERWINAZE,hyperglycemia,systemic hypersensitivity,0
ERWINAZE,hyperglycemia,hyperglycemia transaminases abnormal fever pancreatitis local,1
ERWINAZE,hyperglycemia,treatment are systemic hyperglycemia transaminases,1
ERWINAZE,hyperglycemia,hyperglycemia transaminases abnormal fever pancreatitis local,1
ERWINAZE,transaminases abnormal,transaminases abnormal,1
ERWINAZE,transaminases abnormal,hyperglycemia transaminases abnormal fever pancreatitis local,1
ERWINAZE,transaminases abnormal,local reactions vomiting,0
ERWINAZE,fever,local reactions vomiting nausea thrombosis,0
ERWINAZE,fever,fever pancreatitis local,1
ERWINAZE,fever,fever pancreatitis local reactions,1
ERWINAZE,fever,fever pancreatitis local reactions vomiting nausea,1
ERWINAZE,fever,fever,1
ERWINAZE,fever,pancreatitis local reactions vomiting nausea thrombosis hyperbilirubinemia abdominal paindi,0
ERWINAZE,fever,pancreatitis local reactions vomiting nausea thrombosis hyperbilirubinemia abdominal,0
ERWINAZE,fever,fever pancreatitis local reactions vomiting nausea,1
ERWINAZE,pancreatitis,pancreatitis local,1
ERWINAZE,pancreatitis,thrombosis,0
ERWINAZE,pancreatitis,hypersensitivity hyperglycemia transaminases abnormal pancreatitis local reactions vomiting nausea thrombosis,1
ERWINAZE,pancreatitis,thrombosis,0
ERWINAZE,pancreatitis,pancreatitis local reactions,1
ERWINAZE,pancreatitis,thrombosis hyperbilirubinemia,0
ERWINAZE,pancreatitis,nausea,0
ERWINAZE,pancreatitis,transaminases,0
ERWINAZE,pancreatitis,abnormal,0
ERWINAZE,pancreatitis,hypersensitivity hyperglycemia transaminases abnormal pancreatitis local,1
ERWINAZE,pancreatitis,abnormal,0
ERWINAZE,local reactions,fever local reactions vomiting nausea thrombosis,1
ERWINAZE,local reactions,abnormal,0
ERWINAZE,local reactions,transaminases abnormal fever local reactions vomiting nausea thrombosis,1
ERWINAZE,local reactions,abnormal,0
ERWINAZE,local reactions,abnormal fever local reactions vomiting nausea,1
ERWINAZE,local reactions,abnormal,0
ERWINAZE,local reactions,hyperglycemia transaminases abnormal fever local reactions vomiting,1
ERWINAZE,local reactions,abnormal,0
ERWINAZE,vomiting,vomiting nausea thrombosis hyperbilirubinemia abdominal paindiscomfort,1
ERWINAZE,vomiting,and diarrhea,0
ERWINAZE,vomiting,reactions,0
ERWINAZE,vomiting,vomiting,1
ERWINAZE,vomiting,local,0
ERWINAZE,vomiting,vomiting nausea thrombosis,1
ERWINAZE,vomiting,vomiting nausea thrombosis hyperbilirubinemia,1
ERWINAZE,vomiting,abnormal fever pancreatitis local vomiting nausea thrombosis hyperbilirubinemia abdominal,1
ERWINAZE,vomiting,vomiting nausea thrombosis hyperbilirubinemia,1
ERWINAZE,vomiting,vomiting,1
ERWINAZE,nausea,pancreatitis local reactions nausea thrombosis hyperbilirubinemia abdominal,1
ERWINAZE,nausea,vomiting,1
ERWINAZE,nausea,nausea,1
ERWINAZE,nausea,vomiting,0
ERWINAZE,nausea,nausea thrombosis hyperbilirubinemia,1
ERWINAZE,nausea,diarrhea EXCERPT,0
ERWINAZE,nausea,EXCERPT Most com,0
ERWINAZE,nausea,diarrhea EXCERPT Most com,0
ERWINAZE,thrombosis,fever pancreatitis local reactions,0
ERWINAZE,thrombosis,reactions vomiting thrombosis hyperbilirubinemia,1
ERWINAZE,thrombosis,fever pancreatitis local reactions,0
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia,1
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia abdominal,1
ERWINAZE,thrombosis,local reactions vomiting thrombosis hyperbilirubinemia abdominal paindiscomfort,1
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia abdominal,1
ERWINAZE,hyperbilirubinemia,ycemia transaminases abnormal fever pancreatitis local,0
ERWINAZE,abdominal pain,vomiting nausea thrombosis abdominal pain,1
ERWINAZE,abdominal pain,ycemia transaminases abnormal fever pancreatitis local,0
ERWINAZE,abdominal pain,hyperbilirubinemia,0
ERWINAZE,abdominal pain,reactions vomiting nausea thrombosis abdominal,1
ERWINAZE,abdominal pain,nausea thrombosis abdominal pain discomfort and diarrhea EXCERPT Most,1
ERWINAZE,abdominal pain,reactions vomiting nausea thrombosis abdominal,1
ERWINAZE,abdominal pain,incidence or greater,0
ERWINAZE,abdominal pain,local reactions vomiting nausea,0
ERWINAZE,abdominal pain,vomiting nausea thrombosis abdominal pain,1
ERWINAZE,abdominal pain,thrombosis abdominal,1
ERWINAZE,abdominal pain,abdominal pain discomfort,1
ERWINAZE,diarrhea,diarrhea EXCERPT Most common adverse reactions,1
ERWINAZE,diarrhea,diarrhea EXCERPT Most common,1
ERWINAZE,systemic hypersensitivity,abnormal fever pancreatitis,0
ERWINAZE,systemic hypersensitivity,greater systemic hypersensitivity hyperglycemia transaminases abnormal fever pancreatitis,1
ERWINAZE,systemic hypersensitivity,abnormal fever pancreatitis,0
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity,1
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal fever pancreatitis,1
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal fever pancreatitis,1
ERWINAZE,systemic hypersensitivity,fever pancreatitis local reactions vomiting nausea,0
ERWINAZE,systemic hypersensitivity,or greater systemic hypersensitivity hyperglycemia transaminases abnormal,1
ERWINAZE,systemic hypersensitivity,fever pancreatitis local reactions vomiting nausea,0
ERWINAZE,systemic hypersensitivity,greater,0
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal fever pancreatitis,1
ERWINAZE,systemic hypersensitivity,systemic hypersensitivity hyperglycemia transaminases abnormal,1
ERWINAZE,hyperglycemia,transaminases abnormal fever pancreatitis local reactions vomiting,0
ERWINAZE,hyperglycemia,pancreatitis local,0
ERWINAZE,hyperglycemia,hyperglycemia transaminases abnormal,1
ERWINAZE,hyperglycemia,hyperglycemia transaminases abnormal fever pancreatitis local,1
ERWINAZE,hyperglycemia,hyperglycemia,1
ERWINAZE,hyperglycemia,hyperglycemia transaminases abnormal fever pancreatitis,1
ERWINAZE,hyperglycemia,reactions,0
ERWINAZE,hyperglycemia,hyperglycemia transaminases,1
ERWINAZE,hyperglycemia,reactions,0
ERWINAZE,hyperglycemia,nausea thrombosis,0
ERWINAZE,transaminases abnormal,vomiting nausea thrombosis hyperbilirubinemia,0
ERWINAZE,transaminases abnormal,transaminases abnormal fever pancreatitis local reactions,1
ERWINAZE,transaminases abnormal,transaminases abnormal fever pancreatitis local reactions vomiting,1
ERWINAZE,transaminases abnormal,hypersensitivity hyperglycemia,0
ERWINAZE,transaminases abnormal,systemic hypersensitivity transaminases,1
ERWINAZE,transaminases abnormal,adverse reactions incidence or,0
ERWINAZE,transaminases abnormal,or greater are systemic hypersensitivity,0
ERWINAZE,transaminases abnormal,fever,0
ERWINAZE,transaminases abnormal,hypersensitivity hyperglycemia,0
ERWINAZE,fever,fever pancreatitis local reactions vomiting nausea,1
ERWINAZE,fever,vomiting nausea thrombosis hyperbilirubinemia abdominal paindi,0
ERWINAZE,fever,fever pancreatitis local,1
ERWINAZE,fever,greater are systemic hypersensitivity hyperglycemia transaminases,0
ERWINAZE,fever,reactions vomiting nausea thrombosis hyperbilirubinemia abdominal paindi,0
ERWINAZE,fever,hyperglycemia transaminases,0
ERWINAZE,fever,fever pancreatitis local reactions,1
ERWINAZE,pancreatitis,pancreatitis local,1
ERWINAZE,pancreatitis,idence or greater are systemic hypersensitivity hyperglycemia transaminases,0
ERWINAZE,pancreatitis,hyperglycemia transaminases abnormal pancreatitis local,1
ERWINAZE,pancreatitis,idence or greater are systemic hypersensitivity hyperglycemia transaminases,0
ERWINAZE,pancreatitis,pancreatitis,1
ERWINAZE,pancreatitis,pancreatitis local reactions vomiting,1
ERWINAZE,pancreatitis,pancreatitis local reactions vomiting nausea thrombosis,1
ERWINAZE,pancreatitis,transaminases abnormal,0
ERWINAZE,pancreatitis,pancreatitis local reactions vomiting nausea thrombosis,1
ERWINAZE,pancreatitis,vomiting nausea thrombosis,0
ERWINAZE,pancreatitis,fever,0
ERWINAZE,local reactions,thrombosis hyperbilirubinemia abdominal paindiscomfort,0
ERWINAZE,local reactions,transaminases abnormal fever local reactions vomiting nausea,1
ERWINAZE,local reactions,thrombosis hyperbilirubinemia abdominal paindiscomfort,0
ERWINAZE,local reactions,and diarrhea To,0
ERWINAZE,vomiting,abnormal fever pancreatitis local vomiting nausea thrombosis hyperbilirubinemia abdominal paindiscomfort,1
ERWINAZE,vomiting,and diarrhea To,0
ERWINAZE,vomiting,pancreatitis local reactions,0
ERWINAZE,vomiting,abdominal paindiscomfort and diarrhea,0
ERWINAZE,vomiting,vomiting nausea,1
ERWINAZE,vomiting,vomiting nausea thrombosis hyperbilirubinemia abdominal paindiscomfort,1
ERWINAZE,vomiting,vomiting nausea,1
ERWINAZE,nausea,nausea thrombosis hyperbilirubinemia abdominal paindiscomfort,1
ERWINAZE,nausea,nausea,1
ERWINAZE,nausea,nausea thrombosis hyperbilirubinemia abdominal,1
ERWINAZE,nausea,nausea thrombosis hyperbilirubinemia,1
ERWINAZE,nausea,local reactions nausea thrombosis,1
ERWINAZE,nausea,nausea thrombosis hyperbilirubinemia,1
ERWINAZE,nausea,nausea thrombosis,1
ERWINAZE,nausea,reactions,0
ERWINAZE,nausea,nausea thrombosis,1
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia,1
ERWINAZE,thrombosis,nausea thrombosis,1
ERWINAZE,thrombosis,thrombosis,1
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia,1
ERWINAZE,thrombosis,local reactions vomiting thrombosis hyperbilirubinemia abdominal paindiscomfort and,1
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia,1
ERWINAZE,thrombosis,hyperbilirubinemia abdominal paindiscomfort and diarrhea To report SUSPECTED ADVERSE,0
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia,1
ERWINAZE,thrombosis,thrombosis hyperbilirubinemia,1
ERWINAZE,thrombosis,hyperbilirubinemia abdominal paindiscomfort and diarrhea To,0
ERWINAZE,thrombosis,hyperbilirubinemia,0
ERWINAZE,hyperbilirubinemia,nausea,0
ERWINAZE,hyperbilirubinemia,SUSPECTED ADVERSE REACTIONS contact Jazz,0
ERWINAZE,hyperbilirubinemia,vomiting nausea,0
ERWINAZE,hyperbilirubinemia,transaminases abnormal,0
ERWINAZE,hyperbilirubinemia,To report SUSPECTED ADVERSE REACTIONS,0
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia abdominal,1
ERWINAZE,hyperbilirubinemia,REACTIONS contact,0
ERWINAZE,abdominal pain,abdominal pain discomfort and,1
ERWINAZE,abdominal pain,abnormal fever pancreatitis local,0
ERWINAZE,abdominal pain,vomiting nausea thrombosis abdominal,1
ERWINAZE,abdominal pain,abdominal pain,1
ERWINAZE,allergic reactions,allergic reactions,1
ERWINAZE,allergic reactions,to completion seven due allergic reactions five due to physician or,1
ERWINAZE,allergic reactions,allergic reactions,1
ERWINAZE,allergic reactions,due to,0
ERWINAZE,allergic reactions,allergic reactions five due to,1
ERWINAZE,allergic reactions,eted all planned therapy Fourteen patients stopped therapy prior to,0
ERWINAZE,allergic reactions,allergic reactions five due to physician,1
ERWINAZE,allergic reactions,eted all planned therapy Fourteen patients stopped therapy prior to,0
ERWINAZE,allergic reactions,allergic reactions five due to physician or,1
ERWINAZE,allergic reactions,completion seven due allergic reactions,1
ERWINAZE,allergic reactions,allergic reactions five,1
ERWINAZE,allergy,interest,0
ERWINAZE,allergy,or,0
ERWINAZE,allergy,allergy pancreatitis,1
ERWINAZE,allergy,allergy pancreatitis coagulopathy hemorrhage,1
ERWINAZE,allergy,allergy pancreatitis,1
ERWINAZE,allergy,allergy,1
ERWINAZE,allergy,events of special allergy pancreatitis coagulopathy hemorrhage,1
ERWINAZE,allergy,allergy,1
ERWINAZE,allergy,allergy pancreatitis,1
ERWINAZE,pancreatitis,events of special interest pancreatitis coagulopathy hemorrhage thrombosis or infarct,1
ERWINAZE,pancreatitis,allergy pancreatitis,1
ERWINAZE,pancreatitis,pancreatitis coagulopathy hemorrhage,1
ERWINAZE,pancreatitis,events of special interest,0
ERWINAZE,pancreatitis,pancreatitis coagulopathy hemorrhage thrombosis or infarct,1
ERWINAZE,pancreatitis,hyperbilirubinemia,0
ERWINAZE,pancreatitis,pancreatitis coagulopathy,1
ERWINAZE,pancreatitis,adverse events of,0
ERWINAZE,coagulopathy,hyperglycemia,0
ERWINAZE,coagulopathy,coagulopathy hemorrhage thrombosis or infarct,1
ERWINAZE,coagulopathy,or infarct hyperbilirubinemia hyperglycemia hyperlipidemia ketoacidosi,0
ERWINAZE,coagulopathy,hyperglycemia,0
ERWINAZE,coagulopathy,interest allergy coagulopathy,1
ERWINAZE,coagulopathy,hyperglycemia,0
ERWINAZE,coagulopathy,e events were,0
ERWINAZE,coagulopathy,hyperglycemia,0
ERWINAZE,coagulopathy,coagulopathy hemorrhage thrombosis or,1
ERWINAZE,hemorrhage,infarct hyperbilirubinemia hyperglycemia hyperlipidemia ketoacidosis and,0
ERWINAZE,hemorrhage,the following adverse events of special interest allergy pancreatitis,0
ERWINAZE,hemorrhage,thrombosis or infarct,0
ERWINAZE,thrombosis,coagulopathy,0
ERWINAZE,infarct,thrombosis or,0
ERWINAZE,infarct,infarct hyperbilirubinemia hyperglycemia hyperlipidemia,1
ERWINAZE,hyperbilirubinemia,events hemorrhage thrombosis or infarction,0
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia hyperglycemia,1
ERWINAZE,hyperbilirubinemia,or hyperbilirubinemia hyperglycemia hyperlipidemia,1
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia hyperglycemia,1
ERWINAZE,hyperbilirubinemia,hyperbilirubinemia hyperglycemia,1
ERWINAZE,hyperglycemia,infarct hyperglycemia hyperlipidemia ketoacidosis,1
ERWINAZE,hyperglycemia,hyperbilirubinemia hyperglycemia,1
ERWINAZE,hyperlipidemia,hyperlipidemia ketoacidosis and CNS,1
ERWINAZE,hyperlipidemia,hyperbilirubinemia hyperglycemia,1
ERWINAZE,hyperlipidemia,hyperlipidemia,1
ERWINAZE,hyperlipidemia,hyperglycemia,0
ERWINAZE,hyperlipidemia,hyperlipidemia ketoacidosis and CNS events,1
ERWINAZE,hyperlipidemia,hyperbilirubinemia hyperlipidemia ketoacidosis and,1
ERWINAZE,hyperlipidemia,hyperlipidemia ketoacidosis and CNS events,1
ERWINAZE,hyperlipidemia,hemorrhage thrombosis or infarct,0
ERWINAZE,hyperlipidemia,hyperlipidemia ketoacidosis and,1
ERWINAZE,ketoacidosis,cerebral,0
ERWINAZE,ketoacidosis,and CNS events hemorrhage,0
ERWINAZE,ketoacidosis,venous,0
ERWINAZE,ketoacidosis,ketoacidosis and CNS events,1
ERWINAZE,ketoacidosis,thrombosis or infarct,0
ERWINAZE,CNS events,ketoacidosis and,0
ERWINAZE,CNS events,CNS,1
ERWINAZE,CNS events,hyperlipidemia ketoacidosis CNS events hemorrhage thrombosis or,1
ERWINAZE,CNS events,CNS,1
ERWINAZE,CNS events,CNS events hemorrhage thrombosis,1
ERWINAZE,CNS events,and,0
ERWINAZE,CNS events,hyperglycemia hyperlipidemia ketoacidosis CNS events hemorrhage thrombosis or,1
ERWINAZE,CNS events,and,0
ERWINAZE,CNS events,hyperlipidemia ketoacidosis and,0
ERWINAZE,CNS events,CNS events hemorrhage thrombosis,1
ERWINAZE,CNS events,hyperlipidemia ketoacidosis and,0
ERWINAZE,CNS events,rhage thrombosis or infarct hyperbilirubinemia hyperglycemia hyperlipidemia,0
ERWINAZE,cerebral venous thrombosis,adverse events In,0
ERWINAZE,cerebral venous thrombosis,for other,0
ERWINAZE,cerebral venous thrombosis,and events,0
ERWINAZE,cerebral venous thrombosis,cerebral venous thrombosis and only,1
ERWINAZE,cerebral venous thrombosis,cerebral venous thrombosis and only Grade,1
ERWINAZE,cerebral venous thrombosis,hyperlipidemia ketoacidosis and CNS events hemorrhage thrombosis,0
ERWINAZE,cerebral venous thrombosis,venous thrombosis and only Grade and events,1
ERWINAZE,cerebral venous thrombosis,cerebral venous thrombosis,1
ERWINAZE,allergic reactions,information on occurrence allergic reactions thrombotic events hemorrhagic events hepatobiliary,1
ERWINAZE,allergic reactions,cerebral venous thrombosis,1
ERWINAZE,allergic reactions,requested information on occurrence allergic reactions thrombotic events hemorrhagic events,1
ERWINAZE,allergic reactions,cerebral venous thrombosis,1
ERWINAZE,allergic reactions,on occurrence allergic reactions thrombotic,1
ERWINAZE,allergic reactions,cerebral venous thrombosis,1
ERWINAZE,allergic reactions,allergic reactions thrombotic,1
ERWINAZE,allergic reactions,on occurrence of,0
ERWINAZE,allergic reactions,on occurrence allergic reactions,1
ERWINAZE,allergic reactions,requested information on occurrence allergic,1
ERWINAZE,allergic reactions,events hemorrhagic events hepatobiliary disorders,0
ERWINAZE,thrombotic events,disorders and,0
ERWINAZE,thrombotic events,allergic,0
ERWINAZE,thrombotic events,on occurrence of allergic thrombotic events,1
ERWINAZE,thrombotic events,information on occurrence of allergic reactions,0
ERWINAZE,thrombotic events,reactions,0
ERWINAZE,thrombotic events,thrombotic,1
ERWINAZE,thrombotic events,thrombotic events hemorrhagic events hepatobiliary disorders pancreatic,1
ERWINAZE,hemorrhagic events,reactions thrombotic hemorrhagic events hepatobiliary disorders,1
ERWINAZE,hemorrhagic events,thrombotic events hemorrhagic events hepatobiliary disorders pancreatic,1
ERWINAZE,hemorrhagic events,The,0
ERWINAZE,hemorrhagic events,on,0
ERWINAZE,hepatobiliary disorders,hepatobiliary disorders pancreatic disorders and,1
ERWINAZE,hepatobiliary disorders,events hemorrhagic events,0
ERWINAZE,hepatobiliary disorders,events hemorrhagic hepatobiliary disorders pancreatic disorders and hyperglycemia The,1
ERWINAZE,hepatobiliary disorders,events hemorrhagic events,0
ERWINAZE,hepatobiliary disorders,hepatobiliary disorders pancreatic,1
ERWINAZE,hepatobiliary disorders,hemorrhagic events,0
ERWINAZE,hepatobiliary disorders,hepatobiliary disorders,1
ERWINAZE,hepatobiliary disorders,hemorrhagic events,0
ERWINAZE,pancreatic disorders,hemorrhagic events hepatobiliary pancreatic disorders,1
ERWINAZE,pancreatic disorders,events hepatobiliary pancreatic disorders,1
ERWINAZE,pancreatic disorders,thrombotic,0
ERWINAZE,pancreatic disorders,adverse events all,0
ERWINAZE,pancreatic disorders,pancreatic disorders and hyperglycemia,1
ERWINAZE,pancreatic disorders,pancreatic disorders and hyperglycemia The incidence of,1
ERWINAZE,hyperglycemia,hyperglycemia The incidence of,1
ERWINAZE,hypersensitivity reactions,patients who developed,0
ERWINAZE,hypersensitivity reactions,hypersensitivity reactions in,1
ERWINAZE,hypersensitivity reactions,a higher risk hypersensitivity reactions,1
ERWINAZE,hypersensitivity reactions,hypersensitivity reactions in,1
ERWINAZE,hypersensitivity reactions,with a higher risk hypersensitivity reactions,1
ERWINAZE,hypersensitivity reactions,neutralizing antibodiesThe presence of ADA to ERWINAZE is associated with,0
ERWINAZE,hypersensitivity reactions,with a higher risk hypersensitivity reactions,1
ERWINAZE,hypersensitivity reactions,neutralizing antibodiesThe presence of ADA to ERWINAZE is associated with,0
ERWINAZE,hypersensitivity reactions,er sections of the label: Hypersensitivity,1
ERWINAZE,hypersensitivity reactions,greater,0
ERWINAZE,hypersensitivity reactions,"in er sections of the label:
 Hypersensitivity",1
ERWINAZE,hypersensitivity reactions,greater,0
ERWINAZE,hypersensitivity reactions,greater detail in er sections,1
ERWINAZE,hypersensitivity reactions,in greater detail,0
ERWINAZE,hypersensitivity reactions,Warnings and Precautions Pancreatitis see,0
ERWINAZE,hypersensitivity reactions,oth,0
ERWINAZE,hypersensitivity reactions,and Precautions Pancreatitis see,0
ERWINAZE,hypersensitivity reactions,sections of the label: Hypersensitivity reactions see,1
ERWINAZE,hypersensitivity reactions,see Warnings,0
ERWINAZE,anaphylaxis,ersensitivi,1
ERWINAZE,anaphylaxis,ersensitivi,1
ERWINAZE,anaphylaxis,Precautions,0
ERWINAZE,anaphylaxis,ersensitivi ty reactions see Warnings,1
ERWINAZE,anaphylaxis,the label ersensitivi ty,1
ERWINAZE,anaphylaxis,ersensitivi ty reactions see Warnings,1
ERWINAZE,anaphylaxis,rious adverse reactions are discussed in greater detail,0
ERWINAZE,hemorrhagic pancreatitis,see Warnings and Precautions Glucose,0
ERWINAZE,hemorrhagic pancreatitis,and Precautions,0
ERWINAZE,hemorrhagic pancreatitis,the label Hypersensitivity reactions s,0
ERWINAZE,hemorrhagic pancreatitis,Warnings and Precauti ons Pancreatitis see,1
ERWINAZE,hemorrhagic pancreatitis,Warnings and Precauti ons Pancreatitis,1
ERWINAZE,hemorrhagic pancreatitis,the label Hypersensitivity reactions ee,1
ERWINAZE,hemorrhagic pancreatitis,ee Warnings and Precauti,1
ERWINAZE,hemorrhagic pancreatitis,the label Hypersensitivity reactions ee,1
ERWINAZE,hemorrhagic pancreatitis,ee Warnings and Precauti ons Pancreatitis see Warnings,1
ERWINAZE,pancreatitis,and Precauti,1
ERWINAZE,Glucose intolerance,Warnings and Precautions,0
ERWINAZE,Glucose intolerance,intolerance see Warnings,0
ERWINAZE,Glucose intolerance,see,0
ERWINAZE,Glucose intolerance,Warnings and *,1
ERWINAZE,Glucose intolerance,* Pancreatitis [ see Warnings,1
ERWINAZE,Glucose intolerance,see Warnings and Precautions Glucose intolerance see Warnings and,0
ERWINAZE,Glucose intolerance,*    Pancreatitis [ see,1
ERWINAZE,Glucose intolerance,see Warnings and Precautions Glucose intolerance see Warnings and,0
ERWINAZE,Glucose intolerance,reactions see Warnings and *    Pancreatitis [ see,1
ERWINAZE,Glucose intolerance,see Warnings and Precautions Glucose intolerance see Warnings and,0
ERWINAZE,Glucose intolerance,*,1
ERWINAZE,Glucose intolerance,*    Pancreatitis [ see Warnings and Precautions,1
ERWINAZE,Glucose intolerance,*,1
ERWINAZE,Glucose intolerance,and *    Pancreatitis [ see Warnings and,1
ERWINAZE,Glucose intolerance,*,1
ERWINAZE,Glucose intolerance,see Warnings and Precautions,0
ERWINAZE,Glucose intolerance,see Warnings and,0
ERWINAZE,Glucose intolerance,Precautions,0
ERWINAZE,Glucose intolerance,reactions see Warnings and * Pancreatitis,1
ERWINAZE,Glucose intolerance,Warnings and * Pancreatitis,1
ERWINAZE,Glucose intolerance,* Pancreatitis [ see Warnings and Precautions Glucose,1
ERWINAZE,Glucose intolerance,see Warnings and Precautions Glucose intolerance see Warnings,0
ERWINAZE,Glucose intolerance,Pancreatitis [ see Warnings and Precautions,1
ERWINAZE,Glucose intolerance,and * Pancreatitis,1
ERWINAZE,Thrombosis,ings and P recautions The,1
ERWINAZE,Thrombosis,with ERWINAZE tr,0
ERWINAZE,Thrombosis,hemorrhage see ings and P recautions The most,1
ERWINAZE,Thrombosis,with ERWINAZE tr,0
ERWINAZE,Thrombosis,with ERWINAZE,0
ERWINAZE,Thrombosis,ings and P recautions The most common adverse,1
ERWINAZE,Thrombosis,and hemorrhage see ings and P recautions The most common adverse,1
ERWINAZE,Thrombosis,ings and P recautions The most common adverse,1
ERWINAZE,Thrombosis,hemorrhage see Warn,0
ERWINAZE,hemorrhage,cautions ( The most,1
ERWINAZE,hemorrhage,or,0
ERWINAZE,hemorrhage,cautions ( The most common,1
ERWINAZE,hemorrhage,or,0
ERWINAZE,hemorrhage,see Warnings and cautions (,1
ERWINAZE,hemorrhage,or,0
ERWINAZE,hypersensitivity reactions,"temic hypersensitivity, hy perglycemia transaminases abnormal",1
ERWINAZE,hypersensitivity reactions,treatment are,0
ERWINAZE,hypersensitivity reactions,pancreatitis,0
ERWINAZE,Pancreatitis,hyperbilirubinemia,0
ERWINAZE,Pancreatitis,hyperbilirubinemia abdominal paindiscomfort and,0
ERWINAZE,glucose intolerance,EMTP an d access,1
ERWINAZE,glucose intolerance,EMTP an d access program (b,1
ERWINAZE,glucose intolerance,and,0
ERWINAZE,glucose intolerance,Treatment Protocol EMTP an d access program (b oth intramuscular,1
ERWINAZE,glucose intolerance,and,0
ERWINAZE,thrombotic events,ERWINAZEStudy enrolled,0
ERWINAZE,thrombotic events,study trial of intravenous administration of ERWINAZEStudy enrolled patie,0
ERWINAZE,thrombotic events,Cancer Institute NCIsponsored,0
ERWINAZE,thrombotic events,of intravenous,0
ERWINAZE,thrombotic events,ALL protocols who were,0
ERWINAZE,thrombotic events,on Na tional Cancer Institute,1
ERWINAZE,thrombotic events,nts treated on Na tional Cancer,1
ERWINAZE,thrombotic events,ALL protocols who,0
ERWINAZE,thrombotic events,ERWINAZEStudy enrolled nts,1
ERWINAZE,sagittal sinus thrombosis,Institute (NCI)-sponsor ed cooperative group ALL protocols,1
ERWINAZE,sagittal sinus thrombosis,Institute (NCI)-sponsor ed cooperative group,1
ERWINAZE,sagittal sinus thrombosis,enrolled patients treated on National,0
ERWINAZE,sagittal sinus thrombosis,treated on National,0
ERWINAZE,sagittal sinus thrombosis,National r Institute,1
ERWINAZE,sagittal sinus thrombosis,unable to continue to,0
ERWINAZE,sagittal sinus thrombosis,ed cooperative group ALL protocols who were unable,0
ERWINAZE,sagittal sinus thrombosis,r Institute (NCI)-sponsor ed,1
ERWINAZE,sagittal sinus thrombosis,ed cooperative group ALL protocols who were unable,0
ERWINAZE,pulmonary embolism,on National Cancer Institute,0
ERWINAZE,pulmonary embolism,Cancer Institute NCIsponsored co,0
ERWINAZE,pulmonary embolism,Cancer Institute NCIsponsored operative,1
SAPHRIS,Neuroleptic Malignant Syndrome,and,0
SAPHRIS,Neuroleptic Malignant Syndrome,with DementiaRelated Psychosis,0
SAPHRIS,Neuroleptic Malignant Syndrome,see Warnings and,0
SAPHRIS,Neuroleptic Malignant Syndrome,Warningand Warnings and Precautions Neuroleptic Malignant Syndrome,1
SAPHRIS,Neuroleptic Malignant Syndrome,see Warnings and,0
SAPHRIS,Neuroleptic Malignant Syndrome,Malignant Syndrome see Warnings and,1
SAPHRIS,Neuroleptic Malignant Syndrome,Psychosis seeBoxed Warningand Warnings and,0
SAPHRIS,Neuroleptic Malignant Syndrome,and Precautions and,0
SAPHRIS,Neuroleptic Malignant Syndrome,Malignant Syndrome see Warnings and Precautions,1
SAPHRIS,Tardive Dyskinesia,Warnings and Tardive,1
SAPHRIS,Tardive Dyskinesia,Tardive Dyskinesia see,1
SAPHRIS,Tardive Dyskinesia,Warnings and,0
SAPHRIS,Tardive Dyskinesia,and Precautions,0
SAPHRIS,Tardive Dyskinesia,Precautions Metabolic Changes see Warnings and Precautions,0
SAPHRIS,Tardive Dyskinesia,Precautions Metabolic Changes see Warnings and Precautions,0
SAPHRIS,Tardive Dyskinesia,Tardive Dyskinesia see Warnings,1
SAPHRIS,Tardive Dyskinesia,Warnings and Tardive Dyskinesia,1
SAPHRIS,Tardive Dyskinesia,Tardive Dyskinesia see Warnings and,1
SAPHRIS,Tardive Dyskinesia,Tardive Dyskinesia,1
SAPHRIS,Metabolic Changes,Hypersensitivity Reactions see,0
SAPHRIS,Hypersensitivity Reactions,Warnings and Precautions Metabolic Changes see Warnings and Precautions,0
SAPHRIS,Orthostatic Hypotension,Orthostatic Hypotension Syncope and other Hemodynamic,1
SAPHRIS,Orthostatic Hypotension,see Adverse Orthostatic,1
SAPHRIS,Orthostatic Hypotension,Orthostatic Hypotension Syncope and other Hemodynamic,1
SAPHRIS,Orthostatic Hypotension,and other Hemodynamic Effects see Warnings and Precautions Leukopenia Neut,0
SAPHRIS,Syncope,Reactions,0
SAPHRIS,Syncope,and inflammation see,0
SAPHRIS,Syncope,Syncope,1
SAPHRIS,Syncope,and,0
SAPHRIS,Syncope,Syncope and other Hemodynamic,1
SAPHRIS,Syncope,and,0
SAPHRIS,Syncope,Syncope and other Hemodynamic Effects,1
SAPHRIS,Syncope,Adverse Reactions Orthostatic Syncope and other Hemodynamic Effects,1
SAPHRIS,Syncope,Syncope and other Hemodynamic Effects,1
SAPHRIS,Syncope,Syncope and other Hemodynamic Effects see,1
SAPHRIS,Hemodynamic Effects,Hemodynamic Effects,1
SAPHRIS,Hemodynamic Effects,Agranulocytosis see Warnin,0
SAPHRIS,Hemodynamic Effects,Hemodynamic Effects see Warnings and Precautions Leukopenia,1
SAPHRIS,Hemodynamic Effects,Reactions Orthostatic Hypotension,0
SAPHRIS,Hemodynamic Effects,and Hemodynamic,1
SAPHRIS,Hemodynamic Effects,Orthostatic Hypotension Syncope and Hemodynamic Effects see Warnings and,1
SAPHRIS,Hemodynamic Effects,and Hemodynamic,1
SAPHRIS,Hemodynamic Effects,and Hemodynamic Effects see Warnings and,1
SAPHRIS,Hemodynamic Effects,and Hemodynamic,1
SAPHRIS,Hemodynamic Effects,and,0
SAPHRIS,Neutropenia,Neutropenia and Agranulocytosis see Warnings,1
SAPHRIS,Neutropenia,Neutropenia and Agranulocytosis see,1
SAPHRIS,Neutropenia,Neutropenia and Agranulocytosis see Warnings and,1
SAPHRIS,Neutropenia,Warnings,0
SAPHRIS,Neutropenia,Neutropenia and Agranulocytosis see,1
SAPHRIS,Neutropenia,Warnings,0
SAPHRIS,Neutropenia,sion Syncope and other Hemodynamic Effects see Warnings and,0
SAPHRIS,Neutropenia,Neutropenia and,1
SAPHRIS,Neutropenia,Neutropenia,1
SAPHRIS,Neutropenia,Neutropenia and Agranulocytosis see Warnings,1
SAPHRIS,Agranulocytosis,and Precautions Leukopenia,0
SAPHRIS,Agranulocytosis,Neutropenia Agranulocytosis,1
SAPHRIS,Agranulocytosis,and Precautions Leukopenia,0
SAPHRIS,QT Interval Prolongation,Warnings,0
SAPHRIS,QT Interval Prolongation,QT Interval Prolongation,1
SAPHRIS,QT Interval Prolongation,QT Interval Prolongation,1
SAPHRIS,QT Interval Prolongation,Warnings and QT Interval Prolongation see,1
SAPHRIS,QT Interval Prolongation,QT Interval Prolongation,1
SAPHRIS,QT Interval Prolongation,Interval Prolongation see,1
SAPHRIS,QT Interval Prolongation,Neutropenia and Agranulocytosis see,0
SAPHRIS,QT Interval Prolongation,QT Interval Prolongation see Warnings and Precautions,1
SAPHRIS,QT Interval Prolongation,Agranulocytosis see Warnings and QT Interval Prolongation,1
SAPHRIS,QT Interval Prolongation,QT Interval Prolongation see Warnings and Precautions,1
SAPHRIS,QT Interval Prolongation,see Warnings and,0
SAPHRIS,Hyperprolactinemia,Warnings and Precautions,0
SAPHRIS,Hyperprolactinemia,see Warnings and Hyperprolactinemia,1
SAPHRIS,Hyperprolactinemia,Warnings and Precautions,0
SAPHRIS,Hyperprolactinemia,Warnings and Hyperprolactinemia see Warnings and Precautions Seizures,1
SAPHRIS,Hyperprolactinemia,Warnings and Precautions,0
SAPHRIS,Hyperprolactinemia,Prolongation see Warnings and Hyperprolactinemia see Warnings,1
SAPHRIS,Hyperprolactinemia,Warnings and Precautions,0
SAPHRIS,Hyperprolactinemia,and,0
SAPHRIS,Hyperprolactinemia,Precautions Seizures,0
SAPHRIS,Hyperprolactinemia,see Warnings and Hyperprolactinemia see,1
SAPHRIS,Hyperprolactinemia,Precautions Seizures,0
SAPHRIS,Seizures,Seizures,1
SAPHRIS,Seizures,Seizures,1
SAPHRIS,Seizures,and Precautions Potential for Cognitive and Motor Impairment,0
SAPHRIS,Seizures,see Warnings and Precautions Potential for,0
SAPHRIS,Seizures,Precautions Hyperprolactinemia,0
SAPHRIS,Suicide,Suicide see,1
SAPHRIS,Suicide,Suicide see Warnings and,1
SAPHRIS,Suicide,Suicide see,1
SAPHRIS,Suicide,Precautions,0
SAPHRIS,Suicide,Temperature Regulation see Warnings,0
SAPHRIS,Suicide,Suicide see Warnings,1
SAPHRIS,Suicide,Temperature Regulation see Warnings,0
SAPHRIS,Suicide,Regulation see Warnings and Suicide,1
SAPHRIS,Suicide,Temperature Regulation see Warnings,0
SAPHRIS,Suicide,Regulation see Warnings and Suicide see,1
SAPHRIS,Suicide,Temperature Regulation see Warnings,0
SAPHRIS,Suicide,Dysphagia see Warnings and,0
SAPHRIS,Dysphagia,Dysphagia see Warnings,1
SAPHRIS,Dysphagia,Dysphagia see Warnings and Precautions Use,1
SAPHRIS,Dysphagia,Dysphagia see Warnings,1
SAPHRIS,Dysphagia,see Warnings and Dysphagia see Warnings and Precautions,1
SAPHRIS,Dysphagia,Dysphagia see Warnings,1
SAPHRIS,Dysphagia,Dysphagia see Warnings and Precautions Use,1
SAPHRIS,Dysphagia,and,0
SAPHRIS,Dysphagia,Dysphagia see Warnings and Precautions Use,1
SAPHRIS,Dysphagia,Dysphagia see Warnings and Precautions Use,1
SAPHRIS,Dysphagia,Warnings and Dysphagia see Warnings and Precautions Use,1
SAPHRIS,Dysphagia,Dysphagia see Warnings and Precautions Use,1
SAPHRIS,Dysphagia,Warnings and Dysphagia see Warnings,1
SAPHRIS,Dysphagia,Dysphagia see Warnings and Precautions Use,1
SAPHRIS,akathisia,akathisia oral hypoesthesia and somnolence,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,adults with schizophrenia akathisia oral hypoesthesia and somnolence,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,schizophrenia akathisia oral,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,in adults with schizophrenia akathisia oral hypoesthesia and,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,safety profile of SAPHRIS in the maintenance treatment of,0
SAPHRIS,oral hypoesthesia,were oral hypoesthesia and somnolence The,1
SAPHRIS,oral hypoesthesia,safety profile of SAPHRIS in the maintenance treatment of,0
SAPHRIS,oral hypoesthesia,oral,1
SAPHRIS,oral hypoesthesia,oral hypoesthesia and somnolence,1
SAPHRIS,oral hypoesthesia,oral hypoesthesia and,1
SAPHRIS,oral hypoesthesia,oral hypoesthesia and somnolence,1
SAPHRIS,oral hypoesthesia,in adults with schizophrenia were akathisia,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,with schizophrenia were oral hypoesthesia and somnolence The safety,1
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,oral hypoesthesia and somnolence The,1
SAPHRIS,somnolence,of schizophrenia in,0
SAPHRIS,somnolence,somnolence The safety profile of,1
SAPHRIS,somnolence,somnolence The safety profile,1
SAPHRIS,somnolence,somnolence The,1
SAPHRIS,somnolence,and,0
SAPHRIS,somnolence,were akathisia oral hypoesthesia,0
SAPHRIS,somnolence,oral hypoesthesia somnolence The safety profile of SAPHRIS,1
SAPHRIS,somnolence,were akathisia oral hypoesthesia,0
SAPHRIS,somnolence,somnolence The safety profile,1
SAPHRIS,somnolence,somnolence dizziness extrapyramidal,1
SAPHRIS,somnolence,other than akathisia and increased weight and during the,0
SAPHRIS,somnolence,somnolence dizziness extrapyramidal,1
SAPHRIS,somnolence,other than akathisia and increased weight and during the,0
SAPHRIS,somnolence,than,0
SAPHRIS,somnolence,somnolence dizziness,1
SAPHRIS,somnolence,bipolar I,0
SAPHRIS,somnolence,adults were,0
SAPHRIS,dizziness,dizziness extrapyramidal symptoms other than,1
SAPHRIS,dizziness,dizziness extrapyramidal symptoms other than akathisia,1
SAPHRIS,dizziness,dizziness extrapyramidal,1
SAPHRIS,extrapyramidal symptoms,bipolar I disorder,0
SAPHRIS,extrapyramidal symptoms,in adults were somnolence dizziness,0
SAPHRIS,extrapyramidal symptoms,in,0
SAPHRIS,akathisia,akathisia and,1
SAPHRIS,akathisia,I,0
SAPHRIS,akathisia,trial in bipolar I disorder in adults,0
SAPHRIS,akathisia,akathisia and increased,1
SAPHRIS,akathisia,trial in bipolar I disorder in adults,0
SAPHRIS,akathisia,the adjunctive,0
SAPHRIS,akathisia,dizziness extrapyramidal symptoms,0
SAPHRIS,akathisia,during the adjunctive therapy trial in bipolar I disorder in adults,0
SAPHRIS,increased weight,symptoms other than akathisia increased,1
SAPHRIS,increased weight,symptoms other than akathisia,0
SAPHRIS,increased weight,somnolence and oral hy,0
SAPHRIS,increased weight,akathisia increased,1
SAPHRIS,increased weight,than,0
SAPHRIS,increased weight,than akathisia increased weight,1
SAPHRIS,increased weight,were somnolence dizziness,0
SAPHRIS,somnolence,hypoesthesia The adult,0
SAPHRIS,somnolence,weight and during the adjunctive therapy trial in bipolar,0
SAPHRIS,somnolence,during the adjunctive therapy trial in bipolar I disorder,0
SAPHRIS,somnolence,hypoesthesia The adult information below is derived from a clinical trial,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia The adult information,1
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,somnolence,somnolence dizziness dysgeusia oral paresthesia nausea,1
SAPHRIS,somnolence,somnolence dizziness,1
SAPHRIS,somnolence,somnolence dizziness dysgeusia,1
SAPHRIS,somnolence,somnolence dizziness,1
SAPHRIS,somnolence,somnolence dizziness dysgeusia oral paresthesia nausea,1
SAPHRIS,somnolence,somnolence dizziness,1
SAPHRIS,somnolence,paresthesia nausea increased appetite fatigue and increased weight,0
SAPHRIS,somnolence,somnolence dizziness dysgeusia oral paresthesia nausea,1
SAPHRIS,somnolence,increased,0
SAPHRIS,dizziness,reported in pediatric patients,0
SAPHRIS,dizziness,dizziness dysgeusia,1
SAPHRIS,dizziness,dizziness dysgeusia,1
SAPHRIS,dizziness,No new maj,0
SAPHRIS,dizziness,dizziness dysgeusia oral,1
SAPHRIS,dizziness,were,0
SAPHRIS,dizziness,oral paresthesia nausea increased,0
SAPHRIS,dizziness,fatigue and increased,0
SAPHRIS,dizziness,dizziness dysgeusia oral,1
SAPHRIS,oral paresthesia,SAPHRIS were somnolence dizziness oral,1
SAPHRIS,oral paresthesia,somnolence dizziness oral paresthesia nausea increased appetite fatigue and,1
SAPHRIS,oral paresthesia,SAPHRIS were somnolence dizziness oral,1
SAPHRIS,oral paresthesia,dizziness oral paresthesia nausea increased appetite fatigue,1
SAPHRIS,oral paresthesia,SAPHRIS were somnolence dizziness oral,1
SAPHRIS,oral paresthesia,somnolence dizziness dysgeusia,0
SAPHRIS,nausea,nausea increased appetite,1
SAPHRIS,fatigue,safety findings were reported,0
SAPHRIS,fatigue,SAPHRIS,0
SAPHRIS,increased weight,increased weight No new major,1
SAPHRIS,akathisia,Bipolar Disorder Adults,0
SAPHRIS,oral hypoesthesia,Bipolar Disorder Adults Monotherapy somnolence dizziness,0
SAPHRIS,oral hypoesthesia,Schizophrenia Adults oral hypoesthesia somnolence Bipolar Disorder Adults,1
SAPHRIS,oral hypoesthesia,Bipolar Disorder Adults Monotherapy somnolence dizziness,0
SAPHRIS,oral hypoesthesia,placebo were Schizophrenia,0
SAPHRIS,oral hypoesthesia,Schizophrenia Adults oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,Schizophrenia Adults oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,dizziness extrapyramidal sym,0
SAPHRIS,oral hypoesthesia,placebo were Schizophrenia Adults oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,dizziness extrapyramidal sym,0
SAPHRIS,oral hypoesthesia,Monotherapy somnolence dizziness extrapyramidal,0
SAPHRIS,oral hypoesthesia,Adults,0
SAPHRIS,oral hypoesthesia,Adults oral hypoesthesia,1
SAPHRIS,somnolence,Bipolar Disorder,0
SAPHRIS,somnolence,hypoesthesia somnolence,0
SAPHRIS,somnolence,increased weight Bipolar,0
SAPHRIS,somnolence,somnolence dizziness,1
SAPHRIS,dizziness,somnolence,0
SAPHRIS,dizziness,increased weight Bipolar Disorder Pediatric P,0
SAPHRIS,dizziness,dizziness extrapyramidal symptoms other than akathisia,1
SAPHRIS,dizziness,than akathisia,0
SAPHRIS,dizziness,extrapyramidal symptoms other than akathisia increased weight Bipolar Disorder,0
SAPHRIS,dizziness,Monotherapy dizziness extrapyramidal symptoms other,1
SAPHRIS,dizziness,extrapyramidal symptoms other than akathisia increased weight Bipolar Disorder,0
SAPHRIS,dizziness,Adults Monotherapy dizziness extrapyramidal symptoms other than,1
SAPHRIS,dizziness,extrapyramidal symptoms other than akathisia increased weight Bipolar Disorder,0
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,Bipolar Disorder Adults,0
SAPHRIS,dizziness,Disorder Pediatric P,0
SAPHRIS,akathisia,akathisia increased,1
SAPHRIS,akathisia,dizziness extrapyramidal symptoms other akathisia increased,1
SAPHRIS,akathisia,akathisia increased,1
SAPHRIS,akathisia,Pediatric,0
SAPHRIS,akathisia,akathisia increased weight Bipolar Disorder,1
SAPHRIS,akathisia,dizziness extrapyramidal symptoms other akathisia increased weight Bipolar Disorder,1
SAPHRIS,akathisia,akathisia increased weight Bipolar Disorder,1
SAPHRIS,akathisia,increased weight,0
SAPHRIS,increased weight,than increased weight Bipolar Disorder Pediatric Patients,1
SAPHRIS,increased weight,increased weight,0
SAPHRIS,increased weight,extrapyramidal symptoms,0
SAPHRIS,increased weight,dizziness extrapyramidal symptoms other than akathisia,0
SAPHRIS,increased weight,Pediatric Patients Monotherapy somnolence dizziness dysgeusia oral pa,0
SAPHRIS,somnolence,fatigue increased weight,0
SAPHRIS,somnolence,somnolence dizziness dysgeusia oral,1
SAPHRIS,dizziness,dizziness dysgeusia oral paresthesia,1
SAPHRIS,dizziness,Monotherapy somnolence,0
SAPHRIS,dizziness,Bipolar Disorder Pediatric,0
SAPHRIS,dizziness,Disorder Pediatric Patients Monotherapy dizziness,1
SAPHRIS,dizziness,Bipolar Disorder Pediatric,0
SAPHRIS,dizziness,dizziness dysgeusia oral paresthesia,1
SAPHRIS,dizziness,Patients,0
SAPHRIS,dizziness,dizziness dysgeusia oral paresthesia,1
SAPHRIS,dizziness,dizziness dysgeusia oral paresthesia nausea increased,1
SAPHRIS,dizziness,dizziness,1
SAPHRIS,dizziness,dizziness dysgeusia oral,1
SAPHRIS,dysgeusia,dysgeusia,1
SAPHRIS,dysgeusia,dysgeusia oral paresthesia nausea increased appetite,1
SAPHRIS,dysgeusia,dizziness,0
SAPHRIS,dysgeusia,nausea increased appetite fatigue increased weight Bipolar Disorder,0
SAPHRIS,oral paresthesia,Patients Monotherapy somnolence dizziness oral paresthesia,1
SAPHRIS,oral paresthesia,dizziness oral paresthesia nausea increased appetite,1
SAPHRIS,oral paresthesia,Patients Monotherapy somnolence dizziness oral paresthesia,1
SAPHRIS,oral paresthesia,Pediatric Patients Monotherapy somnolence dizziness dysgeusia,0
SAPHRIS,oral paresthesia,oral,1
SAPHRIS,nausea,nausea,1
SAPHRIS,nausea,nausea increased appetite fatigue,1
SAPHRIS,nausea,nausea,1
SAPHRIS,nausea,dysgeusia oral paresthesia,0
SAPHRIS,increased appetite,increased appetite,1
SAPHRIS,increased appetite,paresthesia increased appetite,1
SAPHRIS,fatigue,fatigue increased,1
SAPHRIS,fatigue,Adults,0
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,Adults,0
SAPHRIS,increased weight,dizziness dysgeusia oral paresthesia nausea increased appetite fatigue,0
SAPHRIS,increased weight,paresthesia nausea increased appetite increased weight,1
SAPHRIS,increased weight,oral hypoesthesia To,0
SAPHRIS,increased weight,nausea increased,0
SAPHRIS,increased weight,increased weight,1
SAPHRIS,increased weight,appetite,0
SAPHRIS,increased weight,increased weight Bipolar Disorder,1
SAPHRIS,somnolence,somnolence oral hypoesthesia To report SUSPECTED,1
SAPHRIS,somnolence,somnolence oral hypoesthesia To report SUSPECTED,1
SAPHRIS,somnolence,Disorder Adults somnolence oral hypoesthesia To,1
SAPHRIS,somnolence,somnolence oral hypoesthesia To report SUSPECTED,1
SAPHRIS,somnolence,somnolence oral hypoesthesia To report SUSPECTED,1
SAPHRIS,somnolence,Bipolar Disorder Adults somnolence oral hypoesthesia To report,1
SAPHRIS,somnolence,somnolence oral hypoesthesia To report SUSPECTED,1
SAPHRIS,somnolence,weight Bipolar Disorder Adults,0
SAPHRIS,somnolence,Disorder Adults somnolence oral,1
SAPHRIS,somnolence,weight Bipolar Disorder Adults,0
SAPHRIS,somnolence,increased weight Bipolar Disorder,0
SAPHRIS,somnolence,contact Forest Laboratories LLC,0
SAPHRIS,oral hypoesthesia,increased,0
SAPHRIS,oral hypoesthesia,To report SUSPECTED ADVERSE REACTIONS contact Forest Laboratories LLC,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia To report,1
SAPHRIS,oral hypoesthesia,Adults Adjunctive oral hypoesthesia,1
SAPHRIS,Akathisia,Akathisia includes,1
SAPHRIS,Akathisia,Extrapyramidal,0
SAPHRIS,Akathisia,Akathisia includes akathisia and,1
SAPHRIS,Akathisia,Trials,0
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,Trials,0
SAPHRIS,hyperkinesia,akathisia hyperkinesia,1
SAPHRIS,hyperkinesia,Trials,0
SAPHRIS,hyperkinesia,in Week Schizophrenia Trials Akathisia includes,0
SAPHRIS,hyperkinesia,in the Placebo Group,0
SAPHRIS,hyperkinesia,hyperkinesia Extrapyramidal symptoms included dystonia oculogyration,1
SAPHRIS,hyperkinesia,includes akathisia hyperkinesia Extrapyramidal,1
SAPHRIS,hyperkinesia,hyperkinesia Extrapyramidal symptoms included dystonia oculogyration,1
SAPHRIS,hyperkinesia,Akathisia includes akathisia hyperkinesia Extrapyramidal symptoms included,1
SAPHRIS,hyperkinesia,hyperkinesia Extrapyramidal symptoms included dystonia oculogyration,1
SAPHRIS,hyperkinesia,hyperkinesia Extrapyramidal symptoms included dystonia oculogyration,1
SAPHRIS,hyperkinesia,hyperkinesia Extrapyramidal symptoms included dystonia oculogyration,1
SAPHRIS,Extrapyramidal symptoms,Akathisia includes akathisia and Extrapyramidal,1
SAPHRIS,Extrapyramidal symptoms,Extrapyramidal symptoms included dystonia oculogyration,1
SAPHRIS,Extrapyramidal symptoms,and hyperkinesia,0
SAPHRIS,Extrapyramidal symptoms,rigidity,0
SAPHRIS,Extrapyramidal symptoms,Extrapyramidal symptoms included dystonia oculogyration dyskinesia,1
SAPHRIS,Extrapyramidal symptoms,rigidity,0
SAPHRIS,Extrapyramidal symptoms,Akathisia includes akathisia and Extrapyramidal symptoms,1
SAPHRIS,Extrapyramidal symptoms,Extrapyramidal symptoms included dystonia,1
SAPHRIS,Extrapyramidal symptoms,Akathisia includes akathisia and Extrapyramidal symptoms,1
SAPHRIS,Extrapyramidal symptoms,dyskinesia,0
SAPHRIS,Extrapyramidal symptoms,akathisia and Extrapyramidal symptoms,1
SAPHRIS,dystonia,dystonia oculogyration,1
SAPHRIS,dystonia,dystonia oculogyration dyskinesia tardive,1
SAPHRIS,dystonia,dyskinesia muscle rigidity parkinsonism tremor and extrapyr,0
SAPHRIS,dystonia,tardive dyskinesia muscle rigidity parkinsonism tremor,0
SAPHRIS,dystonia,dystonia oculogyration dyskinesia tardive,1
SAPHRIS,dystonia,oculogyration dyskinesia tardive dyskinesia muscle rigidity parkinsonism tremor,0
SAPHRIS,dystonia,rigidity parkinsonism tremor and,0
SAPHRIS,dystonia,Extrapyramidal symptoms dystonia oculogyration dyskinesia tardive dyskinesia,1
SAPHRIS,dystonia,rigidity parkinsonism tremor and,0
SAPHRIS,dystonia,hyperkinesia Extrapyramidal symptoms,0
SAPHRIS,dystonia,symptoms,0
SAPHRIS,oculogyration,hyperkinesia Extrapyramidal symptoms included,0
SAPHRIS,oculogyration,Extrapyramidal symptoms included oculogyration dyskinesia tardive dyskinesia muscle,1
SAPHRIS,oculogyration,hyperkinesia Extrapyramidal symptoms included,0
SAPHRIS,dyskinesia,dyskinesia tardive dyskinesia,1
SAPHRIS,tardive dyskinesia,tardive dyskinesia,1
SAPHRIS,tardive dyskinesia,oculogyration tardive dyskinesia muscle,1
SAPHRIS,tardive dyskinesia,tardive dyskinesia,1
SAPHRIS,tardive dyskinesia,parkinsonism tremor and extrapyramidal,0
SAPHRIS,tardive dyskinesia,and,0
SAPHRIS,tardive dyskinesia,tardive dyskinesia muscle rigidity parkinsonism tremor,1
SAPHRIS,muscle rigidity,dyskinesia,0
SAPHRIS,muscle rigidity,tardive muscle rigidity,1
SAPHRIS,muscle rigidity,dyskinesia,0
SAPHRIS,muscle rigidity,included,0
SAPHRIS,muscle rigidity,muscle rigidity parkinsonism tremor and extrapyramidal disorder,1
SAPHRIS,muscle rigidity,oculogyration dyskinesia tardive muscle,1
SAPHRIS,muscle rigidity,included dystonia oculogyration dyskinesia tardive,0
SAPHRIS,parkinsonism,parkinsonism tremor and,1
SAPHRIS,tremor,muscle rigidity tremor and extrapyramidal disorder excluding,1
SAPHRIS,tremor,parkinsonism tremor and,1
SAPHRIS,extrapyramidal disorder,muscle rigidity parkinsonism tremor extrapyramidal disorder excluding akathisia Somnolence includes,1
SAPHRIS,extrapyramidal disorder,parkinsonism tremor and,1
SAPHRIS,extrapyramidal disorder,extrapyramidal disorder excluding akathisia Somnolence,1
SAPHRIS,extrapyramidal disorder,extrapyramidal disorder excluding,1
SAPHRIS,extrapyramidal disorder,extrapyramidal disorder excluding akathisia Somnolence,1
SAPHRIS,extrapyramidal disorder,Somnolence includes,0
SAPHRIS,extrapyramidal disorder,akathisia Somnolence includes the following,0
SAPHRIS,extrapyramidal disorder,includes the following events,0
SAPHRIS,akathisia,and hypersomnia S,0
SAPHRIS,akathisia,dyskinesia muscle rigidity parkinsonism tremor and extrapyramidal disorder excluding,0
SAPHRIS,akathisia,extrapyramidal disorder excluding,0
SAPHRIS,akathisia,excluding,0
SAPHRIS,akathisia,tremor and extrapyramidal disorder akathisia Somnolence includes the,1
SAPHRIS,akathisia,excluding,0
SAPHRIS,akathisia,rigidity,0
SAPHRIS,akathisia,akathisia Somnolence includes the following events,1
SAPHRIS,akathisia,parkinsonism,0
SAPHRIS,akathisia,muscle rigidity,0
SAPHRIS,Somnolence,extrapyramidal disorder excluding Somnolence includes the,1
SAPHRIS,Somnolence,muscle rigidity,0
SAPHRIS,Somnolence,Somnolence includes the,1
SAPHRIS,Somnolence,Somnolence includes,1
SAPHRIS,Somnolence,Somnolence,1
SAPHRIS,Somnolence,somnolence sedation and hypersomnia S Also includes,0
SAPHRIS,somnolence,somnolence sedation and,1
SAPHRIS,somnolence,somnolence sedation and hypersomnia,1
SAPHRIS,somnolence,somnolence sedation and,1
SAPHRIS,somnolence,disorder excluding akathisia Somnolence includes the following events,0
SAPHRIS,somnolence,includes the Flexibledose trial,0
SAPHRIS,somnolence,the following events,0
SAPHRIS,somnolence,somnolence sedation and hypersomnia S,1
SAPHRIS,somnolence,events,0
SAPHRIS,somnolence,Somnolence includes the following somnolence sedation and,1
SAPHRIS,somnolence,events,0
SAPHRIS,somnolence,somnolence sedation and,1
SAPHRIS,sedation,sedation and,1
SAPHRIS,sedation,trial,0
SAPHRIS,sedation,sedation and hypersomnia S Also includes,1
SAPHRIS,sedation,disorder excluding akathisia,0
SAPHRIS,hypersomnia,hypersomnia S Also,1
SAPHRIS,hypersomnia,disorder excluding akathisia,0
SAPHRIS,akathisia,the incidence akathisia appeared to be,1
SAPHRIS,akathisia,disorder excluding akathisia,0
SAPHRIS,akathisia,akathisia appeared to be doserelated,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,schizophrenia trials the incidence akathisia appeared to be doserelated seeTable,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,Reactions In the short term schizophrenia trials the,0
SAPHRIS,akathisia,akathisia appeared to be,1
SAPHRIS,anxiety,oral hypoesthesia compared to placebo Adverse Reactions Occurring,0
SAPHRIS,anxiety,the placebo rate anxiety and,1
SAPHRIS,anxiety,oral hypoesthesia compared to placebo Adverse Reactions Occurring,0
SAPHRIS,anxiety,treated with SAPHRIS rates,0
SAPHRIS,anxiety,the,0
SAPHRIS,anxiety,placebo Adverse Reactions Occurring a,0
SAPHRIS,anxiety,anxiety and oral,1
SAPHRIS,anxiety,anxiety and oral,1
SAPHRIS,anxiety,anxiety and,1
SAPHRIS,anxiety,placebo rate anxiety and oral hypoesthesia,1
SAPHRIS,anxiety,anxiety and,1
SAPHRIS,oral hypoesthesia,least and at least twice the placebo rate were anxiety,0
SAPHRIS,Extrapyramidal symptoms,twice daily with flexible Extrapyramidal symptoms included,1
SAPHRIS,Extrapyramidal symptoms,least and at least twice the placebo rate were anxiety,0
SAPHRIS,dystonia,muscle rigidity,0
SAPHRIS,dystonia,with flexible dosing Extrapyramidal,0
SAPHRIS,dystonia,Extrapyramidal symptoms dystonia blepharospasm torticollis dyskinesia tardive,1
SAPHRIS,dystonia,with flexible dosing Extrapyramidal,0
SAPHRIS,dystonia,dystonia blepharospasm torticollis dyskinesia,1
SAPHRIS,blepharospasm,dosing Extrapyramidal symptoms included blepharospasm torticollis,1
SAPHRIS,blepharospasm,dystonia blepharospasm torticollis dyskinesia,1
SAPHRIS,blepharospasm,daily with flexible dosing,0
SAPHRIS,blepharospasm,blepharospasm torticollis dyskinesia tardive,1
SAPHRIS,torticollis,disturbance masked facies,0
SAPHRIS,torticollis,flexible,0
SAPHRIS,torticollis,symptoms included dystonia torticollis dyskinesia,1
SAPHRIS,torticollis,flexible,0
SAPHRIS,torticollis,torticollis dyskinesia tardive,1
SAPHRIS,torticollis,included dystonia torticollis dyskinesia tardive dyskinesia,1
SAPHRIS,torticollis,torticollis dyskinesia tardive,1
SAPHRIS,torticollis,included dystonia torticollis dyskinesia tardive dyskinesia muscle rigidity,1
SAPHRIS,torticollis,torticollis dyskinesia tardive,1
SAPHRIS,tardive dyskinesia,torticollis tardive dyskinesia,1
SAPHRIS,tardive dyskinesia,and,0
SAPHRIS,tardive dyskinesia,blepharospasm torticollis tardive dyskinesia muscle rigidity parkinsonism gait,1
SAPHRIS,tardive dyskinesia,and,0
SAPHRIS,tardive dyskinesia,tardive dyskinesia muscle rigidity parkinsonism,1
SAPHRIS,tardive dyskinesia,tremor excluding akathisia,0
SAPHRIS,muscle rigidity,tardive muscle rigidity,1
SAPHRIS,muscle rigidity,symptoms included dystonia blepharospasm torticollis dyskinesia tardive dyskinesia,0
SAPHRIS,muscle rigidity,blepharospasm torticollis dyskinesia tardive muscle rigidity parkinsonism gait,1
SAPHRIS,muscle rigidity,symptoms included dystonia blepharospasm torticollis dyskinesia tardive dyskinesia,0
SAPHRIS,parkinsonism,rigidity,0
SAPHRIS,parkinsonism,tardive dyskinesia muscle parkinsonism gait disturbance,1
SAPHRIS,parkinsonism,rigidity,0
SAPHRIS,parkinsonism,and tremor excluding akathisia,0
SAPHRIS,parkinsonism,parkinsonism gait disturbance masked facies,1
SAPHRIS,parkinsonism,parkinsonism gait disturbance,1
SAPHRIS,parkinsonism,muscle,0
SAPHRIS,gait disturbance,gait disturbance masked facies and tremor excluding,1
SAPHRIS,gait disturbance,gait disturbance masked facies,1
SAPHRIS,gait disturbance,gait disturbance masked facies and tremor excluding,1
SAPHRIS,gait disturbance,gait disturbance masked facies and,1
SAPHRIS,masked facies,rigidity parkinsonism,0
SAPHRIS,masked facies,muscle rigidity parkinsonism gait disturbance,0
SAPHRIS,masked facies,and tremor excluding akathisia Somnolence includes the following events,0
SAPHRIS,masked facies,muscle rigidity parkinsonism gait masked facies,1
SAPHRIS,masked facies,masked facies,1
SAPHRIS,masked facies,parkinsonism gait masked facies,1
SAPHRIS,masked facies,excluding,0
SAPHRIS,tremor,somnolence,0
SAPHRIS,tremor,tremor excluding akathisia Somnolence,1
SAPHRIS,tremor,tremor,1
SAPHRIS,tremor,gait disturbance masked facies tremor excluding,1
SAPHRIS,tremor,tremor,1
SAPHRIS,tremor,tremor excluding akathisia Somnolence,1
SAPHRIS,tremor,tremor excluding akathisia Somnolence includes the,1
SAPHRIS,akathisia,akathisia Somnolence includes,1
SAPHRIS,akathisia,akathisia Somnolence includes the following,1
SAPHRIS,akathisia,akathisia Somnolence includes,1
SAPHRIS,akathisia,disturbance masked facies and tremor,0
SAPHRIS,akathisia,events somnolence sedation,0
SAPHRIS,akathisia,akathisia Somnolence includes the,1
SAPHRIS,akathisia,tremor akathisia,1
SAPHRIS,akathisia,akathisia Somnolence includes the,1
SAPHRIS,akathisia,somnolence sedation and hypersomnia,0
SAPHRIS,Somnolence,facies and tremor excluding akathisia,0
SAPHRIS,Somnolence,Somnolence includes the following events,1
SAPHRIS,Somnolence,facies and tremor excluding akathisia,0
SAPHRIS,Somnolence,Somnolence,1
SAPHRIS,Somnolence,Somnolence includes,1
SAPHRIS,Somnolence,rigidity,0
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence sedation and hypersomnia,1
SAPHRIS,somnolence,somnolence,1
SAPHRIS,somnolence,somnolence sedation,1
SAPHRIS,somnolence,somnolence sedation and hypersomnia System,1
SAPHRIS,somnolence,facies and tremor excluding akathisia Somnolence includes,0
SAPHRIS,sedation,sedation and,1
SAPHRIS,sedation,and hypersomnia System Organ ClassPreferred,0
SAPHRIS,sedation,sedation and hypersomnia System,1
SAPHRIS,sedation,and tremor excluding akathisia Somnolence includes the following,0
SAPHRIS,hypersomnia,hypersomnia System Organ ClassPreferred,1
SAPHRIS,hypersomnia,hypersomnia System Organ ClassPreferred,1
SAPHRIS,hypersomnia,events,0
SAPHRIS,hypersomnia,somnolence sedation hypersomnia System Organ ClassPreferred Term Placebo,1
SAPHRIS,hypersomnia,events,0
SAPHRIS,hypersomnia,sedation hypersomnia System Organ ClassPreferred Term Placebo,1
SAPHRIS,hypersomnia,events,0
SAPHRIS,hypersomnia,Organ,0
SAPHRIS,hypersomnia,sedation and,0
SAPHRIS,abdominal pain,in the mg twice daily group and nausea in the mg twice daily,0
SAPHRIS,abdominal pain,mg twice daily abdominal pain in the mg twice,1
SAPHRIS,abdominal pain,in the mg twice daily group and nausea in the mg twice daily,0
SAPHRIS,abdominal pain,in the mg twice daily group and in the mg twice daily,0
SAPHRIS,abdominal pain,abdominal pain,1
SAPHRIS,tachycardia,terms oral hypoesthesia oral paresthesia,0
SAPHRIS,tachycardia,oral hypoesthesia oral,0
SAPHRIS,tachycardia,a,0
SAPHRIS,tachycardia,tachycardia and heart,1
SAPHRIS,tachycardia,Placebo Group,0
SAPHRIS,heart rate increased,tachycardia heart,1
SAPHRIS,heart rate increased,rate increased Includes the,1
SAPHRIS,heart rate increased,heart rate increased Includes,1
SAPHRIS,heart rate increased,rate increased Includes the preferred,1
SAPHRIS,heart rate increased,and,0
SAPHRIS,heart rate increased,rate increased Includes,1
SAPHRIS,heart rate increased,the Placebo Group in a Week Bipolar Mania Trial Includes the,0
SAPHRIS,heart rate increased,heart rate increased Includes the preferred terms oral,1
SAPHRIS,heart rate increased,Includes the preferred,0
SAPHRIS,oral hypoesthesia,terms,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,increased Includes the preferred terms,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,tachycardia and heart rate increased Includes the preferred terms,0
SAPHRIS,oral hypoesthesia,Includes the,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,Includes the,0
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral hypoesthesia,Includes the preferred oral hypoesthesia oral paresthesia,1
SAPHRIS,oral hypoesthesia,oral hypoesthesia,1
SAPHRIS,oral paresthesia,oral oral paresthesia and oral dysesthesia Includes,1
SAPHRIS,oral paresthesia,oral hypoesthesia,1
SAPHRIS,oral paresthesia,the preferred terms oral oral paresthesia and oral dysesthesia Includes the,1
SAPHRIS,oral paresthesia,oral hypoesthesia,1
SAPHRIS,oral paresthesia,terms oral oral paresthesia,1
SAPHRIS,oral paresthesia,oral hypoesthesia,1
SAPHRIS,oral paresthesia,hypoesthesia,0
SAPHRIS,oral dysesthesia,oral paresthesia and,0
SAPHRIS,oral dysesthesia,oral dysesthesia Includes the preferred terms abdominal,1
SAPHRIS,oral dysesthesia,paresthesia oral dysesthesia Includes the preferred,1
SAPHRIS,oral dysesthesia,oral dysesthesia Includes the preferred terms abdominal,1
SAPHRIS,oral dysesthesia,paresthesia oral dysesthesia,1
SAPHRIS,oral dysesthesia,oral paresthesia oral dysesthesia Includes the,1
SAPHRIS,oral dysesthesia,paresthesia oral dysesthesia,1
SAPHRIS,oral dysesthesia,paresthesia oral dysesthesia Includes the preferred terms,1
SAPHRIS,oral dysesthesia,paresthesia oral dysesthesia,1
SAPHRIS,oral dysesthesia,preferred terms oral hypoesthesia oral,0
SAPHRIS,abdominal pain,erms oral hypoesthesia oral paresthesia and oral dysesthesia Includes,0
SAPHRIS,abdominal pain,and abdominal,0
SAPHRIS,abdominal pain,discomfort Includes,0
SAPHRIS,abdominal pain,lower,0
SAPHRIS,abdominal pain,preferred abdominal pain,1
SAPHRIS,abdominal pain,lower,0
SAPHRIS,abdominal pain,Includes the,0
SAPHRIS,abdominal pain,oral,0
SAPHRIS,abdominal pain upper,preferred terms,0
SAPHRIS,abdominal pain upper,abdominal abdominal,1
SAPHRIS,abdominal pain upper,Includes the,0
SAPHRIS,abdominal pain upper,terms abdominal abdominal pain upper,1
SAPHRIS,abdominal pain upper,Includes the,0
SAPHRIS,abdominal pain upper,abdominal pain upper abdominal pain lower and abdominal,1
SAPHRIS,abdominal pain upper,the preferred terms abdominal abdominal pain upper abdominal,1
SAPHRIS,abdominal pain upper,abdominal pain upper abdominal pain lower and abdominal,1
SAPHRIS,abdominal pain upper,terms abdominal abdominal pain upper abdominal,1
SAPHRIS,abdominal pain upper,abdominal pain upper abdominal pain lower and abdominal,1
SAPHRIS,abdominal pain upper,pain upper abdominal pain lower and abdominal,1
SAPHRIS,abdominal pain lower,pain,0
SAPHRIS,abdominal pain lower,oral dysesthesia Includes,0
SAPHRIS,abdominal pain lower,pain lower,1
SAPHRIS,abdominal pain lower,pain abdominal pain lower and abdominal discomfort,1
SAPHRIS,abdominal pain lower,pain lower,1
SAPHRIS,abdominal pain lower,Includes the,0
SAPHRIS,abdominal pain lower,abdominal discomfort Includes,0
SAPHRIS,abdominal pain lower,Includes the preferred terms abdominal,0
SAPHRIS,abdominal discomfort,and,0
SAPHRIS,abdominal discomfort,abdominal discomfort Includes the preferred,1
SAPHRIS,abdominal discomfort,abdominal discomfort Includes the preferred terms,1
SAPHRIS,abdominal discomfort,abdominal discomfort Includes,1
SAPHRIS,abdominal discomfort,preferred terms abdominal pain abdominal pain,0
SAPHRIS,abdominal discomfort,pain lower abdominal discomfort Includes the,1
SAPHRIS,abdominal discomfort,preferred terms abdominal pain abdominal pain,0
SAPHRIS,abdominal discomfort,abdominal pain,0
SAPHRIS,abdominal discomfort,upper abdominal pain lower abdominal discomfort Includes the preferred terms fatigue,1
SAPHRIS,abdominal discomfort,abdominal pain,0
SAPHRIS,abdominal discomfort,abdominal pain lower abdominal discomfort,1
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,fatigue and,1
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,discomfort Includes the preferred fatigue and lethargy Includes the preferred,1
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,preferred fatigue,1
SAPHRIS,fatigue,fatigue,1
SAPHRIS,fatigue,fatigue,1
SAPHRIS,lethargy,the preferred terms fatigue lethargy Includes the preferred terms,1
SAPHRIS,lethargy,fatigue,1
SAPHRIS,lethargy,lethargy,1
SAPHRIS,lethargy,the preferred terms fatigue lethargy Includes the preferred terms hyperinsulinemia,1
SAPHRIS,lethargy,lethargy,1
SAPHRIS,lethargy,preferred terms fatigue lethargy Includes,1
SAPHRIS,lethargy,lethargy,1
SAPHRIS,lethargy,insulin,0
SAPHRIS,lethargy,terms fatigue lethargy Includes,1
SAPHRIS,lethargy,insulin,0
SAPHRIS,lethargy,lethargy Includes the preferred terms,1
SAPHRIS,lethargy,lethargy Includes,1
SAPHRIS,lethargy,lethargy Includes the preferred terms,1
SAPHRIS,lethargy,terms fatigue,0
SAPHRIS,hyperinsulinemia,hyperinsulinemia and blood,1
SAPHRIS,hyperinsulinemia,lethargy Includes the preferred hyperinsulinemia and blood insulin increased,1
SAPHRIS,hyperinsulinemia,hyperinsulinemia and blood,1
SAPHRIS,hyperinsulinemia,hyperinsulinemia and blood insulin,1
SAPHRIS,hyperinsulinemia,preferred,0
SAPHRIS,hyperinsulinemia,hyperinsulinemia and blood insulin increased Includes,1
SAPHRIS,hyperinsulinemia,hyperinsulinemia and blood insulin increased,1
SAPHRIS,blood insulin increased,blood insulin increased Includes the,1
SAPHRIS,blood insulin increased,blood insulin increased Includes the preferred,1
SAPHRIS,blood insulin increased,blood insulin increased Includes the,1
SAPHRIS,blood insulin increased,hyperinsulinemia blood insulin increased,1
SAPHRIS,blood insulin increased,blood insulin increased Includes the,1
SAPHRIS,blood insulin increased,the preferred terms hyperinsulinemia blood,1
SAPHRIS,blood insulin increased,the preferred terms somnolence sedation,0
SAPHRIS,sedation,increased Includes the,0
SAPHRIS,sedation,sedation and,1
SAPHRIS,sedation,terms somnolence,0
SAPHRIS,sedation,sedation and,1
SAPHRIS,sedation,terms somnolence,0
SAPHRIS,sedation,the preferred,0
SAPHRIS,sedation,insulin increased Includes the preferred,0
SAPHRIS,sedation,System Organ,0
SAPHRIS,sedation,and blood insulin,0
SAPHRIS,sedation,Includes the preferred terms sedation and hypersomnia System,1
SAPHRIS,sedation,and blood insulin,0
SAPHRIS,fatigue,bipolar trials the incidence fatigue appeared to be doserelated see,1
SAPHRIS,fatigue,and blood insulin,0
SAPHRIS,fatigue,be doserelated,0
SAPHRIS,depression,ideation bipolar,0
SAPHRIS,depression,depression suicidal ideation bipolar I disorder,1
SAPHRIS,depression,disorder insomnia,0
SAPHRIS,depression,depression,1
SAPHRIS,suicidal ideation,and at least,0
SAPHRIS,suicidal ideation,disorder insomnia and depressive symptoms,0
SAPHRIS,suicidal ideation,suicidal ideation,1
SAPHRIS,suicidal ideation,disorder insomnia and depressive symptoms,0
SAPHRIS,suicidal ideation,suicidal ideation bipolar I disorder insomnia and,1
SAPHRIS,suicidal ideation,suicidal ideation,1
SAPHRIS,suicidal ideation,suicidal ideation bipolar I disorder insomnia and,1
SAPHRIS,bipolar I disorder,rate were depression suicidal bipolar I disorder,1
SAPHRIS,bipolar I disorder,suicidal ideation bipolar I disorder insomnia and,1
SAPHRIS,bipolar I disorder,rate were depression suicidal bipolar I disorder insomnia and depressive,1
SAPHRIS,bipolar I disorder,suicidal ideation bipolar I disorder insomnia and,1
SAPHRIS,bipolar I disorder,bipolar,1
SAPHRIS,bipolar I disorder,at least twice the placebo,0
SAPHRIS,bipolar I disorder,bipolar,1
SAPHRIS,bipolar I disorder,bipolar I disorder insomnia and depressive,1
SAPHRIS,insomnia,ideation bipolar I disorder,0
SAPHRIS,insomnia,insomnia,1
SAPHRIS,insomnia,insomnia and depressive symptoms,1
SAPHRIS,insomnia,insomnia,1
SAPHRIS,insomnia,at an Incidence,0
SAPHRIS,insomnia,insomnia and depressive symptoms Adverse Reactions,1
SAPHRIS,depressive symptoms,depressive symptoms Adverse,1
SAPHRIS,depressive symptoms,bipolar I disorder insomnia depressive symptoms Adverse Reactions Occurring,1
SAPHRIS,depressive symptoms,depressive symptoms Adverse,1
SAPHRIS,depressive symptoms,and,0
SAPHRIS,depressive symptoms,Incidence of,0
SAPHRIS,depressive symptoms,and,0
SAPHRIS,depressive symptoms,disorder insomnia depressive,1
SAPHRIS,depressive symptoms,or More Among SAPHRISTreated,0
SAPHRIS,depressive symptoms,depressive symptoms Adverse Reactions Occurring at,1
SAPHRIS,dystonia,mg to mg twice daily,0
SAPHRIS,dystonia,dystonia parkinsonism oculogyration and tremor excluding,1
SAPHRIS,dystonia,flexible dosing Extrapyramidal symptoms included,0
SAPHRIS,dystonia,Extrapyramidal symptoms dystonia parkinsonism oculogyration and,1
SAPHRIS,dystonia,flexible dosing Extrapyramidal symptoms included,0
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,flexible dosing Extrapyramidal symptoms dystonia parkinsonism,1
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,flexible dosing,0
SAPHRIS,dystonia,dystonia parkinsonism oculogyration and tremor,1
SAPHRIS,dystonia,oculogyration,0
SAPHRIS,dystonia,oculogyration and,0
SAPHRIS,parkinsonism,parkinsonism oculogyration and,1
SAPHRIS,parkinsonism,parkinsonism oculogyration and tremor excluding,1
SAPHRIS,parkinsonism,parkinsonism oculogyration and tremor,1
SAPHRIS,parkinsonism,dosing Extrapyramidal symptoms included dystonia,0
SAPHRIS,parkinsonism,parkinsonism oculogyration,1
SAPHRIS,parkinsonism,Extrapyramidal symptoms included dystonia,0
SAPHRIS,parkinsonism,with flexible dosing Extrapyramidal,0
SAPHRIS,oculogyration,oculogyration and,1
SAPHRIS,oculogyration,with flexible dosing Extrapyramidal,0
SAPHRIS,oculogyration,oculogyration,1
SAPHRIS,oculogyration,oculogyration and tremor excluding akathisia,1
SAPHRIS,oculogyration,Extrapyramidal symptoms included dystonia oculogyration and,1
SAPHRIS,oculogyration,oculogyration and tremor excluding akathisia,1
SAPHRIS,oculogyration,flexible dosing Extrapyramidal symptoms included dystonia,0
SAPHRIS,oculogyration,Somnolence includes the,0
SAPHRIS,oculogyration,oculogyration and tremor excluding akathisia,1
SAPHRIS,oculogyration,dosing Extrapyramidal symptoms included,0
SAPHRIS,oculogyration,included dystonia oculogyration and tremor excluding akathisia Somnolence,1
SAPHRIS,oculogyration,dosing Extrapyramidal symptoms included,0
SAPHRIS,oculogyration,excluding akathisia Somnolence includes the,0
SAPHRIS,tremor,excluding akathisia Somnolence includes the following,0
SAPHRIS,tremor,tremor excluding akathisia,1
SAPHRIS,akathisia,and sedation System Organ,0
SAPHRIS,akathisia,Somnolence includes the,0
SAPHRIS,akathisia,akathisia Somnolence includes the following,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,parkinsonism oculogyration and tremor excluding,0
SAPHRIS,akathisia,oculogyration,0
SAPHRIS,Somnolence,and tremor excluding Somnolence includes the following events,1
SAPHRIS,Somnolence,oculogyration,0
SAPHRIS,Somnolence,System,0
SAPHRIS,Somnolence,includes the following events,0
SAPHRIS,Somnolence,Somnolence includes the following events somnolence,1
SAPHRIS,Somnolence,Somnolence includes the following events,1
SAPHRIS,somnolence,events,0
SAPHRIS,somnolence,the following somnolence and sedation,1
SAPHRIS,somnolence,events,0
SAPHRIS,somnolence,sedation System Organ ClassPreferred Term Placebo N,0
SAPHRIS,somnolence,somnolence and sedation System Organ ClassPreferred,1
SAPHRIS,somnolence,the following somnolence and sedation System,1
SAPHRIS,somnolence,somnolence and sedation System Organ ClassPreferred,1
SAPHRIS,somnolence,Term Placebo,0
SAPHRIS,sedation,events somnolence,0
SAPHRIS,sedation,sedation System Organ ClassPreferred Term,1
SAPHRIS,sedation,Organ ClassPreferred Term Placebo,0
SAPHRIS,sedation,following,0
SAPHRIS,sedation,ClassPreferred Term Placebo N SAPHRIS,0
SAPHRIS,sedation,somnolence sedation System Organ ClassPreferred,1
SAPHRIS,sedation,ClassPreferred Term Placebo N SAPHRIS,0
SAPHRIS,sedation,the following events somnolence sedation,1
SAPHRIS,sedation,ClassPreferred Term Placebo N SAPHRIS,0
SAPHRIS,sedation,and tremor,0
SAPHRIS,sedation,tremor excluding akathisia Somnolence includes,0
SAPHRIS,dystonia,dystonia prolonged,1
SAPHRIS,dystonia,of,0
SAPHRIS,prolonged abnormal contractions of muscle groups,prolonged abnormal contractions of muscle groups may occur in,1
SAPHRIS,prolonged abnormal contractions of muscle groups,of,0
SAPHRIS,prolonged abnormal contractions of muscle groups,contractions of muscle groups may occur,1
SAPHRIS,prolonged abnormal contractions of muscle groups,Dystonia Symptoms of,0
SAPHRIS,prolonged abnormal contractions of muscle groups,Dystonia Symptoms of dystonia,0
SAPHRIS,prolonged abnormal contractions of muscle groups,individuals during the first few days of treatment,0
SAPHRIS,prolonged abnormal contractions of muscle groups,in susceptible individuals during the first few days of treatment Dystonic,0
SAPHRIS,Dystonic symptoms,of muscle groups may occur in susceptible individuals during the first,0
SAPHRIS,Dystonic symptoms,treatment,0
SAPHRIS,Dystonic symptoms,Dystonic symptoms include spasm of the neck,1
SAPHRIS,Dystonic symptoms,Dystonic symptoms include spasm of the,1
SAPHRIS,Dystonic symptoms,Dystonic symptoms include spasm of the neck,1
SAPHRIS,spasm of the neck muscles,symptoms spasm of the,1
SAPHRIS,spasm of the neck muscles,spasm of the neck muscles sometimes progressing to tightness of,1
SAPHRIS,spasm of the neck muscles,of treatment Dystonic symptoms spasm of the neck muscles,1
SAPHRIS,spasm of the neck muscles,spasm of the neck muscles sometimes progressing to tightness of,1
SAPHRIS,spasm of the neck muscles,neck muscles sometimes,1
SAPHRIS,spasm of the neck muscles,the first few days of treatment Dystonic symptoms include,0
SAPHRIS,spasm of the neck muscles,of treatment Dystonic symptoms spasm of,1
SAPHRIS,spasm of the neck muscles,difficulty,0
SAPHRIS,spasm of the neck muscles,Dystonic symptoms spasm of the neck muscles sometimes progressing to tightness of,1
SAPHRIS,spasm of the neck muscles,difficulty,0
SAPHRIS,spasm of the neck muscles,spasm of,1
SAPHRIS,tightness of the throat,andor protrusion of the tongue While these,0
SAPHRIS,tightness of the throat,muscles sometimes,0
SAPHRIS,tightness of the throat,tightness of the throat swallowing difficulty difficulty,1
SAPHRIS,tightness of the throat,muscles sometimes,0
SAPHRIS,tightness of the throat,swallowing difficulty difficulty breathing andor protrusion of the tongue While,0
SAPHRIS,tightness of the throat,progressing tightness,1
SAPHRIS,swallowing difficulty,of the neck,0
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing,1
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing andor protrusion of,1
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing,1
SAPHRIS,swallowing difficulty,symptoms,0
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing andor protrusion,1
SAPHRIS,swallowing difficulty,tightness of the swallowing difficulty,1
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing andor protrusion,1
SAPHRIS,swallowing difficulty,of the swallowing difficulty difficulty breathing andor,1
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing andor protrusion,1
SAPHRIS,swallowing difficulty,of the swallowing difficulty difficulty breathing andor,1
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing andor protrusion,1
SAPHRIS,swallowing difficulty,tightness of the swallowing difficulty difficulty breathing andor protrusion,1
SAPHRIS,swallowing difficulty,swallowing difficulty difficulty breathing andor protrusion,1
SAPHRIS,difficulty breathing,difficulty breathing,1
SAPHRIS,difficulty breathing,symptoms can occur,0
SAPHRIS,difficulty breathing,of the throat swallowing difficulty,0
SAPHRIS,protrusion of the tongue,the throat swallowing difficulty difficulty breathing,0
SAPHRIS,protrusion of the tongue,of the tongue,1
SAPHRIS,protrusion of the tongue,occur at low,0
SAPHRIS,protrusion of the tongue,andor,0
SAPHRIS,acute dystonia,is observed in males and younger age groups see Dosage and Administration Use in Specific,0
SAPHRIS,extrapyramidal symptoms,Simpson Angus Rating Scale extrapyramidal,1
SAPHRIS,extrapyramidal symptoms,Scale extrapyramidal,1
SAPHRIS,extrapyramidal symptoms,akathisia and the,0
SAPHRIS,EPS,EPS,1
SAPHRIS,EPS,the Assessments of Involuntary,0
SAPHRIS,EPS,EPS the Barnes Akathisia Scale,1
SAPHRIS,EPS,collected on the,0
SAPHRIS,EPS,for akathisia and the Assessments of,0
SAPHRIS,EPS,extrapyramidal symptoms,0
SAPHRIS,EPS,EPS the Barnes Akathisia,1
SAPHRIS,EPS,akathisia and the Assessments of Involuntary,0
SAPHRIS,akathisia,symptoms EPS the Barnes,0
SAPHRIS,akathisia,akathisia and,1
SAPHRIS,akathisia,akathisia and,1
SAPHRIS,akathisia,Barnes Akathisia Scale for,0
SAPHRIS,akathisia,change from,0
SAPHRIS,akathisia,akathisia and the,1
SAPHRIS,dyskinesias,dyskinesias The,1
SAPHRIS,dyskinesias,Scales dyskinesias The mean change,1
SAPHRIS,dyskinesias,dyskinesias The,1
SAPHRIS,EPS-related events,placebocontrolled schizophrenia adult trials the incidence of,0
SAPHRIS,EPS-related events,the incidence,0
SAPHRIS,EPS-related events,excluding events,0
SAPHRIS,akathisia,akathisia related events for,1
SAPHRIS,EPS-related events,In shortterm placebocontrolled bipolar mania adult trials,0
SAPHRIS,EPS-related events,was,0
SAPHRIS,EPS-related events,shortterm placebocontrolled bipolar mania adult trials the incidence,0
SAPHRIS,EPS-related events,placebo In shortterm placebocontrolled bipolar mania adult trials the,0
SAPHRIS,EPS-related events,the,0
SAPHRIS,EPS-related events,EPS-related events excluding events related to akathisia,1
SAPHRIS,EPS-related events,EPS-related events excluding events related to akathisia,1
SAPHRIS,EPS-related events,EPS-related events excluding events related to akathisia,1
SAPHRIS,EPS-related events,adult trials the incidence,0
SAPHRIS,EPS-related events,EPS-related events,1
SAPHRIS,EPS-related events,the,0
SAPHRIS,akathisia,versus for,0
SAPHRIS,akathisia,versus for placebo and the,0
SAPHRIS,akathisia,akathisia for SAPHRIStreated patients was,1
SAPHRIS,akathisia,akathisia for,1
SAPHRIS,akathisia,akathisia for,1
SAPHRIS,akathisia,EPSrelated events excluding events related,0
SAPHRIS,akathisia,akathisia for SAPHRIStreated patients was,1
SAPHRIS,akathisia,akathisia for SAPHRIStreated patients was,1
SAPHRIS,akathisia,the incidence akathisia related events for SAPHRIStreated patients,1
SAPHRIS,akathisia,akathisia for SAPHRIStreated patients was,1
SAPHRIS,akathisia,and the incidence,0
SAPHRIS,akathisia,SAPHRIStreated patients,0
SAPHRIS,akathisia,In a week,0
SAPHRIS,akathisia,placebo and the incidence akathisia related events,1
SAPHRIS,akathisia,In a week,0
SAPHRIS,akathisia,akathisia related events for,1
SAPHRIS,akathisia,akathisia related events for SAPHRIStreated patients,1
SAPHRIS,akathisia,akathisia related events for,1
SAPHRIS,EPS-related events,with SAPHRIS m,0
SAPHRIS,akathisia,mg twice daily,0
SAPHRIS,akathisia,mg twice daily,0
SAPHRIS,akathisia,excluding events related akathisia were and for patients treated,1
SAPHRIS,akathisia,mg twice daily,0
SAPHRIS,EPS-related events,respectively as compared to for placebotreated,0
SAPHRIS,EPS-related events,to for placebotreated EPS-related events,1
SAPHRIS,EPS-related events,daily respectively as,0
SAPHRIS,bradykinesia,bradykinesia dyskinesia dystonia oromandibular,1
SAPHRIS,bradykinesia,oromandibular dystonia muscle contractions,0
SAPHRIS,bradykinesia,to for placebotreated patients,0
SAPHRIS,bradykinesia,placebotreated patients EPSrelated events bradykinesia dyskinesia dystonia oromandibular dystonia muscle,1
SAPHRIS,bradykinesia,to for placebotreated patients,0
SAPHRIS,bradykinesia,bradykinesia dyskinesia dystonia oromandibular,1
SAPHRIS,bradykinesia,bradykinesia dyskinesia dystonia oromandibular,1
SAPHRIS,bradykinesia,bradykinesia dyskinesia dystonia oromandibular,1
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular dystonia muscle contractions,1
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular dystonia muscle,1
SAPHRIS,dyskinesia,include bradykinesia,0
SAPHRIS,dyskinesia,patients EPSrelated events include bradykinesia,0
SAPHRIS,dyskinesia,include dyskinesia dystonia oromandibular,1
SAPHRIS,dyskinesia,patients EPSrelated events include bradykinesia,0
SAPHRIS,dyskinesia,EPSrelated events include dyskinesia dystonia,1
SAPHRIS,dyskinesia,patients EPSrelated events include bradykinesia,0
SAPHRIS,dyskinesia,as compared to for placebotreated patients EPSrelated events include,0
SAPHRIS,dyskinesia,involuntary muscle twitching,0
SAPHRIS,dyskinesia,dyskinesia,1
SAPHRIS,dyskinesia,dyskinesia dystonia oromandibular,1
SAPHRIS,dystonia,dystonia oromandibular dystonia muscle contractions involuntary,1
SAPHRIS,dystonia,dyskinesia,0
SAPHRIS,dystonia,dystonia,1
SAPHRIS,dystonia,dystonia oromandibular,1
SAPHRIS,dystonia,dystonia muscle contractions,0
SAPHRIS,dystonia,oromandibular dystonia muscle,0
SAPHRIS,oromandibular dystonia,oromandibular dystonia muscle,1
SAPHRIS,oromandibular dystonia,events include bradykinesia dyskinesia oromandibular dystonia muscle contractions,1
SAPHRIS,oromandibular dystonia,oromandibular dystonia muscle,1
SAPHRIS,oromandibular dystonia,events include bradykinesia dyskinesia oromandibular dystonia,1
SAPHRIS,oromandibular dystonia,oromandibular dystonia muscle,1
SAPHRIS,oromandibular dystonia,oromandibular dystonia,1
SAPHRIS,oromandibular dystonia,oromandibular,1
SAPHRIS,muscle contractions involuntary,oromandibular,0
SAPHRIS,muscle contractions involuntary,bradykinesia dyskinesia dystonia oromandibular muscle contractions,1
SAPHRIS,muscle contractions involuntary,muscle contractions involuntary,1
SAPHRIS,muscle contractions involuntary,contractions involuntary,1
SAPHRIS,muscle twitching,dystonia muscle contractions muscle twitching,1
SAPHRIS,muscle twitching,contractions involuntary,1
SAPHRIS,muscle twitching,muscle twitching musculoskeletal stiffness parkinsonism protrusion tongue,1
SAPHRIS,muscle twitching,muscle twitching musculoskeletal,1
SAPHRIS,muscle twitching,muscle twitching musculoskeletal stiffness parkinsonism protrusion,1
SAPHRIS,muscle twitching,contractions muscle twitching musculoskeletal stiffness parkinsonism protrusion tongue,1
SAPHRIS,muscle twitching,muscle twitching musculoskeletal stiffness parkinsonism protrusion,1
SAPHRIS,muscle twitching,dystonia muscle contractions muscle,1
SAPHRIS,muscle twitching,and tremor,0
SAPHRIS,muscle twitching,dystonia muscle contractions muscle twitching,1
SAPHRIS,muscle twitching,oromandibular dystonia muscle contractions muscle,1
SAPHRIS,muscle twitching,muscle twitching musculoskeletal stiffness parkinsonism protrusion tongue,1
SAPHRIS,musculoskeletal stiffness,protrusion tongue resting tremor and tremor For events,0
SAPHRIS,musculoskeletal stiffness,parkinsonism protrusion tongue resting tremor and tremor For events of akathisia,0
SAPHRIS,musculoskeletal stiffness,musculoskeletal stiffness parkinsonism protrusion,1
SAPHRIS,musculoskeletal stiffness,events of,0
SAPHRIS,musculoskeletal stiffness,dystonia muscle contractions involuntary muscle twitching,0
SAPHRIS,musculoskeletal stiffness,involuntary muscle musculoskeletal stiffness,1
SAPHRIS,musculoskeletal stiffness,muscle contractions involuntary muscle musculoskeletal stiffness parkinsonism protrusion tongue resting,1
SAPHRIS,musculoskeletal stiffness,involuntary muscle musculoskeletal stiffness,1
SAPHRIS,musculoskeletal stiffness,contractions involuntary muscle musculoskeletal stiffness,1
SAPHRIS,musculoskeletal stiffness,musculoskeletal,1
SAPHRIS,musculoskeletal stiffness,involuntary muscle musculoskeletal stiffness parkinsonism protrusion,1
SAPHRIS,musculoskeletal stiffness,musculoskeletal,1
SAPHRIS,parkinsonism,muscle,0
SAPHRIS,parkinsonism,parkinsonism protrusion tongue resting,1
SAPHRIS,parkinsonism,parkinsonism protrusion tongue resting tremor and,1
SAPHRIS,parkinsonism,parkinsonism protrusion,1
SAPHRIS,parkinsonism,parkinsonism protrusion tongue,1
SAPHRIS,protrusion tongue,muscle twitching musculoskeletal stiffness protrusion tongue resting,1
SAPHRIS,protrusion tongue,parkinsonism protrusion tongue,1
SAPHRIS,resting tremor,resting tremor and tremor For events of,1
SAPHRIS,resting tremor,resting tremor and tremor,1
SAPHRIS,resting tremor,protrusion resting,1
SAPHRIS,resting tremor,twitching musculoskeletal stiffness parkinsonism protrusion tongue,0
SAPHRIS,resting tremor,protrusion resting,1
SAPHRIS,resting tremor,ractions involuntary muscle,0
SAPHRIS,resting tremor,protrusion resting tremor and tremor For events,1
SAPHRIS,resting tremor,ractions involuntary muscle,0
SAPHRIS,resting tremor,resting tremor and tremor For events of,1
SAPHRIS,resting tremor,resting tremor and tremor For events of,1
SAPHRIS,resting tremor,musculoskeletal stiffness parkinsonism protrusion resting tremor,1
SAPHRIS,tremor,tremor For events of akathisia incidences,1
SAPHRIS,tremor,treated,0
SAPHRIS,akathisia,For events akathisia incidences were and for,1
SAPHRIS,akathisia,treated,0
SAPHRIS,akathisia,akathisia incidences were and,1
SAPHRIS,akathisia,akathisia incidences were and,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,akathisia,1
SAPHRIS,akathisia,akathisia incidences were and for,1
SAPHRIS,Oral hypoesthesia,usually resolves wit,0
SAPHRIS,Oral hypoesthesia,administration,0
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia andor oral,1
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia andor oral,1
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia andor oral,1
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia,1
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia,1
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia andor oral paresthesia may,1
SAPHRIS,Oral hypoesthesia,patients Other,0
SAPHRIS,Oral hypoesthesia,for placebotreated patients Other Findings,0
SAPHRIS,Oral hypoesthesia,Oral hypoesthesia andor oral paresthesia may occur,1
SAPHRIS,oral paresthesia,andor,0
SAPHRIS,increase in transaminase levels,transaminase levels for,1
SAPHRIS,increase in transaminase levels,mania trials the increase in transaminase levels for SAPHRIStreated patients was,1
SAPHRIS,increase in transaminase levels,transaminase levels for,1
SAPHRIS,increase in transaminase levels,in transaminase levels,1
SAPHRIS,increase in transaminase levels,increase in transaminase levels for,1
SAPHRIS,increase in transaminase levels,the increase in transaminase levels for SAPHRIStreated patients was unitsL,1
SAPHRIS,increase in transaminase levels,increase in transaminase levels for,1
SAPHRIS,increase in transaminase levels,adult mania trials the increase,1
SAPHRIS,increase in transaminase levels,mean,0
SAPHRIS,increase in transaminase levels,in transaminase levels for,1
SAPHRIS,increase in transaminase levels,the increase in transaminase levels,1
SAPHRIS,increase in transaminase levels,in transaminase levels for,1
SAPHRIS,transaminase elevations,of patients transaminase elevations times upper limit of normal,1
SAPHRIS,transaminase elevations,in transaminase levels for,1
SAPHRIS,transaminase elevations,of unitsL in placebotreated,0
SAPHRIS,transaminase elevations,of patients transaminase elevations times upper limit of normal,1
SAPHRIS,transaminase elevations,of unitsL in placebotreated,0
SAPHRIS,transaminase elevations,ULN at,0
SAPHRIS,transaminase elevations,for SAPHRIStreated patients,0
SAPHRIS,transaminase elevations,unitsL in placebotreated patients,0
SAPHRIS,transaminase elevations,The proportion of patients transaminase elevations times upper limit of normal,1
SAPHRIS,transaminase elevations,unitsL in placebotreated patients,0
SAPHRIS,transaminase elevations,patients transaminase elevations times upper limit,1
SAPHRIS,transaminase elevations,unitsL in placebotreated patients,0
SAPHRIS,elevations in serum transaminases,I disorder,0
SAPHRIS,elevations in serum transaminases,I disorder,0
SAPHRIS,elevations in serum transaminases,elevations in serum transaminases primarily ALT were,1
SAPHRIS,elevations in serum transaminases,bipolar I disorder elevations in serum transaminases primarily ALT were more common,1
SAPHRIS,elevations in serum transaminases,elevations in serum transaminases primarily ALT were,1
SAPHRIS,elevations in serum transaminases,In a week placebocontrolled pediatric,0
SAPHRIS,elevations in serum transaminases,disorder elevations in serum transaminases primarily ALT were more,1
SAPHRIS,elevations in serum transaminases,In a week placebocontrolled pediatric,0
SAPHRIS,elevations in serum transaminases,patients with,0
SAPHRIS,elevations in serum transaminases,disorder elevations in serum transaminases primarily ALT were more,1
SAPHRIS,elevations in serum transaminases,patients with,0
SAPHRIS,ALT elevations,ALT elevations times upper limit of normal,1
SAPHRIS,decreases in prolactin levels,prolactin levels were ngmL,1
SAPHRIS,decreases in prolactin levels,ngmL for placebotreated,0
SAPHRIS,decreases in prolactin levels,schizophrenia trials the decreases,1
SAPHRIS,decreases in prolactin levels,decreases in prolactin levels,1
SAPHRIS,decreases in prolactin levels,decreases in prolactin levels were,1
SAPHRIS,decreases in prolactin levels,decreases in prolactin levels were ngmL for,1
SAPHRIS,decreases in prolactin levels,in prolactin levels were,1
SAPHRIS,decreases in prolactin levels,patients compared to,0
SAPHRIS,decreases in prolactin levels,trials the decreases in prolactin levels,1
SAPHRIS,decreases in prolactin levels,patients compared to,0
SAPHRIS,decreases in prolactin levels,trials the decreases in prolactin levels were ngmL,1
SAPHRIS,decreases in prolactin levels,patients compared to,0
SAPHRIS,prolactin elevations,eated patients compared to ngmL for placebotreated,0
SAPHRIS,increase in prolactin levels,to a decrease,0
SAPHRIS,increase in prolactin levels,mania adult trials the increase in prolactin levels was ngmL,1
SAPHRIS,increase in prolactin levels,to a decrease,0
SAPHRIS,increase in prolactin levels,for SAPHRIStreated patients compared to a decrease of ngmL,0
SAPHRIS,increase in prolactin levels,increase in prolactin levels was ngmL for,1
SAPHRIS,increase in prolactin levels,for SAPHRIStreated patients compared to a decrease of ngmL,0
SAPHRIS,increase in prolactin levels,patients compared to a decrease,0
SAPHRIS,increase in prolactin levels,adult,0
SAPHRIS,increase in prolactin levels,mania adult trials the increase in,1
SAPHRIS,increase in prolactin levels,adult trials the increase in prolactin levels,1
SAPHRIS,increase in prolactin levels,adult trials,0
SAPHRIS,increase in prolactin levels,trials the increase in prolactin levels,1
SAPHRIS,prolactin elevations,of patients prolactin elevations times ULN,1
SAPHRIS,prolactin elevations,trials the increase in prolactin levels,1
SAPHRIS,prolactin elevations,of patients prolactin elevations times,1
SAPHRIS,prolactin elevations,trials the increase in prolactin levels,1
SAPHRIS,prolactin elevations,prolactin elevations times ULN at,1
SAPHRIS,prolactin elevations,prolactin elevations times ULN,1
SAPHRIS,decrease in prolactin,decrease in prolactin from baseline for SAPHRIStreated,1
SAPHRIS,decrease in prolactin,patients with schizophrenia the mean,0
SAPHRIS,decrease in prolactin,included primarily patients,0
SAPHRIS,decrease in prolactin,trial that included,0
SAPHRIS,decrease in prolactin,that included,0
SAPHRIS,decrease in prolactin,with schizophrenia the decrease in prolactin from,1
SAPHRIS,decrease in prolactin,that included,0
SAPHRIS,prolactin elevations,There were no reports prolactin,1
SAPHRIS,prolactin elevations,reports prolactin elevations times ULN,1
SAPHRIS,prolactin elevations,There were no reports prolactin,1
SAPHRIS,prolactin elevations,prolactin elevations times ULN at,1
SAPHRIS,prolactin elevations,There were no reports prolactin,1
SAPHRIS,prolactin elevations,There were no reports prolactin elevations times ULN at Endpoint for,1
SAPHRIS,prolactin elevations,There were no reports prolactin,1
SAPHRIS,Galactorrhea,Galactorrhea or dysmenorrhea,1
SAPHRIS,Galactorrhea,Galactorrhea,1
SAPHRIS,Galactorrhea,Galactorrhea or dysmenorrhea were reported,1
SAPHRIS,Galactorrhea,Galactorrhea or,1
SAPHRIS,Galactorrhea,or Galactorrhea or dysmenorrhea were reported in,1
SAPHRIS,Galactorrhea,Galactorrhea or,1
SAPHRIS,Galactorrhea,with SAPHRIS or placebo,0
SAPHRIS,Galactorrhea,with SAPHRIS or placebo,0
SAPHRIS,Galactorrhea,Galactorrhea or dysmenorrhea,1
SAPHRIS,Galactorrhea,Galactorrhea or dysmenorrhea were,1
SAPHRIS,dysmenorrhea,patients treated with SAPHRIS or placebo Galactorrhea,0
SAPHRIS,dysmenorrhea,or placebo Galactorrhea or,0
SAPHRIS,dysmenorrhea,patients treated with SAPHRIS or,0
SAPHRIS,dysmenorrhea,dysmenorrhea were reported,1
SAPHRIS,dysmenorrhea,or placebo Galactorrhea dysmenorrhea were,1
SAPHRIS,dysmenorrhea,dysmenorrhea were reported,1
SAPHRIS,dysmenorrhea,dysmenorrhea,1
SAPHRIS,dysmenorrhea,placebo Galactorrhea dysmenorrhea were reported,1
SAPHRIS,dysmenorrhea,dysmenorrhea,1
SAPHRIS,gynecomastia,gynecomastia in this trial Creatine,1
SAPHRIS,gynecomastia,gynecomastia in this trial,1
SAPHRIS,gynecomastia,There were no reports gynecomastia in,1
SAPHRIS,gynecomastia,gynecomastia in this trial,1
SAPHRIS,gynecomastia,gynecomastia in this trial Creatine Kinase,1
SAPHRIS,gynecomastia,placebotreated patients There were no reports,0
SAPHRIS,gynecomastia,patients with,0
SAPHRIS,CK elevations,patients,0
SAPHRIS,CK elevations,with,0
SAPHRIS,CK elevations,CK elevations times ULN at any time,1
SAPHRIS,CK elevations,with,0
SAPHRIS,CK elevations,times ULN at any time were,0
SAPHRIS,CK elevations,CK elevations times ULN at any time,1
SAPHRIS,CK elevations,of gynecomastia in this trial Creatine Kinase CK,0
SAPHRIS,CK elevations,adult patients CK elevations times ULN,1
SAPHRIS,CK elevations,of gynecomastia in this trial Creatine Kinase CK,0
SAPHRIS,CK elevations,CK elevations,1
SAPHRIS,CK elevations,treated,0
SAPHRIS,CK elevations,this finding is unknown The,0
SAPHRIS,CK elevations,during a,0
SAPHRIS,CK elevations,disorder at any,0
SAPHRIS,CK elevations,ULN,0
SAPHRIS,CK elevations,CK elevations,1
SAPHRIS,CK elevations,of patients CK elevations times ULN during a,1
SAPHRIS,CK elevations,CK elevations,1
SAPHRIS,CK elevations,of patients with,0
SAPHRIS,CK elevations,trial in pediatric bipolar I disorder at any time,0
SAPHRIS,CK elevations,at any,0
SAPHRIS,anemia,temporary bundle,0
SAPHRIS,anemia,Blood and lymphatic disorders anemia rare thrombocytopenia Cardiac disorders infrequent,1
SAPHRIS,anemia,temporary bundle,0
SAPHRIS,anemia,anemia rare thrombocytopenia Cardiac,1
SAPHRIS,anemia,thrombocytopenia Cardiac,0
SAPHRIS,thrombocytopenia,bundle,0
SAPHRIS,thrombocytopenia,Blood and,0
SAPHRIS,thrombocytopenia,Eye disorders inf,0
SAPHRIS,thrombocytopenia,thrombocytopenia Cardiac disorders infrequent temporary,1
SAPHRIS,thrombocytopenia,Eye disorders inf,0
SAPHRIS,thrombocytopenia,thrombocytopenia Cardiac disorders infrequent temporary bundle,1
SAPHRIS,thrombocytopenia,thrombocytopenia Cardiac disorders infrequent temporary,1
SAPHRIS,thrombocytopenia,r,0
SAPHRIS,thrombocytopenia,Blood and lymphatic disorders infrequent,0
SAPHRIS,thrombocytopenia,disorders infrequent anemia rare,0
SAPHRIS,temporary bundle branch block,thrombocytopenia Cardiac disorders temporary bundle branch block,1
SAPHRIS,temporary bundle branch block,Eye disorders infrequent accommodation disorder Gastrointestinal disorders,0
SAPHRIS,temporary bundle branch block,infrequent,0
SAPHRIS,accommodation disorder,infrequent temporary bundle,0
SAPHRIS,accommodation disorder,accommodation disorder Gastrointestinal disorders infrequent swollen tongue,1
SAPHRIS,accommodation disorder,Eye disorders,0
SAPHRIS,accommodation disorder,accommodation disorder Gastrointestinal disorders infrequent swollen,1
SAPHRIS,swollen tongue,accommodation disorder Gastrointestinal disorders swollen,1
SAPHRIS,swollen tongue,accommodation disorder Gastrointestinal disorders swollen tongue General disorders rare,1
SAPHRIS,swollen tongue,accommodation disorder Gastrointestinal disorders swollen,1
SAPHRIS,swollen tongue,swollen tongue General disorders rare idiosyncratic,1
SAPHRIS,swollen tongue,disorder Gastrointestinal disorders swollen tongue General disorders,1
SAPHRIS,swollen tongue,swollen tongue General disorders rare idiosyncratic,1
SAPHRIS,swollen tongue,Gastrointestinal disorders swollen tongue,1
SAPHRIS,swollen tongue,swollen tongue General disorders rare idiosyncratic,1
SAPHRIS,swollen tongue,disorder Gastrointestinal disorders swollen tongue General disorders rare idiosyncratic drug,1
SAPHRIS,swollen tongue,swollen tongue General disorders rare idiosyncratic,1
SAPHRIS,swollen tongue,Gastrointestinal disorders,0
SAPHRIS,swollen tongue,disorder Gastrointestinal disorders swollen tongue,1
SAPHRIS,swollen tongue,Gastrointestinal disorders,0
SAPHRIS,idiosyncratic drug reaction,infrequent swollen tongue General,0
SAPHRIS,idiosyncratic drug reaction,idiosyncratic drug reaction Investigations infrequent hyponatremia Nervous system,1
SAPHRIS,idiosyncratic drug reaction,infrequent swollen tongue General,0
SAPHRIS,idiosyncratic drug reaction,drug reaction,1
SAPHRIS,idiosyncratic drug reaction,swollen tongue General disorders idiosyncratic drug reaction Investigations infrequent hyponatremia,1
SAPHRIS,idiosyncratic drug reaction,drug reaction,1
SAPHRIS,idiosyncratic drug reaction,drug reaction,1
SAPHRIS,hyponatremia,hyponatremia,1
SAPHRIS,hyponatremia,hyponatremia,1
SAPHRIS,hyponatremia,reaction Investigations hyponatremia Nervous system disorders,1
SAPHRIS,hyponatremia,hyponatremia,1
SAPHRIS,hyponatremia,drug reaction Investigations infrequent,0
SAPHRIS,hyponatremia,hyponatremia Nervous,1
SAPHRIS,hyponatremia,rare idiosyncratic drug,0
SAPHRIS,hyponatremia,infrequent,0
SAPHRIS,hyponatremia,hyponatremia,1
SAPHRIS,dysarthria,dysarthria Following is a,1
SAPHRIS,dysarthria,adults or pediatric patients,0
SAPHRIS,dysarthria,already,0
SAPHRIS,dysarthria,terms not,0
SAPHRIS,dysarthria,dysarthria Following is a list,1
SAPHRIS,dysarthria,dysarthria Following is,1
SAPHRIS,dysarthria,disorders infrequent,0
SAPHRIS,dysarthria,hyponatremia Nervous system disorders,0
SAPHRIS,diplopia,diplopia,1
SAPHRIS,diplopia,diplopia vision blurred Gastrointestinal disorders,1
SAPHRIS,vision blurred,Eye disorders infrequent vision blurred Gastrointestinal disorders infrequent gastroesophageal,1
SAPHRIS,vision blurred,diplopia vision blurred Gastrointestinal disorders,1
SAPHRIS,vision blurred,Eye disorders infrequent vision blurred Gastrointestinal disorders infrequent,1
SAPHRIS,vision blurred,diplopia vision blurred Gastrointestinal disorders,1
SAPHRIS,vision blurred,Eye disorders infrequent vision blurred Gastrointestinal disorders infrequent,1
SAPHRIS,vision blurred,diplopia vision blurred Gastrointestinal disorders,1
SAPHRIS,vision blurred,vision blurred Gastrointestinal disorders,1
SAPHRIS,vision blurred,Eye disorders infrequent vision blurred,1
SAPHRIS,vision blurred,vision blurred Gastrointestinal disorders,1
SAPHRIS,vision blurred,Eye disorders infrequent vision blurred,1
SAPHRIS,vision blurred,vision blurred Gastrointestinal disorders,1
SAPHRIS,vision blurred,reflux disease,0
SAPHRIS,vision blurred,Eye disorders infrequent vision,1
SAPHRIS,gastroesophageal reflux disease,reflux disease Injury Poisoning and Procedural,1
SAPHRIS,gastroesophageal reflux disease,vision blurred Gastrointestinal disorders infrequent,0
SAPHRIS,gastroesophageal reflux disease,vision blurred Gastrointestinal,0
SAPHRIS,gastroesophageal reflux disease,vision blurred Gastrointestinal disorders gastroesophageal reflux,1
SAPHRIS,gastroesophageal reflux disease,Gastrointestinal disorders gastroesophageal,1
SAPHRIS,gastroesophageal reflux disease,blurred,0
SAPHRIS,gastroesophageal reflux disease,gastroesophageal,1
SAPHRIS,gastroesophageal reflux disease,gastroesophageal reflux disease Injury Poisoning,1
SAPHRIS,gastroesophageal reflux disease,vision blurred Gastrointestinal disorders gastroesophageal reflux disease,1
SAPHRIS,gastroesophageal reflux disease,reflux disease,1
SAPHRIS,fall,and Procedural Complications fall Skin,1
SAPHRIS,fall,reflux disease,1
SAPHRIS,fall,infrequent,0
SAPHRIS,fall,and Procedural Complications fall Skin,1
SAPHRIS,fall,infrequent,0
SAPHRIS,fall,Poisoning and Procedural Complications fall Skin and,1
SAPHRIS,fall,infrequent,0
SAPHRIS,fall,fall Skin and,1
SAPHRIS,fall,fall Skin and subcutaneous tissue,1
SAPHRIS,fall,fall Skin and,1
SAPHRIS,fall,Injury,0
SAPHRIS,photosensitivity reaction,disorders photosensitivity reaction Renal and urinary disorders infrequent,1
SAPHRIS,photosensitivity reaction,Injury,0
SAPHRIS,photosensitivity reaction,disorders photosensitivity,1
SAPHRIS,photosensitivity reaction,photosensitivity reaction Renal and urinary disorders infrequent,1
SAPHRIS,photosensitivity reaction,tissue disorders photosensitivity,1
SAPHRIS,photosensitivity reaction,tissue disorders photosensitivity reaction Renal and,1
SAPHRIS,photosensitivity reaction,tissue disorders photosensitivity,1
SAPHRIS,photosensitivity reaction,photosensitivity,1
SAPHRIS,photosensitivity reaction,and subcutaneous tissue disorders photosensitivity reaction,1
SAPHRIS,photosensitivity reaction,photosensitivity,1
SAPHRIS,photosensitivity reaction,subcutaneous tissue disorders photosensitivity reaction,1
SAPHRIS,photosensitivity reaction,tissue disorders photosensitivity reaction Renal,1
SAPHRIS,photosensitivity reaction,subcutaneous tissue disorders photosensitivity reaction,1
SAPHRIS,enuresis,urinary disorders enuresis Postmarketing Experience The following,1
SAPHRIS,enuresis,subcutaneous tissue disorders photosensitivity reaction,1
SAPHRIS,enuresis,disorders,0
SAPHRIS,enuresis,enuresis Postmarketing Experience The following,1
SAPHRIS,enuresis,Renal and urinary disorders enuresis Postmarketing,1
SAPHRIS,enuresis,enuresis Postmarketing Experience The following,1
SAPHRIS,enuresis,enuresis Postmarketing,1
SAPHRIS,enuresis,enuresis Postmarketing Experience The following adverse,1
SAPHRIS,enuresis,enuresis Postmarketing Experience The following,1
SAPHRIS,enuresis,enuresis Postmarketing Experience The following,1
SAPHRIS,Application site reactions,of Application,1
SAPHRIS,Application site reactions,area have been reported These application,0
SAPHRIS,Application site reactions,Application site reactions primarily,1
SAPHRIS,Application site reactions,area have been reported These application,0
SAPHRIS,Application site reactions,Application site reactions,1
SAPHRIS,Application site reactions,to discontinuation of Application,1
SAPHRIS,Application site reactions,site reactions primarily in the sublingual area,1
SAPHRIS,Application site reactions,reported These application site reactions,0
SAPHRIS,Application site reactions,of Application site reactions primarily in the,1
SAPHRIS,Application site reactions,reported These application site reactions,0
SAPHRIS,Application site reactions,occurrence of these adverse reactions led to discontinuation,0
SAPHRIS,Application site reactions,application site reactions included,0
SAPHRIS,application site reactions,peelingsloughing and inflammation Choking has,0
SAPHRIS,application site reactions,application site reactions included oral ulcers blisters,1
SAPHRIS,application site reactions,has been,0
SAPHRIS,application site reactions,area have been reported application site,1
SAPHRIS,application site reactions,reported application site reactions,1
SAPHRIS,application site reactions,area have been reported application site,1
SAPHRIS,application site reactions,application site reactions,1
SAPHRIS,application site reactions,area have been reported application site,1
SAPHRIS,Choking,blisters peelingsloughing and Choking has been reported,1
SAPHRIS,Choking,area have been reported application site,1
SAPHRIS,oropharyngeal muscular dysfunction,nd inflammation Choking has been reported by patients,0
SAPHRIS,oropharyngeal muscular dysfunction,muscular dysfunction,1
SAPHRIS,oropharyngeal muscular dysfunction,muscular dysfunction,1
SAPHRIS,oropharyngeal muscular dysfunction,inflammation Choking has been reported by patients some of whom may have,0
SAPHRIS,oropharyngeal muscular dysfunction,whom may have also oropharyngeal muscular,1
SAPHRIS,oropharyngeal muscular dysfunction,have also oropharyngeal muscular,1
SAPHRIS,oropharyngeal muscular dysfunction,have also oropharyngeal muscular dysfunction,1
SAPHRIS,oropharyngeal muscular dysfunction,have also oropharyngeal muscular,1
SAPHRIS,INCREASED MORTALITY,REACTIONS  following adverse  reactions are discussed in more,1
SAPHRIS,INCREASED MORTALITY,have also oropharyngeal muscular,1
SAPHRIS,INCREASED MORTALITY,following adverse reactions,1
SAPHRIS,INCREASED MORTALITY,following adverse reactions,1
SAPHRIS,INCREASED MORTALITY,REACTIONS,0
SAPHRIS,INCREASED MORTALITY,REACTIONS,0
SAPHRIS,INCREASED MORTALITY,The,0
SAPHRIS,INCREASED MORTALITY,"eling:



 *  Use i n Elderly Patients with",1
SAPHRIS,INCREASED MORTALITY,The,0
SAPHRIS,INCREASED MORTALITY,"eling:



 *  Use i n Elderly Patients with DementiaRelated",1
SAPHRIS,INCREASED MORTALITY,The,0
SAPHRIS,INCREASED MORTALITY,* Use i n Elderly,1
SAPHRIS,death,see Warnings and Precautions Metabolic,0
SAPHRIS,death,and ution s Tardive Dyskinesia see Warnings,1
SAPHRIS,death,see Warnings and Precautions Metabolic,0
SAPHRIS,INCREASED MORTALITY,"Reactions see ations, Warnings an",1
SAPHRIS,INCREASED MORTALITY,"see ations, Warnings an",1
SAPHRIS,INCREASED MORTALITY,"Reactions see ations, Warnings an",1
SAPHRIS,death,Syncope and r Hem odynamic,1
SAPHRIS,death,"Reactions see ations, Warnings an",1
SAPHRIS,stroke,ts wit h DementiaRelated,1
SAPHRIS,transient ischemic attack,Elderly Patients Dementia-Related Psychosi,1
SAPHRIS,transient ischemic attack,Dementia-Related,1
SAPHRIS,Neuroleptic Malignant Syndrome,Warnings and ions (5.3)],1
SAPHRIS,Neuroleptic Malignant Syndrome,inesia see Warnings,0
SAPHRIS,Neuroleptic Malignant Syndrome,see Warnings,0
SAPHRIS,Neuroleptic Malignant Syndrome,ions (5.3)] * Tardive Dysk inesia see Warnings,1
SAPHRIS,Neuroleptic Malignant Syndrome,and ions (5.3)] * Tardive Dysk,1
SAPHRIS,Neuroleptic Malignant Syndrome,inesia see Warnings and Precautions Metabolic Changes see Warnings,0
SAPHRIS,Neuroleptic Malignant Syndrome,Warnings and Precautions and Neuroleptic Malignant Syndrome,0
SAPHRIS,Neuroleptic Malignant Syndrome,ions (5.3)] * Tardive Dysk,1
SAPHRIS,Neuroleptic Malignant Syndrome,Warnings and Precautions,0
SAPHRIS,Neuroleptic Malignant Syndrome,ions (5.3)] * Tardive,1
SAPHRIS,Tardive Dyskinesia,Contraindications Warnings and,0
SAPHRIS,Tardive Dyskinesia,arnings and Precau tions Hypersensitivity Reactions see Contraindications,1
SAPHRIS,Tardive Dyskinesia,arnings and Precau tions Hypersensitivity Reactions see Contraindications,1
SAPHRIS,Metabolic Changes,"blisters, peeling sloughing and",1
SAPHRIS,Metabolic Changes,"oral blisters, peeling",1
SAPHRIS,Metabolic Changes,"blisters, peeling sloughing and",1
SAPHRIS,Metabolic Changes,Counseling Information Application site reactions,0
SAPHRIS,Metabolic Changes,Orthostatic Hypotension,0
SAPHRIS,Metabolic Changes,and inflammation see,0
SAPHRIS,Metabolic Changes,inflammation see Adverse Reactions,0
SAPHRIS,Metabolic Changes,Application site reactions including oral,0
SAPHRIS,Metabolic Changes,Reactions Orthostatic Hypotension Syncope,0
SAPHRIS,Metabolic Changes,"reactions including oral blisters, peeling",1
SAPHRIS,metabolic changes,* Orthostati c Hypotension,1
SAPHRIS,metabolic changes,* Orthostati,1
SAPHRIS,metabolic changes,"Adverse   
 *  Orthostati c Hypotension Syncope and other",1
SAPHRIS,metabolic changes,* Orthostati,1
SAPHRIS,metabolic changes,"see Adverse   
 *  Orthostati c",1
SAPHRIS,metabolic changes,* Orthostati,1
SAPHRIS,metabolic changes,and,0
SAPHRIS,metabolic changes,* Orthostati c Hypotension Syncope and,1
SAPHRIS,cerebrovascular risk,and Hemodynamic Effects,1
SAPHRIS,cerebrovascular risk,Syncope and Hemodynamic Effects,1
SAPHRIS,cerebrovascular risk,Hemodynamic Effects see Warnings,1
SAPHRIS,cerebrovascular risk,and Hemodynamic Effects,1
SAPHRIS,metabolic changes,Agranulocytosis see,0
SAPHRIS,hyperglycemia,and other Hemodynamic Effects see,0
SAPHRIS,hyperglycemia,"and )]  
 *  Leuk openia Neutropenia and",1
SAPHRIS,hyperglycemia,and other Hemodynamic Effects see,0
SAPHRIS,dyslipidemia,"Precautions enia, Neutro",1
SAPHRIS,dyslipidemia,and other Hemodynamic Effects see,0
SAPHRIS,dyslipidemia,"enia, Neutro",1
SAPHRIS,dyslipidemia,and other Hemodynamic Effects see,0
SAPHRIS,dyslipidemia,"enia, Neutro",1
SAPHRIS,dyslipidemia,Warnings and Precautions QT Interval,0
SAPHRIS,dyslipidemia,"enia, Neutro",1
SAPHRIS,dyslipidemia,and Precautions Leukop,0
SAPHRIS,dyslipidemia,Warnings and Precautions QT Interval Prolongation see,0
SAPHRIS,dyslipidemia,see Warnings and Precautions QT Interval,0
SAPHRIS,weight gain,Precautions Leukopenia and,1
SAPHRIS,weight gain,other Hemodynamic Effects see Warnings and Precautions Leukopenia,0
SAPHRIS,weight gain,and Precautions Leukopenia and Agranu,1
SAPHRIS,weight gain,see Warnings and,0
SAPHRIS,Hypersensitivity reactions,* QT Interval Pro,1
SAPHRIS,Hypersensitivity reactions,"Warnings and .8)]  
 *  QT Interval Pro longation see",1
SAPHRIS,Hypersensitivity reactions,* QT Interval Pro,1
SAPHRIS,Hypersensitivity reactions,Warnings and Precautions,0
SAPHRIS,anaphylaxis,Precautions QT Interval Prolongation s,0
SAPHRIS,anaphylaxis,s,0
SAPHRIS,anaphylaxis,Warnings and Precautions,0
SAPHRIS,anaphylaxis,Interval Prolongation ee Warnings and Precautions Hyperprolactinemia see Warnings,1
SAPHRIS,anaphylaxis,Warnings and Precautions,0
SAPHRIS,anaphylaxis,QT Interval Prolongation ee Warnings and Precautions,1
SAPHRIS,anaphylaxis,Warnings and Precautions,0
SAPHRIS,anaphylaxis,Interval Prolongation ee,1
SAPHRIS,anaphylaxis,Precautions QT Interval Prolongation ee Warnings,1
SAPHRIS,angioedema,see Warnings and,0
SAPHRIS,Orthostatic Hypotension,Prolongation see Warnings and,0
SAPHRIS,Orthostatic Hypotension,and Precautions [see Warnings and Preca utions Seizures,1
SAPHRIS,Orthostatic Hypotension,Prolongation see Warnings and,0
SAPHRIS,Orthostatic Hypotension,Warnings and Preca utions Seizures see Warnings and,1
SAPHRIS,Orthostatic Hypotension,Potential for Cognitive,0
SAPHRIS,Syncope,Warnings,0
SAPHRIS,Syncope,and Precautions Potential for Cognitive,0
SAPHRIS,Syncope,see Warnings and ions (5,1
SAPHRIS,Hemodynamic Effects,arnings and Precautions Hyperprolactinemia see,0
SAPHRIS,Hemodynamic Effects,and Seizures [see Warni ngs,1
SAPHRIS,Hemodynamic Effects,arnings and Precautions Hyperprolactinemia see,0
SAPHRIS,Hemodynamic Effects,[see Warni,1
SAPHRIS,Hemodynamic Effects,Hyperprolactinemia see Warnings and Seizures [see Warni ngs and Precautions Potential,1
SAPHRIS,Hemodynamic Effects,[see Warni,1
SAPHRIS,Hemodynamic Effects,Seizures [see Warni,1
SAPHRIS,Dizziness,Precautions Seizures see s and Pre,1
SAPHRIS,Dizziness,Potential for,0
SAPHRIS,Dizziness,Seizures see s,1
SAPHRIS,Dizziness,s and,1
SAPHRIS,Dizziness,and Pre cautions Potential for,1
SAPHRIS,Dizziness,see s and Pre,1
SAPHRIS,Dizziness,Seizures see s and Pre cautions Potential,1
SAPHRIS,Dizziness,see s and Pre,1
SAPHRIS,Dizziness,and Precautions Seizures see s and,1
SAPHRIS,tachycardia,utions (5.1 Potential,1
SAPHRIS,tachycardia,and Motor Impairment see,0
SAPHRIS,bradycardia,see Warnings and,0
SAPHRIS,bradycardia,Precautions,0
SAPHRIS,bradycardia," 
 *  Poten tial for",1
SAPHRIS,bradycardia,Precautions,0
SAPHRIS,bradycardia,"Seizures see Warnings and  
 *  Poten tial for Cognitive and Motor",1
SAPHRIS,bradycardia,Precautions,0
SAPHRIS,bradycardia,"Warnings and  
 *  Poten",1
SAPHRIS,bradycardia,Precautions,0
SAPHRIS,bradycardia," 
 *  Poten tial for Cognitive and",1
SAPHRIS,bradycardia,Precautions,0
SAPHRIS,bradycardia,* Poten tial for Cognitive,1
SAPHRIS,bradycardia,Warnings and * Poten,1
SAPHRIS,bradycardia,* Poten tial for Cognitive and,1
SAPHRIS,syncope,or Cogn itive,1
SAPHRIS,syncope,or Cogn itive,1
SAPHRIS,syncope,or Cogn itive,1
SAPHRIS,syncope,or Cogn itive and Motor Impairment,1
SAPHRIS,syncope,Potential f,0
SAPHRIS,Leukopenia,Precau,0
SAPHRIS,Leukopenia,tions (5.1 Dysphagia,1
SAPHRIS,Leukopenia,Suicide see Warnings and tions,1
SAPHRIS,Leukopenia,and tions (5.1 Dysphagia see Warnings and,1
SAPHRIS,Leukopenia,Suicide see Warnings and tions,1
SAPHRIS,Leukopenia,see Warnings and Precautions Use in Patients with Concomitant,0
SAPHRIS,Leukopenia,Precau,0
SAPHRIS,Leukopenia,tions (5.1 Dysphagia see,1
SAPHRIS,Leukopenia,Precau,0
SAPHRIS,Leukopenia,see Warnings and tions (5.1,1
SAPHRIS,Leukopenia,see Warnings and tions,1
SAPHRIS,Neutropenia,Concomitant Illness see,0
SAPHRIS,Neutropenia,Suicide see Warnings and ] *,1
SAPHRIS,Agranulocytosis,Patients with Concomitant Illness,0
SAPHRIS,Agranulocytosis,in Patients with Concomitant Illness,0
SAPHRIS,Agranulocytosis,Precautions [see,1
SAPHRIS,Agranulocytosis,Precautions,0
SAPHRIS,Agranulocytosis,[see Warnings and,1
SAPHRIS,Agranulocytosis,[see Warnings and Precautions Use in,1
SAPHRIS,Agranulocytosis,Precautions  [see Warnings  and Precautions,1
SAPHRIS,Agranulocytosis,[see Warnings and Precautions Use in,1
SAPHRIS,QT Prolongation,in adults was similar to,1
SAPHRIS,QT Prolongation,renia in,1
SAPHRIS,QT Prolongation,most common adverse reactions,0
SAPHRIS,QT Prolongation,most common adverse,0
SAPHRIS,QT Prolongation,treatment of renia in,1
SAPHRIS,QT Prolongation,the maintenance,0
SAPHRIS,Increases in QT interval,treatment The most common adverse reactions and at least twice,0
SAPHRIS,Increases in QT interval,w,0
SAPHRIS,Increases in QT interval,rate of pla,0
SAPHRIS,Increases in QT interval,with acute treatment The most common adverse reactions and at least twice the rate of,0
SAPHRIS,Increases in QT interval,of schizophrenia in adults as similar to that seen  with,1
SAPHRIS,Increases in QT interval,with acute treatment The most common adverse reactions and at least twice the rate of,0
SAPHRIS,Increases in QT interval,similar to that seen with acute treatment The most,1
SAPHRIS,Increases in QT interval,to that seen with acute treatment The,1
SAPHRIS,Increases in QT interval,adults as similar,1
SAPHRIS,Increases in QT interval,schizophrenia in adults as similar to that seen  with acute treatment,1
SAPHRIS,Increases in QT interval,adults as similar,1
SAPHRIS,Increases in QT interval,SAPHRIS in the maintenance treatment of,0
SAPHRIS,Seizures,reported with acute herapy,1
SAPHRIS,Seizures,acute herapy t reatment of,1
SAPHRIS,Seizures,reported with acute herapy,1
SAPHRIS,Seizures,with acute,0
SAPHRIS,Seizures,herapy t reatment of manic or mixed,1
SAPHRIS,Seizures,herapy t reatment of manic,1
SAPHRIS,Seizures,herapy t,1
SAPHRIS,Seizures,herapy t,1
SAPHRIS,Seizures,mixed episodes associated with bipolar I disorder in adults,0
SAPHRIS,Seizures,mixed episodes associated with bipolar I disorder in adults,0
SAPHRIS,Motor Impairment,"sia, and",1
SAPHRIS,Suicide,bipolar I disorder in adults were,1
SAPHRIS,Suicide,akathisia and increased weight and during the adjunctive therapy,0
SAPHRIS,Suicide,bipolar I disorder in adults were,1
SAPHRIS,Suicide,bipolar I disorder in,1
SAPHRIS,death,APHRI Streated patients had,1
SAPHRIS,death,APHRI Streated patients had,1
SAPHRIS,death,es of SAPHRIS A total of SAPHRIStreated patients were treated for at least weeks and,0
SAPHRIS,death, and  at least twice the,1
SAPHRIS,death,adverse reactions,0
SAPHRIS,death,"sia, ",1
SAPHRIS,death,"sia, ",1
SAPHRIS,death,weight No new,0
SAPHRIS,deaths,"rial.
",1
SAPHRIS,deaths,"safety rial.
 A total of pediatric",1
SAPHRIS,deaths,"rial.
",1
SAPHRIS,deaths,"rial.
 A total of pediatric",1
SAPHRIS,deaths,"rial.
 A total",1
SAPHRIS,deaths,were treated with SAPHRIS Of,0
SAPHRIS,heart failure,with SA PHRIS Of these patients,1
SAPHRIS,heart failure,with SA PHRIS Of these patients,1
SAPHRIS,heart failure,of pediatric patients were eated with SA,1
SAPHRIS,heart failure,pediatric patients were eated with SA,1
SAPHRIS,heart failure,of pediatric patients were eated with SA,1
SAPHRIS,heart failure,safety trial A,0
SAPHRIS,heart failure,eated with SA PHRIS Of these patients pediatric,1
SAPHRIS,heart failure,safety trial A,0
SAPHRIS,heart failure,with SA PHRIS Of these patients,1
SAPHRIS,sudden death,patients were treated with RIS. Of thes e patients,1
SAPHRIS,sudden death,with SA PHRIS Of these patients,1
SAPHRIS,sudden death,treated with RIS. Of thes e patients pediatric patients,1
SAPHRIS,sudden death,with SA PHRIS Of these patients,1
SAPHRIS,sudden death,pediatric patients were treated with SAPHRIS for at least days and pediatric,0
SAPHRIS,sudden death,treated with SAPHRIS for at least days,0
SAPHRIS,sudden death,were treated with RIS. Of thes e patients pediatric patients were,1
SAPHRIS,sudden death,treated with SAPHRIS for at least days,0
SAPHRIS,sudden death,with RIS. Of,1
SAPHRIS,sudden death,patients were,0
SAPHRIS,sudden death,patients were treated with RIS. Of,1
SAPHRIS,sudden death,patients were treated with RIS. Of thes e patients pediatric,1
SAPHRIS,sudden death,patients were treated with RIS. Of,1
SAPHRIS,pneumonia,ic patien ts were treated with,1
SAPHRIS,pneumonia,Of these patients ic,1
SAPHRIS,pneumonia,ic patien ts were,1
SAPHRIS,pneumonia,pediatr,0
SAPHRIS,pneumonia,patients were treated with SAPHRIS Of,0
SAPHRIS,pneumonia,ic patien ts were,1
SAPHRIS,pneumonia,ic patien,1
SAPHRIS,increased mortality,in pediatric patients bipolar,1
SAPHRIS,increased mortality,pediatric patients bipolar,1
SAPHRIS,increased mortality,who participated in,0
SAPHRIS,cerebrovascular adverse reactions,least twice that for placebo),1
SAPHRIS,cerebrovascular adverse reactions,evaluation,0
SAPHRIS,cerebrovascular adverse reactions,incidence and least twice that for placebo),1
SAPHRIS,cerebrovascular adverse reactions,oral hypoesthesia somnolence,0
SAPHRIS,cerebrovascular adverse reactions,reactions incidence and least twice that for placebo) wer e Schizophrenia,1
SAPHRIS,cerebrovascular adverse reactions,oral hypoesthesia somnolence,0
SAPHRIS,cerebrovascular adverse reactions,placebo) wer e,1
SAPHRIS,cerebrovascular adverse reactions,Adults akathisia oral hypoesthesia somnolence Bipolar,0
SAPHRIS,cerebrovascular adverse reactions,hypoesthesia somnolence Bipolar,0
SAPHRIS,cerebrovascular adverse reactions,and least twice,1
SAPHRIS,cerebrovascular accidents,incidence and at least twice that for,0
SAPHRIS,cerebrovascular accidents,twice that for placebo (6.1): *,1
SAPHRIS,cerebrovascular accidents,Disorder Adults Monotherapy s,0
SAPHRIS,cerebrovascular accidents,akathisia oral hypoesthesia somnolence Bipolar Disorder Adults Monotherapy s,0
SAPHRIS,cerebrovascular accidents,* Schizophre nia Adults,1
SAPHRIS,cerebrovascular accidents,placebo (6.1):,1
SAPHRIS,transient ischemic attacks,"for placebo were Schizophrenia dults: akathisia, oral hyp oesthesia somnolence Bipolar Disorder",1
SAPHRIS,transient ischemic attacks,placebo (6.1):,1
SAPHRIS,transient ischemic attacks,oral hyp oesthesia somnolence Bipolar Disorder Adults,1
SAPHRIS,transient ischemic attacks,"Schizophrenia dults: akathisia, oral hyp oesthesia somnolence",1
SAPHRIS,transient ischemic attacks,oral hyp oesthesia somnolence Bipolar Disorder Adults,1
SAPHRIS,transient ischemic attacks,"Schizophrenia dults: akathisia, oral hyp",1
SAPHRIS,fatalities,akathisia oral hypoesthesia omnolence. Bipolar Disorder Adults Monotherapy,1
SAPHRIS,fatalities,"Schizophrenia dults: akathisia, oral hyp",1
SAPHRIS,fatalities,omnolence.,1
SAPHRIS,fatalities,hypoesthesia,0
SAPHRIS,fatalities,akathisia oral hypoesthesia omnolence. Bipolar Disorder Adults Monotherapy,1
SAPHRIS,fatalities,hypoesthesia,0
SAPHRIS,fatalities,were Schizophrenia Adults akathisia,0
SAPHRIS,fatalities,omnolence.,1
SAPHRIS,fatalities,omnolence.,1
SAPHRIS,fatalities,omnolence. Bipolar Disorder Adults Monotherapy somnolence,1
SAPHRIS,fatalities,omnolence. Bipolar,1
SAPHRIS,Neuroleptic Malignant Syndrome,hypoesthesia To report SUSPECTED,0
SAPHRIS,Neuroleptic Malignant Syndrome,appetite fatigue increased Bipolar Disorder Adults (Ad,1
SAPHRIS,Neuroleptic Malignant Syndrome,fatigue increased weight,0
SAPHRIS,Neuroleptic Malignant Syndrome,paresthesia nausea increased appetite fatigue increased,0
SAPHRIS,Neuroleptic Malignant Syndrome,SUSPECTED ADVERSE REACTIONS contact,0
SAPHRIS,NMS,weight Bipolar Disorder Adults,0
SAPHRIS,NMS,Disorder Adults nct ive,1
SAPHRIS,NMS,weight Bipolar Disorder Adults,0
SAPHRIS,NMS,SUSPECTED,0
SAPHRIS,NMS,-67 or FDA at,1
SAPHRIS,NMS,contact Forest Laboratories LLC -67,1
SAPHRIS,NMS,-67 or FDA at,1
SAPHRIS,NMS,LLC -67 or FDA at FDA,1
SAPHRIS,NMS,-67 or FDA at,1
SAPHRIS,NMS,ADVERSE REACTIONS,0
SAPHRIS,NMS,at FDA or wwwfdagovmedwatch Clinical Trials Experience,0
SAPHRIS,hyperpyrexia,FDA or wwwfdagovmedwatch Clinical Trials Experience,0
SAPHRIS,hyperpyrexia,or wwwfdagovmedwatch Clinical Trials,0
SAPHRIS,hyperpyrexia,contact Forest Laboratories LLC 5 or FDA at  FDA or wwwfdagovmedwatch,1
SAPHRIS,hyperpyrexia,or wwwfdagovmedwatch Clinical Trials,0
SAPHRIS,hyperpyrexia,contact Forest Laboratories LLC at,0
SAPHRIS,hyperpyrexia,Experience Because clinical,0
SAPHRIS,hyperpyrexia,Forest Laboratories LLC 5,1
SAPHRIS,hyperpyrexia,Trials Experience,0
SAPHRIS,muscle rigidity,800-FDA-1088 or wwwfdagovmedwatch Clinical Trials Experience,1
SAPHRIS,muscle rigidity,at,0
SAPHRIS,muscle rigidity,800-FDA-1088 or wwwfdagovmedwatch Clinical Trials Experience Because,1
SAPHRIS,muscle rigidity,ADVERSE REACTIONS contact Forest,0
SAPHRIS,muscle rigidity,800-FDA-1088 or wwwfdagovmedwatch Clinical Trials,1
SAPHRIS,muscle rigidity,800-FDA-1088 or wwwfdagovmedwatch Clinical,1
SAPHRIS,muscle rigidity,wwwfdagovmedwatch Clinical Trials,0
SAPHRIS,altered mental status,LLC at,0
SAPHRIS,altered mental status,under widely varyi,0
SAPHRIS,altered mental status,ww.fda.gov/medwatch. ,1
SAPHRIS,altered mental status,Clinical Trials Experience Because clinical trials are conducted,0
SAPHRIS,altered mental status,ww.fda.gov/medwatch.  Clinical Trials Experience Because,1
SAPHRIS,altered mental status,Clinical Trials Experience Because,0
SAPHRIS,altered mental status,LLC at or FDA at FDA,0
SAPHRIS,autonomic instability,or wwwfdagovmedwatch ical Trials Experienc e Because clinical,1
SAPHRIS,autonomic instability,LLC at or FDA at FDA,0
SAPHRIS,autonomic instability,Clin,0
SAPHRIS,autonomic instability,wwwfdagovmedwatch ical Trials,1
SAPHRIS,autonomic instability,FDA,0
SAPHRIS,autonomic instability,wwwfdagovmedwatch ical Trials Experienc,1
SAPHRIS,autonomic instability,FDA,0
SAPHRIS,autonomic instability,ical Trials Experienc,1
SAPHRIS,autonomic instability,FDA or wwwfdagovmedwatch ical Trials Experienc e Because clinical,1
SAPHRIS,autonomic instability,ical Trials Experienc,1
SAPHRIS,autonomic instability,ical Trials Experienc e Because clinical trials are,1
SAPHRIS,irregular pulse,at FDA or wwwfdagovmedwatch Clinical Trials,0
SAPHRIS,irregular pulse,conducted under widely varying conditions,0
SAPHRIS,irregular pulse,"or wwwfdagovmedwatch Clinical Trials 
  Because clin",1
SAPHRIS,irregular pulse,conducted under widely varying conditions,0
SAPHRIS,irregular pulse,"or wwwfdagovmedwatch Clinical Trials 
  Because clin ical trials are conducted",1
SAPHRIS,irregular pulse,conducted under widely varying conditions,0
SAPHRIS,irregular pulse,"Trials 
  Because clin ical trials",1
SAPHRIS,irregular pulse,conducted under widely varying conditions,0
SAPHRIS,irregular pulse,Because clin ical trials are conducted,1
SAPHRIS,irregular pulse,Trials Experience,0
SAPHRIS,tachycardia,trials are ucted under,1
SAPHRIS,tachycardia,ucted under,1
SAPHRIS,tachycardia,clinical trials of a,0
SAPHRIS,tachycardia,Because clinical trials are ucted under,1
SAPHRIS,elevated creatine phosphokinase,rates observed in the nical trials of a drug cannot,1
SAPHRIS,elevated creatine phosphokinase,under widely varying conditions adverse,0
SAPHRIS,elevated creatine phosphokinase,reflect the rates,0
SAPHRIS,elevated creatine phosphokinase,trials of a drug cannot b e directly compared,1
SAPHRIS,elevated creatine phosphokinase,drug cannot b e,1
SAPHRIS,myoglobinuria,directly comp,1
SAPHRIS,myoglobinuria,directly comp,1
SAPHRIS,myoglobinuria,directly,1
SAPHRIS,myoglobinuria,cannot,0
SAPHRIS,myoglobinuria,rates observed in,0
SAPHRIS,myoglobinuria,reflect the,0
SAPHRIS,myoglobinuria,observed,0
SAPHRIS,myoglobinuria,clinical trials of another drug,0
SAPHRIS,myoglobinuria,directly comp ared to rates in,1
SAPHRIS,myoglobinuria,the rates observed in,0
SAPHRIS,rhabdomyolysis,drug cannot be directly ed to rates in the clinical trials,1
SAPHRIS,rhabdomyolysis,the rates observed in,0
SAPHRIS,rhabdomyolysis,observed,0
SAPHRIS,rhabdomyolysis,in the clinical trials of a drug cannot be,0
SAPHRIS,rhabdomyolysis,ed to rates in the clinical trials of another,1
SAPHRIS,rhabdomyolysis,in the clinical trials of a drug cannot be directly,0
SAPHRIS,rhabdomyolysis,cannot be directly ed to rates in the clinical trials,1
SAPHRIS,rhabdomyolysis,in the clinical trials of a drug cannot be directly,0
SAPHRIS,rhabdomyolysis,be directly,0
SAPHRIS,rhabdomyolysis,in practice,0
SAPHRIS,rhabdomyolysis,drug cannot be directly,0
SAPHRIS,rhabdomyolysis,drug and may,0
SAPHRIS,acute renal failure,rates in the inical trials of an,1
SAPHRIS,acute renal failure,drug and may,0
SAPHRIS,acute renal failure,of an other drug and may,1
SAPHRIS,acute renal failure,compared to,0
SAPHRIS,acute renal failure,inical trials of an other drug,1
SAPHRIS,acute renal failure,compared to,0
SAPHRIS,acute renal failure,Patients with Schizophr,0
SAPHRIS,acute renal failure,trials of an other drug and may not,1
SAPHRIS,"involuntary, dyskinetic movements",in Week Schizophrenia,0
SAPHRIS,"involuntary, dyskinetic movements",Adult Patients in Any PHRIS Dose,1
SAPHRIS,"involuntary, dyskinetic movements",Dose Group and Which Occurr ed at Greater,1
SAPHRIS,"involuntary, dyskinetic movements",Any PHRIS Dose Group and Which Occurr ed at,1
SAPHRIS,"involuntary, dyskinetic movements",Dose Group and Which Occurr ed at Greater,1
SAPHRIS,"involuntary, dyskinetic movements",Which Occurr ed at Greater Incidence Than,1
SAPHRIS,"involuntary, dyskinetic movements",and Which Occurr ed at,1
SAPHRIS,"involuntary, dyskinetic movements",Group and Which Occurr ed,1
SAPHRIS,"involuntary, dyskinetic movements",Placebo Group in Week Schizophrenia Trials Akathisia,0
SAPHRIS,Tardive Dyskinesia," hypersomnia.    
",1
SAPHRIS,Tardive Dyskinesia,"sedation  hypersomnia.    
",1
SAPHRIS,Tardive Dyskinesia," hypersomnia.    
",1
SAPHRIS,Tardive Dyskinesia,events somnolence,0
SAPHRIS,TD,ia Somnolence,0
SAPHRIS,TD,and S  Also includes the Flexibledose trial,1
SAPHRIS,TD,ia Somnolence,0
SAPHRIS,TD,somnolence sedation and S  Also includes,1
SAPHRIS,TD,ia Somnolence,0
SAPHRIS,TD,the following events,0
SAPHRIS,TD,S  Also includes the,1
SAPHRIS,TD,S  Also,1
SAPHRIS,TD,and S  Also includes the Flexibledose trial,1
SAPHRIS,TD,S  Also,1
SAPHRIS,TD,S  Also includes the Flexibledose,1
SAPHRIS,TD,somnolence sedation,0
SAPHRIS,TD,Also includes the Flexibledose trial N,0
SAPHRIS,TD,trial    System Organ Class Preferred Term,1
SAPHRIS,TD,Also includes the Flexibledose trial N,0
SAPHRIS,TD,Flexibledose trial,0
SAPHRIS,TD,   System,1
SAPHRIS,TD,trial    System Organ Class Preferred Term,1
SAPHRIS,TD,   System,1
SAPHRIS,TD,   System,1
SAPHRIS,TD,S Also includes the Flexibledose,0
SAPHRIS,metabolic changes,appetit,0
SAPHRIS,metabolic changes,Nervous system,0
SAPHRIS,metabolic changes,e                ,1
SAPHRIS,metabolic changes,e                 Nervous system disorders,1
SAPHRIS,metabolic changes,e                 Nervous,1
SAPHRIS,metabolic changes,Increased appetite,0
SAPHRIS,metabolic changes,"        
   Nervo us",1
SAPHRIS,metabolic changes,"        
   Nervo us system",1
SAPHRIS,metabolic changes,"Increased         
   Nervo",1
SAPHRIS,metabolic changes,"        
   Nervo us system",1
SAPHRIS,metabolic changes,"        
   Nervo us system disorders",1
SAPHRIS,metabolic changes,"        
   Nervo us",1
SAPHRIS,metabolic changes,"        
   Nervo",1
SAPHRIS,hyperglycemia,In the short term enia trials t he incidence of akathisia,1
SAPHRIS,hyperglycemia,"        
   Nervo",1
SAPHRIS,hyperglycemia,short term enia,1
SAPHRIS,hyperglycemia,the short term enia trials t he incidence of,1
SAPHRIS,hyperglycemia,short term enia,1
SAPHRIS,hyperglycemia,trials t he incidence of,1
SAPHRIS,hyperglycemia,enia,1
SAPHRIS,hyperglycemia,trials t he incidence of akathisia appeared,1
SAPHRIS,hyperglycemia,enia trials t he incidence of akathisia,1
SAPHRIS,hyperglycemia,trials t he incidence of akathisia appeared,1
SAPHRIS,hyperglycemia,the short term enia trials t he,1
SAPHRIS,hyperglycemia,trials t he incidence of akathisia appeared,1
SAPHRIS,hyperglycemia,of akathisia,0
SAPHRIS,Undesirable alterations in lipids,trapyramidal symptoms excluding Somnolence,1
SAPHRIS,Undesirable alterations in lipids,excluding,0
SAPHRIS,Undesirable alterations in lipids,Somnolence ?,1
SAPHRIS,Undesirable alterations in lipids,symptoms,0
SAPHRIS,Undesirable alterations in lipids,trapyramidal symptoms excluding Somnolence ?,1
SAPHRIS,Undesirable alterations in lipids,"     
      Somnolence  ?         Psychiatric",1
SAPHRIS,Undesirable alterations in lipids,trapyramidal symptoms excluding Somnolence ?,1
SAPHRIS,Undesirable alterations in lipids,"symptoms excluding      
      Somnolence  ?         Psychiatric",1
SAPHRIS,Undesirable alterations in lipids,trapyramidal symptoms excluding Somnolence ?,1
SAPHRIS,total cholesterol elevations,in a Week Bipolar Mania,0
SAPHRIS,total cholesterol elevations,at Greater ce Than in the Placebo Group,1
SAPHRIS,elevations in triglycerides,terms tachycardia and heart rate increased Includes the preferred ter,0
SAPHRIS,elevations in triglycerides,"ms oral hypoesthesia, oral",1
SAPHRIS,elevations in triglycerides,paresthesia and oral dysesthesia Includes the preferred terms,0
SAPHRIS,elevations in triglycerides,oral dysesthesia Includes the preferred terms abdominal pain abdominal pai,0
SAPHRIS,elevations in triglycerides,paresthesia and oral dysesthesia Includes the preferred terms abdominal pain abdominal pai,0
SAPHRIS,elevations in triglycerides,"oral hypoesthesia, oral paresthesia",1
SAPHRIS,total cholesterol elevations,gue and lethargy.,1
SAPHRIS,total cholesterol elevations,"preferred terms gue and lethargy.    
  5Inc ludes the preferred",1
SAPHRIS,total cholesterol elevations,gue and lethargy.,1
SAPHRIS,total cholesterol elevations,preferred terms gue and,1
SAPHRIS,total cholesterol elevations,"Includes the preferred terms gue and lethargy.    
  5Inc",1
SAPHRIS,total cholesterol elevations,preferred terms gue and,1
SAPHRIS,total cholesterol elevations,gue and lethargy. 5Inc,1
SAPHRIS,total cholesterol elevations,terms hyperinsulinemia and blood,0
SAPHRIS,total cholesterol elevations,lower and abdominal,0
SAPHRIS,total cholesterol elevations,blood insulin increased Includes,0
SAPHRIS,elevations in triglycerides,Term Placebo N,0
SAPHRIS,elevations in triglycerides,SAPHRIS mg twice,0
SAPHRIS,elevations in triglycerides,"sedation and somnia.    
  
   System Or",1
SAPHRIS,elevations in triglycerides,SAPHRIS mg twice,0
SAPHRIS,weight gain, 0         ,1
SAPHRIS,weight gain, 0          Metabolism and,1
SAPHRIS,weight gain,Metabolism,0
SAPHRIS,weight gain,increased,0
SAPHRIS,weight gain, 0         ,1
SAPHRIS,weight gain,nd Mediasti nal Disorders Oro,1
SAPHRIS,weight gain,Respiratory Thoracic nd Mediasti,1
SAPHRIS,Increase in Body Weight,discontinued atment due to an advers e reaction compared with about,1
SAPHRIS,Increase in Body Weight,Respiratory Thoracic nd Mediasti,1
SAPHRIS,Increase in Body Weight,an advers e,1
SAPHRIS,Increase in Body Weight,SAPHRIStreated patients discontinued atment,1
SAPHRIS,Increase in Body Weight,common,0
SAPHRIS,Increase in Body Weight,to an advers e reaction compared,1
SAPHRIS,Increase in Body Weight,e reaction,0
SAPHRIS,increase in body weight,an,0
SAPHRIS,increase in body weight,to an adverse reaction red with about 11% (18/,1
SAPHRIS,increase in body weight,an,0
SAPHRIS,increase in body weight,most common adverse,0
SAPHRIS,increase in body weight,SAPHRIStreated patients discontinued treatment due to,0
SAPHRIS,Hypersensitivity reactions,re depression suicidal ideation bipolar I disorder insomnia and,0
SAPHRIS,hypersensitivity reactions,symptoms,0
SAPHRIS,hypersensitivity reactions,More Among SAPHRISTreated Adjunctive Bipolar Patients Adverse,0
SAPHRIS,hypersensitivity reactions,insomnia,0
SAPHRIS,hypersensitivity reactions,Adverse,1
SAPHRIS,hypersensitivity reactions,"
     Adverse Reactions Oc curring at",1
SAPHRIS,hypersensitivity reactions,Adverse,1
SAPHRIS,hypersensitivity reactions,"depressive 
     Adverse Reactions Oc curring at",1
SAPHRIS,hypersensitivity reactions,Adverse,1
SAPHRIS,hypersensitivity reactions,depressive Adverse Reactions Oc,1
SAPHRIS,angioedema,Reactions Occurring at an of 2% or M ore Among SAPHRISTreated,1
SAPHRIS,angioedema,depressive Adverse Reactions Oc,1
SAPHRIS,angioedema,Reactions Occurring at an,0
SAPHRIS,angioedema,of 2% or M,1
SAPHRIS,angioedema,or M,1
SAPHRIS,angioedema,of 2%,1
SAPHRIS,angioedema,Adjunctive Bipolar Patients Adverse reactions,0
SAPHRIS,angioedema,an of 2% or M ore Among SAPHRISTreated Adjunctive,1
SAPHRIS,angioedema,Adjunctive Bipolar Patients Adverse reactions,0
SAPHRIS,hypotension,Among SAP HRISTreated Adjunctive Bipolar Patients Adverse,1
SAPHRIS,hypotension,with the use,0
SAPHRIS,hypotension,an Incidence of,0
SAPHRIS,tachycardia,Among IS-Treated  Adjunctive Bipolar Patients Adverse,1
SAPHRIS,tachycardia,an Incidence of,0
SAPHRIS,tachycardia,IS-Treated  Adjunctive Bipolar Patients Adverse reactions,1
SAPHRIS,tachycardia,or More Among IS-Treated  Adjunctive,1
SAPHRIS,tachycardia,IS-Treated  Adjunctive Bipolar Patients Adverse reactions,1
SAPHRIS,tachycardia,Incidence of,0
SAPHRIS,tachycardia,IS-Treated ,1
SAPHRIS,tachycardia,associated with,0
SAPHRIS,swollen tongue,djunctive) Bip olar Patients Adverse reactions,1
SAPHRIS,swollen tongue,or More Among SAPHRISTreated,0
SAPHRIS,swollen tongue,djunctive),1
SAPHRIS,wheezing,More Among SAPHRISTreated Adjunctive,0
SAPHRIS,rash,rounded,0
SAPHRIS,rash,reac,1
SAPHRIS,rash,reac tions associated with the use,1
SAPHRIS,rash,reac tions associated with,1
SAPHRIS,rash,to the nearest percent,0
SAPHRIS,rash,to the nearest percent,0
SAPHRIS,rash,Bipolar Patients reac tions associated with,1
SAPHRIS,rash,to the nearest percent,0
SAPHRIS,orthostatic hypotension,that occurred,0
SAPHRIS,orthostatic hypotension,adjunctive therapy at weeks a time when,0
SAPHRIS,orthostatic hypotension,incidence great er than,1
SAPHRIS,orthostatic hypotension,SAPHRIS incidence great er,1
SAPHRIS,orthostatic hypotension,during acute adjunctive therapy at,0
SAPHRIS,syncope,incidence greater an,1
SAPHRIS,syncope,an plac ebo that occurred during acute,1
SAPHRIS,syncope,n Tabl e Table Adverse,1
SAPHRIS,syncope,More of Adult,0
SAPHRIS,syncope,the trial are shown n  Tabl e Table Adverse,1
SAPHRIS,syncope,More of Adult,0
SAPHRIS,syncope,n Tabl e Table Adverse Reactions Reported,1
SAPHRIS,syncope,n Tabl,1
SAPHRIS,syncope,the trial are shown n  Tabl e Table Adverse Reactions Reported,1
SAPHRIS,syncope,n Tabl,1
SAPHRIS,syncope,"ials 
  SAPHRIS",1
SAPHRIS,syncope,mg to mg twice daily with flexible dosing Extrapyramidal symptoms,0
SAPHRIS,syncope,"ials 
  SAPHRIS mg",1
SAPHRIS,syncope,Group at Weeks,0
SAPHRIS,syncope,"ials 
  SAPHRIS mg",1
SAPHRIS,syncope,"ials 
  SAPHRIS mg to mg twice",1
SAPHRIS,syncope,at,0
SAPHRIS,syncope,"ials 
  SAPHRIS mg",1
SAPHRIS,syncope,"ials 
 ",1
SAPHRIS,syncope,Weeks in Adjunctive Bipolar,0
SAPHRIS,syncope,d Term,1
SAPHRIS,syncope,SAPHRIS mg or mg twice,0
SAPHRIS,syncope,d Term,1
SAPHRIS,syncope,N testina l disorders,1
SAPHRIS,syncope,d Term,1
SAPHRIS,syncope,l disorders,0
SAPHRIS,neutropenia,"dystonia, p",1
SAPHRIS,neutropenia,Dystonia,0
SAPHRIS,neutropenia,occur in susceptible,0
SAPHRIS,neutropenia,"dystonia, p rolonged abnormal contractions of",1
SAPHRIS,neutropenia,"dystonia, p rolonged abnormal contractions of muscle",1
SAPHRIS,Agranulocytosis,during the f irst few days of treatment,1
SAPHRIS,Agranulocytosis,during the f irst few,1
SAPHRIS,Agranulocytosis,of,0
SAPHRIS,Agranulocytosis,susceptible ls during the,1
SAPHRIS,Agranulocytosis,contractions of muscle groups may occur in,0
SAPHRIS,Agranulocytosis,include spasm of the neck muscles sometimes,0
SAPHRIS,Agranulocytosis,ls during the f,1
SAPHRIS,Agranulocytosis,include spasm of the neck muscles sometimes,0
SAPHRIS,fatal,few s of,1
SAPHRIS,fatal,spasm of the neck muscles sometimes progressing to,0
SAPHRIS,fatal,of the neck muscles,0
SAPHRIS,fatal,s of treatment Dystonic symptoms include spasm,1
SAPHRIS,fatal,s of treatment Dystonic symptoms include,1
SAPHRIS,fatal,s of,1
SAPHRIS,fatal,of muscle groups may occur in susceptible,0
SAPHRIS,increases in QTc interval,adult trials the incidence of EPSre,0
SAPHRIS,increases in QTc interval,for d patients was 6% versus  for placebo In shortterm placebocontrolled,1
SAPHRIS,increases in QTc interval,adult trials the incidence of EPSre,0
SAPHRIS,increases in QTc interval,placebocontrolled bipolar mania adult trials,0
SAPHRIS,increases in QTc interval,d patients was,1
SAPHRIS,increases in QTc interval,versus for placebo and the incidence of akathisiarelated,0
SAPHRIS,increases in QTc interval,akathisiarelated events for d patients,1
SAPHRIS,QTc increases,events related to akathisia for SAPHRIStreated patients was versus for,0
SAPHRIS,QTc increases,was versus,0
SAPHRIS,QTc increases,f EPS-related events excluding,1
SAPHRIS,QTc increases,f EPS-related events excluding events,1
SAPHRIS,QTc increases,mania,0
SAPHRIS,QTc of >=500 msec,ents was 7% versu s for placebo and the,1
SAPHRIS,QTc of >=500 msec,mania,0
SAPHRIS,QTc of >=500 msec,and the,0
SAPHRIS,QTc of >=500 msec,for SAPHRIStreated,0
SAPHRIS,QTc of >=500 msec,for SAPHRIStreated ents was 7%,1
SAPHRIS,QTc of >=500 msec,for SAPHRIStreated ents was 7% versu s for placebo and,1
SAPHRIS,QTc of >=500 msec,for SAPHRIStreated ents was 7%,1
SAPHRIS,QT prolongations,disorder,0
SAPHRIS,QT prolongations,pediatric al with bipolar  I disorder the,1
SAPHRIS,QT prolongations,disorder,0
SAPHRIS,QT prolongations,al with bipolar I disorder,1
SAPHRIS,QT prolongations,of EPSrelated events,0
SAPHRIS,delayed ventricular repolarization,daily respectively compared,1
SAPHRIS,delayed ventricular repolarization,as,0
SAPHRIS,delayed ventricular repolarization,twice daily respectively compared to,1
SAPHRIS,delayed ventricular repolarization,oromandibular dystonia m,0
SAPHRIS,delayed ventricular repolarization,twice daily respectively compared to 3% for placebo-treated patients EPSrelated events,1
SAPHRIS,delayed ventricular repolarization,oromandibular dystonia m,0
SAPHRIS,delayed ventricular repolarization,twice daily respectively compared,1
SAPHRIS,delayed ventricular repolarization,daily respectively compared to,1
SAPHRIS,delayed ventricular repolarization,3% for placebo-treated patients EPSrelated,1
SAPHRIS,delayed ventricular repolarization,3% for placebo-treated patients EPSrelated events include bradykinesia,1
SAPHRIS,Hyperprolactinemia,was unitsL compared to a decrease,0
SAPHRIS,Hyperprolactinemia,S-treated patients was unitsL compared,1
SAPHRIS,Hyperprolactinemia,transaminase levels for S-treated patients,1
SAPHRIS,Hyperprolactinemia,to a decrease of unitsL for placebotreated patients The,0
SAPHRIS,Hyperprolactinemia,S-treated patients was unitsL compared to a,1
SAPHRIS,Hyperprolactinemia,to a decrease of unitsL for placebotreated patients The,0
SAPHRIS,Hyperprolactinemia,S-treated patients was unitsL,1
SAPHRIS,Hyperprolactinemia,schizophrenia adult trials the mean,0
SAPHRIS,suppress hypothalamic GnRH,patients The proportion of patients with transaminase e,0
SAPHRIS,suppress hypothalamic GnRH,for SAPHRIStreated patients 1.6 units/L compared to a,1
SAPHRIS,suppress hypothalamic GnRH,patients,0
SAPHRIS,suppress hypothalamic GnRH,levels for SAPHRIStreated patients 1.6 units/L compared to a  decrease of unitsL for placebotreated,1
SAPHRIS,suppress hypothalamic GnRH,patients,0
SAPHRIS,suppress hypothalamic GnRH,of patients,0
SAPHRIS,suppress hypothalamic GnRH,for placebotreated patients The proportion,0
SAPHRIS,suppress hypothalamic GnRH,trials the,0
SAPHRIS,suppress hypothalamic GnRH,1.6 units/L compared to a,1
SAPHRIS,suppress hypothalamic GnRH,SAPHRIStreated patients 1.6 units/L compared to a,1
SAPHRIS,suppress hypothalamic GnRH,1.6 units/L compared to a,1
SAPHRIS,impairing gonadal steroidogenesis,for placebotreated,0
SAPHRIS,impairing gonadal steroidogenesis,with transaminase  >=3 times ULN (at Endpoint) was  for SAPHRIStreated patients,1
SAPHRIS,impairing gonadal steroidogenesis,for placebotreated,0
SAPHRIS,impairing gonadal steroidogenesis, >=3 times ULN (at Endpoint) was  for SAPHRIStreated patients,1
SAPHRIS,impairing gonadal steroidogenesis,for placebotreated,0
SAPHRIS,impairing gonadal steroidogenesis,(at Endpoint) was for SAPHRIStreated patients,1
SAPHRIS,impairing gonadal steroidogenesis,Endpoint) was for SAPHRIStreated,1
SAPHRIS,impairing gonadal steroidogenesis,of patients with transaminase  >=3 times ULN (at Endpoint) was  for SAPHRIStreated patients versus for,1
SAPHRIS,impairing gonadal steroidogenesis,Endpoint) was for SAPHRIStreated,1
SAPHRIS,impairing gonadal steroidogenesis,SAPHRIStreated patients versus for placebotreated patients,0
SAPHRIS,impairing gonadal steroidogenesis,Endpoint) was for SAPHRIStreated patients versus,1
SAPHRIS,impairing gonadal steroidogenesis,with transaminase  >=3 times ULN (at Endpoint) was  for SAPHRIStreated patients,1
SAPHRIS,impairing gonadal steroidogenesis,Endpoint) was for SAPHRIStreated patients versus,1
SAPHRIS,impairing gonadal steroidogenesis,for placebotreated patients The proportion of patients with,0
SAPHRIS,Galactorrhea,ersus 1.3% f or placebotreated patients,1
SAPHRIS,Galactorrhea,for placebotreated patients The proportion of patients with,0
SAPHRIS,Galactorrhea,SAPHRIStreated patients ersus 1.3% f or placebotreated,1
SAPHRIS,Galactorrhea,for placebotreated patients The proportion of patients with,0
SAPHRIS,Galactorrhea,ULN at Endpoint was,0
SAPHRIS,Galactorrhea,for SAPHRIStreated,0
SAPHRIS,gynecomastia,ated patient,1
SAPHRIS,gynecomastia,ated patient s In shortterm placebocontrolled,1
SAPHRIS,gynecomastia,for ated patient s In shortterm placebocontrolled bipolar,1
SAPHRIS,gynecomastia,ated patient s In shortterm placebocontrolled,1
SAPHRIS,gynecomastia,patients versus for ated patient,1
SAPHRIS,gynecomastia,SAPHRIStreated patients versus for ated,1
SAPHRIS,gynecomastia,versus for ated,1
SAPHRIS,hyperprolactinemia,of unitsL in,0
SAPHRIS,hyperprolactinemia,mean increase in transaminase els for,1
SAPHRIS,hyperprolactinemia,mean increase in transaminase els for SAPHRIS-tr eated patients was,1
SAPHRIS,hyperprolactinemia,mean increase in transaminase els for,1
SAPHRIS,hyperprolactinemia,in transaminase els for,1
SAPHRIS,hyperprolactinemia,els for SAPHRIS-tr eated patients was unitsL,1
SAPHRIS,hyperprolactinemia,in transaminase els for,1
SAPHRIS,hyperprolactinemia,for SAPHRIS-tr eated patients,1
SAPHRIS,hyperprolactinemia,for SAPHRIS-tr eated patients,1
SAPHRIS,hyperprolactinemia,mean increase in transaminase els for SAPHRIS-tr eated patients was,1
SAPHRIS,hyperprolactinemia,for SAPHRIS-tr eated patients,1
SAPHRIS,hypogonadism,adult mania trials the mean,0
SAPHRIS,decreased bone density,crease,1
SAPHRIS,decreased bone density,in placebotreated patients The proportion of patients with transaminase elevations times upper,0
SAPHRIS,decreased bone density,compared to a crease of 4.9,1
SAPHRIS,decreased bone density,to a crease of 4.9,1
SAPHRIS,decreased bone density,of 4.9 units/L in placebotreated patients The proportion,1
SAPHRIS,decreased bone density,transaminase levels for SAPHRIStreated patients was unitsL compared to a,0
SAPHRIS,decreased bone density,The proportion,0
SAPHRIS,decreased bone density,was unitsL compared,0
SAPHRIS,decreased bone density,crease of 4.9 units/L in placebotreated patients,1
SAPHRIS,decreased bone density,crease of 4.9 units/L in,1
SAPHRIS,abnormal prolactin levels,placebotreated patients In,0
SAPHRIS,abnormal prolactin levels,of mal,1
SAPHRIS,abnormal prolactin levels,placebotreated patients In,0
SAPHRIS,abnormal prolactin levels,a week,0
SAPHRIS,abnormal prolactin levels,upper limit of mal (ULN) (at Endpoint) w as for SAPHRIStreated patients versus,1
SAPHRIS,abnormal prolactin levels,a week,0
SAPHRIS,abnormal prolactin levels,of mal (ULN),1
SAPHRIS,abnormal prolactin levels,times upper limit of mal (ULN) (at,1
SAPHRIS,abnormal prolactin levels,elevations times upper limit of,0
SAPHRIS,abnormal prolactin levels,upper limit of mal (ULN) (at Endpoint) w as for,1
SAPHRIS,abnormal prolactin levels,elevations times upper limit of,0
SAPHRIS,abnormal prolactin levels,upper limit of mal (ULN) (at Endpoint) w as for,1
SAPHRIS,abnormal prolactin levels,elevations times upper limit of,0
SAPHRIS,tumorigenesis,of patients,0
SAPHRIS,tumorigenesis,trials the mean decreases in prolactin levels were ngmL for,0
SAPHRIS,tumorigenesis,proportion of patients with prolactin,0
SAPHRIS,tumorigenesis,patients,1
SAPHRIS,tumorigenesis,patients comp ared to ngmL for placebotreated,1
SAPHRIS,tumorigenesis,patients comp ared to,1
SAPHRIS,Seizures,for SAPHRIStreated patients versus,0
SAPHRIS,Seizures,prolactin =4 times,1
SAPHRIS,Seizures,for SAPHRIStreated patients versus,0
SAPHRIS,Seizures,d to ngmL for placebotreated patients The proportion of patients with prolactin,0
SAPHRIS,Seizures,patients versus,0
SAPHRIS,Seizures,with prolactin =4 times,1
SAPHRIS,Seizures,=4 times ULN at Endpoint were,1
SAPHRIS,Seizures,d to ngmL for placebotreated patients The proportion of patients with prolactin elevations,0
SAPHRIS,Seizures,for SAPHRIStreated patients versus for placebotreated,0
SAPHRIS,Seizures,ngmL for placebotreated patients The proportion of patients with prolactin,0
SAPHRIS,Seizures,for SAPHRIStreated patients versus for placebotreated,0
SAPHRIS,seizures,oint) we re for SAPHRIStreated,1
SAPHRIS,seizures,re for SAPHRIStreated patients versus for placebotreated patients In a longterm,0
SAPHRIS,seizures,times ULN at oint) we re for SAPHRIStreated patients versus,1
SAPHRIS,seizures,re for SAPHRIStreated patients versus for placebotreated patients In a longterm,0
SAPHRIS,seizures,oint) we re for,1
SAPHRIS,seizures,for SAPHRIStreated patients versus for,0
SAPHRIS,seizures,at oint) we re for SAPHRIStreated patients versus,1
SAPHRIS,seizures,for SAPHRIStreated patients versus for,0
SAPHRIS,seizures,at oint),1
SAPHRIS,seizures,oint) we,1
SAPHRIS,seizures,g-term (,1
SAPHRIS,seizures,In a g-term (,1
SAPHRIS,seizures,placebotreated patients In a g-term (,1
SAPHRIS,seizures,g-term ( week doubleblind comparatorcontrolled,1
SAPHRIS,seizures,placebotreated patients In a g-term (,1
SAPHRIS,seizures,g-term ( week doubleblind comparatorcontrolled adult trial,1
SAPHRIS,seizures,patients,0
SAPHRIS,seizures,patients In a g-term ( week,1
SAPHRIS,seizures,patients,0
SAPHRIS,seizures,placebotreated patients In a g-term ( week,1
SAPHRIS,seizures,patients,0
SAPHRIS,seizures,primarily,0
SAPHRIS,seizures,In a g-term (,1
SAPHRIS,Somnolence,with SAPH RIS mg,1
SAPHRIS,Somnolence,twice,0
SAPHRIS,Somnolence, with SAPH RIS,1
SAPHRIS,Somnolence,twice,0
SAPHRIS,Somnolence, with SAPH RIS mg twice,1
SAPHRIS,Somnolence,twice,0
SAPHRIS,somnolence,for placebotreated patients There were no reports of,0
SAPHRIS,somnolence,Endpoint) ,1
SAPHRIS,somnolence,were reported in of pa,0
SAPHRIS,somnolence,Endpoint)  for patients treated,1
SAPHRIS,somnolence,of prolactin elevations times,0
SAPHRIS,somnolence,prolactin elevations times ULN Endpoint)  for patients treated with SAPHRIS,1
SAPHRIS,somnolence,of prolactin elevations times,0
SAPHRIS,somnolence,Endpoint)  for patients treated with,1
SAPHRIS,somnolence,cebo-treat ed patients There,1
SAPHRIS,somnolence,cebo-treat ed,1
SAPHRIS,somnolence,ed patients There were no reports of gynecomastia in this,0
SAPHRIS,somnolence,cebo-treat ed,1
SAPHRIS,somnolence,cebo-treat ed patients There were,1
SAPHRIS,somnolence,with SAP HRIS mg twice daily,1
SAPHRIS,somnolence,for patients d with,1
SAPHRIS,somnolence,patients d with SAP HRIS mg,1
SAPHRIS,somnolence,for patients d with,1
SAPHRIS,somnolence,times ULN at any time were and for patients treate,0
SAPHRIS,somnolence,with SAP HRIS mg twice,1
SAPHRIS,somnolence,as compared,0
SAPHRIS,somnolence,were and for patients d with SAP HRIS,1
SAPHRIS,somnolence,as compared,0
SAPHRIS,somnolence,ULN at any time were and,0
SAPHRIS,Somnolence,in schizophrenia and,0
SAPHRIS,sedation,ed patients in shortterm fixeddose trials in schizophrenia and bipolar mania The,0
SAPHRIS,sedation,to for bo-treat,1
SAPHRIS,sedation,ed patients in shortterm fixeddose trials in schizophrenia and bipolar mania The,0
SAPHRIS,somnolence,>=3 times ULN during,1
SAPHRIS,sedation,The proportion of patients with,0
SAPHRIS,sedation,ULN during a,0
SAPHRIS,sedation, 3-week  trial in pediatric bipolar I,1
SAPHRIS,sedation, 3-week  trial,1
SAPHRIS,sedation,ULN during  3-week  trial in pediatric bipolar I,1
SAPHRIS,sedation, 3-week  trial,1
SAPHRIS,hypersomnia,in pediatr ic bipolar I disorder,1
SAPHRIS,Somnolence,respectively versus for -treated p,1
SAPHRIS,Somnolence,-treated p,1
SAPHRIS,Somnolence,for -treated p atients Other Adverse,1
SAPHRIS,Somnolence,-treated p,1
SAPHRIS,Somnolence,Observed During the Premarketing Evaluation of SAPHRIS Fo,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,adults or p ediatric patients,1
SAPHRIS,Disruption of the body's ability to reduce core body temperature,drugrelated on pharmacologic o,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,r other grounds. Reactions already listed for either adults or p ediatric patients,1
SAPHRIS,Disruption of the body's ability to reduce core body temperature,drugrelated on pharmacologic o,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,patients in other parts of Adverse Reactions or those,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,already listed for either adults or p ediatric patients,1
SAPHRIS,Disruption of the body's ability to reduce core body temperature,other parts of Adverse Reactions,0
SAPHRIS,Disruption of the body's ability to reduce core body temperature,either adults or p ediatric patients in,1
SAPHRIS,Disruption of the body's ability to reduce core body temperature,r other grounds. Reactions already listed for either adults or p ediatric patients in,1
SAPHRIS,Disruption of the body's ability to reduce core body temperature,either adults or p ediatric patients in,1
SAPHRIS,body temperature increases,or,0
SAPHRIS,body temperature increases,included Reactions e further categorized by M edDRA,1
SAPHRIS,body temperature increases,or,0
SAPHRIS,body temperature increases,e further categorized by M,1
SAPHRIS,body temperature increases,e further categorized by,1
SAPHRIS,body temperature increases,included Reactions e further categorized by M edDRA system organ class,1
SAPHRIS,body temperature increases,e further categorized by,1
SAPHRIS,body temperature increases,are not included Reactions e further categorized by M edDRA system,1
SAPHRIS,body temperature increases,e further categorized by,1
SAPHRIS,body temperature increases,according,0
SAPHRIS,body temperature increases,are not included Reactions e further categorized by M edDRA system,1
SAPHRIS,body temperature increases,according,0
SAPHRIS,body temperature increases,e further categorized by M edDRA system organ,1
SAPHRIS,body temperature increases,according,0
SAPHRIS,body temperature increases,are not included Reactions e further categorized by M edDRA system organ class and,1
SAPHRIS,body temperature increases,according,0
SAPHRIS,body temperature increases,liste,0
SAPHRIS,body temperature increases,in the tabulated results from,1
SAPHRIS,body temperature increases,d in the tabulated results from placebocontrolled trials appear in,1
SAPHRIS,body temperature increases,already liste,0
SAPHRIS,body temperature increases,least patients frequent only,0
SAPHRIS,body temperature increases,in,0
SAPHRIS,body temperature increases,those occurring in at least patients frequent only those not already liste,0
SAPHRIS,body temperature increases,d in,1
SAPHRIS,body temperature increases,not already d in the tabulated results,1
SAPHRIS,body temperature increases,d in,1
SAPHRIS,pyrexia,tabulated results rom pla,1
SAPHRIS,pyrexia,rom pla,1
SAPHRIS,pyrexia,rom pla cebocontrolled trials appear in this,1
SAPHRIS,pyrexia,in the tabulated results rom pla cebocontrolled trials appear in,1
SAPHRIS,pyrexia,rom pla cebocontrolled trials appear in this,1
SAPHRIS,pyrexia,listing those occurring,0
SAPHRIS,pyrexia,least,0
SAPHRIS,feeling hot,controlled  trials appear in this listing,1
SAPHRIS,feeling hot,controlled  trials appear in this listing,1
SAPHRIS,feeling hot,controlled  trials appear in,1
SAPHRIS,aspiration,and Precautions or Overdosage that reflect,0
SAPHRIS,aspiration,se conside red,1
SAPHRIS,aspiration,Reactions or se conside red in Contraindications Warnings,1
SAPHRIS,aspiration,se conside red,1
SAPHRIS,aspiration,se conside,1
SAPHRIS,aspiration,or se,1
SAPHRIS,aspiration,Reactions or se,1
SAPHRIS,aspiration,either for adults or pediatric patients in other parts of Adverse Reactions or tho,0
SAPHRIS,aspiration,adults,0
SAPHRIS,aspiration,Warnings and Precautions or,0
SAPHRIS,Dysphagia,Contraindications Warnings,0
SAPHRIS,Dysphagia,Precaut,0
SAPHRIS,Dysphagia,in Contraindications Warnings and ions,1
SAPHRIS,Dysphagia,Contraindications Warnings and ions (5)  or Overdosage that reflect,1
SAPHRIS,Dysphagia,in Contraindications Warnings and ions,1
SAPHRIS,Dysphagia,Precaut,0
SAPHRIS,Dysphagia,ions (5) or Overdosage,1
SAPHRIS,Dysphagia,in Contraindications Warnings and ions (5)  or Overdosage,1
SAPHRIS,Dysphagia,ions (5) or Overdosage,1
SAPHRIS,dysphagia,Complications,0
CARBAGLU,Infections,adverse reactions in of,0
CARBAGLU,Infections,pain pyrexia,0
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia,1
CARBAGLU,Infections,Infections vomiting abdominal pain,1
CARBAGLU,Infections,Infections vomiting,1
CARBAGLU,Infections,Infections vomiting abdominal pain,1
CARBAGLU,Infections,are,0
CARBAGLU,Infections,pain pyrexia,0
CARBAGLU,Infections,in of,0
CARBAGLU,vomiting,ear infection diarrhea nasopharyngitis,0
CARBAGLU,vomiting,of patients are vomiting abdominal pain,1
CARBAGLU,vomiting,ear infection diarrhea nasopharyngitis,0
CARBAGLU,vomiting,vomiting,1
CARBAGLU,vomiting,tonsilitis anemia,0
CARBAGLU,vomiting,vomiting abdominal pain pyrexia,1
CARBAGLU,vomiting,common adverse reactions,0
CARBAGLU,vomiting,adverse,0
CARBAGLU,abdominal pain,patients are Infections abdominal pain,1
CARBAGLU,abdominal pain,reactions in,0
CARBAGLU,abdominal pain,abdominal pain,1
CARBAGLU,abdominal pain,pyrexia tonsilitis anemia ear,0
CARBAGLU,abdominal pain,Infections abdominal pain pyrexia tonsilitis anemia,1
CARBAGLU,abdominal pain,pyrexia tonsilitis anemia ear,0
CARBAGLU,abdominal pain,nasopharyngitis,0
CARBAGLU,abdominal pain,Infections abdominal,1
CARBAGLU,pyrexia,Infections vomiting abdominal pyrexia tonsilitis anemia ear,1
CARBAGLU,pyrexia,Infections abdominal,1
CARBAGLU,pyrexia,are Infections vomiting abdominal pyrexia,1
CARBAGLU,pyrexia,Infections abdominal,1
CARBAGLU,pyrexia,tonsilitis anemia ear infection,0
CARBAGLU,pyrexia,most common adverse reactions in of patients are Infections vomiting abdominal pain,0
CARBAGLU,pyrexia,The most common adverse reactions in of patients are Infections,0
CARBAGLU,pyrexia,pyrexia tonsilitis,1
CARBAGLU,pyrexia,The most common adverse reactions in of patients are Infections,0
CARBAGLU,tonsilitis,tonsilitis anemia ear,1
CARBAGLU,tonsilitis,anemia ear infection diarrhea nasopharyngitis and headache To report,0
CARBAGLU,tonsilitis,and headache To,0
CARBAGLU,tonsilitis,abdominal pain tonsilitis anemia ear infection,1
CARBAGLU,tonsilitis,and headache To,0
CARBAGLU,tonsilitis,vomiting abdominal pain tonsilitis anemia ear,1
CARBAGLU,tonsilitis,and headache To,0
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea nasopharyngitis,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea nasopharyngitis,1
CARBAGLU,tonsilitis,Infections vomiting abdominal pain tonsilitis anemia ear,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea nasopharyngitis,1
CARBAGLU,anemia,pain pyrexia,0
CARBAGLU,anemia,nasopharyngitis and headache To report SUSPECTED ADVERS,0
CARBAGLU,anemia,pain pyrexia anemia,1
CARBAGLU,anemia,nasopharyngitis and headache To report SUSPECTED ADVERS,0
CARBAGLU,anemia,vomiting abdominal pain pyrexia anemia,1
CARBAGLU,anemia,nasopharyngitis and headache To report SUSPECTED ADVERS,0
CARBAGLU,anemia,headache To,0
CARBAGLU,anemia,anemia ear infection,1
CARBAGLU,anemia,nasopharyngitis and headache To report SUSPECTED,0
CARBAGLU,diarrhea,infection,0
CARBAGLU,diarrhea,SUSPECTED ADVERSE REACTIONS contact Accr,0
CARBAGLU,diarrhea,tonsilitis anemia ear diarrhea nasopharyngitis and,1
CARBAGLU,diarrhea,SUSPECTED ADVERSE REACTIONS contact Accr,0
CARBAGLU,nasopharyngitis,nasopharyngitis and,1
CARBAGLU,headache,diarrhea nasopharyngitis,0
CARBAGLU,headache,headache To report SUSPECTED ADVERSE REACTIONS,1
CARBAGLU,headache,headache To,1
CARBAGLU,headache,headache To report,1
CARBAGLU,headache,headache To report SUSPECTED,1
CARBAGLU,headache,headache To report,1
CARBAGLU,Infections,common adverse reactions occurring in of patients regardless of,0
CARBAGLU,Infections,of patients regardless of causality,0
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia,1
CARBAGLU,Infections,causality,0
CARBAGLU,Infections,regardless of causality Infections vomiting abdominal,1
CARBAGLU,Infections,causality,0
CARBAGLU,Infections,of,0
CARBAGLU,Infections,causality Infections vomiting abdominal pain,1
CARBAGLU,Infections,of,0
CARBAGLU,Infections,of causality are,0
CARBAGLU,Infections,ear infection,0
CARBAGLU,Infections,Infections vomiting abdominal pain pyrexia tonsilitis,1
CARBAGLU,vomiting,vomiting abdominal,1
CARBAGLU,vomiting,of patients regardless,0
CARBAGLU,vomiting,nasopharyngitis and,0
CARBAGLU,vomiting,are vomiting abdominal pain pyrexia,1
CARBAGLU,vomiting,nasopharyngitis and,0
CARBAGLU,vomiting,vomiting abdominal,1
CARBAGLU,abdominal pain,abdominal pain pyrexia,1
CARBAGLU,pyrexia,pyrexia tonsilitis anemia,1
CARBAGLU,pyrexia,abdominal pain pyrexia,1
CARBAGLU,pyrexia,pyrexia tonsilitis,1
CARBAGLU,pyrexia,pyrexia tonsilitis anemia,1
CARBAGLU,pyrexia,Infections vomiting abdominal pyrexia tonsilitis anemia ear,1
CARBAGLU,pyrexia,pyrexia tonsilitis anemia,1
CARBAGLU,pyrexia,Table,0
CARBAGLU,pyrexia,ear infection diarrhea nasopharyngitis and headache,0
CARBAGLU,pyrexia,pyrexia tonsilitis,1
CARBAGLU,tonsilitis,tonsilitis anemia,1
CARBAGLU,tonsilitis,headache Table summarizes,0
CARBAGLU,tonsilitis,n of patients regardless of causality are Infections vomiting abdominal,0
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1
CARBAGLU,tonsilitis,vomiting abdominal pain tonsilitis anemia,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea nasopharyngitis,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection,1
CARBAGLU,tonsilitis,abdominal pain tonsilitis anemia ear infection diarrhea nasopharyngitis,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection,1
CARBAGLU,tonsilitis,tonsilitis anemia ear,1
CARBAGLU,tonsilitis,tonsilitis anemia ear infection diarrhea nasopharyngitis,1
CARBAGLU,anemia,summarizes adverse reactions,0
CARBAGLU,anemia,headache Table summarizes adverse,0
CARBAGLU,anemia,pyrexia anemia ear,1
CARBAGLU,anemia,headache Table summarizes adverse,0
CARBAGLU,anemia,and headache,0
CARBAGLU,anemia,anemia,1
CARBAGLU,ear infection,tonsilitis ear infection diarrhea nasopharyngitis and,1
CARBAGLU,ear infection,anemia,1
CARBAGLU,ear infection,ear infection diarrhea nasopharyngitis,1
CARBAGLU,ear infection,tonsilitis ear infection diarrhea nasopharyngitis and headache,1
CARBAGLU,ear infection,ear infection diarrhea nasopharyngitis,1
CARBAGLU,diarrhea,diarrhea nasopharyngitis and headache,1
CARBAGLU,diarrhea,vomiting abdominal pain pyrexia tonsilitis anemia ear,0
CARBAGLU,nasopharyngitis,nasopharyngitis,1
CARBAGLU,nasopharyngitis,nasopharyngitis and,1
CARBAGLU,nasopharyngitis,tonsilitis anemia ear infection nasopharyngitis and headache Table,1
CARBAGLU,nasopharyngitis,nasopharyngitis and,1
CARBAGLU,headache,headache Table,1
CARBAGLU,headache,nasopharyngitis and,1
CARBAGLU,headache,diarrhea nasopharyngitis headache Table,1
CARBAGLU,headache,nasopharyngitis and,1
CARBAGLU,headache,headache Table summarizes adverse reactions occurring,1
CARBAGLU,headache,pain pyrexia tonsilitis anemia,0
CARBAGLU,headache,headache,1
CARBAGLU,headache,headache Table summarizes adverse reactions occurring,1
CARBAGLU,headache,headache Table summarizes adverse reactions,1
CARBAGLU,headache,nasopharyngitis,0
PROMACTA,Hepatic Decompensation,Warnings and,0
PROMACTA,Hepatic Decompensation,other Hepatic Decompensation in Patients with Chronic Hepatitis,1
PROMACTA,Hepatic Decompensation,Warnings and,0
PROMACTA,Hepatic Decompensation,Hepatic Decompensation in Patients with Chronic,1
PROMACTA,Hepatic Decompensation,Hepatic Decompensation in,1
PROMACTA,Hepatic Decompensation,sections,0
PROMACTA,Hepatic Decompensation,in Patients with Chronic Hepatitis C see Warnings and Precautions Hepatotoxicity,0
PROMACTA,Hepatotoxicity,Hepatotoxicity see Warnings and,1
PROMACTA,Hepatotoxicity,see Warnings and Hepatotoxicity see Warnings and,1
PROMACTA,Hepatotoxicity,Hepatotoxicity see Warnings and,1
PROMACTA,Hepatotoxicity,and,0
PROMACTA,Thromboembolic Complications,see,0
PROMACTA,Thromboembolic Complications,Precautions Thromboembolic,1
PROMACTA,Thromboembolic Complications,Thromboembolic Complications see Warnings and Precautions,1
PROMACTA,Thromboembolic Complications,Precautions Thromboembolic,1
PROMACTA,Thromboembolic Complications,Thromboembolic Complications see Warnings and Precautions Cataracts,1
PROMACTA,Thromboembolic Complications,Hepatotoxicity see Warnings,0
PROMACTA,Cataracts,Cataracts see Warnings and,1
PROMACTA,Cataracts,Complications see Warnings and Cataracts,1
PROMACTA,Cataracts,Cataracts see Warnings and,1
PROMACTA,nausea,nausea diarrhea,1
PROMACTA,nausea,to and,0
PROMACTA,nausea,nausea diarrhea upper,1
PROMACTA,nausea,nausea diarrhea upper respiratory tract,1
PROMACTA,nausea,and greater than placebo nausea diarrhea upper respiratory tract,1
PROMACTA,nausea,nausea diarrhea upper respiratory tract,1
PROMACTA,nausea,ALT myalgia and urinary tract i,0
PROMACTA,nausea,urinary,0
PROMACTA,diarrhea,diarrhea upper respiratory,1
PROMACTA,diarrhea,diarrhea upper respiratory,1
PROMACTA,upper respiratory tract infection,nausea upper respiratory tract infection vomiting increased ALT myalgia and,1
PROMACTA,upper respiratory tract infection,diarrhea upper respiratory,1
PROMACTA,upper respiratory tract infection,In,0
PROMACTA,upper respiratory tract infection,upper respiratory tract infection vomiting increased ALT,1
PROMACTA,upper respiratory tract infection,In,0
PROMACTA,upper respiratory tract infection,myalgia and urinary tract infection In pediatric patie,0
PROMACTA,upper respiratory tract infection,In pediatric,0
PROMACTA,upper respiratory tract infection,than placebo were nausea upper respiratory tract infection,1
PROMACTA,upper respiratory tract infection,In pediatric,0
PROMACTA,upper respiratory tract infection,urinary,0
PROMACTA,upper respiratory tract infection,tract infection vomiting increased ALT,1
PROMACTA,vomiting,vomiting increased ALT myalgia and urinary,1
PROMACTA,vomiting,vomiting increased,1
PROMACTA,vomiting,vomiting increased ALT myalgia,1
PROMACTA,vomiting,and greater than placebo,0
PROMACTA,increased ALT,vomiting,0
PROMACTA,increased ALT,placebo,0
PROMACTA,increased ALT,myalgia and urinary tract infection In pediatric patients,0
PROMACTA,increased ALT,upper respiratory tract infection increased,1
PROMACTA,increased ALT,tract infection increased ALT,1
PROMACTA,increased ALT,upper respiratory tract infection increased,1
PROMACTA,increased ALT,increased ALT,1
PROMACTA,increased ALT,tract infection In pediatric patients,0
PROMACTA,increased ALT,tract infection increased,1
PROMACTA,increased ALT,upper respiratory tract infection increased ALT,1
PROMACTA,increased ALT,tract infection increased,1
PROMACTA,urinary tract infection,the most common adverse,0
PROMACTA,urinary tract infection,age years and older with ITP the most common adverse rea,0
PROMACTA,urinary tract infection,patients age years and older,0
PROMACTA,urinary tract infection,urinary tract infection In,1
PROMACTA,urinary tract infection,ALT myalgia urinary tract,1
PROMACTA,urinary tract infection,pediatric patients age years and older with ITP the most common,0
PROMACTA,upper respiratory tract infection,rhinitis In patients with chronic,0
PROMACTA,upper respiratory tract infection,tract infection nasopharyngitis and rhinitis,1
PROMACTA,upper respiratory tract infection,upper respiratory tract infection nasopharyngitis,1
PROMACTA,upper respiratory tract infection,than placebo upper respiratory tract infection nasopharyngitis and rhinitis In,1
PROMACTA,upper respiratory tract infection,upper respiratory tract infection nasopharyngitis,1
PROMACTA,upper respiratory tract infection,upper respiratory tract infection nasopharyngitis and rhinitis,1
PROMACTA,upper respiratory tract infection,In,0
PROMACTA,nasopharyngitis,upper respiratory tract nasopharyngitis and rhinitis In patients with,1
PROMACTA,nasopharyngitis,In,0
PROMACTA,nasopharyngitis,nasopharyngitis and rhinitis In patients,1
PROMACTA,nasopharyngitis,nasopharyngitis,1
PROMACTA,nasopharyngitis,hepatitis Cassociated thrombocytopenia,0
PROMACTA,nasopharyngitis,nasopharyngitis,1
PROMACTA,nasopharyngitis,ons greater than or equal to,0
PROMACTA,nasopharyngitis,respiratory tract nasopharyngitis and rhinitis In,1
PROMACTA,nasopharyngitis,ons greater than or equal to,0
PROMACTA,nasopharyngitis,equal to and greater than placebo were upper,0
PROMACTA,rhinitis,rhinitis In,1
PROMACTA,rhinitis,infection nasopharyngitis rhinitis In,1
PROMACTA,rhinitis,rhinitis In,1
PROMACTA,rhinitis,rhinitis In,1
PROMACTA,rhinitis,infection nasopharyngitis rhinitis In patients with chronic hepatitis,1
PROMACTA,rhinitis,rhinitis In,1
PROMACTA,rhinitis,rhinitis In patients,1
PROMACTA,rhinitis,infection nasopharyngitis rhinitis In patients,1
PROMACTA,rhinitis,rhinitis In patients,1
PROMACTA,rhinitis,and greater,0
PROMACTA,rhinitis,rhinitis In patients with,1
PROMACTA,rhinitis,Cassociated thrombocytopenia,0
PROMACTA,anemia,reactions greater than or equal to and greater than,0
PROMACTA,anemia,diarrhea decreased,0
PROMACTA,anemia,were,0
PROMACTA,pyrexia,greater than placebo were pyrexia,1
PROMACTA,pyrexia,were,0
PROMACTA,pyrexia,pyrexia fatigue headache nausea diarrhea,1
PROMACTA,pyrexia,pyrexia fatigue headache nausea,1
PROMACTA,fatigue,fatigue headache nausea diarrhea decreased appetite,1
PROMACTA,fatigue,pyrexia fatigue headache nausea,1
PROMACTA,fatigue,than placebo were anemia fatigue headache nausea,1
PROMACTA,fatigue,pyrexia fatigue headache nausea,1
PROMACTA,fatigue,fatigue headache,1
PROMACTA,fatigue,fatigue headache,1
PROMACTA,fatigue,fatigue,1
PROMACTA,fatigue,anemia fatigue headache nausea,1
PROMACTA,fatigue,fatigue,1
PROMACTA,fatigue,or equal to and greater,0
PROMACTA,fatigue,decreased appetite,0
PROMACTA,nausea,influenzalike illness asthenia insomnia cough pruritus,0
PROMACTA,nausea,nausea diarrhea decreased appetite influenzalike,1
PROMACTA,nausea,nausea diarrhea decreased,1
PROMACTA,nausea,nausea diarrhea decreased,1
PROMACTA,nausea,nausea diarrhea decreased,1
PROMACTA,nausea,appetite influenzalike illness asthenia insomnia cough pruritus,0
PROMACTA,diarrhea,headache diarrhea decreased appetite influenzalike illness asthenia,1
PROMACTA,diarrhea,appetite influenzalike illness asthenia insomnia cough pruritus,0
PROMACTA,decreased appetite,equal to,0
PROMACTA,decreased appetite,to and greater than,0
PROMACTA,decreased appetite,placebo were anemia pyrexia fatigue,0
PROMACTA,decreased appetite,fatigue headache nausea decreased appetite,1
PROMACTA,decreased appetite,fatigue headache nausea decreased appetite,1
PROMACTA,decreased appetite,fatigue headache nausea decreased appetite,1
PROMACTA,decreased appetite,pyrexia fatigue headache nausea decreased appetite influenzalike illness asthenia,1
PROMACTA,decreased appetite,fatigue headache nausea decreased appetite,1
PROMACTA,decreased appetite,nausea decreased appetite,1
PROMACTA,decreased appetite,illness,0
PROMACTA,decreased appetite,nausea,0
PROMACTA,influenza-like illness,headache nausea diarrhea decreased influenza-like illness,1
PROMACTA,influenza-like illness,nausea diarrhea decreased influenza-like illness asthenia,1
PROMACTA,influenza-like illness,headache nausea diarrhea decreased influenza-like illness,1
PROMACTA,influenza-like illness,nausea diarrhea decreased influenza-like illness asthenia,1
PROMACTA,influenza-like illness,headache nausea diarrhea decreased influenza-like illness,1
PROMACTA,asthenia,peripheral,0
PROMACTA,asthenia,asthenia insomnia cough pruritus chills,1
PROMACTA,asthenia,cough,0
PROMACTA,asthenia,asthenia insomnia cough pruritus,1
PROMACTA,asthenia,asthenia,1
PROMACTA,asthenia,appetite,0
PROMACTA,asthenia,diarrhea decreased appetite influenzalike asthenia insomnia cough pruritus chills,1
PROMACTA,asthenia,appetite,0
PROMACTA,asthenia,asthenia,1
PROMACTA,asthenia,asthenia insomnia,1
PROMACTA,asthenia,asthenia,1
PROMACTA,insomnia,appetite influenzalike illness,0
PROMACTA,insomnia,insomnia cough pruritus chills,1
PROMACTA,insomnia,insomnia cough pruritus,1
PROMACTA,insomnia,insomnia cough pruritus chills,1
PROMACTA,insomnia,edema,0
PROMACTA,cough,cough pruritus,1
PROMACTA,cough,peripheral edema In patients,0
PROMACTA,cough,cough pruritus chills myalgia alopecia,1
PROMACTA,cough,chills myalgia alopecia,0
PROMACTA,cough,cough pruritus chills myalgia alopecia,1
PROMACTA,cough,chills myalgia alopecia,0
PROMACTA,cough,atigue headache nausea diarrhea decreased,0
PROMACTA,cough,cough pruritus chills myalgia,1
PROMACTA,cough,atigue headache nausea diarrhea decreased,0
PROMACTA,cough,cough pruritus chills,1
PROMACTA,cough,atigue headache nausea diarrhea decreased,0
PROMACTA,cough,cough pruritus chills,1
PROMACTA,pruritus,insomnia pruritus chills myalgia alopecia,1
PROMACTA,pruritus,cough pruritus chills,1
PROMACTA,pruritus,asthenia insomnia pruritus,1
PROMACTA,pruritus,cough pruritus chills,1
PROMACTA,pruritus,pruritus,1
PROMACTA,pruritus,pruritus chills myalgia alopecia and peripheral,1
PROMACTA,pruritus,insomnia pruritus chills,1
PROMACTA,pruritus,pruritus chills myalgia alopecia and peripheral,1
PROMACTA,pruritus,influenzalike illness asthenia insomnia pruritus chills myalgia alopecia and peripheral,1
PROMACTA,pruritus,pruritus chills myalgia alopecia and peripheral,1
PROMACTA,pruritus,pruritus chills,1
PROMACTA,pruritus,pruritus,1
PROMACTA,myalgia,decreased appetite influenzalike illness asthenia insomnia cough pruritus,0
PROMACTA,myalgia,myalgia alopecia and peripheral edema In,1
PROMACTA,myalgia,influenzalike illness asthenia insomnia cough pruritus chills,0
PROMACTA,myalgia,aplastic,0
PROMACTA,myalgia,myalgia alopecia and peripheral,1
PROMACTA,myalgia,decreased appetite influenzalike illness asthenia insomnia cough,0
PROMACTA,alopecia,with severe aplastic anemia the most common ad,0
PROMACTA,alopecia,alopecia and peripheral edema,1
PROMACTA,alopecia,pruritus chills,0
PROMACTA,alopecia,and peripheral edema In patients with severe aplastic anemia,0
PROMACTA,alopecia,alopecia and peripheral,1
PROMACTA,alopecia,peripheral edema In,0
PROMACTA,alopecia,insomnia cough pruritus chills alopecia and peripheral edema In,1
PROMACTA,alopecia,peripheral edema In,0
PROMACTA,alopecia,alopecia and peripheral edema In,1
PROMACTA,peripheral edema,illness asthenia insomnia cough pruritus,0
PROMACTA,peripheral edema,alopecia peripheral,1
PROMACTA,peripheral edema,and,0
PROMACTA,peripheral edema,chills myalgia alopecia peripheral edema,1
PROMACTA,peripheral edema,myalgia alopecia peripheral edema,1
PROMACTA,peripheral edema,chills myalgia alopecia peripheral edema,1
PROMACTA,peripheral edema,insomnia cough pruritus chills myalgia alopecia and,0
PROMACTA,peripheral edema,patients with severe aplastic anemia the most common adverse reactions great,0
PROMACTA,peripheral edema,influenzalike illness asthenia insomnia cough pruritus chills myalgia alopecia,0
PROMACTA,peripheral edema,alopecia and,0
PROMACTA,peripheral edema,peripheral edema,1
PROMACTA,nausea,nausea fatigue cough,1
PROMACTA,fatigue,fatigue,1
PROMACTA,fatigue,nausea,0
PROMACTA,fatigue,fatigue cough diarrhea and,1
PROMACTA,fatigue,nausea,0
PROMACTA,fatigue,fatigue cough diarrhea and headache EXCERPT,1
PROMACTA,fatigue,nausea,0
PROMACTA,fatigue,fatigue cough,1
PROMACTA,fatigue,fatigue,1
PROMACTA,fatigue,To,0
PROMACTA,fatigue,common adverse,0
PROMACTA,fatigue,EXCERPT To report,0
PROMACTA,cough,report SUSPECTED ADVERSE REACTIONS conta,0
PROMACTA,cough,cough diarrhea,1
PROMACTA,cough,to were nausea cough,1
PROMACTA,cough,cough diarrhea,1
PROMACTA,cough,cough diarrhea and headache,1
PROMACTA,cough,cough,1
PROMACTA,cough,cough diarrhea and headache,1
PROMACTA,cough,diarrhea and headache EXCERPT To report,0
PROMACTA,cough,cough diarrhea and headache EXCERPT,1
PROMACTA,diarrhea,diarrhea and headache EXCERPT To report,1
PROMACTA,diarrhea,and headache EXCERPT To report SUSPECTED ADVERSE REACTIONS,0
PROMACTA,headache,headache EXCERPT To report SUSPECTED,1
PROMACTA,headache,headache,1
PROMACTA,headache,ADVERSE REACTIONS contact GlaxoSmithKline at,0
PROMACTA,headache,ADVERSE REACTIONS contact GlaxoSmithKline at,0
PROMACTA,headache,SUSPECTED ADVERSE REACTIONS contact GlaxoSmithKline at,0
PROMACTA,hemorrhage,hemorrhage was the most common,1
PROMACTA,hemorrhage,hemorrhage,1
PROMACTA,hemorrhage,ed in practice Chronic Immune Idiopathic Thrombocytopenia Adults In,0
PROMACTA,hemorrhagic reactions,hemorrhage was the most common serious,0
PROMACTA,hemorrhagic reactions,clinical trials hemorrhage was the most common serious,0
PROMACTA,hemorrhagic reactions,most common serious adverse,0
PROMACTA,hemorrhagic reactions,hemorrhagic reactions followed discontinuation of PROMACTA Other,1
PROMACTA,hemorrhagic reactions,most common serious adverse,0
PROMACTA,thromboembolic complications,Warnings and Precautions The data described below reflect,0
PROMACTA,thromboembolic complications,adverse,0
PROMACTA,thromboembolic complications,adverse reactions included,0
PROMACTA,thromboembolic complications,reactions included thromboembolic complications see Warnings and,1
PROMACTA,thromboembolic complications,adverse reactions included,0
PROMACTA,thromboembolic complications,thromboembolic complications see Warnings,1
PROMACTA,thromboembolic complications,thromboembolic complications see,1
PROMACTA,thromboembolic complications,adverse reactions included thromboembolic complications,1
PROMACTA,thromboembolic complications,Precautions The data described below reflect exposure of PROMACTA to,0
PROMACTA,thromboembolic complications,included thromboembolic complications see Warnings and Precautions,1
PROMACTA,thromboembolic complications,Precautions The data described below reflect exposure of PROMACTA to,0
PROMACTA,alopecia,alopecia musculoskeletal,1
PROMACTA,alopecia,Precautions The data described below reflect exposure of PROMACTA to,0
PROMACTA,alopecia,mouth were the,0
PROMACTA,alopecia,alopecia,1
PROMACTA,alopecia,trials,0
PROMACTA,musculoskeletal pain,the adverse,0
PROMACTA,musculoskeletal pain,trials musculoskeletal pain,1
PROMACTA,musculoskeletal pain,controlled clinical chronic ITP trials,0
PROMACTA,musculoskeletal pain,musculoskeletal pain,1
PROMACTA,musculoskeletal pain,dry mouth were the adverse reactions reported in of p,0
PROMACTA,musculoskeletal pain,dry mouth were the adverse,0
PROMACTA,blood alkaline phosphatase increased,musculoskeletal blood alkaline phosphatase increased and dry mouth,1
PROMACTA,blood alkaline phosphatase increased,dry mouth were the adverse,0
PROMACTA,blood alkaline phosphatase increased,alopecia musculoskeletal blood alkaline phosphatase increased and dry,1
PROMACTA,blood alkaline phosphatase increased,dry mouth were the adverse,0
PROMACTA,blood alkaline phosphatase increased,phosphatase increased,1
PROMACTA,blood alkaline phosphatase increased,trials alopecia musculoskeletal blood alkaline phosphatase,1
PROMACTA,blood alkaline phosphatase increased,ITP trials alopecia musculoskeletal blood alkaline phosphatase,1
PROMACTA,dry mouth,dry mouth were,1
PROMACTA,dry mouth,phosphatase increased dry,1
PROMACTA,dry mouth,alkaline phosphatase increased dry,1
PROMACTA,dry mouth,musculoskeletal pain blood alkaline phosphatase,0
PROMACTA,dry mouth,dry mouth were the adverse reactions,1
PROMACTA,serum liver test abnormalities,controlled chronic ITP serum liver test abnormalities,1
PROMACTA,serum liver test abnormalities,dry mouth were the adverse reactions,1
PROMACTA,serum liver test abnormalities,the three,0
PROMACTA,serum liver test abnormalities,controlled chronic ITP serum,1
PROMACTA,serum liver test abnormalities,ITP serum liver test abnormalities predominantly Grade or,1
PROMACTA,serum liver test abnormalities,controlled chronic ITP serum,1
PROMACTA,serum liver test abnormalities,three controlled chronic ITP serum,1
PROMACTA,serum liver test abnormalities,controlled,0
PROMACTA,serum liver test abnormalities,in severity were reported in and of patients for PROMACTA an,0
PROMACTA,serum liver test abnormalities,three controlled,0
PROMACTA,serum liver test abnormalities,Grade or less in severity were reported in and of patients for,0
PROMACTA,serum liver test abnormalities,chronic ITP trials,0
PROMACTA,serum liver test abnormalities,three controlled chronic ITP serum liver,1
PROMACTA,serum liver test abnormalities,three controlled chronic ITP serum liver test abnormalities predominantly Grade,1
PROMACTA,serum liver test abnormalities,three controlled chronic ITP serum liver,1
PROMACTA,serum liver test abnormalities,liver test abnormalities predominantly Grade or less,1
PROMACTA,serum liver test abnormalities,serum liver test abnormalities,1
PROMACTA,serum liver test abnormalities,liver test abnormalities predominantly Grade or less,1
PROMACTA,serum liver test abnormalities,chronic ITP serum liver test abnormalities,1
PROMACTA,hepatobiliary laboratory abnormalities,Seven of the,0
PROMACTA,hepatobiliary laboratory abnormalities,with PROMACTA and three patients in the,0
PROMACTA,hepatobiliary laboratory abnormalities,PROMACTA,0
PROMACTA,hepatobiliary laboratory abnormalities,group discontinued treatment due hepatobiliary laboratory abnormalities Seven of,1
PROMACTA,hepatobiliary laboratory abnormalities,PROMACTA,0
PROMACTA,hepatobiliary laboratory abnormalities,patients treated with PROMACTA in the,0
PROMACTA,hepatobiliary laboratory abnormalities,patients,0
PROMACTA,hepatobiliary laboratory abnormalities,with,0
PROMACTA,hepatobiliary laboratory abnormalities,hepatobiliary laboratory abnormalities Seven,1
PROMACTA,hepatobiliary laboratory abnormalities,due hepatobiliary,1
PROMACTA,hepatobiliary laboratory abnormalities,laboratory abnormalities were reexposed to,1
PROMACTA,hepatobiliary laboratory abnormalities,of the patients treated with PROMACTA in the controlled trials,0
PROMACTA,hepatobiliary laboratory abnormalities,trials hepatobiliary laboratory abnormalities were reexposed to,1
PROMACTA,hepatobiliary laboratory abnormalities,of the patients treated with PROMACTA in the controlled trials,0
PROMACTA,hepatobiliary laboratory abnormalities,the patients treated with PROMACTA in the controlled,0
PROMACTA,hepatobiliary laboratory abnormalities,hepatobiliary laboratory abnormalities were reexposed,1
PROMACTA,hepatobiliary laboratory abnormalities,with,0
PROMACTA,hepatobiliary laboratory abnormalities,laboratory abnormalities were reexposed to PROMACTA in,1
PROMACTA,hepatobiliary laboratory abnormalities,in the extension trial Six of these patients again experienced liver t,0
PROMACTA,hepatobiliary laboratory abnormalities,with,0
PROMACTA,liver test abnormalities,trial Six of these patients again,0
PROMACTA,liver test abnormalities,patient,0
PROMACTA,liver test abnormalities,these patients again liver test,1
PROMACTA,liver test abnormalities,test abnormalities predominantly Grade resulting,1
PROMACTA,liver test abnormalities,patients again liver test abnormalities,1
PROMACTA,liver test abnormalities,in discontinuation of PROMACTA,0
PROMACTA,liver test abnormalities,liver test abnormalities predominantly,1
PROMACTA,liver test abnormalities,had PROMACTA discontinued due liver test,1
PROMACTA,liver test abnormalities,liver test abnormalities less than,1
PROMACTA,liver test abnormalities,had PROMACTA discontinued due liver test abnormalities,1
PROMACTA,liver test abnormalities,one additional patient had PROMACTA discontinued,0
PROMACTA,liver test abnormalities,due liver test abnormalities,1
PROMACTA,liver test abnormalities,one additional patient had PROMACTA discontinued,0
PROMACTA,liver test abnormalities,placebocontrolled,0
PROMACTA,liver test abnormalities,due liver test abnormalities less than,1
PROMACTA,liver test abnormalities,placebocontrolled,0
PROMACTA,liver test abnormalities,PROMACTA discontinued due liver test abnormalities less than or equal,1
PROMACTA,liver test abnormalities,placebocontrolled,0
PROMACTA,liver test abnormalities,trial of PROMACTA in patients with,0
PROMACTA,portal vein thromboses,the placebo group portal vein thromboses see Warnings and,1
PROMACTA,portal vein thromboses,trial of PROMACTA in patients with,0
PROMACTA,portal vein thromboses,portal vein thromboses,1
PROMACTA,portal vein thromboses,trial of PROMACTA in patients with,0
PROMACTA,portal vein thromboses,portal,1
PROMACTA,portal vein thromboses,the placebo group portal vein thromboses see Warnings and,1
PROMACTA,portal vein thromboses,portal,1
PROMACTA,portal vein thromboses,vein thromboses see Warnings and,1
PROMACTA,portal vein thromboses,described below,0
PROMACTA,portal vein thromboses,Patients The data described,0
PROMACTA,portal vein thromboses,data described below reflec,0
PROMACTA,portal vein thromboses,placebo group portal,1
PROMACTA,portal vein thromboses,portal vein thromboses see,1
PROMACTA,hyperbilirubinemia,was reported in of patients receiving PROMACTA compared with for placebo,0
PROMACTA,hyperbilirubinemia,chronic hepatitis hyperbilirubinemia was,1
PROMACTA,hyperbilirubinemia,was reported in of patients receiving PROMACTA compared with for placebo,0
PROMACTA,hyperbilirubinemia,for placebo Total bilirubin gre,0
PROMACTA,hyperbilirubinemia,hyperbilirubinemia was reported in of,1
PROMACTA,hyperbilirubinemia,controlled clinical trials in patients with chronic hepatitis,0
PROMACTA,hyperbilirubinemia,was reported in of patients receiving PROMACTA compared with for placebo,0
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,than or equal to 1.5 x ULN was reported in,1
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,in and of patients receiving,0
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,greater than or equal to 1.5 x ULN was reported in and of,1
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,placebo respectively ALT or AST gr,0
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,and of patients receiving PROMACTA and placebo respectively ALT or AST gr,0
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,with for Total bilirubin greater than or equal to 1.5 x ULN was,1
PROMACTA,Total bilirubin greater than or equal to 1.5 x ULN,and of patients receiving PROMACTA and placebo respectively ALT or AST gr,0
PROMACTA,AST greater than or equal to 3 x ULN,3 x ULN was reported in and,1
PROMACTA,AST greater than or equal to 3 x ULN,was reported in and of,0
PROMACTA,AST greater than or equal to 3 x ULN,or equal to 3 x ULN was reported in and of,1
PROMACTA,AST greater than or equal to 3 x ULN,reported in,0
PROMACTA,AST greater than or equal to 3 x ULN,ALT AST greater than or equal to 3 x ULN was reported,1
PROMACTA,AST greater than or equal to 3 x ULN,reported in,0
PROMACTA,AST greater than or equal to 3 x ULN,patients receiving PROMACTA and,0
PROMACTA,nausea,greater than or equal to were,0
PROMACTA,nausea,headache Table Adverse,0
PROMACTA,nausea,or equal to nausea fatigue cough diarrhea and,1
PROMACTA,nausea,headache Table Adverse,0
PROMACTA,nausea,Adverse,0
PROMACTA,nausea,nausea fatigue cough diarrhea and,1
PROMACTA,nausea,were,0
PROMACTA,fatigue,fatigue cough diarrhea,1
PROMACTA,fatigue,were,0
PROMACTA,fatigue,to were fatigue cough diarrhea,1
PROMACTA,fatigue,were,0
PROMACTA,cough,reactions greater than or equal to,0
PROMACTA,cough,cough diarrhea,1
PROMACTA,cough,adverse,0
PROMACTA,cough,cough diarrhea and headache Table,1
PROMACTA,cough,Trial in Adults,0
PROMACTA,cough,cough,1
PROMACTA,cough,cough,1
PROMACTA,cough,cough diarrhea and,1
PROMACTA,cough,cough diarrhea,1
PROMACTA,cough,The most common adverse,0
PROMACTA,diarrhea,diarrhea,1
PROMACTA,diarrhea,Openlabel Trial in Adults,0
PROMACTA,diarrhea,adverse reactions,0
PROMACTA,headache,Openlabel Trial in Adults with Severe,0
PROMACTA,headache,than,0
PROMACTA,headache,headache Table Adverse Reactions from One,1
PROMACTA,headache,from One Openlabel Trial in Adults with,0
PROMACTA,headache,Table Adverse Reactions from One,0
PROMACTA,Febrile neutropenia,Febrile neutropenia Abdominal,1
PROMACTA,Febrile neutropenia,yngeal,0
PROMACTA,cytogenetic abnormality,cytogenetic abnormality reported on therapy including patients,1
PROMACTA,cytogenetic abnormality,including patients who had complex changes in chromosome,0
PROMACTA,changes in chromosome 7,changes in chromosome 7 Postmarketing,1
PROMACTA,changes in chromosome 7,including patients who had complex changes in chromosome,0
PROMACTA,changes in chromosome 7,The following adverse reactions have,0
PROMACTA,changes in chromosome 7,including patients who had changes in chromosome 7,1
PROMACTA,changes in chromosome 7,patients who had changes in chromosome,1
PROMACTA,changes in chromosome 7,patients who had changes in chromosome 7 Postmarketing Experience,1
PROMACTA,changes in chromosome 7,patients who had changes in chromosome,1
PROMACTA,changes in chromosome 7,in chromosome 7 Postmarketing Experience The,1
PROMACTA,changes in chromosome 7,who had changes in chromosome 7 Postmarketing Experience,1
PROMACTA,changes in chromosome 7,in chromosome 7 Postmarketing Experience The,1
PROMACTA,changes in chromosome 7,in chromosome 7 Postmarketing Experience The following,1
PROMACTA,Thrombotic microangiopathy,Thrombotic microangiopathy,1
PROMACTA,Thrombotic microangiopathy,Disorders,0
PROMACTA,Thrombotic microangiopathy,acute,0
PROMACTA,Thrombotic microangiopathy,exposure Vascular Thrombotic microangiopathy,1
PROMACTA,Thrombotic microangiopathy,to drug exposure Vascular Thrombotic microangiopathy,1
PROMACTA,Thrombotic microangiopathy,Vascular Thrombotic microangiopathy with,1
PROMACTA,Thrombotic microangiopathy,to drug exposure Vascular Thrombotic microangiopathy,1
PROMACTA,Thrombotic microangiopathy,acute renal,0
PROMACTA,Thrombotic microangiopathy,to drug exposure Vascular Thrombotic,1
PROMACTA,HEPATIC DECOMPENSATION,The g serious adverse reac tions,1
PROMACTA,HEPATIC DECOMPENSATION,to drug exposure Vascular Thrombotic,1
PROMACTA,HEPATIC DECOMPENSATION,The g serious adverse reac tions,1
PROMACTA,HEPATIC DECOMPENSATION,to drug exposure Vascular Thrombotic,1
PROMACTA,HEPATIC DECOMPENSATION,described in other sections,0
PROMACTA,HEPATIC DECOMPENSATION,in other sections Hepatic Decompensation in P,0
PROMACTA,HEPATIC DECOMPENSATION,REACTIONS The g serious adverse reac tions,1
PROMACTA,HEPATIC DECOMPENSATION,in other sections Hepatic Decompensation in P,0
PROMACTA,HEPATIC DECOMPENSATION,serious adverse reac tions associated with PROMACTA are,1
PROMACTA,HEPATIC DECOMPENSATION,REACTIONS The g,1
PROMACTA,HEPATIC DECOMPENSATION,g serious adverse reac tions associated,1
PROMACTA,HEPATIC DECOMPENSATION,followin,0
PROMACTA,HEPATIC DECOMPENSATION,ons. * Hepatic Decompensation in Patients with Chronic,1
PROMACTA,hepatic decompensation,see Warnings and Precautions /Thromboembolic Compli cations see Warnings and Precautions,1
PROMACTA,hepatic decompensation,ons. * Hepatic Decompensation in Patients with Chronic,1
PROMACTA,hepatic decompensation,see Warnings and Precautions /Thromboembolic Compli,1
PROMACTA,hepatic decompensation,ons. * Hepatic Decompensation in Patients with Chronic,1
PROMACTA,HEPATIC DECOMPENSATION,Warnings and Precautions Cataracts see,0
PROMACTA,HEPATIC DECOMPENSATION,Cataracts see Warnings,0
PROMACTA,HEPATIC DECOMPENSATION,"see Warnings  Precautions (5.4)]  
 In adult patients",1
PROMACTA,HEPATIC DECOMPENSATION,Cataracts see Warnings,0
PROMACTA,HEPATIC DECOMPENSATION,Precautions (5.4)] In,1
PROMACTA,hepatic decompensation,upper respiratory tract infection vomiting increased,0
PROMACTA,hepatic decompensation,and tract infection. (  6. In pediatric patients,1
PROMACTA,hepatic decompensation,upper respiratory tract infection vomiting increased,0
PROMACTA,hepatic decompensation,diarrhea upper respiratory tract infection,0
PROMACTA,hepatic decompensation,ALT myalgia and tract infection. (  6. In pediatric patients age,1
PROMACTA,hepatic decompensation,diarrhea upper respiratory tract infection,0
PROMACTA,Hepatotoxicity,REACTIONS The following serious se reactions a ssociated with PROMACTA,1
PROMACTA,Hepatotoxicity,diarrhea upper respiratory tract infection,0
PROMACTA,Hepatotoxicity,ADVERSE REACTIONS The following,0
PROMACTA,Hepatotoxicity,following serious se reactions a ssociated with PROMACTA are,1
PROMACTA,Hepatotoxicity,ADVERSE REACTIONS The following,0
PROMACTA,Hepatotoxicity,se,1
PROMACTA,Hepatotoxicity,following serious,0
PROMACTA,Hepatotoxicity,The following serious se reactions,1
PROMACTA,Hepatotoxicity,se reactions a ssociated,1
PROMACTA,Hepatotoxicity,The following serious se reactions,1
PROMACTA,Hepatotoxicity,serious se,1
PROMACTA,Hepatotoxicity,following serious se reactions a,1
PROMACTA,Hepatotoxicity,REACTIONS The following serious,0
PROMACTA,Thromboembolic Complications,Patients with Ch ronic,1
PROMACTA,Thromboembolic Complications,in,0
PROMACTA,Thromboembolic Complications,and Precautions Hepatotoxicity see Warnings,0
PROMACTA,Portal vein thrombosis,Hepatitis C [see W arnings and Precautions Hepatotoxicity,1
PROMACTA,Portal vein thrombosis,Patients with nic Hepatitis C [see W arnings and,1
PROMACTA,Portal vein thrombosis,Hepatitis C [see W arnings and Precautions Hepatotoxicity,1
PROMACTA,Portal vein thrombosis,in other sections,0
PROMACTA,Portal vein thrombosis,nic,1
PROMACTA,Portal vein thrombosis,C [see W arnings,1
PROMACTA,Portal vein thrombosis,in Patients with nic Hepatitis C [see W,1
PROMACTA,hepatic decompensation,ns In adult patients with,0
PROMACTA,hepatic decompensation,qual to 5% and greater than placebo were nausea,1
PROMACTA,hepatic decompensation,ns In adult patients with,0
PROMACTA,ascites,nausea diarrhea,0
PROMACTA,ascites,"increased LT, mya lgia and urinary tract infection",1
PROMACTA,ascites,nausea diarrhea,0
PROMACTA,ascites,"vomiting increased LT,",1
PROMACTA,ascites,infection In pediatric patients age,0
PROMACTA,ascites,"LT, mya lgia and",1
PROMACTA,encephalopathy,and urinary t ract infection In,1
PROMACTA,encephalopathy,infection vomiting increased ALT and urinary,1
PROMACTA,hepatic decompensation,associated thrombocyto,1
PROMACTA,hepatic decompensation,associated thrombocyto penia the most common,1
PROMACTA,hepatic decompensation,associated thrombocyto,1
PROMACTA,hepatic decompensation,chronic hepatitis associated thrombocyto,1
PROMACTA,hepatic decompensation,chronic hepatitis,0
PROMACTA,hepatic decompensation,associated thrombocyto penia the most common,1
PROMACTA,hepatic decompensation,chronic hepatitis associated thrombocyto penia the,1
PROMACTA,hepatic decompensation,associated thrombocyto penia the most common,1
PROMACTA,liver enzyme elevations,appet,0
PROMACTA,liver enzyme elevations,influenza-like ill ness asthenia insomnia cough,1
PROMACTA,indirect hyperbilirubinemia,headache EXCERPT To,0
PROMACTA,indirect hyperbilirubinemia,diarrhea and headache EXCERPT To report SUSPECTED,0
PROMACTA,indirect hyperbilirubinemia,"NS, contact GlaxoSmithKline",1
PROMACTA,indirect hyperbilirubinemia,at or,0
PROMACTA,indirect hyperbilirubinemia,diarrhea and headache EXCERPT To,0
PROMACTA,indirect hyperbilirubinemia,cough diarrhea and headache EXCERPT To report,0
PROMACTA,indirect hyperbilirubinemia,"NS, contact GlaxoSmithKline at or FDA",1
PROMACTA,indirect hyperbilirubinemia,cough diarrhea and headache EXCERPT To report,0
PROMACTA,indirect hyperbilirubinemia,report SUSPECTED ADVERSE REACTIO,0
PROMACTA,Hepatotoxicity, administered  to patients for,1
PROMACTA,Hepatotoxicity,for at least year Table presents,0
PROMACTA,thrombotic event,Table Adverse tions (>=3%) fro m,1
PROMACTA,thrombotic event,for at least year Table presents,0
PROMACTA,thrombotic complications,"    
  Pharyngitis       Back pai",1
PROMACTA,thrombotic complications,"    
  Pharyngitis       Back pai",1
PROMACTA,thrombotic complications,"    
  Pharyngitis       Back pai",1
PROMACTA,portal venous thrombosis,clinical chronic ITP trials alopecia musculoskeletal pain,1
PROMACTA,portal venous thrombosis,In the three rolled,1
PROMACTA,portal venous thrombosis,increased and dry mouth,0
PROMACTA,portal venous thrombosis,rolled clinical chronic ITP trials,1
PROMACTA,portal venous thrombosis,alopecia,0
PROMACTA,portal venous thrombosis,pain,0
PROMACTA,cataracts,ceived PR OMACTA in the,1
PROMACTA,cataracts,singlearm extension trial the adverse reactions occurred in a,0
PROMACTA,cataracts,reactions experienced by greater than or,0
PROMACTA,cataracts,occurred in a,0
PROMACTA,cataracts,placebocontrolled .,1
PROMACTA,cataracts,to,0
PROMACTA,cataracts,. Table 5 presents,1
PROMACTA,cataracts,Reactions from Extension Trial in,1
PROMACTA,cataracts,the extension,0
PROMACTA,cataracts,Reactions from Extension Trial in Adults,1
PROMACTA,cataracts,Reactions from Extension,1
PROMACTA,cataracts,extension trial Table Treatmentrelated Reactions from,1
PROMACTA,cataracts,Reactions from Extension,1
PROMACTA,Cataracts,action    PROMACTA mg,1
PROMACTA,Cataracts,action    PROMACTA mg,1
PROMACTA,Cataracts,Thrombocytopenia Adverse action    PROMACTA,1
PROMACTA,Cataracts,action    PROMACTA mg,1
PROMACTA,Cataracts,Thrombocytopenia Adverse action    PROMACTA mg n,1
PROMACTA,Cataracts,action    PROMACTA mg,1
PROMACTA,Cataracts,mg,0
PROMACTA,Cataracts,action    PROMACTA mg n,1
PROMACTA,Cataracts,mg,0
PROMACTA,Cataracts,Adverse Re,0
BESIVANCE,ocular adverse reaction,adverse reaction was conjunctival,1
BESIVANCE,conjunctival redness,of bacterial conjunctivitis The most frequently reported ocular adverse reaction,0
BESIVANCE,conjunctival redness,ocular adverse reaction conjunctival redness reported in approximately of,1
BESIVANCE,conjunctival redness,of bacterial conjunctivitis The most frequently reported ocular adverse reaction,0
BESIVANCE,conjunctival redness,adverse reactions,0
BESIVANCE,conjunctival redness,adverse reaction conjunctival redness,1
BESIVANCE,conjunctival redness,adverse reactions,0
BESIVANCE,conjunctival redness,reported ocular adverse,0
BESIVANCE,conjunctival redness,of bacterial conjunctivitis The,0
BESIVANCE,conjunctival redness,reported ocular adverse reaction conjunctival redness reported in approximately,1
BESIVANCE,conjunctival redness,of bacterial conjunctivitis The,0
BESIVANCE,conjunctival redness,adverse reaction conjunctival redness reported in,1
BESIVANCE,conjunctival redness,of bacterial conjunctivitis The,0
BESIVANCE,conjunctival redness,reaction,0
BESIVANCE,conjunctival redness,in,0
BESIVANCE,blurred vision,in approximately of patients blurred vision,1
BESIVANCE,blurred vision,blurred vision,1
BESIVANCE,blurred vision,included,0
BESIVANCE,blurred vision,blurred vision eye pain eye,1
BESIVANCE,blurred vision,patients receiving Besivance occurring,0
BESIVANCE,blurred vision,patients blurred vision eye pain eye irritation,1
BESIVANCE,blurred vision,patients receiving Besivance occurring,0
BESIVANCE,blurred vision,blurred vision eye pain eye irritation eye,1
BESIVANCE,blurred vision,patients receiving Besivance occurring,0
BESIVANCE,blurred vision,in approximately of patients blurred vision eye pain,1
BESIVANCE,blurred vision,patients receiving Besivance occurring,0
BESIVANCE,eye pain,patients included blurred eye pain eye,1
BESIVANCE,eye pain,patients receiving Besivance occurring,0
BESIVANCE,eye pain,most common,0
BESIVANCE,eye irritation,eye irritation eye,1
BESIVANCE,eye irritation,eye,1
BESIVANCE,eye irritation,eye irritation eye,1
BESIVANCE,eye irritation,eye,1
BESIVANCE,eye irritation,eye irritation,1
BESIVANCE,eye irritation,reaction reported,0
BESIVANCE,eye irritation,vision,0
BESIVANCE,eye pruritus,common adverse reaction reported in of patients treated,0
BESIVANCE,eye pruritus,reaction reported in of patients treated,0
BESIVANCE,eye pruritus,eye eye pruritus,1
BESIVANCE,eye pruritus,pain eye eye pruritus,1
BESIVANCE,eye pruritus,eye eye pruritus,1
BESIVANCE,eye pruritus,eye pruritus,1
BESIVANCE,eye pruritus,pain eye eye pruritus,1
BESIVANCE,eye pruritus,headache EXCERPT The most common adverse reaction reported in of,0
BESIVANCE,eye pruritus,eye eye pruritus,1
BESIVANCE,headache,headache EXCERPT The most common,1
BESIVANCE,headache,headache EXCERPT The most common,1
BESIVANCE,headache,headache EXCERPT The,1
BESIVANCE,headache,eye pruritus and,0
BESIVANCE,headache,approximately of patients included blurred vision eye pain eye irritation,0
BESIVANCE,headache,headache EXCERPT The most common,1
BESIVANCE,headache,headache EXCERPT The most,1
BESIVANCE,headache,headache EXCERPT The most,1
BESIVANCE,headache,headache EXCERPT The,1
BESIVANCE,headache,most common adverse reaction,0
BESIVANCE,conjunctival redness,most common,0
BESIVANCE,conjunctival redness,conjunctival redness,1
BESIVANCE,conjunctival redness,most common,0
BESIVANCE,conjunctival redness,Bausch Lomb,0
BESIVANCE,conjunctival redness,conjunctival redness To report SUSPECTED,1
BESIVANCE,conjunctival redness,Bausch Lomb,0
BESIVANCE,conjunctival redness,adverse reaction reported in,0
BESIVANCE,conjunctival redness,conjunctival redness To report SUSPECTED ADVERSE REACTIONS,1
BESIVANCE,conjunctival redness,The most common adverse reaction reported in of patients treated with,0
BESIVANCE,overgrowth of non-susceptible organisms,"vision eye pain eye itation, eye pruritus and headache.



 EXCERPT The most",1
BESIVANCE,overgrowth of non-susceptible organisms,The most common adverse reaction reported in of patients treated with,0
BESIVANCE,overgrowth of non-susceptible organisms,"eye itation, eye pruritus and headache.",1
BESIVANCE,overgrowth of non-susceptible organisms,blurred vision eye pain,0
BESIVANCE,overgrowth of non-susceptible organisms,"eye itation, eye pruritus",1
BESIVANCE,overgrowth of non-susceptible organisms,pruritus and headache. EXCERPT The most,1
BESIVANCE,overgrowth of non-susceptible organisms,"vision eye pain eye itation,",1
BESIVANCE,overgrowth of non-susceptible organisms,"vision eye pain eye itation, eye pruritus and headache.",1
BESIVANCE,overgrowth of non-susceptible organisms,"eye pain eye itation, eye pruritus and headache.



 EXCERPT The most",1
BESIVANCE,overgrowth of non-susceptible organisms,"vision eye pain eye itation, eye pruritus and headache.",1
BESIVANCE,overgrowth of non-susceptible organisms,vision eye pain,0
INLYTA,hypertension,hypertension arterial thromboembolic,1
INLYTA,hypertension,cardiac failure,0
INLYTA,hypertension,events venous thromboembolic events hemorrhage,0
INLYTA,hypertension,ussed in greater detail in other sections of the label seeWarnings and Precautions,0
INLYTA,arterial thromboembolic events,arterial thromboembolic,1
INLYTA,arterial thromboembolic events,and Precautions arterial thromboembolic events venous thromboembolic,1
INLYTA,arterial thromboembolic events,arterial thromboembolic,1
INLYTA,arterial thromboembolic events,thromboembolic events venous thromboembolic events,1
INLYTA,venous thromboembolic events,hemorrhage cardiac failure,0
INLYTA,venous thromboembolic events,failure gastrointestinal perforation and,0
INLYTA,venous thromboembolic events,hypertension arterial thromboembolic venous,1
INLYTA,venous thromboembolic events,venous thromboembolic events hemorrhage cardiac failure gastrointestinal,1
INLYTA,venous thromboembolic events,hypertension arterial thromboembolic venous thromboembolic events hemorrhage,1
INLYTA,venous thromboembolic events,venous thromboembolic events hemorrhage cardiac failure gastrointestinal,1
INLYTA,venous thromboembolic events,venous thromboembolic events hemorrhage cardiac failure,1
INLYTA,venous thromboembolic events,Precautions hypertension arterial thromboembolic,0
INLYTA,hemorrhage,thromboembolic events,0
INLYTA,hemorrhage,thromboembolic events,0
INLYTA,hemorrhage,hemorrhage cardiac,1
INLYTA,hemorrhage,hypertension arterial thromboembolic events venous,0
INLYTA,hemorrhage,thromboembolic,0
INLYTA,hemorrhage,hemorrhage cardiac failure gastrointestinal perforation and,1
INLYTA,hemorrhage,events,0
INLYTA,hemorrhage,hemorrhage cardiac failure gastrointestinal perforation,1
INLYTA,cardiac failure,cardiac failure,1
INLYTA,cardiac failure,cardiac failure gastrointestinal perforation and fistula formation,1
INLYTA,cardiac failure,events,0
INLYTA,cardiac failure,gastrointestinal perforation and fistula formation thyroid,0
INLYTA,gastrointestinal perforation,hemorrhage cardiac gastrointestinal perforation,1
INLYTA,gastrointestinal perforation,venous,0
INLYTA,fistula formation,fistula formation,1
INLYTA,fistula formation,healing complications RPLS proteinuria elevation of liver enzymes,0
INLYTA,fistula formation,fistula formation thyroid dysfunction wound,1
INLYTA,fistula formation,healing complications RPLS proteinuria elevation of liver enzymes,0
INLYTA,fistula formation,perforation fistula formation,1
INLYTA,fistula formation,failure gastrointestinal perforation and,0
INLYTA,fistula formation,perforation fistula,1
INLYTA,fistula formation,cardiac failure gastrointestinal perforation fistula formation thyroid dysfunction wound healing complications,1
INLYTA,fistula formation,perforation fistula,1
INLYTA,fistula formation,fistula formation thyroid dysfunction,1
INLYTA,fistula formation,fistula formation thyroid dysfunction wound healing complications,1
INLYTA,thyroid dysfunction,mboembolic events,0
INLYTA,thyroid dysfunction,thyroid dysfunction wound,1
INLYTA,thyroid dysfunction,wound healing complications RPLS proteinuria,0
INLYTA,thyroid dysfunction,thyroid dysfunction wound healing complications RPLS proteinuria,1
INLYTA,thyroid dysfunction,perforation and fistula thyroid,1
INLYTA,thyroid dysfunction,and fistula thyroid,1
INLYTA,thyroid dysfunction,thyroid dysfunction wound healing complications,1
INLYTA,thyroid dysfunction,hepatic,0
INLYTA,thyroid dysfunction,formation,0
INLYTA,RPLS,RPLS proteinuria elevation of liver enzymes,1
INLYTA,proteinuria,wound healing complications,0
INLYTA,proteinuria,proteinuria elevation of,1
INLYTA,proteinuria,proteinuria elevation of liver,1
INLYTA,proteinuria,healing complications,0
INLYTA,proteinuria,proteinuria elevation,1
INLYTA,proteinuria,proteinuria,1
INLYTA,hepatic impairment,of liver hepatic,1
INLYTA,hepatic impairment,dysfunction wound,0
INLYTA,hepatic impairment,hepatic impairment,1
INLYTA,hepatic impairment,are,0
INLYTA,hepatic impairment,proteinuria elevation of liver hepatic,1
INLYTA,hepatic impairment,liver hepatic impairment and fetal,1
INLYTA,hepatic impairment,proteinuria elevation of liver hepatic,1
INLYTA,hepatic impairment,hepatic impairment and,1
INLYTA,diarrhea,diarrhea,1
INLYTA,hypertension,nausea dysphonia palmarplantar erythrodysesthesia handfoot synd,0
INLYTA,hypertension,hypertension fatigue decreased appetite nausea dysphonia,1
INLYTA,hypertension,nausea dysphonia palmarplantar erythrodysesthesia handfoot synd,0
INLYTA,hypertension,dysphonia palmarplantar,0
INLYTA,hypertension,reactions are hypertension fatigue decreased appetite nausea,1
INLYTA,hypertension,dysphonia palmarplantar,0
INLYTA,fatigue,fatigue decreased appetite nausea,1
INLYTA,fatigue,fatigue decreased appetite nausea dysphonia,1
INLYTA,fatigue,fatigue decreased appetite nausea dysphonia,1
INLYTA,fatigue,fatigue decreased appetite nausea dysphonia palmarplantar,1
INLYTA,fatigue,fatigue decreased appetite nausea dysphonia palmarplantar,1
INLYTA,fatigue,dysphonia palmarplantar,0
INLYTA,fatigue,reactions are diarrhea fatigue decreased appetite,1
INLYTA,fatigue,dysphonia palmarplantar,0
INLYTA,fatigue,diarrhea fatigue,1
INLYTA,fatigue,dysphonia palmarplantar,0
INLYTA,fatigue,fatigue decreased appetite nausea dysphonia palmarplantar,1
INLYTA,decreased appetite,decreased appetite nausea,1
INLYTA,decreased appetite,reactions are diarrhea hypertension,0
INLYTA,decreased appetite,diarrhea hypertension decreased appetite nausea dysphonia palmarplantar,1
INLYTA,decreased appetite,reactions are diarrhea hypertension,0
INLYTA,decreased appetite,are diarrhea hypertension decreased appetite,1
INLYTA,decreased appetite,weight decreased vomit,0
INLYTA,decreased appetite,decreased appetite nausea,1
INLYTA,decreased appetite,EXCERPT The most,0
INLYTA,nausea,nausea dysphonia palmarplantar,1
INLYTA,dysphonia,dysphonia palmarplantar erythrodysesthesia handfoot,1
INLYTA,dysphonia,palmarplantar erythrodysesthesia handfoot syndrome weight decreased vomiting asthenia and,0
INLYTA,dysphonia,dysphonia palmarplantar erythrodysesthesia handfoot syndrome,1
INLYTA,weight decreased,ADVERSE REACTIONS contact,0
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot syndrome,0
INLYTA,weight decreased,weight decreased vomiting asthenia and,1
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot syndrome,0
INLYTA,weight decreased,SUSPECTED ADVERSE,0
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot weight decreased vomiting asthenia and constipation To,1
INLYTA,weight decreased,SUSPECTED ADVERSE,0
INLYTA,weight decreased,weight decreased,1
INLYTA,weight decreased,weight decreased,1
INLYTA,vomiting,vomiting asthenia,1
INLYTA,vomiting,weight decreased,1
INLYTA,vomiting,handfoot syndrome weight decreased,0
INLYTA,vomiting,vomiting asthenia,1
INLYTA,vomiting,vomiting,1
INLYTA,asthenia,and constipation To report SUSPECTED ADVERSE REACTIONS,0
INLYTA,asthenia,ADVERSE REACTIONS contact Pfizer Inc,0
INLYTA,asthenia,handfoot syndrome weight decreased asthenia,1
INLYTA,asthenia,ADVERSE REACTIONS contact Pfizer Inc,0
INLYTA,constipation,constipation,1
INLYTA,constipation,ADVERSE REACTIONS contact Pfizer Inc,0
INLYTA,constipation,handfoot syndrome weight decreased vomiting asthenia,0
INLYTA,constipation,erythrodysesthesia handfoot syndrome,0
INLYTA,constipation,palmarplantar erythrodysesthesia handfoot syndrome,0
INLYTA,constipation,and,0
INLYTA,constipation,constipation To report SUSPECTED ADVERSE REACTIONS,1
INLYTA,constipation,constipation To report SUSPECTED ADVERSE REACTIONS,1
INLYTA,constipation,To report SUSPECTED ADVERSE REACTIONS,0
INLYTA,diarrhea,diarrhea hypertension fatigue,1
INLYTA,diarrhea,reactions observed,0
INLYTA,diarrhea,diarrhea hypertension fatigue decreased appetite nausea,1
INLYTA,diarrhea,reactions observed,0
INLYTA,diarrhea,INLYTA diarrhea,1
INLYTA,diarrhea,reactions observed,0
INLYTA,diarrhea,following treatment with INLYTA diarrhea hypertension fatigue,1
INLYTA,diarrhea,reactions observed,0
INLYTA,hypertension,adverse reactions observed following treatment with INLYTA were diarrhea,0
INLYTA,hypertension,INLYTA were hypertension fatigue,1
INLYTA,hypertension,adverse reactions observed following treatment with INLYTA were diarrhea,0
INLYTA,hypertension,palmarplantar erythrodysesthesia handfoot,0
INLYTA,hypertension,hypertension fatigue,1
INLYTA,hypertension,hypertension fatigue,1
INLYTA,fatigue,were diarrhea fatigue decreased appetite nausea,1
INLYTA,fatigue,hypertension fatigue,1
INLYTA,fatigue,fatigue decreased appetite,1
INLYTA,fatigue,with INLYTA were diarrhea fatigue decreased,1
INLYTA,fatigue,fatigue decreased appetite,1
INLYTA,fatigue,fatigue decreased,1
INLYTA,fatigue,with INLYTA were diarrhea fatigue decreased appetite nausea dysphonia,1
INLYTA,fatigue,fatigue decreased,1
INLYTA,fatigue,mon adverse reactions observed following treatment,0
INLYTA,fatigue,fatigue decreased,1
INLYTA,fatigue,fatigue decreased appetite nausea,1
INLYTA,decreased appetite,diarrhea hypertension decreased appetite,1
INLYTA,decreased appetite,were diarrhea hypertension decreased,1
INLYTA,decreased appetite,adverse reactions observed following treatment with INLYTA were diarrhea,0
INLYTA,decreased appetite,decreased appetite nausea dysphonia palmarplantar erythrodysesthesia,1
INLYTA,decreased appetite,adverse reactions observed following treatment with INLYTA were diarrhea,0
INLYTA,decreased appetite,decreased appetite,1
INLYTA,decreased appetite,reactions observed following treatment with INLYTA were diarrhea,0
INLYTA,decreased appetite,erythrodysesthesia handfoot syndrome weight decreased,0
INLYTA,decreased appetite,hypertension decreased appetite nausea dysphonia palmarplantar erythrodysesthesia handfoot,1
INLYTA,decreased appetite,erythrodysesthesia handfoot syndrome weight decreased,0
INLYTA,decreased appetite,hypertension decreased,1
INLYTA,nausea,fatigue decreased,0
INLYTA,nausea,observed,0
INLYTA,dysphonia,d following treatment with,0
INLYTA,dysphonia,decreased appetite nausea,0
INLYTA,dysphonia,dysphonia palmarplantar,1
INLYTA,dysphonia,treatment with INLYTA were diarrhea hypertension,0
INLYTA,dysphonia,decreased appetite dysphonia,1
INLYTA,dysphonia,treatment with INLYTA were diarrhea hypertension,0
INLYTA,dysphonia,dysphonia palmarplantar erythrodysesthesia handfoot syndrome weight,1
INLYTA,dysphonia,treatment with INLYTA were diarrhea hypertension,0
INLYTA,dysphonia,following,0
INLYTA,dysphonia,dysphonia palmarplantar erythrodysesthesia handfoot syndrome weight,1
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot weight decreased vomiting asthenia and constipation Table,1
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot syndrome weight,1
INLYTA,weight decreased,palmarplantar erythrodysesthesia handfoot weight,1
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot syndrome,0
INLYTA,weight decreased,palmarplantar erythrodysesthesia handfoot weight decreased vomiting asthenia,1
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot syndrome,0
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot weight decreased vomiting asthenia and constipation,1
INLYTA,weight decreased,dysphonia palmarplantar erythrodysesthesia handfoot syndrome,0
INLYTA,vomiting,decreased,0
INLYTA,asthenia,asthenia and constipation Table,1
INLYTA,asthenia,decreased,0
INLYTA,asthenia,asthenia and constipation Table presents,1
INLYTA,asthenia,asthenia,1
INLYTA,asthenia,handfoot syndrome weight decreased asthenia,1
INLYTA,asthenia,asthenia,1
INLYTA,asthenia,syndrome weight decreased asthenia and constipation Table presents,1
INLYTA,asthenia,asthenia,1
INLYTA,asthenia,handfoot syndrome weight decreased asthenia and constipation Table presents adverse,1
INLYTA,asthenia,asthenia,1
INLYTA,asthenia,asthenia and constipation Table presents,1
INLYTA,asthenia,asthenia and constipation,1
INLYTA,asthenia,dysphonia,0
INLYTA,constipation,decreased,0
INLYTA,constipation,vomiting asthenia constipation Table,1
INLYTA,constipation,decreased,0
INLYTA,constipation,decreased vomiting asthenia constipation Table presents adverse reactions reported,1
INLYTA,constipation,decreased,0
INLYTA,constipation,Table presents adverse reactions,0
INLYTA,constipation,adverse reactions reported in patients who received INLYTA or,0
INLYTA,constipation,constipation,1
INLYTA,constipation,constipation Table presents adverse reactions,1
INLYTA,constipation,Table presents,0
INLYTA,constipation,handfoot syndrome weight,0
INLYTA,dizziness,adverse reactions all grades,0
INLYTA,myalgia,myalgia,1
INLYTA,dehydration,treated with INLYTA included,0
INLYTA,dehydration,tinnitus,0
INLYTA,dehydration,abdominal pain dehydration epistaxis anemia hemorrhoids hematuria tinnitus,1
INLYTA,dehydration,tinnitus,0
INLYTA,dehydration,dehydration epistaxis anemia hemorrhoids hematuria,1
INLYTA,dehydration,tinnitus,0
INLYTA,dehydration,dehydration epistaxis,1
INLYTA,dehydration,hemorrhoids hematuria tinnitus,0
INLYTA,dehydration,upper abdominal pain dehydration epistaxis,1
INLYTA,dehydration,hemorrhoids hematuria tinnitus,0
INLYTA,dehydration,dehydration epistaxis anemia hemorrhoids hematuria,1
INLYTA,dehydration,dehydration epistaxis anemia hemorrhoids hematuria tinnitus,1
INLYTA,epistaxis,epistaxis anemia hemorrhoids hematuria tinnitus,1
INLYTA,anemia,dehydration anemia hemorrhoids hematuria tinnitus,1
INLYTA,anemia,epistaxis anemia hemorrhoids hematuria tinnitus,1
INLYTA,anemia,lipase increased,0
INLYTA,hemorrhoids,hemorrhoids,1
INLYTA,hemorrhoids,hemorrhoids hematuria tinnitus lipase increased,1
INLYTA,hemorrhoids,hemorrhoids,1
INLYTA,hemorrhoids,hematuria tinnitus lipase increased glossodynia,0
INLYTA,hemorrhoids,myalgia dehydration epistaxis hemorrhoids hematuria tinnitus lipase increased,1
INLYTA,hemorrhoids,hematuria tinnitus lipase increased glossodynia,0
INLYTA,hemorrhoids,dehydration epistaxis hemorrhoids hematuria tinnitus lipase increased glossodynia,1
INLYTA,hemorrhoids,hematuria tinnitus lipase increased glossodynia,0
INLYTA,hematuria,glossodynia pulmonary,0
INLYTA,hematuria,tinnitus,0
INLYTA,hematuria,pain myalgia dehydration epistaxis anemia,0
INLYTA,hematuria,increased glossodynia pulmonary embolism,0
INLYTA,hematuria,epistaxis,0
INLYTA,lipase increased,hemorrhoids,0
INLYTA,glossodynia,glossodynia,1
INLYTA,glossodynia,glossodynia pulmonary embolism,1
INLYTA,glossodynia,glossodynia,1
INLYTA,glossodynia,increased,0
INLYTA,glossodynia,glossodynia,1
INLYTA,glossodynia,pulmonary embolism rectal,0
INLYTA,glossodynia,glossodynia pulmonary embolism rectal hemorrhage,1
INLYTA,glossodynia,hemoptysis deep,0
INLYTA,glossodynia,glossodynia pulmonary embolism rectal hemorrhage hemoptysis,1
INLYTA,pulmonary embolism,pulmonary,1
INLYTA,pulmonary embolism,increased pulmonary,1
INLYTA,pulmonary embolism,increased,0
INLYTA,pulmonary embolism,pulmonary embolism rectal hemorrhage,1
INLYTA,pulmonary embolism,pulmonary embolism rectal hemorrhage hemoptysis deep,1
INLYTA,pulmonary embolism,pulmonary embolism rectal hemorrhage,1
INLYTA,pulmonary embolism,increased pulmonary,1
INLYTA,pulmonary embolism,tinnitus lipase increased glossodynia,0
INLYTA,pulmonary embolism,pulmonary embolism,1
INLYTA,pulmonary embolism,hematuria tinnitus lipase increased pulmonary embolism rectal,1
INLYTA,pulmonary embolism,pulmonary embolism,1
INLYTA,rectal hemorrhage,hemoptysis deep vein thrombosis retinalvein occlusionthrombosis polycythe,0
INLYTA,rectal hemorrhage,rectal hemorrhage,1
INLYTA,rectal hemorrhage,retinalvein occlusionthrombosis,0
INLYTA,rectal hemorrhage,pulmonary rectal hemorrhage,1
INLYTA,rectal hemorrhage,rectal hemorrhage hemoptysis deep vein,1
INLYTA,rectal hemorrhage,hemoptysis deep vein thrombosis retinalvein occlusionthrombosis,0
INLYTA,rectal hemorrhage,hemoptysis deep vein thrombosis retinalvein,0
INLYTA,rectal hemorrhage,rectal hemorrhage,1
INLYTA,hemoptysis,deep vein,0
INLYTA,hemoptysis,deep vein thrombosis retinalvein occlusionthrombosis polycythemia,0
INLYTA,hemoptysis,rectal hemoptysis deep vein,1
INLYTA,hemoptysis,deep vein thrombosis retinalvein occlusionthrombosis polycythemia,0
INLYTA,hemoptysis,hemoptysis deep vein thrombosis retinalvein occlusionthrombosis,1
INLYTA,hemoptysis,hemoptysis deep vein thrombosis retinalvein,1
INLYTA,hemoptysis,polycythemia,0
INLYTA,hemoptysis,deep vein thrombosis retinalvein occlusionthrombosis,0
INLYTA,hemoptysis,hemorrhage,0
INLYTA,hemoptysis,glossodynia pulmonary embolism,0
INLYTA,deep vein thrombosis,deep,1
INLYTA,deep vein thrombosis,glossodynia pulmonary,0
INLYTA,deep vein thrombosis,embolism rectal hemorrhage deep vein thrombosis,1
INLYTA,deep vein thrombosis,glossodynia pulmonary,0
INLYTA,deep vein thrombosis,deep vein thrombosis retinalvein,1
INLYTA,deep vein thrombosis,glossodynia,0
INLYTA,deep vein thrombosis,hemorrhage deep vein thrombosis retinalvein occlusionthrombosis polycythemia and,1
INLYTA,deep vein thrombosis,glossodynia,0
INLYTA,deep vein thrombosis,pulmonary embolism rectal,0
INLYTA,deep vein thrombosis,hemoptysis,0
INLYTA,retinal-vein occlusion,vein,0
INLYTA,retinal-vein occlusion,hemorrhage hemoptysis deep vein retinal-vein occlusion thrombosis polycythemia and transient ischemic,1
INLYTA,retinal-vein occlusion,vein,0
INLYTA,retinal-vein occlusion,retinal-vein occlusion thrombosis polycythemia and,1
INLYTA,polycythemia,polycythemia and transient ischemic,1
INLYTA,polycythemia,polycythemia and transient ischemic attack Table,1
INLYTA,polycythemia,attack Table presents,0
INLYTA,polycythemia,polycythemia and transient ischemic,1
INLYTA,hemoglobin increased,with INLYTA hemoglobin,1
INLYTA,hemoglobin increased,and hypercalcemia for,0
INLYTA,hemoglobin increased,hemoglobin increased above the upper limit of,1
INLYTA,hemoglobin increased,and hypercalcemia for,0
INLYTA,hemoglobin increased,hemoglobin increased above,1
INLYTA,hemoglobin increased,with INLYTA hemoglobin,1
INLYTA,hemoglobin increased,with INLYTA hemoglobin,1
INLYTA,hypercalcemia,INLYTA versus for sorafenib,0
INLYTA,hypercalcemia,hypercalcemia for INLYTA versus,1
INLYTA,hypercalcemia,hypercalcemia for,1
INLYTA,hypercalcemia,versus,0
INLYTA,hypercalcemia,hypercalcemia for INLYTA versus for,1
INLYTA,hypercalcemia,for,0
INLYTA,hypercalcemia,INLYTA versus for sorafenib hypercalcemia for INLYTA,1
INLYTA,hypercalcemia,for,0
INLYTA,hypercalcemia,hypercalcemia,1
INLYTA,hypercalcemia,hypercalcemia for INLYTA versus for,1
INLYTA,Hypertension,are conduct,1
INLYTA,Hypertension,ADVERSE REACTIONS,0
INLYTA,Hypertension,of,0
INLYTA,hypertensive crisis,varying condit,1
INLYTA,hypertensive crisis,varying condit ions,1
INLYTA,hypertensive crisis,drug cannot be,0
INLYTA,hypertensive crisis,are conducted under,0
INLYTA,venous thrombotic events,rates observed in clinical practice The safety of INLYTA has been evaluated,0
INLYTA,fatal,studies which included atien ts with,1
INLYTA,fatal,rates observed in clinical practice The safety of INLYTA has been evaluated,0
INLYTA,fatal,which included atien ts with advanced RCC The,1
INLYTA,fatal,rates observed in clinical practice The safety of INLYTA has been evaluated,0
INLYTA,fatal,atien ts,1
INLYTA,fatal,atien ts,1
INLYTA,fatal,monotherapy studies which included atien ts,1
INLYTA,fatal,atien ts,1
INLYTA,fatal,monotherapy studies which included atien ts with advanced RCC The,1
INLYTA,fatal,atien ts,1
INLYTA,fatal,p,0
INLYTA,fatal,included p,0
INLYTA,fatal,atien ts with,1
INLYTA,fatal,included p,0
INLYTA,fatal,which included atien ts with,1
INLYTA,fatal,included p,0
INLYTA,Hemorrhagic events,INLYTA in 359 pa tients,1
INLYTA,Hemorrhagic events,INLYTA in 359 pa tients with,1
INLYTA,Hemorrhagic events,study versus,0
INLYTA,Hemorrhagic events,359 pa tients with advanced RCC who,1
INLYTA,Hemorrhagic events,with,0
INLYTA,Hemorrhagic events,patients with advanced RCC The data described seeAdverse Reactions reflect exposure,0
INLYTA,Hemorrhagic events,advanced RCC The data described,0
INLYTA,fatal,reflect exposure to INLYTA in,0
INLYTA,fatal,INLYTA in,0
INLYTA,fatal,a,0
INLYTA,fatal,advan ced RCC who participated,1
INLYTA,fatal,patients advan ced RCC who,1
INLYTA,fatal,advan ced RCC who participated,1
INLYTA,fatal,advan ced RCC,1
INLYTA,fatal,advan ced RCC who participated,1
INLYTA,fatal,advan,1
INLYTA,fatal,patients advan ced RCC who participated,1
INLYTA,fatal,advan,1
INLYTA,fatal,The data described seeAdverse,0
INLYTA,Cardiac failure,sections of the,1
INLYTA,Cardiac failure,detail in er sections of,1
INLYTA,Cardiac failure,detail in er,1
INLYTA,Cardiac failure,sections of the label seeWarnings,1
INLYTA,Cardiac failure,er sections of,1
INLYTA,Cardiac failure,action to be,0
INLYTA,Cardiac failure,and Precautions,0
INLYTA,Cardiac failure,sections of the,1
INLYTA,Cardiac failure,following risks including appropriate action to be taken are discussed in greater,0
INLYTA,fatal,label seeWarnings and ecaut ions,1
INLYTA,fatal,following risks including appropriate action to be taken are discussed in greater,0
INLYTA,fatal,the label seeWarnings and ecaut ions hypertension arterial thromboembolic events,1
INLYTA,fatal,following risks including appropriate action to be taken are discussed in greater,0
INLYTA,fatal,ions,0
INLYTA,fatal,ions hypertension arterial thromboembolic events venous,0
INLYTA,fatal,ecaut ions hypertension arterial thromboembolic,1
INLYTA,fatal,ecaut ions hypertension arterial thromboembolic events,1
INLYTA,Gastrointestinal perforation,"hemorrhage, cardiac",1
INLYTA,Gastrointestinal perforation,"hemorrhage, cardiac failure, gastrointestinal perforation",1
INLYTA,death,ation,1
INLYTA,death,gastrointestinal ation and fistula formation,1
INLYTA,death,ation,1
INLYTA,death,wound healing complications RPLS proteinuria,0
INLYTA,death,ation and,1
INLYTA,death,wound healing,0
INLYTA,death,ation,1
INLYTA,death,formation thyroid dysfunction wound healing complications RPLS,0
INLYTA,death,gastrointestinal,0
INLYTA,death,ation and fistula,1
INLYTA,death,ation,1
INLYTA,Hypothyroidism,most,0
INLYTA,Hypothyroidism,"RPLS proteinuria elevation of r enzymes,",1
INLYTA,Hypothyroidism,"of r enzymes, hep atic impairment and fetal",1
INLYTA,Hypothyroidism,"RPLS proteinuria elevation of r enzymes,",1
INLYTA,Hypothyroidism,"of r enzymes,",1
INLYTA,Hypothyroidism,"r enzymes, hep atic impairment and fetal development",1
INLYTA,Hypothyroidism,of r,1
INLYTA,Reversible Posterior Leukoencephalopathy Syndrome,"erythrodysesthesia handfoot syndrome decreased, vomiting, asthenia, and",1
INLYTA,RPLS,"and .1)
",1
INLYTA,RPLS,"erythrodysesthesia handfoot syndrome decreased, vomiting, asthenia, and",1
INLYTA,RPLS,".1)
 To report SUSPECTED ADVERSE",1
INLYTA,RPLS,".1)
 To",1
INLYTA,RPLS,"vomiting asthenia and .1)
 To report SUSPECTED",1
INLYTA,RPLS,".1)
 To",1
INLYTA,RPLS,".1)
 To report",1
INLYTA,RPLS,"decreased vomiting asthenia and .1)
 To",1
INLYTA,RPLS,".1)
 To report",1
INLYTA,RPLS,".1)
 To report",1
INLYTA,RPLS,".1)
 To report",1
INLYTA,RPLS,"decreased vomiting asthenia and .1)
 To report SUSPECTED ADVERSE REACTIONS",1
INLYTA,RPLS,".1)
 To report",1
INLYTA,RPLS,REACTIONS contact Pfizer Inc at,0
INLYTA,Liver enzyme elevation,and months range 20.1) for patients who received,1
INLYTA,Liver enzyme elevation,REACTIONS contact Pfizer Inc at,0
INLYTA,Liver enzyme elevation,adverse reaction,0
INLYTA,fetal harm,sorafenib The most 0%) advers,1
INLYTA,fetal harm,diarrhea,0
INLYTA,fetal harm,patients receiving,0
INLYTA,fetal harm,receiving sorafenib The most 0%) advers e,1
INLYTA,fetal harm,patients receiving,0
INLYTA,fetal harm,The most 0%),1
INLYTA,hypertension,Adverse ctions Occur,1
INLYTA,hypertension,Adverse ctions Occur ring in,1
INLYTA,hypertension,Adverse ctions Occur,1
INLYTA,hypertension,reactions reported in patients who received INLYTA or sorafenib Table,0
INLYTA,hypertension,ctions Occur,1
INLYTA,hypertension,Adverse ctions Occur ring in of,1
INLYTA,hypertension,ctions Occur,1
INLYTA,hypertension,sorafenib Table Adverse ctions Occur,1
INLYTA,hypertension,sorafenib Table Adverse ctions,1
INLYTA,hypertension,ctions Occur ring in of Patients,1
INLYTA,hypertension,sorafenib Table Adverse ctions,1
INLYTA,hypertension,N N,0
INLYTA,hypertension,        Sora fenib,1
INLYTA,hypertension,N N,0
INLYTA,hypertension,        Sora fenib N,1
INLYTA,hypertension,        Sora fenib,1
INLYTA,hypertension,        Sora fenib N N All,1
INLYTA,hypertension,        Sora fenib N N All,1
INLYTA,hypertension,Sorafenib Adverse Reaction         Sora fenib N N,1
INLYTA,hypertension,        Sora fenib N N All,1
INLYTA,hypertension,        Sora fenib,1
INLYTA,hypertension,        Sora fenib N N All,1
INLYTA,hypertension,        Sora fenib N N All Grades,1
INLYTA,Hypertensive crisis,                 Gr ade All,1
INLYTA,Hypertensive crisis,All,0
INLYTA,hemorrhagic events,pper abdominal pai n myalgia dehydration epistaxis,1
INLYTA,hemorrhagic events,n myalgia dehydration epistaxis anemia,0
INLYTA,hemorrhagic events,INLYTA included dizziness pper abdominal pai,1
INLYTA,hemorrhagic events,dizziness pper abdominal pai,1
INLYTA,hemorrhagic events,included,0
INLYTA,hemorrhagic events,pper abdominal pai n myalgia dehydration epistaxis,1
INLYTA,hemorrhagic events,included,0
INLYTA,hemorrhagic events,epistaxis anemia hemorrhoids,0
INLYTA,hemorrhagic events,of,0
INLYTA,hemorrhagic events,"%), lipase increas ed glossodynia pulmonary embolism rectal",1
INLYTA,hemorrhagic events,of,0
INLYTA,hemorrhagic events,lipase increas ed glossodynia pulmonary embolism,1
INLYTA,hemorrhagic events,"hematuria %), lipase increas",1
INLYTA,hemorrhagic events,lipase increas ed glossodynia pulmonary embolism,1
INLYTA,hemorrhagic events,"epistaxis anemia hemorrhoids hematuria %),",1
INLYTA,cerebral hemorrhage,"age (2%), hemoptysi s",1
INLYTA,cerebral hemorrhage,pulmonary embolism rectal age,1
INLYTA,cerebral hemorrhage,"(2%), hemoptysi s deep vein",1
INLYTA,cerebral hemorrhage,"pulmonary embolism rectal age (2%), hemoptysi s deep",1
INLYTA,cerebral hemorrhage,"(2%), hemoptysi s deep vein",1
INLYTA,cerebral hemorrhage,rectal age,1
INLYTA,cerebral hemorrhage,"glossodynia pulmonary embolism rectal age (2%), hemoptysi",1
INLYTA,hematuria,"embolism rectal hemorrhage (2%), dee p",1
INLYTA,hematuria,"glossodynia pulmonary embolism rectal age (2%), hemoptysi",1
INLYTA,hematuria,"pulmonary embolism rectal hemorrhage (2%),",1
INLYTA,hematuria,"embolism rectal hemorrhage (2%), dee",1
INLYTA,hematuria,rectal hemorrhage,0
INLYTA,hemoptysis,rectal hemorrhage hemoptysis vein throm bosis retinalvein occlusionthrombosis,1
INLYTA,hemoptysis,rectal hemorrhage,0
INLYTA,lower gastrointestinal hemorrhage,"deep vein sis (1%), retinal-vein",1
INLYTA,lower gastrointestinal hemorrhage,"hemoptysis deep vein sis (1%), retinal-vein occlusion/ thrombosis polycythemia and transient ischemic",1
INLYTA,lower gastrointestinal hemorrhage,"deep vein sis (1%), retinal-vein",1
INLYTA,lower gastrointestinal hemorrhage,Table presents the,0
INLYTA,lower gastrointestinal hemorrhage,deep vein thrombo,0
INLYTA,lower gastrointestinal hemorrhage,"vein sis (1%), retinal-vein occlusion/",1
INLYTA,lower gastrointestinal hemorrhage,and transient ischemic attack Table,0
INLYTA,lower gastrointestinal hemorrhage,"sis (1%), retinal-vein occlusion/ thrombosis polycythemia and",1
INLYTA,lower gastrointestinal hemorrhage,"(1%), retinal-vein occlusion/ thrombosis polycythemia and",1
INLYTA,lower gastrointestinal hemorrhage,thrombosis polycythemia and transient ischemic,0
INLYTA,lower gastrointestinal hemorrhage,deep,0
INLYTA,Fatal,ttack Table presents,1
INLYTA,Fatal,transient ischemic ttack Table presents the,1
INLYTA,Fatal,ttack Table presents,1
INLYTA,Fatal,in patients who,0
INLYTA,Fatal,ttack Table presents,1
INLYTA,Fatal,presents the most common laboratory abnormalities reported in,0
INLYTA,Fatal,ischemic,0
INLYTA,hemorrhage,reported in,0
INLYTA,gastric hemorrhage,the most common laboratory s reported in >=10 patients who,1
INLYTA,gastric hemorrhage,reported in,0
INLYTA,gastric hemorrhage,s reported in >=10 patients who,1
INLYTA,gastric hemorrhage,reported in,0
INLYTA,gastric hemorrhage,most common laboratory abnormalitie,0
INLYTA,gastric hemorrhage,patients who received INLYTA or sorafenib Table Laboratory Abnormalities Occurring,0
INLYTA,gastric hemorrhage,reported in >=10 patients,1
INLYTA,gastric hemorrhage,s reported in >=10 patients who received,1
INLYTA,gastric hemorrhage,reported in >=10 patients,1
INLYTA,gastric hemorrhage,s reported in >=10 patients who received INLYTA or,1
INLYTA,gastric hemorrhage,the most common laboratory s reported in >=10 patients who received INLYTA or,1
INLYTA,gastric hemorrhage,s reported in >=10 patients who received INLYTA or,1
INLYTA,gastric hemorrhage,reported in >=10 patients who received,1
INLYTA,gastric hemorrhage,common,0
INLYTA,cardiac failure,aminotransferase AST aspartate,0
INLYTA,cardiac failure,aminotransferase AST,0
INLYTA,cardiac failure,sphatase;,1
INLYTA,cardiac failure,AST aspartate aminotransferase Hematology,0
INLYTA,cardiac failure,ALP,0
INLYTA,cardiac failure,sphatase; ALT:,1
INLYTA,cardiac failure,ALP alkaline sphatase;,1
INLYTA,cardiac failure,sphatase; ALT:,1
INLYTA,cardiac failure,ALP alkaline sphatase; ALT: ,1
INLYTA,cardiac failure,sphatase; ALT:,1
INLYTA,cardiac failure,sphatase; ALT: alanine aminotransferase,1
INLYTA,cardiac failure,                Hemoglobin decreased,1
INLYTA,cardiac failure,                Hemoglobin decreased,1
INLYTA,cardiac failure,AST aspartate aminotransferase                 Hemoglobin,1
INLYTA,cardiac failure,                Hemoglobin decreased,1
INLYTA,cardiac failure,aspartate aminotransferase Hematology,0
INLYTA,Fatal,   32 Lymphocytes absolute decreas,1
INLYTA,Fatal,aspartate aminotransferase Hematology,0
INLYTA,Fatal,Hemoglobin    32 Lymphocytes absolute,1
INLYTA,Fatal,aspartate aminotransferase Hematology,0
INLYTA,Fatal,   32 Lymphocytes absolute,1
INLYTA,Fatal,Lymphocytes,0
INLYTA,Fatal,decreased,0
INLYTA,Fatal,   32,1
INLYTA,Fatal,   32 Lymphocytes,1
INLYTA,Fatal,   32 Lymphocytes absolute,1
INLYTA,cardiac failure,decreased,0
INLYTA,cardiac failure,          35    Lymphocytes absolute decreased,1
INLYTA,cardiac failure,          35    Lymphocytes absolute,1
INLYTA,cardiac failure,          35    Lymphocytes absolute decreased,1
INLYTA,cardiac failure,          35    Lymphocytes absolute decreased,1
INLYTA,cardiac failure,          35    Lymphocytes absolute decreased,1
INLYTA,cardiac failure,          35    Lymphocytes,1
INLYTA,gastrointestinal perforation,istry                       ,1
INLYTA,gastrointestinal perforation,          35    Lymphocytes,1
INLYTA,gastrointestinal perforation,istry                        Creatinine,1
INLYTA,gastrointestinal perforation,          35    Lymphocytes,1
INLYTA,gastrointestinal perforation,istry                        Creatinine,1
INLYTA,gastrointestinal perforation,Creatinine 55,1
INLYTA,gastrointestinal perforation,increased,0
INLYTA,gastrointestinal perforation,Creatinine         55          0       ,1
INLYTA,gastrointestinal perforation,increased,0
INLYTA,gastrointestinal perforation,        55          0        Bicarbonate,1
INLYTA,gastrointestinal perforation,increased,0
INLYTA,gastrointestinal perforation,Creatinine 55,1
INLYTA,gastrointestinal perforation,Creatinine increased,0
INLYTA,gastrointestinal perforation,55,1
INLYTA,elevations of TSH,Amylase 319 33,1
INLYTA,elevations of TSH,319 33,1
INLYTA,elevations of TSH,Amylase   319          33,1
INLYTA,elevations of TSH,319 33,1
INLYTA,elevations of TSH,Amylase 319,1
INLYTA,elevations of TSH,increased,0
INLYTA,elevations of TSH,increased,0
INLYTA,elevations of TSH,319 33 ALT,1
INLYTA,elevations of TSH,319 33 ALT,1
INLYTA,RPLS,that were reported in f pa,1
INLYTA,RPLS,f pa,1
INLYTA,RPLS,f pa,1
INLYTA,RPLS,upper limit of normal for,0
INLYTA,RPLS,f pa tients treated with,1
INLYTA,headache, INLYTA  versus for sorafenib,1
INLYTA,headache, INLYTA ,1
INLYTA,headache, INLYTA  versus for sorafenib and hypercalcemia,1
INLYTA,headache,of normal  INLYTA  versus for,1
INLYTA,headache, INLYTA  versus for sorafenib and hypercalcemia,1
INLYTA,headache,normal,0
INLYTA,headache, INLYTA  versus,1
INLYTA,headache,sorafenib and hypercalcemia,0
INLYTA,headache,of,0
INLYTA,seizure,reated with INLYTA included hemoglobin increased above the upper limit of,0
INLYTA,seizure,rsus 1% for sorafenib,1
INLYTA,seizure,the upper limit of,0
INLYTA,seizure,INLYTA versus for,0
INLYTA,seizure,for INLYTA rsus 1%,1
INLYTA,seizure,for INLYTA rsus,1
INLYTA,seizure,INLYTA rsus 1%,1
INLYTA,seizure,for INLYTA rsus,1
INLYTA,lethargy,th INLYTA included hemoglobin increased above the upper limit of,0
INLYTA,lethargy,for,0
INLYTA,lethargy,normal for INLYTA versus or soraf enib and hypercalcemia,1
INLYTA,lethargy,for,0
INLYTA,lethargy,of normal,0
INLYTA,lethargy,normal,0
INLYTA,confusion,versus for ib) and h,1
INLYTA,confusion,ypercalcemia for INLYTA versus for sorafenib,0
INLYTA,blindness,for INLYTA versus for,0
INLYTA,blindness,sorafenib and ercalcemi a for INLYTA versus,1
INLYTA,blindness,for INLYTA versus for,0
INLYTA,blindness,ercalcemi a for INLYTA versus,1
INLYTA,blindness,ercalcemi a for INLYTA,1
NORTHERA,Supine Hypertension,of the Supine Hypertension see Warnings and Precautions Hyperpyrexia,1
NORTHERA,Supine Hypertension,ercalcemi a for INLYTA,1
NORTHERA,Supine Hypertension,the Supine Hypertension see Warnings and Precautions Hyperpyrexia,1
NORTHERA,Supine Hypertension,ercalcemi a for INLYTA,1
NORTHERA,Supine Hypertension,in more detail in the Warnings,0
NORTHERA,Supine Hypertension,section of the Supine Hypertension see Warnings and Precautions Hyperpyrexia,1
NORTHERA,Supine Hypertension,in more detail in the Warnings,0
NORTHERA,Hyperpyrexia,Hyperpyrexia and Confusion see,1
NORTHERA,Hyperpyrexia,Hyperpyrexia and Confusion see Warnings and,1
NORTHERA,Hyperpyrexia,Precautions,0
NORTHERA,Hyperpyrexia,ons section of the label Supine Hypertension see Warnings,0
NORTHERA,Hyperpyrexia,Precautions,0
NORTHERA,Confusion,Confusion see Warnings and Precautions,1
NORTHERA,Confusion,Confusion see Warnings and Precautions May,1
NORTHERA,Confusion,Confusion see Warnings and Precautions,1
NORTHERA,Confusion,Warnings and Precautions Hyperpyrexia,0
NORTHERA,Headache,Headache dizziness,1
NORTHERA,Headache,Headache dizziness nausea hypertension and fatigue,1
NORTHERA,Headache,Warnings and Precautions Headache,1
NORTHERA,Headache,Headache dizziness nausea hypertension and fatigue,1
NORTHERA,Headache,and congestive heart failure see Warnings and Precautions EXCERPT,0
NORTHERA,Headache,EXCERPT,0
NORTHERA,dizziness,Precautions EXCERPT dizziness nausea hypertension and fatigue,1
NORTHERA,dizziness,EXCERPT,0
NORTHERA,dizziness,dizziness nausea hypertension and fatigue,1
NORTHERA,dizziness,Warnings and,0
NORTHERA,dizziness,dizziness nausea hypertension,1
NORTHERA,dizziness,dizziness,1
NORTHERA,dizziness,dizziness nausea hypertension,1
NORTHERA,dizziness,dizziness nausea hypertension and fatigue greater,1
NORTHERA,dizziness,EXCERPT dizziness nausea hypertension and,1
NORTHERA,dizziness,dizziness nausea hypertension and fatigue greater,1
NORTHERA,dizziness,see Warnings and Precautions EXCERPT,0
NORTHERA,dizziness,Precautions,0
NORTHERA,nausea,nausea,1
NORTHERA,nausea,Headache dizziness,0
NORTHERA,nausea,nausea hypertension and fatigue greater than,1
NORTHERA,nausea,Precautions EXCERPT Headache nausea hypertension and fatigue greater,1
NORTHERA,nausea,nausea hypertension and fatigue greater than,1
NORTHERA,nausea,Precautions EXCERPT Headache dizziness,0
NORTHERA,nausea,dizziness,0
NORTHERA,nausea,tive heart failure see Warnings and,0
NORTHERA,nausea,nausea,1
NORTHERA,hypertension,Headache dizziness nausea,0
NORTHERA,hypertension,Headache,0
NORTHERA,hypertension,hypertension and,1
NORTHERA,fatigue,fatigue greater than,1
NORTHERA,fatigue,hypertension and,1
NORTHERA,fatigue,fatigue greater,1
NORTHERA,fatigue,hypertension and,1
NORTHERA,fatigue,fatigue greater,1
NORTHERA,fatigue,REACTIONS contact Lundbeck at,0
NORTHERA,fatigue,and,0
NORTHERA,fatigue,fatigue greater than To,1
NORTHERA,fatigue,fatigue greater,1
NORTHERA,fatigue,nausea hypertension fatigue greater than To report SUSPECTED,1
NORTHERA,fatigue,fatigue greater,1
NORTHERA,fatigue,than To report SUSPECTED ADVERSE REACTIONS contact Lundbeck,0
NORTHERA,fatigue,SUSPECTED ADVERSE,0
NORTHERA,headache,were,0
NORTHERA,headache,headache dizziness,1
NORTHERA,headache,headache dizziness nausea hypertension The most,1
NORTHERA,headache,headache dizziness,1
NORTHERA,headache,placebocontrolled,0
NORTHERA,headache,headache dizziness,1
NORTHERA,headache,The most,0
NORTHERA,headache,headache dizziness,1
NORTHERA,headache,the three placebocontrolled trials headache dizziness nausea hypertension,1
NORTHERA,headache,headache dizziness,1
NORTHERA,headache,three,0
NORTHERA,dizziness,dizziness nausea,1
NORTHERA,nausea,nausea,1
NORTHERA,nausea,dizziness,0
NORTHERA,nausea,adverse,0
NORTHERA,nausea,adverse reactions leading to,0
NORTHERA,nausea,nausea hypertension,1
NORTHERA,nausea,adverse reactions leading to,0
NORTHERA,nausea,nausea hypertension The,1
NORTHERA,nausea,nausea hypertension The most common,1
NORTHERA,nausea,headache nausea,1
NORTHERA,nausea,nausea hypertension The most common,1
NORTHERA,hypertension,from NORTHERA,0
NORTHERA,hypertension,the three placebocontrolled trials were,0
NORTHERA,hypertension,trials were headache dizziness hypertension The most common,1
NORTHERA,hypertension,the three placebocontrolled trials were,0
NORTHERA,hypertension,hypertension The,1
NORTHERA,hypertension,hypertension The most,1
NORTHERA,hypertension,NORTHERA were,0
NORTHERA,hypertension,dizziness hypertension The most common adverse reactions,1
NORTHERA,hypertension,NORTHERA were,0
NORTHERA,hypertension,trials were headache dizziness hypertension The,1
NORTHERA,hypertension,NORTHERA were,0
NORTHERA,hypertension,placebocontrolled,0
NORTHERA,increased blood pressure,increased blood pressure,1
NORTHERA,increased blood pressure,increased blood pressure and,1
NORTHERA,increased blood pressure,n The most common adverse reactions leading to discontinuation from NORTHERA,0
NORTHERA,increased blood pressure,increased,1
NORTHERA,increased blood pressure,from NORTHERA were,0
NORTHERA,increased blood pressure,discontinuation from NORTHERA were,0
NORTHERA,increased blood pressure,discontinuation from NORTHERA,0
NORTHERA,increased blood pressure,More,0
NORTHERA,increased blood pressure,blood pressure,1
NORTHERA,nausea,nausea Table Most,1
NORTHERA,nausea,nausea Table Most,1
NORTHERA,falls,a mean total exposure of approximately one,0
NORTHERA,falls,falls urinary,1
NORTHERA,falls,urinary tract infections headache syncope and dizziness,0
NORTHERA,falls,adverse events falls urinary tract,1
NORTHERA,falls,urinary tract infections headache syncope and dizziness,0
NORTHERA,falls,falls urinary tract infections,1
NORTHERA,falls,year,0
NORTHERA,falls,falls urinary tract,1
NORTHERA,urinary tract infections,syncope and dizziness,0
NORTHERA,urinary tract infections,headache syncope and,0
NORTHERA,urinary tract infections,urinary tract infections headache,1
NORTHERA,urinary tract infections,reported adverse events were urinary tract infections headache syncope and dizziness,1
NORTHERA,urinary tract infections,urinary tract infections headache,1
NORTHERA,urinary tract infections,syncope and dizziness,0
NORTHERA,urinary tract infections,urinary tract infections headache,1
NORTHERA,urinary tract infections,syncope and dizziness,0
NORTHERA,urinary tract infections,events were urinary tract infections headache syncope and,1
NORTHERA,urinary tract infections,syncope and dizziness,0
NORTHERA,urinary tract infections,urinary tract infections headache,1
NORTHERA,headache,infections,0
NORTHERA,headache,headache syncope and,1
NORTHERA,headache,urinary tract,0
NORTHERA,headache,headache syncope and,1
NORTHERA,headache,were falls urinary tract headache,1
NORTHERA,headache,headache syncope and,1
NORTHERA,headache,tract infections,0
NORTHERA,headache,headache syncope,1
NORTHERA,headache,tract headache,1
NORTHERA,headache,headache syncope,1
NORTHERA,syncope,syncope,1
NORTHERA,syncope,syncope and,1
NORTHERA,syncope,syncope,1
NORTHERA,syncope,syncope and,1
NORTHERA,syncope,syncope and,1
NORTHERA,syncope,syncope,1
NORTHERA,SUPINE HYPERTENSION,following adverse reactions,1
NORTHERA,SUPINE HYPERTENSION,the Warnings,0
NORTHERA,SUPINE HYPERTENSION,the Warnings and Precautions section,0
NORTHERA,SUPINE HYPERTENSION,reactions,0
NORTHERA,SUPINE HYPERTENSION,nausea hypertension,0
NORTHERA,SUPINE HYPERTENSION,fatigue er than 5%),1
NORTHERA,SUPINE HYPERTENSION,nausea hypertension and fatigue er than 5%) ( 6.1,1
NORTHERA,SUPINE HYPERTENSION,and fatigue er than 5%) (  6.1  To report SUSPECTED ADVERSE,1
NORTHERA,SUPINE HYPERTENSION,nausea hypertension and fatigue er than 5%) ( 6.1,1
NORTHERA,SUPINE HYPERTENSION,( 6.1 To report SUSPECTED,1
NORTHERA,SUPINE HYPERTENSION,er than 5%) (  6.1  To report SUSPECTED ADVERSE REACTIONS,1
NORTHERA,SUPINE HYPERTENSION,( 6.1 To report SUSPECTED,1
NORTHERA,SUPINE HYPERTENSION,er than 5%) (  6.1  To report SUSPECTED ADVERSE,1
NORTHERA,SUPINE HYPERTENSION,( 6.1 To report SUSPECTED,1
NORTHERA,cardiovascular risk,in more detail in Warnings and Precau tions section of the,1
NORTHERA,cardiovascular risk,( 6.1 To report SUSPECTED,1
NORTHERA,cardiovascular risk,Warnings and Precau,1
NORTHERA,cardiovascular risk,Warnings and Precau tions section of the label,1
NORTHERA,supine hypertension,s section of the la bel Supine Hypertension,1
NORTHERA,supine hypertension,Warnings and Precau tions section of the label,1
NORTHERA,supine hypertension,s section of the la bel Supine Hypertension see,1
NORTHERA,supine hypertension,and,0
NORTHERA,supine hypertension,the la bel Supine,1
NORTHERA,supine hypertension,section of the la bel Supine,1
NORTHERA,confusion,Precautions section of the,0
NORTHERA,Allergic reactions,and congestive,1
NORTHERA,Allergic reactions,disease arrhythmi,0
NORTHERA,Allergic reactions,see Warnings and Precautions EXCERPT Headache dizziness naus,0
NORTHERA,Allergic reactions,"existing ischemic heart disease as, and congestive",1
NORTHERA,Allergic reactions,"as, and congestive heart",1
NORTHERA,Allergic reactions,"as, and",1
NORTHERA,Allergic reactions,and Precautions May exacerbate existing ischemic heart disease,0
NORTHERA,supine hypertension,"s, nausea, hyperten sion and",1
NORTHERA,supine hypertension,see Warnings and Precautions,0
NORTHERA,neuroleptic malignant syndrome,clinical practice. The,1
NORTHERA,neuroleptic malignant syndrome,in clinical practice. The safety evaluation of NORTHERA,1
NORTHERA,neuroleptic malignant syndrome,based on,0
NORTHERA,neuroleptic malignant syndrome,in clinical practice. The safety evaluation of NORTHERA,1
NORTHERA,NMS,of NORTHERA is based on two placebocontrolled studies to weeks in duration Studie,0
NORTHERA,NMS,fet y evaluation of,1
NORTHERA,NMS,fet y evaluation of NORTHERA,1
NORTHERA,NMS,fet,1
NORTHERA,NMS,fet y,1
NORTHERA,NMS,sa,0
NORTHERA,NMS,in clinical practice,0
NORTHERA,NMS,drug and may not reflect the rates observed in,0
NORTHERA,fever,deficiency,0
NORTHERA,fever,rophy pure autonomic failure dopamine,1
NORTHERA,hyperthermia,multiple system atrophy re,1
NORTHERA,hyperthermia,re autonomic failure dopamine betahydroxylase deficiency,1
NORTHERA,hyperthermia,dopamine betahydroxylase,0
NORTHERA,hyperthermia,deficiency or nondiabetic autonomic,0
NORTHERA,hyperthermia,multiple system atrophy re,1
NORTHERA,muscle rigidity,neuropathy were randomized,0
NORTHERA,muscle rigidity,"autonomic ailure, dopamin e betahydroxylase deficiency or nondiabetic",1
NORTHERA,muscle rigidity,neuropathy were randomized,0
NORTHERA,muscle rigidity,"system atrophy pure autonomic ailure, dopamin e betahydroxylase deficiency or",1
NORTHERA,muscle rigidity,neuropathy were randomized,0
NORTHERA,muscle rigidity,"atrophy pure autonomic ailure,",1
NORTHERA,muscle rigidity,"ailure, dopamin e betahydroxylase deficiency",1
NORTHERA,muscle rigidity,"atrophy pure autonomic ailure,",1
NORTHERA,muscle rigidity,"autonomic ailure, dopamin e betahydroxylase deficiency or nondiabetic",1
NORTHERA,muscle rigidity,"atrophy pure autonomic ailure,",1
NORTHERA,involuntary movements,beta-hydroxylase defi ciency,1
NORTHERA,involuntary movements,pure,0
NORTHERA,involuntary movements,failure beta-hydroxylase defi,1
NORTHERA,altered consciousness,randomized and,0
NORTHERA,altered consciousness,"autonomic failure dopamine betahydroxylase ency,",1
NORTHERA,mental status changes,neuropathy were randomized and treated,1
NORTHERA,allergic-type reactions,blood pressure,0
NORTHERA,allergic-type reactions,common adverse ns leading to discontin uation,1
NORTHERA,allergic-type reactions,blood pressure,0
NORTHERA,allergic-type reactions,common adverse ns leading to discontin uation from NORTHERA were hypertension,1
NORTHERA,allergic-type reactions,blood pressure,0
NORTHERA,allergic-type reactions,leading to discontin uation from NORTHERA were hypertension,1
NORTHERA,bronchial asthma,Table Most Common Adverse Reactions,0
NORTHERA,bronchial asthma,NORTHERA were hy pertension or increased blood,1
NORTHERA,bronchial asthma,Table Most Common Adverse Reactions,0
NORTHERA,bronchial asthma,leading to discontinuation NORTHERA were,1
NORTHERA,bronchial asthma,to discontinuation,0
NORTHERA,bronchial asthma,The,0
NORTHERA,bronchial asthma,were hy pertension or increased blood pressure,1
NORTHERA,bronchial asthma,reactions,0
NORTHERA,bronchial asthma,NORTHERA were hy pertension or increased blood,1
